Generalized	B-MED
Epilepsy	I-MED
and	O
Myoclonic	B-MED
Seizures	I-MED
in	O
22q11.2	B-MED
Deletion	I-MED
Syndrome	I-MED
Prompted	O
by	O
the	O
observations	O
of	O
juvenile	B-MED
myoclonic	I-MED
epilepsy	I-MED
(	O
JME	B-MED
)	O
in	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
(	O
22q11DS	B-MED
)	O
and	O
recurrent	B-MED
copy	I-MED
number	I-MED
variants	I-MED
in	O
genetic	B-MED
generalized	B-MED
epilepsy	I-MED
(	O
GGE	B-MED
)	O
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	B-MED
of	O
22q11DS	B-MED
with	O
GGE	B-MED
and	O
with	O
myoclonic	B-MED
seizures	I-MED
.	O
Through	O
routine	B-MED
diagnostics	I-MED
,	O
we	O
identified	O
3	O
novel	O
individuals	B-MED
with	O
the	O
seemingly	O
uncommon	B-MED
combination	B-MED
of	O
22q11DS	B-MED
and	O
JME	B-MED
.	O
We	O
subsequently	O
screened	B-MED
the	O
literature	B-MED
for	O
reports	B-MED
focussing	O
on	O
the	O
epilepsy	B-MED
phenotype	I-MED
in	O
22q11DS	B-MED
.	O
We	O
additionally	O
screened	B-MED
a	O
database	B-MED
of	O
173	O
22q11DS	B-MED
patients	B-MED
and	O
identified	O
a	O
fourth	O
individual	B-MED
with	O
JME	B-MED
as	O
well	O
as	O
2	O
additional	O
cases	B-MED
with	O
GGE	B-MED
.	O
We	O
describe	O
6	O
novel	B-MED
and	O
22	O
published	B-MED
cases	B-MED
with	O
co	B-MED
-	I-MED
occurrence	I-MED
of	O
22q11DS	B-MED
and	O
GGE	B-MED
.	O
In	O
many	O
patients	B-MED
,	O
GGE	B-MED
was	O
associated	B-MED
with	I-MED
myoclonic	B-MED
seizures	I-MED
allowing	O
for	O
a	O
diagnosis	B-MED
of	O
JME	B-MED
in	O
at	O
least	O
6	O
individuals	B-MED
.	O
Seventeen	O
of	O
the	O
173	O
22q11DS	B-MED
cases	B-MED
(	O
10	O
%	O
)	O
had	O
a	O
diagnosis	B-MED
of	O
either	O
focal	B-MED
or	O
generalized	B-MED
epilepsy	I-MED
.	O
In	O
these	O
cases	B-MED
,	O
focal	B-MED
epilepsy	I-MED
could	O
often	O
be	O
attributed	O
to	O
syndrome	B-MED
-	I-MED
associated	I-MED
hypocalcaemia	I-MED
,	O
cerebral	B-MED
bleeds	I-MED
,	O
or	O
structural	B-MED
brain	I-MED
anomalies	I-MED
.	O
However	O
,	O
the	O
cause	O
of	O
GGE	B-MED
remained	O
unclear	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	B-MED
with	O
22q11DS	B-MED
and	O
GGE	B-MED
(	O
especially	O
JME	B-MED
)	O
,	O
showing	O
that	O
both	O
disorders	B-MED
frequently	B-MED
co	I-MED
-	I-MED
occur	I-MED
.	O
Compared	O
to	O
the	O
reported	B-MED
prevalence	I-MED
of	O
15	O
-	O
21	O
%	O
,	O
in	O
our	O
case	B-MED
series	I-MED
only	O
10	O
%	O
of	O
22q11DS	B-MED
individuals	B-MED
were	O
found	O
to	O
have	O
epilepsy	B-MED
,	O
often	O
GGE	B-MED
.	O
Since	O
22q11.2	B-MED
does	O
not	O
contain	O
convincing	O
GGE	B-MED
candidate	B-MED
genes	I-MED
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	B-MED
correlation	B-MED
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
GABAB	B-MED
receptor	I-MED
.	O
The	O
Histone	B-MED
Acetyltransferase	I-MED
Gcn5	I-MED
Positively	B-MED
Regulates	I-MED
T	I-MED
Cell	I-MED
Activation	I-MED
Histone	B-MED
acetyltransferases	I-MED
(	O
HATs	B-MED
)	O
regulate	B-MED
inducible	I-MED
transcription	I-MED
in	O
multiple	B-MED
cellular	B-MED
processes	I-MED
and	O
during	O
inflammatory	B-MED
and	O
immune	B-MED
response	I-MED
.	O
However	O
,	O
the	O
functions	B-MED
of	O
general	B-MED
control	I-MED
nonrepressed	I-MED
-	I-MED
protein	I-MED
5	I-MED
(	O
Gcn5	B-MED
)	O
,	O
an	O
evolutionarily	O
conserved	O
HAT	B-MED
from	O
yeast	B-MED
to	O
human	B-MED
,	O
in	O
immune	B-MED
regulation	I-MED
remain	O
unappreciated	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
conditionally	O
deleted	B-MED
Gcn5	B-MED
(	O
encoded	B-MED
by	O
the	O
Kat2a	B-MED
gene	I-MED
)	O
specifically	O
in	O
T	B-MED
lymphocytes	I-MED
by	O
crossing	B-MED
floxed	B-MED
Gcn5	I-MED
and	O
Lck	B-MED
-	I-MED
Cre	I-MED
mice	B-MED
,	O
and	O
demonstrated	O
that	O
Gcn5	B-MED
plays	O
important	B-MED
roles	I-MED
in	O
multiple	O
stages	B-MED
of	O
T	B-MED
cell	I-MED
functions	I-MED
including	O
development	B-MED
,	O
clonal	B-MED
expansion	I-MED
,	O
and	O
differentiation	B-MED
.	O
Loss	B-MED
of	I-MED
Gcn5	B-MED
functions	O
impaired	B-MED
T	I-MED
cell	I-MED
proliferation	I-MED
,	O
IL-2	B-MED
production	I-MED
,	O
and	O
Th1	B-MED
/	O
Th17	B-MED
,	O
but	O
not	O
Th2	B-MED
and	O
regulatory	B-MED
T	I-MED
cell	I-MED
differentiation	I-MED
.	O
Gcn5	B-MED
is	O
recruited	O
onto	O
the	O
il-2	B-MED
promoter	B-MED
by	O
interacting	B-MED
with	O
the	O
NFAT	B-MED
in	O
T	B-MED
cells	I-MED
upon	O
TCR	B-MED
TCR	B-MED
stimulation	I-MED
.	O
Interestingly	O
,	O
instead	O
of	O
directly	O
acetylating	B-MED
NFAT	B-MED
,	O
Gcn5	B-MED
catalyzes	B-MED
histone	B-MED
H3	I-MED
lysine	I-MED
H9	I-MED
acetylation	I-MED
to	O
promote	B-MED
IL-2	B-MED
production	I-MED
.	O
T	B-MED
cell	I-MED
-specific	O
suppression	B-MED
of	O
Gcn5	B-MED
partially	O
protected	O
mice	B-MED
from	O
myelin	B-MED
oligodendrocyte	I-MED
glycoprotein	I-MED
-	O
induced	B-MED
experimental	B-MED
autoimmune	I-MED
encephalomyelitis	I-MED
,	O
an	O
experimental	B-MED
model	I-MED
for	O
human	B-MED
multiple	B-MED
sclerosis	I-MED
.	O
Our	O
study	O
reveals	B-MED
previously	O
unknown	O
physiological	B-MED
functions	I-MED
for	O
Gcn5	B-MED
and	O
a	O
molecular	B-MED
mechanism	I-MED
underlying	O
these	O
functions	B-MED
in	O
regulating	B-MED
T	I-MED
cell	I-MED
immunity	I-MED
.	O
Hence	O
Gcn5	B-MED
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune	B-MED
disease	I-MED
therapy	B-MED
.	O
Effects	O
of	O
soybean	B-MED
isoflavone	I-MED
on	O
intestinal	B-MED
antioxidant	B-MED
capacity	I-MED
and	O
cytokines	B-MED
in	O
young	O
piglets	B-MED
fed	B-MED
oxidized	B-MED
fish	B-MED
oil	I-MED
To	O
investigate	O
the	O
effect	O
of	O
glycitein	B-MED
,	O
a	O
synthetic	B-MED
soybean	B-MED
isoflavone	I-MED
(	O
ISF	B-MED
)	O
,	O
on	O
the	O
intestinal	B-MED
antioxidant	B-MED
capacity	I-MED
,	O
morphology	B-MED
,	O
and	O
cytokine	B-MED
content	O
in	O
young	O
piglets	B-MED
fed	B-MED
oxidized	B-MED
fish	B-MED
oil	I-MED
,	O
72	O
4	O
-	O
d	O
-	O
old	O
male	O
piglets	B-MED
were	O
assigned	O
to	O
three	O
treatments	B-MED
.	O
The	O
control	B-MED
group	I-MED
was	O
fed	B-MED
a	O
basal	B-MED
diet	I-MED
containing	O
fresh	B-MED
fish	B-MED
oil	I-MED
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	B-MED
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
alone	O
or	O
with	O
ISF	B-MED
(	O
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
ISF	B-MED
)	O
.	O
After	O
21	O
d	O
of	O
feeding	B-MED
,	O
supplementation	B-MED
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
increased	O
the	O
levels	O
of	O
malondialdehyde	B-MED
(	O
MDA	B-MED
)	O
,	O
oxidized	B-MED
glutathione	I-MED
(	O
GSSG	B-MED
)	O
,	O
interleukin-1β	B-MED
(	O
IL-1β	B-MED
)	O
,	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
-	I-MED
α	I-MED
(	O
TNF	B-MED
-	I-MED
α	I-MED
)	O
,	O
interleukin-2	B-MED
(	O
IL-2	B-MED
)	O
,	O
nuclear	B-MED
factor	I-MED
κ	I-MED
B	I-MED
(	B-MED
NF	I-MED
-	I-MED
κB	I-MED
)	O
,	O
inducible	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
(	O
iNOS	B-MED
)	O
,	O
NO	B-MED
,	O
and	O
Caspase-3	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
,	O
and	O
decreased	O
the	O
villous	B-MED
height	B-MED
in	O
duodenum	B-MED
and	O
the	O
levels	O
of	O
secretory	B-MED
immunoglobulin	I-MED
A	I-MED
(	B-MED
sIgA	I-MED
)	O
and	O
IL-4	B-MED
in	O
the	O
jejunal	B-MED
mucosa	I-MED
compared	O
with	O
supplementation	B-MED
with	O
fresh	B-MED
oil	B-MED
.	O
The	O
addition	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
ISF	B-MED
partially	O
alleviated	O
this	O
negative	O
effect	O
.	O
The	O
addition	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
plus	O
ISF	B-MED
increased	O
the	O
villous	B-MED
height	B-MED
and	O
levels	O
of	O
sIgA	B-MED
and	O
IL-4	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
,	O
but	O
decreased	O
the	O
levels	O
of	O
IL-1β	B-MED
and	O
IL-2	B-MED
in	O
jejunal	B-MED
mucosa	I-MED
(	O
P<0.05	O
)	O
compared	O
with	O
oxidized	B-MED
fish	B-MED
oil	I-MED
.	O
Collectively	O
,	O
these	O
results	O
show	O
that	O
dietary	B-MED
supplementation	I-MED
of	O
ISF	B-MED
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	B-MED
fish	B-MED
oil	I-MED
by	O
improving	O
the	O
intestinal	B-MED
morphology	I-MED
as	O
well	O
as	O
the	O
antioxidant	B-MED
capacity	I-MED
and	O
immune	B-MED
function	I-MED
in	O
young	O
piglets	B-MED
piglets	B-MED
.	O
Preclinical	B-MED
fibrinolysis	B-MED
in	O
patients	B-MED
with	O
ST	B-MED
-	I-MED
segment	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
in	O
a	O
rural	B-MED
region	I-MED
In	O
the	O
current	B-MED
guidelines	I-MED
for	O
the	O
treatment	B-MED
of	O
patients	B-MED
with	O
ST	B-MED
-	I-MED
segment	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
(	O
STEMI	B-MED
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	B-MED
preclinical	B-MED
fibrinolysis	B-MED
as	O
a	O
reperfusion	B-MED
therapy	I-MED
if	O
,	O
due	O
to	O
long	O
transportation	B-MED
times	B-MED
,	O
no	O
cardiac	B-MED
catheterisation	I-MED
is	O
available	B-MED
within	O
90	O
-	O
120	O
min	B-MED
.	O
However	O
,	O
there	O
is	O
little	O
remaining	B-MED
in	O
-	O
depth	O
expertise	B-MED
in	O
this	O
method	B-MED
because	O
fibrinolysis	B-MED
is	O
presently	B-MED
only	O
rarely	B-MED
indicated	B-MED
.	O
In	O
a	O
rural	B-MED
area	I-MED
in	O
southwestern	B-MED
Germany	B-MED
,	O
where	O
an	O
emergency	B-MED
primary	I-MED
percutaneous	I-MED
coronary	I-MED
intervention	I-MED
was	O
not	O
routinely	B-MED
available	B-MED
within	O
90	O
-	O
120	O
min	B-MED
,	O
156	O
STEMI	B-MED
patients	B-MED
underwent	O
fibrinolysis	B-MED
with	O
the	O
plasminogen	B-MED
activator	I-MED
reteplase	I-MED
,	O
performed	B-MED
by	I-MED
trained	O
emergency	B-MED
physicians	B-MED
.	O
The	O
practicality	B-MED
of	O
the	O
treatment	B-MED
,	O
as	O
well	O
as	O
complications	B-MED
and	O
the	O
mortality	B-MED
of	O
the	O
patients	B-MED
in	O
the	O
preclinical	B-MED
phase	B-MED
until	O
arrival	B-MED
at	O
the	O
hospital	B-MED
,	O
were	O
retrospectively	B-MED
studied	I-MED
.	O
The	O
mean	B-MED
time	I-MED
from	O
onset	B-MED
of	I-MED
the	O
symptoms	B-MED
to	O
first	O
medical	B-MED
contact	I-MED
was	O
114	O
±	O
116	O
min	B-MED
.	O
The	O
mean	B-MED
interval	I-MED
to	O
the	O
start	B-MED
of	O
fibrinolysis	B-MED
of	O
13.5	O
±	O
6.4	O
min	B-MED
was	O
within	O
the	O
30	O
min	B-MED
mandated	B-MED
by	O
the	O
ESC	O
.	O
Patients	B-MED
with	O
inferior	B-MED
STEMI	I-MED
represented	B-MED
the	O
largest	B-MED
subgroup	B-MED
.	O
Occurring	O
in	O
39	O
cases	B-MED
(	O
25	O
%	O
)	O
,	O
complications	B-MED
due	O
to	O
infarction	B-MED
were	O
relatively	O
common	B-MED
during	O
the	O
prehospital	B-MED
phase	B-MED
,	O
including	O
15	O
cases	B-MED
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	B-MED
shock	I-MED
,	O
but	O
in	O
all	O
cases	B-MED
the	O
complications	B-MED
were	O
manageable	B-MED
.	O
No	O
patient	B-MED
died	B-MED
before	O
arrival	B-MED
at	O
the	O
hospital	B-MED
.	O
As	O
lysis	B-MED
-	O
associated	B-MED
adverse	B-MED
effects	I-MED
,	O
merely	O
two	O
uncomplicated	B-MED
mucosal	B-MED
haemorrhages	I-MED
and	O
one	O
case	O
of	O
mild	B-MED
allergic	I-MED
skin	I-MED
reactions	I-MED
were	O
seen	B-MED
.	O
In	O
emergency	B-MED
situations	I-MED
with	O
long	O
transportation	B-MED
times	B-MED
to	O
the	O
nearest	O
suitable	B-MED
cardiac	B-MED
catheterisation	I-MED
laboratory	B-MED
,	O
preclinical	B-MED
fibrinolysis	B-MED
in	O
STEMI	B-MED
still	O
represents	O
a	O
workable	B-MED
method	I-MED
.	O
Success	B-MED
of	O
this	O
strategy	B-MED
requires	O
particularly	O
strong	B-MED
training	I-MED
of	O
the	O
emergency	B-MED
physicians	B-MED
in	O
ECG	B-MED
and	O
lysis	B-MED
therapy	B-MED
,	O
and	O
co	B-MED
-	I-MED
operation	I-MED
with	O
nearby	O
cardiac	B-MED
centres	I-MED
.	O
How	O
should	O
proxies	B-MED
of	O
cognitive	B-MED
reserve	I-MED
be	O
evaluated	B-MED
in	O
a	O
population	B-MED
of	O
healthy	B-MED
older	B-MED
adults	I-MED
?	O
While	O
some	O
tools	B-MED
have	O
been	O
developed	O
to	O
estimate	B-MED
an	O
individual	B-MED
's	I-MED
cognitive	B-MED
reserve	I-MED
(	O
CR	B-MED
)	O
,	O
no	O
study	O
has	O
assessed	B-MED
the	O
adequacy	B-MED
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
CR	B-MED
proxy	B-MED
indicators	O
.	O
Therefore	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	B-MED
method	O
to	O
estimate	B-MED
CR	B-MED
by	O
comparing	O
two	O
approaches	O
:	O
(	O
1	O
)	O
the	O
common	B-MED
assessment	B-MED
of	O
CR	B-MED
proxies	B-MED
in	O
the	O
literature	B-MED
(	O
e.g.	O
years	B-MED
of	I-MED
education	I-MED
)	O
and	O
(	O
2	O
)	O
the	O
calculation	B-MED
of	O
a	O
comprehensive	B-MED
index	B-MED
based	O
on	O
most	B-MED
significant	I-MED
parameters	B-MED
used	O
in	O
the	O
estimation	B-MED
of	O
CR	B-MED
.	O
Data	O
on	O
CR	B-MED
proxies	B-MED
(	O
i.e.	O
education	B-MED
,	O
occupation	B-MED
,	O
and	O
leisure	B-MED
activities	I-MED
)	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older	B-MED
adults	I-MED
.	O
Regression	B-MED
analyses	I-MED
were	O
used	O
to	O
develop	O
the	O
two	O
indices	B-MED
of	O
CR	B-MED
(	O
i.e.	O
ICR	B-MED
-	I-MED
standard	I-MED
and	O
ICR	B-MED
-	I-MED
detailed	I-MED
)	O
and	O
to	O
determine	O
which	O
index	B-MED
best	O
represented	O
the	O
level	O
of	O
one	O
's	O
CR	B-MED
.	O
The	O
ICR	B-MED
-	I-MED
standard	I-MED
was	O
calculated	B-MED
using	O
a	O
combination	B-MED
of	O
the	O
three	O
most	O
common	B-MED
measures	B-MED
of	O
reserve	B-MED
in	O
the	O
literature	B-MED
:	O
number	B-MED
of	I-MED
schooling	I-MED
years	I-MED
,	O
complexity	B-MED
of	O
the	O
primary	O
occupation	B-MED
,	O
and	O
amount	O
of	O
current	B-MED
participation	B-MED
in	O
stimulating	B-MED
activities	B-MED
.	O
The	O
ICR	B-MED
-	I-MED
detailed	I-MED
was	O
calculated	B-MED
using	O
the	O
most	B-MED
significant	I-MED
parameters	B-MED
(	O
established	O
in	O
initial	B-MED
analyses	B-MED
)	O
of	O
CR	B-MED
:	O
highest	B-MED
level	I-MED
of	I-MED
education	I-MED
combined	B-MED
with	O
the	O
number	O
of	O
training	B-MED
courses	I-MED
,	O
last	B-MED
occupation	B-MED
,	O
and	O
amount	B-MED
of	O
current	O
participation	B-MED
in	O
social	B-MED
and	O
intellectual	B-MED
activities	I-MED
.	O
The	O
comparison	B-MED
of	O
both	O
indices	B-MED
showed	O
that	O
higher	O
levels	O
of	O
ICR	B-MED
-	I-MED
standard	I-MED
and	O
ICR	B-MED
-	I-MED
detailed	I-MED
were	O
associated	B-MED
with	I-MED
a	O
greater	B-MED
minimization	B-MED
of	O
the	O
effects	B-MED
of	I-MED
age	B-MED
on	O
cognition	B-MED
.	O
However	O
,	O
the	O
ICR	B-MED
-	I-MED
detailed	I-MED
was	O
more	O
strongly	O
associated	B-MED
to	O
this	O
minimization	B-MED
than	O
the	O
ICR	B-MED
-	I-MED
standard	I-MED
,	O
suggesting	O
that	O
the	O
ICR	B-MED
-	I-MED
detailed	I-MED
best	O
reflect	O
one	O
's	O
CR	B-MED
.	O
This	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	B-MED
importance	B-MED
to	O
question	O
methods	O
measuring	B-MED
CR	B-MED
proxies	B-MED
in	O
order	O
to	O
develop	O
a	O
clinical	B-MED
tool	I-MED
allowing	O
a	O
comprehensive	B-MED
and	O
accurate	B-MED
estimation	B-MED
of	O
CR	B-MED
.	O
Identification	B-MED
of	O
potential	O
predictive	B-MED
markers	B-MED
of	O
dexamethasone	B-MED
resistance	B-MED
in	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
Response	B-MED
to	O
dexamethasone	B-MED
(	O
DEXA	B-MED
)	O
,	O
as	O
a	O
hallmark	B-MED
drug	I-MED
in	O
the	O
treatment	B-MED
of	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
(	O
ALL	B-MED
)	O
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	B-MED
factors	I-MED
in	O
the	O
prediction	B-MED
of	I-MED
outcome	I-MED
in	O
ALL	B-MED
.	O
Identification	B-MED
of	O
predictive	B-MED
markers	B-MED
of	O
chemoresistance	B-MED
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	B-MED
protocol	I-MED
with	O
the	O
lowest	O
effect	B-MED
adverse	I-MED
.	O
Hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	B-MED
targets	I-MED
using	O
the	O
2DE	B-MED
/	O
MS	B-MED
proteomics	B-MED
study	I-MED
of	O
a	O
DEXA	B-MED
-	O
resistant	B-MED
cell	I-MED
line	I-MED
(	O
REH	B-MED
)	O
as	O
a	O
model	B-MED
for	O
poor	O
DEXA	B-MED
responding	O
patients	B-MED
before	O
and	O
after	O
drug	B-MED
treatment	I-MED
.	O
Using	O
the	O
proteomic	B-MED
methods	I-MED
,	O
three	O
differentially	O
expressed	B-MED
proteins	B-MED
were	O
detected	B-MED
,	O
including	O
voltage	B-MED
dependent	I-MED
anion	I-MED
channel	I-MED
1	I-MED
(	O
VDAC1	B-MED
)	O
,	O
sorting	B-MED
Nexin	I-MED
3	I-MED
(	O
SNX3	B-MED
)	O
,	O
and	O
prefoldin	B-MED
subunit	I-MED
6	I-MED
(	O
PFDN6	B-MED
)	O
.	O
We	O
observed	O
low	O
expression	B-MED
of	O
three	O
proteins	B-MED
after	O
DEXA	B-MED
treatment	B-MED
in	O
REH	B-MED
cells	I-MED
.	O
We	O
subsequently	O
verified	O
low	O
expression	B-MED
of	O
resulted	O
proteins	B-MED
at	O
the	O
mRNA	B-MED
level	B-MED
using	O
the	O
quantitative	B-MED
PCR	I-MED
method	I-MED
.	O
These	O
proteins	B-MED
are	O
promising	O
proteins	B-MED
because	O
of	O
their	O
important	O
roles	B-MED
in	O
drug	B-MED
resistance	I-MED
and	O
regulation	B-MED
of	I-MED
apoptosis	I-MED
(	O
VDAC1	B-MED
)	O
,	O
protein	B-MED
trafficking	I-MED
(	O
SNX3	B-MED
)	O
,	O
and	O
protein	B-MED
folding	I-MED
(	O
PFDN6	B-MED
)	O
.	O
Additionally	O
,	O
mRNA	B-MED
expression	B-MED
level	I-MED
of	O
these	O
proteins	B-MED
was	O
assessed	B-MED
in	O
17	O
bone	B-MED
marrow	I-MED
samples	I-MED
from	O
children	B-MED
with	O
newly	B-MED
diagnosed	I-MED
ALL	B-MED
and	O
7	O
non	B-MED
-	I-MED
cancerous	I-MED
samples	I-MED
as	O
controls	B-MED
.	O
The	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	B-MED
subtypes	I-MED
of	O
leukemia	B-MED
,	O
mRNA	B-MED
expression	B-MED
of	O
VDAC1	B-MED
,	O
SNX3	B-MED
,	O
and	O
PFDN6	B-MED
decreased	O
in	O
ALL	B-MED
samples	B-MED
compared	O
with	O
non	B-MED
-	I-MED
cancerous	I-MED
samples	I-MED
particularly	O
in	O
VDAC1	B-MED
(	O
p	O
<	O
0.001	O
)	O
.	O
Additionally	O
,	O
mRNA	B-MED
expression	B-MED
of	O
three	O
proteins	B-MED
was	O
also	O
declined	O
in	O
high	B-MED
-	I-MED
risk	I-MED
samples	B-MED
compared	O
with	O
standard	B-MED
risk	B-MED
cases	B-MED
.	O
These	O
results	O
demonstrated	O
diagnostic	B-MED
and	O
prognostic	B-MED
value	B-MED
of	O
these	O
proteins	B-MED
in	O
childhood	B-MED
ALL	B-MED
.	O
Furthermore	O
,	O
investigation	B-MED
of	O
protein	B-MED
-	I-MED
protein	I-MED
interaction	I-MED
using	O
STRING	B-MED
database	B-MED
indicated	O
that	O
these	O
proteins	B-MED
involved	O
in	O
the	O
signaling	B-MED
pathway	I-MED
of	O
NR3C1	B-MED
as	O
dexamethasone	B-MED
target	B-MED
.	O
In	O
conclusion	O
,	O
our	O
proteomic	B-MED
study	I-MED
in	O
DEXA	B-MED
resistant	B-MED
leukemic	B-MED
cells	I-MED
revealed	O
VDAC1	B-MED
,	O
SNX3	B-MED
,	O
and	O
PFDN6	B-MED
are	O
promising	O
proteins	B-MED
that	O
might	O
serve	O
as	O
potential	O
biomarkers	B-MED
of	O
prognosis	B-MED
and	O
chemotherapy	B-MED
in	O
childhood	B-MED
ALL	B-MED
.	O
Beneficial	B-MED
effects	I-MED
of	O
voglibose	B-MED
administration	B-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
via	O
gastrointestinal	B-MED
bile	B-MED
acid	I-MED
modification	B-MED
This	O
study	B-MED
was	O
designed	O
with	O
the	O
goal	B-MED
of	O
examining	O
the	O
effects	B-MED
of	O
voglibose	B-MED
administration	B-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
and	O
underlying	O
mechanism	B-MED
high	B-MED
fat	I-MED
diet	I-MED
-induced	O
obese	B-MED
mice	I-MED
.	O
Male	B-MED
C57BL/6	B-MED
mice	I-MED
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-MED
:	O
a	O
control	B-MED
diet	I-MED
(	O
CTL	B-MED
)	O
,	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
(	O
HF	B-MED
)	O
,	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
supplemented	I-MED
with	I-MED
voglibose	I-MED
(	O
VO	B-MED
)	O
,	O
and	O
high	B-MED
fat	I-MED
diet	I-MED
pair	I-MED
-	I-MED
fed	I-MED
group	I-MED
(	O
PF	B-MED
)	O
.	O
After	O
12	O
weeks	B-MED
,	O
the	O
following	O
characteristics	B-MED
were	O
investigated	O
:	O
serum	B-MED
lipid	I-MED
and	O
glucose	B-MED
levels	I-MED
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	B-MED
levels	I-MED
of	O
genes	B-MED
involved	O
in	O
lipid	B-MED
and	O
bile	B-MED
acid	I-MED
metabolism	I-MED
.	O
In	O
addition	O
,	O
pyrosequencing	B-MED
was	O
used	O
to	O
analyze	O
the	O
composition	B-MED
of	O
gut	B-MED
microbiota	I-MED
found	O
in	O
feces	B-MED
.	O
Total	B-MED
body	I-MED
weight	I-MED
gain	I-MED
was	O
significantly	B-MED
lower	I-MED
in	O
the	O
VO	B-MED
group	I-MED
than	O
in	O
the	O
CTL	B-MED
,	O
HF	B-MED
,	O
and	O
PF	B-MED
groups	I-MED
.	O
The	O
VO	B-MED
group	I-MED
exhibited	O
improved	O
metabolic	B-MED
profiles	I-MED
including	O
those	O
of	O
blood	B-MED
glucose	I-MED
,	O
triglyceride	B-MED
,	O
and	O
total	B-MED
cholesterol	I-MED
levels	I-MED
.	O
The	O
12-	O
week	B-MED
voglibose	B-MED
administration	B-MED
decreased	O
the	O
ratio	O
of	O
Firmicutes	B-MED
to	O
Bacteroidetes	B-MED
found	O
in	O
feces	B-MED
.	O
Circulating	O
levels	B-MED
of	O
taurocholic	B-MED
and	O
cholic	B-MED
acid	I-MED
were	O
significantly	B-MED
higher	I-MED
in	O
the	O
VO	B-MED
group	I-MED
than	O
in	O
the	O
HF	B-MED
and	O
CTL	B-MED
groups	I-MED
.	O
Deoxycholic	B-MED
acid	I-MED
levels	B-MED
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	B-MED
group	I-MED
than	O
in	O
the	O
HF	B-MED
group	I-MED
.	O
Voglibose	B-MED
administration	B-MED
downregulated	B-MED
expression	B-MED
levels	I-MED
of	O
CYP8B1	B-MED
and	O
HNF4α	B-MED
genes	I-MED
and	O
upregulated	B-MED
those	O
of	O
PGC1α	B-MED
,	O
whereas	O
FXRα	B-MED
was	O
not	O
affected	O
.	O
Voglibose	B-MED
administration	B-MED
elicits	O
changes	O
in	O
the	O
composition	B-MED
of	O
the	O
intestinal	B-MED
microbiota	I-MED
and	O
circulating	B-MED
metabolites	I-MED
,	O
which	O
ultimately	O
has	O
systemic	B-MED
effects	I-MED
on	O
body	B-MED
weight	I-MED
and	O
lipid	B-MED
metabolism	I-MED
in	O
mice	B-MED
.	O
Smooth	B-MED
versus	O
Textured	B-MED
Surfaces	B-MED
:	O
Feature	B-MED
-Based	O
Category	B-MED
Selectivity	B-MED
in	O
Human	B-MED
Visual	B-MED
Cortex	I-MED
In	O
fMRI	B-MED
studies	I-MED
,	O
human	B-MED
lateral	B-MED
occipital	I-MED
(	I-MED
LO	I-MED
)	I-MED
cortex	I-MED
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	B-MED
of	O
objects	B-MED
,	O
compared	B-MED
with	O
nonobjects	B-MED
.	O
However	O
,	O
it	O
remains	O
unresolved	B-MED
whether	O
all	O
objects	B-MED
evoke	O
equivalent	B-MED
levels	B-MED
of	O
activity	B-MED
in	O
LO	B-MED
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	B-MED
features	I-MED
produce	O
stronger	B-MED
activation	B-MED
.	O
Here	O
,	O
we	O
used	O
an	O
unbiased	B-MED
parametric	I-MED
texture	I-MED
model	I-MED
to	O
predict	B-MED
preferred	B-MED
versus	O
nonpreferred	B-MED
stimuli	I-MED
in	O
LO	B-MED
.	O
Observation	B-MED
and	O
psychophysical	B-MED
results	I-MED
showed	O
that	O
predicted	B-MED
preferred	B-MED
stimuli	B-MED
(	O
both	O
objects	B-MED
and	O
nonobjects	B-MED
)	O
had	O
smooth	B-MED
(	O
rather	O
than	O
textured	B-MED
)	O
surfaces	B-MED
.	O
These	O
predictions	B-MED
were	O
confirmed	B-MED
using	O
fMRI	B-MED
,	O
for	O
objects	B-MED
and	O
nonobjects	B-MED
.	O
Similar	O
preferences	B-MED
were	O
also	O
found	O
in	O
the	O
fusiform	B-MED
face	I-MED
area	I-MED
(	O
FFA	B-MED
)	O
.	O
Consistent	B-MED
with	I-MED
this	O
:	O
(	O
1	O
)	O
FFA	B-MED
and	O
LO	B-MED
responded	O
more	O
strongly	O
to	O
nonfreckled	B-MED
(	O
smooth	B-MED
)	O
faces	B-MED
,	O
compared	B-MED
with	O
otherwise	O
identical	O
freckled	B-MED
(	O
textured	B-MED
)	O
faces	B-MED
;	O
and	O
(	O
2	O
)	O
strong	O
functional	B-MED
connections	B-MED
were	O
found	O
between	O
LO	B-MED
and	O
FFA	B-MED
.	O
Thus	O
,	O
LO	B-MED
and	O
FFA	B-MED
may	O
be	O
part	O
of	O
an	O
information	B-MED
-	O
processing	B-MED
stream	O
distinguished	O
by	O
feature	B-MED
-based	O
category	B-MED
selectivity	B-MED
(	O
smooth	B-MED
>	O
textured	B-MED
)	O
.	O
In	B-MED
situ	I-MED
stabilization	B-MED
of	O
heavy	B-MED
metals	I-MED
in	O
multiple-	O
metal	B-MED
contaminated	B-MED
paddy	B-MED
soil	B-MED
using	O
different	O
steel	B-MED
slag	B-MED
-based	O
silicon	B-MED
fertilizer	B-MED
Steel	B-MED
slag	B-MED
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	B-MED
fertilizer	B-MED
to	O
alleviate	O
the	O
mobility	B-MED
and	O
bioavailability	B-MED
of	O
heavy	B-MED
metals	I-MED
in	O
soil	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
influence	B-MED
of	O
particle	B-MED
size	I-MED
,	O
composition	B-MED
,	O
and	O
application	O
rate	O
of	O
slag	B-MED
on	O
metal	B-MED
immobilization	B-MED
in	O
acidic	B-MED
soil	B-MED
,	O
metals	B-MED
uptake	B-MED
by	O
rice	B-MED
and	O
rice	B-MED
growth	B-MED
.	O
The	O
results	O
indicated	O
that	O
application	O
of	O
slag	B-MED
increased	O
soil	B-MED
pH	B-MED
,	O
plant	B-MED
-available	O
silicon	B-MED
concentrations	B-MED
in	O
soil	B-MED
,	O
and	O
decreased	B-MED
the	O
bioavailability	B-MED
of	O
metals	B-MED
compared	O
with	O
control	B-MED
treatment	I-MED
,	O
whereas	O
pulverous	B-MED
slag	I-MED
(	O
S1	B-MED
)	O
was	O
more	B-MED
effective	I-MED
than	O
granular	B-MED
slag	B-MED
(	O
S2	O
and	O
S3	O
)	O
.	O
The	O
acid	B-MED
-	O
extractable	B-MED
fraction	I-MED
of	I-MED
Cd	B-MED
in	O
the	O
spiked	O
soil	B-MED
was	O
significantly	O
decreased	B-MED
with	O
application	O
of	O
S1	B-MED
at	O
rates	O
of	O
1	O
and	O
3	O
%	O
,	O
acid	O
-	O
extractable	O
fractions	O
of	O
Cu	B-MED
and	O
Zn	B-MED
were	O
decreased	B-MED
when	O
treated	B-MED
at	O
3	O
%	O
.	O
Use	O
of	O
S1	B-MED
at	O
both	O
rates	O
resulted	O
in	O
significantly	B-MED
lower	I-MED
Cd	B-MED
,	O
Cu	B-MED
,	O
and	O
Zn	B-MED
concentrations	B-MED
in	O
rice	B-MED
tissues	B-MED
than	O
in	O
controls	B-MED
by	O
82.6	O
-	O
92.9	O
,	O
88.4	O
-	O
95.6	O
,	O
and	O
67.4	O
-	O
81.4	O
%	O
,	O
respectively	O
.	O
However	O
,	O
use	O
of	O
pulverous	B-MED
slag	I-MED
at	O
1	O
%	O
significantly	O
promotes	B-MED
rice	B-MED
growth	B-MED
,	O
restricted	O
rice	B-MED
growth	B-MED
when	O
treated	B-MED
at	O
3	O
%	O
.	O
Thus	O
,	O
the	O
results	O
explained	O
that	O
reduced	B-MED
particle	B-MED
size	I-MED
and	O
suitable	O
application	O
rate	O
of	O
slag	B-MED
could	O
be	O
beneficial	O
to	O
rice	B-MED
growth	B-MED
and	O
metals	B-MED
stabilization	B-MED
.	O
Genetic	B-MED
Diversity	I-MED
in	O
Various	O
Accessions	B-MED
of	O
Pineapple	B-MED
[	O
Ananas	B-MED
comosus	I-MED
(	I-MED
L.	I-MED
)	I-MED
Merr	I-MED
.	I-MED
]	O
Using	O
ISSR	B-MED
and	O
SSR	B-MED
Markers	B-MED
Inter	B-MED
simple	I-MED
sequence	I-MED
repeat	I-MED
(	O
ISSR	B-MED
)	O
and	O
simple	B-MED
sequence	I-MED
repeat	I-MED
(	O
SSR	B-MED
)	O
markers	B-MED
were	O
used	O
to	O
assess	O
the	O
genetic	B-MED
diversity	I-MED
of	O
36	O
pineapple	B-MED
accessions	B-MED
that	O
were	O
introduced	O
from	O
10	O
countries	B-MED
/	O
regions	B-MED
.	O
Thirteen	O
ISSR	B-MED
primers	B-MED
amplified	B-MED
96	O
bands	O
,	O
of	O
which	O
91	O
(	O
93.65	O
%	O
)	O
were	O
polymorphic	B-MED
,	O
whereas	O
20	O
SSR	B-MED
primers	B-MED
amplified	B-MED
73	O
bands	O
,	O
of	O
which	O
70	O
(	O
96.50	O
%	O
)	O
were	O
polymorphic	B-MED
.	O
Nei	B-MED
's	I-MED
gene	I-MED
diversity	I-MED
(	O
h	B-MED
=	O
0.28	O
)	O
,	O
Shannon	B-MED
's	I-MED
information	I-MED
index	I-MED
(	O
I	B-MED
=	O
0.43	O
)	O
,	O
and	O
polymorphism	B-MED
information	I-MED
content	I-MED
(	O
PIC	B-MED
=	O
0.29	O
)	O
generated	O
using	O
the	O
SSR	B-MED
primers	B-MED
were	O
higher	O
than	O
that	O
with	O
ISSR	B-MED
primers	B-MED
(	O
h	B-MED
=	O
0.23	O
,	O
I	B-MED
=	O
0.37	O
,	O
PIC	B-MED
=	O
0.24	O
)	O
,	O
thereby	O
suggesting	O
that	O
the	O
SSR	B-MED
system	I-MED
is	O
more	O
efficient	O
than	O
the	O
ISSR	B-MED
system	I-MED
in	O
assessing	O
genetic	B-MED
diversity	I-MED
in	O
various	O
pineapple	B-MED
accessions	B-MED
.	O
Mean	O
genetic	B-MED
similarities	B-MED
were	O
0.74	O
,	O
0.61	O
,	O
and	O
0.69	O
,	O
as	O
determined	O
using	O
ISSR	B-MED
,	O
SSR	B-MED
,	O
and	O
combined	O
ISSR	B-MED
/	O
SSR	B-MED
,	O
respectively	O
.	O
These	O
results	O
suggest	O
that	O
the	O
genetic	B-MED
diversity	I-MED
among	O
pineapple	B-MED
accessions	B-MED
is	O
very	O
high	O
.	O
We	O
clustered	B-MED
the	O
36	O
pineapple	B-MED
accessions	B-MED
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	B-MED
trees	I-MED
constructed	O
based	O
on	O
the	O
results	O
of	O
ISSR	B-MED
,	O
SSR	B-MED
,	O
and	O
combined	O
ISSR	B-MED
/	O
SSR	B-MED
analyses	B-MED
using	O
the	O
unweighted	B-MED
pair	I-MED
-	I-MED
group	I-MED
with	I-MED
arithmetic	I-MED
averaging	I-MED
(	I-MED
UPGMA	I-MED
)	I-MED
method	I-MED
.	O
The	O
results	O
of	O
principal	B-MED
components	I-MED
analysis	I-MED
(	O
PCA	B-MED
)	O
also	O
supported	O
the	O
UPGMA	B-MED
clustering	B-MED
.	O
These	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	B-MED
germplasm	B-MED
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	B-MED
breeding	B-MED
strategies	I-MED
.	O
An	O
evaluation	B-MED
of	O
neuroendocrine	B-MED
dysfunction	B-MED
following	O
acute	B-MED
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
:	O
A	O
prospective	B-MED
study	I-MED
The	O
aim	B-MED
was	O
to	O
investigate	B-MED
the	O
incidence	O
and	O
pattern	B-MED
of	O
neuroendocrine	B-MED
changes	O
in	O
cases	B-MED
of	O
acute	B-MED
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
(	O
SAH	B-MED
)	O
.	O
Endocrine	B-MED
assessment	B-MED
was	O
performed	O
in	O
100	O
consecutive	O
cases	B-MED
of	O
acute	B-MED
aneurysmal	B-MED
SAH	I-MED
presenting	O
within	O
7	O
days	B-MED
of	O
ictus	B-MED
.	O
The	O
gonadotropic	B-MED
,	O
somatotrophic	B-MED
,	O
thyrotropic	B-MED
,	O
and	O
corticotrophic	B-MED
axes	O
were	O
evaluated	B-MED
for	O
their	O
possible	O
dysfunction	B-MED
.	O
A	O
total	O
of	O
100	O
cases	B-MED
(	O
38	O
males	B-MED
,	O
62	O
females	B-MED
;	O
age	B-MED
range	B-MED
-	O
17	O
-	O
76	O
years	B-MED
;	O
mean	B-MED
age	B-MED
-	O
43.6	O
years	B-MED
)	O
of	O
acute	B-MED
SAH	B-MED
were	O
studied	B-MED
.	O
The	O
aneurysms	B-MED
were	O
located	O
in	O
the	O
anterior	B-MED
circulation	I-MED
(	O
n	O
=	O
95	O
)	O
and	O
posterior	B-MED
circulation	I-MED
(	O
n	O
=	O
5	O
)	O
.	O
The	O
most	O
common	O
hormone	B-MED
deficiency	I-MED
was	O
of	O
growth	B-MED
hormone	I-MED
(	O
n	O
=	O
67	O
)	O
,	O
followed	O
by	O
gonadotrophin	B-MED
(	O
n	O
=	O
50	O
)	O
,	O
corticotrophin	B-MED
(	O
n	O
=	O
49	O
)	O
and	O
thyrotrophin	B-MED
(	O
n	O
=	O
35	O
)	O
.	O
Hyperprolactinemia	B-MED
was	O
noted	O
in	O
10	O
cases	B-MED
.	O
One	B-MED
-	I-MED
pituitary	I-MED
hormone	I-MED
axis	I-MED
deficiency	I-MED
was	O
noted	O
in	O
26	O
cases	B-MED
while	O
67	O
cases	B-MED
had	O
two	O
or	O
more	O
pituitary	B-MED
hormone	I-MED
axes	O
dysfunction	B-MED
.	O
A	O
total	O
of	O
93	O
cases	B-MED
had	O
hormonal	B-MED
dysfunction	B-MED
in	O
one	O
or	O
more	O
pituitary	B-MED
hormone	I-MED
axes	I-MED
,	O
and	O
seven	O
cases	B-MED
had	O
no	O
hormonal	B-MED
dysfunction	B-MED
.	O
Endocrine	B-MED
dysfunction	I-MED
occurs	O
in	O
93	O
%	O
cases	B-MED
of	O
acute	B-MED
SAH	B-MED
and	O
multiple	O
pituitary	B-MED
hormone	I-MED
axes	I-MED
dysfunction	B-MED
occurs	O
in	O
67	O
%	O
cases	B-MED
.	O
It	O
is	O
suggested	O
that	O
hormonal	B-MED
evaluation	B-MED
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	B-MED
SAH	B-MED
.	O
Determining	O
putative	B-MED
vectors	I-MED
of	O
the	O
Bogia	B-MED
Coconut	I-MED
Syndrome	I-MED
phytoplasma	B-MED
using	O
loop	B-MED
-	I-MED
mediated	I-MED
isothermal	I-MED
amplification	I-MED
of	O
single	B-MED
-	I-MED
insect	I-MED
feeding	I-MED
media	I-MED
Phytoplasmas	B-MED
are	O
insect	B-MED
vectored	I-MED
mollicutes	I-MED
responsible	O
for	O
disease	B-MED
in	O
many	O
economically	O
important	O
crops	B-MED
.	O
Determining	O
which	O
insect	B-MED
species	I-MED
are	O
vectors	B-MED
of	O
a	O
given	O
phytoplasma	B-MED
is	O
important	O
for	O
managing	O
disease	B-MED
but	O
is	O
methodologically	O
challenging	O
because	O
disease	B-MED
-	I-MED
free	I-MED
plants	I-MED
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	B-MED
,	O
often	O
over	O
many	O
months	B-MED
.	O
A	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	B-MED
involves	O
molecular	B-MED
testing	I-MED
for	O
phytoplasma	B-MED
DNA	B-MED
in	O
sucrose	B-MED
solution	B-MED
that	O
insects	B-MED
have	O
fed	B-MED
upon	O
.	O
In	O
this	O
study	B-MED
we	O
combined	O
this	O
feeding	B-MED
medium	I-MED
method	I-MED
with	O
a	O
loop	B-MED
-	I-MED
mediated	I-MED
isothermal	I-MED
amplification	I-MED
(	I-MED
LAMP	I-MED
)	I-MED
assay	I-MED
to	O
study	O
627	O
insect	B-MED
specimens	B-MED
of	O
11	O
Hemiptera	B-MED
taxa	I-MED
sampled	O
from	O
sites	O
in	O
Papua	B-MED
New	I-MED
Guinea	I-MED
affected	O
by	O
Bogia	B-MED
coconut	I-MED
syndrome	I-MED
(	O
BCS	B-MED
)	O
.	O
The	O
LAMP	B-MED
assay	I-MED
detected	O
phytoplasma	B-MED
DNA	B-MED
from	O
the	O
feeding	B-MED
solution	I-MED
and	O
head	B-MED
tissue	B-MED
of	O
insects	B-MED
from	O
six	O
taxa	B-MED
belonging	O
to	O
four	O
families	O
:	O
Derbidae	B-MED
,	O
Lophopidae	B-MED
,	O
Flatidae	B-MED
and	O
Ricaniidae	B-MED
.	O
Two	O
other	O
taxa	B-MED
yielded	O
positives	O
only	O
from	O
the	O
heads	B-MED
and	O
the	O
remainder	O
tested	O
negative	O
.	O
These	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single	B-MED
-	I-MED
insect	I-MED
feeding	I-MED
medium	I-MED
tests	I-MED
with	O
LAMP	B-MED
assays	I-MED
to	O
identify	O
putative	B-MED
vectors	I-MED
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	B-MED
tests	B-MED
and	O
to	O
better	O
understand	O
phytoplasma	B-MED
pathosystems	B-MED
.	O
A	O
Case	O
Presenting	O
with	O
Splenic	B-MED
Infarct	I-MED
Diagnosed	B-MED
as	O
Primary	B-MED
Bone	I-MED
Marrow	I-MED
CD5	B-MED
Positive	I-MED
DLBCL	B-MED
:	O
A	O
Clinicopathological	B-MED
Correlation	I-MED
De	B-MED
novo	I-MED
CD5	B-MED
+	I-MED
Diffuse	B-MED
large	I-MED
B	I-MED
cell	I-MED
lymphoma	I-MED
(	O
DLBCL	B-MED
)	O
is	O
a	O
rare	B-MED
and	O
aggressive	B-MED
subtype	I-MED
of	O
DLBCL	B-MED
.	O
It	O
is	O
a	O
distinct	O
clinicopathologic	B-MED
entity	B-MED
with	O
complex	B-MED
molecular	I-MED
profile	I-MED
and	O
poor	B-MED
prognosis	I-MED
.	O
A	O
59	O
year	B-MED
old	O
female	B-MED
presented	B-MED
with	I-MED
pyrexia	B-MED
of	I-MED
unknown	I-MED
origin	I-MED
since	O
1	O
month	B-MED
.	O
On	O
examination	B-MED
,	O
there	O
was	O
severe	B-MED
pallor	I-MED
,	O
hepatosplenomegaly	B-MED
and	O
no	B-MED
palpable	I-MED
lymphadenopathy	B-MED
.	O
Complete	B-MED
blood	I-MED
count	I-MED
revealed	B-MED
bicytopenia	B-MED
with	O
normal	B-MED
total	I-MED
leucocyte	I-MED
count	I-MED
.	O
Liver	B-MED
and	O
renal	B-MED
function	I-MED
tests	I-MED
were	O
normal	B-MED
.	O
Ultrasonography	B-MED
abdomen	I-MED
revealed	B-MED
splenic	B-MED
enlargement	I-MED
with	O
two	B-MED
focal	I-MED
lesions	I-MED
attributed	O
to	O
either	O
splenic	B-MED
abscess	I-MED
or	O
infarcts	B-MED
.	O
Patient	B-MED
was	O
being	O
managed	O
as	O
splenic	B-MED
infarct	I-MED
but	O
continued	O
to	O
have	O
bicytopenia	B-MED
.	O
Further	O
investigation	B-MED
showed	O
elevated	B-MED
serum	I-MED
ferritin	I-MED
,	O
triglycerides	B-MED
and	O
LDH	B-MED
.	O
With	O
a	O
clinical	B-MED
suspicion	B-MED
of	O
infection	B-MED
and	O
haemophagocytic	B-MED
lymphohistiocytosis	I-MED
bone	B-MED
marrow	I-MED
aspiration	I-MED
bone	B-MED
marrow	I-MED
aspiration	I-MED
(	I-MED
BMA	I-MED
)	I-MED
and	I-MED
biopsy	I-MED
(	I-MED
BMBx	I-MED
)	I-MED
BMA	B-MED
biopsy	B-MED
was	O
done	O
.	O
BMA	O
showed	O
extensive	B-MED
haemophagocytosis	B-MED
and	O
~7.4	O
%	O
large	B-MED
lymphoma	I-MED
-	I-MED
like	I-MED
cells	I-MED
.	O
On	O
this	O
basis	O
PET	B-MED
-	I-MED
CT	I-MED
was	O
suggested	O
which	O
showed	O
enlarged	B-MED
spleen	I-MED
with	O
diffuse	B-MED
uptake	I-MED
.	O
BMBx	B-MED
showed	O
nodular	B-MED
and	O
intrasinusoidal	B-MED
collection	O
of	O
abnormal	B-MED
lymphoid	I-MED
cells	I-MED
.	O
On	O
immunohistochemistry	B-MED
,	O
these	O
cells	B-MED
were	O
positive	B-MED
for	I-MED
CD20	I-MED
,	O
CD5	B-MED
,	O
MUM1	B-MED
,	O
BCL-2	B-MED
,	O
BCL-6	B-MED
and	O
negative	B-MED
for	O
CD3	B-MED
,	O
CD10	B-MED
and	O
CD23	B-MED
.	O
CD34	B-MED
highlighted	O
focal	B-MED
intrasinusoidal	B-MED
pattern	B-MED
.	O
The	O
complete	O
clinicopathological	B-MED
profile	I-MED
suggested	O
the	O
diagnosis	B-MED
of	O
de	B-MED
novo	I-MED
CD5	B-MED
+	I-MED
DLBCL	B-MED
,	O
with	O
primary	B-MED
hepatosplenic	I-MED
pattern	B-MED
of	O
involvement	O
.	O
CD5	B-MED
+	I-MED
DLBCL	B-MED
presenting	O
as	O
splenic	B-MED
infarct	I-MED
is	O
very	B-MED
rare	I-MED
.	O
This	O
case	O
was	O
unusual	B-MED
as	O
the	O
diagnosis	B-MED
of	O
a	O
primary	B-MED
aggressive	I-MED
lymphoma	I-MED
with	O
haemophagocytosis	B-MED
was	O
established	B-MED
in	O
a	O
patient	B-MED
who	O
presented	O
with	O
fever	B-MED
and	O
splenic	B-MED
infarct	I-MED
without	O
lymphadenopathy	B-MED
.	O
This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	B-MED
assessment	B-MED
of	O
a	O
bone	B-MED
marrow	I-MED
aspirate	I-MED
and	O
biopsy	B-MED
to	O
make	O
a	O
correct	B-MED
diagnosis	I-MED
.	O
Opioid	B-MED
Use	O
in	O
Chronic	B-MED
Pain	I-MED
Patients	B-MED
with	O
Chronic	B-MED
Kidney	I-MED
Disease	I-MED
:	O
A	O
Systematic	B-MED
Review	I-MED
To	O
investigate	O
the	O
prevalence	B-MED
of	O
chronic	B-MED
pain	I-MED
and	O
opioid	B-MED
management	B-MED
among	O
patients	B-MED
with	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
.	O
Systematic	B-MED
review	I-MED
.	O
A	O
systematic	O
search	O
was	O
performed	O
,	O
including	O
citations	O
from	O
1960	O
to	O
May	O
2015	O
.	O
The	O
review	O
highlights	O
methodological	B-MED
quality	I-MED
assessment	I-MED
of	O
the	O
selected	O
studies	B-MED
;	O
prevalence	B-MED
of	O
pain	B-MED
;	O
type	B-MED
,	O
dose	B-MED
,	O
and	O
reason	O
for	O
opioid	B-MED
use	O
;	O
effectiveness	B-MED
of	O
pain	B-MED
control	I-MED
and	O
associated	O
adverse	B-MED
effects	I-MED
of	O
opioids	B-MED
in	O
CKD	B-MED
patients	B-MED
.	O
Twelve	O
of	O
131	O
articles	O
met	O
inclusion	B-MED
criteria	I-MED
.	O
There	O
were	O
no	O
randomized	B-MED
controlled	I-MED
trials	I-MED
(	O
RCT	B-MED
)	O
evaluable	O
,	O
and	O
12	O
were	O
observational	B-MED
studies	I-MED
.	O
Out	O
of	O
12	O
studies	B-MED
,	O
four	O
were	O
of	O
high	B-MED
quality	B-MED
,	O
six	O
were	O
of	O
moderate	B-MED
quality	B-MED
,	O
and	O
the	O
remaining	O
two	O
were	O
low	B-MED
-	O
quality	B-MED
studies	B-MED
.	O
The	O
studies	B-MED
were	O
from	O
different	O
countries	B-MED
with	O
sample	B-MED
size	I-MED
ranging	O
from	O
10	O
to	O
12,782	O
.	O
Several	O
studies	B-MED
showed	O
a	O
high	O
prevalence	B-MED
of	O
chronic	B-MED
uncontrolled	B-MED
pain	I-MED
.	O
The	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-MED
,	O
dose	B-MED
,	O
duration	B-MED
,	O
and	O
commonly	O
prescribed	B-MED
opioids	B-MED
varied	O
across	O
studies	B-MED
.	O
Based	O
on	O
a	O
systematic	B-MED
review	I-MED
of	O
the	O
current	O
literature	O
,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	B-MED
of	O
chronic	B-MED
pain	I-MED
among	O
patients	B-MED
with	O
CKD	B-MED
,	O
which	O
is	O
not	O
being	O
effectively	O
managed	O
,	O
probably	O
due	O
to	O
underprescription	B-MED
of	O
analgesics	B-MED
or	O
opioids	B-MED
in	O
the	O
CKD	B-MED
population	B-MED
.	O
Clinicians	B-MED
are	O
in	O
need	O
of	O
additional	O
and	O
well	O
-	O
designed	O
randomized	B-MED
control	I-MED
trials	I-MED
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-MED
therapy	B-MED
,	O
appropriate	O
opioid	B-MED
doses	B-MED
and	O
dosing	B-MED
intervals	B-MED
,	O
outcomes	O
with	O
adequacy	B-MED
of	O
symptom	B-MED
control	I-MED
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse	B-MED
side	I-MED
effects	I-MED
.	O
Genome	B-MED
-	I-MED
Wide	I-MED
SNP	I-MED
Linkage	I-MED
Mapping	I-MED
and	O
QTL	B-MED
Analysis	B-MED
for	O
Fiber	B-MED
Quality	B-MED
and	O
Yield	B-MED
Traits	B-MED
in	O
the	O
Upland	B-MED
Cotton	I-MED
Recombinant	B-MED
Inbred	I-MED
Lines	I-MED
Population	O
It	O
is	O
of	O
significance	O
to	O
discover	O
genes	B-MED
related	O
to	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
and	O
tightly	O
linked	O
markers	B-MED
for	O
marker	B-MED
-	I-MED
assisted	I-MED
selection	I-MED
(	O
MAS	B-MED
)	O
in	O
cotton	B-MED
breeding	B-MED
.	O
In	O
this	O
study	O
,	O
188	B-MED
F8	I-MED
recombinant	B-MED
inbred	I-MED
lines	I-MED
(	O
RILs	B-MED
)	O
,	O
derived	O
from	O
a	O
intraspecific	B-MED
cross	B-MED
between	O
HS46	B-MED
and	O
MARCABUCAG8US-1	B-MED
-	I-MED
88	I-MED
were	O
genotyped	B-MED
by	O
the	O
cotton	B-MED
63	O
K	O
single	B-MED
nucleotide	I-MED
polymorphism	I-MED
(	I-MED
SNP	I-MED
)	I-MED
assay	I-MED
.	O
Field	B-MED
trials	I-MED
were	O
conducted	O
in	O
Sanya	B-MED
,	I-MED
Hainan	I-MED
Province	I-MED
,	O
during	O
the	O
2014	O
-	O
2015	O
cropping	B-MED
seasons	B-MED
under	O
standard	B-MED
conditions	B-MED
.	O
Results	O
revealed	O
significant	B-MED
differences	B-MED
(	O
P	O
<	O
0.05	O
)	O
among	O
RILs	B-MED
,	O
environments	B-MED
and	O
replications	B-MED
for	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
.	O
Broad	O
-	O
sense	O
heritabilities	B-MED
of	O
all	O
traits	B-MED
including	O
fiber	B-MED
length	B-MED
,	O
fiber	B-MED
uniformity	B-MED
,	O
micronaire	B-MED
,	O
fiber	B-MED
elongation	B-MED
,	O
fiber	B-MED
strength	B-MED
,	O
boll	B-MED
weight	B-MED
,	O
and	O
lint	B-MED
percentage	B-MED
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O
A	O
1784.28	O
cM	B-MED
(	O
centimorgans	B-MED
)	O
linkage	B-MED
map	I-MED
,	O
harboring	O
2618	O
polymorphic	B-MED
SNP	B-MED
markers	B-MED
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cM	B-MED
per	O
marker	B-MED
density	O
.	O
Seventy	O
-	O
one	O
quantitative	B-MED
trait	I-MED
locus	I-MED
(	O
QTLs	B-MED
)	O
for	O
fiber	B-MED
quality	B-MED
and	O
yield	B-MED
traits	B-MED
were	O
detected	O
on	O
21	O
chromosomes	B-MED
,	O
explaining	O
4.70~32.28	O
%	O
phenotypic	B-MED
variance	B-MED
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	B-MED
QTLs	B-MED
across	O
two	O
environments	B-MED
.	O
Meanwhile	O
,	O
12	O
certain	O
regions	B-MED
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	B-MED
)	O
or	O
more	O
(	O
cluster	B-MED
)	O
traits	B-MED
,	O
mainly	O
focused	O
on	O
Chr05	B-MED
,	O
Chr09	B-MED
,	O
Chr10	B-MED
,	O
Chr14	B-MED
,	O
Chr19	B-MED
,	O
and	O
Chr20	B-MED
.	O
Nineteen	O
pairs	O
of	O
epistatic	B-MED
QTLs	B-MED
(	O
e	B-MED
-	I-MED
QTLs	I-MED
)	O
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	B-MED
QTLs	B-MED
.	O
These	O
additive	B-MED
QTLs	B-MED
,	O
e	B-MED
-	I-MED
QTLs	I-MED
,	O
and	O
QTL	B-MED
clusters	B-MED
were	O
tightly	O
linked	O
to	O
SNP	B-MED
markers	B-MED
,	O
which	O
may	O
serve	O
as	O
target	B-MED
regions	B-MED
for	O
map	B-MED
-	I-MED
based	I-MED
cloning	I-MED
,	O
gene	B-MED
discovery	I-MED
,	O
and	O
MAS	B-MED
in	O
cotton	B-MED
breeding	B-MED
.	O
Safety	B-MED
and	O
immunogenecity	B-MED
of	O
a	O
live	O
attenuated	B-MED
Rift	B-MED
Valley	I-MED
fever	I-MED
vaccine	I-MED
(	O
CL13	B-MED
T	I-MED
)	O
in	O
camels	B-MED
Rift	B-MED
Valley	I-MED
fever	I-MED
is	O
an	O
emerging	O
zoonotic	B-MED
viral	B-MED
disease	I-MED
,	O
enzootic	B-MED
and	O
endemic	B-MED
in	O
Africa	B-MED
and	O
the	O
Arabian	B-MED
Peninsula	I-MED
,	O
which	O
poses	O
a	O
significant	B-MED
threat	B-MED
to	O
both	O
human	B-MED
and	O
animal	B-MED
health	B-MED
.	O
The	O
disease	B-MED
is	O
most	O
severe	B-MED
in	O
ruminants	B-MED
causing	B-MED
abortions	B-MED
in	O
pregnant	B-MED
animals	B-MED
,	O
especially	O
sheep	B-MED
animals	I-MED
and	O
high	O
mortality	B-MED
in	O
young	B-MED
populations	B-MED
.	O
High	O
mortality	B-MED
rates	I-MED
and	O
severe	B-MED
clinical	B-MED
manifestation	B-MED
have	O
also	O
been	O
reported	B-MED
among	O
camel	B-MED
populations	B-MED
in	O
Africa	B-MED
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	B-MED
available	B-MED
live	B-MED
vaccines	I-MED
against	O
RVF	B-MED
have	O
been	O
tested	B-MED
for	O
safety	B-MED
and	O
efficacy	B-MED
in	O
this	O
species	B-MED
.	O
In	O
this	O
study	B-MED
,	O
the	O
safety	B-MED
and	O
efficacy	B-MED
(	O
through	O
a	O
neutralizing	B-MED
antibody	I-MED
response	B-MED
)	O
of	O
the	O
thermostable	B-MED
live	I-MED
attenuated	I-MED
RVF	B-MED
CL13	I-MED
T	I-MED
vaccine	I-MED
were	O
evaluated	B-MED
in	O
camels	B-MED
in	O
two	O
different	B-MED
preliminary	B-MED
experiments	B-MED
involving	O
16	O
camels	B-MED
,	O
(	O
that	O
12	O
camels	B-MED
and	O
4	O
pregnant	B-MED
camels	B-MED
)	O
.	O
The	O
study	B-MED
revealed	B-MED
that	O
the	O
CL13	B-MED
T	I-MED
vaccine	I-MED
was	O
safe	B-MED
to	O
use	B-MED
in	O
camels	B-MED
and	O
no	O
abortions	B-MED
or	O
teratogenic	B-MED
effects	I-MED
were	O
observed	B-MED
.	O
The	O
single	O
dose	B-MED
of	O
the	O
vaccine	B-MED
stimulated	O
a	O
strong	B-MED
and	O
long	O
-	O
lasting	O
neutralizing	B-MED
antibody	I-MED
response	B-MED
for	O
up	O
to	O
12	O
months	B-MED
.	O
The	O
presence	B-MED
of	O
neutralization	B-MED
antibodies	I-MED
is	O
likely	O
to	O
correlate	B-MED
with	I-MED
protection	B-MED
;	O
however	O
protection	B-MED
would	O
need	O
to	O
be	O
confirmed	B-MED
by	I-MED
challenge	O
experiments	B-MED
using	O
the	O
virulent	B-MED
RVF	B-MED
virus	I-MED
.	O
Adverse	B-MED
events	I-MED
risk	B-MED
associated	B-MED
with	I-MED
angiogenesis	B-MED
inhibitors	I-MED
addition	O
to	O
therapy	B-MED
in	O
ovarian	B-MED
cancer	I-MED
:	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
randomized	B-MED
controlled	I-MED
trials	I-MED
Inhibition	B-MED
of	I-MED
angiogenesis	I-MED
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-MED
strategy	I-MED
for	O
advanced	B-MED
or	O
recurrent	B-MED
ovarian	I-MED
cancer	I-MED
.	O
We	O
conduct	O
this	O
meta	B-MED
-	I-MED
analysis	I-MED
to	O
investigate	B-MED
the	O
risk	B-MED
of	O
adverse	B-MED
events	I-MED
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-MED
inhibitors	I-MED
(	O
AIs	B-MED
)	O
in	O
ovarian	B-MED
cancer	I-MED
.	O
Databases	B-MED
from	O
PubMed	B-MED
,	O
Web	B-MED
of	I-MED
Science	I-MED
and	O
Cochrane	B-MED
library	I-MED
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	B-MED
studies	B-MED
.	O
Eligible	O
studies	B-MED
included	O
prospective	B-MED
randomized	I-MED
controlled	I-MED
phase	I-MED
II	I-MED
/	I-MED
III	I-MED
clinical	I-MED
trials	I-MED
evaluating	B-MED
therapy	B-MED
with	O
or	O
without	O
AIs	B-MED
for	O
ovarian	B-MED
cancer	I-MED
.	O
Summary	O
relative	B-MED
risk	I-MED
(	O
RR	B-MED
)	O
and	O
95	O
%	O
confidence	B-MED
intervals	I-MED
(	O
CIs	B-MED
)	O
were	O
calculated	B-MED
using	O
random	B-MED
-	I-MED
effects	I-MED
or	O
fixed	B-MED
-	I-MED
effects	I-MED
according	O
to	O
the	O
heterogeneity	B-MED
among	O
included	O
trials	B-MED
.	O
A	O
total	O
of	O
7,761	O
patients	B-MED
from	O
ten	O
clinical	B-MED
trials	I-MED
were	O
included	O
in	O
the	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
Pooled	B-MED
RR	B-MED
showed	O
that	O
the	O
use	B-MED
of	I-MED
AIs	B-MED
was	O
associated	B-MED
with	I-MED
a	O
statistically	O
increased	B-MED
risk	B-MED
in	O
four	O
of	O
the	O
adverse	B-MED
outcomes	B-MED
studied	O
:	O
arterial	B-MED
thromboembolic	I-MED
events	B-MED
(	O
RR	B-MED
=	O
2.0	O
)	O
,	O
gastrointestinal	B-MED
(	I-MED
GI	I-MED
)	I-MED
perforation	I-MED
(	O
RR	B-MED
=	O
3.86	O
)	O
,	O
proteinuria	B-MED
(	O
RR	B-MED
=	O
2.44	O
)	O
,	O
and	O
hypertension	B-MED
(	O
RR	B-MED
=	O
5.39	O
)	O
.	O
No	B-MED
statistically	I-MED
significant	I-MED
differences	B-MED
were	O
found	O
for	O
hemorrhagic	B-MED
events	B-MED
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	B-MED
thromboembolic	I-MED
events	B-MED
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	B-MED
adverse	B-MED
events	I-MED
(	O
p	O
=	O
0.26	O
)	O
.	O
The	O
addition	O
of	O
AIs	B-MED
to	O
therapy	B-MED
in	O
ovarian	B-MED
cancer	I-MED
did	O
significantly	O
increase	B-MED
the	O
risk	B-MED
of	O
arterial	B-MED
thromboembolic	I-MED
events	B-MED
,	O
GI	B-MED
perforation	I-MED
,	O
proteinuria	B-MED
and	O
hypertension	B-MED
,	O
but	O
not	O
for	O
venous	B-MED
thromboembolic	I-MED
events	B-MED
,	O
hemorrhagic	B-MED
events	B-MED
,	O
or	O
fatal	B-MED
adverse	B-MED
events	I-MED
.	O
The	O
Aortic	B-MED
Root	I-MED
:	O
Natural	B-MED
History	I-MED
After	O
Root	B-MED
-	I-MED
Sparing	I-MED
Ascending	I-MED
Replacement	I-MED
in	O
Nonsyndromic	B-MED
Aneurysmal	B-MED
Patients	I-MED
Leaving	O
native	B-MED
aortic	B-MED
tissue	I-MED
in	B-MED
situ	I-MED
in	O
root	B-MED
-	I-MED
sparing	I-MED
ascending	I-MED
aortic	I-MED
replacement	I-MED
raises	O
concern	B-MED
regarding	O
potential	B-MED
later	B-MED
need	B-MED
for	O
root	B-MED
reoperation	B-MED
or	O
for	O
the	O
potential	B-MED
occurrence	B-MED
of	O
localized	B-MED
dissections	B-MED
or	O
rupture	B-MED
in	O
the	O
residual	B-MED
root	B-MED
.	O
The	O
purpose	B-MED
of	I-MED
this	I-MED
study	I-MED
was	O
to	O
evaluate	B-MED
the	O
natural	B-MED
growth	I-MED
of	O
the	O
aortic	B-MED
root	I-MED
after	O
root	B-MED
-	I-MED
sparing	I-MED
aortic	I-MED
replacement	I-MED
.	O
In	O
all	O
,	O
102	O
consecutive	B-MED
patients	B-MED
(	O
mean	B-MED
age	B-MED
61.8	O
±	O
12.5	O
years	B-MED
;	O
60	O
%	O
male	B-MED
)	O
who	O
had	O
undergone	O
root	B-MED
-	I-MED
sparing	I-MED
aortic	I-MED
replacement	I-MED
had	O
sufficient	B-MED
retrievable	B-MED
information	I-MED
regarding	O
their	O
aortic	B-MED
root	I-MED
diameter	B-MED
at	O
postoperative	B-MED
baseline	B-MED
and	O
follow	B-MED
-	I-MED
up	I-MED
imaging	B-MED
by	O
computed	B-MED
tomography	I-MED
or	O
echocardiography	B-MED
.	O
The	O
annual	B-MED
growth	B-MED
rate	I-MED
was	O
evaluated	B-MED
and	O
also	O
compared	B-MED
according	O
to	O
the	O
influence	B-MED
of	O
valve	B-MED
morphology	I-MED
and	O
concomitant	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
.	O
Furthermore	O
,	O
the	O
years	B-MED
of	O
natural	B-MED
history	I-MED
that	O
would	O
require	B-MED
for	O
root	B-MED
enlargement	B-MED
to	O
meet	O
a	O
50	O
mm	B-MED
threshold	B-MED
of	O
the	O
root	B-MED
diameter	B-MED
were	O
calculated	B-MED
.	O
The	O
estimated	B-MED
growth	B-MED
rate	I-MED
of	O
the	O
aortic	B-MED
root	I-MED
after	O
root	B-MED
-	I-MED
sparing	I-MED
aortic	I-MED
replacement	I-MED
is	O
between	O
0.27	O
and	O
0.51	O
mm	B-MED
per	B-MED
year	I-MED
(	O
mean	B-MED
0.41	O
mm	B-MED
,	O
varying	O
according	O
to	O
the	O
underlying	B-MED
diameter	I-MED
)	O
and	O
therefore	O
fivefold	O
less	B-MED
than	I-MED
other	O
aortic	B-MED
regions	I-MED
.	O
Accordingly	O
,	O
a	O
root	B-MED
aneurysm	I-MED
indicating	O
reoperation	B-MED
would	O
not	O
be	O
expected	B-MED
for	O
29.1	O
years	B-MED
on	O
average	B-MED
.	O
Only	O
patients	B-MED
with	O
a	O
diameter	B-MED
of	O
45	O
mm	B-MED
or	O
more	O
are	O
at	B-MED
risk	I-MED
for	O
reoperation	B-MED
,	O
and	O
not	O
until	B-MED
at	O
least	O
after	B-MED
10.4	O
years	B-MED
have	B-MED
passed	I-MED
.	O
Neither	B-MED
the	O
valve	B-MED
morphology	I-MED
(	O
p	O
=	O
0.62	O
)	O
nor	O
concomitant	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
(	O
p	O
=	O
0.86	O
)	O
influenced	B-MED
rate	B-MED
of	O
root	B-MED
dilation	I-MED
.	O
In	O
nonsyndromic	B-MED
patients	B-MED
,	O
the	O
aortic	B-MED
root	I-MED
is	O
the	O
slowest	B-MED
growing	B-MED
portion	B-MED
of	O
the	O
thoracic	B-MED
aorta	I-MED
.	O
Leaving	O
the	O
native	B-MED
root	B-MED
,	O
as	O
in	O
root	B-MED
-	I-MED
sparing	I-MED
ascending	I-MED
aortic	I-MED
replacement	I-MED
,	O
is	O
a	O
safe	B-MED
approach	I-MED
regarding	O
secondary	B-MED
root	I-MED
intervention	B-MED
for	O
aortic	B-MED
root	I-MED
diameters	B-MED
of	O
45	O
mm	B-MED
or	O
less	O
.	O
Acute	B-MED
clinical	B-MED
adverse	B-MED
radiation	I-MED
effects	I-MED
after	O
Gamma	B-MED
Knife	I-MED
surgery	I-MED
for	O
vestibular	B-MED
schwannomas	I-MED
OBJECTIVE	O
Vestibular	B-MED
schwannomas	I-MED
(	O
VSs	B-MED
)	O
represent	O
a	O
common	O
indication	O
of	O
Gamma	B-MED
Knife	I-MED
surgery	I-MED
(	O
GKS	B-MED
)	O
.	O
While	O
most	O
studies	B-MED
focus	O
on	O
the	O
long	B-MED
-	I-MED
term	I-MED
morbidity	B-MED
and	O
adverse	B-MED
radiation	I-MED
effects	I-MED
(	O
AREs	B-MED
)	O
,	O
none	O
describe	O
the	O
acute	B-MED
clinical	B-MED
AREs	B-MED
that	O
might	O
appear	O
on	O
a	O
short	B-MED
-	I-MED
term	I-MED
basis	O
.	O
These	O
types	O
of	O
events	O
are	O
investigated	B-MED
,	O
and	O
their	O
incidence	B-MED
,	O
type	B-MED
,	O
and	O
outcomes	B-MED
are	O
reported	B-MED
in	O
the	O
present	O
paper	O
.	O
METHODS	O
The	O
included	O
patients	B-MED
were	O
treated	B-MED
between	O
July	O
2010	O
and	O
March	O
2016	O
,	O
underwent	O
at	O
least	O
6	O
months	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
,	O
and	O
presented	O
with	O
a	O
disabling	B-MED
symptom	B-MED
during	O
the	O
first	O
6	O
months	B-MED
after	O
GKS	B-MED
that	O
affected	B-MED
their	O
quality	B-MED
of	I-MED
life	I-MED
.	O
The	O
timing	O
of	O
appearance	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-MED
and	O
outcome	B-MED
,	O
were	O
noted	O
.	O
The	O
prescribed	B-MED
dose	B-MED
was	O
12	O
Gy	O
at	O
the	O
margin	O
.	O
RESULTS	O
Thirty	O
-	O
five	O
(	O
22	O
%	O
)	O
of	O
159	O
patients	B-MED
who	O
fulfilled	O
the	O
inclusion	B-MED
criteria	O
had	O
acute	B-MED
clinical	B-MED
AREs	B-MED
.	O
The	O
mean	B-MED
followup	B-MED
period	O
was	O
30	O
months	B-MED
(	O
range	B-MED
6	O
-	O
49.2	O
months	B-MED
)	O
.	O
The	O
mean	B-MED
time	O
of	O
appearance	O
was	O
37.9	O
days	B-MED
(	O
median	B-MED
31	O
days	B-MED
;	O
range	B-MED
3	O
-	O
110	O
days	B-MED
)	O
.	O
In	O
patients	B-MED
with	O
de	B-MED
novo	I-MED
symptoms	B-MED
,	O
the	O
more	O
frequent	O
symptoms	B-MED
were	O
vertigo	B-MED
(	O
n	O
=	O
4	O
;	O
11.4	O
%	O
)	O
and	O
gait	B-MED
disturbance	I-MED
(	O
n	O
=	O
3	O
;	O
8.6	O
%	O
)	O
.	O
The	O
exacerbation	B-MED
of	O
a	O
preexisting	O
symptom	B-MED
was	O
more	O
frequently	O
related	O
to	O
hearing	B-MED
loss	I-MED
(	O
n	O
=	O
10	O
;	O
28.6	O
%	O
)	O
,	O
followed	O
by	O
gait	B-MED
disturbance	I-MED
(	O
n	O
=	O
7	O
;	O
20	O
%	O
)	O
and	O
vertigo	B-MED
(	O
n	O
=	O
3	O
,	O
8.6	O
%	O
)	O
.	O
In	O
the	O
univariate	B-MED
logistic	B-MED
regression	I-MED
analysis	I-MED
,	O
the	O
following	O
factors	B-MED
were	O
statistically	B-MED
significant	I-MED
:	O
age	B-MED
(	O
p	O
=	O
0.002	O
;	O
odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
0.96	O
)	O
,	O
hearing	O
at	O
baseline	B-MED
by	O
Gardner	B-MED
-	I-MED
Robertson	I-MED
(	O
GR	B-MED
)	O
class	O
(	O
p	O
=	O
0.006	O
;	O
OR	B-MED
0.21	O
)	O
,	O
pure	B-MED
tone	I-MED
average	I-MED
at	O
baseline	B-MED
(	O
p	O
=	O
0.006	O
;	O
OR	B-MED
0.97	O
)	O
,	O
and	O
Koos	B-MED
grade	I-MED
at	O
baseline	B-MED
(	O
with	O
Koos	B-MED
Grade	I-MED
I	I-MED
used	O
as	O
a	O
reference	O
)	O
(	O
for	O
Koos	B-MED
Grade	I-MED
II	I-MED
,	O
OR	B-MED
0.17	O
and	O
p	O
=	O
0.002	O
;	O
for	O
Koos	B-MED
Grade	I-MED
III	I-MED
,	O
OR	B-MED
0.42	O
and	O
p	O
=	O
0.05	O
)	O
.	O
The	O
following	O
were	O
not	O
statistically	B-MED
significant	I-MED
but	O
showed	O
a	O
tendency	O
toward	O
significance	O
:	O
the	O
number	O
of	O
isocenters	B-MED
(	O
p	O
=	O
0.06	O
;	O
OR	B-MED
0.94	O
)	O
and	O
the	O
maximal	B-MED
dose	B-MED
received	O
by	O
the	O
cochlea	B-MED
(	O
p	O
=	O
0.07	O
;	O
OR	B-MED
0.74	O
)	O
.	O
Fractional	B-MED
polynomial	I-MED
regression	I-MED
analysis	I-MED
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	B-MED
and	O
the	O
radiation	B-MED
dose	I-MED
rate	I-MED
(	O
minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2.5	O
Gy	O
/	O
minute	O
)	O
and	O
the	O
maximal	B-MED
vestibular	B-MED
dose	B-MED
(	O
maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
Gy	O
)	O
,	O
but	O
the	O
small	O
sample	B-MED
size	I-MED
precludes	B-MED
a	O
detailed	O
analysis	B-MED
of	O
the	O
former	O
.	O
The	O
clinical	B-MED
acute	B-MED
AREs	B-MED
disappeared	O
in	O
32	O
(	O
91.4	O
%	O
)	O
patients	B-MED
during	O
the	O
first	O
6	O
months	B-MED
after	O
appearance	O
.	O
Permanent	O
and	O
somewhat	O
disabling	B-MED
morbidity	B-MED
was	O
found	O
in	O
3	O
cases	B-MED
(	O
1.9	O
%	O
from	O
the	O
whole	O
series	O
):	O
1	O
each	O
with	O
complete	B-MED
hearing	I-MED
loss	I-MED
(	O
GR	B-MED
Class	I-MED
I	I-MED
before	O
and	O
V	B-MED
after	O
)	O
,	O
hemifacial	B-MED
spasm	I-MED
(	O
persistent	B-MED
but	O
alleviated	O
)	O
,	O
and	O
dysgeusia	B-MED
.	O
CONCLUSIONS	O
Acute	B-MED
effects	B-MED
after	O
radiosurgery	B-MED
for	O
VS	B-MED
are	O
not	O
rare	O
.	O
They	O
concern	O
predominantly	O
de	B-MED
novo	I-MED
vertigo	B-MED
and	O
gait	B-MED
disturbance	I-MED
and	O
the	O
exacerbation	B-MED
of	O
preexistent	O
hearing	B-MED
loss	I-MED
.	O
In	O
de	B-MED
novo	I-MED
vestibular	B-MED
symptom	B-MED
s	O
,	O
a	O
vestibular	B-MED
dose	B-MED
of	O
more	O
than	O
8	O
Gy	O
is	O
thought	O
to	O
play	O
a	O
role	O
.	O
In	O
most	O
cases	B-MED
,	O
none	O
of	O
these	O
effects	B-MED
are	O
permanent	O
,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid	B-MED
therapy	I-MED
.	O
Permanent	O
AREs	B-MED
remain	O
very	O
rare	B-MED
.	O
Adenosine	B-MED
and	O
the	O
adenosine	B-MED
A2A	I-MED
receptor	I-MED
agonist	I-MED
,	O
CGS21680	B-MED
,	O
upregulate	B-MED
CD39	B-MED
and	O
CD73	B-MED
expression	B-MED
through	O
E2F-1	B-MED
and	O
CREB	B-MED
in	O
regulatory	B-MED
T	I-MED
cells	I-MED
isolated	B-MED
from	O
septic	B-MED
mice	B-MED
The	O
number	O
of	O
regulatory	B-MED
T	I-MED
cells	I-MED
(	O
Treg	B-MED
cells	I-MED
)	O
and	O
the	O
expression	B-MED
of	O
ectonucleoside	B-MED
triphosphate	I-MED
diphosphohydrolase	I-MED
1	I-MED
(	O
ENTPD1	B-MED
;	O
also	O
known	O
as	O
CD39	B-MED
)	O
and	O
5'-ectonucleotidase	B-MED
(	O
NT5E	B-MED
;	O
also	O
known	O
as	O
CD73	B-MED
)	O
on	O
the	O
Treg	B-MED
cell	I-MED
surface	B-MED
are	O
increased	B-MED
during	O
sepsis	B-MED
.	O
In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	B-MED
leading	O
to	O
the	O
high	B-MED
expression	B-MED
of	O
CD39	B-MED
and	O
CD73	B-MED
,	O
and	O
the	O
regulation	B-MED
of	I-MED
the	O
CD39	B-MED
/	O
CD73	B-MED
/	O
adenosine	B-MED
pathway	B-MED
in	O
Treg	B-MED
cells	I-MED
under	O
septic	B-MED
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-MED
model	I-MED
of	O
sepsis	B-MED
and	O
separated	O
the	O
Treg	B-MED
cells	I-MED
using	O
a	O
flow	B-MED
cytometer	I-MED
.	O
The	O
Treg	B-MED
cells	I-MED
isolated	B-MED
from	O
the	O
peritoneal	B-MED
lavage	I-MED
and	O
splenocytes	B-MED
of	O
the	O
mice	B-MED
were	O
treated	B-MED
with	I-MED
adenosine	B-MED
or	O
the	O
specific	O
adenosine	B-MED
A2A	I-MED
receptor	I-MED
agonist	I-MED
,	O
CGS21680	B-MED
,	O
and	O
were	O
transfected	B-MED
with	O
specific	O
siRNA	B-MED
targeting	B-MED
E2F	B-MED
transcription	I-MED
factor	I-MED
1	I-MED
(	O
E2F-1	B-MED
)	O
or	O
cyclic	B-MED
adenosine	I-MED
monophosphate	I-MED
(	I-MED
cAMP	I-MED
)	I-MED
response	I-MED
element	I-MED
-	I-MED
binding	I-MED
protein	I-MED
(	O
CREB	B-MED
)	O
,	O
which	O
are	O
predicted	O
transcription	B-MED
regulatory	I-MED
factors	I-MED
of	O
CD39	B-MED
or	O
CD73	B-MED
.	O
The	O
regulatory	B-MED
relationships	O
among	O
these	O
factors	B-MED
were	O
then	O
determined	O
by	O
western	B-MED
blot	I-MED
analysis	I-MED
and	O
dual	B-MED
-	I-MED
luciferase	I-MED
reporter	I-MED
assay	I-MED
.	O
In	O
addition	O
,	O
changes	B-MED
in	O
adenosine	B-MED
metabolism	I-MED
were	O
measured	O
in	O
the	O
treated	B-MED
cells	B-MED
.	O
The	O
results	O
revealed	O
that	O
adenosine	B-MED
and	O
CGS21680	B-MED
significantly	O
upregulated	B-MED
CD39	B-MED
and	O
CD73	B-MED
expression	B-MED
(	O
P<0.01	O
)	O
.	O
E2F-1	B-MED
and	O
CREB	B-MED
induced	O
CD39	B-MED
and	O
CD73	B-MED
expression	B-MED
,	O
and	O
were	O
upregulated	B-MED
by	O
adenosine	B-MED
and	O
CGS21680	B-MED
.	O
Adenosine	B-MED
triphosphate	I-MED
(	I-MED
ATP	I-MED
)	I-MED
hydrolysis	I-MED
and	O
adenosine	B-MED
generation	B-MED
were	O
inhibited	B-MED
by	O
the	O
knockdown	B-MED
of	O
E2F-1	B-MED
or	O
CREB	B-MED
,	O
and	O
were	O
accelerated	B-MED
in	O
the	O
presence	O
of	O
CGS21680	B-MED
.	O
Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-MED
,	O
the	O
adenosine	B-MED
A2A	I-MED
receptor	I-MED
agonist	I-MED
,	O
E2F-1	B-MED
and	O
CREB	B-MED
are	O
the	O
possible	O
factors	B-MED
contributing	O
to	O
the	O
high	B-MED
expression	B-MED
of	O
CD39	B-MED
and	O
CD73	B-MED
on	O
the	O
Treg	B-MED
cell	I-MED
surface	B-MED
during	O
sepsis	B-MED
.	O
Adenosine	B-MED
and	O
its	O
A2A	B-MED
receptor	I-MED
agonist	I-MED
served	O
as	O
the	O
signal	B-MED
transducer	I-MED
factors	B-MED
of	O
the	O
CD39	B-MED
/	O
CD73	B-MED
/	O
adenosine	B-MED
pathway	B-MED
,	O
accelerating	B-MED
adenosine	B-MED
generation	B-MED
.	O
Our	O
study	O
may	O
benefit	O
further	O
research	B-MED
on	O
adenosine	B-MED
metabolism	I-MED
for	O
the	O
treatment	B-MED
of	O
sepsis	B-MED
.	O
Variation	B-MED
in	I-MED
the	I-MED
age	I-MED
of	O
first	B-MED
reproduction	I-MED
:	O
different	B-MED
strategies	I-MED
or	O
individual	B-MED
quality	I-MED
?	O
Although	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
is	O
a	O
key	O
demographic	B-MED
parameter	I-MED
that	O
is	O
probably	O
under	O
high	B-MED
selective	I-MED
pressure	I-MED
,	O
it	O
is	O
highly	O
variable	B-MED
and	O
the	O
cause	O
of	O
this	O
variability	B-MED
is	O
not	O
well	O
understood	O
.	O
Two	O
non	O
-	O
exclusive	O
hypotheses	B-MED
may	O
explain	O
such	O
variability	B-MED
.	O
It	O
could	O
be	O
the	O
expression	B-MED
of	O
different	O
individual	B-MED
strategies	I-MED
,	O
i.e.	O
,	O
different	O
allocation	B-MED
strategies	I-MED
in	O
fitness	B-MED
components	I-MED
,	O
or	O
the	O
consequences	O
of	O
individual	B-MED
difference	I-MED
in	O
intrinsic	B-MED
quality	I-MED
,	O
i.e.	O
,	O
some	O
individuals	B-MED
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness	B-MED
components	I-MED
.	O
We	O
tested	B-MED
these	O
hypotheses	B-MED
in	O
the	O
Wandering	B-MED
Albatross	I-MED
investigating	O
relationships	B-MED
between	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
and	O
subsequent	O
adult	B-MED
demographic	B-MED
traits	B-MED
.	O
Using	O
finite	B-MED
mixture	I-MED
capture	I-MED
recapture	I-MED
modeling	I-MED
,	O
we	O
demonstrate	O
that	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
is	O
negatively	B-MED
related	O
to	O
both	O
reproductive	B-MED
performances	B-MED
and	O
adult	B-MED
survival	B-MED
,	O
suggesting	O
that	O
individual	B-MED
quality	I-MED
was	O
an	O
important	O
factor	O
explaining	O
variation	B-MED
in	O
the	O
age	B-MED
at	O
first	B-MED
reproduction	I-MED
.	O
Our	O
results	O
suggest	O
that	O
age	B-MED
at	O
first	B-MED
breeding	I-MED
is	O
a	O
good	O
predictor	B-MED
of	O
quality	B-MED
in	O
this	O
long	O
-	O
lived	O
seabird	B-MED
species	I-MED
.	O
Methodology	B-MED
development	B-MED
on	O
aquatic	B-MED
environmental	I-MED
assessment	B-MED
The	O
Water	B-MED
Framework	I-MED
Directive	I-MED
aims	B-MED
at	O
reaching	O
the	O
good	O
ecological	B-MED
status	B-MED
of	O
the	O
surface	B-MED
and	O
ground	B-MED
water	I-MED
bodies	I-MED
(	O
László	O
et	O
al	O
.	O
Microchem	O
J	O
85(1):65	O
-	O
71	O
,	O
2007	O
)	O
.	O
The	O
paper	O
deals	O
with	O
quality	B-MED
evaluation	B-MED
of	O
waters	B-MED
with	O
special	B-MED
focus	O
on	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
as	O
defined	O
in	O
the	O
Water	B-MED
Framework	I-MED
Directive	I-MED
and	O
pertaining	O
legal	B-MED
regulations	I-MED
.	O
The	O
purpose	B-MED
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	B-MED
type	O
of	O
water	B-MED
quality	B-MED
assessment	B-MED
method	B-MED
which	O
could	O
provide	B-MED
rapid	B-MED
,	O
accurate	B-MED
,	O
and	O
reliable	B-MED
information	B-MED
on	O
the	O
quality	B-MED
of	O
the	O
surface	B-MED
waters	B-MED
by	O
using	O
water	B-MED
chemistry	B-MED
parameters	B-MED
.	O
Quality	B-MED
classes	B-MED
have	O
been	O
defined	B-MED
for	O
every	O
water	B-MED
chemistry	B-MED
parameter	B-MED
in	O
light	O
of	O
the	O
legal	B-MED
limit	I-MED
values	I-MED
of	O
the	O
water	B-MED
parameters	B-MED
.	O
In	O
addition	O
to	O
this	O
,	O
weight	B-MED
indices	I-MED
were	O
calculated	B-MED
on	O
the	O
basis	O
of	O
the	O
outcome	B-MED
of	O
the	O
paired	B-MED
comparison	I-MED
of	O
water	B-MED
chemistry	B-MED
parameters	B-MED
and	O
normalized	B-MED
matrix	B-MED
.	O
This	O
was	O
followed	O
by	O
the	O
parametric	B-MED
level	I-MED
analysis	I-MED
of	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
,	O
and	O
finally	O
,	O
the	O
aquatic	B-MED
environment	I-MED
index	I-MED
(	O
AEI	B-MED
)	O
was	O
calculated	B-MED
,	O
which	O
provided	B-MED
general	B-MED
information	I-MED
on	O
the	O
quality	B-MED
of	O
water	B-MED
regarding	O
the	O
water	B-MED
chemistry	B-MED
parameters	B-MED
.	O
The	O
method	B-MED
was	O
illustrated	O
on	O
Lake	B-MED
Balaton	B-MED
,	O
Hungary	B-MED
in	O
which	O
case	O
water	B-MED
samples	B-MED
taken	O
from	O
Balatonfüred	B-MED
City	I-MED
lake	B-MED
area	B-MED
were	O
analyzed	B-MED
and	O
evaluated	B-MED
with	O
the	O
method	B-MED
devised	O
.	O
Nutrients	B-MED
influence	O
the	O
thermal	B-MED
ecophysiology	I-MED
of	O
an	O
intertidal	B-MED
macroalga	B-MED
:	O
multiple	B-MED
stressors	I-MED
or	O
multiple	B-MED
drivers	I-MED
?	O
Urbanization	B-MED
of	O
coastlines	B-MED
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	B-MED
from	O
the	O
terrestrial	B-MED
environment	I-MED
to	O
nearshore	B-MED
habitats	I-MED
.	O
While	O
such	O
nutrient	B-MED
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	B-MED
marine	B-MED
organisms	I-MED
due	O
to	O
increased	O
eutrophication	B-MED
and	O
subsequent	O
reduced	B-MED
oxygen	B-MED
,	O
they	O
could	O
also	O
have	O
positive	B-MED
effects	I-MED
(	O
i.e.	O
,	O
increased	O
food	B-MED
availability	B-MED
)	O
on	O
species	B-MED
that	O
are	O
nitrogen	B-MED
-	I-MED
limited	I-MED
such	O
as	O
macroalgae	B-MED
.	O
Nutrient	B-MED
enrichment	B-MED
in	O
this	O
environment	B-MED
thus	O
has	O
the	O
potential	B-MED
to	O
counteract	O
some	O
of	O
the	O
negative	B-MED
impacts	I-MED
of	O
increasing	B-MED
temperatures	B-MED
,	O
at	O
least	O
for	O
some	O
species	B-MED
.	O
Characterizing	O
the	O
physiological	B-MED
response	I-MED
of	O
organisms	B-MED
to	O
simultaneous	B-MED
changes	B-MED
in	O
multiple	B-MED
drivers	I-MED
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	B-MED
climate	B-MED
change	I-MED
may	O
lead	O
to	O
ecological	B-MED
responses	B-MED
at	O
more	O
local	B-MED
levels	I-MED
.	O
We	O
evaluated	O
how	O
nutrient	B-MED
enrichment	B-MED
(	O
i.e.	O
,	O
nitrogen	B-MED
availability	B-MED
)	O
affected	O
the	O
growth	B-MED
of	O
Fucus	B-MED
vesiculosus	I-MED
,	O
a	O
foundational	O
macroalgal	B-MED
species	B-MED
in	O
the	O
North	B-MED
Atlantic	I-MED
rocky	I-MED
intertidal	I-MED
zone	I-MED
,	O
and	O
found	O
that	O
nutrient	B-MED
-enriched	O
algal	B-MED
blades	I-MED
showed	O
a	O
significant	O
increase	O
in	O
tissue	B-MED
growth	I-MED
compared	O
to	O
individuals	B-MED
grown	O
under	O
ambient	B-MED
conditions	O
.	O
We	O
further	O
quantified	O
net	O
photosynthesis	B-MED
by	O
ambient	O
and	O
nutrient	B-MED
-enriched	O
tissues	B-MED
at	O
saturating	B-MED
irradiance	I-MED
over	O
a	O
range	O
of	O
temperature	B-MED
conditions	O
(	O
6	O
-	O
30	O
°	O
C	O
)	O
.	O
Respiration	B-MED
was	O
unaffected	O
by	O
nutrient	B-MED
treatment	B-MED
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	B-MED
oxygen	B-MED
production	O
for	O
nutrient	B-MED
-enriched	O
tissue	B-MED
compared	O
to	O
ambient	B-MED
,	O
but	O
only	O
at	O
elevated	B-MED
(	O
≥18	O
°	O
C	O
)	O
temperatures	B-MED
.	O
This	O
study	B-MED
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	B-MED
showing	O
the	O
complexity	O
of	O
responses	B-MED
to	I-MED
changes	I-MED
in	O
multiple	B-MED
drivers	I-MED
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	B-MED
the	O
impacts	B-MED
of	O
global	B-MED
climate	B-MED
change	I-MED
within	O
the	O
context	O
of	O
more	O
local	O
environmental	B-MED
conditions	B-MED
.	O
Gga	B-MED
-	I-MED
miR-21	I-MED
inhibits	B-MED
chicken	B-MED
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
in	O
part	O
by	O
down	B-MED
-	I-MED
regulating	I-MED
Kruppel	B-MED
-	I-MED
like	I-MED
factor	I-MED
5	I-MED
Gga	B-MED
-	I-MED
miR-21	I-MED
is	O
abundantly	O
expressed	B-MED
in	O
chicken	B-MED
pre	B-MED
-	I-MED
adipocytes	I-MED
,	O
but	O
its	O
role	O
is	O
unclear	O
.	O
The	O
present	O
study	O
investigated	B-MED
the	O
role	O
of	O
gga	B-MED
-	I-MED
miR-21	I-MED
in	O
chicken	B-MED
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
.	O
Cell	B-MED
proliferation	I-MED
assay	I-MED
and	O
gene	B-MED
expression	I-MED
analysis	I-MED
of	O
proliferating	B-MED
cell	I-MED
nuclear	I-MED
antigen	I-MED
(	O
PCNA	B-MED
)	O
showed	O
that	O
the	O
gga	B-MED
-	I-MED
miR-21	I-MED
mimic	B-MED
inhibited	B-MED
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
.	O
In	O
contrast	O
,	O
the	O
gga	B-MED
-	I-MED
miR-21	I-MED
inhibitor	B-MED
enhanced	B-MED
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
.	O
The	O
subsequent	O
investigation	B-MED
identified	O
Kruppel	B-MED
-	I-MED
like	I-MED
factor	I-MED
5	I-MED
(	O
KLF5	B-MED
)	O
mRNA	B-MED
as	O
a	O
target	B-MED
of	O
gga	B-MED
-	I-MED
miR-21	I-MED
.	O
The	O
gga	B-MED
-	I-MED
miR-21	I-MED
mimic	B-MED
inhibited	B-MED
KLF5	B-MED
3(')UTR	B-MED
reporter	B-MED
activity	B-MED
and	O
decreased	B-MED
endogenous	B-MED
KLF5	B-MED
expression	B-MED
in	O
primary	B-MED
pre	B-MED
-	I-MED
adipocytes	I-MED
.	O
KLF5	B-MED
knockdown	B-MED
using	O
RNAi	B-MED
had	O
a	O
similar	O
effect	B-MED
to	O
that	O
of	O
the	O
gga	B-MED
-	I-MED
miR-21	I-MED
mimic	B-MED
on	O
cell	B-MED
proliferation	I-MED
.	O
The	O
promoting	B-MED
effect	B-MED
of	O
the	O
gga	B-MED
-	I-MED
miR-21	I-MED
inhibitor	B-MED
on	O
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
was	O
partially	O
attenuated	B-MED
by	O
KLF5	B-MED
knockdown	B-MED
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
miR-21	B-MED
inhibits	O
chicken	B-MED
pre	B-MED
-	I-MED
adipocyte	I-MED
proliferation	B-MED
,	O
at	O
least	O
in	O
part	O
,	O
by	O
targeting	B-MED
KLF5	B-MED
.	O
Distal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
revascularization	B-MED
for	O
a	O
fusiform	B-MED
PCA	B-MED
aneurysm	B-MED
:	O
A	O
lesson	O
learned	O
The	O
need	O
for	O
revascularization	B-MED
with	O
proximal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
in	O
the	O
treatment	B-MED
of	O
giant	B-MED
and	O
fusiform	B-MED
aneurysms	I-MED
is	O
unclear	O
.	O
While	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10	O
%	O
chance	O
of	O
infarction	B-MED
following	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
,	O
recently	O
several	O
authors	B-MED
have	O
advocated	O
a	O
bypass	B-MED
prior	O
to	O
parent	O
vessel	B-MED
sacrifice	O
in	O
all	O
cases	O
.	O
We	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	B-MED
aneurysm	I-MED
of	O
the	O
right	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
at	O
the	O
P2	B-MED
-	I-MED
P3	I-MED
junction	I-MED
.	O
He	O
clinically	B-MED
failed	I-MED
a	O
balloon	B-MED
test	I-MED
occlusion	I-MED
preoperatively	B-MED
and	O
therefore	O
underwent	O
an	O
occipital	B-MED
artery	I-MED
to	O
distal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
bypass	B-MED
with	O
subsequent	O
endovascular	B-MED
occlusion	I-MED
of	I-MED
the	I-MED
parent	I-MED
vessel	I-MED
and	O
aneurysm	B-MED
.	O
Despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	B-MED
up	I-MED
cerebral	B-MED
angiography	I-MED
confirmed	O
a	O
patent	O
bypass	B-MED
,	O
the	O
patient	B-MED
still	O
developed	O
a	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
territory	B-MED
stroke	I-MED
.	O
We	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	B-MED
revascularization	B-MED
in	O
the	O
setting	O
of	O
proximal	B-MED
posterior	B-MED
cerebral	I-MED
artery	I-MED
occlusion	B-MED
does	O
not	O
guarantee	O
against	O
cerebral	B-MED
ischemia	I-MED
and	O
infarction	B-MED
even	O
in	O
those	O
patients	B-MED
that	O
fail	O
a	O
test	B-MED
occlusion	I-MED
.	O
Transcriptome	B-MED
sequencing	I-MED
and	O
de	B-MED
novo	I-MED
characterization	B-MED
of	O
Korean	B-MED
endemic	O
land	B-MED
snail	I-MED
,	O
Koreanohadra	B-MED
kurodana	I-MED
for	O
functional	O
transcripts	B-MED
and	O
SSR	B-MED
markers	B-MED
The	O
Korean	B-MED
endemic	O
land	B-MED
snail	I-MED
Koreanohadra	B-MED
kurodana	I-MED
(	O
Gastropoda	B-MED
:	O
Bradybaenidae	B-MED
)	O
found	O
in	O
humid	B-MED
areas	I-MED
of	O
broadleaf	B-MED
forests	I-MED
and	O
shrubs	B-MED
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	B-MED
are	O
declining	O
in	O
recent	O
years	B-MED
.	O
The	O
species	B-MED
is	O
poorly	O
characterized	O
at	O
the	O
genomic	B-MED
level	I-MED
that	O
limits	O
the	O
understanding	O
of	O
functions	B-MED
at	O
the	O
molecular	B-MED
and	O
genetics	B-MED
level	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
performed	O
de	B-MED
novo	I-MED
transcriptome	B-MED
sequencing	I-MED
to	O
produce	O
a	O
comprehensive	O
transcript	B-MED
dataset	B-MED
of	O
visceral	B-MED
mass	I-MED
tissue	I-MED
of	O
K.	B-MED
kurodana	I-MED
by	O
the	O
Illumina	B-MED
paired	I-MED
-	I-MED
end	I-MED
sequencing	I-MED
technology	I-MED
.	O
Over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315,924	O
contigs	B-MED
and	O
191,071	O
unigenes	B-MED
,	O
with	O
an	O
average	O
and	O
N50	B-MED
length	B-MED
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O
Overall	O
,	O
36.32	O
%	O
of	O
the	O
unigenes	B-MED
found	O
matches	O
to	O
known	O
protein	B-MED
/	O
nucleotide	B-MED
sequences	I-MED
in	O
the	O
public	B-MED
databases	I-MED
.	O
The	O
direction	B-MED
of	O
the	O
unigenes	B-MED
to	O
functional	O
categories	O
was	O
determined	O
using	O
COG	B-MED
,	O
GO	B-MED
,	O
KEGG	B-MED
,	O
and	O
InterProScan	B-MED
protein	B-MED
domain	I-MED
search	B-MED
.	O
The	O
GO	B-MED
analysis	B-MED
search	O
resulted	O
in	O
22,967	O
unigenes	B-MED
(	O
12.02	O
%	O
)	O
being	O
categorized	O
into	O
40	O
functional	B-MED
groups	I-MED
.	O
The	O
KEGG	B-MED
annotation	I-MED
revealed	O
that	O
metabolism	B-MED
pathway	I-MED
genes	B-MED
were	O
enriched	O
.	O
The	O
most	O
prominent	O
protein	B-MED
motifs	I-MED
include	O
the	O
zinc	B-MED
finger	I-MED
,	O
ribonuclease	B-MED
H	I-MED
,	O
reverse	B-MED
transcriptase	I-MED
,	O
and	O
ankyrin	B-MED
repeat	I-MED
domains	I-MED
.	O
The	O
simple	B-MED
sequence	I-MED
repeats	I-MED
(	O
SSRs	B-MED
)	O
identified	O
from	O
>	O
1	O
kb	O
length	B-MED
of	O
unigenes	B-MED
show	O
a	O
dominancy	O
of	O
dinucleotide	B-MED
repeat	I-MED
motifs	I-MED
followed	O
with	O
tri-	B-MED
and	O
tetranucleotide	B-MED
motifs	I-MED
.	O
A	O
number	O
of	O
unigenes	B-MED
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	B-MED
and	O
defense	B-MED
mechanisms	I-MED
including	O
heat	B-MED
shock	I-MED
proteins	I-MED
70	I-MED
,	O
Toll	B-MED
-	I-MED
like	I-MED
receptor	I-MED
4	I-MED
,	O
AMP	B-MED
-	I-MED
activated	I-MED
protein	I-MED
kinase	I-MED
,	O
aquaporin-2	B-MED
,	O
etc	O
.	O
Our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	B-MED
and	O
functional	O
characterization	B-MED
of	O
new	O
genes	B-MED
and	O
candidate	O
polymorphic	B-MED
SSR	B-MED
markers	B-MED
in	O
K.	B-MED
kurodana	I-MED
.	O
The	O
availability	O
of	O
transcriptome	B-MED
information	O
(	O
http://bioinfo.sch.ac.kr/submission/	B-MED
)	O
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	B-MED
study	I-MED
and	O
genetic	B-MED
diversity	I-MED
assessment	B-MED
.	O
The	O
cancer	B-MED
Warburg	B-MED
effect	I-MED
may	O
be	O
a	O
testable	B-MED
example	B-MED
of	O
the	O
minimum	B-MED
entropy	B-MED
production	B-MED
rate	I-MED
principle	B-MED
Cancer	B-MED
cells	I-MED
consume	B-MED
more	O
glucose	B-MED
by	O
glycolytic	B-MED
fermentation	I-MED
to	O
lactate	B-MED
than	O
by	O
respiration	B-MED
,	O
a	O
characteristic	B-MED
known	O
as	O
the	O
Warburg	B-MED
effect	I-MED
.	O
In	O
contrast	O
with	O
the	O
34	O
moles	B-MED
of	O
ATP	B-MED
produced	O
by	O
respiration	B-MED
,	O
fermentation	B-MED
produces	O
two	O
moles	B-MED
of	O
ATP	B-MED
per	O
mole	B-MED
of	O
glucose	B-MED
consumed	B-MED
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	B-MED
of	O
the	O
Warburg	B-MED
effect	I-MED
.	O
Productions	B-MED
of	O
free	B-MED
energy	I-MED
(	O
ΔG	B-MED
)	O
,	O
enthalpy	B-MED
(	O
ΔH	B-MED
)	O
and	O
entropy	B-MED
(	O
ΔS	B-MED
)	O
per	O
mole	B-MED
linearly	B-MED
vary	O
with	O
the	O
fraction	B-MED
(	I-MED
x	I-MED
)	I-MED
of	I-MED
glucose	B-MED
consumed	B-MED
by	O
fermentation	B-MED
that	O
is	O
frequently	B-MED
estimated	B-MED
around	O
0.9	O
.	O
Hence	O
,	O
calculation	B-MED
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	B-MED
respiration	B-MED
,	O
the	O
predominant	O
fermentative	B-MED
metabolism	B-MED
decreases	B-MED
around	O
10	O
%	O
the	O
production	B-MED
of	O
entropy	B-MED
per	O
mole	B-MED
of	O
glucose	B-MED
consumed	B-MED
in	O
cancer	B-MED
cells	I-MED
.	O
We	O
hypothesize	B-MED
that	O
increased	B-MED
fermentation	B-MED
could	O
allow	O
cancer	B-MED
cells	I-MED
to	O
accomplish	B-MED
the	O
Prigogine	B-MED
theorem	I-MED
of	O
the	O
trend	B-MED
to	O
minimize	B-MED
the	O
rate	B-MED
of	O
production	B-MED
of	O
entropy	B-MED
.	O
According	O
the	O
theorem	B-MED
,	O
open	B-MED
cellular	I-MED
systems	I-MED
near	O
the	O
steady	B-MED
state	I-MED
could	O
evolve	B-MED
to	O
minimize	B-MED
the	O
rates	B-MED
of	O
entropy	B-MED
production	B-MED
that	O
may	O
be	O
reached	O
by	O
modified	B-MED
replicating	B-MED
cells	B-MED
producing	O
entropy	B-MED
at	O
low	O
rate	B-MED
.	O
Remarkably	O
,	O
at	O
CO2	B-MED
concentrations	B-MED
above	O
930	O
ppm	B-MED
,	O
glucose	B-MED
respiration	B-MED
produces	O
less	O
entropy	B-MED
than	O
fermentation	B-MED
,	O
which	O
suggests	O
experimental	B-MED
tests	B-MED
to	O
validate	B-MED
the	O
hypothesis	B-MED
of	O
minimization	B-MED
of	O
the	O
rate	B-MED
of	O
entropy	B-MED
production	B-MED
through	O
the	O
Warburg	B-MED
effect	I-MED
.	O
Birth	B-MED
Preparedness	I-MED
and	I-MED
Complication	I-MED
Readiness	I-MED
Practice	I-MED
and	O
Associated	B-MED
Factors	B-MED
among	O
Pregnant	B-MED
Women	I-MED
,	O
Northwest	B-MED
Ethiopia	I-MED
Background	O
.	O
Little	O
is	O
known	O
about	O
birth	B-MED
preparedness	I-MED
and	I-MED
complication	I-MED
readiness	I-MED
(	O
BPCR	B-MED
)	O
plan	B-MED
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal	B-MED
mortality	I-MED
.	O
Therefore	O
,	O
this	O
study	B-MED
was	O
done	O
to	O
assess	B-MED
the	O
status	B-MED
of	O
BPCR	B-MED
and	O
associated	B-MED
factors	B-MED
among	O
pregnant	B-MED
women	I-MED
in	O
South	B-MED
Wollo	I-MED
,	O
Northwest	B-MED
Ethiopia	I-MED
,	O
by	O
involving	O
819	O
pregnant	B-MED
women	I-MED
from	O
March	O
to	O
April	O
,	O
2014	O
.	O
Data	B-MED
were	O
collected	O
by	O
using	O
pretested	O
interviewer	B-MED
administered	B-MED
questionnaire	I-MED
and	O
analyzed	B-MED
using	O
a	O
computer	B-MED
program	I-MED
of	O
SPSS	B-MED
version	I-MED
20.00	I-MED
.	O
Results	B-MED
.	O
Pregnant	B-MED
women	I-MED
who	O
were	O
prepared	B-MED
for	O
at	O
least	O
three	O
elements	B-MED
of	O
BPCR	B-MED
were	O
24.1	O
%	O
.	O
Pregnant	B-MED
women	I-MED
knowing	O
at	O
least	O
three	O
key	O
danger	B-MED
signs	I-MED
during	O
pregnancy	B-MED
,	O
delivery	B-MED
,	O
and	O
postnatal	B-MED
period	I-MED
were	O
23.2	O
%	O
,	O
22.6	O
%	O
,	O
and	O
9.6	O
%	O
,	O
respectively	O
.	O
Women	B-MED
having	O
secondary	B-MED
education	I-MED
and	O
higher	O
were	O
6.20	O
(	O
95	O
%	O
CI	B-MED
=	O
[	O
1.36	O
,	O
28.120	O
]	O
)	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-MED
than	O
illiterates	B-MED
.	O
Women	B-MED
having	O
a	O
lifetime	B-MED
history	I-MED
of	O
stillbirth	B-MED
[	O
5.80	O
(	O
1.13	O
,	O
29.63	O
)	O
]	O
,	O
attending	B-MED
ANC	B-MED
for	O
last	O
child	B-MED
pregnancy	B-MED
[	O
5.44	O
(	O
2.07	O
,	O
14.27	O
)	O
]	O
,	O
participating	B-MED
in	O
community	B-MED
BPCR	B-MED
group	B-MED
discussion	I-MED
[	O
4.36	O
(	O
1.17	O
,	O
16.26	O
)	O
]	O
,	O
and	O
having	O
their	O
male	B-MED
partner	B-MED
involved	O
in	O
BPCR	B-MED
counseling	B-MED
during	O
ANC	B-MED
follow	B-MED
-	I-MED
up	I-MED
[	O
4.45	O
(	O
1.95	O
,	O
10.16	O
)	O
]	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-MED
.	O
Conclusions	B-MED
.	O
BPCR	B-MED
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health	B-MED
communication	I-MED
by	O
involving	O
partner	B-MED
in	O
BPCR	B-MED
counseling	B-MED
.	O
A	O
child	B-MED
with	O
phenylketonuria	B-MED
and	O
focal	B-MED
segmental	I-MED
glomerulosclerosis	I-MED
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-MED
Phenylketonuria	B-MED
(	O
PKU	B-MED
)	O
is	O
the	O
most	O
common	B-MED
inborn	B-MED
error	I-MED
of	I-MED
amino	I-MED
acid	I-MED
metabolism	I-MED
.	O
Phenylalanine	B-MED
hydroxylase	I-MED
is	O
the	O
underlying	O
deficient	B-MED
enzyme	B-MED
.	O
If	O
left	O
untreated	B-MED
,	O
growth	B-MED
failure	I-MED
,	O
microcephaly	B-MED
,	O
global	B-MED
developmental	I-MED
delay	I-MED
,	O
seizures	B-MED
and	O
severe	B-MED
intellectual	I-MED
impairment	I-MED
would	O
characterize	B-MED
the	O
clinical	B-MED
picture	I-MED
of	O
PKU	B-MED
.	O
On	O
the	O
other	O
side	O
of	O
protein	B-MED
homeostasis	B-MED
lies	O
nephrotic	B-MED
syndrome	I-MED
.	O
It	O
is	O
a	O
well	O
-	O
known	O
quantitative	B-MED
defect	B-MED
due	O
to	O
significant	B-MED
proteinuria	B-MED
.	O
Focal	B-MED
segmental	I-MED
glomerulosclerosis	I-MED
(	O
FSGS	B-MED
)	O
is	O
a	O
special	B-MED
congenital	B-MED
variant	B-MED
affecting	B-MED
children	B-MED
and	O
adults	B-MED
.	O
Hereby	O
,	O
we	O
describe	O
a	O
three-	O
year	O
old	O
male	B-MED
child	B-MED
who	O
presented	B-MED
with	O
generalized	B-MED
edema	I-MED
and	O
global	B-MED
developmental	I-MED
delay	I-MED
.	O
Investigations	B-MED
revealed	B-MED
PKU	B-MED
along	O
with	O
FSGS	B-MED
.	O
We	O
assume	O
that	O
congenital	B-MED
nephrosis	I-MED
ameliorated	B-MED
the	O
picture	O
of	O
PKU	B-MED
,	O
and	O
had	O
a	O
salutary	B-MED
effect	I-MED
on	O
the	O
growth	B-MED
and	I-MED
development	I-MED
.	O
Such	O
coexistence	O
between	O
PKU	B-MED
and	O
FSGS	B-MED
has	O
n't	O
been	O
described	O
before	O
.	O
Targeting	B-MED
the	O
Nrf2	B-MED
/	O
Amyloid	B-MED
-	I-MED
Beta	I-MED
Liaison	I-MED
in	O
Alzheimer	B-MED
's	I-MED
Disease	I-MED
:	O
A	O
Rational	B-MED
Approach	I-MED
Amyloid	B-MED
is	O
a	O
prominent	B-MED
feature	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
.	O
Yet	O
,	O
a	O
linear	B-MED
linkage	B-MED
between	O
amyloid	B-MED
-	I-MED
β	I-MED
peptide	I-MED
(	O
Aβ	B-MED
)	O
and	O
the	O
disease	B-MED
onset	I-MED
and	O
progression	B-MED
has	O
recently	O
been	O
questioned	O
.	O
In	O
this	O
context	B-MED
,	O
the	O
crucial	O
partnership	B-MED
between	O
Aβ	B-MED
and	O
Nrf2	B-MED
pathways	I-MED
is	O
acquiring	B-MED
paramount	B-MED
importance	B-MED
,	O
offering	O
prospects	O
for	O
deciphering	B-MED
the	O
Aβ	B-MED
-centered	O
disease	B-MED
network	B-MED
.	O
Here	O
,	O
we	O
report	O
on	O
a	O
new	B-MED
class	O
of	O
antiaggregating	B-MED
agents	I-MED
rationally	O
designed	O
to	O
simultaneously	B-MED
activate	B-MED
transcription	I-MED
-based	O
antioxidant	B-MED
responses	B-MED
,	O
whose	O
lead	B-MED
1	I-MED
showed	O
interesting	O
properties	B-MED
in	O
a	O
preliminary	B-MED
investigation	O
.	O
Relying	O
on	O
the	O
requirements	B-MED
of	O
Aβ	B-MED
recognition	B-MED
,	O
we	O
identified	B-MED
the	O
catechol	B-MED
derivative	I-MED
12	I-MED
.	O
In	O
SH	B-MED
-	I-MED
SY5Y	I-MED
neuroblastoma	I-MED
cells	I-MED
,	O
12	B-MED
combined	B-MED
remarkable	O
free	B-MED
radical	I-MED
scavenger	I-MED
properties	B-MED
to	O
the	O
ability	O
to	O
trigger	B-MED
the	O
Nrf2	B-MED
pathway	I-MED
and	O
induce	B-MED
the	O
Nrf2	B-MED
-	O
dependent	B-MED
defensive	B-MED
gene	B-MED
NQO1	I-MED
by	O
means	O
of	O
electrophilic	B-MED
activation	I-MED
of	O
the	O
transcriptional	B-MED
response	I-MED
.	O
Moreover	O
,	O
12	O
prevented	O
the	O
formation	B-MED
of	O
cytotoxic	B-MED
stable	B-MED
oligomeric	B-MED
intermediates	I-MED
,	O
being	O
significantly	B-MED
more	B-MED
effective	B-MED
,	O
and	O
per	O
se	O
less	B-MED
toxic	I-MED
,	O
than	O
prototype	B-MED
1	I-MED
.	O
More	O
importantly	O
,	O
as	O
different	B-MED
chemical	B-MED
features	I-MED
were	O
exploited	O
to	O
regulate	B-MED
Nrf2	I-MED
and	O
Aβ	B-MED
activities	B-MED
,	O
the	O
two	O
pathways	B-MED
could	O
be	O
tuned	O
independently	O
.	O
These	O
findings	O
point	O
to	O
compound	B-MED
12	I-MED
and	O
its	O
derivatives	B-MED
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	B-MED
potential	B-MED
of	O
the	O
Nrf2	B-MED
/	O
Aβ	B-MED
cellular	B-MED
network	B-MED
,	O
laying	O
foundation	O
for	O
generating	B-MED
new	O
drug	B-MED
leads	I-MED
to	O
confront	O
AD	B-MED
.	O
Pediatric	B-MED
Hypovitaminosis	B-MED
D	I-MED
:	O
Molecular	O
Perspectives	B-MED
and	O
Clinical	B-MED
Implications	B-MED
Vitamin	B-MED
D	I-MED
,	O
a	O
secosteroid	B-MED
,	O
is	O
essential	B-MED
for	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
healthy	B-MED
bone	B-MED
in	O
both	O
the	O
adult	B-MED
and	O
pediatric	B-MED
populations	B-MED
.	O
Low	B-MED
level	I-MED
of	O
25	B-MED
-	I-MED
hydroxy	I-MED
vitamin	I-MED
D	I-MED
(	O
25-(OH)-D	B-MED
)	O
is	O
highly	O
prevalent	O
in	O
children	B-MED
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	B-MED
health	B-MED
outcomes	I-MED
including	O
rickets	B-MED
,	O
osteomalacia	B-MED
,	O
osteomalacic	B-MED
myopathy	I-MED
,	O
sarcopenia	B-MED
,	O
and	O
weakness	B-MED
,	O
growth	B-MED
retardation	I-MED
,	O
hypocalcemia	B-MED
,	O
seizure	B-MED
and	O
tetany	B-MED
,	O
autism	B-MED
,	O
cardiovascular	B-MED
diseases	I-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
cancers	B-MED
(	O
prostate	B-MED
,	O
colon	B-MED
,	O
breast	B-MED
)	O
,	O
infectious	B-MED
diseases	I-MED
(	O
viral	B-MED
,	O
tuberculosis	B-MED
)	O
,	O
and	O
autoimmune	B-MED
diseases	I-MED
,	I-MED
such	O
as	O
multiple	B-MED
sclerosis	I-MED
and	O
Hashimoto	B-MED
's	I-MED
thyroiditis	I-MED
.	O
Risk	B-MED
factors	I-MED
for	O
hypovitaminosis	B-MED
D	I-MED
are	O
people	B-MED
with	O
darker	B-MED
skin	I-MED
pigmentation	I-MED
,	O
use	B-MED
of	O
sunscreen	B-MED
,	O
insufficient	B-MED
ultraviolet	B-MED
B	I-MED
exposure	B-MED
,	O
prematurity	B-MED
,	O
living	B-MED
in	I-MED
northern	I-MED
latitudes	I-MED
,	O
malnutrition	B-MED
,	O
obesity	B-MED
,	O
exclusive	B-MED
breastfeeding	I-MED
,	O
low	B-MED
maternal	I-MED
vitamin	I-MED
D	I-MED
level	I-MED
,	O
certain	O
medications	B-MED
,	O
drinking	B-MED
unfortified	B-MED
cow	I-MED
's	I-MED
milk	I-MED
,	O
liver	B-MED
failure	I-MED
,	O
chronic	B-MED
renal	I-MED
insufficiency	I-MED
,	O
cystic	B-MED
fibrosis	I-MED
,	O
asthma	B-MED
,	O
and	O
sickle	B-MED
cell	I-MED
hemoglobinopathy	I-MED
.	O
This	O
review	B-MED
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin	B-MED
D	I-MED
deficiency	I-MED
and	O
its	O
potential	O
adverse	B-MED
health	B-MED
outcomes	I-MED
in	O
pediatric	B-MED
age	B-MED
groups	I-MED
.	O
The	O
recommended	B-MED
treatment	I-MED
regimen	I-MED
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	B-MED
.	O
A	O
new	O
light	O
on	O
Alkaptonuria	B-MED
:	O
A	O
Fourier	B-MED
-	I-MED
transform	I-MED
infrared	I-MED
microscopy	I-MED
(	O
FTIRM	B-MED
)	O
and	O
low	B-MED
energy	I-MED
X	I-MED
-	I-MED
ray	I-MED
fluorescence	I-MED
microscopy	I-MED
(	O
LEXRF	B-MED
)	O
correlative	B-MED
study	I-MED
on	O
a	O
rare	B-MED
disease	I-MED
Alkaptonuria	B-MED
(	O
AKU	B-MED
)	O
is	O
an	O
ultra	B-MED
-	I-MED
rare	I-MED
disease	I-MED
associated	B-MED
to	O
the	O
lack	B-MED
of	O
an	O
enzyme	B-MED
involved	O
in	O
tyrosine	B-MED
catabolism	I-MED
.	O
This	O
deficiency	B-MED
results	O
in	O
the	O
accumulation	B-MED
of	O
homogentisic	B-MED
acid	I-MED
(	O
HGA	B-MED
)	O
in	O
the	O
form	O
of	O
ochronotic	B-MED
pigment	I-MED
in	O
joint	B-MED
cartilage	B-MED
,	O
leading	O
to	O
a	O
severe	B-MED
arthropathy	B-MED
.	O
Secondary	B-MED
amyloidosis	I-MED
has	O
been	O
also	O
unequivocally	B-MED
assessed	B-MED
as	O
a	O
comorbidity	B-MED
of	O
AKU	B-MED
arthropathy	B-MED
.	O
Composition	O
of	O
ochronotic	B-MED
pigment	I-MED
and	O
how	O
it	O
is	O
structurally	B-MED
related	O
to	O
amyloid	B-MED
is	O
still	O
unknown	O
.	O
We	O
exploited	O
Synchrotron	B-MED
Radiation	I-MED
Infrared	B-MED
and	O
X	B-MED
-	I-MED
Ray	I-MED
Fluorescence	I-MED
microscopies	I-MED
in	O
combination	O
with	O
conventional	O
bio	B-MED
-	I-MED
assays	I-MED
and	O
analytical	B-MED
tools	O
to	O
characterize	O
chemical	B-MED
composition	I-MED
and	O
morphology	B-MED
of	O
AKU	B-MED
cartilage	B-MED
.	O
We	O
evinced	B-MED
that	O
AKU	B-MED
cartilage	B-MED
is	O
characterized	O
by	O
proteoglycans	B-MED
depletion	B-MED
,	O
increased	B-MED
Sodium	I-MED
levels	I-MED
,	O
accumulation	B-MED
of	O
lipids	B-MED
in	O
the	O
peri	B-MED
-	I-MED
lacunar	I-MED
regions	I-MED
and	O
amyloid	B-MED
formation	B-MED
.	O
We	O
also	O
highlighted	O
an	O
increase	B-MED
of	O
aromatic	B-MED
compounds	I-MED
and	O
oxygen	B-MED
-	I-MED
containing	I-MED
species	I-MED
,	O
depletion	B-MED
in	O
overall	O
Magnesium	B-MED
content	B-MED
(	O
although	O
localized	B-MED
in	O
the	O
peri	B-MED
-	I-MED
lacunar	I-MED
region	I-MED
)	O
and	O
the	O
presence	B-MED
of	O
calcium	B-MED
carbonate	I-MED
fragments	O
in	O
proximity	B-MED
of	O
cartilage	B-MED
lacunae	I-MED
.	O
We	O
highlighted	O
common	B-MED
features	O
between	O
AKU	B-MED
and	O
arthropathy	B-MED
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-MED
,	O
like	O
presence	B-MED
of	O
amyloids	B-MED
and	O
peculiar	B-MED
calcifications	B-MED
.	O
Our	O
analyses	B-MED
provide	O
a	O
unified	O
picture	O
of	O
AKU	B-MED
cartilage	B-MED
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-MED
and	O
opening	O
new	B-MED
perspectives	O
.	O
Ochronotic	B-MED
pigment	I-MED
is	O
a	O
hallmark	O
of	O
AKU	B-MED
and	O
responsible	O
of	O
tissue	B-MED
degeneration	I-MED
.	O
Conventional	O
bio	B-MED
-	I-MED
assays	I-MED
have	O
not	O
yet	O
clarified	O
its	O
composition	B-MED
and	O
its	O
structural	B-MED
relationship	B-MED
with	O
amyloids	B-MED
.	O
The	O
present	B-MED
work	B-MED
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	B-MED
of	O
new	O
analytical	B-MED
approaches	O
with	O
standardized	B-MED
analyses	B-MED
.	O
Production	O
of	O
bioactive	B-MED
conjugated	B-MED
linoleic	I-MED
acid	I-MED
by	O
the	O
multifunctional	B-MED
enolase	B-MED
from	O
Lactobacillus	B-MED
plantarum	I-MED
Lactobacillus	B-MED
plantarum	I-MED
α	B-MED
-	I-MED
enolase	I-MED
,	O
a	O
multifunctional	B-MED
-anchorless-	O
surface	B-MED
protein	I-MED
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-MED
with	O
a	O
central	O
role	O
in	O
glycolytic	B-MED
metabolism	B-MED
,	O
was	O
characterized	B-MED
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	B-MED
metabolism	I-MED
of	O
biohydrogenation	B-MED
of	O
linoleic	B-MED
acid	I-MED
,	O
catalyzing	B-MED
the	O
formation	B-MED
of	O
bioactive	B-MED
9	B-MED
-	I-MED
cis-11	I-MED
-	I-MED
trans	I-MED
-	I-MED
CLA	I-MED
through	O
dehydration	B-MED
and	O
isomerization	B-MED
of	O
10	B-MED
-	I-MED
hydroxy-12	I-MED
-	I-MED
cis	I-MED
-	I-MED
octadecenoic	I-MED
acid	I-MED
.	O
The	O
identity	O
of	O
the	O
enolase	B-MED
was	O
confirmed	O
through	O
mass	B-MED
spectrometric	I-MED
analysis	I-MED
that	O
showed	O
the	O
characteristic	O
442	O
amino	B-MED
acid	I-MED
sequence	I-MED
with	O
a	O
molecular	B-MED
mass	I-MED
of	O
48.03	O
kDa	B-MED
.	O
The	O
enolase	B-MED
was	O
not	O
capable	O
of	O
using	O
linoleic	B-MED
acid	I-MED
directly	O
as	O
a	O
substrate	B-MED
but	O
instead	O
uses	O
its	O
hydroxyl	B-MED
derivative	B-MED
10	B-MED
-	I-MED
hydroxi-12	I-MED
-	I-MED
cis	I-MED
-	I-MED
octadecenoic	I-MED
acid	I-MED
to	O
finally	O
form	O
bioactive	B-MED
conjugated	B-MED
linoleic	I-MED
acid	I-MED
.	O
Biochemical	B-MED
optimization	B-MED
studies	B-MED
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9	B-MED
-	I-MED
cis-11	I-MED
-	I-MED
trans	I-MED
-	I-MED
CLA	I-MED
and	O
maximum	O
stability	B-MED
of	O
α	B-MED
-	I-MED
enolase	I-MED
when	O
catalyzing	B-MED
this	O
reaction	B-MED
.	O
Furthermore	O
,	O
through	O
structural	B-MED
analysis	I-MED
of	O
the	O
protein	B-MED
,	O
we	O
propose	O
the	O
binding	B-MED
sites	I-MED
of	O
substrate	B-MED
and	O
product	B-MED
molecules	B-MED
that	O
were	O
characterized	B-MED
as	O
two	O
hydrophobic	B-MED
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-MED
connected	O
through	O
a	O
channel	B-MED
where	O
the	O
catalysis	B-MED
of	O
dehydration	B-MED
and	O
isomerization	B-MED
might	O
occur	O
.	O
These	O
results	O
prove	O
that	O
multifunctional	B-MED
α	B-MED
-	I-MED
enolase	I-MED
also	O
plays	O
a	O
role	O
in	O
cell	B-MED
detoxification	I-MED
from	O
polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
such	O
as	O
linoleic	B-MED
acid	I-MED
,	O
along	O
with	O
the	O
linoleate	B-MED
isomerase	I-MED
complex	B-MED
.	O
Museum	B-MED
specimen	B-MED
data	B-MED
reveal	O
emergence	O
of	O
a	O
plant	B-MED
disease	I-MED
may	O
be	O
linked	O
to	O
increases	B-MED
in	O
the	O
insect	B-MED
vector	I-MED
insect	B-MED
vector	I-MED
population	I-MED
The	O
emergence	B-MED
rate	I-MED
of	O
new	O
plant	B-MED
diseases	I-MED
is	O
increasing	B-MED
due	O
to	O
novel	O
introductions	O
,	O
climate	B-MED
change	I-MED
,	O
and	O
changes	B-MED
in	O
vector	B-MED
populations	I-MED
,	O
posing	O
risks	B-MED
to	O
agricultural	B-MED
agricultural	B-MED
sustainability	I-MED
.	O
Assessing	B-MED
and	I-MED
managing	I-MED
future	O
disease	B-MED
risks	B-MED
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary	B-MED
and	I-MED
historical	I-MED
emergence	I-MED
events	I-MED
.	O
Since	O
the	O
mid-1990s	O
,	O
potato	B-MED
growers	I-MED
in	O
the	O
western	B-MED
United	I-MED
States	I-MED
,	O
Mexico	B-MED
,	O
and	O
Central	B-MED
America	I-MED
have	O
experienced	O
severe	O
yield	B-MED
loss	I-MED
from	O
Zebra	B-MED
Chip	I-MED
disease	I-MED
and	O
have	O
responded	O
by	O
increasing	O
insecticide	B-MED
use	O
to	O
suppress	O
populations	B-MED
of	O
the	O
insect	B-MED
vector	I-MED
,	O
the	O
potato	B-MED
psyllid	I-MED
,	O
Bactericera	B-MED
cockerelli	I-MED
(	O
Hemiptera	B-MED
:	O
Triozidae	B-MED
)	O
.	O
Despite	O
the	O
severe	O
nature	O
of	O
Zebra	B-MED
Chip	I-MED
outbreaks	B-MED
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown	O
.	O
We	O
tested	O
the	O
hypotheses	B-MED
that	O
1	O
)	O
B.	B-MED
cockerelli	I-MED
occupancy	B-MED
has	O
increased	B-MED
over	O
the	O
last	O
century	B-MED
in	O
California	B-MED
and	O
2	O
)	O
such	O
increases	O
are	O
related	O
to	O
climate	B-MED
change	I-MED
,	O
specifically	O
warmer	B-MED
winters	I-MED
.	O
We	O
compiled	O
a	O
dataset	B-MED
of	O
87,000	O
museum	B-MED
specimen	B-MED
occurrence	O
records	B-MED
across	O
the	O
order	O
Hemiptera	B-MED
collected	O
between	O
1900	O
and	O
2014	O
.	O
We	O
then	O
analyzed	B-MED
changes	O
in	O
B.	B-MED
cockerelli	I-MED
distribution	O
using	O
a	O
hierarchical	B-MED
occupancy	I-MED
model	I-MED
using	O
changes	O
in	O
background	O
species	B-MED
species	B-MED
lists	I-MED
to	O
correct	O
for	O
collecting	O
effort	O
.	O
We	O
found	O
evidence	B-MED
that	O
B.	B-MED
cockerelli	I-MED
occupancy	B-MED
has	O
increased	B-MED
over	O
the	O
last	O
century	B-MED
.	O
However	O
,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate	B-MED
changes	I-MED
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	B-MED
.	O
To	O
the	O
extent	O
that	O
species	B-MED
occupancy	B-MED
is	O
related	O
to	O
abundance	O
,	O
our	O
analysis	B-MED
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	B-MED
that	O
B.	B-MED
cockerelli	I-MED
population	B-MED
abundance	O
has	O
increased	B-MED
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
B.	B-MED
cockerelli	I-MED
population	B-MED
dynamics	B-MED
to	O
Zebra	B-MED
Chip	I-MED
Zebra	B-MED
Chip	I-MED
epidemics	I-MED
.	O
Finally	O
,	O
we	O
demonstrate	O
how	O
this	O
historical	B-MED
macro	I-MED
-	I-MED
ecological	I-MED
approach	I-MED
provides	O
a	O
general	O
framework	O
for	O
comparative	B-MED
risk	I-MED
assessment	I-MED
of	O
future	O
pest	B-MED
and	O
insect	B-MED
vector	I-MED
outbreaks	B-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Elective	B-MED
Nephron	B-MED
Sparing	I-MED
Surgery	I-MED
Decreases	B-MED
Other	B-MED
Cause	I-MED
Mortality	I-MED
Relative	B-MED
to	O
Radical	B-MED
Nephrectomy	I-MED
Only	O
in	O
Specific	B-MED
Subgroups	B-MED
of	O
Patients	B-MED
with	O
Renal	B-MED
Cell	I-MED
Carcinoma	I-MED
There	O
is	O
no	O
consensus	B-MED
regarding	O
a	O
protective	B-MED
effect	I-MED
on	O
mortality	B-MED
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-MED
in	O
patients	B-MED
treated	B-MED
with	I-MED
elective	B-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
relative	B-MED
to	O
their	O
radical	B-MED
nephrectomy	I-MED
counterparts	O
.	O
We	O
test	B-MED
whether	O
the	O
protective	B-MED
effect	I-MED
of	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
relative	B-MED
to	O
radical	B-MED
nephrectomy	I-MED
is	O
universal	B-MED
or	O
present	O
in	O
specific	B-MED
subgroups	B-MED
of	O
patients	B-MED
.	O
A	O
collaborative	B-MED
database	B-MED
of	O
5	O
institutions	B-MED
was	O
queried	B-MED
to	O
evaluate	B-MED
1,783	O
patients	B-MED
without	O
chronic	B-MED
kidney	I-MED
disease	I-MED
diagnosed	B-MED
with	O
a	O
clinical	B-MED
T1	B-MED
renal	I-MED
mass	I-MED
that	O
was	O
treated	B-MED
with	I-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
or	O
radical	B-MED
nephrectomy	I-MED
.	O
Multivariable	B-MED
Cox	I-MED
regression	I-MED
analysis	I-MED
was	O
done	O
to	O
assess	B-MED
the	O
impact	B-MED
of	O
surgery	B-MED
type	O
(	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
vs	O
radical	B-MED
nephrectomy	I-MED
)	O
on	O
other	B-MED
cause	I-MED
mortality	I-MED
after	O
adjustment	O
for	O
patient	B-MED
and	O
cancer	B-MED
characteristics	B-MED
.	O
Interaction	B-MED
terms	O
were	O
used	O
to	O
test	B-MED
the	O
hypothesis	O
that	O
the	O
impact	B-MED
of	O
surgery	B-MED
type	O
varies	O
according	O
to	O
specific	B-MED
subcohorts	B-MED
of	O
patients	B-MED
.	O
Ten	B-MED
-	I-MED
year	I-MED
other	B-MED
cause	I-MED
mortality	I-MED
-free	O
survival	B-MED
rates	I-MED
were	O
90	O
%	O
and	O
88	O
%	O
after	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
and	O
radical	B-MED
nephrectomy	I-MED
,	O
respectively	O
.	O
In	O
the	O
overall	B-MED
population	B-MED
radical	B-MED
nephrectomy	I-MED
was	O
not	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
other	B-MED
cause	I-MED
mortality	I-MED
on	O
multivariable	B-MED
analysis	I-MED
compared	O
to	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
(	O
HR	B-MED
0.91	O
,	O
95	O
%	O
CI	B-MED
0.6	O
-	O
1.38	O
,	O
p	O
=	O
0.6	O
)	O
.	O
However	O
,	O
radical	B-MED
nephrectomy	I-MED
increased	B-MED
the	O
risk	B-MED
of	O
other	B-MED
cause	I-MED
mortality	I-MED
according	O
to	O
the	O
increasing	B-MED
baseline	B-MED
Charlson	B-MED
comorbidity	I-MED
index	I-MED
(	O
interaction	B-MED
test	B-MED
p	O
=	O
0.0008	O
)	O
.	O
For	O
example	O
,	O
in	O
a	O
patient	B-MED
with	O
a	O
Charlson	B-MED
comorbidity	I-MED
index	I-MED
of	O
4	O
the	O
probability	B-MED
of	O
10	B-MED
-	I-MED
year	I-MED
other	B-MED
cause	I-MED
mortality	I-MED
-free	O
survival	B-MED
was	O
86	O
%	O
after	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
and	O
60	O
%	O
after	O
radical	B-MED
nephrectomy	I-MED
.	O
Elective	B-MED
nephron	B-MED
sparing	I-MED
surgery	I-MED
does	O
not	O
improve	B-MED
other	O
cause	O
survival	B-MED
relative	B-MED
to	O
radical	B-MED
nephrectomy	I-MED
consistently	O
in	O
all	O
patients	B-MED
with	O
kidney	B-MED
cancer	I-MED
.	O
Patients	B-MED
who	O
are	O
more	O
ill	B-MED
with	O
relevant	B-MED
comorbidities	B-MED
are	O
those	O
who	O
benefit	B-MED
the	O
most	O
from	O
nephron	B-MED
sparing	I-MED
surgery	I-MED
in	O
terms	O
of	O
other	B-MED
cause	I-MED
mortality	I-MED
.	O
Morphological	B-MED
characteristics	B-MED
regulating	O
phallic	B-MED
glans	I-MED
engorgement	B-MED
in	O
the	O
American	B-MED
alligator	I-MED
The	O
distal	B-MED
part	I-MED
of	O
the	O
crocodilian	B-MED
phallus	B-MED
consists	O
of	O
a	O
bulbous	B-MED
glans	I-MED
containing	O
well	O
-	O
developed	O
vascular	B-MED
tissues	I-MED
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	B-MED
activity	I-MED
,	O
enlarging	B-MED
and	O
elaborating	O
the	O
glans	B-MED
into	O
a	O
complex	B-MED
,	O
though	O
still	O
functionally	B-MED
undefined	B-MED
,	O
copulatory	B-MED
structure	O
.	O
An	O
enlarged	B-MED
glans	B-MED
putatively	O
interacts	B-MED
with	O
the	O
female	B-MED
cloaca	B-MED
and	O
may	O
change	B-MED
the	O
shape	B-MED
of	O
her	B-MED
reproductive	I-MED
tract	I-MED
to	O
facilitate	O
insemination	B-MED
and	O
increase	B-MED
the	O
probability	B-MED
of	O
fertilization	B-MED
.	O
Here	O
,	O
we	O
investigated	O
the	O
cellular	B-MED
-	I-MED
level	I-MED
properties	I-MED
of	O
the	O
glans	B-MED
and	O
other	O
inflatable	B-MED
phallic	I-MED
tissues	I-MED
associated	O
with	O
the	O
sperm	B-MED
-conducting	O
sulcus	B-MED
spermaticus	B-MED
in	O
the	O
American	B-MED
alligator	I-MED
(	O
Alligator	B-MED
mississippiensis	I-MED
)	O
.	O
Using	O
histochemical	B-MED
staining	I-MED
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-MED
and	O
elastin	B-MED
fiber	I-MED
densities	B-MED
and	O
orientations	B-MED
in	O
these	O
tissues	B-MED
.	O
Extracellular	B-MED
matrix	I-MED
architectures	O
provided	O
insights	O
about	O
phallic	B-MED
glans	I-MED
material	O
properties	O
and	O
how	O
they	O
may	O
affect	B-MED
tissue	B-MED
strength	B-MED
and	O
flexibility	B-MED
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	B-MED
forces	B-MED
.	O
We	O
also	O
investigated	O
the	O
potential	B-MED
sources	O
of	O
fluids	B-MED
that	O
induce	B-MED
inflation	O
in	O
alligator	B-MED
phalli	B-MED
.	O
Combining	O
serial	B-MED
sectioning	I-MED
and	O
three	B-MED
-	I-MED
dimensional	I-MED
reconstruction	I-MED
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-MED
plexus	I-MED
vascular	I-MED
bodies	B-MED
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-MED
phallus	B-MED
that	O
extend	O
distally	B-MED
adjacent	I-MED
to	O
ventro	B-MED
-	I-MED
medial	I-MED
sulcus	I-MED
tissues	I-MED
.	O
Together	O
,	O
our	O
gross	B-MED
and	O
histological	B-MED
examination	I-MED
of	O
the	O
American	B-MED
alligator	I-MED
phallic	B-MED
glans	I-MED
suggests	O
that	O
its	O
tissues	B-MED
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-MED
inflation	O
to	O
expand	O
the	O
glans	B-MED
to	O
a	O
specific	O
and	O
repeatable	O
shape	B-MED
,	O
and	O
potentially	B-MED
release	O
secretory	B-MED
products	I-MED
into	O
the	O
female	B-MED
reproductive	I-MED
tract	I-MED
.	O
Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	B-MED
sexual	B-MED
selection	I-MED
,	O
by	O
mechanically	B-MED
and/or	O
chemically	O
affecting	B-MED
female	I-MED
reproductive	I-MED
physiology	I-MED
.	O
Gut	B-MED
microbiota	I-MED
after	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
gastric	I-MED
bypass	I-MED
and	O
sleeve	B-MED
gastrectomy	I-MED
in	O
a	O
diabetic	B-MED
rat	B-MED
model	B-MED
:	O
Increased	O
diversity	B-MED
and	O
associations	O
of	O
discriminant	B-MED
genera	B-MED
with	O
metabolic	B-MED
changes	B-MED
Recent	O
work	O
with	O
gut	B-MED
microbiota	I-MED
after	O
bariatric	B-MED
surgery	I-MED
is	O
limited	O
,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement	O
.	O
Given	O
the	O
role	O
of	O
the	O
gut	B-MED
microbiota	I-MED
in	O
regulating	O
host	B-MED
metabolism	B-MED
,	O
we	O
explored	O
the	O
effect	O
of	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
gastric	I-MED
bypass	I-MED
(	O
RYGB	B-MED
)	O
and	O
sleeve	B-MED
gastrectomy	I-MED
(	O
SG	B-MED
)	O
on	O
the	O
modifications	O
of	O
gut	B-MED
microbiota	I-MED
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	B-MED
intake	B-MED
and/or	O
weight	B-MED
loss	B-MED
loss	B-MED
and	O
examined	O
their	O
links	O
with	O
host	B-MED
metabolism	B-MED
.	O
Zucker	O
diabetic	B-MED
fatty	B-MED
rats	I-MED
were	O
divided	O
into	O
the	O
following	O
groups	B-MED
:	O
RYGB	B-MED
;	O
sham	B-MED
-	I-MED
operated	I-MED
with	O
pair	O
-	O
fed	O
as	O
RYGB	B-MED
;	O
sham	B-MED
-	I-MED
operated	I-MED
fed	O
ad	O
libitum	O
;	O
and	O
SG	B-MED
.	O
The	O
metabolic	B-MED
effects	I-MED
and	O
gut	B-MED
microbiota	I-MED
profile	B-MED
were	O
analyzed	B-MED
10	O
weeks	B-MED
postoperatively	O
.	O
Associations	O
between	O
discriminating	B-MED
genera	B-MED
and	O
metabolic	B-MED
markers	I-MED
after	O
RYGB	B-MED
were	O
explored	O
.	O
The	O
2	O
procedures	B-MED
induced	O
similar	O
glucose	B-MED
improvement	B-MED
and	O
increased	O
flora	B-MED
diversity	B-MED
after	O
10	O
weeks	B-MED
compared	B-MED
with	O
sham	B-MED
-	I-MED
operated	I-MED
groups	O
.	O
RYGB	B-MED
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
Proteobacteria	B-MED
/	O
Gammaproteobacteria	B-MED
and	O
Betaproteobacteria	B-MED
and	O
increased	O
emergence	O
of	O
Fusobacteria	B-MED
and	O
Clostridium	B-MED
,	O
whereas	O
SG	B-MED
resulted	O
in	O
more	O
abundant	O
Actinobacteria	B-MED
compared	B-MED
with	O
other	O
groups	O
.	O
Most	O
of	O
the	O
12	O
discriminant	B-MED
genera	B-MED
correlated	B-MED
with	O
changes	B-MED
in	O
metabolic	B-MED
phenotype	B-MED
,	O
but	O
only	O
28.6	O
%	O
of	O
these	O
correlations	B-MED
were	O
independent	O
of	O
weight	B-MED
,	O
and	O
4	O
discriminant	B-MED
genera	B-MED
still	O
negatively	O
correlated	B-MED
with	O
serum	B-MED
insulin	I-MED
level	I-MED
independent	O
of	O
food	B-MED
intake	B-MED
and	O
weight	B-MED
loss	B-MED
after	O
RYGB	B-MED
.	O
These	O
data	B-MED
demonstrate	O
that	O
RYGB	B-MED
and	O
SG	B-MED
surgery	B-MED
produced	O
similar	O
diversity	B-MED
but	O
different	O
microbiota	B-MED
compositions	O
changes	O
in	O
Zucker	O
diabetic	B-MED
fatty	B-MED
rats	I-MED
.	O
These	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	B-MED
of	O
the	O
discriminate	B-MED
microbiota	B-MED
and	O
the	O
mechanisms	B-MED
linking	O
postsurgical	B-MED
modulation	B-MED
of	O
gut	B-MED
microbiota	I-MED
and	O
improvements	B-MED
in	O
insulin	B-MED
resistance	I-MED
.	O
Malignancy	B-MED
is	O
associated	B-MED
with	I-MED
microcalcification	B-MED
and	O
higher	B-MED
AP	I-MED
/	I-MED
T	I-MED
ratio	I-MED
in	O
ultrasonography	B-MED
,	O
but	O
not	O
with	O
Hashimoto	B-MED
's	I-MED
thyroiditis	I-MED
in	O
histopathology	B-MED
in	O
patients	B-MED
with	O
thyroid	B-MED
nodules	I-MED
evaluated	O
as	O
Bethesda	B-MED
Category	I-MED
III	I-MED
(	O
AUS	B-MED
/	O
FLUS	B-MED
)	O
in	O
cytology	B-MED
The	O
predictors	B-MED
of	O
malignancy	B-MED
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-MED
in	O
nodules	B-MED
with	O
atypia	B-MED
of	I-MED
undetermined	I-MED
significance	I-MED
/	O
follicular	B-MED
lesion	I-MED
of	I-MED
undetermined	I-MED
significance	I-MED
(	O
AUS	B-MED
/	O
FLUS	B-MED
)	O
.	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B-MED
,	O
clinical	B-MED
,	O
and	O
biochemical	B-MED
predictors	I-MED
of	O
malignancy	B-MED
in	O
these	O
patients	B-MED
.	O
A	O
total	O
of	O
427	O
patients	B-MED
with	O
cytologically	B-MED
Bethesda	I-MED
Category	I-MED
III	I-MED
(	O
AUS	B-MED
/	O
FLUS	B-MED
)	O
thyroid	B-MED
nodules	I-MED
were	O
included	O
in	O
this	O
retrospective	B-MED
study	I-MED
.	O
We	O
divided	O
the	O
nodules	B-MED
into	O
two	O
subgroups	B-MED
according	O
to	O
the	O
histopathology	B-MED
as	O
benign	B-MED
and	O
malignant	B-MED
,	O
and	O
compared	O
the	O
preoperative	B-MED
ultrasonographical	B-MED
,	O
clinical	B-MED
,	O
and	O
biochemical	B-MED
findings	I-MED
.	O
In	O
overall	O
,	O
427	O
patients	B-MED
with	O
449	O
AUS	B-MED
/	O
FLUS	B-MED
nodules	B-MED
who	O
had	O
undergone	O
surgery	B-MED
,	O
the	O
rate	O
of	O
malignancy	B-MED
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O
When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-MED
was	O
25.8	O
%	O
in	O
nodules	B-MED
with	O
AUS	B-MED
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	B-MED
with	O
FLUS	B-MED
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O
The	O
vast	O
majority	O
of	O
malignant	B-MED
specimens	I-MED
in	O
histopathology	B-MED
consisted	O
of	O
papillary	B-MED
thyroid	I-MED
carcinoma	I-MED
(	O
PTC	B-MED
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O
Preoperative	B-MED
ultrasonographic	B-MED
features	I-MED
of	O
105	O
malignant	B-MED
nodules	I-MED
in	O
histopathology	B-MED
were	O
compared	O
with	O
the	O
344	O
benign	B-MED
nodules	I-MED
in	O
histopathology	B-MED
.	O
Anteroposterior	B-MED
/	I-MED
Transverse	I-MED
(	I-MED
AP	I-MED
/	I-MED
T	I-MED
)	I-MED
ratio	I-MED
was	O
significantly	O
higher	O
in	O
malignant	B-MED
group	I-MED
compared	O
to	O
benign	B-MED
group	I-MED
(	O
p	O
=	O
0.013	O
)	O
.	O
In	O
multiple	B-MED
logistic	I-MED
analysis	I-MED
,	O
we	O
found	O
that	O
higher	B-MED
AP	I-MED
/	I-MED
T	I-MED
ratio	I-MED
and	O
microcalcification	B-MED
were	O
independently	O
associated	B-MED
with	I-MED
malignancy	B-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
The	O
malignancy	B-MED
-associated	O
cut	O
-	O
off	O
value	O
of	O
AP	B-MED
/	I-MED
T	I-MED
ratio	I-MED
at	O
maximum	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
was	O
≥0.81	O
.	O
We	O
did	O
not	O
find	O
any	O
correlation	B-MED
between	O
malignancy	B-MED
and	O
Hashimoto	B-MED
's	I-MED
thyroiditis	I-MED
in	O
histopathology	B-MED
in	O
multivariate	B-MED
analysis	I-MED
(	O
p	O
>	O
0.05	O
)	O
.	O
In	O
Bethesda	B-MED
Category	I-MED
III	I-MED
nodules	I-MED
with	O
higher	B-MED
AP	I-MED
/	I-MED
T	I-MED
ratio	I-MED
and	O
microcalcification	B-MED
,	O
surgery	B-MED
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	B-MED
-	I-MED
needle	I-MED
aspiration	I-MED
biopsy	I-MED
or	O
observation	B-MED
.	O
Differential	O
control	B-MED
and	O
function	B-MED
of	O
Arabidopsis	B-MED
ProDH1	B-MED
and	O
ProDH2	B-MED
genes	I-MED
on	O
infection	B-MED
with	O
biotrophic	B-MED
and	O
necrotrophic	B-MED
pathogens	B-MED
Arabidopsis	B-MED
contains	O
two	O
proline	B-MED
dehydrogenase	I-MED
(	I-MED
ProDH	I-MED
)	I-MED
genes	I-MED
,	O
ProDH1	B-MED
and	O
ProDH2	B-MED
,	O
encoding	B-MED
for	O
homologous	B-MED
and	O
functional	B-MED
isoenzymes	B-MED
.	O
Although	O
ProDH1	B-MED
has	O
been	O
studied	O
extensively	O
,	O
especially	O
under	O
abiotic	B-MED
stress	I-MED
,	O
ProDH2	B-MED
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	B-MED
.	O
These	O
genes	B-MED
display	O
distinctive	O
expression	B-MED
patterns	B-MED
and	O
show	O
weak	B-MED
transcriptional	B-MED
co	I-MED
-	I-MED
regulation	I-MED
,	O
but	O
are	O
both	O
activated	B-MED
in	O
pathogen	B-MED
-	O
infected	B-MED
tissues	B-MED
.	O
We	O
have	O
demonstrated	O
previously	O
that	O
Arabidopsis	B-MED
plants	I-MED
with	O
silenced	B-MED
ProDH1	B-MED
/	O
2	B-MED
expression	B-MED
fail	B-MED
to	O
trigger	O
defences	B-MED
against	O
the	O
hemibiotrophic	B-MED
bacterial	B-MED
pathogen	B-MED
Pseudomonas	B-MED
syringae	I-MED
pv	I-MED
.	I-MED
tomato	I-MED
AvrRpm1	I-MED
(	O
Pst	B-MED
-	I-MED
AvrRpm1	I-MED
)	O
,	O
and	O
that	O
ProDH1	B-MED
and	O
ProDH2	B-MED
are	O
differentially	O
regulated	B-MED
by	O
salicylic	B-MED
acid	I-MED
(	O
SA	B-MED
)	O
.	O
In	O
the	O
current	O
work	O
,	O
we	O
used	O
prodh1	B-MED
and	O
prodh2	B-MED
single-	O
mutant	B-MED
plants	B-MED
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	B-MED
to	O
resistance	B-MED
against	O
Pst	B-MED
-	I-MED
AvrRpm1	I-MED
and	O
the	O
necrotrophic	B-MED
fungal	B-MED
pathogen	I-MED
Botrytis	B-MED
cinerea	I-MED
.	O
In	O
addition	O
,	O
we	O
studied	O
the	O
sensitivity	B-MED
of	O
ProDH1	B-MED
and	O
ProDH2	B-MED
to	O
the	O
jasmonic	B-MED
acid	I-MED
(	O
JA	B-MED
)	O
defence	B-MED
pathway	B-MED
.	O
We	O
found	O
that	O
ProDH1	B-MED
and	O
ProDH2	B-MED
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	B-MED
against	O
Pst	B-MED
-	I-MED
AvrRpm1	I-MED
and	O
B.	B-MED
cinerea	I-MED
.	O
However	O
,	O
ProDH2	B-MED
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	B-MED
of	O
B.	B-MED
cinerea	I-MED
growth	B-MED
.	O
Interestingly	O
,	O
ProDH1	B-MED
is	O
up	B-MED
-	I-MED
regulated	I-MED
by	O
SA	B-MED
and	O
JA	B-MED
,	O
whereas	O
ProDH2	B-MED
is	O
only	O
activated	B-MED
by	O
JA	B-MED
,	O
and	O
both	O
genes	B-MED
display	O
transcriptional	B-MED
inter	I-MED
-	I-MED
regulation	I-MED
at	O
basal	B-MED
and	O
infection	B-MED
conditions	B-MED
.	O
These	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
ProDH2	B-MED
to	O
disease	B-MED
resistance	I-MED
,	O
and	O
describe	O
the	O
differential	O
regulation	B-MED
and	O
non	O
-	O
redundant	O
but	O
complementary	B-MED
function	I-MED
of	O
both	O
enzyme	B-MED
isoforms	I-MED
in	O
infected	B-MED
tissues	B-MED
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
ProDH	B-MED
in	O
the	O
control	O
of	O
biotrophic	B-MED
and	O
necrotrophic	B-MED
pathogens	B-MED
.	O
Quantification	B-MED
of	O
intact	B-MED
plasma	B-MED
AGT	B-MED
consisting	O
of	O
oxidized	O
and	O
reduced	B-MED
conformations	I-MED
using	O
a	O
modified	O
ELISA	B-MED
The	O
pleiotropic	B-MED
actions	I-MED
of	O
the	O
renin	B-MED
-	I-MED
angiotensin	I-MED
system	I-MED
(	O
RAS	B-MED
)	O
depend	O
on	O
the	O
availability	B-MED
of	I-MED
angiotensinogen	B-MED
(	O
AGT	B-MED
)	O
which	O
generates	B-MED
angiotensin	B-MED
I	I-MED
(	O
ANG	B-MED
I	I-MED
)	O
when	O
cleaved	B-MED
by	O
renin	B-MED
.	O
Thus	O
,	O
quantification	B-MED
of	O
the	O
intact	B-MED
AGT	B-MED
(	O
iAGT	B-MED
)	O
concentrations	B-MED
is	O
important	B-MED
to	O
evaluate	O
the	O
actual	B-MED
renin	B-MED
substrate	I-MED
available	B-MED
.	O
The	O
iAGT	B-MED
conformation	B-MED
exists	O
as	O
oxidized	B-MED
AGT	I-MED
(	O
oxi	B-MED
-	I-MED
AGT	I-MED
)	O
and	O
reduced	B-MED
AGT	I-MED
(	O
red	B-MED
-	I-MED
AGT	I-MED
)	O
in	O
a	O
disulfide	B-MED
bond	I-MED
,	O
and	O
oxi	B-MED
-	I-MED
AGT	I-MED
has	O
a	O
higher	B-MED
affinity	B-MED
for	O
renin	B-MED
,	O
which	O
may	O
exacerbate	O
RAS	B-MED
-	O
associated	B-MED
diseases	I-MED
.	O
Accordingly	O
,	O
we	O
determined	B-MED
iAGT	B-MED
,	O
oxi	B-MED
-	I-MED
AGT	I-MED
,	O
and	O
red	B-MED
-	I-MED
AGT	I-MED
levels	B-MED
in	O
plasma	B-MED
from	O
rats	B-MED
and	O
mice	B-MED
.	O
Blood	B-MED
samples	I-MED
were	O
obtained	B-MED
by	O
cardiac	B-MED
puncture	I-MED
and	O
then	O
immediately	B-MED
mixed	B-MED
with	O
an	O
inhibitor	B-MED
solution	B-MED
containing	B-MED
a	O
renin	B-MED
inhibitor	I-MED
.	O
Total	B-MED
AGT	B-MED
(	O
tAGT	B-MED
)	O
levels	B-MED
were	O
measured	B-MED
by	O
tAGT	B-MED
ELISA	B-MED
which	O
detects	B-MED
both	O
cleaved	B-MED
and	O
iAGT	B-MED
.	O
iAGT	B-MED
levels	B-MED
were	O
determined	B-MED
by	I-MED
iAGT	B-MED
ELISA	B-MED
which	O
was	O
found	O
to	O
only	O
detect	B-MED
red	B-MED
-	I-MED
AGT	I-MED
.	O
Thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	B-MED
with	O
dithiothreitol	B-MED
,	O
a	O
reducing	B-MED
agent	I-MED
,	O
to	O
quantify	B-MED
total	B-MED
iAGT	B-MED
concentration	B-MED
.	O
tAGT	B-MED
levels	B-MED
in	O
rat	B-MED
and	O
mouse	B-MED
plasma	B-MED
were	O
1,839	O
±	O
139	O
and	O
1,082	O
±	O
77	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O
iAGT	B-MED
levels	B-MED
were	O
53	O
%	O
of	O
tAGT	B-MED
in	O
rat	B-MED
plasma	B-MED
but	O
only	O
22	O
%	O
in	O
mouse	B-MED
plasma	B-MED
,	O
probably	O
reflecting	O
the	O
greater	B-MED
plasma	B-MED
renin	B-MED
activity	B-MED
in	O
mice	B-MED
.	O
The	O
ratios	B-MED
of	O
oxi	B-MED
-	I-MED
AGT	I-MED
and	O
red	B-MED
-	I-MED
AGT	I-MED
were	O
∼4:1	O
(	O
rat	B-MED
)	O
and	O
16:1	O
(	O
mouse	B-MED
)	O
.	O
Plasma	B-MED
iAGT	B-MED
consists	O
of	O
oxi	B-MED
-	I-MED
AGT	I-MED
and	O
red	B-MED
-	I-MED
AGT	I-MED
,	O
suggesting	B-MED
that	O
oxidative	B-MED
stress	I-MED
can	O
influence	B-MED
ANG	B-MED
I	I-MED
generation	B-MED
by	O
the	O
AGT	B-MED
conformation	B-MED
switch	O
.	O
Furthermore	O
,	O
the	O
lower	B-MED
availability	B-MED
of	I-MED
plasma	B-MED
iAGT	B-MED
in	O
mice	B-MED
suggests	B-MED
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	B-MED
factor	B-MED
in	O
ANG	B-MED
I	I-MED
formation	B-MED
in	O
this	O
species	B-MED
.	O
Neutrophil	B-MED
and	O
Monocyte	B-MED
Function	B-MED
in	O
Patients	B-MED
with	O
Chronic	B-MED
Hepatitis	I-MED
C	I-MED
Undergoing	O
Antiviral	B-MED
Therapy	I-MED
with	O
Regimens	B-MED
Containing	O
Protease	B-MED
Inhibitors	I-MED
with	O
and	O
without	O
Interferon	B-MED
Real	B-MED
-	I-MED
life	I-MED
data	I-MED
showed	O
an	O
increased	B-MED
incidence	B-MED
of	O
bacterial	B-MED
infections	I-MED
in	O
patients	B-MED
with	O
advanced	O
liver	B-MED
disease	I-MED
receiving	B-MED
a	O
protease	B-MED
inhibitor	I-MED
PI	B-MED
(	O
PI)-containing	O
antiviral	B-MED
regimen	I-MED
against	O
hepatitis	B-MED
C	I-MED
(	O
HCV	B-MED
)	O
.	O
However	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O
We	O
hypothesized	O
that	O
PIs	B-MED
might	O
impair	O
innate	B-MED
immune	I-MED
responses	I-MED
through	O
the	O
inhibition	B-MED
of	I-MED
proteases	I-MED
participating	O
in	O
the	O
anti	B-MED
-	I-MED
bacterial	I-MED
functions	I-MED
of	O
neutrophils	B-MED
and	O
monocytes	B-MED
.	O
The	O
aims	O
of	O
the	O
study	B-MED
were	O
to	O
assess	B-MED
phagocytic	B-MED
and	I-MED
oxidative	I-MED
burst	I-MED
capacity	B-MED
in	O
neutrophils	B-MED
and	O
monocytes	B-MED
obtained	O
from	O
patients	B-MED
receiving	B-MED
a	O
PI	B-MED
containing-	O
antiviral	B-MED
regimen	I-MED
,	O
and	O
to	O
determine	O
cytokine	B-MED
secretion	I-MED
after	O
neutrophil	B-MED
stimulation	B-MED
with	O
flagellin	B-MED
.	O
Forty	O
patients	B-MED
with	O
chronic	B-MED
HCV	I-MED
(	O
80	O
%	O
with	O
cirrhosis	B-MED
)	O
were	O
enrolled	O
in	O
the	O
study	B-MED
,	O
28	O
received	B-MED
triple	B-MED
therapy	I-MED
(	O
Group	B-MED
A	I-MED
)	O
with	O
pegylated	B-MED
-	I-MED
interferon	I-MED
and	O
ribavirin	B-MED
for	O
4	O
weeks	B-MED
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	B-MED
(	O
telaprevir	B-MED
,	O
boceprevir	B-MED
or	O
simeprevir	B-MED
)	O
,	O
and	O
12	O
patients	B-MED
received	B-MED
an	O
interferon	B-MED
interferon	B-MED
-free	I-MED
regimen	I-MED
(	O
Group	B-MED
B	I-MED
)	O
with	O
simeprevir	B-MED
and	O
sofosbuvir	B-MED
.	O
Phagocytosis	B-MED
and	I-MED
oxidative	I-MED
burst	I-MED
capacity	B-MED
were	O
analyzed	O
by	O
flow	B-MED
cytometry	I-MED
at	O
baseline	B-MED
,	O
week	B-MED
4	O
,	O
and	O
week	B-MED
8	O
of	O
therapy	B-MED
.	O
In	O
neutrophils	B-MED
from	O
Group	B-MED
A	I-MED
patients	B-MED
,	O
oxidative	B-MED
burst	I-MED
rate	B-MED
and	O
oxidative	B-MED
enzymatic	B-MED
activity	I-MED
per	I-MED
cell	I-MED
significantly	O
decreased	B-MED
throughout	O
the	O
study	B-MED
period	I-MED
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O
Pairwise	B-MED
comparisons	I-MED
showed	O
a	O
decrease	B-MED
between	O
baseline	B-MED
and	O
week	B-MED
4	O
and	O
8	O
of	O
therapy	B-MED
.	O
No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	B-MED
of	O
the	O
PI	B-MED
.	O
The	O
oxidative	B-MED
enzymatic	B-MED
activity	I-MED
per	I-MED
cell	I-MED
in	O
monocytes	B-MED
significantly	O
decrease	B-MED
during	O
the	O
study	B-MED
period	I-MED
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	B-MED
from	O
baseline	B-MED
to	O
week	B-MED
8	O
of	O
therapy	B-MED
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	B-MED
from	O
Group	B-MED
A	I-MED
A.	O
None	O
of	O
these	O
findings	B-MED
were	O
observed	O
in	O
Group	B-MED
B	I-MED
patients	B-MED
.	O
Cytokine	B-MED
secretion	I-MED
did	O
not	O
significantly	O
change	O
during	O
the	O
study	B-MED
in	O
both	O
groups	B-MED
.	O
In	O
conclusion	O
,	O
our	O
data	B-MED
suggest	O
that	O
the	O
use	O
interferon	B-MED
(	O
rather	O
than	O
the	O
PI	B-MED
)	O
has	O
a	O
deleterious	B-MED
effect	I-MED
on	O
neutrophil	B-MED
and	O
monocyte	B-MED
phagocytic	B-MED
and	I-MED
oxidative	I-MED
burst	I-MED
capacity	B-MED
in	O
this	O
cohort	B-MED
of	O
patients	B-MED
with	O
HCV	B-MED
-related	O
advanced	B-MED
liver	I-MED
fibrosis	I-MED
.	O
Studying	B-MED
neuroprotective	B-MED
effect	I-MED
of	O
Atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
drug	B-MED
on	O
high	B-MED
glucose	I-MED
-	O
induced	B-MED
neurotoxicity	B-MED
in	O
undifferentiated	B-MED
PC12	B-MED
cells	I-MED
:	O
role	B-MED
of	O
NADPH	B-MED
oxidase	I-MED
Overproduction	B-MED
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
by	O
NADPH	B-MED
oxidase	I-MED
(	O
NOX	B-MED
)	O
activation	B-MED
has	O
been	O
considered	B-MED
the	O
essential	B-MED
mechanism	B-MED
induced	B-MED
by	O
hyperglycemia	B-MED
in	O
various	O
tissues	B-MED
.	O
However	O
,	O
there	O
is	O
no	B-MED
comprehensive	I-MED
study	B-MED
on	O
the	O
role	B-MED
of	O
NOXs	B-MED
in	O
high	B-MED
glucose	I-MED
HG	B-MED
(	O
HG)-	O
induced	B-MED
toxic	B-MED
effect	I-MED
in	O
neural	B-MED
tissues	I-MED
.	O
Recently	O
,	O
a	O
therapeutic	B-MED
strategy	B-MED
in	O
oxidative	B-MED
related	B-MED
pathologies	B-MED
has	O
been	O
introduced	B-MED
by	O
blocking	B-MED
the	O
undesirable	B-MED
actions	I-MED
of	O
NOX	B-MED
enzymes	I-MED
by	O
small	B-MED
molecules	I-MED
.	O
The	O
protective	B-MED
roles	B-MED
of	O
Statins	B-MED
in	O
ameliorating	B-MED
oxidative	B-MED
stress	I-MED
by	O
NOX	B-MED
inhibition	B-MED
have	O
been	O
shown	O
in	O
some	O
tissues	B-MED
except	O
neural	B-MED
.	O
We	O
hypothesized	B-MED
then	O
,	O
that	O
different	B-MED
NOXs	B-MED
may	O
have	O
role	B-MED
in	O
HG	B-MED
-	O
induced	B-MED
neural	B-MED
cell	I-MED
injury	I-MED
.	O
Furthermore	O
,	O
we	O
postulate	B-MED
that	O
Atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
may	O
modulate	B-MED
this	O
NOXs	B-MED
activity	I-MED
to	O
protect	B-MED
neural	B-MED
cells	I-MED
.	O
Undifferentiated	B-MED
PC12	B-MED
cells	I-MED
were	O
treated	B-MED
with	I-MED
HG	B-MED
(	O
140	O
mM/	O
24	B-MED
h	I-MED
)	O
in	O
the	O
presence	B-MED
and	O
absence	B-MED
of	O
Atorvastatin	B-MED
(	O
1	O
μM/	O
96	B-MED
h	I-MED
)	O
.	O
The	O
cell	B-MED
viability	I-MED
was	O
measured	B-MED
by	O
MTT	B-MED
assay	I-MED
and	O
the	O
gene	B-MED
and	O
protein	B-MED
expressions	I-MED
profile	I-MED
of	O
NOX	B-MED
(	O
1	O
-	O
4	O
)	O
were	O
determined	B-MED
by	I-MED
RT	B-MED
-	I-MED
PCR	I-MED
and	O
western	B-MED
blotting	I-MED
,	O
respectively	O
.	O
Levels	B-MED
of	O
ROS	B-MED
and	O
malondialdehyde	B-MED
(	O
MDA	B-MED
)	O
were	O
also	O
evaluated	B-MED
.	O
Gene	B-MED
and	O
protein	B-MED
expression	I-MED
levels	B-MED
of	O
NOX	B-MED
(	O
1	O
-	O
4	O
)	O
and	O
consequently	B-MED
ROS	B-MED
and	O
MDA	B-MED
levels	B-MED
were	O
elevated	B-MED
in	O
HG	B-MED
-	O
treated	B-MED
PC12	B-MED
cells	I-MED
.	O
Atorvastatin	B-MED
could	O
significantly	B-MED
decrease	B-MED
HG	B-MED
-	O
induced	B-MED
NOXs	B-MED
,	O
ROS	B-MED
and	O
MDA	B-MED
elevation	B-MED
and	O
improve	B-MED
impaired	B-MED
cell	B-MED
viability	I-MED
.	O
It	O
can	O
be	O
concluded	B-MED
that	O
HG	B-MED
could	O
elevate	B-MED
NOXs	B-MED
activity	I-MED
,	O
ROS	B-MED
and	O
MDA	B-MED
levels	B-MED
in	O
neural	B-MED
tissues	I-MED
and	O
Atorvastatin	B-MED
as	O
a	O
small	B-MED
molecule	I-MED
NOX	B-MED
inhibitor	I-MED
drug	I-MED
may	O
prevent	B-MED
and	O
delay	B-MED
diabetic	B-MED
complications	I-MED
,	O
particularly	O
neuropathy	B-MED
.	O
Characterization	B-MED
of	O
novel	B-MED
DeoR	B-MED
-	I-MED
family	I-MED
member	B-MED
from	O
the	O
Streptomyces	B-MED
ahygroscopicus	I-MED
strain	B-MED
CK-15	I-MED
that	O
acts	O
as	O
a	O
repressor	B-MED
of	O
morphological	B-MED
development	B-MED
Wuyiencin	B-MED
is	O
produced	B-MED
by	O
Streptomyces	B-MED
ahygroscopicus	I-MED
var	I-MED
.	I-MED
wuyiensis	I-MED
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
China	B-MED
as	O
an	O
industrially	B-MED
produced	B-MED
biopesticide	B-MED
to	O
control	B-MED
various	O
fungal	B-MED
diseases	I-MED
.	O
Although	O
its	O
mechanism	B-MED
of	O
action	B-MED
,	O
breeding	B-MED
,	O
and	O
fermentation	B-MED
had	O
been	O
extensively	O
characterized	B-MED
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	B-MED
functions	I-MED
that	O
affect	O
its	O
biosynthesis	B-MED
or	O
morphological	B-MED
development	B-MED
.	O
The	O
wysR3	B-MED
gene	I-MED
of	O
S.	B-MED
ahygroscopicus	I-MED
strain	B-MED
CK-15	I-MED
,	O
a	O
novel	B-MED
member	B-MED
of	O
the	O
DeoR	B-MED
family	I-MED
of	O
regulatory	B-MED
genes	I-MED
,	O
was	O
assessed	B-MED
to	O
determine	O
its	O
function	B-MED
by	O
gene	B-MED
knockdown	I-MED
.	O
Herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DeoR	B-MED
family	I-MED
proteins	I-MED
derived	O
from	O
the	O
same	O
source	B-MED
are	O
likely	O
to	O
be	O
a	O
single	B-MED
branch	B-MED
in	O
a	O
phylogenetic	B-MED
tree	I-MED
and	O
show	O
that	O
wysR3	B-MED
acts	O
as	O
a	O
repressor	B-MED
for	O
its	O
morphological	B-MED
development	B-MED
without	O
effecting	O
wuyiencin	B-MED
production	B-MED
.	O
We	O
found	O
that	O
the	O
ΔwysR3	B-MED
strain	B-MED
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	B-MED
stage	B-MED
of	O
maximum	O
biomass	B-MED
at	O
60	O
h	O
,	O
which	O
is	O
~12	O
h	O
faster	B-MED
than	O
the	O
wild	B-MED
-	I-MED
type	I-MED
strain	B-MED
.	O
In	O
the	O
industrial	B-MED
fermentation	B-MED
production	B-MED
process	B-MED
,	O
the	O
ΔwysR3	B-MED
strain	B-MED
can	O
reduce	B-MED
consumption	B-MED
and	O
save	O
both	O
time	B-MED
and	O
money	B-MED
.	O
Role	B-MED
of	O
cysteine	B-MED
residues	B-MED
in	O
regulation	B-MED
of	O
peptidyl	B-MED
-	I-MED
prolyl	I-MED
cis	I-MED
-	I-MED
trans	I-MED
isomerase	I-MED
activity	I-MED
of	O
wheat	B-MED
cyclophilin	B-MED
TaCYPA-1	B-MED
Oxidative	B-MED
conditions	B-MED
result	O
in	O
inhibition	B-MED
of	O
peptidyl	B-MED
-	I-MED
prolyl	I-MED
cis	I-MED
-	I-MED
trans	I-MED
isomerase	I-MED
(	I-MED
PPIase	I-MED
)	I-MED
activity	I-MED
of	O
several	O
cyclophilins	B-MED
.	O
Thiol	B-MED
groups	O
have	O
been	O
implicated	O
in	O
redox	B-MED
regulation	B-MED
of	O
these	O
proteins	B-MED
.	O
In	O
our	O
previous	O
study	O
,	O
we	O
proposed	O
that	O
activity	B-MED
of	O
wheat	B-MED
cyclophilin	B-MED
,	O
TaCYPA-1	B-MED
,	O
may	O
be	O
modulated	B-MED
through	O
a	O
novel	O
dual	O
mechanism	B-MED
of	O
redox	B-MED
regulation	B-MED
.	O
To	O
further	O
understand	O
the	O
regulation	B-MED
of	O
PPIase	B-MED
activity	I-MED
of	O
TaCYPA-1	B-MED
,	O
we	O
generated	O
mutants	B-MED
of	O
TaCYPA-1	B-MED
by	O
substituting	B-MED
cysteine	B-MED
residues	B-MED
at	O
positions	B-MED
-40	O
and	O
-122	O
with	O
serine	B-MED
,	O
and	O
at	O
-126	O
with	O
proline	B-MED
.	O
Comparative	B-MED
analysis	I-MED
of	O
their	O
PPIase	B-MED
activity	I-MED
revealed	O
that	O
catalytic	B-MED
efficiencies	B-MED
(	O
Kcat	O
/	O
Km	O
)	O
of	O
TaCYPA-1C40S	B-MED
(	O
0.37	O
X	O
106	O
M-1	O
s-1	O
)	O
and	O
TaCYPA-1C122S	B-MED
(	O
0.31	O
X	O
106	O
M-1	O
s-1	O
)	O
were	O
significantly	B-MED
lower	I-MED
as	O
compared	O
to	O
the	O
native	O
TaCYPA-1	B-MED
(	O
1.33	O
X	O
106	O
M-1	O
s-1	O
)	O
,	O
whereas	O
Kcat	O
/	O
Km	O
of	O
the	O
double	O
mutant	B-MED
TaCYPA-1C40S	B-MED
/	I-MED
C122S	I-MED
was	O
significantly	B-MED
higher	I-MED
(	O
2.36	O
X	O
106	O
M-1	O
s-1	O
)	O
.	O
Compared	O
to	O
wild	B-MED
-	I-MED
type	I-MED
TaCYPA-1	B-MED
,	O
the	O
different	O
mutants	B-MED
also	O
showed	O
differential	B-MED
sensitivity	B-MED
to	O
Cu2	B-MED
+	I-MED
.	O
Furthermore	O
,	O
the	O
results	B-MED
of	O
this	O
study	B-MED
also	O
revealed	B-MED
that	O
despite	O
lacking	B-MED
PPIase	B-MED
activity	I-MED
,	O
the	O
mutant	B-MED
TaCYPA-1C126P	B-MED
was	O
able	O
to	O
confer	O
partial	B-MED
protection	B-MED
against	O
heat	B-MED
stress	I-MED
.	O
These	O
observations	B-MED
suggest	O
that	O
the	O
mechanism	B-MED
of	O
TaCYPA-1	B-MED
-induced	O
thermotolerance	B-MED
may	O
also	O
involve	O
other	O
activities	B-MED
besides	O
cis	B-MED
to	I-MED
trans	I-MED
isomerisation	I-MED
,	O
which	O
needs	O
to	O
be	O
identified	B-MED
further	O
.	O
Manipulation	O
of	O
an	O
existing	O
crystal	B-MED
form	I-MED
unexpectedly	B-MED
results	I-MED
in	O
interwoven	B-MED
packing	I-MED
networks	I-MED
with	O
pseudo	B-MED
-	I-MED
translational	I-MED
symmetry	I-MED
Nonribosomal	B-MED
peptide	I-MED
synthetases	I-MED
(	O
NRPSs	B-MED
)	O
are	O
multimodular	B-MED
enzymes	I-MED
that	O
synthesize	B-MED
a	O
myriad	B-MED
of	O
diverse	B-MED
molecules	I-MED
.	O
Tailoring	B-MED
domains	I-MED
have	O
been	O
co	O
-	O
opted	O
into	O
NRPSs	B-MED
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal	B-MED
peptide	I-MED
products	I-MED
.	O
Linear	B-MED
gramicidin	I-MED
synthetase	I-MED
contains	B-MED
a	O
unique	O
formylation	B-MED
-	O
tailoring	B-MED
domain	I-MED
in	O
its	O
initiation	B-MED
module	I-MED
(	O
F	B-MED
-	I-MED
A	I-MED
-	O
PCP	B-MED
)	O
.	O
The	O
structure	O
of	O
the	O
F	B-MED
-	I-MED
A	I-MED
di	B-MED
-	I-MED
domain	I-MED
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal	B-MED
form	I-MED
which	O
had	O
large	O
solvent	B-MED
channels	B-MED
and	O
no	B-MED
density	I-MED
for	O
the	O
minor	O
Asub	B-MED
subdomain	I-MED
.	O
An	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	B-MED
by	O
removing	B-MED
the	O
Asub	B-MED
subdomain	I-MED
from	O
the	O
construct	O
(	O
F	B-MED
-	I-MED
A	I-MED
Δ	O
sub	B-MED
)	O
in	O
order	O
to	O
produce	O
a	O
crystal	B-MED
that	O
could	O
accommodate	O
the	O
PCP	B-MED
domain	I-MED
.	O
In	O
the	O
resulting	O
crystal	B-MED
the	O
original	B-MED
packing	I-MED
network	I-MED
was	O
still	O
present	O
,	O
but	O
a	O
second	B-MED
network	I-MED
with	O
the	O
same	O
packing	B-MED
and	O
almost	O
no	O
contact	O
with	O
the	O
original	B-MED
network	I-MED
took	O
the	O
place	O
of	O
the	O
solvent	B-MED
channels	B-MED
and	O
changed	O
the	O
space	B-MED
group	I-MED
of	I-MED
the	I-MED
crystal	I-MED
.	O
Metatranscriptomics	B-MED
Reveals	O
the	O
Active	O
Bacterial	B-MED
and	O
Eukaryotic	B-MED
Fibrolytic	I-MED
Communities	I-MED
in	O
the	O
Rumen	B-MED
of	O
Dairy	B-MED
Cow	I-MED
Fed	O
a	O
Mixed	B-MED
Diet	B-MED
Ruminants	B-MED
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	B-MED
from	O
the	O
degradation	B-MED
of	O
plant	B-MED
polysaccharides	B-MED
through	O
the	O
activity	B-MED
of	O
the	O
rumen	B-MED
microbiota	B-MED
.	O
Although	O
this	O
process	B-MED
is	O
well	O
studied	O
in	B-MED
vitro	I-MED
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota	B-MED
members	I-MED
and	O
enzymes	B-MED
in	B-MED
vivo	I-MED
.	O
The	O
present	O
study	O
used	O
RNA	B-MED
-	I-MED
sequencing	I-MED
to	O
reveal	O
both	O
the	O
expression	B-MED
of	O
genes	B-MED
encoding	O
carbohydrate	B-MED
-	I-MED
active	I-MED
enzymes	I-MED
(	O
CAZymes	B-MED
)	O
by	O
the	O
rumen	B-MED
microbiota	B-MED
of	O
a	O
lactating	B-MED
dairy	I-MED
cow	I-MED
and	O
the	O
microorganisms	B-MED
forming	O
the	O
fiber	B-MED
-degrading	O
community	B-MED
.	O
Functional	B-MED
analysis	I-MED
identified	O
12,237	O
CAZymes	B-MED
,	O
accounting	O
for	O
1	O
%	O
of	O
the	O
transcripts	B-MED
.	O
The	O
CAZyme	B-MED
profile	O
was	O
dominated	O
by	O
families	O
GH94	B-MED
(	O
cellobiose	B-MED
-	I-MED
phosphorylase	I-MED
)	O
,	O
GH13	B-MED
(	O
amylase	B-MED
)	O
,	O
GH43	B-MED
and	O
GH10	B-MED
(	O
hemicellulases	B-MED
)	O
,	O
GH9	B-MED
and	O
GH48	B-MED
(	O
cellulases	B-MED
)	O
,	O
PL11	B-MED
(	O
pectinase	B-MED
)	O
as	O
well	O
as	O
GH2	B-MED
and	O
GH3	B-MED
(	O
oligosaccharidases	B-MED
)	O
.	O
Our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic	B-MED
bacteria	I-MED
(	O
Prevotella	B-MED
,	O
Ruminocccus	B-MED
and	O
Fibrobacter	B-MED
)	O
,	O
and	O
highlight	O
a	O
substantial	O
,	O
although	O
most	O
probably	O
underestimated	O
,	O
contribution	B-MED
of	O
fungi	B-MED
and	O
ciliate	B-MED
protozoa	I-MED
to	O
polysaccharide	B-MED
degradation	B-MED
.	O
Particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	B-MED
in	O
the	O
rumen	B-MED
.	O
Moreover	O
,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic	B-MED
bacterial	I-MED
community	I-MED
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
CAZyme	B-MED
transcripts	B-MED
originated	O
from	O
distantly	O
related	O
strains	B-MED
.	O
These	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-MED
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-MED
microbial	B-MED
community	I-MED
and	O
opportunities	O
to	O
circumvent	O
them	O
.	O
Draft	B-MED
Genome	I-MED
Sequence	B-MED
of	O
Providencia	B-MED
stuartii	I-MED
PS71	I-MED
,	O
a	O
Multidrug	B-MED
-	I-MED
Resistant	I-MED
Strain	B-MED
Associated	B-MED
with	I-MED
Nosocomial	B-MED
Infections	I-MED
in	O
Greece	B-MED
Providencia	B-MED
stuartii	I-MED
is	O
frequently	B-MED
associated	B-MED
with	I-MED
nosocomial	B-MED
outbreaks	I-MED
and	O
displays	O
intrinsic	B-MED
resistance	B-MED
to	O
many	O
commonly	B-MED
used	O
antimicrobials	B-MED
.	O
We	O
report	O
here	O
the	O
draft	B-MED
genome	I-MED
sequence	B-MED
of	O
a	O
P.	B-MED
stuartii	I-MED
strain	I-MED
carrying	O
acquired	B-MED
resistance	B-MED
genes	I-MED
conferring	O
panresistance	B-MED
to	O
cephalosporins	B-MED
(	O
blaSHV-5	B-MED
and	O
blaVEB-1	B-MED
)	O
,	O
carbapenems	B-MED
(	O
blaVIM-1	B-MED
)	O
,	O
and	O
aminoglycosides	B-MED
(	O
rmtB	B-MED
)	O
involved	O
in	O
an	O
outbreak	B-MED
in	O
Greek	B-MED
hospitals	B-MED
.	O
Interventions	B-MED
to	O
Improve	B-MED
Grandparent	B-MED
Caregivers	B-MED
'	I-MED
Mental	B-MED
and	O
Physical	B-MED
Health	I-MED
:	O
An	O
Integrative	B-MED
Review	I-MED
The	O
aim	B-MED
of	O
this	O
integrative	B-MED
review	I-MED
is	O
to	O
appraise	O
grandparent	B-MED
caregiver	B-MED
interventions	B-MED
that	O
are	O
designed	O
to	O
improve	B-MED
their	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
.	O
A	O
database	B-MED
search	B-MED
was	O
performed	O
to	O
identify	O
relevant	B-MED
studies	B-MED
published	B-MED
between	O
January	O
1	O
,	O
1980	O
,	O
and	O
December	O
31	O
,	O
2014	O
.	O
Thirteen	O
publications	B-MED
,	O
including	O
11	O
studies	B-MED
,	O
met	O
all	O
inclusion	B-MED
and	O
exclusion	B-MED
criteria	I-MED
.	O
All	O
studies	B-MED
included	O
grandparent	B-MED
mental	B-MED
health	I-MED
outcomes	B-MED
with	O
fewer	O
focusing	O
on	O
physical	B-MED
health	I-MED
and	O
social	B-MED
relations	I-MED
.	O
Improvements	B-MED
were	O
found	O
in	O
all	O
three	O
areas	B-MED
with	O
fewer	O
improvements	B-MED
seen	O
in	O
physical	B-MED
health	I-MED
.	O
However	O
,	O
small	B-MED
effect	I-MED
sizes	I-MED
were	O
seen	O
with	O
most	O
measures	B-MED
of	O
these	O
outcomes	B-MED
.	O
Although	O
the	O
interventions	B-MED
led	O
to	O
positive	O
grandparent	B-MED
caregiver	B-MED
outcomes	O
,	O
the	O
studies	B-MED
were	O
limited	B-MED
by	O
their	O
design	B-MED
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
Also	O
,	O
interventions	B-MED
did	O
not	O
consider	O
variations	B-MED
in	O
the	O
grandchild	B-MED
's	I-MED
or	O
parent	B-MED
's	I-MED
ages	B-MED
or	O
if	O
the	O
grandparent	B-MED
provided	O
primary	B-MED
or	O
shared	B-MED
care	B-MED
.	O
These	O
gaps	O
should	O
be	O
addressed	O
in	O
future	B-MED
research	B-MED
.	O
Perspectives	B-MED
on	O
cardiovascular	B-MED
effects	B-MED
of	I-MED
incretin	B-MED
-based	O
drugs	B-MED
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
Recently	O
,	O
cardiovascular	B-MED
outcome	B-MED
trials	B-MED
with	O
glucose	B-MED
-lowering	O
drugs	B-MED
used	O
in	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
,	O
namely	O
glucagon	B-MED
-	I-MED
like	I-MED
peptide-1	I-MED
receptor	I-MED
agonists	B-MED
(	O
GLP-1RA	B-MED
)	O
,	O
liraglutide	B-MED
and	O
semaglutide	B-MED
,	O
showed	O
a	O
reduction	B-MED
in	O
cardiovascular	B-MED
events	I-MED
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B-MED
with	O
other	O
incretin	B-MED
-based	O
drugs	B-MED
,	O
such	O
as	O
lixisenatide	B-MED
or	O
with	O
dipeptidyl	B-MED
peptidase-4	I-MED
inhibitors	I-MED
(	O
DPP4i	B-MED
)	O
.	O
Mechanisms	B-MED
underlying	O
the	O
observed	O
cardiovascular	B-MED
differences	B-MED
between	O
DPP4i	B-MED
and	O
GLP1	B-MED
-	I-MED
RA	I-MED
,	O
and	O
across	O
individual	O
GLP1	B-MED
-	I-MED
RA	I-MED
are	O
poorly	O
understood	O
.	O
This	O
review	B-MED
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	B-MED
from	O
experimental	B-MED
and	O
mechanistic	B-MED
studies	I-MED
on	O
the	O
action	B-MED
of	O
GLP1	B-MED
-	I-MED
RA	I-MED
and	O
DPP4i	B-MED
on	O
the	O
cardiovascular	B-MED
system	I-MED
,	O
both	O
deriving	O
from	O
clinical	B-MED
and	O
pre	B-MED
-	I-MED
clinical	I-MED
sources	I-MED
.	O
The	O
results	B-MED
of	O
cardiovascular	B-MED
outcome	B-MED
trials	B-MED
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B-MED
preclinical	B-MED
data	I-MED
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B-MED
failure	I-MED
results	B-MED
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	B-MED
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	B-MED
of	O
cardioprotection	B-MED
of	O
incretin	B-MED
-based	O
drugs	B-MED
.	O
In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-MED
cardiovascular	B-MED
effects	B-MED
of	I-MED
a	O
direct	O
cardiac	B-MED
action	B-MED
of	O
GLP-1	B-MED
metabolites	B-MED
through	O
GLP-1	B-MED
receptor	I-MED
-independent	O
pathways	B-MED
,	O
and	O
of	O
DPP4	B-MED
substrates	B-MED
other	O
than	O
GLP-1	B-MED
.	O
Physical	B-MED
Exercise	I-MED
for	O
Late	B-MED
-	I-MED
Life	I-MED
Depression	B-MED
:	O
Effects	B-MED
on	O
Heart	B-MED
Rate	I-MED
Variability	B-MED
Late	B-MED
-	I-MED
life	I-MED
major	B-MED
depression	I-MED
is	O
associated	B-MED
with	I-MED
increased	B-MED
cardiovascular	B-MED
risk	I-MED
and	O
impaired	B-MED
autonomic	I-MED
control	I-MED
of	I-MED
the	I-MED
heart	I-MED
,	O
as	O
evident	O
from	O
reduced	B-MED
heart	B-MED
rate	I-MED
variability	B-MED
(	O
HRV	B-MED
)	O
.	O
Moreover	O
,	O
antidepressant	B-MED
drug	I-MED
therapy	B-MED
also	O
might	O
be	O
associated	B-MED
with	I-MED
further	O
reductions	B-MED
of	O
HRV	B-MED
.	O
In	O
the	O
SEEDS	B-MED
study	I-MED
,	O
we	O
investigated	O
whether	O
sertraline	B-MED
associated	B-MED
with	I-MED
physical	B-MED
exercise	I-MED
protocols	O
led	O
to	O
improvements	B-MED
of	O
HRV	B-MED
,	O
compared	O
with	O
antidepressant	B-MED
drug	I-MED
therapy	B-MED
alone	O
.	O
Single	B-MED
-	I-MED
blind	I-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
Psychiatric	B-MED
consultation	I-MED
-liaison	O
program	O
for	O
primary	B-MED
care	I-MED
.	O
Patients	B-MED
aged	O
65	O
-	O
85	O
years	O
with	O
major	B-MED
depression	I-MED
,	O
recruited	O
from	O
primary	B-MED
care	I-MED
.	O
Sertraline	B-MED
plus	O
structured	O
,	O
tailored	B-MED
group	I-MED
physical	B-MED
exercise	I-MED
(	O
S	B-MED
+	I-MED
EX	I-MED
)	O
versus	O
sertraline	B-MED
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	B-MED
.	O
HRV	B-MED
indices	B-MED
(	O
RR	O
,	O
percentage	B-MED
of	I-MED
NN	I-MED
intervals	I-MED
greater	I-MED
than	I-MED
50	I-MED
msec	I-MED
[	O
pNN50	B-MED
]	O
,	O
square	B-MED
root	I-MED
of	I-MED
the	I-MED
mean	I-MED
squared	I-MED
differences	I-MED
of	I-MED
successive	I-MED
NN	I-MED
intervals	I-MED
[	O
RMSSD	B-MED
]	O
,	O
standard	B-MED
deviation	I-MED
of	O
heart	B-MED
rate	I-MED
[	O
SDHR	B-MED
]	O
,	O
standard	B-MED
deviation	I-MED
of	I-MED
the	I-MED
NN	I-MED
interval	I-MED
[	O
SDNN	B-MED
]	O
,	O
high	B-MED
-	I-MED
frequency	I-MED
band	I-MED
[	O
HF	B-MED
]	O
,	O
low	B-MED
-	I-MED
frequency	I-MED
band	I-MED
[	O
LF	B-MED
]	O
,	O
and	O
their	O
ratio	B-MED
[	O
LF	B-MED
/	I-MED
HF	I-MED
]	O
)	O
were	O
measured	B-MED
at	O
baseline	B-MED
,	O
week	B-MED
12	O
,	O
and	O
week	B-MED
24	O
.	O
Psychiatric	B-MED
and	O
medical	B-MED
assessments	I-MED
.	O
Participants	B-MED
displayed	O
significant	O
improvements	B-MED
of	O
most	O
HRV	B-MED
indices	B-MED
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	B-MED
,	O
RMSSD	B-MED
,	O
SDHR	B-MED
,	O
SDNN	B-MED
,	O
HF	B-MED
,	O
LF	B-MED
,	O
and	O
LF	B-MED
/	I-MED
HF	I-MED
)	O
.	O
Moreover	O
,	O
patients	B-MED
in	O
the	O
S	B-MED
+	I-MED
EX	I-MED
group	I-MED
displayed	O
greater	O
increases	B-MED
of	O
different	O
HRV	B-MED
indices	B-MED
(	O
RR	B-MED
,	O
pNN50	B-MED
,	O
RMSSD	B-MED
,	O
SDHR	B-MED
,	O
SDNN	B-MED
,	O
HF	B-MED
,	O
and	O
LF	B-MED
)	O
compared	O
with	O
those	O
in	O
the	O
S	B-MED
group	I-MED
.	O
The	O
combination	B-MED
of	O
structured	O
physical	B-MED
exercise	I-MED
and	O
sertraline	B-MED
might	O
exert	O
positive	B-MED
effects	B-MED
on	O
the	O
autonomic	B-MED
control	I-MED
of	I-MED
the	I-MED
heart	I-MED
among	O
older	O
patients	B-MED
with	O
major	B-MED
depression	I-MED
.	O
Effect	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
on	O
the	O
pharmacokinetics	B-MED
and	O
transplacental	B-MED
transfer	I-MED
of	O
nifedipine	B-MED
in	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
Diabetes	B-MED
mellitus	I-MED
can	O
inhibit	B-MED
cytochrome	B-MED
P450	I-MED
3A4	I-MED
,	O
an	O
enzyme	B-MED
responsible	O
for	O
the	O
metabolism	B-MED
of	O
nifedipine	B-MED
,	O
used	O
for	O
the	O
treatment	B-MED
of	O
hypertension	B-MED
in	O
pregnant	B-MED
women	I-MED
.	O
We	O
aimed	B-MED
to	O
assess	B-MED
the	O
effect	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
(	O
T2DM	B-MED
)	O
on	O
the	O
pharmacokinetics	B-MED
,	O
placental	B-MED
transfer	I-MED
and	O
distribution	O
of	O
nifedipine	B-MED
in	O
amniotic	B-MED
fluid	I-MED
in	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
.	O
The	O
study	B-MED
was	O
conducted	O
in	O
12	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
[	O
control	B-MED
group	I-MED
(	O
CG	B-MED
)	O
]	O
and	O
10	O
hypertensive	B-MED
pregnant	B-MED
women	I-MED
with	O
T2DM	B-MED
taking	O
slow	O
-	O
release	O
nifedipine	B-MED
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O
On	O
the	O
34th	O
week	B-MED
of	O
gestation	B-MED
,	O
serial	O
blood	B-MED
samples	I-MED
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	B-MED
of	O
the	O
medication	B-MED
.	O
At	B-MED
delivery	I-MED
,	O
samples	B-MED
of	O
maternal	B-MED
and	O
fetal	B-MED
blood	I-MED
and	O
amniotic	B-MED
fluid	I-MED
were	O
collected	O
for	O
determination	B-MED
of	O
nifedipine	B-MED
distribution	O
in	O
these	O
compartments	O
.	O
The	O
median	B-MED
pharmacokinetic	B-MED
parameters	B-MED
of	O
CG	B-MED
were	O
:	O
peak	B-MED
plasma	I-MED
concentration	I-MED
(	O
Cmax	B-MED
)	O
26.41	O
ng	O
ml(-1	O
)	O
,	O
time	B-MED
to	I-MED
reach	I-MED
Cmax	I-MED
(	O
tmax	B-MED
)	O
1.79	O
h	O
,	O
area	B-MED
under	I-MED
the	I-MED
plasma	I-MED
concentration	I-MED
vs.	O
time	B-MED
curve	I-MED
from	O
0	O
-	O
12	O
h	O
(	O
AUC	B-MED
0	O
-	O
12	O
)	O
235.99	O
ng.h	O
ml(-1	O
)	O
,	O
half	B-MED
-	I-MED
life	I-MED
(	O
t½	O
)	O
4.34	O
h	O
,	O
volume	B-MED
of	I-MED
distribution	I-MED
divided	O
by	O
bioavailability	B-MED
(	O
Vd	B-MED
/	O
F	B-MED
)	O
560.96	O
l	O
,	O
and	O
ClT	B-MED
/	O
F	B-MED
84.77	O
l	O
h(-1	O
)	O
.	O
The	O
parameters	B-MED
for	O
T2DM	B-MED
group	B-MED
were	O
:	O
Cmax	B-MED
23.52	O
ng	O
ml(-1	O
)	O
,	O
tmax	B-MED
1.48	O
h	O
,	O
AUC	B-MED
0	O
-	O
12	O
202.23	O
ng.h	O
ml(-1	O
)	O
,	O
t½	O
5.00	O
h	O
,	O
Vd	B-MED
/	O
F	B-MED
609.40	O
l	O
,	O
and	O
apparent	O
total	B-MED
clearance	I-MED
(	O
ClT	B-MED
/	O
F	B-MED
)	O
98.94	O
l	O
h(-1	O
)	O
.	O
The	O
ratios	B-MED
of	O
plasma	B-MED
concentrations	I-MED
of	O
nifedipine	B-MED
in	O
the	O
umbilical	B-MED
vein	I-MED
,	O
intervillous	B-MED
space	I-MED
and	O
amniotic	B-MED
fluid	I-MED
to	O
those	O
in	O
the	O
maternal	B-MED
vein	O
for	O
CG	B-MED
and	O
T2DM	B-MED
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	B-MED
fluid	I-MED
/	O
maternal	B-MED
plasma	B-MED
ratio	B-MED
of	O
0.05	O
for	O
both	O
groups	B-MED
.	O
The	O
ratios	B-MED
of	O
plasma	B-MED
concentrations	I-MED
in	O
the	O
umbilical	B-MED
artery	I-MED
to	O
those	O
in	O
the	O
umbilical	B-MED
vein	I-MED
were	O
0.82	O
for	O
CG	B-MED
and	O
0.88	O
for	O
T2DM	B-MED
.	O
There	O
was	O
no	O
influence	B-MED
of	O
T2DM	B-MED
on	O
the	O
pharmacokinetics	B-MED
or	O
placental	B-MED
transfer	I-MED
of	O
nifedipine	B-MED
in	O
hypertensive	B-MED
women	B-MED
with	O
controlled	B-MED
diabetes	B-MED
.	O
A	O
Delayed	B-MED
Diagnosis	B-MED
of	O
Chronic	B-MED
Mesenteric	I-MED
Ischaemia	I-MED
:	O
The	O
Role	O
of	O
Clinicians	B-MED
'	O
Cognitive	B-MED
Errors	B-MED
Chronic	B-MED
diarrhoeal	B-MED
illnesses	I-MED
with	O
nausea	B-MED
and	O
weight	B-MED
loss	I-MED
are	O
a	O
common	B-MED
indication	B-MED
for	O
gastroenterology	B-MED
review	B-MED
.	O
While	O
many	O
such	O
cases	O
have	O
intra	B-MED
-	I-MED
luminal	I-MED
aetiologies	B-MED
,	O
such	O
as	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
,	O
coeliac	B-MED
disease	I-MED
or	O
other	O
malabsorptive	B-MED
conditions	I-MED
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	B-MED
gut	B-MED
disorders	B-MED
or	O
systemic	B-MED
malignancy	B-MED
,	O
clinicians	B-MED
must	O
also	O
keep	O
vascular	B-MED
disorders	I-MED
in	O
mind	O
.	O
Here	O
we	O
report	O
a	O
patient	B-MED
with	O
a	O
delayed	B-MED
diagnosis	B-MED
of	O
chronic	B-MED
mesenteric	I-MED
ischaemia	I-MED
after	O
6	O
months	B-MED
of	O
gastrointestinal	B-MED
symptoms	I-MED
strongly	O
mimicking	O
an	O
alternative	B-MED
diagnosis	B-MED
such	O
as	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
due	O
an	O
atypical	B-MED
predominance	B-MED
of	O
nausea	B-MED
and	O
diarrhoea	B-MED
rather	O
than	O
pain	B-MED
.	O
We	O
briefly	O
review	B-MED
the	O
literature	B-MED
on	O
treatment	B-MED
of	O
this	O
condition	B-MED
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	B-MED
of	O
cognitive	B-MED
errors	B-MED
made	O
by	O
clinicians	B-MED
that	O
led	O
to	O
a	O
diagnostic	B-MED
delay	B-MED
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	B-MED
can	O
be	O
minimised	B-MED
in	O
their	O
practice	B-MED
.	O
Erlotinib	B-MED
plus	O
gemcitabine	B-MED
versus	O
gemcitabine	B-MED
for	O
pancreatic	B-MED
cancer	I-MED
:	O
real	B-MED
-	O
world	B-MED
analysis	B-MED
of	O
Korean	B-MED
national	B-MED
database	B-MED
A	O
randomized	B-MED
clinical	I-MED
trial	I-MED
has	O
found	O
that	O
the	O
addition	B-MED
of	O
erlotinib	B-MED
to	O
gemcitabine	B-MED
(	O
GEM	B-MED
-	O
E	B-MED
)	O
for	O
pancreatic	B-MED
cancer	I-MED
led	O
to	O
a	O
modest	B-MED
increase	B-MED
in	O
survival	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
national	B-MED
population	B-MED
-	O
based	B-MED
retrospective	B-MED
study	I-MED
was	O
to	O
compare	B-MED
the	O
effectiveness	B-MED
of	O
GEM	B-MED
-	O
E	B-MED
to	O
GEM	B-MED
alone	O
for	O
pancreatic	B-MED
cancer	I-MED
patients	B-MED
in	O
real	B-MED
clinical	I-MED
practice	I-MED
.	O
Patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
(	B-MED
ICD-10	I-MED
:	O
C25	O
)	O
with	O
prescription	B-MED
claims	O
of	O
gemcitabine	B-MED
or	O
erlotinib	B-MED
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	B-MED
identified	B-MED
from	O
the	O
Korean	B-MED
Health	B-MED
Insurance	I-MED
claims	O
database	B-MED
.	O
To	O
be	O
included	O
in	O
the	O
study	B-MED
population	B-MED
,	O
patients	B-MED
were	O
required	B-MED
to	O
have	O
had	O
a	O
histological	B-MED
or	O
cytological	B-MED
diagnosis	I-MED
within	O
one	O
year	O
before	O
chemotherapy	B-MED
.	O
Patients	B-MED
treated	B-MED
with	I-MED
prior	O
radiotherapy	B-MED
,	O
surgery	B-MED
,	O
or	O
chemotherapy	B-MED
were	O
excluded	B-MED
to	O
reduce	B-MED
heterogeneity	B-MED
.	O
Overall	O
survival	B-MED
from	O
the	O
initiation	B-MED
of	O
therapy	B-MED
and	O
the	O
medical	B-MED
costs	I-MED
of	O
GEM	B-MED
-	O
E	B-MED
and	O
GEM	B-MED
were	O
compared	B-MED
.	O
A	O
total	O
of	O
4,267	O
patients	B-MED
were	O
included	O
in	O
the	O
analysis	B-MED
.	O
Overall	O
survival	B-MED
was	O
not	O
significantly	B-MED
longer	B-MED
in	O
patients	B-MED
treated	B-MED
with	O
GEM	B-MED
-	O
E	B-MED
(	O
median	B-MED
6.77	O
months	O
for	O
GEM	B-MED
-	O
E	B-MED
vs.	O
6.68	O
months	O
for	O
GEM	B-MED
,	O
p	O
=	O
0.0977	O
)	O
.	O
There	O
was	O
also	O
no	B-MED
significant	I-MED
difference	B-MED
in	O
the	O
respective	O
one	O
-	O
year	O
survival	B-MED
rates	I-MED
(	O
27.0	O
%	O
vs.	O
27.3	O
%	O
;	O
p	O
=	O
0.5988	O
)	O
.	O
Multivariate	B-MED
analysis	I-MED
using	O
age	B-MED
,	O
gender	B-MED
,	O
and	O
comorbidities	B-MED
as	O
covariates	B-MED
did	O
not	O
reveal	B-MED
any	O
significant	B-MED
differences	B-MED
in	O
survival	B-MED
.	O
Based	B-MED
on	O
this	O
relative	B-MED
effectiveness	I-MED
,	O
the	O
incremental	B-MED
cost	B-MED
per	O
life	B-MED
year	B-MED
gained	B-MED
over	O
GEM	B-MED
was	O
estimated	B-MED
at	O
USD	B-MED
70,843.64	O
for	O
GEM	B-MED
E	B-MED
-	O
E.	O
GEM	B-MED
-	O
E	B-MED
for	O
pancreatic	B-MED
cancer	I-MED
is	O
not	O
more	O
effective	B-MED
than	O
GEM	B-MED
in	O
a	O
real	B-MED
-	O
world	B-MED
setting	B-MED
,	O
and	O
it	O
does	O
not	O
provide	B-MED
reasonable	B-MED
cost	B-MED
-	I-MED
effectiveness	I-MED
over	O
GEM	B-MED
.	O
Eosinophilic	B-MED
Gastroenteritis	I-MED
as	O
a	O
Rare	B-MED
Cause	B-MED
of	O
Recurrent	B-MED
Epigastric	I-MED
Pain	I-MED
Eosinophilic	B-MED
gastroenteritis	I-MED
(	O
EGE	B-MED
)	O
is	O
a	O
rare	O
inflammatory	B-MED
disorder	I-MED
of	O
gastrointestinal	B-MED
tract	I-MED
characterized	B-MED
by	O
eosinophilic	B-MED
infiltration	I-MED
of	O
the	O
bowel	B-MED
wall	I-MED
.	O
It	O
can	O
mimic	O
many	O
gastrointestinal	B-MED
disorders	I-MED
due	O
to	O
its	O
wide	B-MED
spectrum	I-MED
of	I-MED
presentations	I-MED
.	O
Diagnose	B-MED
is	O
mostly	O
based	O
on	O
excluding	B-MED
other	B-MED
disorders	B-MED
and	O
a	O
high	B-MED
suspicion	B-MED
.	O
Here	O
we	O
report	B-MED
a	I-MED
case	I-MED
of	O
26	O
year	B-MED
old	B-MED
man	B-MED
with	O
a	O
history	B-MED
of	O
sever	B-MED
epigastric	I-MED
pain	I-MED
followed	O
by	O
nausea	B-MED
,	O
vomiting	B-MED
since	O
a	O
few	B-MED
days	B-MED
before	B-MED
admission	B-MED
with	O
final	O
diagnosis	B-MED
of	O
EGE	B-MED
.	O
Peer	B-MED
Exclusion	B-MED
During	O
the	O
Pubertal	B-MED
Transition	B-MED
:	O
The	O
Role	O
of	O
Social	B-MED
Competence	I-MED
For	O
some	O
youth	B-MED
,	O
early	B-MED
puberty	I-MED
is	O
accompanied	O
by	O
peer	B-MED
exclusion	B-MED
.	O
Yet	O
early	B-MED
developers	B-MED
may	O
experience	B-MED
less	O
peer	B-MED
exclusion	B-MED
if	O
they	O
have	O
social	B-MED
competence	I-MED
,	O
which	O
would	O
bolster	B-MED
their	O
ability	O
to	O
develop	B-MED
and	O
maintain	B-MED
positive	B-MED
relationships	B-MED
with	O
their	O
peers	B-MED
.	O
Accordingly	O
,	O
the	O
present	B-MED
study	B-MED
tests	O
whether	O
pubertal	B-MED
timing	B-MED
and	O
tempo	B-MED
predicts	B-MED
decrements	B-MED
in	O
children	B-MED
's	I-MED
social	B-MED
competence	I-MED
and	O
whether	O
decrements	B-MED
in	O
social	B-MED
competence	I-MED
account	O
for	O
associations	B-MED
between	O
puberty	B-MED
(	O
timing	B-MED
and	O
tempo	B-MED
)	O
and	O
peer	B-MED
exclusion	B-MED
over	O
time	B-MED
.	O
Longitudinal	B-MED
data	B-MED
were	O
drawn	O
from	O
1364	O
families	B-MED
(	O
48	O
%	O
female	B-MED
;	O
76	O
%	O
White	B-MED
;	O
M	O
=	O
9.32	O
years	B-MED
,	O
SD	O
=	O
.48	O
,	O
at	O
Wave	O
3	O
)	O
who	O
participated	B-MED
in	O
Waves	O
3	O
-	O
5	O
(	O
i.e.	O
,	O
grades	O
4	O
-	O
6	O
)	O
of	O
Phase	B-MED
III	I-MED
of	O
the	O
NICHD	B-MED
-	O
SECCYD	B-MED
.	O
The	O
results	B-MED
from	O
latent	B-MED
growth	I-MED
curve	I-MED
models	I-MED
indicated	O
that	O
earlier	B-MED
pubertal	B-MED
timing	B-MED
and	O
more	O
rapid	B-MED
pubertal	B-MED
tempo	B-MED
among	O
girls	B-MED
were	O
associated	B-MED
with	I-MED
high	B-MED
initial	B-MED
levels	B-MED
of	O
peer	B-MED
exclusion	B-MED
.	O
Moreover	O
,	O
mediation	B-MED
analyses	I-MED
revealed	O
that	O
early	B-MED
developers	B-MED
'	I-MED
susceptibility	B-MED
to	O
peer	B-MED
exclusion	B-MED
was	O
associated	B-MED
with	I-MED
their	O
initial	B-MED
level	B-MED
of	O
social	B-MED
competence	I-MED
.	O
In	O
boys	B-MED
,	O
pubertal	B-MED
timing	B-MED
and	O
tempo	B-MED
were	O
not	O
directly	O
associated	B-MED
with	I-MED
peer	B-MED
exclusion	B-MED
;	O
instead	O
,	O
indirect	O
effects	B-MED
of	I-MED
pubertal	B-MED
timing	B-MED
on	O
peer	B-MED
exclusion	B-MED
(	O
intercept	B-MED
,	O
slope	B-MED
)	O
occurred	O
through	O
initial	B-MED
levels	B-MED
of	O
social	B-MED
competence	I-MED
.	O
On	O
average	B-MED
,	O
early	B-MED
developers	B-MED
'	I-MED
who	O
had	O
low	B-MED
levels	B-MED
of	O
social	B-MED
competence	I-MED
also	O
had	O
high	B-MED
initial	B-MED
levels	B-MED
of	O
peer	B-MED
exclusion	B-MED
but	O
experienced	B-MED
decrements	B-MED
in	O
peer	B-MED
exclusion	B-MED
over	O
time	O
.	O
The	O
association	B-MED
between	O
the	O
intercepts	B-MED
for	O
puberty	B-MED
and	O
peer	B-MED
exclusion	B-MED
and	O
the	O
slopes	B-MED
for	O
social	B-MED
competence	I-MED
and	O
peer	B-MED
exclusion	B-MED
were	O
stronger	B-MED
for	O
boys	B-MED
than	O
girls	B-MED
.	O
Overall	O
,	O
our	O
findings	B-MED
suggest	O
that	O
early	B-MED
developers	B-MED
'	I-MED
susceptibility	B-MED
to	O
and	O
experiences	B-MED
of	O
peer	B-MED
exclusion	B-MED
are	O
associated	B-MED
with	I-MED
their	O
development	B-MED
of	O
social	B-MED
competence	I-MED
.	O
Differential	B-MED
Roles	B-MED
of	O
AXIN1	B-MED
and	O
AXIN2	B-MED
in	O
Tankyrase	B-MED
Inhibitor	B-MED
-	I-MED
Induced	I-MED
Formation	B-MED
of	O
Degradasomes	B-MED
and	O
β	B-MED
-	I-MED
Catenin	I-MED
Degradation	B-MED
Inhibition	B-MED
of	O
the	O
tankyrase	B-MED
enzymes	I-MED
(	O
TNKS1	B-MED
and	O
TNKS2	B-MED
)	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	B-MED
dynamic	B-MED
assemblies	B-MED
of	O
β	B-MED
-	I-MED
catenin	I-MED
destruction	B-MED
complex	I-MED
components	B-MED
known	O
as	O
degradasomes	B-MED
,	O
which	O
promote	B-MED
degradation	B-MED
of	O
β	B-MED
-	I-MED
catenin	I-MED
and	O
reduced	B-MED
Wnt	B-MED
signaling	I-MED
activity	B-MED
in	O
colorectal	B-MED
cancer	I-MED
cells	B-MED
.	O
AXIN1	B-MED
and	O
AXIN2	B-MED
/	O
Conductin	B-MED
,	O
the	O
rate	B-MED
-	I-MED
limiting	I-MED
factors	B-MED
for	O
the	O
stability	B-MED
and	O
function	B-MED
of	O
endogenous	B-MED
destruction	B-MED
complexes	I-MED
,	O
are	O
stabilized	B-MED
upon	O
TNKS	B-MED
inhibition	B-MED
due	O
to	O
abrogated	O
degradation	B-MED
of	O
AXIN	B-MED
by	O
the	O
proteasome	B-MED
.	O
Since	O
the	O
role	B-MED
of	O
AXIN1	B-MED
versus	O
AXIN2	B-MED
as	O
scaffolding	B-MED
proteins	I-MED
in	O
the	O
Wnt	B-MED
signaling	I-MED
pathway	I-MED
still	O
remains	B-MED
incompletely	B-MED
understood	B-MED
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	B-MED
contribution	B-MED
in	O
the	O
formation	B-MED
of	O
degradasomes	B-MED
,	O
as	O
these	O
protein	B-MED
assemblies	B-MED
most	O
likely	O
represent	O
the	O
morphological	B-MED
and	O
functional	B-MED
correlates	B-MED
of	O
endogenous	B-MED
β	B-MED
-	I-MED
catenin	I-MED
destruction	B-MED
complexes	I-MED
.	O
In	O
SW480	B-MED
colorectal	B-MED
cancer	I-MED
cells	B-MED
treated	B-MED
with	O
the	O
tankyrase	B-MED
inhibitor	I-MED
(	O
TNKSi	B-MED
)	O
G007	B-MED
-	I-MED
LK	I-MED
we	O
found	B-MED
that	O
AXIN1	B-MED
was	O
not	O
required	O
for	O
degradasome	B-MED
formation	B-MED
.	O
In	O
contrast	O
,	O
the	O
formation	B-MED
of	O
degradasomes	B-MED
as	O
well	O
as	O
their	O
capacity	B-MED
to	O
degrade	B-MED
β	B-MED
-	I-MED
catenin	I-MED
were	O
considerably	B-MED
impaired	B-MED
in	O
G007	B-MED
-	I-MED
LK	I-MED
-	I-MED
treated	I-MED
cells	B-MED
depleted	O
of	O
AXIN2	B-MED
.	O
These	O
findings	B-MED
give	O
novel	B-MED
insights	B-MED
into	O
differential	B-MED
functional	B-MED
roles	I-MED
of	O
AXIN1	B-MED
versus	O
AXIN2	B-MED
in	O
the	O
β	B-MED
-	I-MED
catenin	I-MED
destruction	B-MED
complex	I-MED
.	O
A	O
case	B-MED
of	O
retrograde	B-MED
intussusception	I-MED
at	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
anastomosis	I-MED
10	O
years	O
after	O
total	B-MED
gastrectomy	I-MED
:	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
A	O
63	O
-	O
year-	O
old	B-MED
man	I-MED
,	O
who	O
had	O
undergone	O
total	B-MED
gastrectomy	I-MED
and	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
reconstruction	I-MED
for	O
gastric	B-MED
cancer	I-MED
10	O
years	O
previously	O
,	O
was	O
admitted	B-MED
to	O
our	O
hospital	B-MED
with	O
complaints	B-MED
of	O
abdominal	B-MED
pain	I-MED
,	O
palpable	B-MED
abdominal	B-MED
tumor	I-MED
,	O
and	O
hematemesis	B-MED
.	O
On	B-MED
admission	I-MED
,	O
the	O
abdominal	B-MED
tenderness	I-MED
was	O
improving	B-MED
and	O
no	O
abdominal	B-MED
tumor	I-MED
was	O
palpable	B-MED
.	O
Mild	B-MED
inflammatory	I-MED
changes	O
and	O
anemia	B-MED
were	O
noted	O
on	O
blood	B-MED
examination	I-MED
.	O
Abdominal	B-MED
computed	B-MED
tomography	I-MED
revealed	O
a	O
tumor	B-MED
with	O
a	O
layered	B-MED
structure	I-MED
in	O
the	O
left	B-MED
abdomen	I-MED
.	O
The	O
patient	B-MED
was	O
diagnosed	B-MED
with	O
intestinal	B-MED
obstruction	I-MED
secondary	O
to	O
intussusception	B-MED
,	O
and	O
surgery	B-MED
was	O
performed	B-MED
.	O
Retrograde	B-MED
intussusception	I-MED
was	O
found	O
at	O
the	O
site	O
of	O
the	O
Y	B-MED
anastomosis	I-MED
.	O
We	O
conducted	O
manual	B-MED
reduction	I-MED
using	O
the	O
Hutchinson	B-MED
procedure	I-MED
.	O
The	O
intestinal	B-MED
color	B-MED
after	O
the	O
reduction	B-MED
was	O
good	O
,	O
and	O
no	O
intestinal	B-MED
resection	I-MED
was	O
required	B-MED
.	O
Postoperative	B-MED
recovery	I-MED
was	O
uneventful	O
,	O
and	O
the	O
patient	B-MED
was	O
discharged	B-MED
12	O
days	O
after	O
surgery	B-MED
.	O
Reports	B-MED
of	O
jejunal	B-MED
intussusception	B-MED
after	O
total	B-MED
gastrectomy	I-MED
with	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
reconstruction	I-MED
are	O
relatively	O
rare	O
.	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-MED
intussusception	B-MED
after	O
total	B-MED
gastrectomy	I-MED
with	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
reconstruction	I-MED
.	O
Dataset	B-MED
of	O
the	O
molecular	B-MED
dynamics	I-MED
simulations	I-MED
of	O
bilayers	B-MED
consisting	O
of	O
short	O
amyloidogenic	B-MED
peptide	I-MED
VDSWNVLVAG	B-MED
from	O
Bgl2p	B-MED
-	I-MED
glucantransferase	I-MED
of	O
S.	B-MED
cerevisiae	I-MED
cell	B-MED
wall	I-MED
The	O
amyloidogenic	B-MED
peptide	I-MED
VDSWNVLVAG	B-MED
from	O
Bgl2p	B-MED
-	I-MED
glucantransferase	I-MED
of	O
Saccharomyces	B-MED
cerevisiae	I-MED
cell	B-MED
wall	I-MED
and	O
its	O
modifying	O
analog	B-MED
VESWNVLVAG	B-MED
were	O
taken	O
for	O
the	O
construction	O
of	O
four	B-MED
types	O
of	O
bilayers	B-MED
which	O
differ	O
by	O
orientation	B-MED
of	O
the	O
peptides	B-MED
in	O
the	O
layers	B-MED
and	O
of	O
the	O
layers	B-MED
relative	O
to	O
each	O
other	O
.	O
These	O
bilayers	B-MED
were	O
used	O
as	O
starting	O
models	B-MED
for	O
the	O
molecular	B-MED
dynamics	I-MED
(	O
MD	B-MED
)	O
at	O
three	O
charge	O
states	O
(	O
neutral	O
,	O
pH3	O
,	O
and	O
pH5	O
)	O
.	O
The	O
changes	B-MED
of	O
the	O
fraction	O
of	O
secondary	B-MED
structure	I-MED
during	O
1	O
ns	O
simulations	B-MED
were	O
received	O
for	O
96	O
MD	O
trajectories	O
.	O
The	O
data	B-MED
article	B-MED
contains	O
the	O
necessary	O
information	B-MED
for	O
the	O
construction	O
of	O
models	B-MED
of	O
β	B-MED
-	I-MED
strands	I-MED
organization	B-MED
in	O
the	O
oligomer	B-MED
structure	B-MED
.	O
These	O
results	B-MED
were	O
used	O
in	O
the	O
associated	O
research	B-MED
article	I-MED
"	O
Structural	B-MED
model	I-MED
of	O
amyloid	B-MED
fibrils	I-MED
for	O
amyloidogenic	B-MED
peptide	I-MED
from	O
Bgl2p	B-MED
-	I-MED
glucantransferase	I-MED
of	O
S.	B-MED
cerevisiae	I-MED
cell	B-MED
wall	I-MED
and	O
its	O
modifying	O
analog	B-MED
.	O
New	O
morphology	B-MED
of	O
amyloid	B-MED
fibrils	I-MED
"	O
(	O
Selivanova	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
Prevalence	B-MED
of	O
Physical	B-MED
Activity	I-MED
and	O
Sitting	B-MED
Time	B-MED
Among	O
South	B-MED
Korean	I-MED
Adolescents	B-MED
:	O
Results	B-MED
From	O
the	O
Korean	B-MED
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
,	O
2013	O
This	O
study	O
aimed	O
to	O
describe	O
physical	B-MED
activity	I-MED
(	O
PA	B-MED
)	O
and	O
sitting	B-MED
time	B-MED
,	O
and	O
to	O
examine	O
associations	B-MED
between	O
sociodemographic	B-MED
factors	I-MED
,	O
weight	B-MED
status	B-MED
,	O
PA	B-MED
,	O
and	O
sitting	B-MED
time	B-MED
among	O
South	B-MED
Korean	I-MED
adolescents	B-MED
(	O
12	O
-	O
18	O
years	B-MED
)	O
.	O
Findings	B-MED
are	O
based	O
on	O
self	B-MED
-	I-MED
report	I-MED
data	I-MED
from	O
638	O
participants	B-MED
in	O
the	O
2013	O
Korea	B-MED
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
.	O
Only	O
4.9	O
%	O
of	O
adolescents	B-MED
accumulated	O
60	O
minutes	B-MED
of	O
moderate	B-MED
-	I-MED
to	I-MED
-	I-MED
vigorous	I-MED
PA	I-MED
daily	B-MED
.	O
Adolescents	B-MED
spent	O
532.4	O
±	O
9.3	O
mins	B-MED
/	I-MED
d	I-MED
sitting	B-MED
.	O
After	O
controlling	O
for	O
age	B-MED
and	O
sex	B-MED
,	O
individuals	B-MED
in	O
higher	B-MED
income	I-MED
groups	I-MED
compared	B-MED
with	O
the	O
lowest	B-MED
income	I-MED
group	I-MED
,	O
living	B-MED
in	O
nonmetro	B-MED
Seoul	B-MED
compared	B-MED
with	O
metro	B-MED
Seoul	B-MED
,	O
and	O
who	O
were	O
overweight	B-MED
compared	B-MED
with	O
nonoverweight	B-MED
were	O
more	O
likely	O
to	O
meet	O
PA	B-MED
guidelines	B-MED
.	O
Participants	B-MED
in	O
the	O
highest	B-MED
income	I-MED
group	I-MED
compared	B-MED
with	O
lowest	B-MED
income	I-MED
group	I-MED
,	O
and	O
residing	B-MED
in	O
nonmetro	B-MED
Seoul	B-MED
compared	B-MED
with	O
metro	B-MED
Seoul	B-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-MED
time	B-MED
group	B-MED
(	O
>	O
720	O
min	B-MED
/	I-MED
d	I-MED
)	O
(	O
P	O
<	O
.05	O
)	O
.	O
Increasing	B-MED
PA	B-MED
and	O
reducing	B-MED
sitting	B-MED
should	O
be	O
a	O
public	B-MED
health	I-MED
priority	B-MED
in	O
South	B-MED
Korea	I-MED
.	O
Masitinib	B-MED
for	O
treatment	B-MED
of	O
severely	B-MED
symptomatic	B-MED
indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
:	O
a	O
randomised	B-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
,	O
phase	B-MED
3	I-MED
study	I-MED
Indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
including	O
the	O
subvariant	B-MED
of	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
is	O
a	O
lifelong	B-MED
condition	O
associated	B-MED
with	I-MED
reduced	B-MED
quality	I-MED
of	I-MED
life	I-MED
.	O
Masitinib	B-MED
inhibits	B-MED
KIT	B-MED
and	O
LYN	B-MED
kinases	I-MED
that	O
are	O
involved	O
in	O
indolent	B-MED
systemic	I-MED
mastocytosis	I-MED
pathogenesis	B-MED
.	O
We	O
aimed	O
to	O
assess	O
safety	B-MED
and	O
efficacy	B-MED
of	O
masitinib	B-MED
versus	O
placebo	B-MED
in	O
severely	B-MED
symptomatic	I-MED
patients	B-MED
who	O
were	O
unresponsive	B-MED
to	O
optimal	B-MED
symptomatic	B-MED
treatments	B-MED
.	O
In	O
this	O
randomised	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
,	O
phase	B-MED
3	I-MED
study	I-MED
,	O
we	O
enrolled	O
adults	B-MED
(	O
aged	B-MED
18	O
-	O
75	O
years	O
)	O
with	O
indolent	B-MED
or	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
,	O
according	O
to	O
WHO	B-MED
classification	B-MED
or	O
documented	B-MED
mastocytosis	B-MED
based	O
on	O
histological	B-MED
criteria	I-MED
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B-MED
.	O
We	O
excluded	O
patients	B-MED
with	O
cutaneous	B-MED
or	O
non	O
-	O
severe	O
systemic	B-MED
mastocytosis	I-MED
after	O
a	O
protocol	B-MED
amendment	I-MED
.	O
Patients	B-MED
were	O
centrally	O
randomised	B-MED
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	B-MED
masitinib	B-MED
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	B-MED
with	O
minimisation	O
according	O
to	O
severe	B-MED
symptoms	I-MED
.	O
The	O
primary	B-MED
endpoint	I-MED
was	O
cumulative	O
response	B-MED
(	O
≥75	O
%	O
improvement	B-MED
from	O
baseline	B-MED
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	B-MED
baseline	I-MED
symptom	I-MED
from	O
the	O
following	O
:	O
pruritus	B-MED
score	B-MED
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	B-MED
Rating	I-MED
Scale	I-MED
for	I-MED
Depression	I-MED
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	B-MED
Impact	I-MED
Scale	I-MED
of	O
75	O
or	O
more	O
.	O
We	O
assessed	O
treatment	B-MED
effect	I-MED
using	O
repeated	O
measures	O
methodology	B-MED
for	O
rare	B-MED
diseases	I-MED
via	O
the	O
generalised	B-MED
estimating	I-MED
equation	I-MED
model	I-MED
in	O
a	O
modified	O
intention	B-MED
-	I-MED
to	I-MED
-	I-MED
treat	I-MED
population	B-MED
,	O
including	O
all	O
participants	B-MED
assigned	O
to	O
treatment	B-MED
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non	B-MED
-	I-MED
treatment	I-MED
-	I-MED
related	I-MED
cause	I-MED
.	O
We	O
assessed	O
safety	B-MED
in	O
all	O
patients	B-MED
who	O
received	O
at	O
least	O
one	O
dose	B-MED
of	O
study	B-MED
drug	I-MED
.	O
This	O
trial	B-MED
is	O
registered	O
with	O
ClinicalTrials.gov	B-MED
,	I-MED
number	I-MED
NCT00814073	I-MED
.	O
Between	O
Feb	B-MED
19	O
,	O
2009	O
,	O
and	O
July	B-MED
15	O
,	O
2015	O
,	O
135	O
patients	B-MED
were	O
randomly	B-MED
assigned	I-MED
to	O
masitinib	B-MED
(	O
n=71	O
)	O
or	O
placebo	B-MED
(	O
n=64	O
)	O
.	O
By	O
24	O
weeks	B-MED
,	O
masitinib	B-MED
was	O
associated	B-MED
with	I-MED
a	O
cumulative	O
response	B-MED
of	O
18·7	O
%	O
in	O
the	O
primary	B-MED
endpoint	I-MED
(	O
122·6	O
responses	B-MED
of	O
656·5	O
possible	O
responses	B-MED
[	O
weighted	B-MED
generalised	I-MED
estimating	I-MED
equation	I-MED
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	B-MED
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	B-MED
ratio	I-MED
3·6	O
;	O
95	O
%	O
CI	O
1·2	O
-	O
10·8	O
;	O
p=0·0076	O
)	O
.	O
Frequent	B-MED
severe	B-MED
adverse	I-MED
events	I-MED
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	B-MED
)	O
were	O
diarrhoea	B-MED
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	B-MED
group	B-MED
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	B-MED
group	B-MED
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	B-MED
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O
The	O
most	O
frequent	B-MED
serious	B-MED
adverse	I-MED
events	I-MED
were	O
diarrhoea	B-MED
(	O
three	O
patients	B-MED
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	B-MED
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	B-MED
-	I-MED
threatening	I-MED
toxicities	B-MED
occurred	O
.	O
One	O
patient	B-MED
in	O
the	O
placebo	B-MED
group	B-MED
died	B-MED
(	O
unrelated	B-MED
to	O
study	B-MED
treatment	I-MED
)	O
.	O
These	O
study	B-MED
findings	I-MED
indicate	O
that	O
masitinib	B-MED
is	O
an	O
effective	B-MED
and	O
well	O
tolerated	B-MED
agent	I-MED
for	O
the	O
treatment	B-MED
of	O
severely	B-MED
symptomatic	I-MED
indolent	B-MED
or	O
smouldering	B-MED
systemic	I-MED
mastocytosis	I-MED
.	O
AB	O
Science	O
(	O
Paris	O
,	O
France	O
)	O
.	O
Collaborating	B-MED
for	O
Systems	B-MED
Change	B-MED
:	O
A	O
Social	B-MED
Science	I-MED
Framework	I-MED
for	O
Academic	B-MED
Roles	I-MED
in	O
Community	B-MED
Partnerships	I-MED
Environmental	B-MED
health	I-MED
researchers	B-MED
,	O
government	B-MED
agencies	I-MED
,	O
and	O
community	B-MED
groups	I-MED
have	O
endorsed	O
long	O
-	O
term	O
community	B-MED
-	O
academic	B-MED
partnerships	B-MED
as	O
an	O
effective	B-MED
strategy	I-MED
to	O
support	B-MED
science	B-MED
-based	O
improvements	B-MED
in	O
environmental	B-MED
health	I-MED
.	O
Social	B-MED
sciences	I-MED
concepts	B-MED
,	O
approaches	B-MED
,	O
and	O
methods	B-MED
are	O
fundamental	O
to	O
these	O
translational	B-MED
partnerships	I-MED
.	O
However	O
,	O
appropriate	B-MED
roles	B-MED
for	O
academic	B-MED
partners	B-MED
vary	O
throughout	O
the	O
process	B-MED
of	O
changing	B-MED
systems	B-MED
(	O
policies	B-MED
,	O
practices	B-MED
,	O
programs	B-MED
,	O
etc	O
.	O
)	O
.	O
This	O
can	O
complicate	O
planning	B-MED
,	O
evaluating	B-MED
,	O
and	O
sustaining	B-MED
such	O
partnerships	B-MED
.	O
We	O
set	O
forth	O
a	O
conceptual	B-MED
framework	I-MED
for	O
academic	B-MED
partners	B-MED
'	O
roles	O
at	O
different	B-MED
stages	I-MED
of	O
systems	B-MED
change	B-MED
.	O
We	O
apply	O
this	O
framework	B-MED
to	O
three	O
longstanding	O
academic	B-MED
-	O
community	B-MED
partnerships	B-MED
involving	O
National	B-MED
Institute	I-MED
of	I-MED
Environmental	I-MED
Health	I-MED
Sciences	I-MED
Community	B-MED
Outreach	I-MED
and	I-MED
Engagement	I-MED
Cores	I-MED
.	O
We	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	B-MED
can	O
help	O
academic	B-MED
partners	B-MED
tap	O
appropriate	B-MED
expertise	B-MED
,	O
redefine	O
their	O
roles	O
,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	B-MED
efforts	O
to	O
improve	B-MED
environmental	B-MED
health	I-MED
.	O
Bioavailability	B-MED
and	O
health	B-MED
risk	I-MED
assessment	I-MED
of	O
potentially	B-MED
toxic	B-MED
elements	I-MED
in	O
Thriasio	B-MED
Plain	I-MED
,	I-MED
near	I-MED
Athens	I-MED
,	O
Greece	B-MED
Elevated	O
concentrations	B-MED
of	O
potentially	B-MED
toxic	B-MED
elements	I-MED
(	O
PTEs	B-MED
)	O
are	O
usually	O
found	O
in	O
areas	B-MED
of	I-MED
intense	I-MED
industrial	I-MED
activity	I-MED
.	O
Thriasio	B-MED
Plain	I-MED
is	O
a	O
plain	B-MED
near	I-MED
Athens	I-MED
,	O
Greece	B-MED
,	O
where	O
most	O
of	O
the	O
heavy	B-MED
industry	I-MED
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades	O
,	O
but	O
it	O
also	O
is	O
a	O
residential	B-MED
and	O
horticultural	B-MED
area	B-MED
.	O
We	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
PTEs	B-MED
in	O
soils	B-MED
soils	B-MED
and	O
indigenous	B-MED
plant	B-MED
species	I-MED
and	O
assessing	B-MED
the	I-MED
health	I-MED
risk	I-MED
associated	B-MED
with	I-MED
direct	O
soil	B-MED
ingestion	B-MED
.	O
Samples	B-MED
of	I-MED
soils	I-MED
at	O
roadsides	B-MED
and	O
growing	O
plants	B-MED
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	B-MED
.	O
Concentrations	B-MED
of	O
Al	B-MED
,	O
As	B-MED
,	O
Cd	B-MED
,	O
Co	B-MED
,	O
Cr	B-MED
,	O
Cu	B-MED
,	O
Fe	B-MED
,	O
Mn	B-MED
,	O
Mo	B-MED
,	O
Ni	B-MED
,	O
Pb	B-MED
,	O
V	B-MED
and	O
Zn	B-MED
were	O
measured	O
in	O
both	O
soils	B-MED
(	O
as	O
pseudo	O
-	O
total	O
)	O
and	O
aerial	O
plant	B-MED
tissues	I-MED
.	O
We	O
found	O
that	O
As	B-MED
,	O
Cd	B-MED
,	O
Cr	B-MED
,	O
Cu	B-MED
,	O
Ni	B-MED
,	O
Pb	B-MED
and	O
Zn	B-MED
were	O
higher	O
than	O
maximum	O
regulatory	B-MED
limits	B-MED
.	O
Element	B-MED
concentrations	B-MED
in	O
plants	B-MED
were	O
rather	O
lower	O
than	O
expected	O
,	O
probably	O
because	O
indigenous	B-MED
plants	B-MED
have	O
developed	O
excluder	B-MED
behaviour	O
over	O
time	O
.	O
Copper	B-MED
and	O
Zn	B-MED
soil	B-MED
-to-	O
plant	B-MED
coefficients	B-MED
were	O
highest	O
among	O
the	O
other	O
elements	B-MED
;	O
for	O
Cu	B-MED
this	O
was	O
unexpected	O
,	O
and	O
probably	O
associated	B-MED
with	I-MED
recent	O
Cu	B-MED
-	O
releasing	B-MED
industrial	B-MED
activity	B-MED
.	O
Risk	B-MED
assessment	I-MED
analysis	I-MED
indicated	O
that	O
As	B-MED
was	O
the	O
element	B-MED
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	B-MED
risk	B-MED
related	O
to	O
direct	O
soil	B-MED
ingestion	B-MED
,	O
followed	O
by	O
Cr	B-MED
,	O
Pb	B-MED
,	O
and	O
,	O
surprisingly	O
,	O
Mn	B-MED
.	O
We	O
concluded	O
that	O
in	O
a	O
multi	B-MED
-	O
element	B-MED
contamination	B-MED
situation	O
,	O
elevated	O
risk	O
of	O
PTEs	B-MED
(	O
such	O
as	O
As	B-MED
,	O
Cr	B-MED
and	O
Pb	B-MED
)	O
may	O
reduce	O
the	O
tolerance	B-MED
limits	B-MED
of	O
exposure	B-MED
to	I-MED
less-	O
toxic	B-MED
elements	I-MED
(	O
here	O
,	O
Mn	B-MED
)	O
.	O
New	B-MED
Breast	B-MED
Pain	I-MED
Chart	B-MED
for	O
Objective	B-MED
Record	I-MED
of	O
Mastalgia	B-MED
Mastalgia	B-MED
is	O
the	O
commonest	B-MED
affliction	B-MED
of	O
mammary	B-MED
gland	I-MED
among	O
ladies	B-MED
of	O
the	O
reproductive	B-MED
age	B-MED
group	I-MED
.	O
Since	O
etiopathogenesis	B-MED
and	O
therapy	B-MED
are	O
different	B-MED
for	O
cyclical	B-MED
and	O
noncyclical	B-MED
pain	I-MED
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O
This	O
is	O
usually	O
done	O
in	O
the	O
breast	B-MED
clinics	I-MED
by	O
advising	O
the	O
patient	B-MED
to	O
fill	O
a	O
pain	B-MED
diary	I-MED
over	O
a	O
period	B-MED
of	O
2	O
months	B-MED
over	O
two	O
menstrual	B-MED
cycles	I-MED
.	O
The	O
Cardiff	B-MED
pain	I-MED
chart	I-MED
records	I-MED
the	O
severity	B-MED
of	O
pain	B-MED
in	O
the	O
form	O
of	O
a	O
triangle	B-MED
for	O
mild	B-MED
to	O
moderate	B-MED
pain	I-MED
and	O
a	O
square	B-MED
for	O
severe	B-MED
pain	I-MED
.	O
Moreover	O
,	O
Cardiff	B-MED
pain	I-MED
chart	I-MED
does	O
not	O
allow	O
a	O
patient	B-MED
to	O
record	B-MED
the	O
severity	B-MED
of	O
pain	B-MED
on	O
days	B-MED
of	O
menses	B-MED
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"	O
P	O
"	O
in	O
the	O
box	O
.	O
These	O
problems	B-MED
have	O
been	O
resolved	B-MED
in	O
the	O
new	B-MED
breast	B-MED
pain	I-MED
chart	B-MED
.	O
In	O
the	O
new	B-MED
pain	B-MED
chart	I-MED
,	O
the	O
lady	B-MED
records	B-MED
pain	B-MED
severity	B-MED
in	O
the	O
form	O
of	O
visual	B-MED
linear	I-MED
analogue	I-MED
scale	I-MED
score	I-MED
on	O
every	B-MED
day	I-MED
of	O
menstrual	B-MED
cycle	I-MED
.	O
She	O
enters	O
her	O
menstrual	B-MED
experience	B-MED
on	O
a	O
separate	O
part	O
of	O
chart	B-MED
,	O
which	O
allows	O
us	O
to	O
visualize	B-MED
the	O
full	O
month	B-MED
's	I-MED
pain	B-MED
severity	B-MED
in	O
an	O
uncluttered	O
way	O
.	O
Effects	O
of	O
Static	B-MED
Cold	I-MED
Storage	I-MED
and	O
Hypothermic	B-MED
Machine	I-MED
Perfusion	I-MED
on	O
Oxidative	B-MED
Stress	I-MED
Factors	I-MED
,	O
Adhesion	B-MED
Molecules	I-MED
,	O
and	O
Zinc	B-MED
Finger	I-MED
Transcription	I-MED
Factor	I-MED
Proteins	I-MED
Before	O
and	O
After	O
Liver	B-MED
Transplantation	I-MED
BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-MED
cold	I-MED
storage	I-MED
(	O
SCS	B-MED
)	O
and	O
hypothermic	B-MED
machine	I-MED
perfusion	I-MED
(	O
HMP	B-MED
)	O
on	O
the	O
oxidative	B-MED
stress	I-MED
factors	I-MED
(	O
OSF	B-MED
)	O
,	O
adhesion	B-MED
molecules	I-MED
(	O
AM	B-MED
)	O
,	O
and	O
zinc	B-MED
finger	I-MED
transcription	I-MED
factor	I-MED
(	O
Snail	B-MED
)	O
before	O
and	O
after	O
liver	B-MED
transplantation	I-MED
.	O
MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	B-MED
were	O
randomly	O
divided	O
into	O
donor	B-MED
(	O
group	B-MED
A	O
)	O
,	O
SCS	B-MED
(	O
group	B-MED
B	O
)	O
,	O
and	O
HMP	B-MED
(	O
group	B-MED
C	O
)	O
(	O
n=30	O
)	O
groups	B-MED
.	O
Livers	B-MED
retrieved	I-MED
from	O
group	B-MED
A	O
were	O
transplanted	B-MED
into	O
group	B-MED
B	O
after	O
SCS	B-MED
,	O
and	O
the	O
livers	B-MED
sampled	O
from	O
group	B-MED
B	O
were	O
transplanted	B-MED
into	O
group	B-MED
C	O
after	O
HMP	B-MED
.	O
The	O
dogs	O
in	O
group	B-MED
A	O
were	O
euthanized	B-MED
and	O
discarded	O
,	O
and	O
the	O
livers	B-MED
sampled	O
from	O
group	B-MED
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O
Twenty	O
dogs	B-MED
with	O
successful	O
liver	B-MED
transplants	I-MED
were	O
randomly	O
selected	O
from	O
groups	B-MED
B	O
and	O
C	O
for	O
analysis	O
.	O
RESULTS	O
During	O
the	O
liver	B-MED
sampling	B-MED
process	I-MED
,	O
the	O
levels	O
of	O
OSF	B-MED
,	O
AM	B-MED
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	B-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
(	O
P>0.05	O
)	O
;	O
before	O
the	O
transplantation	B-MED
,	O
the	O
levels	O
of	O
chemokine	B-MED
CXCL14	I-MED
and	O
Snail	B-MED
between	O
the	O
2	O
groups	B-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
(	O
P>0.05	O
)	O
,	O
and	O
compared	O
with	O
group	B-MED
B	O
,	O
HIF-1α	O
and	O
P	B-MED
-	I-MED
selectin	I-MED
in	O
group	B-MED
C	O
were	O
lower	O
(	O
P<0.01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	B-MED
,	O
HIF-1α	B-MED
,	O
chemokine	B-MED
CXCL14	I-MED
,	O
P	B-MED
-	I-MED
selectin	I-MED
,	O
and	O
Snail	B-MED
in	O
group	B-MED
C	O
were	O
lower	O
than	O
that	O
in	O
group	B-MED
B	O
(	O
P<0.01	O
)	O
.	O
CONCLUSIONS	O
HMP	B-MED
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-MED
and	O
inflammatory	B-MED
factors	I-MED
,	O
which	O
is	O
conducive	B-MED
for	O
liver	B-MED
transplantation	I-MED
.	O
Impact	B-MED
of	O
Chemotherapy	B-MED
on	O
Diet	B-MED
and	O
Nutritional	B-MED
Status	I-MED
of	O
Women	B-MED
with	O
Breast	B-MED
Cancer	I-MED
:	O
A	O
Prospective	B-MED
Study	I-MED
Certain	O
food	B-MED
groups	I-MED
are	O
often	O
rejected	B-MED
during	O
chemotherapy	B-MED
(	O
CT	B-MED
)	O
due	O
to	O
the	O
side	B-MED
effects	I-MED
of	I-MED
treatment	I-MED
,	O
which	O
may	O
interfere	B-MED
with	I-MED
adequate	B-MED
diet	I-MED
and	O
nutritional	B-MED
status	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
treatment	B-MED
impact	B-MED
on	O
the	O
diet	B-MED
and	O
nutritional	B-MED
status	I-MED
of	O
women	B-MED
with	O
breast	B-MED
cancer	I-MED
(	O
BC	B-MED
)	O
.	O
In	O
this	O
prospective	B-MED
longitudinal	I-MED
study	I-MED
,	O
conducted	O
in	O
2014	O
-	O
2015	O
,	O
55	O
women	B-MED
diagnosed	O
with	O
BC	B-MED
,	O
with	O
a	O
mean	O
age	B-MED
51.5±10.1	O
years	B-MED
,	O
were	O
followed	O
and	O
data	B-MED
were	O
collected	O
at	O
three	O
different	O
times	O
.	O
Anthropometric	B-MED
and	O
dietary	B-MED
assessments	I-MED
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-MED
recall	I-MED
s	O
,	O
by	O
using	O
the	O
Brazilian	B-MED
Healthy	I-MED
Eating	I-MED
Index	I-MED
Revised	I-MED
(	O
BHEI	B-MED
-	I-MED
R	I-MED
)	O
,	O
and	O
calculating	B-MED
the	O
prevalence	B-MED
of	O
inadequacy	B-MED
by	O
the	O
EAR	B-MED
cut	I-MED
-	I-MED
off	I-MED
point	I-MED
method	I-MED
.	O
Regarding	O
the	O
BHEI	B-MED
-	I-MED
R	I-MED
analysis	B-MED
,	O
the	O
majority	O
of	O
women	B-MED
had	O
a	O
"	O
diet	B-MED
requires	O
modification	B-MED
'	O
,	O
both	O
at	O
the	O
beginning	B-MED
(	O
T0	O
,	O
58.2	O
%	O
,	O
n	O
=	O
32	O
)	O
and	O
during	B-MED
treatment	I-MED
(	O
T1	O
,	O
54.5	O
%	O
,	O
n	O
=	O
30	O
)	O
.	O
However	O
,	O
after	O
the	O
end	O
of	O
the	O
CT	B-MED
,	O
the	O
greater	B-MED
percentage	I-MED
of	O
patients	B-MED
(	O
T2	O
,	O
49.1	O
%	O
,	O
n	O
=	O
27	O
)	O
were	O
classified	O
as	O
having	O
an	O
"	O
inadequate	B-MED
diet	I-MED
"	O
,	O
since	O
the	O
Total	B-MED
Fruit	B-MED
consumption	B-MED
as	O
well	O
as	O
the	O
Dark	B-MED
Green	I-MED
and	O
Orange	B-MED
Vegetable	I-MED
and	O
Legume	B-MED
consumption	B-MED
decreased	B-MED
significantly	I-MED
during	B-MED
treatment	I-MED
(	O
p	O
=	O
0.043	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O
There	O
was	O
a	O
significant	B-MED
reduction	I-MED
in	O
the	O
intake	B-MED
of	O
macro	B-MED
and	O
micronutrients	B-MED
,	O
with	O
a	O
high	O
prevalence	B-MED
of	O
inadequacy	B-MED
,	O
of	O
up	O
to	O
100	O
%	O
,	O
for	O
calcium	B-MED
,	O
iron	B-MED
,	O
phosphorus	B-MED
,	O
magnesium	B-MED
,	O
niacin	B-MED
,	O
riboflavin	B-MED
,	O
thiamin	B-MED
,	O
vitamin	B-MED
B6	I-MED
,	O
vitamin	B-MED
C	I-MED
and	O
zinc	B-MED
.	O
Assessment	B-MED
of	O
the	O
nutritional	B-MED
status	I-MED
indicated	O
that	O
56	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	B-MED
were	O
overweight	B-MED
at	O
these	O
three	O
different	O
times	O
.	O
Weight	B-MED
,	O
BMI	B-MED
and	O
Waist	B-MED
Circumference	I-MED
increased	B-MED
significantly	I-MED
,	O
indicating	O
a	O
worse	B-MED
nutritional	B-MED
status	I-MED
,	O
and	O
there	O
was	O
a	O
correlation	B-MED
between	O
poor	B-MED
diet	I-MED
quality	I-MED
and	O
higher	B-MED
values	I-MED
for	O
BMI	B-MED
,	O
Waist	B-MED
-	I-MED
Hip	I-MED
Ratio	I-MED
and	O
Waist	B-MED
-	I-MED
to	I-MED
-	I-MED
Height	I-MED
Ratio	I-MED
.	O
Chemotherapy	B-MED
interferes	B-MED
in	O
the	O
patients	B-MED
'	O
diet	B-MED
generating	O
a	O
negative	B-MED
impact	I-MED
on	O
the	O
quality	B-MED
and	O
intake	B-MED
of	O
micro	B-MED
and	O
macronutrients	B-MED
,	O
as	O
well	O
as	O
an	O
impact	B-MED
on	O
their	O
nutritional	B-MED
status	I-MED
,	O
with	O
an	O
increase	O
in	O
anthropometric	B-MED
measurements	I-MED
.	O
Women	B-MED
's	I-MED
perspectives	O
on	O
human	B-MED
papillomavirus	I-MED
self	B-MED
-	I-MED
sampling	I-MED
in	O
the	O
context	O
of	O
the	O
UK	B-MED
cervical	B-MED
screening	B-MED
programme	I-MED
Testing	B-MED
for	O
human	B-MED
papillomavirus	I-MED
(	O
HPV	B-MED
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-MED
screening	B-MED
programme	I-MED
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	B-MED
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	B-MED
self	B-MED
-	I-MED
sampling	I-MED
.	O
In	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	B-MED
and	O
practice	B-MED
by	O
identifying	O
potential	B-MED
barriers	B-MED
to	O
HPV	B-MED
self	B-MED
-	I-MED
sampling	I-MED
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
survey	I-MED
of	O
194	O
women	B-MED
aged	O
20	O
-	O
64	O
years	O
was	O
conducted	O
.	O
Logistic	B-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
identify	O
determinants	B-MED
of	O
self	B-MED
-	I-MED
sampling	I-MED
intentions	O
.	O
A	O
purposive	O
subsample	O
of	O
19	O
women	B-MED
who	O
reported	O
low	O
self	B-MED
-	I-MED
sampling	I-MED
intentions	O
were	O
interviewed	O
.	O
Interviews	B-MED
were	O
framework	O
-	O
analysed	O
.	O
Most	O
survey	B-MED
participants	B-MED
(	O
N=133	O
,	O
69.3	O
%	O
)	O
intended	O
to	O
HPV	B-MED
self	O
-	O
sample	O
.	O
Lower	B-MED
intention	B-MED
was	O
associated	B-MED
with	I-MED
lower	B-MED
self	O
-	O
efficacy	O
(	O
OR=24.96	O
,	O
P≤.001	O
)	O
,	O
lower	B-MED
education	B-MED
(	O
OR=6.06	O
,	O
P≤.05	O
)	O
and	O
lower	B-MED
perceived	B-MED
importance	O
of	O
HPV	B-MED
as	O
a	O
cause	O
of	O
cervical	B-MED
cancer	I-MED
(	O
OR=2.33	O
,	O
P≤.05	O
)	O
.	O
Interviews	B-MED
revealed	O
personal	B-MED
and	O
system	O
-	O
related	O
barriers	B-MED
.	O
Personal	B-MED
barriers	B-MED
included	O
a	O
lack	O
of	O
knowledge	B-MED
about	O
HPV	B-MED
self	B-MED
-	I-MED
sampling	I-MED
,	O
women	B-MED
's	I-MED
low	B-MED
confidence	I-MED
in	O
their	O
ability	O
to	O
self	O
-	O
sample	O
correctly	O
and	O
low	B-MED
confidence	I-MED
in	O
the	O
subsequent	O
results	O
.	O
System	O
-	O
related	O
factors	O
included	O
a	O
lack	B-MED
of	I-MED
confidence	I-MED
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-MED
screening	B-MED
programme	I-MED
,	O
and	O
concerns	O
about	O
sample	B-MED
contamination	B-MED
and	O
identity	B-MED
theft	I-MED
.	O
Insights	O
gained	O
from	O
this	O
research	B-MED
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	B-MED
self	B-MED
-	I-MED
sampling	I-MED
and	O
to	O
help	O
inform	O
future	O
policy	B-MED
and	O
practice	B-MED
.	O
Personal	B-MED
and	O
system	B-MED
-	I-MED
related	I-MED
barriers	I-MED
including	O
low	B-MED
confidence	I-MED
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-MED
screening	B-MED
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
HPV	B-MED
self	B-MED
-	I-MED
sampling	I-MED
be	O
incorporated	O
into	O
the	O
cervical	B-MED
screening	B-MED
programme	I-MED
.	O
Difference	B-MED
-	I-MED
in	I-MED
-	I-MED
Differences	I-MED
Method	I-MED
in	O
Comparative	B-MED
Effectiveness	I-MED
Research	I-MED
:	O
Utility	O
with	O
Unbalanced	B-MED
Groups	I-MED
Comparative	B-MED
effectiveness	I-MED
research	I-MED
(	O
CER	B-MED
)	O
often	O
includes	O
observational	B-MED
studies	I-MED
utilizing	O
administrative	B-MED
data	I-MED
.	O
Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
CER	B-MED
to	O
adjust	O
for	O
group	B-MED
differences	B-MED
,	O
including	O
difference	B-MED
-	I-MED
in	I-MED
-	I-MED
differences	I-MED
(	I-MED
DiD	I-MED
)	I-MED
estimation	I-MED
.	O
This	O
study	O
presents	O
DiD	B-MED
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B-MED
to	O
estimate	O
treatment	B-MED
outcomes	I-MED
in	O
the	O
CER	B-MED
setting	O
by	O
utilizing	O
the	O
MarketScan	B-MED
®	I-MED
Databases	I-MED
for	O
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
patients	B-MED
receiving	O
different	O
therapies	B-MED
.	O
The	O
sample	O
included	O
6762	O
patients	B-MED
,	O
with	O
363	O
in	O
the	O
Test	B-MED
Cohort	I-MED
[	O
glatiramer	B-MED
acetate	I-MED
(	O
GA	B-MED
)	O
switched	B-MED
to	O
fingolimod	B-MED
(	O
FTY	B-MED
)	O
]	O
and	O
6399	O
in	O
the	O
Control	B-MED
Cohort	I-MED
(	O
GA	B-MED
only	O
,	O
no	B-MED
switch	I-MED
)	O
from	O
a	O
US	B-MED
administrative	I-MED
claims	I-MED
database	I-MED
.	O
A	O
trend	B-MED
analysis	I-MED
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B-MED
to	O
the	O
mean	B-MED
and	O
to	O
compare	O
relapse	B-MED
rates	O
among	O
treatment	B-MED
cohorts	I-MED
.	O
DiD	B-MED
analysis	I-MED
was	O
used	O
to	O
enable	O
comparisons	B-MED
among	O
the	O
Test	B-MED
and	O
Control	B-MED
Cohorts	I-MED
.	O
Logistic	B-MED
regression	I-MED
was	O
used	O
to	O
estimate	O
the	O
probability	B-MED
of	O
relapse	B-MED
after	O
switching	B-MED
from	O
GA	B-MED
to	O
FTY	B-MED
,	O
and	O
to	O
compare	B-MED
group	B-MED
differences	B-MED
in	O
the	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
index	B-MED
periods	I-MED
.	O
Crude	O
DiD	B-MED
analysis	I-MED
showed	O
that	O
in	O
the	O
pre	B-MED
-	O
index	B-MED
period	I-MED
more	O
patients	B-MED
in	O
the	O
Test	B-MED
Cohort	I-MED
experienced	O
an	O
MS	B-MED
relapse	B-MED
and	O
had	O
a	O
higher	O
mean	B-MED
number	I-MED
of	O
relapses	B-MED
than	O
in	O
the	O
Control	B-MED
Cohort	I-MED
.	O
During	O
the	O
pre	B-MED
-	O
index	B-MED
period	I-MED
,	O
numeric	B-MED
and	O
relative	O
data	O
for	O
MS	B-MED
relapses	B-MED
in	O
patients	B-MED
in	O
the	O
Test	B-MED
Cohort	I-MED
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	B-MED
Cohort	I-MED
,	O
while	O
no	B-MED
significant	I-MED
between-	O
group	B-MED
differences	B-MED
emerged	O
during	O
the	O
post	B-MED
-	O
index	B-MED
period	I-MED
.	O
Generalized	O
linear	B-MED
modeling	I-MED
with	O
DiD	B-MED
regression	B-MED
estimation	I-MED
showed	O
that	O
the	O
mean	O
number	O
of	O
MS	B-MED
relapses	B-MED
decreased	O
significantly	O
in	O
the	O
post	B-MED
-	O
index	B-MED
period	I-MED
among	O
patients	B-MED
in	O
the	O
Test	B-MED
Cohort	I-MED
compared	O
with	O
patients	B-MED
in	O
the	O
Control	B-MED
Cohort	I-MED
.	O
In	O
this	O
study	O
,	O
an	O
MS	B-MED
population	B-MED
was	O
utilized	O
to	O
demonstrate	O
how	O
DiD	B-MED
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-MED
effects	I-MED
in	O
a	O
heterogeneous	B-MED
population	B-MED
,	O
where	O
the	O
Test	B-MED
and	O
Control	B-MED
Cohorts	I-MED
varied	O
greatly	O
.	O
The	O
results	O
show	O
that	O
DiD	B-MED
offers	O
a	O
robust	O
method	O
for	O
comparing	B-MED
diverse	B-MED
cohorts	B-MED
when	O
other	O
risk	B-MED
-	I-MED
adjustment	I-MED
methods	I-MED
may	O
not	O
be	O
adequate	O
.	O
A	O
Comparative	B-MED
Study	I-MED
of	O
the	O
Efficacy	B-MED
of	O
IV	B-MED
Dexketoprofen	B-MED
,	O
Lornoxicam	B-MED
,	O
and	O
Diclophenac	B-MED
Sodium	I-MED
on	O
Postoperative	B-MED
Analgesia	I-MED
and	O
Tramadol	B-MED
Consumption	B-MED
in	O
Patients	B-MED
Receiving	O
Patient	B-MED
-	I-MED
Controlled	I-MED
Tramadol	B-MED
This	O
study	B-MED
was	O
designed	B-MED
to	O
compare	B-MED
the	O
effects	B-MED
of	I-MED
dexketoprofen	B-MED
,	O
lornoxicam	B-MED
,	O
and	O
diclophenac	B-MED
sodium	I-MED
on	O
postoperative	B-MED
analgesia	I-MED
and	O
tramadol	B-MED
consumption	B-MED
in	O
patients	B-MED
receiving	O
postoperative	B-MED
patient	B-MED
-	I-MED
controlled	I-MED
tramadol	B-MED
after	O
a	O
major	B-MED
abdominal	B-MED
surgery	I-MED
.	O
Eighty	O
patients	B-MED
were	O
randomized	B-MED
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-MED
drugs	B-MED
.	O
Patients	B-MED
in	O
group	B-MED
dexketoprofen	B-MED
(	O
DT	B-MED
)	O
received	O
IV	B-MED
50	O
mg	O
dexketoprofen	B-MED
,	O
group	B-MED
lornoxicam	B-MED
(	O
LR	B-MED
)	O
received	O
IV	B-MED
8	O
mg	O
lornoxicam	B-MED
,	O
group	B-MED
diclophenac	B-MED
sodium	I-MED
(	O
DS	B-MED
)	O
received	O
75	O
mg	O
IV	B-MED
diclophenac	B-MED
sodium	I-MED
and	O
group	B-MED
saline	B-MED
(	O
S	B-MED
)	O
received	O
0.9	O
%	O
saline	B-MED
in	O
2	O
mL	O
syringes	B-MED
,	O
20	O
min	B-MED
before	O
the	O
end	O
of	O
anaesthesia	B-MED
.	O
A	O
standardized	B-MED
(	O
1	O
mg	O
kg(-1	O
)	O
)	O
dose	B-MED
of	O
tramadol	B-MED
was	O
routinely	B-MED
administered	B-MED
to	O
all	O
patients	B-MED
as	O
the	O
loading	B-MED
dose	I-MED
at	O
the	O
end	O
of	O
surgery	B-MED
.	O
Postoperatively	B-MED
,	O
whenever	O
patients	B-MED
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-MED
patient	B-MED
-	I-MED
controlled	I-MED
analgesia	I-MED
device	I-MED
giving	O
a	O
bolus	B-MED
dose	I-MED
(	O
0.2	O
mg	O
kg(-1	O
)	O
)	O
of	O
tramadol	B-MED
.	O
Pain	B-MED
,	O
discomfort	B-MED
,	O
and	O
sedation	B-MED
scores	B-MED
,	O
cumulative	B-MED
tramadol	B-MED
consumption	B-MED
,	O
supplemental	B-MED
meperidine	B-MED
requirement	B-MED
,	O
and	O
side	B-MED
effects	I-MED
were	O
recorded	O
.	O
Visual	B-MED
rating	I-MED
scale	I-MED
and	O
patient	B-MED
discomfort	B-MED
scores	B-MED
were	O
significantly	B-MED
lower	B-MED
in	O
DT	B-MED
,	O
LR	B-MED
and	O
DS	B-MED
groups	B-MED
compared	O
to	O
those	O
in	O
in	O
group	B-MED
S	B-MED
(	O
p<0.001	O
)	O
.	O
Cumulative	B-MED
tramadol	B-MED
consumption	B-MED
was	O
significantly	B-MED
lower	B-MED
in	O
non	B-MED
-	I-MED
steroidal	I-MED
anti	I-MED
-	I-MED
inflammatory	I-MED
drug	I-MED
NSAID	B-MED
(	O
NSAID)-	O
treated	B-MED
groups	B-MED
at	O
each	O
study	B-MED
period	I-MED
after	O
the	O
second	O
postoperative	B-MED
hour	B-MED
than	O
in	O
group	B-MED
S	B-MED
(	O
p<0.001	O
)	O
.	O
Supplemental	B-MED
meperidine	B-MED
requirement	B-MED
was	O
significantly	B-MED
higher	O
in	O
group	B-MED
S	B-MED
at	O
each	O
study	B-MED
period	I-MED
after	O
postoperative	B-MED
30	O
min	B-MED
than	O
in	O
NSAID	B-MED
-	O
treated	B-MED
groups	B-MED
(	O
p<0.01	O
)	O
.	O
After	O
major	B-MED
abdominal	B-MED
surgery	I-MED
,	O
adding	O
IV	B-MED
diclophenac	B-MED
,	O
lornoxicam	B-MED
or	O
dexketoprofen	B-MED
to	O
patient	B-MED
-	I-MED
controlled	I-MED
tramadol	B-MED
resulted	O
in	O
lower	B-MED
pain	B-MED
scores	B-MED
,	O
smaller	B-MED
tramadol	B-MED
consumption	B-MED
,	O
less	O
rescue	O
supplemental	B-MED
analgesic	B-MED
requirement	B-MED
,	O
and	O
fewer	O
side	B-MED
effects	I-MED
compared	O
with	O
the	O
tramadol	B-MED
alone	O
group	B-MED
.	O
Non	B-MED
-	I-MED
intubated	I-MED
subxiphoid	B-MED
uniportal	B-MED
video	I-MED
-	I-MED
assisted	I-MED
thoracoscopic	I-MED
thymectomy	I-MED
thymectomy	B-MED
using	O
glasses	B-MED
-	I-MED
free	I-MED
3D	B-MED
vision	B-MED
Trans	B-MED
-	I-MED
sternal	I-MED
thymectomy	I-MED
has	O
long	O
been	O
accepted	B-MED
as	O
the	O
standard	B-MED
surgical	B-MED
procedure	I-MED
for	O
thymic	B-MED
masses	I-MED
.	O
Recently	B-MED
,	O
minimally	B-MED
invasive	B-MED
methods	B-MED
,	O
such	O
as	O
video	B-MED
-	I-MED
assisted	I-MED
thoracoscopic	I-MED
surgery	I-MED
(	B-MED
VATS	I-MED
)	I-MED
and	O
,	O
even	O
more	O
recently	O
,	O
non	B-MED
-	I-MED
intubated	I-MED
anesthesia	B-MED
,	O
have	O
emerged	B-MED
.	O
These	O
methods	B-MED
provide	O
advantages	B-MED
including	B-MED
reductions	B-MED
in	O
surgical	B-MED
trauma	I-MED
,	O
postoperative	B-MED
associated	I-MED
pain	I-MED
,	O
and	O
in	O
regards	O
to	O
VATS	B-MED
,	O
provide	O
certain	O
cosmetic	B-MED
benefits	B-MED
.	O
Considering	B-MED
these	O
advantages	B-MED
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	B-MED
uniportal	B-MED
VATS	I-MED
for	O
thymic	B-MED
mass	I-MED
using	O
a	O
glasses	B-MED
-	I-MED
free	I-MED
3D	B-MED
thoracoscopic	B-MED
display	B-MED
system	I-MED
.	O
Pirfenidone	B-MED
normalizes	B-MED
the	O
tumor	B-MED
microenvironment	I-MED
to	O
improve	O
chemotherapy	B-MED
Normalization	B-MED
of	O
the	O
tumor	B-MED
microenvironment	I-MED
by	O
selectively	O
targeting	B-MED
components	B-MED
of	O
the	O
tumor	B-MED
extracellular	B-MED
matrix	I-MED
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	B-MED
to	O
decompress	B-MED
tumor	B-MED
blood	B-MED
vessels	I-MED
,	O
increase	B-MED
vessel	B-MED
perfusion	B-MED
and	O
thus	O
,	O
improve	O
drug	B-MED
delivery	I-MED
and	O
the	O
efficacy	B-MED
of	O
cancer	B-MED
therapy	I-MED
.	O
Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	B-MED
safe	O
and	O
well	O
tolerated	B-MED
pharmaceutical	B-MED
agents	I-MED
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	B-MED
of	O
solid	B-MED
tumors	I-MED
and	O
enhance	B-MED
chemotherapy	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
repurposed	O
Pirfenidone	B-MED
,	O
a	O
clinically	B-MED
approved	B-MED
anti	B-MED
-	I-MED
fibrotic	I-MED
drug	I-MED
for	O
the	O
treatment	B-MED
of	O
idiopathic	B-MED
pulmonary	I-MED
fibrosis	I-MED
,	O
to	O
investigate	B-MED
its	O
possible	O
role	O
on	O
tumor	B-MED
microenvironment	I-MED
normalization	B-MED
.	O
Using	O
two	O
orthotopic	B-MED
mammary	B-MED
tumor	B-MED
models	I-MED
we	O
demonstrate	O
that	O
Pirfenidone	B-MED
reduces	B-MED
collagen	B-MED
and	O
hyaluronan	B-MED
levels	B-MED
and	O
,	O
as	O
a	O
result	B-MED
,	O
significantly	B-MED
increases	B-MED
blood	B-MED
vessel	I-MED
functionality	B-MED
and	O
perfusion	B-MED
and	O
improves	O
the	O
anti	B-MED
-	I-MED
tumor	I-MED
efficacy	I-MED
of	O
doxorubicin	B-MED
.	O
Reduction	B-MED
of	O
extracellular	B-MED
matrix	I-MED
components	I-MED
were	O
mediated	O
via	O
TGFβ	B-MED
signaling	I-MED
pathway	I-MED
inhibition	B-MED
due	O
to	O
downregulation	B-MED
of	O
TGFβ1	B-MED
,	O
COL1A1	B-MED
,	O
COL3A1	B-MED
,	O
HAS2	B-MED
,	O
HAS3	B-MED
expression	B-MED
levels	B-MED
.	O
Our	O
findings	B-MED
provide	O
evidence	B-MED
that	O
repurposing	O
Pirfenidone	B-MED
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B-MED
to	O
enhance	B-MED
drug	B-MED
delivery	I-MED
to	O
solid	B-MED
tumors	I-MED
by	O
normalizing	B-MED
the	O
tumor	B-MED
microenvironment	I-MED
.	O
Contextual	B-MED
Factors	I-MED
for	O
Stunting	B-MED
Among	O
Children	B-MED
of	O
Age	B-MED
6	O
to	O
24	O
Months	B-MED
in	O
an	O
Under	B-MED
-	I-MED
Privileged	I-MED
Community	I-MED
of	O
Dhaka	B-MED
,	O
Bangladesh	B-MED
To	O
determine	O
factors	B-MED
associated	B-MED
with	I-MED
stunting	B-MED
among	O
children	B-MED
aged	B-MED
6	O
to	O
24	O
months	B-MED
in	O
a	O
slum	B-MED
of	O
Dhaka	B-MED
,	O
Bangladesh	B-MED
.	O
We	O
conducted	O
this	O
case	B-MED
control	I-MED
study	I-MED
during	O
November	O
2009	O
to	O
December	O
2012	O
.	O
Children	B-MED
were	O
classified	O
as	O
case	O
if	O
length	B-MED
-	I-MED
for	I-MED
-	I-MED
age	I-MED
Z	I-MED
-	I-MED
score	I-MED
(	O
LAZ	B-MED
)	O
was	O
<	O
-2	O
and	O
as	O
control	B-MED
if	O
LAZ	B-MED
was	O
>	O
-1	O
SD	O
.	O
The	O
logistic	B-MED
regression	I-MED
model	I-MED
was	O
used	O
to	O
find	O
the	O
factors	B-MED
associated	B-MED
with	I-MED
stunting	B-MED
.	O
The	O
significant	O
risk	B-MED
factors	I-MED
for	O
stunting	B-MED
were	O
:	O
child	B-MED
's	I-MED
age	B-MED
>	O
12	O
months	B-MED
,	O
maternal	B-MED
undernutrition	B-MED
,	O
mother	B-MED
's	I-MED
education	I-MED
<	O
5	O
years	B-MED
,	O
consumption	B-MED
of	O
untreated	B-MED
drinking	I-MED
water	I-MED
and	O
monthly	B-MED
family	B-MED
income	B-MED
<	O
100	O
USD	B-MED
.	O
The	O
findings	B-MED
of	O
this	O
study	B-MED
reiterated	O
the	O
role	O
of	O
maternal	B-MED
undernutrition	B-MED
and	O
less	B-MED
education	I-MED
,	O
consumption	B-MED
of	O
untreated	B-MED
drinking	I-MED
water	I-MED
and	O
poor	O
family	B-MED
income	B-MED
as	O
important	O
associated	B-MED
factors	B-MED
of	O
childhood	B-MED
stunting	B-MED
in	O
resource	O
-	O
poor	O
setting	O
.	O
Quality	B-MED
of	O
nursing	B-MED
intensity	I-MED
data	I-MED
:	O
inter	B-MED
-	I-MED
rater	I-MED
reliability	I-MED
of	O
the	O
patient	B-MED
classification	B-MED
after	O
two	B-MED
decades	I-MED
in	O
clinical	B-MED
use	B-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
measure	B-MED
the	O
inter	B-MED
-	I-MED
rater	I-MED
reliability	I-MED
of	O
the	O
Oulu	B-MED
Patient	I-MED
Classification	I-MED
and	O
to	O
discuss	O
existing	O
methods	B-MED
of	O
reliability	B-MED
testing	I-MED
.	O
The	O
Oulu	B-MED
Patient	I-MED
Classification	I-MED
,	O
part	O
of	O
the	O
RAFAELA	B-MED
(	I-MED
®	I-MED
)	I-MED
System	I-MED
,	O
has	O
been	O
developed	O
to	O
assist	B-MED
nursing	B-MED
managers	I-MED
with	O
the	O
proper	O
allocation	B-MED
of	O
nursing	B-MED
resources	B-MED
.	O
Due	O
to	O
the	O
increased	B-MED
intensity	B-MED
of	O
inpatient	B-MED
care	I-MED
during	O
recent	O
years	B-MED
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability	B-MED
testing	I-MED
of	O
the	O
classification	B-MED
,	O
which	O
has	O
been	O
in	O
clinical	B-MED
use	B-MED
for	O
20	O
years	B-MED
.	O
Retrospective	B-MED
statistical	B-MED
study	I-MED
.	O
To	O
test	B-MED
inter	B-MED
-	I-MED
rater	I-MED
reliability	I-MED
,	O
a	O
pair	O
of	O
nurses	B-MED
classified	B-MED
the	O
same	O
patients	B-MED
,	O
without	O
knowledge	O
of	O
each	O
other	O
's	O
ratings	B-MED
,	O
as	O
a	O
part	O
of	O
annually	B-MED
conducted	O
standardization	B-MED
.	O
Data	B-MED
on	O
the	O
parallel	B-MED
classifications	I-MED
(	O
n	O
=	O
19,997	O
)	O
was	O
obtained	B-MED
from	O
inpatient	B-MED
units	O
(	O
n	O
=	O
32	O
)	O
with	O
different	B-MED
specialties	B-MED
at	O
a	O
university	B-MED
hospital	I-MED
in	O
Finland	B-MED
during	O
2010	O
-	O
2015	O
.	O
Parallel	B-MED
classification	I-MED
practices	B-MED
were	O
also	O
analysed	O
.	O
The	O
reliability	B-MED
of	O
the	O
overall	O
classification	B-MED
and	O
its	O
subareas	O
were	O
calculated	B-MED
using	O
suitable	O
statistical	B-MED
coefficients	I-MED
.	O
Inter	B-MED
-	I-MED
rater	I-MED
reliability	I-MED
coefficients	B-MED
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-MED
intensity	B-MED
category	B-MED
and	O
various	O
practices	B-MED
,	O
but	O
there	O
were	O
detectable	B-MED
differences	B-MED
between	O
subareas	O
.	O
The	O
lowest	O
agreement	B-MED
levels	B-MED
occurred	B-MED
in	O
the	O
subareas	O
'	O
Planning	B-MED
and	I-MED
Coordination	I-MED
of	I-MED
Nursing	I-MED
Care	I-MED
'	O
and	O
'	O
Guiding	B-MED
of	I-MED
Care	I-MED
/	O
Continued	B-MED
Care	I-MED
and	O
Emotional	B-MED
Support	I-MED
'	O
.	O
There	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	B-MED
of	O
subareas	O
and	O
to	O
clarify	B-MED
the	O
related	O
concepts	B-MED
.	O
Precise	O
nursing	B-MED
documentation	I-MED
can	O
promote	B-MED
a	O
high	O
level	B-MED
of	O
agreement	B-MED
and	O
reliable	O
results	B-MED
.	O
The	O
traditional	O
overall	O
proportion	O
of	O
agreement	B-MED
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa	B-MED
coefficients	I-MED
should	O
be	O
used	O
instead	O
.	O
Identification	B-MED
of	O
Predictive	O
DNA	B-MED
Methylation	I-MED
Biomarkers	B-MED
for	O
Chemotherapy	B-MED
Response	B-MED
in	O
Colorectal	B-MED
Cancer	I-MED
Resistance	B-MED
to	O
5	B-MED
-	I-MED
Fluorouracil	I-MED
(	O
5	B-MED
-	I-MED
FU	I-MED
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	B-MED
of	O
colorectal	B-MED
cancer	I-MED
(	O
CRC	B-MED
)	O
and	O
posed	O
an	O
increased	O
risk	B-MED
of	I-MED
recurrence	I-MED
.	O
DNA	B-MED
methylation	I-MED
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	B-MED
for	O
recurrent	B-MED
disease	I-MED
and	O
its	O
contribution	B-MED
to	O
the	O
development	O
of	O
drug	B-MED
resistance	I-MED
remains	O
to	O
be	O
clarified	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
determine	O
the	O
methylation	B-MED
phenotype	B-MED
in	O
CRC	B-MED
for	O
identification	B-MED
of	O
predictive	O
markers	B-MED
for	O
chemotherapy	B-MED
response	B-MED
.	O
We	O
performed	O
DNA	B-MED
methylation	I-MED
profiling	B-MED
on	O
43	O
non	B-MED
-	I-MED
recurrent	I-MED
and	O
five	O
recurrent	B-MED
CRC	B-MED
patients	B-MED
using	O
the	O
Illumina	B-MED
Infinium	I-MED
HumanMethylation450	I-MED
Beadchip	I-MED
assay	I-MED
.	O
In	O
addition	O
,	O
CRC	B-MED
cells	B-MED
with	O
different	O
genetic	B-MED
backgrounds	I-MED
,	O
response	B-MED
to	O
5	B-MED
-	I-MED
FU	I-MED
and	O
global	B-MED
methylation	I-MED
levels	B-MED
(	O
HT29	B-MED
and	O
SW48	B-MED
)	O
were	O
treated	B-MED
with	O
5	B-MED
-	I-MED
FU	I-MED
and	O
DNA	B-MED
methylation	I-MED
inhibitor	B-MED
5	B-MED
-	I-MED
aza-2'-deoxycytidine	I-MED
(	O
5	B-MED
-	I-MED
azadC	I-MED
)	O
.	O
The	O
singular	O
and	O
combined	O
effects	B-MED
of	O
these	O
two	O
drug	B-MED
classes	B-MED
on	O
cell	B-MED
viability	I-MED
and	O
global	B-MED
methylation	I-MED
profiles	B-MED
were	O
investigated	O
.	O
Our	O
genome	B-MED
-	I-MED
wide	I-MED
methylation	I-MED
study	I-MED
on	O
the	O
clinical	B-MED
specimens	B-MED
showed	O
that	O
recurrent	B-MED
CRCs	B-MED
exhibited	O
higher	O
methylation	B-MED
levels	B-MED
compared	O
to	O
non	B-MED
-	I-MED
recurrent	I-MED
CRCs	B-MED
.	O
We	O
identified	B-MED
4787	O
significantly	O
differentially	O
methylated	B-MED
genes	I-MED
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	B-MED
were	O
hyper	B-MED
-	O
while	O
1675	O
genes	B-MED
were	O
hypomethylated	B-MED
in	O
the	O
recurrent	B-MED
group	B-MED
compared	O
to	O
the	O
non	B-MED
-	I-MED
recurrent	I-MED
.	O
Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	B-MED
and	I-MED
hypomethylated	I-MED
genes	I-MED
have	O
an	O
absolute	O
recurrent	B-MED
/	O
non	B-MED
-	I-MED
recurrent	I-MED
methylation	B-MED
difference	O
of	O
≥20	O
%	O
.	O
Most	O
of	O
the	O
hypermethylated	B-MED
genes	I-MED
were	O
involved	O
in	O
the	O
MAPK	B-MED
signaling	I-MED
pathway	I-MED
which	O
is	O
a	O
key	O
regulator	B-MED
for	O
apoptosis	B-MED
while	O
the	O
hypomethylated	B-MED
genes	I-MED
were	O
involved	O
in	O
the	O
PI3K	B-MED
-	I-MED
AKT	I-MED
signaling	I-MED
pathway	I-MED
and	O
proliferation	B-MED
process	I-MED
.	O
We	O
also	O
demonstrate	O
that	O
5	B-MED
-	I-MED
azadC	I-MED
treatment	B-MED
enhanced	O
response	B-MED
to	O
5	B-MED
-	I-MED
FU	I-MED
which	O
resulted	O
in	O
significant	O
growth	B-MED
inhibition	I-MED
compared	O
to	O
5	B-MED
-	I-MED
FU	I-MED
alone	O
in	O
hypermethylated	B-MED
cell	I-MED
lines	I-MED
SW48	I-MED
.	O
In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B-MED
in	O
recurrent	B-MED
CRCs	B-MED
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-MED
targets	B-MED
for	O
patients	B-MED
with	O
chemoresistance	B-MED
.	O
We	O
postulate	O
that	O
aberrant	B-MED
methylation	B-MED
of	O
CCNEI	B-MED
,	O
CCNDBP1	B-MED
,	O
PON3	B-MED
,	O
DDX43	B-MED
,	O
and	O
CHL1	B-MED
in	O
CRC	B-MED
might	O
be	O
associated	B-MED
with	I-MED
the	O
recurrence	B-MED
of	O
CRC	B-MED
and	O
5	B-MED
-	I-MED
azadC	I-MED
-mediated	O
restoration	O
of	O
5	B-MED
-	I-MED
FU	I-MED
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	B-MED
signaling	I-MED
pathway	I-MED
.	O
3Mo	B-MED
:	O
A	O
Model	B-MED
for	O
Music	B-MED
-	O
Based	B-MED
Biofeedback	B-MED
In	O
the	O
domain	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
,	O
it	O
is	O
of	O
major	B-MED
importance	B-MED
to	O
regulate	B-MED
and	O
control	B-MED
physiological	B-MED
processes	I-MED
and	O
physical	B-MED
motion	I-MED
in	O
most	B-MED
optimal	B-MED
ways	O
.	O
For	O
that	O
purpose	B-MED
,	O
real	B-MED
-	I-MED
time	I-MED
auditory	B-MED
feedback	I-MED
of	O
physiological	B-MED
and	O
physical	B-MED
information	B-MED
based	B-MED
on	O
sound	B-MED
signals	I-MED
,	O
often	O
termed	O
"	O
sonification	B-MED
,	O
"	O
has	O
been	O
proven	B-MED
particularly	O
useful	B-MED
.	O
However	O
,	O
the	O
use	B-MED
of	O
music	B-MED
in	O
biofeedback	B-MED
systems	B-MED
has	O
been	O
much	O
less	B-MED
explored	B-MED
.	O
In	O
the	O
current	B-MED
article	B-MED
,	O
we	O
assert	O
that	O
the	O
use	B-MED
of	O
music	B-MED
,	O
and	O
musical	B-MED
principles	B-MED
,	O
can	O
have	O
a	O
major	B-MED
added	O
value	B-MED
,	O
on	O
top	O
of	O
mere	B-MED
sound	B-MED
signals	I-MED
,	O
to	O
the	O
benefit	B-MED
of	O
psychological	B-MED
and	O
physical	B-MED
optimization	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
tasks	B-MED
.	O
In	O
this	O
article	B-MED
,	O
we	O
present	B-MED
the	O
3Mo	B-MED
model	I-MED
to	O
describe	O
three	O
main	B-MED
functions	B-MED
of	O
music	B-MED
that	O
contribute	B-MED
to	O
these	O
benefits	B-MED
.	O
These	O
functions	B-MED
relate	O
the	O
power	B-MED
of	O
music	B-MED
to	O
Motivate	B-MED
,	O
and	O
to	O
Monitor	B-MED
and	O
Modify	B-MED
physiological	B-MED
and	O
physical	B-MED
processes	B-MED
.	O
The	O
model	B-MED
brings	O
together	O
concepts	B-MED
and	O
theories	B-MED
related	O
to	O
human	B-MED
sensorimotor	B-MED
interaction	I-MED
with	O
music	B-MED
,	O
and	O
specifies	B-MED
the	O
underlying	O
psychological	B-MED
and	O
physiological	B-MED
principles	B-MED
.	O
This	O
3Mo	B-MED
model	I-MED
is	O
intended	B-MED
to	O
provide	B-MED
a	O
conceptual	B-MED
framework	I-MED
that	O
guides	B-MED
future	B-MED
research	B-MED
on	O
musical	B-MED
biofeedback	B-MED
systems	B-MED
in	O
the	O
domain	B-MED
of	O
sports	B-MED
and	O
motor	B-MED
rehabilitation	B-MED
.	O
Journal	O
Professional	B-MED
reinventions	I-MED
:	O
Swedish	B-MED
psychologists	B-MED
,	O
1990	O
-	O
2010	O
Since	O
the	O
early	O
20th	B-MED
century	I-MED
,	O
the	O
Swedish	B-MED
psychology	B-MED
profession	I-MED
has	O
undergone	O
several	O
changes	B-MED
in	O
its	O
essential	B-MED
tasks	I-MED
,	O
epistemological	B-MED
foundations	I-MED
,	O
and	O
social	B-MED
roles	I-MED
.	O
These	O
changes	B-MED
occurred	B-MED
through	O
an	O
ongoing	O
"	O
tuning	O
"	O
with	O
Swedish	B-MED
society	B-MED
,	O
in	O
which	O
the	O
profession	B-MED
strove	O
to	O
appear	O
relevant	O
to	O
society	B-MED
's	I-MED
concerns	B-MED
and	O
problems	B-MED
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession	B-MED
's	I-MED
goals	B-MED
and	O
aims	B-MED
.	O
Studying	O
the	O
history	B-MED
of	O
the	O
profession	B-MED
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	B-MED
definitions	B-MED
and	O
contours	B-MED
of	O
the	O
psychology	B-MED
profession	I-MED
itself	O
as	O
well	O
as	O
on	O
the	O
organization	B-MED
of	O
the	O
society	B-MED
in	O
which	O
it	O
acts	O
.	O
This	O
article	B-MED
examines	O
the	O
history	B-MED
of	O
the	O
Swedish	B-MED
psychology	B-MED
profession	I-MED
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	B-MED
of	O
the	O
discussions	B-MED
and	O
debates	B-MED
taking	O
place	O
in	O
the	O
Swedish	B-MED
Psychological	B-MED
Association	I-MED
's	I-MED
journal	I-MED
.	O
The	O
analytical	B-MED
framework	I-MED
used	O
draws	O
on	O
work	O
done	O
within	O
actor	B-MED
-	I-MED
network	I-MED
theory	I-MED
and	O
science	B-MED
studies	I-MED
.	O
We	O
argue	O
that	O
the	O
profession	B-MED
's	I-MED
institutional	B-MED
connections	I-MED
,	O
defining	O
tasks	B-MED
,	O
epistemological	B-MED
underpinnings	B-MED
,	O
and	O
social	B-MED
position	I-MED
have	O
changed	B-MED
in	O
major	O
ways	O
during	O
these	O
2	O
decades	B-MED
.	O
Overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-MED
,	O
the	O
profession	B-MED
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	B-MED
itself	O
to	O
politicians	B-MED
,	O
the	O
media	B-MED
,	O
patients	B-MED
,	O
and	O
customers	B-MED
through	O
means	O
such	O
as	O
a	O
more	O
economized	B-MED
vocabulary	B-MED
and	O
novel	B-MED
forms	O
of	O
empirical	B-MED
research	I-MED
.	O
These	O
changes	B-MED
have	O
led	O
to	O
a	O
more	O
socialized	B-MED
profession	B-MED
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-MED
in	O
Swedish	B-MED
society	B-MED
,	O
leading	O
to	O
conflicts	B-MED
within	O
the	O
profession	B-MED
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	B-MED
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	B-MED
of	I-MED
autonomy	I-MED
.	O
(	O
PsycINFO	B-MED
Database	I-MED
Record	I-MED
Albumin	B-MED
-Bioinspired	O
Gd	B-MED
:	O
CuS	B-MED
Nanotheranostic	B-MED
Agent	I-MED
for	O
In	B-MED
Vivo	I-MED
Photoacoustic	B-MED
Photoacoustic	B-MED
/	I-MED
Magnetic	I-MED
Resonance	I-MED
Imaging	I-MED
-Guided	I-MED
Tumor	I-MED
-Targeted	I-MED
Photothermal	I-MED
Therapy	I-MED
Magnetic	B-MED
Resonance	I-MED
Imaging	I-MED
Tumor	B-MED
Photothermal	B-MED
therapy	I-MED
(	O
PTT	B-MED
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	B-MED
skin	B-MED
cancer	I-MED
therapy	I-MED
in	O
the	O
clinic	B-MED
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	B-MED
and	O
low	B-MED
systemic	I-MED
adverse	I-MED
effects	I-MED
.	O
However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	B-MED
PTT	I-MED
agents	I-MED
,	O
which	O
enable	O
accurate	B-MED
imaging	B-MED
,	O
monitoring	B-MED
,	O
and	O
diagnosis	B-MED
.	O
Herein	O
,	O
a	O
biocompatible	B-MED
Gd	I-MED
-integrated	I-MED
CuS	I-MED
nanotheranostic	I-MED
agent	I-MED
Gd	B-MED
CuS	B-MED
(	O
Gd	B-MED
:	O
CuS	B-MED
@	O
BSA	B-MED
)	O
was	O
synthesized	B-MED
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	B-MED
strategy	I-MED
,	O
using	O
bovine	B-MED
serum	I-MED
albumin	I-MED
(	O
BSA	B-MED
)	O
as	O
a	O
biotemplate	B-MED
at	O
physiological	B-MED
temperature	I-MED
.	O
The	O
as	O
-	O
prepared	O
Gd	B-MED
:	O
CuS	B-MED
@	O
BSA	B-MED
nanoparticles	B-MED
(	O
NPs	B-MED
)	O
with	O
ultrasmall	B-MED
sizes	I-MED
(	O
ca	O
.	O
9	O
nm	O
)	O
exhibited	O
high	O
photothermal	B-MED
conversion	I-MED
efficiency	I-MED
and	O
good	O
photostability	B-MED
under	O
near	B-MED
-	I-MED
infrared	I-MED
(	I-MED
NIR	I-MED
)	I-MED
laser	I-MED
irradiation	B-MED
.	O
With	O
doped	B-MED
Gd	I-MED
species	I-MED
and	O
strong	O
tunable	B-MED
NIR	I-MED
absorbance	I-MED
,	O
Gd	B-MED
:	O
CuS	B-MED
@	O
BSA	B-MED
NPs	B-MED
demonstrate	O
prominent	O
tumor	B-MED
-	I-MED
contrasted	I-MED
imaging	I-MED
performance	O
both	O
on	O
the	O
photoacoustic	B-MED
photoacoustic	B-MED
and	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
modalities	I-MED
magnetic	B-MED
resonance	I-MED
imaging	I-MED
.	O
The	O
subsequent	O
Gd	B-MED
Gd	B-MED
:	I-MED
CuS	I-MED
@	I-MED
BSA	I-MED
-mediated	I-MED
PTT	I-MED
CuS	B-MED
BSA	B-MED
result	O
shows	O
high	O
therapy	B-MED
efficacy	I-MED
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	B-MED
absorption	I-MED
and	O
high	O
photothermal	B-MED
conversion	I-MED
efficiency	I-MED
.	O
The	O
immune	B-MED
response	I-MED
triggered	B-MED
by	I-MED
Gd	B-MED
Gd	B-MED
:	I-MED
CuS	I-MED
@	I-MED
BSA	I-MED
-mediated	I-MED
PTT	I-MED
CuS	B-MED
BSA	B-MED
is	O
preliminarily	O
explored	O
.	O
In	O
addition	O
,	O
toxicity	B-MED
studies	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
verify	O
that	O
Gd	B-MED
:	O
CuS	B-MED
@	O
BSA	B-MED
NPs	B-MED
qualify	O
as	O
biocompatible	B-MED
agents	I-MED
.	O
A	O
biodistribution	B-MED
study	I-MED
demonstrated	O
that	O
the	O
NPs	B-MED
can	O
undergo	O
hepatic	B-MED
clearance	I-MED
from	O
the	O
body	B-MED
.	O
This	O
study	O
highlights	O
the	O
practicality	B-MED
and	O
versatility	B-MED
of	O
albumin	B-MED
albumin	B-MED
-mediated	I-MED
biomimetic	I-MED
mineralization	I-MED
of	O
a	O
nanotheranostic	B-MED
agent	I-MED
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	B-MED
:	O
CuS	B-MED
@	O
BSA	B-MED
NPs	B-MED
possess	O
promising	O
imaging	B-MED
guidance	I-MED
and	O
effective	O
tumor	B-MED
ablation	I-MED
properties	I-MED
,	O
with	O
high	O
spatial	B-MED
resolution	I-MED
and	O
deep	B-MED
tissue	I-MED
penetration	I-MED
tissue	B-MED
.	O
Causes	O
of	O
ecological	B-MED
gradients	B-MED
in	O
leaf	B-MED
margin	B-MED
entirety	B-MED
:	O
Evaluating	B-MED
the	O
roles	B-MED
of	O
biomechanics	B-MED
,	O
hydraulics	B-MED
,	O
vein	B-MED
geometry	I-MED
,	O
and	O
bud	B-MED
packing	B-MED
A	O
recent	B-MED
commentary	B-MED
by	O
Edwards	O
et	O
al	O
.	O
(	O
Am	O
.	O
J.	O
Bot	O
.	O
103	O
:	O
975	O
-	O
978	O
)	O
proposed	B-MED
that	O
constraints	B-MED
imposed	O
by	O
the	O
packing	B-MED
of	O
young	B-MED
leaves	B-MED
in	O
buds	B-MED
could	O
explain	O
the	O
positive	B-MED
association	B-MED
between	O
non	B-MED
-	I-MED
entire	I-MED
leaf	B-MED
margins	B-MED
and	O
latitude	B-MED
but	O
did	O
not	O
thoroughly	O
consider	B-MED
alternative	B-MED
explanations	B-MED
.	O
We	O
review	B-MED
the	O
logic	B-MED
and	O
evidence	B-MED
underlying	O
six	O
major	B-MED
hypotheses	B-MED
for	O
the	O
functional	B-MED
significance	B-MED
of	O
marginal	B-MED
teeth	B-MED
,	O
involving	O
putative	B-MED
effects	B-MED
on	O
(	O
1	O
)	O
leaf	B-MED
cooling	B-MED
,	O
(	O
2	O
)	O
optimal	B-MED
support	O
and	O
supply	O
of	O
the	O
areas	B-MED
served	O
by	O
major	B-MED
veins	B-MED
,	O
(	O
3	O
)	O
enhanced	B-MED
leaf	B-MED
-	O
margin	B-MED
photosynthesis	B-MED
,	O
(	O
4	O
)	O
hydathodal	B-MED
function	I-MED
,	O
(	O
5	O
)	O
defense	B-MED
against	B-MED
herbivores	B-MED
,	O
and	O
(	O
6	O
)	O
bud	B-MED
packing	B-MED
.	O
Theoretical	B-MED
and	O
empirical	B-MED
problems	B-MED
undermine	O
all	O
hypotheses	B-MED
except	B-MED
the	O
support	B-MED
-	I-MED
supply	I-MED
hypothesis	I-MED
,	O
which	O
implies	O
that	O
thinner	B-MED
leaves	B-MED
should	O
have	O
non	B-MED
-	I-MED
entire	I-MED
margins	B-MED
.	O
Phylogenetically	B-MED
structured	B-MED
analyses	I-MED
across	O
angiosperms	B-MED
,	O
the	O
El	B-MED
Yunque	I-MED
flora	B-MED
,	O
and	O
the	O
genus	B-MED
Viburnum	B-MED
all	O
demonstrate	O
that	O
non	B-MED
-	I-MED
entire	I-MED
margins	B-MED
are	O
indeed	B-MED
more	O
common	B-MED
in	O
thinner	B-MED
leaves	B-MED
.	O
Across	O
angiosperms	B-MED
,	O
the	O
association	B-MED
of	O
leaf	B-MED
thickness	B-MED
with	O
non	B-MED
-	I-MED
entire	I-MED
leaf	B-MED
margins	B-MED
is	O
stronger	B-MED
than	O
that	O
of	O
latitude	B-MED
.	O
We	O
outline	B-MED
a	O
synthetic	B-MED
model	I-MED
showing	O
how	O
biomechanics	B-MED
,	O
hydraulics	B-MED
,	O
vein	B-MED
geometry	B-MED
,	O
rates	B-MED
of	O
leaf	B-MED
expansion	B-MED
,	O
and	O
length	O
of	O
development	B-MED
within	O
resting	B-MED
buds	B-MED
,	O
all	O
tied	O
to	O
leaf	B-MED
thickness	B-MED
,	O
drive	B-MED
patterns	B-MED
in	O
the	O
distribution	B-MED
of	O
entire	B-MED
vs.	O
non	B-MED
-	I-MED
entire	I-MED
leaf	B-MED
margins	B-MED
.	O
Our	O
model	B-MED
accounts	O
for	O
dominance	B-MED
of	O
entire	B-MED
margins	B-MED
in	O
the	O
tropics	B-MED
,	O
Mediterranean	B-MED
scrub	I-MED
,	O
and	O
tundra	B-MED
,	O
non	B-MED
-	I-MED
entire	I-MED
margins	B-MED
in	O
cold	B-MED
temperate	I-MED
deciduous	B-MED
forests	I-MED
and	O
tropical	B-MED
vines	B-MED
and	O
early	B-MED
-	I-MED
successional	I-MED
trees	I-MED
,	O
and	O
entire	B-MED
leaf	B-MED
margins	B-MED
in	O
monocots	B-MED
.	O
Spinose	B-MED
-	I-MED
toothed	I-MED
leaves	I-MED
should	O
be	O
favored	O
in	O
short	B-MED
-	I-MED
statured	I-MED
evergreen	B-MED
trees	I-MED
and	O
shrubs	B-MED
,	O
primarily	O
in	O
Mediterranean	B-MED
scrub	I-MED
and	O
related	O
semiarid	B-MED
habitats	I-MED
.	O
Diffuse	B-MED
traumatic	I-MED
brain	I-MED
injury	I-MED
affects	O
chronic	B-MED
corticosterone	B-MED
function	B-MED
in	O
the	O
rat	B-MED
As	O
many	O
as	O
20	O
-	O
55	O
%	O
of	O
patients	B-MED
with	O
a	O
history	B-MED
of	O
traumatic	B-MED
brain	I-MED
injury	I-MED
(	O
TBI	B-MED
)	O
experience	O
chronic	B-MED
endocrine	B-MED
dysfunction	I-MED
,	O
leading	O
to	O
impaired	B-MED
quality	I-MED
of	I-MED
life	I-MED
,	O
impaired	B-MED
rehabilitation	B-MED
efforts	B-MED
and	O
lowered	B-MED
life	I-MED
expectancy	I-MED
.	O
Endocrine	B-MED
dysfunction	I-MED
after	O
TBI	B-MED
is	O
thought	O
to	O
result	B-MED
from	O
acceleration	B-MED
-	O
deceleration	B-MED
forces	B-MED
to	O
the	O
brain	B-MED
within	O
the	O
skull	B-MED
,	O
creating	O
enduring	O
hypothalamic	B-MED
and	O
pituitary	B-MED
neuropathology	B-MED
,	O
and	O
subsequent	O
hypothalamic	B-MED
hypothalamic	B-MED
-pituitary	I-MED
endocrine	I-MED
(	O
HPE	B-MED
)	O
dysfunction	B-MED
.	O
These	O
experiments	B-MED
were	O
designed	O
to	O
test	O
the	O
hypothesis	B-MED
that	O
a	O
single	O
diffuse	B-MED
TBI	I-MED
results	B-MED
in	O
chronic	B-MED
dysfunction	B-MED
of	O
corticosterone	B-MED
(	O
CORT	B-MED
)	O
,	O
a	O
glucocorticoid	B-MED
released	B-MED
in	O
response	O
to	O
stress	B-MED
and	O
testosterone	B-MED
.	O
We	O
used	O
a	O
rodent	B-MED
model	I-MED
of	O
diffuse	B-MED
TBI	I-MED
induced	O
by	O
midline	B-MED
fluid	I-MED
percussion	I-MED
injury	I-MED
(	O
mFPI	B-MED
)	O
.	O
At	O
2	O
months	B-MED
postinjury	B-MED
compared	B-MED
with	O
uninjured	B-MED
control	I-MED
animals	I-MED
,	O
circulating	B-MED
levels	B-MED
of	O
CORT	B-MED
were	O
evaluated	O
at	B-MED
rest	I-MED
,	O
under	O
restraint	B-MED
stress	I-MED
and	O
in	O
response	O
to	O
dexamethasone	B-MED
,	O
a	O
synthetic	B-MED
glucocorticoid	I-MED
commonly	O
used	O
to	O
test	O
HPE	B-MED
axis	B-MED
regulation	B-MED
.	O
Testosterone	B-MED
was	O
evaluated	B-MED
at	B-MED
rest	I-MED
.	O
Further	O
,	O
we	O
assessed	O
changes	B-MED
in	O
injury	B-MED
-	O
induced	B-MED
neuron	B-MED
morphology	B-MED
(	O
Golgi	B-MED
stain	I-MED
)	O
,	O
neuropathology	B-MED
(	O
silver	B-MED
stain	I-MED
)	O
and	O
activated	B-MED
astrocytes	B-MED
(	O
GFAP	B-MED
)	O
in	O
the	O
paraventricular	B-MED
nucleus	I-MED
(	O
PVN	B-MED
)	O
of	O
the	O
hypothalamus	B-MED
.	O
Resting	O
plasma	B-MED
CORT	B-MED
levels	B-MED
were	O
decreased	B-MED
at	O
2	O
months	B-MED
postinjury	B-MED
and	O
there	O
was	O
a	O
blunted	O
CORT	B-MED
increase	B-MED
in	O
response	O
to	O
restraint	B-MED
induced	I-MED
stress	I-MED
.	O
No	B-MED
changes	I-MED
in	O
testosterone	B-MED
were	O
measured	B-MED
.	O
These	O
changes	B-MED
in	O
CORT	B-MED
were	O
observed	O
concomitantly	B-MED
with	O
altered	B-MED
complexity	B-MED
of	O
neuron	B-MED
processes	B-MED
in	O
the	O
PVN	B-MED
over	O
time	B-MED
,	O
devoid	O
of	O
neuropathology	B-MED
or	O
astrocytosis	B-MED
.	O
Results	B-MED
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	B-MED
TBI	I-MED
leads	O
to	O
changes	B-MED
in	O
CORT	B-MED
function	B-MED
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	B-MED
of	I-MED
symptoms	I-MED
related	O
to	O
endocrine	B-MED
dysfunction	I-MED
.	O
Future	O
experiments	B-MED
aim	O
to	O
evaluate	B-MED
additional	O
HP	B-MED
-	I-MED
related	I-MED
hormones	I-MED
and	O
endocrine	B-MED
circuit	B-MED
pathology	I-MED
following	O
diffuse	B-MED
TBI	I-MED
.	O
High	O
-	O
Throughput	O
Genotyping	B-MED
with	O
TaqMan	B-MED
Allelic	I-MED
Discrimination	I-MED
and	O
Allele	B-MED
-	I-MED
Specific	I-MED
Genotyping	I-MED
Assays	I-MED
Real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
-based	O
genotyping	B-MED
methods	I-MED
,	O
such	O
as	O
TaqMan	B-MED
allelic	I-MED
discrimination	I-MED
assays	I-MED
and	O
allele	B-MED
-	I-MED
specific	I-MED
genotyping	I-MED
,	O
are	O
particularly	O
useful	B-MED
when	O
screening	B-MED
a	O
handful	O
of	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
in	O
hundreds	O
of	O
samples	B-MED
;	O
either	O
derived	O
from	O
different	B-MED
individuals	B-MED
,	O
tissues	B-MED
,	O
or	O
pre	B-MED
-	O
amplified	B-MED
DNA	I-MED
.	O
Although	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
-	O
based	B-MED
methods	B-MED
such	O
as	O
TaqMan	B-MED
are	O
well	B-MED
-	I-MED
established	I-MED
,	O
alternative	B-MED
methods	B-MED
,	O
like	O
allele	B-MED
-	I-MED
specific	I-MED
genotyping	I-MED
,	O
are	O
powerful	O
alternatives	B-MED
,	O
especially	O
for	O
genotyping	B-MED
short	B-MED
tandem	I-MED
repeat	I-MED
(	B-MED
STR	I-MED
)	I-MED
length	B-MED
polymorphisms	B-MED
.	O
Here	O
,	O
we	O
describe	O
all	O
relevant	B-MED
aspects	B-MED
when	O
developing	B-MED
an	O
assay	B-MED
for	O
a	O
new	O
SNP	B-MED
or	O
STR	B-MED
using	O
either	O
TaqMan	B-MED
or	O
allele	B-MED
-	I-MED
specific	I-MED
genotyping	I-MED
,	O
respectively	O
,	O
such	O
as	O
primer	B-MED
and	O
probe	B-MED
design	O
,	O
optimization	B-MED
of	O
reaction	B-MED
conditions	B-MED
,	O
the	O
experimental	B-MED
procedure	I-MED
for	I-MED
typing	I-MED
hundreds	O
of	O
samples	B-MED
,	O
and	O
finally	O
the	O
data	B-MED
evaluation	B-MED
.	O
Our	O
goal	B-MED
is	O
to	O
provide	B-MED
a	O
guideline	B-MED
for	O
developing	B-MED
genotyping	B-MED
assays	I-MED
using	O
these	O
two	O
approaches	B-MED
that	O
render	O
reliable	O
and	O
reproducible	B-MED
genotype	B-MED
calls	I-MED
involving	B-MED
minimal	B-MED
optimization	B-MED
.	O
Effect	B-MED
of	O
New	B-MED
-	I-MED
Onset	I-MED
Left	B-MED
Bundle	I-MED
Branch	I-MED
Block	I-MED
After	O
Transcatheter	B-MED
Aortic	I-MED
Valve	I-MED
Implantation	I-MED
(	O
CoreValve	B-MED
)	O
on	O
Mortality	B-MED
,	O
Frequency	B-MED
of	O
Re	B-MED
-	I-MED
Hospitalization	I-MED
,	O
and	O
Need	O
for	O
Pacemaker	B-MED
New	B-MED
-	I-MED
onset	I-MED
conduction	B-MED
disturbances	I-MED
are	O
common	O
after	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
(	O
TAVI	B-MED
)	O
.	O
The	O
most	O
common	O
complication	B-MED
is	O
left	B-MED
bundle	I-MED
branch	I-MED
block	I-MED
(	O
LBBB	B-MED
)	O
.	O
The	O
clinical	B-MED
impact	B-MED
of	O
new	B-MED
-	I-MED
onset	I-MED
LBBB	B-MED
after	O
TAVI	B-MED
remains	O
controversial	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	B-MED
impact	B-MED
of	O
new	B-MED
-	I-MED
onset	I-MED
LBBB	B-MED
in	O
terms	O
of	O
mortality	B-MED
and	O
morbidity	B-MED
(	O
need	O
for	O
pacemakers	B-MED
and	O
admissions	B-MED
for	O
heart	B-MED
failure	I-MED
)	O
at	O
long	B-MED
-	I-MED
term	I-MED
follow	I-MED
-	I-MED
up	I-MED
.	O
From	O
April	O
2008	O
to	O
December	O
2014	O
,	O
220	O
patients	B-MED
who	O
had	O
severe	O
aortic	B-MED
stenosis	I-MED
were	O
treated	B-MED
with	I-MED
the	O
implantation	B-MED
of	O
a	O
CoreValve	B-MED
prosthesis	I-MED
.	O
Sixty	O
-	O
seven	O
of	O
these	O
patients	B-MED
were	O
excluded	O
from	O
the	O
analysis	B-MED
,	O
including	O
22	O
patients	B-MED
with	O
pre	B-MED
-	I-MED
existing	I-MED
LBBB	B-MED
and	O
45	O
with	O
a	O
permanent	B-MED
pacemaker	I-MED
,	O
implanted	B-MED
previously	O
or	O
within	O
72	O
hours	B-MED
of	O
implantation	B-MED
.	O
The	O
remaining	O
153	O
patients	B-MED
were	O
divided	O
into	O
2	O
groups	B-MED
:	O
group	B-MED
1	O
(	O
n	O
=	O
80	O
)	O
,	O
those	O
with	O
persistent	B-MED
new	B-MED
-	I-MED
onset	I-MED
LBBB	B-MED
,	O
and	O
group	B-MED
2	O
(	O
n	O
=	O
73	O
)	O
,	O
those	O
without	O
conduction	B-MED
disturbances	I-MED
after	O
treatment	B-MED
.	O
Both	O
groups	B-MED
were	O
followed	B-MED
up	I-MED
at	O
1	O
month	B-MED
,	O
6	O
months	B-MED
,	O
12	O
months	B-MED
,	O
and	O
yearly	B-MED
thereafter	O
.	O
Persistent	B-MED
new	B-MED
-	I-MED
onset	I-MED
LBBB	B-MED
occurred	O
in	O
80	O
patients	B-MED
(	O
36	O
%	O
)	O
immediately	O
after	O
TAVI	B-MED
;	O
73	O
patients	B-MED
(	O
33	O
%	O
)	O
did	O
not	O
develop	O
conduction	B-MED
disturbances	I-MED
.	O
The	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
of	O
both	O
groups	B-MED
was	O
32	O
±	O
22	O
months	B-MED
(	O
range	O
3	O
to	O
82	O
months	B-MED
)	O
,	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	B-MED
between	O
the	O
groups	B-MED
.	O
There	O
were	O
no	O
differences	O
in	O
mortality	B-MED
between	O
the	O
groups	B-MED
(	O
39	O
%	O
vs	O
48	O
%	O
,	O
p	O
=	O
0.58	O
)	O
.	O
No	O
differences	O
were	O
observed	O
between	O
the	O
groups	B-MED
in	O
re	B-MED
-	I-MED
hospitalizations	I-MED
for	O
heart	B-MED
failure	I-MED
(	O
11	O
%	O
vs	O
16	O
%	O
,	O
p	O
=	O
0.55	O
)	O
.	O
Group	B-MED
1	O
did	O
not	O
require	O
pacemaker	B-MED
implantation	I-MED
more	O
often	O
at	O
follow	B-MED
-	I-MED
up	I-MED
(	O
10	O
%	O
vs	O
13	O
%	O
,	O
p	O
=	O
0.38	O
)	O
than	O
group	B-MED
2	O
.	O
In	O
conclusion	O
,	O
new	B-MED
-	I-MED
onset	I-MED
LBBB	B-MED
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	B-MED
incidence	B-MED
of	O
late	O
need	O
for	O
a	O
permanent	B-MED
pacemaker	I-MED
after	O
CoreValve	B-MED
implantation	B-MED
.	O
In	O
addition	O
,	O
it	O
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	O
risk	O
of	O
late	O
mortality	B-MED
or	O
re	B-MED
-	I-MED
hospitalization	I-MED
.	O
The	O
sensitivity	B-MED
and	I-MED
specifity	I-MED
of	O
DR-70	B-MED
immunoassay	B-MED
as	O
a	O
tumor	B-MED
marker	I-MED
for	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
Lung	B-MED
cancer	I-MED
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	B-MED
related	I-MED
mortality	I-MED
.	O
Patients	B-MED
with	O
lung	B-MED
cancer	I-MED
are	O
usually	O
diagnosed	B-MED
at	O
advanced	B-MED
or	O
locally	B-MED
advanced	I-MED
stage	I-MED
,	O
for	O
this	O
reason	O
early	B-MED
diagnosis	I-MED
of	O
lung	B-MED
cancer	I-MED
is	O
very	O
important	O
.	O
For	O
early	B-MED
detection	I-MED
of	O
lung	B-MED
cancer	I-MED
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	B-MED
-	I-MED
dose	I-MED
computed	I-MED
tomography	I-MED
or	O
tumor	B-MED
biomarkers	I-MED
.	O
In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-MED
DR-70	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
as	O
a	O
tumor	B-MED
marker	I-MED
in	O
detection	B-MED
of	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancers	I-MED
.	O
Between	O
May	B-MED
2013	O
and	O
April	B-MED
2014	O
,	O
the	O
serum	B-MED
samples	I-MED
from	O
88	O
non	B-MED
lung	I-MED
cancer	I-MED
patients	B-MED
,	O
86	O
patients	B-MED
with	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disesase	I-MED
were	O
obtained	O
.	O
Blood	B-MED
samples	I-MED
from	O
each	O
participant	B-MED
were	O
analyzed	B-MED
for	O
DR-70	B-MED
level	B-MED
.	O
Totally	O
174	O
patients	B-MED
were	O
enrolled	O
to	O
the	O
study	B-MED
(	O
152	O
male	B-MED
,	O
22	O
female	B-MED
)	O
.	O
Histopathologically	B-MED
47(53.4	O
%	O
)	O
patients	B-MED
were	O
diagnosed	B-MED
with	O
squamous	B-MED
cell	I-MED
lung	I-MED
cancer	I-MED
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	B-MED
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
The	O
mean	B-MED
serum	I-MED
DR-70	I-MED
levels	B-MED
in	O
lung	B-MED
cancer	I-MED
patients	B-MED
(	O
2.43	O
±	O
1.82	O
µg	O
/	O
mL	O
)	O
was	O
significantly	B-MED
higher	I-MED
compared	B-MED
to	O
the	O
86	O
non	B-MED
-	I-MED
cancerous	I-MED
subjects	B-MED
(	O
1.15	O
±	O
0.70	O
µg	O
/	O
mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O
DR-70	B-MED
exhibited	O
clinical	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	B-MED
cut	B-MED
off	I-MED
at	O
1.98	O
µg	O
/	O
mL.	O
It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-MED
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	B-MED
level	B-MED
is	O
1.98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O
DR-70	B-MED
,	O
a	O
marker	B-MED
used	O
to	O
measure	B-MED
fibrin	B-MED
degradation	I-MED
products	I-MED
,	O
generated	O
by	O
all	O
major	O
cancers	B-MED
,	O
may	O
helps	O
to	O
find	O
high	B-MED
risk	I-MED
lung	B-MED
cancer	I-MED
patients	B-MED
.	O
Patient	B-MED
Mobility	I-MED
for	O
Elective	B-MED
Secondary	B-MED
Health	I-MED
Care	I-MED
Services	I-MED
in	O
Response	B-MED
to	O
Patient	B-MED
Choice	I-MED
Policies	I-MED
:	O
A	O
Systematic	B-MED
Review	I-MED
Our	O
review	O
establishes	O
the	O
empirical	B-MED
evidence	B-MED
for	O
patient	B-MED
mobility	I-MED
for	O
elective	B-MED
secondary	I-MED
care	I-MED
services	I-MED
in	O
countries	B-MED
that	O
allow	O
patients	B-MED
to	O
choose	O
their	O
health	B-MED
care	I-MED
provider	I-MED
.	O
PubMed	B-MED
and	O
Embase	B-MED
were	O
searched	O
for	O
relevant	O
articles	B-MED
between	O
1990	O
and	O
2015	O
.	O
Of	O
5,994	O
titles	B-MED
/	O
abstracts	B-MED
reviewed	B-MED
,	O
26	O
studies	B-MED
were	O
included	O
.	O
The	O
studies	B-MED
used	O
three	O
main	O
methodological	B-MED
models	B-MED
to	O
establish	O
mobility	B-MED
.	O
Variation	B-MED
in	O
the	O
extent	O
of	O
patient	B-MED
mobility	I-MED
was	O
observed	O
across	O
the	O
studies	O
.	O
Mobility	B-MED
was	O
positively	O
associated	B-MED
with	I-MED
lower	B-MED
waiting	I-MED
times	I-MED
,	O
indicators	B-MED
of	O
better	B-MED
service	I-MED
quality	I-MED
,	O
and	O
access	O
to	O
advanced	B-MED
technology	I-MED
.	O
It	O
was	O
negatively	O
associated	O
with	O
advanced	B-MED
age	I-MED
or	O
lower	O
socioeconomic	B-MED
backgrounds	O
.	O
From	O
a	O
policy	B-MED
perspective	B-MED
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	B-MED
of	O
patients	B-MED
are	O
prepared	O
to	O
travel	B-MED
beyond	O
their	O
nearest	O
provider	B-MED
for	O
elective	B-MED
services	I-MED
.	O
As	O
a	O
consequence	O
,	O
some	O
providers	B-MED
are	O
likely	O
to	O
be	O
"	O
winners	B-MED
"	O
and	O
others	O
"	O
losers	B-MED
,	O
"	O
which	O
could	O
result	O
in	O
overall	O
decreased	B-MED
provider	B-MED
capacity	B-MED
or	O
inefficient	B-MED
utilization	O
of	O
existing	O
services	B-MED
.	O
Equity	B-MED
also	O
remains	O
a	O
key	O
concern	O
.	O
Comprehensive	B-MED
functional	B-MED
analysis	I-MED
of	O
large	O
lists	O
of	O
genes	B-MED
and	O
proteins	B-MED
The	O
interpretation	B-MED
of	O
high	B-MED
dimensional	I-MED
datasets	I-MED
resulting	O
from	O
genomic	B-MED
and	O
proteomic	B-MED
experiments	I-MED
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging	O
.	O
ClueGO	B-MED
software	I-MED
is	O
a	O
Cytoscape	B-MED
App	I-MED
that	O
extracts	O
representative	O
functional	O
biological	B-MED
information	B-MED
for	O
large	O
lists	O
of	O
genes	B-MED
or	O
proteins	B-MED
.	O
The	O
functional	B-MED
enrichment	I-MED
analysis	I-MED
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	B-MED
from	O
multiple	O
annotation	B-MED
and	O
ontology	B-MED
resources	B-MED
that	O
can	O
be	O
automatically	B-MED
accessed	B-MED
through	O
ClueGO	B-MED
.	O
Predefined	B-MED
settings	I-MED
for	O
the	O
selection	B-MED
of	O
the	O
terms	B-MED
are	O
provided	O
to	O
facilitate	O
the	O
analysis	B-MED
.	O
Results	B-MED
are	O
visualized	O
as	O
networks	B-MED
in	O
which	O
Gene	B-MED
Ontology	I-MED
(	O
GO	B-MED
)	O
terms	O
and	O
pathways	B-MED
are	O
grouped	O
based	O
on	O
their	O
biological	O
role	O
.	O
Many	O
species	B-MED
are	O
now	O
supported	O
by	O
ClueGO	B-MED
and	O
additional	O
organisms	B-MED
are	O
added	O
on	O
demand	O
.	O
ClueGO	B-MED
can	O
be	O
used	O
together	O
with	O
the	O
CluePedia	B-MED
App	I-MED
to	O
enable	O
the	O
visualization	O
of	O
protein	B-MED
-	I-MED
protein	I-MED
interactions	I-MED
within	O
or	O
between	O
pathways	B-MED
.	O
The	O
relationship	B-MED
between	O
histological	B-MED
prostatitis	B-MED
and	O
lower	B-MED
urinary	I-MED
tract	I-MED
symptoms	I-MED
and	O
sexual	B-MED
function	I-MED
This	O
prospective	B-MED
analysis	I-MED
assessed	B-MED
the	O
effect	B-MED
of	O
histological	B-MED
prostatitis	B-MED
on	O
lower	B-MED
urinary	I-MED
tract	I-MED
functions	B-MED
and	O
sexual	B-MED
function	I-MED
.	O
The	O
patients	B-MED
were	O
separated	B-MED
into	O
two	O
groups	B-MED
as	O
histologically	B-MED
observed	B-MED
prostatitis	B-MED
(	O
Group	B-MED
A	I-MED
)	O
and	O
no	B-MED
prostatitis	I-MED
(	O
Group	B-MED
B	I-MED
)	O
according	O
to	O
the	O
biopsy	B-MED
outcomes	B-MED
.	O
International	B-MED
prostate	I-MED
symptom	I-MED
score	I-MED
,	O
international	B-MED
index	I-MED
of	I-MED
erectile	I-MED
function-5	I-MED
scores	I-MED
,	O
maximal	B-MED
and	O
average	B-MED
flow	I-MED
rate	I-MED
,	O
and	O
residual	B-MED
urine	I-MED
volumes	I-MED
were	O
compared	B-MED
statistically	O
between	O
groups	B-MED
.	O
There	O
was	O
no	O
significant	B-MED
difference	B-MED
(	O
P>0.05	O
)	O
in	O
baseline	B-MED
age	B-MED
(	O
t=0.64	O
)	O
,	O
body	B-MED
mass	I-MED
index	I-MED
value	I-MED
(	O
t=0.51	O
)	O
,	O
prostate	B-MED
volume	I-MED
(	O
t=0.87	O
)	O
,	O
prostate	B-MED
-	I-MED
specific	I-MED
antigen	I-MED
levels	I-MED
(	O
t=0.43	O
)	O
,	O
maximal	B-MED
(	O
t=0.84	O
)	O
and	O
average	B-MED
flow	I-MED
rate	I-MED
(	O
t=0.59	O
)	O
,	O
and	O
post	B-MED
-	I-MED
void	I-MED
residual	B-MED
urine	I-MED
volume	I-MED
(	O
t=0.71	O
)	O
.	O
Mean	B-MED
international	B-MED
prostate	I-MED
symptom	I-MED
score	I-MED
in	O
patients	B-MED
with	O
prostatitis	B-MED
was	O
numerically	B-MED
but	O
not	O
significantly	B-MED
higher	I-MED
than	O
that	O
in	O
those	O
without	B-MED
prostatitis	B-MED
(	O
t=0.794	O
,	O
P=0.066	O
)	O
.	O
Mean	B-MED
international	B-MED
index	I-MED
of	I-MED
erectile	I-MED
function-5	I-MED
score	I-MED
in	O
the	O
prostatitis	B-MED
group	B-MED
was	O
significantly	B-MED
lower	I-MED
than	O
that	O
in	O
those	O
without	B-MED
prostatitis	B-MED
(	O
t=1.854	O
,	O
P=0.013	O
)	O
.	O
Histological	B-MED
prostatitis	B-MED
notably	O
affected	B-MED
sexual	B-MED
function	I-MED
of	O
patients	B-MED
and	O
may	O
serve	O
as	O
a	O
major	B-MED
risk	B-MED
factor	I-MED
for	O
sexual	B-MED
dysfunction	I-MED
while	O
having	O
little	O
effect	B-MED
on	O
lower	B-MED
urinary	I-MED
tract	I-MED
symptoms	I-MED
.	O
Clinical	B-MED
Features	I-MED
and	O
Complications	B-MED
of	O
the	O
HLA	B-MED
-	I-MED
B27	I-MED
-associated	O
Acute	B-MED
Anterior	I-MED
Uveitis	I-MED
:	O
A	O
Metanalysis	B-MED
In	O
this	O
article	B-MED
,	O
we	O
report	O
a	O
literature	B-MED
-	I-MED
based	I-MED
metanalysis	B-MED
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-MED
features	I-MED
of	O
the	O
HLA	B-MED
-	I-MED
B27	I-MED
Acute	B-MED
Anterior	I-MED
Uveitis	I-MED
(	O
AAU	B-MED
)	O
.	O
The	O
examined	B-MED
material	O
was	O
based	O
on	O
observational	B-MED
studies	I-MED
in	O
which	O
participants	B-MED
were	O
affected	O
by	O
Acute	B-MED
Anterior	I-MED
Uveitis	I-MED
and	O
divided	O
into	O
HLA	B-MED
B27	I-MED
+	I-MED
and	O
HLA	B-MED
B27-	I-MED
.	O
We	O
performed	O
a	O
search	O
on	O
articles	B-MED
with	O
the	O
words	O
"	O
HLA	B-MED
B27	I-MED
uveitis	I-MED
"	O
dated	O
before	O
May	O
2014	O
.	O
Among	O
these	O
,	O
29	O
articles	B-MED
were	O
selected	O
for	O
a	O
second	O
review	B-MED
.	O
After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	B-MED
were	O
analyzed	B-MED
.	O
The	O
clinical	B-MED
characteristics	I-MED
studied	O
in	O
the	O
metanalysis	B-MED
were	O
:	O
(	O
1	O
)	O
systemic	B-MED
disease	I-MED
;	O
(	O
2	O
)	O
sex	B-MED
distribution	I-MED
;	O
(	O
3	O
)	O
laterality	B-MED
;	O
(	O
4	O
)	O
visual	B-MED
acuity	I-MED
;	O
(	O
5	O
)	O
hypopion	B-MED
;	O
(	O
6	O
)	O
anterior	B-MED
chamber	I-MED
's	I-MED
fibrin	I-MED
;	O
(	O
7	O
)	O
elevated	B-MED
intraocular	I-MED
pressure	I-MED
(	O
IOP	B-MED
)	O
during	O
inflammation	B-MED
;	O
(	O
8)	O
glaucoma	B-MED
;	O
(	O
9	O
)	O
posterior	B-MED
synechiae	I-MED
;	O
(	O
10	O
)	O
cataract	B-MED
;	O
(	O
11	O
)	O
cystoid	B-MED
macular	I-MED
edema	I-MED
;	O
(	O
12	O
)	O
papillitis	B-MED
.	O
We	O
have	O
calculated	O
a	O
relative	B-MED
risk	I-MED
(	O
RR	B-MED
)	O
for	O
each	O
outcome	B-MED
measured	I-MED
.	O
The	O
results	B-MED
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	B-MED
B27	I-MED
Acute	B-MED
Anterior	I-MED
Uveitis	I-MED
,	O
such	O
as	O
strong	O
association	B-MED
with	I-MED
ankylosing	B-MED
spondylitis	I-MED
(	O
RR	B-MED
=	O
6.80	O
)	O
and	O
systemic	B-MED
diseases	I-MED
(	O
RR	B-MED
=	O
9.9	O
)	O
,	O
male	B-MED
prevalence	B-MED
(	O
RR	B-MED
=	O
1.2	O
)	O
,	O
unilateral	B-MED
(	O
RR	B-MED
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	B-MED
(	O
RR	B-MED
=	O
2.2	O
)	O
involvement	B-MED
,	O
hypopion	B-MED
(	O
RR	B-MED
=	O
5.5	O
)	O
,	O
fibrinous	B-MED
reaction	B-MED
and	O
even	O
papillitis	B-MED
(	O
R	O
=	O
7.7	O
)	O
.	O
Simultaneous	O
bilateral	B-MED
(	O
RR	B-MED
=	O
0.3	O
)	O
AAU	B-MED
is	O
more	O
frequent	B-MED
in	O
HLA	B-MED
-	I-MED
B27	I-MED
negative	B-MED
form	O
.	O
We	O
report	O
higher	O
risk	B-MED
of	O
elevated	B-MED
IOP	I-MED
and	O
glaucoma	B-MED
(	O
RR	B-MED
=	O
0.6	O
)	O
in	O
B27-	B-MED
Acute	I-MED
Anterior	I-MED
Uveitis	I-MED
.	O
No	O
significant	O
difference	O
between	O
HLA	B-MED
B	I-MED
27	I-MED
positive	I-MED
and	O
negative	B-MED
AAU	B-MED
was	O
observed	B-MED
according	O
to	O
final	O
visual	B-MED
acuity	I-MED
and	O
complications	B-MED
such	O
as	O
posterior	B-MED
synechiae	I-MED
,	O
cataract	B-MED
,	O
and	O
maculare	B-MED
edema	I-MED
.	O
We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-MED
evaluation	I-MED
and	O
therapeutic	B-MED
decision	B-MED
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	B-MED
condition	B-MED
.	O
Influence	O
of	O
ozone	B-MED
and	O
paracetic	B-MED
acid	I-MED
disinfection	B-MED
on	O
adhesion	B-MED
of	I-MED
resilient	B-MED
liners	I-MED
to	O
acrylic	B-MED
resin	I-MED
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	B-MED
acid	I-MED
(	O
PAA	B-MED
)	O
and	O
ozone	B-MED
disinfection	B-MED
on	O
the	O
tensile	B-MED
bond	I-MED
strength	I-MED
(	O
TBS	B-MED
)	O
of	O
silicone	B-MED
-	I-MED
based	I-MED
resilient	B-MED
liners	I-MED
to	O
acrylic	B-MED
resins	I-MED
.	O
One	O
hundred	O
and	O
twenty	O
dumbbell	B-MED
shaped	I-MED
heat	B-MED
-	I-MED
polymerized	I-MED
acrylic	B-MED
resins	I-MED
were	O
prepared	O
.	O
From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	B-MED
,	O
3	O
mm	O
of	O
acrylic	B-MED
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	B-MED
liners	I-MED
.	O
The	O
specimens	B-MED
were	O
divided	O
into	O
2	B-MED
control	I-MED
(	O
control1	B-MED
,	O
control7	B-MED
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	B-MED
and	O
ozone	B-MED
disinfection	B-MED
(	O
PAA1	B-MED
,	O
PAA7	B-MED
,	O
ozone1	B-MED
and	O
ozone7	B-MED
;	O
n=10	O
)	O
.	O
While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	B-MED
water	I-MED
for	O
10	O
min	O
(	O
control1	B-MED
)	O
and	O
7	O
days	O
(	O
control7	B-MED
)	O
,	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	B-MED
(	O
16	O
g	O
/	O
L	O
)	O
or	O
ozone	B-MED
rich	O
water	B-MED
(	O
4	O
mg	O
/	O
L	O
)	O
for	O
1	O
cycle	O
(	O
10	O
min	O
for	O
PAA	B-MED
and	O
60	O
min	O
for	O
ozone	B-MED
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	B-MED
tests	B-MED
.	O
Measurements	O
of	O
the	O
TBS	B-MED
were	O
analyzed	O
using	O
3	O
-	O
way	O
ANOVA	B-MED
and	O
Tukey	B-MED
's	I-MED
HSD	I-MED
test	I-MED
.	O
Adhesive	B-MED
strength	B-MED
of	O
Mollosil	B-MED
decreased	O
significantly	O
by	O
application	O
of	O
ozone	B-MED
disinfection	B-MED
.	O
PAA	B-MED
disinfection	B-MED
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	B-MED
values	O
of	O
Mollosil	B-MED
and	O
Molloplast	B-MED
B	I-MED
to	O
acrylic	B-MED
resin	I-MED
.	O
Single	O
application	O
of	O
ozone	B-MED
disinfection	B-MED
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	B-MED
values	O
of	O
Molloplast	B-MED
B	I-MED
,	O
but	O
prolonged	B-MED
exposure	B-MED
to	I-MED
ozone	I-MED
decreased	O
its	O
adhesive	B-MED
strength	B-MED
.	O
The	O
adhesion	B-MED
of	O
resilient	B-MED
liners	I-MED
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	B-MED
disinfection	B-MED
.	O
Immersion	O
in	O
ozonated	B-MED
water	B-MED
significantly	O
decreased	O
TBS	B-MED
of	O
Mollosil	B-MED
.	O
Prolonged	O
exposure	O
to	O
ozone	B-MED
negatively	O
affects	O
adhesion	B-MED
of	O
Molloplast	B-MED
B	I-MED
to	O
denture	B-MED
base	I-MED
materials	I-MED
.	O
Modeling	B-MED
nurse	B-MED
-	I-MED
patient	I-MED
assignments	I-MED
considering	O
patient	B-MED
acuity	I-MED
and	O
travel	B-MED
distance	B-MED
metrics	B-MED
Balancing	B-MED
workload	B-MED
among	O
nurses	B-MED
on	O
a	O
hospital	B-MED
unit	I-MED
is	O
important	O
for	O
the	O
satisfaction	B-MED
and	O
safety	B-MED
of	O
nurses	B-MED
and	O
patients	B-MED
.	O
To	O
balance	B-MED
nurse	B-MED
workloads	B-MED
,	O
direct	B-MED
patient	B-MED
care	I-MED
activities	I-MED
,	O
indirect	B-MED
patient	B-MED
care	I-MED
activities	I-MED
,	O
and	O
non	B-MED
-	I-MED
patient	I-MED
care	I-MED
activities	I-MED
that	O
occur	O
throughout	O
a	O
shift	B-MED
must	O
be	O
considered	O
.	O
The	O
layout	O
of	O
a	O
hospital	B-MED
unit	I-MED
and	O
the	O
location	B-MED
of	O
a	O
nurse	B-MED
's	I-MED
assigned	B-MED
patients	B-MED
relative	B-MED
to	O
other	O
resources	B-MED
on	O
the	O
unit	B-MED
are	O
also	O
important	B-MED
factors	I-MED
in	O
achieving	B-MED
workload	B-MED
balance	B-MED
.	O
In	O
most	O
hospitals	B-MED
,	O
a	O
unit	O
charge	O
nurse	B-MED
is	O
responsible	B-MED
for	O
the	O
shift	B-MED
assignment	B-MED
of	O
patients	B-MED
to	O
nurses	B-MED
based	O
on	O
experience	B-MED
and	O
past	B-MED
practices	I-MED
.	O
The	O
nurse	B-MED
-	I-MED
patient	I-MED
assignment	I-MED
process	B-MED
is	O
also	O
often	O
a	O
manual	B-MED
process	I-MED
in	O
which	O
the	O
charge	O
nurse	B-MED
must	O
sort	B-MED
through	O
multiple	B-MED
decision	I-MED
criteria	I-MED
in	O
a	O
limited	O
amount	O
of	O
time	B-MED
.	O
In	O
this	O
paper	O
,	O
a	O
methodology	B-MED
for	O
the	O
construction	O
of	O
balanced	B-MED
nurse	B-MED
-	I-MED
patient	I-MED
workload	I-MED
assignments	I-MED
is	O
proposed	B-MED
.	O
Through	O
the	O
illustration	O
of	O
this	O
methodology	B-MED
new	O
scoring	B-MED
metrics	B-MED
are	O
developed	B-MED
using	O
measures	B-MED
currently	O
available	B-MED
on	O
,	O
or	O
from	O
,	O
the	O
hospital	B-MED
unit	I-MED
.	O
It	O
was	O
demonstrated	B-MED
that	O
the	O
complex	B-MED
scheduling	I-MED
problem	B-MED
can	O
be	O
captured	O
.	O
While	O
the	O
methodology	B-MED
was	O
illustrated	O
for	O
a	O
scheduling	B-MED
problem	B-MED
commonly	O
encountered	O
on	O
a	O
hospital	B-MED
unit	I-MED
,	O
the	O
approach	B-MED
can	O
be	O
adapted	O
to	O
other	O
workforce	B-MED
scheduling	B-MED
problems	B-MED
in	O
which	O
measures	B-MED
of	O
workload	B-MED
are	O
required	B-MED
and	O
composed	O
of	O
elements	B-MED
imposed	O
by	O
the	O
work	B-MED
environment	I-MED
,	O
variability	B-MED
within	O
the	O
required	B-MED
tasks	B-MED
,	O
and	O
a	O
measurable	B-MED
perception	B-MED
of	O
the	O
relative	B-MED
intensity	B-MED
of	O
the	O
work	B-MED
elements	I-MED
.	O
Interaction	B-MED
of	O
multiple	B-MED
gene	B-MED
variants	I-MED
and	O
their	O
effects	B-MED
on	O
schizophrenia	B-MED
phenotypes	B-MED
Schizophrenia	B-MED
is	O
a	O
clinically	B-MED
heterogeneous	B-MED
disorder	I-MED
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic	B-MED
architecture	I-MED
.	O
Many	O
schizophrenia	B-MED
susceptibility	B-MED
genes	B-MED
were	O
identified	B-MED
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	B-MED
or	O
contradictory	B-MED
genetic	B-MED
association	I-MED
studies	I-MED
.	O
This	O
confusion	O
may	O
,	O
in	O
part	O
,	O
be	O
because	O
symptoms	B-MED
result	O
from	O
the	O
combined	O
interaction	B-MED
of	O
many	O
genes	B-MED
and	O
these	O
interacting	B-MED
genes	B-MED
are	O
associated	B-MED
with	I-MED
specific	B-MED
sub	B-MED
-	I-MED
phenotypes	I-MED
of	O
schizophrenia	B-MED
rather	O
than	O
schizophrenia	B-MED
as	O
a	O
whole	O
.	O
This	O
study	O
investigates	B-MED
the	O
relationship	B-MED
between	O
schizophrenia	B-MED
susceptibility	B-MED
genes	B-MED
and	O
schizophrenia	B-MED
sub	B-MED
-	I-MED
phenotypes	I-MED
by	O
identifying	B-MED
multiple	B-MED
gene	B-MED
variant	I-MED
interactions	B-MED
.	O
Fifty	O
SNPs	B-MED
from	O
21	O
genes	B-MED
were	O
genotyped	B-MED
in	O
235	O
Australian	B-MED
participants	B-MED
with	O
schizophrenia	B-MED
screened	B-MED
for	O
various	O
phenotypes	B-MED
.	O
Schizophrenia	B-MED
participants	B-MED
were	O
grouped	O
into	O
relevant	B-MED
phenotype	B-MED
clusters	B-MED
using	O
cluster	B-MED
analysis	I-MED
and	O
normalized	B-MED
phenotype	B-MED
cluster	B-MED
scores	B-MED
were	O
calculated	O
for	O
each	O
patient	B-MED
.	O
The	O
relationship	B-MED
between	O
genotypes	B-MED
and	O
normalized	B-MED
phenotype	B-MED
cluster	B-MED
scores	B-MED
were	O
analyzed	O
by	O
linear	B-MED
regression	I-MED
analysis	I-MED
.	O
Three	O
phenotype	B-MED
clusters	B-MED
were	O
identified	B-MED
.	O
There	O
was	O
some	O
overlap	O
in	O
symptoms	B-MED
between	O
phenotype	B-MED
clusters	B-MED
,	O
particularly	O
for	O
depression	B-MED
.	O
However	O
,	O
cluster	B-MED
1	I-MED
appears	O
to	O
be	O
characterized	O
by	O
speech	B-MED
disorder	I-MED
and	O
affective	O
behavior	B-MED
symptoms	I-MED
,	O
cluster	B-MED
2	I-MED
has	O
predominantly	O
hallucination	B-MED
symptoms	B-MED
and	O
cluster	B-MED
3	I-MED
has	O
mainly	O
delusion	B-MED
symptoms	B-MED
.	O
Interaction	B-MED
of	O
five	O
SNPs	B-MED
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster	B-MED
1	I-MED
symptoms	B-MED
;	O
ten	O
SNPs	B-MED
on	O
cluster	B-MED
2	I-MED
symptoms	B-MED
;	O
and	O
eight	O
SNPs	B-MED
on	O
cluster	B-MED
3	I-MED
symptoms	B-MED
.	O
The	O
interaction	B-MED
of	O
specific	B-MED
susceptibility	B-MED
genes	B-MED
is	O
likely	O
to	O
lead	O
to	O
specific	B-MED
clinical	B-MED
sub	B-MED
-	I-MED
phenotypes	I-MED
of	O
schizophrenia	B-MED
.	O
Larger	O
patient	B-MED
cohorts	B-MED
with	O
more	O
extensive	O
clinical	B-MED
data	B-MED
will	O
improve	O
the	O
detection	B-MED
of	O
gene	B-MED
interactions	I-MED
and	O
the	O
resultant	O
schizophrenia	B-MED
clinical	B-MED
phenotypes	B-MED
.	O
Implementing	B-MED
Non	B-MED
-	I-MED
Invasive	I-MED
Prenatal	B-MED
Diagnosis	I-MED
(	O
NIPD	B-MED
)	O
in	O
a	O
National	B-MED
Health	I-MED
Service	I-MED
Laboratory	I-MED
;	O
From	O
Dominant	B-MED
to	O
Recessive	B-MED
Disorders	B-MED
Our	O
UK	B-MED
National	I-MED
Health	I-MED
Service	I-MED
regional	I-MED
genetics	I-MED
laboratory	I-MED
offers	O
NIPD	B-MED
for	O
autosomal	B-MED
dominant	I-MED
and	O
de	B-MED
novo	I-MED
conditions	B-MED
(	O
achondroplasia	B-MED
,	O
thanataphoric	B-MED
dysplasia	I-MED
,	O
Apert	B-MED
syndrome	I-MED
)	O
,	O
paternal	B-MED
mutation	B-MED
exclusion	B-MED
for	O
cystic	B-MED
fibrosis	I-MED
and	O
a	O
range	O
of	O
bespoke	B-MED
tests	I-MED
.	O
NIPD	B-MED
avoids	O
the	O
risks	B-MED
associated	B-MED
with	I-MED
invasive	B-MED
testing	I-MED
,	O
making	O
prenatal	B-MED
diagnosis	I-MED
more	B-MED
accessible	O
to	O
families	B-MED
at	O
high	B-MED
genetic	B-MED
risk	I-MED
.	O
However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	B-MED
diagnosis	B-MED
for	O
autosomal	B-MED
recessive	I-MED
diseases	I-MED
,	O
which	O
is	O
complicated	B-MED
by	O
the	O
predominance	B-MED
of	O
the	O
maternal	B-MED
mutant	B-MED
allele	B-MED
in	O
the	O
cell	B-MED
-	I-MED
free	I-MED
DNA	I-MED
sample	B-MED
and	O
thus	O
requires	O
a	O
variety	B-MED
of	O
different	B-MED
approaches	B-MED
.	O
Validation	B-MED
and	O
diagnostic	B-MED
implementation	B-MED
for	O
NIPD	B-MED
of	O
congenital	B-MED
adrenal	I-MED
hyperplasia	I-MED
(	O
CAH	B-MED
)	O
is	O
further	O
complicated	B-MED
by	O
presence	B-MED
of	O
a	O
pseudogene	B-MED
that	O
requires	O
a	O
different	B-MED
approach	B-MED
.	O
We	O
have	O
used	O
an	O
assay	B-MED
targeting	B-MED
approximately	B-MED
6700	O
heterozygous	B-MED
SNPs	B-MED
around	O
the	O
CAH	B-MED
gene	I-MED
(	O
CYP21A2	B-MED
)	O
to	O
construct	O
the	O
high	B-MED
-	I-MED
risk	I-MED
parental	B-MED
haplotypes	B-MED
and	O
tested	O
this	O
approach	B-MED
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	B-MED
of	O
the	O
parental	B-MED
alleles	B-MED
can	O
be	O
correctly	O
identified	B-MED
using	O
NIPD	B-MED
.	O
We	O
are	O
evaluating	O
various	O
measures	B-MED
of	O
the	O
fetal	B-MED
fraction	O
to	O
help	O
determine	O
inheritance	B-MED
of	O
parental	B-MED
mutations	B-MED
.	O
We	O
are	O
currently	O
exploring	O
the	O
utility	B-MED
of	O
an	O
NIPD	B-MED
multi	B-MED
-	I-MED
disorder	I-MED
panel	I-MED
for	O
autosomal	B-MED
recessive	I-MED
disease	I-MED
,	O
to	O
make	O
testing	B-MED
more	O
widely	O
applicable	B-MED
to	O
families	B-MED
with	O
a	O
variety	O
of	O
serious	B-MED
genetic	B-MED
conditions	I-MED
.	O
Comparison	B-MED
of	O
Gasoline	B-MED
Direct	I-MED
-	I-MED
Injection	I-MED
(	O
GDI	B-MED
)	O
and	O
Port	B-MED
Fuel	I-MED
Injection	I-MED
(	O
PFI	B-MED
)	O
Vehicle	B-MED
Emissions	I-MED
:	O
Emission	B-MED
Certification	B-MED
Standards	B-MED
,	O
Cold	B-MED
-	I-MED
Start	I-MED
,	O
Secondary	O
Organic	B-MED
Aerosol	B-MED
Formation	B-MED
Potential	B-MED
,	O
and	O
Potential	B-MED
Climate	B-MED
Impacts	B-MED
Recent	O
increases	B-MED
in	O
the	O
Corporate	B-MED
Average	B-MED
Fuel	I-MED
Economy	I-MED
standards	B-MED
have	O
led	O
to	O
widespread	B-MED
adoption	O
of	O
vehicles	B-MED
equipped	O
with	O
gasoline	B-MED
direct	I-MED
-	I-MED
injection	I-MED
(	O
GDI	B-MED
)	O
engines	B-MED
.	O
Changes	O
in	O
engine	B-MED
technologies	B-MED
can	O
alter	O
emissions	B-MED
.	O
To	O
quantify	B-MED
these	O
effects	B-MED
,	O
we	O
measured	B-MED
gas-	B-MED
and	O
particle	B-MED
-	I-MED
phase	I-MED
emissions	B-MED
from	O
82	O
light	B-MED
-	I-MED
duty	I-MED
gasoline	B-MED
vehicles	B-MED
recruited	O
from	O
the	O
California	B-MED
in	O
-	O
use	O
fleet	O
tested	B-MED
on	O
a	O
chassis	B-MED
dynamometer	B-MED
using	O
the	O
cold	B-MED
-	I-MED
start	I-MED
unified	O
cycle	O
.	O
The	O
fleet	O
included	O
15	O
GDI	B-MED
vehicles	B-MED
,	O
including	O
8	O
GDIs	B-MED
certified	B-MED
to	O
the	O
most	O
-	O
stringent	O
emissions	B-MED
standard	B-MED
,	O
superultra	B-MED
-	I-MED
low	I-MED
-	I-MED
emission	I-MED
vehicles	I-MED
(	O
SULEV	B-MED
)	O
.	O
We	O
quantified	B-MED
the	O
effects	B-MED
of	I-MED
engine	B-MED
technology	B-MED
,	O
emission	B-MED
certification	B-MED
standards	B-MED
,	O
and	O
cold	B-MED
-	I-MED
start	I-MED
on	O
emissions	B-MED
.	O
For	O
vehicles	B-MED
certified	B-MED
to	O
the	O
same	O
emissions	B-MED
standard	B-MED
,	O
there	O
is	O
no	O
statistical	B-MED
difference	B-MED
of	O
regulated	O
gas	B-MED
-	I-MED
phase	I-MED
pollutant	B-MED
emissions	B-MED
between	O
PFIs	B-MED
and	O
GDIs	B-MED
.	O
However	O
,	O
GDIs	B-MED
had	O
,	O
on	O
average	B-MED
,	O
a	O
factor	B-MED
of	O
2	O
higher	O
particulate	B-MED
matter	I-MED
(	O
PM	B-MED
)	O
mass	O
emissions	B-MED
than	O
PFIs	B-MED
due	O
to	O
higher	O
elemental	B-MED
carbon	I-MED
(	O
EC	B-MED
)	O
emissions	B-MED
.	O
SULEV	B-MED
certified	B-MED
GDIs	B-MED
have	O
a	O
factor	B-MED
of	O
2	O
lower	O
PM	B-MED
mass	O
emissions	B-MED
than	O
GDIs	B-MED
certified	B-MED
as	O
ultralow	B-MED
-	I-MED
emission	I-MED
vehicles	I-MED
(	O
3.0	O
±	O
1.1	O
versus	O
6.3	O
±	O
1.1	O
mg	O
/	O
mi	O
)	O
,	O
suggesting	O
improvements	B-MED
in	O
engine	B-MED
design	B-MED
and	O
calibration	B-MED
.	O
Comprehensive	B-MED
organic	B-MED
speciation	O
revealed	B-MED
no	O
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
composition	B-MED
of	O
the	O
volatile	B-MED
organic	B-MED
compounds	I-MED
emissions	B-MED
between	O
PFI	B-MED
and	O
GDIs	B-MED
,	O
including	O
benzene	B-MED
,	O
toluene	B-MED
,	O
ethylbenzene	B-MED
,	O
and	O
xylenes	B-MED
(	O
BTEX	B-MED
)	O
.	O
Therefore	O
,	O
the	O
secondary	O
organic	B-MED
aerosol	B-MED
and	O
ozone	B-MED
formation	B-MED
potential	B-MED
of	O
the	O
exhaust	B-MED
does	O
not	O
depend	O
on	O
engine	B-MED
technology	B-MED
.	O
Cold	B-MED
-	I-MED
start	I-MED
contributes	B-MED
a	O
larger	B-MED
fraction	B-MED
of	I-MED
the	O
total	O
unified	O
cycle	O
emissions	B-MED
for	O
vehicles	B-MED
meeting	O
more	O
-	O
stringent	O
emission	B-MED
standards	B-MED
.	O
Organic	B-MED
gas	B-MED
emissions	B-MED
were	O
the	O
most	O
sensitive	B-MED
to	O
cold	B-MED
-	I-MED
start	I-MED
compared	B-MED
to	O
the	O
other	O
pollutants	B-MED
tested	B-MED
here	O
.	O
There	O
were	O
no	O
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
effects	B-MED
of	I-MED
cold	B-MED
-	I-MED
start	I-MED
on	O
GDIs	B-MED
and	O
PFIs	B-MED
.	O
For	O
our	O
test	O
fleet	O
,	O
the	O
measured	B-MED
14.5	O
%	O
decrease	B-MED
in	O
CO2	B-MED
emissions	B-MED
from	O
GDIs	B-MED
was	O
much	O
greater	B-MED
than	O
the	O
potential	B-MED
climate	B-MED
forcing	O
associated	B-MED
with	I-MED
higher	O
black	B-MED
carbon	I-MED
emissions	B-MED
.	O
Thus	O
,	O
switching	O
from	O
PFI	B-MED
to	O
GDI	B-MED
vehicles	B-MED
will	O
likely	O
lead	O
to	O
a	O
reduction	B-MED
in	O
net	O
global	B-MED
warming	I-MED
.	O
Methods	B-MED
,	O
tools	B-MED
and	O
current	B-MED
perspectives	B-MED
in	O
proteogenomics	B-MED
With	O
combined	O
technological	B-MED
advancements	I-MED
in	O
high	B-MED
-	I-MED
throughput	I-MED
next	I-MED
-	I-MED
generation	I-MED
sequencing	I-MED
and	O
deep	B-MED
mass	I-MED
spectrometry	I-MED
-based	O
proteomics	B-MED
,	O
proteogenomics	B-MED
,	O
i.e.	O
,	O
the	O
integrative	B-MED
analysis	I-MED
of	O
proteomic	B-MED
and	I-MED
genomic	I-MED
data	I-MED
,	O
has	O
emerged	O
as	O
a	O
new	O
research	B-MED
field	I-MED
.	O
Early	O
efforts	O
in	O
the	O
field	B-MED
were	O
focused	O
on	O
improving	O
protein	B-MED
identification	B-MED
using	O
sample	B-MED
-	I-MED
specific	I-MED
genomic	I-MED
and	O
transcriptomic	B-MED
sequencing	I-MED
data	I-MED
.	O
More	O
recently	O
,	O
integrative	B-MED
analysis	I-MED
of	O
quantitative	B-MED
measurements	B-MED
from	O
genomic	B-MED
and	I-MED
proteomic	I-MED
studies	I-MED
have	O
identified	B-MED
novel	O
insights	O
into	O
gene	B-MED
expression	I-MED
regulation	I-MED
,	O
cell	B-MED
signaling	I-MED
,	O
and	O
disease	B-MED
.	O
Many	O
methods	B-MED
and	O
tools	B-MED
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	B-MED
of	O
integrative	B-MED
proteogenomic	I-MED
approaches	I-MED
and	O
in	O
this	O
article	B-MED
,	O
we	O
systematically	B-MED
classify	B-MED
published	B-MED
methods	B-MED
and	O
tools	B-MED
into	O
four	O
major	B-MED
categories	I-MED
,	O
(	O
1	O
)	O
Sequence	B-MED
Sequence	B-MED
-centric	I-MED
proteogenomics	I-MED
;	O
(	O
2	O
)	O
Analysis	B-MED
of	O
proteogenomic	B-MED
relationships	I-MED
;	O
(	O
3	O
)	O
Integrative	B-MED
modeling	I-MED
of	O
proteogenomic	B-MED
data	I-MED
;	O
and	O
(	O
4	O
)	O
Data	B-MED
sharing	I-MED
and	O
visualization	B-MED
.	O
We	O
provide	O
a	O
comprehensive	B-MED
review	B-MED
of	I-MED
methods	B-MED
and	O
available	B-MED
tools	B-MED
in	O
each	O
category	B-MED
and	O
highlight	O
their	O
typical	B-MED
applications	B-MED
.	O
Tissue	B-MED
reservoirs	O
of	O
antiviral	B-MED
T	B-MED
cell	I-MED
immunity	I-MED
in	O
persistent	O
human	B-MED
CMV	B-MED
infection	I-MED
T	B-MED
cell	I-MED
responses	B-MED
to	O
viruses	B-MED
are	O
initiated	O
and	O
maintained	O
in	O
tissue	B-MED
sites	O
;	O
however	O
,	O
knowledge	O
of	O
human	B-MED
antiviral	B-MED
T	B-MED
cells	I-MED
is	O
largely	O
derived	O
from	O
blood	B-MED
.	O
Cytomegalovirus	B-MED
(	O
CMV	B-MED
)	O
persists	O
in	O
most	O
humans	B-MED
,	O
requires	O
T	B-MED
cell	I-MED
immunity	I-MED
to	O
control	O
,	O
yet	O
tissue	B-MED
immune	B-MED
responses	I-MED
remain	O
undefined	O
.	O
Here	O
,	O
we	O
investigated	O
human	B-MED
CMV	B-MED
CMV	B-MED
-specific	O
T	B-MED
cells	I-MED
,	O
virus	B-MED
persistence	B-MED
and	O
CMV	B-MED
-associated	O
T	B-MED
cell	I-MED
homeostasis	B-MED
in	O
blood	B-MED
,	O
lymphoid	B-MED
,	O
mucosa	B-MED
l	O
and	O
secretory	B-MED
tissues	I-MED
of	O
44	O
CMV	B-MED
seropositive	B-MED
and	O
28	O
seronegative	B-MED
donors	B-MED
.	O
CMV	B-MED
-specific	O
T	B-MED
cells	I-MED
were	O
maintained	O
in	O
distinct	O
distribution	B-MED
patterns	I-MED
,	O
highest	O
in	O
blood	B-MED
,	O
bone	B-MED
marrow	I-MED
(	O
BM	B-MED
)	O
,	O
or	O
lymph	B-MED
nodes	I-MED
(	O
LN	B-MED
)	O
,	O
with	O
the	O
frequency	B-MED
and	O
function	B-MED
in	O
blood	B-MED
distinct	O
from	O
tissues	B-MED
.	O
CMV	B-MED
genomes	B-MED
were	O
detected	B-MED
predominantly	O
in	O
lung	B-MED
and	O
also	O
in	O
spleen	B-MED
,	O
BM	B-MED
,	O
blood	B-MED
and	O
LN	B-MED
.	O
High	O
frequencies	O
of	O
activated	O
CMV	B-MED
-specific	O
T	B-MED
cells	I-MED
were	O
found	O
in	O
blood	B-MED
and	O
BM	B-MED
samples	B-MED
with	O
low	O
virus	B-MED
detection	I-MED
,	O
whereas	O
in	O
lung	B-MED
,	O
CMV	B-MED
-specific	O
T	B-MED
cells	I-MED
were	O
present	O
along	O
with	O
detectable	O
virus	B-MED
.	O
In	O
LNs	B-MED
,	O
CMV	B-MED
-specific	O
T	B-MED
cells	I-MED
exhibited	O
quiescent	O
phenotypes	B-MED
independent	O
of	O
virus	B-MED
.	O
Overall	O
,	O
T	B-MED
cell	I-MED
differentiation	B-MED
was	O
enhanced	B-MED
in	O
sites	O
of	O
viral	B-MED
persistence	B-MED
with	O
age	O
.	O
Together	O
,	O
our	O
results	O
suggest	O
tissue	B-MED
T	B-MED
cell	I-MED
reservoirs	O
for	O
CMV	B-MED
control	B-MED
shaped	O
by	O
both	O
viral	B-MED
and	O
tissue	B-MED
-	O
intrinsic	B-MED
factors	I-MED
,	O
with	O
global	O
effects	O
on	O
homeostasis	B-MED
of	O
tissue	B-MED
T	B-MED
cells	I-MED
over	O
the	O
lifespan	B-MED
.	O
Unbiased	B-MED
estimates	I-MED
of	O
cerebrospinal	B-MED
fluid	I-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
cutoffs	B-MED
in	O
a	O
large	O
memory	B-MED
clinic	I-MED
population	B-MED
We	O
sought	O
to	O
define	O
a	O
cutoff	B-MED
for	O
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
in	O
cerebrospinal	B-MED
fluid	I-MED
(	O
CSF	B-MED
)	O
,	O
a	O
key	O
marker	B-MED
for	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
,	O
with	O
data	B-MED
-	I-MED
driven	I-MED
Gaussian	B-MED
mixture	I-MED
modeling	I-MED
in	O
a	O
memory	B-MED
clinic	I-MED
population	B-MED
.	O
We	O
performed	O
a	O
combined	O
cross	B-MED
-	I-MED
sectional	I-MED
and	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
We	O
selected	O
2462	O
subjects	B-MED
with	O
subjective	B-MED
cognitive	I-MED
decline	I-MED
,	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
,	O
AD	B-MED
-type	O
dementia	B-MED
,	O
and	O
dementia	B-MED
other	O
than	O
AD	B-MED
from	O
the	O
Amsterdam	B-MED
Dementia	B-MED
Cohort	B-MED
.	O
We	O
defined	O
CSF	B-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
cutoffs	B-MED
by	O
data	B-MED
-	I-MED
driven	I-MED
Gaussian	B-MED
mixture	I-MED
modeling	I-MED
in	O
the	O
total	B-MED
population	I-MED
and	O
in	O
subgroups	B-MED
based	O
on	O
clinical	B-MED
diagnosis	I-MED
,	O
age	B-MED
,	O
and	O
apolipoprotein	B-MED
E	I-MED
(	I-MED
APOE	I-MED
)	I-MED
genotype	I-MED
.	O
We	O
investigated	B-MED
whether	O
abnormal	B-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
as	O
defined	O
by	O
the	O
data	B-MED
-	I-MED
driven	I-MED
cutoff	B-MED
could	O
better	O
predict	B-MED
progression	B-MED
to	O
AD	B-MED
-type	O
dementia	B-MED
than	O
abnormal	B-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
defined	O
by	O
a	O
clinical	B-MED
diagnosis	I-MED
-based	O
cutoff	B-MED
using	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
.	O
In	O
the	O
total	O
group	B-MED
of	O
patients	B-MED
,	O
we	O
found	O
a	O
cutoff	B-MED
for	O
abnormal	B-MED
CSF	B-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
of	O
680	O
pg	O
/	O
ml	O
(	O
95	O
%	O
CI	B-MED
660	O
-	O
705	O
pg	O
/	O
ml	O
)	O
.	O
Similar	O
cutoffs	B-MED
were	O
found	O
within	O
diagnostic	B-MED
and	O
APOE	B-MED
genotype	I-MED
subgroups	B-MED
.	O
The	O
cutoff	B-MED
was	O
higher	B-MED
in	O
elderly	B-MED
subjects	B-MED
than	O
in	O
younger	O
subjects	B-MED
.	O
The	O
data	B-MED
-	I-MED
driven	I-MED
cutoff	B-MED
was	O
higher	B-MED
than	O
our	O
clinical	B-MED
diagnosis	I-MED
-based	O
cutoff	B-MED
and	O
had	O
a	O
better	O
predictive	B-MED
accuracy	B-MED
for	O
progression	B-MED
to	O
AD	B-MED
-type	O
dementia	B-MED
in	O
nondemented	O
subjects	B-MED
(	O
HR	B-MED
7.6	O
versus	O
5.2	O
,	O
p	B-MED
<	O
0.01	O
)	O
.	O
Mixture	B-MED
modeling	I-MED
is	O
a	O
robust	B-MED
method	B-MED
to	O
determine	O
cutoffs	B-MED
for	O
CSF	B-MED
β	B-MED
-	I-MED
amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
.	O
It	O
might	O
better	O
capture	O
biological	B-MED
changes	B-MED
that	O
are	O
related	O
to	O
AD	B-MED
than	O
cutoffs	B-MED
based	O
on	O
clinical	B-MED
diagnosis	I-MED
.	O
A	O
new	O
parametric	B-MED
model	I-MED
to	O
assess	B-MED
delay	B-MED
and	O
compression	B-MED
of	O
mortality	B-MED
A	O
decrease	B-MED
in	O
mortality	B-MED
across	O
all	O
ages	B-MED
causes	O
a	O
shift	O
of	O
the	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
,	O
or	O
mortality	B-MED
delay	B-MED
,	O
while	O
differences	B-MED
in	O
the	O
rate	B-MED
of	O
decrease	B-MED
across	O
ages	B-MED
cause	O
a	O
change	O
in	O
the	O
shape	B-MED
of	O
the	O
age	B-MED
-	I-MED
at	I-MED
-	I-MED
death	I-MED
distribution	B-MED
,	O
mortality	B-MED
compression	B-MED
or	O
expansion	B-MED
.	O
Evidence	B-MED
exists	O
for	O
both	O
compression	B-MED
and	O
delay	B-MED
of	O
mortality	B-MED
.	O
Existing	O
parametric	B-MED
models	I-MED
to	O
describe	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
are	O
not	O
able	O
to	O
capture	O
mortality	B-MED
delay	B-MED
versus	O
mortality	B-MED
compression	B-MED
.	O
More	O
recent	O
models	B-MED
that	O
assess	O
delay	B-MED
versus	O
compression	B-MED
mostly	O
focused	O
on	O
the	O
adult	B-MED
or	O
old	B-MED
ages	I-MED
alone	O
and	O
did	O
not	O
distinguish	O
mortality	B-MED
compression	B-MED
below	O
and	O
above	O
the	O
modal	B-MED
age	I-MED
at	O
death	B-MED
,	O
although	O
they	O
represent	O
different	B-MED
mechanisms	B-MED
.	O
This	O
paper	B-MED
presents	O
a	O
new	O
parametric	B-MED
model	I-MED
that	O
describes	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
and	O
assesses	O
compression	B-MED
-	O
at	O
different	B-MED
stages	B-MED
of	I-MED
life	I-MED
-	O
and	O
delay	B-MED
of	O
mortality	B-MED
:	O
the	O
CoDe	B-MED
model	I-MED
.	O
The	O
model	B-MED
includes	O
10	O
parameters	B-MED
,	O
of	O
which	O
five	O
are	O
constant	B-MED
over	O
time	B-MED
.	O
The	O
five	O
time	B-MED
-varying	O
parameters	B-MED
reflect	O
delay	B-MED
of	O
mortality	B-MED
and	O
compression	B-MED
of	O
mortality	B-MED
in	O
infancy	B-MED
,	O
adolescence	B-MED
,	O
young	B-MED
adulthood	I-MED
,	O
late	B-MED
adulthood	I-MED
,	O
and	O
old	B-MED
age	I-MED
.	O
The	O
model	B-MED
describes	O
infant	B-MED
and	O
background	O
mortality	B-MED
by	O
two	O
simple	O
functions	B-MED
,	O
uses	O
a	O
mixed	B-MED
logistic	I-MED
model	I-MED
with	O
different	B-MED
slopes	B-MED
in	O
adult	B-MED
,	O
middle	B-MED
,	O
and	O
old	B-MED
age	I-MED
,	O
and	O
includes	O
the	O
modal	B-MED
age	I-MED
at	O
death	B-MED
as	O
a	O
parameter	B-MED
to	O
account	O
for	O
the	O
delay	B-MED
in	O
mortality	B-MED
.	O
Applying	O
the	O
CoDe	B-MED
model	I-MED
to	O
age	B-MED
-	O
specific	B-MED
probabilities	B-MED
of	O
death	B-MED
for	O
Japanese	B-MED
,	O
French	B-MED
,	O
American	B-MED
,	O
and	O
Danish	B-MED
men	B-MED
and	O
women	B-MED
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
.	O
Delay	B-MED
of	O
mortality	B-MED
explained	O
about	O
two	O
-	O
thirds	O
of	O
the	O
increase	B-MED
in	O
life	B-MED
expectancy	I-MED
at	O
birth	B-MED
,	O
whereas	O
compression	B-MED
of	O
mortality	B-MED
due	O
to	O
mortality	B-MED
declines	I-MED
in	O
young	B-MED
age	I-MED
explained	O
about	O
one	O
-	O
third	O
.	O
No	O
strong	O
compression	B-MED
of	O
mortality	B-MED
in	O
late	B-MED
adulthood	I-MED
age	I-MED
was	O
observed	O
.	O
Mortality	B-MED
compression	B-MED
in	O
old	B-MED
age	I-MED
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life	B-MED
expectancy	I-MED
.	O
The	O
CoDe	B-MED
model	I-MED
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	B-MED
pattern	B-MED
of	O
mortality	B-MED
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	B-MED
delay	B-MED
and	O
compression	B-MED
-	O
at	O
different	B-MED
stages	B-MED
of	I-MED
life	I-MED
-	O
on	O
the	O
increase	B-MED
in	O
life	B-MED
expectancy	I-MED
.	O
Non	B-MED
-	I-MED
toxigenic	I-MED
environmental	B-MED
Vibrio	B-MED
cholerae	I-MED
O1	I-MED
strain	B-MED
from	O
Haiti	B-MED
provides	B-MED
evidence	B-MED
of	O
pre	B-MED
-	I-MED
pandemic	I-MED
cholera	B-MED
in	O
Hispaniola	B-MED
Vibrio	B-MED
cholerae	I-MED
is	O
ubiquitous	B-MED
in	O
aquatic	B-MED
environments	I-MED
,	O
with	O
environmental	B-MED
toxigenic	B-MED
V.	B-MED
cholerae	I-MED
O1	I-MED
strains	B-MED
serving	B-MED
as	O
a	O
source	B-MED
for	O
recurrent	B-MED
cholera	B-MED
epidemics	I-MED
and	O
pandemic	B-MED
disease	B-MED
.	O
However	O
,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long	B-MED
-	I-MED
term	I-MED
survival	B-MED
and	O
evolution	O
of	O
V.	B-MED
cholerae	I-MED
strains	B-MED
within	O
these	O
aquatic	B-MED
environmental	I-MED
reservoirs	B-MED
.	O
Through	O
monitoring	B-MED
of	O
the	O
Haitian	B-MED
aquatic	B-MED
environment	I-MED
following	O
the	O
2010	O
cholera	B-MED
epidemic	I-MED
,	O
we	O
isolated	B-MED
two	B-MED
novel	B-MED
non	B-MED
-	I-MED
toxigenic	I-MED
(	O
ctxA	B-MED
/	I-MED
B	I-MED
-	O
negative	B-MED
)	O
Vibrio	B-MED
cholerae	I-MED
O1	I-MED
.	O
These	O
two	B-MED
isolates	B-MED
underwent	O
whole	B-MED
-	I-MED
genome	I-MED
sequencing	I-MED
and	O
were	O
investigated	B-MED
through	B-MED
comparative	B-MED
genomics	B-MED
and	O
Bayesian	B-MED
coalescent	I-MED
analysis	I-MED
.	O
These	O
isolates	B-MED
cluster	O
in	O
the	O
evolutionary	O
tree	B-MED
with	O
strains	B-MED
responsible	O
for	O
clinical	B-MED
cholera	B-MED
,	O
possessing	B-MED
genomic	B-MED
components	I-MED
of	O
6(th	O
)	O
and	O
7(th	O
)	O
pandemic	B-MED
lineages	B-MED
,	O
and	O
diverge	B-MED
from	O
"	O
modern	B-MED
"	O
cholera	B-MED
strains	B-MED
around	O
1548	O
C.E.	O
[	O
95	O
%	O
HPD	O
:	O
1532	O
-	O
1555	O
]	O
.	O
Vibrio	B-MED
Pathogenicity	I-MED
Island	I-MED
(	B-MED
VPI)-1	I-MED
was	O
present	B-MED
;	O
however	O
,	O
SXT	B-MED
/	I-MED
R391	I-MED
-	I-MED
family	I-MED
ICE	I-MED
and	O
VPI-2	B-MED
were	O
absent	B-MED
.	O
Rugose	B-MED
phenotype	I-MED
conversion	B-MED
and	O
vibriophage	B-MED
resistance	B-MED
evidenced	B-MED
adaption	O
for	O
persistence	B-MED
in	O
aquatic	B-MED
environments	I-MED
.	O
The	O
identification	B-MED
of	O
V.	B-MED
cholerae	I-MED
O1	I-MED
strains	B-MED
in	O
the	O
Haitian	B-MED
environment	B-MED
,	O
which	O
predate	O
the	O
first	O
reported	B-MED
cholera	B-MED
pandemic	B-MED
in	O
1817	O
,	O
broadens	O
our	O
understanding	B-MED
of	O
the	O
history	B-MED
of	O
pandemics	B-MED
.	O
It	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	B-MED
environmental	B-MED
strains	B-MED
could	O
acquire	B-MED
virulence	B-MED
genes	B-MED
from	O
the	O
2010	O
Haitian	B-MED
epidemic	B-MED
clone	B-MED
,	O
including	O
the	O
cholera	B-MED
toxin	I-MED
producing	B-MED
CTXϕ	B-MED
CTXϕ.	O
Alanine	B-MED
Aminotransferase	I-MED
Is	O
a	O
Marker	B-MED
of	O
Lipotoxicity	B-MED
Consequences	B-MED
and	O
Hyperandrogenemia	B-MED
in	O
Women	B-MED
with	O
Polycystic	B-MED
Ovary	I-MED
Syndrome	I-MED
Several	O
studies	B-MED
have	O
reported	O
higher	O
levels	O
of	O
Alanine	B-MED
aminotransferase	I-MED
(	O
ALT	B-MED
)	O
in	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
(	O
PCOS	B-MED
)	O
compared	O
with	O
control	B-MED
subjects	I-MED
.	O
Plasma	B-MED
ALT	I-MED
levels	I-MED
are	O
considered	O
a	O
marker	B-MED
of	O
hepatic	B-MED
lipotoxicity	B-MED
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B-MED
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B-MED
steatosis	I-MED
and	O
hepatic	B-MED
insulin	B-MED
resistance	I-MED
.	O
Retrospective	B-MED
chart	I-MED
review	O
aiming	O
to	O
assess	O
,	O
in	O
PCOS	B-MED
women	B-MED
,	O
the	O
relationship	O
between	O
ALT	B-MED
levels	I-MED
and	O
measures	O
of	O
lipotoxicity	B-MED
consequences	B-MED
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-MED
and	O
using	O
the	O
oral	B-MED
glucose	I-MED
tolerance	I-MED
test	I-MED
.	O
Women	B-MED
(	O
n	O
=	O
132	O
)	O
with	O
PCOS	B-MED
,	O
were	O
in	O
average	O
27.9	O
years	B-MED
of	O
age	B-MED
,	O
with	O
a	O
mean	O
body	B-MED
mass	I-MED
index	I-MED
of	O
34.1	O
kg	O
/	O
m(2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	B-MED
syndrome	I-MED
(	O
MetS	B-MED
)	O
.	O
ALT	B-MED
levels	I-MED
were	O
significantly	O
correlated	O
with	O
homeostatic	B-MED
model	I-MED
assessment	I-MED
for	I-MED
insulin	I-MED
resistance	I-MED
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	B-MED
-	I-MED
C	I-MED
(	O
r	O
=	O
-0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	B-MED
index	I-MED
(	O
-0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	B-MED
secretion	I-MED
-	I-MED
sensitivity	I-MED
index-2	I-MED
(	O
-0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	B-MED
testosterone	I-MED
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	B-MED
glucose	I-MED
and	O
triglyceride	B-MED
levels	I-MED
.	O
ALT	B-MED
cutoff	O
≥24	O
IU	O
/	O
L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	B-MED
glucose	I-MED
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	B-MED
levels	I-MED
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	B-MED
with	O
the	O
MetS	B-MED
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	B-MED
-	I-MED
body	I-MED
insulin	I-MED
resistance	I-MED
(	O
Matsuda	B-MED
index	I-MED
<	O
12.3	O
L(2)·10	O
/	O
mmol(2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O
Plasma	B-MED
ALT	I-MED
levels	I-MED
seem	O
to	O
be	O
a	O
strong	O
predictor	B-MED
not	O
only	O
of	O
liver	B-MED
lipotoxicity	B-MED
but	O
also	O
of	O
systemic	B-MED
lipotoxic	I-MED
consequences	B-MED
and	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
PCOS	B-MED
.	O
Although	O
it	O
requires	O
validation	B-MED
in	O
another	O
study	B-MED
,	O
an	O
ALT	B-MED
cutoff	O
of	O
≥24	O
IU	O
/	O
L	O
may	O
help	O
clinicians	B-MED
identify	O
women	B-MED
with	O
increased	O
metabolic	B-MED
risks	I-MED
.	O
Secondary	B-MED
Ossification	I-MED
Center	I-MED
Appearance	B-MED
and	O
Closure	B-MED
in	I-MED
the	I-MED
Pelvis	I-MED
and	O
Proximal	B-MED
Femur	I-MED
Variable	O
ossification	B-MED
patterns	B-MED
of	O
the	O
pelvis	B-MED
in	O
skeletally	B-MED
immature	B-MED
patients	B-MED
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-MED
radiographs	B-MED
challenging	O
.	O
Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	B-MED
comparisons	B-MED
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-MED
ossification	I-MED
centers	I-MED
.	O
This	O
study	O
evaluates	B-MED
the	O
chronology	B-MED
and	O
sex	B-MED
differences	I-MED
for	O
appearance	B-MED
and	O
closure	B-MED
of	I-MED
pelvic	I-MED
and	O
proximal	B-MED
femoral	I-MED
secondary	B-MED
ossification	I-MED
centers	I-MED
using	O
computed	B-MED
tomography	I-MED
(	O
CT	B-MED
)	O
.	O
Patients	B-MED
who	O
underwent	O
abdominal	B-MED
and	O
pelvic	B-MED
CT	I-MED
scans	I-MED
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	B-MED
centers	I-MED
were	O
retrospectively	B-MED
reviewed	B-MED
.	O
Patients	B-MED
between	O
the	O
ages	B-MED
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-MED
of	O
the	O
pelvis	B-MED
and	O
proximal	B-MED
femurs	I-MED
were	O
included	O
.	O
Patients	B-MED
with	O
a	O
history	O
of	O
orthopaedic	B-MED
trauma	I-MED
or	O
pathology	B-MED
affecting	B-MED
ossification	B-MED
were	O
excluded	O
.	O
CT	B-MED
scans	I-MED
were	O
assessed	B-MED
for	O
the	O
appearance	B-MED
and	O
closure	B-MED
of	O
the	O
following	O
secondary	B-MED
ossification	I-MED
centers	I-MED
:	O
anterior	B-MED
inferior	I-MED
iliac	I-MED
spine	I-MED
(	O
AIIS	B-MED
)	O
,	O
anterior	B-MED
superior	I-MED
iliac	I-MED
spine	I-MED
(	O
ASIS	B-MED
)	O
,	O
femoral	B-MED
head	I-MED
(	O
FH	B-MED
)	O
,	O
greater	B-MED
trochanter	I-MED
(	O
GT	B-MED
)	O
,	O
iliac	B-MED
crest	I-MED
(	O
IC	B-MED
)	O
,	O
ischial	B-MED
tuberosity	I-MED
(	O
IT	B-MED
)	O
,	O
lesser	B-MED
trochanter	I-MED
(	O
LT	B-MED
)	O
,	O
posterior	B-MED
superior	I-MED
iliac	I-MED
spine	I-MED
(	O
PSIS	B-MED
)	O
,	O
symphysis	B-MED
pubis	I-MED
(	O
SP	B-MED
)	O
,	O
and	O
triradiate	B-MED
cartilage	I-MED
(	O
TRC	B-MED
)	O
.	O
Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O
A	O
total	O
of	O
496	O
CT	B-MED
scans	I-MED
met	O
inclusion	B-MED
criteria	I-MED
(	O
240	O
males	B-MED
and	O
256	O
females	B-MED
)	O
.	O
The	O
order	O
of	O
appearance	B-MED
of	O
the	O
secondary	B-MED
ossification	I-MED
centers	I-MED
was	O
:	O
(	O
male	B-MED
)	O
GT	B-MED
,	O
LT	B-MED
,	O
AIIS	B-MED
,	O
IT	B-MED
,	O
ASIS	B-MED
,	O
PSIS	B-MED
,	O
IC	B-MED
,	O
and	O
SP	B-MED
;	O
(	O
female	B-MED
)	O
GT	B-MED
,	O
LT	B-MED
,	O
IT	B-MED
,	O
AIIS	B-MED
,	O
PSIS	B-MED
,	O
IC	B-MED
,	O
ASIS	B-MED
,	O
and	O
SP	B-MED
.	O
The	O
order	O
of	O
closure	B-MED
was	O
similar	O
:	O
(	O
male	B-MED
)	O
TRC	B-MED
,	O
LT	B-MED
,	O
FH	B-MED
,	O
AIIS	B-MED
,	O
GT	B-MED
,	O
ASIS	B-MED
,	O
PSIS	B-MED
,	O
IT	B-MED
,	O
IC	B-MED
,	O
and	O
SP	B-MED
;	O
(	O
female	B-MED
)	O
LT	B-MED
,	O
TRC	B-MED
,	O
AIIS	B-MED
,	O
FH	B-MED
,	O
GT	B-MED
,	O
ASIS	B-MED
,	O
PSIS	B-MED
,	O
IT	B-MED
,	O
IC	B-MED
,	O
and	O
SP	B-MED
.	O
Female	B-MED
ossification	B-MED
centers	I-MED
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	B-MED
in	O
all	O
locations	B-MED
.	O
Female	B-MED
ossification	B-MED
centers	I-MED
closed	O
~1	O
to	O
2	O
years	O
before	O
males	B-MED
in	O
all	O
locations	B-MED
except	O
TRC	B-MED
,	O
IC	B-MED
,	O
and	O
SP	B-MED
.	O
The	O
appearance	B-MED
and	O
closure	B-MED
of	I-MED
the	I-MED
pelvis	I-MED
and	O
proximal	B-MED
femur	I-MED
secondary	B-MED
ossification	I-MED
centers	I-MED
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	B-MED
than	O
males	B-MED
.	O
Knowledge	O
of	O
more	O
precise	O
ages	B-MED
of	I-MED
developmen	I-MED
t	O
and	O
sex	B-MED
differences	I-MED
better	O
characterize	O
this	O
complex	O
skeletal	B-MED
development	I-MED
.	O
Future	O
studies	O
may	O
use	O
secondary	B-MED
ossification	I-MED
centers	I-MED
to	O
further	O
evaluate	B-MED
skeletal	B-MED
maturity	I-MED
,	O
assess	O
pediatric	B-MED
pathology	B-MED
,	O
and	O
aid	O
surgical	B-MED
management	I-MED
.	O
Level	O
III	O
.	O
Evaluation	B-MED
of	O
MIF	B-MED
-173	I-MED
G	I-MED
/	I-MED
C	I-MED
Polymorphism	B-MED
in	O
Turkish	B-MED
Patients	B-MED
with	O
Ankylosing	B-MED
Spondylitis	I-MED
Ankylosing	B-MED
spondylitis	I-MED
(	O
AS	B-MED
)	O
is	O
a	O
chronic	B-MED
inflammatory	I-MED
disease	I-MED
mainly	O
affecting	O
the	O
spine	B-MED
and	O
sacroiliac	B-MED
joints	I-MED
.	O
Macrophage	B-MED
migration	I-MED
inhibitory	I-MED
(	I-MED
MIF	I-MED
)	I-MED
factor	I-MED
is	O
a	O
regulatory	B-MED
cytokine	B-MED
that	O
inhibits	B-MED
random	O
immune	B-MED
cell	I-MED
migration	I-MED
.	O
MIF	B-MED
gene	I-MED
promoter	B-MED
polymorphisms	B-MED
play	O
a	O
role	O
in	O
the	O
progression	B-MED
of	O
several	O
inflammatory	B-MED
disorders	I-MED
.	O
To	O
investigate	B-MED
the	O
relationship	O
between	O
the	O
MIF	B-MED
gene	I-MED
-173	I-MED
G	I-MED
/	I-MED
C	I-MED
single	B-MED
-	I-MED
nucleotide	I-MED
polymorphism	I-MED
(	O
SNP	B-MED
)	O
and	O
AS	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
total	O
of	O
161	O
AS	B-MED
and	O
194	O
normal	B-MED
controls	B-MED
were	O
recruited	O
.	O
The	O
MIF	B-MED
gene	I-MED
-173	I-MED
G	I-MED
/	I-MED
C	I-MED
SNP	B-MED
was	O
analyzed	B-MED
by	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
using	O
the	O
restriction	B-MED
fragment	I-MED
length	I-MED
polymorphism	I-MED
method	I-MED
.	O
There	O
was	O
no	O
significant	B-MED
difference	O
between	O
groups	B-MED
in	O
terms	O
of	O
genotype	B-MED
distribution	O
(	O
p>0.05	O
)	O
.	O
When	O
wild	B-MED
-	I-MED
type	I-MED
G	B-MED
/	I-MED
G	I-MED
and	O
G	B-MED
/	I-MED
C+C	I-MED
/	I-MED
C	I-MED
genotypes	I-MED
are	O
compared	O
in	O
terms	O
of	O
clinical	B-MED
characteristics	I-MED
,	O
there	O
is	O
a	O
significant	B-MED
difference	O
between	O
the	O
average	O
age	B-MED
and	O
the	O
duration	B-MED
of	I-MED
disease	I-MED
in	O
AS	B-MED
patients	B-MED
(	O
p<0.05	O
)	O
.	O
No	O
significant	B-MED
relationship	O
between	O
AS	B-MED
disease	B-MED
and	O
MIF	B-MED
-173	I-MED
G	I-MED
/	I-MED
C	I-MED
polymorphism	B-MED
was	O
found	O
.	O
MIF	B-MED
-173	I-MED
G	I-MED
/	I-MED
C	I-MED
polymorphism	B-MED
(	O
C	B-MED
allele	I-MED
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	B-MED
of	I-MED
disease	I-MED
in	O
AS	B-MED
patients	B-MED
.	O
Clinical	B-MED
Experience	B-MED
With	O
the	O
Subcutaneous	B-MED
Implantable	I-MED
Cardioverter	I-MED
-	I-MED
Defibrillator	I-MED
in	O
Adults	B-MED
With	O
Congenital	B-MED
Heart	I-MED
Disease	I-MED
Sudden	B-MED
cardiac	I-MED
death	I-MED
is	O
a	O
major	O
contributor	O
to	O
mortality	B-MED
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
.	O
The	O
subcutaneous	B-MED
implantable	B-MED
cardioverter	I-MED
-	I-MED
defibrillator	I-MED
(	O
ICD	B-MED
)	O
has	O
emerged	O
as	O
a	O
novel	B-MED
tool	B-MED
for	O
prevention	B-MED
of	O
sudden	B-MED
cardiac	I-MED
death	I-MED
,	O
but	O
clinical	B-MED
performance	I-MED
data	B-MED
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
are	O
limited	O
.	O
A	O
retrospective	B-MED
study	I-MED
involving	O
7	O
centers	O
over	O
a	O
5-	O
year	B-MED
period	B-MED
beginning	O
in	O
2011	O
was	O
performed	B-MED
.	O
Twenty	O
-	O
one	O
patients	B-MED
(	O
median	B-MED
33.9	O
years	B-MED
)	O
were	O
identified	O
.	O
The	O
most	O
common	O
diagnosis	B-MED
was	O
single	B-MED
ventricle	I-MED
physiology	B-MED
(	O
52	O
%	O
)	O
,	O
9	O
palliated	B-MED
by	O
Fontan	B-MED
operation	I-MED
and	O
2	O
by	O
aortopulmonary	B-MED
shunts	I-MED
:	O
d	B-MED
-	I-MED
transposition	I-MED
of	I-MED
the	I-MED
great	I-MED
arteries	I-MED
after	O
Mustard	B-MED
/	O
Senning	B-MED
(	O
n=2	O
)	O
,	O
tetralogy	B-MED
of	I-MED
Fallot	I-MED
(	O
n=2	O
)	O
,	O
aortic	B-MED
valve	I-MED
disease	I-MED
(	O
n=2	O
)	O
,	O
and	O
other	O
biventricular	B-MED
surgery	B-MED
(	O
n=4	O
)	O
.	O
A	O
prior	O
cardiac	B-MED
device	I-MED
had	O
been	O
implanted	B-MED
in	O
7	O
(	O
33	O
%	O
)	O
.	O
The	O
ICD	B-MED
indication	B-MED
was	O
primary	B-MED
prevention	I-MED
in	O
67	O
%	O
and	O
secondary	B-MED
in	O
33	O
%	O
patient	B-MED
s	I-MED
s.	O
The	O
most	O
common	O
reason	O
for	O
subcutaneous	B-MED
ICD	B-MED
placement	B-MED
was	O
limited	O
transvenous	B-MED
access	I-MED
for	O
ventricular	B-MED
lead	I-MED
placement	B-MED
(	O
n=10	O
)	O
followed	O
by	O
intracardiac	B-MED
right	I-MED
-	I-MED
to	I-MED
-	I-MED
left	I-MED
shunt	I-MED
(	O
n=5	O
)	O
.	O
Ventricular	B-MED
arrhythmia	I-MED
was	O
induced	B-MED
in	O
17	O
(	O
81	O
%	O
)	O
and	O
was	O
converted	O
with	O
≤80	O
Joules	B-MED
in	O
all	O
.	O
There	O
was	O
one	O
implant	B-MED
complication	I-MED
related	I-MED
to	I-MED
infection	I-MED
,	O
not	B-MED
requiring	O
device	B-MED
removal	I-MED
.	O
Over	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
14	O
months	B-MED
,	O
4	O
patients	B-MED
(	O
21	O
%	O
)	O
received	O
inappropriate	B-MED
and	O
1	O
(	O
5	O
%	O
)	O
patient	B-MED
received	O
appropriate	B-MED
shocks	I-MED
.	O
There	O
was	O
one	O
arrhythmic	B-MED
death	I-MED
related	O
to	O
asystole	B-MED
in	O
a	O
single	B-MED
ventricle	I-MED
patient	B-MED
.	O
Subcutaneous	B-MED
ICD	B-MED
implantation	B-MED
is	O
feasible	O
for	O
adults	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
patients	B-MED
.	O
Most	O
candidates	B-MED
have	O
single	B-MED
ventricle	I-MED
heart	B-MED
disease	I-MED
and	O
limited	O
transvenous	B-MED
options	I-MED
for	O
ICD	B-MED
placement	B-MED
.	O
Despite	O
variable	B-MED
anatomy	B-MED
,	O
this	O
study	B-MED
demonstrates	O
successful	B-MED
conversion	B-MED
of	O
induced	B-MED
ventricular	B-MED
arrhythmia	I-MED
and	O
reasonable	B-MED
rhythm	B-MED
discrimination	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Limb	B-MED
remote	B-MED
ischaemic	I-MED
postconditioning	I-MED
-	O
induced	B-MED
elevation	B-MED
of	O
fibulin-5	B-MED
confers	O
neuroprotection	B-MED
to	O
rats	B-MED
with	O
cerebral	B-MED
ischaemia	I-MED
/	O
reperfusion	B-MED
injury	I-MED
:	O
Activation	B-MED
of	O
the	O
AKT	B-MED
pathway	I-MED
Limb	B-MED
remote	B-MED
ischaemic	I-MED
postconditioning	I-MED
(	O
RIPostC	B-MED
)	O
is	O
an	O
effective	O
and	O
well	O
-	O
acknowledged	O
treatment	B-MED
for	O
brain	B-MED
ischaemia	I-MED
injury	I-MED
.	O
The	O
present	O
study	B-MED
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin-5	B-MED
in	O
the	O
neuroprotection	B-MED
of	O
RIPostC	B-MED
against	O
cerebral	B-MED
ischaemia	I-MED
/	O
reperfusion	B-MED
(	I-MED
I	I-MED
/	I-MED
R	I-MED
)	I-MED
injury	I-MED
in	O
rats	B-MED
.	O
The	O
middle	B-MED
cerebral	I-MED
artery	I-MED
occlusion	I-MED
(	O
MCAO	B-MED
)	O
model	B-MED
was	O
established	O
in	O
rats	B-MED
and	O
then	O
RIPostC	B-MED
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	B-MED
occlusion	B-MED
/10	O
minutes	B-MED
release	O
of	O
the	O
bilateral	B-MED
femoral	B-MED
artery	I-MED
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-MED
.	O
To	O
downregulate	B-MED
the	O
fibulin-5	B-MED
level	B-MED
,	O
fibulin-5	B-MED
siRNA	I-MED
was	O
injected	B-MED
into	O
the	O
lateral	B-MED
ventricle	I-MED
24	O
hours	B-MED
before	O
MCAO	B-MED
.	O
According	O
to	O
our	O
present	O
study	B-MED
,	O
RIPostC	B-MED
attenuated	B-MED
cerebral	B-MED
I	I-MED
/	O
R	B-MED
injury	I-MED
by	O
decreasing	B-MED
infarct	B-MED
volume	B-MED
,	O
improving	O
neurobehavioral	B-MED
score	I-MED
and	O
suppressing	B-MED
blood	B-MED
brain	I-MED
barrier	I-MED
(	O
BBB	B-MED
)	O
leakage	B-MED
.	O
Moreover	O
,	O
the	O
mRNA	B-MED
and	O
protein	B-MED
levels	I-MED
of	O
fibulin-5	B-MED
were	O
upregulated	B-MED
by	O
RIPostC	B-MED
at	O
24	O
hours	B-MED
and	O
72	O
hours	B-MED
after	O
reperfusion	B-MED
.	O
Downregulation	B-MED
of	O
fibulin-5	B-MED
attenuated	B-MED
the	O
neuroprotection	B-MED
RIPostC	B-MED
of	O
RIPostC.	O
Finally	O
,	O
the	O
result	O
showed	O
that	O
fibulin-5	B-MED
was	O
upregulated	B-MED
by	O
RIPostC	B-MED
via	O
activation	B-MED
of	O
the	O
PI3K	B-MED
/	I-MED
AKT	I-MED
pathway	I-MED
.	O
Taken	O
together	O
,	O
these	O
results	B-MED
provide	O
evidence	B-MED
that	O
upregulation	B-MED
of	O
fibulin-5	B-MED
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
RIPostC	B-MED
against	O
cerebral	B-MED
I	I-MED
/	O
R	B-MED
injury	I-MED
.	O
Analysis	B-MED
of	O
Low	B-MED
-	I-MED
Biomass	I-MED
Microbial	B-MED
Communities	I-MED
in	O
the	O
Deep	B-MED
Biosphere	I-MED
Over	O
the	O
past	O
few	B-MED
decades	I-MED
,	O
the	O
subseafloor	B-MED
biosphere	I-MED
has	O
been	O
explored	O
by	O
scientific	B-MED
ocean	I-MED
drilling	I-MED
to	O
depths	B-MED
of	O
about	O
2.5	O
km	O
below	O
the	O
seafloor	B-MED
.	O
Although	O
organic	B-MED
-	I-MED
rich	I-MED
anaerobic	I-MED
sedimentary	I-MED
habitats	I-MED
in	O
the	O
ocean	B-MED
margins	I-MED
harbor	I-MED
large	O
numbers	O
of	O
microbial	B-MED
cells	I-MED
,	O
microbial	B-MED
populations	I-MED
in	O
ultraoligotrophic	B-MED
aerobic	I-MED
sedimentary	I-MED
habitats	I-MED
in	O
the	O
open	O
ocean	B-MED
gyres	I-MED
are	O
several	O
orders	O
of	O
magnitude	B-MED
less	O
abundant	B-MED
.	O
Despite	O
advances	O
in	O
cultivation	B-MED
-	I-MED
independent	I-MED
molecular	I-MED
ecological	I-MED
techniques	I-MED
,	O
exploring	O
the	O
low	B-MED
-	I-MED
biomass	I-MED
environment	B-MED
remains	O
technologically	B-MED
challenging	I-MED
,	O
especially	O
in	O
the	O
deep	B-MED
subseafloor	I-MED
biosphere	I-MED
.	O
Reviewing	B-MED
the	O
historical	B-MED
background	I-MED
of	O
deep	B-MED
-	I-MED
biosphere	I-MED
analytical	B-MED
methods	I-MED
,	O
the	O
importance	B-MED
of	O
obtaining	O
clean	B-MED
samples	I-MED
and	O
tracing	B-MED
contamination	B-MED
,	O
as	O
well	O
as	O
methods	B-MED
for	O
detecting	B-MED
microbial	B-MED
life	B-MED
,	O
technological	B-MED
aspects	I-MED
of	O
molecular	B-MED
microbiology	I-MED
,	O
and	O
detecting	B-MED
subseafloor	B-MED
metabolic	B-MED
activity	I-MED
will	O
be	O
discussed	O
.	O
The	O
Pre	B-MED
-	I-MED
Eclampsia	I-MED
Ontology	B-MED
:	O
A	O
Disease	B-MED
Ontology	I-MED
Representing	O
the	O
Domain	O
Knowledge	O
Specific	O
to	O
Pre	B-MED
-	I-MED
Eclampsia	I-MED
Pre	B-MED
-	I-MED
eclampsia	I-MED
(	O
PE	B-MED
)	O
is	O
a	O
clinical	B-MED
syndrome	I-MED
characterized	O
by	O
new	B-MED
-	I-MED
onset	I-MED
hypertension	I-MED
and	O
proteinuria	B-MED
at	O
≥20	B-MED
weeks	I-MED
of	I-MED
gestation	I-MED
,	O
and	O
is	O
a	O
leading	O
cause	B-MED
of	O
maternal	B-MED
and	O
perinatal	B-MED
morbidity	I-MED
and	O
mortality	B-MED
.	O
Previous	O
studies	O
have	O
gathered	O
abundant	B-MED
data	B-MED
about	O
PE	B-MED
such	O
as	O
risk	B-MED
factors	I-MED
and	O
pathological	B-MED
findings	I-MED
.	O
However	O
,	O
most	O
of	O
these	O
data	B-MED
are	O
not	O
semantically	O
structured	O
.	O
Clinical	B-MED
data	I-MED
on	O
PE	B-MED
patients	B-MED
are	O
often	O
generated	O
with	O
semantic	B-MED
heterogeneity	B-MED
such	O
as	O
using	O
disparate	B-MED
terminology	I-MED
to	O
describe	O
the	O
same	O
phenomena	B-MED
.	O
In	O
clinical	B-MED
studies	I-MED
,	O
interoperability	O
of	O
heterogenic	B-MED
clinical	B-MED
data	I-MED
is	O
required	O
in	O
various	O
situations	B-MED
.	O
In	O
such	O
a	O
situation	B-MED
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	B-MED
framework	B-MED
to	O
research	B-MED
the	O
pathology	B-MED
of	O
PE	B-MED
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	B-MED
clinical	B-MED
data	I-MED
of	O
PE	B-MED
patients	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
an	O
ontology	B-MED
representing	O
clinical	B-MED
features	I-MED
,	O
treatments	B-MED
,	O
genetic	B-MED
factors	I-MED
,	O
environmental	B-MED
factors	I-MED
,	O
and	O
other	O
aspects	B-MED
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
PE	B-MED
.	O
We	O
call	O
this	O
pre	B-MED
-	I-MED
eclampsia	I-MED
ontology	B-MED
"	O
PEO	B-MED
"	O
.	O
To	O
achieve	O
interoperability	O
with	O
other	O
ontologies	B-MED
,	O
the	O
core	O
structure	O
of	O
PEO	B-MED
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
Basic	B-MED
Formal	I-MED
Ontology	I-MED
(	O
BFO	B-MED
)	O
.	O
The	O
PEO	B-MED
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	B-MED
and	O
terms	B-MED
of	O
PE	B-MED
from	O
clinical	B-MED
and	O
biomedical	B-MED
research	I-MED
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
PE	B-MED
;	O
therefore	O
,	O
PEO	B-MED
is	O
expected	O
to	O
enhance	B-MED
PE	B-MED
-specific	O
information	B-MED
retrieval	I-MED
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	B-MED
and	O
biomedical	B-MED
research	I-MED
fields	B-MED
.	O
Antagonistic	B-MED
Self	B-MED
-	I-MED
Organizing	I-MED
Patterning	I-MED
Systems	O
Control	B-MED
Maintenance	B-MED
and	O
Regeneration	B-MED
of	O
the	O
Anteroposterior	B-MED
Axis	B-MED
in	O
Planarians	B-MED
Planarian	B-MED
flatworms	B-MED
maintain	B-MED
their	O
body	B-MED
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	B-MED
from	O
arbitrary	B-MED
tissue	B-MED
fragments	B-MED
.	O
Both	O
phenomena	B-MED
require	O
self	B-MED
-	I-MED
maintaining	I-MED
and	O
self	B-MED
-	I-MED
organizing	I-MED
patterning	I-MED
mechanisms	B-MED
,	O
the	O
molecular	B-MED
mechanisms	B-MED
of	O
which	O
remain	O
poorly	O
understood	O
.	O
We	O
show	O
that	O
a	O
morphogenic	B-MED
gradient	B-MED
of	O
canonical	B-MED
Wnt	I-MED
signaling	I-MED
patterns	O
gene	B-MED
expression	I-MED
along	O
the	O
planarian	B-MED
anteroposterior	B-MED
(	O
A	B-MED
/	I-MED
P	I-MED
)	O
axis	B-MED
.	O
Our	O
results	B-MED
demonstrate	O
that	O
gradient	B-MED
formation	B-MED
likely	O
occurs	O
autonomously	B-MED
in	O
the	O
tail	B-MED
and	O
that	O
an	O
autoregulatory	B-MED
module	O
of	O
Wnt	B-MED
-mediated	O
Wnt	B-MED
expression	B-MED
both	O
shapes	O
the	O
gradient	B-MED
at	O
steady	B-MED
state	I-MED
and	O
governs	O
its	O
re	O
-	O
establishment	O
during	O
regeneration	B-MED
.	O
Functional	B-MED
antagonism	B-MED
between	O
the	O
tail	B-MED
Wnt	B-MED
gradient	B-MED
and	O
an	O
unknown	B-MED
head	B-MED
patterning	B-MED
system	O
further	O
determines	O
the	O
spatial	B-MED
proportions	B-MED
of	O
the	O
planarian	B-MED
A	B-MED
/	I-MED
P	I-MED
axis	B-MED
and	O
mediates	O
mutually	B-MED
exclusive	B-MED
molecular	B-MED
fate	I-MED
choices	O
during	B-MED
regeneration	B-MED
.	O
Overall	O
,	O
our	O
results	B-MED
suggest	O
that	O
the	O
planarian	B-MED
A	B-MED
/	I-MED
P	I-MED
axis	B-MED
is	O
patterned	O
by	O
self	B-MED
-	I-MED
organizing	I-MED
patterning	I-MED
systems	O
deployed	B-MED
from	O
either	O
end	O
that	O
are	O
functionally	B-MED
coupled	B-MED
by	O
mutual	B-MED
antagonism	B-MED
.	O
Questionable	O
diagnostic	B-MED
benefit	B-MED
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B-MED
venom	I-MED
components	B-MED
For	O
many	O
years	B-MED
,	O
only	O
the	O
major	O
allergen	B-MED
rApi	B-MED
m	I-MED
1	I-MED
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	B-MED
system	I-MED
for	O
routine	O
diagnosis	B-MED
of	O
bee	B-MED
venom	I-MED
(	I-MED
BV	I-MED
)	I-MED
allergy	I-MED
.	O
Now	O
,	O
there	O
are	O
five	O
components	B-MED
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
rApi	B-MED
m	I-MED
1	I-MED
,	O
2	B-MED
,	O
3	B-MED
,	O
5	B-MED
,	O
and	O
10	B-MED
in	O
BV	B-MED
-	I-MED
allergic	I-MED
patients	B-MED
.	O
We	O
further	O
evaluated	O
the	O
sensitivity	B-MED
of	O
rApi	B-MED
m	I-MED
1	I-MED
and	O
2	B-MED
of	O
an	O
alternative	O
platform	O
and	O
investigated	B-MED
possible	O
differences	O
in	O
the	O
sensitization	B-MED
profile	O
between	O
monosensitization	B-MED
and	O
clinically	O
relevant	O
double	B-MED
sensitization	I-MED
.	O
Analysis	B-MED
of	O
the	O
whole	O
panel	O
of	O
BV	B-MED
allergens	B-MED
of	O
the	O
CAP	B-MED
system	I-MED
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	B-MED
than	O
analysis	B-MED
of	O
the	O
combination	O
of	O
rApi	B-MED
m	I-MED
1	I-MED
and	O
2	B-MED
of	O
the	O
Immulite	B-MED
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O
Sensitization	B-MED
rate	B-MED
of	O
rApi	B-MED
m	I-MED
5	I-MED
was	O
more	O
than	O
doubled	O
in	O
double	B-MED
-	I-MED
sensitized	I-MED
patients	B-MED
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	B-MED
m	I-MED
2	I-MED
.	O
The	O
benefit	B-MED
of	O
the	O
commercially	O
available	O
panel	O
of	O
BV	B-MED
components	B-MED
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	B-MED
sensitivity	B-MED
and	O
still	O
unavailable	O
important	O
cross	B-MED
-	I-MED
reacting	I-MED
allergens	B-MED
.	O
Treatment	B-MED
for	O
Rheumatoid	B-MED
Arthritis	I-MED
and	O
Risk	B-MED
of	O
Alzheimer	B-MED
's	I-MED
Disease	I-MED
:	O
A	O
Nested	B-MED
Case	I-MED
-	I-MED
Control	I-MED
Analysis	I-MED
It	O
is	O
increasingly	B-MED
becoming	O
accepted	B-MED
that	O
inflammation	B-MED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
,	O
as	O
several	B-MED
immune	B-MED
-related	O
genes	B-MED
have	O
been	O
associated	B-MED
with	I-MED
AD	B-MED
.	O
Among	O
these	O
is	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
(	I-MED
TNF)-α	I-MED
,	O
a	O
proinflammatory	B-MED
cytokine	I-MED
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-MED
disorders	I-MED
,	O
including	O
rheumatoid	B-MED
arthritis	I-MED
(	O
RA	B-MED
)	O
.	O
Although	O
AD	B-MED
and	O
RA	B-MED
appear	O
to	O
involve	O
similar	B-MED
pathological	B-MED
mechanisms	I-MED
through	O
the	O
production	B-MED
of	O
TNF	B-MED
-	I-MED
α	I-MED
,	I-MED
the	O
relationship	B-MED
between	O
AD	B-MED
and	O
RA	B-MED
remains	O
unknown	B-MED
.	O
To	O
determine	O
the	O
relative	B-MED
risk	I-MED
of	O
AD	B-MED
among	O
RA	B-MED
patients	B-MED
and	O
non-	O
RA	B-MED
patients	B-MED
,	O
and	O
whether	O
anti	B-MED
-	I-MED
TNF	I-MED
therapy	I-MED
for	O
RA	B-MED
was	O
associated	B-MED
with	I-MED
a	O
lower	B-MED
risk	B-MED
of	O
AD	B-MED
in	O
RA	B-MED
patients	B-MED
.	O
We	O
performed	O
a	O
nested	B-MED
case	I-MED
-	I-MED
control	I-MED
study	I-MED
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	B-MED
adults	B-MED
(	O
aged	O
≥18	O
years	O
)	O
in	O
all	O
50	O
US	B-MED
states	I-MED
,	O
Puerto	B-MED
Rico	I-MED
,	O
and	O
US	B-MED
Virgin	I-MED
Islands	I-MED
in	O
the	O
Verisk	B-MED
Health	I-MED
claims	I-MED
database	I-MED
.	O
We	O
derived	O
a	O
sub	B-MED
-	I-MED
cohort	I-MED
of	O
subjects	O
with	O
a	O
diagnosis	B-MED
of	O
RA	B-MED
(	O
controls	B-MED
)	O
,	O
or	O
RA	B-MED
and	O
AD	B-MED
(	O
cases	B-MED
)	O
,	O
matching	B-MED
cases	B-MED
and	O
controls	O
based	O
on	O
age	B-MED
,	O
sex	B-MED
,	O
exposure	B-MED
assessment	I-MED
period	I-MED
,	O
and	O
methotrexate	B-MED
treatment	I-MED
.	O
We	O
also	O
assessed	B-MED
relative	I-MED
risk	I-MED
of	O
AD	B-MED
following	O
exposure	B-MED
to	I-MED
standard	B-MED
RA	B-MED
therapies	B-MED
,	O
including	O
anti	B-MED
-	I-MED
TNF	I-MED
agents	I-MED
(	O
infliximab	B-MED
,	O
adalimumab	B-MED
,	O
etanercept	B-MED
)	O
,	O
methotrexate	B-MED
,	O
prednisone	B-MED
,	O
sulfasalazine	B-MED
,	O
and	O
rituximab	B-MED
.	O
Odds	B-MED
ratios	I-MED
were	O
adjusted	O
for	O
comorbidities	B-MED
,	O
including	O
coronary	B-MED
artery	I-MED
disease	I-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
peripheral	B-MED
vascular	I-MED
disease	I-MED
.	O
AD	B-MED
was	O
more	O
prevalent	B-MED
(	O
p	O
<	O
0.0001	O
)	O
among	O
RA	B-MED
patients	B-MED
(	O
0.79	O
%	O
)	O
than	O
among	O
those	O
without	B-MED
RA	B-MED
(	O
0.11	O
%	O
)	O
.	O
Chronic	B-MED
conditions	I-MED
such	O
as	O
coronary	B-MED
artery	I-MED
disease	I-MED
(	O
odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
1.48	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
1.04	O
-	O
2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	B-MED
(	O
OR	B-MED
1.86	O
;	O
95	O
%	O
CI	B-MED
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	B-MED
vascular	I-MED
disease	I-MED
(	O
OR	B-MED
1.61	O
;	O
95	O
%	O
CI	B-MED
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	B-MED
risk	I-MED
of	O
AD	B-MED
among	O
RA	B-MED
patients	B-MED
.	O
Exposure	B-MED
to	I-MED
anti	B-MED
-	I-MED
TNF	I-MED
agents	I-MED
as	O
a	O
class	B-MED
,	O
but	O
not	O
other	O
immunosuppressive	B-MED
drugs	I-MED
studied	O
,	O
was	O
associated	B-MED
with	I-MED
lowered	B-MED
risk	B-MED
of	O
AD	B-MED
among	O
RA	B-MED
patients	B-MED
(	O
unadjusted	O
OR	B-MED
0.44	O
;	O
95	O
%	O
CI	B-MED
0.22	O
-	O
0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	B-MED
0.45	O
;	O
95	O
%	O
CI	B-MED
0.23	O
-	O
0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O
Sub	B-MED
-	I-MED
group	I-MED
analysis	I-MED
demonstrated	O
that	O
of	O
the	O
three	O
anti	B-MED
-	I-MED
TNF	I-MED
agents	I-MED
studied	O
,	O
only	O
etanercept	B-MED
(	O
unadjusted	O
OR	B-MED
,	O
0.33	O
;	O
95	O
%	O
CI	B-MED
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	B-MED
0.30	O
;	O
95	O
%	O
CI	B-MED
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	B-MED
with	I-MED
a	O
decreased	B-MED
risk	B-MED
of	O
AD	B-MED
in	O
RA	B-MED
patients	B-MED
.	O
There	O
is	O
an	O
increased	B-MED
risk	B-MED
of	O
AD	B-MED
in	O
the	O
studied	O
RA	B-MED
population	B-MED
.	O
The	O
relative	B-MED
risk	I-MED
of	O
AD	B-MED
among	O
RA	B-MED
subjects	O
was	O
lowered	B-MED
in	O
those	O
exposed	B-MED
to	I-MED
etanercept	B-MED
.	O
Anti	B-MED
-	I-MED
TNF	I-MED
therapy	I-MED
with	O
etanercept	B-MED
shows	O
promise	B-MED
as	O
a	O
potential	B-MED
treatment	B-MED
for	O
AD	B-MED
.	O
Development	B-MED
of	O
an	O
automaton	B-MED
model	I-MED
of	O
rotational	B-MED
activity	I-MED
driving	O
atrial	B-MED
fibrillation	I-MED
Atrial	B-MED
fibrillation	I-MED
(	O
AF	B-MED
)	O
is	O
difficult	O
to	O
treat	B-MED
effectively	B-MED
,	O
owing	O
to	O
uncertainty	B-MED
in	O
where	O
to	O
best	O
ablate	B-MED
to	O
eliminate	B-MED
arrhythmogenic	B-MED
substrate	B-MED
.	O
A	O
model	B-MED
providing	O
insight	O
into	O
the	O
electrical	B-MED
activation	B-MED
events	B-MED
would	O
be	O
useful	O
to	O
guide	O
catheter	B-MED
ablation	I-MED
strategy	I-MED
.	O
Method	O
A	O
two	B-MED
-	I-MED
dimensional	I-MED
,	O
576×576	B-MED
node	I-MED
automaton	I-MED
was	O
developed	O
to	O
simulate	B-MED
atrial	B-MED
atrial	B-MED
electrical	I-MED
activity	I-MED
.	O
The	O
substrate	B-MED
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	B-MED
refractory	B-MED
period	I-MED
at	O
varying	O
locations	B-MED
.	O
Fibrosis	B-MED
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	B-MED
block	B-MED
.	O
Larger	B-MED
areas	B-MED
of	O
block	B-MED
were	O
used	O
to	O
simulate	B-MED
ablation	B-MED
lesions	I-MED
.	O
Anisotropy	B-MED
was	O
imposed	O
in	O
a	O
2:1	O
ratio	B-MED
.	O
A	O
premature	B-MED
electrical	B-MED
impulse	I-MED
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	B-MED
activation	B-MED
.	O
Rotational	B-MED
activity	I-MED
was	O
uninducible	O
when	O
refractory	B-MED
patch	I-MED
dimensions	I-MED
were	O
less	O
than	O
20×20	O
mm	O
.	O
For	O
larger	B-MED
refractory	B-MED
regions	I-MED
,	O
a	O
single	O
premature	B-MED
stimulus	B-MED
was	O
capable	O
of	O
inducing	B-MED
an	O
average	B-MED
of	O
1.19±1.10	O
rotors	B-MED
,	O
which	O
often	O
formed	O
near	O
the	O
patch	B-MED
edges	I-MED
.	O
A	O
maximum	B-MED
of	O
5	O
rotors	B-MED
formed	O
when	O
refractory	B-MED
patch	I-MED
dimensions	I-MED
approached	O
the	O
size	B-MED
of	O
the	O
entire	O
left	B-MED
atrial	I-MED
virtual	B-MED
field	I-MED
.	O
Rotors	B-MED
formed	O
along	O
a	O
refractory	B-MED
patch	I-MED
edge	I-MED
,	O
after	O
wavefront	B-MED
arrival	I-MED
was	I-MED
delayed	I-MED
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	B-MED
cluster	B-MED
of	O
sufficient	O
size	B-MED
.	O
However	O
,	O
rotational	B-MED
activity	I-MED
could	O
also	O
occur	O
around	O
a	O
large	B-MED
fiber	B-MED
cluster	B-MED
without	O
the	O
need	O
of	O
spatially	B-MED
variable	I-MED
refractoriness	I-MED
.	O
When	O
obstacles	B-MED
to	O
conduction	B-MED
were	O
lacking	B-MED
in	O
size	B-MED
,	O
nascent	B-MED
rotors	I-MED
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	B-MED
upon	O
anchoring	B-MED
at	O
a	O
sufficiently	O
large	B-MED
fiber	B-MED
cluster	B-MED
elsewhere	O
in	O
the	O
field	O
.	O
Transient	B-MED
rotors	B-MED
terminated	O
when	O
traversing	B-MED
a	O
region	B-MED
with	O
differing	O
refractory	B-MED
periods	I-MED
,	O
if	O
no	O
obstacle	B-MED
to	O
conduction	B-MED
was	O
present	O
to	O
sufficiently	O
delay	B-MED
wavefront	I-MED
arrival	I-MED
beyond	O
the	O
longest	B-MED
refractory	B-MED
period	I-MED
.	O
Other	O
rotors	B-MED
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	B-MED
with	O
faster	O
spin	B-MED
rate	I-MED
gradually	O
interrupted	O
the	O
activation	B-MED
pathway	I-MED
.	O
Elimination	B-MED
of	O
anchors	B-MED
by	O
removal	B-MED
,	O
or	O
by	O
simulated	O
ablation	B-MED
over	O
a	O
sufficient	O
region	B-MED
,	O
prevented	O
rotor	B-MED
onset	B-MED
at	O
a	O
particular	O
location	B-MED
where	O
it	O
would	O
otherwise	O
form	O
.	O
The	O
presence	O
of	O
obstacles	B-MED
to	O
conduction	B-MED
and	O
spatial	B-MED
differences	I-MED
in	O
refractory	B-MED
period	I-MED
are	O
important	O
parameters	B-MED
for	O
initiating	O
and	O
maintaining	B-MED
rotational	B-MED
activity	I-MED
in	O
this	O
simulation	B-MED
of	O
an	O
atrial	B-MED
substrate	B-MED
.	O
Perineal	B-MED
injuries	I-MED
and	O
birth	B-MED
positions	I-MED
among	O
2992	O
women	B-MED
with	O
a	O
low	B-MED
risk	I-MED
pregnancy	I-MED
who	O
opted	O
for	O
a	O
homebirth	B-MED
Whether	O
certain	O
birth	B-MED
positions	I-MED
are	O
associated	B-MED
with	I-MED
perineal	B-MED
injuries	I-MED
and	O
severe	B-MED
perineal	I-MED
trauma	I-MED
(	O
SPT	B-MED
)	O
is	O
still	O
unclear	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
describe	O
the	O
prevalence	B-MED
of	O
perineal	B-MED
injuries	I-MED
of	O
different	O
severity	B-MED
in	O
a	O
low	B-MED
-	I-MED
risk	I-MED
population	B-MED
of	O
women	B-MED
who	O
planned	O
to	O
give	O
birth	B-MED
at	I-MED
home	I-MED
and	O
to	O
compare	O
the	O
prevalence	B-MED
of	O
perineal	B-MED
injuries	I-MED
,	O
SPT	B-MED
and	O
episiotomy	B-MED
in	O
different	O
birth	B-MED
positions	I-MED
in	O
four	O
Nordic	B-MED
countries	I-MED
.	O
A	O
population	B-MED
-based	O
prospective	B-MED
cohort	I-MED
study	I-MED
of	O
planned	O
home	B-MED
births	I-MED
in	O
four	O
Nordic	B-MED
countries	I-MED
.	O
To	O
assess	B-MED
medical	I-MED
outcomes	I-MED
a	O
questionnaire	B-MED
completed	O
after	O
birth	B-MED
by	O
the	O
attending	O
midwife	B-MED
was	O
used	O
.	O
Descriptive	B-MED
statistics	I-MED
,	O
bivariate	B-MED
analysis	I-MED
and	O
logistic	B-MED
regression	I-MED
were	O
used	O
to	O
analyze	O
the	O
data	B-MED
.	O
Two	O
thousand	O
nine	O
hundred	O
ninety	O
-	O
two	O
women	B-MED
with	O
planned	O
home	B-MED
births	I-MED
,	O
who	O
birthed	O
spontaneously	O
at	O
home	B-MED
or	O
after	O
transfer	B-MED
to	I-MED
hospital	I-MED
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O
The	O
prevalence	B-MED
of	O
SPT	B-MED
was	O
0.7	O
%	O
and	O
the	O
prevalence	B-MED
of	O
episiotomy	B-MED
was	O
1.0	O
%	O
.	O
There	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-MED
characteristics	B-MED
.	O
No	O
association	O
between	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
and	O
sutured	B-MED
perineal	B-MED
injuries	I-MED
was	O
found	O
(	O
OR	B-MED
1.02	O
;	O
95	O
%	O
CI	B-MED
0.86	O
-	O
1.21	O
)	O
or	O
SPT	B-MED
(	O
OR	B-MED
0.68	O
;	O
CI	B-MED
95	O
%	O
0.26	O
-	O
1.79	O
)	O
.	O
Flexible	B-MED
sacrum	B-MED
positions	B-MED
were	O
associated	B-MED
with	I-MED
fewer	O
episiotomies	B-MED
(	O
OR	B-MED
0.20	O
;	O
CI	B-MED
95	O
%	O
0.10	O
-	O
0.54	O
)	O
.	O
A	O
low	O
prevalence	B-MED
of	O
SPT	B-MED
and	O
episiotomy	B-MED
was	O
found	O
among	O
women	B-MED
opting	O
for	O
a	O
home	B-MED
birth	I-MED
in	O
four	O
Nordic	B-MED
countries	I-MED
.	O
Women	B-MED
used	O
a	O
variety	O
of	O
birth	B-MED
positions	I-MED
and	O
a	O
majority	O
gave	O
birth	B-MED
in	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
.	O
No	O
associations	O
were	O
found	O
between	O
flexible	B-MED
sacrum	B-MED
positions	B-MED
and	O
SPT	B-MED
.	O
Flexible	B-MED
sacrum	B-MED
positions	B-MED
were	O
associated	B-MED
with	I-MED
fewer	O
episiotomies	B-MED
.	O
Ophthalmic	B-MED
Manifestations	I-MED
of	O
Facial	B-MED
Dog	B-MED
Bites	I-MED
in	O
Children	B-MED
To	O
characterize	O
ophthalmic	B-MED
manifestations	I-MED
and	O
periocular	B-MED
injuries	I-MED
of	O
pediatric	B-MED
facial	B-MED
dog	B-MED
bites	I-MED
.	O
A	O
retrospective	B-MED
review	B-MED
of	O
all	O
children	B-MED
younger	B-MED
than	O
18	O
years	B-MED
who	O
sought	O
medical	B-MED
attention	B-MED
after	O
a	O
dog	B-MED
bite	I-MED
to	O
the	O
face	B-MED
between	O
January	B-MED
1	O
,	O
2003	O
and	O
May	B-MED
22	O
,	O
2014	O
was	O
performed	B-MED
at	O
a	O
large	B-MED
tertiary	I-MED
pediatric	B-MED
hospital	I-MED
.	O
Data	B-MED
on	O
type	B-MED
and	O
location	B-MED
of	I-MED
injury	I-MED
,	O
surgical	B-MED
intervention	I-MED
,	O
and	O
complications	B-MED
were	O
collected	B-MED
.	O
A	O
total	B-MED
of	O
1,989	O
children	B-MED
aged	B-MED
0.19	O
to	O
17	O
years	B-MED
were	O
identified	B-MED
with	O
dog	B-MED
bite	I-MED
dog	B-MED
bite	I-MED
s	I-MED
s.	O
Dog	B-MED
bite	I-MED
Dog	B-MED
bite	I-MED
s	I-MED
to	O
the	O
face	B-MED
occurred	B-MED
in	O
most	B-MED
patients	B-MED
(	O
n	O
=	O
1	O
,	O
414	O
[	O
71	O
%	O
]	O
)	O
.	O
Of	O
those	O
children	B-MED
with	O
facial	B-MED
dog	B-MED
bite	I-MED
injuries	I-MED
,	O
230	O
(	O
16	O
%	O
)	O
suffered	B-MED
ophthalmic	B-MED
manifestations	I-MED
.	O
The	O
average	B-MED
age	B-MED
was	O
4.3	O
years	B-MED
.	O
Eyelid	B-MED
injuries	I-MED
occurred	B-MED
in	O
227	O
(	O
99	O
%	O
)	O
of	O
children	B-MED
,	O
47	O
(	O
20	O
%	O
)	O
sustained	B-MED
canalicular	B-MED
system	I-MED
injuries	B-MED
,	O
3	O
(	O
1.3	O
%	O
)	O
suffered	B-MED
corneal	B-MED
abrasions	I-MED
,	O
and	O
2	O
patients	B-MED
sustained	B-MED
facial	B-MED
nerve	B-MED
injury	I-MED
resulting	B-MED
in	I-MED
lagophthalmos	B-MED
.	O
No	O
patients	B-MED
suffered	B-MED
vision	B-MED
loss	I-MED
.	O
Complications	B-MED
occurred	B-MED
in	O
32	O
patients	B-MED
(	O
14	O
%	O
)	O
,	O
with	O
the	O
most	B-MED
common	B-MED
being	O
epiphora	B-MED
in	O
9	O
patients	B-MED
(	O
28	O
%	O
)	O
,	O
upper	B-MED
eyelid	I-MED
ptosis	I-MED
in	O
8	O
(	O
25	O
%	O
)	O
,	O
and	O
prominent	B-MED
scar	B-MED
formation	I-MED
in	O
4	O
patients	B-MED
(	O
13	O
%	O
)	O
.	O
Thirteen	O
children	B-MED
(	O
5.7	O
%	O
)	O
needed	B-MED
one	O
or	O
more	O
secondary	B-MED
procedure	I-MED
to	O
correct	B-MED
complications	B-MED
.	O
The	O
authors	B-MED
report	B-MED
the	O
clinical	B-MED
features	I-MED
and	O
management	B-MED
on	O
the	O
largest	B-MED
series	I-MED
of	O
ophthalmic	B-MED
and	O
periocular	B-MED
injuries	I-MED
associated	B-MED
with	I-MED
pediatric	B-MED
facial	B-MED
dog	B-MED
bite	I-MED
dog	B-MED
bite	I-MED
s	I-MED
s.	O
These	O
injuries	B-MED
occur	B-MED
in	O
about	O
1	O
in	O
6	O
dog	B-MED
bite	I-MED
dog	B-MED
bite	I-MED
s	I-MED
to	O
the	O
face	B-MED
and	O
primarily	O
involve	O
the	O
ocular	B-MED
adnexa	I-MED
.	O
Despite	O
early	B-MED
and	O
appropriate	B-MED
surgical	B-MED
management	I-MED
,	O
complications	B-MED
and	O
the	O
need	B-MED
for	O
revision	B-MED
surgery	I-MED
are	O
relatively	O
common	B-MED
.	O
Child	B-MED
death	I-MED
and	O
maternal	B-MED
psychosis	B-MED
-	I-MED
like	I-MED
experiences	I-MED
in	O
44	O
low-	B-MED
and	O
middle	B-MED
-	I-MED
income	I-MED
countries	B-MED
:	O
The	O
role	O
of	O
depression	B-MED
Studies	O
on	O
the	O
effect	O
of	O
child	B-MED
death	I-MED
on	O
the	O
mental	B-MED
wellbeing	I-MED
of	O
women	B-MED
in	O
low-	B-MED
and	O
middle	B-MED
-	I-MED
income	I-MED
countries	B-MED
(	O
LMICs	B-MED
)	O
are	O
scarce	O
despite	O
the	O
high	O
child	B-MED
mortality	I-MED
rates	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	B-MED
between	O
child	B-MED
death	I-MED
and	O
psychosis	B-MED
-	I-MED
like	I-MED
experiences	I-MED
(	O
PLEs	B-MED
)	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-MED
in	O
this	O
association	B-MED
.	O
Data	B-MED
from	O
44	O
LMICs	B-MED
which	O
participated	O
in	O
the	O
World	B-MED
Health	I-MED
Survey	I-MED
(	O
WHS	B-MED
)	O
were	O
analyzed	O
.	O
A	O
total	O
of	O
59,444	O
women	B-MED
who	O
ever	O
gave	O
birth	B-MED
,	O
aged	O
18	O
-	O
49	O
years	B-MED
,	O
without	O
a	O
self	B-MED
-	I-MED
reported	I-MED
lifetime	B-MED
psychosis	B-MED
diagnosis	I-MED
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
The	O
World	B-MED
Mental	I-MED
Health	I-MED
Survey	I-MED
version	O
of	O
the	O
Composite	B-MED
International	I-MED
Diagnostic	I-MED
Interview	I-MED
(	O
CIDI	B-MED
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	B-MED
of	O
past	O
12-	O
month	B-MED
DSM	B-MED
-	I-MED
IV	I-MED
depression	B-MED
,	O
and	O
assess	O
four	O
positive	B-MED
psychotic	I-MED
symptoms	I-MED
.	O
Depression	B-MED
was	O
defined	O
as	O
self	B-MED
-	I-MED
reported	I-MED
lifetime	B-MED
depression	B-MED
diagnosis	I-MED
and/or	O
past	O
12-	O
month	B-MED
depression	B-MED
.	O
Multivariable	O
logistic	B-MED
regression	I-MED
analyses	I-MED
were	O
performed	O
.	O
After	O
adjustment	O
for	O
potential	B-MED
confounders	I-MED
,	O
women	B-MED
who	O
experienced	O
child	B-MED
death	I-MED
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	B-MED
(	O
when	O
unadjusted	O
for	O
depression	B-MED
)	O
(	O
OR	B-MED
1.20	O
-	O
1.71	O
;	O
p<0.05	O
)	O
and	O
depression	B-MED
(	O
OR	B-MED
=	O
1.64	O
;	O
95	O
%	O
CI	B-MED
=	O
1.39	O
-	O
1.93	O
)	O
.	O
When	O
adjusted	O
for	O
depression	B-MED
,	O
only	O
delusion	B-MED
of	I-MED
control	I-MED
was	O
strongly	O
associated	B-MED
with	I-MED
child	B-MED
death	I-MED
(	O
OR	B-MED
=	O
1.54	O
;	O
95	O
%	O
CI	B-MED
=	O
1.20	O
-	O
1.97	O
)	O
.	O
Child	B-MED
death	I-MED
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	B-MED
wellbeing	I-MED
among	O
women	B-MED
in	O
LMICs	B-MED
.	O
Given	O
the	O
known	O
adverse	B-MED
health	I-MED
outcomes	I-MED
associated	B-MED
with	I-MED
PLEs	B-MED
and	O
depression	B-MED
,	O
as	O
well	O
as	O
the	O
co	O
-	O
occurrence	O
of	O
these	O
symptoms	B-MED
,	O
mental	B-MED
health	I-MED
care	I-MED
may	O
be	O
particularly	O
important	O
for	O
mothers	B-MED
who	O
have	O
experienced	O
child	B-MED
loss	I-MED
in	O
LMICs	B-MED
.	O
Appearance	B-MED
Differences	B-MED
Between	O
Lots	B-MED
and	O
Brands	B-MED
of	O
Similar	O
Shade	B-MED
Designations	B-MED
of	O
Dental	B-MED
Composite	I-MED
Resins	I-MED
The	O
purposes	B-MED
of	O
this	O
study	B-MED
were	O
to	O
investigate	B-MED
differences	B-MED
in	O
two	O
inherent	B-MED
appearance	B-MED
characteristics	B-MED
between	O
lots	B-MED
of	O
an	O
enamel	B-MED
dental	I-MED
composite	I-MED
resin	I-MED
of	O
the	O
same	O
shade	B-MED
and	O
brand	B-MED
,	O
and	O
to	O
further	O
compare	B-MED
these	O
differences	B-MED
to	O
those	O
of	O
similar	O
shade	B-MED
designation	B-MED
of	O
a	O
different	B-MED
brand	B-MED
of	O
dental	B-MED
composite	I-MED
resins	I-MED
.	O
Appearance	B-MED
analyses	B-MED
proceeded	B-MED
for	O
three	O
different	O
lots	B-MED
of	O
shades	B-MED
A1	B-MED
,	O
B2	B-MED
,	O
and	O
D3	B-MED
manufactured	B-MED
by	O
one	O
company	B-MED
and	O
for	O
one	O
lot	B-MED
of	O
shade	B-MED
EA1	B-MED
manufactured	B-MED
by	O
another	O
.	O
Samples	B-MED
were	O
measured	B-MED
on	O
black	B-MED
,	O
white	B-MED
,	O
and	O
gray	B-MED
backings	B-MED
using	O
spectroradiometry	B-MED
.	O
Kubelka	B-MED
-	I-MED
Munk	I-MED
theory	I-MED
was	O
used	O
to	O
determine	O
reflectivity	B-MED
of	O
each	O
lot	B-MED
studied	B-MED
.	O
CIELAB	B-MED
values	I-MED
and	O
color	B-MED
differences	B-MED
between	O
shades	B-MED
and	O
lots	B-MED
were	O
analyzed	B-MED
.	O
Translucency	B-MED
indicators	B-MED
were	O
compared	B-MED
between	O
lots	B-MED
over	O
thicknesses	B-MED
from	O
0.5	O
to	O
3.0	O
mm	O
.	O
Differences	B-MED
in	O
inherent	B-MED
color	B-MED
between	O
some	O
lots	B-MED
of	O
same	O
shade	B-MED
designations	B-MED
within	O
a	O
brand	B-MED
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	B-MED
threshold	B-MED
.	O
Color	B-MED
difference	B-MED
between	O
an	O
enamel	B-MED
composite	I-MED
resin	I-MED
of	O
shade	B-MED
A1	B-MED
and	O
a	O
composite	B-MED
resin	I-MED
of	O
shade	B-MED
EA1	B-MED
was	O
also	O
above	O
the	O
acceptability	B-MED
threshold	B-MED
.	O
Statistically	B-MED
significant	I-MED
differences	B-MED
in	O
the	O
translucency	B-MED
were	O
found	O
between	O
some	O
lots	B-MED
of	O
one	O
shade	B-MED
over	O
the	O
entire	O
range	B-MED
of	O
thicknesses	B-MED
studied	B-MED
.	O
Appearance	B-MED
analyses	B-MED
indicate	B-MED
substantial	O
variation	B-MED
between	O
lots	B-MED
of	O
same	O
shade	B-MED
designations	B-MED
as	O
well	O
as	O
between	O
brands	B-MED
of	O
similar	O
shade	B-MED
designations	B-MED
.	O
Optical	B-MED
principles	O
applied	B-MED
to	O
important	B-MED
clinical	B-MED
appearance	B-MED
attributes	O
are	O
described	O
which	O
characterize	B-MED
inherent	B-MED
appearance	B-MED
attributes	O
and	O
provide	O
aid	B-MED
in	O
the	O
appearance	B-MED
matching	B-MED
process	B-MED
for	O
dental	B-MED
composite	I-MED
resins	I-MED
used	O
in	O
restorative	B-MED
and	O
operative	B-MED
dental	I-MED
procedures	I-MED
.	O
(	O
J	O
Esthet	O
Restor	O
Dent	O
29	O
:	O
E6	O
-	O
E14	O
,	O
2017	O
)	O
.	O
SIRT2	B-MED
Deacetylates	B-MED
and	O
Inhibits	B-MED
the	I-MED
Peroxidase	I-MED
Activity	I-MED
of	O
Peroxiredoxin-1	B-MED
to	O
Sensitize	B-MED
Breast	I-MED
Cancer	I-MED
Cells	I-MED
to	O
Oxidant	B-MED
Stress	I-MED
-	O
Inducing	B-MED
Agents	O
SIRT2	B-MED
is	O
a	O
protein	B-MED
deacetylase	I-MED
with	O
tumor	B-MED
suppressor	I-MED
activity	I-MED
in	O
breast	B-MED
and	O
liver	B-MED
tumors	I-MED
where	O
it	O
is	O
mutated	B-MED
;	O
however	O
,	O
the	O
critical	O
substrates	B-MED
mediating	O
its	O
antitumor	B-MED
activity	I-MED
are	O
not	O
fully	O
defined	O
.	O
Here	O
we	O
demonstrate	O
that	O
SIRT2	B-MED
binds	B-MED
,	O
deacetylates	B-MED
,	O
and	O
inhibits	B-MED
the	I-MED
peroxidase	I-MED
activity	I-MED
of	O
the	O
antioxidant	B-MED
protein	I-MED
peroxiredoxin	I-MED
(	O
Prdx-1	B-MED
)	O
in	O
breast	B-MED
cancer	I-MED
cells	I-MED
.	O
Ectopic	B-MED
overexpression	B-MED
of	O
SIRT2	B-MED
,	O
but	O
not	O
its	O
catalytically	B-MED
dead	I-MED
mutant	I-MED
,	O
increased	B-MED
intracellular	B-MED
levels	I-MED
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
induced	B-MED
by	I-MED
hydrogen	I-MED
peroxide	I-MED
,	I-MED
which	O
led	O
to	O
increased	B-MED
levels	B-MED
of	O
an	O
overoxidized	B-MED
and	I-MED
multimeric	I-MED
form	I-MED
of	I-MED
Prdx-1	I-MED
with	O
activity	B-MED
as	I-MED
a	I-MED
molecular	I-MED
chaperone	I-MED
.	O
Elevated	B-MED
levels	B-MED
of	O
SIRT2	B-MED
sensitized	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
intracellular	B-MED
DNA	I-MED
damage	I-MED
and	O
cell	B-MED
death	I-MED
induced	I-MED
by	I-MED
oxidative	I-MED
stress	I-MED
,	O
as	O
associated	O
with	O
increased	B-MED
levels	B-MED
of	O
nuclear	B-MED
FOXO3A	I-MED
and	O
the	O
proapoptotic	B-MED
BIM	I-MED
protein	I-MED
.	O
In	O
addition	O
,	O
elevated	B-MED
levels	B-MED
of	O
SIRT2	B-MED
sensitized	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
arsenic	B-MED
trioxide	I-MED
,	O
an	O
approved	O
therapeutic	B-MED
agent	I-MED
,	O
along	O
with	O
other	O
intracellular	B-MED
ROS	I-MED
-	O
inducing	B-MED
agents	I-MED
.	O
Conversely	O
,	O
antisense	B-MED
RNA	I-MED
-	O
mediated	B-MED
attenuation	I-MED
of	O
SIRT2	B-MED
reversed	B-MED
ROS	B-MED
-	O
induced	B-MED
toxicity	I-MED
as	O
demonstrated	O
in	O
a	O
zebrafish	B-MED
embryo	B-MED
model	I-MED
system	I-MED
.	O
Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	B-MED
suppressor	I-MED
activity	I-MED
of	O
SIRT2	B-MED
requires	O
its	O
ability	O
to	O
restrict	B-MED
the	O
antioxidant	B-MED
activity	I-MED
of	O
Prdx-1	B-MED
,	O
thereby	O
sensitizing	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
to	O
ROS	B-MED
-	O
induced	B-MED
DNA	I-MED
damage	I-MED
and	O
cell	B-MED
cytotoxicity	I-MED
.	O
Cancer	O
Res	O
;	O
76(18	O
)	O
;	O
5467	O
-	O
78	O
.	O
©	O
2016	O
AACR	O
.	O
Body	B-MED
Diffusion	B-MED
Weighted	I-MED
Imaging	I-MED
Using	O
Non	B-MED
-	I-MED
CPMG	I-MED
Fast	I-MED
Spin	I-MED
Echo	I-MED
SS	B-MED
-	I-MED
FSE	I-MED
is	O
a	O
fast	B-MED
technique	B-MED
that	O
does	O
not	O
suffer	O
from	O
off	B-MED
-	I-MED
resonance	I-MED
distortions	B-MED
to	O
the	O
degree	O
that	O
EPI	B-MED
does	O
.	O
Unlike	O
EPI	B-MED
,	O
SS	B-MED
-	I-MED
FSE	I-MED
is	O
ill	O
-	O
suited	O
to	O
diffusion	B-MED
weighted	I-MED
imaging	I-MED
(	O
DWI	B-MED
)	O
due	O
to	O
the	O
Carr	B-MED
-	I-MED
Purcell	I-MED
-	I-MED
Meiboom	I-MED
-	I-MED
Geill	I-MED
(	I-MED
CPMG	I-MED
)	I-MED
condition	I-MED
.	O
Non	B-MED
-	I-MED
CPMG	I-MED
phase	B-MED
cycling	B-MED
does	O
accommodate	O
SS	B-MED
-	I-MED
FSE	I-MED
and	O
DWI	B-MED
but	O
places	B-MED
constraints	B-MED
on	O
reconstruction	B-MED
,	O
which	O
are	O
resolved	B-MED
here	O
through	O
parallel	B-MED
imaging	I-MED
.	O
Additionally	O
,	O
improved	B-MED
echo	B-MED
stability	I-MED
can	O
be	O
achieved	O
by	O
using	O
short	B-MED
duration	I-MED
and	O
highly	O
selective	O
DIVERSE	B-MED
radiofrequency	B-MED
pulses	B-MED
.	O
Here	O
,	O
signal	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
(	O
SNR	B-MED
)	O
comparisons	O
between	O
EPI	B-MED
and	O
nCPMG	B-MED
SS	B-MED
-	I-MED
FSE	I-MED
acquisitions	B-MED
and	O
reconstruction	B-MED
techniques	I-MED
give	O
similar	B-MED
values	B-MED
.	O
Diffusion	B-MED
imaging	I-MED
with	O
nCPMG	B-MED
SS	B-MED
-	I-MED
FSE	I-MED
gives	O
similar	B-MED
SNR	B-MED
to	O
an	O
EPI	B-MED
acquisition	B-MED
,	O
though	O
apparent	B-MED
diffusion	I-MED
coefficient	I-MED
values	B-MED
are	O
higher	B-MED
than	O
seen	O
with	O
EPI	B-MED
.	O
In	B-MED
vivo	I-MED
images	B-MED
have	O
good	O
image	B-MED
quality	I-MED
with	O
little	O
distortion	B-MED
.	O
This	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	B-MED
-	O
free	B-MED
DWI	B-MED
images	B-MED
near	O
areas	B-MED
of	O
significant	B-MED
off	B-MED
-	I-MED
resonance	I-MED
as	O
well	O
as	O
preserve	O
adequate	O
SNR	B-MED
.	O
Parallel	B-MED
imaging	I-MED
and	O
DIVERSE	B-MED
refocusing	O
RF	B-MED
pulses	B-MED
allow	O
shorter	B-MED
ETL	I-MED
compared	O
to	O
previous	O
implementations	B-MED
and	O
thus	O
reduces	B-MED
phase	B-MED
encode	B-MED
direction	B-MED
blur	B-MED
and	O
SAR	B-MED
accumulation	B-MED
.	O
The	O
MEssaging	B-MED
for	I-MED
Diabetes	I-MED
Intervention	B-MED
Reduced	O
Barriers	B-MED
to	O
Medication	B-MED
Adherence	I-MED
Among	O
Low	B-MED
-	I-MED
Income	I-MED
,	O
Diverse	O
Adults	B-MED
With	O
Type	B-MED
2	I-MED
Nonadherence	B-MED
to	O
diabetes	B-MED
medication	B-MED
is	O
prevalent	O
and	O
costly	O
.	O
MEssaging	B-MED
for	I-MED
Diabetes	I-MED
(	O
MED	B-MED
)	O
,	O
a	O
mobile	B-MED
health	I-MED
(	O
mHealth	B-MED
)	O
intervention	B-MED
,	O
identified	O
and	O
addressed	O
user	B-MED
-specific	O
barriers	B-MED
to	O
medication	B-MED
adherence	I-MED
.	O
We	O
assessed	O
whether	O
MED	B-MED
reduced	O
users	B-MED
'	O
targeted	O
barriers	B-MED
and	O
if	O
barrier	B-MED
reductions	O
were	O
associated	O
with	O
within	B-MED
-	I-MED
participant	I-MED
improvements	O
in	O
adherence	B-MED
or	O
glycemic	B-MED
control	I-MED
(	O
HbA1c	B-MED
)	O
.	O
Adults	B-MED
(	O
N	O
=	O
80	O
)	O
with	O
type	B-MED
2	I-MED
diabetes	I-MED
completed	O
self	O
-	O
report	O
measures	O
identifying	O
barriers	B-MED
to	O
adherence	B-MED
at	O
baseline	O
and	O
monthly	B-MED
for	O
3	O
months	B-MED
.	O
At	O
each	O
assessment	B-MED
,	O
17	O
barriers	B-MED
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	B-MED
.	O
Each	O
subsequent	O
month	B-MED
,	O
users	B-MED
received	O
daily	O
text	B-MED
messages	I-MED
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	B-MED
.	O
Targeted	O
barriers	B-MED
were	O
different	O
for	O
each	O
participant	B-MED
and	O
could	O
change	O
monthly	B-MED
.	O
Paired	O
t	B-MED
-	I-MED
tests	I-MED
assessed	O
within	B-MED
-	I-MED
participant	I-MED
improvement	O
in	O
targeted	O
barriers	B-MED
each	O
month	B-MED
,	O
and	O
nested	O
regression	B-MED
models	I-MED
assessed	O
if	O
changes	O
in	O
a	O
participant	B-MED
's	I-MED
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	B-MED
and	O
HbA1c	B-MED
.	O
Participants	B-MED
were	O
69	O
%	O
non	O
-	O
white	O
and	O
82	O
%	O
had	O
incomes	O
<	O
$	O
25K.	O
Average	O
HbA1c	B-MED
was	O
8.2	O
±	O
2.0	O
%	O
.	O
Assessment	O
completion	O
rates	O
were	O
100	O
%	O
at	O
baseline	O
,	O
59	O
%	O
at	O
1	O
month	B-MED
,	O
30	O
%	O
at	O
2	O
months	B-MED
,	O
and	O
65	O
%	O
at	O
3	O
months	B-MED
.	O
The	O
most	O
commonly	O
reported	O
barriers	B-MED
were	O
the	O
cost	B-MED
of	O
medications	B-MED
(	O
76	O
%	O
)	O
,	O
believing	O
medications	B-MED
are	O
harmful	O
(	O
58	O
%	O
)	O
,	O
and	O
lacking	O
information	O
about	O
medications	B-MED
(	O
53	O
%	O
)	O
.	O
Participants	B-MED
'	O
barrier	B-MED
scores	O
improved	O
each	O
month	B-MED
and	O
barrier	B-MED
improvement	O
predicted	O
adherence	B-MED
assessed	O
via	O
nightly	O
adherence	B-MED
assessment	O
text	B-MED
messages	I-MED
(	O
P	O
<	O
.001	O
)	O
.	O
Among	O
participants	B-MED
who	O
completed	O
assessments	O
each	O
month	B-MED
,	O
barrier	B-MED
improvement	O
in	O
months	B-MED
2	O
and	O
3	O
(	O
P	O
<	O
.05	O
)	O
predicted	O
HbA1c	B-MED
improvement	O
.	O
Iterative	O
,	O
individual	O
tailoring	O
may	O
overcome	O
users	B-MED
'	O
barriers	B-MED
to	O
adherence	B-MED
.	O
Attrition	O
is	O
a	O
challenge	O
for	O
mHealth	B-MED
interventions	B-MED
among	O
low	B-MED
-	I-MED
income	I-MED
patients	B-MED
.	O
Neoadjuvant	B-MED
Chemotherapy	I-MED
of	O
Ovarian	B-MED
Cancer	I-MED
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	B-MED
-	I-MED
Infiltrating	I-MED
Lymphocyte	I-MED
Response	B-MED
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	B-MED
Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	B-MED
can	O
enhance	O
antitumor	B-MED
immunity	B-MED
through	O
immunogenic	B-MED
cell	B-MED
death	I-MED
,	O
resulting	O
in	O
increased	O
T	B-MED
-	I-MED
cell	I-MED
activation	I-MED
and	O
tumor	B-MED
infiltration	I-MED
.	O
Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-MED
to	O
immunotherapies	B-MED
,	O
including	O
checkpoint	B-MED
blockade	I-MED
.	O
We	O
investigated	O
whether	O
platinum	B-MED
-	O
and	O
taxane	B-MED
-based	O
chemotherapy	B-MED
for	O
ovarian	B-MED
cancer	I-MED
induces	O
immunologic	B-MED
changes	O
consistent	O
with	O
this	O
possibility	O
.	O
Experimental	B-MED
Design	I-MED
:	O
Matched	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
neoadjuvant	B-MED
chemotherapy	I-MED
tumor	B-MED
samples	I-MED
from	O
26	O
high	B-MED
-	I-MED
grade	I-MED
serous	I-MED
carcinoma	I-MED
(	O
HGSC	B-MED
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-MED
(	O
IHC	B-MED
)	O
for	O
a	O
large	O
panel	O
of	O
immune	B-MED
cells	I-MED
and	O
associated	O
factors	O
.	O
The	O
prognostic	O
significance	O
of	O
post	B-MED
-	O
chemotherapy	B-MED
TIL	B-MED
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B-MED
(	O
n	O
=	O
90).Results	O
:	O
Neoadjuvant	B-MED
chemotherapy	I-MED
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	B-MED
(	O
+	O
)	O
,	O
CD8	B-MED
(	O
+	O
)	O
,	O
CD8	B-MED
(	O
+	O
)	O
TIA-1	B-MED
(	O
+	O
)	O
,	O
PD-1	B-MED
(	O
+	O
)	O
and	O
CD20	B-MED
(	O
+	O
)	O
TIL	B-MED
.	O
Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	B-MED
(	O
+	O
)	O
CD138	B-MED
(	O
+	O
)	O
plasma	B-MED
cells	I-MED
,	O
CD68	B-MED
(	O
+	O
)	O
macrophages	B-MED
,	O
and	O
MHC	B-MED
class	I-MED
I	I-MED
on	O
tumor	B-MED
cells	I-MED
.	O
Immunosuppressive	B-MED
cell	B-MED
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	B-MED
(	O
+	O
)	O
PD-1	B-MED
(	O
+	O
)	O
cells	B-MED
(	O
putative	O
regulatory	B-MED
T	I-MED
cells	I-MED
)	O
,	O
IDO-1	B-MED
(	O
+	O
)	O
cells	O
,	O
and	O
PD	B-MED
-	I-MED
L1	I-MED
(	O
+	O
)	O
cells	O
(	O
both	O
macrophages	B-MED
and	O
tumor	B-MED
cells	I-MED
)	O
.	O
Hierarchical	B-MED
clustering	I-MED
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	B-MED
(	O
high	O
)	O
tumors	B-MED
showed	O
increases	O
in	O
multiple	O
immune	B-MED
markers	I-MED
after	O
chemotherapy	B-MED
;	O
(	O
ii	O
)	O
TIL	B-MED
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	B-MED
(	O
negative	B-MED
)	O
cases	O
generally	O
remained	O
negative	B-MED
.	O
Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	B-MED
TIL	B-MED
showed	O
limited	O
prognostic	O
significance	O
.	O
Conclusions	O
:	O
Chemotherapy	B-MED
augments	O
pre	O
-	O
existing	O
TIL	B-MED
responses	B-MED
but	O
fails	O
to	O
relieve	O
major	O
immune	B-MED
-	I-MED
suppressive	I-MED
mechanisms	I-MED
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O
Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-MED
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	B-MED
microenvironment	I-MED
.	O
Clin	O
Cancer	O
Res	O
;	O
23(4	O
)	O
;	O
925	O
-	O
34	O
.	O
©	O
2016	O
AACR	O
.	O
Co	B-MED
-	I-MED
ChIP	I-MED
enables	O
genome	B-MED
-	I-MED
wide	I-MED
mapping	I-MED
of	O
histone	B-MED
mark	I-MED
co	B-MED
-	I-MED
occurrence	I-MED
at	O
single	B-MED
-	I-MED
molecule	I-MED
resolution	I-MED
Histone	B-MED
modifications	I-MED
play	O
an	O
important	B-MED
role	B-MED
in	O
chromatin	B-MED
organization	I-MED
and	O
transcriptional	B-MED
regulation	I-MED
,	O
but	O
despite	O
the	O
large	B-MED
amount	I-MED
of	O
genome	B-MED
-	I-MED
wide	I-MED
histone	B-MED
modification	I-MED
data	B-MED
collected	B-MED
in	O
different	B-MED
cells	B-MED
and	O
tissues	B-MED
,	O
little	O
is	O
known	O
about	O
co	B-MED
-	I-MED
occurrence	I-MED
of	O
modifications	B-MED
on	O
the	O
same	O
nucleosome	B-MED
.	O
Here	O
we	O
present	B-MED
a	O
genome	B-MED
-	I-MED
wide	I-MED
quantitative	I-MED
method	I-MED
for	O
combinatorial	B-MED
indexed	I-MED
chromatin	B-MED
immunoprecipitation	I-MED
(	O
co	B-MED
-	I-MED
ChIP	I-MED
)	O
to	O
characterize	O
co	B-MED
-	I-MED
occurrence	I-MED
of	O
histone	B-MED
modifications	I-MED
on	O
nucleosomes	B-MED
.	O
Using	O
co	B-MED
-	I-MED
ChIP	I-MED
,	O
we	O
study	B-MED
the	O
genome	B-MED
-	I-MED
wide	I-MED
co	B-MED
-	I-MED
occurrence	I-MED
of	O
14	O
chromatin	B-MED
marks	I-MED
(	O
70	O
pairwise	B-MED
combinations	I-MED
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co	B-MED
-	I-MED
occurrence	I-MED
patterns	B-MED
,	O
including	O
the	O
co	B-MED
-	I-MED
occurrence	I-MED
of	O
H3K9me1	B-MED
and	O
H3K27ac	B-MED
in	O
super	B-MED
-	I-MED
enhancers	I-MED
.	O
Finally	O
,	O
we	O
apply	B-MED
co	B-MED
-	I-MED
ChIP	I-MED
to	O
measure	B-MED
the	O
distribution	B-MED
of	O
the	O
bivalent	B-MED
H3K4me3	B-MED
-	O
H3K27me3	B-MED
domains	B-MED
in	O
two	O
distinct	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cell	I-MED
(	O
mESC	B-MED
)	O
states	O
and	O
in	O
four	O
adult	B-MED
tissues	I-MED
.	O
We	O
observe	B-MED
dynamic	B-MED
changes	B-MED
in	O
5,786	O
regions	O
and	O
discover	B-MED
both	O
loss	B-MED
and	O
de	B-MED
novo	I-MED
gain	B-MED
of	O
bivalency	B-MED
in	O
key	O
tissue	B-MED
-	I-MED
specific	I-MED
regulatory	B-MED
genes	I-MED
,	O
suggesting	B-MED
a	O
functional	B-MED
role	I-MED
for	O
bivalent	B-MED
domains	B-MED
during	O
different	O
stages	B-MED
of	O
development	B-MED
.	O
These	O
results	B-MED
show	O
that	O
co	B-MED
-	I-MED
ChIP	I-MED
can	O
reveal	B-MED
the	O
complex	B-MED
interactions	I-MED
between	O
histone	B-MED
modifications	I-MED
.	O
Utilization	B-MED
and	O
Outcomes	B-MED
of	O
Sentinel	B-MED
Lymph	I-MED
Node	I-MED
Biopsy	I-MED
for	O
Vulvar	B-MED
Cancer	I-MED
To	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
in	O
women	B-MED
with	O
vulvar	B-MED
cancer	I-MED
.	O
The	O
Perspective	B-MED
database	I-MED
,	O
an	O
all	B-MED
-	I-MED
payer	I-MED
database	I-MED
that	O
collects	B-MED
data	I-MED
from	O
more	O
than	O
500	O
hospitals	B-MED
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
of	O
women	B-MED
with	O
vulvar	B-MED
cancer	I-MED
who	O
underwent	O
vulvectomy	B-MED
and	O
lymph	B-MED
node	I-MED
assessment	I-MED
from	O
2006	O
to	O
2015	O
.	O
Multivariable	B-MED
models	I-MED
were	O
used	O
to	O
determine	O
factors	B-MED
associated	O
with	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
.	O
Length	B-MED
of	I-MED
stay	I-MED
and	O
cost	B-MED
were	O
compared	O
between	O
women	B-MED
who	O
underwent	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
and	O
lymphadenectomy	B-MED
.	O
Among	O
2,273	O
women	B-MED
,	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
was	O
utilized	O
in	O
618	O
(	O
27.2	O
%	O
)	O
and	O
1,655	O
(	O
72.8	O
%	O
)	O
underwent	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
.	O
Performance	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
increased	O
from	O
17.0	O
%	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
12.0	O
-	O
22.0	O
%	O
)	O
in	O
2006	O
to	O
39.1	O
%	O
(	O
95	O
%	O
CI	B-MED
27.1	O
-	O
51.0	O
%	O
)	O
in	O
2015	O
.	O
In	O
a	O
multivariable	B-MED
model	I-MED
,	O
women	B-MED
treated	B-MED
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
,	O
whereas	O
women	B-MED
with	O
more	O
comorbidities	B-MED
and	O
those	O
treated	B-MED
at	O
rural	B-MED
hospitals	I-MED
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-MED
.	O
The	O
median	B-MED
length	B-MED
of	I-MED
stay	I-MED
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
(	O
median	B-MED
2	O
days	O
,	O
interquartile	B-MED
range	I-MED
1	O
-	O
3	O
)	O
compared	O
with	O
women	B-MED
who	O
underwent	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
(	O
median	O
3	O
days	O
,	O
interquartile	B-MED
range	I-MED
2	O
-	O
4	O
)	O
.	O
The	O
cost	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
was	O
$	O
7,599	O
(	O
interquartile	B-MED
range	I-MED
$	O
5,739	O
-	O
9,922	O
)	O
compared	O
with	O
$	O
8,095	O
(	O
interquartile	B-MED
range	I-MED
$	O
5,917	O
-	O
11,281	O
)	O
for	O
lymphadenectomy	B-MED
.	O
The	O
use	O
of	O
sentinel	B-MED
node	I-MED
biopsy	I-MED
for	O
vulvar	B-MED
cancer	I-MED
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O
Sentinel	B-MED
lymph	I-MED
node	I-MED
biopsy	I-MED
is	O
associated	O
with	O
a	O
shorter	B-MED
hospital	I-MED
stay	I-MED
and	O
decreased	B-MED
cost	I-MED
compared	O
with	O
inguinofemoral	B-MED
lymphadenectomy	I-MED
.	O
Recruitment	B-MED
of	O
Minority	B-MED
Adolescents	B-MED
and	O
Young	B-MED
Adults	I-MED
into	O
Randomised	B-MED
Clinical	I-MED
Trials	I-MED
:	O
Testing	B-MED
the	O
Design	B-MED
of	O
the	O
Technology	B-MED
Enhanced	I-MED
Community	I-MED
Health	I-MED
Nursing	I-MED
(	O
TECH	B-MED
-	I-MED
N	I-MED
)	O
Pelvic	B-MED
Inflammatory	I-MED
Disease	I-MED
Trial	O
Pelvic	B-MED
inflammatory	I-MED
disease	I-MED
(	O
PID	B-MED
)	O
disproportionately	B-MED
affects	O
adolescent	B-MED
and	O
young	B-MED
adult	I-MED
(	O
AYA	B-MED
)	O
women	B-MED
and	O
can	O
negatively	O
influence	B-MED
reproductive	B-MED
health	I-MED
trajectories	O
.	O
Few	O
randomized	B-MED
controlled	I-MED
trials	I-MED
(	O
RCTs	B-MED
)	O
have	O
focused	O
on	O
strategies	O
to	O
improve	B-MED
outpatient	B-MED
adherence	B-MED
or	O
to	O
reduce	B-MED
reproductive	B-MED
morbidity	B-MED
in	O
this	O
population	B-MED
.	O
This	O
paper	O
describes	O
the	O
research	B-MED
methods	I-MED
and	O
preliminary	B-MED
effectiveness	B-MED
of	O
recruitment	B-MED
,	O
retention	B-MED
,	O
and	O
intervention	B-MED
strategies	O
employed	O
in	O
a	O
novel	O
RCT	B-MED
designed	O
to	O
test	O
a	O
technology	B-MED
-	I-MED
enhanced	I-MED
community	I-MED
-	I-MED
health	I-MED
nursing	I-MED
(	O
TECH	B-MED
-	I-MED
N	I-MED
)	O
intervention	B-MED
among	O
urban	O
AYA	B-MED
with	O
PID	B-MED
.	O
AYA	B-MED
women	B-MED
aged	B-MED
13	O
-	O
25	O
years	B-MED
were	O
recruited	B-MED
during	O
acute	B-MED
PID	I-MED
visits	B-MED
in	O
outpatient	B-MED
clinics	I-MED
and	O
emergency	B-MED
departments	I-MED
(	O
ED	B-MED
)	O
to	O
participate	B-MED
in	O
this	O
IRB	B-MED
-	I-MED
approved	I-MED
trial	O
.	O
Participants	B-MED
completed	B-MED
an	O
audio	B-MED
-	I-MED
computerized	I-MED
self	I-MED
-	I-MED
interview	I-MED
(	O
ACASI	B-MED
)	O
,	O
provided	O
vaginal	B-MED
specimens	I-MED
,	O
and	O
were	O
randomized	B-MED
to	O
standard	B-MED
treatment	B-MED
or	O
the	O
intervention	B-MED
.	O
Intervention	B-MED
participants	B-MED
received	B-MED
text	B-MED
-	I-MED
messaging	I-MED
support	B-MED
for	O
30	O
days	B-MED
and	O
a	O
community	B-MED
health	I-MED
nurse	I-MED
(	I-MED
CHN	I-MED
)	I-MED
interventionist	I-MED
performed	B-MED
a	O
home	B-MED
visit	I-MED
with	I-MED
clinical	I-MED
assessment	I-MED
within	O
5	O
days	B-MED
after	O
enrollment	B-MED
.	O
All	O
patients	B-MED
received	O
a	O
full	O
course	B-MED
of	O
medications	B-MED
and	O
completed	B-MED
research	O
visits	B-MED
at	O
14-	O
days	B-MED
(	O
adherence	B-MED
)	O
,	O
30	O
days	B-MED
and	O
90	O
days	B-MED
with	O
by	O
an	O
outreach	B-MED
worker	I-MED
.	O
STI	B-MED
testing	B-MED
performed	B-MED
at	O
the	O
30	O
-	O
and	O
90-	O
day	B-MED
visits	B-MED
.	O
Exploratory	B-MED
analyses	I-MED
using	O
descriptive	B-MED
statistics	I-MED
were	O
conducted	O
to	O
examine	O
recruitment	B-MED
,	O
retention	B-MED
,	O
and	O
follow	B-MED
-	I-MED
up	I-MED
data	B-MED
to	O
test	O
the	O
overall	O
design	B-MED
of	O
the	O
intervention	B-MED
.	O
In	O
the	O
first	O
48	O
months	B-MED
,	O
64	O
%	O
of	O
463	O
patients	B-MED
were	O
eligible	B-MED
for	O
the	O
study	O
and	O
81.2	O
%	O
of	O
293	O
eligible	B-MED
patients	B-MED
were	O
recruited	B-MED
for	O
the	O
study	O
(	O
63.3	O
%	O
)	O
;	O
238	O
(	O
81.2	O
%	O
)	O
of	O
eligible	B-MED
patients	B-MED
were	O
enrolled	B-MED
.	O
Most	O
participants	B-MED
were	O
African	B-MED
American	I-MED
(	O
95.6	O
%	O
)	O
with	O
a	O
mean	B-MED
age	B-MED
of	O
18.6	O
(	O
2.3	O
)	O
.	O
Ninety	O
-	O
four	O
percent	O
of	O
individuals	B-MED
assigned	O
to	O
the	O
TECH	B-MED
-	I-MED
N	I-MED
intervention	I-MED
completed	B-MED
the	O
nursing	B-MED
visits	I-MED
.	O
All	O
completed	B-MED
visits	B-MED
have	O
been	O
within	O
the	O
5-	O
day	B-MED
window	B-MED
and	O
over	O
90	O
%	O
of	O
patients	B-MED
in	O
both	O
arms	O
have	O
been	O
retained	B-MED
over	O
the	O
3-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
.	O
Biological	B-MED
data	B-MED
suggests	O
a	O
shift	B-MED
in	I-MED
the	I-MED
biological	I-MED
milieu	I-MED
with	O
the	O
predominance	O
of	O
Chlamydia	B-MED
trachomatis	I-MED
,	O
Mycoplasma	B-MED
genitalium	I-MED
,	O
and	O
Trichomonas	B-MED
vaginalis	I-MED
infections	I-MED
.	O
Preliminary	B-MED
data	B-MED
from	O
the	O
TECH	B-MED
-	I-MED
N	I-MED
study	O
demonstrated	O
that	O
urban	B-MED
,	O
low	B-MED
-	I-MED
income	I-MED
,	O
minority	B-MED
AYA	B-MED
with	O
PID	B-MED
can	O
effectively	O
be	O
recruited	B-MED
and	O
retained	B-MED
to	O
participate	B-MED
in	O
sexual	B-MED
and	O
reproductive	B-MED
health	I-MED
RCTs	B-MED
with	O
sufficient	B-MED
investment	B-MED
in	O
the	O
design	B-MED
and	O
infrastructure	B-MED
of	I-MED
the	I-MED
study	I-MED
.	O
Community	B-MED
-based	O
sexual	B-MED
health	I-MED
interventions	B-MED
appear	O
to	O
be	O
both	O
feasible	B-MED
and	O
acceptable	B-MED
in	O
this	O
population	B-MED
.	O
Biochemical	B-MED
evidence	O
for	O
a	O
mitochondrial	B-MED
genetic	B-MED
modifier	B-MED
in	O
the	O
phenotypic	B-MED
manifestation	B-MED
of	O
Leber	B-MED
's	I-MED
hereditary	I-MED
optic	I-MED
neuropathy	I-MED
-associated	O
mitochondrial	B-MED
DNA	I-MED
mutation	I-MED
Leber	B-MED
's	I-MED
hereditary	I-MED
optic	I-MED
neuropathy	I-MED
(	O
LHON	B-MED
)	O
is	O
the	O
most	O
common	O
mitochondrial	B-MED
disease	I-MED
.	O
Mitochondrial	B-MED
modifiers	B-MED
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	B-MED
expression	I-MED
of	O
primary	O
LHON	B-MED
-associated	O
mitochondrial	B-MED
DNA	I-MED
(	O
mtDNA	B-MED
)	O
mutations	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
demonstrated	O
that	O
the	O
LHON	B-MED
susceptibility	B-MED
allele	B-MED
(	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
,	O
p.	B-MED
58I	I-MED
>	I-MED
V	I-MED
)	O
in	O
the	O
ND6	B-MED
gene	I-MED
modulated	B-MED
the	O
phenotypic	B-MED
expression	I-MED
of	O
primary	O
LHON	B-MED
-associated	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
.	O
Twenty	O
-	O
two	O
Han	B-MED
Chinese	I-MED
pedigrees	B-MED
carrying	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
and	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutations	I-MED
exhibited	O
significantly	O
higher	O
penetrance	B-MED
of	O
optic	B-MED
neuropathy	I-MED
than	O
those	O
carrying	O
only	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
.	O
We	O
performed	O
functional	B-MED
assays	B-MED
using	O
the	O
cybrid	B-MED
cell	I-MED
models	I-MED
,	O
generated	O
by	O
fusing	O
mtDNA	B-MED
-	I-MED
less	I-MED
ρ(o	I-MED
)	I-MED
cells	I-MED
with	O
enucleated	B-MED
cells	I-MED
from	O
LHON	B-MED
patients	B-MED
carrying	O
both	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
and	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
mutations	I-MED
,	O
only	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
or	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	B-MED
haplogroup	B-MED
.	O
These	O
cybrids	B-MED
cell	I-MED
lines	I-MED
bearing	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
mutation	I-MED
exhibited	O
mild	O
effects	B-MED
on	O
mitochondrial	B-MED
functions	B-MED
compared	O
with	O
those	O
carrying	O
only	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
.	O
However	O
,	O
more	O
severe	O
mitochondrial	B-MED
dysfunctions	B-MED
were	O
observed	O
in	O
cell	B-MED
lines	I-MED
bearing	O
both	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
and	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutations	I-MED
than	O
those	O
carrying	O
only	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
or	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
mutation	I-MED
.	O
In	O
particular	O
,	O
the	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
mutation	I-MED
altered	O
assemble	O
of	O
complex	B-MED
I	I-MED
,	O
thereby	O
aggravating	O
the	O
respiratory	B-MED
phenotypes	B-MED
associated	O
with	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
,	O
resulted	O
in	O
a	O
more	O
defective	B-MED
complex	B-MED
I	I-MED
I.	O
Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-MED
ATP	B-MED
and	O
increasing	O
production	O
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
were	O
also	O
observed	O
in	O
mutant	B-MED
cells	B-MED
bearing	O
both	O
m.14502	B-MED
T	I-MED
>	I-MED
C	I-MED
and	O
m.11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
than	O
those	O
carrying	O
only	O
11778	B-MED
G	I-MED
>	I-MED
A	I-MED
mutation	I-MED
.	O
Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	B-MED
of	O
LHON	B-MED
that	O
were	O
manifested	B-MED
by	I-MED
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	B-MED
mutations	B-MED
.	O
Antiadipogenic	B-MED
Activity	I-MED
of	O
γ	B-MED
-	I-MED
Oryzanol	I-MED
and	O
Its	O
Stability	B-MED
in	O
Pigmented	B-MED
Rice	B-MED
γ	B-MED
-	I-MED
Oryzanol	I-MED
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	B-MED
rice	B-MED
varieties	B-MED
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity	B-MED
-	I-MED
associated	I-MED
metabolic	I-MED
disorders	I-MED
.	O
Antiadipogenic	B-MED
activities	I-MED
of	O
γ	B-MED
-	I-MED
oryzanol	I-MED
were	O
determined	O
in	O
human	B-MED
adipose	B-MED
-	O
derived	B-MED
mesenchymal	B-MED
stem	I-MED
cells	I-MED
and	O
mouse	B-MED
-	O
derived	B-MED
3T3	B-MED
-	I-MED
L1	I-MED
cells	I-MED
.	O
γ	B-MED
-	I-MED
Oryzanol	I-MED
significantly	O
decreased	B-MED
lipid	B-MED
accumulation	I-MED
and	O
reduced	B-MED
glycerol-3	B-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
activities	I-MED
in	O
both	O
adipocytes	B-MED
.	O
In	O
addition	O
,	O
γ	B-MED
-	I-MED
oryzanol	I-MED
in	O
four	O
pigmented	B-MED
rice	B-MED
varieties	B-MED
(	O
black	B-MED
with	I-MED
giant	I-MED
embryo	I-MED
,	O
brown	B-MED
,	O
sugary	B-MED
brown	I-MED
,	O
and	O
red	B-MED
)	O
was	O
stable	B-MED
when	O
stored	B-MED
at	O
4	O
°	O
C	O
and	O
also	O
at	O
room	B-MED
temperature	I-MED
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	B-MED
such	O
as	O
lutein	B-MED
and	O
β	B-MED
-	I-MED
carotene	I-MED
were	O
stable	B-MED
only	O
at	O
-80	O
°	O
C	O
.	O
Furthermore	O
,	O
the	O
yield	B-MED
of	O
γ	B-MED
-	I-MED
oryzanol	I-MED
from	O
these	O
rice	B-MED
varieties	B-MED
was	O
significantly	O
increased	O
through	O
steaming	B-MED
and	O
roasting	B-MED
processes	I-MED
.	O
Therefore	O
,	O
γ	B-MED
-	I-MED
oryzanol	I-MED
exerts	O
antiadipogenic	B-MED
activity	I-MED
by	O
suppressing	B-MED
adipocyte	B-MED
differentiations	I-MED
and	O
is	O
stable	B-MED
in	O
pigmented	B-MED
rice	B-MED
for	O
an	O
extended	B-MED
period	B-MED
of	I-MED
time	I-MED
during	O
storage	B-MED
and	O
after	B-MED
cooking	B-MED
.	O
Thus	O
,	O
the	O
intake	B-MED
of	O
pigmented	B-MED
rice	B-MED
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	B-MED
obesity	B-MED
.	O
Firecracker	B-MED
eye	B-MED
exposure	I-MED
:	O
experimental	B-MED
study	I-MED
and	O
simulation	B-MED
Understanding	O
the	O
mechanisms	B-MED
of	O
traumatic	B-MED
ocular	B-MED
injury	I-MED
is	O
helpful	O
to	O
make	O
accurate	B-MED
diagnoses	B-MED
before	O
the	O
symptoms	B-MED
emerge	O
and	O
to	O
develop	O
specific	O
eye	B-MED
protection	I-MED
.	O
The	O
comprehension	B-MED
of	O
the	O
dynamics	B-MED
of	O
primary	B-MED
blast	B-MED
injury	I-MED
mechanisms	B-MED
is	O
a	O
challenging	O
issue	B-MED
.	O
The	O
question	O
is	O
whether	O
the	O
pressure	B-MED
wave	B-MED
propagation	B-MED
and	O
reflection	B-MED
alone	O
could	O
cause	B-MED
ocular	B-MED
damage	I-MED
.	O
To	O
date	O
,	O
there	O
are	O
dissenting	B-MED
opinions	B-MED
and	O
no	O
conclusive	B-MED
evidence	B-MED
thereupon	O
.	O
A	O
previous	O
numerical	B-MED
investigation	I-MED
of	O
blast	B-MED
trauma	B-MED
highlighted	O
the	O
dynamic	B-MED
effect	B-MED
of	O
pressure	B-MED
propagation	B-MED
and	O
its	O
amplification	B-MED
by	O
the	O
geometry	B-MED
of	O
the	O
bony	B-MED
orbit	I-MED
,	O
inducing	B-MED
a	O
resonance	B-MED
cavity	B-MED
effect	B-MED
and	O
a	O
standing	B-MED
wave	I-MED
hazardous	B-MED
for	O
eye	B-MED
tissues	B-MED
.	O
The	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	B-MED
evidence	B-MED
of	O
the	O
numerically	B-MED
identified	B-MED
phenomenon	B-MED
.	O
Therefore	O
,	O
tests	B-MED
aimed	O
at	O
evaluating	B-MED
the	O
response	B-MED
of	O
porcine	B-MED
eyes	B-MED
to	O
blast	B-MED
overpressure	B-MED
generated	O
by	O
firecrackers	B-MED
explosion	B-MED
were	O
performed	B-MED
.	O
The	O
orbital	B-MED
cavity	I-MED
effect	B-MED
was	O
considered	O
mounting	O
the	O
enucleated	B-MED
eyes	I-MED
inside	O
a	O
dummy	O
orbit	B-MED
.	O
The	O
experimental	B-MED
measurements	B-MED
obtained	B-MED
during	O
the	O
explosion	B-MED
tests	B-MED
presented	O
in	O
this	O
paper	B-MED
corroborate	B-MED
the	O
numerical	B-MED
evidence	I-MED
of	O
a	O
high	B-MED
-	I-MED
frequency	I-MED
pressure	B-MED
amplification	B-MED
,	O
enhancing	B-MED
the	O
loading	O
on	O
the	O
ocular	B-MED
tissues	B-MED
,	O
attributable	B-MED
to	O
the	O
orbital	B-MED
bony	I-MED
walls	I-MED
surrounding	O
the	O
eye	B-MED
.	O
Allogeneic	B-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
for	O
adult	B-MED
patients	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
who	O
had	O
central	B-MED
nervous	I-MED
system	I-MED
involvement	I-MED
:	O
a	O
study	B-MED
from	O
the	O
Adult	B-MED
ALL	B-MED
Working	B-MED
Group	I-MED
of	O
the	O
Japan	B-MED
Society	B-MED
for	O
Hematopoietic	B-MED
Cell	I-MED
Transplantation	I-MED
The	O
prognosis	B-MED
for	O
adult	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
(	O
ALL	B-MED
)	O
patients	B-MED
with	O
central	B-MED
nervous	I-MED
system	I-MED
(	I-MED
CNS	I-MED
)	I-MED
involvement	I-MED
(	O
CNS+	B-MED
)	O
who	O
received	O
allogeneic	B-MED
hematopoietic	I-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
(	O
allo	B-MED
-	I-MED
SCT	I-MED
)	O
remains	O
unclear	O
.	O
We	O
retrospectively	B-MED
compared	O
the	O
outcomes	B-MED
of	O
allo	B-MED
-	I-MED
SCT	I-MED
for	O
patients	B-MED
with	O
CNS	B-MED
involvement	I-MED
and	O
for	O
patients	B-MED
without	B-MED
CNS	B-MED
involvement	I-MED
(	O
CNS-	B-MED
)	O
using	O
a	O
database	B-MED
in	O
Japan	B-MED
.	O
The	O
eligibility	O
criteria	B-MED
for	O
this	O
study	B-MED
were	O
as	O
follows	O
:	O
diagnosis	B-MED
of	O
ALL	B-MED
,	O
aged	O
more	O
than	O
16	O
years	B-MED
,	O
allo	B-MED
-	I-MED
SCT	I-MED
between	O
2005	O
and	O
2012	O
,	O
and	O
first	B-MED
SCT	B-MED
.	O
Data	B-MED
for	O
2582	O
patients	B-MED
including	O
136	O
CNS+	B-MED
patients	I-MED
and	O
2446	O
CNS-	B-MED
patients	I-MED
were	O
used	O
for	O
analyses	B-MED
.	O
As	O
compared	O
with	O
CNS-	B-MED
patients	I-MED
,	O
CNS+	B-MED
patients	I-MED
were	O
younger	B-MED
,	O
had	O
worse	B-MED
disease	B-MED
status	B-MED
at	O
SCT	B-MED
and	O
had	O
poorer	O
performance	B-MED
status	I-MED
(	O
PS	B-MED
)	O
at	O
SCT	B-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
Incidence	B-MED
of	O
relapse	B-MED
was	O
higher	O
in	O
CNS+	B-MED
patients	I-MED
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
incidence	B-MED
of	O
CNS	B-MED
relapse	B-MED
was	O
also	O
higher	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
probability	B-MED
of	O
3-	O
year	B-MED
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
was	O
better	O
in	O
CNS-	B-MED
patients	I-MED
(	O
P	O
<	O
0.01	O
)	O
by	O
univariate	B-MED
analysis	I-MED
.	O
However	O
,	O
in	O
patients	B-MED
who	O
received	B-MED
SCT	B-MED
in	O
CR	B-MED
,	O
there	O
was	O
no	B-MED
difference	I-MED
in	O
the	O
probability	B-MED
of	O
OS	B-MED
between	O
CNS+	B-MED
and	O
CNS-	B-MED
patients	B-MED
(	O
P	O
=	O
0.38	O
)	O
and	O
CNS	B-MED
involvement	I-MED
did	O
not	O
have	O
an	O
unfavorable	B-MED
effect	B-MED
on	O
OS	B-MED
by	O
multivariate	B-MED
analysis	I-MED
.	O
CNS+	B-MED
patients	I-MED
who	O
achieved	O
CR	B-MED
showed	O
OS	B-MED
comparable	O
to	O
that	O
of	O
CNS-	B-MED
patients	I-MED
.	O
Gene	B-MED
expression	I-MED
reveals	O
evidence	B-MED
for	O
EGFR	B-MED
-dependent	O
proximal	B-MED
-	I-MED
distal	I-MED
limb	I-MED
patterning	B-MED
in	O
a	O
myriapod	B-MED
Evolution	B-MED
of	O
segmented	B-MED
limbs	I-MED
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
Arthropoda	B-MED
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	B-MED
and	O
trunk	B-MED
appendages	B-MED
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success	O
.	O
Proximodistal	B-MED
limb	I-MED
patterning	B-MED
is	O
controlled	O
by	O
two	O
regulatory	B-MED
networks	I-MED
in	O
the	O
vinegar	B-MED
fly	I-MED
Drosophila	B-MED
melanogaster	I-MED
,	O
and	O
other	O
insects	B-MED
.	O
The	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	B-MED
Wingless	B-MED
(	O
Wg	B-MED
)	O
and	O
Decapentaplegic	B-MED
(	O
Dpp	B-MED
)	O
;	O
the	O
second	O
by	O
the	O
EGFR	B-MED
-	I-MED
signaling	I-MED
cascade	I-MED
.	O
While	O
the	O
role	O
of	O
Wg	B-MED
and	O
Dpp	B-MED
has	O
been	O
studied	B-MED
in	O
a	O
wide	O
range	O
of	O
arthropods	B-MED
representing	O
all	O
main	O
branches	O
,	O
that	O
is	O
,	O
Pancrustacea	B-MED
(=	O
Hexapoda	B-MED
+	O
Crustacea	B-MED
)	O
,	O
Myriapoda	B-MED
and	O
Chelicerata	B-MED
,	O
investigation	B-MED
of	O
the	O
potential	O
role	O
of	O
EGFR	B-MED
-	I-MED
signaling	I-MED
is	O
restricted	O
to	O
insects	B-MED
(	O
Hexapoda	B-MED
)	O
.	O
Gene	B-MED
expression	I-MED
analysis	I-MED
of	O
Egfr	B-MED
,	O
its	O
potential	B-MED
ligands	B-MED
,	O
and	O
putative	B-MED
downstream	I-MED
factors	I-MED
in	O
the	O
pill	B-MED
millipede	I-MED
Glomeris	B-MED
marginata	I-MED
(	O
Myriapoda	B-MED
:	O
Diplopoda	B-MED
)	O
,	O
reveals	O
that	O
-	O
in	O
at	O
least	O
mandibulate	B-MED
arthropods	B-MED
-	O
EGFR	B-MED
-	I-MED
signaling	I-MED
is	O
likely	O
a	O
conserved	O
regulatory	B-MED
mechanism	I-MED
in	O
proximodistal	B-MED
limb	I-MED
patterning	B-MED
.	O
Impact	B-MED
of	O
alcohol	B-MED
use	I-MED
on	O
EEG	B-MED
dynamics	I-MED
of	O
response	B-MED
inhibition	I-MED
:	O
a	O
cotwin	B-MED
control	I-MED
analysis	I-MED
Research	O
indicates	O
that	O
alcohol	B-MED
misuse	I-MED
is	O
associated	B-MED
with	I-MED
behavioral	B-MED
disinhibition	I-MED
,	O
but	O
the	O
neurophysiological	B-MED
mechanisms	I-MED
governing	O
this	O
relationship	B-MED
remain	O
largely	O
unknown	O
.	O
Recent	O
work	O
suggests	O
that	O
successful	O
inhibition	B-MED
and	O
cognitive	B-MED
control	I-MED
involve	O
electrophysiological	B-MED
theta	I-MED
-	I-MED
band	I-MED
dynamics	I-MED
,	O
including	O
medial	B-MED
frontal	I-MED
cortex	I-MED
(	O
MFC	B-MED
)	O
power	B-MED
enhancement	I-MED
and	O
functional	B-MED
connectivity	I-MED
between	O
the	O
MFC	B-MED
and	O
dorsal	B-MED
prefrontal	I-MED
cortex	I-MED
(	O
dPFC	B-MED
)	O
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	B-MED
misuse	I-MED
.	O
In	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	B-MED
,	O
women	B-MED
are	O
at	O
heightened	O
risk	B-MED
of	O
experiencing	O
the	O
negative	O
physical	B-MED
and	O
neurocognitive	B-MED
correlates	I-MED
of	O
drinking	B-MED
.	O
The	O
present	O
study	B-MED
tested	O
the	O
hypothesis	O
that	O
alcohol	B-MED
misuse	I-MED
has	O
a	O
deleterious	B-MED
effect	I-MED
on	O
theta	B-MED
-	I-MED
band	I-MED
response	B-MED
inhibition	I-MED
EEG	B-MED
dynamics	I-MED
in	O
a	O
sample	B-MED
of	O
300	O
24	O
-	O
year	O
-	O
old	O
same	O
-	O
sex	O
twins	B-MED
.	O
A	O
cotwin	B-MED
control	I-MED
(	I-MED
CTC	I-MED
)	I-MED
design	I-MED
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	B-MED
for	O
alcohol	B-MED
use	I-MED
from	O
the	O
causal	B-MED
effects	I-MED
of	O
alcohol	B-MED
exposure	I-MED
.	O
Drinking	B-MED
was	O
negatively	O
associated	B-MED
with	I-MED
theta	B-MED
-	I-MED
band	I-MED
MFC	B-MED
power	I-MED
and	O
MFC	B-MED
-	O
dPFC	B-MED
connectivity	B-MED
during	O
response	B-MED
inhibition	I-MED
,	O
and	O
this	O
effect	B-MED
was	O
stronger	O
among	O
women	B-MED
.	O
The	O
CTC	B-MED
analysis	I-MED
suggested	O
that	O
,	O
for	O
women	B-MED
,	O
reduced	O
nogo	O
-	O
related	O
theta	B-MED
-	I-MED
band	I-MED
MFC	B-MED
power	I-MED
and	O
MFC	B-MED
-	O
dPFC	B-MED
connectivity	B-MED
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	B-MED
causal	I-MED
effects	I-MED
of	O
alcohol	B-MED
exposure	I-MED
.	O
These	O
findings	O
suggest	O
that	O
diminished	B-MED
theta	B-MED
-	I-MED
band	I-MED
MFC	B-MED
power	I-MED
and	O
MFC	B-MED
-	O
dPFC	B-MED
connectivity	B-MED
may	O
be	O
neurophysiological	B-MED
mechanisms	I-MED
underlying	O
alcohol	B-MED
-	I-MED
related	I-MED
disinhibition	I-MED
.	O
Although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	B-MED
levels	I-MED
of	O
alcohol	B-MED
use	I-MED
during	O
emerging	O
adulthood	B-MED
have	O
potential	O
sex	O
-	O
specific	O
causal	B-MED
effects	I-MED
on	O
response	B-MED
inhibition	I-MED
EEG	B-MED
dynamics	I-MED
,	O
and	O
thus	O
have	O
potentially	O
significant	O
public	O
health	O
implications	O
.	O
Cucurbitacin	B-MED
B	I-MED
Protects	O
Against	O
Pressure	B-MED
Overload	B-MED
Induced	O
Cardiac	B-MED
Hypertrophy	I-MED
Lack	O
of	O
effective	O
anti	B-MED
-	I-MED
cardiac	I-MED
hypertrophy	I-MED
drugs	I-MED
creates	O
a	O
major	O
cause	B-MED
for	O
the	O
increasing	O
prevalence	B-MED
of	O
heart	B-MED
failure	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
anti	B-MED
-	I-MED
hypertrophy	I-MED
and	O
anti	B-MED
-	I-MED
fibrosis	I-MED
potential	B-MED
of	O
a	O
natural	B-MED
plant	I-MED
triterpenoid	B-MED
,	O
Cucurbitacin	B-MED
B	I-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Aortic	B-MED
banding	I-MED
(	O
AB	B-MED
)	O
was	O
performed	O
to	O
induce	O
cardiac	B-MED
hypertrophy	I-MED
.	O
After	O
1	O
week	O
of	O
surgery	B-MED
,	O
mice	B-MED
were	O
receive	O
cucurbitacin	B-MED
B	I-MED
treatment	B-MED
(	O
Gavage	B-MED
,	O
0.2	O
mg	O
/	O
kg	O
body	B-MED
weight	I-MED
/2	O
day	O
)	O
.	O
After	O
4	O
weeks	O
of	O
AB	B-MED
,	O
cucurbitacin	B-MED
B	I-MED
demonstrated	O
a	O
strong	O
anti	B-MED
-	I-MED
hypertrophy	I-MED
and	O
-fibrosis	B-MED
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-MED
weight	B-MED
,	O
myocardial	B-MED
cell	I-MED
cross	B-MED
-	I-MED
sectional	I-MED
area	I-MED
and	O
interstitial	B-MED
fibrosis	I-MED
,	O
ameliorated	O
of	O
systolic	B-MED
and	O
diastolic	B-MED
abnormalities	B-MED
,	O
normalized	O
in	O
gene	B-MED
expression	I-MED
of	O
hypertrophic	B-MED
and	O
fibrotic	B-MED
markers	B-MED
,	O
reserved	O
microvascular	B-MED
density	I-MED
in	O
pressure	B-MED
overload	B-MED
induced	O
hypertrophic	B-MED
mice	B-MED
.	O
Cucurbitacin	B-MED
B	I-MED
also	O
showed	O
significant	O
hypertrophy	B-MED
inhibitory	B-MED
effect	I-MED
in	O
phenylephrine	B-MED
stimulated	B-MED
cardiomyocytes	B-MED
.	O
The	O
Cucurbitacin	B-MED
B	I-MED
-mediated	O
mitigated	B-MED
cardiac	B-MED
hypertrophy	I-MED
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	B-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
the	O
blockade	B-MED
of	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
FoxO3a	B-MED
signal	B-MED
pathway	I-MED
,	O
validated	O
by	O
SC79	B-MED
,	O
MK2206	B-MED
,	O
and	O
3	B-MED
-	I-MED
MA	I-MED
,	O
the	O
Akt	B-MED
agonist	B-MED
,	O
inhibitor	B-MED
and	O
autophagy	B-MED
inhibitor	B-MED
in	B-MED
vitro	I-MED
.	O
The	O
overexpression	B-MED
of	O
constitutively	O
active	O
Akt	B-MED
completely	O
abolished	O
the	O
Cucurbitacin	B-MED
B	I-MED
-mediated	O
protection	O
of	O
cardiac	B-MED
hypertrophy	I-MED
in	O
human	B-MED
cardiomyocytes	B-MED
AC16	I-MED
.	O
Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin	B-MED
B	I-MED
protects	O
against	O
cardiac	B-MED
hypertrophy	I-MED
through	O
increasing	O
the	O
autophagy	B-MED
level	O
in	O
cardiomyocytes	B-MED
,	O
which	O
is	O
associated	B-MED
with	I-MED
the	O
inhibition	B-MED
of	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
FoxO3a	B-MED
signal	B-MED
axis	I-MED
.	O
J.	O
Cell	O
.	O
Biochem	O
.	O
9999	O
:	O
1	O
-	O
12	O
,	O
2017	O
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Histomorphometric	B-MED
and	O
transcriptome	B-MED
evaluation	B-MED
of	O
early	O
healing	B-MED
bone	I-MED
treated	B-MED
with	I-MED
a	O
novel	B-MED
human	B-MED
particulate	I-MED
dentin	I-MED
powder	B-MED
Human	B-MED
particulate	I-MED
dentin	I-MED
(	O
HPD	B-MED
)	O
shows	O
potential	B-MED
as	O
an	O
alternative	B-MED
bone	B-MED
grafting	I-MED
material	B-MED
.	O
However	O
,	O
the	O
mechanism	B-MED
of	O
bone	B-MED
healing	I-MED
at	O
the	O
molecular	B-MED
level	B-MED
after	O
grafting	B-MED
with	O
HPD	B-MED
is	O
unclear	O
.	O
This	O
study	B-MED
assessed	B-MED
the	O
histological	B-MED
and	O
global	B-MED
gene	B-MED
expression	I-MED
of	O
bone	B-MED
tissues	I-MED
grafted	B-MED
with	O
HPD	B-MED
.	O
The	O
HPD	B-MED
was	O
prepared	B-MED
to	O
250	O
-	O
500	O
µm	O
in	O
size	O
.	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
(	O
XRD	B-MED
)	O
and	O
energy	B-MED
dispersive	I-MED
x	I-MED
-	I-MED
ray	I-MED
spectroscopy	I-MED
(	O
EDX	B-MED
)	O
were	O
performed	B-MED
to	O
confirm	B-MED
the	O
crystal	B-MED
structure	I-MED
,	O
organic	B-MED
compound	I-MED
residues	B-MED
,	O
and	O
surface	B-MED
morphology	I-MED
,	O
respectively	O
.	O
Bony	B-MED
defects	B-MED
were	O
created	B-MED
on	O
the	O
heads	B-MED
of	O
24	O
New	B-MED
Zealand	I-MED
White	I-MED
rabbits	I-MED
.	O
Sterilized	B-MED
HPD	B-MED
was	O
used	O
as	O
the	O
grafting	B-MED
material	I-MED
.	O
The	O
quality	B-MED
and	O
quantity	B-MED
of	O
new	B-MED
bone	I-MED
formation	I-MED
was	O
evaluated	B-MED
using	O
micro	B-MED
-	I-MED
CT	I-MED
and	O
histologic	B-MED
analyses	B-MED
during	B-MED
the	O
8	O
week	O
experimental	B-MED
periods	B-MED
.	O
For	O
microarray	B-MED
assay	I-MED
,	O
bone	B-MED
tissue	I-MED
and	O
blood	B-MED
samples	I-MED
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post	B-MED
-	I-MED
implantation	I-MED
.	O
The	O
results	B-MED
of	O
XRD	B-MED
and	O
EDX	B-MED
showed	O
that	O
HPD	B-MED
exhibited	O
physical	B-MED
and	O
chemical	B-MED
properties	I-MED
similar	B-MED
to	O
natural	B-MED
hydroxyapatite	B-MED
.	O
New	B-MED
bone	I-MED
formation	I-MED
was	O
observed	B-MED
after	O
HPD	B-MED
implantation	B-MED
compared	B-MED
to	O
the	O
controls	B-MED
,	O
as	O
shown	O
on	O
hematoxylin	B-MED
and	I-MED
eosin	I-MED
staining	I-MED
and	O
micro	B-MED
-	I-MED
CT	I-MED
.	O
The	O
bone	B-MED
volume	I-MED
of	O
HPD	B-MED
treated	B-MED
animals	B-MED
was	O
higher	B-MED
than	O
that	O
of	O
the	O
control	B-MED
group	I-MED
at	O
all	O
observation	B-MED
times	B-MED
.	O
Microarray	B-MED
analysis	I-MED
showed	O
that	O
vascular	B-MED
development	I-MED
coupled	O
with	O
immune	B-MED
and	O
inflammatory	B-MED
related	O
genes	B-MED
were	O
expressed	B-MED
in	O
the	O
early	B-MED
healing	B-MED
stage	B-MED
.	O
The	O
gene	B-MED
coding	I-MED
for	O
the	O
IL-1	B-MED
antagonist	I-MED
,	O
IL1RN	B-MED
,	O
was	O
expressed	B-MED
to	O
inhibit	B-MED
the	O
inflammatory	B-MED
response	I-MED
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
CCL2	B-MED
gene	I-MED
was	O
activated	B-MED
to	O
2.3	O
times	O
the	O
normal	B-MED
level	B-MED
.	O
BMP2	B-MED
,	O
RUNX2	B-MED
,	O
COL1A	B-MED
,	O
and	O
OPN	B-MED
expression	B-MED
were	O
also	O
up	B-MED
-	I-MED
regulated	I-MED
.	O
CCL2	B-MED
predominated	B-MED
in	O
osteoblastogenesis	B-MED
of	O
the	O
HPD	B-MED
-	O
treated	B-MED
bony	B-MED
defect	B-MED
in	O
the	O
early	B-MED
stage	I-MED
of	O
healing	B-MED
.	O
HPD	B-MED
accelerated	B-MED
bone	B-MED
regeneration	I-MED
and	O
augmentation	B-MED
.	O
These	O
results	B-MED
suggested	B-MED
that	O
HPD	B-MED
provided	B-MED
potential	B-MED
as	O
a	O
bone	B-MED
graft	I-MED
resource	B-MED
during	B-MED
the	O
bone	B-MED
healing	B-MED
process	I-MED
.	O
A	O
novel	O
role	B-MED
for	O
poly(C	B-MED
)	I-MED
binding	I-MED
proteins	I-MED
in	O
programmed	B-MED
ribosomal	I-MED
frameshifting	I-MED
Translational	B-MED
control	B-MED
through	O
programmed	B-MED
ribosomal	I-MED
frameshifting	I-MED
(	O
PRF	B-MED
)	O
is	O
exploited	O
widely	O
by	O
viruses	B-MED
and	O
increasingly	O
documented	O
in	O
cellular	B-MED
genes	B-MED
.	O
Frameshifting	B-MED
is	O
induced	B-MED
by	O
mRNA	B-MED
secondary	I-MED
structures	I-MED
that	O
compromise	O
ribosome	B-MED
fidelity	B-MED
during	O
decoding	B-MED
of	O
a	O
heptanucleotide	B-MED
'	I-MED
slippery	I-MED
'	I-MED
sequence	I-MED
.	O
The	O
nsp2	B-MED
PRF	B-MED
signal	B-MED
of	O
porcine	B-MED
reproductive	I-MED
and	I-MED
respiratory	I-MED
syndrome	I-MED
virus	I-MED
is	O
distinctive	O
in	O
directing	O
both	O
-2	B-MED
and	O
-1	B-MED
PRF	I-MED
and	O
in	O
its	O
requirement	B-MED
for	O
a	O
trans	B-MED
-	I-MED
acting	I-MED
protein	I-MED
factor	I-MED
,	O
the	O
viral	B-MED
replicase	B-MED
subunit	I-MED
nsp1β	I-MED
.	O
Here	O
we	O
show	O
that	O
the	O
the	O
trans	B-MED
-	I-MED
activation	I-MED
of	O
frameshifting	B-MED
is	O
carried	O
out	O
by	O
a	O
protein	B-MED
complex	I-MED
composed	O
of	O
nsp1β	B-MED
and	O
a	O
cellular	B-MED
poly(C	B-MED
)	I-MED
binding	I-MED
protein	I-MED
(	O
PCBP	B-MED
)	O
.	O
From	O
the	O
results	O
of	O
in	B-MED
vitro	I-MED
translation	B-MED
and	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	B-MED
/	O
nsp1β	B-MED
complex	B-MED
binds	O
to	O
a	O
C	B-MED
-	I-MED
rich	I-MED
sequence	I-MED
downstream	B-MED
of	O
the	O
slippery	B-MED
sequence	I-MED
and	O
here	O
mimics	O
the	O
activity	B-MED
of	O
a	O
structured	O
mRNA	B-MED
stimulator	B-MED
of	O
PRF	B-MED
.	O
This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	B-MED
for	O
a	O
trans	B-MED
-	I-MED
acting	I-MED
cellular	I-MED
protein	I-MED
in	O
PRF	B-MED
.	O
The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	B-MED
associated	B-MED
with	I-MED
poly(C	B-MED
)	I-MED
binding	I-MED
proteins	I-MED
and	O
prototypes	B-MED
a	O
new	O
class	O
of	O
virus	B-MED
-	O
host	B-MED
interactions	B-MED
.	O
Liver	B-MED
Inflammation	I-MED
Relates	O
to	O
Decreased	B-MED
Canalicular	B-MED
Bile	B-MED
Transporter	I-MED
Expression	B-MED
in	O
Pediatric	B-MED
Onset	B-MED
Intestinal	B-MED
Failure	I-MED
Although	O
liver	B-MED
disease	I-MED
is	O
a	O
major	O
complication	B-MED
of	O
parenteral	B-MED
nutrition	I-MED
(	O
PN	B-MED
)	O
for	O
intestinal	B-MED
failure	I-MED
(	O
IF	B-MED
)	O
,	O
its	O
pathogenesis	B-MED
remains	O
unclear	O
.	O
We	O
investigated	B-MED
potential	O
molecular	B-MED
mechanisms	B-MED
of	O
liver	B-MED
injury	I-MED
in	O
pediatric	B-MED
onset	B-MED
IF	B-MED
.	O
Liver	B-MED
expression	B-MED
of	O
canalicular	B-MED
phospholipid	B-MED
(	O
ABCB4	B-MED
)	O
,	O
bile	B-MED
acid	I-MED
(	O
ABCB11	B-MED
)	O
,	O
and	O
sterol	B-MED
(	O
ABCG5/8	B-MED
)	O
transporters	B-MED
,	O
their	O
upstream	B-MED
regulators	I-MED
LXR	B-MED
and	O
FXR	B-MED
as	O
well	O
as	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokines	I-MED
interleukin-6	B-MED
(	O
IL6	B-MED
)	O
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
(	O
TNF	B-MED
)	O
were	O
investigated	B-MED
among	O
patients	B-MED
with	O
IF	B-MED
[	O
age	B-MED
median	O
3.8	O
(	O
IQR	B-MED
1.2	O
to	O
11	O
)	O
]	O
in	O
relation	O
to	O
biochemical	B-MED
and	O
histologic	B-MED
liver	B-MED
injury	I-MED
,	O
PN	B-MED
,	O
serum	B-MED
plant	B-MED
sterols	I-MED
,	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
19	I-MED
,	O
and	O
α	B-MED
-	I-MED
tocopherol	I-MED
.	O
Patients	B-MED
receiving	O
PN	B-MED
currently	O
(	O
n	O
=	O
18	O
)	O
showed	O
more	O
advanced	O
liver	B-MED
injury	I-MED
than	O
patients	B-MED
after	O
weaning	B-MED
off	O
PN	B-MED
(	O
n	O
=	O
30	O
)	O
.	O
Histologic	B-MED
portal	B-MED
inflammation	I-MED
strongly	O
segregated	O
PN	B-MED
-	O
dependent	B-MED
(	O
44	O
%	O
)	O
from	O
weaned	B-MED
off	O
patients	B-MED
(	O
3	O
%	O
,	O
P	O
=	O
0.001	O
)	O
and	O
coupled	O
with	O
progression	B-MED
of	O
cholestasis	B-MED
and	O
liver	B-MED
fibrosis	I-MED
.	O
Patients	B-MED
with	O
portal	B-MED
inflammation	I-MED
demonstrated	O
markedly	O
induced	O
liver	B-MED
RNA	B-MED
expression	I-MED
of	O
IL6	B-MED
and	O
TNF	B-MED
,	O
repression	B-MED
of	O
FXR	B-MED
and	O
its	O
canalicular	B-MED
bile	B-MED
transporter	I-MED
target	O
gene	B-MED
RNA	B-MED
expression	I-MED
,	O
including	O
ABCB4	B-MED
and	O
ABCB11	B-MED
as	O
well	O
as	O
decreased	B-MED
protein	B-MED
expression	I-MED
of	O
ABCB11	B-MED
and	O
ABCB4	B-MED
.	O
Furthermore	O
,	O
upregulation	B-MED
of	O
LXR	B-MED
and	O
ABCG5/8	B-MED
RNA	B-MED
expression	I-MED
was	O
suppressed	B-MED
in	O
patients	B-MED
with	O
portal	B-MED
inflammation	I-MED
.	O
Current	O
PN	B-MED
,	O
increased	B-MED
serum	B-MED
levels	B-MED
of	O
plant	B-MED
sterols	I-MED
stigmasterol	B-MED
,	O
avenasterol	B-MED
,	O
and	O
sitosterol	B-MED
along	O
with	O
serum	B-MED
citrulline	B-MED
,	O
a	O
marker	B-MED
of	O
enterocyte	B-MED
mass	I-MED
,	O
predicted	O
portal	B-MED
inflammation	I-MED
.	O
In	O
pediatric	B-MED
onset	B-MED
IF	B-MED
,	O
current	O
PN	B-MED
delivery	O
synergistically	O
with	O
intestinal	B-MED
compromise	B-MED
promote	O
liver	B-MED
inflammation	I-MED
,	O
which	O
associates	B-MED
with	O
progression	B-MED
of	O
biochemical	B-MED
and	O
histologic	B-MED
liver	B-MED
injury	I-MED
,	O
while	O
reducing	B-MED
expression	B-MED
of	O
canalicular	B-MED
bile	B-MED
transporters	I-MED
.	O
Mitochondrial	B-MED
Ultrastructure	B-MED
and	O
Glucose	B-MED
Signaling	I-MED
Pathways	I-MED
Attributed	O
to	O
the	O
Kv1.3	B-MED
Ion	I-MED
Channel	I-MED
Gene	B-MED
-	I-MED
targeted	I-MED
deletion	B-MED
of	O
the	O
potassium	B-MED
channel	I-MED
Kv1.3	I-MED
(	O
Kv1.3(-∕-	B-MED
)	I-MED
)	I-MED
results	I-MED
i	I-MED
n	O
"	O
S	O
uper	B-MED
-	I-MED
smeller	I-MED
"	I-MED
mice	I-MED
with	O
a	O
se	O
nsory	B-MED
p	I-MED
h	O
enotype	B-MED
t	I-MED
hat	O
includes	O
an	O
increased	B-MED
olfactory	B-MED
ability	B-MED
linked	O
to	O
changes	O
in	O
olfactory	B-MED
circuitry	B-MED
,	O
increased	B-MED
abundance	B-MED
of	O
olfactory	B-MED
cilia	I-MED
,	O
and	O
increased	B-MED
expression	B-MED
of	O
odorant	B-MED
receptors	I-MED
and	O
the	O
G	B-MED
-	I-MED
protein	I-MED
,	I-MED
Golf	I-MED
.	O
Kv1.3(-∕-	B-MED
)	I-MED
mice	I-MED
a	I-MED
lso	O
have	O
a	O
metabolic	B-MED
p	I-MED
h	O
enotype	B-MED
i	I-MED
ncluding	O
lo	O
wer	B-MED
b	I-MED
o	O
dy	B-MED
weight	I-MED
a	I-MED
nd	O
de	O
creased	B-MED
a	I-MED
d	O
iposity	B-MED
,	I-MED
in	O
creased	B-MED
total	I-MED
energy	I-MED
expenditure	I-MED
(	O
TEE	B-MED
)	O
,	O
increased	B-MED
locomotor	B-MED
activity	I-MED
,	O
and	O
resistance	B-MED
to	O
both	O
diet	B-MED
-	O
and	O
genetic	B-MED
-	I-MED
induced	I-MED
obesity	B-MED
.	O
We	O
explored	O
two	O
cellular	B-MED
aspects	I-MED
to	O
elucidate	O
the	O
mechanism	B-MED
by	O
which	O
loss	B-MED
of	O
Kv1.3	B-MED
channel	I-MED
in	O
the	O
olfactory	B-MED
bulb	I-MED
(	O
OB	B-MED
)	O
may	O
enhance	O
glucose	B-MED
utilization	I-MED
and	O
metabolic	B-MED
rate	I-MED
.	O
First	O
,	O
using	O
in	B-MED
situ	I-MED
hybridization	I-MED
we	O
find	O
that	O
Kv1.3	B-MED
and	O
the	O
insulin	B-MED
-	O
dependent	B-MED
glucose	B-MED
transporter	I-MED
type	I-MED
4	I-MED
(	O
GLUT4	B-MED
)	O
are	O
co	O
-	O
localized	O
to	O
the	O
mitral	B-MED
cell	B-MED
layer	I-MED
of	O
the	O
OB	B-MED
.	O
Disruption	B-MED
of	O
Kv1.3	B-MED
conduction	B-MED
via	O
construction	O
of	O
a	O
pore	B-MED
mutation	I-MED
(	O
W386F	B-MED
Kv1.3	I-MED
)	O
was	O
sufficient	O
to	O
independently	O
translocate	B-MED
GLUT4	B-MED
to	O
the	O
plasma	B-MED
membrane	I-MED
in	O
HEK	B-MED
293	I-MED
cells	I-MED
.	O
Because	O
olfactory	B-MED
sensory	I-MED
perception	I-MED
and	O
the	O
maintenance	B-MED
of	O
action	B-MED
potential	I-MED
(	I-MED
AP	I-MED
)	I-MED
firing	O
frequency	O
by	O
mitral	B-MED
cells	B-MED
of	O
the	O
OB	B-MED
is	O
highly	O
energy	O
demanding	O
and	O
Kv1.3	B-MED
is	O
also	O
expressed	O
in	O
mitochondria	B-MED
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	B-MED
in	O
mitral	B-MED
cells	B-MED
.	O
We	O
challenged	O
wildtype	B-MED
(	O
WT	B-MED
)	O
and	O
Kv1.3(-∕-	B-MED
)	I-MED
male	I-MED
mice	I-MED
with	O
a	O
m	O
oderately	B-MED
high	I-MED
-	I-MED
fat	I-MED
diet	I-MED
(	I-MED
M	O
HF	B-MED
,	I-MED
31.8	O
%	O
kcal	O
fat	O
)	O
for	O
4	O
months	B-MED
and	O
then	O
examined	O
OB	B-MED
ultrastructure	B-MED
using	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
.	O
In	O
WT	B-MED
mice	I-MED
,	O
mitochondria	B-MED
were	O
significantly	O
enlarged	B-MED
following	O
diet	B-MED
-	I-MED
induced	I-MED
obesity	I-MED
(	O
DIO	B-MED
)	O
and	O
there	O
were	O
fewer	O
mitochondria	B-MED
,	O
likely	O
due	O
to	O
mitophagy	B-MED
.	O
Interestingly	O
,	O
mitochondria	B-MED
were	O
significantly	O
smaller	B-MED
in	O
Kv1.3(-∕-	B-MED
)	I-MED
mice	I-MED
c	I-MED
ompared	O
with	O
that	O
of	O
W	O
T	B-MED
mice	I-MED
.	I-MED
Similar	O
to	O
their	O
m	O
etabolic	B-MED
r	I-MED
esistance	O
to	O
D	O
IO	B-MED
,	I-MED
the	O
K	O
v1.3(-∕-	B-MED
)	I-MED
mice	I-MED
ha	I-MED
d	O
unchanged	O
mit	O
ochondria	B-MED
in	I-MED
terms	O
of	O
cros	O
s	B-MED
sectional	I-MED
area	B-MED
and	O
abundance	B-MED
following	O
a	O
challenge	O
with	O
modified	B-MED
diet	I-MED
.	O
We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	B-MED
of	O
the	O
Kv1.3	B-MED
channel	I-MED
in	O
the	O
OB	B-MED
can	O
modify	O
TEE	B-MED
.	O
Our	O
study	O
demonstrates	O
that	O
Kv1.3	B-MED
regulates	O
mitochondrial	B-MED
structure	I-MED
and	O
alters	O
glucose	B-MED
utilization	I-MED
;	O
two	O
important	O
metabolic	B-MED
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	B-MED
initiated	O
at	O
the	O
OB	B-MED
.	O
Risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
associated	B-MED
with	I-MED
adolescent	B-MED
girls	I-MED
'	I-MED
substance	B-MED
use	I-MED
:	O
Data	B-MED
from	O
a	O
nationwide	O
Facebook	B-MED
sample	O
Despite	O
overall	O
reductions	B-MED
in	O
teenage	B-MED
substance	B-MED
use	I-MED
,	O
adolescent	B-MED
girls	I-MED
'	O
rates	B-MED
of	O
substance	B-MED
use	I-MED
remain	O
unacceptably	B-MED
high	I-MED
.	O
This	O
article	B-MED
examines	O
whether	O
girls	B-MED
'	O
substance	B-MED
use	I-MED
is	O
associated	B-MED
with	I-MED
general	O
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
(	O
goal	B-MED
setting	I-MED
,	O
problem	B-MED
solving	I-MED
,	O
refusal	B-MED
skills	I-MED
,	O
peer	B-MED
use	I-MED
,	O
and	O
self	B-MED
-	I-MED
efficacy	I-MED
)	O
and	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
(	O
communication	B-MED
style	I-MED
,	O
coping	B-MED
skills	I-MED
,	O
self	B-MED
-	I-MED
esteem	I-MED
,	O
body	B-MED
image	I-MED
,	O
perceived	B-MED
stress	I-MED
,	O
anxiety	B-MED
,	O
and	O
depression	B-MED
)	O
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
data	I-MED
were	O
collected	O
in	O
2013	O
via	O
online	B-MED
surveys	I-MED
from	O
a	O
nationwide	O
sample	O
of	O
adolescent	B-MED
girls	I-MED
(	O
N	O
=	O
788	O
)	O
,	O
aged	O
13	O
and	O
14	O
years	O
,	O
who	O
were	O
recruited	O
through	O
Facebook	B-MED
.	O
In	O
multivariate	B-MED
analyses	I-MED
,	O
controlling	O
for	O
correlates	B-MED
of	O
adolescent	B-MED
substance	B-MED
use	I-MED
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
were	O
consistently	O
associated	B-MED
with	I-MED
past	O
-	O
month	O
alcohol	B-MED
,	O
cigarette	B-MED
,	O
and	O
other	O
drug	B-MED
use	I-MED
in	O
the	O
expected	O
direction	O
;	O
past	B-MED
-	I-MED
month	I-MED
marijuana	I-MED
use	I-MED
was	O
associated	B-MED
with	I-MED
8	O
of	O
the	O
13	O
factors	B-MED
.	O
Refusal	B-MED
skill	I-MED
s	O
,	O
peer	B-MED
use	I-MED
,	O
coping	B-MED
,	O
and	O
depressive	B-MED
mood	I-MED
were	O
most	O
consistently	O
and	O
strongly	O
associated	B-MED
with	I-MED
substance	B-MED
use	I-MED
.	O
Substance	B-MED
abuse	I-MED
prevention	I-MED
programs	B-MED
targeting	O
adolescent	B-MED
girls	I-MED
should	O
focus	O
on	O
such	O
general	O
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
as	O
problem	B-MED
solving	I-MED
,	O
refusal	B-MED
skill	I-MED
s	O
,	O
peer	B-MED
influences	I-MED
,	O
and	O
self	B-MED
-	I-MED
efficacy	I-MED
,	O
as	O
well	O
as	O
such	O
gender	B-MED
-	O
specific	B-MED
risk	B-MED
and	I-MED
protective	I-MED
factors	I-MED
as	O
communication	B-MED
style	I-MED
,	O
coping	B-MED
,	O
self	B-MED
-	I-MED
esteem	I-MED
,	O
body	B-MED
image	I-MED
,	O
perceived	B-MED
stress	I-MED
,	O
and	O
mood	B-MED
management	I-MED
.	O
Genetic	B-MED
parameters	B-MED
for	O
tick	B-MED
count	I-MED
and	O
udder	B-MED
health	B-MED
in	O
commercial	B-MED
and	O
indigenous	B-MED
ewes	B-MED
in	O
South	B-MED
Africa	I-MED
The	O
genetics	B-MED
of	O
tick	B-MED
infestation	I-MED
in	O
sheep	B-MED
need	O
study	O
,	O
as	O
host	B-MED
resistance	I-MED
often	O
forms	O
part	O
of	O
integrated	O
pest	B-MED
control	I-MED
programs	I-MED
.	O
Repeated	O
udder	B-MED
health	B-MED
scores	I-MED
,	O
site	B-MED
-	I-MED
specific	I-MED
tick	B-MED
count	I-MED
,	O
mating	B-MED
weight	B-MED
and	O
reproduction	B-MED
records	B-MED
(	O
N=879	O
-	O
1204	O
)	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	B-MED
of	O
the	O
indigenous	B-MED
Namaqua	B-MED
Afrikaner	I-MED
(	O
NA	B-MED
)	O
fat	B-MED
-	I-MED
tailed	I-MED
breed	I-MED
,	O
as	O
well	O
as	O
the	O
commercial	B-MED
Dorper	B-MED
and	O
SA	B-MED
Mutton	I-MED
Merino	I-MED
(	I-MED
SAMM	I-MED
)	I-MED
breeds	I-MED
.	O
Udder	B-MED
s	O
were	O
scored	B-MED
subjectively	O
on	O
a	O
1	O
-	O
5	O
scale	O
(	O
1	O
-	O
udder	B-MED
intact	B-MED
and	O
5	O
-	O
udder	B-MED
damaged	B-MED
severely	I-MED
)	O
and	O
ticks	B-MED
were	O
counted	B-MED
on	O
three	B-MED
locations	I-MED
.	O
The	O
body	B-MED
sites	I-MED
counted	B-MED
were	O
the	O
head	B-MED
and	I-MED
thoracic	I-MED
limb	I-MED
(	O
HTLTC	B-MED
)	O
,	O
udder	B-MED
-	I-MED
pelvic	I-MED
limb	I-MED
(	O
UPLTC	B-MED
)	O
and	O
perineum	B-MED
-	I-MED
breech	I-MED
-	I-MED
tail	I-MED
(	O
PBTTC	B-MED
)	O
.	O
These	O
counts	B-MED
were	O
also	O
totaled	O
for	O
a	O
total	B-MED
tick	I-MED
count	I-MED
(	O
TTC	B-MED
)	O
.	O
Reproduction	B-MED
traits	B-MED
were	O
number	O
of	O
lambs	B-MED
weaned	B-MED
per	O
ewe	B-MED
lambed	I-MED
and	O
total	O
weight	O
of	O
lamb	B-MED
weaned	I-MED
per	O
ewe	B-MED
lambed	I-MED
.	O
Udder	B-MED
health	B-MED
scores	I-MED
of	O
NA	B-MED
ewes	B-MED
were	O
lower	O
than	O
those	O
of	O
Dorpers	B-MED
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
SAMM	B-MED
ewes	B-MED
.	O
NA	B-MED
ewes	B-MED
had	O
lower	O
values	O
for	O
HTLTC	B-MED
,	O
UPLTC	B-MED
and	O
TTC	B-MED
than	O
the	O
commercial	B-MED
breeds	B-MED
,	O
but	O
higher	O
values	O
for	O
PBTTC	B-MED
than	O
Dorpers	B-MED
.	O
Heritability	B-MED
estimates	B-MED
amounted	O
to	O
0.26±0.04	O
for	O
HTLTC	B-MED
,	O
0.53±0.04	O
for	O
UPLTC	B-MED
,	O
0.07±0.06	O
for	O
PBTTC	B-MED
,	O
0.44±0.06	O
for	O
TTC	B-MED
and	O
0.61±0.03	O
for	O
udder	B-MED
health	B-MED
score	I-MED
.	O
Animal	B-MED
permanent	I-MED
environment	I-MED
also	O
affected	O
PBTTC	B-MED
(	O
0.14±0.07	O
)	O
.	O
Significant	B-MED
genetic	I-MED
correlations	I-MED
were	O
found	O
between	O
the	O
HTLTC	B-MED
and	O
UPLTC	B-MED
(	O
0.47±0.10	O
)	O
,	O
UPLTC	B-MED
and	O
udder	B-MED
health	B-MED
score	I-MED
(	O
0.52±0.07	O
)	O
,	O
HTLTC	B-MED
and	O
UPLTC	B-MED
(	O
0.24±0.11	O
)	O
as	O
well	O
as	O
UPLTC	B-MED
and	O
PBTTC	B-MED
(	O
-0.44±0.11	O
)	O
.	O
Heavier	O
ewes	B-MED
had	O
higher	O
UPLTC	B-MED
(	O
0.38±0.09	O
)	O
,	O
TTC	B-MED
(	O
0.33±0.09	O
)	O
and	O
impaired	B-MED
udder	B-MED
health	B-MED
(	O
0.21±0.08	O
)	O
.	O
Udder	B-MED
health	B-MED
score	I-MED
s	O
and	O
tick	B-MED
counts	I-MED
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	B-MED
traits	B-MED
.	O
The	O
indigenous	B-MED
NA	B-MED
breed	B-MED
outperformed	O
the	O
commercial	B-MED
breeds	B-MED
with	O
lower	O
values	O
for	O
HTLTC	B-MED
,	O
UPLTC	B-MED
,	O
TTC	B-MED
and	O
a	O
better	O
udder	B-MED
health	B-MED
score	I-MED
.	O
Mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
NA	B-MED
breed	B-MED
under	O
pastoral	B-MED
conditions	I-MED
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-MED
tolerance	B-MED
within	O
breeds	B-MED
should	O
be	O
studied	O
further	O
.	O
Rubinstein	B-MED
-	I-MED
Taybi	I-MED
Syndrome	I-MED
Associated	B-MED
with	I-MED
Pituitary	B-MED
Macroadenoma	I-MED
:	O
A	O
Case	B-MED
Report	I-MED
Rubinstein	B-MED
-	I-MED
Taybi	I-MED
Syndrome	I-MED
(	O
RSTS	B-MED
)	O
is	O
an	O
autosomal	B-MED
dominant	I-MED
disorder	I-MED
that	O
is	O
classically	O
characterized	B-MED
by	O
prenatal	B-MED
and	O
postnatal	B-MED
growth	B-MED
restriction	I-MED
,	O
microcephaly	B-MED
,	O
dysmorphic	B-MED
craniofacial	I-MED
features	I-MED
,	O
broad	B-MED
thumbs	I-MED
and	O
toes	B-MED
,	O
and	O
intellectual	B-MED
disability	I-MED
.	O
We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	B-MED
macroadenoma	I-MED
associated	B-MED
with	I-MED
RSTS	B-MED
.	O
A	O
39	O
-	O
year	O
-	O
old	O
Caucasian	B-MED
female	B-MED
with	O
a	O
past	B-MED
medical	I-MED
history	I-MED
of	O
RSTS	B-MED
diagnosed	B-MED
at	O
age	B-MED
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	B-MED
-enhancing	O
pituitary	B-MED
mass	I-MED
on	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
of	O
the	O
brain	B-MED
three	O
years	B-MED
ago	O
during	O
workup	O
for	O
migraine	B-MED
-	I-MED
like	I-MED
headaches	I-MED
.	O
Subsequent	O
serial	O
imaging	B-MED
showed	O
radiographic	B-MED
evidence	I-MED
of	O
growth	B-MED
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	B-MED
.	O
The	O
pituitary	B-MED
sellar	B-MED
lesion	I-MED
was	O
resected	B-MED
through	O
an	O
endoscopic	B-MED
transnasal	B-MED
transsphenoidal	B-MED
approach	I-MED
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	B-MED
adenoma	I-MED
.	O
RSTS	B-MED
is	O
a	O
rare	B-MED
,	O
neurodevelopmental	B-MED
genetic	B-MED
disease	I-MED
where	O
most	O
patients	B-MED
with	I-MED
disabilities	I-MED
survive	B-MED
into	O
adulthood	B-MED
.	O
The	O
disorder	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
predisposition	B-MED
for	O
development	B-MED
of	O
nervous	B-MED
system	I-MED
tumors	I-MED
,	O
including	O
pituitary	B-MED
adenomas	I-MED
.	O
Water	B-MED
pipe	I-MED
(	O
Shisha	O
,	O
Hookah	O
,	O
Arghile	O
)	O
Smoking	B-MED
and	O
Secondhand	B-MED
Tobacco	I-MED
Smoke	I-MED
Effects	B-MED
on	O
CYP1A2	B-MED
and	O
CYP2A6	B-MED
Phenotypes	B-MED
as	O
Measured	O
by	O
Caffeine	B-MED
Urine	I-MED
Test	I-MED
Public	B-MED
policies	I-MED
to	O
stop	O
or	O
reduce	O
cigarette	B-MED
smoking	I-MED
and	O
exposure	B-MED
to	O
secondhand	B-MED
smoke	I-MED
and	O
associated	B-MED
diseases	I-MED
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O
Yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	B-MED
consumption	I-MED
,	O
water	B-MED
pipe	I-MED
smoking	B-MED
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	B-MED
pipe	I-MED
smoking	B-MED
on	O
cytochrome	B-MED
P450	I-MED
(	I-MED
CYP450	I-MED
)	I-MED
activities	I-MED
and	O
drug	B-MED
interaction	I-MED
potential	B-MED
in	O
humans	B-MED
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	B-MED
smoke	I-MED
on	O
drug	B-MED
metabolism	I-MED
.	O
In	O
a	O
sample	O
of	O
99	O
healthy	B-MED
volunteers	I-MED
(	O
28	O
water	B-MED
pipe	I-MED
smokers	I-MED
,	O
30	O
secondhand	B-MED
tobacco	I-MED
smoke	I-MED
exposed	O
persons	B-MED
,	O
and	O
41	O
controls	B-MED
)	O
,	O
we	O
systematically	B-MED
compared	I-MED
CYP1A2	B-MED
and	O
CYP2A6	B-MED
enzyme	B-MED
activities	I-MED
in	B-MED
vivo	I-MED
using	O
caffeine	B-MED
urine	I-MED
test	I-MED
.	O
The	O
median	O
self	B-MED
-	I-MED
reported	I-MED
duration	B-MED
of	O
water	B-MED
pipe	I-MED
smoking	B-MED
was	O
7.5	O
h	B-MED
/	O
week	B-MED
and	O
3	O
years	B-MED
of	O
exposure	B-MED
in	O
total	O
.	O
The	O
secondhand	B-MED
smoke	I-MED
group	B-MED
had	O
a	O
median	O
of	O
14	O
h	B-MED
of	O
self	B-MED
-	I-MED
reported	I-MED
weekly	B-MED
exposure	B-MED
to	O
tobacco	B-MED
smoke	I-MED
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	B-MED
were	O
smoked	B-MED
/	O
hour	B-MED
for	O
a	O
total	O
of	O
3.5	O
years	B-MED
(	O
median	O
)	O
.	O
Analysis	B-MED
of	O
variance	B-MED
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	B-MED
and	O
CYP2A6	B-MED
activities	B-MED
among	O
the	O
three	O
study	B-MED
groups	B-MED
(	O
p	O
>	O
0.05	O
)	O
.	O
Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	B-MED
pipe	I-MED
or	O
secondhand	B-MED
smoke	I-MED
exposure	B-MED
and	O
the	O
CYP1A2	B-MED
and	O
CYP2A6	B-MED
activities	B-MED
(	O
p	O
>	O
0.05	O
)	O
.	O
Further	O
analysis	B-MED
in	O
a	O
subsample	O
with	O
smoke	O
exposure	B-MED
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	B-MED
.	O
Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	B-MED
pipe	I-MED
smoke	O
and	O
secondhand	B-MED
smoke	I-MED
on	O
in	B-MED
vivo	I-MED
activities	B-MED
of	O
these	O
two	O
drug	B-MED
metabolism	I-MED
pathways	B-MED
,	O
variability	O
in	O
smoke	O
constituents	B-MED
from	O
different	O
tobacco	B-MED
consumption	I-MED
methods	O
(	O
e.g.	O
,	O
water	B-MED
pipe	I-MED
)	O
might	O
affect	O
drug	B-MED
metabolism	I-MED
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	B-MED
smoke	I-MED
.	O
Further	O
studies	B-MED
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	B-MED
pipe	I-MED
and	O
secondhand	B-MED
tobacco	I-MED
smoke	I-MED
effects	O
on	O
CYP450	B-MED
function	O
,	O
particularly	O
at	O
higher	O
smoke	B-MED
exposure	B-MED
conditions	O
.	O
Self	B-MED
-	I-MED
assembled	I-MED
polymeric	B-MED
vectors	B-MED
mixtures	B-MED
:	O
characterization	B-MED
of	O
the	O
polymorphism	B-MED
and	O
existence	O
of	O
synergistic	B-MED
effects	B-MED
in	O
photodynamic	B-MED
therapy	I-MED
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	B-MED
of	O
polymeric	B-MED
self	B-MED
-	I-MED
assemblies	I-MED
vectors	B-MED
solution	B-MED
and	O
their	O
photodynamic	B-MED
therapeutic	I-MED
efficiency	B-MED
.	O
For	O
this	O
,	O
several	O
amphiphilic	B-MED
block	B-MED
copolymers	I-MED
of	O
poly(ethyleneoxide	B-MED
-	I-MED
b	I-MED
-	I-MED
ε	I-MED
-	I-MED
caprolactone	I-MED
)	I-MED
have	O
been	O
used	O
to	O
form	O
self	B-MED
-	I-MED
assemblies	I-MED
with	O
different	O
morphologies	B-MED
(	O
micelles	B-MED
,	O
worm	B-MED
-	I-MED
like	I-MED
micelles	I-MED
or	O
vesicles	B-MED
)	O
.	O
In	O
a	O
first	O
step	O
,	O
controlled	B-MED
mixtures	I-MED
of	O
preformed	O
micelles	B-MED
and	O
vesicles	B-MED
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-MED
light	I-MED
scattering	I-MED
and	O
asymmetrical	B-MED
flow	I-MED
field	I-MED
flow	I-MED
fractionation	I-MED
(	O
AsFlFFF	B-MED
)	O
.	O
For	O
this	O
,	O
a	O
custom	B-MED
-	I-MED
made	I-MED
program	B-MED
,	O
STORMS	B-MED
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-MED
data	B-MED
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	B-MED
.	O
This	O
showed	O
that	O
DLS	B-MED
only	O
sensed	O
the	O
larger	B-MED
vesicles	B-MED
when	O
the	O
micelles	B-MED
/	O
vesicles	B-MED
ratio	B-MED
was	O
80/20	O
w	O
/	O
w.	O
On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-MED
allowed	O
clear	O
detection	B-MED
of	O
the	O
presence	O
of	O
micelles	B-MED
when	O
this	O
same	O
ratio	B-MED
was	O
as	O
low	O
as	O
10/90	O
.	O
Subsequently	O
,	O
the	O
photodynamic	B-MED
therapy	I-MED
efficiency	B-MED
of	O
various	O
controlled	B-MED
mixtures	I-MED
was	O
assessed	O
using	O
multicellular	O
spheroids	B-MED
when	O
a	O
photosensitizer	B-MED
,	O
pheophorbide	B-MED
a	I-MED
,	O
was	O
encapsulated	B-MED
in	O
the	O
polymer	B-MED
self	B-MED
-	I-MED
assemblies	I-MED
.	O
Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	B-MED
as	O
monomorphous	B-MED
systems	I-MED
.	O
In	O
some	O
cases	O
,	O
mixtures	B-MED
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	B-MED
efficiency	B-MED
compared	O
to	O
the	O
individual	O
nano	B-MED
-	O
objects	B-MED
,	O
revealing	O
a	O
synergistic	B-MED
effect	B-MED
for	O
the	O
efficient	O
delivery	B-MED
of	O
the	O
photosensitizer	B-MED
.	O
Polymorphous	B-MED
vectors	B-MED
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	B-MED
applications	I-MED
.	O
Multidetector	B-MED
CT	I-MED
of	O
expected	B-MED
findings	B-MED
and	O
complications	B-MED
after	O
contemporary	B-MED
inguinal	B-MED
hernia	I-MED
repair	I-MED
surgery	B-MED
Inguinal	B-MED
hernia	I-MED
repair	I-MED
(	O
IHR	B-MED
)	O
with	O
prosthetic	B-MED
mesh	B-MED
implantation	B-MED
is	O
the	O
most	O
common	O
procedure	B-MED
in	O
general	B-MED
surgery	I-MED
,	O
and	O
may	O
be	O
performed	B-MED
using	O
either	O
an	O
open	B-MED
or	O
laparoscopic	B-MED
approach	I-MED
.	O
This	O
paper	B-MED
provides	O
an	O
overview	B-MED
of	O
contemporary	B-MED
tension	O
-	O
free	O
IHR	B-MED
techniques	B-MED
and	O
materials	B-MED
,	O
and	O
illustrates	O
the	O
expected	B-MED
postoperative	B-MED
imaging	B-MED
findings	I-MED
and	O
iatrogenic	B-MED
injuries	I-MED
.	O
Emphasis	O
is	O
placed	O
on	O
multidetector	B-MED
CT	I-MED
,	O
which	O
represents	O
the	O
ideal	B-MED
modality	B-MED
to	O
comprehensively	O
visualize	O
the	O
operated	B-MED
groin	B-MED
region	I-MED
and	O
deeper	B-MED
intra	B-MED
-	I-MED
abdominal	I-MED
structures	I-MED
.	O
CT	B-MED
consistently	O
depicts	O
seroma	B-MED
,	O
mesh	B-MED
infections	I-MED
,	O
hemorrhages	B-MED
,	O
bowel	B-MED
complications	B-MED
and	O
urinary	B-MED
bladder	I-MED
injuries	B-MED
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	B-MED
basis	O
for	O
therapeutic	B-MED
choice	B-MED
.	O
Since	O
radiologists	B-MED
are	O
increasingly	B-MED
requested	O
to	O
investigate	B-MED
suspected	B-MED
iatrogenic	B-MED
complications	B-MED
,	O
this	O
paper	B-MED
aims	O
to	O
provide	O
an	O
increased	B-MED
familiarity	B-MED
with	O
early	B-MED
CT	B-MED
studies	B-MED
after	O
IHR	B-MED
,	O
including	O
complications	B-MED
and	O
normal	B-MED
postoperative	B-MED
appearances	B-MED
such	O
as	O
focal	B-MED
pseudolesions	B-MED
,	O
in	O
order	O
to	O
avoid	B-MED
misinterpretation	I-MED
and	O
inappropriate	B-MED
management	B-MED
.	O
Breast	B-MED
Augmentation	I-MED
after	O
Conservation	B-MED
Surgery	I-MED
and	O
Radiation	B-MED
Therapy	I-MED
There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	B-MED
undergoing	O
breast	B-MED
augmentation	I-MED
with	O
implants	B-MED
after	O
breast	B-MED
conservation	I-MED
surgery	I-MED
(	O
BCS	B-MED
)	O
and	O
radiotherapy	B-MED
.	O
This	O
retrospective	B-MED
study	I-MED
examined	O
outcomes	O
for	O
patients	B-MED
with	O
breast	B-MED
implant	I-MED
-only	O
augmentation	B-MED
after	O
BCS	B-MED
and	O
radiotherapy	B-MED
.	O
Between	O
June	O
1998	O
and	O
December	O
2010	O
,	O
671	O
women	B-MED
underwent	O
prosthetic	B-MED
breast	B-MED
reconstruction	I-MED
.	O
Nineteen	O
patients	B-MED
(	O
2.8	O
%	O
)	O
underwent	O
an	O
augmentation	B-MED
after	O
BCS	B-MED
and	O
radiotherapy	B-MED
.	O
The	O
mean	B-MED
age	B-MED
was	O
55.8	O
years	B-MED
(	O
range	B-MED
,	O
40	O
-	O
69	O
years	B-MED
)	O
.	O
Sixteen	O
of	O
these	O
patients	B-MED
underwent	O
one	B-MED
-	I-MED
stage	I-MED
implant	I-MED
-only	O
breast	B-MED
augmentation	I-MED
,	O
whereas	O
3	O
patients	B-MED
underwent	O
two	B-MED
-	I-MED
stage	I-MED
expander	I-MED
and	O
then	O
implant	B-MED
augmentation	I-MED
.	O
All	O
surgeries	B-MED
were	O
successful	O
.	O
The	O
average	O
size	O
of	O
breast	B-MED
implant	I-MED
used	O
was	O
258.7	O
�	O
€‰g	O
.	O
Seven	O
patients	B-MED
also	O
received	O
contralateral	B-MED
augmentation	B-MED
with	O
an	O
average	O
implant	O
size	O
of	O
232.2	O
�	O
€‰g	O
.	O
One	O
patient	B-MED
received	O
oral	B-MED
antibiotics	B-MED
for	O
minor	O
wound	B-MED
infection	I-MED
.	O
Patients	B-MED
were	O
judged	O
to	O
have	O
an	O
excellent	O
(	O
14/19	O
;	O
73.7	O
%	O
)	O
,	O
good	O
(	O
3/19	O
;	O
15.8	O
%	O
)	O
,	O
or	O
fair	O
(	O
2/19	O
;	O
10.5	O
%	O
)	O
cosmetic	B-MED
result	B-MED
.	O
The	O
breasts	B-MED
of	O
selected	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
after	O
BCS	B-MED
and	O
radiotherapy	B-MED
.	O
with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	B-MED
with	O
breast	B-MED
implants	I-MED
alone	O
.	O
Variation	B-MED
in	O
the	O
Intensity	B-MED
of	O
Selection	B-MED
on	O
Codon	B-MED
Bias	B-MED
over	O
Time	B-MED
Causes	O
Contrasting	B-MED
Patterns	I-MED
of	O
Base	B-MED
Composition	I-MED
Evolution	B-MED
in	O
Drosophila	B-MED
Four	O
-	O
fold	O
degenerate	B-MED
coding	B-MED
sites	I-MED
form	O
a	O
major	O
component	O
of	O
the	O
genome	B-MED
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	B-MED
and	O
demography	B-MED
,	O
so	O
that	O
understanding	O
their	O
evolution	B-MED
is	O
important	O
.	O
Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	B-MED
composition	I-MED
changes	B-MED
at	O
these	O
sites	B-MED
in	O
Drosophila	B-MED
remain	O
unanswered	O
.	O
To	O
shed	O
further	O
light	O
on	O
this	O
issue	B-MED
,	O
we	O
obtained	O
a	O
new	O
whole	B-MED
-	I-MED
genome	I-MED
polymorphism	I-MED
data	I-MED
set	I-MED
from	O
D.	B-MED
simulans	I-MED
.	O
We	O
analyzed	B-MED
samples	B-MED
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D.	B-MED
simulans	I-MED
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	B-MED
data	I-MED
set	I-MED
from	O
an	O
African	O
population	O
of	O
D.	B-MED
melanogaster	I-MED
.	O
By	O
using	O
D.	B-MED
yakuba	I-MED
as	O
an	O
outgroup	B-MED
,	O
we	O
found	O
clear	O
evidence	B-MED
for	O
selection	B-MED
on	O
4	O
-	O
fold	O
sites	B-MED
along	O
both	O
lineages	B-MED
over	O
a	O
substantial	B-MED
period	I-MED
,	O
with	O
the	O
intensity	B-MED
of	O
selection	B-MED
increasing	O
with	O
GC	B-MED
content	I-MED
.	O
Based	O
on	O
an	O
explicit	O
model	B-MED
of	O
base	B-MED
composition	I-MED
evolution	B-MED
,	O
we	O
suggest	O
that	O
the	O
observed	B-MED
AT-	O
biased	B-MED
substitution	B-MED
pattern	I-MED
in	O
both	O
lineages	B-MED
is	O
probably	O
due	O
to	O
an	O
ancestral	B-MED
reduction	I-MED
in	O
selection	B-MED
intensity	B-MED
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	B-MED
of	O
an	O
increase	B-MED
in	O
mutational	B-MED
bias	B-MED
towards	O
AT	O
alone	O
.	O
By	O
using	O
two	O
polymorphism	B-MED
-	I-MED
based	I-MED
methods	I-MED
for	O
estimating	B-MED
selection	B-MED
coefficients	B-MED
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	B-MED
intensity	B-MED
on	O
codon	B-MED
usage	O
has	O
been	O
rather	O
stable	B-MED
in	O
D.	B-MED
simulans	I-MED
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long	B-MED
-	I-MED
term	I-MED
estimates	B-MED
in	O
D.	B-MED
melanogaster	I-MED
are	O
much	O
higher	B-MED
than	O
the	O
short	B-MED
-	I-MED
term	I-MED
ones	O
,	O
indicating	O
a	O
continuing	B-MED
decline	B-MED
in	O
selection	B-MED
intensity	B-MED
,	O
to	O
such	O
an	O
extent	B-MED
that	O
the	O
short	B-MED
-	I-MED
term	I-MED
estimates	B-MED
suggest	O
that	O
selection	B-MED
is	O
only	O
active	B-MED
in	O
the	O
most	O
GC	B-MED
-rich	O
parts	O
of	O
the	O
genome	B-MED
.	O
Finally	O
,	O
we	O
provide	O
evidence	B-MED
for	O
complex	B-MED
evolutionary	B-MED
patterns	I-MED
in	O
the	O
putatively	O
neutral	B-MED
short	I-MED
introns	I-MED
,	O
which	O
can	O
not	O
be	O
explained	O
by	O
the	O
standard	B-MED
GC	B-MED
-	O
biased	B-MED
gene	B-MED
conversion	I-MED
model	B-MED
.	O
These	O
results	B-MED
reveal	O
a	O
dynamic	B-MED
picture	O
of	O
base	B-MED
composition	I-MED
evolution	B-MED
.	O
International	B-MED
Liver	I-MED
Transplant	I-MED
Society	I-MED
Practice	I-MED
Guidelines	I-MED
:	O
Diagnosis	B-MED
and	O
Management	B-MED
of	O
Hepatopulmonary	B-MED
Syndrome	I-MED
and	O
Portopulmonary	B-MED
Hypertension	I-MED
Two	O
distinct	O
pulmonary	B-MED
vascular	I-MED
disorders	I-MED
,	O
hepatopulmonary	B-MED
syndrome	I-MED
(	O
HPS	B-MED
)	O
and	O
portopulmonary	B-MED
hypertension	I-MED
(	O
POPH	B-MED
)	O
may	O
occur	O
as	O
a	O
consequence	B-MED
of	I-MED
hepatic	B-MED
parenchymal	I-MED
or	O
vascular	B-MED
abnormalities	I-MED
.	O
HPS	B-MED
and	O
POPH	B-MED
have	O
major	O
clinical	B-MED
implications	B-MED
for	O
liver	B-MED
transplantation	I-MED
.	O
A	O
European	B-MED
Respiratory	I-MED
Society	I-MED
Task	I-MED
Force	I-MED
on	O
Pulmonary	B-MED
-	I-MED
Hepatic	I-MED
Disorders	I-MED
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-MED
and	O
guide	B-MED
management	I-MED
of	O
these	O
disorders	B-MED
.	O
These	O
International	B-MED
Liver	I-MED
Transplant	I-MED
Society	I-MED
diagnostic	I-MED
and	I-MED
management	I-MED
guidelines	I-MED
are	O
based	O
on	O
that	O
task	B-MED
force	I-MED
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	B-MED
experience	O
dictates	O
.	O
Based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
HPS	B-MED
and	O
POPH	B-MED
articles	O
identified	O
via	O
a	O
MEDLINE	B-MED
search	I-MED
(	O
1985	O
-	O
2015	O
)	O
,	O
clinical	B-MED
guidelines	I-MED
were	O
based	O
on	O
,	O
selected	B-MED
single	I-MED
care	I-MED
reports	I-MED
,	O
small	B-MED
series	I-MED
,	O
registries	B-MED
,	O
databases	B-MED
,	O
and	O
expert	B-MED
opinion	I-MED
.	O
The	O
paucity	O
of	O
randomized	B-MED
,	I-MED
controlled	I-MED
trials	I-MED
in	O
either	O
of	O
these	O
disorders	B-MED
was	O
noted	O
.	O
Guidelines	B-MED
are	O
presented	O
in	O
5	O
parts	O
;	O
I.	O
Definitions	B-MED
/	O
Diagnostic	B-MED
criteria	I-MED
;	O
II	O
.	O
Hepatopulmonary	B-MED
syndrome	I-MED
;	O
III	O
.	O
Portopulmonary	B-MED
hypertension	I-MED
;	O
IV	O
.	O
Implications	B-MED
for	O
liver	B-MED
transplantation	I-MED
;	O
and	O
V.	O
Suggestions	B-MED
for	O
future	O
clinical	B-MED
research	I-MED
.	O
Association	B-MED
between	O
postpartum	B-MED
depression	I-MED
and	O
the	O
practice	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
in	O
the	O
first	O
three	O
months	B-MED
of	O
life	B-MED
To	O
investigate	B-MED
the	O
association	B-MED
between	O
postpartum	B-MED
depression	I-MED
and	O
the	O
occurrence	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
.	O
This	O
is	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
conducted	O
in	O
the	O
states	B-MED
of	O
the	O
Northeast	B-MED
region	I-MED
,	O
during	O
the	O
vaccination	B-MED
campaign	I-MED
in	O
2010	O
.	O
The	O
sample	O
consisted	O
of	O
2583	O
mother	B-MED
-	O
child	B-MED
pairs	B-MED
,	O
with	O
children	B-MED
aged	B-MED
from	O
15	O
days	B-MED
to	O
3	O
months	B-MED
.	O
The	O
Edinburgh	B-MED
Postnatal	I-MED
Depression	I-MED
Scale	I-MED
was	O
used	O
to	O
screen	B-MED
for	O
postpartum	B-MED
depression	I-MED
.	O
The	O
outcome	B-MED
was	O
lack	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
,	O
defined	O
as	O
the	O
occurrence	B-MED
of	O
this	O
practice	B-MED
in	O
the	O
24h	O
preceding	B-MED
the	O
interview	B-MED
.	O
Postpartum	B-MED
depression	I-MED
was	O
the	O
explanatory	B-MED
variable	I-MED
of	O
interest	O
and	O
the	O
covariates	B-MED
were	O
:	O
socioeconomic	B-MED
and	O
demographic	B-MED
conditions	I-MED
;	O
maternal	B-MED
health	I-MED
care	I-MED
;	O
prenatal	B-MED
,	O
delivery	B-MED
,	O
and	O
postnatal	B-MED
care	I-MED
;	O
and	O
the	O
child	B-MED
's	I-MED
biological	I-MED
factors	I-MED
.	O
Multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding	B-MED
factors	I-MED
.	O
Exclusive	B-MED
breastfeeding	I-MED
was	O
observed	B-MED
in	O
50.8	O
%	O
of	O
the	O
infants	B-MED
and	O
11.8	O
%	O
of	O
women	B-MED
had	O
symptoms	B-MED
of	O
postpartum	B-MED
depression	I-MED
.	O
In	O
the	O
multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
,	O
a	O
higher	O
chance	O
of	O
exclusive	B-MED
breastfeeding	I-MED
absence	B-MED
was	O
found	O
among	O
mothers	B-MED
with	O
symptoms	B-MED
of	O
postpartum	B-MED
depression	I-MED
(	O
OR=1.67	O
;	O
p<0.001	O
)	O
,	O
among	O
younger	B-MED
subjects	I-MED
(	O
OR=1.89	O
;	O
p<0.001	O
)	O
,	O
those	O
who	O
reported	O
receiving	O
benefits	B-MED
from	O
the	O
Bolsa	B-MED
Família	I-MED
Program	I-MED
(	O
OR=1.25	O
;	O
p=0.016	O
)	O
,	O
and	O
those	O
started	O
antenatal	B-MED
care	I-MED
later	O
during	O
pregnancy	B-MED
(	O
OR=2.14	O
;	O
p=0.032	O
)	O
.	O
Postpartum	B-MED
depression	I-MED
contributed	O
to	O
reducing	B-MED
the	O
practice	B-MED
of	O
exclusive	B-MED
breastfeeding	I-MED
.	O
Therefore	O
,	O
this	O
disorder	B-MED
should	O
be	O
included	O
in	O
the	O
prenatal	B-MED
and	O
early	B-MED
postpartum	I-MED
support	B-MED
guidelines	I-MED
for	O
breastfeeding	B-MED
,	O
especially	O
in	O
low	B-MED
socioeconomic	I-MED
status	I-MED
women	B-MED
.	O
Discordance	B-MED
in	O
pathology	B-MED
report	I-MED
after	O
central	B-MED
pathology	I-MED
review	I-MED
:	O
Implications	O
for	O
breast	B-MED
cancer	I-MED
adjuvant	B-MED
treatment	I-MED
Pathological	B-MED
predictive	B-MED
factors	I-MED
are	O
the	O
most	O
important	O
markers	B-MED
when	O
selecting	O
early	O
breast	B-MED
cancer	I-MED
adjuvant	B-MED
therapy	I-MED
.	O
In	O
randomized	B-MED
clinical	I-MED
trials	I-MED
the	O
variability	B-MED
in	O
pathology	B-MED
report	I-MED
after	O
central	B-MED
pathology	I-MED
review	I-MED
is	O
noteworthy	O
.	O
We	O
evaluated	O
the	O
discordance	B-MED
rate	B-MED
(	O
DR	B-MED
)	O
and	O
inter	B-MED
-	I-MED
rater	I-MED
agreement	I-MED
between	O
local	B-MED
and	O
central	B-MED
histopathological	B-MED
report	I-MED
and	O
the	O
clinical	B-MED
implication	O
on	O
treatment	B-MED
decision	I-MED
.	O
A	O
retrospective	B-MED
analysis	I-MED
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B-MED
cancer	I-MED
tumors	I-MED
diagnosed	O
by	O
local	B-MED
pathologists	I-MED
and	O
subsequently	O
reviewed	B-MED
at	O
the	O
Pathology	B-MED
Division	I-MED
of	O
European	B-MED
Institute	I-MED
of	I-MED
Oncology	I-MED
.	O
The	O
inter	B-MED
-	I-MED
rater	I-MED
agreement	I-MED
(	O
k	O
)	O
between	O
local	O
and	O
central	B-MED
pathology	I-MED
was	O
calculated	O
for	O
Ki-67	B-MED
,	O
grading	B-MED
,	O
hormone	B-MED
receptors	I-MED
(	O
ER	B-MED
/	O
PgR	B-MED
)	O
and	O
HER2	B-MED
/	I-MED
neu	I-MED
.	O
The	O
Bland	B-MED
-	I-MED
Altman	I-MED
plots	I-MED
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	B-MED
,	O
ER	B-MED
PgR	B-MED
and	O
PgR.	O
DR	B-MED
was	O
calculated	O
for	O
ER	B-MED
/	O
PgR	B-MED
and	O
HER2	B-MED
.	O
From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	B-MED
specimens	I-MED
from	O
10	O
Cancer	B-MED
Centers	I-MED
were	O
reviewed	B-MED
.	O
Substantial	O
agreement	O
was	O
observed	O
for	O
ER	B-MED
(	O
k0.612	O
;	O
95	O
%	O
CI	B-MED
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	B-MED
(	O
k0.659	O
;	O
95	O
%	O
CI	B-MED
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	B-MED
(	O
k0.609	O
;	O
95	O
%	O
CI	B-MED
,	O
0.534	O
-	O
0.684	O
)	O
and	O
grading	B-MED
(	O
k0.669	O
;	O
95	O
%	O
CI	B-MED
,	O
0.569	O
-	O
0.769	O
)	O
.	O
Moderate	O
agreement	O
was	O
found	O
for	O
HER2	B-MED
(	O
k0.546	O
;	O
95	O
%	O
CI	B-MED
,	O
0444	O
-	O
0.649	O
)	O
.	O
DR	B-MED
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	B-MED
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	B-MED
PgR	B-MED
/	O
PgR.	O
According	O
to	O
changes	O
in	O
Her2	B-MED
and	O
ER	B-MED
/	O
PgR	B-MED
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	B-MED
prescription	B-MED
were	O
respectively	O
modified	O
.	O
In	O
our	O
retrospective	B-MED
analysis	I-MED
,	O
central	B-MED
pathological	I-MED
review	I-MED
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	B-MED
-	I-MED
making	I-MED
process	I-MED
in	O
early	O
breast	B-MED
cancer	I-MED
,	O
as	O
shown	O
in	O
clinical	B-MED
trials	I-MED
.	O
Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O
The	O
Prevalence	B-MED
and	O
Clinical	B-MED
Relevance	B-MED
of	O
ASA	B-MED
Nonresponse	B-MED
After	O
Cardiac	B-MED
Surgery	I-MED
We	O
aimed	O
to	O
identify	O
the	O
prevalence	B-MED
of	O
acetylsalicylic	B-MED
acid	I-MED
(	O
ASA	B-MED
)	O
nonresponse	B-MED
in	O
patients	B-MED
after	O
coronary	B-MED
artery	I-MED
bypass	I-MED
graft	I-MED
(	I-MED
CABG	I-MED
)	I-MED
surgery	I-MED
and	O
the	O
possible	O
consequences	B-MED
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B-MED
events	I-MED
.	O
This	O
prospective	B-MED
,	O
observational	B-MED
,	O
bicentric	B-MED
cohort	I-MED
study	I-MED
was	O
conducted	O
in	O
two	O
German	B-MED
University	I-MED
hospitals	I-MED
.	O
A	O
total	O
of	O
400	O
patients	B-MED
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	B-MED
CABG	B-MED
surgery	I-MED
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O
Platelet	B-MED
function	I-MED
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	B-MED
following	O
stimulation	O
with	O
arachidonic	B-MED
acid	I-MED
(	O
ASPItest	B-MED
)	O
and	O
with	O
thrombin	B-MED
receptor	I-MED
-	I-MED
activating	I-MED
peptide	I-MED
6	I-MED
(	O
TRAPtest	B-MED
)	O
using	O
multiple	B-MED
electrode	I-MED
aggregometry	I-MED
(	O
Multiplate	B-MED
)	O
.	O
Individuals	O
with	O
an	O
ASPItest	B-MED
≥40	O
AU·min	O
were	O
categorized	O
as	O
ASA	B-MED
nonresponders	B-MED
.	O
A	O
1	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B-MED
events	I-MED
,	O
hospital	B-MED
admissions	I-MED
,	O
or	O
deaths	B-MED
related	O
to	O
cardiovascular	B-MED
disease	I-MED
.	O
The	O
prevalence	B-MED
of	O
ASA	B-MED
nonresponse	B-MED
was	O
51.5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	B-MED
increased	B-MED
to	O
71.3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.0049	O
)	O
.	O
The	O
area	O
under	O
the	O
aggregation	B-MED
curve	I-MED
in	O
the	O
TRAPtest	B-MED
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	B-MED
count	I-MED
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	B-MED
bypass	I-MED
time	I-MED
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
ASA	B-MED
nonresponse	B-MED
.	O
A	O
1	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	B-MED
point	I-MED
with	O
no	O
difference	O
between	O
ASA	B-MED
responders	B-MED
and	O
nonresponders	B-MED
.	O
This	O
study	B-MED
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	B-MED
ASA	B-MED
nonresponse	B-MED
in	O
patients	B-MED
following	O
CABG	B-MED
.	O
No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B-MED
events	I-MED
was	O
recorded	O
in	O
the	O
1	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Therefore	O
,	O
a	O
randomized	B-MED
dosage	I-MED
adjustment	I-MED
trial	I-MED
should	O
elucidate	O
whether	O
a	O
tailored	O
ASA	B-MED
treatment	B-MED
after	O
CABG	B-MED
surgery	I-MED
represents	O
a	O
useful	O
concept	O
.	O
Halogenated	B-MED
phenolic	I-MED
compounds	I-MED
in	O
wild	B-MED
fish	I-MED
from	O
Canadian	B-MED
Areas	I-MED
of	O
Concern	B-MED
Concentrations	O
of	O
halogenated	B-MED
phenolic	I-MED
compounds	I-MED
were	O
measured	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
(	O
Ameiurus	B-MED
nebulosus	I-MED
)	O
from	O
4	O
Canadian	B-MED
Areas	I-MED
of	O
Concern	B-MED
(	O
AOCs	B-MED
)	O
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-MED
-	O
disrupting	B-MED
chemicals	I-MED
.	O
Hydroxylated	B-MED
polychlorinated	I-MED
biphenyls	I-MED
(	O
OH	B-MED
-	I-MED
PCBs	I-MED
)	O
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
AOCs	B-MED
;	O
the	O
detection	B-MED
frequency	B-MED
was	O
lower	O
in	O
samples	O
from	O
the	O
Detroit	B-MED
River	I-MED
AOC	B-MED
.	O
The	O
OH	B-MED
-	I-MED
PCBs	I-MED
most	O
frequently	O
detected	O
were	O
pentachloro	B-MED
,	I-MED
hexachloro	I-MED
,	I-MED
and	I-MED
heptachloro	I-MED
congeners	I-MED
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	B-MED
hormones	I-MED
.	O
Pentachlorophenol	B-MED
(	O
PCP	B-MED
)	O
was	O
detected	O
at	O
highest	O
concentrations	O
(	O
1.8	O
ng	O
/	O
g	O
)	O
in	O
fish	B-MED
from	O
Prince	B-MED
Edward	I-MED
Bay	I-MED
,	O
the	O
Bay	B-MED
of	I-MED
Quinte	I-MED
Lake	I-MED
reference	I-MED
site	I-MED
,	O
and	O
Hillman	B-MED
Marsh	I-MED
(	O
the	B-MED
Wheatley	I-MED
Harbour	I-MED
reference	I-MED
site	I-MED
)	O
,	O
suggesting	O
local	O
sources	B-MED
of	I-MED
contamination	I-MED
.	O
Elevated	B-MED
PCP	I-MED
concentrations	I-MED
were	O
also	O
detected	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
from	O
exposed	O
sites	O
in	O
the	O
Toronto	B-MED
and	I-MED
Region	I-MED
AOC	I-MED
(	O
0.4	O
-	O
0.6	O
ng	O
/	O
g	O
)	O
.	O
Triclosan	B-MED
was	O
consistently	O
detected	O
in	O
the	O
Toronto	B-MED
and	I-MED
Region	I-MED
AOC	I-MED
(	O
0.05	O
-	O
0.9	O
ng	O
/	O
g	O
)	O
,	O
consistent	O
with	O
wastewater	B-MED
emission	O
.	O
Greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	B-MED
of	O
brown	B-MED
bullhead	I-MED
from	O
the	O
Bay	B-MED
of	I-MED
Quinte	I-MED
AOC	B-MED
.	O
Concentrations	O
of	O
polybrominated	B-MED
diphenyl	I-MED
ethers	I-MED
were	O
highest	O
in	O
the	O
Toronto	B-MED
and	I-MED
Region	I-MED
AOC	I-MED
,	O
and	O
at	O
2	O
of	O
the	O
Bay	B-MED
of	I-MED
Quinte	I-MED
AOC	B-MED
exposed	O
sites	O
near	O
Trenton	B-MED
and	I-MED
Belleville	I-MED
.	O
Distribution	B-MED
patterns	I-MED
reflected	O
the	O
properties	B-MED
and	O
usage	B-MED
of	O
the	O
compounds	O
under	O
investigation	B-MED
and	O
the	O
characteristics	B-MED
of	O
each	O
AOC	B-MED
.	O
Environ	O
Toxicol	O
Chem	O
2017;9999:1	O
-	O
8	O
.	O
©	O
2017	O
SETAC	O
.	O
Grade	B-MED
Group	I-MED
Underestimation	B-MED
in	O
Prostate	B-MED
Biopsy	I-MED
:	O
Predictive	B-MED
Factors	I-MED
and	O
Outcomes	B-MED
in	O
Candidates	B-MED
for	O
Active	B-MED
Surveillance	I-MED
We	O
intended	O
to	O
analyze	O
the	O
outcomes	B-MED
and	O
predictive	B-MED
factors	I-MED
for	O
underestimating	O
the	O
prostate	B-MED
cancer	I-MED
(	O
PCa	B-MED
)	O
grade	B-MED
group	I-MED
(	O
GG	B-MED
)	O
from	O
prostate	B-MED
biopsies	I-MED
in	O
a	O
large	O
monocentric	B-MED
cohort	I-MED
of	O
patients	B-MED
treated	B-MED
by	O
minimally	B-MED
invasive	I-MED
radical	I-MED
prostatectomy	I-MED
(	O
RP	B-MED
)	O
.	O
Using	O
a	O
monocentric	B-MED
prospectively	I-MED
maintained	I-MED
database	I-MED
,	O
we	O
included	O
3062	O
patients	B-MED
who	O
underwent	O
minimally	B-MED
invasive	I-MED
RP	I-MED
between	O
2006	O
and	O
2013	O
.	O
We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-MED
associated	B-MED
with	I-MED
a	O
GG	B-MED
upgrade	O
from	O
biopsy	B-MED
to	O
RP	B-MED
.	O
Multivariate	B-MED
logistic	I-MED
regression	I-MED
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B-MED
to	O
predict	O
upgrading	O
for	O
GG1	B-MED
.	O
Biopsy	B-MED
GG	B-MED
was	O
upgraded	O
after	O
RP	B-MED
in	O
51.5	O
%	O
of	O
cases	O
.	O
Patients	B-MED
upgraded	O
from	O
GG1	B-MED
to	O
GG2	B-MED
or	O
GG3	B-MED
after	O
RP	B-MED
had	O
a	O
longer	B-MED
time	I-MED
to	O
biochemical	B-MED
recurrence	I-MED
than	O
those	O
with	O
GG2	B-MED
or	O
GG3	B-MED
respectively	O
,	O
on	O
both	O
biopsy	B-MED
and	O
RP	B-MED
,	O
but	O
a	O
shorter	B-MED
time	I-MED
to	O
biochemical	B-MED
recurrence	I-MED
than	O
those	O
who	O
remained	O
GG1	B-MED
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O
In	O
multivariate	B-MED
analyses	I-MED
,	O
variables	B-MED
predicting	O
upgrading	O
for	O
GG1	B-MED
PCa	B-MED
were	O
age	B-MED
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	B-MED
digital	I-MED
rectal	I-MED
examination	I-MED
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	B-MED
prostate	B-MED
-specific	I-MED
antigen	I-MED
density	I-MED
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	B-MED
of	I-MED
positive	I-MED
cores	I-MED
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	B-MED
mass	I-MED
index	I-MED
(	O
P	O
=	O
.037	O
)	O
.	O
A	O
nomogram	B-MED
was	O
generated	O
and	O
validated	O
internally	O
.	O
Biopsy	B-MED
grading	B-MED
system	I-MED
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O
Upgrading	O
GG	B-MED
from	O
biopsy	B-MED
to	O
RP	B-MED
may	O
have	O
consequences	O
on	O
clinical	B-MED
outcomes	I-MED
.	O
A	O
nomogram	B-MED
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	B-MED
of	O
needing	O
to	O
upgrade	O
GG1	B-MED
patients	B-MED
at	O
their	O
initial	O
evaluation	B-MED
.	O
A	O
trial	B-MED
to	O
determine	O
whether	O
septic	B-MED
shock	I-MED
-	O
reversal	B-MED
is	O
quicker	B-MED
in	O
pediatric	B-MED
patients	B-MED
randomized	B-MED
to	O
an	O
early	B-MED
goal	B-MED
-	I-MED
directed	I-MED
fluid	I-MED
-	I-MED
sparing	I-MED
strategy	I-MED
versus	O
usual	B-MED
care	I-MED
(	O
SQUEEZE	B-MED
):	O
study	B-MED
protocol	I-MED
for	O
a	O
pilot	B-MED
randomized	I-MED
controlled	I-MED
trial	I-MED
Current	B-MED
pediatric	B-MED
septic	B-MED
shock	I-MED
resuscitation	B-MED
guidelines	B-MED
from	O
the	O
American	B-MED
College	I-MED
of	I-MED
Critical	I-MED
Care	I-MED
Medicine	I-MED
focus	O
on	O
the	O
early	B-MED
and	O
goal	B-MED
-	I-MED
directed	I-MED
administration	I-MED
of	O
intravascular	B-MED
fluid	B-MED
followed	O
by	O
vasoactive	B-MED
medication	B-MED
infusions	B-MED
for	O
persistent	B-MED
and	O
fluid	B-MED
-	I-MED
refractory	I-MED
shock	I-MED
.	O
However	O
,	O
accumulating	B-MED
adult	B-MED
and	O
pediatric	B-MED
data	B-MED
suggest	O
that	O
excessive	B-MED
fluid	B-MED
administration	I-MED
is	O
associated	O
with	O
worse	B-MED
patient	B-MED
outcomes	B-MED
and	O
even	O
increased	B-MED
risk	I-MED
of	I-MED
death	I-MED
.	O
The	O
optimal	B-MED
amount	I-MED
of	O
intravascular	B-MED
fluid	B-MED
required	O
in	O
early	B-MED
pediatric	B-MED
septic	B-MED
shock	I-MED
resuscitation	B-MED
prior	O
to	O
the	O
initiation	B-MED
of	O
vasoactive	B-MED
support	I-MED
remains	O
unanswered	O
.	O
The	O
SQUEEZE	B-MED
Pilot	I-MED
Trial	I-MED
is	O
a	O
pragmatic	B-MED
,	O
two	B-MED
-	I-MED
arm	I-MED
,	O
parallel	B-MED
-	I-MED
group	I-MED
,	O
open	B-MED
-	I-MED
label	I-MED
,	O
prospective	B-MED
pilot	I-MED
randomized	I-MED
controlled	I-MED
trial	I-MED
.	O
Participants	B-MED
are	O
children	B-MED
aged	B-MED
29	O
days	B-MED
to	O
under	O
18	O
years	B-MED
with	O
suspected	B-MED
or	O
confirmed	B-MED
septic	B-MED
shock	I-MED
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-MED
.	O
Eligible	O
participants	B-MED
are	O
enrolled	B-MED
under	O
an	O
exception	B-MED
to	O
consent	B-MED
process	B-MED
and	O
randomly	B-MED
assigned	B-MED
via	O
concealed	B-MED
allocation	B-MED
to	O
either	O
the	O
Usual	B-MED
Care	I-MED
(	O
control	B-MED
)	O
or	O
Fluid	B-MED
Sparing	I-MED
(	I-MED
intervention	I-MED
)	I-MED
resuscitation	I-MED
strategy	I-MED
.	O
The	O
primary	B-MED
objective	B-MED
of	O
this	O
pilot	B-MED
trial	I-MED
is	O
to	O
determine	O
feasibility	B-MED
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-MED
participants	B-MED
and	O
to	O
adhere	O
to	O
the	O
study	B-MED
protocol	I-MED
.	O
The	O
primary	B-MED
outcome	I-MED
measure	I-MED
by	O
which	O
success	B-MED
will	O
be	O
determined	O
is	O
participant	B-MED
enrollment	B-MED
rate	B-MED
(	O
"	O
pass	O
"	O
defined	O
as	O
at	O
least	O
two	O
participants	B-MED
/	O
site	B-MED
/	O
month	B-MED
,	O
recognizing	O
that	O
enrollment	B-MED
may	O
be	O
slower	O
during	O
the	O
run	O
-	O
in	O
phase	O
)	O
.	O
Secondary	O
objectives	B-MED
include	O
assessing	O
(	O
1	O
)	O
appropriateness	B-MED
of	O
eligibility	B-MED
criteria	I-MED
,	O
and	O
(	O
2	O
)	O
completeness	B-MED
of	O
clinical	B-MED
outcomes	I-MED
to	O
inform	O
the	O
endpoints	B-MED
for	O
the	O
planned	B-MED
multisite	B-MED
trial	I-MED
.	O
To	O
support	O
the	O
nested	B-MED
translational	I-MED
study	I-MED
,	O
SQUEEZE	B-MED
-	I-MED
D	I-MED
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	B-MED
of	O
describing	O
cell	B-MED
-	I-MED
free	I-MED
DNA	I-MED
(	O
a	O
procoagulant	B-MED
molecule	I-MED
with	O
prognostic	B-MED
utility	I-MED
)	O
in	O
blood	B-MED
samples	I-MED
obtained	O
from	O
children	B-MED
enrolled	B-MED
into	O
the	O
SQUEEZE	B-MED
Pilot	I-MED
Trial	I-MED
at	O
baseline	B-MED
and	O
at	O
24	O
h.	O
The	O
optimal	O
degree	B-MED
of	O
fluid	B-MED
resuscitation	B-MED
and	O
the	O
timing	B-MED
of	O
initiation	B-MED
of	O
vasoactive	B-MED
support	I-MED
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	B-MED
targets	B-MED
in	O
children	B-MED
with	O
septic	B-MED
shock	I-MED
remains	O
unanswered	O
.	O
No	O
prospective	B-MED
study	I-MED
to	O
date	B-MED
has	O
examined	O
this	O
important	O
question	B-MED
for	O
children	B-MED
in	O
developed	B-MED
countries	I-MED
including	O
Canada	B-MED
.	O
Recruitment	B-MED
for	O
the	O
SQUEEZE	B-MED
Pilot	I-MED
Trial	I-MED
opened	B-MED
on	O
6	O
January	O
2014	O
.	O
Findings	B-MED
will	O
inform	O
the	O
feasibility	B-MED
of	O
the	O
planned	B-MED
multicenter	B-MED
trial	I-MED
to	O
answer	O
our	O
overall	B-MED
research	B-MED
question	I-MED
.	O
ClinicalTrials.gov	O
Identifier	O
NCT01973907	O
,	O
registered	O
on	O
23	O
October	O
2013	O
.	O
The	O
relationship	B-MED
between	O
polymorphisms	B-MED
of	O
BDNFOS	B-MED
and	O
BDNF	B-MED
genes	I-MED
and	O
heroin	B-MED
addiction	I-MED
in	O
the	O
Han	B-MED
Chinese	I-MED
population	I-MED
The	O
number	O
of	O
heroin	B-MED
addicts	B-MED
is	O
increasing	B-MED
in	O
the	O
world	B-MED
.	O
Both	O
environmental	B-MED
and	O
genetic	B-MED
factors	I-MED
both	O
play	O
critical	B-MED
roles	O
in	O
the	O
process	B-MED
of	O
heroin	B-MED
addiction	I-MED
.	O
We	O
aimed	B-MED
to	O
investigate	B-MED
the	O
associations	B-MED
between	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
(	O
SNPs	B-MED
)	O
in	O
LIN7C	B-MED
,	O
BDNFOS	B-MED
and	O
BDNF	B-MED
genes	I-MED
and	O
drug	B-MED
addiction	I-MED
in	O
the	O
Han	B-MED
Chinese	I-MED
population	I-MED
.	O
We	O
conducted	O
a	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
among	O
692	O
cases	B-MED
and	O
700	O
healthy	B-MED
controls	I-MED
from	O
Xi'an	B-MED
,	O
China	B-MED
.	O
Eight	O
SNPs	B-MED
were	O
selected	B-MED
and	O
genotyped	B-MED
using	O
MassARRAY	B-MED
technology	I-MED
(	O
Sequenom	B-MED
,	O
San	B-MED
Diego	I-MED
,	I-MED
CA	I-MED
,	O
USA	B-MED
)	O
.	O
Odds	B-MED
ratios	I-MED
(	O
OR	B-MED
)	O
and	O
95	O
%	O
confidence	B-MED
intervals	I-MED
(	O
CIs	B-MED
)	O
were	O
calculated	B-MED
by	O
unconditional	B-MED
logistic	I-MED
regression	I-MED
adjusting	O
for	O
age	B-MED
and	O
sex	B-MED
.	O
Using	O
the	O
chi	B-MED
-	I-MED
squared	I-MED
test	I-MED
,	O
we	O
found	O
that	O
rs7481311	B-MED
(	O
OR	B-MED
=	O
1.275	O
,	O
95	O
%	O
CI	B-MED
=	O
1.087	O
-	O
1.497	O
,	O
p	O
=	O
0.009	O
)	O
and	O
rs11030096	B-MED
(	O
OR	B-MED
=	O
1.227	O
,	O
95	O
%	O
CI	B-MED
=	O
1.049	O
-	O
1.436	O
,	O
p	O
=	O
0.011	O
)	O
in	O
the	O
BNDFOS	B-MED
were	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
.	O
By	O
contrast	O
,	O
rs988712	B-MED
located	O
in	O
BDNFOS	B-MED
showed	O
a	O
decreased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
(	O
OR	B-MED
=	O
0.734	O
,	O
95	O
%	O
CI	B-MED
=	O
0.582	O
-	O
0.925	O
,	O
p	O
=	O
0.003	O
)	O
.	O
By	O
genetic	B-MED
model	I-MED
analysis	B-MED
,	O
we	O
found	O
that	O
the	O
'	B-MED
T	I-MED
'	I-MED
allele	I-MED
of	O
rs988712	B-MED
in	O
BDNFOS	B-MED
had	O
a	O
protective	O
role	O
for	O
heroin	B-MED
addiction	I-MED
in	O
the	O
additive	B-MED
model	I-MED
and	O
dominant	B-MED
model	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
By	O
contrast	O
,	O
the	O
allele	B-MED
'	I-MED
T	I-MED
'	I-MED
of	O
rs7481311	B-MED
in	O
BDNFOS	B-MED
significantly	O
elevated	B-MED
the	O
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
in	O
the	O
additive	B-MED
model	I-MED
,	O
recessive	B-MED
model	I-MED
and	O
dominant	B-MED
model	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
We	O
also	O
found	O
that	O
allele	B-MED
'	I-MED
C	I-MED
'	O
of	O
rs11030096	B-MED
was	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
addiction	B-MED
in	O
the	O
dominant	B-MED
model	I-MED
and	O
additive	B-MED
model	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
Additionally	O
,	O
we	O
found	O
that	O
rs6265	B-MED
,	O
rs11030104	B-MED
and	O
rs10767664	B-MED
in	O
BDNF	B-MED
were	O
associated	B-MED
with	I-MED
a	O
decreased	B-MED
risk	B-MED
of	O
heroin	B-MED
addiction	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
However	O
,	O
only	O
rs7481311	B-MED
in	O
BDNFOS	B-MED
remained	O
significant	B-MED
after	O
Bonferroni	B-MED
correction	I-MED
(	O
p	O
<	O
0.00625	O
)	O
.	O
These	O
results	B-MED
suggest	O
that	O
polymorphisms	B-MED
of	O
BDNFOS	B-MED
play	O
an	O
important	B-MED
role	O
in	O
heroin	B-MED
addiction	I-MED
susceptibility	B-MED
in	O
the	O
Chinese	B-MED
Han	I-MED
population	I-MED
.	O
Pathophysiology	B-MED
,	O
treatment	B-MED
and	O
prevention	B-MED
of	O
ovarian	B-MED
hyperstimulation	I-MED
syndrome	I-MED
Severe	B-MED
ovarian	B-MED
hyperstimulation	I-MED
syndrome	I-MED
(	O
OHSS	B-MED
)	O
is	O
an	O
iatrogenic	B-MED
condition	B-MED
that	O
affects	B-MED
1	O
%	O
of	O
women	B-MED
that	O
undergo	O
treatment	B-MED
with	O
assisted	B-MED
reproductive	I-MED
technology	I-MED
.	O
The	O
review	B-MED
aims	B-MED
to	O
summarize	B-MED
recent	B-MED
evidence	B-MED
on	O
pathophysiology	B-MED
,	O
treatment	B-MED
,	O
and	O
prevention	B-MED
of	O
OHSS	B-MED
.	O
The	O
pathophysiology	B-MED
is	O
still	O
not	O
completely	B-MED
understood	B-MED
;	O
however	O
,	O
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
is	O
likely	O
to	O
be	O
an	O
important	B-MED
mediator	O
.	O
Human	B-MED
chorionic	I-MED
gonadotropin	I-MED
was	O
previously	O
thought	B-MED
to	O
be	O
necessary	O
for	O
OHSS	B-MED
to	O
occur	B-MED
;	O
however	O
,	O
recent	B-MED
case	I-MED
reports	I-MED
have	O
proven	B-MED
otherwise	O
.	O
The	O
contribution	B-MED
of	O
an	O
attenuated	B-MED
anti	B-MED
-	I-MED
Mullerian	I-MED
hormone	I-MED
signalling	B-MED
pathway	I-MED
and	O
CD11c	B-MED
+	O
HLA	B-MED
-	I-MED
DR	I-MED
+	O
dendritic	B-MED
cells	I-MED
and	O
associated	B-MED
interleukins	B-MED
has	O
been	O
explored	O
recently	B-MED
as	O
contributors	B-MED
to	O
pathogenesis	B-MED
.	O
Treatment	B-MED
is	O
largely	O
supportive	B-MED
and	O
is	O
based	B-MED
mainly	O
on	O
consensus	B-MED
statements	B-MED
rather	O
than	O
evidence	B-MED
.	O
Therefore	O
,	O
it	O
is	O
important	B-MED
to	O
prevent	B-MED
this	O
condition	B-MED
by	O
identifying	B-MED
women	B-MED
at	B-MED
risk	I-MED
,	O
allowing	B-MED
the	O
clinician	B-MED
to	O
implement	B-MED
preventive	B-MED
strategies	I-MED
,	O
including	B-MED
the	O
use	O
of	O
GnRH	B-MED
antagonist	I-MED
cycles	B-MED
with	O
agonist	B-MED
triggers	O
.	O
More	O
research	B-MED
is	O
required	B-MED
to	O
elucidate	O
the	O
pathophysiology	B-MED
behind	O
the	O
condition	B-MED
.	O
Clinicians	B-MED
should	O
employ	B-MED
strategies	B-MED
to	O
prevent	B-MED
OHSS	B-MED
.	O
Pedicle	B-MED
Screw	I-MED
Combined	B-MED
With	O
Lateral	B-MED
Mass	I-MED
Screw	I-MED
Fixation	B-MED
in	O
the	O
Treatment	B-MED
of	O
Basilar	B-MED
Invagination	I-MED
and	O
Congenital	B-MED
C2	I-MED
-	I-MED
C3	I-MED
Fusion	I-MED
Clinical	B-MED
evaluation	I-MED
of	O
a	O
surgical	B-MED
fixation	B-MED
technique	B-MED
featuring	O
combined	B-MED
use	O
of	O
pedicle	B-MED
screw	I-MED
and	O
lateral	B-MED
mass	I-MED
screw	I-MED
(	O
LMS	B-MED
)	O
.	O
Introduction	O
of	O
a	O
novel	O
technique	B-MED
for	O
the	O
treatment	B-MED
of	O
congenital	B-MED
C2	I-MED
-	I-MED
C3	I-MED
fusion	I-MED
and	O
basilar	B-MED
invagination	I-MED
(	O
BI	B-MED
)	O
.	O
Posterior	B-MED
occipitocervical	B-MED
fixation	B-MED
using	O
C2	B-MED
pedicle	I-MED
screw	I-MED
was	O
widely	O
used	O
for	O
BI	B-MED
.	O
However	O
,	O
in	O
cases	B-MED
where	O
BI	B-MED
is	O
concurrent	B-MED
with	O
congenital	B-MED
C2	I-MED
-	I-MED
C3	I-MED
fusion	I-MED
,	O
the	O
C2	B-MED
pedicles	I-MED
tend	O
to	O
be	O
thinner	B-MED
than	O
that	O
in	O
normal	B-MED
population	B-MED
and	O
hence	O
more	O
likely	O
to	O
fail	B-MED
.	O
We	O
prompted	O
to	O
tackle	O
the	O
issue	B-MED
by	O
combining	B-MED
the	O
pedicle	B-MED
screw	I-MED
with	O
the	O
additional	O
use	O
of	O
LMS	B-MED
in	O
attempt	O
to	O
strengthen	B-MED
the	O
fixation	B-MED
.	O
Twenty	O
-	O
five	O
patients	B-MED
who	O
underwent	O
combined	B-MED
pedicle	B-MED
screw	I-MED
with	O
LMS	B-MED
fixation	B-MED
were	O
retrospectively	B-MED
studied	I-MED
.	O
The	O
instrument	B-MED
position	B-MED
,	O
fusion	B-MED
status	B-MED
,	O
and	O
complications	B-MED
were	O
analyzed	B-MED
.	O
None	O
had	O
spinal	B-MED
cord	I-MED
or	O
vertebral	B-MED
artery	I-MED
injury	I-MED
.	O
The	O
average	O
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
was	O
20	O
months	B-MED
.	O
Solid	O
fusion	B-MED
was	O
achieved	O
in	O
23	O
patients	B-MED
(	O
92	O
%	O
)	O
as	O
detected	O
radiologically	B-MED
.	O
Two	O
cases	B-MED
suffered	O
from	O
recurred	B-MED
BI	B-MED
and	O
instrument	B-MED
failure	B-MED
but	O
eventually	O
achieved	O
solid	O
fusion	B-MED
between	O
the	O
occiput	B-MED
and	O
C2	B-MED
was	O
after	O
revision	B-MED
.	O
Among	O
all	O
25	O
patients	B-MED
,	O
4	O
suffered	O
from	O
complications	B-MED
including	O
instrument	B-MED
s	O
failure	B-MED
,	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
,	O
and	O
intracranial	B-MED
infection	B-MED
.	O
The	O
clinical	B-MED
outcome	B-MED
indicates	O
that	O
the	O
technique	B-MED
is	O
reliable	O
for	O
the	O
treatment	B-MED
of	O
BI	B-MED
with	O
congenital	B-MED
C2	I-MED
-	I-MED
C3	I-MED
fusion	I-MED
.	O
Impact	B-MED
of	O
diabetic	B-MED
ketoacidosis	I-MED
management	B-MED
in	O
the	O
medical	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
after	O
order	B-MED
set	I-MED
implementation	B-MED
To	O
determine	O
the	O
rate	B-MED
of	O
compliance	B-MED
to	O
the	O
2006	O
and	O
2009	O
ADA	B-MED
DKA	I-MED
guidelines	I-MED
in	O
the	O
medical	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
(	O
MICU	B-MED
)	O
at	O
a	O
large	O
academic	B-MED
medical	I-MED
centre	I-MED
after	O
the	O
implementation	B-MED
of	O
a	O
computerised	B-MED
DKA	I-MED
order	I-MED
set	I-MED
and	O
protocol	B-MED
.	O
Retrospective	B-MED
chart	B-MED
review	I-MED
of	O
adult	B-MED
patients	I-MED
with	O
DKA	B-MED
admitted	B-MED
to	O
the	O
MICU	B-MED
.	O
Results	O
of	O
pre	B-MED
-	I-MED
order	I-MED
set	I-MED
(	O
PRE	B-MED
)	O
were	O
compared	O
to	O
those	O
of	O
data	O
post	B-MED
-	I-MED
order	I-MED
set	I-MED
(	O
POST	B-MED
)	O
.	O
The	O
primary	B-MED
outcome	I-MED
was	O
a	O
composite	O
administration	B-MED
of	O
intravenous	B-MED
fluid	I-MED
resuscitation	I-MED
in	O
the	O
first	O
24	O
h	O
,	O
insulin	B-MED
bolus	B-MED
and	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
.	O
Twelve	O
of	O
60	O
patients	B-MED
(	O
20	O
%	O
)	O
in	O
the	O
PRE	B-MED
group	I-MED
received	O
treatment	B-MED
compliant	B-MED
with	O
the	O
2006	O
guidelines	B-MED
versus	O
14	O
of	O
55	O
patients	B-MED
(	O
25.5	O
%	O
)	O
in	O
the	O
POST	B-MED
group	I-MED
(	O
OR	B-MED
1.22	O
95	O
%	O
CI	B-MED
0.44	O
to	O
3.4	O
,	O
P	O
=	O
0.51	O
)	O
.	O
Compliance	B-MED
to	O
the	O
2009	O
guidelines	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
the	O
POST	B-MED
group	I-MED
(	O
31.7	O
%	O
versus	O
65.5	O
%	O
,	O
OR	B-MED
4.44	O
95	O
%	O
CI	B-MED
1.8	O
to	O
10.92	O
,	O
P	O
=	O
0.0004	O
)	O
.	O
Compliance	B-MED
for	O
individual	O
components	O
was	O
26.7	O
%	O
versus	O
70.9	O
%	O
for	O
fluid	B-MED
resuscitation	I-MED
(	O
P	O
=	O
0.0001	O
)	O
,	O
55	O
%	O
versus	O
49.1	O
%	O
for	O
insulin	B-MED
bolus	B-MED
(	O
P	O
=	O
0.58	O
)	O
and	O
60	O
%	O
versus	O
81.3	O
%	O
for	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
(	O
P	O
=	O
0.014	O
)	O
,	O
respectively	O
.	O
Time	B-MED
to	O
DKA	B-MED
resolution	B-MED
was	O
decreased	B-MED
(	O
P	O
=	O
0.04	O
)	O
,	O
and	O
hypoglycaemia	B-MED
was	O
increased	B-MED
(	O
P	O
=	O
0.0022	O
)	O
.	O
Implementation	B-MED
of	O
a	O
computerised	B-MED
DKA	I-MED
order	I-MED
set	I-MED
and	O
protocol	B-MED
was	O
associated	B-MED
with	I-MED
improved	B-MED
compliance	B-MED
to	O
the	O
2009	O
ADA	B-MED
DKA	I-MED
guidelines	I-MED
,	O
24	O
-	O
h	O
fluid	B-MED
resuscitation	I-MED
,	O
initial	B-MED
insulin	B-MED
infusion	B-MED
rate	I-MED
,	O
time	B-MED
to	O
DKA	B-MED
resolution	B-MED
and	O
appropriate	O
transition	B-MED
to	O
subcutaneous	B-MED
insulin	B-MED
.	O
However	O
,	O
patients	B-MED
in	O
the	O
POST	B-MED
implementation	I-MED
group	I-MED
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-MED
.	O
Future	O
assessment	O
is	O
warranted	O
.	O
Volumetric	B-MED
absorptive	I-MED
microsampling	I-MED
at	O
home	B-MED
as	O
an	O
alternative	B-MED
tool	B-MED
for	O
the	O
monitoring	B-MED
of	O
HbA1c	B-MED
in	O
diabetes	B-MED
patients	B-MED
Microsampling	B-MED
techniques	I-MED
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-MED
collection	I-MED
.	O
Dried	B-MED
blood	I-MED
spot	I-MED
(	I-MED
DBS	I-MED
)	I-MED
sampling	I-MED
and	O
blood	B-MED
collection	I-MED
with	O
heparinized	B-MED
capillaries	I-MED
are	O
the	O
standard	B-MED
techniques	B-MED
.	O
Volumetric	B-MED
absorptive	I-MED
microsampling	I-MED
(	O
VAMS	B-MED
)	O
is	O
a	O
novel	O
technique	B-MED
that	O
collects	O
a	O
fixed	O
volume	B-MED
of	O
blood	B-MED
by	O
applying	O
an	O
absorbent	O
tip	B-MED
to	O
a	O
blood	B-MED
drop	I-MED
.	O
In	O
the	O
present	O
study	B-MED
we	O
explored	O
the	O
feasibility	O
of	O
HbA1c	B-MED
monitoring	B-MED
with	O
VAMS	B-MED
sampling	I-MED
at	O
home	B-MED
and	O
analysis	B-MED
in	O
the	O
laboratory	B-MED
.	O
Diabetic	B-MED
patients	B-MED
were	O
enrolled	O
in	O
this	O
study	B-MED
during	O
consultation	B-MED
with	O
the	O
endocrinologist	B-MED
.	O
A	O
venous	B-MED
(	O
adults	B-MED
)	O
or	O
capillary	B-MED
(	I-MED
children	I-MED
)	I-MED
sample	I-MED
was	O
taken	O
for	O
immediate	O
HbA1c	B-MED
analysis	B-MED
.	O
DBS	B-MED
(	O
n=1	O
)	O
and	O
dried	B-MED
VAMS	I-MED
(	O
n=2	O
)	O
were	O
collected	O
at	O
home	B-MED
and	O
sent	O
to	O
the	O
laboratory	B-MED
.	O
For	O
25	O
pediatric	B-MED
patients	B-MED
one	O
VAMS	B-MED
was	O
collected	O
during	O
consultation	B-MED
for	O
immediate	O
analysis	B-MED
(	O
without	O
drying	O
)	O
,	O
referred	O
to	O
as	O
"	O
wet	B-MED
VAMS	I-MED
"	O
.	O
HbA1c	B-MED
analyses	B-MED
were	O
performed	O
on	O
a	O
Tosoh	B-MED
HLC-723	I-MED
G8	I-MED
high	I-MED
-	I-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
(	I-MED
HPLC	I-MED
)	I-MED
analyzer	I-MED
.	O
The	O
median	O
time	O
between	O
sampling	B-MED
at	O
home	B-MED
and	O
analysis	B-MED
was	O
3	O
days	B-MED
.	O
Results	B-MED
of	O
HbA1c	B-MED
in	O
dried	O
VAMS	B-MED
showed	O
a	O
poor	O
agreement	O
with	O
venous	B-MED
/	O
capillary	B-MED
blood	I-MED
collected	O
in	O
hospital	B-MED
(	O
concordance	B-MED
correlation	I-MED
coefficient	I-MED
CCC	B-MED
=	O
0.72	O
)	O
.	O
Similar	O
observations	O
were	O
found	O
with	O
standard	B-MED
DBS	B-MED
.	O
An	O
excellent	O
agreement	O
was	O
obtained	O
between	O
HbA1c	B-MED
results	B-MED
on	O
wet	B-MED
VAMS	I-MED
(	O
CCC	B-MED
=	O
0.996	O
)	O
and	O
standard	B-MED
blood	B-MED
samples	I-MED
.	O
Patients	B-MED
experienced	O
VAMS	B-MED
and	O
DBS	B-MED
as	O
easy	B-MED
and	O
convenient	B-MED
to	O
use	B-MED
.	O
Utilizing	O
equipment	B-MED
standard	B-MED
available	O
in	O
the	O
clinical	B-MED
laboratory	B-MED
,	O
the	O
use	O
of	O
home	B-MED
-sampled	O
dried	B-MED
VAMS	I-MED
and	O
DBS	B-MED
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-MED
of	O
HbA1c	B-MED
.	O
However	O
,	O
perfect	O
agreement	O
between	O
HbA1c	B-MED
measured	O
on	O
wet	B-MED
VAMS	I-MED
and	O
capillary	B-MED
microsamples	I-MED
was	O
obtained	O
.	O
Effect	B-MED
of	O
emodin	B-MED
on	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
of	O
gallbladder	B-MED
smooth	B-MED
muscle	I-MED
in	O
Guinea	B-MED
pig	I-MED
with	O
cholelithiasis	B-MED
To	O
study	B-MED
the	O
effect	B-MED
of	O
emodin	B-MED
on	O
protein	B-MED
and	O
gene	B-MED
expressions	I-MED
of	O
the	O
massagers	B-MED
in	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
of	O
cholecyst	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
in	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
.	O
The	O
guinea	B-MED
pigs	I-MED
were	O
randomly	O
divided	O
into	O
4	O
groups	B-MED
,	O
such	O
as	O
control	B-MED
group	I-MED
,	O
gall	B-MED
-	I-MED
stone	I-MED
(	O
GS	B-MED
)	O
group	B-MED
,	O
emodin	B-MED
group	B-MED
and	O
ursodeoxycholic	B-MED
acid	I-MED
(	O
UA	B-MED
)	O
group	B-MED
.	O
Cholesterol	B-MED
calculus	I-MED
models	B-MED
were	O
induced	O
in	O
guinea	B-MED
pigs	I-MED
of	O
GS	B-MED
,	O
emodin	B-MED
and	O
UA	B-MED
groups	B-MED
by	O
lithogenic	B-MED
diet	I-MED
,	O
while	O
emodin	B-MED
or	O
UA	B-MED
were	O
given	O
to	O
the	O
corresponding	O
group	B-MED
for	O
7	O
weeks	B-MED
.	O
The	O
histomorphological	B-MED
and	O
ultrastructure	B-MED
change	B-MED
of	O
gallbladder	B-MED
were	O
detected	B-MED
by	O
microscope	B-MED
and	O
electron	B-MED
microscope	I-MED
,	O
the	O
content	O
of	O
plasma	B-MED
cholecystokinin	B-MED
(	O
CCK	B-MED
)	O
and	O
[	B-MED
Ca(2+)]i	I-MED
were	O
analyzed	B-MED
successively	O
by	O
radioimmunoassay	B-MED
and	O
flow	B-MED
cytometry	I-MED
.	O
The	O
protein	B-MED
and	O
mRNA	B-MED
of	O
Gsα	B-MED
,	O
Giα	B-MED
and	O
Cap	B-MED
in	O
cholecyst	B-MED
cells	B-MED
were	O
determined	B-MED
by	I-MED
western	B-MED
blotting	I-MED
and	O
real	B-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
RT	B-MED
-	I-MED
PCR	I-MED
)	O
.	O
Emodin	B-MED
or	O
UA	B-MED
can	O
relieve	O
pathogenic	B-MED
changes	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
muscle	B-MED
cells	I-MED
in	O
gallbladder	B-MED
of	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
by	O
microscope	B-MED
and	O
transmission	B-MED
electron	I-MED
microscope	I-MED
.	O
In	O
the	O
cholecyst	B-MED
cells	B-MED
of	O
GS	B-MED
group	B-MED
,	O
CCK	B-MED
levels	B-MED
in	O
plasma	B-MED
and	O
[	B-MED
Ca(2+)]i	I-MED
decreased	B-MED
,	O
the	O
protein	B-MED
and	O
mRNA	B-MED
of	O
GS	B-MED
were	O
down	B-MED
-	I-MED
regulated	I-MED
,	O
the	O
protein	B-MED
and	O
mRNA	B-MED
of	O
Gi	B-MED
and	O
Cap	B-MED
were	O
up	B-MED
-	I-MED
regulated	I-MED
.	O
Emodin	B-MED
significantly	B-MED
decreased	B-MED
the	O
formative	B-MED
rate	B-MED
of	O
gallstone	B-MED
,	O
improved	O
the	O
pathogenic	B-MED
change	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
muscle	B-MED
cells	I-MED
,	O
increased	O
CCK	B-MED
levels	B-MED
in	O
plasma	B-MED
and	O
[	B-MED
Ca(2+)]i	I-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
enhanced	O
the	O
protein	B-MED
and	O
mRNA	B-MED
of	O
Gs	B-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
reduced	B-MED
the	O
protein	B-MED
and	O
mRNA	B-MED
of	O
Gi	B-MED
and	O
Cap	B-MED
in	O
cholecyst	B-MED
cells	B-MED
in	O
guinea	B-MED
pig	I-MED
with	O
cholesterol	B-MED
calculus	I-MED
.	O
The	O
dysfunction	B-MED
of	O
gallbladder	B-MED
contraction	I-MED
gives	O
rise	O
to	O
the	O
disorders	B-MED
of	O
mobility	B-MED
signal	I-MED
transduction	I-MED
system	I-MED
in	O
cholecyst	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
,	O
including	B-MED
low	O
content	O
of	O
plasma	B-MED
CCK	B-MED
and	O
[	B-MED
Ca(2+)]i	I-MED
in	O
cholecyst	B-MED
cells	B-MED
,	O
abnormal	B-MED
protein	I-MED
and	O
mRNA	B-MED
of	O
Gs	B-MED
,	O
Gi	B-MED
and	O
Cap	B-MED
.	O
Emodin	B-MED
can	O
enhance	B-MED
the	O
contractibility	B-MED
of	I-MED
gallbladder	I-MED
and	O
alleviate	B-MED
cholestasis	B-MED
by	O
regulating	B-MED
plasma	B-MED
CCK	B-MED
levels	B-MED
,	O
[	B-MED
Ca(2+)]i	I-MED
in	O
cholecyst	B-MED
cells	B-MED
and	O
the	O
protein	B-MED
and	O
mRNA	B-MED
of	O
Gs	B-MED
,	O
Gi	B-MED
and	O
Cap	B-MED
.	O
The	O
R2R3MYB	B-MED
VvMYBPA1	B-MED
from	O
grape	B-MED
reprograms	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
in	O
tobacco	B-MED
flowers	B-MED
This	O
work	O
shows	O
that	O
,	O
in	O
tobacco	B-MED
,	O
the	O
ectopic	B-MED
expression	I-MED
of	O
VvMYBPA1	B-MED
,	O
a	O
grape	B-MED
regulator	B-MED
of	O
proanthocyanidin	B-MED
biosynthesis	O
,	O
up-	B-MED
or	I-MED
down	I-MED
-	I-MED
regulates	I-MED
different	O
branches	O
of	O
the	O
phenylproanoid	B-MED
pathway	I-MED
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O
Proanthocyanidins	B-MED
are	O
flavonoids	B-MED
of	O
paramount	O
importance	O
for	O
animal	B-MED
and	O
human	B-MED
diet	I-MED
.	O
Research	B-MED
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	B-MED
enriched	O
with	O
these	O
health	B-MED
-promoting	O
compounds	B-MED
.	O
Flavonoids	B-MED
synthesis	B-MED
is	O
regulated	O
by	O
the	O
MBW	B-MED
transcriptional	B-MED
complex	I-MED
,	O
made	O
of	O
R2R3MYB	B-MED
,	O
bHLH	B-MED
and	O
WD40	B-MED
proteins	I-MED
,	O
with	O
the	O
MYB	B-MED
components	O
liable	O
for	O
channeling	B-MED
the	O
complex	B-MED
towards	O
specific	O
branches	O
of	O
the	O
pathway	B-MED
.	O
Hence	O
,	O
using	O
tobacco	B-MED
as	O
a	O
model	B-MED
,	O
here	O
,	O
we	O
tested	B-MED
if	O
the	O
ectopic	B-MED
expression	I-MED
of	O
the	O
proanthocyanidin	B-MED
regulator	B-MED
VvMYBPA1	B-MED
from	O
grape	B-MED
induces	B-MED
the	O
biosynthesis	B-MED
of	O
these	O
compounds	B-MED
in	O
not	O
-	O
naturally	O
committed	B-MED
cells	I-MED
.	O
Here	O
,	O
we	O
show	O
,	O
via	O
targeted	O
transcriptomic	B-MED
and	O
metabolic	B-MED
analyses	B-MED
of	O
primary	O
transgenic	B-MED
lines	I-MED
and	O
their	O
progeny	B-MED
,	O
that	O
VvMYBPA1	B-MED
alters	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
in	O
tobacco	B-MED
floral	B-MED
organs	I-MED
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O
We	O
also	O
report	O
that	O
a	O
modest	O
VvMYBPA1	B-MED
expression	B-MED
is	O
sufficient	O
to	O
induce	O
the	O
expression	B-MED
of	O
both	O
proanthocyanidin	B-MED
-specific	O
and	O
early	B-MED
genes	I-MED
of	O
the	O
phenylpropanoid	B-MED
pathway	I-MED
.	O
Consequently	O
,	O
proanthocyanidins	B-MED
and	O
chlorogenic	B-MED
acids	I-MED
are	O
induced	O
or	O
de	B-MED
novo	I-MED
synthetised	O
in	O
floral	B-MED
limbs	I-MED
,	I-MED
tubes	I-MED
and	O
stamens	B-MED
.	O
Other	O
phenylpropanoid	B-MED
branches	I-MED
are	O
conversely	O
induced	O
or	O
depleted	B-MED
according	O
to	O
the	O
floral	B-MED
structure	I-MED
.	O
Our	O
study	O
documents	O
a	O
novel	B-MED
and	O
distinct	O
function	O
of	O
VvMYBPA1	B-MED
with	O
respect	O
to	O
other	O
MYBs	B-MED
regulating	O
proanthocyanidins	B-MED
.	O
Present	O
findings	B-MED
may	O
have	O
major	O
implications	O
in	O
designing	B-MED
strategies	I-MED
for	O
enriching	O
crops	B-MED
with	O
health	B-MED
-promoting	O
compounds	B-MED
.	O
Splicing	B-MED
variants	O
of	O
ADAR2	B-MED
and	O
ADAR2	B-MED
-mediated	O
RNA	B-MED
editing	I-MED
in	O
glioma	B-MED
The	O
roles	O
of	O
alternative	B-MED
splicing	I-MED
and	O
RNA	B-MED
editing	I-MED
in	O
gene	B-MED
regulation	I-MED
and	O
transcriptome	B-MED
diversity	O
are	O
well	O
documented	O
.	O
Adenosine	B-MED
deaminases	I-MED
acting	O
on	O
RNA	B-MED
(	O
ADARs	B-MED
)	O
are	O
responsible	O
for	O
adenosine	B-MED
-	I-MED
to	I-MED
-	I-MED
inosine	I-MED
(	I-MED
A	I-MED
-	I-MED
to	I-MED
-	I-MED
I	I-MED
)	I-MED
editing	I-MED
and	O
exemplify	O
the	O
complex	O
association	O
between	O
RNA	B-MED
editing	I-MED
and	O
alternative	B-MED
splicing	I-MED
.	O
The	O
self	B-MED
-	I-MED
editing	I-MED
activity	O
of	O
ADAR2	B-MED
,	O
which	O
acts	O
on	O
its	O
own	O
pre	B-MED
-	I-MED
mRNA	I-MED
,	O
leads	O
to	O
its	O
alternative	B-MED
splicing	I-MED
.	O
Alternative	B-MED
splicing	I-MED
occurs	O
independently	O
at	O
nine	O
splicing	B-MED
sites	O
on	O
ADAR2	B-MED
pre	B-MED
-	I-MED
mRNA	I-MED
,	O
generating	O
numerous	O
alternative	B-MED
splicing	I-MED
variants	O
with	O
various	O
catalytic	B-MED
activities	I-MED
.	O
A	B-MED
-	I-MED
to	I-MED
-	I-MED
I	I-MED
RNA	I-MED
editing	I-MED
is	O
important	O
in	O
a	O
range	O
of	O
physiological	B-MED
processes	I-MED
in	O
humans	B-MED
and	O
is	O
associated	O
with	O
several	O
diseases	B-MED
,	O
including	O
amyotrophic	B-MED
lateral	I-MED
sclerosis	I-MED
,	O
mood	B-MED
disorders	I-MED
,	O
epilepsy	B-MED
and	O
glioma	B-MED
.	O
Reduced	O
editing	B-MED
at	O
the	O
glutamine	B-MED
/	O
arginine	B-MED
site	O
of	O
the	O
AMPA	B-MED
receptor	I-MED
subunit	I-MED
GluA2	I-MED
in	O
glioma	B-MED
,	O
without	O
any	O
alteration	O
in	O
ADAR2	B-MED
expression	B-MED
,	O
is	O
a	O
notable	O
phenomenon	O
.	O
Several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	B-MED
in	O
the	O
catalytic	B-MED
activity	I-MED
of	O
ADAR2	B-MED
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O
The	O
present	O
review	B-MED
summarizes	O
the	O
relevant	O
literature	B-MED
and	O
shares	O
experimental	B-MED
results	I-MED
concerning	O
ADAR2	B-MED
alternative	B-MED
splicing	I-MED
.	O
In	O
particular	O
,	O
the	O
present	O
review	B-MED
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-MED
variants	O
of	O
ADAR2	B-MED
may	O
reduce	O
the	O
ADAR2	B-MED
editing	B-MED
activity	O
in	O
glioma	B-MED
.	O
Dominant	O
expression	B-MED
of	O
ADAR2	B-MED
splicing	B-MED
variant	O
with	O
low	O
enzyme	B-MED
activity	I-MED
causes	O
reduced	O
RNA	B-MED
editing	I-MED
of	O
GluA2	B-MED
subunit	I-MED
at	O
the	O
glutamine	B-MED
/	O
arginine	B-MED
site	O
in	O
glioma	B-MED
.	O
Assessing	B-MED
the	O
learning	B-MED
potential	B-MED
of	O
an	O
interactive	B-MED
digital	B-MED
game	I-MED
versus	O
an	O
interactive	B-MED
-	I-MED
style	I-MED
didactic	B-MED
lecture	B-MED
:	O
the	O
continued	O
importance	O
of	O
didactic	B-MED
teaching	B-MED
in	O
medical	B-MED
student	I-MED
education	B-MED
Games	B-MED
with	O
educational	B-MED
intent	O
offer	O
a	O
possible	B-MED
advantage	O
of	O
being	O
more	O
interactive	B-MED
and	O
increasing	B-MED
learner	B-MED
satisfaction	B-MED
.	O
We	O
conducted	O
a	O
two	B-MED
-	I-MED
armed	I-MED
experiment	I-MED
to	O
evaluate	B-MED
student	B-MED
satisfaction	B-MED
and	O
content	B-MED
mastery	B-MED
for	O
an	O
introductory	O
pediatric	B-MED
radiology	I-MED
topic	B-MED
,	O
taught	B-MED
by	O
either	O
an	O
interactive	B-MED
digital	B-MED
game	I-MED
or	O
with	O
a	O
traditional	B-MED
didactic	B-MED
lecture	B-MED
.	O
Medical	B-MED
students	I-MED
participating	B-MED
in	O
a	O
fourth	O
-	O
year	O
radiology	B-MED
elective	B-MED
were	O
invited	O
to	O
participate	B-MED
.	O
Student	B-MED
cohorts	B-MED
were	O
alternatively	B-MED
given	O
a	O
faculty	B-MED
-	O
supervised	B-MED
1h	O
session	B-MED
playing	B-MED
a	O
simple	O
interactive	B-MED
digital	B-MED
Tic	B-MED
-	I-MED
tac	I-MED
-	I-MED
toe	I-MED
quiz	B-MED
module	I-MED
on	O
pediatric	B-MED
gastrointestinal	I-MED
radiology	I-MED
or	O
a	O
1h	O
didactic	B-MED
introductory	O
lecture	B-MED
on	O
the	O
same	O
topic	B-MED
.	O
Survey	B-MED
questions	B-MED
assessed	B-MED
the	O
learners	B-MED
'	I-MED
perceived	B-MED
ability	B-MED
to	I-MED
recall	I-MED
the	O
material	B-MED
as	O
well	O
as	O
their	O
satisfaction	B-MED
with	O
the	O
educational	B-MED
experience	B-MED
.	O
Results	O
of	O
an	O
end	B-MED
-	I-MED
of	I-MED
-	I-MED
rotation	I-MED
exam	B-MED
were	O
reviewed	B-MED
to	O
evaluate	B-MED
a	O
quantitative	B-MED
measure	I-MED
of	O
learning	B-MED
between	O
groups	B-MED
.	O
Survey	B-MED
responses	B-MED
were	O
analyzed	B-MED
with	O
a	O
chi	B-MED
-	I-MED
squared	I-MED
test	I-MED
.	O
Exam	B-MED
results	O
for	O
both	O
groups	B-MED
were	O
analyzed	B-MED
with	O
a	O
paired	O
Student	B-MED
's	I-MED
t	I-MED
-	I-MED
test	I-MED
.	O
Students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
had	O
higher	B-MED
test	B-MED
scores	I-MED
compared	B-MED
to	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
(	O
4.0/5	O
versus	O
3.6/5	O
,	O
P	O
=	O
0.045	O
)	O
.	O
Students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
reported	B-MED
greater	B-MED
understanding	B-MED
and	O
recall	B-MED
of	O
the	O
material	B-MED
than	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O
Students	B-MED
in	O
the	O
lecture	B-MED
group	B-MED
perceived	B-MED
the	O
lecture	B-MED
to	O
be	O
more	O
enjoyable	B-MED
and	O
a	O
better	O
use	O
of	O
their	O
time	B-MED
compared	B-MED
to	O
those	O
in	O
the	O
game	B-MED
group	B-MED
(	O
P	O
=	O
0.04	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
statistically	B-MED
significant	I-MED
difference	B-MED
between	O
the	O
lecture	B-MED
and	O
game	B-MED
group	B-MED
in	O
ability	B-MED
to	O
maintain	O
interest	B-MED
(	O
P	O
=	O
0.187	O
)	O
.	O
In	O
comparison	O
to	O
pre	B-MED
-	I-MED
survey	I-MED
results	O
,	O
there	O
was	O
a	O
statistically	B-MED
significant	I-MED
decrease	B-MED
in	O
interest	B-MED
for	O
further	O
digital	B-MED
interactive	B-MED
materials	B-MED
reported	B-MED
by	O
students	B-MED
in	O
the	O
game	B-MED
group	B-MED
(	O
P	O
=	O
0.146	O
)	O
.	O
Our	O
experience	B-MED
supported	O
the	O
use	O
of	O
a	O
traditional	B-MED
lecture	B-MED
over	O
a	O
digital	B-MED
game	I-MED
module	O
.	O
While	O
these	O
results	O
might	O
be	O
affected	B-MED
by	O
the	O
specific	B-MED
lecture	B-MED
and	O
digital	B-MED
content	B-MED
in	O
any	O
given	O
comparison	B-MED
,	O
a	O
digital	B-MED
module	B-MED
is	O
not	O
always	O
the	O
superior	O
option	O
.	O
The	O
use	O
of	O
informativity	O
in	O
the	O
development	B-MED
of	O
robust	B-MED
viromics	I-MED
-based	O
examinations	B-MED
Metagenomics	B-MED
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	B-MED
communities	I-MED
responsible	O
for	O
maintaining	B-MED
life	I-MED
on	I-MED
this	I-MED
planet	I-MED
.	O
Sequencing	B-MED
efforts	O
often	O
uncover	O
novel	O
genetic	B-MED
content	I-MED
;	O
this	O
is	O
most	O
evident	O
for	O
phage	B-MED
communities	I-MED
,	O
in	O
which	O
upwards	O
of	O
90	O
%	O
of	O
all	O
sequences	B-MED
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-MED
in	O
current	O
data	B-MED
repositories	I-MED
.	O
For	O
the	O
small	B-MED
fraction	I-MED
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
BLAST	B-MED
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	B-MED
of	O
a	O
viral	B-MED
taxon	I-MED
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O
Homology	B-MED
-based	O
classification	B-MED
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	B-MED
repositories	I-MED
capture	O
but	O
a	O
small	B-MED
fraction	I-MED
of	O
phage	B-MED
diversity	I-MED
.	O
Furthermore	O
,	O
lateral	B-MED
gene	B-MED
transfer	I-MED
is	O
pervasive	B-MED
within	O
phage	B-MED
communities	I-MED
.	O
As	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	B-MED
gene	I-MED
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	B-MED
viral	I-MED
species	I-MED
.	O
Rather	O
,	O
it	O
is	O
just	O
that	O
:	O
an	O
indication	B-MED
of	O
the	O
presence	O
of	O
a	O
specific	B-MED
gene	I-MED
.	O
To	O
circumvent	O
this	O
limitation	B-MED
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-MED
of	I-MED
viral	I-MED
metagenomic	I-MED
datasets	I-MED
.	O
BLAST	B-MED
hits	O
are	O
weighted	O
,	O
integrating	B-MED
the	I-MED
sequence	I-MED
identity	I-MED
and	O
length	B-MED
of	I-MED
alignments	I-MED
as	O
well	O
as	O
a	O
taxonomic	B-MED
signal	I-MED
,	O
such	O
that	O
each	B-MED
gene	I-MED
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	B-MED
content	I-MED
.	O
Through	O
this	O
quantifiable	B-MED
metric	I-MED
,	O
predictions	B-MED
of	O
viral	B-MED
community	I-MED
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O
As	O
a	O
proof	B-MED
-	I-MED
of	I-MED
-	I-MED
concept	I-MED
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	B-MED
and	O
applied	O
to	O
seven	O
freshwater	B-MED
viral	I-MED
metagenomes	I-MED
.	O
While	O
providing	O
a	O
robust	B-MED
method	I-MED
for	O
evaluating	O
viral	B-MED
metagenomic	I-MED
data	I-MED
,	O
the	O
tool	B-MED
is	O
versatile	B-MED
and	O
can	O
easily	O
be	O
customized	B-MED
to	O
investigations	B-MED
of	O
any	O
environment	B-MED
or	O
biome	B-MED
.	O
Size	B-MED
matters	O
to	O
function	O
:	O
Brain	B-MED
volume	I-MED
correlates	B-MED
with	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
across	O
healthy	B-MED
individuals	B-MED
A	O
fundamental	O
issue	O
in	O
neuroscience	B-MED
is	O
to	O
understand	O
the	O
structural	B-MED
substrates	B-MED
of	O
neural	O
activities	O
.	O
Intrinsic	B-MED
brain	B-MED
activity	I-MED
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	B-MED
functions	I-MED
.	O
Structurally	O
,	O
cognitive	B-MED
functions	I-MED
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
.	O
Therefore	O
,	O
an	O
association	B-MED
between	O
intrinsic	B-MED
brain	B-MED
activities	I-MED
and	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
can	O
be	O
hypothesized	O
,	O
and	O
brain	B-MED
volume	I-MED
/	O
size	B-MED
may	O
impact	B-MED
intrinsic	B-MED
brain	B-MED
activity	I-MED
in	O
human	B-MED
brains	B-MED
.	O
The	O
present	O
study	B-MED
aimed	O
to	O
explicitly	O
investigate	B-MED
this	O
brain	B-MED
structure	I-MED
-	O
function	B-MED
relationship	B-MED
using	O
two	O
large	O
independent	O
cohorts	B-MED
of	O
176	O
and	O
236	O
young	B-MED
adults	I-MED
.	O
Structural	B-MED
-	O
MRI	B-MED
was	O
performed	B-MED
to	O
estimate	B-MED
the	O
brain	B-MED
volume	I-MED
,	O
and	O
resting	B-MED
-	I-MED
state	I-MED
functional	I-MED
-	I-MED
MRI	I-MED
was	O
applied	O
to	O
extract	O
the	O
amplitude	B-MED
of	I-MED
low	I-MED
-	I-MED
frequency	I-MED
fluctuations	I-MED
(	O
ALFF	B-MED
)	O
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
.	O
Intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	B-MED
correlation	B-MED
between	O
whole	B-MED
-	I-MED
brain	I-MED
size	I-MED
and	O
ALFF	B-MED
.	O
Moreover	O
,	O
specific	B-MED
brain	B-MED
lobes	I-MED
/	O
regions	B-MED
,	O
including	O
the	O
frontal	B-MED
lobe	I-MED
,	O
the	O
left	B-MED
middle	I-MED
frontal	I-MED
gyrus	I-MED
,	O
anterior	B-MED
cingulate	I-MED
gyrus	I-MED
,	O
Rolandic	B-MED
operculum	I-MED
,	O
and	O
insula	B-MED
,	O
also	O
showed	O
a	O
reliable	B-MED
,	O
positive	B-MED
volume	B-MED
-	O
ALFF	B-MED
correlation	B-MED
in	O
the	O
two	O
cohorts	B-MED
.	O
These	O
findings	O
offer	O
direct	B-MED
,	O
empirical	B-MED
evidence	B-MED
of	I-MED
a	O
strong	B-MED
association	B-MED
between	O
brain	B-MED
size	I-MED
/	O
volume	B-MED
and	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	B-MED
substrates	B-MED
of	O
the	O
intrinsic	B-MED
brain	B-MED
activity	I-MED
of	O
the	O
human	B-MED
brain	B-MED
.	O
Macular	B-MED
Ganglion	B-MED
Cell	I-MED
-	O
Inner	B-MED
Plexiform	I-MED
Layer	I-MED
Thickness	B-MED
Is	O
Associated	B-MED
with	I-MED
Clinical	B-MED
Progression	I-MED
in	O
Mild	B-MED
Cognitive	I-MED
Impairment	I-MED
and	O
Alzheimers	B-MED
Disease	I-MED
We	O
investigated	O
the	O
association	O
of	O
the	O
macular	B-MED
ganglion	B-MED
cell	I-MED
-	O
inner	B-MED
plexiform	I-MED
layer	I-MED
(	O
GCIPL	B-MED
)	O
and	O
peripapillary	B-MED
retinal	I-MED
nerve	I-MED
fiber	I-MED
layer	I-MED
(	O
RNFL	B-MED
)	O
thicknesses	B-MED
with	O
disease	B-MED
progression	I-MED
in	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
(	O
MCI	B-MED
)	O
and	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
.	O
We	O
recruited	O
42	O
patients	B-MED
with	O
AD	B-MED
,	O
26	O
with	O
MCI	B-MED
,	O
and	O
66	O
normal	O
elderly	B-MED
controls	I-MED
.	O
The	O
thicknesses	B-MED
of	O
the	O
RNFL	B-MED
and	O
GCIPL	B-MED
were	O
measured	O
via	O
spectral	B-MED
-	I-MED
domain	I-MED
optic	I-MED
coherent	I-MED
tomography	I-MED
in	O
all	O
participants	B-MED
at	O
baseline	B-MED
.	O
The	O
patients	B-MED
with	O
MCI	B-MED
or	O
AD	B-MED
underwent	O
clinical	B-MED
and	O
neuropsychological	B-MED
tests	I-MED
at	O
baseline	B-MED
and	O
once	B-MED
every	I-MED
year	I-MED
thereafter	I-MED
for	I-MED
2	I-MED
years	I-MED
.	O
The	O
Clinical	B-MED
Dementia	I-MED
Rating	I-MED
scale	I-MED
-	I-MED
Sum	I-MED
of	I-MED
Boxes	I-MED
(	O
CDR	B-MED
-	I-MED
SB	I-MED
)	O
score	B-MED
exhibited	O
significant	O
negative	B-MED
relationships	B-MED
with	O
the	O
average	B-MED
GCIPL	I-MED
thickness	B-MED
(	O
β	O
=	O
-0.15	O
,	O
p	O
<	O
0.05	O
)	O
and	O
the	O
GCIPL	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
superonasal	B-MED
,	O
and	O
inferonasal	B-MED
sectors	I-MED
.	O
The	O
composite	B-MED
memory	I-MED
score	I-MED
exhibited	O
significant	O
positive	B-MED
associations	B-MED
with	O
the	O
average	B-MED
GCIPL	I-MED
thickness	B-MED
and	O
the	O
GCIPL	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
inferonasal	B-MED
,	O
and	O
inferotemporal	B-MED
sectors	I-MED
.	O
The	O
temporal	B-MED
RNFL	I-MED
thickness	B-MED
,	O
the	O
average	O
and	O
minimum	O
GCIPL	B-MED
thicknesses	B-MED
,	O
and	O
the	O
GCIPL	B-MED
thickness	B-MED
in	O
the	O
inferonasal	B-MED
,	O
inferior	B-MED
,	O
and	O
inferotemporal	B-MED
sectors	I-MED
at	O
baseline	B-MED
were	O
significantly	O
reduced	B-MED
in	O
MCI	B-MED
patients	B-MED
who	O
were	O
converted	O
to	O
AD	B-MED
compared	O
to	O
stable	O
MCI	B-MED
patients	B-MED
.	O
The	O
change	O
of	O
CDR	B-MED
-	I-MED
SB	I-MED
from	O
baseline	B-MED
to	O
2	O
years	B-MED
exhibited	O
significant	O
negative	B-MED
associations	B-MED
with	O
the	O
average	O
(	O
β	O
=	O
-0.150	O
,	O
p	O
=	O
0.006	O
)	O
and	O
minimum	B-MED
GCIPL	I-MED
thicknesses	B-MED
as	O
well	O
as	O
GCIPL	B-MED
thickness	B-MED
in	O
the	O
superotemporal	B-MED
,	O
superior	B-MED
,	O
superonasal	B-MED
,	O
and	O
inferonasal	B-MED
sectors	I-MED
at	O
baseline	B-MED
.	O
Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	B-MED
thickness	B-MED
represents	O
a	O
promising	O
biomarker	B-MED
for	O
monitoring	O
the	O
progression	B-MED
of	O
MCI	B-MED
and	O
AD	B-MED
.	O
Expressional	B-MED
divergence	B-MED
of	O
insect	B-MED
GOX	B-MED
genes	I-MED
:	O
From	O
specialist	O
to	O
generalist	O
glucose	B-MED
oxidase	I-MED
Insect	B-MED
herbivores	I-MED
often	O
secrete	B-MED
glucose	B-MED
oxidase	I-MED
(	O
GOX	B-MED
)	O
onto	O
plants	B-MED
to	O
counteract	B-MED
plant	B-MED
defenses	B-MED
and	O
potential	B-MED
pathogens	B-MED
.	O
Whether	O
generalist	O
herbivores	B-MED
always	O
have	O
significantly	B-MED
higher	I-MED
GOX	B-MED
activities	B-MED
than	O
their	O
specialist	O
counterparts	B-MED
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown	O
.	O
To	O
address	O
these	O
two	O
general	O
questions	O
,	O
we	O
subjected	O
larvae	B-MED
of	O
a	O
pair	O
of	O
sister	O
species	B-MED
differed	O
mainly	O
in	O
host	O
range	O
,	O
the	O
generalist	O
Helicoverpa	B-MED
armigera	I-MED
and	O
its	O
specialist	O
counterpart	B-MED
Helicoverpa	B-MED
assulta	I-MED
,	O
to	O
the	O
same	O
sets	O
of	O
stage	O
,	O
protein	B-MED
to	O
digestible	B-MED
carbohydrate	B-MED
(	O
P	O
:	O
C	O
)	O
ratio	O
,	O
allelochemical	B-MED
or	O
host	B-MED
plant	I-MED
treatments	B-MED
for	O
simultaneous	O
analyses	O
of	O
GOX	B-MED
transcripts	B-MED
and	O
activities	B-MED
in	O
their	O
labial	B-MED
glands	I-MED
.	O
GOX	B-MED
activity	B-MED
and	O
transcripts	B-MED
are	O
upregulated	B-MED
concurrently	O
with	O
food	B-MED
ingestion	B-MED
and	O
body	B-MED
growth	I-MED
,	O
downregulated	B-MED
with	O
stopping	O
ingestion	B-MED
and	O
wandering	B-MED
for	O
pupation	B-MED
in	O
both	O
species	B-MED
.	O
The	O
three	O
tested	O
host	B-MED
plants	I-MED
upregulated	B-MED
GOX	B-MED
transcripts	B-MED
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
GOX	B-MED
activity	B-MED
in	O
both	O
species	B-MED
.	O
There	O
were	O
significant	O
differences	O
in	O
both	O
GOX	B-MED
transcripts	B-MED
and	O
activity	B-MED
elicited	O
by	O
allelochemicals	B-MED
,	O
but	O
only	O
in	O
GOX	B-MED
transcripts	B-MED
by	O
P	O
:	O
C	O
ratios	O
in	O
both	O
species	B-MED
.	O
GOX	B-MED
activities	B-MED
were	O
higher	O
in	O
H.	B-MED
armigera	I-MED
than	O
H.	B-MED
assulta	I-MED
in	O
all	O
the	O
comparable	O
treatments	O
,	O
but	O
GOX	B-MED
transcripts	B-MED
were	O
significantly	B-MED
higher	I-MED
either	O
in	O
generalists	O
or	O
in	O
specialists	O
,	O
depending	O
on	O
the	O
developmental	B-MED
stages	I-MED
,	O
host	B-MED
plants	I-MED
,	O
P	O
:	O
C	O
ratio	O
and	O
allelochemicals	B-MED
they	O
encounter	B-MED
.	O
These	O
data	B-MED
indicate	O
that	O
the	O
greater	B-MED
GOX	B-MED
activity	B-MED
in	O
generalist	O
herbivores	B-MED
is	O
not	O
achieved	O
by	O
greater	B-MED
transcription	B-MED
rate	O
,	O
but	O
by	O
greater	O
transcript	B-MED
stability	O
,	O
greater	O
translation	B-MED
rate	O
,	O
better	B-MED
enzyme	I-MED
stability	I-MED
and/or	O
their	O
combination	O
.	O
Proteomics	B-MED
analysis	B-MED
of	O
the	O
endogenous	B-MED
,	O
constitutive	O
,	O
leaf	B-MED
SUMOylome	B-MED
SUMOylation	B-MED
is	O
a	O
post	B-MED
-	I-MED
translational	I-MED
modification	I-MED
which	O
regulates	B-MED
a	O
number	O
of	O
critical	B-MED
biological	B-MED
processes	I-MED
in	O
,	O
for	O
example	O
mammals	B-MED
,	O
yeast	B-MED
and	O
plants	B-MED
.	O
In	O
order	O
to	O
fully	O
understand	B-MED
the	O
functional	B-MED
effects	I-MED
of	O
SUMOylation	B-MED
an	O
essential	B-MED
first	O
step	O
is	O
the	O
identification	B-MED
of	O
endogenous	B-MED
targets	B-MED
for	O
SUMOylation	B-MED
.	O
Here	O
we	O
report	B-MED
the	O
results	B-MED
of	O
using	O
a	O
recently	O
developed	O
proteomic	B-MED
approach	I-MED
based	O
on	O
the	O
use	O
of	O
3D	B-MED
gels	B-MED
to	O
identify	O
the	O
endogenous	B-MED
SUMO	B-MED
targets	B-MED
in	O
leaves	B-MED
of	O
Solanum	B-MED
tuberosum	I-MED
.	O
By	O
using	O
3D	B-MED
gels	B-MED
we	O
avoid	O
the	O
problem	O
of	O
co	B-MED
-	I-MED
migration	I-MED
of	O
proteins	B-MED
,	O
which	O
is	O
a	O
major	B-MED
limitation	B-MED
of	O
2D	B-MED
gels	B-MED
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	B-MED
sensitive	I-MED
CyDye	B-MED
DIGE	I-MED
fluor	I-MED
saturation	I-MED
dyes	I-MED
.	O
Using	O
this	O
new	O
method	O
we	O
have	O
identified	B-MED
39	O
individual	B-MED
proteins	I-MED
as	O
probable	B-MED
SUMO	B-MED
targets	B-MED
in	O
leaves	B-MED
of	O
Solanum	B-MED
tuberosum	I-MED
.	O
The	O
advantages	O
of	O
this	O
method	B-MED
compared	O
with	O
other	O
approaches	B-MED
are	O
discussed	O
,	O
and	O
possible	B-MED
future	B-MED
developments	B-MED
are	O
outlined	O
.	O
The	O
authors	B-MED
have	O
no	O
conflicts	B-MED
of	I-MED
interest	I-MED
to	O
declare	O
.	O
All	O
authors	B-MED
have	O
approved	B-MED
the	O
manuscript	B-MED
and	O
agree	B-MED
with	O
submission	B-MED
to	O
Journal	B-MED
of	I-MED
Proteomics	I-MED
.	O
'	O
You	O
ca	O
n't	O
be	O
a	O
person	B-MED
and	O
a	O
docto	B-MED
r	O
'	O
:	O
the	O
work	B-MED
-	I-MED
life	I-MED
balance	I-MED
of	O
doctors	B-MED
in	O
training	B-MED
-a	O
qualitative	B-MED
study	I-MED
Investigate	B-MED
the	O
work	B-MED
-	I-MED
life	I-MED
balance	I-MED
of	O
doctors	B-MED
in	O
training	B-MED
in	O
the	O
UK	B-MED
from	O
the	O
perspectives	O
of	O
trainers	B-MED
and	O
trainees	O
.	O
Qualitative	B-MED
semistructured	O
focus	O
groups	O
and	O
interviews	B-MED
with	O
trainees	O
and	O
trainers	B-MED
.	O
Postgraduate	B-MED
medical	I-MED
training	I-MED
in	O
London	B-MED
,	O
Yorkshire	B-MED
and	O
Humber	B-MED
,	O
Kent	B-MED
,	O
Surrey	B-MED
and	O
Sussex	B-MED
,	O
and	O
Wales	B-MED
during	O
the	O
junior	B-MED
doctor	I-MED
contract	B-MED
dispute	B-MED
at	O
the	O
end	O
of	O
2015	O
.	O
Part	O
of	O
a	O
larger	O
General	B-MED
Medical	I-MED
Council	I-MED
study	B-MED
about	O
the	O
fairness	O
of	O
postgraduate	B-MED
medical	I-MED
training	I-MED
.	O
96	O
trainees	O
and	O
41	O
trainers	B-MED
.	O
Trainees	O
comprised	O
UK	B-MED
graduates	B-MED
and	O
International	B-MED
Medical	I-MED
Graduates	I-MED
,	O
across	O
all	O
stages	O
of	O
training	B-MED
in	O
6	O
specialties	B-MED
(	O
General	B-MED
Practice	I-MED
,	O
Medicine	B-MED
,	O
Obstetrics	B-MED
and	I-MED
Gynaecology	I-MED
,	O
Psychiatry	B-MED
,	O
Radiology	B-MED
,	O
Surgery	B-MED
)	O
and	O
Foundation	B-MED
.	O
Postgraduate	B-MED
training	I-MED
was	O
characterised	O
by	O
work	B-MED
-	I-MED
life	I-MED
imbalance	I-MED
.	O
Long	B-MED
hours	B-MED
at	O
work	B-MED
were	O
typically	O
supplemented	O
with	O
revision	B-MED
and	O
completion	B-MED
of	O
the	O
e	B-MED
-	I-MED
portfolio	I-MED
.	O
Trainees	O
regularly	O
moved	O
workplaces	B-MED
which	O
could	O
disrupt	B-MED
their	O
personal	B-MED
lives	I-MED
and	O
sometimes	O
led	O
to	O
separation	B-MED
from	O
friends	B-MED
and	O
family	B-MED
.	O
This	O
made	O
it	O
challenging	O
to	O
cope	B-MED
with	O
personal	O
pressures	O
,	O
the	O
stresses	B-MED
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	B-MED
and	O
training	B-MED
,	O
while	O
also	O
leaving	B-MED
trainees	O
with	O
a	O
lack	B-MED
of	O
social	B-MED
support	I-MED
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-MED
of	O
training	B-MED
.	O
Low	B-MED
morale	B-MED
and	O
harm	B-MED
to	O
well	B-MED
-	I-MED
being	I-MED
resulted	O
in	O
some	O
trainees	O
feeling	B-MED
dehumanised	B-MED
.	O
Work	B-MED
-	I-MED
life	I-MED
imbalance	I-MED
was	O
particularly	O
severe	B-MED
for	O
those	O
with	O
children	B-MED
and	O
especially	O
women	B-MED
who	O
faced	O
a	O
lack	B-MED
of	O
less	B-MED
-	I-MED
than	I-MED
-	O
full	B-MED
-	I-MED
time	I-MED
positions	I-MED
and	O
discriminatory	B-MED
attitudes	B-MED
.	O
Female	B-MED
trainees	O
frequently	O
talked	B-MED
about	O
having	O
to	O
choose	B-MED
a	O
specialty	B-MED
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work	B-MED
-	I-MED
life	I-MED
balance	I-MED
such	O
as	O
General	B-MED
Practice	I-MED
.	O
The	O
proposed	O
junior	B-MED
doctor	I-MED
contract	B-MED
was	O
felt	O
to	O
exacerbate	B-MED
existing	B-MED
problems	B-MED
.	O
A	O
lack	B-MED
of	O
work	B-MED
-	I-MED
life	I-MED
balance	I-MED
in	O
postgraduate	B-MED
medical	I-MED
training	I-MED
negatively	B-MED
impacted	B-MED
on	O
trainees	O
'	O
learning	B-MED
and	O
well	B-MED
-	I-MED
being	I-MED
.	O
Women	B-MED
with	O
children	B-MED
were	O
particularly	O
affected	B-MED
,	O
suggesting	O
this	O
group	B-MED
would	O
benefit	B-MED
the	O
greatest	B-MED
from	O
changes	B-MED
to	O
improve	B-MED
the	O
work	B-MED
-	I-MED
life	I-MED
balance	I-MED
of	O
trainees	O
.	O
Exploring	O
Consumer	B-MED
and	O
Patient	B-MED
Knowledge	B-MED
,	O
Behavior	B-MED
,	O
and	O
Attitude	B-MED
Toward	B-MED
Medicinal	B-MED
and	O
Lifestyle	B-MED
Products	I-MED
Purchased	B-MED
From	O
the	O
Internet	B-MED
:	O
A	O
Web	B-MED
-	O
Based	B-MED
Survey	B-MED
In	O
recent	O
years	O
,	O
lifestyle	B-MED
products	I-MED
have	O
emerged	O
to	O
help	O
improve	B-MED
people	B-MED
's	I-MED
physical	B-MED
and	O
mental	B-MED
performance	B-MED
.	O
The	O
Internet	B-MED
plays	O
a	O
major	B-MED
role	B-MED
in	O
the	O
spread	B-MED
of	O
these	O
products	B-MED
.	O
However	O
,	O
the	O
literature	B-MED
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	B-MED
of	O
medicines	B-MED
purchased	B-MED
from	O
the	O
Internet	B-MED
and	O
the	O
impact	B-MED
of	O
counterfeit	B-MED
medicines	I-MED
on	O
public	B-MED
health	B-MED
.	O
Little	O
or	O
no	B-MED
data	I-MED
are	I-MED
available	I-MED
on	O
the	O
authenticity	B-MED
of	O
lifestyle	B-MED
products	I-MED
and	O
actual	O
toxicity	B-MED
associated	B-MED
with	I-MED
their	O
use	B-MED
and	O
misuse	B-MED
.	O
Our	O
aim	O
was	O
to	O
investigate	B-MED
consumer	B-MED
and	O
patient	B-MED
attitudes	I-MED
toward	B-MED
the	O
purchase	B-MED
of	O
lifestyle	B-MED
products	I-MED
from	O
the	O
Internet	B-MED
,	O
their	O
knowledge	B-MED
of	O
product	B-MED
authenticity	B-MED
and	O
toxicity	B-MED
,	O
and	O
their	O
experiences	B-MED
with	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
.	O
A	O
Web	B-MED
-	O
based	B-MED
study	B-MED
was	O
performed	B-MED
between	O
May	O
2014	O
and	O
May	O
2015	O
.	O
Uniform	B-MED
collection	B-MED
of	I-MED
data	I-MED
was	O
performed	B-MED
through	B-MED
an	O
anonymous	B-MED
online	B-MED
questionnaire	B-MED
.	O
Participants	B-MED
were	O
invited	O
worldwide	B-MED
via	O
email	B-MED
,	O
social	B-MED
media	I-MED
,	O
or	O
personal	B-MED
communication	I-MED
to	O
complete	B-MED
the	O
online	B-MED
questionnaire	B-MED
.	O
A	O
total	B-MED
of	O
320	O
participants	B-MED
completed	B-MED
the	O
questionnaire	B-MED
.	O
The	O
results	B-MED
of	O
the	O
questionnaire	B-MED
showed	O
that	O
208	O
(	O
65.0	O
%	O
)	O
participants	B-MED
purchased	B-MED
lifestyle	B-MED
products	I-MED
from	O
the	O
Internet	B-MED
mainly	B-MED
due	B-MED
to	I-MED
convenience	B-MED
and	O
reduced	B-MED
cost	B-MED
.	O
More	B-MED
than	I-MED
half	B-MED
(	O
55.6	O
%	O
,	O
178/320	O
)	O
of	O
participants	B-MED
purchased	B-MED
cosmetic	B-MED
products	I-MED
,	O
whereas	O
only	O
a	O
minority	B-MED
purchased	B-MED
medicinal	B-MED
products	I-MED
.	O
Yet	O
,	O
62.8	O
%	O
(	O
201/320	O
)	O
of	O
participants	B-MED
were	O
aware	B-MED
of	O
the	O
presence	B-MED
of	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
from	O
the	O
Internet	B-MED
,	O
and	O
11.9	O
%	O
(	O
38/320	O
)	O
experienced	B-MED
counterfeit	B-MED
products	B-MED
.	O
In	O
only	O
0.9	O
%	O
(	O
3/320	O
)	O
of	O
those	O
cases	B-MED
were	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
reported	B-MED
to	O
authorities	B-MED
.	O
Moreover	O
,	O
7.2	O
%	O
(	O
23/320	O
)	O
of	O
the	O
participants	B-MED
experienced	B-MED
adverse	B-MED
effects	I-MED
due	O
to	O
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
.	O
In	O
summary	O
,	O
patients	B-MED
experienced	B-MED
counterfeit	B-MED
lifestyle	B-MED
products	I-MED
that	O
resulted	B-MED
in	I-MED
adverse	B-MED
effects	I-MED
on	O
their	O
health	B-MED
.	O
Although	O
certain	O
adverse	B-MED
effects	I-MED
were	O
reported	B-MED
in	O
this	O
study	B-MED
,	O
counterfeit	B-MED
products	B-MED
were	O
underreported	B-MED
to	O
authorities	B-MED
.	O
Further	O
public	B-MED
awareness	I-MED
campaigns	I-MED
and	O
patient	B-MED
education	I-MED
are	O
needed	B-MED
.	O
Geographical	B-MED
Factors	B-MED
Associated	B-MED
With	I-MED
Health	B-MED
Disparities	I-MED
in	O
Prostate	B-MED
Cancer	I-MED
Treatment	B-MED
variation	B-MED
in	O
prostate	B-MED
cancer	I-MED
is	O
common	O
,	O
and	O
it	O
is	O
driven	O
by	O
clinical	B-MED
and	O
clinician	B-MED
factors	B-MED
,	O
patient	B-MED
preferences	I-MED
,	O
availability	B-MED
of	I-MED
resources	B-MED
,	O
and	O
access	B-MED
to	O
physicians	B-MED
and	O
treating	B-MED
facilities	I-MED
.	O
Most	O
research	B-MED
on	O
treatment	B-MED
disparities	B-MED
in	O
men	B-MED
with	O
prostate	B-MED
cancer	I-MED
has	O
focused	O
on	O
race	B-MED
and	O
socioeconomic	B-MED
factors	I-MED
.	O
However	O
,	O
the	O
geography	B-MED
of	O
disparities	B-MED
-	O
capturing	O
racial	B-MED
and	O
socioeconomic	B-MED
differences	I-MED
based	O
on	O
where	O
patients	B-MED
live	B-MED
-	O
can	O
provide	O
insight	O
into	O
barriers	B-MED
to	O
care	B-MED
and	O
help	O
identify	O
outlier	O
areas	B-MED
in	O
which	O
access	B-MED
to	O
care	B-MED
,	O
health	B-MED
resources	I-MED
,	O
or	O
both	O
are	O
more	O
pronounced	O
.	O
Research	B-MED
regarding	O
treatment	B-MED
patterns	B-MED
and	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
using	O
the	O
Geographical	B-MED
Information	I-MED
System	I-MED
(	O
GIS	B-MED
)	O
was	O
searched	B-MED
.	O
Studies	B-MED
were	O
limited	O
to	O
English	B-MED
-	I-MED
language	I-MED
articles	B-MED
and	O
research	B-MED
focused	O
on	O
US	B-MED
populations	B-MED
.	O
A	O
total	O
of	O
43	O
articles	B-MED
were	O
found	O
;	O
of	O
those	O
,	O
30	O
provided	O
information	B-MED
about	O
or	O
used	O
spatial	B-MED
or	O
geographical	B-MED
analyses	B-MED
to	O
assess	B-MED
and	O
describe	O
differences	B-MED
or	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
and	O
its	O
treatment	B-MED
.	O
Two	O
additional	O
GIS	B-MED
resources	O
were	O
included	O
.	O
The	O
research	B-MED
on	O
geographical	B-MED
and	O
spatial	B-MED
determinants	I-MED
of	O
prostate	B-MED
cancer	I-MED
disparities	B-MED
was	O
reviewed	B-MED
.	O
We	O
also	O
examined	O
geographical	B-MED
analyses	B-MED
at	O
the	O
state	B-MED
level	I-MED
,	O
focusing	O
on	O
Florida	B-MED
.	O
Overall	O
,	O
we	O
described	O
a	O
geographical	B-MED
framework	O
to	O
disparities	B-MED
that	O
affect	O
men	B-MED
with	O
prostate	B-MED
cancer	I-MED
and	O
reviewed	B-MED
existing	O
published	O
evidence	B-MED
supporting	O
the	O
interplay	O
of	O
geographical	B-MED
factors	B-MED
and	O
disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
.	O
Disparities	B-MED
in	O
prostate	B-MED
cancer	I-MED
are	O
common	B-MED
and	O
persistent	B-MED
,	O
and	O
notable	O
differences	O
in	O
treatment	B-MED
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata	O
.	O
Geographical	B-MED
analysis	B-MED
provides	O
additional	O
information	B-MED
about	O
where	O
disparate	B-MED
groups	B-MED
live	B-MED
and	O
also	O
helps	O
to	O
map	B-MED
access	B-MED
to	O
care	B-MED
.	O
This	O
information	B-MED
can	O
be	O
used	O
by	O
public	B-MED
health	I-MED
officials	I-MED
,	O
health	B-MED
-	I-MED
systems	I-MED
administrators	I-MED
,	O
clinicians	B-MED
,	O
and	O
policymakers	B-MED
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	B-MED
barriers	B-MED
that	O
contribute	O
to	O
disparities	B-MED
in	I-MED
care	I-MED
.	O
Utility	B-MED
and	O
applicability	B-MED
of	O
the	O
"	B-MED
Childhood	I-MED
Obesity	I-MED
Risk	I-MED
Evaluation	I-MED
"	I-MED
(	I-MED
CORE)-index	I-MED
in	O
predicting	O
obesity	B-MED
in	O
childhood	B-MED
and	O
adolescence	B-MED
in	O
Greece	B-MED
from	O
early	B-MED
life	B-MED
:	O
the	O
"	O
National	O
Action	O
Plan	O
for	O
Public	O
Health	O
"	O
Early	B-MED
identification	B-MED
of	O
infants	B-MED
being	O
at	O
high	B-MED
risk	I-MED
to	O
become	O
obese	B-MED
at	O
their	O
later	B-MED
childhood	B-MED
or	O
adolescence	B-MED
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-MED
prevention	B-MED
initiative	B-MED
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
"	B-MED
Childhood	I-MED
Obesity	I-MED
Risk	I-MED
Evaluation	I-MED
(	I-MED
CORE	I-MED
)	I-MED
"	I-MED
index	I-MED
as	O
a	O
screening	B-MED
tool	B-MED
for	O
the	O
early	B-MED
prediction	B-MED
of	O
obesity	B-MED
in	O
childhood	B-MED
and	O
adolescence	B-MED
.	O
Anthropometric	B-MED
,	O
socio	B-MED
-	I-MED
demographic	I-MED
data	I-MED
were	O
collected	B-MED
cross	B-MED
-	I-MED
sectionally	I-MED
and	O
retrospectively	B-MED
from	O
a	O
representative	O
sample	B-MED
of	O
5946	O
children	B-MED
,	O
and	O
adolescents	B-MED
and	O
were	O
combined	O
for	O
calculating	B-MED
the	O
CORE	B-MED
-	I-MED
index	I-MED
score	I-MED
.	O
Logistic	B-MED
regression	I-MED
analyses	I-MED
were	O
performed	O
to	O
examine	O
the	O
associations	B-MED
of	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
score	I-MED
with	O
obesity	B-MED
by	O
gender	B-MED
and	O
age	B-MED
group	I-MED
,	O
and	O
cut	B-MED
-	I-MED
off	I-MED
point	I-MED
analysis	I-MED
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	B-MED
value	B-MED
of	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
score	I-MED
that	O
differentiates	B-MED
obese	B-MED
from	O
non	B-MED
-	I-MED
obese	I-MED
children	I-MED
.	O
Mean	B-MED
CORE	I-MED
-	I-MED
index	I-MED
score	I-MED
in	O
the	O
total	B-MED
sample	B-MED
was	O
3.06	O
(	O
sd	B-MED
1.92	O
)	O
units	O
(	O
range	O
0	O
-	O
11	O
units	O
)	O
.	O
Each	O
unit	O
increase	B-MED
in	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
score	I-MED
was	O
found	O
to	O
be	O
associated	B-MED
with	I-MED
a	O
30	O
%	O
(	O
95	O
%	O
C.I.	B-MED
1.24	O
-	O
1.36	O
)	O
increased	B-MED
likelihood	B-MED
for	O
obesity	B-MED
in	O
childhood	B-MED
or	O
adolescence	B-MED
,	O
while	O
the	O
optimal	B-MED
cut	B-MED
-	I-MED
off	I-MED
value	I-MED
of	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
score	I-MED
that	O
predicted	B-MED
obesity	B-MED
with	O
the	O
highest	B-MED
possible	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
was	O
found	O
to	O
be	O
3.5	O
.	O
The	O
present	O
study	O
supports	O
the	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
as	O
a	O
screening	B-MED
tool	B-MED
for	O
the	O
early	B-MED
identification	B-MED
of	O
infants	B-MED
that	O
are	O
potentially	O
at	O
a	O
higher	B-MED
risk	I-MED
for	O
becoming	O
obese	B-MED
at	O
their	O
childhood	B-MED
and	O
adolescence	B-MED
.	O
This	O
tool	B-MED
could	O
be	O
routinely	O
used	O
by	O
health	B-MED
professionals	I-MED
to	O
identify	O
infants	B-MED
at	O
high	B-MED
risk	I-MED
and	O
provide	O
appropriate	O
counselling	B-MED
to	O
their	O
parents	B-MED
and	O
caregivers	B-MED
so	O
as	O
to	O
maximize	O
the	O
effectiveness	B-MED
of	O
early	B-MED
obesity	B-MED
prevention	B-MED
initiatives	B-MED
.	O
What	O
is	O
known	O
?	O
•	O
Childhood	B-MED
obesity	B-MED
has	O
reached	O
epidemic	B-MED
proportions	I-MED
worldwide	O
.	O
•	O
Certain	O
perinatal	B-MED
and	O
socio	B-MED
-	I-MED
demographic	I-MED
indices	I-MED
that	O
were	O
previously	O
identified	B-MED
as	O
correlates	O
of	O
childhood	B-MED
obesity	B-MED
in	O
children	B-MED
were	O
combined	O
to	O
develop	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
,	O
a	O
screening	B-MED
tool	B-MED
that	O
estimates	O
obesity	B-MED
risk	B-MED
in	O
9	O
-	O
13	O
year	B-MED
-	I-MED
old	I-MED
children	B-MED
.	O
What	O
is	O
new	O
?	O
•	O
The	O
utility	B-MED
and	O
applicability	B-MED
of	O
the	O
CORE	B-MED
-	I-MED
index	I-MED
as	O
screening	B-MED
tool	B-MED
can	O
be	O
extended	O
to	O
the	O
age	B-MED
range	O
of	O
6	O
-	O
15	O
years	B-MED
.	O
•	O
The	O
CORE	B-MED
-	I-MED
index	I-MED
is	O
a	O
cost	B-MED
-	I-MED
effective	I-MED
screening	B-MED
tool	B-MED
that	O
can	O
assist	O
health	B-MED
professionals	I-MED
in	O
initiating	O
obesity	B-MED
preventive	B-MED
measures	I-MED
from	O
early	B-MED
life	B-MED
.	O
Internet	B-MED
Gaming	I-MED
Disorder	B-MED
Explains	O
Unique	B-MED
Variance	I-MED
in	O
Psychological	B-MED
Distress	I-MED
and	O
Disability	B-MED
After	O
Controlling	O
for	O
Comorbid	B-MED
Depression	B-MED
,	O
OCD	B-MED
,	O
ADHD	B-MED
,	O
and	O
Anxiety	B-MED
This	O
study	B-MED
extends	O
knowledge	B-MED
about	O
the	O
relationship	B-MED
of	O
Internet	B-MED
Gaming	I-MED
Disorder	I-MED
(	O
IGD	B-MED
)	O
to	O
other	O
established	O
mental	B-MED
disorders	I-MED
by	O
exploring	O
comorbidities	B-MED
with	O
anxiety	B-MED
,	O
depression	B-MED
,	O
Attention	B-MED
Deficit	I-MED
Hyperactivity	I-MED
Disorder	I-MED
(	O
ADHD	B-MED
)	O
,	O
and	O
obsessive	B-MED
compulsive	I-MED
disorder	I-MED
(	O
OCD	B-MED
)	O
,	O
and	O
assessing	B-MED
whether	O
IGD	B-MED
accounts	O
for	O
unique	B-MED
variance	I-MED
in	O
distress	B-MED
and	O
disability	B-MED
.	O
An	O
online	B-MED
survey	I-MED
was	O
completed	O
by	O
a	O
convenience	B-MED
sample	I-MED
that	O
engages	O
in	O
Internet	B-MED
gaming	I-MED
(	O
N	O
=	O
404	O
)	O
.	O
Participants	B-MED
meeting	B-MED
criteria	I-MED
for	O
IGD	B-MED
based	O
on	O
the	O
Personal	B-MED
Internet	I-MED
Gaming	I-MED
Disorder	I-MED
Evaluation-9	I-MED
(	O
PIE-9	B-MED
)	O
reported	O
higher	B-MED
comorbidity	I-MED
with	O
depression	B-MED
,	O
OCD	B-MED
,	O
ADHD	B-MED
,	O
and	O
anxiety	B-MED
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
IGD	B-MED
criteria	B-MED
.	O
IGD	B-MED
explained	O
a	O
small	O
proportion	B-MED
of	O
unique	B-MED
variance	I-MED
in	O
distress	B-MED
(	O
1	O
%	O
)	O
and	O
disability	B-MED
(	O
3	O
%	O
)	O
.	O
IGD	B-MED
accounted	O
for	O
a	O
larger	B-MED
proportion	I-MED
of	O
unique	B-MED
variance	I-MED
in	O
disability	B-MED
than	O
anxiety	B-MED
and	O
ADHD	B-MED
,	O
and	O
a	O
similar	O
proportion	B-MED
to	O
depression	B-MED
.	O
Replications	B-MED
with	O
clinical	B-MED
samples	I-MED
using	O
longitudinal	B-MED
designs	I-MED
and	O
structured	B-MED
diagnostic	I-MED
interviews	I-MED
are	O
required	O
.	O
THSD7A	B-MED
expression	B-MED
in	O
human	B-MED
cancer	B-MED
We	O
recently	O
described	O
a	O
case	O
of	O
a	O
Thrombospondin	B-MED
Type-1	I-MED
Domain	I-MED
containing	I-MED
7A	I-MED
(	O
THSD7A	B-MED
)	O
associated	O
membranous	B-MED
nephropathy	I-MED
in	O
a	O
female	B-MED
patient	I-MED
who	O
was	O
synchronously	B-MED
suffering	B-MED
from	O
a	O
THSD7A	B-MED
-	O
positive	B-MED
malignancy	B-MED
.	O
We	O
here	O
investigated	O
the	O
role	O
of	O
THSD7A	B-MED
as	O
a	O
new	O
potential	O
tumor	B-MED
antigen	I-MED
by	O
evaluating	O
over	O
20	O
000	O
tissue	B-MED
spots	I-MED
in	O
more	O
than	O
70	O
different	O
tumor	B-MED
entities	I-MED
by	O
immunohistochemistry	B-MED
using	O
tissue	B-MED
microarrays	I-MED
.	O
THSD7A	B-MED
expression	B-MED
was	O
highly	O
variable	O
in	O
different	B-MED
neoplasias	I-MED
with	O
differing	O
staining	B-MED
patterns	I-MED
.	O
Both	O
gain	B-MED
and	I-MED
loss	I-MED
of	O
THSD7A	B-MED
expression	B-MED
compared	O
to	O
expression	B-MED
status	I-MED
in	O
non	B-MED
-	I-MED
tumor	I-MED
tissue	I-MED
were	O
linked	O
to	O
tumor	B-MED
-	I-MED
specific	I-MED
markers	I-MED
in	O
the	O
different	O
tumor	B-MED
entities	I-MED
and	O
were	O
of	O
prognostic	B-MED
value	I-MED
.	O
The	O
potential	O
role	O
of	O
THSD7A	B-MED
in	O
tumor	B-MED
development	I-MED
and	O
therapy	B-MED
needs	O
further	O
investigation	O
.	O
Impaired	B-MED
mobility	I-MED
,	O
depressed	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
are	O
independently	O
associated	O
with	O
disability	B-MED
in	O
older	O
cancer	B-MED
outpatients	B-MED
:	O
The	O
prospective	O
Physical	B-MED
Frailty	I-MED
in	O
Elderly	B-MED
Cancer	B-MED
patients	I-MED
(	O
PF	B-MED
-	O
EC	B-MED
)	O
cohort	B-MED
study	I-MED
To	O
assess	O
the	O
prevalence	O
of	O
disability	B-MED
and	O
the	O
oncologic	B-MED
factors	I-MED
associated	O
with	O
disability	B-MED
in	O
older	O
outpatients	B-MED
with	O
cancer	B-MED
.	O
The	O
Physical	B-MED
Frailty	I-MED
in	O
Elderly	B-MED
Cancer	B-MED
patients	I-MED
(	O
PF	B-MED
-	O
EC	B-MED
)	O
study	O
(	O
France	B-MED
)	O
is	O
a	O
prospective	B-MED
bicentric	I-MED
observational	I-MED
cohort	I-MED
study	I-MED
.	O
Two	O
hundred	O
and	O
ninety	O
outpatients	B-MED
with	O
cancer	B-MED
were	O
included	O
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
analysis	I-MED
of	O
oncologic	B-MED
factors	I-MED
and	O
geriatric	B-MED
variables	B-MED
associated	O
with	O
disability	B-MED
that	O
were	O
collected	O
using	O
a	O
comprehensive	B-MED
geriatric	B-MED
assessment	I-MED
(	O
CGA	B-MED
)	O
was	O
conducted	O
.	O
Disability	B-MED
was	O
defined	O
as	O
impairment	B-MED
in	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
(	O
ADL	B-MED
)	O
and/or	O
instrumental	B-MED
activities	I-MED
of	I-MED
daily	I-MED
living	I-MED
(	B-MED
IADL	I-MED
)	O
,	O
simplified	O
to	O
four	O
items	O
.	O
Univariate	B-MED
and	O
multivariate	B-MED
logistic	B-MED
models	I-MED
of	O
disabled	B-MED
patients	I-MED
were	O
performed	O
.	O
The	O
three	O
final	O
multivariate	B-MED
models	B-MED
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
curve	I-MED
(	O
AUC	B-MED
/	O
ROC	B-MED
)	O
of	O
the	O
logistic	B-MED
model	I-MED
.	O
The	O
mean	O
age	O
was	O
80.6years	O
,	O
and	O
51	O
%	O
of	O
the	O
patients	O
were	O
women	B-MED
with	O
various	O
types	O
of	O
cancer	B-MED
.	O
The	O
prevalence	O
of	O
disability	B-MED
was	O
67.6	O
%	O
.	O
No	O
oncologic	B-MED
factors	I-MED
(	O
cancer	B-MED
site	I-MED
,	O
cancer	B-MED
extension	I-MED
)	O
were	O
associated	O
with	O
disability	B-MED
.	O
Impaired	B-MED
mobility	I-MED
,	O
poor	B-MED
functional	I-MED
status	I-MED
,	O
depressive	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
were	O
independently	O
associated	O
with	O
disability	B-MED
(	O
P<0.05	O
)	O
.	O
The	O
AUC	O
/	O
ROC	O
of	O
the	O
final	O
models	O
was	O
similar	O
.	O
Disability	B-MED
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-MED
outpatients	B-MED
before	O
cancer	B-MED
treatment	I-MED
but	O
was	O
not	O
associated	O
with	O
oncologic	B-MED
factors	I-MED
.	O
Impaired	B-MED
mobility	I-MED
,	O
depressed	B-MED
mood	I-MED
,	O
cognitive	B-MED
impairment	I-MED
and	O
polypharmacy	B-MED
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-MED
.	O
Identifying	O
these	O
factors	O
prior	O
to	O
cancer	B-MED
treatment	I-MED
could	O
enable	O
the	O
implementation	O
of	O
corrective	B-MED
actions	I-MED
to	O
improve	O
patient	B-MED
autonomy	B-MED
before	O
treatment	B-MED
and	O
during	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Blood	B-MED
Collection	I-MED
Tubes	I-MED
and	O
Storage	B-MED
Temperature	I-MED
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
for	O
Measuring	B-MED
25	I-MED
-	I-MED
Hydroxyvitamin	I-MED
D	I-MED
A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
for	O
measurement	B-MED
of	I-MED
25	I-MED
-	I-MED
hydroxyvitamin	I-MED
D	I-MED
(	O
25OHD	B-MED
)	O
with	O
VACUETTE	B-MED
®	I-MED
tubes	I-MED
with	I-MED
Serum	I-MED
Clot	I-MED
Activator	I-MED
and	I-MED
Gel	I-MED
.	O
Here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	B-MED
or	O
temperatures	B-MED
affected	O
25OHD	B-MED
results	I-MED
obtained	O
with	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
.	O
Serum	B-MED
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	B-MED
blood	I-MED
collection	I-MED
tubes	I-MED
from	O
three	O
manufacturers	O
,	O
and	O
25OHD	B-MED
was	I-MED
analyzed	I-MED
using	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
and	O
liquid	B-MED
chromatography	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
(	O
LC	B-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
)	O
immediately	O
or	O
after	O
storage	O
at	O
4	O
°	O
C	O
or	O
-80	O
°	O
C	O
for	O
48	O
h.	O
Significantly	B-MED
higher	I-MED
25OHD	B-MED
values	I-MED
were	O
found	O
when	O
using	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
with	O
VACUETTE	B-MED
®	I-MED
tubes	I-MED
with	I-MED
serum	I-MED
clot	I-MED
activator	I-MED
and	I-MED
gel	I-MED
and	O
VACUETTE	B-MED
®	I-MED
tubes	I-MED
with	I-MED
clot	I-MED
activator	I-MED
but	O
no	O
gel	O
compared	O
with	O
VACUETTE	B-MED
®	I-MED
tubes	I-MED
with	O
no	O
additives	O
.	O
The	O
25OHD	B-MED
values	I-MED
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC	B-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
.	O
Moreover	O
,	O
after	O
storage	O
at	O
-80	O
°	O
C	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER	B-MED
®	I-MED
tubes	I-MED
with	I-MED
serum	I-MED
clot	I-MED
activator	I-MED
and	I-MED
ge	I-MED
l	O
significantly	B-MED
increased	I-MED
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
%	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
.	O
VACUETTE	B-MED
®	I-MED
tubes	I-MED
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD	B-MED
results	I-MED
obtained	O
using	O
the	O
Siemens	B-MED
ADVIA	I-MED
Centaur	I-MED
XP	I-MED
system	O
.	O
Additionally	O
,	O
the	O
composition	O
of	O
serum	B-MED
collected	O
in	O
IMPROVEVACUTER	B-MED
®	I-MED
tubes	I-MED
was	O
affected	O
by	O
freezing	B-MED
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	B-MED
assay	B-MED
platform	I-MED
.	O
Shout	O
louder	O
about	O
poor	B-MED
pay	I-MED
It	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
NHS	B-MED
pay	B-MED
campaign	B-MED
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
NHS	B-MED
or	O
with	O
the	O
public	B-MED
.	O
Extra	O
carbohydrate	B-MED
binding	I-MED
module	I-MED
contributes	B-MED
to	O
the	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
of	O
a	O
non	B-MED
-	I-MED
modular	I-MED
hydrolase	I-MED
family	O
5	B-MED
endoglucanase	I-MED
from	O
Fomitiporia	B-MED
mediterranea	I-MED
MF3/22	I-MED
FmEG	B-MED
from	O
Fomitiporia	B-MED
mediterranea	I-MED
is	O
a	O
non	B-MED
-	I-MED
modular	I-MED
endoglucanase	I-MED
composed	O
of	O
a	O
24	B-MED
-	I-MED
amino	I-MED
acids	I-MED
extension	B-MED
and	O
13	B-MED
-	I-MED
amino	I-MED
acids	I-MED
linker	B-MED
-	I-MED
like	I-MED
peptide	I-MED
at	O
the	O
N	B-MED
-	I-MED
terminus	I-MED
and	O
a	O
312	B-MED
-	I-MED
amino	I-MED
acids	I-MED
GH5	B-MED
catalytic	I-MED
domain	I-MED
(	O
CD	B-MED
)	O
at	O
the	O
C	B-MED
-	I-MED
terminus	I-MED
.	O
In	O
this	O
study	O
,	O
six	O
FmEG	B-MED
derivatives	O
with	O
deletion	B-MED
of	O
N	B-MED
-	I-MED
terminal	I-MED
fragments	I-MED
or	O
fusion	B-MED
with	O
an	O
extra	O
family	B-MED
1	I-MED
carbohydrate	I-MED
-	I-MED
binding	I-MED
module	I-MED
(	O
CBM1	B-MED
)	O
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	B-MED
of	O
CBM1	B-MED
to	O
FmEG	B-MED
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
.	O
FmEG	B-MED
showed	O
a	O
weak	O
processivity	B-MED
and	O
released	O
cellobiose	B-MED
(	O
G2	B-MED
)	O
and	O
cellotriose	B-MED
(	O
G3	B-MED
)	O
as	O
main	B-MED
end	I-MED
products	I-MED
,	O
and	O
cellotriose	B-MED
(	O
G4	B-MED
)	O
as	O
minor	B-MED
end	I-MED
product	I-MED
from	O
filter	B-MED
paper	I-MED
(	O
FP	B-MED
)	O
,	O
but	O
more	O
amount	O
of	O
G4	B-MED
was	O
released	O
from	O
regenerated	B-MED
amorphous	I-MED
cellulose	I-MED
(	O
RAC	B-MED
)	O
.	O
All	O
derivatives	B-MED
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-MED
(	O
CMC	B-MED
)	O
with	O
the	O
same	B-MED
optimal	I-MED
pH	B-MED
(	O
7.0	O
)	O
and	O
temperature	B-MED
(	O
50	O
°	O
C	O
)	O
.	O
However	O
,	O
fusing	O
an	O
extra	O
CBM1	B-MED
to	O
FmEG	B-MED
△	I-MED
24	I-MED
or	O
FmEG	B-MED
△	I-MED
37	I-MED
with	O
flexible	B-MED
peptide	I-MED
significantly	O
improved	O
its	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
to	O
FP	B-MED
and	O
RAC	B-MED
.	O
Overall	O
,	O
1.79-	O
and	O
1.84	O
-	O
fold	O
increases	O
in	O
the	O
soluble	B-MED
/insoluble	O
product	O
ratio	B-MED
on	O
FP	B-MED
,	O
and	O
1.38-	O
and	O
1.39	O
-	O
fold	O
increases	O
on	O
RAC	B-MED
,	O
compared	O
to	O
FmEG	B-MED
△	I-MED
24	I-MED
,	O
were	O
recorded	O
for	O
CBM1	B-MED
-	O
FmEG	B-MED
△	I-MED
24	I-MED
and	O
CBM1	B-MED
-linker-	O
FmEG	B-MED
△	I-MED
24	I-MED
,	O
respectively	O
.	O
Meanwhile	O
,	O
they	O
displayed	O
2.64-	O
and	O
2.67	B-MED
-	I-MED
fold	I-MED
more	I-MED
activity	I-MED
on	O
RAC	B-MED
,	O
and	O
1.68-	O
and	O
1.77	O
-	O
fold	O
on	O
FP	B-MED
,	O
respectively	O
.	O
Similar	O
improvement	O
was	O
also	O
obtained	O
for	O
CBM1	B-MED
-linker-	O
FmEG	B-MED
△	I-MED
37	I-MED
as	O
compared	O
with	O
FmEG	B-MED
△	I-MED
37	I-MED
.	O
Interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
CBM1	B-MED
with	O
FmEG	B-MED
also	O
caused	O
an	O
alteration	B-MED
of	O
cleavage	B-MED
pattern	I-MED
on	O
insoluble	B-MED
celluloses	I-MED
.	O
Our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
may	O
arise	O
from	O
CBM1	B-MED
binding	B-MED
affinity	I-MED
.	O
The	O
N	B-MED
-	I-MED
terminal	I-MED
24-	I-MED
or	I-MED
37	I-MED
-	I-MED
amino	I-MED
acids	I-MED
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	B-MED
separation	I-MED
of	O
the	O
two	B-MED
domains	I-MED
required	O
for	O
processivity	B-MED
and	O
catalytic	B-MED
activity	I-MED
.	O
In	O
addition	O
,	O
deletion	B-MED
of	O
the	O
N	B-MED
-	I-MED
terminal	I-MED
24-	I-MED
or	I-MED
37	I-MED
-	I-MED
amino	I-MED
acids	I-MED
led	O
to	O
significant	B-MED
reduction	I-MED
in	O
thermostability	B-MED
but	O
not	O
the	O
enzymatic	B-MED
activity	I-MED
.	O
Intensive	O
social	B-MED
cognitive	B-MED
treatment	I-MED
(	O
can	O
do	O
treatment	B-MED
)	O
with	O
participation	B-MED
of	O
support	O
partners	B-MED
in	O
persons	B-MED
with	O
relapsing	B-MED
remitting	I-MED
multiple	I-MED
sclerosis	I-MED
:	O
observation	B-MED
of	O
improved	B-MED
self	B-MED
-	I-MED
efficacy	I-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
,	O
anxiety	B-MED
and	O
depression	B-MED
1	O
year	B-MED
later	O
In	O
persons	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
self	B-MED
-	I-MED
efficacy	I-MED
positively	B-MED
affects	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
(	O
HRQoL	B-MED
)	O
and	O
physical	B-MED
activity	I-MED
.	O
In	O
a	O
previous	O
study	O
we	O
observed	B-MED
that	O
6	O
months	B-MED
after	O
an	O
intensive	O
3-	O
day	B-MED
social	B-MED
cognitive	B-MED
treatment	I-MED
(	O
Can	O
Do	O
treatment	B-MED
)	O
with	O
the	O
participation	B-MED
of	O
support	O
partners	B-MED
,	O
self	B-MED
-	I-MED
efficacy	I-MED
and	O
HRQoL	B-MED
had	O
improved	B-MED
in	O
persons	B-MED
with	O
relapsing	B-MED
remitting	I-MED
MS	I-MED
(	O
RRMS	B-MED
)	O
.	O
Given	O
the	O
chronic	B-MED
nature	B-MED
of	I-MED
the	I-MED
disease	I-MED
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	B-MED
changes	B-MED
may	O
last	O
.	O
Can	O
Do	O
treatment	B-MED
was	O
given	O
to	O
60	O
persons	B-MED
with	O
MS	B-MED
and	O
their	O
support	O
partners	B-MED
.	O
At	O
baseline	B-MED
and	O
12	O
months	B-MED
after	O
treatment	B-MED
self	B-MED
-	I-MED
efficacy	I-MED
control	B-MED
,	O
self	B-MED
-	I-MED
efficacy	I-MED
function	B-MED
,	O
physical	B-MED
and	O
mental	B-MED
HRQoL	B-MED
,	O
anxiety	B-MED
,	O
depression	B-MED
and	O
fatigue	B-MED
were	O
assessed	B-MED
via	O
self	B-MED
-	I-MED
report	I-MED
questionnaires	B-MED
.	O
Differences	B-MED
were	O
tested	B-MED
via	O
a	O
paired	B-MED
t	I-MED
test	I-MED
.	O
Of	O
the	O
57	O
persons	B-MED
with	O
MS	B-MED
that	O
completed	B-MED
the	O
baseline	B-MED
assessment	B-MED
and	O
the	O
3-	O
day	B-MED
treatment	B-MED
,	O
38	O
filled	O
in	O
the	O
12th	O
month	B-MED
questionnaires	B-MED
(	O
response	B-MED
rate	B-MED
66.7	O
%	O
)	O
,	O
22	O
with	O
RRMS	B-MED
and	O
14	O
with	O
progressive	B-MED
MS	B-MED
.	O
In	O
the	O
RR	B-MED
group	B-MED
self	B-MED
-	I-MED
efficacy	I-MED
control	B-MED
had	O
increased	B-MED
by	O
20.2	O
%	O
and	O
physical	B-MED
HRQoL	B-MED
by	O
15.0	O
%	O
,	O
and	O
depression	B-MED
and	O
anxiety	B-MED
had	O
decreased	B-MED
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	B-MED
in	O
mental	B-MED
HRQoL	B-MED
(	O
+17	O
%	O
)	O
and	O
fatigue	B-MED
(	O
-20	O
%	O
)	O
failed	B-MED
to	O
be	O
statistically	B-MED
significant	I-MED
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O
In	O
the	O
progressive	B-MED
group	B-MED
no	O
changes	B-MED
suggestive	B-MED
of	I-MED
improvement	B-MED
were	O
seen	O
.	O
The	O
findings	B-MED
suggest	B-MED
that	O
a	O
3-	O
day	B-MED
intensive	O
social	B-MED
cognitive	B-MED
treatment	I-MED
(	O
Can	O
Do	O
treatment	B-MED
)	O
with	O
the	O
participation	B-MED
of	O
support	O
partners	B-MED
may	O
have	O
long	B-MED
lasting	I-MED
beneficial	B-MED
effects	B-MED
on	O
the	O
self	B-MED
-	I-MED
efficacy	I-MED
and	O
HRQoL	B-MED
in	O
persons	B-MED
with	O
RRMS	B-MED
;	O
and	O
that	O
improvements	B-MED
in	O
anxiety	B-MED
and	O
depression	B-MED
,	O
not	O
seen	O
in	O
the	O
6-	O
month	B-MED
study	O
,	O
may	O
yet	O
develop	B-MED
at	O
12	O
months	B-MED
.	O
Map	B-MED
learning	I-MED
and	O
working	B-MED
memory	I-MED
:	O
Multimodal	O
learning	B-MED
strategies	I-MED
The	O
current	O
research	B-MED
investigated	O
whether	O
learning	B-MED
spatial	I-MED
information	B-MED
from	O
a	O
map	B-MED
involves	O
different	B-MED
modalities	I-MED
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	B-MED
memory	I-MED
.	O
In	O
four	O
experiments	O
,	O
participants	B-MED
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	B-MED
interference	B-MED
task	I-MED
(	O
high	O
cognitive	B-MED
load	I-MED
)	O
or	O
without	B-MED
interference	I-MED
(	O
low	O
cognitive	B-MED
load	I-MED
)	O
.	O
The	O
modality	B-MED
of	O
interference	B-MED
varied	O
between	O
experiments	O
.	O
Experiment	O
1	O
used	O
a	O
tapping	B-MED
task	I-MED
(	O
visuospatial	B-MED
)	O
,	O
Experiment	O
2	O
a	O
backwards	B-MED
counting	I-MED
task	I-MED
(	O
verbal	B-MED
)	O
,	O
Experiment	O
3	O
an	O
articulatory	B-MED
suppression	B-MED
task	I-MED
(	O
verbal	B-MED
)	O
and	O
Experiment	O
4	O
an	O
n	B-MED
-	I-MED
back	I-MED
task	I-MED
(	O
central	B-MED
executive	I-MED
)	O
.	O
Spatial	B-MED
recall	I-MED
was	O
assessed	B-MED
in	O
two	O
tests	O
,	O
directional	B-MED
judgements	I-MED
and	O
map	B-MED
drawing	I-MED
.	O
Cognitive	B-MED
load	I-MED
was	O
found	O
to	O
affect	O
spatial	B-MED
recall	I-MED
detrimentally	O
regardless	B-MED
of	O
interference	B-MED
modality	B-MED
.	O
The	O
findings	O
suggest	O
that	O
when	O
learning	B-MED
maps	I-MED
people	O
use	O
a	O
multimodal	O
learning	B-MED
strategy	I-MED
,	O
utilising	O
resources	B-MED
from	O
all	O
components	O
of	O
working	B-MED
memory	I-MED
.	O
Creative	O
approach	O
for	O
successful	B-MED
aging	B-MED
:	O
A	O
pilot	B-MED
study	I-MED
of	O
an	O
intergenerational	B-MED
health	B-MED
promotion	I-MED
program	I-MED
To	O
develop	O
and	O
evaluate	B-MED
the	O
effectiveness	B-MED
of	O
an	O
intergenerational	B-MED
health	B-MED
promotion	I-MED
program	I-MED
.	O
This	O
was	O
an	O
action	O
research	B-MED
project	I-MED
.	O
A	O
total	B-MED
of	O
34	O
participants	B-MED
attended	O
the	O
12-	O
week	B-MED
program	B-MED
and	O
completed	B-MED
the	O
pre	B-MED
-	I-MED
test	I-MED
and	I-MED
post	I-MED
-	I-MED
test	I-MED
.	O
There	O
were	O
16	O
middle	B-MED
-	I-MED
aged	I-MED
and	O
nine	O
older	B-MED
adults	I-MED
recruited	B-MED
from	O
a	O
district	O
of	O
Taipei	B-MED
,	O
and	O
nine	O
young	B-MED
adults	I-MED
recruited	B-MED
from	O
the	O
principal	B-MED
investigator	I-MED
's	I-MED
university	B-MED
.	O
The	O
"	O
Attitudes	B-MED
toward	I-MED
Aging	I-MED
Scale	I-MED
"	O
and	O
the	O
"	O
Spiritual	B-MED
Health	I-MED
Scale	I-MED
"	O
were	O
two	O
assessment	B-MED
instruments	B-MED
used	O
in	O
the	O
study	B-MED
.	O
The	O
results	B-MED
showed	O
that	O
there	O
were	O
significant	B-MED
improvements	B-MED
in	O
the	O
Attitudes	B-MED
toward	I-MED
Aging	I-MED
Scale	I-MED
for	O
the	O
young	B-MED
adult	I-MED
group	B-MED
(	O
aged	O
18	O
-	O
29	O
years	B-MED
)	O
and	O
in	O
the	O
Spiritual	B-MED
Health	I-MED
Scale	I-MED
for	O
the	O
older	B-MED
adult	I-MED
group	B-MED
(	O
aged	B-MED
65	O
-	O
80	O
years	B-MED
)	O
.	O
The	O
evaluation	B-MED
showed	O
that	O
participants	B-MED
were	O
satisfied	B-MED
with	O
the	O
program	B-MED
.	O
The	O
results	B-MED
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	B-MED
aging	B-MED
and	O
intergenerational	B-MED
learning	B-MED
.	O
Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
••	O
:	O
••-••.	O
Adoptively	O
transferred	O
natural	B-MED
killer	I-MED
cells	I-MED
maintain	O
long	O
-	O
term	O
antitumor	B-MED
activity	I-MED
by	O
epigenetic	B-MED
imprinting	I-MED
and	O
CD4(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
help	O
Natural	B-MED
killer	I-MED
(	I-MED
NK	I-MED
)	I-MED
cell	I-MED
infusions	B-MED
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	B-MED
with	O
different	O
types	O
of	O
cancer	B-MED
.	O
The	O
optimal	O
strategies	O
for	O
NK	B-MED
cell	I-MED
activation	B-MED
prior	O
to	O
infusion	B-MED
are	O
still	O
under	O
debate	O
.	O
There	O
is	O
recent	O
evidence	O
that	O
NK	B-MED
cells	I-MED
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B-MED
IL-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
.	O
The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long	O
-	O
term	O
NK	B-MED
cell	I-MED
antitumor	B-MED
activity	I-MED
are	O
incompletely	O
under	O
-	O
stood	O
.	O
Here	O
,	O
we	O
show	O
that	O
NK	B-MED
cells	I-MED
preactivated	O
in	B-MED
vitro	I-MED
with	O
IL-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
,	O
but	O
not	O
with	O
IL-15	B-MED
alone	O
,	O
maintained	O
high	O
antitumor	B-MED
activity	I-MED
even	O
1	B-MED
mo	I-MED
after	O
transfer	O
into	O
lymphopenic	B-MED
RAG-2(-/-	B-MED
)	I-MED
γc(-/-	O
)	O
mice	B-MED
.	O
The	O
NK	B-MED
cell	I-MED
intrinsic	O
ability	O
for	O
IFNγ	B-MED
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non	B-MED
-	I-MED
coding	I-MED
sequence	I-MED
(	O
CNS	B-MED
)	O
1	O
in	O
the	O
Ifng	B-MED
locus	B-MED
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B-MED
of	O
Ifng	B-MED
.	O
In	O
a	O
xenograft	B-MED
melanoma	I-MED
mouse	I-MED
model	I-MED
,	O
human	B-MED
IL-12	B-MED
/	O
15	B-MED
/	O
18	B-MED
-preactivated	O
NK	B-MED
cells	I-MED
rejected	O
tumors	B-MED
more	O
efficiently	O
.	O
In	O
RAG-2(-/-	B-MED
)	I-MED
γc(-/-	O
)	O
mice	B-MED
,	O
co	O
-	O
transfer	O
of	O
CD4(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	B-MED
cells	I-MED
for	O
IFNγ	B-MED
production	O
that	O
was	O
dependent	O
on	O
IL-2	B-MED
.	O
CD4(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
activation	B-MED
during	O
homeostatic	B-MED
proliferation	I-MED
required	O
macrophages	B-MED
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	B-MED
cell	I-MED
antitumor	B-MED
activity	I-MED
.	O
Thus	O
,	O
NK	B-MED
cells	I-MED
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	B-MED
by	O
epigenetic	B-MED
imprinting	I-MED
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFNγ	B-MED
-producing	O
phenotype	B-MED
after	O
adoptive	O
transfer	O
.	O
In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B-MED
-preactivated	O
NK	B-MED
cells	I-MED
with	O
CD4(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
activation	B-MED
upon	O
lymphopenic	B-MED
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	B-MED
cell	I-MED
effector	O
function	O
for	O
cancer	B-MED
immunotherapy	I-MED
.	O
Multicentric	B-MED
Castleman	I-MED
disease	I-MED
of	O
hyaline	B-MED
vascular	B-MED
variant	B-MED
presenting	O
with	O
unusual	B-MED
systemic	B-MED
manifestations	B-MED
:	O
a	O
case	B-MED
report	I-MED
Castleman	B-MED
disease	I-MED
is	O
a	O
rare	B-MED
lymphoproliferative	B-MED
disorder	I-MED
presenting	O
with	O
localized	B-MED
or	O
disseminated	B-MED
lymphadenopathy	B-MED
and	O
systemic	B-MED
manifestations	B-MED
.	O
It	O
can	O
be	O
categorized	B-MED
in	O
numerous	B-MED
ways	O
,	O
such	O
as	O
unicentric	B-MED
versus	O
multicentric	B-MED
,	O
histopathological	B-MED
variants	B-MED
(	O
hyaline	B-MED
-	O
vascular	B-MED
,	O
plasma	B-MED
cell	I-MED
,	O
and	O
mixed	B-MED
)	O
,	O
or	O
subtypes	B-MED
based	O
on	O
causative	B-MED
viral	B-MED
infections	I-MED
(	O
human	B-MED
immunodeficiency	I-MED
virus	I-MED
,	O
human	B-MED
herpesvirus-8	I-MED
,	O
or	O
Kaposi	B-MED
sarcoma	I-MED
herpesvirus	I-MED
)	O
.	O
Presentation	O
ranges	O
from	O
asymptomatic	B-MED
to	O
symptoms	B-MED
involving	O
multiple	B-MED
organs	B-MED
.	O
Even	O
though	O
the	O
exact	O
mechanism	B-MED
of	O
pathogenesis	B-MED
is	O
unknown	O
,	O
treatment	B-MED
is	O
directed	B-MED
toward	O
possible	O
etiologies	B-MED
such	O
as	O
interleukin-6	B-MED
,	O
cluster	B-MED
of	I-MED
differentiation	I-MED
20	I-MED
,	O
and	O
viral	B-MED
agents	I-MED
.	O
A	O
36-	O
year	B-MED
-old	O
Sri	B-MED
Lankan	I-MED
woman	B-MED
presented	O
with	O
generalized	O
body	B-MED
swelling	I-MED
and	O
foamy	B-MED
urine	I-MED
of	O
2	O
weeks	B-MED
'	O
duration	B-MED
.	O
Examination	B-MED
revealed	O
pallor	B-MED
;	O
generalized	B-MED
edema	I-MED
;	O
axillary	B-MED
,	O
cervical	B-MED
,	O
and	O
inguinal	B-MED
lymphadenopathy	I-MED
;	O
hypertension	B-MED
;	O
and	O
hepatomegaly	B-MED
.	O
Investigations	B-MED
showed	O
bicytopenia	B-MED
,	O
nephrotic	B-MED
range	I-MED
proteinuria	I-MED
with	O
hypoalbuminemia	B-MED
,	O
hypogammaglobulinemia	B-MED
,	O
and	O
features	B-MED
of	O
hyaline	B-MED
-	O
vascular	B-MED
type	B-MED
Castleman	B-MED
disease	I-MED
in	O
a	O
lymph	B-MED
node	I-MED
biopsy	I-MED
.	O
She	O
was	O
managed	B-MED
with	O
rituximab	B-MED
and	O
had	O
good	O
clinical	B-MED
improvement	B-MED
.	O
Castleman	B-MED
disease	I-MED
has	O
a	O
broad	B-MED
spectrum	B-MED
of	O
clinical	B-MED
manifestations	B-MED
,	O
disease	B-MED
pathogeneses	B-MED
,	O
and	O
associations	B-MED
and/or	O
complications	B-MED
.	O
Medical	B-MED
professionals	B-MED
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	B-MED
because	O
timely	O
diagnosis	B-MED
and	O
aggressive	B-MED
targeted	I-MED
therapy	I-MED
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	B-MED
.	O
Dynamin	B-MED
-	I-MED
related	I-MED
protein	I-MED
1	I-MED
mediates	B-MED
low	B-MED
glucose	I-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
in	O
human	B-MED
arterioles	B-MED
Intensive	O
glycemic	B-MED
regulation	I-MED
has	O
resulted	O
in	O
an	O
increased	B-MED
incidence	B-MED
of	O
hypoglycemia	B-MED
.	O
Hypoglycemic	B-MED
burden	B-MED
correlates	O
with	O
adverse	B-MED
cardiovascular	B-MED
complications	I-MED
and	O
contributes	O
acutely	B-MED
and	O
chronically	B-MED
to	O
endothelial	B-MED
dysfunction	I-MED
.	O
Prior	O
data	B-MED
indicate	O
that	O
mitochondrial	B-MED
dysfunction	I-MED
contributes	O
to	O
hypoglycemia	B-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
,	O
but	O
the	O
mechanisms	B-MED
behind	O
this	O
linkage	B-MED
remain	O
unknown	B-MED
.	O
We	O
attempt	O
to	O
determine	O
whether	O
clinically	B-MED
relevant	B-MED
low	B-MED
-	I-MED
glucose	I-MED
(	O
LG	B-MED
)	O
exposures	B-MED
acutely	B-MED
induce	B-MED
endothelial	B-MED
dysfunction	I-MED
through	O
activation	B-MED
of	O
the	O
mitochondrial	B-MED
fission	I-MED
process	I-MED
.	O
Characterization	B-MED
of	O
mitochondrial	B-MED
morphology	I-MED
was	O
carried	O
out	O
in	O
cultured	B-MED
endothelial	B-MED
cells	I-MED
by	O
using	O
confocal	B-MED
microscopy	I-MED
.	O
Isolated	B-MED
human	B-MED
arterioles	B-MED
were	O
used	O
to	O
explore	O
the	O
effect	B-MED
LG	B-MED
-	O
induced	B-MED
mitochondrial	B-MED
fission	I-MED
has	O
on	O
the	O
formation	B-MED
of	O
detrimental	B-MED
reactive	I-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
,	O
bioavailability	B-MED
of	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
,	O
and	O
endothelial	B-MED
-	I-MED
dependent	I-MED
vascular	I-MED
relaxation	I-MED
.	O
Fluorescence	B-MED
microscopy	I-MED
was	O
employed	O
to	O
visualize	O
changes	B-MED
in	O
mitochondrial	B-MED
ROS	B-MED
and	O
NO	B-MED
levels	B-MED
and	O
videomicroscopy	B-MED
applied	O
to	O
measure	B-MED
vasodilation	B-MED
response	B-MED
.	O
Pharmacological	B-MED
disruption	B-MED
of	O
the	O
profission	B-MED
protein	I-MED
Drp1	B-MED
with	O
Mdivi-1	B-MED
during	O
LG	B-MED
exposure	B-MED
reduced	B-MED
mitochondrial	B-MED
fragmentation	I-MED
among	O
vascular	B-MED
endothelial	I-MED
cells	I-MED
(	O
LG	B-MED
:	O
0.469	O
;	O
LG	B-MED
+	O
Mdivi-1	B-MED
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	B-MED
formation	B-MED
of	O
vascular	B-MED
ROS	B-MED
(	O
LG	B-MED
:	O
2.036	O
;	O
LG	B-MED
+	O
Mdivi-1	B-MED
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	B-MED
the	O
presence	B-MED
of	O
NO	B-MED
(	O
LG	B-MED
:	O
1.352	O
;	O
LG	B-MED
+	O
Mdivi-1	B-MED
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	B-MED
vascular	B-MED
dilation	I-MED
response	B-MED
to	O
acetylcholine	B-MED
(	O
LG	B-MED
:	O
31.6	O
%	O
;	O
LG	B-MED
+	O
Mdivi-1	B-MED
;	O
78.5	O
%	O
at	O
maximum	B-MED
dose	B-MED
;	O
P	O
<	O
0.001	O
)	O
.	O
Additionally	O
,	O
decreased	B-MED
expression	B-MED
of	O
Drp1	B-MED
via	O
siRNA	B-MED
knockdown	B-MED
during	O
LG	B-MED
conditions	B-MED
also	O
improved	B-MED
vascular	B-MED
relaxation	I-MED
.	O
Exposure	B-MED
to	I-MED
LG	B-MED
imparts	O
endothelial	B-MED
dysfunction	I-MED
coupled	B-MED
with	O
altered	B-MED
mitochondrial	B-MED
phenotypes	B-MED
among	O
isolated	B-MED
human	B-MED
arterioles	B-MED
.	O
Disruption	B-MED
of	O
Drp1	B-MED
and	O
subsequent	B-MED
mitochondrial	B-MED
fragmentation	I-MED
events	O
prevents	B-MED
impaired	B-MED
vascular	B-MED
dilation	I-MED
,	O
restores	B-MED
mitochondrial	B-MED
phenotype	B-MED
,	O
and	O
implicates	O
mitochondrial	B-MED
fission	I-MED
as	O
a	O
primary	B-MED
mediator	B-MED
of	O
LG	B-MED
-	O
induced	B-MED
endothelial	B-MED
dysfunction	I-MED
.NEW	O
&	O
NOTEWORTHY	O
Acute	B-MED
low	B-MED
-	I-MED
glucose	I-MED
exposure	B-MED
induces	B-MED
mitochondrial	B-MED
fragmentation	I-MED
in	O
endothelial	B-MED
cells	I-MED
via	O
Drp1	B-MED
and	O
is	O
associated	B-MED
with	I-MED
impaired	B-MED
endothelial	B-MED
function	B-MED
in	O
human	B-MED
arterioles	B-MED
.	O
Targeting	B-MED
of	O
Drp1	B-MED
prevents	B-MED
fragmentation	B-MED
,	O
improves	O
vasofunction	B-MED
,	O
and	O
may	O
provide	O
a	O
therapeutic	B-MED
target	B-MED
for	O
improving	O
cardiovascular	B-MED
complications	I-MED
among	O
diabetics	B-MED
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/	B-MED
.Listen	O
to	O
this	O
article	O
's	O
corresponding	O
podcast	O
@	O
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/.	O
Modifiable	B-MED
Healthy	B-MED
Lifestyle	I-MED
Behaviors	I-MED
:	O
10	O
-	O
Year	O
Health	B-MED
Outcomes	I-MED
From	O
a	O
Health	B-MED
Promotion	I-MED
Program	I-MED
Previous	O
studies	O
have	O
examined	O
the	O
impact	B-MED
of	I-MED
healthy	B-MED
lifestyle	I-MED
choices	I-MED
on	O
health	B-MED
-	I-MED
related	I-MED
outcomes	I-MED
;	O
however	O
,	O
given	O
their	O
fragmented	B-MED
,	O
often	O
cross	B-MED
-	I-MED
sectional	I-MED
nature	I-MED
,	O
assessing	B-MED
the	I-MED
relative	I-MED
impact	I-MED
of	O
daily	O
modifiable	B-MED
behaviors	B-MED
on	O
overall	O
long	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
,	O
particularly	O
for	O
a	O
diverse	O
working	B-MED
adult	I-MED
population	I-MED
,	O
remains	B-MED
challenging	I-MED
.	O
Relationships	O
between	O
ten	O
self	B-MED
-	I-MED
reported	I-MED
healthy	B-MED
lifestyle	I-MED
behaviors	I-MED
and	O
health	B-MED
outcomes	I-MED
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	B-MED
of	O
10,248	O
participants	B-MED
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	B-MED
workplace	B-MED
wellness	B-MED
program	I-MED
were	O
assessed	O
.	O
Cox	B-MED
proportional	I-MED
-	I-MED
hazards	I-MED
models	I-MED
computed	B-MED
hazard	I-MED
ratios	I-MED
(	O
HRs	B-MED
)	O
for	O
lifestyle	B-MED
characteristics	I-MED
associated	O
with	O
time	B-MED
to	O
one	O
of	O
seven	O
self	B-MED
-	I-MED
reported	I-MED
chronic	B-MED
diseases	I-MED
or	O
death	B-MED
.	O
Data	B-MED
were	I-MED
collected	I-MED
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016	O
.	O
Behaviors	B-MED
that	O
most	O
significantly	O
affected	O
future	B-MED
outcomes	I-MED
were	O
low	B-MED
-	I-MED
fat	I-MED
diet	I-MED
,	O
aerobic	B-MED
exercise	I-MED
,	O
nonsmoking	B-MED
,	O
and	O
adequate	B-MED
sleep	I-MED
.	O
A	O
dose	B-MED
-	I-MED
response	I-MED
effect	I-MED
was	O
seen	O
between	O
dietary	B-MED
fat	I-MED
intake	I-MED
and	O
hypertension	B-MED
,	O
obesity	B-MED
,	O
diabetes	B-MED
,	O
heart	B-MED
disease	I-MED
,	O
and	O
hypercholesterolemia	B-MED
.	O
After	O
dietary	B-MED
fat	I-MED
intake	I-MED
,	O
aerobic	B-MED
exercise	I-MED
was	O
the	O
next	O
most	O
significant	O
behavior	B-MED
associated	O
with	O
development	B-MED
of	I-MED
outcomes	I-MED
.	O
Compared	O
with	O
sedentary	B-MED
participants	B-MED
,	O
those	O
who	O
exercised	B-MED
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new	B-MED
-	I-MED
onset	I-MED
diabetes	I-MED
(	O
HR	B-MED
=	O
0.31	O
,	O
95	O
%	O
CI	B-MED
=	O
0.20	O
,	O
0.48	O
)	O
;	O
heart	B-MED
disease	I-MED
(	O
HR	B-MED
=	O
0.46	O
,	O
95	O
%	O
CI	B-MED
=	O
0.27	O
,	O
0.80	O
)	O
;	O
and	O
hypercholesterolemia	B-MED
(	O
HR	B-MED
=	O
0.61	O
,	O
95	O
%	O
CI	B-MED
=	O
0.50	O
,	O
0.74	O
)	O
.	O
Low	B-MED
-	I-MED
fat	I-MED
diet	I-MED
and	O
adequate	B-MED
sleep	I-MED
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy	B-MED
behaviors	I-MED
,	O
such	O
as	O
eating	B-MED
a	I-MED
daily	I-MED
breakfast	I-MED
.	O
Modifiable	B-MED
lifestyle	B-MED
behaviors	I-MED
targeted	O
in	O
health	B-MED
promotion	I-MED
programs	I-MED
should	O
be	O
prioritized	O
in	O
an	O
evidence	B-MED
-	I-MED
based	I-MED
manner	I-MED
.	O
Top	O
priorities	O
for	O
workplace	B-MED
health	B-MED
promotion	I-MED
should	O
include	O
low	B-MED
-	I-MED
fat	I-MED
diet	I-MED
,	O
aerobic	B-MED
exercise	I-MED
,	O
nonsmoking	B-MED
,	O
and	O
adequate	B-MED
sleep	I-MED
.	O
Antenatal	B-MED
consultation	B-MED
following	B-MED
limb	B-MED
malformation	I-MED
discovery	B-MED
using	O
ultrasound	B-MED
scan	I-MED
Our	O
unit	B-MED
has	O
been	O
providing	B-MED
antenatal	B-MED
consultations	B-MED
for	O
30	O
years	O
following	B-MED
the	O
discovery	B-MED
of	O
limb	B-MED
malformation	I-MED
with	O
the	O
fetus	B-MED
.	O
Each	O
of	O
these	O
consultations	B-MED
is	O
specific	B-MED
and	O
carried	B-MED
out	I-MED
by	O
a	O
multi	B-MED
-	I-MED
professional	I-MED
team	I-MED
.	O
It	O
requires	B-MED
a	O
physical	O
and	O
rehabilitation	B-MED
doctor	B-MED
,	O
an	O
orthopedic	B-MED
surgeon	I-MED
,	O
an	O
occupational	B-MED
therapist	I-MED
for	O
upper	B-MED
limb	I-MED
malformation	I-MED
,	O
a	O
physiotherapist	B-MED
for	O
lower	B-MED
malformation	I-MED
and	O
a	O
psychologist	B-MED
.	O
This	O
multidisciplinary	B-MED
consultation	B-MED
is	O
unique	B-MED
because	O
of	O
each	O
pregnancy	B-MED
story	O
,	O
because	O
of	O
each	O
patient	B-MED
life	B-MED
story	I-MED
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	B-MED
when	O
announcing	O
the	O
diagnosis	B-MED
.	O
We	O
deal	O
with	O
couples	B-MED
shocked	B-MED
by	O
the	O
prenatal	B-MED
diagnosis	I-MED
.	O
We	O
help	O
them	O
get	O
acceptance	B-MED
of	O
the	O
child	B-MED
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	B-MED
child	B-MED
.	O
Medical	B-MED
information	I-MED
is	O
often	O
perceived	B-MED
as	O
being	O
"	O
a	O
surfeit	B-MED
of	O
information	B-MED
"	O
difficult	B-MED
to	O
handle	O
by	O
the	O
couple	B-MED
stunned	B-MED
by	O
the	O
overwhelming	B-MED
diagnosis	B-MED
.	O
We	O
must	O
stress	O
that	O
it	O
is	O
critical	B-MED
to	O
not	O
only	O
have	O
a	O
good	O
medical	B-MED
description	I-MED
of	O
the	O
malformations	B-MED
and	O
potential	B-MED
treatments	I-MED
but	O
also	O
a	O
good	O
psychological	B-MED
support	I-MED
(	O
parents	B-MED
personal	B-MED
life	B-MED
story	I-MED
,	O
self	B-MED
-	I-MED
defense	I-MED
mechanism	I-MED
,	O
guilt	B-MED
feeling	I-MED
)	O
.	O
The	O
ethical	B-MED
aspect	I-MED
of	O
this	O
consultation	B-MED
is	O
also	O
important	B-MED
.	O
Team	B-MED
members	B-MED
must	O
be	O
as	O
neutral	B-MED
as	O
possible	B-MED
in	O
their	O
assessments	B-MED
in	O
order	O
to	O
let	O
the	O
couple	B-MED
take	O
the	O
final	O
decision	B-MED
:	O
the	O
continuation	B-MED
of	O
the	O
pregnancy	B-MED
or	O
a	O
request	B-MED
of	O
voluntary	B-MED
termination	B-MED
of	I-MED
pregnancy	I-MED
.	O
These	O
prenatal	B-MED
consultations	B-MED
highlight	O
the	O
importance	B-MED
of	O
the	O
multidisciplinary	B-MED
global	B-MED
care	B-MED
.	O
The	O
cost	B-MED
-	I-MED
effectiveness	I-MED
of	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
therapy	I-MED
for	O
treatment	B-MED
of	O
externalizing	B-MED
disorders	I-MED
,	O
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
:	O
a	O
systematic	O
review	B-MED
Family	B-MED
therapy	I-MED
and	O
family	B-MED
-	I-MED
based	I-MED
treatment	I-MED
has	O
been	O
commonly	O
applied	O
in	O
children	B-MED
and	O
adolescents	B-MED
in	O
mental	B-MED
health	I-MED
care	I-MED
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O
There	O
is	O
an	O
increased	O
interest	O
in	O
economic	B-MED
evaluations	I-MED
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-MED
.	O
The	O
aim	O
of	O
this	O
systematic	O
review	B-MED
is	O
to	O
summarize	O
and	O
evaluate	B-MED
the	O
evidence	O
on	O
cost	B-MED
-	I-MED
effectiveness	I-MED
of	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
therapy	I-MED
for	O
externalizing	B-MED
disorders	I-MED
,	O
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
.	O
A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	B-MED
,	O
Education	B-MED
Resource	I-MED
information	I-MED
Centre	I-MED
(	O
ERIC	B-MED
)	O
,	O
Psycinfo	B-MED
and	O
Cochrane	B-MED
reviews	B-MED
including	O
studies	B-MED
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013	O
.	O
Full	O
economic	B-MED
evaluations	I-MED
investigating	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
interventions	I-MED
for	O
adolescents	B-MED
between	O
10	O
and	O
20	O
years	B-MED
treated	B-MED
for	O
substance	B-MED
use	I-MED
disorders	I-MED
,	O
delinquency	B-MED
or	O
externalizing	B-MED
disorders	I-MED
were	O
included	O
.	O
Seven	O
hundred	O
thirty	O
-	O
one	O
articles	B-MED
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-MED
were	O
initially	O
selected	O
.	O
The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-MED
.	O
The	O
quality	B-MED
of	O
these	O
studies	B-MED
was	O
assessed	B-MED
.	O
Within	O
the	O
identified	O
studies	B-MED
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
interventions	I-MED
and	O
disorders	B-MED
.	O
According	O
to	O
the	O
outcomes	B-MED
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	B-MED
of	O
the	O
economic	B-MED
evaluations	I-MED
was	O
low	O
.	O
Results	O
varied	O
by	O
study	B-MED
.	O
Due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
The	O
quality	B-MED
of	O
the	O
identified	O
economic	B-MED
evaluations	I-MED
of	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
therapy	I-MED
for	O
treatment	B-MED
of	O
externalizing	B-MED
disorders	I-MED
,	O
adolescent	B-MED
substance	B-MED
use	I-MED
disorders	I-MED
and	O
delinquency	B-MED
was	O
insufficient	O
to	O
determine	O
the	O
cost	B-MED
-	I-MED
effectiveness	I-MED
.	O
Although	O
commonly	O
applied	O
,	O
family	B-MED
/	O
family	B-MED
-	I-MED
based	I-MED
therapy	I-MED
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	B-MED
is	O
needed	O
.	O
Real	B-MED
-	I-MED
world	I-MED
impact	I-MED
of	O
non	B-MED
-	I-MED
breast	I-MED
cancer	I-MED
-	I-MED
specific	I-MED
death	I-MED
on	O
overall	B-MED
survival	I-MED
in	O
resectable	B-MED
breast	B-MED
cancer	I-MED
The	O
real	O
-	O
world	O
occurrence	B-MED
rate	I-MED
of	O
non	B-MED
-	I-MED
breast	I-MED
cancer	I-MED
-	I-MED
specific	I-MED
death	I-MED
(	O
non	B-MED
-	I-MED
BCSD	I-MED
)	O
and	O
its	O
impact	B-MED
on	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
are	O
poorly	O
recognized	O
.	O
Women	B-MED
with	O
resectable	B-MED
breast	B-MED
cancer	I-MED
from	O
1990	O
to	O
2007	O
in	O
the	O
Surveillance	B-MED
,	I-MED
Epidemiology	I-MED
,	I-MED
and	I-MED
End	I-MED
Results	I-MED
database	I-MED
(	O
n	O
=	O
199,963	O
)	O
were	O
analyzed	B-MED
.	O
The	O
outcome	B-MED
events	B-MED
of	O
breast	B-MED
cancer	I-MED
were	O
classified	O
as	O
breast	B-MED
cancer	I-MED
-	I-MED
specific	I-MED
death	I-MED
(	O
BCSD	B-MED
)	O
,	O
non	B-MED
-	I-MED
BCSD	I-MED
,	O
or	O
survival	B-MED
.	O
Binary	B-MED
logistics	I-MED
was	O
used	O
to	O
estimate	B-MED
the	O
occurrence	B-MED
rates	I-MED
of	O
non	B-MED
-	I-MED
BCSD	I-MED
and	O
BCSD	B-MED
with	O
different	O
clinicopathological	B-MED
factors	I-MED
.	O
The	O
Gray	B-MED
method	I-MED
was	O
used	O
to	O
measure	B-MED
the	O
cumulative	B-MED
incidence	I-MED
of	O
non	B-MED
-	I-MED
BCSD	I-MED
and	O
BCSD	B-MED
.	O
The	O
ratio	B-MED
of	O
non	B-MED
-	I-MED
BCSDs	I-MED
to	O
all	O
causes	B-MED
of	I-MED
death	I-MED
and	O
stacked	B-MED
cumulative	B-MED
incidence	I-MED
function	B-MED
plots	I-MED
were	O
used	O
to	O
present	O
the	O
impact	B-MED
of	O
non	B-MED
-	I-MED
BCSD	I-MED
on	O
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
.	O
Models	B-MED
of	I-MED
Cox	I-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
and	O
competing	B-MED
risk	I-MED
regression	I-MED
were	O
compared	O
to	O
highlight	O
the	O
suitable	B-MED
model	I-MED
.	O
There	O
were	O
12,879	O
non	B-MED
-	I-MED
BCSDs	I-MED
(	O
6.44	O
%	O
)	O
and	O
28,784	O
BCSDs	B-MED
(	O
14.39	O
%	O
)	O
.	O
The	O
oldest	B-MED
age	I-MED
group	I-MED
(	O
>	O
62	O
years	O
)	O
,	O
black	B-MED
race	I-MED
,	O
and	O
a	O
single	B-MED
or	I-MED
divorced	I-MED
marital	I-MED
status	I-MED
were	O
associated	B-MED
with	I-MED
more	O
non	B-MED
-	I-MED
BCSDs	I-MED
.	O
With	O
adjustments	O
for	O
age	B-MED
,	O
a	O
hormone	B-MED
receptor	I-MED
-	I-MED
positive	I-MED
(	I-MED
HoR+	I-MED
)	I-MED
status	I-MED
was	O
no	O
longer	O
related	O
to	O
increased	B-MED
non	B-MED
-	I-MED
BCSD	I-MED
s.	O
In	O
patients	B-MED
with	O
grade	B-MED
1	I-MED
,	I-MED
stage	I-MED
I	I-MED
disease	I-MED
and	O
an	O
HoR+	B-MED
status	I-MED
as	O
well	O
as	O
the	O
oldest	O
subgroup	O
,	O
a	O
great	O
dilution	O
of	O
non	B-MED
-	I-MED
BCSD	I-MED
on	O
all	O
causes	B-MED
of	I-MED
death	I-MED
could	O
be	O
observed	O
,	O
and	O
this	O
led	O
to	O
incorrect	B-MED
interpretations	I-MED
.	O
The	O
inaccuracy	B-MED
,	O
caused	O
by	O
the	O
commonly	O
used	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
model	I-MED
,	O
could	O
be	O
corrected	O
by	O
a	O
competing	B-MED
risk	I-MED
model	I-MED
.	O
OS	B-MED
was	O
largely	O
impaired	B-MED
by	O
non	B-MED
-	I-MED
BCSD	I-MED
during	O
early	O
breast	B-MED
cancer	I-MED
.	O
For	O
some	O
future	O
clinical	B-MED
trial	I-MED
planning	B-MED
,	O
especially	O
for	O
the	O
oldest	B-MED
patients	B-MED
and	O
those	O
with	O
HoR+	B-MED
breast	B-MED
cancer	I-MED
,	O
non	B-MED
-	I-MED
BCSD	I-MED
should	O
be	O
considered	O
a	O
competing	B-MED
risk	I-MED
event	I-MED
.	O
Cancer	O
2017	O
.	O
©	O
2017	O
American	B-MED
Cancer	I-MED
Society	I-MED
.	O
A	O
16	O
Yin	B-MED
Yang	I-MED
gene	B-MED
expression	I-MED
ratio	B-MED
signature	B-MED
for	O
ER+	B-MED
/	O
node-	B-MED
breast	I-MED
cancer	I-MED
Breast	B-MED
cancer	I-MED
is	O
one	O
of	O
the	O
leading	O
causes	B-MED
of	O
cancer	B-MED
death	B-MED
in	O
women	B-MED
.	O
It	O
is	O
a	O
complex	B-MED
and	O
heterogeneous	B-MED
disease	B-MED
with	O
different	O
clinical	B-MED
outcomes	B-MED
.	O
Stratifying	B-MED
patients	B-MED
into	O
subgroups	B-MED
with	O
different	O
outcomes	B-MED
could	O
help	O
guide	O
clinical	B-MED
decision	I-MED
making	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
used	O
two	O
opposing	O
groups	B-MED
of	O
genes	B-MED
,	O
Yin	B-MED
and	I-MED
Yang	I-MED
,	O
to	O
develop	O
a	O
prognostic	B-MED
expression	B-MED
ratio	B-MED
signature	B-MED
.	O
Using	O
the	O
METABRIC	B-MED
cohort	B-MED
we	O
identified	O
a16-	O
gene	B-MED
signature	I-MED
capable	O
of	O
stratifying	B-MED
breast	B-MED
cancer	I-MED
patients	B-MED
into	O
four	O
risk	B-MED
levels	I-MED
with	O
intention	O
that	O
low	B-MED
-	I-MED
risk	I-MED
patients	B-MED
would	O
not	O
undergo	O
adjuvant	B-MED
systemic	B-MED
therapy	I-MED
,	O
intermediate	B-MED
-	O
low	B-MED
-	I-MED
risk	I-MED
patients	B-MED
will	O
be	O
treated	B-MED
with	I-MED
hormonal	B-MED
therapy	I-MED
only	O
,	O
and	O
intermediate	B-MED
-high-	O
and	O
high	B-MED
-	I-MED
risk	I-MED
groups	I-MED
will	O
be	O
treated	B-MED
by	O
chemotherapy	B-MED
in	O
addition	O
to	O
the	O
hormonal	B-MED
therapy	I-MED
.	O
The	O
16-	O
gene	B-MED
signature	I-MED
for	O
four	O
risk	B-MED
level	I-MED
stratifications	B-MED
of	O
breast	B-MED
cancer	I-MED
patients	B-MED
has	O
been	O
validated	B-MED
using	O
14	O
independent	O
datasets	B-MED
.	O
Notably	O
,	O
the	O
low	B-MED
-	I-MED
risk	I-MED
group	B-MED
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	B-MED
receptor	I-MED
-	I-MED
positive	I-MED
and	O
node	B-MED
negative	I-MED
(	O
ER+	B-MED
/	O
node-	B-MED
)	O
patients	B-MED
from	O
three	O
different	O
datasets	B-MED
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B-MED
therapy	I-MED
had	O
100	O
%	O
15-	O
year	B-MED
disease	B-MED
-	I-MED
specific	I-MED
survival	I-MED
rate	I-MED
.	O
The	O
Concordance	B-MED
Index	I-MED
of	O
YMR	B-MED
for	O
ER+	B-MED
/	O
node	B-MED
negative	I-MED
patients	B-MED
is	O
close	O
to	O
the	O
commercially	B-MED
available	O
signatures	B-MED
.	O
However	O
,	O
YMR	B-MED
showed	O
more	O
significance	B-MED
(	O
HR	B-MED
=	O
3.7	O
,	O
p	O
=	O
8.7e-12	O
)	O
in	O
stratifying	B-MED
ER+	B-MED
/	O
node-	B-MED
subgroup	B-MED
than	O
OncotypeDx	B-MED
(	O
HR	B-MED
=	O
2.7	O
,	O
p	O
=	O
1.3e-7	O
)	O
,	O
MammaPrint	B-MED
(	O
HR	B-MED
=	O
2.5	O
,	O
p	O
=	O
5.8e-7	O
)	O
,	O
rorS	B-MED
(	O
HR	B-MED
=	O
2.4	O
,	O
p	O
=	O
1.4e-6	O
)	O
,	O
and	O
NPI	B-MED
(	O
HR	B-MED
=	O
2.6	O
,	O
p	O
=	O
1.2e-6	O
)	O
.	O
YMR	B-MED
signature	B-MED
may	O
be	O
developed	O
as	O
a	O
clinical	B-MED
tool	B-MED
to	O
select	O
a	O
subgroup	B-MED
of	O
low	B-MED
-	I-MED
risk	I-MED
ER+	B-MED
/	O
node-	B-MED
patients	B-MED
who	O
do	O
not	O
require	O
any	O
adjuvant	B-MED
hormonal	B-MED
therapy	I-MED
(	O
AHT	B-MED
)	O
.	O
Results	B-MED
of	O
an	O
International	B-MED
Postmarketing	I-MED
Surveillance	I-MED
Study	I-MED
of	O
pl	B-MED
-	I-MED
VEGF165	I-MED
Safety	B-MED
and	O
Efficacy	B-MED
in	O
210	O
Patients	B-MED
with	O
Peripheral	B-MED
Arterial	I-MED
Disease	I-MED
The	O
effective	O
treatment	B-MED
of	O
chronic	B-MED
lower	B-MED
limb	I-MED
ischemia	B-MED
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	B-MED
surgeons	I-MED
.	O
Current	O
pharmacological	B-MED
therapies	B-MED
play	O
an	O
auxiliary	O
role	O
and	O
can	O
not	O
prevent	O
disease	B-MED
progression	I-MED
,	O
and	O
new	O
treatment	B-MED
methods	I-MED
are	O
needed	O
.	O
pl	B-MED
-	I-MED
VEGF165	I-MED
,	O
a	O
gene	B-MED
therapy	I-MED
drug	B-MED
,	O
was	O
approved	O
in	O
Russia	B-MED
for	O
the	O
treatment	B-MED
of	O
atherosclerotic	B-MED
peripheral	B-MED
arterial	I-MED
disease	I-MED
(	O
PAD	B-MED
)	O
after	O
clinical	B-MED
studies	I-MED
in	O
2011	O
.	O
The	O
study	B-MED
drug	B-MED
is	O
an	O
original	O
gene	B-MED
construction	I-MED
in	O
which	O
pl	B-MED
-	I-MED
VEGF165	I-MED
1.2	O
mg	O
is	O
the	O
active	B-MED
substance	I-MED
.	O
This	O
postmarketing	B-MED
surveillance	I-MED
study	I-MED
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	B-MED
(	O
identification	O
of	O
uncommon	O
side	B-MED
effects	I-MED
)	O
and	O
efficacy	B-MED
of	O
gene	B-MED
therapy	I-MED
in	O
patients	B-MED
in	O
routine	O
clinical	B-MED
practice	I-MED
.	O
In	O
total	O
,	O
210	O
patients	B-MED
with	O
stage	B-MED
II	I-MED
-	I-MED
III	I-MED
chronic	B-MED
limb	B-MED
ischemia	B-MED
(	O
according	O
to	O
the	O
Fontaine	B-MED
classification	I-MED
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	B-MED
facilities	I-MED
in	O
Russia	B-MED
and	O
the	O
Ukraine	B-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
.	O
The	O
control	B-MED
group	I-MED
(	O
n	O
=	O
60	O
)	O
received	O
conservative	B-MED
therapy	I-MED
without	O
prostaglandins	B-MED
and	O
prostacyclins	B-MED
,	O
and	O
the	O
treatment	B-MED
group	I-MED
(	O
n	O
=	O
150	O
)	O
received	O
treatment	B-MED
with	O
pl	B-MED
-	I-MED
VEGF165	I-MED
as	O
two	O
intramuscular	B-MED
injections	I-MED
for	O
a	O
total	O
dose	B-MED
of	O
2.4	O
mg	O
.	O
Pain	B-MED
-	I-MED
free	I-MED
walking	I-MED
distance	I-MED
(	O
PWD	B-MED
)	O
(	O
the	O
primary	O
efficacy	B-MED
criterion	O
for	O
Fontaine	B-MED
stages	B-MED
II	I-MED
-	I-MED
III	I-MED
)	O
,	O
blood	B-MED
flow	I-MED
linear	I-MED
velocity	I-MED
(	O
BFLV	B-MED
)	O
,	O
and	O
ankle	B-MED
-	I-MED
brachial	I-MED
index	I-MED
(	O
ABI	B-MED
)	O
were	O
monitored	O
for	O
6	O
months	B-MED
.	O
The	O
safety	B-MED
of	O
pl	B-MED
-	I-MED
VEGF165	I-MED
gene	B-MED
transfer	I-MED
in	O
terms	O
of	O
the	O
trial	B-MED
protocol	I-MED
was	O
initially	O
evaluated	O
6	O
months	B-MED
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	B-MED
events	I-MED
(	O
AEs	B-MED
)	O
and	O
serious	B-MED
adverse	I-MED
events	I-MED
(	O
SAEs	B-MED
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	B-MED
and	O
unscheduled	O
requests	O
for	O
medical	B-MED
care	I-MED
.	O
Overall	O
,	O
PWD	B-MED
increased	O
by	O
177	O
%	O
,	O
from	O
100.3	O
±	O
6.9	O
to	O
277.1	O
±	O
16.2	O
m	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
in	O
the	O
treatment	B-MED
group	I-MED
,	O
whereas	O
the	O
mean	B-MED
value	O
was	O
unchanged	O
in	O
the	O
control	B-MED
group	I-MED
(	O
p	O
=	O
0.218	O
)	O
.	O
Both	O
BFLV	B-MED
and	O
ABI	B-MED
values	I-MED
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
treatment	B-MED
group	I-MED
but	O
decreased	O
in	O
the	O
control	B-MED
group	I-MED
.	O
The	O
greatest	O
therapeutic	B-MED
effect	I-MED
was	O
observed	O
for	O
stage	B-MED
III	I-MED
disease	B-MED
:	O
PWD	B-MED
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
.	O
No	B-MED
angiogenic	B-MED
therapy	I-MED
-related	O
AEs	B-MED
or	O
side	B-MED
effects	I-MED
were	O
recorded	O
,	O
and	O
target	O
limb	B-MED
salvage	I-MED
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	B-MED
and	O
control	B-MED
groups	I-MED
,	O
respectively	O
.	O
The	O
results	B-MED
obtained	O
in	O
this	O
study	B-MED
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	B-MED
IIb	I-MED
/	O
III	B-MED
registration	O
clinical	B-MED
study	I-MED
completed	O
in	O
2011	O
.	O
pl	B-MED
-	I-MED
VEGF165	I-MED
intramuscular	B-MED
gene	B-MED
transfer	I-MED
is	O
an	O
effective	O
treatment	B-MED
for	O
moderate	O
to	O
severe	O
claudication	B-MED
due	O
to	O
chronic	B-MED
lower	B-MED
limb	I-MED
ischemia	B-MED
in	O
routine	O
clinical	B-MED
practice	I-MED
.	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02369809	O
.	O
Optomechanical	B-MED
Control	I-MED
of	O
Quantum	B-MED
Yield	I-MED
in	O
Trans	B-MED
-	I-MED
Cis	I-MED
Ultrafast	I-MED
Photoisomerization	I-MED
of	O
a	O
Retinal	B-MED
Chromophore	B-MED
Model	B-MED
The	O
quantum	B-MED
yield	I-MED
of	O
a	O
photochemical	B-MED
reaction	I-MED
is	O
one	O
of	O
the	O
most	O
fundamental	B-MED
quantities	I-MED
in	O
photochemistry	B-MED
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction	B-MED
of	I-MED
light	I-MED
energy	I-MED
into	I-MED
chemical	I-MED
energy	I-MED
.	O
Nature	B-MED
has	O
evolved	O
photoreceptors	B-MED
in	O
which	O
the	O
reactivity	B-MED
of	O
a	O
chromophore	B-MED
is	O
enhanced	O
by	O
its	O
molecular	B-MED
environment	I-MED
to	O
achieve	O
high	O
quantum	B-MED
yields	I-MED
.	O
The	O
retinal	B-MED
chromophore	B-MED
sterically	O
constrained	O
inside	O
rhodopsin	B-MED
proteins	I-MED
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control	O
.	O
In	O
a	O
more	O
general	O
framework	O
,	O
mechanical	B-MED
forces	I-MED
acting	O
on	O
a	O
molecular	B-MED
system	I-MED
can	O
strongly	O
modify	O
its	O
reactivity	B-MED
.	O
Herein	O
,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile	B-MED
forces	I-MED
on	O
a	O
simplified	O
retinal	B-MED
chromophore	B-MED
model	B-MED
provokes	O
a	O
substantial	B-MED
and	I-MED
regular	I-MED
increase	I-MED
in	O
the	O
trans	B-MED
-	I-MED
to	I-MED
-	I-MED
cis	I-MED
photoisomerization	I-MED
quantum	B-MED
yield	I-MED
in	O
a	O
counterintuitive	O
way	O
,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis	B-MED
photoisomer	I-MED
.	O
A	O
rationale	B-MED
for	O
the	O
mechanochemical	B-MED
effect	I-MED
on	O
this	O
photoisomerization	B-MED
mechanism	I-MED
is	O
also	O
proposed	O
.	O
Ultrasonography	B-MED
for	O
acute	B-MED
appendicitis	I-MED
-	O
the	O
way	O
it	O
looks	O
today	O
Despite	O
sophisticated	O
physical	B-MED
examination	I-MED
and	O
laboratory	B-MED
support	I-MED
,	O
diagnosis	B-MED
of	O
acute	B-MED
appendicitis	I-MED
remained	O
challenging	O
in	O
clinical	B-MED
practice	I-MED
with	O
a	O
negative	B-MED
appendectomy	I-MED
rate	B-MED
of	O
15	O
-	O
30	O
%	O
.	O
As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-MED
(	O
US	B-MED
)	O
has	O
been	O
proven	O
a	O
reliable	B-MED
diagnostic	B-MED
method	I-MED
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	B-MED
presentation	B-MED
and	O
enables	O
to	O
rule	B-MED
out	I-MED
many	O
differential	B-MED
diagnoses	I-MED
.Recent	O
publications	B-MED
emphasized	O
the	O
role	O
of	O
multidetector	B-MED
computed	I-MED
tomography	I-MED
(	O
CT	B-MED
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	B-MED
negative	I-MED
findings	I-MED
at	O
operation	B-MED
.	O
Extensive	B-MED
as	O
well	O
as	O
uncritical	B-MED
application	I-MED
of	O
this	O
method	O
even	O
in	O
children	B-MED
inevitably	O
causes	O
substantial	O
radiation	B-MED
exposure	I-MED
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	B-MED
performance	B-MED
of	O
US	B-MED
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-MED
or	O
economic	B-MED
preponderance	B-MED
.Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-MED
(	O
and	O
CT	B-MED
)	O
in	O
acute	B-MED
appendicitis	I-MED
.	O
Therefore	O
,	O
1	O
generation	O
after	O
US	B-MED
with	I-MED
graded	I-MED
compression	I-MED
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-MED
acute	B-MED
appendicitis	I-MED
(	O
Puylaert	O
)	O
,	O
a	O
visual	B-MED
arousal	B-MED
fostering	B-MED
its	O
role	O
and	O
performance	O
in	O
clinical	B-MED
medicine	I-MED
appears	O
justified	O
.	O
Construction	O
of	O
an	O
Acetylcholinesterase	B-MED
Sensor	B-MED
Based	O
on	O
Synthesized	B-MED
Paramagnetic	I-MED
Nanoparticles	I-MED
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic	B-MED
Compounds	I-MED
Assay	B-MED
Magnetic	B-MED
particles	I-MED
(	O
MPs	B-MED
)	O
have	O
been	O
widely	O
used	O
in	O
biological	B-MED
applications	I-MED
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	B-MED
.	O
Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	B-MED
molecules	B-MED
including	O
enzymes	B-MED
.	O
Acetylcholinesterase	B-MED
(	O
AChE	B-MED
)	O
is	O
an	O
enzyme	B-MED
playing	O
crucial	O
role	O
in	O
neurotransmission	B-MED
and	O
the	O
enzyme	B-MED
is	O
targeted	B-MED
by	O
various	O
molecules	B-MED
like	O
Alzheimer	B-MED
's	I-MED
drugs	B-MED
,	O
pesticides	B-MED
and	O
warfare	B-MED
agents	I-MED
.	O
In	O
this	O
work	O
,	O
an	O
electrochemical	B-MED
biosensor	I-MED
having	O
AChE	B-MED
immobilized	B-MED
onto	O
MPs	B-MED
and	O
stabilized	B-MED
through	O
glutaraldehyde	B-MED
(	I-MED
GA	I-MED
)	I-MED
molecule	I-MED
was	O
proposed	O
for	O
assay	B-MED
of	O
the	O
neurotoxic	B-MED
compounds	I-MED
.	O
The	O
prepared	B-MED
nanoparticles	I-MED
were	O
modified	B-MED
by	I-MED
pure	B-MED
AChE	I-MED
and	O
they	O
were	O
used	O
for	O
the	O
measurement	B-MED
anti	B-MED
-	I-MED
Alzheimer	I-MED
's	I-MED
drug	B-MED
galantamine	B-MED
and	O
carbamate	B-MED
pesticide	I-MED
carbofuran	B-MED
with	O
limit	B-MED
of	O
detection	B-MED
1.5	O
µM	O
and	O
20	O
nM	O
,	O
respectively	O
.	O
All	O
measurements	B-MED
were	O
carried	O
out	O
using	O
screen	B-MED
-	I-MED
printed	I-MED
sensor	I-MED
with	O
carbon	B-MED
working	B-MED
,	O
silver	B-MED
reference	B-MED
,	O
and	O
carbon	B-MED
auxiliary	B-MED
electrode	I-MED
.	O
Standard	B-MED
Ellman	I-MED
's	I-MED
assay	I-MED
was	O
used	O
for	O
validation	B-MED
measurement	B-MED
of	O
both	O
inhibitors	B-MED
.	O
Part	O
of	O
this	O
work	O
was	O
the	O
elimination	B-MED
of	O
reversible	B-MED
inhibitors	B-MED
represented	O
by	O
galantamine	B-MED
from	O
the	O
active	B-MED
site	I-MED
AChE	B-MED
of	O
AChE.	O
For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	B-MED
pH	B-MED
to	O
get	O
the	O
original	B-MED
activity	B-MED
of	O
AChE	B-MED
after	O
inhibition	B-MED
by	O
galantamine	B-MED
.	O
We	O
also	O
observed	B-MED
decarbamylation	B-MED
of	O
the	O
AChE	B-MED
-	O
carbofuran	B-MED
adduct	B-MED
.	O
Influence	O
of	O
organic	B-MED
solvents	I-MED
to	O
AChE	B-MED
as	O
well	O
as	O
repeatability	O
of	O
measurement	B-MED
with	O
MPs	B-MED
with	O
AChE	B-MED
was	O
also	O
established	O
.	O
Endurance	B-MED
based	O
personalized	B-MED
fitness	I-MED
planner	I-MED
Endurance	B-MED
is	O
an	O
important	B-MED
factor	B-MED
of	O
cardiovascular	B-MED
fitness	I-MED
indicating	O
the	O
capacity	B-MED
of	O
an	O
individual	B-MED
to	O
perform	B-MED
exercise	B-MED
for	O
a	O
longer	B-MED
duration	I-MED
with	O
increased	B-MED
intensity	B-MED
.	O
Various	O
subject	B-MED
specific	I-MED
and	O
exercise	B-MED
related	O
parameters	B-MED
affect	O
endurance	B-MED
of	O
an	O
individual	B-MED
.	O
In	O
this	O
work	O
,	O
we	O
propose	O
a	O
statistical	B-MED
technique	I-MED
to	O
model	B-MED
endurance	B-MED
as	O
a	O
function	O
of	O
these	O
factors	B-MED
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	B-MED
generated	O
by	O
individuals	B-MED
over	B-MED
time	I-MED
.	O
The	O
proposed	B-MED
model	B-MED
provides	O
a	O
device	B-MED
to	O
predict	O
future	O
endurance	B-MED
of	O
a	O
test	O
subject	B-MED
following	O
particular	O
exercise	B-MED
regime	I-MED
.	O
This	O
facilitates	O
a	O
test	B-MED
user	I-MED
with	O
a	O
fitness	B-MED
planner	I-MED
with	O
the	O
provision	O
to	O
fix	O
exercise	B-MED
regimes	I-MED
to	O
reach	O
a	O
set	O
fitness	B-MED
goal	B-MED
.	O
A	O
thermophilic	B-MED
-like	O
ene	B-MED
-	I-MED
reductase	I-MED
originating	O
from	O
an	O
acidophilic	B-MED
iron	B-MED
oxidizer	I-MED
Ene	B-MED
-	I-MED
reductases	I-MED
originating	O
from	O
extremophiles	B-MED
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	B-MED
due	O
to	O
higher	B-MED
-	O
stability	B-MED
properties	B-MED
.	O
The	O
genome	B-MED
of	O
the	O
acidophilic	B-MED
iron	B-MED
-	I-MED
oxidizing	I-MED
bacterium	I-MED
"	O
Ferrovum	B-MED
"	I-MED
sp	I-MED
.	I-MED
JA12	I-MED
was	O
found	O
to	O
harbor	O
a	O
thermophilic	B-MED
-like	O
ene	B-MED
-	I-MED
reductase	I-MED
(	O
FOYE-1	B-MED
)	O
.	O
The	O
foye-1	B-MED
gene	I-MED
was	O
ligated	O
into	O
a	O
pET16bp	B-MED
expression	B-MED
vector	B-MED
system	I-MED
,	O
and	O
the	O
enzyme	B-MED
was	O
produced	O
in	O
Escherichia	B-MED
coli	I-MED
BL21	B-MED
(	I-MED
DE3	I-MED
;	I-MED
pLysS	I-MED
)	I-MED
cells	I-MED
in	O
yields	O
of	O
10	O
mg	O
L(-1	O
)	O
.	O
FOYE-1	B-MED
showed	O
remarkable	O
activity	B-MED
and	O
rates	B-MED
on	O
N	B-MED
-	I-MED
phenylmaleimide	I-MED
and	O
N	B-MED
-	I-MED
phenyl-2	I-MED
-	I-MED
methylmaleimide	I-MED
(	O
up	O
to	O
89	O
U	O
mg(-1	O
)	O
,	O
>	O
97	O
%	O
conversion	B-MED
,	O
95	O
%	O
(	O
R)-selective	O
)	O
with	O
both	O
nicotinamide	B-MED
cofactors	I-MED
,	O
NADPH	B-MED
and	O
NADH	B-MED
.	O
The	O
catalytic	B-MED
efficiency	B-MED
with	O
NADPH	B-MED
was	O
27	O
times	O
higher	B-MED
compared	O
to	O
NADH	B-MED
.	O
At	O
the	O
temperature	B-MED
maximum	B-MED
(	O
50	O
°	O
C	O
)	O
and	O
pH	B-MED
optimum	I-MED
(	O
6.5	O
)	O
,	O
activity	B-MED
was	O
almost	O
doubled	B-MED
to	O
160	O
U	O
mg(-1	O
)	O
.	O
These	O
findings	B-MED
accomplish	O
FOYE-1	B-MED
for	O
a	O
valuable	O
biocatalyst	B-MED
in	O
the	O
synthesis	B-MED
of	O
succinimides	B-MED
.	O
The	O
appearance	O
of	O
a	O
thermophilic	B-MED
-like	O
ene	B-MED
-	I-MED
reductase	I-MED
in	O
an	O
acidic	B-MED
habitat	I-MED
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	B-MED
neighborhood	B-MED
of	O
the	O
encoding	B-MED
gene	B-MED
,	O
awarding	O
FOYE-1	B-MED
a	O
putative	O
involvement	O
in	O
a	O
quorum	B-MED
-	I-MED
sensing	I-MED
process	O
.	O
Growth	B-MED
differentiation	I-MED
factor	I-MED
15	I-MED
is	O
a	O
myomitokine	B-MED
governing	B-MED
systemic	I-MED
energy	I-MED
homeostasis	I-MED
Reduced	B-MED
mitochondrial	B-MED
electron	I-MED
transport	I-MED
chain	I-MED
activity	B-MED
promotes	B-MED
longevity	B-MED
and	O
improves	B-MED
energy	B-MED
homeostasis	I-MED
via	O
cell	B-MED
-	I-MED
autonomous	I-MED
and	O
-	O
non	B-MED
-	I-MED
autonomous	I-MED
factors	I-MED
in	O
multiple	B-MED
model	I-MED
systems	I-MED
.	O
This	O
mitohormetic	B-MED
effect	B-MED
is	O
thought	O
to	O
involve	O
the	O
mitochondrial	B-MED
unfolded	I-MED
protein	I-MED
response	I-MED
(	O
UPR(mt	B-MED
)	I-MED
)	O
,	O
an	O
adaptive	B-MED
stress	I-MED
-	I-MED
response	I-MED
pathway	B-MED
activated	B-MED
by	O
mitochondrial	B-MED
proteotoxic	B-MED
stress	I-MED
.	O
Using	O
mice	B-MED
with	O
skeletal	B-MED
muscle	I-MED
-	I-MED
specific	I-MED
deficiency	B-MED
of	O
Crif1	B-MED
(	O
muscle	B-MED
-	I-MED
specific	I-MED
knockout	B-MED
[	O
MKO	B-MED
]	O
)	O
,	O
an	O
integral	B-MED
protein	I-MED
of	O
the	O
large	B-MED
mitoribosomal	I-MED
subunit	I-MED
(	O
39S	B-MED
)	O
,	O
we	O
identified	O
growth	B-MED
differentiation	I-MED
factor	I-MED
15	I-MED
(	O
GDF15	B-MED
)	O
as	O
a	O
UPR(mt	B-MED
)	I-MED
-associated	O
cell	B-MED
-	I-MED
non	I-MED
-	I-MED
autonomous	I-MED
myomitokine	B-MED
that	O
regulates	B-MED
systemic	I-MED
energy	I-MED
homeostasis	I-MED
.	O
MKO	B-MED
mice	I-MED
were	O
protected	B-MED
against	O
obesity	B-MED
and	O
sensitized	B-MED
to	O
insulin	B-MED
,	O
an	O
effect	O
associated	B-MED
with	I-MED
elevated	B-MED
GDF15	B-MED
secretion	B-MED
after	O
UPR(mt	B-MED
)	I-MED
activation	B-MED
.	O
In	O
ob	B-MED
/	I-MED
ob	I-MED
mice	I-MED
,	O
administration	O
of	O
recombinant	B-MED
GDF15	B-MED
decreased	B-MED
body	B-MED
weight	I-MED
and	O
improved	B-MED
insulin	B-MED
sensitivity	I-MED
,	O
which	O
was	O
attributed	O
to	O
elevated	B-MED
oxidative	B-MED
metabolism	I-MED
and	O
lipid	B-MED
mobilization	I-MED
in	O
the	O
liver	B-MED
,	O
muscle	B-MED
,	O
and	O
adipose	B-MED
tissue	I-MED
.	O
Thus	O
,	O
GDF15	B-MED
is	O
a	O
potent	B-MED
mitohormetic	B-MED
signal	B-MED
that	O
safeguards	O
against	O
the	O
onset	B-MED
of	I-MED
obesity	I-MED
and	O
insulin	B-MED
resistance	I-MED
.	O
Estimation	O
of	O
the	O
HIV-1	B-MED
backward	B-MED
mutation	B-MED
rate	I-MED
from	O
transmitted	B-MED
drug	I-MED
-	I-MED
resistant	I-MED
strains	B-MED
One	O
of	O
the	O
serious	O
threats	B-MED
facing	O
the	O
administration	O
of	O
antiretroviral	B-MED
therapy	I-MED
to	O
human	B-MED
immunodeficiency	I-MED
virus	I-MED
(	O
HIV-1	B-MED
)	O
infected	B-MED
patients	B-MED
is	O
the	O
reported	O
increasing	B-MED
prevalence	I-MED
of	O
transmitted	B-MED
drug	I-MED
resistance	I-MED
.	O
However	O
,	O
given	O
that	O
HIV-1	B-MED
drug	B-MED
-	I-MED
resistant	I-MED
strains	B-MED
are	O
often	O
less	O
fit	O
than	O
the	O
wild	B-MED
-	I-MED
type	I-MED
strains	B-MED
,	O
it	O
is	O
expected	O
that	O
drug	B-MED
-	I-MED
resistant	I-MED
strains	B-MED
that	O
are	O
present	O
during	O
the	O
primary	B-MED
phase	B-MED
of	O
the	O
HIV-1	B-MED
infection	I-MED
are	O
replaced	B-MED
by	O
the	O
fitter	O
wild	B-MED
-	I-MED
type	I-MED
strains	B-MED
.	O
This	O
replacement	B-MED
of	O
HIV-1	B-MED
resistant	I-MED
mutations	B-MED
involves	O
the	O
emergence	O
of	O
wild	B-MED
-	I-MED
type	I-MED
strains	B-MED
by	O
a	O
process	B-MED
of	O
backward	B-MED
mutation	B-MED
.	O
How	O
quickly	O
the	O
replacement	B-MED
happens	O
is	O
dependent	B-MED
on	O
the	O
class	O
of	O
HIV-1	B-MED
mutation	B-MED
group	B-MED
.	O
We	O
estimate	O
the	O
backward	B-MED
mutation	B-MED
rates	I-MED
and	O
relative	O
fitness	O
of	O
various	O
mutational	B-MED
groups	B-MED
known	O
to	O
confer	O
HIV-1	B-MED
drug	B-MED
resistance	I-MED
.	O
We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	B-MED
model	I-MED
to	O
data	B-MED
for	O
individuals	B-MED
who	O
were	O
originally	O
infected	B-MED
by	O
an	O
HIV-1	B-MED
strain	B-MED
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	B-MED
resistance	I-MED
-conferring	O
mutations	B-MED
and	O
observed	O
over	O
a	O
period	B-MED
of	I-MED
time	I-MED
to	O
see	O
whether	O
the	O
resistant	B-MED
strain	B-MED
is	O
replaced	B-MED
.	O
To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	B-MED
,	O
generated	O
from	O
simulations	B-MED
of	O
the	O
stochastic	B-MED
model	I-MED
,	O
that	O
best	O
describes	O
the	O
observed	B-MED
(	O
clinical	B-MED
data	I-MED
)	O
replacement	B-MED
times	B-MED
of	O
a	O
given	O
mutation	B-MED
.	O
We	O
found	O
that	O
Lamivudine	B-MED
/	I-MED
Emtricitabine	I-MED
-associated	O
mutations	B-MED
have	O
a	O
distinctly	O
higher	O
,	O
backward	B-MED
mutation	B-MED
rate	I-MED
and	O
low	O
relative	B-MED
fitness	B-MED
compared	O
to	O
the	O
other	O
classes	B-MED
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	B-MED
inhibitors	I-MED
-associated	O
mutations	B-MED
have	O
a	O
slower	O
backward	B-MED
mutation	B-MED
rate	I-MED
and	O
high	O
relative	B-MED
fitness	B-MED
.	O
For	O
the	O
other	O
mutation	B-MED
classes	B-MED
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	B-MED
.	O
TANGO	B-MED
-	O
a	O
screening	B-MED
tool	I-MED
to	O
identify	O
comorbidities	B-MED
on	O
the	O
causal	B-MED
pathway	I-MED
of	O
nocturia	B-MED
To	O
develop	O
a	O
robust	B-MED
screening	I-MED
metric	I-MED
for	O
use	O
in	O
identifying	O
non	O
-	O
lower	O
urinary	B-MED
tract	I-MED
comorbidities	B-MED
pertinent	O
to	O
the	O
multidisciplinary	B-MED
assessment	I-MED
of	O
patients	B-MED
with	O
nocturia	B-MED
.	O
Variables	B-MED
having	O
a	O
significant	O
risk	O
association	B-MED
with	I-MED
nocturia	B-MED
of	O
greater	O
than	O
once	O
per	O
night	B-MED
were	O
identified	O
.	O
Discriminating	B-MED
items	O
from	O
validated	O
and	O
reliable	O
tools	B-MED
measuring	O
these	O
comorbidities	B-MED
were	O
identified	O
.	O
A	O
self	O
-	O
completed	O
57	O
-	O
item	O
questionnaire	B-MED
was	O
developed	O
and	O
a	O
medical	B-MED
checklist	B-MED
and	O
pertinent	O
clinical	B-MED
measures	I-MED
added	O
.	O
Pre	O
-	O
determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short	B-MED
-	I-MED
Form	I-MED
(	O
SF	B-MED
)	O
screening	B-MED
tool	I-MED
.	O
The	O
tool	B-MED
was	O
administered	O
to	O
252	O
individuals	B-MED
with	O
nocturia	B-MED
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	B-MED
,	O
Continence	B-MED
,	O
Falls	B-MED
or	O
Rehabilitation	B-MED
service	I-MED
for	O
routine	B-MED
care	I-MED
.	O
Data	B-MED
collected	I-MED
were	O
subjected	O
to	O
descriptive	B-MED
analysis	I-MED
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O
Using	O
pre	O
-	O
determined	O
domains	O
,	O
a	O
nocturia	B-MED
screening	B-MED
metric	I-MED
,	O
entitled	O
TANGO	B-MED
,	O
was	O
generated	O
.	O
The	O
acronym	O
TANGO	B-MED
stands	O
for	O
Targeting	B-MED
the	O
individual	B-MED
's	I-MED
Aetiology	I-MED
of	O
Nocturia	B-MED
to	O
Guide	O
Outcomes	O
.	O
The	O
demographic	B-MED
characteristics	I-MED
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O
The	O
statistical	B-MED
and	O
structural	B-MED
framework	I-MED
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	B-MED
Long	O
-	O
Form	O
to	O
the	O
SF	B-MED
is	O
presented	O
.	O
The	O
resultant	O
TANGO	B-MED
-	O
SF	B-MED
patient	B-MED
-completed	O
nocturia	B-MED
screening	B-MED
tool	I-MED
is	O
reported	O
.	O
A	O
novel	O
all	O
-	O
cause	O
diagnostic	B-MED
metric	O
for	O
identifying	O
co	O
-	O
existing	O
morbidities	B-MED
of	O
clinical	B-MED
relevance	I-MED
to	O
nocturia	B-MED
in	O
patients	B-MED
who	O
present	O
across	O
disciplines	B-MED
and	O
medical	B-MED
specialties	I-MED
has	O
been	O
developed	O
.	O
TANGO	B-MED
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	B-MED
inequalities	I-MED
associated	B-MED
with	I-MED
a	O
siloed	O
approach	O
to	O
assessment	B-MED
and	O
subsequent	O
care	B-MED
of	O
patients	B-MED
with	O
nocturia	B-MED
.	O
Survey	B-MED
of	O
Neonatal	B-MED
Intensive	I-MED
Care	I-MED
Unit	I-MED
Nurse	B-MED
Attitudes	B-MED
Toward	O
Therapeutic	B-MED
Hypothermia	I-MED
Treatment	I-MED
The	O
traumatic	B-MED
experiences	O
of	O
parent	B-MED
s	O
of	O
babies	B-MED
treated	B-MED
with	I-MED
therapeutic	B-MED
hypothermia	I-MED
(	O
TH	B-MED
)	O
have	O
been	O
described	O
.	O
No	O
research	B-MED
has	O
assessed	B-MED
neonatal	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
(	O
NICU	B-MED
)	O
nurse	B-MED
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-MED
babies	B-MED
and	O
emotional	O
support	O
to	O
their	O
parents	B-MED
.	O
To	O
assess	O
NICU	B-MED
nurse	B-MED
attitudes	B-MED
to	O
the	O
provision	O
of	O
TH	B-MED
with	O
respect	O
to	O
perceptions	B-MED
about	O
baby	B-MED
pain	B-MED
/	O
sedation	B-MED
,	O
need	O
for	O
nurse	B-MED
and	O
parent	B-MED
education	B-MED
,	O
decision	B-MED
making	I-MED
about	O
initiation	B-MED
of	O
TH	B-MED
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O
A	O
survey	B-MED
was	O
electronically	O
sent	O
to	O
219	O
nurses	B-MED
at	O
2	O
affiliated	O
academic	O
level	O
III	O
NICUs	B-MED
:	O
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O
There	O
were	O
17	O
questions	O
where	O
responses	B-MED
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	B-MED
to	O
provide	O
free	O
text	O
responses	B-MED
.	O
The	O
response	B-MED
rate	O
was	O
38	O
%	O
(	O
N	O
=	O
83	O
)	O
.	O
Overwhelming	B-MED
similarities	O
between	O
the	O
urban	B-MED
and	O
rural	B-MED
institutions	I-MED
were	O
found	O
with	O
NICU	B-MED
nurses	B-MED
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
TH	B-MED
,	O
agreement	O
that	O
TH	B-MED
improves	O
long	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
and	O
that	O
the	O
benefits	O
of	O
TH	B-MED
outweigh	O
the	O
risks	O
.	O
Nurses	B-MED
at	O
the	O
urban	B-MED
institution	I-MED
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-MED
of	O
baby	B-MED
pain	B-MED
/	O
sedation	B-MED
,	O
and	O
nurses	B-MED
at	O
both	O
institutions	B-MED
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	B-MED
and	O
parent	B-MED
education	B-MED
about	O
TH	B-MED
and	O
improved	O
timeliness	O
of	O
decision	B-MED
making	I-MED
for	O
initiation	B-MED
of	O
TH	B-MED
.	O
NICU	B-MED
nurses	B-MED
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	B-MED
of	O
babies	B-MED
after	O
treatment	B-MED
with	O
TH	B-MED
and	O
feel	O
that	O
parents	B-MED
need	O
more	O
education	B-MED
about	O
TH	B-MED
.	O
Research	B-MED
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
TH	B-MED
treatment	I-MED
for	O
parent	B-MED
-	O
baby	B-MED
bonding	O
.	O
Quantitative	B-MED
Susceptibility	I-MED
Mapping	I-MED
using	O
Structural	B-MED
Feature	I-MED
based	I-MED
Collaborative	I-MED
Reconstruction	I-MED
(	O
SFCR	B-MED
)	O
in	O
the	O
Human	B-MED
Brain	B-MED
The	O
reconstruction	B-MED
of	O
MR	B-MED
quantitative	B-MED
susceptibility	I-MED
mapping	I-MED
(	O
QSM	B-MED
)	O
from	O
local	B-MED
phase	I-MED
measurements	B-MED
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	B-MED
strategies	I-MED
incorporating	O
a	O
priori	B-MED
information	B-MED
extracted	O
from	O
magnitude	B-MED
and	O
phase	B-MED
images	I-MED
have	O
been	O
proposed	B-MED
.	O
However	O
,	O
the	O
anatomy	B-MED
observed	O
in	O
magnitude	B-MED
and	O
phase	B-MED
images	I-MED
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	B-MED
maps	I-MED
,	O
which	O
could	O
give	O
erroneous	B-MED
estimation	B-MED
in	O
the	O
reconstructed	B-MED
susceptibility	I-MED
map	I-MED
.	O
In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	B-MED
feature	I-MED
based	I-MED
collaborative	I-MED
reconstruction	I-MED
(	O
SFCR	B-MED
)	O
method	O
for	O
QSM	B-MED
including	O
both	O
magnitude	B-MED
and	O
susceptibility	B-MED
based	O
information	B-MED
.	O
The	O
SFCR	B-MED
algorithm	B-MED
is	O
composed	O
of	O
two	O
consecutive	B-MED
steps	I-MED
corresponding	O
to	O
complementary	O
reconstruction	B-MED
models	I-MED
,	O
each	O
with	O
a	O
structural	B-MED
feature	I-MED
based	O
l1	O
norm	B-MED
constraint	I-MED
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	B-MED
constraint	I-MED
,	O
which	O
allows	O
both	O
the	O
structure	B-MED
edges	O
and	O
tiny	O
features	B-MED
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	B-MED
and	O
artifacts	B-MED
could	O
be	O
reduced	O
.	O
In	O
the	O
M	B-MED
-	I-MED
step	I-MED
,	O
the	O
initial	O
susceptibility	B-MED
map	I-MED
is	O
reconstructed	B-MED
by	O
employing	O
a	O
k	O
-	O
space	O
based	O
compressed	B-MED
sensing	I-MED
model	I-MED
incorporating	O
magnitude	B-MED
prior	O
.	O
In	O
the	O
S	B-MED
-	I-MED
step	I-MED
,	O
the	O
susceptibility	B-MED
map	I-MED
is	O
fitted	O
in	O
spatial	B-MED
domain	I-MED
using	O
weighted	O
constraints	B-MED
derived	O
from	O
the	O
initial	O
susceptibility	B-MED
map	I-MED
from	O
the	O
M	B-MED
-	I-MED
step	I-MED
.	O
Simulations	B-MED
and	O
in	B-MED
vivo	I-MED
human	B-MED
experiments	B-MED
at	O
7	O
T	O
MRI	B-MED
show	O
that	O
the	O
SFCR	B-MED
method	O
provides	O
high	O
quality	B-MED
susceptibility	B-MED
maps	I-MED
with	O
improved	O
RMSE	B-MED
and	O
MSSIM	B-MED
.	O
Finally	O
,	O
the	O
susceptibility	B-MED
values	O
of	O
deep	O
gray	B-MED
matter	I-MED
are	O
analyzed	O
in	O
multiple	B-MED
head	I-MED
positions	I-MED
,	O
with	O
the	O
supine	B-MED
position	I-MED
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	B-MED
result	B-MED
.	O
Doctor	B-MED
Competence	B-MED
and	O
the	O
Demand	B-MED
for	O
Healthcare	B-MED
:	O
Evidence	B-MED
from	O
Rural	B-MED
China	I-MED
The	O
agency	B-MED
problem	B-MED
between	O
patients	B-MED
and	O
doctors	B-MED
has	O
long	O
been	O
emphasised	O
in	O
the	O
health	B-MED
economics	I-MED
literature	I-MED
,	O
but	O
the	O
empirical	B-MED
evidence	B-MED
on	O
whether	O
patients	B-MED
can	O
evaluate	B-MED
and	O
respond	O
to	O
better	B-MED
quality	B-MED
care	I-MED
remains	O
mixed	B-MED
and	O
inconclusive	B-MED
.	O
Using	O
household	B-MED
data	B-MED
linked	O
to	O
an	O
assessment	B-MED
of	O
village	B-MED
doctors	B-MED
'	I-MED
clinical	B-MED
competence	I-MED
in	O
rural	B-MED
China	I-MED
,	O
we	O
show	O
that	O
there	O
is	O
no	B-MED
correlation	I-MED
between	O
doctor	B-MED
competence	B-MED
and	O
patients	B-MED
'	I-MED
healthcare	B-MED
utilisation	B-MED
,	O
with	O
confidence	B-MED
intervals	I-MED
reasonably	O
tight	O
around	O
zero	O
.	O
Household	B-MED
perceptions	B-MED
of	O
quality	B-MED
are	O
an	O
important	B-MED
determinant	B-MED
of	O
care	B-MED
-	I-MED
seeking	I-MED
behaviour	I-MED
,	O
yet	O
patients	B-MED
appear	B-MED
unable	B-MED
to	O
recognise	B-MED
more	O
competent	B-MED
doctors	B-MED
-	O
there	O
is	O
no	O
relationship	B-MED
between	O
doctor	B-MED
competence	B-MED
and	O
perceptions	B-MED
of	O
quality	B-MED
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
JOURNAL	O
ARTICLE	O
The	O
flavor	B-MED
and	O
nutritional	B-MED
characteristic	B-MED
of	O
four	O
strawberry	B-MED
varieties	B-MED
cultured	B-MED
in	O
soilless	B-MED
system	I-MED
Strawberry	B-MED
fruits	I-MED
(	O
cv	B-MED
.	I-MED
Benihoppe	I-MED
,	O
Tochiotome	B-MED
,	O
Sachinoka	B-MED
,	O
and	O
Guimeiren	B-MED
)	O
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	B-MED
and	O
nutritional	B-MED
parameters	B-MED
.	O
By	O
principal	B-MED
component	I-MED
analysis	I-MED
and	O
hierarchical	B-MED
clustering	I-MED
analysis	I-MED
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	B-MED
compounds	I-MED
composition	B-MED
,	O
sugar	B-MED
and	O
acid	B-MED
concentration	B-MED
,	O
sweetness	B-MED
,	O
and	O
total	B-MED
soluble	I-MED
sugars	I-MED
/	O
total	B-MED
organic	I-MED
acids	I-MED
of	O
the	O
four	O
varieties	B-MED
.	O
A	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	B-MED
compounds	I-MED
were	O
identified	B-MED
and	O
determined	B-MED
in	O
cv	B-MED
.	I-MED
Benihoppe	I-MED
,	O
Tochiotome	B-MED
,	O
Sachinoka	B-MED
,	O
and	O
Guimeiren	B-MED
strawberry	I-MED
fruits	I-MED
extracted	B-MED
by	O
head	B-MED
-	I-MED
space	I-MED
solid	I-MED
-	I-MED
phase	I-MED
microextraction	I-MED
(	O
HS	B-MED
-	I-MED
SPME	I-MED
)	O
,	O
respectively	O
.	O
Esters	B-MED
significantly	O
dominated	O
the	O
chemical	B-MED
composition	I-MED
of	O
the	O
four	O
varieties	B-MED
.	O
Furaneol	B-MED
was	O
detected	O
in	O
cultivars	B-MED
of	O
Sachinoka	B-MED
and	O
Guimeiren	B-MED
,	O
but	O
mesifuran	B-MED
was	O
only	O
found	O
in	O
cv	B-MED
.	I-MED
Tochiotome	I-MED
.	O
Tochiotome	B-MED
and	O
Sachinoka	B-MED
showed	O
higher	O
content	B-MED
of	O
linalool	B-MED
and	O
(	B-MED
E)-nerolidol	I-MED
.	O
Sachinoka	B-MED
showed	O
the	O
highest	B-MED
content	B-MED
of	O
total	B-MED
sugars	I-MED
and	O
total	B-MED
acids	I-MED
.	O
Guimeiren	B-MED
showed	O
higher	O
sweetness	B-MED
index	B-MED
than	O
the	O
other	O
three	O
cultivars	B-MED
.	O
Firmness	B-MED
of	O
Tochiotome	B-MED
was	O
highest	B-MED
among	O
all	O
the	O
varieties	B-MED
.	O
The	O
highest	B-MED
total	B-MED
soluble	I-MED
solids	I-MED
TSS	I-MED
value	I-MED
was	O
found	O
in	O
cv	B-MED
.	I-MED
Sachinoka	I-MED
,	O
followed	O
by	O
the	O
Guimeiren	B-MED
and	O
Tochiotome	B-MED
varieties	B-MED
.	O
Sachinoka	B-MED
had	O
the	O
highest	B-MED
titratable	B-MED
acidity	I-MED
TA	I-MED
value	I-MED
.	O
The	O
content	B-MED
of	O
ascorbic	B-MED
acid	I-MED
(	O
AsA	B-MED
)	O
of	O
cv	B-MED
.	I-MED
Tochiotome	I-MED
was	O
higher	B-MED
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	B-MED
significant	I-MED
difference	B-MED
in	O
cultivars	B-MED
of	O
Benihoppe	B-MED
,	O
Tochiotome	B-MED
,	O
and	O
Sachinoka	B-MED
.	O
Fructose	B-MED
and	O
glucose	B-MED
were	O
the	O
major	O
sugars	B-MED
in	O
all	O
cultivars	B-MED
.	O
Citric	B-MED
acid	I-MED
was	O
the	O
major	O
organic	B-MED
acid	I-MED
in	O
cv	B-MED
.	I-MED
Tochiotome	I-MED
,	O
cv	B-MED
.	I-MED
Sachinoka	I-MED
,	O
and	O
cv	B-MED
.	I-MED
Guimeiren	I-MED
.	O
Tochiotome	B-MED
had	O
higher	B-MED
ratios	B-MED
of	O
TSS	B-MED
/	O
TA	B-MED
and	O
total	B-MED
sugars	I-MED
/	O
total	B-MED
organic	I-MED
acids	I-MED
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	B-MED
content	B-MED
.	O
The	O
order	O
of	O
the	O
comprehensive	B-MED
evaluation	I-MED
score	I-MED
was	O
Sachinoka	B-MED
>	O
Guimeiren	B-MED
>	O
Tochiotome	B-MED
>	O
Benihoppe	B-MED
.	O
Tead1	B-MED
regulates	O
the	O
expression	B-MED
of	O
Peripheral	B-MED
Myelin	I-MED
Protein	I-MED
22	I-MED
during	O
Schwann	B-MED
cell	I-MED
development	I-MED
Schwann	B-MED
cells	I-MED
are	O
myelinating	B-MED
glia	I-MED
in	O
the	O
peripheral	B-MED
nervous	I-MED
system	I-MED
that	O
form	O
the	O
myelin	B-MED
sheath	I-MED
.	O
A	O
major	O
cause	O
of	O
peripheral	B-MED
neuropathy	I-MED
is	O
a	O
copy	B-MED
number	I-MED
variant	I-MED
involving	O
the	O
Peripheral	B-MED
Myelin	I-MED
Protein	I-MED
22	I-MED
(	I-MED
PMP22	I-MED
)	I-MED
gene	I-MED
,	O
which	O
is	O
located	O
within	O
a	O
1.4	O
-	O
Mb	O
duplication	B-MED
on	O
chromosome	B-MED
17	I-MED
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
Charcot	B-MED
-	I-MED
Marie	I-MED
-	I-MED
Tooth	I-MED
Disease	I-MED
(	O
CMT1A	B-MED
)	O
.	O
Rodent	B-MED
models	I-MED
of	O
CMT1A	B-MED
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
Pmp22	B-MED
overexpression	B-MED
mitigates	O
several	O
aspects	O
of	O
a	O
CMT1A	B-MED
-related	O
phenotype	B-MED
.	O
Mechanistic	B-MED
studies	B-MED
of	O
Pmp22	B-MED
regulation	B-MED
identified	O
enhancers	B-MED
regulated	O
by	O
the	O
Sox10	B-MED
(	O
SRY	B-MED
sex	I-MED
determining	I-MED
region	I-MED
Y	I-MED
-	I-MED
box	I-MED
10	I-MED
)	O
and	O
Egr2	B-MED
/	O
Krox20	B-MED
(	O
Early	B-MED
growth	I-MED
response	I-MED
protein	I-MED
2	I-MED
)	O
transcription	B-MED
factors	I-MED
in	O
myelinated	B-MED
nerves	I-MED
.	O
However	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	B-MED
factors	I-MED
induce	B-MED
Pmp22	B-MED
expression	B-MED
during	O
Schwann	B-MED
cell	I-MED
development	I-MED
and	O
myelination	B-MED
.	O
Here	O
,	O
we	O
examined	O
Pmp22	B-MED
enhancers	B-MED
as	O
a	O
function	O
of	O
cell	B-MED
type	I-MED
-	I-MED
specificity	I-MED
,	O
nerve	B-MED
injury	I-MED
and	O
development	B-MED
.	O
While	O
Pmp22	B-MED
enhancers	B-MED
marked	O
by	O
active	B-MED
histone	B-MED
modifications	I-MED
were	O
lost	B-MED
or	O
remodeled	O
after	O
injury	B-MED
,	O
we	O
found	O
that	O
these	O
enhancers	B-MED
were	O
permissive	O
in	O
early	O
development	B-MED
prior	O
to	O
Pmp22	B-MED
upregulation	B-MED
.	O
Pmp22	B-MED
enhancers	B-MED
contain	O
binding	B-MED
motifs	I-MED
for	O
TEA	B-MED
domain	I-MED
(	O
Tead	B-MED
)	O
transcription	B-MED
factors	I-MED
of	O
the	O
Hippo	B-MED
signaling	I-MED
pathway	I-MED
.	O
We	O
discovered	O
that	O
Tead1	B-MED
and	O
co	O
-	O
activators	O
Yap	B-MED
and	O
Taz	B-MED
are	O
required	O
for	O
Pmp22	B-MED
expression	B-MED
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-MED
of	O
Egr2	B-MED
Tead1	B-MED
directly	O
binds	O
Pmp22	B-MED
and	O
Egr2	B-MED
enhancers	B-MED
early	O
in	O
development	B-MED
and	O
Tead1	B-MED
binding	B-MED
is	O
induced	B-MED
during	O
myelination	B-MED
,	O
correlating	O
with	O
Pmp22	B-MED
expression	B-MED
.	O
The	O
data	B-MED
identify	O
Tead1	B-MED
as	O
a	O
novel	O
regulator	B-MED
of	O
Pmp22	B-MED
expression	B-MED
during	O
development	B-MED
in	O
concert	O
with	O
Sox10	B-MED
and	O
Egr2	B-MED
.	O
Proliferation	B-MED
-Related	O
Activity	O
in	O
Endothelial	B-MED
Cells	I-MED
Is	O
Enhanced	B-MED
by	O
Micropower	O
Plasma	B-MED
Nonthermal	B-MED
plasma	I-MED
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical	B-MED
treatment	I-MED
technique	I-MED
in	O
recent	O
years	O
.	O
It	O
can	O
easily	O
create	O
various	O
reactive	B-MED
chemical	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
and	O
is	O
harmless	O
to	O
living	B-MED
body	I-MED
.	O
Although	O
plasma	B-MED
plasma	B-MED
at	O
gas	B-MED
-	O
liquid	B-MED
interface	B-MED
has	O
a	O
potential	O
for	O
a	O
biomedical	B-MED
application	I-MED
,	O
the	O
interactions	O
between	O
the	O
gas	B-MED
-	O
liquid	B-MED
plasma	B-MED
and	O
living	B-MED
cells	I-MED
remain	O
unclear	O
.	O
Here	O
,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	B-MED
with	O
0.018	O
W	O
of	O
the	O
power	O
input	O
,	O
generated	O
at	O
gas	B-MED
-	O
liquid	B-MED
interface	B-MED
.	O
We	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	B-MED
-induced	O
enhancement	B-MED
in	O
proliferation	B-MED
activity	O
of	O
endothelial	B-MED
cells	I-MED
.	O
The	O
plasma	B-MED
produced	O
H2O2	B-MED
,	O
HNO2	B-MED
,	O
and	O
HNO3	B-MED
in	O
phosphate	B-MED
buffered	I-MED
saline	B-MED
containing	O
Mg(++	B-MED
)	I-MED
and	O
Ca(++	B-MED
)	I-MED
(	O
PBS	B-MED
(	O
+	O
)	O
)	O
,	O
and	O
their	O
concentration	B-MED
increased	O
linearly	O
during	O
600	B-MED
-	I-MED
second	I-MED
discharge	I-MED
.	O
The	O
value	O
of	O
pH	B-MED
in	O
PBS	B-MED
(	O
+	O
)	O
against	O
the	O
plasma	B-MED
discharge	B-MED
time	I-MED
was	O
stable	O
at	O
about	O
7.0	O
.	O
Temperature	B-MED
in	O
PBS	B-MED
(	O
+	O
)	O
rose	O
monotonically	O
,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0.8	O
°	O
C	O
at	O
the	O
bottom	O
of	O
a	O
cell	B-MED
-	I-MED
cultured	I-MED
dish	O
by	O
the	O
plasma	B-MED
discharge	B-MED
for	I-MED
600	I-MED
s	I-MED
s.	O
Short	O
-	O
time	O
treatment	B-MED
treatment	B-MED
of	O
the	O
plasma	B-MED
enhanced	B-MED
proliferation	B-MED
activity	O
of	O
endothelial	B-MED
cells	I-MED
.	O
In	O
contrast	O
,	O
the	O
treatment	B-MED
of	O
H2O2	B-MED
does	O
not	O
enhance	O
the	O
cell	B-MED
proliferation	I-MED
.	O
Thus	O
,	O
the	O
ROS	B-MED
production	O
and	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
activation	O
due	O
to	O
the	O
plasma	B-MED
treatment	B-MED
might	O
be	O
related	O
to	O
enhancement	B-MED
of	O
the	O
cell	B-MED
proliferation	I-MED
.	O
Our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical	B-MED
applications	I-MED
using	O
the	O
gas	B-MED
-	O
liquid	B-MED
plasma	B-MED
.	O
Application	B-MED
of	O
Laparoscopic	B-MED
Lumbar	B-MED
Discectomy	I-MED
and	O
Artificial	B-MED
Disc	I-MED
Replacement	I-MED
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow	B-MED
-	I-MED
Up	I-MED
This	O
prospective	B-MED
observational	B-MED
study	I-MED
included	O
22	O
patients	B-MED
who	O
were	O
diagnosed	B-MED
with	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
treated	O
via	O
artificial	B-MED
disc	I-MED
replacement	I-MED
(	O
ADR	B-MED
)	O
with	O
a	O
laparoscopic	B-MED
technique	B-MED
.	O
The	O
current	O
study	B-MED
aimed	B-MED
to	O
assess	B-MED
the	O
safety	B-MED
and	O
efficacy	B-MED
of	O
ADR	B-MED
using	O
a	O
laparoscopic	B-MED
technique	B-MED
for	O
lumbar	B-MED
disc	I-MED
herniation	I-MED
.	O
Symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
is	O
the	O
major	O
cause	O
of	O
low	B-MED
back	I-MED
pain	I-MED
with	O
lumbar	B-MED
segmental	B-MED
instability	B-MED
.	O
ADR	B-MED
has	O
increased	B-MED
in	O
popularity	B-MED
as	O
an	O
alternative	B-MED
treatment	I-MED
for	O
lumbar	B-MED
disc	I-MED
herniation	I-MED
.	O
However	O
,	O
the	O
traditional	B-MED
approach	B-MED
to	O
spinal	B-MED
surgery	I-MED
carries	O
the	O
risk	B-MED
of	O
catastrophic	B-MED
bleeding	B-MED
from	O
injury	B-MED
to	O
major	O
vessels	B-MED
,	O
as	O
well	O
as	O
iatrogenic	B-MED
injury	B-MED
to	O
the	O
viscera	B-MED
and	O
associated	B-MED
structures	I-MED
.	O
Therefore	O
,	O
laparoscopic	B-MED
lumbar	B-MED
discectomy	I-MED
and	O
ADR	B-MED
may	O
represent	B-MED
a	O
useful	O
alternative	B-MED
.	O
Twenty	O
-	O
two	O
patients	B-MED
(	O
8	O
males	B-MED
and	O
14	O
females	B-MED
)	O
who	O
were	O
diagnosed	B-MED
with	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
were	O
included	O
in	O
this	O
study	B-MED
.	O
Seven	O
cases	B-MED
involved	O
the	O
L4/5	O
level	O
,	O
and	O
15	O
cases	B-MED
involved	O
the	O
L5	O
/	O
S1	O
level	O
.	O
All	O
patients	B-MED
were	O
ineffective	B-MED
after	O
at	O
least	O
6	O
months	O
of	O
conservative	B-MED
treatments	I-MED
;	O
all	O
patients	B-MED
were	O
informed	O
of	O
the	O
surgery	B-MED
before	O
the	O
operation	B-MED
and	O
provided	O
consent	B-MED
.	O
Three	B-MED
-	I-MED
dimensional	I-MED
computed	B-MED
tomographic	I-MED
angiography	I-MED
(	O
3D	B-MED
-	O
CTA	B-MED
)	O
of	O
the	O
iliac	B-MED
great	O
blood	B-MED
vessels	I-MED
was	O
completed	B-MED
before	O
the	O
surgery	B-MED
.	O
All	O
surgical	B-MED
procedures	I-MED
were	O
performed	O
under	O
a	O
laparoscope	B-MED
.	O
All	O
patients	B-MED
were	O
followed	B-MED
up	I-MED
.	O
All	O
surgeries	B-MED
were	O
successfully	B-MED
completed	B-MED
.	O
The	O
average	B-MED
operation	B-MED
time	B-MED
was	O
120	O
minutes	O
(	O
range	B-MED
110	O
-	O
150	O
min	O
)	O
,	O
and	O
the	O
average	B-MED
hemorrhage	B-MED
was	O
145	O
mL	O
(	O
range	B-MED
80	O
-	O
360	O
mL	O
)	O
.	O
All	O
cases	B-MED
underwent	O
X	B-MED
-	I-MED
rays	I-MED
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
The	O
outcome	B-MED
indicated	O
that	O
there	O
was	O
no	O
mobilization	B-MED
,	O
displacement	B-MED
,	O
or	O
subsidence	B-MED
in	O
all	O
patients	B-MED
with	O
the	O
exception	B-MED
of	O
one	O
case	B-MED
with	O
prosthesis	B-MED
migration	I-MED
.	O
The	O
follow	B-MED
-	I-MED
up	I-MED
time	O
was	O
43.8	O
months	O
(	O
range	B-MED
24	O
-	O
64	O
months	O
)	O
.	O
The	O
mean	B-MED
visual	B-MED
analog	I-MED
scale	I-MED
(	O
VAS	B-MED
)	O
and	O
Oswestry	B-MED
scores	I-MED
were	O
decreased	B-MED
postoperatively	B-MED
.	O
The	O
mean	B-MED
improvement	B-MED
rate	B-MED
of	O
the	O
VAS	B-MED
score	I-MED
was	O
73.5	O
%	O
.	O
Lumbar	B-MED
ADR	B-MED
using	O
a	O
laparoscope	B-MED
represents	O
a	O
novel	O
,	O
minimally	B-MED
invasive	I-MED
treatment	B-MED
for	O
symptomatic	B-MED
degenerative	B-MED
disc	I-MED
disease	I-MED
and	O
severe	B-MED
lumbar	B-MED
discogenic	I-MED
pain	I-MED
.	O
Hospitalist	B-MED
Co	B-MED
-	I-MED
management	I-MED
of	O
Pediatric	B-MED
Orthopaedic	B-MED
Surgical	B-MED
Patients	I-MED
at	O
a	O
Community	B-MED
Hospital	I-MED
The	O
benefits	O
of	O
hospitalist	B-MED
co	B-MED
-	I-MED
management	I-MED
of	O
pediatric	B-MED
surgical	B-MED
patients	I-MED
include	O
bettering	B-MED
patient	B-MED
safety	I-MED
,	O
decreasing	B-MED
negative	B-MED
patient	B-MED
outcomes	I-MED
,	O
providing	O
comprehensive	B-MED
medical	I-MED
care	I-MED
,	O
and	O
establishing	O
a	O
dedicated	B-MED
resource	I-MED
to	O
patients	B-MED
for	O
postoperative	B-MED
care	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
characterize	B-MED
the	O
nature	B-MED
of	O
patients	B-MED
co	O
-	O
managed	O
by	O
a	O
pediatric	B-MED
hospitalist	B-MED
.	O
The	O
authors	B-MED
hypothesize	B-MED
that	O
hospitalist	B-MED
co	B-MED
-	I-MED
management	I-MED
is	O
safe	B-MED
and	O
efficacious	B-MED
in	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
who	O
are	O
admitted	B-MED
to	O
a	O
community	B-MED
hospital	I-MED
.	O
A	O
retrospective	B-MED
review	I-MED
was	O
performed	O
of	O
all	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
admitted	B-MED
to	O
a	O
community	B-MED
hospital	I-MED
who	O
were	O
co	O
-	O
managed	O
by	O
a	O
pediatric	B-MED
hospitalist	B-MED
.	O
Indications	O
for	O
hospitalization	B-MED
included	O
pain	B-MED
control	I-MED
,	O
antibiotic	B-MED
infusion	I-MED
,	O
and	O
need	O
for	O
neurovascular	B-MED
monitoring	I-MED
.	O
Parameters	B-MED
of	O
postoperative	B-MED
care	I-MED
and	O
co	B-MED
-	I-MED
management	I-MED
were	O
assessed	B-MED
,	O
including	O
presence	B-MED
of	O
complications	B-MED
,	O
medication	B-MED
introduction	I-MED
or	O
adjustment	O
by	O
the	O
hospitalist	B-MED
,	O
follow	B-MED
-	I-MED
up	I-MED
adherence	B-MED
,	O
and	O
readmission	B-MED
/	O
complication	B-MED
rates	B-MED
after	O
discharge	B-MED
.	O
Thirty	O
-	O
two	O
patients	B-MED
were	O
assessed	B-MED
with	O
an	O
average	B-MED
age	I-MED
of	O
8.8	O
years	B-MED
.	O
Twenty	O
-	O
five	O
percent	B-MED
of	O
patients	B-MED
had	O
an	O
associated	B-MED
comorbidity	I-MED
,	O
including	O
asthma	B-MED
,	O
attention	B-MED
deficit	I-MED
disorder	I-MED
,	O
and/or	O
autism	B-MED
.	O
The	O
pediatric	B-MED
hospitalist	B-MED
added	O
pain	B-MED
medication	I-MED
to	O
the	O
original	O
postoperative	B-MED
orders	I-MED
placed	O
by	O
the	O
orthopaedics	B-MED
team	I-MED
in	O
44	O
percent	B-MED
of	O
patients	B-MED
(	O
14	O
of	O
the	O
32	O
)	O
either	O
for	O
breakthrough	B-MED
pain	I-MED
or	O
better	O
long	O
-	O
term	O
coverage	O
.	O
Additionally	O
,	O
25	O
percent	B-MED
of	O
patients	B-MED
had	O
pain	B-MED
medication	I-MED
adjusted	O
from	O
the	O
original	O
dosing	B-MED
and	O
schedule	B-MED
.	O
The	O
hospitalist	B-MED
team	B-MED
contacted	O
the	O
surgeon	B-MED
about	O
the	O
four	O
patients	B-MED
(	O
12.5	O
percent	B-MED
)	O
.	O
In	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	B-MED
was	O
contacted	O
to	O
discuss	O
pain	B-MED
medication	I-MED
,	O
and	O
one	O
patient	B-MED
woke	O
up	O
agitated	O
from	O
anesthesia	B-MED
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-MED
on	O
the	O
pediatrics	O
floor	O
.	O
The	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	B-MED
.	O
The	O
hospitalists	B-MED
rounded	O
on	O
and	O
discharged	B-MED
patients	I-MED
the	O
subsequent	O
morning	O
.	O
All	O
patients	B-MED
were	O
given	O
a	O
follow	B-MED
-	I-MED
up	I-MED
appointment	I-MED
and	I-MED
schedule	I-MED
by	O
the	O
hospitalist	B-MED
team	O
,	O
and	O
every	B-MED
patient	I-MED
followed	B-MED
up	I-MED
accordingly	O
within	O
ten	O
days	B-MED
of	O
discharge	B-MED
.	O
No	O
complications	B-MED
or	O
hospital	B-MED
readmissions	I-MED
occurred	O
within	O
thirty	O
days	B-MED
of	O
discharge	B-MED
.	O
Hospitalist	B-MED
co	B-MED
-	I-MED
management	I-MED
of	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
patients	B-MED
in	O
a	O
community	B-MED
hospital	I-MED
allows	O
for	O
better	O
medical	B-MED
comorbidity	I-MED
and	O
medication	B-MED
management	I-MED
.	O
Hospitalist	B-MED
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	B-MED
stay	I-MED
and	O
help	B-MED
streamline	B-MED
communication	I-MED
between	O
providers	B-MED
and	O
patients	B-MED
while	O
allowing	O
the	O
surgeon	B-MED
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O
Co	B-MED
-	I-MED
management	I-MED
is	O
safe	B-MED
and	O
efficacious	B-MED
in	O
pediatric	B-MED
orthopaedic	B-MED
surgical	B-MED
patients	I-MED
patients	B-MED
who	O
are	O
admitted	B-MED
to	O
a	O
community	B-MED
hospital	I-MED
.	O
A	O
Giant	B-MED
Aneurysmal	B-MED
Bone	I-MED
Cyst	I-MED
in	O
the	O
Mandibular	B-MED
Condyle	I-MED
Aneurysmal	B-MED
bone	I-MED
cyst	I-MED
(	O
ABC	B-MED
)	O
is	O
a	O
rare	B-MED
,	O
rapidly	B-MED
expanding	B-MED
,	O
locally	B-MED
destructive	B-MED
,	O
and	O
easily	B-MED
misdiagnosed	B-MED
lesion	B-MED
.	O
An	O
ABC	B-MED
of	O
the	O
condyle	B-MED
is	O
rare	B-MED
.	O
This	O
report	O
presents	O
a	O
25-	O
year	B-MED
-	O
old	B-MED
female	B-MED
with	O
a	O
giant	B-MED
ABC	B-MED
in	O
the	O
left	B-MED
mandibular	I-MED
condyle	I-MED
mandibular	B-MED
condyle	I-MED
.	O
This	O
patient	B-MED
was	O
treated	B-MED
with	I-MED
surgical	B-MED
resection	I-MED
of	O
the	O
affected	B-MED
bone	B-MED
and	O
immediate	O
mandibular	B-MED
reconstruction	I-MED
using	O
autologous	B-MED
bone	B-MED
.	O
Follow	B-MED
-	I-MED
up	I-MED
to	I-MED
date	I-MED
showed	O
no	O
signs	B-MED
of	O
recurrence	B-MED
.	O
The	O
clinical	B-MED
feature	B-MED
,	O
imaging	B-MED
finding	I-MED
,	O
pathogenesis	B-MED
,	O
and	O
treatment	B-MED
methods	I-MED
of	O
ABCs	B-MED
are	O
discussed	O
.	O
Double	B-MED
strand	I-MED
break	I-MED
induction	B-MED
and	O
kinetics	B-MED
indicate	O
preserved	O
hypersensitivity	B-MED
in	O
keratinocytes	B-MED
to	O
subtherapeutic	B-MED
doses	B-MED
for	O
7	O
weeks	B-MED
of	O
radiotherapy	B-MED
Previously	O
we	O
reported	O
that	O
hyper	B-MED
-	I-MED
radiosensitivity	I-MED
(	O
HRS	B-MED
)	O
was	O
evidenced	O
by	O
quantifying	B-MED
DNA	B-MED
double	I-MED
strand	I-MED
break	I-MED
(	I-MED
DSB	I-MED
)	I-MED
foci	I-MED
in	O
epidermis	B-MED
biopsies	B-MED
collected	O
after	O
delivering	O
radiotherapeutic	B-MED
one	O
and	O
five	O
dose	B-MED
fractions	I-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
whether	O
HRS	B-MED
was	O
preserved	O
throughout	O
a	O
7-	O
week	B-MED
radiotherapy	B-MED
treatment	B-MED
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B-MED
decline	O
and	O
foci	B-MED
persistence	O
between	O
dose	B-MED
fractions	I-MED
.	O
42	O
patients	B-MED
with	O
prostate	B-MED
cancer	I-MED
received	O
7-	O
week	B-MED
fractionated	O
radiotherapy	B-MED
treatment	I-MED
(	O
RT	B-MED
)	O
with	O
daily	O
dose	B-MED
fractions	I-MED
of	O
0.05	O
-	O
1.10Gy	O
to	O
the	O
skin	B-MED
.	O
Before	O
RT	B-MED
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-MED
,	O
skin	B-MED
biopsies	I-MED
(	O
n=452	O
)	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	B-MED
fractions	I-MED
.	O
DSB	B-MED
-	I-MED
foci	I-MED
markers	B-MED
,	O
γH2AX	B-MED
and	O
53BP1	B-MED
,	O
were	O
labelled	O
in	O
epidermal	B-MED
keratinocytes	B-MED
with	O
immunofluorescence	B-MED
and	O
immunohistochemical	B-MED
staining	I-MED
.	O
Foci	O
were	O
counted	O
both	O
with	O
digital	B-MED
image	I-MED
analysis	I-MED
and	O
manually	O
.	O
HRS	B-MED
in	O
keratinocytes	B-MED
was	O
evidenced	O
by	O
the	O
dose	B-MED
-	I-MED
response	I-MED
relationships	I-MED
of	O
DSB	B-MED
foci	I-MED
,	O
observed	O
throughout	O
the	O
treatment	B-MED
course	I-MED
,	O
independent	B-MED
of	I-MED
sampling	B-MED
time	B-MED
and	O
quantification	B-MED
method	B-MED
.	O
Foci	B-MED
observed	O
at	O
24h	O
after	O
dose	B-MED
fractions	I-MED
indicated	O
considerable	O
DSB	B-MED
persistence	O
.	O
Accordingly	O
,	O
foci	B-MED
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	B-MED
fractions	I-MED
.	O
For	O
doses	B-MED
below	O
0.3Gy	O
,	O
persistent	O
foci	B-MED
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B-MED
induction	B-MED
.	O
A	O
comparison	B-MED
of	O
γH2AX	B-MED
and	O
53BP1	B-MED
quantifications	B-MED
in	O
double	B-MED
-	I-MED
staine	I-MED
d	O
biopsies	B-MED
showed	O
similar	O
HRS	B-MED
dose	B-MED
-	I-MED
response	I-MED
relationships	I-MED
.	O
These	O
results	O
represented	O
the	O
first	O
evidence	B-MED
of	O
preserved	O
HRS	B-MED
,	O
assessed	B-MED
by	O
γH2AX	B-MED
-	O
and	O
53BP1	B-MED
-labelled	O
DSB	B-MED
foci	I-MED
,	O
throughout	O
a	O
7-	O
week	B-MED
treatment	B-MED
course	I-MED
with	O
daily	B-MED
repeated	O
subtherapeutic	B-MED
dose	B-MED
fractions	I-MED
.	O
Geographical	B-MED
variations	I-MED
in	O
incidence	B-MED
,	O
management	B-MED
and	O
survival	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
in	O
a	O
Western	B-MED
country	I-MED
Information	B-MED
on	O
the	O
incidence	B-MED
,	O
management	B-MED
,	O
and	O
prognosis	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
(	O
HCC	B-MED
)	O
is	O
derived	O
from	O
population	B-MED
samples	I-MED
,	O
regional	B-MED
data	B-MED
,	O
or	O
registries	B-MED
.	O
Comprehensive	B-MED
national	B-MED
evaluations	B-MED
within	O
a	O
given	O
country	B-MED
are	O
lacking	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
investigate	B-MED
regional	B-MED
variations	B-MED
in	O
HCC	B-MED
care	B-MED
within	O
France	B-MED
.	O
This	O
observational	B-MED
study	I-MED
analysed	O
data	B-MED
from	O
French	B-MED
administrative	B-MED
databases	I-MED
for	O
more	O
than	O
30,000	O
patients	B-MED
with	O
HCC	B-MED
diagnosed	B-MED
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O
The	O
incidence	B-MED
of	O
HCC	B-MED
,	O
access	B-MED
to	O
surgery	B-MED
,	O
and	O
survival	B-MED
,	O
at	O
both	O
the	O
national	B-MED
level	I-MED
and	O
two	O
geographical	B-MED
levels	I-MED
(	O
the	O
21	O
French	B-MED
regions	I-MED
and	O
95	O
French	B-MED
departments	B-MED
into	O
which	O
France	B-MED
is	O
divided	B-MED
administratively	I-MED
)	O
,	O
were	O
determined	O
.	O
The	O
influence	B-MED
on	O
outcome	B-MED
of	O
the	O
structure	O
of	O
the	O
hospital	B-MED
where	O
HCC	B-MED
was	O
first	O
managed	B-MED
was	O
assessed	B-MED
.	O
At	O
the	O
national	B-MED
level	I-MED
,	O
the	O
median	B-MED
survival	I-MED
was	O
9.4	O
months	B-MED
and	O
only	O
22.8	O
%	O
of	O
patients	B-MED
had	O
curative	B-MED
treatment	I-MED
.	O
There	O
were	O
marked	O
variations	O
between	O
regions	B-MED
and	O
departments	B-MED
in	O
incidence	B-MED
,	O
access	B-MED
to	O
curative	B-MED
treatment	I-MED
(	O
range	O
1.3	O
-	O
28.8	O
%	O
and	O
8.1	O
-	O
32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	B-MED
survival	I-MED
(	O
range	B-MED
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	B-MED
respectively	O
)	O
.	O
The	O
administrative	B-MED
type	I-MED
and	O
annual	B-MED
HCC	B-MED
-	O
caseload	B-MED
of	O
the	O
hospital	B-MED
where	O
patients	B-MED
were	O
first	O
admitted	B-MED
also	O
had	O
an	O
independent	B-MED
influence	B-MED
on	O
treatment	B-MED
and	O
survival	B-MED
.	O
Despite	O
full	O
insurance	B-MED
coverage	I-MED
for	O
all	O
citizens	B-MED
,	O
national	B-MED
measures	B-MED
to	O
reduce	B-MED
inequities	I-MED
in	O
the	O
management	B-MED
of	O
cancer	B-MED
patients	I-MED
,	O
standardised	O
recommendations	B-MED
for	O
HCC	B-MED
surveillance	B-MED
and	O
management	B-MED
,	O
the	O
percentage	B-MED
of	O
patients	B-MED
undergoing	O
curative	B-MED
treatment	I-MED
and	O
their	O
survival	B-MED
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	B-MED
.	O
The	O
hospital	B-MED
in	O
which	O
patients	B-MED
are	O
first	O
managed	B-MED
has	O
a	O
clear	O
influence	B-MED
on	O
accessibility	B-MED
to	O
both	O
good	B-MED
care	I-MED
and	O
survival	B-MED
.	O
Population	B-MED
-	I-MED
based	I-MED
studies	I-MED
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B-MED
in	O
the	O
survival	B-MED
of	O
patients	B-MED
with	O
malignancy	B-MED
.	O
As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	B-MED
of	O
health	B-MED
systems	I-MED
,	O
in	O
addition	O
to	O
the	O
incidence	B-MED
of	O
the	O
cancer	B-MED
or	O
quality	B-MED
of	O
registration	B-MED
,	O
variations	O
within	O
a	O
given	O
country	B-MED
should	O
be	O
minimal	B-MED
.	O
However	O
,	O
similar	O
to	O
between	O
countries	B-MED
differences	O
,	O
this	O
study	B-MED
shows	O
differences	O
within	O
the	O
same	O
country	B-MED
in	O
the	O
incidence	B-MED
,	O
curative	B-MED
treatment	I-MED
rate	B-MED
,	O
and	O
survival	B-MED
of	O
patients	B-MED
with	O
HCC	B-MED
.	O
Evidence	B-MED
that	O
access	O
to	O
care	B-MED
and	O
survival	B-MED
varies	O
within	O
a	O
country	B-MED
can	O
strengthen	B-MED
the	I-MED
impetus	I-MED
for	O
government	B-MED
and	O
clinicians	B-MED
to	O
address	O
these	O
disparities	B-MED
.	O
Evaluation	O
of	O
DNMT1	B-MED
gene	B-MED
expression	I-MED
profile	I-MED
and	O
methylation	B-MED
of	O
its	O
promoter	B-MED
region	I-MED
in	O
patients	B-MED
with	O
ankylosing	B-MED
spondylitis	I-MED
Ankylosing	B-MED
spondylitis	I-MED
(	O
AS	B-MED
)	O
is	O
an	O
autoimmune	B-MED
disease	I-MED
with	O
a	O
chronic	B-MED
inflammatory	I-MED
arthritis	I-MED
.	O
The	O
critical	O
role	O
of	O
methylation	B-MED
in	O
the	O
biology	B-MED
of	O
immunocytes	B-MED
has	O
increasingly	O
been	O
surveyed	B-MED
to	O
discover	O
disease	B-MED
etiology	B-MED
.	O
DNA	B-MED
methyltransferase	I-MED
1	I-MED
(	O
DNMT1	B-MED
)	O
is	O
an	O
enzyme	B-MED
,	O
which	O
establishes	O
and	O
regulates	B-MED
patterns	B-MED
of	O
methylated	B-MED
cytosine	I-MED
residues	O
.	O
The	O
aim	B-MED
of	O
the	O
current	O
investigation	B-MED
was	O
to	O
unveil	O
if	O
methylation	B-MED
circumstances	O
of	O
CpG	B-MED
sites	B-MED
in	O
DNMT1	B-MED
promoter	B-MED
could	O
affect	O
the	O
mRNA	B-MED
expression	I-MED
level	B-MED
of	O
this	O
gene	B-MED
in	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
(	O
PBMCs	B-MED
)	O
from	O
AS	B-MED
patients	B-MED
.	O
PBMCs	B-MED
were	O
isolated	O
from	O
whole	B-MED
blood	I-MED
of	O
40	O
AS	B-MED
patients	B-MED
and	O
40	O
healthy	B-MED
individuals	B-MED
.	O
Total	O
RNA	B-MED
and	O
DNA	B-MED
contents	O
of	O
leukocytes	B-MED
were	O
extracted	B-MED
.	O
Afterward	O
,	O
quantitative	B-MED
analysis	I-MED
was	O
carried	O
out	O
by	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
using	O
the	O
SYBR	B-MED
Green	I-MED
PCR	I-MED
Master	I-MED
Mix	I-MED
.	O
Finally	O
,	O
to	O
determine	O
the	O
methylation	B-MED
level	B-MED
,	O
PCR	B-MED
products	B-MED
of	O
bisulfite	B-MED
-	I-MED
treated	I-MED
DNA	I-MED
from	O
patients	B-MED
and	O
controls	B-MED
were	O
sequenced	B-MED
.	O
Compared	O
with	O
healthy	B-MED
controls	B-MED
,	O
expression	B-MED
level	I-MED
of	O
DNMT1	B-MED
in	O
AS	B-MED
patients	B-MED
was	O
significantly	O
downregulated	B-MED
.	O
Methylation	B-MED
of	O
DNMT1	B-MED
promoter	B-MED
was	O
significantly	O
higher	O
in	O
AS	B-MED
patients	B-MED
in	O
comparison	O
to	O
controls	B-MED
.	O
While	O
a	O
negative	B-MED
correlation	B-MED
between	O
methylation	B-MED
and	O
expression	B-MED
level	I-MED
of	O
DNMT1	B-MED
was	O
observed	O
in	O
AS	B-MED
patients	B-MED
,	O
both	O
methylation	B-MED
and	O
expression	B-MED
level	I-MED
of	O
DNMT1	B-MED
did	O
not	O
correlate	B-MED
with	O
clinical	B-MED
manifestations	B-MED
.	O
Considering	O
the	O
observation	O
that	O
decreased	B-MED
expression	B-MED
level	I-MED
of	O
DNMT1	B-MED
was	O
associated	O
with	O
hypermethylation	B-MED
of	O
DNMT1	B-MED
promoter	B-MED
in	O
PBMCs	B-MED
from	O
AS	B-MED
patients	B-MED
,	O
this	O
survey	B-MED
suggests	O
that	O
dysregulation	O
of	O
DNMT1	B-MED
expression	B-MED
through	O
altered	B-MED
methylation	B-MED
level	B-MED
of	O
other	O
target	B-MED
genes	B-MED
would	O
probably	O
contribute	O
to	O
AS	B-MED
development	O
.	O
Psychological	B-MED
factors	I-MED
associated	B-MED
with	I-MED
NAFLD	B-MED
/	O
NASH	B-MED
:	O
a	O
systematic	B-MED
review	I-MED
Nonalcoholic	B-MED
fatty	I-MED
liver	I-MED
disease	I-MED
(	O
NAFLD	B-MED
)	O
represents	O
one	O
of	O
the	O
most	O
common	O
chronic	B-MED
liver	I-MED
diseases	I-MED
worldwide	O
.	O
So	O
far	O
,	O
the	O
pathogenesis	B-MED
of	O
NAFLD	B-MED
and	O
its	O
more	O
severe	B-MED
variant	O
nonalcoholic	B-MED
steatohepatitis	I-MED
(	O
NASH	B-MED
)	O
is	O
yet	O
unclear	O
,	O
with	O
many	O
mechanisms	B-MED
being	O
proposed	O
as	O
possible	O
causes	O
.	O
This	O
article	O
aims	O
to	O
review	B-MED
the	O
psychological	B-MED
factors	I-MED
associated	B-MED
with	I-MED
NAFLD	B-MED
/	O
NASH	B-MED
.	O
Three	O
main	O
categories	O
of	O
factors	B-MED
have	O
been	O
investigated	B-MED
:	O
emotional	B-MED
,	O
cognitive	B-MED
and	O
behavioral	B-MED
.	O
Five	O
electronic	B-MED
databases	I-MED
were	O
searched	O
,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
English	B-MED
language	I-MED
,	O
during	O
the	O
period	B-MED
2005	O
-	O
2015	O
:	O
PubMed	B-MED
,	O
Thomson	B-MED
ISI	I-MED
-	I-MED
Web	I-MED
of	I-MED
Science	I-MED
,	O
Scopus	B-MED
,	O
ProQuest	B-MED
,	O
and	O
ScienceDirect	B-MED
.	O
Results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-MED
factors	B-MED
to	O
be	O
depression	B-MED
and	O
anxiety	B-MED
.	O
The	O
areas	O
of	O
investigation	B-MED
for	O
cognitive	B-MED
functioning	I-MED
concern	O
those	O
contents	B-MED
and	O
processes	B-MED
related	O
to	O
the	O
ability	O
to	O
initiate	B-MED
and	O
maintain	O
lifestyle	B-MED
changes	I-MED
.	O
The	O
most	O
important	O
behavioral	B-MED
factors	B-MED
identified	O
are	O
physical	B-MED
activity	I-MED
,	O
nutrition	B-MED
/	O
food	B-MED
intake	I-MED
and	O
substance	B-MED
consumption	B-MED
:	O
coffee	B-MED
,	O
alcohol	B-MED
,	O
cigarettes	B-MED
.	O
Some	O
of	O
the	O
factors	B-MED
identified	O
act	O
as	O
protective	B-MED
factors	I-MED
,	O
other	O
as	O
vulnerability	B-MED
factors	I-MED
.	O
NAFLD	B-MED
/	O
NASH	B-MED
may	O
be	O
considered	O
a	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
disease	I-MED
,	O
the	O
most	O
effective	O
management	B-MED
being	O
lifestyle	B-MED
changes	I-MED
,	O
with	O
emphasis	O
on	O
diet	B-MED
and	O
exercise	B-MED
.	O
WDR26	B-MED
promotes	B-MED
mitophagy	B-MED
of	O
cardiomyocytes	B-MED
induced	B-MED
by	O
hypoxia	B-MED
through	O
Parkin	B-MED
translocation	B-MED
Myocardial	B-MED
ischemia	I-MED
is	O
a	O
heart	B-MED
condition	B-MED
caused	O
by	O
reduction	B-MED
of	O
blood	B-MED
flow	I-MED
to	O
the	O
heart	B-MED
,	O
preventing	O
heart	B-MED
from	O
receiving	B-MED
enough	O
oxygen	B-MED
.	O
Myocardial	B-MED
ischemia	I-MED
is	O
the	O
most	O
common	O
cause	B-MED
of	I-MED
death	I-MED
globally	B-MED
.	O
Heart	B-MED
ischemic	B-MED
preconditioning	I-MED
(	O
IPC	B-MED
)	O
has	O
a	O
protective	B-MED
effect	I-MED
against	O
myocardial	B-MED
cell	I-MED
death	B-MED
induced	B-MED
by	O
ischemia	B-MED
and	O
ischemia	B-MED
-	I-MED
reperfusion	I-MED
injury	I-MED
.	O
WDR26	B-MED
has	O
recently	O
been	O
identified	B-MED
as	O
a	O
protein	B-MED
that	O
is	O
increased	B-MED
following	O
rat	B-MED
cardiac	B-MED
IPC	B-MED
.	O
WDR26	B-MED
can	O
promote	B-MED
the	O
proliferation	B-MED
of	O
H9c2	B-MED
cells	I-MED
and	O
protect	O
cardiomyocytes	B-MED
against	O
oxidative	B-MED
stress	I-MED
through	O
inhibiting	B-MED
apoptosis	B-MED
.	O
However	O
,	O
its	O
role	B-MED
in	O
myocardial	B-MED
ischemia	I-MED
is	O
unclear	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
explore	O
the	O
role	O
of	O
WDR26	B-MED
in	O
myocardial	B-MED
ischemia	I-MED
and	O
H9c2	B-MED
cell	I-MED
hypoxia	B-MED
.	O
Our	O
results	B-MED
showed	O
that	O
WDR26	B-MED
is	O
induced	B-MED
by	O
myocardial	B-MED
ischemia	I-MED
and	O
H9c2	B-MED
cell	I-MED
hypoxia	B-MED
.	O
WDR26	B-MED
protects	O
H9c2	B-MED
cells	I-MED
against	O
hypoxia	B-MED
injury	B-MED
through	O
inhibiting	B-MED
LDH	B-MED
release	O
and	O
increasing	O
cell	B-MED
viability	I-MED
.	O
WDR26	B-MED
promotes	B-MED
hypoxia	B-MED
-	O
induced	B-MED
autophagy	B-MED
in	O
hypoxia	B-MED
of	O
H9c2	B-MED
cells	I-MED
.	O
We	O
further	O
demonstrated	O
that	O
in	O
H9c2	B-MED
cell	I-MED
hypoxia	B-MED
,	O
WDR26	B-MED
increases	B-MED
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
,	O
thereby	O
increases	B-MED
Parkin	B-MED
translocation	B-MED
of	O
mitochondria	B-MED
.	O
After	O
Parkin	B-MED
is	O
translocated	B-MED
at	O
mitochondria	B-MED
,	O
WDR26	B-MED
can	O
increase	B-MED
mitochondria	B-MED
l	O
protein	B-MED
ubiquitination	I-MED
in	O
hypoxia	B-MED
of	O
H9c2	B-MED
cells	I-MED
.	O
WDR26	B-MED
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	B-MED
,	O
and	O
WDR26	B-MED
plays	O
an	O
important	O
role	O
in	O
hypoxia	B-MED
-mediated	O
autophagy	B-MED
and	O
mitophagy	B-MED
.	O
This	O
study	B-MED
provides	O
novel	B-MED
insights	O
into	O
the	O
protective	O
role	O
of	O
WDR26	B-MED
in	O
cardiomyocyte	B-MED
injury	B-MED
during	O
hypoxia	B-MED
.	O
WDR26	B-MED
may	O
serve	O
as	O
a	O
potential	O
target	B-MED
for	O
the	O
treatment	B-MED
of	O
myocardial	B-MED
ischemia	I-MED
.	O
Targeting	B-MED
the	O
ecology	B-MED
within	O
:	O
The	O
role	B-MED
of	O
the	O
gut	B-MED
-	I-MED
brain	I-MED
axis	I-MED
and	O
human	B-MED
microbiota	B-MED
in	O
drug	B-MED
addiction	I-MED
Despite	O
major	B-MED
advances	I-MED
in	O
our	O
understanding	B-MED
of	O
the	O
brain	B-MED
using	B-MED
traditional	B-MED
neuroscience	I-MED
,	O
reliable	B-MED
and	O
efficacious	B-MED
treatments	B-MED
for	O
drug	B-MED
addiction	I-MED
have	O
remained	B-MED
elusive	I-MED
.	O
Hence	O
,	O
the	O
time	B-MED
has	O
come	O
to	O
utilize	B-MED
novel	B-MED
approaches	B-MED
,	O
particularly	O
those	O
drawing	B-MED
upon	O
contemporary	B-MED
advances	B-MED
in	O
fields	B-MED
outside	O
of	O
established	B-MED
neuroscienc	B-MED
e	O
and	O
psychiatry	B-MED
.	O
Put	O
another	O
way	O
,	O
the	O
time	B-MED
has	O
come	O
for	O
a	O
paradigm	B-MED
shift	I-MED
in	O
the	O
addiction	B-MED
sciences	B-MED
.	O
Apropos	B-MED
,	O
a	O
revolution	B-MED
in	O
the	O
area	B-MED
of	O
human	B-MED
health	B-MED
is	O
underway	B-MED
,	O
which	O
is	O
occurring	B-MED
at	O
the	O
nexus	B-MED
between	O
enteric	B-MED
microbiology	B-MED
and	O
neuroscience	B-MED
.	O
It	O
has	O
become	O
increasingly	B-MED
clear	B-MED
that	O
the	O
human	B-MED
microbiota	B-MED
(	O
the	O
vast	O
ecology	B-MED
of	O
bacteria	B-MED
residing	B-MED
within	O
the	O
human	B-MED
organism	B-MED
)	O
,	O
plays	O
an	O
important	B-MED
role	B-MED
in	O
health	B-MED
and	O
disease	B-MED
.	O
This	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	B-MED
that	O
bacteria	B-MED
living	B-MED
in	O
the	O
human	B-MED
body	I-MED
(	O
approximately	B-MED
1	O
kg	O
of	O
mass	B-MED
,	O
roughly	O
equivalent	B-MED
to	O
that	O
of	O
the	O
human	B-MED
brain	B-MED
)	O
outnumber	O
human	B-MED
cells	I-MED
10	O
to	O
1	O
.	O
While	O
advances	O
in	O
the	O
understanding	B-MED
of	O
the	O
role	B-MED
of	O
microbiota	B-MED
in	O
other	O
areas	B-MED
of	O
human	B-MED
health	B-MED
have	O
yielded	B-MED
intriguing	B-MED
results	B-MED
(	O
e.g.	O
,	O
Clostridium	B-MED
difficile	I-MED
,	O
irritable	B-MED
bowel	I-MED
syndrome	I-MED
,	O
autism	B-MED
,	O
etc	O
.	O
)	O
,	O
to	O
date	B-MED
,	O
no	O
systematic	B-MED
programs	B-MED
of	O
research	B-MED
have	O
examined	B-MED
the	O
role	B-MED
of	O
microbiota	B-MED
in	O
drug	B-MED
addiction	I-MED
.	O
The	O
current	B-MED
hypothesis	B-MED
,	O
therefore	O
,	O
is	O
that	O
gut	B-MED
dysbiosis	I-MED
plays	O
a	O
key	O
role	B-MED
in	O
addictive	B-MED
disorders	B-MED
.	O
In	O
the	O
context	B-MED
of	O
this	O
hypothesis	B-MED
,	O
this	O
paper	B-MED
provides	B-MED
a	O
rationale	B-MED
for	O
future	B-MED
research	B-MED
to	O
target	B-MED
the	O
"	O
gut	B-MED
-	O
brain	B-MED
axis	B-MED
"	O
in	O
addiction	B-MED
.	O
A	O
brief	O
background	B-MED
of	O
the	O
gut	B-MED
-	O
brain	B-MED
axis	B-MED
is	O
provided	B-MED
,	O
along	O
with	O
a	O
series	B-MED
of	O
hypothesis	B-MED
-	I-MED
driven	I-MED
ideas	B-MED
outlining	O
potential	B-MED
treatments	B-MED
for	O
addiction	B-MED
via	O
manipulations	B-MED
of	O
the	O
"	O
ecology	B-MED
within	O
.	O
"	O
Assessment	B-MED
of	O
cerebral	B-MED
blood	B-MED
perfusion	I-MED
reserve	O
with	O
acetazolamide	B-MED
using	O
3D	B-MED
spiral	I-MED
ASL	I-MED
MRI	I-MED
:	O
Preliminary	O
experience	O
in	O
pediatric	B-MED
patients	B-MED
To	O
demonstrate	O
the	O
clinical	B-MED
feasibility	I-MED
of	O
a	O
new	O
non	B-MED
-	I-MED
Cartesian	I-MED
cylindrically	I-MED
-	I-MED
distributed	I-MED
spiral	I-MED
3D	I-MED
pseudo	I-MED
-	I-MED
continuous	I-MED
arterial	I-MED
spin	I-MED
labeling	I-MED
(	I-MED
pCASL	I-MED
)	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	I-MED
MRI	I-MED
)	I-MED
pulse	B-MED
sequence	I-MED
in	O
pediatric	B-MED
patients	B-MED
in	O
quantifying	B-MED
cerebral	B-MED
blood	I-MED
flow	I-MED
(	O
CBF	B-MED
)	O
response	O
to	O
an	O
acetazolamide	B-MED
(	I-MED
ACZ	I-MED
)	I-MED
vasodilator	I-MED
challenge	O
.	O
MRI	B-MED
exams	I-MED
were	O
performed	O
on	O
two	O
3	B-MED
Tesla	I-MED
Philips	I-MED
Ingenia	I-MED
systems	I-MED
using	I-MED
32	I-MED
channel	I-MED
head	I-MED
coil	I-MED
arrays	I-MED
.	O
After	O
local	O
institutional	B-MED
review	I-MED
board	I-MED
approval	I-MED
,	O
the	O
3D	B-MED
spiral	I-MED
-	I-MED
based	I-MED
pCASL	I-MED
technique	I-MED
was	O
added	O
to	O
a	O
standard	O
brain	B-MED
MRI	I-MED
exam	I-MED
and	O
evaluated	O
in	O
13	O
pediatric	B-MED
patients	B-MED
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4	O
-	O
22.2years	O
)	O
.	O
All	O
patients	B-MED
were	O
administered	B-MED
ACZ	B-MED
for	O
clinically	B-MED
indicated	I-MED
reasons	O
.	O
Quantitative	O
whole	B-MED
-	I-MED
brain	I-MED
CBF	I-MED
measurements	I-MED
were	O
computed	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
ACZ	B-MED
to	O
assess	O
cerebrovascular	B-MED
reserve	I-MED
.	O
3D	B-MED
spiral	I-MED
pCASL	I-MED
data	B-MED
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B-MED
.	O
In	O
11	O
patients	B-MED
,	O
CBF	B-MED
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	B-MED
of	I-MED
ACZ	B-MED
.	O
In	O
the	O
two	O
remaining	O
patients	B-MED
,	O
CBF	B-MED
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
ACZ	B-MED
.	O
The	O
group	O
average	O
change	O
in	O
CBF	B-MED
due	O
to	O
ACZ	B-MED
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	B-MED
significant	I-MED
(	O
p<0.01	O
)	O
in	O
all	O
patients	B-MED
using	O
a	O
paired	O
t	B-MED
-	I-MED
test	I-MED
analysis	I-MED
.	O
CBF	B-MED
perfusion	B-MED
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B-MED
angiography	I-MED
and	O
clinical	B-MED
findings	I-MED
.	O
3D	B-MED
cylindrically	I-MED
-	I-MED
distributed	I-MED
spiral	I-MED
pCASL	I-MED
MRI	I-MED
provides	O
a	O
robust	O
approach	O
to	O
assess	B-MED
cerebral	B-MED
blood	I-MED
flow	I-MED
and	O
reserve	O
in	O
pediatric	B-MED
patients	B-MED
.	O
Group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferents	B-MED
limit	B-MED
the	O
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
during	O
whole	B-MED
body	I-MED
exercise	B-MED
in	O
humans	B-MED
The	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	B-MED
the	O
role	B-MED
of	O
group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferents	B-MED
in	O
limiting	B-MED
the	O
endurance	B-MED
exercise	B-MED
-	O
induced	B-MED
metabolic	B-MED
perturbation	B-MED
assayed	B-MED
in	O
muscle	B-MED
biopsy	B-MED
samples	I-MED
taken	O
from	O
locomotor	B-MED
muscle	B-MED
.	O
Lumbar	B-MED
intrathecal	B-MED
fentanyl	B-MED
was	O
used	O
to	O
attenuate	B-MED
the	O
central	B-MED
projection	B-MED
of	O
μ	B-MED
-	I-MED
opioid	I-MED
receptor	I-MED
-	O
sensitive	B-MED
locomotor	B-MED
muscle	B-MED
afferents	B-MED
during	O
a	O
5	O
km	O
cycling	B-MED
time	B-MED
trial	B-MED
.	O
The	O
findings	B-MED
suggest	O
that	O
the	O
central	B-MED
projection	B-MED
of	O
group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferent	B-MED
feedback	B-MED
constrains	B-MED
voluntary	B-MED
neural	B-MED
'	O
drive	B-MED
'	O
to	O
working	B-MED
locomotor	B-MED
muscle	B-MED
and	O
limits	B-MED
the	O
exercise	B-MED
-	O
induced	B-MED
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
.	O
Therefore	O
,	O
the	O
CNS	B-MED
might	O
regulate	B-MED
the	O
degree	B-MED
of	O
metabolic	B-MED
perturbation	B-MED
within	O
locomotor	B-MED
muscle	B-MED
and	O
thereby	O
limit	B-MED
peripheral	B-MED
fatigue	B-MED
.	O
It	O
appears	B-MED
that	O
the	O
group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferents	B-MED
are	O
an	O
important	B-MED
neural	B-MED
link	B-MED
in	O
this	O
regulatory	B-MED
mechanism	B-MED
,	O
which	O
probably	B-MED
serves	O
to	O
protect	B-MED
locomotor	B-MED
muscle	B-MED
from	O
the	O
potentially	B-MED
severe	B-MED
functional	B-MED
impairment	I-MED
as	O
a	O
consequence	B-MED
of	O
severe	B-MED
intramuscular	B-MED
metabolic	B-MED
disturbance	B-MED
.	O
To	O
investigate	B-MED
the	O
role	B-MED
of	O
metabo	B-MED
-	O
and	O
mechanosensitive	B-MED
group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferents	B-MED
in	O
limiting	B-MED
the	O
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
during	O
whole	B-MED
body	I-MED
endurance	B-MED
exercise	B-MED
,	O
eight	O
subjects	B-MED
performed	B-MED
5	O
km	O
cycling	B-MED
time	B-MED
trials	B-MED
under	B-MED
control	I-MED
conditions	I-MED
(	O
CTRL	B-MED
)	O
and	O
with	O
lumbar	B-MED
intrathecal	B-MED
fentanyl	B-MED
impairing	B-MED
lower	B-MED
limb	I-MED
muscle	B-MED
afferent	B-MED
feedback	B-MED
(	O
FENT	B-MED
)	O
.	O
Vastus	B-MED
lateralis	I-MED
muscle	B-MED
biopsies	B-MED
were	O
obtained	B-MED
before	B-MED
and	O
immediately	B-MED
after	B-MED
exercise	B-MED
.	O
Motoneuronal	B-MED
output	B-MED
was	I-MED
estimated	I-MED
through	O
vastus	B-MED
lateralis	I-MED
surface	I-MED
electromyography	B-MED
(	O
EMG	B-MED
)	O
.	O
Exercise	B-MED
-	O
induced	B-MED
changes	B-MED
in	O
intramuscular	B-MED
metabolites	B-MED
were	O
determine	B-MED
d	O
using	O
liquid	B-MED
and	O
gas	B-MED
chromatography	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
.	O
Quadriceps	B-MED
fatigue	B-MED
was	O
quantified	B-MED
by	O
pre	B-MED
-	O
to	O
post	B-MED
-	O
exercise	B-MED
changes	B-MED
in	O
potentiated	B-MED
quadriceps	I-MED
twitch	I-MED
torque	I-MED
(	O
ΔQTsingle	B-MED
)	O
evoked	B-MED
by	O
electrical	B-MED
femoral	B-MED
nerve	I-MED
stimulation	B-MED
.	O
Although	O
motoneuronal	B-MED
output	B-MED
was	O
21	O
±	O
12	O
%	O
higher	B-MED
during	O
FENT	B-MED
compared	B-MED
to	O
CTRL	B-MED
(	O
P	O
<	O
0.05	O
)	O
,	O
time	B-MED
to	O
complete	B-MED
the	O
time	B-MED
trial	B-MED
was	O
similar	B-MED
(	O
∼8.8	O
min	O
)	O
.	O
Compared	B-MED
to	O
CTRL	B-MED
,	O
power	B-MED
output	I-MED
during	O
FENT	B-MED
was	O
10	O
±	O
4	O
%	O
higher	B-MED
in	O
the	O
first	B-MED
half	I-MED
of	O
the	O
time	B-MED
trial	B-MED
,	O
but	O
11	O
±	O
5	O
%	O
lower	B-MED
in	O
the	O
second	B-MED
half	I-MED
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O
The	O
exercise	B-MED
-	O
induced	B-MED
increase	B-MED
in	O
intramuscular	B-MED
inorganic	B-MED
phosphate	I-MED
,	O
H(+	B-MED
)	I-MED
,	O
adenosine	B-MED
diphosphate	I-MED
,	O
lactate	B-MED
and	O
phosphocreatine	B-MED
depletion	B-MED
was	O
55	O
±	O
30	O
,	O
62	O
±	O
18	O
,	O
129	O
±	O
63	O
,	O
47	O
±	O
14	O
(	O
P	O
<	O
0.001	O
)	O
and	O
27	O
±	O
14	O
%	O
(	O
P	O
<	O
0.01	O
)	O
greater	B-MED
in	O
FENT	B-MED
than	O
CTRL	B-MED
.	O
ΔQTsingle	B-MED
was	O
greater	B-MED
following	O
FENT	B-MED
than	O
CTRL	B-MED
(	O
-52	O
±	O
2	O
vs	O
-31	O
±	O
1	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
this	O
difference	B-MED
was	O
positively	B-MED
correlated	B-MED
with	O
the	O
difference	B-MED
in	O
inorganic	B-MED
phosphate	I-MED
(	O
r(2	O
)	O
=	O
0.79	O
;	O
P	O
<	O
0.01	O
)	O
and	O
H(+	O
)	O
(	O
r(2	O
)	O
=	O
0.92	O
;	O
P	O
<	O
0.01	O
)	O
.	O
In	O
conclusion	B-MED
,	O
during	O
whole	B-MED
body	I-MED
exercise	B-MED
,	O
group	B-MED
III	I-MED
/	I-MED
IV	I-MED
muscle	I-MED
afferents	B-MED
provide	B-MED
feedback	B-MED
to	O
the	O
CNS	B-MED
which	O
,	O
in	O
turn	O
,	O
constrains	B-MED
motoneuronal	B-MED
output	B-MED
to	O
the	O
active	B-MED
skeletal	B-MED
muscle	I-MED
.	O
This	O
regulatory	B-MED
mechanism	B-MED
limits	B-MED
the	O
exercise	B-MED
-	O
induced	B-MED
intramuscular	B-MED
metabolic	B-MED
perturbation	B-MED
,	O
preventing	O
an	O
abnormal	B-MED
homeostatic	I-MED
challenge	B-MED
and	O
excessive	B-MED
peripheral	B-MED
fatigue	B-MED
.	O
High	O
Diversity	B-MED
of	O
Planctomycetes	B-MED
in	O
Soils	B-MED
of	O
Two	O
Lichen	B-MED
-Dominated	O
Sub	B-MED
-	I-MED
Arctic	I-MED
Ecosystems	B-MED
of	O
Northwestern	B-MED
Siberia	B-MED
A	O
wide	O
variety	O
of	O
terrestrial	B-MED
ecosystems	B-MED
in	O
tundra	B-MED
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	B-MED
(	O
genera	B-MED
Cladonia	B-MED
and	O
Cetraria	B-MED
)	O
.	O
The	O
microbial	B-MED
communities	O
of	O
two	O
lichen	B-MED
-dominated	O
ecosystems	B-MED
typical	O
of	O
the	O
sub	B-MED
-	I-MED
arctic	I-MED
zone	I-MED
of	O
northwestern	B-MED
Siberia	B-MED
,	O
that	O
is	O
a	O
forested	B-MED
tundra	B-MED
soil	B-MED
and	O
a	O
shallow	B-MED
acidic	I-MED
peatland	I-MED
,	O
were	O
examined	O
in	O
our	O
study	B-MED
.	O
As	O
revealed	O
by	O
molecular	O
analyses	O
,	O
soil	B-MED
and	O
peat	B-MED
layers	O
just	O
beneath	O
the	O
lichen	B-MED
cover	O
were	O
abundantly	O
colonized	B-MED
by	O
bacteria	B-MED
from	O
the	O
phylum	B-MED
Planctomycetes	B-MED
.	O
Highest	O
abundance	O
of	O
planctomycetes	B-MED
detected	O
by	O
fluorescence	B-MED
in	B-MED
situ	I-MED
hybridization	I-MED
was	O
in	O
the	O
range	O
2.2	O
-	O
2.7	O
×	O
10(7	O
)	O
cells	B-MED
per	I-MED
gram	I-MED
of	I-MED
wet	I-MED
weight	I-MED
.	O
16S	B-MED
rRNA	I-MED
gene	B-MED
fragments	I-MED
from	O
the	O
Planctomycetes	B-MED
comprised	O
8	O
-	O
13	O
%	O
of	O
total	O
16S	B-MED
rRNA	I-MED
gene	B-MED
reads	O
retrieved	O
using	O
Illumina	B-MED
pair	I-MED
-	I-MED
end	I-MED
sequencing	I-MED
from	O
the	O
soil	B-MED
and	O
peat	B-MED
samples	I-MED
.	O
Lichen	B-MED
-associated	O
assemblages	O
of	O
planctomycetes	B-MED
displayed	O
unexpectedly	O
high	O
diversity	B-MED
,	O
with	O
a	O
total	O
of	O
89,662	O
reads	O
representing	O
1723	O
operational	B-MED
taxonomic	I-MED
units	I-MED
determined	O
at	O
97	O
%	O
sequence	B-MED
identity	I-MED
.	O
The	O
soil	B-MED
of	O
forested	O
tundra	B-MED
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	B-MED
Planctomycetaceae	B-MED
(	O
53	O
-	O
71	O
%	O
of	O
total	O
Planctomycetes	B-MED
-like	O
reads	O
)	O
,	O
while	O
sequences	B-MED
affiliated	O
with	O
the	O
Phycisphaera	B-MED
-	I-MED
related	I-MED
group	I-MED
WD2101	I-MED
(	O
recently	O
assigned	O
to	O
the	O
order	B-MED
Tepidisphaerales	B-MED
)	O
were	O
most	O
abundant	O
in	O
peat	B-MED
(	O
28	O
-	O
51	O
%	O
of	O
total	O
reads	O
)	O
.	O
Representatives	O
of	O
the	O
Isosphaera	B-MED
-	O
Singulisphaera	B-MED
group	I-MED
(	O
14	O
-	O
28	O
%	O
of	O
total	O
reads	O
)	O
and	O
the	O
lineages	B-MED
defined	O
by	O
the	O
genera	B-MED
Gemmata	B-MED
(	O
1	O
-	O
4	O
%	O
)	O
and	O
Planctopirus	B-MED
-	O
Rubinisphaera	B-MED
(	O
1	O
-	O
3	O
%	O
)	O
were	O
present	O
in	O
both	O
habitats	B-MED
.	O
Two	O
strains	O
of	O
Singulisphaera	B-MED
-	I-MED
like	I-MED
bacteria	I-MED
were	O
isolated	O
from	O
studied	O
soil	B-MED
and	O
peat	B-MED
samples	I-MED
.	O
These	O
planctomycetes	B-MED
displayed	O
good	O
tolerance	O
of	O
low	B-MED
temperatures	I-MED
(	O
4	O
-	O
15	O
°	O
C	O
)	O
and	O
were	O
capable	O
of	O
growth	B-MED
on	O
a	O
number	O
of	O
polysaccharides	B-MED
,	O
including	O
lichenan	B-MED
,	O
a	O
characteristic	O
component	O
of	O
lichen	B-MED
-derived	O
phytomass	B-MED
.	O
A	O
Novel	O
Potent	O
Anticancer	B-MED
Compound	I-MED
Optimized	O
from	O
a	O
Natural	B-MED
Oridonin	B-MED
Scaffold	O
Induces	O
Apoptosis	B-MED
and	O
Cell	B-MED
Cycle	I-MED
Arrest	I-MED
through	O
the	O
Mitochondrial	B-MED
Pathway	I-MED
The	O
cytotoxicity	B-MED
of	O
the	O
natural	B-MED
ent	B-MED
-	I-MED
kaurene	I-MED
diterpenoid	I-MED
,	O
oridonin	B-MED
,	O
has	O
been	O
extensively	O
studied	O
.	O
However	O
,	O
the	O
application	O
of	O
oridonin	B-MED
for	O
cancer	B-MED
therapy	I-MED
was	O
hampered	O
primarily	O
by	O
its	O
moderate	B-MED
potency	I-MED
.	O
In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B-MED
A	B-MED
-	I-MED
ring	I-MED
modified	I-MED
analogues	I-MED
,	I-MED
and	I-MED
their	I-MED
derivatives	I-MED
bearing	O
various	O
substituents	B-MED
on	I-MED
14	I-MED
-	I-MED
OH	I-MED
position	I-MED
,	O
were	O
designed	O
,	O
synthesized	B-MED
,	O
and	O
evaluated	B-MED
for	O
anticancer	B-MED
efficacy	B-MED
.	O
Some	O
of	O
the	O
derivatives	B-MED
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-MED
against	O
both	O
drug	B-MED
-	O
sensitive	B-MED
and	O
drug	B-MED
-	I-MED
resistant	I-MED
cancer	B-MED
cells	I-MED
.	O
The	O
most	O
potent	O
compound	B-MED
,	I-MED
13p	I-MED
,	O
was	O
200	B-MED
-	I-MED
fold	I-MED
more	O
efficacious	B-MED
than	O
oridonin	B-MED
in	O
MCF-7	B-MED
cancer	I-MED
cells	I-MED
.	O
Furthermore	O
,	O
13p	B-MED
induced	O
apoptosis	B-MED
and	O
cell	B-MED
cycle	I-MED
arrest	I-MED
at	O
the	O
G2	B-MED
/	I-MED
M	I-MED
phase	I-MED
.	O
A	O
decrease	O
in	O
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
and	O
an	O
increase	O
in	O
Bax	B-MED
/	I-MED
Bcl-2	I-MED
ratio	O
,	O
accompanied	O
by	O
activated	B-MED
caspase-3	I-MED
cleavage	B-MED
,	O
were	O
observed	O
in	O
MCF-7	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
13p	B-MED
,	O
suggesting	O
that	O
the	O
mitochondrial	B-MED
pathway	I-MED
was	O
involved	O
in	O
the	O
13p	B-MED
-mediated	O
apoptosis	B-MED
.	O
Moreover	O
,	O
13p	B-MED
significantly	O
inhibited	O
tumor	B-MED
growth	I-MED
in	O
mouse	B-MED
xenograft	B-MED
models	I-MED
and	O
had	O
no	B-MED
observable	I-MED
toxic	I-MED
effect	I-MED
.	O
Genome	B-MED
-	I-MED
Wide	I-MED
Detection	I-MED
of	O
Selective	B-MED
Signatures	I-MED
in	O
Chicken	B-MED
through	O
High	B-MED
Density	I-MED
SNPs	I-MED
Chicken	B-MED
is	O
recognized	O
as	O
an	O
excellent	O
model	B-MED
for	O
studies	O
of	O
genetic	B-MED
mechanism	B-MED
of	O
phenotypic	B-MED
and	O
genomic	B-MED
evolution	B-MED
,	O
with	O
large	O
effective	O
population	B-MED
size	I-MED
and	O
strong	O
human	B-MED
-driven	O
selection	B-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
performed	O
Extended	B-MED
Haplotype	I-MED
Homozygosity	I-MED
(	O
EHH	B-MED
)	O
tests	O
to	O
identify	O
significant	O
core	B-MED
regions	I-MED
employing	O
600	O
K	O
SNP	B-MED
Chicken	B-MED
chip	B-MED
in	O
an	O
F2	B-MED
population	I-MED
of	O
1,534	O
hens	B-MED
,	O
which	O
was	O
derived	O
from	O
reciprocal	B-MED
crosses	I-MED
between	O
White	B-MED
Leghorn	I-MED
and	O
Dongxiang	B-MED
chicken	I-MED
.	O
Results	O
indicated	O
that	O
a	O
total	O
of	O
49,151	O
core	B-MED
regions	I-MED
with	O
an	O
average	O
length	B-MED
of	O
9.79	O
Kb	O
were	O
identified	B-MED
,	O
which	O
occupied	O
approximately	O
52.15	O
%	O
of	O
genome	B-MED
across	O
all	O
autosomes	B-MED
,	O
and	O
806	O
significant	O
core	B-MED
regions	I-MED
attracted	O
us	O
mostly	O
.	O
Genes	B-MED
in	O
candidate	B-MED
regions	I-MED
may	O
experience	O
positive	B-MED
selection	I-MED
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	B-MED
traits	I-MED
.	O
A	O
panel	B-MED
of	O
genes	B-MED
including	O
AASDHPPT	B-MED
,	O
GDPD5	B-MED
,	O
PAR3	B-MED
,	O
SOX6	B-MED
,	O
GPC1	B-MED
and	O
a	O
signal	B-MED
pathway	I-MED
of	O
AKT1	B-MED
were	O
detected	B-MED
with	O
the	O
most	O
extreme	O
P	B-MED
-	I-MED
values	I-MED
.	O
Further	O
enrichment	B-MED
analyses	I-MED
indicated	O
that	O
these	O
genes	B-MED
were	O
associated	B-MED
with	I-MED
immune	B-MED
function	I-MED
,	O
sensory	B-MED
organ	I-MED
development	I-MED
and	O
neurogenesis	B-MED
,	O
and	O
may	O
have	O
experienced	O
positive	B-MED
selection	I-MED
in	O
chicken	B-MED
.	O
Moreover	O
,	O
some	O
of	O
core	B-MED
regions	I-MED
exactly	O
overlapped	O
with	O
genes	B-MED
excavated	O
in	O
our	O
previous	O
GWAS	B-MED
,	O
suggesting	O
that	O
these	O
genes	B-MED
have	O
undergone	O
positive	B-MED
selection	I-MED
may	O
affect	O
egg	B-MED
production	B-MED
.	O
Findings	B-MED
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome	B-MED
-	I-MED
wide	I-MED
map	I-MED
of	O
selection	B-MED
signature	I-MED
in	O
the	O
chicken	B-MED
genome	B-MED
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	B-MED
mechanisms	B-MED
of	O
phenotypic	B-MED
diversity	B-MED
in	O
poultry	B-MED
breeding	B-MED
.	O
A	O
novel	B-MED
method	B-MED
for	O
interactive	B-MED
multi	B-MED
-	I-MED
objective	I-MED
dose	B-MED
-	I-MED
guided	I-MED
patient	I-MED
positioning	I-MED
In	O
intensity	B-MED
-	I-MED
modulated	I-MED
radiation	I-MED
therapy	I-MED
(	O
IMRT	B-MED
)	O
,	O
3D	O
in	O
-	O
room	O
imaging	B-MED
data	B-MED
is	O
typically	O
utilized	O
for	O
accurate	B-MED
patient	B-MED
alignment	I-MED
on	O
the	O
basis	O
of	O
anatomical	B-MED
landmarks	I-MED
.	O
In	O
the	O
presence	O
of	O
non	O
-	O
rigid	O
anatomical	B-MED
changes	I-MED
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	B-MED
position	I-MED
is	O
most	O
suitable	O
.	O
Thus	O
,	O
dose	B-MED
-guided	O
patient	B-MED
alignment	I-MED
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in	O
-	O
room	O
imaging	B-MED
data	B-MED
for	O
up	O
-	O
to	O
-	O
date	O
dose	B-MED
calculation	B-MED
,	O
aimed	O
at	O
finding	B-MED
the	O
position	O
that	O
yields	O
the	O
optimal	B-MED
dose	B-MED
distribution	B-MED
.	O
This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	B-MED
-guided	O
patient	B-MED
alignment	I-MED
as	O
multi	O
-	O
criteria	O
optimization	O
problem	O
.	O
User	O
-	O
defined	O
clinical	B-MED
objectives	B-MED
are	O
employed	O
for	O
setting	O
up	O
a	O
multi	B-MED
-	I-MED
objective	I-MED
problem	O
.	O
Using	O
pre	O
-	O
calculated	O
dose	B-MED
distributions	B-MED
at	O
a	O
limited	O
number	O
of	O
patient	B-MED
shifts	I-MED
and	O
dose	B-MED
interpolation	B-MED
,	O
a	O
continuous	O
space	O
of	O
Pareto	B-MED
-	I-MED
efficient	I-MED
patient	I-MED
shifts	I-MED
becomes	O
accessible	O
.	O
Pareto	O
sliders	O
facilitate	O
interactive	B-MED
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real	O
-	O
time	O
dose	B-MED
display	O
to	O
the	O
user	O
.	O
Dose	B-MED
interpolation	B-MED
accuracy	B-MED
is	O
validated	O
and	O
the	O
potential	O
of	O
multi	B-MED
-	I-MED
objective	I-MED
dose	B-MED
-	I-MED
guided	I-MED
positioning	I-MED
demonstrated	O
for	O
three	O
head	B-MED
and	I-MED
neck	I-MED
(	O
H&N	B-MED
)	O
and	O
three	O
prostate	B-MED
cancer	I-MED
patients	B-MED
.	O
Dose	B-MED
-	I-MED
guided	I-MED
positioning	I-MED
is	O
compared	B-MED
to	O
replanning	O
for	O
all	O
cases	O
.	O
A	O
delineated	O
replanning	O
CT	B-MED
served	O
as	O
surrogate	O
for	O
in	O
-	O
room	O
imaging	B-MED
data	B-MED
.	O
Dose	B-MED
interpolation	B-MED
accuracy	B-MED
was	O
high	B-MED
.	O
Using	O
a	O
[	O
Formula	O
:	O
see	O
text	O
]	O
dose	B-MED
difference	O
criterion	O
,	O
a	O
median	O
pass	O
-	O
rate	O
of	O
95.7	O
%	O
for	O
H&N	B-MED
and	O
99.6	O
%	O
for	O
prostate	B-MED
cases	I-MED
was	O
determined	O
in	O
a	O
comparison	B-MED
to	O
exact	O
dose	B-MED
calculations	B-MED
.	O
For	O
all	O
patients	B-MED
,	O
dose	B-MED
-	I-MED
guided	I-MED
positioning	I-MED
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	B-MED
distribution	B-MED
compared	B-MED
to	O
bony	B-MED
anatomy	I-MED
based	I-MED
alignment	I-MED
.	O
For	O
all	O
H&N	B-MED
cases	O
,	O
mean	O
dose	B-MED
to	O
the	O
spared	O
parotid	B-MED
glands	I-MED
was	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
up	O
to	O
[	O
Formula	O
:	O
see	O
text	O
]	O
with	O
bony	B-MED
alignment	I-MED
)	O
and	O
clinical	B-MED
target	I-MED
volume	I-MED
(	O
CTV	B-MED
)	O
[	O
Formula	O
:	O
see	O
text	O
]	O
above	O
99.1	O
%	O
(	O
compared	B-MED
to	O
95.1	O
%	O
)	O
.	O
For	O
all	O
prostate	B-MED
patients	B-MED
,	O
CTV	B-MED
[	O
Formula	O
:	O
see	O
text	O
]	O
was	O
above	O
98.9	O
%	O
(	O
compared	B-MED
to	O
88.5	O
%	O
)	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
to	O
the	O
rectum	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
compared	B-MED
to	O
56.1	O
%	O
)	O
.	O
Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H&N	B-MED
cases	O
.	O
For	O
the	O
prostate	B-MED
cases	I-MED
,	O
differences	O
to	O
dose	B-MED
-	I-MED
guided	I-MED
positioning	I-MED
were	O
minor	O
.	O
Wnt-5a	B-MED
/	O
Frizzled9	B-MED
receptor	B-MED
signaling	I-MED
through	O
the	O
Gαo	B-MED
/	O
Gβγ	B-MED
complex	I-MED
regulates	B-MED
dendritic	B-MED
spine	I-MED
formation	B-MED
Wnt	B-MED
ligands	I-MED
play	O
crucial	O
roles	O
in	O
the	O
development	B-MED
and	O
regulation	B-MED
of	I-MED
synapse	I-MED
structure	I-MED
and	I-MED
function	I-MED
.	O
Specifically	O
,	O
Wnt-5a	B-MED
acts	O
as	O
a	O
secreted	B-MED
growth	I-MED
factor	I-MED
that	O
regulates	B-MED
dendritic	B-MED
spine	I-MED
formation	B-MED
in	O
rodent	B-MED
hippocampal	B-MED
neurons	B-MED
,	O
resulting	O
in	O
postsynaptic	B-MED
development	B-MED
that	O
promotes	O
the	O
clustering	B-MED
of	I-MED
the	I-MED
postsynaptic	I-MED
density	I-MED
protein-95	I-MED
(	I-MED
PSD-95	I-MED
)	I-MED
.	O
Here	O
,	O
we	O
focused	O
on	O
the	O
early	B-MED
events	B-MED
occurring	O
after	O
the	O
interaction	B-MED
between	O
Wnt-5a	B-MED
and	O
its	O
Frizzled	B-MED
receptor	I-MED
at	O
the	O
neuronal	B-MED
cell	B-MED
surface	I-MED
.	O
Additionally	O
,	O
we	O
studied	O
the	O
role	B-MED
of	O
heterotrimeric	B-MED
G	I-MED
proteins	I-MED
in	O
Wnt-5a	B-MED
-dependent	O
synaptic	B-MED
development	B-MED
.	O
We	O
report	O
that	O
Frizzled9	B-MED
(	O
FZD9	B-MED
)	O
,	O
a	O
Wnt	B-MED
receptor	B-MED
related	O
to	O
Williams	B-MED
'	I-MED
syndrome	I-MED
,	O
is	O
localized	O
in	O
the	O
postsynaptic	B-MED
region	I-MED
,	O
where	O
it	O
interacts	B-MED
with	O
Wnt-5a	B-MED
.	O
Functionally	O
,	O
FZD9	B-MED
is	O
required	O
for	O
the	O
Wnt-5a	B-MED
-mediated	O
increase	B-MED
in	O
dendritic	B-MED
spine	I-MED
density	I-MED
.	O
FZD9	B-MED
forms	O
a	O
pre	B-MED
-	I-MED
coupled	I-MED
complex	I-MED
with	O
Gαo	B-MED
under	O
basal	B-MED
conditions	I-MED
that	O
dissociates	B-MED
after	O
Wnt-5a	B-MED
stimulation	B-MED
.	O
Accordingly	O
,	O
we	O
found	O
that	O
G	B-MED
-	I-MED
protein	I-MED
inhibition	I-MED
abrogates	I-MED
Wnt-5a	B-MED
-dependent	O
pathway	B-MED
in	O
hippocampal	B-MED
neurons	B-MED
.	O
In	O
particular	O
,	O
the	O
activation	B-MED
of	O
Gαo	B-MED
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	B-MED
the	O
Wnt-5a	B-MED
-	O
induced	B-MED
dendritic	B-MED
spine	I-MED
density	I-MED
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
Gβγ	B-MED
is	O
required	O
for	O
the	O
Wnt-5a	B-MED
-mediated	O
increase	B-MED
in	O
cytosolic	B-MED
calcium	B-MED
levels	B-MED
and	O
spinogenesis	B-MED
.	O
Our	O
findings	B-MED
reveal	O
that	O
FZD9	B-MED
and	O
heterotrimeric	B-MED
G	I-MED
proteins	I-MED
regulate	B-MED
Wnt-5a	B-MED
signaling	B-MED
and	O
dendritic	B-MED
spines	I-MED
in	O
cultured	B-MED
hippocampal	B-MED
neurons	B-MED
.	O
Treated	B-MED
Prevalence	B-MED
of	O
Attention	B-MED
-	I-MED
Deficit	I-MED
/	I-MED
Hyperactivity	I-MED
Disorder	I-MED
Increased	B-MED
from	O
2009	O
to	O
2015	O
Among	O
School	B-MED
-	I-MED
Aged	I-MED
Children	I-MED
and	O
Adolescents	B-MED
in	O
the	O
United	B-MED
States	I-MED
The	O
purpose	B-MED
of	O
this	O
brief	O
is	O
to	O
describe	B-MED
changes	B-MED
in	O
the	O
treated	B-MED
prevalence	B-MED
of	O
medically	B-MED
managed	B-MED
attention	B-MED
-	I-MED
deficit	I-MED
/	I-MED
hyperactivity	I-MED
disorder	I-MED
(	O
ADHD	B-MED
)	O
among	O
insured	B-MED
school	B-MED
-	I-MED
aged	I-MED
children	I-MED
and	O
adolescents	B-MED
in	O
the	O
United	B-MED
States	I-MED
from	O
2009	O
to	O
2015	O
.	O
We	O
examine	B-MED
the	O
differences	B-MED
between	O
those	O
with	O
employer	B-MED
-	I-MED
sponsored	I-MED
insurance	I-MED
(	O
ESI	B-MED
)	O
and	O
with	O
Medicaid	B-MED
insurance	I-MED
.	O
We	O
utilized	O
two	O
large	O
longitudinal	B-MED
administrative	B-MED
datasets	I-MED
containing	O
medical	B-MED
and	O
drug	B-MED
claims	B-MED
data	B-MED
on	O
individuals	B-MED
with	O
ESI	B-MED
and	O
Medicaid	B-MED
insurance	I-MED
from	O
Truven	B-MED
Health	I-MED
MarketScan	I-MED
(	I-MED
®	I-MED
)	I-MED
Administrative	I-MED
Claims	I-MED
Databases	I-MED
.	O
Treated	B-MED
prevalence	B-MED
was	O
measured	B-MED
as	O
the	O
percentage	B-MED
of	O
school	B-MED
-	I-MED
aged	I-MED
children	I-MED
and	O
adolescents	B-MED
enrolled	O
in	O
a	O
calendar	B-MED
year	I-MED
who	O
met	O
the	O
criteria	B-MED
for	O
medically	B-MED
managed	B-MED
ADHD	B-MED
in	O
the	O
same	O
calendar	B-MED
year	I-MED
.	O
Subjects	B-MED
were	O
eligible	B-MED
for	O
inclusion	B-MED
if	O
they	O
were	O
aged	B-MED
6	O
-	O
17	O
years	B-MED
and	O
were	O
continuously	B-MED
enrolled	O
during	O
a	O
calendar	B-MED
year	I-MED
.	O
The	O
annual	B-MED
prevalence	B-MED
of	O
treated	B-MED
ADHD	B-MED
among	O
school	B-MED
-	I-MED
aged	I-MED
children	I-MED
and	O
adolescents	B-MED
with	O
ESI	B-MED
increased	B-MED
from	O
4.5	O
%	O
in	O
2009	O
to	O
6.7	O
%	O
in	O
2015	O
.	O
Among	O
those	O
with	O
Medicaid	B-MED
it	O
increased	B-MED
from	O
11.3	O
%	O
in	O
2009	O
to	O
13.3	O
%	O
in	O
2012	O
,	O
and	O
fell	O
after	O
2012	O
,	O
remaining	O
steady	B-MED
from	O
2013	O
through	O
2015	O
.	O
Treated	B-MED
prevalence	B-MED
of	O
ADHD	B-MED
increased	B-MED
continuously	B-MED
over	O
time	B-MED
among	O
school	B-MED
-	I-MED
aged	I-MED
children	I-MED
and	O
adolescents	B-MED
with	O
ESI	B-MED
,	O
but	O
declined	B-MED
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
Medicaid	B-MED
sample	I-MED
.	O
Quantification	B-MED
of	O
urinary	B-MED
mono	B-MED
-	I-MED
hydroxylated	I-MED
metabolites	I-MED
of	O
polycyclic	B-MED
aromatic	I-MED
hydrocarbons	I-MED
by	O
on	B-MED
-	I-MED
line	I-MED
solid	I-MED
phase	I-MED
extraction	I-MED
-	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
Human	B-MED
exposure	B-MED
to	I-MED
polycyclic	B-MED
aromatic	I-MED
hydrocarbons	I-MED
(	O
PAHs	B-MED
)	O
can	O
be	O
assessed	B-MED
through	O
monitoring	B-MED
of	O
urinary	B-MED
mono	B-MED
-	I-MED
hydroxylated	I-MED
PAHs	I-MED
(	O
OH	B-MED
-	I-MED
PAHs	I-MED
)	O
.	O
Gas	B-MED
chromatography	I-MED
(	O
GC	B-MED
)	O
has	O
been	O
widely	O
used	O
to	O
separate	B-MED
OH	B-MED
-	I-MED
PAHs	I-MED
before	O
quantification	B-MED
by	O
mass	B-MED
spectrometry	I-MED
in	O
biomonitoring	B-MED
studies	B-MED
.	O
However	O
,	O
because	O
GC	B-MED
requires	O
derivatization	B-MED
,	O
it	O
can	O
be	O
time	B-MED
consuming	I-MED
.	O
We	O
developed	B-MED
an	O
on	B-MED
-	I-MED
line	I-MED
solid	I-MED
phase	I-MED
extraction	I-MED
coupled	B-MED
to	O
isotope	B-MED
dilution	B-MED
-	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
(	O
on	B-MED
-	I-MED
line	I-MED
-	I-MED
SPE	I-MED
-	O
HPLC	B-MED
-	I-MED
MS	I-MED
/	O
MS	B-MED
)	O
method	B-MED
for	O
the	O
quantification	B-MED
in	O
urine	B-MED
of	O
1	B-MED
-	I-MED
OH	I-MED
-	I-MED
naphthalene	I-MED
,	O
2	B-MED
-	I-MED
OH	I-MED
-	I-MED
naphthalene	I-MED
,	O
2	B-MED
-	I-MED
OH	I-MED
-	I-MED
fluorene	I-MED
,	O
3	B-MED
-	I-MED
OH	I-MED
-	I-MED
fluorene	I-MED
,	O
1	B-MED
-	I-MED
OH	I-MED
-	I-MED
phenanthrene	I-MED
,	O
the	O
sum	O
of	O
2	B-MED
-	I-MED
OH	I-MED
and	O
3	B-MED
-	I-MED
OH	I-MED
-	I-MED
phenanthrene	I-MED
,	O
4	B-MED
-	I-MED
OH	I-MED
-	I-MED
phenanthrene	I-MED
,	O
and	O
1	B-MED
-	I-MED
OH	I-MED
-	I-MED
pyrene	I-MED
.	O
The	O
method	B-MED
,	O
which	O
employed	B-MED
a	O
96-	O
well	B-MED
plate	I-MED
platform	I-MED
and	O
on	B-MED
-	I-MED
line	I-MED
SPE	I-MED
,	O
showed	O
good	B-MED
sensitivity	I-MED
(	O
i.e.	O
,	O
limits	B-MED
of	O
detection	B-MED
ranged	B-MED
from	O
0.007	O
to	O
0.09	O
ng	O
/	O
mL	O
)	O
and	O
used	O
only	O
100	O
μL	O
of	O
urine	B-MED
.	O
Accuracy	B-MED
,	O
calculated	B-MED
from	O
the	O
recovery	B-MED
percentage	B-MED
at	O
three	O
spiking	B-MED
levels	B-MED
,	O
varied	B-MED
from	O
94	O
to	O
113	O
%	O
,	O
depending	B-MED
on	O
the	O
analyte	B-MED
.	O
The	O
inter	B-MED
-	O
and	O
intra	B-MED
-	O
day	B-MED
precision	I-MED
,	O
calculated	B-MED
from	O
20	O
repeated	B-MED
measurements	B-MED
of	O
two	O
quality	B-MED
control	I-MED
materials	B-MED
,	O
varied	B-MED
from	O
5.2	O
to	O
16.7	O
%	O
.	O
Adequate	B-MED
method	B-MED
performance	B-MED
was	O
also	O
confirmed	B-MED
by	I-MED
acceptable	B-MED
recovery	B-MED
(	O
83	O
-	O
102	O
%	O
)	O
of	O
two	O
NIST	B-MED
standard	B-MED
reference	I-MED
materials	B-MED
(	O
3672	O
and	O
3673	O
)	O
.	O
This	O
high	B-MED
-	I-MED
throughput	I-MED
on	B-MED
-	I-MED
line	I-MED
-	I-MED
SPE	I-MED
-	O
HPLC	B-MED
-	I-MED
MS	I-MED
/	O
MS	B-MED
method	B-MED
can	O
be	O
applied	O
in	O
large	B-MED
-	O
scale	B-MED
epidemiological	B-MED
studies	I-MED
.	O
Graphical	B-MED
abstract	I-MED
Example	O
LC	B-MED
-	I-MED
MS	I-MED
chromatogram	I-MED
of	O
urinary	B-MED
mono	B-MED
-	I-MED
hydroxylated	I-MED
PAH	I-MED
metabolites	B-MED
.	O
Remitting	B-MED
Seronegative	I-MED
Symmetrical	I-MED
Synovitis	I-MED
With	I-MED
Pitting	I-MED
Edema	I-MED
:	O
Appearance	O
on	O
FDG	B-MED
PET	I-MED
/	I-MED
CT	I-MED
Remitting	B-MED
seronegative	I-MED
symmetrical	I-MED
synovitis	I-MED
with	I-MED
pitting	I-MED
edema	I-MED
(	O
RS3PE	B-MED
)	O
is	O
a	O
rare	B-MED
condition	I-MED
in	O
the	O
elderly	B-MED
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	B-MED
of	O
rheumatic	B-MED
and	O
malignant	B-MED
diseases	I-MED
.	O
We	O
presented	O
a	O
62-	O
year	B-MED
-old	O
man	B-MED
with	O
the	O
diagnosis	B-MED
of	O
RS3PE	B-MED
based	O
on	O
the	O
clinical	B-MED
sign	I-MED
and	O
laboratory	B-MED
data	I-MED
.	O
Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-MED
in	O
RS3PE	B-MED
,	O
FDG	B-MED
PET	I-MED
/	I-MED
CT	I-MED
was	O
performed	O
to	O
exclude	O
occult	B-MED
tumors	I-MED
.	O
The	O
images	B-MED
showed	O
multiple	B-MED
,	O
symmetrically	B-MED
,	O
diffusely	B-MED
increased	B-MED
F	B-MED
-	I-MED
FDG	I-MED
uptake	B-MED
in	O
the	O
soft	B-MED
tissue	I-MED
around	O
joints	B-MED
and	O
bones	B-MED
in	O
the	O
shoulders	B-MED
,	O
hips	B-MED
,	O
knees	B-MED
,	O
and	O
ankles	B-MED
.	O
A	O
comparison	B-MED
of	O
the	O
localization	B-MED
of	O
rectal	B-MED
carcinomas	I-MED
according	O
to	O
the	O
general	B-MED
rules	B-MED
of	O
the	O
Japanese	B-MED
classification	I-MED
of	I-MED
colorectal	I-MED
carcinoma	I-MED
(	O
JCCRC	B-MED
)	O
and	O
Western	B-MED
guidelines	B-MED
The	O
aim	B-MED
of	O
this	O
study	O
was	O
to	O
compare	B-MED
the	O
localization	B-MED
of	O
rectal	B-MED
cancers	I-MED
as	O
classified	B-MED
according	O
to	O
the	O
general	B-MED
rules	B-MED
of	O
the	O
Japanese	B-MED
classification	I-MED
of	I-MED
colorectal	I-MED
carcinoma	I-MED
(	O
JCCRC	B-MED
)	O
and	O
also	O
according	O
to	O
the	O
European	B-MED
Society	I-MED
for	I-MED
Medical	I-MED
Oncology	I-MED
(	O
ESMO	B-MED
)	O
and	O
the	O
National	B-MED
Comprehensive	I-MED
Cancer	I-MED
Network	I-MED
(	O
NCCN	B-MED
)	O
guidelines	B-MED
,	O
which	O
are	O
based	O
on	O
rigid	B-MED
endoscopic	I-MED
measurements	B-MED
.	O
The	O
medical	B-MED
records	I-MED
of	O
patients	B-MED
scheduled	B-MED
to	O
receive	B-MED
curative	B-MED
surgery	I-MED
for	O
histologically	B-MED
proven	O
rectal	B-MED
adenocarcinoma	I-MED
during	B-MED
2009	O
-	O
2015	O
were	O
investigated	B-MED
(	O
n	O
=	O
230	O
)	O
.	O
Rigid	B-MED
proctoscopy	I-MED
was	O
performed	B-MED
in	O
patients	B-MED
with	O
rectal	B-MED
cancer	I-MED
located	B-MED
in	I-MED
the	O
upper	B-MED
(	O
Ra	B-MED
)	O
or	O
lower	B-MED
(	O
Rb	B-MED
)	O
division	B-MED
using	O
double	B-MED
-	I-MED
contrast	I-MED
barium	I-MED
enema	I-MED
.	O
The	O
median	B-MED
values	O
of	O
height	B-MED
from	O
the	O
anal	B-MED
verge	I-MED
were	O
7.5	O
cm	O
(	O
range	B-MED
2	O
-	O
12	O
)	O
and	O
3	O
cm	O
(	O
0	O
-	O
9.5	O
)	O
on	O
rigid	B-MED
proctoscopy	I-MED
for	O
cancers	B-MED
assigned	B-MED
as	O
Ra	B-MED
and	O
Rb	B-MED
,	O
respectively	O
.	O
All	O
159	O
cancers	B-MED
at	O
Ra	B-MED
or	O
Rb	B-MED
were	O
located	B-MED
within	B-MED
12	O
cm	O
from	O
the	O
anal	B-MED
verge	I-MED
by	O
rigid	B-MED
proctoscopy	I-MED
,	O
while	O
only	O
79.7	O
%	O
of	O
Ra	B-MED
or	O
82.1	O
%	O
of	O
Rb	B-MED
cancers	B-MED
were	O
located	B-MED
in	I-MED
the	O
mid	B-MED
(	O
5.1	O
-	O
10	O
cm	O
)	O
or	O
low	B-MED
(	O
≤5	O
cm	O
)	O
rectum	B-MED
,	O
respectively	O
.	O
Ra	B-MED
and	O
Rb	B-MED
cancers	B-MED
are	O
deemed	O
to	O
be	O
rectal	B-MED
cancers	I-MED
according	O
to	O
NCCN	B-MED
guidelines	B-MED
,	O
but	O
these	O
classifications	B-MED
are	O
not	O
interchangeable	O
with	O
mid-	B-MED
and	O
low	B-MED
-	O
rectal	B-MED
cancers	I-MED
,	O
respectively	O
,	O
according	O
to	O
the	O
ESMO	B-MED
guidelines	B-MED
.	O
ANTI	B-MED
ANGIOGENIC	I-MED
EFFECT	I-MED
OF	O
CHEBULAGIC	B-MED
ACID	I-MED
INVOLVES	O
INHIBITION	B-MED
OF	O
VEGFR2	B-MED
AND	O
GSK3β	B-MED
DEPENDENT	I-MED
SIGNALING	I-MED
PATHWAYS	I-MED
Inhibition	B-MED
of	O
angiogenesis	B-MED
is	O
a	O
useful	O
strategy	B-MED
to	O
prevent	B-MED
cancer	B-MED
growth	I-MED
,	O
which	O
targets	B-MED
new	O
vessels	B-MED
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	B-MED
tumor	B-MED
cells	I-MED
.	O
Endothelial	B-MED
cells	I-MED
can	O
use	O
a	O
number	O
of	O
different	O
pathways	B-MED
to	O
cause	O
angiogenesis	B-MED
and	O
each	O
step	O
in	O
these	O
pathways	B-MED
can	O
be	O
targeted	B-MED
.	O
The	O
use	O
of	O
multi	B-MED
targeted	I-MED
drugs	I-MED
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O
Our	O
previous	O
results	O
have	O
shown	O
the	O
anti	B-MED
angiogenic	I-MED
effect	I-MED
of	O
Chebulagic	B-MED
acid	I-MED
-	O
a	O
benzopyran	B-MED
tannin	B-MED
present	O
in	O
the	O
fruits	B-MED
of	O
Terminalia	B-MED
chebula	I-MED
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	B-MED
mechanism	I-MED
of	O
the	O
anti	B-MED
angiogenic	I-MED
effect	I-MED
of	O
chebulagic	B-MED
acid	I-MED
.	O
Results	O
of	O
our	O
investigations	O
using	O
molecular	B-MED
docking	I-MED
studies	I-MED
and	O
HUVECs	B-MED
in	O
culture	B-MED
suggested	O
that	O
Chebulagic	B-MED
acid	I-MED
inhibited	B-MED
GSK-3β	B-MED
dependent	B-MED
β	B-MED
-	I-MED
catenin	I-MED
phosphorylation	B-MED
,	O
an	O
important	O
mediator	O
of	O
VE	B-MED
-	I-MED
cadherin	I-MED
/	O
β	B-MED
-	I-MED
catenin	I-MED
signaling	B-MED
and	O
VEGFR2	B-MED
phosphorylation	B-MED
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF	B-MED
signaling	I-MED
.	O
Chebulagic	B-MED
acid	I-MED
inhibits	B-MED
angiogenesis	B-MED
by	O
blocking	B-MED
both	O
VEGF	B-MED
/	O
VEGFR2	B-MED
and	O
cell	B-MED
-	I-MED
cell	I-MED
contact	I-MED
dependent	I-MED
downstream	I-MED
signaling	I-MED
pathway	I-MED
.	O
Nodal	B-MED
skip	B-MED
metastasis	B-MED
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
:	O
a	O
cohort	B-MED
study	I-MED
Nodal	B-MED
skip	B-MED
metastasis	B-MED
is	O
a	O
prognostic	B-MED
factor	I-MED
in	O
some	O
sites	O
of	O
malignancies	B-MED
,	O
but	O
its	O
role	O
in	O
esophageal	B-MED
cancer	I-MED
is	O
still	O
unclear	B-MED
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	B-MED
occurrence	O
and	O
effect	B-MED
of	O
nodal	B-MED
skip	B-MED
metastases	O
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
.	O
All	O
578	O
patients	B-MED
undergoing	O
esophagectomy	B-MED
for	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
at	O
the	O
Center	B-MED
for	I-MED
Esophageal	I-MED
Diseases	I-MED
located	O
in	O
Padova	B-MED
between	O
January	B-MED
1992	O
and	O
December	B-MED
2010	O
were	O
retrospectively	B-MED
evaluated	I-MED
.	O
Selection	B-MED
criteria	I-MED
were	O
R0	B-MED
resection	I-MED
,	O
pathological	B-MED
M0	B-MED
stage	I-MED
and	O
pathological	B-MED
lymph	B-MED
node	I-MED
involvement	I-MED
.	O
Patients	B-MED
receiving	O
neoadjuvant	B-MED
therapy	I-MED
were	O
excluded	O
.	O
The	O
selection	O
identified	O
88	O
patients	B-MED
with	O
lymph	B-MED
node	I-MED
involvement	I-MED
confirmed	O
by	O
pathological	B-MED
evaluation	B-MED
.	O
Sixteen	O
patients	B-MED
(	O
18.2	O
%	O
)	O
had	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
.	O
Adjusting	O
for	O
the	O
number	O
of	O
lymph	B-MED
node	I-MED
metastases	I-MED
,	O
patient	B-MED
with	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
had	O
similar	O
5	O
-	O
year	O
overall	B-MED
survival	I-MED
(	O
14	O
%	O
vs.	O
13	O
%	O
,	O
p	O
=	O
0.93	O
)	O
and	O
5	O
-	O
year	O
disease	B-MED
free	I-MED
survival	I-MED
(	O
14	O
%	O
vs.	O
9	O
%	O
,	O
p	O
=	O
0.48	O
)	O
compared	O
to	O
patients	B-MED
with	O
both	O
peritumoral	B-MED
and	O
distant	B-MED
lymph	B-MED
node	I-MED
metastases	I-MED
.	O
The	O
risk	O
difference	O
of	O
nodal	B-MED
skip	B-MED
metastasis	B-MED
C.I	B-MED
was	O
:	O
-24.1	O
%	O
(	O
95	O
%	O
C.I.	O
-43.1	O
%	O
to	O
-5.2	O
%	O
)	O
in	O
patients	B-MED
with	O
more	O
than	O
one	O
lymph	B-MED
node	I-MED
metastasis	I-MED
compared	O
to	O
those	O
with	O
one	O
lymph	B-MED
node	I-MED
metastasis	I-MED
C.I	B-MED
;	O
-2.3	O
%	O
(	O
95	O
%	O
C.I.	O
-29.8	O
%	O
to	O
25.2	O
%	O
)	O
in	O
middle	B-MED
thoracic	B-MED
esophagus	I-MED
C.I	B-MED
and	O
-23.0	O
%	O
(	O
95	O
%	O
C.I.	O
-47.8	O
%	O
to	O
1.8	O
%	O
)	O
in	O
lower	B-MED
thoracic	B-MED
esophagus	I-MED
compared	O
to	O
upper	B-MED
thoracic	B-MED
esophagus	I-MED
;	O
18.1	O
%	O
(	O
95	O
%	O
C.I.	B-MED
3.2	O
%	O
to	O
33.0	O
%	O
)	O
in	O
clinical	B-MED
N0	B-MED
stage	I-MED
vs.	O
clinical	B-MED
N+	B-MED
stage	I-MED
.	O
Nodal	B-MED
skip	B-MED
metastasis	B-MED
is	O
a	O
common	O
pattern	O
of	O
metastatic	B-MED
lymph	I-MED
involvement	I-MED
in	O
thoracic	B-MED
esophageal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
.	O
However	O
,	O
neither	B-MED
overall	B-MED
survival	I-MED
nor	O
disease	B-MED
free	I-MED
survival	I-MED
are	O
associated	B-MED
with	I-MED
nodal	B-MED
skip	B-MED
metastasis	B-MED
occurrence	O
.	O
Activation	B-MED
of	O
general	B-MED
control	I-MED
nonderepressible	I-MED
2	I-MED
kinase	I-MED
protects	B-MED
human	B-MED
glomerular	B-MED
endothelial	I-MED
cells	I-MED
from	O
harmful	O
high	B-MED
-	I-MED
glucose	I-MED
-	O
induced	B-MED
molecular	B-MED
pathways	I-MED
Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-MED
restriction	B-MED
on	O
diabetic	B-MED
nephropathy	I-MED
(	O
DN	B-MED
)	O
and	O
the	O
role	O
of	O
renal	B-MED
endothelium	B-MED
in	O
its	O
pathogenesis	B-MED
,	O
we	O
evaluated	B-MED
the	O
effect	O
of	O
general	B-MED
control	I-MED
nonderepressible	I-MED
2	I-MED
(	I-MED
GCN2	I-MED
)	I-MED
kinase	I-MED
activation	B-MED
,	O
a	O
sensor	B-MED
of	O
amino	B-MED
acid	I-MED
deprivation	B-MED
,	O
on	O
known	O
detrimental	O
molecular	B-MED
pathways	I-MED
in	O
primary	O
human	B-MED
glomerular	B-MED
endothelial	I-MED
cells	I-MED
(	O
GEnC	B-MED
)	O
.	O
GEnC	B-MED
were	O
cultured	B-MED
under	O
normal	O
or	O
high	B-MED
high	B-MED
-glucose	I-MED
conditions	I-MED
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2	B-MED
kinase	I-MED
activator	B-MED
,	O
tryptophanol	B-MED
.	O
Glucose	B-MED
transporter	I-MED
1	I-MED
(	O
GLUT1	B-MED
)	O
expression	B-MED
was	O
assessed	B-MED
by	O
western	B-MED
blotting	I-MED
and	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
using	O
a	O
fluorogenic	B-MED
probe	I-MED
.	O
Activities	B-MED
of	O
glyceraldehyde	B-MED
3	I-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
(	O
GAPDH	B-MED
)	O
and	O
protein	B-MED
kinase	I-MED
C	I-MED
(	O
PKC	B-MED
)	O
were	O
assessed	B-MED
by	O
commercial	B-MED
activity	I-MED
assays	I-MED
,	O
sorbitol	B-MED
colorimetrically	B-MED
,	O
methylglyoxal	B-MED
by	O
ELISA	B-MED
and	O
O	B-MED
-	I-MED
linked	I-MED
β	I-MED
-	I-MED
N	I-MED
-	I-MED
acetyl	I-MED
glucosamine	I-MED
(	I-MED
O	I-MED
-	I-MED
GlcNAc)-modified	I-MED
proteins	I-MED
by	O
western	B-MED
blotting	I-MED
.	O
High	B-MED
glucose	I-MED
induced	B-MED
GLUT1	B-MED
expression	B-MED
,	O
increased	B-MED
ROS	B-MED
and	O
inhibited	B-MED
GAPDH	B-MED
.	O
Also	O
it	O
increased	B-MED
the	O
polyol	B-MED
pathway	B-MED
product	O
sorbitol	B-MED
,	O
PKC	B-MED
activity	B-MED
,	O
the	O
level	O
of	O
the	O
O	B-MED
-	I-MED
GlcNAc	I-MED
-	I-MED
modified	I-MED
proteins	I-MED
that	O
produced	O
by	O
the	O
hexosamine	B-MED
pathway	B-MED
and	O
the	O
advanced	B-MED
glycation	I-MED
endproducts	I-MED
'	I-MED
precursor	B-MED
methylglyoxal	B-MED
.	O
Co	B-MED
-	I-MED
treatment	I-MED
of	O
GEnC	B-MED
with	O
tryptophanol	B-MED
restored	O
the	O
above	O
high	B-MED
-	I-MED
glucose	I-MED
-	O
induced	B-MED
alterations	O
.	O
Activation	B-MED
of	O
GCN2	B-MED
kinase	I-MED
protects	O
GEnC	B-MED
from	O
high	B-MED
-	I-MED
glucose	I-MED
-	O
induced	B-MED
harmful	O
molecular	B-MED
pathways	I-MED
.	O
By	O
inhibiting	O
concurrently	B-MED
many	O
pathways	B-MED
involved	O
in	O
DN	B-MED
pathogenesis	B-MED
,	O
GCN2	B-MED
kinase	I-MED
may	O
serve	O
as	O
a	O
pharmaceutical	B-MED
target	B-MED
for	O
the	O
treatment	B-MED
of	O
DN	B-MED
.	O
BJN	B-MED
Awards	I-MED
2016	O
:	O
IV	B-MED
therapy	I-MED
Claire	O
Rickard	O
Professor	B-MED
of	O
Nursing	B-MED
,	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
)	O
Centre	B-MED
of	I-MED
Research	I-MED
Excellence	I-MED
in	O
Nursing	B-MED
,	O
Griffith	O
University	O
,	O
was	O
awarded	B-MED
second	O
place	O
in	O
the	O
BJN	B-MED
Awards	I-MED
2016	O
for	O
IV	B-MED
Therapy	I-MED
Nurse	B-MED
of	O
the	O
Year	B-MED
.	O
Here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
field	B-MED
.	O
Visualization	B-MED
of	O
the	O
Intimal	B-MED
Flap	I-MED
in	O
Intracranial	B-MED
Arterial	I-MED
Dissection	I-MED
Using	O
High	B-MED
-	I-MED
Resolution	I-MED
3	B-MED
T	I-MED
MRI	I-MED
Presence	B-MED
of	O
an	O
intimal	B-MED
flap	I-MED
is	O
a	O
critical	B-MED
imaging	B-MED
finding	I-MED
in	O
diagnosing	B-MED
intracranial	B-MED
artery	I-MED
dissection	I-MED
(	O
ICAD	B-MED
)	O
.	O
Recent	O
reports	B-MED
showed	O
that	O
high	B-MED
-	I-MED
resolution	I-MED
magnetic	B-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
was	O
better	B-MED
at	O
identifying	O
intimal	B-MED
flaps	I-MED
as	O
compared	B-MED
with	O
routine	O
MRI	B-MED
techniques	I-MED
used	O
in	O
clinical	B-MED
settings	I-MED
.	O
However	O
,	O
no	O
current	O
standardized	O
sequence	B-MED
for	O
high	B-MED
-	I-MED
resolution	I-MED
MRI	B-MED
without	O
gadolinium	B-MED
enhancement	B-MED
produces	O
images	B-MED
of	O
satisfactory	O
quality	B-MED
with	O
clinically	O
tolerable	O
scanning	B-MED
times	B-MED
.	O
This	O
study	O
evaluated	B-MED
a	O
nonenhanced	B-MED
high	I-MED
-	I-MED
resolution	I-MED
fast	I-MED
spin	I-MED
echo	I-MED
(	I-MED
HR	I-MED
-	I-MED
FSE	I-MED
)	I-MED
MRI	I-MED
sequence	B-MED
for	O
visualizing	O
intimal	B-MED
flaps	I-MED
in	O
patients	B-MED
with	O
ICAD	B-MED
.	O
Three	O
patients	B-MED
with	O
ICAD	B-MED
underwent	O
plain	O
MRI	B-MED
examination	O
using	O
a	O
2	B-MED
-	I-MED
dimensional	I-MED
T2	B-MED
-	I-MED
weighted	I-MED
FSE	I-MED
imaging	I-MED
sequence	B-MED
optimized	O
for	O
our	O
3	B-MED
T	I-MED
system	I-MED
(	O
in	O
-	O
plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-MED
with	O
conventional	B-MED
modalities	B-MED
,	O
including	O
CT	B-MED
angiography	I-MED
,	O
magnetic	B-MED
resonance	I-MED
angiography	I-MED
,	O
and	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
.	O
We	O
assessed	B-MED
whether	O
these	O
imaging	B-MED
methods	I-MED
could	O
visualize	O
an	O
intimal	B-MED
flap	I-MED
and/or	O
double	B-MED
lumen	I-MED
sign	I-MED
in	O
the	O
participants	B-MED
and	O
compared	B-MED
the	O
results	B-MED
between	O
HR	B-MED
-	I-MED
FSE	I-MED
and	O
the	O
other	O
modalities	B-MED
.	O
HR	B-MED
-	I-MED
FSE	I-MED
images	B-MED
clearly	O
showed	O
intimal	B-MED
flaps	I-MED
and	O
double	B-MED
lumen	I-MED
signs	I-MED
in	O
all	O
3	O
patients	B-MED
,	O
whereas	O
the	O
conventional	B-MED
modalities	B-MED
identified	B-MED
a	O
double	B-MED
lumen	I-MED
sign	I-MED
in	O
only	O
2	O
of	O
the	O
3	O
patients	B-MED
.	O
The	O
present	O
method	O
of	O
optimized	O
HR	B-MED
-	I-MED
FSE	I-MED
imaging	I-MED
with	O
a	O
3	B-MED
T	I-MED
system	I-MED
improved	B-MED
visualization	B-MED
of	O
intimal	B-MED
flaps	I-MED
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	B-MED
patients	B-MED
with	O
suspected	B-MED
ICAD	B-MED
that	O
can	O
not	O
be	O
definitively	O
diagnosed	B-MED
by	O
conventional	B-MED
imaging	B-MED
modalities	I-MED
.	O
Alleviation	B-MED
of	O
hepatic	B-MED
fat	B-MED
accumulation	I-MED
by	O
betaine	B-MED
involves	O
reduction	B-MED
of	O
homocysteine	B-MED
via	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
betaine	B-MED
-	I-MED
homocysteine	I-MED
methyltransferase	I-MED
(	O
BHMT	B-MED
)	O
We	O
investigated	B-MED
the	O
anti	B-MED
-	I-MED
lipogenic	I-MED
effect	I-MED
of	O
betaine	B-MED
in	O
rats	B-MED
fed	O
methionine	B-MED
and	O
choline	B-MED
-	O
deficient	B-MED
diet	B-MED
(	O
MCD	B-MED
)	O
.	O
Intake	O
of	O
MCD	B-MED
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	B-MED
accumulation	B-MED
of	O
hepatic	B-MED
lipids	B-MED
,	O
which	O
was	O
prevented	B-MED
by	O
betaine	B-MED
supplementation	B-MED
in	O
drinking	B-MED
water	I-MED
(	O
1	O
%	O
)	O
.	O
Phosphorylation	B-MED
of	O
AMP	B-MED
-	I-MED
activated	I-MED
protein	I-MED
kinase	I-MED
(	O
AMPK	B-MED
)	O
,	O
acetyl	B-MED
-	I-MED
CoA	I-MED
carboxylase	I-MED
(	O
ACC	B-MED
)	O
,	O
sterol	B-MED
regulatory	I-MED
element	I-MED
-	I-MED
binding	I-MED
protein	I-MED
1c	I-MED
(	O
SREBP-1c	B-MED
)	O
,	O
and	O
liver	B-MED
kinase	I-MED
B1	I-MED
(	O
LKB1	B-MED
)	O
was	O
inhibited	B-MED
by	O
MCD	B-MED
intake	B-MED
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	B-MED
by	O
betaine	B-MED
feeding	B-MED
.	O
Meanwhile	O
,	O
betaine	B-MED
supplementation	B-MED
reversed	B-MED
the	O
reduction	B-MED
of	O
methionine	B-MED
and	I-MED
S	I-MED
-	I-MED
adenosylmethionine	I-MED
(	O
SAM	B-MED
)	O
,	O
and	O
the	O
elevation	B-MED
of	O
homocysteine	B-MED
levels	I-MED
in	O
the	O
liver	B-MED
,	I-MED
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-MED
of	O
betaine	B-MED
-	I-MED
homocysteine	I-MED
methyltransfease	I-MED
(	O
BHMT	B-MED
)	O
and	O
methionine	B-MED
adenosyltransferase	I-MED
(	O
MAT	B-MED
)	O
.	O
Different	B-MED
cell	B-MED
lines	I-MED
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-MED
on	O
activation	B-MED
of	O
the	O
AMPK	B-MED
pathway	B-MED
.	O
Homocysteine	B-MED
treatment	B-MED
decreased	B-MED
pAMPK	B-MED
,	O
pACC	B-MED
,	O
pSREBP-1c	B-MED
and	O
pLKB1	B-MED
in	O
HepG2	B-MED
cells	I-MED
.	O
Metformin	B-MED
-	O
induced	B-MED
activation	B-MED
of	O
AMPK	B-MED
was	O
also	O
inhibited	B-MED
by	O
homocysteine	B-MED
.	O
Treatment	B-MED
with	O
hydroxylamine	B-MED
,	O
a	O
cystathionine	B-MED
β	I-MED
-	I-MED
synthase	I-MED
inhibitor	B-MED
,	O
resulted	O
in	O
a	O
reduction	B-MED
of	O
pAMPK	B-MED
,	O
pACC	B-MED
and	O
pSREBP-1c	B-MED
,	O
accompanied	O
by	O
an	O
elevation	B-MED
of	O
intracellular	B-MED
homocysteine	B-MED
.	O
Betaine	B-MED
treatment	B-MED
prevented	B-MED
the	O
homocysteine	B-MED
-	O
induced	B-MED
reduction	B-MED
of	O
pAMPK	B-MED
,	O
pACC	B-MED
,	O
pSREBP-1c	B-MED
and	O
pLKB1	B-MED
in	O
H4IIE	B-MED
cells	I-MED
,	O
but	O
not	O
in	O
HepG2	B-MED
cells	I-MED
.	O
Also	O
the	O
elevation	B-MED
of	O
cellular	O
homocysteine	B-MED
and	O
inhibition	B-MED
of	O
protein	B-MED
expression	I-MED
of	O
BHMT	B-MED
were	O
prevented	B-MED
by	O
betaine	B-MED
only	O
in	O
H4IIE	B-MED
cells	I-MED
which	O
express	B-MED
BHMT	B-MED
.	O
The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-MED
against	O
hepatic	B-MED
lipid	B-MED
accumulation	B-MED
may	O
be	O
attributed	B-MED
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	B-MED
of	O
homocysteine	B-MED
via	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
BHMT	B-MED
in	O
hepatocytes	B-MED
.	O
Everolimus	B-MED
for	O
Treatment	B-MED
of	O
Pseudomyogenic	B-MED
Hemangioendothelioma	I-MED
Pseudomyogenic	B-MED
hemangioendothelioma	I-MED
(	O
PMH	B-MED
)	O
is	O
a	O
recently	O
described	O
vascular	B-MED
neoplasm	I-MED
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	B-MED
tissue	I-MED
of	O
the	O
distal	O
extremities	O
of	O
young	B-MED
adults	I-MED
.	O
Metastatic	B-MED
PMH	B-MED
can	O
be	O
fatal	B-MED
and	O
there	O
are	O
no	O
effective	B-MED
medications	B-MED
.	O
We	O
describe	O
a	O
case	B-MED
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	B-MED
with	O
metastatic	B-MED
PMH	B-MED
,	O
who	O
responded	B-MED
to	I-MED
treatment	I-MED
with	O
everolimus	B-MED
,	O
a	O
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
inhibitor	I-MED
.	O
Immunohistochemistry	B-MED
showed	O
that	O
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
was	O
expressed	B-MED
in	O
PMH	B-MED
biopsy	B-MED
specimens	I-MED
,	O
which	O
may	O
explain	O
the	O
reduction	B-MED
in	O
PMH	B-MED
tumor	B-MED
size	I-MED
following	O
treatment	B-MED
.	O
Physicians	B-MED
'	I-MED
knowledge	O
on	O
the	O
work	B-MED
-	I-MED
related	I-MED
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
Chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
may	O
be	O
induced	O
by	O
the	O
work	B-MED
environment	I-MED
conditions	B-MED
.	O
According	O
to	O
the	O
estimates	B-MED
,	O
10	O
-	O
20	O
%	O
of	O
all	O
COPD	B-MED
cases	B-MED
are	O
associated	B-MED
with	I-MED
occupational	B-MED
exposure	I-MED
to	O
dusts	B-MED
and	O
irritant	B-MED
gases	B-MED
.	O
However	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	B-MED
of	O
work	B-MED
-	I-MED
related	I-MED
COPD	B-MED
were	O
recognized	O
in	O
Poland	B-MED
.	O
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
analyze	B-MED
the	O
reasons	O
for	O
the	O
low	B-MED
incidence	B-MED
of	O
work	B-MED
-	I-MED
related	I-MED
COPD	B-MED
in	O
the	O
context	B-MED
of	O
pulmonologists	B-MED
'	O
knowledge	O
about	O
occupational	B-MED
risk	B-MED
factors	I-MED
and	O
procedures	B-MED
on	O
reporting	B-MED
suspected	B-MED
occupational	B-MED
diseases	I-MED
.	O
A	O
survey	B-MED
included	O
94	O
pulmonologists	B-MED
randomly	B-MED
selected	O
out	O
of	O
225	O
specialists	B-MED
registered	O
at	O
the	O
Local	B-MED
Physicians	I-MED
Chamber	I-MED
in	O
Łódź	B-MED
.	O
The	O
study	B-MED
was	O
performed	B-MED
anonymously	B-MED
with	O
the	O
use	O
of	O
original	O
questionnaire	B-MED
.	O
More	O
than	O
a	O
half	O
of	O
the	O
surveyed	B-MED
pulmonologists	B-MED
identified	B-MED
environmental	B-MED
risk	B-MED
factors	I-MED
for	O
COPD	B-MED
correctly	O
,	O
while	O
only	O
23.4	O
%	O
properly	O
identified	B-MED
the	O
main	O
occupational	B-MED
risk	B-MED
factors	I-MED
as	O
the	O
cause	B-MED
of	O
COPD	B-MED
.	O
Only	O
58.5	O
%	O
of	O
the	O
pulmonologists	B-MED
always	O
asked	O
their	O
patients	B-MED
suffering	B-MED
from	O
COPD	B-MED
about	O
their	O
job	B-MED
/	O
profession	B-MED
and	O
60.6	O
%	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	B-MED
on	O
reporting	B-MED
suspected	B-MED
occupational	B-MED
diseases	I-MED
.	O
The	O
physicians	B-MED
rarely	B-MED
ask	O
patients	B-MED
suffering	B-MED
from	O
COPD	B-MED
about	O
their	O
job	B-MED
/	O
profession	B-MED
and	O
the	O
relationship	B-MED
between	O
their	O
ailments	B-MED
and	O
occupational	B-MED
exposure	I-MED
.	O
What	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	B-MED
regulations	I-MED
on	O
proper	O
referral	B-MED
of	I-MED
a	I-MED
patient	I-MED
with	O
a	O
suspected	B-MED
case	B-MED
of	O
occupational	B-MED
disease	I-MED
.	O
The	O
results	B-MED
of	O
the	O
study	B-MED
clearly	O
indicate	B-MED
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	B-MED
pulmonologists	B-MED
'	O
knowledge	O
on	O
work	B-MED
-	I-MED
related	I-MED
COPD	B-MED
.	O
Med	O
Pr	O
2016;67(3):375	O
-	O
384	O
.	O
When	O
emotion	B-MED
and	O
expression	B-MED
diverge	O
:	O
The	O
social	B-MED
costs	I-MED
of	O
Parkinson	B-MED
's	I-MED
disease	I-MED
Patients	B-MED
with	O
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
are	O
perceived	B-MED
more	O
negatively	B-MED
than	O
their	O
healthy	B-MED
peers	B-MED
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	B-MED
contribute	B-MED
to	O
this	O
negative	B-MED
social	B-MED
perception	I-MED
.	O
Based	O
on	O
a	O
cohort	B-MED
of	O
17	O
PD	B-MED
patients	B-MED
and	O
20	O
healthy	B-MED
controls	I-MED
,	O
we	O
assessed	B-MED
how	O
naïve	O
raters	O
judge	O
the	O
emotion	B-MED
and	O
emotional	B-MED
intensity	B-MED
displayed	B-MED
in	O
dynamic	B-MED
facial	B-MED
expressions	I-MED
as	O
adults	B-MED
with	O
and	O
without	O
PD	B-MED
watched	B-MED
emotionally	B-MED
evocative	O
films	B-MED
(	O
Experiment	B-MED
1	O
)	O
,	O
and	O
how	O
age	B-MED
-matched	O
peers	B-MED
naïve	O
to	O
patients	B-MED
'	O
disease	B-MED
status	O
judge	O
their	O
social	B-MED
desirability	I-MED
along	O
various	O
dimensions	B-MED
from	O
audiovisual	B-MED
stimuli	B-MED
(	O
interview	B-MED
excerpts	I-MED
)	O
recorded	O
after	O
certain	O
films	B-MED
(	O
Experiment	B-MED
2	O
)	O
.	O
In	O
Experiment	B-MED
1	O
,	O
participants	B-MED
with	O
PD	B-MED
were	O
rated	B-MED
as	O
significantly	B-MED
more	I-MED
facially	B-MED
expressive	I-MED
than	O
healthy	B-MED
controls	I-MED
;	O
moreover	O
,	O
ratings	B-MED
demonstrated	O
that	O
PD	B-MED
patients	B-MED
were	O
routinely	O
mistaken	O
for	O
experiencing	B-MED
a	O
negative	B-MED
emotion	B-MED
,	O
whereas	O
controls	B-MED
were	O
rated	B-MED
as	O
displaying	B-MED
a	O
more	O
positive	B-MED
emotion	B-MED
than	O
they	O
reported	B-MED
feeling	B-MED
.	O
In	O
Experiment	B-MED
2	O
,	O
results	B-MED
showed	O
that	O
age	B-MED
-	I-MED
peers	I-MED
rated	B-MED
PD	B-MED
patients	B-MED
as	O
significantly	B-MED
less	I-MED
socially	B-MED
desirable	I-MED
than	O
control	B-MED
participants	B-MED
.	O
Specifically	O
,	O
PD	B-MED
patients	B-MED
were	O
rated	B-MED
as	O
less	O
involved	B-MED
,	O
interested	B-MED
,	O
friendly	B-MED
,	O
intelligent	O
,	O
optimistic	B-MED
,	O
attentive	O
,	O
and	O
physically	B-MED
attractive	I-MED
than	O
healthy	B-MED
controls	I-MED
.	O
Taken	O
together	O
,	O
our	O
results	B-MED
point	O
to	O
a	O
disconnect	O
between	O
how	O
PD	B-MED
patients	B-MED
report	B-MED
feeling	B-MED
and	O
attributions	B-MED
that	O
others	O
make	O
about	O
their	O
emotions	B-MED
and	O
social	B-MED
characteristics	I-MED
,	O
underlining	O
significant	B-MED
social	B-MED
challenges	I-MED
of	O
the	O
disease	B-MED
.	O
In	O
particular	O
,	O
changes	B-MED
in	O
the	O
ability	B-MED
to	O
modulate	B-MED
the	O
expression	B-MED
of	O
negative	B-MED
emotions	B-MED
may	O
contribute	B-MED
to	O
the	O
negative	B-MED
social	B-MED
impressions	B-MED
that	O
many	O
PD	B-MED
patients	B-MED
face	O
.	O
Talking	B-MED
or	O
Keeping	B-MED
Silent	I-MED
About	O
Parental	B-MED
Mental	B-MED
Health	I-MED
Problems	I-MED
-A	O
Grounded	B-MED
Theory	I-MED
of	O
Parents	B-MED
'	O
Decision	B-MED
Making	I-MED
and	O
Experiences	B-MED
with	O
Their	O
Children	B-MED
This	O
grounded	B-MED
theory	I-MED
study	B-MED
explored	O
parents	B-MED
'	O
experiences	B-MED
of	O
responding	O
to	O
their	O
children	B-MED
's	I-MED
need	O
for	O
understanding	O
parental	B-MED
mental	B-MED
health	I-MED
concerns	B-MED
.	O
Fifteen	O
parents	B-MED
with	O
severe	B-MED
and	O
enduring	O
mental	B-MED
health	I-MED
difficulties	I-MED
participated	O
in	O
the	O
study	B-MED
.	O
The	O
findings	B-MED
suggest	O
four	O
main	O
social	B-MED
processes	I-MED
that	O
influence	O
parents	B-MED
'	O
talk	B-MED
with	O
their	O
children	B-MED
about	O
parental	B-MED
mental	B-MED
health	I-MED
issues	I-MED
,	O
namely	O
"	O
Protecting	B-MED
and	O
being	B-MED
protected	I-MED
,	O
"	O
"	O
Responding	B-MED
to	O
children	B-MED
's	I-MED
search	B-MED
for	O
understanding	B-MED
,	O
"	O
"	O
Prioritizing	B-MED
family	B-MED
life	I-MED
,	O
"	O
and	O
"	O
Relating	B-MED
to	I-MED
others	I-MED
.	O
"	O
Implications	O
of	O
the	O
findings	B-MED
for	O
clinical	B-MED
practice	I-MED
and	O
future	O
research	B-MED
are	O
considered	O
.	O
In	O
particular	O
,	O
the	O
need	O
for	O
more	O
family	B-MED
-	I-MED
orientated	I-MED
services	I-MED
where	O
parents	B-MED
experience	B-MED
parental	B-MED
mental	B-MED
health	I-MED
problems	I-MED
is	O
highlighted	O
.	O
Dexmedetomidine	B-MED
Effect	B-MED
on	O
Emergence	B-MED
Agitation	I-MED
and	O
Delirium	B-MED
in	O
Children	B-MED
Undergoing	O
Laparoscopic	B-MED
Hernia	I-MED
Repair	I-MED
:	O
a	O
Preliminary	B-MED
Study	B-MED
Objective	O
To	O
evaluate	O
the	O
safety	B-MED
and	O
efficacy	B-MED
of	O
dexmedetomidine	B-MED
(	O
Dex	B-MED
)	O
to	O
prevent	O
emergence	B-MED
agitation	I-MED
(	O
EA	B-MED
)	O
and	O
delirium	B-MED
(	O
ED	B-MED
)	O
in	O
children	B-MED
undergoing	O
laparoscopic	B-MED
hernia	I-MED
repair	I-MED
under	O
general	B-MED
anesthesia	I-MED
.	O
Methods	O
100	O
children	B-MED
(	O
1	O
-	O
5	O
years	B-MED
,	O
10	O
-	O
25	O
kg	O
)	O
were	O
randomized	B-MED
into	O
four	O
groups	B-MED
:	O
controls	B-MED
(	O
saline	B-MED
)	O
and	O
intravenous	B-MED
Dex	B-MED
at	O
0.25	O
,	O
0.5	O
,	O
and	O
1.0	O
µg	O
/	O
kg	O
(	O
D1	B-MED
,	O
D2	B-MED
,	O
D3	B-MED
,	O
respectively	O
)	O
.	O
Dex	B-MED
/	O
saline	B-MED
infusion	B-MED
was	O
started	O
following	O
anesthesia	B-MED
.	O
EA	B-MED
and	O
ED	B-MED
were	O
evaluated	O
on	O
a	O
5	B-MED
-	I-MED
point	I-MED
scale	I-MED
.	O
Results	O
For	O
the	O
C	B-MED
,	O
D1	B-MED
,	O
D2	B-MED
,	O
and	O
D3	B-MED
groups	B-MED
,	O
respectively	O
,	O
EA	B-MED
frequencies	B-MED
were	O
45.8	O
%	O
,	O
30.4	O
%	O
,	O
12	O
%	O
,	O
4	O
%	O
;	O
ED	B-MED
frequencies	B-MED
29.1	O
%	O
,	O
13	O
%	O
,	O
4	O
%	O
,	O
4	O
%	O
;	O
CHIPPS	B-MED
scores	B-MED
8	O
,	O
6	O
,	O
3	O
,	O
3	O
;	O
sevoflurane	B-MED
doses	B-MED
from	O
13.2	O
±	O
3.4	O
(	O
controls	B-MED
)	O
to	O
9.4	O
±	O
3.5	O
ml	O
(	O
D3	B-MED
)	O
.	O
Intervals	B-MED
until	O
mask	B-MED
removal	B-MED
/	O
spontaneous	B-MED
eye	I-MED
opening	I-MED
were	O
significantly	O
longer	B-MED
for	O
D2	B-MED
and	O
D3	B-MED
than	O
controls	B-MED
.	O
PACU	B-MED
stay	B-MED
was	O
longer	B-MED
for	O
D3	B-MED
.	O
Conclusions	O
There	O
was	O
significantly	O
less	O
postoperative	B-MED
EA	B-MED
and	O
pain	B-MED
,	O
with	O
less	O
sevoflurane	B-MED
required	O
,	O
using	O
Dex	B-MED
.	O
Stress	B-MED
and	O
binge	B-MED
drinking	I-MED
:	O
A	O
toxic	B-MED
combination	O
for	O
the	O
teenage	B-MED
brain	B-MED
Young	B-MED
adult	I-MED
university	B-MED
students	I-MED
frequently	O
binge	B-MED
on	O
alcohol	B-MED
and	O
have	O
high	B-MED
stress	B-MED
levels	I-MED
.	O
Based	O
on	O
findings	O
in	O
rodents	B-MED
,	O
we	O
predicted	O
that	O
heavy	B-MED
current	I-MED
alcohol	I-MED
use	I-MED
and	O
elevated	B-MED
stress	B-MED
and	O
depression	B-MED
scores	I-MED
would	O
be	O
associated	B-MED
with	I-MED
deficits	B-MED
on	O
high	B-MED
interference	B-MED
memory	B-MED
tasks	B-MED
,	O
while	O
early	B-MED
onset	I-MED
,	O
prolonged	O
binge	B-MED
patterns	B-MED
would	O
lead	O
to	O
broader	O
cognitive	B-MED
deficits	I-MED
on	O
tests	O
of	O
associative	B-MED
encoding	I-MED
and	O
executive	B-MED
functions	I-MED
.	O
We	O
developed	O
the	O
Concentration	B-MED
Memory	B-MED
Task	B-MED
,	O
a	O
novel	O
computerized	B-MED
version	I-MED
of	O
the	O
Concentration	B-MED
card	B-MED
game	I-MED
with	O
a	O
high	B-MED
degree	O
of	O
interference	B-MED
.	O
We	O
found	O
that	O
young	B-MED
adults	I-MED
with	O
elevated	B-MED
stress	B-MED
,	O
depression	B-MED
,	O
and	O
alcohol	B-MED
consumption	I-MED
scores	I-MED
were	O
impaired	B-MED
in	O
the	O
Concentration	B-MED
Memory	B-MED
Task	B-MED
.	O
We	O
also	O
analyzed	B-MED
data	I-MED
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	B-MED
alcohol	B-MED
consumption	I-MED
scores	I-MED
were	O
associated	B-MED
with	I-MED
impaired	B-MED
performance	B-MED
on	O
another	O
high	B-MED
interference	B-MED
memory	B-MED
task	B-MED
,	O
based	O
on	O
Kirwan	B-MED
and	I-MED
Stark	I-MED
's	I-MED
Mnemonic	I-MED
Similarity	I-MED
Test	I-MED
.	O
On	O
the	O
other	O
hand	O
,	O
adolescent	B-MED
onset	B-MED
of	O
binge	B-MED
drinking	I-MED
predicted	O
poorer	B-MED
performance	B-MED
on	O
broader	O
range	O
of	O
memory	B-MED
tests	B-MED
,	O
including	O
a	O
more	O
systematic	B-MED
test	I-MED
of	I-MED
spatial	I-MED
recognition	I-MED
memory	I-MED
,	O
and	O
an	O
associative	B-MED
learning	I-MED
task	B-MED
.	O
Our	O
results	B-MED
are	O
broadly	O
consistent	B-MED
with	I-MED
findings	O
in	O
rodents	B-MED
that	O
acute	B-MED
alcohol	I-MED
and	O
stress	B-MED
exposure	O
suppress	B-MED
neurogenesis	B-MED
in	O
the	O
adult	B-MED
hippocampus	B-MED
,	O
which	O
in	O
turn	O
impairs	B-MED
performance	B-MED
in	O
high	B-MED
interference	B-MED
memory	B-MED
tasks	B-MED
,	O
while	O
adolescent	B-MED
onset	B-MED
binge	B-MED
drinking	I-MED
causes	O
more	O
extensive	B-MED
brain	B-MED
damage	I-MED
and	O
cognitive	B-MED
deficits	I-MED
.	O
Voriconazole	B-MED
metabolism	B-MED
is	O
influenced	B-MED
by	O
severe	B-MED
inflammation	B-MED
:	O
a	O
prospective	B-MED
study	I-MED
During	O
an	O
infection	B-MED
or	O
inflammation	B-MED
,	O
several	B-MED
drug	B-MED
-	O
metabolizing	B-MED
enzymes	B-MED
in	O
the	O
liver	B-MED
are	O
down	B-MED
-	I-MED
regulated	I-MED
,	O
including	O
cytochrome	B-MED
P450	I-MED
iso	I-MED
-	I-MED
enzymes	I-MED
.	O
Since	O
voriconazole	B-MED
is	O
extensively	B-MED
metabolized	B-MED
by	O
cytochrome	B-MED
P450	I-MED
iso	I-MED
-	I-MED
enzymes	I-MED
,	O
the	O
metabolism	B-MED
of	O
voriconazole	B-MED
can	O
be	O
influenced	B-MED
during	O
inflammation	B-MED
via	O
reduced	B-MED
clearance	B-MED
of	I-MED
the	I-MED
drug	I-MED
,	O
resulting	O
in	O
higher	B-MED
voriconazole	B-MED
trough	B-MED
concentrations	I-MED
.	O
To	O
investigate	O
prospectively	O
the	O
influence	B-MED
of	O
inflammation	B-MED
on	O
voriconazole	B-MED
metabolism	B-MED
and	O
voriconazole	B-MED
trough	B-MED
concent	I-MED
ratio	I-MED
ns	I-MED
ratio	B-MED
.	O
A	O
prospective	B-MED
observational	I-MED
study	I-MED
was	O
performed	O
at	O
the	O
University	B-MED
Medical	I-MED
Center	I-MED
Groningen	B-MED
.	O
Patients	B-MED
were	O
eligible	B-MED
for	O
inclusion	B-MED
if	O
they	O
were	O
≥18	O
years	O
old	O
and	O
treated	B-MED
with	I-MED
voriconazole	B-MED
.	O
Voriconazole	B-MED
and	O
voriconazole	B-MED
-	I-MED
N	I-MED
-	I-MED
oxide	I-MED
concentrations	B-MED
were	O
determined	O
in	O
discarded	O
blood	B-MED
samples	I-MED
.	O
To	O
determine	O
the	O
degree	B-MED
of	O
inflammation	B-MED
,	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	I-MED
CRP	I-MED
)	I-MED
concentrations	I-MED
were	O
used	O
.	O
Subsequently	O
,	O
a	O
longitudinal	B-MED
data	I-MED
analysis	I-MED
was	O
performed	O
to	O
assess	B-MED
the	O
effect	B-MED
of	O
inflammation	B-MED
on	O
the	O
metabolic	B-MED
ratio	B-MED
and	O
voriconazole	B-MED
trough	B-MED
concentration	I-MED
.	O
Thirty	O
-	O
four	O
patients	B-MED
were	O
included	O
.	O
In	O
total	O
489	O
voriconazole	B-MED
trough	B-MED
concentrations	I-MED
were	O
included	O
in	O
the	O
longitudinal	B-MED
data	I-MED
analysis	I-MED
.	O
This	O
analysis	B-MED
showed	O
that	O
inflammation	B-MED
,	O
reflected	O
by	O
CRP	B-MED
concentrations	I-MED
,	O
significantly	O
influence	B-MED
d	O
the	O
metabolic	B-MED
ratio	B-MED
,	O
voriconazole	B-MED
trough	B-MED
concentration	I-MED
and	O
voriconazole	B-MED
-	I-MED
N	I-MED
-	I-MED
oxide	I-MED
concentration	B-MED
(	O
all	O
P	O
<	O
0.001	O
)	O
,	O
when	O
corrected	O
for	O
other	O
factors	B-MED
that	O
could	O
influence	B-MED
voriconazole	B-MED
metabolism	B-MED
.	O
The	O
metabolic	B-MED
ratio	B-MED
was	O
decreased	B-MED
by	O
0.99229(N	O
)	O
and	O
the	O
voriconazole	B-MED
-	I-MED
N	I-MED
-	I-MED
oxide	I-MED
concentration	B-MED
by	O
0.99775(N	O
)	O
,	O
while	O
the	O
voriconazole	B-MED
trough	B-MED
concentration	I-MED
was	O
increased	B-MED
by	O
1.005321(N	O
)	O
,	O
where	O
N	O
is	O
the	O
difference	O
in	O
CRP	B-MED
units	O
(	O
in	O
mg	O
/	O
L	O
)	O
.	O
This	O
study	O
shows	O
that	O
voriconazole	B-MED
metabolism	B-MED
is	O
decreased	B-MED
during	O
inflammation	B-MED
,	O
resulting	O
in	O
higher	B-MED
voriconazole	B-MED
trough	B-MED
concentration	I-MED
s.	O
Therefore	O
,	O
frequent	B-MED
monitoring	B-MED
of	O
voriconazole	B-MED
serum	B-MED
concentrations	I-MED
is	O
recommended	O
during	O
and	O
following	O
severe	B-MED
inflammation	B-MED
.	O
Recombinant	B-MED
protein	B-MED
transduction	I-MED
domain	I-MED
-	O
Cu	B-MED
/	I-MED
Zn	I-MED
superoxide	I-MED
dismutase	I-MED
alleviates	B-MED
bone	B-MED
cancer	I-MED
pain	B-MED
via	O
peroxiredoxin	B-MED
4	I-MED
modulation	B-MED
and	O
antioxidation	B-MED
Bone	B-MED
cancer	I-MED
pain	B-MED
(	O
BCP	B-MED
)	O
is	O
a	O
serious	B-MED
chronic	B-MED
clinical	B-MED
condition	I-MED
and	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
were	O
considered	B-MED
to	O
be	O
involved	B-MED
in	O
its	O
development	B-MED
and	O
persistency	B-MED
.	O
Normally	B-MED
,	O
superoxide	B-MED
dismutase	I-MED
(	O
SOD	B-MED
)	O
converts	O
superoxide	B-MED
anions	I-MED
to	O
hydrogen	B-MED
peroxide	I-MED
(	O
H2O2	B-MED
)	O
and	O
H2O2	B-MED
is	O
then	O
naturalized	O
to	O
be	O
water	B-MED
by	O
peroxiredoxin	B-MED
4	I-MED
.	O
We	O
reported	B-MED
previously	O
that	O
recombinant	B-MED
protein	B-MED
transduction	I-MED
domain	I-MED
PTD	B-MED
(	O
PTD)-	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
effectively	B-MED
scavenged	B-MED
excessive	B-MED
ROS	B-MED
and	O
prevented	B-MED
cardiomyocytes	B-MED
from	O
hypoxia	B-MED
-	I-MED
reoxygenation	I-MED
damage	B-MED
.	O
However	O
,	O
whether	O
PTD	B-MED
-	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
would	O
prevent	B-MED
BCP	B-MED
development	B-MED
is	O
unknown	B-MED
.	O
In	O
the	O
current	B-MED
study	B-MED
,	O
we	O
found	B-MED
that	O
an	O
implanted	B-MED
carcinoma	B-MED
in	O
the	O
rat	B-MED
tibia	B-MED
induced	B-MED
remarkable	O
hyperalgesia	B-MED
,	O
increased	B-MED
H2O2	B-MED
levels	B-MED
and	O
decreased	B-MED
SOD	B-MED
and	O
peroxiredoxin	B-MED
4	I-MED
levels	B-MED
.	O
After	O
administration	B-MED
of	O
recombinant	B-MED
PTD	B-MED
-	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
to	O
these	O
tumor	B-MED
-	I-MED
burden	I-MED
rats	B-MED
,	O
their	O
hyperalgesia	B-MED
was	O
significantly	B-MED
attenuated	B-MED
and	O
peroxiredoxin	B-MED
4	I-MED
expression	B-MED
was	O
significantly	B-MED
increased	I-MED
.	O
In	B-MED
addition	I-MED
,	O
an	O
increased	B-MED
expression	B-MED
of	O
N	B-MED
-	I-MED
methyl	I-MED
-	I-MED
d	I-MED
-	I-MED
aspartic	I-MED
acid	I-MED
(	I-MED
NMDA	I-MED
)	I-MED
receptors	I-MED
and	O
a	O
decreased	B-MED
expression	B-MED
of	O
γ	B-MED
-	I-MED
aminobutyric	I-MED
acid	I-MED
(	I-MED
GABA	I-MED
)	I-MED
receptors	I-MED
in	O
this	O
cancer	B-MED
pain	I-MED
were	O
prevented	B-MED
by	O
PTD	B-MED
-	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
administration	B-MED
or	O
peroxiredoxin	B-MED
4	I-MED
overexpression	B-MED
.	O
Our	O
data	B-MED
suggested	B-MED
that	O
reactive	B-MED
oxygen	I-MED
species	I-MED
,	O
at	O
least	O
in	O
part	O
,	O
play	O
a	O
role	B-MED
in	O
cancer	B-MED
metastatic	I-MED
pain	B-MED
development	B-MED
and	O
persistency	B-MED
which	O
can	O
be	O
attenuated	B-MED
by	I-MED
the	O
adminstration	B-MED
of	O
recombinant	B-MED
PTD	I-MED
-	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
via	O
the	O
peroxiredoxin	B-MED
4	I-MED
modulation	B-MED
from	O
oxidative	B-MED
stress	I-MED
.	O
Effects	B-MED
of	O
a	O
specific	B-MED
blend	I-MED
of	O
essential	B-MED
oils	I-MED
on	O
apparent	B-MED
nutrient	B-MED
digestion	B-MED
,	O
rumen	B-MED
fermentation	B-MED
and	O
rumen	B-MED
microbial	B-MED
populations	I-MED
in	O
sheep	B-MED
fed	O
a	O
50:50	O
alfalfa	B-MED
hay	I-MED
:	O
concentrate	B-MED
diet	I-MED
An	O
experiment	B-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	O
a	O
specific	O
mixture	B-MED
of	O
essential	B-MED
oils	I-MED
(	O
MEO	B-MED
)	O
,	O
containing	O
thyme	B-MED
,	O
clove	B-MED
and	O
cinnamon	B-MED
EO	I-MED
,	O
on	O
rumen	B-MED
microbial	B-MED
fermentation	I-MED
,	O
nutrient	B-MED
apparent	B-MED
digestibility	B-MED
and	O
blood	B-MED
metabolites	B-MED
in	O
fistulated	B-MED
sheep	I-MED
.	O
Six	O
sheep	B-MED
fitted	O
with	O
ruminal	B-MED
fistulas	I-MED
were	O
used	O
in	O
a	O
repeated	B-MED
measurement	I-MED
design	I-MED
with	O
two	O
24	O
-	O
d	O
periods	B-MED
to	O
investigate	O
the	O
effect	B-MED
of	O
adding	O
MEO	B-MED
at	O
0	O
(	O
control	O
)	O
,	O
0.8	O
,	O
and	O
1.6	O
mL	O
/	O
d	O
on	O
apparent	B-MED
nutrient	B-MED
digestibility	B-MED
,	O
rumen	B-MED
fermentation	B-MED
characteristics	B-MED
,	O
rumen	B-MED
microbial	B-MED
population	I-MED
and	O
blood	B-MED
chemical	B-MED
metabolites	I-MED
.	O
Animals	B-MED
were	O
fed	O
with	O
a	O
50:50	O
alfalfa	B-MED
hay	I-MED
:	O
concentrate	B-MED
diet	I-MED
.	O
Ruminal	B-MED
pH	I-MED
,	O
total	O
volatile	B-MED
fatty	I-MED
acids	I-MED
(	O
VFA	B-MED
)	O
concentration	B-MED
,	O
molar	B-MED
proportion	I-MED
of	I-MED
individual	I-MED
VFA	B-MED
,	O
acetate	B-MED
:	I-MED
propionate	I-MED
ratio	I-MED
and	O
methane	B-MED
production	I-MED
were	O
not	O
affected	O
with	O
MEO	B-MED
.	O
Relative	O
to	O
the	O
control	B-MED
,	O
Small	B-MED
peptides	I-MED
Small	B-MED
peptides	I-MED
plus	I-MED
amino	I-MED
acid	I-MED
nitrogen	I-MED
and	O
large	B-MED
peptides	I-MED
large	B-MED
peptides	I-MED
nitrogen	I-MED
concentration	I-MED
in	O
rumen	B-MED
fluid	I-MED
were	O
not	O
affected	O
with	O
MEO	B-MED
supplementation	B-MED
;	O
while	O
,	O
rumen	B-MED
fluid	I-MED
ammonia	B-MED
nitrogen	O
concentration	B-MED
at	O
0	O
and	O
6	O
h	O
after	O
morning	B-MED
feeding	I-MED
in	O
sheep	B-MED
fed	O
with	O
1.6	O
mL	O
/	O
d	O
of	O
MEO	B-MED
was	O
lower	O
(	O
p<0.05	O
)	O
compared	O
to	O
the	O
control	B-MED
and	O
0.8	O
mL	O
/	O
d	O
of	O
MEO	B-MED
.	O
At	O
0	O
h	O
after	O
morning	B-MED
feeding	I-MED
,	O
ammonia	B-MED
nitrogen	B-MED
concentration	I-MED
was	O
higher	O
(	O
p<0.05	O
)	O
in	O
sheep	B-MED
fed	O
0.8	O
mL	O
/	O
d	O
of	O
MEO	B-MED
relative	O
to	O
1.6	O
mL	O
/	O
d	O
and	O
control	B-MED
diet	B-MED
.	O
Ruminal	B-MED
protozoa	I-MED
and	O
hyper	B-MED
ammonia	I-MED
producing	I-MED
(	I-MED
HAP	I-MED
)	I-MED
bacteria	I-MED
counts	B-MED
were	O
not	O
affected	O
by	O
addition	O
of	O
MEO	B-MED
in	O
the	O
diet	B-MED
.	O
Relative	O
to	O
the	O
control	B-MED
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	B-MED
and	O
white	B-MED
blood	I-MED
cells	I-MED
,	O
hemoglobin	B-MED
,	O
hematocrit	B-MED
,	O
glucose	B-MED
,	O
beta	B-MED
-	I-MED
hydroxybutyric	I-MED
acid	I-MED
,	O
cholesterol	B-MED
,	O
total	B-MED
protein	I-MED
,	O
albumin	B-MED
,	O
blood	B-MED
urea	I-MED
nitrogen	I-MED
and	O
aspartate	B-MED
aminotransferase	I-MED
and	O
alanine	B-MED
aminotransferase	I-MED
concentration	B-MED
.	O
Apparent	B-MED
total	B-MED
tract	I-MED
digestibility	I-MED
of	O
dry	B-MED
matter	I-MED
,	O
crude	B-MED
proten	I-MED
,	O
organic	B-MED
matter	I-MED
,	O
and	O
neutral	B-MED
detergent	I-MED
fiber	I-MED
were	O
not	O
influenced	O
by	O
MEO	B-MED
supplementation	B-MED
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	B-MED
of	O
MEO	B-MED
may	O
have	O
limited	B-MED
effects	I-MED
on	O
apparent	B-MED
nutrient	B-MED
digestibility	B-MED
,	O
ruminal	B-MED
fermentation	I-MED
and	O
protozoa	B-MED
and	O
HAP	B-MED
bacteria	I-MED
count	B-MED
,	O
blood	B-MED
cells	I-MED
and	O
metabolites	B-MED
.	O
Uveitis	B-MED
in	O
children	B-MED
The	O
review	O
provides	O
updates	O
on	O
novel	B-MED
risk	B-MED
markers	I-MED
for	O
the	O
development	B-MED
of	O
pediatric	B-MED
inflammatory	B-MED
uveitis	I-MED
and	O
a	O
severe	B-MED
disease	I-MED
course	I-MED
,	O
on	O
treatment	B-MED
of	O
refractory	B-MED
disease	I-MED
,	O
and	O
on	O
the	O
measurement	B-MED
of	O
visual	B-MED
outcomes	I-MED
.	O
There	O
are	O
several	O
new	O
genetic	B-MED
markers	I-MED
,	O
biomarkers	B-MED
,	O
and	O
clinical	B-MED
factors	B-MED
that	O
may	O
influence	O
a	O
child	B-MED
's	I-MED
uveitis	B-MED
disease	B-MED
course	I-MED
.	O
It	O
is	O
important	O
to	O
identify	O
children	B-MED
at	O
risk	B-MED
for	O
poor	B-MED
visual	I-MED
outcomes	I-MED
and	O
who	O
are	O
refractory	B-MED
to	O
traditional	B-MED
therapy	I-MED
.	O
Racial	B-MED
disparities	I-MED
have	O
recently	O
been	O
reported	B-MED
.	O
We	O
describe	O
agents	B-MED
of	O
potential	B-MED
benefit	I-MED
.	O
In	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	B-MED
reported	I-MED
outcomes	I-MED
in	O
this	O
population	B-MED
.	O
Uveitis	B-MED
can	O
lead	O
to	O
vision	B-MED
-	I-MED
threatening	I-MED
complications	I-MED
.	O
Timely	B-MED
and	I-MED
aggressive	I-MED
treatment	I-MED
of	O
children	B-MED
identified	O
to	O
be	O
at	O
risk	B-MED
for	O
a	O
severe	B-MED
uveitis	I-MED
course	I-MED
may	O
lead	O
to	O
improved	B-MED
outcomes	I-MED
.	O
Synthesis	B-MED
and	O
characterization	B-MED
of	O
acetylated	B-MED
amylose	I-MED
and	O
development	B-MED
of	O
inclusion	B-MED
complexes	I-MED
with	O
rifampicin	B-MED
Amylose	B-MED
(	O
AM	B-MED
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	B-MED
complexes	I-MED
with	O
suitable	O
agents	B-MED
.	O
These	O
complexes	B-MED
are	O
considered	B-MED
promising	O
biomaterial	B-MED
carrier	O
since	O
the	O
guest	B-MED
molecules	I-MED
can	O
be	O
released	B-MED
later	B-MED
,	O
leading	O
to	O
many	O
applications	B-MED
,	O
especially	O
in	O
the	O
pharmaceutical	B-MED
industry	I-MED
.	O
Rifampicin	B-MED
(	O
RIF	B-MED
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	B-MED
drug	B-MED
against	O
Mycobacterium	B-MED
tuberculosis	I-MED
,	O
however	O
,	O
the	O
administration	B-MED
of	O
RIF	B-MED
in	O
high	O
dosages	B-MED
can	O
originate	O
unwanted	O
side	B-MED
-	I-MED
effects	I-MED
.	O
Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	B-MED
amylose	B-MED
(	O
AM	B-MED
)	O
in	O
the	O
formation	B-MED
of	O
complexes	B-MED
is	O
limited	O
by	O
their	O
low	O
water	B-MED
solubility	I-MED
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	B-MED
of	O
substitution	B-MED
(	O
DS	B-MED
)	O
,	O
allowing	O
solubilizing	B-MED
(	O
0.5gL(-1	O
)	O
)	O
acetylated	B-MED
amylose	I-MED
(	O
AMA	B-MED
)	O
in	O
water	B-MED
at	O
neutral	B-MED
pH	I-MED
,	O
in	O
opposition	O
to	O
that	O
observed	B-MED
with	O
native	B-MED
amylose	B-MED
(	O
trace	B-MED
solubility	B-MED
)	O
.	O
The	O
resulting	O
acetylated	B-MED
amylose	I-MED
was	O
characterized	B-MED
by	O
means	O
of	O
Fourier	B-MED
Transform	I-MED
Infrared	I-MED
(	I-MED
FT	I-MED
-	I-MED
IR	I-MED
)	I-MED
spectroscopy	I-MED
and	O
Scanning	B-MED
Electron	I-MED
Microscopy	I-MED
(	O
SEM	B-MED
)	O
.	O
FT	B-MED
-	I-MED
IR	I-MED
results	B-MED
indicated	B-MED
that	O
the	O
acetylation	B-MED
of	O
anhydroglucose	B-MED
units	B-MED
of	O
amylose	B-MED
corresponds	O
to	O
a	O
low	B-MED
DS	B-MED
,	O
whereas	O
SEM	B-MED
results	B-MED
suggested	O
that	O
the	O
smooth	B-MED
surfaces	I-MED
of	O
amylose	B-MED
granules	B-MED
were	O
changed	B-MED
into	O
rougher	O
surfaces	B-MED
after	O
acetylation	B-MED
.	O
Ultraviolet	B-MED
absorption	I-MED
spectroscopy	I-MED
(	O
UV	B-MED
-	I-MED
vis	I-MED
)	O
analysis	B-MED
confirmed	B-MED
the	O
formation	B-MED
and	O
allowed	O
the	O
quantification	B-MED
of	O
both	O
native	B-MED
(	O
AM	B-MED
-	O
RIF	B-MED
)	O
and	O
acetylated	O
(	O
AMA	B-MED
-	O
RIF	B-MED
)	O
amylose	B-MED
inclusion	B-MED
complexes	I-MED
.	O
Their	O
characterization	B-MED
in	O
solution	B-MED
was	O
performed	B-MED
by	O
dynamic	B-MED
light	I-MED
scattering	I-MED
(	O
DLS	B-MED
)	O
and	O
zeta	B-MED
potential	I-MED
(	O
ZP	B-MED
)	O
measurements	B-MED
.	O
The	O
average	B-MED
size	I-MED
of	O
inclusion	B-MED
complexes	I-MED
as	O
determined	B-MED
by	I-MED
DLS	B-MED
,	O
ranged	B-MED
between	O
70	O
and	O
100	O
nm	O
.	O
Besides	O
,	O
ZP	B-MED
analysis	B-MED
showed	O
that	O
both	O
complexes	B-MED
are	O
more	O
stable	B-MED
in	O
the	O
presence	B-MED
of	O
RIF	B-MED
.	O
This	O
study	O
may	O
lead	O
to	O
the	O
development	B-MED
of	O
an	O
effective	B-MED
method	O
for	O
the	O
preparation	B-MED
of	O
amylose	B-MED
inclusion	B-MED
complexes	I-MED
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B-MED
application	B-MED
in	O
drug	B-MED
delivery	I-MED
systems	I-MED
.	O
On	O
the	O
identity	B-MED
of	O
the	O
Palearctic	B-MED
species	B-MED
of	O
the	O
wolf	B-MED
spider	I-MED
genus	B-MED
<	O
i	O
>	O
Trebacosa	B-MED
Araneae	B-MED
<	O
/i>(Araneae	O
:	O
Lycosidae	B-MED
)	O
In	O
this	O
paper	B-MED
we	O
propose	O
Trebacosa	B-MED
brunhesi	I-MED
Villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	B-MED
of	O
Trebacosa	B-MED
europaea	I-MED
Szinetár	O
&	O
Kan	O
-	O
csal	O
,	O
2007	O
based	O
on	O
the	O
examination	B-MED
of	O
specimens	B-MED
from	O
all	O
the	O
localities	B-MED
from	O
where	O
those	O
species	B-MED
are	O
known	O
.	O
Illustration	O
of	O
the	O
type	B-MED
species	B-MED
of	O
the	O
genus	B-MED
,	O
Trebacosa	B-MED
marxi	I-MED
(	O
Stone	O
,	O
1890	O
)	O
and	O
specimens	B-MED
from	O
all	O
known	O
localities	B-MED
of	O
T.	B-MED
europaea	I-MED
are	O
given	O
to	O
show	O
both	O
the	O
inter-	B-MED
and	O
the	O
intraspecific	B-MED
differences	I-MED
of	O
the	O
genus	B-MED
.	O
Scanning	B-MED
electron	I-MED
micrographs	I-MED
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	B-MED
of	O
the	O
female	B-MED
's	I-MED
genitalia	I-MED
.	O
Neuroticism	B-MED
and	O
Fatigue	B-MED
3	B-MED
Months	I-MED
After	O
Ischemic	B-MED
Stroke	I-MED
:	O
A	O
Cross	B-MED
-	I-MED
Sectional	I-MED
Study	I-MED
To	O
examine	B-MED
the	O
relation	O
between	O
neuroticism	B-MED
and	O
fatigue	B-MED
in	O
Chinese	B-MED
patients	B-MED
with	O
stroke	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
Acute	B-MED
stroke	B-MED
unit	I-MED
.	O
Survivors	B-MED
of	O
ischemic	B-MED
stroke	I-MED
(	O
N=191	O
)	O
recruited	O
from	O
the	O
acute	B-MED
stroke	B-MED
unit	I-MED
between	O
May	O
1	O
,	O
2010	O
,	O
and	O
September	O
1	O
,	O
2011	O
.	O
Not	O
applicable	O
.	O
The	O
personality	B-MED
trait	I-MED
of	O
neuroticism	B-MED
was	O
measured	B-MED
with	O
the	O
neuroticism	B-MED
subscale	B-MED
of	O
the	O
Chinese	B-MED
version	B-MED
of	O
the	O
NEO	B-MED
Five	I-MED
-	I-MED
Factor	I-MED
Inventory	I-MED
.	O
The	O
level	B-MED
of	O
fatigue	B-MED
was	O
measured	B-MED
with	O
the	O
Fatigue	B-MED
Assessment	I-MED
Scale	I-MED
.	O
The	O
National	B-MED
Institutes	I-MED
of	I-MED
Health	I-MED
Stroke	I-MED
Scale	I-MED
,	O
Geriatric	B-MED
Depression	I-MED
Scale	I-MED
,	O
Barthel	B-MED
Index	I-MED
,	O
and	O
Mini	B-MED
-	I-MED
Mental	I-MED
State	I-MED
Examination	I-MED
were	O
administered	B-MED
to	O
obtain	O
demographic	B-MED
and	O
clinical	B-MED
information	I-MED
.	O
Fatigue	B-MED
severity	I-MED
3	B-MED
months	I-MED
after	O
stroke	B-MED
positively	O
correlated	B-MED
with	O
Geriatric	B-MED
Depression	I-MED
Scale	I-MED
and	O
NEO	B-MED
Five	I-MED
-	I-MED
Factor	I-MED
Inventory	I-MED
neuroticism	B-MED
scores	B-MED
and	O
negatively	B-MED
correlated	B-MED
with	O
the	O
Barthel	B-MED
Index	I-MED
score	I-MED
.	O
Neuroticism	B-MED
,	O
independent	B-MED
of	O
depressive	B-MED
symptoms	I-MED
,	O
is	O
a	O
predictor	O
of	O
fatigue	B-MED
severity	I-MED
3	B-MED
months	I-MED
after	O
stroke	B-MED
.	O
Interventions	O
such	O
as	O
psychological	B-MED
screening	B-MED
programs	I-MED
are	O
warranted	O
for	O
early	O
detection	B-MED
of	O
patients	B-MED
at	O
high	B-MED
risk	I-MED
of	I-MED
poststroke	B-MED
depression	I-MED
.	O
Extended	O
use	O
of	O
Prostate	B-MED
Health	I-MED
Index	I-MED
and	O
percentage	O
of	O
[	B-MED
-2]pro	I-MED
-	I-MED
prostate	I-MED
-	I-MED
specific	I-MED
antigen	I-MED
in	O
Chinese	B-MED
men	B-MED
with	O
prostate	B-MED
specific	I-MED
antigen	I-MED
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	B-MED
digital	B-MED
rectal	I-MED
examination	I-MED
We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	B-MED
Health	I-MED
Index	I-MED
(	O
PHI	B-MED
)	O
and	O
percentage	O
of	O
[	B-MED
-2]pro	I-MED
-	I-MED
prostate	I-MED
-	I-MED
specific	I-MED
antigen	I-MED
(	O
%	B-MED
p2PSA	I-MED
)	O
in	O
Chinese	B-MED
men	B-MED
with	O
prostate	B-MED
-	I-MED
specific	I-MED
antigen	I-MED
(	O
PSA	B-MED
)	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	B-MED
digital	B-MED
rectal	I-MED
examination	I-MED
(	O
DRE	B-MED
)	O
.	O
All	O
consecutive	O
Chinese	B-MED
men	B-MED
with	O
PSA	B-MED
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	B-MED
DRE	B-MED
who	O
agreed	O
for	O
transrectal	B-MED
ultrasound	I-MED
TRUS	B-MED
(	O
TRUS)-guided	O
10	O
-	O
core	O
prostate	B-MED
biopsy	I-MED
were	O
recruited	O
.	O
Blood	B-MED
samples	I-MED
were	O
taken	O
immediately	O
before	O
TRUS	B-MED
-guided	O
prostate	B-MED
biopsy	I-MED
.	O
The	O
performances	O
of	O
total	B-MED
PSA	I-MED
(	O
tPSA	B-MED
)	O
,	O
%	O
free	B-MED
-	I-MED
to	I-MED
-	I-MED
total	I-MED
PSA	I-MED
(	O
%	O
fPSA	B-MED
)	O
,	O
%	B-MED
p2PSA	I-MED
,	O
and	O
PHI	B-MED
were	O
compared	O
using	O
logistic	B-MED
regression	I-MED
,	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
,	O
and	O
decision	B-MED
curve	I-MED
analyses	I-MED
(	O
DCA	B-MED
)	O
.	O
From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	B-MED
men	B-MED
were	O
included	O
.	O
Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	B-MED
were	O
diagnosed	B-MED
to	O
have	O
prostate	B-MED
cancer	I-MED
on	O
biopsy	B-MED
.	O
The	O
proportions	O
of	O
men	B-MED
with	O
positive	B-MED
biopsies	I-MED
biopsies	B-MED
were	O
6.7	O
%	O
in	O
PHI	B-MED
<	O
35	O
,	O
22.8	O
%	O
in	O
PHI	B-MED
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
PHI	B-MED
>	O
55	O
(	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
,	O
p<0.001	O
)	O
.	O
The	O
area	B-MED
under	I-MED
curves	I-MED
(	O
AUC	B-MED
)	O
of	O
the	O
base	B-MED
model	I-MED
including	O
age	B-MED
,	O
tPSA	B-MED
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	B-MED
was	O
0.64	O
.	O
Adding	O
%	B-MED
p2PSA	I-MED
and	O
PHI	B-MED
to	O
the	O
base	B-MED
model	I-MED
improved	B-MED
the	O
AUC	B-MED
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
DCA	B-MED
.	O
The	O
positive	B-MED
biopsy	I-MED
biopsy	B-MED
rates	O
of	O
Gleason	B-MED
7	I-MED
or	I-MED
above	I-MED
prostate	B-MED
cancers	I-MED
were	O
2.2	O
%	O
for	O
PHI	B-MED
<	O
35	O
,	O
7.9	O
%	O
for	O
PHI	B-MED
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
PHI	B-MED
>	O
55	O
(	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
,	O
p<0.001	O
)	O
.	O
By	O
utilizing	O
the	O
PHI	B-MED
cutoff	O
of	O
35	O
to	O
men	B-MED
with	O
PSA	B-MED
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	B-MED
DRE	B-MED
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	B-MED
could	O
be	O
avoided	B-MED
.	O
Both	O
PHI	B-MED
and	O
%	B-MED
p2PSA	I-MED
performed	O
well	O
in	O
predicting	O
prostate	B-MED
cancer	I-MED
and	O
high	B-MED
grade	I-MED
prostate	I-MED
cancer	I-MED
.	O
The	O
use	O
of	O
PHI	B-MED
and	O
%	B-MED
p2PSA	I-MED
should	O
be	O
extended	O
to	O
Chinese	B-MED
men	B-MED
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	B-MED
DRE	B-MED
.	O
Development	B-MED
and	O
Evaluation	B-MED
of	O
the	O
ADHD	B-MED
ADHD	B-MED
Cognitions	I-MED
Scale	I-MED
for	O
Adults	B-MED
The	O
clinical	B-MED
literature	I-MED
on	O
ADHD	B-MED
in	O
adults	B-MED
suggests	O
that	O
"	O
overly	B-MED
positive	I-MED
"	O
or	O
optimistic	B-MED
cognitions	I-MED
may	O
contribute	O
to	O
impairment	B-MED
and	O
failure	B-MED
to	O
use	O
self	B-MED
-	I-MED
regulation	I-MED
skills	I-MED
in	O
this	O
population	B-MED
,	O
yet	O
the	O
research	B-MED
literature	B-MED
on	O
this	O
topic	O
is	O
limited	O
.	O
We	O
developed	O
the	O
ADHD	B-MED
ADHD	B-MED
Cognitions	I-MED
Scale	I-MED
(	O
ACS	B-MED
)	O
,	O
a	O
brief	O
self	B-MED
-	I-MED
report	I-MED
measure	B-MED
of	O
ADHD	B-MED
-related	O
thoughts	B-MED
,	O
and	O
evaluated	O
its	O
psychometric	B-MED
properties	I-MED
.	O
We	O
collected	O
self	B-MED
-	I-MED
report	I-MED
measures	B-MED
,	O
inculding	O
the	O
ACS	B-MED
,	O
from	O
two	O
large	O
community	B-MED
samples	I-MED
(	O
Ns	O
=	O
262	O
,	O
304	O
)	O
.	O
The	O
measure	O
demonstrated	O
a	O
one	B-MED
-	I-MED
factor	I-MED
solution	I-MED
that	O
replicated	B-MED
in	O
the	O
second	O
sample	B-MED
.	O
Evidence	O
of	O
good	O
internal	B-MED
consistency	I-MED
and	O
also	O
convergent	B-MED
and	O
divergent	B-MED
validity	I-MED
was	O
obtained	O
for	O
both	O
samples	B-MED
.	O
Scores	B-MED
on	O
the	O
ACS	B-MED
correlated	O
with	O
functional	B-MED
impairment	I-MED
,	O
time	B-MED
management	I-MED
problems	I-MED
,	O
and	O
avoidant	B-MED
coping	I-MED
strategies	B-MED
.	O
With	O
additional	O
study	B-MED
,	O
the	O
ACS	B-MED
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	B-MED
ADHD	B-MED
-related	O
cognitions	B-MED
during	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
treatment	I-MED
,	O
and	O
to	O
further	O
study	B-MED
the	O
role	O
of	O
these	O
thoughts	B-MED
in	O
ADHD	B-MED
ADHD	B-MED
-related	I-MED
impairment	I-MED
.	O
Immature	B-MED
stages	B-MED
and	O
larval	B-MED
chaetotaxy	B-MED
of	O
Notofairchildia	B-MED
stenygros	I-MED
(	O
Quate	O
&	O
Alexander	O
)	O
(	O
Diptera	B-MED
:	O
Psychodidae	B-MED
:	O
Bruchomyiinae	B-MED
)	O
Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	B-MED
is	O
"	O
the	O
most	O
plesiomorphic	B-MED
subfamily	I-MED
of	O
Psychodidae	B-MED
"	O
and	O
its	O
members	B-MED
"	O
are	O
among	O
the	O
most	O
primitive	B-MED
living	B-MED
Diptera	B-MED
"	O
.	O
Although	O
Bruchomyiinae	B-MED
is	O
of	O
no	B-MED
medical	B-MED
importance	B-MED
,	O
it	O
is	O
of	O
great	O
evolutionary	B-MED
significance	B-MED
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	B-MED
group	I-MED
of	O
Phlebotominae	B-MED
.	O
In	O
general	O
,	O
species	B-MED
of	O
this	O
subfamily	B-MED
are	O
rarely	O
collected	O
in	O
their	O
natural	B-MED
environment	I-MED
;	O
therefore	O
,	O
adults	B-MED
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	B-MED
stages	B-MED
of	O
these	O
flies	B-MED
are	O
poorly	O
known	O
.	O
We	O
describe	O
the	O
egg	B-MED
,	O
larvae	B-MED
and	O
pupae	B-MED
of	O
Notofairchildia	B-MED
stenygros	I-MED
and	O
provide	O
nomenclatural	B-MED
notes	I-MED
on	O
larval	B-MED
chaetotaxy	B-MED
based	O
on	O
analyses	O
using	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
(	O
SEM	B-MED
)	O
and	O
optic	B-MED
microscopy	I-MED
.	O
The	O
morphology	B-MED
of	O
immature	B-MED
Nt	B-MED
.	I-MED
stenygros	I-MED
is	O
compared	O
with	O
other	O
Bruchomyiinae	B-MED
and	O
Psychodidae	B-MED
species	B-MED
,	O
especially	O
with	O
species	B-MED
of	O
Phlebotominae	B-MED
that	O
are	O
superficially	O
similar	B-MED
to	O
Bruchomyiinae	B-MED
.	O
Results	B-MED
of	O
this	O
study	B-MED
revealed	O
striking	O
morphological	B-MED
differences	B-MED
between	O
the	O
immature	B-MED
stages	B-MED
of	O
Bruchomyiinae	B-MED
and	O
Phlebotominae	B-MED
;	O
the	O
former	O
are	O
lacking	O
abdominal	B-MED
pseudopods	B-MED
and	O
microtrichia	B-MED
on	O
the	O
cephalic	B-MED
integument	B-MED
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	B-MED
of	O
Phlebotominae	B-MED
.	O
These	O
morphological	B-MED
differences	B-MED
observed	O
in	O
the	O
immature	B-MED
stages	B-MED
between	O
members	B-MED
of	O
the	O
two	O
subfamilies	B-MED
support	O
the	O
findings	B-MED
of	O
recent	O
molecular	B-MED
studies	I-MED
indicating	O
that	O
Bruchomyiinae	B-MED
and	O
Phlebtominae	B-MED
are	O
evolutionarily	B-MED
not	B-MED
closely	I-MED
related	I-MED
.	O
Notofairchildia	B-MED
stenygros	I-MED
is	O
now	O
the	O
fourth	B-MED
species	B-MED
of	O
Bruchomyiinae	B-MED
for	O
which	O
the	O
immature	B-MED
stages	B-MED
are	O
described	O
.	O
An	O
HIV	B-MED
-	O
tailored	B-MED
quit	B-MED
-	O
smoking	B-MED
counselling	B-MED
pilot	B-MED
intervention	B-MED
targeting	B-MED
depressive	B-MED
symptoms	I-MED
plus	O
Nicotine	B-MED
Replacement	I-MED
Therapy	I-MED
Cardiovascular	B-MED
disease	I-MED
(	O
CVD	B-MED
)	O
rates	B-MED
among	O
people	B-MED
living	B-MED
with	I-MED
HIV	I-MED
/	I-MED
AIDS	I-MED
(	O
PHAs	B-MED
)	O
are	O
high	B-MED
.	O
Rates	B-MED
of	O
cigarette	B-MED
smoking	I-MED
,	O
a	O
leading	B-MED
contributor	B-MED
to	O
CVD	B-MED
among	O
PHAs	B-MED
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	B-MED
than	O
the	O
general	B-MED
population	I-MED
)	O
.	O
Furthermore	O
,	O
PHAs	B-MED
have	O
high	B-MED
rates	B-MED
of	O
depression	B-MED
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	B-MED
factor	I-MED
for	O
smoking	B-MED
cessation	B-MED
relapse	B-MED
.	O
The	O
current	O
pilot	B-MED
study	I-MED
examined	B-MED
the	O
effectiveness	B-MED
of	O
a	O
specifically	O
tailored	B-MED
5-	O
session	B-MED
smoking	B-MED
cessation	B-MED
counselling	B-MED
programme	I-MED
for	O
PHAs	B-MED
,	O
which	O
addressed	O
depression	B-MED
,	O
in	O
combination	O
with	O
Nicotine	B-MED
Replacement	I-MED
Therapy	I-MED
(	O
NRT	B-MED
)	O
in	O
a	O
cohort	B-MED
of	O
PHA	B-MED
smokers	B-MED
(	O
n	O
=	O
50	O
)	O
.	O
At	O
6-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
28	O
%	O
of	O
participants	B-MED
demonstrated	O
biochemically	B-MED
verified	B-MED
abstinence	B-MED
from	O
smoking	B-MED
.	O
This	O
result	B-MED
compares	B-MED
favourably	O
to	O
other	O
quit	B-MED
-	O
smoking	B-MED
intervention	B-MED
studies	B-MED
,	O
particularly	O
given	O
the	O
high	B-MED
percentage	B-MED
of	O
HIV+	B-MED
smokers	B-MED
with	O
depression	B-MED
.	O
At	O
study	B-MED
baseline	B-MED
,	O
52	O
%	O
of	O
HIV+	B-MED
smokers	B-MED
scored	O
above	O
the	O
clinical	B-MED
cut	B-MED
-	I-MED
off	I-MED
for	O
depression	B-MED
on	O
the	O
Centre	B-MED
for	I-MED
Epidemiological	I-MED
Studies	I-MED
-	I-MED
Depression	I-MED
(	I-MED
CES	I-MED
-	I-MED
D	I-MED
)	I-MED
scale	I-MED
.	O
HIV+	B-MED
smokers	B-MED
with	O
depression	B-MED
at	O
study	B-MED
baseline	B-MED
demonstrated	O
quantitatively	B-MED
lower	B-MED
depression	B-MED
at	O
6-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
with	O
a	O
large	B-MED
effect	B-MED
size	I-MED
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	B-MED
significance	I-MED
(	O
p	O
=	O
.058	O
)	O
.	O
Furthermore	O
,	O
those	O
with	O
depression	B-MED
were	O
no	O
more	O
likely	O
to	O
relapse	B-MED
than	O
those	O
without	O
depression	B-MED
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	B-MED
programme	I-MED
adequately	B-MED
addressed	O
this	O
significant	B-MED
barrier	B-MED
to	O
smoking	B-MED
cessation	B-MED
among	O
PHAs	B-MED
.	O
Our	O
pilot	B-MED
study	I-MED
indicates	O
the	O
importance	B-MED
of	O
tailored	B-MED
programmes	I-MED
to	O
help	O
PHAs	B-MED
quit	B-MED
smoking	B-MED
,	O
the	O
significance	B-MED
of	O
addressing	O
depressive	B-MED
symptoms	I-MED
,	O
and	O
the	O
need	O
for	O
tailored	B-MED
counselling	I-MED
programmes	I-MED
to	O
enhance	B-MED
quit	B-MED
rates	B-MED
among	O
PHAs	B-MED
.	O
The	O
relationship	B-MED
between	O
anthropometry	B-MED
and	O
body	B-MED
composition	I-MED
from	O
computed	B-MED
tomography	I-MED
:	O
The	O
Mediators	O
of	O
Atherosclerosis	B-MED
in	O
South	B-MED
Asians	I-MED
Living	B-MED
in	O
America	B-MED
Study	O
Few	O
studies	O
examine	O
the	O
relationships	B-MED
between	O
anthropometry	B-MED
and	O
the	O
body	B-MED
composition	I-MED
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	B-MED
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	B-MED
in	O
South	B-MED
Asians	I-MED
living	O
in	O
the	O
US	B-MED
.	O
We	O
conducted	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
of	O
871	O
participants	B-MED
in	O
the	O
Mediators	O
of	O
Atherosclerosis	B-MED
in	O
South	B-MED
Asians	I-MED
Living	B-MED
in	O
America	B-MED
(	B-MED
MASALA	I-MED
)	I-MED
Study	I-MED
who	O
had	O
BMI	B-MED
<	O
40	O
kg	O
/	O
m(2	O
)	O
and	O
underwent	O
abdominal	B-MED
CT	I-MED
scans	I-MED
for	O
measurement	B-MED
of	O
visceral	B-MED
and	O
subcutaneous	B-MED
fat	I-MED
.	O
Linear	B-MED
regression	I-MED
was	O
used	O
to	O
model	B-MED
the	O
associations	O
between	O
anthropometric	B-MED
measures	I-MED
and	O
naturally	O
log	O
-	O
transformed	O
body	B-MED
composition	I-MED
measures	O
.	O
All	O
measures	O
of	O
anthropometry	B-MED
,	O
except	O
height	B-MED
,	O
were	O
significantly	O
associated	B-MED
with	I-MED
visceral	B-MED
fat	I-MED
and	O
had	O
a	O
significant	B-MED
non	O
-	O
linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O
The	O
only	O
associations	O
for	O
visceral	B-MED
fat	I-MED
that	O
exhibited	O
significant	B-MED
heterogeneity	B-MED
by	O
sex	B-MED
were	O
waist	B-MED
circumference	I-MED
(	O
%	O
difference	O
in	O
visceral	B-MED
fat	I-MED
slope	O
:	O
women	B-MED
1.92	O
,	O
men	B-MED
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist	B-MED
-	I-MED
to	I-MED
-	I-MED
hip	I-MED
ratio	I-MED
(	O
women	B-MED
25.9	O
,	O
men	B-MED
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O
Except	O
for	O
height	B-MED
,	O
all	O
measures	O
of	O
anthropometry	B-MED
were	O
significantly	O
associated	B-MED
with	I-MED
subcutaneous	B-MED
fat	I-MED
,	O
had	O
a	O
significant	B-MED
quadratic	O
component	O
,	O
and	O
significant	B-MED
heterogeneity	B-MED
by	O
sex	B-MED
(	O
weight	B-MED
(	O
kg	O
):	O
2.74	O
for	O
women	B-MED
,	O
4.08	O
for	O
men	B-MED
;	O
BMI	B-MED
(	O
kg	O
/	O
m(2	O
)	O
):	O
10.3	O
,	O
14.0	O
;	O
waist	B-MED
circumference	I-MED
(	O
cm	O
):	O
1.51	O
,	O
3.36	O
;	O
hip	B-MED
circumference	I-MED
(	O
cm	O
):	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O
In	O
MASALA	O
participants	B-MED
,	O
the	O
relationships	B-MED
of	O
anthropometric	B-MED
measures	I-MED
with	O
visceral	B-MED
and	O
subcutaneous	B-MED
fat	I-MED
appear	O
similar	O
to	O
other	O
race	B-MED
/	O
ethnic	B-MED
groups	I-MED
,	O
but	O
with	O
weaker	B-MED
non	O
-	O
linearity	O
and	O
heterogeneity	B-MED
by	O
sex	B-MED
.	O
Given	O
these	O
results	O
,	O
researchers	B-MED
should	O
consider	O
separate	O
models	O
by	O
sex	B-MED
for	O
US	O
South	B-MED
Asians	I-MED
when	O
approximating	O
subcutaneous	B-MED
fat	I-MED
or	O
when	O
using	O
waist	B-MED
circumference	I-MED
to	O
approximate	O
visceral	B-MED
fat	I-MED
.	O
Interaction	B-MED
-	I-MED
driven	I-MED
distinctive	O
electronic	B-MED
states	I-MED
of	O
artificial	B-MED
atoms	I-MED
at	O
the	O
ZnO	B-MED
interface	B-MED
We	O
have	O
investigated	B-MED
the	O
electronic	B-MED
states	I-MED
of	O
planar	B-MED
quantum	I-MED
dots	I-MED
at	O
the	O
ZnO	B-MED
interface	B-MED
containing	O
a	O
few	O
interacting	B-MED
electrons	B-MED
in	O
an	O
externally	B-MED
applied	I-MED
magnetic	B-MED
field	I-MED
.	O
The	O
electron	B-MED
-	I-MED
electron	I-MED
interaction	B-MED
effects	B-MED
are	O
expected	O
to	O
be	O
much	B-MED
stronger	I-MED
in	O
this	O
case	B-MED
than	O
in	O
traditional	B-MED
semiconductor	I-MED
quantum	I-MED
systems	I-MED
,	O
such	O
as	O
in	O
GaAs	B-MED
or	O
InAs	B-MED
quantum	B-MED
dots	I-MED
.	O
In	O
order	O
to	O
highlight	O
that	O
stronger	B-MED
Coulomb	B-MED
effects	I-MED
in	O
the	O
ZnO	B-MED
quantum	B-MED
dots	I-MED
,	O
we	O
have	O
compared	B-MED
the	O
energy	B-MED
spectra	I-MED
and	O
the	O
magnetization	B-MED
in	O
this	O
system	B-MED
to	O
those	O
of	O
the	O
InAs	B-MED
quantum	B-MED
dots	I-MED
.	O
We	O
have	O
found	O
that	O
in	O
the	O
ZnO	B-MED
quantum	B-MED
dots	I-MED
the	O
signatures	O
of	O
stronger	B-MED
Coulomb	B-MED
interaction	I-MED
manifests	B-MED
in	O
an	O
unique	B-MED
ground	B-MED
state	I-MED
that	O
has	O
very	O
different	B-MED
properties	B-MED
than	O
the	O
corresponding	O
ones	O
in	O
the	O
InAs	B-MED
dot	B-MED
.	O
Our	O
results	B-MED
for	O
the	O
magnetization	B-MED
also	O
exhibits	B-MED
behaviors	I-MED
never	B-MED
before	B-MED
observed	B-MED
in	O
a	O
quantum	B-MED
dot	I-MED
for	O
a	O
realistic	B-MED
set	I-MED
of	I-MED
parameters	I-MED
.	O
We	O
have	O
found	O
a	O
stronger	B-MED
temperature	B-MED
dependence	B-MED
and	O
other	O
unexpected	B-MED
features	I-MED
,	O
such	O
as	O
paramagnetic	B-MED
-	I-MED
like	I-MED
behavior	I-MED
at	O
high	B-MED
temperatures	I-MED
for	O
a	O
quantum	B-MED
-	I-MED
dot	I-MED
helium	B-MED
.	O
Dynamics	B-MED
of	O
bacterial	B-MED
class	B-MED
Bacilli	I-MED
in	O
the	O
deepest	B-MED
valley	I-MED
lake	I-MED
of	O
Kashmir	B-MED
-the	O
Manasbal	B-MED
Lake	I-MED
In	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-MED
as	O
ecological	B-MED
indicators	I-MED
of	O
the	O
aquatic	B-MED
systems	I-MED
a	O
comprehensive	B-MED
and	I-MED
systematic	I-MED
analysis	I-MED
was	O
carried	O
out	O
on	O
Manasbal	B-MED
Lake	I-MED
,	O
the	O
deepest	B-MED
spring	I-MED
fed	I-MED
valley	I-MED
lake	I-MED
of	O
Kashmir	B-MED
.	O
The	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	B-MED
bacterial	B-MED
community	I-MED
composition	I-MED
(	O
BCC	B-MED
)	O
and	O
for	O
this	O
purpose	O
systematic	B-MED
and	O
regular	B-MED
sampling	I-MED
of	I-MED
waters	I-MED
waters	B-MED
from	O
ten	O
different	O
sampling	B-MED
stations	I-MED
,	O
predetermined	O
in	O
the	O
Lake	B-MED
according	O
to	O
differences	O
in	O
degree	B-MED
of	I-MED
human	I-MED
interference	I-MED
and	O
also	O
as	O
zones	B-MED
of	O
special	O
ecological	B-MED
interests	I-MED
were	O
selected	O
.	O
The	O
isolated	B-MED
species	B-MED
were	O
identified	B-MED
according	O
to	O
Bergey	B-MED
's	I-MED
Manual	I-MED
specification	I-MED
by	O
examining	O
their	O
micro	B-MED
and	I-MED
macro	I-MED
morphological	I-MED
characteristics	I-MED
and	O
biochemical	B-MED
characteristics	I-MED
on	O
different	O
culture	B-MED
media	I-MED
.	O
Further	O
confirmation	B-MED
was	O
done	O
by	O
sequencing	B-MED
the	O
16s	B-MED
rRNA	I-MED
gene	I-MED
by	O
using	O
universal	B-MED
bacterial	I-MED
primers	I-MED
27F	B-MED
1429R	B-MED
and	O
1429R.	O
From	O
all	O
the	O
sampling	B-MED
stations	I-MED
the	O
class	B-MED
Bacilli	I-MED
showed	O
a	O
maximum	B-MED
relative	B-MED
abundance	I-MED
with	O
a	O
contribution	B-MED
of	O
16	O
bacterial	B-MED
species	I-MED
.	O
The	O
whole	O
process	B-MED
resulted	O
in	O
the	O
identification	B-MED
of	O
Bacillus	B-MED
aerius	I-MED
,	O
Bacillus	B-MED
altitudinis	I-MED
,	O
Bacillus	B-MED
anthracis	I-MED
,	O
Bacillus	B-MED
cereus	I-MED
,	O
Bacillus	B-MED
ginsengisoli	I-MED
,	O
Bacillus	B-MED
pumilus	I-MED
,	O
Bacillus	B-MED
safensis	I-MED
,	O
Bacillus	B-MED
stratosphericus	I-MED
,	O
Bacillus	B-MED
subtilis	I-MED
,	O
Bacillus	B-MED
tequilensis	I-MED
,	O
Bacillus	B-MED
thermocopriae	I-MED
,	O
Bacillus	B-MED
thuringiensis	I-MED
,	O
Brevibacillus	B-MED
agri	I-MED
strain	I-MED
,	O
Lysinibacillus	B-MED
boronitolerans	I-MED
,	O
Lysinibacillus	B-MED
pakistanensis	I-MED
and	O
Lysinibacillus	B-MED
sphaericus	I-MED
.	O
A	O
method	B-MED
of	O
providing	B-MED
engaging	O
formative	B-MED
feedback	I-MED
to	O
large	B-MED
cohort	B-MED
first	B-MED
-	I-MED
year	I-MED
physiology	B-MED
and	O
anatomy	B-MED
students	B-MED
A	O
growing	O
body	O
of	O
evidence	B-MED
demonstrates	B-MED
a	O
critical	B-MED
role	O
for	O
effective	B-MED
,	O
meaningful	B-MED
feedback	B-MED
to	O
enhance	B-MED
student	B-MED
learning	B-MED
.	O
Effective	B-MED
feedback	B-MED
can	O
become	O
part	B-MED
of	I-MED
the	O
learning	B-MED
cycle	B-MED
that	O
is	O
not	O
only	O
a	O
learning	B-MED
opportunity	B-MED
for	O
the	O
student	B-MED
but	O
can	O
also	O
be	O
used	O
to	O
inform	B-MED
the	O
teacher	B-MED
and	O
ongoing	B-MED
curriculum	B-MED
development	I-MED
.	O
Feedback	B-MED
is	O
considered	B-MED
particularly	O
important	B-MED
during	B-MED
the	O
first	B-MED
year	I-MED
of	O
university	B-MED
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	B-MED
strategy	O
that	O
can	O
help	O
attenuate	B-MED
student	B-MED
performance	B-MED
anxieties	I-MED
and	O
solidify	B-MED
perceptions	B-MED
of	O
academic	B-MED
support	I-MED
.	O
Unfortunately	O
,	O
the	O
provision	O
of	O
individualized	B-MED
,	O
timely	B-MED
feedback	B-MED
can	O
be	O
particularly	O
challenging	O
in	O
first	B-MED
-	I-MED
year	I-MED
courses	B-MED
as	O
they	O
tend	O
to	O
be	O
large	B-MED
and	O
diverse	B-MED
cohort	B-MED
classes	B-MED
that	O
pose	O
challenges	O
of	O
time	B-MED
and	O
logistics	B-MED
.	O
Various	O
forms	O
of	O
generic	O
feedback	B-MED
can	O
provide	B-MED
rapid	B-MED
and	O
cost	B-MED
-	I-MED
effect	I-MED
feedback	B-MED
to	O
large	B-MED
cohorts	B-MED
but	O
may	O
be	O
of	O
limited	B-MED
benefit	B-MED
to	O
students	B-MED
other	O
than	O
signaling	O
weaknesses	B-MED
in	O
knowledge	B-MED
.	O
The	O
present	B-MED
study	B-MED
describes	B-MED
a	O
method	B-MED
that	O
was	O
used	O
to	O
provide	B-MED
formative	B-MED
task	I-MED
-	I-MED
related	I-MED
feedback	I-MED
to	O
a	O
large	B-MED
cohort	B-MED
of	O
first	B-MED
-	I-MED
year	I-MED
physiology	B-MED
and	O
anatomy	B-MED
students	B-MED
.	O
Based	O
on	O
student	B-MED
evaluations	B-MED
presented	B-MED
in	O
this	O
study	B-MED
,	O
this	O
method	B-MED
provided	B-MED
feedback	B-MED
in	O
a	O
manner	O
that	O
engaged	O
students	B-MED
,	O
uncovered	B-MED
underlying	B-MED
misconceptions	I-MED
,	O
facilitated	O
peer	B-MED
discussion	B-MED
,	O
and	O
provided	B-MED
opportunity	O
for	O
new	B-MED
instruction	B-MED
while	O
allowing	B-MED
the	O
lecturer	B-MED
to	O
recognize	B-MED
common	B-MED
gaps	B-MED
in	O
knowledge	B-MED
and	O
inform	O
ongoing	B-MED
curriculum	B-MED
development	I-MED
.	O
Validation	B-MED
of	O
the	O
Neogen	B-MED
®	I-MED
Fentanyl	I-MED
ELISA	B-MED
Kit	O
for	O
Blood	B-MED
and	O
Urine	B-MED
The	O
Neogen	B-MED
®	I-MED
Fentanyl	I-MED
ready	O
-	O
to	O
-	O
use	O
enzyme	B-MED
-	I-MED
linked	I-MED
immunosorbent	I-MED
assay	I-MED
kit	O
was	O
validated	O
following	O
the	O
Scientific	B-MED
Working	I-MED
Group	I-MED
for	O
Forensic	B-MED
Toxicology	I-MED
Standard	B-MED
Practices	I-MED
for	O
Method	O
Validation	B-MED
in	O
Forensic	B-MED
Toxicology	I-MED
Laboratory	B-MED
Guidelines	I-MED
.	I-MED
Two	O
decision	O
points	O
,	O
0.5	O
and	O
1	O
ng	O
/	O
mL	O
,	O
were	O
successfully	O
validated	O
for	O
whole	B-MED
blood	I-MED
.	O
For	O
urine	B-MED
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng	O
/	O
mL	O
,	O
were	O
also	O
successfully	O
validated	O
.	O
The	O
validation	B-MED
included	O
the	O
evaluation	B-MED
of	O
sensitivity	B-MED
,	O
precision	B-MED
,	O
specificity	B-MED
,	O
carryover	B-MED
,	O
plate	B-MED
drift	I-MED
,	O
ruggedness	O
/	O
robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-MED
.	O
The	O
empirically	O
determined	O
limit	B-MED
of	I-MED
detection	I-MED
was	O
0.25	O
ng	O
/	O
mL	O
for	O
blood	B-MED
and	O
0.5	O
ng	O
/	O
mL	O
for	O
urine	B-MED
.	O
Precision	B-MED
was	O
determined	O
at	O
five	O
different	O
concentrations	B-MED
ranging	O
from	O
0.25	O
to	O
1.5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	B-MED
at	O
each	O
level	O
for	O
whole	B-MED
blood	I-MED
and	O
demonstrated	O
a	O
<	O
2.4	O
%	O
coefficient	B-MED
of	I-MED
variation	I-MED
(	O
CV	B-MED
)	O
.	O
In	O
urine	B-MED
,	O
the	O
CV	B-MED
was	O
<	O
5.6	O
%	O
at	O
six	O
different	O
concentrations	B-MED
from	O
0.5	O
to	O
7.5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	B-MED
at	O
each	O
level	O
.	O
Cross	B-MED
-	I-MED
reactivity	I-MED
was	O
evaluated	B-MED
for	O
norfentanyl	B-MED
,	O
acetyl	B-MED
fentanyl	I-MED
,	O
4	B-MED
-	I-MED
anilino	I-MED
-	I-MED
N	I-MED
-	I-MED
phenethylpiperidine	I-MED
,	O
beta	B-MED
-	I-MED
hydroxythiofentanyl	I-MED
,	O
butyryl	B-MED
fentanyl	I-MED
and	O
furanyl	B-MED
fentanyl	I-MED
.	O
Receipt	O
of	O
thyroid	B-MED
hormone	I-MED
deficiency	I-MED
treatment	B-MED
and	O
risk	B-MED
of	O
herpes	B-MED
zoster	I-MED
Thyroid	B-MED
hormone	I-MED
(	O
TH	B-MED
)	O
has	O
been	O
suggested	O
to	O
control	O
herpes	B-MED
virus	I-MED
gene	B-MED
expression	I-MED
and	O
replication	B-MED
in	O
neurons	B-MED
via	O
epigenetics	B-MED
through	O
its	O
nuclear	B-MED
receptors	I-MED
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
patients	B-MED
with	O
hypothyroidism	B-MED
are	O
predisposed	O
to	O
herpes	B-MED
zoster	I-MED
(	O
HZ	B-MED
)	O
,	O
suggesting	O
that	O
the	O
TH	B-MED
deficiency	I-MED
may	O
be	O
a	O
risk	B-MED
factor	I-MED
for	O
varicella	B-MED
zoster	I-MED
virus	I-MED
(	O
VZV	B-MED
)	O
reactivation	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
test	O
the	O
hypothesis	B-MED
that	O
TH	B-MED
treatment	I-MED
will	O
ameliorate	O
the	O
complication	B-MED
of	O
HZ	B-MED
.	O
This	O
study	B-MED
investigated	B-MED
the	O
hypothesis	B-MED
by	O
enquiring	O
into	O
a	O
comprehensive	B-MED
medical	I-MED
database	I-MED
at	O
Kaiser	B-MED
Permanente	I-MED
Southern	I-MED
California	I-MED
(	O
KPSC	B-MED
)	O
to	O
verify	O
whether	O
patients	B-MED
taking	O
TH	B-MED
medication	B-MED
experience	O
a	O
reduction	O
in	O
HZ	B-MED
occurrence	O
.	O
It	O
was	O
shown	O
by	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
that	O
hypothyroidism	B-MED
patients	B-MED
taking	O
TH	B-MED
medicines	B-MED
had	O
a	O
lower	O
risk	B-MED
of	O
HZ	B-MED
.	O
The	O
fully	O
adjusted	O
analysis	B-MED
indicated	O
that	O
patients	B-MED
receiving	O
medication	B-MED
for	O
the	O
treatment	B-MED
of	O
TH	B-MED
deficiency	I-MED
exhibited	O
a	O
reduced	O
risk	B-MED
of	O
HZ	B-MED
(	O
hazard	B-MED
ratio	I-MED
0.60	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
0.51	O
-	O
0.71	O
)	O
.	O
This	O
lower	O
risk	B-MED
of	O
HZ	B-MED
was	O
significant	O
in	O
all	O
age	B-MED
groups	I-MED
except	O
the	O
18	O
-	O
39	O
years	B-MED
cohort	B-MED
.	O
In	O
addition	O
,	O
female	B-MED
patients	B-MED
taking	O
TH	B-MED
treatment	I-MED
exhibited	O
a	O
lower	O
risk	B-MED
than	O
their	O
male	B-MED
counterparts	O
.	O
Together	O
these	O
findings	B-MED
support	O
the	O
hypothesis	B-MED
that	O
a	O
constant	O
level	O
of	O
TH	B-MED
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
HZ	B-MED
.	O
More	O
studies	B-MED
are	O
underway	O
to	O
evaluate	B-MED
the	I-MED
laboratory	I-MED
data	I-MED
for	O
an	O
analysis	B-MED
of	O
hormonal	B-MED
effects	B-MED
on	O
individuals	B-MED
.	O
The	O
effects	B-MED
of	I-MED
paternal	B-MED
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
exposure	B-MED
on	O
offspring	B-MED
metabolism	B-MED
with	O
epigenetic	B-MED
changes	I-MED
in	O
the	O
mouse	O
adiponectin	B-MED
and	O
leptin	B-MED
gene	B-MED
promoters	I-MED
Recent	O
studies	B-MED
have	O
demonstrated	O
that	O
epigenetic	B-MED
changes	I-MED
resulting	O
from	O
malnutrition	B-MED
might	O
play	O
important	O
roles	B-MED
in	O
transgenerational	B-MED
links	I-MED
with	O
metabolic	B-MED
diseases	I-MED
.	O
Previously	O
,	O
we	O
observed	B-MED
that	O
exposure	B-MED
to	O
a	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
(	O
HFD	B-MED
)	O
in	B-MED
utero	I-MED
caused	B-MED
a	O
metabolic	B-MED
syndrome	B-MED
-like	O
phenomenon	B-MED
through	B-MED
epigenetic	B-MED
modifications	I-MED
of	O
the	O
adiponectin	B-MED
and	O
leptin	B-MED
genes	I-MED
that	O
persisted	O
for	O
multiple	B-MED
generations	B-MED
.	O
Recent	O
etiological	B-MED
studies	B-MED
indicated	B-MED
that	O
paternal	B-MED
BMI	B-MED
had	O
effects	B-MED
on	O
offspring	B-MED
BMI	B-MED
that	O
were	O
independent	B-MED
of	I-MED
but	O
additive	B-MED
to	O
maternal	B-MED
BMI	B-MED
effects	B-MED
.	O
Thus	O
,	O
we	O
examined	O
whether	O
paternal	B-MED
HFD	B-MED
-	O
induced	B-MED
obesity	B-MED
affected	B-MED
the	O
metabolic	B-MED
status	B-MED
of	O
offspring	B-MED
through	B-MED
epigenetic	B-MED
changes	I-MED
in	O
the	O
adiponectin	B-MED
and	O
leptin	B-MED
genes	I-MED
.	O
Additionally	O
,	O
we	O
investigated	B-MED
whether	O
a	O
normal	B-MED
diet	I-MED
during	B-MED
subsequent	B-MED
generations	I-MED
abolished	B-MED
the	O
epigenetic	B-MED
changes	I-MED
associated	B-MED
with	I-MED
paternal	B-MED
HFD	B-MED
exposure	B-MED
before	B-MED
conception	B-MED
.	O
We	O
observed	B-MED
the	O
effects	B-MED
of	I-MED
paternal	B-MED
HFD	B-MED
exposure	B-MED
before	B-MED
conception	B-MED
over	O
multiple	B-MED
generations	B-MED
on	O
offspring	B-MED
metabolic	B-MED
traits	B-MED
,	O
including	B-MED
weight	B-MED
and	O
fat	B-MED
gain	B-MED
,	O
glucose	B-MED
intolerance	I-MED
,	O
hypertriglyceridemia	B-MED
,	O
abnormal	B-MED
adipocytokine	I-MED
levels	B-MED
,	O
hypertension	B-MED
,	O
and	O
adiponectin	B-MED
and	O
leptin	B-MED
gene	I-MED
expression	B-MED
and	O
epigenetic	B-MED
changes	I-MED
.	O
Normal	B-MED
diet	I-MED
consumption	O
by	O
male	O
offspring	B-MED
during	O
the	O
subsequent	O
generation	O
following	O
paternal	B-MED
HFD	B-MED
exposure	B-MED
diminished	B-MED
whereas	O
consumption	B-MED
for	O
two	O
generations	B-MED
completely	O
abolished	B-MED
the	O
effect	B-MED
of	O
paternal	B-MED
HFD	B-MED
exposure	B-MED
on	O
metabolic	B-MED
traits	B-MED
and	O
adipocytokine	B-MED
promoter	O
epigenetic	B-MED
changes	I-MED
in	O
the	O
offspring	B-MED
.	O
The	O
effects	B-MED
of	I-MED
paternal	B-MED
HFD	B-MED
exposure	B-MED
on	O
offspring	B-MED
were	O
relatively	O
weaker	B-MED
than	O
those	O
following	B-MED
HFD	B-MED
exposure	B-MED
in	B-MED
utero	I-MED
.	O
However	O
,	O
paternal	B-MED
HFD	B-MED
exposure	B-MED
had	O
an	O
additive	B-MED
metabolic	B-MED
effect	B-MED
for	O
two	O
generations	B-MED
,	O
suggesting	O
that	O
both	O
paternal	B-MED
and	O
maternal	B-MED
nutrition	B-MED
might	O
affect	B-MED
offspring	B-MED
metabolism	B-MED
through	B-MED
epigenetic	B-MED
modifications	I-MED
of	O
adipocytokine	B-MED
genes	I-MED
for	O
multiple	B-MED
generations	B-MED
.	O
Parks	B-MED
as	O
Social	B-MED
and	O
Cultural	B-MED
Spaces	B-MED
Among	O
U.S	B-MED
.-	O
and	O
Foreign	B-MED
-	O
Born	B-MED
Latinas	B-MED
Parks	B-MED
provide	O
opportunities	B-MED
for	O
people	B-MED
to	O
engage	O
in	O
activities	B-MED
that	O
can	O
promote	B-MED
physical	B-MED
and	O
emotional	B-MED
well	B-MED
-	I-MED
being	I-MED
.	O
Using	O
focus	B-MED
groups	I-MED
and	O
personal	B-MED
interviews	B-MED
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
Northeastern	B-MED
city	B-MED
with	O
a	O
high	B-MED
rate	B-MED
of	O
obesity	B-MED
,	O
we	O
examined	B-MED
perceptions	B-MED
of	O
barriers	B-MED
and	O
facilitators	B-MED
regarding	O
the	O
use	B-MED
of	I-MED
parks	B-MED
and	O
park	B-MED
features	B-MED
that	O
would	O
promote	B-MED
physical	B-MED
activity	I-MED
among	O
Latina	B-MED
women	B-MED
(	O
N	O
=	O
39	O
)	O
.	O
Foreign	B-MED
-	O
born	B-MED
Latinas	B-MED
emphasized	O
the	O
environmental	B-MED
characteristics	B-MED
of	O
parks	B-MED
and	O
the	O
types	B-MED
of	O
amenities	B-MED
that	O
can	O
support	O
preferred	O
cultural	B-MED
and	O
social	B-MED
activities	I-MED
,	O
while	O
U.S.	B-MED
-	O
born	B-MED
Latinas	B-MED
emphasized	O
the	O
use	O
of	O
parks	B-MED
for	O
physical	B-MED
activity	I-MED
and	O
weight	B-MED
management	B-MED
.	O
Most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	B-MED
-	O
born	B-MED
participants	B-MED
conceptualized	B-MED
parks	B-MED
as	O
sociocultural	B-MED
family	I-MED
centers	I-MED
,	O
extending	O
more	O
common	B-MED
conceptualizations	B-MED
centered	O
on	O
exercise	B-MED
or	O
individual	B-MED
health	B-MED
gain	B-MED
.	O
These	O
findings	B-MED
suggest	O
the	O
need	O
for	O
new	B-MED
policies	B-MED
that	O
incorporate	O
culturally	B-MED
specific	B-MED
park	B-MED
programming	B-MED
to	O
promote	B-MED
national	O
goals	B-MED
of	O
increasing	B-MED
levels	B-MED
of	O
physical	B-MED
activity	I-MED
for	O
health	B-MED
.	O
Metabolomic	B-MED
analysis	B-MED
of	O
glycerophospholipid	B-MED
signatures	O
of	O
inflammation	B-MED
treated	B-MED
with	I-MED
non	B-MED
-	I-MED
steroidal	I-MED
anti	I-MED
-	I-MED
inflammatory	I-MED
drugs	I-MED
-induced-	O
RAW264.7	B-MED
cells	I-MED
using	O
(	B-MED
1)H	I-MED
NMR	I-MED
and	O
U	B-MED
-	I-MED
HPLC	I-MED
/	O
Q	B-MED
-	I-MED
TOF	I-MED
-	I-MED
MS	I-MED
Non	B-MED
-	I-MED
destructive	I-MED
proton	I-MED
nuclear	I-MED
magnetic	I-MED
resonance	I-MED
(	I-MED
(	I-MED
1)H	I-MED
NMR	I-MED
)	I-MED
spectroscopy	I-MED
and	O
highly	B-MED
sensitive	I-MED
ultra	B-MED
-	I-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
quadrupole	B-MED
time	I-MED
-	I-MED
of	I-MED
-	I-MED
flight	I-MED
mass	I-MED
spectrometry	I-MED
(	O
U	B-MED
-	I-MED
HPLC	I-MED
/	O
Q	B-MED
-	I-MED
TOF	I-MED
-	I-MED
MS	I-MED
)	O
coupled	O
to	O
data	B-MED
processing	I-MED
methods	B-MED
were	O
applied	O
to	O
analyze	O
the	O
metabolic	B-MED
profiling	I-MED
changes	O
of	O
glycerophospholipids	B-MED
(	O
GPLs	B-MED
)	O
in	O
RAW264.7	B-MED
cells	I-MED
from	O
inflammation	B-MED
to	O
prognosis	B-MED
.	O
Analysis	B-MED
of	O
(	B-MED
1)H	I-MED
NMR	I-MED
was	O
shown	O
that	O
the	O
models	B-MED
were	O
grouped	B-MED
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	B-MED
.	O
Based	O
on	O
the	O
highly	B-MED
simple	I-MED
,	O
accurate	B-MED
,	O
non	O
-	O
targeted	O
and	O
non	O
-	O
destructively	O
advantages	O
of	O
(	B-MED
1)H	I-MED
NMR	I-MED
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti	B-MED
-	I-MED
inflammatory	I-MED
drugs	I-MED
in	O
the	O
metabolic	B-MED
profiling	I-MED
of	O
GPLs	B-MED
.	O
58	O
GPLs	B-MED
were	O
identified	B-MED
by	O
U	B-MED
-	I-MED
HPLC	I-MED
/	O
Q	B-MED
-	I-MED
TOF	I-MED
-	I-MED
MS	I-MED
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	B-MED
in	O
this	O
study	B-MED
compared	O
with	O
our	O
previous	O
results	O
.	O
In	O
addition	O
,	O
ten	O
potential	B-MED
biomarkers	B-MED
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-MED
(	O
PC	B-MED
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0/18:1	O
)	O
changed	B-MED
consistently	O
in	O
three	O
drug	B-MED
-	I-MED
induced	I-MED
groups	B-MED
and	O
might	O
be	O
the	O
important	O
biomarkers	B-MED
.	O
Compared	O
with	O
(	B-MED
1)H	I-MED
NMR	I-MED
,	O
U	B-MED
-	I-MED
HPLC	I-MED
/	O
Q	B-MED
-	I-MED
TOF	I-MED
-	I-MED
MS	I-MED
showed	O
higher	B-MED
sensitivity	B-MED
and	I-MED
specificity	I-MED
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-MED
of	O
biomarkers	B-MED
apart	O
from	O
the	O
deficiency	B-MED
of	O
time	B-MED
-	I-MED
consuming	I-MED
sample	B-MED
preparation	I-MED
steps	I-MED
and	O
unambiguous	O
metabolite	B-MED
identification	B-MED
.	O
Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	B-MED
of	O
GPLs	B-MED
during	O
inflammation	B-MED
by	O
combining	O
(	B-MED
1)H	I-MED
NMR	I-MED
spectroscopy	I-MED
with	O
U	B-MED
-	I-MED
HPLC	I-MED
/	O
Q	B-MED
-	I-MED
TOF	I-MED
-	I-MED
MS	I-MED
.	O
The	O
metabolic	B-MED
profiling	I-MED
of	O
GPLs	B-MED
provides	O
valuable	O
evidence	B-MED
for	O
inflammation	B-MED
diagnosis	B-MED
and	O
prognosis	B-MED
,	O
and	O
might	O
unravel	O
the	O
mechanisms	B-MED
involved	O
in	O
inflammation	B-MED
progression	B-MED
.	O
Multi	B-MED
-	I-MED
drug	I-MED
-	I-MED
resistant	I-MED
Acinetobacter	B-MED
calcoaceticus	I-MED
-	I-MED
Acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
infection	B-MED
outbreak	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
in	O
a	O
veterinary	B-MED
hospital	I-MED
Members	O
of	O
the	O
Acinetobacter	B-MED
calcoaceticus	I-MED
-	I-MED
Acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
cause	O
severe	B-MED
outbreaks	B-MED
in	O
humans	B-MED
,	O
and	O
are	O
increasingly	B-MED
reported	B-MED
in	O
animals	B-MED
.	O
A	O
retrospective	B-MED
study	I-MED
,	O
describing	O
a	O
severe	B-MED
outbreak	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
caused	O
by	O
a	O
multidrug	B-MED
resistant	I-MED
member	I-MED
of	O
the	O
Acinetobacter	B-MED
calcoaceticus	I-MED
-	I-MED
Acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
in	O
a	O
veterinary	B-MED
hospital	I-MED
,	O
between	O
July	O
2010	O
and	O
November	O
2012	O
.	O
The	O
study	B-MED
included	B-MED
19	O
dogs	B-MED
and	O
4	O
cats	B-MED
.	O
Acinetobacter	B-MED
calcoaceticus	I-MED
-	I-MED
Acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
bacteria	I-MED
were	O
isolated	B-MED
from	O
urine	B-MED
(	O
9	O
animals	B-MED
)	O
,	O
respiratory	B-MED
tract	I-MED
(	O
11	O
)	O
,	O
tissues	B-MED
(	O
3	O
)	O
and	O
blood	B-MED
(	O
1	O
)	O
.	O
The	O
most	B-MED
common	B-MED
infection	B-MED
-	O
associated	B-MED
findings	I-MED
included	B-MED
fever	B-MED
,	O
purulent	B-MED
discharge	I-MED
from	O
endotracheal	B-MED
tubes	I-MED
,	O
hypotension	B-MED
,	O
and	O
neutropaenia	B-MED
.	O
Infection	B-MED
s	O
led	O
to	O
pneumonia	B-MED
,	O
urinary	B-MED
tract	I-MED
infection	I-MED
,	O
cellulitis	B-MED
and	O
sepsis	B-MED
.	O
Infection	B-MED
was	O
transmitted	B-MED
in	O
the	O
intensive	B-MED
care	I-MED
unit	I-MED
,	O
where	O
22	O
of	O
23	O
animals	B-MED
were	O
initially	B-MED
hospitalised	B-MED
.	O
The	O
mortality	B-MED
rate	I-MED
was	O
70	O
%	O
(	O
16	O
of	O
23	O
animals	B-MED
)	O
,	O
and	O
was	O
higher	B-MED
in	O
cases	O
of	O
respiratory	B-MED
infection	I-MED
compared	B-MED
to	O
other	O
infections	B-MED
.	O
Aggressive	O
environmental	B-MED
cleaning	B-MED
and	O
disinfection	B-MED
,	O
with	O
staff	B-MED
education	I-MED
for	O
personal	B-MED
hygiene	I-MED
and	O
antisepsis	B-MED
,	O
sharply	O
decreased	B-MED
the	O
infection	B-MED
incidence	B-MED
.	O
Health	B-MED
care	I-MED
-	O
associated	B-MED
outbreaks	B-MED
with	O
multidrug	B-MED
resistant	I-MED
Acinetobacter	B-MED
calcoaceticus	I-MED
-	I-MED
Acinetobacter	I-MED
baumannii	I-MED
complex	I-MED
in	O
dogs	B-MED
and	O
cats	B-MED
are	O
potentially	O
highly	B-MED
fatal	B-MED
and	O
difficult	B-MED
to	O
eradicate	B-MED
,	O
warranting	O
monitoring	B-MED
,	O
antiseptic	B-MED
techniques	B-MED
and	O
judicious	O
antibiotic	B-MED
use	B-MED
.	O
Overcoming	B-MED
structural	B-MED
inequalities	B-MED
in	O
oral	B-MED
health	I-MED
:	O
the	O
role	O
of	O
dental	B-MED
curricula	B-MED
To	O
date	O
the	O
role	O
of	O
health	B-MED
professional	I-MED
schools	I-MED
in	O
addressing	O
oral	B-MED
health	I-MED
inequalities	B-MED
have	O
been	O
minimal	O
,	O
as	O
attempts	B-MED
have	O
focused	B-MED
principally	O
upon	O
systemic	B-MED
reform	B-MED
and	O
broader	O
societal	B-MED
obligations	I-MED
.	O
Professionalism	B-MED
is	O
a	O
broad	O
competency	B-MED
that	O
is	O
taught	O
throughout	O
dental	B-MED
schools	I-MED
and	O
encompasses	O
a	O
range	B-MED
of	O
attributes	O
.	O
Professionalism	B-MED
as	O
a	O
competency	B-MED
draws	O
some	O
debate	B-MED
and	O
appears	O
to	O
be	O
a	O
shifting	B-MED
phenomenon	I-MED
.	O
We	O
may	O
ask	O
if	O
professionalism	B-MED
in	O
the	O
dental	B-MED
curricula	B-MED
may	O
be	O
better	O
addressed	O
by	O
social	B-MED
accountability	I-MED
?	O
Social	B-MED
accountability	I-MED
directs	O
oral	B-MED
health	I-MED
professional	B-MED
curricula	I-MED
(	O
education	B-MED
,	O
research	B-MED
,	O
and	O
service	B-MED
activities	I-MED
)	O
towards	O
addressing	O
the	O
priority	B-MED
health	B-MED
concerns	B-MED
of	O
the	O
community	B-MED
,	O
in	O
our	O
case	O
oral	B-MED
health	I-MED
inequalities	B-MED
.	O
Although	O
working	O
toward	O
dental	B-MED
schools	I-MED
becoming	O
more	O
socially	B-MED
accountable	I-MED
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	B-MED
oral	B-MED
health	I-MED
inequalities	B-MED
,	O
it	O
might	O
have	O
limitations	O
.	O
We	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-MED
curricula	B-MED
by	O
considering	O
some	O
of	O
the	O
political	B-MED
,	O
structural	B-MED
,	O
social	B-MED
and	O
ethical	B-MED
factors	B-MED
that	O
influence	B-MED
our	O
institutions	B-MED
and	O
our	O
graduates	B-MED
.	O
Caries	B-MED
with	O
Dental	B-MED
Fluorosis	I-MED
and	O
Oral	B-MED
Health	I-MED
Behaviour	I-MED
Among	O
12	B-MED
-	I-MED
Year	I-MED
School	B-MED
Children	I-MED
in	O
Moderate	B-MED
-	I-MED
Fluoride	I-MED
Drinking	I-MED
Water	I-MED
Community	I-MED
in	O
Quetta	B-MED
,	O
Pakistan	B-MED
To	O
determine	O
the	O
prevalence	B-MED
of	O
dental	B-MED
caries	I-MED
and	O
its	O
relationship	B-MED
with	O
dental	B-MED
fluorosis	I-MED
,	O
oral	B-MED
health	I-MED
behaviour	I-MED
and	O
dietary	B-MED
behaviour	I-MED
among	O
12	B-MED
-	I-MED
year	I-MED
school	B-MED
children	I-MED
in	O
moderate	B-MED
-	I-MED
fluoride	I-MED
drinking	I-MED
water	I-MED
community	I-MED
in	O
Quetta	B-MED
,	O
Pakistan	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
Government	B-MED
and	O
private	B-MED
schools	I-MED
of	O
Quetta	B-MED
,	O
from	O
November	B-MED
2012	O
to	O
February	B-MED
2013	O
.	O
Atotal	O
of	O
349	O
children	B-MED
aged	O
12	B-MED
-	I-MED
year	I-MED
from	O
14	O
randomly	O
selected	O
schools	B-MED
were	O
included	O
.	O
The	O
data	B-MED
collection	I-MED
was	O
done	O
on	O
questionnaire	B-MED
designed	O
for	O
children	B-MED
.	O
Dental	B-MED
caries	I-MED
status	B-MED
status	B-MED
was	O
examined	B-MED
by	O
using	O
WHO	B-MED
criteria	O
.	O
Dental	B-MED
caries	I-MED
was	O
found	O
in	O
81	O
children	B-MED
(	O
23.2	O
%	O
)	O
with	O
mean	O
DMFT	B-MED
0.61	O
.	O
Boys	B-MED
had	O
1.6	O
times	O
more	O
chance	O
to	O
have	O
dental	B-MED
caries	I-MED
than	O
girls	B-MED
.	O
Dental	B-MED
fluorosis	I-MED
was	O
found	O
in	O
63.6	O
%	O
of	O
children	B-MED
with	O
majority	O
of	O
moderate	B-MED
degree	O
(	O
50.5	O
%	O
)	O
.	O
Dental	B-MED
fluorosis	I-MED
status	B-MED
was	O
found	O
significantly	O
associated	B-MED
with	I-MED
dental	B-MED
caries	I-MED
status	B-MED
in	O
children	B-MED
.	O
The	O
children	B-MED
who	O
had	O
mild	B-MED
,	O
moderate	B-MED
and	O
severe	B-MED
fluorosis	B-MED
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	B-MED
caries	B-MED
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	B-MED
.	O
There	O
was	O
no	O
significant	O
association	B-MED
between	O
children	B-MED
's	I-MED
caries	B-MED
status	B-MED
and	O
use	O
of	O
paste	B-MED
,	O
brushing	B-MED
habit	I-MED
,	O
miswak	B-MED
,	O
and	O
visit	B-MED
to	O
the	O
dentist	B-MED
.	O
The	O
use	O
of	O
pastries	B-MED
and	O
juices	B-MED
had	O
a	O
direct	O
relation	O
with	O
the	O
children	B-MED
's	I-MED
dental	B-MED
caries	I-MED
status	B-MED
.	O
Dental	B-MED
caries	I-MED
in	O
children	B-MED
of	O
Quetta	B-MED
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	B-MED
deficient	B-MED
countries	B-MED
.	O
However	O
,	O
the	O
high	O
prevalence	B-MED
of	O
moderate	O
dental	B-MED
fluorosis	I-MED
and	O
consumption	B-MED
of	O
pastries	B-MED
and	O
juices	B-MED
resulted	O
in	O
dental	B-MED
caries	I-MED
.	O
The	O
NCAM1	B-MED
gene	I-MED
set	I-MED
is	O
linked	O
to	O
depressive	B-MED
symptoms	I-MED
and	O
their	O
brain	B-MED
structural	I-MED
correlates	B-MED
in	O
healthy	B-MED
individuals	I-MED
Depressive	B-MED
symptoms	I-MED
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	B-MED
disorders	I-MED
.	O
Utilizing	O
the	O
continuous	B-MED
spectrum	I-MED
of	O
depressive	B-MED
symptoms	I-MED
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	B-MED
underpinnings	I-MED
of	O
depression	B-MED
.	O
Gene	B-MED
set	I-MED
enrichment	I-MED
analysis	I-MED
(	O
GSEA	B-MED
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	B-MED
groups	I-MED
linked	O
to	O
complex	B-MED
traits	I-MED
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
study	I-MED
(	O
GWAS	B-MED
)	O
data	B-MED
of	I-MED
depression	I-MED
scores	I-MED
and	O
their	O
brain	B-MED
-	I-MED
level	I-MED
structural	I-MED
correlates	B-MED
in	O
healthy	B-MED
young	I-MED
individuals	I-MED
.	O
On	O
symptom	B-MED
level	I-MED
(	O
i.e.	O
depression	B-MED
scores	I-MED
)	O
,	O
robust	B-MED
enrichment	O
was	O
identified	O
for	O
two	O
gene	B-MED
sets	I-MED
:	O
NCAM1	B-MED
Interactions	B-MED
and	O
Collagen	B-MED
Formation	I-MED
.	O
Depression	B-MED
scores	I-MED
were	O
also	O
associated	B-MED
with	I-MED
decreased	B-MED
fractional	B-MED
anisotropy	I-MED
(	O
FA	B-MED
)	O
-	O
a	O
brain	B-MED
white	I-MED
matter	I-MED
property	I-MED
-	O
within	B-MED
the	I-MED
forceps	I-MED
minor	I-MED
and	O
the	O
left	B-MED
superior	I-MED
temporal	I-MED
longitudinal	I-MED
fasciculus	I-MED
.	O
Within	O
each	O
of	O
these	O
tracts	O
,	O
mean	B-MED
FA	I-MED
value	O
of	O
depression	B-MED
score	I-MED
-	O
associated	B-MED
voxels	I-MED
was	O
used	O
as	O
a	O
phenotype	B-MED
in	O
a	O
subsequent	O
GSEA	B-MED
.	O
The	O
NCAM1	B-MED
Interactions	B-MED
gene	B-MED
set	I-MED
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O
By	O
linking	O
the	O
NCAM1	B-MED
Interactions	B-MED
gene	B-MED
set	I-MED
to	O
depression	B-MED
scores	I-MED
and	O
their	O
structural	B-MED
brain	I-MED
correlates	B-MED
in	O
healthy	B-MED
participants	I-MED
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	B-MED
underpinnings	I-MED
of	O
depressive	B-MED
symptomatology	I-MED
.	O
Minimally	B-MED
invasive	I-MED
treatment	I-MED
of	O
difficult	O
bleeding	B-MED
lesions	B-MED
of	O
the	O
small	B-MED
bowel	I-MED
Bleeding	B-MED
lesions	B-MED
of	O
the	O
small	B-MED
bowel	I-MED
are	O
often	O
difficult	O
to	O
identify	B-MED
due	O
to	O
the	O
obscure	B-MED
symptomatology	B-MED
.	O
Localizing	B-MED
these	O
lesions	B-MED
requires	O
specific	B-MED
techniques	B-MED
.	O
The	O
Double	B-MED
-	I-MED
balloon	I-MED
enteroscopy	I-MED
(	O
DBE	B-MED
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	B-MED
and	O
mark	O
lesions	B-MED
,	O
so	O
that	O
a	O
minimally	B-MED
invasive	I-MED
surgical	I-MED
treatment	I-MED
could	O
be	O
performed	O
.	O
Twenty	O
robot	B-MED
-	O
assisted	B-MED
small	B-MED
bowel	I-MED
procedures	I-MED
are	O
presented	O
using	O
a	O
combination	B-MED
of	O
DBE	B-MED
for	O
localization	B-MED
and	O
robotic	B-MED
resection	I-MED
.	O
There	O
were	O
10	O
jejunal	B-MED
resections	I-MED
and	O
10	O
ileal	B-MED
resections	I-MED
.	O
Mean	O
age	B-MED
was	O
58.7	O
years	B-MED
.	O
Mean	O
operative	B-MED
time	I-MED
was	O
153.4	O
minutes	B-MED
,	O
mean	O
blood	B-MED
loss	I-MED
of	O
46	O
mL.	O
No	O
conversion	B-MED
-	I-MED
to	I-MED
-	I-MED
open	I-MED
and	O
there	O
were	O
4	O
post	B-MED
-	I-MED
operative	I-MED
complications	B-MED
.	O
The	O
90-	O
day	B-MED
mortality	B-MED
was	O
nil	O
and	O
the	O
median	O
length	B-MED
of	I-MED
stay	I-MED
was	O
4.1	O
days	B-MED
.	O
Final	O
pathology	B-MED
was	O
consistent	B-MED
with	I-MED
malignancy	B-MED
in	O
10	O
cases	B-MED
.	O
The	O
combination	B-MED
of	O
double	B-MED
-	I-MED
balloon	I-MED
enteroscopy	I-MED
and	O
robotic	B-MED
technology	I-MED
allows	O
accurate	B-MED
identification	B-MED
and	O
selective	O
treatment	B-MED
of	O
lesions	B-MED
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	B-MED
in	O
a	O
minimally	B-MED
invasive	I-MED
fashion	I-MED
.	O
Blur	B-MED
perception	B-MED
throughout	O
the	O
visual	B-MED
field	I-MED
in	O
myopia	B-MED
and	O
emmetropia	B-MED
We	O
evaluated	B-MED
the	O
ability	B-MED
of	O
emmetropic	B-MED
and	O
myopic	B-MED
observers	B-MED
to	O
detect	B-MED
and	O
discriminate	B-MED
blur	B-MED
across	O
the	O
retina	B-MED
under	O
monocular	B-MED
or	O
binocular	B-MED
viewing	I-MED
conditions	B-MED
.	O
We	O
recruited	B-MED
39	O
young	B-MED
(	O
23	O
-	O
30	O
years	O
)	O
healthy	B-MED
adults	I-MED
(	O
n	O
=	O
19	O
myopes	B-MED
)	O
with	O
best	B-MED
-	I-MED
corrected	I-MED
visual	B-MED
acuity	I-MED
0.0	O
LogMAR	B-MED
(	I-MED
20/20	I-MED
)	I-MED
or	O
better	B-MED
in	O
each	O
eye	B-MED
and	O
no	B-MED
binocular	I-MED
or	O
accommodative	B-MED
dysfunction	I-MED
.	O
Monocular	B-MED
and	O
binocular	B-MED
blur	B-MED
discrimination	B-MED
thresholds	B-MED
were	O
measured	B-MED
as	O
a	O
function	B-MED
of	O
pedestal	B-MED
blur	I-MED
using	O
naturalistic	B-MED
stimuli	B-MED
with	O
an	O
adaptive	B-MED
4AFC	I-MED
procedure	I-MED
.	O
Stimuli	B-MED
were	O
presented	B-MED
in	O
a	O
46	O
°	O
diameter	B-MED
window	O
at	O
40	O
cm	O
.	O
Gaussian	B-MED
blur	I-MED
pedestals	I-MED
were	O
confined	B-MED
to	O
an	O
annulus	B-MED
at	O
either	O
0	O
°	O
,	O
4	O
°	O
,	O
8	O
°	O
,	O
or	O
12	O
°	O
eccentricity	B-MED
,	O
with	O
a	O
blur	B-MED
increment	B-MED
applied	B-MED
to	O
only	O
one	B-MED
quadrant	I-MED
of	O
the	O
image	B-MED
.	O
The	O
adaptive	B-MED
procedure	I-MED
efficiently	B-MED
estimated	B-MED
a	O
dipper	B-MED
shaped	I-MED
blur	B-MED
discrimination	B-MED
threshold	B-MED
function	B-MED
with	O
two	B-MED
parameters	B-MED
:	O
intrinsic	B-MED
blur	B-MED
and	O
blur	B-MED
sensitivity	B-MED
.	O
The	O
amount	B-MED
of	O
intrinsic	B-MED
blur	B-MED
increased	B-MED
for	O
retinal	B-MED
eccentricities	I-MED
beyond	O
4	O
°	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
lower	B-MED
in	O
binocular	B-MED
than	O
monocular	B-MED
conditions	B-MED
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
similar	B-MED
across	O
refractive	B-MED
groups	B-MED
(	O
p	O
=	O
0.47	O
)	O
.	O
Blur	B-MED
sensitivity	B-MED
decreased	B-MED
with	O
retinal	B-MED
eccentricity	I-MED
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
highest	B-MED
for	O
binocular	B-MED
viewing	O
,	O
but	O
only	O
for	O
central	B-MED
vision	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
Myopes	B-MED
showed	O
worse	B-MED
blur	B-MED
sensitivity	B-MED
than	O
emmetropes	B-MED
monocularly	B-MED
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
binocularly	B-MED
(	O
p	O
=	O
0.66	O
)	O
.	O
As	O
expected	O
,	O
blur	B-MED
perception	B-MED
worsens	B-MED
in	O
the	O
visual	B-MED
periphery	I-MED
and	O
binocular	B-MED
summation	B-MED
is	O
most	O
evident	B-MED
in	O
central	B-MED
vision	I-MED
.	O
Furthermore	O
,	O
myopes	B-MED
exhibit	O
a	O
monocular	B-MED
impairment	B-MED
in	O
blur	B-MED
sensitivity	B-MED
that	O
improves	B-MED
under	O
binocular	B-MED
conditions	B-MED
.	O
Implications	B-MED
for	O
the	O
development	B-MED
of	O
myopia	B-MED
are	O
discussed	O
.	O
CAGEd	B-MED
-	I-MED
oPOSSUM	I-MED
:	O
motif	B-MED
enrichment	I-MED
analysis	I-MED
from	O
CAGE	B-MED
-derived	O
TSSs	B-MED
With	O
the	O
emergence	O
of	O
large	B-MED
-	I-MED
scale	I-MED
Cap	I-MED
Analysis	I-MED
of	I-MED
Gene	I-MED
Expression	I-MED
(	I-MED
CAGE	I-MED
)	I-MED
datasets	I-MED
from	O
individual	B-MED
labs	I-MED
and	O
the	O
FANTOM	B-MED
consortium	I-MED
,	O
one	O
can	O
now	O
analyze	O
the	O
cis	B-MED
-	I-MED
regulatory	I-MED
regions	I-MED
associated	O
with	O
gene	B-MED
transcription	I-MED
at	O
an	O
unprecedented	B-MED
level	I-MED
of	I-MED
refinement	I-MED
.	O
By	O
coupling	O
transcription	B-MED
factor	I-MED
binding	I-MED
site	I-MED
(	O
TFBS	B-MED
)	O
enrichment	B-MED
analysis	I-MED
with	O
CAGE	B-MED
-derived	O
genomic	B-MED
regions	I-MED
,	O
CAGEd	B-MED
-	I-MED
oPOSSUM	I-MED
can	O
identify	B-MED
TFs	B-MED
that	O
act	O
as	O
key	B-MED
regulators	B-MED
of	O
genes	B-MED
involved	O
in	O
specific	B-MED
mammalian	B-MED
cell	I-MED
and	O
tissue	B-MED
types	I-MED
.	O
The	O
webtool	B-MED
allows	O
for	O
the	O
analysis	B-MED
of	O
CAGE	B-MED
-derived	O
transcription	B-MED
start	I-MED
sites	I-MED
(	O
TSSs	B-MED
)	O
either	O
provided	O
by	O
the	O
user	B-MED
or	O
selected	O
from	O
∼1300	O
mammalian	B-MED
samples	B-MED
from	O
the	O
FANTOM5	B-MED
project	I-MED
with	O
pre	B-MED
-	I-MED
computed	I-MED
TFBS	B-MED
predicted	O
with	O
JASPAR	B-MED
TF	I-MED
binding	I-MED
profiles	I-MED
.	O
The	O
tool	B-MED
helps	O
power	O
insights	B-MED
into	O
the	O
regulation	B-MED
of	I-MED
genes	I-MED
through	O
the	O
study	B-MED
of	O
the	O
specific	B-MED
usage	B-MED
of	O
TSSs	B-MED
within	O
specific	B-MED
cell	B-MED
types	I-MED
and/or	O
under	O
specific	B-MED
conditions	I-MED
.	O
The	O
CAGEd	B-MED
-	I-MED
oPOSUM	I-MED
web	I-MED
tool	I-MED
is	O
implemented	O
in	O
Perl	B-MED
,	O
MySQL	B-MED
and	O
Apache	B-MED
and	O
is	O
available	O
at	O
http://cagedop.cmmt.ubc.ca/CAGEd_oPOSSUM	B-MED
CONTACTS	O
:	O
anthony.mathelier@ncmm.uio.no	B-MED
or	O
wyeth@cmmt.ubc.ca	B-MED
Supplementary	B-MED
information	I-MED
:	O
Supplementary	B-MED
data	I-MED
are	O
available	O
at	O
Bioinformatics	B-MED
online	B-MED
.	O
Is	O
Modern	B-MED
Medical	B-MED
Management	I-MED
Changing	B-MED
Ultimate	O
Patient	B-MED
Outcomes	I-MED
in	O
Inflammatory	B-MED
Bowel	I-MED
Disease	I-MED
?	O
The	O
impact	B-MED
of	O
modern	B-MED
medical	B-MED
management	I-MED
of	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
(	O
IBD	B-MED
)	O
on	O
surgical	B-MED
necessity	I-MED
and	O
outcomes	B-MED
remains	O
unclear	B-MED
.	O
We	O
hypothesized	O
that	O
surgery	B-MED
rates	B-MED
have	O
decreased	B-MED
while	O
outcomes	B-MED
have	O
worsened	B-MED
due	O
to	O
operating	B-MED
on	O
"	O
sicker	B-MED
"	O
patients	B-MED
since	O
the	O
introduction	B-MED
of	O
biologic	B-MED
medications	I-MED
.	O
The	O
Nationwide	O
Inpatient	B-MED
Sample	B-MED
and	O
ICD-9	B-MED
-	I-MED
CM	I-MED
codes	I-MED
were	O
used	O
to	O
identify	O
inpatient	B-MED
admissions	B-MED
for	O
Crohn	B-MED
's	I-MED
disease	I-MED
and	O
ulcerative	B-MED
colitis	I-MED
.	O
Trends	B-MED
in	O
IBD	B-MED
nutrition	B-MED
,	O
surgeries	B-MED
,	O
and	O
postoperative	B-MED
complications	I-MED
were	O
determined	O
.	O
There	O
were	O
191,743	O
admissions	B-MED
for	O
IBD	B-MED
during	O
the	O
study	B-MED
period	B-MED
.	O
Surgery	B-MED
rates	B-MED
were	O
largely	O
unchanged	B-MED
over	O
the	O
study	B-MED
period	B-MED
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-MED
in	O
both	O
Crohn	B-MED
's	I-MED
disease	I-MED
and	O
ulcerative	B-MED
colitis	I-MED
.	O
The	O
rate	B-MED
of	O
poor	B-MED
nutrition	I-MED
increased	B-MED
by	O
67	O
%	O
in	O
ulcerative	B-MED
colitis	I-MED
and	O
by	O
83	O
%	O
in	O
Crohn	B-MED
's	I-MED
disease	I-MED
.	O
Rates	B-MED
of	O
postoperative	B-MED
anastomotic	B-MED
leak	I-MED
(	O
10.2	O
-	O
13.9	O
%	O
)	O
were	O
unchanged	B-MED
over	O
the	O
years	O
.	O
Postoperative	B-MED
infection	I-MED
rates	B-MED
decreased	B-MED
by	O
17	O
%	O
in	O
Crohn	B-MED
's	I-MED
disease	I-MED
(	O
18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012	O
;	O
P	O
<	O
0.001	O
)	O
but	O
did	O
not	O
show	O
a	O
trend	B-MED
in	O
any	O
direction	O
in	O
ulcerative	B-MED
colitis	I-MED
.	O
Rates	B-MED
of	O
IBD	B-MED
surgery	B-MED
have	O
remained	O
stable	B-MED
while	O
postoperative	B-MED
infectious	I-MED
complications	I-MED
have	O
remained	O
stable	B-MED
or	O
decreased	B-MED
since	O
the	O
implementation	B-MED
of	O
biologic	B-MED
therapies	I-MED
.	O
We	O
identified	O
an	O
increase	B-MED
in	O
poor	B-MED
nutrition	I-MED
in	O
surgical	B-MED
patients	I-MED
.	O
Source	O
apportionment	O
and	O
heavy	B-MED
metal	I-MED
health	B-MED
risk	I-MED
(	O
HMHR	B-MED
)	O
quantification	B-MED
from	O
sources	B-MED
in	O
a	O
southern	B-MED
city	B-MED
in	O
China	B-MED
,	O
using	O
an	O
ME2	B-MED
-	O
HMHR	B-MED
model	B-MED
Heavy	B-MED
metals	I-MED
(	O
Cr	B-MED
,	O
Co	B-MED
,	O
Ni	B-MED
,	O
As	B-MED
,	O
Cd	B-MED
,	O
and	O
Pb	B-MED
)	O
can	O
be	O
bound	O
to	O
PM	B-MED
adversely	B-MED
affecting	I-MED
human	B-MED
health	B-MED
.	O
Quantifying	O
the	O
source	B-MED
impacts	O
on	O
heavy	B-MED
metals	I-MED
can	O
provide	O
source	B-MED
-	O
specific	B-MED
estimates	O
of	O
the	O
heavy	B-MED
metal	I-MED
health	B-MED
risk	I-MED
(	O
HMHR	B-MED
)	O
to	O
guide	O
effective	B-MED
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	B-MED
from	O
exposure	B-MED
to	I-MED
heavy	B-MED
metals	I-MED
in	O
PM2.5	B-MED
(	O
particulate	B-MED
matter	I-MED
(	O
PM	B-MED
)	O
with	O
aerodynamic	B-MED
diameter	I-MED
less	O
than	O
or	O
equal	O
to	O
2.5	O
μm	O
)	O
.	O
In	O
this	O
study	O
,	O
a	O
method	O
combining	O
Multilinear	B-MED
Engine	I-MED
2	I-MED
(	O
ME2	B-MED
)	O
and	O
a	O
risk	B-MED
assessment	I-MED
model	B-MED
is	O
developed	O
to	O
more	O
effectively	O
quantify	B-MED
source	B-MED
contributions	B-MED
to	O
HMHR	B-MED
,	O
including	O
heavy	B-MED
metal	I-MED
non	B-MED
-	I-MED
cancer	I-MED
risk	I-MED
(	O
non	B-MED
-	I-MED
HMCR	I-MED
)	O
and	O
cancer	B-MED
risk	I-MED
(	O
HMCR	B-MED
)	O
.	O
The	O
combined	O
model	B-MED
(	O
called	O
ME2	B-MED
-	I-MED
HMHR	I-MED
)	O
has	O
two	O
steps	O
:	O
step1	O
,	O
source	B-MED
contributions	B-MED
to	O
heavy	B-MED
metals	I-MED
are	O
estimated	O
by	O
employing	O
the	O
ME2	B-MED
model	B-MED
;	O
step2	O
,	O
the	O
source	B-MED
contributions	B-MED
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk	B-MED
assessment	I-MED
model	B-MED
to	O
calculate	O
the	O
source	B-MED
contributions	B-MED
to	O
HMHR	B-MED
.	O
The	O
approach	O
was	O
applied	O
to	O
Huzou	B-MED
,	O
China	B-MED
and	O
five	O
significant	O
sources	B-MED
were	O
identified	O
.	O
Soil	B-MED
dust	B-MED
is	O
the	O
largest	O
source	B-MED
of	O
non	B-MED
-	I-MED
HMCR	I-MED
.	O
For	O
HMCR	B-MED
,	O
the	O
source	B-MED
contributions	B-MED
of	O
soil	B-MED
dust	B-MED
,	O
coal	B-MED
combustion	B-MED
,	O
cement	B-MED
dust	I-MED
dust	B-MED
,	O
vehicle	B-MED
,	O
and	O
secondary	O
sources	B-MED
are	O
1.0	O
×	O
10(-4	O
)	O
,	O
3.7	O
×	O
10(-5	O
)	O
,	O
2.7	O
×	O
10(-6	O
)	O
,	O
1.6	O
×	O
10(-6	O
)	O
and	O
1.9	O
×	O
10(-9	O
)	O
,	O
respectively	O
.	O
The	O
soil	B-MED
dust	B-MED
is	O
the	O
largest	O
contributor	B-MED
to	O
HMCR	B-MED
,	O
being	O
driven	O
by	O
the	O
high	O
impact	B-MED
of	O
soil	B-MED
dust	B-MED
on	O
PM2.5	B-MED
and	O
the	O
abundance	B-MED
of	O
heavy	B-MED
metals	I-MED
in	O
soil	B-MED
dust	B-MED
.	O
Intravascular	B-MED
Inflammation	B-MED
Triggers	B-MED
Intracerebral	B-MED
Activated	B-MED
Microglia	B-MED
and	O
Contributes	O
to	O
Secondary	B-MED
Brain	I-MED
Injury	I-MED
After	O
Experimental	B-MED
Subarachnoid	B-MED
Hemorrhage	I-MED
(	O
eSAH	B-MED
)	O
Activation	B-MED
of	O
innate	B-MED
immunity	I-MED
contributes	O
to	O
secondary	B-MED
brain	I-MED
injury	I-MED
after	O
experimental	B-MED
subarachnoid	B-MED
hemorrhage	I-MED
(	O
eSAH	B-MED
)	O
.	O
Microglia	B-MED
accumulation	B-MED
and	O
activation	B-MED
within	O
the	O
brain	B-MED
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	B-MED
cell	I-MED
death	I-MED
after	O
eSAH	B-MED
.	O
In	O
isolated	B-MED
mouse	B-MED
brain	B-MED
capillaries	B-MED
after	O
eSAH	B-MED
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	B-MED
expression	I-MED
for	O
intercellular	B-MED
adhesion	I-MED
molecule-1	I-MED
(	O
ICAM-1	B-MED
)	O
and	O
P	B-MED
-	I-MED
selectin	I-MED
.	O
Hence	O
,	O
we	O
hypothesized	B-MED
that	O
extracerebral	B-MED
intravascular	B-MED
inflammatory	B-MED
processes	I-MED
might	O
initiate	O
the	O
previously	O
reported	B-MED
microglia	B-MED
accumulation	B-MED
within	O
the	O
brain	B-MED
tissue	I-MED
.	O
We	O
therefore	O
induced	O
eSAH	B-MED
in	O
knockout	B-MED
mice	I-MED
for	O
ICAM-1	B-MED
(	O
ICAM-1(-/-	B-MED
)	I-MED
)	O
and	O
P	B-MED
-	I-MED
selectin	I-MED
glycoprotein	I-MED
ligand-1	I-MED
(	O
PSGL-1(-/-	B-MED
)	I-MED
)	O
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-MED
-	O
endothelial	B-MED
interaction	B-MED
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-MED
in	O
a	O
chronic	B-MED
cranial	B-MED
window	B-MED
model	I-MED
.	O
This	O
inhibition	B-MED
of	O
neutrophil	B-MED
recruitment	I-MED
to	O
the	O
endothelium	B-MED
results	O
in	O
significantly	O
ameliorated	B-MED
microglia	B-MED
accumulation	B-MED
and	O
neuronal	B-MED
cell	I-MED
death	I-MED
in	O
knockout	B-MED
animals	I-MED
in	O
comparison	O
to	O
controls	O
.	O
Our	O
results	O
suggest	O
an	O
outside	O
-	O
in	O
activation	B-MED
of	O
the	O
CNS	B-MED
innate	I-MED
immune	B-MED
system	I-MED
at	O
the	O
vessel	B-MED
/	O
brain	B-MED
interface	O
following	O
eSAH	B-MED
.	O
Microglia	B-MED
cells	B-MED
,	O
as	O
part	O
of	O
the	O
brain	B-MED
's	I-MED
innate	B-MED
immune	I-MED
system	I-MED
,	O
are	O
triggered	B-MED
by	O
an	O
inflammatory	B-MED
reaction	I-MED
in	O
the	O
microvasculature	B-MED
after	O
eSAH	B-MED
,	O
thus	O
contributing	O
to	O
neuronal	B-MED
cell	I-MED
death	I-MED
.	O
This	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-MED
targets	B-MED
,	O
as	O
well	O
as	O
possible	O
therapy	B-MED
options	O
for	O
patients	B-MED
suffering	O
from	O
eSAH	B-MED
.	O
Early	B-MED
assessment	B-MED
of	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
:	O
A	O
comparison	B-MED
between	O
the	O
laparoscopic	B-MED
total	I-MED
extraperitoneal	I-MED
and	O
Stoppa	B-MED
approaches	I-MED
The	O
present	B-MED
clinical	B-MED
trial	I-MED
was	O
designed	O
to	O
compare	B-MED
the	O
results	B-MED
of	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
between	O
patients	B-MED
who	O
underwent	O
the	O
conventional	B-MED
Stoppa	B-MED
technique	I-MED
and	O
laparoscopic	B-MED
total	I-MED
extraperitoneal	I-MED
repair	I-MED
(	O
LTE	B-MED
)	O
with	O
a	O
single	O
mesh	B-MED
and	O
without	O
staple	B-MED
fixation	I-MED
.	O
This	O
controlled	O
,	O
randomised	B-MED
clinical	B-MED
trial	I-MED
was	O
conducted	O
at	O
General	B-MED
Surgery	I-MED
and	I-MED
Trauma	I-MED
of	I-MED
the	I-MED
Clinics	I-MED
Hospital	I-MED
,	O
Medical	B-MED
School	I-MED
,	O
the	O
University	B-MED
of	I-MED
Sγo	I-MED
Paulo	I-MED
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O
Totally	O
,	O
50	O
male	B-MED
patients	B-MED
,	O
with	O
a	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
,	O
older	O
than	O
25	O
years	B-MED
were	O
considered	O
eligible	B-MED
for	O
the	O
study	B-MED
.	O
The	O
following	O
parameters	B-MED
were	O
analysed	B-MED
during	O
the	O
early	B-MED
post	B-MED
-	I-MED
operative	I-MED
period	I-MED
:	O
(	O
1	O
)	O
The	O
intensity	B-MED
of	O
surgical	B-MED
trauma	I-MED
,	O
operation	B-MED
time	I-MED
,	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
levels	B-MED
,	O
white	B-MED
blood	I-MED
cell	I-MED
count	I-MED
,	O
bleeding	B-MED
and	O
pain	B-MED
intensity	I-MED
;	O
(	O
2	O
)	O
quality	B-MED
of	I-MED
life	I-MED
assessment	B-MED
;	O
and	O
(	O
3	O
)	O
post	B-MED
-	I-MED
operative	I-MED
complications	I-MED
.	O
LTE	B-MED
procedure	I-MED
was	O
longer	B-MED
than	O
the	O
Stoppa	B-MED
procedure	I-MED
(	O
134.6	O
min	O
΁	O
38.3	O
vs.	O
90.6	O
min	O
΁	O
41.3	O
;	O
P	O
<	O
0.05	O
)	O
.	O
The	O
levels	B-MED
of	O
CRP	B-MED
were	O
higher	B-MED
in	O
the	O
Stoppa	B-MED
group	B-MED
(	O
P	O
<	O
0.05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	B-MED
,	O
haematocrit	B-MED
,	O
and	O
haemoglobin	B-MED
were	O
similar	B-MED
between	O
the	O
groups	B-MED
(	O
P	O
>	O
0.05	O
)	O
.	O
There	O
was	O
no	B-MED
difference	I-MED
in	O
pain	B-MED
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post	B-MED
-	I-MED
operative	I-MED
,	O
physical	B-MED
functioning	I-MED
,	O
physical	B-MED
limitation	I-MED
,	O
the	O
impact	B-MED
of	O
pain	B-MED
on	O
daily	B-MED
activities	I-MED
,	O
and	O
the	O
Carolinas	B-MED
Comfort	I-MED
Scale	I-MED
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post	B-MED
-	I-MED
operative	I-MED
(	O
P	O
>	O
0.05	O
)	O
.	O
Complications	B-MED
occurred	O
in	O
88	O
%	O
of	O
Stoppa	B-MED
group	B-MED
(	O
22	O
patients	B-MED
)	O
and	O
64	O
%	O
in	O
LTE	B-MED
group	B-MED
(	O
16	O
patients	B-MED
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
comparative	B-MED
study	I-MED
between	O
the	O
Stoppa	B-MED
and	O
LTE	B-MED
approaches	O
for	O
the	O
bilateral	B-MED
inguinal	I-MED
hernia	I-MED
repair	I-MED
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	B-MED
approach	O
showed	O
less	O
surgical	B-MED
trauma	I-MED
despite	O
the	O
longer	B-MED
operation	B-MED
time	I-MED
;	O
(	O
2	O
)	O
Quality	B-MED
of	I-MED
life	I-MED
during	O
the	O
early	B-MED
post	B-MED
-	I-MED
operative	I-MED
period	I-MED
were	O
similar	B-MED
;	O
and	O
(	O
3	O
)	O
Complication	B-MED
rates	B-MED
were	O
higher	B-MED
in	O
the	O
Stoppa	B-MED
group	B-MED
.	O
Spectral	B-MED
fingerprints	I-MED
of	O
large	O
-	O
scale	O
cortical	B-MED
dynamics	B-MED
during	B-MED
ambiguous	B-MED
motion	B-MED
perception	I-MED
Ambiguous	B-MED
stimuli	B-MED
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-MED
correlates	B-MED
of	O
consciousness	B-MED
.	O
Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-MED
perception	B-MED
might	O
arise	O
from	O
the	O
dynamic	B-MED
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-MED
areas	I-MED
.	O
While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	B-MED
coupling	I-MED
as	O
a	O
correlate	B-MED
of	O
cortical	B-MED
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	B-MED
modes	I-MED
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	B-MED
functions	I-MED
.	O
Here	O
,	O
we	O
studied	O
two	O
coupling	B-MED
modes	I-MED
,	O
namely	O
phase	B-MED
and	I-MED
envelope	I-MED
coupling	I-MED
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	B-MED
.	O
Therefore	O
,	O
we	O
recorded	O
128	O
-	O
channel	O
EEG	B-MED
while	O
participants	B-MED
performed	O
a	O
bistable	B-MED
motion	I-MED
task	I-MED
and	O
utilized	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
source	O
-	O
space	O
connectivity	B-MED
analysis	B-MED
techniques	B-MED
to	O
study	O
the	O
functional	B-MED
relevance	I-MED
of	O
different	O
coupling	B-MED
modes	I-MED
for	O
cortical	B-MED
communication	O
.	O
Our	O
results	O
indicate	O
that	O
gamma	B-MED
-	I-MED
band	I-MED
phase	I-MED
coupling	I-MED
in	O
extrastriate	B-MED
visual	B-MED
cortex	I-MED
might	O
mediate	O
the	O
integration	O
of	O
visual	B-MED
tokens	I-MED
into	O
a	O
moving	B-MED
stimulus	B-MED
during	O
ambiguous	B-MED
visual	B-MED
stimulation	I-MED
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long	O
-	O
range	O
fronto	O
-	O
occipital	O
gamma	O
-	O
band	O
envelope	B-MED
coupling	I-MED
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	B-MED
motion	B-MED
perception	I-MED
.	O
Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-MED
parieto	I-MED
-	I-MED
occipital	I-MED
alpha	B-MED
-	I-MED
band	I-MED
phase	I-MED
coupling	I-MED
controls	O
the	O
inter-	O
hemispheric	B-MED
information	B-MED
transfer	I-MED
.	O
These	O
findings	O
provide	O
correlative	B-MED
evidence	B-MED
for	O
the	O
notion	O
that	O
synchronized	B-MED
oscillatory	O
brain	B-MED
activity	I-MED
reflects	O
the	O
processing	B-MED
of	I-MED
sensory	I-MED
input	O
as	O
well	O
as	O
the	O
information	B-MED
integration	I-MED
across	O
several	O
spatiotemporal	B-MED
scales	I-MED
.	O
The	O
results	O
indicate	O
that	O
distinct	B-MED
coupling	I-MED
modes	I-MED
are	O
involved	O
in	O
different	O
cortical	B-MED
computations	B-MED
and	O
that	O
the	O
rich	O
spatiotemporal	B-MED
correlation	I-MED
structure	B-MED
of	I-MED
the	I-MED
brain	I-MED
might	O
constitute	O
the	O
functional	B-MED
architecture	O
for	O
cortical	B-MED
processing	O
and	O
specific	O
multi	O
-	O
site	O
communication	O
.	O
Hum	O
Brain	O
Mapp	O
37:4099	O
-	O
4111	O
,	O
2016	O
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Effect	B-MED
of	O
Hepatitis	B-MED
C	I-MED
Virus	I-MED
Coinfection	I-MED
on	O
the	O
Content	O
of	O
CD4(+	B-MED
)	I-MED
and	I-MED
CD8(+	I-MED
)	I-MED
T	B-MED
Cell	I-MED
Subpopulations	B-MED
in	O
HIV	B-MED
-	O
Infected	B-MED
Patients	B-MED
Receiving	B-MED
Antiretroviral	B-MED
Therapy	I-MED
We	O
studied	O
the	O
effect	B-MED
of	O
hepatitis	B-MED
C	I-MED
virus	I-MED
coinfection	I-MED
on	O
T	B-MED
cell	I-MED
subpopulations	B-MED
in	O
HIV	B-MED
-	O
infected	B-MED
patients	B-MED
receiving	O
antiretroviral	B-MED
therapy	I-MED
.	O
Coinfection	B-MED
with	O
hepatitis	B-MED
C	I-MED
virus	I-MED
was	O
followed	O
by	O
a	O
decrease	B-MED
in	O
the	O
number	O
of	O
naive	B-MED
CD4(+	I-MED
)	I-MED
T	I-MED
cells	I-MED
and	O
an	O
increase	B-MED
in	O
the	O
count	B-MED
of	O
central	O
CD8(+	B-MED
)	I-MED
memory	I-MED
T	I-MED
cells	I-MED
in	O
these	O
patients	B-MED
.	O
Hepatitis	B-MED
C	I-MED
virus	I-MED
had	O
no	B-MED
effect	I-MED
on	O
the	O
number	O
of	O
CD4(+	B-MED
)	I-MED
memory	I-MED
T	I-MED
cells	I-MED
(	O
main	O
target	O
for	O
HIV	B-MED
)	O
.	O
This	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-MED
effect	B-MED
of	O
hepatitis	B-MED
C	I-MED
virus	I-MED
on	O
the	O
course	B-MED
of	O
HIV	B-MED
infection	B-MED
.	O
Impact	B-MED
of	O
Blood	B-MED
Transfusions	I-MED
on	O
Survival	B-MED
of	O
Locally	B-MED
Advanced	B-MED
Cervical	B-MED
Cancer	I-MED
Patients	B-MED
Undergoing	O
Neoadjuvant	B-MED
Chemotherapy	I-MED
Plus	O
Radical	B-MED
Surgery	I-MED
Transfusions	B-MED
represent	O
one	O
of	O
the	O
main	O
progresses	B-MED
of	O
modern	B-MED
medicine	I-MED
.	O
However	O
,	O
accumulating	O
evidence	B-MED
supports	O
that	O
transfusions	B-MED
correlate	O
with	O
worse	O
survival	B-MED
outcomes	B-MED
in	O
patients	B-MED
affected	B-MED
by	O
solid	B-MED
cancers	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
aimed	B-MED
to	O
investigate	B-MED
the	O
effects	O
of	O
perioperative	B-MED
blood	B-MED
transfusion	I-MED
in	O
locally	B-MED
advanced	B-MED
cervical	B-MED
cancer	I-MED
.	O
Data	O
of	O
consecutive	O
patients	B-MED
affected	B-MED
by	O
locally	B-MED
advanced	B-MED
cervical	B-MED
cancer	I-MED
scheduled	O
to	O
undergo	O
neoadjuvant	B-MED
chemotherapy	I-MED
plus	O
radical	B-MED
surgery	I-MED
were	O
retrospectively	B-MED
searched	B-MED
to	O
test	B-MED
the	O
impact	B-MED
of	O
perioperative	B-MED
transfusions	B-MED
on	O
survival	B-MED
outcomes	B-MED
.	O
Five-	O
year	B-MED
survival	B-MED
outcomes	B-MED
were	O
evaluated	O
using	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
and	O
Cox	B-MED
models	I-MED
.	O
The	O
study	B-MED
included	O
275	O
patients	B-MED
.	O
Overall	O
,	O
170	O
(	O
62	O
%	O
)	O
patients	B-MED
had	O
blood	B-MED
transfusion	I-MED
.	O
Via	O
univariate	B-MED
analysis	I-MED
,	O
we	O
observed	B-MED
that	O
transfusion	B-MED
correlated	O
with	O
an	O
increased	O
risk	B-MED
of	O
developing	B-MED
recurrence	B-MED
(	O
hazard	B-MED
ratio	I-MED
[	O
HR	B-MED
]	O
,	O
2.2	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
,	O
1.09	O
-	O
4.40	O
;	O
P	B-MED
=	O
0.02	O
)	O
.	O
Other	O
factors	O
associated	O
with	O
5-	O
year	B-MED
disease	B-MED
-	I-MED
free	I-MED
survival	I-MED
were	O
noncomplete	B-MED
clinical	B-MED
response	I-MED
after	O
neoadjuvant	B-MED
chemotherapy	I-MED
(	O
HR	B-MED
,	O
2.99	O
;	O
95	O
%	O
CI	B-MED
,	O
0.92	O
-	O
9.63	O
;	O
P	B-MED
=	O
0.06	O
)	O
and	O
pathological	B-MED
(	O
P	B-MED
=	O
0.03	O
)	O
response	B-MED
at	O
neoadjuvant	B-MED
chemotherapy	I-MED
as	O
well	O
as	O
parametrial	B-MED
(	O
P	B-MED
=	O
0.004	O
)	O
,	O
vaginal	B-MED
(	O
P	B-MED
<	O
0.001	O
)	O
,	O
and	O
lymph	B-MED
node	I-MED
(	O
P	B-MED
=	O
0.002	O
)	O
involvements	O
.	O
However	O
,	O
via	O
multivariate	B-MED
analysis	I-MED
,	O
only	O
vaginal	B-MED
(	O
HR	B-MED
,	O
3.07	O
;	O
95	O
%	O
CI	B-MED
,	O
1.20	O
-	O
7.85	O
;	O
P	B-MED
=	O
0.01	O
)	O
and	O
lymph	B-MED
node	I-MED
involvements	O
(	O
HR	B-MED
,	O
2.4	O
;	O
95	O
%	O
CI	B-MED
,	O
1.00	O
-	O
6.06	O
;	O
P	B-MED
P	B-MED
=	O
0.05	O
)	O
correlate	O
with	O
worse	O
disease	B-MED
-	I-MED
free	I-MED
survival	I-MED
.	O
No	O
association	O
with	O
worse	O
outcomes	B-MED
was	O
observed	B-MED
for	O
patients	B-MED
undergoing	O
blood	B-MED
transfusion	I-MED
(	O
HR	B-MED
,	O
2.71	O
;	O
95	O
%	O
CI	B-MED
,	O
0.91	O
-	O
8.03	O
;	O
P	B-MED
=	O
0.07	O
)	O
.	O
Looking	O
at	O
factors	O
influencing	O
overall	B-MED
survival	I-MED
,	O
we	O
observed	B-MED
that	O
lymph	B-MED
node	I-MED
status	O
(	O
P	B-MED
=	O
0.01	O
)	O
and	O
vaginal	B-MED
involvement	O
(	O
P	B-MED
=	O
0.06	O
)	O
were	O
independently	O
associated	O
with	O
survival	B-MED
.	O
The	O
role	O
of	O
blood	B-MED
transfusions	I-MED
in	O
increasing	O
the	O
risk	B-MED
of	O
developing	B-MED
recurrence	B-MED
in	O
LAAC	B-MED
patients	B-MED
treated	B-MED
by	O
neoadjuvant	B-MED
chemotherapy	I-MED
plus	O
radical	B-MED
surgery	I-MED
remains	O
unclear	B-MED
;	O
further	O
prospective	B-MED
studies	I-MED
are	O
warranted	O
.	O
How	O
Should	O
I	O
Study	O
for	O
the	O
Exam	B-MED
?	O
Self	B-MED
-	I-MED
Regulated	I-MED
Learning	I-MED
Strategies	B-MED
and	O
Achievement	B-MED
in	O
Introductory	B-MED
Biology	I-MED
In	O
college	B-MED
introductory	B-MED
science	I-MED
courses	B-MED
,	O
students	B-MED
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary	B-MED
content	I-MED
while	O
developing	O
as	O
autonomous	B-MED
and	O
effective	B-MED
learners	B-MED
.	O
Self	B-MED
-	I-MED
regulated	I-MED
learning	I-MED
(	O
SRL	B-MED
)	O
is	O
the	O
process	O
of	O
setting	O
learning	B-MED
goals	I-MED
,	O
monitoring	O
progress	B-MED
toward	O
them	O
,	O
and	O
applying	O
appropriate	O
study	B-MED
strategies	I-MED
.	O
SRL	B-MED
characterizes	O
successful	O
,	O
"	O
expert	O
"	O
learners	B-MED
,	O
and	O
develops	O
with	O
time	O
and	O
practice	O
.	O
In	O
a	O
large	O
,	O
undergraduate	B-MED
introductory	B-MED
biology	I-MED
course	B-MED
,	O
we	O
investigated	O
:	O
1	O
)	O
what	O
SRL	B-MED
strategies	B-MED
students	B-MED
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	B-MED
,	O
2	O
)	O
which	O
strategies	B-MED
were	O
associated	O
with	O
higher	O
achievement	B-MED
and	O
with	O
grade	B-MED
improvement	B-MED
on	O
exams	B-MED
,	O
and	O
3	O
)	O
what	O
study	O
approaches	O
students	B-MED
proposed	O
to	O
use	O
for	O
future	O
exams	B-MED
.	O
Higher	B-MED
-	O
achieving	B-MED
students	B-MED
,	O
and	O
students	B-MED
whose	O
exam	B-MED
grades	B-MED
improved	B-MED
in	O
the	O
first	B-MED
half	I-MED
of	O
the	O
semester	B-MED
,	O
reported	O
using	O
specific	O
cognitive	B-MED
and	O
metacognitive	B-MED
strategies	I-MED
significantly	O
more	O
frequently	B-MED
than	O
their	O
lower	B-MED
-	O
achieving	B-MED
peers	B-MED
.	O
Lower	B-MED
-	O
achieving	B-MED
students	B-MED
more	O
frequently	B-MED
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	B-MED
or	O
,	O
if	O
they	O
did	O
,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	B-MED
.	O
These	O
results	O
suggest	O
that	O
many	O
students	B-MED
entering	O
introductory	B-MED
biology	I-MED
have	O
limited	B-MED
knowledge	B-MED
of	O
SRL	B-MED
strategies	B-MED
and/or	O
limited	B-MED
ability	O
to	O
implement	O
them	O
,	O
which	O
can	O
impact	B-MED
their	O
achievement	B-MED
.	O
Course	B-MED
-specific	O
interventions	B-MED
that	O
promote	O
SRL	B-MED
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical	B-MED
tools	I-MED
,	O
aimed	O
at	O
fostering	B-MED
development	O
of	O
students	B-MED
'	O
lifelong	B-MED
learning	B-MED
skills	I-MED
.	O
Haemoglobinopathies	B-MED
and	O
β	B-MED
-	I-MED
Thalassaemia	I-MED
among	O
the	O
Tribals	B-MED
Working	B-MED
in	O
the	O
Tea	B-MED
Gardens	B-MED
of	O
Assam	B-MED
,	O
India	B-MED
Prevalence	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β	B-MED
-	I-MED
thalassaemia	I-MED
are	O
very	B-MED
high	I-MED
in	O
India	B-MED
but	O
information	B-MED
about	O
its	O
status	O
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
Assam	B-MED
is	O
very	B-MED
less	I-MED
.	O
The	O
present	O
study	B-MED
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β	B-MED
-	I-MED
thalassaemia	I-MED
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
Assam	B-MED
.	O
A	O
total	O
1204	O
samples	O
from	O
the	O
tribals	B-MED
working	B-MED
in	O
tea	B-MED
gardens	B-MED
of	O
Assam	B-MED
were	O
analysed	B-MED
for	O
both	O
Complete	B-MED
Blood	I-MED
Count	I-MED
(	O
CBC	B-MED
)	O
and	O
High	B-MED
Pressure	I-MED
Liquid	I-MED
Chromatography	I-MED
(	O
HPLC	B-MED
)	O
for	O
detection	B-MED
of	O
haemoglobinopathies	B-MED
and	O
β	B-MED
-	I-MED
thalassaemia	I-MED
.	O
This	O
study	B-MED
showed	O
that	O
the	O
prevalence	B-MED
of	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
and	O
β	B-MED
-	I-MED
thalassaemia	I-MED
were	O
very	B-MED
high	I-MED
among	O
this	O
population	B-MED
.	O
Our	O
results	B-MED
indicated	B-MED
a	O
higher	O
prevalence	B-MED
of	O
β	B-MED
-	I-MED
thalassaemia	I-MED
(	O
3.07	O
%	O
)	O
among	O
the	O
Munda	B-MED
ethnic	I-MED
group	I-MED
and	O
higher	O
prevalence	B-MED
of	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
(	O
4.73	O
%	O
)	O
among	O
the	O
Lohar	B-MED
ethnic	I-MED
group	I-MED
.	O
This	O
was	O
the	O
first	O
study	B-MED
to	O
report	O
the	O
presence	B-MED
of	O
HbE	B-MED
among	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
Assam	B-MED
.	O
Based	O
on	O
the	O
present	O
findings	B-MED
,	O
sickle	B-MED
cell	I-MED
anaemia	I-MED
and	O
β	B-MED
-	I-MED
thalassaemia	I-MED
were	O
major	O
health	B-MED
problem	B-MED
for	O
the	O
tribals	B-MED
working	B-MED
in	O
the	O
tea	B-MED
gardens	B-MED
of	O
Assam	B-MED
.	O
Proper	O
diagnostic	B-MED
facilities	I-MED
for	O
haemoglobinopathy	B-MED
and	O
thalassaemia	B-MED
should	O
be	O
established	B-MED
in	O
these	O
areas	B-MED
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-MED
and	O
thalassaemia	B-MED
database	B-MED
collection	B-MED
,	O
haematological	B-MED
analysis	I-MED
laboratories	I-MED
,	O
genetic	B-MED
counselling	I-MED
clinics	I-MED
,	O
prenatal	B-MED
diagnosis	I-MED
centres	I-MED
and	O
neonatal	B-MED
screening	I-MED
centres	I-MED
.	O
Assessing	B-MED
sex	B-MED
-	I-MED
differences	I-MED
and	O
the	O
effect	B-MED
of	O
timing	B-MED
of	O
vaccination	B-MED
on	O
immunogenicity	B-MED
,	O
reactogenicity	B-MED
and	O
efficacy	B-MED
of	I-MED
vaccines	I-MED
in	O
young	B-MED
children	B-MED
:	O
study	B-MED
protocol	I-MED
for	O
an	O
individual	B-MED
participant	B-MED
data	B-MED
meta	B-MED
-	I-MED
analysis	I-MED
of	O
randomised	B-MED
controlled	I-MED
trials	I-MED
Disease	B-MED
incidence	B-MED
differs	O
between	O
males	B-MED
and	O
females	B-MED
for	O
some	O
infectious	B-MED
or	O
inflammatory	B-MED
diseases	I-MED
.	O
Sex	B-MED
-	I-MED
differences	I-MED
in	O
immune	B-MED
responses	I-MED
to	O
some	O
vaccines	B-MED
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-MED
vaccines	I-MED
in	O
adults	B-MED
.	O
Little	O
evidence	B-MED
is	O
available	B-MED
on	O
whether	O
sex	B-MED
-	I-MED
differences	I-MED
occur	O
in	O
response	B-MED
to	O
immunisation	B-MED
in	O
infancy	B-MED
even	O
though	O
this	O
is	O
the	O
age	B-MED
group	I-MED
in	O
which	O
most	O
vaccines	B-MED
are	O
administered	B-MED
.	O
Factors	B-MED
other	O
than	O
sex	B-MED
,	O
such	O
as	O
timing	B-MED
or	O
coadministration	B-MED
of	O
other	O
vaccines	B-MED
,	O
can	O
also	O
influence	B-MED
the	O
immune	B-MED
response	I-MED
to	O
vaccination	B-MED
.	O
Individual	B-MED
participant	B-MED
data	B-MED
meta	B-MED
-	I-MED
analysis	I-MED
of	O
randomised	B-MED
controlled	I-MED
trials	I-MED
of	O
vaccines	B-MED
in	O
healthy	O
infants	B-MED
and	O
young	B-MED
children	B-MED
will	O
be	O
conducted	O
.	O
Fully	O
anonymised	O
data	B-MED
from	O
∼170	O
randomised	B-MED
controlled	I-MED
trials	I-MED
of	O
v	O
accines	B-MED
for	O
diphtheria	B-MED
,	O
tetanus	B-MED
,	O
Bordetella	B-MED
pertussis	I-MED
,	O
polio	B-MED
,	O
Haemophilus	B-MED
influenzae	I-MED
type	I-MED
B	I-MED
,	O
hepatitis	B-MED
B	I-MED
,	O
Streptococcus	B-MED
pneumoniae	I-MED
,	O
Neisseria	B-MED
meningitidis	I-MED
,	O
measles	B-MED
,	O
mumps	B-MED
,	O
rubella	B-MED
,	O
varicella	B-MED
and	O
rotavirus	B-MED
will	O
be	O
combined	O
for	O
analysis	B-MED
.	O
Outcomes	B-MED
include	O
measures	B-MED
of	O
immunogenicity	B-MED
(	O
immunoglobulins	B-MED
)	O
,	O
reactogenicity	B-MED
,	O
safety	B-MED
and	O
disease	B-MED
-specific	O
clinical	B-MED
efficacy	I-MED
.	O
Data	B-MED
from	O
trials	B-MED
of	O
vaccines	B-MED
containing	O
similar	O
components	B-MED
will	O
be	O
combined	O
in	O
hierarchical	B-MED
models	B-MED
and	O
the	O
effect	B-MED
of	O
sex	B-MED
and	O
timing	B-MED
of	O
vaccinations	B-MED
estimated	O
for	O
each	O
outcome	B-MED
separately	O
.	O
Systematic	B-MED
reviews	I-MED
of	O
published	B-MED
estimates	O
of	O
sex	B-MED
-	I-MED
differences	I-MED
can	O
not	O
adequately	O
answer	B-MED
questions	I-MED
in	O
this	O
field	B-MED
since	O
such	O
comparisons	B-MED
are	O
never	O
the	O
main	O
purpose	B-MED
of	O
a	O
clinical	B-MED
trial	I-MED
,	O
thus	O
a	O
large	B-MED
degree	B-MED
of	O
reporting	B-MED
bias	B-MED
exists	B-MED
in	O
the	O
published	B-MED
literature	B-MED
.	O
Recent	O
improvements	B-MED
in	O
the	O
widespread	B-MED
availability	B-MED
of	I-MED
individual	B-MED
participant	B-MED
data	B-MED
from	O
randomised	B-MED
controlled	I-MED
trials	I-MED
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	B-MED
individual	B-MED
participant	B-MED
data	B-MED
meta	B-MED
-	I-MED
analyses	I-MED
which	O
were	O
previously	B-MED
impossible	B-MED
,	O
thereby	O
reducing	B-MED
the	O
effect	B-MED
of	O
publication	B-MED
or	O
reporting	B-MED
bias	B-MED
on	O
the	O
understanding	B-MED
of	O
the	O
infant	B-MED
immune	B-MED
response	I-MED
.	O
Preliminary	B-MED
results	I-MED
will	O
be	O
available	B-MED
in	O
2016	O
with	O
final	O
results	B-MED
available	B-MED
in	O
2019	O
.	O
No	B-MED
ethics	B-MED
review	B-MED
is	O
required	O
for	O
secondary	B-MED
analyses	I-MED
of	O
anonymised	O
data	B-MED
.	O
Patient	B-MED
-	O
Physician	B-MED
Discordance	B-MED
in	O
Global	B-MED
Assessment	I-MED
in	O
Rheumatoid	B-MED
Arthritis	I-MED
:	O
A	O
Systematic	B-MED
Literature	B-MED
Review	I-MED
With	O
Meta	B-MED
-	I-MED
Analysis	I-MED
The	O
integration	O
of	O
the	O
patient	B-MED
in	O
therapeutic	B-MED
decision	B-MED
-	I-MED
making	I-MED
is	O
important	O
in	O
the	O
management	B-MED
of	O
rheumatoid	B-MED
arthritis	I-MED
(	O
RA	B-MED
)	O
,	O
but	O
the	O
patient	B-MED
opinion	B-MED
regarding	O
disease	B-MED
status	B-MED
may	O
differ	O
from	O
the	O
physician	B-MED
's	I-MED
opinion	B-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
in	O
the	O
published	B-MED
literature	I-MED
the	O
frequency	B-MED
and	O
drivers	O
of	O
patient	B-MED
-	O
physician	B-MED
discordance	B-MED
in	O
global	B-MED
assessment	I-MED
in	O
RA	B-MED
.	O
A	O
systematic	B-MED
literature	B-MED
review	I-MED
of	O
all	O
articles	B-MED
published	B-MED
up	O
to	O
January	O
2015	O
in	O
Medline	B-MED
or	O
Embase	B-MED
,	O
reporting	O
discordance	B-MED
in	O
RA	B-MED
,	O
was	O
conducted	O
by	O
2	O
investigators	B-MED
.	O
Discordance	B-MED
was	O
defined	O
based	O
on	O
the	O
absolute	B-MED
difference	I-MED
of	O
patient	B-MED
global	I-MED
(	O
PGA	B-MED
)	O
and	O
physician	B-MED
global	I-MED
assessments	I-MED
(	O
PhGA	B-MED
)	O
on	O
0	O
-	O
10	O
-	O
cm	O
scales	O
.	O
The	O
frequency	B-MED
of	O
discordance	B-MED
and	O
its	O
predictors	B-MED
were	O
collected	O
in	O
each	O
study	B-MED
.	O
Frequencies	B-MED
of	O
discordance	B-MED
were	O
pooled	B-MED
by	O
meta	B-MED
-	I-MED
analysis	I-MED
using	O
random	B-MED
effect	B-MED
.	O
In	O
all	O
,	O
12	O
studies	B-MED
were	O
selected	O
(	O
i.e.	O
,	O
11,879	O
patients	B-MED
):	O
weighted	B-MED
mean	I-MED
±	O
SD	O
age	B-MED
was	O
55.1	O
±	O
13.9	O
years	B-MED
,	O
weighted	B-MED
mean	I-MED
±	O
SD	O
disease	B-MED
duration	I-MED
was	O
10.4	O
±	O
9.3	O
years	B-MED
,	O
and	O
80.7	O
%	O
were	O
women	B-MED
.	O
The	O
value	B-MED
of	O
the	O
difference	B-MED
   	O
Changes	B-MED
in	O
Cardiovascular	B-MED
Health	B-MED
Status	I-MED
and	O
the	O
Risk	B-MED
of	I-MED
New	B-MED
-	I-MED
Onset	I-MED
Hypertension	I-MED
in	O
Kailuan	B-MED
Cohort	B-MED
Study	I-MED
American	B-MED
Heart	I-MED
Association	I-MED
cardiovascular	B-MED
health	B-MED
metrics	I-MED
are	O
intimately	O
related	O
to	O
cardiovascular	B-MED
diseases	I-MED
.	O
Acting	O
as	O
a	O
key	B-MED
independent	O
risk	B-MED
factor	I-MED
for	O
high	B-MED
morbidity	B-MED
and	O
mortality	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
,	O
hypertension	B-MED
and	O
its	O
relationship	B-MED
between	O
health	B-MED
status	I-MED
get	O
urgent	O
attention	B-MED
.	O
While	O
the	O
influence	B-MED
of	O
individual	B-MED
health	B-MED
status	I-MED
changes	B-MED
and	O
the	O
future	O
risk	B-MED
of	I-MED
new	B-MED
-	I-MED
onset	I-MED
hypertension	I-MED
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-MED
the	O
changes	B-MED
of	O
cardiovascular	B-MED
health	B-MED
status	I-MED
and	O
the	O
morbidity	B-MED
of	O
hypertension	B-MED
in	O
Kailuan	B-MED
cohort	B-MED
study	I-MED
in	O
north	B-MED
China	B-MED
.	O
The	O
Cardiovascular	B-MED
Health	B-MED
Score	I-MED
(	O
CHS	B-MED
)	O
was	O
evaluated	B-MED
by	O
the	O
follow	B-MED
-	I-MED
ups	I-MED
of	O
2006	O
-	O
2007	O
,	O
2008	O
-	O
2009	O
,	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
.	O
The	O
study	B-MED
population	I-MED
(	O
n	O
=	O
19381	O
)	O
was	O
divided	B-MED
into	O
5	O
groups	B-MED
based	O
on	O
the	O
changes	B-MED
in	O
their	O
CHS	B-MED
score	I-MED
between	O
the	O
first	O
two	O
follow	B-MED
-	I-MED
ups	I-MED
(	O
△	O
CHS	O
)	O
of	O
2006	O
-	O
2007	O
and	O
2008	O
-	O
2009	O
(	O
≤-2	O
,	O
-1	O
,	O
0	O
,	O
1	O
,	O
≥2	O
)	O
.	O
The	O
morbidity	B-MED
of	O
hypertension	B-MED
was	O
collected	B-MED
during	B-MED
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
follow	B-MED
-	I-MED
ups	I-MED
.	O
Data	B-MED
analysis	I-MED
showed	O
that	O
during	B-MED
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
3.79±0.96	O
years	O
,	O
morbidity	B-MED
of	O
hypertension	B-MED
had	O
a	O
graded	O
relationship	B-MED
with	O
△	O
CHS	O
.	O
As	O
△	O
CHS	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	B-MED
morbidity	B-MED
of	O
hypertension	B-MED
for	O
all	O
participants	B-MED
were	O
81.40	O
,	O
75.47	O
,	O
68.37	O
,	O
71.43	O
and	O
83.13	O
per	O
1000	O
person	O
-	O
year	O
,	O
respectively	O
.	O
An	O
increased	B-MED
△	O
CHS	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10	O
%	O
decrease	B-MED
in	O
the	O
future	B-MED
risk	B-MED
of	I-MED
new	B-MED
-	I-MED
onset	I-MED
hypertension	I-MED
(	O
HR	O
:	O
0.90	O
,	O
95	O
%	O
CI	B-MED
:	O
0.88	O
-	O
0.92	O
)	O
.	O
In	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	B-MED
between	O
the	O
incidence	O
of	O
new	B-MED
-	I-MED
onset	I-MED
hypertension	I-MED
and	O
elevation	B-MED
of	O
cardiovascular	B-MED
health	B-MED
metrics	I-MED
.	O
Population	B-MED
-wide	O
prevention	B-MED
,	O
especially	O
the	O
promotion	B-MED
of	O
lifestyle	B-MED
improvements	B-MED
,	O
is	O
critical	B-MED
to	O
reducing	B-MED
the	O
morbidity	B-MED
of	O
new	B-MED
-	I-MED
onset	I-MED
hypertension	I-MED
.	O
Management	B-MED
and	O
Case	B-MED
Outcome	I-MED
of	O
Gastric	B-MED
Impaction	I-MED
in	O
Four	O
Raptors	B-MED
:	O
A	O
Case	B-MED
Series	I-MED
Four	O
captive	O
raptors	B-MED
,	O
an	O
American	B-MED
kestrel	I-MED
(	O
Falco	B-MED
sparverius	I-MED
)	O
,	O
peregrine	B-MED
falcon	I-MED
(	O
Falco	B-MED
peregrinus	I-MED
)	O
,	O
golden	B-MED
eagle	I-MED
(	O
Aquila	B-MED
chrysaetos	I-MED
)	O
,	O
and	O
barn	B-MED
owl	I-MED
(	O
Tyto	B-MED
alba	I-MED
)	O
,	O
were	O
diagnosed	B-MED
with	O
ventricular	B-MED
and/or	O
proventricular	B-MED
foreign	B-MED
material	I-MED
impactions	B-MED
consisting	O
of	O
artificial	B-MED
turf	I-MED
substrate	I-MED
,	O
paper	B-MED
and	O
plastic	B-MED
substrate	I-MED
,	O
grass	B-MED
,	O
and	O
newspaper	B-MED
.	O
Partial	B-MED
or	I-MED
total	I-MED
anorexia	I-MED
was	O
reported	O
in	O
all	O
birds	B-MED
and	O
decreased	B-MED
casting	B-MED
in	O
2	O
birds	B-MED
.	O
Survey	B-MED
radiographs	B-MED
confirmed	O
presence	O
of	O
gastric	B-MED
enlargement	B-MED
in	O
all	O
4	O
birds	B-MED
.	O
The	O
kestrel	B-MED
and	O
eagle	B-MED
were	O
treated	B-MED
unsuccessfully	O
with	O
gastroscopy	B-MED
and	O
gastric	B-MED
lavage	I-MED
,	O
respectively	O
,	O
followed	O
by	O
surgical	B-MED
intervention	I-MED
to	O
remove	O
the	O
ventricular	B-MED
impactions	B-MED
.	O
Both	O
birds	B-MED
died	B-MED
of	I-MED
undetermined	I-MED
causes	I-MED
after	B-MED
surgery	I-MED
.	O
The	O
peregrine	B-MED
falcon	I-MED
died	B-MED
before	B-MED
medical	I-MED
or	O
surgical	B-MED
intervention	I-MED
was	O
started	O
,	O
and	O
the	O
owl	B-MED
was	O
managed	O
successfully	O
with	O
oral	B-MED
mineral	I-MED
oil	I-MED
and	O
liquid	B-MED
diet	I-MED
to	O
facilitate	B-MED
egestion	I-MED
of	I-MED
the	I-MED
foreign	I-MED
material	I-MED
as	O
a	O
pellet	B-MED
.	O
Lead	B-MED
poisoning	I-MED
was	O
suspected	O
as	O
the	O
predisposing	B-MED
cause	I-MED
for	O
foreign	B-MED
body	I-MED
ingestion	I-MED
in	O
the	O
eagle	B-MED
,	O
but	O
underlying	B-MED
causes	I-MED
for	O
pica	B-MED
in	O
the	O
other	O
birds	B-MED
were	O
not	B-MED
determined	I-MED
.	O
Radiographs	B-MED
can	O
provide	O
useful	O
diagnostic	B-MED
information	I-MED
in	O
sick	B-MED
raptors	B-MED
that	O
exhibit	B-MED
vomiting	I-MED
or	O
changes	B-MED
in	I-MED
appetite	I-MED
or	O
casting	B-MED
frequency	I-MED
,	O
and	O
may	O
help	O
guide	O
treatment	B-MED
decisions	I-MED
of	O
impacted	B-MED
birds	B-MED
.	O
Careful	O
consideration	B-MED
of	O
substrate	B-MED
,	O
enrichment	B-MED
items	I-MED
,	O
and	O
access	O
to	O
potential	B-MED
foreign	B-MED
material	I-MED
that	I-MED
could	I-MED
be	I-MED
ingested	I-MED
may	O
be	O
the	O
best	O
pre	O
-	O
emptive	O
management	B-MED
strategy	I-MED
in	O
captive	O
raptors	B-MED
.	O
A	O
tanshinone	B-MED
I	I-MED
derivative	B-MED
enhances	O
the	O
activities	B-MED
of	O
antibiotics	B-MED
against	O
Staphylococcus	B-MED
aureus	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
Infections	B-MED
caused	O
by	O
Staphylococcus	B-MED
aureus	I-MED
are	O
prevalent	O
.	O
The	O
dramatically	O
reduced	O
discovery	B-MED
of	O
new	O
antibiotics	B-MED
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant	B-MED
bacteria	I-MED
,	O
represents	O
a	O
major	O
health	B-MED
problem	B-MED
in	O
both	O
hospital	B-MED
and	O
community	B-MED
settings	I-MED
.	O
Using	O
antibiotic	B-MED
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-MED
is	O
an	O
attractive	O
strategy	O
.	O
In	O
this	O
study	B-MED
,	O
16	B-MED
-	I-MED
aldehyde	I-MED
tanshinone	I-MED
I	I-MED
(	O
ALT	B-MED
)	O
was	O
synthesized	B-MED
and	O
bacteriostatic	B-MED
activity	I-MED
was	O
explored	O
.	O
In	O
addition	O
,	O
synergistic	B-MED
or	O
additive	B-MED
activity	B-MED
between	O
ALT	B-MED
and	O
aminoglycoside	B-MED
antibiotics	I-MED
or	O
β	B-MED
-	I-MED
lactam	I-MED
antibiotics	I-MED
in	B-MED
vitro	I-MED
was	O
identified	O
.	O
Moreover	O
,	O
ALT	B-MED
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-MED
(	O
STR	B-MED
)	O
and	O
ampicillin	B-MED
(	O
AMP	B-MED
)	O
against	O
S.	B-MED
aureus	I-MED
in	O
a	O
murine	B-MED
infection	I-MED
model	I-MED
.	O
Primary	O
mechanistic	B-MED
insight	I-MED
indicated	O
that	O
ALT	B-MED
could	O
damage	B-MED
the	O
bacterial	B-MED
cell	B-MED
membrane	I-MED
,	O
leading	O
to	O
accumulation	B-MED
of	O
antibiotics	B-MED
inside	O
bacterial	B-MED
cells	I-MED
.	O
This	O
finding	O
might	O
be	O
useful	O
for	O
treating	B-MED
infections	B-MED
caused	O
by	O
S.	B-MED
aureus	I-MED
and	O
expand	O
the	O
scope	O
of	O
application	B-MED
of	O
tanshinones	B-MED
.	O
Are	O
Eyes	B-MED
a	O
Mirror	B-MED
of	O
the	O
Soul	B-MED
?	O
What	O
Eye	B-MED
Wrinkles	B-MED
Reveal	B-MED
about	O
a	O
Horse	B-MED
's	I-MED
Emotional	B-MED
State	I-MED
Finding	O
valid	B-MED
indicators	B-MED
of	O
emotional	B-MED
states	I-MED
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal	B-MED
welfare	I-MED
science	I-MED
.	O
Here	O
,	O
we	O
investigated	B-MED
in	O
horses	B-MED
whether	O
variation	B-MED
in	O
the	O
expression	B-MED
of	O
eye	B-MED
wrinkles	B-MED
caused	O
by	O
contraction	B-MED
of	O
the	O
inner	B-MED
eyebrow	I-MED
raiser	O
reflects	B-MED
emotional	B-MED
valence	I-MED
.	O
By	O
confronting	O
horses	B-MED
with	O
positive	B-MED
and	O
negative	B-MED
conditions	B-MED
,	O
we	O
aimed	O
to	O
induce	B-MED
positive	B-MED
and	O
negative	B-MED
emotional	B-MED
states	I-MED
,	O
hypothesising	B-MED
that	O
positive	B-MED
emotions	B-MED
would	O
reduce	B-MED
whereas	O
negative	B-MED
emotions	B-MED
would	O
increase	B-MED
eye	B-MED
wrinkle	B-MED
expression	B-MED
.	O
Sixteen	O
horses	B-MED
were	O
individually	O
exposed	B-MED
in	O
a	O
balanced	B-MED
order	O
to	O
two	O
positive	B-MED
(	O
grooming	B-MED
,	O
food	B-MED
anticipation	I-MED
)	O
and	O
two	O
negative	B-MED
condition	B-MED
s	O
(	O
food	B-MED
competition	B-MED
,	O
waving	B-MED
a	O
plastic	B-MED
bag	I-MED
)	O
.	O
Each	O
condition	B-MED
lasted	O
for	O
60	O
seconds	B-MED
and	O
was	O
preceded	O
by	O
a	O
60	O
second	B-MED
control	B-MED
phase	I-MED
.	O
Throughout	O
both	O
phases	B-MED
,	O
pictures	B-MED
of	O
the	O
eyes	B-MED
were	O
taken	O
,	O
and	O
for	O
each	O
horse	B-MED
four	O
pictures	B-MED
per	O
condition	B-MED
and	O
phase	B-MED
were	O
randomly	B-MED
selected	I-MED
.	O
Pictures	B-MED
were	O
scored	O
in	O
random	B-MED
order	I-MED
and	O
by	O
two	O
experimenters	B-MED
blind	B-MED
to	O
condition	B-MED
and	O
phase	B-MED
for	O
six	O
outcome	B-MED
measures	I-MED
:	O
qualitative	B-MED
impression	B-MED
,	O
eyelid	B-MED
shape	B-MED
,	O
markedness	B-MED
of	O
the	O
wrinkles	B-MED
,	O
presence	B-MED
of	O
eye	B-MED
white	I-MED
,	O
number	B-MED
of	O
wrinkles	B-MED
,	O
and	O
the	O
angle	B-MED
between	O
the	O
line	O
through	O
the	O
eyeball	B-MED
and	O
the	O
highest	B-MED
wrinkle	B-MED
.	O
The	O
angle	B-MED
decreased	B-MED
during	O
grooming	B-MED
and	O
increased	B-MED
during	O
food	B-MED
competition	B-MED
compared	B-MED
to	O
control	B-MED
phase	I-MED
s	O
,	O
whereas	O
the	O
two	O
phases	B-MED
did	O
not	O
differ	O
during	O
food	B-MED
anticipation	I-MED
and	O
the	O
plastic	B-MED
bag	I-MED
condition	B-MED
.	O
No	B-MED
effects	I-MED
on	O
the	O
other	O
outcome	B-MED
measures	I-MED
were	O
detected	B-MED
.	O
Taken	O
together	O
,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	B-MED
to	O
assess	B-MED
eye	B-MED
wrinkle	B-MED
expression	B-MED
reliably	O
,	O
of	O
which	O
one	O
measure	B-MED
was	O
affected	B-MED
by	O
the	O
conditions	B-MED
the	O
horses	B-MED
were	O
exposed	B-MED
to	I-MED
.	O
Variation	B-MED
in	O
eye	B-MED
wrinkle	B-MED
expression	B-MED
might	O
provide	B-MED
valuable	O
information	B-MED
on	O
horse	B-MED
welfare	B-MED
but	O
further	O
validation	B-MED
of	O
specific	B-MED
measures	B-MED
across	O
different	B-MED
conditions	B-MED
is	O
needed	O
.	O
Opportunities	B-MED
for	O
genomic	B-MED
prediction	B-MED
for	O
fertility	B-MED
using	O
endocrine	B-MED
and	O
classical	B-MED
fertility	B-MED
traits	B-MED
in	O
dairy	B-MED
cattle	I-MED
Endocrine	B-MED
fertility	B-MED
traits	B-MED
,	O
defined	O
from	O
progesterone	B-MED
concentration	B-MED
levels	B-MED
in	O
milk	B-MED
,	O
have	O
been	O
suggested	O
as	O
alternative	B-MED
indicators	B-MED
for	O
fertility	B-MED
in	O
dairy	B-MED
cows	I-MED
because	O
they	O
are	O
less	O
biased	O
by	O
farm	B-MED
management	B-MED
decisions	B-MED
and	O
more	O
directly	O
reflect	O
a	O
cow	B-MED
's	O
reproductive	B-MED
physiology	B-MED
than	O
classical	B-MED
traits	B-MED
derived	O
from	O
insemination	B-MED
and	O
calving	O
data	B-MED
.	O
To	O
determine	O
the	O
potential	O
use	B-MED
of	I-MED
endocrine	B-MED
fertility	B-MED
traits	B-MED
in	O
genomic	B-MED
evaluations	B-MED
,	O
the	O
improvement	B-MED
in	O
accuracy	B-MED
from	O
using	O
endocrine	B-MED
fertility	B-MED
traits	B-MED
concurrent	B-MED
with	O
classical	B-MED
traits	B-MED
in	O
the	O
genomic	B-MED
prediction	B-MED
of	O
fertility	B-MED
was	O
quantified	B-MED
.	O
The	O
impact	B-MED
of	O
recording	O
all	O
traits	B-MED
on	O
all	O
training	O
animals	B-MED
was	O
also	O
investigated	B-MED
.	O
Endocrine	B-MED
and	O
classical	B-MED
fertility	B-MED
records	O
were	O
available	O
on	O
5,339	O
lactations	B-MED
from	O
2,447	O
Holstein	B-MED
cows	I-MED
in	O
Ireland	B-MED
,	O
the	O
Netherlands	B-MED
,	O
Sweden	B-MED
,	O
and	O
the	O
United	B-MED
Kingdom	I-MED
.	O
The	O
endocrine	B-MED
traits	B-MED
were	O
commencement	B-MED
of	I-MED
luteal	I-MED
activity	I-MED
(	O
C	B-MED
-	I-MED
LA	I-MED
)	O
and	O
proportion	B-MED
of	O
samples	B-MED
with	O
luteal	B-MED
activity	I-MED
(	O
PLA	B-MED
)	O
;	O
the	O
classical	B-MED
trait	B-MED
was	O
the	O
interval	B-MED
from	O
calving	O
to	O
first	O
service	O
(	O
CFS	O
)	O
.	O
The	O
interval	B-MED
from	O
C	B-MED
-	I-MED
LA	I-MED
to	O
first	O
service	O
(	O
C	O
-	O
LAFS	O
)	O
,	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	B-MED
trait	B-MED
and	O
a	O
classical	B-MED
trait	B-MED
,	O
was	O
also	O
investigated	B-MED
.	O
The	O
target	B-MED
(	O
breeding	B-MED
goal	I-MED
)	O
trait	B-MED
for	O
fertility	B-MED
was	O
CFS	O
or	O
C	O
-	O
LAFS	O
,	O
whereas	O
C	B-MED
-	I-MED
LA	I-MED
and	O
PLA	B-MED
served	O
as	O
predictor	B-MED
traits	B-MED
.	O
Genomic	B-MED
EBV	I-MED
(	O
GEBV	B-MED
)	O
for	O
fertility	B-MED
were	O
derived	O
using	O
genomic	B-MED
BLUP	I-MED
in	O
bivariate	B-MED
models	I-MED
with	O
85,485	O
SNP	B-MED
.	O
Genomic	O
EBV	O
for	O
the	O
separate	O
fertility	B-MED
traits	B-MED
were	O
also	O
computed	O
,	O
in	O
univariate	B-MED
models	I-MED
.	O
The	O
accuracy	B-MED
of	O
GEBV	B-MED
was	O
evaluated	O
by	O
5	O
-	O
fold	O
cross	B-MED
-	I-MED
validation	I-MED
.	O
The	O
highest	O
accuracy	B-MED
of	O
GEBV	B-MED
was	O
achieved	O
using	O
bivariate	B-MED
predictions	B-MED
,	O
where	O
both	O
an	O
endocrine	B-MED
fertility	B-MED
trait	B-MED
and	O
the	O
classical	B-MED
fertility	B-MED
trait	B-MED
were	O
used	O
.	O
Accuracy	B-MED
of	O
GEBV	B-MED
for	O
predicting	B-MED
adjusted	O
phenotypes	B-MED
for	O
CFS	O
in	O
the	O
univariate	B-MED
model	I-MED
was	O
0.04	O
,	O
but	O
when	O
predicting	B-MED
CFS	O
using	O
a	O
bivariate	B-MED
model	I-MED
with	O
C	B-MED
-	I-MED
LA	I-MED
,	O
the	O
accuracy	B-MED
increased	B-MED
to	O
0.14	O
when	O
all	O
training	B-MED
animals	I-MED
were	O
phenotyped	B-MED
for	O
C	B-MED
-	I-MED
LA	I-MED
and	O
(	O
or	O
not	O
)	O
for	O
CFS	O
.	O
On	O
phenotyping	B-MED
all	O
training	B-MED
animals	I-MED
for	O
both	O
C	B-MED
-	I-MED
LA	I-MED
and	O
CFS	O
,	O
accuracy	B-MED
for	O
CFS	O
increased	B-MED
to	O
0.18	O
;	O
however	O
,	O
when	O
validation	B-MED
animals	B-MED
were	O
also	O
phenotyped	B-MED
for	O
C	B-MED
-	I-MED
LA	I-MED
,	O
there	O
was	O
no	B-MED
substantial	B-MED
increase	I-MED
in	O
accuracy	B-MED
.	O
When	O
predicting	B-MED
CFS	O
in	O
bivariate	B-MED
analysis	I-MED
with	O
PLA	B-MED
,	O
accuracy	B-MED
ranged	O
from	O
0.07	O
to	O
0.14	O
.	O
This	O
first	O
study	B-MED
on	O
genomic	B-MED
predictions	B-MED
for	O
fertility	B-MED
using	O
endocrine	B-MED
traits	B-MED
suggests	O
some	O
improvement	B-MED
in	O
the	O
accuracy	B-MED
of	O
prediction	B-MED
over	O
using	O
only	O
the	O
classical	B-MED
traits	B-MED
.	O
Further	O
studies	B-MED
with	O
larger	B-MED
training	B-MED
populations	I-MED
may	O
show	O
greater	B-MED
improvements	B-MED
.	O
Modeling	B-MED
the	O
hospital	B-MED
safety	B-MED
partnership	B-MED
preferences	B-MED
of	I-MED
patients	I-MED
and	O
their	O
families	B-MED
:	O
a	O
discrete	B-MED
choice	B-MED
conjoint	B-MED
experiment	I-MED
Patients	B-MED
and	O
their	O
families	B-MED
play	O
an	O
important	O
role	B-MED
in	O
efforts	O
to	O
improve	B-MED
health	B-MED
service	I-MED
safety	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
is	O
to	O
understand	O
the	O
safety	B-MED
partnership	B-MED
preferences	B-MED
of	I-MED
patients	I-MED
and	O
their	O
families	B-MED
.	O
We	O
used	O
a	O
discrete	B-MED
choice	B-MED
conjoint	B-MED
experiment	I-MED
to	O
model	O
the	O
safety	B-MED
partnership	B-MED
preferences	B-MED
of	O
1,084	O
patients	B-MED
or	O
those	O
such	O
as	O
parents	B-MED
acting	O
on	O
their	O
behalf	O
.	O
Participants	B-MED
made	O
choices	B-MED
between	O
hypothetical	O
safety	B-MED
partnerships	B-MED
composed	O
by	O
experimentally	O
varying	O
15	O
four	O
-	O
level	O
partnership	B-MED
design	B-MED
attributes	B-MED
.	O
Participants	B-MED
preferred	B-MED
an	O
approach	B-MED
to	O
safety	B-MED
based	O
on	O
partnerships	B-MED
between	O
patients	B-MED
and	O
staff	B-MED
rather	O
than	O
a	O
model	O
delegating	O
responsibility	B-MED
for	O
safety	B-MED
to	O
hospital	B-MED
staff	I-MED
.	O
They	O
valued	O
the	O
opportunity	B-MED
to	I-MED
participate	I-MED
in	O
point	O
of	O
service	O
safety	B-MED
partnerships	B-MED
,	O
such	O
as	O
identity	O
and	O
medication	B-MED
double	I-MED
checks	I-MED
,	O
that	O
might	O
afford	O
an	O
immediate	B-MED
risk	B-MED
reduction	I-MED
.	O
Latent	O
class	O
analysis	B-MED
yielded	O
two	O
segments	O
.	O
Actively	B-MED
engaged	I-MED
participants	I-MED
(	O
73.3	O
%	O
)	O
comprised	O
outpatients	B-MED
with	O
higher	B-MED
education	I-MED
,	O
who	O
anticipated	B-MED
more	O
benefits	B-MED
to	O
safety	B-MED
partnerships	B-MED
,	O
were	O
more	B-MED
confident	I-MED
in	O
their	O
ability	B-MED
to	O
contribute	B-MED
,	O
and	O
were	O
more	O
intent	B-MED
on	O
participating	B-MED
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	B-MED
a	O
personal	O
engagement	B-MED
strategy	B-MED
,	O
valued	O
scientific	B-MED
evidence	I-MED
,	O
preferred	B-MED
a	O
more	O
active	O
approach	B-MED
to	O
safety	B-MED
education	I-MED
,	O
and	O
advocated	O
disclosure	B-MED
of	I-MED
errors	I-MED
.	O
The	O
passively	O
engaged	O
segment	O
(	O
26.7	O
%	O
)	O
anticipated	B-MED
fewer	B-MED
benefits	B-MED
,	O
were	O
less	O
confident	B-MED
in	O
their	O
ability	B-MED
to	O
contribute	B-MED
,	O
and	O
were	O
less	O
intent	O
on	O
participating	B-MED
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-MED
strategy	B-MED
based	O
on	O
signage	B-MED
.	O
They	O
preferred	B-MED
that	O
staff	B-MED
explain	O
why	O
they	O
thought	O
patients	B-MED
should	O
help	O
make	O
care	B-MED
safer	O
and	O
decide	O
whether	O
errors	B-MED
were	O
disclosed	O
.	O
Inpatients	B-MED
,	O
those	O
with	O
immigrant	B-MED
backgrounds	I-MED
,	O
and	O
those	O
with	O
less	B-MED
education	I-MED
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment	O
.	O
Health	B-MED
services	I-MED
need	O
to	O
communicate	O
information	B-MED
regarding	O
risks	B-MED
,	O
ask	O
about	O
partnership	B-MED
preferences	B-MED
,	O
create	O
opportunities	B-MED
respecting	O
individual	B-MED
differences	I-MED
,	O
and	O
ensure	O
a	O
positive	B-MED
response	I-MED
when	O
patients	B-MED
raise	O
safety	B-MED
concerns	B-MED
.	O
Succinic	B-MED
acid	I-MED
production	B-MED
by	O
immobilized	B-MED
cultures	B-MED
using	O
spent	B-MED
sulphite	I-MED
liquor	I-MED
as	O
fermentation	B-MED
medium	B-MED
Spent	B-MED
sulphite	I-MED
liquor	I-MED
(	O
SSL	B-MED
)	O
was	O
used	O
as	O
carbon	B-MED
source	B-MED
for	O
the	O
production	B-MED
of	O
succinic	B-MED
acid	I-MED
using	O
immobilized	B-MED
cultures	B-MED
of	O
Actinobacillus	B-MED
succinogenes	I-MED
and	O
Basfia	B-MED
succiniciproducens	I-MED
on	O
two	O
different	O
supports	B-MED
,	O
delignified	B-MED
cellulosic	I-MED
material	I-MED
(	O
DCM	B-MED
)	O
and	O
alginate	B-MED
beads	B-MED
.	O
Fed	B-MED
-	I-MED
batch	I-MED
immobilized	I-MED
cultures	I-MED
with	O
A.	B-MED
succinogenes	I-MED
in	O
alginates	B-MED
resulted	O
in	O
higher	B-MED
sugar	B-MED
to	O
succinic	B-MED
acid	I-MED
conversion	B-MED
yield	I-MED
(	O
0.81g	O
/	O
g	O
)	O
than	O
the	O
respective	O
yield	B-MED
achieved	O
(	O
0.65g	O
/	O
g	O
)	O
when	O
DCM	B-MED
immobilized	B-MED
cultures	B-MED
were	O
used	O
.	O
The	O
final	O
succinic	B-MED
acid	I-MED
concentration	B-MED
and	O
yield	B-MED
achieved	O
in	O
fed	B-MED
-	I-MED
batch	I-MED
with	O
immobilized	B-MED
cultures	B-MED
of	O
B.	B-MED
succiniciproducens	I-MED
in	O
alginates	B-MED
(	O
45g	O
/	O
L	O
and	O
0.66g	O
/	O
g	O
)	O
were	O
higher	B-MED
than	O
A.	B-MED
succinogenes	I-MED
immobilized	B-MED
cultures	B-MED
(	O
35.4g	O
/	O
L	O
and	O
0.61g	O
/	O
g	O
)	O
using	O
nano	B-MED
-	O
filtrated	B-MED
SSL	I-MED
as	O
fermentation	B-MED
medium	B-MED
.	O
Immobilized	B-MED
cultures	B-MED
of	O
B.	B-MED
succiniciproducens	I-MED
in	O
alginate	B-MED
beads	B-MED
were	O
reused	O
in	O
four	O
sequential	B-MED
fed	I-MED
-	I-MED
batch	I-MED
fermentations	B-MED
of	O
nano	B-MED
-	O
filtrated	B-MED
SSL	I-MED
leading	O
to	O
the	O
production	B-MED
of	O
64.7	O
g	O
of	O
succinic	B-MED
acid	I-MED
with	O
a	O
yield	B-MED
range	O
of	O
0.42	O
-	O
0.67g	O
/	O
g	O
and	O
productivity	B-MED
range	O
of	O
0.29	O
-	O
0.65g	O
/	O
L	O
/	O
h.	O
The	O
immobilized	B-MED
cultures	B-MED
improved	O
the	O
efficiency	B-MED
of	O
succinic	B-MED
acid	I-MED
production	B-MED
as	O
compared	B-MED
to	O
free	B-MED
cell	I-MED
cultures	I-MED
.	O
Four	B-MED
-	I-MED
Dimensional	I-MED
Graded	B-MED
Consciousness	B-MED
Both	O
the	O
multidimensional	B-MED
phenomenon	B-MED
and	O
the	O
polysemous	B-MED
notion	I-MED
of	O
consciousness	B-MED
continue	O
to	O
prove	O
resistant	B-MED
to	O
consistent	B-MED
measurement	B-MED
and	O
unambiguous	B-MED
definition	I-MED
.	O
This	O
is	O
hardly	O
surprising	O
,	O
given	O
that	O
there	O
is	O
no	B-MED
agreement	I-MED
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-MED
they	O
involve	O
.	O
One	O
of	O
the	O
basic	O
disagreements	B-MED
present	O
in	O
the	O
continuing	O
debate	B-MED
about	O
consciousness	B-MED
pertains	O
to	O
its	O
gradational	B-MED
nature	B-MED
.	O
The	O
general	O
aim	O
of	O
this	O
article	B-MED
is	O
to	O
show	O
how	O
consciousness	B-MED
might	O
be	O
graded	B-MED
and	O
multidimensional	B-MED
at	O
the	O
same	O
time	B-MED
.	O
We	O
therefore	O
focus	O
on	O
the	O
question	B-MED
of	O
what	O
it	O
is	O
,	O
exactly	O
,	O
that	O
is	O
or	O
could	O
be	O
graded	B-MED
in	O
cases	B-MED
of	O
consciousness	B-MED
,	O
and	O
how	O
we	O
can	O
measure	B-MED
it	O
.	O
Ultimately	O
,	O
four	O
different	O
gradable	B-MED
aspects	B-MED
of	O
consciousness	B-MED
will	O
be	O
described	O
:	O
quality	B-MED
,	O
abstractness	B-MED
,	O
complexity	B-MED
and	O
usefulness	B-MED
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	B-MED
,	O
these	O
being	O
understood	O
,	O
respectively	O
,	O
as	O
phenomenal	B-MED
,	O
semantic	B-MED
,	O
physiological	B-MED
,	O
and	O
functional	B-MED
.	O
Consequently	O
,	O
consciousness	B-MED
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	B-MED
quality	B-MED
,	O
semantic	B-MED
abstraction	B-MED
,	O
physiological	B-MED
complexity	B-MED
,	O
and	O
functional	B-MED
usefulness	B-MED
.	O
It	O
is	O
hoped	O
that	O
such	O
a	O
four	B-MED
-	I-MED
dimensional	I-MED
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical	B-MED
nature	I-MED
of	O
consciousness	B-MED
.	O
The	O
approach	B-MED
also	O
proves	O
explanatorily	O
advantageous	B-MED
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	B-MED
to	O
certain	O
new	O
and	O
important	B-MED
differences	B-MED
in	O
respect	O
of	O
subjective	B-MED
measures	B-MED
of	O
awareness	B-MED
and	O
to	O
justify	O
how	O
a	O
given	O
creature	B-MED
may	O
be	O
ranked	B-MED
higher	B-MED
in	O
one	O
dimension	O
of	O
consciousness	B-MED
and	O
lower	O
in	O
terms	O
of	O
another	O
,	O
but	O
also	O
allows	O
for	O
innovative	B-MED
explanations	I-MED
of	O
a	O
variety	O
of	O
well	O
-	O
known	O
phenomena	B-MED
(	O
amongst	O
these	O
,	O
the	O
interpretations	B-MED
of	O
blindsight	B-MED
and	O
locked	B-MED
-	I-MED
in	I-MED
syndrome	I-MED
will	O
be	O
briefly	O
outlined	O
here	O
)	O
.	O
Moreover	O
,	O
a	O
4D	B-MED
framework	O
makes	O
possible	O
many	O
predictions	B-MED
and	O
hypotheses	B-MED
that	O
may	O
be	O
experimentally	B-MED
tested	B-MED
(	O
We	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional	B-MED
dependencies	I-MED
)	O
.	O
Impact	B-MED
of	O
femoral	B-MED
artery	I-MED
puncture	B-MED
using	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
and	O
road	B-MED
mapping	I-MED
on	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
The	O
use	O
of	O
large	B-MED
-	O
diameter	B-MED
sheaths	O
carries	O
the	O
risk	B-MED
of	O
significant	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
(	O
TAVI	B-MED
)	O
.	O
In	O
this	O
analysis	B-MED
,	O
we	O
sought	O
to	O
assess	B-MED
the	O
impact	B-MED
of	O
a	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
digital	B-MED
subtraction	I-MED
angiography	I-MED
(	O
DSA	B-MED
)	O
and	O
road	B-MED
mapping	I-MED
during	O
transfemoral	O
TAVI	B-MED
on	O
periprocedural	B-MED
vascular	B-MED
and	O
bleeding	B-MED
events	O
.	O
This	O
is	O
a	O
retrospective	O
analysis	B-MED
of	O
transfemoral	O
TAVI	B-MED
patients	B-MED
included	O
in	O
a	O
prospective	B-MED
institutional	I-MED
database	I-MED
.	O
The	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
DSA	B-MED
-derived	O
road	B-MED
mapping	I-MED
guidance	O
was	O
introduced	O
in	O
October	O
2012	O
.	O
Before	O
the	O
introduction	O
of	O
this	O
technique	B-MED
,	O
vascular	B-MED
puncture	B-MED
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-MED
data	B-MED
,	O
the	O
bony	B-MED
iliofemoral	B-MED
landmarks	B-MED
and	O
a	O
radiopaque	B-MED
object	I-MED
.	O
Consecutive	O
patients	B-MED
who	O
underwent	O
TAVI	B-MED
with	O
the	O
road	B-MED
mapping	I-MED
technique	B-MED
(	O
RM	B-MED
group	I-MED
,	O
n=160	O
)	O
were	O
compared	O
with	O
consecutive	O
patients	B-MED
who	O
underwent	O
TAVI	B-MED
without	O
road	B-MED
mapping	I-MED
(	O
control	B-MED
group	I-MED
,	O
n=160	O
)	O
prior	O
to	O
its	O
introduction	O
.	O
A	O
standardised	O
strategy	O
of	O
periprocedural	B-MED
anticoagulation	I-MED
was	O
adopted	O
in	O
both	O
groups	B-MED
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	B-MED
suture	I-MED
-	I-MED
based	I-MED
closure	I-MED
device	I-MED
.	O
All	O
endpoints	B-MED
were	O
defined	O
according	O
to	O
the	O
VARC-2	B-MED
criteria	I-MED
for	O
event	O
definition	O
.	O
The	O
mean	O
age	O
in	O
the	O
RM	B-MED
group	I-MED
was	O
80±7.7	O
years	B-MED
compared	O
to	O
81±5.9	O
years	B-MED
in	O
the	O
control	B-MED
group	I-MED
(	O
p=0.19	O
)	O
,	O
and	O
females	B-MED
were	O
equally	O
distributed	O
between	O
both	O
groups	B-MED
(	O
63.1	O
%	O
vs.	O
58.1	O
%	O
,	O
p=0.36	O
)	O
.	O
The	O
baseline	B-MED
logistic	I-MED
EuroSCORE	I-MED
was	O
20.7±14.4	O
%	O
vs.	O
24.9±15.2	O
%	O
in	O
the	O
RM	B-MED
and	O
control	B-MED
group	I-MED
,	O
respectively	O
(	O
p=0.01	O
)	O
.	O
Notably	O
,	O
sheath	B-MED
size	I-MED
was	O
significantly	O
larger	O
in	O
the	O
RM	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(	O
23.8	O
%	O
vs.	O
1.8	O
%	O
,	O
p<0.001	O
,	O
respectively	O
)	O
associated	B-MED
with	I-MED
the	O
more	O
frequent	O
implantation	B-MED
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM	B-MED
group	I-MED
(	O
43.8	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
,	O
p<0.001	O
)	O
.	O
Despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	B-MED
complications	I-MED
and	O
major	O
bleeding	B-MED
at	O
30	O
days	B-MED
were	O
significantly	O
lower	B-MED
in	O
the	O
RM	B-MED
group	I-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
(	O
4.3	O
%	O
vs.	O
11.8	O
%	O
,	O
p=0.01	O
,	O
and	O
14.4	O
%	O
vs.	O
25.6	O
%	O
,	O
p=0.01	O
)	O
.	O
An	O
analysis	B-MED
limited	O
to	O
access	O
site	O
-	O
related	O
complications	B-MED
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	B-MED
map	I-MED
group	I-MED
but	O
did	O
not	O
reach	O
statistical	B-MED
significance	I-MED
(	O
8.1	O
%	O
vs.	O
13.8	O
%	O
,	O
p=0.1	O
)	O
.	O
Other	O
forms	O
of	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
as	O
well	O
as	O
all	B-MED
-	I-MED
cause	I-MED
mortality	I-MED
were	O
comparable	O
in	O
both	O
groups	B-MED
.	O
A	O
modified	O
femoral	B-MED
artery	I-MED
puncture	B-MED
technique	B-MED
using	O
DSA	B-MED
and	O
road	B-MED
mapping	I-MED
was	O
associated	B-MED
with	I-MED
a	O
reduction	O
in	O
major	O
vascular	B-MED
and	O
bleeding	B-MED
complications	B-MED
after	O
transfemoral	O
TAVI	B-MED
,	O
and	O
provides	O
a	O
simple	B-MED
and	O
effective	B-MED
strategy	O
for	O
potentially	O
improving	O
patient	B-MED
outcomes	I-MED
.	O
Truncated	B-MED
Bovine	I-MED
Integrin	B-MED
Alpha	I-MED
-	I-MED
v	I-MED
/	I-MED
Beta-6	I-MED
as	O
a	O
Universal	B-MED
Capture	I-MED
Ligand	I-MED
for	O
FMD	B-MED
Diagnosis	B-MED
Foot	B-MED
-	I-MED
and	I-MED
-	I-MED
mouth	I-MED
disease	I-MED
(	O
FMD	B-MED
)	O
is	O
endemic	B-MED
in	O
many	O
regions	B-MED
of	O
the	O
world	B-MED
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	B-MED
animal	B-MED
diseases	I-MED
.	O
FMD	B-MED
affects	O
livestock	B-MED
,	O
such	O
as	O
cattle	B-MED
,	O
sheep	B-MED
,	O
goats	B-MED
and	O
pigs	B-MED
,	O
and	O
causes	O
enormous	B-MED
economic	I-MED
losses	I-MED
due	O
to	O
reduced	O
productivity	B-MED
and	O
trade	B-MED
restrictions	I-MED
.	O
Preparedness	B-MED
and	O
early	B-MED
diagnosis	I-MED
are	O
essential	B-MED
for	O
effective	B-MED
control	I-MED
of	O
FMD	B-MED
.	O
Many	O
diagnostic	B-MED
assays	I-MED
are	O
dependent	B-MED
on	O
raising	O
high	B-MED
-	I-MED
affinity	I-MED
,	O
anti	B-MED
-	I-MED
FMD	I-MED
virus	I-MED
(	O
FMDV	B-MED
)	O
serotype	B-MED
-	I-MED
specific	I-MED
antibodies	I-MED
in	O
small	O
animals	B-MED
(	O
rabbits	B-MED
and	O
guinea	B-MED
pigs	I-MED
)	O
that	O
give	O
broad	O
virus	B-MED
coverage	O
.	O
Here	O
we	O
show	O
that	O
soluble	B-MED
,	O
truncated	B-MED
forms	I-MED
of	O
bovine	B-MED
αvβ6	B-MED
bind	B-MED
FMDV	B-MED
in	O
an	O
authentic	O
RGD	B-MED
and	O
divalent	B-MED
cation	I-MED
dependent	I-MED
interaction	I-MED
and	O
can	O
be	O
used	O
as	O
the	O
trapping	B-MED
reagent	I-MED
in	O
a	O
FMDV	B-MED
sandwich	B-MED
ELISA	I-MED
.	O
In	O
addition	O
,	O
inclusion	B-MED
of	O
FLAG	B-MED
or	O
His	B-MED
tags	I-MED
facilitates	O
simple	O
purification	B-MED
without	O
the	O
loss	B-MED
of	O
virus	B-MED
binding	I-MED
.	O
We	O
also	O
provide	O
evidence	B-MED
that	O
when	O
combined	B-MED
with	O
a	O
guinea	B-MED
pig	I-MED
polyclonal	B-MED
serum	I-MED
,	O
or	O
serotype	B-MED
-	I-MED
specific	I-MED
monoclonal	I-MED
antibodies	I-MED
,	O
the	O
integrin	B-MED
can	O
be	O
used	O
to	O
detect	B-MED
viruses	B-MED
representative	O
of	O
all	O
FMDV	B-MED
serotypes	I-MED
.	O
We	O
also	O
show	O
that	O
recombinant	B-MED
FMDV	I-MED
empty	B-MED
capsids	I-MED
,	O
with	O
stabilising	B-MED
disulphide	I-MED
bonds	I-MED
,	O
can	O
serve	O
as	O
an	O
antigen	B-MED
in	O
the	O
ELISA	B-MED
and	O
can	O
therefore	O
replace	O
inactivated	B-MED
virus	I-MED
antigen	I-MED
as	O
a	O
positive	B-MED
control	I-MED
for	O
the	O
assay	B-MED
.	O
Our	O
results	B-MED
demonstrate	O
the	O
potential	B-MED
use	O
of	O
bovine	B-MED
αvβ6	B-MED
and	O
FMDV	B-MED
empty	B-MED
capsids	I-MED
in	O
FMD	B-MED
diagnostic	B-MED
assays	I-MED
.	O
Impact	B-MED
of	O
Clinical	B-MED
Trial	I-MED
Results	B-MED
on	O
the	O
Temporal	B-MED
Trends	B-MED
of	O
Carotid	B-MED
Endarterectomy	I-MED
and	O
Stenting	B-MED
From	O
2002	O
to	O
2014	O
Randomized	B-MED
trials	I-MED
provide	O
conflicting	B-MED
data	B-MED
for	O
the	O
efficacy	B-MED
of	O
carotid	B-MED
-	I-MED
artery	I-MED
stenting	I-MED
compared	O
with	O
endarterectomy	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	B-MED
of	O
conflicting	B-MED
clinical	B-MED
trial	I-MED
publications	I-MED
on	O
the	O
utilization	B-MED
utilization	B-MED
rates	I-MED
of	O
carotid	B-MED
revascularization	I-MED
procedures	I-MED
.	O
We	O
conducted	O
a	O
population	B-MED
-	I-MED
level	I-MED
time	I-MED
-	I-MED
series	I-MED
analysis	I-MED
of	O
all	O
individuals	B-MED
who	O
underwent	O
carotid	B-MED
endarterectomy	I-MED
and	O
stenting	B-MED
in	O
Ontario	B-MED
,	O
Canada	B-MED
(	O
2002	O
-	O
2014	O
)	O
.	O
The	O
primary	B-MED
analysis	I-MED
examined	O
temporal	B-MED
changes	B-MED
in	O
the	O
rates	B-MED
of	O
carotid	B-MED
revascularization	I-MED
procedures	I-MED
after	O
publications	B-MED
of	O
major	O
randomized	B-MED
trials	I-MED
.	O
Secondary	B-MED
analyses	I-MED
examined	O
changes	B-MED
in	O
overall	B-MED
and	O
age	B-MED
,	O
sex	B-MED
,	O
carotid	B-MED
-	I-MED
artery	I-MED
symptom	I-MED
,	O
and	O
operator	B-MED
specialty	I-MED
-	I-MED
specific	I-MED
procedure	I-MED
rates	I-MED
.	O
A	O
total	O
of	O
16	O
772	O
patients	B-MED
were	O
studied	O
(	O
14	O
394	O
endarterectomy	B-MED
[	O
86	O
%	O
]	O
;	O
2378	O
stenting	B-MED
[	O
14	O
%	O
]	O
)	O
.	O
The	O
overall	O
rate	O
of	O
carotid	B-MED
revascularization	I-MED
decreased	O
from	O
6.0	O
procedures	B-MED
per	O
100	O
000	O
individuals	B-MED
≥40	O
years	O
old	O
in	O
April	O
2002	O
to	O
4.3	O
procedures	B-MED
in	O
the	O
first	O
quarter	O
of	O
2014	O
(	O
29	O
%	O
decrease	O
;	O
P<0.001	O
)	O
.	O
The	O
rate	B-MED
of	O
endarterectomy	B-MED
decreased	B-MED
by	O
36	O
%	O
(	O
P<0.001	O
)	O
,	O
whereas	O
the	O
rate	B-MED
of	O
carotid	B-MED
-	I-MED
artery	I-MED
stenting	I-MED
increased	B-MED
by	O
72	O
%	O
(	O
P=0.006	O
)	O
.	O
We	O
observed	O
a	O
marked	B-MED
increase	I-MED
(	O
P=0.01	O
)	O
in	O
stenting	B-MED
after	O
publication	B-MED
of	O
the	O
SAPPHIRE	B-MED
trial	I-MED
(	O
Stenting	B-MED
and	I-MED
Angioplasty	I-MED
With	I-MED
Protection	I-MED
in	I-MED
Patients	I-MED
at	I-MED
High	I-MED
Risk	I-MED
for	I-MED
Endarterectomy	I-MED
)	O
in	O
2004	O
,	O
whereas	O
stenting	B-MED
remained	O
relatively	O
unchanged	B-MED
after	O
subsequent	O
randomized	B-MED
trials	I-MED
published	O
in	O
2006	O
(	O
P=0.11	O
)	O
and	O
2010	O
(	O
P=0.34	O
)	O
.	O
In	O
contrast	O
,	O
endarterectomy	B-MED
decreased	B-MED
after	O
trials	B-MED
published	O
in	O
2006	O
(	O
P=0.04	O
)	O
and	O
2010	O
(	O
P=0.005	O
)	O
.	O
Although	O
the	O
overall	B-MED
rates	I-MED
of	O
carotid	B-MED
revascularization	I-MED
and	O
endarterectomy	B-MED
have	O
fallen	O
since	O
2002	O
,	O
the	O
rate	B-MED
of	O
carotid	B-MED
-	I-MED
artery	I-MED
stenting	I-MED
has	O
risen	B-MED
since	O
the	O
publication	B-MED
of	O
stenting	B-MED
-favorable	O
SAPPHIRE	B-MED
trial	I-MED
.	O
Subsequent	O
conflicting	B-MED
randomized	B-MED
trials	I-MED
were	O
associated	B-MED
with	I-MED
a	O
decreasing	B-MED
rate	I-MED
of	O
carotid	B-MED
endarterectomy	I-MED
.	O
Unintentional	B-MED
insecticide	B-MED
poisoning	I-MED
by	O
age	B-MED
:	O
an	O
analysis	B-MED
of	O
Queensland	O
Poisons	O
Information	O
Centre	O
calls	B-MED
Data	B-MED
from	O
the	O
Queensland	O
Poisons	O
Information	O
Centre	O
(	O
QPIC	O
)	O
was	O
assessed	B-MED
to	O
determine	B-MED
mechanisms	B-MED
of	O
acute	O
insecticide	B-MED
poisoning	I-MED
in	O
young	B-MED
children	I-MED
(	O
<	B-MED
5	I-MED
years	I-MED
)	O
and	O
whether	O
age	B-MED
affects	B-MED
insecticide	B-MED
-	I-MED
poisoning	I-MED
patterns	B-MED
.	O
Records	B-MED
of	O
all	O
insecticide	B-MED
-	I-MED
related	I-MED
calls	I-MED
placed	O
to	O
QPIC	O
in	O
2014	O
were	O
obtained	B-MED
.	O
A	O
stratified	B-MED
analysis	B-MED
of	O
call	B-MED
patterns	B-MED
by	O
age	B-MED
was	O
conducted	B-MED
.	O
Of	O
743	O
insecticide	B-MED
-	I-MED
related	I-MED
calls	I-MED
received	B-MED
by	I-MED
QPIC	O
364	O
(	O
49.0	O
%	O
)	O
were	O
for	O
young	B-MED
children	I-MED
.	O
The	O
number	O
of	O
calls	B-MED
peaked	B-MED
in	O
children	B-MED
aged	B-MED
one	I-MED
.	O
Ant	B-MED
and	O
cockroach	B-MED
baits	B-MED
accounted	B-MED
for	O
39.0	O
%	O
of	O
calls	B-MED
.	O
Sprays	B-MED
,	O
which	O
were	O
found	B-MED
to	O
contain	O
not	O
only	O
pyrethroids	B-MED
,	O
pyrethrins	B-MED
and/or	O
piperonly	B-MED
butoxide	I-MED
but	O
also	O
the	O
organophosphate	B-MED
diazinon	I-MED
,	O
accounted	B-MED
for	O
25.8	O
%	O
of	O
calls	B-MED
.	O
Mouthing	B-MED
or	O
ingesting	B-MED
a	O
pest	B-MED
-	I-MED
control	I-MED
product	I-MED
and	O
consuming	B-MED
an	O
item	O
/	O
insect	O
after	O
treatment	B-MED
were	O
common	O
mechanisms	B-MED
for	O
children	B-MED
under	O
the	O
age	B-MED
of	I-MED
two	I-MED
.	O
Topical	B-MED
exposure	B-MED
to	I-MED
sprays	B-MED
,	O
via	O
direct	B-MED
application	B-MED
,	O
typically	O
by	O
the	O
child	B-MED
or	O
an	O
older	B-MED
sibling	I-MED
,	O
peaked	B-MED
in	O
children	B-MED
aged	B-MED
two	I-MED
.	O
In	O
12.3	O
%	O
of	O
calls	B-MED
medical	B-MED
attention	I-MED
for	O
the	O
child	B-MED
was	O
already	O
sought	B-MED
or	O
advised	B-MED
by	I-MED
QPIC	O
.	O
Normal	B-MED
behaviours	I-MED
associated	B-MED
with	I-MED
child	B-MED
development	I-MED
,	O
particularly	O
mouthing	B-MED
behaviours	B-MED
,	O
explained	O
the	O
peak	B-MED
of	I-MED
exposure	I-MED
in	O
one	B-MED
-	I-MED
year	I-MED
-	O
olds	B-MED
.	O
This	O
finding	B-MED
should	O
guide	O
strategies	B-MED
to	O
minimise	B-MED
poisonings	B-MED
in	O
this	O
vulnerable	B-MED
population	I-MED
.	O
ACR	B-MED
Appropriateness	B-MED
Criteria	I-MED
(	O
®	O
)	O
Radiologic	B-MED
Management	B-MED
of	O
Mesenteric	B-MED
Ischemia	I-MED
Mesenteric	B-MED
vascular	I-MED
insufficiency	I-MED
is	O
a	O
serious	O
medical	B-MED
condition	I-MED
that	O
may	O
lead	O
to	O
bowel	B-MED
infarction	I-MED
,	O
morbidity	B-MED
,	O
and	O
mortality	B-MED
that	O
may	O
approach	B-MED
50	O
%	O
.	O
Recommended	O
therapy	B-MED
for	O
acute	B-MED
mesenteric	I-MED
ischemia	I-MED
includes	O
aspiration	B-MED
embolectomy	B-MED
,	O
transcatheter	B-MED
thrombolysis	B-MED
,	O
and	O
angioplasty	B-MED
with	O
or	O
without	O
stenting	B-MED
for	O
the	O
treatment	B-MED
of	O
underlying	O
arterial	B-MED
stenosis	I-MED
.	O
Nonocclusive	B-MED
mesenteric	I-MED
ischemia	I-MED
may	O
respond	O
to	O
transarterial	B-MED
infusion	I-MED
of	O
vasodilators	B-MED
such	O
as	O
nitroglycerin	B-MED
,	O
papaverine	B-MED
,	O
glucagon	B-MED
,	O
and	O
prostaglandin	B-MED
E1	I-MED
.	O
Recommended	O
therapy	B-MED
for	O
chronic	B-MED
mesenteric	I-MED
ischemia	I-MED
includes	O
angioplasty	B-MED
with	O
or	O
without	O
stent	B-MED
placement	I-MED
and	O
,	O
if	O
an	O
endovascular	B-MED
approach	I-MED
is	O
not	O
possible	O
,	O
surgical	B-MED
bypass	I-MED
or	O
endarterectomy	B-MED
.	O
The	O
diagnosis	B-MED
of	O
median	B-MED
arcuate	I-MED
ligament	I-MED
syndrome	I-MED
is	O
controversial	O
,	O
but	O
surgical	B-MED
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	B-MED
situation	I-MED
.	O
Venous	B-MED
mesenteric	B-MED
ischemia	I-MED
may	O
respond	O
to	O
systemic	B-MED
anticoagulation	B-MED
alone	O
.	O
Transhepatic	B-MED
or	O
transjugular	B-MED
superior	B-MED
mesenteric	I-MED
vein	I-MED
catheterization	B-MED
and	I-MED
thrombolytic	I-MED
infusion	I-MED
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-MED
,	O
condition	B-MED
of	I-MED
the	I-MED
patient	I-MED
,	O
and	O
response	B-MED
to	O
systemic	B-MED
anticoagulation	B-MED
.	O
Adjunct	B-MED
transjugular	B-MED
intrahepatic	I-MED
portosystemic	I-MED
shunt	I-MED
creation	I-MED
can	O
be	O
considered	O
for	O
outflow	O
improvement	B-MED
.	O
The	O
American	B-MED
College	I-MED
of	I-MED
Radiology	I-MED
Appropriateness	B-MED
Criteria	I-MED
are	O
evidence	B-MED
-	I-MED
based	I-MED
guidelines	B-MED
for	O
specific	O
clinical	B-MED
conditions	I-MED
that	O
are	O
reviewed	B-MED
annually	B-MED
by	O
a	O
multidisciplinary	B-MED
expert	I-MED
panel	I-MED
.	O
The	O
guideline	B-MED
development	B-MED
and	O
revision	B-MED
include	O
an	O
extensive	B-MED
analysis	I-MED
of	O
current	O
medical	B-MED
literature	I-MED
from	O
peer	B-MED
-	I-MED
reviewed	I-MED
journals	I-MED
and	O
the	O
application	O
of	O
well	O
-	O
established	O
methodologies	B-MED
(	O
RAND	B-MED
/	O
UCLA	B-MED
Appropriateness	B-MED
Method	O
and	O
Grading	B-MED
of	I-MED
Recommendations	I-MED
Assessment	I-MED
,	I-MED
Development	I-MED
,	I-MED
and	I-MED
Evaluation	I-MED
or	O
GRADE	B-MED
)	O
to	O
rate	O
the	O
appropriateness	B-MED
of	O
imaging	B-MED
and	O
treatment	B-MED
procedures	I-MED
for	O
specific	O
clinical	B-MED
scenarios	B-MED
.	O
In	O
those	O
instances	B-MED
where	O
evidence	B-MED
is	O
lacking	B-MED
or	O
equivocal	B-MED
,	O
expert	B-MED
opinion	I-MED
may	O
supplement	B-MED
the	O
available	O
evidence	B-MED
to	O
recommend	O
imaging	B-MED
or	O
treatment	B-MED
.	O
The	O
CLASP2	B-MED
Protein	B-MED
Interaction	I-MED
Network	I-MED
in	O
Adipocytes	B-MED
Links	O
CLIP2	B-MED
to	O
AGAP3	B-MED
,	O
CLASP2	B-MED
to	O
G2L1	B-MED
,	O
MARK2	B-MED
,	O
and	O
SOGA1	B-MED
,	O
and	O
Identifies	O
SOGA1	B-MED
as	O
a	O
Microtubule	B-MED
-	I-MED
Associated	I-MED
Protein	I-MED
CLASP2	B-MED
is	O
a	O
microtubule	B-MED
-	I-MED
associated	I-MED
protein	I-MED
that	O
undergoes	O
insulin	B-MED
-	O
stimulated	B-MED
phosphorylation	B-MED
and	O
co	B-MED
-	I-MED
localization	I-MED
with	O
reorganized	B-MED
actin	B-MED
and	O
GLUT4	B-MED
at	O
the	O
plasma	B-MED
membrane	I-MED
.	O
To	O
gain	B-MED
insight	B-MED
to	O
the	O
role	B-MED
of	O
CLASP2	B-MED
in	O
this	O
system	B-MED
,	O
we	O
developed	B-MED
and	O
successfully	B-MED
executed	B-MED
a	O
streamlined	B-MED
interactome	B-MED
approach	B-MED
and	O
built	O
a	O
CLASP2	B-MED
protein	B-MED
network	I-MED
in	O
3T3	B-MED
-	I-MED
L1	I-MED
adipocytes	I-MED
.	O
Using	O
two	O
different	B-MED
commercially	B-MED
available	B-MED
antibodies	B-MED
for	O
CLASP2	B-MED
and	O
an	O
antibody	B-MED
for	O
epitope	B-MED
-tagged	O
,	O
overexpressed	B-MED
CLASP2	B-MED
,	O
we	O
performed	B-MED
multiple	B-MED
affinity	B-MED
purification	I-MED
coupled	B-MED
with	O
mass	B-MED
spectrometry	I-MED
(	O
AP	B-MED
-	O
MS	B-MED
)	O
experiments	B-MED
in	O
combination	B-MED
with	O
label	B-MED
-	I-MED
free	I-MED
quantitative	B-MED
proteomics	B-MED
and	O
analyzed	B-MED
the	O
data	B-MED
with	O
the	O
bioinformatics	B-MED
tool	B-MED
Significance	B-MED
Analysis	I-MED
of	I-MED
Interactome	I-MED
(	O
SAINT	B-MED
)	O
.	O
We	O
discovered	B-MED
that	O
CLASP2	B-MED
co	B-MED
-	I-MED
immunoprecipitates	I-MED
(	O
co	B-MED
-	I-MED
IPs	I-MED
)	O
the	O
novel	O
protein	B-MED
SOGA1	B-MED
,	O
the	O
microtubule	B-MED
-	I-MED
associated	I-MED
protein	I-MED
kinase	I-MED
MARK2	B-MED
,	O
and	O
the	O
microtubule	B-MED
/	O
actin	B-MED
-	O
regulating	B-MED
protein	B-MED
G2L1	B-MED
.	O
The	O
GTPase	B-MED
-	I-MED
activating	I-MED
proteins	I-MED
AGAP1	B-MED
and	O
AGAP3	B-MED
were	O
also	O
enriched	O
in	O
the	O
CLASP2	B-MED
interactome	B-MED
,	O
although	O
subsequent	B-MED
AGAP3	B-MED
and	O
CLIP2	B-MED
interactome	B-MED
analysis	B-MED
suggests	O
a	O
preference	B-MED
of	O
AGAP3	B-MED
for	O
CLIP2	B-MED
.	O
Follow	O
-	O
up	O
MARK2	B-MED
interactome	B-MED
analysis	B-MED
confirmed	B-MED
reciprocal	B-MED
co	B-MED
-	I-MED
IP	I-MED
of	O
CLASP2	B-MED
and	O
also	O
revealed	O
MARK2	B-MED
can	O
co	B-MED
-	I-MED
IP	I-MED
SOGA1	B-MED
,	O
glycogen	B-MED
synthase	I-MED
,	O
and	O
glycogenin	B-MED
.	O
Investigating	B-MED
the	O
SOGA1	B-MED
interactome	B-MED
confirmed	B-MED
SOGA1	B-MED
can	O
reciprocal	B-MED
co	B-MED
-	I-MED
IP	I-MED
both	O
CLASP2	B-MED
and	O
MARK2	B-MED
as	O
well	O
as	O
glycogen	B-MED
synthase	I-MED
and	O
glycogenin	B-MED
.	O
SOGA1	B-MED
was	O
confirmed	B-MED
to	O
colocalize	B-MED
with	O
CLASP2	B-MED
and	O
also	O
with	O
tubulin	B-MED
,	O
which	O
identifies	O
SOGA1	B-MED
as	O
a	O
new	O
microtubule	B-MED
-	I-MED
associated	I-MED
protein	I-MED
.	O
These	O
results	B-MED
introduce	O
the	O
metabolic	B-MED
function	I-MED
of	O
these	O
proposed	B-MED
novel	O
protein	B-MED
networks	I-MED
and	O
their	O
relationship	B-MED
with	O
microtubules	B-MED
as	O
new	O
fields	O
of	O
cytoskeleton	B-MED
-	O
associated	B-MED
protein	B-MED
biology	I-MED
.	O
Photosensitizer	B-MED
Decorated	B-MED
Red	B-MED
Blood	I-MED
Cells	I-MED
as	O
an	O
Ultra	B-MED
-	I-MED
Sensitive	I-MED
Light	I-MED
-	I-MED
Responsive	I-MED
Drug	I-MED
Delivery	I-MED
System	I-MED
Red	B-MED
blood	I-MED
cells	I-MED
(	O
RBCs	B-MED
)	O
,	O
the	O
most	O
abundant	B-MED
type	O
of	O
cells	B-MED
in	O
our	O
blood	B-MED
,	O
have	O
shown	O
promises	O
as	O
a	O
natural	B-MED
drug	I-MED
delivery	I-MED
system	I-MED
(	O
DDS	B-MED
)	O
with	O
inherent	O
biocompatibility	B-MED
.	O
Herein	O
,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-MED
,	O
chlorin	B-MED
e6	I-MED
(	O
Ce6	B-MED
)	O
,	O
could	O
be	O
decorated	B-MED
into	O
the	O
membrane	B-MED
of	O
RBCs	B-MED
upon	O
simple	O
mixing	B-MED
,	O
without	O
affecting	O
the	O
membrane	B-MED
integrity	B-MED
and	O
stability	B-MED
in	O
dark	O
.	O
Upon	O
light	B-MED
irradiation	B-MED
with	O
a	O
rather	O
low	O
power	O
density	B-MED
,	O
the	O
generated	B-MED
singlet	B-MED
oxygen	I-MED
by	O
Ce6	B-MED
as	O
the	O
result	B-MED
of	I-MED
photodynamic	I-MED
effect	I-MED
would	O
lead	O
to	O
rather	O
efficient	O
disruption	B-MED
of	O
RBC	B-MED
membrane	B-MED
.	O
With	O
doxorubicin	B-MED
(	O
DOX	B-MED
DOX	B-MED
)	O
,	O
a	O
typical	O
chemotherapy	B-MED
drug	B-MED
,	O
as	O
the	O
model	B-MED
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light	B-MED
-	I-MED
responsive	I-MED
RBC	I-MED
-	I-MED
based	I-MED
DDS	I-MED
by	O
decorating	B-MED
Ce6	B-MED
on	O
the	O
cell	B-MED
membrane	I-MED
and	O
loading	O
DOX	B-MED
inside	O
cells	B-MED
.	O
The	O
light	B-MED
triggered	B-MED
cell	B-MED
membrane	I-MED
break	O
down	O
would	O
thus	O
trigger	B-MED
instant	O
release	O
of	O
DOX	B-MED
,	O
enabling	O
light	B-MED
-	I-MED
controlled	I-MED
chemotherapy	I-MED
with	O
great	O
specificity	B-MED
.	O
Beyond	O
that	O
,	O
our	O
RBC	B-MED
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	B-MED
such	O
as	O
enzymes	B-MED
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	B-MED
function	B-MED
is	O
also	O
controlled	O
by	O
light	B-MED
.	O
Our	O
work	B-MED
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible	B-MED
cell	I-MED
-	I-MED
based	I-MED
DDS	I-MED
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	B-MED
,	O
promising	O
not	O
only	O
for	O
cancer	B-MED
therapy	I-MED
but	O
also	O
for	O
other	O
potential	O
applications	B-MED
in	O
biotechnologies	B-MED
.	O
High	O
Occurrence	O
of	O
Non	B-MED
-	I-MED
Clear	I-MED
Cell	I-MED
Renal	I-MED
Cell	I-MED
Carcinoma	I-MED
in	O
Oman	B-MED
It	O
is	O
conventionally	O
accepted	O
that	O
renal	B-MED
cell	I-MED
carcinoma	I-MED
(	O
RCC	B-MED
)	O
occurs	O
in	O
older	B-MED
patients	I-MED
and	O
the	O
clear	B-MED
cell	I-MED
type	I-MED
is	O
the	O
most	O
common	O
histology	B-MED
.	O
However	O
,	O
ethnic	B-MED
variations	I-MED
exist	O
and	O
this	O
study	B-MED
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	B-MED
pattern	I-MED
of	O
RCC	B-MED
in	O
Oman	B-MED
.	O
Ninety	O
RCC	B-MED
patients	B-MED
who	O
presented	B-MED
to	O
a	O
tertiary	B-MED
care	I-MED
center	I-MED
in	O
the	O
Sultanate	B-MED
of	I-MED
Oman	I-MED
from	O
2010	O
to	O
2014	O
were	O
studied	B-MED
.	O
The	O
main	B-MED
findings	I-MED
were	O
that	O
the	O
median	B-MED
age	I-MED
of	O
presentation	B-MED
was	O
low	B-MED
,	O
more	O
patients	B-MED
presented	B-MED
with	O
localized	B-MED
stage	B-MED
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non	B-MED
-	I-MED
clear	I-MED
(	O
especially	O
papillary	B-MED
)	O
histology	B-MED
.	O
Data	B-MED
from	O
other	O
Gulf	B-MED
countries	I-MED
and	O
possible	O
reasons	O
for	O
the	O
different	O
profile	O
are	O
discussed	O
.	O
Modeling	B-MED
the	O
flux	B-MED
of	O
metabolites	B-MED
in	O
the	O
juvenile	B-MED
hormone	I-MED
biosynthesis	B-MED
pathway	B-MED
using	O
generalized	B-MED
additive	I-MED
models	I-MED
and	O
ordinary	B-MED
differential	I-MED
equations	I-MED
Juvenile	B-MED
hormone	I-MED
(	O
JH	B-MED
)	O
regulates	O
development	B-MED
and	O
reproductive	B-MED
maturation	I-MED
in	O
insects	B-MED
.	O
The	O
corpora	B-MED
allata	I-MED
(	O
CA	B-MED
)	O
from	O
female	B-MED
adult	B-MED
mosquitoes	I-MED
synthesize	O
fluctuating	B-MED
levels	B-MED
of	O
JH	B-MED
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian	B-MED
development	I-MED
and	O
are	O
influenced	O
by	O
nutritional	B-MED
signals	B-MED
.	O
The	O
rate	B-MED
of	O
JH	B-MED
biosynthesis	B-MED
is	O
controlled	O
by	O
the	O
rate	B-MED
of	O
flux	B-MED
of	O
isoprenoids	B-MED
in	O
the	O
pathway	B-MED
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	B-MED
in	O
precursor	B-MED
pools	O
and	O
enzyme	B-MED
levels	B-MED
.	O
A	O
comprehensive	B-MED
study	B-MED
of	O
the	O
changes	B-MED
in	O
enzymatic	B-MED
activities	I-MED
and	O
precursor	B-MED
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	B-MED
Aedes	B-MED
aegypti	I-MED
JH	B-MED
biosynthesis	B-MED
pathway	B-MED
.	O
In	O
the	O
present	O
studies	B-MED
,	O
we	O
used	O
two	O
different	O
quantitative	B-MED
approaches	I-MED
to	O
describe	O
and	O
predict	O
how	O
changes	B-MED
in	O
the	O
individual	O
metabolic	B-MED
reactions	B-MED
in	O
the	O
pathway	B-MED
affect	O
JH	B-MED
synthesis	B-MED
.	O
First	O
,	O
we	O
constructed	O
generalized	B-MED
additive	I-MED
models	I-MED
(	O
GAMs	B-MED
)	O
that	O
described	O
the	O
association	O
between	O
changes	B-MED
in	O
specific	O
metabolite	B-MED
concentrations	B-MED
with	O
changes	B-MED
in	O
enzymatic	B-MED
activities	I-MED
and	O
substrate	B-MED
concentrations	B-MED
.	O
Changes	B-MED
in	O
substrate	B-MED
concentrations	B-MED
explained	O
50	O
%	O
or	O
more	O
of	O
the	O
model	B-MED
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	B-MED
steps	B-MED
analyzed	B-MED
.	O
Addition	O
of	O
information	O
on	O
enzymatic	B-MED
activities	I-MED
almost	O
always	O
improved	O
the	O
fitness	B-MED
of	O
GAMs	B-MED
built	O
solely	O
based	O
on	O
substrate	B-MED
concentrations	B-MED
.	O
GAMs	B-MED
were	O
validated	O
using	O
experimental	B-MED
data	B-MED
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built	O
.	O
In	O
addition	O
,	O
a	O
system	O
of	O
ordinary	B-MED
differential	I-MED
equations	I-MED
(	O
ODE	B-MED
)	O
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	B-MED
in	O
metabolites	B-MED
as	O
a	O
function	B-MED
of	O
the	O
levels	B-MED
of	O
enzymatic	B-MED
catalytic	I-MED
activities	I-MED
.	O
The	O
results	B-MED
demonstrated	O
the	O
ability	O
of	O
the	O
models	B-MED
to	O
predict	O
changes	B-MED
in	O
the	O
flux	B-MED
of	O
metabolites	B-MED
in	O
the	O
JH	B-MED
pathway	B-MED
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	B-MED
and	O
validate	B-MED
experimental	B-MED
manipulations	B-MED
of	O
JH	B-MED
synthesis	B-MED
.	O
Human	B-MED
brucellosis	B-MED
in	O
South	B-MED
Africa	I-MED
:	O
Public	B-MED
health	I-MED
and	O
diagnostic	B-MED
pitfalls	I-MED
Human	B-MED
brucellosis	B-MED
in	O
South	B-MED
Africa	I-MED
(	O
SA	B-MED
)	O
is	O
under	B-MED
-	I-MED
diagnosed	I-MED
and	O
under	B-MED
-	I-MED
reported	I-MED
.	O
This	O
is	O
because	O
many	O
clinicians	B-MED
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected	B-MED
patients	I-MED
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	B-MED
and	O
insidious	B-MED
nature	B-MED
of	I-MED
the	I-MED
disease	I-MED
.	O
A	O
case	B-MED
of	O
human	B-MED
brucellosis	B-MED
caused	O
by	O
Brucella	B-MED
melitensis	I-MED
in	O
a	O
patient	B-MED
from	O
the	O
Western	B-MED
Cape	I-MED
Province	I-MED
of	O
SA	B-MED
is	O
described	B-MED
,	O
and	O
the	O
resulting	B-MED
exposure	O
of	O
staff	B-MED
members	I-MED
at	O
two	O
medical	B-MED
microbiology	I-MED
laboratories	I-MED
,	O
as	O
well	O
as	O
the	O
public	B-MED
health	I-MED
investigation	I-MED
that	O
was	O
conducted	O
,	O
are	O
discussed	O
.	O
This	O
article	B-MED
aims	B-MED
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	B-MED
between	O
public	B-MED
health	I-MED
,	O
medical	B-MED
and	O
veterinary	B-MED
services	B-MED
and	O
exposing	B-MED
deficiencies	I-MED
in	O
public	B-MED
health	I-MED
,	O
veterinary	B-MED
and	O
laboratory	B-MED
practices	O
.	O
Request	B-MED
and	O
fulfillment	B-MED
of	O
postpartum	B-MED
tubal	B-MED
ligation	I-MED
in	O
patients	B-MED
after	O
high	B-MED
-	I-MED
risk	I-MED
pregnancy	I-MED
Female	B-MED
sterilization	I-MED
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	B-MED
of	O
contraception	B-MED
in	O
the	O
United	B-MED
States	I-MED
.	O
Prior	O
studies	B-MED
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	B-MED
tubal	B-MED
ligation	I-MED
(	O
PPTL	B-MED
)	O
requests	B-MED
go	O
unfulfilled	B-MED
.	O
This	O
study	B-MED
seeks	O
to	O
establish	O
whether	O
obstetric	B-MED
or	O
medical	B-MED
risk	I-MED
status	B-MED
influences	O
patients	B-MED
'	O
request	B-MED
for	O
or	O
subsequent	O
completion	B-MED
of	O
PPTL	B-MED
.	O
This	O
study	B-MED
was	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
of	O
women	B-MED
delivering	B-MED
at	O
a	O
university	B-MED
hospital	I-MED
in	O
2009	O
-	O
2010	O
who	O
received	O
prenatal	B-MED
care	I-MED
in	O
the	O
faculty	B-MED
and	O
resident	B-MED
clinics	I-MED
.	O
High	B-MED
-	I-MED
risk	I-MED
status	B-MED
was	O
defined	O
by	O
Society	B-MED
for	I-MED
Maternal	I-MED
-	I-MED
Fetal	I-MED
Medicine	I-MED
guidelines	I-MED
.	O
Documentation	B-MED
of	O
contraceptive	B-MED
plan	I-MED
and	O
administration	B-MED
of	O
contraceptive	B-MED
methods	I-MED
was	O
abstracted	B-MED
from	O
patient	B-MED
records	I-MED
.	O
Subsequent	O
pregnancies	B-MED
through	O
March	O
1	O
,	O
2013	O
,	O
were	O
abstracted	B-MED
.	O
Of	O
3063	O
participants	B-MED
(	O
2048	O
low	B-MED
risk	I-MED
and	O
1015	O
high	B-MED
risk	I-MED
)	O
,	O
231	O
requested	B-MED
PPTL	B-MED
(	O
7.5	O
%	O
)	O
.	O
This	O
was	O
more	O
likely	O
among	O
high	B-MED
-	I-MED
risk	I-MED
patients	B-MED
than	O
low	B-MED
-	I-MED
risk	I-MED
patients	B-MED
(	O
10.0	O
%	O
vs.	O
6.3	O
%	O
,	O
p<.001	O
)	O
,	O
those	O
with	O
public	B-MED
insurance	I-MED
(	O
13.8	O
%	O
vs.	O
3.2	O
%	O
,	O
p<.001	O
)	O
and	O
those	O
with	O
an	O
unintended	B-MED
index	I-MED
pregnancy	I-MED
(	O
13.8	O
%	O
vs.	O
4.1	O
%	O
,	O
p<.001	O
)	O
.	O
Of	O
the	O
patients	B-MED
requesting	B-MED
PPTL	B-MED
,	O
118	O
(	O
51.1	O
%	O
)	O
underwent	O
the	O
procedure	B-MED
immediately	O
postpartum	B-MED
.	O
Completion	B-MED
was	O
not	O
associated	O
with	O
high	B-MED
-	I-MED
risk	I-MED
status	B-MED
(	O
54.0	O
%	O
)	O
,	O
or	O
with	O
race	B-MED
,	O
insurance	B-MED
status	I-MED
or	O
parity	B-MED
.	O
Among	O
113	O
women	B-MED
with	O
an	O
unfulfilled	B-MED
PPTL	B-MED
request	B-MED
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	B-MED
(	O
15.0	O
%	O
)	O
during	O
the	O
27	O
months	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Though	O
women	B-MED
with	O
high	B-MED
-	I-MED
risk	I-MED
pregnancies	I-MED
were	O
more	O
likely	O
to	O
request	B-MED
PPTL	B-MED
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-MED
the	O
procedure	B-MED
.	O
Over	O
one	O
third	O
of	O
high	B-MED
-	I-MED
risk	I-MED
patients	B-MED
'	O
requests	B-MED
were	O
unfulfilled	B-MED
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain	O
.	O
Though	O
women	B-MED
with	O
high	B-MED
-	I-MED
risk	I-MED
pregnancies	I-MED
were	O
more	O
likely	O
to	O
request	B-MED
PPTL	B-MED
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-MED
the	O
procedure	B-MED
.	O
Providers	O
should	O
consider	O
these	O
procedures	B-MED
urgent	B-MED
,	O
especially	O
in	O
high	B-MED
-	I-MED
risk	I-MED
women	B-MED
,	O
and	O
advocate	O
for	O
their	O
patients	B-MED
'	O
access	O
to	O
this	O
procedure	B-MED
.	O
Extract	B-MED
of	I-MED
Caulis	I-MED
Spatholobi	I-MED
Caulis	B-MED
Spatholobi	I-MED
,	O
a	O
novel	O
blocker	B-MED
targeting	O
tumor	B-MED
cell	I-MED
tumor	B-MED
cell	I-MED
‑induced	I-MED
platelet	I-MED
aggregation	I-MED
,	O
inhibits	O
breast	B-MED
cancer	I-MED
metastasis	B-MED
Metastasis	B-MED
of	O
breast	B-MED
cancer	I-MED
is	O
the	O
vital	O
step	O
for	O
malignant	B-MED
progression	I-MED
.	O
During	O
such	O
a	O
process	O
,	O
hematogenous	B-MED
metastasis	I-MED
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	B-MED
cells	I-MED
.	O
A	O
platelet	B-MED
,	O
contributes	O
to	O
hypercoagulable	B-MED
state	I-MED
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	B-MED
in	O
the	O
coagulation	B-MED
system	B-MED
for	O
supporting	O
metastasis	B-MED
.	O
Therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	B-MED
and	O
a	O
tumor	B-MED
cell	I-MED
plays	O
a	O
critical	O
role	O
in	O
tumor	B-MED
cell	I-MED
metastasis	B-MED
.	O
Consequently	O
,	O
inhibiting	O
tumor	B-MED
cell	I-MED
tumor	B-MED
cell	I-MED
‑induced	I-MED
platelet	I-MED
aggregation	I-MED
(	O
TCIPA	B-MED
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	B-MED
of	O
tumor	B-MED
metastasis	I-MED
such	O
as	O
aspirin	B-MED
(	O
ASA	B-MED
)	O
.	O
Under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor‑platelet	B-MED
(	I-MED
T‑P	I-MED
)	I-MED
complex	I-MED
,	I-MED
80	O
%	O
ethanol	B-MED
extracts	B-MED
of	I-MED
Caulis	I-MED
Spatholobi	I-MED
Caulis	B-MED
Spatholobi	I-MED
(	O
SET	B-MED
)	O
successfully	O
alleviated	O
the	O
hypercoagulation	B-MED
state	I-MED
,	O
thereby	O
reducing	O
tumor	B-MED
metastasis	I-MED
and	O
improving	O
the	O
prospects	O
of	O
survival	B-MED
in	O
breast	B-MED
cancer	B-MED
cell	I-MED
model	B-MED
.	O
Through	O
MTT	B-MED
and	O
anti‑aggregation	B-MED
assay	I-MED
stimulated	I-MED
by	I-MED
ADP	I-MED
,	O
we	O
detected	O
the	O
optimum	B-MED
treatment	I-MED
time	I-MED
and	O
the	O
optimum	B-MED
dose	I-MED
of	O
SET	B-MED
.	O
By	O
using	O
confocal	B-MED
microscopy	I-MED
,	O
we	O
observed	O
that	O
SET	B-MED
can	O
strongly	O
block	O
the	O
formation	B-MED
of	O
T‑P	B-MED
complex	I-MED
i	O
n	B-MED
vitro	I-MED
.	O
The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS	B-MED
analysis	I-MED
.	O
The	O
fluorescent	B-MED
value	I-MED
of	O
T‑P	B-MED
complex	I-MED
was	O
obviously	O
decreased	O
in	O
the	O
drug‑treated	B-MED
groups	I-MED
.	I-MED
In	B-MED
vivo	I-MED
,	O
4T1	B-MED
cells	I-MED
were	O
injected	B-MED
through	O
the	O
mouse	B-MED
tail	B-MED
vein	I-MED
for	O
dynamic	B-MED
visualization	I-MED
by	O
small	B-MED
animal	I-MED
imaging	I-MED
system	I-MED
.	O
The	O
metastatic	B-MED
intensity	I-MED
was	O
quantified	O
and	O
the	O
survival	B-MED
curve	I-MED
was	O
analyzed	B-MED
.	O
Additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	B-MED
and	I-MED
eosin	I-MED
(	I-MED
H&E	I-MED
)	I-MED
staining	I-MED
of	O
lung	B-MED
tissue	B-MED
was	O
performed	O
.	O
SET	B-MED
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	B-MED
of	O
metastasis	B-MED
and	O
increasing	O
the	O
survival	B-MED
rate	I-MED
of	O
mice	B-MED
.	O
For	O
the	O
molecular	B-MED
mechanism	I-MED
study	B-MED
of	O
anti‑TCIPA	B-MED
,	O
zymography	B-MED
and	O
R	O
T‑PCR	B-MED
assay	I-MED
preliminarily	O
revealed	O
the	O
molecular	B-MED
mechanism	I-MED
of	O
SET	B-MED
in	O
the	O
regulation	O
of	O
P	O
‑T	B-MED
interaction	I-MED
.	O
Collectively	O
,	O
through	O
drug	B-MED
efficacy	I-MED
identification	O
and	O
pharmacological	B-MED
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	B-MED
metastasis	B-MED
by	O
suppressing	O
TCIPA	B-MED
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	B-MED
cancer	B-MED
treatment	I-MED
.	O
Advanced	B-MED
age	I-MED
is	O
not	O
a	O
barrier	B-MED
to	O
creating	O
a	O
functional	B-MED
arteriovenous	B-MED
fistula	I-MED
:	O
a	O
retrospective	B-MED
study	I-MED
Arteriovenous	B-MED
fistulas	I-MED
(	O
AVFs	B-MED
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	B-MED
access	I-MED
for	O
hemodialysis	B-MED
.	O
However	O
,	O
controversy	B-MED
exists	O
regarding	O
whether	O
AVFs	B-MED
are	O
suitable	O
for	O
elderly	B-MED
patients	B-MED
.	O
Single	B-MED
-	I-MED
center	I-MED
retrospective	I-MED
review	I-MED
to	O
investigate	B-MED
the	O
impact	B-MED
of	O
age	B-MED
on	O
AVF	B-MED
outcomes	B-MED
.	O
Five	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	B-MED
with	O
AVF	B-MED
creation	B-MED
were	O
stratified	B-MED
based	O
on	O
age	B-MED
<	B-MED
65	I-MED
,	O
65	B-MED
-	I-MED
75	I-MED
,	O
and	O
>	B-MED
75	I-MED
years	B-MED
.	O
AVF	B-MED
outcomes	B-MED
including	O
primary	B-MED
failure	B-MED
,	O
AVF	B-MED
patency	B-MED
(	O
primary	B-MED
,	O
secondary	B-MED
,	O
and	O
functional	B-MED
)	O
,	O
and	O
AVF	B-MED
complications	B-MED
were	O
studied	O
for	O
3	O
years	B-MED
following	O
AVF	B-MED
creation	B-MED
.	O
The	O
cohort	B-MED
was	O
63	O
%	O
male	B-MED
,	O
44	O
%	O
Caucasian	B-MED
,	O
and	O
55	O
%	O
had	O
diabetes	B-MED
or	O
cardiovascular	B-MED
disease	I-MED
.	O
39	O
%	O
were	O
aged	B-MED
<	B-MED
65	I-MED
years	B-MED
,	O
33	O
%	O
65	B-MED
-	I-MED
75	I-MED
years	B-MED
,	O
and	O
28	O
%	O
were	O
aged	B-MED
>	B-MED
75	I-MED
years	B-MED
.	O
No	O
differences	O
in	O
rates	O
of	O
primary	B-MED
failure	B-MED
,	O
loss	O
of	O
primary	B-MED
patency	B-MED
,	O
complications	B-MED
,	O
or	O
need	O
for	O
intervention	B-MED
were	O
observed	O
between	O
age	B-MED
groups	I-MED
.	O
There	O
was	O
a	O
significant	O
association	B-MED
of	O
age	B-MED
with	O
secondary	B-MED
patency	B-MED
and	O
functional	B-MED
patency	B-MED
,	O
with	O
age	B-MED
>	B-MED
75	I-MED
being	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
shortened	B-MED
lifespan	B-MED
of	O
the	O
fistula	O
.	O
For	O
patients	B-MED
aged	B-MED
>	B-MED
75	I-MED
years	B-MED
,	O
secondary	B-MED
patency	B-MED
at	O
3	O
years	B-MED
was	O
64	O
%	O
compared	O
to	O
75%-78	O
%	O
for	O
younger	B-MED
patients	B-MED
.	O
Functional	B-MED
patency	B-MED
at	O
2	O
years	B-MED
was	O
69	O
%	O
for	O
those	O
aged	B-MED
>	B-MED
75	I-MED
years	B-MED
compared	O
to	O
78%-81	O
%	O
for	O
younger	B-MED
patients	B-MED
.	O
We	O
found	O
no	O
difference	O
in	O
AVF	B-MED
maturation	B-MED
,	O
primary	B-MED
patency	B-MED
,	O
complications	B-MED
,	O
or	O
interventions	B-MED
in	O
those	O
over	O
the	O
age	B-MED
of	O
75	B-MED
compared	O
to	O
younger	B-MED
counterparts	O
.	O
While	O
secondary	B-MED
and	O
functional	B-MED
patency	B-MED
rates	B-MED
were	O
significantly	O
lower	O
in	O
those	O
aged	B-MED
>	B-MED
75	I-MED
years	B-MED
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O
Therefore	O
,	O
we	O
recommend	O
that	O
advanced	B-MED
age	I-MED
alone	O
should	O
not	O
preclude	O
patients	B-MED
from	O
AVF	B-MED
creation	B-MED
.	O
Activation	B-MED
of	I-MED
transcription	I-MED
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear	B-MED
bodies	I-MED
in	O
zebrafish	B-MED
embryos	B-MED
Nuclear	B-MED
bodies	I-MED
are	O
cellular	B-MED
compartments	I-MED
that	O
lack	B-MED
lipid	B-MED
bilayers	I-MED
and	O
harbor	O
specific	B-MED
RNAs	B-MED
and	O
proteins	B-MED
.	O
Recent	O
proposals	O
that	O
nuclear	B-MED
bodies	I-MED
form	O
through	O
liquid	O
-	O
liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear	B-MED
bodies	I-MED
maintain	O
their	O
distinct	O
identities	O
unanswered	O
.	O
Here	O
we	O
investigate	B-MED
Cajal	B-MED
bodies	I-MED
(	O
CBs	B-MED
)	O
,	O
histone	B-MED
locus	I-MED
bodies	I-MED
(	O
HLBs	B-MED
)	O
and	O
nucleoli	B-MED
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing	B-MED
machinery	I-MED
,	O
histone	B-MED
mRNA	I-MED
3	I-MED
'	I-MED
end	I-MED
processing	I-MED
,	O
and	O
rRNA	B-MED
processing	I-MED
,	O
respectively	O
-	O
in	O
the	O
embryos	B-MED
of	O
the	O
zebrafish	B-MED
,	O
Danio	B-MED
rerio	I-MED
.	O
We	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1	O
-	O
cell	O
embryo	B-MED
and	O
follow	O
nuclear	B-MED
body	I-MED
appearance	O
as	O
zygotic	B-MED
transcription	B-MED
becomes	O
activated	B-MED
.	O
CBs	B-MED
are	O
present	O
from	O
fertilization	B-MED
onwards	O
,	O
while	O
HLB	B-MED
and	O
nucleolar	B-MED
components	B-MED
formed	O
foci	B-MED
several	O
hours	O
later	O
when	O
histone	B-MED
genes	B-MED
and	O
rDNA	B-MED
became	O
active	B-MED
.	O
HLB	B-MED
formation	O
was	O
blocked	B-MED
by	O
transcription	B-MED
inhibition	I-MED
,	O
suggesting	O
nascent	B-MED
histone	I-MED
transcripts	I-MED
recruit	O
HLB	B-MED
components	B-MED
like	O
U7	B-MED
snRNP	I-MED
.	O
Surprisingly	O
,	O
we	O
found	O
that	O
U7	O
base	B-MED
-	I-MED
pairing	I-MED
with	O
nascent	B-MED
histone	I-MED
transcripts	I-MED
was	O
not	O
required	O
for	O
localization	B-MED
to	O
HLBs	B-MED
.	O
Rather	O
,	O
the	O
type	O
of	O
Sm	O
ring	O
assembled	O
on	O
U7	O
determined	O
its	O
targeting	O
to	O
HLBs	B-MED
or	O
CBs	B-MED
;	O
the	O
spliceosomal	O
Sm	O
ring	O
targeted	O
snRNAs	B-MED
to	O
CBs	B-MED
while	O
the	O
specialized	O
U7	O
Sm	O
-	O
ring	O
localized	O
to	O
HLBs	B-MED
,	O
demonstrating	O
the	O
contribution	B-MED
of	O
protein	B-MED
constituents	B-MED
to	O
the	O
distinction	O
among	O
nuclear	B-MED
bodies	I-MED
.	O
Thus	O
,	O
nucleolar	B-MED
,	O
HLB	B-MED
,	O
and	O
CB	B-MED
components	B-MED
can	O
mix	O
in	O
early	B-MED
embryogenesis	B-MED
when	O
transcription	B-MED
is	O
naturally	O
or	O
artificially	O
silenced	O
.	O
These	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	B-MED
of	O
specific	B-MED
gene	B-MED
loci	I-MED
nucleates	O
nuclear	B-MED
body	I-MED
components	B-MED
with	O
high	O
specificity	B-MED
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	B-MED
functions	B-MED
.	O
Gain	B-MED
-	I-MED
of	I-MED
-	I-MED
function	I-MED
mutation	I-MED
in	O
SCN5A	B-MED
causes	O
ventricular	B-MED
arrhythmias	I-MED
and	O
early	B-MED
onset	I-MED
atrial	B-MED
fibrillation	I-MED
Mutations	B-MED
in	O
SCN5A	B-MED
,	O
the	O
gene	B-MED
encoding	B-MED
the	O
α	O
-	O
subunit	O
of	O
the	O
cardiac	B-MED
sodium	B-MED
channel	I-MED
(	I-MED
NaV1.5	I-MED
)	I-MED
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	B-MED
of	O
inherited	B-MED
cardiac	B-MED
arrhythmia	I-MED
disorders	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
identify	O
the	O
genetic	B-MED
and	O
functional	B-MED
determinants	I-MED
underlying	O
a	O
Dutch	B-MED
family	B-MED
that	O
presented	O
with	O
a	O
combined	O
phenotype	B-MED
of	O
ventricular	B-MED
arrhythmias	I-MED
with	O
a	O
likely	O
adrenergic	B-MED
component	B-MED
,	O
either	O
in	O
isolation	B-MED
or	O
in	O
combination	B-MED
with	O
a	O
mildly	O
decreased	O
heart	B-MED
function	I-MED
and	O
early	B-MED
onset	I-MED
(	O
<	O
55	O
years	B-MED
)	O
atrial	B-MED
fibrillation	I-MED
.	O
We	O
performed	O
next	O
generation	B-MED
sequencing	B-MED
in	O
the	O
proband	B-MED
of	O
a	O
two-	O
generation	B-MED
Dutch	B-MED
family	B-MED
and	O
demonstrated	O
a	O
novel	O
missense	B-MED
mutation	I-MED
in	O
SCN5A-(p	B-MED
.	I-MED
M1851V	I-MED
)	I-MED
which	O
co	O
-	O
segregated	O
with	O
the	O
clinical	B-MED
phenotype	B-MED
in	O
the	O
family	B-MED
.	O
We	O
functionally	B-MED
evaluated	O
the	O
putative	O
genetic	B-MED
defect	B-MED
by	O
patch	B-MED
clamp	I-MED
electrophysiological	B-MED
studies	I-MED
in	O
human	B-MED
embryonic	I-MED
kidney	B-MED
cells	I-MED
transfected	B-MED
with	O
mutant	B-MED
or	O
wild	B-MED
-	I-MED
type	I-MED
Nav1.5	I-MED
.	O
The	O
current	B-MED
inactivation	B-MED
was	O
slower	O
and	O
recovery	O
from	O
inactivation	B-MED
was	O
faster	O
in	O
SCN5A	B-MED
-	I-MED
M1851V	I-MED
channels	I-MED
.	O
The	O
voltage	B-MED
dependence	B-MED
of	O
inactivation	B-MED
was	O
shifted	O
towards	O
more	O
positive	B-MED
potentials	B-MED
and	O
consequently	O
,	O
a	O
larger	O
TTX	B-MED
-	O
sensitive	B-MED
window	B-MED
current	I-MED
was	O
observed	O
in	O
SCN5A	B-MED
-	I-MED
M1851V	I-MED
channels	I-MED
.	O
Furthermore	O
,	O
a	O
higher	O
upstroke	B-MED
velocity	I-MED
was	O
observed	O
for	O
the	O
SCN5A	B-MED
-	I-MED
M1851V	I-MED
channels	I-MED
,	O
while	O
the	O
depolarization	B-MED
voltage	I-MED
was	O
more	O
negative	B-MED
,	O
both	O
indicating	O
increased	O
excitability	O
.	O
This	O
mutation	B-MED
leads	O
to	O
a	O
gain	B-MED
-	I-MED
of	I-MED
-	I-MED
function	I-MED
mechanism	I-MED
based	O
on	O
increased	O
channel	B-MED
availability	O
and	O
increased	O
window	B-MED
current	I-MED
,	O
fitting	O
the	O
observed	O
clinical	B-MED
phenotype	B-MED
of	O
(	O
likely	O
adrenergic	O
-	O
induced	O
)	O
ventricular	B-MED
arrhythmias	I-MED
and	O
atrial	B-MED
fibrillation	I-MED
.	O
These	O
findings	B-MED
further	O
expand	O
the	O
range	O
of	O
cardiac	B-MED
arrhythmias	I-MED
associated	O
with	O
mutations	B-MED
SCN5A	B-MED
in	O
SCN5A.	O
Assessment	B-MED
the	O
Exposure	B-MED
Level	B-MED
of	O
Rare	B-MED
Earth	I-MED
Elements	I-MED
in	O
Workers	B-MED
Producing	B-MED
Cerium	B-MED
,	O
Lanthanum	B-MED
Oxide	I-MED
Ultrafine	B-MED
and	O
Nanoparticles	B-MED
In	O
order	O
to	O
assess	B-MED
occupational	B-MED
exposure	B-MED
level	B-MED
of	O
15	O
rare	B-MED
earth	I-MED
elements	I-MED
(	O
REEs	B-MED
)	O
and	O
identify	B-MED
the	O
associated	B-MED
influence	B-MED
,	O
we	O
used	O
inductively	B-MED
coupled	I-MED
plasma	I-MED
mass	I-MED
spectrometry	I-MED
(	O
ICP	B-MED
-	I-MED
MS	I-MED
)	O
based	B-MED
on	O
closed	B-MED
-	O
vessel	B-MED
microwave	B-MED
-	O
assisted	B-MED
wet	B-MED
digestion	I-MED
procedure	I-MED
to	O
determinate	B-MED
the	O
concentration	B-MED
of	O
Y	B-MED
,	O
La	B-MED
,	O
Ce	B-MED
,	O
Pr	B-MED
,	O
Nd	B-MED
,	O
Sm	B-MED
,	O
Eu	B-MED
,	O
Gd	B-MED
,	O
Tb	B-MED
,	O
Dy	B-MED
,	O
Ho	B-MED
,	O
Er	B-MED
,	O
Tm	B-MED
,	O
Yb	B-MED
and	O
Lu	B-MED
in	O
urinary	B-MED
samples	I-MED
obtained	B-MED
from	O
workers	B-MED
producing	B-MED
ultrafine	B-MED
and	O
nanoparticles	B-MED
containing	O
cerium	B-MED
and	O
lanthanum	B-MED
oxide	I-MED
.	O
The	O
results	B-MED
suggest	B-MED
that	O
La	B-MED
and	O
Ce	B-MED
were	O
the	O
primary	B-MED
component	B-MED
,	O
together	O
accounting	B-MED
for	O
97	O
%	O
of	O
total	O
REEs	B-MED
in	O
workers	B-MED
.	O
The	O
urinary	B-MED
levels	B-MED
of	O
La	B-MED
,	O
and	O
Ce	B-MED
among	O
the	O
workers	B-MED
(	O
6.36	O
,	O
15.32	O
μg.g(-1	O
)	O
creatinine	B-MED
,	O
respectively	O
)	O
were	O
significantly	B-MED
enriched	B-MED
compared	B-MED
to	O
those	O
levels	B-MED
measured	B-MED
in	O
the	O
control	B-MED
subjects	B-MED
(	O
1.52	O
,	O
4.04	O
μg.g(-1	O
)	O
creatinine	B-MED
,	O
respectively	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
This	O
study	B-MED
simultaneously	B-MED
identified	B-MED
the	O
associated	B-MED
individual	B-MED
factors	B-MED
,	O
the	O
results	B-MED
indicate	B-MED
that	O
the	O
concentrations	B-MED
in	O
over	O
5	O
years	O
group	B-MED
(	O
11.64	O
±	O
10.93	O
for	O
La	B-MED
,	O
27.83	O
±	O
24.38	O
for	O
Ce	B-MED
)	O
were	O
significantly	B-MED
elevated	B-MED
compared	B-MED
to	O
1	O
-	O
5	O
years	O
group	B-MED
(	O
2.58	O
±	O
1.51	O
for	O
La	B-MED
,	O
6.87	O
±	O
3.90	O
for	O
Ce	B-MED
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Compared	B-MED
the	O
urinary	B-MED
levels	B-MED
of	O
La	B-MED
and	O
Ce	B-MED
at	O
the	O
separation	B-MED
and	O
packaging	B-MED
locations	B-MED
(	O
9.10	O
±	O
9.51	O
for	O
La	B-MED
,	O
22.29	O
±	O
21.01	O
for	O
Ce	B-MED
)	O
with	O
the	O
other	O
locations	B-MED
(	O
2.85	O
±	O
0.98	O
for	O
La	B-MED
,	O
6.37	O
±	O
2.12	O
for	O
Ce	B-MED
)	O
,	O
the	O
results	B-MED
show	O
urinary	B-MED
concentrations	B-MED
were	O
significantly	B-MED
higher	B-MED
in	O
workers	B-MED
at	O
separation	B-MED
and	O
packaging	B-MED
locations	B-MED
(	O
p	O
<	O
0.01	O
)	O
.	O
Inter	B-MED
-	O
individual	B-MED
variation	B-MED
in	O
levels	B-MED
of	O
La	B-MED
and	O
Ce	B-MED
in	O
urine	B-MED
is	O
the	O
result	B-MED
of	O
multi	B-MED
-	I-MED
factorial	I-MED
comprehensive	B-MED
action	B-MED
.	O
Further	O
researches	B-MED
should	O
focus	B-MED
on	O
the	O
multiple	B-MED
factors	B-MED
contributing	B-MED
to	O
the	O
REEs	B-MED
levels	B-MED
of	O
the	O
occupationally	B-MED
exposed	B-MED
workers	B-MED
.	O
Orai1	B-MED
-Mediated	O
Antimicrobial	B-MED
Secretion	B-MED
from	O
Pancreatic	B-MED
Acini	I-MED
Shapes	O
the	O
Gut	B-MED
Microbiome	I-MED
and	O
Regulates	B-MED
Gut	B-MED
Innate	B-MED
Immunity	I-MED
The	O
gut	B-MED
microbiome	I-MED
participates	O
in	O
numerous	O
physiologic	B-MED
functions	I-MED
and	O
communicates	B-MED
intimately	O
with	O
the	O
host	B-MED
immune	B-MED
system	I-MED
.	O
Antimicrobial	B-MED
peptides	I-MED
are	O
critica	B-MED
l	O
components	B-MED
of	O
intestinal	B-MED
innate	B-MED
immunity	I-MED
.	O
We	O
report	O
a	O
prominent	B-MED
role	O
for	O
antimicrobials	B-MED
secreted	I-MED
by	O
pancreatic	B-MED
acini	I-MED
in	O
shaping	O
the	O
gut	B-MED
microbiome	I-MED
that	O
is	O
essential	O
for	O
intestinal	B-MED
innate	B-MED
immunity	I-MED
,	O
barrier	B-MED
function	I-MED
,	O
and	O
survival	B-MED
.	O
Deletion	B-MED
of	O
the	O
Ca(2	B-MED
+	I-MED
)	I-MED
channel	I-MED
Orai1	I-MED
in	O
pancreatic	B-MED
acini	I-MED
of	O
adult	O
mice	B-MED
resulted	O
in	O
60%-70	O
%	O
mortality	B-MED
within	O
3	O
weeks	O
.	O
Despite	O
robust	O
activation	B-MED
of	I-MED
the	I-MED
intestinal	I-MED
innate	I-MED
immune	I-MED
response	I-MED
,	O
mice	B-MED
lacking	O
acinar	B-MED
Orai1	B-MED
exhibited	O
intestinal	B-MED
bacterial	B-MED
outgrowth	B-MED
and	O
dysbiosis	B-MED
,	O
ultimately	O
causing	O
systemic	B-MED
translocation	B-MED
,	O
inflammation	B-MED
,	O
and	O
death	B-MED
.	O
While	O
digestive	B-MED
enzyme	I-MED
supplementation	B-MED
was	O
ineffective	B-MED
,	O
treatments	B-MED
constraining	O
bacterial	B-MED
outgrowth	B-MED
(	O
purified	B-MED
liquid	B-MED
diet	I-MED
,	O
broad	B-MED
-	I-MED
spectrum	I-MED
antibiotics	I-MED
)	O
rescued	O
survival	B-MED
,	O
feeding	B-MED
,	O
and	O
weight	B-MED
gain	I-MED
.	O
Pancreatic	B-MED
levels	I-MED
of	O
cathelicidin	B-MED
-related	O
antimicrobial	B-MED
peptide	I-MED
(	O
CRAMP	B-MED
)	O
were	O
reduced	B-MED
,	O
and	O
supplement	B-MED
of	O
synthetic	O
CRAMP	B-MED
prevented	O
intestinal	B-MED
disease	I-MED
.	O
These	O
findings	B-MED
reveal	O
a	O
critical	B-MED
role	O
for	O
antimicrobial	B-MED
pancreatic	B-MED
secretion	I-MED
in	O
gut	B-MED
innate	B-MED
immunity	I-MED
.	O
Genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
mapping	I-MED
in	O
winter	B-MED
barley	I-MED
for	O
grain	B-MED
yield	B-MED
and	O
culm	B-MED
cell	B-MED
wall	I-MED
polymer	B-MED
content	B-MED
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-MED
technique	I-MED
A	O
collection	B-MED
of	O
112	O
winter	B-MED
barley	I-MED
varieties	I-MED
(	O
Hordeum	B-MED
vulgare	I-MED
L.	I-MED
)	O
was	O
grown	B-MED
in	O
the	O
field	B-MED
for	O
two	O
years	B-MED
(	O
2008/09	O
and	O
2009/10	O
)	O
in	O
northern	B-MED
Italy	B-MED
and	O
grain	B-MED
and	O
straw	B-MED
yields	B-MED
recorded	O
.	O
In	O
the	O
first	O
year	B-MED
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	B-MED
yellow	I-MED
mosaic	I-MED
virus	I-MED
(	O
BaYMV	B-MED
)	O
strongly	O
influenced	B-MED
final	O
performances	B-MED
with	O
an	O
average	B-MED
reduction	B-MED
of	O
~	O
50	O
%	O
for	O
grain	B-MED
and	O
straw	B-MED
harvested	B-MED
in	O
comparison	B-MED
to	O
the	O
second	B-MED
year	B-MED
.	O
The	O
genetic	B-MED
determination	I-MED
(	O
GD	B-MED
)	O
for	O
grain	B-MED
yield	B-MED
was	O
0.49	O
and	O
0.70	O
,	O
for	O
the	O
two	O
years	B-MED
respectively	O
,	O
and	O
for	O
straw	B-MED
yield	B-MED
GD	B-MED
was	O
low	O
in	O
2009	O
(	O
0.09	O
)	O
and	O
higher	O
in	O
2010	O
(	O
0.29	O
)	O
.	O
Cell	B-MED
wall	I-MED
polymers	B-MED
in	O
culms	B-MED
culms	B-MED
were	O
quantified	B-MED
by	O
means	O
of	O
the	O
monoclonal	B-MED
antibodies	I-MED
LM6	B-MED
,	O
LM11	B-MED
,	O
JIM13	B-MED
and	O
BS-400	B-MED
-	I-MED
3	I-MED
and	O
the	O
carbohydrate	B-MED
-	I-MED
binding	I-MED
module	I-MED
CBM3a	I-MED
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-MED
technique	I-MED
.	O
Of	O
these	O
,	O
LM6	B-MED
,	O
which	O
detects	B-MED
arabinan	B-MED
components	B-MED
,	O
showed	O
a	O
relatively	O
high	O
GD	B-MED
in	O
both	O
years	B-MED
and	O
a	O
significantly	B-MED
negative	B-MED
correlation	B-MED
with	O
grain	B-MED
yield	B-MED
(	O
GYLD	B-MED
)	O
.	O
Overall	O
,	O
heritability	B-MED
(	O
H2	B-MED
)	O
was	O
calculated	B-MED
for	O
GYLD	B-MED
,	O
LM6	B-MED
and	O
JIM	B-MED
and	O
resulted	O
to	O
be	O
0.42	O
,	O
0.32	O
and	O
0.20	O
,	O
respectively	O
.	O
A	O
total	B-MED
of	O
4,976	O
SNPs	B-MED
from	O
the	O
9	O
K	O
iSelect	O
array	O
were	O
used	O
in	O
the	O
study	B-MED
for	O
the	O
analysis	O
of	O
population	B-MED
structure	I-MED
,	O
linkage	B-MED
disequilibrium	I-MED
(	O
LD	B-MED
)	O
and	O
genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
study	I-MED
(	O
GWAS	B-MED
)	O
.	O
Marker	B-MED
-	I-MED
trait	I-MED
associations	I-MED
(	O
MTA	B-MED
)	O
were	O
analyzed	O
for	O
grain	B-MED
yield	B-MED
and	O
cell	B-MED
wall	I-MED
determination	O
by	O
LM6	B-MED
and	O
JIM13	B-MED
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	B-MED
correlations	B-MED
between	O
the	O
years	B-MED
.	O
A	O
single	B-MED
QTL	I-MED
for	O
GYLD	B-MED
containing	O
three	O
MTAs	B-MED
was	O
found	O
on	O
chromosome	B-MED
3H	I-MED
located	O
close	O
to	O
the	O
Hv	B-MED
-	I-MED
eIF4E	I-MED
gene	I-MED
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	B-MED
to	O
BaYMV	B-MED
.	O
Subsequently	O
the	O
QTL	B-MED
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	B-MED
,	O
a	O
locus	B-MED
for	O
resistance	B-MED
to	O
the	O
virus	B-MED
.	O
GWAs	B-MED
on	O
arabinans	B-MED
quantified	B-MED
by	O
LM6	B-MED
resulted	O
in	O
the	O
identification	B-MED
of	O
major	B-MED
QTLs	B-MED
closely	O
located	O
on	O
3H	B-MED
and	O
hypotheses	O
regarding	O
putative	B-MED
candidate	I-MED
genes	I-MED
were	O
formulated	O
through	O
the	O
study	B-MED
of	O
gene	B-MED
expression	I-MED
levels	B-MED
based	O
on	O
bioinformatics	B-MED
tools	O
.	O
Extracellular	B-MED
Potassium	B-MED
and	O
Seizures	B-MED
:	O
Excitation	B-MED
,	O
Inhibition	B-MED
and	O
the	O
Role	O
of	O
Ih	B-MED
Seizure	B-MED
activity	I-MED
leads	O
to	O
increases	O
in	O
extracellular	B-MED
potassium	B-MED
concentration	B-MED
(	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
)	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-MED
passive	B-MED
and	O
active	B-MED
membrane	B-MED
properties	O
as	O
well	O
as	O
in	O
population	B-MED
activities	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
examined	O
how	O
extracellular	B-MED
potassium	B-MED
modulates	O
seizure	B-MED
activities	I-MED
using	O
an	O
acute	O
4	B-MED
-	I-MED
AP	I-MED
induced	O
seizure	B-MED
model	B-MED
in	O
the	O
neocortex	B-MED
,	O
both	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
.	O
Moderately	O
elevated	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
up	O
to	O
9[Formula	O
:	O
see	O
text]mM	O
prolonged	B-MED
seizure	B-MED
durations	B-MED
and	O
shortened	B-MED
interictal	I-MED
intervals	I-MED
as	O
well	O
as	O
depolarized	B-MED
the	O
neuronal	B-MED
resting	B-MED
membrane	I-MED
potential	I-MED
(	O
RMP	B-MED
)	O
.	O
However	O
,	O
when	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
reached	O
higher	O
than	O
9[Formula	O
:	O
see	O
text]mM	O
,	O
seizure	B-MED
like	I-MED
events	I-MED
(	O
SLEs	B-MED
)	O
were	O
blocked	B-MED
and	O
neurons	B-MED
went	O
into	O
a	O
depolarization	B-MED
-	O
blocked	B-MED
state	O
.	O
Spreading	B-MED
depression	B-MED
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-MED
events	I-MED
could	O
be	O
reversed	O
within	O
1	O
-	O
2[Formula	O
:	O
see	O
text]min	O
after	O
the	O
raised	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O
This	O
concentration	B-MED
-dependent	O
dual	O
effect	O
of	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
was	O
observed	O
using	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
mouse	B-MED
brain	I-MED
preparations	I-MED
as	O
well	O
as	O
in	O
human	B-MED
neocortical	B-MED
tissue	B-MED
resected	O
during	O
epilepsy	B-MED
surgery	B-MED
.	O
Blocking	B-MED
the	O
Ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization	B-MED
-	I-MED
activated	I-MED
cyclic	I-MED
nucleotide	I-MED
-	I-MED
gated	I-MED
(	I-MED
HCN	I-MED
)	I-MED
channels	I-MED
,	O
modulated	O
the	O
elevated	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
influence	B-MED
on	O
SLEs	B-MED
by	O
promoting	O
the	O
high	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
inhibitory	B-MED
actions	I-MED
.	O
These	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
[	O
K	B-MED
[	O
Formula	O
:	O
see	O
text]]o	O
on	O
neuronal	B-MED
excitability	B-MED
and	O
seizure	B-MED
activity	I-MED
.	O
Medication	B-MED
Intervention	I-MED
for	O
Chronic	B-MED
Kidney	I-MED
Disease	I-MED
Patients	B-MED
Transitioning	B-MED
from	O
Hospital	B-MED
to	O
Home	B-MED
:	O
Study	B-MED
Design	I-MED
and	O
Baseline	B-MED
Characteristics	B-MED
The	O
hospital	B-MED
readmission	I-MED
rate	B-MED
in	O
the	O
population	B-MED
with	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	B-MED
are	O
urgently	O
needed	B-MED
.	O
The	O
CKD	B-MED
-	O
Medication	B-MED
Intervention	I-MED
Trial	I-MED
(	O
CKD	B-MED
-	O
MIT	B-MED
;	O
www.clinicaltrials.gov	B-MED
;	I-MED
NCTO1459770	I-MED
)	O
is	O
a	O
single	B-MED
-	I-MED
blind	I-MED
(	O
investigators	B-MED
)	O
,	O
randomized	B-MED
,	O
clinical	B-MED
trial	I-MED
conducted	O
at	O
Providence	B-MED
Health	I-MED
Care	I-MED
in	O
Spokane	B-MED
,	I-MED
Washington	I-MED
.	O
Study	B-MED
participants	I-MED
are	O
hospitalized	B-MED
patients	I-MED
with	O
CKD	B-MED
stages	B-MED
3	O
-	O
5	O
(	O
not	O
treated	B-MED
with	I-MED
kidney	B-MED
replacement	I-MED
therapy	I-MED
)	O
and	O
acute	B-MED
illness	I-MED
.	O
The	O
study	B-MED
intervention	I-MED
is	O
a	O
pharmacist	B-MED
-	I-MED
led	I-MED
,	O
home	B-MED
-	I-MED
based	I-MED
,	O
medication	B-MED
management	I-MED
intervention	B-MED
delivered	B-MED
within	O
7	O
days	B-MED
after	O
hospital	B-MED
discharge	I-MED
.	O
The	O
primary	B-MED
outcome	I-MED
is	O
a	O
composite	O
of	O
hospital	B-MED
readmissions	I-MED
and	O
visits	O
to	O
emergency	B-MED
departments	I-MED
and	O
urgent	B-MED
care	I-MED
centers	I-MED
for	O
90	O
days	B-MED
following	O
hospital	B-MED
discharge	I-MED
.	O
Secondary	B-MED
outcomes	I-MED
are	O
achievements	B-MED
of	O
guideline	B-MED
-	I-MED
based	I-MED
targets	B-MED
for	O
CKD	B-MED
risk	B-MED
factors	I-MED
and	O
complications	B-MED
.	O
Enrollment	B-MED
began	O
in	O
February	B-MED
2012	O
and	O
ended	O
in	O
May	B-MED
2015	O
.	O
At	O
baseline	B-MED
,	O
the	O
age	B-MED
of	O
participants	B-MED
was	O
69	O
±	O
11	O
years	B-MED
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	B-MED
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	B-MED
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	B-MED
.	O
At	O
baseline	B-MED
,	O
the	O
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	B-MED
was	O
41	O
±	O
14	O
ml	O
/	O
min/1.73	O
m2	O
and	O
urine	B-MED
albumin	I-MED
-	I-MED
to	I-MED
-	I-MED
creatinine	I-MED
ratio	I-MED
was	O
43	O
mg	O
/	O
g	O
(	O
interquartile	B-MED
range	I-MED
8	O
-	O
528	O
mg	O
/	O
g	O
)	O
.	O
The	O
most	O
frequent	O
diagnosis	B-MED
category	I-MED
for	O
the	O
index	O
hospital	B-MED
admission	I-MED
was	O
cardiovascular	B-MED
diseases	I-MED
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	B-MED
diagnosis	I-MED
for	O
admission	B-MED
was	O
community	B-MED
-	I-MED
acquired	I-MED
acute	B-MED
kidney	I-MED
injury	I-MED
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O
Participants	B-MED
in	O
CKD	B-MED
-	O
MIT	B-MED
are	O
typical	O
of	O
acutely	B-MED
ill	I-MED
hospitalized	B-MED
patients	I-MED
with	O
CKD	B-MED
.	O
A	O
medication	B-MED
management	I-MED
intervention	B-MED
after	O
hospital	B-MED
discharge	I-MED
is	O
under	O
study	B-MED
to	O
reduce	B-MED
post	B-MED
-	O
hospitalization	B-MED
acute	B-MED
care	I-MED
utilization	B-MED
and	O
to	O
improve	O
CKD	B-MED
management	B-MED
.	O
Form	B-MED
and	O
function	B-MED
in	O
gene	B-MED
regulatory	I-MED
networks	I-MED
:	O
the	O
structure	B-MED
of	O
network	B-MED
motifs	I-MED
determines	O
fundamental	B-MED
properties	I-MED
of	O
their	O
dynamical	B-MED
state	I-MED
space	I-MED
Network	B-MED
motifs	I-MED
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	B-MED
,	O
such	O
as	O
the	O
feed	B-MED
-	I-MED
forward	I-MED
loop	I-MED
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	B-MED
networks	I-MED
.	O
Recent	B-MED
studies	B-MED
have	O
used	O
Boolean	B-MED
network	B-MED
motifs	B-MED
to	O
explore	O
the	O
link	O
between	O
form	B-MED
and	O
function	B-MED
in	O
gene	B-MED
regulatory	I-MED
networks	I-MED
and	O
have	O
found	O
that	O
the	O
structure	B-MED
of	O
a	O
motif	B-MED
does	O
not	O
strongly	O
determine	O
its	O
function	B-MED
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	B-MED
expression	I-MED
patterns	B-MED
the	O
motif	B-MED
can	O
produce	O
.	O
Here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	B-MED
-	O
level	B-MED
definition	B-MED
of	O
the	O
'	O
function	B-MED
'	O
of	O
a	O
motif	B-MED
,	O
in	O
terms	O
of	O
two	O
fundamental	B-MED
properties	I-MED
of	O
its	O
dynamical	B-MED
state	I-MED
space	I-MED
as	O
a	O
Boolean	B-MED
network	B-MED
.	O
One	O
is	O
the	O
basin	B-MED
entropy	I-MED
,	O
which	O
is	O
a	O
complexity	B-MED
measure	B-MED
of	O
the	O
dynamics	B-MED
of	O
Boolean	B-MED
networks	B-MED
.	O
The	O
other	O
is	O
the	O
diversity	B-MED
of	O
cyclic	B-MED
attractor	I-MED
lengths	I-MED
that	O
a	O
given	O
motif	B-MED
can	O
produce	O
.	O
Using	O
these	O
two	O
measures	B-MED
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three	B-MED
-	I-MED
node	I-MED
motifs	B-MED
and	O
show	O
that	O
the	O
structural	B-MED
properties	B-MED
of	O
a	O
motif	B-MED
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	B-MED
loops	I-MED
and	O
feed	B-MED
-	I-MED
forward	I-MED
loops	I-MED
,	O
predict	O
fundamental	B-MED
characteristics	I-MED
of	O
its	O
dynamical	B-MED
state	I-MED
space	I-MED
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	B-MED
versatility	I-MED
.	O
We	O
also	O
show	O
that	O
these	O
higher	B-MED
-	O
level	B-MED
properties	B-MED
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	B-MED
networks	I-MED
,	O
as	O
both	O
basin	B-MED
entropy	I-MED
and	O
cycle	B-MED
length	I-MED
diversity	B-MED
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	B-MED
,	O
in	O
neural	B-MED
and	O
genetic	B-MED
regulatory	I-MED
networks	I-MED
,	O
of	O
the	O
13	O
connected	O
motifs	B-MED
without	O
self	B-MED
-	I-MED
interactions	I-MED
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
literature	B-MED
.	O
A	O
comparison	B-MED
of	O
two	O
comorbidity	B-MED
indices	I-MED
for	O
predicting	B-MED
inpatient	B-MED
rehabilitation	B-MED
outcomes	B-MED
Comorbid	B-MED
conditions	I-MED
are	O
important	O
in	O
health	B-MED
care	I-MED
.	O
The	O
best	O
comorbidity	B-MED
index	I-MED
for	O
predicting	B-MED
the	O
impact	B-MED
of	O
comorbidities	B-MED
on	O
rehabilitation	B-MED
outcomes	B-MED
has	O
not	O
been	O
determined	B-MED
.	O
Compare	B-MED
the	O
associations	B-MED
of	O
comorbidity	B-MED
measured	B-MED
using	O
the	O
Charlson	B-MED
Comorbidity	I-MED
Index	I-MED
(	O
CCI	B-MED
)	O
and	O
the	O
Cumulative	B-MED
Index	I-MED
Rating	I-MED
Scale	I-MED
(	O
CIRS	B-MED
)	O
with	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
Aim	O
was	O
to	O
determine	B-MED
whether	O
either	O
of	O
these	O
comorbidity	B-MED
indices	I-MED
helped	O
explain	O
the	O
variation	B-MED
in	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
Prospective	B-MED
open	I-MED
-	I-MED
cohort	I-MED
study	I-MED
.	O
Inpatient	B-MED
rehabilitation	B-MED
ward	B-MED
,	O
Melbourne	B-MED
,	O
Australia	B-MED
.	O
Adults	B-MED
admitted	B-MED
for	O
inpatient	B-MED
rehabilitation	B-MED
(	O
n=280	O
)	O
.	O
The	O
main	O
outcomes	B-MED
were	O
demographic	B-MED
(	O
e.g.	O
age	B-MED
,	O
gender	B-MED
,	O
discharge	B-MED
destination	B-MED
)	O
and	O
clinical	B-MED
outcomes	B-MED
(	O
reason	B-MED
for	O
rehabilitation	B-MED
,	O
length	B-MED
of	I-MED
stay	I-MED
,	O
Functional	B-MED
Independence	I-MED
Measure	I-MED
,	O
CCI	B-MED
and	O
CIRS	B-MED
)	O
.	O
A	O
series	O
of	O
regression	B-MED
analyses	I-MED
were	O
performed	B-MED
to	O
determine	B-MED
the	O
influence	B-MED
of	O
comorbidity	B-MED
on	O
three	O
dependent	B-MED
variables	I-MED
:	O
LOS	B-MED
in	O
rehabilitation	B-MED
;	O
2	O
)	O
the	O
change	B-MED
in	O
Functional	B-MED
Independence	I-MED
Measure	I-MED
-	I-MED
motor	I-MED
score	B-MED
between	O
rehabilitation	B-MED
discharge	B-MED
and	O
admission	B-MED
;	O
and	O
3	O
)	O
the	O
discharge	B-MED
destination	B-MED
(	O
home	B-MED
vs	O
other	O
)	O
.	O
The	O
mean	B-MED
age	B-MED
was	O
57.7	O
years	B-MED
,	O
there	O
were	O
slightly	O
more	O
females	B-MED
(	O
51	O
%	O
)	O
,	O
most	O
(	O
95	O
%	O
)	O
patients	B-MED
previously	B-MED
lived	B-MED
at	I-MED
home	I-MED
with	O
family	B-MED
or	O
other	O
relatives	B-MED
(	O
63	O
%	O
)	O
.	O
The	O
most	O
common	O
reason	B-MED
for	O
rehabilitation	B-MED
was	O
orthopaedic	B-MED
or	O
other	O
conditions	B-MED
(	O
52	O
%	O
)	O
and	O
most	O
(	O
80	O
%	O
)	O
people	B-MED
were	O
discharged	B-MED
home	B-MED
.	O
The	O
median	O
LOS	B-MED
was	O
27	O
days	B-MED
.	O
There	O
were	O
100	O
(	O
35.7	O
%	O
)	O
patients	B-MED
who	O
had	O
no	O
comorbidity	B-MED
recorded	B-MED
using	O
the	O
CCI	B-MED
,	O
112	O
(	O
40.0	O
%	O
)	O
and	O
26	O
(	O
9.3	O
%	O
)	O
who	O
three	O
or	O
more	O
.	O
All	O
patients	B-MED
had	O
at	O
least	O
one	O
comorbidity	B-MED
recorded	B-MED
with	O
the	O
CIRS	B-MED
,	O
and	O
264	O
(	O
94.3	O
%	O
)	O
had	O
3	O
or	O
more	O
comorbidities	B-MED
.	O
There	O
was	O
little	O
or	O
no	O
difference	B-MED
between	O
the	O
CCI	B-MED
or	O
CIRS	B-MED
in	O
terms	O
of	O
their	O
ability	B-MED
to	O
explain	O
the	O
variance	B-MED
in	O
LOS	B-MED
(	O
adjusted	O
R2	B-MED
=	O
0.38	O
with	O
and	O
without	O
comorbidities	B-MED
)	O
,	O
change	B-MED
in	O
disability	B-MED
during	O
rehabilitation	B-MED
(	O
adjusted	O
R2	B-MED
=	O
0.31	O
-	O
0.33	O
with	O
and	O
without	O
comorbidities	B-MED
)	O
or	O
the	O
discharge	B-MED
destination	B-MED
(	O
AUC=0.72	O
without	O
comorbidities	B-MED
;	O
0.73	O
-	O
0.74	O
with	O
comorbidities	B-MED
)	O
beyond	O
that	O
accounted	O
for	O
by	O
demographic	B-MED
and	O
clinical	B-MED
information	I-MED
.	O
Neither	O
the	O
CIRS	B-MED
nor	O
the	O
CCI	B-MED
in	O
our	O
patient	B-MED
sample	B-MED
provide	B-MED
additional	O
information	B-MED
that	O
explains	O
the	O
impact	B-MED
of	O
comorbidities	B-MED
on	O
key	O
rehabilitation	B-MED
outcomes	B-MED
.	O
Further	O
research	B-MED
is	O
needed	O
to	O
determine	B-MED
the	O
most	O
appropriate	B-MED
measure	B-MED
of	O
comorbidity	B-MED
of	O
relevance	B-MED
to	O
inpatient	B-MED
rehabilitation	B-MED
outcomes	B-MED
.	O
Loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
in	O
rats	B-MED
depends	O
on	O
individual	B-MED
vulnerability	B-MED
and	O
duration	O
of	O
alcohol	B-MED
consumption	I-MED
experience	O
Alcohol	B-MED
use	I-MED
disorder	I-MED
(	O
AUD	B-MED
)	O
is	O
characterized	O
by	O
excessive	B-MED
alcohol	I-MED
use	I-MED
and	O
persistent	B-MED
alcohol	B-MED
seeking	I-MED
despite	O
knowledge	O
of	O
its	O
negative	O
consequences	O
.	O
Importantly	O
,	O
AUD	B-MED
typically	O
develops	O
after	O
chronic	B-MED
excessive	B-MED
alcohol	I-MED
use	I-MED
in	O
a	O
subgroup	B-MED
of	O
individuals	B-MED
who	O
drink	B-MED
alcohol	I-MED
,	O
suggesting	O
that	O
AUD	B-MED
results	O
from	O
an	O
interaction	B-MED
between	O
individual	B-MED
vulnerability	B-MED
and	O
prolonged	B-MED
alcohol	I-MED
exposure	I-MED
.	O
The	O
present	O
study	B-MED
assessed	B-MED
the	O
contribution	O
of	O
prolonged	B-MED
exposure	I-MED
to	I-MED
alcohol	I-MED
and	O
individual	B-MED
levels	I-MED
of	I-MED
alcohol	I-MED
intake	I-MED
to	O
the	O
development	B-MED
of	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
in	O
a	O
conditioned	B-MED
suppression	I-MED
model	I-MED
.	O
To	O
investigate	B-MED
the	O
impact	O
of	O
prolonged	B-MED
alcohol	I-MED
exposure	I-MED
,	O
conditioned	B-MED
suppression	I-MED
of	O
alcohol	B-MED
seeking	I-MED
was	O
assessed	B-MED
after	O
2	O
and	O
4	O
months	O
of	O
intermittent	B-MED
alcohol	I-MED
access	I-MED
(	O
IAA	B-MED
)	O
in	O
a	O
subgroup	B-MED
of	O
rats	B-MED
drinking	O
moderate	O
amounts	O
of	O
alcohol	O
.	O
We	O
observed	O
that	O
suppression	B-MED
of	O
alcohol	B-MED
seeking	I-MED
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
IAA	B-MED
.	O
The	O
influence	B-MED
of	O
individual	O
levels	O
of	O
alcohol	B-MED
intake	I-MED
on	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
was	O
subsequently	O
determined	B-MED
by	I-MED
assessing	B-MED
conditioned	B-MED
suppression	I-MED
in	O
subgroups	B-MED
of	O
low	B-MED
and	I-MED
high	I-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
.	O
Unlike	O
the	O
low	B-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
,	O
the	O
high	B-MED
alcohol	I-MED
drinking	I-MED
rats	B-MED
showed	O
aversion	B-MED
-	I-MED
resistant	I-MED
alcohol	B-MED
seeking	I-MED
after	O
2	O
months	O
of	O
IAA	B-MED
,	O
although	O
both	O
groups	B-MED
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing	O
.	O
These	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss	B-MED
of	I-MED
control	I-MED
over	O
alcohol	B-MED
seeking	I-MED
,	O
a	O
key	O
characteristic	O
of	O
AUD	B-MED
in	O
humans	B-MED
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol	B-MED
exposure	I-MED
and	O
the	O
individual	B-MED
's	I-MED
propensity	O
to	O
consume	O
alcohol	O
.	O
Identification	O
of	O
protective	O
B	B-MED
-	I-MED
cell	I-MED
epitopes	I-MED
within	O
the	O
novel	O
malaria	B-MED
vaccine	I-MED
candidate	O
P.	B-MED
falciparum	I-MED
Schizont	I-MED
Egress	I-MED
Antigen-1	I-MED
Naturally	B-MED
-acquired	O
antibodies	B-MED
to	O
PfSEA-1A	B-MED
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-MED
in	O
children	B-MED
.	O
Vaccination	B-MED
of	O
mice	B-MED
with	O
PbSEA-1A	B-MED
decreases	O
parasitemia	B-MED
and	O
prolongs	O
survival	O
following	O
Plasmodium	B-MED
berghei	I-MED
ANKA	I-MED
challenge	O
.	O
To	O
enhance	O
the	O
immunogenicity	B-MED
of	O
PfSEA-1A	B-MED
,	O
we	O
identified	O
five	O
linear	O
,	O
B	B-MED
-	I-MED
cell	I-MED
epitopes	I-MED
using	O
peptide	B-MED
microarrays	B-MED
probed	O
with	O
anti	B-MED
-	I-MED
sera	I-MED
from	O
rPfSEA-1A	B-MED
-	O
vaccinated	B-MED
non	O
-	O
human	O
primates	B-MED
.	O
We	O
evaluated	B-MED
the	O
relationship	O
between	O
epitope	B-MED
-specific	O
antibody	B-MED
levels	O
and	O
protection	O
from	O
parasitemia	B-MED
in	O
a	O
longitudinal	O
treatment	B-MED
-	O
reinfection	B-MED
cohort	B-MED
in	O
Western	B-MED
Kenya	I-MED
.	O
Antibodies	B-MED
to	O
three	O
epitopes	B-MED
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	B-MED
over	O
an	O
18-	O
week	B-MED
high	O
transmission	B-MED
season	O
.	O
We	O
are	O
currently	O
designing	O
immunogens	B-MED
to	O
enhance	O
antibody	B-MED
responses	I-MED
to	O
these	O
three	O
epitopes	B-MED
.	O
A	O
single	B-MED
session	I-MED
of	O
exhaustive	B-MED
exercise	I-MED
markedly	O
decreases	B-MED
circulating	B-MED
levels	O
of	O
guanidinoacetic	B-MED
acid	I-MED
in	O
healthy	B-MED
men	B-MED
and	O
women	B-MED
We	O
evaluated	B-MED
the	O
effects	B-MED
of	I-MED
exercise	B-MED
on	O
circulating	B-MED
concentrations	B-MED
of	O
guanidinoacetic	B-MED
acid	I-MED
(	O
GAA	B-MED
)	O
and	O
creatine	B-MED
in	O
23	O
healthy	B-MED
volunteers	I-MED
subjected	O
to	O
running	B-MED
to	O
exhaustion	B-MED
and	O
free	B-MED
-	I-MED
weight	I-MED
bench	I-MED
-	I-MED
press	I-MED
to	O
volitional	B-MED
failure	I-MED
.	O
Blood	B-MED
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	B-MED
session	B-MED
.	O
Running	B-MED
induced	B-MED
a	O
significant	O
decrease	B-MED
in	O
serum	B-MED
GAA	B-MED
by	O
20.1	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
free	B-MED
-	I-MED
weight	I-MED
exercise	I-MED
reduced	B-MED
GAA	B-MED
by	O
11.7	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	B-MED
GAA	B-MED
as	O
a	O
novel	O
biomarker	B-MED
of	O
exhaustion	B-MED
.	O
Risk	B-MED
Factors	I-MED
of	O
Neurological	B-MED
Deterioration	I-MED
in	O
Patients	B-MED
with	O
Cerebral	B-MED
Infarction	I-MED
due	O
to	O
Large	B-MED
-	I-MED
Artery	I-MED
Atherosclerosis	I-MED
In	O
some	O
patients	B-MED
with	O
acute	B-MED
ischemic	B-MED
stroke	I-MED
,	O
neurological	B-MED
deterioration	I-MED
(	O
ND	B-MED
)	O
is	O
observed	B-MED
,	O
and	O
it	O
is	O
difficult	B-MED
to	O
predict	B-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
.	O
Especially	O
in	O
some	O
patients	B-MED
with	O
large	B-MED
-	I-MED
artery	I-MED
atherosclerosis	I-MED
(	O
LAA	B-MED
)	O
,	O
aggressive	B-MED
medical	B-MED
treatments	I-MED
and	O
surgical	B-MED
interventions	I-MED
might	O
be	O
helpful	B-MED
to	O
prevent	O
ND	B-MED
.	O
Therefore	O
,	O
we	O
investigated	B-MED
factors	B-MED
associated	B-MED
with	I-MED
ND	B-MED
in	O
patients	B-MED
with	O
LAA	B-MED
.	O
We	O
studied	B-MED
patients	B-MED
with	O
LAA	B-MED
who	O
were	O
admitted	B-MED
to	I-MED
our	I-MED
hospital	I-MED
.	O
We	O
divided	B-MED
them	O
into	O
2	O
groups	B-MED
with	O
(	O
group	B-MED
1	O
)	O
and	O
without	O
deterioration	B-MED
(	O
group	B-MED
2	O
)	O
,	O
and	O
evaluated	B-MED
their	O
medical	B-MED
records	I-MED
,	O
risk	B-MED
factors	I-MED
,	O
and	O
radiological	B-MED
findings	B-MED
,	O
such	O
as	O
number	O
of	O
diffusion	B-MED
-	O
positive	B-MED
lesion	B-MED
and	O
degree	B-MED
of	I-MED
stenosis	I-MED
.	O
Our	O
study	B-MED
population	I-MED
consisted	O
of	O
171	O
patients	B-MED
;	O
71	O
(	O
41.5	O
%	O
)	O
did	O
and	O
100	O
(	O
58.5	O
%	O
)	O
did	O
not	O
suffer	B-MED
deterioration	B-MED
.	O
By	O
univariate	B-MED
analysis	I-MED
,	O
blood	B-MED
pressure	I-MED
(	O
BP	B-MED
)	O
,	O
heart	B-MED
rate	I-MED
,	O
National	B-MED
Institutes	I-MED
of	I-MED
Health	I-MED
Stroke	I-MED
Scale	I-MED
(	I-MED
NIHSS	I-MED
)	I-MED
score	I-MED
,	O
number	O
of	O
diffusion	B-MED
-	O
positive	B-MED
lesion	B-MED
,	O
count	B-MED
of	I-MED
red	I-MED
blood	I-MED
cell	I-MED
,	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
,	O
and	O
degree	B-MED
of	I-MED
stenosis	I-MED
differed	O
significantly	B-MED
between	O
the	O
2	O
groups	B-MED
.	O
By	O
multivariate	B-MED
analysis	I-MED
,	O
systolic	B-MED
BP	I-MED
(	O
≥170	O
mm	O
Hg	O
,	O
odds	B-MED
ratio	I-MED
:	O
7.20	O
,	O
P	O
<	O
.001	O
)	O
was	O
associated	B-MED
with	I-MED
ND	B-MED
.	O
Furthermore	O
,	O
number	O
of	O
diffusion	B-MED
-	I-MED
weighted	I-MED
image	I-MED
DWI	B-MED
(	O
DWI)-	O
positive	B-MED
lesion	B-MED
(	O
≥8	O
)	O
,	O
degree	B-MED
of	I-MED
stenosis	I-MED
(	O
>	O
80.0	O
%	O
)	O
,	O
and	O
NIHSS	B-MED
score	I-MED
(	O
≥4	O
)	O
were	O
also	O
independent	B-MED
factors	B-MED
associated	B-MED
with	I-MED
ND	B-MED
.	O
High	B-MED
BP	I-MED
,	O
severity	B-MED
of	O
neurological	B-MED
deficit	I-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
,	O
and	O
radiological	B-MED
findings	B-MED
,	O
such	O
as	O
degree	B-MED
of	I-MED
stenosis	I-MED
and	O
number	O
of	O
DWI	B-MED
-	O
positive	B-MED
lesion	B-MED
,	O
are	O
independently	B-MED
associated	B-MED
with	I-MED
ND	B-MED
in	O
patients	B-MED
with	O
LAA	B-MED
.	O
A	O
Recombinant	B-MED
Human	B-MED
Anti	B-MED
-	I-MED
Platelet	I-MED
scFv	I-MED
Antibody	I-MED
scFv	B-MED
Produced	O
in	O
Pichia	B-MED
pastoris	I-MED
for	O
Atheroma	B-MED
Targeting	O
Cells	B-MED
of	O
the	O
innate	O
and	O
adaptive	O
immune	B-MED
system	I-MED
are	O
key	O
factors	O
in	O
the	O
progression	B-MED
of	O
atherosclerotic	B-MED
plaque	I-MED
,	O
leading	O
to	O
plaque	B-MED
instability	B-MED
and	O
rupture	B-MED
,	O
potentially	O
resulting	O
in	O
acute	B-MED
atherothrombotic	B-MED
events	O
such	O
as	O
coronary	B-MED
artery	I-MED
disease	I-MED
,	O
cerebrovascular	B-MED
disease	I-MED
and	O
peripheral	B-MED
arterial	I-MED
disease	I-MED
.	O
Here	O
,	O
we	O
describe	O
the	O
cloning	B-MED
,	O
expression	B-MED
,	O
purification	B-MED
,	O
and	O
immunoreactivity	B-MED
assessment	B-MED
of	O
a	O
recombinant	B-MED
single	B-MED
-	I-MED
chain	I-MED
variable	I-MED
fragment	I-MED
(	O
scFv	B-MED
)	O
derived	O
from	O
a	O
human	B-MED
anti	B-MED
-	I-MED
αIIbβ3	I-MED
antibody	I-MED
(	O
HuAb	B-MED
)	O
selected	O
to	O
target	O
atheromatous	B-MED
lesions	B-MED
for	O
the	O
presence	B-MED
of	O
platelets	B-MED
.	O
Indeed	O
,	O
platelets	B-MED
within	O
atheroma	B-MED
plaques	I-MED
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	B-MED
,	O
in	O
platelet	B-MED
-	O
leucocyte	B-MED
aggregates	B-MED
and	O
in	O
thrombi	B-MED
formation	B-MED
and	O
might	O
thus	O
be	O
considered	O
relevant	B-MED
biomarkers	B-MED
of	O
atherosclerotic	B-MED
progression	B-MED
.	O
The	O
DNA	B-MED
sequence	I-MED
that	O
encodes	B-MED
the	O
anti	B-MED
-	I-MED
αIIbβ3	I-MED
TEG4	I-MED
scFv	I-MED
previously	O
obtained	O
from	O
a	O
phage	B-MED
-	I-MED
display	I-MED
selection	I-MED
on	O
activated	B-MED
platelets	B-MED
,	O
was	O
inserted	B-MED
into	O
the	O
eukaryote	B-MED
vector	B-MED
(	O
pPICZαA	B-MED
)	O
in	O
fusion	O
with	O
a	O
tag	B-MED
sequence	I-MED
encoding	B-MED
2	O
cysteines	B-MED
useable	O
for	O
specific	B-MED
probes	O
grafting	B-MED
experiments	I-MED
.	O
The	O
recombinant	B-MED
protein	I-MED
was	O
expressed	B-MED
at	O
high	B-MED
yields	O
in	O
Pichia	B-MED
pastoris	I-MED
(	O
30	O
mg	O
/	O
L	O
culture	B-MED
)	O
.	O
The	O
advantage	O
of	O
P.	B-MED
pastoris	I-MED
as	O
an	O
expression	B-MED
system	B-MED
is	O
the	O
production	O
and	O
secretion	B-MED
of	O
recombinant	B-MED
proteins	I-MED
in	O
the	O
supernatant	B-MED
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	B-MED
are	O
produced	O
in	O
the	O
cytoplasm	B-MED
of	O
bacteria	B-MED
(	O
low	B-MED
yield	B-MED
,	O
low	B-MED
solubility	B-MED
and	O
reduced	B-MED
affinity	B-MED
)	O
.	O
The	O
improved	B-MED
conditions	O
allowed	O
for	O
the	O
recovery	B-MED
of	O
highly	B-MED
purified	B-MED
and	O
biologically	B-MED
active	I-MED
scFv	I-MED
fragments	I-MED
scFv	B-MED
ready	O
to	O
be	O
grafted	B-MED
in	O
a	O
site	B-MED
-directed	O
way	O
to	O
nanoparticles	B-MED
for	O
the	O
imaging	B-MED
of	O
atherosclerotic	B-MED
plaques	I-MED
involving	O
inflammatory	B-MED
processes	B-MED
and	O
thus	O
at	O
high	B-MED
risk	I-MED
of	I-MED
instability	B-MED
.	O
Novel	O
insights	O
into	O
development	O
of	O
diabetic	B-MED
bladder	B-MED
disorder	I-MED
provided	O
by	O
metabolomic	B-MED
analysis	I-MED
of	O
the	O
rat	B-MED
nondiabetic	O
and	O
diabetic	B-MED
detrusor	B-MED
and	O
urothelial	B-MED
layer	I-MED
There	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	B-MED
in	O
bladder	B-MED
metabolism	B-MED
resulting	O
from	O
diabetes	B-MED
.	O
Such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-MED
bladder	B-MED
disorder	I-MED
(	I-MED
DBD	I-MED
)	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	B-MED
of	O
detrusor	B-MED
and	O
urothelial	B-MED
layer	I-MED
in	O
a	O
1	O
-	O
mo	O
streptozotocin	B-MED
-induced	O
rat	B-MED
model	B-MED
of	O
type	B-MED
1	I-MED
diabetes	I-MED
with	O
nondiabetic	B-MED
controls	I-MED
.	O
Our	O
studies	O
revealed	O
that	O
diabetes	B-MED
caused	O
both	O
common	O
and	O
differential	O
changes	B-MED
in	O
the	O
detrusor	B-MED
and	O
urothelial	B-MED
layer	I-MED
's	I-MED
metabolome	B-MED
.	O
Diabetes	B-MED
resulted	O
in	O
similar	O
changes	B-MED
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-MED
markers	B-MED
in	O
both	O
tissues	B-MED
,	O
such	O
as	O
glucose	B-MED
,	O
lactate	B-MED
,	O
2	B-MED
-	I-MED
hydroxybutyrate	I-MED
,	O
branched	B-MED
-	I-MED
chain	I-MED
amino	I-MED
acid	I-MED
degradation	I-MED
products	I-MED
,	O
bile	B-MED
acids	I-MED
,	O
and	O
1,5	B-MED
-	I-MED
anhydroglucitol	I-MED
,	O
as	O
well	O
as	O
markers	B-MED
of	O
oxidative	B-MED
stress	I-MED
.	O
In	O
the	O
detrusor	B-MED
(	O
but	O
not	O
the	O
urothelial	B-MED
layer	I-MED
)	O
,	O
diabetes	B-MED
caused	O
activation	O
of	O
the	O
pentose	B-MED
-	I-MED
phosphate	I-MED
and	O
polyol	B-MED
pathways	B-MED
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
TCA	B-MED
cycle	I-MED
and	O
β	B-MED
-	I-MED
oxidation	I-MED
.	O
Changes	B-MED
in	O
detrusor	B-MED
energy	B-MED
-	I-MED
generating	I-MED
pathways	I-MED
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-MED
that	O
,	O
through	O
generation	O
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
DBD	B-MED
.	O
In	O
the	O
diabetic	B-MED
urothelial	B-MED
layer	I-MED
there	O
was	O
decreased	O
flux	B-MED
of	O
glucose	B-MED
via	O
glycolysis	B-MED
and	O
changes	B-MED
changes	B-MED
in	O
lipid	B-MED
metabolism	I-MED
,	O
particularly	O
prostaglandin	B-MED
synthesis	B-MED
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	B-MED
dysfunction	B-MED
.	O
Penile	B-MED
Erosion	I-MED
in	O
a	O
Paraplegic	B-MED
Man	B-MED
With	O
Indwelling	B-MED
Urinary	I-MED
Catheter	I-MED
and	O
Scrotal	B-MED
Edema	I-MED
The	O
chronic	B-MED
use	B-MED
of	I-MED
urinary	B-MED
indwelling	I-MED
catheters	I-MED
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long	B-MED
-	I-MED
term	I-MED
patient	B-MED
care	I-MED
and	O
is	O
associated	O
with	O
numerous	O
complications	B-MED
.	O
More	O
awareness	B-MED
about	O
urogenital	B-MED
trauma	B-MED
from	O
urinary	B-MED
catheterization	I-MED
is	O
needed	O
,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	B-MED
urinary	B-MED
tract	I-MED
infections	I-MED
.	O
There	O
are	O
a	O
number	O
of	O
preventable	B-MED
measures	I-MED
that	O
can	O
be	O
taken	O
to	O
decrease	B-MED
the	O
risk	B-MED
of	O
mechanical	B-MED
trauma	I-MED
to	O
the	O
urethra	B-MED
and	O
glans	B-MED
penis	I-MED
caused	O
by	O
chronic	B-MED
catheterization	B-MED
.	O
We	O
present	O
a	O
case	O
of	O
a	O
27-	O
year	B-MED
old	B-MED
paraplegic	B-MED
male	B-MED
needing	O
a	O
chronic	B-MED
indwelling	B-MED
catheter	I-MED
that	O
acquired	B-MED
ventral	B-MED
penile	B-MED
erosion	I-MED
while	O
being	O
cared	B-MED
for	O
in	O
the	O
ICU	B-MED
setting	I-MED
.	O
Straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
popliteal	B-MED
artery	I-MED
for	O
vascular	B-MED
access	I-MED
The	O
saphenous	B-MED
vein	I-MED
is	O
commonly	O
used	O
as	O
a	O
vascular	B-MED
graft	I-MED
in	O
peripheral	B-MED
artery	I-MED
surgery	B-MED
but	O
rarely	B-MED
used	O
for	O
vascular	B-MED
access	I-MED
.	O
The	O
literature	B-MED
on	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
is	O
scarce	B-MED
.	O
Here	O
we	O
present	O
two	O
cases	O
of	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
for	O
vascular	B-MED
access	I-MED
,	O
the	O
surgical	B-MED
technique	I-MED
and	O
respective	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Two	O
young	B-MED
men	B-MED
,	O
aged	O
29	O
and	O
36	O
years	B-MED
,	O
were	O
chosen	O
for	O
lower	B-MED
-	I-MED
limb	I-MED
vascular	I-MED
access	I-MED
for	O
hemodialysis	B-MED
.	O
The	O
first	O
patient	B-MED
was	O
paraplegic	B-MED
since	O
birth	O
.	O
He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	B-MED
extremity	I-MED
vascular	I-MED
access	I-MED
was	O
avoided	O
.	O
The	O
second	O
patient	B-MED
presented	O
with	O
an	O
infected	B-MED
upper	B-MED
extremity	I-MED
arteriovenous	I-MED
graft	I-MED
(	B-MED
AVG	I-MED
)	O
and	O
after	O
multiple	O
closed	B-MED
AVFs	B-MED
he	O
had	O
no	O
more	O
available	O
arm	B-MED
veins	I-MED
.	O
Both	O
patients	B-MED
received	B-MED
autologous	B-MED
lower	B-MED
extremity	I-MED
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transpositions	B-MED
to	O
the	O
popliteal	B-MED
artery	I-MED
under	O
spinal	B-MED
anesthesia	I-MED
in	O
May	O
and	O
October	O
2012	O
,	O
respectively	O
.	O
Cannulation	B-MED
of	O
the	O
fistula	B-MED
was	O
allowed	O
after	O
one	O
month	B-MED
.	O
There	O
were	O
no	B-MED
early	I-MED
complications	I-MED
.	O
Slight	B-MED
swelling	I-MED
on	O
the	O
leg	B-MED
appeared	B-MED
in	O
one	O
of	O
the	O
patients	B-MED
.	O
Both	O
fistulas	B-MED
were	O
still	O
functional	B-MED
after	O
36	O
and	O
32	O
months	B-MED
,	O
respectively	O
.	O
The	O
straight	B-MED
configuration	I-MED
saphenous	I-MED
vein	I-MED
transposition	B-MED
to	O
popliteal	B-MED
artery	I-MED
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	B-MED
and	I-MED
straight	I-MED
segment	I-MED
for	O
cannulation	B-MED
and	O
may	O
be	O
a	O
suitable	O
autologous	B-MED
vascular	B-MED
access	I-MED
in	O
selected	O
patients	B-MED
.	O
DNA	B-MED
annealing	I-MED
by	O
Redβ	B-MED
is	O
insufficient	O
for	O
homologous	B-MED
recombination	I-MED
and	O
the	O
additional	O
requirements	O
involve	O
intra-	B-MED
and	I-MED
inter	I-MED
-	I-MED
molecular	I-MED
interactions	I-MED
Single	B-MED
strand	I-MED
annealing	I-MED
proteins	I-MED
(	O
SSAPs	B-MED
)	O
like	O
Redβ	B-MED
initiate	O
homologous	B-MED
recombination	I-MED
by	O
annealing	B-MED
complementary	I-MED
DNA	I-MED
strands	I-MED
.	O
We	O
show	O
that	O
C	B-MED
-	I-MED
terminally	I-MED
truncated	I-MED
Redβ	B-MED
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	B-MED
and	O
nucleoprotein	B-MED
filament	I-MED
formation	I-MED
,	O
is	O
unable	O
to	O
mediate	O
homologous	B-MED
recombination	I-MED
.	O
Mutations	B-MED
of	O
the	O
C	B-MED
-	I-MED
terminal	I-MED
domain	I-MED
were	O
evaluated	O
using	O
both	O
single	B-MED
-	O
and	O
double	B-MED
stranded	I-MED
(	O
ss	B-MED
and	O
ds	B-MED
)	O
substrates	O
in	O
recombination	B-MED
assays	B-MED
.	O
Mutations	B-MED
of	O
critical	B-MED
amino	I-MED
acids	I-MED
affected	O
either	O
dsDNA	B-MED
recombination	B-MED
or	O
both	O
ssDNA	B-MED
and	O
dsDNA	B-MED
recombination	I-MED
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA	B-MED
recombination	I-MED
and	O
the	O
second	O
for	O
recombination	B-MED
per	O
se	O
.	O
As	O
evaluated	O
by	O
co	B-MED
-	I-MED
immunoprecipitation	I-MED
experiments	I-MED
,	O
the	O
dsDNA	B-MED
recombination	I-MED
function	I-MED
relates	O
to	O
the	O
Redα	B-MED
-	O
Redβ	B-MED
protein	B-MED
-	I-MED
protein	I-MED
interaction	I-MED
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C	B-MED
-	I-MED
terminal	I-MED
domain	I-MED
but	O
also	O
a	O
region	O
near	O
the	O
N	B-MED
-	I-MED
terminus	I-MED
.	O
Because	O
the	O
nucleoprotein	B-MED
filament	I-MED
formed	I-MED
with	O
C	B-MED
-	I-MED
terminally	I-MED
truncated	I-MED
Redβ	B-MED
has	O
altered	O
properties	O
,	O
the	O
second	O
C	B-MED
-	I-MED
terminal	I-MED
function	I-MED
could	O
be	O
due	O
to	O
an	O
interaction	B-MED
required	O
for	O
functional	B-MED
filaments	B-MED
.	O
Alternatively	O
the	O
second	O
C	B-MED
-	I-MED
terminal	I-MED
function	I-MED
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	B-MED
-	O
host	B-MED
factor	I-MED
interaction	I-MED
.	O
These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red	B-MED
recombination	I-MED
and	O
the	O
proposition	O
that	O
Redβ	B-MED
and	O
RAD52	B-MED
SSAPs	B-MED
share	O
ancestral	O
and	O
mechanistic	O
roots	O
.	O
Supramolecular	B-MED
Recognition	I-MED
of	O
Amino	B-MED
Acids	I-MED
by	O
Twisted	B-MED
Cucurbit[14]uril	I-MED
Binding	B-MED
interactions	B-MED
between	B-MED
twisted	B-MED
cucurbit[14]uril	I-MED
(	B-MED
tQ[14	I-MED
]	I-MED
)	I-MED
and	O
twenty	O
standard	B-MED
amino	B-MED
acids	I-MED
(	B-MED
AAs	I-MED
)	I-MED
have	O
been	O
investigated	B-MED
by	O
NMR	B-MED
spectroscopy	I-MED
and	O
isothermal	B-MED
titration	I-MED
calorimetry	I-MED
(	B-MED
ITC	I-MED
)	I-MED
in	O
aqueous	B-MED
HCl	B-MED
solutions	I-MED
and	O
in	O
DMSO	B-MED
.	O
The	O
results	B-MED
showed	O
that	O
tQ[14	B-MED
]	I-MED
displays	B-MED
clear	O
binding	B-MED
affinity	B-MED
for	O
AAs	B-MED
with	O
a	O
positively	B-MED
charged	I-MED
side	I-MED
chain	I-MED
or	O
containing	B-MED
an	O
aromatic	B-MED
ring	I-MED
,	O
but	O
weaker	B-MED
binding	B-MED
affinity	B-MED
for	O
AAs	B-MED
with	O
hydrophobic	B-MED
or	O
polar	B-MED
side	I-MED
chains	I-MED
,	O
with	O
the	O
binding	B-MED
mode	B-MED
depending	O
on	O
the	O
type	O
of	O
side	B-MED
chain	I-MED
present	O
in	O
the	O
AAs	B-MED
.	O
Downregulation	B-MED
of	O
Endothelial	B-MED
Transient	I-MED
Receptor	I-MED
Potential	I-MED
Vanilloid	I-MED
Type	I-MED
4	I-MED
Channel	I-MED
and	O
Small	B-MED
-	I-MED
Conductance	I-MED
of	I-MED
Ca2	I-MED
+	I-MED
-Activated	I-MED
K+	I-MED
Channels	I-MED
Underpins	O
Impaired	B-MED
Endothelium	B-MED
-	I-MED
Dependent	I-MED
Hyperpolarization	I-MED
in	O
Hypertension	B-MED
Endothelium	B-MED
-	I-MED
dependent	I-MED
hyperpolarization	I-MED
EDH	B-MED
(	O
EDH)-mediated	O
responses	B-MED
are	O
impaired	B-MED
in	O
hypertension	B-MED
,	O
but	O
the	O
underlying	O
mechanisms	B-MED
have	O
not	O
yet	O
been	O
determined	O
.	O
The	O
activation	B-MED
of	O
small-	B-MED
and	O
intermediate	B-MED
-	I-MED
conductance	I-MED
of	I-MED
Ca(2+)-activated	I-MED
K(+	I-MED
)	I-MED
channels	I-MED
(	O
SKCa	B-MED
and	O
IKCa	B-MED
)	O
underpins	O
EDH	B-MED
-mediated	O
responses	B-MED
.	O
It	O
was	O
recently	O
reported	B-MED
that	O
Ca(2	B-MED
+	I-MED
)	I-MED
influx	I-MED
through	O
endothelial	B-MED
transient	I-MED
receptor	I-MED
potential	I-MED
vanilloid	I-MED
type	I-MED
4	I-MED
channel	I-MED
(	O
TRPV4	B-MED
)	O
is	O
a	O
prerequisite	B-MED
for	O
the	O
activation	B-MED
of	O
SKCa	B-MED
/	O
IKCa	B-MED
in	O
endothelial	B-MED
cells	I-MED
in	O
specific	O
beds	O
.	O
Here	O
,	O
we	O
attempted	B-MED
to	O
determine	O
whether	O
the	O
impairment	B-MED
of	O
EDH	B-MED
in	O
hypertension	B-MED
is	O
attributable	O
to	O
the	O
dysfunction	B-MED
of	O
TRPV4	B-MED
and	O
S	B-MED
/	O
IKCa	B-MED
,	O
using	O
isolated	O
superior	B-MED
mesenteric	I-MED
arteries	I-MED
of	O
20	O
-	O
week	O
-	O
old	O
stroke	B-MED
-	I-MED
prone	I-MED
spontaneously	I-MED
hypertensive	I-MED
rats	I-MED
(	O
SHRSP	B-MED
)	O
and	O
age	O
-	O
matched	O
Wistar	B-MED
-	I-MED
Kyoto	I-MED
(	I-MED
WKY	I-MED
)	I-MED
rats	I-MED
.	O
In	O
the	O
WKY	B-MED
arteries	B-MED
,	O
EDH	B-MED
-mediated	O
responses	B-MED
were	O
reduced	B-MED
by	O
a	O
combination	B-MED
of	O
SKCa	B-MED
/	O
IKCa	B-MED
blockers	B-MED
(	O
apamin	B-MED
plus	O
TRAM-34	B-MED
;	O
1-[(2	B-MED
-	I-MED
chlorophenyl)diphenylmethl]-1H	I-MED
-	I-MED
pyrazole	I-MED
)	O
and	O
by	O
the	O
blockade	B-MED
of	O
TRPV4	B-MED
with	O
the	O
selective	O
antagonist	B-MED
RN-1734	B-MED
or	O
HC-067047	B-MED
.	O
In	O
the	O
SHRSP	B-MED
arteries	B-MED
,	O
EDH	B-MED
-	I-MED
mediated	I-MED
hyperpolarization	I-MED
and	O
relaxation	B-MED
were	O
significantly	B-MED
impaired	B-MED
when	O
compared	O
with	O
WKY	B-MED
.	O
GSK1016790A	B-MED
,	O
a	O
selective	O
TRPV4	B-MED
activator	B-MED
,	O
evoked	O
robust	O
hyperpolarization	B-MED
and	O
relaxation	B-MED
in	O
WKY	B-MED
arteries	B-MED
.	O
In	O
contrast	O
,	O
in	O
SHRSP	B-MED
arteries	B-MED
,	O
the	O
GSK1016790A	B-MED
-evoked	O
hyperpolarization	B-MED
was	O
small	O
and	O
relaxation	B-MED
was	O
absent	B-MED
.	O
Hyperpolarization	B-MED
and	O
relaxation	B-MED
to	O
cyclohexyl-[2-(3,5	B-MED
-	I-MED
dimethyl	I-MED
-	I-MED
pyrazol-1	I-MED
-	I-MED
yl)-6	I-MED
-	I-MED
methyl	I-MED
-	I-MED
pyrimidin-4	I-MED
-	I-MED
yl]-amine	I-MED
,	O
a	O
selective	O
SKCa	B-MED
activator	B-MED
,	O
were	O
marginally	B-MED
decreased	B-MED
in	O
SHRSP	B-MED
arteries	B-MED
compared	O
with	O
WKY	B-MED
arteries	B-MED
.	O
The	O
expression	B-MED
of	O
endothelial	B-MED
TRPV4	I-MED
and	O
SKCa	B-MED
protein	O
was	O
significantly	B-MED
decreased	I-MED
in	O
the	O
SHRSP	B-MED
mesenteric	B-MED
arteries	I-MED
compared	O
with	O
those	O
of	O
WKY	B-MED
,	O
whereas	O
function	B-MED
and	O
expression	B-MED
of	O
IKCa	B-MED
were	O
preserved	O
in	O
SHRSP	B-MED
arteries	B-MED
.	O
These	O
findings	B-MED
suggest	O
that	O
EDH	B-MED
-mediated	O
responses	B-MED
are	O
impaired	B-MED
in	O
superior	B-MED
mesenteric	I-MED
arteries	I-MED
of	O
SHRSP	B-MED
because	O
of	O
a	O
reduction	B-MED
in	O
both	O
TRPV4	B-MED
and	O
SKCa	B-MED
input	B-MED
to	O
EDH	B-MED
.	O
Silent	B-MED
strain	I-MED
of	I-MED
caregiving	I-MED
:	O
exploring	O
the	O
best	B-MED
predictors	I-MED
of	O
distress	B-MED
in	O
family	B-MED
carers	I-MED
of	O
geriatric	B-MED
patients	I-MED
The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	B-MED
predictors	I-MED
of	O
distress	B-MED
suffered	I-MED
by	O
family	B-MED
carers	I-MED
(	O
FCs	B-MED
)	O
of	O
geriatric	B-MED
patients	I-MED
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
of	O
100	O
FC	B-MED
-	O
geriatric	B-MED
patient	I-MED
dyads	B-MED
was	O
conducted	O
.	O
The	O
negative	B-MED
impact	I-MED
of	I-MED
care	I-MED
(	O
NIoC	B-MED
)	O
subscale	B-MED
of	O
the	O
COPE	B-MED
index	I-MED
was	O
dichotomized	O
to	O
identify	O
lower	B-MED
stress	I-MED
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	B-MED
stress	I-MED
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	B-MED
by	O
the	O
process	B-MED
of	I-MED
providing	I-MED
care	I-MED
.	O
The	O
set	O
of	O
explanatory	B-MED
variables	B-MED
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	B-MED
and	O
care	B-MED
-	I-MED
related	I-MED
attributes	I-MED
,	O
including	O
patient	B-MED
-	I-MED
related	I-MED
results	I-MED
from	O
comprehensive	O
geriatric	B-MED
assessments	I-MED
and	O
disease	B-MED
profiles	B-MED
.	O
The	O
best	O
combination	O
of	O
explanatory	B-MED
variables	B-MED
that	O
provided	O
the	O
highest	B-MED
predictive	I-MED
powe	I-MED
r	O
for	O
distress	B-MED
among	O
FCs	B-MED
in	O
the	O
multiple	B-MED
logistic	I-MED
regression	I-MED
(	I-MED
LR	I-MED
)	I-MED
model	I-MED
LR	B-MED
was	O
determined	O
according	O
to	O
statistical	B-MED
information	I-MED
criteria	I-MED
.	O
The	O
statistical	B-MED
robustness	I-MED
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	B-MED
power	I-MED
of	O
the	O
model	B-MED
were	O
verified	O
with	O
the	O
cross	B-MED
-	I-MED
validation	I-MED
method	I-MED
.	O
The	O
mean	O
age	B-MED
of	O
FCs	B-MED
was	O
57.2	O
(	O
±10.6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	B-MED
patients	I-MED
was	O
81.7	O
(	O
±6.4	O
)	O
years	O
.	O
Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	B-MED
variables	B-MED
,	O
only	O
five	O
predictors	B-MED
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	B-MED
model	I-MED
.	O
A	O
higher	O
level	O
of	O
distress	B-MED
was	O
independently	O
predicted	O
by	O
lower	B-MED
self	I-MED
-	I-MED
evaluation	I-MED
of	I-MED
health	I-MED
;	O
worse	O
self	B-MED
-	I-MED
appraisal	I-MED
of	O
coping	B-MED
well	O
as	O
a	O
caregiver	B-MED
;	O
lower	B-MED
sense	O
of	O
general	B-MED
support	I-MED
;	O
more	O
hours	O
of	O
care	B-MED
per	O
week	O
;	O
and	O
the	O
motor	B-MED
retardation	I-MED
of	O
the	O
cared	B-MED
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-MED
Up	I-MED
and	I-MED
Go	I-MED
(	I-MED
TUG	I-MED
)	I-MED
test	I-MED
.	O
Worse	O
performance	O
on	O
the	O
TUG	B-MED
test	I-MED
was	O
only	O
the	O
patient	B-MED
-related	O
predictor	B-MED
of	O
distress	B-MED
among	O
the	O
variables	B-MED
NIoC	B-MED
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC.	O
Enhancing	O
the	O
mobility	B-MED
of	I-MED
geriatric	I-MED
patients	I-MED
through	O
suitably	O
tailored	O
kinesitherapeutic	B-MED
methods	I-MED
during	O
their	O
hospital	B-MED
stay	I-MED
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	B-MED
.	O
Inflammatory	B-MED
and	O
Oxidative	B-MED
Stress	I-MED
Markers	B-MED
in	O
Experimental	B-MED
Allergic	B-MED
Asthma	I-MED
Ovalbumin	B-MED
-	O
induced	B-MED
allergic	B-MED
lung	I-MED
inflammation	I-MED
(	O
ALI	B-MED
)	O
is	O
a	O
condition	B-MED
believed	O
to	O
be	O
mediated	O
by	O
cytokines	B-MED
,	O
extracellular	B-MED
matrix	I-MED
remodeling	B-MED
,	O
and	O
redox	B-MED
imbalance	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
evaluated	B-MED
pulmonary	B-MED
function	I-MED
together	O
with	O
inflammatory	B-MED
markers	B-MED
as	O
interleukin-4	B-MED
(	O
IL-4	B-MED
)	O
,	O
myeloperoxidase	B-MED
(	O
MPO	B-MED
)	O
,	O
eosinophil	B-MED
cells	I-MED
,	O
and	O
redox	B-MED
markers	B-MED
in	O
the	O
lungs	B-MED
of	O
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
after	O
ovalbumin	B-MED
(	O
OVA	B-MED
)	O
sensitization	B-MED
and	O
challenge	B-MED
.	O
Our	O
results	B-MED
showed	O
an	O
increase	B-MED
in	O
bronchial	B-MED
hyperresponsiveness	I-MED
stimulated	B-MED
by	O
methacholine	B-MED
(	O
Mch	B-MED
)	O
,	O
inflammatory	B-MED
cell	B-MED
influx	I-MED
,	O
especially	O
eosinophils	B-MED
together	O
with	O
an	O
increase	B-MED
of	O
high	B-MED
mobility	I-MED
group	I-MED
box	I-MED
1	I-MED
(	O
HMGB1	B-MED
)	O
and	O
altered	O
lipid	B-MED
peroxidation	I-MED
(	O
LP	B-MED
)	O
and	O
antioxidant	B-MED
defenses	B-MED
in	O
the	O
OVA	B-MED
group	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
(	O
p	O
≤	O
0.5	O
)	O
.	O
Thus	O
,	O
we	O
demonstrated	O
that	O
OVA	B-MED
-	O
induced	B-MED
ALI	B-MED
altered	O
redox	B-MED
status	O
concomitantly	B-MED
with	O
impaired	B-MED
lung	B-MED
function	I-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
HMGB1	B-MED
expression	B-MED
and	O
proteolytic	B-MED
remodeling	B-MED
.	O
Taken	O
together	O
all	O
results	B-MED
found	O
here	O
,	O
we	O
may	O
suggest	O
HMGB1	B-MED
is	O
an	O
important	B-MED
therapeutic	B-MED
target	B-MED
for	O
asthma	B-MED
,	O
once	O
orchestrates	B-MED
the	O
redox	B-MED
signaling	B-MED
,	O
inflammation	B-MED
,	O
and	O
remodeling	B-MED
that	O
contribute	O
to	O
the	O
disease	B-MED
development	B-MED
.	O
Case	B-MED
Report	I-MED
of	O
Necrotizing	B-MED
Fasciitis	I-MED
Associated	B-MED
with	I-MED
Streptococcus	B-MED
pneumoniae	I-MED
Necrotizing	B-MED
fasciitis	I-MED
,	O
caused	O
by	O
Streptococcus	B-MED
pneumoniae	I-MED
,	O
is	O
an	O
extremely	B-MED
rare	I-MED
and	O
life	B-MED
-	I-MED
threatening	I-MED
bacterial	B-MED
soft	B-MED
tissue	I-MED
infection	I-MED
.	O
We	O
report	B-MED
a	O
case	B-MED
of	O
early	O
necrotizing	B-MED
fasciitis	I-MED
associated	B-MED
with	I-MED
Streptococcus	B-MED
pneumoniae	I-MED
infection	B-MED
in	O
a	O
26-	O
year	B-MED
-old	O
man	B-MED
who	O
was	O
immunocompromised	B-MED
with	O
mixed	B-MED
connective	I-MED
tissue	I-MED
disease	I-MED
.	O
The	O
patient	B-MED
presented	O
with	O
acute	B-MED
,	O
painful	B-MED
,	O
erythematous	B-MED
,	O
and	O
edematous	B-MED
skin	I-MED
lesions	B-MED
of	O
his	O
right	B-MED
lower	I-MED
back	I-MED
,	O
which	O
rapidly	O
progressed	B-MED
to	O
the	O
right	B-MED
knee	I-MED
.	O
The	O
patient	B-MED
underwent	O
surgical	B-MED
exploration	I-MED
,	O
and	O
a	O
diagnosis	B-MED
of	O
necrotizing	B-MED
fasciitis	I-MED
was	O
confirmed	O
by	O
pathological	B-MED
evidence	B-MED
of	O
necrosis	B-MED
of	O
the	O
fascia	B-MED
and	O
neutrophil	B-MED
infiltration	I-MED
in	O
tissue	B-MED
biopsies	I-MED
.	O
Cultures	B-MED
of	O
fascial	B-MED
tissue	B-MED
biopsies	I-MED
and	O
blood	B-MED
samples	I-MED
were	O
positive	B-MED
for	O
Streptococcus	B-MED
pneumoniae	I-MED
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-MED
of	O
necrotizing	B-MED
fasciitis	I-MED
resulting	O
from	O
Streptococcus	B-MED
pneumoniae	I-MED
diagnosed	B-MED
at	O
early	O
phase	B-MED
;	O
the	O
patient	B-MED
recovered	I-MED
well	O
without	O
surgical	B-MED
debridement	I-MED
.	O
Spinal	B-MED
load	B-MED
in	O
nurses	B-MED
during	O
emergency	B-MED
lifting	B-MED
of	O
obese	B-MED
patients	B-MED
:	O
preliminary	B-MED
results	I-MED
Nurses	B-MED
are	O
exposed	O
to	O
the	O
risk	B-MED
of	O
injury	B-MED
while	O
handling	B-MED
patients	B-MED
.	O
This	O
is	O
particularly	O
true	O
for	O
obese	B-MED
patients	B-MED
.	O
The	O
goal	B-MED
of	O
this	O
paper	O
is	O
to	O
estimate	B-MED
the	O
spinal	B-MED
loads	B-MED
and	O
the	O
related	O
risk	B-MED
of	O
injury	B-MED
to	O
nurses	B-MED
while	O
lifting	B-MED
obese	B-MED
patients	B-MED
from	O
the	O
floor	B-MED
with	O
a	O
bariatric	B-MED
sheet	I-MED
during	O
a	O
hospital	B-MED
emergency	B-MED
.	O
Six	O
male	B-MED
nurses	B-MED
participated	O
in	O
this	O
study	B-MED
.	O
The	O
biomechanical	B-MED
analysis	I-MED
focused	O
on	O
the	O
lifting	B-MED
strategy	O
.	O
Thirty	O
obese	B-MED
in	B-MED
-	I-MED
patients	I-MED
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	B-MED
study	I-MED
and	O
divided	O
into	O
three	O
groups	B-MED
according	O
to	O
their	O
Body	B-MED
Mass	I-MED
Index	I-MED
(	O
BMI	B-MED
)	O
.	O
Three	B-MED
-	I-MED
dimensional	I-MED
motion	I-MED
analysis	I-MED
was	O
conducted	O
using	O
an	O
optoelectronic	B-MED
system	I-MED
.	O
The	O
trunk	B-MED
kinematics	B-MED
and	O
the	O
loading	B-MED
on	O
the	O
spines	B-MED
of	O
the	O
operating	O
nurses	B-MED
were	O
computed	B-MED
.	O
Our	O
data	B-MED
showed	O
that	O
when	O
the	O
nurse	B-MED
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	B-MED
was	O
more	O
flexed	B-MED
at	O
the	O
end	O
of	O
the	O
lift	B-MED
with	O
a	O
reduced	B-MED
range	B-MED
of	I-MED
motion	I-MED
.	O
The	O
values	B-MED
were	O
higher	B-MED
when	O
the	O
nurse	B-MED
lifted	O
patients	B-MED
with	O
higher	B-MED
BMIs	B-MED
.	O
All	O
kinetic	B-MED
parameters	I-MED
and	O
tension	B-MED
in	O
the	O
lumbar	B-MED
muscles	I-MED
at	O
the	O
end	O
of	O
the	O
movement	B-MED
were	O
characterised	O
by	O
lower	B-MED
values	B-MED
for	O
the	O
nurse	B-MED
placed	O
beside	O
the	O
patient	B-MED
's	I-MED
head	B-MED
or	O
feet	B-MED
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	B-MED
groups	I-MED
.	O
Our	O
preliminary	O
data	B-MED
suggest	O
that	O
only	O
the	O
reaction	O
load	B-MED
on	O
the	O
spine	B-MED
of	O
the	O
nurse	B-MED
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	B-MED
's	I-MED
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	B-MED
safety	B-MED
limits	B-MED
.	O
Hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
:	O
prevalence	B-MED
,	O
characteristics	B-MED
and	O
association	B-MED
with	I-MED
body	B-MED
mass	I-MED
index	I-MED
Hyperandrogenemia	B-MED
is	O
one	O
of	O
the	O
major	O
diagnostic	B-MED
features	O
for	O
the	O
diagnosis	B-MED
of	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
(	O
PCOS	B-MED
)	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	B-MED
the	O
prevalence	B-MED
and	O
the	O
characteristics	B-MED
of	O
hyperandrogenemia	B-MED
in	O
women	B-MED
with	O
PCOS	B-MED
and	O
to	O
investigate	B-MED
the	O
association	O
of	O
clinical	B-MED
and	O
biochemical	B-MED
characteristics	B-MED
with	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
according	O
to	O
the	O
presence	B-MED
of	O
hyperandrogenemia	B-MED
.	O
We	O
studied	O
266	O
women	B-MED
diagnosed	B-MED
with	O
PCOS	B-MED
.	O
Hyperandrogenemia	B-MED
was	O
defined	O
by	O
testosterone	B-MED
(	O
T	B-MED
)	O
and/or	O
free	B-MED
testosterone	I-MED
(	O
FT	B-MED
)	O
and/or	O
∆4	B-MED
androstenedione	I-MED
(	O
Δ4	B-MED
-	I-MED
A	I-MED
)	O
higher	O
than	O
75	O
%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	B-MED
.	O
Patients	B-MED
were	O
stratified	B-MED
in	O
two	O
groups	B-MED
according	O
to	O
a	O
BMI	B-MED
threshold	B-MED
of	O
25	O
kg	O
/	O
m2	O
.	O
Hyperandrogenemia	B-MED
was	O
present	B-MED
in	O
78.2	O
%	O
of	O
the	O
patients	B-MED
.	O
Elevated	B-MED
levels	O
of	O
T	B-MED
were	O
found	O
in	O
58.4	O
%	O
,	O
while	O
elevated	B-MED
levels	O
of	O
FT	B-MED
and	O
Δ4	B-MED
-	I-MED
A	I-MED
were	O
found	O
in	O
42.5	O
%	O
and	O
34.1	O
%	O
of	O
patients	B-MED
.	O
In	O
normal	B-MED
weight	I-MED
women	B-MED
(	O
BMI	B-MED
≤25	O
kg	O
/	O
m2	O
)	O
with	O
hyperandrogenemia	B-MED
lower	O
values	O
of	O
hip	B-MED
circumference	I-MED
and	O
HOMA	B-MED
-	I-MED
IR	I-MED
and	O
increased	B-MED
levels	O
of	O
T	B-MED
,	O
FT	B-MED
,	O
Δ4	B-MED
-	I-MED
A	I-MED
,	O
17	B-MED
-	I-MED
hydroxyprogesterone	I-MED
(	O
17	B-MED
-	I-MED
OHP	I-MED
)	O
,	O
dehydroepiandrosterone	B-MED
sulfate	I-MED
(	O
DHEAS	B-MED
)	O
,	O
white	B-MED
blood	I-MED
cells	I-MED
(	O
WBC	B-MED
)	O
and	O
neutrophils	B-MED
were	O
observed	O
compared	O
to	O
women	B-MED
without	O
hyperandrogenemia	B-MED
.	O
Also	O
,	O
in	O
overweight	B-MED
women	B-MED
higher	O
levels	O
of	O
T	B-MED
,	O
FT	B-MED
,	O
Δ4	B-MED
-	I-MED
A	I-MED
,	O
17	B-MED
-	I-MED
OHP	I-MED
,	O
DHEAS	B-MED
and	O
cortisol	B-MED
were	O
measured	B-MED
,	O
while	O
lower	O
thyroid	B-MED
-	I-MED
stimulating	I-MED
hormone	I-MED
(	I-MED
TSH	I-MED
)	I-MED
levels	I-MED
were	O
comparable	O
to	O
women	B-MED
without	O
hyperandrogenemia	B-MED
.	O
This	O
study	O
showed	O
high	O
prevalence	B-MED
of	O
hyperandrogenemia	B-MED
in	O
PCOS	B-MED
women	B-MED
.	O
Women	B-MED
with	O
BMI	B-MED
≤25	O
kg	O
/	O
m2	O
have	O
significant	B-MED
differences	O
in	O
androgens	B-MED
,	O
WBC	B-MED
,	O
neutrophils	B-MED
and	O
HOMA	B-MED
-	I-MED
IR	I-MED
and	O
women	B-MED
with	O
BMI	B-MED
≥25	O
kg	O
/	O
m2	O
in	O
androgens	B-MED
,	O
TSH	B-MED
and	O
cortisol	B-MED
according	O
to	O
the	O
presence	B-MED
or	O
not	O
of	O
hyperandrogenemia	B-MED
.	O
Predictors	B-MED
and	O
Moderators	B-MED
of	O
Spontaneous	B-MED
Pretend	B-MED
Play	I-MED
in	O
Children	B-MED
with	O
and	O
without	O
Autism	B-MED
Spectrum	I-MED
Disorder	I-MED
Although	O
pretend	B-MED
play	I-MED
has	O
long	O
been	O
linked	O
to	O
children	B-MED
's	I-MED
normative	B-MED
cognitive	B-MED
development	I-MED
,	O
inconsistent	B-MED
findings	B-MED
call	O
for	O
greater	O
rigor	O
in	O
examining	B-MED
this	O
relation	B-MED
(	O
Lillard	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Spontaneous	B-MED
pretend	B-MED
play	I-MED
is	O
often	O
impacted	O
in	O
atypical	B-MED
development	B-MED
,	O
notably	O
in	O
autism	B-MED
spectrum	I-MED
disorder	I-MED
(	O
ASD	B-MED
)	O
.	O
Since	O
ASD	B-MED
traits	B-MED
exist	O
along	O
a	O
continuum	B-MED
in	O
the	O
general	B-MED
population	I-MED
,	O
investigating	B-MED
how	O
pretend	B-MED
play	I-MED
varies	O
across	O
the	O
range	O
of	O
ASD	B-MED
symptoms	B-MED
by	O
indexing	O
variations	B-MED
in	O
ASD	B-MED
traits	B-MED
in	O
both	O
typically	O
developing	O
and	O
ASD	B-MED
populations	B-MED
may	O
provide	O
insight	O
into	O
how	O
ASD	B-MED
symptoms	B-MED
may	O
influence	O
the	O
relation	B-MED
between	O
pretend	B-MED
play	I-MED
and	O
associated	O
processes	O
in	O
cognitive	B-MED
development	I-MED
.	O
This	O
study	B-MED
used	O
rigorous	B-MED
observational	I-MED
methods	I-MED
to	O
assess	O
spontaneous	B-MED
pretend	B-MED
play	I-MED
.	O
Specifically	O
,	O
5-	O
min	B-MED
free	B-MED
-	I-MED
play	I-MED
sessions	I-MED
with	O
two	O
discrete	B-MED
toy	B-MED
sets	O
were	O
double	O
-	O
coded	O
by	O
blinded	B-MED
coders	I-MED
(	O
coder	O
assignment	O
counterbalanced	O
)	O
.	O
Key	O
facets	O
of	O
pretense	B-MED
development	I-MED
[	O
attribution	B-MED
of	I-MED
pretend	I-MED
properties	I-MED
(	O
APP	B-MED
)	O
,	O
object	B-MED
substitution	I-MED
(	O
OS	B-MED
)	O
,	O
imaginary	B-MED
objects	I-MED
]	O
were	O
examined	B-MED
.	O
These	O
facets	O
of	O
pretend	B-MED
play	I-MED
production	B-MED
were	O
then	O
analyzed	B-MED
in	O
relation	B-MED
to	O
ASD	B-MED
symptoms	B-MED
,	O
as	O
well	O
as	O
plausible	O
,	O
long	O
-	O
theorized	O
correlates	O
[	O
theory	B-MED
of	I-MED
mind	I-MED
(	O
ToM	B-MED
)	O
,	O
verbal	B-MED
ability	I-MED
,	O
familiarity	B-MED
,	O
and	O
interest	B-MED
in	O
specific	B-MED
toys	B-MED
]	O
.	O
Forty	O
children	B-MED
(	O
Mage	O
=	O
6;5	O
,	O
SDage	O
=	O
1.45	O
;	O
29	O
males	B-MED
)	O
,	O
six	O
of	O
whom	O
met	O
the	O
threshold	B-MED
for	O
ASD	B-MED
diagnosis	B-MED
via	O
parent	B-MED
-reported	O
ASD	B-MED
symptoms	B-MED
,	O
participated	O
in	O
play	B-MED
sessions	I-MED
and	O
completed	O
measures	B-MED
of	O
verbal	B-MED
IQ	I-MED
ToM	B-MED
and	O
ToM.	O
Besides	O
the	O
measure	B-MED
of	O
child	B-MED
ASD	B-MED
symptoms	B-MED
,	O
parents	B-MED
completed	O
a	O
survey	B-MED
of	O
their	O
child	B-MED
's	I-MED
interest	B-MED
in	O
and	O
familiarity	B-MED
with	O
the	O
play	B-MED
session	I-MED
toys	B-MED
.	O
Overall	O
,	O
greater	O
ToM	B-MED
predicted	B-MED
more	O
APP	B-MED
,	O
and	O
more	O
interest	B-MED
in	O
the	O
toys	B-MED
presented	O
predicted	B-MED
more	O
OS	B-MED
.	O
In	O
terms	O
of	O
overall	O
pretend	B-MED
play	I-MED
production	B-MED
,	O
two	O
results	O
were	O
counterintuitive	O
.	O
First	O
,	O
among	O
children	B-MED
with	O
more	O
ASD	B-MED
symptoms	B-MED
,	O
verbal	B-MED
ability	I-MED
marginally	O
negatively	O
predicted	B-MED
pretend	B-MED
play	I-MED
production	B-MED
.	O
Second	O
,	O
among	O
children	B-MED
with	O
fewer	O
ASD	B-MED
symptoms	B-MED
,	O
ToM	B-MED
negatively	O
predicted	B-MED
pretend	B-MED
play	I-MED
production	B-MED
.	O
Further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
ASD	B-MED
symptoms	B-MED
on	O
pretend	B-MED
play	I-MED
was	O
simultaneously	O
moderated	O
by	O
both	O
variables	O
:	O
low	O
ToM	B-MED
and	O
high	O
verbal	B-MED
ability	I-MED
both	O
related	O
to	O
less	O
pretend	B-MED
play	I-MED
production	O
among	O
children	B-MED
with	O
more	O
ASD	B-MED
symptoms	B-MED
.	O
Implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-MED
for	O
pretend	B-MED
ability	I-MED
among	O
children	B-MED
with	O
varying	O
degrees	O
of	O
ASD	B-MED
symptoms	B-MED
,	O
as	O
well	O
as	O
for	O
future	O
research	O
,	O
are	O
discussed	O
.	O
Binding	B-MED
of	O
Pollutants	B-MED
to	O
Biomolecules	B-MED
:	O
A	O
Simulation	B-MED
Study	I-MED
A	O
number	O
of	O
cases	B-MED
around	O
the	O
world	B-MED
have	O
been	O
reported	O
where	O
animals	B-MED
were	O
found	B-MED
dead	I-MED
or	O
dying	B-MED
with	O
symptoms	B-MED
resembling	O
a	O
thiamine	B-MED
(	B-MED
vitamin	I-MED
B	I-MED
)	I-MED
deficiency	I-MED
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	B-MED
has	O
been	O
suggested	O
.	O
Here	O
,	O
we	O
investigate	B-MED
whether	O
biomolecules	B-MED
involved	O
in	O
thiamin	B-MED
binding	I-MED
and	O
transport	B-MED
could	O
be	O
blocked	B-MED
by	O
a	O
range	O
of	O
different	O
pollutants	B-MED
.	O
We	O
used	O
in	B-MED
silico	I-MED
docking	B-MED
of	O
five	O
compound	B-MED
classes	B-MED
(	O
25	O
compounds	B-MED
in	O
total	O
)	O
to	O
each	O
of	O
five	O
targets	O
(	O
prion	B-MED
protein	I-MED
,	O
ECF	B-MED
-	I-MED
type	I-MED
ABC	I-MED
transporter	I-MED
,	O
thi	B-MED
-	I-MED
box	I-MED
riboswitch	I-MED
receptor	I-MED
,	O
thiamin	B-MED
pyrophosphokinase	I-MED
,	O
and	O
YKoF	B-MED
protein	I-MED
)	O
and	O
subsequently	O
performed	O
molecular	B-MED
dynamics	I-MED
(	I-MED
MD	I-MED
)	I-MED
simulations	I-MED
to	O
assess	O
the	O
stability	B-MED
of	O
the	O
complexes	B-MED
.	O
The	O
compound	B-MED
classes	B-MED
were	O
thiamin	B-MED
analogues	B-MED
(	O
control	B-MED
)	O
,	O
pesticides	B-MED
,	O
veterinary	B-MED
medicines	B-MED
,	O
polychlorinated	B-MED
biphenyls	I-MED
,	O
and	O
dioxins	B-MED
,	O
all	O
of	O
which	O
are	O
prevalent	B-MED
in	O
the	O
environment	B-MED
to	O
some	O
extent	O
.	O
A	O
few	O
anthropogenic	O
compounds	B-MED
were	O
found	O
to	O
bind	B-MED
the	O
ECF	B-MED
-	I-MED
type	I-MED
ABC	I-MED
transporter	I-MED
,	O
but	O
none	B-MED
binds	I-MED
stably	I-MED
to	O
prion	B-MED
protein	I-MED
.	O
For	O
the	O
riboswitch	B-MED
,	O
most	O
compounds	B-MED
remained	O
in	O
their	O
binding	B-MED
pockets	I-MED
during	O
50	O
ns	O
of	O
MD	B-MED
simulation	I-MED
,	O
indicating	O
that	O
RNA	B-MED
provides	O
a	O
promiscuous	O
binding	B-MED
site	I-MED
.	O
In	O
both	O
YKoF	B-MED
and	O
thiamin	B-MED
pyrophosphokinase	I-MED
(	O
TPK	B-MED
)	O
,	O
most	O
compounds	B-MED
remain	O
tightly	B-MED
bound	I-MED
.	O
However	O
,	O
TPK	B-MED
biomolecules	B-MED
undergo	O
pollutant	B-MED
-	O
induced	B-MED
conformational	B-MED
changes	I-MED
.	O
Although	O
most	O
compounds	B-MED
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	B-MED
methods	I-MED
like	O
free	B-MED
energy	I-MED
perturbation	I-MED
calculations	B-MED
before	O
firm	O
conclusions	B-MED
can	O
be	O
drawn	O
.	O
This	O
study	B-MED
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large	O
-	O
scale	O
quantitative	B-MED
computational	B-MED
screening	I-MED
of	O
interactions	B-MED
between	O
biological	B-MED
entities	I-MED
and	O
pollutant	B-MED
molecules	I-MED
.	O
Comparing	B-MED
the	O
effects	B-MED
of	I-MED
different	B-MED
dynamic	B-MED
sitting	I-MED
strategies	I-MED
in	O
wheelchair	B-MED
seating	I-MED
on	O
lumbar	B-MED
-	I-MED
pelvic	I-MED
angle	I-MED
Prolonged	B-MED
static	B-MED
sitting	I-MED
in	O
a	O
wheelchair	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
lower	B-MED
back	I-MED
pain	I-MED
.	O
The	O
wheelchair	B-MED
seating	I-MED
system	I-MED
is	O
a	O
key	B-MED
factor	I-MED
of	O
this	O
risk	B-MED
because	O
it	O
affects	O
spinal	B-MED
loading	B-MED
in	O
the	O
sitting	B-MED
position	I-MED
.	O
In	O
this	O
study	B-MED
,	O
7	O
dynamic	B-MED
sitting	I-MED
strategies	I-MED
(	O
DSSs	B-MED
)	O
are	O
examined	B-MED
:	O
lumbar	B-MED
prominent	I-MED
dynamic	I-MED
sitting	I-MED
(	O
LPDS	B-MED
)	O
,	O
back	B-MED
reclined	I-MED
dynamic	I-MED
sitting	I-MED
(	O
BRDS	B-MED
)	O
,	O
femur	B-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
(	O
FUDS	B-MED
)	O
,	O
lumbar	B-MED
prominent	I-MED
with	I-MED
back	I-MED
reclined	I-MED
dynamic	I-MED
sitting	I-MED
(	O
LBDS	B-MED
)	O
,	O
lumbar	B-MED
prominent	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
(	O
LFDS	B-MED
)	O
,	O
back	B-MED
reclined	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
(	O
BFDS	B-MED
)	O
,	O
and	O
lumbar	B-MED
prominent	I-MED
with	I-MED
back	I-MED
reclined	I-MED
with	I-MED
femur	I-MED
upward	I-MED
dynamic	I-MED
sitting	I-MED
(	O
LBFDS	B-MED
)	O
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
analyze	B-MED
the	O
biomechanical	B-MED
effects	B-MED
of	I-MED
these	O
sitting	B-MED
strategies	I-MED
on	O
lumbar	B-MED
-	I-MED
pelvic	I-MED
angles	I-MED
.	O
Twenty	O
able	B-MED
-	I-MED
bodied	I-MED
participants	B-MED
were	O
recruited	B-MED
for	O
the	O
study	B-MED
.	O
All	O
participants	B-MED
performed	B-MED
LPDS	B-MED
,	O
BRDS	B-MED
,	O
FUDS	B-MED
,	O
LBDS	B-MED
,	O
LFDS	B-MED
,	O
BFDS	B-MED
,	O
and	O
LBFDS	B-MED
in	O
a	O
random	B-MED
order	B-MED
.	O
All	O
lumbar	B-MED
-	I-MED
pelvic	I-MED
angle	I-MED
parameters	B-MED
,	O
including	O
the	O
static	B-MED
lumbar	B-MED
angle	I-MED
,	O
static	B-MED
pelvic	B-MED
angle	I-MED
,	O
lumbar	B-MED
range	I-MED
of	I-MED
motion	I-MED
,	O
and	O
pelvic	B-MED
range	I-MED
of	I-MED
motion	I-MED
were	O
measured	B-MED
and	O
compared	B-MED
.	O
Results	B-MED
show	O
that	O
LBDS	B-MED
and	O
LBFDS	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
lumbar	B-MED
movements	I-MED
,	O
although	O
the	O
difference	B-MED
between	O
the	O
2	O
strategies	B-MED
was	O
nonsignificant	B-MED
.	O
BRDS	B-MED
and	O
BFDS	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
pelvic	B-MED
movements	I-MED
,	O
although	O
the	O
difference	B-MED
between	O
the	O
2	O
strategies	B-MED
was	O
nonsignificant	B-MED
.	O
Among	O
all	O
the	O
upright	O
DSSs	B-MED
,	O
LPDS	B-MED
and	O
LFDS	B-MED
enabled	B-MED
the	O
most	O
beneficial	B-MED
lumbar	B-MED
and	O
pelvic	B-MED
movements	I-MED
,	O
although	O
no	B-MED
significant	I-MED
difference	B-MED
was	O
observed	B-MED
between	O
these	O
2	O
strategies	B-MED
.	O
We	O
identified	B-MED
the	O
effects	B-MED
and	O
differences	B-MED
among	O
7	O
DSSs	B-MED
on	O
lumbar	B-MED
-	I-MED
pelvic	I-MED
angles	I-MED
.	O
Wheelchair	B-MED
users	I-MED
can	O
choose	B-MED
the	O
most	O
suitable	B-MED
DSS	B-MED
that	O
meets	B-MED
their	O
needs	B-MED
.	O
These	O
findings	B-MED
may	O
serve	O
as	O
a	O
reference	B-MED
for	O
practicing	B-MED
physicians	I-MED
or	O
wheelchair	B-MED
users	I-MED
to	O
choose	B-MED
an	O
appropriate	B-MED
dynamic	O
wheelchair	B-MED
seating	I-MED
system	O
.	O
ISRCTN12389808	O
,	O
18th	O
November	O
2016	O
,	O
retrospectively	O
registered	O
.	O
Propranolol	B-MED
Effects	O
on	O
Decompression	B-MED
Sickness	I-MED
in	O
a	O
Simulated	O
DISSUB	B-MED
Rescue	B-MED
in	O
Swine	B-MED
Disabled	B-MED
submarine	I-MED
(	O
DISSUB	B-MED
)	O
survivors	B-MED
may	O
face	O
elevated	B-MED
CO2	I-MED
levels	I-MED
and	O
inert	B-MED
gas	I-MED
saturation	I-MED
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	B-MED
toxicity	B-MED
and	O
decompression	B-MED
sickness	I-MED
(	O
DCS	B-MED
)	O
.	O
Propranolol	B-MED
was	O
shown	O
to	O
reduce	B-MED
CO2	I-MED
production	I-MED
in	O
an	O
experimental	O
DISSUB	B-MED
model	B-MED
in	O
humans	B-MED
but	O
its	O
effects	O
on	O
DCS	B-MED
in	O
a	O
DISSUB	B-MED
rescue	B-MED
scenario	I-MED
are	O
unknown	O
.	O
A	O
100	O
%	O
oxygen	B-MED
prebreathe	I-MED
(	O
OPB	B-MED
)	O
reduces	O
DCS	B-MED
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	B-MED
rescue	B-MED
protocols	I-MED
.	O
We	O
used	O
a	O
swine	B-MED
model	I-MED
of	O
DISSUB	B-MED
rescue	B-MED
to	O
study	O
the	O
effect	O
of	O
propranolol	B-MED
on	O
DCS	B-MED
incidence	O
and	O
mortality	B-MED
with	O
and	O
without	O
an	O
OPB	B-MED
.	O
In	O
Experiment	O
1	O
,	O
male	B-MED
Yorkshire	B-MED
Swine	I-MED
(	O
70	O
kg	O
)	O
were	O
pressurized	B-MED
to	O
2.8	O
ATA	O
for	O
22	O
h.	O
Propranolol	B-MED
1.0	O
mg	O
·	O
kg-1	O
(	O
IV	O
)	O
was	O
administered	B-MED
at	I-MED
21.25	O
h.	O
At	O
22	O
h	O
,	O
the	O
animal	B-MED
was	O
rapidly	B-MED
decompressed	I-MED
and	O
observed	O
for	O
DCS	B-MED
type	O
,	O
onset	B-MED
time	I-MED
,	O
and	O
mortality	B-MED
.	O
Experimental	O
animals	B-MED
(	O
N	O
=	O
21	O
;	O
69	O
±	O
4.1	O
kg	O
)	O
,	O
PROP1.0	B-MED
,	O
were	O
compared	O
to	O
PROP1.0	B-MED
-	O
OPB45	B-MED
(	O
N	O
=	O
8	O
;	O
69	O
±	O
2.8	O
kg	O
)	O
with	O
the	O
same	O
dive	B-MED
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
OPB	B-MED
prior	O
to	O
decompression	B-MED
.	O
In	O
Experiment	O
2	O
,	O
the	O
same	O
methodology	B-MED
was	O
used	O
with	O
the	O
following	O
changes	O
:	O
swine	B-MED
pressurized	B-MED
to	O
2.8	O
ATA	O
for	O
28	O
h	O
;	O
experimental	O
group	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.3	O
kg	O
)	O
,	O
PROP0.5	B-MED
bis	O
,	O
propranolol	B-MED
0.5	O
mg	O
·	O
kg-1	O
bis	O
(	O
twice	O
)	O
(	O
IV	O
)	O
was	O
administered	B-MED
at	I-MED
22	O
h	O
and	O
26	O
h.	O
Control	B-MED
animals	I-MED
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.9	O
kg	O
)	O
received	O
normal	B-MED
saline	I-MED
.	O
OPB	B-MED
reduced	B-MED
mortality	I-MED
in	O
PROP1.0	B-MED
-	O
OBP45	B-MED
compared	O
to	O
PROP1.0	B-MED
(	O
0	O
%	O
vs.	O
71	O
%	O
)	O
.	O
PROP0.5	B-MED
bis	O
had	O
increased	B-MED
mortality	I-MED
compared	O
to	O
CONTROL	O
(	O
60-%	O
vs.	O
4	O
%	O
)	O
.	O
Administration	O
of	O
beta	B-MED
blockers	I-MED
prior	O
to	O
saturation	B-MED
decompression	I-MED
appears	O
to	O
increase	O
DCS	B-MED
and	O
worsen	B-MED
mortality	I-MED
in	O
a	O
swine	B-MED
model	B-MED
;	O
however	O
,	O
their	O
effects	O
in	O
bounce	B-MED
diving	I-MED
remain	O
unknown	O
.	O
Forbes	O
AS	O
,	O
Regis	O
DP	O
,	O
HallAA	O
,	O
Mahon	O
RT	O
,	O
Cronin	O
WA	O
.	O
Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine	O
.	O
Aerosp	O
Med	O
Hum	O
Perform	O
.	O
2017	O
;	O
88(4):385	O
-	O
391	O
.	O
Silk	B-MED
fibroin	I-MED
based	O
carrier	B-MED
system	I-MED
for	O
delivery	B-MED
of	O
fibrinogen	B-MED
and	O
thrombin	B-MED
as	O
coagulant	B-MED
supplements	B-MED
The	O
control	B-MED
of	O
bleeding	B-MED
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-MED
after	O
a	O
traumatic	B-MED
injury	I-MED
.	O
Hemostatic	B-MED
devices	I-MED
delivering	B-MED
blood	B-MED
clotting	I-MED
accelerating	O
agents	B-MED
such	O
as	O
fibrinogen	B-MED
are	O
increasingly	B-MED
used	O
due	O
to	O
their	O
efficacy	B-MED
and	O
their	O
ease	O
of	O
application	B-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	B-MED
to	O
incorporate	B-MED
the	O
coagulant	B-MED
supplements	B-MED
fibrinogen	B-MED
and	O
thrombin	B-MED
in	O
silk	B-MED
protein	I-MED
sponges	B-MED
by	O
mixing	O
the	O
coagulants	B-MED
with	O
an	O
aqueous	B-MED
silk	B-MED
solution	O
,	O
followed	O
by	O
molding	B-MED
,	O
freeze	B-MED
-	I-MED
drying	I-MED
and	O
water	B-MED
annealing	I-MED
.	O
In	O
this	O
combination	B-MED
system	B-MED
we	O
demonstrate	O
the	O
delivery	B-MED
of	O
fibrinogen	B-MED
while	O
maintaining	O
its	O
hemostatic	B-MED
potential	I-MED
.	O
Concentration	B-MED
ratios	I-MED
of	O
silk	B-MED
to	O
fibrinogen	B-MED
of	O
1.0%/2.8	O
%	O
,	O
2.3%/1.5	O
%	O
and	O
3.0%/0.8	O
%	O
were	O
used	O
.	O
The	O
thrombin	B-MED
-induced	O
fibrin	B-MED
polymeric	B-MED
network	B-MED
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-MED
spongy	B-MED
structure	I-MED
but	O
also	O
remained	O
interconnected	B-MED
to	O
the	O
silk	B-MED
,	O
providing	O
an	O
intact	B-MED
network	B-MED
.	O
The	O
mechanical	B-MED
characterization	I-MED
of	O
the	O
fibrinogen	B-MED
-	I-MED
releasing	I-MED
silk	B-MED
sponges	B-MED
before	O
and	O
after	O
the	O
induction	B-MED
of	O
the	O
fibrinogen	B-MED
polymerization	B-MED
demonstrated	O
that	O
the	O
fibrin	B-MED
network	B-MED
resulted	O
in	O
reduced	B-MED
permanent	B-MED
deformation	B-MED
from	O
21.1	O
%	O
to	O
6.5	O
%	O
,	O
19.6	O
%	O
to	O
5.7	O
%	O
and	O
12.7	O
%	O
to	O
9.4	O
%	O
for	O
the	O
2.8	O
%	O
,	O
1.5	O
%	O
and	O
0.8	O
%	O
fibrinogen	B-MED
-containing	O
silk	B-MED
sponges	B-MED
,	O
respectively	O
.	O
Moreover	O
,	O
the	O
fibrin	B-MED
formation	B-MED
lead	O
to	O
a	O
more	O
linear	B-MED
elastic	B-MED
behavior	I-MED
over	O
longer	O
strain	O
ranges	O
.	O
In	O
combination	O
,	O
the	O
Calcein	B-MED
-	I-MED
AM	I-MED
/	O
PI	B-MED
stainings	B-MED
and	O
MTT	B-MED
assay	I-MED
results	O
indicate	O
uniform	B-MED
cell	B-MED
adhesion	I-MED
on	O
the	O
surface	B-MED
and	O
cytocompatibility	B-MED
of	O
the	O
silk	B-MED
/	O
fibrin	B-MED
sponges	B-MED
,	O
respectively	O
.	O
Moreover	O
,	O
the	O
co	B-MED
-	I-MED
delivery	I-MED
of	O
thrombin	B-MED
with	O
fibrinogen	B-MED
via	O
silk	B-MED
as	O
carrier	B-MED
material	I-MED
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	B-MED
robust	B-MED
and	O
durable	B-MED
system	I-MED
while	O
preserving	B-MED
hemostatic	B-MED
features	I-MED
of	O
the	O
coagulant	B-MED
substances	I-MED
for	O
the	O
generation	B-MED
of	O
hemostatic	B-MED
devices	I-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Naphthohydroquinones	B-MED
,	O
naphthoquinones	B-MED
,	O
anthraquinones	B-MED
,	O
and	O
a	O
naphthohydroquinone	B-MED
dimer	B-MED
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
Morinda	B-MED
parvifolia	I-MED
and	O
their	O
cytotoxic	B-MED
effects	I-MED
through	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
p53	B-MED
Five	O
unknown	B-MED
compounds	B-MED
,	O
morindaparvins	B-MED
C	I-MED
-	I-MED
G	I-MED
,	O
consisting	O
of	O
naphthohydroquinones	B-MED
,	O
a	O
naphthoquinone	B-MED
,	O
an	O
anthraquinone	B-MED
,	O
and	O
a	O
naphthohydroquinone	B-MED
dimer	B-MED
,	O
together	O
with	O
three	O
known	O
quinones	B-MED
and	O
seven	O
other	O
known	O
compounds	B-MED
,	O
were	O
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
Morinda	B-MED
parvifolia	I-MED
.	O
The	O
structures	O
of	O
morindaparvins	B-MED
C	I-MED
,	O
D	B-MED
,	O
E	B-MED
,	O
F	B-MED
,	O
and	O
G	B-MED
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-MED
or	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
analysis	I-MED
as	O
methyl	B-MED
4	I-MED
-	I-MED
hydroxy-1,6	I-MED
-	I-MED
dimethoxy	I-MED
-	I-MED
naphthalene-2	I-MED
-	I-MED
carboxylate	I-MED
,	O
methyl	B-MED
4,8	I-MED
-	I-MED
dihydroxy-1	I-MED
-	I-MED
methoxy	I-MED
-	I-MED
naphthalene-2	I-MED
-	I-MED
carboxylate	I-MED
,	O
3	B-MED
-	I-MED
amino-6	I-MED
-	I-MED
methoxy-2	I-MED
-	I-MED
methoxycarbonyl-1,4	I-MED
-	I-MED
naphthoquinone	I-MED
,	O
1,4	B-MED
-	I-MED
dihydroxy-7	I-MED
-	I-MED
hydroxymethyl	I-MED
-	I-MED
anthraquinone	I-MED
,	O
and	O
dimethyl	B-MED
1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	I-MED
,	O
respectively	O
.	O
Naphthoquinones	B-MED
and	O
naphthohydroquinone	B-MED
dimers	B-MED
were	O
previously	O
unknown	B-MED
in	O
the	O
genus	B-MED
Morinda	B-MED
.	O
In	O
addition	O
,	O
the	O
compounds	B-MED
were	O
tested	B-MED
for	O
cytotoxicity	B-MED
against	O
four	O
human	B-MED
cancer	B-MED
cell	I-MED
lines	I-MED
HeLa	B-MED
,	O
A2780	B-MED
,	O
Ketr3	B-MED
and	O
MCF-7	B-MED
and	O
their	O
effects	B-MED
on	O
p53	B-MED
-	O
activated	B-MED
transcription	B-MED
.	O
Three	O
naphthoquinones	B-MED
had	O
moderate	B-MED
cytotoxic	B-MED
effects	I-MED
with	O
IC50	B-MED
values	O
ranging	B-MED
from	O
1.51	O
to	O
9.56	O
μM	O
,	O
through	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
p53	B-MED
transcriptional	B-MED
activity	I-MED
.	O
Treatment	B-MED
of	O
erythematotelangiectatic	B-MED
rosacea	I-MED
with	O
the	O
fractionation	B-MED
of	O
high	B-MED
-	I-MED
fluence	I-MED
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	B-MED
dye	I-MED
laser	I-MED
Various	O
lasers	B-MED
have	O
been	O
used	O
for	O
the	O
treatment	B-MED
of	O
erythematotelangiectatic	B-MED
rosacea	I-MED
(	O
ETR	B-MED
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	B-MED
or	O
topical	B-MED
therapy	I-MED
.	O
The	O
pulsed	B-MED
dye	I-MED
lasers	I-MED
(	O
PDLs	B-MED
)	O
are	O
an	O
effective	O
option	O
for	O
ETR	B-MED
,	O
and	O
the	O
purpuragenic	B-MED
fluence	B-MED
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O
Given	O
that	O
purpura	B-MED
and	O
subsequent	O
possible	O
postinflammatory	B-MED
hyperpigmentation	I-MED
(	O
PIH	B-MED
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	B-MED
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-MED
fluence	B-MED
were	O
reported	O
.	O
To	O
deliver	O
the	O
sufficient	O
high	B-MED
fluence	I-MED
of	O
a	O
PDL	B-MED
without	O
generating	O
purpura	B-MED
,	O
we	O
designed	O
the	O
fractionation	B-MED
of	O
high	B-MED
fluence	I-MED
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	B-MED
in	O
succession	O
.	O
A	O
total	O
of	O
eight	O
patients	B-MED
with	O
ETR	B-MED
were	O
enrolled	O
in	O
this	O
study	O
;	O
all	O
patients	B-MED
were	O
treated	O
with	O
PDL	B-MED
10	O
times	O
at	O
2	O
-	O
week	O
intervals	O
.	O
Erythema	B-MED
and	O
telangiectasia	B-MED
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	B-MED
using	O
the	O
digital	B-MED
photographs	I-MED
.	O
Moderate	O
-	O
to	O
-	O
marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	B-MED
,	O
and	O
erythema	B-MED
and	O
telangiectasia	B-MED
scores	O
were	O
significantly	O
decreased	O
.	O
Purpura	B-MED
and	O
PIH	B-MED
were	O
not	O
reported	O
in	O
all	O
patients	B-MED
.	O
The	O
fractionation	B-MED
of	O
high	B-MED
-	I-MED
fluence	I-MED
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	B-MED
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-MED
for	O
ETR	B-MED
.	O
Minimally	B-MED
invasive	I-MED
percutaneous	B-MED
nephrolithotomy	I-MED
improves	O
stone	O
-	O
free	O
rates	O
for	O
impacted	B-MED
proximal	B-MED
ureteral	B-MED
stones	I-MED
:	O
A	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
Urinary	B-MED
stones	I-MED
are	O
common	O
medical	B-MED
disorders	B-MED
and	O
the	O
treatment	B-MED
of	O
impacted	B-MED
proximal	I-MED
ureteral	I-MED
stones	I-MED
proximal	B-MED
(	O
IPUS	B-MED
)	O
is	O
still	O
a	O
challenge	O
for	O
urologists	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	I-MED
efficacy	I-MED
and	O
safety	B-MED
of	O
minimally	B-MED
invasive	I-MED
percutaneous	B-MED
nephrolithotomy	I-MED
(	O
MI	B-MED
-	O
PCNL	B-MED
)	O
and	O
ureteroscopic	B-MED
lithotripsy	I-MED
(	O
URL	B-MED
)	O
in	O
the	O
treatment	B-MED
of	O
IPUS	B-MED
via	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
We	O
collected	O
studies	B-MED
using	O
PubMed	B-MED
,	O
Embase	B-MED
,	O
and	O
Cochrane	B-MED
Library	I-MED
from	O
1978	B-MED
to	I-MED
November	I-MED
2016	I-MED
and	O
analyzed	B-MED
them	O
using	O
Stata	B-MED
12.0	I-MED
and	O
RevMan	B-MED
5.3	I-MED
.	O
Odds	B-MED
ratios	I-MED
(	O
OR	B-MED
s	O
)	O
and	O
standard	B-MED
mean	I-MED
difference	I-MED
(	O
SMD	B-MED
)	O
were	O
calculated	O
for	O
binary	B-MED
and	O
continuous	B-MED
variables	I-MED
respectively	O
,	O
accompanied	O
with	O
95	O
%	O
confidence	B-MED
intervals	I-MED
(	O
CIs	B-MED
)	O
.	O
All	O
study	B-MED
procedures	O
followed	O
the	O
PRISMA	B-MED
guidelines	I-MED
.	O
Five	O
prospective	B-MED
studies	I-MED
were	O
included	B-MED
in	O
our	O
meta	B-MED
-	I-MED
analysis	I-MED
,	O
with	O
242	O
MI	B-MED
-	O
PCNL	B-MED
and	O
256	O
URL	B-MED
cases	O
.	O
MI	B-MED
-	O
PCNL	B-MED
was	O
associated	B-MED
with	I-MED
a	O
longer	B-MED
postoperative	I-MED
hospital	B-MED
stay	I-MED
than	O
URL	B-MED
(	O
SMD	B-MED
,	O
3.14	O
;	O
95	O
%	O
CI	B-MED
,	O
1.27	O
to	O
5.55	O
)	O
.	O
However	O
,	O
no	O
significant	O
difference	B-MED
was	O
observed	B-MED
in	O
operative	B-MED
time	I-MED
(	O
SMD	B-MED
,	O
-0.38	O
;	O
95	O
%	O
CI	B-MED
,	O
-3.15	O
to	O
2.38	O
)	O
.	O
In	O
addition	O
,	O
MI	B-MED
-	O
PCNL	B-MED
had	O
higher	O
initial	O
(	O
OR	B-MED
,	O
11.12	O
;	O
95	O
%	O
CI	B-MED
,	O
5.56	O
to	O
22.24	O
)	O
and	O
overall	O
stone	O
-	O
free	O
rates	O
(	O
OR	B-MED
,	O
8.70	O
;	O
95	O
%	O
CI	B-MED
,	O
3.23	O
to	O
23.45	O
)	O
than	O
URL	B-MED
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical	B-MED
conversion	I-MED
(	O
OR	B-MED
,	O
0.11	O
;	O
95	O
%	O
CI	B-MED
,	O
0.03	O
to	O
0.49	O
)	O
and	O
postoperative	B-MED
shock	B-MED
wave	I-MED
lithotripsy	I-MED
(	O
OR	B-MED
,	O
0.06	O
;	O
95	O
%	O
CI	B-MED
,	O
0.02	O
to	O
0.18	O
)	O
.	O
Regarding	O
complications	B-MED
,	O
no	O
significant	O
differences	B-MED
were	O
observed	B-MED
between	B-MED
MI	B-MED
-	O
PCNL	B-MED
and	O
URL	B-MED
(	O
OR	B-MED
,	O
1.39	O
;	O
95	O
%	O
CI	B-MED
,	O
0.93	O
to	O
2.10	O
)	O
,	O
except	O
for	O
hematuria	B-MED
(	O
OR	B-MED
,	O
4.80	O
;	O
95	O
%	O
CI	B-MED
,	O
1.45	O
to	O
15.94	O
)	O
.	O
MI	B-MED
-	O
PCNL	B-MED
is	O
optimal	B-MED
and	O
should	O
be	O
considered	B-MED
as	O
the	O
preferred	B-MED
treatment	B-MED
method	I-MED
for	O
IPUS	B-MED
,	O
as	O
it	O
has	O
better	B-MED
efficacy	I-MED
and	O
a	O
safety	B-MED
profile	O
similar	O
to	O
that	O
of	O
URL	B-MED
.	O
However	O
,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	B-MED
in	O
future	B-MED
.	O
Safe	B-MED
with	O
Self	B-MED
-	I-MED
Injury	I-MED
:	O
A	O
Practical	B-MED
Guide	I-MED
to	O
Understanding	B-MED
,	O
Responding	B-MED
and	O
Harm	B-MED
-	I-MED
reduction	I-MED
Inckle	B-MED
Kay	I-MED
Safe	B-MED
with	O
Self	B-MED
-	I-MED
Injury	I-MED
:	O
A	O
Practical	B-MED
Guide	I-MED
to	O
Understanding	B-MED
,	O
Responding	B-MED
and	O
Harm	B-MED
-	I-MED
reduction	I-MED
274pp	O
£	O
23.99	O
PCCS	O
Books	O
9781910919163	O
1910919160	O
[	O
Formula	O
:	O
see	O
text	O
The	O
author	B-MED
begins	O
her	O
book	B-MED
with	O
a	O
concise	B-MED
exploration	B-MED
of	O
the	O
stereotypes	B-MED
and	O
truths	B-MED
of	O
self	B-MED
-	I-MED
harm	I-MED
.	O
In	O
the	O
following	O
seven	O
chapters	B-MED
,	O
she	O
sets	O
out	O
a	O
grounded	B-MED
and	O
often	O
challenging	B-MED
view	I-MED
of	O
how	O
self	B-MED
-	I-MED
harm	I-MED
is	O
understood	B-MED
from	O
differing	O
perspectives	B-MED
.	O
Association	B-MED
of	O
Toll	B-MED
-	I-MED
Like	I-MED
Receptor	I-MED
4	I-MED
on	O
Human	B-MED
Monocyte	B-MED
Subsets	B-MED
and	O
Vulnerability	B-MED
Characteristics	B-MED
of	O
Coronary	B-MED
Plaque	B-MED
as	O
Assessed	B-MED
by	O
64	B-MED
-	I-MED
Slice	I-MED
Multidetector	I-MED
Computed	I-MED
Tomography	I-MED
Although	O
Toll	B-MED
-	I-MED
like	I-MED
receptor	I-MED
4	I-MED
(	O
TLR-4	B-MED
)	O
is	O
involved	O
in	O
monocyte	B-MED
activation	I-MED
in	O
patients	B-MED
with	O
accelerated	B-MED
forms	O
of	O
atherosclerosis	B-MED
,	O
the	O
relationship	B-MED
between	O
the	O
expression	B-MED
of	O
TLR-4	B-MED
on	O
circulating	B-MED
monocyte	B-MED
s	O
and	O
coronary	B-MED
plaque	B-MED
vulnerability	B-MED
has	O
not	O
previously	O
been	O
evaluated	B-MED
.	O
We	O
investigated	O
this	O
relationship	B-MED
using	O
64	B-MED
-	I-MED
slice	I-MED
multidetector	I-MED
computed	I-MED
tomography	I-MED
(	O
MDCT	B-MED
)	O
in	O
patients	B-MED
with	O
stable	B-MED
angina	I-MED
pectoris	I-MED
SAP	B-MED
(	O
SAP).Methods	O
and	O
Results	O
:	O
We	O
enrolled	O
65	O
patients	B-MED
with	O
SAP	B-MED
who	O
underwent	O
MDCT	B-MED
.	O
Three	O
monocyte	B-MED
subsets	B-MED
(	O
CD14(++)CD16(-	B-MED
)	I-MED
,	O
CD14(++)CD16(+	B-MED
)	I-MED
,	O
and	O
CD14(+)CD16(+	B-MED
)	I-MED
)	O
and	O
expression	B-MED
of	O
TLR-4	B-MED
were	O
measured	O
by	O
flow	B-MED
cytometry	I-MED
.	O
Intracoronary	B-MED
plaques	B-MED
were	O
assessed	B-MED
by	O
64	B-MED
-	I-MED
slice	I-MED
MDCT	I-MED
.	O
We	O
defined	O
vulnerability	B-MED
of	O
intracoronary	B-MED
plaques	B-MED
according	O
to	O
the	O
presence	O
of	O
positive	B-MED
remodeling	I-MED
(	O
remodeling	B-MED
index	I-MED
>	O
1.05	O
)	O
and/or	O
low	O
CT	B-MED
attenuation	B-MED
(	O
<	O
35	O
HU	O
)	O
.	O
The	O
circulating	B-MED
CD14(++)CD16(+)monocytes	B-MED
more	O
frequently	O
expressed	B-MED
TLR-4	B-MED
than	O
CD14(++)CD16(-	B-MED
)	I-MED
and	O
CD14(+)CD16(+)monocytes	B-MED
(	O
P<0.001	O
)	O
.	O
The	O
relative	O
proportion	O
of	O
the	O
expression	B-MED
of	O
TLR-4	B-MED
on	O
CD14(++)CD16(+)monocytes	B-MED
was	O
significantly	O
greater	O
in	O
patients	B-MED
with	O
vulnerable	B-MED
plaque	I-MED
compared	O
with	O
those	O
without	O
(	O
10.4	O
[	O
4.1	O
-	O
14.5	O
]	O
%	O
vs.	O
4.5	O
[	O
2.8	O
-	O
7.8	O
]	O
%	O
,	O
P=0.012	O
)	O
.	O
In	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
TLR-4	B-MED
expression	B-MED
on	O
CD14(++)CD16(+)monocytes	B-MED
positively	O
correlated	B-MED
with	O
the	O
remodeling	B-MED
index	I-MED
(	O
r=0.28	O
,	O
P=0.025	O
)	O
and	O
negatively	O
correlated	B-MED
with	O
CT	B-MED
attenuation	B-MED
value	I-MED
(	O
r=-0.31	O
,	O
P=0.013	O
)	O
.	O
Upregulation	B-MED
of	O
TLR-4	B-MED
on	O
CD14(++)CD16(+)monocytes	B-MED
might	O
be	O
associated	B-MED
with	I-MED
coronary	B-MED
plaque	B-MED
vulnerability	B-MED
in	O
patients	B-MED
with	O
SAP	B-MED
.	O
Evolution	B-MED
:	O
Enhanced	B-MED
Footing	B-MED
for	O
Snake	B-MED
Limb	B-MED
Development	I-MED
Two	O
groups	O
have	O
studied	O
the	O
loss	B-MED
of	O
limbs	B-MED
in	O
snake	B-MED
evolution	B-MED
by	O
focusing	O
on	O
a	O
long	B-MED
-	I-MED
distance	I-MED
cis	B-MED
-	I-MED
acting	I-MED
enhancer	I-MED
of	O
Sonic	B-MED
Hedgehog	I-MED
.	O
They	O
find	O
a	O
progressive	B-MED
degeneration	B-MED
of	O
binding	B-MED
sites	I-MED
for	O
key	O
transcription	B-MED
factors	I-MED
,	O
mirroring	O
the	O
progressive	B-MED
limblessness	B-MED
occurring	B-MED
in	O
these	O
reptiles	B-MED
.	O
Methamphetamine	B-MED
,	O
3,4	B-MED
-	I-MED
methylenedioxymethamphetamine	I-MED
(	O
MDMA	B-MED
)	O
and	O
3,4	B-MED
-	I-MED
methylenedioxypyrovalerone	I-MED
(	O
MDPV	B-MED
)	O
induce	B-MED
differential	B-MED
cytotoxic	B-MED
effects	I-MED
in	O
bovine	B-MED
brain	B-MED
microvessel	B-MED
endothelial	B-MED
cells	I-MED
Designer	B-MED
drugs	I-MED
such	O
as	O
synthetic	B-MED
psychostimulants	I-MED
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-MED
of	O
drug	B-MED
abuse	I-MED
and	O
addiction	B-MED
.	O
In	O
addition	O
to	O
methamphetamine	B-MED
(	O
METH	B-MED
)	O
,	O
these	O
drugs	B-MED
include	O
3,4	B-MED
-	I-MED
methylenedioxy	I-MED
-	I-MED
methamphetamine	I-MED
(	O
MDMA	B-MED
)	O
and	O
commercial	B-MED
preparations	B-MED
of	O
synthetic	B-MED
cathinones	I-MED
including	O
3,4	B-MED
-	I-MED
methylenedioxypyrovalerone	I-MED
(	O
MDPV	B-MED
)	O
,	O
typically	O
referred	O
to	O
as	O
"	O
bath	B-MED
salts	I-MED
.	O
"	O
These	O
psychostimulants	B-MED
exert	O
neurotoxic	B-MED
effects	I-MED
by	O
altering	B-MED
monoamine	B-MED
systems	I-MED
in	O
the	O
brain	B-MED
.	O
Additionally	O
,	O
METH	B-MED
and	O
MDMA	B-MED
adversely	B-MED
affect	I-MED
the	O
integrity	B-MED
of	O
the	O
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
(	O
BBB	B-MED
):	O
there	O
are	O
no	O
current	O
reports	B-MED
on	O
the	O
effects	B-MED
of	I-MED
MDPV	B-MED
on	O
the	O
BBB	B-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
effects	B-MED
of	I-MED
METH	B-MED
,	O
MDMA	B-MED
and	O
MDPV	B-MED
on	O
bovine	B-MED
brain	B-MED
microvessel	B-MED
endothelial	B-MED
cells	I-MED
(	O
bBMVECs	B-MED
)	O
,	O
an	O
accepted	O
in	B-MED
vitro	I-MED
model	I-MED
of	O
the	O
BBB	B-MED
.	O
Confluent	B-MED
bBMVEC	B-MED
monolayers	B-MED
were	O
treated	B-MED
with	O
METH	B-MED
,	O
MDMA	B-MED
and	O
MDPV	B-MED
(	O
0.5mM-2.5mM	O
)	O
for	O
24h	O
.	O
METH	B-MED
and	O
MDMA	B-MED
increased	B-MED
lactate	B-MED
dehydrogenase	I-MED
release	B-MED
only	O
at	O
the	O
highest	B-MED
concentration	B-MED
(	O
2.5mM	O
)	O
,	O
whereas	O
MDPV	B-MED
induced	B-MED
cytotoxicity	B-MED
at	O
all	O
concentration	B-MED
s.	O
MDMA	B-MED
and	O
METH	B-MED
decreased	B-MED
cellular	B-MED
proliferation	I-MED
only	O
at	O
2.5mM	O
,	O
with	O
similar	O
effects	B-MED
observed	O
after	O
MDPV	B-MED
exposures	B-MED
starting	O
at	O
1mM.	O
Only	O
MDPV	B-MED
increased	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
production	B-MED
at	O
all	O
concentrations	B-MED
tested	B-MED
whereas	O
all	O
3	O
drugs	B-MED
increased	B-MED
nitric	B-MED
oxide	I-MED
production	B-MED
.	O
Morphological	B-MED
analysis	I-MED
revealed	O
different	B-MED
patterns	O
of	O
compound	B-MED
-	O
induced	B-MED
cell	B-MED
damage	I-MED
.	O
METH	B-MED
induced	B-MED
vacuole	B-MED
formatio	B-MED
n	O
at	O
1mM	O
and	O
disruption	B-MED
of	O
the	O
monolayer	B-MED
at	O
2.5mM.	O
MDMA	B-MED
induced	B-MED
disruption	B-MED
of	O
the	O
endothelial	B-MED
monolayer	B-MED
from	O
1mM	O
without	O
vacuolization	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
MDPV	B-MED
induced	B-MED
monolayer	B-MED
disruption	B-MED
at	O
doses	B-MED
≥0.5mM	O
without	O
vacuole	B-MED
formation	B-MED
;	O
at	O
2.5mM	O
,	O
the	O
few	O
remaining	O
cells	B-MED
lacked	O
endothelial	B-MED
morphology	I-MED
.	O
These	O
data	B-MED
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-MED
psychostimulants	I-MED
alter	O
monoaminergic	B-MED
systems	I-MED
,	O
they	O
each	O
induce	B-MED
BBB	B-MED
toxicity	B-MED
by	O
different	B-MED
mechanisms	B-MED
with	O
MDPV	B-MED
being	O
the	O
most	O
toxic	B-MED
.	O
The	O
anatomical	B-MED
mummies	I-MED
of	O
Mombello	B-MED
:	O
detection	B-MED
of	O
cocaine	B-MED
,	O
nicotine	B-MED
,	O
and	O
caffeine	B-MED
in	O
the	O
hair	B-MED
of	O
psychiatric	B-MED
patients	I-MED
of	O
the	O
early	O
20th	O
century	O
The	O
Mombello	B-MED
Psychiatric	I-MED
Hospital	I-MED
in	O
Limbiate	B-MED
,	O
near	O
Milan	B-MED
,	O
replaced	O
the	O
old	O
Senavra	B-MED
Hospital	I-MED
as	O
the	O
Psychiatric	B-MED
Hospital	I-MED
for	O
the	O
Province	B-MED
of	I-MED
Milan	I-MED
in	O
the	O
19th	O
century	O
.	O
During	O
the	O
early	O
20th	O
century	O
,	O
bodies	B-MED
of	O
several	O
Mombello	B-MED
patients	I-MED
were	O
dissected	B-MED
and	O
preserved	B-MED
by	O
Giuseppe	B-MED
Paravicini	I-MED
,	O
an	O
anatomist	B-MED
who	O
operated	O
within	O
the	O
asylum	B-MED
.	O
The	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	B-MED
.	O
To	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	B-MED
the	O
head	B-MED
hair	I-MED
of	O
six	O
such	O
preparations	B-MED
for	O
toxicological	B-MED
analysis	B-MED
.	O
By	O
means	O
of	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
,	O
cocaine	B-MED
and	O
its	O
main	O
metabolite	B-MED
,	O
benzoylecgonine	B-MED
,	O
were	O
detected	B-MED
in	O
two	O
out	O
of	O
six	O
hair	B-MED
samples	I-MED
.	O
The	O
concentrations	B-MED
for	O
cocaine	B-MED
were	O
0.151	O
and	O
0.09ng	O
/	O
mg	O
and	O
for	O
benzoylecgonine	B-MED
0.103	O
and	O
0.147ng	O
/	O
mg	O
,	O
respectively	O
.	O
Given	O
that	O
cocaine	B-MED
was	O
a	O
commonly	O
used	O
medicine	B-MED
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	B-MED
may	O
have	O
ingested	B-MED
this	O
drug	B-MED
.	O
In	O
addition	O
to	O
the	O
detection	B-MED
of	O
cocaine	B-MED
,	O
these	O
analyses	B-MED
also	O
provided	O
evidence	O
of	O
nicotine	B-MED
and	O
caffeine	B-MED
intake	B-MED
.	O
A	O
Randomized	B-MED
Controlled	I-MED
Noninferiority	I-MED
Trial	I-MED
of	O
Single	B-MED
Dose	I-MED
of	O
Oral	B-MED
Dexamethasone	I-MED
Versus	O
5	O
Days	B-MED
of	O
Oral	B-MED
Prednisone	I-MED
in	O
Acute	O
Adult	B-MED
Asthma	B-MED
Oral	B-MED
dexamethasone	I-MED
demonstrates	B-MED
bioavailability	B-MED
similar	B-MED
to	O
that	O
of	O
oral	B-MED
prednisone	I-MED
but	O
has	O
a	O
longer	O
half	B-MED
-	I-MED
life	I-MED
.	O
We	O
evaluate	O
whether	O
a	O
single	B-MED
dose	I-MED
of	O
oral	B-MED
dexamethasone	I-MED
plus	B-MED
4	O
days	B-MED
of	O
placebo	B-MED
is	O
not	O
inferior	B-MED
to	O
5	O
days	B-MED
of	O
oral	B-MED
prednisone	I-MED
in	O
treatment	B-MED
of	O
adults	B-MED
with	O
mild	B-MED
to	O
moderate	B-MED
asthma	B-MED
exacerbations	I-MED
to	O
prevent	B-MED
relapse	B-MED
defined	O
as	O
an	O
unscheduled	B-MED
return	O
visit	O
for	O
additional	B-MED
treatment	I-MED
for	O
persistent	B-MED
or	O
worsening	B-MED
asthma	B-MED
within	O
14	O
days	B-MED
.	O
Adult	B-MED
emergency	B-MED
department	I-MED
patients	B-MED
(	O
aged	B-MED
18	O
to	O
55	O
years	B-MED
)	O
were	O
randomized	B-MED
to	O
receive	B-MED
either	O
a	O
single	B-MED
dose	I-MED
of	O
12	O
mg	O
of	O
oral	B-MED
dexamethasone	I-MED
with	O
4	O
days	B-MED
of	O
placebo	B-MED
or	O
a	O
5-	O
day	B-MED
course	B-MED
of	O
oral	B-MED
prednisone	I-MED
60	O
mg	O
a	O
day	B-MED
.	O
Outcomes	B-MED
including	B-MED
relapse	B-MED
were	O
assessed	B-MED
by	O
a	O
follow	B-MED
-	I-MED
up	I-MED
telephone	I-MED
interview	I-MED
at	O
2	O
weeks	B-MED
.	O
One	O
hundred	B-MED
seventy	I-MED
-	I-MED
three	I-MED
dexamethasone	B-MED
and	O
203	O
prednisone	B-MED
subjects	B-MED
completed	B-MED
the	O
study	O
regimen	O
and	O
telephone	B-MED
follow	I-MED
-	I-MED
up	I-MED
.	O
The	O
dexamethasone	B-MED
group	B-MED
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	B-MED
between	O
groups	B-MED
for	O
noninferiority	B-MED
in	O
relapse	B-MED
rates	B-MED
within	O
14	O
days	B-MED
(	O
12.1	O
%	O
versus	O
9.8	O
%	O
;	O
difference	B-MED
2.3	O
%	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
-4.1	O
%	O
to	O
8.6	O
%	O
)	O
.	O
Subjects	B-MED
in	O
the	O
2	O
groups	B-MED
had	O
similar	O
rates	B-MED
of	O
hospitalization	B-MED
for	O
their	O
relapse	B-MED
visit	B-MED
(	O
dexamethasone	B-MED
3.4	O
%	O
versus	O
prednisone	B-MED
2.9	O
%	O
;	O
difference	B-MED
0.5	O
%	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
-4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O
Adverse	B-MED
effect	I-MED
rates	B-MED
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	B-MED
.	O
A	O
single	B-MED
dose	I-MED
of	O
oral	B-MED
dexamethasone	I-MED
did	O
not	O
demonstrate	B-MED
noninferiority	B-MED
to	O
prednisone	B-MED
for	O
5	O
days	B-MED
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	B-MED
of	O
adults	B-MED
with	O
mild	B-MED
to	O
moderate	B-MED
asthma	B-MED
exacerbations	I-MED
.	O
Enhanced	B-MED
compliance	B-MED
and	O
convenience	B-MED
may	O
support	O
the	O
use	B-MED
of	O
dexamethasone	B-MED
regardless	O
.	O
ATP	B-MED
release	B-MED
from	O
bladder	B-MED
urothelium	I-MED
and	O
serosa	B-MED
in	O
a	O
rat	O
model	B-MED
of	O
partial	B-MED
bladder	I-MED
outlet	I-MED
obstruction	I-MED
Overactive	B-MED
bladder	I-MED
is	O
one	O
of	O
the	O
major	O
health	B-MED
problem	I-MED
especially	O
in	O
elderly	B-MED
people	I-MED
.	O
Adenosine	B-MED
triphosphate	I-MED
(	O
ATP	B-MED
)	O
is	O
released	B-MED
from	O
urinary	B-MED
bladder	I-MED
cells	I-MED
and	O
acts	O
as	O
a	O
smooth	B-MED
muscle	I-MED
contraction	I-MED
and	O
sensory	B-MED
signal	I-MED
in	O
micturition	B-MED
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
ATP	B-MED
release	O
in	O
the	O
pathophysiology	B-MED
of	O
overactive	B-MED
bladder	I-MED
.	O
To	O
assess	O
the	O
relationship	O
between	O
ATP	B-MED
and	O
overactive	B-MED
bladder	I-MED
,	O
we	O
used	O
a	O
partial	B-MED
bladder	I-MED
outlet	I-MED
obstruction	I-MED
(	O
pBOO	B-MED
)	O
model	B-MED
in	O
rats	B-MED
.	O
The	O
bladder	B-MED
caused	O
several	O
changes	O
by	O
pBOO	B-MED
:	O
An	O
increase	B-MED
in	O
bladder	B-MED
weight	B-MED
,	O
hypertrophy	B-MED
of	O
sub	B-MED
-	I-MED
urothelium	I-MED
and	O
sub	B-MED
-	I-MED
serosal	I-MED
area	I-MED
,	O
and	O
frequent	O
non	B-MED
-	O
voiding	B-MED
bladder	I-MED
contraction	I-MED
during	O
urine	B-MED
storage	O
.	O
Basal	B-MED
ATP	B-MED
release	O
from	O
urothelium	B-MED
and	O
serosa	B-MED
of	O
pBOO	B-MED
rats	B-MED
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	B-MED
.	O
Distention	B-MED
induced	O
ATP	B-MED
release	B-MED
from	O
urothelium	B-MED
of	O
normal	O
and	O
pBOO	B-MED
rats	B-MED
had	O
no	O
significant	O
change	O
.	O
However	O
,	O
distention	B-MED
-	O
induced	B-MED
ATP	B-MED
release	B-MED
from	O
serosa	B-MED
of	O
pBOO	B-MED
rats	B-MED
was	O
higher	O
than	O
that	O
of	O
normal	O
.	O
These	O
findings	O
may	O
identify	O
ATP	B-MED
especially	O
released	B-MED
from	O
serosa	B-MED
as	O
one	O
of	O
causes	O
of	O
non	B-MED
-	O
voiding	B-MED
contractions	I-MED
and	O
overactive	B-MED
bladder	I-MED
symptoms	B-MED
.	O
Percentile	B-MED
categorization	B-MED
of	O
QT	B-MED
interval	I-MED
as	O
an	O
approach	B-MED
for	O
identifying	B-MED
adult	B-MED
patients	B-MED
at	O
risk	B-MED
for	O
cardiovascular	B-MED
death	I-MED
The	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
QT	B-MED
prolongation	I-MED
with	O
cardiovascular	B-MED
death	I-MED
(	O
CVD	B-MED
)	O
have	O
been	O
inconsistent	B-MED
.	O
The	O
purpose	B-MED
of	I-MED
this	I-MED
study	I-MED
was	O
to	O
compare	B-MED
the	O
major	O
correction	B-MED
formulas	I-MED
to	O
percentile	B-MED
values	I-MED
of	O
QT	B-MED
for	O
heart	B-MED
rate	I-MED
ranges	B-MED
as	O
to	O
their	O
ability	B-MED
to	O
remove	B-MED
the	O
relationship	B-MED
of	O
QT	B-MED
to	O
heart	B-MED
rate	I-MED
and	O
to	O
predict	O
CVD	B-MED
.	O
Participants	B-MED
were	O
16,531	O
veterans	B-MED
who	O
had	O
an	O
initial	O
ECG	B-MED
at	O
the	O
Veterans	B-MED
Affairs	I-MED
Medical	I-MED
Center	I-MED
,	O
Palo	B-MED
Alto	I-MED
,	O
between	O
March	B-MED
31	O
,	O
1987	O
,	O
and	O
December	B-MED
20	O
,	O
1999	O
,	O
and	O
were	O
followed	O
for	O
CVD	B-MED
.	O
The	O
4	O
major	O
correction	B-MED
formulas	I-MED
(	O
Bazett	B-MED
,	O
Fridericia	B-MED
,	O
Framingham	B-MED
,	O
and	O
Hodges	B-MED
)	O
were	O
used	O
to	O
correct	O
QT	B-MED
interval	I-MED
.	O
In	O
addition	O
,	O
the	O
percentiles	B-MED
for	O
heart	B-MED
rate	I-MED
ranges	B-MED
as	O
proposed	O
by	O
Schwartz	B-MED
were	O
calculated	O
.	O
During	O
median	B-MED
follow	O
-	O
up	O
of	O
17.8	O
years	B-MED
,	O
455	O
CVD	B-MED
events	O
occurred	O
.	O
When	O
compared	O
to	O
the	O
other	O
equations	B-MED
,	O
QTc	O
Bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart	B-MED
rate	I-MED
(	O
R(2	O
)	O
=	O
0.18	O
)	O
.	O
The	O
hazard	B-MED
ratio	I-MED
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
)	O
for	O
CVD	B-MED
was	O
2.08	O
(	O
1.28	O
-	O
3.9	O
)	O
for	O
the	O
98th	O
percentile	B-MED
of	O
QT	B-MED
interval	I-MED
by	O
heart	B-MED
rate	I-MED
ranges	B-MED
,	O
2.05	O
(	O
1.27	O
-	O
3.33	O
)	O
for	O
QTc	B-MED
Bazett	I-MED
,	O
1.39	O
(	O
0.44	O
-	O
4.34	O
)	O
for	O
QTc	O
Fridericia	O
,	O
1.05	O
(	O
0.26	O
-	O
4.24	O
)	O
for	O
QTc	B-MED
Hodges	I-MED
,	O
and	O
1.12	O
(	O
0.28	O
-	O
4.52	O
)	O
for	O
QTc	B-MED
Framingham	I-MED
.	O
The	O
hazard	O
ratio	O
of	O
QTc	B-MED
Bazett	I-MED
was	O
significantly	B-MED
higher	I-MED
than	O
the	O
other	O
formulas	B-MED
except	O
for	O
the	O
98th	O
percentile	B-MED
method	O
.	O
The	O
Framingham	B-MED
,	O
Hodges	B-MED
,	O
and	O
Fridericia	B-MED
equations	I-MED
remove	B-MED
the	O
effect	B-MED
of	O
heart	B-MED
rate	I-MED
on	O
QT	B-MED
interval	I-MED
significantly	O
better	O
than	O
the	O
Bazett	B-MED
equation	I-MED
.	O
Using	O
QT	B-MED
-	I-MED
interval	I-MED
percentiles	B-MED
based	O
on	O
heart	B-MED
rate	I-MED
provides	O
a	O
consistent	O
approach	B-MED
both	O
for	O
identifying	O
those	O
whose	O
QT	B-MED
intervals	I-MED
prolong	O
due	O
to	O
drugs	B-MED
or	O
other	O
stressors	B-MED
and	O
for	O
assessing	O
CVD	B-MED
risk	B-MED
.	O
A	O
numerical	B-MED
study	B-MED
on	O
the	O
application	O
of	O
the	O
functionally	B-MED
graded	I-MED
materials	I-MED
in	O
the	O
stent	B-MED
design	B-MED
Undesirable	B-MED
deformation	B-MED
of	O
the	O
stent	B-MED
can	O
induce	O
a	O
significant	B-MED
amount	O
of	O
injure	B-MED
not	O
only	O
to	O
the	O
blood	B-MED
vessel	I-MED
but	O
also	O
to	O
the	O
plaque	B-MED
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce	B-MED
/	I-MED
minimize	I-MED
these	O
undesirable	B-MED
deformations	B-MED
by	O
the	O
application	O
of	O
Functionally	B-MED
Graded	I-MED
Materials	I-MED
(	O
FGM	B-MED
)	O
.	O
To	O
do	O
this	O
,	O
Finite	B-MED
Element	I-MED
(	I-MED
FE	I-MED
)	I-MED
method	I-MED
was	O
employed	B-MED
to	O
simulate	B-MED
the	O
expansion	B-MED
of	O
a	O
stent	B-MED
and	O
the	O
corresponding	O
displacement	B-MED
of	O
the	O
stenosis	B-MED
plaque	B-MED
.	O
Three	O
hyperelastic	B-MED
plaque	B-MED
types	O
as	O
well	O
as	O
five	O
elastoplastic	B-MED
stents	I-MED
were	O
simulated	O
.	O
Dogboning	B-MED
,	O
foreshortening	B-MED
,	O
maximum	B-MED
stress	B-MED
in	O
the	O
plaque	B-MED
,	O
and	O
the	O
pressure	B-MED
which	O
is	O
needed	O
to	O
fully	O
expand	B-MED
the	O
stent	B-MED
for	O
different	O
stent	B-MED
materials	B-MED
,	O
were	O
acquired	O
.	O
While	O
all	O
FGMs	B-MED
had	O
lower	B-MED
dogboning	B-MED
in	O
comparison	O
to	O
the	O
stents	B-MED
made	O
of	O
the	O
uniform	B-MED
materials	B-MED
,	O
the	O
stent	B-MED
with	O
the	O
lowest	B-MED
heterogeneous	B-MED
index	I-MED
displayed	O
the	O
lowest	B-MED
amount	O
of	O
dogboning	B-MED
.	O
Steel	B-MED
stent	B-MED
showed	O
the	O
lowest	B-MED
foreshortening	B-MED
and	O
fully	O
expansion	B-MED
pressure	I-MED
but	O
the	O
difference	B-MED
was	O
much	O
lower	B-MED
than	O
that	O
the	O
one	O
for	O
dogboning	B-MED
.	O
Therefore	O
,	O
the	O
FGM	B-MED
with	O
the	O
heterogeneous	B-MED
index	I-MED
of	O
0.5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	B-MED
results	B-MED
.	O
In	O
addition	O
,	O
the	O
results	B-MED
revealed	O
that	O
the	O
material	B-MED
parameters	B-MED
has	O
crucial	B-MED
effects	B-MED
on	O
the	O
deformation	B-MED
of	O
the	O
stent	B-MED
and	O
,	O
as	O
a	O
result	B-MED
,	O
as	O
a	O
design	B-MED
point	O
of	O
view	O
the	O
FGM	B-MED
parameters	B-MED
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	B-MED
optimization	B-MED
.	O
Tracking	O
children	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
who	O
abandoned	B-MED
therapy	B-MED
:	O
Experience	B-MED
,	O
challenges	B-MED
,	O
parental	B-MED
perspectives	B-MED
,	O
and	O
impact	O
of	O
treatment	B-MED
subsidies	B-MED
and	O
intensified	B-MED
counseling	I-MED
Refusal	B-MED
for	I-MED
treatment	I-MED
and	O
therapy	B-MED
abandonment	B-MED
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	B-MED
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
(	O
ALL	B-MED
)	O
in	O
resource	B-MED
-poor	O
countries	B-MED
.	O
The	O
present	O
study	B-MED
,	O
conducted	O
on	O
children	B-MED
with	O
ALL	B-MED
whose	O
treatment	B-MED
was	O
abandoned	B-MED
,	O
attempted	O
to	O
track	O
all	O
these	O
children	B-MED
to	O
ascertain	O
the	O
causes	O
and	O
outcome	B-MED
of	O
therapy	B-MED
abandonment	B-MED
/	O
refusal	B-MED
.	O
In	O
order	O
to	O
improve	O
outcome	B-MED
of	O
ALL	B-MED
,	O
measures	O
to	O
prevent	O
abandonment	B-MED
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-MED
subsidies	B-MED
and	O
intensified	B-MED
multistage	I-MED
counseling	I-MED
.	O
Of	O
the	O
77	O
(	O
of	O
418	O
)	O
children	B-MED
abandoning	O
therapy	B-MED
,	O
17	O
(	O
22	O
%	O
)	O
refused	B-MED
upfront	I-MED
,	O
whereas	O
the	O
rest	O
abandoned	B-MED
during	O
various	O
phases	O
of	O
chemotherapy	B-MED
.	O
Only	O
39	O
(	O
50.6	O
%	O
)	O
of	O
these	O
77	O
families	B-MED
could	O
be	O
subsequently	O
contacted	O
.	O
Financial	B-MED
problems	I-MED
,	O
too	O
many	O
dependents	B-MED
at	O
home	B-MED
,	O
and	O
wrong	O
perceptions	B-MED
about	O
cancer	B-MED
led	O
to	O
abandonment	B-MED
in	O
majority	O
.	O
Children	B-MED
abandoning	I-MED
treatment	I-MED
before	O
completion	O
of	O
induction	B-MED
had	O
a	O
significantly	O
shorter	O
survival	B-MED
than	O
who	O
abandoned	B-MED
post	B-MED
induction	I-MED
(	O
P	O
<	O
.0001	O
)	O
.	O
Intensified	B-MED
preabandonment	I-MED
counseling	I-MED
and	O
subsidized	O
treatment	B-MED
led	O
to	O
significant	O
reduction	B-MED
in	O
abandonment	B-MED
rates	I-MED
(	O
P	O
<	O
.0001	O
)	O
.	O
Green	B-MED
and	O
rapid	B-MED
synthesis	B-MED
of	O
silver	B-MED
nanoparticles	B-MED
using	O
Borago	B-MED
officinalis	I-MED
leaf	B-MED
extract	B-MED
:	O
anticancer	B-MED
and	O
antibacterial	B-MED
activities	I-MED
This	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	B-MED
effective	B-MED
,	O
and	O
ecofriendly	B-MED
synthesis	B-MED
of	O
silver	B-MED
nanoparticles	B-MED
(	O
AgNPs	B-MED
)	O
using	O
Borago	B-MED
officinalis	I-MED
leaves	B-MED
extract	B-MED
efficiently	B-MED
.	O
The	O
biosynthesis	B-MED
of	O
AgNPs	B-MED
was	O
verified	B-MED
by	O
UV	B-MED
-	I-MED
Vis	I-MED
spectrum	I-MED
which	O
showed	O
the	O
surface	B-MED
plasmon	I-MED
resonance	I-MED
(	O
SPR	B-MED
)	O
band	O
at	O
422	O
nm	O
.	O
Transmission	B-MED
electron	I-MED
microscope	I-MED
(	I-MED
TEM	I-MED
)	I-MED
analysis	I-MED
revealed	O
that	O
the	O
particles	B-MED
were	O
spherical	B-MED
,	O
hexagonal	B-MED
,	O
and	O
irregular	B-MED
in	O
shape	B-MED
and	O
had	O
size	B-MED
ranging	B-MED
from	O
30	O
to	O
80	O
nm	O
.	O
The	O
energy	B-MED
dispersive	I-MED
X	I-MED
-	I-MED
ray	I-MED
spectroscopy	I-MED
(	O
EDX	B-MED
)	O
and	O
elemental	B-MED
mapping	I-MED
have	O
displayed	O
the	O
purity	B-MED
and	O
maximum	B-MED
distribution	B-MED
of	O
silver	B-MED
in	O
the	O
AgNPs	B-MED
.	O
The	O
crystalline	B-MED
nature	O
of	O
AgNPs	B-MED
had	O
been	O
identified	B-MED
using	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
(	O
XRD	B-MED
)	O
and	O
selected	B-MED
area	I-MED
diffraction	I-MED
pattern	I-MED
(	O
SAED	O
)	O
.	O
The	O
particle	B-MED
size	I-MED
analysis	B-MED
revealed	O
that	O
the	O
Z	B-MED
-	I-MED
average	I-MED
diameter	B-MED
of	O
the	O
AgNPs	B-MED
was	O
50.86	O
nm	O
with	O
polydispersity	B-MED
index	I-MED
(	O
PDI	B-MED
)	O
0.136	O
.	O
Zeta	B-MED
potential	I-MED
analysis	B-MED
displayed	O
the	O
colloidal	B-MED
stability	I-MED
of	O
AgNPs	B-MED
.	O
This	O
work	O
also	O
showed	O
the	O
efficacy	B-MED
of	O
AgNPs	B-MED
against	O
lung	B-MED
cancer	B-MED
cell	I-MED
lines	I-MED
(	O
A549	B-MED
)	O
and	O
cervical	B-MED
cancer	B-MED
cell	I-MED
line	I-MED
(	O
HeLa	B-MED
)	O
,	O
in	B-MED
vitro	I-MED
.	O
The	O
AgNPs	B-MED
showed	O
cytotoxicity	B-MED
to	O
the	O
A549	B-MED
and	O
HeLa	B-MED
cancer	B-MED
cell	I-MED
line	I-MED
at	O
the	O
concentrations	B-MED
5	O
and	O
2	O
μg	O
/	O
ml	O
.	O
The	O
AgNPs	B-MED
were	O
also	O
explored	O
for	O
the	O
antibacterial	B-MED
activity	I-MED
including	O
biofilm	B-MED
inhibition	B-MED
against	O
pathogenic	B-MED
bacteria	B-MED
.	O
The	O
B.	B-MED
officinalis	I-MED
leaves	B-MED
extract	B-MED
can	O
be	O
used	O
efficiently	B-MED
for	O
green	O
synthesis	B-MED
AgNPs	B-MED
.	O
The	O
biosynthesized	O
AgNPs	B-MED
demonstrated	O
potentials	B-MED
as	O
anticancer	B-MED
and	O
antibacterial	B-MED
agents	I-MED
.	O
This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	B-MED
of	O
new	O
anticancer	B-MED
and	O
antimicrobial	B-MED
agents	I-MED
.	O
Elastin	B-MED
Is	O
Differentially	B-MED
Regulated	I-MED
by	O
Pressure	B-MED
Therapy	I-MED
in	O
a	O
Porcine	B-MED
Model	B-MED
of	O
Hypertrophic	B-MED
Scar	I-MED
Beneficial	B-MED
effects	I-MED
of	O
pressure	B-MED
therapy	I-MED
for	O
hypertrophic	B-MED
scars	I-MED
have	O
been	O
reported	O
,	O
but	O
the	O
mechanisms	B-MED
of	O
action	O
are	O
not	O
fully	O
understood	O
.	O
This	O
study	B-MED
evaluated	O
elastin	B-MED
and	O
its	O
contribution	O
to	O
scar	B-MED
pliability	B-MED
.	O
The	O
relationship	B-MED
between	O
changes	O
in	O
Vancouver	B-MED
Scar	I-MED
Scale	I-MED
(	O
VSS	B-MED
)	O
scores	B-MED
of	O
pressure	B-MED
-	I-MED
treated	I-MED
scars	B-MED
and	O
differential	O
regulation	O
of	O
elastin	B-MED
was	O
assessed	O
.	O
Hypertrophic	B-MED
scars	I-MED
were	O
created	O
and	O
assessed	O
weekly	B-MED
using	O
VSS	B-MED
and	O
biopsy	B-MED
procurement	B-MED
.	O
Pressure	B-MED
treatment	I-MED
began	O
on	O
day	B-MED
70	O
postinjury	B-MED
.	O
Treated	B-MED
scars	B-MED
were	O
compared	B-MED
with	O
untreated	O
shams	B-MED
.	O
Treatment	B-MED
lasted	O
2	O
weeks	B-MED
,	O
through	O
day	B-MED
84	O
,	O
and	O
scars	B-MED
were	O
assessed	O
weekly	B-MED
through	O
day	B-MED
126	O
.	O
Transcript	B-MED
and	O
protein	B-MED
levels	I-MED
of	O
elastin	B-MED
were	O
quantified	B-MED
.	O
Pressure	B-MED
treatment	I-MED
resulted	O
in	O
lower	O
VSS	B-MED
scores	B-MED
compared	B-MED
with	O
sham	B-MED
-	I-MED
treated	I-MED
scars	B-MED
.	O
Pliability	B-MED
(	O
VSSP	B-MED
)	O
was	O
a	O
key	O
contributor	O
to	O
this	O
difference	O
.	O
At	O
day	B-MED
70	O
pretreatment	B-MED
,	O
VSSP	B-MED
=	O
2	O
.	O
Without	B-MED
treatment	I-MED
,	O
sham	B-MED
-	I-MED
treated	I-MED
scars	B-MED
became	O
less	O
pliable	B-MED
,	O
while	O
pressure	B-MED
-	I-MED
treated	I-MED
scars	B-MED
became	O
more	O
pliable	B-MED
.	O
The	O
percentage	O
of	O
elastin	B-MED
in	O
scars	B-MED
at	O
day	B-MED
70	O
was	O
higher	O
than	O
in	O
uninjured	B-MED
skin	I-MED
.	O
Following	O
treatment	B-MED
,	O
the	O
percentage	O
of	O
elastin	B-MED
increased	B-MED
and	O
continued	O
to	O
increase	B-MED
through	O
day	B-MED
126	O
.	O
Untreated	O
sham	B-MED
scars	B-MED
did	O
not	O
show	O
a	O
similar	O
increase	B-MED
.	O
Quantification	B-MED
of	O
Verhoeff	B-MED
-	I-MED
Van	I-MED
Gieson	I-MED
staining	I-MED
corroborated	O
the	O
findings	B-MED
and	O
immunofluorescence	B-MED
revealed	O
the	O
alignment	B-MED
of	O
elastin	B-MED
fibers	I-MED
.	O
Pressure	B-MED
treatment	I-MED
results	O
in	O
increased	B-MED
protein	B-MED
level	I-MED
expression	I-MED
of	O
elastin	B-MED
compared	B-MED
with	O
sham	B-MED
-untreated	O
scars	B-MED
.	O
These	O
findings	B-MED
further	O
characterize	O
the	O
extracellular	B-MED
matrix	I-MED
's	I-MED
response	O
to	O
the	O
application	O
of	O
pressure	B-MED
as	O
a	O
scar	B-MED
treatment	B-MED
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	B-MED
practices	O
and	O
ultimately	O
improvements	B-MED
in	O
functional	B-MED
and	O
psychosocial	B-MED
outcomes	B-MED
for	O
patients	B-MED
.	O
A	O
novel	B-MED
rapid	B-MED
analysis	B-MED
using	O
mass	B-MED
spectrometry	I-MED
to	O
evaluate	O
downstream	B-MED
refolding	B-MED
of	O
recombinant	B-MED
human	I-MED
insulin	I-MED
-	I-MED
like	I-MED
growth	I-MED
factor-1	I-MED
(	O
mecasermin	B-MED
)	O
Mecasermin	B-MED
is	O
used	O
to	O
treat	O
elevated	B-MED
blood	I-MED
sugar	I-MED
as	O
well	O
as	O
growth	B-MED
hormone	I-MED
-	O
resistant	B-MED
Laron	B-MED
-	I-MED
type	I-MED
dwarfism	I-MED
.	O
Mecasermin	B-MED
isolated	O
from	O
inclusion	B-MED
bodies	I-MED
in	O
extracts	O
of	O
E.coli	B-MED
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O
However	O
,	O
there	O
is	O
no	O
rapid	B-MED
analytical	B-MED
method	I-MED
for	O
monitoring	O
refolding	B-MED
during	O
the	O
purification	B-MED
process	O
.	O
We	O
prepared	O
mecasermin	B-MED
drug	B-MED
product	I-MED
,	O
in	O
-	O
process	O
samples	B-MED
during	O
the	O
oxidation	B-MED
of	O
mecasermin	B-MED
,	O
forced	O
-	O
reduced	O
mecasermin	B-MED
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-MED
after	O
forced	O
reduction	B-MED
.	O
Desalted	O
mecasermin	B-MED
samples	B-MED
were	O
analyzed	O
using	O
MALDI	B-MED
-	I-MED
ISD	I-MED
.	O
The	O
peak	B-MED
intensity	I-MED
ratio	I-MED
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O
The	O
charge	B-MED
state	I-MED
distribution	I-MED
(	O
CSD	B-MED
)	O
of	O
mecasermin	B-MED
ions	O
was	O
evaluated	O
using	O
ESI	B-MED
-	I-MED
MS	I-MED
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-MED
.	O
The	O
drift	B-MED
time	I-MED
and	O
collision	B-MED
cross	I-MED
-	I-MED
sectional	I-MED
areas	I-MED
(	O
CCS	B-MED
)	O
of	O
mecasermin	B-MED
ions	O
were	O
evaluated	O
using	O
ESI	B-MED
-	I-MED
IMS	I-MED
-	I-MED
MS	I-MED
coupled	B-MED
with	O
SEC	O
-	O
mode	O
HPLC	B-MED
.	O
MALDI	B-MED
-	I-MED
ISD	I-MED
data	O
,	O
CSD	B-MED
values	I-MED
determined	O
using	O
ESI	B-MED
-	I-MED
MS	I-MED
,	O
and	O
the	O
CCS	B-MED
acquired	O
using	O
ESI	B-MED
-	I-MED
IMS	I-MED
-	I-MED
MS	I-MED
revealed	O
the	O
relationship	B-MED
between	O
the	O
folded	B-MED
and	O
unfolded	B-MED
proteoforms	B-MED
of	O
forced	O
-	O
reduced	O
mecasermin	B-MED
and	O
aerially	O
oxidized	O
mecasermin	B-MED
with	O
the	O
free	B-MED
-	I-MED
SH	I-MED
:	I-MED
protein	I-MED
ratio	I-MED
of	O
mecasermin	B-MED
drug	B-MED
product	I-MED
.	O
The	O
collision	B-MED
cross	I-MED
-	I-MED
sectional	I-MED
area	I-MED
,	O
which	O
is	O
determined	O
using	O
ESI	B-MED
-	I-MED
IMS	I-MED
-	I-MED
MS	I-MED
,	O
provided	O
proteoform	B-MED
information	O
through	O
rapid	B-MED
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	B-MED
during	O
the	O
manufacture	O
of	O
mecasermin	B-MED
.	O
ESI	B-MED
-	I-MED
IMS	I-MED
-	I-MED
MS	I-MED
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-MED
is	O
a	O
rapid	B-MED
and	O
robust	B-MED
method	O
for	O
analyzing	O
the	O
free	B-MED
-	I-MED
SH	I-MED
:	I-MED
protein	I-MED
ratio	I-MED
of	O
mecasermin	B-MED
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B-MED
changes	O
during	O
the	O
oxidation	B-MED
of	O
mecasermin	B-MED
.	O
ESI	B-MED
-	I-MED
IMS	I-MED
-	I-MED
MS	I-MED
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	B-MED
quality	B-MED
attributes	B-MED
"	O
and	O
implementing	O
"	O
quality	B-MED
by	O
design	B-MED
"	O
for	O
manufacturing	O
mecasermin	B-MED
.	O
Modification	B-MED
of	O
Mechanical	B-MED
Properties	I-MED
,	O
Polymerization	B-MED
Temperature	B-MED
,	O
and	O
Handling	B-MED
Time	I-MED
of	O
Polymethylmethacrylate	B-MED
Cement	B-MED
for	O
Enhancing	O
Applicability	B-MED
in	O
Vertebroplasty	B-MED
Polymethylmethacrylate	B-MED
(	O
PMMA	B-MED
)	O
bone	B-MED
cement	I-MED
is	O
a	O
popular	O
bone	B-MED
void	B-MED
filler	B-MED
for	O
vertebroplasty	B-MED
.	O
However	O
,	O
the	O
use	O
of	O
PMMA	B-MED
has	O
some	O
drawbacks	O
,	O
including	O
the	O
material	B-MED
's	I-MED
excessive	O
stiffness	B-MED
,	O
exothermic	B-MED
polymerization	I-MED
,	O
and	O
short	B-MED
handling	B-MED
time	I-MED
.	O
This	O
study	B-MED
aimed	O
to	O
create	O
an	O
ideal	O
modified	B-MED
bone	B-MED
cement	I-MED
to	O
solve	O
the	O
above	O
-	O
mentioned	O
problems	B-MED
.	O
Modified	B-MED
bone	B-MED
cements	I-MED
were	O
prepared	B-MED
by	O
combining	O
PMMA	B-MED
with	O
three	O
different	O
volume	B-MED
fractions	I-MED
of	O
castor	B-MED
oil	I-MED
(	O
5	O
%	O
,	O
10	O
%	O
,	O
and	O
15	O
%	O
)	O
.	O
The	O
peak	B-MED
polymerization	B-MED
temperatures	B-MED
,	O
times	O
to	O
achieve	O
the	O
peak	B-MED
polymerization	B-MED
temperature	B-MED
,	O
porosities	B-MED
,	O
densities	B-MED
,	O
modulus	B-MED
and	O
maximum	B-MED
compression	B-MED
strengths	I-MED
of	O
standard	B-MED
(	O
without	O
castor	B-MED
oil	I-MED
)	O
,	O
and	O
modified	B-MED
cements	B-MED
were	O
investigated	B-MED
following	O
storage	O
at	O
ambient	B-MED
temperature	I-MED
(	O
22	O
°	O
C	O
)	O
or	O
under	O
precooling	B-MED
conditions	B-MED
(	O
3	O
°	O
C	O
)	O
.	O
Six	O
specimens	B-MED
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	B-MED
.	O
Increasing	B-MED
castor	B-MED
oil	I-MED
content	O
and	O
precooling	B-MED
treatment	B-MED
effectively	O
decreased	B-MED
the	O
peak	B-MED
polymerization	B-MED
temperatures	B-MED
and	O
increased	B-MED
the	O
duration	B-MED
to	O
achieve	O
the	O
peak	B-MED
polymerization	B-MED
temperature	B-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
the	O
mechanical	B-MED
properties	I-MED
of	O
the	O
material	B-MED
,	O
including	O
density	B-MED
,	O
modulus	B-MED
,	O
and	O
maximum	B-MED
compression	B-MED
strength	I-MED
,	O
decreased	B-MED
with	O
increasing	B-MED
castor	B-MED
oil	I-MED
content	B-MED
.	O
However	O
,	O
preparation	B-MED
temperature	B-MED
(	O
room	B-MED
temperature	I-MED
versus	O
precooling	B-MED
)	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
on	O
these	O
mechanical	B-MED
properties	I-MED
.	O
In	O
conclusion	O
,	O
the	O
addition	O
of	O
castor	B-MED
oil	I-MED
to	O
PMMA	B-MED
followed	O
by	O
precooling	B-MED
created	O
an	O
ideal	O
modified	B-MED
bone	B-MED
cement	I-MED
with	O
a	O
low	O
modulus	B-MED
,	O
low	O
polymerization	B-MED
temperature	B-MED
,	O
and	O
long	O
handling	B-MED
time	I-MED
,	O
enhancing	O
its	O
applicability	B-MED
and	O
safety	B-MED
for	O
vertebroplasty	B-MED
.	O
Novel	B-MED
Strategy	I-MED
to	O
Expand	O
Super	B-MED
-	I-MED
Charged	I-MED
NK	I-MED
Cells	I-MED
with	O
Significant	B-MED
Potential	I-MED
to	O
Lyse	B-MED
and	O
Differentiate	B-MED
Cancer	B-MED
Stem	I-MED
Cells	I-MED
:	O
Differences	B-MED
in	O
NK	B-MED
Expansion	I-MED
and	O
Function	B-MED
between	O
Healthy	B-MED
and	O
Cancer	B-MED
Patients	I-MED
Natural	B-MED
killer	I-MED
(	I-MED
NK	I-MED
)	I-MED
cells	I-MED
are	O
known	O
to	O
target	O
cancer	B-MED
stem	I-MED
cells	I-MED
and	O
undifferentiated	B-MED
tumors	I-MED
.	O
In	O
this	O
paper	O
,	O
we	O
provide	O
a	O
novel	B-MED
strategy	I-MED
for	O
expanding	O
large	O
numbers	O
of	O
super	B-MED
-	I-MED
charged	I-MED
NK	I-MED
cells	I-MED
with	O
significant	B-MED
potential	I-MED
to	O
lyse	B-MED
and	O
differentiate	B-MED
cancer	B-MED
stem	I-MED
cells	I-MED
and	O
demonstrate	O
the	O
differences	B-MED
in	O
the	O
dynamics	B-MED
of	O
NK	B-MED
cell	I-MED
expansion	B-MED
between	O
healthy	B-MED
donors	I-MED
and	O
cancer	B-MED
patients	I-MED
.	O
Decline	B-MED
in	I-MED
cytotoxicity	I-MED
and	O
lower	B-MED
interferon	B-MED
(	I-MED
IFN)-γ	I-MED
secretion	I-MED
by	O
osteoclast	B-MED
OC	B-MED
(	O
OC)-expanded	O
NK	B-MED
cells	I-MED
from	O
cancer	B-MED
patients	I-MED
correlates	O
with	O
faster	B-MED
expansion	B-MED
of	O
residual	O
contaminating	B-MED
T	B-MED
cells	I-MED
within	O
purified	B-MED
NK	B-MED
cells	I-MED
,	O
whereas	O
healthy	B-MED
donors	I-MED
'	O
OCs	B-MED
continue	O
expanding	O
super	B-MED
-	I-MED
charged	I-MED
NK	I-MED
cells	I-MED
while	O
limiting	O
T	B-MED
cell	I-MED
expansion	B-MED
for	O
up	O
to	O
60	O
days	B-MED
.	O
Similar	O
to	O
patient	B-MED
NK	B-MED
cells	I-MED
,	O
NK	B-MED
cells	I-MED
from	O
tumor	B-MED
-bearing	O
BLT	B-MED
-	I-MED
humanized	I-MED
mice	I-MED
promote	O
faster	B-MED
expansion	B-MED
of	O
residual	O
T	B-MED
cells	I-MED
resulting	I-MED
in	I-MED
decreased	I-MED
numbers	I-MED
and	O
function	B-MED
of	O
NK	B-MED
cells	I-MED
,	O
whereas	O
NK	B-MED
cells	I-MED
from	O
mice	B-MED
with	O
no	B-MED
tumor	B-MED
continue	O
expanding	B-MED
NK	B-MED
cells	I-MED
and	O
retain	O
their	O
cytotoxicity	B-MED
.	O
In	O
addition	O
,	O
dendritic	B-MED
cells	I-MED
(	O
DCs	B-MED
)	O
in	O
contrast	O
to	O
OCs	B-MED
are	O
found	O
to	O
promote	O
faster	B-MED
expansion	B-MED
of	O
residual	O
T	B-MED
cells	I-MED
within	O
purified	B-MED
NK	B-MED
cells	I-MED
resulting	O
in	O
the	O
decline	B-MED
in	I-MED
NK	I-MED
cell	I-MED
numbers	I-MED
from	O
healthy	B-MED
individuals	I-MED
.	O
Addition	O
of	O
anti	B-MED
-	I-MED
CD3	I-MED
mAb	I-MED
inhibits	O
T	B-MED
cell	I-MED
proliferation	I-MED
while	O
enhancing	B-MED
NK	B-MED
cell	I-MED
expansion	B-MED
;	O
however	O
,	O
expanding	B-MED
NK	B-MED
cells	I-MED
have	O
lower	B-MED
cytotoxicity	B-MED
but	O
higher	B-MED
secretion	B-MED
of	I-MED
IFN	I-MED
-	I-MED
γ	I-MED
.	O
Expansion	B-MED
and	O
functional	B-MED
activation	B-MED
of	O
super	B-MED
-	I-MED
charged	I-MED
NK	I-MED
cells	I-MED
by	O
OCs	B-MED
is	O
dependent	B-MED
on	O
interleukin	B-MED
(	I-MED
IL)-12	I-MED
and	O
IL-15	B-MED
.	O
Thus	O
,	O
in	O
this	O
report	O
,	O
we	O
not	O
only	O
provide	O
a	O
novel	B-MED
strategy	I-MED
to	O
expand	B-MED
super	B-MED
-	I-MED
charged	I-MED
NK	I-MED
cells	I-MED
,	O
but	O
also	O
demonstrate	O
that	O
rapid	B-MED
and	I-MED
sustained	I-MED
expansion	I-MED
of	O
residual	O
T	B-MED
cells	I-MED
within	O
the	O
purified	B-MED
NK	B-MED
cells	I-MED
during	O
expansion	B-MED
with	O
DCs	B-MED
or	O
OCs	B-MED
could	O
be	O
a	O
potential	B-MED
mechanism	B-MED
by	O
which	O
the	O
numbers	B-MED
and	O
function	B-MED
of	O
NK	B-MED
cells	I-MED
decline	I-MED
in	O
cancer	B-MED
patients	I-MED
and	O
in	O
BLT	B-MED
-	I-MED
humanized	I-MED
mice	I-MED
.	O
Genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	I-MED
for	O
studying	O
long	B-MED
-	I-MED
term	I-MED
calcium	B-MED
dynamics	B-MED
during	O
apoptosis	B-MED
Intracellular	B-MED
calcium	I-MED
release	I-MED
is	O
essential	B-MED
for	O
regulating	B-MED
almost	O
all	O
cellular	B-MED
functions	I-MED
.	O
Specific	B-MED
spatio	B-MED
-	I-MED
temporal	I-MED
patterns	B-MED
of	O
cytosolic	B-MED
calcium	B-MED
elevations	B-MED
are	O
critical	B-MED
determinants	B-MED
of	O
cell	B-MED
fate	I-MED
in	O
response	O
to	O
pro	B-MED
-	I-MED
apoptotic	I-MED
cellular	B-MED
stressors	B-MED
.	O
As	O
the	O
apoptotic	B-MED
program	I-MED
can	O
take	O
hours	B-MED
or	O
days	B-MED
,	O
measurement	B-MED
of	O
long	B-MED
-	I-MED
term	I-MED
calcium	B-MED
dynamics	B-MED
are	O
essential	B-MED
for	O
understanding	B-MED
the	O
mechanistic	B-MED
role	B-MED
of	O
calcium	B-MED
in	O
apoptotic	B-MED
cell	I-MED
death	I-MED
.	O
Due	O
to	O
the	O
technical	B-MED
limitations	B-MED
of	O
using	O
calcium	B-MED
-	O
sensitive	B-MED
dyes	B-MED
to	O
measure	B-MED
cytosolic	B-MED
calcium	B-MED
little	O
is	O
known	O
about	O
long	B-MED
-	I-MED
term	I-MED
calcium	B-MED
dynamics	B-MED
in	O
living	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
apoptosis	B-MED
-	O
inducing	B-MED
drugs	B-MED
.	O
Genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	I-MED
could	O
potentially	O
overcome	B-MED
some	O
of	O
the	O
limitations	B-MED
of	O
calcium	B-MED
-	O
sensitive	B-MED
dyes	B-MED
.	O
Here	O
,	O
we	O
compared	O
the	O
performance	B-MED
of	O
the	O
genetically	B-MED
encoded	B-MED
calcium	B-MED
indicators	B-MED
GCaMP6s	B-MED
and	O
GCaMP6f	B-MED
with	O
the	O
ratiometric	B-MED
dye	I-MED
Fura-2	B-MED
.	O
GCaMP6s	B-MED
performed	O
as	O
well	O
or	O
better	O
than	O
Fura-2	B-MED
in	O
detecting	O
agonist	B-MED
-	O
induced	B-MED
calcium	B-MED
transients	B-MED
.	O
We	O
then	O
examined	O
the	O
utility	B-MED
of	O
GCaMP6s	B-MED
for	O
continuously	B-MED
measuring	B-MED
apoptotic	B-MED
calcium	B-MED
release	I-MED
over	O
the	O
course	B-MED
of	O
ten	O
hours	B-MED
after	O
treatment	B-MED
with	O
staurosporine	B-MED
.	O
We	O
found	O
that	O
GCaMP6s	B-MED
was	O
suitable	O
for	O
measuring	B-MED
apoptotic	B-MED
calcium	B-MED
release	I-MED
over	O
long	O
time	O
courses	B-MED
and	O
revealed	O
significant	B-MED
heterogeneity	B-MED
in	O
calcium	B-MED
release	I-MED
dynamics	B-MED
in	O
individual	O
cells	B-MED
challenged	O
with	O
staurosporine	B-MED
.	O
Our	O
results	O
suggest	O
GCaMP6s	B-MED
is	O
an	O
excellent	B-MED
indicator	B-MED
for	O
monitoring	B-MED
long	B-MED
-	I-MED
term	I-MED
changes	B-MED
cytosolic	B-MED
calcium	B-MED
during	O
apoptosis	B-MED
.	O
Anti	B-MED
-	I-MED
inflammatory	I-MED
effect	I-MED
of	O
Yu	B-MED
-	I-MED
Ping	I-MED
-	I-MED
Feng	I-MED
-	I-MED
San	I-MED
via	O
TGF	B-MED
-	I-MED
β1	I-MED
signaling	B-MED
suppression	I-MED
in	O
rat	B-MED
model	B-MED
of	O
COPD	B-MED
Yu	B-MED
-	I-MED
Ping	I-MED
-	I-MED
Feng	I-MED
-	I-MED
San	I-MED
(	O
YPFS	B-MED
)	O
is	O
a	O
classical	O
traditional	O
Chinese	B-MED
medicine	I-MED
that	O
is	O
widely	O
used	O
for	O
treatment	B-MED
of	O
the	O
diseases	B-MED
in	O
respiratory	B-MED
systems	I-MED
,	O
including	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
recognized	O
as	O
chronic	B-MED
inflammatory	I-MED
disease	I-MED
.	O
However	O
,	O
the	O
molecular	B-MED
mechanism	I-MED
remains	O
unclear	O
.	O
Here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
1	I-MED
(	O
TGF	B-MED
-	I-MED
β1	I-MED
β1)/	O
Smad2	B-MED
signaling	B-MED
pathway	I-MED
and	O
inflammatory	B-MED
cytokines	I-MED
,	O
to	O
clarify	O
whether	O
YPFS	B-MED
could	O
attenuate	B-MED
inflammatory	B-MED
response	I-MED
dependent	O
on	O
TGF	B-MED
-	I-MED
β1	I-MED
/	O
Smad2	B-MED
signaling	B-MED
in	O
COPD	B-MED
rats	B-MED
or	O
cigarette	B-MED
smoke	I-MED
extract	I-MED
CSE	B-MED
(	O
CSE)-	O
treated	B-MED
human	B-MED
bronchial	B-MED
epithelial	I-MED
(	I-MED
Beas-2B	I-MED
)	I-MED
cells	I-MED
.	O
The	O
COPD	B-MED
rat	B-MED
model	B-MED
was	O
established	O
by	O
exposure	B-MED
to	O
cigarette	B-MED
smoke	I-MED
and	O
intratracheal	B-MED
instillation	I-MED
of	O
lipopolysaccharide	B-MED
,	O
YPFS	B-MED
was	O
administered	O
to	O
the	O
animals	B-MED
.	O
The	O
efficacy	B-MED
of	O
YPFS	B-MED
was	O
evaluated	O
by	O
comparing	O
the	O
severity	B-MED
of	O
pulmonary	B-MED
pathological	I-MED
damage	I-MED
,	O
pro	B-MED
-	I-MED
inflammation	I-MED
cytokines	I-MED
,	O
collagen	B-MED
related	I-MED
genes	I-MED
and	O
the	O
activation	B-MED
of	O
TGF	B-MED
-	I-MED
β1	I-MED
/	O
Smad2	B-MED
signaling	B-MED
pathway	I-MED
.	O
Furthermore	O
,	O
CSE	B-MED
-	O
treated	B-MED
cells	B-MED
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	B-MED
of	O
YPFS	B-MED
was	O
dependent	O
on	O
the	O
TGF	B-MED
-	I-MED
β1	I-MED
/	O
Smad2	B-MED
signaling	B-MED
via	O
knockdown	B-MED
Smad2	B-MED
(	O
Si	B-MED
-	I-MED
RNA	I-MED
)	O
,	O
or	O
pretreatment	B-MED
with	O
the	O
inhibitor	B-MED
of	O
TGF	B-MED
-	I-MED
β1	I-MED
.	O
Administration	O
of	O
YPFS	B-MED
effectively	O
alleviated	O
injury	B-MED
of	I-MED
lung	I-MED
,	O
suppressed	B-MED
releasing	O
of	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokines	I-MED
and	O
collagen	B-MED
deposition	I-MED
in	O
COPD	B-MED
animals	B-MED
(	O
P<0.05	O
)	O
,	O
whereas	O
exogenous	B-MED
TGF	I-MED
-	I-MED
β1	I-MED
promoted	O
releasing	O
of	O
IL-1β	B-MED
,	O
IL-6	B-MED
,	O
TNFα	B-MED
(	O
P<0.05	O
)	O
.	O
Administration	O
YPFS	B-MED
reduced	O
inflammatory	B-MED
response	I-MED
significantly	O
,	O
also	O
down	B-MED
-	I-MED
regulated	I-MED
TGF	B-MED
-	I-MED
β1	I-MED
/	O
Smad2	B-MED
signaling	B-MED
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
.	O
Unexpectedly	O
,	O
knockdown	B-MED
Smad2	B-MED
or	O
inhibition	B-MED
of	O
TGF	B-MED
-	I-MED
β1	I-MED
abolished	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effect	I-MED
of	O
YPFS	B-MED
in	O
CSE	B-MED
-	O
treated	B-MED
cells	B-MED
.	O
YPFS	B-MED
accomplished	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effects	I-MED
mainly	O
by	O
suppressing	B-MED
phosphorylation	B-MED
of	O
Smad2	B-MED
,	O
TGF	B-MED
-	I-MED
β1	I-MED
/	O
Smad2	B-MED
signaling	B-MED
pathway	I-MED
was	O
required	O
for	O
YPFS	B-MED
-mediated	O
anti	B-MED
-	I-MED
inflammation	I-MED
in	O
COPD	B-MED
rats	B-MED
or	O
CSE	B-MED
-	O
treated	B-MED
Beas-2B	B-MED
cells	I-MED
.	O
Evidence	B-MED
of	I-MED
toothpick	B-MED
groove	B-MED
formation	B-MED
in	O
Neandertal	B-MED
anterior	B-MED
and	O
posterior	B-MED
teeth	B-MED
During	O
the	O
microscopic	B-MED
examination	I-MED
of	O
the	O
Neandertal	B-MED
dentitions	B-MED
from	O
El	B-MED
Sidrón	I-MED
(	O
Spain	B-MED
)	O
and	O
Hortus	B-MED
(	O
France	B-MED
)	O
,	O
we	O
found	O
unusual	B-MED
fine	O
parallel	O
microstriations	B-MED
on	O
the	O
mesial	B-MED
and	O
distal	B-MED
sides	I-MED
of	O
all	O
tooth	B-MED
types	O
,	O
near	O
the	O
cervix	B-MED
.	O
As	O
its	O
appearance	O
was	O
similar	B-MED
to	O
toothpick	B-MED
grooves	B-MED
described	O
in	O
other	O
Homo	B-MED
species	I-MED
,	O
it	O
could	O
correspond	O
to	O
early	B-MED
stages	I-MED
on	O
its	O
formation	B-MED
.	O
To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	B-MED
replication	I-MED
of	O
a	O
groove	B-MED
using	O
grass	B-MED
stalks	B-MED
.	O
Comparisons	B-MED
between	O
204	O
isolated	B-MED
Neandertal	B-MED
teeth	B-MED
and	O
the	O
two	O
experimental	B-MED
dental	B-MED
specimens	B-MED
corroborate	O
that	O
the	O
marks	B-MED
correspond	O
to	O
initial	B-MED
stages	I-MED
of	O
toothpick	B-MED
groove	B-MED
formation	B-MED
,	O
and	O
we	O
propose	O
a	O
five	B-MED
-	I-MED
grade	I-MED
recording	I-MED
scale	I-MED
that	O
summarized	O
the	O
groove	B-MED
formation	B-MED
process	I-MED
.	O
Using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
Hortus	B-MED
individuals	B-MED
have	O
higher	O
incidence	B-MED
of	O
this	O
trait	O
(	O
eight	O
individuals	B-MED
out	O
of	O
nine	O
)	O
than	O
the	O
El	B-MED
Sidrón	I-MED
individuals	B-MED
(	O
nine	O
out	O
of	O
11	O
)	O
.	O
Toothpick	B-MED
grooves	B-MED
from	O
El	B-MED
Sidrón	I-MED
show	O
the	O
earliest	B-MED
stages	I-MED
of	O
development	B-MED
,	O
whereas	O
the	O
grooves	B-MED
found	O
on	O
Hortus	B-MED
Neandertals	B-MED
were	O
well	B-MED
-	I-MED
developed	I-MED
.	O
Toothpick	B-MED
grooves	B-MED
were	O
also	O
found	O
in	O
21	O
incisors	B-MED
and	O
canines	B-MED
.	O
These	O
differences	B-MED
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	B-MED
dental	B-MED
wear	I-MED
in	O
Hortus	B-MED
individuals	B-MED
,	O
maybe	O
age	B-MED
-related	O
and	O
with	O
a	O
more	O
meat	B-MED
-based	O
diet	B-MED
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	B-MED
debris	B-MED
and	O
thus	O
probing	B-MED
as	O
the	O
cleaning	B-MED
methodology	I-MED
.	O
Our	O
results	O
allow	O
the	O
identification	B-MED
and	O
characterization	B-MED
of	O
incipient	B-MED
toothpick	B-MED
grooves	B-MED
on	O
the	O
human	B-MED
fossil	B-MED
record	B-MED
and	O
contribute	B-MED
to	O
increase	B-MED
our	O
knowledge	B-MED
on	O
Neandertals	B-MED
behavioral	B-MED
and	O
oral	B-MED
care	I-MED
habits	I-MED
.	O
The	O
value	O
of	O
transesophageal	B-MED
echocardiography	I-MED
for	O
embolic	B-MED
strokes	I-MED
of	I-MED
undetermined	I-MED
source	I-MED
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-MED
yield	I-MED
of	O
transesophageal	B-MED
echocardiography	I-MED
(	O
TEE	B-MED
)	O
in	O
consecutive	O
patients	B-MED
with	O
ischemic	B-MED
stroke	I-MED
(	O
IS	B-MED
)	O
fulfilling	O
the	O
diagnostic	B-MED
criteria	I-MED
of	O
embolic	B-MED
strokes	I-MED
of	I-MED
undetermined	I-MED
source	I-MED
(	O
ESUS	B-MED
)	O
.	O
We	O
prospectively	O
evaluated	O
consecutive	O
patients	B-MED
with	O
acute	O
IS	B-MED
satisfying	O
ESUS	B-MED
criteria	O
who	O
underwent	O
in-	O
hospital	B-MED
TEE	B-MED
examination	I-MED
in	O
3	O
tertiary	B-MED
care	I-MED
stroke	I-MED
centers	I-MED
during	B-MED
a	I-MED
12	I-MED
-	I-MED
month	I-MED
period	I-MED
.	O
We	O
also	O
performed	O
a	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
estimating	I-MED
the	O
cumulative	O
effect	O
of	O
TEE	B-MED
findings	B-MED
on	O
therapeutic	B-MED
management	I-MED
for	O
secondary	B-MED
stroke	I-MED
prevention	I-MED
among	O
different	O
IS	B-MED
subgroups	O
.	O
We	O
identified	O
61	O
patients	B-MED
with	O
ESUS	B-MED
who	O
underwent	B-MED
investigation	I-MED
with	O
TEE	B-MED
(	O
mean	O
age	O
44	O
±	O
12	O
years	O
,	O
49	O
%	O
men	B-MED
,	O
median	O
NIH	B-MED
Stroke	I-MED
Scale	I-MED
score	I-MED
=	O
5	O
points	O
[	O
interquartile	B-MED
range	I-MED
:	O
3	O
-	O
8	O
]	O
)	O
.	O
TEE	B-MED
revealed	O
additional	O
findings	B-MED
in	O
52	O
%	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
:	O
40%-65	O
%	O
)	O
of	O
the	O
study	B-MED
population	I-MED
.	O
TEE	B-MED
findings	B-MED
changed	O
management	O
(	O
initiation	B-MED
of	O
anticoagulation	B-MED
therapy	I-MED
,	O
administration	B-MED
of	O
IV	B-MED
antibiotic	I-MED
therapy	I-MED
,	O
and	O
patent	B-MED
foramen	I-MED
ovale	I-MED
closure	I-MED
)	O
in	O
10	O
(	O
16	O
%	O
[	O
95	O
%	O
CI	B-MED
:	O
9%-28	O
%	O
]	O
)	O
patients	B-MED
.	O
The	O
pooled	B-MED
rate	I-MED
of	O
reported	O
anticoagulation	B-MED
therapy	I-MED
attributed	O
to	O
abnormal	B-MED
TEE	B-MED
findings	B-MED
among	O
3,562	O
acute	O
IS	B-MED
patients	B-MED
included	O
in	O
the	O
meta	B-MED
-	I-MED
analysis	I-MED
(	O
12	O
studies	O
)	O
was	O
8.7	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
7.3%-10.4	O
%	O
)	O
.	O
In	O
subgroup	B-MED
analysis	I-MED
,	O
the	O
rates	O
of	O
initiation	B-MED
of	O
anticoagulation	B-MED
therapy	I-MED
on	O
the	O
basis	O
of	O
TEE	B-MED
investigation	O
did	O
not	O
differ	O
(	O
p	O
=	O
0.315	O
)	O
among	O
patients	B-MED
with	O
cryptogenic	B-MED
stroke	I-MED
(	O
6.9	O
%	O
[	O
95	O
%	O
CI	B-MED
:	O
4.9%-9.6	O
%	O
]	O
)	O
,	O
ESUS	B-MED
(	O
8.1	O
%	O
[	O
95	O
%	O
CI	B-MED
:	O
3.4%-18.1	O
%	O
]	O
)	O
,	O
and	O
IS	B-MED
(	O
9.4	O
%	O
[	O
95	O
%	O
CI	B-MED
:	O
7.5%-11.8	O
%	O
]	O
)	O
.	O
Abnormal	O
TEE	B-MED
findings	B-MED
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	B-MED
therapeutic	B-MED
strategy	I-MED
in	O
approximately	O
1	O
of	O
7	O
patients	B-MED
with	O
ESUS	B-MED
.	O
Treating	B-MED
the	O
binge	B-MED
or	O
the	O
(	B-MED
fat	I-MED
)	I-MED
body	I-MED
?	O
Representations	B-MED
of	O
fatness	B-MED
in	O
a	O
gold	B-MED
standard	I-MED
psychological	B-MED
treatment	B-MED
manual	I-MED
for	O
binge	B-MED
eating	I-MED
disorder	I-MED
This	O
article	O
reports	B-MED
the	O
results	B-MED
of	O
a	O
Foucauldian	B-MED
-informed	O
discourse	B-MED
analysis	I-MED
exploring	O
representations	B-MED
of	O
fatness	B-MED
embedded	O
within	O
an	O
empirically	B-MED
based	O
psychological	B-MED
treatment	B-MED
manual	I-MED
for	O
binge	B-MED
eating	I-MED
disorder	I-MED
,	O
a	O
condition	B-MED
characterized	B-MED
by	O
overvaluation	O
of	O
weight	B-MED
and	O
shape	B-MED
.	O
Analyses	B-MED
indicate	B-MED
that	O
the	O
manual	B-MED
prioritizes	O
weight	B-MED
loss	I-MED
with	O
relatively	B-MED
less	O
emphasis	O
placed	O
on	O
treating	B-MED
the	O
diagnostic	B-MED
symptoms	B-MED
and	O
underlying	O
mechanisms	B-MED
of	O
binge	B-MED
eating	I-MED
disorder	I-MED
.	O
We	O
raise	O
critical	B-MED
concerns	I-MED
about	O
these	O
observations	B-MED
and	O
link	O
our	O
findings	B-MED
to	O
mainstream	O
psychology	B-MED
's	I-MED
adoption	O
of	O
the	O
medical	B-MED
framing	I-MED
of	O
fatness	B-MED
as	O
obesity	B-MED
within	O
the	O
"	O
gold	B-MED
standard	I-MED
"	O
approach	O
to	O
intervention	B-MED
.	O
We	O
recommend	O
that	O
psychology	B-MED
as	O
a	O
discipline	B-MED
abandons	O
the	O
weight	B-MED
loss	I-MED
imperative	O
associated	B-MED
with	I-MED
binge	B-MED
eating	I-MED
disorder	I-MED
and	O
fat	B-MED
bodies	I-MED
.	O
We	O
recommend	O
that	O
practitioners	B-MED
locate	O
the	O
problem	B-MED
of	O
fat	B-MED
shame	I-MED
in	O
society	B-MED
as	O
opposed	O
to	O
the	O
individual	B-MED
person	O
's	O
body	B-MED
and	O
provide	B-MED
individuals	B-MED
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat	B-MED
stigma	I-MED
and	O
oppression	B-MED
,	O
rather	O
than	O
provide	B-MED
them	O
with	O
tools	O
to	O
reshape	O
their	O
bodies	B-MED
.	O
Lipid	B-MED
levels	I-MED
and	O
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
:	O
results	B-MED
from	O
the	O
MEGA	B-MED
follow	I-MED
-	I-MED
up	I-MED
study	I-MED
Essentials	O
The	O
role	O
of	O
lipid	B-MED
levels	I-MED
in	O
the	O
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
is	O
unclear	B-MED
.	O
Lipids	B-MED
were	O
assessed	B-MED
in	O
patients	B-MED
with	O
a	O
first	O
venous	B-MED
thrombosis	I-MED
(	O
n	O
=	O
2106	O
)	O
followed	B-MED
for	O
6.9	O
years	B-MED
.	O
Lipids	B-MED
were	O
not	O
associated	B-MED
with	I-MED
recurrence	B-MED
,	O
overall	O
or	O
in	O
patients	B-MED
with	O
unprovoked	O
first	O
events	B-MED
.	O
Testing	B-MED
lipid	I-MED
levels	I-MED
is	O
not	O
useful	B-MED
to	O
identify	B-MED
patients	B-MED
at	O
an	O
increased	B-MED
risk	B-MED
of	O
recurrence	B-MED
.	O
Background	O
Knowledge	O
of	O
risk	B-MED
factors	I-MED
for	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
may	O
guide	O
decisions	O
on	O
duration	B-MED
of	O
anticoagulation	B-MED
.	O
The	O
association	B-MED
between	O
lipid	B-MED
levels	I-MED
and	O
first	O
venous	B-MED
thrombosis	I-MED
has	O
been	O
studied	O
extensively	O
.	O
However	O
,	O
data	B-MED
on	O
the	O
role	O
of	O
lipids	B-MED
in	O
the	O
risk	B-MED
of	O
recurrence	B-MED
are	O
scarce	O
.	O
Objective	O
To	O
assess	B-MED
the	O
association	B-MED
between	O
lipid	B-MED
levels	I-MED
and	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
.	O
Patients	B-MED
/Methods	O
Patients	B-MED
with	O
a	O
first	O
venous	B-MED
thrombosis	I-MED
from	O
the	O
MEGA	B-MED
study	I-MED
were	O
included	B-MED
.	O
Follow	B-MED
-	I-MED
up	I-MED
started	B-MED
at	O
the	O
date	B-MED
of	O
end	B-MED
of	O
anticoagulant	B-MED
treatment	I-MED
.	O
Percentile	B-MED
categories	B-MED
of	O
total	B-MED
/	O
low	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
/	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
cholesterol	I-MED
,	O
triglycerides	B-MED
and	O
apolipoproteins	B-MED
B	I-MED
and	O
A1	B-MED
were	O
established	B-MED
(	O
<	O
10th	O
,	O
10th-25th	O
,	O
25th-75th	O
[	O
reference	B-MED
]	O
,	O
75th-90th	O
,	O
>	O
90th	O
percentile	B-MED
)	O
.	O
Lipids	B-MED
were	O
measured	B-MED
at	O
least	O
3	O
months	B-MED
after	O
discontinuing	B-MED
anticoagulation	B-MED
.	O
Results	B-MED
Of	O
2106	O
patients	B-MED
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	B-MED
,	O
326	O
developed	O
recurrence	B-MED
(	O
incidence	B-MED
rate	I-MED
,	O
2.7/100	O
patient	B-MED
-	O
years	B-MED
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
,	O
2.5	O
-	O
3.1	O
)	O
.	O
With	O
hazard	B-MED
ratios	I-MED
ranging	B-MED
from	O
0.88	O
(	O
95	O
%	O
CI	B-MED
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	B-MED
,	O
0.86	O
-	O
2.04	O
)	O
in	O
the	O
highest	O
percentile	B-MED
category	B-MED
vs.	O
the	O
reference	B-MED
,	O
we	O
found	O
no	O
association	B-MED
across	O
percentile	B-MED
categories	B-MED
between	O
recurrence	B-MED
and	O
lipid	B-MED
levels	I-MED
in	O
age-	B-MED
and	O
sex	B-MED
-adjusted	O
models	B-MED
,	O
nor	O
after	O
further	B-MED
adjustments	B-MED
for	O
body	B-MED
mass	I-MED
index	I-MED
,	O
diabetes	B-MED
,	O
estrogen	B-MED
and	O
statin	B-MED
use	B-MED
,	O
and	O
duration	B-MED
of	O
anticoagulation	B-MED
.	O
Subgroup	B-MED
analyses	B-MED
stratified	B-MED
by	O
unprovoked	O
or	O
provoked	B-MED
first	O
events	B-MED
,	O
location	B-MED
(	O
deep	B-MED
vein	I-MED
thrombosis	I-MED
or	O
pulmonary	B-MED
embolism	I-MED
)	O
and	O
sex	B-MED
also	O
did	O
not	O
reveal	B-MED
an	O
association	B-MED
with	O
any	O
of	O
the	O
lipid	B-MED
levels	I-MED
studied	O
.	O
Conclusions	O
Testing	B-MED
lipid	I-MED
levels	I-MED
did	O
not	O
identify	B-MED
patients	B-MED
at	O
an	O
increased	B-MED
risk	B-MED
of	O
recurrent	B-MED
venous	I-MED
thrombosis	I-MED
in	O
this	O
study	B-MED
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	B-MED
,	O
and	O
these	O
should	O
not	O
influence	B-MED
decisions	O
on	O
duration	B-MED
of	O
anticoagulation	B-MED
.	O
The	O
burden	O
of	O
HPV	B-MED
-related	O
diseases	B-MED
in	O
Italy	B-MED
,	O
2001	O
-	O
12	O
Human	B-MED
papillomavirus	I-MED
(	I-MED
HPV	I-MED
)	I-MED
infection	I-MED
is	O
the	O
main	O
cause	O
of	O
cervical	B-MED
cancer	I-MED
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	B-MED
of	O
genital	B-MED
warts	I-MED
and	O
of	O
the	O
cancer	B-MED
of	O
penis	B-MED
and	O
anus	B-MED
,	O
head	B-MED
/	O
neck	B-MED
,	O
oropharynx	B-MED
and	O
genitourinary	B-MED
system	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
is	O
the	O
evaluation	B-MED
of	O
hospitalizations	B-MED
due	O
to	O
HPV	B-MED
-	I-MED
related	I-MED
pathologies	I-MED
in	O
2001	O
-	O
12	O
in	O
Italy	B-MED
.	O
The	O
national	B-MED
hospital	I-MED
discharge	I-MED
forms	B-MED
were	O
provided	O
by	O
the	O
Ministry	B-MED
of	I-MED
Health	I-MED
.	O
The	O
HPV	B-MED
-related	O
hospitalizations	B-MED
were	O
identified	O
using	O
specific	O
diagnostic	B-MED
codes	B-MED
,	O
accordingly	O
to	O
the	O
ICD-9	B-MED
-	I-MED
CM	I-MED
coding	B-MED
system	I-MED
.	O
The	O
proportion	O
of	O
hospitalizations	B-MED
of	O
potentially	O
HPV	B-MED
-	I-MED
related	I-MED
pathologies	I-MED
,	O
obtained	O
from	O
the	O
literature	B-MED
,	O
was	O
evaluated	B-MED
as	O
well	O
as	O
the	O
hospitalization	B-MED
rates	I-MED
(	O
hr	B-MED
)	O
and	O
their	O
trend	B-MED
over	O
time	B-MED
.	O
Uterine	B-MED
cervical	I-MED
cancer	I-MED
and	O
CIN	B-MED
III	I-MED
accounted	O
for	O
40	O
%	O
of	O
hospitalizations	B-MED
(	O
hr	B-MED
:	O
15.6/100	O
000	O
and	O
17.6/100	O
000	O
,	O
respectively	O
)	O
.	O
Head	B-MED
/	O
neck	B-MED
and	O
oropharynx	B-MED
pathologies	B-MED
accounted	O
for	O
24.5	O
%	O
of	O
cases	B-MED
(	O
hr	B-MED
:	O
16/100	O
000	O
and	O
3.9/100	O
000	O
,	O
in	O
males	B-MED
and	O
females	B-MED
,	O
respectively	O
)	O
,	O
followed	O
by	O
genital	B-MED
warts	I-MED
(	O
17.3	O
%	O
of	O
hospitalizations	B-MED
;	O
hr	B-MED
:	O
7.5/100	O
000	O
in	O
males	B-MED
and	O
8.52/100	O
000	O
in	O
females	B-MED
)	O
,	O
anal	B-MED
(	O
8.1	O
%	O
of	O
hospitalizations	B-MED
)	O
,	O
genitourinary	B-MED
(	O
7.7	O
%	O
)	O
and	O
penis	B-MED
cancers	I-MED
(	O
2.2	O
%	O
)	O
.	O
The	O
study	B-MED
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	B-MED
of	O
hospitalizations	B-MED
,	O
points	O
out	O
how	O
HPV	B-MED
-	I-MED
related	I-MED
pathologies	I-MED
continue	O
to	O
be	O
a	O
relevant	O
public	B-MED
health	I-MED
issue	B-MED
in	O
Italy	B-MED
with	O
a	O
high	O
impact	B-MED
on	O
population	B-MED
.	O
Air	B-MED
pollution	I-MED
characteristics	B-MED
and	O
health	B-MED
risks	I-MED
in	O
Henan	B-MED
Province	I-MED
,	O
China	B-MED
Events	O
of	O
severe	B-MED
air	B-MED
pollution	I-MED
occurred	O
frequently	O
in	O
China	B-MED
recently	O
,	O
thus	O
understanding	O
of	O
the	O
air	B-MED
pollution	I-MED
characteristics	B-MED
and	O
its	O
health	B-MED
risks	B-MED
is	O
very	O
important	O
.	O
In	O
this	O
work	O
,	O
we	O
analyzed	O
a	O
two	O
-	O
year	O
dataset	B-MED
(	O
March	O
2014	O
-	O
February	O
2016	O
)	O
including	O
daily	B-MED
concentrations	B-MED
of	O
six	O
criteria	O
pollutants	B-MED
(	O
PM2.5	B-MED
,	O
PM10	B-MED
,	O
CO	B-MED
,	O
SO2	B-MED
,	O
NO2	B-MED
,	O
and	O
O3	B-MED
)	O
from	O
18	O
cities	O
in	O
Henan	B-MED
province	I-MED
.	O
Results	O
reveal	O
the	O
serious	O
air	B-MED
pollution	I-MED
status	B-MED
in	O
Henan	B-MED
province	I-MED
,	O
especially	O
the	O
northern	B-MED
part	I-MED
,	O
and	O
Zhengzhou	B-MED
is	O
the	O
city	B-MED
with	O
the	O
worst	B-MED
air	B-MED
quality	I-MED
.	O
Annual	O
average	O
PM2.5	B-MED
concentrations	B-MED
exceed	O
the	O
second	O
grade	O
of	O
Chinese	B-MED
Ambient	I-MED
Air	I-MED
Quality	I-MED
Standard	I-MED
(	O
75μg	O
/	O
m(3	O
)	O
)	O
at	O
both	O
2014	O
and	O
2015	O
.	O
PM2.5	B-MED
is	O
typically	O
the	O
major	O
pollutant	B-MED
,	O
but	O
ozone	B-MED
pollution	B-MED
can	O
be	O
significant	O
during	O
summer	B-MED
.	O
Furthermore	O
,	O
as	O
the	O
commonly	O
used	O
air	B-MED
quality	I-MED
index	I-MED
(	O
AQI	B-MED
)	O
neglects	O
the	O
mutual	O
health	B-MED
effects	O
from	O
multiple	O
pollutants	B-MED
,	O
we	O
introduced	O
the	O
aggregate	B-MED
air	I-MED
quality	I-MED
index	I-MED
(	O
AAQI	B-MED
)	O
and	O
health	B-MED
-	I-MED
risk	I-MED
based	I-MED
air	I-MED
quality	I-MED
index	I-MED
(	O
HAQI	B-MED
)	O
to	O
evaluate	B-MED
the	I-MED
health	I-MED
risks	I-MED
.	O
Results	O
show	O
that	O
based	O
on	O
HAQI	B-MED
,	O
the	O
current	O
AQI	B-MED
system	O
likely	O
significantly	O
underestimate	O
the	O
health	B-MED
risks	B-MED
of	O
air	B-MED
pollution	I-MED
,	O
highlighting	O
that	O
the	O
general	B-MED
public	I-MED
may	O
need	O
stricter	O
health	B-MED
protection	I-MED
measures	I-MED
.	O
The	O
population	B-MED
-weighted	O
two	O
-	O
year	O
average	O
HAQI	B-MED
data	O
further	O
demonstrates	O
that	O
all	O
population	B-MED
in	O
the	O
studied	O
cities	B-MED
in	O
Henan	B-MED
province	I-MED
live	O
with	O
polluted	B-MED
air	I-MED
-	O
72	O
%	O
of	O
the	O
population	B-MED
is	O
exposed	B-MED
to	I-MED
air	B-MED
that	O
is	O
unhealthy	B-MED
for	O
sensitive	B-MED
people	B-MED
,	O
while	O
28	O
%	O
of	O
people	B-MED
is	O
exposed	B-MED
to	I-MED
air	B-MED
that	O
can	O
be	O
harmful	O
to	O
healthy	B-MED
people	B-MED
;	O
and	O
the	O
health	B-MED
risks	B-MED
are	O
much	O
greater	O
during	O
winter	B-MED
than	O
during	O
other	O
seasons	B-MED
.	O
Future	O
works	O
should	O
further	O
improve	O
the	O
HAQI	B-MED
algorithm	B-MED
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	B-MED
/	O
epidemiologic	B-MED
data	B-MED
and	O
the	O
HAQI	B-MED
values	O
.	O
In	O
Search	O
of	O
the	O
E.	B-MED
coli	I-MED
Compounds	B-MED
that	O
Change	O
the	O
Antibiotic	B-MED
Production	B-MED
Pattern	O
of	O
Streptomyces	B-MED
coelicolor	I-MED
During	O
Inter	B-MED
-	I-MED
species	I-MED
Interaction	I-MED
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	B-MED
the	O
interaction	B-MED
between	O
E.coli	B-MED
and	O
Streptomyces	B-MED
coelicolor	I-MED
A3	I-MED
(	I-MED
2	I-MED
)	I-MED
for	O
the	O
increased	B-MED
production	B-MED
of	O
undecylprodigiosin	B-MED
and	O
identify	O
the	O
E.	B-MED
coli	I-MED
actives	B-MED
mediating	B-MED
this	O
inter	B-MED
-	I-MED
species	I-MED
interaction	I-MED
.	O
The	O
antibiotics	B-MED
of	O
interest	O
were	O
the	O
red	B-MED
-	I-MED
pigmented	I-MED
undecylprodigiosin	I-MED
and	O
blue	B-MED
-	I-MED
pigmented	I-MED
actinorhodin	B-MED
.	O
Pure	O
cultures	B-MED
of	O
S.	B-MED
coelicolor	I-MED
in	O
a	O
defined	O
medium	B-MED
produced	O
higher	O
concentrations	B-MED
of	O
actinorhodin	B-MED
compared	B-MED
to	O
those	O
of	O
undecylprodigiosin	B-MED
.	O
The	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-MED
and	O
antitumor	B-MED
properties	I-MED
.	O
As	O
a	O
strategy	O
to	O
increase	B-MED
undecylprodigiosin	B-MED
production	B-MED
,	O
we	O
added	O
separately	O
,	O
live	B-MED
cells	I-MED
and	O
heat	B-MED
-	I-MED
killed	I-MED
cells	B-MED
of	O
E.	B-MED
coli	I-MED
C600	I-MED
,	O
and	O
the	O
cell	B-MED
-	I-MED
free	I-MED
supernatant	I-MED
of	O
E.	B-MED
coli	I-MED
culture	B-MED
to	O
S.	B-MED
coelicolor	I-MED
cultures	B-MED
in	I-MED
shake	I-MED
flasks	I-MED
.	O
The	O
interaction	B-MED
with	O
live	B-MED
cells	I-MED
of	O
E.	B-MED
coli	I-MED
altered	O
the	O
antibiotic	B-MED
production	B-MED
pattern	O
and	O
undecylprodigiosin	B-MED
production	B-MED
was	O
enhanced	B-MED
by	O
3.5	O
-	O
fold	O
compared	O
to	O
the	O
pure	B-MED
cultures	I-MED
of	O
S.	B-MED
coelicolor	I-MED
and	O
actinorhodin	B-MED
decreased	B-MED
by	O
15	O
-	O
fold	O
.	O
The	O
heat	B-MED
-	I-MED
killed	I-MED
cells	B-MED
of	O
E.	B-MED
coli	I-MED
however	O
,	O
had	O
no	B-MED
effect	I-MED
on	O
antibiotic	B-MED
production	B-MED
.	O
In	O
all	O
cases	O
,	O
growth	B-MED
and	O
glucose	B-MED
consumption	I-MED
of	O
S.	B-MED
coelicolor	I-MED
remained	O
almost	O
the	O
same	B-MED
as	O
those	O
observed	B-MED
in	O
the	O
pure	B-MED
culture	I-MED
indicating	O
that	O
the	O
changes	B-MED
in	O
antibiotic	B-MED
production	B-MED
were	O
not	O
due	O
to	O
nutritional	B-MED
stress	B-MED
.	O
Results	B-MED
with	O
cell	B-MED
-	I-MED
free	I-MED
supernatant	I-MED
of	O
E.	B-MED
coli	I-MED
culture	B-MED
indicated	O
that	O
the	O
interaction	B-MED
between	O
S.	B-MED
coelicolor	I-MED
and	O
E.	B-MED
coli	I-MED
was	O
mediated	B-MED
via	O
diffusible	B-MED
molecule(s	I-MED
)	I-MED
.	O
Using	O
a	O
set	O
of	O
extraction	B-MED
procedures	I-MED
and	O
agar	B-MED
-	I-MED
well	I-MED
diffusion	I-MED
bioassays	I-MED
,	O
we	O
isolated	B-MED
and	O
preliminarily	O
identified	B-MED
a	O
class	B-MED
of	I-MED
compounds	I-MED
.	O
For	O
the	O
preliminary	O
verification	B-MED
,	O
we	O
added	O
the	O
compound	B-MED
which	O
was	O
the	O
common	O
chemical	B-MED
structural	I-MED
moiety	I-MED
in	O
this	O
class	B-MED
of	I-MED
compounds	I-MED
to	O
the	O
pure	O
S.	B-MED
coelicolor	I-MED
cultures	B-MED
.	O
We	O
observed	O
similar	O
effects	B-MED
on	O
antibiotic	B-MED
production	B-MED
as	O
with	O
the	O
live	O
E.	B-MED
coli	I-MED
cells	B-MED
and	O
their	O
supernatant	B-MED
indicating	O
that	O
this	O
class	B-MED
of	I-MED
compounds	I-MED
secreted	B-MED
by	O
E.	B-MED
coli	I-MED
indeed	O
could	O
act	O
as	O
actives	B-MED
during	O
interspecies	B-MED
interaction	I-MED
and	O
increase	B-MED
the	O
production	B-MED
of	O
undecylprodigiosin	B-MED
.	O
Pediatric	B-MED
Orthopaedic	B-MED
Trauma	B-MED
and	O
Associated	B-MED
Injuries	I-MED
of	O
Snowmobile	B-MED
,	O
ATV	B-MED
,	O
and	O
Dirtbike	B-MED
Accidents	I-MED
:	O
A	O
19	B-MED
-	I-MED
Year	I-MED
Experience	O
at	O
a	O
Level	O
1	O
Pediatric	B-MED
Trauma	B-MED
Center	I-MED
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
type	B-MED
and	O
severity	B-MED
of	O
orthopaedic	B-MED
and	O
associated	B-MED
injuries	I-MED
for	O
snowmobile	B-MED
,	O
All	B-MED
-	I-MED
terrain	I-MED
vehicles	I-MED
(	O
ATV	B-MED
)	O
and	O
motorized	B-MED
dirtbike	I-MED
accidents	I-MED
in	O
a	O
pediatric	B-MED
patient	B-MED
population	I-MED
.	O
A	O
total	O
of	O
758	O
patients	B-MED
who	O
presented	O
following	O
either	O
snowmobile	B-MED
(	O
n=87	O
)	O
,	O
ATV	B-MED
-	I-MED
related	I-MED
(	O
n=308	O
)	O
or	O
dirtbike	B-MED
(	I-MED
n=363)-related	I-MED
trauma	I-MED
at	O
our	O
institution	B-MED
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	B-MED
.	O
A	O
total	O
of	O
441	O
axial	B-MED
and	O
appendicular	B-MED
fractures	I-MED
occurred	O
requiring	O
533	O
procedures	B-MED
.	O
Snowmobile	B-MED
and	O
dirtbike	B-MED
accidents	I-MED
were	O
associated	B-MED
with	I-MED
a	O
higher	O
rate	O
of	O
fractures	B-MED
(	O
63	O
%	O
,	O
64	O
%	O
)	O
than	O
the	O
ATV	B-MED
group	I-MED
(	O
50	O
%	O
)	O
(	O
P=0.0008	O
)	O
.	O
Snowmobile	B-MED
injuries	I-MED
had	O
the	O
highest	O
rate	O
of	O
spinal	B-MED
(	O
23	O
%	O
)	O
and	O
lower	B-MED
extremity	I-MED
fractures	I-MED
(	O
53	O
%	O
)	O
(	O
P=0.0004	O
)	O
.	O
Snowmobile	B-MED
and	O
dirtbike	B-MED
cohorts	I-MED
had	O
higher	O
rate	O
of	O
femur	B-MED
fractures	I-MED
(	O
22	O
%	O
,	O
17	O
%	O
,	O
P=0.001	O
)	O
whereas	O
the	O
ATV	B-MED
cohort	I-MED
had	O
higher	O
rates	O
of	O
upper	B-MED
extremity	I-MED
(	O
18	O
%	O
)	O
,	O
hand	B-MED
(	O
11	O
%	O
)	O
,	O
scapula	B-MED
(	O
4.6	O
%	O
)	O
,	O
and	O
open	B-MED
fractures	I-MED
(	O
28.6	O
%	O
)	O
(	O
P<0.01	O
)	O
.	O
Head	B-MED
trauma	I-MED
was	O
the	O
most	O
commonly	O
associated	B-MED
injury	I-MED
in	O
275	O
patients	B-MED
with	O
the	O
highest	O
rate	O
in	O
the	O
ATV	B-MED
group	I-MED
(	O
44	O
%	O
)	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
(	O
76	O
%	O
)	O
.	O
Snowmobile	B-MED
and	O
ATV	B-MED
patients	I-MED
had	O
higher	O
Injury	B-MED
Severity	I-MED
Score	I-MED
(	O
11.3	O
,	O
9.6	O
)	O
than	O
dirtbike	B-MED
patients	I-MED
(	O
7.8	O
)	O
(	O
P=0.001	O
)	O
.	O
ATV	B-MED
patients	I-MED
were	O
found	O
to	O
be	O
younger	B-MED
(	O
11.8	O
y	O
)	O
compared	O
with	O
snowmobile	B-MED
(	O
13.2	O
y	O
)	O
and	O
dirtbike	B-MED
(	O
13.5	O
y	O
)	O
(	O
P<0.01	O
)	O
.	O
Pediatric	B-MED
snowmobile	B-MED
,	O
ATV	B-MED
and	O
dirtbike	B-MED
accidents	I-MED
result	O
in	O
severe	B-MED
orthopaedic	B-MED
and	O
associated	B-MED
injuries	I-MED
with	O
each	O
vehicle	B-MED
demonstrating	O
significantly	O
different	O
injury	B-MED
patterns	B-MED
.	O
Injury	B-MED
prevention	I-MED
should	O
focus	O
on	O
improved	O
safety	B-MED
mechanisms	I-MED
,	O
protective	B-MED
gear	I-MED
,	O
safe	O
areas	O
for	O
off	B-MED
-	I-MED
road	I-MED
vehicle	I-MED
use	O
and	O
strict	B-MED
laws	I-MED
with	O
minimum	O
age	B-MED
requirements	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
:	O
Level	O
IV	O
.	O
Did	O
FIDELIS	B-MED
projects	B-MED
contribute	B-MED
to	O
the	O
detection	B-MED
of	O
new	O
smear	B-MED
-	O
positive	B-MED
pulmonary	B-MED
tuberculosis	I-MED
cases	O
in	O
China	B-MED
?	O
Setting	O
:	O
The	O
first	B-MED
phase	I-MED
of	I-MED
the	I-MED
Fund	I-MED
for	I-MED
Innovative	I-MED
DOTS	I-MED
Expansion	I-MED
through	I-MED
Local	I-MED
Initiatives	I-MED
to	I-MED
Stop	I-MED
TB	I-MED
(	O
FIDELIS	B-MED
)	O
projects	B-MED
in	O
China	B-MED
started	O
in	O
2003	O
.	O
Objective	O
:	O
To	O
determine	O
whether	O
the	O
FIDELIS	B-MED
projects	B-MED
contribute	B-MED
d	O
to	O
the	O
increased	B-MED
case	B-MED
detection	B-MED
rate	B-MED
for	O
new	O
smear	B-MED
-	O
positive	B-MED
pulmonary	B-MED
tuberculosis	I-MED
(	O
PTB	B-MED
)	O
in	O
China	B-MED
.	O
Methods	O
:	O
We	O
compared	B-MED
the	O
case	B-MED
notification	I-MED
rates	I-MED
(	O
CNRs	B-MED
)	O
in	O
the	O
intervention	B-MED
year	I-MED
with	O
those	O
of	O
the	O
previous	B-MED
year	B-MED
in	O
the	O
FIDELIS	B-MED
areas	B-MED
,	O
then	O
compared	B-MED
the	O
difference	B-MED
between	O
the	O
CNRs	B-MED
of	O
the	O
intervention	B-MED
year	I-MED
and	O
the	O
previous	B-MED
year	B-MED
in	O
the	O
FIDELIS	B-MED
areas	B-MED
with	O
those	O
in	O
the	O
non	B-MED
-	I-MED
FI	I-MED
-	I-MED
DELIS	I-MED
areas	B-MED
within	O
the	O
province	B-MED
.	O
Results	O
:	O
There	O
was	O
an	O
increase	B-MED
in	O
the	O
CNR	B-MED
in	O
the	O
intervention	B-MED
year	I-MED
compared	B-MED
with	O
the	O
previous	B-MED
year	B-MED
for	O
all	O
the	O
project	B-MED
sites	O
.	O
The	O
differences	B-MED
between	O
the	O
CNR	B-MED
in	O
the	O
intervention	B-MED
year	I-MED
and	O
the	O
previous	B-MED
year	B-MED
ranged	B-MED
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	B-MED
in	O
the	O
FIDELIS	B-MED
areas	B-MED
and	O
from	O
2.9	O
to	O
20.4/100	O
000	O
in	O
the	O
non	B-MED
-	I-MED
FIDELIS	I-MED
areas	B-MED
.	O
Differences	B-MED
-in-	O
differences	B-MED
analysis	B-MED
shows	O
that	O
the	O
differences	B-MED
in	O
the	O
CNRs	B-MED
in	O
the	O
FIDELIS	B-MED
areas	B-MED
were	O
not	O
statistically	B-MED
significantly	I-MED
different	B-MED
from	O
those	O
in	O
the	O
non-	O
FIDELIS	B-MED
areas	B-MED
(	O
P	O
=	O
0.393	O
)	O
.	O
Conclusion	O
:	O
The	O
FIDELIS	B-MED
projects	B-MED
may	O
have	O
contributed	B-MED
to	O
the	O
increase	B-MED
in	O
case	B-MED
detection	B-MED
of	O
new	O
smear	B-MED
-	O
positive	B-MED
PTB	B-MED
in	O
China	B-MED
,	O
but	O
the	O
level	B-MED
of	O
evidence	B-MED
is	O
low	B-MED
.	O
Shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	B-MED
leadership	B-MED
-	O
a	O
qualitative	B-MED
study	I-MED
in	O
Australia	B-MED
Purpose	O
The	O
paper	O
aims	B-MED
to	O
explore	O
the	O
beliefs	B-MED
of	O
doctors	B-MED
in	O
leadership	B-MED
roles	O
of	O
the	O
concept	B-MED
of	O
"	O
the	O
dark	O
side	O
"	O
,	O
using	O
data	B-MED
collected	O
from	O
interviews	B-MED
carried	O
out	O
with	O
45	O
doctors	B-MED
in	O
medical	B-MED
leadership	B-MED
roles	O
across	O
Australia	B-MED
.	O
The	O
paper	O
looks	O
at	O
the	O
beliefs	B-MED
from	O
the	O
perspectives	B-MED
of	O
doctors	B-MED
who	O
are	O
already	O
in	O
leadership	B-MED
roles	O
themselves	O
;	O
to	O
identify	O
potential	O
barriers	B-MED
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better	O
-	O
informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-MED
in	O
the	O
leadership	B-MED
of	O
the	O
Australian	B-MED
health	B-MED
system	I-MED
.	O
The	O
research	B-MED
question	O
is	O
:	O
"	O
What	O
are	O
the	O
beliefs	B-MED
of	O
medical	B-MED
leaders	B-MED
that	O
form	O
the	O
key	O
themes	B-MED
or	O
dimensions	B-MED
of	O
the	O
negative	O
perception	O
of	O
the	O
'	O
dark	O
side	O
'	O
?	O
"	O
.	O
Design	O
/	O
methodology	O
/	O
approach	O
The	O
paper	O
analysed	O
data	B-MED
from	O
two	O
similar	O
qualitative	B-MED
studies	I-MED
examining	O
medical	B-MED
leadership	B-MED
and	O
engagement	O
in	O
Australia	B-MED
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	B-MED
with	O
other	O
researchers	B-MED
,	O
which	O
used	O
in	O
-	O
depth	O
semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
with	O
45	O
purposively	O
sampled	O
senior	O
medical	B-MED
leaders	B-MED
in	O
leadership	B-MED
roles	O
across	O
Australia	B-MED
in	O
health	B-MED
services	I-MED
,	O
private	B-MED
and	O
public	B-MED
hospitals	I-MED
,	O
professional	B-MED
associations	I-MED
and	O
health	B-MED
departments	I-MED
.	O
The	O
data	B-MED
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	B-MED
through	O
a	O
coding	B-MED
framework	O
based	O
on	O
the	O
interview	B-MED
data	B-MED
and	O
literature	B-MED
review	I-MED
,	O
with	O
all	O
sections	O
of	O
coded	B-MED
data	B-MED
grouped	B-MED
into	O
themes	B-MED
.	O
Findings	O
Medical	B-MED
leaders	B-MED
had	O
four	O
key	O
beliefs	B-MED
about	O
the	O
"	O
dark	O
side	O
"	O
as	O
perceived	O
through	O
the	O
eyes	B-MED
of	O
their	O
own	O
past	O
clinical	B-MED
experience	I-MED
and/or	O
their	O
clinical	B-MED
colleagues	B-MED
.	O
These	O
four	O
beliefs	B-MED
or	O
dimensions	B-MED
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"	O
the	O
dark	O
side	O
"	O
are	O
the	O
belief	B-MED
that	O
they	O
lack	O
both	O
managerial	B-MED
and	O
clinical	B-MED
credibility	B-MED
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	B-MED
with	O
clinicians	B-MED
,	O
their	O
clinical	B-MED
colleagues	B-MED
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	B-MED
leadership	B-MED
and	O
,	O
as	O
a	O
result	O
,	O
doctors	B-MED
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	B-MED
practice	I-MED
to	O
medical	B-MED
leadership	B-MED
roles	O
in	O
the	O
first	O
place	O
.	O
Research	O
limitations	O
/	O
implications	O
This	O
research	B-MED
was	O
conducted	O
within	O
the	O
Western	B-MED
developed	B-MED
-	I-MED
nation	I-MED
setting	O
of	O
Australia	B-MED
and	O
only	O
involved	O
interviews	B-MED
with	O
doctors	B-MED
in	O
medical	B-MED
leadership	B-MED
roles	O
.	O
The	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-MED
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	B-MED
.	O
Future	O
research	B-MED
involving	O
doctors	B-MED
who	O
have	O
not	O
chosen	O
to	O
transition	B-MED
to	O
leadership	B-MED
roles	O
,	O
or	O
other	O
health	B-MED
practitioners	I-MED
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	B-MED
.	O
Also	O
,	O
this	O
research	B-MED
was	O
exploratory	O
and	O
descriptive	B-MED
in	O
nature	O
using	O
qualitative	B-MED
methods	I-MED
,	O
and	O
quantitative	B-MED
research	I-MED
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-MED
for	O
statistical	B-MED
generalisation	I-MED
.	O
Practical	O
implications	O
The	O
paper	O
includes	O
implications	O
for	O
health	B-MED
organisations	I-MED
,	O
training	O
providers	O
,	O
medical	B-MED
employers	B-MED
and	O
health	B-MED
departments	I-MED
and	O
describes	O
a	O
multi	O
-	O
prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O
Originality	O
/	O
value	O
This	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-MED
the	O
concept	B-MED
of	O
"	O
moving	O
to	O
the	O
dark	O
side	O
"	O
as	O
a	O
negative	O
perception	O
of	O
medical	B-MED
leadership	B-MED
and	O
contributes	O
to	O
the	O
evidence	B-MED
in	O
this	O
under-	O
researched	B-MED
area	O
.	O
This	O
paper	O
has	O
used	O
data	B-MED
from	O
two	O
similar	O
studies	B-MED
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	B-MED
and	O
coding	B-MED
,	O
looking	O
at	O
the	O
concept	B-MED
of	O
the	O
"	O
dark	O
side	O
"	O
to	O
discover	O
new	O
emergent	O
findings	O
.	O
A	O
randomized	B-MED
trial	I-MED
of	O
Plasma	B-MED
-	I-MED
Lyte	I-MED
A	I-MED
and	O
0.9	B-MED
%	I-MED
sodium	I-MED
chloride	I-MED
in	O
acute	B-MED
pediatric	I-MED
gastroenteritis	I-MED
Compare	O
the	O
efficacy	B-MED
and	O
safety	O
of	O
Plasma	B-MED
-	I-MED
Lyte	I-MED
A	I-MED
(	O
PLA	B-MED
)	O
versus	O
0.9	B-MED
%	I-MED
sodium	I-MED
chloride	I-MED
(	O
NaCl	B-MED
)	O
intravenous	B-MED
(	I-MED
IV	I-MED
)	I-MED
fluid	I-MED
replacement	I-MED
in	O
children	B-MED
with	O
moderate	O
to	O
severe	B-MED
dehydration	I-MED
secondary	O
to	O
acute	B-MED
gastroenteritis	I-MED
(	O
AGE	B-MED
)	O
.	O
Prospective	B-MED
,	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
study	I-MED
conducted	O
at	O
eight	O
pediatric	B-MED
emergency	B-MED
departments	I-MED
(	O
EDs	B-MED
)	O
in	O
the	O
US	B-MED
and	O
Canada	B-MED
(	O
NCT#01234883	O
)	O
.	O
The	O
primary	B-MED
outcome	I-MED
measure	I-MED
was	O
serum	B-MED
bicarbonate	I-MED
level	I-MED
at	O
4	O
h.	O
Secondary	B-MED
outcomes	I-MED
included	O
safety	O
and	O
tolerability	B-MED
.	O
The	O
hypothesis	B-MED
was	O
that	O
PLA	B-MED
would	O
be	O
superior	O
to	O
0.9	B-MED
%	I-MED
NaCl	I-MED
in	O
improvement	B-MED
of	I-MED
4	I-MED
-	I-MED
h	I-MED
bicarbonate	I-MED
.	O
Patients	B-MED
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	B-MED
-induced	O
moderate	O
-	O
to-	O
severe	B-MED
dehydration	I-MED
were	O
enrolled	O
.	O
Patients	B-MED
with	O
a	O
baseline	B-MED
bicarbonate	B-MED
level	I-MED
≤22	O
mEq	O
/	O
L	O
formed	B-MED
the	O
modified	B-MED
intent	B-MED
to	I-MED
treat	I-MED
(	O
mITT	B-MED
)	O
group	B-MED
.	O
At	O
baseline	B-MED
,	O
the	O
treatment	B-MED
groups	B-MED
were	O
comparable	O
except	O
that	O
the	O
PLA	B-MED
group	B-MED
was	O
older	O
.	O
At	O
hour	O
4	O
,	O
the	O
PLA	B-MED
group	B-MED
had	O
greater	O
increases	B-MED
in	I-MED
serum	I-MED
bicarbonate	I-MED
from	O
baseline	B-MED
than	O
did	O
the	O
0.9	B-MED
%	I-MED
NaCl	I-MED
group	B-MED
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3.74	O
vs	O
18.0	O
±	O
3.67	O
;	O
change	O
from	O
baseline	B-MED
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
;	O
P	O
=	O
.004	O
)	O
.	O
Both	O
treatment	B-MED
groups	B-MED
received	O
similar	O
fluid	B-MED
volumes	I-MED
.	O
The	O
PLA	B-MED
group	B-MED
had	O
less	O
abdominal	B-MED
pain	I-MED
and	O
better	O
dehydration	B-MED
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O
No	O
patient	B-MED
experienced	O
clinically	B-MED
relevant	I-MED
worsening	I-MED
of	O
laboratory	B-MED
findings	I-MED
or	O
physical	B-MED
examination	I-MED
,	O
and	O
hospital	B-MED
admission	I-MED
rates	I-MED
were	O
similar	B-MED
.	O
One	O
patient	B-MED
in	O
each	O
treatment	B-MED
group	B-MED
developed	O
hyponatremia	B-MED
.	O
Four	O
patients	B-MED
developed	O
hyperkalemia	B-MED
(	O
PLA	B-MED
:1	O
,	O
0.9	B-MED
%	I-MED
NaCl	I-MED
:3	O
)	O
.	O
In	O
comparison	B-MED
with	O
0.9	B-MED
%	I-MED
NaCl	I-MED
,	O
PLA	B-MED
for	O
rehydration	B-MED
in	O
children	B-MED
with	O
AGE	B-MED
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-MED
in	I-MED
serum	I-MED
bicarbonate	I-MED
and	O
dehydration	B-MED
score	O
.	O
NCT#01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O
The	O
relationships	B-MED
between	O
symptoms	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
over	O
the	O
course	B-MED
of	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
therapy	I-MED
for	O
panic	B-MED
disorder	I-MED
in	O
Japan	B-MED
This	O
study	B-MED
examined	B-MED
the	O
relationships	B-MED
between	O
changes	B-MED
in	O
symptoms	B-MED
and	O
changes	B-MED
in	O
quality	B-MED
of	I-MED
life	I-MED
(	O
QOL	B-MED
)	O
during	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
therapy	I-MED
(	O
CBT	B-MED
)	O
for	O
panic	B-MED
disorder	I-MED
(	O
PD	B-MED
)	O
.	O
We	O
treated	B-MED
198	O
PD	B-MED
patients	B-MED
with	O
group	O
CBT	B-MED
in	O
Japan	B-MED
.	O
Using	O
multiple	B-MED
regression	I-MED
analysis	I-MED
,	O
we	O
examined	B-MED
the	O
associations	B-MED
between	O
changes	B-MED
in	O
QOL	B-MED
and	O
changes	B-MED
in	O
PD	B-MED
symptoms	B-MED
or	O
comorbid	B-MED
psychological	I-MED
symptoms	I-MED
during	O
CBT	B-MED
.	O
Changes	B-MED
in	O
anticipatory	B-MED
anxiety	I-MED
,	O
agoraphobic	B-MED
fear	I-MED
/	O
avoidance	B-MED
,	O
and	O
somatization	B-MED
were	O
significant	O
predictors	B-MED
of	O
changes	B-MED
in	O
some	O
aspects	O
of	O
QOL	B-MED
.	O
It	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-MED
,	O
anticipatory	B-MED
anxiety	I-MED
,	O
and	O
agoraphobic	B-MED
fear	I-MED
to	O
improve	O
QOL	B-MED
in	O
CBT	B-MED
for	O
PD	B-MED
.	O
PRESENCE	B-MED
OF	I-MED
CITRININ	B-MED
IN	O
GRAINS	B-MED
AND	O
ITS	O
POSSIBLE	B-MED
HEALTH	B-MED
EFFECTS	B-MED
Citrinin	B-MED
is	O
a	O
mycotoxin	B-MED
produced	B-MED
by	O
several	O
species	B-MED
of	O
the	O
genera	B-MED
Aspergillus	I-MED
,	O
Penicillium	B-MED
and	O
Monascus	B-MED
and	O
it	O
occurs	B-MED
mainly	O
in	O
stored	B-MED
grain	I-MED
.	O
Citrinin	B-MED
is	O
generally	O
formed	B-MED
after	O
harvest	B-MED
and	O
occurs	B-MED
mainly	O
in	O
stored	B-MED
grains	I-MED
,	O
it	O
also	O
occurs	B-MED
in	O
other	B-MED
plant	I-MED
products	I-MED
.	O
Often	O
,	O
the	O
co	B-MED
-	I-MED
occurrence	I-MED
with	O
other	O
mycotoxins	B-MED
is	O
observed	B-MED
,	O
especially	O
ochratoxin	B-MED
A	I-MED
,	O
which	O
is	O
usually	O
associated	B-MED
with	I-MED
endemic	B-MED
nephropathy	I-MED
.	O
At	O
the	O
European	B-MED
Union	I-MED
level	B-MED
,	O
systematic	B-MED
monitoring	B-MED
of	O
Citrinin	B-MED
in	O
grains	B-MED
began	O
with	O
the	O
aim	B-MED
of	O
determining	B-MED
its	O
highest	O
permissible	B-MED
amount	I-MED
in	O
food	B-MED
.	O
Thus	O
,	O
far	O
the	O
systematic	B-MED
monitoring	B-MED
of	O
the	O
above	B-MED
mentioned	I-MED
mycotoxin	I-MED
in	O
Croatia	B-MED
is	O
yet	O
to	O
begin	B-MED
.	O
The	O
main	B-MED
goal	I-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	B-MED
the	O
presence	B-MED
of	I-MED
Citrinin	B-MED
in	O
grains	B-MED
sampled	B-MED
in	O
the	O
area	B-MED
of	O
Međimurje	B-MED
,	O
Osijek	B-MED
-	I-MED
Baranja	I-MED
,	O
Vukovar	B-MED
-	I-MED
Srijem	I-MED
and	O
Brod	B-MED
-	I-MED
Posavina	I-MED
County	I-MED
.	O
For	O
the	O
purpose	B-MED
of	O
identification	B-MED
and	O
quantification	B-MED
of	O
citrinin	B-MED
,	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatograph	I-MED
(	I-MED
HPLC	I-MED
)	I-MED
with	I-MED
fluorescence	I-MED
was	O
used	B-MED
(	O
Calibration	B-MED
curve	I-MED
k	O
>	O
0.999	O
;	O
Intra	B-MED
assay	I-MED
CV	I-MED
=	O
2.1	O
%	O
;	O
Inter	B-MED
assay	I-MED
CV	I-MED
=	O
4.3	O
%	O
;	O
LOQ	B-MED
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O
From	O
the	O
area	B-MED
of	O
Međimurje	B-MED
County	I-MED
,	O
10	O
samples	B-MED
of	O
corn	B-MED
and	O
10	O
samples	B-MED
of	O
wheat	B-MED
were	O
analyzed	B-MED
.	O
None	O
of	O
the	O
samples	B-MED
contained	B-MED
Citrinin	B-MED
(	O
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O
From	O
the	O
area	B-MED
of	O
Osijek	B-MED
-	I-MED
Baranja	I-MED
and	O
Vukovar	B-MED
-	I-MED
Srijem	I-MED
County	I-MED
,	O
15	O
samples	B-MED
from	O
each	O
County	B-MED
were	O
analyzed	B-MED
.	O
The	O
mean	B-MED
value	I-MED
for	O
the	O
samples	B-MED
of	O
Osijek	B-MED
-	I-MED
Baranja	I-MED
County	I-MED
was	O
19.63	O
μg	O
/	O
kg	O
(	O
median	B-MED
=	O
15.8	O
μg	O
/	O
kg	O
)	O
,	O
while	O
for	O
Vukovar	B-MED
-	I-MED
Srijem	I-MED
County	I-MED
the	O
mean	B-MED
value	I-MED
of	O
citrinin	B-MED
was	O
14,6	O
μg	O
/	O
kg	O
(	O
median	B-MED
=	O
1.23	O
μg	O
/	O
kg	O
)	O
.	O
From	O
5	O
analyzed	B-MED
samples	B-MED
from	O
Brod	B-MED
-	I-MED
Posavina	I-MED
County	I-MED
,	O
one	O
of	O
the	O
samples	B-MED
contained	B-MED
citrinin	B-MED
in	O
the	O
amount	B-MED
of	O
23.8	O
μg	O
/	O
kg	O
,	O
while	O
the	O
registered	B-MED
amount	B-MED
s	O
in	O
the	O
other	O
samples	B-MED
were	O
<	O
1	O
μg	O
/	O
kg	O
.	O
The	O
results	B-MED
show	O
that	O
grains	B-MED
from	O
several	B-MED
Counties	B-MED
contain	B-MED
certain	O
amounts	B-MED
of	O
Citrinin	B-MED
possibly	O
indicating	B-MED
a	O
significant	B-MED
intake	B-MED
of	O
citrinin	B-MED
in	O
humans	B-MED
.	O
It	O
must	O
be	O
stated	O
that	O
grains	B-MED
and	O
grain	B-MED
-	I-MED
based	I-MED
products	I-MED
are	O
the	O
basis	O
of	O
everyday	B-MED
diet	B-MED
of	O
all	O
age	B-MED
groups	I-MED
,	O
especially	O
small	B-MED
children	I-MED
,	O
where	O
higher	B-MED
intake	B-MED
of	O
citrinin	B-MED
can	O
occur	B-MED
.	O
Consequently	O
,	O
we	O
emphasize	B-MED
the	O
need	O
for	O
systematic	B-MED
analysis	B-MED
of	O
larger	B-MED
amount	I-MED
of	O
samples	B-MED
,	O
from	O
both	O
large	B-MED
grains	I-MED
and	O
small	B-MED
grains	I-MED
,	O
especially	O
in	O
the	O
area	B-MED
of	O
Brod	B-MED
-	I-MED
Posavina	I-MED
County	I-MED
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-MED
contamination	B-MED
of	O
grains	B-MED
and	O
to	O
asses	B-MED
the	O
health	B-MED
risk	B-MED
in	O
humans	B-MED
.	O
Mitochondrial	B-MED
pyruvate	I-MED
dehydrogenase	I-MED
phosphatase	I-MED
1	I-MED
regulates	O
the	O
early	O
differentiation	B-MED
of	I-MED
cardiomyocytes	I-MED
from	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
Mitochondria	B-MED
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	B-MED
stem	I-MED
cells	I-MED
(	O
ESCs	B-MED
)	O
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	B-MED
into	O
diverse	O
cell	B-MED
lineages	I-MED
,	O
including	O
cardiomyocytes	B-MED
.	O
However	O
,	O
mitochondrial	B-MED
regulators	I-MED
that	O
manage	O
the	O
rate	B-MED
of	I-MED
differentiation	I-MED
or	O
cell	B-MED
fate	I-MED
have	O
been	O
rarely	O
identified	O
.	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	B-MED
factor	I-MED
that	O
controls	O
the	O
differentiation	B-MED
of	I-MED
ESCs	I-MED
into	O
cardiac	B-MED
myocytes	I-MED
.	O
We	O
induced	O
cardiomyocyte	B-MED
differentiation	I-MED
from	O
mouse	B-MED
ESCs	I-MED
(	O
mESCs	B-MED
)	O
and	O
performed	O
microarray	B-MED
assays	I-MED
to	O
assess	O
messenger	B-MED
RNA	I-MED
(	O
mRNA	B-MED
)	O
expression	B-MED
changes	O
at	O
differentiation	B-MED
day	I-MED
8	I-MED
(	O
D8	B-MED
)	O
compared	O
with	O
undifferentiated	B-MED
mESCs	B-MED
(	O
D0	O
)	O
.	O
Among	O
the	O
differentially	O
expressed	B-MED
genes	I-MED
,	O
Pdp1	B-MED
expression	B-MED
was	O
significantly	O
decreased	O
(	O
27	O
-	O
fold	O
)	O
on	O
D8	B-MED
compared	O
to	O
D0	B-MED
,	O
which	O
was	O
accompanied	O
by	O
suppressed	B-MED
mitochondrial	B-MED
indices	B-MED
,	O
including	O
ATP	B-MED
levels	O
,	O
membrane	B-MED
potential	I-MED
,	O
ROS	B-MED
and	O
mitochondrial	B-MED
Ca(2	I-MED
+	I-MED
)	I-MED
.	O
Notably	O
,	O
Pdp1	B-MED
overexpression	B-MED
significantly	O
enhanced	O
the	O
mitochondrial	B-MED
indices	B-MED
and	O
pyruvate	B-MED
dehydrogenase	I-MED
activity	I-MED
and	O
reduced	O
the	O
expression	B-MED
of	O
cardiac	B-MED
differentiation	I-MED
marker	B-MED
mRNA	I-MED
and	O
the	O
cardiac	B-MED
differentiation	I-MED
rate	B-MED
compared	O
to	O
a	O
mock	O
control	O
.	O
In	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	B-MED
of	O
the	O
Pdp1	B-MED
gene	I-MED
promoted	O
the	O
expression	B-MED
of	O
cardiac	B-MED
differentiation	I-MED
marker	B-MED
mRNA	I-MED
and	O
the	O
cardiac	B-MED
differentiation	I-MED
rate	B-MED
.	O
In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	B-MED
PDP1	I-MED
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	B-MED
differentiation	I-MED
at	O
an	O
early	O
differentiation	B-MED
stage	I-MED
in	O
ESCs	B-MED
.	O
Validity	B-MED
and	O
reliability	B-MED
of	O
fluoroscopy	B-MED
for	O
digital	B-MED
radiography	I-MED
:	O
a	O
new	O
way	O
to	O
evaluate	B-MED
diaphragmatic	B-MED
mobility	B-MED
Fluoroscopy	B-MED
is	O
considered	O
the	O
most	O
accurate	O
method	B-MED
to	O
evaluate	B-MED
the	O
diaphragm	B-MED
,	O
yet	O
most	O
existing	O
methods	B-MED
for	O
measuring	O
diaphragmatic	B-MED
mobility	B-MED
using	O
fluoroscopy	B-MED
are	O
complex	O
.	O
To	O
assess	O
the	O
validity	B-MED
and	O
reliability	B-MED
of	O
a	O
new	O
evaluation	B-MED
method	I-MED
of	O
diaphragmatic	B-MED
motion	B-MED
using	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
of	O
healthy	B-MED
adults	B-MED
.	O
Twenty	O
-	O
six	O
adults	B-MED
were	O
evaluated	B-MED
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	B-MED
and	O
pulmonary	B-MED
function	I-MED
test	I-MED
.	O
The	O
evaluation	B-MED
of	O
diaphragm	B-MED
mobility	B-MED
by	O
means	O
of	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
method	B-MED
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O
The	O
Pearson	B-MED
correlation	I-MED
coefficient	I-MED
and	O
the	O
intraclass	B-MED
correlation	I-MED
coefficient	I-MED
(	O
ICC	B-MED
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	B-MED
.	O
The	O
inter	O
-	O
rater	O
and	O
intra	O
-	O
rater	O
reliability	B-MED
of	O
the	O
measurement	B-MED
of	O
diaphragmatic	B-MED
motion	B-MED
was	O
determined	O
using	O
ICC	B-MED
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O
There	O
was	O
a	O
relationship	B-MED
in	O
the	O
assessment	B-MED
of	O
the	O
concurrent	O
validity	B-MED
.	O
There	O
was	O
good	O
inter	O
-	O
rater	O
reliability	B-MED
for	O
right	O
hemidiaphragm	B-MED
mobility	B-MED
and	O
moderate	O
reliability	B-MED
for	O
left	B-MED
hemidiaphragm	I-MED
in	O
the	O
first	O
assessment	B-MED
.	O
In	O
the	O
second	O
assessment	B-MED
,	O
there	O
was	O
good	O
reliability	B-MED
for	O
the	O
mobility	B-MED
of	O
both	O
hemidiaphragms	B-MED
.	O
There	O
was	O
good	O
intra	O
-	O
rater	O
reliability	B-MED
in	O
the	O
mobility	B-MED
of	O
both	O
hemidiaphragms	B-MED
for	O
raters	O
A	O
and	O
B.	O
The	O
evaluation	B-MED
of	O
diaphragmatic	B-MED
motion	B-MED
using	O
fluoroscopy	B-MED
by	O
digital	B-MED
radiography	I-MED
proved	O
to	O
be	O
a	O
valid	B-MED
and	O
reliable	B-MED
method	B-MED
of	O
healthy	B-MED
adults	B-MED
.	O
Capsular	B-MED
Polysaccharide	I-MED
Types	B-MED
and	O
Virulence	B-MED
-	I-MED
Related	I-MED
Traits	B-MED
of	O
Epidemic	B-MED
KPC	B-MED
-	O
Producing	B-MED
Klebsiella	B-MED
pneumoniae	I-MED
Isolates	B-MED
in	O
a	O
Chinese	B-MED
University	B-MED
Hospital	I-MED
Klebsiella	B-MED
pneumoniae	I-MED
is	O
an	O
important	B-MED
human	B-MED
pathogen	B-MED
associated	B-MED
with	I-MED
a	O
variety	B-MED
of	O
diseases	B-MED
and	O
the	O
prevalence	B-MED
of	O
blaKPC	B-MED
carrying	O
K.	B-MED
pneumoniae	I-MED
(	O
KPC	B-MED
-	I-MED
Kp	I-MED
)	O
is	O
rapidly	B-MED
increasing	I-MED
.	O
Capsule	B-MED
is	O
an	O
important	B-MED
virulence	B-MED
factor	I-MED
in	O
K.	B-MED
pneumoniae	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
determined	O
to	O
first	O
systematically	B-MED
characterize	B-MED
capsular	B-MED
polysaccharide	I-MED
(	O
CPS	B-MED
)	O
and	O
virulence	B-MED
traits	B-MED
in	O
KPC	B-MED
-	I-MED
Kp	I-MED
strains	B-MED
.	O
A	O
total	O
of	O
56	O
KPC	B-MED
-	I-MED
Kp	I-MED
isolates	B-MED
were	O
recovered	B-MED
from	O
clinical	B-MED
samples	I-MED
in	O
a	O
Chinese	B-MED
hospital	I-MED
,	O
which	O
were	O
assigned	B-MED
to	O
clonal	B-MED
lineages	I-MED
by	O
multilocus	B-MED
sequence	I-MED
typing	I-MED
(	O
MLST	B-MED
)	O
.	O
Capsule	B-MED
typing	B-MED
(	O
wzi	B-MED
sequencing	I-MED
and	O
wzc	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
[	O
PCR	B-MED
]	O
)	O
and	O
virulence	B-MED
genes	B-MED
were	O
characterized	B-MED
by	O
molecular	B-MED
approaches	I-MED
.	O
The	O
virulence	B-MED
of	O
these	O
strains	B-MED
was	O
determined	O
by	O
biofilm	B-MED
formation	I-MED
,	O
serum	B-MED
killing	B-MED
resistance	B-MED
,	O
phagocytosis	B-MED
,	O
and	O
infection	B-MED
models	B-MED
.	O
Six	O
different	O
STs	B-MED
were	O
found	B-MED
among	O
56	O
KPC	B-MED
-	I-MED
Kp	I-MED
isolates	B-MED
:	O
76.8	O
%	O
(	O
43	O
of	O
56	O
isolates	B-MED
)	O
belonged	O
to	O
ST11	B-MED
,	O
6	B-MED
isolates	B-MED
belonged	O
to	O
ST147	B-MED
,	O
4	O
isolates	B-MED
belonged	O
to	O
ST15	B-MED
,	O
1	O
isolate	O
belonged	O
to	O
ST1456	B-MED
,	O
1	O
isolate	O
belonged	O
to	O
ST65	B-MED
,	O
and	O
1	O
isolate	O
was	O
ST23	B-MED
.	O
Based	O
on	O
the	O
wzi	B-MED
gene	I-MED
DNA	I-MED
sequences	I-MED
and	O
wzc	B-MED
PCR	I-MED
,	O
these	O
56	O
strains	B-MED
were	O
classified	O
as	O
capsular	B-MED
type	B-MED
wzi47	B-MED
-	I-MED
K47	I-MED
(	O
n	O
=	O
37	O
)	O
,	O
wzi64	B-MED
-	I-MED
K64	I-MED
(	O
n	O
=	O
8)	O
,	O
wzi8	B-MED
-	I-MED
K8	I-MED
(	O
n	O
=	O
4	O
)	O
,	O
wzi37	B-MED
-	I-MED
K37	I-MED
(	O
n	O
=	O
4	O
)	O
,	O
wzi53	B-MED
-	I-MED
K53	I-MED
(	O
n	O
=	O
1	O
)	O
,	O
wzi125	B-MED
-	I-MED
K2	I-MED
(	O
n	O
=	O
1	O
)	O
,	O
and	O
wzi1	B-MED
-	I-MED
K1	I-MED
(	O
n	O
=	O
1	O
)	O
.	O
Heterogeneity	B-MED
was	O
detected	B-MED
in	O
biofilm	B-MED
formation	I-MED
and	O
phagocytosis	B-MED
among	O
different	O
CPS	B-MED
types	B-MED
.	O
ST11	B-MED
strains	B-MED
were	O
less	O
virulent	B-MED
than	O
other	O
ST	B-MED
strains	B-MED
.	O
KPC	B-MED
-	I-MED
Kp	I-MED
strains	B-MED
exhibit	O
variability	B-MED
of	O
virulence	B-MED
-	I-MED
associated	I-MED
traits	B-MED
.	O
Differences	O
were	O
associated	O
with	O
the	O
ST	B-MED
types	B-MED
and	O
CPS	B-MED
.	O
Persistent	B-MED
effects	B-MED
of	O
pre	B-MED
-	I-MED
Columbian	I-MED
plant	B-MED
domestication	B-MED
on	O
Amazonian	B-MED
forest	I-MED
composition	B-MED
The	O
extent	O
to	O
which	O
pre	B-MED
-	I-MED
Columbian	I-MED
societies	B-MED
altered	O
Amazonian	B-MED
landscapes	B-MED
is	O
hotly	O
debated	O
.	O
We	O
performed	O
a	O
basin	B-MED
-	I-MED
wide	I-MED
analysis	I-MED
of	O
pre	B-MED
-	I-MED
Columbian	I-MED
impacts	B-MED
on	O
Amazonian	B-MED
forests	I-MED
by	O
overlaying	O
known	O
archaeological	B-MED
sites	I-MED
in	O
Amazonia	B-MED
with	O
the	O
distributions	O
and	O
abundances	B-MED
of	O
85	O
woody	B-MED
species	B-MED
domesticated	B-MED
by	O
pre	B-MED
-	I-MED
Columbian	I-MED
peoples	B-MED
.	O
Domesticated	B-MED
species	B-MED
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated	B-MED
species	I-MED
to	O
be	O
hyperdominant	B-MED
.	O
Across	O
the	O
basin	O
,	O
the	O
relative	O
abundance	B-MED
and	O
richness	B-MED
of	O
domesticated	B-MED
species	B-MED
increase	O
in	O
forests	B-MED
on	O
and	O
around	O
archaeological	B-MED
sites	I-MED
.	O
In	O
southwestern	B-MED
and	I-MED
eastern	I-MED
Amazonia	I-MED
,	O
distance	O
to	O
archaeological	B-MED
sites	I-MED
strongly	O
influences	O
the	O
relative	O
abundance	B-MED
and	O
richness	O
of	O
domesticated	B-MED
species	B-MED
.	O
Our	O
analyses	B-MED
indicate	O
that	O
modern	O
tree	B-MED
communities	B-MED
in	O
Amazonia	B-MED
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	B-MED
of	O
plant	B-MED
domestication	B-MED
by	O
Amazonian	B-MED
peoples	B-MED
.	O
Engineering	B-MED
the	O
ribosomal	B-MED
DNA	I-MED
in	O
a	O
megabase	B-MED
synthetic	I-MED
chromosome	I-MED
We	O
designed	O
and	O
synthesized	O
a	O
976,067	B-MED
-	I-MED
base	I-MED
pair	I-MED
linear	I-MED
chromosome	I-MED
,	O
synXII	B-MED
,	O
based	O
on	O
native	O
chromosome	B-MED
XII	I-MED
in	O
Saccharomyces	B-MED
cerevisiae	I-MED
SynXII	B-MED
was	O
assembled	O
using	O
a	O
two	B-MED
-	I-MED
step	I-MED
method	I-MED
,	O
specified	O
by	O
successive	O
megachunk	B-MED
integration	I-MED
and	O
meiotic	B-MED
recombination	I-MED
-	I-MED
mediated	I-MED
assembly	I-MED
,	O
producing	O
a	O
functional	B-MED
chromosome	B-MED
in	O
S.	B-MED
cerevisiae	I-MED
.	O
Minor	B-MED
growth	I-MED
defect	I-MED
"	O
bugs	B-MED
"	O
detected	B-MED
in	O
synXII	B-MED
,	O
caused	O
by	O
deletion	B-MED
of	O
tRNA	B-MED
genes	B-MED
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic	B-MED
copy	I-MED
of	O
a	O
single	B-MED
tRNA	I-MED
gene	B-MED
.	O
The	O
ribosomal	B-MED
gene	I-MED
cluster	I-MED
(	O
rDNA	B-MED
)	O
on	O
synXII	B-MED
was	O
left	O
intact	O
during	O
the	O
assembly	B-MED
process	I-MED
and	O
subsequently	O
replaced	O
by	O
a	O
modified	B-MED
rDNA	B-MED
unit	O
used	O
to	O
regenerate	B-MED
rDNA	B-MED
at	O
three	O
distinct	O
chromosomal	B-MED
locations	I-MED
.	O
The	O
signature	O
sequences	B-MED
within	O
rDNA	B-MED
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	B-MED
identity	B-MED
,	O
were	O
swapped	O
to	O
generate	O
a	O
Saccharomyces	B-MED
synXII	B-MED
strain	B-MED
that	O
would	O
be	O
identified	B-MED
as	O
Saccharomyces	B-MED
bayanus	I-MED
by	O
standard	B-MED
DNA	O
barcoding	O
procedures	O
.	O
Left	B-MED
ventricular	I-MED
rotational	B-MED
mechanics	B-MED
in	O
infants	B-MED
with	O
hypoxic	B-MED
ischemic	I-MED
encephalopathy	I-MED
and	O
preterm	B-MED
infants	I-MED
at	O
36	O
weeks	B-MED
postmenstrual	B-MED
age	I-MED
:	O
A	O
comparison	B-MED
with	O
healthy	B-MED
term	B-MED
controls	I-MED
There	O
is	O
a	O
paucity	O
of	O
data	B-MED
on	O
left	B-MED
ventricle	I-MED
(	O
LV	B-MED
)	O
rotational	B-MED
physiology	I-MED
in	O
neonates	B-MED
.	O
We	O
aimed	O
to	O
assess	O
rotational	B-MED
mechanics	B-MED
in	O
infants	B-MED
with	O
hypoxic	B-MED
ischemic	I-MED
encephalopathy	I-MED
(	O
HIE	B-MED
)	O
and	O
premature	B-MED
infants	I-MED
(	O
<	O
32	O
weeks	B-MED
)	O
at	O
36	O
weeks	B-MED
postmenstrual	B-MED
age	I-MED
(	O
PMA	B-MED
)	O
(	O
preterm	B-MED
group	I-MED
)	O
and	O
compare	B-MED
them	O
with	O
healthy	B-MED
term	B-MED
controls	I-MED
(	O
term	B-MED
controls	I-MED
)	O
.	O
We	O
also	O
compared	B-MED
the	O
parameters	B-MED
in	O
preterm	B-MED
infants	I-MED
with	O
and	O
without	O
chronic	B-MED
lung	I-MED
disease	I-MED
(	O
CLD	B-MED
)	O
.	O
Echocardiography	B-MED
was	O
performed	O
within	O
48	O
hours	B-MED
of	O
birth	B-MED
or	O
at	O
36	O
weeks	B-MED
PMA	B-MED
.	O
LV	B-MED
basal	B-MED
and	O
apical	O
rotation	B-MED
,	O
twist	B-MED
(	O
and	O
torsion	O
=	O
twist	B-MED
/	O
LV	B-MED
length	I-MED
)	O
,	O
twist	B-MED
rate	I-MED
(	O
LVTR	B-MED
)	O
,	O
and	O
untwist	B-MED
rate	I-MED
(	O
LVUTR	B-MED
)	O
were	O
measured	O
.	O
One	B-MED
-	I-MED
way	I-MED
ANOVA	I-MED
was	O
used	O
to	O
compare	B-MED
values	B-MED
.	O
There	O
was	O
no	O
difference	O
in	O
gestation	B-MED
(	O
40.0	O
[	O
39.1	O
-	O
40.3	O
]	O
vs	O
39.9	O
[	O
39.0	O
-	O
40.9	O
]	O
,	O
P>.05	O
)	O
or	O
birthweight	B-MED
(	O
3.7	O
[	O
3.4	O
-	O
4.1	O
]	O
vs	O
3.5	O
[	O
3.2	O
-	O
3.9	O
]	O
,	O
P>.05	O
)	O
between	O
the	O
HIE	B-MED
group	B-MED
(	O
n=16	O
)	O
and	O
term	B-MED
controls	I-MED
(	O
n=30	O
)	O
.	O
The	O
preterm	B-MED
group	I-MED
(	O
n=35	O
)	O
had	O
a	O
gestation	B-MED
and	O
weight	B-MED
of	O
36.0	O
[	O
34.6	O
-	O
36.3	O
]	O
weeks	B-MED
and	O
2.3	O
[	O
2.0	O
-	O
2.4	O
]	O
kg	O
.	O
The	O
HIE	B-MED
group	O
had	O
lower	O
twist	B-MED
,	O
torsion	O
,	O
LVTR	B-MED
,	O
and	O
LVUTR	B-MED
than	O
the	O
other	O
two	O
groups	O
.	O
The	O
preterm	B-MED
group	I-MED
had	O
a	O
more	O
negative	O
(	O
clockwise	B-MED
)	O
basal	B-MED
rotation	B-MED
while	O
the	O
term	B-MED
group	I-MED
had	O
a	O
more	O
positive	O
(	O
counterclockwise	B-MED
)	O
apical	B-MED
rotation	B-MED
.	O
Preterm	B-MED
infants	I-MED
with	O
CLD	B-MED
had	O
higher	O
apical	B-MED
rotation	B-MED
,	O
twist	B-MED
,	O
and	O
torsion	O
when	O
compared	B-MED
to	O
infants	B-MED
without	O
CLD	B-MED
.	O
Infants	B-MED
with	O
HIE	B-MED
have	O
reduced	O
rotational	B-MED
mechanics	B-MED
.	O
Preterm	B-MED
infants	I-MED
at	O
36	O
weeks	B-MED
PMA	B-MED
have	O
comparable	B-MED
measurements	B-MED
of	O
twist	B-MED
to	O
term	B-MED
infants	I-MED
.	O
This	O
is	O
achieved	O
by	O
predominant	O
basal	B-MED
basal	B-MED
rather	O
than	O
apical	B-MED
rotation	B-MED
.	O
Infants	B-MED
with	O
CLD	B-MED
have	O
increased	O
apical	B-MED
rotation	B-MED
.	O
Mimicking	O
the	O
cell	B-MED
membrane	I-MED
:	O
bio	B-MED
-	I-MED
inspired	I-MED
simultaneous	B-MED
functions	O
with	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
and	O
antifouling	B-MED
properties	I-MED
of	O
anion	B-MED
exchange	O
membrane	B-MED
A	O
new	O
bio	B-MED
-	I-MED
inspired	I-MED
method	I-MED
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	B-MED
improve	O
the	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
and	O
antifouling	B-MED
properties	I-MED
of	O
anion	B-MED
exchange	O
membranes	B-MED
(	O
AEMs	O
)	O
.	O
Three	O
-	O
layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-MED
(	O
PDA	B-MED
)	O
and	O
electro	O
-	O
deposition	O
of	O
N	B-MED
-	I-MED
O	I-MED
-	I-MED
sulfonic	I-MED
acid	I-MED
benzyl	I-MED
chitosan	I-MED
(	O
NSBC	B-MED
)	O
.	O
The	O
innermost	B-MED
and	O
outermost	B-MED
layers	B-MED
were	O
PDA	B-MED
with	O
different	O
deposition	O
time	O
.	O
The	O
middle	B-MED
layer	B-MED
was	O
prepared	O
by	O
NSBC	B-MED
.	O
Fourier	B-MED
transform	I-MED
infrared	I-MED
spectroscopy	I-MED
and	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
confirmed	O
that	O
PDA	B-MED
and	O
NSBC	B-MED
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
AEMs	O
.	O
The	O
contact	O
angle	O
of	O
the	O
membranes	B-MED
indicated	O
an	O
improved	O
hydrophilicity	B-MED
of	O
the	O
modified	O
membranes	B-MED
.	O
A	O
series	O
of	O
electrodialysis	B-MED
experiments	I-MED
in	O
which	O
Cl(-	B-MED
)	I-MED
/	O
SO4(2-	B-MED
)	I-MED
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	B-MED
anion	B-MED
selectivity	B-MED
of	O
the	O
samples	O
.	O
The	O
Cl(-	B-MED
)	I-MED
/	O
SO4(2-	B-MED
)	I-MED
permselectivity	B-MED
of	O
the	O
modified	O
membranes	B-MED
can	O
reach	O
up	O
to	O
2.20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	B-MED
membrane	I-MED
(	O
only	O
0.78	O
)	O
during	O
90	O
minutes	O
in	O
electrodialysis	B-MED
(	O
ED	B-MED
)	O
.	O
The	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	B-MED
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	B-MED
properties	I-MED
.	O
Sodium	B-MED
dodecyl	I-MED
benzene	I-MED
sulfonate	I-MED
(	O
SDBS	B-MED
)	O
was	O
used	O
as	O
the	O
fouling	B-MED
material	O
in	O
the	O
ED	B-MED
process	O
and	O
the	O
membrane	B-MED
area	O
resistance	O
of	O
modified	B-MED
membrane	I-MED
increase	O
value	O
of	O
was	O
only	O
0.08	O
Ωcm(2	O
)	O
30	O
minutes	O
later	O
.	O
Help	O
end	O
the	O
HIV	B-MED
epidemic	B-MED
After	O
many	O
delays	O
,	O
the	O
public	B-MED
consultation	I-MED
on	O
HIV	B-MED
prevention	I-MED
tool	B-MED
PrEP	B-MED
(	O
pre	B-MED
-	I-MED
exposure	I-MED
prophylaxis	I-MED
)	O
is	O
finally	O
here	O
.	O
Now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
HIV	B-MED
epidemic	B-MED
by	O
responding	O
to	O
this	O
NHS	B-MED
England	I-MED
consultation	I-MED
before	O
23	O
September	B-MED
.	O
New	O
directions	O
for	O
psychiatric	B-MED
rehabilitation	I-MED
in	O
the	O
USA	B-MED
American	B-MED
researchers	B-MED
have	O
led	O
the	O
world	B-MED
in	O
developing	B-MED
,	O
evaluating	B-MED
,	O
and	O
disseminating	B-MED
evidence	B-MED
-based	O
psychiatric	B-MED
rehabilitation	I-MED
practices	B-MED
for	O
people	B-MED
with	O
serious	B-MED
mental	B-MED
illness	I-MED
.	O
Paradoxically	O
,	O
however	O
,	O
the	O
USA	B-MED
lags	O
behind	O
most	O
industrialized	B-MED
nations	I-MED
in	O
providing	O
access	B-MED
to	O
high	B-MED
-	I-MED
quality	I-MED
mental	B-MED
health	I-MED
and	O
psychiatric	B-MED
services	I-MED
.	O
This	O
essay	B-MED
examines	O
several	O
evidence	B-MED
-	I-MED
based	I-MED
practices	I-MED
developed	O
in	O
the	O
USA	B-MED
,	O
the	O
spread	O
of	O
these	O
practices	B-MED
,	O
the	O
barriers	B-MED
to	O
ensuring	O
availability	B-MED
to	O
people	B-MED
who	O
could	O
benefit	B-MED
from	O
these	O
services	B-MED
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	B-MED
the	O
barriers	B-MED
.	O
Factors	B-MED
influencing	O
the	O
growth	O
and	O
sustainment	B-MED
of	O
effective	B-MED
client	B-MED
-centred	O
practices	B-MED
include	O
the	O
availability	B-MED
of	O
adequate	B-MED
and	I-MED
stable	I-MED
funding	I-MED
,	O
committed	B-MED
leadership	I-MED
,	O
and	O
the	O
influence	B-MED
of	O
vested	O
interests	O
.	O
Two	O
strategies	O
for	O
promoting	B-MED
the	O
spread	B-MED
and	O
sustainment	B-MED
of	O
well	B-MED
-	I-MED
implemented	I-MED
evidence	I-MED
-	I-MED
based	I-MED
practices	I-MED
are	O
the	O
adoption	B-MED
of	O
fidelity	B-MED
scales	I-MED
and	O
learning	B-MED
communities	B-MED
.	O
Dabigatran	B-MED
:	O
A	O
new	O
oral	B-MED
anticoagulant	I-MED
.	O
Guidelines	B-MED
to	O
follow	O
in	O
oral	B-MED
surgery	I-MED
procedures	I-MED
.	O
A	O
systematic	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
Dabigatran	B-MED
is	O
a	O
newly	O
commercialized	O
drug	B-MED
that	O
is	O
replacing	O
other	O
anticoagulants	B-MED
in	O
the	O
prevention	O
of	O
venous	B-MED
thromboembolism	I-MED
,	O
stroke	B-MED
and	O
systemic	B-MED
arterial	I-MED
valve	I-MED
embolism	I-MED
.	O
It	O
acts	O
directly	O
on	O
thrombin	B-MED
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	B-MED
.	O
Therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	B-MED
the	O
risk	B-MED
of	I-MED
bleeding	I-MED
involved	O
before	O
any	O
dental	B-MED
treatment	I-MED
.	O
We	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	B-MED
search	I-MED
in	O
PubMed	B-MED
/	O
Medline	B-MED
along	O
with	O
the	O
Cochrane	B-MED
Library	I-MED
.	O
We	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-MED
other	O
than	O
dabigatran	B-MED
,	O
and	O
works	O
about	O
surgical	B-MED
treatments	I-MED
in	O
anatomical	B-MED
locations	I-MED
other	O
than	O
the	O
oral	B-MED
cavity	I-MED
.	O
We	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
,	O
9	O
narrative	B-MED
literature	I-MED
reviews	I-MED
,	O
1	O
case	B-MED
series	I-MED
,	O
2	O
clinical	B-MED
cases	I-MED
and	O
1	O
expert	B-MED
opinion	I-MED
.	O
Because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	B-MED
trials	I-MED
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
Currently	O
,	O
there	O
is	O
no	O
consensus	B-MED
on	O
the	O
procedure	B-MED
to	O
be	O
followed	O
in	O
patients	B-MED
taking	O
dabigatran	B-MED
.	O
However	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	B-MED
of	O
embolism	B-MED
,	O
postoperative	B-MED
bleeding	I-MED
and	O
renal	B-MED
function	I-MED
.	O
Also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-MED
interventions	I-MED
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti	B-MED
-	I-MED
hemolytic	I-MED
measures	I-MED
.	O
Anemia	B-MED
complicating	B-MED
type	B-MED
2	I-MED
diabetes	I-MED
:	O
Prevalence	B-MED
,	O
risk	B-MED
factors	I-MED
and	O
prognosis	B-MED
To	O
determine	O
the	O
prevalence	B-MED
,	O
risk	B-MED
factors	I-MED
and	O
prognosis	B-MED
of	O
anemia	B-MED
in	O
representative	B-MED
community	O
-	O
based	O
patients	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
Data	O
from	O
the	O
Fremantle	B-MED
Diabetes	I-MED
Study	I-MED
Phase	I-MED
II	I-MED
(	O
FDS2	B-MED
;	O
n=1551	O
,	O
mean	O
age	O
65.7years	O
,	O
51.9	O
%	O
males	B-MED
)	O
and	O
Busselton	B-MED
Diabetes	I-MED
Study	I-MED
(	O
BDS	B-MED
;	O
n=186	O
,	O
mean	O
age	O
70.2years	O
,	O
50.0	O
%	O
males	B-MED
)	O
cohorts	B-MED
,	O
and	O
from	O
186	O
matched	O
BDS	B-MED
participants	B-MED
without	O
diabetes	B-MED
,	O
were	O
analyzed	B-MED
.	O
The	O
prevalence	B-MED
of	O
anemia	B-MED
(	O
hemoglobin	B-MED
≤130g	O
/	O
L	O
males	B-MED
,	O
≤120g	O
/	O
L	O
females	B-MED
)	O
was	O
determined	B-MED
in	O
each	O
sample	B-MED
.	O
In	O
FDS2	B-MED
,	O
associates	O
of	O
anemia	B-MED
were	O
assessed	B-MED
using	O
multiple	O
logistic	B-MED
regression	I-MED
and	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
modeling	I-MED
identified	O
predictors	B-MED
of	O
death	B-MED
during	O
4.3±1.2years	O
post	O
-	O
recruitment	O
.	O
The	O
prevalence	B-MED
of	O
anemia	B-MED
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	B-MED
participants	B-MED
,	O
17.8	O
%	O
in	O
BDS	B-MED
type	O
2	O
patients	B-MED
and	O
5.4	O
%	O
in	O
BDS	B-MED
participants	B-MED
without	O
diabetes	B-MED
.	O
In	O
FDS2	B-MED
,	O
163	O
of	O
178	O
patients	B-MED
with	O
anemia	B-MED
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	B-MED
factor	I-MED
(	O
serum	B-MED
vitamin	I-MED
B12	I-MED
<	O
140pmol	O
/	O
L	O
,	O
serum	B-MED
ferritin	I-MED
<	O
30μg	O
/	O
L	O
and/or	O
transferrin	B-MED
saturation	I-MED
<	O
20	O
%	O
,	O
serum	B-MED
testosterone	I-MED
<	O
10nmol	O
/	O
L	O
(	O
males	B-MED
)	O
,	O
glitazone	B-MED
therapy	B-MED
,	O
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	I-MED
(	O
eGFR	B-MED
)	O
<	O
60mL	O
/	O
min	O
1.73m(2	O
)	O
,	O
malignancy	B-MED
,	O
hemoglobinopathy	B-MED
)	O
.	O
More	O
anemic	B-MED
than	O
non	B-MED
-	I-MED
anemic	I-MED
FDS2	B-MED
patients	B-MED
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P<0.001	O
)	O
.	O
After	O
adjustment	O
for	O
other	O
independent	O
predictors	B-MED
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	B-MED
,	O
marital	B-MED
status	I-MED
,	O
smoking	B-MED
,	O
eGFR	B-MED
)	O
,	O
anemia	B-MED
was	O
associated	B-MED
with	I-MED
a	O
57	O
%	O
increase	B-MED
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O
Type	B-MED
2	I-MED
diabetes	I-MED
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-MED
but	O
other	O
mostly	O
modifiable	O
risk	B-MED
factors	I-MED
are	O
usually	O
present	B-MED
.	O
Anemia	B-MED
is	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	I-MED
of	I-MED
death	I-MED
after	O
adjustment	O
for	O
other	O
predictors	B-MED
.	O
Integrating	B-MED
molecular	B-MED
QTL	B-MED
data	B-MED
into	O
genome	B-MED
-	I-MED
wide	I-MED
genetic	I-MED
association	I-MED
analysis	I-MED
:	O
Probabilistic	B-MED
assessment	B-MED
of	O
enrichment	B-MED
and	O
colocalization	B-MED
We	O
propose	O
a	O
novel	O
statistical	B-MED
framework	I-MED
for	O
integrating	B-MED
the	O
result	B-MED
from	O
molecular	B-MED
quantitative	B-MED
trait	I-MED
loci	I-MED
(	O
QTL	B-MED
)	O
mapping	B-MED
into	O
genome	B-MED
-	I-MED
wide	I-MED
genetic	I-MED
association	I-MED
analysis	I-MED
of	O
complex	B-MED
traits	B-MED
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	B-MED
assessing	B-MED
the	O
enrichment	B-MED
of	O
the	O
molecular	B-MED
QTLs	B-MED
in	O
complex	B-MED
trait	B-MED
-	O
associated	B-MED
genetic	B-MED
variants	I-MED
and	O
the	O
colocalizations	B-MED
of	O
the	O
two	O
types	B-MED
of	O
association	B-MED
signals	B-MED
.	O
We	O
introduce	O
a	O
natural	B-MED
Bayesian	I-MED
hierarchical	I-MED
model	I-MED
that	O
treats	O
the	O
latent	O
association	B-MED
status	O
of	O
molecular	B-MED
QTLs	B-MED
as	O
SNP	B-MED
-	O
level	B-MED
annotations	O
for	O
candidate	O
SNPs	B-MED
of	O
complex	B-MED
traits	B-MED
.	O
We	O
detail	O
a	O
computational	B-MED
procedure	B-MED
to	O
seamlessly	O
perform	O
enrichment	B-MED
,	O
fine	B-MED
-	I-MED
mapping	I-MED
and	O
colocalization	B-MED
analyses	B-MED
,	O
which	O
is	O
a	O
distinct	B-MED
feature	I-MED
compared	B-MED
to	O
the	O
existing	O
colocalization	B-MED
analysis	B-MED
procedures	B-MED
in	O
the	O
literature	B-MED
.	O
The	O
proposed	O
approach	B-MED
is	O
computationally	B-MED
efficient	B-MED
and	O
requires	O
only	O
summary	B-MED
-	O
level	B-MED
statistics	B-MED
.	O
We	O
evaluate	B-MED
and	O
demonstrate	O
the	O
proposed	O
computational	B-MED
approach	B-MED
through	O
extensive	B-MED
simulation	B-MED
studies	B-MED
and	O
analyses	B-MED
of	O
blood	B-MED
lipid	I-MED
data	B-MED
and	O
the	O
whole	B-MED
blood	I-MED
eQTL	B-MED
data	B-MED
from	O
the	O
GTEx	B-MED
project	I-MED
.	O
In	O
addition	O
,	O
a	O
useful	O
utility	B-MED
from	O
our	O
proposed	O
method	B-MED
enables	O
the	O
computation	B-MED
of	O
expected	O
colocalization	B-MED
signals	B-MED
using	O
simple	O
characteristics	B-MED
of	O
the	O
association	B-MED
data	B-MED
.	O
Using	O
this	O
utility	B-MED
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	B-MED
analysis	B-MED
on	O
the	O
ability	O
to	O
discover	O
colocalized	B-MED
signals	B-MED
and	O
the	O
potential	B-MED
limitations	B-MED
of	O
currently	O
available	O
molecular	B-MED
QTL	B-MED
data	B-MED
.	O
The	O
software	B-MED
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	B-MED
procedures	B-MED
,	O
enloc	B-MED
,	O
is	O
freely	O
available	O
at	O
https://github.com/xqwen/integrative	B-MED
.	O
Mucosa	B-MED
-	O
associated	B-MED
biohydrogenating	B-MED
microbes	I-MED
protect	O
the	O
simulated	O
colon	B-MED
microbiome	B-MED
from	O
stress	B-MED
associated	B-MED
with	I-MED
high	B-MED
concentrations	I-MED
of	O
poly	B-MED
-	I-MED
unsaturated	I-MED
fat	I-MED
Polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
(	O
PUFAs	B-MED
)	O
may	O
affect	O
colon	B-MED
microbiome	B-MED
homeostasis	B-MED
by	O
exerting	B-MED
(	O
specific	B-MED
)	O
antimicrobial	B-MED
effects	B-MED
and/or	O
interfering	O
with	O
mucosal	B-MED
biofilm	B-MED
formation	B-MED
at	O
the	O
gut	B-MED
mucosal	I-MED
interface	I-MED
.	O
We	O
used	O
standardized	B-MED
batch	I-MED
incubations	I-MED
and	O
the	O
Mucosal	B-MED
-	I-MED
Simulator	I-MED
of	I-MED
the	I-MED
Human	I-MED
Microbial	I-MED
Intestinal	I-MED
Ecosystem	I-MED
(	O
M	B-MED
-	I-MED
SHIME	I-MED
)	O
to	O
show	O
the	O
in	B-MED
vitro	I-MED
luminal	B-MED
and	O
mucosal	B-MED
effects	B-MED
of	I-MED
the	O
main	O
PUFA	B-MED
in	O
the	O
Western	B-MED
diet	I-MED
,	O
linoleic	B-MED
acid	I-MED
(	O
LA	B-MED
)	O
.	O
High	B-MED
concentrations	I-MED
of	O
LA	B-MED
were	O
found	O
to	O
decrease	B-MED
butyrate	B-MED
production	B-MED
and	O
Faecalibacterium	B-MED
prausnitzii	I-MED
numbers	O
dependent	O
on	O
LA	B-MED
biohydrogenation	B-MED
to	O
vaccenic	B-MED
acid	I-MED
(	O
VA	B-MED
)	O
and	O
stearic	B-MED
acid	I-MED
(	O
SA	B-MED
)	O
.	O
In	O
faecal	B-MED
batch	B-MED
incubations	I-MED
,	O
LA	B-MED
biohydrogenation	B-MED
and	O
butyrate	B-MED
production	B-MED
were	O
positively	B-MED
correlated	I-MED
and	O
SA	B-MED
did	O
not	O
inhibit	B-MED
butyrate	B-MED
production	B-MED
.	O
In	O
the	O
M	B-MED
-	I-MED
SHIME	I-MED
,	O
addition	O
of	O
a	O
mucosal	B-MED
environment	B-MED
stimulated	B-MED
biohydrogenation	B-MED
to	O
SA	B-MED
and	O
protected	O
F.	B-MED
prausnitzii	I-MED
from	O
inhibition	B-MED
by	O
LA	B-MED
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
preference	B-MED
of	O
two	O
biohydrogenating	B-MED
genera	B-MED
Roseburia	B-MED
and	O
Pseudobutyrivibrio	B-MED
for	O
the	O
mucosal	B-MED
niche	O
.	O
Co	B-MED
-	I-MED
culture	I-MED
batch	B-MED
incubations	I-MED
using	O
Roseburia	B-MED
hominis	I-MED
and	O
F.	B-MED
prausnitzii	I-MED
validated	B-MED
these	O
observations	B-MED
.	O
Correlations	B-MED
networks	B-MED
further	O
uncovered	O
the	O
central	O
role	O
of	O
Roseburia	B-MED
and	O
Pseudobutyrivibrio	B-MED
in	O
protecting	O
luminal	B-MED
and	O
mucosal	B-MED
SHIME	I-MED
microbiota	I-MED
from	O
LA	B-MED
-	O
induced	B-MED
stress	I-MED
.	O
Our	O
results	B-MED
confirm	O
how	O
cross	B-MED
-	I-MED
shielding	I-MED
interactions	I-MED
provide	O
resilience	O
to	O
the	O
microbiome	B-MED
and	O
demonstrate	O
the	O
importance	B-MED
of	O
biohydrogenating	B-MED
,	O
mucosal	B-MED
bacteria	B-MED
for	O
recovery	B-MED
from	O
LA	B-MED
stress	B-MED
.	O
Establishment	O
and	O
application	O
of	O
a	O
flow	B-MED
cytometry	I-MED
-based	O
method	B-MED
for	O
detecting	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
Histone	B-MED
deacetylase	I-MED
inhibitors	I-MED
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	B-MED
and	O
other	O
diseases	B-MED
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B-MED
drugs	I-MED
developed	O
in	O
recent	O
years	O
.	O
However	O
,	O
there	O
is	O
still	O
a	O
lack	B-MED
of	O
a	O
unified	B-MED
and	O
reliable	B-MED
method	B-MED
for	O
detecting	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
in	O
basic	B-MED
and	O
clinical	B-MED
research	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
developed	O
a	O
flow	B-MED
cytometry	I-MED
-based	O
method	B-MED
to	O
detect	B-MED
detect	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
by	O
comparing	B-MED
different	O
sample	B-MED
processing	B-MED
temperature	B-MED
(	O
on	O
ice	B-MED
vs.	O
room	B-MED
temperature	I-MED
room	B-MED
temperature	I-MED
)	O
,	O
permeabilization	B-MED
method	B-MED
(	O
intracellular	B-MED
vs.	O
nuclear	B-MED
)	O
,	O
antibody	B-MED
dose	B-MED
(	O
antibody	B-MED
titration	I-MED
)	O
and	O
antibody	B-MED
incubation	B-MED
time	I-MED
(	O
time	B-MED
gradient	I-MED
)	O
using	O
whole	B-MED
blood	I-MED
and	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
.	O
In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	B-MED
method	B-MED
in	O
in	B-MED
vitro	I-MED
experiment	B-MED
and	O
clinical	B-MED
trial	I-MED
of	O
Chidamide	B-MED
(	O
the	O
only	O
China	B-MED
FDA	B-MED
approved	I-MED
HDACi	I-MED
)	O
,	O
the	O
result	B-MED
of	O
which	O
confirmed	B-MED
that	O
the	O
flow	B-MED
cytometry	I-MED
-based	O
method	B-MED
for	O
detecting	B-MED
histone	B-MED
acetylation	I-MED
levels	B-MED
is	O
a	O
reliable	B-MED
,	O
fast	B-MED
and	O
convenient	B-MED
method	B-MED
which	O
can	O
be	O
used	O
in	O
basic	B-MED
and	O
clinical	B-MED
research	I-MED
.	O
Data	B-MED
-Driven	O
Implementation	B-MED
of	O
Alarm	B-MED
Reduction	B-MED
Interventions	B-MED
in	O
a	O
Cardiovascular	B-MED
Surgical	I-MED
ICU	I-MED
Alarm	B-MED
fatigue	I-MED
in	O
the	O
ICU	B-MED
setting	B-MED
has	O
been	O
well	O
documented	B-MED
in	O
the	O
literature	B-MED
.	O
The	O
ICU	B-MED
's	I-MED
high	B-MED
-	I-MED
intensity	I-MED
environment	B-MED
requires	O
staff	B-MED
's	I-MED
vigilant	B-MED
attention	B-MED
,	O
and	O
distraction	B-MED
from	O
false	B-MED
and	O
non	O
-	O
actionable	O
alarms	B-MED
pulls	O
staff	B-MED
away	O
from	O
important	O
tasks	B-MED
,	O
creates	O
dissatisfaction	B-MED
,	O
and	O
is	O
a	O
potential	O
patient	B-MED
safety	I-MED
risk	B-MED
if	O
alarms	B-MED
are	O
missed	B-MED
or	O
ignored	B-MED
.	O
This	O
project	O
was	O
intended	O
to	O
improve	O
patient	B-MED
safety	I-MED
by	O
optimizing	O
alarm	B-MED
systems	B-MED
in	O
a	O
cardiovascular	B-MED
surgical	I-MED
intensive	I-MED
care	I-MED
unit	I-MED
(	O
CVSICU	B-MED
)	O
.	O
Specific	O
aims	O
were	O
to	O
examine	B-MED
nurses	B-MED
'	O
attitudes	B-MED
toward	O
clinical	B-MED
alarm	B-MED
signals	B-MED
,	O
assess	O
nurses	B-MED
'	O
ability	O
to	O
discriminate	O
audible	B-MED
alarm	I-MED
signals	B-MED
,	O
and	O
implement	B-MED
a	O
bundled	O
set	O
of	O
best	B-MED
practices	I-MED
for	O
monitor	B-MED
alarm	I-MED
reduction	B-MED
without	O
undermining	O
patient	B-MED
safety	I-MED
.	O
CVSICU	B-MED
nurses	B-MED
completed	O
an	O
alarm	B-MED
perception	B-MED
survey	I-MED
and	O
participated	O
in	O
alarm	B-MED
discriminability	B-MED
testing	I-MED
.	O
Nurse	B-MED
survey	I-MED
data	I-MED
and	O
baseline	B-MED
monitor	O
alarm	B-MED
data	B-MED
were	O
used	O
to	O
select	O
targeted	B-MED
alarm	B-MED
reduction	B-MED
interventions	B-MED
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O
Monitor	O
alarm	B-MED
data	B-MED
and	O
cardiorespiratory	B-MED
event	I-MED
data	B-MED
were	O
trended	O
over	O
one	O
year	B-MED
.	O
Five	O
of	O
the	O
most	O
frequent	O
CVSICU	B-MED
monitor	B-MED
alarm	I-MED
types-	O
pulse	B-MED
oximetry	I-MED
,	O
heart	B-MED
rate	I-MED
,	O
systolic	B-MED
and	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
,	O
pulse	B-MED
oximetry	I-MED
sensor	B-MED
,	O
and	O
ventricular	B-MED
tachycardia	I-MED
>	O
2	O
-	O
were	O
targeted	B-MED
.	O
After	O
implementation	B-MED
,	O
there	O
was	O
a	O
61	O
%	O
reduction	B-MED
in	O
average	O
alarms	B-MED
per	O
monitored	O
bed	B-MED
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	B-MED
events	I-MED
.	O
To	O
reduce	B-MED
alarm	B-MED
fatigue	I-MED
it	O
is	O
important	O
to	O
decrease	B-MED
alarm	B-MED
burden	B-MED
through	O
targeted	B-MED
interventions	B-MED
.	O
Methods	O
to	O
reduce	O
non	O
-	O
actionable	O
alarms	B-MED
include	O
adding	O
short	O
delays	B-MED
to	O
allow	O
alarm	B-MED
self	B-MED
-	I-MED
correction	I-MED
,	O
adjusting	O
default	O
alarm	B-MED
threshold	B-MED
limits	B-MED
,	O
providing	O
alarm	B-MED
notification	B-MED
through	O
a	O
secondary	B-MED
device	I-MED
,	O
and	O
teaching	B-MED
staff	B-MED
to	O
optimize	O
alarm	B-MED
settings	O
for	O
individual	B-MED
patients	B-MED
.	O
Prospective	O
study	O
of	O
dietary	B-MED
Non	B-MED
Enzymatic	I-MED
Antioxidant	I-MED
Capacity	I-MED
on	O
the	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
in	O
the	O
elderly	B-MED
Dietary	B-MED
antioxidants	I-MED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-MED
loss	I-MED
and	O
associated	O
fractures	B-MED
by	O
reducing	O
levels	O
of	O
oxidative	B-MED
stress	I-MED
.	O
We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-MED
Non	B-MED
Enzymatic	I-MED
Antioxidant	I-MED
Capacity	I-MED
(	O
NEAC	B-MED
)	O
and	O
the	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	B-MED
.	O
In	O
the	O
Swedish	B-MED
National	I-MED
March	I-MED
Cohort	I-MED
13,409	O
men	B-MED
and	O
women	B-MED
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-MED
,	O
cardiovascular	B-MED
disease	I-MED
or	O
hip	B-MED
fracture	I-MED
,	O
were	O
followed	O
through	O
record	B-MED
-	I-MED
linkages	I-MED
from	O
1997	O
through	O
2010	O
.	O
NEAC	B-MED
was	O
assessed	O
by	O
a	O
validated	O
food	B-MED
frequency	I-MED
questionnaire	I-MED
collected	O
at	O
baseline	B-MED
.	O
We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-MED
into	O
sex	B-MED
-	O
specific	B-MED
quartiles	B-MED
and	O
used	O
multivariable	B-MED
adjusted	I-MED
Cox	I-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
models	I-MED
to	O
estimate	O
hazard	B-MED
ratios	I-MED
(	O
HRs	B-MED
)	O
with	O
95	O
%	O
confidence	B-MED
intervals	I-MED
(	O
95	O
%	O
CI	B-MED
)	O
.	O
During	O
a	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	B-MED
fracture	I-MED
.	O
Subjects	O
in	O
the	O
highest	O
quartile	B-MED
of	O
dietary	B-MED
NEAC	B-MED
had	O
a	O
39	O
%	O
lower	B-MED
risk	I-MED
of	O
incident	O
hip	B-MED
fracture	I-MED
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	B-MED
(	O
HR	B-MED
:	O
0.61	O
;	O
95	O
%	O
CI	B-MED
:	O
0.44	O
-	O
0.85	O
)	O
.	O
The	O
association	O
was	O
non	O
-	O
linear	O
(	O
p	O
for	O
non	O
-	O
linearity	O
:	O
0.004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	B-MED
and	O
no	O
further	O
risk	B-MED
reduction	I-MED
at	O
higher	O
levels	O
of	O
dietary	B-MED
NEAC	B-MED
.	O
Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-MED
NEAC	B-MED
and	O
smoking	B-MED
on	O
a	O
multiplicative	B-MED
or	O
additive	B-MED
scale	I-MED
.	O
Higher	O
dietary	O
NEAC	B-MED
intake	O
is	O
associated	O
with	O
lower	O
risk	B-MED
of	O
hip	B-MED
fracture	I-MED
in	O
the	O
elderly	O
.	O
Effect	B-MED
of	I-MED
alpha	B-MED
lipoic	I-MED
acid	I-MED
on	O
in	B-MED
vitro	I-MED
development	B-MED
of	O
bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
The	O
present	O
study	B-MED
aimed	O
to	O
evaluate	B-MED
the	O
in	B-MED
vitro	I-MED
effect	B-MED
of	I-MED
alpha	B-MED
lipoic	I-MED
acid	I-MED
(	O
ALA	B-MED
)	O
addition	O
to	O
the	O
culture	B-MED
medium	I-MED
on	O
the	O
development	B-MED
of	O
the	O
bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
.	O
Bovine	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
were	O
collected	B-MED
and	O
divided	B-MED
into	O
two	O
groups	B-MED
depending	O
on	O
their	O
size	B-MED
(	O
80	O
-	O
100	O
μm	O
and	O
100	O
-	O
110	O
μm	O
)	O
.	O
They	O
were	O
cultured	O
in	B-MED
vitro	I-MED
for	O
15	O
days	O
(	O
D	O
)	O
using	O
different	O
media	B-MED
including	O
at	O
three	O
different	O
doses	B-MED
of	O
ALA	B-MED
.	O
The	O
genes	B-MED
expression	I-MED
levels	B-MED
of	O
follicle	B-MED
-	I-MED
stimulating	I-MED
hormone	I-MED
beta	I-MED
-	I-MED
subunit	I-MED
(	O
FSHR	B-MED
)	O
,	O
insulin	B-MED
-	I-MED
like	I-MED
growth	I-MED
factor	I-MED
(	O
IGF-1	B-MED
)	O
,	O
Activin	B-MED
,	O
luteinizing	B-MED
hormone	I-MED
/	I-MED
choriogonadotropin	I-MED
receptor	I-MED
,	O
bone	B-MED
morphogenetic	I-MED
protein	I-MED
receptor	I-MED
type	I-MED
IA	I-MED
,	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
receptor	I-MED
1	I-MED
,	O
growth	B-MED
differentiation	I-MED
factor	I-MED
9	I-MED
,	O
BCL2	B-MED
-	I-MED
associated	I-MED
X	I-MED
protein	I-MED
(	O
BAX	B-MED
)	O
,	O
and	O
C	B-MED
-	I-MED
Myc	I-MED
were	O
studied	O
using	O
real	B-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
The	O
protein	B-MED
expression	I-MED
levels	B-MED
of	O
FSHR	B-MED
,	O
IGF-1	B-MED
,	O
and	O
BAX	B-MED
were	O
measured	O
using	O
Western	B-MED
blot	I-MED
analysis	I-MED
.	O
The	O
results	B-MED
of	O
the	O
present	O
work	O
revealed	O
that	O
in	B-MED
vitro	I-MED
addition	O
of	O
ALA	B-MED
-	O
induced	B-MED
significant	B-MED
increase	B-MED
in	I-MED
the	I-MED
growth	I-MED
and	O
development	B-MED
of	O
secondary	B-MED
preantral	I-MED
follicles	I-MED
throughout	O
the	O
culture	B-MED
period	B-MED
as	O
compared	B-MED
to	O
control	B-MED
.	O
The	O
FSHR	B-MED
,	O
IGF-1	B-MED
,	O
luteinizing	B-MED
hormone	I-MED
/	I-MED
choriogonadotropin	I-MED
receptor	I-MED
,	O
bone	B-MED
morphogenetic	I-MED
protein	I-MED
receptor	I-MED
type	I-MED
IA	I-MED
,	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
receptor	I-MED
1	I-MED
,	O
growth	B-MED
differentiation	I-MED
factor	I-MED
9	I-MED
,	O
and	O
Activin	B-MED
A	I-MED
genes	I-MED
were	O
upregulated	B-MED
in	O
ALA	B-MED
-	O
treated	B-MED
follicles	B-MED
as	O
compared	B-MED
to	O
the	O
control	B-MED
.	O
On	O
contrary	O
,	O
preapoptotic	B-MED
genes	I-MED
BAX	B-MED
and	O
C	B-MED
-	I-MED
Myc	I-MED
were	O
downregulated	B-MED
in	O
treated	B-MED
follicles	B-MED
compared	B-MED
to	O
control	B-MED
ones	O
.	O
The	O
protein	B-MED
levels	I-MED
of	O
FSHR	B-MED
and	O
IGF-1	B-MED
were	O
highly	O
expressed	B-MED
in	O
treated	B-MED
follicles	B-MED
compared	B-MED
to	O
control	B-MED
;	O
however	O
,	O
BAX	B-MED
protein	I-MED
was	O
downregulated	B-MED
in	O
the	O
treated	B-MED
follicles	B-MED
groups	B-MED
.	O
The	O
addition	O
of	O
ALA	B-MED
to	O
the	O
culture	B-MED
medium	I-MED
enhances	B-MED
secondary	B-MED
preantral	I-MED
follicles	I-MED
development	B-MED
and	O
growth	B-MED
.	O
Terahertz	B-MED
identification	I-MED
and	O
quantification	B-MED
of	O
neurotransmitter	B-MED
and	O
neurotrophy	B-MED
mixture	I-MED
Terahertz	B-MED
spectroscopy	I-MED
has	O
been	O
widely	O
used	O
for	O
investigating	B-MED
the	O
fingerprint	B-MED
spectrum	I-MED
of	O
different	O
substances	B-MED
.	O
For	O
cancerous	B-MED
tissues	B-MED
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	B-MED
peaks	O
of	O
various	O
substances	B-MED
contained	O
in	O
tissues	B-MED
overlap	B-MED
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	B-MED
analyze	B-MED
.	O
As	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	B-MED
cell	I-MED
and	O
then	O
to	O
diagnose	B-MED
accurately	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	B-MED
(	O
γ	B-MED
-	I-MED
aminobutyric	I-MED
acid	I-MED
,	O
L	B-MED
-	I-MED
glutamic	I-MED
acid	I-MED
,	O
dopamine	B-MED
hydrochloride	I-MED
)	O
and	O
two	O
typical	O
metabolites	B-MED
(	O
inositol	B-MED
and	O
creatine	B-MED
)	O
in	O
neurons	B-MED
to	O
measure	O
their	O
terahertz	B-MED
spectra	I-MED
with	O
different	O
mixture	B-MED
ratios	I-MED
.	O
By	O
choosing	O
characteristic	B-MED
absorption	B-MED
peaks	O
,	O
removing	O
baseline	B-MED
and	O
using	O
the	O
least	B-MED
square	I-MED
method	I-MED
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	B-MED
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	B-MED
of	I-MED
fit	I-MED
to	O
practical	O
situation	O
is	O
up	O
to	O
94	O
%	O
.	O
These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	B-MED
substances	I-MED
and	O
obtaining	O
exact	O
quantitative	B-MED
analysis	B-MED
.	O
Utility	B-MED
of	O
a	O
mHealth	B-MED
App	I-MED
for	O
Self	B-MED
-	I-MED
Management	I-MED
and	O
Education	B-MED
of	O
Cardiac	B-MED
Diseases	I-MED
in	O
Spanish	B-MED
Urban	B-MED
and	I-MED
Rural	I-MED
Areas	I-MED
Analyze	B-MED
the	O
utility	B-MED
of	O
a	O
mobile	B-MED
health	I-MED
app	I-MED
named	O
HeartKeeper	B-MED
in	O
several	B-MED
groups	I-MED
of	I-MED
population	I-MED
and	O
obtain	B-MED
conclusions	B-MED
to	O
be	O
applied	B-MED
to	O
other	B-MED
similar	I-MED
apps	I-MED
.	O
A	O
questionnaire	B-MED
has	O
been	O
designed	B-MED
to	O
evaluate	O
the	O
usage	B-MED
and	O
utility	B-MED
of	O
the	O
HeartKeeper	B-MED
app	I-MED
.	O
The	O
questionnaire	B-MED
information	B-MED
was	O
collected	B-MED
by	O
collaborating	O
cardiologists	B-MED
from	O
32	O
patients	B-MED
before	B-MED
and	I-MED
after	I-MED
they	O
used	B-MED
the	O
app	B-MED
.	O
Patients	B-MED
were	O
randomly	B-MED
selected	I-MED
with	O
established	O
quotas	B-MED
within	O
interest	B-MED
groups	I-MED
,	O
so	O
that	O
men	B-MED
and	O
women	B-MED
,	O
patients	B-MED
older	B-MED
or	O
younger	B-MED
than	O
60	O
years	B-MED
old	I-MED
and	O
patients	B-MED
living	O
in	O
urban	B-MED
or	I-MED
rural	I-MED
areas	I-MED
were	O
equally	B-MED
represented	I-MED
.	O
Using	O
the	O
appropriate	O
statistical	B-MED
techniques	I-MED
we	O
see	O
that	O
the	O
HeartKeeper	B-MED
app	I-MED
was	O
useful	O
for	O
patients	B-MED
as	O
they	O
qualify	B-MED
with	O
70	O
points	O
(	O
out	O
of	O
100	O
)	O
the	O
overall	B-MED
opinion	I-MED
of	O
the	O
app	B-MED
,	O
it	O
helps	O
them	O
remember	B-MED
more	O
easily	O
taking	O
their	O
pills	B-MED
with	O
a	O
mean	O
improvement	B-MED
of	O
20.94	O
points	O
(	O
p	O
<	O
0.001	O
)	O
and	O
they	O
perceive	O
a	O
global	B-MED
improvement	I-MED
of	O
their	O
health	O
(	O
8.28	O
points	O
,	O
p	O
<	O
0.001	O
)	O
.	O
We	O
also	O
observe	B-MED
that	O
these	O
improvements	B-MED
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	B-MED
(	I-MED
urban	I-MED
or	I-MED
rural	I-MED
)	I-MED
where	O
the	O
patient	B-MED
comes	O
from	O
or	O
on	O
their	O
sex	B-MED
.	O
Although	O
older	B-MED
patients	I-MED
needed	B-MED
more	O
help	O
to	O
use	B-MED
the	O
app	B-MED
and	O
used	B-MED
it	O
slightly	O
less	B-MED
frequently	I-MED
,	O
the	O
improvements	B-MED
on	O
several	B-MED
measures	I-MED
considered	O
,	O
such	O
as	O
remembering	B-MED
taking	O
pills	B-MED
,	O
breathing	B-MED
problems	I-MED
or	O
trouble	B-MED
developing	I-MED
activities	I-MED
,	O
depend	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
on	O
age	O
with	O
older	B-MED
patients	I-MED
reporting	O
higher	B-MED
improvements	B-MED
than	O
younger	B-MED
ones	I-MED
.	O
The	O
results	B-MED
obtained	O
with	O
the	O
sample	B-MED
of	O
patients	B-MED
considered	O
in	O
this	O
research	B-MED
prove	O
the	O
utility	B-MED
of	O
the	O
HeartKeeper	B-MED
app	I-MED
.	O
This	O
utility	B-MED
is	O
similar	O
in	O
urban	B-MED
and	I-MED
rural	I-MED
areas	I-MED
and	O
for	O
patients	B-MED
of	O
both	B-MED
sexes	I-MED
and	O
,	O
to	B-MED
some	I-MED
extent	I-MED
,	O
depends	O
on	O
the	O
age	B-MED
of	O
the	O
patient	B-MED
with	O
older	B-MED
patients	I-MED
reporting	O
slightly	B-MED
lower	I-MED
frequency	I-MED
of	O
use	B-MED
but	O
higher	B-MED
health	B-MED
improvements	I-MED
than	O
younger	B-MED
ones	I-MED
.	O
Generation	B-MED
of	O
High	B-MED
-	I-MED
Quality	I-MED
SWATH	B-MED
(	I-MED
®	I-MED
)	I-MED
Acquisition	B-MED
Data	B-MED
for	O
Label	B-MED
-	I-MED
free	I-MED
Quantitative	B-MED
Proteomics	B-MED
Studies	I-MED
Using	O
TripleTOF	B-MED
(	I-MED
®	I-MED
)	I-MED
Mass	I-MED
Spectrometers	I-MED
Data	B-MED
-	O
independent	B-MED
acquisition	B-MED
is	O
a	O
powerful	O
mass	B-MED
spectrometry	I-MED
technique	I-MED
that	O
enables	O
comprehensive	O
MS	B-MED
and	O
MS	B-MED
/	I-MED
MS	I-MED
analysis	B-MED
of	O
all	O
detectable	B-MED
species	B-MED
,	O
providing	O
an	O
information	B-MED
rich	O
data	B-MED
file	O
that	O
can	O
be	O
mined	B-MED
deeply	O
.	O
Here	O
,	O
we	O
describe	O
how	O
to	O
acquire	B-MED
high	B-MED
-	I-MED
quality	I-MED
SWATH	B-MED
(	I-MED
®	I-MED
)	I-MED
Acquisition	B-MED
data	B-MED
to	O
be	O
used	O
for	O
large	B-MED
quantitative	B-MED
proteomic	B-MED
studies	I-MED
.	O
We	O
specifically	O
focus	O
on	O
using	O
variable	B-MED
sized	B-MED
Q1	B-MED
windows	I-MED
for	O
acquisition	B-MED
of	O
MS	B-MED
/	I-MED
MS	I-MED
data	B-MED
for	O
generating	B-MED
higher	O
specificity	B-MED
quantitative	B-MED
data	B-MED
.	O
Characterisation	B-MED
of	O
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
clinical	B-MED
isolates	B-MED
from	O
animals	B-MED
in	O
New	B-MED
Zealand	I-MED
,	O
2012	O
-	O
2013	O
,	O
and	O
subclinical	B-MED
colonisation	B-MED
in	O
dogs	B-MED
and	O
cats	B-MED
in	O
Auckland	B-MED
To	O
characterise	B-MED
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
(	O
MRSA	B-MED
)	O
isolates	B-MED
from	O
infection	B-MED
sites	I-MED
in	O
animals	B-MED
in	O
New	B-MED
Zealand	I-MED
and	O
assess	O
the	O
prevalence	B-MED
of	O
subclinical	B-MED
MRSA	B-MED
colonisation	I-MED
in	O
dogs	B-MED
and	O
cats	B-MED
attending	O
veterinary	B-MED
clinics	I-MED
in	O
Auckland	B-MED
.	O
MRSA	B-MED
isolates	B-MED
from	O
clinical	B-MED
specimens	B-MED
obtained	O
by	O
the	O
main	O
New	B-MED
Zealand	I-MED
veterinary	B-MED
diagnostic	I-MED
laboratories	I-MED
between	O
June	B-MED
2012	O
and	O
June	B-MED
2013	O
,	O
were	O
genotypically	B-MED
characterised	I-MED
by	O
DNA	B-MED
microarray	I-MED
hybridisation	I-MED
analysis	I-MED
and	O
spa	B-MED
typing	B-MED
.	O
In	O
addition	O
,	O
nasal	B-MED
or	O
perineal	B-MED
skin	I-MED
swabs	B-MED
collected	O
from	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
sample	I-MED
of	O
dogs	B-MED
(	O
n=361	O
)	O
and	O
cats	B-MED
(	O
n=225	O
)	O
attending	O
29	O
veterinary	B-MED
clinics	I-MED
in	O
Auckland	B-MED
during	O
the	O
same	O
period	B-MED
were	O
analysed	B-MED
for	O
MRSA	B-MED
by	O
culture	B-MED
.	O
Eight	O
MRSA	B-MED
clinical	B-MED
isolates	B-MED
were	O
submitted	O
for	O
characterisation	B-MED
by	O
the	O
participating	O
laboratories	B-MED
.	O
The	O
isolates	B-MED
originated	O
from	O
five	O
dogs	B-MED
,	O
including	O
two	O
isolates	B-MED
from	O
the	O
same	O
dog	B-MED
,	O
one	O
foal	B-MED
,	O
and	O
one	O
isolate	B-MED
had	O
no	O
identification	O
of	O
the	O
source	B-MED
.	O
The	O
strain	B-MED
-	O
types	B-MED
identified	B-MED
were	O
AK3	B-MED
(	I-MED
ST-5	I-MED
SCCmecIV	I-MED
t045	O
;	O
n=1	O
)	O
,	O
USA500	B-MED
(	I-MED
ST8	I-MED
SCCmecIV	I-MED
t064	O
;	O
n=1	O
)	O
,	O
WSPP	B-MED
(	I-MED
ST30	I-MED
SCCmecIV	I-MED
t019	O
;	O
n=1	O
)	O
,	O
Rhine	B-MED
Hesse	I-MED
(	I-MED
ST5	I-MED
SCCmecII	I-MED
t002	O
;	O
n=2	O
)	O
,	O
and	O
EMRSA-15	B-MED
(	I-MED
ST22	I-MED
SCCmecIV	I-MED
t032	O
;	O
n=3	O
)	O
.	O
No	O
MRSA	B-MED
were	O
isolated	B-MED
from	O
586	O
cultured	B-MED
swabs	I-MED
.	O
Methicillin	B-MED
-	I-MED
susceptible	I-MED
S.	I-MED
aureus	I-MED
were	O
detected	B-MED
in	O
9/257	O
(	O
3.5	O
%	O
)	O
swabs	B-MED
and	O
non	B-MED
-	I-MED
aureus	I-MED
staphylococci	I-MED
in	O
22/257	O
(	O
8.5	O
%	O
)	O
swabs	B-MED
.	O
The	O
estimated	O
true	O
MRSA	B-MED
subclinical	B-MED
colonisation	B-MED
prevalence	B-MED
was	O
0	O
%	O
,	O
with	O
an	O
upper	O
95	O
%	O
CI	B-MED
boundary	O
of	O
1.9	O
%	O
for	O
cats	B-MED
and	O
1.4	O
%	O
for	O
dogs	B-MED
.	O
The	O
modest	B-MED
number	I-MED
of	O
MRSA	B-MED
isolates	B-MED
submitted	O
for	O
this	O
study	B-MED
by	O
the	O
participating	O
laboratories	B-MED
suggests	O
clinical	B-MED
MRSA	B-MED
infection	I-MED
in	O
animals	B-MED
in	O
New	B-MED
Zealand	I-MED
continues	O
to	O
be	O
sporadic	B-MED
.	O
The	O
wide	O
variety	O
of	O
strain	B-MED
-	O
types	B-MED
found	O
mirrored	O
the	O
evolving	O
strain	B-MED
-	O
type	B-MED
diversity	B-MED
observed	O
in	O
humans	B-MED
.	O
We	O
can	O
not	O
rule	O
out	O
bias	B-MED
due	O
to	O
the	O
non	B-MED
-	I-MED
random	I-MED
sampling	I-MED
of	O
dogs	B-MED
and	O
cats	B-MED
,	O
but	O
the	O
apparent	O
colonisation	B-MED
prevalence	B-MED
of	O
0	O
%	O
was	O
consistent	B-MED
with	I-MED
the	O
low	O
prevalence	B-MED
of	O
subclinical	B-MED
colonisation	B-MED
in	O
humans	B-MED
in	O
New	B-MED
Zealand	I-MED
.	O
These	O
similarities	B-MED
indicate	O
the	O
epidemiology	B-MED
of	O
animal	B-MED
and	O
human	B-MED
MRSA	B-MED
infections	I-MED
are	O
linked	O
.	O
In	O
the	O
last	O
decade	B-MED
,	O
the	O
prevalence	B-MED
of	O
human	B-MED
MRSA	B-MED
infections	I-MED
in	O
New	B-MED
Zealand	I-MED
has	O
steadily	O
increased	B-MED
.	O
This	O
is	O
the	O
second	O
published	O
study	B-MED
of	O
MRSA	B-MED
in	O
animals	B-MED
in	O
New	B-MED
Zealand	I-MED
.	O
The	O
results	O
indicate	O
clinical	B-MED
MRSA	B-MED
infection	I-MED
in	O
animals	B-MED
remains	O
sporadic	B-MED
,	O
but	O
the	O
diversification	B-MED
of	O
the	O
strain	B-MED
-	O
types	B-MED
may	O
pose	O
new	O
therapeutic	B-MED
challenges	O
to	O
veterinarians	B-MED
,	O
due	O
to	O
their	O
diverse	O
resistome	B-MED
.	O
Fluoranthene	B-MED
degradation	B-MED
and	O
binding	B-MED
mechanism	B-MED
study	B-MED
based	O
on	O
the	O
active	B-MED
-	I-MED
site	I-MED
structure	B-MED
of	O
ring	B-MED
-	I-MED
hydroxylating	I-MED
dioxygenase	I-MED
in	O
Microbacterium	B-MED
paraoxydans	I-MED
JPM1	I-MED
In	O
this	O
study	B-MED
,	O
a	O
gram	B-MED
-	I-MED
positive	I-MED
fluoranthene	I-MED
-	I-MED
degrading	I-MED
bacterial	I-MED
strain	B-MED
was	O
isolated	B-MED
from	O
crude	B-MED
oil	I-MED
in	O
Dagang	B-MED
Oilfield	I-MED
and	O
identified	B-MED
as	O
Microbacterium	B-MED
paraoxydans	I-MED
JPM1	I-MED
by	O
the	O
analysis	B-MED
of	O
16S	B-MED
rDNA	I-MED
sequence	B-MED
.	O
After	O
25	O
days	B-MED
of	O
incubation	B-MED
,	O
the	O
strain	B-MED
JPM1	B-MED
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	B-MED
amount	B-MED
of	O
fluoranthene	B-MED
.	O
Moreover	O
,	O
four	O
metabolites	B-MED
9	B-MED
-	I-MED
fluorenone-1	I-MED
-	I-MED
carboxylic	I-MED
acid	I-MED
,	O
9	B-MED
-	I-MED
fluorenone	I-MED
,	O
phthalic	B-MED
acid	I-MED
,	O
and	O
benzoic	B-MED
acid	I-MED
were	O
detected	O
in	O
the	O
culture	B-MED
solution	I-MED
.	O
The	O
gene	B-MED
sequence	I-MED
encoding	B-MED
the	O
aromatic	B-MED
-	I-MED
ring	I-MED
-	I-MED
hydroxylating	I-MED
dioxygenase	I-MED
was	O
amplified	B-MED
in	O
the	O
strain	B-MED
JPM1	B-MED
by	O
PCR	B-MED
.	O
Based	O
on	O
the	O
translated	O
protein	B-MED
sequence	I-MED
,	O
a	O
homology	B-MED
modeling	I-MED
method	I-MED
was	O
applied	O
to	O
build	O
the	O
crystal	B-MED
structure	I-MED
of	O
dioxygenase	B-MED
.	O
Subsequently	O
,	O
the	O
interaction	B-MED
mechanism	B-MED
between	O
fluoranthene	B-MED
and	O
the	O
active	B-MED
site	I-MED
of	O
dioxygenase	B-MED
was	O
simulated	B-MED
and	O
analyzed	B-MED
by	O
molecular	B-MED
docking	I-MED
.	O
Consequently	O
,	O
a	O
feasible	O
degrading	B-MED
pathway	B-MED
of	O
fluoranthene	B-MED
in	O
the	O
strain	B-MED
JPM1	B-MED
was	O
proposed	O
based	O
on	O
the	O
metabolites	B-MED
and	O
the	O
interaction	B-MED
analyses	I-MED
.	O
Additionally	O
,	O
the	O
thermodynamic	B-MED
analysis	I-MED
showed	O
that	O
the	O
strain	B-MED
JPM1	B-MED
had	O
high	B-MED
tolerance	B-MED
for	O
fluoranthene	B-MED
,	O
and	O
the	O
influence	B-MED
of	O
fluoranthene	B-MED
for	O
the	O
bacterial	B-MED
growth	B-MED
activity	O
was	O
negligible	B-MED
under	O
100	O
to	O
400	O
mg	O
L(-1	O
)	O
concentrations	B-MED
.	O
Taken	O
together	O
,	O
this	O
study	B-MED
indicates	O
that	O
the	O
strain	B-MED
JPM1	B-MED
has	O
high	O
potential	B-MED
for	O
further	O
study	B-MED
in	O
bioremediation	B-MED
of	O
polycyclic	B-MED
aromatic	I-MED
hydrocarbon	I-MED
PAH	B-MED
(	O
PAH)-	O
contaminated	B-MED
sites	B-MED
.	O
Nonylphenol	B-MED
diethoxylate	I-MED
inhibits	B-MED
apoptosis	B-MED
induced	B-MED
in	O
PC12	B-MED
cells	I-MED
Nonylphenol	B-MED
and	O
short	B-MED
-	I-MED
chain	I-MED
nonylphenol	I-MED
ethoxylates	I-MED
such	O
as	O
NP2	B-MED
EO	I-MED
are	O
present	B-MED
in	O
aquatic	B-MED
environment	I-MED
as	O
wastewater	B-MED
contaminants	B-MED
,	O
and	O
their	O
toxic	B-MED
effects	I-MED
on	O
aquatic	B-MED
species	I-MED
have	O
been	O
reported	O
.	O
Apoptosis	B-MED
has	O
been	O
shown	O
to	O
be	O
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
or	O
copper	B-MED
treatment	B-MED
.	O
To	O
understand	O
the	O
toxicity	B-MED
of	O
nonylphenol	B-MED
diethoxylate	I-MED
,	O
we	O
investigated	O
the	O
effects	B-MED
of	I-MED
NP2	B-MED
EO	I-MED
on	O
apoptosis	B-MED
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
and	O
copper	B-MED
by	O
using	O
PC12	B-MED
cell	I-MED
system	I-MED
.	O
Nonylphenol	B-MED
diethoxylate	I-MED
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-MED
viability	I-MED
from	O
apoptosis	B-MED
.	O
In	O
addition	O
,	O
nonylphenol	B-MED
diethoxylate	I-MED
decreased	B-MED
DNA	B-MED
fragmentation	I-MED
caused	O
by	O
apoptosis	B-MED
in	O
PC12	B-MED
cells	I-MED
.	O
This	O
phenomenon	B-MED
was	O
confirmed	O
after	O
treating	B-MED
apoptotic	B-MED
PC12	B-MED
cells	I-MED
with	O
nonylphenol	B-MED
diethoxylate	I-MED
,	O
whereas	O
the	O
cytochrome	B-MED
c	I-MED
release	O
into	O
the	O
cytosol	B-MED
decreased	B-MED
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-MED
cells	I-MED
not	O
treated	B-MED
with	O
nonylphenol	B-MED
diethoxylate	I-MED
s.	O
Furthermore	O
,	O
Bax	B-MED
contents	B-MED
in	O
apoptotic	B-MED
cells	I-MED
were	O
reduced	B-MED
after	O
exposure	B-MED
to	I-MED
nonylphenol	B-MED
diethoxylate	I-MED
.	O
Thus	O
,	O
nonylphenol	B-MED
diethoxylate	I-MED
has	O
the	O
opposite	B-MED
effect	I-MED
on	O
apoptosis	B-MED
in	O
PC12	B-MED
cells	I-MED
compared	O
to	O
nonylphenol	B-MED
,	O
which	O
enhances	B-MED
apoptosis	B-MED
induced	B-MED
by	O
serum	B-MED
deprivation	B-MED
.	O
The	O
difference	B-MED
in	O
structure	B-MED
of	O
the	O
two	O
compounds	B-MED
is	O
hypothesized	B-MED
to	O
be	O
responsible	O
for	O
this	O
phenomenon	B-MED
.	O
These	O
results	B-MED
indicated	O
that	O
nonylphenol	B-MED
diethoxylate	I-MED
has	O
capability	B-MED
to	O
affect	O
cell	B-MED
differentiation	I-MED
and	O
development	B-MED
and	O
has	O
potentially	B-MED
harmful	B-MED
effect	I-MED
on	O
organisms	B-MED
because	O
of	O
its	O
unexpected	O
impact	B-MED
on	O
apoptosis	B-MED
.	O
©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Environ	O
Toxicol	O
31	O
:	O
1389	O
-	O
1398	O
,	O
2016	O
.	O
Activation	B-MED
of	O
ephrinB	B-MED
-	I-MED
EphB	I-MED
receptor	I-MED
signalling	I-MED
in	O
rat	B-MED
spinal	I-MED
cord	I-MED
contributes	O
to	O
maintenance	B-MED
of	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
Diabetic	B-MED
neuropathic	B-MED
pain	I-MED
(	O
DNP	B-MED
)	O
is	O
severe	B-MED
and	O
intractable	B-MED
in	O
clinic	B-MED
.	O
The	O
specific	B-MED
cellular	B-MED
and	O
molecular	B-MED
mechanisms	B-MED
underlying	O
DNP	B-MED
remain	O
elusive	O
and	O
its	O
treatment	B-MED
are	O
limited	B-MED
.	O
We	O
investigated	B-MED
roles	B-MED
of	O
EphB1	B-MED
receptor	I-MED
in	O
the	O
development	O
of	O
DNP	B-MED
.	O
Diabetic	B-MED
neuropathic	B-MED
pain	I-MED
was	O
produced	O
in	O
male	B-MED
,	O
adult	B-MED
,	O
Sprague	B-MED
-	I-MED
Dawley	I-MED
rats	I-MED
by	O
a	O
single	O
i.p	O
.	O
streptozotocin	B-MED
(	O
STZ	B-MED
)	O
or	O
alloxan	B-MED
.	O
Western	B-MED
blot	I-MED
analysis	I-MED
and	O
immunohistochemistry	B-MED
were	O
used	O
to	O
analyse	O
expression	B-MED
of	O
EphB1	B-MED
receptor	I-MED
as	O
well	O
as	O
the	O
activation	B-MED
of	O
the	O
glial	B-MED
cells	I-MED
and	O
the	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokines	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
.	O
DNP	B-MED
manifested	B-MED
as	O
mechanical	B-MED
allodynia	I-MED
,	O
which	O
was	O
determined	O
by	O
measuring	B-MED
incidence	B-MED
of	O
foot	B-MED
withdrawal	B-MED
in	O
response	B-MED
to	O
mechanical	B-MED
indentation	I-MED
of	O
the	O
hind	B-MED
paw	B-MED
by	O
an	O
electro	B-MED
von	I-MED
Frey	I-MED
filament	I-MED
.	O
Diabetic	B-MED
neuropathic	B-MED
pain	I-MED
and	O
high	B-MED
blood	I-MED
glucose	I-MED
were	O
exhibited	O
simultaneously	B-MED
in	O
around	O
70	O
%	O
of	O
animals	B-MED
that	O
received	O
i.p	O
.	O
STZ	B-MED
or	O
alloxan	B-MED
.	O
Phosphorylation	B-MED
of	O
EphB1	B-MED
,	O
activation	B-MED
of	O
the	O
astrocytes	B-MED
and	O
microglial	B-MED
cells	I-MED
,	O
and	O
level	B-MED
of	O
tumour	B-MED
necrosis	I-MED
factor	I-MED
(	B-MED
TNF)-α	I-MED
and	O
interleukin	B-MED
(	I-MED
IL)-1β	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
were	O
significantly	O
increased	O
in	O
rats	B-MED
with	O
DNP	B-MED
.	O
Spinal	B-MED
blocking	B-MED
EphB1	B-MED
receptor	I-MED
activation	B-MED
in	O
the	O
late	O
phase	O
after	O
STZ	B-MED
injection	B-MED
significantly	O
suppressed	B-MED
the	O
established	O
mechanical	B-MED
allodynia	I-MED
as	O
well	O
as	O
activation	B-MED
of	O
the	O
astrocytes	B-MED
and	O
microglial	B-MED
cells	I-MED
and	O
activity	B-MED
of	O
TNF	B-MED
-	I-MED
α	I-MED
and	O
IL-1β	B-MED
.	O
However	O
,	O
spinal	B-MED
treatment	B-MED
of	O
EphB1	B-MED
-	O
Fc	B-MED
in	O
the	O
early	B-MED
phase	I-MED
after	O
STZ	B-MED
injection	B-MED
did	O
not	O
prevent	O
the	O
induction	B-MED
of	O
DNP	B-MED
.	O
EphB1	B-MED
receptor	I-MED
activation	B-MED
in	O
the	O
spinal	B-MED
cord	I-MED
is	O
critical	B-MED
to	O
the	O
maintenance	B-MED
,	O
but	O
not	O
induction	B-MED
of	O
diabetic	B-MED
pain	B-MED
.	O
EphB1	B-MED
receptor	I-MED
may	O
be	O
a	O
potential	B-MED
target	B-MED
for	O
relieving	B-MED
the	O
established	O
diabetic	B-MED
pain	B-MED
.	O
Activation	B-MED
of	O
EphB1	B-MED
receptor	I-MED
in	O
the	O
spinal	B-MED
cord	I-MED
is	O
critical	B-MED
to	O
maintaining	B-MED
the	O
established	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
,	O
but	O
not	O
to	O
diabetic	B-MED
pain	B-MED
induction	B-MED
.	O
Spinal	B-MED
blocking	B-MED
EphB1	B-MED
receptor	I-MED
activation	B-MED
suppresses	B-MED
ongoing	O
diabetic	B-MED
neuropathic	B-MED
pain	I-MED
.	O
Conservation	B-MED
of	O
the	O
Red	B-MED
Kite	I-MED
Milvus	B-MED
milvus	I-MED
(	O
Aves	B-MED
:	O
Accipitriformes	B-MED
)	O
Is	O
Not	O
Affected	B-MED
by	O
the	O
Establishment	O
of	O
a	O
Broad	O
Hybrid	B-MED
Zone	B-MED
with	O
the	O
Black	B-MED
Kite	I-MED
Milvus	B-MED
migrans	I-MED
migrans	I-MED
in	O
Central	B-MED
Europe	I-MED
Among	O
Accipitriformes	B-MED
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	B-MED
have	O
been	O
reported	B-MED
to	O
form	O
hybrid	B-MED
zones	B-MED
;	O
these	O
include	O
the	O
red	B-MED
kite	I-MED
Milvus	B-MED
milvus	I-MED
and	O
black	B-MED
kite	I-MED
Milvus	B-MED
migrans	I-MED
migrans	I-MED
.	O
M.	B-MED
milvus	I-MED
is	O
endemic	B-MED
to	O
the	O
western	B-MED
Palearctic	I-MED
and	O
has	O
an	O
estimated	O
total	O
population	B-MED
of	O
20	O
-	O
24,000	O
breeding	B-MED
pairs	B-MED
.	O
The	O
species	B-MED
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	B-MED
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-MED
of	O
rodenticide	B-MED
-	I-MED
treated	I-MED
baits	I-MED
,	O
illegal	B-MED
poisoning	B-MED
and	O
changes	O
in	O
agricultural	B-MED
practices	I-MED
,	O
particularly	O
in	O
its	O
core	B-MED
range	B-MED
.	O
Whereas	O
F1	B-MED
M.	B-MED
milvus	I-MED
×	O
M.	B-MED
migr	I-MED
.	I-MED
migrans	I-MED
hybrid	B-MED
offspring	B-MED
have	O
been	O
found	O
,	O
F2	B-MED
and	O
F3	B-MED
hybrids	B-MED
have	O
only	O
rarely	O
been	O
reported	B-MED
,	O
with	O
low	O
nesting	B-MED
success	B-MED
rates	B-MED
of	O
F1	B-MED
hybrids	B-MED
and	O
partial	B-MED
hybrid	B-MED
sterility	O
likely	O
playing	O
a	O
role	O
.	O
Here	O
,	O
we	O
analyzed	B-MED
the	O
mitochondrial	B-MED
(	O
CO1	B-MED
and	O
CytB	B-MED
)	O
and	O
nuclear	B-MED
(	O
Myc	B-MED
)	O
DNA	B-MED
loci	B-MED
of	O
184	O
M.	B-MED
milvus	I-MED
,	O
124	O
M.	B-MED
migr	I-MED
.	I-MED
migrans	I-MED
and	O
3	O
F1	B-MED
hybrid	B-MED
individuals	O
collected	O
across	O
central	B-MED
Europe	I-MED
.	O
In	O
agreement	B-MED
with	O
previous	O
studies	B-MED
,	O
we	O
found	O
low	O
heterozygosity	B-MED
in	O
M.	B-MED
milvus	I-MED
regardless	O
of	O
locus	B-MED
.	O
We	O
found	O
that	O
populations	B-MED
of	O
both	O
examined	B-MED
species	B-MED
were	O
characterized	B-MED
by	O
a	O
high	O
gene	B-MED
flow	I-MED
within	O
populations	B-MED
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	B-MED
distributed	O
across	O
the	O
entire	O
examined	B-MED
area	B-MED
.	O
Few	O
haplotypes	B-MED
displayed	O
statistically	B-MED
significant	I-MED
aggregation	B-MED
in	O
one	O
region	B-MED
over	O
another	O
.	O
We	O
did	O
not	O
find	O
mitochondrial	B-MED
DNA	I-MED
of	O
one	O
species	B-MED
in	O
individuals	O
with	O
the	O
plumage	B-MED
of	O
the	O
other	O
species	B-MED
,	O
except	O
in	O
F1	B-MED
hybrids	B-MED
,	O
which	O
agrees	O
with	O
Haldane´s	B-MED
Rule	I-MED
.	O
It	O
remains	O
to	O
be	O
investigated	B-MED
by	O
genomic	B-MED
methods	B-MED
whether	O
occasional	O
gene	B-MED
flow	I-MED
occurs	O
through	O
the	O
paternal	B-MED
line	O
,	O
as	O
the	O
examined	B-MED
Myc	B-MED
gene	I-MED
displayed	O
only	O
marginal	O
divergence	B-MED
between	O
M.	B-MED
milvus	I-MED
and	O
M.	B-MED
migr	I-MED
.	I-MED
migrans	I-MED
.	O
The	O
central	B-MED
Europe	I-MED
an	O
population	B-MED
of	O
M.	B-MED
milvus	I-MED
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	B-MED
flow	I-MED
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	B-MED
of	O
individuals	O
in	O
M.	B-MED
milvus	I-MED
re	O
-	O
introduction	O
programs	O
.	O
Tissue	B-MED
MicroRNA	B-MED
profiles	O
as	O
diagnostic	B-MED
and	O
prognostic	B-MED
biomarkers	I-MED
in	O
patients	B-MED
with	O
resectable	B-MED
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
and	O
periampullary	B-MED
cancers	I-MED
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
validate	O
previously	O
described	O
diagnostic	B-MED
and	O
prognostic	B-MED
microRNA	B-MED
expression	B-MED
profiles	I-MED
in	O
tissue	B-MED
samples	O
from	O
patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
and	O
other	O
periampullary	B-MED
cancers	I-MED
.	O
Expression	B-MED
of	O
46	O
selected	O
microRNAs	B-MED
was	O
studied	O
in	O
formalin	B-MED
-fixed	O
paraffin	B-MED
-	I-MED
embedded	I-MED
tissue	I-MED
from	O
patients	B-MED
with	O
resected	B-MED
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
(	O
n	O
=	O
165	O
)	O
,	O
ampullary	B-MED
cancer	I-MED
(	O
n=59	O
)	O
,	O
duodenal	B-MED
cancer	I-MED
(	O
n	O
=	O
6	O
)	O
,	O
distal	B-MED
common	B-MED
bile	I-MED
duct	I-MED
cancer	I-MED
(	O
n	O
=	O
21	O
)	O
,	O
and	O
gastric	B-MED
cancer	I-MED
(	O
n	O
=	O
20	O
)	O
;	O
chronic	B-MED
pancreatitis	I-MED
(	O
n	O
=	O
39	O
)	O
;	O
and	O
normal	B-MED
pancreas	I-MED
(	O
n	O
=	O
35	O
)	O
.	O
The	O
microRNAs	B-MED
were	O
analyzed	O
by	O
PCR	B-MED
using	O
the	O
Fluidigm	B-MED
platform	I-MED
.	O
Twenty	O
-	O
two	O
microRNAs	B-MED
were	O
significantly	O
differently	O
expressed	B-MED
in	O
patients	B-MED
with	O
pancreatic	B-MED
cancer	I-MED
when	O
compared	O
to	O
healthy	B-MED
controls	I-MED
and	O
chronic	B-MED
pancreatitis	I-MED
patients	B-MED
;	O
17	O
miRNAs	B-MED
were	O
upregulated	B-MED
(	O
miR-21	B-MED
-	I-MED
5p	I-MED
,	O
-	O
23a-3p	B-MED
,	O
-	O
31	B-MED
-	I-MED
5p	I-MED
,	O
-	O
34c-5p	B-MED
,	O
-	O
93	B-MED
-	I-MED
3p	I-MED
,	O
-	O
135b-3p	B-MED
,	O
-	O
155	B-MED
-	I-MED
5p	I-MED
,	O
-	O
186	B-MED
-	I-MED
5p	I-MED
,	O
-	O
196b-5p	B-MED
,	I-MED
-	O
203	B-MED
,	O
-	O
205	B-MED
-	I-MED
5p	I-MED
,	O
-	O
210	B-MED
,	O
-	O
222	B-MED
-	I-MED
3p	I-MED
,	O
-	O
451	B-MED
,	O
-	O
492	B-MED
,	O
-	O
614	B-MED
,	O
and	O
miR-622	B-MED
)	O
and	O
5	O
were	O
downregulated	B-MED
(	O
miR-122	B-MED
-	I-MED
5p	I-MED
,	O
-	O
130b-3p	B-MED
,	O
-	O
216b	B-MED
,	O
-	O
217	B-MED
,	O
and	O
miR-375	B-MED
)	O
.	O
MicroRNAs	B-MED
were	O
grouped	O
into	O
diagnostic	B-MED
indices	O
of	O
varying	O
complexity	B-MED
.	O
Ten	O
microRNAs	B-MED
associated	B-MED
with	I-MED
prognosis	B-MED
were	O
identified	O
(	O
let-7	B-MED
g	I-MED
,	O
miR-29a-5p	B-MED
,	O
-	O
34a-5p	B-MED
,	O
-	O
125a-3p	B-MED
,	O
-	O
146a-5p	B-MED
,	O
-	O
187	B-MED
,	O
-	O
205	B-MED
-	I-MED
5p	I-MED
,	O
-	O
212	B-MED
-	I-MED
3p	I-MED
,	O
-	O
222	B-MED
-	I-MED
5p	I-MED
,	O
and	O
miR-450b-5p	B-MED
)	O
.	O
Prognostic	B-MED
indices	I-MED
based	O
on	O
differences	O
in	O
expression	B-MED
of	O
2	O
different	O
microRNAs	B-MED
were	O
constructed	O
for	O
pancreatic	B-MED
and	O
ampullary	B-MED
cancer	I-MED
combined	O
and	O
separately	O
(	O
30	O
,	O
5	O
,	O
and	O
21	O
indices	O
)	O
.	O
The	O
study	B-MED
confirms	O
that	O
pancreatic	B-MED
cancer	I-MED
tissue	B-MED
has	O
a	O
microRNA	B-MED
expression	B-MED
profile	I-MED
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary	B-MED
cancers	I-MED
,	O
chronic	B-MED
pancreatitis	I-MED
,	O
and	O
normal	B-MED
pancreas	I-MED
.	O
We	O
identified	O
prognostic	B-MED
microRNAs	B-MED
and	O
microRNA	B-MED
indices	O
that	O
were	O
associated	B-MED
with	I-MED
shorter	O
overall	B-MED
survival	I-MED
in	O
patients	B-MED
with	O
radically	O
resected	B-MED
pancreatic	B-MED
cancer	I-MED
.	O
In	B-MED
Vivo	I-MED
Three	B-MED
-	I-MED
Dimensional	I-MED
Patellar	B-MED
Mechanics	B-MED
:	O
Normal	B-MED
Knees	B-MED
Compared	B-MED
with	O
Domed	B-MED
and	O
Anatomic	B-MED
Patellar	B-MED
Components	B-MED
Patellofemoral	B-MED
complications	B-MED
are	O
a	O
major	O
cause	O
of	O
revision	B-MED
surgery	I-MED
following	B-MED
total	B-MED
knee	I-MED
arthroplasty	I-MED
(	O
TKA	B-MED
)	O
.	O
High	B-MED
forces	B-MED
occurring	O
at	O
the	O
patellofemoral	B-MED
articulation	I-MED
coupled	B-MED
with	O
a	O
small	B-MED
patellofemoral	B-MED
contact	B-MED
area	I-MED
pose	O
substantial	O
design	B-MED
challenges	O
.	O
In	O
this	O
study	B-MED
,	O
the	O
three	B-MED
-	I-MED
dimensional	I-MED
(	O
3D	B-MED
)	O
in	B-MED
vivo	I-MED
mechanics	B-MED
of	O
domed	B-MED
and	O
anatomically	B-MED
shaped	B-MED
patellar	B-MED
components	B-MED
were	O
compared	B-MED
with	O
those	O
of	O
native	B-MED
patellae	B-MED
.	O
Ten	O
normal	B-MED
knees	B-MED
,	O
10	O
treated	B-MED
with	I-MED
an	O
LCS	B-MED
-	I-MED
PS	I-MED
(	I-MED
low	I-MED
contact	I-MED
stress	I-MED
-	I-MED
posterior	I-MED
stabilized	I-MED
)	I-MED
TKA	I-MED
(	O
anatomically	B-MED
shaped	B-MED
patellar	B-MED
component	B-MED
)	O
,	O
and	O
10	O
treated	B-MED
with	I-MED
a	O
PFC	B-MED
Sigma	I-MED
RP	I-MED
-	I-MED
PS	I-MED
(	I-MED
press	I-MED
-	I-MED
fit	I-MED
condylar	I-MED
Sigma	I-MED
rotating	I-MED
platform	I-MED
-	I-MED
posterior	I-MED
stabilized	I-MED
)	I-MED
TKA	I-MED
(	O
domed	B-MED
patellar	B-MED
component	B-MED
)	O
were	O
analyzed	B-MED
under	O
fluoroscopic	B-MED
surveillance	B-MED
while	O
the	O
patient	B-MED
performed	B-MED
a	O
weight	B-MED
-	I-MED
bearing	I-MED
deep	B-MED
knee	B-MED
bend	I-MED
from	O
full	B-MED
knee	B-MED
extension	I-MED
to	O
maximum	B-MED
knee	B-MED
flexion	I-MED
.	O
Relevant	O
bone	O
geometries	O
were	O
segmented	B-MED
out	O
from	O
computed	B-MED
tomography	I-MED
(	O
CT	B-MED
)	O
scans	B-MED
,	O
and	O
computer	B-MED
-	I-MED
assisted	I-MED
-	I-MED
design	I-MED
(	O
CAD	B-MED
)	O
models	B-MED
of	O
the	O
implanted	B-MED
components	B-MED
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O
Three	B-MED
-	I-MED
dimensional	I-MED
patellofemoral	B-MED
kinematics	B-MED
were	O
obtained	O
using	O
a	O
3D	B-MED
-to-	O
2D	B-MED
registration	O
process	O
.	O
Contact	B-MED
mechanics	I-MED
were	O
calculated	B-MED
using	O
a	O
distance	B-MED
map	I-MED
between	O
the	O
articulating	B-MED
patellar	I-MED
and	O
femoral	B-MED
surfaces	I-MED
.	O
Both	O
patellar	B-MED
component	B-MED
designs	O
exhibited	O
good	B-MED
rotational	B-MED
kinematics	I-MED
and	O
tracked	O
well	O
within	O
the	O
femoral	B-MED
trochlea	I-MED
when	O
compared	B-MED
with	O
the	O
normal	B-MED
patella	B-MED
.	O
The	O
contact	B-MED
areas	I-MED
in	O
the	O
TKA	B-MED
groups	B-MED
peaked	O
at	O
60	O
°	O
of	O
knee	B-MED
flexion	I-MED
(	O
mean	B-MED
and	O
standard	B-MED
deviation	I-MED
,	O
201	O
±	O
63.4	O
mm	O
for	O
the	O
LCS	B-MED
-	I-MED
PS	I-MED
group	I-MED
and	O
218	O
±	O
95.4	O
mm	O
for	O
the	O
Sigma	B-MED
RP	I-MED
-	I-MED
PS	I-MED
group	I-MED
)	O
,	O
and	O
the	O
areas	B-MED
were	O
substantially	O
smaller	B-MED
than	O
those	O
previously	O
reported	B-MED
for	O
the	O
normal	B-MED
patella	B-MED
.	O
Contact	B-MED
points	I-MED
in	O
the	O
TKA	B-MED
groups	B-MED
stayed	O
close	O
to	O
the	O
center	B-MED
of	O
the	O
patellar	B-MED
components	B-MED
.	O
Both	O
designs	B-MED
performed	B-MED
satisfactorily	B-MED
,	O
although	O
patellofemoral	B-MED
contact	B-MED
areas	I-MED
were	O
reduced	B-MED
in	O
comparison	B-MED
with	O
those	O
in	O
the	O
native	B-MED
patella	B-MED
.	O
Therapeutic	O
Level	O
III	O
.	O
See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O
Most	O
Americans	B-MED
Have	O
Good	B-MED
Health	I-MED
,	O
Little	O
Unmet	B-MED
Need	I-MED
,	O
And	O
Few	O
Health	B-MED
Care	I-MED
Expenses	I-MED
The	O
distribution	O
of	O
health	B-MED
care	I-MED
expenditures	I-MED
remains	O
highly	O
concentrated	B-MED
,	O
but	O
most	O
Americans	B-MED
use	O
few	O
health	B-MED
care	I-MED
resources	I-MED
and	O
have	O
low	O
out	B-MED
-	I-MED
of	I-MED
-	I-MED
pocket	I-MED
spending	I-MED
.	O
More	O
than	O
93	O
percent	O
of	O
"	O
low	B-MED
spenders	I-MED
"	O
(	O
those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	B-MED
)	O
believe	O
they	O
have	O
received	B-MED
all	O
needed	O
care	B-MED
in	O
a	O
timely	B-MED
manner	O
.	O
The	O
low	O
spending	B-MED
by	O
the	O
majority	O
of	O
the	O
population	B-MED
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty	O
-	O
seven-	O
year	B-MED
period	B-MED
examined	B-MED
.	O
Precise	O
prediction	B-MED
of	O
activators	B-MED
for	O
the	O
human	B-MED
constitutive	B-MED
androstane	I-MED
receptor	I-MED
using	O
structure	B-MED
-based	O
three	B-MED
-	I-MED
dimensional	I-MED
quantitative	I-MED
structure	I-MED
-	I-MED
activity	I-MED
relationship	I-MED
methods	B-MED
The	O
constitutive	B-MED
androstane	I-MED
receptor	I-MED
(	O
CAR	B-MED
,	O
NR1I3	B-MED
)	I-MED
regulates	B-MED
the	I-MED
expression	I-MED
of	O
numerous	B-MED
drug	B-MED
-	I-MED
metabolizing	I-MED
enzymes	B-MED
and	O
transporters	B-MED
.	O
The	O
upregulation	B-MED
of	O
various	O
enzymes	B-MED
,	O
including	O
CYP2B6	B-MED
,	O
by	O
CAR	B-MED
activators	B-MED
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	B-MED
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
(	O
DDIs	B-MED
)	O
.	O
To	O
date	O
,	O
however	O
,	O
few	O
effective	B-MED
computational	B-MED
approaches	I-MED
for	O
identifying	O
CAR	B-MED
activators	O
exist	O
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	B-MED
-	I-MED
dimensional	I-MED
quantitative	I-MED
structure	I-MED
-	I-MED
activity	I-MED
relationship	I-MED
(	O
3D	B-MED
-	I-MED
QSAR	I-MED
)	O
models	B-MED
to	O
predict	O
the	O
CAR	B-MED
activating	B-MED
potency	B-MED
of	O
compounds	B-MED
emerging	O
in	O
the	O
drug	B-MED
-	I-MED
discovery	I-MED
process	B-MED
.	O
Models	B-MED
were	O
constructed	O
using	O
comparative	B-MED
molecular	I-MED
field	I-MED
analysis	I-MED
(	O
CoMFA	B-MED
)	O
based	O
on	O
the	O
molecular	B-MED
alignments	B-MED
of	O
ligands	B-MED
binding	I-MED
to	O
CAR	B-MED
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	B-MED
-	I-MED
docking	I-MED
using	O
28	B-MED
compounds	I-MED
as	O
a	O
training	O
set	O
.	O
The	O
CoMFA	B-MED
model	B-MED
,	O
modified	B-MED
by	I-MED
adding	O
a	O
lipophilic	B-MED
parameter	B-MED
with	O
calculated	O
logD7.4	O
(	O
S+logD7.4	O
)	O
,	O
demonstrated	O
statistically	O
good	O
predictive	B-MED
ability	I-MED
(	O
r(2	O
)	O
=	O
0.99	O
,	O
q(2	O
)	O
=	O
0.74	O
)	O
.	O
We	O
also	O
confirmed	O
the	O
excellent	O
predictability	B-MED
of	O
the	O
3D	B-MED
-	I-MED
QSAR	I-MED
model	B-MED
for	O
CAR	B-MED
activation	B-MED
(	O
r(2)pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	B-MED
as	O
a	O
test	O
set	O
for	O
external	B-MED
validation	I-MED
.	O
Collectively	O
,	O
our	O
results	B-MED
indicate	O
that	O
the	O
3D	B-MED
-	I-MED
QSAR	I-MED
model	B-MED
developed	O
in	O
this	O
study	O
provides	O
precise	B-MED
prediction	B-MED
of	O
CAR	B-MED
activating	B-MED
potency	B-MED
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B-MED
candidates	I-MED
with	O
minimized	B-MED
DDI	B-MED
risk	B-MED
related	O
to	O
enzyme	B-MED
-	I-MED
induction	I-MED
in	O
the	O
early	B-MED
drug	B-MED
-	I-MED
discovery	I-MED
stage	B-MED
.	O
Delicaflavone	B-MED
induces	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
in	O
lung	B-MED
cancer	I-MED
via	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
p70S6	B-MED
K	I-MED
signaling	B-MED
pathway	I-MED
Searching	O
for	O
potential	B-MED
anticancer	B-MED
agents	I-MED
from	O
natural	B-MED
sources	I-MED
is	O
an	O
effective	B-MED
strategy	O
for	O
developing	O
novel	B-MED
chemotherapeutic	B-MED
agents	I-MED
.	O
In	O
this	O
study	B-MED
,	O
data	B-MED
supporting	O
the	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
anticancer	B-MED
effects	I-MED
of	O
delicaflavone	B-MED
,	O
a	O
rarely	O
occurring	O
biflavonoid	B-MED
from	O
Selaginella	B-MED
doederleinii	I-MED
,	O
were	O
reported	O
.	O
Delicaflavone	B-MED
exhibited	O
favorable	B-MED
anticancer	B-MED
properties	B-MED
,	O
as	O
shown	O
by	O
the	O
MTT	B-MED
assay	I-MED
and	O
xenograft	B-MED
model	I-MED
of	O
human	B-MED
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
in	O
male	B-MED
BALB	B-MED
/	I-MED
c	I-MED
nude	I-MED
mice	I-MED
without	O
observable	O
adverse	B-MED
effect	I-MED
.	O
By	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
with	O
acridine	B-MED
orange	I-MED
and	O
Cyto	B-MED
-	I-MED
ID	I-MED
®	I-MED
Autophagy	I-MED
detection	O
dyes	B-MED
,	O
Western	B-MED
blot	I-MED
analysis	B-MED
,	O
and	O
RT	B-MED
-	I-MED
PCR	I-MED
assay	I-MED
,	O
we	O
confirmed	O
that	O
delicaflavone	B-MED
induces	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
by	O
increasing	B-MED
the	O
ratio	O
of	O
LC3	B-MED
-	I-MED
II	I-MED
to	O
LC3	B-MED
-	I-MED
I	I-MED
,	O
which	O
are	O
autophagy	B-MED
-	I-MED
related	I-MED
proteins	I-MED
,	O
and	O
promoting	B-MED
the	O
generation	B-MED
of	O
acidic	B-MED
vesicular	I-MED
organelles	I-MED
and	O
autolysosomes	B-MED
in	O
the	O
cytoplasm	B-MED
of	O
human	O
lung	B-MED
cancer	I-MED
A549	B-MED
and	O
PC-9	B-MED
cells	I-MED
in	O
a	O
time	B-MED
-	O
and	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
.	O
Delicaflavone	B-MED
downregulated	B-MED
the	O
expression	B-MED
of	I-MED
phospho	I-MED
-	I-MED
Akt	I-MED
,	O
phospho	B-MED
-	I-MED
mTOR	I-MED
,	O
and	O
phospho	B-MED
-	I-MED
p70S6	I-MED
K	I-MED
in	O
a	O
time	B-MED
-	O
and	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
,	O
suggesting	B-MED
that	O
it	O
induced	B-MED
autophagy	B-MED
by	O
inhibiting	B-MED
the	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
p70S6	B-MED
K	I-MED
pathway	B-MED
in	O
A549	B-MED
and	O
PC-9	B-MED
cells	I-MED
.	O
Delicaflavone	B-MED
is	O
a	O
potential	B-MED
anticancer	B-MED
agent	I-MED
that	O
can	O
induce	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
in	O
human	B-MED
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
via	O
the	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
p70S6	B-MED
K	I-MED
signaling	B-MED
pathway	I-MED
.	O
Delicaflavone	B-MED
showed	O
anti	B-MED
-	I-MED
lung	I-MED
cancer	I-MED
effects	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Delicaflavone	B-MED
induced	B-MED
autophagic	B-MED
cell	I-MED
death	I-MED
via	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
p70S6	B-MED
K	I-MED
signaling	B-MED
pathway	I-MED
.	O
Delicaflavone	B-MED
did	O
not	O
show	O
observable	O
side	B-MED
effects	I-MED
in	O
a	O
xenograft	B-MED
mouse	I-MED
model	I-MED
.	O
Delicaflavone	B-MED
may	O
represent	O
a	O
potential	B-MED
therapeutic	B-MED
agent	I-MED
for	O
lung	B-MED
cancer	I-MED
.	O
Delicaflavone	B-MED
showed	O
anti	B-MED
-	I-MED
lung	I-MED
cancer	I-MED
effects	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Delicaflavone	B-MED
induced	O
autophagic	B-MED
cell	I-MED
death	I-MED
via	O
Akt	B-MED
/	O
mTOR	B-MED
/	O
p70S6	B-MED
K	I-MED
signaling	B-MED
pathway	I-MED
.	O
Delicaflavone	B-MED
did	O
not	O
show	O
observable	O
side	B-MED
effects	I-MED
in	O
a	O
xenograft	B-MED
mouse	I-MED
model	I-MED
.	O
Delicaflavone	B-MED
may	O
represent	O
a	O
potential	B-MED
therapeutic	B-MED
agent	I-MED
for	O
lung	B-MED
cancer	I-MED
.	O
Complete	B-MED
Genome	B-MED
Sequences	B-MED
of	O
Three	O
Outbreak	B-MED
-Associated	O
Legionella	B-MED
pneumophila	I-MED
Isolates	B-MED
We	O
report	O
here	O
the	O
complete	B-MED
genome	B-MED
sequences	B-MED
of	O
three	O
Legionella	B-MED
pneumophila	I-MED
isolates	B-MED
that	O
are	O
associated	B-MED
with	I-MED
a	O
Legionnaires	B-MED
'	I-MED
disease	I-MED
outbreak	B-MED
in	O
New	B-MED
York	I-MED
in	O
2012	O
.	O
Two	O
clinical	B-MED
isolates	B-MED
(	O
D7630	B-MED
and	O
D7632	B-MED
)	O
and	O
one	O
environmental	B-MED
isolate	B-MED
(	O
D7631	B-MED
)	O
were	O
recovered	B-MED
from	O
this	O
outbreak	B-MED
.	O
A	O
single	O
isolate	B-MED
-	I-MED
specific	I-MED
virulence	B-MED
gene	B-MED
was	O
found	O
in	O
D7632	B-MED
.	O
These	O
isolates	B-MED
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-MED
the	O
genomic	B-MED
resolution	B-MED
of	O
various	O
bioinformatics	B-MED
approaches	B-MED
for	O
L.	B-MED
pneumophila	I-MED
serogroup	B-MED
1	I-MED
isolates	B-MED
.	O
Coupling	B-MED
of	O
TRPV6	B-MED
and	O
TMEM16A	B-MED
in	O
epithelial	B-MED
principal	I-MED
cells	I-MED
of	O
the	O
rat	B-MED
epididymis	I-MED
The	O
epididymis	B-MED
establishes	O
a	O
congenial	B-MED
environment	B-MED
for	O
sperm	B-MED
maturation	I-MED
and	O
protection	B-MED
.	O
Its	O
fluid	B-MED
is	O
acidic	B-MED
,	O
and	O
the	O
calcium	B-MED
concentration	B-MED
is	O
low	B-MED
and	O
declines	O
along	O
the	O
length	B-MED
of	O
the	O
epididymal	B-MED
tubule	I-MED
.	O
However	O
,	O
our	O
knowledge	O
of	O
ionic	B-MED
currents	I-MED
and	O
mechanisms	B-MED
of	O
calcium	B-MED
homeostasis	I-MED
in	O
rat	B-MED
epididymal	I-MED
epithelial	B-MED
cells	I-MED
remains	O
enigmatic	O
.	O
In	O
this	O
study	B-MED
,	O
to	O
better	O
understand	O
calcium	B-MED
regulation	I-MED
in	O
the	O
epididymis	B-MED
,	O
we	O
use	O
the	O
patch	B-MED
-	I-MED
clamp	I-MED
method	I-MED
to	O
record	O
from	O
single	O
rat	B-MED
cauda	B-MED
epididymal	I-MED
principal	B-MED
cells	I-MED
.	O
We	O
detect	B-MED
a	O
constitutively	O
active	B-MED
Ca(2	B-MED
+	I-MED
)	I-MED
current	B-MED
with	O
characteristics	B-MED
that	O
match	O
the	O
epithelial	B-MED
calcium	B-MED
channel	I-MED
TRPV6	B-MED
.	O
Electrophysiological	B-MED
and	O
pharmacological	B-MED
data	I-MED
also	O
reveal	O
a	O
constitutively	O
active	B-MED
calcium	I-MED
-	I-MED
activated	I-MED
chloride	I-MED
conductance	I-MED
(	O
CaCC	B-MED
)	O
.	O
Removal	O
of	O
extracellular	B-MED
calcium	B-MED
attenuates	B-MED
not	O
only	O
the	O
TRPV6	B-MED
-like	O
conductance	B-MED
,	O
but	O
also	O
the	O
CaCC	B-MED
.	O
Lanthanide	B-MED
block	B-MED
is	O
time	B-MED
dependent	B-MED
such	O
that	O
the	O
TRPV6	B-MED
-like	O
component	O
is	O
inhibited	B-MED
first	O
,	O
followed	O
by	O
the	O
CaCC	B-MED
.	O
The	O
putative	O
CaCC	B-MED
blocker	B-MED
niflumic	B-MED
acid	I-MED
partially	O
inhibits	B-MED
whole	B-MED
-	I-MED
cell	I-MED
currents	B-MED
,	O
whereas	O
La(3	B-MED
+	I-MED
)	I-MED
almost	O
abolishes	O
whole	B-MED
-	I-MED
cell	I-MED
currents	B-MED
in	O
principal	B-MED
cells	I-MED
.	O
Membrane	B-MED
potential	I-MED
measurements	B-MED
reveal	O
an	O
interplay	O
between	O
La(3	B-MED
+	I-MED
)	I-MED
-	O
sensitive	B-MED
ion	I-MED
channels	I-MED
and	O
those	O
that	O
are	O
sensitive	B-MED
to	O
the	O
specific	B-MED
TMEM16A	B-MED
inhibitor	B-MED
tannic	B-MED
acid	I-MED
.	O
In	B-MED
vivo	I-MED
perfusion	B-MED
of	O
the	O
cauda	B-MED
epididymal	I-MED
tubule	I-MED
shows	O
a	O
substantial	O
rate	O
of	O
Ca(2	B-MED
+	I-MED
)	I-MED
reabsorption	B-MED
from	O
the	O
luminal	B-MED
side	I-MED
,	O
which	O
is	O
dose	O
-	O
dependently	O
suppressed	B-MED
by	O
ruthenium	B-MED
red	I-MED
,	O
a	O
putative	O
blocker	B-MED
of	O
epithelial	B-MED
Ca(2	B-MED
+	I-MED
)	I-MED
channels	I-MED
and	O
CaCC	B-MED
.	O
Finally	O
,	O
we	O
discover	O
messenger	B-MED
RNA	I-MED
for	O
both	O
TRPV6	B-MED
and	O
TMEM16A	B-MED
in	O
the	O
rat	B-MED
epididymis	I-MED
and	O
show	O
that	O
their	O
proteins	B-MED
colocalize	B-MED
in	O
the	O
apical	B-MED
membrane	I-MED
of	O
principal	B-MED
cells	I-MED
.	O
Collectively	O
,	O
these	O
data	B-MED
provide	O
evidence	B-MED
for	O
a	O
coupling	B-MED
mechanism	B-MED
between	O
TRPV6	B-MED
and	O
TMEM16A	B-MED
in	O
principal	B-MED
cells	I-MED
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	B-MED
of	I-MED
calcium	I-MED
homeostasis	I-MED
in	O
the	O
epididymis	B-MED
.	O
How	O
Integrated	B-MED
Management	I-MED
Strategies	I-MED
Promote	B-MED
Protein	B-MED
Quality	B-MED
of	O
Cotton	B-MED
Embryos	I-MED
:	O
High	B-MED
Levels	B-MED
of	O
Soil	B-MED
Available	B-MED
N	B-MED
,	O
N	B-MED
Assimilation	B-MED
and	O
Protein	B-MED
Accumulation	B-MED
Rate	B-MED
Cottonseed	B-MED
is	O
widely	O
used	O
as	O
a	O
source	B-MED
of	O
ruminant	B-MED
feed	B-MED
and	O
for	O
industrial	B-MED
purposes	B-MED
.	O
Therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-MED
the	O
nutritional	B-MED
value	I-MED
of	O
cotton	B-MED
embryos	I-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
conventional	B-MED
management	I-MED
(	O
CM	B-MED
)	O
and	O
two	O
integrated	O
cotton	B-MED
management	B-MED
strategies	I-MED
(	O
IMS1	B-MED
,	O
IMS2	B-MED
)	O
were	O
performed	B-MED
at	O
two	O
soil	B-MED
fertility	B-MED
levels	B-MED
to	O
study	B-MED
the	O
relationships	B-MED
among	O
soil	B-MED
N	B-MED
,	O
N	B-MED
assimilation	B-MED
,	O
embryonic	B-MED
protein	B-MED
accumulation	B-MED
and	O
protein	B-MED
quality	B-MED
.	O
The	O
levels	B-MED
of	I-MED
proteins	I-MED
,	O
essential	B-MED
amino	I-MED
acids	I-MED
,	O
and	O
semi	B-MED
-	I-MED
essential	I-MED
amino	I-MED
acids	I-MED
,	O
especially	O
those	O
of	O
glutamate	B-MED
,	O
lysine	B-MED
,	O
and	O
methionine	B-MED
,	O
were	O
higher	B-MED
in	O
IMS1	B-MED
and	O
IMS2	B-MED
embryos	B-MED
than	O
in	O
CM	B-MED
embryos	B-MED
.	O
These	O
changes	B-MED
were	O
significantly	O
positively	B-MED
correlated	B-MED
with	O
the	O
soil	B-MED
-	O
available	B-MED
N	B-MED
content	I-MED
,	O
glutamine	B-MED
synthetase	I-MED
activity	I-MED
and	O
peak	B-MED
value	O
of	O
protein	B-MED
accumulation	B-MED
rate	B-MED
and	O
were	O
negatively	B-MED
correlated	B-MED
with	O
the	O
free	B-MED
amino	B-MED
acid	I-MED
level	I-MED
.	O
These	O
results	B-MED
illustrated	O
that	O
integrated	B-MED
management	I-MED
strategies	I-MED
,	O
especially	O
the	O
rates	B-MED
and	O
timing	B-MED
of	O
N	B-MED
application	B-MED
,	O
raise	B-MED
the	O
level	B-MED
of	O
soil	B-MED
available	B-MED
N	B-MED
,	O
which	O
is	O
beneficial	O
for	O
N	B-MED
assimilation	B-MED
in	O
developing	O
cotton	B-MED
embryos	I-MED
.	O
The	O
protein	B-MED
content	I-MED
was	O
limited	B-MED
by	O
the	O
rate	B-MED
of	O
protein	B-MED
accumulation	B-MED
rather	O
than	O
by	O
the	O
free	B-MED
amino	B-MED
acid	I-MED
content	I-MED
.	O
The	O
combination	B-MED
of	O
target	B-MED
yield	I-MED
fertilization	B-MED
,	O
a	O
growth	B-MED
-driven	O
N	B-MED
application	B-MED
schedule	O
,	O
a	O
high	B-MED
plant	B-MED
density	B-MED
and	O
the	O
seedling	B-MED
raising	O
with	O
bio	B-MED
-	I-MED
organic	I-MED
fertilizer	I-MED
can	O
substantially	O
improve	B-MED
protein	B-MED
quality	B-MED
in	O
cotton	B-MED
embryos	I-MED
,	O
especially	O
at	O
a	O
soil	B-MED
with	O
low	O
soil	B-MED
organic	B-MED
matter	I-MED
and	O
total	B-MED
nitrogen	B-MED
.	O
Two	O
known	B-MED
and	O
one	O
new	B-MED
species	B-MED
of	O
Draconematidae	B-MED
and	O
Epsilonematida	B-MED
(	O
Nematoda	B-MED
,	O
Desmodorida	B-MED
)	O
from	O
the	O
White	B-MED
Sea	I-MED
,	O
North	B-MED
Russia	I-MED
Morphological	B-MED
descriptions	B-MED
of	O
three	O
"	O
walking	B-MED
nematode	I-MED
"	O
species	B-MED
found	O
for	O
the	O
first	O
time	O
in	O
the	O
White	B-MED
Sea	I-MED
are	O
presented	O
.	O
Draconema	B-MED
ophicephalum	I-MED
(	O
Claparède	B-MED
,	O
1863	O
)	O
(	O
Draconematidae	B-MED
)	O
and	O
Epsilonema	B-MED
steineri	I-MED
Chitwood	B-MED
,	O
1935	O
(	O
Epsilonematidae	B-MED
)	O
,	O
both	O
known	O
from	O
insufficient	B-MED
material	O
and	O
females	B-MED
only	O
,	O
are	O
re	O
-	O
described	O
and	O
problems	B-MED
of	O
their	O
taxonomic	B-MED
identification	B-MED
as	O
well	O
as	O
species	B-MED
compositions	B-MED
of	O
respective	O
genera	B-MED
are	O
discussed	O
.	O
The	O
new	B-MED
species	B-MED
Prochaetosoma	B-MED
marisalbi	I-MED
sp	I-MED
.	O
n.	O
(	O
Draconematidae	B-MED
)	O
differs	O
from	O
other	O
Prochaetosoma	B-MED
species	I-MED
except	O
P.	B-MED
longicapitatum	I-MED
(	O
Allgén	B-MED
,	O
1935	O
)	O
in	O
that	O
the	O
pharyngeal	B-MED
bulb	B-MED
lumen	B-MED
is	O
not	B-MED
cuticularised	I-MED
,	O
from	O
P.	B-MED
longicapitatum	I-MED
by	O
shape	B-MED
of	I-MED
body	I-MED
and	O
rostrum	B-MED
,	O
greater	B-MED
number	O
of	O
cephalic	B-MED
adhesive	B-MED
tubes	I-MED
,	O
and	O
from	O
P.	B-MED
maertensi	I-MED
Decraemer	B-MED
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	B-MED
tail	B-MED
,	O
fewer	O
anterior	B-MED
adhesive	B-MED
tubes	I-MED
and	O
longer	B-MED
spicules	B-MED
,	O
besides	O
lacking	O
cuticular	B-MED
thickening	I-MED
in	O
the	O
pharyngeal	B-MED
bulb	B-MED
.	O
Draconema	B-MED
hoonsooi	I-MED
,	O
D.	B-MED
youngeouni	I-MED
,	O
P.rochaetosoma	B-MED
beomseomense	I-MED
,	O
P.	B-MED
brevicaudatum	I-MED
,	O
P.	B-MED
byungilli	I-MED
,	O
P.	B-MED
cracense	I-MED
,	O
P.	B-MED
saheungi	I-MED
,	O
P.	B-MED
sujungi	I-MED
,	O
P.	B-MED
supseomense	I-MED
erected	B-MED
by	O
Rho	B-MED
&	O
Min	B-MED
(	O
2011	O
)	O
are	O
considered	O
as	O
invalid	B-MED
species	B-MED
while	O
Prochaetosoma	B-MED
arcticum	I-MED
,	O
P.	B-MED
lugubre	I-MED
and	O
Epsilonema	B-MED
cygnoides	I-MED
are	O
assumed	O
as	O
species	B-MED
inquirenda	I-MED
.	O
From	O
a	O
phylogenetic	B-MED
tree	I-MED
based	O
on	O
the	O
18S	B-MED
rRNA	I-MED
gene	I-MED
,	O
all	O
three	O
White	B-MED
Sea	I-MED
species	B-MED
adjoin	B-MED
to	O
unidentified	B-MED
species	B-MED
of	O
their	O
respective	O
genera	B-MED
.	O
Automated	O
basal	B-MED
cell	I-MED
carcinoma	I-MED
detection	O
in	O
high	B-MED
-	I-MED
definition	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
Basal	B-MED
cell	I-MED
carcinoma	I-MED
(	O
BCC	B-MED
)	O
is	O
the	O
most	O
common	O
non	B-MED
-	I-MED
melanoma	I-MED
skin	I-MED
cancer	I-MED
.	O
Conventional	O
diagnosis	O
of	O
BCC	B-MED
requires	O
invasive	B-MED
biopsies	B-MED
.	O
Recently	O
,	O
a	O
high	B-MED
-	I-MED
definition	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
(	O
HD	B-MED
-	I-MED
OCT	I-MED
)	O
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non	B-MED
-	I-MED
invasive	I-MED
in	B-MED
vivo	I-MED
imaging	I-MED
method	I-MED
of	O
skin	B-MED
.	O
Good	O
agreements	O
of	O
BCC	B-MED
features	O
between	O
HD	B-MED
-	I-MED
OCT	I-MED
images	B-MED
and	O
histopathological	B-MED
architecture	I-MED
have	O
been	O
found	O
.	O
Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	B-MED
using	O
HD	B-MED
-	I-MED
OCT	I-MED
.	O
This	O
paper	O
presents	O
a	O
novel	O
BCC	B-MED
detection	B-MED
method	I-MED
that	O
consists	O
of	O
four	O
steps	O
:	O
graph	O
based	O
skin	B-MED
surface	I-MED
segmentation	B-MED
,	O
surface	B-MED
flattening	I-MED
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	B-MED
classification	O
.	O
The	O
effectiveness	B-MED
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5,040	O
images	O
.	O
It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	B-MED
.	O
Long	B-MED
Non	I-MED
-	I-MED
Coding	I-MED
RNA	I-MED
SNHG6	B-MED
as	O
a	O
Potential	O
Biomarker	B-MED
for	O
Hepatocellular	B-MED
Carcinoma	I-MED
Long	B-MED
Non	I-MED
-	I-MED
coding	I-MED
RNAs	I-MED
(	O
lncRNAs	B-MED
)	O
refer	O
to	O
all	O
non	B-MED
-	I-MED
protein	I-MED
coding	I-MED
transcripts	B-MED
longer	O
than	O
200	O
nucleotides	B-MED
.	O
Their	O
critical	O
roles	O
in	O
different	O
biological	B-MED
pathways	B-MED
have	O
been	O
already	O
well	O
established	O
.	O
Altered	O
expression	B-MED
of	O
lncRNAs	B-MED
can	O
be	O
involved	O
in	O
the	O
cancer	B-MED
initiation	I-MED
and/or	O
progression	B-MED
.	O
Since	O
patients	B-MED
with	O
hepatocellular	B-MED
carcinoma	I-MED
(	O
HCC	B-MED
)	O
are	O
usually	O
diagnosed	B-MED
in	O
late	B-MED
stages	I-MED
,	O
developing	O
diagnostic	B-MED
methods	I-MED
seems	O
to	O
be	O
essential	O
.	O
In	O
this	O
study	B-MED
,	O
the	O
expression	B-MED
levels	O
of	O
different	O
lncRNAs	B-MED
were	O
systematically	O
analysed	B-MED
in	O
different	O
genomic	B-MED
and	O
transcriptome	B-MED
datasets	I-MED
.	O
The	O
analyses	B-MED
showed	O
that	O
SNHG6	B-MED
is	O
among	O
the	O
lncRNAs	B-MED
with	O
distinctive	O
dysregulation	B-MED
of	O
expression	B-MED
and	O
copy	O
number	O
variation	O
in	O
HCC	B-MED
tumors	I-MED
compared	O
with	O
normal	B-MED
tissues	I-MED
.	O
The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	B-MED
of	O
SNHG6	B-MED
is	O
highly	O
cancer	B-MED
type	O
specific	O
.	O
Through	O
co	O
-	O
occurrence	O
analyses	B-MED
,	O
we	O
found	O
that	O
SNHG6	B-MED
and	O
its	O
related	O
co	B-MED
-	I-MED
expressed	I-MED
genes	B-MED
on	O
8q	B-MED
are	O
involved	O
in	O
the	O
structural	B-MED
integrity	B-MED
of	O
ribosome	B-MED
and	O
translation	B-MED
.	O
This	O
comprehensive	B-MED
in	B-MED
silico	I-MED
analysis	B-MED
,	O
provides	O
a	O
resource	O
for	O
investigating	B-MED
SNHG6	B-MED
in	O
hepatocellular	B-MED
carcinoma	I-MED
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	B-MED
.	O
Identification	B-MED
and	O
SAR	B-MED
Evaluation	B-MED
of	O
Hemozoin	B-MED
-	O
Inhibiting	B-MED
Benzamides	B-MED
Active	B-MED
against	O
Plasmodium	B-MED
falciparum	I-MED
Quinoline	B-MED
antimalarials	B-MED
target	B-MED
hemozoin	B-MED
formation	B-MED
causing	O
a	O
cytotoxic	B-MED
accumulation	B-MED
of	O
ferriprotoporphyrin	B-MED
IX	I-MED
(	O
Fe(III)PPIX	B-MED
)	O
.	O
Well	O
-	O
developed	O
SAR	B-MED
models	B-MED
exist	O
for	O
β	B-MED
-	I-MED
hematin	I-MED
inhibition	B-MED
,	O
parasite	B-MED
activity	B-MED
,	O
and	O
cellular	B-MED
mechanisms	I-MED
for	O
this	O
compound	B-MED
class	I-MED
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-MED
exist	O
for	O
other	O
hemozoin	B-MED
inhibiting	B-MED
chemotypes	B-MED
.	O
Here	O
,	O
benzamide	B-MED
analogues	B-MED
based	O
on	O
previous	O
HTS	B-MED
hits	O
have	O
been	O
purchased	B-MED
or	O
synthesized	B-MED
.	O
Only	O
derivatives	B-MED
containing	I-MED
an	I-MED
electron	I-MED
deficient	I-MED
aromatic	I-MED
ring	I-MED
and	O
capable	O
of	O
adopting	O
flat	B-MED
conformations	I-MED
,	O
optimal	O
for	O
π	B-MED
-	I-MED
π	I-MED
interactions	I-MED
with	O
Fe(III)PPIX	B-MED
,	O
inhibited	B-MED
β	B-MED
-	I-MED
hematin	I-MED
formation	B-MED
.	O
The	O
two	O
most	O
potent	O
analogues	B-MED
showed	O
nanomolar	B-MED
parasite	B-MED
activity	B-MED
,	O
with	O
little	O
CQ	B-MED
cross	B-MED
-	I-MED
resistance	I-MED
,	O
low	O
cytotoxicity	B-MED
,	O
and	O
high	O
in	B-MED
vitro	I-MED
microsomal	B-MED
stability	B-MED
.	O
Selected	O
analogues	B-MED
inhibited	B-MED
hemozoin	B-MED
formation	B-MED
in	O
Plasmodium	B-MED
falciparum	I-MED
causing	O
high	O
levels	B-MED
of	O
free	O
heme	B-MED
.	O
In	O
contrast	O
to	O
quinolines	B-MED
,	O
introduction	B-MED
of	O
amine	B-MED
side	I-MED
chains	I-MED
did	O
not	O
lead	O
to	O
benzamide	B-MED
accumulation	B-MED
in	O
the	O
parasite	B-MED
.	O
These	O
data	B-MED
reveal	O
complex	O
relationships	B-MED
between	O
heme	B-MED
binding	I-MED
,	O
free	O
heme	B-MED
levels	B-MED
,	O
cellular	B-MED
accumulation	I-MED
,	O
and	O
in	B-MED
vitro	I-MED
activity	B-MED
of	O
potential	O
novel	B-MED
antimalarials	B-MED
.	O
Comparing	O
the	O
bulking	O
effect	O
of	O
calcium	B-MED
hydroxyapatite	I-MED
and	O
Deflux	B-MED
injection	B-MED
into	O
the	O
bladder	B-MED
neck	I-MED
for	O
improvement	B-MED
of	O
urinary	B-MED
incontinence	I-MED
in	O
bladder	B-MED
exstrophy	I-MED
-	I-MED
epispadias	I-MED
complex	I-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
efficacy	B-MED
of	O
the	O
endoscopic	B-MED
injection	I-MED
of	O
calcium	B-MED
hydroxyapatite	I-MED
(	O
CaHA	B-MED
)	O
into	O
the	O
bladder	B-MED
neck	I-MED
(	O
BN	B-MED
)	O
region	O
of	O
patients	B-MED
with	O
urinary	B-MED
incontinence	I-MED
and	O
bladder	B-MED
exstrophy	I-MED
-	I-MED
epispadias	I-MED
complex	I-MED
(	O
BEEC	B-MED
)	O
.	O
We	O
designed	O
a	O
retrospective	B-MED
cohort	I-MED
study	I-MED
in	O
which	O
we	O
retrospectively	B-MED
studied	I-MED
medical	B-MED
charts	I-MED
of	O
female	B-MED
and	O
male	B-MED
patients	B-MED
of	O
BEEC	B-MED
who	O
had	O
undergone	O
CaHA	B-MED
or	O
Deflux	B-MED
injection	B-MED
for	O
continence	B-MED
improvement	I-MED
between	O
2009	O
and	O
2014	O
.	O
Sixteen	O
incontinent	B-MED
patients	B-MED
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
8.09	O
±	O
3.5	O
years	O
received	O
an	O
endoscopic	B-MED
submucosal	I-MED
injection	I-MED
of	O
5.4	O
ml	O
of	O
pure	O
CaHA	B-MED
powder	O
with	O
autologous	B-MED
plasma	B-MED
(	O
group	O
A	O
)	O
.	O
Patients	B-MED
in	O
group	O
B	O
(	O
N	O
=	O
21	O
)	O
,	O
control	B-MED
group	I-MED
,	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
7.51	O
±	O
2.8	O
years	O
received	O
Deflux	B-MED
injection	B-MED
(	O
5.1	O
ml	O
)	O
.	O
The	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
after	O
injection	B-MED
was	O
38	O
±	O
5.2	O
and	O
33	O
±	O
4.1	O
months	O
in	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
.	O
No	O
post	B-MED
-	I-MED
injection	I-MED
complication	I-MED
was	O
detected	B-MED
in	O
none	O
of	O
the	O
patients	B-MED
during	O
the	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Eleven	O
patients	B-MED
(	O
68.75	O
%	O
)	O
in	O
group	O
A	O
became	O
socially	O
dry	B-MED
following	O
1	O
-	O
2	O
injections	B-MED
,	O
the	O
degree	O
of	O
incontinence	B-MED
was	O
improved	O
in	O
4	O
patients	B-MED
(	O
25	O
%	O
)	O
,	O
and	O
there	O
was	O
no	B-MED
change	I-MED
in	O
one	O
patient	B-MED
(	O
6.25	O
%	O
)	O
.	O
However	O
,	O
Deflux	B-MED
injection	B-MED
resulted	O
in	O
complete	B-MED
dryness	I-MED
in	O
14	O
(	O
66.66	O
%	O
)	O
,	O
improvement	B-MED
in	O
the	O
degree	O
of	O
incontinence	B-MED
in	O
5	O
(	O
23.81	O
%	O
)	O
and	O
no	B-MED
change	I-MED
in	O
2	O
patients	B-MED
(	O
9.52	O
%	O
)	O
,	O
leading	O
to	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
continence	B-MED
achievement	I-MED
between	O
CaHA	B-MED
and	O
Deflux	B-MED
groups	O
(	O
p	O
=	O
0.9	O
)	O
.	O
The	O
statistical	B-MED
analysis	I-MED
was	O
not	B-MED
significantly	I-MED
different	I-MED
in	O
terms	O
of	O
bladder	B-MED
capacity	I-MED
(	O
p	O
=	O
0.7	O
)	O
or	O
Q	O
max	O
(	O
p	O
=	O
0.8	O
)	O
.	O
The	O
preliminary	B-MED
results	I-MED
of	O
this	O
study	B-MED
revealed	B-MED
that	O
CaHA	B-MED
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking	B-MED
agent	I-MED
in	O
treatment	B-MED
of	O
urinary	B-MED
incontinence	I-MED
in	O
BEEC	B-MED
.	O
Real	O
role	O
of	O
β	B-MED
-	I-MED
blockers	I-MED
in	O
regression	B-MED
of	O
left	B-MED
ventricular	I-MED
mass	I-MED
in	O
hypertension	B-MED
patients	B-MED
:	O
Bayesian	B-MED
network	I-MED
meta	B-MED
-	I-MED
analysis	I-MED
Left	B-MED
ventricular	I-MED
hypertrophy	I-MED
(	O
LVH	B-MED
)	O
is	O
commonly	O
present	O
in	O
patients	B-MED
with	O
hypertension	B-MED
(	O
HT	B-MED
)	O
.	O
According	O
to	O
the	O
expert	B-MED
consensus	I-MED
document	I-MED
from	O
American	B-MED
,	O
angiotensin	B-MED
-	I-MED
converting	I-MED
enzyme	I-MED
inhibitor	I-MED
(	O
ACEI	B-MED
)	O
and	O
angiotensin	B-MED
receptor	I-MED
blockers	I-MED
(	O
ARBs	B-MED
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	B-MED
drugs	I-MED
.	O
However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	B-MED
between	O
fat	B-MED
-	I-MED
soluble	I-MED
and	I-MED
selective	I-MED
β1	I-MED
-	I-MED
receptor	I-MED
blockers	I-MED
(	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
)	O
and	O
other	O
β	B-MED
-	I-MED
blockers	I-MED
on	O
regression	B-MED
of	O
LVH	B-MED
before	O
.	O
The	O
aim	O
of	O
this	O
analysis	B-MED
was	O
to	O
compare	B-MED
the	O
efficacy	B-MED
of	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B-MED
drugs	I-MED
(	O
ACEI	B-MED
,	O
ARBs	B-MED
,	O
calcium	B-MED
channel	I-MED
blockers	I-MED
[	O
CCBs	B-MED
]	O
,	O
and	O
diuretics	B-MED
)	O
on	O
regression	B-MED
of	O
LVH	B-MED
.	O
Relative	B-MED
trials	B-MED
were	O
identified	O
in	O
the	O
PubMed	B-MED
,	O
Web	B-MED
of	I-MED
Science	I-MED
,	O
OVID	B-MED
EBM	I-MED
Reviews	I-MED
and	O
Cochrane	B-MED
databases	I-MED
,	O
and	O
the	O
relevant	O
papers	B-MED
were	O
examined	B-MED
.	O
We	O
performed	O
both	O
traditional	O
and	O
Bayesian	B-MED
meta	B-MED
-	I-MED
analysis	I-MED
of	O
randomized	B-MED
controlled	I-MED
trials	I-MED
(	O
RCTs	B-MED
)	O
about	O
the	O
regression	B-MED
of	O
LVH	B-MED
.	O
Sensitivity	B-MED
analysis	I-MED
and	O
regression	B-MED
analysis	I-MED
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	B-MED
.	O
Inconsistency	B-MED
analysis	I-MED
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B-MED
of	O
the	O
trials	B-MED
in	O
the	O
network	B-MED
was	O
indeed	O
consistent	B-MED
.	O
A	O
total	O
of	O
41	O
RCTs	B-MED
involving	O
2566	O
patients	B-MED
with	O
HT	B-MED
and	O
LVH	B-MED
were	O
included	O
in	O
this	O
analysis	B-MED
.	O
Bayesian	B-MED
network	I-MED
meta	B-MED
-	I-MED
analysis	I-MED
indicated	O
no	O
statistically	B-MED
significant	I-MED
differences	O
between	O
these	O
groups	B-MED
:	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
and	O
ACEI	B-MED
(	O
MD	O
,	O
-7.09	O
;	O
95	O
%	O
CI	B-MED
,	O
-14.99	O
,	O
1.27	O
)	O
;	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
and	O
ARB	B-MED
(	O
MD	O
,	O
-2.66	O
;	O
95	O
%	O
Cl	B-MED
,	O
-12.02	O
,	O
6.31	O
)	O
.	O
Although	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
showed	O
greater	O
efficacy	B-MED
when	O
compared	B-MED
with	O
diuretic	B-MED
(	O
MD	O
,	O
13.04	O
;	O
95	O
%	O
CI	B-MED
,	O
3.38	O
,	O
22.59	O
)	O
or	O
CCB	B-MED
(	O
MD	O
,	O
10.90	O
;	O
95	O
%	O
CI	B-MED
,	O
1.98	O
,	O
19.49	O
)	O
.	O
The	O
probabilities	B-MED
of	O
being	O
among	O
the	O
most	O
efficacious	B-MED
treatments	B-MED
were	O
:	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
(	O
72	O
%	O
)	O
,	O
ARB	B-MED
(	O
27	O
%	O
)	O
,	O
ACEI	B-MED
(	O
0.01	O
%	O
)	O
,	O
CCB	B-MED
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	B-MED
(	O
0.00	O
%	O
)	O
.	O
Evidence	O
from	O
our	O
analysis	B-MED
reveals	O
that	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	B-MED
drugs	I-MED
in	O
HT	B-MED
and	O
LVH	B-MED
patients	B-MED
.	O
However	O
,	O
the	O
real	O
efficacy	B-MED
of	O
FS	B-MED
-	I-MED
β	I-MED
-	I-MED
B	I-MED
on	O
regression	B-MED
of	O
LVH	B-MED
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	B-MED
trials	B-MED
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O
Simultaneous	B-MED
edited	B-MED
MRS	B-MED
of	O
GABA	B-MED
and	O
glutathione	B-MED
Edited	B-MED
MRS	B-MED
allows	O
the	O
detection	B-MED
of	O
low	B-MED
-	O
concentration	B-MED
metabolites	B-MED
,	O
whose	O
signals	B-MED
are	O
not	B-MED
resolved	B-MED
in	O
the	O
MR	B-MED
spectrum	I-MED
.	O
Tailored	B-MED
acquisitions	I-MED
can	O
be	O
designed	B-MED
to	O
detect	B-MED
,	O
for	O
example	B-MED
,	O
the	O
inhibitory	B-MED
neurotransmitter	B-MED
γ	B-MED
-	I-MED
aminobutyric	I-MED
acid	I-MED
(	O
GABA	B-MED
)	O
,	O
or	O
the	O
reduction	B-MED
-	I-MED
oxidation	I-MED
(	O
redox	B-MED
)	O
compound	O
glutathione	B-MED
(	O
GSH	B-MED
)	O
,	O
and	O
single	B-MED
-	O
voxel	B-MED
edited	B-MED
experiments	B-MED
are	O
generally	O
acquired	O
at	O
a	O
rate	B-MED
of	O
one	B-MED
metabolite	B-MED
-	O
per	B-MED
-	I-MED
experiment	I-MED
.	O
We	O
demonstrate	O
that	O
simultaneous	B-MED
detection	B-MED
of	O
the	O
overlapping	B-MED
signals	B-MED
of	O
GABA	B-MED
and	O
GSH	B-MED
is	O
possible	O
using	B-MED
Hadamard	B-MED
Encoding	I-MED
and	I-MED
Reconstruction	I-MED
of	I-MED
Mega	I-MED
-	I-MED
Edited	I-MED
Spectroscopy	I-MED
(	O
HERMES	B-MED
)	O
.	O
HERMES	B-MED
applies	B-MED
orthogonal	B-MED
editing	I-MED
encoding	I-MED
(	O
following	B-MED
a	O
Hadamard	B-MED
scheme	I-MED
)	O
,	O
such	O
that	O
GSH-	B-MED
and	O
GABA	B-MED
-	O
edited	B-MED
difference	B-MED
spectra	B-MED
can	O
be	O
reconstructed	O
from	O
a	O
single	B-MED
multiplexed	I-MED
experiment	I-MED
.	O
At	O
a	O
TE	B-MED
of	O
80ms	O
,	O
20	O
-	O
ms	O
editing	B-MED
pulses	B-MED
are	O
applied	B-MED
GSH	B-MED
at	O
4.56ppm	O
(	O
on	O
GSH),1.9ppm	O
(	O
on	O
GABA	B-MED
)	O
,	O
both	B-MED
offsets	B-MED
(	O
using	O
a	O
dual	B-MED
-	I-MED
lobe	I-MED
cosine	I-MED
-	I-MED
modulated	I-MED
pulse	I-MED
)	O
or	O
neither	O
.	O
Hadamard	B-MED
combinations	I-MED
of	O
the	O
four	O
sub	B-MED
-	I-MED
experiments	I-MED
yield	O
GABA	B-MED
and	O
GSH	B-MED
difference	B-MED
spectra	B-MED
.	O
It	O
is	O
shown	O
that	O
HERMES	B-MED
gives	O
excellent	B-MED
separation	B-MED
of	O
the	O
edited	B-MED
GABA	B-MED
and	O
GSH	B-MED
signals	B-MED
in	O
phantoms	B-MED
,	O
and	O
resulting	O
edited	B-MED
lineshapes	B-MED
agree	B-MED
well	B-MED
with	O
separate	B-MED
Mescher	B-MED
-	I-MED
Garwood	I-MED
Point	I-MED
-	I-MED
resolved	I-MED
Spectroscopy	I-MED
(	O
MEGA	B-MED
-	I-MED
PRESS	I-MED
)	O
acquisitions	B-MED
.	O
In	B-MED
vivo	I-MED
,	O
the	O
quality	B-MED
and	O
signal	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
(	O
SNR	B-MED
)	O
of	O
HERMES	B-MED
spectra	B-MED
are	O
similar	B-MED
to	O
those	O
of	O
sequentially	B-MED
acquired	B-MED
MEGA	B-MED
-	I-MED
PRESS	I-MED
spectra	B-MED
,	O
with	O
the	O
benefit	B-MED
of	O
saving	O
half	O
the	O
acquisition	B-MED
time	B-MED
.	O
Draft	B-MED
Genome	I-MED
Sequences	I-MED
of	O
15	O
Isolates	B-MED
of	O
Listeria	B-MED
monocytogenes	I-MED
Serotype	I-MED
1/2a	I-MED
,	O
Subgroup	B-MED
ST204	B-MED
Listeria	B-MED
monocytogenes	I-MED
sequence	B-MED
type	I-MED
204	I-MED
(	I-MED
ST204	I-MED
)	I-MED
strains	I-MED
have	O
been	O
isolated	B-MED
from	O
a	O
range	B-MED
of	I-MED
food	I-MED
,	O
environmental	B-MED
,	O
and	O
clinical	B-MED
sources	B-MED
in	O
Australia	B-MED
.	O
This	O
study	O
describes	O
the	O
draft	B-MED
genome	I-MED
sequences	I-MED
of	O
15	O
isolates	O
collected	O
from	O
meat	B-MED
and	O
dairy	B-MED
associated	I-MED
sources	I-MED
.	O
Suppressed	B-MED
translation	B-MED
and	O
ULK1	B-MED
degradation	B-MED
as	O
potential	B-MED
mechanisms	B-MED
of	O
autophagy	B-MED
limitation	O
under	O
prolonged	B-MED
starvation	B-MED
Macroautophagy	B-MED
/	O
autophagy	B-MED
is	O
a	O
well	O
-	O
organized	O
process	O
of	O
intracellular	B-MED
degradation	I-MED
,	O
which	O
is	O
rapidly	O
activated	B-MED
under	O
starvation	B-MED
conditions	O
.	O
Recent	O
data	B-MED
demonstrate	O
a	O
transcriptional	B-MED
upregulation	B-MED
of	O
several	O
autophagy	B-MED
genes	B-MED
as	O
a	O
mechanism	B-MED
that	O
controls	B-MED
autophagy	B-MED
in	O
response	O
to	O
starvation	B-MED
.	O
Here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	B-MED
of	O
mRNA	B-MED
of	O
the	O
essential	O
autophagy	B-MED
initiation	B-MED
gene	I-MED
ULK1	B-MED
,	O
its	O
protein	B-MED
level	B-MED
is	O
rapidly	O
reduced	B-MED
under	O
starvation	B-MED
.	O
Although	O
both	O
autophagic	B-MED
and	O
proteasomal	B-MED
systems	I-MED
contribute	O
to	O
the	O
degradation	B-MED
of	O
ULK1	B-MED
,	O
under	O
prolonged	B-MED
nitrogen	B-MED
deprivation	B-MED
,	O
its	O
level	B-MED
was	O
still	O
reduced	B-MED
in	O
ATG7	B-MED
knockout	B-MED
cells	I-MED
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	B-MED
treated	B-MED
with	O
the	O
lysosomal	B-MED
or	O
proteasomal	B-MED
inhibitors	I-MED
.	O
We	O
demonstrate	O
that	O
under	O
starvation	B-MED
,	O
protein	B-MED
translation	I-MED
is	O
rapidly	O
diminished	B-MED
and	O
,	O
similar	O
to	O
treatments	B-MED
with	O
the	O
proteosynthesis	B-MED
inhibitors	I-MED
cycloheximide	B-MED
or	O
anisomycin	B-MED
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	B-MED
of	O
ULK1	B-MED
.	O
Furthermore	O
,	O
it	O
was	O
found	O
that	O
inhibition	B-MED
of	O
the	O
mitochondrial	B-MED
respiratory	B-MED
complexes	I-MED
or	O
the	O
mitochondrial	B-MED
ATP	B-MED
synthase	I-MED
function	I-MED
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	B-MED
of	O
substrates	B-MED
,	O
promote	O
upregulation	B-MED
of	O
ULK1	B-MED
mRNA	I-MED
and	O
protein	B-MED
expression	I-MED
in	O
an	O
AMPK	B-MED
-	O
dependent	B-MED
manner	O
in	O
U1810	B-MED
lung	I-MED
cancer	I-MED
cells	I-MED
growing	O
in	O
complete	O
culture	B-MED
medium	I-MED
.	O
These	O
inhibitors	B-MED
could	O
also	O
drastically	O
increase	B-MED
the	O
ULK1	B-MED
protein	I-MED
in	O
U1810	B-MED
cells	I-MED
with	O
knockout	O
of	O
ATG13	B-MED
,	O
where	O
the	O
ULK1	B-MED
expression	B-MED
is	O
significantly	O
diminished	B-MED
.	O
However	O
,	O
such	O
upregulation	B-MED
of	O
ULK1	B-MED
protein	I-MED
is	O
negligible	O
under	O
starvation	B-MED
conditions	O
,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	B-MED
and	O
suggesting	O
that	O
transcriptional	B-MED
upregulation	B-MED
of	O
ULK1	B-MED
protein	I-MED
will	O
be	O
diminished	B-MED
under	O
such	O
conditions	O
.	O
Thus	O
,	O
we	O
propose	O
a	O
model	B-MED
where	O
inhibition	B-MED
of	O
protein	B-MED
translation	I-MED
,	O
together	O
with	O
the	O
degradation	B-MED
systems	O
,	O
limit	O
autophagy	B-MED
during	O
starvation	B-MED
.	O
Combination	B-MED
of	O
telmisartan	B-MED
with	O
sildenafil	B-MED
ameliorate	B-MED
progression	B-MED
of	O
diabetic	B-MED
nephropathy	I-MED
in	O
streptozotocin	B-MED
-	O
induced	B-MED
diabetic	B-MED
model	O
Diabetic	B-MED
nephropathy	I-MED
(	O
DN	B-MED
)	O
is	O
a	O
leading	O
cause	O
of	O
end	B-MED
-	I-MED
stage	I-MED
renal	I-MED
disease	I-MED
in	O
the	O
world	O
.	O
Several	O
signaling	B-MED
pathways	I-MED
are	O
involved	O
in	O
the	O
pathogenesis	B-MED
of	O
DN	B-MED
including	O
elevation	B-MED
in	O
level	O
of	O
angiotensin	B-MED
II	I-MED
,	O
formation	B-MED
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
(	O
AGE	B-MED
)	O
,	O
activation	B-MED
of	O
protein	B-MED
kinase	I-MED
c	I-MED
(	O
PKC	B-MED
)	O
,	O
and	O
lipid	B-MED
accumulation	I-MED
.	O
These	O
pathways	B-MED
activate	B-MED
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B-MED
stress	I-MED
,	O
increasing	O
expression	B-MED
of	O
transforming	B-MED
growth	I-MED
factor	I-MED
beta-1	I-MED
(	O
TGF	B-MED
-	I-MED
β	I-MED
1	I-MED
)	O
and	O
release	B-MED
of	O
interleukins	B-MED
and	O
adhesion	B-MED
molecules	I-MED
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-MED
pathway	B-MED
to	O
ameliorate	B-MED
the	O
progression	B-MED
of	O
DN	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
white	B-MED
male	I-MED
rats	I-MED
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	B-MED
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	B-MED
control	I-MED
and	O
a	O
control	B-MED
vehicle	I-MED
group	I-MED
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-MED
by	O
a	O
single	O
intraperitoneal	B-MED
injection	I-MED
of	O
Streptozotocin	B-MED
(	O
STZ	B-MED
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	B-MED
.	O
Thereafter	O
,	O
the	O
rats	B-MED
were	O
divided	O
into	O
DN	B-MED
group	O
,	O
DN	B-MED
group	O
receiving	O
Telmisartan	B-MED
or	O
Sildenafil	B-MED
or	O
Telmisartan	B-MED
Sildenafil	B-MED
combination	B-MED
.	O
After	O
the	O
specified	B-MED
treatment	B-MED
period	B-MED
,	O
urine	B-MED
samples	I-MED
were	O
collected	B-MED
(	O
using	O
metabolic	B-MED
cages	I-MED
)	O
to	O
measure	O
proteinuria	B-MED
,	O
animals	B-MED
were	O
then	O
euthanized	B-MED
,	O
blood	B-MED
and	O
tissue	B-MED
samples	I-MED
were	O
collected	B-MED
for	O
measurement	B-MED
of	I-MED
Blood	I-MED
glucose	I-MED
,	O
BUN	B-MED
,	O
S.Cr	B-MED
,	O
LDL	B-MED
,	O
NO	B-MED
,	O
TGF	B-MED
-	I-MED
β1	I-MED
,	O
IL-1β	B-MED
,	O
AGEPs	B-MED
,	O
and	O
SOD	B-MED
.	O
The	O
combination	B-MED
therapy	I-MED
showed	O
significant	O
decrease	O
in	O
BUN	B-MED
,	O
S.Cr	B-MED
,	O
LDL	B-MED
,	O
TGF	B-MED
-	I-MED
β1	I-MED
,	O
IL-1β	B-MED
,	O
Proteinuria	B-MED
and	O
AGEPs	B-MED
and	O
significant	O
increase	O
in	O
SOD	B-MED
and	O
NO	B-MED
.	O
The	O
findings	O
showed	O
that	O
combination	B-MED
therapy	I-MED
was	O
able	O
to	O
ameliorate	B-MED
DN	B-MED
and	O
that	O
the	O
effects	O
were	O
superior	B-MED
to	O
the	O
single	O
drugs	B-MED
alone	O
.	O
CXCL5	B-MED
Plays	O
a	O
Promoting	O
Role	O
in	O
Osteosarcoma	B-MED
Cell	B-MED
Migration	I-MED
and	I-MED
Invasion	I-MED
in	O
Autocrine	B-MED
-	O
and	O
Paracrine	B-MED
-Dependent	O
Manners	O
CXCL5	B-MED
,	O
a	O
CXC	B-MED
-	I-MED
type	I-MED
chemokine	I-MED
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic	B-MED
immune	I-MED
cells	I-MED
by	O
binding	B-MED
to	I-MED
its	I-MED
receptor	I-MED
CXCR2	I-MED
.	O
Recently	O
,	O
CXCL5	B-MED
/	O
CXCR2	B-MED
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	B-MED
role	O
in	O
many	O
human	B-MED
cancers	B-MED
.	O
However	O
,	O
the	O
exact	O
role	O
of	O
CXCL5	B-MED
in	O
osteosarcoma	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
has	O
not	O
been	O
revealed	O
.	O
Here	O
we	O
found	O
that	O
the	O
protein	B-MED
expression	I-MED
of	O
CXCL5	B-MED
was	O
significantly	O
increased	B-MED
in	O
osteosarcoma	B-MED
tissues	B-MED
compared	O
with	O
that	O
in	O
matched	B-MED
adjacent	I-MED
nontumor	I-MED
tissues	I-MED
.	O
Moreover	O
,	O
the	O
expression	B-MED
of	O
CXCL5	B-MED
was	O
significantly	O
associated	O
with	O
advanced	B-MED
clinical	I-MED
stage	I-MED
and	O
metastasis	B-MED
.	O
Further	O
investigation	O
showed	O
that	O
the	O
CXCL5	B-MED
expression	B-MED
levels	I-MED
were	O
also	O
significantly	O
increased	B-MED
in	O
osteosarcoma	B-MED
cell	B-MED
lines	I-MED
,	O
including	O
Saos-2	B-MED
,	O
MG63	B-MED
,	O
U2OS	B-MED
,	O
and	O
SW1353	B-MED
,	O
when	O
compared	O
with	O
those	O
in	O
normal	B-MED
osteoblast	I-MED
hFoB1.19	B-MED
cells	I-MED
.	O
U2OS	B-MED
cells	I-MED
were	O
further	O
transfected	B-MED
with	O
CXCL5	B-MED
-	O
specific	B-MED
siRNA	I-MED
or	O
overexpression	B-MED
plasmid	B-MED
.	O
Knockdown	B-MED
of	O
CXCL5	B-MED
significantly	O
suppressed	B-MED
U2OS	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
.	O
On	O
the	O
contrary	O
,	O
overexpression	B-MED
of	O
CXLC5	B-MED
remarkably	O
promoted	O
the	O
migration	B-MED
and	I-MED
invasion	I-MED
of	O
U2OS	B-MED
cells	I-MED
.	O
Interestingly	O
,	O
both	O
exogenous	B-MED
CXCL5	B-MED
treatment	B-MED
and	O
the	O
conditioned	O
medium	O
of	O
CXCL5	B-MED
-	O
overexpressing	B-MED
hFoB1.19	B-MED
cells	I-MED
could	O
also	O
enhance	O
the	O
migration	B-MED
and	I-MED
invasion	I-MED
of	O
U2OS	B-MED
cells	I-MED
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
CXCL5	B-MED
in	O
U2OS	B-MED
cell	B-MED
migration	I-MED
and	I-MED
invasion	I-MED
is	O
also	O
in	O
a	O
paracrine	B-MED
-dependent	O
manner	O
.	O
According	O
to	O
these	O
data	O
,	O
our	O
study	O
demonstrates	O
that	O
CXCL5	B-MED
is	O
upregulated	O
in	O
osteosarcoma	B-MED
and	O
may	O
play	O
an	O
oncogenic	B-MED
role	O
in	O
osteosarcoma	B-MED
metastasis	B-MED
.	O
Therefore	O
,	O
CXCL5	B-MED
may	O
become	O
a	O
potential	B-MED
therapeutic	B-MED
target	I-MED
for	O
osteosarcoma	B-MED
treatment	B-MED
.	O
Fading	B-MED
With	B-MED
Time	I-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
Immunoreactivity	B-MED
in	O
Non	B-MED
-	I-MED
Small	I-MED
Cells	I-MED
Lung	I-MED
Cancer	I-MED
Tissues	B-MED
:	O
A	O
Methodological	B-MED
Study	I-MED
Blockade	B-MED
of	O
inhibitory	B-MED
immune	I-MED
checkpoints	I-MED
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	B-MED
option	B-MED
for	O
tumor	B-MED
therapy	I-MED
.	O
Inhibition	B-MED
of	O
programmed	B-MED
cell	I-MED
death	I-MED
protein	I-MED
1	I-MED
and/or	O
its	O
specific	O
ligand	B-MED
programmed	B-MED
death	I-MED
-	I-MED
ligand	I-MED
1	I-MED
(	O
PD	B-MED
-	I-MED
L1	I-MED
)	O
was	O
effective	O
in	O
clinical	B-MED
trials	I-MED
in	O
advanced	B-MED
melanoma	B-MED
,	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
(	O
NSCLC	B-MED
)	O
bladder	B-MED
and	O
kidney	B-MED
cancer	I-MED
.	O
The	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-MED
(	O
IHC	B-MED
)	O
expression	B-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
is	O
highly	O
debated	O
.	O
Different	O
reagents	B-MED
,	O
clones	B-MED
,	O
cutoffs	O
of	O
cell	B-MED
expression	B-MED
and	O
subjective	B-MED
interpretation	B-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
immunoreactivity	B-MED
in	O
epithelial	B-MED
cells	I-MED
and	O
lymphocytes	B-MED
are	O
the	O
main	O
issue	B-MED
.	O
In	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
NSCLC	B-MED
surgical	B-MED
specimens	I-MED
that	O
underwent	O
pathologic	B-MED
examination	I-MED
from	O
January	B-MED
2014	O
to	O
July	B-MED
2015	O
.	O
Using	O
a	O
tissue	O
microarray	B-MED
approach	I-MED
we	O
evaluated	O
the	O
IHC	B-MED
expression	I-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
in	O
tumor	B-MED
-	I-MED
infiltrating	I-MED
lymphocytes	I-MED
and	O
tumor	B-MED
cells	I-MED
(	O
TCs	B-MED
)	O
and	O
compared	O
the	O
ICH	B-MED
staining	I-MED
with	O
tumor	B-MED
histology	I-MED
,	O
grade	B-MED
and	O
the	O
age	O
of	O
the	O
tissue	B-MED
blocks	I-MED
.	O
The	O
main	O
new	O
finding	B-MED
was	O
the	O
fading	B-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
IHC	B-MED
expression	I-MED
in	O
TCs	B-MED
in	O
tissues	B-MED
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O
PD	B-MED
-	I-MED
L1	I-MED
expression	B-MED
in	O
tumor	B-MED
-	I-MED
infiltrating	I-MED
lymphocytes	I-MED
in	O
the	O
2	O
years	B-MED
was	O
similar	B-MED
.	O
We	O
also	O
found	O
a	O
significant	B-MED
higher	I-MED
immunoreactivity	B-MED
of	O
TCs	B-MED
in	O
high	B-MED
grade	I-MED
NSCLC	B-MED
and	O
in	O
the	O
squamous	B-MED
carcinoma	I-MED
histotype	B-MED
compared	O
with	O
low	B-MED
grade	I-MED
tumors	B-MED
and	O
the	O
adenocarcinoma	B-MED
histology	B-MED
(	O
P=0.013	O
)	O
.	O
We	O
demonstrated	O
that	O
the	O
IHC	B-MED
evaluation	I-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
in	O
NSCLC	B-MED
archival	B-MED
tissues	I-MED
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	B-MED
setting	I-MED
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	B-MED
blocks	I-MED
older	O
than	O
1	O
year	B-MED
.	O
Comparison	O
of	O
sonoelastography	B-MED
with	O
sonourethrography	B-MED
and	O
retrograde	B-MED
urethrography	I-MED
in	O
the	O
evaluation	B-MED
of	O
male	B-MED
anterior	B-MED
urethral	I-MED
strictures	I-MED
Retrograde	B-MED
urethrography	I-MED
(	O
RUG	B-MED
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	B-MED
modality	I-MED
for	O
imaging	B-MED
of	O
the	O
anterior	B-MED
urethral	I-MED
strictures	I-MED
despite	O
its	O
well	O
-	O
known	O
limitations	B-MED
and	O
disadvantages	O
.	O
Sonourethrography	B-MED
(	O
SUG	B-MED
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	B-MED
the	O
limitations	B-MED
of	O
RUG	B-MED
and	O
to	O
provide	O
more	O
accurate	B-MED
results	I-MED
.	O
As	O
proper	O
selection	O
of	O
imaging	B-MED
modality	I-MED
is	O
very	O
important	O
for	O
planning	B-MED
the	I-MED
treatment	I-MED
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O
One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	B-MED
of	O
stricture	B-MED
disease	I-MED
is	O
spongiofibrosis	B-MED
.	O
Sonoelastography	B-MED
(	O
SE	B-MED
)	O
is	O
a	O
newer	B-MED
technique	I-MED
,	O
tried	O
in	O
various	O
other	O
pathologies	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	B-MED
in	O
the	O
evaluation	O
of	O
anterior	B-MED
urethral	I-MED
stricture	I-MED
disease	I-MED
by	O
comparison	O
with	O
RUG	B-MED
and	O
SUG	B-MED
.	O
Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	B-MED
with	O
clinical	O
features	O
of	O
anterior	B-MED
urethral	I-MED
stricture	I-MED
disease	I-MED
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-MED
followed	O
by	O
SUG	B-MED
and	O
SE	B-MED
for	O
stricture	B-MED
location	B-MED
,	O
length	B-MED
,	O
depth	B-MED
of	O
spongiofibrosis	B-MED
and	O
periurethral	B-MED
pathologies	B-MED
.	O
The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	B-MED
findings	I-MED
.	O
Overall	O
diagnostic	B-MED
accuracy	I-MED
of	O
SE	B-MED
,	O
SUG	B-MED
,	O
and	O
RGU	B-MED
for	O
the	O
estimation	O
of	O
stricture	B-MED
location	B-MED
,	O
and	O
length	B-MED
were	O
estimated	O
92.68	O
%	O
vs.	O
91.54	O
%	O
,	O
79	O
%	O
vs.	O
78.87	O
%	O
and	O
80.48	O
%	O
vs.	O
43.66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	B-MED
of	O
spongiofibrosis	B-MED
SE	B-MED
,	O
and	O
SUG	B-MED
had	O
accuracy	B-MED
rates	I-MED
of	O
87.3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O
The	O
mean	O
length	O
measured	O
on	O
SE	B-MED
was	O
nearest	O
to	O
the	O
mean	O
intra	B-MED
-	I-MED
operative	I-MED
stricture	B-MED
length	B-MED
(	O
21.34	O
+	O
11.8	O
mm	O
)	O
.	O
SE	B-MED
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-MED
of	I-MED
bladder	I-MED
mucosa	I-MED
on	O
cystoscopic	B-MED
examination	I-MED
(	O
p=0.003	O
)	O
whereas	O
the	O
association	O
was	O
non	O
-	O
significant	O
(	O
p=0.127	O
)	O
for	O
difficulty	O
in	O
incision	B-MED
.	O
While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-MED
findings	O
related	O
both	O
to	O
the	O
colour	B-MED
of	I-MED
the	I-MED
bladder	I-MED
mucosa	I-MED
and	O
difficulty	O
in	O
incision	B-MED
on	O
cystoscopy	B-MED
,	O
SE	B-MED
findings	O
had	O
a	O
significant	O
association	O
(	O
p<0.001	O
)	O
with	O
histopathology	B-MED
findings	I-MED
for	O
severe	O
degree	B-MED
of	I-MED
fibrosis	I-MED
.	O
Sonoelastography	B-MED
estimates	O
stricture	B-MED
site	I-MED
and	I-MED
length	I-MED
better	O
in	O
comparison	O
with	O
RUG	B-MED
and	O
SUG	B-MED
.	O
It	O
estimates	O
degree	O
of	O
spongiofibrosis	B-MED
which	O
serves	O
as	O
an	O
important	O
prognostic	B-MED
factor	I-MED
for	O
stricture	B-MED
recurrence	I-MED
more	O
accurately	B-MED
than	O
SUG	B-MED
.	O
The	O
Effect	B-MED
of	O
l	B-MED
-	I-MED
Arginine	I-MED
on	O
Dural	B-MED
Healing	I-MED
After	O
Experimentally	O
Induced	B-MED
Dural	B-MED
Defect	B-MED
in	O
a	O
Rat	B-MED
Model	B-MED
Incomplete	B-MED
repair	B-MED
of	O
the	O
dura	B-MED
mater	I-MED
may	O
result	B-MED
in	O
numerous	B-MED
complications	B-MED
such	O
as	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
and	O
meningitis	B-MED
.	O
For	O
this	O
reason	O
,	O
accurate	B-MED
repair	B-MED
of	O
the	O
dura	B-MED
mater	I-MED
is	O
essential	B-MED
.	O
In	O
this	O
study	O
,	O
the	O
effect	B-MED
of	O
systemic	B-MED
and	O
local	B-MED
supplementation	B-MED
of	O
l	B-MED
-	I-MED
arginine	I-MED
on	O
dural	B-MED
healing	I-MED
was	O
evaluated	O
.	O
Thirty	O
male	B-MED
Wistar	B-MED
rats	I-MED
were	O
used	O
and	O
divided	B-MED
into	O
control	B-MED
,	O
local	B-MED
,	O
and	O
systemic	B-MED
l	B-MED
-	I-MED
arginine	I-MED
groups	B-MED
,	O
with	O
10	O
rats	B-MED
in	O
each	O
.	O
In	O
each	O
group	B-MED
,	O
a	O
5	O
-	O
mm	O
experimental	B-MED
incision	I-MED
was	O
made	O
at	O
the	O
lumbar	B-MED
segment	I-MED
of	I-MED
the	I-MED
dura	I-MED
mater	I-MED
and	O
cerebrospinal	B-MED
fluid	I-MED
leakage	I-MED
was	O
induced	B-MED
.	O
Each	O
group	B-MED
was	O
divided	B-MED
into	O
2	O
subgroups	B-MED
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-MED
,	O
the	O
rats	B-MED
were	O
killed	B-MED
and	O
the	O
damaged	B-MED
segments	B-MED
of	O
the	O
dura	B-MED
were	O
separated	B-MED
,	O
histologically	B-MED
evaluated	O
and	O
the	O
dural	B-MED
healing	I-MED
indicators	B-MED
including	O
cell	B-MED
types	I-MED
,	O
granulation	B-MED
tissue	I-MED
formation	B-MED
,	O
collagen	B-MED
deposit	B-MED
,	O
and	O
vascularization	B-MED
were	O
compared	B-MED
between	O
groups	B-MED
.	O
The	O
systematic	B-MED
supplementation	B-MED
of	O
l	B-MED
-	I-MED
arginine	I-MED
showed	O
a	O
significant	B-MED
effect	B-MED
in	O
dural	B-MED
healing	I-MED
compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
.	O
After	O
the	O
first	O
week	B-MED
,	O
granulation	B-MED
formation	B-MED
increased	B-MED
considerably	O
(	O
P	O
<	O
0.031	O
)	O
,	O
and	O
after	O
6	O
weeks	B-MED
,	O
collagen	B-MED
deposition	B-MED
and	O
neovascularization	B-MED
were	O
significantly	O
different	B-MED
compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
(	O
P	O
<	O
0.030	O
;	O
P	O
<	O
0.009	O
)	O
.	O
In	O
comparison	B-MED
between	O
different	B-MED
groups	B-MED
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-MED
,	O
maximum	B-MED
changes	B-MED
in	O
healing	B-MED
indicators	B-MED
were	O
observed	B-MED
in	O
the	O
systemic	B-MED
group	B-MED
and	O
the	O
least	O
variations	B-MED
were	O
related	O
to	O
the	O
control	B-MED
group	I-MED
.	O
The	O
systemic	B-MED
supplementation	B-MED
of	O
l	B-MED
-	I-MED
arginine	I-MED
may	O
accelerate	B-MED
dural	B-MED
healing	I-MED
by	O
increasing	B-MED
the	O
level	B-MED
of	O
granulation	B-MED
tissue	I-MED
formation	B-MED
,	O
collagen	B-MED
deposition	B-MED
,	O
and	O
vascularization	B-MED
.	O
Zoonotic	B-MED
and	O
Non	B-MED
-	I-MED
zoonotic	I-MED
Parasites	B-MED
of	O
Wild	B-MED
Rodents	B-MED
in	O
Turkman	B-MED
Sahra	I-MED
,	I-MED
Northeastern	I-MED
Iran	I-MED
This	O
study	B-MED
was	O
conducted	O
to	O
collect	B-MED
informative	I-MED
data	I-MED
on	O
the	O
parasitic	B-MED
infection	I-MED
of	O
wild	B-MED
rodents	B-MED
,	O
emphasizing	O
on	O
finding	B-MED
parasites	B-MED
,	O
which	O
have	O
medical	B-MED
importance	B-MED
to	O
human	B-MED
.	O
During	O
2012	O
-	O
2014	O
,	O
a	O
total	B-MED
number	I-MED
of	O
91	O
wild	B-MED
rodents	B-MED
were	O
captured	B-MED
from	O
rural	B-MED
areas	I-MED
of	O
Turkmen	B-MED
Sahra	I-MED
,	I-MED
Golestan	I-MED
Province	I-MED
,	O
using	O
handmade	B-MED
traps	I-MED
.	O
Animals	B-MED
were	O
anesthetized	B-MED
,	O
surveyed	B-MED
for	O
any	O
ectoparasite	B-MED
and	O
then	O
their	O
carcasses	B-MED
were	O
carefully	O
dissected	B-MED
for	O
examination	B-MED
of	O
endoparsites	B-MED
.	O
Four	O
species	B-MED
of	O
rodents	B-MED
including	B-MED
Mus	B-MED
musculus	I-MED
(	O
52.75	O
%	O
)	O
,	O
Rattus	B-MED
norvegicus	I-MED
(	O
38.46	O
%	O
)	O
,	O
Rhombomys	B-MED
opimus	I-MED
(	O
4.40	O
%	O
)	O
and	O
Meriones	B-MED
libycus	I-MED
(	O
4.40	O
%	O
)	O
were	O
captured	B-MED
.	O
Parasitic	B-MED
infestation	I-MED
was	O
detected	B-MED
in	O
38.5	O
%	O
of	O
sampled	B-MED
rodents	B-MED
.	O
Parasite	B-MED
infestation	I-MED
rates	B-MED
of	O
sampled	B-MED
rodents	B-MED
was	O
Hymenolepis	B-MED
diminuta	I-MED
=	O
7.7	O
%	O
,	O
Cryptosporidium	B-MED
spp	I-MED
=	O
6.6	O
%	O
,	O
Trichuris	B-MED
spp	I-MED
.=	O
5.5	O
%	O
,	O
Cysticercus	B-MED
fasciolaris	I-MED
=	O
2.20	O
%	O
,	O
Angiostrongylus	B-MED
spp	I-MED
.=	O
2.20	O
%	O
,	O
Capillaria	B-MED
sp	I-MED
.=	O
1.09	O
%	O
,	O
Rhipicephalus	B-MED
spp	I-MED
.	O
=	O
8.70	O
%	O
,	O
Nosopsyllus	B-MED
fasciatus	I-MED
=	O
1.09	O
%	O
,	O
and	O
Laelaps	B-MED
nuttalli	I-MED
=	O
3.29	O
%	O
.	O
Among	O
10	O
genera	B-MED
/	O
species	B-MED
of	O
identified	B-MED
parasites	B-MED
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	B-MED
with	O
public	B-MED
health	I-MED
importance	B-MED
.	O
L.	B-MED
nuttalli	I-MED
and	O
N.	B-MED
fasciatus	I-MED
were	O
the	O
only	O
two	O
non	B-MED
-	I-MED
zoonotic	I-MED
detected	B-MED
parasites	B-MED
in	O
this	O
survey	B-MED
.	O
Harboring	B-MED
a	O
wide	B-MED
variety	O
of	O
zoonotic	B-MED
parasites	B-MED
in	O
sampled	B-MED
wild	B-MED
rodents	B-MED
particularly	B-MED
when	O
they	O
live	O
nearby	B-MED
villages	B-MED
,	O
represents	O
a	O
potential	B-MED
risk	B-MED
to	O
native	B-MED
inhabitants	I-MED
.	O
Hence	O
,	O
controlling	B-MED
rodents	B-MED
'	O
population	B-MED
in	O
residential	B-MED
regions	I-MED
and	O
improving	B-MED
awareness	B-MED
of	O
local	B-MED
people	B-MED
about	O
the	O
risk	B-MED
of	O
disease	B-MED
transmission	I-MED
through	O
rodents	B-MED
seems	O
to	O
be	O
entirely	O
necessary	B-MED
.	O
Improving	B-MED
Care	B-MED
Transitions	I-MED
Across	O
Healthcare	B-MED
Settings	B-MED
Through	O
a	O
Human	B-MED
Factors	I-MED
Approach	O
After	O
more	O
than	O
two	O
decades	B-MED
of	O
research	B-MED
focused	O
on	O
care	B-MED
transition	I-MED
improvement	B-MED
and	O
intervention	B-MED
development	B-MED
,	O
unfavorable	B-MED
outcome	I-MED
measures	B-MED
associated	B-MED
with	I-MED
care	B-MED
transitions	I-MED
across	O
healthcare	B-MED
settings	B-MED
persist	O
.	O
Readmissions	B-MED
rates	B-MED
remain	O
an	O
important	O
outcome	B-MED
to	O
target	B-MED
for	O
intervention	B-MED
,	O
adverse	B-MED
events	I-MED
associated	B-MED
with	I-MED
care	B-MED
transitions	I-MED
continue	O
to	O
be	O
an	O
issue	B-MED
,	O
and	O
patients	B-MED
are	O
often	O
dissatisfied	B-MED
with	O
the	O
quality	B-MED
of	O
their	O
care	B-MED
.	O
Currently	O
,	O
interventions	B-MED
to	O
improve	O
care	B-MED
transitions	I-MED
are	O
disease	B-MED
specific	B-MED
,	O
require	O
substantial	B-MED
financial	B-MED
investments	I-MED
in	O
training	B-MED
allied	B-MED
healthcare	I-MED
professionals	I-MED
,	O
or	O
focus	O
primarily	O
on	O
hospital	B-MED
-	I-MED
based	I-MED
discharge	I-MED
planning	I-MED
with	O
mixed	O
results	O
.	O
This	O
complex	B-MED
situation	I-MED
requires	O
a	O
method	B-MED
of	I-MED
evaluation	I-MED
that	O
can	O
provide	O
a	O
comprehensive	B-MED
,	O
in	B-MED
-	I-MED
depth	I-MED
,	O
and	O
context	B-MED
-	I-MED
driven	I-MED
investigation	B-MED
of	O
potential	B-MED
risks	I-MED
to	O
safe	O
care	B-MED
transitions	I-MED
across	O
healthcare	B-MED
settings	B-MED
,	O
which	O
can	O
lead	O
to	O
the	O
creation	B-MED
of	O
effective	B-MED
,	O
usable	B-MED
,	O
and	O
sustainable	B-MED
interventions	B-MED
.	O
A	O
systems	O
'	O
approach	O
known	O
as	O
Human	B-MED
Factors	I-MED
and	I-MED
Ergonomics	I-MED
(	O
HFE	B-MED
)	O
evaluates	B-MED
the	O
factors	B-MED
in	O
a	O
system	O
that	O
affect	O
human	B-MED
performance	I-MED
.	O
This	O
article	B-MED
describes	O
how	O
HFE	B-MED
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	B-MED
care	B-MED
transitions	I-MED
.	O
Autoantibodies	B-MED
to	O
MOG	B-MED
in	O
a	O
distinct	O
subgroup	B-MED
of	O
adult	B-MED
multiple	B-MED
sclerosis	I-MED
To	O
evaluate	B-MED
the	O
presence	O
of	O
antibodies	B-MED
to	O
conformation	B-MED
-intact	O
myelin	B-MED
oligodendrocyte	I-MED
glycoprotein	I-MED
(	O
MOG	B-MED
)	O
in	O
a	O
subgroup	B-MED
of	O
adult	B-MED
patients	B-MED
with	O
clinically	B-MED
definite	O
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
preselected	O
for	O
a	O
specific	O
clinical	B-MED
phenotype	B-MED
including	O
severe	B-MED
spinal	B-MED
cord	I-MED
,	O
optic	B-MED
nerve	I-MED
,	O
and	O
brainstem	B-MED
involvement	O
.	O
Antibodies	B-MED
to	O
MOG	B-MED
were	O
investigated	B-MED
using	O
a	O
cell	B-MED
-	I-MED
based	I-MED
assay	I-MED
in	O
3	O
groups	B-MED
of	O
patients	B-MED
:	O
104	O
preselected	O
patients	B-MED
with	O
MS	B-MED
(	O
group	B-MED
1	I-MED
)	O
,	O
55	O
age	B-MED
-	O
and	O
sex	B-MED
-matched	O
,	O
otherwise	O
unselected	O
patients	B-MED
with	O
MS	B-MED
(	O
group	B-MED
2	I-MED
)	O
,	O
and	O
in	O
22	O
brain	B-MED
-	I-MED
biopsied	I-MED
patients	B-MED
with	O
demyelinating	B-MED
diseases	I-MED
of	O
the	O
CNS	B-MED
(	O
n	O
=	O
19	O
with	O
MS	B-MED
)	O
,	O
4	O
of	O
whom	O
classified	B-MED
as	O
MS	B-MED
type	I-MED
II	I-MED
(	O
group	B-MED
3	I-MED
)	O
.	O
Recognized	O
epitopes	B-MED
were	O
identified	O
with	O
mutated	B-MED
variants	B-MED
of	O
MOG	B-MED
.	O
Antibodies	B-MED
to	O
MOG	B-MED
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	B-MED
patients	B-MED
with	O
MS	B-MED
.	O
In	O
contrast	O
,	O
in	O
groups	B-MED
2	I-MED
and	O
3	B-MED
,	O
none	O
of	O
the	O
patients	B-MED
tested	B-MED
positive	O
for	O
MOG	B-MED
antibodies	B-MED
.	O
Patients	B-MED
with	O
MS	B-MED
with	O
antibodies	B-MED
to	O
MOG	B-MED
predominantly	O
manifested	B-MED
with	O
concomitant	B-MED
severe	B-MED
brainstem	B-MED
and	O
spinal	B-MED
cord	I-MED
involvement	O
and	O
had	O
a	O
severe	B-MED
disease	B-MED
course	I-MED
with	O
high	O
relapse	B-MED
rates	B-MED
and	O
failure	B-MED
to	O
several	O
disease	B-MED
-	I-MED
modifying	I-MED
therapies	I-MED
.	O
Three	O
of	O
them	O
had	O
been	O
treated	B-MED
with	I-MED
plasma	B-MED
exchange	I-MED
with	O
a	O
favorable	B-MED
response	I-MED
.	O
All	O
anti	B-MED
-	I-MED
MOG	I-MED
-positive	O
patients	B-MED
with	O
MS	B-MED
showed	O
typical	O
MS	B-MED
lesions	B-MED
on	O
brain	B-MED
MRI	I-MED
.	O
Longitudinal	B-MED
analysis	I-MED
up	O
to	O
9	O
years	B-MED
revealed	O
fluctuations	B-MED
and	O
reappearance	O
of	O
anti	B-MED
-	I-MED
MOG	I-MED
reactivity	I-MED
.	O
Epitope	B-MED
mapping	I-MED
indicated	O
interindividual	B-MED
heterogeneity	I-MED
,	O
yet	O
intraindividual	B-MED
stability	I-MED
of	O
the	O
antibody	B-MED
response	I-MED
.	O
Antibodies	B-MED
to	O
MOG	B-MED
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B-MED
of	O
adult	B-MED
MS	B-MED
with	O
a	O
specific	O
clinical	B-MED
phenotype	B-MED
and	O
may	O
indicate	O
disease	B-MED
heterogeneity	B-MED
.	O
Activation	B-MED
of	O
the	O
orphan	B-MED
receptor	I-MED
GPR55	I-MED
by	O
lysophosphatidylinositol	B-MED
promotes	B-MED
metastasis	B-MED
in	O
triple	B-MED
-	I-MED
negative	I-MED
breast	I-MED
cancer	I-MED
The	O
orphan	B-MED
G	I-MED
protein	I-MED
-	I-MED
coupled	I-MED
receptor	I-MED
GPR55	B-MED
has	O
been	O
directly	B-MED
or	O
indirectly	B-MED
related	B-MED
to	O
basic	O
alterations	B-MED
that	O
drive	O
malignant	B-MED
growth	B-MED
:	O
uncontrolled	B-MED
cancer	O
cell	B-MED
proliferation	I-MED
,	O
sustained	B-MED
angiogenesis	I-MED
,	O
and	O
cancer	O
cell	B-MED
adhesion	I-MED
and	O
migration	B-MED
.	O
However	O
,	O
little	B-MED
is	O
known	B-MED
about	O
the	O
involvement	B-MED
of	O
this	O
receptor	B-MED
in	O
metastasis	B-MED
.	O
Here	O
,	O
we	O
show	O
that	O
elevated	B-MED
GPR55	B-MED
expression	I-MED
in	O
human	B-MED
tumors	B-MED
is	O
associated	B-MED
with	I-MED
the	O
aggressive	B-MED
basal	I-MED
/	O
triple	B-MED
-	I-MED
negative	I-MED
breast	I-MED
cancer	I-MED
population	B-MED
,	O
higher	B-MED
probability	I-MED
to	O
develop	O
metastases	B-MED
,	O
and	O
therefore	O
poor	B-MED
patient	B-MED
prognosis	B-MED
.	O
Activation	B-MED
of	O
GPR55	B-MED
by	O
its	O
proposed	O
endogenous	B-MED
ligand	B-MED
lysophosphatidylinositol	B-MED
confers	O
pro	B-MED
-	I-MED
invasive	I-MED
features	B-MED
on	O
breast	B-MED
cancer	I-MED
cells	I-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Specifically	O
,	O
this	O
effect	B-MED
is	O
elicited	B-MED
by	I-MED
coupling	B-MED
to	O
Gq/11	B-MED
heterotrimeric	I-MED
proteins	I-MED
and	O
the	O
subsequent	B-MED
activation	B-MED
,	O
through	O
ERK	B-MED
,	O
of	O
the	O
transcription	B-MED
factor	I-MED
ETV4	I-MED
/	O
PEA3	B-MED
.	O
Together	B-MED
,	O
these	O
data	B-MED
show	O
that	O
GPR55	B-MED
promotes	B-MED
breast	B-MED
cancer	I-MED
metastasis	B-MED
,	O
and	O
supports	B-MED
the	O
notion	O
that	O
this	O
orphan	B-MED
receptor	I-MED
may	O
constitute	O
a	O
new	B-MED
therapeutic	B-MED
target	B-MED
and	O
potential	B-MED
biomarker	B-MED
in	O
the	O
highly	O
aggressive	B-MED
triple	I-MED
-	I-MED
negative	I-MED
subtype	I-MED
.	O
A	O
pilot	B-MED
study	I-MED
exploring	O
the	O
relationship	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
self	B-MED
-	O
judgement	B-MED
,	O
self	B-MED
-	O
kindness	B-MED
,	O
compassion	B-MED
,	O
professional	B-MED
quality	I-MED
of	I-MED
life	I-MED
and	O
wellbeing	B-MED
among	O
UK	B-MED
community	B-MED
nurses	I-MED
Compassion	B-MED
fatigue	I-MED
and	O
burnout	B-MED
can	O
impact	B-MED
on	O
performance	B-MED
of	O
nurses	B-MED
.	O
This	O
paper	O
explores	O
the	O
relationship	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
self	B-MED
-	O
judgement	B-MED
,	O
self	B-MED
-	O
kindness	B-MED
,	O
compassion	B-MED
,	O
professional	B-MED
quality	I-MED
of	I-MED
life	I-MED
,	O
and	O
wellbeing	B-MED
among	O
community	B-MED
nurses	I-MED
.	O
To	O
measure	B-MED
associations	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
compassion	B-MED
fatigue	I-MED
,	O
wellbeing	B-MED
,	O
and	O
burnout	B-MED
in	O
community	B-MED
nurses	I-MED
.	O
Quantitative	B-MED
data	B-MED
were	O
collected	B-MED
using	O
standardised	B-MED
psychometric	B-MED
questionnaires	I-MED
:	O
(	O
1	O
)	O
Professional	B-MED
Quality	I-MED
of	I-MED
Life	I-MED
Scale	I-MED
;	O
(	O
2	O
)	O
Self	B-MED
-	I-MED
Compassion	I-MED
Scale	I-MED
;	O
(	O
3	O
)	O
short	B-MED
Warwick	I-MED
Edinburgh	I-MED
Mental	I-MED
Wellbeing	I-MED
Scale	I-MED
;	O
(	O
4	O
)	O
Compassion	B-MED
For	I-MED
Others	I-MED
Scale	I-MED
,	O
used	O
to	O
measure	B-MED
relationships	B-MED
between	O
self	B-MED
-	O
compassion	B-MED
,	O
compassion	B-MED
fatigue	I-MED
,	O
wellbeing	B-MED
,	O
and	O
burnout	B-MED
.	O
A	O
cross	B-MED
sectional	I-MED
sample	O
of	O
registered	B-MED
community	I-MED
nurses	I-MED
(	O
n=37	O
)	O
studying	O
for	O
a	O
postgraduate	B-MED
diploma	B-MED
at	O
a	O
University	B-MED
in	O
the	O
North	B-MED
of	I-MED
England	I-MED
took	O
part	O
in	O
this	O
study	B-MED
.	O
Results	B-MED
show	O
that	O
community	B-MED
nurses	I-MED
who	O
score	B-MED
high	B-MED
on	O
measures	B-MED
of	O
self	B-MED
-	O
compassion	B-MED
and	O
wellbeing	B-MED
,	O
also	O
report	O
less	B-MED
burnout	B-MED
.	O
Greater	B-MED
compassion	B-MED
satisfaction	B-MED
was	O
also	O
positively	B-MED
associated	B-MED
with	I-MED
compassion	B-MED
for	O
others	O
,	O
and	O
wellbeing	B-MED
,	O
whilst	O
also	O
being	O
negatively	B-MED
correlated	B-MED
with	O
burnout	B-MED
.	O
High	B-MED
levels	B-MED
of	O
self	B-MED
-	O
compassion	B-MED
were	O
linked	O
with	O
lower	B-MED
levels	B-MED
of	O
burnout	B-MED
.	O
Furthermore	O
when	O
community	B-MED
nurses	I-MED
have	O
greater	B-MED
compassion	B-MED
satisfaction	B-MED
they	O
also	O
report	O
more	O
compassion	B-MED
for	O
others	O
,	O
increased	B-MED
wellbeing	B-MED
,	O
and	O
less	B-MED
burnout	B-MED
.	O
The	O
implications	B-MED
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	B-MED
for	O
the	O
promotion	B-MED
of	O
greater	B-MED
compassion	B-MED
Evaluation	B-MED
of	O
an	O
international	B-MED
educational	B-MED
programme	I-MED
for	O
health	B-MED
care	I-MED
professionals	I-MED
on	O
best	O
practice	O
in	O
the	O
management	B-MED
of	O
a	O
perinatal	B-MED
death	B-MED
:	O
IMproving	B-MED
Perinatal	I-MED
mortality	I-MED
Review	I-MED
and	I-MED
Outcomes	I-MED
Via	I-MED
Education	I-MED
(	O
IMPROVE	B-MED
)	O
Stillbirths	B-MED
and	O
neonatal	B-MED
deaths	I-MED
are	O
devastating	B-MED
events	I-MED
for	O
both	O
parents	B-MED
and	O
clinicians	B-MED
and	O
are	O
global	B-MED
public	I-MED
health	I-MED
concerns	B-MED
.	O
Careful	O
clinical	B-MED
management	I-MED
after	O
these	O
deaths	B-MED
is	O
required	O
,	O
including	O
appropriate	O
investigation	B-MED
and	O
assessment	B-MED
to	O
determine	O
cause	O
(	O
s	O
)	O
to	O
prevent	O
future	O
losses	O
,	O
and	O
to	O
improve	O
bereavement	B-MED
care	I-MED
for	O
families	B-MED
.	O
An	O
educational	B-MED
programme	I-MED
for	O
health	B-MED
care	I-MED
professionals	I-MED
working	O
in	O
maternal	B-MED
and	O
child	B-MED
health	I-MED
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
Perinatal	B-MED
Society	I-MED
of	I-MED
Australia	I-MED
and	I-MED
New	I-MED
Zealand	I-MED
Guideline	I-MED
for	I-MED
Perinatal	I-MED
Mortality	I-MED
:	O
IMproving	B-MED
Perinatal	I-MED
mortality	I-MED
Review	I-MED
and	I-MED
Outcomes	I-MED
Via	I-MED
Education	I-MED
(	O
IMPROVE	B-MED
)	O
.	O
The	O
programme	B-MED
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-MED
and	O
is	O
delivered	O
as	O
six	O
interactive	B-MED
skills	I-MED
-based	O
stations	B-MED
.	O
We	O
aimed	O
to	O
determine	O
participants	B-MED
'	O
pre-	B-MED
and	O
post	B-MED
-	I-MED
programme	I-MED
knowledge	B-MED
of	O
and	O
confidence	B-MED
in	O
the	O
management	B-MED
of	O
perinatal	B-MED
deaths	B-MED
,	O
along	O
with	O
satisfaction	B-MED
with	O
the	O
programme	B-MED
.	O
We	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	B-MED
use	O
.	O
The	O
IMPROVE	B-MED
programme	I-MED
was	O
delivered	O
to	O
health	B-MED
professionals	I-MED
in	O
maternity	B-MED
hospitals	I-MED
in	O
all	O
seven	O
Australian	B-MED
states	B-MED
and	O
territories	B-MED
and	O
modified	O
for	O
use	O
internationally	B-MED
with	O
piloting	O
in	O
Vietnam	B-MED
,	O
Fiji	B-MED
,	O
and	O
the	O
Netherlands	B-MED
(	O
with	O
the	O
assistance	B-MED
of	O
the	O
International	B-MED
Stillbirth	I-MED
Alliance	I-MED
,	O
ISA	B-MED
)	O
.	O
Modifications	O
were	O
made	O
to	O
programme	B-MED
materials	I-MED
in	O
consultation	B-MED
with	O
local	O
teams	O
and	O
included	O
translation	B-MED
for	O
the	O
Vietnam	B-MED
programme	I-MED
.	O
Participants	B-MED
completed	O
pre-	B-MED
and	O
post	B-MED
-	I-MED
programme	I-MED
evaluation	B-MED
questionnaires	B-MED
on	O
knowledge	B-MED
and	O
confidence	B-MED
on	O
six	O
key	O
components	O
of	O
perinatal	B-MED
death	B-MED
management	B-MED
as	O
well	O
as	O
a	O
satisfaction	B-MED
questionnaire	I-MED
.	O
Over	O
the	O
period	O
May	O
2012	O
to	O
May	O
2015	O
,	O
30	O
IMPROVE	B-MED
workshops	B-MED
were	O
conducted	O
,	O
including	O
26	O
with	O
758	O
participants	B-MED
in	O
Australia	B-MED
and	O
four	O
with	O
136	O
participants	B-MED
internationally	B-MED
.	O
Evaluations	B-MED
showed	O
a	O
significant	B-MED
improvement	B-MED
between	O
pre-	B-MED
and	O
post	B-MED
-	I-MED
programme	I-MED
knowledge	B-MED
and	O
confidence	B-MED
in	O
all	O
six	O
stations	B-MED
and	O
overall	O
,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	B-MED
in	O
all	O
settings	B-MED
.	O
The	O
IMPROVE	B-MED
programme	I-MED
has	O
been	O
well	O
received	O
in	O
Australia	B-MED
and	O
in	O
three	O
different	O
international	B-MED
settings	B-MED
and	O
is	O
now	O
being	O
made	O
available	O
through	O
ISA	B-MED
.	O
Future	O
research	B-MED
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	B-MED
in	O
knowledge	B-MED
are	O
sustained	B-MED
with	O
less	O
causes	O
of	O
death	B-MED
being	O
classified	O
as	O
unknown	O
,	O
changes	B-MED
in	I-MED
clinical	I-MED
practice	I-MED
and	O
improvement	B-MED
in	O
parents	B-MED
'	I-MED
experiences	O
with	O
care	B-MED
.	O
The	O
suitability	O
for	O
this	O
programme	B-MED
in	O
low	B-MED
-	I-MED
income	I-MED
countries	B-MED
also	O
needs	O
to	O
be	O
established	O
.	O
RELIABILITY	B-MED
AND	I-MED
VALIDITY	I-MED
OF	O
THE	O
DIABETES	B-MED
EATING	I-MED
PROBLEM	I-MED
SURVEY	I-MED
-	I-MED
REVISED	I-MED
ON	O
TURKISH	B-MED
CHILDREN	B-MED
AND	O
ADOLESCENTS	B-MED
WITH	O
TYPE	B-MED
1	I-MED
DIABETES	I-MED
MELLITUS	I-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
examine	B-MED
the	O
reliability	B-MED
and	I-MED
validity	I-MED
of	O
Turkish	B-MED
version	B-MED
of	O
Diabetes	B-MED
Eating	I-MED
Problem	I-MED
Survey	I-MED
-	I-MED
Revised	I-MED
(	O
DEPS	B-MED
-	I-MED
R	I-MED
)	O
for	O
children	B-MED
and	O
adolescent	B-MED
with	O
Type	B-MED
1	I-MED
Diabetes	I-MED
Mellitus	I-MED
.	O
A	O
total	O
of	O
200	O
children	B-MED
and	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
,	O
ages	B-MED
9	O
-	O
18	O
years	B-MED
,	O
completed	O
the	O
DEPS	B-MED
-	I-MED
R	I-MED
Turkish	B-MED
version	B-MED
.	O
In	O
addition	O
to	O
tests	B-MED
of	O
validity	B-MED
,	O
confirmatory	B-MED
factor	I-MED
analysis	I-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
factor	B-MED
structure	I-MED
of	O
the	O
16	O
-	O
item	O
Turkish	B-MED
version	B-MED
of	O
DEPS	B-MED
-	I-MED
R	I-MED
R.	O
The	O
Turkish	B-MED
version	B-MED
of	O
DEPS	B-MED
-	I-MED
R	I-MED
demonstrated	O
satisfactory	B-MED
Cronbach	B-MED
's	I-MED
∝	O
(	O
0.847	O
)	O
and	O
was	O
significantly	O
correlated	B-MED
with	O
ag	B-MED
e	O
(	O
r=0.194	O
;	O
p<0.01	O
)	O
,	O
hemoglobin	B-MED
A1c	I-MED
levels	I-MED
(	O
r=0.303	O
;	O
p<0.01	O
)	O
and	O
BMI	B-MED
-	O
SDS	B-MED
(	O
r=0.412	O
;	O
p<0.01	O
)	O
indicating	O
criterion	B-MED
validity	I-MED
.	O
Median	O
DEPS	B-MED
-	I-MED
R	I-MED
scores	B-MED
of	O
Turkish	B-MED
version	B-MED
for	O
the	O
total	O
samples	B-MED
,	O
females	B-MED
and	O
males	B-MED
were	O
as	O
follows	O
:	O
11.0	O
,	O
11.5	O
and	O
10.5	O
respectively	O
.	O
Disturbed	B-MED
eating	I-MED
behaviors	I-MED
and	O
insulin	B-MED
restriction	B-MED
were	O
associated	O
with	O
poor	O
metabolic	B-MED
control	I-MED
.	O
A	O
short	O
,	O
self	B-MED
-	I-MED
administered	I-MED
diabetes	B-MED
specific	O
screening	B-MED
tool	O
for	O
disordered	B-MED
eating	I-MED
behavior	I-MED
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	B-MED
care	B-MED
of	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
.	O
The	O
Turkish	B-MED
version	B-MED
of	O
DEPS	B-MED
-	I-MED
R	I-MED
is	O
a	O
valid	O
screening	B-MED
tool	O
for	O
disordered	B-MED
eating	I-MED
behaviors	I-MED
in	O
type	B-MED
1	I-MED
diabetes	I-MED
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered	B-MED
eating	I-MED
behaviors	I-MED
.	O
Perioperative	B-MED
Management	I-MED
of	O
Severe	B-MED
Hypertension	I-MED
during	O
Laparoscopic	B-MED
Surgery	I-MED
for	O
Pheochromocytoma	B-MED
Phaeochromocytoma	B-MED
is	O
a	O
catecholamine	B-MED
-	I-MED
secreting	I-MED
vascular	B-MED
tumour	I-MED
that	O
is	O
derived	O
from	O
chromaffin	B-MED
cell	I-MED
.	O
Lethal	B-MED
cardiovascular	B-MED
complications	I-MED
,	O
such	O
as	O
serious	O
hypertension	B-MED
,	O
myocardial	B-MED
infarction	I-MED
and	O
aortic	B-MED
dissection	I-MED
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-MED
catecholamine	I-MED
release	I-MED
.	O
Each	O
stage	B-MED
of	O
anaesthesia	B-MED
management	I-MED
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-MED
catecholamine	I-MED
secretion	I-MED
that	O
may	O
occur	O
during	O
induction	B-MED
,	O
perioperative	B-MED
stage	I-MED
and	O
surgical	B-MED
manipulation	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-MED
preparation	I-MED
and	O
severe	B-MED
,	I-MED
persistent	I-MED
hypertension	I-MED
attack	I-MED
management	I-MED
with	O
a	O
combination	O
of	O
α	B-MED
-	I-MED
adrenergic	I-MED
blockade	I-MED
,	O
β	B-MED
-	I-MED
adrenergic	I-MED
blockade	I-MED
,	O
sodium	B-MED
nitroprusside	I-MED
and	O
remifentanil	B-MED
in	O
a	O
patient	B-MED
who	O
underwent	O
laparoscopic	B-MED
surgery	I-MED
for	O
phaeochromocytoma	B-MED
.	O
Association	B-MED
of	O
leukemia	B-MED
inhibitory	I-MED
factor	I-MED
gene	I-MED
polymorphism	B-MED
and	O
in	B-MED
vitro	I-MED
fertilization	B-MED
outcome	B-MED
in	O
a	O
population	B-MED
in	O
northern	B-MED
Iran	I-MED
Several	O
studies	B-MED
have	O
been	O
demonstrated	O
that	O
endometrial	B-MED
leukemia	B-MED
inhibitory	I-MED
factor	I-MED
(	O
LIF	B-MED
)	O
is	O
important	O
in	O
embryo	B-MED
implantation	I-MED
.	O
LIF	B-MED
is	O
a	O
secreted	O
glycoprotein	B-MED
with	O
a	O
variety	O
of	O
biological	B-MED
functions	I-MED
including	O
stimulation	B-MED
of	O
cell	B-MED
proliferation	I-MED
,	O
differentiation	B-MED
and	O
survival	B-MED
that	O
are	O
all	O
essential	B-MED
for	O
blastocyete	B-MED
development	B-MED
and	O
implantation	B-MED
.	O
The	O
LIF	B-MED
receptor	I-MED
activates	B-MED
several	O
signaling	B-MED
pathways	I-MED
in	O
diverse	B-MED
cell	I-MED
types	I-MED
,	O
including	O
Jak	B-MED
/	I-MED
STAT	I-MED
,	O
MAPK	B-MED
and	O
PI3	B-MED
-	I-MED
kinase	I-MED
pathways	B-MED
in	O
the	O
endometrium	B-MED
of	O
fertile	B-MED
woman	B-MED
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	B-MED
of	O
LIF	B-MED
in	O
proliferative	B-MED
phase	B-MED
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	B-MED
of	O
implantation	B-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
association	B-MED
between	O
maternal	B-MED
genotype	B-MED
of	O
SNP	B-MED
3951C	I-MED
/	I-MED
T	I-MED
LIF	B-MED
and	O
in	B-MED
vitro	I-MED
fertilization	I-MED
and	O
embryo	B-MED
transfer	I-MED
(	O
IVF	B-MED
-	O
ET	B-MED
)	O
outcome	B-MED
in	O
infertile	B-MED
women	B-MED
.	O
This	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
was	O
comprised	O
of	O
infertile	B-MED
patients	B-MED
(	O
n=70	O
)	O
and	O
women	B-MED
having	O
one	O
healthy	B-MED
child	I-MED
as	O
controls	B-MED
(	O
n=73	O
)	O
.	O
Genotyping	B-MED
for	O
SNP-3951C	B-MED
/	I-MED
T	I-MED
was	O
performed	O
by	O
PCR	B-MED
/	I-MED
RFLP	I-MED
.	O
Allele	B-MED
and	O
genotype	B-MED
distribution	B-MED
did	O
not	O
differ	O
significantly	O
between	O
patients	B-MED
and	O
controls	B-MED
(	O
P>0.05	O
)	O
.	O
The	O
LIF	B-MED
genotype	B-MED
frequencies	B-MED
amongst	O
the	O
70	O
cases	B-MED
were	O
C	B-MED
/	I-MED
C	I-MED
=	O
40	O
%	O
,	O
C	B-MED
/	I-MED
T	I-MED
=	O
52.8	O
%	O
and	O
T	B-MED
/	I-MED
T	I-MED
=	O
7.2	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	B-MED
frequencies	B-MED
were	O
66	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O
The	O
LIF	B-MED
genotype	B-MED
frequencies	B-MED
amongst	O
the	O
73	O
controls	B-MED
were	O
C	B-MED
/	I-MED
C	I-MED
=	O
45.20	O
%	O
,	O
C	B-MED
/	I-MED
T	I-MED
=	O
50.70	O
%	O
and	O
T	B-MED
/	I-MED
T	I-MED
=	O
4.1	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	B-MED
frequencies	B-MED
were	O
70	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
the	O
results	B-MED
of	O
this	O
study	O
indicate	O
that	O
SNP	B-MED
3951C	I-MED
/	I-MED
T	I-MED
of	O
LIF	B-MED
may	O
not	O
be	O
associated	B-MED
with	I-MED
IVF	B-MED
-	O
ET	B-MED
outcome	B-MED
in	O
this	O
population	B-MED
.	O
Although	O
more	O
studies	B-MED
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	B-MED
and	O
control	B-MED
subjects	I-MED
to	O
confirm	B-MED
our	O
results	B-MED
.	O
A	O
novel	B-MED
mechanical	B-MED
simulator	I-MED
for	O
cannulation	B-MED
and	O
sphincterotomy	B-MED
after	O
Billroth	B-MED
II	I-MED
or	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
reconstruction	I-MED
In	O
patients	B-MED
with	O
Billroth	B-MED
II	I-MED
(	O
B	B-MED
II	I-MED
)	O
or	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
anatomy	B-MED
,	O
endoscopic	B-MED
retrograde	I-MED
cholangiopancreatography	I-MED
(	O
ERCP	B-MED
)	O
is	O
demanding	O
.	O
Here	O
,	O
we	O
describe	O
a	O
novel	B-MED
simulator	B-MED
with	O
simulated	B-MED
fluoroscopy	B-MED
for	O
cannulation	B-MED
and	O
sphincterotomy	B-MED
training	B-MED
in	O
such	O
situations	O
.	O
A	O
custom	O
-	O
made	O
simulation	B-MED
system	I-MED
was	O
built	B-MED
based	O
upon	O
a	O
common	B-MED
chassis	B-MED
of	O
a	O
series	B-MED
of	O
previously	B-MED
described	O
ERCP	B-MED
simulators	B-MED
.	O
The	O
papilla	B-MED
is	O
made	O
out	O
of	O
organic	B-MED
material	B-MED
and	O
can	O
be	O
cut	B-MED
by	O
high	B-MED
frequency	I-MED
current	B-MED
.	O
The	O
advancement	B-MED
of	O
guidewires	B-MED
and	O
other	O
instruments	B-MED
within	O
transparent	B-MED
mock	O
bile	B-MED
ducts	I-MED
can	O
be	O
viewed	O
in	O
the	O
window	B-MED
of	O
the	O
simulator	B-MED
without	O
the	O
need	O
for	O
fluoroscopy	B-MED
.	O
The	O
ERCP	B-MED
B	B-MED
II	I-MED
/	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
simulation	B-MED
system	I-MED
was	O
first	O
evaluated	B-MED
during	O
an	O
ERCP	B-MED
course	B-MED
.	O
There	O
were	O
no	O
technical	B-MED
problems	I-MED
related	O
to	O
the	O
novel	B-MED
simulator	B-MED
during	O
the	O
course	B-MED
.	O
After	O
sphincterotomy	B-MED
,	O
the	O
organic	B-MED
papillae	B-MED
could	O
easily	O
be	O
exchanged	B-MED
within	O
a	O
few	O
seconds	B-MED
.	O
Overall	O
,	O
the	O
novel	B-MED
B	B-MED
II	I-MED
/	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
simulator	B-MED
achieved	O
favorable	B-MED
results	B-MED
by	O
trainees	B-MED
and	O
expert	B-MED
endoscopists	B-MED
in	O
all	O
categories	B-MED
assessed	B-MED
.	O
The	O
new	O
B	B-MED
II	I-MED
/	O
Roux	B-MED
-	I-MED
en	I-MED
-	I-MED
Y	I-MED
mechanical	B-MED
simulator	I-MED
is	O
simple	B-MED
and	O
practicable	B-MED
.	O
A	O
first	O
evaluation	B-MED
during	O
an	O
ERCP	B-MED
course	B-MED
showed	O
promising	O
results	B-MED
.	O
Overall	O
Quality	B-MED
Properties	I-MED
of	O
Kiwifruit	B-MED
Treated	B-MED
by	I-MED
Cinnamaldehyde	B-MED
and	O
Citral	B-MED
:	O
Microbial	B-MED
,	O
Antioxidant	B-MED
Capacity	I-MED
during	O
Cold	B-MED
Storage	I-MED
This	O
work	O
was	O
undertaken	O
to	O
evaluate	B-MED
the	O
microbiological	B-MED
characteristics	B-MED
and	O
antioxidant	B-MED
and	O
physiological	B-MED
activities	I-MED
in	O
kiwifruits	B-MED
(	O
Actinida	B-MED
deliciosa	I-MED
var	O
.	O
Qinmei	O
)	O
with	O
/	O
without	O
cinnamaldehyde	B-MED
(	O
C1	O
)	O
and	O
citral	B-MED
(	O
C2	O
)	O
fumigation	B-MED
treatments	B-MED
(	O
5	O
μL	O
/	O
L	O
)	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	B-MED
at	O
4	O
°	O
C	O
.	O
Essential	B-MED
oils	I-MED
(	O
EOs	B-MED
)	O
treatment	B-MED
lowered	O
the	O
total	O
viable	B-MED
counts	I-MED
,	O
yeast	B-MED
,	O
and	O
mold	B-MED
to	O
1.54	O
,	O
2.36	O
,	O
and	O
2.05	O
log	O
CFU	O
/	O
g	O
,	O
respectively	O
.	O
Moreover	O
,	O
EOs	B-MED
improved	O
the	O
antioxidant	B-MED
activities	I-MED
of	O
kiwifruit	B-MED
.	O
They	O
enhanced	B-MED
phenolics	B-MED
and	O
flavonoids	B-MED
content	O
in	O
fruit	B-MED
tissue	B-MED
by	O
49.48	O
%	O
at	O
day	O
3	O
and	O
56.93	O
%	O
at	O
day	O
6	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
ascorbic	B-MED
acid	I-MED
in	O
treated	B-MED
groups	B-MED
had	O
the	O
lower	O
losing	O
rate	B-MED
.	O
Similarly	O
,	O
MDA	B-MED
(	O
malondialdehyde	B-MED
)	O
,	O
H2	B-MED
O2	I-MED
(	O
hydrogen	B-MED
peroxide	I-MED
)	O
,	O
and	O
(	O
•	O
)	O
O2(-	B-MED
)	I-MED
(	O
superoxide	B-MED
anion	I-MED
)	O
production	O
were	O
effectively	B-MED
decreased	B-MED
in	O
the	O
range	O
of	O
27.27	O
%	O
to	O
54.38	O
%	O
.	O
Physicochemical	B-MED
characteristics	I-MED
showed	O
that	O
kiwifruits	B-MED
from	O
treated	B-MED
group	B-MED
maintained	O
higher	O
levels	O
of	O
flesh	B-MED
luminosity	I-MED
and	O
firmness	B-MED
.	O
EOs	B-MED
also	O
decreased	B-MED
the	O
levels	O
of	O
reducing	B-MED
sugar	I-MED
by	O
45.97	O
%	O
at	O
day	O
3	O
,	O
and	O
increased	B-MED
the	O
content	O
of	O
soluble	B-MED
protein	I-MED
and	O
hydrolyzed	O
amino	B-MED
acid	I-MED
.	O
Therefore	O
,	O
postharvest	O
EOs	B-MED
treatment	B-MED
has	O
positive	B-MED
effects	I-MED
on	O
delaying	O
senescence	B-MED
and	O
enhancing	B-MED
antioxidant	B-MED
capacities	I-MED
in	O
kiwifruit	B-MED
.	O
Simultaneous	B-MED
thrombosis	B-MED
of	O
multiple	B-MED
coronary	I-MED
arteries	I-MED
in	O
a	O
patient	B-MED
with	O
rheumatoid	B-MED
arthritis	I-MED
We	O
present	O
a	O
case	B-MED
of	O
simultaneous	B-MED
coronary	B-MED
thrombosis	I-MED
of	I-MED
the	I-MED
left	I-MED
main	I-MED
,	O
the	O
left	B-MED
anterior	I-MED
descending	I-MED
artery	I-MED
and	O
the	O
right	B-MED
coronary	I-MED
artery	I-MED
in	O
a	O
patient	B-MED
,	O
recently	O
diagnosed	B-MED
with	O
rheumatoid	B-MED
arthritis	I-MED
.	O
Effects	B-MED
of	I-MED
Application	B-MED
of	O
Social	B-MED
Marketing	I-MED
Theory	B-MED
and	O
the	O
Health	B-MED
Belief	I-MED
Model	I-MED
in	O
Promoting	B-MED
Cervical	B-MED
Cancer	I-MED
Screening	I-MED
among	O
Targeted	B-MED
Women	B-MED
in	O
Sisaket	B-MED
Province	I-MED
,	O
Thailand	B-MED
Cervical	B-MED
cancer	I-MED
is	O
a	O
major	B-MED
public	B-MED
health	I-MED
problem	I-MED
in	O
Thailand	B-MED
,	O
being	O
ranked	B-MED
second	O
only	O
to	O
breast	B-MED
cancer	I-MED
.	O
Thai	B-MED
women	B-MED
have	O
been	O
reported	B-MED
to	O
have	O
a	O
low	B-MED
rate	B-MED
of	O
cervical	B-MED
cancer	I-MED
screening	I-MED
(	O
27.7	O
%	O
of	O
the	O
80	O
%	O
goal	B-MED
of	O
WHO	B-MED
)	O
.	O
We	O
therefore	O
aimed	B-MED
to	O
apply	B-MED
the	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
health	B-MED
belief	I-MED
model	I-MED
in	O
promoting	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
in	O
Kanthararom	B-MED
District	I-MED
,	O
Sisaket	B-MED
Province	I-MED
.	O
A	O
total	B-MED
of	O
92	O
from	O
974	O
targeted	B-MED
women	B-MED
aged	B-MED
3060	O
years	B-MED
were	O
randomly	B-MED
divided	B-MED
into	O
two	O
groups	B-MED
.	O
The	O
experimental	B-MED
group	I-MED
underwent	O
application	B-MED
of	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
a	O
health	B-MED
belief	I-MED
model	I-MED
program	B-MED
promoting	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
while	O
the	O
control	B-MED
group	I-MED
received	B-MED
normal	B-MED
services	I-MED
.	O
Two	O
research	B-MED
tools	I-MED
were	O
used	O
:	O
(	O
1	O
)	O
application	B-MED
of	O
social	B-MED
marketing	I-MED
theory	B-MED
and	O
health	B-MED
belief	I-MED
model	I-MED
program	B-MED
and	O
(	O
2	O
)	O
questionnaire	B-MED
used	O
to	O
evaluate	B-MED
perceptions	B-MED
of	O
cervical	B-MED
cancer	I-MED
.	O
Descriptive	B-MED
and	O
inferential	B-MED
statistics	I-MED
including	B-MED
paired	B-MED
sample	B-MED
ttest	I-MED
and	O
independent	B-MED
ttest	B-MED
were	O
used	O
to	O
analyze	B-MED
the	I-MED
data	I-MED
.	O
After	O
the	O
program	B-MED
had	O
been	O
used	O
,	O
the	O
mean	B-MED
score	I-MED
of	O
perception	B-MED
of	O
cervical	B-MED
cancer	I-MED
of	O
experimental	B-MED
group	I-MED
was	O
at	O
a	O
higher	B-MED
level	B-MED
(	O
x=4.09	O
;	O
S.D.	B-MED
=	O
0.30	O
)	O
,	O
than	O
in	O
the	O
control	B-MED
group	I-MED
(	O
x=3.82	O
;	O
S.D.	B-MED
=	O
0.20	O
)	O
with	O
statistical	B-MED
significance	I-MED
(	O
p<0.001	O
)	O
.	O
This	O
research	B-MED
demonstrated	O
an	O
appropriate	B-MED
communication	B-MED
process	B-MED
in	O
behavioral	B-MED
modification	B-MED
to	O
prevent	O
cervical	B-MED
cancer	I-MED
.	O
It	O
can	O
be	O
recommended	B-MED
that	O
this	O
program	B-MED
featuring	B-MED
social	B-MED
marketing	I-MED
and	O
the	O
health	B-MED
belief	I-MED
model	I-MED
be	O
used	O
to	O
promote	B-MED
cervical	B-MED
cancer	I-MED
screening	I-MED
in	O
targeted	B-MED
women	B-MED
and	O
it	O
can	O
be	O
promoted	B-MED
as	O
a	O
guideline	B-MED
for	O
other	O
health	B-MED
services	I-MED
,	O
especially	O
in	O
health	B-MED
promotion	I-MED
and	O
disease	B-MED
prevention	I-MED
.	O
Active	B-MED
packaging	B-MED
of	O
chicken	B-MED
meats	I-MED
with	O
modified	B-MED
atmosphere	B-MED
including	O
oxygen	B-MED
scavengers	B-MED
The	O
effects	B-MED
of	I-MED
modified	B-MED
atmosphere	B-MED
packaging	B-MED
(	O
MAP	B-MED
-70	O
%	O
CO2	B-MED
/30	O
%	O
N2	B-MED
)	O
and	O
iron	B-MED
-based	O
oxygen	B-MED
scavengers	B-MED
(	O
OS	B-MED
)	O
with	O
various	O
absorption	O
capacities	O
(	O
Ageless	O
(	O
®	O
)	O
ss100	O
,	O
ss300	O
,	O
and	O
ss500	O
)	O
as	O
an	O
active	O
packaging	B-MED
system	I-MED
on	O
microbiological	B-MED
and	O
oxidative	B-MED
changes	B-MED
in	O
chicken	B-MED
thigh	I-MED
meats	I-MED
were	O
evaluated	O
during	O
refrigerated	B-MED
storage	I-MED
(	O
4	O
°	O
C	O
)	O
for	O
19	O
d	O
at	O
3-	O
day	B-MED
intervals	B-MED
.	O
Total	B-MED
aerobic	I-MED
mesophilic	I-MED
bacteria	I-MED
counts	I-MED
exceeded	O
the	O
acceptability	B-MED
limit	I-MED
at	O
d	O
7	O
in	O
the	O
control	B-MED
group	I-MED
without	O
MAP	B-MED
(	O
AIR	B-MED
)	O
,	O
and	O
at	O
d	O
19	O
in	O
MAP	B-MED
and	O
OS	B-MED
containing	O
samples	B-MED
.	O
OS	B-MED
utilization	B-MED
resulted	O
in	O
around	O
1.5	O
and	O
1.0	O
log	O
unit	O
reductions	B-MED
in	O
Pseudomonas	B-MED
spp	I-MED
.	I-MED
counts	B-MED
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	B-MED
,	O
respectively	O
,	O
as	O
compared	O
with	O
AIR	B-MED
and	O
MAP	B-MED
groups	B-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
MAP	B-MED
and	O
OS	B-MED
groups	B-MED
had	O
fewer	O
(	O
P	O
<	O
0.05	O
)	O
coliform	B-MED
counts	I-MED
than	O
did	O
the	O
AIR	B-MED
group	B-MED
,	O
with	O
an	O
approximately	O
1.0	O
log	O
reduction	B-MED
observed	O
at	O
d	O
10	O
.	O
Although	O
in	O
some	O
cases	B-MED
OS	B-MED
utilization	B-MED
resulted	O
in	O
lower	O
TBARS	B-MED
values	B-MED
and	O
carbonyl	B-MED
and	O
sulphydryl	B-MED
contents	I-MED
,	O
particularly	O
during	O
later	O
stages	B-MED
of	O
refrigerated	B-MED
storage	I-MED
as	O
compared	O
to	O
AIR	B-MED
and	O
MAP	B-MED
groups	B-MED
,	O
in	O
general	O
,	O
these	O
effects	B-MED
were	O
not	O
always	O
apparent	O
.	O
The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
MAP	B-MED
suppressed	B-MED
microbiological	B-MED
growth	I-MED
and	O
retarded	O
lipid	B-MED
and	O
protein	B-MED
oxidation	I-MED
in	O
chicken	B-MED
thigh	I-MED
meats	I-MED
,	O
with	O
a	O
9-	O
day	B-MED
shelf	B-MED
-	I-MED
life	I-MED
extention	O
with	O
insignificant	O
effects	B-MED
of	I-MED
OS	B-MED
.	O
Grapevine	B-MED
Subtilase	B-MED
Family	I-MED
:	O
Update	O
on	O
New	O
Sequences	B-MED
and	O
Nomenclature	B-MED
Proposal	I-MED
In	O
grapevine	B-MED
,	O
serine	B-MED
peptidases	I-MED
from	O
the	O
subtilase	B-MED
family	I-MED
were	O
recently	O
associated	O
to	O
Plasmopara	B-MED
viticola	I-MED
resistance	B-MED
.	O
This	O
family	O
in	O
grapevine	B-MED
,	O
first	O
characterized	O
in	O
2014	O
,	O
was	O
re	B-MED
-	I-MED
analyzed	I-MED
last	O
year	O
and	O
82	O
subtilase	B-MED
genes	B-MED
were	O
identified	O
.	O
However	O
,	O
in	O
November	O
of	O
2016	O
,	O
the	O
National	B-MED
Center	I-MED
for	I-MED
Biotechnology	I-MED
Information	I-MED
database	B-MED
(	O
NCBI	B-MED
)	O
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	B-MED
genome	B-MED
annotation	I-MED
based	O
on	O
new	O
sequencing	B-MED
data	I-MED
and	O
better	O
prediction	B-MED
algorithms	B-MED
.	O
As	O
a	O
consequence	B-MED
,	O
some	O
gene	B-MED
annotations	I-MED
and	O
lengths	O
changed	O
.	O
Here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	B-MED
subtilase	B-MED
gene	B-MED
family	I-MED
sequences	B-MED
(	O
SBT	B-MED
)	O
,	O
namely	O
sequence	B-MED
identifiers	I-MED
,	O
bioinformatic	B-MED
predictions	B-MED
and	O
recommend	O
a	O
nomenclature	B-MED
for	O
the	O
grapevine	B-MED
SBT	B-MED
genes	B-MED
.	O
Our	O
results	B-MED
show	O
that	O
grapevine	B-MED
subtilase	B-MED
gene	B-MED
family	I-MED
is	O
now	O
constituted	O
by	O
87	O
subtilase	B-MED
genes	B-MED
encoding	B-MED
for	O
109	O
subtilase	B-MED
proteins	I-MED
and	O
,	O
despite	O
the	O
reported	O
alterations	B-MED
,	O
expression	B-MED
data	B-MED
on	O
subtilases	B-MED
associated	O
to	O
grapevine	B-MED
resistance	B-MED
to	O
P.	B-MED
viticola	I-MED
pathosystem	B-MED
did	O
not	O
suffer	O
any	O
alteration	B-MED
.	O
Associations	B-MED
between	O
human	B-MED
breast	I-MED
milk	I-MED
hormones	B-MED
and	O
adipocytokines	B-MED
and	O
infant	B-MED
growth	I-MED
and	O
body	B-MED
composition	I-MED
in	O
the	O
first	B-MED
6	I-MED
months	I-MED
of	I-MED
life	I-MED
Much	O
is	O
to	O
be	O
learnt	O
about	O
human	B-MED
breast	I-MED
milk	I-MED
(	O
HBM	B-MED
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	B-MED
by	O
investigating	O
the	O
role	O
of	O
maternal	B-MED
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
,	O
sex	B-MED
and	O
stage	B-MED
of	I-MED
lactation	I-MED
(	O
month	O
1	O
vs.	O
6	O
)	O
on	O
HBM	B-MED
insulin	B-MED
,	O
glucose	B-MED
,	O
leptin	B-MED
,	O
IL-6	B-MED
and	O
TNF	B-MED
-	I-MED
α	I-MED
and	O
their	O
associations	B-MED
with	O
infant	B-MED
body	B-MED
composition	I-MED
.	O
Thirty	O
-	O
seven	O
exclusively	O
breastfeeding	B-MED
infants	I-MED
(	O
n	O
=	O
37	O
;	O
16	O
♀	O
,	O
21	O
♂	O
)	O
,	O
and	O
their	O
mothers	B-MED
(	O
19	O
-	O
47	O
kg	O
m(-2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	B-MED
.	O
Infants	B-MED
had	O
body	B-MED
composition	I-MED
measured	I-MED
(	O
using	O
dual	B-MED
-	I-MED
energy	I-MED
X	I-MED
-	I-MED
ray	I-MED
absorptiometry	I-MED
)	O
and	O
HBM	B-MED
collected	O
.	O
A	O
significant	O
interaction	B-MED
between	O
maternal	B-MED
BMI	B-MED
and	O
infant	B-MED
sex	I-MED
on	O
insulin	B-MED
levels	I-MED
(	O
p	O
=	O
0.0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	B-MED
was	I-MED
229	I-MED
%	I-MED
higher	I-MED
in	O
obese	B-MED
mothers	B-MED
nursing	O
female	B-MED
infants	I-MED
than	O
in	O
normal	B-MED
weight	I-MED
mothers	B-MED
nursing	B-MED
nursing	B-MED
female	B-MED
infants	I-MED
and	O
179	O
%	O
higher	O
than	O
obese	B-MED
mothers	B-MED
nursing	O
male	B-MED
infants	I-MED
.	O
For	O
leptin	B-MED
,	O
a	O
significant	O
association	B-MED
with	O
BMI	B-MED
category	O
was	O
observed	O
(	O
p	O
<	O
0.0001	O
)	O
such	O
that	O
overweight	B-MED
and	O
obese	B-MED
mothers	B-MED
had	O
96.5	O
%	O
and	O
315.1	O
%	O
higher	B-MED
leptin	I-MED
levels	I-MED
than	O
normal	B-MED
weight	I-MED
mothers	B-MED
,	O
respectively	O
.	O
Leptin	B-MED
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0.0004	O
)	O
33.7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	B-MED
category	O
and	O
sex	B-MED
.	O
A	O
significant	O
inverse	B-MED
relationship	B-MED
between	O
month	O
1	O
leptin	B-MED
levels	B-MED
and	O
infant	B-MED
length	I-MED
(	O
p	O
=	O
0.0257	O
)	O
,	O
percent	B-MED
fat	I-MED
(	O
p	O
=	O
0.0223	O
)	O
,	O
total	B-MED
fat	I-MED
mass	I-MED
(	O
p	O
=	O
0.0226	O
)	O
and	O
trunk	B-MED
fat	I-MED
mass	I-MED
(	O
p	O
=	O
0.0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O
No	O
associations	B-MED
or	O
interactions	B-MED
were	O
observed	O
for	O
glucose	B-MED
,	O
TNF	B-MED
-	I-MED
α	I-MED
or	O
IL-6	B-MED
.	O
These	O
data	O
demonstrate	O
that	O
maternal	B-MED
BMI	B-MED
,	O
infant	B-MED
sex	B-MED
and	O
stage	B-MED
of	I-MED
lactation	I-MED
affect	O
the	O
compositional	O
make	O
-	O
up	O
of	O
insulin	B-MED
and	O
leptin	B-MED
.	O
Bilateral	B-MED
sternal	B-MED
infusion	B-MED
of	O
ropivacaine	B-MED
and	O
length	B-MED
of	I-MED
stay	I-MED
in	O
ICU	B-MED
after	O
cardiac	B-MED
surgery	I-MED
with	O
increased	B-MED
respiratory	B-MED
risk	I-MED
:	O
A	O
randomised	B-MED
controlled	I-MED
trial	I-MED
The	O
continuous	O
bilateral	B-MED
infusion	B-MED
of	O
a	O
local	B-MED
anaesthetic	I-MED
solution	B-MED
around	O
the	O
sternotomy	B-MED
wound	B-MED
(	O
bilateral	B-MED
sternal	B-MED
)	O
is	O
an	O
innovative	O
technique	B-MED
for	O
reducing	B-MED
pain	B-MED
after	O
sternotomy	B-MED
.	O
To	O
assess	O
the	O
effects	B-MED
of	O
the	O
technique	B-MED
on	O
the	O
need	O
for	O
intensive	B-MED
care	I-MED
in	O
cardiac	B-MED
patients	I-MED
at	O
increased	B-MED
risk	B-MED
of	O
respiratory	B-MED
complications	I-MED
.	O
Randomised	B-MED
,	I-MED
observer	I-MED
-	I-MED
blind	I-MED
controlled	I-MED
trial	I-MED
.	O
Single	O
centre	O
,	O
French	B-MED
University	I-MED
Hospital	I-MED
.	O
In	O
total	O
,	O
120	O
adults	B-MED
scheduled	O
for	O
open	B-MED
-	I-MED
heart	I-MED
surgery	I-MED
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	B-MED
more	O
than	O
75	O
years	B-MED
,	O
BMI	B-MED
>	O
30	O
kg	O
m	O
,	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
,	O
active	B-MED
smoking	I-MED
habit	I-MED
.	O
Either	O
a	O
bilateral	B-MED
sternal	B-MED
infusion	B-MED
of	O
0.2	O
%	O
ropivacaine	B-MED
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	B-MED
;	O
'	B-MED
intervention	I-MED
'	I-MED
group	I-MED
)	O
,	O
or	O
standardised	B-MED
care	I-MED
only	O
(	O
'	B-MED
control	I-MED
'	I-MED
group	I-MED
)	O
.	O
Analgesia	B-MED
was	O
provided	O
with	O
paracetamol	B-MED
and	O
self	B-MED
-	I-MED
administered	I-MED
intravenous	B-MED
morphine	B-MED
.	O
The	O
length	B-MED
of	I-MED
time	I-MED
to	O
readiness	B-MED
for	O
discharge	B-MED
from	O
ICU	B-MED
,	O
blindly	O
assessed	B-MED
by	O
a	O
committee	B-MED
of	O
experts	B-MED
.	O
No	B-MED
effect	I-MED
was	O
found	O
between	O
groups	B-MED
for	O
the	O
primary	B-MED
outcome	I-MED
(	O
P	O
=	O
0.680	O
,	O
intention	B-MED
to	I-MED
treat	I-MED
)	O
;	O
the	O
median	B-MED
values	I-MED
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	B-MED
and	O
intervention	B-MED
groups	I-MED
(	O
P	O
=	O
0.873	O
)	O
.	O
Similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-MED
delays	B-MED
.	O
Significant	O
effects	B-MED
favouring	O
the	O
intervention	B-MED
were	O
noted	O
for	O
dynamic	B-MED
pain	I-MED
,	O
patient	B-MED
satisfaction	I-MED
,	O
occurrence	B-MED
of	I-MED
nausea	I-MED
and	O
vomiting	B-MED
,	O
occurrence	B-MED
of	O
delirium	B-MED
or	O
mental	B-MED
confusion	I-MED
and	O
occurrence	B-MED
of	O
pulmonary	B-MED
complications	I-MED
.	O
In	O
12	O
patients	B-MED
,	O
although	O
no	O
symptoms	B-MED
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B-MED
symptoms	I-MED
have	O
been	O
observed	O
in	O
healthy	B-MED
volunteers	I-MED
.	O
Because	O
of	O
a	O
small	B-MED
size	I-MED
effect	I-MED
,	O
and	O
despite	O
significant	O
analgesic	B-MED
effects	I-MED
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	B-MED
spent	O
in	O
ICU	B-MED
.	O
EudraCT	B-MED
(	O
N	O
°	O
:	O
2012	O
-	O
005225	O
-	O
69	O
)	O
;	O
ClinicalTrials.gov	B-MED
(	O
NCT01828788	O
)	O
.	O
Dual	B-MED
-	I-MED
color	I-MED
STED	I-MED
microscopy	I-MED
reveals	O
a	O
sandwich	B-MED
structure	I-MED
of	O
Bassoon	B-MED
and	O
Piccolo	B-MED
in	O
active	B-MED
zones	I-MED
of	O
adult	B-MED
and	O
aged	B-MED
mice	B-MED
Presynaptic	B-MED
active	I-MED
zones	I-MED
play	O
a	O
pivotal	O
role	O
as	O
synaptic	B-MED
vesicle	I-MED
release	B-MED
sites	I-MED
for	O
synaptic	B-MED
transmission	I-MED
,	O
but	O
the	O
molecular	B-MED
architecture	I-MED
of	O
active	B-MED
zones	I-MED
in	O
mammalian	B-MED
neuromuscular	B-MED
junctions	I-MED
(	O
NMJs	B-MED
)	O
at	O
sub	B-MED
-	I-MED
diffraction	I-MED
limited	I-MED
resolution	I-MED
remains	O
unknown	O
.	O
Bassoon	B-MED
and	O
Piccolo	B-MED
are	O
active	B-MED
zone	I-MED
specific	O
cytosolic	B-MED
proteins	B-MED
essential	O
for	O
active	B-MED
zone	I-MED
assembly	I-MED
in	O
NMJs	B-MED
,	O
ribbon	B-MED
synapses	I-MED
,	O
and	O
brain	B-MED
synapses	B-MED
.	O
These	O
proteins	B-MED
are	O
thought	O
to	O
colocalize	B-MED
and	O
share	O
some	O
functions	O
at	O
active	B-MED
zones	I-MED
.	O
Here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non	B-MED
-	I-MED
overlapping	I-MED
localization	I-MED
of	O
these	O
two	O
proteins	B-MED
in	O
mouse	B-MED
NMJs	B-MED
revealed	O
using	O
dual	B-MED
-	I-MED
color	I-MED
stimulated	I-MED
emission	I-MED
depletion	I-MED
(	O
STED	B-MED
)	O
super	B-MED
resolution	I-MED
microscopy	I-MED
.	O
Piccolo	B-MED
puncta	B-MED
sandwiched	O
Bassoon	B-MED
puncta	B-MED
and	O
aligned	B-MED
in	O
a	O
Piccolo	B-MED
-	O
Bassoon	B-MED
-	O
Piccolo	B-MED
structure	B-MED
in	O
adult	B-MED
NMJs	B-MED
.	O
P	B-MED
/	I-MED
Q	I-MED
-	I-MED
type	I-MED
voltage	I-MED
-	I-MED
gated	I-MED
calcium	I-MED
channel	I-MED
(	O
VGCC	B-MED
)	O
puncta	B-MED
colocalized	B-MED
with	O
Bassoon	B-MED
puncta	B-MED
.	O
The	O
P	B-MED
/	I-MED
Q	I-MED
-	I-MED
type	I-MED
VGCC	I-MED
and	O
Bassoon	B-MED
protein	B-MED
levels	I-MED
decreased	B-MED
significantly	O
in	O
NMJs	B-MED
from	O
aged	B-MED
mouse	B-MED
.	O
In	O
contrast	O
,	O
the	O
Piccolo	B-MED
levels	B-MED
in	O
NMJs	B-MED
from	O
aged	B-MED
mice	B-MED
were	O
comparable	O
to	O
levels	B-MED
in	O
adult	B-MED
mice	B-MED
.	O
This	O
study	O
revealed	O
the	O
molecular	B-MED
architecture	I-MED
of	O
active	B-MED
zones	I-MED
in	O
mouse	B-MED
NMJs	B-MED
at	O
sub	B-MED
-	I-MED
diffraction	I-MED
limited	I-MED
resolution	I-MED
,	O
and	O
described	O
the	O
selective	B-MED
degeneration	I-MED
mechanism	I-MED
of	O
active	B-MED
zone	I-MED
proteins	B-MED
in	O
NMJs	B-MED
from	O
aged	B-MED
mice	B-MED
.	O
Interestingly	O
,	O
the	O
localization	B-MED
pattern	I-MED
of	O
active	B-MED
zone	I-MED
proteins	B-MED
described	O
herein	O
is	O
similar	O
to	O
active	B-MED
zone	I-MED
structures	B-MED
described	O
using	O
electron	B-MED
microscope	I-MED
tomography	I-MED
.	O
Description	B-MED
of	O
Ancylomarina	B-MED
subtilis	I-MED
gen	I-MED
.	I-MED
nov	I-MED
.	I-MED
,	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
,	O
isolated	B-MED
from	O
coastal	B-MED
sediment	I-MED
,	O
proposal	B-MED
of	O
Marinilabiliales	B-MED
ord	I-MED
.	I-MED
nov	I-MED
.	I-MED
and	O
transfer	B-MED
of	O
Marinilabiliaceae	B-MED
,	O
Prolixibacteraceae	B-MED
and	O
Marinifilaceae	B-MED
to	O
the	O
order	B-MED
Marinilabiliales	B-MED
A	O
Gram	B-MED
-	I-MED
stain	I-MED
-	I-MED
negative	I-MED
,	O
facultatively	B-MED
anaerobic	I-MED
,	O
moderately	B-MED
halophilic	I-MED
,	O
filamentous	B-MED
,	O
non	B-MED
-	I-MED
motile	I-MED
bacterium	I-MED
,	O
designated	B-MED
FA102	B-MED
T	I-MED
,	O
was	O
isolated	B-MED
from	O
marine	B-MED
sediment	I-MED
of	O
the	O
coast	B-MED
of	O
Weihai	B-MED
,	I-MED
China	I-MED
.	O
Phylogenetic	B-MED
analysis	I-MED
based	B-MED
on	O
16S	B-MED
rRNA	I-MED
gene	I-MED
sequences	I-MED
showed	B-MED
that	O
strain	B-MED
FA102	B-MED
T	I-MED
formed	O
a	O
distinct	B-MED
evolutionary	B-MED
lineage	B-MED
within	O
the	O
family	B-MED
Marinifilaceae	B-MED
and	O
its	O
closest	B-MED
relative	I-MED
was	O
Marinifilum	B-MED
fragile	I-MED
JCM	I-MED
15579	I-MED
T	I-MED
(	O
93.2	O
%	O
sequence	B-MED
similarity	I-MED
)	O
.	O
The	O
DNA	B-MED
G+C	B-MED
content	I-MED
of	O
the	O
novel	B-MED
strain	B-MED
was	O
36.5	O
mol%	O
.	O
The	O
predominant	B-MED
cellular	B-MED
fatty	B-MED
acids	I-MED
and	O
respiratory	B-MED
quinone	B-MED
were	O
iso	B-MED
-	I-MED
C15:0	I-MED
and	O
iso	B-MED
-	I-MED
C15:0	I-MED
3	I-MED
-	I-MED
OH	I-MED
,	O
and	O
MK-7	B-MED
,	O
respectively	B-MED
.	O
On	O
the	O
basis	B-MED
of	O
the	O
phylogenetic	B-MED
,	O
phenotypic	B-MED
and	O
physiological	B-MED
data	B-MED
,	O
strain	B-MED
FA102	B-MED
T	I-MED
represents	B-MED
a	O
novel	B-MED
genus	B-MED
and	O
species	B-MED
,	O
for	O
which	O
the	O
name	O
Ancylomarina	B-MED
subtilis	I-MED
gen	I-MED
.	I-MED
nov	I-MED
.	I-MED
,	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
is	O
proposed	B-MED
.	O
The	O
type	B-MED
strain	B-MED
of	O
Ancylomarina	B-MED
subtilis	I-MED
is	O
FA102	B-MED
T	I-MED
(=	O
KCTC	B-MED
42257	I-MED
T	I-MED
=	O
DSM	B-MED
28825	I-MED
T	I-MED
=	O
CICC	B-MED
10902	I-MED
T	I-MED
)	O
.	O
Furthermore	O
,	O
a	O
new	B-MED
order	B-MED
named	O
Marinilabiliales	B-MED
is	O
proposed	B-MED
to	O
accommodate	B-MED
three	O
families	B-MED
previously	B-MED
classified	B-MED
in	O
the	O
order	B-MED
Bacteroidales	B-MED
.	O
Marinilabiliales	B-MED
ord	I-MED
.	I-MED
nov	I-MED
.	I-MED
encompasses	O
the	O
families	B-MED
Marinilabiliaceae	B-MED
,	O
Prolixibacteraceae	B-MED
and	O
Marinifilaceae	B-MED
.	O
Stepwise	O
cyclopropanation	B-MED
on	O
the	O
polycyclopropanated	B-MED
polyketide	I-MED
formation	O
in	O
jawsamycin	B-MED
biosynthesis	B-MED
Jawsamycin	B-MED
is	O
a	O
polyketide	B-MED
-	O
nucleoside	B-MED
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-MED
moiety	O
on	O
a	O
single	O
polyketide	B-MED
chain	I-MED
.	O
The	O
unexpected	O
isolation	O
of	O
cyclopropane	B-MED
deficient	O
jawsamycin	B-MED
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	B-MED
mechanism	B-MED
for	O
the	O
enzymatic	B-MED
synthesis	B-MED
of	O
this	O
polyketide	B-MED
.	O
The	O
concise	O
timing	O
of	O
the	O
cyclopropanation	B-MED
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction	B-MED
rates	I-MED
of	O
the	O
condensation	B-MED
and	O
cyclopropanation	B-MED
reactions	I-MED
.	O
Liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
quantification	B-MED
of	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
residues	B-MED
in	O
butterbur	B-MED
grown	O
under	O
regulated	B-MED
conditions	I-MED
An	O
analytical	B-MED
method	I-MED
was	O
developed	O
to	O
quantify	B-MED
the	O
residual	B-MED
levels	B-MED
of	O
the	O
neonicotinoid	B-MED
insecticides	I-MED
,	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
,	O
in	O
field	B-MED
-	I-MED
incurred	I-MED
butterbur	B-MED
samples	B-MED
using	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
(	O
LC	B-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
)	O
.	O
Samples	B-MED
were	O
extracted	B-MED
with	O
acetonitrile	B-MED
and	O
partitioned	O
with	O
dichloromethane	B-MED
.	O
After	O
partitioning	O
,	O
purification	B-MED
was	O
conducted	O
using	O
a	O
Florisil	B-MED
(	I-MED
®	I-MED
)	I-MED
cartridge	I-MED
.	O
Linearity	B-MED
of	O
a	O
matrix	B-MED
-	I-MED
matched	I-MED
calibration	I-MED
curve	I-MED
of	O
the	O
two	O
compounds	B-MED
over	O
a	O
concentration	B-MED
range	B-MED
of	O
0.004	O
-	O
0.4μg	O
/	O
g	O
was	O
excellent	O
,	O
with	O
determination	B-MED
coefficients	I-MED
R(2	B-MED
)	I-MED
(	O
R(2))≥0.9998	O
.	O
The	O
limits	B-MED
of	I-MED
detection	I-MED
(	O
LOD	B-MED
)	O
and	O
quantitation	B-MED
(	O
LOQ	B-MED
)	O
for	O
both	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
were	O
0.0006	O
and	O
0.002mg	O
/	O
kg	O
,	O
respectively	O
.	O
The	O
average	O
recoveries	O
for	O
acetamiprid	B-MED
and	O
thiacloprid	B-MED
at	O
two	O
spiking	B-MED
levels	I-MED
(	O
0.02	O
and	O
0.1mg	O
/	O
kg	O
,	O
i.e.	O
,	O
10×	O
LOQ	B-MED
and	O
50×	O
LOQ	B-MED
)	O
were	O
between	O
78.23	O
to	O
82.17	O
%	O
,	O
with	O
relative	B-MED
standard	I-MED
deviations	I-MED
RSDs	B-MED
(	O
RSDs)≤7.22	O
%	O
.	O
The	O
method	B-MED
was	O
successfully	O
applied	O
to	O
field	B-MED
-	I-MED
incurred	I-MED
samples	B-MED
treated	B-MED
with	O
a	O
commercial	B-MED
pesticide	B-MED
product	I-MED
,	O
either	O
once	O
(	O
zero	O
or	O
7	O
days	B-MED
before	O
harvest	B-MED
)	O
or	O
twice	O
(	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	B-MED
before	O
harvest	B-MED
)	O
.	O
The	O
highest	O
and	O
lowest	O
residues	B-MED
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	B-MED
'	O
treatment	B-MED
and	O
the	O
21	O
and	O
14	O
days	B-MED
'	O
treatment	B-MED
,	O
respectively	O
.	O
The	O
developed	O
method	B-MED
is	O
simple	O
and	O
accurate	B-MED
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	B-MED
vegetables	I-MED
.	O
Evaluation	B-MED
of	O
the	O
relationship	B-MED
between	O
the	O
static	B-MED
measurement	B-MED
of	O
transverse	B-MED
arch	I-MED
flexibility	B-MED
of	O
the	O
forefoot	B-MED
and	O
gait	B-MED
parameters	B-MED
in	O
healthy	B-MED
subjects	I-MED
[	O
Purpose	B-MED
]	O
To	O
investigate	B-MED
the	O
relationship	B-MED
between	O
the	O
static	B-MED
measurement	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
,	O
using	O
a	O
3	B-MED
-	I-MED
dimensional	I-MED
(	O
3D	B-MED
)	O
foot	B-MED
scanner	I-MED
,	O
and	O
kinetics	B-MED
and	O
kinematics	B-MED
of	O
gait	B-MED
parameters	B-MED
in	O
the	O
sagittal	B-MED
plane	I-MED
.	O
[	O
Subjects	B-MED
and	O
Methods	B-MED
]	O
Twenty	O
healthy	B-MED
subjects	I-MED
participated	O
in	O
this	O
study	B-MED
.	O
The	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
measured	B-MED
under	O
three	O
conditions	B-MED
as	O
follows	O
:	O
condition	B-MED
1	O
,	O
sitting	B-MED
;	O
condition	B-MED
2	O
,	O
standing	B-MED
;	O
and	O
condition	B-MED
3	O
,	O
foot	B-MED
forward	B-MED
and	O
lower	B-MED
leg	I-MED
tilting	B-MED
anteriorly	B-MED
to	O
the	O
maximum	B-MED
position	B-MED
with	O
heel	B-MED
contact	B-MED
.	O
Gait	B-MED
parameters	B-MED
were	O
recorded	B-MED
using	O
a	O
3D	B-MED
motion	I-MED
analysis	I-MED
system	I-MED
and	O
force	B-MED
plate	I-MED
.	O
Correlation	B-MED
coefficients	B-MED
between	O
TAF	B-MED
for	O
each	O
comparison	B-MED
of	O
conditions	B-MED
and	O
gait	B-MED
parameters	B-MED
were	O
calculated	B-MED
using	O
the	O
Spearman	B-MED
correlation	I-MED
analysis	I-MED
.	O
[	O
Results	B-MED
]	O
Rates	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
width	B-MED
and	O
height	B-MED
between	O
condition	B-MED
2	O
and	O
condition	B-MED
3	O
were	O
significantly	B-MED
correlated	I-MED
with	O
the	O
anterior	B-MED
and	O
posterior	B-MED
component	B-MED
of	O
ground	B-MED
reaction	I-MED
forces	I-MED
,	O
the	O
hip	B-MED
joint	I-MED
extension	B-MED
angle	B-MED
,	O
and	O
the	O
ankle	B-MED
plantar	B-MED
flexion	I-MED
moment	I-MED
.	O
[	O
Conclusion	B-MED
]	O
Our	O
study	B-MED
's	I-MED
findings	B-MED
indicated	B-MED
that	O
increased	B-MED
stiffness	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
related	B-MED
to	O
the	O
increase	B-MED
in	O
ankle	B-MED
plantar	B-MED
moment	I-MED
,	O
and	O
decreased	B-MED
stiffness	B-MED
of	O
the	O
transverse	B-MED
arch	I-MED
of	O
the	O
forefoot	B-MED
was	O
related	B-MED
to	O
the	O
increase	B-MED
in	O
hip	B-MED
joint	I-MED
extension	B-MED
angle	B-MED
during	O
gait	B-MED
.	O
Initial	O
clinical	B-MED
results	I-MED
with	O
the	O
ThermoCool	B-MED
®	I-MED
SmartTouch	I-MED
®	I-MED
Surround	I-MED
Flow	I-MED
catheter	I-MED
The	O
Biosense	B-MED
Webster	I-MED
ThermoCool	I-MED
(	I-MED
®	I-MED
)	I-MED
SmartTouch	I-MED
(	I-MED
®	I-MED
)	I-MED
Surround	I-MED
Flow	I-MED
(	I-MED
STSF	I-MED
)	I-MED
catheter	I-MED
is	O
a	O
recently	O
developed	O
ablation	B-MED
catheter	B-MED
incorporating	O
Surround	B-MED
Flow	I-MED
(	O
SF	B-MED
)	O
technology	B-MED
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	B-MED
tissue	B-MED
contact	B-MED
.	O
In	O
our	O
unit	O
,	O
it	O
superseded	O
the	O
ThermoCool	B-MED
(	I-MED
®	I-MED
)	I-MED
SF	I-MED
catheter	I-MED
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
May	O
2015	O
.	O
Procedure	B-MED
-related	O
data	B-MED
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation	B-MED
procedures	I-MED
performed	O
in	O
our	O
department	O
using	O
the	O
STSF	B-MED
catheter	I-MED
.	O
From	O
a	O
database	B-MED
of	O
654	O
procedures	B-MED
performed	O
in	O
our	O
unit	O
using	O
the	O
SF	B-MED
catheter	I-MED
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
STSF	B-MED
procedure	I-MED
,	O
matching	O
for	O
procedure	B-MED
type	I-MED
,	O
operator	B-MED
experience	B-MED
,	O
patient	B-MED
age	I-MED
,	O
and	O
gender	B-MED
.	O
The	O
groups	B-MED
were	O
well	O
matched	O
for	O
patient	B-MED
age	I-MED
,	O
gender	B-MED
,	O
and	O
procedure	B-MED
type	I-MED
.	O
Procedure	B-MED
duration	I-MED
was	O
similar	O
in	O
both	O
groups	B-MED
(	O
mean	O
225.5	O
vs.	O
221.4	O
min	O
,	O
IQR	B-MED
106.5	O
vs.	O
91.5	O
,	O
P	O
=	O
0.55	O
)	O
,	O
but	O
fluoroscopy	B-MED
duration	I-MED
was	O
shorter	B-MED
in	O
the	O
STSF	B-MED
group	I-MED
(	O
mean	O
25.8	O
vs.	O
30.0	O
,	O
IQR	B-MED
19.6	O
vs.	O
18.5	O
,	O
P	O
=	O
0.03	O
)	O
.	O
No	B-MED
complication	I-MED
occurred	O
in	O
the	O
STSF	B-MED
group	I-MED
.	O
Complications	B-MED
occurred	O
in	O
two	O
cases	B-MED
in	O
the	O
SF	B-MED
group	I-MED
(	O
one	O
pericardial	B-MED
effusion	I-MED
requiring	O
drainage	B-MED
and	O
one	O
need	O
for	O
permanent	B-MED
pacing	B-MED
)	O
.	O
Complete	B-MED
procedural	I-MED
success	I-MED
was	O
achieved	O
in	O
98	O
cases	B-MED
in	O
the	O
STSF	B-MED
group	I-MED
and	O
94	O
cases	B-MED
in	O
the	O
SF	B-MED
group	I-MED
(	O
P	O
=	O
0.15	O
)	O
.	O
The	O
composite	O
endpoint	O
of	O
procedure	O
failure	B-MED
or	O
acute	B-MED
complication	B-MED
was	O
less	O
common	O
in	O
the	O
STSF	B-MED
group	I-MED
(	O
2	O
vs.	O
8	O
,	O
P	O
=	O
0.05	O
)	O
.	O
The	O
STSF	B-MED
catheter	I-MED
is	O
safe	O
and	O
effective	B-MED
in	O
treating	B-MED
a	O
range	O
of	O
arrhythmias	B-MED
.	O
Compared	O
with	O
the	O
SF	B-MED
catheter	I-MED
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	B-MED
-	O
efficacy	B-MED
balance	O
.	O
Diagnosis	B-MED
of	O
retinal	B-MED
health	B-MED
in	O
digital	B-MED
fundus	I-MED
images	I-MED
using	O
continuous	B-MED
wavelet	I-MED
transform	I-MED
(	O
CWT	B-MED
)	O
and	O
entropies	B-MED
Vision	B-MED
is	O
paramount	O
to	O
humans	B-MED
to	O
lead	O
an	O
active	O
personal	B-MED
and	O
professional	B-MED
life	I-MED
.	O
The	O
prevalence	B-MED
of	O
ocular	B-MED
diseases	I-MED
is	O
rising	O
,	O
and	O
diseases	B-MED
such	O
as	O
glaucoma	B-MED
,	O
Diabetic	B-MED
Retinopathy	I-MED
(	O
DR	B-MED
)	O
and	O
Age	B-MED
-	I-MED
related	I-MED
Macular	I-MED
Degeneration	I-MED
(	O
AMD	B-MED
)	O
are	O
the	O
leading	B-MED
causes	B-MED
of	O
blindness	B-MED
in	O
developed	B-MED
countries	I-MED
.	O
Identifying	O
these	O
diseases	B-MED
in	O
mass	B-MED
screening	I-MED
programmes	I-MED
is	O
time	B-MED
-	I-MED
consuming	I-MED
,	O
labor	B-MED
-intensive	O
and	O
the	O
diagnosis	B-MED
can	O
be	O
subjective	B-MED
.	O
The	O
use	O
of	O
an	O
automated	B-MED
computer	I-MED
aided	I-MED
diagnosis	I-MED
system	I-MED
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	B-MED
and	O
will	O
also	O
reduce	O
the	O
inter	B-MED
-	I-MED
observer	I-MED
subjective	I-MED
variabilities	I-MED
in	O
image	B-MED
interpretation	I-MED
.	O
In	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	B-MED
classification	B-MED
of	O
normal	B-MED
from	O
abnormal	B-MED
(	O
DR	B-MED
,	O
AMD	B-MED
,	O
glaucoma	B-MED
)	O
images	B-MED
.	O
We	O
had	O
a	O
total	O
of	O
404	O
normal	B-MED
and	O
1082	O
abnormal	B-MED
fundus	B-MED
images	I-MED
in	O
our	O
database	B-MED
.	O
As	O
the	O
first	O
step	O
,	O
2D	B-MED
-	I-MED
Continuous	I-MED
Wavelet	I-MED
Transform	I-MED
(	O
CWT	B-MED
)	O
decomposition	O
on	O
the	O
fundus	B-MED
images	I-MED
of	O
two	O
classes	O
was	O
performed	O
.	O
Subsequently	O
,	O
energy	B-MED
features	O
and	O
various	O
entropies	B-MED
namely	O
Yager	O
,	O
Renyi	O
,	O
Kapoor	O
,	O
Shannon	O
,	O
and	O
Fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	B-MED
.	O
Then	O
,	O
adaptive	O
synthetic	O
sampling	B-MED
approach	I-MED
was	O
applied	O
to	O
balance	O
the	O
normal	B-MED
and	O
abnormal	B-MED
datasets	B-MED
.	O
Next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
Particle	B-MED
Swarm	I-MED
Optimization	I-MED
(	O
PSO	B-MED
)	O
.	O
Thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	B-MED
10	O
-	O
fold	O
cross	B-MED
validation	I-MED
.	O
Overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	B-MED
rate	I-MED
of	O
92.48	O
%	O
,	O
and	O
a	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
89.37	O
%	O
and	O
95.58	O
%	O
respectively	O
using	O
15	O
features	O
.	O
This	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-MED
fundus	B-MED
images	I-MED
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-MED
health	B-MED
screening	B-MED
tool	I-MED
that	O
could	O
be	O
employed	O
in	O
polyclinics	B-MED
,	O
and	O
thereby	O
reduce	O
the	O
workload	B-MED
of	O
specialists	B-MED
at	O
hospitals	B-MED
.	O
Pre	B-MED
-	I-MED
hospital	I-MED
policies	B-MED
for	O
the	O
care	B-MED
of	I-MED
patients	I-MED
with	O
acute	B-MED
coronary	I-MED
syndromes	I-MED
in	O
India	B-MED
:	O
A	O
policy	B-MED
document	B-MED
analysis	B-MED
Ischemic	B-MED
heart	I-MED
disease	I-MED
is	O
the	O
leading	B-MED
cause	B-MED
of	I-MED
death	I-MED
in	O
India	B-MED
.	O
In	O
high	B-MED
-	I-MED
income	I-MED
countries	B-MED
,	O
pre	B-MED
-	I-MED
hospital	I-MED
systems	I-MED
of	I-MED
care	I-MED
have	O
been	O
developed	O
to	O
manage	B-MED
acute	B-MED
manifestations	B-MED
of	I-MED
ischemic	B-MED
heart	I-MED
disease	I-MED
,	O
such	O
as	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
(	O
ACS	B-MED
)	O
.	O
However	O
,	O
it	O
is	O
unknown	B-MED
whether	O
guidelines	B-MED
,	O
policies	B-MED
,	O
regulations	B-MED
,	O
or	O
laws	B-MED
exist	B-MED
to	O
guide	O
pre	B-MED
-	I-MED
hospital	I-MED
ACS	B-MED
care	B-MED
in	O
India	B-MED
.	O
We	O
undertook	O
a	O
nation	B-MED
-	I-MED
wide	I-MED
document	B-MED
analysis	B-MED
to	O
address	O
this	O
gap	O
in	O
knowledge	B-MED
.	O
From	O
November	B-MED
2014	O
to	O
May	B-MED
2016	O
,	O
we	O
searched	B-MED
for	O
publicly	B-MED
available	B-MED
emergency	B-MED
care	I-MED
guidelines	B-MED
and	O
legislation	B-MED
addressing	O
pre	B-MED
-	I-MED
hospital	I-MED
ACS	B-MED
care	B-MED
in	O
all	O
29	O
Indian	B-MED
states	B-MED
and	O
7	O
Union	B-MED
Territories	I-MED
via	O
Internet	B-MED
search	B-MED
and	O
direct	B-MED
correspondence	B-MED
.	O
We	O
found	B-MED
two	O
documents	B-MED
addressing	O
pre	B-MED
-	I-MED
hospital	I-MED
ACS	B-MED
care	B-MED
.	O
Though	O
India	B-MED
has	O
legislation	B-MED
mandating	I-MED
acute	B-MED
care	I-MED
for	O
emergencies	B-MED
such	O
as	O
trauma	B-MED
,	O
regulations	B-MED
or	O
laws	B-MED
to	O
guide	O
pre	B-MED
-	I-MED
hospital	I-MED
ACS	B-MED
care	B-MED
are	O
largely	O
absent	B-MED
.	O
Policy	B-MED
makers	I-MED
urgently	B-MED
need	B-MED
to	O
develop	O
comprehensive	B-MED
,	O
multi	B-MED
-	I-MED
stakeholder	I-MED
policies	B-MED
for	O
pre	B-MED
-	I-MED
hospital	I-MED
emergency	B-MED
cardiovascular	B-MED
care	I-MED
in	O
India	B-MED
.	O
Potential	B-MED
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
among	O
prescriptions	B-MED
for	O
elderly	B-MED
patients	B-MED
in	O
primary	B-MED
health	I-MED
care	I-MED
Elderly	B-MED
patients	B-MED
are	O
at	O
high	B-MED
risk	I-MED
from	O
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
(	O
DDIs	B-MED
)	O
.	O
This	O
study	B-MED
evaluates	B-MED
the	O
potential	B-MED
DDIs	B-MED
in	O
Turkish	O
elderly	B-MED
patients	B-MED
at	O
a	O
primary	B-MED
health	I-MED
care	I-MED
outpatient	B-MED
clinic	I-MED
.	O
Online	B-MED
database	I-MED
systems	I-MED
were	O
used	O
to	O
examine	O
DDIs	B-MED
on	O
the	O
prescriptions	B-MED
of	O
patients	B-MED
(	O
n	O
=	O
1206	O
)	O
.	O
The	O
clinical	B-MED
severity	I-MED
of	O
DDIs	B-MED
was	O
classified	O
by	O
the	O
Lexi	B-MED
-	I-MED
Interact	I-MED
Online	I-MED
database	I-MED
.	O
Of	O
the	O
5059	O
prescriptions	B-MED
,	O
33	O
%	O
were	O
found	O
to	O
have	O
DDIs	B-MED
.	O
We	O
detected	B-MED
29	O
(	O
0.9	O
%	O
)	O
A	O
,	O
380	O
(	O
11.8	O
%	O
)	O
B	O
,	O
2494	O
(	O
77.7	O
%	O
)	O
C	O
,	O
289	O
(	O
9	O
%	O
)	O
D	O
,	O
and	O
18	O
(	O
0.6	O
%	O
)	O
X	O
risk	O
rating	O
category	O
DDIs	B-MED
among	O
the	O
prescriptions	B-MED
.	O
Prescriptions	B-MED
of	O
female	O
patients	B-MED
and	O
patients	B-MED
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly	B-MED
higher	I-MED
number	O
of	O
DDIs	B-MED
.	O
The	O
frequency	B-MED
of	O
DDIs	B-MED
increased	B-MED
both	O
with	O
the	O
number	O
of	O
drugs	B-MED
and	O
combined	O
preparations	O
per	O
prescription	B-MED
.	O
Acetylsalicylic	B-MED
acid	I-MED
and	O
salbutamol	B-MED
were	O
the	O
most	O
frequently	B-MED
prescribed	B-MED
drugs	B-MED
contributing	O
to	O
clinically	B-MED
important	I-MED
DDIs	B-MED
.	O
Additionally	O
,	O
acetylsalicylic	B-MED
acid	I-MED
and	O
escitalopram	B-MED
,	O
which	O
interact	B-MED
with	O
each	O
other	O
,	O
were	O
found	O
on	O
the	O
list	O
of	O
Beers	B-MED
criteria	I-MED
.	O
The	O
most	O
predicted	B-MED
clinical	I-MED
outcomes	I-MED
of	O
DDIs	B-MED
were	O
increase	O
in	O
therapeutic	B-MED
efficacy	I-MED
and	O
adverse	B-MED
/	O
toxic	B-MED
reactions	I-MED
.	O
Conclusions	O
:	O
Prediction	B-MED
of	O
DDIs	B-MED
in	O
elderly	B-MED
patients	B-MED
will	O
provide	O
better	O
prescribing	B-MED
and	O
drug	B-MED
safety	I-MED
.	O
Use	O
of	O
nonsteroidal	B-MED
anti	I-MED
-	I-MED
inflammatory	I-MED
agents	I-MED
,	O
selective	B-MED
serotonin	I-MED
reuptake	I-MED
inhibitors	I-MED
,	O
and	O
beta-2	B-MED
adrenergic	I-MED
receptor	I-MED
agonists	I-MED
should	O
be	O
closely	O
monitored	O
.	O
Anatomical	B-MED
subgroup	B-MED
analysis	B-MED
of	O
the	O
MERIDIAN	B-MED
cohort	B-MED
:	O
Posterior	B-MED
fossa	I-MED
abnormalities	I-MED
To	O
assess	B-MED
the	O
diagnostic	B-MED
and	O
clinical	B-MED
contribution	B-MED
of	O
in	B-MED
utero	I-MED
magnetic	I-MED
resonance	I-MED
(	I-MED
iuMR	I-MED
)	I-MED
imaging	I-MED
in	O
fetuses	B-MED
diagnosed	B-MED
with	O
abnormalities	B-MED
of	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
as	O
the	O
only	O
intracranial	B-MED
abnormality	I-MED
recognised	O
on	O
antenatal	B-MED
ultrasonography	I-MED
(	O
USS	B-MED
)	O
.	O
We	O
report	B-MED
a	O
sub	B-MED
-	I-MED
group	I-MED
analysis	B-MED
of	O
fetuses	B-MED
with	O
abnormalities	B-MED
of	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
diagnosed	B-MED
on	O
antenatal	B-MED
USS	I-MED
(	O
with	O
or	O
without	O
ventriculomegaly	B-MED
)	O
from	O
the	O
MERIDIAN	B-MED
cohort	B-MED
who	O
had	O
iuMR	B-MED
imaging	I-MED
within	O
2	O
weeks	O
of	O
USS	B-MED
and	O
outcome	B-MED
reference	B-MED
data	I-MED
were	O
available	B-MED
.	O
The	O
diagnostic	B-MED
accuracy	I-MED
of	O
USS	B-MED
and	O
iuMR	B-MED
are	O
reported	B-MED
as	O
well	O
as	O
indicators	B-MED
of	O
diagnostic	B-MED
confidence	I-MED
and	O
effects	B-MED
on	O
prognosis	B-MED
and	O
clinical	B-MED
management	I-MED
.	O
Abnormalities	B-MED
confined	I-MED
to	I-MED
the	I-MED
posterior	I-MED
fossa	I-MED
according	O
to	O
USS	B-MED
were	O
found	O
in	O
81	O
fetuses	B-MED
(	O
67	O
with	O
parenchymal	B-MED
and	O
14	O
with	O
CSF	B-MED
-containing	O
lesions	B-MED
)	O
.	O
The	O
overall	O
diagnostic	B-MED
accuracy	I-MED
for	O
detecting	B-MED
an	O
isolated	B-MED
posterior	B-MED
fossa	I-MED
abnormality	I-MED
was	O
65	O
%	O
for	O
USS	B-MED
and	O
88	O
%	O
for	O
iuMR	B-MED
(	O
difference	B-MED
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14.0	O
to	O
30.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
There	O
was	O
an	O
improvement	B-MED
in	O
'	O
appropriate	B-MED
'	O
diagnostic	B-MED
confidence	I-MED
as	O
assessed	B-MED
by	O
a	O
score	B-MED
-	O
based	B-MED
weighted	B-MED
average	B-MED
'	O
method	B-MED
(	O
p	O
<	O
0.0001	O
)	O
and	O
a	O
three	O
-	O
fold	O
reduction	B-MED
in	O
'	B-MED
high	I-MED
confidence	O
but	O
incorrect	B-MED
diagnoses	B-MED
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-MED
imaging	I-MED
.	O
The	O
prognostic	B-MED
information	I-MED
given	O
to	O
the	O
women	B-MED
after	O
iuMR	B-MED
imaging	I-MED
changed	O
in	O
44	O
%	O
of	O
cases	B-MED
and	O
the	O
overall	B-MED
effect	B-MED
of	O
iuMR	B-MED
on	O
clinical	B-MED
management	I-MED
was	O
considered	O
to	O
be	O
'	O
significant	B-MED
'	O
,	O
'	O
major	B-MED
'	O
or	O
'	O
decisive	B-MED
'	O
in	O
35	O
%	O
of	O
cases	B-MED
.	O
Our	O
data	B-MED
suggests	O
that	O
any	O
woman	B-MED
whose	O
fetus	B-MED
has	O
a	O
posterior	B-MED
fossa	I-MED
abnormality	I-MED
as	O
the	O
only	O
intracranial	B-MED
finding	I-MED
on	O
USS	B-MED
should	O
have	O
iuMR	B-MED
imaging	I-MED
for	O
further	O
evaluation	B-MED
.	O
This	O
is	O
on	O
the	O
basis	B-MED
of	O
improved	B-MED
diagnostic	B-MED
accuracy	I-MED
and	O
confidence	B-MED
which	O
has	O
substantial	B-MED
effects	B-MED
on	O
the	O
prognostic	B-MED
information	I-MED
given	O
to	O
women	B-MED
and	O
changes	O
in	O
clinical	B-MED
management	I-MED
.	O
Estradiol	B-MED
prodrugs	B-MED
(	O
EP	B-MED
)	O
for	O
efficient	O
oral	B-MED
estrogen	B-MED
treatment	I-MED
and	O
abolished	O
effects	O
on	O
estrogen	B-MED
modulated	O
liver	B-MED
functions	I-MED
Oral	B-MED
compared	O
to	O
parenteral	B-MED
estrogen	B-MED
administration	I-MED
is	O
characterized	O
by	O
reduced	O
systemic	B-MED
but	O
prominent	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
on	O
lipids	B-MED
,	O
hemostatic	B-MED
factors	I-MED
,	O
GH	B-MED
-/	O
IGF	B-MED
I	I-MED
axis	O
,	O
angiotensinogen	B-MED
.	O
In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	B-MED
effects	I-MED
of	O
oral	B-MED
treatment	I-MED
,	O
estradiol	B-MED
(	O
E2	B-MED
)	O
prodrugs	B-MED
(	O
EP	B-MED
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	B-MED
tissue	I-MED
as	O
inactive	O
molecules	O
.	O
Carbone17	B-MED
-	I-MED
OH	I-MED
sulfonamide	I-MED
[	I-MED
-O2	I-MED
-	I-MED
NH2	I-MED
]	I-MED
substituted	I-MED
esters	I-MED
of	O
E2	B-MED
(	O
EC508	B-MED
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B-MED
anhydrase	I-MED
II	I-MED
(	O
CA	B-MED
-	I-MED
II	I-MED
)	O
binding	B-MED
.	O
CA	B-MED
II	I-MED
in	O
erythrocytes	B-MED
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	B-MED
from	O
portal	B-MED
vein	I-MED
blood	I-MED
during	O
liver	B-MED
passage	B-MED
.	O
Ovariectomized	B-MED
(	O
OVX	B-MED
,	O
day	O
minus	O
14	O
)	O
rats	B-MED
were	O
orally	B-MED
treated	I-MED
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O
Sacrifice	O
day	O
4	O
.	O
Uteri	B-MED
were	O
dissected	B-MED
and	O
weighed	B-MED
.	O
Cholesterol	B-MED
fractions	I-MED
and	O
angiotensinogen	B-MED
were	O
determined	O
in	O
plasma	B-MED
.	O
Oral	B-MED
E2	I-MED
and	O
ethinyl	B-MED
estradiol	I-MED
(	O
EE	B-MED
)	O
generated	O
dose	O
related	O
uterine	B-MED
growth	B-MED
and	O
important	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
.	O
EP	B-MED
induced	O
uterine	B-MED
growth	I-MED
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O
This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-MED
cholesterol	B-MED
or	O
angiotensinogen	B-MED
.	O
Preliminary	O
pharmacokinetic	B-MED
studies	I-MED
with	O
EC508	B-MED
used	O
intravenous	B-MED
and	O
oral	B-MED
administration	I-MED
in	O
male	B-MED
rats	B-MED
.	O
Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-MED
bioavailability	B-MED
.	O
Further	O
high	O
blood	B-MED
-	O
but	O
low	O
plasma	B-MED
concentrations	O
indicated	O
erythrocyte	B-MED
binding	B-MED
of	O
EC508	B-MED
in	B-MED
vivo	I-MED
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-MED
passage	B-MED
.	O
Very	O
high	O
systemic	B-MED
estrogenicity	B-MED
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-MED
estrogenic	B-MED
effects	I-MED
is	O
evidence	O
for	O
a	O
systemic	B-MED
release	O
of	O
E2	B-MED
from	O
sulfonamide	B-MED
EP	I-MED
.	O
In	O
conclusion	O
,	O
tested	O
oral	B-MED
EP	B-MED
bypass	O
the	O
liver	B-MED
in	O
erythrocytes	B-MED
furnishing	O
systemic	B-MED
estradiol	B-MED
at	O
hydrolysis	B-MED
.	O
This	O
mechanism	O
avoids	O
the	O
hepatic	B-MED
estrogenic	B-MED
impact	O
of	O
conventional	O
oral	B-MED
estrogen	B-MED
therapy	I-MED
.	O
Nutrient	B-MED
intake	I-MED
of	O
infants	B-MED
and	O
toddlers	B-MED
in	O
the	O
United	B-MED
Arab	I-MED
Emirates	I-MED
:	O
the	O
Feeding	O
Infants	B-MED
and	O
Toddlers	B-MED
Study	O
This	O
descriptive	O
study	O
evaluated	O
the	O
nutrient	B-MED
adequacy	I-MED
of	O
the	O
diet	B-MED
of	O
infants	B-MED
(	O
aged	O
6	O
-	O
11.9	O
months	O
)	O
and	O
toddlers	B-MED
(	O
aged	O
12	O
-	O
24	O
months	O
)	O
in	O
the	O
United	B-MED
Arab	I-MED
Emirates	I-MED
.	O
A	O
random	O
sample	O
of	O
1000	O
infants	B-MED
and	O
toddlers	B-MED
was	O
recruited	O
from	O
2	O
cities	O
(	O
Al	B-MED
Ain	I-MED
and	O
Dubai	B-MED
)	O
from	O
March	B-MED
2011	O
to	O
February	B-MED
2012	O
and	O
their	O
usual	O
nutrient	B-MED
intake	I-MED
was	O
determined	O
using	O
24	O
-	O
hour	O
recall	O
.	O
In	O
all	O
,	O
54.2	O
%	O
of	O
infants	B-MED
and	O
25.2	O
%	O
of	O
toddlers	B-MED
were	O
breastfeeding	B-MED
.	O
Mean	O
energy	B-MED
intake	I-MED
of	O
infant	B-MED
girls	I-MED
in	O
Al	B-MED
Ain	I-MED
and	O
Dubai	B-MED
was	O
747	O
(	O
SD	O
189	O
)	O
kcal	B-MED
and	O
773	O
(	O
SD	O
215	O
)	O
kcal	B-MED
respectively	O
and	O
810.5	O
(	O
SD	O
232.2	O
)	O
kcal	B-MED
and	O
821.9	O
(	O
SD	O
262	O
)	O
kcal	B-MED
for	O
boys	B-MED
.	O
In	O
toddlers	B-MED
,	O
mean	O
energy	B-MED
intake	I-MED
for	O
girls	B-MED
in	O
Al	O
Ain	O
and	O
Dubai	O
was	O
1032.8	O
(	O
SD	O
252	O
)	O
kcal	B-MED
and	O
1013	O
(	O
SD	O
339.1	O
)	O
kcal	B-MED
respectively	O
and	O
1057.2	O
(	O
SD	O
201.8	O
)	O
kcal	B-MED
and	O
1030.3	O
(	O
SD	O
341.7	O
)	O
kcal	B-MED
for	O
boys	B-MED
.	O
Iron	B-MED
intake	I-MED
was	O
low	B-MED
in	O
both	O
groups	O
.	O
Mean	O
body	B-MED
mass	I-MED
index	I-MED
and	O
body	B-MED
weight	I-MED
and	O
height	B-MED
were	O
similar	O
to	O
World	B-MED
Health	I-MED
Organization	I-MED
figures	O
but	O
significant	O
numbers	O
of	O
infants	B-MED
and	O
toddlers	B-MED
of	O
both	O
sexes	O
were	O
over	B-MED
-	O
or	O
underweight	B-MED
.	O
Although	O
mean	O
energy	O
and	O
macronutrient	B-MED
intakes	B-MED
were	O
comparable	O
to	O
the	O
RDA	B-MED
,	O
significant	O
numbers	O
were	O
over	B-MED
-	O
or	O
underfed	B-MED
.	O
Dobutamine	B-MED
Stress	I-MED
Echocardiography	I-MED
:	O
Impact	B-MED
of	O
Abnormal	B-MED
Blood	B-MED
Potassium	I-MED
Levels	I-MED
on	O
Cardiac	B-MED
Arrhythmias	I-MED
Guidelines	B-MED
suggest	O
that	O
an	O
abnormal	B-MED
blood	B-MED
potassium	I-MED
level	I-MED
is	O
a	O
relative	O
contraindication	B-MED
to	O
performing	B-MED
dobutamine	B-MED
stress	I-MED
echocardiography	I-MED
(	O
DSE	B-MED
)	O
.	O
However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O
We	O
reviewed	B-MED
a	O
consecutive	B-MED
series	I-MED
of	I-MED
patients	I-MED
who	O
had	O
potassium	B-MED
testing	B-MED
within	O
48	O
hours	B-MED
of	O
undergoing	O
DSE	B-MED
for	O
the	O
evaluation	B-MED
of	O
myocardial	B-MED
ischemia	I-MED
over	O
a	O
10-	O
year	B-MED
period	B-MED
(	O
N	O
=	O
13,198	O
)	O
.	O
Normal	O
potassium	B-MED
range	B-MED
in	O
our	O
laboratory	B-MED
is	O
3.6	O
-	O
5.2	O
mmol	O
/	O
L.	O
Hemolyzed	B-MED
samples	I-MED
were	O
not	O
included	O
.	O
The	O
association	B-MED
of	O
potassium	B-MED
levels	I-MED
with	O
the	O
development	B-MED
of	O
supraventricular	B-MED
and	O
ventricular	B-MED
arrhythmias	I-MED
was	O
assessed	B-MED
.	O
The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-MED
was	O
very	O
low	B-MED
(	O
supraventricular	B-MED
tachycardia	I-MED
/	O
atrial	B-MED
fibrillation	I-MED
,	O
4.9	O
%	O
;	O
nonsustained	B-MED
ventricular	I-MED
tachycardia	I-MED
,	O
2.9	O
%	O
;	O
sustained	B-MED
ventricular	I-MED
tachycardia	I-MED
or	O
ventricular	B-MED
fibrillation	I-MED
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	B-MED
safety	I-MED
of	O
DSE	B-MED
.	O
Most	O
arrhythmias	B-MED
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	B-MED
with	O
normal	O
potassium	B-MED
levels	I-MED
,	O
and	O
arrhythmia	B-MED
rates	B-MED
remained	O
low	B-MED
in	O
patients	B-MED
with	O
potassium	B-MED
abnormalities	B-MED
.	O
Patients	B-MED
with	O
hyperkalemia	B-MED
had	O
a	O
lower	O
risk	B-MED
of	O
developing	O
mild	B-MED
(	O
odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	B-MED
,	O
0.22	O
-	O
0.71	O
)	O
and	O
severe	B-MED
(	O
OR	B-MED
,	O
0.13	O
;	O
95	O
%	O
CI	B-MED
,	O
0.01	O
-	O
0.68	O
)	O
supraventricular	B-MED
arrhythmias	I-MED
as	O
well	O
as	O
mild	B-MED
ventricular	B-MED
arrhythmias	I-MED
(	O
OR	B-MED
,	O
0.58	O
;	O
95	O
%	O
CI	B-MED
,	O
0.40	O
-	O
0.83	O
)	O
.	O
Even	O
though	O
events	O
were	O
rare	B-MED
,	O
patients	B-MED
with	O
severe	B-MED
hypokalemia	B-MED
(	O
potassium	B-MED
levels	I-MED
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	B-MED
risk	B-MED
of	O
supraventricular	B-MED
arrhythmia	I-MED
and	O
ventricular	B-MED
ectopy	I-MED
.	O
DSE	B-MED
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-MED
in	O
blood	B-MED
potassium	I-MED
concentrations	I-MED
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-MED
in	O
patients	B-MED
with	O
potassium	B-MED
abnormalities	B-MED
does	O
not	O
appear	O
warranted	O
.	O
Elevated	B-MED
potassium	B-MED
levels	I-MED
are	O
associated	B-MED
with	I-MED
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B-MED
and	O
ventricular	B-MED
arrhythmias	I-MED
.	O
While	O
remaining	O
at	O
relatively	O
low	B-MED
risk	B-MED
,	O
patients	B-MED
with	O
very	O
low	B-MED
potassium	B-MED
levels	I-MED
(	O
≤3.1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-MED
have	O
a	O
modestly	O
increased	B-MED
risk	B-MED
of	O
arrhythmia	B-MED
.	O
Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	B-MED
hypokalemia	B-MED
prior	B-MED
to	O
DSE	B-MED
.	O
Experimental	B-MED
study	I-MED
in	O
pulmonary	B-MED
artery	I-MED
sealing	B-MED
with	O
a	O
vessel	B-MED
-	I-MED
sealing	I-MED
device	I-MED
The	O
development	O
of	O
vessel	B-MED
-	I-MED
sealing	I-MED
devices	I-MED
will	O
facilitate	O
safety	B-MED
in	O
video	B-MED
-	I-MED
assisted	I-MED
thoracoscopic	I-MED
surgery	I-MED
.	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	B-MED
and	O
safety	B-MED
of	O
sealing	B-MED
pulmonary	B-MED
arteries	I-MED
with	O
the	O
Enseal	B-MED
tissue	I-MED
-	I-MED
sealing	I-MED
device	I-MED
.	O
Pulmonary	B-MED
arteries	I-MED
from	O
beagle	B-MED
dogs	I-MED
(	O
mean	O
body	O
weight	O
13.1	O
kg	O
,	O
range	O
10.5	O
-	O
15.4	O
kg	O
)	O
were	O
divided	O
into	O
3	O
groups	B-MED
according	O
to	O
the	O
in	B-MED
-	I-MED
vivo	I-MED
sealing	B-MED
method	I-MED
used	O
(	O
Enseal	B-MED
,	O
ligation	B-MED
,	O
and	O
proximal	B-MED
ligation	B-MED
plus	O
distal	B-MED
Enseal	B-MED
)	O
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	B-MED
tolerance	B-MED
up	O
to	O
75	O
mm	O
Hg	O
at	O
the	O
sealed	B-MED
end	B-MED
.	O
A	O
left	O
lower	O
lobectomy	B-MED
was	O
performed	O
to	O
evaluate	O
chronic	B-MED
-	I-MED
phase	I-MED
durability	O
of	O
the	O
sealed	B-MED
stumps	I-MED
in	O
a	O
survival	B-MED
model	I-MED
.	O
Two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-MED
arteries	I-MED
in	O
each	O
dog	B-MED
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	B-MED
.	O
After	O
the	O
scheduled	O
survival	B-MED
period	B-MED
,	O
the	O
pulmonary	B-MED
arteries	I-MED
were	O
sampled	O
.	O
Pressure	B-MED
tolerance	B-MED
at	O
the	O
sealed	B-MED
end	B-MED
was	O
evaluated	O
in	O
91	O
pulmonary	B-MED
artery	I-MED
sections	O
.	O
All	O
sealed	B-MED
ends	B-MED
showed	O
pressure	B-MED
tolerance	B-MED
>	O
75	O
mm	O
Hg	O
.	O
A	O
left	O
lower	O
lobectomy	B-MED
was	O
performed	O
in	O
13	O
dogs	B-MED
in	O
which	O
35	O
pulmonary	B-MED
artery	I-MED
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	B-MED
.	O
No	B-MED
sealing	B-MED
failure	B-MED
was	O
found	O
,	O
and	O
pathological	B-MED
findings	B-MED
showed	O
healing	B-MED
and	O
persistent	B-MED
hemostasis	B-MED
at	O
all	O
sealed	B-MED
ends	B-MED
of	O
the	O
pulmonary	B-MED
arteries	I-MED
after	O
2	O
and	O
4	O
weeks	B-MED
of	O
the	O
survival	B-MED
period	B-MED
.	O
Pulmonary	B-MED
arteries	I-MED
sealed	B-MED
in	B-MED
vivo	I-MED
with	O
the	O
Enseal	B-MED
device	I-MED
showed	O
pressure	B-MED
tolerance	B-MED
>	O
75	O
mm	O
Hg	O
in	O
the	O
acute	B-MED
phase	I-MED
,	O
and	O
persistent	B-MED
hemostasis	B-MED
after	O
2	O
or	O
4	O
weeks	B-MED
.	O
Pulmonary	B-MED
artery	I-MED
sealing	B-MED
with	O
the	O
Enseal	B-MED
device	I-MED
is	O
feasible	B-MED
and	O
safe	B-MED
in	O
thoracic	B-MED
surgery	I-MED
settings	O
.	O
Anticholinergic	B-MED
premedication	B-MED
to	O
prevent	O
bradycardia	B-MED
in	O
combined	O
spinal	B-MED
anesthesia	I-MED
and	O
dexmedetomidine	B-MED
sedation	B-MED
:	O
a	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
study	I-MED
When	O
dexmedetomidine	B-MED
is	O
used	O
in	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
,	O
high	O
incidence	B-MED
of	O
bradycardia	B-MED
in	O
response	O
to	O
parasympathetic	B-MED
activation	B-MED
is	O
reported	O
.	O
Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	B-MED
of	O
atropine	B-MED
premedication	B-MED
for	O
preventing	B-MED
the	O
incidence	B-MED
of	O
bradycardia	B-MED
and	O
the	O
hemodynamic	B-MED
effect	I-MED
on	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
with	O
sedation	B-MED
by	O
dexmedetomidine	B-MED
.	O
Randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
study	I-MED
.	O
Operating	B-MED
room	I-MED
.	O
One	O
hundred	O
fourteen	O
patients	B-MED
(	O
age	O
range	O
,	O
2	O
-	O
65	O
years	B-MED
;	O
American	B-MED
Society	I-MED
of	I-MED
Anesthesiology	I-MED
class	I-MED
I	I-MED
-	I-MED
II	I-MED
)	O
participated	O
in	O
this	O
study	B-MED
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	B-MED
anesthesia	I-MED
.	O
The	O
patients	B-MED
were	O
divided	O
into	O
2	O
groups	B-MED
:	O
group	B-MED
A	I-MED
and	O
group	B-MED
C	I-MED
C.	O
After	O
performing	O
spinal	B-MED
anesthesia	I-MED
,	O
dexmedetomidine	B-MED
was	O
infused	B-MED
at	O
a	O
loading	B-MED
dose	I-MED
of	O
0.6	O
μg	O
/	O
kg	O
for	O
10	O
minutes	B-MED
,	O
followed	O
by	O
an	O
infusion	B-MED
at	O
0.25	O
μg/(kg	O
h	O
)	O
.	O
Simultaneously	O
with	O
the	O
loading	B-MED
dose	I-MED
of	O
dexmedetomidine	B-MED
,	O
patients	B-MED
in	O
group	B-MED
A	I-MED
received	O
an	O
intravenous	B-MED
bolus	I-MED
of	O
0.5	O
mg	O
atropine	B-MED
,	O
whereas	O
patients	B-MED
in	O
group	B-MED
C	I-MED
received	O
an	O
intravenous	B-MED
normal	I-MED
saline	I-MED
bolus	B-MED
.	O
Data	B-MED
on	O
administration	B-MED
of	O
atropine	B-MED
and	O
ephedrine	B-MED
were	O
collected	O
.	O
Hemodynamic	B-MED
data	B-MED
including	O
heart	B-MED
rate	I-MED
,	O
systolic	B-MED
blood	I-MED
pressure	I-MED
,	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
(	O
DBP	B-MED
)	O
,	O
and	O
mean	B-MED
blood	I-MED
pressure	I-MED
(	O
MBP	B-MED
)	O
were	O
also	O
recorded	O
.	O
The	O
incidence	B-MED
of	O
bradycardia	B-MED
requiring	O
atropine	B-MED
treatment	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
group	B-MED
C	I-MED
than	O
group	B-MED
A	I-MED
(	O
P=.035	O
)	O
.	O
However	O
,	O
the	O
incidence	B-MED
of	O
hypotension	B-MED
needing	O
ephedrine	B-MED
treatment	B-MED
showed	O
no	B-MED
significant	I-MED
difference	I-MED
between	O
the	O
2	O
groups	B-MED
(	O
P=.7	O
)	O
.	O
Systolic	B-MED
blood	I-MED
pressure	I-MED
and	O
heart	B-MED
rate	I-MED
showed	O
no	B-MED
significant	I-MED
differences	I-MED
between	O
the	O
2	O
groups	B-MED
(	O
P=.138	O
and	O
.464	O
,	O
respectively	O
)	O
.	O
However	O
,	O
group	B-MED
A	I-MED
showed	O
significant	O
increases	B-MED
in	O
DBP	B-MED
and	O
MBP	B-MED
,	O
and	O
group	B-MED
C	I-MED
did	O
not	O
(	O
P=.014	O
and	O
.008	O
,	O
respectively	O
)	O
.	O
Prophylactic	B-MED
atropine	B-MED
reduces	O
the	O
incidence	B-MED
of	O
bradycardia	B-MED
in	O
patients	B-MED
undergoing	O
spinal	B-MED
anesthesia	I-MED
with	O
dexmedetomidine	B-MED
sedation	B-MED
.	O
However	O
,	O
DBP	B-MED
and	O
MBP	B-MED
showed	O
significant	O
increases	B-MED
in	O
patients	B-MED
when	O
prophylactic	B-MED
atropine	B-MED
was	O
administrated	B-MED
.	O
Therefore	O
,	O
atropine	B-MED
premedication	B-MED
should	O
be	O
administered	B-MED
cautiously	O
.	O
Changes	B-MED
in	O
parenting	B-MED
strategies	B-MED
after	O
a	O
young	B-MED
person	B-MED
's	I-MED
self	B-MED
-	I-MED
harm	I-MED
:	O
a	O
qualitative	B-MED
study	I-MED
When	O
faced	O
with	O
the	O
discovery	B-MED
of	O
their	O
child	B-MED
's	I-MED
self	B-MED
-	I-MED
harm	I-MED
,	O
mothers	B-MED
and	O
fathers	B-MED
may	O
re	B-MED
-	I-MED
evaluate	I-MED
their	O
parenting	B-MED
strategies	B-MED
.	O
This	O
can	O
include	O
changes	B-MED
to	O
the	O
amount	O
of	O
support	B-MED
they	O
provide	O
their	O
child	B-MED
and	O
changes	B-MED
to	O
the	O
degree	B-MED
to	O
which	O
they	O
control	B-MED
and	O
monitor	B-MED
their	O
child	B-MED
.	O
We	O
conducted	O
an	O
in	B-MED
-	I-MED
depth	I-MED
qualitative	I-MED
study	I-MED
with	O
37	O
parents	B-MED
of	O
young	B-MED
people	B-MED
who	O
had	O
self	B-MED
-	I-MED
harmed	I-MED
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	B-MED
changed	B-MED
after	O
the	O
discovery	B-MED
of	O
self	B-MED
-	I-MED
harm	I-MED
.	O
Early	B-MED
on	O
,	O
parents	B-MED
often	O
found	O
themselves	O
"	O
walking	O
on	O
eggshells	O
"	O
so	O
as	O
not	O
to	O
upset	B-MED
their	O
child	B-MED
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	B-MED
.	O
Parents	B-MED
'	O
reactions	B-MED
to	O
the	O
self	B-MED
-	I-MED
harm	I-MED
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
:	O
as	O
part	O
of	O
adolescence	B-MED
,	O
as	O
a	O
mental	B-MED
health	I-MED
issue	I-MED
or	O
as	O
"	O
naughty	B-MED
behaviour	I-MED
"	O
.	O
Parenting	B-MED
of	O
other	O
children	B-MED
in	O
the	O
family	B-MED
could	O
also	O
be	O
affected	O
,	O
with	O
parents	B-MED
worrying	O
about	O
less	O
of	O
their	O
time	B-MED
being	O
available	O
for	O
siblings	B-MED
.	O
Many	O
parents	B-MED
developed	O
specific	O
strategies	B-MED
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	B-MED
,	O
such	O
as	O
learning	B-MED
to	O
avoid	O
blaming	B-MED
themselves	O
or	O
their	O
child	B-MED
for	O
the	O
self	B-MED
-	I-MED
harm	I-MED
and	O
developing	O
new	O
ways	O
to	O
communicate	B-MED
with	O
their	O
child	B-MED
.	O
Parents	B-MED
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	B-MED
on	O
to	O
other	O
people	B-MED
in	O
the	O
same	O
situation	B-MED
.	O
Parents	B-MED
reported	O
changes	B-MED
in	O
their	O
parenting	B-MED
behaviours	B-MED
after	O
the	O
discovery	B-MED
of	O
a	O
child	B-MED
's	O
self	B-MED
-	I-MED
harm	I-MED
.	O
Professionals	B-MED
involved	O
in	O
the	O
care	B-MED
of	O
young	B-MED
people	B-MED
who	O
self	B-MED
-	I-MED
harm	I-MED
might	O
use	O
this	O
information	B-MED
in	O
supporting	B-MED
and	O
advising	B-MED
parents	B-MED
.	O
Fine	B-MED
Mapping	I-MED
of	O
Carbon	B-MED
Assimilation	I-MED
Rate	I-MED
8	I-MED
,	O
a	O
Quantitative	B-MED
Trait	I-MED
Locus	I-MED
for	O
Flag	B-MED
Leaf	I-MED
Nitrogen	B-MED
Content	B-MED
,	O
Stomatal	B-MED
Conductance	B-MED
and	O
Photosynthesis	B-MED
in	O
Rice	B-MED
Increasing	B-MED
the	O
rate	B-MED
of	O
leaf	B-MED
photosynthesis	I-MED
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain	B-MED
yield	I-MED
in	O
rice	B-MED
(	O
Oryza	B-MED
sativa	I-MED
)	O
.	O
Exploiting	O
the	O
natural	O
variation	B-MED
in	O
CO2	B-MED
assimilation	I-MED
rate	I-MED
(	O
A	O
)	O
between	O
rice	B-MED
cultivars	I-MED
using	O
quantitative	B-MED
genetics	I-MED
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	B-MED
contributing	O
to	O
higher	O
photosynthesis	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
determined	O
precise	O
location	B-MED
of	O
Carbon	B-MED
Assimilation	I-MED
Rate	I-MED
8	I-MED
(	O
CAR8	B-MED
)	O
by	O
crossing	B-MED
a	O
high	O
-	O
yielding	O
indica	B-MED
cultivar	I-MED
with	O
a	O
Japanese	B-MED
commercial	B-MED
cultivar	B-MED
.	O
Fine	B-MED
mapping	I-MED
suggested	O
that	O
CAR8	B-MED
encodes	B-MED
a	O
putative	B-MED
Heme	I-MED
Activator	I-MED
Protein	I-MED
3	I-MED
(	O
OsHAP3	B-MED
)	O
subunit	O
of	O
a	O
CCAAT	B-MED
-	I-MED
box	I-MED
-	I-MED
binding	I-MED
transcription	I-MED
factor	I-MED
OsHAP3H	B-MED
called	O
OsHAP3H.	O
Sequencing	B-MED
analysis	I-MED
revealed	O
that	O
the	O
indica	B-MED
allele	B-MED
of	O
CAR8	B-MED
has	O
a	O
1	B-MED
-	I-MED
bp	I-MED
deletion	I-MED
at	O
322	O
bp	B-MED
from	O
the	O
start	B-MED
codon	I-MED
,	O
resulting	O
in	O
a	O
truncated	B-MED
protein	I-MED
of	O
125	O
amino	B-MED
acids	I-MED
.	O
In	O
addition	O
,	O
CAR8	B-MED
is	O
identical	B-MED
to	O
DTH8	B-MED
/	O
Ghd8	B-MED
/	O
LHD1	B-MED
,	O
which	O
was	O
reported	O
to	O
control	O
rice	B-MED
flowering	B-MED
date	B-MED
.	O
The	O
increase	B-MED
of	O
A	B-MED
is	O
largely	O
due	O
to	O
an	O
increase	B-MED
of	O
RuBP	B-MED
regeneration	I-MED
rate	I-MED
via	O
increased	B-MED
leaf	B-MED
nitrogen	B-MED
content	B-MED
,	O
and	O
partially	O
explained	O
by	O
reduced	B-MED
stomatal	B-MED
limitation	B-MED
via	O
increased	B-MED
stomatal	B-MED
conductance	B-MED
A	B-MED
relative	O
to	O
A.	O
This	O
allele	B-MED
also	O
increases	O
hydraulic	B-MED
conductivity	I-MED
,	O
which	O
would	O
promote	B-MED
higher	O
stomatal	B-MED
conductance	B-MED
.	O
This	O
indicates	O
that	O
CAR8	B-MED
affects	O
multiple	O
physiological	B-MED
aspects	I-MED
relating	O
to	O
photosynthesis	B-MED
.	O
The	O
detailed	O
analysis	B-MED
of	O
molecular	B-MED
functions	I-MED
of	O
CAR8	B-MED
would	O
help	O
to	O
understand	O
the	O
association	B-MED
between	O
photosynthesis	B-MED
and	O
flowering	B-MED
and	O
demonstrate	O
specific	O
genetic	B-MED
mechanisms	B-MED
that	O
can	O
be	O
exploited	O
to	O
improve	B-MED
photosynthesis	B-MED
in	O
rice	B-MED
and	O
potentially	O
other	O
crops	B-MED
.	O
Associations	B-MED
of	O
Body	B-MED
Mass	I-MED
Index	I-MED
and	O
Physical	B-MED
Activity	I-MED
With	O
Sexual	B-MED
Dysfunction	I-MED
in	O
Breast	B-MED
Cancer	I-MED
Survivors	B-MED
Sexual	B-MED
dysfunction	I-MED
is	O
a	O
common	O
and	O
distressing	B-MED
consequence	B-MED
of	I-MED
breast	B-MED
cancer	I-MED
(	O
BC	B-MED
)	O
treatment	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
investigated	O
the	O
sexual	B-MED
functioning	I-MED
of	O
BC	B-MED
patients	B-MED
and	O
its	O
association	B-MED
with	O
women	B-MED
's	I-MED
personal	B-MED
characteristics	B-MED
and	O
cancer	B-MED
treatments	I-MED
.	O
In	O
this	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
,	O
sexual	B-MED
function	I-MED
was	O
assessed	O
using	O
the	O
Female	B-MED
Sexual	I-MED
Function	I-MED
Index	I-MED
(	O
FSFI	B-MED
)	O
.	O
The	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
(	O
HRQOL	B-MED
)	O
was	O
measured	O
using	O
the	O
European	B-MED
Organization	I-MED
for	I-MED
Research	I-MED
and	I-MED
Treatment	I-MED
of	I-MED
Cancer	I-MED
(	O
EORTC	B-MED
)	O
QLQ	B-MED
-	I-MED
C30	I-MED
and	O
its	O
breast	B-MED
module	I-MED
BR-23	I-MED
.	O
Of	O
the	O
235	O
participants	B-MED
approached	O
,	O
216	O
participants	B-MED
were	O
included	O
in	O
the	O
study	O
.	O
Of	O
these	O
,	O
63	O
patients	B-MED
reported	O
no	B-MED
sexual	I-MED
activity	I-MED
in	O
the	O
last	O
month	B-MED
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	B-MED
desire	I-MED
domain	B-MED
of	O
FSFI	B-MED
.	O
A	O
total	O
of	O
154	O
(	O
71.3	O
%	O
)	O
patients	B-MED
were	O
classified	O
with	O
hypoactive	B-MED
sexual	I-MED
desire	I-MED
disorder	I-MED
(	O
HSDD	B-MED
)	O
.	O
From	O
those	O
patients	B-MED
reporting	O
sexual	B-MED
activity	I-MED
in	O
the	O
last	O
month	B-MED
,	O
63.3	O
%	O
(	O
97	O
out	O
of	O
153	O
)	O
were	O
classified	O
with	O
sexual	B-MED
dysfunction	I-MED
.	O
Using	O
hierarchical	B-MED
logistic	I-MED
regression	I-MED
,	O
the	O
variance	O
explained	O
(	O
change	O
in	O
R	O
(	O
2	O
)	O
)	O
by	O
the	O
addition	O
of	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
and	O
mild	O
to	O
moderate	O
physical	B-MED
activity	I-MED
in	O
the	O
prediction	B-MED
models	B-MED
of	O
sexual	B-MED
dysfunction	I-MED
and	O
HSDD	B-MED
were	O
6.8	O
and	O
7.2	O
%	O
,	O
respectively	O
.	O
Age	B-MED
,	O
BMI	B-MED
,	O
and	O
physical	B-MED
activity	I-MED
were	O
independently	O
associated	O
with	O
sexual	B-MED
dysfunction	I-MED
and	O
HSDD	B-MED
.	O
Additionally	O
,	O
BC	B-MED
patients	B-MED
with	O
sexual	B-MED
dysfunction	I-MED
reported	O
lower	B-MED
scores	B-MED
on	O
global	O
HRQOL	B-MED
,	O
role	O
functioning	B-MED
,	O
and	O
fatigue	B-MED
.	O
Based	O
on	O
our	O
findings	B-MED
,	O
BC	B-MED
survivors	B-MED
should	O
be	O
encouraged	O
to	O
practice	B-MED
regular	O
physical	B-MED
activity	I-MED
and	O
to	O
lose	B-MED
weight	I-MED
in	O
order	O
to	O
avoid	O
sexual	B-MED
dysfunction	I-MED
.	O
However	O
,	O
future	O
clinical	B-MED
trials	I-MED
are	O
needed	O
to	O
confirm	O
these	O
findings	B-MED
.	O
Comparison	B-MED
of	O
alkaline	B-MED
phosphatase	I-MED
activity	I-MED
of	O
MC3T3	B-MED
-	I-MED
E1	I-MED
cells	I-MED
cultured	O
on	O
different	O
Ti	B-MED
surfaces	B-MED
:	O
modified	O
sandblasted	B-MED
with	O
large	O
grit	B-MED
and	O
acid	B-MED
-	I-MED
etched	I-MED
(	O
MSLA	B-MED
)	O
,	O
laser	B-MED
-	I-MED
treated	I-MED
,	O
and	O
laser	B-MED
and	I-MED
acid	I-MED
-	I-MED
treated	I-MED
Ti	B-MED
surfaces	B-MED
In	O
this	O
study	B-MED
,	O
the	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
effect	O
of	O
implant	O
surface	B-MED
treatment	O
on	O
cell	B-MED
differentiation	I-MED
of	O
osteoblast	B-MED
cells	I-MED
.	O
For	O
this	O
purpose	O
,	O
three	O
surfaces	B-MED
were	O
compared	O
:	O
(	O
1	O
)	O
a	O
modified	O
SLA	O
(	O
MSLA	O
:	O
sand	O
-	O
blasted	O
with	O
large	O
grit	B-MED
,	O
acid	O
-	O
etched	O
,	O
and	O
immersed	O
in	O
0.9	O
%	O
NaCl	B-MED
)	O
,	O
(	O
2	O
)	O
a	O
laser	B-MED
treatment	I-MED
(	O
LT	B-MED
:	O
laser	B-MED
treatment	I-MED
)	O
titanium	B-MED
surface	B-MED
and	O
(	O
3	O
)	O
a	O
laser	B-MED
and	I-MED
acid	I-MED
-	I-MED
treated	I-MED
(	O
LAT	O
:	O
laser	B-MED
treatment	I-MED
,	I-MED
acid	I-MED
-	I-MED
etched	I-MED
)	O
titanium	B-MED
surface	B-MED
.	O
The	O
MSLA	B-MED
surfaces	B-MED
were	O
considered	O
as	O
the	O
control	B-MED
group	I-MED
,	O
and	O
LT	B-MED
and	O
LAT	B-MED
surfaces	B-MED
as	O
test	B-MED
groups	I-MED
.	O
Alkaline	B-MED
phosphatase	I-MED
expression	B-MED
(	O
ALP	B-MED
)	O
was	O
used	O
to	O
quantify	O
osteoblastic	B-MED
differentiation	I-MED
of	O
MC3T3	B-MED
-	I-MED
E1	I-MED
cell	I-MED
.	O
Surface	B-MED
roughness	B-MED
was	O
evaluated	B-MED
by	O
a	O
contact	B-MED
profilometer	I-MED
(	O
URFPAK	O
-	O
SV	O
;	O
Mitutoyo	O
,	O
Kawasaki	O
,	O
Japan	B-MED
)	O
and	O
characterized	O
by	O
two	O
parameters	O
:	O
mean	B-MED
roughness	I-MED
(	O
Ra	B-MED
)	O
and	O
maximum	B-MED
peak	I-MED
-	I-MED
to	I-MED
-	I-MED
valley	I-MED
height	I-MED
(	O
Rt	B-MED
)	O
.	O
Scanning	B-MED
electron	I-MED
microscope	I-MED
revealed	O
that	O
MSLA	O
(	O
control	B-MED
group	I-MED
)	O
surface	B-MED
was	O
not	O
as	O
rough	B-MED
as	O
LT	B-MED
,	O
LAT	B-MED
surface	B-MED
(	O
test	B-MED
groups	I-MED
)	O
.	O
Alkaline	B-MED
phosphatase	I-MED
expression	B-MED
,	O
the	O
measure	O
of	O
osteoblastic	B-MED
differentiation	I-MED
,	O
and	O
total	O
ALP	B-MED
expression	B-MED
by	O
surface	B-MED
-	I-MED
adherent	I-MED
cells	I-MED
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	B-MED
for	O
all	O
three	O
surfaces	B-MED
tested	O
(	O
P<.05	O
)	O
.	O
Furthermore	O
,	O
ALP	B-MED
expression	B-MED
levels	B-MED
of	O
MSLA	B-MED
and	O
LAT	B-MED
surfaces	B-MED
were	O
significantly	O
higher	O
than	O
expression	B-MED
levels	B-MED
of	O
LT	B-MED
surface	B-MED
-	I-MED
adherent	I-MED
cells	I-MED
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-MED
,	O
respectively	O
(	O
P<.05	O
)	O
.	O
However	O
,	O
ALP	B-MED
expression	B-MED
levels	B-MED
between	O
MSLA	B-MED
and	O
LAT	B-MED
surface	B-MED
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-MED
(	O
P>.05	O
)	O
.	O
This	O
study	B-MED
suggested	O
that	O
MSLA	B-MED
and	O
LAT	B-MED
surfaces	B-MED
exhibited	O
more	O
favorable	B-MED
environment	B-MED
for	O
osteoblast	B-MED
differentiation	I-MED
when	O
compared	O
with	O
LT	B-MED
surface	B-MED
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-MED
surface	B-MED
modification	B-MED
studies	B-MED
.	O
Alanine	B-MED
to	O
Serine	B-MED
Variant	B-MED
at	O
Position	O
986	O
of	O
Calcium	B-MED
Sensing	I-MED
Receptor	I-MED
and	O
Colorectal	B-MED
Cancer	I-MED
Risk	B-MED
With	O
regard	O
to	O
the	O
effect	B-MED
of	O
calcium	B-MED
against	O
colorectal	B-MED
cancer	I-MED
(	O
CRC	B-MED
)	O
and	O
considering	O
the	O
key	O
role	B-MED
of	O
calcium	B-MED
sensing	I-MED
receptor	I-MED
(	O
CaSR	B-MED
)	O
in	O
calcium	B-MED
homeostasis	I-MED
,	O
this	O
study	O
investigated	B-MED
whether	O
CaSR	B-MED
gene	I-MED
rs1801725	B-MED
or	O
A986S	B-MED
variant	I-MED
was	O
associated	B-MED
with	I-MED
susceptibility	B-MED
to	O
CRC	B-MED
risk	B-MED
.	O
This	O
study	O
was	O
conducted	O
as	O
a	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
and	O
303	O
cases	B-MED
with	O
CRC	B-MED
and	O
354	O
controls	B-MED
were	O
enrolled	O
.	O
All	O
657	O
subjects	B-MED
were	O
genotyped	B-MED
for	O
CaSR	B-MED
gene	I-MED
A986S	B-MED
variant	I-MED
using	O
PCR	B-MED
-	O
RFLP	B-MED
method	I-MED
.	O
No	B-MED
significant	I-MED
difference	B-MED
was	O
observed	B-MED
for	O
the	O
A986S	B-MED
variant	I-MED
of	O
CaSR	B-MED
gene	I-MED
in	O
either	O
genotype	B-MED
or	O
allele	B-MED
frequencies	I-MED
between	O
the	O
cases	B-MED
and	O
the	O
controls	B-MED
and	O
this	O
lack	B-MED
of	O
difference	B-MED
remained	O
non	O
-	O
significant	O
even	O
after	O
adjustment	B-MED
for	O
age	B-MED
,	O
BMI	B-MED
,	O
sex	B-MED
,	O
smoking	B-MED
status	I-MED
,	O
and	O
family	B-MED
history	I-MED
of	O
CRC	B-MED
.	O
No	B-MED
evidence	I-MED
for	O
the	O
effect	B-MED
modification	B-MED
of	O
the	O
association	B-MED
A986S	B-MED
variant	I-MED
and	O
CRC	B-MED
by	O
BMI	B-MED
,	O
sex	B-MED
,	O
or	O
tumor	B-MED
site	I-MED
was	O
also	O
observed	B-MED
.	O
Furthermore	O
,	O
the	O
risk	B-MED
of	O
obesity	B-MED
in	O
relation	B-MED
to	O
the	O
A986S	B-MED
variant	I-MED
in	O
the	O
controls	B-MED
and	O
the	O
cases	B-MED
was	O
separately	O
analyzed	B-MED
and	O
we	O
observed	O
no	B-MED
significant	I-MED
difference	I-MED
between	O
normal	B-MED
weight	I-MED
(	O
BMI	B-MED
<	O
25kg	O
/	O
m(2	O
)	O
)	O
and	O
overweight	B-MED
/	O
obese	B-MED
(	O
BMI	B-MED
≥	O
25kg	O
/	O
m(2	O
)	O
)	O
subjects	B-MED
.	O
Our	O
findings	B-MED
do	O
not	O
support	O
a	O
role	O
for	O
effect	B-MED
of	O
the	O
CaSR	B-MED
gene	I-MED
A986S	B-MED
variant	I-MED
on	O
CRC	B-MED
risk	B-MED
;	O
nevertheless	O
,	O
this	O
finding	B-MED
requires	O
confirmation	B-MED
and	O
the	O
role	B-MED
of	O
the	O
gene	B-MED
variant	I-MED
in	O
carcinogenesis	B-MED
needs	O
to	O
be	O
further	O
investigated	B-MED
.	O
Biogeography	B-MED
and	O
Character	O
Evolution	B-MED
of	O
the	O
Ciliate	B-MED
Genus	B-MED
Euplotes	B-MED
(	O
Spirotrichea	B-MED
,	O
Euplotia	B-MED
)	O
,	O
with	O
Description	B-MED
of	O
Euplotes	B-MED
curdsi	I-MED
sp	I-MED
.	I-MED
nov	I-MED
Ciliates	B-MED
comprise	O
a	O
diverse	B-MED
and	O
ecologically	B-MED
important	B-MED
phylum	B-MED
of	O
unicellular	B-MED
protists	I-MED
.	O
One	O
of	O
the	O
most	O
specious	O
and	O
best	O
-	O
defined	O
genera	B-MED
is	O
Euplotes	B-MED
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	B-MED
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly	B-MED
tested	I-MED
.	O
The	O
increasing	O
number	O
of	O
described	O
Euplotes	B-MED
taxa	B-MED
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	B-MED
of	O
new	O
ones	O
,	O
requiring	O
standardized	O
morphological	B-MED
observations	B-MED
,	O
sequencing	B-MED
of	O
molecular	B-MED
markers	I-MED
and	O
careful	O
comparison	B-MED
with	O
previous	O
literature	B-MED
.	O
Here	O
we	O
describe	O
Euplotes	B-MED
curdsi	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	O
,	O
distinguishable	B-MED
by	O
the	O
combination	B-MED
of	O
the	O
following	O
features	B-MED
:	O
45	O
-	O
65	O
μm	O
length	B-MED
,	O
oval	B-MED
or	I-MED
elongated	I-MED
shape	I-MED
with	O
both	O
ends	O
rounded	O
,	O
narrow	B-MED
peristome	I-MED
with	O
25	O
-	O
34	O
adoral	B-MED
membranelles	I-MED
,	O
conspicuous	B-MED
paroral	I-MED
membrane	I-MED
,	O
double	B-MED
-	I-MED
eurystomus	I-MED
dorsal	I-MED
argyrome	I-MED
type	I-MED
,	O
6	O
-	O
7	O
dorsolateral	B-MED
kineties	I-MED
and	O
10	O
frontoventral	B-MED
cirri	I-MED
.	O
Three	O
populations	B-MED
of	O
the	O
novel	O
species	B-MED
have	O
been	O
found	O
in	O
brackish	B-MED
and	O
marine	B-MED
samples	I-MED
in	O
the	O
Mediterranean	B-MED
and	O
the	O
White	B-MED
Sea	I-MED
.	O
We	O
provide	O
the	O
SSU	B-MED
rRNA	I-MED
gene	I-MED
sequences	B-MED
of	O
these	O
populations	B-MED
,	O
and	O
an	O
updated	O
phylogeny	B-MED
of	O
the	O
genus	B-MED
Euplotes	B-MED
.	O
Using	O
the	O
molecular	B-MED
phylogenetic	B-MED
tree	I-MED
,	O
we	O
inferred	O
aspects	B-MED
of	O
the	O
biogeographical	B-MED
history	I-MED
of	O
the	O
genus	B-MED
and	O
the	O
evolution	B-MED
of	O
its	O
most	O
important	O
taxonomic	B-MED
characters	B-MED
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	B-MED
.	O
Ultimately	O
,	O
these	O
data	B-MED
reveal	O
recurrent	B-MED
trends	B-MED
of	O
freshwater	B-MED
invasion	O
and	O
highlight	O
the	O
dynamic	O
,	O
yet	O
convergent	O
,	O
morphological	B-MED
evolution	B-MED
of	O
Euplotes	B-MED
.	O
Progressive	B-MED
subcortical	B-MED
calcifications	B-MED
secondary	O
to	O
venous	B-MED
hypertension	I-MED
in	O
an	O
intracranial	B-MED
dural	B-MED
arteriovenous	I-MED
fistula	I-MED
Intracranial	B-MED
dural	B-MED
arteriovenous	I-MED
fistulas	I-MED
(	O
dAVF	B-MED
)	O
are	O
acquired	B-MED
lesions	I-MED
,	O
with	O
the	O
most	O
commonly	O
reported	B-MED
findings	B-MED
on	O
CT	B-MED
haemorrhage	B-MED
or	O
focal	B-MED
oedema	I-MED
.	O
We	O
describe	O
a	O
case	O
of	O
progressive	B-MED
subcortical	B-MED
calcification	B-MED
on	O
CT	B-MED
secondary	O
to	O
venous	B-MED
hypertension	I-MED
from	O
a	O
high	O
grade	O
dAVF	B-MED
.	O
pH	B-MED
-Dependent	O
Transmembrane	B-MED
Activity	I-MED
of	O
Peptide	B-MED
-Functionalized	O
Gold	B-MED
Nanostars	I-MED
for	O
Computed	B-MED
Tomography	I-MED
/	O
Photoacoustic	B-MED
Imaging	I-MED
and	O
Photothermal	B-MED
Therapy	I-MED
Progress	B-MED
in	O
multifunctional	B-MED
nanomaterials	I-MED
for	O
tumor	B-MED
therapy	I-MED
mostly	O
depends	O
on	O
the	O
development	B-MED
of	O
tumor	B-MED
-	O
targeting	B-MED
delivery	B-MED
strategies	I-MED
.	O
One	O
approach	B-MED
is	O
to	O
explore	O
a	O
pH	B-MED
-responsive	O
strategy	B-MED
to	O
target	B-MED
the	O
slightly	O
acidic	B-MED
solid	I-MED
tumor	I-MED
microenvironment	I-MED
.	O
A	O
novel	O
class	O
of	O
pH	B-MED
(	I-MED
low	I-MED
)	I-MED
insertion	I-MED
peptides	I-MED
(	O
pHLIPs	B-MED
)	O
with	O
pH	B-MED
-dependent	O
transmembrane	B-MED
activity	I-MED
can	O
fold	B-MED
and	O
rapidly	O
insert	B-MED
into	O
the	O
lipid	B-MED
bilayer	I-MED
of	O
tumor	B-MED
cells	I-MED
triggered	O
by	O
acidity	B-MED
,	O
facilitating	O
the	O
cellular	B-MED
internalization	I-MED
of	O
nanomaterials	B-MED
synchronously	B-MED
.	O
Here	O
,	O
we	O
innovatively	O
decorated	O
gold	B-MED
nanostars	I-MED
(	O
GNSs	B-MED
)	O
with	O
pHLIPs	B-MED
(	O
GNS	B-MED
-	O
pHLIP	B-MED
)	O
to	O
improve	O
their	O
targeting	B-MED
ability	O
and	O
photothermal	B-MED
therapeutic	I-MED
(	O
PTT	B-MED
)	O
efficiency	B-MED
.	O
The	O
obtained	O
GNS	B-MED
-	O
pHLIP	B-MED
exhibited	O
the	O
excellent	O
characteristics	B-MED
of	O
uniform	O
size	B-MED
and	O
good	O
biocompatibility	B-MED
.	O
As	O
compared	O
to	O
GNS	B-MED
-	O
mPEG	B-MED
,	O
the	O
cellular	B-MED
internalization	I-MED
of	O
GNS	B-MED
-	O
pHLIP	B-MED
was	O
1	O
-	O
fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	B-MED
in	O
media	B-MED
at	O
pH	B-MED
6.4	O
than	O
at	O
pH	B-MED
7.4	O
.	O
Moreover	O
,	O
the	O
tumor	B-MED
accumulation	B-MED
of	O
the	O
GNS	B-MED
-	O
pHLIP	B-MED
was	O
3	O
-	O
fold	O
higher	O
than	O
that	O
of	O
GNS	B-MED
-	O
mPEG	B-MED
after	O
intravenous	B-MED
injection	I-MED
into	O
MCF-7	B-MED
breast	B-MED
tumor	I-MED
animal	B-MED
models	I-MED
for	O
24	O
h.	O
Furthermore	O
,	O
GNS	B-MED
-	O
pHLIP	B-MED
exhibited	O
stronger	O
signals	B-MED
than	O
the	O
GNS	B-MED
-	O
mPEG	B-MED
through	O
computed	B-MED
tomography	I-MED
(	O
CT	B-MED
)	O
and	O
photoacoustic	B-MED
(	I-MED
PA	I-MED
)	I-MED
imaging	I-MED
.	O
Simultaneously	O
,	O
the	O
desirable	O
targeting	B-MED
efficiency	B-MED
significantly	O
improved	O
the	O
PTT	B-MED
efficacy	B-MED
to	O
tumors	B-MED
,	O
with	O
low	O
side	B-MED
effects	I-MED
on	O
normal	O
tissues	B-MED
.	O
The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	B-MED
-	O
pHLIP	B-MED
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-MED
-	O
targeting	B-MED
ability	O
of	O
pHLIPs	B-MED
and	O
the	O
good	O
characteristics	B-MED
of	O
GNS	B-MED
GNS	B-MED
s	I-MED
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	B-MED
imaging	B-MED
and	O
therapy	B-MED
.	O
Retirement	B-MED
crisis	B-MED
warnings	B-MED
becoming	O
a	O
reality	B-MED
The	O
figures	B-MED
are	O
startling	B-MED
:	O
the	O
number	O
of	O
NHS	B-MED
staff	B-MED
applying	O
to	O
retire	B-MED
has	O
surged	B-MED
by	O
a	O
quarter	O
since	O
2012	O
.	O
The	O
potential	O
consequences	B-MED
are	O
alarming	B-MED
;	O
a	O
serious	O
shortage	B-MED
of	O
nurses	B-MED
and	O
other	O
healthcare	B-MED
professionals	I-MED
now	O
seems	O
inevitable	B-MED
.	O
Parallel	B-MED
-	I-MED
processing	I-MED
continuous	B-MED
-	I-MED
flow	I-MED
device	I-MED
for	O
optimization	B-MED
-	O
free	B-MED
polymerase	B-MED
chain	I-MED
reaction	I-MED
A	O
parallel	B-MED
-	I-MED
processing	I-MED
four	B-MED
-	I-MED
station	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
PCR	B-MED
)	O
device	B-MED
has	O
been	O
developed	O
,	O
which	O
performs	B-MED
continuous	B-MED
-	I-MED
flow	I-MED
PCR	B-MED
without	O
optimization	B-MED
of	O
the	O
annealing	B-MED
temperature	B-MED
.	O
Since	O
the	O
annealing	B-MED
temperature	B-MED
of	O
each	O
station	B-MED
can	O
be	O
controlled	B-MED
independently	B-MED
,	O
the	O
device	B-MED
covers	B-MED
an	O
annealing	B-MED
temperature	B-MED
range	B-MED
of	O
50	O
-	O
68	O
°	O
C	O
,	O
which	O
is	O
wide	B-MED
enough	O
to	O
perform	B-MED
PCR	B-MED
for	O
any	O
DNA	B-MED
fragment	I-MED
regardless	O
of	O
its	O
optimum	B-MED
annealing	B-MED
condition	B-MED
.	O
This	O
arrangement	B-MED
lets	O
us	O
continuously	B-MED
obtain	B-MED
an	O
amplified	B-MED
amount	B-MED
of	O
a	O
DNA	B-MED
fragment	I-MED
at	O
least	O
from	O
one	O
of	O
the	O
stations	B-MED
.	O
The	O
device	B-MED
consists	O
of	O
four	O
identical	B-MED
cylindrical	B-MED
stations	B-MED
(	O
diameter	B-MED
20	O
mm	O
,	O
height	B-MED
55	O
mm	O
)	O
.	O
A	O
polytetrafluoroethylene	B-MED
capillary	B-MED
reactor	I-MED
(	O
length	B-MED
2	O
m	O
,	O
I.D.	O
100	O
μm	O
,	O
O.D.	O
400	O
μm	O
)	O
is	O
wound	B-MED
helically	I-MED
up	B-MED
around	B-MED
each	O
station	B-MED
.	O
The	O
whole	O
assembly	B-MED
is	O
designed	B-MED
to	O
minimize	B-MED
the	O
number	B-MED
of	O
heating	B-MED
blocks	I-MED
(	O
for	O
providing	B-MED
temperatures	B-MED
of	O
denaturation	B-MED
,	O
annealing	B-MED
,	O
and	O
extension	B-MED
)	O
to	O
be	O
seven	O
and	O
to	O
shape	B-MED
a	O
compact	B-MED
cube	B-MED
(	O
height	B-MED
55	O
mm	O
,	O
base	B-MED
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O
The	O
reproducibility	B-MED
for	O
continuous	B-MED
-	I-MED
flow	I-MED
PCR	B-MED
is	O
reasonably	O
high	B-MED
(	O
run	B-MED
-to-	O
run	B-MED
and	O
station	B-MED
-to-	O
station	B-MED
relative	O
standard	B-MED
deviation	I-MED
of	O
their	O
amplification	B-MED
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O
Performance	B-MED
on	O
the	O
optimization	B-MED
-	O
free	B-MED
DNA	B-MED
amplification	I-MED
has	O
been	O
evaluated	B-MED
with	O
four	O
DNA	B-MED
samples	I-MED
with	O
different	B-MED
annealing	B-MED
conditions	B-MED
and	O
product	B-MED
sizes	B-MED
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	B-MED
that	O
in	O
all	O
cases	B-MED
,	O
PCR	B-MED
is	O
successful	B-MED
at	O
least	O
on	O
one	O
station	B-MED
.	O
In	O
addition	B-MED
,	O
three	O
DNA	B-MED
fragment	I-MED
s	O
with	O
different	B-MED
lengths	B-MED
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	B-MED
amplified	B-MED
in	O
a	O
segmented	B-MED
-	O
flow	B-MED
mode	B-MED
without	O
the	O
carry	O
-	O
over	O
contamination	B-MED
between	O
segments	B-MED
.	O
This	O
result	B-MED
suggests	O
that	O
this	O
device	B-MED
could	O
serve	O
as	O
the	O
PCR	B-MED
module	B-MED
of	O
a	O
continuous	B-MED
-	I-MED
flow	I-MED
high	B-MED
-	I-MED
throughput	I-MED
on	I-MED
-	I-MED
line	I-MED
total	I-MED
DNA	I-MED
analysis	I-MED
system	B-MED
integrating	B-MED
all	O
necessary	O
modules	B-MED
from	O
cell	B-MED
lysis	B-MED
/	O
DNA	B-MED
extraction	I-MED
to	O
PCR	B-MED
product	B-MED
analysis	B-MED
.	O
A	O
Fast	B-MED
Peak	I-MED
-	I-MED
Searching	I-MED
Algorithm	I-MED
for	O
Ultrasonic	B-MED
Elastography	I-MED
Tissue	B-MED
axial	I-MED
strain	I-MED
estimation	I-MED
with	I-MED
ultrasound	I-MED
elastography	I-MED
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O
However	O
,	O
for	O
keypoints	O
tracking	B-MED
-	I-MED
based	I-MED
elastography	I-MED
algorithms	I-MED
,	O
locating	B-MED
extrema	B-MED
in	O
multimodal	O
ultrasonic	B-MED
radiofrequency	B-MED
signals	B-MED
is	O
still	O
a	O
challenging	O
problem	B-MED
.	O
In	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	B-MED
to	O
locate	B-MED
the	O
local	O
maxima	B-MED
and	O
minima	B-MED
of	O
the	O
RF	B-MED
signals	B-MED
directly	O
without	O
derivation	B-MED
operation	B-MED
.	O
This	O
algorithm	B-MED
can	O
accurately	O
locate	B-MED
extrema	B-MED
even	O
if	O
disturbed	O
peaks	B-MED
resulting	O
from	O
different	O
noise	B-MED
exist	O
.	O
Furthermore	O
,	O
the	O
new	O
algorithm	B-MED
can	O
speed	O
up	O
approximately	O
79	O
%	O
of	O
the	O
implementation	B-MED
process	O
as	O
compared	B-MED
with	O
the	O
standard	B-MED
cross	I-MED
-	I-MED
correlation	I-MED
method	I-MED
on	O
the	O
same	O
computing	B-MED
platform	O
.	O
In	O
addition	O
,	O
the	O
elastographic	O
signal	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
and	O
the	O
contrast	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
are	O
also	O
significantly	O
improved	O
with	O
this	O
new	O
method	O
.	O
The	O
Loop	B-MED
2	I-MED
Region	I-MED
of	O
Ribosomal	B-MED
Protein	I-MED
uS5	I-MED
Influences	O
Spectinomycin	B-MED
Sensitivity	B-MED
,	O
Translational	B-MED
Fidelity	I-MED
,	O
and	O
Ribosome	B-MED
Biogenesis	I-MED
Ribosomal	B-MED
protein	I-MED
uS5	I-MED
is	O
an	O
essential	B-MED
component	I-MED
of	O
the	O
small	B-MED
ribosomal	I-MED
subunit	I-MED
that	O
is	O
involved	O
in	O
subunit	B-MED
assembly	I-MED
,	O
maintenance	B-MED
of	I-MED
translational	I-MED
fidelity	I-MED
,	O
and	O
the	O
ribosome	B-MED
's	I-MED
response	B-MED
to	O
the	O
antibiotic	B-MED
spectinomycin	I-MED
.	O
While	O
many	O
of	O
the	O
characterized	O
uS5	B-MED
mutations	I-MED
that	O
affect	O
decoding	B-MED
map	O
to	O
its	O
interface	B-MED
with	O
uS4	B-MED
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	B-MED
distant	O
from	O
the	O
uS4	B-MED
-	I-MED
uS5	I-MED
interface	I-MED
can	O
also	O
affect	O
the	O
decoding	B-MED
process	I-MED
.	O
We	O
targeted	O
one	O
such	O
interface	B-MED
-	I-MED
remote	I-MED
area	I-MED
,	O
the	O
loop	B-MED
2	I-MED
region	I-MED
(	O
residues	B-MED
20	O
to	O
31	O
)	O
,	O
for	O
mutagenesis	B-MED
in	O
Escherichia	B-MED
.	I-MED
coli	I-MED
and	O
generated	O
21	O
unique	B-MED
mutants	I-MED
.	O
A	O
majority	O
of	O
the	O
loop	B-MED
2	I-MED
alterations	O
confer	O
resistance	B-MED
to	O
spectinomycin	B-MED
and	O
affect	O
the	O
fidelity	B-MED
of	I-MED
translation	I-MED
.	O
However	O
,	O
only	O
a	O
minority	O
show	O
altered	O
rRNA	B-MED
processing	O
or	O
ribosome	B-MED
biogenesis	I-MED
defects	B-MED
.	O
Mechanisms	B-MED
of	O
replacement	B-MED
of	O
circulating	B-MED
viruses	B-MED
by	O
seasonal	B-MED
and	O
pandemic	B-MED
influenza	I-MED
A	I-MED
viruses	I-MED
Seasonal	B-MED
influenza	I-MED
causes	O
annual	O
epidemics	B-MED
by	O
the	O
accumulation	B-MED
of	O
antigenic	B-MED
changes	I-MED
.	O
Pandemic	B-MED
influenza	I-MED
occurs	O
through	O
a	O
major	O
antigenic	B-MED
change	I-MED
of	O
the	O
influenza	B-MED
A	I-MED
virus	I-MED
,	O
which	O
can	O
originate	B-MED
from	O
other	O
hosts	B-MED
.	O
Although	O
new	O
antigenic	B-MED
variants	I-MED
of	O
the	O
influenza	B-MED
A	I-MED
virus	I-MED
replace	O
formerly	O
circulating	B-MED
seasonal	B-MED
and	O
pandemic	B-MED
viruses	I-MED
,	O
replacement	B-MED
mechanisms	B-MED
remain	O
poorly	O
understood	O
.	O
A	O
stochastic	B-MED
individual	I-MED
-	I-MED
based	I-MED
SEIR	I-MED
(	I-MED
susceptible	I-MED
-	I-MED
exposed	I-MED
-	I-MED
infectious	I-MED
-	I-MED
recovered	I-MED
)	I-MED
model	I-MED
with	O
two	O
viral	B-MED
strains	I-MED
(	O
formerly	O
circulating	B-MED
old	B-MED
strain	I-MED
and	O
newly	B-MED
emerged	I-MED
strain	I-MED
)	O
was	O
developed	O
for	O
simulations	B-MED
to	O
elucidate	O
the	O
replacement	B-MED
mechanisms	B-MED
.	O
Factors	B-MED
and	O
conditions	B-MED
of	O
virus	B-MED
and	O
host	B-MED
populations	O
affecting	O
the	O
replacement	B-MED
were	O
identified	O
.	O
Replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical	B-MED
regions	I-MED
than	O
temperate	B-MED
regions	I-MED
.	O
The	O
magnitude	B-MED
of	O
the	O
ongoing	O
epidemic	B-MED
by	O
the	O
old	B-MED
strain	I-MED
,	O
herd	B-MED
immunity	I-MED
against	O
the	O
old	B-MED
strain	I-MED
,	O
and	O
timing	B-MED
of	O
appearance	B-MED
of	O
the	O
new	B-MED
strain	I-MED
are	O
not	O
that	O
important	O
for	O
replacement	B-MED
.	O
It	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	B-MED
by	O
a	O
pandemic	B-MED
virus	I-MED
is	O
higher	O
than	O
a	O
seasonal	B-MED
virus	I-MED
because	O
of	O
the	O
high	O
initial	O
susceptibility	B-MED
and	O
high	O
basic	O
reproductive	B-MED
number	O
of	O
the	O
pandemic	B-MED
virus	I-MED
.	O
The	O
findings	O
of	O
this	O
study	O
on	O
replacement	B-MED
mechanisms	B-MED
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus	B-MED
transmission	I-MED
dynamics	B-MED
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	B-MED
strategy	O
to	O
mitigate	B-MED
the	O
impact	O
of	O
seasonal	B-MED
and	O
pandemic	B-MED
influenza	I-MED
.	O
Determinants	B-MED
of	O
On	B-MED
-	I-MED
Road	I-MED
Driving	B-MED
in	O
Multiple	B-MED
Sclerosis	I-MED
To	O
investigate	B-MED
the	O
cognitive	B-MED
,	O
visual	B-MED
,	O
and	O
motor	B-MED
deficits	I-MED
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-MED
of	O
on	B-MED
-	I-MED
road	I-MED
driving	B-MED
in	O
individuals	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
.	O
Prospective	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
MS	B-MED
clinic	I-MED
and	O
driving	B-MED
simulator	B-MED
lab	B-MED
.	O
Active	B-MED
drivers	I-MED
(	O
N=102	O
)	O
with	O
various	O
types	O
of	O
MS	B-MED
.	O
Not	O
applicable	O
.	O
Off	B-MED
-	I-MED
road	I-MED
cognitive	B-MED
,	O
visual	B-MED
,	O
and	O
motor	B-MED
functions	I-MED
,	O
as	O
well	O
as	O
13	O
specific	B-MED
driving	B-MED
skills	I-MED
.	O
These	O
skills	B-MED
were	O
categorized	B-MED
into	O
hierarchic	B-MED
clusters	I-MED
of	O
operational	B-MED
,	O
tactical	B-MED
,	O
visuo	B-MED
-	I-MED
integrative	I-MED
,	O
and	O
mixed	B-MED
driving	I-MED
.	O
Stepwise	B-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
determine	O
the	O
off	B-MED
-	I-MED
road	I-MED
functions	O
influencing	O
performance	O
on	O
the	O
on	B-MED
-	I-MED
road	I-MED
test	B-MED
and	O
each	O
cluster	B-MED
.	O
Visuospatial	B-MED
function	I-MED
(	O
P=.002	O
)	O
,	O
inhibition	B-MED
(	O
P=.008	O
)	O
,	O
binocular	B-MED
acuity	I-MED
(	O
P=.04	O
)	O
,	O
vertical	B-MED
visual	I-MED
field	I-MED
(	O
P=.02	O
)	O
,	O
and	O
stereopsis	B-MED
(	O
P=.03	O
)	O
best	O
determined	O
variance	B-MED
in	O
total	O
on	B-MED
-	I-MED
road	I-MED
score	B-MED
(	O
unadjusted	O
R(2)=.37	O
)	O
.	O
Attentional	B-MED
shift	I-MED
(	O
P=.0004	O
)	O
,	O
stereopsis	B-MED
(	O
P=.007	O
)	O
,	O
glare	B-MED
recovery	I-MED
(	O
P=.047	O
)	O
,	O
and	O
use	O
of	O
assistive	B-MED
devices	I-MED
(	O
P=.03	O
)	O
best	O
predicted	O
the	O
operational	B-MED
cluster	I-MED
(	O
unadjusted	O
R(2)=.28	O
)	O
.	O
Visuospatial	B-MED
function	I-MED
(	O
P=.002	O
)	O
,	O
inhibition	B-MED
(	O
P=.002	O
)	O
,	O
reasoning	B-MED
(	O
P=.003	O
)	O
,	O
binocular	B-MED
acuity	I-MED
(	O
P=.04	O
)	O
,	O
and	O
stereopsis	B-MED
(	O
P=.005	O
)	O
best	O
determined	O
the	O
tactical	B-MED
cluster	I-MED
(	O
unadjusted	O
R(2)=.41	O
)	O
.	O
The	O
visuo	B-MED
-	I-MED
integrative	I-MED
mode	I-MED
l	O
(	O
unadjusted	O
R(2)=.12	O
)	O
comprised	O
binocular	B-MED
acuity	I-MED
(	O
P=.007	O
)	O
and	O
stereopsis	B-MED
(	O
P=.045	O
)	O
.	O
Inhibition	B-MED
(	O
P=.0001	O
)	O
and	O
binocular	B-MED
acuity	I-MED
(	O
P=.001	O
)	O
provided	O
the	O
best	O
model	B-MED
of	O
the	O
mixed	B-MED
cluster	I-MED
(	O
unadjusted	O
R(2)=.25	O
)	O
.	O
Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	B-MED
that	O
influence	O
different	O
dimensions	O
of	O
on	B-MED
-	I-MED
road	I-MED
driving	B-MED
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	B-MED
driving	B-MED
intervention	B-MED
programs	I-MED
in	O
MS	B-MED
.	O
Evaluation	B-MED
of	O
Choroidal	B-MED
Thickness	B-MED
in	O
Patients	B-MED
with	O
Pseudoexfoliation	B-MED
Syndrome	I-MED
and	O
Pseudoexfoliation	B-MED
Glaucoma	I-MED
Purpose	B-MED
.	O
To	O
compare	B-MED
the	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thickness	B-MED
in	O
eyes	B-MED
with	O
pseudoexfoliation	B-MED
(	I-MED
PEX	I-MED
)	I-MED
syndrome	I-MED
and	O
PEX	B-MED
glaucoma	I-MED
with	O
the	O
normal	B-MED
eyes	B-MED
of	O
healthy	B-MED
controls	B-MED
.	O
Materials	O
and	O
Methods	O
.	O
In	O
this	O
prospective	B-MED
study	I-MED
,	O
30	O
eyes	B-MED
of	O
30	O
patients	B-MED
with	O
PEX	B-MED
syndrome	I-MED
,	O
28	O
eyes	B-MED
of	O
28	O
patients	B-MED
with	O
PEX	B-MED
glaucoma	I-MED
,	O
and	O
30	O
eyes	B-MED
of	O
30	O
age	B-MED
-matched	O
healthy	B-MED
subjects	B-MED
were	O
enrolled	O
.	O
Choroidal	B-MED
thicknesses	B-MED
in	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
areas	B-MED
were	O
measured	B-MED
by	O
using	O
spectral	B-MED
domain	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
.	O
Results	O
.	O
Gender	B-MED
,	O
age	B-MED
,	O
and	O
axial	B-MED
length	I-MED
did	O
not	B-MED
significantly	I-MED
differ	O
between	O
the	O
groups	B-MED
(	O
all	O
,	O
p	O
>	O
0.05	O
)	O
.	O
The	O
mean	B-MED
values	I-MED
of	O
choroidal	B-MED
thickness	B-MED
in	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
areas	B-MED
(	O
except	B-MED
the	O
superior	B-MED
quadrant	B-MED
)	O
in	O
the	O
patients	B-MED
with	O
PEX	B-MED
syndrome	I-MED
and	O
PEX	B-MED
glaucoma	I-MED
were	O
lower	B-MED
compared	B-MED
with	O
controls	B-MED
(	O
all	O
p	O
<	O
0.05	O
)	O
.	O
The	O
mean	B-MED
values	I-MED
of	O
the	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thickness	B-MED
in	O
the	O
PEX	B-MED
glaucoma	I-MED
group	B-MED
were	O
lower	B-MED
compared	B-MED
with	O
PEX	B-MED
syndrome	I-MED
group	B-MED
;	O
however	O
this	O
difference	B-MED
was	O
not	B-MED
significant	I-MED
.	O
Conclusions	O
.	O
The	O
findings	B-MED
of	O
this	O
study	B-MED
revealed	B-MED
that	O
macular	B-MED
and	O
peripapillary	B-MED
choroidal	B-MED
thicknesses	B-MED
were	O
decreased	B-MED
in	O
PEX	B-MED
syndrome	I-MED
and	O
PEX	B-MED
glaucoma	I-MED
cases	B-MED
.	O
The	O
role	O
of	O
choroid	B-MED
in	O
the	O
development	B-MED
of	O
glaucomatous	B-MED
damage	B-MED
in	O
patients	B-MED
with	O
PEX	B-MED
syndrome	I-MED
remains	O
unclear	B-MED
.	O
Plasmodium	B-MED
falciparum	I-MED
Choline	B-MED
Kinase	I-MED
Inhibition	B-MED
Leads	O
to	O
a	O
Major	O
Decrease	B-MED
in	O
Phosphatidylethanolamine	B-MED
Causing	O
Parasite	B-MED
Death	B-MED
Malaria	B-MED
is	O
a	O
life	B-MED
-	I-MED
threatening	I-MED
disease	B-MED
caused	O
by	O
different	O
species	B-MED
of	O
the	O
protozoan	B-MED
parasite	I-MED
Plasmodium	B-MED
,	O
with	O
P.	B-MED
falciparum	I-MED
being	O
the	O
deadliest	O
.	O
Increasing	B-MED
parasitic	B-MED
resistance	B-MED
to	O
existing	O
antimalarials	B-MED
makes	O
the	O
necessity	O
of	O
novel	B-MED
avenues	O
to	O
treat	B-MED
this	O
disease	B-MED
an	O
urgent	O
priority	O
.	O
The	O
enzymes	B-MED
responsible	O
for	O
the	O
synthesis	B-MED
of	O
phosphatidylcholine	B-MED
and	O
phosphatidylethanolamine	B-MED
are	O
attractive	O
drug	B-MED
targets	I-MED
to	O
treat	B-MED
malaria	B-MED
as	O
their	O
selective	O
inhibition	B-MED
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite	B-MED
's	I-MED
growth	B-MED
and	O
cures	B-MED
malaria	B-MED
in	O
a	O
mouse	B-MED
model	I-MED
.	O
We	O
present	O
here	O
a	O
detailed	O
study	B-MED
that	O
reveals	O
a	O
mode	B-MED
of	I-MED
action	I-MED
for	O
two	O
P.	B-MED
falciparum	I-MED
choline	B-MED
kinase	I-MED
inhibitors	B-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
The	O
compounds	B-MED
present	O
distinct	O
binding	B-MED
modes	O
to	O
the	O
choline	B-MED
/	O
ethanolamine	B-MED
-	O
binding	B-MED
site	I-MED
of	O
P.	B-MED
falciparum	I-MED
choline	B-MED
kinase	I-MED
,	O
reflecting	O
different	O
types	O
of	O
inhibition	B-MED
.	O
Strikingly	O
,	O
these	O
compounds	B-MED
primarily	O
inhibit	O
the	O
ethanolamine	B-MED
kinase	I-MED
activity	I-MED
of	O
the	O
P.	B-MED
falciparum	I-MED
choline	B-MED
kinase	I-MED
,	O
leading	O
to	O
a	O
severe	O
decrease	B-MED
in	O
the	O
phosphatidylethanolamine	B-MED
levels	B-MED
within	O
P.	B-MED
falciparum	I-MED
,	O
which	O
explains	O
the	O
resulting	O
growth	B-MED
phenotype	I-MED
and	O
the	O
parasites	B-MED
death	B-MED
.	O
These	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode	B-MED
of	I-MED
action	I-MED
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial	B-MED
development	I-MED
efforts	O
selectively	O
targeting	O
P.	B-MED
falciparum	I-MED
choline	B-MED
kinase	I-MED
.	O
Effect	B-MED
of	O
Successive	B-MED
Administration	I-MED
of	O
Vancomycin	B-MED
and	O
Amikacin	B-MED
on	O
Auditory	B-MED
Function	I-MED
of	O
Immature	B-MED
Animals	I-MED
Effect	B-MED
of	O
successive	B-MED
administration	I-MED
vancomycin	B-MED
and	O
amikacin	B-MED
in	O
therapeutic	B-MED
doses	B-MED
on	O
immature	B-MED
auditory	B-MED
organ	I-MED
was	O
compared	B-MED
to	O
single	B-MED
administration	B-MED
of	O
the	O
same	B-MED
drugs	B-MED
in	O
chronic	B-MED
experiments	B-MED
on	O
immature	B-MED
rabbits	B-MED
by	O
recording	B-MED
of	O
short	B-MED
-	I-MED
latency	I-MED
auditory	B-MED
brainstem	I-MED
response	I-MED
(	O
ABR	B-MED
)	O
and	O
distortion	B-MED
product	I-MED
otoacoustic	I-MED
emission	I-MED
(	O
DPOAE	B-MED
)	O
.	O
Drug	B-MED
administration	I-MED
always	O
increased	B-MED
significantly	O
the	O
ABR	B-MED
peak	O
I	O
threshold	B-MED
.	O
Ototoxic	B-MED
antibiotics	B-MED
did	O
not	O
change	O
DPOAE	B-MED
,	O
but	O
selectively	O
affected	B-MED
activity	B-MED
of	O
outer	B-MED
hair	I-MED
cells	I-MED
.	O
No	B-MED
enhancement	B-MED
of	O
the	O
ototoxic	B-MED
effects	I-MED
was	O
observed	B-MED
after	O
successive	B-MED
administration	I-MED
of	O
the	O
two	O
antibiotics	B-MED
.	O
Congenital	B-MED
anomalies	I-MED
following	O
use	O
of	O
isotretinoin	B-MED
:	O
Emphasis	O
on	O
its	O
legal	B-MED
aspects	I-MED
We	O
described	O
a	O
neonate	B-MED
with	O
severe	B-MED
and	O
multiple	B-MED
abnormalities	I-MED
following	O
use	O
of	O
isotretinoin	B-MED
,	O
in	O
spite	O
of	O
the	O
mother	B-MED
's	O
previous	O
knowledge	B-MED
of	O
drug	B-MED
complications	I-MED
.	O
Initial	O
physical	B-MED
examination	I-MED
after	O
delivery	B-MED
showed	O
congenital	B-MED
absence	I-MED
of	O
both	B-MED
eyes	I-MED
and	O
both	O
auricles	B-MED
as	O
well	O
as	O
anal	B-MED
atresia	I-MED
and	O
a	O
cleft	B-MED
palate	I-MED
.	O
Due	O
to	O
severe	B-MED
respiratory	B-MED
distress	I-MED
and	O
atresia	B-MED
of	O
the	O
anus	B-MED
,	O
the	O
neonate	B-MED
was	O
admitted	O
to	O
a	O
neonatal	B-MED
intensive	B-MED
care	I-MED
unit	I-MED
and	O
underwent	O
reconstructive	B-MED
surgery	I-MED
.	O
The	O
drug	B-MED
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	B-MED
.	O
Using	O
this	O
drug	B-MED
within	O
pregnancy	B-MED
with	O
awareness	O
of	O
its	O
side	B-MED
effects	I-MED
may	O
have	O
legal	B-MED
consequences	B-MED
.	O
Chitosan	B-MED
-functionalised	O
poly(2	B-MED
-	I-MED
hydroxyethyl	I-MED
methacrylate	I-MED
)	I-MED
core	B-MED
-	I-MED
shell	I-MED
microgels	I-MED
as	O
drug	B-MED
delivery	I-MED
carriers	I-MED
:	O
salicylic	B-MED
acid	I-MED
loading	B-MED
and	I-MED
release	I-MED
This	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-MED
-functionalised	O
poly(2	B-MED
-	I-MED
hydroxyethyl	I-MED
methacrylate	I-MED
)	I-MED
(	O
CS	B-MED
/	O
PHEMA	B-MED
)	O
core	B-MED
-	I-MED
shell	I-MED
microgels	I-MED
as	O
drug	B-MED
delivery	I-MED
carriers	I-MED
.	O
CS	B-MED
/	O
PHEMA	B-MED
microgels	B-MED
were	O
prepared	O
by	O
emulsifier	B-MED
-	I-MED
free	I-MED
emulsion	I-MED
polymerisation	I-MED
with	O
N	B-MED
,	I-MED
N	I-MED
'	I-MED
-methylenebisacrylamide	I-MED
(	O
MBA	B-MED
)	O
as	O
a	O
crosslinker	B-MED
.	O
The	O
study	B-MED
on	I-MED
drug	I-MED
loading	I-MED
,	O
using	O
salicylic	B-MED
acid	I-MED
(	O
SA	B-MED
)	O
as	O
a	O
model	B-MED
drug	I-MED
,	O
was	O
performed	O
.	O
The	O
results	O
showed	O
that	O
the	O
encapsulation	B-MED
efficiency	I-MED
(	O
EE	B-MED
)	O
increased	O
as	O
drug	B-MED
-to-	O
microgel	O
ratio	B-MED
was	O
increased	O
.	O
Higher	O
EE	B-MED
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	B-MED
,	O
by	O
increasing	O
the	O
amount	O
of	O
MBA	B-MED
from	O
0.01	O
g	O
to	O
0.03	O
g.	O
In	O
addition	O
,	O
the	O
highest	O
EE	B-MED
(	O
61.1	O
%	O
)	O
was	O
observed	O
at	O
pH	B-MED
3	O
.	O
The	O
highest	O
release	B-MED
of	I-MED
SA	I-MED
(	O
60	O
%	O
)	O
was	O
noticed	O
at	O
pH	B-MED
2.4	O
,	O
while	O
the	O
lowest	O
one	O
(	O
49.4	O
%	O
)	O
was	O
obtained	O
at	O
pH	B-MED
7.4	O
.	O
Moreover	O
,	O
the	O
highest	O
release	B-MED
of	I-MED
SA	I-MED
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0.2	O
M	O
NaCl	B-MED
.	O
The	O
pH	B-MED
-	O
and	O
ionic	B-MED
-	I-MED
sensitivity	I-MED
of	O
CS	B-MED
/	O
PHEMA	B-MED
could	O
be	O
useful	O
as	O
a	O
sustained	B-MED
release	I-MED
delivery	I-MED
device	I-MED
,	O
especially	O
for	O
oral	B-MED
delivery	I-MED
.	O
Disease	B-MED
Activity	I-MED
and	O
Increased	B-MED
Risk	I-MED
of	I-MED
Cardiovascular	B-MED
Death	I-MED
among	O
Patients	B-MED
with	O
Psoriatic	B-MED
Arthritis	I-MED
Recent	O
studies	O
indicate	O
increased	O
cardiovascular	B-MED
(	I-MED
CV	I-MED
)	I-MED
morbidity	I-MED
and	O
mortality	B-MED
in	O
patients	B-MED
with	O
psoriatic	B-MED
arthritis	I-MED
(	O
PsA	B-MED
)	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O
This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	B-MED
rate	I-MED
,	O
cause	B-MED
of	I-MED
death	I-MED
,	O
and	O
incidence	O
of	O
acute	O
CV	B-MED
events	I-MED
in	O
patients	B-MED
from	O
northern	B-MED
Sweden	B-MED
PsA	B-MED
with	O
PsA.	O
Patients	B-MED
with	O
established	O
PsA	B-MED
(	O
464	O
)	O
were	O
included	O
.	O
To	O
calculate	O
standardized	B-MED
mortality	I-MED
ratio	I-MED
(	O
SMR	B-MED
)	O
and	O
standardized	B-MED
incidence	I-MED
ratio	I-MED
(	O
SIR	B-MED
)	O
for	O
CV	B-MED
events	I-MED
,	O
data	O
were	O
extracted	O
from	O
the	O
National	B-MED
Causes	I-MED
of	I-MED
Death	I-MED
Register	I-MED
and	O
the	O
National	B-MED
Inpatient	I-MED
Care	I-MED
Register	I-MED
in	O
Sweden	B-MED
,	O
and	O
compared	O
with	O
the	O
general	B-MED
population	I-MED
.	O
The	O
study	O
period	O
was	O
1995	O
-	O
2011	O
.	O
To	O
study	O
the	O
effect	O
of	O
inflammatory	B-MED
activity	O
,	O
a	O
composite	O
disease	B-MED
activity	I-MED
index	I-MED
(	O
DAI	B-MED
)	O
was	O
used	O
.	O
The	O
SMR	B-MED
(	O
95	O
%	O
CI	O
)	O
for	O
overall	B-MED
mortality	I-MED
and	O
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
(	O
International	B-MED
Classification	I-MED
of	I-MED
Diseases	I-MED
,	O
10th	O
edition	O
;	O
I00	O
-	O
I99	O
)	O
was	O
1.22	O
(	O
0.89	O
-	O
1.63	O
)	O
and	O
1.64	O
(	O
1.02	O
-	O
2.52	O
)	O
,	O
respectively	O
.	O
In	O
regression	B-MED
analysis	I-MED
,	O
DAI	B-MED
was	O
significantly	O
associated	O
with	O
death	B-MED
(	O
OR	O
1.99	O
,	O
95	O
%	O
CI	O
1.41	O
-	O
2.80	O
)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	B-MED
patients	B-MED
into	O
the	O
2	O
major	O
causes	B-MED
of	I-MED
death	I-MED
:	O
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
and	O
malignant	B-MED
neoplasms	I-MED
.	O
Peripheral	B-MED
and	O
axial	B-MED
disease	I-MED
was	O
associated	O
with	O
death	B-MED
(	O
OR	O
4.02	O
,	O
95	O
%	O
CI	O
1.84	O
-	O
8.84	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
peripheral	B-MED
disease	I-MED
only	O
.	O
The	O
SIR	B-MED
(	O
95	O
%	O
CI	O
)	O
for	O
a	O
CV	B-MED
event	I-MED
(	O
myocardial	B-MED
infarction	I-MED
or	O
stroke	B-MED
)	O
was	O
0.597	O
(	O
0.40	O
-	O
0.86	O
)	O
;	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	B-MED
.	O
Patients	B-MED
with	O
PsA	B-MED
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	B-MED
for	O
death	B-MED
due	O
to	O
diseases	B-MED
of	I-MED
the	I-MED
circulatory	I-MED
system	I-MED
compared	O
with	O
the	O
general	B-MED
population	I-MED
.	O
Among	O
patients	B-MED
,	O
death	B-MED
was	O
associated	O
with	O
DAI	B-MED
,	O
as	O
well	O
as	O
axial	B-MED
involvement	I-MED
in	O
combination	O
with	O
peripheral	B-MED
disease	I-MED
,	O
indicating	O
more	O
aggressive	O
disease	B-MED
phenotypes	I-MED
.	O
Attributable	B-MED
risk	I-MED
of	O
ambient	B-MED
PM10	B-MED
on	O
daily	O
mortality	B-MED
and	O
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
in	O
Chengdu	B-MED
,	O
China	B-MED
Attributable	B-MED
risk	I-MED
is	O
an	O
important	O
indicator	O
for	O
planning	B-MED
and	O
evaluating	B-MED
public	I-MED
health	I-MED
interventions	I-MED
.	O
However	O
,	O
most	O
current	O
measures	O
of	O
the	O
attributable	B-MED
risk	I-MED
of	O
air	B-MED
pollutants	I-MED
have	O
not	O
considered	O
temporal	B-MED
relationships	I-MED
between	O
exposure	B-MED
and	O
risk	B-MED
.	O
More	O
importantly	O
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable	B-MED
risk	I-MED
due	O
to	O
ambient	B-MED
air	B-MED
pollutants	I-MED
in	O
basin	B-MED
regions	I-MED
like	O
the	O
Sichuan	B-MED
Basin	I-MED
,	O
China	B-MED
.	O
To	O
quantify	O
the	O
association	O
between	O
PM10	B-MED
and	O
deaths	B-MED
in	O
the	O
Basin	B-MED
region	I-MED
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed	B-MED
lag	I-MED
non	I-MED
-	I-MED
linear	I-MED
model	I-MED
to	O
estimate	O
the	O
attributable	B-MED
risk	I-MED
in	O
Chengdu	B-MED
,	O
China	B-MED
.	O
Meanwhile	O
,	O
we	O
examined	O
the	O
association	B-MED
between	O
PM10	B-MED
and	O
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
(	O
YLL	B-MED
)	O
.	O
Our	O
analysis	B-MED
showed	O
that	O
population	B-MED
-	I-MED
attributable	I-MED
fractions	I-MED
for	O
non	B-MED
-	I-MED
accidental	I-MED
,	O
respiratory	B-MED
,	O
and	O
cardiovascular	B-MED
mortality	I-MED
were	O
0.569	O
%	O
(	O
95	O
%	O
CI	O
:	O
-3.474	O
%	O
,	O
4.374	O
%	O
)	O
,	O
0.695	O
%	O
(	O
95	O
%	O
CI	O
:	O
-5.260	O
%	O
,	O
6.457	O
%	O
)	O
,	O
and	O
0.631	O
%	O
(	O
95	O
%	O
CI	O
:	O
-6.973	O
%	O
,	O
7.390	O
%	O
)	O
,	O
respectively	O
.	O
On	O
average	O
,	O
a	O
1μg	O
/	O
m(3	O
)	O
increase	O
in	O
PM10	B-MED
was	O
associated	O
with	O
cumulative	B-MED
increases	I-MED
of	O
0.26893	O
,	O
0.30437	O
,	O
and	O
0.21924	O
YLL	B-MED
for	O
non	B-MED
-	I-MED
accidental	I-MED
,	O
respiratory	B-MED
,	O
and	O
cardiovascular	B-MED
mortality	I-MED
,	O
respectively	O
,	O
referring	O
to	O
20μg	O
/	O
m(3	O
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
an	O
inverse	B-MED
U	I-MED
-	I-MED
shaped	I-MED
pattern	I-MED
for	O
the	O
cumulative	B-MED
risk	I-MED
with	O
350μg	O
/	O
m(3	O
)	O
as	O
the	O
reverse	O
point	O
.	O
With	O
a	O
1μg	O
/	O
m(3	O
)	O
increase	O
in	O
PM10	B-MED
,	O
YLL	B-MED
changed	O
more	O
significantly	O
than	O
mortality	B-MED
.	O
Moreover	O
,	O
PM10	B-MED
demonstrated	O
remarkable	O
effects	B-MED
on	O
YLL	B-MED
among	O
men	B-MED
and	O
the	O
elderly	B-MED
.	O
Prognostic	B-MED
value	I-MED
of	O
GLUT-1	B-MED
expression	B-MED
in	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
:	O
A	O
prisma	B-MED
-	I-MED
compliant	I-MED
meta	I-MED
-	I-MED
analysis	I-MED
A	O
variety	O
of	O
studies	B-MED
have	O
evaluated	B-MED
the	O
correlation	B-MED
between	O
glucose	B-MED
transporter-1	I-MED
(	O
GLUT-1	B-MED
)	O
expression	B-MED
and	O
prognosis	B-MED
of	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
OSCC	B-MED
)	O
;	O
however	O
,	O
the	O
results	B-MED
were	O
inconsistent	B-MED
and	O
inconclusive	B-MED
.	O
A	O
meta	B-MED
-	I-MED
analysis	I-MED
was	O
performed	O
to	O
assess	B-MED
the	O
prognostic	B-MED
significance	B-MED
of	O
GLUT-1	B-MED
in	O
OSCC	B-MED
.	O
Electronic	B-MED
databases	I-MED
of	O
PubMed	B-MED
,	O
Embase	B-MED
,	O
and	O
Web	B-MED
of	I-MED
Science	I-MED
were	O
searched	O
for	O
relevant	B-MED
studies	I-MED
.	O
The	O
last	O
search	O
was	O
updated	O
on	O
July	B-MED
2016	O
.	O
Odds	B-MED
ratio	I-MED
(	O
OR	B-MED
)	O
and	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
were	O
pooled	O
to	O
evaluate	B-MED
the	O
relationship	B-MED
between	O
GLUT-1	B-MED
and	O
clinical	B-MED
features	I-MED
and	O
hazard	B-MED
ratio	I-MED
(	O
HR	B-MED
)	O
and	O
95	O
%	O
CI	B-MED
were	O
combined	O
to	O
measure	B-MED
the	O
effect	B-MED
of	O
GLUT-1	B-MED
on	O
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
.	O
P	O
value	O
<	O
0.05	O
was	O
considered	O
as	O
statistically	B-MED
significant	I-MED
.	O
A	O
total	O
of	O
13	O
studies	B-MED
with	O
1301	O
subjects	B-MED
were	O
included	O
for	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
The	O
pooled	B-MED
data	I-MED
showed	O
that	O
high	O
GLUT-1	B-MED
expression	B-MED
was	O
associated	B-MED
with	I-MED
advanced	B-MED
tumor	I-MED
stages	I-MED
(	O
n	O
=	O
7	O
,	O
OR	B-MED
=	O
2.99	O
,	O
95	O
%	O
CI	B-MED
:	O
2.01	O
-	O
4.46	O
,	O
P	O
<	O
0.001	O
)	O
,	O
higher	B-MED
tumor	I-MED
grade	I-MED
(	O
n	O
=	O
5	O
,	O
OR	B-MED
=	O
3.34	O
,	O
95	O
%	O
CI	B-MED
:	O
1.12	O
-	O
9.94	O
,	O
P	O
=	O
0.031	O
)	O
,	O
tumor	B-MED
size	I-MED
(	O
n	O
=	O
5	O
,	O
OR	B-MED
=	O
3.36	O
,	O
95	O
%	O
CI	B-MED
:	O
2.04	O
-	O
5.51	O
,	O
P	O
<	O
0.001	O
)	O
,	O
lymph	B-MED
node	I-MED
metastasis	I-MED
(	O
n	O
=	O
5	O
,	O
OR	B-MED
=	O
3.15	O
,	O
95	O
%	O
CI	B-MED
:	O
1.89	O
-	O
5.25	O
,	O
P	O
<	O
0.001	O
)	O
,	O
tobacco	B-MED
use	I-MED
(	O
n	O
=	O
3	O
,	O
OR	B-MED
=	O
2.18	O
,	O
95	O
%	O
CI	B-MED
:	O
1.18	O
-	O
4.01	O
,	O
P	O
=	O
0.013	O
)	O
,	O
and	O
distant	B-MED
metastasis	I-MED
(	O
n	O
=	O
2	O
,	O
OR	B-MED
=	O
3.06	O
,	O
95	O
%	O
CI	B-MED
:	O
1.19	O
-	O
7.9	O
,	O
P	O
=	O
0.02	O
)	O
.	O
Furthermore	O
,	O
increased	B-MED
GLUT-1	B-MED
expression	B-MED
was	O
also	O
correlated	B-MED
with	O
shorter	B-MED
OS	I-MED
(	O
n	O
=	O
8	O
,	O
HR	B-MED
=	O
1.88	O
,	O
95	O
%	O
CI	B-MED
:	O
1.51	O
-	O
2.33	O
,	O
P	O
<	O
0.001	O
)	O
.	O
No	O
significant	B-MED
publication	I-MED
bias	I-MED
was	O
detected	B-MED
in	O
this	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
GLUT-1	B-MED
overexpression	B-MED
was	O
in	O
connection	O
with	O
aggressive	B-MED
clinical	I-MED
features	I-MED
and	O
worse	B-MED
OS	I-MED
in	O
OSCC	B-MED
.	O
However	O
,	O
further	O
studies	B-MED
are	O
still	O
needed	O
to	O
verify	O
whether	O
GLUT-1	B-MED
could	O
serve	O
as	O
a	O
prognostic	B-MED
biomarker	B-MED
for	O
OSCC	B-MED
.	O
Early	B-MED
high	B-MED
school	I-MED
engagement	I-MED
in	O
students	B-MED
with	O
attention	B-MED
/	I-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
Students	B-MED
with	O
attention	B-MED
/	I-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
(	O
ADHD	B-MED
)	O
continue	O
to	O
languish	O
behind	O
their	O
peers	B-MED
with	O
regard	O
to	O
academic	B-MED
achievement	I-MED
and	O
education	B-MED
attainment	I-MED
.	O
School	B-MED
engagement	I-MED
is	O
potentially	O
modifiable	O
,	O
and	O
targeting	O
engagement	B-MED
may	O
be	O
a	O
means	O
to	O
improve	O
education	B-MED
outcomes	B-MED
.	O
To	O
investigate	O
school	B-MED
engagement	I-MED
for	O
students	B-MED
with	O
ADHD	B-MED
during	O
the	O
crucial	O
high	B-MED
school	I-MED
transition	I-MED
period	B-MED
and	O
to	O
identify	O
factors	O
associated	O
with	O
low	B-MED
school	I-MED
engagement	I-MED
.	O
Participants	B-MED
are	O
adolescents	B-MED
(	O
12	O
-	O
15	O
years	B-MED
)	O
in	O
the	O
first	O
and	O
third	O
year	B-MED
of	O
high	B-MED
school	I-MED
with	O
diagnosed	B-MED
ADHD	B-MED
(	O
n	O
=	O
130	O
)	O
.	O
Participants	B-MED
were	O
recruited	O
from	O
21	O
paediatric	B-MED
practices	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
assessing	O
school	B-MED
engagement	I-MED
.	O
Data	B-MED
were	O
collected	O
through	O
direct	O
assessment	B-MED
and	O
child	B-MED
,	O
parent	B-MED
,	O
and	O
teacher	B-MED
surveys	B-MED
.	O
School	B-MED
engagement	I-MED
is	O
measured	O
as	O
student	B-MED
attitudes	I-MED
to	O
school	B-MED
(	O
cognitive	B-MED
and	O
emotional	B-MED
)	O
and	O
suspension	B-MED
rates	B-MED
(	O
behavioural	B-MED
)	O
.	O
Multivariable	B-MED
regression	I-MED
analyses	I-MED
examined	O
student	B-MED
,	O
family	B-MED
,	O
and	O
school	B-MED
factors	I-MED
affecting	O
engagement	B-MED
.	O
In	O
comparison	O
with	O
state	O
data	O
,	O
students	B-MED
with	O
ADHD	B-MED
in	O
the	O
first	O
year	B-MED
of	O
high	B-MED
school	I-MED
were	O
less	O
motivated	O
(	O
p	O
<	O
.01	O
)	O
and	O
less	O
connected	O
to	O
peers	B-MED
(	O
p	O
<	O
.01	O
)	O
.	O
Overall	O
,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	B-MED
attitudes	B-MED
.	O
There	O
were	O
high	B-MED
rates	I-MED
of	I-MED
suspension	I-MED
in	O
both	O
years	B-MED
in	O
comparison	O
to	O
state	O
-	O
wide	O
suspensions	B-MED
(	O
21	O
%	O
vs.	O
6	O
%	O
,	O
p	O
<	O
.01	O
)	O
.	O
Explanatory	O
factors	O
for	O
poor	O
attitudes	B-MED
include	O
adolescent	B-MED
depression	B-MED
,	O
poor	O
adolescent	B-MED
supervision	B-MED
,	O
and	O
devaluing	B-MED
education	B-MED
.	O
Conduct	B-MED
problems	I-MED
and	O
increased	O
hyperactivity	B-MED
were	O
related	O
to	O
increased	B-MED
likelihood	I-MED
of	I-MED
being	I-MED
suspended	I-MED
,	O
whilst	O
higher	O
cognitive	B-MED
ability	I-MED
,	O
family	B-MED
socio	B-MED
-	I-MED
economic	I-MED
status	I-MED
,	O
and	O
independent	O
schools	B-MED
reduced	O
risk	B-MED
.	O
Potentially	O
modifiable	O
individual	B-MED
and	O
family	B-MED
factors	B-MED
including	O
adolescent	B-MED
depression	B-MED
,	O
behavioural	B-MED
problems	I-MED
,	O
education	B-MED
values	B-MED
,	O
and	O
family	B-MED
supervision	B-MED
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high	B-MED
school	I-MED
transition	I-MED
for	O
students	B-MED
with	O
ADHD	B-MED
.	O
Electronic	B-MED
tongues	I-MED
to	O
assess	O
wine	B-MED
sensory	B-MED
descriptors	B-MED
This	O
work	B-MED
reports	B-MED
the	O
application	B-MED
of	O
an	O
electronic	B-MED
tongue	I-MED
as	O
a	O
tool	B-MED
towards	O
the	O
analysis	B-MED
of	O
wine	B-MED
in	O
tasks	O
such	O
as	O
its	O
discrimination	B-MED
based	O
on	O
the	O
maturing	B-MED
in	O
barrels	B-MED
or	O
the	O
prediction	B-MED
of	O
the	O
global	B-MED
scores	B-MED
assigned	O
by	O
a	O
sensory	B-MED
panel	I-MED
.	O
To	O
this	O
aim	O
,	O
red	B-MED
wine	I-MED
samples	B-MED
were	O
first	O
analysed	B-MED
with	O
the	O
voltammetric	B-MED
sensor	I-MED
array	I-MED
,	O
without	O
performing	O
any	O
sample	B-MED
pretreatment	B-MED
.	O
Afterwards	O
,	O
obtained	O
responses	B-MED
were	O
preprocessed	B-MED
employing	O
fast	B-MED
Fourier	I-MED
transform	I-MED
(	O
FFT	B-MED
)	O
for	O
the	O
compression	B-MED
and	O
reduction	B-MED
of	O
signal	B-MED
complexity	B-MED
,	O
and	O
obtained	O
coefficients	B-MED
were	O
then	O
used	O
as	O
inputs	B-MED
to	O
build	O
the	O
qualitative	B-MED
and	O
quantitative	B-MED
models	B-MED
employing	O
either	O
linear	B-MED
discriminant	I-MED
analysis	I-MED
(	O
LDA	B-MED
)	O
or	O
partial	B-MED
least	I-MED
squares	I-MED
regression	I-MED
(	O
PLS	B-MED
)	O
,	O
respectively	O
.	O
Satisfactory	O
results	B-MED
were	O
obtained	O
overall	O
,	O
with	O
a	O
classification	B-MED
rate	B-MED
of	O
100	O
%	O
in	O
the	O
discrimination	B-MED
of	O
the	O
type	O
of	O
barrel	B-MED
used	O
during	O
wine	B-MED
maturing	B-MED
,	O
a	O
normalized	B-MED
NRMSE	I-MED
of	O
0.077	O
in	O
the	O
estimation	O
of	O
ageing	B-MED
time	B-MED
(	O
months	B-MED
)	O
or	O
0.11	O
in	O
the	O
prediction	B-MED
of	O
the	O
scores	B-MED
(	O
0	O
-	O
10	O
)	O
from	O
a	O
trained	B-MED
sensory	I-MED
panel	I-MED
(	O
all	O
for	O
the	O
external	O
test	B-MED
subset	B-MED
)	O
.	O
Serum	B-MED
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
receptor-3	I-MED
levels	B-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
cancer	I-MED
Esophageal	B-MED
cancer	I-MED
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-MED
of	I-MED
the	I-MED
gastrointestinal	I-MED
tract	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	B-MED
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor-3	I-MED
(	O
VEGFR-3	B-MED
)	O
expression	B-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
ESCC	B-MED
)	O
to	O
evaluate	O
the	O
role	O
of	O
VEGFR-3	B-MED
in	O
ESCC	B-MED
.	O
Ninety	O
five	O
patients	B-MED
with	O
ESCC	B-MED
were	O
studied	O
.	O
Pre	B-MED
-	I-MED
therapy	I-MED
and	O
preoperative	B-MED
samples	B-MED
were	O
stored	O
and	O
ELISA	B-MED
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
VEGFR-3	B-MED
.	O
The	O
serum	B-MED
values	I-MED
of	O
VEGFR-3	B-MED
were	O
significantly	O
higher	O
in	O
patients	B-MED
with	O
ESCC	B-MED
than	O
in	O
healthy	B-MED
donors	B-MED
(	O
p<0.0001	O
)	O
.	O
The	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	B-MED
of	O
VEGFR-3	B-MED
in	O
ESCC	B-MED
.	O
VEGFR-3	B-MED
may	O
be	O
a	O
good	O
diagnostic	B-MED
biomarker	B-MED
for	O
ESCC	B-MED
.	O
Biomarker	B-MED
,	O
ESCC	B-MED
,	O
VEGFR-3	B-MED
.	O
Influence	B-MED
of	O
Surface	B-MED
Properties	I-MED
on	O
Adhesion	B-MED
Forces	I-MED
and	O
Attachment	B-MED
of	O
Streptococcus	B-MED
mutans	I-MED
to	O
Zirconia	B-MED
In	B-MED
Vitro	I-MED
Zirconia	B-MED
is	O
becoming	O
a	O
prevalent	B-MED
material	I-MED
in	O
dentistry	B-MED
.	O
However	O
,	O
any	O
foreign	B-MED
bodies	I-MED
inserted	B-MED
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-MED
in	O
oral	B-MED
cavity	I-MED
.	O
The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	B-MED
of	O
surface	B-MED
properties	I-MED
including	O
surface	B-MED
roughness	I-MED
and	O
hydrophobicity	B-MED
on	O
the	O
adhesion	B-MED
and	O
biofilm	B-MED
formation	I-MED
of	O
Streptococcus	B-MED
mutans	I-MED
(	O
S.	B-MED
mutans	I-MED
)	O
to	O
zirconia	B-MED
.	O
Atomic	B-MED
force	I-MED
microscopy	I-MED
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-MED
surface	B-MED
morphology	B-MED
and	O
the	O
adhesion	B-MED
forces	I-MED
between	O
the	O
S.	B-MED
mutans	I-MED
and	O
zirconia	B-MED
.	O
The	O
results	B-MED
showed	O
that	O
the	O
surface	B-MED
roughness	I-MED
was	O
nanoscale	B-MED
and	O
significantly	O
different	B-MED
among	O
tested	B-MED
groups	I-MED
(	O
P	O
<	O
0.05	O
):	O
Coarse	B-MED
(	O
23.94	O
±	O
2.52	O
nm	O
)	O
>	O
Medium	B-MED
(	O
17.00	O
±	O
3.81	O
nm	O
)	O
>	O
Fine	B-MED
(	O
11.89	O
±	O
1.68	O
nm	O
)	O
.	O
The	O
contact	B-MED
angles	I-MED
of	O
the	O
Coarse	B-MED
group	I-MED
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
Medium	B-MED
and	O
the	O
Fine	B-MED
groups	I-MED
.	O
Increasing	O
the	O
surface	B-MED
roughness	I-MED
and	O
hydrophobicity	B-MED
resulted	O
in	O
an	O
increase	O
of	O
adhesion	B-MED
forces	I-MED
and	O
early	O
attachment	B-MED
(	O
2	O
h	O
and	O
4	O
h	O
)	O
of	O
S.	B-MED
mutans	I-MED
on	O
the	O
zirconia	B-MED
but	O
no	O
influence	B-MED
on	O
the	O
further	O
development	B-MED
of	O
biofilm	B-MED
(	O
6	O
h~24	O
h	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
surface	B-MED
roughness	I-MED
in	O
nanoscale	B-MED
and	O
hydrophobicity	B-MED
of	O
zirconia	B-MED
had	O
influence	B-MED
on	O
the	O
S.	B-MED
mutans	I-MED
initial	O
adhesion	B-MED
force	I-MED
and	O
early	O
attachment	B-MED
instead	O
of	O
whole	O
stages	O
of	O
biofilm	B-MED
formation	I-MED
.	O
Antigen	B-MED
specificity	I-MED
determines	O
anti	B-MED
-	I-MED
red	I-MED
blood	I-MED
cell	I-MED
IgG	I-MED
-	I-MED
Fc	I-MED
alloantibody	I-MED
glycosylation	B-MED
and	O
thereby	O
severity	B-MED
of	O
haemolytic	B-MED
disease	I-MED
of	I-MED
the	I-MED
fetus	I-MED
and	I-MED
newborn	I-MED
Haemolytic	B-MED
disease	I-MED
of	I-MED
the	I-MED
fetus	I-MED
and	I-MED
newborn	I-MED
(	O
HDFN	B-MED
)	O
is	O
a	O
severe	O
disease	B-MED
in	O
which	O
fetal	B-MED
red	B-MED
blood	I-MED
cells	I-MED
(	O
RBC	B-MED
)	O
are	O
destroyed	B-MED
by	O
maternal	B-MED
anti	I-MED
-	I-MED
RBC	I-MED
IgG	I-MED
alloantibodies	I-MED
.	O
HDFN	B-MED
is	O
most	O
often	O
caused	O
by	O
anti	B-MED
-	I-MED
D	I-MED
but	O
may	O
also	O
occur	O
due	B-MED
to	I-MED
anti	B-MED
-	I-MED
K	I-MED
,	O
-c	B-MED
-E	B-MED
-	O
or	O
-E.	O
We	O
recently	O
found	O
N	B-MED
-	I-MED
linked	I-MED
glycosylation	I-MED
of	O
anti	B-MED
-	I-MED
D	I-MED
to	O
be	O
skewed	O
towards	O
low	B-MED
fucosylation	B-MED
,	O
thereby	O
increasing	B-MED
the	O
affinity	B-MED
to	O
IgG	B-MED
-	I-MED
Fc	I-MED
receptor	I-MED
IIIa	I-MED
and	O
IIIb	B-MED
,	O
which	O
correlated	B-MED
with	O
HDFN	B-MED
disease	B-MED
severity	B-MED
.	O
Here	O
,	O
we	O
analysed	O
230	O
pregnant	B-MED
women	I-MED
with	O
anti	B-MED
-	I-MED
c	I-MED
,	O
-E	B-MED
or	O
-K	B-MED
alloantibodies	B-MED
from	O
a	O
prospective	O
screening	B-MED
cohort	I-MED
and	O
investigated	B-MED
the	O
type	O
of	O
Fc	B-MED
-	I-MED
tail	I-MED
glycosylation	I-MED
of	O
these	O
antibodies	B-MED
in	O
relation	O
to	O
the	O
trigger	B-MED
of	O
immunisation	B-MED
and	O
pregnancy	B-MED
outcome	I-MED
.	O
Anti	B-MED
-	I-MED
c	I-MED
,	O
-E	B-MED
and	O
-K	B-MED
show	O
-	O
independent	B-MED
of	I-MED
the	O
event	B-MED
that	O
had	O
led	O
to	O
immunisation	B-MED
-	O
a	O
different	B-MED
kind	O
of	O
Fc	B-MED
-	I-MED
glycosylation	I-MED
compared	O
to	O
that	O
of	O
the	O
total	O
IgG	B-MED
IgG	B-MED
fraction	I-MED
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti	B-MED
-	I-MED
D	I-MED
D.	O
High	O
Fc	B-MED
-	I-MED
galactosylation	I-MED
and	O
sialylation	B-MED
of	O
anti	B-MED
-	I-MED
c	I-MED
correlated	O
with	O
HDFN	B-MED
disease	B-MED
severity	B-MED
,	O
while	O
low	O
anti	B-MED
-	I-MED
K	I-MED
Fc	B-MED
-	I-MED
fucosylation	I-MED
correlated	B-MED
with	O
severe	B-MED
fetal	B-MED
anaemia	I-MED
.	O
IgG	B-MED
-	I-MED
Fc	I-MED
glycosylation	I-MED
of	O
anti	B-MED
-	I-MED
RBC	I-MED
antibodies	I-MED
is	O
shaped	O
depending	O
on	O
the	O
antigen	B-MED
.	O
These	O
features	B-MED
influence	O
their	O
clinical	B-MED
potency	I-MED
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	B-MED
severity	B-MED
and	O
identify	O
those	O
needing	O
treatment	B-MED
.	O
Significance	B-MED
of	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
in	O
early	B-MED
-	I-MED
stage	I-MED
cervical	B-MED
cancer	I-MED
To	O
examine	O
characteristics	B-MED
and	O
survival	B-MED
outcomes	B-MED
of	O
women	B-MED
with	O
surgically	B-MED
-	I-MED
treated	I-MED
cervical	B-MED
cancer	I-MED
exhibiting	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
.	O
We	O
utilized	O
The	O
Surveillance	B-MED
,	I-MED
Epidemiology	I-MED
,	I-MED
and	I-MED
End	I-MED
Results	I-MED
Program	I-MED
to	O
identify	O
cervical	B-MED
cancer	I-MED
patients	B-MED
who	O
underwent	O
hysterectomy	B-MED
between	O
1973	O
and	O
2003	O
.	O
Logistic	B-MED
regression	I-MED
models	I-MED
were	O
used	O
to	O
identify	O
risk	B-MED
factors	I-MED
for	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
on	O
multivariable	B-MED
analysis	I-MED
.	O
Association	B-MED
of	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
and	O
cause	B-MED
-	I-MED
specific	I-MED
survival	I-MED
(	O
CSS	B-MED
)	O
from	O
cervical	B-MED
cancer	I-MED
was	O
examined	O
with	O
Cox	B-MED
proportional	I-MED
hazard	I-MED
regression	I-MED
models	I-MED
on	O
multivariable	B-MED
analysis	I-MED
.	O
We	O
identified	O
837	O
(	O
4.9	O
%	O
)	O
cases	O
of	O
uterine	B-MED
corpus	I-MED
invasion	B-MED
and	O
16,237	O
(	O
95.1	O
%	O
)	O
cases	O
of	O
non	B-MED
-	I-MED
invasion	I-MED
.	O
Median	B-MED
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
was	O
14.0	O
years	O
.	O
There	O
were	O
1642	O
deaths	B-MED
due	O
to	O
cervical	B-MED
cancer	I-MED
.	O
Uterine	B-MED
corpus	I-MED
invasion	B-MED
was	O
independently	B-MED
associated	B-MED
with	I-MED
older	B-MED
age	I-MED
,	O
non	B-MED
-	I-MED
squamous	I-MED
histology	I-MED
,	O
high	B-MED
-	I-MED
grade	I-MED
tumors	I-MED
,	O
large	B-MED
tumor	I-MED
size	I-MED
,	O
and	O
nodal	B-MED
metastasis	B-MED
on	O
multivariable	B-MED
analysis	I-MED
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O
On	O
univariable	B-MED
analysis	I-MED
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
decreased	B-MED
CSS	B-MED
compared	O
to	O
the	O
non	B-MED
-	I-MED
invasion	I-MED
(	O
5	O
-	O
year	O
rates	O
,	O
79.0	O
%	O
versus	O
94.5	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O
After	O
controlling	B-MED
for	O
other	O
significant	B-MED
prognostic	B-MED
factors	I-MED
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
remained	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
CSS	B-MED
(	O
adjusted	B-MED
-	I-MED
hazard	I-MED
ratio	I-MED
1.45	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
1.21	O
-	O
1.74	O
)	O
.	O
Among	O
stage	B-MED
T1b	I-MED
cases	O
(	O
n	O
=	O
6730	O
)	O
,	O
uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
remained	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
CSS	B-MED
(	O
adjusted	B-MED
-	I-MED
hazard	I-MED
ratio	I-MED
1.95	O
,	O
95%CI	O
1.47	O
-	O
2.60	O
)	O
.	O
Uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
decreased	B-MED
CSS	B-MED
in	O
stage	B-MED
T1b1	I-MED
disease	B-MED
(	O
74.5	O
%	O
versus	O
90.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
in	O
stage	B-MED
T1b2	I-MED
disease	B-MED
(	O
67.0	O
%	O
versus	O
79.5	O
%	O
,	O
P	O
=	O
0.01	O
)	O
.	O
Uterine	B-MED
corpus	I-MED
tumor	I-MED
invasion	B-MED
is	O
an	O
independent	B-MED
prognostic	B-MED
factor	I-MED
for	O
decreased	B-MED
survival	B-MED
of	O
women	B-MED
with	O
early	B-MED
-	I-MED
stage	I-MED
cervical	B-MED
cancer	I-MED
.	O
Temporal	B-MED
Stability	B-MED
of	O
Heavy	B-MED
Drinking	I-MED
Days	O
and	O
Drinking	B-MED
Reductions	B-MED
Among	O
Heavy	B-MED
Drinkers	I-MED
in	O
the	O
COMBINE	B-MED
Study	I-MED
Recently	O
,	O
the	O
Food	B-MED
and	I-MED
Drug	I-MED
Administration	I-MED
(	O
FDA	B-MED
)	O
proposed	O
to	O
expand	B-MED
the	O
options	O
for	O
primary	B-MED
end	B-MED
points	I-MED
in	O
the	O
development	B-MED
of	O
medications	B-MED
for	O
alcohol	B-MED
use	I-MED
disorder	I-MED
to	O
include	O
either	O
abstinence	B-MED
from	O
alcohol	B-MED
or	O
a	O
nonabstinent	B-MED
outcome	B-MED
:	O
no	O
heavy	B-MED
drinking	I-MED
days	O
(	O
with	O
a	O
heavy	B-MED
drinking	I-MED
day	O
defined	B-MED
as	O
more	O
than	O
3	O
drinks	B-MED
per	O
day	O
for	O
women	B-MED
and	O
more	O
than	O
4	O
drinks	B-MED
per	O
day	O
for	O
men	B-MED
[	O
>	O
3/>4	O
cutoff	B-MED
]	O
)	O
.	O
The	O
FDA	B-MED
also	O
suggested	B-MED
that	O
6	O
months	B-MED
would	O
be	O
the	O
most	O
appropriate	B-MED
length	B-MED
for	I-MED
a	I-MED
clinical	I-MED
trial	I-MED
to	O
demonstrate	O
the	O
stability	B-MED
of	O
this	O
nonabstinent	B-MED
drinking	B-MED
outcome	B-MED
.	O
However	O
,	O
few	O
alcohol	O
clinical	B-MED
trials	I-MED
have	O
examined	B-MED
the	O
stability	B-MED
of	O
nonheavy	B-MED
drinking	I-MED
during	B-MED
and	O
after	B-MED
treatment	I-MED
.	O
In	O
a	O
secondary	B-MED
analysis	I-MED
of	O
the	O
COMBINE	B-MED
study	I-MED
data	B-MED
(	O
n	O
=	O
1,383	O
)	O
,	O
we	O
examined	B-MED
transitions	B-MED
in	O
heavy	B-MED
drinking	I-MED
days	O
during	B-MED
the	I-MED
course	I-MED
of	I-MED
treatment	I-MED
(	O
months	B-MED
1	O
through	O
4	O
)	O
,	O
during	B-MED
the	O
transition	B-MED
out	O
of	O
treatment	B-MED
(	O
months	B-MED
4	O
through	O
7	O
)	O
,	O
and	O
up	O
to	O
12	O
months	B-MED
afterward	O
(	O
months	B-MED
13	O
through	O
16	O
)	O
using	O
latent	B-MED
variable	I-MED
mixture	I-MED
models	I-MED
.	O
Heavy	B-MED
drinking	I-MED
and	O
nonheavy	B-MED
drinking	I-MED
were	O
relatively	O
stable	B-MED
in	O
consecutive	B-MED
months	B-MED
(	O
minimum	B-MED
agreement	O
[	O
kappa	O
]	O
=	O
0.64	O
for	O
months	B-MED
1	O
to	O
2	O
)	O
.	O
Most	O
individuals	B-MED
were	O
stable	B-MED
low	B-MED
-	I-MED
risk	I-MED
drinkers	B-MED
/	O
abstainers	B-MED
or	O
heavy	B-MED
drinkers	I-MED
by	O
the	O
end	O
of	O
treatment	B-MED
,	O
as	O
characterized	B-MED
by	O
a	O
10	O
%	O
probability	B-MED
(	O
or	O
less	O
)	O
of	O
transitioning	B-MED
out	O
of	O
either	O
a	O
no	O
heavy	B-MED
drinking	I-MED
state	B-MED
or	O
a	O
heavy	B-MED
drinking	I-MED
state	B-MED
.	O
More	O
than	O
two	O
-	O
thirds	O
of	O
the	O
heavy	B-MED
drinkers	I-MED
who	O
exceeded	O
the	O
heavy	B-MED
drinking	I-MED
threshold	B-MED
during	B-MED
treatment	I-MED
reported	B-MED
,	O
on	O
average	B-MED
,	O
a	O
64	O
%	O
reduction	B-MED
in	O
drinking	B-MED
frequency	I-MED
and	O
a	O
38	O
%	O
reduction	B-MED
in	O
drinking	B-MED
intensity	O
from	O
pretreatment	B-MED
drinking	B-MED
levels	B-MED
.	O
The	O
results	B-MED
show	O
stability	B-MED
of	O
no	O
heavy	B-MED
drinking	I-MED
as	O
an	O
outcome	B-MED
within	O
the	O
first	O
4	O
months	B-MED
of	O
treatment	B-MED
and	O
that	O
the	O
>	O
3/>4	O
drink	B-MED
cutoff	B-MED
may	O
mask	O
substantial	O
reductions	B-MED
in	O
alcohol	B-MED
consumption	I-MED
among	O
some	O
patients	B-MED
.	O
Future	O
studies	B-MED
should	O
explore	O
the	O
clinical	B-MED
utility	O
of	O
reduction	B-MED
end	B-MED
points	I-MED
.	O
Quantitative	B-MED
analysis	I-MED
of	O
cell	B-MED
proliferation	I-MED
by	O
a	O
dye	B-MED
dilution	I-MED
assay	I-MED
:	O
Application	B-MED
to	O
cell	B-MED
lines	I-MED
and	O
cocultures	B-MED
Cell	B-MED
proliferation	I-MED
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	B-MED
in	I-MED
biological	I-MED
systems	I-MED
,	O
thus	O
the	O
quantitative	B-MED
analysis	I-MED
of	O
cell	B-MED
proliferation	I-MED
is	O
important	O
in	O
many	O
biological	B-MED
applications	B-MED
such	O
as	O
drug	B-MED
screening	I-MED
,	O
production	O
of	O
biologics	B-MED
,	O
and	O
assessment	B-MED
of	O
cytotoxicity	B-MED
.	O
Conventional	B-MED
proliferation	B-MED
assays	I-MED
mainly	O
quantify	O
cell	B-MED
number	I-MED
based	O
on	O
a	O
calibration	B-MED
curve	I-MED
of	O
a	O
homogeneous	B-MED
cell	B-MED
population	I-MED
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	B-MED
of	O
cocultured	B-MED
cells	I-MED
.	O
Moreover	O
,	O
these	O
assays	B-MED
measure	B-MED
cell	B-MED
proliferation	I-MED
indirectly	O
,	O
based	O
on	O
cellular	B-MED
metabolic	I-MED
activity	I-MED
or	O
DNA	B-MED
content	I-MED
.	O
To	O
overcome	B-MED
these	O
shortcomings	O
,	O
a	O
dye	B-MED
dilution	I-MED
assay	I-MED
employing	O
fluorescent	B-MED
cell	I-MED
tracking	I-MED
dyes	I-MED
that	O
are	O
retained	B-MED
within	O
cells	B-MED
was	O
applied	O
and	O
was	O
diluted	B-MED
proportionally	B-MED
by	O
subsequent	O
cell	B-MED
divisions	I-MED
.	O
Here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-MED
could	O
be	O
implemented	O
to	O
quantitatively	B-MED
analyze	I-MED
the	O
cell	B-MED
proliferation	I-MED
of	O
different	O
types	O
of	O
cell	B-MED
lines	I-MED
,	O
and	O
to	O
concurrently	B-MED
analyze	B-MED
the	O
proliferation	B-MED
of	O
two	O
types	O
of	O
cell	B-MED
lines	I-MED
in	O
coculture	B-MED
by	O
utilizing	O
cell	B-MED
tracking	I-MED
dyes	B-MED
with	O
different	O
spectral	B-MED
characteristics	B-MED
.	O
The	O
mean	B-MED
division	I-MED
time	I-MED
estimated	B-MED
by	O
the	O
dye	B-MED
dilution	I-MED
assay	I-MED
is	O
compared	O
with	O
the	O
population	B-MED
doubling	I-MED
time	I-MED
obtained	O
from	O
conventional	B-MED
methods	B-MED
and	O
values	B-MED
from	O
literature	B-MED
.	O
Additionally	O
,	O
dye	B-MED
transfer	O
between	O
cocultured	B-MED
cells	I-MED
was	O
investigated	B-MED
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	B-MED
of	O
the	O
cells	B-MED
rather	O
than	O
a	O
characteristic	B-MED
of	O
the	O
dye	B-MED
.	O
It	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-MED
cytometric	I-MED
analyses	I-MED
of	O
cellular	B-MED
properties	B-MED
,	O
providing	O
valuable	B-MED
information	B-MED
on	O
cell	B-MED
status	I-MED
under	O
diverse	B-MED
conditions	B-MED
.	O
©	O
2017	O
International	O
Society	O
for	O
Advancement	O
of	O
Cytometry	O
.	O
Iterative	B-MED
Development	B-MED
and	O
Evaluation	B-MED
of	O
a	O
Pharmacogenomic	B-MED
-Guided	O
Clinical	B-MED
Decision	I-MED
Support	I-MED
System	I-MED
for	O
Warfarin	B-MED
Dosing	I-MED
Pharmacogenomic	B-MED
-guided	O
dosing	B-MED
has	O
the	O
potential	O
to	O
improve	O
patient	B-MED
outcomes	O
but	O
its	O
implementation	B-MED
has	O
been	O
met	O
with	O
clinical	B-MED
challenges	B-MED
.	O
Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-MED
a	O
clinical	B-MED
decision	I-MED
support	I-MED
system	I-MED
(	O
CDSS	B-MED
)	O
for	O
pharmacogenomic	B-MED
-guided	O
warfarin	B-MED
dosing	I-MED
designed	B-MED
for	O
physicians	B-MED
and	O
pharmacists	B-MED
.	O
Twelve	O
physicians	B-MED
and	O
pharmacists	B-MED
completed	O
6	O
prescribing	B-MED
tasks	B-MED
using	O
simulated	B-MED
patient	I-MED
scenarios	B-MED
in	O
two	O
iterations	B-MED
(	O
development	B-MED
and	O
validation	B-MED
phases	B-MED
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	B-MED
-driven	O
CDSS	B-MED
prototype	B-MED
.	O
For	O
each	O
scenario	B-MED
,	O
usability	B-MED
was	O
measured	B-MED
via	O
efficiency	B-MED
,	O
recorded	B-MED
as	O
time	B-MED
to	I-MED
task	I-MED
completion	I-MED
,	O
and	O
participants	B-MED
'	O
perceived	B-MED
satisfaction	B-MED
which	O
were	O
compared	O
using	O
Kruskal	B-MED
-	I-MED
Wallis	I-MED
and	I-MED
Mann	I-MED
Whitney	I-MED
U	I-MED
tests	I-MED
,	O
respectively	O
.	O
Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-MED
analyzed	I-MED
.	O
Usability	B-MED
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	B-MED
)	O
iteration	B-MED
were	O
incorporated	O
into	O
the	O
CDSS	B-MED
design	B-MED
for	O
the	O
second	B-MED
(	O
i.e.	O
validation	B-MED
)	O
iteration	B-MED
.	O
During	O
the	O
CDSS	B-MED
validation	B-MED
iteration	B-MED
,	O
participants	B-MED
took	O
more	O
time	B-MED
to	I-MED
complete	I-MED
tasks	I-MED
with	O
a	O
median	B-MED
(	O
IQR	O
)	O
of	O
183	O
(	O
124	O
-	O
247	O
)	O
seconds	B-MED
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	B-MED
in	O
the	O
development	B-MED
iteration	B-MED
(	O
p=0.01	O
)	O
.	O
This	O
increase	B-MED
in	O
time	B-MED
on	I-MED
task	I-MED
was	O
due	O
to	O
the	O
increase	B-MED
in	O
time	B-MED
spent	O
in	O
the	O
CDSS	B-MED
corresponding	O
to	O
several	O
design	B-MED
changes	O
.	O
Efficiency	B-MED
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B-MED
and	O
physicians	B-MED
in	O
the	O
development	B-MED
iteration	B-MED
were	O
eliminated	O
in	O
the	O
validation	B-MED
iteration	B-MED
.	O
The	O
increased	B-MED
use	O
of	O
the	O
CDSS	B-MED
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	B-MED
recommended	O
doses	B-MED
in	O
the	O
validation	B-MED
iteration	B-MED
(	O
4	O
%	O
in	O
the	O
first	O
iteration	B-MED
vs.	O
37.5	O
%	O
in	O
the	O
second	B-MED
iteration	B-MED
,	O
p<0.001	O
)	O
.	O
Overall	O
satisfaction	B-MED
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-MED
but	O
the	O
qualitative	B-MED
analysis	I-MED
revealed	O
greater	O
trust	O
in	O
the	O
second	B-MED
prototype	B-MED
.	O
A	O
pharmacogenomic	B-MED
-guided	O
CDSS	B-MED
has	O
been	O
developed	O
using	O
warfarin	B-MED
as	O
the	O
test	O
drug	B-MED
.	O
The	O
final	O
CDSS	B-MED
prototype	B-MED
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	B-MED
the	O
time	B-MED
using	O
the	O
tool	B-MED
and	O
acceptance	O
of	O
the	O
recommended	O
doses	B-MED
.	O
This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B-MED
into	O
CDSS	B-MED
design	B-MED
for	O
clinical	B-MED
testing	I-MED
.	O
Morphogenetic	B-MED
Alterations	B-MED
of	O
Alternaria	B-MED
alternata	I-MED
Exposed	B-MED
to	I-MED
Dicarboximide	B-MED
Fungicide	I-MED
,	O
Iprodione	B-MED
Fungicide	B-MED
-	I-MED
resistant	I-MED
Alternaria	B-MED
alternata	I-MED
impede	O
the	O
practical	O
control	B-MED
of	O
the	O
Alternaria	B-MED
diseases	I-MED
in	O
crop	B-MED
fields	B-MED
.	O
This	O
study	O
aimed	O
to	O
investigate	B-MED
cytological	B-MED
fungicide	B-MED
resistance	B-MED
mechanisms	B-MED
of	O
A.	B-MED
alternata	I-MED
against	O
dicarboximide	B-MED
fungicide	I-MED
iprodione	B-MED
.	O
A.	B-MED
alternata	I-MED
isolated	B-MED
from	O
cactus	B-MED
brown	B-MED
spot	I-MED
was	O
cultured	B-MED
on	O
potato	B-MED
-	I-MED
dextrose	I-MED
agar	I-MED
(	O
PDA	B-MED
)	O
with	O
or	O
without	B-MED
iprodione	B-MED
,	O
and	O
the	O
fungal	B-MED
cultures	I-MED
with	O
different	B-MED
growth	B-MED
characteristics	B-MED
from	O
no	B-MED
,	O
initial	B-MED
and	O
full	B-MED
growth	B-MED
were	O
observed	B-MED
by	O
light	B-MED
and	O
electron	B-MED
microscopy	I-MED
.	O
Mycelia	B-MED
began	O
to	O
grow	B-MED
from	O
one	B-MED
day	I-MED
after	I-MED
incubation	I-MED
(	O
DAI	B-MED
)	O
and	O
continued	B-MED
to	O
be	O
in	O
full	B-MED
growth	B-MED
(	O
control	B-MED
-	I-MED
growth	I-MED
,	O
Con	B-MED
-	I-MED
G	I-MED
)	O
on	O
PDA	B-MED
without	O
fungicide	B-MED
,	O
while	O
on	O
PDA	B-MED
with	O
iprodione	B-MED
,	O
no	B-MED
fungal	I-MED
growth	I-MED
(	O
iprodione	B-MED
-	I-MED
no	I-MED
growth	I-MED
,	O
Ipr	B-MED
-	I-MED
N	I-MED
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	B-MED
,	O
but	O
once	O
the	O
initial	B-MED
growth	B-MED
(	O
iprodione	B-MED
-	I-MED
initial	I-MED
growth	I-MED
,	O
Ipr	B-MED
-	I-MED
I	I-MED
)	O
began	O
at	O
4	O
-	O
5	O
DAI	B-MED
,	O
the	O
colonies	B-MED
grew	O
and	O
expanded	B-MED
continuously	B-MED
to	O
be	O
in	O
full	B-MED
growth	B-MED
(	O
iprodione	B-MED
-	I-MED
growth	I-MED
,	O
Ipr	B-MED
-	I-MED
G	I-MED
)	O
,	O
suggesting	O
Ipr	B-MED
-	I-MED
I	I-MED
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	B-MED
changes	B-MED
resisting	B-MED
fungicidal	B-MED
toxicity	B-MED
.	O
Con	B-MED
-	I-MED
G	I-MED
formed	O
multicellular	B-MED
conidia	I-MED
with	O
cell	B-MED
walls	I-MED
and	O
septa	B-MED
and	O
intact	B-MED
dense	B-MED
cytoplasm	B-MED
.	O
In	O
Ipr	B-MED
-	I-MED
N	I-MED
,	O
fungal	B-MED
sporulation	B-MED
was	O
inhibited	B-MED
by	O
forming	O
mostly	O
undeveloped	B-MED
unicellular	B-MED
conidia	I-MED
with	O
degraded	B-MED
and	O
necrotic	B-MED
cytoplasm	B-MED
.	O
However	O
,	O
in	O
Ipr	B-MED
-	I-MED
I	I-MED
,	O
conspicuous	B-MED
cellular	I-MED
changes	I-MED
occurred	O
during	O
sporulation	B-MED
by	O
forming	O
multicellular	B-MED
conidia	I-MED
with	O
double	B-MED
layered	I-MED
(	O
thickened	B-MED
)	O
cell	B-MED
walls	I-MED
and	O
accumulation	B-MED
of	O
proliferated	B-MED
lipid	B-MED
bodies	I-MED
in	O
the	O
conidial	B-MED
cytoplasm	B-MED
,	O
which	O
may	O
inhibit	B-MED
the	O
penetration	B-MED
of	O
the	O
fungicide	B-MED
into	O
conidial	B-MED
cells	B-MED
,	O
reducing	O
fungicide	B-MED
-	O
associated	B-MED
toxicity	B-MED
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	B-MED
and	O
nutritional	B-MED
sources	B-MED
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	B-MED
growth	B-MED
to	O
form	O
mature	B-MED
colonies	B-MED
as	O
in	O
Ipr	B-MED
-	I-MED
G	I-MED
that	O
formed	O
multicellular	B-MED
conidia	I-MED
with	O
cell	B-MED
walls	I-MED
and	O
intact	B-MED
cytoplasm	B-MED
with	O
lipid	B-MED
bodies	I-MED
as	O
in	O
Con	B-MED
-	I-MED
G	I-MED
G.	O
Effect	B-MED
of	I-MED
peritoneal	B-MED
lavage	I-MED
solution	B-MED
temperature	B-MED
on	O
body	B-MED
temperature	I-MED
in	O
anaesthetised	B-MED
cats	B-MED
and	O
small	O
dogs	B-MED
A	O
prospective	B-MED
,	O
randomised	B-MED
,	O
non	B-MED
-	I-MED
blinded	I-MED
,	O
clinical	B-MED
study	I-MED
to	O
assess	O
the	O
effect	B-MED
of	I-MED
peritoneal	B-MED
lavage	I-MED
using	O
warmed	B-MED
fluid	B-MED
on	O
body	B-MED
temperature	I-MED
in	O
anesthetised	B-MED
cats	B-MED
and	O
dogs	B-MED
of	O
less	O
than	O
10	O
kg	O
body	B-MED
mass	I-MED
undergoing	O
coeliotomy	B-MED
.	O
A	O
standardised	B-MED
anaesthetic	I-MED
protocol	I-MED
was	O
used	O
.	O
Oesophageal	B-MED
and	O
rectal	B-MED
temperatures	I-MED
were	O
measured	B-MED
at	O
various	B-MED
time	I-MED
points	I-MED
.	O
At	O
the	O
end	O
of	O
surgery	B-MED
,	O
group	B-MED
1	I-MED
patients	I-MED
(	O
n=10	O
)	O
were	O
lavaged	B-MED
with	O
200	O
ml	O
/	O
kg	O
sterile	B-MED
isotonic	B-MED
saline	I-MED
at	O
34±1	O
°	O
C	O
and	O
group	B-MED
2	O
(	O
n=10	O
)	O
at	O
40±1	O
°	O
C	O
.	O
Groups	B-MED
were	O
similar	O
with	O
respect	O
to	O
age	B-MED
,	O
mass	B-MED
,	O
body	B-MED
condition	I-MED
and	O
surgical	B-MED
incision	I-MED
length	O
.	O
Duration	B-MED
of	O
anaesthesia	B-MED
,	O
surgical	B-MED
procedures	I-MED
and	O
peritoneal	B-MED
lavage	I-MED
was	O
similar	O
between	O
groups	B-MED
.	O
Linear	B-MED
regression	I-MED
showed	O
no	B-MED
significant	I-MED
change	I-MED
in	O
oesophageal	B-MED
temperature	I-MED
during	O
the	O
lavage	B-MED
period	B-MED
for	O
group	B-MED
1	O
(	O
P=0.64	O
)	O
,	O
but	O
a	O
significant	O
increase	O
for	O
group	B-MED
2	I-MED
patients	I-MED
(	O
P<0.0001	O
)	O
,	O
with	O
mean	B-MED
temperature	B-MED
changes	I-MED
of	O
-0.5	O
°	O
C	O
(	O
from	O
(	O
36.3	O
°	O
C	O
to	O
35.9	O
°	O
C	O
)	O
and	O
+0.9	O
°	O
C	O
(	O
from	O
35.4	O
°	O
C	O
to	O
36.3	O
°	O
C	O
)	O
,	O
respectively	O
.	O
Similar	O
results	B-MED
were	O
found	O
for	O
rectal	B-MED
temperature	I-MED
,	O
with	O
mean	B-MED
changes	O
of	O
-0.5	O
°	O
C	O
and	O
+0.8	O
°	O
C	O
(	O
P=0.922	O
and	O
0.045	O
)	O
,	O
respectively	O
.	O
The	O
use	O
of	O
isotonic	B-MED
crystalloid	B-MED
solution	I-MED
for	O
peritoneal	B-MED
lavage	I-MED
at	O
a	O
temperature	B-MED
of	O
40±1	O
°	O
C	O
significantly	O
warms	B-MED
small	B-MED
animal	I-MED
patients	I-MED
,	O
when	O
applied	O
in	O
a	O
clinical	B-MED
setting	I-MED
,	O
compared	O
with	O
lavage	B-MED
solution	O
at	O
34±1	O
°	O
C	O
.	O
Reversible	O
Humidity	B-MED
Sensitive	B-MED
Clothing	B-MED
for	O
Personal	B-MED
Thermoregulation	I-MED
Two	O
kinds	O
of	O
humidity	B-MED
-	O
induced	B-MED
,	O
bendable	O
smart	B-MED
clothing	I-MED
have	O
been	O
designed	B-MED
to	I-MED
reversibly	I-MED
adapt	I-MED
their	O
thermal	B-MED
insulation	I-MED
functionality	I-MED
.	O
The	O
first	O
design	O
mimics	O
the	O
pores	B-MED
in	O
human	B-MED
skin	I-MED
,	O
in	O
which	O
pre	O
-	O
cut	O
flaps	O
open	O
to	O
produce	O
pores	B-MED
in	O
Nafion	B-MED
sheets	B-MED
when	O
humidity	B-MED
increases	O
,	O
as	O
might	O
occur	O
during	O
human	B-MED
sweating	I-MED
thus	O
permitting	O
air	B-MED
flow	I-MED
and	O
reducing	O
both	O
the	O
humidity	B-MED
level	O
and	O
the	O
apparent	B-MED
temperature	I-MED
.	O
Like	O
the	O
smart	O
human	B-MED
sweating	I-MED
pores	I-MED
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-MED
to	O
keep	O
the	O
wearer	B-MED
warm	I-MED
.	O
The	O
second	O
design	O
involves	O
thickness	B-MED
adjustable	B-MED
clothes	I-MED
by	O
inserting	O
the	O
bent	B-MED
polymer	I-MED
sheets	I-MED
between	O
two	O
fabrics	B-MED
.	O
As	O
the	O
humidity	B-MED
increases	O
,	O
the	O
sheets	B-MED
become	O
thinner	O
,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	B-MED
to	O
reduce	O
the	O
thermal	B-MED
insulation	I-MED
.	O
The	O
insulation	B-MED
layer	I-MED
can	O
recover	O
its	O
original	O
thickness	B-MED
upon	O
humidity	B-MED
reduction	O
to	O
restore	O
its	O
warmth	B-MED
-	I-MED
preservation	I-MED
function	O
.	O
Such	O
humidity	B-MED
sensitive	B-MED
smart	O
polymer	B-MED
materials	I-MED
can	O
be	O
utilized	O
to	O
adjust	O
personal	B-MED
comfort	I-MED
,	O
and	O
be	O
effective	O
in	O
reducing	B-MED
energy	I-MED
consumption	I-MED
for	O
building	O
heating	B-MED
or	I-MED
cooling	I-MED
with	O
numerous	O
smart	B-MED
design	I-MED
.	O
SARS	B-MED
-	O
CoV	B-MED
fusion	O
peptides	B-MED
induce	O
membrane	B-MED
surface	B-MED
ordering	B-MED
and	O
curvature	B-MED
Viral	B-MED
membrane	I-MED
fusion	I-MED
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane	B-MED
-	I-MED
anchored	I-MED
viral	B-MED
fusion	I-MED
glycoproteins	I-MED
.	O
The	O
S2	B-MED
subunit	B-MED
of	O
the	O
spike	B-MED
glycoprotein	I-MED
from	O
severe	B-MED
acute	I-MED
respiratory	I-MED
syndrome	I-MED
(	O
SARS	B-MED
)	O
coronavirus	B-MED
(	O
CoV	B-MED
)	O
contains	O
internal	B-MED
domains	I-MED
called	O
fusion	B-MED
peptides	I-MED
(	O
FP	B-MED
)	O
that	O
play	O
essential	O
roles	O
in	O
virus	B-MED
entry	I-MED
.	O
Although	O
membrane	B-MED
fusion	I-MED
has	O
been	O
broadly	O
studied	B-MED
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	B-MED
details	O
of	O
lipid	B-MED
rearrangements	B-MED
in	O
the	O
bilayer	B-MED
during	O
fusion	B-MED
peptide	I-MED
-	O
membrane	B-MED
interactions	B-MED
.	O
Here	O
we	O
employed	O
differential	B-MED
scanning	I-MED
calorimetry	I-MED
(	O
DSC	B-MED
)	O
and	O
electron	B-MED
spin	I-MED
resonance	I-MED
(	O
ESR	B-MED
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	B-MED
fusion	I-MED
mechanism	B-MED
promoted	B-MED
by	O
two	O
putative	O
SARS	B-MED
FPs	B-MED
.	O
DSC	B-MED
data	B-MED
showed	O
the	O
peptides	B-MED
strongly	O
perturb	O
the	O
structural	B-MED
integrity	B-MED
of	O
anionic	B-MED
vesicles	I-MED
and	O
support	O
the	O
hypothesis	B-MED
that	O
the	O
peptides	B-MED
generate	O
opposing	O
curvature	B-MED
stresses	O
on	O
phosphatidylethanolamine	B-MED
membranes	B-MED
.	O
ESR	B-MED
showed	O
that	O
both	O
FPs	B-MED
increase	O
lipid	B-MED
packing	B-MED
and	O
head	O
group	O
ordering	B-MED
as	O
well	O
as	O
reduce	O
the	O
intramembrane	B-MED
water	B-MED
content	I-MED
for	O
anionic	B-MED
membranes	I-MED
.	O
Therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	B-MED
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	B-MED
.	O
The	O
significance	B-MED
of	O
the	O
ordering	B-MED
effect	I-MED
,	O
membrane	B-MED
dehydration	B-MED
,	O
changes	O
in	O
the	O
curvature	B-MED
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-MED
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	B-MED
-	O
CoV	B-MED
-mediated	O
membrane	B-MED
fusion	I-MED
are	O
discussed	O
.	O
Juicer	B-MED
Provides	B-MED
a	O
One	O
-	O
Click	O
System	O
for	O
Analyzing	B-MED
Loop	B-MED
-	I-MED
Resolution	I-MED
Hi	I-MED
-	I-MED
C	I-MED
Experiments	I-MED
Hi	B-MED
-	I-MED
C	I-MED
experiments	I-MED
explore	O
the	O
3D	B-MED
structure	I-MED
of	O
the	O
genome	B-MED
,	O
generating	B-MED
terabases	B-MED
of	I-MED
data	I-MED
to	O
create	O
high	B-MED
-	I-MED
resolution	I-MED
contact	B-MED
maps	I-MED
.	O
Here	O
,	O
we	O
introduce	O
Juicer	B-MED
,	O
an	O
open	B-MED
-	I-MED
source	I-MED
tool	I-MED
for	O
analyzing	O
terabase	B-MED
-	I-MED
scale	I-MED
Hi	B-MED
-	I-MED
C	I-MED
datasets	I-MED
.	O
Juicer	B-MED
allows	O
users	B-MED
without	B-MED
a	O
computational	B-MED
background	B-MED
to	O
transform	B-MED
raw	B-MED
sequence	I-MED
data	I-MED
into	O
normalized	O
contact	B-MED
maps	I-MED
with	O
one	O
click	O
.	O
Juicer	B-MED
produces	O
a	O
hic	B-MED
file	I-MED
containing	O
compressed	B-MED
contact	B-MED
matrices	I-MED
at	O
many	O
resolutions	B-MED
,	O
facilitating	O
visualization	B-MED
and	O
analysis	B-MED
at	O
multiple	B-MED
scales	I-MED
.	O
Structural	B-MED
features	I-MED
,	O
such	O
as	O
loops	B-MED
and	O
domains	B-MED
,	O
are	O
automatically	B-MED
annotated	B-MED
.	O
Juicer	B-MED
is	O
available	O
as	O
open	B-MED
source	B-MED
software	B-MED
at	O
http://aidenlab.org/juicer/.	O
Impact	B-MED
of	O
antibiotic	B-MED
de	B-MED
-	I-MED
escalation	I-MED
on	O
clinical	B-MED
outcomes	I-MED
in	O
community	B-MED
-	I-MED
acquired	I-MED
pneumococcal	B-MED
pneumonia	I-MED
Although	O
antibiotic	B-MED
de	B-MED
-	I-MED
escalation	I-MED
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	B-MED
selection	O
pressure	O
,	O
adverse	B-MED
drug	I-MED
effects	I-MED
and	O
costs	B-MED
,	O
evidence	B-MED
supporting	O
this	O
practice	O
in	O
community	B-MED
-	I-MED
acquired	I-MED
pneumococcal	I-MED
pneumonia	I-MED
(	O
CAPP	B-MED
)	O
is	O
lacking	B-MED
.	O
We	O
carried	O
out	O
a	O
retrospective	B-MED
analysis	B-MED
of	O
prospectively	O
collected	O
data	B-MED
of	O
a	O
cohort	B-MED
of	O
hospitalized	B-MED
adults	I-MED
with	O
CAPP	B-MED
.	O
Pneumococcal	B-MED
aetiology	B-MED
was	O
established	B-MED
in	O
patients	B-MED
with	O
one	O
or	O
more	O
positive	B-MED
cultures	I-MED
for	O
Streptococcus	B-MED
pneumoniae	I-MED
obtained	O
from	O
blood	B-MED
,	O
sterile	B-MED
fluids	I-MED
or	O
sputum	B-MED
,	O
and/or	O
a	O
positive	B-MED
urinary	B-MED
antigen	I-MED
test	I-MED
.	O
De	B-MED
-	I-MED
escalation	I-MED
therapy	I-MED
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B-MED
therapy	I-MED
was	O
narrowed	O
to	O
penicillin	B-MED
,	O
amoxicillin	B-MED
or	O
amoxicillin	B-MED
/	I-MED
clavulanate	I-MED
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-MED
.	O
The	O
primary	O
outcomes	B-MED
were	O
30	O
day	B-MED
mortality	B-MED
and	O
length	B-MED
of	I-MED
hospital	I-MED
stay	I-MED
(	O
LOS	B-MED
)	O
.	O
Adjustment	B-MED
for	O
confounders	O
was	O
performed	B-MED
with	O
multivariate	B-MED
and	O
propensity	B-MED
score	I-MED
analyses	B-MED
.	O
Of	O
1410	O
episodes	O
of	O
CAPP	B-MED
,	O
antibiotic	B-MED
de	B-MED
-	I-MED
escalation	I-MED
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-MED
was	O
performed	B-MED
in	O
166	O
cases	B-MED
.	O
After	O
adjustment	B-MED
,	O
antibiotic	B-MED
de	B-MED
-	I-MED
escalation	I-MED
was	O
not	O
associated	B-MED
with	I-MED
a	O
higher	O
risk	B-MED
of	O
mortality	B-MED
(	O
OR	B-MED
=	O
0.83	O
,	O
95	O
%	O
CI	B-MED
=	O
0.24	O
-	O
2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	B-MED
factor	I-MED
for	O
prolonged	B-MED
LOS	B-MED
(	O
above	O
the	O
median	B-MED
)	O
(	O
OR	B-MED
=	O
0.46	O
,	O
95	O
%	O
CI	B-MED
=	O
0.30	O
-	O
0.70	O
)	O
.	O
Similar	O
results	B-MED
were	O
found	O
in	O
patients	B-MED
classified	O
into	O
high	B-MED
-	I-MED
risk	I-MED
pneumonia	B-MED
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	B-MED
instability	I-MED
and	O
those	O
with	O
bacteraemia	B-MED
.	O
No	B-MED
significant	I-MED
differences	I-MED
were	O
documented	B-MED
in	O
adverse	B-MED
drug	I-MED
reactions	I-MED
or	O
readmission	B-MED
(	O
<	O
30	O
days	B-MED
)	O
.	O
Antibiotic	B-MED
de	B-MED
-	I-MED
escalation	I-MED
seems	O
to	O
be	O
safe	O
and	O
effective	B-MED
in	O
reducing	B-MED
the	O
duration	B-MED
of	O
LOS	B-MED
,	O
and	O
did	O
not	O
adversely	B-MED
affect	I-MED
outcomes	B-MED
of	O
patients	B-MED
with	O
CAPP	B-MED
,	O
even	O
those	O
with	O
bacteraemia	B-MED
and	O
severe	B-MED
disease	I-MED
,	O
and	O
those	O
who	O
were	O
clinically	B-MED
unstable	I-MED
.	O
Signs	B-MED
of	O
dysarthria	B-MED
in	O
adults	B-MED
with	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
investigate	O
how	O
adults	B-MED
with	O
22q11.2	B-MED
deletion	I-MED
syndrome	I-MED
(	O
22q11DS	B-MED
)	O
performed	O
on	O
dysarthria	B-MED
and	O
intelligibility	B-MED
tests	B-MED
compared	B-MED
with	O
a	O
control	B-MED
group	I-MED
.	O
Ten	O
participants	B-MED
with	O
confirmed	O
22q11.2	B-MED
deletion	I-MED
,	O
five	O
males	B-MED
and	O
five	O
females	B-MED
with	O
a	O
mean	O
age	B-MED
of	O
31	O
years	B-MED
(	O
range	O
:	O
19	O
-	O
49	O
)	O
,	O
were	O
compared	B-MED
with	O
a	O
control	B-MED
group	I-MED
matched	O
for	O
gender	B-MED
and	O
age	B-MED
(	O
five	O
males	B-MED
and	O
five	O
females	B-MED
,	O
mean	O
age	B-MED
:	O
32	O
years	B-MED
,	O
range	O
:	O
19	O
-	O
49	O
)	O
.	O
Assessment	B-MED
of	O
non	B-MED
-	I-MED
verbal	I-MED
and	I-MED
verbal	I-MED
tasks	I-MED
reflecting	O
respiration	B-MED
,	O
phonation	B-MED
,	O
oral	B-MED
motor	I-MED
function	I-MED
,	O
velopharyngeal	B-MED
function	I-MED
,	O
articulation	B-MED
,	O
and	O
prosody	B-MED
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	B-MED
Test	I-MED
of	I-MED
Intelligibility	I-MED
(	O
STI	B-MED
)	O
.	O
All	O
assessments	B-MED
were	O
made	O
by	O
two	O
raters	O
;	O
inter	B-MED
-	I-MED
rater	I-MED
and	O
intra	B-MED
-	I-MED
rater	I-MED
reliability	I-MED
was	O
acceptable	O
.	O
The	O
participants	B-MED
with	O
22q11DS	B-MED
had	O
significantly	O
more	O
problems	B-MED
than	O
the	O
control	B-MED
group	I-MED
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	B-MED
.	O
Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	B-MED
deviation	I-MED
was	O
rated	B-MED
as	O
mild	O
to	O
moderate	O
.	O
The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	B-MED
respiration	B-MED
,	O
phonation	B-MED
,	O
oral	B-MED
motor	I-MED
function	I-MED
,	O
and	O
velopharyngeal	B-MED
function	I-MED
.	O
The	O
results	O
of	O
the	O
present	O
study	B-MED
suggest	O
that	O
a	O
neurological	B-MED
etiology	I-MED
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	B-MED
etiology	I-MED
explaining	O
the	O
speech	B-MED
difficulties	I-MED
found	O
in	O
22q11DS	B-MED
.	O
Signs	B-MED
of	O
difficulties	O
in	O
both	O
speech	B-MED
motor	I-MED
planning	I-MED
and	O
speech	B-MED
motor	I-MED
programming	I-MED
were	O
found	O
.	O
Further	O
studies	B-MED
are	O
needed	O
to	O
confirm	O
the	O
results	B-MED
,	O
as	O
are	O
studies	B-MED
of	O
the	O
association	O
between	O
structural	B-MED
brain	I-MED
abnormalities	I-MED
and	O
neurological	B-MED
speech	I-MED
symptoms	I-MED
.	O
For	O
clinical	B-MED
purposes	I-MED
,	O
it	O
is	O
important	O
that	O
clinicians	B-MED
have	O
knowledge	O
about	O
the	O
variable	O
speech	B-MED
symptoms	I-MED
that	O
may	O
occur	O
in	O
individuals	B-MED
with	O
22q11DS	B-MED
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	B-MED
of	O
such	O
speech	B-MED
symptoms	I-MED
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Regulation	B-MED
of	O
ABCA1	B-MED
and	O
ABCG1	B-MED
gene	B-MED
expression	I-MED
in	O
the	O
intraabdominal	B-MED
adipose	I-MED
tissue	I-MED
Tissue	B-MED
specific	I-MED
expression	I-MED
of	I-MED
genes	I-MED
encoding	B-MED
cholesterol	B-MED
transporters	B-MED
ABCA1	B-MED
and	O
ABCG1	B-MED
as	O
well	O
as	O
genes	B-MED
encoding	B-MED
the	O
most	O
important	O
transcriptional	B-MED
regulators	B-MED
of	O
adipogenesis	B-MED
-	O
LXRa	B-MED
,	O
LXRb	B-MED
,	O
PPARg	B-MED
and	O
RORa	B-MED
has	O
been	O
investigated	B-MED
in	O
intraabdominal	B-MED
adipose	I-MED
tissue	I-MED
(	O
IAT	B-MED
)	O
samples	B-MED
.A	O
direct	O
correlation	B-MED
between	O
the	O
content	O
of	O
ABCA1	B-MED
and	O
ABCG1	B-MED
proteins	I-MED
with	O
RORa	B-MED
protein	I-MED
level	B-MED
(	O
r=0.480	O
,	O
p<0.05	O
;	O
r=0.435	O
,	O
p<0.05	O
,	O
respectively	O
)	O
suggests	B-MED
the	O
role	O
of	O
the	O
transcription	B-MED
factor	I-MED
RORa	B-MED
in	O
the	O
regulation	B-MED
of	O
IAT	B-MED
ABCA1	B-MED
and	O
ABCG1	B-MED
protein	I-MED
levels	B-MED
.	O
ABCA1	B-MED
and	O
ABCG1	B-MED
gene	B-MED
expression	I-MED
positively	O
correlated	B-MED
with	O
obesity	B-MED
indicators	B-MED
such	O
as	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
(	O
r=0.522	O
,	O
p=0.004	O
;	O
r=0.594	O
,	O
p=0.001	O
,	O
respectively	O
)	O
and	O
waist	B-MED
circumference	I-MED
(	O
r=0.403	O
,	O
p=0.033	O
;	O
r=0.474	O
,	O
p=0.013	O
,	O
respectively	O
)	O
.	O
The	O
development	B-MED
of	O
obesity	B-MED
is	O
associated	B-MED
with	I-MED
decreased	B-MED
IAT	B-MED
levels	B-MED
of	O
RORa	B-MED
and	O
LXRb	B-MED
mRNA	B-MED
(	O
p=0.016	O
and	O
p=0.002	O
,	O
respectively	O
)	O
.	O
These	O
data	B-MED
suggest	B-MED
that	O
the	O
nuclear	B-MED
factor	I-MED
RORa	I-MED
can	O
play	O
a	O
significant	B-MED
role	O
in	O
the	O
regulation	B-MED
of	O
cholesterol	B-MED
metabolism	I-MED
and	O
control	B-MED
IAT	B-MED
expression	B-MED
of	O
ABCA1	B-MED
and	O
ABCG1	B-MED
,	O
while	O
the	O
level	B-MED
of	O
IAT	B-MED
LXRb	B-MED
gene	B-MED
expression	I-MED
may	O
be	O
an	O
important	O
factor	O
associated	B-MED
with	I-MED
the	O
development	B-MED
of	O
obesity	B-MED
.	O
Entropy	B-MED
-	I-MED
driven	I-MED
reactions	I-MED
in	O
living	B-MED
cells	B-MED
for	O
assay	B-MED
let-7a	B-MED
microRNA	I-MED
Imaging	B-MED
of	O
microRNA	B-MED
(	O
miRNA	B-MED
)	O
in	O
living	B-MED
cells	B-MED
could	O
facilitate	O
the	O
monitoring	B-MED
of	O
the	O
expression	B-MED
and	O
distribution	B-MED
of	O
miRNA	B-MED
and	O
research	B-MED
on	O
miRNA	B-MED
-related	O
diseases	B-MED
.	O
Given	O
the	O
low	O
expression	B-MED
levels	I-MED
and	O
even	O
down	B-MED
-	I-MED
regulation	I-MED
of	O
cellular	B-MED
miRNA	B-MED
that	O
is	O
associated	B-MED
with	I-MED
some	O
diseases	B-MED
,	O
enzyme	B-MED
-	O
free	B-MED
amplification	B-MED
strategies	I-MED
are	O
imperative	O
for	O
intracellular	B-MED
miRNA	B-MED
assay	B-MED
.	O
In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy	B-MED
-	I-MED
driven	I-MED
reaction	I-MED
for	O
amplification	B-MED
assay	B-MED
miRNA	B-MED
with	O
a	O
detection	B-MED
limit	I-MED
of	O
0.27	O
pM.	O
The	O
resulting	O
signal	B-MED
amplification	B-MED
provides	O
excellent	O
recognition	O
and	O
signal	B-MED
enhancement	B-MED
of	O
specific	B-MED
miRNA	B-MED
s	O
in	O
living	B-MED
cells	B-MED
.	O
This	O
method	O
supplies	O
accurate	B-MED
information	B-MED
regarding	O
cellular	B-MED
miRNA	B-MED
-related	O
biological	B-MED
events	I-MED
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	B-MED
sensitive	I-MED
and	O
simultaneous	B-MED
imaging	B-MED
of	O
multiple	B-MED
low	O
-	O
level	O
biomarkers	B-MED
,	O
thereby	O
improving	O
the	O
accuracy	B-MED
of	O
early	B-MED
disease	I-MED
diagnosis	I-MED
.	O
Audiovisual	B-MED
integration	B-MED
supports	O
face	B-MED
-	O
name	B-MED
associative	B-MED
memory	B-MED
formation	I-MED
Prior	O
multisensory	B-MED
experience	B-MED
influences	O
how	O
we	O
perceive	O
our	O
environment	B-MED
,	O
and	O
hence	O
how	O
memories	B-MED
are	O
encoded	O
for	O
subsequent	O
retrieval	B-MED
.	O
This	O
study	B-MED
investigated	O
if	O
audiovisual	B-MED
(	O
AV	B-MED
)	O
integration	B-MED
and	O
associative	B-MED
memory	B-MED
formation	I-MED
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O
Our	O
functional	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
results	O
demonstrate	O
that	O
the	O
neural	B-MED
mechanisms	B-MED
underlying	O
AV	B-MED
integration	B-MED
and	O
associative	B-MED
memory	B-MED
overlap	B-MED
substantially	O
.	O
In	O
particular	O
,	O
activity	B-MED
in	O
anterior	B-MED
superior	I-MED
temporal	I-MED
sulcus	I-MED
(	O
STS	B-MED
)	O
is	O
increased	O
during	O
AV	B-MED
integration	B-MED
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
AV	B-MED
face	B-MED
-	O
name	B-MED
association	O
formation	O
.	O
Dynamic	B-MED
causal	I-MED
modeling	I-MED
results	O
further	O
demonstrate	O
how	O
the	O
anterior	B-MED
STS	I-MED
interacts	O
with	O
the	O
associative	B-MED
memory	B-MED
system	I-MED
to	O
facilitate	O
successful	O
memory	B-MED
formation	I-MED
for	O
AV	B-MED
face	B-MED
-	O
name	B-MED
associations	B-MED
.	O
Specifically	O
,	O
the	O
connection	O
of	O
fusiform	B-MED
gyrus	I-MED
to	O
anterior	B-MED
STS	I-MED
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	B-MED
subsequently	O
remembered	B-MED
both	O
face	B-MED
and	O
name	B-MED
.	O
Collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	B-MED
associative	B-MED
memories	B-MED
can	O
be	O
formed	O
for	O
subsequent	O
retrieval	B-MED
.	O
Environmental	B-MED
factors	I-MED
and	O
hypertension	B-MED
Environmental	B-MED
factors	I-MED
are	O
a	O
major	O
cause	O
of	O
poor	B-MED
health	I-MED
worldwide	B-MED
.	O
The	O
most	O
solid	O
evidence	B-MED
is	O
for	O
air	B-MED
pollution	I-MED
,	O
leading	O
to	O
increased	O
disability	B-MED
-	I-MED
adjusted	I-MED
life	I-MED
years	I-MED
.	O
Outdoor	B-MED
temperature	B-MED
and	O
other	O
seasonal	B-MED
climate	B-MED
changes	I-MED
may	O
also	O
influence	O
cardiovascular	B-MED
health	B-MED
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air	B-MED
pollution	I-MED
.	O
Moreover	O
,	O
an	O
increasing	O
body	O
of	O
evidence	B-MED
associates	O
environmental	B-MED
exposure	I-MED
to	O
noise	B-MED
with	O
poor	B-MED
cardiovascular	I-MED
outcome	I-MED
,	O
and	O
in	O
particular	O
with	O
hypertension	B-MED
.	O
This	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	B-MED
about	O
the	O
role	O
of	O
these	O
environmental	B-MED
factors	I-MED
in	O
cardiovascular	B-MED
disease	I-MED
and	O
specifically	O
hypertension	B-MED
.	O
In	O
particular	O
,	O
the	O
impact	B-MED
of	O
air	B-MED
pollution	I-MED
,	O
with	O
its	O
short	B-MED
-	I-MED
term	I-MED
and	O
long	B-MED
-	I-MED
term	I-MED
effects	I-MED
,	O
the	O
outdoor	B-MED
temperature	B-MED
and	O
noise	B-MED
pollution	I-MED
will	O
be	O
investigated	O
.	O
People	B-MED
belonging	O
to	O
low	B-MED
social	B-MED
classes	I-MED
,	O
as	O
well	O
as	O
children	B-MED
,	O
women	B-MED
,	O
older	B-MED
people	I-MED
and	O
those	O
with	O
established	O
cardiovascular	B-MED
diseases	I-MED
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	B-MED
to	O
the	O
effects	B-MED
of	O
environmental	B-MED
stressors	I-MED
,	O
recalling	O
the	O
concept	B-MED
of	O
"	O
environmental	B-MED
justice	I-MED
"	O
.	O
The	O
accumulating	O
strong	O
scientific	O
evidence	B-MED
may	O
thus	O
support	O
public	B-MED
health	I-MED
policies	I-MED
aimed	O
at	O
reducing	O
social	B-MED
inequalities	I-MED
in	O
cardiovascular	B-MED
health	B-MED
.	O
Staphylococcus	B-MED
pseudintermedius	I-MED
Human	B-MED
Infection	B-MED
Cases	B-MED
in	O
Spain	B-MED
:	O
Dog	B-MED
-to-	O
Human	B-MED
Transmission	B-MED
Staphylococcus	B-MED
pseudintermedius	I-MED
is	O
an	O
opportunistic	B-MED
pathogen	I-MED
that	O
has	O
been	O
identified	B-MED
as	O
infectious	B-MED
agent	I-MED
or	O
colonizer	B-MED
mainly	O
in	O
dogs	B-MED
.	O
S.	B-MED
pseudintermedius	I-MED
has	O
been	O
also	O
detected	B-MED
in	O
humans	B-MED
and	O
more	O
specifically	O
in	O
people	B-MED
in	O
contact	B-MED
with	I-MED
dogs	B-MED
.	O
In	O
this	O
study	B-MED
,	O
the	O
possible	B-MED
S.	B-MED
pseudintermedius	I-MED
pet	B-MED
-to-	O
human	B-MED
transmission	B-MED
was	O
analyzed	B-MED
in	O
four	O
clinical	B-MED
human	B-MED
cases	B-MED
.	O
Two	O
patients	B-MED
were	O
dog	B-MED
owners	B-MED
and	O
S.	B-MED
pseudintermedius	I-MED
was	O
also	O
detected	B-MED
as	O
colonizer	B-MED
in	O
these	O
healthy	B-MED
animals	B-MED
.	O
S.	B-MED
pseudintermedius	I-MED
isolates	B-MED
from	O
patients	B-MED
and	O
dogs	B-MED
of	O
the	O
same	O
household	B-MED
showed	O
identical	B-MED
pulsed	B-MED
-	I-MED
field	I-MED
gel	I-MED
electrophoresis	I-MED
patterns	B-MED
,	O
sequence	B-MED
types	I-MED
(	O
STs	B-MED
)	O
,	O
and	O
antimicrobial	B-MED
resistance	I-MED
phenotypes	B-MED
and	I-MED
genotypes	I-MED
,	O
and	O
were	O
methicillin	B-MED
susceptible	I-MED
.	O
Resistance	B-MED
to	O
erythromycin	B-MED
,	O
clindamycin	B-MED
,	O
tetracycline	B-MED
,	O
trimetoprim	B-MED
-	I-MED
sulfamethoxazole	I-MED
,	O
and/or	O
ciprofloxacin	B-MED
was	O
identified	B-MED
among	O
S.	B-MED
pseudintermedius	I-MED
strains	B-MED
.	O
The	O
lineages	B-MED
ST241	B-MED
and	O
the	O
new	O
ST521	B-MED
were	O
detected	B-MED
in	O
the	O
strains	B-MED
of	O
the	O
two	O
dog	B-MED
-	O
owner	B-MED
patients	B-MED
,	O
respectively	O
.	O
The	O
strains	B-MED
from	O
the	O
other	B-MED
two	O
patients	B-MED
presented	B-MED
two	O
new	O
STs	B-MED
,	O
ST719	B-MED
and	O
ST720	B-MED
.	O
To	O
our	O
knowledge	B-MED
,	O
this	O
is	O
the	O
first	O
description	B-MED
of	O
human	B-MED
infections	B-MED
caused	O
by	O
S.	B-MED
pseudintermedius	I-MED
in	O
Spain	B-MED
.	O
It	O
's	O
not	O
All	O
Doom	O
and	O
Gloom	O
:	O
Prune	B-MED
Belly	I-MED
Syndrome	I-MED
Associated	B-MED
with	I-MED
VACTERL	I-MED
Prune	B-MED
belly	I-MED
syndrome	I-MED
is	O
a	O
rare	B-MED
abnormality	B-MED
;	O
its	O
association	B-MED
with	I-MED
VACTERL	I-MED
is	O
even	O
rarer	B-MED
.	O
This	O
association	B-MED
has	O
been	O
reported	B-MED
in	O
literature	B-MED
a	O
few	O
times	O
since	O
first	O
reported	B-MED
in	O
1993	O
and	O
so	O
far	O
the	O
majority	B-MED
have	O
either	O
been	O
stillbirths	B-MED
or	I-MED
died	I-MED
shortly	I-MED
after	I-MED
birth	I-MED
.	O
We	O
present	O
a	O
case	B-MED
of	O
Prune	B-MED
belly	I-MED
syndrome	I-MED
associated	B-MED
with	I-MED
VACTERL	I-MED
who	O
is	O
now	O
one	O
year	O
old	O
.	O
Synthesis	B-MED
of	O
Some	O
Unique	O
Carbamate	B-MED
Derivatives	B-MED
bearing	O
2	B-MED
-	I-MED
Furoyl-1	I-MED
-	I-MED
piperazine	I-MED
as	O
a	O
Valuable	O
Therapeutic	B-MED
Agents	I-MED
The	O
aim	B-MED
of	O
the	O
research	B-MED
work	I-MED
was	O
to	O
synthesize	O
different	O
biologically	B-MED
active	I-MED
carbamate	B-MED
derivatives	B-MED
bearing	O
2	B-MED
-	I-MED
furoyl-1	I-MED
-	I-MED
piperazine	I-MED
and	O
having	O
modest	O
toxicity	B-MED
.	O
The	O
synthesis	B-MED
was	O
completed	O
as	O
a	O
multiple	B-MED
sequence	I-MED
.	O
The	O
structural	B-MED
confirmation	B-MED
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI	B-MED
-	I-MED
MS	I-MED
,	O
IR	B-MED
and	O
1H	B-MED
-	I-MED
NMR	I-MED
spectral	O
data	O
.	O
The	O
enzyme	B-MED
inhibition	I-MED
and	O
antibacterial	B-MED
potential	I-MED
of	O
the	O
synthesized	B-MED
compounds	I-MED
was	O
evaluated	B-MED
.	O
To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	B-MED
as	O
possible	O
therapeutic	B-MED
agents	I-MED
their	O
cytotoxicity	B-MED
was	O
also	O
checked	O
.	O
All	O
the	O
compounds	B-MED
were	O
active	B-MED
against	O
acetylcholinesterase	B-MED
enzyme	I-MED
,	O
especially	O
12	B-MED
and	O
14	B-MED
showed	O
very	O
good	B-MED
inhibitory	B-MED
potential	I-MED
relative	O
to	O
Eserine	B-MED
,	O
a	O
reference	B-MED
standard	I-MED
.	O
Almost	O
all	O
the	O
compounds	B-MED
showed	O
good	O
activities	O
against	O
both	O
Gram	B-MED
-	I-MED
positive	I-MED
and	O
Gram	B-MED
-	I-MED
negative	I-MED
bacterial	I-MED
strains	I-MED
.	O
Like	O
Father	B-MED
,	O
Like	O
Daughter	B-MED
-	O
inherited	B-MED
cutis	B-MED
aplasia	I-MED
occurring	O
in	O
a	O
family	B-MED
with	O
Marfan	B-MED
syndrome	I-MED
:	O
a	O
case	B-MED
report	I-MED
We	O
present	O
the	O
case	B-MED
of	O
a	O
newborn	B-MED
with	O
co	B-MED
-	I-MED
occurrence	I-MED
of	O
Marfan	B-MED
syndrome	I-MED
and	O
aplasia	B-MED
cutis	I-MED
congenita	I-MED
(	O
ACC	B-MED
)	O
and	O
a	O
family	B-MED
history	I-MED
significant	B-MED
for	O
Marfan	B-MED
syndrome	I-MED
and	O
ACC	B-MED
in	O
the	O
father	B-MED
.	O
This	O
case	B-MED
details	B-MED
a	O
previously	O
unreported	O
mutation	B-MED
in	O
Marfan	B-MED
syndrome	I-MED
and	O
describes	O
a	O
novel	O
coinheritance	B-MED
of	O
Marfan	B-MED
syndrome	I-MED
and	O
ACC	B-MED
.	O
Surrogate	B-MED
inaccuracy	B-MED
in	O
predicting	O
older	B-MED
adults	I-MED
'	I-MED
desire	B-MED
for	O
life	B-MED
-	I-MED
sustaining	I-MED
interventions	I-MED
in	O
the	O
event	O
of	O
decisional	B-MED
incapacity	B-MED
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	B-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
assessments	I-MED
?	O
Family	B-MED
members	I-MED
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	B-MED
for	O
an	O
incapacitated	O
relative	B-MED
.	O
Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one	O
's	O
desire	B-MED
to	O
receive	O
treatments	B-MED
in	O
hypothetical	O
situations	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
assessments	I-MED
.	O
The	O
data	B-MED
come	O
from	O
235	O
community	B-MED
-	I-MED
dwelling	I-MED
adults	B-MED
aged	O
70	O
years	B-MED
and	O
over	O
who	O
rated	O
their	O
quality	B-MED
of	I-MED
life	I-MED
and	O
desire	B-MED
for	O
specified	O
interventions	B-MED
in	O
four	O
health	B-MED
states	I-MED
(	O
current	B-MED
state	I-MED
,	O
mild	B-MED
to	O
moderate	B-MED
stroke	B-MED
,	O
incurable	O
brain	B-MED
cancer	I-MED
,	O
and	O
severe	B-MED
dementia	B-MED
)	O
.	O
All	O
ratings	B-MED
were	O
made	O
on	O
Likert	B-MED
-	I-MED
type	I-MED
scales	I-MED
.	O
Using	O
identical	O
rating	B-MED
scales	I-MED
,	O
a	O
surrogate	B-MED
chosen	O
by	O
the	O
older	B-MED
adult	I-MED
was	O
asked	O
to	O
predict	O
the	O
latter	O
's	O
responses	O
.	O
Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
ratings	B-MED
between	O
the	O
older	B-MED
adult	I-MED
and	O
surrogate	B-MED
were	O
associated	O
with	O
surrogates	B-MED
'	I-MED
inaccuracy	B-MED
in	O
predicting	O
desire	B-MED
for	O
treatment	B-MED
.	O
The	O
difference	O
in	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
ratings	B-MED
was	O
a	O
significant	O
predictor	B-MED
of	O
prediction	O
inaccuracy	B-MED
for	O
the	O
three	O
hypothetical	O
health	B-MED
states	I-MED
(	O
p	O
<	O
0.01	O
)	O
and	O
nearly	O
significant	O
for	O
the	O
current	B-MED
health	I-MED
state	I-MED
(	O
p	O
=	O
0.077	O
)	O
.	O
All	O
regression	B-MED
coefficients	I-MED
were	O
negative	B-MED
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	B-MED
overestimated	O
quality	B-MED
of	I-MED
life	I-MED
compared	O
to	O
the	O
older	B-MED
adult	I-MED
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	B-MED
adult	I-MED
's	O
desire	B-MED
to	O
be	O
treated	O
.	O
Discrepant	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
ratings	B-MED
are	O
associated	O
with	O
surrogates	B-MED
'	I-MED
difficulty	O
in	O
predicting	O
desire	B-MED
for	O
life	B-MED
-	I-MED
sustaining	I-MED
interventions	I-MED
in	O
hypothetical	O
situations	O
.	O
This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	B-MED
of	I-MED
life	I-MED
in	O
states	O
of	O
cognitive	B-MED
decline	I-MED
,	O
to	O
better	O
prepare	O
family	B-MED
members	I-MED
for	O
making	O
difficult	O
decisions	B-MED
for	O
their	O
loved	O
ones	O
.	O
ISRCTN89993391	O
.	O
Propulsion	B-MED
strategy	I-MED
in	O
the	O
gait	B-MED
of	O
primary	B-MED
school	I-MED
children	B-MED
;	O
the	O
effect	B-MED
of	O
age	B-MED
and	O
speed	B-MED
The	O
strategy	B-MED
used	O
to	O
generate	B-MED
power	B-MED
for	O
forward	O
propulsion	B-MED
in	O
walking	B-MED
and	O
running	B-MED
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	B-MED
of	O
gait	B-MED
maturation	B-MED
and	O
elastic	B-MED
energy	I-MED
recycling	B-MED
.	O
This	O
study	B-MED
investigated	B-MED
ankle	B-MED
and	O
hip	B-MED
power	B-MED
generation	B-MED
as	O
a	O
propulsion	B-MED
strategy	I-MED
(	O
PS	B-MED
)	O
during	O
the	O
late	B-MED
stance	I-MED
/	O
early	B-MED
swing	I-MED
phases	I-MED
of	O
walking	B-MED
and	O
running	B-MED
in	O
typically	B-MED
developing	I-MED
(	O
TD	B-MED
)	O
children	B-MED
(	O
15	O
:	O
six	O
to	O
nine	O
years	B-MED
;	O
17	O
:	O
nine	O
to	O
13	O
years	B-MED
)	O
using	O
three	B-MED
-	I-MED
dimensional	I-MED
gait	B-MED
analysis	I-MED
.	O
Peak	B-MED
ankle	B-MED
power	B-MED
generation	B-MED
at	O
push	B-MED
-	I-MED
off	I-MED
(	O
peakA2	B-MED
)	O
,	O
peak	B-MED
hip	B-MED
power	B-MED
generation	B-MED
in	O
early	B-MED
swing	I-MED
(	O
peakH3	B-MED
)	O
and	O
propulsion	B-MED
strategy	I-MED
(	B-MED
PS	I-MED
)	I-MED
[	O
peakA2	B-MED
/	O
(	B-MED
peakA2+peakH3	I-MED
)	O
]	O
were	O
calculated	B-MED
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	B-MED
power	B-MED
to	O
total	O
propulsion	B-MED
.	O
Mean	B-MED
PS	B-MED
values	B-MED
decreased	B-MED
as	O
speed	B-MED
increased	B-MED
for	O
comfortable	B-MED
walking	I-MED
(	O
p<0.001	O
)	O
,	O
fast	B-MED
walking	B-MED
(	O
p<0.001	O
)	O
and	O
fast	B-MED
running	B-MED
(	O
p<0.001	O
)	O
,	O
and	O
less	O
consistently	O
during	O
jogging	B-MED
(	O
p=0.054	O
)	O
.	O
PS	B-MED
varied	O
with	O
age	B-MED
(	O
p<0.001	O
)	O
only	O
during	O
fast	B-MED
walking	B-MED
.	O
At	O
any	O
speed	B-MED
of	O
fast	B-MED
walking	B-MED
,	O
older	B-MED
children	I-MED
generated	B-MED
more	O
peakA2	B-MED
(	O
p=0.001	O
)	O
and	O
less	O
peakH3	B-MED
(	O
p=0.001	O
)	O
than	O
younger	B-MED
children	I-MED
.	O
While	O
the	O
kinetics	B-MED
of	O
running	B-MED
propulsion	B-MED
appear	O
to	O
be	O
developed	O
by	O
age	B-MED
six	O
years	B-MED
,	O
the	O
skills	B-MED
of	O
fast	B-MED
walking	B-MED
appeared	O
to	O
require	O
additional	O
neuromuscular	B-MED
maturity	B-MED
.	O
These	O
findings	B-MED
support	O
the	O
concept	O
that	O
running	B-MED
is	O
a	O
skill	B-MED
that	O
matures	B-MED
early	B-MED
for	O
TD	B-MED
children	B-MED
.	O
Participation	B-MED
in	O
and	O
adherence	B-MED
to	O
physical	B-MED
exercise	I-MED
after	O
completion	B-MED
of	O
primary	B-MED
cancer	I-MED
treatment	B-MED
The	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
identify	B-MED
demographic	B-MED
,	O
clinical	B-MED
,	O
psychosocial	B-MED
,	O
physical	B-MED
and	O
environmental	B-MED
factors	B-MED
that	O
are	O
associated	B-MED
with	I-MED
participation	B-MED
in	O
and	O
adherence	B-MED
to	O
a	O
combined	B-MED
resistance	B-MED
and	O
endurance	B-MED
exercise	I-MED
program	B-MED
among	O
cancer	B-MED
survivors	I-MED
,	O
shortly	O
after	O
completion	B-MED
of	O
primary	B-MED
cancer	I-MED
treatment	B-MED
.	O
Data	B-MED
from	O
the	O
randomized	B-MED
controlled	B-MED
Resistance	B-MED
and	I-MED
Endurance	I-MED
exercise	I-MED
After	I-MED
ChemoTherapy	I-MED
(	O
REACT	B-MED
)	O
study	B-MED
were	O
used	O
for	O
this	O
study	B-MED
.	O
The	O
participants	B-MED
of	O
the	O
REACT	B-MED
study	B-MED
were	O
randomly	B-MED
allocated	B-MED
to	O
either	O
a	O
high	B-MED
intensity	I-MED
(	O
HI	B-MED
)	O
or	O
low	B-MED
-to-	O
moderate	B-MED
intensity	I-MED
(	O
LMI	B-MED
)	O
exercise	B-MED
program	B-MED
.	O
Patients	B-MED
'	O
participation	B-MED
rate	B-MED
was	O
defined	O
as	O
the	O
cancer	B-MED
survivors	I-MED
'	O
decision	O
to	O
participate	B-MED
in	O
the	O
REACT	B-MED
study	B-MED
.	O
Exercise	B-MED
adherence	B-MED
reflected	B-MED
participants	B-MED
'	O
attendance	B-MED
to	O
the	O
scheduled	B-MED
exercise	B-MED
sessions	B-MED
and	O
their	O
compliance	B-MED
to	O
the	O
prescribed	B-MED
exercises	B-MED
.	O
High	B-MED
session	B-MED
attendance	B-MED
rates	B-MED
were	O
defined	O
as	O
attending	B-MED
at	O
least	O
80	O
%	O
of	O
the	O
sessions	B-MED
.	O
High	B-MED
compliance	B-MED
rates	B-MED
were	O
defined	O
as	O
performing	B-MED
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	B-MED
exercise	B-MED
across	O
all	O
sessions	B-MED
.	O
Correlates	B-MED
of	O
exercise	B-MED
adherence	B-MED
were	O
studied	B-MED
separately	B-MED
for	O
HI	B-MED
and	O
LMI	B-MED
exercise	B-MED
.	O
Demographic	B-MED
,	O
clinical	B-MED
,	O
and	O
physical	B-MED
factors	B-MED
were	O
assessed	B-MED
using	O
self	B-MED
-	I-MED
reported	I-MED
questionnaires	B-MED
.	O
Relevant	B-MED
clinical	B-MED
information	I-MED
was	O
extracted	B-MED
from	O
medical	B-MED
records	I-MED
.	O
Multivariable	B-MED
logistic	I-MED
regression	I-MED
analyses	I-MED
were	O
applied	B-MED
to	O
identify	B-MED
correlates	B-MED
that	O
were	O
significantly	B-MED
associated	B-MED
with	I-MED
participation	B-MED
,	O
high	B-MED
session	B-MED
attendance	B-MED
,	O
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
high	B-MED
compliance	B-MED
with	O
endurance	B-MED
exercises	I-MED
.	O
Participants	B-MED
were	O
more	B-MED
likely	I-MED
to	O
have	O
higher	B-MED
education	I-MED
,	O
be	O
non	B-MED
-	I-MED
smokers	I-MED
,	O
have	O
lower	B-MED
psychological	B-MED
distress	I-MED
,	O
higher	B-MED
outcome	B-MED
expectations	B-MED
,	O
and	O
perceive	B-MED
more	B-MED
exercise	B-MED
barriers	B-MED
than	O
non	B-MED
-	I-MED
participants	I-MED
.	O
In	O
HI	B-MED
exercise	B-MED
,	O
higher	B-MED
self	B-MED
-	I-MED
efficacy	I-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
session	B-MED
attendance	B-MED
and	O
high	B-MED
compliance	B-MED
with	O
endurance	B-MED
exercises	I-MED
,	O
and	O
lower	B-MED
psychological	B-MED
distress	I-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
exercise	B-MED
s.	O
In	O
LMI	B-MED
exercise	B-MED
,	O
being	O
a	O
non	B-MED
-	I-MED
smoker	I-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
exercises	B-MED
and	O
higher	B-MED
BMI	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
endurance	B-MED
exercises	I-MED
.	O
Furthermore	O
,	O
breast	B-MED
cancer	I-MED
survivors	I-MED
were	O
less	B-MED
likely	B-MED
to	O
report	B-MED
high	B-MED
compliance	B-MED
with	O
resistance	B-MED
and	O
endurance	B-MED
exercises	I-MED
in	O
LMI	B-MED
exercise	B-MED
compared	B-MED
to	O
survivors	B-MED
of	O
other	O
types	O
of	O
cancer	B-MED
.	O
The	O
discriminative	B-MED
ability	B-MED
of	O
the	O
multivariable	B-MED
models	B-MED
ranged	B-MED
from	O
0.62	O
to	O
0.75	O
.	O
Several	O
demographic	B-MED
,	O
clinical	B-MED
and	O
psychosocial	B-MED
factors	B-MED
were	O
associated	B-MED
with	I-MED
participation	B-MED
in	O
and	O
adherence	B-MED
to	O
exercise	B-MED
among	O
cancer	B-MED
survivors	I-MED
.	O
Psychosocial	B-MED
factors	B-MED
were	O
more	B-MED
strongly	B-MED
associated	B-MED
with	I-MED
adherence	B-MED
in	O
HI	B-MED
than	O
LMI	B-MED
exercise	B-MED
.	O
This	O
study	B-MED
was	O
registered	B-MED
at	O
the	O
Netherlands	B-MED
Trial	I-MED
Register	I-MED
[	O
NTR2153	B-MED
]	O
on	O
the	O
5(th	O
)	O
of	O
January	O
2010	O
.	O
ISX-9	B-MED
can	O
potentiate	O
cell	B-MED
proliferation	I-MED
and	O
neuronal	B-MED
commitment	B-MED
in	O
the	O
rat	B-MED
dentate	B-MED
gyrus	I-MED
Adult	B-MED
hippocampal	B-MED
neurogenesis	B-MED
can	O
be	O
modulated	B-MED
by	O
various	O
physiological	B-MED
and	O
pathological	B-MED
conditions	I-MED
,	O
including	O
stress	B-MED
,	O
affective	B-MED
disorders	I-MED
,	O
and	O
several	O
neurological	B-MED
conditions	B-MED
.	O
Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	B-MED
plasticity	I-MED
in	O
the	O
functioning	B-MED
of	O
the	O
hippocampus	B-MED
(	O
namely	O
learning	B-MED
and	O
memory	B-MED
and	O
affective	B-MED
behaviors	B-MED
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	B-MED
in	O
hippocampal	B-MED
neurogenesis	B-MED
might	O
underlie	O
some	O
of	O
the	O
behavioral	B-MED
deficits	B-MED
associated	B-MED
with	I-MED
these	O
psychiatric	B-MED
and	O
neurological	B-MED
conditions	B-MED
.	O
Thus	O
,	O
the	O
search	B-MED
for	O
compounds	B-MED
that	O
can	O
reverse	B-MED
these	O
deficits	B-MED
with	O
minimal	B-MED
side	B-MED
effects	I-MED
has	O
become	O
a	O
recognized	O
priority	O
.	O
In	O
the	O
present	O
study	B-MED
we	O
tested	B-MED
the	O
pro	B-MED
-	I-MED
neurogenic	I-MED
effects	B-MED
of	O
isoxazole	B-MED
9	I-MED
(	O
Isx-9	B-MED
)	O
,	O
a	O
small	O
synthetic	B-MED
molecule	B-MED
that	O
has	O
been	O
recently	O
identified	B-MED
through	O
the	O
screening	B-MED
of	I-MED
chemical	I-MED
libraries	I-MED
in	O
stem	B-MED
cell	I-MED
-	I-MED
based	I-MED
assays	I-MED
.	O
We	O
found	O
that	O
administration	B-MED
of	O
Isx-9	B-MED
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	B-MED
proliferation	I-MED
and	O
increase	B-MED
the	O
number	B-MED
of	O
immature	B-MED
neurons	B-MED
in	O
the	O
hippocampal	B-MED
DG	B-MED
of	O
adult	B-MED
rats	B-MED
.	O
In	B-MED
addition	I-MED
,	O
Isx-9	B-MED
treatment	B-MED
was	O
able	O
to	O
completely	B-MED
reverse	B-MED
the	O
marked	B-MED
reduction	B-MED
in	O
these	O
initial	B-MED
stages	B-MED
of	O
the	O
neurogenic	B-MED
process	I-MED
observed	B-MED
in	O
vehicle	B-MED
-	O
treated	B-MED
animals	B-MED
(	O
which	O
were	O
submitted	O
to	O
repeated	B-MED
handling	B-MED
and	O
exposure	B-MED
to	I-MED
daily	B-MED
intraperitoneal	B-MED
injections	I-MED
)	O
.	O
Based	O
on	O
these	O
results	B-MED
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-MED
studies	B-MED
that	O
require	O
repeated	B-MED
handling	B-MED
and	O
manipulation	B-MED
of	O
animals	B-MED
should	O
include	O
a	O
naïve	O
(	O
non	O
-	O
manipulated	O
)	O
control	B-MED
to	O
determine	O
the	O
baseline	B-MED
levels	B-MED
of	O
hippocampal	B-MED
cell	B-MED
proliferation	I-MED
and	O
neuronal	B-MED
differentiation	B-MED
.	O
Overall	O
,	O
these	O
findings	B-MED
demonstrate	O
that	O
Isx-9	B-MED
is	O
a	O
promising	O
synthetic	B-MED
compound	B-MED
for	O
the	O
mitigation	B-MED
of	O
stress	B-MED
-	O
induced	B-MED
deficits	B-MED
in	O
adult	B-MED
hippocampal	B-MED
neurogenesis	B-MED
.	O
Future	O
studies	B-MED
are	O
thus	O
warranted	O
to	O
evaluate	B-MED
the	O
pro	B-MED
-	I-MED
neurogenic	I-MED
properties	B-MED
of	O
Isx-9	B-MED
in	O
animal	B-MED
models	I-MED
of	O
affective	B-MED
and	O
neurological	B-MED
disorders	I-MED
associated	B-MED
with	I-MED
impaired	B-MED
hippocampal	B-MED
structural	B-MED
plasticity	I-MED
.	O
Anger	B-MED
and	O
aggression	B-MED
in	O
borderline	B-MED
personality	I-MED
disorder	I-MED
and	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
-	O
does	O
stress	B-MED
matter	O
?	O
The	O
impact	B-MED
of	O
stress	B-MED
on	O
anger	B-MED
and	O
aggression	B-MED
in	O
Borderline	B-MED
Personality	I-MED
Disorder	I-MED
(	O
BPD	B-MED
)	O
and	O
Attention	B-MED
Deficit	I-MED
Hyperactivity	I-MED
Disorder	I-MED
(	O
ADHD	B-MED
)	O
has	O
not	O
been	O
thoroughly	O
investigated	B-MED
.	O
The	O
goal	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
different	O
aspects	O
of	O
anger	B-MED
and	O
aggression	B-MED
in	O
patients	B-MED
with	O
these	O
disorders	B-MED
.	O
Twenty	O
-	O
nine	O
unmedicated	B-MED
female	B-MED
BPD	B-MED
patients	B-MED
,	O
28	O
ADHD	B-MED
patients	B-MED
and	O
30	O
healthy	B-MED
controls	I-MED
(	O
HC	B-MED
)	O
completed	O
self	B-MED
-	I-MED
reports	I-MED
measuring	B-MED
trait	B-MED
anger	B-MED
,	O
aggression	B-MED
and	O
emotion	B-MED
regulation	I-MED
capacities	O
.	O
A	O
modified	O
version	O
of	O
the	O
Point	B-MED
Subtraction	I-MED
Aggression	I-MED
Paradigm	I-MED
and	O
a	O
state	B-MED
anger	I-MED
measurement	I-MED
were	O
applied	O
under	O
resting	B-MED
and	O
stress	B-MED
conditions	I-MED
.	O
Stress	B-MED
was	O
induced	B-MED
by	O
the	O
Mannheim	B-MED
Multicomponent	I-MED
Stress	I-MED
Test	I-MED
(	O
MMST	B-MED
)	O
.	O
Both	O
patient	B-MED
groups	O
scored	B-MED
significantly	O
higher	O
on	O
all	O
self	B-MED
-	I-MED
report	I-MED
measures	B-MED
compared	B-MED
to	O
HCs	B-MED
.	O
Compared	B-MED
to	O
ADHD	B-MED
patients	B-MED
,	O
BPD	B-MED
patients	B-MED
reported	O
higher	O
trait	B-MED
aggression	B-MED
and	O
hostility	B-MED
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	B-MED
when	O
provoked	O
and	O
to	O
direct	O
anger	B-MED
inwardly	O
.	O
Furthermore	O
,	O
BPD	B-MED
patients	B-MED
exhibited	O
higher	O
state	O
anger	B-MED
than	O
HCs	B-MED
and	O
ADHD	B-MED
patients	B-MED
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress	B-MED
-	I-MED
dependent	I-MED
anger	B-MED
increase	O
.	O
At	O
the	O
behavioral	B-MED
level	I-MED
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O
In	O
BPD	B-MED
patients	B-MED
,	O
aggression	B-MED
and	O
anger	B-MED
were	O
positively	O
correlated	O
with	O
emotion	B-MED
regulation	I-MED
deficits	B-MED
.	O
Our	O
findings	B-MED
suggest	O
a	O
significant	O
impact	B-MED
of	O
stress	B-MED
on	O
self	O
-	O
perceived	O
state	O
anger	B-MED
in	O
BPD	B-MED
patients	B-MED
but	O
not	O
on	O
aggressive	B-MED
behavior	I-MED
towards	O
others	O
in	O
females	B-MED
with	O
BPD	B-MED
or	O
ADHD	B-MED
.	O
However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	B-MED
which	O
is	O
of	O
clinical	B-MED
importance	B-MED
in	O
BPD	B-MED
patients	B-MED
.	O
Blastocystis	B-MED
subtyping	I-MED
and	O
its	O
association	O
with	O
intestinal	B-MED
parasites	I-MED
in	O
children	B-MED
from	O
different	O
geographical	B-MED
regions	I-MED
of	I-MED
Colombia	I-MED
Blastocystis	B-MED
is	O
a	O
common	O
enteric	B-MED
protist	I-MED
colonizing	I-MED
probably	O
more	O
than	O
1	O
billion	O
people	B-MED
with	O
a	O
large	O
variety	O
of	O
non	B-MED
-	I-MED
human	I-MED
hosts	I-MED
.	O
Remarkable	O
genetic	B-MED
diversity	I-MED
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	B-MED
of	I-MED
the	I-MED
genus	I-MED
into	O
multiple	B-MED
subtypes	I-MED
(	O
ST	B-MED
)	O
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non	B-MED
-	I-MED
human	I-MED
hosts	I-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
Blastocystis	B-MED
STs	I-MED
/	O
18S	B-MED
alleles	I-MED
in	O
symptomatic	B-MED
(	O
abdominal	B-MED
pain	I-MED
,	O
anal	B-MED
pruritus	I-MED
,	O
diarrhea	B-MED
,	O
headache	B-MED
,	O
nauseas	B-MED
and/or	O
vomit	B-MED
)	O
and	O
asymptomatic	B-MED
children	B-MED
from	O
nine	O
geographical	B-MED
regions	I-MED
of	I-MED
Colombia	I-MED
.	O
A	O
total	O
of	O
2026	O
fecal	B-MED
samples	I-MED
were	O
collected	O
as	O
part	O
of	O
a	O
national	B-MED
survey	I-MED
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	B-MED
parasites	I-MED
in	O
children	B-MED
.	O
A	O
set	O
of	O
256	O
samples	O
that	O
were	O
Blastocystis	B-MED
positive	I-MED
was	O
finally	O
selected	O
.	O
The	O
samples	O
were	O
submitted	O
to	O
DNA	B-MED
extraction	I-MED
,	O
Real	B-MED
Time	I-MED
PCR	I-MED
and	O
sequencing	B-MED
using	O
Blastocystis	B-MED
-specific	O
primers	B-MED
targeting	O
the	O
small	B-MED
subunit	I-MED
rRNA	B-MED
gene	I-MED
for	O
ST	B-MED
identification	I-MED
.	O
DNA	B-MED
of	O
Ascaris	B-MED
lumbricoides	I-MED
(	O
16.4	O
%	O
)	O
,	O
Trichuris	B-MED
trichiura	I-MED
(	O
8.2	O
%	O
)	O
,	O
hookworms	B-MED
(	O
Necator	B-MED
americanus	I-MED
/	O
Ancylostoma	B-MED
duodenale	I-MED
)	O
(	O
7.3	O
%	O
)	O
,	O
Giardia	B-MED
duodenalis	I-MED
(	O
23.1	O
%	O
)	O
,	O
Entamoeba	B-MED
complex	I-MED
(	O
82	O
%	O
)	O
,	O
Entamoeba	B-MED
coli	I-MED
(	O
55	O
%	O
)	O
,	O
Hymenolepis	B-MED
nana	I-MED
(	O
0.8	O
%	O
)	O
,	O
Endolimax	B-MED
nana	I-MED
(	O
33.2	O
%	O
)	O
and	O
Neobalantidium	B-MED
coli	I-MED
(	O
2.7	O
%	O
)	O
was	O
detected	O
in	O
the	O
Blastocystis	B-MED
-	O
positive	B-MED
samples	I-MED
.	O
We	O
detected	O
ST1	B-MED
(	O
21.4	O
%	O
)	O
,	O
ST2	B-MED
(	O
19.5	O
%	O
)	O
,	O
ST3	B-MED
(	O
55.5	O
%	O
)	O
,	O
ST4	B-MED
(	O
0.8	O
%	O
)	O
,	O
ST6	B-MED
(	O
2	O
%	O
)	O
and	O
ST7	B-MED
(	O
0.8	O
%	O
)	O
;	O
alleles	B-MED
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
ST1	B-MED
;	O
alleles	B-MED
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
ST2	B-MED
;	O
alleles	B-MED
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
ST3	B-MED
;	O
allele	B-MED
42	O
for	O
ST4	B-MED
;	O
allele	B-MED
122	O
for	O
ST6	B-MED
,	O
and	O
allele	B-MED
142	O
for	O
ST7	B-MED
.	O
Further	O
studies	O
implementing	O
high	B-MED
-	I-MED
resolution	I-MED
molecular	B-MED
markers	I-MED
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
Blastocystis	B-MED
transmission	B-MED
and	O
the	O
role	O
of	O
this	O
Stramenopila	B-MED
in	O
health	B-MED
and	I-MED
disease	I-MED
.	O
What	O
Is	O
the	O
Real	B-MED
Impact	B-MED
of	O
Urinary	B-MED
Incontinence	I-MED
on	O
Female	B-MED
Sexual	I-MED
Dysfunction	I-MED
?	O
A	O
Case	B-MED
Control	I-MED
Study	I-MED
Urinary	B-MED
incontinence	I-MED
(	O
UI	B-MED
)	O
has	O
been	O
associated	B-MED
with	I-MED
negative	B-MED
effects	B-MED
on	O
women	B-MED
's	I-MED
sexuality	B-MED
.	O
Women	B-MED
's	I-MED
sexuality	B-MED
and	O
sexual	B-MED
function	I-MED
are	O
a	O
complex	B-MED
issue	B-MED
,	O
and	O
the	O
role	B-MED
of	O
UI	B-MED
is	O
not	B-MED
completely	I-MED
clear	O
.	O
To	O
assess	B-MED
the	O
impact	B-MED
of	O
UI	B-MED
on	O
female	B-MED
sexual	I-MED
function	I-MED
by	O
comparing	B-MED
this	O
population	B-MED
with	O
a	O
control	B-MED
group	I-MED
of	O
continent	B-MED
women	B-MED
.	O
We	O
performed	O
a	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O
We	O
evaluated	B-MED
continent	B-MED
and	O
incontinent	B-MED
women	B-MED
(	O
age	B-MED
range	B-MED
=	O
30	O
-	O
70	O
years	O
)	O
for	O
their	O
sexuality	B-MED
.	O
All	O
patients	B-MED
were	O
evaluated	B-MED
by	O
anamnesis	B-MED
,	O
physical	B-MED
examination	I-MED
,	O
and	O
self	B-MED
-	I-MED
report	I-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
questionnaires	I-MED
.	O
In	O
addition	O
,	O
incontinent	B-MED
women	B-MED
underwent	O
a	O
1	O
-	O
hour	O
pad	B-MED
test	I-MED
.	O
Patients	B-MED
without	O
sexual	B-MED
activity	I-MED
were	O
evaluated	B-MED
for	O
the	O
role	B-MED
of	O
UI	B-MED
in	O
their	O
sexual	B-MED
abstinence	I-MED
.	O
Sexual	B-MED
abstinence	I-MED
was	O
defined	O
as	O
the	O
absence	B-MED
of	I-MED
sexual	I-MED
activity	I-MED
for	O
more	O
than	O
6	O
months	O
.	O
All	O
sexually	B-MED
active	I-MED
women	B-MED
completed	O
the	O
self	B-MED
-	I-MED
report	I-MED
Sexuality	B-MED
Quotient	B-MED
-	O
Female	B-MED
Version	B-MED
(	O
SQ	O
-	O
F	O
)	O
questionnaire	B-MED
.	O
A	O
total	O
of	O
356	O
women	B-MED
were	O
included	O
in	O
the	O
study	B-MED
(	O
incontinent	B-MED
,	O
n	O
=	O
243	O
;	O
continent	B-MED
,	O
n	O
=	O
113	O
)	O
.	O
Sexual	B-MED
abstinence	I-MED
was	O
found	O
in	O
162	O
women	B-MED
(	O
45	O
%	O
)	O
.	O
Incontinent	B-MED
women	B-MED
presented	O
a	O
higher	B-MED
prevalence	I-MED
(	O
P	O
<	O
.001	O
)	O
of	O
sexual	B-MED
abstinence	I-MED
than	O
their	O
counterparts	B-MED
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29.2	O
%	O
]	O
,	O
respectively	O
)	O
.	O
Age	B-MED
,	O
marital	B-MED
status	I-MED
,	O
and	O
UI	B-MED
were	O
found	O
to	O
be	O
isolated	B-MED
predictive	B-MED
factors	I-MED
for	O
more	O
sexual	B-MED
abstinence	I-MED
in	O
incontinent	B-MED
women	B-MED
.	O
Sexually	B-MED
active	I-MED
women	B-MED
(	O
incontinent	B-MED
,	O
n	O
=	O
114	O
;	O
continent	B-MED
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	B-MED
data	B-MED
.	O
Despite	O
a	O
similar	O
frequency	B-MED
of	O
sexual	B-MED
activity	I-MED
,	O
incontinent	B-MED
women	B-MED
had	O
less	O
sexual	B-MED
desire	I-MED
,	O
foreplay	B-MED
,	O
harmony	B-MED
with	O
a	O
partner	B-MED
,	O
sexual	B-MED
comfort	I-MED
,	O
and	O
sexual	B-MED
satisfaction	I-MED
than	O
their	O
counterparts	O
.	O
Women	B-MED
with	O
greater	B-MED
urinary	B-MED
leakage	I-MED
during	O
the	O
1	O
-	O
hour	O
pad	B-MED
test	I-MED
(	O
weight	B-MED
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	B-MED
function	I-MED
(	O
SQ	O
-	O
F	O
)	O
score	B-MED
.	O
Women	B-MED
with	O
UI	B-MED
were	O
more	O
likely	O
to	O
be	O
sexual	B-MED
abstinent	I-MED
than	O
continent	B-MED
women	B-MED
.	O
Furthermore	O
,	O
women	B-MED
with	O
UI	B-MED
showed	O
less	O
sexual	B-MED
desire	I-MED
,	O
sexual	B-MED
comfort	I-MED
,	O
and	O
sexual	B-MED
satisfaction	I-MED
than	O
their	O
counterparts	B-MED
despite	O
having	O
a	O
similar	O
frequency	B-MED
of	O
sexual	B-MED
activity	I-MED
.	O
The	O
Demand	O
for	O
Cigarettes	B-MED
in	O
Tanzania	B-MED
and	O
Implications	B-MED
for	O
Tobacco	B-MED
Taxation	B-MED
Policy	I-MED
The	O
study	B-MED
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-MED
in	O
Tanzania	B-MED
and	O
presents	O
simulation	B-MED
results	B-MED
on	O
the	O
effect	B-MED
of	O
the	O
cigarette	B-MED
excise	B-MED
tax	I-MED
on	O
smoking	B-MED
participation	B-MED
,	O
government	B-MED
revenue	I-MED
,	O
and	O
related	O
topics	O
.	O
After	O
briefly	O
summarizing	O
the	O
magnitude	B-MED
and	O
spread	O
of	O
cigarette	B-MED
consumption	I-MED
in	O
the	O
country	B-MED
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
African	B-MED
and	O
other	O
countries	B-MED
.	O
The	O
2008	O
Tanzanian	B-MED
household	B-MED
budget	I-MED
survey	B-MED
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-MED
in	O
Tanzania	B-MED
.	O
The	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	B-MED
prevalence	O
for	O
Tanzania	B-MED
is	O
15.35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	B-MED
(	I-MED
income	I-MED
)	I-MED
groups	I-MED
.	O
Smoking	B-MED
intensity	O
and	O
per	B-MED
capita	I-MED
consumption	I-MED
were	O
estimated	O
at	O
7.08	O
cigarettes	B-MED
and	O
1.33	O
cigarettes	B-MED
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O
A	O
two	B-MED
-	I-MED
part	I-MED
demand	I-MED
equation	I-MED
model	I-MED
was	O
used	O
to	O
estimate	O
various	O
elasticities	B-MED
.	O
For	O
the	O
overall	O
equation	B-MED
,	O
the	O
price	B-MED
elasticities	I-MED
of	O
smoking	B-MED
participation	B-MED
,	O
smoking	B-MED
intensity	O
,	O
and	O
total	O
elasticity	B-MED
were	O
estimated	O
at	O
-0.879	O
,	O
-0.853	O
,	O
and	O
-1.732	O
,	O
respectively	O
.	O
Compared	O
to	O
similar	O
results	O
in	O
other	O
developing	B-MED
countries	I-MED
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O
When	O
estimated	O
by	O
expenditure	B-MED
(	I-MED
income	I-MED
)	I-MED
groups	I-MED
,	O
the	O
magnitude	B-MED
of	O
the	O
elasticity	B-MED
appears	O
higher	O
among	O
high	B-MED
expenditure	I-MED
groups	I-MED
than	O
among	O
low	B-MED
expenditure	I-MED
groups	I-MED
.	O
Two	O
simulation	B-MED
exercises	O
were	O
undertaken	O
.	O
First	O
,	O
the	O
effect	B-MED
of	O
different	O
excise	B-MED
rates	B-MED
on	O
smoking	B-MED
participation	B-MED
rate	I-MED
,	O
cigarette	B-MED
consumption	I-MED
,	O
tax	B-MED
revenue	I-MED
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O
Second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	B-MED
of	O
a	O
given	O
increase	B-MED
in	O
the	O
cigarette	B-MED
excise	B-MED
tax	I-MED
on	O
various	O
expenditure	B-MED
groups	I-MED
.	O
The	O
overall	O
results	B-MED
suggest	O
that	O
an	O
increase	B-MED
in	O
the	O
excise	B-MED
tax	I-MED
on	O
cigarettes	B-MED
in	O
Tanzania	B-MED
would	O
reduce	O
cigarette	B-MED
consumption	I-MED
and	O
increase	B-MED
government	B-MED
tax	I-MED
revenue	I-MED
.	O
Visual	B-MED
Confidence	B-MED
Visual	B-MED
confidence	B-MED
refers	O
to	O
an	O
observer	B-MED
's	I-MED
ability	B-MED
to	O
judge	B-MED
the	O
accuracy	B-MED
of	O
her	O
perceptual	B-MED
decisions	I-MED
.	O
Even	O
though	O
confidence	B-MED
judgments	B-MED
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	B-MED
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual	B-MED
perception	I-MED
.	O
The	O
reluctance	O
to	O
study	O
visual	B-MED
confidence	B-MED
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental	B-MED
evidence	I-MED
in	O
favor	O
of	O
metacognitive	B-MED
abilities	I-MED
rather	O
than	O
just	O
perceptual	B-MED
sensitivity	I-MED
.	O
Some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental	B-MED
paradigms	I-MED
to	O
study	B-MED
visual	B-MED
confidence	B-MED
in	O
humans	B-MED
and	O
nonhuman	B-MED
animals	I-MED
.	O
To	O
understand	O
the	O
origins	B-MED
of	O
confidence	B-MED
judgments	B-MED
,	O
investigators	B-MED
have	O
developed	O
two	O
competing	O
frameworks	O
.	O
The	O
approach	O
based	O
on	O
signal	B-MED
decision	I-MED
theory	I-MED
is	O
popular	O
but	O
fails	B-MED
to	O
account	O
for	O
response	B-MED
times	I-MED
.	O
In	O
contrast	O
,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	B-MED
models	B-MED
naturally	O
includes	O
the	O
dynamics	B-MED
of	O
perceptual	B-MED
decisions	I-MED
.	O
These	O
models	B-MED
can	O
explain	O
a	O
range	O
of	O
results	B-MED
,	O
including	O
the	O
apparently	O
paradoxical	B-MED
dissociation	B-MED
between	O
performance	B-MED
and	O
confidence	B-MED
that	O
is	O
sometimes	O
observed	O
.	O
An	O
attenuated	B-MED
Mycobacterium	B-MED
tuberculosis	I-MED
clinical	B-MED
strain	B-MED
with	O
a	O
defect	B-MED
in	O
ESX-1	B-MED
secretion	B-MED
induces	O
minimal	B-MED
host	B-MED
immune	B-MED
responses	I-MED
and	O
pathology	B-MED
Although	O
Mycobacterium	B-MED
tuberculosis	I-MED
(	I-MED
M.tb	I-MED
)	I-MED
DK9897	I-MED
is	O
an	O
attenuated	B-MED
strain	B-MED
,	O
it	O
was	O
isolated	B-MED
from	O
a	O
patient	B-MED
with	O
extrapulmonary	B-MED
tuberculosis	I-MED
and	O
vaccination	B-MED
with	O
a	O
subunit	B-MED
vaccine	I-MED
(	O
H56	B-MED
)	O
induced	B-MED
poor	B-MED
protection	B-MED
against	O
it	O
.	O
Both	O
attenuation	B-MED
and	O
lack	B-MED
of	O
protection	B-MED
are	O
because	O
M.tb	B-MED
DK9897	I-MED
can	O
not	O
secrete	B-MED
the	O
EsxA	B-MED
virulence	B-MED
factor	I-MED
nor	O
induce	O
a	O
host	B-MED
response	I-MED
against	O
it	O
.	O
Genome	B-MED
sequencing	I-MED
identified	O
a	O
frameshift	B-MED
mutation	I-MED
in	O
the	O
eccCa1	B-MED
gene	I-MED
.	O
Since	O
the	O
encoded	B-MED
EccCa1	B-MED
protein	I-MED
provides	O
energy	B-MED
for	O
ESX-1	B-MED
secretion	B-MED
,	O
it	O
suggested	O
a	O
defect	B-MED
in	O
the	O
ESX-1	B-MED
type	B-MED
VII	I-MED
secretion	I-MED
system	I-MED
.	O
Genetic	B-MED
complementation	I-MED
with	O
a	O
plasmid	B-MED
carrying	O
the	O
M.tb	B-MED
H37Rv	I-MED
sequence	O
of	O
eccCa1	B-MED
-	I-MED
eccCb1	I-MED
-	I-MED
pe35	I-MED
re	O
-	O
established	O
EsxA	B-MED
secretion	B-MED
,	O
host	B-MED
specific	O
EsxA	B-MED
T	B-MED
-	I-MED
cell	I-MED
responses	B-MED
,	O
and	O
increased	B-MED
strain	B-MED
virulence	B-MED
.	O
The	O
ESX-1	B-MED
secretion	B-MED
defect	B-MED
prevents	B-MED
several	O
virulence	B-MED
factors	I-MED
from	O
being	O
functional	O
during	O
infection	B-MED
and	O
therefore	O
attenuates	B-MED
M.tb	B-MED
.	O
It	O
precludes	O
specific	O
T	B-MED
-	I-MED
cell	I-MED
responses	B-MED
against	O
strong	O
antigens	B-MED
and	O
we	O
found	O
very	O
little	O
in	B-MED
vivo	I-MED
cytokine	B-MED
production	I-MED
,	O
gross	B-MED
pathology	I-MED
or	O
granuloma	B-MED
formation	I-MED
in	O
lungs	B-MED
from	O
M.tb	B-MED
DK9897	I-MED
infected	B-MED
animals	I-MED
.	O
This	O
coincides	O
with	O
M.tb	B-MED
DK9897	I-MED
being	O
unable	O
to	O
disrupt	O
the	O
phagosome	B-MED
membrane	I-MED
and	O
make	O
contact	O
to	O
the	O
cytosol	B-MED
.	O
Benthic	B-MED
injury	I-MED
dose	I-MED
-	I-MED
response	I-MED
models	I-MED
for	O
polychlorinated	B-MED
biphenyl	I-MED
-	O
contaminated	B-MED
sediment	B-MED
using	O
equilibrium	B-MED
partitioning	I-MED
The	O
study	B-MED
goal	O
was	O
to	O
develop	O
a	O
sediment	B-MED
polychlorinated	B-MED
biphenyl	I-MED
(	O
PCB	B-MED
)	O
dose	B-MED
-	I-MED
response	I-MED
model	I-MED
based	O
on	O
benthic	B-MED
invertebrate	I-MED
effects	O
to	O
PCBs	B-MED
.	O
The	O
authors	O
used	O
an	O
equilibrium	B-MED
partitioning	I-MED
(	I-MED
EqP	I-MED
)	I-MED
approach	I-MED
to	O
generate	O
predicted	O
PCB	B-MED
sediment	B-MED
effect	O
concentrations	B-MED
(	O
largely	O
Aroclor	B-MED
1254	I-MED
)	O
associated	O
with	O
a	O
gradient	B-MED
of	O
toxic	B-MED
effects	I-MED
in	O
benthic	B-MED
organisms	I-MED
from	O
effects	O
observed	O
in	O
aquatic	B-MED
toxicity	B-MED
studies	B-MED
.	O
The	O
present	O
study	B-MED
differs	O
from	O
all	O
other	O
EqP	B-MED
collective	O
sediment	B-MED
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose	B-MED
-	I-MED
response	I-MED
gradient	B-MED
of	O
effects	O
for	O
PCBs	B-MED
rather	O
than	O
a	O
single	O
,	O
protective	O
value	O
.	O
The	O
authors	O
reviewed	O
the	O
chronic	B-MED
aquatic	B-MED
toxicity	B-MED
literature	B-MED
to	O
identify	O
measured	O
aqueous	B-MED
PCB	B-MED
concentrations	B-MED
and	O
associated	O
benthic	B-MED
invertebrate	I-MED
effects	O
.	O
The	O
authors	O
control	O
-	O
normalized	O
the	O
aquatic	B-MED
toxic	B-MED
effect	I-MED
data	B-MED
and	O
expressed	O
results	O
from	O
various	O
studies	B-MED
as	O
a	O
common	B-MED
metric	I-MED
,	O
percent	B-MED
injury	I-MED
.	O
Then	O
,	O
they	O
calculated	O
organic	B-MED
carbon	I-MED
-normalized	O
sediment	B-MED
PCB	B-MED
concentrations	B-MED
(	O
mg	O
/	O
kg	O
organic	B-MED
carbon	I-MED
)	O
from	O
the	O
aqueous	B-MED
PCB	B-MED
toxicity	B-MED
data	B-MED
set	I-MED
using	O
EqP	B-MED
theory	O
based	O
on	O
the	O
US	B-MED
Environmental	I-MED
Protection	I-MED
Agency	I-MED
's	I-MED
(	O
EPIWEB	B-MED
4.1	I-MED
)	O
derivation	O
of	O
the	O
water	B-MED
-	I-MED
organic	I-MED
carbon	I-MED
partition	I-MED
coefficient	I-MED
(	O
KOC	B-MED
)	O
.	O
Lastly	O
,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose	B-MED
-	I-MED
response	I-MED
numerical	I-MED
model	I-MED
for	O
these	O
synoptic	O
sediment	B-MED
PCB	B-MED
concentrations	B-MED
and	O
biological	B-MED
effects	I-MED
:	O
Y	O
=	O
100/1	O
+	O
10(([logEC50	O
-	O
logX	O
]	O
×	O
[	O
Hill	O
slope	O
]	O
)	O
)	O
(	O
EC50	O
=	O
median	B-MED
effective	I-MED
concentration	I-MED
)	O
.	O
These	O
models	B-MED
were	O
used	O
to	O
generate	O
"	O
look	O
-	O
up	O
"	O
tables	B-MED
reporting	O
percent	B-MED
injury	I-MED
in	O
benthic	B-MED
biota	I-MED
for	O
a	O
range	O
of	O
Aroclor	B-MED
-specific	O
sediment	B-MED
concentrations	B-MED
.	O
For	O
example	O
,	O
the	O
model	B-MED
using	O
the	O
EPIWEB	B-MED
KOC	B-MED
estimate	O
predicts	O
mean	B-MED
benthic	I-MED
injury	I-MED
of	O
23.3	O
%	O
,	O
46.0	O
%	O
,	O
70.6	O
%	O
,	O
87.1	O
%	O
,	O
and	O
95	O
%	O
for	O
hypothetical	O
sediment	B-MED
concentrations	B-MED
of	O
1	O
mg	O
/	O
kg	O
,	O
2	O
mg	O
/	O
kg	O
,	O
4	O
mg	O
/	O
kg	O
,	O
8	O
mg	O
/	O
kg	O
,	O
and	O
16	O
mg	O
/	O
kg	O
dry	O
weight	O
of	O
Aroclor	B-MED
1254	I-MED
,	O
respectively	O
(	O
at	O
1	O
%	O
organic	B-MED
carbon	I-MED
)	O
.	O
The	O
authors	O
recommend	O
the	O
model	B-MED
presented	O
for	O
screening	O
but	O
suggest	O
,	O
when	O
possible	O
,	O
determining	O
a	O
site	B-MED
-	I-MED
specific	I-MED
KOC	B-MED
that	O
,	O
along	O
with	O
the	O
tables	B-MED
and	O
equations	B-MED
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose	B-MED
-	I-MED
response	I-MED
sediment	B-MED
concentration	B-MED
.	O
Environ	O
Toxicol	O
Chem	O
2017;36:1311	O
-	O
1329	O
.	O
©	O
2016	O
SETAC	O
.	O
Elucidating	O
a	O
chemical	O
defense	B-MED
mechanism	I-MED
of	O
Antarctic	B-MED
sponges	B-MED
:	O
A	O
computational	B-MED
study	I-MED
In	O
2000	O
,	O
a	O
novel	O
secondary	B-MED
metabolite	I-MED
(	O
erebusinone	B-MED
,	O
Ereb	B-MED
)	O
was	O
isolated	O
from	O
the	O
Antarctic	B-MED
sea	B-MED
sponge	I-MED
,	O
Isodictya	B-MED
erinacea	I-MED
.	O
The	O
bioactivity	B-MED
of	O
Ereb	B-MED
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	B-MED
molting	B-MED
when	O
fed	O
to	O
the	O
arthropod	B-MED
species	I-MED
Orchomene	B-MED
plebs	I-MED
.	O
Xanthurenic	B-MED
acid	I-MED
(	O
XA	B-MED
)	O
is	O
a	O
known	O
endogenous	B-MED
molt	B-MED
regulator	I-MED
present	O
in	O
arthropods	B-MED
.	O
Experimental	O
studies	O
have	O
confirmed	O
that	O
XA	B-MED
inhibits	B-MED
molting	B-MED
by	O
binding	B-MED
to	O
either	O
(	O
or	O
both	O
)	O
of	O
two	O
P450	B-MED
enzymes	I-MED
(	O
CYP315a1	B-MED
or	O
CYP314a1	B-MED
)	O
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	B-MED
in	O
the	O
production	O
of	O
the	O
molt	B-MED
-	I-MED
inducing	I-MED
hormone	I-MED
,	O
20	B-MED
-	I-MED
hydroxyecdysone	I-MED
(	O
20E	B-MED
)	O
.	O
The	O
lack	O
of	O
crystal	B-MED
structures	I-MED
and	O
biochemical	B-MED
assays	I-MED
for	O
CYP315a1	B-MED
or	O
CYP314a1	B-MED
,	O
has	O
prevented	O
further	O
experimental	O
exploration	B-MED
of	O
XA	B-MED
and	O
Ereb	B-MED
's	I-MED
molt	B-MED
inhibition	B-MED
mechanisms	B-MED
.	O
Herein	O
,	O
a	O
wide	O
array	O
of	O
computational	B-MED
techniques	I-MED
-	O
homology	B-MED
modeling	I-MED
,	O
molecular	B-MED
dynamics	I-MED
simulations	I-MED
,	O
binding	B-MED
site	I-MED
bioinformatics	B-MED
,	O
flexible	B-MED
receptor	I-MED
-	I-MED
flexible	I-MED
ligand	I-MED
docking	I-MED
,	O
and	O
molecular	O
mechanics	O
-	O
generalized	O
Born	B-MED
surface	I-MED
area	I-MED
calculations	I-MED
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure	B-MED
-	I-MED
function	I-MED
relationships	I-MED
between	O
the	O
aforementioned	O
P450s	B-MED
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	B-MED
(	O
Ereb	B-MED
and	O
XA	B-MED
)	O
.	O
Results	O
indicate	O
that	O
Ereb	B-MED
likely	O
targets	O
CYP315a1	B-MED
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	B-MED
residues	I-MED
in	O
the	O
binding	B-MED
site	I-MED
,	O
while	O
XA	B-MED
may	O
inhibit	O
both	O
CYP315a1	B-MED
and	O
CYP314a1	B-MED
because	O
of	O
its	O
aromatic	B-MED
,	O
as	O
well	O
as	O
charged	B-MED
nature	I-MED
.	O
Multidrug	B-MED
Resistance	I-MED
of	O
Acinetobacter	B-MED
Baumannii	I-MED
in	O
Ladoke	B-MED
Akintola	I-MED
University	I-MED
Teaching	I-MED
Hospital	I-MED
,	O
Osogbo	B-MED
,	I-MED
Nigeria	I-MED
Acinetobacter	B-MED
baumannii	I-MED
is	O
a	O
ubiquitous	O
pathogen	B-MED
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare	B-MED
-	I-MED
associated	I-MED
infections	I-MED
at	O
Ladoke	B-MED
Akintola	I-MED
University	I-MED
Teaching	I-MED
Hospital	I-MED
.	O
Isolates	B-MED
were	O
assayed	B-MED
according	O
to	O
standard	B-MED
protocol	I-MED
.	O
The	O
isolates	B-MED
were	O
subjected	O
to	O
molecular	B-MED
techniques	I-MED
to	O
detect	O
blaOXA	B-MED
,	I-MED
blaTEM	I-MED
,	I-MED
blaCTX	I-MED
-	I-MED
M	I-MED
,	I-MED
and	I-MED
blaSHV	I-MED
genes	I-MED
in	O
strains	B-MED
of	O
the	O
A.	B-MED
baumannii	I-MED
isolates	B-MED
.	O
The	O
prevalence	O
of	O
A.	B-MED
baumannii	I-MED
was	O
8.5	O
%	O
and	O
was	O
most	O
prevalent	O
among	O
patients	B-MED
in	O
the	O
age	B-MED
group	I-MED
51	O
-	O
60	O
(	O
36	O
%	O
)	O
;	O
the	O
male	B-MED
patients	B-MED
(	O
63.6	O
%	O
)	O
were	O
more	O
infected	B-MED
than	O
their	O
female	B-MED
counterparts	O
.	O
Patients	B-MED
(	O
72.7	O
%	O
)	O
in	O
the	O
intensive	B-MED
care	I-MED
unit	I-MED
(	O
ICU	B-MED
)	O
were	O
most	O
infected	B-MED
with	O
this	O
organism	B-MED
.	O
The	O
isolates	B-MED
showed	O
100	O
%	O
resistance	B-MED
to	O
both	O
amikacin	B-MED
and	O
ciprofloxacin	B-MED
and	O
90.9	O
%	O
to	O
both	O
ceftriaxone	B-MED
and	O
ceftazidime	B-MED
,	O
while	O
resistance	B-MED
to	O
the	O
other	O
antibiotics	B-MED
used	O
in	O
this	O
study	B-MED
were	O
:	O
piperacillin	B-MED
(	O
81.8	O
%	O
)	O
,	O
imipenem	B-MED
(	O
72.7	O
%	O
)	O
,	O
gentamycin	B-MED
(	O
72.2	O
%	O
)	O
,	O
and	O
meropenem	B-MED
(	O
63.6	O
%	O
)	O
.	O
None	O
of	O
the	O
isolates	B-MED
was	O
,	O
however	O
,	O
resistant	B-MED
to	O
colistin	B-MED
.	O
PCR	B-MED
results	B-MED
showed	O
that	O
blaOXA	B-MED
,	I-MED
blaTEM	I-MED
,	I-MED
and	I-MED
blaCTX	I-MED
-	I-MED
M	I-MED
genes	I-MED
were	O
positive	B-MED
in	O
some	O
isolates	B-MED
,	O
while	O
blaSHV	B-MED
was	O
not	B-MED
detected	I-MED
in	O
any	O
of	O
the	O
isolates	B-MED
.	O
This	O
study	B-MED
has	O
revealed	B-MED
that	O
the	O
strains	B-MED
of	O
A.	B-MED
baumannii	I-MED
isolated	B-MED
are	O
multiple	B-MED
drug	I-MED
resistant	I-MED
.	O
Regular	O
monitoring	B-MED
,	O
judicious	O
prescription	B-MED
,	O
and	O
early	O
detection	B-MED
of	O
resistance	B-MED
to	O
these	O
antibiotics	B-MED
are	O
,	O
therefore	O
,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
organism	B-MED
.	O
Causes	B-MED
of	I-MED
Death	I-MED
among	O
Children	B-MED
Aged	B-MED
5	O
to	O
14	O
Years	B-MED
Old	B-MED
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	B-MED
The	O
global	O
burden	O
of	O
mortality	B-MED
among	I-MED
children	I-MED
is	O
still	O
very	O
huge	O
though	O
its	O
trend	B-MED
has	O
started	O
declining	O
following	O
the	O
improvements	B-MED
in	O
the	O
living	B-MED
standard	I-MED
.	O
It	O
presents	O
serious	O
challenges	B-MED
to	O
the	O
well	O
-	O
being	O
of	O
children	B-MED
in	O
many	O
African	B-MED
countries	I-MED
.	O
Today	O
,	O
Sub	B-MED
-	I-MED
Saharan	I-MED
Africa	I-MED
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	B-MED
child	B-MED
mortality	I-MED
.	O
The	O
overall	O
objective	B-MED
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	B-MED
and	O
distribution	B-MED
of	O
causes	B-MED
of	I-MED
death	I-MED
among	O
children	B-MED
aged	B-MED
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-MED
of	O
Kersa	O
HDSS	O
using	O
verbal	B-MED
autopsy	B-MED
method	O
for	O
the	O
period	B-MED
2008	O
to	O
2013	O
.	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	B-MED
2007	O
.	O
The	O
center	O
consists	O
of	O
10	O
rural	B-MED
and	O
2	O
urban	B-MED
kebeles	B-MED
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-MED
in	O
the	O
district	B-MED
.	O
Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	B-MED
was	O
taken	O
from	O
Kersa	B-MED
HDSS	I-MED
database	I-MED
.	O
The	O
study	B-MED
population	B-MED
included	O
all	O
children	B-MED
aged	B-MED
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	B-MED
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	B-MED
specific	O
VA	O
questionnaires	B-MED
.	O
Data	B-MED
were	O
extracted	O
from	O
SPSS	B-MED
database	I-MED
and	O
analyzed	O
using	O
STATA	B-MED
.	O
A	O
total	O
of	O
229	O
deaths	B-MED
were	O
recorded	O
over	O
the	O
period	B-MED
of	O
six	O
years	O
with	O
a	O
crude	O
death	B-MED
rate	I-MED
of	O
219.6	O
per	O
100,000	O
population	B-MED
of	O
this	O
age	B-MED
group	I-MED
over	O
the	O
study	B-MED
period	B-MED
.	O
This	O
death	B-MED
rate	I-MED
was	O
217.5	O
and	O
221.5	O
per	O
100,000	O
populations	B-MED
for	O
females	B-MED
and	O
males	B-MED
,	O
respectively	O
.	O
75	O
%	O
of	O
deaths	B-MED
took	O
place	O
at	O
home	O
.	O
The	O
study	B-MED
identified	O
severe	O
malnutrition	B-MED
(	O
33.9	O
%	O
)	O
,	O
intestinal	B-MED
infectious	I-MED
diseases	I-MED
(	O
13.8	O
%	O
)	O
and	O
acute	B-MED
lower	I-MED
respiratory	I-MED
infections	I-MED
(	O
9.2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
.	O
In	O
broad	O
causes	B-MED
of	I-MED
death	I-MED
classification	B-MED
,	O
injuries	B-MED
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-MED
of	I-MED
death	I-MED
next	O
to	O
communicable	B-MED
diseases	I-MED
(	O
56.3	O
%	O
)	O
attributing	O
to	O
13.1	O
%	O
of	O
the	O
total	O
deaths	B-MED
.	O
In	O
specific	O
causes	B-MED
of	I-MED
death	I-MED
classification	B-MED
severe	O
malnutrition	B-MED
,	O
intestinal	B-MED
infectious	I-MED
diseases	I-MED
and	O
acute	B-MED
lower	I-MED
respiratory	I-MED
infections	I-MED
were	O
the	O
three	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
where	O
,	O
in	O
broad	O
causes	B-MED
of	I-MED
death	I-MED
communicable	B-MED
diseases	I-MED
and	O
injuries	B-MED
were	O
among	O
the	O
leading	O
causes	B-MED
of	I-MED
death	I-MED
.	O
Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	B-MED
from	O
these	O
causes	B-MED
of	I-MED
death	I-MED
and	O
further	O
inferential	B-MED
analysis	I-MED
into	O
the	O
prevention	B-MED
and	O
management	B-MED
of	O
infectious	B-MED
diseases	I-MED
should	O
also	O
be	O
taken	O
.	O
Acute	B-MED
Ph	I-MED
-	I-MED
negative	I-MED
lymphoblastic	I-MED
leukemias	I-MED
in	O
adults	B-MED
:	O
Risk	B-MED
factors	I-MED
in	O
the	O
use	O
of	O
the	O
ALL-2009	B-MED
protocol	I-MED
to	O
analyze	O
well	O
-	O
known	O
risk	B-MED
factors	I-MED
(	O
RFs	B-MED
)	O
,	O
such	O
as	O
age	B-MED
,	O
immunophenotype	B-MED
,	O
baseline	B-MED
leukocytosis	B-MED
,	O
enhanced	B-MED
lactate	B-MED
dehydrogenase	I-MED
(	O
LDH	B-MED
)	O
activity	B-MED
,	O
time	O
to	O
achieve	O
complete	O
remission	B-MED
,	O
a	O
risk	B-MED
group	I-MED
,	O
and	O
cytogenetic	B-MED
abnormalities	I-MED
)	O
in	O
patients	B-MED
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
(	O
ALL	B-MED
)	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	B-MED
protocol	I-MED
.	O
The	O
protocol	B-MED
covered	O
298	O
patients	B-MED
(	O
137	O
women	B-MED
(	O
including	B-MED
13	O
pregnant	B-MED
women	I-MED
)	O
and	O
161	O
men	B-MED
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph	B-MED
-	I-MED
negative	I-MED
ALL	I-MED
.	O
The	O
phenotype	B-MED
was	O
unknown	O
in	O
6	O
patients	B-MED
.	O
Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O
182	O
(	O
62.4	O
%	O
)	O
patients	B-MED
were	O
found	O
to	O
have	O
B	B-MED
-	I-MED
cell	I-MED
ALL	I-MED
(	O
early	O
pre	B-MED
-	I-MED
B	I-MED
ALL	I-MED
(	O
n=51	O
)	O
;	O
common	O
ALL	B-MED
(	O
n=92	O
)	O
,	O
and	O
pre	B-MED
-	I-MED
B	I-MED
ALL	I-MED
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	B-MED
had	O
T	B-MED
-	I-MED
cell	I-MED
ALL	I-MED
(	O
early	O
T	B-MED
-	I-MED
ALL	I-MED
(	O
n=56	O
)	O
;	O
thymic	B-MED
T	B-MED
-	I-MED
ALL	I-MED
(	O
n=41	O
)	O
,	O
and	O
mature	B-MED
T	B-MED
-	I-MED
ALL	I-MED
(	O
n=10	O
)	O
.	O
According	O
to	O
the	O
baseline	B-MED
clinical	B-MED
and	O
laboratory	B-MED
parameters	B-MED
(	O
leukocytosis	B-MED
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	B-MED
-	I-MED
ALL	I-MED
;	O
and	O
that	O
of	O
100·109	O
/	O
l	O
and	O
more	O
for	O
T	B-MED
-	I-MED
ALL	I-MED
;	O
phenotype	B-MED
В	O
-	O
I	O
for	O
B	B-MED
-	I-MED
ALL	I-MED
,	O
phenotype	B-MED
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	B-MED
-	I-MED
ALL	I-MED
;	O
LDH	B-MED
activity	B-MED
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	B-MED
of	O
translocation	B-MED
t(4;11	I-MED
)	I-MED
)	O
,	O
the	O
high	B-MED
-	I-MED
risk	I-MED
group	I-MED
included	B-MED
most	O
patients	B-MED
with	O
B	B-MED
-	I-MED
ALL	I-MED
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	B-MED
-	I-MED
ALL	I-MED
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O
Thirty	O
-	O
five	O
patients	B-MED
with	O
T	B-MED
-	I-MED
ALL	I-MED
underwent	O
autologous	B-MED
bone	I-MED
marrow	I-MED
transplantation	I-MED
(	O
BMT	B-MED
)	O
.	O
Allogeneic	B-MED
BMT	I-MED
was	O
performed	B-MED
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	B-MED
who	O
had	O
undergone	O
an	O
induction	B-MED
phase	I-MED
.	O
Five	O
-	O
year	O
overall	B-MED
survival	I-MED
for	O
all	O
the	O
patients	B-MED
included	B-MED
in	O
the	O
investigation	B-MED
was	O
59	O
%	O
;	O
relapse	B-MED
-	I-MED
free	I-MED
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	B-MED
with	O
B	B-MED
-	I-MED
ALL	I-MED
and	O
in	O
those	O
with	O
T	B-MED
-	I-MED
ALL	I-MED
:	O
the	O
overall	B-MED
survival	I-MED
rates	I-MED
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O
Multivariate	B-MED
analysis	I-MED
including	B-MED
the	O
well	O
-	O
known	O
RFs	B-MED
demonstrated	O
that	O
the	O
latter	O
for	O
T	B-MED
-	I-MED
ALL	I-MED
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	B-MED
's	I-MED
age	B-MED
was	O
identified	O
for	O
B	B-MED
-	I-MED
ALL	I-MED
(	O
p=0.013	O
)	O
.	O
A	O
lower	O
chemotherapeutic	B-MED
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-MED
BMTs	I-MED
did	O
not	O
affect	O
total	O
positive	O
treatment	B-MED
results	B-MED
in	O
adult	B-MED
patients	B-MED
with	O
ALL	B-MED
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-MED
effects	B-MED
and	O
by	O
preserving	B-MED
the	O
total	O
cytostatic	B-MED
loading	B-MED
dose	I-MED
.	O
The	O
results	B-MED
of	O
the	O
Russian	B-MED
investigation	B-MED
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-MED
BMTs	I-MED
in	O
adult	B-MED
patients	B-MED
with	O
ALL	B-MED
.	O
Social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
:	O
Factor	B-MED
structure	I-MED
of	O
emotion	B-MED
processing	B-MED
and	O
theory	B-MED
of	I-MED
mind	I-MED
Factor	B-MED
analytic	I-MED
studies	I-MED
examining	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
have	O
yielded	O
inconsistent	O
results	B-MED
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	B-MED
of	I-MED
measures	I-MED
.	O
With	O
the	O
recent	O
conclusion	O
of	O
Phase	B-MED
3	I-MED
of	O
the	O
Social	B-MED
Cognition	I-MED
Psychometric	B-MED
Evaluation	I-MED
(	I-MED
SCOPE	I-MED
)	I-MED
Study	I-MED
,	O
the	O
most	O
psychometrically	B-MED
sound	B-MED
measures	I-MED
of	O
social	B-MED
cognition	I-MED
have	O
been	O
identified	O
.	O
Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	B-MED
were	O
to	O
:	O
1	O
)	O
examine	B-MED
the	O
factor	B-MED
structure	I-MED
of	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
through	O
the	O
utilization	O
of	O
psychometrically	B-MED
sound	B-MED
measures	I-MED
,	O
2	O
)	O
examine	B-MED
the	O
stability	B-MED
of	O
the	O
factor	B-MED
structure	I-MED
across	O
two	O
study	B-MED
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	B-MED
structure	I-MED
of	O
social	B-MED
cognition	I-MED
in	O
schizophrenia	B-MED
to	O
that	O
in	O
healthy	B-MED
controls	I-MED
,	O
and	O
4	O
)	O
examine	B-MED
the	O
relationship	O
between	O
the	O
factors	B-MED
and	O
relevant	O
outcome	B-MED
measures	I-MED
including	O
social	B-MED
functioning	I-MED
and	O
symptoms	B-MED
.	O
Results	B-MED
supported	O
a	O
one	B-MED
-	I-MED
factor	I-MED
model	I-MED
for	O
the	O
patient	B-MED
and	O
healthy	B-MED
control	I-MED
samples	O
at	O
both	O
visits	B-MED
visits	B-MED
.	O
This	O
single	O
factor	O
was	O
significantly	O
associated	B-MED
with	I-MED
negative	B-MED
symptoms	I-MED
in	O
the	O
schizophrenia	B-MED
sample	B-MED
and	O
with	O
social	B-MED
functioning	I-MED
in	O
both	O
groups	B-MED
at	O
both	O
study	B-MED
visits	B-MED
.	O
Transcriptomic	B-MED
insights	O
into	O
the	O
allelopathic	B-MED
effects	B-MED
of	I-MED
the	O
garlic	B-MED
allelochemical	B-MED
diallyl	B-MED
disulfide	I-MED
on	O
tomato	B-MED
roots	B-MED
Garlic	B-MED
is	O
an	O
allelopathic	B-MED
crop	B-MED
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	B-MED
cropping	B-MED
of	O
vegetable	B-MED
crops	I-MED
.	O
Diallyl	B-MED
disulfide	I-MED
(	O
DADS	B-MED
)	O
,	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	B-MED
in	O
garlic	B-MED
,	O
promotes	B-MED
tomato	B-MED
root	B-MED
growth	I-MED
.	O
Therefore	O
,	O
the	O
global	B-MED
transcriptome	B-MED
profiles	B-MED
of	O
DADS	B-MED
-	O
treated	B-MED
tomato	B-MED
roots	B-MED
over	O
time	O
were	O
investigated	B-MED
to	O
reveal	O
the	O
potential	B-MED
growth	B-MED
-	I-MED
promoting	I-MED
mechanisms	I-MED
.	O
We	O
detected	B-MED
1828	O
,	O
1296	O
and	O
1190	O
differentially	B-MED
expressed	I-MED
genes	B-MED
(	O
DEGs	B-MED
)	O
in	O
the	O
4	O
,	O
24	O
and	O
48	O
h	O
samples	O
,	O
respectively	O
.	O
Most	O
DEGs	B-MED
involved	O
in	O
assimilatory	B-MED
sulfate	I-MED
reduction	I-MED
and	O
glutathione	B-MED
metabolism	I-MED
were	O
up	B-MED
-	I-MED
regulated	I-MED
after	O
short	B-MED
-	I-MED
term	I-MED
(	O
4	O
h	O
)	O
DADS	B-MED
treatment	B-MED
.	O
In	O
addition	O
,	O
increased	B-MED
activity	I-MED
of	I-MED
defensive	I-MED
enzymes	I-MED
and	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
six	O
peroxidase	B-MED
genes	I-MED
were	O
observed	B-MED
,	O
suggesting	O
that	O
DADS	B-MED
could	O
induce	B-MED
tomato	B-MED
resistance	B-MED
.	O
In	O
plant	B-MED
-	I-MED
pathogen	I-MED
interactions	I-MED
,	O
DEGs	B-MED
related	O
to	O
calcium	B-MED
signaling	I-MED
were	O
primarily	O
inhibited	B-MED
,	O
while	O
those	O
encoding	B-MED
pathogenesis	B-MED
-	I-MED
related	I-MED
proteins	I-MED
were	O
primarily	O
up	B-MED
-	I-MED
regulated	I-MED
.	O
Although	O
plant	B-MED
hormone	B-MED
synthesis	I-MED
and	O
signal	B-MED
transduction	I-MED
were	O
both	O
significantly	B-MED
affected	I-MED
by	O
DADS	B-MED
,	O
the	O
expression	B-MED
trends	B-MED
of	O
the	O
genes	B-MED
in	O
these	O
two	O
pathways	B-MED
were	O
conflicting	O
.	O
This	O
research	B-MED
provides	O
comprehensive	B-MED
information	B-MED
concerning	O
the	O
changes	B-MED
in	O
the	O
tomato	B-MED
root	B-MED
transcriptome	B-MED
affected	B-MED
by	O
DADS	B-MED
and	O
may	O
help	O
direct	O
further	O
studies	B-MED
on	O
DADS	B-MED
-	O
responsive	B-MED
genes	B-MED
to	O
enhance	B-MED
the	O
current	B-MED
understanding	O
of	O
the	O
mechanisms	B-MED
by	O
which	O
DADS	B-MED
alleviates	O
the	O
obstacles	O
to	O
continuous	B-MED
cropping	B-MED
.	O
Cognitive	B-MED
impairment	I-MED
in	O
first	B-MED
-	I-MED
episode	I-MED
drug	B-MED
-	I-MED
naïve	I-MED
patients	I-MED
with	O
schizophrenia	B-MED
:	O
Relationships	B-MED
with	O
serum	B-MED
concentrations	I-MED
of	O
brain	B-MED
-	I-MED
derived	I-MED
neurotrophic	I-MED
factor	I-MED
and	O
glial	B-MED
cell	I-MED
line	I-MED
-	I-MED
derived	I-MED
neurotrophic	I-MED
factor	I-MED
Evidence	O
suggests	O
that	O
brain	B-MED
-	I-MED
derived	I-MED
neurotrophic	I-MED
factor	I-MED
(	O
BDNF	B-MED
)	O
and	O
glial	B-MED
cell	I-MED
line	I-MED
-derived	I-MED
neurotrophic	I-MED
factor	I-MED
(	O
GDNF	B-MED
)	O
are	O
important	O
in	O
the	O
regulation	B-MED
of	I-MED
synaptic	I-MED
plasticity	I-MED
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	B-MED
processes	I-MED
in	O
psychiatric	B-MED
disorders	I-MED
.	O
Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	B-MED
between	O
serum	B-MED
BDNF	B-MED
and	O
GDNF	B-MED
levels	O
and	O
cognitive	B-MED
functions	I-MED
in	O
first	B-MED
-	I-MED
episode	I-MED
drug	I-MED
-	I-MED
naïve	I-MED
(	I-MED
FEDN	I-MED
)	I-MED
patients	I-MED
with	O
schizophrenia	B-MED
.	O
The	O
BDNF	B-MED
and	O
GDNF	B-MED
levels	O
of	O
58	O
FEDN	B-MED
patients	I-MED
and	O
55	O
age	B-MED
-	O
and	O
sex	B-MED
-matched	O
healthy	B-MED
controls	I-MED
were	O
measured	O
and	O
test	B-MED
subjects	I-MED
were	O
examined	O
using	O
several	O
neurocognitive	B-MED
tests	I-MED
including	O
the	O
verbal	B-MED
fluency	I-MED
test	I-MED
(	O
VFT	B-MED
)	O
,	O
the	O
trail	B-MED
making	I-MED
test	I-MED
(	O
TMT	B-MED
)	O
,	O
the	O
digit	B-MED
span	I-MED
test	I-MED
(	O
DST	B-MED
)	O
,	O
and	O
the	O
Stroop	B-MED
test	I-MED
.	O
Patients	B-MED
performed	O
significantly	O
worse	O
than	O
controls	B-MED
in	O
nearly	O
all	O
neurocognitive	B-MED
performances	I-MED
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	B-MED
.	O
BDNF	B-MED
levels	B-MED
were	O
inversely	O
correlated	O
to	O
TMT	B-MED
-	I-MED
part	I-MED
B	I-MED
scores	I-MED
and	O
positively	O
correlated	O
to	O
VFT	B-MED
-	I-MED
action	I-MED
in	O
the	O
FEDN	O
group	O
.	O
GDNF	B-MED
levels	B-MED
showed	O
a	O
positive	O
correlation	O
with	O
VFT	B-MED
-	I-MED
action	I-MED
scores	I-MED
and	O
a	O
negative	O
correlation	O
with	O
TMT	B-MED
-	I-MED
part	I-MED
B	I-MED
scores	I-MED
of	O
these	O
patients	B-MED
.	O
Current	O
data	O
suggests	O
that	O
cognitive	B-MED
dysfunction	I-MED
widely	O
exists	O
in	O
the	O
early	B-MED
stages	I-MED
of	O
schizophrenia	B-MED
.	O
BDNF	B-MED
and	O
GDNF	B-MED
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	B-MED
mechanisms	B-MED
involved	O
in	O
cognitive	B-MED
impairment	I-MED
in	O
FEDN	B-MED
patients	I-MED
with	O
schizophrenia	B-MED
.	O
Investigation	O
of	O
argyrophilic	B-MED
nucleolar	B-MED
organizing	I-MED
region	I-MED
Ischemia	B-MED
/	I-MED
reperfusion	I-MED
(	I-MED
I	I-MED
/	I-MED
R	I-MED
)	I-MED
injury	I-MED
is	O
a	O
complex	B-MED
event	I-MED
frequently	O
observed	B-MED
in	O
vascular	B-MED
surgery	I-MED
and	O
can	O
cause	O
functional	B-MED
and	O
structural	B-MED
cell	B-MED
damage	I-MED
.	O
Nucleolar	B-MED
-	I-MED
organizing	I-MED
regions	I-MED
(	O
NORs	B-MED
)	O
are	O
sites	B-MED
of	O
the	O
ribosomal	B-MED
genes	I-MED
located	O
on	O
chromosomes	B-MED
and	O
can	O
be	O
stained	B-MED
with	O
silver	B-MED
when	O
they	O
are	O
active	B-MED
.	O
Thus	O
these	O
proteins	B-MED
are	O
named	O
as	O
argyrophilic	B-MED
-	I-MED
NOR	I-MED
(	I-MED
AgNOR)-associated	I-MED
proteins	I-MED
.	O
We	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	B-MED
of	I-MED
renal	B-MED
I	B-MED
/	I-MED
R	I-MED
injury	I-MED
on	O
the	O
NOR	B-MED
protein	I-MED
synthesis	B-MED
and	O
association	O
between	O
the	O
AgNOR	B-MED
proteins	I-MED
amount	B-MED
and	O
histopathological	B-MED
injuring	I-MED
score	I-MED
.	O
Nine	O
female	B-MED
wistar	B-MED
-	I-MED
albino	I-MED
rats	I-MED
with	O
weight	O
of	O
200	O
-	O
250	O
g	O
were	O
included	O
into	O
the	O
study	O
.	O
The	O
animals	B-MED
were	O
randomly	B-MED
divided	B-MED
in	O
two	O
groups	B-MED
,	O
a	O
Control	B-MED
Group	I-MED
and	O
an	O
I	B-MED
/	I-MED
R	I-MED
Group	B-MED
.	O
In	O
I	B-MED
/	I-MED
R	I-MED
group	B-MED
,	O
rats	B-MED
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	B-MED
pedicle	I-MED
occlusion	B-MED
followed	O
by	O
24	O
hours	O
of	O
reperfusion	B-MED
.	O
In	O
the	O
control	B-MED
group	I-MED
no	O
drug	B-MED
injections	I-MED
or	O
ischemia	B-MED
reperfusion	I-MED
were	O
performed	B-MED
in	O
animals	B-MED
.	O
Then	O
histopathological	B-MED
injury	I-MED
score	I-MED
,	O
mean	B-MED
AgNOR	I-MED
number	I-MED
and	O
total	B-MED
AgNOR	I-MED
area	I-MED
/	O
nuclear	B-MED
area	I-MED
(	O
TAA	B-MED
/	O
NA	B-MED
)	O
were	O
detected	B-MED
for	O
each	O
rat	B-MED
.	O
The	O
differences	O
between	O
control	B-MED
and	O
I	B-MED
/	I-MED
R	I-MED
groups	B-MED
were	O
significant	B-MED
for	O
histopathological	B-MED
injury	I-MED
scores	I-MED
(	O
p	O
=	O
0.016	O
)	O
.	O
Also	O
the	O
differences	O
between	O
control	B-MED
group	I-MED
and	O
I	B-MED
/	I-MED
R	I-MED
group	B-MED
were	O
significant	B-MED
for	O
mean	B-MED
AgNOR	I-MED
number	I-MED
(	O
p	O
=	O
0.000	O
)	O
and	O
TAA	B-MED
/	I-MED
NA	I-MED
ratio	I-MED
(	O
p	O
=	O
0.000	O
)	O
.	O
Additionally	O
,	O
there	O
was	O
a	O
positive	B-MED
correlation	I-MED
between	O
TAA	B-MED
/	I-MED
NA	I-MED
ratio	I-MED
and	O
histopathological	B-MED
injury	I-MED
score	I-MED
(	O
r	O
=	O
0.728	O
;	O
p	O
=	O
0.026	O
)	O
and	O
between	O
mean	B-MED
AgNOR	I-MED
number	I-MED
and	O
histopathological	B-MED
injury	I-MED
score	I-MED
(	O
r	O
=	O
0.670	O
;	O
p	O
=	O
0.048	O
)	O
.	O
The	O
detection	B-MED
of	O
AgNOR	B-MED
proteins	I-MED
amount	B-MED
may	O
be	O
used	O
as	O
an	O
indicator	B-MED
to	O
obtain	O
information	B-MED
about	O
the	O
cellular	B-MED
behaviour	I-MED
(	O
self	B-MED
-	I-MED
protective	I-MED
mechanism	O
of	O
tubular	B-MED
epithelial	I-MED
cells	I-MED
)	O
against	O
I	B-MED
/	I-MED
R	I-MED
injury	I-MED
and	O
cellular	B-MED
damage	I-MED
levels	B-MED
(	O
Tab	O
.	O
2	O
,	O
Fig	O
.	O
4	O
,	O
Ref	O
.	O
24	O
)	O
.	O
From	O
'	O
sense	B-MED
of	I-MED
number	I-MED
'	O
to	O
'	O
sense	B-MED
of	I-MED
magnitude	B-MED
'	O
-	O
The	O
role	O
of	O
continuous	B-MED
magnitudes	B-MED
in	O
numerical	B-MED
cognition	B-MED
In	O
this	O
review	O
,	O
we	O
are	O
pitting	B-MED
two	O
theories	B-MED
against	O
each	O
other	O
:	O
the	O
more	O
accepted	O
theory	B-MED
-the	O
'	O
number	B-MED
sense	I-MED
'	O
theory	B-MED
-suggesting	O
that	O
a	O
sense	B-MED
of	I-MED
number	I-MED
is	O
innate	B-MED
and	O
non	B-MED
-	I-MED
symbolic	I-MED
numerosity	I-MED
is	O
being	O
processed	O
independently	O
of	O
continuous	B-MED
magnitudes	B-MED
(	O
e.g.	O
,	O
size	B-MED
,	O
area	B-MED
,	O
density	B-MED
)	O
;	O
and	O
the	O
newly	O
emerging	O
theory	B-MED
suggesting	O
that	O
(	O
1	O
)	O
both	O
numerosities	B-MED
and	O
continuous	B-MED
magnitudes	B-MED
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	B-MED
,	O
and	O
(	O
2	O
)	O
a	O
sense	B-MED
of	I-MED
number	I-MED
might	O
not	O
be	O
innate	B-MED
.	O
In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	B-MED
sense	I-MED
'	O
theory	B-MED
.	O
Against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	B-MED
between	O
numerosities	B-MED
and	O
continuous	B-MED
magnitudes	B-MED
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non	B-MED
-	I-MED
symbolic	I-MED
numerosity	I-MED
processing	I-MED
in	O
isolation	O
from	O
continuous	B-MED
magnitudes	B-MED
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	B-MED
and	O
imaging	B-MED
studies	I-MED
with	O
infants	B-MED
,	O
adults	B-MED
and	O
animals	B-MED
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	B-MED
magnitudes	B-MED
.	O
In	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	B-MED
of	I-MED
magnitude	B-MED
'	O
theory	B-MED
theory	B-MED
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	B-MED
magnitudes	B-MED
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	B-MED
.	O
Finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O
Our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	B-MED
sense	I-MED
theory	B-MED
theory	B-MED
anymore	O
.	O
Therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	B-MED
sense	I-MED
is	O
simply	O
innate	B-MED
,	O
but	O
to	O
put	O
this	O
hypothesis	B-MED
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	B-MED
of	O
numerosity	B-MED
and	O
continuous	B-MED
magnitudes	B-MED
.	O
Modified	B-MED
anastomotic	B-MED
technique	I-MED
for	O
thoracolaparoscopic	B-MED
Ivor	I-MED
-	I-MED
Lewis	I-MED
esophagectomy	I-MED
:	O
early	B-MED
outcomes	B-MED
and	O
technical	B-MED
details	I-MED
Thoracoscopic	B-MED
intrathoracic	I-MED
esophagogastrostomy	I-MED
is	O
a	O
technically	O
demanding	O
operation	O
;	O
these	O
technical	B-MED
requirements	I-MED
restrict	O
the	O
extensive	O
application	B-MED
of	I-MED
minimally	B-MED
invasive	B-MED
Ivor	B-MED
-	I-MED
Lewis	I-MED
esophagectomy	I-MED
.	O
In	O
an	O
attempt	O
to	O
reduce	B-MED
the	O
difficulty	O
of	O
this	O
surgical	B-MED
procedure	I-MED
,	O
this	O
study	O
developed	O
a	O
modified	B-MED
anastomotic	B-MED
technique	I-MED
for	O
thoracolaparoscopic	B-MED
Ivor	I-MED
-	I-MED
Lewis	I-MED
esophagectomy	I-MED
.	O
During	O
the	O
entirety	O
of	O
this	O
modified	B-MED
approach	B-MED
,	O
neither	O
technically	O
challenging	O
operations	B-MED
such	O
as	O
intrathoracic	B-MED
suturing	I-MED
or	O
knotting	B-MED
,	O
nor	O
special	O
instruments	B-MED
such	O
as	O
an	O
OrVil	B-MED
system	I-MED
or	O
a	O
reverse	B-MED
-	I-MED
puncture	I-MED
head	I-MED
are	O
required	O
.	O
Between	O
October	O
2015	O
and	O
January	O
2016	O
,	O
15	O
consecutive	B-MED
patients	B-MED
with	O
cancer	B-MED
in	O
the	O
distal	B-MED
third	I-MED
of	I-MED
the	I-MED
esophagus	I-MED
or	O
the	O
gastric	B-MED
cardia	I-MED
underwent	O
this	O
modified	B-MED
surgical	B-MED
procedure	I-MED
.	O
The	O
good	O
short	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	B-MED
anastomotic	B-MED
technique	I-MED
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic	B-MED
Ivor	I-MED
-	I-MED
Lewis	I-MED
esophagectomy	I-MED
.	O
Water	B-MED
safety	B-MED
in	O
healthcare	B-MED
facilities	I-MED
.	O
The	O
Vieste	B-MED
Charter	I-MED
The	O
Study	B-MED
Group	I-MED
on	O
Hospital	B-MED
Hygiene	B-MED
of	O
the	O
Italian	B-MED
Society	I-MED
of	I-MED
Hygiene	I-MED
,	I-MED
Preventive	I-MED
Medicine	I-MED
and	I-MED
Public	I-MED
Health	I-MED
(	O
GISIO	B-MED
-	I-MED
SItI	I-MED
)	O
and	O
the	O
Local	B-MED
Health	I-MED
Authority	I-MED
of	O
Foggia	B-MED
,	O
Apulia	B-MED
,	O
Italy	B-MED
,	O
after	O
the	O
National	B-MED
Convention	I-MED
"	O
Safe	O
water	B-MED
in	O
healthcare	B-MED
facilities	I-MED
"	O
held	O
in	O
Vieste	B-MED
-	I-MED
Pugnochiuso	I-MED
on	O
27	O
-	O
28	O
May	O
2016	O
,	O
present	O
the	O
"	O
Vieste	B-MED
Charter	I-MED
"	O
,	O
drawn	O
up	O
in	O
collaboration	B-MED
with	O
experts	B-MED
from	O
the	O
National	B-MED
Institute	I-MED
of	I-MED
Health	I-MED
and	O
the	B-MED
Ministry	I-MED
of	I-MED
Health	I-MED
.	O
This	O
paper	O
considers	O
the	O
risk	B-MED
factors	I-MED
that	O
may	O
affect	B-MED
the	O
water	B-MED
safety	B-MED
in	O
healthcare	B-MED
facilities	I-MED
and	O
reports	O
the	O
current	O
regulatory	B-MED
frameworks	I-MED
governing	O
the	O
management	B-MED
of	I-MED
installations	I-MED
and	O
the	O
quality	B-MED
of	O
the	O
water	B-MED
.	O
The	O
Authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	B-MED
that	O
characterize	O
the	O
health	B-MED
facilities	I-MED
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas	O
,	O
including	O
water	B-MED
safety	I-MED
plans	I-MED
;	O
approval	O
of	O
treatments	B-MED
;	O
healthcare	B-MED
facilities	I-MED
responsibility	B-MED
,	O
installation	O
and	O
maintenance	B-MED
of	O
facilities	B-MED
;	O
multidisciplinary	B-MED
approach	I-MED
;	O
education	B-MED
and	O
research	B-MED
;	O
regional	B-MED
and	I-MED
national	I-MED
coordination	I-MED
;	O
communication	B-MED
.	O
Salvianolic	B-MED
Acids	I-MED
for	O
Injection	B-MED
(	O
SAFI	B-MED
)	O
suppresses	B-MED
inflammatory	B-MED
responses	I-MED
in	O
activated	B-MED
microglia	B-MED
to	O
attenuate	B-MED
brain	B-MED
damage	I-MED
in	O
focal	B-MED
cerebral	I-MED
ischemia	I-MED
Inflammatory	B-MED
reactions	I-MED
induced	O
by	O
microglia	B-MED
in	O
the	O
brain	B-MED
play	O
crucial	O
roles	B-MED
in	O
ischemia	B-MED
/	O
reperfusion	B-MED
(	I-MED
I	I-MED
/	I-MED
R	I-MED
)	I-MED
cerebral	I-MED
injuries	I-MED
.	O
Microglia	B-MED
activation	B-MED
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
TLR4	B-MED
/	O
NF	B-MED
-	I-MED
κB	I-MED
signal	I-MED
pathways	I-MED
.	O
Salvianolic	B-MED
acids	I-MED
for	O
injection	B-MED
(	O
SAFI	B-MED
)	O
have	O
been	O
used	O
in	O
clinical	B-MED
practice	I-MED
to	O
treat	B-MED
ischemic	B-MED
stroke	I-MED
with	O
reported	B-MED
neuroprotective	B-MED
effects	I-MED
;	O
however	O
,	O
the	O
underlying	O
mechanisms	B-MED
are	O
still	O
uncertain	O
.	O
First	O
,	O
we	O
studied	B-MED
the	O
effect	B-MED
of	O
SAFI	B-MED
on	O
inflammatory	B-MED
responses	I-MED
in	O
LPS	B-MED
-	O
stimulated	B-MED
BV-2	B-MED
microglia	B-MED
.	O
Then	O
,	O
to	O
discover	B-MED
whether	O
the	O
beneficial	B-MED
in	B-MED
vitro	I-MED
effects	B-MED
of	O
SAFI	B-MED
lead	O
to	O
in	B-MED
vivo	I-MED
therapeutic	B-MED
effect	I-MED
s	O
,	O
an	O
MCAO	B-MED
(	O
Middle	B-MED
cerebral	I-MED
artery	I-MED
occlusion	I-MED
)	O
rat	B-MED
model	B-MED
was	O
further	O
employed	B-MED
to	O
elucidate	O
the	O
probable	O
mechanism	B-MED
of	O
SAFI	B-MED
in	O
treating	B-MED
ischemic	B-MED
stroke	I-MED
.	O
Rats	B-MED
in	O
the	O
SAFI	B-MED
group	B-MED
were	O
given	O
SAFI	B-MED
(	O
23	O
or	O
46mg	O
/	O
kg	O
)	O
before	O
I	B-MED
/	O
R	B-MED
injury	I-MED
.	O
The	O
results	B-MED
showed	O
that	O
SAFI	B-MED
treatment	B-MED
significantly	B-MED
decreased	I-MED
neuroinflammation	B-MED
and	O
the	O
infarction	B-MED
volume	B-MED
compared	O
with	O
the	O
vehicle	B-MED
group	B-MED
.	O
Activation	B-MED
of	O
microglia	B-MED
cells	I-MED
was	O
reduced	B-MED
,	O
and	O
TLR4	B-MED
/	O
NF	B-MED
-	I-MED
κB	I-MED
signals	I-MED
,	O
which	O
were	O
markedly	O
inhibited	B-MED
by	O
SAFI	B-MED
treatment	B-MED
in	O
ischemic	B-MED
hemisphere	B-MED
,	O
were	O
accompanied	O
by	O
reduced	B-MED
expression	B-MED
and	O
release	B-MED
of	O
cytokines	B-MED
IL-1β	B-MED
and	O
IL-6	B-MED
.	O
This	O
study	B-MED
provides	O
evidence	B-MED
that	O
SAFI	B-MED
effectively	B-MED
protects	O
the	O
brain	B-MED
after	O
cerebral	B-MED
ischemia	I-MED
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	B-MED
inflammation	B-MED
in	O
microglia	B-MED
.	O
Heat	B-MED
-	I-MED
shock	I-MED
protein	I-MED
60	I-MED
of	O
Porphyromonas	B-MED
gingivalis	I-MED
may	O
induce	O
dysfunction	B-MED
of	O
human	B-MED
umbilical	I-MED
endothelial	I-MED
cells	I-MED
via	O
regulation	B-MED
of	O
endothelial	B-MED
-	I-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
and	O
vascular	B-MED
endothelial	I-MED
-	I-MED
cadherin	I-MED
Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-MED
was	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
coronary	B-MED
heart	I-MED
disease	I-MED
(	O
CAD	B-MED
)	O
.	O
Porphyromonus	B-MED
gingivalis	I-MED
(	O
P.	B-MED
gingivalis	I-MED
)	O
,	O
a	O
major	O
periodontal	B-MED
pathogen	B-MED
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	B-MED
response	I-MED
of	O
CAD	B-MED
in	B-MED
vivo	I-MED
.	O
The	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
identify	O
whether	O
P.	B-MED
gingivalis	I-MED
heat	B-MED
-	I-MED
shock	I-MED
protein	I-MED
60	I-MED
(	O
HSP60	B-MED
)	O
induced	O
the	O
dysfunction	B-MED
of	O
human	B-MED
umbilical	I-MED
vein	I-MED
endothelial	I-MED
cells	I-MED
(	O
HUVECs	B-MED
)	O
in	B-MED
vitro	I-MED
.	O
HUVECs	B-MED
were	O
stimulated	B-MED
with	O
a	O
range	O
of	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
concentrations	B-MED
(	O
1	O
,	O
10	O
and	O
100	O
ng	O
/	O
l	O
)	O
at	O
different	O
time	B-MED
-	I-MED
points	I-MED
.	O
The	O
levels	B-MED
of	O
vascular	B-MED
endothelial	I-MED
(	I-MED
VE)-cadherin	I-MED
,	O
endothelial	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
(	O
eNOS	B-MED
)	O
and	O
cysteinyl	B-MED
aspartate	I-MED
-	I-MED
specific	I-MED
protease-3	I-MED
(	O
caspase-3	B-MED
)	O
were	O
measured	O
using	O
western	B-MED
blot	I-MED
analysis	B-MED
.	O
The	O
apoptotic	B-MED
rate	B-MED
of	O
HUVECs	B-MED
was	O
detected	O
using	O
flow	B-MED
cytometry	I-MED
.	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
at	O
a	O
concentration	B-MED
of	O
10	O
ng	O
/	O
l	O
significantly	O
decreased	O
the	O
expression	B-MED
levels	B-MED
of	O
VE	B-MED
-	I-MED
cadherin	I-MED
and	O
eNOS	B-MED
protein	I-MED
at	O
24	O
h	B-MED
stimulation	B-MED
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-MED
was	O
identified	O
following	O
a	O
low	B-MED
dose	I-MED
of	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
(	O
1	O
ng	O
/	O
l	O
)	O
.	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
at	O
100	O
ng	O
/	O
l	O
significantly	O
downregulated	B-MED
the	O
expression	B-MED
levels	B-MED
of	O
VE	B-MED
-	I-MED
cadherin	I-MED
and	O
eNOS	B-MED
protein	I-MED
at	O
12	O
h	O
in	O
HUVECs	B-MED
.	O
However	O
,	O
the	O
cleavage	B-MED
of	O
caspase-3	B-MED
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	B-MED
.	O
Consistently	O
,	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
induced	O
apoptosis	B-MED
of	O
HUVECs	B-MED
in	O
a	O
concentration	B-MED
-	O
dependent	B-MED
manner	O
.	O
These	O
results	B-MED
indicated	O
that	O
P.	B-MED
gingivalis	I-MED
HSP60	B-MED
may	O
induce	O
dysfunction	B-MED
and	O
apoptosis	B-MED
in	O
HUVECs	B-MED
via	O
downregulating	B-MED
the	O
expression	B-MED
levels	B-MED
of	O
VE	B-MED
-	I-MED
cadherin	I-MED
and	O
eNOS	B-MED
,	O
and	O
promoting	O
the	O
cleavage	B-MED
of	O
caspase-3	B-MED
.	O
Identification	O
and	O
functional	O
analysis	O
of	O
the	O
GTPV	B-MED
bidirectional	B-MED
promoter	B-MED
region	I-MED
The	O
goat	B-MED
pox	I-MED
chick	I-MED
embryo	I-MED
-	I-MED
attenuated	I-MED
virus	I-MED
(	O
GTPV	B-MED
)	O
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-MED
that	O
can	O
elicit	O
protective	O
immune	B-MED
responses	I-MED
.	O
It	O
possesses	O
a	O
large	O
genome	B-MED
and	O
a	O
robust	O
ability	O
to	O
express	B-MED
exogenous	B-MED
genes	B-MED
.	O
Thus	O
,	O
this	O
virus	B-MED
is	O
an	O
ideal	B-MED
vector	B-MED
for	O
recombinant	B-MED
live	I-MED
vaccines	I-MED
for	O
infectious	B-MED
diseases	I-MED
in	O
ruminant	B-MED
animals	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	B-MED
promoter	B-MED
region	I-MED
of	O
GTPV	B-MED
through	O
screening	O
named	O
PbVV(±	B-MED
)	I-MED
.	O
PbVV(±	B-MED
)	I-MED
is	O
located	O
between	O
ETF	B-MED
-	I-MED
l	I-MED
and	O
VITF-3	B-MED
,	O
which	O
are	O
transcribed	B-MED
in	O
opposite	B-MED
directions	B-MED
.	O
A	O
new	O
recombinant	B-MED
goat	I-MED
pox	I-MED
virus	I-MED
(	O
rGTPV	B-MED
)	O
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
PbVV(+	B-MED
)	I-MED
was	O
used	O
as	O
a	O
promoter	B-MED
element	O
to	O
enhance	B-MED
Brucella	B-MED
OMP31	I-MED
expression	B-MED
,	O
and	O
duplicate	O
PbVV	B-MED
(	O
-	O
)	O
was	O
used	O
as	O
a	O
promoter	B-MED
element	I-MED
to	O
regulate	O
enhanced	B-MED
green	I-MED
fluorescent	I-MED
protein	I-MED
(	O
EGFP	B-MED
)	O
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O
PbVV(-	B-MED
)	I-MED
promoter	I-MED
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
P7.5	B-MED
promoter	I-MED
of	O
vaccinia	B-MED
virus	I-MED
,	O
as	O
measured	O
by	O
EGFP	B-MED
expression	B-MED
;	O
the	O
fluorescence	B-MED
intensity	I-MED
of	O
EGFP	B-MED
expressed	B-MED
in	O
cells	B-MED
was	O
confirmed	O
by	O
fluorescence	B-MED
microscopy	I-MED
and	O
flow	B-MED
cytometry	I-MED
.	O
PbVV(+	B-MED
)	I-MED
promoter	I-MED
activity	O
was	O
measured	O
by	O
Brucella	B-MED
OMP31	I-MED
expression	B-MED
.	O
Interaction	O
with	O
the	O
anti	B-MED
-	I-MED
Brucella	I-MED
-	I-MED
OMP31	I-MED
monoclonal	I-MED
antibody	I-MED
was	O
confirmed	O
by	O
western	B-MED
blotting	I-MED
,	O
and	O
OMP31	B-MED
mRNA	B-MED
expression	I-MED
was	O
assessed	O
by	O
qRT	B-MED
-	I-MED
PCR	I-MED
.	O
The	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	B-MED
multivalent	B-MED
vaccines	I-MED
based	O
on	O
rGTPV	B-MED
.	O
This	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	B-MED
of	O
exogenous	B-MED
genes	B-MED
.	O
Clinical	B-MED
and	O
angiographic	B-MED
correlation	B-MED
of	O
high	B-MED
-	I-MED
sensitivity	I-MED
C	I-MED
-	I-MED
reactive	I-MED
protein	I-MED
with	O
acute	B-MED
ST	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
Vascular	B-MED
inflammation	I-MED
and	O
associated	O
ongoing	O
inflammatory	B-MED
responses	I-MED
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	B-MED
of	O
acute	B-MED
atherothrombotic	B-MED
events	B-MED
such	O
as	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
(	O
ACS	B-MED
)	O
and	O
myocardial	B-MED
infarction	I-MED
(	O
MI	B-MED
)	O
.	O
ST	B-MED
segment	I-MED
elevation	I-MED
myocardial	I-MED
infarction	I-MED
(	O
STEMI	B-MED
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	B-MED
forms	B-MED
of	O
ACS	B-MED
.	O
Moreover	O
,	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
is	O
an	O
important	O
acute	B-MED
phase	I-MED
prsotein	I-MED
,	O
which	O
may	O
be	O
estimated	O
using	O
high	B-MED
-	I-MED
sensitivity	I-MED
methods	I-MED
(	O
hs	B-MED
-	I-MED
CRP	I-MED
)	O
,	O
and	O
its	O
elevated	B-MED
level	B-MED
in	O
body	B-MED
fluids	I-MED
reflects	O
chronic	B-MED
inflammatory	I-MED
status	B-MED
.	O
The	O
circulating	O
hs	B-MED
-	I-MED
CRP	I-MED
level	B-MED
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	B-MED
marker	B-MED
of	O
coronary	B-MED
artery	I-MED
disease	I-MED
(	O
CAD	B-MED
)	O
.	O
The	O
present	O
study	B-MED
investigated	B-MED
the	O
correlation	B-MED
of	O
hs	B-MED
-	I-MED
CRP	I-MED
level	B-MED
with	O
clinical	B-MED
and	O
angiographic	B-MED
features	B-MED
of	O
STEMI	B-MED
,	O
various	O
other	O
traditional	O
risk	B-MED
factors	I-MED
,	O
complications	B-MED
of	O
myocardial	B-MED
infarction	I-MED
and	O
angiographically	B-MED
significant	I-MED
CAD	B-MED
.	O
Out	O
of	O
190	O
patients	B-MED
with	O
STEMI	B-MED
that	O
were	O
analyzed	B-MED
,	O
the	O
interval	B-MED
between	O
symptom	B-MED
onset	I-MED
and	O
reperfusion	B-MED
therapy	I-MED
(	O
window	B-MED
period	I-MED
h	B-MED
)	O
varied	O
from	O
0.5	O
to	O
24	O
h.	O
The	O
hs	B-MED
-	I-MED
CRP	I-MED
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non	B-MED
-	I-MED
diabetic	I-MED
patients	I-MED
(	O
0.61	O
mg	O
/	O
dl	O
)	O
compared	B-MED
with	O
diabetic	B-MED
patients	B-MED
(	O
0.87	O
mg	O
/	O
dl	O
)	O
.	O
Moreover	O
,	O
a	O
significant	O
correlation	B-MED
between	O
hs	B-MED
-	I-MED
CRP	I-MED
and	O
hs	B-MED
-	I-MED
troponin	I-MED
T	I-MED
was	O
also	O
recorded	O
(	O
P<0.001	O
)	O
.	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs	B-MED
-	I-MED
CRP	I-MED
values	B-MED
in	O
patients	B-MED
with	O
or	O
without	O
mortality	B-MED
.	O
It	O
is	O
considered	O
that	O
the	O
present	O
study	B-MED
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-MED
in	O
general	O
and	O
may	O
also	O
have	O
clinical	B-MED
applications	I-MED
in	O
the	O
targeting	O
of	O
therapy	B-MED
for	O
this	O
harmful	O
disease	B-MED
.	O
The	O
epigenetic	B-MED
landscape	I-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
:	O
the	O
geroscience	B-MED
perspective	B-MED
In	O
this	O
review	B-MED
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	B-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
,	O
focusing	O
on	O
those	O
studies	B-MED
that	O
have	O
described	O
DNA	B-MED
methylation	I-MED
landscape	I-MED
in	O
cardio	B-MED
-	I-MED
vascular	I-MED
diseases	I-MED
,	O
musculoskeletal	B-MED
function	I-MED
and	O
frailty	B-MED
.	O
We	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual	B-MED
framework	I-MED
of	O
"	O
geroscience	B-MED
"	O
,	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	B-MED
age	B-MED
is	O
the	O
major	O
risk	B-MED
factor	I-MED
for	O
several	O
of	O
these	O
pathologies	B-MED
and	O
aims	B-MED
at	O
identifying	O
the	O
mechanistic	B-MED
links	I-MED
between	O
aging	B-MED
and	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
.	O
DNA	B-MED
methylation	I-MED
undergoes	O
a	O
profound	O
remodeling	B-MED
during	O
aging	B-MED
,	O
which	O
includes	O
global	B-MED
hypomethylation	I-MED
of	O
the	O
genome	B-MED
,	O
hypermethylation	B-MED
at	O
specific	B-MED
loci	B-MED
and	O
an	O
increase	B-MED
in	O
inter	B-MED
-	I-MED
individual	I-MED
variation	I-MED
and	O
in	O
stochastic	B-MED
changes	B-MED
of	O
DNA	B-MED
methylation	I-MED
values	B-MED
.	O
These	O
epigenetic	B-MED
modifications	B-MED
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	B-MED
of	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	B-MED
relationship	B-MED
between	O
the	O
epigenetic	B-MED
signatures	I-MED
of	O
aging	B-MED
and	O
age	B-MED
-	O
related	B-MED
disease	B-MED
is	O
still	O
poor	O
.	O
The	O
most	O
relevant	B-MED
results	B-MED
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
"	O
epigenetics	B-MED
clocks	I-MED
"	O
in	O
cohorts	B-MED
of	O
subjects	B-MED
affected	B-MED
by	O
age	B-MED
-	O
related	B-MED
diseases	B-MED
.	O
We	O
report	O
these	O
studies	B-MED
in	O
final	O
section	O
of	O
this	O
review	B-MED
.	O
Investigating	O
Synthetic	B-MED
Oligonucleotide	B-MED
Targeting	O
of	O
Mir31	B-MED
in	O
Duchenne	B-MED
Muscular	I-MED
Dystrophy	I-MED
Exon	B-MED
-	I-MED
skipping	I-MED
via	O
synthetic	B-MED
antisense	B-MED
oligonucleotides	I-MED
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-MED
for	O
Duchenne	B-MED
muscular	I-MED
dystrophy	I-MED
(	O
DMD	B-MED
)	O
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence	B-MED
-	I-MED
specific	I-MED
and	O
thus	O
each	O
oligonucleotide	B-MED
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	B-MED
.	O
The	O
discovery	B-MED
that	O
dystrophin	B-MED
mRNA	B-MED
is	O
subject	O
to	O
translational	B-MED
suppression	I-MED
by	O
the	O
microRNA	B-MED
miR31	B-MED
,	O
and	O
that	O
miR31	B-MED
is	O
elevated	O
in	O
the	O
muscle	B-MED
of	O
DMD	B-MED
patients	B-MED
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	B-MED
chemistries	O
employed	O
for	O
exon	B-MED
skipping	I-MED
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	B-MED
block	I-MED
.	O
This	O
approach	O
would	O
act	O
synergistically	B-MED
with	O
exon	B-MED
skipping	I-MED
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'UTR	B-MED
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	B-MED
patients	B-MED
who	O
express	O
low	O
levels	O
of	O
in	B-MED
-	I-MED
frame	I-MED
transcript	B-MED
.	O
We	O
here	O
present	O
investigations	B-MED
into	O
the	O
feasibility	O
of	O
combining	O
exon	B-MED
skipping	I-MED
with	O
several	O
different	O
strategies	O
for	O
miR31	B-MED
-	O
modulation	B-MED
,	O
using	O
both	O
in	B-MED
vitro	I-MED
models	B-MED
and	O
the	O
mdx	B-MED
mouse	I-MED
(	O
the	O
classical	O
animal	B-MED
model	I-MED
of	O
DMD	B-MED
)	O
,	O
and	O
monitoring	B-MED
effects	B-MED
on	O
dystrophin	B-MED
at	O
the	O
transcriptional	B-MED
and	O
translational	B-MED
level	O
.	O
We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-MED
culture	I-MED
model	B-MED
,	O
our	O
in	B-MED
vivo	I-MED
data	B-MED
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	B-MED
of	O
dystrophin	B-MED
translation	B-MED
,	O
suggesting	O
that	O
miR31	B-MED
-	O
modulation	B-MED
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	B-MED
approaches	O
.	O
Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	B-MED
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	B-MED
.	O
Structural	O
and	O
functional	O
characterization	O
of	O
the	O
TYW3	B-MED
/	O
Taw3	B-MED
class	O
of	O
SAM	B-MED
-	I-MED
dependent	I-MED
methyltransferases	I-MED
S	B-MED
-	I-MED
adenosylmethionine	I-MED
(	I-MED
SAM)-dependent	I-MED
methyltransferases	I-MED
regulate	B-MED
a	O
wide	O
range	O
of	O
biological	B-MED
processes	I-MED
through	O
the	O
modification	B-MED
of	O
proteins	B-MED
,	O
nucleic	B-MED
acids	I-MED
,	O
polysaccharides	B-MED
,	O
as	O
well	O
as	O
various	O
metabolites	B-MED
.	O
TYW3	B-MED
/	O
Taw3	B-MED
is	O
a	O
SAM	B-MED
-	I-MED
dependent	I-MED
methyltransferase	I-MED
responsible	O
for	O
the	O
formation	O
of	O
a	O
tRNA	B-MED
modification	I-MED
known	O
as	O
wybutosine	B-MED
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	B-MED
in	O
protein	B-MED
synthesis	I-MED
.	O
Here	O
,	O
we	O
report	O
the	O
crystal	B-MED
structure	I-MED
of	O
Taw3	B-MED
,	O
a	O
homolog	O
of	O
TYW3	B-MED
from	O
Sulfolobus	B-MED
solfataricus	I-MED
,	O
which	O
revealed	O
a	O
novel	O
α	B-MED
/	I-MED
β	I-MED
fold	I-MED
.	O
The	O
sequence	O
motif	O
(	O
S	B-MED
/	I-MED
T)xSSCxGR	I-MED
and	O
invariant	O
aspartate	B-MED
and	O
histidine	B-MED
,	O
conserved	O
in	O
TYW3	B-MED
/	O
Taw3	B-MED
,	O
cluster	B-MED
to	O
form	O
the	O
catalytic	B-MED
center	O
.	O
These	O
structural	B-MED
and	O
sequence	B-MED
features	O
indicate	O
that	O
TYW3	B-MED
/	O
Taw3	B-MED
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
SAM	B-MED
-	I-MED
dependent	I-MED
methyltransferases	I-MED
.	O
Using	O
site	B-MED
-	I-MED
directed	I-MED
mutagenesis	I-MED
along	O
with	O
in	B-MED
vivo	I-MED
complementation	I-MED
assays	I-MED
combined	O
with	O
mass	B-MED
spectrometry	I-MED
as	O
well	O
as	O
ligand	B-MED
docking	I-MED
and	O
cofactor	B-MED
binding	I-MED
assays	B-MED
,	O
we	O
have	O
identified	O
the	O
active	B-MED
site	I-MED
of	O
TYW3	B-MED
and	O
residues	O
essential	O
for	O
cofactor	B-MED
binding	I-MED
and	O
methyltransferase	B-MED
activity	I-MED
.	O
Prevalence	B-MED
of	O
Psychiatric	B-MED
Disorders	I-MED
among	O
Female	B-MED
Juvenile	B-MED
Offenders	I-MED
Inmates	B-MED
of	O
Juvenile	B-MED
Developmental	I-MED
Centers	I-MED
are	O
the	O
special	B-MED
group	B-MED
of	O
youth	B-MED
population	B-MED
who	O
are	O
in	O
conflict	B-MED
with	O
law	B-MED
.	O
They	O
are	O
vulnerable	B-MED
to	O
psychiatric	B-MED
illness	I-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
see	O
the	O
prevalence	B-MED
and	O
type	B-MED
of	O
psychiatric	B-MED
disorders	I-MED
in	O
institutionalized	B-MED
female	B-MED
juvenile	B-MED
offenders	I-MED
and	O
non	B-MED
-	I-MED
offenders	I-MED
of	O
same	B-MED
age	B-MED
,	O
sex	B-MED
and	O
socioeconomic	B-MED
group	I-MED
in	O
the	O
community	B-MED
.	O
The	O
association	B-MED
of	O
mental	B-MED
disorders	I-MED
was	O
examined	B-MED
in	O
43	O
female	B-MED
inmates	B-MED
of	O
Juvenile	B-MED
Development	I-MED
Centers	I-MED
and	O
43	O
randomly	B-MED
selected	B-MED
comparison	B-MED
subjects	B-MED
in	O
community	B-MED
.	O
One	B-MED
stage	I-MED
-	I-MED
structured	I-MED
assessment	I-MED
of	O
psychopathology	B-MED
was	O
carried	O
out	O
by	O
using	O
a	O
structured	B-MED
and	O
valid	B-MED
Bangla	B-MED
version	B-MED
of	O
the	O
Development	B-MED
and	I-MED
Well	I-MED
-	I-MED
Being	I-MED
Assessment	I-MED
(	O
DAWBA	B-MED
)	O
.	O
Development	B-MED
and	I-MED
Well	I-MED
-	I-MED
Being	I-MED
Assessment	I-MED
generated	O
psychiatric	B-MED
diagnosis	B-MED
was	O
assigned	O
based	O
on	O
ICD-10	B-MED
diagnostic	B-MED
criteria	I-MED
for	O
research	B-MED
.	O
The	O
result	B-MED
revealed	B-MED
that	O
,	O
of	O
those	O
who	O
were	O
in	O
conflict	B-MED
with	O
law	B-MED
,	O
93	O
%	O
had	O
mental	B-MED
disorder	I-MED
,	O
whereas	O
14	O
%	O
of	O
non	B-MED
-	I-MED
offenders	I-MED
had	O
psychiatric	B-MED
disorder	I-MED
.	O
Among	O
the	O
offenders	B-MED
with	O
psychiatric	B-MED
disorders	I-MED
,	O
most	O
of	O
them	O
(	O
32.6	O
%	O
)	O
suffered	O
from	O
Major	B-MED
Depressive	I-MED
Disorder	I-MED
(	O
MDD	B-MED
)	O
,	O
followed	O
by	O
combined	B-MED
MDD	B-MED
&	O
Post	B-MED
Traumatic	I-MED
Stress	I-MED
Disorder	I-MED
(	O
PTSD	B-MED
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
among	O
the	O
non	B-MED
-	I-MED
offenders	I-MED
with	O
psychiatric	B-MED
disorder	I-MED
9.3	O
%	O
suffered	O
from	O
MDD	B-MED
.	O
It	O
can	O
be	O
concluded	B-MED
that	O
considerable	B-MED
psychiatric	B-MED
disorders	I-MED
are	O
prevalent	B-MED
among	O
the	O
female	B-MED
juvenile	B-MED
offenders	I-MED
with	O
comparison	B-MED
to	O
non	B-MED
-	I-MED
offenders	I-MED
.	O
Broad	B-MED
-based	O
replication	B-MED
study	I-MED
could	O
confirm	B-MED
these	O
findings	B-MED
.	O
Increased	B-MED
cerebral	B-MED
blood	I-MED
volume	I-MED
pulsatility	B-MED
during	O
head	B-MED
-	I-MED
down	I-MED
tilt	I-MED
with	O
elevated	B-MED
carbon	I-MED
dioxide	I-MED
elevated	B-MED
carbon	I-MED
dioxide	I-MED
:	O
The	O
SPACECOT	B-MED
Study	I-MED
Astronauts	B-MED
aboard	O
the	O
International	O
Space	O
Station	O
(	O
ISS	O
)	O
have	O
exhibited	O
hyperopic	B-MED
shifts	I-MED
,	O
posterior	B-MED
eye	B-MED
globe	I-MED
flattening	B-MED
,	O
dilated	B-MED
optic	B-MED
nerve	I-MED
sheaths	I-MED
,	O
and	O
even	O
optic	B-MED
disc	I-MED
swelling	I-MED
from	O
spaceflight	B-MED
.	O
Elevated	B-MED
intracranial	I-MED
pressure	I-MED
(	O
ICP	B-MED
)	O
consequent	O
to	O
cephalad	B-MED
fluid	B-MED
shifts	I-MED
is	O
commonly	O
hypothesized	B-MED
as	O
contributing	O
to	O
these	O
ocular	B-MED
changes	I-MED
.	O
Head	B-MED
-	I-MED
down	I-MED
tilt	I-MED
(	O
HDT	B-MED
)	O
is	O
frequently	O
utilized	O
as	O
an	O
Earth	B-MED
-based	O
analog	O
to	O
study	O
similar	B-MED
fluid	B-MED
shifts	I-MED
.	O
Sealed	B-MED
environments	I-MED
like	O
the	O
ISS	O
also	O
exhibit	O
elevated	B-MED
carbon	B-MED
dioxide	I-MED
(	O
CO2	B-MED
)	O
,	O
a	O
potent	B-MED
arteriolar	B-MED
vasodilator	I-MED
that	O
could	O
further	O
affect	O
cerebral	B-MED
blood	I-MED
volume	I-MED
and	O
flow	B-MED
,	O
intracranial	B-MED
compliance	B-MED
,	O
and	O
ICP	B-MED
.	O
A	O
collaborative	B-MED
pilot	I-MED
study	I-MED
between	O
the	O
National	B-MED
Space	I-MED
Biomedical	I-MED
Research	I-MED
Institute	I-MED
and	O
the	O
German	B-MED
Aerospace	I-MED
Center	I-MED
tested	O
the	O
hypotheses	B-MED
that	O
:	O
(	O
1	O
)	O
HDT	B-MED
and	O
elevated	B-MED
CO2	B-MED
physiologically	B-MED
interact	B-MED
,	O
and	O
(	O
2	O
)	O
cerebrovascular	B-MED
pulsatility	B-MED
is	O
related	O
to	O
HDT	B-MED
and/or	O
elevated	B-MED
CO2	B-MED
In	O
a	O
double	B-MED
-	I-MED
blind	I-MED
crossover	B-MED
study	I-MED
(	O
n=6	O
)	O
,	O
we	O
measured	O
cerebral	B-MED
blood	I-MED
volume	I-MED
(	O
CBV	B-MED
)	O
pulsatility	B-MED
via	O
near	B-MED
-	I-MED
infrared	I-MED
spectroscopy	I-MED
,	O
alongside	O
non	B-MED
-	I-MED
invasive	I-MED
ICP	B-MED
and	O
intraocular	B-MED
pressure	I-MED
(	O
IOP	B-MED
)	O
during	O
28	O
-	O
hr	O
-12	O
°	O
HDT	B-MED
at	O
both	O
nominal	B-MED
(	O
0.04	O
%	O
)	O
and	O
elevated	B-MED
(	O
0.5	O
%	O
)	O
ambient	B-MED
CO2	B-MED
In	O
our	O
cohort	B-MED
,	O
CBV	B-MED
pulsatility	B-MED
increased	B-MED
significantly	I-MED
over	O
time	O
at	O
cardiac	B-MED
frequencies	B-MED
(	O
0.031±0.009	O
μM	O
/	O
hr	O
increase	B-MED
in	O
[	O
HbT	O
]	O
pulsatility	B-MED
amplitude	B-MED
)	O
and	O
Mayer	B-MED
wave	I-MED
frequencies	I-MED
(	O
0.019±0.005	O
μM	O
/	O
hr	O
increase	B-MED
)	O
.	O
The	O
HDT	B-MED
-	O
CO2	B-MED
interaction	B-MED
on	O
pulsatility	B-MED
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	B-MED
.	O
Significant	O
differences	B-MED
between	O
atmospheres	B-MED
were	O
not	B-MED
detected	I-MED
in	O
ICP	B-MED
or	O
IOP	B-MED
.	O
Further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	B-MED
,	O
to	O
determine	O
whether	O
a	O
"	B-MED
water	I-MED
hammer	I-MED
"	I-MED
effect	I-MED
in	O
cerebral	B-MED
pulsatility	B-MED
is	O
also	O
present	O
during	O
spaceflight	B-MED
,	O
and	O
whether	O
it	O
is	O
associated	B-MED
with	I-MED
ocular	B-MED
changes	I-MED
in	O
astronauts	B-MED
.	O
Farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
lipid	B-MED
-	I-MED
polyethylene	I-MED
glycol	I-MED
-	I-MED
polymer	I-MED
hybrid	I-MED
nanoparticles	I-MED
for	O
treatment	B-MED
of	O
glioblastoma	B-MED
We	O
aimed	O
to	O
develop	O
lipid	B-MED
-	I-MED
polyethylene	I-MED
glycol	I-MED
(	I-MED
PEG)-polymer	I-MED
hybrid	I-MED
nanoparticles	I-MED
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	B-MED
tissue	I-MED
with	O
active	B-MED
ingredient	I-MED
,	O
a	O
new	O
generation	B-MED
antineoplastic	B-MED
drug	I-MED
,	O
farnesylthiosalicylic	B-MED
acid	I-MED
(	O
FTA	B-MED
)	O
for	O
treatment	B-MED
of	O
glioblastoma	B-MED
.	O
Farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
poly(lactic	B-MED
-	I-MED
co	I-MED
-	I-MED
glycolic	I-MED
acid)-1,2	I-MED
distearoyl	I-MED
-	I-MED
glycerol-3	I-MED
-	I-MED
phospho	I-MED
-	I-MED
ethanolamine	I-MED
-	I-MED
N	I-MED
[	I-MED
methoxy	I-MED
(	I-MED
PEG)-2000	I-MED
]	I-MED
ammonium	I-MED
salt	I-MED
(	O
PLGA	B-MED
-	I-MED
DSPE	I-MED
-	I-MED
PEG	I-MED
)	O
with	O
or	O
without	O
1,2	B-MED
-	I-MED
dioleoyl-3	I-MED
-	I-MED
trimethylammonium	I-MED
-	I-MED
propane	I-MED
(	I-MED
DOTAP	I-MED
)	I-MED
hybrid	I-MED
nanoparticles	I-MED
has	O
been	O
prepared	B-MED
and	O
evaluated	B-MED
for	O
in	B-MED
-	I-MED
vitro	I-MED
characterization	I-MED
.	O
Cytotoxicity	B-MED
of	O
FTA	B-MED
-	I-MED
loaded	I-MED
nanoparticles	I-MED
along	O
with	O
its	O
efficacy	B-MED
on	O
rat	B-MED
glioma-2	I-MED
(	I-MED
RG2	I-MED
)	I-MED
cells	I-MED
was	O
also	O
evaluated	B-MED
both	O
in	B-MED
vitro	I-MED
(	O
in	O
comparison	O
with	O
non	B-MED
-	I-MED
malignant	I-MED
cell	I-MED
line	I-MED
,	I-MED
L929	I-MED
)	O
and	O
in	B-MED
vivo	I-MED
.	O
Scanning	B-MED
electron	I-MED
microscopy	I-MED
studies	I-MED
showed	O
that	O
all	O
formulations	B-MED
prepared	I-MED
had	O
smooth	B-MED
surface	I-MED
and	O
spherical	B-MED
in	I-MED
shape	I-MED
.	O
FTA	B-MED
and	O
FTA	B-MED
-	I-MED
loaded	I-MED
nanoparticles	I-MED
have	O
cytotoxic	B-MED
activity	I-MED
against	O
RG2	B-MED
glioma	I-MED
cell	I-MED
lines	I-MED
in	O
cell	B-MED
culture	I-MED
studies	I-MED
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	B-MED
.	O
Magnetic	B-MED
resonance	I-MED
imaging	I-MED
and	O
histopathologic	B-MED
evaluation	B-MED
on	O
RG2	B-MED
tumour	I-MED
cells	I-MED
in	O
rat	B-MED
glioma	I-MED
model	I-MED
(	O
49	O
female	O
Wistar	B-MED
rats	I-MED
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	B-MED
and	O
intratumoral	B-MED
injections	I-MED
of	O
the	O
drug	B-MED
have	O
been	O
performed	O
and	O
FTA	B-MED
-	I-MED
loaded	I-MED
nanoparticles	I-MED
reduced	O
tumour	B-MED
size	I-MED
significantly	O
in	O
in	B-MED
-	I-MED
vivo	I-MED
studies	I-MED
,	O
with	O
higher	O
efficiency	B-MED
of	O
intratumoral	B-MED
administration	I-MED
than	O
intravenous	B-MED
route	I-MED
.	O
Farnesylthiosalicylic	B-MED
acid	I-MED
-loaded	O
PLGA	B-MED
-	I-MED
DSPE	I-MED
-	I-MED
PEG	I-MED
-	I-MED
DOTAP	I-MED
hybrid	I-MED
nanoparticles	I-MED
are	O
proven	O
to	O
be	O
effective	B-MED
against	O
glioblastoma	B-MED
in	O
both	O
in	B-MED
-	I-MED
vitro	I-MED
and	O
in	B-MED
-	I-MED
vivo	I-MED
experiments	I-MED
.	O
Effect	B-MED
of	O
ultrasound	B-MED
and	O
enzymatic	B-MED
pre	B-MED
-	I-MED
treatment	I-MED
on	O
yield	B-MED
and	O
properties	B-MED
of	O
banana	B-MED
juice	B-MED
Effect	B-MED
of	O
ultrasound	B-MED
and	O
enzymatic	B-MED
pre	B-MED
-	I-MED
treatments	I-MED
with	O
cellulase	B-MED
and	O
pectinase	B-MED
on	O
yield	B-MED
and	O
properties	B-MED
of	O
banana	B-MED
juice	B-MED
were	O
investigated	B-MED
.	O
A	O
two	B-MED
-	I-MED
level	I-MED
full	I-MED
factorial	I-MED
design	I-MED
was	O
employed	O
.	O
The	O
factors	O
selected	O
were	O
ultrasonication	B-MED
time	I-MED
(	O
0	O
and	O
30	O
min	B-MED
)	O
,	O
cellulase	B-MED
concentration	B-MED
(	O
0	O
and	O
0.2	O
%	O
)	O
and	O
pectinase	B-MED
concentration	B-MED
(	O
0	O
and	O
0.2	O
%	O
)	O
.	O
The	O
responses	O
studied	O
were	O
yield	B-MED
,	O
viscosity	B-MED
,	O
clarity	B-MED
,	O
total	B-MED
soluble	I-MED
solids	I-MED
(	O
TSS	B-MED
pH	B-MED
)	O
and	O
pH.	O
It	O
was	O
observed	O
that	O
pectinase	B-MED
was	O
more	O
effective	B-MED
in	O
increasing	B-MED
the	O
yield	B-MED
of	O
juice	B-MED
compared	O
to	O
cellulase	B-MED
.	O
Ultrasonic	B-MED
pre	I-MED
-	I-MED
treatment	I-MED
alone	O
did	O
not	B-MED
significantly	B-MED
increase	I-MED
the	O
yield	B-MED
of	O
juice	B-MED
.	O
When	O
ultrasound	B-MED
was	O
combined	O
with	O
pre	B-MED
-	I-MED
treatment	I-MED
with	O
both	O
the	O
enzymes	B-MED
maximum	B-MED
yield	I-MED
of	O
89.40	O
%	O
was	O
obtained	O
compared	O
to	O
47.30	O
%	O
in	O
the	O
control	B-MED
.	O
The	O
viscosity	B-MED
of	O
the	O
juice	B-MED
decreased	B-MED
with	O
addition	O
of	O
enzymes	B-MED
and	O
with	O
application	O
of	O
ultrasound	B-MED
.	O
The	O
clarity	B-MED
of	O
the	O
juice	B-MED
was	O
not	O
affected	O
by	O
cellulase	B-MED
treatment	B-MED
,	O
but	O
improved	B-MED
with	O
pectinase	B-MED
treatment	B-MED
.	O
Ultrasonication	B-MED
alone	O
was	O
found	O
to	O
be	O
more	O
effective	B-MED
than	O
pectinase	B-MED
or	O
cellulase	B-MED
treatment	B-MED
in	O
improving	B-MED
the	O
clarity	B-MED
of	O
the	O
juice	B-MED
.	O
The	O
TSS	B-MED
increased	B-MED
with	O
enzymatic	B-MED
treatment	B-MED
,	O
ultrasonication	B-MED
and	O
their	O
combination	O
.	O
pH	B-MED
was	O
not	O
affected	O
by	O
treatment	B-MED
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	B-MED
juices	B-MED
.	O
Significant	B-MED
correlations	I-MED
were	O
observed	O
between	O
the	O
various	O
responses	O
.	O
Diazoxide	B-MED
prevents	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
and	O
mitochondrial	B-MED
damage	I-MED
,	O
leading	O
to	O
anti	B-MED
-	I-MED
hypertrophic	I-MED
effects	I-MED
Pathological	B-MED
cardiac	B-MED
hypertrophy	I-MED
is	O
characterized	B-MED
by	O
wall	B-MED
thickening	B-MED
or	O
chamber	B-MED
enlargement	B-MED
of	O
the	O
heart	B-MED
in	O
response	O
to	O
pressure	B-MED
or	O
volume	B-MED
overload	O
,	O
respectively	O
.	O
This	O
condition	B-MED
will	O
,	O
initially	O
,	O
improve	B-MED
the	O
organ	B-MED
contractile	B-MED
function	I-MED
,	O
but	O
if	O
sustained	B-MED
will	O
render	O
dysfunctional	B-MED
mitochondria	B-MED
and	O
oxidative	B-MED
stress	I-MED
.	O
Mitochondrial	B-MED
ATP	I-MED
-	I-MED
sensitive	I-MED
K(+	I-MED
)	I-MED
channels	I-MED
(	O
mitoKATP	B-MED
)	O
modulate	B-MED
the	O
redox	B-MED
status	I-MED
of	O
the	O
cell	B-MED
and	O
protect	B-MED
against	O
several	O
cardiac	B-MED
insults	B-MED
.	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	B-MED
that	O
mitoKATP	B-MED
opening	B-MED
(	O
using	O
diazoxide	B-MED
)	O
will	O
avoid	O
isoproterenol	B-MED
-	O
induced	B-MED
cardiac	B-MED
hypertrophy	I-MED
in	B-MED
vivo	I-MED
by	O
decreasing	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	B-MED
ROS	I-MED
)	O
production	O
and	O
mitochondrial	B-MED
Ca(2	B-MED
+	I-MED
)	I-MED
-	O
induced	B-MED
swelling	B-MED
.	O
To	O
induce	B-MED
cardiac	B-MED
hypertrophy	I-MED
,	O
Swiss	B-MED
mice	I-MED
were	O
treated	B-MED
intraperitoneally	B-MED
with	O
isoproterenol	B-MED
(	O
30	O
mg	O
/	O
kg/	O
day	B-MED
)	O
for	O
8	O
days	B-MED
.	O
Diazoxide	B-MED
(	O
5	O
mg	O
/	O
kg/	O
day	B-MED
)	O
was	O
used	O
to	O
open	O
mitoKATP	B-MED
and	O
5	B-MED
-	I-MED
hydroxydecanoate	I-MED
(	O
5	O
mg	O
/	O
kg/	O
day	B-MED
)	O
was	O
administrated	O
as	O
a	O
mitoKATP	B-MED
blocker	B-MED
.	O
Isoproterenol	B-MED
-	O
treated	B-MED
mice	B-MED
had	O
elevated	B-MED
heart	B-MED
weight	B-MED
/	O
tibia	B-MED
length	B-MED
ratios	B-MED
and	O
increased	B-MED
myocyte	B-MED
cross	B-MED
-	I-MED
sectional	I-MED
areas	I-MED
.	O
Additionally	O
,	O
hypertrophic	B-MED
hearts	B-MED
produced	O
higher	B-MED
levels	B-MED
of	O
H2O2	B-MED
and	O
had	O
lower	O
glutathione	B-MED
peroxidase	I-MED
activity	I-MED
.	O
In	O
contrast	O
,	O
mitoKATP	B-MED
opening	B-MED
with	O
diazoxide	B-MED
blocked	B-MED
all	O
isoproterenol	B-MED
effects	B-MED
in	O
a	O
manner	O
reversed	B-MED
by	O
5	B-MED
-	I-MED
hydroxydecanoate	I-MED
.	O
Isolated	B-MED
mitochondria	B-MED
from	O
Isoproterenol	B-MED
-	O
induced	B-MED
hypertrophic	B-MED
hearts	B-MED
had	O
increased	B-MED
susceptibility	B-MED
to	O
Ca(2	B-MED
+	I-MED
)	I-MED
-	O
induced	B-MED
swelling	B-MED
secondary	O
to	O
mitochondrial	B-MED
permeability	I-MED
transition	I-MED
pore	I-MED
opening	B-MED
.	O
MitokATP	B-MED
opening	B-MED
was	O
accompanied	O
by	O
lower	O
Ca(2	B-MED
+	I-MED
)	I-MED
-	O
induced	B-MED
mitochondrial	B-MED
swelling	I-MED
,	O
an	O
effect	B-MED
blocked	B-MED
by	O
5	B-MED
-	I-MED
hydroxydecanoate	I-MED
.	O
Our	O
results	O
suggest	O
that	O
mitoKATP	B-MED
opening	B-MED
negatively	B-MED
regulates	B-MED
cardiac	B-MED
hypertrophy	I-MED
by	O
avoiding	O
oxidative	B-MED
impairment	B-MED
and	O
mitochondrial	B-MED
damage	I-MED
.	O
Differences	B-MED
in	O
pain	B-MED
experience	B-MED
and	O
cooperation	B-MED
between	O
consecutive	B-MED
surgeries	I-MED
in	O
patients	B-MED
undergoing	O
phacoemulsification	B-MED
The	O
purpose	O
of	O
this	O
study	B-MED
is	O
to	O
compare	O
pain	B-MED
experience	B-MED
and	O
cooperation	B-MED
between	O
consecutive	B-MED
surgeries	I-MED
in	O
patients	B-MED
undergoing	O
phacoemulsification	B-MED
in	O
both	O
eyes	B-MED
,	O
using	O
sub	B-MED
-	I-MED
Tenon	I-MED
's	I-MED
local	I-MED
anesthesia	I-MED
without	O
sedation	B-MED
.	O
In	O
this	O
study	B-MED
,	O
268	O
patients	B-MED
with	O
bilateral	B-MED
senile	I-MED
cataracts	I-MED
were	O
recruited	O
.	O
All	O
operations	B-MED
were	O
performed	O
without	O
sedation	B-MED
,	O
using	O
a	O
clear	O
corneal	B-MED
phacoemulsification	B-MED
technique	I-MED
and	O
sub	B-MED
-	I-MED
Tenon	I-MED
's	I-MED
local	I-MED
anesthesia	I-MED
,	O
by	O
one	O
of	O
four	O
surgeons	B-MED
.	O
The	O
first	O
surgery	B-MED
was	O
performed	O
on	O
the	O
eye	B-MED
with	O
the	O
higher	O
grade	O
cataract	B-MED
.	O
The	O
other	O
eye	B-MED
was	O
operated	B-MED
on	O
within	O
3	B-MED
months	I-MED
by	O
the	O
same	O
surgeon	B-MED
(	O
mean	O
interval	O
1.9	O
±	O
1.1	O
months	B-MED
)	O
.	O
All	O
patients	B-MED
were	O
asked	O
to	O
grade	O
their	O
pain	B-MED
experience	B-MED
during	O
induction	B-MED
and	O
maintenance	B-MED
of	O
anesthesia	B-MED
and	O
also	O
during	O
the	O
phacoemulsification	B-MED
surgery	I-MED
,	O
using	O
a	O
visual	B-MED
analogue	I-MED
scale	I-MED
(	O
VAS	B-MED
)	O
from	O
0	O
(	O
no	B-MED
pain	I-MED
)	O
to	O
10	O
(	O
unbearable	B-MED
pain	I-MED
)	O
administered	O
after	O
the	O
surgery	B-MED
.	O
The	O
cooperation	B-MED
of	O
the	O
patient	B-MED
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	B-MED
and	O
head	B-MED
movement	I-MED
and	O
lid	B-MED
squeezing	I-MED
)	O
by	O
the	O
attending	O
surgeon	B-MED
.	O
The	O
VAS	B-MED
scores	I-MED
and	O
cooperation	B-MED
scores	B-MED
of	O
the	O
patients	B-MED
were	O
the	O
outcome	B-MED
measurements	I-MED
.	O
The	O
mean	B-MED
pain	I-MED
score	I-MED
was	O
2.11	O
±	O
0.79	O
in	O
the	O
first	O
eye	B-MED
and	O
3.33	O
±	O
0.80	O
in	O
the	O
second	O
eye	B-MED
during	O
the	O
administration	B-MED
of	O
sub	B-MED
-	I-MED
Tenon	I-MED
's	I-MED
anesthesia	I-MED
,	O
and	O
1.50	O
±	O
0.60	O
in	O
the	O
first	O
eye	B-MED
and	O
2.10	O
±	O
0.57	O
in	O
the	O
second	O
eye	B-MED
during	O
the	O
phacoemulsification	B-MED
surgery	I-MED
.	O
The	O
patient	B-MED
cooperation	I-MED
score	B-MED
was	O
1.60	O
±	O
0.75	O
in	O
the	O
first	O
surgery	B-MED
and	O
2.08	O
±	O
0.72	O
in	O
the	O
second	O
surgery	B-MED
.	O
The	O
differences	B-MED
between	O
the	O
first	O
and	O
second	O
surgeries	B-MED
were	O
statistically	O
significant	O
for	O
all	O
outcome	B-MED
measures	I-MED
(	O
p	O
<	O
0.01	O
)	O
.	O
Patients	B-MED
who	O
previously	O
underwent	O
phaco	B-MED
surgery	I-MED
in	O
one	O
eye	B-MED
experienced	O
more	O
pain	B-MED
and	O
showed	O
worse	B-MED
cooperation	B-MED
during	O
the	O
phaco	B-MED
surgery	I-MED
in	O
the	O
second	O
eye	B-MED
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-MED
,	O
viz	O
.	O
,	O
less	O
than	O
3	O
months	B-MED
.	O
Therefore	O
,	O
if	O
the	O
surgeon	B-MED
has	O
difficulty	B-MED
in	O
the	O
first	O
operation	B-MED
gaining	O
the	O
patient	B-MED
's	I-MED
cooperation	I-MED
,	O
the	O
surgeon	B-MED
must	O
be	O
careful	O
:	O
if	O
contralateral	B-MED
eye	I-MED
surgery	I-MED
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-MED
/	O
analgesia	B-MED
should	O
be	O
considered	O
or	O
the	O
surgery	B-MED
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	B-MED
of	O
recent	B-MED
memory	I-MED
on	O
the	O
patient	B-MED
's	I-MED
subsequent	O
pain	B-MED
experience	B-MED
.	O
Association	B-MED
of	O
Fat	B-MED
Mass	I-MED
and	O
Obesity	B-MED
-	O
associated	B-MED
Gene	B-MED
Variant	I-MED
with	O
Lifestyle	B-MED
Factors	B-MED
and	O
Body	B-MED
Fat	I-MED
in	O
Indian	B-MED
Children	B-MED
Common	O
intronic	B-MED
variants	I-MED
of	O
the	O
fat	B-MED
mass	I-MED
and	O
obesity	B-MED
-	O
associated	B-MED
(	B-MED
FTO	I-MED
)	I-MED
gene	I-MED
have	O
been	O
associated	B-MED
with	I-MED
obesity	B-MED
-related	O
traits	B-MED
in	O
humans	B-MED
.	O
(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	B-MED
is	O
to	O
study	B-MED
the	O
distribution	O
of	O
FTO	B-MED
gene	I-MED
variants	B-MED
across	O
different	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	B-MED
between	O
FTO	B-MED
gene	I-MED
variants	B-MED
and	O
lifestyle	B-MED
factors	B-MED
in	O
obese	B-MED
and	O
normal	B-MED
weight	I-MED
Indian	B-MED
children	B-MED
.	O
Fifty	O
-	O
six	O
children	B-MED
(	O
26	O
boys	B-MED
,	O
mean	O
age	B-MED
10.3	O
±	O
2.2	O
years	B-MED
)	O
were	O
studied	B-MED
.	O
Height	B-MED
,	O
weight	B-MED
,	O
and	O
waist	B-MED
and	O
hip	B-MED
circumference	I-MED
were	O
measured	B-MED
.	O
Physical	B-MED
activity	I-MED
(	O
questionnaire	B-MED
)	O
and	O
food	B-MED
intake	B-MED
(	O
food	B-MED
frequency	I-MED
questionnaire	I-MED
)	O
were	O
assessed	B-MED
.	O
Body	B-MED
fat	I-MED
percentage	I-MED
(	O
%	B-MED
BF	I-MED
)	O
was	O
measured	O
by	O
dual	B-MED
-	I-MED
energy	I-MED
X	I-MED
-	I-MED
ray	I-MED
absorptiometry	I-MED
.	O
FTO	B-MED
allelic	I-MED
variants	I-MED
at	O
rs9939609	B-MED
site	I-MED
were	O
detected	O
by	O
SYBR	B-MED
Green	I-MED
Amplification	I-MED
Refractory	I-MED
Mutation	I-MED
System	I-MED
real	I-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
using	O
allele	B-MED
-	O
specific	B-MED
primers	B-MED
.	O
Generalized	B-MED
linear	I-MED
model	I-MED
was	O
used	O
to	O
investigate	B-MED
the	O
simultaneous	B-MED
influence	B-MED
of	O
genetic	B-MED
and	O
lifestyle	B-MED
factors	B-MED
on	O
%	B-MED
BF	I-MED
.	O
Mean	O
height	B-MED
,	O
weight	B-MED
,	O
and	O
BMI	B-MED
of	O
normal	B-MED
and	O
obese	B-MED
children	B-MED
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6	O
,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8	O
,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2	O
,	O
respectively	O
.	O
The	O
frequency	O
of	O
AA	B-MED
allele	I-MED
was	O
57	O
%	O
among	O
obese	B-MED
children	B-MED
and	O
35	O
%	O
in	O
normal	B-MED
weight	I-MED
children	B-MED
.	O
Children	B-MED
with	O
the	O
AA	B-MED
allele	I-MED
who	O
were	O
obese	B-MED
had	O
least	O
physical	B-MED
activity	I-MED
,	O
whereas	O
children	B-MED
with	O
AT	B-MED
allele	I-MED
and	O
obesity	B-MED
had	O
the	O
highest	B-MED
intake	B-MED
of	I-MED
calories	I-MED
when	O
compared	B-MED
to	O
children	B-MED
who	O
had	O
AT	B-MED
allele	I-MED
and	O
were	O
normal	B-MED
.	O
%	B-MED
BF	I-MED
was	O
positively	O
associated	B-MED
with	I-MED
AA	B-MED
alleles	I-MED
and	O
junk	B-MED
food	I-MED
intake	B-MED
and	O
negatively	O
with	O
healthy	B-MED
food	B-MED
intake	B-MED
and	O
moderate	O
physical	B-MED
activity	I-MED
.	O
Healthy	B-MED
lifestyle	I-MED
with	O
high	O
physical	B-MED
activity	I-MED
and	O
diet	B-MED
low	B-MED
in	O
calories	B-MED
and	O
fat	B-MED
may	O
help	O
in	O
modifying	B-MED
the	O
risk	B-MED
imposed	O
by	O
FTO	B-MED
variants	I-MED
in	O
children	B-MED
.	O
The	O
discovery	B-MED
of	O
potent	B-MED
and	O
selective	B-MED
kynurenine	B-MED
3	I-MED
-	I-MED
monooxygenase	I-MED
inhibitors	B-MED
for	O
the	O
treatment	B-MED
of	O
acute	B-MED
pancreatitis	I-MED
A	O
series	B-MED
of	O
potent	B-MED
,	O
competitive	B-MED
and	O
highly	B-MED
selective	B-MED
kynurenine	B-MED
monooxygenase	I-MED
inhibitors	B-MED
have	O
been	O
discovered	B-MED
via	O
a	O
substrate	B-MED
-based	O
approach	B-MED
for	O
the	O
treatment	B-MED
of	O
acute	B-MED
pancreatitis	I-MED
.	O
The	O
lead	B-MED
compound	B-MED
demonstrated	O
good	B-MED
cellular	B-MED
potency	B-MED
and	O
clear	O
pharmacodynamic	B-MED
activity	B-MED
in	B-MED
vivo	I-MED
.	O
Skin	B-MED
Conductance	I-MED
Responses	B-MED
and	O
Neural	B-MED
Activations	B-MED
During	O
Fear	B-MED
Conditioning	B-MED
and	O
Extinction	B-MED
Recall	B-MED
Across	O
Anxiety	B-MED
Disorders	I-MED
The	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
neurocircuitry	B-MED
has	O
been	O
extensively	B-MED
studied	B-MED
in	O
healthy	B-MED
and	O
clinical	B-MED
populations	B-MED
,	O
with	O
a	O
particular	B-MED
focus	I-MED
on	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
.	O
Despite	O
significant	B-MED
overlap	B-MED
of	O
symptoms	B-MED
between	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
and	O
anxiety	B-MED
disorders	I-MED
,	O
the	O
latter	O
has	O
received	B-MED
less	B-MED
attention	B-MED
.	O
Given	O
that	O
dysregulated	O
fear	B-MED
levels	B-MED
characterize	B-MED
anxiety	B-MED
disorders	I-MED
,	O
examining	B-MED
the	O
neural	B-MED
correlates	B-MED
of	O
fear	B-MED
and	O
extinction	B-MED
learning	B-MED
may	O
shed	O
light	O
on	O
the	O
pathogenesis	B-MED
of	O
underlying	O
anxiety	B-MED
disorders	I-MED
.	O
To	O
investigate	B-MED
the	O
psychophysiological	B-MED
and	O
neural	B-MED
correlates	B-MED
of	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
recall	B-MED
in	O
anxiety	B-MED
disorders	I-MED
and	O
to	O
document	B-MED
how	O
these	O
features	B-MED
differ	O
as	O
a	O
function	B-MED
of	O
multiple	B-MED
diagnoses	B-MED
or	O
anxiety	B-MED
severity	B-MED
.	O
This	O
investigation	B-MED
was	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
,	O
case	B-MED
-	I-MED
control	I-MED
,	O
functional	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
study	B-MED
at	O
an	O
academic	B-MED
medical	I-MED
center	I-MED
.	O
Participants	B-MED
were	O
healthy	B-MED
controls	B-MED
and	O
individuals	B-MED
with	O
at	O
least	O
1	O
of	O
the	O
following	B-MED
anxiety	B-MED
disorders	I-MED
:	O
generalized	B-MED
anxiety	I-MED
disorder	I-MED
,	O
social	B-MED
anxiety	I-MED
disorder	I-MED
,	O
specific	B-MED
phobia	I-MED
,	O
and	O
panic	B-MED
disorder	I-MED
.	O
The	O
study	B-MED
dates	B-MED
were	O
between	O
March	O
2013	O
and	O
May	O
2015	O
.	O
Two	O
-	O
day	O
fear	B-MED
conditioning	B-MED
and	O
extinction	B-MED
paradigm	B-MED
.	O
Skin	B-MED
conductance	I-MED
responses	B-MED
,	O
blood	B-MED
oxygenation	I-MED
level	I-MED
-	I-MED
dependent	I-MED
responses	B-MED
,	O
trait	B-MED
anxiety	B-MED
scores	I-MED
from	O
the	O
State	B-MED
Trait	I-MED
Anxiety	I-MED
Inventory	I-MED
-	O
Trait	B-MED
Form	B-MED
,	O
and	O
functiona	B-MED
l	O
connectivity	B-MED
.	O
This	O
study	B-MED
included	B-MED
21	O
healthy	B-MED
controls	B-MED
(	O
10	O
women	B-MED
)	O
and	O
61	O
individuals	B-MED
with	O
anxiety	B-MED
disorders	I-MED
(	O
36	O
women	B-MED
)	O
.	O
P	B-MED
values	I-MED
reported	B-MED
for	O
the	O
neuroimaging	B-MED
results	B-MED
are	O
all	O
familywise	B-MED
error	B-MED
corrected	B-MED
.	O
Skin	B-MED
conductance	I-MED
responses	B-MED
during	O
extinction	B-MED
recall	B-MED
did	O
not	O
differ	O
between	O
individuals	B-MED
with	O
anxiety	B-MED
disorders	I-MED
and	O
healthy	B-MED
controls	B-MED
(	O
ηp2	B-MED
=	O
0.001	O
,	O
P	O
=	O
.79	O
)	O
,	O
where	O
ηp2	B-MED
is	O
partial	B-MED
eta	I-MED
squared	I-MED
.	O
The	O
anxiety	B-MED
group	B-MED
had	O
lower	B-MED
activation	B-MED
of	O
the	O
ventromedial	B-MED
prefrontal	I-MED
cortex	I-MED
(	O
vmPFC	B-MED
)	O
during	O
extinction	B-MED
recall	B-MED
(	O
ηp2	B-MED
=	O
0.178	O
,	O
P	O
=	O
.02	O
)	O
.	O
A	O
similar	O
hypoactive	B-MED
pattern	B-MED
was	O
found	O
during	O
early	B-MED
conditioning	B-MED
(	O
ηp2	B-MED
=	O
0.106	O
,	O
P	O
=	O
.009	O
)	O
.	O
The	O
vmPFC	B-MED
hypoactivation	B-MED
was	O
associated	B-MED
with	I-MED
anxiety	B-MED
symptom	I-MED
severity	B-MED
(	O
r	O
=	O
-0.420	O
,	O
P	O
=	O
.01	O
for	O
conditioning	B-MED
and	O
r	O
=	O
-0.464	O
,	O
P	O
=	O
.004	O
for	O
extinction	B-MED
recall	B-MED
)	O
and	O
the	O
number	B-MED
of	O
co	B-MED
-	I-MED
occuring	I-MED
anxiety	B-MED
disorders	I-MED
diagnosed	B-MED
(	O
ηp2	B-MED
=	O
0.137	O
,	O
P	O
=	O
.009	O
for	O
conditioning	B-MED
and	O
ηp2	B-MED
=	O
0.227	O
,	O
P	O
=	O
.004	O
for	O
extinction	B-MED
recall	B-MED
)	O
.	O
Psychophysiological	B-MED
interaction	B-MED
analyses	I-MED
revealed	B-MED
that	O
the	O
fear	B-MED
network	B-MED
connectivity	I-MED
differed	O
between	O
healthy	B-MED
controls	B-MED
and	O
the	O
anxiety	B-MED
group	B-MED
during	O
fear	B-MED
learning	B-MED
(	O
ηp2	B-MED
range	B-MED
between	O
0.088	O
and	O
0.176	O
and	O
P	B-MED
range	B-MED
between	O
0.02	O
and	O
0.003	O
)	O
and	O
extinction	B-MED
recall	B-MED
(	O
ηp2	B-MED
range	B-MED
between	O
0.111	O
and	O
0.235	O
and	O
P	B-MED
range	B-MED
between	O
0.02	O
and	O
0.002	O
)	O
.	O
Despite	O
no	O
skin	B-MED
conductance	I-MED
response	B-MED
group	B-MED
differences	B-MED
during	O
extinction	B-MED
recall	B-MED
,	O
brain	B-MED
activation	B-MED
patterns	B-MED
between	O
anxious	B-MED
and	O
healthy	B-MED
individuals	B-MED
differed	O
.	O
These	O
findings	B-MED
encourage	O
future	B-MED
studies	B-MED
to	O
examine	B-MED
the	O
conditions	B-MED
longitudinally	B-MED
and	O
in	O
the	O
context	B-MED
of	O
treatment	B-MED
trials	I-MED
to	O
improve	B-MED
and	O
guide	B-MED
therapeutics	I-MED
via	O
advanced	B-MED
neurobiological	B-MED
understanding	B-MED
of	O
each	O
disorder	B-MED
.	O
Effects	B-MED
of	O
an	O
early	O
intervention	B-MED
using	O
human	B-MED
amniotic	B-MED
epithelial	B-MED
cells	I-MED
in	O
a	O
COPD	B-MED
rat	B-MED
model	B-MED
The	O
study	B-MED
aimed	O
to	O
investigate	B-MED
the	O
effect	B-MED
of	O
an	O
early	O
intervention	B-MED
using	O
human	B-MED
amniotic	B-MED
epithelial	B-MED
cell	I-MED
(	O
hAEC	B-MED
)	O
in	O
a	O
rat	B-MED
model	B-MED
of	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
.	O
Twenty	O
-	O
four	O
specific	B-MED
pathogen	I-MED
-	I-MED
free	I-MED
Wistar	B-MED
rats	I-MED
were	O
randomized	B-MED
to	O
the	O
control	B-MED
,	O
COPD	B-MED
,	O
and	O
COPD	B-MED
+	O
hAEC	B-MED
groups	B-MED
.	O
COPD	B-MED
was	O
established	O
by	O
intratracheal	B-MED
LPS	B-MED
injection	O
combined	O
with	O
smoke	B-MED
fumigation	B-MED
over	O
30	O
days	B-MED
.	O
On	O
the	O
first	O
day	B-MED
of	O
model	B-MED
establishment	O
rats	B-MED
in	O
the	O
AEC	B-MED
group	B-MED
also	O
received	O
intratracheal	B-MED
instillation	I-MED
of	O
500,000	O
hAECs	B-MED
isolated	O
from	O
the	O
placenta	B-MED
of	O
healthy	B-MED
donors	B-MED
.	O
The	O
mean	B-MED
linear	I-MED
intercept	I-MED
(	O
MLI	B-MED
)	O
and	O
mean	B-MED
alveolar	I-MED
number	I-MED
(	O
MAN	B-MED
)	O
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	B-MED
emphysema	I-MED
.	O
IL-8	B-MED
was	O
measured	O
using	O
a	O
radioimmunoassay	B-MED
,	O
surfactant	B-MED
protein	I-MED
D	I-MED
(	O
SP	B-MED
-	I-MED
D	I-MED
)	O
was	O
measured	O
by	O
ELISA	B-MED
,	O
and	O
matrix	B-MED
metalloproteinase	I-MED
(	I-MED
MMP)2	I-MED
and	O
MMP8	B-MED
expression	B-MED
was	O
assessed	O
by	O
PCR	B-MED
.	O
Smoke	B-MED
fumigation	B-MED
combined	O
to	O
LPS	B-MED
injection	O
successfully	O
established	O
a	O
COPD	B-MED
rat	B-MED
model	B-MED
with	O
significant	O
emphysema	B-MED
and	O
airway	B-MED
inflammation	I-MED
,	O
elevated	B-MED
MLI	B-MED
and	O
MAN	B-MED
,	O
elevated	B-MED
systemic	B-MED
and	O
lung	B-MED
tissue	B-MED
levels	B-MED
of	O
IL-8	B-MED
and	O
SP	B-MED
-	I-MED
D	I-MED
(	O
P<0.05	O
)	O
,	O
and	O
high	O
expression	B-MED
of	O
MMP2	B-MED
and	O
MMP8	B-MED
.	O
Rats	B-MED
in	O
the	O
COPD	B-MED
+	O
hAEC	B-MED
group	B-MED
exhibited	O
alleviated	B-MED
lung	B-MED
damage	B-MED
,	O
MLI	B-MED
and	O
MAN	B-MED
(	O
P<0.05	O
)	O
,	O
reduced	B-MED
systemic	B-MED
and	O
lung	B-MED
tissue	B-MED
levels	B-MED
of	O
IL-8	B-MED
and	O
SP	B-MED
-	I-MED
D	I-MED
(	O
P<0.05	O
)	O
and	O
MMP2	B-MED
and	O
MMP8	B-MED
expression	B-MED
(	O
P<0.05	O
)	O
.	O
Early	O
intervention	B-MED
using	O
hAECs	B-MED
could	O
delay	O
disease	B-MED
progression	I-MED
in	O
rats	B-MED
with	O
COPD	B-MED
.	O
Undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
art	B-MED
use	B-MED
in	O
the	O
kenya	B-MED
AIDS	I-MED
indicator	I-MED
survey	I-MED
2012	I-MED
:	O
relevance	B-MED
to	O
targets	B-MED
for	O
HIV	B-MED
diagnosis	I-MED
and	O
treatment	B-MED
in	O
kenya	B-MED
To	O
assess	B-MED
the	O
impact	B-MED
of	O
undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
antiretroviral	B-MED
(	I-MED
ARV	I-MED
)	I-MED
therapy	I-MED
(	O
ART	B-MED
)	O
on	O
national	B-MED
estimates	B-MED
of	O
diagnosed	B-MED
HIV	I-MED
and	O
ART	B-MED
coverage	B-MED
in	O
Kenya	B-MED
.	O
HIV	B-MED
-	I-MED
positive	I-MED
dried	B-MED
blood	I-MED
spot	I-MED
samples	I-MED
from	O
Kenya	B-MED
's	I-MED
second	I-MED
AIDS	I-MED
Indicator	I-MED
Survey	I-MED
were	O
tested	B-MED
for	O
an	O
ARV	B-MED
biomarker	B-MED
by	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
.	O
Estimates	B-MED
of	O
diagnosed	B-MED
HIV	I-MED
and	O
ART	B-MED
use	B-MED
based	O
on	O
self	B-MED
-	I-MED
report	I-MED
were	O
compared	B-MED
with	O
those	O
corrected	O
for	O
undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
ART	B-MED
use	B-MED
based	O
on	O
ARV	B-MED
testing	O
.	O
Multivariate	B-MED
analysis	I-MED
determined	B-MED
factors	B-MED
associated	B-MED
with	I-MED
undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
ART	B-MED
use	B-MED
among	O
persons	B-MED
on	O
ART	B-MED
.	O
Among	O
559	O
HIV	B-MED
-	I-MED
positive	I-MED
samples	B-MED
,	O
the	O
ARV	B-MED
biomarker	B-MED
was	O
detected	B-MED
in	O
42.5	O
%	O
(	O
CI	O
37.4	O
-	O
47.7	O
)	O
.	O
ARV	B-MED
drugs	I-MED
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	B-MED
HIV	I-MED
-	I-MED
positive	I-MED
status	O
and	O
receiving	B-MED
ART	B-MED
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	B-MED
HIV	I-MED
-	I-MED
positive	I-MED
status	O
irrespective	O
of	O
ART	B-MED
use	B-MED
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-	O
28.6	O
)	O
reporting	B-MED
HIV	B-MED
-	I-MED
negative	I-MED
status	I-MED
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	B-MED
no	B-MED
previous	B-MED
HIV	B-MED
test	I-MED
.	O
After	O
correcting	O
for	O
undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
ART	B-MED
use	B-MED
,	O
diagnosed	B-MED
HIV	I-MED
increased	B-MED
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	B-MED
coverage	B-MED
increased	B-MED
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O
Undisclosed	B-MED
HIV	B-MED
infection	I-MED
on	O
ART	B-MED
was	O
associated	B-MED
with	I-MED
being	O
aged	B-MED
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	B-MED
provider	I-MED
in	O
the	O
past	O
year	O
,	O
while	O
younger	B-MED
age	I-MED
and	O
higher	B-MED
wealth	I-MED
was	O
associated	B-MED
with	I-MED
undisclosed	B-MED
ART	B-MED
use	B-MED
.	O
Substantial	B-MED
levels	B-MED
of	O
undisclosed	B-MED
HIV	B-MED
infection	I-MED
and	O
ART	B-MED
use	B-MED
while	O
on	O
ART	B-MED
were	O
observed	B-MED
,	O
resulting	B-MED
in	I-MED
diagnosed	B-MED
HIV	I-MED
underestimated	O
by	O
112,000	O
persons	B-MED
and	O
ART	B-MED
coverage	B-MED
by	O
131,000	O
persons	B-MED
.	O
Supplementing	O
self	B-MED
-	I-MED
reported	I-MED
ART	B-MED
status	B-MED
with	O
objective	B-MED
measures	I-MED
of	O
ART	B-MED
use	B-MED
in	O
national	B-MED
population	B-MED
-based	O
sero	B-MED
-	I-MED
surveys	I-MED
can	O
improve	B-MED
monitoring	B-MED
of	O
treatment	B-MED
targets	B-MED
in	O
countries	B-MED
.	O
The	O
association	B-MED
between	O
maternal	B-MED
hydronephrosis	B-MED
and	O
acute	B-MED
flank	B-MED
pain	I-MED
during	O
pregnancy	B-MED
:	O
a	O
prospective	B-MED
pilot	B-MED
-	I-MED
study	I-MED
Maternal	B-MED
hydronephrosis	B-MED
may	O
cause	O
flank	B-MED
pain	I-MED
during	O
pregnancy	B-MED
.	O
We	O
aimed	B-MED
to	O
investigate	B-MED
the	O
association	O
between	O
maternal	B-MED
hydronephrosis	B-MED
and	O
flank	B-MED
pain	I-MED
intensity	B-MED
.	O
From	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	B-MED
women	B-MED
with	O
singleton	B-MED
pregnancies	I-MED
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	B-MED
flank	B-MED
pain	I-MED
,	O
were	O
prospectively	B-MED
evaluated	B-MED
by	O
renal	B-MED
ultrasonography	B-MED
and	O
pain	B-MED
questionnaires	B-MED
.	O
A	O
visual	B-MED
analogue	I-MED
scale	I-MED
was	O
used	O
to	O
assess	O
pain	B-MED
intensity	I-MED
.	O
The	O
study	B-MED
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
significant	B-MED
correlation	B-MED
between	O
hydronephrosis	B-MED
and	O
flank	B-MED
pain	I-MED
(	O
Spearman	B-MED
's	I-MED
test	I-MED
)	O
.	O
A	O
total	O
of	O
51	O
consecutive	B-MED
women	B-MED
with	O
left	B-MED
-	I-MED
sided	I-MED
(	O
13.7	O
%	O
)	O
,	O
right	B-MED
-	I-MED
sided	I-MED
(	O
64.7	O
%	O
)	O
or	O
bilateral	B-MED
(	O
21.6	O
%	O
)	O
pain	B-MED
were	O
enrolled	O
.	O
The	O
mean	B-MED
gestational	B-MED
age	I-MED
of	O
these	O
women	B-MED
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-MED
,	O
was	O
27.5	O
±	O
6.8	O
weeks	B-MED
at	O
the	O
time	O
of	O
consultation	B-MED
.	O
The	O
mean	B-MED
VAS	B-MED
score	I-MED
was	O
7.6	O
±	O
2.2	O
.	O
In	O
43/51	O
(	O
84.3	O
%	O
)	O
women	B-MED
,	O
hydronephrosis	B-MED
was	O
found	O
on	O
renal	B-MED
sonograms	O
.	O
No	O
correlation	B-MED
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-MED
and	O
pain	B-MED
intensity	I-MED
(	O
p	O
=	O
0.466	O
;	O
r=	O
-0.28	O
)	O
.	O
Women	B-MED
delivered	O
at	O
a	O
mean	B-MED
gestational	B-MED
age	I-MED
of	O
38.1	O
±	O
2.4	O
weeks	B-MED
and	O
their	O
infants	B-MED
had	O
a	O
mean	B-MED
birthweight	B-MED
of	O
3138	O
±	O
677	O
g.	O
Hydronephrosis	B-MED
is	O
a	O
common	O
finding	B-MED
among	O
pregnant	B-MED
women	I-MED
with	O
acute	B-MED
flank	B-MED
pain	I-MED
.	O
The	O
grade	O
of	O
hydronephrosis	B-MED
does	O
not	O
affect	O
pain	B-MED
intensity	I-MED
.	O
This	O
study	B-MED
suggests	O
normal	B-MED
pregnancy	I-MED
outcomes	B-MED
in	O
these	O
women	B-MED
.	O
Electrocardiographic	B-MED
appearance	I-MED
of	O
aortic	B-MED
stenosis	I-MED
before	O
and	O
after	O
aortic	B-MED
valve	I-MED
replacement	I-MED
So	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
QRS	B-MED
complex	I-MED
,	O
ST	B-MED
-	I-MED
segment	I-MED
,	O
and	O
T	B-MED
wave	I-MED
was	O
observed	B-MED
in	O
aortic	B-MED
stenosis	I-MED
(	O
AS	B-MED
)	O
.	O
S	B-MED
-	I-MED
wave	I-MED
dynamic	B-MED
change	B-MED
in	O
leads	B-MED
V1	I-MED
-	O
V3	B-MED
was	O
not	O
reported	O
in	O
AS	B-MED
.	O
In	O
a	O
single	O
-	O
center	O
,	O
prospective	B-MED
study	I-MED
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	B-MED
who	O
underwent	O
surgical	B-MED
aortic	B-MED
valve	I-MED
replacement	I-MED
(	O
AVR	B-MED
)	O
.	O
We	O
conducted	O
3	O
-	O
year	O
gathering	O
of	O
patients	B-MED
with	O
symptomatic	B-MED
and	O
asymptomatic	B-MED
severe	O
AS	B-MED
,	O
and	O
separated	O
them	O
by	O
hemodynamic	B-MED
stability	I-MED
into	O
groups	O
A	O
and	O
B	O
,	O
through	O
EFLV	B-MED
(	O
of	O
more	O
or	O
less	O
than	O
50	O
%	O
)	O
,	O
AVA	B-MED
(	O
of	O
more	O
or	O
less	O
than	O
0.9	O
cm(2	O
)	O
)	O
,	O
PG	B-MED
(	O
between	O
55	O
and	O
75	O
mm	B-MED
Hg	I-MED
or	O
over	O
75	O
mm	B-MED
Hg	I-MED
)	O
,	O
and	O
end	B-MED
-	I-MED
diastolic	I-MED
LV	I-MED
dimension	I-MED
(	O
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
)	O
.	O
We	O
evaluated	B-MED
the	O
impact	B-MED
of	O
S	B-MED
-	I-MED
wave	I-MED
magnitude	B-MED
in	O
right	B-MED
precordial	I-MED
leads	O
before	O
and	O
after	O
AVR	B-MED
in	O
all	O
patients	B-MED
.	O
We	O
followed	O
S	B-MED
-	I-MED
wave	I-MED
changes	B-MED
in	O
electrocardiogram	B-MED
altogether	O
with	O
hemodynamic	B-MED
measurements	I-MED
derived	O
from	O
echocardiography	B-MED
.	O
Analysis	B-MED
of	O
echocardiographic	B-MED
parameters	B-MED
,	O
measured	B-MED
in	O
patients	B-MED
before	O
surgery	B-MED
,	O
did	O
not	O
show	O
statistical	B-MED
significance	I-MED
between	O
asymptomatic	B-MED
and	O
symptomatic	B-MED
group	O
.	O
The	O
statistical	B-MED
significance	I-MED
was	O
observed	B-MED
in	O
the	O
change	B-MED
in	O
S	B-MED
-	I-MED
wave	I-MED
magnitude	B-MED
in	O
the	O
right	B-MED
precordial	I-MED
leads	O
in	O
both	O
subsets	O
of	O
patients	B-MED
before	O
AVR	B-MED
.	O
We	O
found	O
statistically	B-MED
significant	I-MED
predictive	B-MED
value	I-MED
of	O
S	B-MED
-	I-MED
wave	I-MED
magnitude	B-MED
in	O
leads	B-MED
V2	I-MED
-	O
V3	B-MED
for	O
dependent	B-MED
variables	I-MED
PG	B-MED
and	O
end	B-MED
-	I-MED
diastolic	I-MED
LV	I-MED
dimension	I-MED
.	O
S	B-MED
-	I-MED
wave	I-MED
changes	O
in	O
right	B-MED
precordial	I-MED
leads	O
can	O
predict	O
increase	B-MED
in	O
PG	B-MED
and	O
critical	O
narrowing	O
of	O
AVA	B-MED
,	O
suggestive	B-MED
of	I-MED
timely	O
referral	B-MED
for	I-MED
AVR	B-MED
.	O
Digital	B-MED
Myopericytoma	B-MED
:	O
A	O
Case	B-MED
Report	I-MED
and	O
Systematic	B-MED
Literature	I-MED
Review	I-MED
A	O
myopericytoma	B-MED
(	O
MP	B-MED
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular	B-MED
tumor	I-MED
of	O
unknown	B-MED
etiology	I-MED
.	O
Given	O
their	O
potential	B-MED
for	O
mimicry	B-MED
and	O
malignancy	B-MED
,	O
MP	B-MED
tumors	I-MED
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	B-MED
and	O
may	O
be	O
overlooked	O
on	O
differential	B-MED
diagnosis	I-MED
.	O
We	O
present	O
a	O
case	B-MED
report	I-MED
of	O
an	O
otherwise	O
healthy	B-MED
33	O
-	O
year	O
-	O
old	O
right	B-MED
-	I-MED
hand	I-MED
dominant	I-MED
male	B-MED
who	O
presented	O
to	O
our	O
outpatient	B-MED
clinic	I-MED
with	O
a	O
2	O
-	O
month	O
history	O
of	O
painless	B-MED
swelling	B-MED
and	O
erythema	B-MED
of	I-MED
the	I-MED
pulp	I-MED
of	I-MED
his	I-MED
left	I-MED
index	I-MED
finger	I-MED
.	O
Subsequent	O
plain	B-MED
film	I-MED
X	I-MED
-	I-MED
ray	I-MED
showed	O
near	B-MED
-	I-MED
complete	I-MED
bony	B-MED
destruction	I-MED
of	O
his	O
distal	B-MED
phalanx	I-MED
.	O
Pathological	B-MED
evaluation	B-MED
of	O
an	O
incisional	B-MED
biopsy	I-MED
showed	O
a	O
benign	B-MED
variant	I-MED
of	O
MP	B-MED
.	O
The	O
lesion	B-MED
was	O
treated	O
by	O
excision	B-MED
with	O
tumor	B-MED
shelling	B-MED
,	O
and	O
there	O
was	O
no	B-MED
evidence	I-MED
of	I-MED
recurrence	B-MED
81	O
days	O
postoperatively	B-MED
.	O
A	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-MED
and	O
outcome	B-MED
of	O
all	O
known	O
cases	B-MED
of	O
hand	B-MED
and	I-MED
wrist	I-MED
MP	B-MED
is	O
presented	O
.	O
Unintentional	B-MED
Injuries	I-MED
in	O
Children	B-MED
Up	O
to	O
Six	O
Years	B-MED
of	O
Age	B-MED
and	O
Related	O
Parental	B-MED
Knowledge	B-MED
,	O
Attitudes	B-MED
,	O
and	O
Behaviors	B-MED
in	O
Italy	B-MED
To	O
describe	O
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
unintentional	B-MED
injuries	I-MED
among	O
children	B-MED
aged	O
<	O
6	O
years	B-MED
and	O
to	O
examine	O
parents	B-MED
'	O
level	O
of	O
knowledge	B-MED
,	O
attitudes	B-MED
,	O
and	O
behaviors	B-MED
about	O
pediatric	B-MED
injuries	B-MED
and	O
related	O
preventive	B-MED
measures	I-MED
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
survey	I-MED
was	O
conducted	O
between	O
May	B-MED
and	O
July	B-MED
2015	O
on	O
a	O
random	B-MED
sample	I-MED
of	O
794	O
parents	B-MED
of	O
3-	O
to	O
6	O
-	O
year	O
-	O
old	O
children	B-MED
through	O
a	O
self	B-MED
-	I-MED
administered	I-MED
anonymous	B-MED
questionnaire	I-MED
.	O
A	O
total	O
of	O
409	O
parents	B-MED
participated	O
.	O
Two	O
-	O
thirds	O
of	O
the	O
children	B-MED
had	O
experienced	O
at	O
least	O
1	O
unintentional	B-MED
injury	I-MED
in	O
the	O
previous	O
12	O
months	B-MED
.	O
More	O
than	O
one	O
-	O
half	O
of	O
these	O
children	B-MED
were	O
boys	B-MED
.	O
The	O
leading	B-MED
cause	I-MED
was	O
falls	B-MED
;	O
the	O
injuries	B-MED
occurred	O
mainly	O
at	O
home	B-MED
,	O
and	O
only	O
9.2	O
%	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	B-MED
department	I-MED
.	O
Parents	B-MED
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	B-MED
injuries	I-MED
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	B-MED
injured	B-MED
.	O
Approximately	O
70	O
%	O
of	O
respondents	B-MED
were	O
aware	B-MED
of	O
security	B-MED
measures	I-MED
to	O
prevent	O
pediatric	B-MED
injuries	B-MED
,	O
and	O
this	O
knowledge	B-MED
was	O
more	O
prevalent	O
in	O
older	O
parents	B-MED
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	B-MED
level	I-MED
of	I-MED
education	I-MED
compared	O
with	O
those	O
with	O
a	O
middle	B-MED
school	I-MED
education	I-MED
.	O
The	O
perceived	B-MED
utility	O
of	O
education	B-MED
about	O
preventive	B-MED
measures	I-MED
of	O
pediatric	B-MED
injuries	B-MED
had	O
a	O
mean	B-MED
value	I-MED
of	O
8.9	O
on	O
a	O
Likert	B-MED
scale	I-MED
of	O
1	O
-	O
10	O
(	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	B-MED
.	O
This	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-MED
health	I-MED
educational	B-MED
programs	I-MED
for	O
parents	B-MED
regarding	O
prevention	B-MED
of	O
unintentional	B-MED
injuries	I-MED
in	O
children	B-MED
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	B-MED
and	O
injury	B-MED
prevention	I-MED
and	O
to	O
reduce	B-MED
risks	B-MED
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-MED
occur	O
at	O
home	B-MED
.	O
Correlation	B-MED
of	O
the	O
Lipid	B-MED
Profile	B-MED
,	O
BMI	B-MED
and	O
Bone	B-MED
Mineral	I-MED
Density	I-MED
in	O
Postmenopausal	B-MED
Women	B-MED
To	O
the	O
reduction	B-MED
of	O
bone	B-MED
density	I-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
contribute	O
elevated	B-MED
lipid	B-MED
parameters	B-MED
and	O
Body	B-MED
Mass	I-MED
Index	I-MED
(	O
BMI	B-MED
)	O
.	O
The	O
goal	O
of	O
our	O
study	B-MED
was	O
to	O
determine	O
the	O
correlation	B-MED
between	O
lipid	B-MED
parameters	B-MED
,	O
BMI	B-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
.	O
The	O
study	B-MED
was	O
carried	O
out	O
by	O
matched	B-MED
type	B-MED
between	O
experimental	B-MED
group	B-MED
and	O
controls	B-MED
.	O
The	O
experimental	B-MED
group	B-MED
consisted	O
of	O
100	O
females	B-MED
at	O
postmenopausal	B-MED
age	B-MED
,	O
in	O
which	O
by	O
the	O
DEXA	B-MED
method	I-MED
was	O
diagnosed	B-MED
osteoporosis	B-MED
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	B-MED
Medical	I-MED
Center	I-MED
of	I-MED
RS	I-MED
during	O
2015	O
-	O
2016	O
,	O
while	O
the	O
control	B-MED
group	I-MED
consisted	O
of	O
100	O
females	B-MED
in	O
a	O
postmenopausal	B-MED
age	B-MED
but	O
without	O
diagnosed	B-MED
osteoporosis	B-MED
.	O
The	O
groups	B-MED
were	O
matched	B-MED
by	O
age	B-MED
(	O
±	O
2	O
years	B-MED
)	O
.	O
To	O
all	O
participants	B-MED
of	O
the	O
study	B-MED
were	O
carried	O
out	O
biochemical	B-MED
analysis	I-MED
of	I-MED
blood	I-MED
,	O
or	O
the	O
analysis	B-MED
of	O
the	O
lipid	B-MED
profile	B-MED
that	O
included	O
total	B-MED
cholesterol	I-MED
,	O
LDL	B-MED
cholesterol	I-MED
,	O
triglycerides	B-MED
(	O
TG	B-MED
)	O
and	O
HDL	B-MED
cholesterol	I-MED
,	O
and	O
was	O
determined	O
the	O
values	B-MED
of	O
BMI	B-MED
and	O
waist	B-MED
circumference	I-MED
(	O
WC	B-MED
)	O
.	O
Analysis	B-MED
of	O
the	O
data	B-MED
of	O
our	O
research	B-MED
shows	O
that	O
by	O
the	O
univariate	B-MED
logistic	I-MED
regression	I-MED
the	O
values	B-MED
of	O
lipid	B-MED
parameters	B-MED
total	B-MED
cholesterol	I-MED
(	O
p=0.000	O
)	O
,	O
LDL	B-MED
(	O
p=0.005	O
)	O
and	O
TG	B-MED
(	O
p=0.033	O
)	O
were	O
significantly	B-MED
associated	B-MED
with	I-MED
osteoporosis	B-MED
,	O
while	O
in	O
multivariate	B-MED
logistic	I-MED
model	I-MED
only	O
total	B-MED
cholesterol	I-MED
(	O
p=	O
0.018	O
)	O
was	O
found	O
as	O
an	O
independent	B-MED
risk	B-MED
factor	I-MED
for	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
.	O
BMI	B-MED
values	B-MED
were	O
not	B-MED
statistically	B-MED
significantly	I-MED
associated	B-MED
with	I-MED
osteoporosis	B-MED
(	O
p=0.727	O
)	O
.	O
On	O
the	O
decrease	B-MED
in	O
bone	B-MED
mineral	I-MED
density	I-MED
and	O
osteoporosis	B-MED
in	O
postmenopausal	B-MED
women	B-MED
influence	O
many	O
risk	B-MED
factors	I-MED
whose	O
identification	B-MED
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	B-MED
prevention	B-MED
of	O
this	O
disease	B-MED
in	O
the	O
elderly	B-MED
.	O
Family	B-MED
and	O
healthcare	B-MED
professionals	I-MED
'	O
perceptions	B-MED
of	O
a	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
for	O
children	B-MED
:	O
a	O
qualitative	O
study	B-MED
Parents	B-MED
commonly	O
report	O
a	O
significant	O
improvement	B-MED
in	O
quality	B-MED
of	I-MED
life	I-MED
following	O
the	O
provision	B-MED
of	O
hospice	B-MED
and	O
supportive	B-MED
care	I-MED
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-MED
in	O
the	O
home	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	B-MED
receiving	O
a	O
nurse	B-MED
led	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
and	O
the	O
experiences	B-MED
of	O
healthcare	B-MED
professionals	I-MED
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-MED
.	O
An	O
exploratory	O
,	O
qualitative	O
study	B-MED
was	O
conducted	O
,	O
including	O
telephone	B-MED
interviews	I-MED
with	O
parents	B-MED
and	O
focus	B-MED
groups	I-MED
and	O
individual	B-MED
interviews	B-MED
with	O
healthcare	B-MED
professionals	I-MED
.	O
All	O
parents	B-MED
of	O
families	B-MED
who	O
received	O
the	O
programme	B-MED
of	O
care	B-MED
between	O
June	O
2014	O
and	O
September	O
2015	O
and	O
healthcare	B-MED
professionals	I-MED
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-MED
were	O
invited	O
to	O
participate	O
.	O
Seven	O
parents	B-MED
participated	O
in	O
telephone	B-MED
interviews	I-MED
.	O
Four	O
focus	B-MED
groups	I-MED
took	O
place	O
,	O
two	O
with	O
external	B-MED
stakeholders	I-MED
(	O
18	O
participants	B-MED
in	O
total	O
)	O
,	O
one	O
with	O
in	B-MED
-	I-MED
patient	I-MED
hospice	B-MED
staff	I-MED
(	O
13	O
participants	B-MED
)	O
and	O
one	O
with	O
the	O
hospice	B-MED
at	O
home	O
team	O
(	O
8	O
participants	B-MED
)	O
.	O
Two	O
additional	O
interviews	B-MED
took	O
place	O
with	O
individual	B-MED
stakeholders	B-MED
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus	B-MED
group	I-MED
.	O
Themes	O
from	O
interviews	B-MED
with	O
parents	B-MED
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-MED
.	O
The	O
findings	O
from	O
healthcare	B-MED
professionals	I-MED
centred	O
on	O
communication	B-MED
within	O
and	O
across	O
services	B-MED
,	O
education	B-MED
and	I-MED
training	I-MED
and	O
lone	B-MED
working	I-MED
.	O
The	O
pilot	O
hospice	B-MED
at	O
home	B-MED
programme	B-MED
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	B-MED
.	O
The	O
programme	B-MED
may	O
be	O
improved	O
by	O
enhanced	O
clarification	B-MED
of	O
roles	O
,	O
enhanced	O
access	O
to	O
multi	O
-	O
disciplinary	O
services	B-MED
,	O
greater	O
communication	B-MED
across	O
services	B-MED
and	O
improved	O
information	O
provision	O
to	O
families	B-MED
.	O
A	O
comparison	O
of	O
functional	B-MED
outcomes	O
in	O
patients	B-MED
undergoing	O
revision	B-MED
arthroscopic	I-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
with	O
and	O
without	B-MED
arthroscopic	B-MED
suprascapular	B-MED
nerve	I-MED
release	I-MED
This	O
study	O
was	O
designed	O
to	O
compare	O
functional	B-MED
outcomes	O
in	O
patients	B-MED
undergoing	O
revision	B-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
(	O
retracted	B-MED
medial	I-MED
to	O
the	O
glenoid	B-MED
)	O
with	O
Goutallier	B-MED
Grade	I-MED
4	I-MED
atrophy	I-MED
and	O
concomitant	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
to	O
a	O
similar	O
group	O
of	O
patients	B-MED
with	O
Grade	B-MED
3	I-MED
atrophy	I-MED
undergoing	O
revision	B-MED
rotator	I-MED
cuff	I-MED
repair	I-MED
(	O
RTCR	B-MED
)	O
without	O
nerve	B-MED
release	I-MED
.	O
We	O
hypothesized	O
that	O
patients	B-MED
undergoing	O
nerve	B-MED
release	I-MED
would	O
have	O
more	O
favorable	O
functional	B-MED
outcomes	O
as	O
measured	O
by	O
the	O
Modified	O
University	B-MED
of	I-MED
California	I-MED
at	O
Los	B-MED
Angeles	I-MED
shoulder	B-MED
rating	I-MED
scale	I-MED
(	O
UCLA	B-MED
)	O
.	O
Twenty	O
-	O
two	O
patients	B-MED
underwent	O
revision	B-MED
repair	I-MED
of	O
massive	O
rotator	B-MED
cuff	I-MED
tears	I-MED
with	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
at	O
the	O
suprascapular	B-MED
notch	I-MED
.	O
We	O
compared	O
total	O
preoperative	B-MED
,	O
postoperative	B-MED
,	O
and	O
change	O
in	O
UCLA	B-MED
score	I-MED
in	O
these	O
patients	B-MED
to	O
a	O
similar	O
group	B-MED
of	O
22	O
patients	B-MED
undergoing	O
revision	B-MED
RTCR	I-MED
without	B-MED
suprascapular	B-MED
nerve	I-MED
release	I-MED
.	O
Additionally	O
,	O
UCLA	O
subscores	O
between	O
the	O
two	O
groups	B-MED
were	O
compared	O
preoperatively	B-MED
and	O
at	O
final	O
follow	B-MED
-	I-MED
up	I-MED
.	O
The	O
average	O
preoperative	B-MED
UCLA	B-MED
score	I-MED
in	O
the	O
nerve	B-MED
-	I-MED
release	I-MED
group	I-MED
was	O
7.91	O
,	O
and	O
final	O
follow	B-MED
-	I-MED
up	I-MED
average	O
was	O
27.86	O
;	O
average	O
3.05	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
In	O
the	O
comparison	O
group	B-MED
,	O
average	O
preoperative	B-MED
UCLA	B-MED
score	I-MED
was	O
11.77	O
,	O
and	O
final	O
follow	B-MED
-	I-MED
up	I-MED
average	O
was	O
29.09	O
;	O
average	O
1.32	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
The	O
average	O
preoperative	B-MED
UCLA	B-MED
score	I-MED
was	O
significantly	O
worse	O
in	O
the	O
nerve	B-MED
-	I-MED
release	I-MED
group	I-MED
(	O
P=0.007	O
)	O
.	O
The	O
average	O
postoperative	B-MED
UCLA	B-MED
score	I-MED
was	O
not	O
significantly	O
different	O
(	O
P=0.590	O
)	O
between	O
the	O
groups	B-MED
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve	B-MED
-	I-MED
release	I-MED
group	I-MED
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	B-MED
,	O
strength	B-MED
,	O
and	O
pain	B-MED
relief	I-MED
.	O
Patients	B-MED
who	O
underwent	O
concomitant	O
release	B-MED
of	I-MED
the	I-MED
suprascapular	I-MED
nerve	I-MED
during	O
revision	B-MED
RTCR	I-MED
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain	B-MED
relief	I-MED
,	O
active	B-MED
forward	I-MED
flexion	I-MED
,	O
and	O
strength	B-MED
,	O
than	O
a	O
comparable	O
group	B-MED
without	B-MED
nerve	B-MED
release	I-MED
.	O
Low	B-MED
birth	I-MED
weight	I-MED
and	O
features	B-MED
of	O
neuroticism	B-MED
and	O
mood	B-MED
disorder	I-MED
in	O
83	O
545	O
participants	B-MED
of	O
the	O
UK	B-MED
Biobank	B-MED
cohort	B-MED
Low	B-MED
birth	I-MED
weight	I-MED
has	O
been	O
inconsistently	O
associated	O
with	O
risk	B-MED
of	O
developing	O
affective	B-MED
disorders	I-MED
,	O
including	O
major	B-MED
depressive	I-MED
disorder	I-MED
(	O
MDD	B-MED
)	O
.	O
To	O
date	O
,	O
studies	B-MED
investigating	B-MED
possible	O
associations	B-MED
between	O
birth	B-MED
weight	I-MED
and	O
bipolar	B-MED
disorder	I-MED
(	O
BD	B-MED
)	O
,	O
or	O
personality	B-MED
traits	I-MED
known	O
to	O
predispose	B-MED
to	O
affective	B-MED
disorders	I-MED
such	O
as	O
neuroticism	B-MED
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	B-MED
.	O
To	O
assess	B-MED
whether	O
very	B-MED
low	I-MED
birth	I-MED
weight	I-MED
(	O
<	O
1500	O
g	O
)	O
and	O
low	B-MED
birth	I-MED
weight	I-MED
(	O
1500	O
-	O
2490	O
g	O
)	O
were	O
associated	B-MED
with	I-MED
higher	B-MED
neuroticism	I-MED
scores	B-MED
assessed	B-MED
in	O
middle	B-MED
age	I-MED
,	O
and	O
lifetime	B-MED
history	I-MED
of	O
either	O
MDD	B-MED
or	O
BD	B-MED
.	O
We	O
controlled	O
for	O
possible	O
confounding	B-MED
factors	I-MED
.	O
Retrospective	B-MED
cohort	B-MED
study	I-MED
using	O
baseline	B-MED
data	B-MED
on	O
the	O
83	O
545	O
UK	B-MED
Biobank	B-MED
participants	B-MED
with	O
detailed	O
mental	B-MED
health	I-MED
and	O
birth	B-MED
weight	I-MED
data	B-MED
.	O
Main	O
outcomes	B-MED
were	O
prevalent	O
MDD	B-MED
and	O
BD	B-MED
,	O
and	O
neuroticism	B-MED
assessed	B-MED
using	O
the	O
Eysenck	B-MED
Personality	I-MED
Inventory	I-MED
Neuroticism	I-MED
scale	I-MED
-	I-MED
Revised	I-MED
(	O
EPIN	B-MED
-	I-MED
R	I-MED
)	O
.	O
Referent	O
to	O
normal	B-MED
birth	I-MED
weight	I-MED
,	O
very	B-MED
low	I-MED
/	O
low	B-MED
birth	I-MED
weight	I-MED
were	O
associated	O
with	O
higher	B-MED
neuroticism	I-MED
scores	B-MED
,	O
increased	B-MED
MDD	B-MED
and	O
BD	B-MED
.	O
The	O
associations	B-MED
between	O
birth	B-MED
weight	I-MED
category	B-MED
and	O
MDD	B-MED
were	O
partially	O
mediated	O
by	O
higher	B-MED
neuroticism	I-MED
.	O
These	O
findings	B-MED
suggest	O
that	O
intrauterine	B-MED
programming	B-MED
may	O
play	O
a	O
role	B-MED
in	O
lifetime	B-MED
vulnerability	B-MED
to	O
affective	B-MED
disorders	I-MED
.	O
None	O
.	O
©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2016	O
.	O
This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non	O
-	O
Commercial	O
,	O
No	O
Derivatives	O
(	O
CC	O
BY	O
-	O
NC	O
-	O
ND	O
)	O
licence	O
.	O
Dynamic	B-MED
disorder	B-MED
can	O
explain	O
non	B-MED
-	I-MED
exponential	I-MED
kinetics	B-MED
of	O
fast	O
protein	B-MED
mechanical	I-MED
unfolding	I-MED
Protein	B-MED
unfolding	I-MED
often	O
does	O
not	O
obey	O
a	O
simple	O
two	O
-	O
state	O
behavior	O
.	O
Previous	O
single	B-MED
molecule	I-MED
force	I-MED
spectroscopy	I-MED
studies	B-MED
demonstrated	O
stretched	B-MED
exponential	I-MED
kinetics	B-MED
of	O
protein	B-MED
unfolding	I-MED
under	O
a	O
constant	B-MED
pulling	I-MED
force	I-MED
,	O
the	O
molecular	B-MED
origin	B-MED
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O
We	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	B-MED
unfolding	I-MED
of	O
ubiquitin	B-MED
and	O
NuG2	B-MED
by	O
Molecular	B-MED
Dynamics	I-MED
(	I-MED
MD	I-MED
)	I-MED
simulations	I-MED
.	O
Both	O
proteins	B-MED
show	O
kinetics	B-MED
best	O
fit	O
by	O
stretched	B-MED
exponentials	I-MED
,	O
with	O
stretching	B-MED
exponents	I-MED
similar	O
to	O
those	O
found	O
in	O
experiments	B-MED
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	B-MED
in	O
our	O
short	O
MD	B-MED
simulations	I-MED
.	O
Instead	O
,	O
we	O
can	O
ascribe	O
non	B-MED
-	I-MED
exponential	I-MED
kinetics	B-MED
to	O
dynamic	B-MED
disorder	B-MED
,	O
due	O
to	O
conformational	B-MED
fluctuations	B-MED
on	O
the	O
nanosecond	B-MED
timescale	I-MED
.	O
Our	O
study	B-MED
highlights	O
the	O
general	O
role	O
of	O
dynamic	B-MED
disorder	B-MED
in	O
protein	B-MED
kinetics	I-MED
on	O
a	O
broad	O
range	O
of	O
time	B-MED
scales	I-MED
even	O
including	O
those	O
probed	O
in	O
MD	B-MED
simulations	I-MED
.	O
Functional	B-MED
1,3a,6a	B-MED
-	I-MED
triazapentalene	I-MED
scaffold	B-MED
:	O
Design	B-MED
of	O
fluorescent	B-MED
probes	I-MED
for	O
kinesin	B-MED
spindle	I-MED
protein	I-MED
(	O
KSP	B-MED
)	O
1,3a,6a	B-MED
-	I-MED
Triazapentalene	I-MED
is	O
a	O
compact	O
fluorescent	B-MED
chromophore	B-MED
.	O
In	O
this	O
study	B-MED
,	O
triazapentalene	B-MED
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl	B-MED
-	I-MED
type	I-MED
inhibitors	B-MED
of	O
kinesin	B-MED
spindle	I-MED
protein	I-MED
(	O
KSP	B-MED
)	O
to	O
develop	O
fluorescent	B-MED
probes	I-MED
for	O
the	O
intracellular	B-MED
visualization	B-MED
of	O
this	O
protein	B-MED
.	O
Microscopic	B-MED
studies	B-MED
demonstrated	O
that	O
these	O
novel	B-MED
triazapentalene	B-MED
-	O
labeled	B-MED
compounds	B-MED
exhibited	O
inhibitory	B-MED
activity	B-MED
towards	O
KSP	B-MED
in	O
cultured	B-MED
cells	I-MED
and	O
provided	O
important	O
information	B-MED
concerning	O
the	O
intracellular	B-MED
distribution	B-MED
.	O
Laparoscopic	B-MED
radical	B-MED
lymph	I-MED
node	I-MED
dissection	I-MED
for	O
advanced	B-MED
colon	I-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
Complete	B-MED
mesocolic	I-MED
excision	I-MED
is	O
currently	O
recognized	O
as	O
a	O
standard	B-MED
procedure	I-MED
for	O
colon	B-MED
cancer	I-MED
.	O
Gastroepiploic	B-MED
,	O
infrapyloric	B-MED
,	O
and	O
superficial	B-MED
pancreatic	I-MED
head	I-MED
lymph	I-MED
node	I-MED
metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
have	O
been	O
reported	O
for	O
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
We	O
sought	O
to	O
investigate	O
metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
in	O
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
This	O
was	O
a	O
single	B-MED
-	I-MED
center	I-MED
retrospective	I-MED
study	I-MED
.	O
All	O
patients	B-MED
with	O
T2	B-MED
or	O
deeper	O
invasive	B-MED
colon	B-MED
cancer	I-MED
in	O
the	O
relevant	O
tumor	B-MED
location	I-MED
who	O
underwent	O
laparoscopic	B-MED
right	I-MED
hemicolectomy	I-MED
or	O
extended	B-MED
right	I-MED
hemicolectomy	I-MED
at	O
our	O
institution	B-MED
between	O
1	O
April	B-MED
2011	O
and	O
31	O
March	B-MED
2015	O
were	O
included	O
.	O
Lymph	B-MED
node	I-MED
dissection	I-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
was	O
performed	O
in	O
35	O
cases	O
.	O
Complications	B-MED
occurred	O
in	O
11	O
patients	B-MED
(	O
31	O
%	O
)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien	B-MED
-	I-MED
Dindo	I-MED
classification	I-MED
.	O
Lymph	B-MED
node	I-MED
metastases	I-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
were	O
found	O
in	O
only	O
three	O
patients	B-MED
(	O
9	O
%	O
)	O
.	O
Each	O
metastasis	B-MED
was	O
larger	O
than	O
9	O
mm	B-MED
.	O
Metastases	B-MED
in	O
the	O
gastrocolic	B-MED
ligament	I-MED
occurred	O
in	O
9	O
%	O
of	O
patients	B-MED
with	O
T2	B-MED
or	O
deeper	O
invasive	B-MED
colon	B-MED
cancer	I-MED
close	O
to	O
the	O
hepatic	B-MED
flexure	I-MED
.	O
Laparoscopy	B-MED
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	B-MED
ligament	I-MED
resection	I-MED
.	O
This	O
study	B-MED
included	O
a	O
small	O
sample	B-MED
and	O
lacked	O
an	O
extended	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
Further	O
studies	B-MED
are	O
needed	O
to	O
determine	O
the	O
clinical	B-MED
relevance	I-MED
of	O
this	O
finding	B-MED
,	O
particularly	O
in	O
terms	O
of	O
recurrence	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
survival	B-MED
.	O
Developmental	B-MED
Profile	B-MED
and	O
Diagnoses	B-MED
in	O
Children	B-MED
Presenting	O
with	O
Motor	B-MED
Stereotypies	I-MED
Motor	B-MED
stereotypies	I-MED
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	B-MED
in	O
distinguishing	O
non	B-MED
-	I-MED
clinical	I-MED
behaviors	I-MED
(	O
physiological	B-MED
and	O
transient	B-MED
)	O
from	O
symptoms	B-MED
or	O
among	O
different	O
disorders	B-MED
[	O
"	O
primary	B-MED
stereotypies	I-MED
,	O
"	O
associated	B-MED
with	I-MED
autistic	B-MED
spectrum	I-MED
disorder	I-MED
(	O
ASD	B-MED
)	O
,	O
intellectual	B-MED
disabilities	I-MED
,	O
genetic	B-MED
syndromes	I-MED
,	O
and	O
sensory	B-MED
impairment	I-MED
]	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
obtain	B-MED
an	O
accurate	O
assessment	B-MED
on	O
the	O
relationship	B-MED
between	O
stereotypies	B-MED
and	O
neurodevelopmental	B-MED
disorders	I-MED
.	O
We	O
studied	B-MED
23	O
children	B-MED
(	O
3	O
girls	B-MED
)	O
,	O
aged	B-MED
36	O
-	O
95	O
months	B-MED
,	O
who	O
requested	O
a	O
consultation	B-MED
due	O
to	O
the	O
persistence	B-MED
or	O
increased	B-MED
severity	B-MED
of	O
motor	B-MED
stereotypies	I-MED
.	O
None	O
of	O
the	O
patients	B-MED
had	O
a	O
previous	O
diagnosis	B-MED
of	O
ASD	B-MED
.	O
The	O
assessment	B-MED
included	O
the	O
Motor	B-MED
Severity	I-MED
Stereotypy	I-MED
Scale	I-MED
(	O
MSSS	B-MED
)	O
,	O
the	O
Repetitive	B-MED
Behavior	I-MED
Scale	I-MED
-	I-MED
Revised	I-MED
(	O
RBS	B-MED
-	I-MED
R	I-MED
)	O
,	O
the	O
Raven	B-MED
's	I-MED
Colored	I-MED
Progressive	I-MED
Matrices	I-MED
,	O
the	O
Child	B-MED
Behavior	I-MED
CheckList	I-MED
for	O
ages	B-MED
1½-5	O
or	O
4	O
-	O
18	O
(	O
CBCL	B-MED
)	O
,	O
the	O
Social	B-MED
Responsiveness	I-MED
Scale	I-MED
(	B-MED
SRS	I-MED
)	I-MED
,	O
and	O
the	O
Autism	B-MED
Diagnostic	I-MED
Observation	I-MED
Schedule	I-MED
-	I-MED
second	I-MED
edition	I-MED
(	O
ADOS	B-MED
2	I-MED
)	O
.	O
All	O
patients	B-MED
were	O
showing	O
motor	B-MED
stereotypies	I-MED
for	O
periods	B-MED
of	I-MED
time	I-MED
varying	O
from	O
6	O
to	O
77	O
months	B-MED
.	O
The	O
MSSS	B-MED
showed	O
that	O
each	O
child	B-MED
had	O
a	O
limited	B-MED
number	B-MED
of	O
stereotypies	B-MED
;	O
their	O
frequency	B-MED
and	O
intensity	B-MED
were	O
mild	B-MED
.	O
The	O
interference	B-MED
of	O
stereotypies	B-MED
was	O
variable	B-MED
;	O
the	O
impairment	B-MED
in	O
daily	O
life	B-MED
was	O
mild	B-MED
.	O
The	O
RBS	B-MED
-	I-MED
R	I-MED
scores	B-MED
were	O
positive	O
for	O
the	O
subscale	O
of	O
"	O
stereotypic	B-MED
behaviors	I-MED
"	O
in	O
all	O
children	B-MED
.	O
Moreover	O
,	O
several	O
children	B-MED
presented	O
other	O
repetitive	B-MED
behaviors	I-MED
,	O
mainly	O
"	O
ritualistic	B-MED
behavior	I-MED
"	O
and	O
"	O
sameness	B-MED
behavior	I-MED
.	O
"	O
All	O
patients	B-MED
showed	O
a	O
normal	B-MED
cognitive	I-MED
level	I-MED
.	O
The	O
CBCL	B-MED
evidenced	B-MED
behavioral	B-MED
problems	I-MED
in	O
22	O
%	O
of	O
the	O
children	B-MED
:	O
internalizing	B-MED
problems	I-MED
,	O
attention	B-MED
,	O
and	O
withdrawn	B-MED
were	O
the	O
main	O
complaints	O
.	O
On	O
the	O
SRS	B-MED
,	O
all	O
but	O
one	O
of	O
the	O
tested	B-MED
patients	B-MED
obtained	B-MED
clinical	B-MED
scores	I-MED
in	O
the	O
clinical	B-MED
range	B-MED
for	O
at	O
least	O
one	O
area	O
.	O
On	O
the	O
ADOS	B-MED
2	I-MED
,	O
4	O
patients	B-MED
obtained	B-MED
scores	B-MED
indicating	O
a	O
moderate	B-MED
level	B-MED
of	O
ASD	B-MED
symptoms	B-MED
,	O
4	O
had	O
a	O
mild	B-MED
level	B-MED
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-MED
of	O
ASD	B-MED
.	O
Motor	B-MED
stereotypies	I-MED
in	O
children	B-MED
with	O
normal	B-MED
cognitive	I-MED
level	I-MED
represent	O
a	O
challenging	O
diagnostic	B-MED
issue	B-MED
for	O
which	O
a	O
finely	O
tailored	B-MED
assessment	B-MED
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	B-MED
profile	B-MED
.	O
Thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	B-MED
tests	I-MED
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-MED
.	O
Furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	B-MED
stereotypies	I-MED
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	B-MED
disorder	I-MED
.	O
Who	O
Persuades	B-MED
Who	O
?	O
An	O
Analysis	B-MED
of	O
Persuasion	B-MED
Choices	B-MED
Related	O
to	O
Antibiotic	B-MED
-	O
Free	B-MED
Food	B-MED
Personal	B-MED
communication	I-MED
,	O
in	O
which	O
one	O
person	B-MED
persuades	B-MED
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	B-MED
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	B-MED
spread	B-MED
.	O
To	O
better	O
understand	B-MED
how	O
personal	B-MED
communication	I-MED
spreads	B-MED
behavior	B-MED
,	O
we	O
investigated	B-MED
adults	B-MED
'	I-MED
(	O
N	O
=	O
228	O
)	O
likelihood	B-MED
of	O
persuading	B-MED
others	O
in	O
a	O
fictitious	O
social	B-MED
network	I-MED
to	O
buy	B-MED
antibiotic	B-MED
-	O
free	B-MED
food	B-MED
,	O
and	O
who	O
they	O
attempted	B-MED
to	O
persuade	B-MED
,	O
based	O
on	O
behavioral	B-MED
determinants	B-MED
,	O
homophily	B-MED
,	O
and	O
superdiffuser	B-MED
traits	B-MED
.	O
For	O
potential	B-MED
consumers	B-MED
,	O
the	O
findings	B-MED
showed	O
that	O
behavioral	B-MED
determinants	B-MED
,	O
behavioral	B-MED
intentions	B-MED
,	O
and	O
mavenism	B-MED
predicted	B-MED
intentions	B-MED
to	O
persuade	B-MED
others	O
.	O
Homophily	B-MED
,	O
mavenism	B-MED
,	O
and	O
connectivity	B-MED
predicted	B-MED
patterns	B-MED
of	O
interpersonal	B-MED
persuasion	B-MED
.	O
For	O
vegetarians	B-MED
(	O
without	O
homophily	B-MED
in	O
action	B-MED
)	O
,	O
behavioral	B-MED
determinants	B-MED
and	O
mavenism	B-MED
predicted	B-MED
persuasion	B-MED
intentions	B-MED
.	O
Persuasiveness	B-MED
was	O
associated	B-MED
with	I-MED
targeting	B-MED
more	O
network	B-MED
members	B-MED
;	O
mavenism	B-MED
was	O
associated	B-MED
with	I-MED
selecting	O
structurally	B-MED
central	B-MED
members	B-MED
.	O
Posterior	B-MED
dislocation	I-MED
of	O
the	O
sternoclavicular	B-MED
joint	I-MED
:	O
report	B-MED
of	O
two	O
cases	B-MED
The	O
authors	O
report	B-MED
the	O
cases	B-MED
of	O
two	O
young	B-MED
patients	B-MED
who	O
had	O
suffered	O
a	O
sporting	B-MED
accident	I-MED
with	O
posterior	B-MED
traumatic	I-MED
dislocation	I-MED
of	O
sternoclavicular	B-MED
joint	I-MED
.	O
In	O
one	O
of	O
the	O
patients	B-MED
closed	B-MED
reduction	I-MED
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-MED
in	O
a	O
sling	B-MED
.	O
The	O
second	O
patient	B-MED
,	O
after	O
reduction	B-MED
was	O
done	O
,	O
presented	O
recurrence	B-MED
of	O
the	O
dislocation	B-MED
,	O
thus	O
requiring	O
surgical	B-MED
treatment	I-MED
.	O
It	O
is	O
important	O
to	O
observe	O
the	O
relevance	B-MED
of	O
computed	B-MED
tomography	I-MED
to	O
help	O
diagnosing	B-MED
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	B-MED
procedure	I-MED
.	O
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-MED
in	O
a	O
rare	B-MED
injury	B-MED
such	O
as	O
the	O
posterior	B-MED
dislocation	I-MED
of	O
sternoclavicular	B-MED
joint	I-MED
.	O
Design	B-MED
,	O
synthesis	B-MED
,	O
and	O
evaluation	B-MED
of	O
curcumin	B-MED
derivatives	B-MED
as	O
Nrf2	B-MED
activators	B-MED
and	O
cytoprotectors	B-MED
against	O
oxidative	B-MED
death	I-MED
Activation	B-MED
of	O
nuclear	B-MED
factor	I-MED
erythroid-2	I-MED
-	I-MED
related	I-MED
factor	I-MED
2	I-MED
(	O
Nrf2	B-MED
)	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-MED
,	O
and	O
natural	O
curcumin	B-MED
stands	O
out	O
as	O
a	O
potent	O
Nrf2	B-MED
activator	B-MED
and	O
cancer	B-MED
chemopreventive	B-MED
agent	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-MED
analogs	B-MED
by	O
introducing	O
the	O
geminal	B-MED
dimethyl	I-MED
substituents	I-MED
on	I-MED
the	I-MED
active	I-MED
methylene	I-MED
group	I-MED
to	O
find	O
more	O
potent	O
Nrf2	B-MED
activators	B-MED
and	O
cytoprotectors	B-MED
against	O
oxidative	B-MED
death	I-MED
.	O
The	O
geminally	B-MED
dimethylated	I-MED
and	O
catechol	B-MED
-type	O
curcumin	B-MED
analog	B-MED
(	O
compound	B-MED
3	I-MED
)	O
was	O
identified	O
as	O
a	O
promising	O
lead	B-MED
molecule	I-MED
in	O
terms	O
of	O
its	O
increased	O
stability	B-MED
and	O
cytoprotective	B-MED
activity	B-MED
against	O
the	O
tert	B-MED
-	I-MED
butyl	I-MED
hydroperoxide	I-MED
(	O
t	B-MED
-	I-MED
BHP	I-MED
BHP)-induced	O
death	B-MED
of	O
HepG2	B-MED
cells	I-MED
.	O
Mechanism	B-MED
studies	B-MED
indicate	O
that	O
its	O
cytoprotective	B-MED
effects	B-MED
are	O
mediated	O
by	O
activating	B-MED
the	O
Nrf2	B-MED
signaling	B-MED
pathway	I-MED
in	O
the	O
Michael	B-MED
acceptor	I-MED
-	O
and	O
catechol	B-MED
-dependent	O
manners	O
.	O
Additionally	O
,	O
we	O
verified	O
by	O
using	O
copper	B-MED
and	O
iron	B-MED
ion	B-MED
chelators	B-MED
that	O
the	O
two	O
metal	B-MED
ion	B-MED
-mediated	O
oxidations	B-MED
of	O
compound	B-MED
3	I-MED
to	O
its	O
corresponding	O
electrophilic	O
o	B-MED
-	I-MED
quinone	I-MED
,	O
contribute	O
significantly	O
to	O
its	O
Nrf2	B-MED
-dependent	O
cytoprotection	B-MED
.	O
This	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	B-MED
natural	B-MED
curcumin	B-MED
-directed	O
Nrf2	B-MED
activators	B-MED
by	O
a	O
stability	B-MED
-increasing	O
and	O
proelectrophilic	B-MED
strategy	O
.	O
Hip	B-MED
segmentation	B-MED
from	O
MRI	B-MED
volumes	O
in	O
infants	B-MED
for	O
DDH	B-MED
diagnosis	B-MED
and	O
treatment	B-MED
planning	I-MED
Diagnosis	B-MED
and	O
surgical	B-MED
management	I-MED
of	O
Developmental	B-MED
Dysplasia	I-MED
of	I-MED
the	I-MED
Hip	I-MED
(	O
DDH	B-MED
)	O
relies	O
on	O
physical	B-MED
examination	I-MED
and	O
2D	O
ultrasound	B-MED
scanning	I-MED
.	O
Magnetic	B-MED
Resonance	I-MED
Imaging	I-MED
(	O
MRI	B-MED
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	B-MED
and	O
could	O
be	O
advantageous	O
in	O
treatment	B-MED
planning	I-MED
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O
In	O
this	O
paper	O
we	O
propose	O
a	O
semi	B-MED
-	I-MED
automatic	I-MED
method	B-MED
to	O
segment	B-MED
surface	I-MED
models	I-MED
of	O
the	O
acetabulum	B-MED
from	O
MRI	B-MED
images	B-MED
.	O
The	O
method	B-MED
incorporates	O
clinical	B-MED
knowledge	B-MED
in	O
the	O
form	O
of	O
intensity	B-MED
priors	I-MED
which	O
are	O
integrated	O
into	O
a	O
Random	B-MED
Walker	I-MED
(	I-MED
RW	I-MED
)	I-MED
formulation	I-MED
.	O
We	O
use	O
a	O
modified	B-MED
RW	B-MED
framework	O
which	O
compensates	B-MED
for	O
incomplete	B-MED
or	O
blurred	B-MED
boundaries	B-MED
in	O
the	O
image	B-MED
by	O
using	O
information	B-MED
from	O
neighboring	B-MED
slices	I-MED
in	O
the	O
sequence	B-MED
incorporated	O
as	O
node	B-MED
weights	I-MED
.	O
We	O
conducted	O
a	O
pilot	B-MED
study	I-MED
to	O
evaluate	B-MED
the	O
segmentation	B-MED
on	O
a	O
set	O
of	O
10	O
infant	B-MED
hip	B-MED
MRI	B-MED
sequences	B-MED
using	O
a	O
1.5	O
Tesla	O
MR	B-MED
scanner	I-MED
.	O
Contours	B-MED
obtained	O
from	O
the	O
semi	B-MED
-	I-MED
automated	I-MED
segmentation	B-MED
were	O
compared	B-MED
against	O
manually	B-MED
segmented	B-MED
hip	B-MED
contours	B-MED
using	O
Dice	B-MED
Ratio	I-MED
(	O
DR	B-MED
)	O
,	O
Hausdorff	B-MED
Distance	I-MED
(	O
HD	B-MED
)	O
and	O
Root	B-MED
Mean	I-MED
Square	I-MED
(	O
RMS	B-MED
)	O
distance	O
.	O
The	O
proposed	O
method	B-MED
gave	O
values	O
of	O
(	O
DR	B-MED
=	O
0.84	O
±	O
0.5	O
,	O
HD	B-MED
=	O
3.0	O
±	O
0.7	O
,	O
RMS	B-MED
=	O
1.9	O
±	O
0.3	O
)	O
and	O
(	O
DR	B-MED
=	O
0.86	O
±	O
0.2	O
,	O
HD	B-MED
=	O
3.0	O
±	O
0.1	O
,	O
RMS	B-MED
=	O
2.0	O
±	O
0.6	O
)	O
for	O
right	B-MED
and	O
left	B-MED
acetabular	I-MED
contours	I-MED
respectively	O
which	O
was	O
higher	B-MED
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	B-MED
RW	B-MED
segmentation	B-MED
.	O
The	O
execution	B-MED
time	B-MED
of	O
the	O
segmentation	B-MED
algorithm	B-MED
was	O
less	O
than	O
~4	O
seconds	B-MED
on	O
a	O
3.5	O
GHz	O
CPU	B-MED
.	O
The	O
relationship	O
between	O
thiamine	B-MED
and	O
two	O
symbioses	B-MED
:	O
Root	B-MED
nodule	I-MED
symbiosis	B-MED
and	O
arbuscular	B-MED
mycorrhiza	I-MED
Lotus	B-MED
japonicus	I-MED
THIC	B-MED
is	O
expressed	B-MED
in	O
all	O
organs	B-MED
,	O
and	O
the	O
encoded	B-MED
protein	I-MED
catalyzes	B-MED
thiamine	B-MED
biosynthesis	I-MED
.	O
Loss	B-MED
of	I-MED
function	I-MED
produces	O
chlorosis	B-MED
,	O
a	O
typical	O
thiamine	B-MED
-deficiency	O
phenotype	B-MED
,	O
and	O
mortality	B-MED
.	O
To	O
investigate	O
thiamine	B-MED
's	I-MED
role	O
in	O
symbiosis	B-MED
,	O
we	O
focused	O
on	O
THI1	B-MED
,	O
a	O
thiamine	B-MED
-	I-MED
biosynthesis	I-MED
gene	I-MED
expressed	B-MED
in	O
roots	B-MED
,	O
nodules	B-MED
,	O
and	O
seeds	B-MED
.	O
The	O
thi1	B-MED
mutant	I-MED
had	O
green	B-MED
leaves	I-MED
,	O
but	O
formed	O
small	B-MED
nodules	B-MED
and	O
immature	B-MED
seeds	B-MED
.	O
These	O
phenotypes	B-MED
were	O
rescued	O
by	O
THI1	B-MED
complementation	B-MED
and	O
by	O
exogenous	B-MED
thiamine	B-MED
.	O
Thus	O
,	O
THI1	B-MED
is	O
required	O
for	O
nodule	B-MED
enlargement	B-MED
and	O
seed	B-MED
maturation	I-MED
.	O
On	O
the	O
other	O
hand	O
,	O
colonization	B-MED
by	O
arbuscular	B-MED
mycorrhiza	I-MED
(	O
AM	B-MED
)	O
fungus	B-MED
Rhizophagus	B-MED
irregularis	I-MED
was	O
not	O
affected	O
in	O
the	O
thi1	B-MED
mutant	I-MED
or	O
by	O
exogenous	B-MED
thiamine	B-MED
.	O
However	O
,	O
spores	B-MED
of	O
R.	B-MED
irregularis	I-MED
stored	O
more	O
thiamine	B-MED
than	O
the	O
source	O
(	O
host	B-MED
plants	I-MED
)	O
,	O
despite	O
lacking	O
thiamine	B-MED
biosynthesis	I-MED
genes	I-MED
.	O
Therefore	O
,	O
disturbance	O
of	O
the	O
thiamine	B-MED
supply	O
would	O
affect	O
progeny	B-MED
phenotypes	B-MED
such	O
as	O
spore	B-MED
formation	I-MED
and	O
hyphal	B-MED
growth	I-MED
.	O
Further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine	B-MED
's	I-MED
effect	O
on	O
AM	B-MED
.	O
Examining	B-MED
the	O
contribution	B-MED
of	O
motor	B-MED
movement	I-MED
and	O
language	B-MED
dominance	B-MED
to	O
increased	B-MED
left	B-MED
lateralization	B-MED
during	O
sign	B-MED
generation	B-MED
in	O
native	B-MED
signers	B-MED
The	O
neural	B-MED
systems	I-MED
supporting	O
speech	B-MED
and	O
sign	B-MED
processing	B-MED
are	O
very	O
similar	B-MED
,	O
although	O
not	O
identical	O
.	O
In	O
a	O
previous	O
fTCD	B-MED
study	I-MED
of	O
hearing	B-MED
native	B-MED
signers	B-MED
(	O
Gutierrez	O
-	O
Sigut	O
,	O
Daws	O
,	O
et	O
al	O
.	O
,	O
2015	O
)	O
we	O
found	O
stronger	O
left	B-MED
lateralization	B-MED
for	O
sign	B-MED
than	O
speech	B-MED
.	O
Given	O
that	O
this	O
increased	B-MED
lateralization	B-MED
could	O
not	O
be	O
explained	O
by	O
hand	B-MED
movement	B-MED
alone	O
,	O
the	O
contribution	O
of	O
motor	B-MED
movement	I-MED
versus	O
'	O
linguistic	B-MED
'	O
processes	B-MED
to	O
the	O
strength	B-MED
of	O
hemispheric	B-MED
lateralization	B-MED
during	O
sign	B-MED
production	B-MED
remains	O
unclear	O
.	O
Here	O
we	O
directly	O
contrast	B-MED
lateralization	B-MED
strength	B-MED
of	O
covert	B-MED
versus	O
overt	B-MED
signing	B-MED
during	O
phonological	B-MED
and	O
semantic	B-MED
fluency	B-MED
tasks	B-MED
.	O
To	O
address	O
the	O
possibility	O
that	O
hearing	B-MED
native	B-MED
signers	B-MED
'	O
elevated	B-MED
lateralization	B-MED
indices	I-MED
(	O
LIs	B-MED
)	O
were	O
due	O
to	O
performing	O
a	O
task	B-MED
in	O
their	O
less	O
dominant	B-MED
language	B-MED
,	O
here	O
we	O
test	O
deaf	B-MED
native	B-MED
signers	B-MED
,	O
whose	O
dominant	B-MED
language	B-MED
is	O
British	B-MED
Sign	I-MED
Language	I-MED
(	O
BSL	B-MED
)	O
.	O
Signers	B-MED
were	O
more	O
strongly	O
left	B-MED
lateralized	B-MED
for	O
overt	B-MED
than	O
covert	B-MED
sign	B-MED
generation	O
.	O
However	O
,	O
the	O
strength	B-MED
of	O
lateralization	B-MED
was	O
not	O
correlated	B-MED
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-MED
of	O
the	O
right	B-MED
hand	I-MED
.	O
Comparisons	B-MED
with	O
previous	O
data	B-MED
from	O
hearing	B-MED
native	B-MED
English	B-MED
speakers	B-MED
suggest	O
stronger	O
laterality	B-MED
indices	I-MED
for	O
sign	B-MED
than	O
speech	B-MED
in	O
both	O
covert	B-MED
and	O
overt	B-MED
tasks	B-MED
.	O
This	O
increased	B-MED
left	B-MED
lateralization	B-MED
may	O
be	O
driven	O
by	O
specific	O
properties	B-MED
of	O
sign	B-MED
production	B-MED
such	O
as	O
the	O
increased	B-MED
use	B-MED
of	O
self	B-MED
-	I-MED
monitoring	I-MED
mechanisms	B-MED
or	O
the	O
nature	B-MED
of	O
phonological	B-MED
encoding	I-MED
of	O
signs	B-MED
.	O
Beneficial	B-MED
effects	I-MED
of	O
natural	B-MED
eggshell	I-MED
membrane	I-MED
(	O
NEM	B-MED
)	O
on	O
multiple	O
indices	O
of	O
arthritis	B-MED
in	O
collagen	B-MED
-	I-MED
induced	I-MED
arthritic	I-MED
rats	B-MED
This	O
study	B-MED
was	O
performed	O
to	O
evaluate	B-MED
the	O
potential	B-MED
efficacy	I-MED
of	O
natural	B-MED
eggshell	I-MED
membrane	I-MED
(	O
NEM	B-MED
)	O
in	O
collagen	B-MED
-	I-MED
induced	I-MED
arthritic	I-MED
rats	B-MED
,	O
a	O
well	O
-	O
established	O
rodent	B-MED
model	I-MED
of	I-MED
inflammation	I-MED
and	O
rheumatoid	B-MED
arthritis	I-MED
.	O
Rats	B-MED
with	O
developing	O
type	B-MED
II	I-MED
collagen	I-MED
-	I-MED
induced	I-MED
arthritis	I-MED
(	O
CIA	B-MED
)	O
were	O
treated	O
once	O
daily	B-MED
by	O
oral	B-MED
gavage	I-MED
on	O
study	B-MED
days	I-MED
-14	O
to	O
17	O
with	O
vehicle	B-MED
or	O
NEM	B-MED
(	O
52	O
mg	O
/	O
kg	O
body	B-MED
weight	I-MED
)	O
.	O
Rats	B-MED
were	O
euthanized	B-MED
on	O
study	B-MED
day	I-MED
17	O
.	O
Efficacy	B-MED
was	O
assessed	B-MED
by	O
daily	B-MED
ankle	B-MED
caliper	B-MED
measurements	B-MED
measurements	B-MED
,	O
ankle	B-MED
diameter	B-MED
expressed	O
as	O
area	B-MED
under	I-MED
the	I-MED
curve	I-MED
(	O
AUCd0	B-MED
-	I-MED
17	I-MED
)	O
,	O
and	O
histopathologic	B-MED
evaluation	I-MED
of	O
ankles	B-MED
and	O
knees	B-MED
.	O
Serum	B-MED
biomarkers	B-MED
of	O
cartilage	B-MED
function	I-MED
and	O
inflammation	B-MED
[	O
collagen	B-MED
type	I-MED
II	I-MED
C	I-MED
-	I-MED
telopeptide	I-MED
(	O
CTXII	B-MED
)	O
,	O
cartilage	B-MED
oligomeric	I-MED
matrix	I-MED
protein	I-MED
(	O
COMP	B-MED
)	O
,	O
and	O
alpha-2	B-MED
-	I-MED
macroglobulin	I-MED
(	O
A2	B-MED
M	I-MED
)	O
]	O
were	O
measured	B-MED
by	O
ELISA	B-MED
.	O
Treatment	B-MED
with	O
NEM	B-MED
resulted	O
in	O
significant	B-MED
beneficial	I-MED
effects	I-MED
on	O
the	O
daily	B-MED
ankle	B-MED
diameter	B-MED
measurements	B-MED
and	O
ankle	B-MED
diameter	B-MED
AUC	B-MED
.	O
Ankle	B-MED
and	O
knee	B-MED
histopathology	B-MED
scores	I-MED
were	O
significantly	B-MED
reduced	I-MED
(	O
36	O
%	O
and	O
43	O
%	O
reduction	B-MED
of	O
summed	O
individual	O
histopathology	B-MED
scores	I-MED
for	O
ankle	B-MED
and	O
knee	B-MED
,	O
respectively	O
;	O
p	O
<	O
0.05	O
)	O
toward	O
normal	O
for	O
rats	B-MED
given	O
NEM	B-MED
compared	O
to	O
vehicle	O
controls	O
.	O
The	O
percent	O
reduction	O
of	O
serum	B-MED
CTXII	B-MED
,	O
COMP	B-MED
,	O
and	O
A2	B-MED
M	I-MED
in	O
NEM	B-MED
-	O
treated	B-MED
rats	B-MED
ranged	O
from	O
30	O
%	O
to	O
72	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O
NEM	B-MED
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	B-MED
arthritis	I-MED
including	O
inflammation	B-MED
,	O
pannus	B-MED
,	O
cartilage	B-MED
damage	I-MED
,	O
bone	B-MED
resorption	I-MED
,	O
and	O
periosteal	B-MED
bone	I-MED
formation	I-MED
.	O
This	O
study	B-MED
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	B-MED
,	O
COMP	B-MED
,	O
and	O
A2	B-MED
M	I-MED
as	O
relevant	O
biomarkers	B-MED
that	O
were	O
responsive	O
to	O
NEM	B-MED
.	O
Anti	B-MED
-	I-MED
helminthic	I-MED
activity	B-MED
of	O
Momordica	B-MED
charantia	I-MED
L	I-MED
L.	O
against	O
Fasciola	B-MED
hepatica	I-MED
eggs	I-MED
after	O
twelve	O
days	B-MED
of	O
incubation	B-MED
in	B-MED
vitro	I-MED
Fasciolosis	B-MED
,	O
a	O
parasitic	B-MED
disease	I-MED
caused	O
by	O
the	O
trematode	B-MED
Fasciola	B-MED
hepatica	I-MED
underreported	O
is	O
expanding	O
both	O
in	O
human	B-MED
and	O
animal	B-MED
population	I-MED
,	O
throughout	O
the	O
world	B-MED
.	O
The	O
constant	O
use	O
of	O
synthetic	B-MED
drugs	I-MED
to	O
treat	B-MED
this	O
condition	B-MED
has	O
led	O
to	O
the	O
natural	B-MED
selection	I-MED
of	O
resistant	B-MED
strains	B-MED
of	O
the	O
parasite	B-MED
.	O
Hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti	B-MED
-	I-MED
helminthic	I-MED
properties	B-MED
of	O
medicinal	B-MED
plants	I-MED
and	O
phytopharmaceuticals	B-MED
.	O
The	O
current	O
study	B-MED
assessed	O
the	O
potential	O
anti	B-MED
-	I-MED
fasciolicide	I-MED
action	B-MED
of	O
Momordica	B-MED
charantia	I-MED
leaf	B-MED
extracts	B-MED
and	O
fractions	B-MED
on	O
the	O
eggs	B-MED
of	I-MED
F.	I-MED
hepatica	I-MED
parasites	I-MED
.	O
The	O
lyophilized	B-MED
crude	B-MED
extract	I-MED
(	O
CE	B-MED
)	O
of	O
M.	B-MED
charantia	I-MED
leaves	I-MED
and	O
its	O
sub	B-MED
-	I-MED
fractions	I-MED
,	O
obtained	O
from	O
liquid	B-MED
-	I-MED
liquid	I-MED
partitioning	I-MED
with	O
organic	B-MED
solvents	I-MED
,	O
were	O
analysed	B-MED
by	O
High	B-MED
Performance	I-MED
Liquid	I-MED
Chromatography	I-MED
(	O
HPLC	B-MED
)	O
,	O
suspended	B-MED
in	O
1	O
%	O
DMSO	B-MED
and	O
used	O
in	O
in	B-MED
vitro	I-MED
tests	B-MED
.	O
Quadruplicates	B-MED
of	O
50	O
F.	B-MED
hepatica	I-MED
eggs	I-MED
were	O
incubated	B-MED
at	O
23	O
°	O
C	O
with	O
M.	B-MED
charantia	I-MED
leaf	B-MED
CE	B-MED
in	O
different	O
concentrations	B-MED
.	O
After	O
12	O
days	B-MED
no	O
larvae	B-MED
were	O
formed	O
in	O
eggs	B-MED
incubated	B-MED
with	O
CE	B-MED
concentrations	B-MED
above	O
12.5mg	O
/	O
mL.	O
Eggs	B-MED
incubated	B-MED
with	O
CE	B-MED
sub	B-MED
-	I-MED
fractions	I-MED
at	O
concentrations	B-MED
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg	O
/	O
mL	O
affected	B-MED
embryonic	B-MED
development	I-MED
,	O
with	O
n	B-MED
-	I-MED
butanol	I-MED
presenting	O
the	O
strongest	O
inhibition	B-MED
of	O
miracidia	B-MED
formation	B-MED
.	O
In	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90	O
%	O
of	O
the	O
miracidia	B-MED
hatched	B-MED
in	O
the	O
control	B-MED
experiments	I-MED
using	O
0.03	O
%	O
DMSO	B-MED
whereas	O
embryogenesis	B-MED
was	O
completely	O
abolished	B-MED
with	O
any	O
concentration	B-MED
of	O
albendazole	B-MED
sulphoxide	I-MED
ABZ(SO	B-MED
)	I-MED
.	O
Chemical	B-MED
analysis	I-MED
of	O
the	O
CE	B-MED
and	O
sub	B-MED
-	I-MED
fractions	I-MED
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	B-MED
.	O
HPLC	B-MED
-	I-MED
MS	I-MED
confirmed	O
Quercetin	B-MED
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	B-MED
present	O
in	O
the	O
CE	B-MED
and	O
the	O
n	B-MED
-	I-MED
butanol	I-MED
subfraction	B-MED
.	O
This	O
is	O
the	O
first	O
study	B-MED
to	O
analyse	B-MED
the	O
potential	O
anti	B-MED
-	I-MED
fasciolicide	I-MED
action	B-MED
of	O
M.	B-MED
charantia	I-MED
leaf	B-MED
CE	B-MED
and	O
subfractions	B-MED
.	O
Graded	B-MED
Structure	I-MED
in	O
Sexual	B-MED
Definitions	B-MED
:	O
Categorizations	B-MED
of	O
Having	O
"	O
Had	B-MED
Sex	I-MED
"	O
and	O
Virginity	B-MED
Loss	B-MED
Among	O
Homosexual	B-MED
and	O
Heterosexual	B-MED
Men	B-MED
and	O
Women	B-MED
Definitions	B-MED
of	O
sexual	B-MED
behavior	I-MED
display	O
a	O
robust	O
hierarchy	B-MED
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	B-MED
should	O
be	O
classed	O
as	O
,	O
for	O
example	O
,	O
sex	B-MED
or	O
virginity	B-MED
loss	B-MED
.	O
The	O
current	O
research	B-MED
offers	O
a	O
theoretical	B-MED
explanation	B-MED
for	O
this	O
hierarchy	B-MED
,	O
proposing	O
that	O
sexual	B-MED
definitions	B-MED
display	O
graded	B-MED
categorical	I-MED
structure	I-MED
,	O
arising	O
from	O
goodness	O
of	O
membership	B-MED
judgments	B-MED
.	O
Moderation	B-MED
of	O
this	O
graded	B-MED
structure	I-MED
is	O
also	O
predicted	O
,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual	B-MED
orientation	I-MED
identity	B-MED
affects	O
sexual	B-MED
definitions	B-MED
.	O
A	O
total	O
of	O
300	O
18-	O
to	O
30-	O
year	B-MED
-old	O
participants	B-MED
completed	O
an	O
online	B-MED
survey	I-MED
,	O
rating	B-MED
18	O
behaviors	B-MED
for	O
how	O
far	O
each	O
constitutes	O
having	O
"	O
had	B-MED
sex	I-MED
"	O
and	O
virginity	B-MED
loss	B-MED
.	O
Participants	B-MED
fell	O
into	O
one	O
of	O
four	O
groups	B-MED
:	O
heterosexual	B-MED
male	B-MED
or	O
female	B-MED
,	O
gay	B-MED
male	I-MED
or	O
lesbian	B-MED
.	O
The	O
predicted	O
ratings	B-MED
hierarchy	B-MED
emerged	O
,	O
in	O
which	O
bidirectional	B-MED
genital	I-MED
acts	I-MED
were	O
rated	B-MED
significantly	O
higher	B-MED
than	O
unidirectional	B-MED
or	O
nonpenetrative	B-MED
contact	I-MED
,	O
which	O
was	O
in	O
turn	O
rated	B-MED
significantly	O
higher	B-MED
than	O
acts	B-MED
involving	O
no	B-MED
genital	I-MED
contact	I-MED
.	O
Moderation	B-MED
of	O
graded	B-MED
structure	I-MED
was	O
also	O
in	O
line	O
with	O
predictions	B-MED
.	O
Compared	O
to	O
the	O
other	O
groups	B-MED
,	O
the	O
lesbian	B-MED
group	I-MED
significantly	O
upgraded	O
ratings	B-MED
of	O
genital	B-MED
contact	I-MED
that	O
was	O
either	O
unidirectional	B-MED
or	O
nonpenetrative	B-MED
.	O
There	O
was	O
also	O
evidence	B-MED
of	O
upgrading	O
by	O
the	O
gay	B-MED
male	I-MED
sample	O
of	O
anal	B-MED
intercourse	I-MED
ratings	B-MED
.	O
These	O
effects	B-MED
are	O
theorized	O
to	O
reflect	O
group	B-MED
-level	O
variation	B-MED
in	O
experience	B-MED
,	O
contextual	B-MED
perspective	I-MED
,	O
and	O
identity	B-MED
-management	O
.	O
The	O
implications	B-MED
of	O
the	O
findings	B-MED
in	O
relation	O
to	O
previous	O
research	B-MED
are	O
discussed	O
.	O
It	O
is	O
suggested	O
that	O
a	O
graded	B-MED
structure	I-MED
approach	O
can	O
greatly	O
benefit	B-MED
future	O
research	B-MED
into	O
sexual	B-MED
definitions	B-MED
,	O
by	O
permitting	O
variable	O
definitions	B-MED
to	O
be	O
predicted	O
and	O
explained	O
,	O
rather	O
than	O
merely	O
identified	O
.	O
Pharmacological	B-MED
Venous	I-MED
Thromboembolism	I-MED
Prophylaxis	I-MED
in	O
Meningioma	B-MED
Patients	B-MED
:	O
Should	O
It	O
Be	O
Earlier	O
Than	O
Clinical	B-MED
Practice	I-MED
?	O
We	O
read	O
the	O
report	B-MED
by	O
Çeltikçi	O
et	O
al	O
in	O
the	O
Turkish	B-MED
Neurosurgery	I-MED
with	O
great	O
interest	O
.	O
In	O
this	O
single	O
-	O
center	O
retrospective	B-MED
study	I-MED
,	O
they	O
analysed	O
449	O
intracranial	B-MED
meningioma	I-MED
patients	B-MED
underwent	O
open	B-MED
surgery	I-MED
.	O
They	O
stated	O
that	O
venous	B-MED
thromboembolism	I-MED
(	O
VTE	B-MED
)	O
had	O
been	O
seen	O
in	O
21	O
(	O
4.6	O
%	O
)	O
of	O
their	O
patients	B-MED
.	O
This	O
is	O
an	O
important	O
issue	O
because	O
VTE	B-MED
,	O
including	O
deep	B-MED
vein	I-MED
thrombosis	I-MED
(	O
DVT	B-MED
)	O
and	O
pulmonary	B-MED
embolism	I-MED
(	O
PE	B-MED
)	O
,	O
is	O
the	O
most	O
common	O
overall	O
complication	B-MED
in	O
meningioma	B-MED
surgery	I-MED
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	B-MED
(	O
2	O
)	O
.	O
We	O
suppose	O
that	O
prophylaxis	B-MED
of	O
VTE	B-MED
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological	B-MED
prophylaxis	I-MED
are	O
combined	O
.	O
We	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical	B-MED
extrapolation	I-MED
.	O
Kinematic	B-MED
and	O
EMG	B-MED
Responses	B-MED
to	O
Pelvis	B-MED
and	O
Leg	B-MED
Assistance	B-MED
Force	B-MED
during	O
Treadmill	B-MED
Walking	I-MED
in	O
Children	B-MED
with	O
Cerebral	B-MED
Palsy	I-MED
Treadmill	B-MED
training	I-MED
has	O
been	O
used	O
for	O
improving	O
locomotor	B-MED
function	I-MED
in	O
children	B-MED
with	O
cerebral	B-MED
palsy	I-MED
(	O
CP	B-MED
)	O
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	B-MED
.	O
The	O
understanding	O
of	O
the	O
kinematic	B-MED
and	O
EMG	B-MED
responses	B-MED
to	O
force	B-MED
s	O
applied	O
to	O
the	O
body	B-MED
of	O
subjects	O
during	O
treadmill	B-MED
walking	I-MED
is	O
crucial	O
for	O
improving	O
current	O
paradigms	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
the	O
kinematic	B-MED
s	O
and	O
EMG	B-MED
responses	B-MED
to	O
the	O
pelvis	B-MED
and/or	O
leg	B-MED
assistance	B-MED
force	B-MED
.	O
Ten	O
children	B-MED
with	O
spastic	B-MED
CP	I-MED
were	O
recruited	O
to	O
participate	B-MED
in	O
this	O
study	B-MED
.	O
A	O
controlled	O
assistance	B-MED
force	B-MED
was	O
applied	O
to	O
the	O
pelvis	B-MED
and/or	O
legs	B-MED
during	O
stance	B-MED
and	O
swing	B-MED
phase	I-MED
of	I-MED
gait	I-MED
through	O
a	O
custom	O
designed	O
robotic	B-MED
system	I-MED
during	O
walking	B-MED
.	O
Muscle	B-MED
activities	B-MED
and	O
spatial	B-MED
-	O
temporal	B-MED
gait	B-MED
parameters	I-MED
were	O
measured	O
at	O
different	O
loading	B-MED
conditions	I-MED
during	O
walking	B-MED
.	O
In	O
addition	O
,	O
the	O
spatial	B-MED
-	I-MED
temporal	I-MED
gait	I-MED
parameters	I-MED
during	O
overground	O
walking	B-MED
before	O
and	O
after	O
treadmill	B-MED
training	I-MED
were	O
also	O
collected	O
.	O
Applying	O
pelvis	B-MED
assistance	B-MED
improved	B-MED
step	B-MED
height	I-MED
and	O
applying	O
leg	B-MED
assistance	B-MED
improved	B-MED
step	B-MED
length	I-MED
during	O
walking	B-MED
,	O
but	O
applying	O
leg	B-MED
assistance	B-MED
also	O
reduced	B-MED
muscle	B-MED
activation	B-MED
of	O
ankle	B-MED
flexor	I-MED
during	O
the	O
swing	B-MED
phase	I-MED
of	I-MED
gait	I-MED
.	O
In	O
addition	O
,	O
step	B-MED
length	I-MED
and	O
self	O
-	O
selected	O
walking	B-MED
speed	I-MED
significantly	O
improved	B-MED
after	O
one	O
session	B-MED
of	O
treadmill	B-MED
training	I-MED
with	O
combined	O
pelvis	B-MED
and	O
leg	B-MED
assistance	B-MED
.	O
Identification	O
of	O
markers	B-MED
for	O
quiescent	B-MED
pancreatic	B-MED
stellate	I-MED
cells	I-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
Pancreatic	B-MED
stellate	I-MED
cells	I-MED
(	O
PSCs	B-MED
)	O
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	B-MED
cells	I-MED
in	O
pancreatic	B-MED
cancer	I-MED
and	O
chronic	B-MED
pancreatitis	I-MED
.	O
In	O
contrast	O
to	O
quiescent	B-MED
hepatic	B-MED
stellate	I-MED
cells	I-MED
(	O
qHSCs	B-MED
)	O
,	O
a	O
specific	O
marker	B-MED
for	O
quiescent	B-MED
PSCs	B-MED
(	O
qPSCs	B-MED
)	O
that	O
can	O
be	O
used	O
in	O
formalin	B-MED
-	I-MED
fixed	I-MED
and	I-MED
paraffin	I-MED
embedded	I-MED
(	I-MED
FFPE	I-MED
)	I-MED
normal	I-MED
human	I-MED
pancreatic	I-MED
tissue	I-MED
has	O
not	O
been	O
identified	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qPSCs	B-MED
in	O
normal	B-MED
human	B-MED
FFPE	B-MED
pancreatic	I-MED
tissue	I-MED
.	O
Immunohistochemical	B-MED
(	O
IHC	B-MED
)	O
,	O
double	B-MED
-	I-MED
IHC	I-MED
,	O
immunofluorescence	B-MED
(	O
IF	B-MED
)	O
and	O
double	B-MED
-	I-MED
IF	I-MED
analyses	I-MED
were	O
carried	O
out	O
using	O
a	O
tissue	B-MED
microarray	I-MED
consisting	O
of	O
cores	O
with	O
normal	B-MED
human	B-MED
pancreatic	B-MED
tissue	I-MED
.	O
Cores	O
with	O
normal	B-MED
human	B-MED
liver	B-MED
served	O
as	O
control	B-MED
.	O
Antibodies	B-MED
directed	O
against	O
adipophilin	B-MED
,	O
α	B-MED
-	I-MED
SMA	I-MED
,	O
CD146	B-MED
,	O
CRBP-1	B-MED
,	O
cytoglobin	B-MED
,	O
desmin	B-MED
,	O
GFAP	B-MED
,	O
nestin	B-MED
,	O
S100A4	B-MED
and	O
vinculin	B-MED
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	B-MED
cells	B-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
and	O
perisinusoidal	B-MED
cells	I-MED
in	O
the	O
normal	B-MED
human	B-MED
liver	B-MED
.	O
The	O
immunolabelling	B-MED
capacity	B-MED
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	B-MED
scoring	I-MED
system	I-MED
.	O
Double	B-MED
-	I-MED
IF	I-MED
of	O
the	O
markers	B-MED
of	O
interest	O
together	O
with	O
markers	B-MED
for	O
other	O
periacinar	B-MED
cells	B-MED
was	O
performed	O
.	O
Moreover	O
,	O
the	O
utility	O
of	O
histochemical	B-MED
stains	I-MED
for	O
the	O
identification	O
of	O
human	B-MED
qPSCs	B-MED
was	O
examined	O
,	O
and	O
their	O
ultrastructure	B-MED
was	O
revisited	O
by	O
electron	B-MED
microscopy	I-MED
.	O
Adipophilin	B-MED
,	O
CRBP-1	B-MED
,	O
cytoglobin	B-MED
and	O
vinculin	B-MED
were	O
expressed	O
in	O
qHSCs	B-MED
in	O
the	O
liver	B-MED
,	O
whereas	O
cytoglobin	B-MED
and	O
adipophilin	B-MED
were	O
expressed	O
in	O
qPSCs	B-MED
in	O
the	O
pancreas	B-MED
.	O
Adipophilin	B-MED
immunohistochemistry	B-MED
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	B-MED
time	I-MED
interval	I-MED
(	O
PATI	B-MED
)	O
from	O
removal	O
of	O
the	O
tissue	B-MED
to	O
formalin	B-MED
fixation	I-MED
.	O
Cytoglobin	B-MED
,	O
S100A4	B-MED
and	O
vinculin	B-MED
were	O
expressed	O
in	O
periacinar	B-MED
fibroblasts	B-MED
(	O
FBs	B-MED
)	O
.	O
The	O
other	O
examined	O
markers	B-MED
were	O
negative	O
in	O
human	B-MED
qPSCs	B-MED
.	O
Our	O
data	O
indicate	O
that	O
cytoglobin	B-MED
and	O
adipophilin	B-MED
are	O
markers	B-MED
of	O
qPSCs	B-MED
in	O
the	O
normal	B-MED
human	B-MED
pancreas	B-MED
.	O
However	O
,	O
the	O
use	O
of	O
adipophilin	B-MED
as	O
a	O
qPSC	B-MED
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
PATI	B-MED
.	O
Cytoglobin	B-MED
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	B-MED
for	O
qPSCs	B-MED
but	O
is	O
expressed	O
in	O
FBs	B-MED
as	O
well	O
.	O
Characterization	B-MED
and	O
Ectopic	B-MED
Expression	I-MED
of	O
CoWRI1	B-MED
,	O
an	O
AP2	B-MED
/	I-MED
EREBP	I-MED
Domain	O
-	O
Containing	O
Transcription	B-MED
Factor	I-MED
from	O
Coconut	B-MED
(	O
Cocos	B-MED
nucifera	I-MED
L	I-MED
.	O
)	O
Endosperm	B-MED
,	O
Changes	O
the	O
Seeds	B-MED
Oil	B-MED
Content	O
in	O
Transgenic	B-MED
Arabidopsis	B-MED
thaliana	I-MED
and	O
Rice	B-MED
(	O
Oryza	B-MED
sativa	I-MED
L	I-MED
.	O
)	O
Coconut	B-MED
(	O
Cocos	B-MED
nucifera	I-MED
L.	I-MED
)	O
is	O
a	O
key	O
tropical	B-MED
crop	B-MED
and	O
a	O
member	O
of	O
the	O
monocotyledonous	B-MED
family	I-MED
Arecaceae	B-MED
(	O
Palmaceae	B-MED
)	O
.	O
Few	O
genes	B-MED
and	O
related	O
metabolic	B-MED
processes	I-MED
involved	O
in	O
coconut	B-MED
endosperm	B-MED
development	O
have	O
been	O
investigated	B-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	B-MED
gene	B-MED
family	I-MED
was	O
isolated	O
from	O
coconut	B-MED
endosperm	B-MED
and	O
was	O
named	O
CoWRI1	B-MED
.	O
Its	O
transcriptional	B-MED
activities	B-MED
and	O
interactions	B-MED
with	O
the	O
acetyl	B-MED
-	I-MED
CoA	I-MED
carboxylase	I-MED
(	O
BCCP2	B-MED
)	O
promoter	B-MED
of	O
CoWRI1	B-MED
were	O
confirmed	O
by	O
the	O
yeast	B-MED
two	I-MED
-	I-MED
hybrid	I-MED
and	O
yeast	B-MED
one	I-MED
-	I-MED
hybrid	I-MED
approaches	O
,	O
respectively	O
.	O
Functional	O
characterization	B-MED
was	O
carried	O
out	O
through	O
seed	B-MED
-specific	O
expression	B-MED
in	O
Arabidopsis	B-MED
and	O
endosperm	B-MED
-specific	O
expression	B-MED
in	O
rice	B-MED
.	O
In	O
transgenic	B-MED
Arabidopsis	B-MED
,	O
high	O
over	B-MED
-	I-MED
expressions	I-MED
of	O
CoWRI1	B-MED
in	O
seven	O
independent	O
T2	B-MED
lines	B-MED
were	O
detected	O
by	O
quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
PCR	I-MED
.	O
The	O
relative	O
mRNA	B-MED
accumulation	O
of	O
genes	B-MED
encoding	B-MED
enzymes	B-MED
involved	O
in	O
either	O
fatty	B-MED
acid	I-MED
biosynthesis	I-MED
or	O
triacylglycerols	B-MED
assembly	O
(	O
BCCP2	B-MED
,	O
KASI	B-MED
,	O
MAT	B-MED
,	O
ENR	B-MED
,	O
FATA	B-MED
,	O
and	O
GPDH	B-MED
)	O
were	O
also	O
assayed	B-MED
in	O
mature	O
seeds	B-MED
.	O
Furthermore	O
,	O
lipid	B-MED
and	O
fatty	B-MED
acids	I-MED
C16:0	B-MED
and	O
C18:0	B-MED
significantly	O
increased	O
.	O
In	O
two	O
homozygous	B-MED
T2	B-MED
transgenic	B-MED
rice	B-MED
lines	I-MED
(	O
G5	B-MED
and	O
G2	B-MED
)	O
,	O
different	O
CoWRI1	B-MED
expression	B-MED
levels	O
were	O
detected	O
,	O
but	O
no	O
CoWRI1	B-MED
transcripts	B-MED
were	O
detected	O
in	O
the	O
wild	B-MED
type	I-MED
.	O
Analyses	B-MED
of	O
the	O
seed	B-MED
oil	B-MED
content	O
,	O
starch	B-MED
content	O
,	O
and	O
total	O
protein	B-MED
content	O
indicated	O
that	O
the	O
two	O
T2	B-MED
transgenic	B-MED
lines	I-MED
showed	O
a	O
significant	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
seed	B-MED
oil	B-MED
content	O
.	O
The	O
transgenic	B-MED
lines	I-MED
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-MED
content	O
,	O
whereas	O
total	O
protein	B-MED
content	O
decreased	O
significantly	O
.	O
Further	O
analysis	B-MED
of	O
the	O
fatty	B-MED
acid	I-MED
composition	O
revealed	O
that	O
palmitic	B-MED
acid	I-MED
(	O
C16:0	B-MED
)	O
and	O
linolenic	B-MED
acid	I-MED
(	O
C18:3	B-MED
)	O
increased	O
significantly	O
in	O
the	O
seeds	B-MED
of	O
the	O
transgenic	B-MED
rice	B-MED
lines	I-MED
,	O
but	O
oleic	B-MED
acid	I-MED
(	O
C18:1	B-MED
)	O
levels	O
significantly	O
declined	O
.	O
Identification	O
of	O
low	O
micromolar	B-MED
dual	O
inhibitors	B-MED
for	O
aldose	B-MED
reductase	I-MED
(	O
ALR2	B-MED
)	O
and	O
poly	B-MED
(	I-MED
ADP	I-MED
-	I-MED
ribose	I-MED
)	I-MED
polymerase	I-MED
(	O
PARP-1	B-MED
)	O
using	O
structure	B-MED
based	O
design	B-MED
approach	O
Clinical	B-MED
studies	I-MED
have	O
revealed	O
that	O
diabetic	B-MED
retinopathy	I-MED
is	O
a	O
multifactorial	O
disorder	B-MED
.	O
Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	B-MED
and	O
PARP-1	B-MED
co	O
-	O
occur	O
in	O
retinal	B-MED
cells	B-MED
,	O
making	O
them	O
appropriate	O
targets	B-MED
for	O
the	O
treatment	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
.	O
To	O
find	O
the	O
dual	O
inhibitors	B-MED
of	O
ALR2	B-MED
and	O
PARP-1	B-MED
,	O
the	O
structure	B-MED
based	O
design	B-MED
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	B-MED
proteins	B-MED
.	O
A	O
series	O
of	O
novel	O
thiazolidine-2,4	B-MED
-	I-MED
dione	I-MED
(	O
TZD	B-MED
)	O
derivatives	B-MED
were	O
therefore	O
rationally	O
designed	B-MED
,	O
synthesized	B-MED
and	O
their	O
in	B-MED
vitro	I-MED
inhibitory	B-MED
activities	I-MED
against	O
ALR2	B-MED
and	O
PARP-1	B-MED
were	O
evaluated	O
.	O
The	O
experimental	B-MED
results	I-MED
showed	O
that	O
compounds	B-MED
5b	I-MED
and	O
5f	B-MED
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	B-MED
activities	B-MED
in	O
micromolar	B-MED
and	O
submicromolar	B-MED
range	B-MED
(	O
IC50	B-MED
1.34	O
-	O
5.03μM	O
)	O
against	O
both	O
the	O
targeted	B-MED
enzymes	B-MED
.	O
The	O
structure	B-MED
-	I-MED
activity	I-MED
relationship	I-MED
elucidated	O
for	O
these	O
novel	O
inhibitors	B-MED
against	O
both	O
the	O
enzymes	B-MED
provide	O
new	O
insight	O
into	O
the	O
binding	B-MED
mode	B-MED
of	O
the	O
inhibitors	B-MED
to	O
the	O
active	B-MED
sites	I-MED
of	O
enzymes	B-MED
.	O
The	O
positive	B-MED
results	B-MED
of	O
the	O
biochemical	B-MED
assay	B-MED
suggest	O
that	O
these	O
compounds	B-MED
may	O
be	O
further	O
optimized	B-MED
and	O
utilized	B-MED
for	O
the	O
treatment	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
.	O
Dimerization	B-MED
of	O
EGFR	B-MED
and	O
HER2	B-MED
induces	O
breast	B-MED
cancer	I-MED
cell	B-MED
motility	I-MED
through	O
STAT1	B-MED
-dependent	O
ACTA2	B-MED
induction	B-MED
The	O
dimerization	B-MED
of	O
EGFR	B-MED
and	O
HER2	B-MED
is	O
associated	O
with	O
poor	O
prognosis	B-MED
such	O
as	O
induction	B-MED
of	O
tumor	B-MED
growth	I-MED
and	O
cell	B-MED
invasion	I-MED
compared	B-MED
to	O
when	O
EGFR	B-MED
remains	O
as	O
a	O
homodimer	B-MED
.	O
However	O
,	O
the	O
mechanism	B-MED
for	O
events	O
after	O
dimerization	B-MED
in	O
breast	B-MED
cancer	I-MED
models	B-MED
is	O
not	O
clear	O
.	O
We	O
found	O
that	O
expressions	B-MED
of	O
alpha	B-MED
-	I-MED
smooth	I-MED
muscle	I-MED
actin	I-MED
(	O
ACTA2	B-MED
)	O
and	O
signal	B-MED
transducer	I-MED
and	I-MED
activator	I-MED
of	I-MED
transcription	I-MED
1	I-MED
(	O
STAT1	B-MED
)	O
significantly	O
increased	B-MED
with	O
transient	O
or	O
stable	O
overexpression	B-MED
of	O
HER2	B-MED
in	O
EGFR	B-MED
-	O
positive	B-MED
breast	B-MED
cancer	I-MED
cells	B-MED
.	O
ACTA2	B-MED
and	O
STAT1	B-MED
expression	B-MED
was	O
also	O
increased	B-MED
in	O
HER2	B-MED
-	O
positive	B-MED
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
In	O
contrast	O
,	O
ACTA2	B-MED
expression	B-MED
was	O
decreased	B-MED
by	O
HER2	B-MED
siRNA	I-MED
.	O
Next	O
,	O
we	O
investigated	O
the	O
co	O
-	O
relation	O
between	O
STAT1	B-MED
and	O
ACTA2	B-MED
expression	B-MED
.	O
Basal	O
ACTA2	B-MED
expression	B-MED
was	O
significantly	O
decreased	B-MED
by	O
treatment	B-MED
with	O
the	O
STAT1	B-MED
inhibitor	I-MED
fludarabine	B-MED
or	O
the	O
JAK2	B-MED
inhibitor	I-MED
AG490	B-MED
.	O
In	O
contrast	O
,	O
ACTA2	B-MED
expression	B-MED
was	O
increased	B-MED
by	O
STAT1	B-MED
overexpression	B-MED
.	O
Levels	O
of	O
ACTA2	B-MED
,	O
STAT1	B-MED
,	O
and	O
HER2	B-MED
were	O
increased	B-MED
and	O
relapse	O
free	B-MED
survival	I-MED
was	O
decreased	B-MED
in	O
high	B-MED
-	I-MED
risk	I-MED
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
We	O
also	O
investigated	B-MED
the	O
effect	O
of	O
ACTA2	B-MED
on	O
cell	B-MED
motility	I-MED
,	O
which	O
was	O
suppressed	B-MED
by	O
ACTA2	B-MED
shRNA	I-MED
overexpression	B-MED
in	O
MDA	B-MED
-	I-MED
MB231	I-MED
HER2	B-MED
and	O
4T1	B-MED
mammary	I-MED
carcinoma	I-MED
cells	I-MED
.	O
The	O
number	O
of	O
lung	B-MED
metastatic	I-MED
nodules	I-MED
was	O
significantly	O
decreased	B-MED
in	O
ACTA2	B-MED
knockdown	B-MED
mice	I-MED
.	O
Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	B-MED
of	O
ACTA2	B-MED
by	O
EGFR	B-MED
and	O
HER2	B-MED
dimerization	B-MED
was	O
regulated	O
through	O
a	O
JAK2	B-MED
/	O
STAT1	B-MED
signaling	B-MED
pathway	I-MED
,	O
and	O
aberrant	O
ACTA2	B-MED
expression	B-MED
expression	B-MED
accelerated	O
the	O
invasiveness	B-MED
and	O
metastasis	B-MED
of	O
breast	B-MED
cancer	I-MED
cells	B-MED
.	O
4	B-MED
-	I-MED
Anilino-2	I-MED
-	I-MED
pyridylquinazolines	I-MED
and	O
-	O
pyrimidines	B-MED
as	O
Highly	O
Potent	B-MED
and	O
Nontoxic	B-MED
Inhibitors	B-MED
of	O
Breast	B-MED
Cancer	I-MED
Resistance	I-MED
Protein	I-MED
(	O
ABCG2	B-MED
)	O
Multidrug	B-MED
resistance	I-MED
(	O
MDR	B-MED
)	O
mediated	O
by	O
ATP	B-MED
-	I-MED
binding	I-MED
cassette	I-MED
(	I-MED
ABC	I-MED
)	I-MED
transport	I-MED
proteins	I-MED
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B-MED
treatment	I-MED
of	O
cancer	B-MED
and	O
might	O
be	O
overcome	B-MED
by	O
inhibition	B-MED
of	O
the	O
transporter	B-MED
.	O
Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	B-MED
involved	O
in	O
the	O
transport	B-MED
process	I-MED
,	O
in	O
particular	O
for	O
breast	B-MED
cancer	I-MED
resistance	I-MED
protein	I-MED
(	O
BCRP	B-MED
/	O
ABCG2	B-MED
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B-MED
of	O
ABCG2	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
investigated	B-MED
a	O
systematic	O
series	O
of	O
4	B-MED
-	I-MED
substituted-2	I-MED
-	I-MED
pyridylquinazolines	I-MED
in	O
terms	O
of	O
their	O
inhibitory	B-MED
potency	B-MED
as	O
well	O
as	O
selectivity	B-MED
toward	O
ABCG2	B-MED
.	O
For	O
comparison	O
,	O
the	O
quinazoline	B-MED
scaffold	I-MED
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4	B-MED
-	I-MED
methylpyrimidine	I-MED
basic	O
structure	O
.	O
Furthermore	O
,	O
the	O
cytotoxicity	B-MED
and	O
the	O
ability	O
to	O
reverse	B-MED
MDR	B-MED
was	O
tested	O
with	O
the	O
chemotherapeutic	B-MED
agents	I-MED
SN-38	B-MED
and	O
mitoxantrone	B-MED
(	O
MX	B-MED
)	O
.	O
Interaction	B-MED
of	O
the	O
compounds	B-MED
with	O
ABCG2	B-MED
was	O
investigated	B-MED
by	O
a	O
colorimetric	B-MED
ATPase	B-MED
assay	B-MED
.	O
Enzyme	B-MED
kinetic	I-MED
studies	I-MED
were	O
carried	O
out	O
with	O
Hoechst	B-MED
33342	I-MED
as	O
fluorescent	B-MED
dye	I-MED
and	O
substrate	B-MED
of	O
ABCG2	B-MED
to	O
elucidate	O
the	O
compounds	B-MED
binding	B-MED
modes	I-MED
.	O
nursingstandard.com	B-MED
1	O
Nurse	B-MED
Donna	O
Wood	O
has	O
been	O
suspended	B-MED
for	O
2	O
months	B-MED
by	O
the	O
Nursing	B-MED
and	I-MED
Midwifery	I-MED
Council	I-MED
(	O
NMC	B-MED
)	O
for	O
concealing	B-MED
the	O
high	B-MED
temperature	I-MED
of	O
colleague	B-MED
Pauline	O
Cafferkey	O
,	O
who	O
later	O
developed	O
Ebola	B-MED
.	O
Read	O
more	O
:	O
rcni.com/donna-wood	B-MED
.	O
Voices	O
:	O
A	O
Conversation	B-MED
with	O
Allen	B-MED
J.	I-MED
Wilcox	I-MED
Allen	B-MED
James	I-MED
Wilcox	I-MED
was	O
born	O
on	O
30	O
September	O
1946	O
in	O
Columbus	B-MED
,	I-MED
OH	I-MED
.	O
He	O
studied	O
medicine	B-MED
at	O
the	O
University	B-MED
of	I-MED
Michigan	I-MED
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	B-MED
,	O
he	O
completed	B-MED
a	I-MED
master	I-MED
's	I-MED
degree	I-MED
in	O
maternal	B-MED
and	I-MED
child	I-MED
health	I-MED
(	O
1976	O
)	O
and	O
a	O
PhD	B-MED
in	O
epidemiology	B-MED
(	O
1979	O
)	O
at	O
the	O
University	B-MED
of	I-MED
North	I-MED
Carolina	I-MED
in	O
Chapel	B-MED
Hill	I-MED
.	O
After	O
graduation	B-MED
,	O
he	O
went	O
to	O
work	B-MED
at	O
the	O
National	B-MED
Institute	I-MED
of	I-MED
Environmental	I-MED
Health	I-MED
Sciences	I-MED
(	O
NIEHS	B-MED
,	O
one	O
of	O
the	O
US	B-MED
National	I-MED
Institutes	I-MED
of	I-MED
Health	I-MED
)	O
in	O
Durham	B-MED
,	I-MED
NC	I-MED
,	O
where	O
he	O
has	O
spent	O
his	O
career	B-MED
.	O
He	O
developed	O
a	O
research	B-MED
program	I-MED
in	O
reproductive	O
and	O
perinatal	B-MED
epidemiology	I-MED
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O
His	O
studies	O
include	O
the	O
early	B-MED
pregnancy	I-MED
study	O
,	O
which	O
documented	B-MED
the	O
extent	O
of	O
subclinical	B-MED
pregnancy	B-MED
loss	I-MED
in	O
humans	B-MED
and	O
established	B-MED
the	O
fertile	B-MED
days	I-MED
of	O
a	O
woman	B-MED
's	I-MED
menstrual	B-MED
cycle	I-MED
.	O
He	O
served	O
as	O
the	O
Chief	B-MED
of	I-MED
the	O
Epidemiology	B-MED
Branch	B-MED
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
Editor	B-MED
-	I-MED
in	I-MED
-	I-MED
Chief	I-MED
of	O
the	O
journal	B-MED
EPIDEMIOLOGY	B-MED
from	O
2001	O
to	O
2014	O
.	O
His	O
textbook	B-MED
,	O
Fertility	B-MED
and	I-MED
Pregnancy	I-MED
-	I-MED
An	I-MED
Epidemiologic	I-MED
Perspective	I-MED
,	O
was	O
published	B-MED
by	O
Oxford	B-MED
University	I-MED
Press	I-MED
in	O
2010	O
.	O
He	O
was	O
elected	B-MED
to	O
the	O
American	B-MED
Epidemiological	I-MED
Society	I-MED
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	B-MED
in	O
2003	O
.	O
He	O
also	O
served	O
as	O
president	B-MED
of	O
the	O
Society	B-MED
of	I-MED
Pediatric	I-MED
and	I-MED
Perinatal	I-MED
Epidemiological	I-MED
Research	I-MED
(	O
1996	O
)	O
and	O
the	O
president	B-MED
of	O
the	O
Society	B-MED
of	I-MED
Epidemiological	I-MED
Research	I-MED
(	O
1998	O
)	O
.	O
He	O
holds	O
adjunct	O
teaching	B-MED
appointments	B-MED
at	O
the	O
University	B-MED
of	I-MED
North	I-MED
Carolina	I-MED
,	O
Harvard	B-MED
University	I-MED
,	O
and	O
the	O
University	B-MED
of	I-MED
Bergen	I-MED
(	O
Norway	B-MED
)	O
,	O
which	O
awarded	B-MED
him	O
an	O
honorary	B-MED
doctoral	B-MED
degree	I-MED
in	O
2008	O
.	O
The	O
role	O
of	O
miR-451	B-MED
in	O
the	O
switching	O
between	O
proliferation	B-MED
and	O
migration	B-MED
in	O
malignant	B-MED
glioma	I-MED
cells	B-MED
:	O
AMPK	B-MED
signaling	B-MED
,	O
mTOR	B-MED
modulation	B-MED
and	O
Rac1	B-MED
activation	B-MED
required	O
Glioblastoma	B-MED
multiforme	I-MED
(	O
GBM	B-MED
)	O
,	O
WHO	B-MED
grade	I-MED
IV	I-MED
astrocytoma	I-MED
,	O
is	O
the	O
most	O
common	O
primary	B-MED
neoplasm	I-MED
of	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
(	O
CNS	B-MED
)	O
and	O
has	O
the	O
highest	O
malignancy	B-MED
and	O
mortality	B-MED
rates	I-MED
.	O
The	O
invasive	B-MED
nature	I-MED
of	O
GBM	B-MED
complicates	O
surgical	B-MED
resection	I-MED
and	O
restricts	O
chemotherapeutic	B-MED
access	I-MED
,	O
contributing	O
to	O
poor	O
patient	B-MED
prognosis	B-MED
.	O
The	O
migration	B-MED
of	O
tumor	B-MED
cells	I-MED
is	O
closely	O
related	O
to	O
the	O
tumor	B-MED
cell	I-MED
proliferation	B-MED
.	O
The	O
acquisition	B-MED
of	O
migratory	B-MED
capability	B-MED
,	O
in	O
addition	O
to	O
intracellular	B-MED
factors	B-MED
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial	B-MED
mechanism	I-MED
during	O
the	O
progression	B-MED
of	O
invasion	B-MED
.	O
Using	O
qRT	B-MED
-	I-MED
PCR	I-MED
analysis	B-MED
,	O
we	O
determined	O
that	O
the	O
expression	B-MED
of	O
miR-451	B-MED
in	O
glioma	B-MED
tissue	B-MED
was	O
lower	O
than	O
in	O
control	B-MED
brain	I-MED
tissue	I-MED
,	O
especially	O
in	O
the	O
central	B-MED
portions	B-MED
of	O
the	O
tumor	B-MED
.	O
In	O
glioma	B-MED
cell	B-MED
lines	I-MED
,	O
we	O
found	O
that	O
decreased	B-MED
miR-451	B-MED
expression	B-MED
suppressed	B-MED
tumor	B-MED
cell	I-MED
proliferation	B-MED
but	O
enhanced	O
migration	B-MED
with	O
a	O
concomitant	B-MED
low	O
level	O
of	O
CAB39	B-MED
/	O
AMPK	B-MED
/	O
mTOR	B-MED
pathway	B-MED
activation	I-MED
and	O
high	O
level	O
of	O
Rac1	B-MED
/	O
cofilin	B-MED
pathway	B-MED
activation	I-MED
,	O
respectively	O
.	O
Notably	O
,	O
the	O
effect	O
of	O
miR-451	B-MED
on	O
cytological	B-MED
behavior	I-MED
and	O
on	O
the	O
activation	B-MED
of	O
mTOR	B-MED
and	O
Rac1	B-MED
was	O
limited	O
when	O
AMPKα1	B-MED
expression	B-MED
was	O
knocked	O
-	O
down	O
with	O
a	O
synthetic	B-MED
shRNA	B-MED
.	O
We	O
suggest	O
that	O
the	O
glioma	B-MED
microenvironment	B-MED
results	O
in	O
heterogeneity	B-MED
of	O
miR-451	B-MED
expression	B-MED
.	O
Our	O
data	O
indicated	O
that	O
miR-451	B-MED
relays	O
environmental	O
signals	O
by	O
upregulating	B-MED
the	O
activity	O
of	O
AMPK	B-MED
signaling	B-MED
,	O
thereby	O
modulating	B-MED
the	O
activation	B-MED
of	O
mTOR	B-MED
and	O
Rac1	B-MED
/	O
cofilin	B-MED
which	O
,	O
in	O
turn	O
,	O
play	O
key	O
roles	O
in	O
glioma	B-MED
cell	O
proliferation	B-MED
and	O
migration	B-MED
,	O
respectively	O
.	O
Our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	B-MED
target	O
which	O
,	O
while	O
suppressing	B-MED
tumor	B-MED
cell	I-MED
proliferation	B-MED
,	O
could	O
also	O
promote	O
cell	B-MED
infiltration	B-MED
.	O
The	O
role	O
of	O
P2X7	B-MED
receptors	I-MED
in	O
a	O
rodent	B-MED
PCP	B-MED
-	O
induced	B-MED
schizophrenia	B-MED
model	B-MED
P2X7	B-MED
receptors	I-MED
(	O
P2X7Rs	B-MED
)	O
are	O
ligand	B-MED
-	I-MED
gated	I-MED
ion	I-MED
channels	I-MED
sensitive	B-MED
to	O
extracellular	B-MED
ATP	B-MED
.	O
Here	O
we	O
examined	B-MED
for	O
the	O
first	O
time	O
the	O
role	O
of	O
P2X7R	B-MED
in	O
an	O
animal	B-MED
model	I-MED
of	O
schizophrenia	B-MED
.	O
Using	O
the	O
PCP	B-MED
induced	B-MED
schizophrenia	B-MED
model	B-MED
we	O
show	O
that	O
both	O
genetic	B-MED
deletion	I-MED
and	O
pharmacological	B-MED
inhibition	B-MED
of	O
P2X7Rs	B-MED
alleviate	B-MED
schizophrenia	B-MED
-	I-MED
like	I-MED
behavioral	B-MED
alterations	B-MED
.	O
In	O
P2rx7+/+	B-MED
mice	B-MED
,	O
PCP	B-MED
induced	B-MED
hyperlocomotion	B-MED
,	O
stereotype	B-MED
behavior	I-MED
,	O
ataxia	B-MED
and	O
social	B-MED
withdrawal	I-MED
.	O
In	O
P2X7	B-MED
receptor	I-MED
deficient	B-MED
mice	B-MED
(	O
P2rx7-/-	B-MED
)	O
,	O
the	O
social	B-MED
interactions	I-MED
were	O
increased	B-MED
,	O
whereas	O
the	O
PCP	B-MED
induced	B-MED
hyperlocomotion	B-MED
and	O
stereotype	B-MED
behavior	I-MED
were	O
alleviated	B-MED
.	O
The	O
selective	O
P2X7	B-MED
receptor	I-MED
antagonist	I-MED
JNJ-47965567	B-MED
partly	O
replicated	O
the	O
effect	B-MED
of	I-MED
gene	B-MED
deficiency	I-MED
on	O
PCP	B-MED
-	O
induced	B-MED
behavioral	B-MED
changes	I-MED
and	O
counteracted	O
PCP	B-MED
-	O
induced	B-MED
social	B-MED
withdrawal	I-MED
.	O
We	O
also	O
show	O
that	O
PCP	B-MED
treatment	B-MED
upregulates	B-MED
and	O
increases	B-MED
the	O
functional	B-MED
responsiveness	B-MED
of	O
P2X7Rs	B-MED
in	O
the	O
prefrontal	B-MED
cortex	I-MED
of	O
young	B-MED
adult	I-MED
animals	B-MED
.	O
The	O
amplitude	B-MED
of	O
NMDA	B-MED
evoked	B-MED
currents	B-MED
recorded	O
from	O
layer	B-MED
V	I-MED
pyramidal	I-MED
neurons	I-MED
of	O
cortical	B-MED
slices	O
were	O
slightly	O
decreased	B-MED
by	O
both	O
genetic	B-MED
deletion	I-MED
of	O
P2rx7	B-MED
and	O
by	O
JNJ-47965567	B-MED
.	O
PCP	B-MED
induced	B-MED
alterations	B-MED
in	O
mRNA	B-MED
expression	I-MED
encoding	O
schizophrenia	B-MED
-	I-MED
related	I-MED
genes	B-MED
,	O
such	O
as	O
NR2A	B-MED
,	O
NR2B	B-MED
,	O
neuregulin	B-MED
1	I-MED
,	O
NR1	B-MED
and	O
GABA	B-MED
α1	I-MED
subunit	O
were	O
absent	B-MED
in	O
the	O
PFC	O
of	O
young	B-MED
adult	I-MED
P2rx7-/-	B-MED
animals	B-MED
.	O
Our	O
findings	B-MED
point	O
to	O
P2X7R	B-MED
as	O
a	O
potential	B-MED
therapeutic	B-MED
target	B-MED
in	O
schizophrenia	B-MED
.	O
Functional	B-MED
adaptation	I-MED
of	O
crustacean	B-MED
exoskeletal	B-MED
elements	B-MED
through	O
structural	B-MED
and	O
compositional	B-MED
diversity	B-MED
:	O
a	O
combined	B-MED
experimental	B-MED
and	O
theoretical	B-MED
study	I-MED
The	O
crustacean	B-MED
cuticle	B-MED
is	O
a	O
composite	B-MED
material	B-MED
that	O
covers	O
the	O
whole	O
animal	B-MED
and	O
forms	O
the	O
continuous	B-MED
exoskeleton	I-MED
.	O
Nano	B-MED
-	I-MED
fibers	I-MED
composed	O
of	O
chitin	B-MED
and	O
protein	B-MED
molecules	I-MED
form	O
most	O
of	O
the	O
organic	B-MED
matrix	B-MED
of	O
the	O
cuticle	B-MED
that	O
,	O
at	O
the	O
macroscale	B-MED
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	B-MED
levels	B-MED
.	O
At	O
least	O
two	O
of	O
them	O
,	O
the	O
exo-	B-MED
and	O
endocuticle	B-MED
,	O
contain	O
a	O
mineral	B-MED
phase	I-MED
of	O
mainly	O
Mg	B-MED
-	O
calcite	B-MED
,	O
amorphous	B-MED
calcium	B-MED
carbonate	I-MED
and	O
phosphate	B-MED
.	O
The	O
high	O
number	O
of	O
hierarchical	B-MED
levels	B-MED
and	O
the	O
compositional	B-MED
diversity	B-MED
provide	O
a	O
high	O
degree	B-MED
of	I-MED
freedom	I-MED
for	O
varying	B-MED
the	O
physical	B-MED
,	O
in	O
particular	O
mechanical	B-MED
,	O
properties	B-MED
of	O
the	O
material	B-MED
.	O
This	O
makes	O
the	O
cuticle	B-MED
a	O
versatile	B-MED
material	I-MED
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	B-MED
elements	B-MED
that	O
are	O
adapted	B-MED
to	O
different	O
functions	B-MED
and	O
the	O
eco	B-MED
-	I-MED
physiological	I-MED
strains	I-MED
of	O
individual	B-MED
species	I-MED
.	O
This	O
review	B-MED
presents	O
our	O
recent	O
analytical	B-MED
,	O
experimental	B-MED
and	O
theoretical	B-MED
studies	I-MED
on	O
the	O
cuticle	B-MED
,	O
summarising	O
at	O
which	O
hierarchical	B-MED
levels	B-MED
structure	B-MED
and	O
composition	B-MED
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical	B-MED
properties	I-MED
.	O
We	O
describe	O
our	O
multi	B-MED
-	I-MED
scale	I-MED
hierarchical	I-MED
modeling	I-MED
approach	I-MED
based	O
on	O
the	O
results	B-MED
from	O
these	O
studies	B-MED
,	O
aiming	O
at	O
systematically	B-MED
predicting	B-MED
the	O
structure	B-MED
-	O
composition	B-MED
-	O
property	B-MED
relations	B-MED
of	O
cuticle	B-MED
composites	B-MED
from	O
the	O
molecular	B-MED
level	B-MED
to	O
the	O
macro	B-MED
-	I-MED
scale	I-MED
.	O
This	O
modeling	B-MED
approach	I-MED
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	B-MED
of	O
optimized	O
biomimetic	B-MED
materials	I-MED
within	O
a	O
knowledge	B-MED
-	I-MED
based	I-MED
design	I-MED
approach	I-MED
.	O
Mechanisms	O
of	O
Global	B-MED
Cerebral	B-MED
Edema	I-MED
Formation	O
in	O
Aneurysmal	B-MED
Subarachnoid	I-MED
Hemorrhage	I-MED
A	O
growing	O
body	O
of	O
clinical	B-MED
literature	B-MED
emphasizes	O
the	O
impact	O
of	O
cerebral	B-MED
edema	I-MED
in	O
early	B-MED
brain	I-MED
injury	I-MED
following	O
aneurysmal	B-MED
subarachnoid	I-MED
hemorrhage	I-MED
(	O
aSAH	B-MED
)	O
.	O
Aneurysm	B-MED
rupture	I-MED
itself	O
initiates	O
global	B-MED
cerebral	B-MED
edema	I-MED
in	O
up	O
to	O
two	O
thirds	O
of	O
cases	O
.	O
Although	O
cerebral	B-MED
edema	I-MED
is	O
not	O
a	O
universal	O
feature	O
of	O
aSAH	B-MED
,	O
it	O
portends	O
a	O
poor	O
clinical	B-MED
course	I-MED
,	O
with	O
quantitative	B-MED
analysis	I-MED
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	B-MED
edema	I-MED
and	O
poor	B-MED
outcome	I-MED
,	O
including	O
mortality	O
and	O
cognitive	O
deficits	O
.	O
Mechanistically	O
,	O
global	B-MED
cerebral	B-MED
edema	I-MED
has	O
been	O
linked	O
to	O
global	B-MED
ischemia	B-MED
at	O
the	O
time	O
of	O
aneurysm	B-MED
rupture	I-MED
,	O
dysfunction	B-MED
of	O
autoregulation	B-MED
,	O
blood	B-MED
breakdown	I-MED
products	B-MED
,	O
neuroinflammation	B-MED
,	O
and	O
hyponatremia	B-MED
/	O
endocrine	B-MED
abnormalities	I-MED
.	O
At	O
a	O
molecular	B-MED
level	B-MED
,	O
several	O
culprits	O
have	O
been	O
identified	O
,	O
including	O
aquaporin-4	B-MED
,	O
matrix	B-MED
metalloproteinase-9	I-MED
,	O
SUR1	B-MED
-	O
TRPM4	B-MED
cation	I-MED
channels	I-MED
,	O
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
,	O
bradykinin	B-MED
,	O
and	O
others	O
.	O
Here	O
,	O
we	O
review	O
these	O
cellular	B-MED
and	O
molecular	B-MED
mechanisms	O
of	O
global	B-MED
cerebral	B-MED
edema	I-MED
formation	O
in	O
aSAH	B-MED
.	O
Given	O
the	O
importance	O
of	O
edema	B-MED
to	O
the	O
outcome	O
of	O
patients	B-MED
with	O
aSAH	B-MED
and	O
its	O
status	B-MED
as	O
a	O
highly	O
modifiable	O
pathological	B-MED
process	I-MED
,	O
a	O
better	O
understanding	O
of	O
cerebral	B-MED
edema	I-MED
in	O
aSAH	B-MED
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	B-MED
therapies	I-MED
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	B-MED
disease	B-MED
.	O
Association	B-MED
of	O
Exclusive	B-MED
Breastfeeding	I-MED
Duration	B-MED
With	O
Systemic	B-MED
Inflammation	I-MED
Markers	B-MED
in	O
Adolescents	B-MED
:	O
A	O
Cross	B-MED
-	I-MED
Sectional	I-MED
Study	I-MED
Breastfeeding	B-MED
duration	I-MED
has	O
been	O
associated	B-MED
with	I-MED
less	B-MED
low	B-MED
-	I-MED
grade	I-MED
inflammation	B-MED
in	O
healthy	B-MED
adolescents	B-MED
,	O
but	O
there	O
is	O
scarce	B-MED
information	B-MED
regarding	O
obese	B-MED
subjects	O
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	B-MED
breastfeeding	I-MED
is	O
related	O
to	O
serum	B-MED
concentrations	I-MED
of	O
inflammatory	B-MED
markers	B-MED
in	O
a	O
population	B-MED
of	O
Spanish	B-MED
adolescents	B-MED
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
was	O
performed	B-MED
on	O
1,001	O
adolescents	B-MED
(	O
13.2	O
±	O
1.2	O
years	O
)	O
randomly	O
recruited	O
from	O
schools	B-MED
in	O
southeast	B-MED
Spain	B-MED
.	O
Data	B-MED
on	O
breastfeeding	B-MED
duration	I-MED
were	O
collected	B-MED
via	O
a	O
parental	B-MED
questionnaire	I-MED
.	O
Interleukin-6	B-MED
(	O
IL-6	B-MED
)	O
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
-	I-MED
alpha	I-MED
(	O
TNF	B-MED
-	I-MED
α	I-MED
)	O
were	O
determined	B-MED
by	I-MED
enzyme	B-MED
-	I-MED
linked	I-MED
immunosorbent	I-MED
assay	I-MED
.	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
was	O
determined	B-MED
by	I-MED
solid	B-MED
-	I-MED
phase	I-MED
chemiluminescent	I-MED
immunometric	I-MED
assay	I-MED
.	O
Nonadjusted	O
and	O
adjusted	O
multivariate	B-MED
correlation	B-MED
analyses	I-MED
confirmed	B-MED
a	O
strong	B-MED
association	B-MED
(	O
p	O
<	O
.001	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
)	O
between	O
the	O
three	O
markers	B-MED
of	O
inflammation	B-MED
and	O
exclusive	B-MED
breastfeeding	I-MED
duration	B-MED
.	O
No	B-MED
significant	I-MED
differences	B-MED
were	O
observed	B-MED
for	O
IL-6	B-MED
,	O
TNF	B-MED
-	I-MED
α	I-MED
,	O
and	O
CRP	B-MED
serum	B-MED
concentrations	I-MED
among	O
normal	B-MED
weight	I-MED
,	O
overweight	B-MED
,	O
and	O
obese	B-MED
adolescents	B-MED
,	O
except	B-MED
for	I-MED
IL-6	B-MED
between	O
normal	B-MED
weight	I-MED
and	O
obese	B-MED
subjects	B-MED
.	O
Likewise	O
,	O
no	B-MED
significant	I-MED
association	B-MED
was	O
found	B-MED
between	O
these	O
markers	B-MED
of	O
inflammation	B-MED
and	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
z	B-MED
-	I-MED
score	I-MED
.	O
We	O
found	B-MED
a	O
possible	B-MED
association	B-MED
between	O
inflammatory	B-MED
markers	B-MED
and	O
exclusive	B-MED
breastfeeding	I-MED
duration	B-MED
in	O
adolescents	B-MED
,	O
regardless	B-MED
of	O
their	O
BMI	B-MED
.	O
This	O
finding	B-MED
suggests	B-MED
that	O
increased	B-MED
body	B-MED
weight	I-MED
or	O
obesity	B-MED
might	O
not	O
mediate	O
the	O
association	B-MED
between	O
breastfeeding	B-MED
and	O
inflammation	B-MED
.	O
These	O
results	B-MED
contribute	O
to	O
the	O
understanding	B-MED
of	O
the	O
relationship	B-MED
between	O
breastfeeding	B-MED
and	O
inflammatory	B-MED
markers	B-MED
in	O
adolescents	B-MED
.	O
The	O
construction	B-MED
of	O
three	B-MED
-	I-MED
dimensional	I-MED
composite	B-MED
fibrous	B-MED
macrostructures	B-MED
with	B-MED
nanotextures	I-MED
for	O
biomedical	B-MED
applications	B-MED
The	O
development	O
of	O
modern	O
biomedical	B-MED
nanotechnology	B-MED
requires	O
three	B-MED
-	I-MED
dimensional	I-MED
macrostructures	B-MED
with	B-MED
nanotextures	I-MED
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	B-MED
in	O
intricate	O
biological	B-MED
systems	I-MED
.	O
Additionally	O
,	O
the	O
restoration	B-MED
and	O
regeneration	B-MED
of	O
some	O
specific	O
body	B-MED
tissues	I-MED
and	O
organs	B-MED
rely	O
on	O
the	O
function	O
of	O
conductive	B-MED
polymers	I-MED
,	O
which	O
can	O
provide	O
electrical	B-MED
cues	B-MED
for	O
cells	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
fabricated	O
three	B-MED
-	I-MED
dimensional	I-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
of	O
polycaprolactone	B-MED
(	O
PCL	B-MED
)	O
with	O
different	O
concentrations	B-MED
of	O
polyaniline	B-MED
(	O
PANi	B-MED
)	O
by	O
employing	O
an	O
improved	O
electrospinning	B-MED
technology	I-MED
with	O
a	O
specially	O
designed	O
collector	O
.	O
The	O
3D	B-MED
structures	B-MED
possessed	O
cap	B-MED
-	I-MED
like	I-MED
macrostructures	I-MED
with	O
centimetre	B-MED
-	I-MED
scale	I-MED
thickness	B-MED
and	O
interconnected	O
pore	B-MED
nanotextures	I-MED
with	O
nanometre	B-MED
-	I-MED
scale	I-MED
nanofibres	B-MED
.	O
To	O
estimate	O
the	O
biocompatibility	B-MED
of	O
the	O
3D	B-MED
PCL	B-MED
/	O
PANi	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
,	O
mouse	B-MED
myoblasts	B-MED
(	O
C2C12	B-MED
cells	I-MED
)	O
were	O
cultured	O
as	O
model	B-MED
cells	B-MED
.	O
The	O
initial	O
responses	O
of	O
C2C12	B-MED
cells	I-MED
to	O
the	O
3D	B-MED
PCL	B-MED
/	O
PANi	B-MED
composite	B-MED
macrostructures	B-MED
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
PCL	B-MED
,	O
that	O
is	O
,	O
the	O
cells	B-MED
exhibited	O
typical	O
myoblast	B-MED
-	I-MED
like	I-MED
morphologies	I-MED
with	O
obvious	O
pseudopodia	B-MED
and	O
the	O
moderate	O
incorporation	O
(	O
less	O
than	O
2.0	O
wt%	O
)	O
of	O
conductive	O
PANi	B-MED
facilitated	O
cell	B-MED
proliferation	I-MED
,	O
which	O
indicated	O
that	O
PANi	B-MED
has	O
appreciable	O
cell	B-MED
affinity	I-MED
.	O
Moreover	O
,	O
the	O
addition	O
of	O
conductive	B-MED
PANi	B-MED
to	O
the	O
3D	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
considerably	O
enhanced	O
myoblast	B-MED
differentiation	I-MED
and	O
myotube	B-MED
maturation	I-MED
.	O
These	O
results	O
suggest	O
that	O
electrospun	B-MED
3D	B-MED
PCL	B-MED
/	O
PANi	B-MED
composite	B-MED
nanofibre	B-MED
macrostructures	B-MED
macrostructures	B-MED
would	O
have	O
promising	O
applications	B-MED
in	O
tissue	B-MED
engineering	I-MED
.	O
Chordoma	B-MED
dedifferentiation	I-MED
after	O
proton	B-MED
beam	I-MED
therapy	I-MED
:	O
a	O
case	B-MED
report	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
Chordoma	B-MED
is	O
a	O
rare	B-MED
invasive	B-MED
bone	B-MED
tumor	I-MED
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	B-MED
.	O
A	O
total	O
of	O
three	O
primary	B-MED
histological	B-MED
varieties	I-MED
have	O
been	O
identified	B-MED
:	O
conventional	B-MED
,	O
chondroid	B-MED
,	O
and	O
dedifferentiated	B-MED
.	O
We	O
report	B-MED
a	O
case	B-MED
of	O
an	O
8	O
-	O
year	O
-	O
old	O
white	B-MED
girl	B-MED
who	O
presented	O
with	O
conventional	B-MED
chordoma	I-MED
,	O
was	O
treated	B-MED
with	O
surgical	B-MED
resection	I-MED
and	O
mixed	B-MED
proton	B-MED
and	O
photon	B-MED
beam	I-MED
therapy	I-MED
,	O
and	O
had	O
a	O
recurrence	B-MED
in	O
the	O
resection	B-MED
cavity	I-MED
2.5	O
years	O
later	O
with	O
dedifferentiated	B-MED
morphology	I-MED
.	O
The	O
recurrent	B-MED
tumor	I-MED
did	O
not	O
express	B-MED
brachyury	B-MED
,	O
a	O
recently	B-MED
identified	B-MED
protein	B-MED
specific	B-MED
to	O
tissue	B-MED
of	O
notochordal	B-MED
origin	B-MED
.	O
The	O
short	B-MED
time	B-MED
period	I-MED
between	O
radiation	B-MED
therapy	I-MED
and	O
dedifferentiation	B-MED
,	O
low	B-MED
dose	I-MED
of	O
photons	B-MED
,	O
and	O
rarity	B-MED
of	O
dedifferentiated	B-MED
skull	I-MED
base	I-MED
chordomas	I-MED
in	O
pediatric	B-MED
patients	B-MED
should	O
alert	B-MED
clinicians	B-MED
to	O
the	O
possibility	B-MED
of	O
chordoma	B-MED
dedifferentiation	I-MED
after	O
proton	B-MED
beam	I-MED
therapy	I-MED
.	O
Evaluation	B-MED
of	O
Spontaneous	B-MED
Bone	B-MED
Regeneration	I-MED
after	O
Enucleation	B-MED
of	O
Large	B-MED
Cysts	B-MED
of	O
the	O
Jaws	B-MED
using	O
Radiographic	B-MED
Computed	B-MED
Software	B-MED
Spontaneous	B-MED
regeneration	B-MED
of	I-MED
bone	I-MED
is	O
commonly	B-MED
seen	O
in	O
the	O
small	B-MED
surgical	B-MED
defects	B-MED
caused	O
by	O
enucleation	B-MED
of	O
cysts	B-MED
.	O
However	O
,	O
in	O
case	O
of	O
large	B-MED
surgical	B-MED
defects	B-MED
caused	O
by	O
the	O
enucleation	B-MED
,	O
spontaneous	B-MED
regeneration	B-MED
of	I-MED
bone	I-MED
is	O
a	O
rare	B-MED
phenomenon	B-MED
and	O
it	O
depends	B-MED
on	O
factors	B-MED
,	O
such	O
as	O
age	B-MED
of	O
the	O
patient	B-MED
,	O
intact	B-MED
periosteum	B-MED
,	O
and	O
proper	O
stabilization	B-MED
.	O
The	O
study	B-MED
included	B-MED
16	O
patients	B-MED
,	O
who	O
reported	B-MED
to	O
the	O
department	B-MED
of	I-MED
oral	I-MED
and	I-MED
maxillofacial	I-MED
surgery	I-MED
with	O
the	O
complaint	B-MED
of	O
pain	B-MED
and	O
swelling	B-MED
in	O
the	O
jaws	B-MED
diagnosed	B-MED
as	O
cyst	B-MED
.	O
The	O
sample	B-MED
included	B-MED
equal	O
numbers	B-MED
of	O
male	B-MED
and	O
female	B-MED
subjects	B-MED
aged	B-MED
between	O
15	O
and	O
40	O
years	O
.	O
Panoramic	B-MED
radiographs	I-MED
were	O
taken	O
pre-	B-MED
and	O
postoperatively	B-MED
on	O
day	O
2	O
of	O
the	O
enucleation	B-MED
.	O
The	O
dimensions	B-MED
of	O
the	O
cyst	B-MED
were	O
evaluated	B-MED
on	O
the	O
radiograph	B-MED
according	O
to	O
the	O
proforma	B-MED
.	O
Subsequent	B-MED
radiographs	B-MED
were	O
taken	O
at	O
regular	B-MED
intervals	B-MED
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	B-MED
parameters	B-MED
and	O
were	O
analyzed	B-MED
using	O
MCID	B-MED
™	I-MED
analysis	I-MED
software	B-MED
of	O
imaging	B-MED
research	I-MED
.	O
Mean	B-MED
reduction	B-MED
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	B-MED
cavity	B-MED
size	B-MED
and	O
increase	B-MED
in	O
the	O
mean	B-MED
density	B-MED
up	O
to	O
59	O
and	O
90.2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	B-MED
respectively	O
.	O
Spontaneous	B-MED
bone	B-MED
regeneration	I-MED
was	O
seen	O
even	O
after	O
primary	B-MED
closure	B-MED
of	O
the	O
large	B-MED
cystic	B-MED
defect	B-MED
without	O
the	O
need	B-MED
for	O
placement	B-MED
of	O
foreign	B-MED
substances	I-MED
or	O
grafts	B-MED
and	O
it	O
also	O
eliminated	B-MED
the	O
complications	B-MED
resulting	B-MED
from	I-MED
placement	B-MED
of	O
foreign	B-MED
substance	I-MED
.	O
Further	O
studies	B-MED
are	O
required	B-MED
in	O
a	O
larger	B-MED
sample	B-MED
with	O
longer	B-MED
follow	B-MED
-	I-MED
up	I-MED
durations	B-MED
to	O
confirm	B-MED
the	O
outcome	B-MED
of	I-MED
the	I-MED
present	I-MED
work	I-MED
for	O
the	O
benefit	B-MED
of	O
patients	B-MED
.	O
The	O
present	B-MED
study	B-MED
depicted	O
that	O
spontaneous	B-MED
bone	B-MED
regeneration	I-MED
can	O
occur	O
with	O
accepted	B-MED
results	B-MED
after	O
simple	B-MED
enucleation	B-MED
of	O
jaw	B-MED
cyst	B-MED
without	O
the	O
aid	B-MED
of	O
any	O
graft	B-MED
material	I-MED
.	O
Hence	O
,	O
simple	B-MED
enucleation	B-MED
may	O
be	O
considered	B-MED
as	O
a	O
first	B-MED
line	I-MED
of	I-MED
treatment	I-MED
modality	B-MED
for	O
cystic	B-MED
lesion	B-MED
of	O
the	O
jaws	B-MED
.	O
This	O
simplifies	O
the	O
surgical	B-MED
procedure	I-MED
,	O
decreases	B-MED
the	O
economic	B-MED
and	O
biologic	B-MED
costs	B-MED
,	O
and	O
reduces	B-MED
the	O
risk	B-MED
of	O
postoperative	B-MED
complications	I-MED
.	O
Follow	B-MED
-	I-MED
up	I-MED
is	O
necessary	O
along	O
with	O
patient	B-MED
's	I-MED
compliance	B-MED
for	O
the	O
success	B-MED
of	I-MED
treatment	I-MED
.	O
Impact	B-MED
of	O
cofactor	B-MED
-	O
binding	B-MED
loop	I-MED
mutations	B-MED
on	O
thermotolerance	B-MED
and	O
activity	B-MED
of	O
E.	B-MED
coli	I-MED
transketolase	B-MED
Improvement	B-MED
of	O
thermostability	B-MED
in	O
engineered	B-MED
enzymes	I-MED
can	O
allow	O
biocatalysis	B-MED
on	O
substrates	B-MED
with	O
poor	O
aqueous	B-MED
solubility	B-MED
.	O
Denaturation	B-MED
of	O
the	O
cofactor	B-MED
-	O
binding	B-MED
loops	I-MED
of	O
Escherichia	B-MED
coli	I-MED
transketolase	B-MED
(	O
TK	B-MED
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	B-MED
of	O
enzyme	B-MED
activity	I-MED
under	O
conditions	B-MED
of	O
high	B-MED
pH	B-MED
or	O
urea	B-MED
.	O
Incubation	B-MED
at	O
temperatures	B-MED
just	O
below	O
the	O
thermal	B-MED
melting	I-MED
transition	I-MED
,	O
above	O
which	O
the	O
protein	B-MED
aggregates	B-MED
,	O
was	O
also	O
found	O
to	O
anneal	B-MED
the	O
enzyme	B-MED
to	O
give	O
an	O
increased	B-MED
specific	O
activity	B-MED
.	O
The	O
potential	O
role	B-MED
of	O
cofactor	B-MED
-	O
binding	B-MED
loop	I-MED
instability	B-MED
in	O
this	O
process	O
remained	O
unclear	O
.	O
In	O
this	O
work	O
,	O
the	O
two	O
cofactor	B-MED
-	O
binding	B-MED
loops	I-MED
(	O
residues	B-MED
185	I-MED
-	I-MED
192	I-MED
and	O
382	B-MED
-	I-MED
392	I-MED
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	B-MED
from	O
the	O
thermostable	B-MED
Thermus	B-MED
thermophilus	I-MED
TK	B-MED
and	O
variants	B-MED
assessed	B-MED
for	O
their	O
impact	B-MED
on	O
both	O
thermostability	B-MED
and	O
activity	B-MED
.	O
Cofactor	B-MED
-	I-MED
binding	I-MED
loop	I-MED
2	I-MED
variants	B-MED
had	O
detrimental	B-MED
effects	I-MED
on	O
specific	O
activity	B-MED
at	O
elevated	B-MED
temperatures	B-MED
,	O
whereas	O
the	O
H192P	B-MED
mutation	I-MED
in	O
cofactor	B-MED
-	I-MED
binding	I-MED
loop	I-MED
1	I-MED
resulted	O
in	O
a	O
two	O
-	O
fold	O
improved	O
stability	B-MED
to	O
inactivation	B-MED
at	O
elevated	B-MED
temperatures	B-MED
,	O
and	O
increased	B-MED
the	O
critical	B-MED
onset	I-MED
temperature	I-MED
for	O
aggregation	B-MED
.	O
The	O
specific	O
activity	B-MED
of	O
H192P	B-MED
was	O
3	O
-	O
fold	O
and	O
19	O
-	O
fold	O
higher	B-MED
than	O
that	O
for	O
wild	B-MED
-	I-MED
type	I-MED
at	O
60	O
°	O
C	O
and	O
65	O
°	O
C	O
respectively	O
,	O
and	O
also	O
remained	O
2.7	O
-	O
4	O
fold	O
higher	B-MED
after	O
re	B-MED
-	I-MED
cooling	I-MED
from	O
pre	B-MED
-	I-MED
incubations	I-MED
at	O
either	O
55	O
°	O
C	O
or	O
60	O
°	O
C	O
for	O
1h	O
.	O
Interestingly	O
,	O
H192P	B-MED
was	O
also	O
2	O
-	O
times	O
more	O
active	B-MED
than	O
wild	B-MED
-	I-MED
type	I-MED
TK	B-MED
at	O
25	O
°	O
C	O
.	O
Optimal	B-MED
activity	B-MED
was	O
achieved	O
at	O
60	O
°	O
C	O
for	O
H192P	B-MED
compared	O
to	O
55	O
°	O
C	O
for	O
wild	B-MED
type	I-MED
.	O
These	O
results	O
show	O
that	O
cofactor	B-MED
-	I-MED
binding	I-MED
loop	I-MED
1	I-MED
,	O
plays	O
a	O
pivotal	O
role	B-MED
in	O
partial	B-MED
denaturation	B-MED
and	O
aggregation	B-MED
at	O
elevated	B-MED
temperatures	B-MED
.	O
Furthermore	O
,	O
a	O
single	B-MED
rigidifying	I-MED
mutation	I-MED
within	O
this	O
loop	B-MED
can	O
significantly	O
improve	O
the	O
enzyme	B-MED
specific	I-MED
activity	I-MED
,	O
as	O
well	O
as	O
the	O
stability	B-MED
to	O
thermal	B-MED
denaturation	B-MED
and	O
aggregation	B-MED
,	O
to	O
give	O
an	O
increased	B-MED
temperature	B-MED
optimum	B-MED
for	O
activity	B-MED
.	O
Draft	B-MED
Genome	I-MED
Sequence	I-MED
of	O
the	O
Soil	B-MED
Isolate	B-MED
Lysinibacillus	B-MED
fusiformis	I-MED
M5	I-MED
,	O
a	O
Potential	B-MED
Hypoxanthine	B-MED
Producer	O
Lysinibacillus	B-MED
fusiformis	I-MED
strain	I-MED
M5	I-MED
is	O
a	O
potential	B-MED
hypoxanthine	B-MED
producer	O
that	O
was	O
isolated	B-MED
from	O
clay	B-MED
soil	B-MED
.	O
Here	O
,	O
we	O
present	O
the	O
draft	B-MED
genome	I-MED
sequence	I-MED
that	O
was	O
annotated	B-MED
in	O
order	O
to	O
facilitate	O
future	O
studies	B-MED
of	O
L.	B-MED
fusiformis	I-MED
M5	I-MED
.	I-MED
Reliability	B-MED
of	O
Fear	B-MED
Assessment	I-MED
in	O
Growing	B-MED
Pigs	B-MED
Exposed	B-MED
to	I-MED
a	O
Novel	B-MED
Object	B-MED
Test	B-MED
in	O
Commercial	B-MED
Conditions	B-MED
The	O
objective	B-MED
of	O
this	O
study	O
was	O
to	O
assess	B-MED
the	O
reliability	B-MED
and	O
feasibility	B-MED
of	O
a	O
novel	B-MED
object	B-MED
test	B-MED
assessing	B-MED
fear	I-MED
in	O
pigs	B-MED
in	O
commercial	B-MED
conditions	B-MED
.	O
A	O
total	O
of	O
18	O
commercial	B-MED
farms	B-MED
were	O
visited	O
,	O
and	O
321	O
pens	B-MED
housing	I-MED
4,220	O
growing	B-MED
pigs	B-MED
were	O
assessed	B-MED
.	O
Three	O
balloons	B-MED
were	O
used	O
as	O
a	O
novel	B-MED
stimulus	B-MED
.	O
Measures	B-MED
were	O
(	O
a	O
)	O
the	O
time	B-MED
it	O
took	O
for	O
the	O
first	O
pig	B-MED
to	O
contact	B-MED
1	O
of	O
the	O
balloons	B-MED
,	O
(	O
b	O
)	O
percentage	O
of	O
nonhuman	B-MED
animals	B-MED
watching	B-MED
the	O
balloons	B-MED
each	O
for	O
10	O
s	O
,	O
and	O
(	O
c	O
)	O
percentage	O
of	O
animals	B-MED
touching	B-MED
the	O
balloons	B-MED
during	O
periods	B-MED
of	O
5	O
s.	O
The	O
time	B-MED
of	O
the	O
first	O
pig	B-MED
to	O
contact	B-MED
1	O
of	O
the	O
balloons	B-MED
ranged	B-MED
from	O
0	O
s	O
to	O
362	O
s.	O
An	O
effect	B-MED
of	O
the	O
farm	B-MED
was	O
found	O
(	O
p	O
<	O
.0001	O
)	O
for	O
contact	B-MED
latency	B-MED
,	O
ranging	B-MED
from	O
6.8	O
s	O
to	O
73.3	O
s	O
,	O
but	O
little	O
difference	B-MED
was	O
found	O
in	O
terms	O
of	O
intrafarm	B-MED
variability	B-MED
.	O
Interobserver	B-MED
repeatability	I-MED
was	O
also	O
high	B-MED
in	O
this	O
measure	B-MED
,	O
ranging	B-MED
from	O
r	O
=	O
.74	O
to	O
r	O
=	O
.96	O
.	O
As	O
a	O
result	O
,	O
it	O
is	O
concluded	O
that	O
contact	B-MED
latency	B-MED
could	O
be	O
a	O
good	O
measure	B-MED
to	O
assess	B-MED
fear	B-MED
of	O
a	O
novel	O
stimulus	B-MED
in	O
commercial	B-MED
farms	B-MED
.	O
Differential	B-MED
transcriptome	B-MED
expression	B-MED
in	O
human	B-MED
nucleus	B-MED
accumbens	I-MED
as	O
a	O
function	O
of	O
loneliness	B-MED
Loneliness	B-MED
is	O
associated	B-MED
with	I-MED
impaired	B-MED
mental	B-MED
and	O
physical	B-MED
health	I-MED
.	O
Studies	O
of	O
lonely	B-MED
individuals	I-MED
reported	O
differential	B-MED
expression	I-MED
of	O
inflammatory	B-MED
genes	B-MED
in	O
peripheral	B-MED
leukocytes	B-MED
and	O
diminished	B-MED
activation	B-MED
in	O
brain	B-MED
reward	B-MED
regions	I-MED
such	O
as	O
nucleus	B-MED
accumbens	I-MED
,	O
but	O
could	O
not	O
address	O
gene	B-MED
expression	I-MED
in	O
the	O
human	B-MED
brain	B-MED
.	O
Here	O
,	O
we	O
examined	O
genome	B-MED
-	I-MED
wide	I-MED
RNA	I-MED
expression	I-MED
in	O
post	B-MED
-	I-MED
mortem	I-MED
nucleus	B-MED
accumbens	I-MED
from	O
donors	B-MED
(	O
N=26	O
)	O
with	O
known	O
loneliness	B-MED
measures	B-MED
.	O
Loneliness	B-MED
was	O
associated	B-MED
with	I-MED
1710	O
differentially	B-MED
expressed	I-MED
transcripts	I-MED
and	O
genes	B-MED
from	O
1599	O
genes	B-MED
(	O
DEGs	B-MED
;	O
false	B-MED
discovery	I-MED
rate	I-MED
P<0.05	O
,	O
fold	O
change	O
⩾	O
Low	B-MED
literacy	I-MED
and	O
written	B-MED
drug	I-MED
information	I-MED
:	O
information	B-MED
-	I-MED
seeking	I-MED
,	O
leaflet	B-MED
evaluation	B-MED
and	O
preferences	B-MED
,	O
and	O
roles	O
for	O
images	B-MED
Background	O
Low	B-MED
-	I-MED
literate	I-MED
patients	B-MED
are	O
at	O
risk	B-MED
to	O
misinterpret	O
written	B-MED
drug	I-MED
information	I-MED
.	O
For	O
the	O
(	O
co-	O
)	O
design	O
of	O
targeted	O
patient	B-MED
information	I-MED
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	B-MED
in	O
determining	O
their	O
communication	B-MED
barriers	I-MED
and	O
information	B-MED
needs	O
.	O
Objective	O
To	O
gain	O
insight	O
into	O
how	O
people	B-MED
with	O
low	B-MED
literacy	I-MED
use	O
and	O
evaluate	O
written	B-MED
drug	I-MED
information	I-MED
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	B-MED
leaflet	B-MED
can	O
be	O
improved	O
,	O
and	O
in	O
particular	O
how	O
images	B-MED
could	O
be	O
used	O
.	O
Setting	O
Food	B-MED
banks	I-MED
and	O
an	O
education	B-MED
institution	I-MED
for	O
Dutch	B-MED
language	I-MED
training	B-MED
in	O
the	O
Netherlands	B-MED
.	O
Method	O
Semi	O
-	O
structured	O
focus	B-MED
groups	I-MED
and	O
individual	B-MED
interviews	B-MED
were	O
held	O
with	O
low	B-MED
-	I-MED
literate	I-MED
participants	I-MED
(	O
n	O
=	O
45	O
)	O
.	O
The	O
thematic	B-MED
framework	I-MED
approach	I-MED
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	B-MED
.	O
Main	O
outcome	B-MED
measure	O
Low	B-MED
-	I-MED
literate	I-MED
people	I-MED
's	I-MED
experience	B-MED
with	O
patient	B-MED
information	I-MED
leaflets	B-MED
,	O
ideas	B-MED
for	O
improvements	B-MED
,	O
and	O
perceptions	B-MED
on	O
possible	O
uses	O
for	O
visuals	B-MED
.	O
Results	O
Patient	B-MED
information	I-MED
leaflets	B-MED
were	O
considered	O
discouraging	O
to	O
use	O
,	O
and	O
information	B-MED
difficult	O
to	O
find	O
and	O
understand	B-MED
.	O
Many	O
rely	O
on	O
alternative	O
information	B-MED
sources	I-MED
.	O
The	O
leaflet	B-MED
should	O
be	O
shorter	O
,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	B-MED
,	O
legibility	B-MED
and	O
readability	B-MED
.	O
Participants	B-MED
thought	O
images	B-MED
could	O
increase	O
the	O
leaflet	B-MED
's	I-MED
appeal	O
,	O
help	O
ask	O
questions	B-MED
,	O
provide	O
an	O
overview	B-MED
,	O
help	O
understand	O
textual	B-MED
information	B-MED
,	O
aid	O
recall	B-MED
,	O
reassure	O
,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	B-MED
,	O
empowerment	B-MED
and	O
feeling	O
of	O
safety	B-MED
.	O
Conclusion	O
Already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	B-MED
and	O
maintaining	O
interest	O
in	O
the	O
message	O
,	O
low	B-MED
-	I-MED
literate	I-MED
patients	I-MED
experience	B-MED
barriers	B-MED
in	I-MED
the	I-MED
communication	I-MED
process	O
through	O
written	B-MED
drug	I-MED
information	I-MED
.	O
Short	O
,	O
structured	O
,	O
visual	B-MED
/	O
textual	B-MED
explanations	B-MED
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	B-MED
,	O
improve	B-MED
understanding	B-MED
,	O
and	O
empower	O
the	O
low	B-MED
-	I-MED
literate	I-MED
target	I-MED
group	I-MED
.	O
Sex	B-MED
differences	I-MED
in	O
the	O
effect	B-MED
of	I-MED
chronic	B-MED
mild	I-MED
stress	I-MED
on	O
mouse	B-MED
prefrontal	B-MED
cortical	I-MED
BDNF	B-MED
levels	O
:	O
A	O
role	O
of	O
major	O
ovarian	B-MED
hormones	I-MED
Depression	B-MED
induced	B-MED
by	O
stress	B-MED
is	O
affected	O
by	O
sex	B-MED
,	O
age	B-MED
and	O
hormonal	B-MED
status	O
of	O
the	O
animal	B-MED
and	O
also	O
by	O
duration	B-MED
and	O
type	O
of	O
the	O
stressors	B-MED
.	O
Moreover	O
,	O
higher	O
prevalence	O
of	O
depression	B-MED
and	O
comorbidities	B-MED
in	O
women	B-MED
than	O
men	B-MED
implies	O
the	O
need	O
to	O
include	O
the	O
sex	B-MED
variable	O
in	O
studies	O
on	O
animal	B-MED
models	I-MED
of	O
depression	B-MED
.	O
The	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect	B-MED
of	I-MED
sex	B-MED
and	O
ovarian	B-MED
hormones	I-MED
on	O
depression	B-MED
-like	O
phenotypes	B-MED
in	O
mice	B-MED
exposed	O
to	O
a	O
21	O
-	O
day	O
Chronic	B-MED
Variable	I-MED
Mild	I-MED
Stress	I-MED
(	O
CVMS	B-MED
)	O
paradigm	B-MED
.	O
Adult	B-MED
male	B-MED
,	O
intact	B-MED
female	I-MED
and	O
,	O
ovariectomized	B-MED
(	I-MED
OVX	I-MED
)	I-MED
female	I-MED
mice	B-MED
exposed	O
to	O
CVMS	B-MED
displayed	O
despair	O
behavior	B-MED
,	O
a	O
depression	B-MED
-like	O
phenotype	B-MED
,	O
in	O
all	O
the	O
groups	O
.	O
However	O
,	O
intact	B-MED
females	I-MED
alone	O
,	O
but	O
not	O
males	B-MED
and	O
OVX	B-MED
females	I-MED
,	O
showed	O
anhedonia	B-MED
,	O
another	O
depression	B-MED
-like	O
phenotype	B-MED
.	O
At	O
the	O
molecular	B-MED
level	I-MED
,	O
the	O
expression	B-MED
of	O
Brain	B-MED
-	I-MED
Derived	I-MED
Neurotrophic	I-MED
Factor	I-MED
(	O
BDNF	B-MED
)	O
,	O
a	O
neuropeptide	B-MED
associated	B-MED
with	I-MED
depression	B-MED
,	O
and	O
few	O
other	O
stress	B-MED
-specific	O
genes	B-MED
CRH	B-MED
,	O
NR3C1	B-MED
,	O
CART	B-MED
,	O
and	O
NPY	B-MED
were	O
measured	O
in	O
the	O
Prefrontal	B-MED
Cortex	I-MED
(	O
PFC	B-MED
)	O
region	O
of	O
the	O
reward	O
circuitry	O
.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
BDNF	B-MED
protein	B-MED
expression	I-MED
along	O
with	O
an	O
increase	O
in	O
the	O
mRNA	B-MED
expression	I-MED
of	O
CRH	B-MED
,	O
NR3C1	B-MED
,	O
CART	B-MED
,	O
and	O
NPY	B-MED
in	O
intact	B-MED
females	I-MED
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	B-MED
.	O
OVX	B-MED
females	I-MED
resembled	O
males	B-MED
in	O
behavioral	B-MED
and	O
molecular	B-MED
responses	I-MED
to	O
CVMS	B-MED
.	O
17β	B-MED
-	I-MED
Estradiol	I-MED
(	O
E2	B-MED
)	O
administration	B-MED
,	O
not	O
Progesterone	B-MED
(	O
P4	B-MED
)	O
,	O
to	O
OVX	B-MED
female	I-MED
stress	B-MED
mice	B-MED
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	B-MED
of	O
BDNF	B-MED
in	O
PFC	B-MED
.	O
This	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects	B-MED
of	I-MED
E2	B-MED
administration	B-MED
in	O
stress	B-MED
condition	O
.	O
Bioengineered	B-MED
3D	B-MED
Models	B-MED
for	O
Studying	B-MED
Human	B-MED
Cell	B-MED
-	O
Tuberculosis	B-MED
Interactions	B-MED
In	B-MED
vivo	I-MED
animal	B-MED
models	I-MED
have	O
intrinsic	O
limitations	O
for	O
studying	B-MED
relationships	B-MED
between	O
tuberculosis	B-MED
and	O
its	O
host	B-MED
and	O
there	O
is	O
a	O
need	O
for	O
alternative	O
,	O
in	B-MED
vitro	I-MED
cellular	B-MED
models	I-MED
.	O
A	O
microsphere	B-MED
-based	O
3D	B-MED
in	B-MED
vitro	I-MED
culture	B-MED
system	I-MED
of	O
Mycobacterium	B-MED
tuberculosis	I-MED
-infected	O
human	B-MED
blood	B-MED
mononuclear	B-MED
cells	I-MED
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	B-MED
-	O
pathogen	B-MED
interactions	B-MED
.	O
Clinical	B-MED
correlates	B-MED
of	O
faecal	B-MED
incontinence	I-MED
in	O
systemic	B-MED
sclerosis	I-MED
:	O
identifying	O
therapeutic	B-MED
avenues	I-MED
The	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	B-MED
and	O
severity	B-MED
of	O
faecal	B-MED
incontinence	I-MED
(	O
FI	B-MED
)	O
in	O
SSc	B-MED
,	O
its	O
association	B-MED
with	O
other	O
intestinal	B-MED
manifestations	B-MED
and	O
potential	B-MED
predictors	B-MED
of	O
FI	B-MED
,	O
and	O
its	O
impact	B-MED
on	O
quality	B-MED
of	I-MED
life	I-MED
.	O
A	O
multicentre	O
,	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
of	O
298	O
SSc	B-MED
subjects	B-MED
followed	O
in	O
the	O
Canadian	B-MED
Scleroderma	I-MED
Research	I-MED
Group	I-MED
cohort	B-MED
was	O
performed	O
using	O
validated	O
questionnaires	B-MED
:	O
Jorge	B-MED
-	I-MED
Wexner	I-MED
score	I-MED
(	O
an	O
FI	B-MED
severity	B-MED
scale	I-MED
)	O
,	O
Bristol	B-MED
stool	I-MED
scale	I-MED
(	O
a	O
visual	O
scale	O
of	O
stool	B-MED
consistency	I-MED
)	O
and	O
FI	B-MED
Quality	B-MED
-	I-MED
of	I-MED
-	I-MED
Life	I-MED
scale	I-MED
.	O
Constipation	B-MED
was	O
defined	O
by	O
the	O
Rome	B-MED
III	I-MED
criteria	I-MED
.	O
Associations	B-MED
between	O
the	O
Jorge	B-MED
-	I-MED
Wexner	I-MED
score	I-MED
and	O
other	O
clinical	B-MED
variables	I-MED
were	O
determined	O
using	O
multivariate	B-MED
regression	I-MED
analyses	I-MED
.	O
Eighty	O
-	O
one	O
(	O
27.2	O
%	O
)	O
subjects	B-MED
had	O
FI	B-MED
,	O
which	O
was	O
mild	B-MED
in	O
37	O
(	O
12.4	O
%	O
)	O
and	O
moderate	B-MED
to	I-MED
severe	I-MED
in	O
44	O
(	O
14.8	O
%	O
)	O
.	O
Most	O
patients	B-MED
had	O
well	O
-	O
formed	O
stools	B-MED
,	O
111	O
(	O
38.8	O
%	O
)	O
reported	O
constipation	B-MED
and	O
38	O
(	O
13.4	O
%	O
)	O
had	O
been	O
previously	B-MED
treated	B-MED
for	O
small	B-MED
intestinal	I-MED
bacterial	I-MED
overgrowth	I-MED
(	O
SIBO	B-MED
)	O
.	O
Variables	B-MED
independently	B-MED
associated	B-MED
with	I-MED
FI	B-MED
were	O
:	O
loose	B-MED
vs	O
well	O
-	O
formed	O
stools	B-MED
[	O
odds	B-MED
ratio	I-MED
(	O
OR	B-MED
)	O
=	O
7.01	O
,	O
95	O
%	O
CI	B-MED
:	O
2.09	O
,	O
23.51	O
)	O
]	O
,	O
constipation	B-MED
(	O
OR	B-MED
=	O
3.64	O
,	O
95	O
%	O
CI	B-MED
:	O
1.61	O
,	O
8.27	O
,	O
P	B-MED
=	O
0.002	O
)	O
,	O
history	B-MED
of	O
SIBO	B-MED
(	O
OR	B-MED
=	O
2.97	O
,	O
95	O
%	O
CI	B-MED
:	O
1.06	O
,	O
8.27	O
)	O
and	O
urinary	B-MED
incontinence	I-MED
(	O
OR	B-MED
=	O
2.45	O
,	O
95	O
%	O
CI	B-MED
:	O
1.14	O
,	O
5.27	O
)	O
.	O
Quality	B-MED
of	I-MED
life	I-MED
measured	B-MED
with	O
the	O
FI	B-MED
Quality	B-MED
-	I-MED
of	I-MED
-	I-MED
Life	I-MED
scale	I-MED
was	O
inversely	B-MED
correlated	B-MED
with	O
FI	B-MED
severity	B-MED
(	O
correlation	B-MED
coefficients	B-MED
between	O
-0.602	O
and	O
-0.702	O
,	O
P	B-MED
<	O
0.001	O
)	O
.	O
FI	B-MED
was	O
common	B-MED
and	O
often	O
severe	B-MED
in	O
SSc	B-MED
.	O
Loose	B-MED
stools	I-MED
,	O
SIBO	B-MED
,	O
constipation	B-MED
and	O
urinary	B-MED
incontinence	I-MED
were	O
strongly	B-MED
associated	B-MED
with	I-MED
FI	B-MED
.	O
Other	O
than	O
targeting	B-MED
anorectal	B-MED
dysfunction	B-MED
,	O
concomitant	B-MED
treatment	B-MED
of	O
clinical	B-MED
correlates	B-MED
could	O
lead	O
to	O
improvement	B-MED
in	O
FI	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
in	O
SSc	B-MED
.	O
Medication	B-MED
,	O
rehabilitation	B-MED
and	O
health	B-MED
care	I-MED
consumption	I-MED
in	O
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
:	O
A	O
population	B-MED
based	I-MED
study	I-MED
To	O
evaluate	O
medication	B-MED
,	O
rehabilitation	B-MED
and	O
healthcare	B-MED
consumption	I-MED
in	O
adults	B-MED
with	O
CP	B-MED
as	O
a	O
function	B-MED
of	O
Gross	B-MED
Motor	I-MED
Function	I-MED
Classification	I-MED
System	I-MED
(	O
GMFCS	B-MED
)	O
level	O
.	O
Questionnaire	B-MED
-based	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
Brittany	B-MED
,	O
a	O
French	B-MED
county	I-MED
.	O
Adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
.	O
Questionnaires	B-MED
relating	O
to	O
drugs	B-MED
,	O
orthotic	B-MED
devices	I-MED
,	O
mobility	B-MED
aids	I-MED
,	O
rehabilitation	B-MED
and	O
medical	B-MED
input	I-MED
were	O
sent	B-MED
to	O
435	O
members	B-MED
of	O
a	O
unique	B-MED
regional	B-MED
French	I-MED
network	B-MED
dedicated	O
to	O
adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
.	O
The	O
questionnaire	B-MED
was	O
completed	B-MED
by	O
the	O
participant	B-MED
or	O
a	O
helper	B-MED
if	O
necessary	O
.	O
Of	O
the	O
282	O
responders	B-MED
,	O
7.8	O
%	O
had	O
a	O
GMFCS	B-MED
level	I-MED
of	O
I	O
,	O
14.2	O
%	O
II	O
,	O
17.7	O
%	O
III	O
,	O
29.1	O
%	O
IV	O
and	O
31.2	O
%	O
V.	O
Participants	B-MED
consumed	O
a	O
large	B-MED
amount	I-MED
of	I-MED
healthcare	I-MED
.	O
Almost	B-MED
three	I-MED
-	I-MED
quarters	I-MED
took	O
orally	B-MED
administered	I-MED
drugs	I-MED
,	O
of	O
which	O
antispastic	B-MED
and	O
antiepileptic	B-MED
drugs	I-MED
were	O
among	O
the	O
most	B-MED
frequent	I-MED
.	O
Nearly	O
all	O
patients	B-MED
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	B-MED
,	O
87.2	O
%	O
had	O
physiotherapy	B-MED
,	O
78	O
%	O
used	O
at	O
least	O
one	O
mobility	B-MED
aid	I-MED
and	O
69.5	O
%	O
used	O
at	O
least	O
one	O
orthotic	B-MED
device	I-MED
.	O
The	O
frequency	B-MED
of	O
numerous	O
inputs	O
increased	O
with	O
GMFCS	B-MED
level	I-MED
.	O
Specificities	B-MED
were	O
found	B-MED
for	O
each	O
GMFCS	B-MED
level	I-MED
,	O
e.g.	O
participants	B-MED
with	O
GMFCS	B-MED
level	I-MED
IV	O
and	O
V	O
had	O
a	O
high	B-MED
level	I-MED
of	O
medical	B-MED
input	I-MED
and	O
a	O
greater	B-MED
use	I-MED
of	I-MED
trunk	B-MED
-	I-MED
supporting	I-MED
devices	I-MED
,	O
antireflux	B-MED
and	O
laxative	B-MED
.	O
Profiles	B-MED
could	O
be	O
established	O
based	O
on	O
GMFCS	B-MED
levels	I-MED
.	O
Adults	B-MED
with	O
cerebral	B-MED
palsy	I-MED
use	O
a	O
large	B-MED
amount	I-MED
of	O
drugs	B-MED
,	O
mobility	B-MED
aids	I-MED
,	O
orthotic	B-MED
devices	I-MED
,	O
rehabilitation	B-MED
and	O
medical	B-MED
input	I-MED
.	O
Healthcare	B-MED
is	O
targeted	B-MED
at	O
cerebral	B-MED
palsy	I-MED
cerebral	B-MED
palsy	I-MED
-related	I-MED
issues	I-MED
.	O
GMFCS	B-MED
is	O
a	O
determinant	B-MED
of	O
healthcare	B-MED
consumption	I-MED
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical	B-MED
practice	I-MED
to	O
target	B-MED
care	B-MED
appropriately	B-MED
.	O
Recurrent	B-MED
noncoding	I-MED
regulatory	I-MED
mutations	I-MED
in	O
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
The	O
contributions	B-MED
of	O
coding	B-MED
mutations	I-MED
to	O
tumorigenesis	B-MED
are	O
relatively	O
well	O
known	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	B-MED
alterations	I-MED
in	O
noncoding	B-MED
DNA	I-MED
.	O
Here	O
we	O
describe	O
GECCO	O
(	O
Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation	O
)	O
to	O
analyze	O
somatic	B-MED
noncoding	I-MED
alterations	I-MED
in	O
308	O
pancreatic	B-MED
ductal	I-MED
adenocarcinomas	I-MED
(	O
PDAs	B-MED
)	O
and	O
identify	O
commonly	O
mutated	B-MED
regulatory	I-MED
regions	I-MED
.	O
We	O
find	O
recurrent	B-MED
noncoding	I-MED
mutations	I-MED
to	O
be	O
enriched	O
in	O
PDA	B-MED
pathways	B-MED
,	O
including	O
axon	B-MED
guidance	I-MED
and	O
cell	B-MED
adhesion	I-MED
,	O
and	O
newly	O
identified	B-MED
processes	B-MED
,	O
including	O
transcription	B-MED
and	O
homeobox	B-MED
genes	I-MED
.	O
We	O
identified	B-MED
mutations	B-MED
in	O
protein	B-MED
binding	I-MED
sites	I-MED
correlating	O
with	O
differential	B-MED
expression	B-MED
of	O
proximal	B-MED
genes	B-MED
and	O
experimentally	O
validated	O
effects	B-MED
of	I-MED
mutations	B-MED
on	O
expression	B-MED
.	O
We	O
developed	O
an	O
expression	B-MED
modulation	I-MED
score	I-MED
that	O
quantifies	B-MED
the	O
strength	B-MED
of	O
gene	B-MED
regulation	I-MED
imposed	O
by	O
each	O
class	O
of	O
regulatory	B-MED
elements	I-MED
,	O
and	O
found	O
the	O
strongest	O
elements	B-MED
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O
Our	O
detailed	O
single	B-MED
-	I-MED
cancer	I-MED
analysis	I-MED
of	O
noncoding	B-MED
alterations	I-MED
identifies	O
regulatory	B-MED
mutations	I-MED
as	O
candidates	B-MED
for	O
diagnostic	B-MED
and	O
prognostic	B-MED
markers	I-MED
,	O
and	O
suggests	O
new	O
mechanisms	B-MED
for	O
tumor	B-MED
evolution	I-MED
.	O
Hematological	B-MED
,	O
biochemical	B-MED
,	O
and	O
toxicopathic	B-MED
effects	I-MED
of	O
subchronic	B-MED
acetamiprid	B-MED
toxicity	B-MED
in	O
Wistar	B-MED
rats	I-MED
Acetamiprid	B-MED
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B-MED
.	O
This	O
study	O
investigates	B-MED
toxic	B-MED
effects	I-MED
of	O
repeated	O
oral	B-MED
administration	I-MED
of	O
three	O
doses	B-MED
of	O
acetamiprid	B-MED
(	O
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
LD50	B-MED
)	O
during	O
60	O
days	B-MED
.	O
For	O
this	O
,	O
male	B-MED
Wistar	B-MED
rats	I-MED
were	O
divided	O
into	O
four	O
different	O
groups	B-MED
.	O
Hematological	B-MED
,	O
biochemical	B-MED
,	O
and	O
toxicopathic	B-MED
effects	I-MED
of	O
acetamiprid	B-MED
were	O
evaluated	B-MED
.	O
According	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	B-MED
in	O
the	O
body	B-MED
weight	I-MED
gain	I-MED
at	O
the	O
highest	O
dose	B-MED
1/5	O
of	O
LD50	B-MED
of	O
acetamiprid	B-MED
was	O
noticed	O
.	O
An	O
increase	B-MED
in	O
the	O
relative	O
liver	B-MED
weight	B-MED
was	O
also	O
observed	O
at	O
this	O
dose	B-MED
level	B-MED
.	O
The	O
hematological	B-MED
constituents	I-MED
were	O
affected	O
.	O
A	O
significant	O
decrease	B-MED
in	O
RBC	B-MED
,	O
HGB	B-MED
,	O
and	O
HCT	B-MED
in	O
rats	B-MED
treated	B-MED
with	O
higher	O
doses	B-MED
of	O
acetamiprid	B-MED
(	O
1/10	O
and	O
1/5	O
of	O
LD50	B-MED
)	O
was	O
noted	O
.	O
However	O
,	O
a	O
significant	O
increase	B-MED
in	O
WBC	B-MED
and	O
PLT	B-MED
were	O
observed	O
at	O
the	O
same	O
doses	B-MED
.	O
Furthermore	O
,	O
acetamiprid	B-MED
induced	B-MED
liver	I-MED
toxicity	I-MED
measured	O
by	O
the	O
increased	B-MED
activities	B-MED
of	O
aspartate	B-MED
aminotransferase	I-MED
(	O
AST	B-MED
)	O
,	O
alanine	B-MED
aminotransferase	I-MED
(	O
ALT	B-MED
)	O
,	O
alkaline	B-MED
phosphates	I-MED
(	O
ALPs	B-MED
)	O
,	O
and	O
lactate	B-MED
dehydrogenase	I-MED
(	O
LDH	B-MED
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	B-MED
of	O
hepatic	B-MED
membrane	I-MED
architecture	I-MED
and	O
hepatocellular	B-MED
damage	I-MED
.	O
In	O
addition	O
,	O
exposure	B-MED
to	I-MED
acetamiprid	B-MED
resulted	O
in	O
a	O
significant	O
decrease	B-MED
in	O
the	O
levels	B-MED
of	O
superoxide	B-MED
dismutase	I-MED
and	O
catalase	B-MED
activities	B-MED
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	B-MED
increase	B-MED
in	O
lipid	B-MED
peroxidation	I-MED
in	O
rat	B-MED
liver	B-MED
.	O
These	O
findings	B-MED
highlight	O
the	O
subchronic	B-MED
hepatotoxicity	B-MED
of	O
acetamiprid	B-MED
.	O
Analysis	B-MED
of	O
tilianin	B-MED
and	O
acacetin	B-MED
in	O
Agastache	B-MED
rugosa	I-MED
by	O
high	B-MED
-	I-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
with	O
ionic	B-MED
liquids	I-MED
-	O
ultrasound	B-MED
based	O
extraction	B-MED
Ionic	B-MED
liquid	I-MED
1	B-MED
-	I-MED
butyl-3	I-MED
-	I-MED
methylimidazolium	I-MED
bromide	I-MED
-	O
methanol	B-MED
-based	O
ultrasonic	B-MED
-assisted	O
extraction	B-MED
(	O
ILUAE	B-MED
)	O
was	O
used	O
to	O
extract	B-MED
tilianin	B-MED
and	O
acacetin	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
Agastache	B-MED
rugose	I-MED
(	O
A.	B-MED
rugose	I-MED
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-MED
phase	I-MED
high	I-MED
performance	I-MED
liquid	I-MED
chromatographic	I-MED
(	O
RP	B-MED
-	I-MED
HPLC	I-MED
)	O
method	O
with	O
ultraviolet	B-MED
detection	I-MED
(	O
RP	B-MED
-	I-MED
HPLC	I-MED
-	I-MED
UV	I-MED
)	I-MED
.	O
An	O
InertSustain	B-MED
RP	I-MED
-	I-MED
C18	I-MED
column	I-MED
was	O
used	O
with	O
the	O
mobile	B-MED
phase	I-MED
consisting	O
of	O
methanol	B-MED
and	O
0.2	O
%	O
acetic	B-MED
acid	I-MED
as	O
gradient	B-MED
elution	B-MED
at	O
the	O
detection	B-MED
wavelength	I-MED
of	O
332	O
nm	O
.	O
The	O
flow	B-MED
rate	I-MED
was	O
0.8	O
mL	O
/	O
min	O
,	O
and	O
the	O
column	B-MED
temperature	B-MED
was	O
30	O
°	O
C	O
.	O
Under	O
the	O
optimized	B-MED
conditions	B-MED
,	O
tilianin	B-MED
and	O
acacetin	B-MED
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595	O
-	O
4.76	O
and	O
0.0585	O
-	O
4.68	O
μg	O
/	O
mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
%	O
,	O
respectively	O
.	O
The	O
method	B-MED
of	O
ILUAE	B-MED
was	O
compared	O
with	O
the	O
traditional	B-MED
methods	I-MED
,	O
it	O
exhibited	O
higher	B-MED
efficiency	B-MED
,	O
higher	B-MED
reproducibility	B-MED
and	O
environmental	B-MED
friendly	I-MED
in	O
analyzing	O
the	O
active	B-MED
compounds	B-MED
in	O
traditional	B-MED
Chinese	I-MED
medicines	I-MED
(	O
TCMs	B-MED
)	O
.	O
Membrane	B-MED
nanoclusters	B-MED
of	O
FcγRI	B-MED
segregate	O
from	O
inhibitory	B-MED
SIRPα	B-MED
upon	O
activation	B-MED
of	I-MED
human	I-MED
macrophages	I-MED
Signal	B-MED
integration	I-MED
between	O
activating	B-MED
Fc	B-MED
receptors	I-MED
and	O
inhibitory	B-MED
signal	B-MED
regulatory	I-MED
protein	I-MED
α	I-MED
(	O
SIRPα	B-MED
)	O
controls	O
macrophage	B-MED
phagocytosis	B-MED
.	O
Here	O
,	O
using	O
dual	B-MED
-	I-MED
color	I-MED
direct	I-MED
stochastic	I-MED
optical	I-MED
reconstruction	I-MED
microscopy	I-MED
,	O
we	O
report	O
that	O
Fcγ	B-MED
receptor	I-MED
I	I-MED
(	O
FcγRI	B-MED
)	O
,	O
FcγRII	B-MED
,	O
and	O
SIRPα	B-MED
are	O
not	O
homogeneously	B-MED
distributed	O
at	O
macrophage	B-MED
surfaces	B-MED
but	O
are	O
organized	O
in	O
discrete	B-MED
nanoclusters	B-MED
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
±	O
11	O
nm	O
,	O
60	O
±	O
6	O
nm	O
,	O
and	O
48	O
±	O
3	O
nm	O
,	O
respectively	O
.	O
Nanoclusters	B-MED
of	O
FcγRI	B-MED
,	O
but	O
not	O
FcγRII	B-MED
,	O
are	O
constitutively	O
associated	B-MED
with	I-MED
nanoclusters	B-MED
of	O
SIRPα	B-MED
,	O
within	O
62	O
±	O
5	O
nm	O
,	O
mediated	O
by	O
the	O
actin	B-MED
cytoskeleton	I-MED
.	O
Upon	O
Fc	B-MED
receptor	I-MED
activation	B-MED
,	O
Src	B-MED
-	I-MED
family	I-MED
kinase	I-MED
signaling	B-MED
leads	O
to	O
segregation	O
of	O
FcγRI	B-MED
and	O
SIRPα	B-MED
nanoclusters	B-MED
to	O
be	O
197	O
±	O
3	O
nm	O
apart	O
.	O
Co	B-MED
-	I-MED
ligation	I-MED
of	O
SIRPα	B-MED
with	O
CD47	B-MED
abrogates	O
nanocluster	B-MED
segregation	O
.	O
If	O
the	O
balance	O
of	O
signals	B-MED
favors	O
activation	B-MED
,	O
FcγRI	B-MED
nanoclusters	B-MED
reorganize	B-MED
into	O
periodically	B-MED
spaced	O
concentric	B-MED
rings	I-MED
.	O
Thus	O
,	O
a	O
nanometer	B-MED
-	O
and	O
micron	B-MED
-	I-MED
scale	I-MED
reorganization	B-MED
of	O
activating	B-MED
and	O
inhibitory	B-MED
receptors	B-MED
occurs	O
at	O
the	O
surface	O
of	O
human	B-MED
macrophages	I-MED
concurrent	B-MED
with	O
signal	B-MED
integration	I-MED
.	O
Nontoxic	B-MED
Formulations	B-MED
of	O
Scintillation	B-MED
Nanocrystals	B-MED
for	O
Use	O
as	O
X	B-MED
-	I-MED
ray	I-MED
Computed	I-MED
Tomography	I-MED
Contrast	B-MED
Agents	I-MED
X	B-MED
-	I-MED
ray	I-MED
computed	I-MED
tomography	I-MED
(	O
CT	B-MED
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	B-MED
,	O
clinical	B-MED
in	B-MED
vivo	I-MED
imaging	B-MED
techniques	I-MED
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	B-MED
-	I-MED
ray	I-MED
device	I-MED
and	O
contrast	B-MED
enhancement	B-MED
technologies	I-MED
.	O
The	O
present	O
study	B-MED
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	B-MED
tungstates	I-MED
(	O
such	O
as	O
CaWO4	B-MED
)	O
are	O
promising	O
contrast	B-MED
agents	I-MED
for	O
X	B-MED
-	I-MED
ray	I-MED
,	O
radiation	B-MED
,	O
and	O
CT	B-MED
imaging	I-MED
,	O
because	O
of	O
the	O
high	O
X	B-MED
-	I-MED
ray	I-MED
mass	B-MED
attenuation	I-MED
of	O
tungsten	B-MED
(	O
W	B-MED
)	O
.	O
We	O
have	O
developed	O
a	O
method	O
of	O
formulation	B-MED
,	O
in	O
which	O
CaWO4	B-MED
(	O
CWO	B-MED
)	O
nanoparticles	B-MED
(	O
NPs	B-MED
)	O
are	O
encapsulated	B-MED
within	O
a	O
biocompatible	O
poly(ethylene	B-MED
glycol	I-MED
-	I-MED
b	I-MED
-	I-MED
d	I-MED
,	I-MED
l	I-MED
-	I-MED
lactic	I-MED
acid	I-MED
)	I-MED
(	I-MED
PEG	I-MED
-	I-MED
PLA	I-MED
)	I-MED
block	I-MED
copolymer	I-MED
(	I-MED
BCP	I-MED
)	I-MED
capsule	I-MED
.	O
We	O
show	O
that	O
these	O
PEG	B-MED
-	I-MED
PLA	I-MED
-	O
encapsulated	B-MED
CWO	B-MED
NPs	I-MED
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
CT	B-MED
contrast	B-MED
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	B-MED
-based	O
radiocontrast	B-MED
agents	I-MED
(	O
e.g.	O
,	O
Iohexol	B-MED
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	B-MED
or	O
I	B-MED
atoms	B-MED
.	O
PEG	B-MED
-	I-MED
PLA	I-MED
-	O
coated	B-MED
CWO	B-MED
NPs	I-MED
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	B-MED
.	O
It	O
was	O
confirmed	O
that	O
the	O
maximum	B-MED
tolerated	I-MED
dose	I-MED
(	O
MTD	B-MED
)	O
of	O
this	O
material	B-MED
in	O
mice	B-MED
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	B-MED
weight	I-MED
following	O
a	O
single	O
intravenous	B-MED
(	I-MED
IV	I-MED
)	I-MED
administration	I-MED
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B-MED
-	O
coated	B-MED
iron	B-MED
oxide	I-MED
nanoparticles	B-MED
that	O
are	O
currently	O
used	O
clinically	B-MED
as	O
MRI	B-MED
contrast	B-MED
agents	I-MED
(	O
MTD	B-MED
in	O
mice	B-MED
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	B-MED
IV	O
)	O
.	O
IV-	O
injected	B-MED
PEG	B-MED
-	I-MED
PLA	I-MED
/	O
CWO	B-MED
NPs	I-MED
caused	O
no	B-MED
histopathologic	B-MED
damage	B-MED
in	O
major	O
excretory	B-MED
organs	I-MED
(	O
heart	B-MED
,	O
liver	B-MED
,	O
lungs	B-MED
,	O
spleen	B-MED
,	O
and	O
kidney	B-MED
)	O
.	O
When	O
an	O
IV	O
dose	B-MED
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	B-MED
,	O
the	O
blood	B-MED
circulation	I-MED
half	B-MED
-	I-MED
life	I-MED
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	B-MED
were	O
cleared	O
from	O
the	O
mice	B-MED
within	O
24	O
h	O
via	O
the	O
renal	B-MED
and	O
hepatobiliary	B-MED
systems	I-MED
.	O
When	O
intratumorally	B-MED
administered	I-MED
,	O
PEG	B-MED
-	I-MED
PLA	I-MED
-	O
coated	B-MED
CWO	B-MED
NPs	I-MED
showed	O
complete	O
retention	O
in	O
a	O
tumor	B-MED
-	I-MED
bearing	I-MED
mouse	I-MED
model	I-MED
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	B-MED
)	O
.	O
These	O
results	O
suggest	O
that	O
PEG	B-MED
-	I-MED
PLA	I-MED
-	O
coated	B-MED
CWO	B-MED
NPs	I-MED
are	O
promising	O
materials	B-MED
for	O
use	O
in	O
CT	B-MED
contrast	B-MED
.	O
Metabolic	B-MED
responses	I-MED
of	O
the	O
growing	O
Daphnia	B-MED
similis	I-MED
to	O
chronic	B-MED
AgNPs	B-MED
exposure	O
as	O
revealed	O
by	O
GC	B-MED
-	I-MED
Q	I-MED
-	I-MED
TOF	I-MED
/	I-MED
MS	I-MED
and	O
LC	B-MED
-	I-MED
Q	I-MED
-	I-MED
TOF	I-MED
/	I-MED
MS	I-MED
Silver	B-MED
nanoparticles	B-MED
(	O
AgNPs	B-MED
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	B-MED
.	O
Their	O
fast	B-MED
-	I-MED
growing	I-MED
utilization	O
has	O
increased	B-MED
the	O
occurrence	O
of	O
AgNPs	B-MED
in	O
the	O
environment	B-MED
,	O
posing	O
potential	O
health	B-MED
and	I-MED
ecological	I-MED
risks	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-MED
toxicity	I-MED
tests	I-MED
and	O
investigated	O
the	O
metabolic	B-MED
changes	B-MED
of	O
the	O
growing	O
Daphna	B-MED
similis	I-MED
with	O
exposure	B-MED
to	I-MED
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
AgNPs	B-MED
,	O
using	O
non	B-MED
-	I-MED
targeted	I-MED
mass	I-MED
spectrometry	I-MED
-based	O
metabolomics	B-MED
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	B-MED
metabolite	B-MED
change	B-MED
of	O
a	O
common	O
aquatic	B-MED
organism	I-MED
Daphnia	B-MED
crustacean	I-MED
through	O
its	O
life	B-MED
-	I-MED
cycle	I-MED
.	O
The	O
results	O
show	O
a	O
dynamic	B-MED
kinetic	I-MED
pattern	I-MED
of	O
the	O
growing	O
Daphnia	B-MED
's	I-MED
metabolome	B-MED
underwent	O
a	O
cycle	B-MED
from	O
day	B-MED
0	O
to	O
day	B-MED
21	O
,	O
with	O
the	O
level	B-MED
of	O
metabolites	B-MED
gradually	O
increasing	B-MED
from	O
day	B-MED
0	O
to	O
day	B-MED
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	B-MED
level	B-MED
of	O
day	B-MED
0	O
on	O
day	B-MED
21	O
.	O
As	O
for	O
the	O
samples	B-MED
exposed	B-MED
to	I-MED
environmental	B-MED
concentrations	I-MED
of	O
AgNPs	B-MED
,	O
although	O
without	O
morphological	B-MED
or	I-MED
structural	I-MED
changes	I-MED
,	O
numerous	O
metabolite	B-MED
changes	B-MED
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	B-MED
,	O
and	O
these	O
changes	B-MED
reached	O
steady	B-MED
state	I-MED
by	O
day	B-MED
13	O
.	O
The	O
significant	O
changes	B-MED
in	O
certain	O
metabolites	B-MED
,	O
such	O
as	O
amino	B-MED
acids	I-MED
(	O
serine	B-MED
,	O
threonine	B-MED
and	O
tyrosine	B-MED
)	O
,	O
sugars	B-MED
(	O
d	B-MED
-	I-MED
allose	I-MED
)	O
and	O
fatty	B-MED
acids	I-MED
(	O
arachidonic	B-MED
acid	I-MED
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	B-MED
in	O
Daphnia	B-MED
respond	O
to	O
chronic	B-MED
AgNPs	B-MED
stress	B-MED
.	O
These	O
findings	B-MED
highlight	O
the	O
capability	B-MED
of	O
metabolomics	B-MED
to	O
discover	O
early	O
metabolic	B-MED
responses	I-MED
to	O
environmental	B-MED
silver	B-MED
nanoparticles	B-MED
.	O
Natural	B-MED
orifice	I-MED
transluminal	I-MED
endoscopic	I-MED
surgery	I-MED
with	O
a	O
snake	B-MED
-	I-MED
mechanism	I-MED
using	O
a	O
movable	B-MED
pulley	I-MED
Natural	B-MED
orifice	I-MED
transluminal	I-MED
endoscopic	I-MED
surgery	I-MED
is	O
an	O
emerging	O
technique	B-MED
.	O
We	O
aimed	O
to	O
develop	B-MED
an	O
advanced	B-MED
surgical	B-MED
robot	I-MED
mechanism	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
We	O
propose	O
the	O
active	B-MED
-	I-MED
controlled	I-MED
overtube	I-MED
-	I-MED
type	I-MED
platform	I-MED
with	O
multiple	O
channels	B-MED
for	O
an	O
endoscopic	B-MED
camera	I-MED
and	O
surgical	B-MED
tools	B-MED
.	O
To	O
make	O
such	O
a	O
platform	B-MED
,	O
we	O
suggest	B-MED
an	O
advanced	B-MED
snake	B-MED
mechanism	I-MED
comprising	O
movable	B-MED
pulleys	I-MED
to	O
make	O
a	O
snake	B-MED
mechanism	I-MED
with	O
multiple	O
degrees	B-MED
of	I-MED
freedom	I-MED
and	O
high	O
operating	O
force	O
.	O
The	O
stiffness	B-MED
and	O
maneuverability	B-MED
of	O
the	O
active	B-MED
-	I-MED
controlled	I-MED
platform	I-MED
appeared	O
satisfactory	B-MED
.	O
Using	O
prototypes	B-MED
and	O
ex	B-MED
vivo	I-MED
experiments	B-MED
,	O
we	O
confirmed	O
that	O
the	O
mechanism	B-MED
was	O
suitable	O
for	O
a	O
snake	B-MED
-	I-MED
like	I-MED
robotic	I-MED
platform	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
The	O
suggested	B-MED
snake	B-MED
mechanism	I-MED
using	O
movable	B-MED
pulleys	I-MED
has	O
the	O
advantages	O
of	O
stiffness	B-MED
and	O
maneuverability	B-MED
.	O
This	O
new	O
mechanism	B-MED
can	O
be	O
an	O
alternative	B-MED
platform	B-MED
for	O
natural	B-MED
orifice	I-MED
surgery	I-MED
.	O
Brassinosteroid	B-MED
-	O
induced	B-MED
changes	B-MED
of	O
lipid	B-MED
composition	B-MED
in	O
leaves	B-MED
of	O
Pisum	B-MED
sativum	I-MED
L.	I-MED
during	O
senescence	B-MED
The	O
effect	B-MED
of	I-MED
steroid	B-MED
phytohormone	B-MED
24	B-MED
-	I-MED
epibrassinolide	I-MED
(	O
EBR	B-MED
)	O
on	O
the	O
composition	B-MED
of	O
some	O
lipid	B-MED
classes	B-MED
(	O
free	B-MED
fatty	I-MED
acids	I-MED
,	O
triacylglycerols	B-MED
and	O
galactolipids	B-MED
)	O
in	O
detached	B-MED
pea	B-MED
leaves	B-MED
was	O
studied	O
for	O
the	O
first	O
time	O
.	O
EBR	B-MED
(	O
0.1μM	O
)	O
promoted	O
senescence	B-MED
and	O
increased	B-MED
the	O
content	B-MED
of	O
14:0	O
,	O
16:0	O
and	O
18:1	O
free	B-MED
fatty	I-MED
acids	I-MED
as	O
well	O
as	O
18:2	O
and	O
18:3	O
bound	O
to	O
triacylglycerols	B-MED
in	O
the	O
detached	B-MED
leaves	B-MED
in	O
contrast	O
to	O
mock	B-MED
-	I-MED
treated	I-MED
leaves	I-MED
.	O
The	O
content	B-MED
of	O
all	O
identified	B-MED
fatty	B-MED
acids	I-MED
bound	O
to	O
galactolipids	B-MED
decreased	B-MED
in	O
the	O
detached	B-MED
leaves	B-MED
treated	B-MED
with	O
EBR	B-MED
compared	O
to	O
that	O
in	O
mock	B-MED
-	I-MED
treated	I-MED
leaves	I-MED
.	O
These	O
findings	B-MED
suggest	O
that	O
free	B-MED
fatty	I-MED
acids	I-MED
are	O
liberated	O
from	O
polar	B-MED
lipids	B-MED
and	O
then	O
undergo	O
esterification	B-MED
to	O
neutral	B-MED
lipids	I-MED
in	O
the	O
detached	B-MED
leaves	B-MED
upon	O
EBR	B-MED
treatment	B-MED
.	O
We	O
propose	O
that	O
steroid	B-MED
phytohormones	B-MED
may	O
be	O
involved	O
into	O
regulation	B-MED
of	O
leaf	B-MED
senescence	B-MED
via	O
alteration	B-MED
of	O
cell	B-MED
lipid	B-MED
composition	B-MED
.	O
Multimodal	B-MED
brain	I-MED
imaging	I-MED
with	O
magnetoencephalography	B-MED
:	O
A	O
method	B-MED
for	O
measuring	B-MED
blood	B-MED
pressure	I-MED
and	O
cardiorespiratory	B-MED
oscillations	I-MED
Studies	B-MED
with	O
magnetoencephalography	B-MED
(	O
MEG	B-MED
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-MED
that	O
can	O
provide	O
a	O
metabolic	B-MED
dimension	I-MED
to	O
MEG	B-MED
investigation	B-MED
s.	O
In	O
addition	O
,	O
continuous	O
blood	B-MED
pressure	I-MED
measurements	I-MED
which	O
comply	O
with	O
MEG	B-MED
compatibility	O
requirements	O
are	O
lacking	O
.	O
For	O
instance	O
,	O
by	O
combining	O
methods	B-MED
reflecting	O
neurovascular	B-MED
status	I-MED
one	O
could	O
obtain	O
more	O
information	O
on	O
low	B-MED
frequency	I-MED
fluctuations	B-MED
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	B-MED
connectivity	I-MED
within	O
brain	B-MED
networks	I-MED
.	O
This	O
paper	O
presents	O
a	O
multimodal	B-MED
brain	I-MED
imaging	I-MED
setup	O
,	O
capable	O
to	O
non	B-MED
-	I-MED
invasively	I-MED
and	O
continuously	O
measure	O
cerebral	B-MED
hemodynamic	B-MED
,	O
cardiorespiratory	B-MED
and	O
blood	B-MED
pressure	I-MED
oscillations	B-MED
simultaneously	O
with	O
MEG	B-MED
.	O
In	O
the	O
setup	O
,	O
all	O
methods	B-MED
apart	O
from	O
MEG	B-MED
rely	O
on	O
the	O
use	O
of	O
fibre	B-MED
optics	I-MED
.	O
In	O
particular	O
,	O
we	O
present	O
a	O
method	B-MED
for	O
measuring	B-MED
of	O
blood	B-MED
pressure	I-MED
and	O
cardiorespiratory	B-MED
oscillations	I-MED
continuously	O
with	O
MEG	B-MED
.	O
The	O
potential	B-MED
of	O
this	O
type	O
of	O
multimodal	B-MED
setup	O
for	O
brain	B-MED
research	I-MED
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	B-MED
,	O
showing	O
effects	B-MED
of	I-MED
mild	B-MED
hypercapnia	I-MED
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	B-MED
.	O
Relationship	B-MED
between	O
polycythemia	B-MED
and	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
in	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
patients	B-MED
with	O
low	B-MED
-	I-MED
risk	I-MED
pulmonary	B-MED
embolism	I-MED
Pulmonary	B-MED
embolism	I-MED
(	O
PE	B-MED
)	O
is	O
frequent	B-MED
in	O
subjects	B-MED
with	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
and	O
associated	B-MED
with	I-MED
high	O
mortality	B-MED
.	O
This	O
multi	B-MED
-	I-MED
center	I-MED
retrospective	I-MED
study	I-MED
was	O
performed	O
to	O
investigate	B-MED
if	O
secondary	O
polycythemia	B-MED
is	O
associated	B-MED
with	I-MED
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
in	O
COPD	B-MED
patients	B-MED
with	O
low	B-MED
-	I-MED
risk	I-MED
PE	B-MED
.	O
We	O
identified	O
COPD	B-MED
patients	B-MED
with	O
proven	O
PE	B-MED
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O
Patients	B-MED
in	O
risk	O
classes	O
III	O
-	O
V	O
on	O
the	O
basis	O
of	O
the	O
PESI	B-MED
score	I-MED
were	O
excluded	O
.	O
We	O
extracted	O
demographic	B-MED
,	O
clinical	B-MED
and	O
laboratory	B-MED
information	I-MED
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
from	O
medical	B-MED
records	I-MED
.	O
All	O
subjects	B-MED
were	O
followed	O
until	O
hospital	B-MED
discharge	I-MED
to	O
identify	O
all	O
-	O
cause	O
mortality	B-MED
.	O
We	O
enrolled	O
629	O
consecutive	O
patients	B-MED
with	O
COPD	B-MED
and	O
PE	B-MED
at	O
low	B-MED
risk	I-MED
:	O
132	O
of	O
them	O
(	O
21.0	O
%	O
)	O
with	O
and	O
497	O
(	O
79.0	O
%	O
)	O
without	O
secondary	O
polycythemia	B-MED
.	O
Compared	O
with	O
those	O
without	O
polycythemia	B-MED
,	O
the	O
polycythemia	B-MED
group	O
had	O
significantly	B-MED
lower	I-MED
forced	B-MED
expiratory	I-MED
volume	I-MED
in	I-MED
one	I-MED
second	I-MED
(	I-MED
FEV1	I-MED
)	I-MED
level	I-MED
(	O
0.9±0.3	O
vs.	O
1.4±0.5	O
,	O
P=0.000	O
)	O
,	O
lower	B-MED
PaO2	I-MED
and	O
SpO2	B-MED
as	O
well	O
as	O
higher	B-MED
PaCO2	I-MED
(	O
P=0.03	O
,	O
P=0.03	O
and	O
P=0.000	O
,	O
respectively	O
)	O
.	O
COPD	B-MED
patients	B-MED
with	O
polycythemia	B-MED
had	O
a	O
higher	B-MED
proportion	B-MED
of	O
arrhythmia	B-MED
in	O
electrocardiogram	B-MED
(	O
ECG	B-MED
)	O
(	O
49.5	O
%	O
vs.	O
35.7	O
%	O
,	O
P=0.02	O
)	O
,	O
a	O
longer	O
hospital	B-MED
duration	I-MED
time	I-MED
(	O
15.3±10.1	O
vs.	O
9.7±9.1	O
,	O
P=0.001	O
)	O
,	O
a	O
higher	B-MED
mechanical	B-MED
ventilation	I-MED
rate	I-MED
(	O
noninvasive	B-MED
and	O
invasive	B-MED
,	O
51.7	O
%	O
vs.	O
30.3	O
%	O
,	O
P=0.04	O
and	O
31.0	O
%	O
vs.	O
7.9	O
%	O
,	O
P=0.04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	B-MED
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
(	O
12.1	O
%	O
vs.	O
6.6	O
%	O
,	O
P=0.04	O
)	O
.	O
Multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
revealed	O
that	O
polycythemia	B-MED
was	O
associated	B-MED
with	I-MED
mortality	B-MED
in	O
COPD	B-MED
patients	B-MED
with	O
low	B-MED
-	I-MED
risk	I-MED
PE	B-MED
(	O
adjusted	O
OR	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
1.04	O
-	O
1.66	O
)	O
.	O
Polycythemia	B-MED
is	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
all	O
-	O
cause	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
in	O
COPD	B-MED
patients	B-MED
with	O
PE	B-MED
at	O
low	B-MED
risk	I-MED
.	O
Does	O
infrared	B-MED
visualization	B-MED
improve	O
selection	B-MED
of	O
venipuncture	B-MED
sites	B-MED
for	O
indwelling	B-MED
needle	B-MED
at	O
the	O
forearm	B-MED
in	O
second	O
-	O
year	O
nursing	B-MED
students	I-MED
?	O
To	O
evaluate	O
the	O
effectiveness	B-MED
of	O
a	O
vein	B-MED
visualization	I-MED
display	I-MED
system	I-MED
using	O
near	B-MED
-	I-MED
infrared	I-MED
light	I-MED
(	O
"	O
Vein	B-MED
Display	I-MED
"	O
)	O
for	O
the	O
safe	O
and	O
proper	O
selection	B-MED
of	O
venipuncture	B-MED
sites	B-MED
for	O
indwelling	B-MED
needle	B-MED
placement	O
in	O
the	O
forearm	B-MED
.	O
Ten	O
second	O
year	O
nursing	B-MED
students	I-MED
were	O
recruited	O
to	O
apply	O
an	O
indwelling	B-MED
needle	B-MED
line	O
with	O
and	O
without	O
Vein	B-MED
Display	B-MED
.	O
Another	O
ten	O
participants	B-MED
were	O
recruited	O
from	O
various	O
faculty	B-MED
to	O
serve	O
as	O
patients	B-MED
.	O
The	O
quality	O
of	O
the	O
venipuncture	B-MED
procedure	I-MED
at	O
various	O
selected	O
sites	B-MED
was	O
evaluated	O
according	O
to	O
a	O
scale	B-MED
developed	O
by	O
the	O
authors	B-MED
.	O
Time	B-MED
,	O
scores	B-MED
and	O
patterns	B-MED
of	O
puncture	B-MED
-	O
site	B-MED
selection	B-MED
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
:	O
[	O
1	O
]	O
attempt	O
1	O
(	O
tourniquet	B-MED
only	O
)	O
,	O
[	O
2	O
]	O
attempt	O
2	O
(	O
Vein	B-MED
Display	I-MED
only	O
)	O
and	O
[	O
3	O
]	O
attempt	O
3	O
(	O
both	O
)	O
.	O
To	O
validate	O
the	O
effectiveness	B-MED
of	O
Vein	B-MED
Display	B-MED
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O
We	O
found	O
that	O
venipuncture	B-MED
site	B-MED
selection	B-MED
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	B-MED
Display	I-MED
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	B-MED
venipuncture	B-MED
sites	B-MED
.	O
Overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-MED
quality	B-MED
,	O
as	O
determined	O
by	O
our	O
scale	B-MED
.	O
These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	B-MED
Display	I-MED
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	B-MED
skills	I-MED
,	O
such	O
as	O
venipuncture	B-MED
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-MED
patients	B-MED
.	O
Diverse	O
Colletotrichum	B-MED
species	I-MED
cause	O
anthracnose	B-MED
of	O
tea	B-MED
plants	I-MED
(	O
Camellia	B-MED
sinensis	I-MED
(	I-MED
L.	I-MED
)	I-MED
O.	I-MED
Kuntze	I-MED
)	O
in	O
China	B-MED
Anthracnose	B-MED
caused	O
by	O
Colletotrichum	B-MED
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-MED
that	O
can	O
afflict	O
Camellia	B-MED
sinensis	I-MED
.	O
However	O
,	O
research	B-MED
on	O
the	O
diversity	B-MED
and	O
geographical	B-MED
distribution	I-MED
of	O
Colletotrichum	B-MED
in	O
China	B-MED
remain	O
limited	O
.	O
In	O
this	O
study	B-MED
,	O
106	O
Colletotrichum	B-MED
isolates	B-MED
were	O
collected	B-MED
from	O
diseased	B-MED
leaves	B-MED
of	O
Ca	B-MED
.	I-MED
sinensis	I-MED
cultivated	O
in	O
the	O
15	O
main	O
tea	B-MED
production	I-MED
provinces	B-MED
in	O
China	B-MED
.	O
Multi	B-MED
-	I-MED
locus	I-MED
phylogenetic	I-MED
analysis	I-MED
coupled	O
with	O
morphological	B-MED
identification	I-MED
showed	O
that	O
the	O
collected	B-MED
isolates	B-MED
belonged	O
to	O
11	O
species	B-MED
,	O
including	O
6	O
known	O
species	B-MED
(	O
C.	B-MED
camelliae	I-MED
,	O
C.	B-MED
cliviae	I-MED
,	O
C.	B-MED
fioriniae	I-MED
,	O
C.	B-MED
fructicola	I-MED
,	O
C.	B-MED
karstii	I-MED
,	O
and	O
C.	B-MED
siamense	I-MED
)	O
,	O
3	O
new	O
record	B-MED
species	I-MED
(	O
C.	B-MED
aenigma	I-MED
,	O
C.	B-MED
endophytica	I-MED
,	O
and	O
C.	B-MED
truncatum	I-MED
)	O
,	O
1	O
novel	O
species	B-MED
(	O
C.	B-MED
wuxiense	I-MED
)	O
,	O
and	O
1	O
indistinguishable	O
strain	B-MED
,	O
herein	O
described	O
as	O
Colletotrichum	B-MED
sp	I-MED
.	I-MED
Of	O
these	O
species	B-MED
,	O
C.	B-MED
camelliae	I-MED
and	O
C.	B-MED
fructicola	I-MED
were	O
the	O
dominant	O
species	B-MED
causing	O
anthracnose	B-MED
in	O
Ca	B-MED
.	I-MED
sinensis	I-MED
.	O
In	O
addition	O
,	O
our	O
study	B-MED
provided	O
further	O
evidence	B-MED
that	O
phylogenetic	B-MED
analysis	I-MED
using	O
a	O
combination	O
of	O
ApMat	B-MED
and	I-MED
GS	I-MED
sequences	I-MED
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	B-MED
relationships	B-MED
within	O
the	O
C.	B-MED
gloeosporioides	I-MED
species	B-MED
complex	I-MED
.	O
Finally	O
,	O
pathogenicity	B-MED
tests	B-MED
suggested	O
that	O
C.	B-MED
camelliae	I-MED
,	O
C.	B-MED
aenigma	I-MED
,	O
and	O
C.	B-MED
endophytica	I-MED
are	O
more	O
invasive	B-MED
than	O
other	O
species	B-MED
after	O
the	O
inoculation	B-MED
of	O
the	O
leaves	B-MED
of	O
Ca	B-MED
.	I-MED
sinensis	I-MED
.	O
Fatty	B-MED
Acids	I-MED
Have	O
Different	B-MED
Adipogenic	B-MED
Differentiation	I-MED
Potentials	B-MED
in	O
Stromal	B-MED
Vascular	I-MED
Cells	I-MED
Isolated	B-MED
from	O
Abdominal	B-MED
Fat	I-MED
in	O
Laying	B-MED
Hens	B-MED
This	O
study	B-MED
was	O
conducted	O
to	O
examine	O
the	O
effects	B-MED
of	I-MED
fatty	B-MED
acids	I-MED
(	O
FA	B-MED
)	O
with	O
/	O
without	O
chicken	B-MED
serum	I-MED
(	O
CS	B-MED
)	O
on	O
the	O
expression	B-MED
of	O
adipogenic	B-MED
transcripts	B-MED
and	O
adipogenesis	B-MED
in	O
chicken	B-MED
stromal	B-MED
vascular	I-MED
cells	I-MED
(	O
SVC	B-MED
)	O
.	O
In	O
experiment	O
1	O
,	O
SVC	B-MED
were	O
grown	O
in	O
DMEM	B-MED
containing	O
10	O
%	O
FBS	B-MED
(	O
Control	B-MED
)	O
and	O
treated	B-MED
with	O
300	O
µM	O
oleic	B-MED
acid	I-MED
(	O
OLA	B-MED
)	O
+	O
FBS	B-MED
,	O
linoleic	B-MED
acid	I-MED
(	O
LNA	B-MED
)	O
+	O
FBS	B-MED
,	O
palmitic	B-MED
acid	I-MED
(	O
PAM	B-MED
)	O
+	O
FBS	B-MED
,	O
or	O
stearic	B-MED
acid	I-MED
(	O
STA	B-MED
)	O
+	O
FBS	B-MED
for	O
48	O
h.	O
In	O
experiment	O
2	O
,	O
cells	B-MED
were	O
grown	O
in	O
DMEM	B-MED
containing	O
5	O
%	O
CS	B-MED
and	O
treated	B-MED
with	O
300	O
µM	O
OLA	B-MED
(	O
CS	B-MED
+	O
OLA	B-MED
)	O
,	O
PAM	B-MED
(	O
CS	B-MED
+	O
PAM	B-MED
)	O
,	O
STA	B-MED
(	O
CS	B-MED
+	O
STA	B-MED
)	O
or	O
200	O
µM	O
LNA	B-MED
(	O
CS	B-MED
+	O
LNA	B-MED
)	O
for	O
48	O
h.	O
Adipogenesis	B-MED
was	O
determined	O
using	O
Oil	B-MED
Red	I-MED
O	I-MED
staining	I-MED
and	O
glycerol-3	B-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
(	I-MED
GPDH	I-MED
)	I-MED
activity	I-MED
.	O
The	O
proportion	O
of	O
OLA	B-MED
,	O
PAM	B-MED
,	O
or	O
STA	B-MED
was	O
increased	B-MED
(	O
P	O
<	O
0.05	O
)	O
in	O
SVC	B-MED
grown	O
in	O
either	O
FBS	B-MED
or	O
CS	B-MED
with	O
OLA	B-MED
,	O
PAM	B-MED
or	O
STA	B-MED
.	O
Adipogenesis	B-MED
was	O
induced	B-MED
in	O
FBS	B-MED
+	O
OLA	B-MED
,	O
FBS	B-MED
+	O
LNA	B-MED
,	O
FBS	B-MED
+	O
PAM	B-MED
,	O
FBS	B-MED
+	O
STA	B-MED
,	O
CS	B-MED
+	O
OLA	B-MED
,	O
CS	B-MED
+	O
LNA	B-MED
,	O
CS	B-MED
+	O
PAM	B-MED
,	O
or	O
CS	B-MED
+	O
STA	B-MED
compared	O
to	O
FBS	B-MED
.	O
GPDH	B-MED
activity	I-MED
was	O
significantly	B-MED
higher	I-MED
in	O
FBS	B-MED
+	O
OLA	B-MED
and	O
FBS	B-MED
+	O
LNA	B-MED
than	O
one	O
in	O
FBS	B-MED
.	O
Compared	O
to	O
FBS	B-MED
,	O
the	O
expression	B-MED
of	O
FABP4	B-MED
mRNA	B-MED
increased	B-MED
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	B-MED
+	O
OLA	B-MED
,	O
FBS	B-MED
+	O
LNA	B-MED
,	O
or	O
FBS	B-MED
+	O
PAM	B-MED
,	O
whereas	O
that	O
of	O
C	B-MED
/	I-MED
EBPα	I-MED
,	O
C	B-MED
/	I-MED
EBPβ	I-MED
,	O
and	O
ATGL	B-MED
increased	B-MED
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	B-MED
+	O
OLA	B-MED
or	O
FBS	B-MED
+	O
LNA	B-MED
cells	B-MED
.	O
Expression	B-MED
of	O
FABP4	B-MED
and	O
C	B-MED
/	I-MED
EBPβ	I-MED
mRNA	B-MED
was	O
higher	B-MED
in	O
CS	B-MED
,	O
CS	B-MED
+	O
OLA	B-MED
,	O
CS	B-MED
+	O
LNA	B-MED
,	O
CS	B-MED
+	O
PAM	B-MED
,	O
or	O
CS	B-MED
+	O
STA	B-MED
compared	B-MED
with	O
(	O
FBS	B-MED
,	O
whereas	O
the	O
expression	B-MED
of	O
ATGL	B-MED
and	O
C	B-MED
/	I-MED
EBPα	I-MED
was	O
higher	B-MED
in	O
CS	B-MED
,	O
CS	B-MED
+	O
OLA	B-MED
,	O
or	O
CS	B-MED
+	O
LNA	B-MED
than	O
FBS	B-MED
cells	B-MED
.	O
In	O
conclusion	O
,	O
these	O
results	B-MED
showed	O
that	O
FA	B-MED
have	O
different	B-MED
potentials	B-MED
to	O
induce	B-MED
adipogenesis	B-MED
,	O
LNA	B-MED
is	O
the	O
most	O
potent	B-MED
among	O
the	O
tested	O
FA	B-MED
,	O
and	O
these	O
potentials	B-MED
can	O
be	O
improved	O
in	O
the	O
presence	B-MED
of	O
CS	B-MED
.	O
A	O
case	B-MED
of	O
bilateral	B-MED
pneumothoraces	B-MED
resulting	O
from	O
tracheostomy	B-MED
for	O
advanced	B-MED
laryngeal	B-MED
cancer	I-MED
Pneumothorax	B-MED
is	O
a	O
possible	O
complication	B-MED
of	O
tracheostomy	B-MED
.	O
We	O
report	B-MED
a	O
rare	O
case	O
of	O
bilateral	B-MED
pneumothoraces	B-MED
resulting	O
from	O
tracheostomy	B-MED
in	O
an	O
advanced	B-MED
laryngeal	B-MED
cancer	I-MED
patient	B-MED
.	O
A	O
59	O
-	O
year	O
-	O
old	O
man	B-MED
was	O
referred	O
to	O
our	O
clinic	B-MED
for	O
evaluation	B-MED
and	O
treatment	B-MED
of	O
laryngeal	B-MED
tumor	I-MED
.	O
Laryngeal	B-MED
endoscopy	I-MED
showed	O
limited	B-MED
movement	I-MED
of	O
bilateral	B-MED
vocal	I-MED
cords	I-MED
,	O
and	O
computed	B-MED
tomography	I-MED
revealed	O
a	O
tumor	B-MED
lesion	B-MED
extending	O
from	O
the	O
vocal	B-MED
cords	I-MED
to	O
the	O
subglottic	B-MED
area	I-MED
.	O
Three	O
days	B-MED
after	O
the	O
first	B-MED
visit	I-MED
,	O
the	O
patient	B-MED
developed	O
respiratory	B-MED
difficulty	I-MED
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-MED
tracheostomy	I-MED
for	O
airway	B-MED
management	I-MED
.	O
Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-MED
,	O
he	O
began	O
hyperventilating	B-MED
,	O
and	O
complained	O
of	O
respiratory	B-MED
discomfort	I-MED
and	O
chest	B-MED
pain	I-MED
.	O
We	O
then	O
recognized	O
a	O
mediastinal	B-MED
air	B-MED
leak	I-MED
,	O
and	O
we	O
suspected	B-MED
pneumothorax	B-MED
resulting	O
from	O
the	O
tracheostomy	B-MED
.	O
Chest	B-MED
X	I-MED
-	I-MED
ray	I-MED
showed	O
bilateral	B-MED
pneumothoraces	B-MED
;	O
therefore	O
,	O
we	O
inserted	B-MED
bilateral	B-MED
chest	B-MED
drainage	B-MED
tubes	I-MED
,	O
which	O
stabilized	B-MED
his	O
respiratory	B-MED
condition	I-MED
.	O
We	O
speculated	O
that	O
the	O
pathogenesis	B-MED
of	O
the	O
bilateral	B-MED
pneumothoraces	B-MED
was	O
weakened	B-MED
alveolar	B-MED
walls	I-MED
secondary	O
to	O
long	B-MED
-	I-MED
term	I-MED
smoking	B-MED
,	O
and	O
a	O
significant	O
rise	B-MED
in	O
airway	B-MED
pressure	I-MED
because	O
of	O
airway	B-MED
constriction	I-MED
by	O
the	O
neck	B-MED
-	I-MED
extended	I-MED
position	I-MED
and	O
hyperventilation	B-MED
,	O
during	O
tracheostomy	B-MED
.	O
Personally	B-MED
Meaningful	I-MED
Rituals	I-MED
:	O
A	O
Way	O
to	O
Increase	B-MED
Compassion	B-MED
and	O
Decrease	B-MED
Burnout	B-MED
among	O
Hospice	B-MED
Staff	B-MED
and	O
Volunteers	B-MED
Rituals	B-MED
can	O
increase	B-MED
a	O
sense	B-MED
of	I-MED
connectedness	I-MED
,	O
meaning	B-MED
,	O
and	O
support	B-MED
,	O
especially	O
after	O
the	O
death	B-MED
of	O
those	O
for	O
whom	O
we	O
care	O
.	O
Hospice	B-MED
staff	B-MED
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	B-MED
rituals	I-MED
as	O
they	O
cope	B-MED
with	I-MED
the	O
frequent	B-MED
deaths	I-MED
of	O
their	O
patients	B-MED
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	B-MED
care	I-MED
while	O
minimizing	O
burnout	B-MED
.	O
This	O
study	O
investigated	O
the	O
role	O
of	O
personally	B-MED
meaningful	I-MED
rituals	I-MED
in	O
increasing	B-MED
compassion	B-MED
and	O
decreasing	B-MED
burnout	B-MED
among	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
.	O
An	O
online	B-MED
survey	I-MED
was	O
completed	O
by	O
members	O
of	O
the	O
National	B-MED
Hospice	I-MED
and	I-MED
Palliative	I-MED
Care	I-MED
Organization	I-MED
Hospice	B-MED
(	O
NHPCO	B-MED
)	O
which	O
inquired	O
about	O
personal	B-MED
ritual	I-MED
practices	O
,	O
and	O
included	O
the	O
Professional	B-MED
Quality	I-MED
of	I-MED
Life	I-MED
(	I-MED
ProQOL	I-MED
)	I-MED
scale	I-MED
ProQOL	B-MED
to	O
measure	O
current	O
levels	O
of	O
Compassion	B-MED
Satisfaction	B-MED
,	O
Burnout	B-MED
,	O
and	O
Secondary	B-MED
Traumatic	I-MED
Stress	I-MED
.	O
Three	O
hundred	O
ninety	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
from	O
across	O
38	O
states	B-MED
completed	O
the	O
online	B-MED
survey	I-MED
.	O
The	O
majority	O
of	O
participants	B-MED
were	O
Caucasian	B-MED
and	O
female	B-MED
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	B-MED
hospice	B-MED
and	I-MED
palliative	I-MED
care	I-MED
.	O
The	O
majority	O
of	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
used	O
personally	O
meaningful	O
rituals	B-MED
after	O
the	O
death	B-MED
of	O
their	O
patients	B-MED
to	O
help	O
them	O
cope	B-MED
(	O
71	O
%	O
)	O
.	O
Those	O
who	O
used	O
rituals	B-MED
demonstrated	O
significantly	O
higher	O
Compassion	B-MED
Satisfaction	B-MED
and	O
significantly	O
lower	O
Burnout	B-MED
as	O
measured	O
by	O
the	O
ProQOL	B-MED
,	O
with	O
professional	B-MED
support	I-MED
,	O
social	B-MED
support	I-MED
,	O
and	O
age	B-MED
playing	O
significant	B-MED
roles	I-MED
as	O
well	O
.	O
Rituals	B-MED
may	O
be	O
an	O
important	O
way	O
to	O
increase	B-MED
compassion	B-MED
and	O
decrease	B-MED
burnout	B-MED
among	O
hospice	B-MED
staff	B-MED
and	O
volunteers	B-MED
.	O
Organizations	B-MED
may	O
benefit	O
from	O
providing	O
training	B-MED
and	I-MED
support	I-MED
for	O
personalized	B-MED
rituals	I-MED
among	O
team	O
members	O
,	O
especially	O
new	B-MED
staff	I-MED
who	O
may	O
be	O
at	B-MED
greater	I-MED
risk	I-MED
for	O
burnout	B-MED
.	O
A	O
case	B-MED
based	O
reflection	B-MED
on	O
communicating	B-MED
end	I-MED
of	O
life	B-MED
information	B-MED
in	O
non	B-MED
-	I-MED
English	I-MED
speaking	I-MED
patients	B-MED
Mr	O
X	O
was	O
a	O
56	O
year	B-MED
old	I-MED
Chinese	B-MED
man	B-MED
(	O
non	B-MED
-	I-MED
English	I-MED
speaking	I-MED
)	O
,	O
who	O
presented	O
to	O
the	O
emergency	B-MED
department	I-MED
with	O
a	O
range	O
of	O
non	B-MED
-	I-MED
specific	I-MED
symptoms	B-MED
.	O
On	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-MED
with	O
an	O
advanced	B-MED
cancer	I-MED
of	I-MED
the	I-MED
pancreas	I-MED
.	O
It	O
was	O
an	O
aggressive	B-MED
,	O
highly	O
treatment	B-MED
resistant	I-MED
cancer	I-MED
,	O
with	O
an	O
alarmingly	O
poor	B-MED
prognosis	I-MED
.	O
Before	O
the	O
diagnosis	B-MED
had	O
been	O
made	O
,	O
the	O
family	B-MED
had	O
informed	O
our	O
team	B-MED
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	B-MED
issues	B-MED
with	O
Mr	O
X	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-MED
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O
They	O
reported	O
that	O
Mr	O
X	O
was	O
in	O
support	B-MED
of	O
this	O
arrangement	O
.	O
Eventually	O
we	O
told	O
the	O
family	B-MED
about	O
Mr	O
X	O
's	O
diagnosis	B-MED
,	O
and	O
they	O
asserted	O
their	O
collective	B-MED
will	I-MED
to	O
keep	O
this	O
information	B-MED
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	B-MED
discussion	B-MED
go	O
through	O
them	O
.	O
However	O
,	O
the	O
doctor	B-MED
in	I-MED
charge	I-MED
explained	O
the	O
diagnosis	B-MED
to	O
Mr	O
X	O
using	O
an	O
interpreter	B-MED
while	O
his	O
family	B-MED
were	O
away	O
from	O
his	O
bed	B-MED
.	O
In	O
this	O
discussion	O
,	O
I	O
consider	O
this	O
case	B-MED
from	O
the	O
perspective	O
of	O
respecting	B-MED
patients	I-MED
'	I-MED
and	I-MED
families	I-MED
'	I-MED
preferences	I-MED
around	O
medical	B-MED
treatment	I-MED
and	I-MED
care	I-MED
.	O
Numerical	B-MED
simulation	I-MED
of	O
emitted	B-MED
particle	I-MED
characteristics	B-MED
and	O
airway	B-MED
deposition	B-MED
distribution	B-MED
of	O
Symbicort	B-MED
(	I-MED
®	I-MED
)	I-MED
Turbuhaler	I-MED
(	I-MED
®	I-MED
)	I-MED
dry	B-MED
powder	I-MED
fixed	O
combination	B-MED
aerosol	B-MED
drug	I-MED
One	O
of	O
the	O
most	O
widespread	O
dry	B-MED
powder	I-MED
fixed	O
combinations	B-MED
used	O
in	O
asthma	B-MED
and	O
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
management	B-MED
is	O
Symbicort	B-MED
(	I-MED
®	I-MED
)	I-MED
Turbuhaler	I-MED
(	I-MED
®	I-MED
)	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
simulate	B-MED
the	O
deposition	B-MED
distribution	B-MED
of	O
both	O
components	B-MED
of	O
this	O
drug	B-MED
within	O
the	O
airways	B-MED
based	O
on	O
realistic	O
airflow	B-MED
measurements	I-MED
.	O
Breathing	B-MED
parameters	B-MED
of	O
25	O
healthy	B-MED
adults	I-MED
(	O
11	O
females	B-MED
and	O
14	O
males	B-MED
)	O
were	O
acquired	B-MED
while	O
inhaling	B-MED
through	O
Turbuhaler	B-MED
(	I-MED
®	I-MED
)	I-MED
.	O
Individual	B-MED
specific	O
emitted	B-MED
doses	I-MED
and	O
particle	B-MED
size	I-MED
distributions	B-MED
of	O
Symbicort	B-MED
(	I-MED
®	I-MED
)	I-MED
Turbuhaler	I-MED
(	I-MED
®	I-MED
)	I-MED
were	O
determined	B-MED
.	O
A	O
self	O
-	O
developed	O
particle	B-MED
deposition	B-MED
model	B-MED
was	O
adapted	B-MED
and	O
validated	B-MED
to	O
simulate	B-MED
the	O
deposition	B-MED
of	O
budesonide	B-MED
(	O
inhaled	B-MED
corticosteroid	I-MED
;	O
ICS	B-MED
)	O
and	O
formoterol	B-MED
(	O
long	B-MED
acting	I-MED
β2	I-MED
agonist	I-MED
;	O
LABA	B-MED
)	O
in	O
the	O
upper	B-MED
airways	I-MED
and	O
lungs	B-MED
of	O
the	O
healthy	B-MED
volunteers	I-MED
.	O
Based	O
on	O
current	B-MED
simulations	B-MED
the	O
emitted	B-MED
doses	I-MED
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	B-MED
for	O
the	O
ICS	B-MED
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	B-MED
component	B-MED
depending	O
on	O
the	O
individual	B-MED
inhalation	B-MED
flow	I-MED
rate	I-MED
.	O
This	O
variability	B-MED
induced	B-MED
a	O
notable	O
inter-	O
individual	B-MED
spread	B-MED
of	O
the	O
deposited	B-MED
lung	B-MED
doses	B-MED
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	B-MED
:	O
20.4%-48.8	O
%	O
for	O
budesonide	B-MED
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	B-MED
:	O
16.4%-42.9	O
%	O
for	O
formoterol	B-MED
)	O
.	O
Significant	B-MED
inter	B-MED
-	I-MED
gender	I-MED
differences	B-MED
were	O
also	O
observed	B-MED
.	O
Average	O
lung	B-MED
dose	B-MED
of	O
budesonide	B-MED
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	B-MED
for	O
females	B-MED
and	O
37	O
%	O
for	O
males	B-MED
,	O
while	O
formoterol	B-MED
deposited	B-MED
with	O
26.4	O
%	O
efficiency	B-MED
for	O
females	B-MED
and	O
32.5	O
%	O
for	O
males	B-MED
.	O
Present	O
results	B-MED
also	O
highlighted	O
the	O
importance	B-MED
of	O
breath	B-MED
-	I-MED
holding	I-MED
after	O
inhalation	B-MED
of	O
the	O
drug	B-MED
.	O
About	O
a	O
half	O
of	O
the	O
total	O
lung	B-MED
deposition	B-MED
occurred	B-MED
during	O
breath	B-MED
-	I-MED
hold	I-MED
at	O
9.6s	O
average	O
breath	B-MED
-	I-MED
hold	I-MED
time	B-MED
.	O
Calculated	O
depositions	B-MED
confirmed	B-MED
appropriate	B-MED
lung	B-MED
deposition	B-MED
of	O
Symbicort	B-MED
(	I-MED
®	I-MED
)	I-MED
Turbuhaler	I-MED
(	I-MED
®	I-MED
)	I-MED
for	O
both	O
genders	B-MED
,	O
however	O
more	O
effort	O
for	O
optimal	B-MED
inhalation	I-MED
technique	I-MED
is	O
advised	B-MED
for	O
persons	B-MED
with	O
low	B-MED
vital	I-MED
capacity	I-MED
.	O
This	O
study	B-MED
demonstrated	O
the	O
possibility	O
of	O
personalized	B-MED
prediction	B-MED
of	O
airway	B-MED
deposition	B-MED
of	O
aerosol	B-MED
drugs	I-MED
by	O
numerical	B-MED
simulations	I-MED
.	O
The	O
methodology	B-MED
developed	O
in	O
this	O
study	B-MED
will	O
be	O
applicable	B-MED
also	O
to	O
other	O
marketed	B-MED
drugs	B-MED
in	O
the	O
future	B-MED
.	O
Heart	B-MED
rate	I-MED
variability	B-MED
as	O
a	O
biomarker	B-MED
for	O
sedation	B-MED
depth	I-MED
estimation	B-MED
in	O
ICU	B-MED
patients	B-MED
An	O
automated	B-MED
patient	I-MED
-	I-MED
specific	I-MED
system	I-MED
to	O
classify	O
the	O
level	B-MED
of	I-MED
sedation	I-MED
in	O
ICU	B-MED
patients	B-MED
using	O
heart	B-MED
rate	I-MED
variability	B-MED
signal	B-MED
is	O
presented	B-MED
in	O
this	O
paper	B-MED
.	O
ECG	B-MED
from	O
70	O
mechanically	B-MED
ventilated	I-MED
adult	B-MED
patients	B-MED
with	O
administered	B-MED
sedatives	B-MED
in	O
an	O
ICU	B-MED
setting	I-MED
were	O
used	O
to	O
develop	O
a	O
support	B-MED
vector	I-MED
machine	I-MED
based	O
system	O
for	O
sedation	B-MED
depth	I-MED
monitoring	B-MED
using	O
several	O
heart	B-MED
rate	I-MED
variability	B-MED
measures	B-MED
.	O
A	O
leave	B-MED
-	I-MED
one	I-MED
-	I-MED
subject	I-MED
-	I-MED
out	I-MED
cross	I-MED
validation	I-MED
was	O
used	O
for	O
classifier	B-MED
training	B-MED
and	O
performance	B-MED
evaluations	B-MED
.	O
The	O
proposed	O
patient	B-MED
-	I-MED
specific	I-MED
system	I-MED
provided	B-MED
a	O
sensitivity	B-MED
,	O
specificity	B-MED
and	O
an	O
AUC	B-MED
of	O
64	O
%	O
,	O
84.8	O
%	O
and	O
0.72	O
,	O
respectively	O
.	O
It	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	B-MED
signals	B-MED
the	O
proposed	O
patient	B-MED
-	O
specific	B-MED
sedation	B-MED
level	I-MED
prediction	B-MED
system	B-MED
could	O
lead	O
to	O
a	O
fully	O
automated	B-MED
multimodal	I-MED
system	I-MED
to	O
assist	O
clinical	B-MED
staff	B-MED
in	O
ICUs	B-MED
to	O
interpret	B-MED
the	O
sedation	B-MED
level	I-MED
of	O
the	O
patient	B-MED
.	O
Epidemiology	B-MED
and	O
outcomes	B-MED
of	O
injuries	B-MED
in	O
Kenya	B-MED
:	O
A	O
multisite	B-MED
surveillance	I-MED
study	I-MED
Injury	B-MED
is	O
a	O
leading	O
cause	O
of	O
disability	B-MED
and	O
death	B-MED
worldwide	O
,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-MED
each	O
year	B-MED
.	O
The	O
injury	B-MED
burden	B-MED
is	O
higher	O
in	O
low-	B-MED
and	I-MED
middle	I-MED
-	I-MED
income	I-MED
countries	I-MED
where	O
more	O
than	O
90	O
%	O
of	O
injury	B-MED
injury	B-MED
-related	I-MED
deaths	I-MED
occur	O
.	O
Despite	O
this	O
burden	B-MED
,	O
the	O
use	O
of	O
prospective	O
trauma	B-MED
registries	B-MED
to	O
describe	O
injury	B-MED
epidemiology	B-MED
and	O
outcomes	B-MED
is	O
limited	O
in	O
low-	B-MED
and	I-MED
middle	I-MED
-	I-MED
income	I-MED
countries	I-MED
.	O
Kenya	B-MED
lacks	O
robust	O
data	B-MED
to	O
describe	O
injury	B-MED
epidemiology	B-MED
and	O
care	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
epidemiology	B-MED
and	O
outcomes	B-MED
of	O
injuries	B-MED
at	O
4	O
referral	B-MED
hospitals	I-MED
in	O
Kenya	B-MED
using	O
hospital	B-MED
-based	O
trauma	B-MED
registries	B-MED
.	O
From	O
January	B-MED
2014	O
to	O
May	B-MED
2015	O
,	O
all	O
injured	B-MED
patients	I-MED
presenting	O
to	O
the	O
casualty	B-MED
departments	I-MED
of	O
Kenyatta	B-MED
National	I-MED
,	O
Thika	B-MED
Level	I-MED
5	I-MED
,	O
Machakos	B-MED
Level	I-MED
5	I-MED
,	O
and	O
Meru	B-MED
Level	I-MED
5	I-MED
Hospitals	I-MED
were	O
enrolled	O
prospectively	O
.	O
Data	B-MED
collected	I-MED
included	O
demographic	B-MED
characteristics	I-MED
,	O
type	B-MED
of	O
prehospital	B-MED
care	I-MED
received	B-MED
,	O
prehospital	B-MED
time	I-MED
,	O
injury	B-MED
pattern	I-MED
,	O
and	O
outcomes	B-MED
.	O
A	O
total	O
of	O
14,237	O
patients	B-MED
were	O
enrolled	O
in	O
our	O
study	O
.	O
Patients	B-MED
were	O
predominantly	O
male	B-MED
(	O
76.1	O
%	O
)	O
and	O
young	B-MED
(	O
mean	B-MED
age	I-MED
28	O
years	B-MED
)	O
.	O
The	O
most	O
common	O
mechanisms	B-MED
of	I-MED
injury	I-MED
were	O
road	B-MED
traffic	B-MED
injuries	I-MED
(	O
36.8	O
%	O
)	O
,	O
falls	B-MED
(	O
26.4	O
%	O
)	O
,	O
and	O
being	O
struck	B-MED
/	I-MED
hit	I-MED
by	I-MED
a	O
person	B-MED
or	O
object	B-MED
(	O
20.1	O
%	O
)	O
.	O
Burn	B-MED
was	O
the	O
most	O
common	O
mechanism	B-MED
of	I-MED
injury	I-MED
in	O
the	O
age	B-MED
category	B-MED
under	O
5	O
years	B-MED
.	O
Body	B-MED
regions	I-MED
commonly	O
injured	B-MED
were	O
lower	B-MED
extremity	I-MED
(	O
35.1	O
%	O
)	O
,	O
upper	B-MED
extremity	I-MED
(	O
33.4	O
%	O
)	O
,	O
and	O
head	B-MED
(	O
26.0	O
%	O
)	O
.	O
The	O
overall	O
mortality	B-MED
rate	I-MED
was	O
2.4	O
%	O
.	O
Significant	B-MED
predictors	I-MED
of	O
mortality	B-MED
from	O
multivariate	B-MED
analysis	I-MED
were	O
Glasgow	B-MED
Coma	I-MED
Scale	I-MED
≤12	I-MED
,	O
estimated	O
injury	B-MED
severity	I-MED
score	I-MED
≥9	O
,	O
burns	B-MED
,	O
and	O
gunshot	B-MED
injuries	I-MED
.	O
Hospital	B-MED
-based	O
trauma	B-MED
registries	B-MED
can	O
be	O
important	O
sources	B-MED
of	I-MED
data	I-MED
to	O
study	B-MED
the	I-MED
epidemiology	I-MED
of	O
injuries	B-MED
in	O
low-	B-MED
and	I-MED
middle	I-MED
-	I-MED
income	I-MED
countries	I-MED
.	O
Data	B-MED
from	O
such	O
trauma	B-MED
registries	B-MED
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	B-MED
health	B-MED
interventions	B-MED
and	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
improvement	I-MED
programs	I-MED
.	O
Patient	B-MED
Satisfaction	I-MED
With	O
Postpartum	B-MED
Teaching	B-MED
Methods	B-MED
Postpartum	B-MED
discharge	B-MED
instructions	I-MED
are	O
a	O
crucial	O
part	O
of	O
a	O
mother	B-MED
's	I-MED
birth	B-MED
experience	B-MED
.	O
Finding	B-MED
the	O
method	B-MED
to	O
provide	O
those	O
discharge	B-MED
instructions	I-MED
in	O
a	O
manner	O
that	O
increases	B-MED
the	O
mother	B-MED
's	I-MED
satisfaction	B-MED
with	O
her	O
hospital	B-MED
experience	B-MED
is	O
important	O
.	O
This	O
quasi	B-MED
-	I-MED
experimental	I-MED
study	I-MED
examined	B-MED
the	O
relationship	B-MED
between	O
new	B-MED
mothers	B-MED
'	I-MED
interaction	B-MED
with	O
nurses	B-MED
providing	O
postpartum	B-MED
instructions	B-MED
by	O
the	O
traditional	B-MED
and	O
class	O
methods	B-MED
and	O
their	O
satisfaction	B-MED
with	O
discharge	B-MED
teaching	I-MED
.	O
The	O
results	O
indicated	O
new	B-MED
mothers	B-MED
were	O
satisfied	B-MED
with	O
both	O
methods	B-MED
of	O
discharge	B-MED
teaching	I-MED
;	O
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	B-MED
with	O
overall	O
satisfaction	B-MED
with	O
the	O
traditional	B-MED
method	B-MED
of	O
discharge	B-MED
teaching	I-MED
than	O
with	O
attending	B-MED
the	O
discharge	B-MED
class	I-MED
.	O
Inhibited	B-MED
Temperament	B-MED
and	O
Hippocampal	B-MED
Volume	B-MED
in	O
Offspring	B-MED
of	O
Parents	B-MED
with	O
Bipolar	B-MED
Disorder	I-MED
Prior	O
studies	O
have	O
suggested	B-MED
that	O
inhibited	B-MED
temperament	B-MED
may	O
be	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
for	O
developing	O
anxiety	B-MED
or	O
mood	B-MED
disorder	I-MED
,	O
including	O
bipolar	B-MED
disorder	I-MED
.	O
However	O
,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	B-MED
risk	B-MED
is	O
unknown	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-MED
temperament	B-MED
in	O
symptomatic	B-MED
and	O
asymptomatic	B-MED
child	B-MED
offspring	B-MED
of	O
parents	B-MED
with	O
bipolar	B-MED
disorder	I-MED
(	O
OBD	B-MED
)	O
and	O
to	O
investigate	B-MED
whether	O
inhibited	B-MED
inhibited	B-MED
temperament	B-MED
is	O
associated	B-MED
with	I-MED
aberrant	B-MED
hippocampal	B-MED
volumes	B-MED
compared	B-MED
with	O
healthy	B-MED
control	I-MED
(	O
HC	B-MED
)	O
youth	B-MED
.	O
The	O
OBD	B-MED
group	B-MED
consisted	O
of	O
45	O
youth	B-MED
,	O
24	O
of	O
whom	O
had	O
current	B-MED
psychiatric	B-MED
symptoms	I-MED
(	B-MED
OBD(+)s	I-MED
)	I-MED
and	O
21	O
without	B-MED
any	O
psychiatric	B-MED
symptoms	I-MED
(	O
OBD(-)s	O
)	O
,	O
and	O
were	O
compared	B-MED
with	O
24	O
HC	B-MED
youth	B-MED
.	O
Temperament	B-MED
characteristics	B-MED
were	O
measured	B-MED
by	O
using	O
the	O
Revised	B-MED
Dimensions	I-MED
of	I-MED
Temperament	I-MED
Survey	I-MED
.	O
Magnetic	B-MED
resonance	I-MED
imaging	I-MED
was	O
used	O
to	O
measure	B-MED
hippocampal	B-MED
volumes	B-MED
.	O
The	O
association	B-MED
between	O
temperament	B-MED
and	O
hippocampal	B-MED
volumes	B-MED
was	O
tested	B-MED
by	O
using	O
multiple	B-MED
regression	I-MED
analysis	I-MED
.	O
Compared	B-MED
with	O
the	O
OBD(-)s	B-MED
group	I-MED
,	O
the	O
OBD(+)s	B-MED
group	B-MED
had	O
significantly	B-MED
more	I-MED
inhibited	B-MED
inhibited	B-MED
temperament	B-MED
traits	B-MED
,	O
less	B-MED
flexibility	B-MED
,	O
more	B-MED
negative	B-MED
mood	B-MED
,	O
and	O
less	B-MED
regular	B-MED
rhythm	B-MED
in	O
their	O
daily	B-MED
routines	B-MED
.	O
In	O
contrast	O
,	O
the	O
OBD(-)s	B-MED
group	I-MED
was	O
more	O
likely	O
to	O
approach	O
novel	B-MED
situations	B-MED
compared	B-MED
with	O
OBD(+)s	B-MED
or	O
HC	B-MED
groups	B-MED
.	O
Within	O
the	O
OBD(+)s	B-MED
group	B-MED
,	O
a	O
more	O
inhibited	B-MED
inhibited	B-MED
temperament	B-MED
was	O
associated	B-MED
with	I-MED
smaller	O
right	B-MED
hippocampal	B-MED
volumes	B-MED
.	O
In	O
this	O
study	O
,	O
symptomatic	B-MED
OBD	B-MED
were	O
characterized	B-MED
by	O
an	O
inhibited	B-MED
inhibited	B-MED
temperament	B-MED
that	O
was	O
inversely	B-MED
correlated	B-MED
with	O
hippocampal	B-MED
volume	B-MED
.	O
Additional	O
longitudinal	B-MED
studies	I-MED
are	O
needed	B-MED
to	O
determine	O
whether	O
inverse	B-MED
correlations	B-MED
between	O
hippocampal	B-MED
volume	B-MED
and	O
inhibited	B-MED
inhibited	B-MED
temperament	B-MED
represent	O
early	O
markers	B-MED
of	O
risk	B-MED
for	O
later	O
developing	O
bipolar	B-MED
disorder	I-MED
.	O
Far	B-MED
-	I-MED
infrared	I-MED
protects	B-MED
vascular	B-MED
endothelial	I-MED
cells	I-MED
from	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
-	O
induced	B-MED
injury	B-MED
via	O
PLZF	B-MED
-mediated	O
autophagy	B-MED
in	O
diabetic	B-MED
mice	I-MED
The	O
accumulation	O
of	O
advanced	B-MED
glycation	I-MED
end	I-MED
products	I-MED
(	O
AGEs	B-MED
)	O
in	O
diabetic	B-MED
patients	B-MED
induces	B-MED
vascular	B-MED
endothelial	I-MED
injury	B-MED
.	O
Promyelocytic	B-MED
leukemia	I-MED
zinc	I-MED
finger	I-MED
protein	I-MED
(	O
PLZF	B-MED
)	O
is	O
a	O
transcription	B-MED
factor	I-MED
that	O
can	O
be	O
activated	B-MED
by	O
low	B-MED
-	I-MED
temperature	I-MED
far	B-MED
-	I-MED
infrared	I-MED
(	O
FIR	B-MED
)	O
irradiation	B-MED
to	O
exert	B-MED
beneficial	I-MED
effects	I-MED
on	O
the	O
vascular	B-MED
endothelium	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
influence	B-MED
of	O
FIR	B-MED
-	O
induced	B-MED
PLZF	B-MED
activation	B-MED
on	O
AGE	B-MED
-	O
induced	B-MED
endothelial	B-MED
injury	B-MED
both	B-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
FIR	B-MED
irradiation	B-MED
inhibited	B-MED
AGE	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
human	B-MED
umbilical	I-MED
vein	I-MED
endothelial	I-MED
cells	I-MED
(	O
HUVECs	B-MED
)	O
.	O
PLZF	B-MED
activation	B-MED
increased	B-MED
the	O
expression	B-MED
of	O
phosphatidylinositol-3	B-MED
kinases	I-MED
(	O
PI3	B-MED
K	I-MED
)	O
,	O
which	O
are	O
important	B-MED
kinases	B-MED
in	O
the	O
autophagic	B-MED
signaling	B-MED
pathway	I-MED
.	O
FIR	B-MED
-	O
induced	B-MED
PLZF	B-MED
activation	B-MED
led	O
to	O
autophagy	B-MED
in	O
HUVEC	B-MED
,	O
which	O
was	O
mediated	O
through	B-MED
the	O
upregulation	B-MED
PI3	B-MED
K	I-MED
of	O
PI3K.	O
Immunofluorescence	B-MED
staining	B-MED
showed	O
that	O
AGEs	B-MED
were	O
engulfed	O
by	O
HUVECs	B-MED
and	O
localized	B-MED
to	O
lysosomes	B-MED
.	O
FIR	B-MED
-	O
induced	B-MED
autophagy	B-MED
promoted	B-MED
AGEs	B-MED
degradation	B-MED
in	O
HUVECs	B-MED
.	O
In	O
nicotinamide	B-MED
/	O
streptozotocin	B-MED
-	O
induced	B-MED
diabetic	B-MED
mice	I-MED
,	O
FIR	B-MED
therapy	B-MED
reduced	B-MED
serum	B-MED
AGEs	I-MED
and	O
AGEs	B-MED
deposition	B-MED
at	O
the	O
vascular	B-MED
endothelium	I-MED
.	O
FIR	B-MED
therapy	B-MED
also	O
reduced	B-MED
diabetes	B-MED
-	O
induced	B-MED
inflammatory	B-MED
markers	I-MED
in	O
the	O
vascular	B-MED
endothelium	I-MED
and	O
improved	B-MED
vascular	B-MED
endothelial	I-MED
function	B-MED
.	O
These	O
protective	B-MED
effects	I-MED
of	O
FIR	B-MED
therapy	B-MED
were	O
not	B-MED
found	I-MED
in	O
PLZF	B-MED
-	O
knockout	B-MED
mice	I-MED
.	O
Our	O
data	B-MED
suggest	B-MED
that	O
FIR	B-MED
-	O
induced	B-MED
PLZF	B-MED
activation	B-MED
in	O
vascular	B-MED
endothelial	I-MED
cells	I-MED
protects	O
the	O
vascular	B-MED
endothelium	I-MED
in	O
diabetic	B-MED
mice	I-MED
from	O
AGE	B-MED
-	O
induced	B-MED
injury	B-MED
.	O
Clonal	B-MED
and	O
serotype	B-MED
dynamics	B-MED
of	O
serogroup	B-MED
6	I-MED
isolates	B-MED
causing	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
Portugal	B-MED
:	O
1999	O
-	O
2012	O
Although	O
serogroup	B-MED
6	I-MED
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
Streptococcus	B-MED
pneumoniae	I-MED
,	O
several	O
new	O
serotypes	B-MED
were	O
identified	B-MED
since	O
the	O
introduction	B-MED
of	O
pneumococcal	B-MED
conjugate	I-MED
vaccines	I-MED
(	O
PCVs	B-MED
)	O
.	O
A	O
decrease	B-MED
of	O
the	O
6B-2	B-MED
variant	I-MED
among	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
(	O
IPD	B-MED
)	O
,	O
but	O
not	O
6B-1	B-MED
,	O
was	O
noted	O
post	B-MED
conjugate	B-MED
vaccine	I-MED
introduction	B-MED
,	O
underpinned	O
by	O
a	O
decrease	B-MED
of	O
CC273	B-MED
isolates	I-MED
.	O
Serotype	B-MED
6C	I-MED
was	O
associated	B-MED
with	I-MED
adult	B-MED
IPD	B-MED
and	O
increased	B-MED
in	O
this	O
age	B-MED
group	I-MED
representing	O
two	O
lineages	B-MED
(	O
CC315	B-MED
and	O
CC395	B-MED
)	O
,	O
while	O
the	O
same	O
lineages	B-MED
expressed	B-MED
other	O
serogroup	B-MED
6	I-MED
serotypes	B-MED
in	O
children	B-MED
.	O
Taken	O
together	O
,	O
these	O
findings	B-MED
suggest	O
a	O
potential	O
cross	B-MED
-	I-MED
protection	I-MED
of	O
PCVs	B-MED
against	O
serotype	B-MED
6C	I-MED
IPD	B-MED
among	O
vaccinated	B-MED
children	B-MED
but	O
not	O
among	O
adults	B-MED
.	O
Serotype	B-MED
6A	I-MED
became	O
the	O
most	O
important	O
serogroup	B-MED
6	I-MED
serotype	B-MED
in	O
children	B-MED
but	O
it	O
decreased	B-MED
in	O
adult	B-MED
IPD	B-MED
.	O
No	O
other	O
serogroup	B-MED
6	I-MED
serotypes	B-MED
were	O
detected	B-MED
,	O
so	O
available	O
phenotypic	B-MED
or	O
simple	O
genotypic	B-MED
assays	B-MED
remain	O
adequate	B-MED
for	O
distinguishing	O
serotypes	B-MED
within	O
serogroup	B-MED
6	I-MED
isolates	B-MED
.	O
Long	B-MED
-	I-MED
chain	I-MED
n-3	I-MED
PUFA	I-MED
supplied	B-MED
by	O
the	O
usual	B-MED
diet	B-MED
decrease	B-MED
plasma	B-MED
stearoyl	I-MED
-	I-MED
CoA	I-MED
desaturase	I-MED
index	B-MED
in	O
non	B-MED
-	I-MED
hypertriglyceridemic	I-MED
older	B-MED
adults	I-MED
at	O
high	O
vascular	B-MED
risk	B-MED
The	O
activity	B-MED
of	O
stearoyl	B-MED
-	I-MED
CoA	I-MED
desaturase-1	I-MED
(	O
SCD1	B-MED
)	O
,	O
the	O
central	B-MED
enzyme	I-MED
in	O
the	O
synthesis	B-MED
of	O
monounsaturated	B-MED
fatty	I-MED
acids	I-MED
(	O
MUFA	B-MED
)	O
,	O
has	O
been	O
associated	B-MED
with	I-MED
de	B-MED
novo	I-MED
lipogenesis	B-MED
.	O
In	O
experimental	B-MED
models	I-MED
SCD1	B-MED
is	O
down	B-MED
-	I-MED
regulated	I-MED
by	O
polyunsaturated	B-MED
fatty	I-MED
acids	I-MED
(	O
PUFA	B-MED
)	O
,	O
but	O
clinical	B-MED
studies	I-MED
are	O
scarce	O
.	O
The	O
effect	B-MED
of	O
long	B-MED
-	I-MED
chain	I-MED
n-3	I-MED
PUFA	I-MED
(	O
LCn-3PUFA	B-MED
)	O
supplied	B-MED
by	O
the	O
regular	B-MED
diet	I-MED
,	O
in	O
the	O
absence	B-MED
of	O
fatty	B-MED
fish	I-MED
or	O
fish	B-MED
oil	I-MED
supplementation	B-MED
,	I-MED
remains	O
to	O
be	O
explored	O
.	O
We	O
related	B-MED
1	O
-	O
y	O
changes	B-MED
in	O
plasma	B-MED
SCD1	I-MED
index	B-MED
,	O
as	O
assessed	B-MED
by	O
the	O
C16:1n-7	B-MED
/	O
C16:0	B-MED
ratio	B-MED
,	O
to	O
both	O
adiposity	B-MED
traits	B-MED
and	O
nutrient	B-MED
intake	I-MED
changes	B-MED
in	O
a	O
sub	B-MED
-	I-MED
cohort	I-MED
(	O
n	O
=	O
243	O
)	O
of	O
non	B-MED
-	I-MED
hypertriglyceridemic	I-MED
subjects	B-MED
of	O
the	O
PREDIMED	B-MED
(	I-MED
PREvención	I-MED
con	I-MED
DIeta	I-MED
MEDiterranea	I-MED
)	I-MED
trial	I-MED
.	O
After	O
adjustment	O
for	O
confounders	O
,	O
including	O
changes	B-MED
in	O
fasting	B-MED
triglycerides	B-MED
,	O
plasma	B-MED
SCD1	I-MED
index	B-MED
increased	B-MED
in	O
parallel	O
with	O
body	B-MED
weight	I-MED
(	O
0.221	O
[	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
0.021	O
to	O
0.422	O
]	O
,	O
P	O
=	O
0.031	O
)	O
and	O
BMI	B-MED
(	O
0.115	O
[	O
0.027	O
to	O
0.202	O
]	O
,	O
P	O
=	O
0.011	O
)	O
.	O
Additionally	O
,	O
dietary	B-MED
LCn-3PUFA	B-MED
(	O
but	O
not	O
MUFA	B-MED
or	O
plant	B-MED
-	I-MED
derived	I-MED
PUFA	I-MED
)	O
were	O
associated	B-MED
with	I-MED
decreased	B-MED
plasma	B-MED
SCD1	I-MED
index	B-MED
(	O
-0.544	O
[	O
-1.044	O
to	O
-0.043	O
]	O
,	O
P	O
=	O
0.033	O
,	O
for	O
each	O
1	O
g	O
/	O
d-	O
increase	B-MED
in	O
LCn-3PUFA	B-MED
)	O
.	O
No	O
associations	B-MED
were	O
found	O
for	O
other	O
food	B-MED
groups	B-MED
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty	B-MED
fish	I-MED
intake	B-MED
(	O
-0.083	O
[	O
-0.177	O
to	O
0.012	O
]	O
,	O
P	O
=	O
0.085	O
,	O
for	O
each	O
10	O
g	O
/	O
d-	O
increase	B-MED
)	O
.	O
Our	O
data	B-MED
add	O
clinical	B-MED
evidence	B-MED
on	O
the	O
down	B-MED
-	I-MED
regulation	I-MED
of	O
plasma	B-MED
SCD1	I-MED
index	B-MED
by	O
LCn-3PUFA	B-MED
in	O
the	O
context	B-MED
of	O
realistic	O
changes	B-MED
in	O
fish	B-MED
consumption	B-MED
in	O
the	O
customary	B-MED
,	O
non	B-MED
-	I-MED
supplemented	I-MED
diet	B-MED
.	O
http://www.Controlled-trials.com/ISRCTN35739639	O
.	O
Chaetomium	B-MED
thermophilum	I-MED
formate	B-MED
dehydrogenase	I-MED
has	O
high	O
activity	O
in	O
the	O
reduction	B-MED
of	O
hydrogen	B-MED
carbonate	I-MED
(	O
HCO3	B-MED
-	I-MED
)	O
to	O
formate	B-MED
While	O
formate	B-MED
dehydrogenases	I-MED
(	O
FDHs	B-MED
)	O
have	O
been	O
used	O
for	O
cofactor	B-MED
recycling	B-MED
in	O
chemoenzymatic	B-MED
synthesis	I-MED
,	O
the	O
ability	O
of	O
FDH	B-MED
to	O
reduce	O
CO2	B-MED
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	B-MED
of	O
CO2	B-MED
to	O
useful	O
products	B-MED
via	O
formate	B-MED
(	O
HCOO(-	B-MED
)	I-MED
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	B-MED
the	O
reduction	B-MED
of	O
CO2	B-MED
in	O
the	O
form	O
of	O
hydrogen	B-MED
carbonate	I-MED
(	O
HCO3(-	B-MED
)	I-MED
)	O
to	O
formate	B-MED
by	O
FDHs	B-MED
from	O
Candida	B-MED
methylica	I-MED
(	O
CmFDH	B-MED
)	O
and	O
Chaetomium	B-MED
thermophilum	I-MED
(	O
CtFDH	B-MED
)	O
in	O
a	O
NADH	B-MED
-dependent	O
reaction	B-MED
.	O
The	O
catalytic	B-MED
performance	I-MED
with	O
HCO3(-	B-MED
)	I-MED
as	O
a	O
substrate	B-MED
was	O
evaluated	O
by	O
measuring	B-MED
the	O
kinetic	B-MED
rates	I-MED
and	O
conducting	O
productivity	B-MED
assays	I-MED
.	O
CtFDH	B-MED
showed	O
a	O
higher	O
efficiency	B-MED
in	O
converting	B-MED
HCO3(-	B-MED
)	I-MED
to	O
formate	B-MED
than	O
CmFDH	B-MED
,	O
whereas	O
CmFDH	B-MED
was	O
better	O
in	O
the	O
oxidation	B-MED
of	O
formate	B-MED
.	O
The	O
pH	B-MED
optimum	O
of	O
the	O
reduction	B-MED
was	O
at	O
pH	B-MED
7	O
-	O
8	O
.	O
However	O
,	O
the	O
high	B-MED
concentrations	I-MED
of	O
HCO3(-	B-MED
)	I-MED
reduced	O
the	O
reaction	B-MED
rate	I-MED
.	O
CtFDH	B-MED
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3(-	B-MED
)	I-MED
showing	O
that	O
it	O
fits	O
to	O
the	O
active	B-MED
site	I-MED
.	O
The	O
active	B-MED
site	I-MED
setting	O
for	O
hydride	B-MED
transfer	I-MED
in	O
CO2	B-MED
reduction	B-MED
was	O
modeled	O
.	O
The	O
hydride	B-MED
donated	I-MED
by	O
NADH	B-MED
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	B-MED
atom	I-MED
of	O
HCO3(-	B-MED
)	I-MED
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	B-MED
within	O
the	O
molecule	B-MED
.	O
This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	B-MED
carbonate	I-MED
and	O
the	O
hydride	B-MED
to	O
break	O
into	O
formate	B-MED
and	O
hydroxide	B-MED
ions	I-MED
.	O
Central	B-MED
Myxoma	I-MED
/	O
Myxofibroma	B-MED
of	O
the	O
Jaws	B-MED
:	O
A	O
Clinico	B-MED
-	O
Epidemiologic	B-MED
Review	B-MED
Myxomas	B-MED
are	O
a	O
group	O
of	O
benign	B-MED
rare	B-MED
tumors	I-MED
of	O
connective	B-MED
-	I-MED
tissue	I-MED
origin	B-MED
that	O
occur	O
in	O
both	O
hard	B-MED
(	I-MED
central	I-MED
)	I-MED
and	O
soft	B-MED
tissues	I-MED
of	O
the	O
body	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central	B-MED
myxoma	I-MED
of	I-MED
the	I-MED
jaw	I-MED
,	O
with	O
emphasis	O
on	O
its	O
clinic	B-MED
-	O
epidemiologic	B-MED
features	O
as	O
seen	O
in	O
our	O
environment	B-MED
.	O
All	O
patients	B-MED
who	O
were	O
managed	O
for	O
central	B-MED
myxoma	I-MED
of	I-MED
the	I-MED
jaw	I-MED
at	O
the	O
Oral	B-MED
and	I-MED
Maxillofacial	I-MED
Surgery	I-MED
department	I-MED
of	O
a	O
regional	B-MED
University	I-MED
Teaching	I-MED
Hospital	I-MED
between	O
September	O
1997	O
and	O
October	O
2015	O
were	O
retrospectively	B-MED
studied	I-MED
.	O
Details	O
sourced	O
included	O
age	B-MED
,	O
sex	B-MED
,	O
site	B-MED
of	I-MED
tumor	I-MED
,	O
duration	B-MED
,	O
signs	B-MED
/	I-MED
symptoms	I-MED
,	O
treatment	B-MED
given	I-MED
,	O
and	O
complications	B-MED
.	O
Data	B-MED
were	O
analyzed	B-MED
using	O
Statistical	B-MED
Package	I-MED
for	I-MED
Social	I-MED
Sciences	I-MED
(	I-MED
SPSS	I-MED
)	I-MED
version	I-MED
16	I-MED
(	O
SPSS	B-MED
Inc	I-MED
.	O
,	O
Chicago	B-MED
,	O
IL	B-MED
,	O
USA	B-MED
)	O
and	O
Microsoft	B-MED
Excel	I-MED
2007	I-MED
(	O
Microsoft	B-MED
,	O
Redmond	B-MED
,	O
WA	B-MED
,	O
USA	B-MED
)	O
.	O
Results	B-MED
from	O
descriptive	B-MED
statistics	I-MED
were	O
represented	O
in	O
the	O
form	O
of	O
tables	B-MED
and	O
charts	B-MED
,	O
with	O
a	O
test	B-MED
for	I-MED
significance	I-MED
(	O
ρ	O
)	O
using	O
Pearson	B-MED
Chi	I-MED
-	I-MED
square	I-MED
(	O
χ(2	O
)	O
)	O
set	O
at	O
0.05	O
.	O
A	O
total	O
of	O
16	O
patients	B-MED
were	O
managed	O
within	O
the	O
period	B-MED
reviewed	B-MED
,	O
consisting	O
of	O
10	O
(	O
62.5	O
%	O
)	O
females	B-MED
and	O
six	O
(	O
37.5	O
%	O
)	O
males	B-MED
,	O
giving	O
a	O
male	B-MED
-	I-MED
to	I-MED
-	I-MED
female	I-MED
ratio	I-MED
of	O
1:1.7	O
.	O
The	O
ages	B-MED
of	O
patients	B-MED
ranged	B-MED
from	O
5	O
to	O
70	O
years	B-MED
,	O
with	O
a	O
mean	O
of	O
27.06±15.45	O
years	B-MED
.	O
The	O
mandible	B-MED
accounted	O
for	O
nine	O
(	O
56.3	O
%	O
)	O
cases	B-MED
and	O
the	O
maxilla	B-MED
for	O
six	O
(	O
37.5	O
%	O
)	O
cases	B-MED
,	O
while	O
a	O
combination	B-MED
of	O
the	O
maxilla	B-MED
and	O
the	O
zygoma	B-MED
were	O
involved	O
in	O
one	O
(	O
6.3	O
%	O
)	O
case	B-MED
.	O
Bucco	B-MED
-	I-MED
lingual	I-MED
or	O
bucco	B-MED
-	I-MED
palatal	I-MED
expansion	B-MED
were	O
the	O
most	O
common	O
presentation	O
(	O
six	O
[	O
46.2	O
%	O
]	O
cases	B-MED
each	O
)	O
.	O
Histological	B-MED
assessment	B-MED
of	O
tissue	B-MED
specimens	I-MED
showed	O
that	O
fibromyxoma	B-MED
accounted	B-MED
for	O
seven	O
(	O
43.8	O
%	O
)	O
cases	B-MED
,	O
while	O
the	O
remaining	O
nine	O
(	O
56.3	O
%	O
)	O
cases	B-MED
were	O
diagnosed	B-MED
as	O
myxoma	B-MED
.	O
All	O
patients	B-MED
had	O
jaw	B-MED
resections	I-MED
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-MED
in	O
nine	O
(	O
60.0	O
%	O
)	O
patients	B-MED
and	O
maxillectomies	B-MED
in	O
six	O
(	O
40.0	O
%	O
)	O
patients	B-MED
.	O
The	O
duration	B-MED
of	I-MED
hospital	I-MED
stay	I-MED
ranged	B-MED
from	O
5	O
to	O
29	O
days	B-MED
,	O
with	O
a	O
mean	O
of	O
17.86±7.68	O
days	B-MED
.	O
Complications	B-MED
were	O
noted	O
in	O
three	O
patients	B-MED
,	O
and	O
all	O
were	O
surgical	B-MED
wound	I-MED
infections	I-MED
.	O
Most	O
patients	B-MED
in	O
our	O
environment	B-MED
present	O
late	O
with	O
large	B-MED
tumors	I-MED
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow	B-MED
-	I-MED
up	I-MED
review	B-MED
.	O
Thus	O
,	O
a	O
radical	B-MED
approach	O
is	O
favored	O
in	O
most	O
patients	B-MED
.	O
Using	O
a	O
graphical	B-MED
risk	I-MED
tool	I-MED
to	O
examine	O
willingness	B-MED
to	I-MED
take	I-MED
migraine	B-MED
prophylactic	B-MED
medications	B-MED
Many	O
migraine	B-MED
sufferers	B-MED
use	O
daily	B-MED
prophylactic	B-MED
therapy	I-MED
to	O
reduce	O
the	O
frequency	B-MED
of	O
their	O
headache	B-MED
attacks	O
.	O
The	O
Food	B-MED
and	I-MED
Drug	I-MED
Administration	I-MED
has	O
approved	B-MED
several	B-MED
different	O
medications	B-MED
for	O
migraine	B-MED
prophylaxis	B-MED
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	B-MED
perceive	O
these	O
treatments	B-MED
to	O
provide	O
clinically	B-MED
significant	I-MED
benefits	B-MED
given	O
their	O
side	B-MED
effect	I-MED
profiles	B-MED
.	O
Three	O
hundred	O
headache	B-MED
sufferers	B-MED
were	O
recruited	O
from	O
the	O
community	B-MED
and	O
local	B-MED
headache	B-MED
clinics	B-MED
using	O
print	B-MED
and	O
television	B-MED
advertising	B-MED
.	O
Participants	B-MED
reported	O
experiencing	O
problematic	O
headache	B-MED
attacks	O
with	O
a	O
median	B-MED
(	O
IQR	O
)	O
frequency	B-MED
of	O
7.0	O
(	O
4	O
-	O
13	O
)	O
headache	B-MED
days	B-MED
per	I-MED
month	I-MED
.	O
These	O
sufferers	B-MED
participated	O
in	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
,	I-MED
single	I-MED
-	I-MED
site	I-MED
,	I-MED
study	I-MED
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O
Participants	B-MED
were	O
instructed	O
on	O
the	O
probability	B-MED
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	B-MED
effects	I-MED
for	O
several	B-MED
blinded	B-MED
medication	B-MED
profiles	B-MED
:	O
divalproex	B-MED
sodium	I-MED
,	O
venlafaxine	B-MED
,	O
gabapentin	B-MED
,	O
propranolol	B-MED
,	O
and	O
topiramate	B-MED
.	O
After	O
learning	O
the	O
likelihood	B-MED
of	O
experiencing	O
side	B-MED
effect	I-MED
profiles	B-MED
of	O
each	O
medication	B-MED
,	O
participants	B-MED
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B-MED
to	I-MED
take	I-MED
the	O
medication	B-MED
for	O
a	O
given	O
headache	B-MED
reduction	B-MED
level	B-MED
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	B-MED
per	I-MED
month	I-MED
.	O
The	O
side	B-MED
effect	I-MED
profile	B-MED
for	O
divalproex	B-MED
sodium	I-MED
was	O
associated	B-MED
with	I-MED
the	O
smallest	B-MED
willingness	I-MED
to	I-MED
take	I-MED
,	O
with	O
gabapentin	B-MED
,	O
propranolol	B-MED
,	O
and	O
topiramate	B-MED
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O
However	O
,	O
<	O
60	O
%	O
of	O
participants	B-MED
reported	O
willingness	B-MED
to	I-MED
take	I-MED
any	O
of	O
these	O
medications	B-MED
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	B-MED
in	O
headache	B-MED
frequency	B-MED
.	O
Several	B-MED
general	O
predictors	B-MED
of	O
willingness	B-MED
to	I-MED
take	I-MED
were	O
observed	O
including	O
high	B-MED
headache	B-MED
-related	O
disability	B-MED
,	O
depressive	B-MED
symptoms	I-MED
,	O
and	O
pain	B-MED
medication	I-MED
concerns	B-MED
including	O
fear	B-MED
of	O
tolerance	B-MED
.	O
These	O
findings	B-MED
suggest	O
that	O
if	O
properly	O
informed	B-MED
of	O
the	O
side	B-MED
effect	I-MED
profiles	B-MED
of	O
these	O
medications	B-MED
,	O
many	O
patients	B-MED
might	O
opt	O
for	O
other	O
treatments	B-MED
.	O
Condition	B-MED
-	O
dependent	B-MED
co	B-MED
-	I-MED
regulation	I-MED
of	O
genomic	B-MED
clusters	I-MED
of	O
virulence	B-MED
factors	I-MED
in	O
the	O
grapevine	B-MED
trunk	I-MED
pathogen	B-MED
Neofusicoccum	B-MED
parvum	I-MED
The	O
ascomycete	B-MED
Neofusicoccum	B-MED
parvum	I-MED
,	O
one	O
of	O
the	O
causal	B-MED
agents	I-MED
of	O
Botryosphaeria	B-MED
dieback	I-MED
,	O
is	O
a	O
destructive	O
wood	B-MED
-	O
infecting	B-MED
fungus	B-MED
and	O
a	O
serious	O
threat	B-MED
to	O
grape	B-MED
production	O
worldwide	B-MED
.	O
The	O
capability	B-MED
of	O
colonizing	B-MED
woody	B-MED
tissue	I-MED
combined	B-MED
with	O
the	O
secretion	B-MED
of	O
phytotoxic	B-MED
compounds	B-MED
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	B-MED
and	O
virulence	B-MED
.	O
Here	O
,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence	B-MED
factors	I-MED
and	O
their	O
transcriptional	B-MED
dynamics	B-MED
as	O
the	O
fungus	B-MED
feeds	B-MED
on	O
different	O
substrates	B-MED
and	O
colonizes	B-MED
the	O
woody	B-MED
stem	I-MED
.	O
We	O
assembled	B-MED
and	O
annotated	B-MED
a	O
highly	B-MED
contiguous	B-MED
genome	B-MED
using	O
single	B-MED
molecule	I-MED
real	I-MED
-	I-MED
time	I-MED
DNA	I-MED
sequencing	I-MED
.	O
Transcriptome	B-MED
profiling	I-MED
by	O
RNA	B-MED
-	I-MED
sequencing	I-MED
determined	O
the	O
genome	B-MED
-wide	O
patterns	B-MED
of	O
expression	B-MED
of	O
virulence	B-MED
factors	I-MED
both	O
in	B-MED
vitro	I-MED
(	O
potato	B-MED
dextrose	B-MED
agar	I-MED
or	O
medium	B-MED
amended	B-MED
with	O
grape	B-MED
wood	B-MED
as	O
substrate	B-MED
)	O
and	O
in	O
planta	B-MED
.	O
Pairwise	B-MED
statistical	I-MED
testing	I-MED
of	O
differential	B-MED
expression	B-MED
followed	O
by	O
co	B-MED
-	I-MED
expression	I-MED
network	I-MED
analysis	I-MED
revealed	O
that	O
physically	B-MED
clustered	B-MED
genes	I-MED
coding	B-MED
for	O
putative	O
virulence	B-MED
functions	B-MED
were	O
induced	O
depending	O
on	O
substrate	B-MED
or	O
stage	B-MED
of	O
plant	B-MED
infection	B-MED
.	O
Co	B-MED
-	I-MED
expressed	I-MED
gene	B-MED
clusters	I-MED
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	B-MED
associated	B-MED
with	I-MED
secondary	B-MED
metabolism	I-MED
,	O
but	O
also	O
with	O
cell	B-MED
wall	I-MED
degradation	I-MED
,	O
suggesting	O
that	O
dynamic	B-MED
co	B-MED
-	I-MED
regulation	I-MED
of	O
transcriptional	B-MED
networks	I-MED
contribute	O
to	O
multiple	O
aspects	O
of	O
N.	B-MED
parvum	I-MED
virulence	B-MED
.	O
In	O
most	O
of	O
the	O
co	B-MED
-	I-MED
expressed	I-MED
clusters	B-MED
,	O
all	O
genes	B-MED
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter	B-MED
region	I-MED
indicative	O
of	O
co	B-MED
-	I-MED
regulation	I-MED
by	O
the	O
same	O
transcription	B-MED
factor	I-MED
.	O
Co	B-MED
-	I-MED
expression	I-MED
analysis	I-MED
also	O
identified	O
chromatin	B-MED
regulators	B-MED
with	O
correlated	B-MED
expression	B-MED
with	O
inducible	B-MED
clusters	B-MED
of	O
virulence	B-MED
factors	I-MED
,	O
suggesting	O
a	O
complex	O
,	O
multi	O
-	O
layered	O
regulation	B-MED
of	O
the	O
virulence	B-MED
repertoire	O
of	O
N.	B-MED
parvum	I-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Evaluation	B-MED
of	O
Tobacco	B-MED
Control	I-MED
Policies	I-MED
in	O
San	B-MED
Francisco	I-MED
Homeless	B-MED
Housing	B-MED
Programs	I-MED
The	O
2014	O
Surgeon	B-MED
General	I-MED
's	I-MED
Report	I-MED
noted	B-MED
that	O
high	B-MED
smoking	B-MED
rates	I-MED
in	O
vulnerable	B-MED
populations	I-MED
such	O
as	O
the	O
homeless	B-MED
have	O
been	O
a	O
persistent	B-MED
public	B-MED
health	B-MED
problem	I-MED
;	O
smoking	B-MED
prevalence	B-MED
among	O
individuals	B-MED
experiencing	B-MED
homelessness	B-MED
exceeds	O
70	O
%	O
.	O
Historically	O
,	O
service	B-MED
providers	I-MED
for	O
the	O
homeless	B-MED
have	O
not	O
enacted	O
comprehensive	B-MED
tobacco	B-MED
control	I-MED
policies	I-MED
.	O
We	O
conducted	B-MED
a	O
qualitative	B-MED
study	I-MED
of	O
homeless	B-MED
housing	B-MED
programs	I-MED
in	O
San	B-MED
Francisco	I-MED
.	O
Administrators	B-MED
representing	B-MED
9	O
of	O
the	O
city	O
's	O
11	O
homeless	B-MED
service	I-MED
agencies	I-MED
were	O
interviewed	B-MED
to	O
assess	B-MED
institutional	B-MED
smoking	B-MED
-related	O
policies	B-MED
and	O
cessation	B-MED
programs	B-MED
and	O
perceived	B-MED
barriers	B-MED
and	O
receptivity	B-MED
to	O
instituting	B-MED
tobacco	B-MED
control	B-MED
interventions	B-MED
.	O
Respondents	B-MED
indicated	B-MED
that	O
although	O
most	O
programs	B-MED
had	O
adopted	B-MED
smoke	B-MED
-	O
free	B-MED
grounds	B-MED
and	O
some	O
had	O
eliminated	B-MED
evidence	B-MED
of	O
staff	B-MED
smoking	B-MED
,	O
the	O
smoking	B-MED
status	B-MED
of	O
clients	B-MED
was	O
assessed	B-MED
only	O
when	O
required	B-MED
by	O
funders	O
.	O
None	O
of	O
the	O
programs	B-MED
offered	B-MED
smoking	B-MED
cessation	I-MED
interventions	B-MED
.	O
Most	O
administrators	B-MED
were	O
receptive	B-MED
to	O
adopting	B-MED
policies	B-MED
that	O
would	O
promote	B-MED
a	O
tobacco	B-MED
-	O
free	B-MED
culture	B-MED
;	O
however	O
,	O
they	O
noted	B-MED
that	O
their	O
clients	B-MED
had	O
unique	B-MED
challenges	B-MED
that	O
made	O
traditional	B-MED
smoking	B-MED
cessation	I-MED
programs	B-MED
unfeasible	O
.	O
Homeless	B-MED
housing	B-MED
programs	I-MED
in	O
San	B-MED
Francisco	I-MED
have	O
not	O
yet	O
adopted	B-MED
a	O
tobacco	B-MED
-	O
free	B-MED
culture	B-MED
.	O
Existing	B-MED
policies	B-MED
were	O
created	B-MED
in	O
response	B-MED
to	O
external	B-MED
mandates	B-MED
,	O
and	O
smoking	B-MED
cessation	I-MED
programs	B-MED
may	O
need	O
to	O
be	O
modified	B-MED
in	O
order	O
to	O
effectively	B-MED
reach	O
clients	B-MED
.	O
Differential	B-MED
effects	B-MED
of	I-MED
crude	B-MED
oil	I-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
,	O
and	O
the	O
impact	B-MED
on	O
N2O	B-MED
production	B-MED
Denitrification	B-MED
and	O
anammox	B-MED
are	O
key	O
processes	B-MED
for	O
reducing	B-MED
the	O
external	B-MED
nitrogen	B-MED
loads	O
delivered	B-MED
to	O
coastal	B-MED
ecosystems	B-MED
,	O
and	O
these	O
processes	B-MED
can	O
be	O
affected	B-MED
by	O
pollutants	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
effect	B-MED
of	I-MED
crude	B-MED
oil	I-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
.	O
Controlled	B-MED
laboratory	I-MED
experiments	I-MED
were	O
performed	O
using	O
sediment	B-MED
slurries	B-MED
from	O
the	O
Lima	B-MED
Estuary	B-MED
(	O
NW	B-MED
Portugal	B-MED
)	O
.	O
Anammox	B-MED
and	O
denitrification	B-MED
rates	B-MED
were	O
measured	O
using	O
(	B-MED
15)N	I-MED
-	I-MED
labeled	I-MED
NO3(-	B-MED
)	I-MED
,	O
and	O
the	O
production	B-MED
of	O
(	B-MED
29)N2	I-MED
and	O
(	B-MED
30)N2	I-MED
quantified	O
by	O
membrane	B-MED
inlet	I-MED
mass	I-MED
spectrometry	I-MED
.	O
Results	O
revealed	O
that	O
while	O
denitrification	B-MED
rates	B-MED
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	B-MED
oil	I-MED
amendment	B-MED
,	O
anammox	B-MED
activity	B-MED
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	B-MED
inhibited	B-MED
by	O
the	O
addition	B-MED
of	O
crude	B-MED
oil	I-MED
when	O
comparing	O
to	O
rates	B-MED
in	O
unamended	B-MED
controls	I-MED
.	O
Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	B-MED
sediment	B-MED
types	B-MED
,	O
despite	O
their	O
different	O
physical	B-MED
-	I-MED
chemical	I-MED
characteristics	I-MED
.	O
Moreover	O
,	O
N2O	B-MED
production	B-MED
was	O
reduced	B-MED
by	O
2	O
-	O
36	O
times	O
following	O
crude	B-MED
oil	I-MED
addition	B-MED
.	O
Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism(s	B-MED
)	I-MED
of	O
the	O
observed	B-MED
reduction	B-MED
in	O
N2O	B-MED
production	B-MED
.	O
This	O
study	B-MED
represents	O
one	O
of	O
the	O
first	O
contributions	B-MED
to	O
the	O
understanding	O
of	O
the	O
impact	B-MED
of	O
crude	B-MED
oil	I-MED
pollution	B-MED
on	O
denitrification	B-MED
and	O
anammox	B-MED
,	O
with	O
profound	O
implications	O
for	O
the	O
management	B-MED
of	O
aquatic	B-MED
ecosystems	B-MED
regarding	O
eutrophication	B-MED
(	O
N	B-MED
-	I-MED
removal	I-MED
)	O
.	O
Role	O
of	O
infrared	B-MED
spectroscopy	I-MED
and	O
imaging	B-MED
in	O
cancer	B-MED
diagnosis	B-MED
FTIR	B-MED
imaging	B-MED
has	O
been	O
used	O
to	O
diagnose	B-MED
and	O
differentiate	B-MED
the	O
molecular	B-MED
differences	B-MED
between	O
normal	B-MED
and	O
diseased	B-MED
tissues	B-MED
.	O
The	O
differences	B-MED
correspond	O
to	O
the	O
distribution	B-MED
and	O
structure	B-MED
of	O
lipids	B-MED
,	O
proteins	B-MED
,	O
nucleic	B-MED
acids	I-MED
as	O
well	O
as	O
other	O
metabolites	B-MED
.	O
These	O
differences	B-MED
depended	O
on	O
the	O
type	B-MED
and	O
the	O
grade	O
of	O
cancer	B-MED
.	O
The	O
sensitivity	B-MED
of	O
chemotherapy	B-MED
drugs	B-MED
on	O
individual	B-MED
specific	O
was	O
also	O
discussed	O
.	O
Here	O
,	O
we	O
emphasize	O
that	O
FTIR	B-MED
spectroscopy	I-MED
and	O
imaging	B-MED
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	B-MED
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-MED
of	O
this	O
dreadful	B-MED
disease	I-MED
because	O
of	O
high	B-MED
sensitivity	I-MED
,	O
accuracy	B-MED
and	O
inexpensive	O
technique	B-MED
.	O
Now	O
the	O
medical	B-MED
community	I-MED
started	O
using	O
and	O
accepting	O
this	O
technique	B-MED
for	O
early	B-MED
stage	I-MED
cancer	B-MED
detection	B-MED
.	O
But	O
,	O
this	O
technique	B-MED
endures	O
several	O
challenges	B-MED
on	O
its	O
application	O
into	O
the	O
diagnosis	B-MED
of	O
cancer	B-MED
in	O
regards	O
of	O
sample	B-MED
preparations	I-MED
,	O
data	B-MED
interpretation	I-MED
,	O
and	O
data	B-MED
analysis	I-MED
.	O
In	O
general	O
,	O
more	O
research	B-MED
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	B-MED
and	O
biology	B-MED
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	B-MED
and	O
imaging	B-MED
because	O
invaluable	B-MED
information	B-MED
to	O
be	O
figured	O
out	O
.	O
A	O
Novel	O
BRCA1	B-MED
-	I-MED
Associated	I-MED
Protein-1	I-MED
Isoform	B-MED
Affects	B-MED
Response	B-MED
of	O
Mesothelioma	B-MED
Cells	I-MED
to	O
Drugs	B-MED
Impairing	B-MED
BRCA1	B-MED
-Mediated	O
DNA	B-MED
Repair	I-MED
BRCA1	B-MED
associated	I-MED
protein1	I-MED
(	O
BAP1	B-MED
)	O
is	O
a	O
tumor	B-MED
suppressor	I-MED
involved	O
in	O
multiple	B-MED
cellular	B-MED
processes	I-MED
such	O
as	O
transcriptional	B-MED
regulation	I-MED
,	O
chromatin	B-MED
modification	I-MED
by	O
deubiquitinating	B-MED
histone	B-MED
2A	I-MED
,	O
and	O
DNA	B-MED
repair	I-MED
.	O
BAP1	B-MED
mutations	B-MED
are	O
frequent	B-MED
in	O
malignant	B-MED
pleural	I-MED
mesothelioma	I-MED
(	O
MPM	B-MED
)	O
.	O
Our	O
aim	B-MED
was	O
to	O
functionally	B-MED
characterize	B-MED
a	O
newly	O
identified	B-MED
isoform	B-MED
of	B-MED
BAP1	I-MED
and	O
investigate	B-MED
the	O
effects	B-MED
of	O
its	O
expression	B-MED
on	O
drug	B-MED
sensitivity	I-MED
in	O
MPM	B-MED
.	O
Expression	B-MED
of	O
BAP1	B-MED
isoforms	O
was	O
detected	B-MED
by	O
quantitative	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
in	O
MPM	B-MED
and	O
normal	B-MED
mesothelium	B-MED
cell	B-MED
lines	I-MED
and	O
tumor	B-MED
and	O
nontumor	B-MED
samples	I-MED
.	O
Histone	B-MED
H2A	I-MED
ubiquitination	B-MED
levels	B-MED
were	O
analyzed	B-MED
by	O
Western	B-MED
blot	I-MED
after	O
acidic	B-MED
extraction	I-MED
of	O
core	B-MED
histones	I-MED
.	O
Subcellular	B-MED
localization	B-MED
of	O
BAP1	B-MED
isoforms	B-MED
was	O
examined	B-MED
by	O
immunofluorescence	B-MED
.	O
MPM	B-MED
cell	B-MED
survival	I-MED
in	O
response	B-MED
to	O
poly(adenosine	B-MED
diphosphate	I-MED
-	I-MED
ribose	I-MED
)	I-MED
polymerase	I-MED
(	O
PARP	B-MED
)	O
and	O
dual	O
phosphoinositide	B-MED
3	I-MED
-	I-MED
kinase	I-MED
PI3	B-MED
K	I-MED
(	O
PI3K)-	O
mammalian	B-MED
target	I-MED
of	I-MED
rapamycin	I-MED
(	O
mTOR	B-MED
)	O
inhibitors	B-MED
was	O
analyzed	B-MED
by	O
in	B-MED
vitro	I-MED
assays	I-MED
.	O
We	O
have	O
identified	B-MED
a	O
novel	O
alternative	B-MED
splice	I-MED
isoform	I-MED
of	O
BAP1	B-MED
(	O
BAP1Δ	B-MED
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	B-MED
domain	I-MED
.	O
Cells	B-MED
transfected	B-MED
with	O
BAP1Δ	B-MED
showed	O
reduced	B-MED
deubiquitinating	B-MED
activity	I-MED
compared	B-MED
with	O
full	O
-	O
length	O
BAP1	B-MED
.	O
The	O
expression	B-MED
of	O
BAP1Δ	B-MED
transcript	B-MED
is	O
more	O
abundant	B-MED
in	O
nontumor	B-MED
than	O
in	O
tumor	O
samples	O
.	O
MPM	B-MED
cell	B-MED
lines	I-MED
expressing	B-MED
more	O
than	O
20	O
%	O
of	O
BAP1Δ	B-MED
are	O
more	O
sensitive	B-MED
to	O
olaparib	B-MED
(	O
a	O
PARP1	B-MED
inhibitor	B-MED
)	O
cytotoxicity	B-MED
,	O
and	O
this	O
sensitivity	B-MED
is	O
enhanced	B-MED
when	O
olaparib	B-MED
treatment	B-MED
is	O
combined	B-MED
with	O
GDC0980	B-MED
(	O
a	O
dual	O
PI3	B-MED
K	I-MED
-	O
mTOR	B-MED
inhibitor	B-MED
)	O
,	O
which	O
induces	B-MED
downregulation	B-MED
of	O
BRCA1	B-MED
.	O
These	O
observations	B-MED
suggest	O
that	O
BAP1Δ	B-MED
does	O
regulate	B-MED
DNA	I-MED
damage	I-MED
response	I-MED
and	O
influences	B-MED
drug	B-MED
sensitivity	I-MED
.	O
It	O
might	O
therefore	O
be	O
relevant	B-MED
to	O
investigate	B-MED
whether	O
patients	B-MED
with	O
high	B-MED
expression	B-MED
of	O
BAP1Δ	B-MED
may	O
be	O
responsive	B-MED
to	O
PARP	B-MED
/	O
PI3	B-MED
K	I-MED
-	O
mTOR	B-MED
inhibitors	B-MED
.	O
Minor	B-MED
physical	I-MED
anomalies	I-MED
and	O
dermatoglyphic	B-MED
signs	O
in	O
affective	B-MED
disorders	I-MED
:	O
A	O
systematic	B-MED
review	I-MED
The	O
increased	B-MED
prevalence	B-MED
of	O
minor	B-MED
physical	I-MED
anomalies	I-MED
(	O
MPAs	B-MED
)	O
and	O
the	O
abnormalities	B-MED
of	I-MED
dermatoglyphic	I-MED
patterns	I-MED
may	O
be	O
physical	B-MED
manifestations	B-MED
of	O
neurodevelopmental	B-MED
disruption	I-MED
in	O
affective	B-MED
disorders	I-MED
.	O
This	O
paper	O
aims	O
to	O
review	B-MED
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	B-MED
of	O
MPAs	B-MED
and	O
dermatoglyphic	B-MED
abnormalities	I-MED
in	O
mood	B-MED
disorders	I-MED
.	O
A	O
MEDLINE	B-MED
,	O
PsychInfo	B-MED
and	O
Web	B-MED
of	I-MED
Science	I-MED
search	I-MED
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	B-MED
on	O
the	O
frequency	B-MED
of	O
MPAs	B-MED
and	O
on	O
dermatoglyphic	B-MED
traits	I-MED
in	O
bipolar	B-MED
disorder	I-MED
and	O
unipolar	B-MED
depression	I-MED
.	O
24	O
studies	B-MED
on	O
MPAs	B-MED
,	O
19	O
on	O
dermatoglyphics	B-MED
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-MED
findings	B-MED
.	O
The	O
relative	B-MED
contribution	B-MED
of	O
neurodevelopmental	B-MED
retardation	I-MED
to	O
the	O
aetiology	B-MED
of	O
affective	B-MED
disorders	I-MED
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	B-MED
.	O
Increased	B-MED
recognition	B-MED
of	O
neurodevelopmental	B-MED
processes	B-MED
in	O
the	O
origin	B-MED
of	O
affective	B-MED
disorders	I-MED
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	B-MED
intervention	B-MED
and	O
prevention	B-MED
.	O
Effect	B-MED
of	O
primary	B-MED
health	I-MED
care	I-MED
reforms	B-MED
in	O
Turkey	B-MED
on	O
health	B-MED
service	I-MED
utilization	I-MED
and	O
user	B-MED
satisfaction	I-MED
Strengthening	B-MED
primary	B-MED
health	I-MED
care	I-MED
(	O
PHC	B-MED
)	O
is	O
considered	O
a	O
priority	O
for	O
efficient	B-MED
and	O
responsive	B-MED
health	B-MED
systems	I-MED
,	O
but	O
empirical	B-MED
evidence	B-MED
from	O
low-	O
and	O
middle-	O
income	B-MED
countries	B-MED
is	O
limited	B-MED
.	O
The	O
stepwise	B-MED
introduction	I-MED
of	O
family	B-MED
medicine	I-MED
across	O
all	O
81	O
provinces	B-MED
of	O
Turkey	B-MED
(	O
a	O
middle	B-MED
-	I-MED
income	I-MED
country	B-MED
)	O
between	O
2005	O
and	O
2010	O
,	O
aimed	O
at	O
PHC	B-MED
strengthening	B-MED
,	O
presents	O
a	O
natural	B-MED
experiment	I-MED
for	O
assessing	B-MED
the	O
effect	B-MED
of	O
family	B-MED
medicine	I-MED
on	O
health	B-MED
service	I-MED
utilization	I-MED
and	O
user	B-MED
satisfaction	I-MED
.The	O
effect	B-MED
of	O
health	B-MED
system	I-MED
reforms	B-MED
,	O
that	O
introduced	O
family	B-MED
medicine	I-MED
,	O
on	O
utilization	B-MED
was	O
assessed	B-MED
using	O
longitudinal	B-MED
,	O
province	B-MED
-	I-MED
level	I-MED
data	I-MED
for	O
12	O
years	B-MED
and	O
multivariate	B-MED
regression	I-MED
models	I-MED
adjusting	O
for	O
supply	B-MED
-	I-MED
side	I-MED
variables	I-MED
,	O
demographics	B-MED
,	O
socio	B-MED
-	I-MED
economic	I-MED
development	I-MED
and	O
underlying	O
yearly	B-MED
trends	B-MED
.	O
User	B-MED
satisfaction	I-MED
with	O
primary	B-MED
and	O
secondary	B-MED
care	I-MED
services	B-MED
was	O
explored	O
using	O
data	B-MED
from	O
annual	B-MED
Life	I-MED
Satisfaction	I-MED
Surveys	I-MED
.	O
Trends	B-MED
in	O
preferred	O
first	O
point	O
of	O
contact	B-MED
(	O
primary	B-MED
vs	O
secondary	B-MED
,	O
public	B-MED
vs.	O
private	B-MED
)	O
,	O
reason	B-MED
for	I-MED
choice	I-MED
and	O
health	B-MED
services	I-MED
issues	B-MED
,	O
were	O
described	B-MED
and	O
stratified	B-MED
by	O
patient	B-MED
characteristics	I-MED
,	O
provider	B-MED
type	I-MED
,	O
and	O
rural	B-MED
/	I-MED
urban	I-MED
settings	I-MED
.Between	O
2002	O
and	O
2013	O
,	O
the	O
average	B-MED
number	I-MED
of	O
PHC	B-MED
consultations	B-MED
increased	B-MED
from	O
1.75	O
to	O
2.83	O
per	O
person	B-MED
per	O
year	B-MED
.	O
In	O
multivariate	B-MED
models	I-MED
,	O
family	B-MED
medicine	I-MED
introduction	B-MED
was	O
associated	B-MED
with	I-MED
an	O
increase	B-MED
of	O
0.37	O
PHC	B-MED
consultations	B-MED
per	O
person	B-MED
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
slower	B-MED
annual	B-MED
growth	I-MED
in	O
PHC	B-MED
and	O
secondary	B-MED
care	I-MED
consultations	B-MED
.	O
Following	O
family	B-MED
medicine	I-MED
introduction	B-MED
,	O
the	O
growth	B-MED
of	O
PHC	B-MED
and	O
secondary	B-MED
care	I-MED
consultations	B-MED
per	O
person	B-MED
was	O
0.08	O
and	O
0.30	O
,	O
respectively	O
,	O
a	O
year	B-MED
.	O
PHC	B-MED
increased	B-MED
as	O
preferred	O
provider	B-MED
by	O
9.5	O
%	O
over	O
7	O
years	B-MED
with	O
the	O
reasons	O
of	O
proximity	B-MED
and	O
service	B-MED
satisfaction	I-MED
,	O
which	O
increased	B-MED
by	O
14.9	O
%	O
and	O
11.8	O
%	O
,	O
respectively	O
.	O
Reporting	B-MED
of	O
poor	B-MED
facility	I-MED
hygiene	I-MED
,	O
difficulty	B-MED
getting	I-MED
an	I-MED
appointment	I-MED
,	O
poor	B-MED
physician	B-MED
behaviour	B-MED
and	O
high	B-MED
costs	B-MED
of	I-MED
health	I-MED
care	I-MED
all	O
declined	B-MED
(	O
P	O
<	O
0.001	O
)	O
in	O
PHC	B-MED
settings	B-MED
,	O
but	O
remained	O
higher	B-MED
among	O
urban	B-MED
,	O
low	B-MED
-	I-MED
income	I-MED
and	O
working	B-MED
-	I-MED
age	I-MED
populations	B-MED
.	O
Study	B-MED
of	O
the	O
Microfocus	B-MED
X	B-MED
-	I-MED
Ray	I-MED
Tube	I-MED
Based	O
on	O
a	O
Point	B-MED
-	I-MED
Like	I-MED
Target	I-MED
Used	O
for	O
Micro	B-MED
-	I-MED
Computed	I-MED
Tomography	I-MED
For	O
a	O
micro	B-MED
-	I-MED
Computed	I-MED
Tomography	I-MED
(	I-MED
Micro	I-MED
-	I-MED
CT	I-MED
)	I-MED
system	I-MED
,	O
the	O
microfocus	B-MED
X	B-MED
-	I-MED
ray	I-MED
tube	I-MED
is	O
an	O
essential	B-MED
component	O
because	O
the	O
spatial	B-MED
resolution	B-MED
of	O
CT	B-MED
images	B-MED
,	O
in	O
theory	B-MED
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	B-MED
and	O
stability	B-MED
of	O
the	O
X	B-MED
-	I-MED
ray	I-MED
focal	B-MED
spot	I-MED
of	O
the	O
microfocus	B-MED
X	B-MED
-	I-MED
ray	I-MED
tube	I-MED
.	O
However	O
,	O
many	O
factors	B-MED
,	O
including	O
voltage	B-MED
fluctuations	B-MED
,	O
mechanical	B-MED
vibrations	B-MED
,	O
and	O
temperature	B-MED
changes	I-MED
,	O
can	O
cause	B-MED
the	O
size	B-MED
and	O
the	O
stability	B-MED
of	O
the	O
X	B-MED
-	I-MED
ray	I-MED
focal	B-MED
spot	I-MED
to	O
degrade	B-MED
.	O
A	O
new	O
microfocus	B-MED
X	B-MED
-	I-MED
ray	I-MED
tube	I-MED
based	O
on	O
a	O
point	B-MED
-	I-MED
like	I-MED
micro	I-MED
-	I-MED
target	I-MED
in	O
which	O
the	O
X	B-MED
-	I-MED
ray	I-MED
target	B-MED
is	O
irradiated	B-MED
with	O
an	O
unfocused	O
electron	B-MED
beam	I-MED
was	O
investigated	B-MED
.	O
EGS4	B-MED
Monte	I-MED
Carlo	I-MED
simulation	I-MED
code	I-MED
was	O
employed	O
for	O
the	O
calculation	B-MED
of	O
the	O
X	B-MED
-	I-MED
ray	I-MED
intensity	B-MED
produced	O
from	O
the	O
point	B-MED
-	I-MED
like	I-MED
micro	I-MED
-	I-MED
target	I-MED
and	O
the	O
substrate	B-MED
.	O
The	O
effects	B-MED
of	I-MED
several	O
arrangements	O
of	O
the	O
target	B-MED
material	B-MED
,	O
target	B-MED
and	O
beam	B-MED
size	B-MED
were	O
studied	B-MED
.	O
The	O
simulation	B-MED
results	B-MED
demonstrated	O
that	O
if	O
the	O
intensity	B-MED
of	O
X	B-MED
-	I-MED
rays	I-MED
generated	B-MED
at	O
the	O
point	B-MED
-	I-MED
like	I-MED
target	I-MED
is	O
greater	B-MED
than	I-MED
half	O
of	O
the	O
X	B-MED
-	I-MED
ray	I-MED
intensity	B-MED
produced	O
on	O
the	O
substrate	B-MED
,	O
the	O
X	B-MED
-	I-MED
ray	I-MED
focal	B-MED
spot	I-MED
is	O
determined	O
in	O
part	O
by	O
the	O
point	B-MED
-	I-MED
like	I-MED
target	I-MED
rather	O
than	O
by	O
the	O
electron	B-MED
beam	I-MED
in	O
the	O
conventional	B-MED
X	B-MED
-	I-MED
ray	I-MED
tube	I-MED
.	O
In	O
theory	B-MED
,	O
since	O
it	O
is	O
able	O
to	O
reduce	B-MED
those	O
unfavorable	O
effects	B-MED
such	O
as	O
the	O
electron	B-MED
beam	I-MED
trajectory	I-MED
swinging	I-MED
and	O
the	O
beam	B-MED
size	B-MED
changing	B-MED
for	O
the	O
microfocus	B-MED
X	B-MED
-	I-MED
ray	I-MED
tube	I-MED
,	O
it	O
could	O
alleviate	B-MED
CT	B-MED
image	B-MED
artifacts	B-MED
caused	B-MED
by	O
the	O
X	B-MED
-	I-MED
ray	I-MED
focal	B-MED
spot	I-MED
shift	B-MED
and	O
size	B-MED
change	I-MED
.	O
Evaluating	O
the	O
relative	B-MED
effectiveness	I-MED
of	O
high	B-MED
-	I-MED
intensity	I-MED
and	O
low	B-MED
-	I-MED
intensity	I-MED
models	I-MED
of	O
behaviour	B-MED
change	I-MED
communication	B-MED
interventions	I-MED
for	O
abortion	B-MED
care	B-MED
-	I-MED
seeking	I-MED
in	O
Bihar	B-MED
and	O
Jharkhand	B-MED
,	O
India	B-MED
:	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
This	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	B-MED
of	O
a	O
high	B-MED
-	I-MED
intensity	I-MED
model	I-MED
(	O
HIM	B-MED
)	O
and	O
a	O
low	B-MED
-	I-MED
intensity	I-MED
model	I-MED
(	O
LIM	B-MED
)	O
of	O
behaviour	B-MED
change	I-MED
communication	B-MED
interventions	I-MED
in	O
Bihar	B-MED
and	O
Jharkhand	B-MED
states	O
of	O
India	B-MED
designed	O
to	O
improve	O
women	B-MED
's	I-MED
knowledge	B-MED
and	O
usage	O
of	O
safe	B-MED
abortion	I-MED
services	O
,	O
as	O
well	O
as	O
the	O
dose	B-MED
effect	I-MED
of	O
intervention	B-MED
exposure	O
.	O
We	O
conducted	O
two	O
cross	B-MED
-	I-MED
sectional	I-MED
household	I-MED
surveys	I-MED
among	O
married	B-MED
women	B-MED
aged	B-MED
15	O
-	O
49	O
years	O
in	O
intervention	B-MED
and	O
comparison	O
districts	B-MED
.	O
Difference	B-MED
-	I-MED
in	I-MED
-	I-MED
difference	I-MED
models	I-MED
were	O
used	O
to	O
assess	O
the	O
efficacy	B-MED
of	O
the	O
intervention	B-MED
,	O
adjusting	O
for	O
sociodemographic	B-MED
characteristics	I-MED
.	O
Although	O
both	O
intervention	B-MED
types	O
improved	O
abortion	B-MED
knowledge	B-MED
,	O
the	O
HIM	B-MED
intervention	B-MED
was	O
more	O
effective	O
in	O
improving	O
comprehensive	B-MED
knowledge	I-MED
about	O
abortion	B-MED
.	O
In	O
particular	O
,	O
there	O
were	O
improvements	O
in	O
knowledge	B-MED
on	O
legality	B-MED
of	I-MED
abortion	I-MED
(	O
AOR=2.2	O
;	O
95	O
%	O
CI	O
1.6	O
to	O
2.9	O
)	O
and	O
nearby	O
sources	O
of	O
safe	B-MED
abortion	I-MED
care	I-MED
(	O
AOR=1.7	O
;	O
95	O
%	O
CI	O
1.2	O
to	O
1.3	O
)	O
.	O
Higher	O
level	O
of	O
exposure	O
to	O
abortion	O
-	O
related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	B-MED
about	O
abortion	B-MED
within	O
both	O
intervention	B-MED
groups	O
.	O
Evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-MED
care	B-MED
-	I-MED
seeking	I-MED
behaviour	B-MED
.	O
More	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	B-MED
seek	O
safe	B-MED
abortion	I-MED
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion	B-MED
complications	I-MED
.	O
The	O
Value	O
of	O
Biosamples	B-MED
in	O
Smoking	B-MED
Cessation	I-MED
Trials	B-MED
:	O
A	O
Review	O
of	O
Genetic	B-MED
,	O
Metabolomic	B-MED
,	O
and	O
Epigenetic	B-MED
Findings	B-MED
Evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	B-MED
and	O
biomarkers	B-MED
are	O
associated	O
with	O
smoking	B-MED
cessation	I-MED
success	O
and	O
efficacy	O
of	O
smoking	B-MED
cessation	I-MED
treatments	I-MED
.	O
We	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking	B-MED
cessation	I-MED
treatment	I-MED
according	O
to	O
an	O
individual	B-MED
's	I-MED
genetic	B-MED
or	O
metabolic	B-MED
profile	I-MED
.	O
These	O
results	O
provide	O
important	O
incentive	B-MED
for	O
smoking	B-MED
cessation	I-MED
researchers	B-MED
to	O
collect	O
biosamples	B-MED
and	O
perform	O
genotyping	B-MED
in	O
research	B-MED
studies	I-MED
and	O
clinical	B-MED
trials	I-MED
.	O
A	O
Microfluidic	B-MED
Platform	O
to	O
design	B-MED
crosslinked	B-MED
Hyaluronic	I-MED
Acid	I-MED
Nanoparticles	I-MED
(	O
cHANPs	B-MED
)	O
for	O
enhanced	B-MED
MRI	I-MED
Recent	B-MED
advancements	B-MED
in	O
imaging	B-MED
diagnostics	I-MED
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	B-MED
that	O
entrap	O
Magnetic	B-MED
Resonance	I-MED
Imaging	I-MED
(	O
MRI	B-MED
)	O
Contrast	B-MED
Agents	I-MED
(	O
CAs	B-MED
)	O
,	O
without	O
the	O
need	O
to	O
chemically	B-MED
modify	B-MED
the	O
clinically	B-MED
approved	B-MED
compounds	B-MED
.	O
Nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	B-MED
platforms	I-MED
for	O
their	O
controlled	B-MED
and	O
continuous	B-MED
production	B-MED
is	O
still	O
missing	O
.	O
Here	O
,	O
a	O
microfluidic	B-MED
platform	I-MED
is	O
used	O
to	O
synthesize	B-MED
crosslinked	B-MED
Hyaluronic	I-MED
Acid	I-MED
NanoParticles	I-MED
(	O
cHANPs	B-MED
)	O
in	O
which	O
a	O
clinically	B-MED
relevant	B-MED
MRI	B-MED
-	O
CAs	B-MED
,	O
gadolinium	B-MED
diethylenetriamine	I-MED
penta	I-MED
-	I-MED
acetic	I-MED
acid	I-MED
(	O
Gd	B-MED
-	I-MED
DTPA	I-MED
)	O
,	O
is	O
entrapped	O
.	O
This	O
microfluidic	B-MED
process	B-MED
facilitates	O
a	O
high	O
degree	B-MED
of	O
control	B-MED
over	O
particle	B-MED
synthesis	B-MED
,	O
enabling	O
the	O
production	B-MED
of	O
monodisperse	B-MED
particles	I-MED
as	O
small	O
as	O
35	O
nm	O
.	O
Furthermore	O
,	O
the	O
interference	B-MED
of	O
Gd	B-MED
-	I-MED
DTPA	I-MED
during	O
polymer	B-MED
precipitation	B-MED
is	O
overcome	O
by	O
finely	O
tuning	O
process	B-MED
parameters	B-MED
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	B-MED
-	I-MED
lipophilic	I-MED
balance	I-MED
(	O
HLB	B-MED
)	O
of	O
surfactants	B-MED
and	O
pH	B-MED
conditions	B-MED
.	O
For	O
both	O
production	B-MED
strategies	O
proposed	O
to	O
design	B-MED
Gd	B-MED
-loaded	O
cHANPs	B-MED
,	O
a	O
boosting	O
of	O
the	O
relaxation	B-MED
rate	I-MED
T1	I-MED
is	O
observed	O
since	O
a	O
T1	B-MED
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	B-MED
-loaded	O
cHANPs	B-MED
while	O
a	O
similar	O
value	B-MED
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	B-MED
clinical	B-MED
Gd	B-MED
-	I-MED
DTPA	I-MED
in	O
solution	B-MED
.	O
The	O
advanced	O
microfluidic	B-MED
platform	O
to	O
synthesize	O
intravascularly	B-MED
-	O
injectable	B-MED
and	O
completely	O
biocompatible	B-MED
hydrogel	I-MED
nanoparticles	B-MED
entrapping	O
clinically	B-MED
approved	B-MED
CAs	B-MED
enables	O
the	O
implementation	B-MED
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	B-MED
and	O
therapy	B-MED
applications	B-MED
.	O
Evaluation	B-MED
of	O
the	O
Condom	B-MED
Barriers	I-MED
Scale	I-MED
for	O
Young	B-MED
Black	B-MED
Men	I-MED
Who	I-MED
Have	I-MED
Sex	I-MED
With	I-MED
Men	I-MED
:	O
Reliability	B-MED
and	I-MED
Validity	I-MED
of	O
3	O
Subscales	B-MED
Reliable	B-MED
and	O
valid	B-MED
scale	B-MED
measures	B-MED
of	O
barriers	B-MED
to	O
condom	B-MED
use	I-MED
are	O
not	O
available	O
for	O
young	B-MED
black	B-MED
men	I-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
(	O
YBMSM	B-MED
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
Condom	B-MED
Barriers	I-MED
Scales	I-MED
for	O
application	O
with	O
YBMSM	B-MED
.	O
A	O
clinic	B-MED
-	I-MED
based	I-MED
sample	B-MED
of	O
600	O
YBMSM	B-MED
completed	O
a	O
computer	B-MED
-	I-MED
assisted	I-MED
self	B-MED
-	I-MED
interview	I-MED
.	O
The	O
primary	O
measure	B-MED
was	O
a	O
14	O
-	O
item	O
abbreviated	B-MED
version	I-MED
of	O
the	O
Condom	B-MED
Barriers	I-MED
Scale	I-MED
.	O
Reliability	B-MED
and	O
criterion	B-MED
validity	I-MED
were	O
assessed	O
.	O
All	O
3	O
subscales	B-MED
were	O
reliable	B-MED
:	O
partner	B-MED
-related	O
barriers	B-MED
(	O
Cronbach	B-MED
α	I-MED
=	O
0.73	O
)	O
,	O
sensation	B-MED
-related	O
barriers	B-MED
(	O
α=0.70	O
)	O
,	O
and	O
motivation	B-MED
-related	O
barriers	B-MED
(	O
α	O
=	O
0.81	O
)	O
.	O
A	O
complete	B-MED
absence	I-MED
of	I-MED
barriers	I-MED
was	O
common	O
:	O
47.0	O
%	O
(	O
partner	B-MED
-related	O
)	O
,	O
30.7	O
%	O
(	O
sensation	B-MED
-related	O
)	O
,	O
and	O
46.5	O
%	O
(	O
motivation	B-MED
-related	O
)	O
.	O
Dichotomized	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
reporting	O
any	O
condomless	B-MED
insertive	B-MED
anal	B-MED
sex	I-MED
(	O
all	O
Ps	B-MED
<	O
0.001	O
)	O
and	O
any	O
condomless	B-MED
receptive	B-MED
anal	B-MED
sex	I-MED
(	O
all	O
Ps	B-MED
<	O
0.001	O
)	O
.	O
The	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
these	O
measures	B-MED
of	O
condomless	B-MED
sex	B-MED
preserved	O
at	O
a	O
continuous	B-MED
level	B-MED
(	O
all	O
Ps	B-MED
<	O
0.001	O
,	O
except	O
for	O
sensation	B-MED
barriers	B-MED
associated	B-MED
with	I-MED
condomless	B-MED
receptive	O
anal	B-MED
sex	I-MED
=	O
0.03	O
)	O
.	O
Further	O
,	O
the	O
subscales	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
reporting	O
any	O
condom	B-MED
use	I-MED
problems	B-MED
(	O
all	O
Ps	B-MED
<	O
0.001	O
)	O
and	O
a	O
measure	B-MED
of	O
condomless	B-MED
oral	B-MED
sex	I-MED
(	O
all	O
Ps	B-MED
<	O
0.001	O
,	O
except	O
for	O
partner	B-MED
-related	O
barriers	B-MED
=	O
0.31	O
)	O
.	O
Finally	O
,	O
the	O
sensation	B-MED
-related	O
barriers	B-MED
subscale	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
testing	O
positive	B-MED
for	O
Chlamydia	B-MED
and/or	O
gonorrhea	B-MED
(	O
P=0.049	O
)	O
.	O
The	O
3	O
identified	O
subscales	B-MED
yielded	O
adequate	O
reliability	B-MED
and	O
strong	O
evidence	O
of	O
validity	B-MED
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	B-MED
for	O
use	O
in	O
observational	B-MED
and	O
experimental	B-MED
research	I-MED
with	O
YBMSM	B-MED
.	O
Function	B-MED
and	O
clinical	B-MED
meaningfulness	B-MED
of	O
treatments	B-MED
for	O
mild	B-MED
Alzheimer	B-MED
's	I-MED
disease	I-MED
Effectiveness	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
treatments	B-MED
is	O
commonly	O
evaluated	O
with	O
coprimary	B-MED
outcomes	I-MED
;	O
cognition	B-MED
with	O
function	B-MED
to	O
ensure	O
clinical	B-MED
meaningfulness	B-MED
of	O
a	O
cognitive	B-MED
effect	B-MED
.	O
We	O
reviewed	B-MED
the	O
literature	B-MED
for	O
functional	B-MED
outcomes	B-MED
in	O
mild	B-MED
AD	B-MED
or	O
mild	B-MED
cognitive	I-MED
impairment	I-MED
(	O
MCI	B-MED
)	O
patients	B-MED
(	O
distinct	O
from	O
combined	O
mild	B-MED
-	I-MED
moderate	I-MED
/	O
severe	B-MED
AD	B-MED
)	O
treated	B-MED
with	I-MED
approved	O
AD	B-MED
drugs	B-MED
.	O
Cognitive	B-MED
and	O
functional	B-MED
treatment	B-MED
differences	O
in	O
mild	B-MED
AD	B-MED
patients	B-MED
in	O
solanezumab	B-MED
EXPEDITION	B-MED
/	O
EXPEDITION2	B-MED
studies	B-MED
were	O
compared	B-MED
across	O
time	B-MED
.	O
Seven	O
publications	B-MED
provided	O
MCI	B-MED
/	O
mild	B-MED
AD	B-MED
functional	B-MED
outcomes	B-MED
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-MED
treatment	B-MED
effect	I-MED
.	O
Secondary	B-MED
analyses	I-MED
of	O
EXPEDITION	B-MED
studies	B-MED
suggested	O
a	O
smaller	O
functional	B-MED
effect	B-MED
of	O
solanezumab	B-MED
relative	O
to	O
cognition	B-MED
.	O
An	O
increasing	B-MED
effect	B-MED
of	O
solanezumab	B-MED
over	O
18	O
months	B-MED
was	O
shown	O
for	O
cognition	B-MED
and	O
function	B-MED
.	O
Function	B-MED
as	O
the	O
sole	O
measure	B-MED
to	O
demonstrate	O
clinical	B-MED
meaningfulness	B-MED
of	O
cognitive	B-MED
effects	B-MED
in	O
mild	B-MED
AD	B-MED
may	O
have	O
limitations	B-MED
.	O
For	O
disease	B-MED
-	O
modifying	B-MED
treatments	B-MED
,	O
point	O
differences	O
on	O
cognitive	B-MED
and	O
functional	B-MED
scales	B-MED
should	O
be	O
qualified	O
with	O
duration	B-MED
of	I-MED
treatment	I-MED
.	O
High	O
Transferability	B-MED
of	O
Homoeolog	B-MED
-	I-MED
Specific	I-MED
Markers	I-MED
between	O
Bread	B-MED
Wheat	B-MED
and	O
Newly	O
Synthesized	B-MED
Hexaploid	B-MED
Wheat	I-MED
Lines	I-MED
Bread	B-MED
wheat	B-MED
(	O
Triticum	B-MED
aestivum	I-MED
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
AABBDD	O
)	O
has	O
a	O
complex	O
allohexaploid	B-MED
genome	I-MED
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	B-MED
between	O
the	O
homoeologous	B-MED
sequences	I-MED
and	O
assign	O
them	O
to	O
the	O
chromosome	B-MED
A	I-MED
,	O
B	B-MED
,	O
or	O
D	B-MED
subgenomes	B-MED
.	O
The	O
chromosome	B-MED
-based	O
draft	O
genome	B-MED
sequence	B-MED
of	O
the	O
'	O
Chinese	B-MED
Spring	I-MED
'	O
common	O
wheat	B-MED
cultivar	I-MED
enables	O
the	O
large	O
-	O
scale	O
development	B-MED
of	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
PCR	B-MED
(	O
PCR)-based	O
markers	B-MED
specific	O
for	O
homoeologs	O
.	O
Based	O
on	O
high	O
-	O
confidence	O
'	O
Chinese	B-MED
Spring	I-MED
'	O
genes	B-MED
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog	B-MED
-	I-MED
specific	I-MED
markers	I-MED
for	O
chromosomes	B-MED
4B	I-MED
7B	B-MED
and	O
7B.	O
These	O
markers	B-MED
were	O
used	O
in	O
PCR	B-MED
assays	I-MED
for	O
the	O
4B	B-MED
and	O
7B	B-MED
nullisomes	O
and	O
their	O
euploid	O
synthetic	B-MED
hexaploid	I-MED
wheat	I-MED
(	I-MED
SHW	I-MED
)	I-MED
line	I-MED
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	B-MED
between	O
Triticum	B-MED
turgidum	I-MED
(	O
AABB	O
)	O
and	O
the	O
wild	O
diploid	B-MED
species	I-MED
Aegilops	B-MED
tauschii	I-MED
(	O
DD	O
)	O
.	O
Up	O
to	O
64	O
%	O
of	O
the	O
markers	B-MED
for	O
chromosomes	B-MED
4B	I-MED
or	O
7B	B-MED
in	O
the	O
SHW	B-MED
background	O
were	O
confirmed	O
to	O
be	O
homoeolog	O
-	O
specific	O
.	O
Thus	O
,	O
these	O
markers	B-MED
were	O
highly	O
transferable	O
between	O
the	O
'	O
Chinese	B-MED
Spring	I-MED
'	O
bread	B-MED
wheat	B-MED
and	O
SHW	B-MED
lines	I-MED
.	O
Homoeolog	B-MED
-	I-MED
specific	I-MED
markers	I-MED
designed	O
using	O
genes	B-MED
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-MED
investigations	I-MED
involving	O
homoeologous	O
chromosome	B-MED
tracking	O
and	O
homoeolog	O
expression	B-MED
and	O
interaction	O
analyses	O
.	O
From	O
training	B-MED
to	O
practice	B-MED
:	O
the	O
impact	B-MED
of	O
ENGAGE	B-MED
,	O
Ireland	B-MED
's	I-MED
national	B-MED
men	I-MED
's	I-MED
health	I-MED
training	I-MED
programme	I-MED
Ireland	B-MED
's	I-MED
National	B-MED
Men	I-MED
's	I-MED
Health	I-MED
Policy	I-MED
recommended	B-MED
developing	O
training	B-MED
programmes	I-MED
tailored	B-MED
to	O
the	O
needs	B-MED
of	O
those	O
working	B-MED
in	O
health	B-MED
and	O
allied	B-MED
health	I-MED
professionals	I-MED
and	O
ENGAGE	B-MED
was	O
developed	O
to	O
meet	O
that	O
recommendation	B-MED
.	O
This	O
study	B-MED
evaluated	B-MED
the	O
impact	B-MED
of	O
ENGAGE	B-MED
on	O
frontline	B-MED
service	I-MED
providers	I-MED
'	I-MED
self	B-MED
-	I-MED
reported	I-MED
knowledge	I-MED
,	O
skills	B-MED
,	O
capacity	B-MED
and	O
practice	B-MED
up	O
to	O
5	O
-	O
months	O
post	B-MED
training	B-MED
.	O
Between	O
2012	O
and	O
2015	O
,	O
ENGAGE	B-MED
Trainers	B-MED
(	O
n	O
=	O
57	O
)	O
delivered	O
62	O
1	O
-	O
day	O
training	B-MED
programmes	I-MED
to	O
810	O
participants	B-MED
.	O
This	O
study	B-MED
was	O
conducted	O
on	O
a	O
subset	B-MED
of	O
those	O
training	B-MED
days	O
(	O
n	O
=	O
26	O
)	O
and	O
participants	B-MED
.	O
Quantitative	B-MED
methodologies	B-MED
were	O
used	O
to	O
collect	O
pre	O
(	O
n	O
=	O
295	O
)	O
,	O
post	B-MED
(	O
n	O
=	O
295	O
)	O
and	O
5	O
-	O
month	O
post	B-MED
(	O
n	O
=	O
128	O
)	O
training	B-MED
questionnaire	B-MED
data	O
.	O
Overall	B-MED
,	O
participants	B-MED
were	O
highly	O
satisfied	B-MED
with	O
the	O
training	B-MED
immediately	B-MED
post	B-MED
training	B-MED
(	O
8.60	O
±	O
1.60	O
out	O
of	O
10	O
)	O
and	O
at	O
5	O
-	O
month	O
follow	B-MED
up	I-MED
(	O
8.06	O
±	O
1.43	O
out	O
of	O
10	O
)	O
.	O
Participants	B-MED
'	I-MED
self	B-MED
-	I-MED
reported	I-MED
level	I-MED
of	I-MED
knowledge	I-MED
,	O
skill	B-MED
and	O
capacity	B-MED
in	O
identifying	O
priorities	B-MED
,	O
engaging	O
men	B-MED
and	O
influencing	B-MED
practice	B-MED
beyond	O
their	O
own	O
organisation	B-MED
increased	B-MED
immediately	B-MED
following	O
training	B-MED
(	O
P	O
<	O
0.001	O
)	O
and	O
,	O
with	O
the	O
exception	B-MED
of	O
improving	B-MED
capacity	B-MED
to	O
engage	O
men	B-MED
and	O
influencing	B-MED
practice	B-MED
beyond	O
their	O
organisation	B-MED
,	O
these	O
improvements	B-MED
were	O
sustained	B-MED
at	O
5	O
-	O
month	O
post	B-MED
training	B-MED
(	O
P	O
<	O
0.001	O
)	O
.	O
The	O
vast	O
majority	B-MED
of	O
service	B-MED
providers	I-MED
(	O
93.4	O
%	O
)	O
reported	B-MED
that	O
ENGAGE	B-MED
had	O
impacted	B-MED
their	O
work	B-MED
practice	B-MED
up	O
to	O
5	O
-	O
month	O
post	B-MED
training	B-MED
.	O
The	O
findings	B-MED
suggest	B-MED
that	O
ENGAGE	B-MED
has	O
succeeded	B-MED
in	O
improving	B-MED
service	B-MED
providers	I-MED
'	I-MED
capacity	B-MED
to	O
engage	O
and	O
work	B-MED
with	O
men	B-MED
;	O
improving	B-MED
gender	B-MED
competency	B-MED
in	O
the	O
delivery	O
of	O
health	B-MED
and	O
health	B-MED
related	I-MED
services	I-MED
may	O
increase	B-MED
the	O
utilisation	B-MED
of	O
such	O
services	B-MED
by	O
men	B-MED
and	O
thereby	O
improve	B-MED
health	B-MED
outcomes	I-MED
for	O
men	B-MED
.	O
Arsenic	B-MED
Triglutathione	I-MED
[	O
As(GS)3	B-MED
]	O
Transport	B-MED
by	O
Multidrug	B-MED
Resistance	I-MED
Protein	I-MED
1	I-MED
(	O
MRP1	B-MED
/	O
ABCC1	B-MED
)	O
Is	O
Selectively	O
Modified	B-MED
by	O
Phosphorylation	B-MED
of	O
Tyr920	B-MED
/	I-MED
Ser921	I-MED
and	O
Glycosylation	B-MED
of	O
Asn19	B-MED
/	I-MED
Asn23	I-MED
The	O
ATP	B-MED
-	I-MED
binding	I-MED
cassette	I-MED
(	I-MED
ABC	I-MED
)	I-MED
transporter	I-MED
multidrug	B-MED
resistance	I-MED
protein	I-MED
1	I-MED
(	O
MRP1	B-MED
/	O
ABCC1	B-MED
)	O
is	O
responsible	O
for	O
the	O
cellular	B-MED
export	B-MED
of	O
a	O
chemically	O
diverse	B-MED
array	B-MED
of	O
xenobiotics	B-MED
and	O
endogenous	B-MED
compounds	B-MED
.	O
Arsenic	B-MED
,	O
a	O
human	B-MED
carcinogen	B-MED
,	O
is	O
a	O
high	B-MED
-	I-MED
affinity	I-MED
MRP1	B-MED
substrate	B-MED
as	O
arsenic	B-MED
triglutathione	I-MED
[	O
As(GS)3	B-MED
]	O
.	O
In	O
this	O
study	O
,	O
marked	O
differences	O
in	O
As(GS)3	B-MED
transport	B-MED
kinetics	B-MED
were	O
observed	O
between	O
MRP1	B-MED
-enriched	O
membrane	B-MED
vesicles	B-MED
prepared	B-MED
from	O
human	B-MED
embryonic	B-MED
kidney	B-MED
293	B-MED
(	I-MED
HEK	I-MED
)	I-MED
(	O
Km	B-MED
3.8	O
µM	O
and	O
Vmax	B-MED
307	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
and	O
HeLa	B-MED
(	O
Km	B-MED
0.32	O
µM	O
and	O
Vmax	B-MED
42	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
cells	B-MED
.	O
Mutant	B-MED
MRP1	B-MED
lacking	O
N	O
-	O
linked	O
glycosylation	B-MED
[	O
Asn19/23/1006Gln	B-MED
;	O
sugar	O
-	O
free	O
(	B-MED
SF)-MRP1	I-MED
]	O
expressed	B-MED
in	O
either	O
HEK293	B-MED
or	O
HeLa	B-MED
cells	I-MED
had	O
low	O
Km	B-MED
and	O
Vmax	B-MED
values	O
for	O
As(GS)3	B-MED
,	O
similar	B-MED
to	O
HeLa	B-MED
wild	I-MED
-	I-MED
type	I-MED
(	O
WT	O
)	O
MRP1	B-MED
.	O
When	O
prepared	B-MED
in	O
the	O
presence	B-MED
of	O
phosphatase	B-MED
inhibitors	I-MED
,	O
both	O
WT-	B-MED
and	O
SF	B-MED
-	I-MED
MRP1	I-MED
-enriched	O
membrane	B-MED
vesicles	B-MED
had	O
a	O
high	O
Km	B-MED
value	O
for	O
As(GS)3	B-MED
(	O
3	O
-	O
6	O
µM	O
)	O
,	O
regardless	O
of	O
the	O
cell	B-MED
line	I-MED
.	O
Kinetic	B-MED
parameters	I-MED
of	O
As(GS)3	B-MED
for	O
HEK	B-MED
-	O
Asn19/23Gln	B-MED
-	I-MED
MRP1	I-MED
were	O
similar	B-MED
to	O
those	O
of	O
HeLa	B-MED
/	O
HEK	B-MED
-	O
SF	B-MED
-	I-MED
MRP1	I-MED
and	O
HeLa	B-MED
-	I-MED
WT	I-MED
-	O
MRP1	B-MED
,	O
whereas	O
those	O
of	O
single	B-MED
glycosylation	B-MED
mutants	B-MED
were	O
like	O
those	O
of	O
HEK	B-MED
-	I-MED
WT	I-MED
-MRP1	O
.	O
Mutation	B-MED
of	O
19	O
potential	B-MED
MRP1	O
phosphorylation	B-MED
sites	B-MED
revealed	O
that	O
HEK	B-MED
-	O
Tyr920Phe	B-MED
/	I-MED
Ser921Ala	I-MED
-	I-MED
MRP1	I-MED
transported	B-MED
As(GS)3	B-MED
like	O
HeLa	B-MED
-	I-MED
WT	I-MED
-	O
MRP1	B-MED
,	O
whereas	O
individual	O
HEK	B-MED
-	O
Tyr920Phe-	B-MED
and	O
-	O
Ser921Ala	B-MED
-	I-MED
MRP1	I-MED
mutants	B-MED
were	O
similar	B-MED
to	O
HEK	B-MED
-	I-MED
WT	I-MED
-	O
MRP1	B-MED
.	O
Together	O
,	O
these	O
results	B-MED
suggest	O
that	O
Asn19	B-MED
/	I-MED
Asn23	I-MED
glycosylation	B-MED
and	O
Tyr920	B-MED
/	I-MED
Ser921	I-MED
phosphorylation	B-MED
are	O
responsible	O
for	O
altering	B-MED
the	O
kinetics	B-MED
of	O
MRP1	B-MED
-mediated	O
As(GS)3	B-MED
transport	B-MED
.	O
The	O
kinetics	B-MED
of	O
As(GS)3	B-MED
transport	B-MED
by	O
HEK	B-MED
-	O
Asn19/23Gln	B-MED
/	I-MED
Tyr920Glu	I-MED
/	I-MED
Ser921Glu	I-MED
were	O
similar	B-MED
to	O
HEK	B-MED
-	I-MED
WT	I-MED
-	O
MRP1	B-MED
,	O
indicating	O
that	O
the	O
phosphorylation	B-MED
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	B-MED
of	O
Asn19/23Gln	B-MED
glycosylation	B-MED
.	O
Overall	O
,	O
these	O
data	O
suggest	O
that	O
cross	O
-	O
talk	O
between	O
MRP1	B-MED
glycosylation	B-MED
and	O
phosphorylation	B-MED
occurs	O
and	O
that	O
phosphorylation	B-MED
of	O
Tyr920	B-MED
and	O
Ser921	B-MED
can	O
switch	O
MRP1	B-MED
to	O
a	O
lower	B-MED
-	I-MED
affinity	I-MED
,	O
higher	B-MED
-	I-MED
capacity	I-MED
As(GS)3	B-MED
transporter	B-MED
,	O
allowing	O
arsenic	B-MED
detoxification	B-MED
over	O
a	O
broad	B-MED
concentration	B-MED
range	B-MED
.	O
MODEM	B-MED
:	O
A	O
comprehensive	B-MED
approach	B-MED
to	O
modelling	B-MED
outcome	B-MED
and	O
costs	B-MED
impacts	B-MED
of	O
interventions	B-MED
for	O
dementia	B-MED
.	O
Protocol	B-MED
paper	B-MED
The	O
MODEM	B-MED
project	I-MED
(	O
A	O
comprehensive	B-MED
approach	B-MED
to	O
MODelling	B-MED
outcome	B-MED
and	O
costs	B-MED
impacts	B-MED
of	O
interventions	B-MED
for	O
DEMentia	B-MED
)	O
explores	O
how	O
changes	B-MED
in	O
arrangements	O
for	O
the	O
future	B-MED
treatment	B-MED
and	O
care	B-MED
of	O
people	B-MED
living	O
with	O
dementia	B-MED
,	O
and	O
support	B-MED
for	O
family	B-MED
and	O
other	O
unpaid	B-MED
carers	B-MED
,	O
could	O
result	B-MED
in	O
better	O
outcomes	B-MED
and	O
more	O
efficient	B-MED
use	B-MED
of	I-MED
resources	B-MED
.	O
MODEM	B-MED
starts	O
with	O
a	O
systematic	B-MED
mapping	B-MED
of	O
the	O
literature	B-MED
on	O
effective	B-MED
and	O
(	O
potentially	O
)	O
cost	B-MED
-	O
effective	B-MED
interventions	B-MED
in	O
dementia	B-MED
care	B-MED
.	O
Those	O
findings	B-MED
,	O
as	O
well	O
as	O
data	B-MED
from	O
a	O
cohort	B-MED
,	O
will	O
then	O
be	O
used	O
to	O
model	B-MED
the	O
quality	B-MED
of	I-MED
life	I-MED
and	O
cost	B-MED
impacts	B-MED
of	O
making	O
these	O
evidence	B-MED
-based	O
interventions	B-MED
more	O
widely	O
available	B-MED
in	O
England	B-MED
over	O
the	O
period	B-MED
from	O
now	O
to	O
2040	O
.	O
Modelling	B-MED
will	O
use	O
a	O
suite	O
of	O
models	B-MED
,	O
combining	B-MED
microsimulation	B-MED
and	O
macrosimulation	B-MED
methods	I-MED
,	O
modelling	B-MED
the	O
costs	B-MED
and	O
outcomes	B-MED
of	O
care	B-MED
,	O
both	O
for	O
an	O
individual	B-MED
over	O
the	O
life	B-MED
-	I-MED
course	I-MED
from	O
the	O
point	O
of	O
dementia	B-MED
diagnosis	I-MED
,	O
and	O
for	O
individuals	B-MED
and	O
England	B-MED
as	O
a	O
whole	B-MED
in	O
a	O
particular	O
year	O
.	O
Project	B-MED
outputs	O
will	O
include	O
an	O
online	B-MED
Dementia	B-MED
Evidence	I-MED
Toolkit	I-MED
,	O
making	O
evidence	B-MED
summaries	B-MED
and	O
a	O
literature	B-MED
database	B-MED
available	B-MED
free	O
to	O
anyone	O
,	O
papers	B-MED
in	O
academic	B-MED
journals	I-MED
and	O
other	O
written	O
outputs	O
,	O
and	O
a	O
MODEM	B-MED
Legacy	I-MED
Model	I-MED
,	O
which	O
will	O
enable	O
local	B-MED
commissioners	I-MED
of	O
services	B-MED
to	O
apply	O
the	O
model	B-MED
to	O
their	O
own	O
populations	B-MED
.	O
Modelling	B-MED
the	O
effects	B-MED
of	I-MED
evidence	B-MED
-based	O
cost	B-MED
-	O
effective	B-MED
interventions	B-MED
and	O
making	O
this	O
information	B-MED
widely	O
available	B-MED
has	O
the	O
potential	B-MED
to	O
improve	B-MED
the	O
health	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
both	O
of	O
people	B-MED
with	O
dementia	B-MED
and	O
their	O
carers	B-MED
,	O
while	O
ensuring	O
that	O
resources	B-MED
are	O
used	O
efficiently	O
.	O
Clinical	B-MED
and	O
radiological	B-MED
outcome	B-MED
following	O
pneumothorax	B-MED
after	O
endoscopic	B-MED
lung	I-MED
volume	I-MED
reduction	I-MED
with	O
valves	B-MED
Valve	B-MED
implantation	B-MED
has	O
evolved	O
as	O
a	O
therapy	B-MED
for	O
patients	B-MED
with	O
advanced	B-MED
emphysema	B-MED
.	O
Although	O
it	O
is	O
a	O
minimally	B-MED
invasive	I-MED
treatmen	I-MED
t	O
,	O
it	O
is	O
associated	B-MED
with	I-MED
complications	B-MED
,	O
the	O
most	O
common	B-MED
being	O
pneumothorax	B-MED
.	O
Pneumothorax	B-MED
occurs	O
due	O
to	O
the	O
rapid	B-MED
target	B-MED
lobe	B-MED
volume	B-MED
reduction	I-MED
and	O
may	O
be	O
a	O
predictor	B-MED
of	O
clinical	B-MED
benefit	B-MED
despite	O
this	O
complication	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
conduct	O
an	O
exploratory	B-MED
data	I-MED
analysis	I-MED
of	O
patients	B-MED
who	O
developed	O
a	O
pneumothorax	B-MED
following	O
endoscopic	B-MED
valve	I-MED
therapy	I-MED
for	O
emphysema	B-MED
.	O
This	O
study	B-MED
performed	B-MED
a	O
retrospective	B-MED
evaluation	I-MED
of	O
pneumothorax	B-MED
management	B-MED
and	O
the	O
impact	B-MED
of	O
pneumothorax	B-MED
on	O
clinical	B-MED
outcomes	I-MED
in	O
70	O
patients	B-MED
following	O
valve	B-MED
therapy	I-MED
in	O
381	O
consecutive	B-MED
patients	B-MED
.	O
Pneumothorax	B-MED
rate	B-MED
following	O
valve	B-MED
therapy	I-MED
was	O
18	O
%	O
.	O
Pneumothorax	B-MED
management	B-MED
consisted	O
of	O
chest	B-MED
tube	I-MED
insertion	I-MED
,	O
valve	B-MED
removal	B-MED
,	O
and	O
surgical	B-MED
intervention	I-MED
in	O
87	O
%	O
(	O
61/70	O
)	O
,	O
44	O
%	O
(	O
31/70	O
)	O
,	O
and	O
19	O
%	O
(	O
13/70	O
)	O
of	O
the	O
patients	B-MED
,	O
respectively	O
.	O
Despite	O
pneumothorax	B-MED
,	O
patients	B-MED
experienced	O
modest	B-MED
but	O
significant	B-MED
improvements	B-MED
in	O
lung	B-MED
function	I-MED
parameters	B-MED
(	O
forced	B-MED
expiratory	I-MED
volume	I-MED
in	O
1	O
second	O
:	O
55±148	O
mL	O
,	O
residual	B-MED
volume	I-MED
:	O
-390±964	O
mL	O
,	O
total	B-MED
lung	I-MED
capacity	I-MED
:	O
-348±876	O
;	O
all	O
P<0.05	O
)	O
.	O
Persistent	B-MED
lobar	B-MED
atelectasis	I-MED
3	O
months	O
after	O
recovering	B-MED
from	O
pneumothorax	B-MED
,	O
which	O
was	O
associated	B-MED
with	I-MED
relevant	B-MED
clinical	B-MED
improvement	B-MED
,	O
was	O
observed	B-MED
in	O
only	O
21	O
%	O
(	O
15/70	O
)	O
of	O
the	O
patients	B-MED
.	O
Pneumothorax	B-MED
is	O
a	O
frequent	B-MED
severe	B-MED
complication	B-MED
following	O
valve	B-MED
therapy	I-MED
that	O
requires	O
further	O
intervention	B-MED
.	O
Nevertheless	O
,	O
the	O
pneumothorax	B-MED
does	O
not	O
impair	B-MED
the	O
clinical	B-MED
status	I-MED
in	O
the	O
majority	O
of	O
patients	B-MED
.	O
Patients	B-MED
with	O
lobar	B-MED
atelectasis	I-MED
benefit	B-MED
after	O
recovering	B-MED
from	O
pneumothorax	B-MED
in	O
terms	O
of	O
lung	B-MED
function	I-MED
parameters	B-MED
.	O
Fall	B-MED
risk	B-MED
factors	I-MED
analysis	B-MED
based	O
on	O
sample	B-MED
entropy	I-MED
of	O
plantar	B-MED
kinematic	B-MED
signal	B-MED
during	O
stance	B-MED
phase	I-MED
Falls	B-MED
are	O
a	O
multi	B-MED
-	I-MED
causal	I-MED
phenomenon	I-MED
with	O
a	O
complex	B-MED
interaction	B-MED
.	O
The	O
aim	O
of	O
our	O
research	B-MED
is	O
to	O
study	B-MED
the	O
effect	B-MED
of	O
multiple	B-MED
variables	B-MED
for	O
potential	B-MED
risk	B-MED
of	I-MED
falls	I-MED
and	O
construct	B-MED
an	O
elderly	B-MED
fall	I-MED
risk	I-MED
assessment	I-MED
model	I-MED
based	O
on	O
demographics	B-MED
data	B-MED
and	O
gait	B-MED
characteristics	I-MED
.	O
A	O
total	O
of	O
101	O
subjects	B-MED
,	O
whom	O
belong	O
to	O
Malianwa	B-MED
Street	I-MED
,	O
aged	B-MED
above	O
50	O
years	B-MED
old	I-MED
and	O
participated	B-MED
in	O
questionnaire	B-MED
survey	B-MED
.	O
Participants	B-MED
were	O
classified	O
into	O
three	O
groups	B-MED
(	O
high	B-MED
,	O
medium	B-MED
and	O
low	B-MED
risk	I-MED
group	B-MED
)	O
according	O
to	O
the	O
score	B-MED
of	O
elderly	B-MED
fall	I-MED
risk	I-MED
assessment	I-MED
scale	I-MED
.	O
In	O
addition	O
,	O
the	O
data	B-MED
of	O
ground	B-MED
reaction	I-MED
force	I-MED
(	O
GRF	B-MED
)	O
and	O
ground	B-MED
reaction	I-MED
moment	I-MED
(	O
GRM	B-MED
)	O
was	O
record	B-MED
when	O
they	O
performed	B-MED
walking	B-MED
at	O
comfortable	B-MED
state	I-MED
.	O
The	O
demographic	B-MED
variables	B-MED
,	O
sample	B-MED
entropy	I-MED
of	O
GRF	B-MED
and	O
GRM	B-MED
,	O
and	O
impulse	B-MED
difference	I-MED
of	O
bilateral	B-MED
foot	I-MED
were	O
considered	O
as	O
potential	B-MED
explanatory	B-MED
variables	B-MED
of	O
risk	B-MED
assessment	I-MED
model	B-MED
.	O
Firstly	O
,	O
we	O
investigated	B-MED
whether	O
different	O
groups	B-MED
could	O
present	O
difference	B-MED
in	O
every	O
variable	B-MED
.	O
Statistical	B-MED
differences	I-MED
were	O
found	B-MED
for	O
the	O
following	O
variables	B-MED
:	O
age	B-MED
(	O
p=2.28e-05	O
)	O
;	O
impulse	B-MED
difference	I-MED
(	O
p=0.02036	O
)	O
;	O
sample	B-MED
entropy	I-MED
of	O
GRF	B-MED
in	O
vertical	B-MED
direction	B-MED
(	O
p=0.0144	O
)	O
;	O
sample	B-MED
entropy	I-MED
of	O
GRM	B-MED
in	O
anterior	B-MED
-	I-MED
posterior	I-MED
direction	B-MED
(	O
p=0.0387	O
)	O
.	O
Finally	O
,	O
the	O
multiple	B-MED
regression	B-MED
analysis	I-MED
results	B-MED
indicated	B-MED
that	O
age	B-MED
,	O
impulse	B-MED
difference	I-MED
and	O
sample	B-MED
entropy	I-MED
of	O
resultant	O
GRM	B-MED
could	O
identify	O
individuals	B-MED
who	O
had	O
different	O
levels	B-MED
of	I-MED
fall	I-MED
risk	I-MED
.	O
Therefore	O
,	O
those	O
results	B-MED
could	O
potentially	B-MED
be	O
useful	B-MED
in	O
the	O
fall	B-MED
risk	I-MED
assessment	I-MED
and	O
monitor	B-MED
the	O
state	B-MED
of	O
physical	B-MED
function	I-MED
in	O
elderly	B-MED
population	I-MED
.	O
Increased	B-MED
risk	B-MED
of	O
PTLD	B-MED
in	O
lung	B-MED
transplant	I-MED
recipients	I-MED
with	O
cystic	B-MED
fibrosis	I-MED
Post	B-MED
-	I-MED
transplant	I-MED
lymphoproliferative	I-MED
disease	I-MED
(	O
PTLD	B-MED
)	O
is	O
an	O
important	O
cause	O
of	O
morbidity	B-MED
and	O
mortality	B-MED
following	O
lung	B-MED
transplantation	I-MED
.	O
Recipients	B-MED
with	O
cystic	B-MED
fibrosis	I-MED
(	O
CF	B-MED
)	O
may	O
have	O
an	O
increased	B-MED
risk	B-MED
of	O
PTLD	B-MED
although	O
the	O
literature	B-MED
is	O
limited	O
to	O
single	B-MED
center	I-MED
cohorts	I-MED
.	O
Our	O
primary	O
aim	O
is	O
to	O
examine	O
PTLD	B-MED
in	O
an	O
adult	B-MED
lung	B-MED
transplant	I-MED
population	B-MED
by	O
utilizing	O
the	O
International	B-MED
Society	I-MED
for	I-MED
Heart	I-MED
and	I-MED
Lung	I-MED
Transplantation	I-MED
Registry	I-MED
.	O
We	O
studied	B-MED
30,598	O
adult	B-MED
recipients	B-MED
of	O
lung	B-MED
transplants	I-MED
performed	O
between	O
1999	O
and	O
2011	O
.	O
The	O
primary	O
outcome	B-MED
was	O
development	B-MED
of	O
and	O
time	B-MED
to	O
PTLD	B-MED
.	O
In	O
addition	O
to	O
indication	O
for	O
transplant	B-MED
,	O
other	O
predictors	B-MED
examined	O
included	O
Epstein	B-MED
-	I-MED
Barr	I-MED
virus	I-MED
(	O
EBV	B-MED
)	O
and	O
cytomegalovirus	B-MED
(	O
CMV	B-MED
)	O
serostatus	B-MED
,	O
gender	B-MED
,	O
and	O
age	B-MED
.	O
Outcomes	B-MED
were	O
assessed	B-MED
with	O
univariable	B-MED
and	O
multivariable	B-MED
Cox	I-MED
proportional	I-MED
hazard	I-MED
models	I-MED
to	O
obtain	O
hazard	B-MED
ratios	I-MED
(	O
HR	B-MED
)	O
.	O
17	O
%	O
of	O
the	O
cohort	B-MED
had	O
a	O
diagnosis	B-MED
of	O
CF	B-MED
.	O
PTLD	B-MED
developed	O
in	O
2	O
%	O
of	O
CF	B-MED
recipients	B-MED
compared	O
to	O
1	O
%	O
for	O
non	B-MED
-	I-MED
CF	I-MED
recipients	I-MED
(	O
p<0.001	O
)	O
.	O
Compared	O
to	O
non	B-MED
-	I-MED
CF	I-MED
recipients	I-MED
,	O
CF	B-MED
recipients	B-MED
had	O
higher	B-MED
prevalence	I-MED
of	O
EBV	B-MED
and	O
CMV	B-MED
seronegativity	I-MED
and	O
higher	B-MED
prevalences	I-MED
of	O
high	B-MED
risk	I-MED
EBV	B-MED
and	O
CMV	B-MED
mismatch	O
(	O
D+/R-	O
)	O
.	O
There	O
is	O
a	O
significant	O
association	O
between	O
CF	B-MED
and	O
the	O
development	B-MED
of	O
PTLD	B-MED
[	O
HR	B-MED
1.66	O
(	O
95	O
%	O
CI	O
1.30	O
-	O
2.12	O
)	O
]	O
.	O
Stratified	B-MED
multivariable	I-MED
analysis	I-MED
controlling	O
for	O
age	B-MED
revealed	O
EBV	B-MED
negative	B-MED
non	B-MED
-	I-MED
CF	I-MED
recipients	I-MED
have	O
an	O
almost	O
2	O
fold	O
increased	B-MED
risk	B-MED
of	O
developing	O
PTLD	B-MED
,	O
whereas	O
EBV	B-MED
negative	O
CF	B-MED
recipients	B-MED
had	O
an	O
almost	O
6.5	O
fold	O
increased	B-MED
risk	B-MED
.	O
CF	B-MED
recipients	B-MED
have	O
a	O
higher	O
risk	B-MED
for	O
PTLD	B-MED
compared	O
to	O
non	B-MED
-	I-MED
CF	I-MED
recipients	I-MED
.	O
Further	O
studies	B-MED
are	O
needed	O
to	O
account	O
for	O
additional	O
risk	B-MED
factors	I-MED
and	O
management	B-MED
in	O
this	O
population	B-MED
post	I-MED
-	I-MED
transplant	I-MED
.	O
Importance	B-MED
of	O
Ecological	B-MED
Factors	I-MED
and	O
Colony	B-MED
Handling	B-MED
for	O
Optimizing	B-MED
Health	B-MED
Status	I-MED
of	O
Apiaries	B-MED
in	O
Mediterranean	B-MED
Ecosystems	B-MED
We	O
analyzed	B-MED
six	O
apiaries	B-MED
in	O
several	O
natural	B-MED
environments	I-MED
with	O
a	O
Mediterranean	B-MED
ecosystem	B-MED
in	O
Madrid	B-MED
,	O
central	B-MED
Spain	I-MED
,	O
in	O
order	O
to	O
understand	B-MED
how	O
landscape	B-MED
and	O
management	B-MED
characteristics	B-MED
may	O
influence	B-MED
apiary	B-MED
health	B-MED
and	O
bee	B-MED
production	O
in	O
the	O
long	B-MED
term	I-MED
.	O
We	O
focused	B-MED
on	O
five	O
criteria	B-MED
(	O
habitat	B-MED
quality	B-MED
,	O
landscape	B-MED
heterogeneity	B-MED
,	O
climate	B-MED
,	O
management	B-MED
and	O
health	B-MED
)	O
,	O
as	O
well	O
as	O
30	O
subcriteria	B-MED
,	O
and	O
we	O
used	O
the	O
analytic	B-MED
hierarchy	I-MED
process	I-MED
(	O
AHP	B-MED
)	O
to	O
rank	B-MED
them	O
according	O
to	O
relevance	B-MED
.	O
Habitat	B-MED
quality	B-MED
proved	O
to	O
have	O
the	O
highest	O
relevance	B-MED
,	O
followed	O
by	O
beehive	B-MED
management	B-MED
.	O
Within	O
habitat	B-MED
quality	B-MED
,	O
the	O
following	O
subcriteria	B-MED
proved	O
to	O
be	O
most	O
relevant	B-MED
:	O
orographic	B-MED
diversity	I-MED
,	O
elevation	B-MED
range	B-MED
and	O
important	B-MED
plant	B-MED
species	B-MED
located	B-MED
1.5	O
km	O
from	O
the	O
apiary	B-MED
.	O
The	O
most	O
important	B-MED
subcriteria	B-MED
under	O
beehive	B-MED
management	B-MED
were	O
honey	B-MED
production	B-MED
,	O
movement	O
of	O
the	O
apiary	B-MED
to	O
a	O
location	B-MED
with	O
a	O
higher	O
altitude	B-MED
and	O
wax	B-MED
renewal	B-MED
.	O
Temperature	B-MED
was	O
the	O
most	O
important	O
subcriterion	B-MED
under	O
climate	B-MED
,	O
while	O
pathogen	B-MED
and	O
Varroa	B-MED
loads	B-MED
were	O
the	O
most	O
significant	B-MED
under	O
health	B-MED
.	O
Two	O
of	O
the	O
six	O
apiaries	B-MED
showed	O
the	O
best	B-MED
values	I-MED
in	O
the	O
AHP	B-MED
analysis	B-MED
and	O
showed	O
annual	B-MED
honey	B-MED
production	B-MED
of	O
70	O
and	O
28	O
kg/	O
colony	B-MED
.	O
This	O
high	O
productivity	B-MED
was	O
due	O
primarily	O
to	O
high	O
elevation	B-MED
range	B-MED
and	O
high	O
orographic	B-MED
diversity	I-MED
,	O
which	O
favored	O
high	O
habitat	B-MED
quality	B-MED
.	O
In	O
addition	O
,	O
one	O
of	O
these	O
apiaries	B-MED
showed	O
the	O
best	B-MED
value	I-MED
for	O
beehive	B-MED
management	B-MED
,	O
while	O
the	O
other	O
showed	O
the	O
best	B-MED
value	I-MED
for	O
health	B-MED
,	O
reflected	O
in	O
the	O
low	B-MED
pathogen	B-MED
load	B-MED
and	O
low	B-MED
average	B-MED
number	B-MED
of	O
viruses	B-MED
.	O
These	O
results	B-MED
highlight	O
the	O
importance	B-MED
of	O
environmental	B-MED
factors	I-MED
and	O
good	O
sanitary	B-MED
practices	I-MED
to	O
maximize	O
apiary	B-MED
health	B-MED
and	O
honey	B-MED
productivity	B-MED
.	O
Physiology	B-MED
of	O
respiratory	B-MED
disturbances	I-MED
in	O
muscular	B-MED
dystrophies	I-MED
Muscular	B-MED
dystrophy	I-MED
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-MED
characterised	O
by	O
progressive	B-MED
skeletal	B-MED
muscle	I-MED
wasting	I-MED
,	O
including	O
of	O
the	O
respiratory	B-MED
muscles	I-MED
.	O
Respiratory	B-MED
failure	I-MED
,	O
i.e.	O
when	O
the	O
respiratory	B-MED
system	I-MED
fails	B-MED
in	O
its	O
gas	B-MED
exchange	I-MED
functions	I-MED
,	O
is	O
a	O
common	O
feature	B-MED
in	O
muscular	B-MED
dystrophy	I-MED
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-MED
,	O
and	O
it	O
is	O
a	O
consequence	B-MED
of	I-MED
lung	B-MED
failure	B-MED
,	O
pump	B-MED
failure	I-MED
or	O
a	O
combination	O
of	O
the	O
two	O
.	O
The	O
former	O
is	O
due	O
to	O
recurrent	B-MED
aspiration	B-MED
,	O
the	O
latter	O
to	O
progressive	B-MED
weakness	B-MED
of	I-MED
respiratory	I-MED
muscles	I-MED
and	O
an	O
increase	B-MED
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	B-MED
.	O
In	O
fact	O
,	O
both	O
the	O
resistive	B-MED
and	I-MED
elastic	I-MED
components	I-MED
of	O
the	O
work	O
of	O
breathing	B-MED
increase	B-MED
due	O
to	O
airway	B-MED
obstruction	I-MED
and	O
chest	B-MED
wall	I-MED
and	O
lung	B-MED
stiffening	B-MED
,	O
respectively	O
.	O
The	O
respiratory	B-MED
disturbances	I-MED
in	O
muscular	B-MED
dystrophy	I-MED
are	O
restrictive	B-MED
pulmonary	I-MED
function	I-MED
,	O
hypoventilation	B-MED
,	O
altered	O
thoracoabdominal	B-MED
pattern	O
,	O
hypercapnia	B-MED
,	O
dyspnoea	B-MED
,	O
impaired	B-MED
regulation	I-MED
of	I-MED
breathing	I-MED
,	O
inefficient	B-MED
cough	I-MED
and	O
sleep	B-MED
disordered	I-MED
breathing	I-MED
.	O
They	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular	B-MED
dystrophy	I-MED
and	O
its	O
progression	B-MED
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-MED
,	O
prognosis	B-MED
and	O
degree	B-MED
of	I-MED
respiratory	I-MED
involvement	I-MED
.	O
A	O
common	O
feature	B-MED
of	O
muscular	B-MED
dystrophy	I-MED
is	O
respiratory	B-MED
failure	I-MED
,	O
i.e.	O
the	O
inability	O
of	O
the	O
respiratory	B-MED
system	I-MED
to	O
provide	O
proper	O
oxygenation	B-MED
and	O
carbon	B-MED
dioxide	I-MED
elimination	I-MED
.In	O
the	O
lung	B-MED
,	O
respiratory	B-MED
failure	I-MED
is	O
caused	O
by	O
recurrent	B-MED
aspiration	B-MED
,	O
and	O
leads	O
to	O
hypoxaemia	B-MED
and	O
hypercarbia	B-MED
.	O
Ventilatory	B-MED
failure	I-MED
in	O
muscular	B-MED
dystrophy	I-MED
is	O
caused	O
by	O
increased	B-MED
respiratory	B-MED
load	I-MED
and	O
respiratory	B-MED
muscles	I-MED
weakness	I-MED
.	O
Respiratory	B-MED
load	I-MED
increases	B-MED
in	O
muscular	B-MED
dystrophy	I-MED
because	O
scoliosis	B-MED
makes	O
chest	B-MED
wall	I-MED
compliance	I-MED
decrease	B-MED
,	O
atelectasis	B-MED
and	O
fibrosis	B-MED
make	O
lung	B-MED
compliance	I-MED
decrease	B-MED
,	O
and	O
airway	B-MED
obstruction	I-MED
makes	O
airway	B-MED
resistance	I-MED
increase	B-MED
.The	O
consequences	B-MED
of	I-MED
respiratory	B-MED
pump	I-MED
failure	I-MED
are	O
restrictive	B-MED
pulmonary	I-MED
function	I-MED
,	O
hypoventilation	B-MED
,	O
altered	O
thoracoabdominal	B-MED
pattern	O
,	O
hypercapnia	B-MED
,	O
dyspnoea	B-MED
,	O
impaired	B-MED
regulation	I-MED
of	I-MED
breathing	I-MED
,	O
inefficient	B-MED
cough	I-MED
and	O
sleep	B-MED
disordered	I-MED
breathing	I-MED
.	O
To	O
understand	O
the	O
mechanisms	B-MED
leading	O
to	O
respiratory	B-MED
disturbances	I-MED
in	O
patients	B-MED
with	O
muscular	B-MED
dystrophy	I-MED
.To	O
understand	O
the	O
impact	O
of	O
respiratory	B-MED
disturbances	I-MED
in	O
patients	B-MED
with	O
muscular	B-MED
dystrophy	I-MED
.To	O
provide	O
a	O
brief	O
description	B-MED
of	O
the	O
main	O
forms	O
of	O
muscular	B-MED
dystrophy	I-MED
with	O
their	O
respiratory	B-MED
implications	I-MED
.	O
A	O
holistic	B-MED
approach	I-MED
to	O
age	B-MED
estimation	B-MED
in	O
refugee	B-MED
children	B-MED
Many	O
refugee	B-MED
children	B-MED
arriving	O
in	O
Australia	B-MED
have	O
an	O
inaccurately	B-MED
documented	B-MED
date	B-MED
of	I-MED
birth	I-MED
(	O
DOB	B-MED
)	O
.	O
A	O
medical	B-MED
assessment	I-MED
of	O
a	O
child	B-MED
's	I-MED
age	I-MED
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	B-MED
that	O
their	O
documented	B-MED
DOB	B-MED
is	O
incorrect	B-MED
.	O
This	O
study	O
's	O
aim	O
was	O
to	O
assess	B-MED
the	O
accuracy	B-MED
a	O
holistic	B-MED
age	I-MED
assessment	I-MED
tool	I-MED
(	O
AAT	B-MED
)	O
in	O
estimating	B-MED
the	O
age	B-MED
of	O
refugee	B-MED
children	B-MED
newly	O
settled	O
in	O
Australia	B-MED
.	O
A	O
holistic	B-MED
AAT	I-MED
that	O
combines	O
medical	B-MED
and	O
non	B-MED
-	I-MED
medical	I-MED
approaches	I-MED
was	O
used	O
to	O
estimate	B-MED
the	O
ages	B-MED
of	O
60	O
refugee	B-MED
children	B-MED
with	O
a	O
known	O
DOB	B-MED
.	O
The	O
tool	B-MED
used	O
four	O
components	B-MED
to	O
assess	B-MED
age	B-MED
:	O
an	O
oral	B-MED
narrative	B-MED
,	O
developmental	B-MED
assessment	B-MED
,	O
anthropometric	B-MED
measures	I-MED
and	O
pubertal	B-MED
assessment	B-MED
.	O
Assessors	B-MED
were	O
blinded	B-MED
to	O
the	O
true	B-MED
age	B-MED
of	O
the	O
child	B-MED
.	O
Correlation	B-MED
coefficients	I-MED
for	O
the	O
actual	B-MED
and	O
estimated	B-MED
age	B-MED
were	O
calculated	B-MED
for	O
the	O
tool	B-MED
overall	B-MED
and	I-MED
individual	I-MED
components	I-MED
.	O
The	O
correlation	B-MED
coefficient	I-MED
between	O
the	O
actual	B-MED
and	O
estimated	B-MED
age	B-MED
from	O
the	O
AAT	B-MED
was	O
very	O
strong	O
at	O
0.9802	O
(	O
boys	B-MED
0.9748	O
,	O
girls	B-MED
0.9876	O
)	O
.	O
The	O
oral	B-MED
narrative	B-MED
component	B-MED
of	O
the	O
tool	B-MED
performed	O
best	O
(	O
R	O
=	O
0.9603	O
)	O
.	O
Overall	O
,	O
86.7	O
%	O
of	O
age	B-MED
estimates	B-MED
were	O
within	O
1	O
year	B-MED
of	O
the	O
true	B-MED
age	B-MED
.	O
The	O
range	O
of	O
differences	O
was	O
-1.43	O
to	O
3.92	O
years	B-MED
with	O
a	O
standard	B-MED
deviation	I-MED
of	O
0.77	O
years	B-MED
(	O
9.24	O
months	B-MED
)	O
.	O
The	O
AAT	B-MED
is	O
a	O
holistic	B-MED
,	O
simple	B-MED
and	O
safe	B-MED
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-MED
age	B-MED
in	O
refugee	B-MED
children	B-MED
with	O
results	O
comparable	O
with	O
radiological	B-MED
methods	I-MED
currently	O
used	O
.	O
Bilateral	B-MED
C1	B-MED
laminar	I-MED
hooks	I-MED
combined	O
with	O
C2	B-MED
pedicle	I-MED
screw	I-MED
fixation	B-MED
in	O
the	O
treatment	B-MED
of	O
atlantoaxial	B-MED
subluxation	I-MED
after	O
Grisel	B-MED
syndrome	I-MED
Many	O
etiologies	B-MED
can	O
lead	O
to	O
atlantoaxial	B-MED
subluxaion	I-MED
.	O
In	O
Grisel	B-MED
syndrome	I-MED
(	O
GS	B-MED
)	O
,	O
this	O
subluxation	B-MED
occurs	O
spontaneously	B-MED
after	O
inflammatory	B-MED
processes	B-MED
of	O
the	O
head	B-MED
and	O
neck	B-MED
.	O
Diagnosis	B-MED
is	O
typically	O
based	O
on	O
clinical	B-MED
history	I-MED
and	O
a	O
strong	O
suspicion	B-MED
of	O
this	O
syndrome	B-MED
.	O
Nonsurgical	B-MED
treatment	I-MED
most	O
often	O
resolves	B-MED
the	O
symptoms	B-MED
;	O
however	O
,	O
in	O
some	O
cases	B-MED
surgical	B-MED
treatment	I-MED
is	O
necessary	O
to	O
repair	B-MED
the	O
subluxation	B-MED
.	O
Various	O
surgical	B-MED
techniques	I-MED
and	O
instrumentation	B-MED
systems	I-MED
have	O
been	O
used	O
to	O
treat	B-MED
atlantoaxial	B-MED
subluxation	I-MED
,	O
although	O
there	O
is	O
no	O
consensus	B-MED
regarding	O
the	O
best	O
treatment	B-MED
method	I-MED
for	O
the	O
pediatric	B-MED
population	B-MED
.	O
To	O
describe	O
a	O
case	B-MED
of	O
atlantoaxial	B-MED
subluxation	I-MED
in	O
a	O
child	B-MED
with	O
GS	B-MED
treated	B-MED
surgically	B-MED
with	O
an	O
alternative	B-MED
construct	B-MED
.	O
This	O
is	O
a	O
case	B-MED
report	I-MED
and	O
literature	B-MED
review	I-MED
.	O
Our	O
case	B-MED
study	I-MED
involves	O
a	O
5-	O
year	B-MED
-old	O
girl	B-MED
with	O
a	O
6-	O
month	B-MED
history	B-MED
of	O
unresolved	B-MED
Fielding	B-MED
type	I-MED
II	I-MED
atlantoaxial	I-MED
subluxation	I-MED
caused	O
by	O
GS	B-MED
.	O
Despite	O
conservative	B-MED
treatment	I-MED
,	O
the	O
patient	B-MED
's	I-MED
symptoms	B-MED
continued	B-MED
to	O
progress	B-MED
.	O
After	O
two	O
failed	B-MED
closed	B-MED
reduction	I-MED
attempts	B-MED
,	O
open	B-MED
reduction	I-MED
and	O
C1	B-MED
-	I-MED
C2	I-MED
fusion	I-MED
were	O
performed	B-MED
with	O
atlas	B-MED
laminar	I-MED
hook	I-MED
and	O
axis	B-MED
pedicle	I-MED
polyaxial	I-MED
screws	I-MED
.	O
A	O
literature	B-MED
review	I-MED
of	O
the	O
surgical	B-MED
treatment	I-MED
of	O
GS	B-MED
was	O
also	O
performed	B-MED
.	O
After	O
surgery	B-MED
,	O
the	O
patient	B-MED
exhibited	O
full	O
clinical	B-MED
and	O
functional	B-MED
recovery	I-MED
with	O
complete	B-MED
resolution	I-MED
of	O
symptoms	B-MED
.	O
At	O
the	O
36-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
examination	B-MED
,	O
there	O
was	O
continual	B-MED
evidence	B-MED
of	O
satisfactory	B-MED
reduction	B-MED
and	O
fusion	B-MED
.	O
No	O
complications	B-MED
were	O
observed	B-MED
.	O
Upon	O
completion	B-MED
of	O
the	O
literature	B-MED
review	I-MED
,	O
eight	O
GS	B-MED
cases	B-MED
were	O
found	O
to	O
have	O
been	O
treated	B-MED
surgically	B-MED
with	O
the	O
minimum	O
patient	B-MED
age	B-MED
being	O
9	O
years	B-MED
.	O
Conservative	B-MED
management	I-MED
of	O
GS	B-MED
is	O
the	O
most	O
common	B-MED
and	O
effective	B-MED
treatment	B-MED
;	O
however	O
,	O
a	O
few	O
surgical	B-MED
cases	I-MED
have	O
been	O
reported	B-MED
in	O
the	O
literature	B-MED
with	O
good	O
results	B-MED
.	O
Satisfactory	B-MED
clinical	B-MED
results	I-MED
and	O
fusion	B-MED
at	O
36	O
months	B-MED
post	B-MED
surgery	I-MED
were	O
seen	O
in	O
a	O
pediatric	B-MED
patient	B-MED
with	O
atlantoaxial	B-MED
subluxation	I-MED
and	O
instability	B-MED
using	O
atlas	B-MED
laminar	I-MED
hook	I-MED
and	O
axis	B-MED
pedicle	I-MED
polyaxial	I-MED
screws	I-MED
.	O
Mesenchymal	B-MED
stem	I-MED
cells	I-MED
enhance	B-MED
the	O
oncolytic	B-MED
effect	B-MED
of	O
Newcastle	B-MED
disease	I-MED
virus	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
glioma	B-MED
stem	B-MED
cells	I-MED
via	O
the	O
secretion	B-MED
of	O
TRAIL	B-MED
Newcastle	B-MED
disease	I-MED
virus	I-MED
(	O
NDV	B-MED
)	O
is	O
an	O
avian	B-MED
paramyxovirus	I-MED
,	O
which	O
selectively	O
exerts	B-MED
oncolytic	B-MED
effects	B-MED
in	O
cancer	B-MED
cells	I-MED
.	O
Mesenchymal	B-MED
stem	I-MED
cells	I-MED
(	O
MSCs	B-MED
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor	B-MED
growth	I-MED
and	O
deliver	B-MED
anti	B-MED
-	I-MED
tumor	I-MED
agents	I-MED
to	O
experimental	B-MED
glioblastoma	B-MED
(	O
GBM	B-MED
)	O
.	O
Here	O
,	O
we	O
explored	O
the	O
effects	B-MED
of	I-MED
NDV	B-MED
-	O
infected	B-MED
MSCs	B-MED
derived	O
from	O
different	O
sources	B-MED
,	O
on	O
glioma	B-MED
cells	B-MED
and	O
glioma	B-MED
stem	B-MED
cells	I-MED
(	O
GSCs	B-MED
)	O
and	O
the	O
mechanisms	B-MED
involved	O
in	O
their	O
effects	B-MED
.	O
The	O
glioma	B-MED
cell	B-MED
lines	I-MED
(	O
A172	B-MED
and	O
U87	B-MED
)	O
and	O
primary	B-MED
GSCs	B-MED
that	O
were	O
generated	B-MED
from	O
GBM	B-MED
tumors	B-MED
were	O
used	O
in	O
this	O
study	B-MED
.	O
MSCs	B-MED
derived	B-MED
from	O
bone	B-MED
marrow	I-MED
,	O
adipose	B-MED
tissue	I-MED
or	O
umbilical	B-MED
cord	I-MED
were	O
infected	B-MED
with	O
NDV	B-MED
(	O
MTH-68	B-MED
/	I-MED
H	I-MED
)	O
.	O
The	O
ability	B-MED
of	O
these	O
cells	B-MED
to	O
deliver	B-MED
the	O
virus	B-MED
to	O
glioma	B-MED
cell	B-MED
lines	I-MED
and	O
GSCs	B-MED
and	O
the	O
effects	B-MED
of	I-MED
NDV	B-MED
-	O
infected	B-MED
MSCs	B-MED
on	O
cell	B-MED
death	I-MED
and	O
on	O
the	O
stemness	B-MED
and	O
self	B-MED
-	I-MED
renewal	I-MED
of	O
GSCs	B-MED
were	O
examined	B-MED
.	O
The	O
mechanisms	B-MED
involved	B-MED
in	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
the	O
NDV	B-MED
-	O
infected	B-MED
MSCs	B-MED
and	O
their	O
influence	B-MED
on	O
the	O
radiation	B-MED
sensitivity	I-MED
of	O
GSCs	B-MED
were	O
examined	B-MED
as	O
well	O
.	O
NDV	B-MED
induced	B-MED
a	O
dose	B-MED
-	I-MED
dependent	I-MED
cell	B-MED
death	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
a	O
low	B-MED
level	B-MED
of	O
apoptosis	B-MED
and	O
inhibition	B-MED
of	O
self	B-MED
-	I-MED
renewal	I-MED
in	O
GSCs	B-MED
.	O
MSCs	B-MED
derived	B-MED
from	O
bone	B-MED
marrow	I-MED
,	O
adipose	B-MED
and	O
umbilical	B-MED
cord	I-MED
that	O
were	O
infected	B-MED
with	O
NDV	B-MED
delivered	B-MED
the	O
virus	B-MED
to	O
co	B-MED
-	I-MED
cultured	I-MED
glioma	B-MED
cells	B-MED
and	O
GSCs	B-MED
.	O
Conditioned	B-MED
medium	I-MED
of	O
NDV	B-MED
-	O
infected	B-MED
MSCs	B-MED
induced	B-MED
higher	B-MED
level	B-MED
of	O
apoptosis	B-MED
in	O
the	O
tumor	B-MED
cells	I-MED
compared	B-MED
with	O
the	O
apoptosis	B-MED
induced	B-MED
by	O
their	O
direct	B-MED
infection	I-MED
with	O
similar	B-MED
virus	B-MED
titers	I-MED
.	O
These	O
results	B-MED
suggest	B-MED
that	O
factor(s	B-MED
)	I-MED
secreted	B-MED
by	O
the	O
infected	B-MED
MSCs	B-MED
sensitized	B-MED
the	O
glioma	B-MED
cells	B-MED
to	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
NDV	B-MED
.	O
We	O
identified	B-MED
TRAIL	B-MED
as	O
a	O
mediator	B-MED
of	O
the	O
cytotoxic	B-MED
effects	B-MED
of	I-MED
the	O
infected	B-MED
MSCs	B-MED
and	O
demonstrated	B-MED
that	O
TRAIL	B-MED
synergized	O
with	O
NDV	B-MED
in	O
the	O
induction	B-MED
of	O
cell	B-MED
death	I-MED
in	O
glioma	B-MED
cells	B-MED
and	O
GSCs	B-MED
.	O
Moreover	O
,	O
conditioned	B-MED
medium	B-MED
of	O
infected	B-MED
MSCs	B-MED
enhanced	B-MED
the	O
sensitivity	O
of	O
GSCs	B-MED
to	O
γ	B-MED
-	I-MED
radiation	I-MED
.	O
NDV	B-MED
-	O
infected	B-MED
umbilical	B-MED
cord	I-MED
-	O
derived	B-MED
MSCs	B-MED
may	O
provide	O
a	O
novel	B-MED
effective	B-MED
therapeutic	B-MED
approach	B-MED
for	O
targeting	B-MED
GSCs	B-MED
and	O
GBM	B-MED
and	O
for	O
sensitizing	O
these	O
tumors	B-MED
to	O
γ	B-MED
-	I-MED
radiation	I-MED
.	O
Arthrobacter	B-MED
ginkgonis	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
,	O
an	O
actinomycete	B-MED
isolated	B-MED
from	O
rhizosphere	B-MED
of	O
Ginkgo	B-MED
biloba	I-MED
L	I-MED
A	O
Gram	B-MED
-	I-MED
stain	I-MED
-	I-MED
positive	I-MED
,	O
aerobic	B-MED
actinobacterial	B-MED
strain	I-MED
(	O
designated	O
SYP	B-MED
-	I-MED
A7299	I-MED
T	I-MED
)	O
,	O
which	O
displayed	O
a	O
rod	B-MED
-	I-MED
coccus	I-MED
growth	I-MED
lifecycle	I-MED
,	O
was	O
isolated	B-MED
from	O
the	O
rhizosphere	B-MED
of	O
Ginkgo	B-MED
biloba	I-MED
L	I-MED
L.	O
Phylogenetic	B-MED
analyses	I-MED
based	O
on	O
16S	B-MED
rRNA	I-MED
gene	I-MED
sequences	I-MED
indicated	O
that	O
strain	B-MED
SYP	I-MED
-	I-MED
A7299	I-MED
T	I-MED
belongs	O
to	O
the	O
genus	B-MED
Arthrobacter	B-MED
and	O
is	O
most	O
closely	O
related	O
to	O
Arthrobacter	B-MED
halodurans	I-MED
JSM	I-MED
078085	I-MED
T	I-MED
(	O
97.4	O
%	O
16S	B-MED
rRNA	I-MED
gene	I-MED
sequence	I-MED
similarity	B-MED
)	O
.	O
The	O
DNA	B-MED
-	O
DNA	B-MED
relatedness	B-MED
value	I-MED
between	O
strain	B-MED
SYP	I-MED
-	I-MED
A7299	I-MED
T	I-MED
and	O
A.	B-MED
halodurans	I-MED
JSM	I-MED
078085	I-MED
T	I-MED
was	O
37	O
%	O
±2.9	O
.	O
The	O
cell	B-MED
-	I-MED
wall	I-MED
peptidoglycan	B-MED
was	O
A4α	B-MED
,	O
and	O
glucose	B-MED
and	O
galactose	B-MED
were	O
whole	B-MED
-	I-MED
cell	I-MED
sugars	I-MED
.	O
The	O
polar	B-MED
lipids	I-MED
consisted	O
of	O
diphosphatidylglycerol	B-MED
,	O
phosphatidylglycerol	B-MED
,	O
phosphatidylinositol	B-MED
,	O
two	O
glycolipids	B-MED
and	O
an	O
unknown	O
polar	B-MED
lipid	I-MED
.	O
The	O
major	O
menaquinone	B-MED
were	O
MK-8(H2	B-MED
)	I-MED
(	O
72	O
%	O
)	O
and	O
MK-9(H2	B-MED
)	I-MED
(	O
28	O
%	O
)	O
,	O
and	O
the	O
predominant	O
cellular	B-MED
fatty	I-MED
acids	I-MED
were	O
anteiso	B-MED
-	I-MED
C15	I-MED
:	I-MED
0	I-MED
,	O
iso	B-MED
-	I-MED
C15	I-MED
:	I-MED
0	I-MED
and	O
anteiso	B-MED
-	I-MED
C17	I-MED
:	I-MED
0	I-MED
.	O
The	O
DNA	B-MED
G+C	B-MED
content	I-MED
was	O
68.9	O
mol%	O
.	O
Based	O
on	O
the	O
morphological	B-MED
,	O
physiological	B-MED
,	O
biochemical	B-MED
and	O
chemotaxonomic	B-MED
characters	I-MED
presented	O
in	O
this	O
study	O
,	O
strain	B-MED
SYP	I-MED
-	I-MED
A7299	I-MED
T	I-MED
represents	O
a	O
novel	O
species	B-MED
of	O
the	O
genus	B-MED
Arthrobacter	B-MED
,	O
for	O
which	O
the	O
name	O
Arthrobacter	B-MED
ginkgonis	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
is	O
proposed	O
.	O
The	O
type	B-MED
strain	I-MED
is	O
SYP	B-MED
-	I-MED
A7299	I-MED
T	I-MED
=	B-MED
(=	O
DSM	I-MED
100491T	I-MED
=	I-MED
KCTC	I-MED
39	I-MED
592	I-MED
T	I-MED
)	O
.	O
Chlamydia	B-MED
pneumoniae	I-MED
infection	B-MED
promotes	B-MED
vascular	B-MED
endothelial	I-MED
cell	I-MED
angiogenesis	B-MED
through	O
an	O
IQGAP1	B-MED
-related	O
signaling	B-MED
pathway	I-MED
Chlamydia	B-MED
pneumoniae	I-MED
(	O
C.	B-MED
pneumoniae	I-MED
)	O
infection	B-MED
plays	O
a	O
potential	B-MED
role	I-MED
in	O
angiogenesis	B-MED
.	O
However	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
C.	B-MED
pneumoniae	I-MED
is	O
involved	B-MED
in	O
this	O
process	B-MED
.	O
Therefore	O
,	O
we	O
investigated	B-MED
the	O
effect	B-MED
of	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
on	O
angiogenesis	B-MED
,	O
and	O
then	O
explored	O
the	O
roles	B-MED
of	O
IQGAP1	B-MED
-related	O
signaling	B-MED
in	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
-	O
induced	B-MED
angiogenesis	B-MED
.	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
significantly	B-MED
enhanced	I-MED
angiogenesis	B-MED
as	O
assessed	B-MED
by	O
the	O
tube	B-MED
formation	I-MED
assay	I-MED
possibly	B-MED
by	O
inducing	B-MED
vascular	B-MED
endothelial	I-MED
cell	I-MED
(	O
VEC	B-MED
)	O
migration	B-MED
in	O
the	O
wound	B-MED
healing	I-MED
and	O
Transwell	B-MED
migration	I-MED
assays	I-MED
.	O
Subsequently	B-MED
,	O
immunoprecipitation	B-MED
,	O
Western	B-MED
blot	I-MED
and	O
tube	B-MED
formation	I-MED
assay	I-MED
results	B-MED
showed	O
that	O
the	O
phosphorylation	B-MED
of	O
both	O
IQGAP1	B-MED
and	O
N	B-MED
-	I-MED
WASP	I-MED
was	O
required	B-MED
for	O
the	O
angiogenesis	B-MED
induced	B-MED
by	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
.	O
Our	O
co	B-MED
-	I-MED
immunoprecipitation	I-MED
study	B-MED
revealed	B-MED
that	O
IQGAP1	B-MED
physically	O
associated	B-MED
with	I-MED
N	B-MED
-	I-MED
WASP	I-MED
after	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
of	O
VECs	B-MED
.	O
Actin	B-MED
polymerization	I-MED
assay	B-MED
further	O
showed	O
that	O
in	O
C.	B-MED
pneumoniae	I-MED
-	O
infected	B-MED
VECs	B-MED
,	O
both	O
IQGAP1	B-MED
and	O
N	B-MED
-	I-MED
WASP	I-MED
were	O
recruited	O
to	O
filamentous	B-MED
actin	I-MED
,	O
and	O
shared	O
some	O
common	B-MED
compartments	O
localized	B-MED
at	O
the	O
leading	B-MED
edge	I-MED
of	O
lamellipodia	B-MED
,	O
which	O
was	O
impaired	B-MED
after	O
the	O
depletion	B-MED
of	O
IQGAP1	B-MED
by	O
using	O
the	O
small	B-MED
interference	I-MED
RNA	I-MED
.	O
Moreover	O
,	O
the	O
knockdown	B-MED
of	O
IQGAP1	B-MED
also	O
significantly	B-MED
decreased	I-MED
N	B-MED
-	I-MED
WASP	I-MED
phosphorylation	B-MED
at	O
Tyr256	B-MED
induced	B-MED
by	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
.	O
We	O
conclude	B-MED
that	O
C.	B-MED
pneumoniae	I-MED
infection	B-MED
promotes	B-MED
VEC	B-MED
migration	B-MED
and	O
angiogenesis	B-MED
presumably	O
through	O
the	O
IQGAP1	B-MED
-related	O
signaling	B-MED
pathway	I-MED
.	O
Function	B-MED
analysis	B-MED
of	O
Mef2c	B-MED
promoter	B-MED
in	O
muscle	B-MED
differentiation	I-MED
Regeneration	B-MED
of	I-MED
adult	I-MED
skeletal	I-MED
muscle	I-MED
following	O
injury	B-MED
occurs	O
through	O
the	O
activation	B-MED
of	O
satellite	B-MED
cells	I-MED
,	O
that	O
proliferates	B-MED
,	O
differentiates	B-MED
,	O
and	O
fuses	B-MED
with	O
injured	B-MED
myofibers	B-MED
.	O
Myocyte	B-MED
enhancer	I-MED
factor	I-MED
2	I-MED
(	I-MED
MEF2	I-MED
)	I-MED
proteins	I-MED
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	B-MED
muscle	B-MED
regeneration	I-MED
.	O
In	O
order	O
to	O
further	O
understand	O
Mef2c	B-MED
gene	I-MED
,	O
the	O
promoter	B-MED
of	O
pig	B-MED
Mef2c	B-MED
gene	I-MED
was	O
analyzed	O
in	O
this	O
paper	O
.	O
Quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
PCR	I-MED
(	O
qRT	B-MED
-	I-MED
PCR	I-MED
)	O
revealed	O
the	O
expression	B-MED
pattern	O
of	O
Mef2c	B-MED
gene	I-MED
in	O
muscle	B-MED
of	O
eight	O
tissues	B-MED
.	O
The	O
Mef2c	B-MED
promoter	B-MED
had	O
the	O
higher	O
transcriptional	B-MED
activity	I-MED
in	O
differentiated	B-MED
C2C12	B-MED
cells	I-MED
than	O
that	O
in	O
proliferating	B-MED
C2C12	B-MED
cells	I-MED
,	O
which	O
was	O
accompanied	O
by	O
the	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
mRNA	B-MED
expression	I-MED
of	O
Mef2c	B-MED
gene	I-MED
.	O
Function	B-MED
deletion	B-MED
and	O
mutation	B-MED
analyses	B-MED
showed	O
that	O
MyoD	B-MED
and	O
MEF2	B-MED
binding	B-MED
sites	I-MED
within	O
the	O
Mef2c	B-MED
promoter	B-MED
were	O
responsible	O
for	O
the	O
regulation	B-MED
of	O
Mef2c	B-MED
transcription	B-MED
.	O
MEF2C	B-MED
could	O
up	B-MED
-	I-MED
regulate	I-MED
the	I-MED
transcriptional	I-MED
activities	I-MED
of	O
Mef2c	B-MED
promoter	B-MED
constructs	I-MED
which	O
contained	O
a	O
3'-end	B-MED
nucleotide	I-MED
sequence	I-MED
with	O
p300	B-MED
binding	B-MED
site	I-MED
.	O
The	O
Electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
(	O
EMSA	B-MED
)	O
and	O
chromatin	B-MED
immunoprecipitation	I-MED
(	I-MED
ChIP	I-MED
)	I-MED
assays	I-MED
determined	O
the	O
MyoD	B-MED
binding	B-MED
site	I-MED
in	O
Mef2c	B-MED
promoter	B-MED
.	O
These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-MED
of	O
the	O
pig	B-MED
Mef2c	B-MED
gene	I-MED
.	O
And	O
the	O
study	O
of	O
Mef2c	B-MED
promoter	B-MED
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	B-MED
mechanisms	I-MED
of	O
Mef2c	B-MED
in	O
muscle	B-MED
differentiation	I-MED
or	O
muscle	B-MED
repair	I-MED
and	O
regeneration	B-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Smartphone	B-MED
-Based	O
Psychotherapeutic	B-MED
Micro	B-MED
-	I-MED
Interventions	I-MED
to	O
Improve	O
Mood	B-MED
in	O
a	O
Real	B-MED
-	I-MED
World	I-MED
Setting	I-MED
Using	O
mobile	B-MED
communication	B-MED
technology	I-MED
as	O
new	O
personalized	O
approach	B-MED
to	O
treat	B-MED
mental	B-MED
disorders	I-MED
or	O
to	O
more	O
generally	O
improve	O
quality	B-MED
of	I-MED
life	I-MED
is	O
highly	O
promising	O
.	O
Knowledge	B-MED
about	O
intervention	B-MED
components	B-MED
that	O
target	O
key	O
psychopathological	B-MED
processes	B-MED
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-MED
approaches	B-MED
is	O
urgently	O
needed	O
.	O
We	O
explored	O
the	O
use	O
of	O
smartphone	B-MED
-based	O
micro	B-MED
-	I-MED
interventions	I-MED
based	O
on	O
psychotherapeutic	B-MED
techniques	I-MED
,	O
guided	O
by	O
short	O
video	B-MED
-	I-MED
clips	I-MED
,	O
to	O
elicit	O
mood	B-MED
changes	I-MED
.	O
As	O
part	O
of	O
a	O
larger	O
neurofeedback	B-MED
study	B-MED
,	O
all	O
subjects	B-MED
-after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-MED
condition	B-MED
-underwent	O
daily	B-MED
smartphone	B-MED
-based	O
micro	B-MED
-	I-MED
interventions	I-MED
for	O
13	O
consecutive	O
days	B-MED
.	O
They	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	B-MED
,	O
including	O
viscerosensory	B-MED
attention	B-MED
,	O
emotional	B-MED
imagery	B-MED
,	O
facial	B-MED
expression	I-MED
,	O
and	O
contemplative	B-MED
repetition	B-MED
.	O
Changes	B-MED
in	O
mood	B-MED
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
Multidimensional	B-MED
Mood	I-MED
State	I-MED
Questionnaire	I-MED
(	O
scales	O
:	O
good	B-MED
-	O
bad	B-MED
,	O
GB	O
;	O
awake	B-MED
-	O
tired	B-MED
,	O
AT	O
;	O
and	O
calm	B-MED
-	O
nervous	B-MED
,	O
CN	O
)	O
.	O
Twenty	O
-	O
seven	O
men	B-MED
participated	O
on	O
at	O
least	O
11	O
days	B-MED
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	B-MED
.	O
Altogether	O
,	O
they	O
underwent	O
335	O
,	O
generally	O
well	O
-	O
tolerated	O
,	O
micro	B-MED
-	I-MED
intervention	I-MED
sessions	I-MED
,	O
with	O
viscerosensory	B-MED
attention	B-MED
(	O
178	O
sessions	B-MED
,	O
53.13	O
%	O
)	O
and	O
contemplative	B-MED
repetition	B-MED
(	O
68	O
sessions	B-MED
,	O
20.30	O
%	O
)	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	B-MED
.	O
Mixed	O
models	B-MED
indicated	O
that	O
subjects	B-MED
showed	O
better	O
mood	B-MED
[	O
GB	O
:	O
b	O
=	O
0.464	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
[	O
0.068	O
,	O
0.860	O
]	O
,	O
t	O
(	O
613.3	O
)	O
=	O
2.298	O
,	O
p	O
=	O
0.022	O
]	O
and	O
became	O
more	O
awake	B-MED
[	O
AT	O
:	O
b	O
=	O
0.514	O
,	O
95	O
%	O
CI	B-MED
[	O
0.103	O
,	O
0.925	O
]	O
,	O
t	O
(	O
612.4	O
)	O
=	O
2.456	O
,	O
p	O
=	O
0.014	O
]	O
and	O
calmer	B-MED
[	O
CN	O
:	O
b	O
=	O
0.685	O
,	O
95	O
%	O
CI	B-MED
[	O
0.360	O
,	O
1.010	O
]	O
,	O
t	O
(	O
612.3	O
)	O
=	O
4.137	O
,	O
p	O
<	O
0.001	O
]	O
from	O
pre	B-MED
-	O
to	O
post	B-MED
-	I-MED
micro	I-MED
-	I-MED
intervention	I-MED
.	O
These	O
mood	B-MED
improvements	B-MED
from	O
pre	B-MED
-	O
to	O
post	B-MED
-	I-MED
micro	I-MED
-	I-MED
intervention	I-MED
were	O
associated	O
with	O
changes	B-MED
in	I-MED
mood	I-MED
from	O
the	O
1st	O
day	B-MED
until	O
the	O
last	O
day	B-MED
with	O
regard	O
to	O
GB	B-MED
mood	I-MED
(	O
r	O
=	O
0.614	O
,	O
95	O
%	O
CI	B-MED
[	O
0.297	O
,	O
0.809	O
]	O
,	O
p	O
<	O
0.001	O
)	O
,	O
but	O
not	O
AT	B-MED
mood	I-MED
(	O
r	O
=	O
0.279	O
,	O
95	O
%	O
CI	B-MED
[	O
-0.122	O
,	O
0.602	O
]	O
,	O
p	O
=	O
0.167	O
)	O
and	O
CN	B-MED
mood	I-MED
(	O
r	O
=	O
0.277	O
,	O
95	O
%	O
CI	B-MED
[	O
0.124	O
,	O
0.601	O
]	O
,	O
p	O
=	O
0.170	O
)	O
.	O
Our	O
findings	B-MED
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	B-MED
-based	O
micro	B-MED
-	I-MED
interventions	I-MED
eliciting	O
short	B-MED
-	I-MED
term	I-MED
mood	B-MED
changes	I-MED
,	O
based	O
on	O
techniques	B-MED
used	O
in	O
psychotherapeutic	B-MED
approaches	B-MED
,	O
such	O
as	O
mindfulness	B-MED
-based	O
psychotherapy	B-MED
,	O
transcendental	B-MED
meditation	I-MED
,	O
and	O
other	O
contemplative	B-MED
therapies	B-MED
.	O
The	O
results	O
encourage	O
exploring	O
these	O
techniques	B-MED
'	O
capability	B-MED
to	O
improve	O
mood	B-MED
in	O
randomized	O
controlled	B-MED
studies	I-MED
and	O
patients	B-MED
.	O
Smartphone	B-MED
-based	O
micro	B-MED
-	I-MED
interventions	I-MED
are	O
promising	O
to	O
modify	O
mood	B-MED
in	O
real	B-MED
-	I-MED
world	I-MED
settings	I-MED
,	O
complementing	O
other	O
psychotherapeutic	B-MED
interventions	I-MED
,	O
in	O
line	O
with	O
the	O
precision	B-MED
medicine	B-MED
approach	I-MED
.	O
The	O
here	O
presented	O
data	B-MED
were	O
collected	O
within	O
a	O
randomized	B-MED
trial	I-MED
,	O
registered	O
at	O
ClinicalTrials.gov	O
(	O
Identifier	O
:	O
NCT01921088	O
)	O
https://clinicaltrials.gov/ct2/show/NCT01921088	O
.	O
Antibacterial	B-MED
Activity	B-MED
of	O
Polyaniline	B-MED
Coated	B-MED
Silver	B-MED
Nanoparticles	B-MED
Synthesized	B-MED
from	O
Piper	B-MED
Betle	I-MED
Leaves	I-MED
Extract	I-MED
Plants	B-MED
or	O
natural	B-MED
resources	I-MED
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	B-MED
method	B-MED
for	O
nanoparticles	B-MED
synthesis	B-MED
.	O
In	O
this	O
study	B-MED
,	O
polyaniline	B-MED
coated	B-MED
silver	B-MED
nanoparticles	B-MED
(	O
AgNPs	B-MED
)	O
synthesized	B-MED
from	O
Piper	B-MED
betle	I-MED
leaves	I-MED
extract	I-MED
were	O
investigated	O
for	O
their	O
antibacterial	B-MED
activity	B-MED
activity	B-MED
.	O
Silver	B-MED
nanoparticles	B-MED
were	O
prepared	O
from	O
the	O
reduction	B-MED
of	O
silver	B-MED
nitrate	I-MED
and	O
NaBH4	B-MED
was	O
used	O
as	O
reducing	B-MED
agent	I-MED
.	O
Silver	B-MED
nanoparticles	B-MED
and	O
extracts	B-MED
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	B-MED
by	O
polyaniline	B-MED
.	O
Prepared	O
nanoparticles	B-MED
were	O
characterized	B-MED
by	O
Visual	B-MED
inspection	I-MED
,	O
Ultraviolet	B-MED
-	I-MED
visible	I-MED
spectroscopy	I-MED
(	O
UV	B-MED
)	O
,	O
Fourier	B-MED
transform	I-MED
infrared	I-MED
Spectroscopy	I-MED
(	O
FT	B-MED
-	I-MED
IR	I-MED
)	O
,	O
Transmission	B-MED
Electron	I-MED
Microscopy	I-MED
(	I-MED
TEM	I-MED
)	I-MED
techniques	I-MED
.	O
Antibacterial	B-MED
activities	B-MED
of	O
the	O
synthesized	B-MED
silver	B-MED
nanoparticles	B-MED
were	O
tested	B-MED
against	O
Staphylococcus	B-MED
aureus	I-MED
ATCC	I-MED
25923	I-MED
,	O
Salmonella	B-MED
typhi	I-MED
ATCC	I-MED
14028	I-MED
,	O
Escherichia	B-MED
coli	I-MED
ATCC	I-MED
25922	I-MED
and	O
Pseudomonas	B-MED
aeruginosa	I-MED
ATCC	I-MED
27853	I-MED
.	O
UV	B-MED
-	I-MED
Vis	I-MED
spectrum	I-MED
of	O
reaction	B-MED
mixture	I-MED
showed	O
strong	B-MED
absorption	I-MED
peak	I-MED
with	O
centering	O
at	O
400	O
nm	O
.	O
The	O
FT	B-MED
-	I-MED
IR	I-MED
results	B-MED
imply	O
that	O
Ag	B-MED
-	I-MED
NPs	I-MED
were	O
successfully	O
synthesized	B-MED
and	O
capped	B-MED
with	I-MED
bio	I-MED
-	I-MED
compounds	I-MED
present	O
in	O
P.	B-MED
betle	I-MED
.	O
TEM	B-MED
image	O
showed	O
that	O
Ag	B-MED
-	I-MED
NPs	I-MED
formed	O
were	O
well	O
dispersed	B-MED
with	O
a	O
spherical	B-MED
structures	I-MED
and	O
particle	B-MED
size	I-MED
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O
The	O
result	B-MED
revealed	B-MED
that	O
Ag	B-MED
-	I-MED
Extract	I-MED
NPs	I-MED
showed	O
32.78±0.64	O
mm	O
zone	O
of	O
inhibition	B-MED
against	O
S.	B-MED
aureus	I-MED
,	O
whereas	O
norfloxacin	B-MED
(	O
positive	B-MED
control	I-MED
)	O
showed	O
maximum	O
32.15±0.40	O
mm	O
zone	O
of	O
inhibition	B-MED
for	O
S.	B-MED
aureus	I-MED
.	O
Again	O
,	O
maximum	B-MED
zone	I-MED
of	O
inhibition	B-MED
29.55±0.45	O
mm	O
was	O
found	O
for	O
S.	B-MED
typhi	I-MED
,	O
27.12±0.38	O
mm	O
for	O
E.	B-MED
coli	I-MED
and	O
21.95±0.45	O
mm	O
for	O
P.	B-MED
aeruginosa	I-MED
.	O
The	O
results	B-MED
obtained	O
by	O
this	O
study	B-MED
ca	O
n't	O
be	O
directly	O
extrapolated	B-MED
to	O
human	B-MED
;	O
so	O
further	B-MED
studies	I-MED
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	B-MED
activity	B-MED
of	O
Ag	B-MED
-	I-MED
Extract	I-MED
NPs	I-MED
for	O
drug	B-MED
development	I-MED
program	I-MED
.	O
Anti	B-MED
-	I-MED
CD45RB	I-MED
and	O
donor	B-MED
-	I-MED
specific	I-MED
spleen	I-MED
cells	I-MED
transfusion	I-MED
inhibition	B-MED
allograft	B-MED
skin	I-MED
rejection	I-MED
mediated	O
by	O
memory	B-MED
T	I-MED
cells	I-MED
Donor	O
-	O
reactive	O
memory	B-MED
T	I-MED
(	I-MED
Tm)cells	I-MED
mediate	O
accelerated	O
rejection	B-MED
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted	B-MED
organs	I-MED
.	O
Selective	O
interference	O
with	O
the	O
anti	B-MED
-	I-MED
CD45RB	I-MED
monoclonal	I-MED
antibody	I-MED
(	I-MED
α	I-MED
-	I-MED
CD45RB	I-MED
)	I-MED
reliably	O
induces	O
donor	B-MED
-	O
specific	B-MED
tolerance	B-MED
.	O
In	O
this	O
study	B-MED
,	O
pre	B-MED
-	I-MED
sensitization	I-MED
to	O
female	B-MED
C57BL/6	B-MED
mice	I-MED
with	O
the	O
skin	B-MED
of	O
female	B-MED
BLAB	B-MED
/	I-MED
c	I-MED
mice	I-MED
generated	O
a	O
large	O
number	O
of	O
Tm	B-MED
cells	I-MED
and	O
resulted	O
in	O
rapid	O
rejection	B-MED
of	O
the	O
secondly	B-MED
transplanted	B-MED
allografts	B-MED
.	O
α	B-MED
-	I-MED
CD45RB	I-MED
did	O
induce	O
the	O
tolerance	B-MED
to	O
skin	B-MED
allograft	I-MED
primarily	B-MED
transplanted	B-MED
but	O
failed	O
to	O
induce	O
tolerance	B-MED
in	O
the	O
pre	B-MED
-	I-MED
sensitized	I-MED
mice	I-MED
.	O
Donor	B-MED
-	I-MED
specific	I-MED
spleen	I-MED
cell	I-MED
transfusion	I-MED
(	O
DST	B-MED
)	O
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	B-MED
in	O
the	O
pre	B-MED
-	I-MED
sensitized	I-MED
recipients	B-MED
.	O
Interestingly	O
,	O
combination	O
of	O
α	B-MED
-	I-MED
CD45RB	I-MED
with	O
DST	B-MED
inhibited	O
the	O
rejection	B-MED
induced	O
by	O
memory	B-MED
T	I-MED
cells	I-MED
in	O
the	O
pre	B-MED
-	I-MED
sensitized	I-MED
mice	I-MED
.	O
CD25	B-MED
+	I-MED
T	I-MED
-	I-MED
cell	I-MED
depletion	B-MED
in	O
α	B-MED
-	I-MED
CD45RB	I-MED
combined	O
with	O
DST	B-MED
therapy	B-MED
recipients	B-MED
could	O
prevent	O
skin	B-MED
allograft	I-MED
tolerance	B-MED
from	O
establishing	O
.	O
In	O
addition	O
,	O
adoptive	B-MED
transfer	I-MED
of	O
donor	B-MED
-primed	O
memory	B-MED
T	I-MED
cells	I-MED
into	O
the	O
tolerant	B-MED
recipients	B-MED
markedly	O
broke	O
the	O
established	O
tolerance	B-MED
.	O
Our	O
findings	B-MED
indicate	O
that	O
α	B-MED
-	I-MED
CD45RB	I-MED
and	O
DST	B-MED
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	B-MED
mediated	O
by	O
memory	B-MED
T	I-MED
cells	I-MED
and	O
induce	O
long	O
-	O
term	O
skin	B-MED
allograft	I-MED
acceptance	B-MED
in	O
mice	B-MED
.	O
Development	O
of	O
a	O
Novel	O
Quantitative	B-MED
Structure	I-MED
-	I-MED
Activity	I-MED
Relationship	I-MED
Model	B-MED
to	O
Accurately	O
Predict	O
Pulmonary	B-MED
Absorption	I-MED
and	O
Replace	O
Routine	O
Use	O
of	O
the	O
Isolated	B-MED
Perfused	B-MED
Respiring	B-MED
Rat	B-MED
Lung	I-MED
Model	B-MED
We	O
developed	O
and	O
tested	O
a	O
novel	O
Quantitative	B-MED
Structure	I-MED
-	I-MED
Activity	I-MED
Relationship	I-MED
(	O
QSAR	B-MED
)	O
model	B-MED
to	O
better	O
understand	O
the	O
physicochemical	B-MED
drivers	O
of	O
pulmonary	B-MED
absorption	I-MED
,	O
and	O
to	O
facilitate	O
compound	B-MED
design	I-MED
through	O
improved	O
prediction	B-MED
of	O
absorption	B-MED
.	O
The	O
model	B-MED
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-MED
.	O
Pulmonary	B-MED
absorption	I-MED
data	O
was	O
generated	O
using	O
the	O
isolated	B-MED
perfused	B-MED
respiring	B-MED
rat	B-MED
lung	I-MED
(	O
IPRLu	B-MED
)	O
model	B-MED
for	O
82	O
drug	B-MED
discovery	I-MED
compounds	B-MED
and	O
17	O
marketed	B-MED
drugs	I-MED
.	O
This	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
QSAR	B-MED
model	B-MED
based	O
on	O
calculated	O
physicochemical	B-MED
properties	I-MED
.	O
A	O
further	O
9	O
compounds	B-MED
were	O
used	O
to	O
test	O
the	O
model	B-MED
's	I-MED
predictive	O
capability	B-MED
.	O
The	O
QSAR	B-MED
model	B-MED
performed	O
well	O
on	O
the	O
9	O
compounds	B-MED
in	O
the	O
"	O
Test	B-MED
set	I-MED
"	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	B-MED
of	O
R(2	O
)	O
=	O
0.85	O
,	O
and	O
>	O
65	O
%	O
of	O
compounds	B-MED
correctly	O
categorised	O
.	O
Calculated	O
descriptors	O
associated	O
with	O
permeability	B-MED
and	O
hydrophobicity	B-MED
positively	O
correlated	O
with	O
pulmonary	B-MED
absorption	I-MED
,	O
whereas	O
those	O
associated	O
with	O
charge	B-MED
,	O
ionisation	B-MED
and	O
size	B-MED
negatively	O
correlated	O
.	O
The	O
novel	O
QSAR	B-MED
model	B-MED
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
IPRLu	B-MED
model	B-MED
data	O
for	O
ranking	B-MED
and	O
classifying	B-MED
compounds	B-MED
prior	O
to	O
synthesis	B-MED
.	O
It	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	B-MED
drug	I-MED
discovery	I-MED
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	B-MED
drivers	O
of	O
pulmonary	B-MED
absorption	I-MED
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-MED
dataset	B-MED
.	O
Association	B-MED
between	O
neutrophil	B-MED
-to-	O
lymphocyte	B-MED
ratio	B-MED
and	O
differentiated	B-MED
thyroid	I-MED
cancer	I-MED
:	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
The	O
association	B-MED
between	O
neutrophil	B-MED
-to-	O
lymphocyte	B-MED
ratio	B-MED
(	O
NLR	B-MED
)	O
and	O
differentiated	B-MED
thyroid	I-MED
cancer	I-MED
(	O
DTC	B-MED
)	O
is	O
undecided	O
.	O
To	O
rectify	O
this	O
question	O
,	O
we	O
conducted	B-MED
a	O
systematic	B-MED
meta	B-MED
-	I-MED
analysis	I-MED
based	O
on	O
7	O
prospective	B-MED
cohort	I-MED
studies	I-MED
published	B-MED
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	B-MED
.	O
Six	O
of	O
these	O
cohorts	B-MED
included	O
pretreatment	B-MED
(	O
baseline	B-MED
)	O
NLR	B-MED
data	B-MED
for	O
patients	B-MED
with	O
thyroid	B-MED
nodules	I-MED
.	O
The	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
these	O
6	O
cohorts	B-MED
showed	O
that	O
the	O
NLR	B-MED
of	O
patients	B-MED
with	O
DTC	B-MED
(	O
4617	O
cases	B-MED
)	O
was	O
statistically	B-MED
similar	O
to	O
patients	B-MED
with	O
benign	B-MED
nodules	I-MED
only	O
(	O
1666	O
cases	B-MED
)	O
,	O
with	O
a	O
mean	O
difference	O
(	O
MD	O
)	O
of	O
0.19	O
(	O
95	O
%	O
CI	B-MED
:	O
-0.09	O
to	O
0.46	O
;	O
I(2	O
)	O
=	O
93	O
%	O
;	O
P	B-MED
<	O
0.001	O
)	O
.	O
No	O
significant	O
difference	O
in	O
NLR	B-MED
was	O
found	O
between	O
patients	B-MED
with	O
DTC	B-MED
and	O
patients	B-MED
with	O
benign	B-MED
nodules	I-MED
.	O
Two	O
studies	B-MED
addressed	O
an	O
association	B-MED
between	O
NLR	B-MED
and	O
papillary	B-MED
thyroid	I-MED
carcinoma	I-MED
in	O
patients	B-MED
stratified	B-MED
by	O
age	B-MED
<	O
45	O
and	O
≥45	O
years	B-MED
(	O
496	O
and	O
891	O
cases	B-MED
,	O
respectively	O
)	O
;	O
the	O
pooled	O
MD	O
was	O
0.09	O
(	O
95	O
%	O
CI	B-MED
:	O
-0.37	O
to	O
0.55	O
;	O
I(2	O
)	O
=	O
92.2	O
%	O
,	O
P	B-MED
<	O
0.001	O
)	O
.	O
An	O
elevated	B-MED
NLR	B-MED
seems	O
not	O
a	O
reliable	B-MED
indicator	B-MED
of	O
progressing	B-MED
DTC	B-MED
in	O
patients	B-MED
with	O
goiters	B-MED
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	B-MED
between	O
patients	B-MED
aged	B-MED
<	O
45	O
years	B-MED
and	O
those	O
aged	B-MED
≥45	O
years	B-MED
.	O
Well	O
-	O
designed	O
and	O
large	O
-	O
scale	O
investigations	B-MED
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	B-MED
in	O
the	O
prognosis	B-MED
of	O
DTC	B-MED
.	O
A	O
modified	B-MED
ESBL	B-MED
ESBL	B-MED
Nordmann	I-MED
/	I-MED
Dortet	I-MED
/	I-MED
Poirel	I-MED
-	I-MED
based	I-MED
protocol	I-MED
to	O
optimize	B-MED
early	B-MED
sepsis	B-MED
management	B-MED
We	O
evaluated	B-MED
a	O
modification	B-MED
of	O
a	O
colorimetric	B-MED
test	I-MED
recently	O
described	O
by	O
Dortet	O
et	O
al	O
.	O
(	O
2015	O
)	O
for	O
the	O
rapid	O
detection	B-MED
of	O
ESBL	B-MED
-producing	O
Enterobacteriaceae	B-MED
directly	O
from	O
positive	B-MED
blood	B-MED
cultures	I-MED
that	O
requires	O
less	O
manipulation	B-MED
,	O
materials	B-MED
and	O
hands	O
-	O
on	O
time	B-MED
.	O
The	O
simplified	O
protocol	B-MED
showed	O
a	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
100	O
%	O
and	O
95.7	O
%	O
respectively	O
.	O
Long	B-MED
-	I-MED
term	I-MED
antibiofilm	B-MED
activity	I-MED
of	O
carboxymethyl	B-MED
chitosan	I-MED
on	O
mixed	B-MED
biofilm	I-MED
on	O
silicone	B-MED
Silicone	B-MED
voice	B-MED
prostheses	I-MED
are	O
most	O
frequently	B-MED
used	O
in	O
voice	B-MED
rehabilitation	I-MED
of	O
laryngectomized	B-MED
patients	B-MED
.	O
However	O
,	O
the	O
functional	B-MED
device	I-MED
lifetimes	B-MED
are	O
limited	B-MED
due	B-MED
to	I-MED
formation	B-MED
of	O
mixed	B-MED
biofilms	I-MED
.	O
Existing	O
in	B-MED
vitro	I-MED
models	I-MED
simulating	O
biofilm	B-MED
formation	I-MED
are	O
restricted	B-MED
to	O
only	O
short	B-MED
-	I-MED
term	I-MED
periods	B-MED
.	O
The	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
the	O
effect	B-MED
of	O
carboxymethyl	B-MED
chitosan	I-MED
on	O
mixed	B-MED
biofilm	I-MED
formation	I-MED
of	O
fungi	B-MED
and	O
bacteria	B-MED
on	O
silicone	B-MED
over	O
a	O
long	B-MED
-	I-MED
term	I-MED
period	B-MED
.	O
Mixed	O
species	B-MED
biofilms	B-MED
of	O
Candida	B-MED
albicans	I-MED
,	O
Candida	B-MED
tropicalis	I-MED
,	O
Lactobacillus	B-MED
gasseri	I-MED
,	O
Streptococcus	B-MED
salivarius	I-MED
,	O
Rothia	B-MED
dentocariosa	I-MED
,	O
and	O
Staphylococcus	B-MED
epidermidis	I-MED
were	O
cultivated	B-MED
on	O
the	O
surfaces	B-MED
of	O
medical	B-MED
-	I-MED
grade	I-MED
silicone	I-MED
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-MED
chitosan	I-MED
.	O
Biofilm	B-MED
kinetics	I-MED
was	O
monitored	O
using	O
specially	O
designed	B-MED
image	I-MED
analysis	I-MED
software	I-MED
to	O
calculate	B-MED
the	O
percentual	B-MED
surface	I-MED
covering	I-MED
of	O
each	O
platelet	B-MED
.	O
Biofilm	B-MED
architecture	I-MED
was	O
investigated	B-MED
by	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
.	O
A	O
cover	B-MED
of	O
living	B-MED
mixed	B-MED
biofilm	I-MED
could	O
be	O
generated	O
over	O
22	O
days	B-MED
on	O
silicone	B-MED
and	O
the	O
maximum	B-MED
of	O
22	O
%	O
biofilm	B-MED
surface	B-MED
covering	I-MED
at	O
day	B-MED
22	O
.	O
However	O
,	O
less	B-MED
than	I-MED
4	O
%	O
surface	B-MED
coverage	I-MED
was	O
observed	B-MED
on	O
the	O
carboxymethyl	B-MED
chitosan	I-MED
-	O
treated	B-MED
plates	O
in	O
the	O
testing	B-MED
period	B-MED
.	O
Scanning	B-MED
electron	I-MED
microscopy	I-MED
confirms	B-MED
that	O
,	O
on	O
surfaces	B-MED
treated	B-MED
by	O
carboxymethyl	B-MED
chitosan	I-MED
,	O
the	O
biofilm	B-MED
was	O
less	B-MED
dense	B-MED
.	O
In	O
addition	O
,	O
there	O
were	O
fewer	B-MED
layers	O
of	O
cells	B-MED
and	O
profuse	B-MED
cellular	I-MED
debris	I-MED
,	O
together	B-MED
with	O
degrading	O
and	O
morphologically	B-MED
altered	I-MED
yeast	B-MED
yeast	B-MED
cells	I-MED
.	O
Carboxymethyl	B-MED
chitosan	I-MED
may	O
serve	O
as	O
a	O
possible	B-MED
antibiofilm	B-MED
agent	I-MED
to	O
limit	O
biofilm	B-MED
formation	I-MED
on	O
voice	B-MED
prostheses	I-MED
.	O
NA	O
Laryngoscope	B-MED
,	O
126	O
:	O
E404	O
-	O
E408	O
,	O
2016	O
.	O
High	B-MED
-	I-MED
fructose	I-MED
diet	I-MED
is	O
as	O
detrimental	O
as	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
in	O
the	O
induction	B-MED
of	O
insulin	B-MED
resistance	I-MED
and	O
diabetes	B-MED
mediated	O
by	O
hepatic	B-MED
/	O
pancreatic	B-MED
endoplasmic	B-MED
reticulum	I-MED
(	I-MED
ER	I-MED
)	I-MED
stress	I-MED
In	O
the	O
context	B-MED
of	O
high	B-MED
human	B-MED
consumption	B-MED
of	O
fructose	B-MED
diets	B-MED
,	O
there	O
is	O
an	O
imperative	O
need	B-MED
to	O
understand	B-MED
how	O
dietary	B-MED
fructose	B-MED
intake	I-MED
influence	B-MED
cellular	B-MED
and	O
molecular	B-MED
mechanisms	B-MED
and	O
thereby	O
affect	B-MED
β	B-MED
-	I-MED
cell	I-MED
dysfunction	I-MED
and	O
insulin	B-MED
resistance	I-MED
.	O
While	O
evidence	B-MED
exists	B-MED
for	O
a	O
relationship	B-MED
between	O
high	B-MED
-	O
fat	B-MED
-	O
induced	B-MED
insulin	B-MED
resistance	I-MED
and	O
metabolic	B-MED
disorders	I-MED
,	O
there	O
is	O
lack	B-MED
of	I-MED
studies	B-MED
in	O
relation	O
to	O
high	B-MED
-	I-MED
fructose	I-MED
diet	I-MED
.	O
Therefore	O
,	O
we	O
attempted	O
to	O
study	B-MED
the	O
effect	B-MED
of	O
different	B-MED
diets	B-MED
viz	O
.	O
,	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
(	O
HFD	B-MED
)	O
,	O
high	B-MED
-	I-MED
fructose	I-MED
diet	I-MED
(	O
HFS	B-MED
)	O
,	O
and	O
a	O
combination	B-MED
(	O
HFS	B-MED
+	O
HFD	B-MED
)	O
diet	B-MED
on	O
glucose	B-MED
homeostasis	I-MED
and	O
insulin	B-MED
sensitivity	I-MED
in	O
male	B-MED
Wistar	B-MED
rats	I-MED
compared	B-MED
to	O
control	B-MED
animals	I-MED
fed	B-MED
with	O
normal	B-MED
pellet	B-MED
diet	B-MED
.	O
Investigations	B-MED
include	O
oral	B-MED
glucose	I-MED
tolerance	I-MED
test	I-MED
,	O
insulin	B-MED
tolerance	I-MED
test	I-MED
,	O
histopathology	B-MED
by	O
H&E	B-MED
and	O
Masson	B-MED
's	I-MED
trichrome	I-MED
staining	I-MED
,	O
mRNA	B-MED
expression	I-MED
by	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
,	O
protein	B-MED
expression	I-MED
by	O
Western	B-MED
blot	I-MED
,	O
and	O
caspase-3	B-MED
activity	I-MED
by	O
colorimetry	B-MED
.	O
Rats	B-MED
subjected	O
to	O
high	B-MED
-	I-MED
fat	I-MED
/	O
fructose	B-MED
diets	I-MED
became	O
glucose	B-MED
intolerant	B-MED
,	O
insulin	B-MED
-	I-MED
resistant	I-MED
,	O
and	O
dyslipidemic	B-MED
.	O
Compared	B-MED
to	O
control	B-MED
animals	I-MED
,	O
rats	B-MED
subjected	O
to	O
different	B-MED
combination	B-MED
of	O
fat	B-MED
/	O
fructose	B-MED
diets	I-MED
showed	O
increased	B-MED
mRNA	B-MED
and	O
protein	B-MED
expression	I-MED
of	O
a	O
battery	O
of	O
ER	B-MED
stress	I-MED
markers	B-MED
both	O
in	O
pancreas	B-MED
and	O
liver	B-MED
.	O
Transcription	B-MED
factors	I-MED
of	O
β	B-MED
-	I-MED
cell	I-MED
function	I-MED
(	O
INSIG1	B-MED
,	O
SREBP1c	B-MED
and	O
PDX1	B-MED
)	O
as	O
well	O
as	O
hepatic	B-MED
gluconeogenesis	B-MED
(	O
FOXO1	B-MED
and	O
PEPCK	B-MED
)	O
were	O
adversely	B-MED
affected	I-MED
in	O
diet	B-MED
-	O
induced	B-MED
insulin	B-MED
-	I-MED
resistant	I-MED
rats	B-MED
.	O
The	O
convergence	B-MED
of	O
chronic	B-MED
ER	B-MED
stress	I-MED
towards	O
apoptosis	B-MED
in	O
pancreas	B-MED
/	O
liver	B-MED
was	O
also	O
indicated	B-MED
by	O
increased	B-MED
levels	B-MED
of	O
CHOP	B-MED
mRNA	I-MED
&	O
increased	B-MED
activity	O
of	O
both	O
JNK	B-MED
and	O
Caspase-3	B-MED
in	O
rats	B-MED
subjected	O
to	O
high	B-MED
-	I-MED
fat	I-MED
/	O
fructose	B-MED
diets	I-MED
.	O
Our	O
study	B-MED
exposes	O
the	O
experimental	B-MED
support	B-MED
in	O
that	O
high	B-MED
-	I-MED
fructose	I-MED
diet	I-MED
is	O
equally	B-MED
detrimental	O
in	O
causing	B-MED
metabolic	B-MED
disorders	I-MED
.	O
Reappraisal	B-MED
Modulates	O
Attentional	B-MED
Bias	I-MED
to	O
Angry	B-MED
Angry	B-MED
Faces	I-MED
Heightened	O
attentional	B-MED
bias	I-MED
to	O
emotional	B-MED
information	B-MED
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	B-MED
related	O
to	O
emotion	B-MED
dysregulation	B-MED
such	O
as	O
anxiety	B-MED
,	O
depression	B-MED
,	O
and	O
substance	B-MED
abuse	I-MED
.	O
Although	O
reappraisal	B-MED
,	O
an	O
emotion	B-MED
regulation	I-MED
strategy	B-MED
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective	B-MED
experience	I-MED
of	O
emotions	B-MED
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	B-MED
can	O
alter	O
attentional	B-MED
biases	I-MED
to	O
emotional	B-MED
information	B-MED
.	O
In	O
the	O
current	O
research	B-MED
,	O
we	O
investigated	B-MED
the	O
influence	O
of	O
instruction	B-MED
-	I-MED
induced	I-MED
state	I-MED
reappraisal	I-MED
(	O
Study	B-MED
1	I-MED
)	O
and	O
trait	B-MED
reappraisal	I-MED
(	O
Study	B-MED
2	I-MED
)	O
on	O
attentional	B-MED
biases	I-MED
to	O
happy	B-MED
and	O
angry	B-MED
angry	B-MED
faces	I-MED
.	O
In	O
Study	B-MED
1	I-MED
,	O
healthy	B-MED
young	B-MED
women	I-MED
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	B-MED
:	O
up	B-MED
-	O
,	O
down	B-MED
-	O
,	O
and	O
no	B-MED
-	I-MED
regulation	I-MED
.	O
Participants	B-MED
were	O
instructed	O
to	O
reappraise	B-MED
their	O
emotions	B-MED
to	O
increase	O
and	O
decrease	O
emotional	B-MED
experience	B-MED
while	O
viewing	O
an	O
emotionally	B-MED
negative	I-MED
film	I-MED
clip	I-MED
.	O
Attentional	B-MED
bias	I-MED
was	O
assessed	O
with	O
a	O
dot	B-MED
-	I-MED
probe	I-MED
task	I-MED
with	O
pictures	B-MED
of	O
angry	B-MED
and	O
happy	B-MED
facial	B-MED
expressions	I-MED
.	O
In	O
Study	B-MED
2	I-MED
,	O
a	O
separate	O
group	B-MED
of	O
healthy	B-MED
young	B-MED
men	I-MED
and	O
women	B-MED
participated	O
.	O
Participants	B-MED
'	O
trait	B-MED
reappraisal	I-MED
and	O
suppression	B-MED
as	O
well	O
as	O
state	B-MED
and	O
trait	B-MED
anxiety	I-MED
were	O
assessed	O
.	O
A	O
dot	B-MED
-	I-MED
probe	I-MED
task	I-MED
was	O
completed	O
by	O
all	O
participants	B-MED
.	O
Statistical	B-MED
tests	I-MED
in	O
Study	B-MED
1	I-MED
revealed	O
that	O
participants	B-MED
who	O
reappraised	B-MED
to	O
decrease	O
negative	B-MED
emotions	I-MED
while	O
viewing	O
an	O
emotionally	B-MED
negative	I-MED
film	I-MED
clip	I-MED
had	O
reduced	O
attentional	B-MED
bias	I-MED
to	O
subsequently	O
presented	O
angry	B-MED
angry	B-MED
faces	I-MED
compared	B-MED
to	O
participants	B-MED
who	O
reappraised	B-MED
to	O
increase	O
negative	B-MED
emotions	I-MED
.	O
Multiple	B-MED
regression	I-MED
analyses	I-MED
in	O
Study	B-MED
2	I-MED
revealed	O
that	O
trait	B-MED
reappraisal	I-MED
predicted	O
slower	O
orienting	O
toward	O
angry	B-MED
angry	B-MED
faces	I-MED
,	O
whereas	O
state	B-MED
anxiety	I-MED
predicted	O
slower	O
disengagement	B-MED
from	O
angry	B-MED
angry	B-MED
faces	I-MED
.	O
Interestingly	O
,	O
trait	B-MED
suppression	I-MED
predicted	O
slower	O
disengagement	B-MED
from	O
happy	B-MED
faces	I-MED
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
both	O
instruction	B-MED
-	I-MED
induced	I-MED
state	I-MED
reappraisal	I-MED
and	O
trait	B-MED
reappraisal	I-MED
are	O
linked	O
to	O
reduced	O
attentional	B-MED
bias	I-MED
to	O
negative	B-MED
information	B-MED
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion	B-MED
regulation	I-MED
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	B-MED
information	B-MED
.	O
Improved	B-MED
risk	B-MED
stratification	B-MED
for	O
patients	B-MED
with	O
high	O
-	O
grade	O
urothelial	B-MED
carcinoma	I-MED
following	O
application	O
of	O
the	O
Paris	B-MED
System	B-MED
for	O
Reporting	B-MED
Urinary	B-MED
Cytology	I-MED
The	O
Paris	B-MED
System	B-MED
for	O
Reporting	B-MED
Urinary	B-MED
Cytology	I-MED
(	O
TPS	B-MED
)	O
requires	O
4	O
cytomorphologic	B-MED
criteria	B-MED
for	O
a	O
definitive	O
diagnosis	B-MED
of	O
high	B-MED
-	I-MED
grade	I-MED
urothelial	I-MED
carcinoma	I-MED
(	O
HGUC	B-MED
)	O
in	O
urinary	B-MED
tract	I-MED
cytology	I-MED
(	O
UTC	B-MED
)	O
specimens	B-MED
:	O
an	O
elevated	B-MED
nuclear	B-MED
-	I-MED
to	I-MED
-	I-MED
cytoplasmic	I-MED
(	I-MED
N	I-MED
/	I-MED
C	I-MED
)	I-MED
ratio	I-MED
(	O
at	O
or	O
above	O
0.7	O
)	O
,	O
markedly	O
atypical	B-MED
nuclear	B-MED
borders	B-MED
,	O
moderate	B-MED
to	O
severe	B-MED
hyperchromasia	B-MED
,	O
and	O
coarse	B-MED
chromatin	I-MED
.	O
However	O
,	O
malignant	B-MED
UTC	B-MED
specimens	B-MED
often	O
contain	O
degenerative	B-MED
changes	B-MED
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	B-MED
cells	I-MED
meeting	O
all	O
4	O
TPS	B-MED
cytomorphologic	B-MED
criteria	B-MED
.	O
One	O
hundred	O
twelve	O
UTC	B-MED
specimens	B-MED
from	O
patients	B-MED
with	O
a	O
subsequent	O
diagnosis	B-MED
of	O
HGUC	B-MED
were	O
reviewed	B-MED
and	O
reclassified	B-MED
according	O
to	O
TPS	B-MED
criteria	B-MED
.	O
The	O
presence	B-MED
of	O
TPS	B-MED
cytomorphologic	B-MED
criteria	B-MED
for	O
HGUC	B-MED
in	O
each	O
specimen	B-MED
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	B-MED
cells	B-MED
meeting	O
all	O
4	O
criteria	B-MED
.	O
The	O
number	O
of	O
specimens	B-MED
definitively	O
diagnosed	B-MED
as	O
HGUC	B-MED
did	O
not	O
significantly	B-MED
change	B-MED
upon	O
reclassification	B-MED
.	O
However	O
,	O
approximately	B-MED
40	O
%	O
of	O
indeterminate	B-MED
specimens	B-MED
(	O
21	O
of	O
51	O
)	O
were	O
reclassified	B-MED
into	O
a	O
higher	O
risk	B-MED
category	B-MED
.	O
The	O
most	O
restrictive	O
cytomorphologic	B-MED
criterion	O
was	O
an	O
N	B-MED
/	I-MED
C	I-MED
ratio	I-MED
of	O
0.7	O
or	O
higher	O
(	O
seen	O
in	O
78	O
%	O
of	O
specimens	B-MED
)	O
,	O
and	O
approximately	B-MED
half	O
of	O
specimens	B-MED
specimens	B-MED
containing	O
all	O
4	O
cytomorphologic	B-MED
criteria	B-MED
did	O
not	O
meet	O
TPS	B-MED
's	O
numerical	O
criterion	O
for	O
HGUC	B-MED
(	O
at	O
least	O
5	O
malignant	B-MED
cells	I-MED
)	O
.	O
In	O
the	O
majority	O
of	O
specimens	B-MED
qualifying	O
for	O
HGUC	B-MED
by	O
TPS	B-MED
standards	O
,	O
only	O
a	O
small	O
fraction	B-MED
of	I-MED
atypical	B-MED
cells	B-MED
(	O
10%-20	O
%	O
)	O
met	O
all	O
the	O
criteria	B-MED
.	O
When	O
applied	O
to	O
malignant	B-MED
UTC	B-MED
specimens	B-MED
,	O
TPS	B-MED
criteria	B-MED
improved	B-MED
specimen	B-MED
risk	B-MED
stratification	B-MED
by	O
upgrading	O
approximately	B-MED
40	O
%	O
of	O
indeterminate	B-MED
specimens	B-MED
into	O
higher	O
risk	B-MED
categories	B-MED
while	O
not	O
significantly	B-MED
changing	B-MED
the	O
frequency	B-MED
of	O
HGUC	B-MED
diagnoses	B-MED
.	O
Cancer	B-MED
Cytopathol	O
2017	O
.	O
©	O
2017	O
American	B-MED
Cancer	I-MED
Society	I-MED
.	O
Expectations	B-MED
for	O
the	O
methodology	B-MED
and	O
translation	B-MED
of	O
animal	B-MED
research	I-MED
:	O
a	O
survey	B-MED
of	O
the	O
general	B-MED
public	I-MED
,	O
medical	B-MED
students	I-MED
and	O
animal	B-MED
researchers	B-MED
in	O
North	B-MED
America	I-MED
To	O
determine	O
what	O
are	O
considered	O
acceptable	B-MED
standards	B-MED
for	O
animal	B-MED
research	I-MED
(	O
AR	B-MED
)	O
methodology	B-MED
and	O
translation	B-MED
rate	I-MED
to	O
humans	B-MED
,	O
a	O
validated	O
survey	B-MED
was	O
sent	O
to	O
:	O
a	O
)	O
a	O
sample	O
of	O
the	O
general	B-MED
public	I-MED
,	O
via	O
Sampling	B-MED
Survey	I-MED
International	I-MED
(	O
SSI	B-MED
;	O
Canada	B-MED
)	O
,	O
Amazon	B-MED
Mechanical	I-MED
Turk	I-MED
(	O
AMT	B-MED
;	O
USA	B-MED
)	O
,	O
a	O
Canadian	B-MED
city	I-MED
festival	B-MED
(	O
CF	B-MED
)	O
and	O
a	O
Canadian	B-MED
children	B-MED
's	I-MED
hospital	I-MED
(	O
CH	B-MED
)	O
;	O
b	O
)	O
a	O
sample	O
of	O
medical	B-MED
students	I-MED
(	O
two	O
first	O
-	O
year	O
classes	O
)	O
;	O
and	O
c	O
)	O
a	O
sample	O
of	O
scientists	B-MED
(	O
corresponding	O
authors	B-MED
and	O
academic	B-MED
paediatricians	B-MED
)	O
.	O
There	O
were	O
1379	O
responses	B-MED
from	O
the	O
general	B-MED
public	I-MED
sample	O
(	O
SSI	B-MED
,	O
n	O
=	O
557	O
;	O
AMT	B-MED
,	O
n	O
=	O
590	O
;	O
CF	B-MED
,	O
n	O
=	O
195	O
;	O
CH	B-MED
,	O
n	O
=	O
102	O
)	O
,	O
205/330	O
(	O
62	O
%	O
)	O
medical	B-MED
student	I-MED
responses	B-MED
,	O
and	O
23/323	O
(	O
7	O
%	O
,	O
too	O
few	O
to	O
report	O
)	O
scientist	B-MED
responses	B-MED
.	O
Asked	O
about	O
methodological	B-MED
quality	I-MED
,	O
most	O
of	O
the	O
general	B-MED
public	I-MED
and	O
medical	B-MED
student	I-MED
respondents	B-MED
expect	O
that	O
:	O
AR	B-MED
is	O
of	O
high	B-MED
quality	I-MED
(	O
e.g.	O
anaesthesia	B-MED
and	O
analgesia	B-MED
are	O
monitored	O
,	O
even	O
overnight	O
,	O
and	O
'	O
humane	O
'	O
euthanasia	B-MED
,	O
optimal	B-MED
statistical	B-MED
design	I-MED
,	O
comprehensive	B-MED
literature	B-MED
review	I-MED
,	O
randomisation	B-MED
and	O
blinding	B-MED
,	O
are	O
performed	O
)	O
,	O
and	O
costs	B-MED
and	O
difficulty	O
are	O
not	O
acceptable	B-MED
justifications	B-MED
for	O
lower	B-MED
quality	I-MED
(	O
e.g.	O
costs	B-MED
of	O
expert	O
consultation	B-MED
,	O
or	O
more	O
laboratory	B-MED
staff	I-MED
)	O
.	O
Asked	O
about	O
their	O
expectations	B-MED
of	O
translation	B-MED
to	O
humans	B-MED
(	O
of	O
toxicity	B-MED
,	O
carcinogenicity	B-MED
,	O
teratogenicity	B-MED
and	O
treatment	B-MED
findings	B-MED
)	O
,	O
most	O
expect	O
translation	B-MED
more	O
than	O
60	O
%	O
of	O
the	O
time	O
.	O
If	O
translation	B-MED
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
,	O
a	O
minority	B-MED
disagreed	O
that	O
this	O
would	O
"	O
significantly	O
reduce	O
your	O
support	O
for	O
AR	B-MED
"	O
.	O
Medical	B-MED
students	I-MED
were	O
more	O
supportive	B-MED
of	O
AR	B-MED
,	O
even	O
if	O
translation	B-MED
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
.	O
Expectations	B-MED
for	O
AR	B-MED
are	O
much	O
higher	O
than	O
empirical	B-MED
data	I-MED
show	O
to	O
have	O
been	O
achieved	O
.	O
The	O
clinico-	O
radiological	B-MED
paradox	B-MED
of	O
cognitive	B-MED
function	I-MED
and	O
MRI	B-MED
burden	B-MED
of	O
white	B-MED
matter	I-MED
lesions	B-MED
in	O
people	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
:	O
A	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
Moderate	B-MED
correlation	B-MED
exists	O
between	O
the	O
imaging	B-MED
quantification	I-MED
of	O
brain	B-MED
white	B-MED
matter	I-MED
lesions	B-MED
and	O
cognitive	B-MED
performance	B-MED
in	O
people	B-MED
with	O
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
.	O
This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	B-MED
,	O
including	O
subvisible	O
pathology	B-MED
,	O
or	O
methodological	B-MED
limitations	B-MED
of	O
the	O
primary	B-MED
literature	B-MED
.	O
To	O
summarise	O
the	O
cognitive	B-MED
clinico-	O
radiological	B-MED
paradox	B-MED
and	O
explore	O
the	O
potential	B-MED
methodological	B-MED
factors	B-MED
that	O
could	O
influence	O
the	O
assessment	B-MED
of	O
this	O
relationship	B-MED
.	O
Systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
primary	B-MED
research	B-MED
relating	O
cognitive	B-MED
function	I-MED
to	O
white	B-MED
matter	I-MED
lesion	B-MED
burden	B-MED
.	O
Fifty	O
papers	B-MED
met	O
eligibility	B-MED
criteria	I-MED
for	O
review	B-MED
,	O
and	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
overall	O
results	B-MED
was	O
possible	O
in	O
thirty	O
-	O
two	O
(	O
2050	O
participants	B-MED
)	O
.	O
Aggregate	B-MED
correlation	B-MED
between	O
cognition	B-MED
and	O
T2	B-MED
lesion	B-MED
burden	B-MED
was	O
r	O
=	O
-0.30	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
:	O
-0.34	O
,	O
-0.26	O
)	O
.	O
Wide	O
methodological	B-MED
variability	B-MED
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	B-MED
in	O
the	O
cognitive	B-MED
data	B-MED
capture	O
and	O
image	B-MED
analysis	I-MED
techniques	I-MED
.	O
Resolving	O
the	O
persistent	O
clinico-	O
radiological	B-MED
paradox	B-MED
will	O
likely	O
require	O
simultaneous	O
evaluation	B-MED
of	O
multiple	B-MED
components	B-MED
of	O
the	O
complex	B-MED
pathology	B-MED
using	O
optimum	B-MED
measurement	B-MED
techniques	B-MED
for	O
both	O
cognitive	B-MED
and	O
MRI	B-MED
feature	B-MED
quantification	B-MED
.	O
We	O
recommend	O
a	O
consensus	B-MED
initiative	O
to	O
support	O
common	O
standards	B-MED
for	O
image	B-MED
analysis	I-MED
in	O
MS	B-MED
,	O
enabling	O
benchmarking	B-MED
while	O
also	O
supporting	O
ongoing	O
innovation	B-MED
.	O
Bending	B-MED
rules	I-MED
:	O
the	O
shape	B-MED
of	O
the	O
perceptual	B-MED
generalisation	B-MED
gradient	B-MED
is	O
sensitive	B-MED
to	O
inference	B-MED
rules	I-MED
Generalising	B-MED
what	O
is	O
learned	B-MED
about	O
one	O
stimulus	B-MED
to	O
other	O
but	O
perceptually	B-MED
related	O
stimuli	B-MED
is	O
a	O
basic	O
behavioural	B-MED
phenomenon	B-MED
.	O
We	O
evaluated	B-MED
whether	O
a	O
rule	B-MED
learning	B-MED
mechanism	B-MED
may	O
serve	O
to	O
explain	O
such	O
generalisation	B-MED
.	O
To	O
this	O
end	O
,	O
we	O
assessed	B-MED
whether	O
inference	B-MED
rules	I-MED
communicated	B-MED
through	O
verbal	B-MED
instructions	I-MED
affect	O
generalisation	B-MED
.	O
Expectancy	B-MED
ratings	B-MED
,	O
but	O
not	O
valence	O
ratings	B-MED
,	O
proved	O
sensitive	B-MED
to	O
this	O
manipulation	B-MED
.	O
In	O
addition	O
to	O
revealing	O
a	O
role	B-MED
for	O
inference	B-MED
rules	I-MED
in	O
generalisation	B-MED
,	O
our	O
study	B-MED
has	O
clinical	B-MED
implications	B-MED
as	O
well	O
.	O
More	O
specifically	O
,	O
we	O
argue	O
that	O
targeting	B-MED
inference	B-MED
rules	I-MED
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	B-MED
to	O
affect	O
the	O
excessive	B-MED
generalisation	B-MED
that	O
is	O
often	O
observed	O
in	O
psychopathology	B-MED
.	O
Fuzheng	B-MED
Qingjie	I-MED
Granules	I-MED
Inhibit	B-MED
Growth	B-MED
of	O
Hepatoma	B-MED
Cells	I-MED
via	O
Inducing	B-MED
Mitochondria	B-MED
-Mediated	O
Apoptosis	B-MED
and	O
Enhancing	B-MED
Immune	B-MED
Function	I-MED
Fuzheng	B-MED
Qingjie	I-MED
(	B-MED
FZQJ	I-MED
)	I-MED
granules	I-MED
,	O
a	O
compound	B-MED
Chinese	B-MED
medicine	I-MED
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-MED
therapy	I-MED
for	O
alimentary	B-MED
tract	I-MED
cancers	B-MED
.	O
However	O
,	O
the	O
underlying	O
anticancer	B-MED
mechanisms	B-MED
are	O
still	O
not	O
well	O
understood	O
.	O
In	O
the	O
present	B-MED
study	B-MED
,	O
HepG2	B-MED
cells	I-MED
were	O
treated	B-MED
with	O
FZQJ	B-MED
-	O
containing	B-MED
serum	B-MED
.	O
Cell	B-MED
proliferation	I-MED
was	O
evaluated	B-MED
using	O
MTT	B-MED
assay	I-MED
.	O
Apoptosis	B-MED
was	O
analyzed	B-MED
using	O
a	O
flow	B-MED
cytometer	I-MED
.	O
Cell	B-MED
ultrastructure	I-MED
was	O
observed	B-MED
under	O
a	O
transmission	B-MED
electron	I-MED
microscope	I-MED
.	O
The	O
mitochondrial	B-MED
membrane	I-MED
potential	I-MED
(	O
Δψ	B-MED
)	O
was	O
examined	B-MED
with	O
JC-1	B-MED
dye	I-MED
.	O
In	O
H22	B-MED
tumor	I-MED
-	I-MED
bearing	I-MED
mice	I-MED
,	O
CD4(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
,	O
CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
,	O
CD3(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
,	O
and	O
natural	B-MED
killer	I-MED
cells	I-MED
(	O
NK	B-MED
)	O
in	O
peripheral	B-MED
blood	I-MED
were	O
evaluated	O
cytometrically	B-MED
.	O
Interleukin	B-MED
(	I-MED
IL)-2	I-MED
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
(	B-MED
TNF)-α	I-MED
levels	B-MED
were	O
measured	B-MED
using	O
radioimmunoassay	B-MED
.The	O
mRNA	B-MED
levels	B-MED
of	O
Bax	B-MED
and	O
Bcl-2	B-MED
were	O
examined	B-MED
by	O
reverse	B-MED
transcription	I-MED
-	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
The	O
protein	B-MED
levels	B-MED
of	O
Bax	B-MED
,	O
Bcl-2	B-MED
,	O
cytochrome	B-MED
C	I-MED
,	O
caspase	B-MED
3	I-MED
and	O
9	B-MED
,	O
PARP	B-MED
,	O
and	O
CD69	B-MED
were	O
examined	B-MED
by	O
Western	B-MED
blotting	I-MED
.	O
The	O
apoptotic	B-MED
cells	B-MED
in	O
tissues	B-MED
were	O
observed	B-MED
using	O
TUNEL	B-MED
method	I-MED
.	O
Alanine	B-MED
transaminase	I-MED
(	O
ALT	B-MED
)	O
,	O
aspartate	B-MED
transaminase	I-MED
(	O
AST	B-MED
)	O
,	O
blood	B-MED
urea	I-MED
nitrogen	I-MED
(	O
BUN	B-MED
)	O
,	O
and	O
creatinine	B-MED
(	O
CRE	B-MED
)	O
were	O
detected	B-MED
by	O
an	O
automatic	B-MED
biochemical	B-MED
analyzer	B-MED
.	O
The	O
results	B-MED
showed	O
that	O
FZQJ	B-MED
-	O
containing	B-MED
serum	B-MED
remarkably	O
inhibited	B-MED
proliferation	B-MED
of	O
HepG2	B-MED
cells	I-MED
in	O
dose	B-MED
-	O
and	O
time	B-MED
-	O
dependent	B-MED
manners	O
,	O
induced	B-MED
HepG2	B-MED
cell	I-MED
apoptosis	B-MED
and	O
caused	O
a	O
decrease	B-MED
of	O
Δψ	B-MED
.	O
Analysis	B-MED
of	O
tumor	B-MED
tissue	I-MED
showed	O
that	O
FZQJ	B-MED
-	O
induced	B-MED
apoptosis	B-MED
was	O
accompanied	O
by	O
downregulation	B-MED
of	O
Bcl-2	B-MED
and	O
upregulation	B-MED
of	O
Bax	B-MED
,	O
release	B-MED
of	O
cytochrome	B-MED
c	I-MED
,	O
activation	B-MED
of	O
caspase	B-MED
3	I-MED
and	O
9	B-MED
,	O
and	O
cleavage	B-MED
of	O
PARP	B-MED
.	O
In	O
addition	O
,	O
FZQJ	B-MED
increased	B-MED
the	O
percentages	B-MED
of	O
CD4(+	B-MED
)	I-MED
T	I-MED
and	O
NK	B-MED
cells	I-MED
,	O
the	O
ratio	B-MED
of	O
CD4(+	B-MED
)	I-MED
/	O
CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
as	O
well	O
as	O
the	O
levels	B-MED
of	O
serum	B-MED
TNF	B-MED
-	I-MED
α	I-MED
.	O
FZQJ	B-MED
also	O
increased	B-MED
CD69	B-MED
expression	B-MED
in	O
tumor	B-MED
tissue	I-MED
.	O
No	B-MED
hepatorenal	I-MED
toxicity	I-MED
was	O
observed	B-MED
in	O
H22	B-MED
tumor	I-MED
-	I-MED
bearing	I-MED
mice	I-MED
.	O
These	O
results	B-MED
indicated	B-MED
that	O
FZQJ	B-MED
could	O
inhibit	B-MED
the	O
growth	B-MED
of	O
hepatoma	B-MED
cells	I-MED
via	O
regulating	O
immune	B-MED
function	I-MED
and	O
inducing	B-MED
mitochondria	B-MED
mediated	O
apoptosis	B-MED
.	O
Aspirin	B-MED
Suppresses	B-MED
Growth	B-MED
in	O
PI3	B-MED
K	I-MED
-	O
Mutant	B-MED
Breast	B-MED
Cancer	I-MED
by	O
Activating	B-MED
AMPK	B-MED
and	O
Inhibiting	B-MED
mTORC1	B-MED
Signaling	O
Despite	O
the	O
high	O
incidence	B-MED
of	O
oncogenic	B-MED
mutations	B-MED
in	O
PIK3CA	B-MED
,	O
the	O
gene	B-MED
encoding	I-MED
the	O
catalytic	B-MED
subunit	I-MED
of	O
PI3	B-MED
K	I-MED
,	O
PI3	B-MED
K	I-MED
inhibitors	B-MED
have	O
yielded	O
little	O
clinical	B-MED
benefit	I-MED
for	O
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
Recent	B-MED
epidemiologic	B-MED
studies	I-MED
have	O
suggested	B-MED
a	O
therapeutic	B-MED
benefit	B-MED
from	O
aspirin	B-MED
intake	O
in	O
cancers	B-MED
harboring	O
oncogenic	B-MED
PIK3CA	I-MED
Here	O
,	O
we	O
show	O
that	O
mutant	B-MED
PIK3CA	B-MED
-	O
expressing	B-MED
breast	B-MED
cancer	I-MED
cells	I-MED
have	O
greater	O
sensitivity	B-MED
to	O
aspirin	B-MED
-mediated	O
growth	B-MED
suppression	B-MED
than	O
their	O
wild	B-MED
-	I-MED
type	I-MED
counterparts	O
.	O
Aspirin	B-MED
decreased	B-MED
viability	B-MED
and	O
anchorage	B-MED
-	I-MED
independent	I-MED
growth	I-MED
of	O
mutant	B-MED
PIK3CA	B-MED
breast	B-MED
cancer	I-MED
cells	I-MED
independently	B-MED
of	O
its	O
effects	B-MED
on	O
COX-2	B-MED
and	O
NF	B-MED
-	I-MED
κB	I-MED
κB.	O
We	O
ascribed	O
the	O
effects	B-MED
of	I-MED
aspirin	B-MED
to	O
AMP	B-MED
-	I-MED
activated	I-MED
protein	I-MED
kinase	I-MED
(	O
AMPK	B-MED
)	O
activation	B-MED
,	O
mTORC1	B-MED
inhibition	B-MED
,	O
and	O
autophagy	B-MED
induction	O
.	O
In	O
vivo	O
,	O
oncogenic	B-MED
PIK3CA	B-MED
-driven	O
mouse	B-MED
mammary	B-MED
tumors	I-MED
treated	B-MED
daily	O
with	O
aspirin	B-MED
resulted	O
in	O
decreased	B-MED
tumor	B-MED
growth	I-MED
kinetics	B-MED
,	O
whereas	O
combination	B-MED
therapy	B-MED
of	O
aspirin	B-MED
and	O
a	O
PI3	B-MED
K	I-MED
inhibitor	B-MED
further	O
attenuated	B-MED
tumor	B-MED
growth	I-MED
.	O
Our	O
study	O
supports	O
the	O
evaluation	B-MED
of	O
aspirin	B-MED
and	O
PI3	B-MED
K	I-MED
pathway	O
inhibitors	B-MED
as	O
a	O
combination	B-MED
therapy	B-MED
for	O
targeting	B-MED
breast	B-MED
cancer	I-MED
.	O
Cancer	O
Res	O
;	O
77(3	O
)	O
;	O
790	O
-	O
801	O
.	O
©	O
2016	O
AACR	O
.	O
Direct	B-MED
Repair	B-MED
of	O
Lumbar	B-MED
Pars	I-MED
Interarticularis	I-MED
Defects	B-MED
by	O
Utilizing	B-MED
Intraoperative	B-MED
O	I-MED
-	I-MED
Arm	I-MED
-	I-MED
Based	I-MED
Navigation	I-MED
and	O
Microendoscopic	B-MED
Techniques	I-MED
A	O
retrospective	B-MED
analysis	I-MED
of	O
the	O
clinical	B-MED
outcomes	I-MED
of	O
eight	O
patients	B-MED
with	O
the	O
lumbar	B-MED
pars	I-MED
interarticulars	I-MED
defects	B-MED
treated	B-MED
by	O
direct	B-MED
repair	B-MED
with	O
the	O
aid	B-MED
of	O
intraoperative	B-MED
O	I-MED
-	I-MED
arm	I-MED
based	I-MED
navigation	I-MED
and	O
microendoscopic	B-MED
techniques	I-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
direct	B-MED
screw	B-MED
repair	B-MED
by	O
using	B-MED
minimally	B-MED
invasive	I-MED
surgery	I-MED
for	O
the	O
lumbar	B-MED
pars	I-MED
interarticulars	I-MED
defects	B-MED
in	O
a	O
pilot	B-MED
study	I-MED
.	O
Direct	B-MED
repair	B-MED
of	O
pars	B-MED
interarticulars	I-MED
defects	B-MED
has	O
been	O
used	B-MED
to	O
treat	B-MED
young	B-MED
adult	I-MED
patients	B-MED
.	O
Reports	B-MED
concerning	B-MED
direct	B-MED
repair	B-MED
by	O
minimally	B-MED
invasive	I-MED
techniques	I-MED
for	O
pars	B-MED
interarticulars	I-MED
defects	B-MED
are	O
quite	O
rare	B-MED
.	O
Review	B-MED
of	O
medical	B-MED
records	I-MED
identified	B-MED
eight	O
consecutive	B-MED
patients	B-MED
treated	B-MED
with	O
intraoperative	B-MED
O	I-MED
-	I-MED
arm	I-MED
based	I-MED
navigation	I-MED
and	O
microendoscopic	B-MED
techniques	I-MED
.	O
Debridement	B-MED
and	O
autograft	B-MED
of	O
pars	B-MED
interarticularis	I-MED
defects	B-MED
was	O
performed	B-MED
under	O
microendoscopic	B-MED
procedure	I-MED
.	O
Then	O
,	O
percutaneous	B-MED
bilateral	B-MED
intralaminar	B-MED
screws	B-MED
were	O
inserted	B-MED
by	O
utilizing	B-MED
intraoperative	B-MED
navigation	I-MED
.	O
The	O
clinical	B-MED
and	O
radiological	B-MED
data	B-MED
were	O
collected	B-MED
and	O
analyzed	B-MED
retrospectively	B-MED
.	O
Eight	O
patients	B-MED
had	O
a	O
mean	B-MED
age	B-MED
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	B-MED
at	O
the	O
time	B-MED
of	O
treatment	B-MED
.	O
Symptoms	B-MED
included	B-MED
axial	B-MED
back	B-MED
pain	I-MED
in	O
100	O
%	O
of	O
patients	B-MED
without	O
concomitant	B-MED
radiculopathy	B-MED
.	O
Autograft	B-MED
was	O
used	B-MED
in	O
all	O
cases	B-MED
.	O
The	O
average	B-MED
follow	B-MED
-	I-MED
up	I-MED
duration	B-MED
was	O
27.4	O
months	O
with	O
a	O
range	B-MED
of	O
20	O
to	O
33	O
months	O
.	O
Symptoms	B-MED
resolved	B-MED
completely	B-MED
or	O
partially	B-MED
in	O
all	O
patients	B-MED
.	O
Low	B-MED
back	I-MED
pain	I-MED
visual	B-MED
analog	I-MED
scores	I-MED
decrease	B-MED
from	O
preoperative	B-MED
6.8	O
to	O
postoperative	B-MED
1.4	O
of	O
eight	O
cases	B-MED
.	O
Of	O
16	O
pars	B-MED
defects	B-MED
,	O
healing	B-MED
was	O
observed	B-MED
in	O
13	O
(	O
81.3	O
%	O
)	O
at	O
last	O
radiological	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
One	O
patient	B-MED
with	O
bilateral	B-MED
fusion	I-MED
failure	I-MED
refused	B-MED
revision	B-MED
surgery	I-MED
because	O
of	O
mild	B-MED
complaint	I-MED
.	O
No	B-MED
complications	I-MED
such	O
as	O
dural	B-MED
tear	I-MED
,	O
nerve	B-MED
root	I-MED
injury	I-MED
,	O
and	O
infection	B-MED
occurred	B-MED
.	O
Minimally	B-MED
invasive	I-MED
direct	B-MED
repair	B-MED
of	O
the	O
pars	B-MED
interarticularis	I-MED
defects	B-MED
with	O
intralaminar	B-MED
screws	B-MED
by	O
using	B-MED
microendoscopic	B-MED
system	I-MED
and	O
navigation	B-MED
procedure	I-MED
can	O
provide	B-MED
safe	O
and	O
effective	B-MED
treatment	B-MED
of	O
spondylolysis	B-MED
with	O
satisfactory	B-MED
clinical	B-MED
and	O
radiological	B-MED
outcomes	B-MED
,	O
which	O
need	B-MED
some	O
special	B-MED
tools	I-MED
with	O
steep	B-MED
learning	B-MED
curve	I-MED
.	O
4	O
.	O
Improving	B-MED
exchange	O
with	O
consumers	B-MED
within	O
mental	B-MED
health	I-MED
organizations	I-MED
:	O
Recognizing	O
mental	B-MED
ill	I-MED
health	I-MED
experience	O
as	O
a	O
'	O
sneaky	O
,	O
special	O
degree	O
'	O
Stigmatizing	B-MED
views	O
towards	O
consumers	B-MED
may	O
be	O
held	O
even	O
by	O
those	O
working	B-MED
within	O
mental	B-MED
health	I-MED
organizations	I-MED
.	O
Contemporary	O
mental	B-MED
health	I-MED
policies	I-MED
require	O
organizations	B-MED
to	O
work	B-MED
collaboratively	B-MED
with	O
consumers	B-MED
in	O
producing	B-MED
and	O
delivering	B-MED
services	B-MED
.	O
Using	O
social	B-MED
exchange	I-MED
theory	I-MED
,	O
which	O
emphasises	O
mutual	B-MED
exchange	B-MED
to	O
maximise	B-MED
benefits	B-MED
in	O
partnership	B-MED
,	O
the	O
current	B-MED
study	B-MED
explores	O
the	O
perspectives	B-MED
of	O
those	O
working	B-MED
within	O
organizations	B-MED
that	O
have	O
some	O
level	B-MED
of	O
consumer	B-MED
leadership	B-MED
.	O
Interviews	B-MED
were	O
conducted	O
with	O
14	O
participants	B-MED
from	O
a	O
range	B-MED
of	O
mental	B-MED
health	I-MED
organizations	I-MED
.	O
Data	B-MED
were	O
transcribed	O
,	O
and	O
analyzed	B-MED
using	O
thematic	B-MED
analytic	I-MED
and	O
discursive	B-MED
psychological	B-MED
techniques	I-MED
.	O
Findings	B-MED
suggest	O
stigma	B-MED
is	O
still	O
prevalent	O
even	O
in	O
organizations	B-MED
that	O
have	O
consumers	B-MED
in	O
leadership	B-MED
positions	I-MED
,	O
and	O
consumers	B-MED
are	O
often	O
perceived	B-MED
as	O
less	O
able	O
to	O
work	B-MED
in	O
mental	B-MED
health	I-MED
organizations	I-MED
than	O
non	O
-	O
consumers	O
.	O
Several	O
discourses	B-MED
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	B-MED
bring	O
value	O
to	O
mental	B-MED
health	I-MED
organizations	I-MED
through	O
their	O
expertise	O
in	O
the	O
mental	B-MED
health	I-MED
system	I-MED
,	O
and	O
their	O
ability	B-MED
to	O
provide	O
safety	B-MED
and	O
support	B-MED
to	O
other	O
consumers	B-MED
.	O
Through	O
a	O
social	B-MED
exchange	I-MED
theory	I-MED
lens	O
,	O
the	O
authors	B-MED
call	O
for	O
organizations	B-MED
to	O
challenge	O
stigma	B-MED
and	O
promote	B-MED
the	O
value	O
that	O
consumers	B-MED
can	O
bring	O
to	O
maximize	B-MED
mutual	B-MED
benefits	B-MED
.	O
Effects	B-MED
of	I-MED
siRNA	B-MED
-mediated	O
suppression	B-MED
of	O
HPV-11	B-MED
L1	I-MED
expression	B-MED
on	O
the	O
proliferation	B-MED
and	O
apoptosis	B-MED
of	O
vaginal	B-MED
epithelial	I-MED
cells	I-MED
The	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
human	B-MED
papillomavirus	I-MED
(	I-MED
HPV	I-MED
)	I-MED
infection	I-MED
on	O
the	O
gynecological	B-MED
disease	I-MED
of	O
vaginitis	B-MED
and	O
to	O
demonstrate	O
how	O
the	O
small	B-MED
interfering	I-MED
RNA	I-MED
(	O
siRNA	B-MED
)	O
method	O
may	O
be	O
used	O
for	O
HPV	B-MED
prevention	B-MED
in	O
the	O
clinic	B-MED
.	O
Human	B-MED
vaginal	B-MED
epithelial	I-MED
cells	I-MED
were	O
transfected	B-MED
with	O
HPV-11	B-MED
L1	I-MED
expression	B-MED
vector	I-MED
and	O
siRNA	B-MED
-	O
HPV-11	B-MED
L1	I-MED
vectors	B-MED
and	O
a	O
control	B-MED
group	I-MED
was	O
transfected	B-MED
with	O
scrambled	O
siRNA	B-MED
.	O
Cell	B-MED
proliferation	I-MED
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
MTT	B-MED
assay	I-MED
and	O
the	O
expression	B-MED
of	O
apoptosis	B-MED
-associated	O
proteins	B-MED
was	O
measured	B-MED
by	O
western	B-MED
blot	I-MED
analysis	I-MED
.	O
Compared	B-MED
with	O
the	O
control	B-MED
group	I-MED
,	O
HPV-11	B-MED
L1	I-MED
mRNA	B-MED
and	O
protein	B-MED
levels	I-MED
were	O
significantly	O
increased	B-MED
following	O
transfection	B-MED
with	O
the	O
HPV-11	B-MED
L1	I-MED
expression	B-MED
vector	I-MED
in	O
cells	B-MED
(	O
P<0.05	O
)	O
,	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	B-MED
of	O
HPV-11	B-MED
L1	I-MED
(	O
P<0.05	O
)	O
.	O
In	O
addition	O
,	O
cell	B-MED
proliferation	I-MED
in	O
the	O
HPV-11	B-MED
group	I-MED
was	O
lower	B-MED
than	O
that	O
in	O
the	O
control	B-MED
group	I-MED
;	O
however	O
,	O
cell	B-MED
proliferation	I-MED
was	O
significantly	O
increased	B-MED
in	O
cells	B-MED
transfected	B-MED
with	O
silenced	B-MED
L1	B-MED
compared	O
with	O
that	O
in	O
the	O
control	B-MED
group	I-MED
(	O
P<0.05	O
)	O
.	O
Furthermore	O
,	O
silencing	B-MED
of	O
HPV-11	B-MED
L1	I-MED
significantly	O
decreased	B-MED
caspase-3	B-MED
and	O
caspase-9	B-MED
expressions	B-MED
in	O
cells	B-MED
,	O
whereas	O
the	O
expression	B-MED
was	O
increased	B-MED
in	O
the	O
HPV-11	B-MED
L1	I-MED
group	O
(	O
P<0.05	O
)	O
.	O
The	O
present	O
study	B-MED
suggested	O
that	O
siRNA	B-MED
-mediated	O
silencing	B-MED
of	O
HPV-11	B-MED
L1	I-MED
may	O
have	O
potential	O
therapeutic	B-MED
applications	I-MED
for	O
treating	O
gynecological	B-MED
diseases	I-MED
associated	B-MED
with	I-MED
HPV-11	B-MED
infection	B-MED
.	O
Distinct	B-MED
cortical	I-MED
and	I-MED
sub	I-MED
-	I-MED
cortical	I-MED
neurogenic	I-MED
domains	I-MED
for	O
GABAergic	B-MED
interneuron	B-MED
precursor	B-MED
transcription	B-MED
factors	I-MED
NKX2.1	B-MED
,	O
OLIG2	B-MED
and	O
COUP	B-MED
-	I-MED
TFII	I-MED
in	O
early	O
fetal	B-MED
human	B-MED
telencephalon	B-MED
The	O
extent	O
of	O
similarities	B-MED
and	O
differences	B-MED
between	O
cortical	B-MED
GABAergic	I-MED
interneuron	I-MED
generation	I-MED
in	O
rodent	B-MED
and	O
primate	B-MED
telencephalon	B-MED
remains	O
contentious	O
.	O
We	O
examined	O
expression	B-MED
of	O
three	O
interneuron	B-MED
precursor	B-MED
transcription	B-MED
factors	I-MED
,	O
alongside	O
other	O
markers	B-MED
,	O
using	O
immunohistochemistry	B-MED
on	O
8	O
-	O
12	O
post	B-MED
-	I-MED
conceptional	I-MED
weeks	I-MED
(	O
PCW	B-MED
)	O
human	B-MED
telencephalon	B-MED
sections	O
.	O
NKX2.1	B-MED
,	O
OLIG2	B-MED
,	O
and	O
COUP	B-MED
-	I-MED
TFII	I-MED
expression	B-MED
occupied	O
distinct	O
(	O
although	O
overlapping	O
)	O
neurogenic	B-MED
domains	I-MED
which	O
extended	O
into	O
the	O
cortex	B-MED
and	O
revealed	O
three	O
CGE	B-MED
compartments	I-MED
:	O
lateral	B-MED
,	O
medial	B-MED
,	O
and	O
ventral	B-MED
.	O
NKX2.1	B-MED
expression	B-MED
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	B-MED
,	O
medial	B-MED
CGE	B-MED
,	O
and	O
ventral	B-MED
septum	B-MED
confirming	O
that	O
,	O
at	O
this	O
developmental	B-MED
stage	I-MED
,	O
interneuron	B-MED
generation	O
from	O
NKX2.1	B-MED
+	O
precursor	B-MED
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	B-MED
.	O
OLIG2	B-MED
immunoreactivity	B-MED
was	O
observed	O
in	O
GABAergic	B-MED
cells	I-MED
of	O
the	O
proliferative	B-MED
zones	B-MED
of	O
the	O
MGE	B-MED
and	O
septum	B-MED
,	O
but	O
not	O
necessarily	O
co	O
-	O
expressed	O
with	O
NKX2.1	B-MED
,	O
and	O
OLIG2	B-MED
expression	B-MED
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	B-MED
,	O
CGE	B-MED
,	O
and	O
cortex	B-MED
.	O
At	O
8	O
PCW	B-MED
,	O
OLIG2	B-MED
+	O
cells	B-MED
were	O
only	O
present	O
in	O
the	O
medial	B-MED
and	O
anterior	B-MED
cortical	B-MED
wall	I-MED
suggesting	O
a	O
migratory	B-MED
pathway	B-MED
for	O
interneuron	B-MED
precursor	B-MED
s	O
via	O
the	O
septum	B-MED
into	O
the	O
medial	B-MED
cortex	B-MED
.	O
By	O
12	O
PCW	B-MED
,	O
OLIG2	B-MED
+	O
cells	B-MED
were	O
present	O
throughout	O
the	O
cortex	B-MED
and	O
many	O
were	O
actively	O
dividing	B-MED
but	O
without	O
co	O
-	O
expressing	O
cortical	B-MED
progenitor	B-MED
markers	B-MED
.	O
Dividing	O
COUP	B-MED
-	I-MED
TFII	I-MED
+	O
progenitor	B-MED
cells	I-MED
were	O
localized	B-MED
to	O
ventral	B-MED
CGE	B-MED
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	B-MED
cortex	B-MED
;	O
in	O
both	O
the	O
cases	O
,	O
COUP	B-MED
-	I-MED
TFII	I-MED
was	O
co	O
-	O
expressed	O
with	O
PAX6	B-MED
in	O
proliferative	B-MED
zones	B-MED
and	O
TBR1	B-MED
or	O
calretinin	B-MED
in	O
post-	O
mitotic	B-MED
cortical	B-MED
neurons	I-MED
.	O
Thus	O
COUP	B-MED
-	I-MED
TFII	I-MED
+	O
progenitors	B-MED
gave	O
rise	O
to	O
pyramidal	B-MED
cells	I-MED
,	O
but	O
also	O
interneurons	B-MED
which	O
not	O
only	O
migrated	B-MED
posteriorly	O
into	O
the	O
cortex	B-MED
from	O
ventral	B-MED
CGE	B-MED
but	O
also	O
anteriorly	B-MED
via	O
the	O
LGE	B-MED
.	O
Assessment	B-MED
of	O
the	O
Extravascular	B-MED
Implantable	I-MED
Defibrillator	I-MED
:	O
Feasibility	B-MED
of	O
Substernal	B-MED
Ventricular	I-MED
Pacing	I-MED
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
feasibility	B-MED
of	O
ventricular	B-MED
pacing	I-MED
and	O
thresholds	B-MED
from	O
within	B-MED
the	O
substernal	B-MED
space	I-MED
to	O
examine	O
a	O
new	B-MED
extravascular	B-MED
ICD	I-MED
configuration	B-MED
with	O
pacing	B-MED
capabilities	B-MED
.	O
In	O
patients	B-MED
undergoing	O
midline	B-MED
sternotomy	I-MED
,	O
a	O
duodecapolar	B-MED
diagnostic	I-MED
pacing	I-MED
catheter	I-MED
was	O
positioned	B-MED
in	O
the	O
substernal	B-MED
space	I-MED
anterior	B-MED
to	O
the	O
pericardium	B-MED
,	O
and	O
a	O
cutaneous	B-MED
patch	I-MED
in	O
left	B-MED
lateral	I-MED
position	I-MED
.	O
Different	B-MED
unipolar	B-MED
and	O
bipolar	B-MED
pacing	B-MED
configurations	B-MED
were	O
assessed	B-MED
.	O
Strength	B-MED
-	I-MED
duration	I-MED
curves	I-MED
were	O
performed	B-MED
to	O
identify	O
the	O
optimal	B-MED
output	B-MED
,	O
starting	O
at	O
25	O
mA	B-MED
with	O
a	O
pulse	B-MED
width	I-MED
of	O
10	O
milliseconds	B-MED
.	O
Eight	O
patients	B-MED
with	O
mean	B-MED
age	B-MED
69	O
±	O
9	O
years	B-MED
were	O
included	B-MED
.	O
In	O
5	O
,	O
ventricular	B-MED
capture	O
was	O
achieved	O
in	O
≥1	O
configuration	B-MED
.	O
The	O
mean	B-MED
bipolar	B-MED
pacing	B-MED
thresholds	B-MED
at	O
PW	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	B-MED
were	O
12.4	O
±	O
3.7	O
mA	B-MED
(	O
5	O
patients	B-MED
)	O
,	O
13.3	O
±	O
5.8	O
mA	B-MED
(	O
3	O
patients	B-MED
)	O
,	O
18.3	O
±	O
5.7	O
mA	B-MED
(	O
3	O
patients	B-MED
)	O
,	O
and	O
25	O
±	O
0	O
mA	B-MED
(	O
2	O
patients	B-MED
)	O
,	O
respectively	O
.	O
The	O
60	O
-	O
mm	O
electrode	B-MED
spacing	B-MED
was	O
the	O
most	O
successful	B-MED
bipolar	B-MED
configuration	B-MED
.	O
Unipolar	B-MED
pacing	B-MED
was	O
successful	B-MED
in	O
3	O
out	O
of	O
4	O
patients	B-MED
with	O
mean	B-MED
thresholds	B-MED
of	O
10	O
±	O
0	O
mA	B-MED
at	O
10	O
milliseconds	B-MED
(	O
3	O
patients	B-MED
)	O
,	O
15	O
±	O
0	O
mA	B-MED
at	O
5	O
milliseconds	B-MED
(	O
3	O
patients	B-MED
)	O
,	O
16.7	O
±	O
2.9	O
mA	B-MED
at	O
3	O
milliseconds	B-MED
(	O
3	O
patients	B-MED
)	O
,	O
and	O
20	O
±	O
7.1	O
mA	B-MED
at	O
1	O
milliseconds	B-MED
(	O
2	O
patients	B-MED
)	O
.	O
Ventricular	B-MED
pacing	I-MED
pacing	B-MED
from	O
the	O
substernal	B-MED
space	I-MED
in	O
patients	B-MED
with	O
midline	B-MED
sternotomy	I-MED
is	O
feasible	B-MED
.	O
Closed	B-MED
sternum	B-MED
studies	B-MED
are	O
needed	B-MED
to	O
determine	O
pacing	B-MED
thresholds	B-MED
more	O
accurately	B-MED
.	O
Metabolomics	B-MED
analysis	B-MED
of	O
anaphylactoid	B-MED
reaction	I-MED
reveals	B-MED
its	O
mechanism	B-MED
in	O
a	O
rat	B-MED
model	B-MED
Anaphylactoid	B-MED
reactions	I-MED
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune	B-MED
-	I-MED
mediated	I-MED
immediate	I-MED
hypersensitivity	I-MED
reactions	I-MED
,	O
have	O
become	O
a	O
serious	B-MED
threat	B-MED
to	O
public	B-MED
health	I-MED
,	O
but	O
their	O
effect	B-MED
mechanism	B-MED
is	O
not	B-MED
clear	I-MED
and	O
diagnostic	B-MED
tests	I-MED
are	O
limited	B-MED
.	O
Comprehensive	B-MED
metabolite	B-MED
analysis	B-MED
may	O
reveal	B-MED
the	O
anaphylactoid	B-MED
effect	B-MED
mechanism	B-MED
systematically	B-MED
and	O
provide	B-MED
reference	B-MED
for	O
future	B-MED
diagnostic	B-MED
purposes	B-MED
.	O
Plasma	B-MED
from	O
Brown	B-MED
Norway	I-MED
rats	I-MED
given	O
intravenous	B-MED
injection	I-MED
of	O
saline	B-MED
,	O
compound	B-MED
48/80	I-MED
(	O
2.5	O
mL	O
/	O
kg	O
)	O
or	O
ovalbumin	B-MED
(	O
20	O
mL	O
/	O
kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	B-MED
to	O
study	B-MED
the	O
effect	B-MED
mechanism	B-MED
of	O
anaphylactoid	B-MED
reactions	I-MED
through	O
metabolomics	B-MED
(	O
UPLC	B-MED
-	I-MED
qTOF	I-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
)	O
.	O
Metabolomics	B-MED
integrated	O
with	O
proteomics	B-MED
data	I-MED
were	O
used	B-MED
to	O
analyze	B-MED
the	O
anaphylactoid	B-MED
pathways	B-MED
by	O
MetaboAnalyst	B-MED
followed	B-MED
by	I-MED
integrated	O
pathway	B-MED
analysis	I-MED
.	O
Thirty	O
metabolites	B-MED
were	O
identified	B-MED
through	O
the	O
METLIN	B-MED
database	I-MED
by	O
MS	B-MED
/	I-MED
MS	I-MED
and	O
18	O
of	O
them	O
were	O
confirmed	B-MED
by	I-MED
authentic	B-MED
standards	I-MED
.	O
The	O
results	B-MED
showed	O
that	O
adenosine	B-MED
,	O
histamine	B-MED
,	O
N	B-MED
-	I-MED
acetylhistamine	I-MED
,	O
N(α)-γ	B-MED
-	I-MED
glutamylhistamine	I-MED
,	O
malate	B-MED
and	O
xanthine	B-MED
are	O
important	B-MED
indices	O
for	O
anaphylactoid	B-MED
reactions	I-MED
.	O
It	O
could	O
be	O
concluded	O
that	O
the	O
effect	B-MED
mechanism	B-MED
is	O
mainly	O
composed	O
of	O
histidine	B-MED
metabolism	I-MED
,	O
arachidonic	B-MED
acid	I-MED
metabolism	I-MED
,	O
energy	B-MED
metabolism	I-MED
,	O
purine	B-MED
metabolism	I-MED
and	O
other	B-MED
small	B-MED
molecules	B-MED
through	B-MED
30	O
metabolites	B-MED
.	O
Multiple	B-MED
linear	I-MED
regression	I-MED
analysis	I-MED
indicated	B-MED
that	O
not	B-MED
only	B-MED
histamine	B-MED
but	O
also	O
N(α)-γ	B-MED
-	I-MED
glutamylhistamine	I-MED
and	O
arachidonic	B-MED
acid	I-MED
could	O
be	O
used	B-MED
to	O
evaluate	O
anaphylactoid	B-MED
symptoms	B-MED
of	O
animals	B-MED
.	O
Furthermore	O
,	O
the	O
citrate	B-MED
cycle	I-MED
,	O
histidine	B-MED
metabolism	I-MED
and	O
arachidonic	B-MED
acid	I-MED
metabolism	I-MED
could	O
be	O
the	O
main	B-MED
pathways	B-MED
of	O
anaphylactoid	B-MED
reactions	I-MED
as	O
determined	B-MED
by	I-MED
MetaboAnalyst	B-MED
.	O
The	O
results	B-MED
may	O
provide	B-MED
a	O
reference	B-MED
to	O
improve	B-MED
diagnostic	B-MED
accuracy	I-MED
and	O
predict	B-MED
and	O
monitor	O
treatment	B-MED
efficacy	I-MED
in	O
anaphylactoid	B-MED
reactions	I-MED
in	O
the	O
clinical	B-MED
setting	I-MED
.	O
Characterising	B-MED
bias	B-MED
in	O
regulatory	B-MED
risk	I-MED
and	O
decision	B-MED
analysis	I-MED
:	O
An	O
analysis	B-MED
of	O
heuristics	B-MED
applied	O
in	O
health	B-MED
technology	I-MED
appraisal	B-MED
,	O
chemicals	B-MED
regulation	B-MED
,	O
and	O
climate	B-MED
change	I-MED
governance	B-MED
In	O
many	O
environmental	B-MED
and	O
public	B-MED
health	I-MED
domains	I-MED
,	O
heuristic	B-MED
methods	I-MED
of	O
risk	B-MED
and	O
decision	B-MED
analysis	I-MED
must	O
be	O
relied	O
upon	O
,	O
either	O
because	O
problem	B-MED
structures	I-MED
are	O
ambiguous	O
,	O
reliable	O
data	B-MED
is	O
lacking	B-MED
,	O
or	O
decisions	B-MED
are	O
urgent	O
.	O
This	O
introduces	O
an	O
additional	O
source	B-MED
of	O
uncertainty	B-MED
beyond	O
model	B-MED
and	O
measurement	B-MED
error	I-MED
-	O
uncertainty	B-MED
stemming	O
from	O
relying	O
on	O
inexact	O
inference	B-MED
rules	I-MED
.	O
Here	O
we	O
identify	B-MED
and	O
analyse	B-MED
heuristics	B-MED
used	O
to	O
prioritise	O
risk	B-MED
objects	B-MED
,	O
to	O
discriminate	B-MED
between	O
signal	B-MED
and	O
noise	B-MED
,	O
to	O
weight	B-MED
evidence	B-MED
,	O
to	O
construct	O
models	B-MED
,	O
to	O
extrapolate	O
beyond	O
datasets	B-MED
,	O
and	O
to	O
make	O
policy	B-MED
.	O
Some	O
of	O
these	O
heuristics	B-MED
are	O
based	O
on	O
causal	O
generalisations	B-MED
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	B-MED
are	O
presumed	O
rather	O
than	O
tested	O
(	O
e.g.	O
surrogates	B-MED
in	O
clinical	B-MED
trials	I-MED
)	O
.	O
Others	O
are	O
conventions	B-MED
designed	O
to	O
confer	O
stability	B-MED
to	O
decision	B-MED
analysis	I-MED
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	B-MED
when	O
applied	O
ritualistically	O
(	O
e.g.	O
significance	B-MED
testing	I-MED
)	O
.	O
Some	O
heuristics	B-MED
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	B-MED
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	B-MED
that	O
are	O
often	O
violated	O
in	O
practical	B-MED
applications	I-MED
.	O
Heuristic	B-MED
decision	B-MED
rules	I-MED
(	O
e.g.	O
feasibility	B-MED
rules	I-MED
)	O
in	O
principle	O
act	O
as	O
surrogates	B-MED
for	O
utility	B-MED
maximisation	I-MED
or	O
distributional	B-MED
concerns	B-MED
,	O
yet	O
in	O
practice	B-MED
may	O
neglect	O
costs	B-MED
and	I-MED
benefits	I-MED
,	O
be	O
based	O
on	O
arbitrary	B-MED
thresholds	B-MED
,	O
and	O
be	O
prone	O
to	O
gaming	O
.	O
We	O
highlight	O
the	O
problem	B-MED
of	O
rule	B-MED
-	I-MED
entrenchment	I-MED
,	O
where	O
analytical	B-MED
choices	I-MED
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	B-MED
,	O
masking	O
uncertainty	B-MED
and	O
potentially	O
introducing	O
bias	B-MED
.	O
Strategies	B-MED
for	O
making	O
risk	B-MED
and	O
decision	B-MED
analysis	I-MED
more	O
rigorous	O
include	O
:	O
formalising	O
the	O
assumptions	B-MED
and	O
scope	B-MED
conditions	B-MED
under	O
which	O
heuristics	B-MED
should	O
be	O
applied	O
;	O
testing	B-MED
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	B-MED
or	O
theoretical	B-MED
justifications	I-MED
;	O
using	O
sensitivity	B-MED
analysis	B-MED
,	O
simulations	B-MED
,	O
multiple	B-MED
bias	I-MED
analysis	I-MED
,	O
and	O
deductive	B-MED
systems	I-MED
of	I-MED
inference	I-MED
(	O
e.g.	O
directed	B-MED
acyclic	I-MED
graphs	I-MED
)	O
to	O
characterise	O
rule	B-MED
uncertainty	B-MED
and	O
refine	O
heuristics	B-MED
;	O
adopting	O
"	O
recovery	B-MED
schemes	I-MED
"	O
to	O
correct	O
for	O
known	O
biases	B-MED
;	I-MED
and	O
basing	O
decision	B-MED
rules	I-MED
on	O
clearly	O
articulated	O
values	B-MED
and	O
evidence	B-MED
,	O
rather	O
than	O
convention	B-MED
.	O
Acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
after	O
pancreas	B-MED
transplantation	I-MED
with	O
accelerated	B-MED
progression	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
The	O
effect	O
of	O
pancreas	B-MED
transplantation	I-MED
on	O
diabetic	B-MED
retinopathy	I-MED
remains	O
inconclusive	B-MED
.	O
Herein	O
,	O
we	O
report	O
six	O
patients	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
(	O
DM	B-MED
)	O
who	O
underwent	O
pancreas	B-MED
transplantation	I-MED
and	O
developed	O
acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
with	O
rapid	B-MED
progression	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
.	O
In	O
this	O
retrospective	B-MED
observational	I-MED
study	I-MED
,	O
diabetic	B-MED
patients	B-MED
who	O
underwent	O
pancreas	B-MED
transplantation	I-MED
in	O
a	O
single	B-MED
medical	B-MED
center	I-MED
and	O
developed	O
symptomatic	B-MED
acute	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
within	B-MED
3	B-MED
months	I-MED
after	B-MED
the	O
operation	B-MED
were	O
enrolled	O
.	O
The	O
complete	B-MED
ophthalmic	B-MED
course	I-MED
and	O
medical	B-MED
records	I-MED
of	O
the	O
patients	B-MED
were	O
retrospectively	B-MED
reviewed	B-MED
.	O
Diabetic	B-MED
retinopathy	I-MED
and	O
progression	B-MED
following	B-MED
treatment	B-MED
after	O
pancreas	B-MED
transplantation	I-MED
were	O
measured	B-MED
.	O
Six	O
Chinese	B-MED
women	B-MED
with	O
type	B-MED
1	I-MED
DM	I-MED
were	O
enrolled	O
in	O
this	O
study	B-MED
.	O
Mean	O
hemoglobin	B-MED
(	I-MED
Hb	I-MED
)	I-MED
A1c	I-MED
was	O
13.4	O
%	O
prior	O
to	O
transplantation	B-MED
and	O
decreased	B-MED
rapidly	B-MED
to	O
6.5	O
%	O
within	B-MED
2	B-MED
months	I-MED
postsurgery	B-MED
.	O
The	O
patients	B-MED
had	O
no	B-MED
or	O
mild	B-MED
pretransplant	B-MED
diabetic	B-MED
retinopathy	I-MED
and	O
developed	O
acute	B-MED
symptomatic	B-MED
macular	B-MED
edema	I-MED
and	O
peripapillary	B-MED
soft	B-MED
exudate	B-MED
in	O
both	B-MED
eyes	I-MED
after	O
pancreas	B-MED
transplantation	I-MED
.	O
All	O
macular	B-MED
edema	I-MED
resolved	B-MED
either	O
with	O
or	O
without	B-MED
treatment	B-MED
.	O
Five	O
cases	B-MED
progressed	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
and	O
received	B-MED
panretinal	B-MED
photocoagulation	I-MED
.	O
Diabetic	B-MED
retinopathy	I-MED
remained	O
stable	B-MED
in	O
all	B-MED
eyes	B-MED
after	B-MED
treatment	B-MED
,	O
and	O
the	O
visual	B-MED
prognosis	B-MED
was	I-MED
good	I-MED
,	O
except	B-MED
in	O
one	B-MED
eye	B-MED
that	O
had	O
macular	B-MED
branch	B-MED
retinal	I-MED
artery	I-MED
occlusion	I-MED
with	O
foveal	B-MED
involvement	B-MED
.	O
Acute	B-MED
macular	B-MED
edema	I-MED
after	O
pancreas	B-MED
transplantation	I-MED
has	O
a	O
favorable	B-MED
treatment	B-MED
outcome	I-MED
despite	O
rapid	O
progression	B-MED
to	O
proliferative	B-MED
diabetic	I-MED
retinopathy	I-MED
.	O
High	B-MED
pretransplant	B-MED
HbA1c	B-MED
and	O
abrupt	B-MED
blood	B-MED
sugar	I-MED
normalization	B-MED
may	O
be	O
related	O
to	O
the	O
disease	B-MED
course	I-MED
.	O
Role	O
of	O
breast	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
in	O
predicting	B-MED
residual	B-MED
lobular	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
after	O
initial	B-MED
excision	B-MED
Breast	B-MED
magnetic	I-MED
resonance	I-MED
(	I-MED
MR	I-MED
)	I-MED
imaging	I-MED
is	O
a	O
useful	O
screening	B-MED
modality	B-MED
in	O
detecting	B-MED
suspicious	B-MED
lesions	B-MED
in	O
patients	B-MED
with	O
a	O
history	B-MED
of	O
lobular	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
(	O
LCIS	B-MED
)	O
.	O
This	O
study	B-MED
aimed	B-MED
to	O
evaluate	B-MED
the	O
effectiveness	B-MED
of	O
breast	B-MED
MR	I-MED
imaging	I-MED
in	O
detecting	B-MED
remnant	B-MED
LCIS	B-MED
lesions	B-MED
after	B-MED
initial	B-MED
excision	B-MED
.	O
Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	B-MED
with	O
LCIS	B-MED
who	O
underwent	B-MED
initial	B-MED
excision	B-MED
were	O
enrolled	O
.	O
Breast	B-MED
ultrasonography	I-MED
and	O
breast	B-MED
MR	I-MED
imaging	I-MED
was	O
conducted	O
after	B-MED
initial	B-MED
excision	B-MED
.	O
Imaging	B-MED
findings	I-MED
were	O
compared	B-MED
with	O
pathologic	B-MED
results	B-MED
.	O
There	O
were	O
nine	O
(	O
31.0	O
%	O
)	O
cases	B-MED
with	O
positive	B-MED
margins	I-MED
after	B-MED
initial	B-MED
excision	B-MED
;	O
they	O
were	O
LCIS	B-MED
(	O
n=8	O
)	O
and	O
atypical	B-MED
lobular	I-MED
hyperplasia	I-MED
(	O
n=1	O
)	O
.	O
Residual	B-MED
lesions	B-MED
were	O
identified	B-MED
in	O
12	O
cases	B-MED
;	O
they	O
were	O
invasive	B-MED
lobular	I-MED
carcinoma	I-MED
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
LCIS	B-MED
(	O
n=9	O
;	O
31.0	O
%	O
)	O
,	O
atypical	B-MED
lobular	I-MED
hyperplasia	I-MED
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
and	O
papillary	B-MED
carcinoma	I-MED
in	I-MED
situ	I-MED
(	O
n=1	O
;	O
3.4	O
%	O
)	O
.	O
Prior	B-MED
to	O
the	O
second	B-MED
operation	B-MED
,	O
these	O
lesions	B-MED
could	O
be	O
detected	O
in	O
seven	O
cases	B-MED
using	O
ultrasonography	B-MED
(	O
sensitivity	B-MED
,	O
53.3	O
%	O
;	O
specificity	B-MED
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	B-MED
using	O
breast	B-MED
MR	I-MED
imaging	I-MED
(	O
sensitivity	B-MED
,	O
83.3	O
%	O
;	O
specificity	B-MED
,	O
100	O
%	O
)	O
.	O
Breast	B-MED
MR	I-MED
imaging	I-MED
showed	O
higher	B-MED
sensitivity	B-MED
than	O
breast	B-MED
ultrasonography	I-MED
in	O
detecting	B-MED
remnant	B-MED
LCIS	B-MED
lesions	B-MED
.	O
If	O
a	O
suspicious	B-MED
lesion	B-MED
was	O
found	O
using	O
breast	B-MED
MR	I-MED
imaging	I-MED
,	O
a	O
second	B-MED
operation	B-MED
should	O
be	O
considered	B-MED
because	O
of	O
the	O
possibility	B-MED
of	O
multifocality	B-MED
,	O
even	O
if	O
LCIS	B-MED
was	O
confirmed	B-MED
at	O
the	O
initial	B-MED
operation	B-MED
.	O
Efficacy	B-MED
of	O
Synbiotics	B-MED
for	O
Treatment	B-MED
of	O
Bacillary	B-MED
Dysentery	I-MED
in	O
Children	B-MED
:	O
A	O
Double	B-MED
-	I-MED
Blind	I-MED
,	O
Randomized	B-MED
,	O
Placebo	B-MED
-	I-MED
Controlled	I-MED
Study	I-MED
Bacillary	B-MED
dysentery	I-MED
is	O
a	O
major	O
cause	O
of	O
children	B-MED
's	I-MED
admission	B-MED
to	I-MED
hospitals	I-MED
.	O
To	O
assess	B-MED
the	O
probiotic	B-MED
and	O
prebiotic	B-MED
(	O
synbiotics	B-MED
)	O
effects	B-MED
in	O
children	B-MED
with	O
dysentery	B-MED
in	O
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
,	O
200	O
children	B-MED
with	O
dysentery	B-MED
were	O
studied	O
in	O
2	O
groups	B-MED
:	O
the	O
synbiotic	B-MED
group	B-MED
received	O
1	O
tablet	B-MED
/day	B-MED
of	O
synbiotic	B-MED
for	O
3	O
-	O
5	O
days	B-MED
and	O
the	O
placebo	B-MED
group	B-MED
received	O
placebo	B-MED
tablets	B-MED
(	O
identical	O
tablet	B-MED
form	O
like	O
probiotics	B-MED
)	O
.	O
The	O
standard	B-MED
treatment	B-MED
was	O
administered	B-MED
for	O
all	O
patients	B-MED
.	O
Duration	B-MED
of	O
hospitalization	B-MED
,	O
dysentery	B-MED
,	O
fever	B-MED
,	O
and	O
the	O
weight	B-MED
loss	I-MED
were	O
assessed	B-MED
in	O
each	O
group	B-MED
.	O
It	O
was	O
concluded	O
that	O
there	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
both	O
groups	B-MED
in	O
the	O
baseline	B-MED
characteristics	B-MED
.	O
The	O
mean	B-MED
duration	I-MED
of	O
dysentery	B-MED
reduced	B-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
mean	B-MED
duration	I-MED
of	O
fever	B-MED
has	O
been	O
significantly	O
reduced	B-MED
in	O
the	O
synbiotic	B-MED
group	B-MED
(	O
1.64	O
±	O
0.87	O
days	B-MED
)	O
in	O
comparison	B-MED
to	O
the	O
placebo	B-MED
group	B-MED
(	O
2.13	O
±	O
0.94	O
days	B-MED
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Average	B-MED
amount	I-MED
of	O
weight	B-MED
loss	I-MED
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	B-MED
group	B-MED
in	O
comparison	B-MED
to	O
that	O
in	O
the	O
placebo	B-MED
group	B-MED
(	O
129.5	O
±	O
23.388	O
grams	O
and	O
278	O
±	O
28.385	O
grams	O
,	O
resp	O
.	O
;	O
P	O
<	O
0.001	O
)	O
.	O
There	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
the	O
mean	B-MED
duration	I-MED
of	O
hospitalization	B-MED
in	O
both	O
groups	B-MED
(	O
P	O
>	O
0.05	O
)	O
.	O
The	O
use	O
of	O
synbiotics	B-MED
as	O
an	O
adjuvant	B-MED
therapy	I-MED
to	O
the	O
standard	B-MED
treatment	B-MED
of	O
dysentery	B-MED
significantly	O
reduces	B-MED
the	O
duration	B-MED
of	O
dysentery	B-MED
,	O
fever	B-MED
,	O
and	O
rate	B-MED
of	I-MED
weight	I-MED
losses	I-MED
.	O
The	O
trial	B-MED
is	O
registered	B-MED
with	O
IRCT201109267647N1	O
.	O
Anti	B-MED
-	I-MED
inflammatory	I-MED
activity	B-MED
of	O
Elaeagnus	B-MED
angustifolia	I-MED
fruit	B-MED
extract	I-MED
on	O
rat	B-MED
paw	B-MED
edema	B-MED
The	O
Elaeagnus	B-MED
angustifolia	I-MED
fruit	B-MED
has	O
been	O
traditionally	O
used	O
in	O
Iranian	B-MED
herbal	B-MED
medicine	I-MED
to	O
treat	B-MED
diarrhea	B-MED
and	O
rheumatoid	B-MED
arthritis	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	B-MED
of	O
E.	B-MED
angustifolia	I-MED
fruit	B-MED
extract	I-MED
on	O
the	O
acute	B-MED
and	O
chronic	B-MED
phases	I-MED
of	O
formalin	B-MED
-	O
induced	B-MED
rat	B-MED
paw	B-MED
edema	B-MED
were	O
examined	B-MED
.	O
The	O
acute	B-MED
and	O
chronic	B-MED
anti	B-MED
-	I-MED
inflammatory	I-MED
effects	I-MED
of	O
E.	B-MED
angustifolia	I-MED
fruit	B-MED
extract	I-MED
were	O
investigated	B-MED
through	O
the	O
subcutaneous	B-MED
injection	I-MED
of	O
100	O
μL	O
of	O
formalin	B-MED
(	O
2.5	O
%	O
)	O
into	O
a	O
rat	B-MED
's	I-MED
hind	O
paw	B-MED
.	O
Thirty	B-MED
minutes	I-MED
before	O
the	O
procedure	B-MED
,	O
the	O
experimental	B-MED
groups	B-MED
were	O
treated	B-MED
intraperitoneally	B-MED
with	O
hydroalcoholic	B-MED
fruit	I-MED
extracts	I-MED
of	O
E.	B-MED
angustifolia	I-MED
(	O
concentrations	B-MED
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg	O
/	O
kg	O
)	O
;	O
sodium	B-MED
salicylate	I-MED
(	O
SS	B-MED
,	O
400	O
mg	O
/	O
kg	O
)	O
and	O
distilled	B-MED
water	I-MED
were	O
used	O
as	O
positive	B-MED
and	O
negative	B-MED
control	B-MED
groups	I-MED
,	O
respectively	O
.	O
Treatment	B-MED
with	O
SS	B-MED
and	O
the	O
fruit	B-MED
extracts	I-MED
were	O
performed	B-MED
daily	B-MED
for	O
8	O
days	B-MED
,	O
and	O
the	O
degree	B-MED
of	O
edema	B-MED
was	O
measured	B-MED
by	O
using	O
mercury	B-MED
plethysmometer	I-MED
and	O
digital	B-MED
caliper	I-MED
.	O
In	O
the	O
acute	B-MED
anti	B-MED
-	I-MED
inflammatory	I-MED
study	B-MED
,	O
the	O
extract	B-MED
showed	O
a	O
significant	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effect	I-MED
in	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
.	O
The	O
results	B-MED
of	O
1000	O
mg	O
/	O
kg	O
of	O
the	O
extract	B-MED
was	O
significantly	O
different	B-MED
compared	B-MED
with	I-MED
the	O
negative	B-MED
control	B-MED
group	I-MED
(	O
p<0.05	O
)	O
and	O
was	O
comparable	O
to	O
sodium	B-MED
salicylate	I-MED
(	O
p<0.05	O
)	O
.	O
Results	B-MED
from	O
the	O
chronic	B-MED
study	B-MED
suggested	B-MED
that	O
E.	B-MED
angustifolia	I-MED
extract	B-MED
significantly	O
reduced	B-MED
paw	B-MED
edema	B-MED
and	O
inflammation	B-MED
in	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
.	O
The	O
results	B-MED
also	O
showed	O
that	O
the	O
measurement	B-MED
by	O
digital	B-MED
caliper	I-MED
and	O
mercury	B-MED
plethysmometer	I-MED
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
(	O
p<0.01	O
)	O
.	O
Phytochemical	B-MED
tests	I-MED
indicated	O
that	O
the	O
hydroalcoholic	B-MED
fruit	I-MED
extract	I-MED
of	O
E.	B-MED
angustifolia	I-MED
was	O
positive	B-MED
for	O
cardiac	B-MED
glycosides	I-MED
,	O
flavonoids	B-MED
,	O
terpenoids	B-MED
,	O
and	O
saponins	B-MED
.	O
Based	O
on	O
our	O
findings	B-MED
,	O
the	O
E.	B-MED
angustifolia	I-MED
fruit	B-MED
extract	I-MED
probably	O
has	O
acute	B-MED
and	O
chronic	B-MED
anti	B-MED
-	I-MED
inflammatory	I-MED
activities	B-MED
to	O
support	O
its	O
applications	O
in	O
folk	B-MED
medicine	I-MED
.	O
'	O
Yarn	B-MED
with	O
me	O
'	O
:	O
applying	O
clinical	B-MED
yarning	I-MED
to	O
improve	O
clinician	B-MED
-	O
patient	B-MED
communication	B-MED
in	O
Aboriginal	B-MED
health	B-MED
care	I-MED
Although	O
successful	O
communication	B-MED
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	B-MED
consultation	I-MED
,	O
communication	B-MED
between	O
Aboriginal	B-MED
patients	B-MED
and	O
practitioners	B-MED
such	O
as	O
doctors	B-MED
,	O
nurses	B-MED
and	O
allied	B-MED
health	I-MED
professionals	I-MED
,	O
continues	O
to	O
be	O
problematic	B-MED
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	B-MED
care	I-MED
to	O
Aboriginal	B-MED
people	I-MED
.	O
This	O
paper	O
presents	O
an	O
overarching	B-MED
framework	I-MED
for	O
practitioners	B-MED
to	O
help	O
them	O
reorientate	O
their	O
communication	B-MED
with	O
Aboriginal	B-MED
patients	B-MED
using	O
'	O
clinical	B-MED
yarning	I-MED
'	O
.	O
Clinical	B-MED
yarning	I-MED
is	O
a	O
patient	B-MED
-centred	O
approach	O
that	O
marries	O
Aboriginal	B-MED
cultural	B-MED
communication	I-MED
preferences	O
with	O
biomedical	B-MED
understandings	O
of	O
health	B-MED
and	I-MED
disease	I-MED
.	O
Clinical	B-MED
yarning	I-MED
consists	O
of	O
three	O
interrelated	O
areas	O
:	O
the	O
social	B-MED
yarn	B-MED
,	O
in	O
which	O
the	O
practitioner	B-MED
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	B-MED
relationship	I-MED
;	O
the	O
diagnostic	B-MED
yarn	B-MED
,	O
in	O
which	O
the	O
practitioner	B-MED
facilitates	O
the	O
patient	B-MED
's	I-MED
health	B-MED
story	I-MED
while	O
interpreting	O
it	O
through	O
a	O
biomedical	B-MED
or	O
scientific	B-MED
lens	I-MED
;	O
and	O
the	O
management	O
yarn	B-MED
,	O
that	O
employs	B-MED
stories	I-MED
and	O
metaphors	B-MED
as	O
tools	O
for	O
patients	B-MED
to	O
help	O
them	O
understand	O
a	O
health	B-MED
issue	I-MED
so	O
a	O
collaborative	B-MED
management	I-MED
approach	I-MED
can	O
be	O
adopted	O
.	O
There	O
is	O
cultural	B-MED
and	O
research	B-MED
evidence	B-MED
that	O
supports	O
this	O
approach	O
.	O
Clinical	B-MED
yarning	I-MED
has	O
the	O
potential	O
to	O
improve	O
outcomes	B-MED
for	O
patients	B-MED
and	O
practitioners	B-MED
.	O
Computational	B-MED
analysis	I-MED
of	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
in	O
the	O
mitochondrial	B-MED
genomic	I-MED
sequences	I-MED
of	O
dermatophytes	B-MED
Dermatophyte	B-MED
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	B-MED
that	O
have	O
the	O
capacity	O
to	O
invade	B-MED
keratinized	B-MED
tissue	B-MED
of	O
humans	B-MED
and	O
other	O
animals	B-MED
.	O
The	O
infection	B-MED
known	O
as	O
dermatophytosis	B-MED
,	O
caused	O
by	O
members	O
of	O
the	O
genera	B-MED
Microsporum	B-MED
,	O
Trichophyton	B-MED
,	O
and	O
Epidermophyton	B-MED
includes	O
infection	B-MED
to	O
the	O
groin	B-MED
(	O
tinea	B-MED
cruris	I-MED
)	O
,	O
beard	B-MED
(	O
tinea	B-MED
barbae	I-MED
)	O
,	O
scalp	B-MED
(	O
tinea	B-MED
capitis	I-MED
)	O
,	O
feet	B-MED
(	O
tinea	B-MED
pedis	I-MED
)	O
,	O
glabrous	B-MED
skin	I-MED
(	O
tinea	B-MED
corporis	I-MED
)	O
,	O
nail	B-MED
(	O
tinea	B-MED
unguium	I-MED
)	O
,	O
and	O
hand	B-MED
(	O
tinea	B-MED
manuum	I-MED
)	O
.	O
The	O
identification	O
of	O
evolutionary	B-MED
relationship	B-MED
between	O
these	O
three	B-MED
genera	I-MED
of	O
dermatophyte	B-MED
is	O
epidemiologically	B-MED
important	I-MED
to	O
understand	O
their	O
pathogenicity	B-MED
.	O
Mitochondrial	B-MED
DNA	I-MED
evolves	B-MED
more	B-MED
rapidly	I-MED
than	O
a	O
nuclear	B-MED
DNA	I-MED
due	O
to	O
higher	O
rate	B-MED
of	I-MED
mutation	I-MED
but	O
is	O
very	O
less	B-MED
affected	I-MED
by	O
genetic	B-MED
recombination	I-MED
,	O
making	O
it	O
an	O
important	B-MED
tool	I-MED
for	O
phylogenetic	B-MED
studies	I-MED
.	O
Thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
of	O
Trichophyton	B-MED
rubrum	I-MED
,	O
Trichophyton	B-MED
mentagrophytes	I-MED
,	O
Epidermophyton	B-MED
floccosum	I-MED
and	O
Microsporum	B-MED
canis	I-MED
.	O
Protein	B-MED
coding	I-MED
sequences	I-MED
of	O
the	O
mitochondrial	B-MED
genome	I-MED
were	O
aligned	O
for	O
their	O
similar	B-MED
sequences	I-MED
and	O
homology	B-MED
modelling	I-MED
was	O
performed	O
for	O
structure	B-MED
and	O
pocket	B-MED
identification	B-MED
.	O
The	O
results	O
obtained	O
from	O
comparative	B-MED
analysis	I-MED
of	O
the	O
protein	B-MED
sequences	I-MED
revealed	O
the	O
presence	O
of	O
functionally	O
active	B-MED
sites	I-MED
in	O
all	O
the	O
species	O
of	O
the	O
genera	B-MED
Trichophyton	B-MED
and	O
Microsporum	B-MED
.	O
However	O
in	O
Epidermophyton	B-MED
floccosum	I-MED
it	O
was	O
observed	O
in	O
three	O
protein	B-MED
sequences	I-MED
of	O
the	O
five	O
studied	O
.	O
The	O
absence	O
of	O
these	O
conserved	B-MED
coil	I-MED
functional	B-MED
residues	I-MED
in	O
E.	B-MED
floccusum	I-MED
may	O
be	O
correlated	O
with	O
lesser	B-MED
infectivity	I-MED
of	O
this	O
organism	B-MED
.	O
The	O
functional	B-MED
residues	I-MED
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-MED
and	O
thus	O
can	O
act	O
as	O
putative	B-MED
target	I-MED
sites	I-MED
for	O
drug	B-MED
designing	I-MED
.	O
Amphetamine	B-MED
Withdrawal	I-MED
Differentially	O
Increases	O
the	O
Expression	B-MED
of	O
Organic	B-MED
Cation	I-MED
Transporter	I-MED
3	I-MED
and	O
Serotonin	B-MED
Transporter	I-MED
in	O
Limbic	B-MED
Brain	B-MED
Regions	I-MED
Amphetamine	B-MED
withdrawal	I-MED
increases	O
anxiety	B-MED
and	O
stress	B-MED
sensitivity	O
related	O
to	O
blunted	B-MED
ventral	B-MED
hippocampus	B-MED
(	O
vHipp	B-MED
)	O
and	O
enhances	O
the	O
central	B-MED
nucleus	I-MED
of	I-MED
the	I-MED
amygdala	I-MED
(	O
CeA	B-MED
)	O
serotonin	B-MED
responses	B-MED
.	O
Extracellular	B-MED
serotonin	B-MED
levels	B-MED
are	O
regulated	O
by	O
the	O
serotonin	B-MED
transporter	I-MED
(	O
SERT	B-MED
)	O
and	O
organic	B-MED
cation	I-MED
transporter	I-MED
3	I-MED
(	O
OCT3	B-MED
)	O
,	O
and	O
vHipp	B-MED
OCT3	B-MED
expression	B-MED
is	O
enhanced	O
during	O
24	B-MED
hours	I-MED
of	O
amphetamine	B-MED
withdrawal	I-MED
,	O
while	O
SERT	B-MED
expression	B-MED
is	O
unaltered	O
.	O
Here	O
,	O
we	O
tested	O
whether	O
OCT3	B-MED
and	O
SERT	B-MED
expression	B-MED
in	O
the	O
CeA	B-MED
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-MED
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-MED
serotonergic	B-MED
neurotransmission	I-MED
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	B-MED
weeks	I-MED
of	O
withdrawal	B-MED
.	O
We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-MED
expression	B-MED
were	O
confined	O
to	O
these	O
regions	O
.	O
Male	B-MED
rats	B-MED
received	O
amphetamine	B-MED
or	O
saline	B-MED
for	O
two	B-MED
weeks	I-MED
followed	O
by	O
24	B-MED
hours	I-MED
or	O
two	B-MED
weeks	I-MED
of	O
withdrawal	B-MED
,	O
with	O
transporter	B-MED
expression	B-MED
measured	O
using	O
Western	B-MED
immunoblot	I-MED
.	O
OCT3	B-MED
and	O
SERT	B-MED
expression	B-MED
increased	O
in	O
the	O
CeA	B-MED
at	O
both	O
withdrawal	B-MED
timepoints	O
.	O
In	O
the	O
vHipp	B-MED
,	O
OCT3	B-MED
expression	B-MED
increased	O
only	O
at	O
24	B-MED
hours	I-MED
of	O
withdrawal	B-MED
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-MED
hypothalamus	I-MED
.	O
No	B-MED
changes	I-MED
were	O
evident	O
in	O
any	O
other	O
regions	B-MED
sampled	O
.	O
These	O
regionally	O
specific	O
changes	O
in	O
limbic	B-MED
OCT3	B-MED
and	O
SERT	B-MED
expression	B-MED
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-MED
imbalance	B-MED
and	O
negative	B-MED
affect	I-MED
during	O
amphetamine	B-MED
withdrawal	I-MED
.	O
Palliative	B-MED
Care	I-MED
with	O
Attachment	B-MED
Hybrid	B-MED
Removable	I-MED
Prosthesis	I-MED
Abutment	B-MED
injury	B-MED
,	O
unsatisfactory	B-MED
aesthetics	B-MED
and	O
lesser	O
retention	B-MED
exist	O
with	O
the	O
cast	B-MED
partial	I-MED
denture	I-MED
.	O
Though	O
these	O
constraints	O
exist	O
in	O
the	O
Removable	B-MED
Partial	I-MED
Denture	I-MED
(	O
RPD	B-MED
)	O
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-MED
,	O
fabrication	B-MED
,	O
economics	B-MED
and	O
patient	B-MED
comfort	I-MED
.	O
This	O
clinical	B-MED
report	I-MED
describes	O
a	O
hybrid	O
RPD	B-MED
technique	B-MED
which	O
uses	O
extra	O
coronal	B-MED
attachment	B-MED
that	O
reduces	B-MED
the	O
limitations	O
and	O
provides	O
better	O
comfort	B-MED
for	O
the	O
patient	B-MED
.	O
Liver	B-MED
Fatty	I-MED
Acid	I-MED
Binding	I-MED
Protein	I-MED
Deficiency	B-MED
Provokes	O
Oxidative	B-MED
Stress	I-MED
,	O
Inflammation	B-MED
,	O
and	O
Apoptosis	B-MED
-Mediated	O
Hepatotoxicity	B-MED
Induced	B-MED
by	O
Pyrazinamide	B-MED
in	O
Zebrafish	B-MED
Larvae	B-MED
Pyrazinamide	B-MED
(	O
PZA	B-MED
)	O
is	O
an	O
essential	B-MED
antitubercular	B-MED
drug	I-MED
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	B-MED
potential	B-MED
.	O
This	O
study	O
examined	O
the	O
effects	B-MED
of	I-MED
PZA	B-MED
exposure	B-MED
on	O
zebrafish	B-MED
(	O
Danio	B-MED
rerio	I-MED
)	O
larvae	B-MED
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	B-MED
.	O
A	O
transgenic	B-MED
line	I-MED
of	O
zebrafish	B-MED
larvae	B-MED
that	O
expressed	B-MED
enhanced	B-MED
green	I-MED
fluorescent	I-MED
protein	I-MED
(	O
EGFP	B-MED
)	O
in	O
the	O
liver	B-MED
was	O
incubated	B-MED
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mM	O
PZA	B-MED
from	O
72	O
h	O
postfertilization	B-MED
(	O
hpf	O
)	O
.	O
Different	O
endpoints	B-MED
such	O
as	O
mortality	B-MED
,	O
morphology	B-MED
changes	B-MED
in	O
the	O
size	B-MED
and	O
shape	B-MED
of	O
the	O
liver	B-MED
,	O
histological	B-MED
changes	B-MED
,	O
transaminase	B-MED
analysis	I-MED
and	O
apoptosis	B-MED
,	O
markers	B-MED
of	O
oxidative	B-MED
and	O
genetic	B-MED
damage	I-MED
,	O
as	O
well	O
as	O
the	O
expression	B-MED
of	O
certain	O
genes	B-MED
were	O
selected	O
to	O
evaluate	B-MED
PZA	B-MED
-	O
induced	B-MED
hepatotoxicity	B-MED
.	O
Our	O
results	O
confirm	B-MED
the	O
manner	O
of	O
PZA	B-MED
dose	B-MED
-	I-MED
dependent	I-MED
hepatotoxicity	B-MED
.	O
PZA	B-MED
was	O
found	O
to	O
induce	B-MED
marked	B-MED
injury	B-MED
in	O
zebrafish	B-MED
larvae	B-MED
,	O
such	O
as	O
liver	B-MED
atrophy	I-MED
,	O
elevations	B-MED
of	I-MED
transaminase	I-MED
levels	I-MED
,	O
oxidative	B-MED
stress	I-MED
,	O
and	O
hepatocyte	B-MED
apoptosis	I-MED
.	O
To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	B-MED
-	O
induced	B-MED
hepatotoxicity	B-MED
,	O
changes	B-MED
in	O
gene	B-MED
expression	I-MED
levels	I-MED
in	O
zebrafish	B-MED
larvae	B-MED
exposed	B-MED
to	I-MED
PZA	B-MED
for	O
72	O
h	O
postexposure	B-MED
(	O
hpe	O
)	O
were	O
determined	O
.	O
The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	B-MED
decreased	B-MED
the	O
expression	B-MED
levels	I-MED
of	O
liver	B-MED
fatty	I-MED
acid	I-MED
binding	I-MED
protein	I-MED
(	O
L	B-MED
-	I-MED
FABP	I-MED
)	O
and	O
its	O
target	B-MED
gene	I-MED
,	O
peroxisome	B-MED
proliferator	I-MED
-	I-MED
activated	I-MED
receptor	I-MED
α	I-MED
(	O
PPAR	B-MED
-	I-MED
α	I-MED
)	O
,	O
and	O
provoked	O
more	O
severe	B-MED
oxidative	B-MED
stress	I-MED
and	O
hepatitis	B-MED
via	O
the	O
upregulation	B-MED
of	O
inflammatory	B-MED
cytokines	I-MED
such	O
as	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
alpha	I-MED
(	O
TNF	B-MED
-	I-MED
α	I-MED
)	O
and	O
transforming	B-MED
growth	I-MED
factor	I-MED
β	I-MED
(	O
TGF	B-MED
-	I-MED
β	I-MED
)	O
.	O
These	O
findings	O
suggest	O
that	O
L	B-MED
-	I-MED
FABP	I-MED
-mediated	O
PPAR	B-MED
-	I-MED
α	I-MED
downregulation	B-MED
appears	O
to	O
be	O
a	O
hepatotoxic	B-MED
response	I-MED
resulting	O
from	O
zebrafish	B-MED
larva	B-MED
liver	B-MED
cell	I-MED
apoptosis	B-MED
,	O
and	O
L	B-MED
-	I-MED
FABP	I-MED
can	O
be	O
used	O
as	O
a	O
biomarker	B-MED
for	O
the	O
early	B-MED
detection	I-MED
of	O
PZA	B-MED
-	O
induced	B-MED
liver	B-MED
damage	I-MED
in	O
zebrafish	B-MED
larvae	B-MED
.	O
Viral	B-MED
Vector	I-MED
Biosafety	B-MED
in	O
Laboratory	B-MED
Animal	I-MED
Research	I-MED
Viral	B-MED
vector	I-MED
research	B-MED
presents	B-MED
unique	B-MED
occupational	B-MED
health	I-MED
and	O
safety	B-MED
challenges	B-MED
to	O
institutions	B-MED
due	O
to	O
the	O
rapid	B-MED
development	B-MED
ofboth	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
gene	B-MED
-	I-MED
editing	I-MED
technologies	I-MED
.	O
Risks	B-MED
to	O
human	B-MED
and	O
animal	B-MED
health	B-MED
make	O
it	O
incumbent	B-MED
on	O
institutions	B-MED
to	O
appropriately	B-MED
evaluate	B-MED
viral	B-MED
vector	I-MED
usage	B-MED
in	O
research	B-MED
on	O
the	O
basis	B-MED
of	O
available	B-MED
information	B-MED
and	O
governmental	B-MED
regulations	I-MED
and	O
guidelines	B-MED
.Here	O
we	O
review	B-MED
the	O
factors	B-MED
related	O
to	O
risk	B-MED
assessment	I-MED
regarding	O
viral	B-MED
vector	I-MED
usage	B-MED
in	O
animals	B-MED
and	O
the	O
relevant	B-MED
regulatory	B-MED
documents	I-MED
associated	B-MED
with	I-MED
this	O
research	B-MED
,	O
and	O
we	O
highlight	O
the	O
most	B-MED
commonly	B-MED
used	O
viral	B-MED
vectors	I-MED
in	O
research	B-MED
today	O
.	O
This	O
review	B-MED
is	O
particularly	B-MED
focused	B-MED
on	O
the	O
background	B-MED
,	O
use	O
in	O
research	B-MED
and	O
associated	B-MED
health	B-MED
and	O
environmental	B-MED
risks	I-MED
related	B-MED
to	O
adenoviral	B-MED
,	O
adeno	B-MED
-	I-MED
associated	I-MED
viral	I-MED
,	O
lentiviral	B-MED
,	O
and	O
herpesviral	B-MED
vectors	B-MED
.	O
Hand	B-MED
-	I-MED
Assisted	I-MED
Laparoscopic	I-MED
Versus	O
Standard	B-MED
Laparoscopic	I-MED
Colectomy	I-MED
:	O
Are	O
Outcomes	B-MED
and	O
Operative	B-MED
Time	I-MED
Different	O
?	O
HAL	B-MED
colectomy	B-MED
is	O
a	O
technique	B-MED
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-MED
surgery	I-MED
while	O
improving	O
tactile	O
feedback	O
and	O
operative	B-MED
time	I-MED
.	O
Published	O
data	B-MED
are	O
largely	O
limited	O
to	O
small	O
,	O
single	B-MED
-	I-MED
institution	I-MED
studies	I-MED
.	O
The	O
2012	O
-	O
2013	O
National	B-MED
Surgical	I-MED
Quality	I-MED
Improvement	I-MED
Program	I-MED
Participant	I-MED
Data	I-MED
Use	I-MED
File	I-MED
was	O
queried	O
for	O
patients	B-MED
undergoing	O
elective	O
SL	B-MED
or	O
HAL	B-MED
colectomy	B-MED
.	O
Patients	B-MED
underwent	O
1:1	O
propensity	O
matching	O
and	O
had	O
outcomes	B-MED
compared	O
.	O
An	O
additional	O
subgroup	B-MED
analysis	I-MED
was	O
performed	O
for	O
patients	B-MED
undergoing	O
segmental	B-MED
resections	B-MED
only	O
.	O
13,949	O
patients	B-MED
were	O
identified	O
,	O
of	O
whom	O
6084	O
(	O
43.6	O
%	O
)	O
underwent	O
HAL	B-MED
colectomy	B-MED
.	O
Patients	B-MED
undergoing	O
HAL	B-MED
versus	O
SL	B-MED
colectomy	I-MED
had	O
higher	O
rates	B-MED
of	O
postoperative	B-MED
ileus	I-MED
(	O
8.7	O
vs.	O
6.3	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
wound	B-MED
complication	I-MED
(	O
8.8	O
vs.	O
6.8	O
%	O
,	O
p	O
=	O
0.006	O
)	O
,	O
and	O
30-	O
day	B-MED
readmission	B-MED
(	O
7.5	O
vs.	O
6.0	O
%	O
,	O
p	O
=	O
0.002	O
)	O
,	O
without	O
any	O
differences	O
in	O
operative	B-MED
time	I-MED
(	O
156	O
vs.	O
157	O
min	O
,	O
p	O
=	O
0.713	O
)	O
.	O
Amongst	O
segmental	B-MED
colectomies	B-MED
,	O
HAL	B-MED
remained	O
associated	O
with	O
higher	O
rates	B-MED
of	O
wound	B-MED
complications	I-MED
(	O
8.6	O
vs.	O
6.5	O
%	O
,	O
p	O
=	O
0.016	O
)	O
,	O
postoperative	B-MED
ileus	I-MED
(	O
8.9	O
vs.	O
6.3	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
30-	O
day	B-MED
readmission	B-MED
(	O
7.1	O
vs.	O
5.9	O
%	O
,	O
p	O
=	O
0.041	O
)	O
with	O
no	O
difference	O
in	O
operative	B-MED
time	I-MED
between	O
HAL	B-MED
and	O
SL	O
(	O
145	O
vs.	O
145	O
min	O
,	O
p	O
=	O
0.334	O
)	O
.	O
Use	O
of	O
HAL	B-MED
colectomy	B-MED
is	O
associated	O
with	O
increased	O
risk	B-MED
of	O
wound	B-MED
complications	I-MED
,	O
postoperative	B-MED
ileus	I-MED
,	O
and	O
readmissions	B-MED
.	O
Importantly	O
,	O
this	O
technique	B-MED
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	B-MED
time	I-MED
.	O
Survey	B-MED
of	O
Trichinella	B-MED
infection	I-MED
from	O
domestic	B-MED
pigs	I-MED
in	O
the	O
historical	B-MED
endemic	B-MED
areas	I-MED
of	O
Henan	B-MED
province	I-MED
,	O
central	B-MED
China	I-MED
The	O
aim	B-MED
of	O
this	O
work	B-MED
was	O
to	O
investigate	B-MED
the	O
current	B-MED
situation	I-MED
of	O
Trichinella	B-MED
infection	I-MED
from	O
domestic	B-MED
pigs	I-MED
in	O
the	O
historical	B-MED
endemic	B-MED
areas	I-MED
of	O
Henan	B-MED
province	I-MED
,	O
central	B-MED
China	I-MED
.	O
A	O
total	O
of	O
823	O
diaphragm	B-MED
samples	I-MED
from	O
the	O
indoor	B-MED
-	I-MED
raised	I-MED
pigs	I-MED
were	O
collected	B-MED
in	O
five	B-MED
cities	B-MED
of	O
Henan	B-MED
during	O
2014	O
-	O
2015	O
and	O
examined	B-MED
by	O
artificial	B-MED
digestion	I-MED
method	I-MED
.	O
The	O
overall	B-MED
prevalence	I-MED
of	O
Trichinella	B-MED
infection	I-MED
in	O
pigs	B-MED
was	O
0.61	O
%	O
(	O
5/823	O
)	O
.	O
Trichinella	B-MED
larvae	I-MED
were	O
detected	B-MED
in	O
0.91	O
%	O
(	O
5/550	O
)	O
of	O
pigs	B-MED
from	O
Nanyang	B-MED
city	I-MED
of	O
Henan	B-MED
.	O
The	O
larval	B-MED
burden	B-MED
in	O
infected	B-MED
animals	I-MED
was	O
0.03	O
larvae	B-MED
per	O
gram	O
(	O
lpg	O
)	O
of	O
muscles	B-MED
with	O
a	O
range	B-MED
from	O
0.02	O
to	O
0.05	O
lpg	O
.	O
The	O
larvae	B-MED
were	O
identified	B-MED
as	O
Trichinella	B-MED
spiralis	I-MED
by	O
multiple	B-MED
PCR	I-MED
.	O
Our	O
study	B-MED
confirms	B-MED
the	O
existence	B-MED
of	O
swine	B-MED
trichinellosis	B-MED
in	O
Henan	B-MED
,	O
but	O
the	O
infection	B-MED
level	B-MED
was	O
under	O
the	O
minimum	B-MED
level	I-MED
for	O
defining	O
infectious	B-MED
sources	I-MED
for	O
humans	B-MED
.	O
However	O
,	O
the	O
prevalence	B-MED
of	O
swine	B-MED
Trichinella	B-MED
infection	I-MED
in	O
Henan	B-MED
need	O
to	O
be	O
further	O
evaluated	B-MED
with	O
a	O
large	B-MED
scale	I-MED
of	O
pork	B-MED
samples	I-MED
for	O
ensuring	O
meat	B-MED
food	B-MED
safety	I-MED
.	O
Beyond	O
"	O
Median	B-MED
Waiting	B-MED
Time	I-MED
"	O
:	O
Development	B-MED
and	O
Validation	B-MED
of	O
a	O
Competing	O
Risk	B-MED
Model	I-MED
to	O
Predict	B-MED
Outcomes	B-MED
on	O
the	O
Kidney	B-MED
Transplant	B-MED
Waiting	I-MED
List	I-MED
Median	B-MED
historical	B-MED
time	B-MED
to	O
kidney	B-MED
transplant	I-MED
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	B-MED
of	O
death	B-MED
or	O
removal	B-MED
from	I-MED
the	I-MED
waiting	I-MED
list	I-MED
.	O
We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	B-MED
model	I-MED
to	O
calculate	B-MED
likelihood	O
of	O
outcomes	B-MED
for	O
kidney	B-MED
transplant	I-MED
candidates	B-MED
and	O
demonstrate	O
how	O
this	O
information	B-MED
differs	B-MED
from	O
median	B-MED
time	B-MED
to	O
transplant	B-MED
.	O
Data	B-MED
were	O
obtained	B-MED
from	O
the	O
US	B-MED
Scientific	I-MED
Registry	I-MED
of	O
Transplant	B-MED
Recipients	I-MED
.	O
The	O
retrospective	B-MED
cohort	I-MED
included	O
163	O
636	O
adults	B-MED
listed	O
for	O
kidney	B-MED
transplant	I-MED
before	O
December	O
31	O
,	O
2011	O
.	O
Predictors	B-MED
were	O
age	B-MED
,	O
sex	B-MED
,	O
blood	B-MED
type	I-MED
,	O
calculated	B-MED
panel	B-MED
-	I-MED
reactive	I-MED
antibodies	I-MED
,	O
donation	B-MED
service	B-MED
area	I-MED
,	O
dialysis	B-MED
duration	B-MED
,	O
comorbid	B-MED
conditions	I-MED
,	O
and	O
body	B-MED
mass	I-MED
index	I-MED
.	O
Outcomes	B-MED
were	O
deceased	O
or	O
living	B-MED
donor	I-MED
transplant	B-MED
,	O
death	B-MED
or	O
removal	B-MED
from	I-MED
the	I-MED
list	I-MED
due	B-MED
to	I-MED
deteriorating	B-MED
medical	B-MED
condition	B-MED
,	O
or	O
removal	B-MED
due	B-MED
to	I-MED
other	B-MED
reasons	I-MED
.	O
We	O
calculated	B-MED
hazards	B-MED
for	O
the	O
possible	B-MED
outcomes	B-MED
,	O
then	O
the	O
cumulative	B-MED
incidence	B-MED
function	B-MED
for	O
a	O
given	O
candidate	B-MED
using	O
competing	O
risk	B-MED
methodology	B-MED
.	O
Discrimination	B-MED
and	O
calibration	B-MED
were	O
assessed	B-MED
through	B-MED
C	B-MED
statistics	I-MED
and	O
calibration	B-MED
plots	B-MED
for	O
each	B-MED
cause	B-MED
-	O
specific	B-MED
Cox	B-MED
proportional	I-MED
hazard	I-MED
model	I-MED
.	O
C	B-MED
statistics	I-MED
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O
Calibration	B-MED
plots	B-MED
showed	O
good	B-MED
calibration	B-MED
.	O
The	O
competing	O
risk	B-MED
model	I-MED
shows	O
probability	B-MED
of	O
all	O
possible	B-MED
outcomes	B-MED
for	O
up	O
to	O
12	B-MED
years	I-MED
given	O
a	O
candidate	B-MED
's	I-MED
characteristics	B-MED
,	O
contrasted	O
with	O
the	O
median	B-MED
waiting	B-MED
time	I-MED
for	O
that	O
candidate	B-MED
's	I-MED
donation	B-MED
service	B-MED
area	I-MED
.	O
A	O
competing	O
risk	B-MED
model	I-MED
conveys	O
more	O
relevant	B-MED
information	B-MED
than	O
the	O
median	B-MED
waiting	B-MED
time	I-MED
for	O
a	O
given	B-MED
transplant	B-MED
center	I-MED
.	O
This	O
model	B-MED
will	O
be	O
updated	B-MED
to	O
create	B-MED
a	O
calculator	O
reflecting	O
the	O
most	O
recent	B-MED
outcomes	B-MED
and	O
changes	B-MED
in	O
allocation	B-MED
policy	B-MED
.	O
It	O
illustrates	O
the	O
conversations	B-MED
that	O
should	O
be	O
initiated	B-MED
with	O
transplant	B-MED
candidates	B-MED
.	O
Nucleic	B-MED
acid	I-MED
detection	I-MED
with	O
CRISPR	B-MED
-	O
Cas13a	B-MED
/	O
C2c2	B-MED
Rapid	B-MED
,	O
inexpensive	O
,	O
and	O
sensitive	B-MED
nucleic	B-MED
acid	I-MED
detection	I-MED
may	O
aid	B-MED
point	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
pathogen	B-MED
detection	B-MED
,	O
genotyping	B-MED
,	O
and	O
disease	B-MED
monitoring	B-MED
.	O
The	O
RNA	B-MED
-guided	O
,	O
RNA	B-MED
-	O
targeting	B-MED
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeats	I-MED
(	O
CRISPR	B-MED
)	O
effector	B-MED
Cas13a	B-MED
(	O
previously	O
known	O
as	O
C2c2	B-MED
)	O
exhibits	O
a	O
"	O
collateral	B-MED
effect	B-MED
"	O
of	O
promiscuous	O
ribonuclease	B-MED
activity	I-MED
upon	O
target	B-MED
recognition	B-MED
.	O
We	O
combine	B-MED
the	O
collateral	B-MED
effect	B-MED
of	O
Cas13a	B-MED
with	O
isothermal	B-MED
amplification	I-MED
to	O
establish	B-MED
a	O
CRISPR	B-MED
-based	O
diagnostic	B-MED
(	O
CRISPR	B-MED
-	O
Dx	B-MED
)	O
,	O
providing	O
rapid	B-MED
DNA	B-MED
or	O
RNA	B-MED
detection	B-MED
with	O
attomolar	B-MED
sensitivity	I-MED
and	O
single	B-MED
-	I-MED
base	I-MED
mismatch	B-MED
specificity	B-MED
.	O
We	O
use	O
this	O
Cas13a	B-MED
-based	O
molecular	B-MED
detection	B-MED
platform	B-MED
,	O
termed	O
Specific	B-MED
High	I-MED
-	I-MED
Sensitivity	I-MED
Enzymatic	I-MED
Reporter	I-MED
UnLOCKing	I-MED
(	O
SHERLOCK	B-MED
)	O
,	O
to	O
detect	B-MED
specific	B-MED
strains	B-MED
of	O
Zika	B-MED
and	O
Dengue	B-MED
virus	I-MED
,	O
distinguish	O
pathogenic	B-MED
bacteria	B-MED
,	O
genotype	B-MED
human	B-MED
DNA	B-MED
,	O
and	O
identify	B-MED
mutations	B-MED
in	O
cell	B-MED
-	I-MED
free	I-MED
tumor	B-MED
DNA	I-MED
.	O
Furthermore	O
,	O
SHERLOCK	B-MED
reaction	B-MED
reagents	B-MED
can	O
be	O
lyophilized	B-MED
for	O
cold	B-MED
-	I-MED
chain	I-MED
independence	O
and	O
long	B-MED
-	I-MED
term	I-MED
storage	B-MED
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	B-MED
applications	I-MED
.	O
The	O
platelet	B-MED
-	I-MED
activating	I-MED
receptor	I-MED
C	B-MED
-	I-MED
type	I-MED
lectin	I-MED
receptor-2	I-MED
plays	O
an	O
essential	O
role	B-MED
in	O
liver	B-MED
regeneration	I-MED
after	O
partial	B-MED
hepatectomy	I-MED
in	O
mice	B-MED
Essentials	O
Regeneration	B-MED
role	B-MED
of	O
C	B-MED
-	I-MED
type	I-MED
lectin	I-MED
receptor-2	I-MED
(	O
CLEC-2	B-MED
)	O
after	O
70	B-MED
%	I-MED
hepatectomy	I-MED
(	O
HPx	B-MED
)	O
was	O
investigated	O
.	O
Wild	B-MED
-	I-MED
type	I-MED
or	O
CLEC-2	B-MED
deleted	B-MED
from	O
platelets	B-MED
of	O
chimeric	B-MED
mice	I-MED
(	O
flKO	B-MED
)	O
underwent	O
HPx	B-MED
.	O
The	O
liver	B-MED
/	I-MED
body	I-MED
weight	I-MED
ratio	I-MED
was	O
significantly	O
lower	O
in	O
the	O
flKO	B-MED
than	O
in	O
the	O
wild	B-MED
-	I-MED
type	I-MED
.	O
CLEC-2	B-MED
plays	O
an	O
essential	O
role	B-MED
in	O
liver	B-MED
regeneration	I-MED
after	O
HPx	B-MED
.	O
Background	O
and	O
aim	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	B-MED
of	O
C	B-MED
-	I-MED
type	I-MED
lectin	I-MED
receptor	I-MED
(	I-MED
CLEC)-2	I-MED
in	O
liver	B-MED
regeneration	I-MED
following	O
partial	B-MED
liver	I-MED
resection	I-MED
in	O
mice	B-MED
.	O
Materials	O
and	O
methods	O
Irradiated	O
chimeric	B-MED
mice	I-MED
transplanted	B-MED
with	O
fetal	B-MED
liver	B-MED
cells	I-MED
from	O
wild	B-MED
-	I-MED
type	I-MED
(	I-MED
WT	I-MED
)	I-MED
mice	I-MED
,	O
CLEC-2	B-MED
-	O
deleted	B-MED
(	O
KO	O
)	O
mice	B-MED
or	O
mice	B-MED
with	O
CLEC-2	B-MED
deleted	B-MED
specifically	O
from	O
platelets	B-MED
(	O
flKO	O
)	O
were	O
generated	B-MED
.	O
Mice	B-MED
underwent	O
70	B-MED
%	I-MED
partial	I-MED
hepatectomy	I-MED
(	O
PH	B-MED
)	O
.	O
Immunohistochemical	B-MED
staining	I-MED
was	O
performed	O
to	O
investigate	O
the	O
expression	B-MED
of	O
the	O
endogenous	B-MED
ligand	B-MED
for	O
CLEC-2	B-MED
,	O
podoplanin	B-MED
.	O
The	O
accumulation	B-MED
of	O
platelets	B-MED
in	O
the	O
liver	B-MED
was	O
also	O
quantified	B-MED
.	O
The	O
hepatic	B-MED
expression	B-MED
of	O
the	O
IL-6	B-MED
/	O
gp130	B-MED
and	O
STAT3	B-MED
,	O
Akt	B-MED
and	O
ERK1/2	B-MED
was	O
also	O
examined	O
.	O
Results	O
The	O
liver	B-MED
/	I-MED
body	I-MED
weight	I-MED
ratio	I-MED
and	O
expression	B-MED
of	O
all	O
cell	B-MED
proliferation	I-MED
markers	B-MED
were	O
significantly	O
lower	O
in	O
the	O
flKO	B-MED
group	I-MED
than	O
in	O
the	O
WT	B-MED
group	I-MED
.	O
The	O
expression	B-MED
of	O
phosphorylated	B-MED
(	I-MED
p	I-MED
)	I-MED
Akt	I-MED
and	O
pERK1	B-MED
/2	O
was	O
similar	O
in	O
the	O
WT	B-MED
and	O
flKO	B-MED
groups	I-MED
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
expression	B-MED
of	O
pSTAT3	B-MED
and	O
IL-6	B-MED
was	O
significantly	O
stronger	O
in	O
the	O
WT	B-MED
group	I-MED
than	O
in	O
the	O
flKO	B-MED
group	I-MED
.	O
The	O
expression	B-MED
of	O
podoplanin	B-MED
was	O
detected	O
in	O
the	O
hepatic	B-MED
sinusoids	I-MED
of	O
both	O
groups	B-MED
.	O
However	O
,	O
the	O
extent	O
to	O
which	O
platelets	B-MED
accumulated	O
in	O
hepatic	B-MED
sinusoids	I-MED
was	O
significantly	O
less	O
in	O
the	O
flKO	B-MED
group	I-MED
than	O
in	O
the	O
WT	B-MED
group	I-MED
.	O
Conclusion	O
CLEC-2	B-MED
was	O
involved	O
in	O
hepatic	B-MED
regeneration	I-MED
after	O
liver	B-MED
resection	I-MED
and	O
CLEC-2	B-MED
-related	O
liver	B-MED
regeneration	I-MED
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	B-MED
and	O
sinusoidal	B-MED
endothelial	B-MED
cells	I-MED
.	O
Neural	B-MED
correlates	B-MED
of	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
Traumatic	B-MED
memories	B-MED
such	O
as	O
intrusions	B-MED
and	O
flashbacks	B-MED
play	O
a	O
major	O
role	O
in	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
post	B-MED
-	I-MED
traumatic	I-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
.	O
A	O
thorough	O
understanding	O
of	O
the	O
neural	B-MED
mechanisms	B-MED
underlying	O
traumatic	B-MED
memories	B-MED
is	O
indispensable	O
for	O
precise	O
diagnosis	B-MED
,	O
for	O
personalized	B-MED
treatment	B-MED
and	O
prevention	B-MED
.	O
In	O
particular	O
,	O
the	O
identification	B-MED
of	O
early	O
neural	B-MED
predictor	B-MED
variables	I-MED
for	O
intrusion	B-MED
development	B-MED
shortly	O
after	O
trauma	B-MED
exposure	B-MED
requires	O
detailed	O
investigation	B-MED
.	O
Here	O
,	O
we	O
examined	B-MED
the	O
neural	B-MED
correlates	I-MED
of	O
early	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
in	O
a	O
traumatic	B-MED
film	I-MED
paradigm	I-MED
in	O
42	O
young	O
healthy	B-MED
females	B-MED
,	O
using	O
both	O
implicit	B-MED
and	O
explicit	B-MED
retrieval	B-MED
tasks	I-MED
.	O
We	O
show	O
that	O
implicit	B-MED
experimental	B-MED
trauma	B-MED
retrieval	B-MED
specifically	O
involved	O
the	O
retrosplenial	B-MED
cortex	I-MED
and	O
the	O
anterior	B-MED
cingulate	I-MED
cortex	I-MED
(	O
ACC	B-MED
)	O
,	O
while	O
both	O
retrieval	B-MED
tasks	I-MED
resulted	O
in	O
trauma	B-MED
-	I-MED
related	I-MED
activity	B-MED
in	O
the	O
posterior	B-MED
cingulate	I-MED
cortex	I-MED
(	O
PCC	B-MED
)	O
and	O
the	O
precuneus	B-MED
.	O
Importantly	O
,	O
neural	B-MED
activity	B-MED
early	O
after	O
experimental	B-MED
trauma	B-MED
exposure	B-MED
predicted	B-MED
later	O
intrusion	B-MED
development	B-MED
,	O
with	O
independent	B-MED
contributions	B-MED
from	O
activity	B-MED
in	O
the	O
retrosplenial	B-MED
cortex	I-MED
(	O
implicit	B-MED
retrieval	B-MED
)	O
and	O
the	O
PCC	B-MED
(	O
explicit	B-MED
retrieval	B-MED
)	O
.	O
Additional	B-MED
analyses	B-MED
revealed	B-MED
a	O
stronger	O
connectivity	B-MED
between	O
the	O
bilateral	B-MED
amygdala	I-MED
and	O
the	O
supplementary	B-MED
motor	I-MED
area	I-MED
,	O
precentral	B-MED
and	O
paracentral	B-MED
lobule	I-MED
for	O
the	O
control	B-MED
group	I-MED
compared	O
to	O
the	O
experimental	B-MED
trauma	B-MED
group	B-MED
.	O
Our	O
study	B-MED
gives	O
new	O
insights	O
in	O
the	O
neural	B-MED
correlates	B-MED
of	O
experimental	B-MED
trauma	B-MED
memory	B-MED
retrieval	I-MED
and	O
their	O
predictive	B-MED
value	I-MED
for	O
subsequent	B-MED
symptom	B-MED
development	B-MED
.	O
Our	O
results	B-MED
could	O
provide	O
the	O
basis	O
for	O
personalized	B-MED
early	B-MED
treatment	I-MED
and	O
prevention	B-MED
of	O
PTSD	B-MED
.	O
Hum	O
Brain	O
Mapp	O
,	O
2017	O
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
In	B-MED
Vitro	I-MED
Differentiation	B-MED
of	O
Human	B-MED
Pluripotent	B-MED
Stem	I-MED
Cells	I-MED
into	O
Trophoblastic	B-MED
Cells	I-MED
The	O
placenta	B-MED
is	O
the	O
first	O
organ	B-MED
to	O
develop	O
during	O
embryogenesis	B-MED
and	O
is	O
required	O
for	O
the	O
survival	B-MED
of	O
the	O
developing	O
embryo	B-MED
.	O
The	O
placenta	B-MED
is	O
comprised	O
of	O
various	O
trophoblastic	B-MED
cells	I-MED
that	O
differentiate	B-MED
from	O
the	O
extra	B-MED
-	I-MED
embryonic	I-MED
trophectoderm	I-MED
cells	I-MED
of	O
the	O
preimplantation	B-MED
blastocyst	B-MED
.	O
As	O
such	O
,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation	B-MED
events	I-MED
of	O
the	O
human	B-MED
placenta	B-MED
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-MED
and	O
manipulation	B-MED
of	O
human	B-MED
embryogenesis	B-MED
.	O
Human	B-MED
pluripotent	I-MED
stem	I-MED
cells	I-MED
(	O
hPSCs	B-MED
)	O
are	O
a	O
robust	O
model	B-MED
system	I-MED
for	O
investigating	O
human	B-MED
development	I-MED
and	O
can	O
also	O
be	O
differentiated	B-MED
in	B-MED
vitro	I-MED
into	O
trophoblastic	B-MED
cells	I-MED
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	B-MED
cell	B-MED
types	I-MED
.	O
Here	O
,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	B-MED
hPSCs	B-MED
into	O
trophoblastic	B-MED
cells	I-MED
using	O
bone	B-MED
morphogenic	I-MED
protein	I-MED
4	I-MED
and	O
inhibitors	B-MED
of	O
the	O
Activin	B-MED
/	O
Nodal	B-MED
signaling	I-MED
pathways	I-MED
.	O
This	O
protocol	O
generates	O
various	O
trophoblast	B-MED
cell	B-MED
types	I-MED
that	O
can	O
be	O
transfected	B-MED
with	O
siRNAs	B-MED
for	O
investigating	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	B-MED
or	O
can	O
be	O
infected	B-MED
with	O
pathogens	B-MED
.	O
Additionally	O
,	O
hPSCs	B-MED
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	B-MED
into	O
trophoblast	B-MED
progenitors	B-MED
for	O
gain	O
-	O
of	O
-	O
function	O
analyses	O
.	O
This	O
in	B-MED
vitro	I-MED
differentiation	B-MED
method	I-MED
for	O
generating	O
human	B-MED
trophoblasts	B-MED
starting	O
from	O
hPSCs	B-MED
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	B-MED
of	O
working	O
with	O
early	O
human	B-MED
embryos	B-MED
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
drug	B-MED
discovery	I-MED
and	O
stem	B-MED
cell	I-MED
research	I-MED
.	O
Tooth	B-MED
Discoloration	I-MED
Resulting	B-MED
from	O
a	O
Nano	B-MED
Zinc	B-MED
Oxide	I-MED
-	I-MED
Eugenol	I-MED
Sealer	B-MED
A	O
desirable	O
quality	B-MED
of	O
any	O
endodontic	B-MED
sealer	I-MED
is	O
its	O
ability	O
to	O
be	O
tooth	B-MED
color	I-MED
friendly	B-MED
.	O
Therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
evaluate	O
the	O
tooth	B-MED
discoloration	I-MED
potential	B-MED
of	O
a	O
nano	B-MED
zinc	B-MED
oxide	I-MED
-	I-MED
eugenol	I-MED
(	O
NZOE	B-MED
)	O
sealer	B-MED
.	O
In	O
order	O
to	O
evaluate	O
tooth	B-MED
discoloration	I-MED
,	O
the	O
pulp	B-MED
chamber	I-MED
of	O
60	O
human	B-MED
maxillary	B-MED
central	I-MED
and	O
lateral	B-MED
incisors	I-MED
were	O
filled	B-MED
with	O
one	O
of	O
the	O
sealers	B-MED
,	O
naming	O
AH-26	B-MED
(	O
resin	B-MED
-	I-MED
based	I-MED
sealer	I-MED
)	O
,	O
Pulpdent	B-MED
sealer	B-MED
(	O
ZOE	B-MED
-based	O
)	O
and	O
a	O
NZOE	B-MED
experimental	O
sealer	B-MED
.	O
Color	B-MED
measurements	B-MED
was	O
assessed	O
at	O
the	O
baseline	B-MED
(	O
before	B-MED
placement	I-MED
of	O
sealers	B-MED
)	O
(	O
T0	O
)	O
,	O
24	O
h	B-MED
(	O
T1	O
)	O
and	O
72	O
h	B-MED
(	O
T2	O
)	O
h	B-MED
,	O
1-	O
week	B-MED
(	O
T3	O
)	O
,	O
and	O
1-	O
month	B-MED
(	O
T4	O
)	O
after	O
the	O
placement	O
of	O
sealers	B-MED
using	O
the	O
Easy	B-MED
Shade	I-MED
spectrophotometer	I-MED
.	O
Data	B-MED
were	O
analyzed	B-MED
in	O
SPSS	B-MED
software	I-MED
using	O
one	B-MED
-	I-MED
way	I-MED
ANOVA	I-MED
,	O
and	O
repeated	O
measured	O
ANOVA	B-MED
.	O
No	O
significant	O
differences	O
were	O
observed	B-MED
when	O
the	O
paired	B-MED
comparison	I-MED
test	I-MED
was	O
performed	O
(	O
P>0.05	O
)	O
.	O
The	O
tested	O
NZOE	B-MED
sealer	B-MED
had	O
similar	O
tooth	B-MED
discoloration	I-MED
potential	B-MED
in	O
comparison	B-MED
with	O
AH-26	B-MED
and	O
ZOE	B-MED
sealer	B-MED
.	O
Relationship	B-MED
between	O
LRRK2	B-MED
R1628P	B-MED
polymorphism	I-MED
and	O
Parkinson	B-MED
's	I-MED
disease	I-MED
in	O
Asian	B-MED
populations	I-MED
Although	O
the	O
leucine	B-MED
-	I-MED
rich	I-MED
repeat	I-MED
kinase	I-MED
2	I-MED
(	O
LRRK2	B-MED
)	O
R1628P	B-MED
polymorphism	I-MED
has	O
been	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
in	O
Taiwan	B-MED
,	O
China	B-MED
,	O
and	O
Singapore	B-MED
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	B-MED
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta	B-MED
-	I-MED
analysis	I-MED
was	O
to	O
evaluate	O
the	O
associations	B-MED
between	O
the	O
LRRK2	B-MED
R1628P	B-MED
polymorphism	I-MED
(	O
rs33949390	B-MED
)	O
and	O
PD	B-MED
in	O
Asian	B-MED
populations	I-MED
.	O
A	O
search	O
for	O
eligible	O
studies	B-MED
was	O
performed	O
in	O
PubMed	B-MED
,	O
Embase	B-MED
,	O
SinoMed	B-MED
,	O
and	O
the	O
China	B-MED
Knowledge	I-MED
Resource	I-MED
Integrated	I-MED
Database	I-MED
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	B-MED
intervals	I-MED
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	B-MED
between	O
the	O
R1628P	B-MED
polymorphism	I-MED
and	O
PD	B-MED
.	O
This	O
meta	B-MED
-	I-MED
analysis	I-MED
assessed	O
19	O
studies	B-MED
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9,927	O
PD	B-MED
patients	B-MED
and	O
8,602	O
controls	B-MED
and	O
found	O
that	O
the	O
R1628P	B-MED
polymorphism	I-MED
was	O
significantly	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
PD	B-MED
in	O
Asian	B-MED
populations	I-MED
.	O
Moreover	O
,	O
stratification	B-MED
analyses	I-MED
indicated	O
that	O
the	O
R1628P	B-MED
polymorphism	I-MED
was	O
significantly	O
associated	B-MED
with	I-MED
an	O
increased	O
risk	B-MED
of	O
PD	B-MED
among	O
Chinese	B-MED
as	O
well	O
as	O
non	B-MED
-	I-MED
Chinese	I-MED
Asian	I-MED
populations	I-MED
and	O
an	O
increased	O
risk	B-MED
of	O
PD	B-MED
in	O
Chinese	B-MED
patients	I-MED
from	O
China	B-MED
,	O
Taiwan	B-MED
,	O
and	O
Singapore	B-MED
.	O
In	O
a	O
stratified	B-MED
analysis	I-MED
conducted	O
according	O
to	O
age	B-MED
,	O
significant	O
associations	B-MED
were	O
found	O
for	O
both	O
late	O
-	O
onset	O
PD	B-MED
and	O
early	O
-	O
onset	O
PD	B-MED
.	O
The	O
present	O
data	O
indicate	O
that	O
the	O
R1628P	B-MED
polymorphism	I-MED
of	O
the	O
LRRK2	B-MED
gene	I-MED
contributes	O
to	O
PD	B-MED
susceptibility	B-MED
in	O
Asian	B-MED
,	O
especially	O
Chinese	B-MED
,	O
populations	B-MED
.	O
The	O
Usefulness	O
of	O
Employing	B-MED
an	O
Electronic	B-MED
Traction	I-MED
Table	I-MED
to	O
Determine	O
Flexibility	B-MED
in	O
Adolescent	B-MED
Idiopathic	I-MED
Scoliosis	I-MED
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
develop	B-MED
new	O
equipment	B-MED
for	O
the	O
assessment	B-MED
of	O
the	O
flexibility	B-MED
of	O
the	O
spine	B-MED
with	O
different	O
forces	B-MED
.	O
This	O
new	O
system	B-MED
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	B-MED
idiopathic	I-MED
scoliosis	I-MED
(	O
AIS	B-MED
)	O
for	O
the	O
selection	B-MED
of	O
fusion	B-MED
levels	I-MED
and	O
surgical	B-MED
success	B-MED
.	O
Eighteen	O
patients	B-MED
suffering	O
from	O
AIS	B-MED
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	B-MED
instrumented	B-MED
spinal	I-MED
fusion	I-MED
in	O
our	O
clinic	B-MED
were	O
recruited	O
in	O
this	O
study	B-MED
.	O
The	O
Electronic	B-MED
Traction	I-MED
Table	I-MED
(	O
ETT	B-MED
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	B-MED
was	O
used	O
to	O
evaluate	O
the	O
radiogical	B-MED
and	O
clinical	B-MED
parameters	B-MED
of	O
the	O
spine	B-MED
.	O
The	O
significant	O
prescriptive	B-MED
angle	I-MED
of	O
major	O
Cobb	B-MED
angles	I-MED
between	O
postoperative	B-MED
angles	I-MED
were	O
longitudinal	B-MED
traction	B-MED
and	O
lateral	B-MED
pushing	I-MED
Cobb	I-MED
angles	I-MED
.	O
Longitudinal	B-MED
traction	B-MED
and	O
lateral	B-MED
pushing	I-MED
angles	I-MED
were	O
more	O
correlated	O
with	O
correction	B-MED
ratios	I-MED
.	O
There	O
was	O
a	O
significant	B-MED
difference	O
between	O
longitudinal	B-MED
traction	B-MED
minor	O
Cobb	B-MED
angle	I-MED
,	O
longitudinal	B-MED
traction	B-MED
lateral	B-MED
pushing	I-MED
minor	I-MED
Cobb	I-MED
angle	I-MED
and	O
postoperative	B-MED
minor	I-MED
Cobb	I-MED
angles	I-MED
.	O
The	O
deformity	B-MED
is	O
needed	O
to	O
balance	O
both	O
tractional	B-MED
and	O
rotational	B-MED
rotational	B-MED
forces	I-MED
and	O
useful	O
technique	B-MED
to	O
evaluate	O
curve	O
flexibility	B-MED
before	O
the	O
operation	B-MED
.	O
Electronic	B-MED
traction	I-MED
table	I-MED
is	O
a	O
new	O
device	B-MED
for	O
determining	O
preoperative	B-MED
flexibility	I-MED
with	O
longitudinal	B-MED
traction	B-MED
and	O
lateral	B-MED
pushing	I-MED
radiographs	I-MED
.	O
It	O
can	O
be	O
useful	O
for	O
choosing	B-MED
selective	O
fusion	B-MED
levels	I-MED
at	O
the	O
proximal	B-MED
and	O
distal	B-MED
end	O
of	O
the	O
vertebral	B-MED
column	I-MED
.	O
Evaluating	O
clinical	B-MED
,	O
dietary	B-MED
and	O
psychological	B-MED
risk	B-MED
factors	I-MED
for	O
relapse	B-MED
of	O
ulcerative	B-MED
colitis	I-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
The	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	B-MED
in	O
patients	B-MED
with	O
ulcerative	B-MED
colitis	I-MED
(	O
UC	B-MED
)	O
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
on	O
long	O
term	O
follow	B-MED
up	I-MED
is	O
scarce	O
.	O
To	O
determine	O
the	O
relapse	B-MED
rate	O
in	O
patients	B-MED
with	O
UC	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	B-MED
of	O
relapse	B-MED
.	O
Patients	B-MED
with	O
UC	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
were	O
enrolled	O
between	O
January	O
-	O
July	O
2010	O
and	O
followed	B-MED
up	I-MED
for	O
1	O
year	B-MED
to	O
determine	O
the	O
effect	O
of	O
clinical	B-MED
,	O
dietary	B-MED
and	O
psychological	B-MED
factors	B-MED
on	O
relapse	B-MED
.	O
Information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	B-MED
such	O
as	O
infection	B-MED
,	O
antibiotic	B-MED
or	O
NSAIDs	B-MED
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	B-MED
felt	O
important	O
,	O
and	O
compliance	B-MED
with	O
medications	B-MED
was	O
obtained	O
.	O
97	O
patients	B-MED
(	O
59	O
males	B-MED
,	O
mean	O
age	B-MED
39	O
+	O
11.9	O
years	B-MED
)	O
were	O
followed	B-MED
up	I-MED
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2.3	O
months	B-MED
.	O
18(18.6	O
%	O
)	O
relapsed	B-MED
with	O
the	O
median	O
time	O
to	O
relapse	B-MED
being	O
3.5	O
months	B-MED
.	O
On	O
univariate	B-MED
analysis	I-MED
more	O
relapsers	O
had	O
significantly	O
higher	O
NSAIDs	B-MED
use	O
within	O
15	O
days	B-MED
of	O
relapse	B-MED
,	O
respiratory	B-MED
tract	I-MED
infection	I-MED
within	O
4	O
weeks	B-MED
,	O
use	O
of	O
steroids	B-MED
more	O
than	O
once	O
in	O
past	O
,	O
higher	O
consumption	B-MED
of	O
calcium	B-MED
,	O
riboflavin	B-MED
,	O
vitamin	B-MED
A	I-MED
and	O
lower	O
consumption	B-MED
of	O
sugars	B-MED
.	O
On	O
multivariate	B-MED
analysis	I-MED
,	O
NSAIDs	B-MED
use	O
[	O
HR(95%CI):6.41(1.88	O
-	O
21.9)]and	O
intake	B-MED
of	O
Vitamin	B-MED
A	I-MED
[	O
HR(95%CI):1.008(1.000	O
-	O
1.016	O
)	O
]	O
were	O
statistically	O
significant	O
predictors	B-MED
of	O
relapse	B-MED
.	O
With	O
a	O
relapse	B-MED
rate	O
of	O
18.6	O
%	O
over	O
a	O
follow	B-MED
up	I-MED
of	O
9	O
months	B-MED
in	O
patients	B-MED
with	O
UC	B-MED
in	O
clinical	B-MED
,	O
endoscopic	B-MED
and	O
histological	B-MED
remission	B-MED
,	O
independent	O
predictors	B-MED
of	O
relapse	B-MED
were	O
history	O
of	O
NSAIDs	B-MED
use	O
within	O
15	O
days	B-MED
of	O
relapse	B-MED
and	O
higher	O
intake	O
of	O
Vitamin	B-MED
A	I-MED
A.	O
Effect	B-MED
of	O
Protein	B-MED
Repetitiveness	B-MED
on	O
Protein	B-MED
-	I-MED
Protein	I-MED
Interaction	I-MED
Prediction	B-MED
Results	B-MED
Using	O
Support	B-MED
Vector	I-MED
Machines	I-MED
There	O
are	O
many	O
computational	B-MED
approaches	I-MED
to	O
predict	O
the	O
protein	B-MED
-	I-MED
protein	I-MED
interactions	I-MED
using	O
support	B-MED
vector	I-MED
machines	I-MED
(	O
SVMs	B-MED
)	O
with	O
high	O
performance	O
.	O
In	O
fact	O
,	O
performance	O
of	O
currently	O
reported	O
methods	B-MED
are	O
significantly	O
over	O
-	O
estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	B-MED
in	O
the	O
datasets	B-MED
used	O
.	O
To	O
study	B-MED
the	O
effect	O
of	O
object	O
repetitiveness	B-MED
of	O
datasets	B-MED
on	O
predicting	B-MED
results	B-MED
.	O
We	O
present	O
novel	O
methods	B-MED
to	O
construct	O
different	O
positive	B-MED
datasets	B-MED
with	O
or	O
without	O
repeating	O
proteins	B-MED
using	O
graph	B-MED
maximum	O
matching	O
in	O
the	O
protein	B-MED
-	I-MED
protein	I-MED
interaction	I-MED
datasets	B-MED
and	O
corresponding	O
series	O
of	O
negative	B-MED
datasets	B-MED
with	O
different	O
proteins	B-MED
repetitiveness	B-MED
are	O
constructed	O
using	O
graph	B-MED
adjacency	B-MED
matrix	I-MED
.	O
The	O
relationship	B-MED
between	O
the	O
SVM	B-MED
prediction	B-MED
results	B-MED
and	O
the	O
repeated	B-MED
proteins	B-MED
(	O
repeat	O
numbers	O
and	O
repeat	O
rates	O
)	O
and	O
the	O
distributions	B-MED
of	O
repeated	B-MED
proteins	B-MED
in	O
the	O
datasets	B-MED
are	O
analyzed	O
.	O
Protein	B-MED
repetitiveness	B-MED
of	O
positive	B-MED
and	O
negative	B-MED
datasets	B-MED
can	O
affect	O
the	O
prediction	B-MED
result	B-MED
:	O
high	O
protein	B-MED
repetitiveness	B-MED
of	O
positive	B-MED
or	O
negative	B-MED
datasets	B-MED
yield	O
high	O
performance	O
prediction	O
result	B-MED
.	O
This	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	B-MED
of	O
datasets	B-MED
is	O
a	O
key	O
issue	O
in	O
protein	B-MED
-	I-MED
protein	I-MED
interactions	I-MED
prediction	B-MED
using	O
SVMs	B-MED
since	O
real	O
world	O
data	B-MED
contain	O
certain	O
degrees	O
of	O
repeat	B-MED
proteins	B-MED
.	O
Inducible	B-MED
Expression	B-MED
of	O
both	O
ermB	B-MED
and	O
ermT	B-MED
Conferred	O
High	B-MED
Macrolide	B-MED
Resistance	I-MED
in	O
Streptococcus	B-MED
gallolyticus	I-MED
subsp	I-MED
.	I-MED
pasteurianus	I-MED
Isolates	B-MED
in	O
China	B-MED
Streptococcus	B-MED
gallolyticus	I-MED
subsp	I-MED
.	I-MED
pasteurianus	I-MED
is	O
an	O
under	O
-	O
recognized	O
pathogen	B-MED
and	O
zoonotic	B-MED
agent	I-MED
causing	O
opportunistic	B-MED
infections	I-MED
in	O
humans	B-MED
.	O
Despite	O
increasing	O
recognition	B-MED
of	O
this	O
subspecies	B-MED
as	O
a	O
cause	O
for	O
human	B-MED
infectious	B-MED
diseases	I-MED
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic	B-MED
resistance	I-MED
mechanism	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular	B-MED
mechanism	I-MED
underlying	O
the	O
high	O
macrolide	B-MED
resistance	I-MED
of	O
six	O
S.	B-MED
gallolyticus	I-MED
subsp	I-MED
.	I-MED
pasteurianus	I-MED
isolates	B-MED
from	O
dead	B-MED
ducklings	B-MED
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
China	B-MED
during	O
2010	O
-	O
2013	O
.	O
All	O
isolates	B-MED
exhibited	O
multi	B-MED
-	I-MED
drug	I-MED
resistance	I-MED
including	O
high	O
macrolide	B-MED
resistance	I-MED
(	O
MIC	B-MED
MIC	B-MED
≥	O
1024	O
mg	O
/	O
L	O
for	O
erythromycin	B-MED
,	O
and	O
512	O
mg	O
/	O
L	O
for	O
clarithromycin	B-MED
)	O
.	O
Efflux	B-MED
-	I-MED
encoding	I-MED
mefA	I-MED
and	O
mefE	B-MED
genes	I-MED
were	O
not	O
detectable	O
in	O
these	O
isolates	B-MED
.	O
The	O
presence	O
of	O
23S	B-MED
rRNA	I-MED
mutations	B-MED
in	O
specific	O
isolates	B-MED
did	O
not	O
significantly	O
change	O
macrolide	B-MED
MIC	B-MED
s.	O
No	O
nucleotide	B-MED
substitutions	B-MED
were	O
found	O
in	O
genes	B-MED
encoding	O
ribosomal	B-MED
proteins	I-MED
L4	I-MED
or	O
L22	B-MED
.	O
The	O
ermB	B-MED
and	O
ermT	B-MED
genes	I-MED
were	O
found	O
in	O
the	O
genomes	B-MED
of	O
all	O
isolates	B-MED
.	O
These	O
two	O
genes	B-MED
were	O
acquired	O
independently	B-MED
in	O
one	O
highly	O
virulent	B-MED
isolate	I-MED
AL101002	I-MED
,	O
and	O
clustered	O
with	O
Tn916	B-MED
and	O
IS1216	B-MED
,	O
respectively	O
.	O
The	O
expression	B-MED
of	O
both	O
ermB	B-MED
and	O
ermT	B-MED
in	O
all	O
isolates	B-MED
was	O
erythromycin	B-MED
inducible	B-MED
and	O
yielded	O
comparable	O
macrolide	B-MED
MICs	B-MED
in	O
all	O
six	O
isolates	B-MED
.	O
Taken	O
together	O
,	O
inducible	B-MED
expression	B-MED
of	O
both	O
ermB	B-MED
and	O
ermT	B-MED
conferred	O
high	O
macrolide	B-MED
resistance	I-MED
in	O
these	O
S.	B-MED
gallolyticus	I-MED
subsp	I-MED
.	I-MED
pasterianus	I-MED
isolates	B-MED
.	O
Our	O
findings	B-MED
reveal	O
new	O
macrolide	B-MED
resistance	I-MED
features	O
in	O
S.	B-MED
gallolyticus	I-MED
subsp	I-MED
.	I-MED
pasteurianus	I-MED
by	O
both	O
ermB	B-MED
ermT	B-MED
and	O
ermT.	O
Human	B-MED
amnion	B-MED
epithelial	B-MED
cells	I-MED
rescue	O
cell	B-MED
death	I-MED
via	O
immunomodulation	B-MED
of	O
microglia	B-MED
in	O
a	O
mouse	B-MED
model	I-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
Human	B-MED
amnion	B-MED
epithelial	B-MED
cells	I-MED
(	O
hAECs	B-MED
)	O
are	O
clonogenic	B-MED
and	O
have	O
been	O
proposed	O
to	O
reduce	B-MED
inflammatory	B-MED
-	O
induced	B-MED
tissue	B-MED
injury	I-MED
.	O
Perturbation	B-MED
of	O
the	O
immune	B-MED
response	I-MED
is	O
implicated	O
in	O
the	O
pathogenesis	B-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
;	O
modulating	B-MED
this	O
response	B-MED
could	O
thus	O
be	O
a	O
novel	B-MED
therapy	B-MED
for	O
treating	B-MED
or	O
preventing	O
such	O
injury	B-MED
.	O
The	O
immunomodulatory	B-MED
properties	O
of	O
hAECs	B-MED
have	O
been	O
shown	O
in	O
other	O
animal	B-MED
models	I-MED
,	O
but	O
a	O
detailed	O
investigation	B-MED
of	O
the	O
effects	B-MED
on	O
brain	B-MED
immune	B-MED
cells	B-MED
following	O
injury	B-MED
has	O
not	O
been	O
undertaken	O
.	O
Here	O
,	O
we	O
investigate	B-MED
the	O
effects	B-MED
of	O
hAECs	B-MED
on	O
microglia	B-MED
,	O
the	O
first	O
immune	B-MED
responders	I-MED
to	O
injury	B-MED
within	O
the	O
brain	B-MED
.	O
We	O
generated	O
a	O
mouse	B-MED
model	I-MED
combining	O
neonatal	B-MED
inflammation	B-MED
and	O
perinatal	B-MED
hyperoxia	B-MED
,	O
both	O
of	O
which	O
are	O
risk	B-MED
factors	I-MED
associated	O
with	O
perinatal	B-MED
brain	I-MED
injury	I-MED
.	O
On	O
embryonic	B-MED
day	B-MED
16	O
we	O
administered	B-MED
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
,	O
or	O
saline	B-MED
(	O
control	B-MED
)	O
,	O
intra	B-MED
-	I-MED
amniotically	I-MED
to	O
C57Bl/6	B-MED
J	I-MED
mouse	I-MED
pups	I-MED
.	O
On	O
postnatal	B-MED
day	B-MED
(	O
P)0	O
,	O
LPS	B-MED
pups	B-MED
were	O
placed	O
in	O
hyperoxia	B-MED
(	O
65	O
%	O
oxygen	B-MED
)	O
and	O
control	B-MED
pups	I-MED
in	O
normoxia	B-MED
for	O
14	O
days	B-MED
.	O
Pups	B-MED
were	O
given	O
either	O
hAECs	B-MED
or	O
saline	B-MED
intravenously	B-MED
on	O
P4	O
.	O
At	O
P14	O
,	O
relative	O
to	O
controls	B-MED
,	O
LPS	B-MED
and	O
hyperoxia	B-MED
pups	B-MED
had	O
reduced	B-MED
body	B-MED
weight	I-MED
,	O
increased	B-MED
density	B-MED
of	O
apoptotic	B-MED
cells	B-MED
(	O
TUNEL	B-MED
)	O
in	O
the	O
cortex	B-MED
,	O
striatum	B-MED
and	O
white	B-MED
matter	I-MED
,	O
astrocytes	B-MED
(	O
GFAP	B-MED
)	O
in	O
the	O
white	B-MED
matter	I-MED
and	O
activated	B-MED
microglia	B-MED
(	O
CD68	B-MED
)	O
in	O
the	O
cortex	B-MED
and	O
striatum	B-MED
,	O
but	O
no	O
change	O
in	O
total	O
microglia	B-MED
density	B-MED
(	O
Iba1	B-MED
)	O
.	O
hAEC	B-MED
administration	B-MED
rescued	O
the	O
decreased	B-MED
body	B-MED
weight	I-MED
and	O
reduced	B-MED
apoptosis	B-MED
and	O
astrocyte	B-MED
areal	B-MED
coverage	I-MED
in	O
the	O
white	B-MED
matter	I-MED
,	O
but	O
increased	B-MED
the	O
density	B-MED
of	O
total	O
and	O
activated	B-MED
microglia	B-MED
.	O
We	O
then	O
stimulated	O
primary	B-MED
microglia	B-MED
(	O
CD45	B-MED
(	O
low	O
)	O
CD11b	B-MED
(	O
+	O
)	O
)	O
with	O
LPS	B-MED
for	O
24	O
h	O
,	O
followed	O
by	O
co	B-MED
-	I-MED
culture	I-MED
with	O
hAEC	B-MED
conditioned	B-MED
medium	I-MED
for	O
48	O
h.	O
hAEC	B-MED
conditioned	B-MED
medium	I-MED
increased	B-MED
microglial	B-MED
phagocytic	B-MED
activity	I-MED
,	O
decreased	B-MED
microglia	B-MED
apoptosis	B-MED
and	O
decreased	B-MED
M1	B-MED
activation	I-MED
markers	I-MED
(	O
CD86	B-MED
)	O
.	O
Stimulating	O
hAECs	B-MED
for	O
24	O
h	O
with	O
LPS	B-MED
did	O
not	O
alter	O
release	B-MED
of	O
cytokines	B-MED
known	O
to	O
modulate	B-MED
microglia	B-MED
activity	B-MED
.	O
These	O
data	B-MED
demonstrate	O
that	O
hAECs	B-MED
can	O
directly	O
immunomodulate	B-MED
brain	B-MED
microglia	B-MED
,	O
probably	O
via	O
release	B-MED
of	O
trophic	B-MED
factors	I-MED
.	O
This	O
observation	B-MED
offers	O
promise	O
that	O
hAECs	B-MED
may	O
afford	O
therapeutic	B-MED
utility	I-MED
in	O
the	O
management	B-MED
of	O
perinatal	B-MED
brain	I-MED
injury	I-MED
.	O
Optimizing	B-MED
Survival	B-MED
of	O
Patients	B-MED
With	O
Marginally	B-MED
Operable	I-MED
Stage	B-MED
IIIA	I-MED
Non	I-MED
-	I-MED
Small	I-MED
-	I-MED
Cell	I-MED
Lung	I-MED
Cancer	I-MED
Receiving	O
Chemoradiotherapy	B-MED
With	B-MED
or	O
Without	B-MED
Surgery	B-MED
For	O
marginally	B-MED
operable	I-MED
stage	B-MED
IIIA	I-MED
non	I-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
(	O
NSCLC	B-MED
)	O
,	O
surgery	B-MED
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-MED
concurrent	B-MED
chemoradiotherapy	I-MED
(	O
CCRT	B-MED
)	O
for	O
reasons	O
(	O
unresectable	B-MED
or	O
medically	B-MED
inoperable	I-MED
conditions	B-MED
,	O
or	O
patient	B-MED
refusal	I-MED
)	O
.	O
This	O
study	B-MED
aims	O
to	O
investigate	B-MED
the	O
outcomes	B-MED
of	O
a	O
phased	B-MED
CCRT	I-MED
protocol	I-MED
established	O
to	O
maximize	O
the	O
operability	B-MED
of	O
marginally	B-MED
operable	I-MED
stage	B-MED
IIIA	I-MED
NSCLC	I-MED
and	O
to	O
care	O
for	O
reassessed	B-MED
inoperable	B-MED
patients	I-MED
,	O
in	O
comparison	O
with	O
continuous	B-MED
-	I-MED
course	I-MED
definitive	I-MED
CCRT	I-MED
.	O
Forty	O
-	O
seven	O
patients	B-MED
with	O
marginally	B-MED
operable	I-MED
stage	B-MED
IIIA	I-MED
NSCLC	I-MED
receiving	O
CCRT	B-MED
were	O
included	O
.	O
Twenty	O
-	O
eight	O
patients	B-MED
were	O
treated	B-MED
with	O
our	O
phased	B-MED
CCRT	I-MED
protocol	I-MED
,	O
including	O
neoadjuvant	B-MED
CCRT	B-MED
followed	O
by	O
surgery	B-MED
(	O
group	B-MED
A	I-MED
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	B-MED
inoperable	B-MED
patients	I-MED
patients	B-MED
,	O
maintenance	B-MED
chemotherapy	I-MED
and	O
split	B-MED
-	I-MED
course	I-MED
CCRT	I-MED
boost	B-MED
(	O
group	B-MED
B	I-MED
,	O
n	O
=	O
12	O
)	O
.	O
The	O
other	O
19	O
were	O
treated	B-MED
with	O
continuous	B-MED
-	I-MED
course	I-MED
definitive	I-MED
CCRT	I-MED
(	O
group	B-MED
C	I-MED
)	O
.	O
Overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
and	O
progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
PFS	B-MED
)	O
were	O
analyzed	B-MED
.	O
Among	O
all	O
,	O
median	B-MED
OS	B-MED
and	O
PFS	B-MED
were	O
35.6	O
and	O
12.8	O
months	B-MED
,	O
respectively	O
(	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
22.3	O
months	B-MED
)	O
.	O
The	O
median	B-MED
OS	B-MED
of	O
group	B-MED
A	I-MED
(	O
not	O
reached	O
)	O
was	O
better	O
than	O
that	O
of	O
group	B-MED
B	I-MED
(	O
34.4	O
months	B-MED
)	O
and	O
group	B-MED
C	I-MED
(	O
15.2	O
months	B-MED
)	O
(	O
P	O
=	O
.009	O
)	O
.	O
On	O
multivariate	B-MED
analysis	I-MED
,	O
performance	B-MED
status	I-MED
0	O
to	O
1	O
(	O
hazard	B-MED
ratio	I-MED
[	O
HR	B-MED
]	O
,	O
0.026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	B-MED
(	O
HR	B-MED
,	O
0.156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	B-MED
A	I-MED
(	O
HR	B-MED
,	O
0.199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	B-MED
prognostic	I-MED
factors	I-MED
.	O
The	O
OS	B-MED
of	O
group	B-MED
B	I-MED
(	O
HR	B-MED
,	O
0.450	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
0.118	O
-	O
1.717	O
;	O
P	O
=	O
.243	O
)	O
was	O
not	O
statistically	B-MED
different	I-MED
from	O
that	O
of	O
group	B-MED
C	I-MED
C.	O
For	O
marginally	B-MED
operable	I-MED
stage	B-MED
IIIA	I-MED
NSCLC	I-MED
,	O
our	O
phased	B-MED
CCRT	I-MED
strategy	I-MED
may	O
optimize	B-MED
survival	B-MED
by	O
maximizing	O
operability	B-MED
and	O
maintain	O
an	O
acceptable	O
survival	B-MED
for	O
reassessed	B-MED
inoperable	B-MED
patients	I-MED
by	O
split	B-MED
-	I-MED
course	I-MED
CCRT	I-MED
boost	B-MED
following	O
maintenance	B-MED
chemotherapy	I-MED
.	O
Normal	B-MED
Levels	I-MED
of	O
Urinary	B-MED
CC16	B-MED
Protein	I-MED
.	O
Comments	B-MED
on	I-MED
Beamer	I-MED
et	I-MED
al	I-MED
.	I-MED
Association	I-MED
of	O
Children	B-MED
's	I-MED
Urinary	B-MED
CC16	B-MED
Levels	B-MED
with	O
Arsenic	B-MED
Concentrations	I-MED
in	O
Multiple	B-MED
Environmental	I-MED
Media	I-MED
.	O
Int	O
.	O
J.	O
Environ	O
.	O
Res	O
.	O
Public	O
Health	O
2016	O
,	O
13	O
,	O
521	O
In	O
1937	O
,	O
Max	B-MED
Clara	I-MED
described	O
a	O
new	O
type	O
of	O
cell	B-MED
in	O
the	O
human	B-MED
lung	B-MED
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	B-MED
secretory	I-MED
cell	I-MED
type	I-MED
containing	I-MED
granules	I-MED
composed	O
of	O
proteins	B-MED
[	O
1	O
]	O
.	O
[	O
...	O
]	O
.	O
Work	B-MED
process	B-MED
,	O
performance	B-MED
and	O
professional	B-MED
profile	I-MED
of	O
a	O
Hearing	B-MED
Health	I-MED
Network	I-MED
:	O
reference	B-MED
for	O
satisfaction	B-MED
To	O
analyze	B-MED
the	O
correlation	B-MED
between	O
the	O
satisfaction	B-MED
of	O
professionals	B-MED
from	O
the	O
Hearing	B-MED
Health	I-MED
Care	I-MED
network	I-MED
in	O
two	O
micro	B-MED
-	O
regions	B-MED
of	O
Minas	B-MED
Gerais	I-MED
state	I-MED
and	O
the	O
sociodemographic	B-MED
profile	I-MED
,	O
work	B-MED
process	B-MED
,	O
and	O
work	B-MED
performance	I-MED
in	O
the	O
health	B-MED
service	I-MED
.	O
This	O
is	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
,	O
observational	B-MED
,	O
analytic	B-MED
study	I-MED
with	O
a	O
non	B-MED
-	I-MED
probabilistic	I-MED
sample	I-MED
including	O
34	O
professionals	B-MED
from	O
the	O
Hearing	B-MED
Health	I-MED
Care	I-MED
services	I-MED
.	O
Data	B-MED
collection	I-MED
occurred	O
through	O
individual	B-MED
interviews	B-MED
in	O
the	O
municipality	B-MED
of	O
professional	B-MED
practice	I-MED
.	O
Associations	B-MED
between	O
the	O
Professional	B-MED
Satisfaction	I-MED
variable	B-MED
and	O
the	O
explanatory	B-MED
variables	B-MED
Sociodemographic	B-MED
Data	I-MED
,	O
Work	B-MED
Routine	I-MED
,	O
and	O
Developed	B-MED
Actions	B-MED
were	O
conducted	O
.	O
Professionals	B-MED
with	O
graduate	B-MED
studies	I-MED
were	O
more	O
satisfied	B-MED
with	O
the	O
human	B-MED
resources	I-MED
policy	I-MED
and	O
the	O
activities	B-MED
developed	B-MED
,	O
whereas	O
health	B-MED
civil	B-MED
servants	I-MED
showed	O
more	O
satisfaction	B-MED
with	O
the	O
wage	B-MED
policy	B-MED
and	O
the	O
work	B-MED
schedule	I-MED
.	O
The	O
correlation	B-MED
analysis	I-MED
between	O
work	B-MED
process	B-MED
and	O
satisfaction	B-MED
revealed	B-MED
a	O
moderate	B-MED
positive	B-MED
correlation	B-MED
between	O
items	O
such	O
as	O
Health	B-MED
Promotion	I-MED
Actions	B-MED
,	O
Satisfaction	B-MED
with	O
Diagnostic	B-MED
Equipment	I-MED
,	O
and	O
Satisfaction	B-MED
with	O
Maintenance	B-MED
Equipment	I-MED
.	O
The	O
present	O
study	B-MED
revealed	O
a	O
higher	B-MED
level	B-MED
of	O
satisfaction	B-MED
among	O
professionals	B-MED
with	O
graduate	B-MED
studies	I-MED
(	O
human	B-MED
resources	I-MED
policy	I-MED
and	O
activities	B-MED
developed	B-MED
)	O
and	O
civil	B-MED
servants	I-MED
(	O
wage	B-MED
policy	B-MED
and	O
work	B-MED
schedule	I-MED
)	O
.	O
The	O
relevance	B-MED
of	O
this	O
study	B-MED
lies	O
on	O
the	O
important	O
role	O
that	O
health	B-MED
professionals	I-MED
play	O
on	O
the	O
Health	B-MED
Care	I-MED
Network	I-MED
.	O
Additionally	O
,	O
the	O
study	B-MED
of	O
satisfaction	B-MED
level	B-MED
can	O
provide	O
a	O
search	O
for	O
improvements	B-MED
,	O
considering	O
that	O
satisfied	B-MED
professionals	B-MED
not	O
only	O
improve	B-MED
service	B-MED
quality	I-MED
,	O
but	O
also	O
show	B-MED
greater	I-MED
creativity	I-MED
,	O
commitment	B-MED
,	O
and	O
performance	B-MED
.	O
Interferon	B-MED
gamma	I-MED
and	O
interleukin	B-MED
10	I-MED
polymorphisms	B-MED
in	O
Chinese	B-MED
children	B-MED
with	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
The	O
aim	O
of	O
the	O
study	B-MED
is	O
to	O
investigate	B-MED
the	O
association	O
of	O
interferon	B-MED
gamma	I-MED
(	O
IFN	B-MED
-	I-MED
γ	I-MED
)	O
and	O
interleukin-10	B-MED
(	O
IL-10	B-MED
)	O
gene	B-MED
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
with	O
the	O
susceptibility	B-MED
of	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
(	O
HLH	B-MED
)	O
in	O
Chinese	B-MED
children	B-MED
without	B-MED
known	I-MED
family	I-MED
history	I-MED
of	I-MED
HLH	B-MED
.	O
Forty	O
children	B-MED
with	O
HLH	B-MED
and	O
160	O
age	B-MED
-	O
and	O
gender	B-MED
-matched	O
healthy	B-MED
controls	I-MED
from	O
Xuzhou	B-MED
Children	I-MED
's	I-MED
Hospital	I-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
.	O
Serum	B-MED
IFN	B-MED
-	I-MED
γ	I-MED
and	O
IL-10	B-MED
levels	O
were	O
measured	B-MED
by	O
enzyme	B-MED
linked	I-MED
-	I-MED
immunosorbent	I-MED
assay	I-MED
.	O
Polymorphisms	B-MED
of	O
the	O
IFN	B-MED
-	I-MED
γ	I-MED
gene	I-MED
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
IL-10	B-MED
at	O
position	O
-1082	O
were	O
analyzed	B-MED
by	O
allele	B-MED
-	O
specific	B-MED
PCR	B-MED
.	O
Median	B-MED
serum	I-MED
concentrations	B-MED
of	O
IFN	B-MED
-γ	I-MED
and	O
IL-10	B-MED
were	O
significantly	B-MED
higher	I-MED
in	O
children	B-MED
with	O
HLH	B-MED
compared	B-MED
to	O
healthy	B-MED
controls	I-MED
.	O
The	O
frequencies	B-MED
of	O
IFN	B-MED
-	I-MED
γ	I-MED
+874	O
T	B-MED
/	I-MED
A	I-MED
and	I-MED
T	I-MED
/	I-MED
T	I-MED
genotypes	I-MED
,	O
as	O
well	O
as	O
T	B-MED
allele	I-MED
,	O
were	O
significantly	B-MED
higher	I-MED
in	O
the	O
HLH	B-MED
group	O
compared	B-MED
with	O
those	O
in	O
the	O
control	B-MED
group	I-MED
.	O
The	O
frequencies	B-MED
of	O
IL-10	B-MED
-1082	O
G	B-MED
/	I-MED
A	I-MED
genotype	I-MED
and	O
G	B-MED
allele	I-MED
were	O
significantly	B-MED
increased	I-MED
in	O
HLH	B-MED
patients	B-MED
compared	B-MED
with	O
healthy	B-MED
controls	I-MED
.	O
No	B-MED
significant	I-MED
difference	B-MED
was	O
found	O
in	O
the	O
distribution	B-MED
of	O
IFN	B-MED
-	I-MED
γ	I-MED
+2109	O
G	B-MED
/	I-MED
A	I-MED
genotypes	I-MED
between	O
children	B-MED
with	O
HLH	B-MED
and	O
controls	B-MED
.	O
This	O
study	B-MED
presents	B-MED
preliminary	B-MED
evidence	B-MED
for	O
the	O
association	O
between	O
IFN	B-MED
+874	O
T	B-MED
/	I-MED
A	I-MED
,	I-MED
T	I-MED
/	I-MED
T	I-MED
,	O
IL-10	B-MED
-1082	O
A	B-MED
/	I-MED
G	I-MED
genotypes	I-MED
,	O
and	O
HLH	B-MED
susceptibility	B-MED
in	O
Chinese	B-MED
children	B-MED
with	O
HLH	B-MED
.	O
A	O
Case	B-MED
of	O
Koch	B-MED
's	I-MED
Spine	I-MED
Treated	B-MED
with	O
Modified	B-MED
Transpedicular	B-MED
Vertebral	I-MED
Curettage	I-MED
and	O
Posterior	B-MED
Fixation	B-MED
:	O
A	O
Novel	O
Technique	B-MED
Tuberculosis	B-MED
(	O
TB	B-MED
)	O
is	O
a	O
chronic	B-MED
granulomatous	B-MED
infection	I-MED
caused	O
by	O
acid	B-MED
-	I-MED
fast	I-MED
mycobacterium	I-MED
tuberculosis	I-MED
bacilli	I-MED
.	O
Spinal	B-MED
involvement	I-MED
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
TB	B-MED
.	O
Spinal	B-MED
TB	I-MED
(	O
Pott	B-MED
's	I-MED
disease	I-MED
)	O
accounts	O
for	O
50	O
%	O
of	O
skeletal	B-MED
TB	I-MED
.	O
Though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	B-MED
junction	I-MED
,	O
it	O
can	O
occur	O
at	O
any	O
level	B-MED
of	O
the	O
spine	B-MED
.	O
Early	O
diagnosis	B-MED
and	O
treatment	B-MED
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	B-MED
complications	I-MED
and	O
spinal	B-MED
deformity	I-MED
.	O
We	O
report	B-MED
a	O
case	B-MED
of	O
a	O
young	B-MED
female	B-MED
with	O
tuberculosis	B-MED
of	O
D12	B-MED
-	I-MED
L1	I-MED
who	O
was	O
treated	B-MED
with	O
posterior	B-MED
decompression	B-MED
using	O
a	O
modified	B-MED
transpedicular	B-MED
approach	I-MED
and	O
posterior	B-MED
instrumentation	B-MED
with	O
a	O
successful	O
outcome	B-MED
.	O
TREK-1	B-MED
(	I-MED
K2P2.1	I-MED
)	I-MED
K(+	I-MED
)	I-MED
channels	I-MED
are	O
suppressed	B-MED
in	O
patients	B-MED
with	O
atrial	B-MED
fibrillation	I-MED
and	O
heart	B-MED
failure	I-MED
and	O
provide	B-MED
therapeutic	B-MED
targets	I-MED
for	O
rhythm	B-MED
control	I-MED
Atrial	B-MED
fibrillation	I-MED
(	O
AF	B-MED
)	O
is	O
the	O
most	O
common	O
cardiac	B-MED
arrhythmia	I-MED
.	O
Concomitant	B-MED
heart	I-MED
failure	I-MED
(	O
HF	B-MED
)	O
poses	O
a	O
particular	O
therapeutic	B-MED
challenge	B-MED
and	O
is	O
associated	O
with	O
prolonged	B-MED
atrial	B-MED
electrical	I-MED
refractoriness	I-MED
compared	O
with	O
non	B-MED
-	I-MED
failing	I-MED
hearts	I-MED
.	O
We	O
hypothesized	O
that	O
downregulation	B-MED
of	O
atrial	B-MED
repolarizing	I-MED
TREK-1	B-MED
(	I-MED
K2P2.1	I-MED
)	I-MED
K(+	I-MED
)	I-MED
channels	I-MED
contributes	B-MED
to	O
electrical	B-MED
remodeling	I-MED
during	O
AF	B-MED
with	O
HF	B-MED
,	O
and	O
that	O
TREK-1	B-MED
gene	I-MED
transfer	I-MED
would	O
provide	O
rhythm	B-MED
control	I-MED
via	O
normalization	B-MED
of	O
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
in	O
this	O
AF	B-MED
subset	B-MED
.	O
In	O
patients	B-MED
with	O
chronic	B-MED
AF	I-MED
and	O
HF	B-MED
,	O
atrial	B-MED
TREK-1	I-MED
mRNA	B-MED
levels	B-MED
were	O
reduced	O
by	O
82	O
%	O
(	O
left	B-MED
atrium	I-MED
)	O
and	O
81	O
%	O
(	O
right	B-MED
atrium	I-MED
)	O
compared	O
with	O
sinus	B-MED
rhythm	I-MED
(	O
SR	B-MED
)	O
subjects	B-MED
.	O
Human	B-MED
findings	B-MED
were	O
recapitulated	O
in	O
a	O
porcine	B-MED
model	I-MED
of	O
atrial	B-MED
tachypacing	I-MED
-	I-MED
induced	I-MED
AF	I-MED
and	O
reduced	B-MED
left	B-MED
ventricular	I-MED
function	I-MED
.	O
TREK-1	B-MED
mRNA	B-MED
(	O
-66	O
%	O
)	O
and	O
protein	B-MED
(	O
-61	O
%	O
)	O
was	O
suppressed	B-MED
in	O
AF	B-MED
animals	B-MED
at	O
14	O
-	O
day	O
follow	O
-	O
up	O
compared	B-MED
with	O
SR	B-MED
controls	O
.	O
Downregulation	B-MED
of	O
repolarizing	B-MED
TREK-1	B-MED
channels	I-MED
was	O
associated	O
with	O
prolongation	B-MED
of	O
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
versus	O
baseline	B-MED
conditions	O
,	O
consistent	B-MED
with	I-MED
prior	B-MED
observations	B-MED
in	O
humans	B-MED
with	O
HF	B-MED
.	O
In	O
a	O
preclinical	B-MED
therapeutic	B-MED
approach	I-MED
,	O
pigs	B-MED
were	O
randomized	B-MED
to	O
either	O
atrial	B-MED
Ad	I-MED
-	I-MED
TREK-1	I-MED
gene	I-MED
therapy	I-MED
or	O
sham	B-MED
treatment	I-MED
.	O
Gene	B-MED
transfer	I-MED
effectively	B-MED
increased	B-MED
TREK-1	B-MED
protein	I-MED
levels	B-MED
and	O
attenuated	B-MED
atrial	B-MED
effective	I-MED
refractory	I-MED
period	I-MED
prolongation	B-MED
in	O
the	O
porcine	B-MED
AF	I-MED
model	I-MED
.	O
Ad	B-MED
-	I-MED
TREK-1	I-MED
increased	O
the	O
SR	B-MED
prevalence	B-MED
to	O
62	O
%	O
during	O
follow	O
-	O
up	O
in	O
AF	B-MED
animals	B-MED
,	O
compared	B-MED
to	O
35	O
%	O
in	O
the	O
untreated	O
AF	B-MED
group	O
.	O
In	O
conclusion	B-MED
,	O
TREK-1	B-MED
downregulation	B-MED
and	O
rhythm	B-MED
control	I-MED
by	O
Ad	B-MED
-	I-MED
TREK-1	I-MED
transfer	I-MED
suggest	B-MED
mechanistic	B-MED
and	I-MED
potential	I-MED
therapeutic	I-MED
significance	B-MED
of	O
TREK-1	B-MED
channels	I-MED
in	O
a	O
subgroup	B-MED
of	O
AF	B-MED
patients	B-MED
with	O
HF	B-MED
and	O
prolonged	B-MED
atrial	B-MED
effective	I-MED
refractory	I-MED
periods	I-MED
.	O
Functional	B-MED
correction	I-MED
of	O
ionic	O
remodeling	O
through	O
TREK-1	B-MED
gene	I-MED
therapy	I-MED
represents	O
a	O
novel	B-MED
paradigm	B-MED
to	O
optimize	O
and	O
specify	O
AF	B-MED
management	O
.	O
BORA	B-MED
-dependent	O
PLK1	B-MED
regulation	B-MED
:	O
A	O
new	O
weapon	O
for	O
cancer	B-MED
therapy	I-MED
?	O
The	O
mitotic	B-MED
kinase	I-MED
polo	I-MED
like	I-MED
kinase	I-MED
1	I-MED
(	O
PLK1	B-MED
)	O
is	O
overexpressed	B-MED
in	O
many	O
cancers	B-MED
and	I-MED
its	I-MED
inhibition	I-MED
slows	B-MED
down	I-MED
proliferation	I-MED
and	O
increases	B-MED
apoptosis	I-MED
in	O
cancer	B-MED
cell	I-MED
lines	I-MED
.	O
Understanding	O
how	O
PLK1	B-MED
is	I-MED
activated	I-MED
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
PLK1	B-MED
inhibitors	I-MED
with	O
anticancer	B-MED
properties	I-MED
.	O
We	O
recently	O
identified	O
a	O
conserved	O
regulatory	B-MED
loop	I-MED
leading	O
to	O
PLK1	B-MED
activation	I-MED
that	O
involves	O
cyclin	B-MED
-	I-MED
dependent	I-MED
kinase	I-MED
1	I-MED
(	O
CDK1	B-MED
)	O
.	O
Catastrophic	B-MED
expenditure	I-MED
and	O
impoverishment	B-MED
of	O
patients	B-MED
affected	O
by	O
7	O
rare	B-MED
diseases	I-MED
in	O
China	B-MED
China	B-MED
is	O
actively	O
promoting	B-MED
regulation	O
of	O
rare	B-MED
diseases	I-MED
,	O
rare	B-MED
disease	I-MED
and	O
orphan	B-MED
drugs	I-MED
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	B-MED
planning	I-MED
.	O
However	O
,	O
few	O
studies	B-MED
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	B-MED
of	O
rare	B-MED
disease	I-MED
patients	B-MED
in	O
China	B-MED
.	O
This	O
study	O
aims	O
to	O
provide	O
policy	B-MED
recommendations	B-MED
for	O
the	O
establishment	B-MED
of	O
social	B-MED
security	I-MED
mechanism	I-MED
for	O
rare	B-MED
diseases	I-MED
in	O
China	B-MED
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	B-MED
caused	O
by	O
these	O
diseases	B-MED
.	O
A	O
total	O
of	O
7	O
rare	B-MED
diseases	I-MED
were	O
selected	O
by	O
Delphi	B-MED
method	I-MED
.	O
Affordability	B-MED
of	O
treatment	B-MED
for	O
the	O
7	O
rare	B-MED
diseases	I-MED
was	O
assessed	B-MED
through	O
annual	B-MED
per	I-MED
capital	I-MED
income	I-MED
,	O
catastrophic	B-MED
expenditure	I-MED
and	O
impoverishment	B-MED
expenditure	B-MED
among	O
urban	B-MED
and	O
rural	B-MED
residents	I-MED
in	O
China	B-MED
.	O
Assessed	B-MED
through	O
annual	B-MED
per	I-MED
capital	I-MED
income	I-MED
,	O
health	B-MED
expenditure	I-MED
for	O
the	O
7	O
rare	B-MED
diseases	I-MED
are	O
all	O
rather	O
high	O
.	O
The	O
highest	O
health	B-MED
expenditure	I-MED
is	O
equivalent	O
to	O
income	B-MED
of	O
69.34	O
years	B-MED
of	O
one	O
urban	B-MED
resident	I-MED
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	B-MED
residents	I-MED
.	O
Through	O
catastrophic	B-MED
expenditure	I-MED
assessment	B-MED
,	O
proportions	B-MED
of	O
the	O
population	B-MED
experiencing	O
catastrophic	B-MED
expenditure	I-MED
caused	O
by	O
the	O
7	O
rare	B-MED
diseases	I-MED
are	O
all	O
under	O
0.167	O
‰.	O
However	O
,	O
once	O
one	O
is	O
ill	B-MED
and	O
taking	O
medications	B-MED
,	O
he	O
will	O
suffer	O
from	O
catastrophic	B-MED
health	I-MED
expenditure	I-MED
.	O
Through	O
impoverishment	B-MED
expenditure	B-MED
assessment	B-MED
,	O
the	O
proportions	B-MED
of	O
impoverishment	B-MED
payment	B-MED
are	O
low	O
among	O
both	O
urban	B-MED
and	O
rural	B-MED
residents	I-MED
,	O
but	O
the	O
7	O
rare	B-MED
diseases	I-MED
could	O
lead	O
nearly	O
4.6	O
million	O
people	B-MED
into	O
poverty	B-MED
on	O
a	O
national	O
scale	O
.	O
The	O
affordability	B-MED
of	O
treatment	B-MED
for	O
rare	B-MED
disease	I-MED
as	O
well	O
as	O
orphan	B-MED
drugs	I-MED
is	O
rather	O
poor	B-MED
.	O
Residents	B-MED
of	O
different	O
income	B-MED
levels	I-MED
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-MED
for	O
rare	B-MED
diseases	I-MED
,	O
so	O
poverty	B-MED
caused	O
by	O
rare	B-MED
diseases	I-MED
is	O
quite	O
widespread	B-MED
.	O
Therefore	O
,	O
social	B-MED
security	I-MED
mechanism	I-MED
for	O
rare	B-MED
disease	I-MED
patients	B-MED
should	O
be	O
established	O
and	O
specific	O
payment	B-MED
pattern	O
for	O
orphan	B-MED
drugs	I-MED
should	O
be	O
set	O
up	O
.	O
Extracellular	B-MED
vesicles	I-MED
from	O
bone	B-MED
marrow	I-MED
derived	O
mesenchymal	B-MED
stem	I-MED
cells	I-MED
protect	B-MED
against	O
murine	B-MED
hepatic	B-MED
ischemia	I-MED
hepatic	B-MED
ischemia	I-MED
-	I-MED
reperfusion	I-MED
injury	I-MED
reperfusion	B-MED
injury	I-MED
Hepatic	B-MED
ischemia	I-MED
-	I-MED
reperfusion	I-MED
injury	I-MED
(	O
IRI	B-MED
)	O
and	O
associated	B-MED
inflammation	I-MED
contributes	O
to	O
liver	B-MED
dysfunction	I-MED
and	O
complications	B-MED
after	O
liver	B-MED
surgery	I-MED
and	O
transplantation	B-MED
.	O
Mesenchymal	B-MED
stem	I-MED
cells	I-MED
(	O
MSC	B-MED
)	O
have	O
been	O
reported	O
to	O
reduce	B-MED
hepatic	B-MED
IRI	I-MED
because	O
of	O
their	O
reparative	B-MED
immunomodulatory	B-MED
immunomodulatory	B-MED
effects	I-MED
in	O
injured	B-MED
tissues	B-MED
.	O
Recent	O
studies	O
have	O
highlighted	O
beneficial	B-MED
effects	I-MED
of	O
extracellular	B-MED
vesicles	I-MED
from	O
MSCs	B-MED
(	O
MSC	B-MED
-	O
EV	B-MED
)	O
on	O
tissue	B-MED
injury	I-MED
.	O
The	O
effects	O
of	O
systemically	B-MED
administered	I-MED
mouse	B-MED
bone	I-MED
marrow	I-MED
derived	O
MSC	B-MED
-	O
EV	B-MED
were	O
evaluated	B-MED
in	O
an	O
experimental	B-MED
murine	I-MED
model	I-MED
of	O
hepatic	B-MED
IRI	I-MED
induced	B-MED
by	O
cross	B-MED
clamping	I-MED
the	O
hepatic	B-MED
artery	I-MED
and	O
portal	B-MED
vein	I-MED
for	O
90	O
minutes	B-MED
followed	O
by	O
reperfusion	B-MED
for	O
periods	B-MED
of	O
upto	O
6	O
hours	B-MED
.	O
Compared	O
with	O
controls	B-MED
,	I-MED
intravenous	I-MED
administration	I-MED
of	O
MSC	B-MED
-	O
EV	B-MED
30	O
minutes	B-MED
prior	O
to	O
IRI	B-MED
dramatically	B-MED
reduced	I-MED
the	O
extent	O
of	O
tissue	B-MED
necrosis	I-MED
,	O
decreased	B-MED
caspase-3	B-MED
positive	I-MED
and	O
apoptotic	B-MED
cells	I-MED
,	O
and	O
reduced	B-MED
serum	O
aminotransferase	B-MED
levels	O
.	O
MSC	B-MED
-	O
EV	B-MED
increased	B-MED
hepatic	B-MED
mRNA	B-MED
expression	I-MED
of	O
NACHT	B-MED
,	I-MED
LRR	I-MED
and	I-MED
PYD	I-MED
domains	I-MED
-	I-MED
containing	I-MED
protein	I-MED
12	I-MED
(	O
Nlrp12	B-MED
)	O
,	O
and	O
the	O
chemokine	B-MED
(	I-MED
C	I-MED
-	I-MED
X	I-MED
-	I-MED
C	I-MED
motif	I-MED
)	I-MED
ligand	I-MED
1	I-MED
(	O
CXCL1	B-MED
)	O
,	O
and	O
reduced	B-MED
mRNA	B-MED
expression	I-MED
of	O
several	O
inflammatory	B-MED
cytokines	B-MED
such	O
as	O
IL-6	B-MED
during	O
IRI	B-MED
.	O
MSC	B-MED
-	O
EV	B-MED
increased	B-MED
cell	B-MED
viability	I-MED
and	O
suppressed	B-MED
both	O
oxidative	B-MED
injury	B-MED
and	O
NF	B-MED
-	I-MED
κB	I-MED
activity	B-MED
in	O
AML12	B-MED
murine	I-MED
hepatocytes	I-MED
in	B-MED
vitro	I-MED
.	O
In	O
conclusion	O
,	O
the	O
administration	B-MED
of	O
EV	B-MED
derived	O
from	O
bone	B-MED
marrow	I-MED
derived	O
MSCs	B-MED
may	O
ameliorate	B-MED
hepatic	B-MED
IRI	I-MED
by	O
reducing	B-MED
hepatic	B-MED
injury	I-MED
through	O
modulation	B-MED
of	O
the	O
inflammatory	B-MED
response	I-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Membrane	B-MED
Protein	I-MED
Solubilization	I-MED
and	O
Composition	B-MED
of	O
Protein	B-MED
Detergent	B-MED
Complexes	B-MED
Membrane	B-MED
proteins	I-MED
are	O
typically	B-MED
expressed	I-MED
in	O
heterologous	B-MED
systems	B-MED
with	O
a	O
view	O
to	O
in	B-MED
vitro	I-MED
characterization	B-MED
.	O
A	O
critical	B-MED
step	I-MED
in	O
the	O
preparation	B-MED
of	O
membrane	B-MED
proteins	I-MED
after	O
expression	B-MED
in	O
any	O
system	B-MED
is	O
the	O
solubilization	B-MED
of	I-MED
the	I-MED
protein	I-MED
in	O
aqueous	B-MED
solution	I-MED
,	O
typically	O
using	O
detergents	B-MED
and	O
lipids	B-MED
,	O
to	O
obtain	O
the	O
protein	B-MED
in	O
a	O
form	O
suitable	B-MED
for	O
purification	B-MED
,	O
structural	B-MED
or	O
functional	B-MED
analysis	B-MED
.	O
This	O
process	B-MED
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-MED
in	O
an	O
unnatural	B-MED
environment	B-MED
,	O
a	O
protein	B-MED
detergent	B-MED
complex	B-MED
,	O
separating	O
it	O
from	O
its	O
natural	B-MED
lipid	B-MED
partners	O
while	O
causing	O
the	O
minimum	B-MED
destabilization	B-MED
or	O
modification	B-MED
of	O
the	O
structure	B-MED
.	O
Although	O
the	O
process	B-MED
is	O
difficult	B-MED
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	B-MED
number	O
of	O
membrane	B-MED
proteins	I-MED
have	O
been	O
successfully	B-MED
isolated	I-MED
after	O
expression	B-MED
in	O
a	O
wide	O
variety	O
of	O
systems	B-MED
.	O
In	O
this	O
chapter	O
we	O
give	O
a	O
general	B-MED
protocol	I-MED
for	O
preparing	O
protein	B-MED
detergent	B-MED
complexes	B-MED
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	B-MED
steps	I-MED
.	O
In	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-MED
the	O
composition	B-MED
of	O
protein	B-MED
detergent	B-MED
complexes	B-MED
;	O
this	O
analysis	B-MED
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	B-MED
variation	B-MED
often	O
causes	O
irreproducible	O
results	O
.	O
Biological	B-MED
basis	B-MED
of	O
radiation	B-MED
protection	I-MED
needs	O
rejuvenation	B-MED
Human	B-MED
beings	I-MED
encounter	O
radiation	B-MED
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	B-MED
to	O
radioactive	B-MED
waste	I-MED
sites	B-MED
to	O
participation	B-MED
in	O
medical	B-MED
procedures	I-MED
using	O
X	B-MED
-	I-MED
rays	I-MED
etc	O
.	O
Limits	O
for	O
radiation	B-MED
exposures	I-MED
are	O
legally	B-MED
regulated	I-MED
;	O
however	O
,	O
current	O
radiation	B-MED
protection	I-MED
policy	B-MED
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	B-MED
,	O
cellular	B-MED
and	O
molecular	B-MED
effects	B-MED
of	I-MED
low	B-MED
doses	I-MED
and	O
low	O
dose	B-MED
rates	I-MED
of	O
radiation	B-MED
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	B-MED
dose	I-MED
radiation	B-MED
exposures	I-MED
.	O
Recent	O
technical	B-MED
developments	I-MED
in	O
biology	B-MED
and	O
medicine	B-MED
,	O
from	O
single	B-MED
cell	I-MED
techniques	I-MED
to	O
big	B-MED
data	I-MED
computational	I-MED
research	I-MED
,	O
have	O
enabled	O
new	O
approaches	B-MED
for	O
study	B-MED
of	O
biology	B-MED
of	O
low	B-MED
doses	I-MED
of	O
radiation	B-MED
.	O
Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	B-MED
the	O
idea	B-MED
that	O
low	B-MED
doses	I-MED
of	O
radiation	B-MED
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	B-MED
with	I-MED
high	B-MED
dose	I-MED
exposures	B-MED
;	O
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	B-MED
for	O
the	O
development	B-MED
of	O
a	O
new	O
theoretical	B-MED
framework	I-MED
needed	O
for	O
the	O
understanding	O
of	O
low	B-MED
dose	I-MED
radiation	B-MED
exposures	I-MED
.	O
Mechanistic	O
understanding	O
of	O
radiation	B-MED
effects	I-MED
at	O
low	B-MED
doses	I-MED
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-MED
protection	I-MED
policy	B-MED
.	O
Did	O
municipal	B-MED
solid	I-MED
waste	I-MED
landfill	B-MED
have	O
obvious	O
influence	B-MED
on	O
polychlorinated	B-MED
dibenzo	I-MED
-	I-MED
p	I-MED
-	I-MED
dioxins	I-MED
and	O
polychlorinated	B-MED
dibenzofurans	I-MED
(	O
PCDD	B-MED
/	O
Fs	B-MED
)	O
in	O
ambient	B-MED
air	I-MED
:	O
A	O
case	B-MED
study	I-MED
in	O
East	B-MED
China	I-MED
Municipal	B-MED
solid	I-MED
waste	I-MED
(	O
MSW	B-MED
)	O
landfill	B-MED
was	O
a	O
main	O
way	O
to	O
disposal	B-MED
of	O
MSW	B-MED
and	O
almost	O
95	O
%	O
of	O
MSW	B-MED
was	O
disposed	B-MED
by	O
landfills	B-MED
in	O
the	O
world	B-MED
.	O
In	O
order	O
to	O
understand	O
the	O
influence	B-MED
of	O
MSW	B-MED
landfill	B-MED
on	O
polychlorinated	B-MED
dibenzo	I-MED
-	I-MED
p	I-MED
-	I-MED
dioxins	I-MED
and	O
polychlorinated	B-MED
dibenzofurans	I-MED
(	O
PCDD	B-MED
/	O
Fs	B-MED
)	O
in	O
surrounding	B-MED
atmosphere	I-MED
,	O
42	O
ambient	B-MED
air	I-MED
samples	O
were	O
collected	O
and	O
analyzed	B-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
of	O
a	O
MSW	B-MED
landfill	B-MED
in	O
East	B-MED
China	I-MED
.	O
The	O
results	O
of	O
present	O
study	B-MED
were	O
summarized	O
as	O
follows	O
.	O
(	O
1	O
)	O
The	O
total	O
concentrations	B-MED
of	O
PCDD	B-MED
/	O
Fs	B-MED
(	O
∑	O
PCDD	B-MED
/	O
Fs	B-MED
)	O
in	O
ambient	B-MED
air	I-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
2.215±1.004	O
,	O
2.058±0.458	O
,	O
2.617±1.092	O
and	O
1.822±0.566pgNm(-3	O
)	O
,	O
respectively	O
.	O
(	O
2	O
)	O
The	O
toxic	B-MED
equivalent	I-MED
concentrations	I-MED
(	O
TEQ	B-MED
)	O
of	O
PCDD	B-MED
/	O
Fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
surrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
0.103±0.017	O
,	O
0.096±0.015	O
,	O
0.120±0.024	O
and	O
0.108±0.014pg	O
I	O
-	O
TEQNm(-3	O
)	O
,	O
respectively	O
.	O
(	O
3	O
)	O
The	O
congener	B-MED
profiles	I-MED
,	O
∑	O
PCDD	B-MED
/	O
Fs	B-MED
and	O
TEQ	B-MED
between	O
background	B-MED
atmosphere	I-MED
and	O
surrounding	B-MED
atmosphere	I-MED
of	O
landfill	B-MED
did	O
not	O
show	O
statistically	B-MED
significant	I-MED
difference	O
.	O
(	O
4	O
)	O
The	O
∑	O
PCDD	B-MED
/	O
Fs	B-MED
and	O
TEQ	B-MED
in	O
ambient	B-MED
air	I-MED
of	O
downwind	B-MED
site	I-MED
were	O
not	O
higher	O
than	O
that	O
of	O
upwind	B-MED
site	I-MED
,	O
suggesting	O
that	O
studied	O
landfill	B-MED
did	O
not	O
have	O
obvious	O
influence	B-MED
on	O
PCDD	B-MED
/	O
Fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
downwind	B-MED
site	I-MED
.	O
(	O
5	O
)	O
The	O
95th	O
percentile	B-MED
carcinogenic	B-MED
risk	I-MED
(	O
CR	B-MED
)	O
of	O
PCDD	B-MED
/	O
Fs	B-MED
in	O
ambient	B-MED
air	I-MED
from	O
s	O
urrounding	B-MED
sites	I-MED
,	O
background	B-MED
site	I-MED
,	O
upwind	B-MED
site	I-MED
and	O
downwind	B-MED
site	I-MED
were	O
8.03×10(-9	O
)	O
,	O
7.57×10(-9	O
)	O
,	O
9.69×10(-9	O
)	O
and	O
8.15×10(-9	O
)	O
,	O
respectively	O
,	O
which	O
were	O
much	B-MED
lower	I-MED
than	I-MED
the	I-MED
threshold	I-MED
value	I-MED
of	O
CR	B-MED
(	O
10(-6	O
)	O
)	O
,	O
suggesting	O
that	O
studied	O
landfill	B-MED
did	O
not	O
influence	B-MED
the	O
CR	B-MED
of	O
PCDD	B-MED
/	O
Fs	B-MED
in	O
surrounding	B-MED
atmosphere	I-MED
and	O
negligible	O
cancer	B-MED
risk	I-MED
occurred	O
.	O
(	O
6	O
)	O
The	O
non	B-MED
-	I-MED
carcinogenic	I-MED
risk	I-MED
(	O
non	B-MED
-	I-MED
CR	I-MED
)	O
analysis	B-MED
indicated	O
that	O
landfill	B-MED
did	O
not	O
have	O
influence	B-MED
on	O
the	O
non	B-MED
-	I-MED
CR	I-MED
of	O
PCDD	B-MED
/	O
Fs	B-MED
in	O
surrounding	B-MED
atmosphere	I-MED
and	O
no	O
obvious	O
non	B-MED
-	I-MED
carcinogenic	I-MED
effects	I-MED
developed	O
.	O
Multiplex	B-MED
social	B-MED
ecological	B-MED
network	B-MED
analysis	I-MED
reveals	B-MED
how	O
social	B-MED
changes	I-MED
affect	B-MED
community	B-MED
robustness	B-MED
more	O
than	O
resource	B-MED
depletion	B-MED
Network	B-MED
analysis	I-MED
provides	B-MED
a	O
powerful	O
tool	O
to	O
analyze	O
complex	B-MED
influences	B-MED
of	O
social	B-MED
and	O
ecological	B-MED
structures	I-MED
on	O
community	B-MED
and	O
household	B-MED
dynamics	O
.	O
Most	O
network	B-MED
studies	I-MED
of	O
social	B-MED
-	O
ecological	B-MED
systems	I-MED
use	O
simple	B-MED
,	O
undirected	O
,	O
unweighted	B-MED
networks	I-MED
.	O
We	O
analyze	O
multiplex	B-MED
,	O
directed	B-MED
,	O
and	O
weighted	B-MED
networks	I-MED
of	O
subsistence	B-MED
food	B-MED
flows	O
collected	B-MED
in	O
three	O
small	O
indigenous	B-MED
communities	B-MED
in	O
Arctic	B-MED
Alaska	B-MED
potentially	O
facing	O
substantial	O
economic	B-MED
and	O
ecological	B-MED
changes	B-MED
.	O
Our	O
analysis	O
of	O
plausible	O
future	B-MED
scenarios	B-MED
suggests	O
that	O
changes	B-MED
to	O
social	B-MED
relations	B-MED
and	O
key	O
households	B-MED
have	O
greater	O
effects	B-MED
on	O
community	B-MED
robustness	B-MED
than	O
changes	B-MED
to	O
specific	B-MED
wild	B-MED
food	I-MED
resources	I-MED
.	O
Uveitis	B-MED
in	O
spondyloarthritis	B-MED
patients	B-MED
and	O
its	O
association	B-MED
with	I-MED
HLA	B-MED
-	I-MED
B27	I-MED
histocompatibility	I-MED
antigen	I-MED
:	O
prospective	B-MED
study	I-MED
T	O
o	O
perform	O
a	O
prospective	B-MED
study	I-MED
of	O
clinical	B-MED
presentation	I-MED
and	O
course	B-MED
of	O
uveitis	B-MED
in	O
spondyloarthritis	B-MED
(	O
SpA	B-MED
)	O
patients	B-MED
as	O
well	O
as	O
its	O
association	B-MED
with	I-MED
the	O
HLA	B-MED
-	I-MED
B27	I-MED
histocompatibility	I-MED
antigen	I-MED
.	O
The	O
study	B-MED
included	O
219	O
patients	B-MED
with	O
uveitis	B-MED
,	O
all	O
tested	B-MED
for	O
HLA	B-MED
-	I-MED
B27	I-MED
antigen	I-MED
and	O
various	O
infections	B-MED
(	O
viral	B-MED
,	O
bacterial	B-MED
,	O
and	O
parasitic	B-MED
)	O
as	O
well	O
as	O
examined	B-MED
for	O
locomotive	B-MED
system	I-MED
involvement	B-MED
.	O
The	O
presence	B-MED
of	O
the	O
HLA	B-MED
-	I-MED
B27	I-MED
antigen	I-MED
was	O
determined	B-MED
in	O
142	O
(	O
64.8	O
%	O
)	O
out	O
of	O
219	O
patients	B-MED
,	O
of	O
them	O
87	O
were	O
diagnosed	B-MED
with	O
an	O
entity	B-MED
of	O
the	O
SpA	B-MED
group	B-MED
.	O
The	O
remaining	B-MED
77	O
(	O
35.2	O
%	O
)	O
patients	B-MED
appeared	O
to	O
be	O
HLA	B-MED
-	I-MED
B27	I-MED
-	O
negative	B-MED
,	O
but	O
13	O
were	O
still	O
diagnosed	B-MED
with	O
an	O
entity	B-MED
of	O
the	O
SpA	B-MED
group	B-MED
.	O
There	O
were	O
10	O
(	O
4.6	O
%	O
)	O
patients	B-MED
with	O
2	O
or	O
more	O
diseases	B-MED
from	O
the	O
SpA	B-MED
group	B-MED
(	O
«	O
clinical	O
decussation	O
»	O
)	O
.	O
When	O
comparing	B-MED
the	O
two	O
groups	B-MED
of	O
HLA	B-MED
-	I-MED
B27	I-MED
-	I-MED
positive	I-MED
and	O
negative	B-MED
patients	B-MED
having	O
both	O
SpA	B-MED
and	O
uveitis	B-MED
,	O
no	O
statistically	B-MED
significant	I-MED
difference	B-MED
was	O
found	O
as	O
to	O
the	O
age	B-MED
of	I-MED
onset	I-MED
,	O
site	B-MED
,	O
frequency	B-MED
of	I-MED
attacks	I-MED
,	O
and	O
uni	B-MED
-	O
or	O
bilateral	B-MED
involvement	B-MED
(	O
p>0.05	O
)	O
.	O
We	O
also	O
performed	B-MED
a	O
comparison	B-MED
of	O
HLA	B-MED
-	I-MED
B27	I-MED
-	I-MED
positive	I-MED
and	O
negative	B-MED
patients	B-MED
with	O
no	O
account	O
to	O
their	O
SpA	B-MED
status	B-MED
and	O
revealed	B-MED
a	O
higher	B-MED
complication	B-MED
rate	B-MED
in	O
those	O
that	O
were	O
«	O
negative	B-MED
»	O
(	O
p<0.0001	O
)	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
HLA	B-MED
-	I-MED
B27	I-MED
-	O
negative	B-MED
patients	B-MED
often	O
have	O
autoimmune	B-MED
or	O
infectious	B-MED
uveitis	I-MED
of	O
different	B-MED
origin	O
notable	O
for	O
long	B-MED
attacks	O
and	O
short	B-MED
remissions	B-MED
.	O
Assessing	B-MED
the	O
site	B-MED
and	O
course	B-MED
of	O
uveitis	B-MED
as	O
well	O
as	O
HLA	B-MED
-	I-MED
B27	I-MED
testing	B-MED
of	O
uveitis	B-MED
patients	B-MED
has	O
proved	O
important	B-MED
for	O
etiological	B-MED
diagnosis	B-MED
.	O
Diseases	B-MED
of	O
the	O
SpA	B-MED
group	B-MED
have	O
been	O
shown	O
to	O
be	O
6.7	O
times	B-MED
more	O
common	O
in	O
HLA	B-MED
-	I-MED
B27	I-MED
-	I-MED
positive	I-MED
patients	B-MED
as	O
compared	B-MED
to	O
HLA	B-MED
-	I-MED
B27	I-MED
-	O
negative	B-MED
ones	O
.	O
Clinical	B-MED
presentation	I-MED
of	O
uveitis	B-MED
in	O
the	O
presence	B-MED
of	O
SpA	B-MED
in	O
both	O
HLA	B-MED
-	I-MED
B27	I-MED
-	I-MED
positive	I-MED
and	O
negative	B-MED
patients	B-MED
resembles	O
that	O
of	O
idiopathic	B-MED
uveitis	I-MED
-	O
an	O
independent	O
HLA	B-MED
-	I-MED
B27	I-MED
-	O
associated	B-MED
syndrome	B-MED
(	O
р>0.05	O
)	O
.	O
Cases	O
of	O
«	O
decussation	O
»	O
between	O
entities	B-MED
of	O
the	O
SpA	B-MED
group	B-MED
are	O
usually	O
more	O
severe	B-MED
in	O
terms	O
of	O
clinical	B-MED
presentation	I-MED
and	O
course	B-MED
of	O
uveitis	B-MED
and	O
are	O
associated	B-MED
with	I-MED
a	O
worse	B-MED
prognosis	I-MED
.	O
Complications	B-MED
of	O
uveitis	B-MED
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non	B-MED
-	I-MED
SpA	I-MED
HLA	B-MED
-	I-MED
B27	I-MED
-	O
negative	B-MED
patients	B-MED
(	O
р<0.0001	O
)	O
.	O
Shift	B-MED
Work	I-MED
Is	O
Associated	B-MED
with	I-MED
Metabolic	B-MED
Syndrome	I-MED
in	O
Young	B-MED
Female	B-MED
Korean	B-MED
Workers	B-MED
Shift	B-MED
work	I-MED
is	O
associated	B-MED
with	I-MED
health	B-MED
problems	I-MED
,	O
including	O
metabolic	B-MED
syndrome	I-MED
.	O
This	O
study	B-MED
investigated	O
the	O
association	B-MED
between	O
shift	B-MED
work	I-MED
and	O
metabolic	B-MED
syndrome	I-MED
in	O
young	B-MED
workers	B-MED
.	O
A	O
total	O
of	O
3,317	O
subjects	B-MED
aged	O
20	O
-	O
40	O
years	O
enrolled	O
in	O
the	O
2011	O
-	O
2012	O
Korean	B-MED
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
were	O
divided	O
into	O
shift	B-MED
and	O
day	B-MED
workers	I-MED
.	O
We	O
conducted	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
and	O
calculated	B-MED
odds	B-MED
ratios	I-MED
using	O
multivariate	B-MED
logistic	B-MED
regression	I-MED
analysis	I-MED
in	O
order	O
to	O
examine	B-MED
the	O
association	B-MED
between	O
shift	B-MED
work	I-MED
and	O
metabolic	B-MED
syndrome	I-MED
.	O
The	O
prevalence	B-MED
of	O
metabolic	B-MED
syndrome	I-MED
was	O
14.3	O
%	O
and	O
7.1	O
%	O
among	O
male	B-MED
and	O
female	B-MED
shift	B-MED
workers	I-MED
,	O
respectively	O
.	O
After	O
adjusting	O
for	O
confounding	B-MED
factors	I-MED
,	O
shift	B-MED
work	I-MED
was	O
associated	B-MED
with	I-MED
metabolic	B-MED
syndrome	I-MED
in	O
female	B-MED
workers	B-MED
(	O
odds	B-MED
ratio	I-MED
,	O
2.53	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
1.12	O
to	O
5.70	O
)	O
.	O
Shift	B-MED
work	I-MED
was	O
associated	B-MED
with	I-MED
metabolic	B-MED
syndrome	I-MED
in	O
young	B-MED
women	B-MED
.	O
Timely	O
efforts	O
are	O
necessary	O
to	O
manage	B-MED
metabolic	B-MED
syndrome	I-MED
in	O
the	O
workplace	B-MED
.	O
N	B-MED
-	I-MED
Terminal	I-MED
Hypothesis	B-MED
for	O
Alzheimer	B-MED
's	I-MED
Disease	I-MED
Although	O
the	O
amyloid	B-MED
(	O
abeta	B-MED
peptide	I-MED
,	O
Aβ	B-MED
)	O
hypothesis	B-MED
is	O
25	O
years	B-MED
old	O
,	O
is	O
the	O
dominant	B-MED
model	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
pathogenesis	B-MED
,	O
and	O
guides	O
the	O
development	B-MED
of	O
potential	O
treatments	B-MED
,	O
it	O
is	O
still	O
controversial	B-MED
.	O
One	O
possible	O
reason	O
is	O
a	O
lack	B-MED
of	O
a	O
mechanistic	B-MED
path	I-MED
from	O
the	O
cleavage	B-MED
products	I-MED
of	O
the	O
amyloid	B-MED
precursor	I-MED
protein	I-MED
(	O
APP	B-MED
)	O
such	O
as	O
soluble	B-MED
Aβ	B-MED
monomer	I-MED
and	O
soluble	O
molecular	B-MED
fragments	B-MED
to	O
the	O
deleterious	B-MED
effects	I-MED
on	O
synaptic	B-MED
form	I-MED
and	O
function	B-MED
.	O
From	O
a	O
review	B-MED
of	I-MED
the	O
recent	O
literature	B-MED
and	O
our	O
own	O
published	B-MED
work	I-MED
including	O
aggregation	B-MED
kinetics	I-MED
and	O
structural	B-MED
morphology	B-MED
,	O
Aβ	B-MED
clearance	B-MED
,	O
molecular	B-MED
simulations	B-MED
,	O
long	B-MED
-	I-MED
term	I-MED
potentiation	I-MED
measurements	B-MED
with	O
inhibition	B-MED
binding	I-MED
,	O
and	O
the	O
binding	B-MED
of	O
a	O
commercial	O
monoclonal	B-MED
antibody	I-MED
,	O
aducanumab	B-MED
,	O
we	O
hypothesize	B-MED
that	O
the	O
N	B-MED
-	I-MED
terminal	I-MED
domains	I-MED
of	O
neurotoxic	B-MED
Aβ	B-MED
oligomers	I-MED
are	O
implicated	O
in	O
causing	B-MED
the	O
disease	B-MED
.	O
An	O
ultrasensitive	B-MED
electrochemiluminescence	B-MED
sensor	B-MED
based	O
on	O
reduced	B-MED
graphene	I-MED
oxide	I-MED
-	O
copper	B-MED
sulfide	I-MED
composite	B-MED
coupled	O
with	O
capillary	B-MED
electrophoresis	I-MED
for	O
determination	B-MED
of	O
amlodipine	B-MED
besylate	I-MED
in	O
mice	B-MED
plasma	B-MED
A	O
new	O
electrochemiluminescence	B-MED
(	O
ECL	B-MED
)	O
sensor	B-MED
based	O
on	O
reduced	B-MED
graphene	I-MED
oxide	I-MED
-	O
copper	B-MED
sulfide	I-MED
(	O
rGO	B-MED
-	O
CuS	B-MED
)	O
composite	B-MED
coupled	O
with	O
capillary	B-MED
electrophoresis	I-MED
(	O
CE	B-MED
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	B-MED
detection	B-MED
of	O
amlodipine	B-MED
besylate	I-MED
(	O
AML	B-MED
)	O
for	O
the	O
first	O
time	O
.	O
In	O
this	O
work	O
,	O
rGO	B-MED
-	O
CuS	B-MED
composite	B-MED
was	O
synthesized	O
by	O
one	O
-	O
pot	O
hydrothermal	B-MED
method	I-MED
and	O
used	O
for	O
electrode	B-MED
modification	B-MED
.	O
The	O
electrochemical	B-MED
and	O
ECL	B-MED
behaviors	O
of	O
the	O
sensor	B-MED
were	O
investigated	B-MED
.	O
More	O
than	O
5	O
-	O
fold	O
enhance	B-MED
in	O
ECL	B-MED
intensity	B-MED
was	O
observed	B-MED
after	O
modified	O
with	O
rGO	B-MED
-	O
CuS	B-MED
composite	B-MED
.	O
The	O
results	B-MED
can	O
be	O
ascribed	O
to	O
the	O
presence	B-MED
of	O
rGO	B-MED
-	O
CuS	B-MED
composite	B-MED
on	O
the	O
electrode	B-MED
surface	B-MED
that	O
facilitates	O
the	O
electron	B-MED
transfer	I-MED
rate	I-MED
between	O
the	O
electroactive	B-MED
center	B-MED
of	O
Ru(bpy)3(2	B-MED
+	I-MED
)	I-MED
and	O
the	O
electrode	B-MED
.	O
The	O
ECL	B-MED
sensor	B-MED
was	O
coupled	B-MED
with	O
CE	B-MED
to	O
improve	O
the	O
selectivity	B-MED
and	O
the	O
CE	B-MED
-	O
ECL	B-MED
parameters	B-MED
that	O
affect	O
separation	B-MED
and	O
detection	B-MED
were	O
optimized	O
.	O
Under	O
the	O
optimum	B-MED
conditions	O
,	O
the	O
linear	B-MED
ranges	I-MED
for	O
AML	B-MED
was	O
0.008	O
-	O
5.0μg	O
/	O
mL	O
with	O
a	O
detection	B-MED
limit	I-MED
of	O
2.8ng	O
/	O
mL	O
(	O
S	O
/	O
N=3	O
)	O
.	O
The	O
method	B-MED
displayed	O
the	O
advantages	O
of	O
high	B-MED
sensitivity	I-MED
,	O
good	B-MED
selectivity	I-MED
,	O
wide	O
linear	B-MED
range	I-MED
,	O
low	O
detection	B-MED
limit	I-MED
and	O
fine	B-MED
reproducibility	I-MED
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	B-MED
in	O
mice	B-MED
plasma	B-MED
with	O
a	O
satisfactory	O
result	B-MED
,	O
which	O
holds	O
a	O
great	O
potential	B-MED
in	O
the	O
field	O
of	O
pharmaceutical	B-MED
analysis	I-MED
.	O
Identification	B-MED
of	O
MiR-21	B-MED
-	I-MED
5p	I-MED
as	O
a	O
Functional	B-MED
Regulator	I-MED
of	O
Mesothelin	B-MED
Expression	B-MED
Using	O
MicroRNA	B-MED
Capture	O
Affinity	B-MED
Coupled	B-MED
with	O
Next	B-MED
Generation	I-MED
Sequencing	I-MED
MicroRNAs	B-MED
(	O
miRNAs	B-MED
)	O
are	O
small	B-MED
non	I-MED
-	I-MED
coding	I-MED
RNAs	I-MED
that	O
regulate	B-MED
mRNA	B-MED
expression	I-MED
mainly	O
by	O
silencing	B-MED
target	B-MED
transcripts	B-MED
via	O
binding	B-MED
to	O
miRNA	B-MED
recognition	I-MED
elements	I-MED
(	I-MED
MREs	I-MED
)	I-MED
in	O
the	O
3'untranslated	B-MED
region	I-MED
(	O
3'UTR	B-MED
)	O
.	O
The	O
identification	B-MED
of	O
bona	B-MED
fide	I-MED
targets	B-MED
is	O
challenging	O
for	O
researchers	B-MED
working	I-MED
on	O
the	O
functional	B-MED
aspect	I-MED
of	O
miRNAs	B-MED
.	O
Recently	O
,	O
we	O
developed	O
a	O
method	B-MED
(	I-MED
miR	I-MED
-	I-MED
CATCH	I-MED
)	I-MED
based	O
on	O
biotinylated	B-MED
DNA	B-MED
antisense	B-MED
oligonucleotides	I-MED
that	O
capture	O
the	O
mRNA	B-MED
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
miRNAs::mRNA	B-MED
interactions	I-MED
in	O
a	O
physiological	B-MED
cellular	I-MED
context	O
.	O
Here	O
,	O
the	O
miR	B-MED
-	I-MED
CATCH	I-MED
technique	I-MED
was	O
applied	O
to	O
the	O
mesothelin	B-MED
(	I-MED
MSLN	I-MED
)	I-MED
gene	I-MED
and	O
coupled	B-MED
with	O
next	B-MED
generation	I-MED
sequencing	I-MED
(	O
NGS	B-MED
)	O
,	O
to	O
identify	O
miRNAs	B-MED
that	O
regulate	B-MED
MSLN	B-MED
mRNA	I-MED
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	B-MED
levels	I-MED
found	O
in	O
malignant	B-MED
pleural	I-MED
mesothelioma	I-MED
(	O
MPM	B-MED
)	O
.	O
Biotinylated	B-MED
MSLN	B-MED
oligos	I-MED
were	O
employed	O
to	O
isolate	O
miRNA::MSLN	B-MED
mRNA	I-MED
complexes	I-MED
from	O
a	O
normal	O
cell	B-MED
line	I-MED
(	I-MED
Met-5A	I-MED
)	I-MED
which	O
expresses	B-MED
low	O
levels	O
of	O
MSLN	B-MED
.	O
MiRNAs	B-MED
targeting	B-MED
the	O
MSLN	B-MED
mRNA	I-MED
were	O
identified	O
by	O
NGS	B-MED
and	O
miR-21	B-MED
-	I-MED
5p	I-MED
and	O
miR-100	B-MED
-	I-MED
5p	I-MED
were	O
selected	O
for	O
further	O
validation	B-MED
analyses	I-MED
.	O
MiR-21	B-MED
-	I-MED
5p	I-MED
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	B-MED
MSLN	B-MED
expression	B-MED
in	O
miRNA	B-MED
mimic	B-MED
experiments	B-MED
in	O
a	O
panel	O
of	O
malignant	B-MED
and	O
non	O
-	O
malignant	O
cell	B-MED
lines	I-MED
.	O
Further	O
miRNA	B-MED
inhibitor	B-MED
experiments	B-MED
and	O
luciferase	B-MED
assays	B-MED
in	O
Mero-14	B-MED
cells	I-MED
validated	O
miR-21	B-MED
-	I-MED
5p	I-MED
as	O
a	O
true	O
regulator	B-MED
of	O
MSLN	B-MED
.	O
Moreover	O
,	O
in	B-MED
vitro	I-MED
experiments	I-MED
showed	O
that	O
treatment	B-MED
with	O
miR-21	B-MED
-	I-MED
5p	I-MED
mimic	B-MED
reduced	O
proliferation	B-MED
of	O
MPM	B-MED
cell	B-MED
lines	I-MED
.	O
Altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
miR	B-MED
-	I-MED
CATCH	I-MED
technique	I-MED
,	O
coupled	B-MED
with	O
NGS	B-MED
and	O
in	B-MED
vitro	I-MED
validation	B-MED
,	O
represents	O
a	O
reliable	O
method	B-MED
to	O
identify	O
native	O
miRNA::mRNA	B-MED
interactions	I-MED
.	O
MiR-21	B-MED
-	I-MED
5p	I-MED
is	O
suggested	O
as	O
novel	O
regulator	B-MED
of	O
MSLN	B-MED
with	O
a	O
possible	O
functional	B-MED
role	I-MED
in	O
cellular	B-MED
growth	I-MED
.	O
Effect	B-MED
of	O
Punica	B-MED
granatum	I-MED
fruit	B-MED
peel	I-MED
on	O
glucose-6	B-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
and	O
malate	B-MED
dehydrogenase	I-MED
in	O
amphistome	B-MED
Gastrothylax	B-MED
indicus	I-MED
Increasing	B-MED
anthelmintic	B-MED
resistance	B-MED
and	O
the	O
impact	B-MED
of	O
conventional	O
anthelmintics	B-MED
on	O
the	O
environment	B-MED
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth	B-MED
parasite	I-MED
in	O
sheep	B-MED
.	O
Important	O
lipogenic	B-MED
enzymes	I-MED
like	O
glucose-6	B-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
(	O
G-6	B-MED
-	I-MED
PDH	I-MED
)	O
and	O
malate	B-MED
dehydrogenase	I-MED
(	O
MDH	B-MED
)	O
show	O
subcellular	B-MED
distribution	B-MED
pattern	I-MED
.	O
Activity	B-MED
of	O
G-6	B-MED
-	I-MED
PDH	I-MED
was	O
largely	O
restricted	O
to	O
cytosolic	B-MED
fraction	I-MED
while	O
MDH	B-MED
was	O
found	O
in	O
both	O
cytosolic	B-MED
and	O
mitochondrial	B-MED
fraction	I-MED
in	O
Gastrothylax	B-MED
indicus	I-MED
.	O
Following	O
in	B-MED
vitro	I-MED
treatment	B-MED
with	O
ethanolic	B-MED
and	O
aqueous	B-MED
extracts	I-MED
of	O
Punica	B-MED
granatum	I-MED
fruit	B-MED
peel	I-MED
and	O
commercial	O
anthelmintic	B-MED
,	O
albendazole	B-MED
G-6	B-MED
-	I-MED
PDH	I-MED
activity	B-MED
was	O
decreased	B-MED
by	O
19	O
-	O
32	O
%	O
,	O
whereas	O
MDH	B-MED
was	O
suppressed	B-MED
by	O
24	O
-	O
41	O
%	O
,	O
compared	O
to	O
the	O
respective	O
control	B-MED
.	O
Albendazole	B-MED
was	O
quite	O
effective	B-MED
when	O
compared	O
with	O
negative	B-MED
control	I-MED
and	O
both	O
the	O
extracts	B-MED
.	O
The	O
results	B-MED
indicate	O
that	O
phytochemicals	B-MED
of	O
plant	B-MED
may	O
act	O
as	O
potential	B-MED
vermifuge	B-MED
or	O
vermicide	B-MED
.	O
Prevalence	B-MED
of	O
Hypothyroidism	B-MED
in	O
Andalusia	B-MED
,	I-MED
Spain	I-MED
,	I-MED
Determined	O
by	O
Thyroid	B-MED
Hormone	I-MED
Comsumption	B-MED
Hypothyroidism	B-MED
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone	B-MED
deficiency	I-MED
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	B-MED
are	O
scarce	O
in	O
Spain	B-MED
.	O
For	O
that	O
reason	O
,	O
we	O
have	O
estimated	O
its	O
prevalence	B-MED
through	O
the	O
registration	B-MED
of	O
patients	B-MED
who	O
had	O
used	O
thyroid	B-MED
hormones	I-MED
in	O
Andalusia	B-MED
(	I-MED
South	I-MED
Spain	I-MED
)	I-MED
.	O
Data	O
of	O
patients	B-MED
who	O
had	O
withdrawn	O
levothyroxine	B-MED
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
Andalusian	B-MED
Health	I-MED
Service	I-MED
were	O
considered	O
.	O
Prevalence	B-MED
were	O
calculated	O
with	O
confidence	B-MED
intervals	I-MED
of	O
95	O
%	O
for	O
each	O
management	B-MED
area	I-MED
,	O
stratified	O
by	O
sex	B-MED
and	O
age	B-MED
groups	I-MED
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-MED
.	O
321,368	O
people	B-MED
(	O
98	O
%	O
older	O
than	O
18	O
years	O
and	O
83	O
%	O
female	B-MED
)	O
were	O
identified	O
as	O
levothyroxine	B-MED
users	O
and	O
a	O
prevalence	B-MED
of	O
hypothyroidism	B-MED
of	O
3.95	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
3.94	O
-	O
3.96	O
)	O
was	O
estimated	O
for	O
the	O
general	O
population	B-MED
.	O
The	O
condition	O
was	O
more	O
common	O
in	O
females	B-MED
,	O
in	O
the	O
older	O
18	O
years	O
7.81	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
7.80	O
to	O
7.82	O
)	O
compared	O
to	O
males	B-MED
1.75	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
1.73	O
-	O
1.77	O
)	O
with	O
a	O
ratio	O
of	O
4.5	B-MED
-	I-MED
fold	I-MED
.	O
It	O
increases	O
in	O
the	O
population	B-MED
of	O
women	B-MED
older	O
than	O
45	O
years	O
,	O
10.32	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
10.30	O
-	O
0.32	O
)	O
and	O
in	O
the	O
over	O
60	O
years	O
11.37	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
11.35	O
-	O
11.40	O
)	O
.	O
The	O
prevalence	B-MED
in	O
adult	B-MED
women	B-MED
in	O
the	O
western	B-MED
provinces	I-MED
is	O
7.38	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
7.36	O
-	O
7.40	O
)	O
,	O
in	O
the	O
eastern	B-MED
provinces	I-MED
8.59	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
8.57	O
-	O
8.62	O
)	O
and	O
in	O
coastal	B-MED
areas	I-MED
6.70	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
6.68	O
-	O
6.72	O
)	O
compared	O
to	O
the	O
mountainous	B-MED
ones	I-MED
,	O
which	O
is	O
8.91	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
8.88	O
-	O
8.94	O
)	O
.	O
The	O
results	O
denote	O
a	O
high	B-MED
prevalence	I-MED
of	O
hypothyroidism	B-MED
in	O
the	O
adult	B-MED
population	B-MED
of	O
Andalusia	B-MED
compared	O
to	O
the	O
nearby	O
countries	B-MED
,	O
with	O
a	O
clear	O
increased	O
associated	B-MED
with	I-MED
females	B-MED
and	O
age	B-MED
.	O
Furthermore	O
,	O
the	O
prevalence	B-MED
of	O
the	O
illness	B-MED
presents	O
also	O
a	O
geographically	B-MED
-	I-MED
related	I-MED
variability	B-MED
.	O
Civil	B-MED
Society	I-MED
-Driven	O
Drug	B-MED
Policy	I-MED
Reform	I-MED
for	O
Health	B-MED
and	O
Human	B-MED
Welfare	I-MED
-	O
India	B-MED
The	O
lack	B-MED
of	O
adequate	B-MED
access	O
to	O
opioids	B-MED
in	O
India	B-MED
as	O
analgesics	B-MED
and	O
for	O
agonist	B-MED
therapies	B-MED
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	B-MED
unalleviated	B-MED
pain	I-MED
,	O
or	O
languish	B-MED
with	O
suffering	B-MED
associated	O
with	O
drug	B-MED
dependence	I-MED
.	O
Although	O
India	B-MED
is	O
a	O
major	O
opium	B-MED
exporter	B-MED
,	O
the	O
excessively	O
prohibitive	B-MED
1985	O
narcotics	B-MED
law	I-MED
formulated	O
to	O
control	B-MED
harmful	B-MED
use	I-MED
of	I-MED
drugs	I-MED
,	O
impeded	O
the	O
availability	B-MED
and	O
access	B-MED
to	O
opioids	B-MED
for	O
medical	B-MED
and	O
scientific	B-MED
purposes	B-MED
.	O
Amendment	B-MED
of	O
this	O
law	B-MED
in	O
2014	O
established	O
a	O
new	O
national	B-MED
regulatory	I-MED
framework	I-MED
for	O
improved	O
access	B-MED
to	O
essential	B-MED
opioid	B-MED
analgesics	I-MED
.	O
This	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	B-MED
.	O
Unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy	B-MED
reforms	I-MED
for	O
law	B-MED
enforcement	I-MED
,	O
realizing	O
the	O
2014	O
drug	B-MED
policy	I-MED
change	O
primarily	O
to	O
mitigate	B-MED
human	B-MED
suffering	I-MED
,	I-MED
was	O
a	O
22	O
-	O
year	O
-	O
long	O
process	O
.	O
The	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered	B-MED
complexities	I-MED
of	O
the	O
prior	O
policy	B-MED
framework	I-MED
and	O
understanding	O
their	O
adverse	B-MED
impact	B-MED
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	B-MED
.	O
The	O
evolution	O
of	O
an	O
informal	O
civil	B-MED
society	I-MED
movement	I-MED
involving	O
health	B-MED
care	I-MED
professionals	I-MED
,	O
lawyers	B-MED
,	O
media	B-MED
,	O
policy	B-MED
analysts	I-MED
,	O
government	B-MED
officials	I-MED
,	O
and	O
the	O
public	B-MED
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-MED
and	O
garnering	O
momentum	O
for	O
reform	B-MED
.	O
The	O
success	B-MED
of	O
the	O
effort	O
for	O
improving	O
access	B-MED
to	O
opioid	B-MED
medications	B-MED
was	O
underpinned	O
by	O
a	O
three	O
-	O
pronged	O
strategy	O
of	O
1	O
)	O
persuading	O
the	O
executive	B-MED
arm	I-MED
of	I-MED
the	I-MED
government	I-MED
to	O
take	O
interim	B-MED
enabling	O
measures	B-MED
;	O
2	O
)	O
leveraging	O
judicial	B-MED
intervention	I-MED
through	O
public	B-MED
interest	B-MED
litigation	B-MED
;	O
and	O
3	O
)	O
crafting	B-MED
a	I-MED
viable	I-MED
policy	I-MED
document	I-MED
for	O
legislative	B-MED
approval	I-MED
and	O
implementation	B-MED
.	O
We	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug	B-MED
policy	I-MED
reforms	I-MED
,	O
given	O
the	O
current	O
transformed	O
global	B-MED
policy	B-MED
mandates	B-MED
emphasizing	O
humanitarian	B-MED
,	O
healthcare	B-MED
,	O
and	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
considerations	B-MED
.	O
Results	B-MED
for	O
patients	B-MED
with	O
sarcoma	B-MED
not	B-MED
otherwise	I-MED
specified	I-MED
and	O
other	O
diagnoses	B-MED
than	O
Ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
the	O
Euro	B-MED
-	I-MED
EWING	I-MED
99	I-MED
trial	I-MED
Euro	B-MED
-	I-MED
EWING	I-MED
99	I-MED
trial	I-MED
of	O
the	O
European	B-MED
Ewing	B-MED
tumor	I-MED
Working	B-MED
Initiative	B-MED
of	O
National	B-MED
Groups	B-MED
(	O
EE99	B-MED
)	O
was	O
an	O
international	B-MED
phase	B-MED
III	I-MED
study	I-MED
in	O
patients	B-MED
with	O
Ewing	B-MED
sarcoma	I-MED
.	O
The	O
German	B-MED
Society	I-MED
of	I-MED
Pediatric	I-MED
Oncology	I-MED
and	I-MED
Hematology	I-MED
(	I-MED
GPOH	I-MED
)	I-MED
data	I-MED
center	I-MED
registered	B-MED
and	O
followed	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
Ewing	B-MED
sarcoma	I-MED
who	O
were	O
treated	B-MED
according	O
to	O
the	O
EE99	B-MED
protocol	I-MED
in	O
an	O
additional	O
non	B-MED
-	I-MED
Ewing	I-MED
database	I-MED
.	O
Data	B-MED
of	O
27	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
Ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
the	O
EE99	B-MED
protocol	I-MED
were	O
analyzed	B-MED
.	O
Patients	B-MED
had	O
miscellaneous	B-MED
histologic	B-MED
diagnoses	B-MED
,	O
the	O
majority	B-MED
were	O
diagnosed	B-MED
with	O
sarcoma	B-MED
not	B-MED
otherwise	I-MED
specified	I-MED
(	O
NOS	B-MED
)	O
arising	O
in	O
bone	B-MED
and	O
soft	B-MED
tissue	I-MED
(	O
63	O
%	O
)	O
.	O
The	O
median	B-MED
age	B-MED
at	O
diagnosis	B-MED
was	O
16.9	O
years	O
(	O
range	O
4.5	O
-	O
41.4	O
)	O
.	O
Localized	B-MED
disease	I-MED
was	O
diagnosed	B-MED
in	O
61.5	O
%	O
of	O
the	O
patients	B-MED
and	O
38.5	O
%	O
had	O
distant	B-MED
metastases	I-MED
at	O
time	O
of	O
primary	B-MED
diagnosis	B-MED
.	O
The	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
was	O
3.7	O
years	O
(	O
range	O
0.5	O
-	O
9.5	O
)	O
.	O
Patients	B-MED
with	O
localized	B-MED
disease	I-MED
showed	O
a	O
3	O
-	O
year	O
event	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
EFS	B-MED
)	O
of	O
68	O
%	O
,	O
compared	O
to	O
3	O
-	O
year	O
EFS	B-MED
of	O
20	O
%	O
in	O
patients	B-MED
with	O
metastases	B-MED
(	O
P	O
=	O
0.042	O
)	O
.	O
Three	O
-	O
year	O
EFS	B-MED
for	O
patients	B-MED
with	O
sarcoma	B-MED
NOS	B-MED
was	O
52	O
%	O
,	O
patients	B-MED
with	O
localized	B-MED
and	O
metastatic	B-MED
disease	I-MED
showed	O
3	O
-	O
year	O
EFS	B-MED
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O
EFS	B-MED
in	O
patients	B-MED
with	O
other	O
diagnoses	B-MED
than	O
Ewing	B-MED
sarcoma	I-MED
treated	B-MED
according	O
to	O
EE99	B-MED
was	O
significantly	B-MED
higher	O
in	O
patients	B-MED
with	O
localized	B-MED
than	O
metastatic	B-MED
disease	I-MED
.	O
Sarcomas	B-MED
of	O
soft	B-MED
tissue	I-MED
and	O
bone	B-MED
that	O
can	O
not	O
be	O
classified	B-MED
to	O
current	B-MED
diagnostic	B-MED
categories	I-MED
constitute	O
a	O
therapeutic	B-MED
challenge	B-MED
.	O
Folate	B-MED
-based	O
single	B-MED
cell	I-MED
screening	I-MED
using	O
surface	B-MED
enhanced	I-MED
Raman	I-MED
microimaging	I-MED
Recent	O
progress	O
in	O
nanotechnology	B-MED
and	O
its	O
application	O
to	O
biomedical	B-MED
settings	I-MED
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-MED
cancer	I-MED
diagnosis	I-MED
.	O
The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	B-MED
cells	I-MED
,	O
such	O
as	O
the	O
expression	B-MED
of	O
particular	O
plasma	B-MED
membrane	I-MED
molecular	B-MED
receptors	I-MED
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	B-MED
the	I-MED
stage	I-MED
of	I-MED
development	I-MED
of	I-MED
the	I-MED
disease	I-MED
.	O
Here	O
we	O
report	O
a	O
single	B-MED
cell	I-MED
screening	I-MED
approach	O
based	O
on	O
Surface	B-MED
Enhanced	I-MED
Raman	I-MED
Scattering	I-MED
(	I-MED
SERS	I-MED
)	I-MED
microimaging	I-MED
SERS	B-MED
.	O
We	O
fabricated	O
a	O
SERS	B-MED
-	I-MED
labelled	I-MED
nanovector	B-MED
based	O
on	O
the	O
biofunctionalization	B-MED
of	O
gold	B-MED
nanoparticles	I-MED
with	O
folic	B-MED
acid	I-MED
.	O
After	O
treating	B-MED
the	I-MED
cells	I-MED
with	O
the	O
nanovector	B-MED
,	O
we	O
were	O
able	O
to	O
distinguish	B-MED
three	I-MED
different	I-MED
cell	I-MED
populations	I-MED
from	O
different	B-MED
cell	I-MED
lines	I-MED
(	O
cancer	B-MED
HeLa	I-MED
and	O
PC-3	B-MED
,	O
and	O
normal	B-MED
HaCaT	I-MED
lines	I-MED
)	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	B-MED
of	O
folate	B-MED
binding	I-MED
proteins	I-MED
.	O
The	O
nanovector	B-MED
,	O
indeed	O
,	O
binds	B-MED
much	I-MED
more	I-MED
efficiently	I-MED
on	O
cancer	B-MED
cell	I-MED
lines	I-MED
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
SERS	B-MED
signal	O
measured	O
on	O
cancer	B-MED
cells	I-MED
.	O
These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	B-MED
cell	I-MED
diagnostics	I-MED
and	O
,	O
potentially	B-MED
,	O
in	O
theranostics	B-MED
.	O
The	O
genetic	B-MED
basis	O
for	O
variation	B-MED
in	O
resistance	B-MED
to	O
infection	B-MED
in	O
the	O
Drosophila	B-MED
melanogaster	I-MED
genetic	I-MED
reference	I-MED
panel	I-MED
Individuals	B-MED
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-MED
but	O
the	O
genetic	B-MED
basis	O
of	O
this	O
variation	B-MED
is	O
not	O
fully	O
understood	O
.	O
We	O
found	O
substantial	O
individual	B-MED
variation	B-MED
in	O
resistance	B-MED
and	O
tolerance	B-MED
to	O
the	O
fungal	B-MED
pathogen	I-MED
Metarhizium	I-MED
anisopliae	I-MED
Ma549	I-MED
using	O
the	O
Drosophila	B-MED
melanogaster	I-MED
Genetic	I-MED
Reference	I-MED
Panel	I-MED
(	O
DGRP	B-MED
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
host	B-MED
defense	I-MED
to	O
Ma549	B-MED
was	O
correlated	O
with	O
defense	B-MED
to	O
the	O
bacterium	B-MED
Pseudomonas	B-MED
aeruginosa	I-MED
Pa14	I-MED
,	O
and	O
several	O
previously	O
published	O
DGRP	B-MED
phenotypes	B-MED
including	O
oxidative	B-MED
stress	I-MED
sensitivity	B-MED
,	O
starvation	B-MED
stress	B-MED
resistance	I-MED
,	O
hemolymph	B-MED
glucose	B-MED
levels	I-MED
,	O
and	O
sleep	B-MED
indices	B-MED
.	O
We	O
identified	O
polymorphisms	B-MED
associated	B-MED
with	I-MED
differences	B-MED
between	O
lines	O
in	O
both	O
their	O
mean	B-MED
survival	I-MED
times	I-MED
and	O
microenvironmental	B-MED
plasticity	B-MED
,	O
suggesting	O
that	O
lines	O
differ	B-MED
in	O
their	O
ability	B-MED
to	O
adapt	B-MED
to	O
variable	B-MED
pathogen	B-MED
exposures	B-MED
.	O
The	O
majority	O
of	O
polymorphisms	B-MED
increasing	B-MED
resistance	B-MED
to	O
Ma549	B-MED
were	O
sex	B-MED
biased	I-MED
,	O
located	O
in	O
non	B-MED
-	I-MED
coding	I-MED
regions	I-MED
,	O
had	O
moderately	O
large	O
effect	B-MED
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	B-MED
.	O
Nevertheless	O
,	O
host	B-MED
defense	I-MED
was	O
not	O
negatively	O
correlated	B-MED
with	O
overall	O
longevity	B-MED
and	O
fecundity	B-MED
.	O
In	O
contrast	O
to	O
Ma549	B-MED
,	O
minor	B-MED
alleles	I-MED
were	O
concentrated	O
in	O
the	O
most	O
Pa14	B-MED
-	O
susceptible	B-MED
as	O
well	O
as	O
the	O
most	O
Pa14	B-MED
-	O
resistant	B-MED
lines	O
.	O
A	O
pathway	B-MED
based	O
analysis	B-MED
revealed	O
a	O
network	O
of	O
Pa14	B-MED
and	O
Ma549	B-MED
-	O
resistance	B-MED
genes	B-MED
that	O
are	O
functionally	B-MED
connected	O
through	O
processes	B-MED
that	O
encompass	O
phagocytosis	B-MED
and	O
engulfment	B-MED
,	O
cell	B-MED
mobility	I-MED
,	O
intermediary	B-MED
metabolism	I-MED
,	O
protein	B-MED
phosphorylation	I-MED
,	O
axon	B-MED
guidance	I-MED
,	O
response	B-MED
to	I-MED
DNA	I-MED
damage	I-MED
,	O
and	O
drug	B-MED
metabolism	I-MED
.	O
Functional	B-MED
testing	B-MED
with	O
insertional	B-MED
mutagenesis	I-MED
lines	O
indicates	O
that	O
12/13	O
candidate	B-MED
genes	I-MED
tested	B-MED
influence	B-MED
susceptibility	B-MED
to	O
Ma549	B-MED
.	O
Many	O
candidate	B-MED
genes	I-MED
have	O
homologs	B-MED
identified	O
in	O
studies	B-MED
of	O
human	B-MED
disease	B-MED
,	O
suggesting	O
that	O
genes	B-MED
affecting	O
variation	B-MED
in	O
susceptibility	B-MED
are	O
conserved	O
across	O
species	B-MED
.	O
Metalloproteinase	B-MED
meprin	B-MED
α	I-MED
regulates	O
migration	B-MED
and	O
invasion	B-MED
of	O
human	B-MED
hepatocarcinoma	B-MED
cells	B-MED
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	B-MED
Reptin	B-MED
Hepatocellular	B-MED
carcinoma	I-MED
is	O
associated	B-MED
with	I-MED
a	O
high	B-MED
rate	B-MED
of	O
intra	B-MED
-	I-MED
hepatic	I-MED
invasion	B-MED
that	O
carries	O
a	O
poor	B-MED
prognosis	I-MED
.	O
Meprin	B-MED
alpha	I-MED
(	O
Mep1A	B-MED
)	O
is	O
a	O
secreted	B-MED
metalloproteinase	B-MED
with	O
many	O
substrates	O
relevant	O
to	O
cancer	B-MED
invasion	I-MED
.	O
We	O
found	O
that	O
Mep1A	B-MED
was	O
a	O
target	B-MED
of	O
Reptin	B-MED
,	O
a	O
protein	B-MED
that	I-MED
is	I-MED
oncogenic	I-MED
in	O
HCC	B-MED
.	O
We	O
studied	O
Mep1A	B-MED
regulation	B-MED
by	O
Reptin	B-MED
,	O
its	O
role	O
in	O
HCC	B-MED
,	O
and	O
whether	O
it	O
mediates	O
Reptin	B-MED
oncogenic	B-MED
effects	B-MED
.	O
MepA	B-MED
and	O
Reptin	B-MED
expression	B-MED
was	O
measured	O
in	O
human	B-MED
HCC	B-MED
by	O
qRT	B-MED
-	I-MED
PCR	I-MED
and	O
in	O
cultured	B-MED
cells	I-MED
by	O
PCR	B-MED
,	O
western	B-MED
blot	I-MED
and	O
enzymatic	B-MED
activity	I-MED
measurements	I-MED
.	O
Cell	B-MED
growth	I-MED
was	O
assessed	B-MED
by	O
counting	B-MED
and	O
MTS	B-MED
assay	I-MED
.	O
Cell	B-MED
migration	I-MED
was	O
measured	O
in	O
Boyden	B-MED
chambers	I-MED
and	O
wound	B-MED
healing	I-MED
assays	B-MED
,	O
and	O
cell	B-MED
invasion	I-MED
in	O
Boyden	B-MED
chambers	I-MED
.	O
Silencing	B-MED
Reptin	B-MED
decreased	B-MED
Mep1A	B-MED
expression	B-MED
and	O
activity	B-MED
,	O
without	O
affecting	O
meprin	B-MED
β	I-MED
.	O
Mep1A	B-MED
,	O
but	O
not	O
meprin	B-MED
β	I-MED
,	O
was	O
overexpressed	B-MED
in	O
a	O
series	O
of	O
242	O
human	B-MED
HCC	B-MED
(	O
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
high	B-MED
expression	B-MED
correlated	B-MED
with	O
a	O
poor	B-MED
prognosis	I-MED
.	O
Mep1A	B-MED
and	O
Reptin	B-MED
expressions	B-MED
were	O
positively	O
correlated	B-MED
(	O
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
Silencing	B-MED
Mep1A	B-MED
had	O
little	O
effect	O
on	O
cell	B-MED
proliferation	I-MED
,	O
but	O
decreased	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
of	O
HuH7	B-MED
and	O
Hep3B	B-MED
cells	I-MED
.	O
Conversely	O
,	O
overexpression	B-MED
of	O
Mep1A	B-MED
or	O
addition	O
of	O
recombinant	B-MED
Mep1A	B-MED
increased	B-MED
migration	B-MED
and	O
invasion	B-MED
.	O
Finally	O
,	O
overexpression	B-MED
of	O
Mep1A	B-MED
restored	O
a	O
normal	B-MED
cell	B-MED
migration	I-MED
in	O
cells	B-MED
where	O
Reptin	B-MED
was	O
depleted	B-MED
.	O
Mep1A	B-MED
is	O
overexpressed	B-MED
in	O
most	O
HCC	B-MED
and	O
induces	B-MED
HCC	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
.	O
Mep1A	B-MED
expression	B-MED
is	O
regulated	O
by	O
Reptin	B-MED
,	O
and	O
Mep1A	B-MED
mediates	O
Reptin	B-MED
-	O
induced	B-MED
migration	B-MED
.	O
Overall	O
,	O
we	O
suggest	O
that	O
Mep1A	B-MED
may	O
be	O
a	O
useful	O
target	B-MED
in	O
HCC	B-MED
.	O
Shear	B-MED
modulus	I-MED
of	O
structured	B-MED
electrorheological	B-MED
fluid	I-MED
mixtures	B-MED
Some	O
immiscible	B-MED
blends	I-MED
under	O
a	O
strong	O
electric	B-MED
field	I-MED
often	O
exhibit	O
periodic	B-MED
structures	B-MED
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-MED
.	O
Upon	O
shear	B-MED
,	O
the	O
structures	B-MED
tilt	B-MED
,	O
and	O
exhibit	O
an	O
elastic	B-MED
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	B-MED
energy	I-MED
.	O
Assuming	O
a	O
two	B-MED
-	I-MED
dimensional	I-MED
stripe	B-MED
structure	I-MED
,	O
we	O
calculate	O
the	O
Maxwell	B-MED
stress	I-MED
,	O
and	O
derive	O
an	O
expression	B-MED
for	O
the	O
shear	B-MED
modulus	I-MED
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	B-MED
field	I-MED
,	O
the	O
composition	B-MED
,	O
and	O
the	O
dielectric	B-MED
properties	I-MED
of	O
the	O
blend	B-MED
.	O
We	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	B-MED
tension	I-MED
,	O
which	O
renormalizes	O
the	O
effect	B-MED
of	I-MED
the	O
electric	B-MED
field	I-MED
.	O
This	O
leads	O
to	O
a	O
simple	O
derivation	B-MED
of	O
the	O
scaling	B-MED
law	I-MED
for	O
the	O
selection	O
of	O
the	O
wavelength	B-MED
of	O
the	O
structure	B-MED
formed	O
under	O
an	O
electric	B-MED
field	I-MED
.	O
A	O
Novel	O
Selective	O
Inhibitor	B-MED
of	O
Delta-5	B-MED
Desaturase	I-MED
Lowers	O
Insulin	B-MED
Resistance	I-MED
and	O
Reduces	B-MED
Body	I-MED
Weight	I-MED
in	O
Diet	B-MED
-Induced	O
Obese	B-MED
C57BL/6J	B-MED
Mice	I-MED
Obesity	B-MED
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low	O
-	O
grade	O
inflammation	B-MED
and	O
is	O
called	O
as	O
metabolic	B-MED
inflammation	B-MED
.	O
Delta-5	B-MED
desaturase	I-MED
(	O
D5D	B-MED
)	O
is	O
an	O
enzyme	B-MED
that	O
metabolizes	O
dihomo	B-MED
-	I-MED
γ	I-MED
-	I-MED
linolenic	I-MED
acid	I-MED
(	O
DGLA	B-MED
)	O
to	O
arachidonic	B-MED
acid	I-MED
(	O
AA	B-MED
)	O
.	O
Thus	O
,	O
D5D	B-MED
inhibition	B-MED
increases	O
DGLA	B-MED
(	O
precursor	O
to	O
anti	B-MED
-	I-MED
inflammatory	I-MED
eicosanoids	B-MED
)	O
while	O
decreasing	O
AA	B-MED
(	O
precursor	O
to	O
pro	O
-	O
inflammatory	O
eicosanoids	B-MED
)	O
,	O
and	O
could	O
result	O
in	O
synergistic	B-MED
improvement	B-MED
in	O
the	O
low	O
-	O
grade	O
inflammatory	O
state	O
.	O
Here	O
,	O
we	O
demonstrate	O
reduced	B-MED
insulin	B-MED
resistance	I-MED
and	O
the	O
anti	B-MED
-	I-MED
obesity	I-MED
effect	O
of	O
a	O
D5D	B-MED
selective	O
inhibitor	O
(	O
compound-326	B-MED
)	O
,	O
an	O
orally	B-MED
active	O
small	B-MED
-	I-MED
molecule	I-MED
,	O
in	O
a	O
high	B-MED
-	I-MED
fat	I-MED
diet	I-MED
-induced	O
obese	B-MED
(	I-MED
DIO	I-MED
)	I-MED
mouse	I-MED
model	B-MED
.	O
In	O
vivo	O
D5D	B-MED
inhibition	B-MED
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	B-MED
AA	B-MED
/	O
DGLA	B-MED
profiles	B-MED
.	O
In	O
DIO	B-MED
mice	I-MED
,	O
chronic	O
treatment	O
with	O
compound-326	B-MED
lowered	O
insulin	B-MED
resistance	I-MED
and	O
caused	O
body	B-MED
weight	I-MED
loss	I-MED
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	B-MED
intake	I-MED
.	O
Decreased	O
macrophage	B-MED
infiltration	I-MED
into	I-MED
adipose	I-MED
tissue	I-MED
was	O
expected	O
from	O
mRNA	B-MED
analysis	I-MED
.	O
Increased	O
daily	O
energy	B-MED
expenditure	I-MED
was	O
also	O
observed	O
following	O
administration	B-MED
of	O
compound-326	B-MED
,	O
in	O
line	O
with	O
sustained	O
body	B-MED
weight	I-MED
loss	I-MED
.	O
These	O
data	O
indicate	O
that	O
the	O
novel	O
D5D	B-MED
selective	O
inhibitor	B-MED
,	O
compound-326	B-MED
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-MED
and	O
diabetic	B-MED
patients	B-MED
.	O
Estrogen	B-MED
deficiency	B-MED
accelerates	B-MED
lumbar	B-MED
facet	I-MED
joints	I-MED
arthritis	B-MED
Dramatic	O
increase	B-MED
in	O
the	O
prevalence	B-MED
of	O
lumbar	B-MED
facet	I-MED
joint	I-MED
(	O
LFJ	B-MED
)	O
arthritis	B-MED
in	O
women	B-MED
around	O
the	O
age	B-MED
of	O
menopause	B-MED
indicates	O
a	O
protective	B-MED
role	I-MED
for	O
estrogen	B-MED
in	O
LFJ	B-MED
arthritis	B-MED
.	O
To	O
date	O
,	O
there	O
is	O
no	B-MED
evidence	I-MED
for	O
this	O
indication	B-MED
and	O
the	O
mechanism	B-MED
of	O
such	O
an	O
effect	B-MED
remains	O
poorly	O
understood	O
.	O
In	O
this	O
study	B-MED
,	O
ovariectomized	B-MED
(	I-MED
OVX	I-MED
)	I-MED
mice	I-MED
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-MED
-	O
deficient	B-MED
status	B-MED
of	O
post	B-MED
-	I-MED
menopausal	I-MED
women	B-MED
.	O
Micro	B-MED
-	I-MED
CT	I-MED
and	O
immunohistochemistry	B-MED
was	O
employed	O
to	O
assess	B-MED
the	O
morphological	B-MED
and	O
molecular	B-MED
changes	B-MED
in	O
ovariectomy	B-MED
-	O
induced	B-MED
LFJ	B-MED
arthritis	B-MED
.	O
The	O
results	B-MED
show	O
that	O
the	O
LFJ	B-MED
subchondral	B-MED
bone	I-MED
mass	I-MED
was	O
significantly	O
decreased	B-MED
in	O
OVX	B-MED
mice	I-MED
,	O
with	O
increased	B-MED
cavities	B-MED
on	O
the	O
interface	B-MED
of	O
the	O
subchondral	B-MED
bone	I-MED
.	O
Severe	B-MED
cartilage	B-MED
degradation	B-MED
was	O
observed	O
in	O
ovariectomy	B-MED
-	O
induced	B-MED
LFJ	B-MED
arthritis	B-MED
.	O
Increased	B-MED
blood	B-MED
vessels	I-MED
and	O
innervations	B-MED
were	O
also	O
found	O
in	O
degenerated	B-MED
LFJ	B-MED
,	O
particularly	O
in	O
the	O
subchondral	B-MED
bone	I-MED
area	B-MED
.	O
17β	B-MED
-	I-MED
Estradiol	I-MED
treatment	B-MED
efficiently	O
suppressed	B-MED
LFJ	B-MED
subchondral	B-MED
bone	I-MED
turnover	I-MED
,	O
markedly	O
inhibited	B-MED
cartilage	B-MED
degradation	B-MED
,	O
and	O
increased	B-MED
blood	B-MED
vessel	I-MED
and	O
nerve	B-MED
ending	I-MED
growth	B-MED
in	O
degenerated	B-MED
LFJ	B-MED
in	O
OVX	B-MED
mice	I-MED
.	O
Our	O
study	B-MED
reveals	O
that	O
estrogen	B-MED
is	O
a	O
key	O
factor	B-MED
in	O
regulating	B-MED
LFJ	I-MED
metabolism	I-MED
.	O
Severe	B-MED
LFJ	B-MED
degeneration	B-MED
occurs	O
when	O
estrogen	B-MED
is	O
absent	B-MED
in	B-MED
vivo	I-MED
.	O
Collapsed	B-MED
subchondral	B-MED
bone	I-MED
may	O
be	O
the	O
initiation	B-MED
of	O
this	O
process	B-MED
,	O
and	O
estrogen	B-MED
replacement	I-MED
therapy	I-MED
can	O
effectively	O
prevent	O
degeneration	B-MED
of	O
LFJ	B-MED
under	O
estrogen	B-MED
-	O
deficient	B-MED
conditions	B-MED
.	O
High	B-MED
throughput	I-MED
selection	B-MED
of	O
antibiotic	B-MED
-	I-MED
resistant	I-MED
transgenic	B-MED
Arabidopsis	B-MED
plants	I-MED
Kanamycin	B-MED
resistance	B-MED
is	O
the	O
most	B-MED
frequently	B-MED
used	O
antibiotic	B-MED
-	I-MED
resistance	I-MED
marker	B-MED
for	O
Arabidopsis	B-MED
transformations	B-MED
,	O
however	O
,	O
this	O
method	B-MED
frequently	B-MED
causes	O
escape	B-MED
of	O
untransformed	B-MED
plants	I-MED
,	O
particularly	O
at	O
the	O
high	B-MED
seedling	B-MED
density	B-MED
during	O
the	O
selection	B-MED
.	O
Here	O
we	O
developed	B-MED
a	O
robust	B-MED
high	B-MED
-	O
density	B-MED
selection	B-MED
method	B-MED
using	O
top	B-MED
agar	B-MED
for	O
Arabidopsis	B-MED
thaliana	I-MED
.	O
Top	B-MED
agar	B-MED
effectively	B-MED
suppressed	B-MED
growth	B-MED
of	O
untransformed	B-MED
wild	I-MED
-	I-MED
type	I-MED
plants	I-MED
on	O
selection	B-MED
media	B-MED
at	O
high	B-MED
density	B-MED
.	O
Survival	B-MED
of	O
the	O
transformed	B-MED
plants	B-MED
during	O
the	O
selection	B-MED
were	O
confirmed	B-MED
by	O
production	O
of	O
green	B-MED
true	B-MED
leaves	B-MED
and	O
expression	B-MED
of	O
a	O
firefly	B-MED
luciferase	I-MED
reporter	B-MED
gene	I-MED
.	O
Top	B-MED
agar	B-MED
method	B-MED
allowed	O
selection	B-MED
using	O
a	O
large	B-MED
amount	B-MED
of	O
seeds	B-MED
in	O
Arabidopsis	B-MED
transformation	B-MED
.	O
Netarsudil	B-MED
Increases	B-MED
Outflow	B-MED
Facility	I-MED
in	O
Human	B-MED
Eyes	B-MED
Through	O
Multiple	B-MED
Mechanisms	B-MED
Netarsudil	B-MED
is	O
a	O
Rho	B-MED
kinase	I-MED
/	I-MED
norepinephrine	I-MED
transporter	I-MED
inhibitor	I-MED
currently	O
in	O
phase	B-MED
3	I-MED
clinical	I-MED
development	I-MED
for	O
glaucoma	B-MED
treatment	B-MED
.	O
We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B-MED
,	O
netarsudil	B-MED
-	I-MED
M1	I-MED
,	O
on	O
outflow	B-MED
facility	I-MED
(	O
C	B-MED
)	O
,	O
outflow	B-MED
hydrodynamics	B-MED
,	O
and	O
morphology	B-MED
of	O
the	O
conventional	B-MED
outflow	B-MED
pathway	I-MED
in	O
enucleated	B-MED
human	I-MED
eyes	I-MED
.	O
Paired	B-MED
human	B-MED
eyes	B-MED
(	O
n	O
=	O
5	O
)	O
were	O
perfused	B-MED
with	O
either	O
0.3	O
μM	O
netarsudil	B-MED
-	I-MED
M1	I-MED
or	O
vehicle	B-MED
solution	I-MED
at	O
constant	B-MED
pressure	I-MED
(	O
15	O
mm	O
Hg	O
)	O
.	O
After	O
3	O
hours	B-MED
,	O
fluorescent	B-MED
microspheres	I-MED
were	O
added	O
to	O
perfusion	B-MED
media	B-MED
to	O
trace	B-MED
the	O
outflow	B-MED
patterns	I-MED
before	O
perfusion	B-MED
-	O
fixation	B-MED
.	O
The	O
percentage	B-MED
effective	I-MED
filtration	I-MED
length	I-MED
(	O
PEFL	B-MED
)	O
was	O
calculated	O
from	O
the	O
measured	B-MED
lengths	B-MED
of	O
tracer	B-MED
distribution	B-MED
in	O
the	O
trabecular	B-MED
meshwork	I-MED
(	O
TM	B-MED
)	O
,	O
episcleral	B-MED
veins	I-MED
(	O
ESVs	B-MED
)	O
,	O
and	O
along	O
the	O
inner	B-MED
wall	I-MED
(	O
IW	B-MED
)	O
of	O
Schlemm	B-MED
's	I-MED
canal	I-MED
after	O
global	B-MED
and	O
confocal	B-MED
imaging	I-MED
.	O
Morphologic	B-MED
changes	I-MED
along	O
the	O
trabecular	B-MED
outflow	B-MED
pathway	I-MED
were	O
investigated	O
by	O
confocal	B-MED
,	O
light	B-MED
,	O
and	O
electron	B-MED
microscopy	I-MED
.	O
Perfusion	B-MED
with	O
netarsudil	B-MED
-	I-MED
M1	I-MED
significantly	B-MED
increased	B-MED
C	B-MED
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	B-MED
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	B-MED
increased	B-MED
PEFL	B-MED
in	O
both	O
IW	B-MED
(	O
P	O
<	O
0.05	O
)	O
and	O
ESVs	B-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
In	O
treated	O
eyes	B-MED
,	O
PEFL	B-MED
was	O
significantly	B-MED
higher	O
in	O
ESVs	B-MED
than	O
in	O
the	O
IW	B-MED
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	B-MED
with	I-MED
increased	B-MED
cross	B-MED
-	I-MED
sectional	I-MED
area	I-MED
of	O
ESVs	B-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
Percentage	B-MED
effective	I-MED
filtration	I-MED
length	I-MED
in	O
ESVs	B-MED
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-MED
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O
A	O
significant	B-MED
increase	B-MED
in	O
juxtacanalicular	B-MED
connective	I-MED
tissue	I-MED
(	O
JCT	B-MED
)	O
thickness	B-MED
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	B-MED
compared	O
to	O
controls	O
.	O
Netarsudil	B-MED
acutely	B-MED
increased	B-MED
C	B-MED
by	O
expansion	O
of	O
the	O
JCT	B-MED
and	O
dilating	O
the	O
ESVs	B-MED
,	O
which	O
led	O
to	O
redistribution	B-MED
of	O
aqueous	O
outflow	B-MED
through	O
a	O
larger	B-MED
area	I-MED
of	O
the	O
IW	B-MED
and	O
ESVs	B-MED
.	O
Opposing	O
Roles	B-MED
of	O
Acetylation	B-MED
and	O
Phosphorylation	B-MED
in	O
LIFR	B-MED
-	O
Dependent	B-MED
Self	B-MED
-	I-MED
Renewal	I-MED
Growth	B-MED
Signaling	B-MED
in	O
Mouse	B-MED
Embryonic	I-MED
Stem	I-MED
Cells	I-MED
LIF	B-MED
promotes	O
self	B-MED
-	I-MED
renewal	I-MED
of	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
(	O
mESCs	B-MED
)	O
,	O
and	O
in	O
its	O
absence	B-MED
,	O
the	O
cells	B-MED
differentiate	B-MED
.	O
LIF	B-MED
binds	O
to	O
the	O
LIF	B-MED
receptor	I-MED
(	O
LIFR	B-MED
)	O
and	O
activates	B-MED
the	O
JAK	B-MED
-	I-MED
STAT3	I-MED
pathway	I-MED
,	O
but	O
it	O
remains	B-MED
unknown	I-MED
how	O
the	O
receptor	B-MED
complex	I-MED
triggers	B-MED
differentiation	B-MED
or	O
self	B-MED
-	I-MED
renewal	I-MED
.	O
Here	O
,	O
we	O
report	O
that	O
the	O
LIFR	B-MED
cytoplasmic	B-MED
domain	I-MED
contains	O
a	O
self	B-MED
-	I-MED
renewal	I-MED
domain	B-MED
within	O
the	O
juxtamembrane	B-MED
region	I-MED
and	O
a	O
differentiation	B-MED
domain	B-MED
within	O
the	O
C	B-MED
-	I-MED
terminal	I-MED
region	I-MED
.	O
The	O
differentiation	B-MED
domain	B-MED
contains	O
four	O
SPXX	B-MED
repeats	I-MED
that	O
are	O
phosphorylated	B-MED
by	O
MAPK	B-MED
to	O
restrict	B-MED
STAT3	B-MED
activation	I-MED
;	O
the	O
self	B-MED
-	I-MED
renewal	I-MED
domain	B-MED
is	O
characterized	O
by	O
a	O
3	B-MED
K	I-MED
motif	I-MED
that	O
is	O
acetylated	B-MED
by	O
p300	O
.	O
In	O
mESCs	B-MED
,	O
acetyl-	O
LIFR	B-MED
undergoes	O
homodimerization	B-MED
,	O
leading	O
to	O
STAT3	B-MED
hypo-	B-MED
or	I-MED
hyper	I-MED
-	I-MED
activation	I-MED
depending	B-MED
on	O
the	O
presence	B-MED
or	O
absence	B-MED
of	O
gp130	B-MED
.	O
LIFR	B-MED
-	O
activated	B-MED
STAT3	B-MED
restricts	B-MED
differentiation	B-MED
via	O
cytokine	B-MED
induction	B-MED
.	O
Thus	O
,	O
LIFR	B-MED
acetylation	B-MED
and	O
serine	B-MED
phosphorylation	I-MED
differentially	B-MED
promote	O
stem	B-MED
cell	I-MED
self	B-MED
-	I-MED
renewal	I-MED
and	O
differentiation	B-MED
.	O
Hard	B-MED
ticks	I-MED
(	O
Acari	B-MED
:	I-MED
Ixodidae	I-MED
)	O
of	O
livestock	B-MED
in	O
Nicaragua	B-MED
,	O
with	O
notes	B-MED
about	O
distribution	B-MED
We	O
document	B-MED
the	O
species	B-MED
of	O
ticks	B-MED
that	O
parasitize	B-MED
livestock	B-MED
in	O
Nicaragua	B-MED
.	O
The	O
study	B-MED
was	O
based	O
on	O
tick	B-MED
collection	B-MED
on	O
cattle	B-MED
and	O
horses	B-MED
from	O
437	O
farms	B-MED
in	O
nine	O
departments	B-MED
.	O
Of	O
4841	O
animals	B-MED
examined	O
(	O
4481	O
cows	B-MED
and	O
360	O
horses	B-MED
)	O
,	O
3299	O
were	O
parasitized	B-MED
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-MED
and	O
67	O
%	O
of	O
the	O
equines	B-MED
in	O
study	B-MED
:	O
59	O
cows	B-MED
and	O
25	O
horses	B-MED
were	O
parasitized	B-MED
by	O
more	O
than	O
one	O
species	B-MED
.	O
In	O
addition	O
,	O
280	O
specimens	B-MED
of	O
the	O
entomological	B-MED
museum	B-MED
in	O
León	B-MED
were	O
examined	O
.	O
The	O
ticks	B-MED
found	O
on	O
cattle	B-MED
were	O
Rhipicephalus	B-MED
microplus	I-MED
(	O
75.2	O
%	O
of	O
the	O
ticks	B-MED
collected	B-MED
)	O
,	O
Amblyomma	B-MED
mixtum	I-MED
(	O
20.8	O
%	O
)	O
,	O
A.	B-MED
parvum	I-MED
(	O
2.6	O
%	O
)	O
,	O
A.	B-MED
tenellum	I-MED
(	O
0.7	O
%	O
)	O
,	O
A.	B-MED
maculatum	I-MED
(	O
0.7	O
%	O
)	O
.	O
While	O
the	O
ticks	B-MED
collected	B-MED
from	O
the	O
horses	B-MED
were	O
:	O
Dermacentor	B-MED
nitens	I-MED
(	O
41.5	O
%	O
)	O
,	O
A.	B-MED
mixtum	I-MED
(	O
31.7	O
%	O
)	O
,	O
R.	B-MED
microplus	I-MED
(	O
13.8	O
%	O
)	O
,	O
A.	B-MED
parvum	I-MED
(	O
6.5	O
%	O
)	O
,	O
A.	B-MED
tenellum	I-MED
(	O
3.3	O
%	O
)	O
,	O
D.	B-MED
dissimilis	I-MED
(	O
2.4	O
%	O
)	O
and	O
A.	B-MED
maculatum	I-MED
(	O
0.8	O
%	O
)	O
.	O
Of	O
Kindlins	B-MED
and	O
Cancer	B-MED
Kindlins	B-MED
are	O
4.1	B-MED
-	I-MED
ezrin	I-MED
-	I-MED
ridixin	I-MED
-	I-MED
moesin	I-MED
(	I-MED
FERM	I-MED
)	I-MED
domain	I-MED
containing	O
proteins	B-MED
.	O
There	O
are	O
three	O
kindlins	B-MED
in	O
mammals	B-MED
,	O
which	O
share	O
high	B-MED
sequence	B-MED
identity	O
.	O
Kindlin-1	B-MED
is	O
expressed	B-MED
primarily	O
in	O
epithelial	B-MED
cells	I-MED
,	O
kindlin-2	B-MED
is	O
widely	O
distributed	B-MED
and	O
is	O
particularly	O
abundant	B-MED
in	O
adherent	B-MED
cells	I-MED
,	O
and	O
kindlin-3	B-MED
is	O
expressed	B-MED
primarily	O
in	O
hematopoietic	B-MED
cells	I-MED
.	O
These	O
distributions	B-MED
are	O
not	O
exclusive	B-MED
;	O
some	O
cells	B-MED
express	B-MED
multiple	B-MED
kindlins	B-MED
,	O
and	O
transformed	B-MED
cells	I-MED
often	B-MED
exhibit	O
aberrant	B-MED
expression	B-MED
,	O
both	O
in	O
the	O
isoforms	B-MED
and	O
the	O
levels	B-MED
of	O
kindlins	B-MED
.	O
Great	O
interest	O
in	O
the	O
kindlins	B-MED
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	B-MED
roles	B-MED
in	O
controlling	B-MED
integrin	B-MED
function	B-MED
.	O
In	B-MED
vitro	I-MED
studies	I-MED
,	O
in	B-MED
vivo	I-MED
studies	I-MED
of	O
mice	B-MED
deficient	B-MED
in	O
kindlins	B-MED
,	O
and	O
studies	B-MED
of	O
patients	B-MED
with	O
genetic	B-MED
deficiencies	B-MED
of	O
kindlins	B-MED
have	O
clearly	O
established	B-MED
that	O
they	O
regulate	O
the	O
capacity	B-MED
of	O
integrins	B-MED
to	O
mediate	B-MED
their	O
functions	B-MED
.	O
Kindlins	B-MED
are	O
adaptor	B-MED
proteins	I-MED
;	O
their	O
function	B-MED
emanate	B-MED
from	O
their	O
interaction	B-MED
with	O
binding	B-MED
partners	O
,	O
including	O
the	O
cytoplasmic	B-MED
tails	I-MED
of	O
integrins	B-MED
and	O
components	O
of	O
the	O
actin	B-MED
cytoskeleton	I-MED
.	O
The	O
purpose	B-MED
of	O
this	O
review	B-MED
is	O
to	O
provide	O
a	O
brief	B-MED
overview	B-MED
of	O
kindlin	B-MED
structure	B-MED
and	O
function	B-MED
,	O
a	O
consideration	B-MED
of	O
their	O
binding	B-MED
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	B-MED
of	O
each	O
kindlin	B-MED
family	B-MED
member	B-MED
with	O
cancer	B-MED
.	O
In	O
view	B-MED
of	O
many	O
correlations	B-MED
of	O
kindlin	B-MED
expression	B-MED
levels	B-MED
and	O
neoplasia	B-MED
and	O
the	O
known	O
association	B-MED
of	O
integrins	B-MED
with	O
tumor	B-MED
progression	I-MED
and	O
metastasis	B-MED
,	O
we	O
consider	B-MED
whether	O
regulation	O
of	O
kindlins	B-MED
or	O
their	O
function	B-MED
would	O
be	O
attractive	B-MED
targets	B-MED
for	O
treatment	B-MED
of	I-MED
cancer	I-MED
.	O
Gleason	B-MED
grade	I-MED
grouping	I-MED
of	O
prostate	B-MED
cancer	I-MED
is	O
of	O
prognostic	B-MED
value	I-MED
in	O
Asian	B-MED
men	B-MED
The	O
International	B-MED
Society	I-MED
of	I-MED
Urological	I-MED
Pathology	I-MED
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	B-MED
Groups	I-MED
(	O
GG	B-MED
)	O
originally	O
described	O
by	O
Epstein	B-MED
and	O
colleagues	B-MED
over	O
Gleason	B-MED
score	I-MED
(	O
GS	B-MED
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B-MED
by	O
the	O
WHO	B-MED
classification	I-MED
in	O
2016	O
.	O
The	O
majority	O
of	O
studies	B-MED
validating	O
this	O
revision	B-MED
have	O
been	O
in	O
Caucasian	B-MED
populations	I-MED
.	O
We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	B-MED
system	I-MED
was	O
retrospectively	O
associated	O
with	O
biochemical	B-MED
disease	I-MED
-	I-MED
free	I-MED
survival	I-MED
in	O
a	O
mixed	B-MED
-	I-MED
ethnicity	I-MED
cohort	B-MED
of	O
Asian	B-MED
men	B-MED
.	O
A	O
total	O
of	O
680	O
radical	B-MED
prostatectomies	I-MED
(	O
RPs	B-MED
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O
GS	B-MED
from	O
initial	O
biopsy	B-MED
and	O
RP	B-MED
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	B-MED
to	O
GG	B-MED
,	O
defined	O
as	O
:	O
1	O
(	O
GS	B-MED
≤6	O
)	O
;	O
2	O
(	O
GS	B-MED
3	O
+	O
4=7	O
)	O
;	O
3	O
(	O
GS	B-MED
4	O
+	O
3=7	O
)	O
;	O
4	O
(	O
GS	B-MED
4	O
+	O
4=8/5	O
+	O
3=8/3	O
+	O
5=8	O
)	O
and	O
5	O
(	O
GS	B-MED
9	O
-	O
10	O
)	O
.	O
Biochemical	B-MED
recurrence	I-MED
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
RP	B-MED
prostate	B-MED
-	I-MED
specific	I-MED
antigen	I-MED
(	O
PSA	B-MED
)	O
levels	O
of	O
>	O
0.2	O
ng	O
/	O
mL	O
after	O
post-	O
RP	B-MED
PSA	B-MED
reaching	O
the	O
nadir	B-MED
of	O
<	O
0.1	O
ng	O
/	O
mL.	O
Our	O
data	B-MED
showed	O
that	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
revealed	O
significant	O
differences	O
in	O
biochemical	B-MED
recurrence	I-MED
within	O
Gleason	B-MED
GG	I-MED
based	O
on	O
either	O
biopsy	B-MED
or	O
prostatectomy	B-MED
scoring	B-MED
.	O
Multivariate	B-MED
analysis	I-MED
further	O
confirmed	O
that	O
a	O
higher	O
GG	B-MED
was	O
significantly	O
associated	O
with	O
risk	B-MED
of	O
biochemical	B-MED
recurrence	I-MED
.	O
This	O
GG	B-MED
system	I-MED
had	O
a	O
higher	O
prognostic	B-MED
discrimination	B-MED
for	O
both	O
initial	O
biopsy	B-MED
and	O
RP	B-MED
than	O
GS	B-MED
.	O
Our	O
study	B-MED
validates	B-MED
the	O
use	O
of	O
the	O
revised	B-MED
and	O
updated	B-MED
GG	B-MED
system	I-MED
in	O
a	O
mixed	B-MED
-	I-MED
ethnicity	I-MED
population	I-MED
of	O
Asian	B-MED
men	B-MED
.	O
Higher	O
GG	B-MED
was	O
significantly	O
associated	O
with	O
increased	O
risk	B-MED
of	O
biochemical	B-MED
recurrence	I-MED
.	O
We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B-MED
management	I-MED
for	O
patients	B-MED
with	O
prostate	B-MED
cancer	I-MED
.	O
Complete	O
Genome	B-MED
Sequence	I-MED
Analysis	I-MED
of	O
a	O
Naturally	O
Reassorted	O
Infectious	B-MED
Bursal	I-MED
Disease	I-MED
Virus	I-MED
from	O
India	B-MED
The	O
novel	O
infectious	B-MED
bursal	I-MED
disease	I-MED
virus	I-MED
(	O
IBDV	B-MED
)	O
isolate	B-MED
BGE14	B-MED
/	I-MED
ABT1	I-MED
/	I-MED
MVC	I-MED
/	I-MED
India	I-MED
is	O
a	O
very	O
virulent	B-MED
IBDV	B-MED
that	O
was	O
isolated	B-MED
from	O
broiler	B-MED
flocks	I-MED
in	O
southern	O
parts	O
of	O
India	B-MED
during	O
2014	O
.	O
Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	B-MED
,	O
the	O
complete	O
genome	B-MED
sequence	I-MED
of	O
BGE14	B-MED
/	I-MED
ABT1	I-MED
/	I-MED
MVC	I-MED
/	I-MED
India	I-MED
,	O
a	O
reassortment	O
strain	B-MED
with	O
segments	B-MED
A	I-MED
and	I-MED
B	I-MED
derived	O
from	O
a	O
very	O
virulent	B-MED
IBDV	B-MED
strain	B-MED
and	O
an	O
attenuated	B-MED
IBDV	B-MED
,	O
respectively	O
.	O
The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	B-MED
exchange	I-MED
between	O
attenuated	B-MED
and	O
very	O
virulent	B-MED
strains	B-MED
of	O
IBDV	B-MED
circulating	B-MED
in	B-MED
the	I-MED
field	I-MED
.	O
Zinc	B-MED
and	O
Wound	B-MED
Healing	I-MED
:	O
A	O
Review	B-MED
of	I-MED
Zinc	B-MED
Physiology	B-MED
and	O
Clinical	B-MED
Applications	I-MED
Our	O
understanding	B-MED
of	O
the	O
role	O
of	O
zinc	B-MED
in	O
normal	O
human	B-MED
physiology	B-MED
is	O
constantly	B-MED
expanding	O
,	O
yet	O
there	O
are	O
major	O
gaps	B-MED
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	B-MED
of	O
zinc	B-MED
in	O
wound	B-MED
healing	I-MED
.	O
This	O
review	B-MED
aims	B-MED
to	O
provide	O
the	O
clinician	B-MED
with	O
sufficient	B-MED
understanding	O
of	O
zinc	B-MED
biology	B-MED
and	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-MED
in	O
wound	B-MED
healing	I-MED
.	O
Zinc	B-MED
is	O
an	O
essential	O
ion	B-MED
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	B-MED
,	O
and	O
zinc	B-MED
deficiency	I-MED
has	O
many	O
manifestations	B-MED
ranging	O
from	O
delayed	B-MED
wound	B-MED
healing	I-MED
to	O
immune	B-MED
dysfunction	I-MED
and	O
impairment	B-MED
of	O
multiple	B-MED
sensory	B-MED
systems	I-MED
.	O
While	O
consensus	B-MED
has	O
been	O
reached	O
regarding	O
the	O
detrimental	B-MED
effects	I-MED
of	O
zinc	B-MED
deficiency	I-MED
on	O
wound	B-MED
healing	I-MED
,	O
there	O
is	O
considerable	O
discord	B-MED
in	O
the	O
literature	B-MED
on	O
the	O
optimal	B-MED
methods	I-MED
and	O
true	B-MED
benefits	I-MED
of	O
zinc	B-MED
supplementation	O
.	O
Discontinued	B-MED
Splenogonadal	B-MED
Fusion	I-MED
and	O
Bilateral	B-MED
Empty	I-MED
Scrotum	I-MED
in	O
an	O
18-	O
Month	B-MED
-Old	O
Boy	B-MED
Splenogonadal	B-MED
fusion	I-MED
is	O
a	O
rare	B-MED
benign	O
congenital	B-MED
anomaly	I-MED
defined	O
as	O
the	O
presence	O
of	O
splenic	B-MED
tissue	I-MED
adherent	B-MED
to	O
gonads	B-MED
.	O
It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	B-MED
,	O
a	O
German	B-MED
pathologist	B-MED
.	O
We	O
present	O
a	O
case	B-MED
of	O
an	O
18-	O
month	B-MED
-old	O
boy	B-MED
who	O
was	O
referred	O
as	O
a	O
case	B-MED
of	O
bilateral	B-MED
empty	I-MED
scrotum	I-MED
since	O
birth	O
.	O
During	O
routine	B-MED
laparoscopic	B-MED
exploration	B-MED
,	O
right	B-MED
vas	I-MED
deferens	I-MED
and	O
testicular	B-MED
vessels	I-MED
were	O
entering	O
the	O
right	B-MED
internal	I-MED
inguinal	I-MED
ring	I-MED
so	O
right	B-MED
inguinal	I-MED
exploration	B-MED
was	O
done	O
,	O
which	O
revealed	O
blind	B-MED
ending	I-MED
vas	B-MED
deferens	I-MED
and	O
testicular	B-MED
vessels	I-MED
and	O
the	O
left	B-MED
testis	I-MED
was	O
found	O
intra	B-MED
-	I-MED
abdominally	I-MED
near	O
the	O
left	O
internal	B-MED
ring	I-MED
with	O
a	O
mass	B-MED
on	O
its	O
upper	B-MED
pole	I-MED
.	O
Wedge	B-MED
biopsy	I-MED
was	O
taken	O
from	O
the	O
upper	B-MED
pole	I-MED
of	I-MED
the	I-MED
testicle	I-MED
(	O
site	B-MED
of	O
the	O
mass	B-MED
)	O
for	O
tissue	B-MED
diagnosis	I-MED
followed	O
by	O
orchidopexy	B-MED
.	O
Histology	B-MED
showed	O
splenic	B-MED
tissue	I-MED
.	O
Although	O
splenogonadal	B-MED
fusion	I-MED
is	O
a	O
rare	B-MED
condition	B-MED
,	O
surgeons	B-MED
should	O
be	O
aware	O
of	O
this	O
rare	B-MED
disease	I-MED
entity	O
to	O
avoid	O
unnecessary	B-MED
aggressive	O
interventions	B-MED
such	O
as	O
orchiectomy	B-MED
.	O
Oxytocin	B-MED
Reduces	B-MED
Face	B-MED
Processing	B-MED
Time	B-MED
but	O
Leaves	B-MED
Recognition	B-MED
Accuracy	B-MED
and	O
Eye	B-MED
-	O
Gaze	B-MED
Unaffected	B-MED
Previous	B-MED
studies	B-MED
have	O
found	O
that	O
oxytocin	B-MED
(	O
OXT	B-MED
)	O
can	O
improve	B-MED
the	O
recognition	B-MED
of	O
emotional	B-MED
facial	B-MED
expressions	I-MED
;	O
it	O
has	O
been	O
proposed	B-MED
that	O
this	O
effect	B-MED
is	O
mediated	B-MED
by	O
an	O
increase	B-MED
in	O
attention	B-MED
to	O
the	O
eye	B-MED
-	I-MED
region	I-MED
of	O
faces	B-MED
.	O
Nevertheless	O
,	O
evidence	B-MED
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	B-MED
,	O
and	O
few	B-MED
studies	B-MED
have	O
directly	B-MED
tested	B-MED
the	O
effect	B-MED
of	O
oxytocin	B-MED
on	O
emotion	B-MED
recognition	B-MED
via	O
altered	B-MED
eye	B-MED
-	O
gaze	B-MED
Methods	B-MED
:	O
In	O
a	O
double	B-MED
-	I-MED
blind	I-MED
,	O
within	B-MED
-	O
subjects	B-MED
,	O
randomized	B-MED
control	I-MED
experiment	I-MED
,	O
40	O
healthy	B-MED
male	B-MED
participants	I-MED
received	B-MED
24	O
IU	B-MED
intranasal	B-MED
OXT	B-MED
and	O
placebo	B-MED
in	O
two	O
identical	B-MED
experimental	B-MED
sessions	B-MED
separated	B-MED
by	O
a	O
2-	O
week	B-MED
interval	B-MED
.	O
Visual	B-MED
attention	I-MED
to	O
the	O
eye	B-MED
-	I-MED
region	I-MED
was	O
assessed	B-MED
on	O
both	O
occasions	O
while	O
participants	B-MED
completed	B-MED
a	O
static	B-MED
facial	B-MED
emotion	B-MED
recognition	B-MED
task	B-MED
using	O
medium	B-MED
intensity	I-MED
facial	B-MED
expressions	I-MED
.	O
Although	O
OXT	B-MED
had	O
no	B-MED
effect	I-MED
on	O
emotion	B-MED
recognition	B-MED
accuracy	B-MED
,	O
recognition	B-MED
performance	B-MED
was	O
improved	B-MED
because	O
face	B-MED
processing	B-MED
was	O
faster	B-MED
across	O
emotions	B-MED
under	O
the	O
influence	B-MED
of	O
OXT	B-MED
.	O
This	O
effect	B-MED
was	O
marginally	B-MED
significant	B-MED
(	O
p<.06	O
)	O
.	O
Consistent	B-MED
with	I-MED
a	O
previous	B-MED
study	B-MED
using	O
dynamic	B-MED
stimuli	I-MED
,	O
OXT	B-MED
had	O
no	B-MED
effect	I-MED
on	O
eye	B-MED
-	O
gaze	B-MED
patterns	B-MED
when	O
viewing	B-MED
static	B-MED
emotional	B-MED
faces	B-MED
and	O
this	O
was	O
not	O
related	O
to	O
recognition	B-MED
accuracy	B-MED
or	O
face	B-MED
processing	B-MED
time	B-MED
.	O
These	O
findings	B-MED
suggest	B-MED
that	O
OXT	B-MED
-	O
induced	B-MED
enhanced	B-MED
facial	B-MED
emotion	B-MED
recognition	B-MED
is	O
not	O
necessarily	O
mediated	B-MED
by	O
an	O
increase	B-MED
in	O
attention	B-MED
to	O
the	O
eye	B-MED
-	I-MED
region	I-MED
of	O
faces	B-MED
,	O
as	O
previously	B-MED
assumed	B-MED
.	O
We	O
discuss	O
several	B-MED
methodological	B-MED
issues	B-MED
which	O
may	O
explain	O
discrepant	B-MED
findings	I-MED
and	O
suggest	B-MED
the	O
effect	B-MED
of	O
OXT	B-MED
on	O
visual	B-MED
attention	I-MED
may	O
differ	O
depending	O
on	O
task	B-MED
requirements	B-MED
.	O
(	O
JINS	O
,	O
2017	O
,	O
23	O
,	O
23	O
-	O
33	O
)	O
.	O
Systematic	B-MED
Identification	B-MED
of	O
Pharmacological	B-MED
Targets	B-MED
from	O
Small	B-MED
-	I-MED
Molecule	I-MED
Phenotypic	B-MED
Screens	I-MED
Phenotypic	B-MED
drug	B-MED
discovery	I-MED
offers	O
some	O
advantages	B-MED
over	O
target	B-MED
-	O
based	B-MED
methods	B-MED
,	O
mainly	O
because	O
it	O
allows	O
drug	B-MED
leads	I-MED
to	O
be	O
tested	B-MED
in	O
systems	B-MED
that	O
more	B-MED
closely	B-MED
model	B-MED
distinct	B-MED
disease	B-MED
states	I-MED
.	O
However	O
,	O
a	O
potential	B-MED
disadvantage	B-MED
is	O
the	O
difficulty	B-MED
of	O
linking	B-MED
the	O
observed	B-MED
phenotype	B-MED
to	O
a	O
specific	B-MED
cellular	B-MED
target	B-MED
.	O
To	O
address	O
this	O
problem	B-MED
,	O
we	O
developed	B-MED
DePick	B-MED
,	O
a	O
computational	B-MED
target	O
de	B-MED
-	I-MED
convolution	I-MED
tool	B-MED
to	O
determine	B-MED
targets	B-MED
specifically	B-MED
linked	B-MED
to	O
small	B-MED
-	I-MED
molecule	I-MED
phenotypic	B-MED
screens	I-MED
.	O
We	O
applied	B-MED
DePick	B-MED
to	O
eight	O
publicly	B-MED
available	O
screens	B-MED
and	O
predicted	B-MED
59	O
drug	B-MED
target	B-MED
-	O
phenotype	B-MED
associations	B-MED
.	O
In	O
addition	O
to	O
literature	B-MED
-	O
based	B-MED
evidence	B-MED
for	O
our	O
predictions	B-MED
,	O
we	O
provide	B-MED
experimental	B-MED
support	B-MED
for	O
seven	O
predicted	B-MED
associations	B-MED
.	O
Interestingly	B-MED
,	O
our	O
analysis	B-MED
led	O
to	O
the	O
discovery	B-MED
of	O
a	O
previously	B-MED
unrecognized	B-MED
connection	B-MED
between	O
the	O
Wnt	B-MED
signaling	I-MED
pathway	I-MED
and	O
an	O
aromatase	B-MED
,	O
CYP19A1	B-MED
.	O
These	O
results	B-MED
demonstrate	B-MED
that	O
the	O
DePick	B-MED
approach	O
can	O
not	O
only	O
accelerate	B-MED
target	B-MED
de	B-MED
-	I-MED
convolution	I-MED
but	O
also	O
aid	B-MED
in	O
discovery	B-MED
of	O
new	O
functionally	B-MED
relevant	B-MED
biological	B-MED
relationships	B-MED
.	O
The	O
EpiDerm	B-MED
™	I-MED
3D	B-MED
human	I-MED
reconstructed	I-MED
skin	I-MED
micronucleus	I-MED
(	I-MED
RSMN	I-MED
)	I-MED
assay	I-MED
:	O
Historical	B-MED
control	I-MED
data	B-MED
and	O
proof	B-MED
of	O
principle	B-MED
studies	I-MED
for	O
mechanistic	B-MED
assay	I-MED
adaptations	O
The	O
in	B-MED
vitro	I-MED
human	I-MED
reconstructed	I-MED
skin	I-MED
micronucleus	I-MED
(	I-MED
RSMN	I-MED
)	I-MED
assay	I-MED
in	O
EpiDerm	B-MED
™	I-MED
is	O
a	O
promising	O
novel	O
animal	B-MED
alternative	I-MED
for	O
evaluating	O
genotoxicity	B-MED
of	O
topically	B-MED
applied	I-MED
chemicals	B-MED
.	O
It	O
is	O
particularly	O
useful	O
for	O
assessing	B-MED
cosmetic	B-MED
ingredients	I-MED
that	O
can	O
no	O
longer	O
be	O
tested	B-MED
using	O
in	B-MED
vivo	I-MED
assays	B-MED
.	O
To	O
advance	O
the	O
use	O
of	O
this	O
test	B-MED
especially	O
for	O
regulatory	B-MED
decision	B-MED
-	I-MED
making	I-MED
,	O
we	O
have	O
established	O
the	O
RSMN	B-MED
assay	I-MED
in	O
our	O
laboratory	B-MED
according	O
to	O
Good	B-MED
Laboratory	I-MED
Practice	I-MED
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	B-MED
test	B-MED
guideline	I-MED
487	I-MED
in	B-MED
vitro	I-MED
mammalian	B-MED
cell	I-MED
micronucleus	B-MED
test	I-MED
.	O
Proficiency	O
with	O
the	O
assay	B-MED
was	O
established	O
by	O
correctly	O
identifying	O
direct	B-MED
-	I-MED
acting	I-MED
genotoxins	I-MED
and	O
genotoxins	B-MED
requiring	O
metabolism	B-MED
,	O
as	O
well	O
as	O
non	B-MED
-	I-MED
genotoxic	I-MED
/	O
non	B-MED
-	I-MED
carcinogenic	I-MED
chemicals	B-MED
.	O
We	O
also	O
report	B-MED
the	O
analysis	B-MED
of	O
our	O
historical	B-MED
control	I-MED
data	B-MED
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	B-MED
control	I-MED
values	B-MED
for	O
%	O
micronuclei	B-MED
in	O
binucleated	B-MED
cells	I-MED
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O
Technical	B-MED
issues	I-MED
including	O
evaluating	O
various	O
solvents	B-MED
with	O
both	O
48h	O
and	O
72h	O
treatment	B-MED
regimens	I-MED
were	O
investigated	B-MED
.	O
For	O
the	O
first	O
time	O
,	O
mechanistic	B-MED
studies	I-MED
using	O
CREST	B-MED
analysis	I-MED
revealed	O
that	O
the	O
RSMN	B-MED
assay	I-MED
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-MED
and	O
clastogens	B-MED
.	O
Moreover	O
,	O
the	O
assay	B-MED
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-MED
as	O
markers	B-MED
for	O
proliferative	B-MED
and	O
toxic	B-MED
effects	I-MED
of	O
chemicals	B-MED
.	O
Trends	B-MED
in	O
dietary	B-MED
intake	I-MED
among	O
adults	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
:	O
NHANES	B-MED
1988	O
-	O
2012	O
Dietary	B-MED
recommendations	B-MED
for	O
adults	B-MED
with	O
diabetes	B-MED
are	O
to	O
follow	O
a	O
healthy	B-MED
diet	I-MED
in	O
appropriate	O
portion	B-MED
sizes	I-MED
.	O
We	O
determined	O
recent	O
trends	B-MED
in	O
energy	B-MED
and	O
nutrient	B-MED
intakes	I-MED
among	O
a	O
nationally	O
representative	O
sample	O
of	O
US	B-MED
adults	B-MED
with	O
and	O
without	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
Participants	B-MED
were	O
adults	B-MED
aged	B-MED
≥20	O
years	B-MED
from	O
the	O
cross	B-MED
-	I-MED
sectional	I-MED
National	I-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Surveys	I-MED
,	O
1988	O
-	O
2012	O
(	O
N	O
=	O
49	O
770	O
)	O
.	O
Diabetes	B-MED
was	O
determined	O
by	O
self	B-MED
-	I-MED
report	I-MED
of	O
a	O
physician	B-MED
's	I-MED
diagnosis	B-MED
(	O
n	O
=	O
4885	O
)	O
.	O
Intake	B-MED
of	I-MED
energy	I-MED
and	O
nutrients	B-MED
were	O
determined	O
from	O
a	O
24-	O
h	B-MED
recall	O
by	O
participants	B-MED
of	O
all	O
food	B-MED
consumed	O
.	O
Linear	B-MED
regression	I-MED
was	O
used	O
to	O
test	B-MED
for	O
trends	B-MED
in	O
mean	O
intake	B-MED
over	O
time	B-MED
for	O
all	O
participants	B-MED
and	O
by	O
demographic	B-MED
characteristics	I-MED
.	O
Among	O
adults	B-MED
with	O
diabetes	B-MED
,	O
overall	O
total	O
energy	B-MED
intake	I-MED
increased	B-MED
between	O
1988	O
-	O
1994	O
and	O
2011	O
-	O
2012	O
(	O
1689	B-MED
kcal	I-MED
versus	O
1895	B-MED
kcal	I-MED
;	O
Ptrend	O
<	O
0.001	O
)	O
with	O
evidence	O
of	O
a	O
plateau	B-MED
between	O
2003	O
-	O
2006	O
and	O
2011	O
-	O
2012	O
.	O
In	O
2007	O
-	O
2012	O
,	O
energy	B-MED
intake	I-MED
was	O
greater	O
for	O
younger	B-MED
than	O
older	B-MED
adults	I-MED
,	O
for	O
men	B-MED
than	O
women	B-MED
,	O
and	O
for	O
non	B-MED
-	I-MED
Hispanic	I-MED
whites	I-MED
versus	O
non	B-MED
-	I-MED
Hispanic	I-MED
blacks	I-MED
.	O
There	O
was	O
no	O
change	O
in	O
the	O
percentage	B-MED
of	O
calories	B-MED
from	O
carbohydrate	B-MED
,	O
total	B-MED
fat	I-MED
or	O
protein	B-MED
.	O
Percentage	B-MED
of	O
calories	B-MED
from	O
saturated	B-MED
fat	I-MED
was	O
similar	O
across	O
study	B-MED
periods	B-MED
but	O
remained	O
above	O
recommendations	B-MED
(	O
11.2	O
%	O
in	O
2011	O
-	O
2012	O
)	O
.	O
Fibre	B-MED
intake	I-MED
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	B-MED
(	O
Ptrend	O
=	O
0.002	O
)	O
.	O
Sodium	B-MED
,	O
cholesterol	B-MED
and	O
calcium	B-MED
intakes	B-MED
increased	B-MED
.	O
There	O
was	O
no	O
change	O
in	O
energy	B-MED
intake	I-MED
among	O
adults	B-MED
without	O
diabetes	B-MED
and	O
dietary	B-MED
trends	B-MED
were	O
similar	O
to	O
those	O
with	O
diabetes	B-MED
.	O
Future	O
data	B-MED
are	O
needed	O
to	O
confirm	O
a	O
plateau	B-MED
in	O
energy	B-MED
intake	I-MED
among	O
adults	B-MED
with	O
diabetes	B-MED
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	B-MED
fibre	B-MED
and	O
reduce	B-MED
saturated	B-MED
fat	I-MED
.	O
High	B-MED
HbA1c	B-MED
at	O
onset	B-MED
can	O
not	O
be	O
used	O
as	O
a	O
predictor	B-MED
for	O
future	O
metabolic	B-MED
control	I-MED
for	O
the	O
individual	B-MED
child	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
mellitus	I-MED
To	O
study	O
how	O
metabolic	B-MED
control	I-MED
at	O
onset	B-MED
of	O
type	B-MED
1	I-MED
diabetes	I-MED
correlates	O
to	O
metabolic	B-MED
control	I-MED
and	O
clinical	B-MED
parameters	B-MED
during	O
childhood	B-MED
until	O
transition	B-MED
from	O
pediatric	B-MED
care	I-MED
to	O
adult	B-MED
diabetes	B-MED
care	I-MED
.	O
Data	B-MED
at	O
onset	B-MED
,	O
three	O
months	B-MED
,	O
one	O
,	O
three	O
,	O
and	O
five	O
years	B-MED
after	O
diagnosis	B-MED
and	O
at	O
transition	B-MED
,	O
on	O
HbA1c	B-MED
and	O
clinical	B-MED
parameters	B-MED
,	O
on	O
8084	O
patients	B-MED
in	O
the	O
Swedish	B-MED
pediatric	I-MED
quality	I-MED
registry	I-MED
,	I-MED
SWEDIABKIDS	I-MED
,	O
were	O
used	O
.	O
Of	O
these	O
patients	B-MED
,	O
26	O
%	O
had	O
been	O
referred	O
to	O
adult	B-MED
diabetes	B-MED
care	I-MED
by	O
2014	O
.	O
Children	B-MED
with	O
HbA1c	B-MED
<	O
72	O
mmol	O
/	O
mol	O
(	O
8.7	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	B-MED
,	O
low	B-MED
group	B-MED
)	O
at	O
diagnosis	B-MED
continued	O
to	O
have	O
good	O
metabolic	B-MED
control	I-MED
during	O
childhood	B-MED
,	O
in	O
contrast	O
to	O
children	B-MED
with	O
HbA1c	B-MED
>	O
114	O
mmol	O
/	O
mol	O
(	O
12.6	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	B-MED
,	O
high	B-MED
group	B-MED
)	O
at	O
diagnosis	B-MED
,	O
who	O
continued	O
to	O
have	O
high	B-MED
HbA1c	B-MED
at	O
follow	B-MED
-	I-MED
up	I-MED
.	O
For	O
the	O
individual	B-MED
,	O
there	O
was	O
no	B-MED
significant	I-MED
correlation	B-MED
between	O
high	B-MED
HbA1c	B-MED
at	O
onset	B-MED
and	O
during	O
follow	B-MED
-	I-MED
up	I-MED
.	O
During	O
follow	B-MED
-	I-MED
up	I-MED
,	O
children	B-MED
in	O
the	O
high	B-MED
group	B-MED
were	O
more	O
often	O
smokers	B-MED
,	O
less	O
physically	B-MED
active	I-MED
,	O
and	O
more	O
often	O
had	O
retinopathy	B-MED
than	O
children	B-MED
in	O
the	O
low	B-MED
group	B-MED
(	O
P	O
<	O
.01	O
,	O
.01	O
,	O
.03	O
respectively	O
)	O
.	O
High	B-MED
HbA1c	B-MED
at	O
onset	B-MED
was	O
associated	B-MED
with	I-MED
high	B-MED
HbA1c	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
on	O
a	O
group	B-MED
level	O
,	O
but	O
it	O
can	O
not	O
be	O
used	O
as	O
a	O
predictor	B-MED
of	O
future	O
metabolic	B-MED
control	I-MED
on	O
an	O
individual	B-MED
level	O
.	O
These	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-MED
team	B-MED
in	O
the	O
first	O
years	O
after	O
diagnosis	B-MED
.	O
It	O
is	O
important	O
to	O
continuously	O
set	O
high	B-MED
goals	B-MED
for	O
the	O
achievement	B-MED
of	O
tight	O
metabolic	B-MED
control	I-MED
,	O
in	O
order	O
to	O
decrease	B-MED
the	O
risk	B-MED
of	O
microvascular	B-MED
complications	I-MED
.	O
Characterization	B-MED
of	O
electrocorticogram	B-MED
high	B-MED
-	O
gamma	B-MED
signal	B-MED
in	O
response	B-MED
to	O
varying	B-MED
upper	B-MED
extremity	I-MED
movement	B-MED
velocity	B-MED
The	O
mechanism	B-MED
by	O
which	O
the	O
human	B-MED
primary	B-MED
motor	I-MED
cortex	I-MED
(	O
M1	B-MED
)	O
encodes	B-MED
upper	B-MED
extremity	I-MED
movement	B-MED
kinematics	B-MED
is	O
not	O
fully	O
understood	O
.	O
For	O
example	O
,	O
human	B-MED
electrocorticogram	B-MED
(	O
ECoG	B-MED
)	O
signals	B-MED
have	O
been	O
shown	O
to	O
modulate	B-MED
with	O
upper	B-MED
extremity	I-MED
movement	B-MED
s	O
;	O
however	O
,	O
this	O
relationship	B-MED
has	O
not	O
been	O
explicitly	B-MED
characterized	B-MED
.	O
To	O
address	O
this	O
issue	B-MED
,	O
we	O
recorded	B-MED
high	B-MED
-	O
density	B-MED
ECoG	B-MED
signals	B-MED
from	O
patients	B-MED
undergoing	O
epilepsy	B-MED
surgery	B-MED
evaluation	B-MED
as	O
they	O
performed	B-MED
elementary	B-MED
upper	B-MED
extremity	I-MED
movements	B-MED
while	O
systematically	B-MED
varying	B-MED
movement	B-MED
speed	B-MED
and	O
duration	B-MED
.	O
Specifically	B-MED
,	O
subjects	B-MED
performed	B-MED
intermittent	B-MED
pincer	B-MED
grasp	I-MED
/	O
release	B-MED
,	O
elbow	B-MED
flexion	I-MED
/	O
extension	B-MED
,	O
and	O
shoulder	B-MED
flexion	I-MED
/	O
extension	B-MED
at	O
slow	B-MED
,	O
moderate	B-MED
,	O
and	O
fast	B-MED
speeds	B-MED
.	O
In	O
all	O
movements	B-MED
,	O
bursts	B-MED
of	O
power	B-MED
in	O
the	O
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80	O
-	O
160	O
Hz	O
)	O
were	O
observed	B-MED
in	O
M1	B-MED
.	O
In	O
addition	B-MED
,	O
the	O
amplitude	B-MED
of	O
these	O
power	B-MED
bursts	B-MED
and	O
the	O
area	B-MED
of	O
M1	B-MED
with	O
elevated	B-MED
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
activity	B-MED
were	O
directly	B-MED
proportional	B-MED
to	O
the	O
movement	B-MED
speed	B-MED
.	O
Likewise	O
,	O
the	O
duration	B-MED
of	O
elevated	B-MED
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
activity	B-MED
increased	B-MED
with	O
movement	B-MED
duration	B-MED
.	O
Based	B-MED
on	O
linear	B-MED
regression	I-MED
,	O
M1	B-MED
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
power	B-MED
amplitude	B-MED
and	O
duration	B-MED
covaried	B-MED
with	O
movement	B-MED
speed	B-MED
and	O
duration	B-MED
,	O
respectively	O
,	O
with	O
an	O
average	B-MED
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O
These	O
findings	B-MED
indicate	B-MED
that	O
the	O
encoding	B-MED
of	O
upper	B-MED
extremity	I-MED
movement	B-MED
speed	B-MED
by	O
M1	B-MED
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
activity	B-MED
is	O
primarily	B-MED
linear	B-MED
.	O
Also	O
,	O
the	O
fact	O
that	O
this	O
activity	B-MED
remained	O
elevated	B-MED
throughout	O
a	O
movement	B-MED
suggests	O
that	O
M1	B-MED
does	O
not	O
merely	O
generate	O
transient	B-MED
instructions	B-MED
for	O
a	O
specific	B-MED
movement	B-MED
duration	B-MED
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	B-MED
of	O
the	O
movement	B-MED
.	O
Finally	O
,	O
the	O
spatial	B-MED
distribution	I-MED
of	O
high	B-MED
-[Formula	O
:	O
see	O
text	O
]	O
activity	B-MED
suggests	O
the	O
presence	B-MED
of	O
a	O
recruitment	B-MED
phenomenon	B-MED
in	O
which	O
higher	B-MED
speeds	B-MED
or	O
increased	B-MED
muscle	B-MED
activity	B-MED
involve	O
activation	B-MED
of	O
larger	O
M1	B-MED
area	B-MED
s.	O
Urachal	B-MED
carcinoma	I-MED
:	O
Report	B-MED
of	O
two	O
cases	B-MED
and	O
review	B-MED
of	I-MED
the	O
literature	B-MED
Urachal	B-MED
carcinoma	I-MED
is	O
a	O
rare	B-MED
tumor	B-MED
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-MED
and	O
less	B-MED
often	I-MED
in	O
the	O
adnexal	B-MED
region	B-MED
and	O
urinary	B-MED
system	I-MED
.	O
We	O
herein	O
present	B-MED
two	O
cases	B-MED
of	O
urachal	B-MED
carcinoma	I-MED
:	O
One	O
case	B-MED
was	O
a	O
32	O
-	O
year	O
-	O
old	O
male	B-MED
patient	B-MED
who	O
presented	B-MED
with	O
painless	B-MED
hematuria	I-MED
with	O
blood	B-MED
clots	I-MED
for	O
1	O
month	B-MED
,	O
whereas	O
the	O
other	O
case	B-MED
was	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	B-MED
who	O
presented	B-MED
with	O
gross	B-MED
hematuria	I-MED
with	O
mild	B-MED
dysuria	B-MED
,	O
urgency	B-MED
and	I-MED
frequent	I-MED
urination	I-MED
for	O
1	O
year	B-MED
.	O
Following	O
surgical	B-MED
resection	I-MED
,	O
the	O
two	O
patients	B-MED
were	O
diagnosed	B-MED
with	O
urachal	B-MED
adenocarcinoma	I-MED
(	O
mixed	B-MED
type	B-MED
)	O
and	O
urachal	B-MED
mucinous	I-MED
adenocarcinoma	I-MED
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	B-MED
examination	B-MED
.	O
A	O
review	B-MED
of	I-MED
previously	O
published	B-MED
cases	B-MED
and	O
relevant	B-MED
literature	B-MED
is	O
also	O
presented	B-MED
.	O
The	O
aim	B-MED
of	O
the	O
present	B-MED
study	B-MED
was	O
to	O
help	O
understand	B-MED
this	O
disease	B-MED
better	B-MED
,	O
in	O
order	O
to	O
reduce	B-MED
the	O
rate	B-MED
of	O
clinical	B-MED
and	O
pathological	B-MED
misdiagnosis	B-MED
.	O
Theory	B-MED
of	I-MED
Mind	I-MED
in	O
Adolescents	B-MED
with	O
Bipolar	B-MED
Disorder	I-MED
in	O
Euthymic	B-MED
Phase	I-MED
:	O
‎Using	O
the	O
Strange	B-MED
Stories	I-MED
Test	I-MED
Objective	O
:	O
This	O
study	O
evaluated	B-MED
the	O
theory	B-MED
of	I-MED
mind	I-MED
(	O
ToM	B-MED
)	O
in	O
adolescents	B-MED
diagnosed	B-MED
with	O
bipolar	B-MED
disorder	I-MED
BD	B-MED
‎‎(BD	O
)	O
during	O
their	O
euthymic	B-MED
period	I-MED
compared	O
to	O
a	O
typically	B-MED
developing	I-MED
(	I-MED
TD	I-MED
)	I-MED
group	I-MED
.‎	O
Method	O
:	O
The	O
BD	B-MED
group	B-MED
consisted	O
of	O
thirty	O
11	O
-	O
18	O
year	O
old	O
inpatients	B-MED
in	O
euthymic	B-MED
phase	I-MED
.	O
The	O
TD	B-MED
‎group	I-MED
included	O
30	O
age	B-MED
,	O
gender	B-MED
,	O
and	O
IQ	B-MED
matched	O
volunteer	O
students	B-MED
.	O
To	O
assess	O
the	O
diagnosis	B-MED
and	O
‎comorbid	B-MED
disorders	I-MED
,	O
we	O
performed	O
the	O
semi	B-MED
-	I-MED
structured	I-MED
interview	I-MED
of	O
the	O
Kiddie	B-MED
Schedule	I-MED
for	I-MED
Affective	I-MED
Disorders	I-MED
‎and	I-MED
Schizophrenia	I-MED
-	I-MED
Present	I-MED
and	I-MED
Lifetime	I-MED
Version	I-MED
(	O
K	B-MED
-	I-MED
SADS	I-MED
-	I-MED
PL	I-MED
)	O
for	O
the	O
BD	B-MED
adolescents	B-MED
.	O
To	O
‎evaluate	B-MED
the	O
severity	O
of	O
attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
(	O
ADHD	B-MED
)	O
and	O
mania	B-MED
,	O
Conner	B-MED
's	I-MED
‎Parent	I-MED
Rating	I-MED
Scale	I-MED
-	I-MED
Revised	I-MED
version	I-MED
(	I-MED
CPRS	I-MED
-	I-MED
R	I-MED
)	I-MED
,	O
and	O
Young	B-MED
Mania	I-MED
Rating	I-MED
Scale	I-MED
(	O
YMRS	B-MED
)	O
were	O
‎used	O
,	O
respectively	O
.	O
Ravens	B-MED
Progressive	I-MED
Matrices	I-MED
was	O
conducted	O
to	O
evaluate	B-MED
intellectual	B-MED
ability	I-MED
in	O
‎the	O
both	O
groups	B-MED
.	O
Happe	B-MED
Strange	I-MED
Stories	I-MED
test	I-MED
was	O
performed	O
to	O
assess	O
ToM	B-MED
in	O
the	O
participants	B-MED
.	O
Data	B-MED
were	O
‎analyzed	O
using	O
the	O
independent	O
t	B-MED
-	I-MED
test	I-MED
,	O
analysis	B-MED
of	I-MED
covariance	I-MED
,	O
and	O
Pearson	B-MED
Correlation	I-MED
analysis	I-MED
.‎	O
Results	O
:	O
The	O
two	O
groups	B-MED
did	O
not	O
show	O
any	O
differences	O
in	O
comprehending	O
the	O
stories	O
;	O
however	O
,	O
the	O
BD	B-MED
‎	O
group	B-MED
's	I-MED
mentalizing	B-MED
scores	I-MED
were	O
significantly	O
weaker	O
than	O
the	O
TD	B-MED
group	I-MED
(	O
p<0.05).‎‎	O
Conclusion	O
:	O
The	O
ToM	B-MED
impairments	B-MED
in	O
adolescents	B-MED
with	O
BD	B-MED
may	O
be	O
explained	O
as	O
a	O
trait	B-MED
marker	I-MED
which	O
may	O
lead	O
‎to	O
continuation	O
of	O
social	B-MED
problems	I-MED
even	O
during	O
remission‏	B-MED
.‏.	O
Molecular	B-MED
serum	B-MED
signature	B-MED
of	O
treatment	B-MED
resistant	I-MED
depression	I-MED
A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-MED
depressive	I-MED
disorder	I-MED
(	O
MDD	B-MED
)	O
do	O
not	O
respond	O
to	O
multiple	B-MED
trials	B-MED
of	O
anti	B-MED
-	I-MED
depressants	I-MED
,	O
develop	O
a	O
chronic	B-MED
course	B-MED
of	I-MED
disease	I-MED
and	O
become	O
treatment	B-MED
resistant	B-MED
.	O
Most	O
of	O
the	O
studies	O
investigating	O
molecular	B-MED
changes	B-MED
in	O
treatment	B-MED
-	I-MED
resistant	I-MED
depression	I-MED
(	O
TRD	B-MED
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B-MED
.	O
Consequently	O
,	O
biomarkers	B-MED
associated	O
with	O
TRD	B-MED
are	O
still	O
lacking	O
.	O
This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	B-MED
-	I-MED
throughput	I-MED
proteomic	I-MED
platforms	I-MED
to	O
identify	O
peripheral	B-MED
biomarkers	B-MED
of	O
TRD	B-MED
defined	O
by	O
two	O
staging	B-MED
models	I-MED
,	O
the	O
Thase	B-MED
and	I-MED
Rush	I-MED
staging	I-MED
model	I-MED
(	O
TRM	B-MED
)	O
and	O
the	O
Maudsley	B-MED
Staging	I-MED
Model	I-MED
(	O
MSM	B-MED
)	O
.	O
Serum	B-MED
collected	O
from	O
an	O
inpatient	B-MED
cohort	O
of	O
65	O
individuals	B-MED
suffering	O
from	O
MDD	B-MED
was	O
analysed	O
using	O
two	O
different	O
mass	B-MED
spectrometric	I-MED
-	I-MED
based	I-MED
platforms	I-MED
,	O
label	B-MED
-	I-MED
free	I-MED
liquid	I-MED
chromatography	I-MED
mass	I-MED
spectrometry	I-MED
(	O
LC	B-MED
-	I-MED
MS(E	I-MED
)	I-MED
)	O
and	O
selective	B-MED
reaction	I-MED
monitoring	I-MED
(	O
SRM	B-MED
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-MED
bead	I-MED
based	I-MED
assay	I-MED
.	O
In	O
the	O
LC	B-MED
-	I-MED
MS(E	I-MED
)	I-MED
analysis	I-MED
,	O
proteins	B-MED
involved	O
in	O
the	O
acute	B-MED
phase	I-MED
response	I-MED
and	O
complement	B-MED
activation	I-MED
and	O
coagulation	B-MED
were	O
significantly	O
different	O
between	O
the	O
staging	B-MED
groups	I-MED
in	O
both	O
models	B-MED
.	O
In	O
the	O
multiplex	B-MED
bead	I-MED
-	I-MED
based	I-MED
assay	I-MED
analysis	O
TNF	B-MED
-	I-MED
α	I-MED
levels	I-MED
(	O
log(odds	B-MED
)	I-MED
=	O
-4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	B-MED
different	B-MED
in	O
the	O
TRM	B-MED
comparison	B-MED
.	O
Using	O
SRM	B-MED
,	O
significant	B-MED
changes	B-MED
of	O
three	O
apolipoproteins	B-MED
A	I-MED
-	I-MED
I	I-MED
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	B-MED
(	O
β	O
=	O
-0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	B-MED
(	O
β	O
=	O
-0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
TRM	B-MED
but	O
not	O
the	O
MSM	B-MED
.	O
Overall	O
,	O
our	O
findings	B-MED
suggest	O
that	O
proteins	B-MED
,	O
which	O
are	O
involved	O
in	O
immune	B-MED
and	O
complement	B-MED
activation	I-MED
,	O
may	O
represent	O
potential	O
biomarkers	B-MED
that	O
could	O
be	O
used	O
by	O
clinicians	B-MED
to	O
identify	O
high	B-MED
-	I-MED
risk	I-MED
patients	B-MED
.	O
Nevertheless	O
,	O
given	O
that	O
the	O
molecular	B-MED
changes	B-MED
between	O
the	O
staging	B-MED
groups	I-MED
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	B-MED
cautiously	O
.	O
Sequence	B-MED
-	I-MED
specific	I-MED
DNA	I-MED
binding	I-MED
by	O
long	B-MED
hairpin	I-MED
pyrrole	B-MED
-	I-MED
imidazole	I-MED
polyamides	I-MED
containing	O
an	O
8	B-MED
-	I-MED
amino-3,6	I-MED
-	I-MED
dioxaoctanoic	I-MED
acid	I-MED
unit	O
With	O
the	O
aim	O
of	O
improving	O
aqueous	B-MED
solubility	I-MED
,	O
we	O
designed	B-MED
and	O
synthesized	B-MED
five	O
N	B-MED
-	I-MED
methylpyrrole	I-MED
(	I-MED
Py)-N	I-MED
-	I-MED
methylimidazole	I-MED
(	I-MED
I	I-MED
m	I-MED
)	I-MED
polyamides	I-MED
capable	O
of	O
recognizing	O
9	B-MED
-	I-MED
bp	I-MED
sequences	I-MED
.	O
Their	O
DNA	B-MED
-	I-MED
binding	I-MED
affinities	B-MED
and	O
sequence	B-MED
specificities	B-MED
were	O
evaluated	O
by	O
SPR	B-MED
and	O
Bind	B-MED
-	I-MED
n	I-MED
-	I-MED
Seq	I-MED
analyses	I-MED
.	O
The	O
design	B-MED
of	O
polyamide	B-MED
1	I-MED
was	O
based	O
on	O
a	O
conventional	O
model	B-MED
,	O
with	O
three	O
consecutive	O
Py	B-MED
or	O
I	B-MED
m	I-MED
rings	O
separated	O
by	O
a	O
β	B-MED
-	I-MED
alanine	I-MED
to	O
match	O
the	O
curvature	O
and	O
twist	B-MED
of	O
long	O
DNA	B-MED
helices	B-MED
.	O
Polyamides	B-MED
2	I-MED
and	I-MED
3	I-MED
contained	O
an	O
8	B-MED
-	I-MED
amino-3,6	I-MED
-	I-MED
dioxaoctanoic	I-MED
acid	I-MED
(	O
AO	B-MED
)	O
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-MED
within	O
linear	O
Py	B-MED
-	I-MED
Im	I-MED
polyamides	I-MED
or	O
between	O
Py	B-MED
Py	B-MED
-	I-MED
I	I-MED
m	I-MED
hairpin	I-MED
motifs	I-MED
I	B-MED
m	I-MED
for	O
tandem	B-MED
hairpin	I-MED
.	O
It	O
is	O
demonstrated	O
herein	O
that	O
AO	B-MED
also	O
functions	O
as	O
a	O
linker	B-MED
element	I-MED
that	O
can	O
extend	O
to	O
2	B-MED
-	I-MED
bp	I-MED
in	O
hairpin	B-MED
motifs	I-MED
.	O
Notably	O
,	O
although	O
the	O
AO	B-MED
-containing	O
unit	O
can	O
fail	B-MED
to	O
bind	B-MED
the	O
expected	O
sequence	B-MED
,	O
polyamide	B-MED
4	I-MED
,	O
which	O
has	O
two	O
AO	B-MED
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	B-MED
form	I-MED
,	O
successfully	O
showed	O
the	O
expected	O
motif	B-MED
and	O
a	O
KD	B-MED
value	I-MED
of	O
16nM	O
was	O
recorded	O
.	O
Polyamide	B-MED
5	I-MED
,	O
containing	O
a	O
β	B-MED
-	I-MED
alanine	I-MED
-	I-MED
β	I-MED
-	I-MED
alanine	I-MED
unit	O
instead	O
of	O
the	O
AO	B-MED
of	O
polyamide	B-MED
2	I-MED
,	O
was	O
synthesized	B-MED
for	O
comparison	B-MED
.	O
The	O
aqueous	B-MED
solubilities	I-MED
and	O
nuclear	B-MED
localization	I-MED
of	O
three	O
of	O
the	O
polyamides	B-MED
were	O
also	O
examined	O
.	O
The	O
results	B-MED
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
AO	B-MED
unit	O
in	O
the	O
core	B-MED
of	O
Py	B-MED
-	I-MED
Im	I-MED
polyamide	I-MED
compounds	I-MED
.	O
Efficacy	B-MED
and	O
safety	B-MED
of	O
cisplatin	B-MED
,	O
dexamethasone	B-MED
,	O
gemcitabine	B-MED
and	O
pegaspargase	B-MED
(	O
DDGP	B-MED
)	O
regimen	B-MED
in	O
newly	B-MED
diagnosed	I-MED
,	O
advanced	B-MED
-	I-MED
stage	I-MED
extranodal	B-MED
natural	I-MED
killer	I-MED
/	I-MED
T	I-MED
-	I-MED
cell	I-MED
lymphoma	I-MED
:	O
interim	B-MED
analysis	B-MED
of	O
a	O
phase	B-MED
4	I-MED
study	B-MED
NCT01501149	O
To	O
explore	O
a	O
more	O
effective	B-MED
treatment	B-MED
for	O
newly	B-MED
diagnosed	I-MED
,	O
advanced	B-MED
-	I-MED
stage	I-MED
extranodal	B-MED
natural	I-MED
killer	I-MED
/	I-MED
T	I-MED
-	I-MED
cell	I-MED
lymphoma	I-MED
,	I-MED
nasal	I-MED
type	I-MED
(	O
ENKTL	B-MED
)	O
,	O
we	O
conducted	O
a	O
phase	B-MED
4	I-MED
study	B-MED
of	O
the	O
cisplatin	B-MED
,	O
dexamethasone	B-MED
,	O
gemcitabine	B-MED
,	O
pegaspargase	B-MED
(	O
DDGP	B-MED
)	O
regimen	B-MED
.	O
The	O
primary	O
end	B-MED
point	I-MED
was	O
the	O
2	O
-	O
year	O
progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
PFS	B-MED
)	O
after	O
the	O
protocol	B-MED
treatment	I-MED
.	O
Secondary	O
endpoints	B-MED
included	O
response	B-MED
rate	I-MED
(	O
RR	B-MED
)	O
,	O
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
and	O
median	B-MED
survival	I-MED
time	I-MED
(	O
MST	B-MED
)	O
.	O
The	O
interim	B-MED
analysis	B-MED
included	O
data	B-MED
only	O
from	O
March	O
2011	O
to	O
September	O
2013	O
,	O
who	O
received	B-MED
six	O
cycles	O
of	O
DDGP	B-MED
chemotherapy	B-MED
.	O
A	O
total	O
of	O
25	O
eligible	B-MED
patients	B-MED
were	O
enrolled	O
.	O
Seventeen	O
patients	B-MED
(	O
17/24	O
,	O
70.83	O
%	O
)	O
achieved	O
complete	B-MED
response	I-MED
(	O
CR	B-MED
)	O
and	O
four	O
(	O
4/24	O
,	O
16.67	O
%	O
)	O
achieved	O
partial	B-MED
response	I-MED
(	O
PR	B-MED
)	O
,	O
three	O
(	O
3/24	O
,	O
12.50	O
%	O
)	O
had	O
progressive	B-MED
disease	I-MED
(	O
PD	B-MED
)	O
.	O
The	O
RR	B-MED
after	O
treatment	B-MED
was	O
87.50	O
%	O
.	O
After	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
duration	B-MED
of	O
24.67	O
months	B-MED
(	O
range	O
4	O
-	O
48	O
months	B-MED
)	O
.	O
The	O
2	O
-	O
year	O
PFS	B-MED
and	O
OS	B-MED
rate	I-MED
were	O
61.80	O
%	O
(	O
95	O
%	O
CI	B-MED
,	O
42.00	O
%	O
to	O
81.60	O
%	O
)	O
and	O
68.50	O
%	O
(	O
95	O
%	O
CI	B-MED
,	O
48.70	O
%	O
to	O
88.30	O
%	O
)	O
,	O
respectively	O
.	O
The	O
MST	B-MED
was	O
36.55	O
months	B-MED
(	O
95	O
%	O
CI	B-MED
,	O
29.41	O
months	B-MED
to	O
43.70	O
months	B-MED
)	O
.	O
Grade	B-MED
3/4	O
leukopenia	B-MED
occurred	B-MED
in	O
fourteen	O
patients	B-MED
(	O
58.33	O
%	O
)	O
and	O
grade	B-MED
3/4	O
thrombocytopenia	B-MED
occurred	B-MED
in	O
eleven	O
patients	B-MED
(	O
45.83	O
%	O
)	O
.	O
Twelve	O
patients	B-MED
(	O
50.00	O
%	O
)	O
experienced	O
Activated	B-MED
Partial	I-MED
Phromboplastin	I-MED
Ptime	I-MED
(	O
APTT	B-MED
)	O
elongation	B-MED
and	O
fourteen	O
patients	B-MED
(	O
58.33	O
%	O
)	O
experienced	O
hypofibrinogenemia	B-MED
.	O
In	O
conclusion	O
,	O
DDGP	B-MED
regimen	B-MED
is	O
an	O
effective	B-MED
and	O
tolerated	B-MED
treatment	B-MED
for	O
newly	B-MED
diagnosed	I-MED
,	O
advanced	B-MED
-	I-MED
stage	I-MED
ENKTL	B-MED
.	O
This	O
trial	B-MED
was	O
registered	B-MED
at	O
www.ClinicalTrials.gov	B-MED
as	O
#	O
NCT01501149	O
.	O
Comparative	B-MED
Effectiveness	I-MED
of	O
Treatments	B-MED
for	O
Chronic	B-MED
Low	I-MED
Back	I-MED
Pain	I-MED
:	O
A	O
Multiple	B-MED
Treatment	I-MED
Comparison	I-MED
Analysis	I-MED
A	O
systematic	B-MED
review	I-MED
and	O
network	B-MED
meta	I-MED
-	I-MED
analysis	I-MED
.	O
To	O
determine	O
current	B-MED
treatment	I-MED
options	I-MED
of	O
chronic	B-MED
low	I-MED
back	I-MED
pain	I-MED
(	O
LBP	B-MED
)	O
as	O
defined	O
by	O
randomized	B-MED
controlled	I-MED
trials	I-MED
(	O
RCTs	B-MED
)	O
and	O
to	O
compare	B-MED
effectiveness	B-MED
of	O
those	O
treatments	B-MED
using	O
a	O
mixed	B-MED
-	I-MED
treatment	I-MED
comparison	I-MED
(	O
MTC	B-MED
)	O
.	O
It	O
is	O
important	O
to	O
provide	O
an	O
evidence	B-MED
-	I-MED
based	I-MED
assessment	B-MED
of	O
the	O
treatment	B-MED
options	I-MED
that	O
exist	O
for	O
LBP	B-MED
.	O
A	O
systematic	B-MED
search	I-MED
of	O
RCTs	B-MED
was	O
conducted	O
in	O
MEDLINE	B-MED
and	O
the	O
Cochrane	B-MED
Collaboration	I-MED
Library	I-MED
from	O
1990	O
to	O
2014	O
.	O
From	O
the	O
selected	B-MED
studies	I-MED
,	O
we	O
extracted	O
preoperative	B-MED
and	O
postoperative	B-MED
ODI	B-MED
and	O
VAS	B-MED
back	I-MED
pain	I-MED
scores	I-MED
,	O
additional	B-MED
surgeries	I-MED
,	O
and	O
complications	B-MED
.	O
Standard	B-MED
and	I-MED
network	I-MED
meta	I-MED
-	I-MED
analytic	I-MED
techniques	I-MED
were	O
used	O
.	O
Twelve	O
RCTs	B-MED
were	O
included	O
in	O
the	O
analysis	B-MED
:	O
5	O
total	B-MED
disk	I-MED
replacement	I-MED
(	O
TDR	B-MED
)	O
versus	O
fusion	B-MED
;	O
1	O
TDR	B-MED
versus	O
exercise	B-MED
and	O
cognitive	B-MED
behavioral	I-MED
therapy	I-MED
(	O
CBT	B-MED
)	O
;	O
5	O
fusion	B-MED
versus	O
exercise	B-MED
and	O
CBT	B-MED
;	O
and	O
1	O
fusion	B-MED
versus	O
physical	B-MED
therapy	I-MED
(	O
PT	B-MED
)	O
.	O
On	O
the	O
basis	O
of	O
MTC	B-MED
,	O
with	O
respect	O
to	O
ODI	B-MED
change	I-MED
scores	I-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
fusion	B-MED
over	O
exercise	B-MED
and	O
CBT	B-MED
was	O
2.0	O
points	O
(	O
95	O
%	O
CI	O
,	O
-1.2	O
to	O
4.8	O
)	O
.	O
The	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
TDR	B-MED
over	O
exercise	B-MED
and	O
CBT	B-MED
was	O
6.4	O
points	O
(	O
95	O
%	O
CI	O
,	O
3.2	O
-	O
9.3	O
)	O
.	O
The	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
fusion	B-MED
over	O
PT	B-MED
was	O
8.8	O
points	O
(	O
95	O
%	O
CI	O
,	O
4.1	O
-	O
13.6	O
)	O
.	O
The	O
pooled	B-MED
mean	I-MED
differences	I-MED
favoring	O
TDR	B-MED
over	O
fusion	B-MED
was	O
4.4	O
points	O
(	O
95	O
%	O
CI	O
,	O
2.37	O
-	O
6.63	O
)	O
.	O
For	O
PT	B-MED
versus	O
structured	B-MED
exercise	I-MED
with	O
CBT	B-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
exercise	B-MED
with	O
CBT	B-MED
over	O
PT	B-MED
was	O
6.8	O
points	O
(	O
95	O
%	O
CI	O
,	O
1.5	O
-	O
12.8	O
)	O
.	O
For	O
TDR	B-MED
versus	O
PT	B-MED
,	O
the	O
pooled	B-MED
mean	I-MED
difference	I-MED
favoring	O
TDR	B-MED
over	O
PT	B-MED
was	O
13.2	O
points	O
(	O
95	O
%	O
CI	O
,	O
8.0	O
-	O
18.4	O
)	O
.	O
Additional	O
surgery	B-MED
rates	I-MED
were	O
similar	O
between	O
treatment	B-MED
options	I-MED
.	O
All	O
4	O
treatments	B-MED
provided	O
some	O
benefit	B-MED
to	O
patients	B-MED
with	O
chronic	B-MED
LBP	I-MED
.	O
According	O
to	O
the	O
MTC	B-MED
analysis	I-MED
,	O
TDR	B-MED
may	O
be	O
the	O
most	B-MED
effective	I-MED
treatment	B-MED
and	O
PT	B-MED
the	O
least	B-MED
effective	I-MED
treatment	B-MED
for	O
chronic	B-MED
LBP	I-MED
.	O
This	O
review	B-MED
is	O
based	O
on	O
a	O
limited	B-MED
number	I-MED
of	O
RCT	B-MED
studies	I-MED
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-MED
modality	B-MED
for	O
all	O
patients	B-MED
.	O
Evolution	B-MED
of	O
Fitness	B-MED
Cost	B-MED
-	I-MED
Neutral	I-MED
Mutant	B-MED
PfCRT	B-MED
Conferring	O
P.	B-MED
falciparum	I-MED
4	B-MED
-	I-MED
Aminoquinoline	I-MED
Drug	B-MED
Resistance	I-MED
Is	O
Accompanied	O
by	O
Altered	B-MED
Parasite	B-MED
Metabolism	B-MED
and	O
Digestive	B-MED
Vacuole	I-MED
Physiology	B-MED
Southeast	B-MED
Asia	I-MED
is	O
an	O
epicenter	O
of	O
multidrug	B-MED
-	I-MED
resistant	I-MED
Plasmodium	B-MED
falciparum	I-MED
strains	I-MED
.	O
Selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	B-MED
variants	B-MED
of	O
parasite	B-MED
drug	B-MED
resistance	I-MED
genes	B-MED
,	O
including	O
the	O
P.	B-MED
falciparum	I-MED
chloroquine	I-MED
resistance	I-MED
transporter	I-MED
(	O
pfcrt	B-MED
)	O
.	O
Despite	O
significant	O
reductions	B-MED
in	O
the	O
deployment	B-MED
of	O
the	O
4	B-MED
-	I-MED
aminoquinoline	I-MED
drug	B-MED
chloroquine	B-MED
(	O
CQ	B-MED
)	O
,	O
which	O
selected	O
for	O
the	O
mutant	B-MED
pfcrt	B-MED
alleles	B-MED
that	O
halted	O
CQ	B-MED
efficacy	B-MED
decades	O
ago	O
,	O
the	O
parasite	B-MED
pfcrt	B-MED
locus	B-MED
is	O
continuously	O
evolving	O
.	O
This	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	B-MED
mutated	B-MED
allele	B-MED
,	O
Cam734	B-MED
pfcrt	I-MED
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	B-MED
CQ	B-MED
resistance	B-MED
without	O
an	O
associated	O
fitness	B-MED
cost	B-MED
.	O
Here	O
,	O
we	O
used	O
pfcrt	B-MED
-specific	O
zinc	B-MED
-	I-MED
finger	I-MED
nucleases	I-MED
to	O
genetically	B-MED
dissect	I-MED
this	O
allele	B-MED
in	O
the	O
pathogenic	B-MED
setting	O
of	O
asexual	B-MED
blood	I-MED
-	I-MED
stage	I-MED
infection	I-MED
.	O
Comparative	B-MED
analysis	I-MED
of	O
drug	B-MED
resistance	I-MED
and	O
growth	B-MED
profiles	O
of	O
recombinant	B-MED
parasites	I-MED
that	O
express	B-MED
Cam734	B-MED
or	O
variants	B-MED
thereof	O
,	O
Dd2	B-MED
(	O
the	O
most	O
common	O
Southeast	B-MED
Asian	I-MED
variant	B-MED
)	O
,	O
or	O
wild	B-MED
-	I-MED
type	I-MED
pfcrt	B-MED
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
PfCRT	B-MED
mutations	B-MED
in	O
modulating	O
parasite	B-MED
susceptibility	O
to	O
multiple	O
antimalarial	B-MED
agents	I-MED
.	O
These	O
results	O
were	O
generated	O
in	O
the	O
GC03	B-MED
strain	B-MED
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	B-MED
studies	B-MED
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	B-MED
.	O
Results	O
presented	O
herein	O
show	O
that	O
Cam734	B-MED
-mediated	O
CQ	B-MED
resistance	B-MED
is	O
dependent	O
on	O
the	O
rare	O
A144F	B-MED
mutation	B-MED
that	O
has	O
not	O
been	O
observed	O
beyond	O
Southeast	B-MED
Asia	I-MED
,	O
and	O
reveal	O
distinct	O
impacts	B-MED
of	O
this	O
and	O
other	O
Cam734	B-MED
-specific	O
mutations	B-MED
on	O
CQ	B-MED
resistance	B-MED
and	O
parasite	B-MED
growth	B-MED
rates	I-MED
.	O
Biochemical	B-MED
assays	I-MED
revealed	O
a	O
broad	O
impact	B-MED
of	O
mutant	B-MED
PfCRT	B-MED
isoforms	B-MED
on	O
parasite	B-MED
metabolism	B-MED
,	O
including	O
nucleoside	B-MED
triphosphate	I-MED
levels	B-MED
,	O
hemoglobin	B-MED
catabolism	I-MED
and	O
disposition	O
of	O
heme	B-MED
,	O
as	O
well	O
as	O
digestive	B-MED
vacuole	I-MED
volume	B-MED
pH	B-MED
and	O
pH.	O
Results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	B-MED
molecular	I-MED
basis	I-MED
and	O
physiological	B-MED
impact	B-MED
of	O
PfCRT	B-MED
-mediated	O
antimalarial	B-MED
drug	B-MED
resistance	I-MED
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	B-MED
alleles	B-MED
that	O
can	O
undermine	O
the	O
efficacy	B-MED
of	O
first	O
-	O
line	O
antimalarial	B-MED
drug	I-MED
regimens	B-MED
.	O
CD169	B-MED
identifies	B-MED
an	O
activated	B-MED
CD8(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
subset	B-MED
in	O
regional	B-MED
lymph	I-MED
nodes	I-MED
that	O
predicts	B-MED
favorable	B-MED
prognosis	B-MED
in	O
colorectal	B-MED
cancer	I-MED
patients	B-MED
CD169	B-MED
was	O
first	O
identified	O
on	O
macrophages	B-MED
(	O
Mϕ	B-MED
)	O
and	O
linked	O
to	O
antigen	B-MED
presentation	I-MED
.	O
Here	O
,	O
we	O
showed	O
CD169	B-MED
expression	I-MED
on	O
some	O
CD8(+	B-MED
)	I-MED
T	I-MED
lymphocytes	I-MED
in	O
regional	B-MED
lymph	I-MED
nodes	I-MED
(	O
LNs	B-MED
)	O
and	O
investigated	B-MED
the	O
function	B-MED
and	O
clinical	B-MED
relevance	I-MED
of	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
in	O
tumor	B-MED
-	I-MED
draining	I-MED
LNs	I-MED
of	O
colorectal	B-MED
cancer	I-MED
(	O
CRC	B-MED
)	O
patients	B-MED
.	O
Fresh	B-MED
tumor	I-MED
-	I-MED
draining	I-MED
LN	I-MED
tissues	I-MED
from	O
39	O
randomly	B-MED
enrolled	B-MED
patients	I-MED
were	O
assessed	B-MED
by	O
flow	B-MED
cytometry	I-MED
for	O
activation	B-MED
and	O
differentiation	B-MED
of	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
and	O
T	B-MED
cell	I-MED
-	I-MED
mediated	I-MED
killing	I-MED
of	I-MED
tumor	I-MED
cells	I-MED
.	O
In	O
total	O
,	O
114	O
tumor	B-MED
-	I-MED
draining	I-MED
LN	I-MED
paraffin	O
sections	O
from	O
CRC	B-MED
patients	B-MED
were	O
analyzed	O
by	O
multiple	B-MED
-	I-MED
color	I-MED
immunofluorescence	I-MED
for	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
distribution	B-MED
and	O
clinical	O
values	O
.	O
The	O
prognostic	B-MED
significance	B-MED
of	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
was	O
evaluated	B-MED
by	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
.	O
A	O
fraction	B-MED
of	I-MED
CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
in	O
regional	B-MED
LNs	I-MED
,	O
but	O
not	O
peripheral	B-MED
blood	I-MED
,	O
tonsils	B-MED
,	O
or	O
tumors	B-MED
,	O
expressed	B-MED
surface	I-MED
CD169	I-MED
.	O
In	B-MED
situ	I-MED
detection	B-MED
of	O
draining	B-MED
LNs	I-MED
revealed	B-MED
preferential	O
localization	B-MED
of	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
to	O
subcapsular	B-MED
sinus	I-MED
and	O
interfollicular	B-MED
regions	I-MED
,	O
closely	O
associated	B-MED
with	I-MED
CD169(+	B-MED
)	I-MED
Mϕ	I-MED
Mϕ.	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
ratios	B-MED
were	O
significantly	O
lower	O
in	O
peri	B-MED
-	I-MED
tumor	I-MED
LNs	B-MED
than	O
distant	B-MED
-	I-MED
tumor	I-MED
LNs	B-MED
.	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
predominantly	B-MED
expressed	O
activation	B-MED
markers	I-MED
(	O
CD69	B-MED
,	O
HLA	B-MED
-	I-MED
DR	I-MED
,	O
PD-1	B-MED
)	O
with	O
slightly	O
lower	O
CD45RA	B-MED
and	O
CD62L	B-MED
levels	B-MED
.	O
They	O
produced	O
high	B-MED
granzyme	B-MED
B	I-MED
,	O
perforin	B-MED
,	O
TNF	B-MED
-	I-MED
α	I-MED
,	O
and	O
IFNγ	B-MED
levels	B-MED
,	O
and	O
promoted	O
tumor	B-MED
-	I-MED
killing	I-MED
efficiency	I-MED
ex	B-MED
vitro	I-MED
.	O
Moreover	O
,	O
CD169(+)CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
infiltrating	B-MED
tumor	B-MED
-	I-MED
draining	I-MED
LNs	I-MED
decreased	B-MED
with	O
disease	B-MED
progression	I-MED
and	O
were	O
strongly	O
associated	B-MED
with	I-MED
CRC	B-MED
patient	B-MED
survival	B-MED
.	O
We	O
identified	B-MED
novel	O
activated	B-MED
/	O
cytolytic	B-MED
CD169(+)CD8(+	I-MED
)	I-MED
T	I-MED
cells	I-MED
selectively	O
present	O
in	O
regional	B-MED
LNs	I-MED
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	B-MED
factor	I-MED
and	O
indicator	B-MED
for	O
selecting	B-MED
patients	B-MED
for	O
immunotherapy	B-MED
.	O
Regulated	B-MED
Intron	B-MED
Removal	B-MED
Integrates	O
Motivational	B-MED
State	I-MED
and	O
Experience	B-MED
Myriad	O
experiences	B-MED
produce	O
transient	B-MED
memory	I-MED
,	O
yet	O
,	O
contingent	O
on	O
the	O
internal	B-MED
state	I-MED
of	O
the	O
organism	B-MED
and	O
the	O
saliency	O
of	O
the	O
experience	B-MED
,	O
only	O
some	O
memories	B-MED
persist	O
over	O
time	B-MED
.	O
How	O
experience	B-MED
and	O
internal	B-MED
state	I-MED
influence	B-MED
the	O
duration	B-MED
of	O
memory	B-MED
at	O
the	O
molecular	O
level	O
remains	O
unknown	O
.	O
A	O
self	B-MED
-	I-MED
assembled	I-MED
aggregated	I-MED
state	O
of	O
Drosophila	B-MED
Orb2A	I-MED
protein	I-MED
is	O
required	O
specifically	O
for	O
long	B-MED
-	I-MED
lasting	I-MED
memory	I-MED
.	O
We	O
report	O
that	O
in	O
the	O
adult	B-MED
fly	I-MED
brain	B-MED
the	O
mRNA	B-MED
encoding	B-MED
Orb2A	B-MED
protein	I-MED
exists	O
in	O
an	O
unspliced	B-MED
non	I-MED
-	I-MED
protein	I-MED
-	I-MED
coding	I-MED
form	I-MED
.	O
The	O
convergence	B-MED
of	O
experience	B-MED
and	O
internal	B-MED
drive	I-MED
transiently	O
increases	B-MED
the	O
spliced	B-MED
protein	I-MED
-	I-MED
coding	I-MED
Orb2A	I-MED
mRNA	I-MED
.	O
A	O
screen	O
identified	O
pasilla	B-MED
,	O
the	O
fly	B-MED
ortholog	O
of	O
mammalian	B-MED
Nova-1	B-MED
/	O
2	B-MED
,	O
as	O
a	O
mediator	B-MED
of	O
Orb2A	B-MED
mRNA	I-MED
processing	B-MED
.	O
A	O
single	B-MED
-	I-MED
nucleotide	I-MED
substitution	B-MED
in	O
the	O
intronic	B-MED
region	O
that	O
reduces	B-MED
Pasilla	B-MED
binding	B-MED
and	O
intron	B-MED
removal	B-MED
selectively	O
impairs	B-MED
long	B-MED
-	I-MED
term	I-MED
memory	I-MED
.	O
We	O
posit	O
that	O
pasilla	B-MED
-mediated	O
processing	B-MED
of	O
unspliced	B-MED
Orb2A	I-MED
mRNA	I-MED
integrates	O
experience	B-MED
and	O
internal	B-MED
state	I-MED
to	O
control	O
Orb2A	B-MED
protein	I-MED
abundance	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
memory	I-MED
formation	B-MED
.	O
How	O
do	O
wettability	B-MED
,	O
zeta	B-MED
potential	I-MED
and	O
hydroxylation	B-MED
hydroxylation	B-MED
degree	I-MED
affect	O
the	O
biological	B-MED
response	I-MED
of	O
biomaterials	B-MED
?	O
It	O
is	O
well	O
known	O
that	O
composition	B-MED
,	O
electric	B-MED
charge	I-MED
,	O
wettability	B-MED
and	O
roughness	B-MED
of	O
implant	B-MED
surfaces	B-MED
have	O
great	O
influence	B-MED
on	O
their	O
interaction	B-MED
with	O
the	O
biological	B-MED
fluids	I-MED
and	O
tissues	B-MED
,	O
but	O
systematic	B-MED
studies	I-MED
of	O
different	O
materials	B-MED
in	O
the	O
same	O
experimental	B-MED
conditions	I-MED
are	O
still	O
lacking	B-MED
in	O
the	O
scientific	B-MED
literature	I-MED
.	O
The	O
aim	O
of	O
this	O
research	B-MED
is	O
to	O
investigate	B-MED
the	O
correlations	B-MED
between	O
some	O
surface	B-MED
characteristics	I-MED
(	O
wettability	B-MED
,	O
zeta	B-MED
potential	I-MED
and	O
hydroxylation	B-MED
hydroxylation	B-MED
degree	I-MED
)	O
and	O
the	O
biological	B-MED
response	I-MED
(	O
protein	B-MED
protein	B-MED
adsorption	I-MED
,	O
blood	B-MED
wettability	B-MED
,	O
cell	B-MED
and	O
bacterial	B-MED
adhesion	I-MED
)	O
to	O
some	O
model	O
biomaterials	B-MED
.	O
The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	B-MED
for	O
implantable	B-MED
biomaterials	I-MED
.	O
Roughness	B-MED
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
:	O
smooth	B-MED
surfaces	I-MED
prepared	O
by	O
a	O
controlled	B-MED
protocol	I-MED
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	B-MED
effects	I-MED
.	O
Three	O
oxides	B-MED
(	O
ZrO2	B-MED
,	O
Al2O3	B-MED
,	O
SiO2	B-MED
)	O
,	O
three	O
metals	B-MED
(	O
316LSS	B-MED
steel	I-MED
,	O
Ti	B-MED
,	O
Nb	B-MED
)	O
and	O
two	O
polymers	B-MED
(	O
corona	B-MED
treated	I-MED
polystyrene	I-MED
for	O
cell	B-MED
culture	I-MED
and	O
untreated	B-MED
polystyrene	I-MED
for	O
bacteria	B-MED
culture	I-MED
)	O
,	O
widely	O
used	O
for	O
biomedical	B-MED
applications	I-MED
,	O
were	O
considered	O
.	O
The	O
surfaces	B-MED
were	O
characterized	B-MED
by	O
contact	B-MED
profilometry	I-MED
,	O
SEM	B-MED
-	O
EDS	B-MED
,	O
XPS	B-MED
,	O
FTIR	B-MED
,	O
zeta	B-MED
potential	I-MED
and	O
wettability	B-MED
with	O
different	O
fluids	B-MED
.	O
Protein	B-MED
Protein	B-MED
adsorption	I-MED
,	O
blood	B-MED
wettability	B-MED
,	O
bacterial	B-MED
and	O
cell	B-MED
adhesion	I-MED
were	O
evaluated	O
in	O
order	O
to	O
investigate	B-MED
the	O
correlations	B-MED
between	O
the	O
surface	B-MED
physiochemical	I-MED
properties	I-MED
and	O
biological	B-MED
responses	I-MED
.	O
From	O
a	O
methodological	O
standpoint	O
,	O
XPS	B-MED
and	O
electrokinetic	B-MED
measurements	I-MED
emerged	O
as	O
the	O
more	O
suitable	O
techniques	B-MED
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	B-MED
hydroxylation	B-MED
degree	I-MED
and	O
surface	B-MED
charge	I-MED
/	O
isoelectric	B-MED
point	I-MED
.	O
Moreover	O
,	O
determination	O
of	O
wettability	B-MED
by	O
blood	B-MED
appeared	O
a	O
specific	O
and	O
crucial	O
test	B-MED
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	B-MED
.	O
Hydroxylation	B-MED
Hydroxylation	B-MED
degree	I-MED
resulted	O
correlated	O
to	O
the	O
wettability	B-MED
by	O
water	B-MED
,	O
but	O
not	O
directly	O
to	O
surface	B-MED
charge	I-MED
.	O
Wetting	B-MED
tests	I-MED
with	O
different	O
media	B-MED
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look	O
-	O
alike	O
materials	B-MED
.	O
A	O
dependence	O
of	O
protein	B-MED
protein	B-MED
absorption	I-MED
on	O
hydroxylation	B-MED
hydroxylation	B-MED
degree	I-MED
,	O
charge	B-MED
and	O
wettability	B-MED
was	O
evidenced	O
and	O
its	O
maximum	B-MED
was	O
registered	O
for	O
surfaces	B-MED
with	O
low	O
wettability	B-MED
in	O
both	O
water	B-MED
based	O
and	O
protein	B-MED
containing	O
media	B-MED
and	O
a	O
moderate	O
surface	B-MED
charge	I-MED
.	O
As	O
far	O
as	O
bacterial	B-MED
adhesion	I-MED
is	O
concerned	O
,	O
no	B-MED
effect	I-MED
of	O
surface	B-MED
charge	I-MED
or	O
protein	B-MED
protein	B-MED
adsorption	I-MED
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	B-MED
component	I-MED
of	O
the	O
surface	B-MED
energy	I-MED
appeared	O
significant	O
.	O
Finally	O
,	O
the	O
combination	O
of	O
hydroxylation	B-MED
hydroxylation	B-MED
degree	I-MED
,	O
wettability	B-MED
,	O
surface	B-MED
charge	I-MED
and	O
energy	B-MED
(	O
polar	B-MED
component	I-MED
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	B-MED
adhesion	I-MED
and	O
viability	B-MED
.	O
Toward	O
optimizing	B-MED
dental	B-MED
implant	I-MED
performance	O
:	O
Surface	B-MED
characterization	B-MED
of	O
Ti	B-MED
and	O
TiZr	B-MED
implant	B-MED
materials	I-MED
Targeting	B-MED
understanding	O
enhanced	B-MED
osseointegration	B-MED
kinetics	B-MED
,	O
the	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
characterize	B-MED
the	O
surface	B-MED
morphology	B-MED
and	O
composition	B-MED
of	O
Ti	B-MED
and	O
TiZr	B-MED
dental	B-MED
implant	I-MED
substrates	B-MED
subjected	O
to	O
one	O
of	O
two	O
surface	B-MED
treatments	B-MED
developed	O
by	O
Straumann	O
.	O
These	O
two	O
treatments	B-MED
are	O
typically	O
known	O
as	O
SLA	B-MED
and	O
SLActive	B-MED
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	B-MED
osseointegration	B-MED
.	O
A	O
range	O
of	O
techniques	B-MED
was	O
applied	B-MED
to	O
characterize	B-MED
four	O
different	B-MED
substrate	B-MED
/	O
surface	B-MED
treatment	B-MED
combinations	B-MED
(	O
TiSLA	B-MED
,	O
TiSLActive	B-MED
,	O
TiZrSLA	B-MED
,	O
and	O
TiZrSLActive	B-MED
)	O
.	O
Contact	B-MED
angle	B-MED
measurements	B-MED
establish	O
establish	O
their	O
hydrophilic	B-MED
/	O
hydrophobic	B-MED
nature	O
.	O
Surface	B-MED
morphology	B-MED
was	O
probed	O
with	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
.	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
,	O
Raman	B-MED
μ	I-MED
-	I-MED
spectroscopy	I-MED
,	O
and	O
X	B-MED
-	I-MED
ray	I-MED
photoelectron	I-MED
spectroscopy	I-MED
were	O
used	O
to	O
elucidate	O
the	O
composition	B-MED
of	O
the	O
near-	O
surface	B-MED
region	O
.	O
Consistent	B-MED
with	I-MED
previous	B-MED
work	O
,	O
surface	B-MED
morphology	B-MED
was	O
found	O
to	O
differ	B-MED
only	O
at	O
the	O
nanoscale	B-MED
,	O
with	O
both	O
SLActive	B-MED
substrates	B-MED
displaying	B-MED
nano	B-MED
-	O
protrusions	B-MED
.	O
Spectroscopic	B-MED
data	B-MED
indicate	O
that	O
all	O
substrates	B-MED
exhibit	O
surface	B-MED
films	B-MED
of	O
titanium	B-MED
oxide	I-MED
displaying	O
near	O
TiO2	B-MED
stoichiometry	B-MED
.	O
Raman	B-MED
μ	I-MED
-	I-MED
spectroscopy	I-MED
reveals	B-MED
that	O
amorphous	B-MED
TiO2	B-MED
is	O
most	O
likely	O
the	O
only	O
phase	B-MED
present	B-MED
on	O
TiSLA	B-MED
,	O
whilst	O
rutile	B-MED
-	O
TiO2	B-MED
is	O
also	O
evidenced	B-MED
on	O
TiSLActive	B-MED
,	O
TiZrSLA	B-MED
,	O
and	O
TiZrSLActive	B-MED
.	O
For	O
TiZr	B-MED
alloy	B-MED
substrates	B-MED
,	O
there	O
is	O
no	O
evidence	B-MED
of	O
discrete	B-MED
phases	B-MED
of	O
oxidized	B-MED
Zr	B-MED
.	O
X	B-MED
-	I-MED
ray	I-MED
photoelectron	I-MED
spectra	I-MED
demonstrate	O
that	O
all	O
samples	B-MED
are	O
terminated	B-MED
by	O
adventitious	B-MED
carbon	B-MED
,	O
with	O
it	O
being	O
somewhat	O
thicker	B-MED
(	O
∼1	O
nm	O
)	O
on	O
TiSLA	B-MED
and	O
TiZrSLA	B-MED
.	O
Given	O
previous	B-MED
in	B-MED
vivo	I-MED
studies	I-MED
,	O
acquired	B-MED
data	B-MED
suggest	O
that	O
both	O
nanoscale	B-MED
protrusions	B-MED
,	O
and	O
a	O
thinner	B-MED
layer	B-MED
of	O
adventitious	B-MED
carbon	B-MED
contribute	B-MED
to	O
the	O
more	O
rapid	B-MED
osseointegration	B-MED
of	O
SLActive	B-MED
dental	B-MED
implants	I-MED
.	O
Composition	B-MED
of	O
the	O
surface	B-MED
oxide	B-MED
layer	B-MED
is	O
apparently	O
less	B-MED
important	B-MED
in	O
determining	O
osseointegration	B-MED
kinetics	B-MED
.	O
Randomized	B-MED
Trials	I-MED
of	O
the	O
Teen	B-MED
Outreach	B-MED
Program	I-MED
in	O
Louisiana	B-MED
and	O
Rochester	B-MED
,	O
New	B-MED
York	I-MED
To	O
evaluate	B-MED
the	O
Teen	B-MED
Outreach	B-MED
Program	I-MED
,	O
a	O
pregnancy	B-MED
prevention	I-MED
program	B-MED
,	O
in	O
2	O
community	B-MED
-based	O
settings	O
.	O
We	O
evaluated	B-MED
the	O
Teen	B-MED
Outreach	B-MED
Program	I-MED
,	O
a	O
9	O
-	O
month	O
positive	B-MED
youth	I-MED
development	I-MED
program	I-MED
,	O
in	O
3	O
cohorts	B-MED
of	O
youths	B-MED
from	O
2012	O
to	O
2015	O
in	O
2	O
states	B-MED
.	O
In	O
Louisiana	B-MED
,	O
7	O
agencies	B-MED
participated	O
in	O
an	O
individualized	B-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
,	O
with	O
youths	B-MED
randomly	O
assigned	O
to	O
a	O
treatment	B-MED
or	O
control	B-MED
condition	I-MED
.	O
Fourteen	O
agencies	B-MED
in	O
Rochester	B-MED
,	O
New	B-MED
York	I-MED
,	O
participated	O
in	O
a	O
cluster	B-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
.	O
We	O
found	O
no	B-MED
differences	I-MED
between	O
the	O
intervention	B-MED
and	O
control	B-MED
youths	I-MED
on	O
delay	B-MED
of	O
sexual	B-MED
onset	B-MED
in	O
Louisiana	B-MED
(	O
adjusted	B-MED
odds	I-MED
ratio	I-MED
[	O
AOR	B-MED
]	O
=	O
0.80	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
=	O
0.62	O
,	O
1.03	O
)	O
or	O
in	O
Rochester	B-MED
,	O
New	B-MED
York	I-MED
(	O
AOR	B-MED
=	O
0.89	O
;	O
95	O
%	O
CI	B-MED
=	O
0.45	O
,	O
1.77	O
)	O
,	O
or	O
for	O
sex	B-MED
with	O
no	O
effective	O
means	O
of	O
birth	B-MED
control	I-MED
(	O
Louisiana	B-MED
,	O
AOR	B-MED
=	O
1.18	O
;	O
95	O
%	O
CI	B-MED
=	O
0.78	O
,	O
1.78	O
;	O
Rochester	B-MED
,	O
AOR	B-MED
=	O
0.41	O
;	O
95	O
%	O
CI	B-MED
=	O
0.13	O
,	O
1.27	O
)	O
after	O
controlling	B-MED
for	O
relevant	O
covariates	B-MED
.	O
We	O
found	O
no	B-MED
short	B-MED
-	I-MED
term	I-MED
effects	B-MED
for	O
the	O
offer	O
of	O
the	O
intervention	B-MED
.	O
Research	B-MED
might	O
be	O
needed	O
for	O
the	O
long	B-MED
-	I-MED
term	I-MED
and	O
intermediate	B-MED
impacts	I-MED
of	O
youth	B-MED
development	I-MED
programs	I-MED
on	O
these	O
and	O
other	O
adolescent	B-MED
risk	B-MED
behaviors	I-MED
.	O
Outlining	O
a	O
Population	B-MED
"	I-MED
at	I-MED
Risk	I-MED
"	I-MED
of	O
Parkinson	B-MED
's	I-MED
Disease	I-MED
:	O
Evidence	B-MED
from	O
a	O
Case	B-MED
-	I-MED
Control	I-MED
Study	I-MED
The	O
multifactorial	B-MED
pathogenesis	I-MED
of	O
Parkinson	B-MED
's	I-MED
Disease	I-MED
(	O
PD	B-MED
)	O
requires	O
a	O
careful	O
identification	O
of	O
populations	B-MED
"	I-MED
at	I-MED
risk	I-MED
"	I-MED
of	O
developing	O
the	O
disease	B-MED
.	O
In	O
this	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
we	O
analyzed	B-MED
a	O
large	O
Italian	B-MED
population	B-MED
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	B-MED
criteria	I-MED
to	O
define	O
a	O
population	B-MED
"	I-MED
at	I-MED
risk	I-MED
"	I-MED
of	O
PD	B-MED
.	O
We	O
enrolled	O
300	O
PD	B-MED
patients	B-MED
and	O
300	O
controls	B-MED
,	O
gender	B-MED
and	O
age	B-MED
matched	B-MED
,	O
from	O
the	O
same	O
urban	B-MED
geographical	B-MED
area	I-MED
.	O
All	O
subjects	B-MED
were	O
interviewed	B-MED
on	O
demographics	B-MED
,	O
family	B-MED
history	I-MED
of	O
PD	B-MED
,	O
occupational	B-MED
and	I-MED
environmental	I-MED
toxicants	I-MED
exposure	I-MED
,	O
smoking	B-MED
status	I-MED
,	O
and	O
alcohol	B-MED
consumption	I-MED
.	O
A	O
sample	O
of	O
65	O
patients	B-MED
and	O
65	O
controls	B-MED
also	O
underwent	O
serum	B-MED
dosing	B-MED
of	O
iron	B-MED
,	O
copper	B-MED
,	O
mercury	B-MED
,	O
and	O
manganese	B-MED
by	O
means	O
of	O
Inductively	B-MED
Coupled	I-MED
-	I-MED
Plasma	I-MED
-	I-MED
Mass	I-MED
-	I-MED
Spectrometry	I-MED
(	O
ICP	B-MED
-	I-MED
MS	I-MED
)	O
.	O
Positive	B-MED
family	B-MED
history	I-MED
,	O
toxicants	B-MED
exposure	I-MED
,	O
non	B-MED
-	I-MED
current	I-MED
-	I-MED
smoker	I-MED
,	O
and	O
alcohol	B-MED
nonconsumer	I-MED
status	I-MED
occurred	O
as	O
significant	O
risk	B-MED
factors	I-MED
in	O
our	O
population	B-MED
.	O
The	O
number	O
of	O
concurring	B-MED
risk	I-MED
factors	I-MED
overlapping	B-MED
in	O
the	O
same	B-MED
subject	I-MED
impressively	O
increased	B-MED
the	O
overall	B-MED
risk	I-MED
.	O
No	B-MED
significant	I-MED
differences	I-MED
were	O
measured	B-MED
in	O
the	O
metal	B-MED
serum	B-MED
levels	B-MED
.	O
Our	O
findings	B-MED
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	B-MED
PD	B-MED
-	O
risk	B-MED
factors	I-MED
defines	O
a	O
condition	O
"	O
at	B-MED
risk	I-MED
"	O
of	O
PD	B-MED
.	O
A	O
simple	O
stratification	B-MED
,	O
based	O
on	O
these	O
questionnaires	B-MED
,	O
might	O
be	O
of	O
help	O
in	O
identifying	B-MED
subjects	I-MED
suitable	O
for	O
neuroprotective	B-MED
strategies	I-MED
.	O
Initial	O
experience	O
with	O
laparoscopic	B-MED
radical	I-MED
antegrade	I-MED
modular	I-MED
pancreatosplenectomy	I-MED
for	O
left	B-MED
-	I-MED
sided	I-MED
pancreatic	I-MED
cancer	I-MED
in	O
a	O
single	O
institution	B-MED
:	O
technical	O
aspects	O
and	O
oncological	B-MED
outcomes	I-MED
Laparoscopic	B-MED
surgery	I-MED
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	B-MED
cancer	I-MED
due	O
to	O
technical	B-MED
difficulties	I-MED
and	O
concerns	O
about	O
oncological	B-MED
safety	B-MED
.	O
Radical	B-MED
antegrade	I-MED
modular	I-MED
pancreatosplenectomy	I-MED
(	O
RAMPS	B-MED
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	B-MED
margin	I-MED
during	O
radical	B-MED
lymph	I-MED
node	I-MED
dissection	I-MED
.	O
We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	B-MED
as	O
a	O
laparoscopic	B-MED
application	I-MED
due	O
to	O
unique	O
features	O
.	O
Fifteen	O
laparoscopic	B-MED
RAMPS	B-MED
for	O
well	O
-	O
selected	O
patients	B-MED
with	O
left	B-MED
-	I-MED
sided	I-MED
pancreatic	I-MED
cancer	I-MED
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O
Five	O
trocars	B-MED
were	O
usually	O
used	O
,	O
and	O
the	O
operative	B-MED
procedures	I-MED
and	O
range	B-MED
of	I-MED
dissection	I-MED
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	B-MED
described	O
by	O
Strasberg	B-MED
.	O
All	O
medical	O
records	O
and	O
follow	B-MED
-	I-MED
up	I-MED
data	I-MED
were	O
reviewed	O
and	O
analyzed	O
.	O
All	O
patients	B-MED
had	O
pancreatic	B-MED
ductal	I-MED
adenocarcinoma	I-MED
.	O
Mean	O
operative	B-MED
time	I-MED
was	O
219.3	O
±	O
53.8	O
min	O
,	O
and	O
estimated	B-MED
blood	I-MED
loss	I-MED
was	O
250	O
±	O
70	O
ml	O
.	O
The	O
length	B-MED
of	I-MED
postoperative	I-MED
hospital	I-MED
stay	I-MED
was	O
6.1	O
±	O
1.2	O
days	O
,	O
and	O
postoperative	B-MED
morbidities	B-MED
developed	O
in	O
two	O
patients	B-MED
(	O
13.3	O
%	O
)	O
with	O
urinary	B-MED
retention	I-MED
.	O
The	O
median	O
number	O
of	O
retrieved	O
lymph	B-MED
nodes	I-MED
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative	B-MED
margins	I-MED
.	O
Median	O
follow	B-MED
-	I-MED
up	I-MED
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3	O
-	O
year	O
disease	B-MED
free	I-MED
survival	I-MED
and	O
overall	B-MED
survival	I-MED
rates	I-MED
were	O
56.3	O
%	O
and	O
74.1	O
%	O
,	O
respectively	O
.	O
Our	O
early	O
experience	O
with	O
laparoscopic	B-MED
RAMPS	B-MED
achieved	O
feasible	O
perioperative	B-MED
results	O
accompanied	O
by	O
acceptable	O
survival	B-MED
outcomes	I-MED
.	O
Laparoscopic	B-MED
RAMPS	B-MED
could	O
be	O
a	O
safe	O
and	O
oncologically	B-MED
feasible	B-MED
procedure	I-MED
in	O
well	O
-	O
selected	O
patients	B-MED
with	O
left	B-MED
-	I-MED
sided	I-MED
pancreatic	I-MED
cancer	I-MED
.	O
Ultrasonic	B-MED
computed	I-MED
tomography	I-MED
imaging	I-MED
of	O
iron	B-MED
oxide	I-MED
nanoparticles	I-MED
Iron	B-MED
oxide	I-MED
nanoparticles	I-MED
(	O
IONPs	B-MED
)	O
are	O
becoming	O
increasingly	B-MED
used	O
and	O
intensively	B-MED
investigated	I-MED
in	O
the	O
field	B-MED
of	O
medical	B-MED
imaging	I-MED
.	O
They	O
are	O
currently	B-MED
FDA	B-MED
approved	B-MED
for	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
,	O
and	O
it	O
would	O
be	O
highly	B-MED
desirable	O
to	O
visualize	B-MED
them	O
by	O
ultrasound	B-MED
as	O
well	O
.	O
Previous	B-MED
reports	B-MED
using	O
the	O
conventional	B-MED
ultrasound	B-MED
B	I-MED
-	I-MED
scan	I-MED
(	I-MED
pulse	I-MED
-	I-MED
echo	I-MED
)	I-MED
imaging	I-MED
technique	I-MED
have	O
shown	O
very	O
limited	B-MED
detectability	B-MED
of	O
these	O
particles	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
is	O
to	O
explore	O
the	O
feasibility	B-MED
of	O
imaging	B-MED
IONPs	B-MED
using	O
the	O
through	B-MED
-	I-MED
transmission	I-MED
ultrasound	I-MED
methodology	I-MED
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-MED
computed	I-MED
tomography	I-MED
(	O
UCT	B-MED
)	O
.	O
Commercially	O
available	O
IONPs	B-MED
were	O
acoustically	B-MED
analysed	B-MED
to	O
quantify	B-MED
their	O
effect	B-MED
on	O
the	O
speed	B-MED
of	O
sound	B-MED
(	O
SOS	B-MED
)	O
and	O
acoustic	B-MED
attenuation	B-MED
as	O
a	O
function	B-MED
of	O
concentration	B-MED
.	O
Next	O
,	O
through	B-MED
-	I-MED
transmission	I-MED
projection	I-MED
and	O
UCT	B-MED
imaging	I-MED
were	O
performed	B-MED
on	O
a	O
breast	B-MED
breast	B-MED
mimicking	I-MED
phantom	I-MED
and	O
on	O
an	O
ex	B-MED
vivo	I-MED
ex	B-MED
vivo	I-MED
tissue	I-MED
model	I-MED
,	O
to	O
which	O
IONPs	B-MED
were	O
injected	O
.	O
Finally	O
,	O
an	O
MRI	B-MED
scan	I-MED
was	O
performed	B-MED
to	O
verify	B-MED
that	O
the	O
same	O
particles	B-MED
examined	B-MED
in	O
the	O
ultrasound	B-MED
experiment	B-MED
can	O
be	O
imaged	B-MED
by	O
magnetic	B-MED
resonance	I-MED
,	O
using	O
the	O
same	O
clinically	B-MED
relevant	I-MED
concentrations	B-MED
.	O
The	O
results	B-MED
have	O
shown	O
a	O
consistent	B-MED
concentration	B-MED
dependent	B-MED
speed	B-MED
of	O
sound	B-MED
increase	B-MED
(	O
1.86	O
[	O
Formula	O
:	O
see	O
text	O
]	O
rise	O
per	O
100	O
µg	O
·	O
ml(-1	O
)	O
IONPs	B-MED
)	O
.	O
Imaging	B-MED
based	B-MED
on	O
this	O
property	B-MED
has	O
shown	O
a	O
substantial	B-MED
contrast	I-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
improvement	B-MED
(	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
)	O
.	O
The	O
SOS	B-MED
-related	O
effect	B-MED
generated	O
a	O
well	O
discernible	B-MED
image	B-MED
contrast	B-MED
and	O
allowed	O
the	O
detection	B-MED
of	O
the	O
particles	B-MED
existence	B-MED
and	O
location	B-MED
,	O
in	O
both	B-MED
raster	B-MED
-	I-MED
scan	I-MED
projection	I-MED
and	O
UCT	B-MED
imaging	I-MED
.	O
Conversely	O
,	O
no	O
significant	B-MED
change	B-MED
in	O
the	O
acoustic	B-MED
attenuation	B-MED
coefficient	I-MED
was	O
noted	B-MED
.	O
Based	B-MED
on	O
these	O
findings	B-MED
,	O
it	O
is	O
concluded	B-MED
that	O
IONPs	B-MED
can	O
be	O
used	O
as	O
an	O
effective	B-MED
SOS	B-MED
-	O
based	B-MED
contrast	B-MED
agent	I-MED
,	O
potentially	B-MED
useful	I-MED
for	O
ultrasonic	B-MED
breast	B-MED
imaging	B-MED
.	O
Furthermore	O
,	O
the	O
particle	B-MED
offers	O
the	O
capacity	B-MED
of	O
significantly	B-MED
enhancing	I-MED
diagnosis	B-MED
accuracy	I-MED
using	O
multimodal	B-MED
MRI	B-MED
-	O
ultrasound	B-MED
imaging	I-MED
capabilities	B-MED
.	O
Neuroprotective	B-MED
Role	I-MED
of	O
MicroRNA-22	B-MED
in	O
a	O
6	B-MED
-	I-MED
Hydroxydopamine	I-MED
-	O
Induced	B-MED
Cell	B-MED
Model	B-MED
of	O
Parkinson	B-MED
's	I-MED
Disease	I-MED
via	O
Regulation	B-MED
of	O
Its	O
Target	B-MED
Gene	B-MED
TRPM7	B-MED
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
,	O
the	O
second	O
most	O
prevalent	B-MED
neurodegenerative	B-MED
disorder	I-MED
with	O
only	O
symptomatic	B-MED
treatment	B-MED
available	B-MED
,	O
is	O
characterized	B-MED
by	O
a	O
progressive	B-MED
loss	B-MED
of	O
dopaminergic	B-MED
neurons	I-MED
in	O
the	O
midbrain	B-MED
.	O
Ample	O
evidence	O
indicated	O
that	O
microRNAs	B-MED
(	O
miRs	B-MED
)	O
could	O
regulate	B-MED
post	I-MED
-	I-MED
transcriptional	I-MED
gene	B-MED
expression	I-MED
and	O
neuronal	B-MED
disease	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
have	O
evaluated	O
the	O
effects	B-MED
and	O
mechanism	B-MED
of	O
miR-22	B-MED
in	O
PC12	B-MED
pheochromocytoma	I-MED
cells	I-MED
treated	B-MED
with	O
6	B-MED
-	I-MED
hydroxydopamine	I-MED
(	O
6	B-MED
-	I-MED
OHDA	I-MED
)	O
to	O
mimic	O
PD	B-MED
.	O
RT	B-MED
-	I-MED
PCR	I-MED
results	B-MED
showed	O
that	O
the	O
expression	B-MED
of	O
miR-22	B-MED
is	O
downregulated	B-MED
in	O
6	B-MED
-	I-MED
OHDA	I-MED
-	O
treated	B-MED
PC12	B-MED
cells	I-MED
,	O
and	O
the	O
overexpression	B-MED
of	O
miR-22	B-MED
significantly	O
promoted	B-MED
the	O
survival	B-MED
and	O
proliferation	B-MED
of	O
6	B-MED
-	I-MED
OHDA	I-MED
-	O
induced	B-MED
PC12	B-MED
cells	I-MED
,	O
whereas	O
miR-22	B-MED
inhibitor	B-MED
reversed	B-MED
these	O
effects	B-MED
.	O
In	O
addition	O
,	O
PC12	B-MED
cells	I-MED
were	O
treated	B-MED
with	O
miR-22	B-MED
mimics	I-MED
or	O
inhibitor	B-MED
following	B-MED
6	B-MED
-	I-MED
OHDA	I-MED
administration	B-MED
,	O
which	O
medicated	O
ROS	B-MED
production	B-MED
and	O
upregulation	B-MED
or	O
downregulation	B-MED
of	O
caspase-3	B-MED
activity	I-MED
,	O
respectively	O
.	O
A	O
luciferase	B-MED
reporter	O
assay	B-MED
revealed	B-MED
that	O
transient	B-MED
receptor	I-MED
potential	I-MED
melastatin	I-MED
7	I-MED
(	O
TRPM7	B-MED
)	O
is	O
a	O
direct	B-MED
target	B-MED
gene	B-MED
of	O
miR-22	B-MED
,	O
and	O
miR-22	B-MED
overexpression	B-MED
markedly	O
downregulated	B-MED
the	O
level	B-MED
of	O
TRPM7	B-MED
.	O
Strikingly	O
,	O
further	O
analysis	B-MED
showed	O
that	O
miR-22	B-MED
mediated	O
6	B-MED
-	I-MED
OHDA	I-MED
-	O
induced	B-MED
PC12	B-MED
cell	B-MED
survival	I-MED
and	O
proliferation	B-MED
by	O
targeting	B-MED
TRPM7	B-MED
.	O
Taken	O
together	O
,	O
the	O
present	O
study	B-MED
showed	O
that	O
miR-22	B-MED
overexpression	B-MED
exhibited	O
neuroprotective	B-MED
and	O
reversal	B-MED
effects	B-MED
on	O
the	O
6	B-MED
-	I-MED
OHDA	I-MED
-	O
induced	B-MED
PC12	B-MED
cell	B-MED
growth	I-MED
and	O
apoptosis	B-MED
by	O
targeting	B-MED
TRPM7	B-MED
.	O
When	O
Is	O
a	O
Test	B-MED
Score	I-MED
Fair	B-MED
for	O
the	O
Individual	B-MED
Who	O
Is	O
Being	O
Tested	B-MED
?	O
Effects	B-MED
of	I-MED
Different	O
Scoring	B-MED
Procedures	I-MED
across	O
Multiple	B-MED
Attempts	B-MED
When	O
Testing	B-MED
a	O
Motor	B-MED
Skill	I-MED
Task	B-MED
Tests	B-MED
or	O
test	B-MED
batteries	I-MED
used	O
for	O
assessing	B-MED
motor	B-MED
skills	I-MED
,	O
either	O
in	O
research	B-MED
studies	I-MED
or	O
in	O
clinical	B-MED
settings	I-MED
,	O
apply	O
a	O
variety	O
of	O
procedures	B-MED
for	O
scoring	B-MED
performances	B-MED
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	B-MED
,	O
of	O
which	O
the	O
best	O
is	O
scored	B-MED
or	O
an	O
average	B-MED
is	O
computed	B-MED
.	O
The	O
rationale	O
behind	O
scoring	B-MED
procedures	B-MED
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	B-MED
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	B-MED
.	O
It	O
is	O
uncertain	O
whether	O
procedures	B-MED
fairly	O
capture	O
an	O
individual	B-MED
's	I-MED
skill	B-MED
level	B-MED
.	O
Thus	O
,	O
the	O
validity	O
of	O
the	O
tests	B-MED
may	O
be	O
compromised	O
.	O
The	O
present	O
study	B-MED
tested	B-MED
24	O
young	O
female	B-MED
soccer	B-MED
players	B-MED
on	O
the	O
juggling	B-MED
of	O
a	O
soccer	B-MED
ball	I-MED
.	O
They	O
were	O
given	O
10	O
attempts	B-MED
,	O
and	O
trials	B-MED
were	O
scored	B-MED
according	O
to	O
nine	O
different	O
procedures	B-MED
including	O
the	O
'	O
best	B-MED
of	I-MED
'	O
or	O
'	O
mean	B-MED
of	I-MED
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	B-MED
.	O
Individual	B-MED
raw	B-MED
scores	I-MED
differed	O
widely	O
across	O
trials	B-MED
,	O
but	O
no	B-MED
general	I-MED
effect	I-MED
of	O
trials	B-MED
was	O
found	O
.	O
The	O
mean	B-MED
(	I-MED
SD	I-MED
)	I-MED
percentage	I-MED
difference	I-MED
between	O
the	O
lowest	B-MED
and	O
highest	B-MED
scores	B-MED
was	O
27.7(9.9)%	O
,	O
with	O
17	O
players	B-MED
(	O
71	O
%	O
)	O
demonstrating	O
a	O
significant	B-MED
change	O
from	O
lowest	B-MED
to	O
highest	B-MED
score	B-MED
.	O
Correlations	B-MED
between	O
raw	B-MED
scores	I-MED
were	O
low	B-MED
across	O
trials	B-MED
,	O
while	O
they	O
were	O
generally	O
higher	B-MED
across	O
scoring	B-MED
procedures	B-MED
.	O
The	O
first	O
trial	B-MED
was	O
significantly	B-MED
different	B-MED
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	B-MED
score	I-MED
and	O
as	O
scoring	B-MED
procedure	B-MED
.	O
The	O
mean	B-MED
percentage	I-MED
difference	I-MED
between	O
best	B-MED
-	I-MED
of	I-MED
-	I-MED
two	I-MED
and	O
best	B-MED
-	I-MED
of	I-MED
-	I-MED
ten	I-MED
scores	I-MED
was	O
95	O
%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	B-MED
demonstrating	O
a	O
significant	B-MED
difference	B-MED
between	O
the	O
two	O
scoring	B-MED
procedures	B-MED
.	O
No	B-MED
significant	I-MED
differences	I-MED
were	O
found	O
across	O
mean	B-MED
-	I-MED
of	I-MED
-	I-MED
rule	I-MED
scorings	I-MED
.	O
Best	B-MED
-	I-MED
of	I-MED
-	I-MED
rule	I-MED
and	O
mean	B-MED
-	I-MED
of	I-MED
-	I-MED
rule	I-MED
scorings	I-MED
were	O
significantly	B-MED
different	B-MED
except	O
for	O
the	O
best	B-MED
-	I-MED
of	I-MED
-	I-MED
two	I-MED
vs.	O
mean	B-MED
-	I-MED
of	I-MED
-	I-MED
two	I-MED
.	O
The	O
mean	B-MED
difference	I-MED
between	O
highest	B-MED
and	O
lowest	B-MED
rank	B-MED
across	O
players	B-MED
was	O
6.7	O
(	O
3.6	O
)	O
,	O
with	O
individual	B-MED
rankings	B-MED
within	O
the	O
group	B-MED
varying	O
33	O
%	O
on	O
average	O
across	O
procedures	B-MED
.	O
One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	B-MED
differences	B-MED
.	O
Therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	B-MED
procedures	B-MED
affect	O
results	B-MED
and	O
may	O
have	O
an	O
impact	O
on	O
test	B-MED
outcomes	I-MED
.	O
This	O
may	O
present	O
consequences	O
for	O
decision	O
-	O
making	O
from	O
test	B-MED
results	I-MED
,	O
such	O
as	O
diagnosing	B-MED
and	O
selection	O
of	O
intervention	B-MED
groups	B-MED
.	O
We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	B-MED
into	O
the	O
scoring	B-MED
procedures	B-MED
of	O
the	O
vast	O
amount	O
of	O
tests	B-MED
and	O
tasks	O
in	O
common	O
use	O
.	O
Ethics	B-MED
Hype	B-MED
?	O
There	O
has	O
been	O
growing	O
concern	B-MED
about	O
the	O
phenomenon	B-MED
of	O
science	B-MED
hype	B-MED
,	O
the	O
tendency	O
to	O
exaggerate	B-MED
the	O
value	O
or	O
near	B-MED
-	O
future	B-MED
application	B-MED
of	O
research	B-MED
results	I-MED
.	O
Although	O
this	O
is	O
a	O
problem	B-MED
that	O
touches	O
every	O
area	B-MED
of	I-MED
biomedicine	I-MED
,	O
the	O
topic	B-MED
of	O
genetics	B-MED
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	B-MED
predictions	B-MED
.	O
The	O
world	B-MED
has	O
been	O
told	O
for	O
over	O
two	O
decades	B-MED
-by	O
the	O
media	B-MED
,	O
researchers	B-MED
,	O
politicians	B-MED
,	O
and	O
the	O
biotech	B-MED
industry	B-MED
-that	O
a	O
genome	B-MED
-driven	O
health	B-MED
care	I-MED
revolution	B-MED
is	O
just	O
around	O
the	O
corner	O
.	O
And	O
while	O
the	O
revolution	B-MED
never	O
seems	O
to	O
arrive	O
,	O
the	O
hopeful	O
rhetoric	B-MED
continues	O
.	O
It	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
"	O
genohype	B-MED
"	O
is	O
having	O
a	O
range	O
of	O
adverse	B-MED
social	B-MED
consequences	I-MED
,	O
including	O
misleading	O
the	O
public	B-MED
and	O
hurting	B-MED
the	O
long	B-MED
-	I-MED
term	I-MED
legitimacy	B-MED
of	O
the	O
field	B-MED
.	O
While	O
we	O
need	O
more	O
good	O
data	B-MED
on	O
the	O
nature	B-MED
and	O
magnitude	B-MED
of	O
these	O
possible	O
harms	B-MED
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	B-MED
that	O
sustained	B-MED
science	B-MED
hype	B-MED
is	O
a	O
bad	O
thing	O
.	O
We	O
all	O
benefit	B-MED
from	O
robust	B-MED
science	B-MED
and	O
accurate	B-MED
public	B-MED
representations	B-MED
of	O
biomedical	B-MED
research	I-MED
.	O
But	O
,	O
to	O
date	O
,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-MED
of	O
the	O
degree	B-MED
to	O
which	O
the	O
scholarship	B-MED
on	O
the	O
related	O
ethical	B-MED
,	O
legal	B-MED
,	O
and	O
social	B-MED
issues	I-MED
has	O
been	O
hyped	O
.	O
Are	O
the	O
conclusions	B-MED
from	O
ELSI	B-MED
scholarship	I-MED
also	O
exaggerated	B-MED
?	O
On	O
the	O
development	B-MED
of	O
conjunctival	B-MED
hyperemia	I-MED
computer	B-MED
-	I-MED
assisted	I-MED
diagnosis	I-MED
tools	I-MED
:	O
Influence	O
of	O
feature	B-MED
selection	B-MED
and	O
class	B-MED
imbalance	I-MED
in	O
automatic	O
gradings	O
The	O
sudden	O
increase	O
of	O
blood	B-MED
flow	I-MED
in	O
the	O
bulbar	B-MED
conjunctiva	I-MED
,	O
known	O
as	O
hyperemia	B-MED
,	O
is	O
associated	O
to	O
a	O
red	B-MED
hue	I-MED
of	O
variable	B-MED
intensity	B-MED
.	O
Experts	O
measure	O
hyperemia	B-MED
using	O
levels	O
in	O
a	O
grading	B-MED
scale	I-MED
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non	O
-	O
repeatable	O
and	O
time	B-MED
consuming	I-MED
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	B-MED
.	O
However	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	B-MED
due	O
to	O
data	O
issues	O
such	O
as	O
class	B-MED
imbalance	I-MED
or	O
correlated	B-MED
features	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	B-MED
of	O
hyperemia	B-MED
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	B-MED
framework	I-MED
for	O
hyperemia	B-MED
grading	B-MED
.	O
Oversampling	B-MED
,	O
undersampling	B-MED
and	O
SMOTE	B-MED
approaches	I-MED
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	B-MED
imbalance	I-MED
.	O
25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	B-MED
methods	I-MED
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	B-MED
scale	I-MED
.	O
The	O
values	O
and	O
relationships	O
among	O
features	B-MED
and	O
experts	B-MED
'	I-MED
values	I-MED
were	O
analysed	O
,	O
and	O
five	O
feature	B-MED
selection	B-MED
techniques	O
were	O
subsequently	O
studied	O
.	O
The	O
lowest	B-MED
mean	I-MED
square	I-MED
error	I-MED
(	O
MSE	B-MED
)	O
for	O
the	O
regression	B-MED
systems	I-MED
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales	O
.	O
Multi	B-MED
-	I-MED
layer	I-MED
perceptron	I-MED
(	O
MLP	B-MED
)	O
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	B-MED
forest	I-MED
(	I-MED
RF	I-MED
)	I-MED
method	I-MED
.	O
When	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
MLP	B-MED
.	O
Correlation	B-MED
based	I-MED
feature	I-MED
selection	I-MED
(	O
CFS	B-MED
)	O
and	O
M5	O
provide	O
the	O
best	O
results	O
,	O
MSE	B-MED
=	O
0.108	O
and	O
MSE	B-MED
=	O
0.061	O
respectively	O
.	O
Finally	O
,	O
the	O
class	B-MED
imbalance	I-MED
problem	I-MED
is	O
minimised	O
with	O
the	O
SMOTE	B-MED
approach	I-MED
for	O
both	O
scales	O
(	O
MSE	B-MED
<	O
0.006	O
)	O
.	O
Machine	B-MED
learning	I-MED
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-MED
grading	B-MED
,	O
removing	O
both	O
intra-	B-MED
and	I-MED
inter	I-MED
-	I-MED
expert	I-MED
subjectivity	I-MED
while	O
providing	O
a	O
gain	O
in	O
computation	B-MED
time	B-MED
.	O
SMOTE	B-MED
and	O
oversampling	B-MED
approaches	I-MED
minimise	O
the	O
class	B-MED
imbalance	I-MED
problem	I-MED
,	O
while	O
feature	B-MED
selection	B-MED
reduces	O
the	O
number	O
of	O
features	B-MED
from	O
25	O
to	O
3	O
-	O
5	O
without	O
worsening	O
the	O
MSE	B-MED
.	O
As	O
the	O
differences	O
between	O
the	O
system	B-MED
and	O
a	O
human	B-MED
expert	I-MED
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	B-MED
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	B-MED
behaves	O
like	O
an	O
expert	B-MED
.	O
Probabilistic	B-MED
acute	B-MED
risk	B-MED
assessment	I-MED
of	O
cumulative	B-MED
exposure	I-MED
to	O
organophosphorus	B-MED
and	O
carbamate	B-MED
pesticides	I-MED
from	O
dietary	B-MED
vegetables	I-MED
and	O
fruits	B-MED
in	O
Shanghai	B-MED
populations	B-MED
Organophosphorus	B-MED
pesticides	I-MED
(	O
OPs	B-MED
)	O
and	O
carbamate	B-MED
pesticides	I-MED
(	O
CPs	B-MED
)	O
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	B-MED
in	O
China	B-MED
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	B-MED
agricultural	B-MED
commodities	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
determined	B-MED
the	O
cumulative	B-MED
acute	I-MED
exposure	I-MED
to	O
OPs	B-MED
and	O
CPs	B-MED
of	O
Shanghai	B-MED
residents	B-MED
from	O
vegetables	B-MED
and	O
fruits	B-MED
(	O
VFs	B-MED
)	O
.	O
The	O
food	B-MED
consumption	I-MED
data	B-MED
were	O
obtained	B-MED
from	O
the	O
Shanghai	B-MED
Food	I-MED
Consumption	I-MED
Survey	I-MED
(	O
SHFCS	B-MED
)	O
of	O
2012	O
-	O
14	O
including	O
a	O
total	O
of	O
1973	O
participants	B-MED
aged	B-MED
2	O
-	O
90	O
years	B-MED
.	O
The	O
pesticide	B-MED
residue	I-MED
data	B-MED
were	O
obtained	B-MED
from	O
the	O
Shanghai	B-MED
monitoring	B-MED
programme	B-MED
during	O
2008	O
-	O
11	O
with	O
34	O
organophosphates	B-MED
and	O
11	O
carbamates	B-MED
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	B-MED
of	O
VFs	B-MED
.	O
A	O
probabilistic	B-MED
approach	O
was	O
performed	B-MED
as	O
recommended	B-MED
by	O
the	O
EFSA	B-MED
,	O
using	O
the	O
optimistic	B-MED
model	I-MED
with	O
non	O
-	O
detects	O
set	O
as	O
zero	B-MED
and	O
with	O
processing	B-MED
factors	B-MED
(	O
PFs	B-MED
)	O
being	O
used	O
and	O
the	O
pessimistic	B-MED
model	I-MED
with	O
non	O
-	O
detects	O
replaced	B-MED
by	I-MED
limit	B-MED
of	I-MED
detection	I-MED
(	O
LOD	B-MED
)	O
and	O
without	B-MED
PFs	B-MED
.	O
We	O
used	O
the	O
relative	B-MED
potency	I-MED
factor	I-MED
(	I-MED
RPF	I-MED
)	I-MED
method	I-MED
to	O
normalise	O
the	O
various	O
pesticides	B-MED
to	O
the	O
index	B-MED
compound	I-MED
(	O
IC	B-MED
)	O
of	O
methamidophos	B-MED
and	O
chlorpyrifos	B-MED
separately	B-MED
.	O
Only	O
in	O
the	O
pessimistic	B-MED
model	I-MED
using	O
methamidophos	B-MED
as	O
the	O
IC	B-MED
was	O
there	O
was	O
small	O
risk	B-MED
of	O
exposure	B-MED
exceeding	O
the	O
ARfD	B-MED
(	O
3	O
µg	O
kg(-)(1	O
)	O
bw	O
day	B-MED
(	O
-)(1	O
)	O
)	O
in	O
the	O
populations	B-MED
of	O
preschool	B-MED
children	I-MED
(	O
0.029	O
%	O
)	O
,	O
school	B-MED
-	I-MED
age	I-MED
children	I-MED
(	O
0.022	O
%	O
)	O
and	O
adults	B-MED
(	O
0.002	O
%	O
)	O
.	O
There	O
were	O
no	B-MED
risk	I-MED
of	O
exposure	B-MED
exceeding	O
the	O
ARfD	B-MED
of	O
methamidophos	B-MED
in	O
the	O
optimistic	B-MED
model	I-MED
and	O
of	O
chlorpyrifos	B-MED
(	O
100	O
µg	O
kg(-)(1	O
)	O
bw	O
day	B-MED
(	O
-)(1	O
)	O
)	O
in	O
both	O
optimistic	B-MED
and	O
pessimistic	B-MED
models	I-MED
in	O
all	O
three	O
populations	B-MED
.	O
Considering	O
the	O
Chinese	B-MED
habits	I-MED
of	O
overwhelmingly	O
eating	B-MED
processed	B-MED
food	I-MED
(	O
vegetables	B-MED
being	O
cooked	B-MED
,	O
and	O
fruits	B-MED
being	O
washed	B-MED
or	O
peeled	B-MED
)	O
,	O
we	O
conclude	O
that	O
little	O
acute	B-MED
risk	B-MED
was	O
found	O
for	O
the	O
exposure	B-MED
to	I-MED
VF	B-MED
-	O
sourced	B-MED
OPs	B-MED
and	O
CPs	B-MED
in	O
Shanghai	B-MED
.	O
CT	B-MED
angiography	I-MED
for	O
planning	B-MED
transcatheter	B-MED
aortic	I-MED
valve	I-MED
replacement	I-MED
using	O
automated	B-MED
tube	I-MED
voltage	I-MED
selection	I-MED
:	O
Image	B-MED
quality	I-MED
and	O
radiation	B-MED
exposure	B-MED
To	O
assess	B-MED
image	B-MED
quality	I-MED
and	O
accuracy	B-MED
of	O
CT	B-MED
angiography	I-MED
(	O
CTA	B-MED
)	O
for	O
transcatheter	B-MED
aortic	I-MED
valve	I-MED
replacement	I-MED
(	O
TAVR	B-MED
)	O
planning	B-MED
performed	O
with	O
3rd	B-MED
generation	I-MED
dual	I-MED
-	I-MED
source	I-MED
CT	I-MED
(	O
DSCT	B-MED
)	O
.	O
We	O
evaluated	O
125	O
patients	B-MED
who	O
underwent	O
TAVR	B-MED
-	O
planning	B-MED
CTA	B-MED
on	O
3rd	B-MED
generation	I-MED
DSCT	I-MED
.	O
A	O
two	B-MED
-	I-MED
part	I-MED
protocol	I-MED
was	O
performed	O
including	O
retrospectively	B-MED
ECG	B-MED
-	I-MED
gated	I-MED
coronary	I-MED
CTA	I-MED
(	O
CCTA	B-MED
)	O
and	O
prospectively	B-MED
ECG	B-MED
-	I-MED
triggered	I-MED
aortoiliac	I-MED
CTA	I-MED
using	O
60mL	O
of	O
contrast	B-MED
medium	I-MED
.	O
Automated	B-MED
tube	I-MED
voltage	I-MED
selection	I-MED
and	O
advanced	B-MED
iterative	I-MED
reconstruction	I-MED
were	O
applied	O
.	O
Effective	B-MED
dose	I-MED
(	O
ED	B-MED
)	O
,	O
signal	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
(	O
SNR	B-MED
)	O
and	O
contrast	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratios	I-MED
(	O
CNR	B-MED
)	O
were	O
calculated	O
.	O
Five	B-MED
-	I-MED
point	I-MED
scales	I-MED
were	O
used	O
for	O
subjective	B-MED
image	B-MED
quality	I-MED
analysis	I-MED
.	O
In	O
patients	B-MED
who	O
underwent	O
TAVR	B-MED
,	O
sizing	B-MED
parameters	I-MED
were	O
obtained	O
.	O
Image	B-MED
quality	I-MED
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
%	O
of	O
CCTA	B-MED
and	O
100	O
%	O
of	O
aortoiliac	B-MED
CTAs	I-MED
.	O
CTA	B-MED
studies	B-MED
at	O
>	O
100kV	O
showed	O
decreased	B-MED
objective	B-MED
image	B-MED
quality	I-MED
compared	O
to	O
70	O
-	O
100kV	O
(	O
SNR	B-MED
,	O
all	O
p≤0.0459	O
;	O
CNR	B-MED
,	O
all	O
p≤0.0462	O
)	O
.	O
Mean	B-MED
ED	B-MED
increased	B-MED
continuously	O
from	O
70	O
to	O
>	O
100kV	O
(	O
CCTA	B-MED
:	O
4.5±1.7mSv-13.6±2.9mSv	O
,	O
all	O
p≤0.0233	O
;	O
aortoiliac	B-MED
CTA	I-MED
:	O
2.4±0.9mSv-6.8±2.7mSv	O
,	O
all	O
p≤0.0414	O
)	O
.	O
In	O
39	O
patients	B-MED
TAVR	B-MED
was	O
performed	O
and	O
annulus	B-MED
diameter	B-MED
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	B-MED
.	O
No	B-MED
severe	B-MED
cardiac	B-MED
or	O
vascular	B-MED
complications	I-MED
were	O
noted	O
.	O
3rd	B-MED
generation	I-MED
DSCT	I-MED
provides	O
diagnostic	B-MED
image	B-MED
quality	I-MED
in	O
TAVR	B-MED
-	O
planning	B-MED
CTA	B-MED
and	O
facilitates	O
reliable	O
assessment	B-MED
of	O
TAVR	B-MED
device	B-MED
and	O
delivery	B-MED
option	O
while	O
reducing	B-MED
radiation	B-MED
dose	I-MED
.	O
Evidence	B-MED
-Based	O
Review	B-MED
and	O
Survey	B-MED
of	O
Expert	B-MED
Opinion	I-MED
of	O
Reconstruction	B-MED
of	O
Metastatic	B-MED
Spine	I-MED
Tumors	I-MED
Systematic	B-MED
review	B-MED
and	O
consensus	B-MED
expert	B-MED
opinion	I-MED
.	O
To	O
provide	O
surgeons	B-MED
and	O
other	O
health	B-MED
care	I-MED
professionals	I-MED
with	O
guidelines	B-MED
for	O
surgical	B-MED
reconstruction	I-MED
of	O
metastatic	B-MED
spine	B-MED
disease	I-MED
based	O
on	O
evidence	B-MED
and	O
expert	B-MED
opinion	I-MED
.	O
The	O
surgical	B-MED
treatment	I-MED
of	O
spinal	B-MED
metastases	I-MED
is	O
controversial	O
.	O
Specifically	O
two	O
aspects	O
of	O
surgical	B-MED
reconstruction	I-MED
are	O
addressed	O
in	O
this	O
study	O
:	O
(	O
i	O
)	O
choice	O
of	O
bone	B-MED
graft	I-MED
used	O
during	B-MED
surgery	B-MED
for	O
metastatic	B-MED
spine	I-MED
tumors	I-MED
and	O
(	O
ii	O
)	O
the	O
design	B-MED
of	O
reconstruction	B-MED
or	O
construct	B-MED
to	O
stabilize	B-MED
.	O
A	O
systematic	B-MED
review	B-MED
of	O
the	O
available	B-MED
medical	B-MED
literature	B-MED
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	B-MED
with	O
consensus	B-MED
expert	B-MED
opinion	I-MED
from	O
a	O
recent	O
survey	B-MED
of	O
spine	B-MED
surgeons	B-MED
who	O
treat	B-MED
metastatic	B-MED
spine	I-MED
tumors	I-MED
.	O
There	O
is	O
very	O
little	O
evidence	B-MED
in	O
the	O
literature	B-MED
to	O
provide	O
guidance	B-MED
on	O
the	O
use	B-MED
of	I-MED
bone	B-MED
graft	I-MED
in	O
metastatic	B-MED
tumor	I-MED
reconstruction	B-MED
.	O
There	O
is	O
little	O
evidence	B-MED
in	O
the	O
literature	B-MED
to	O
support	O
the	O
preferential	O
use	B-MED
of	I-MED
one	O
graft	B-MED
type	I-MED
over	O
the	O
other	O
.	O
Approximately	O
,	O
41	O
%	O
of	O
respondents	B-MED
said	O
they	O
used	O
bone	B-MED
graft	I-MED
or	O
bone	B-MED
graft	I-MED
substitutes	B-MED
to	O
accomplish	O
fusion	B-MED
.	O
There	O
were	O
17	O
studies	B-MED
that	O
described	O
the	O
use	B-MED
of	I-MED
a	O
prefabricated	B-MED
prosthetic	I-MED
,	O
10	O
studies	B-MED
describing	O
the	O
use	B-MED
of	I-MED
polymethyl	B-MED
methacrylate	I-MED
(	O
PMMA	B-MED
)	O
bone	B-MED
cement	I-MED
,	O
and	O
only	O
three	O
studies	B-MED
describing	O
the	O
use	B-MED
of	I-MED
bone	B-MED
graft	I-MED
for	O
anterior	B-MED
column	B-MED
reconstruction	B-MED
.	O
The	O
use	B-MED
of	I-MED
structural	B-MED
allograft	I-MED
was	O
most	O
popular	O
among	O
the	O
experts	B-MED
for	O
anterior	B-MED
reconstruction	B-MED
,	O
followed	B-MED
by	I-MED
cage	B-MED
reconstruction	B-MED
,	O
and	O
PMMA	B-MED
bone	B-MED
cement	I-MED
.	O
Achieving	O
bony	B-MED
union	I-MED
may	O
be	O
of	O
importance	B-MED
for	O
the	O
maintenance	B-MED
of	O
spinal	B-MED
stability	B-MED
in	O
the	O
long	B-MED
term	I-MED
after	O
reconstruction	B-MED
.	O
Whether	O
bony	B-MED
union	I-MED
is	O
required	B-MED
for	O
patients	B-MED
with	O
shorter	B-MED
life	B-MED
expectancies	I-MED
is	O
debatable	O
.	O
The	O
literature	B-MED
supports	O
the	O
use	B-MED
of	I-MED
anterior	B-MED
reconstruction	B-MED
with	O
either	O
a	O
prefabricated	B-MED
prosthetic	I-MED
or	O
PMMA	B-MED
bone	B-MED
cement	I-MED
.	O
It	O
also	O
supports	O
the	O
use	B-MED
of	I-MED
an	O
anterior	B-MED
construct	B-MED
reinforced	O
with	O
bilateral	B-MED
posterior	B-MED
instrumentation	B-MED
when	O
performing	B-MED
a	O
three	B-MED
-	I-MED
column	I-MED
reconstruction	I-MED
.	O
N	O
/	O
A.	O
Estrogen	B-MED
and	O
Progesterone	B-MED
hormone	B-MED
receptor	B-MED
expression	I-MED
in	O
oral	B-MED
cavity	I-MED
cancer	I-MED
Recent	O
studies	O
have	O
shown	O
an	O
increase	B-MED
in	O
the	O
incidence	B-MED
of	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
OSCC	B-MED
)	O
in	O
younger	B-MED
patients	B-MED
.	O
The	O
hypothesis	B-MED
that	O
tumors	B-MED
could	O
be	O
hormonally	B-MED
induced	B-MED
during	O
pregnancy	B-MED
or	O
in	O
young	B-MED
female	B-MED
patients	B-MED
without	O
the	O
well	O
-	O
known	O
risk	B-MED
factors	I-MED
alcohol	B-MED
or	O
tobacco	B-MED
abuse	I-MED
seems	O
to	O
be	O
plausible	O
.	O
Estrogen	B-MED
Receptor	I-MED
alpha	I-MED
(	O
ERα	B-MED
)	O
and	O
Progesterone	B-MED
Receptor	I-MED
(	O
PR	B-MED
)	O
expression	B-MED
were	O
analyzed	B-MED
in	O
normal	O
oral	B-MED
mucosa	I-MED
(	O
n=5	O
)	O
,	O
oral	B-MED
precursor	I-MED
lesions	I-MED
(	O
simple	B-MED
hyperplasia	I-MED
,	O
n=11	O
;	O
squamous	B-MED
intraepithelial	I-MED
neoplasia	I-MED
,	O
SIN	B-MED
I	I-MED
-	I-MED
III	I-MED
,	O
n=35	O
)	O
,	O
and	O
OSCC	B-MED
specimen	B-MED
.	O
OSCCs	B-MED
were	O
stratified	B-MED
in	O
a	O
young	B-MED
female	B-MED
(	O
n=7	O
)	O
study	O
cohort	B-MED
and	O
older	B-MED
patients	B-MED
(	O
n=46	O
)	O
.	O
In	O
the	O
young	B-MED
female	B-MED
study	O
cohort	B-MED
three	O
patients	B-MED
(	O
n=3/7	O
)	O
developed	O
OSCC	B-MED
during	O
or	O
shortly	O
after	O
pregnancy	B-MED
.	O
Breast	B-MED
cancer	I-MED
tissues	B-MED
were	O
used	O
as	O
positive	B-MED
control	I-MED
for	O
ERα	B-MED
and	O
PR	B-MED
expression	B-MED
.	O
ERα	B-MED
expression	B-MED
was	O
found	O
in	O
four	O
oral	B-MED
precursor	I-MED
lesions	I-MED
(	O
squamous	B-MED
intraepithelial	I-MED
neoplasia	I-MED
,	O
SIN	B-MED
I	I-MED
-	I-MED
III	I-MED
,	O
n=4/35	O
,	O
11	O
%	O
)	O
and	O
in	O
five	O
OSCC	B-MED
specimen	B-MED
(	O
n=5/46	O
,	O
11	O
%	O
)	O
.	O
The	O
five	O
ERα	B-MED
positive	B-MED
OSCC	B-MED
samples	B-MED
were	O
older	B-MED
male	B-MED
patients	B-MED
.	O
All	O
patients	B-MED
within	O
the	O
young	B-MED
female	B-MED
study	O
cohort	B-MED
were	O
negatively	B-MED
stained	O
for	O
both	O
ERα	B-MED
and	O
PR	B-MED
.	O
ER	B-MED
expression	B-MED
could	O
be	O
regarded	O
as	O
a	O
seldom	B-MED
risk	B-MED
factor	I-MED
for	O
OSCC	B-MED
.	O
PR	B-MED
expression	B-MED
seems	O
to	O
be	O
not	O
relevant	B-MED
for	O
the	O
development	B-MED
of	O
OSCC	B-MED
.	O
Limits	O
of	O
the	O
possible	O
:	O
diagnostic	B-MED
image	I-MED
quality	B-MED
in	O
coronary	B-MED
angiography	I-MED
with	O
third	B-MED
-	I-MED
generation	I-MED
dual	I-MED
-	I-MED
source	I-MED
CT	I-MED
The	O
usage	B-MED
of	O
coronary	B-MED
CT	I-MED
angiography	I-MED
(	O
CTA	B-MED
)	O
is	O
appropriate	O
in	O
patients	B-MED
with	O
acute	B-MED
or	O
chronic	B-MED
chest	I-MED
pain	I-MED
;	O
however	O
the	O
diagnostic	B-MED
accuracy	I-MED
may	O
be	O
challenged	O
with	O
increased	O
Agatston	B-MED
score	I-MED
(	O
AS	B-MED
)	O
,	O
increased	O
heart	B-MED
rate	I-MED
,	O
arrhythmia	B-MED
and	O
severe	B-MED
obesity	I-MED
.	O
Thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third	B-MED
-	I-MED
generation	I-MED
dual	I-MED
-	I-MED
source	I-MED
CT	I-MED
(	O
DSCT	B-MED
)	O
for	O
CTA	B-MED
in	O
a	O
'	O
real	O
-	O
life	O
'	O
clinical	B-MED
setting	I-MED
.	O
Two	O
hundred	O
and	O
sixty	O
-	O
eight	O
consecutive	O
patients	B-MED
(	O
age	O
:	O
67	O
±	O
10	O
years	O
;	O
BMI	B-MED
:	O
27	O
±	O
5	O
kg	O
/	O
m²	O
;	O
61	O
%	O
male	B-MED
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-MED
with	O
DSCT	B-MED
were	O
included	O
in	O
the	O
retrospective	B-MED
single	I-MED
-	I-MED
center	I-MED
analysis	I-MED
.	O
A	O
contrast	B-MED
-	I-MED
enhanced	I-MED
volume	I-MED
dataset	I-MED
was	O
acquired	O
in	O
sequential	B-MED
(	O
SSM	B-MED
)	O
(	O
n	O
=	O
151	O
)	O
or	O
helical	B-MED
scan	I-MED
mode	I-MED
(	O
HSM	B-MED
)	O
(	O
n	O
=	O
117	O
)	O
.	O
Coronary	B-MED
segments	I-MED
were	O
classified	O
in	O
diagnostic	B-MED
or	O
non	B-MED
-	I-MED
diagnostic	I-MED
image	I-MED
quality	I-MED
.	O
A	O
subset	O
underwent	O
invasive	B-MED
angiography	I-MED
to	O
determine	O
the	O
diagnostic	B-MED
accuracy	I-MED
of	O
CTA	B-MED
.	O
SSM	B-MED
(	O
96.8	O
±	O
6	O
%	O
)	O
and	O
HSM	B-MED
(	O
97.5	O
±	O
8	O
%	O
)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	B-MED
image	I-MED
quality	B-MED
.	O
However	O
,	O
AS	B-MED
had	O
significant	O
influence	B-MED
on	O
diagnostic	B-MED
image	I-MED
quality	B-MED
exclusively	O
in	O
SSM	B-MED
(	O
B	O
=	O
0.003	O
;	O
p	O
=	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
HSM	B-MED
.	O
Diagnostic	B-MED
image	I-MED
quality	B-MED
significantly	O
decreased	O
in	O
SSM	B-MED
in	O
patients	B-MED
with	O
AS	B-MED
≥2,000	O
(	O
p	O
=	O
0.03	O
)	O
.	O
SSM	B-MED
(	O
sensitivity	B-MED
:	O
93.9	O
%	O
;	O
specificity	B-MED
:	O
96.7	O
%	O
;	O
PPV	B-MED
:	O
88.6	O
%	O
;	O
NPV	B-MED
:	O
98.3	O
%	O
)	O
and	O
HSM	B-MED
(	O
sensitivity	B-MED
:	O
97.4	O
%	O
;	O
specificity	B-MED
:	O
94.3	O
%	O
;	O
PPV	B-MED
:	O
86.0	O
%	O
;	O
NPV	B-MED
:	O
99.0	O
%	O
)	O
provided	O
comparable	O
diagnostic	B-MED
accuracy	I-MED
(	O
p	O
=	O
n.s	O
.	O
)	O
.	O
SSM	B-MED
yielded	O
significantly	O
lower	O
radiation	B-MED
doses	I-MED
as	O
compared	O
to	O
HSM	B-MED
(	O
2.1	O
±	O
2.0	O
vs.	O
5.1	O
±	O
3.3	O
mSv	O
;	O
p	O
=	O
0.0001	O
)	O
in	O
age	B-MED
and	O
BMI	B-MED
-matched	O
cohorts	B-MED
.	O
SSM	B-MED
in	O
third	B-MED
-	I-MED
generation	I-MED
DSCT	I-MED
enables	O
significant	O
dose	B-MED
savings	O
and	O
provides	O
robust	O
diagnostic	B-MED
image	I-MED
quality	B-MED
in	O
patients	B-MED
with	O
AS	B-MED
≤2000	O
independent	O
of	O
heart	B-MED
rate	I-MED
,	O
heart	B-MED
rhythm	I-MED
or	O
obesity	B-MED
.	O
Synthesis	B-MED
,	O
SAR	B-MED
and	O
molecular	B-MED
docking	I-MED
study	B-MED
of	O
novel	O
non	B-MED
-	I-MED
β	I-MED
-	I-MED
lactam	I-MED
inhibitors	I-MED
of	O
TEM	B-MED
type	I-MED
β	I-MED
-	I-MED
lactamase	I-MED
The	O
novel	O
classes	O
of	O
acylated	B-MED
phenoxyanilide	I-MED
and	O
thiourea	B-MED
compounds	I-MED
were	O
investigated	B-MED
for	O
their	O
ability	O
to	O
inhibit	B-MED
TEM	B-MED
type	I-MED
β	I-MED
-	I-MED
lactamase	I-MED
enzyme	I-MED
.	O
Two	O
compounds	B-MED
4	I-MED
g	I-MED
and	O
5c	B-MED
reveal	O
the	O
inhibition	B-MED
potency	B-MED
in	O
micromolar	B-MED
range	O
and	O
show	O
their	O
action	B-MED
by	O
non	B-MED
-	I-MED
covalent	I-MED
binding	I-MED
in	O
the	O
vicinity	O
of	O
the	O
TEM-171	B-MED
active	B-MED
site	I-MED
.	O
The	O
structure	B-MED
activity	I-MED
relationship	I-MED
around	O
carbon	B-MED
chain	I-MED
length	I-MED
and	O
different	O
substituents	B-MED
in	I-MED
ortho-	I-MED
and	I-MED
para	I-MED
-	I-MED
positions	I-MED
of	O
acylated	B-MED
phenoxyanilide	I-MED
as	O
well	O
as	O
molecular	B-MED
modelling	I-MED
study	B-MED
has	O
been	O
performed	O
.	O
Triterpenoids	B-MED
from	O
the	O
stems	B-MED
of	O
Tripterygium	B-MED
regelii	I-MED
Three	O
new	O
triterpenoids	B-MED
,	O
triregelolides	B-MED
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	B-MED
acid	I-MED
(	O
3	O
)	O
,	O
were	O
isolated	B-MED
from	O
the	O
stems	B-MED
of	O
Tripterygium	B-MED
regelii	I-MED
along	O
with	O
twenty	O
known	O
triterpene	B-MED
analogues	B-MED
(	O
4	O
-	O
23	O
)	O
.	O
The	O
structures	O
of	O
three	O
new	O
compounds	B-MED
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-MED
spectroscopic	I-MED
and	O
HRESIMS	B-MED
data	O
.	O
Compounds	B-MED
4	B-MED
,	O
7	B-MED
,	O
8	B-MED
,	O
10	B-MED
,	O
13	B-MED
,	O
14	B-MED
,	O
17	B-MED
,	O
21	B-MED
-	I-MED
23	I-MED
were	O
isolated	B-MED
from	O
T.	B-MED
regelii	I-MED
for	O
the	O
first	O
time	O
.	O
Compounds	B-MED
3	B-MED
,	O
5	B-MED
,	O
6	B-MED
,	O
8	B-MED
,	O
9	B-MED
,	O
10	B-MED
,	O
14	B-MED
and	O
16	B-MED
showed	O
inhibitory	B-MED
effects	I-MED
on	I-MED
the	I-MED
proliferation	I-MED
of	O
human	B-MED
breast	I-MED
cancer	I-MED
cells	I-MED
MCF-7	B-MED
by	O
24.1	O
%	O
,	O
69.6	O
%	O
,	O
72.8	O
%	O
,	O
21.6	O
%	O
,	O
23.1	O
%	O
,	O
43.3	O
%	O
,	O
25.5	O
%	O
and	O
23.5	O
%	O
(	O
p<0.05	O
)	O
at	O
a	O
concentration	B-MED
of	O
10μM	O
,	O
respectively	O
.	O
Lubiprostone	B-MED
Accelerates	B-MED
Intestinal	B-MED
Transit	I-MED
and	O
Alleviates	B-MED
Small	B-MED
Intestinal	I-MED
Bacterial	I-MED
Overgrowth	I-MED
in	O
Patients	B-MED
With	O
Chronic	B-MED
Constipation	I-MED
Lubiprostone	B-MED
is	O
an	O
effective	B-MED
treatment	B-MED
for	O
chronic	B-MED
constipation	I-MED
(	O
CC	B-MED
)	O
.	O
The	O
mechanism	B-MED
of	I-MED
action	I-MED
of	O
lubiprostone	B-MED
is	O
through	O
increasing	B-MED
fluid	B-MED
secretion	I-MED
and	O
lubrication	B-MED
of	O
the	O
intestinal	B-MED
lumen	I-MED
.	O
The	O
effects	B-MED
of	O
lubiprostone	B-MED
on	O
gastrointestinal	B-MED
transit	I-MED
and	O
small	B-MED
intestinal	I-MED
bacterial	I-MED
overgrowth	I-MED
(	O
SIBO	B-MED
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O
The	O
current	O
study	B-MED
was	O
designed	O
to	O
investigate	B-MED
whether	O
lubiprostone	B-MED
(	O
1	O
)	O
alters	O
gastrointestinal	B-MED
transit	I-MED
and	O
(	O
2	O
)	O
affects	O
SIBO	B-MED
in	O
patients	B-MED
with	O
constipation	B-MED
.	O
A	O
total	O
of	O
29	O
female	B-MED
patients	I-MED
(	O
mean	B-MED
age	I-MED
=	O
39	O
years	B-MED
;	O
range	B-MED
:	O
19	O
-	O
64	O
)	O
with	O
CC	B-MED
received	B-MED
2	O
weeks	B-MED
of	O
lubiprostone	B-MED
(	O
24mcg	O
b.i.d	O
.	O
,	O
P.O.	O
)	O
.	O
Stool	B-MED
consistency	I-MED
based	O
on	O
Bristol	B-MED
stool	I-MED
scale	I-MED
and	O
the	O
frequency	B-MED
of	I-MED
bowel	I-MED
movements	I-MED
(	O
BMs	B-MED
)	O
were	O
recorded	O
.	O
Gastric	B-MED
emptying	I-MED
time	I-MED
,	O
small	B-MED
bowel	I-MED
transit	I-MED
time	I-MED
,	O
colon	B-MED
transit	B-MED
time	I-MED
(	O
CTT	B-MED
)	O
,	O
combined	O
small	B-MED
and	I-MED
large	I-MED
bowel	I-MED
transit	I-MED
time	I-MED
(	O
SLBTT	B-MED
)	O
and	O
whole	O
gut	B-MED
transit	B-MED
time	I-MED
were	O
measured	B-MED
using	O
wireless	B-MED
motility	I-MED
capsule	I-MED
.	O
The	O
SIBO	B-MED
status	B-MED
was	O
assessed	O
by	O
the	O
lactulose	B-MED
breath	I-MED
test	I-MED
.	O
Data	B-MED
were	O
analyzed	B-MED
using	O
Wilcoxon	B-MED
rank	I-MED
,	O
Mann	B-MED
-	I-MED
Whitney	I-MED
U	I-MED
,	O
Spearman׳s	B-MED
rank	I-MED
correlation	I-MED
and	O
Chi	B-MED
-	I-MED
square	I-MED
tests	I-MED
.	O
Lubiprostone	B-MED
significantly	O
softened	B-MED
the	O
stool	B-MED
and	O
increased	B-MED
the	O
frequency	B-MED
of	I-MED
BM	I-MED
from	O
median	B-MED
of	O
2	O
to	O
4	O
times	B-MED
per	O
week	B-MED
.	O
The	O
CTT	B-MED
and	O
SLBTT	B-MED
were	O
significantly	O
shorter	B-MED
in	O
responders	B-MED
to	O
lubiprostone	B-MED
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	B-MED
increase	B-MED
in	O
the	O
number	B-MED
of	O
their	O
weekly	B-MED
BM	B-MED
)	O
compared	B-MED
with	O
nonresponders	B-MED
.	O
The	O
higher	B-MED
frequency	B-MED
of	I-MED
BM	I-MED
after	O
treatment	B-MED
was	O
significantly	O
correlated	B-MED
with	O
the	O
acceleration	B-MED
of	O
CTT	B-MED
,	O
SLBTT	B-MED
and	O
whole	O
gut	B-MED
transit	B-MED
time	I-MED
.	O
In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	B-MED
,	O
who	O
were	O
tested	B-MED
for	O
SIBO	B-MED
at	O
baseline	B-MED
,	O
were	O
positive	B-MED
.	O
In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
SIBO	B-MED
-	O
positive	B-MED
patients	B-MED
became	O
SIBO	B-MED
-	O
negative	B-MED
after	O
lubiprostone	B-MED
treatment	B-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
In	O
CC	B-MED
,	O
lubiprostone	B-MED
improves	O
the	O
frequency	B-MED
of	I-MED
BMs	I-MED
,	O
softens	B-MED
the	O
stool	B-MED
,	O
accelerates	B-MED
intestinal	B-MED
transit	I-MED
and	O
decreases	B-MED
accompanying	O
SIBO	B-MED
.	O
The	O
improvement	B-MED
of	O
SIBO	B-MED
could	O
be	O
explained	O
by	O
the	O
cleansing	B-MED
effect	B-MED
of	O
increased	B-MED
intestinal	B-MED
fluid	I-MED
and	O
mucus	B-MED
combined	O
with	O
enhanced	B-MED
intestinal	B-MED
motility	I-MED
with	O
lubiprostone	B-MED
.	O
Pupil	B-MED
Sizes	I-MED
Scale	B-MED
with	O
Attentional	B-MED
Load	I-MED
and	O
Task	B-MED
Experience	B-MED
in	O
a	O
Multiple	B-MED
Object	B-MED
Tracking	B-MED
Task	B-MED
Previous	O
studies	O
have	O
related	O
changes	B-MED
in	O
attentional	B-MED
load	I-MED
to	O
pupil	B-MED
size	I-MED
modulations	B-MED
.	O
However	O
,	O
studies	O
relating	O
changes	B-MED
in	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
on	O
a	O
finer	O
scale	B-MED
to	O
pupil	B-MED
size	I-MED
modulations	B-MED
are	O
scarce	O
.	O
Here	O
,	O
we	O
investigated	B-MED
how	O
these	O
changes	B-MED
affect	B-MED
pupil	B-MED
sizes	I-MED
.	O
To	O
manipulate	B-MED
attentional	B-MED
load	I-MED
,	O
participants	B-MED
covertly	O
tracked	B-MED
between	O
zero	B-MED
and	O
five	B-MED
objects	B-MED
among	O
several	O
randomly	B-MED
moving	O
objects	B-MED
on	O
a	O
computer	B-MED
screen	B-MED
.	O
To	O
investigate	B-MED
effects	B-MED
of	I-MED
task	B-MED
experience	B-MED
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	B-MED
consecutive	B-MED
days	B-MED
.	O
We	O
found	O
that	O
pupil	B-MED
sizes	I-MED
increased	O
with	O
each	O
increment	B-MED
in	O
attentional	B-MED
load	I-MED
.	O
Across	O
days	B-MED
,	O
we	O
found	O
systematic	B-MED
pupil	B-MED
size	I-MED
reductions	B-MED
.	O
We	O
compared	O
the	O
model	B-MED
fit	I-MED
for	O
predicting	O
pupil	B-MED
size	I-MED
modulations	B-MED
using	O
attentional	B-MED
load	I-MED
,	O
task	B-MED
experience	B-MED
,	O
and	O
task	B-MED
performance	I-MED
as	O
predictors	B-MED
.	O
We	O
found	O
that	O
a	O
model	B-MED
which	O
included	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
as	O
predictors	B-MED
had	O
the	O
best	O
model	B-MED
fit	I-MED
while	O
adding	O
performance	B-MED
as	O
a	O
predictor	B-MED
to	O
this	O
model	B-MED
reduced	O
the	O
overall	O
model	B-MED
fit	I-MED
.	O
Overall	O
,	O
results	B-MED
suggest	O
that	O
pupillometry	B-MED
provides	O
a	O
viable	B-MED
metric	B-MED
for	O
precisely	O
assessing	O
attentional	B-MED
load	I-MED
and	O
task	B-MED
experience	B-MED
in	O
visuospatial	B-MED
tasks	B-MED
.	O
Jak1	B-MED
-	O
STAT3	B-MED
Signals	B-MED
Are	O
Essential	B-MED
Effectors	B-MED
of	O
the	O
USP6	B-MED
/	O
TRE17	B-MED
Oncogene	I-MED
in	O
Tumorigenesis	B-MED
Bone	B-MED
and	O
soft	B-MED
tissue	I-MED
tumors	I-MED
(	O
BSTT	B-MED
)	O
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	B-MED
of	O
effective	B-MED
therapies	B-MED
.	O
Here	O
we	O
report	B-MED
a	O
role	O
for	O
the	O
ubiquitin	B-MED
-	I-MED
specific	I-MED
protease	I-MED
6	I-MED
USP6	B-MED
(	O
USP6)/	O
TRE17	B-MED
oncogene	I-MED
,	O
which	O
is	O
overexpressed	B-MED
upon	O
chromosome	B-MED
translocation	I-MED
in	O
various	O
human	B-MED
tumors	B-MED
,	O
including	O
aneurysmal	B-MED
bone	I-MED
cyst	I-MED
(	O
ABC	B-MED
)	O
,	O
and	O
the	O
related	O
benign	B-MED
lesion	B-MED
nodular	B-MED
fasciitis	I-MED
.	O
Ectopic	B-MED
expression	I-MED
of	O
USP6	B-MED
is	O
known	O
to	O
drive	O
formation	B-MED
of	O
tumors	B-MED
,	O
which	O
recapitulate	O
key	B-MED
features	I-MED
of	O
ABC	B-MED
and	O
nodular	B-MED
fasciitis	I-MED
;	O
however	O
,	O
the	O
identity	B-MED
of	O
USP6	B-MED
's	I-MED
relevant	O
substrates	B-MED
has	O
been	O
obscure	O
.	O
Here	O
we	O
report	B-MED
that	O
the	O
Jak1	B-MED
-	O
STAT3	B-MED
signaling	B-MED
pathway	I-MED
serves	O
as	O
an	O
essential	B-MED
effector	B-MED
of	O
USP6	B-MED
in	O
BSTT	B-MED
formation	B-MED
.	O
We	O
found	O
that	O
USP6	B-MED
directly	O
deubiquitinated	B-MED
Jak1	B-MED
,	O
leading	B-MED
to	O
its	O
stabilization	B-MED
and	O
activation	B-MED
of	O
STAT3	B-MED
.	O
The	O
tumorigenic	B-MED
potential	B-MED
of	O
USP6	B-MED
was	O
attenuated	B-MED
significantly	I-MED
by	I-MED
CRISPR	B-MED
-mediated	O
deletion	B-MED
of	O
Jak1	B-MED
or	O
STAT3	B-MED
,	O
or	O
by	O
administration	B-MED
of	O
a	O
Jak	B-MED
family	I-MED
inhibitor	B-MED
.	O
Analysis	B-MED
of	O
primary	B-MED
clinical	I-MED
samples	I-MED
of	O
nodular	B-MED
fasciitis	I-MED
confirmed	B-MED
the	O
activation	B-MED
of	O
a	O
Jak1	B-MED
-	O
STAT3	B-MED
gene	B-MED
signature	I-MED
in	B-MED
vivo	I-MED
Together	O
,	O
our	O
studies	B-MED
highlight	O
Jak1	B-MED
as	O
the	O
first	O
identified	O
substrate	B-MED
for	O
USP6	B-MED
,	O
and	O
they	O
offer	O
a	O
mechanistic	B-MED
rationale	I-MED
for	O
the	O
clinical	B-MED
investigation	I-MED
of	O
Jak	B-MED
and	O
STAT3	B-MED
inhibitors	B-MED
as	O
therapeutics	B-MED
for	O
the	O
treatment	B-MED
of	O
bone	B-MED
and	O
soft	B-MED
tissue	I-MED
tumors	I-MED
along	O
with	O
other	O
neoplasms	B-MED
driven	O
by	O
USP6	B-MED
overexpression	B-MED
.	O
Cancer	O
Res	O
;	O
76(18	O
)	O
;	O
5337	O
-	O
47	O
.	O
©	O
2016	O
AACR	O
.	O
Neutrophil	B-MED
gelatinase	I-MED
-	I-MED
associated	I-MED
lipocalin	I-MED
in	O
a	O
triphasic	B-MED
rat	B-MED
model	I-MED
of	O
adenine	B-MED
-	O
induced	B-MED
kidney	B-MED
injury	I-MED
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	B-MED
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-MED
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-MED
tubulointerstitial	I-MED
insult	I-MED
caused	O
by	O
adenine	B-MED
.	O
Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	B-MED
as	O
a	O
biomarker	B-MED
of	O
any	O
acute	B-MED
kidney	I-MED
injury	I-MED
,	O
on	O
top	O
of	O
chronic	B-MED
interstitial	I-MED
disease	I-MED
,	O
if	O
NGAL	B-MED
levels	B-MED
are	O
stable	B-MED
through	B-MED
the	O
chronic	B-MED
phase	I-MED
of	O
our	O
adenine	B-MED
model	I-MED
.	O
Study	B-MED
group	I-MED
rats	B-MED
were	O
fed	O
an	O
adenine	B-MED
diet	B-MED
,	O
and	O
control	B-MED
group	I-MED
rats	B-MED
were	O
fed	O
a	O
regular	B-MED
diet	I-MED
only	O
.	O
Blood	B-MED
and	O
urine	B-MED
samples	I-MED
for	O
urea	B-MED
,	O
creatinine	B-MED
and	O
NGAL	B-MED
were	O
drawn	O
from	O
each	O
rat	B-MED
at	O
the	O
beginning	B-MED
of	O
the	O
study	B-MED
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O
Kidney	B-MED
slices	B-MED
from	O
these	O
rats	B-MED
were	O
stained	B-MED
with	O
Hematoxylin	B-MED
-	I-MED
eosin	I-MED
(	O
HE	B-MED
)	O
and	O
β	B-MED
-	I-MED
actin	I-MED
stainings	B-MED
.	O
Serum	B-MED
urea	I-MED
,	O
creatinine	B-MED
and	O
NGAL	B-MED
levels	B-MED
and	O
urinary	B-MED
NGAL	I-MED
/	I-MED
creatinine	I-MED
ratio	I-MED
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	B-MED
and	O
than	O
in	O
the	O
control	B-MED
group	I-MED
;	O
these	O
differences	O
were	O
statistically	B-MED
significant	I-MED
in	O
some	O
of	O
the	O
intervals	B-MED
.	O
Tubulointerstitial	B-MED
changes	O
and	O
adenine	B-MED
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-MED
.	O
In	O
the	O
rats	B-MED
fed	O
adenine	B-MED
,	O
serum	B-MED
urea	I-MED
,	O
creatinine	B-MED
and	O
NGAL	B-MED
levels	B-MED
and	O
urinary	B-MED
NGAL	I-MED
/	I-MED
creatinine	I-MED
ratio	I-MED
followed	O
a	O
triphasic	B-MED
pattern	I-MED
of	O
kidney	B-MED
injury	I-MED
:	O
an	O
acute	B-MED
phase	I-MED
while	O
on	O
the	O
adenine	B-MED
diet	B-MED
,	O
a	O
partial	B-MED
recovery	B-MED
phase	B-MED
after	O
switching	O
to	O
the	O
regular	B-MED
diet	I-MED
and	O
a	O
chronic	B-MED
kidney	I-MED
disease	I-MED
phase	B-MED
after	O
stabilization	O
of	O
renal	B-MED
function	I-MED
.	O
NGAL	B-MED
can	O
serve	O
a	O
biomarker	B-MED
for	O
acute	B-MED
kidney	I-MED
injury	I-MED
and	O
possibly	O
for	O
chronic	B-MED
kidney	I-MED
disease	I-MED
in	O
the	O
tubulointerstitial	B-MED
rat	B-MED
model	I-MED
.	O
Long	B-MED
Term	I-MED
Outcome	B-MED
in	O
Patients	B-MED
with	O
Esophageal	B-MED
Stenting	I-MED
for	O
Cancer	B-MED
Esophagus	I-MED
-	O
Our	O
Experience	O
at	O
a	O
Rural	B-MED
Hospital	I-MED
of	O
Punjab	B-MED
,	O
India	B-MED
Cancer	B-MED
of	I-MED
the	I-MED
esophagus	I-MED
is	O
among	O
the	O
leading	O
cause	B-MED
of	O
cancer	B-MED
deaths	I-MED
in	O
Punjab	B-MED
,	O
India	B-MED
.	O
Patients	B-MED
generally	O
present	B-MED
with	O
dysphagia	B-MED
as	O
their	O
first	O
symptom	B-MED
and	O
more	O
often	O
they	O
have	O
advanced	B-MED
disease	I-MED
at	O
the	O
time	B-MED
of	O
presentation	B-MED
to	O
a	O
tertiary	B-MED
care	I-MED
centre	I-MED
.	O
Palliative	B-MED
procedures	I-MED
have	O
important	B-MED
roles	O
in	O
this	O
setting	O
.	O
Stenting	B-MED
is	O
the	O
best	O
option	B-MED
to	O
palliate	B-MED
the	O
symptoms	B-MED
of	O
dysphagia	B-MED
,	O
from	O
which	O
patient	B-MED
is	O
suffering	B-MED
the	I-MED
most	I-MED
.	O
To	O
know	O
the	O
success	B-MED
rate	B-MED
,	O
early	B-MED
and	O
long	B-MED
term	I-MED
complications	B-MED
and	O
mortality	B-MED
in	O
esophageal	B-MED
stenting	I-MED
,	O
when	O
it	O
was	O
done	O
in	O
malignant	B-MED
esophageal	I-MED
stricture	I-MED
patients	B-MED
.	O
One	B-MED
hundred	I-MED
patients	B-MED
,	O
who	O
had	O
undergone	O
esophageal	B-MED
stenting	I-MED
from	O
January	B-MED
2012	O
to	O
January	B-MED
2015	O
,	O
were	O
included	B-MED
in	O
the	O
study	B-MED
.	O
We	O
retrospectively	B-MED
analysed	I-MED
the	O
data	B-MED
for	O
patient	B-MED
characteristics	B-MED
,	O
causes	B-MED
of	O
non	B-MED
-	I-MED
operability	I-MED
,	O
early	B-MED
and	O
long	B-MED
term	I-MED
complications	B-MED
,	O
re	B-MED
-	I-MED
interventions	I-MED
,	O
efficacy	B-MED
and	O
mortality	B-MED
.	O
Out	O
of	O
100	O
patients	B-MED
,	O
indications	B-MED
for	O
stenting	B-MED
were	O
locally	O
advanced	B-MED
disease	I-MED
not	O
amenable	B-MED
to	O
surgery	B-MED
(	O
52	O
%	O
)	O
,	O
metastatic	B-MED
disease	I-MED
(	O
35	O
%	O
)	O
,	O
CVA	B-MED
(	O
1	O
%	O
)	O
,	O
cardiac	B-MED
and	O
respiratory	B-MED
problem	I-MED
(	O
8	O
%	O
)	O
,	O
un	O
-	O
willing	O
for	O
surgery	B-MED
in	O
5	O
%	O
of	O
patients	B-MED
.	O
Majority	O
of	O
patients	B-MED
(	O
94	O
%	O
)	O
had	O
squamous	B-MED
cell	I-MED
carcinoma	I-MED
,	O
while	O
only	O
6	O
%	O
had	O
adenocarcinoma	B-MED
.	O
84	O
%	O
of	O
patients	B-MED
presented	B-MED
with	O
dysphagia	B-MED
with	O
or	O
without	O
chest	B-MED
pain	I-MED
and	O
recurrent	B-MED
cough	I-MED
while	O
16	O
%	O
had	O
recurrent	B-MED
vomiting	I-MED
.	O
58	O
%	O
had	O
dysphagia	B-MED
to	O
liquids	B-MED
and	O
solids	B-MED
and	O
17	O
%	O
had	O
complete	B-MED
dysphagia	I-MED
.	O
After	O
stenting	B-MED
93	O
%	O
had	O
significant	B-MED
improvement	B-MED
in	O
dysphagia	B-MED
score	B-MED
from	O
median	O
of	O
3	O
to	O
1	O
.	O
Post	B-MED
procedure	I-MED
stay	B-MED
was	O
3.61±1.0	O
days	B-MED
.	O
One	O
patient	B-MED
had	O
procedure	B-MED
related	O
major	O
complication	B-MED
in	O
the	O
form	O
of	O
post	B-MED
procedural	I-MED
bleed	I-MED
(	O
after	O
16	O
days	B-MED
of	O
stenting	B-MED
)	O
leading	O
to	O
death	B-MED
of	O
that	O
patient	B-MED
.	O
Minor	B-MED
complications	B-MED
were	O
present	B-MED
in	O
52	O
patients	B-MED
treated	B-MED
conservatively	O
not	O
affecting	B-MED
the	O
efficacy	B-MED
of	O
procedure	B-MED
.	O
These	O
include	B-MED
pain	B-MED
after	O
stenting	B-MED
(	O
38	O
%	O
)	O
,	O
stent	B-MED
obstruction	I-MED
(	O
23	O
%	O
)	O
and	O
stent	B-MED
migration	I-MED
(	O
6	O
%	O
)	O
.	O
All	O
the	O
minor	B-MED
complications	B-MED
were	O
treated	B-MED
conservatively	O
except	B-MED
in	O
six	O
patients	B-MED
in	O
whom	O
re	B-MED
-	I-MED
stenting	I-MED
was	O
done	O
.	O
Esophageal	B-MED
stenting	I-MED
is	O
relatively	O
safe	O
procedure	B-MED
with	O
short	O
stay	B-MED
of	O
the	O
patient	B-MED
in	O
the	O
hospital	B-MED
.	O
Although	O
,	O
it	O
helps	O
in	O
alleviating	O
patients	B-MED
'	O
morbidity	B-MED
very	O
effectively	B-MED
and	O
reliably	O
,	O
there	O
are	O
many	O
technical	B-MED
glitches	I-MED
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	B-MED
should	O
be	O
properly	O
counseled	B-MED
before	O
the	O
procedure	B-MED
to	O
prevent	B-MED
and	O
manage	B-MED
post	B-MED
procedure	I-MED
complications	B-MED
and	O
medico	O
legal	O
aspects	O
.	O
Hypocretin	B-MED
/	I-MED
Orexin	I-MED
Peptides	I-MED
Excite	B-MED
Rat	B-MED
Neuroendocrine	B-MED
Dopamine	B-MED
Neurons	I-MED
through	O
Orexin	B-MED
2	I-MED
Receptor	I-MED
-Mediated	O
Activation	B-MED
of	O
a	O
Mixed	B-MED
Cation	B-MED
Current	B-MED
Hypocretin	B-MED
/	I-MED
Orexin	I-MED
(	O
H	B-MED
/	I-MED
O	I-MED
)	O
neurons	B-MED
of	O
the	O
lateral	B-MED
hypothalamus	I-MED
are	O
compelling	B-MED
modulator	B-MED
candidates	I-MED
for	O
the	O
chronobiology	B-MED
of	O
neuroendocrine	B-MED
output	B-MED
and	O
,	O
as	O
a	O
consequence	B-MED
,	O
hormone	B-MED
release	I-MED
from	O
the	O
anterior	B-MED
pituitary	I-MED
.	O
Here	O
we	O
investigate	O
the	O
effects	B-MED
of	O
H	B-MED
/	I-MED
O	I-MED
peptides	I-MED
upon	O
tuberoinfundibular	B-MED
dopamine	I-MED
(	I-MED
TIDA	I-MED
)	I-MED
neurons	I-MED
-	O
cells	B-MED
which	O
control	B-MED
,	O
via	O
inhibition	B-MED
,	O
the	O
pituitary	B-MED
secretion	B-MED
of	I-MED
prolactin	I-MED
.	O
In	O
whole	B-MED
cell	I-MED
recordings	I-MED
performed	B-MED
in	O
male	B-MED
rat	B-MED
hypothalamic	B-MED
slices	I-MED
,	O
application	O
of	O
H	B-MED
/	I-MED
O	I-MED
-	I-MED
A	I-MED
,	O
as	O
well	O
as	O
H	B-MED
/	I-MED
O	I-MED
-	I-MED
B	I-MED
,	O
excited	B-MED
oscillating	O
TIDA	B-MED
neurons	I-MED
,	O
inducing	B-MED
a	O
reversible	B-MED
depolarising	B-MED
switch	O
from	O
phasic	B-MED
to	I-MED
tonic	I-MED
discharge	I-MED
.	O
The	O
H	B-MED
/	I-MED
O	I-MED
-	O
induced	B-MED
inward	B-MED
current	B-MED
underpinning	B-MED
this	O
effect	B-MED
was	O
post	B-MED
-	I-MED
synaptic	I-MED
(	O
as	O
it	O
endured	O
in	O
the	O
presence	B-MED
of	O
tetrodotoxin	B-MED
)	O
,	O
appeared	B-MED
to	O
be	O
carried	O
by	O
a	O
Na(+	B-MED
)	I-MED
-	O
dependent	B-MED
transient	B-MED
receptor	I-MED
potential	I-MED
-	I-MED
like	I-MED
channel	I-MED
(	O
as	O
it	O
was	O
blocked	B-MED
by	O
2	B-MED
-	I-MED
APB	I-MED
and	O
was	O
diminished	B-MED
by	O
removal	B-MED
of	O
extracellular	B-MED
Na(+	B-MED
)	I-MED
)	O
,	O
and	O
was	O
a	O
consequence	B-MED
of	I-MED
OX2R	B-MED
receptor	I-MED
activation	B-MED
(	O
as	O
it	O
was	O
blocked	B-MED
by	O
the	O
OX2R	B-MED
receptor	I-MED
antagonist	B-MED
TCS	B-MED
OX2	I-MED
29	I-MED
,	O
but	O
not	O
the	O
OX1R	B-MED
receptor	I-MED
antagonist	B-MED
SB	B-MED
334867	I-MED
)	O
.	O
Application	B-MED
of	O
the	O
hormone	B-MED
,	O
melatonin	B-MED
,	O
failed	B-MED
to	O
alter	B-MED
TIDA	B-MED
membrane	B-MED
potential	I-MED
or	O
oscillatory	B-MED
activity	I-MED
.	O
This	O
first	O
description	B-MED
of	O
the	O
electrophysiological	B-MED
effects	I-MED
of	O
H	B-MED
/	I-MED
Os	I-MED
upon	O
the	O
TIDA	B-MED
network	I-MED
identifies	B-MED
cellular	B-MED
mechanisms	I-MED
that	O
may	O
contribute	B-MED
to	O
the	O
circadian	B-MED
rhythmicity	I-MED
of	O
prolactin	B-MED
secretion	I-MED
.	O
Naïve	B-MED
CD8(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
derived	O
tumor	B-MED
-	O
specific	B-MED
cytotoxic	B-MED
effectors	I-MED
as	O
a	O
potential	O
remedy	B-MED
for	O
overcoming	O
TGF	B-MED
-	I-MED
β	I-MED
immunosuppression	B-MED
in	O
the	O
tumor	B-MED
microenvironment	I-MED
Despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-MED
immunotherapy	I-MED
,	O
conventional	B-MED
approaches	B-MED
using	O
in	B-MED
vitro	I-MED
expanded	B-MED
CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
have	O
suboptimal	B-MED
outcomes	B-MED
,	O
mostly	O
due	O
to	O
loss	B-MED
of	O
functionality	B-MED
from	O
cellular	B-MED
exhaustion	B-MED
.	O
We	O
therefore	O
investigated	O
the	O
phenotypic	B-MED
and	O
functional	B-MED
differences	B-MED
among	O
in	B-MED
vitro	I-MED
activated	B-MED
CD8(+	B-MED
)	I-MED
T	I-MED
cells	I-MED
of	O
three	O
different	O
sources	B-MED
,	O
namely	O
naïve	B-MED
(	O
NTeff	B-MED
)	O
,	O
memory	B-MED
(	O
MTeff	B-MED
)	O
and	O
tumor	B-MED
-	I-MED
infiltrating	I-MED
lymphocytes	I-MED
(	O
TILeff	B-MED
)	O
from	O
human	B-MED
and	O
mice	B-MED
,	O
to	O
better	O
understand	O
mechanisms	B-MED
behind	O
potent	O
effector	B-MED
functions	B-MED
and	O
potential	O
for	O
overcoming	O
current	O
limitations	B-MED
.	O
In	O
line	O
with	O
the	O
greater	O
proliferation	B-MED
activity	B-MED
and	O
longer	O
telomere	B-MED
lengths	B-MED
of	O
NTeff	B-MED
populations	I-MED
,	O
cells	B-MED
of	O
naïve	B-MED
origin	I-MED
exhibited	O
significantly	O
less	O
amounts	O
of	O
T	B-MED
cell	I-MED
exhaustion	B-MED
markers	B-MED
than	O
those	O
of	O
MTeff	B-MED
and	O
TILeff	B-MED
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	B-MED
patterns	I-MED
of	O
memory	B-MED
-	I-MED
promoting	I-MED
transcription	I-MED
factors	I-MED
,	O
T	B-MED
-	I-MED
bet	I-MED
and	O
Eomes	B-MED
,	O
induced	B-MED
in	O
a	O
rapid	B-MED
and	O
sustainable	B-MED
manner	B-MED
.	O
NTeff	B-MED
cells	I-MED
appeared	O
to	O
have	O
lower	O
expression	B-MED
of	O
Foxp1	B-MED
and	O
were	O
refractory	O
to	O
apoptosis	B-MED
upon	O
TGF	B-MED
-	I-MED
β	I-MED
conditioning	B-MED
,	O
implying	O
better	O
survival	B-MED
potential	B-MED
and	O
resistance	B-MED
to	O
tumor	B-MED
-	O
induced	B-MED
immune	B-MED
suppression	I-MED
.	O
Of	O
CD8(+	B-MED
)	I-MED
T	I-MED
cell	I-MED
pools	O
activated	B-MED
to	O
tumor	B-MED
-	O
specific	B-MED
CTLs	B-MED
,	O
naïve	B-MED
cell	I-MED
generated	B-MED
effectors	B-MED
possessed	O
the	O
most	O
potent	O
cytotoxic	B-MED
activity	I-MED
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	B-MED
of	O
adoptive	B-MED
immunotherapy	I-MED
.	O
Psychosocial	B-MED
impact	I-MED
on	O
families	B-MED
with	O
an	O
infant	B-MED
with	O
a	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
during	B-MED
and	I-MED
after	I-MED
the	I-MED
interstage	I-MED
monitoring	I-MED
period	I-MED
-	O
a	O
prospective	B-MED
mixed	I-MED
-	I-MED
method	I-MED
study	I-MED
To	O
investigate	O
parents	B-MED
'	I-MED
experiences	I-MED
,	O
coping	B-MED
ability	I-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
while	O
monitoring	B-MED
their	O
sick	B-MED
child	I-MED
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
at	O
home	B-MED
.	O
Interstage	B-MED
home	I-MED
monitoring	I-MED
for	O
children	B-MED
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
reduces	O
interstage	O
mortality	B-MED
between	O
Norwood	B-MED
stages	I-MED
I	I-MED
and	I-MED
II	I-MED
.	O
Little	O
is	O
known	O
about	O
the	O
psychosocial	B-MED
impact	I-MED
of	O
interstage	B-MED
home	I-MED
monitoring	I-MED
.	O
Prospective	B-MED
mixed	I-MED
-	I-MED
method	I-MED
study	I-MED
.	O
This	O
study	O
assessed	O
the	O
psychosocial	B-MED
impact	I-MED
on	O
parents	B-MED
during	O
interstage	B-MED
home	I-MED
monitoring	I-MED
.	O
This	O
contains	O
for	O
quantitative	B-MED
assessment	I-MED
the	O
Short	B-MED
Form	I-MED
Health	I-MED
Survey	I-MED
questionnaire	I-MED
and	O
the	O
Impact	O
of	O
Family	B-MED
Scale	I-MED
administered	I-MED
one	O
and	O
five	O
weeks	O
following	O
discharge	B-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
II	I-MED
.	O
For	O
qualitative	B-MED
assessment	I-MED
,	O
semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
focussing	O
on	O
the	O
postdischarge	B-MED
coping	B-MED
strategies	I-MED
were	O
conducted	O
twice	O
,	O
five	O
weeks	O
after	B-MED
hospital	I-MED
discharge	I-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
II	I-MED
.	O
Ten	O
infants	B-MED
(	O
eight	O
males	B-MED
)	O
with	O
hypoplastic	B-MED
left	I-MED
heart	I-MED
syndrome	I-MED
(	O
n	O
=	O
7	O
)	O
or	O
other	O
types	O
of	O
univentricular	B-MED
heart	I-MED
malformations	I-MED
(	O
n	O
=	O
3	O
)	O
,	O
and	O
their	O
parents	B-MED
(	O
nine	O
mother	B-MED
/	I-MED
father	I-MED
two-	O
parent	B-MED
households	B-MED
,	O
one	O
single	B-MED
mother	I-MED
)	O
were	O
included	O
.	O
There	O
were	O
no	B-MED
interstage	I-MED
deaths	I-MED
.	O
Mental	B-MED
Health	I-MED
Composite	B-MED
Summary	I-MED
scores	I-MED
were	O
low	O
in	O
both	O
parents	B-MED
(	O
mothers	B-MED
:	O
40·45	O
±	O
9·07	O
;	O
fathers	B-MED
:	O
40·58	O
±	O
9·69	O
)	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-MED
'	O
(	O
mothers	B-MED
:	O
37·0	O
±	O
19·46	O
;	O
fathers	B-MED
:	O
43·12	O
±	O
25·9	O
)	O
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
II	I-MED
.	O
Impact	O
of	O
Family	B-MED
Scale	I-MED
values	I-MED
showed	O
higher	O
daily	O
and	O
social	B-MED
burdens	I-MED
for	O
mothers	B-MED
.	O
'	O
Becoming	O
a	O
family	O
'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping	B-MED
strategy	I-MED
to	O
equilibrate	O
the	O
fragile	B-MED
emotional	I-MED
balance	I-MED
.	O
The	O
parents	B-MED
judged	O
interstage	B-MED
home	I-MED
monitoring	I-MED
as	O
a	O
protective	B-MED
intervention	I-MED
.	O
Although	O
psychosocial	B-MED
burden	I-MED
before	B-MED
and	I-MED
after	I-MED
stage	I-MED
II	I-MED
remains	O
high	O
,	O
becoming	O
a	O
family	B-MED
is	O
an	O
essential	O
experience	O
for	O
parents	B-MED
and	O
confirms	O
their	O
parenthood	B-MED
.	O
Healthcare	B-MED
professionals	I-MED
must	O
be	O
aware	O
of	O
parents	B-MED
'	O
needs	O
during	O
this	O
vulnerable	B-MED
interstage	I-MED
period	I-MED
and	O
to	O
provide	O
psychosocial	B-MED
and	O
nursing	B-MED
support	I-MED
.	O
Effect	B-MED
of	O
halotolerant	B-MED
rhizobacteria	I-MED
isolated	B-MED
from	O
halophytes	B-MED
on	O
the	O
growth	B-MED
of	O
sugar	B-MED
beet	I-MED
(	O
Beta	B-MED
vulgaris	I-MED
L	I-MED
.	O
)	O
under	O
salt	B-MED
stress	I-MED
Utilization	B-MED
of	O
rhizobacteria	B-MED
that	O
have	O
associated	B-MED
with	I-MED
plant	B-MED
roots	I-MED
in	O
harsh	B-MED
environments	B-MED
could	O
be	O
a	O
feasible	B-MED
strategy	I-MED
to	O
deal	O
with	O
limits	O
to	O
agricultural	B-MED
production	I-MED
caused	O
by	O
soil	B-MED
salinity	B-MED
.	O
Halophytes	B-MED
occur	O
naturally	O
in	O
high	B-MED
-	O
salt	B-MED
environments	I-MED
,	O
and	O
their	O
roots	B-MED
may	O
be	O
associated	B-MED
with	I-MED
promising	O
microbial	B-MED
candidates	I-MED
for	O
promoting	B-MED
growth	B-MED
and	O
salt	B-MED
tolerance	I-MED
in	O
crops	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
isolate	B-MED
efficient	O
halotolerant	B-MED
plant	I-MED
-	O
growth	B-MED
-	O
promoting	B-MED
rhizobacterial	B-MED
strains	B-MED
from	O
halophytes	B-MED
and	O
evaluate	B-MED
their	O
activity	B-MED
and	O
effects	B-MED
on	O
sugar	B-MED
beet	I-MED
(	O
Beta	B-MED
vulgaris	I-MED
L	I-MED
.	O
)	O
growth	B-MED
under	O
salinity	B-MED
stress	I-MED
.	O
A	O
total	O
of	O
23	O
isolates	B-MED
were	O
initially	O
screened	O
for	O
their	O
ability	B-MED
to	O
secrete	O
1	B-MED
-	I-MED
aminocyclopropane-1	I-MED
-	I-MED
carboxylate	I-MED
deaminase	I-MED
(	O
ACD	B-MED
)	O
as	O
well	O
as	O
other	O
plant	B-MED
-	I-MED
growth	I-MED
-	O
promoting	B-MED
characteristics	B-MED
and	O
subsequently	O
identified	B-MED
by	O
sequencing	B-MED
the	O
16S	B-MED
rRNA	I-MED
gene	B-MED
.	O
Three	O
isolates	B-MED
,	O
identified	O
as	O
Micrococcus	B-MED
yunnanensis	I-MED
,	O
Planococcus	B-MED
rifietoensis	I-MED
and	O
Variovorax	B-MED
paradoxus	I-MED
,	O
enhanced	B-MED
salt	B-MED
stress	I-MED
tolerance	B-MED
remarkably	O
in	O
sugar	B-MED
beet	I-MED
,	O
resulting	B-MED
in	I-MED
greater	B-MED
seed	B-MED
germination	I-MED
and	O
plant	B-MED
biomass	B-MED
,	O
higher	B-MED
photosynthetic	B-MED
capacity	B-MED
and	O
lower	B-MED
stress	B-MED
-	O
induced	B-MED
ethylene	B-MED
production	B-MED
at	O
different	B-MED
NaCl	B-MED
concentrations	B-MED
(	O
50	O
-	O
125	O
mM	O
)	O
.	O
These	O
results	B-MED
demonstrate	O
that	O
salinity	B-MED
-	O
adapted	B-MED
,	O
ACD	B-MED
-producing	O
bacteria	B-MED
isolated	B-MED
from	O
halophytes	B-MED
could	O
promote	B-MED
sugar	B-MED
beet	I-MED
growth	B-MED
under	O
saline	B-MED
stress	I-MED
conditions	I-MED
.	O
Graphene	B-MED
/	O
Nafion	B-MED
composite	B-MED
film	I-MED
modified	O
glassy	B-MED
carbon	B-MED
electrode	I-MED
for	O
simultaneous	B-MED
determination	B-MED
of	O
paracetamol	B-MED
,	O
aspirin	B-MED
and	O
caffeine	B-MED
in	O
pharmaceutical	B-MED
formulations	I-MED
A	O
graphene	B-MED
-	O
Nafion	B-MED
composite	B-MED
film	I-MED
was	O
fabricated	B-MED
on	O
the	O
glassy	B-MED
carbon	B-MED
electrode	I-MED
(	O
GR	B-MED
-	I-MED
NF	I-MED
/	I-MED
GCE	I-MED
)	O
,	O
and	O
used	O
for	O
simultaneous	B-MED
determination	B-MED
of	O
paracetamol	B-MED
(	O
PAR	B-MED
)	O
,	O
aspirin	B-MED
(	O
ASA	B-MED
)	O
and	O
caffeine	B-MED
(	O
CAF	B-MED
)	O
.	O
The	O
electrochemical	B-MED
behaviors	I-MED
of	O
PAR	B-MED
,	O
ASA	B-MED
and	O
CAF	B-MED
were	O
investigated	B-MED
by	O
cyclic	B-MED
voltammetry	I-MED
and	O
square	B-MED
-	I-MED
wave	I-MED
adsorptive	I-MED
anodic	I-MED
stripping	I-MED
voltammetry	I-MED
.	O
By	O
using	O
stripping	B-MED
one	O
for	O
simultaneous	B-MED
determination	B-MED
of	O
PAR	B-MED
,	O
ASA	B-MED
and	O
CAF	B-MED
,	O
their	O
electrochemical	B-MED
oxidation	I-MED
peaks	I-MED
appeared	B-MED
at	O
+0.64	O
,	O
1.04	O
and	O
1.44V	O
,	O
and	O
good	B-MED
linear	B-MED
current	I-MED
responses	I-MED
were	O
obtained	B-MED
with	O
the	O
detection	B-MED
limits	I-MED
of	O
18ngmL(-1	O
)	O
(	O
1.2×10(-9)M	O
)	O
,	O
11.7ngmL(-1	O
)	O
(	O
6.5×10(-8)M	O
)	O
and	O
7.3ngmL(-1	O
)	O
(	O
3.8×10(-8)M	O
)	O
,	O
respectively	O
.	O
Finally	O
,	O
the	O
proposed	B-MED
electrochemical	B-MED
sensor	I-MED
was	O
successfully	B-MED
applied	B-MED
for	O
quantifying	B-MED
PAR	B-MED
,	O
ASA	B-MED
and	O
CAF	B-MED
in	O
commercial	B-MED
tablet	B-MED
formulations	I-MED
.	O
Carbon	B-MED
Monoxide	I-MED
Improves	B-MED
Efficacy	B-MED
of	O
Mesenchymal	B-MED
Stromal	I-MED
Cells	I-MED
During	B-MED
Sepsis	B-MED
by	O
Production	O
of	O
Specialized	B-MED
Proresolving	B-MED
Lipid	B-MED
Mediators	I-MED
Mesenchymal	B-MED
stromal	I-MED
cells	I-MED
are	O
being	O
investigated	B-MED
as	O
a	O
cell	B-MED
-	I-MED
based	I-MED
therapy	I-MED
for	O
a	O
number	O
of	O
disease	B-MED
processes	I-MED
,	O
with	O
promising	O
results	B-MED
in	O
animal	B-MED
models	I-MED
of	O
systemic	B-MED
inflammation	I-MED
and	O
sepsis	B-MED
.	O
Studies	B-MED
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-MED
the	O
therapeutic	B-MED
potential	B-MED
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
.	O
A	O
gas	B-MED
molecule	B-MED
that	O
improves	B-MED
outcome	B-MED
in	O
experimental	B-MED
sepsis	B-MED
is	O
carbon	B-MED
monoxide	I-MED
.	O
We	O
hypothesized	O
that	O
preconditioning	B-MED
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
with	O
carbon	B-MED
monoxide	I-MED
ex	B-MED
vivo	I-MED
would	O
promote	B-MED
further	O
therapeutic	B-MED
benefit	B-MED
when	O
cells	B-MED
are	O
administered	B-MED
in	B-MED
vivo	I-MED
after	O
the	O
onset	B-MED
of	I-MED
polymicrobial	B-MED
sepsis	B-MED
in	O
mice	B-MED
.	O
Animal	B-MED
study	I-MED
and	O
primary	B-MED
cell	I-MED
culture	I-MED
.	O
Laboratory	B-MED
investigation	B-MED
.	O
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
.	O
Polymicrobial	B-MED
sepsis	B-MED
was	O
induced	B-MED
by	O
cecal	B-MED
ligation	B-MED
and	O
puncture	B-MED
.	O
Mesenchymal	B-MED
stromal	I-MED
cells	I-MED
,	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
-	O
conditioned	B-MED
with	O
carbon	B-MED
monoxide	I-MED
,	O
fibroblasts	B-MED
,	O
or	O
fibroblasts	B-MED
-	O
conditioned	B-MED
with	O
carbon	B-MED
monoxide	I-MED
were	O
delivered	B-MED
by	O
tail	B-MED
vein	I-MED
injections	B-MED
to	O
septic	B-MED
mice	B-MED
.	O
The	O
mice	B-MED
were	O
assessed	B-MED
for	O
survival	B-MED
,	O
bacterial	B-MED
clearance	B-MED
,	O
and	O
the	O
inflammatory	B-MED
response	I-MED
during	B-MED
sepsis	B-MED
in	O
each	O
of	O
the	O
groups	B-MED
.	O
Mesenchymal	B-MED
stromal	I-MED
cells	I-MED
were	O
also	O
assessed	B-MED
for	O
their	O
ability	B-MED
to	O
promote	B-MED
bacterial	B-MED
phagocytosis	B-MED
by	O
neutrophils	B-MED
,	O
the	O
production	O
of	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
,	O
and	O
their	O
importance	O
for	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
function	B-MED
using	O
gene	B-MED
silencing	I-MED
.	O
Ex	B-MED
vivo	I-MED
preconditioning	B-MED
with	O
carbon	B-MED
monoxide	I-MED
allowed	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
to	O
be	O
administered	B-MED
later	O
after	O
the	O
onset	B-MED
of	I-MED
sepsis	B-MED
(	O
6	O
hr	O
)	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	B-MED
effect	I-MED
with	O
increased	B-MED
survival	B-MED
.	O
Carbon	B-MED
monoxide	I-MED
preconditioned	B-MED
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
were	O
also	O
able	O
to	O
alleviate	O
organ	B-MED
injury	I-MED
,	O
improve	B-MED
bacterial	B-MED
clearance	B-MED
,	O
and	O
promote	B-MED
the	O
resolution	B-MED
of	O
inflammation	B-MED
.	O
Mesenchymal	B-MED
stromal	I-MED
cells	I-MED
exposed	B-MED
to	I-MED
carbon	B-MED
monoxide	I-MED
,	O
with	O
docosahexaenoic	B-MED
acid	I-MED
substrate	B-MED
,	O
produced	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
,	O
particularly	O
D	B-MED
-	I-MED
series	I-MED
resolvins	B-MED
,	O
which	O
promoted	B-MED
survival	B-MED
.	O
Silencing	B-MED
of	O
lipoxygenase	B-MED
pathways	I-MED
(	O
5	B-MED
-	I-MED
lipoxygenase	I-MED
and	O
12	B-MED
/	O
15	B-MED
-	I-MED
lipoxygenase	I-MED
)	O
,	O
which	O
are	O
important	B-MED
enzymes	B-MED
for	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediator	I-MED
biosynthesis	B-MED
,	O
resulted	B-MED
in	O
a	O
loss	O
of	O
therapeutic	B-MED
benefit	B-MED
bestowed	O
on	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
by	O
carbon	B-MED
monoxide	I-MED
.	O
Taken	O
together	O
,	O
these	O
data	B-MED
suggest	O
that	O
production	O
of	O
specialized	B-MED
proresolving	B-MED
lipid	B-MED
mediators	I-MED
contribute	B-MED
to	O
improved	B-MED
mesenchymal	B-MED
stromal	I-MED
cell	I-MED
efficacy	B-MED
when	O
exposed	B-MED
to	I-MED
carbon	B-MED
monoxide	I-MED
,	O
resulting	O
in	O
an	O
improved	B-MED
therapeutic	B-MED
response	I-MED
during	B-MED
sepsis	B-MED
.	O
Biliary	B-MED
Phospholipids	B-MED
Sustain	B-MED
Enterocyte	B-MED
Proliferation	B-MED
and	O
Intestinal	B-MED
Tumor	I-MED
Progression	B-MED
via	O
Nuclear	B-MED
Receptor	I-MED
Lrh1	B-MED
in	O
mice	B-MED
The	O
proliferative-	O
crypt	B-MED
compartment	I-MED
of	O
the	O
intestinal	B-MED
epithelium	I-MED
is	O
enriched	O
in	O
phospholipids	B-MED
and	O
accumulation	B-MED
of	O
phospholipids	B-MED
has	O
been	O
described	O
in	O
colorectal	B-MED
tumors	I-MED
.	O
Here	O
we	O
hypothesize	O
that	O
biliary	B-MED
phospholipid	B-MED
flow	B-MED
could	O
directly	O
contribute	O
to	O
the	O
proliferative	B-MED
power	I-MED
of	O
normal	B-MED
and	O
dysplastic	B-MED
enterocytes	I-MED
.	O
We	O
used	O
Abcb4	B-MED
(	O
-/-	O
)	O
mice	B-MED
which	O
lack	O
biliary	B-MED
phospholipid	B-MED
secretion	B-MED
.	O
We	O
first	O
show	O
that	O
Abcb4	B-MED
(	O
-/-	O
)	O
mice	B-MED
are	O
protected	B-MED
against	O
intestinal	B-MED
tumorigenesis	B-MED
.	O
At	O
the	O
molecular	B-MED
level	B-MED
,	O
the	O
transcriptional	B-MED
activity	I-MED
of	O
the	O
nuclear	B-MED
receptor	I-MED
Liver	B-MED
Receptor	I-MED
Homolog-1	I-MED
(	O
Lrh1	B-MED
)	O
is	O
reduced	B-MED
in	O
Abcb4	B-MED
(	O
-/-	O
)	O
mice	B-MED
and	O
its	O
re	B-MED
-	I-MED
activation	I-MED
re	O
-	O
establishes	O
a	O
tumor	B-MED
burden	B-MED
comparable	O
to	O
control	B-MED
mice	B-MED
.	O
Feeding	B-MED
Abcb4	B-MED
(	O
-/-	O
)	O
mice	B-MED
a	O
diet	B-MED
supplemented	I-MED
with	O
phospholipids	B-MED
completely	O
overcomes	B-MED
the	O
intestinal	B-MED
tumor	I-MED
protective	O
phenotype	B-MED
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	B-MED
of	O
biliary	B-MED
phospholipids	B-MED
and	O
not	O
lack	O
of	O
Abcb4	B-MED
gene	I-MED
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	B-MED
.	O
In	O
turn	O
,	O
phospholipids	B-MED
can	O
not	O
re	O
-	O
establish	O
intestinal	B-MED
tumorigenesis	B-MED
in	O
Abcb4	B-MED
(	O
-/-	O
)	O
mice	B-MED
crossed	O
with	O
mice	B-MED
with	O
intestinal	B-MED
specific	B-MED
ablation	B-MED
of	O
Lrh1	B-MED
,	O
a	O
nuclear	B-MED
hormone	I-MED
receptor	I-MED
that	O
is	O
activates	B-MED
by	O
phospholipids	B-MED
.	O
Our	O
data	B-MED
identify	O
the	O
key	O
role	O
of	O
biliary	B-MED
phospholipids	B-MED
in	O
sustaining	O
intestinal	B-MED
mucosa	I-MED
proliferation	B-MED
and	O
tumor	B-MED
progression	I-MED
through	O
the	O
activation	B-MED
of	O
nuclear	B-MED
receptor	I-MED
Lrh1	B-MED
.	O
Can	O
We	O
Predict	B-MED
Burnout	B-MED
among	O
Student	B-MED
Nurses	I-MED
?	O
An	O
Exploration	O
of	O
the	O
ICWR-1	B-MED
Model	I-MED
of	O
Individual	B-MED
Psychological	B-MED
Resilience	I-MED
The	O
nature	O
of	O
nursing	B-MED
work	I-MED
is	O
demanding	B-MED
and	O
can	O
be	O
stressful	B-MED
.	O
Previous	O
studies	O
have	O
shown	O
a	O
high	B-MED
rate	B-MED
of	O
burnout	B-MED
among	O
employed	B-MED
nurses	B-MED
.	O
Recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	B-MED
in	O
determining	O
the	O
psychological	B-MED
adjustment	I-MED
of	O
employed	B-MED
nurses	B-MED
.	O
A	O
theoretical	B-MED
model	I-MED
of	O
resilience	B-MED
was	O
proposed	O
recently	O
that	O
includes	B-MED
several	B-MED
constructs	B-MED
identified	O
in	O
the	O
literature	B-MED
related	O
to	O
resilience	B-MED
and	O
to	O
psychological	B-MED
functioning	I-MED
.	O
As	O
nursing	B-MED
students	I-MED
are	O
the	O
future	B-MED
of	O
the	O
nursing	B-MED
workforce	B-MED
it	O
is	O
important	B-MED
to	O
advance	B-MED
our	O
understanding	O
of	O
the	O
determinants	B-MED
of	O
resilience	B-MED
in	O
this	O
population	B-MED
.	O
Student	B-MED
nurses	I-MED
who	O
had	O
completed	B-MED
their	O
final	B-MED
practicum	B-MED
were	O
invited	O
to	O
participate	O
in	O
an	O
online	B-MED
survey	I-MED
measuring	B-MED
the	O
key	O
constructs	B-MED
of	O
the	O
ICWR-1	B-MED
model	I-MED
.	O
422	O
students	B-MED
from	O
across	O
Australia	B-MED
and	O
Canada	B-MED
completed	B-MED
the	O
survey	B-MED
between	O
July	O
2014	O
and	O
July	O
2015	O
.	O
As	O
well	O
as	O
several	B-MED
key	O
demographics	B-MED
,	O
trait	B-MED
negative	I-MED
affect	I-MED
,	O
mindfulness	B-MED
,	O
self	B-MED
-	I-MED
efficacy	I-MED
,	O
coping	B-MED
,	O
resilience	B-MED
,	O
and	O
burnout	B-MED
were	O
measured	B-MED
.	O
We	O
used	O
structural	B-MED
equation	I-MED
modeling	I-MED
and	O
found	O
support	O
for	O
the	O
major	B-MED
pathways	B-MED
of	O
the	O
model	B-MED
;	O
namely	O
that	O
resilience	B-MED
had	O
a	O
significant	B-MED
influence	B-MED
on	O
the	O
relationship	B-MED
between	O
mindfulness	B-MED
,	O
self	B-MED
-	I-MED
efficacy	I-MED
and	O
coping	B-MED
,	O
and	O
psychological	B-MED
adjustment	I-MED
(	O
burnout	B-MED
scores	B-MED
)	O
.	O
Furthermore	O
,	O
as	O
predicted	B-MED
,	O
Neuroticism	B-MED
moderated	O
the	O
relationship	B-MED
between	O
coping	B-MED
and	O
burnout	B-MED
.	O
Results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	B-MED
approaches	B-MED
to	O
supporting	O
nursing	B-MED
students	I-MED
who	O
may	O
be	O
at	B-MED
risk	I-MED
of	O
burnout	B-MED
.	O
Treatment	B-MED
of	O
Carcinoma	B-MED
In	I-MED
Situ	I-MED
of	I-MED
the	I-MED
Glans	I-MED
Penis	I-MED
With	O
Topical	B-MED
Imiquimod	I-MED
Followed	O
by	O
Carbon	B-MED
Dioxide	I-MED
Laser	I-MED
Excision	B-MED
Different	B-MED
approaches	B-MED
have	O
been	O
described	B-MED
in	O
published	O
studies	O
for	O
carcinoma	B-MED
in	I-MED
situ	I-MED
(	I-MED
CIS	I-MED
)	I-MED
of	I-MED
the	I-MED
glans	I-MED
penis	I-MED
(	O
erythroplasia	B-MED
of	I-MED
Queyrat	I-MED
)	O
,	O
including	B-MED
topical	B-MED
chemotherapy	I-MED
or	O
immunotherapy	B-MED
and	O
laser	B-MED
or	O
surgical	B-MED
excision	I-MED
.	O
We	O
evaluated	B-MED
the	O
efficacy	B-MED
of	O
topical	B-MED
imiquimod	I-MED
(	O
IQ	B-MED
)	O
followed	O
by	O
carbon	B-MED
dioxide	I-MED
laser	I-MED
ablation	B-MED
of	O
the	O
lesion	B-MED
.	O
From	O
2010	O
to	O
2015	O
,	O
10	O
patients	B-MED
affected	I-MED
by	O
CIS	B-MED
of	O
the	O
glans	B-MED
were	O
treated	B-MED
by	O
IQ	B-MED
,	O
followed	O
by	O
carbon	B-MED
dioxide	I-MED
laser	I-MED
ablation	B-MED
.	O
For	O
every	O
patient	B-MED
,	O
we	O
performed	B-MED
histologic	B-MED
examination	I-MED
before	B-MED
and	O
after	B-MED
IQ	B-MED
.	O
Local	O
toxicity	B-MED
and	O
adverse	B-MED
effects	I-MED
were	O
recorded	O
.	O
After	B-MED
treatment	I-MED
,	O
histologic	B-MED
examination	I-MED
showed	O
no	B-MED
residual	I-MED
tumor	I-MED
in	O
6	O
patients	B-MED
(	O
complete	B-MED
response	I-MED
[	O
CR	B-MED
]	O
)	O
,	O
stable	B-MED
disease	I-MED
in	O
2	O
patients	B-MED
,	O
and	O
progressive	B-MED
disease	I-MED
in	O
2	O
patients	B-MED
.	O
Those	O
with	O
a	O
CR	B-MED
had	O
human	B-MED
papillomavirus	I-MED
-	O
related	B-MED
lesions	B-MED
,	O
and	O
they	O
had	O
no	B-MED
experienced	O
relapses	B-MED
after	B-MED
a	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
of	O
26	O
months	B-MED
.	O
The	O
2	O
patients	B-MED
with	O
progressive	B-MED
disease	I-MED
underwent	O
total	O
penectomy	B-MED
.	O
All	O
patients	B-MED
were	O
alive	B-MED
at	O
the	O
last	O
follow	B-MED
-	I-MED
up	I-MED
examination	I-MED
.	O
All	O
patients	B-MED
experienced	O
a	O
mild	B-MED
local	O
toxicity	B-MED
(	O
burning	B-MED
erythema	I-MED
)	O
but	O
no	B-MED
major	B-MED
adverse	B-MED
effects	I-MED
.	O
Local	O
treatment	B-MED
with	O
IQ	B-MED
for	O
glans	B-MED
CIS	B-MED
is	O
effective	B-MED
mainly	O
for	O
human	B-MED
papillomavirus	I-MED
-	O
related	B-MED
lesions	B-MED
.	O
The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-MED
examination	I-MED
findings	O
before	B-MED
and	O
after	B-MED
IQ	B-MED
treatment	B-MED
.	O
The	O
small	O
number	O
of	O
patients	B-MED
,	O
owing	O
to	O
the	O
rarity	B-MED
of	O
this	O
disease	B-MED
,	O
was	O
the	O
main	O
limitation	B-MED
of	O
the	O
present	O
study	O
.	O
IQ	B-MED
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow	B-MED
-	I-MED
up	I-MED
protocol	B-MED
is	O
mandatory	B-MED
because	O
of	O
the	O
lack	B-MED
of	O
long	B-MED
-	I-MED
term	I-MED
efficacy	B-MED
data	O
.	O
BEST	B-MED
:	O
Next	B-MED
-	I-MED
Generation	I-MED
Biomedical	B-MED
Entity	I-MED
Search	I-MED
Tool	I-MED
for	O
Knowledge	B-MED
Discovery	B-MED
from	O
Biomedical	B-MED
Literature	I-MED
As	O
the	O
volume	B-MED
of	O
publications	B-MED
rapidly	B-MED
increases	B-MED
,	O
searching	B-MED
for	O
relevant	B-MED
information	B-MED
from	O
the	O
literature	B-MED
becomes	O
more	O
challenging	B-MED
.	O
To	O
complement	O
standard	B-MED
search	B-MED
engines	I-MED
such	O
as	O
PubMed	B-MED
,	O
it	O
is	O
desirable	B-MED
to	O
have	O
an	O
advanced	B-MED
search	I-MED
tool	I-MED
that	O
directly	B-MED
returns	B-MED
relevant	B-MED
biomedical	B-MED
entities	B-MED
such	O
as	O
targets	B-MED
,	O
drugs	B-MED
,	O
and	O
mutations	B-MED
rather	O
than	O
a	O
long	O
list	O
of	O
articles	O
.	O
Some	O
existing	B-MED
tools	B-MED
submit	B-MED
a	O
query	B-MED
to	O
PubMed	B-MED
and	O
process	B-MED
retrieved	O
abstracts	B-MED
to	O
extract	O
information	B-MED
at	O
query	B-MED
time	B-MED
,	O
resulting	B-MED
in	O
a	O
slow	B-MED
response	O
time	B-MED
and	O
limited	B-MED
coverage	B-MED
of	O
only	O
a	O
fraction	B-MED
of	I-MED
the	O
PubMed	B-MED
corpus	I-MED
.	O
Other	O
tools	B-MED
preprocess	B-MED
the	O
PubMed	B-MED
corpus	I-MED
to	O
speed	O
up	O
the	O
response	O
time	B-MED
;	O
however	O
,	O
they	O
are	O
not	O
constantly	B-MED
updated	B-MED
,	O
and	O
thus	O
produce	B-MED
outdated	B-MED
results	B-MED
.	O
Further	O
,	O
most	O
existing	O
tools	B-MED
can	O
not	O
process	B-MED
sophisticated	B-MED
queries	B-MED
such	O
as	O
searches	B-MED
for	O
mutations	B-MED
that	O
co	B-MED
-	I-MED
occur	I-MED
with	O
query	B-MED
terms	O
in	O
the	O
literature	B-MED
.	O
To	O
address	O
these	O
problems	B-MED
,	O
we	O
introduce	B-MED
BEST	B-MED
,	O
a	O
biomedical	B-MED
entity	I-MED
search	I-MED
tool	I-MED
.	O
BEST	B-MED
returns	B-MED
,	O
as	O
a	O
result	B-MED
,	O
a	O
list	O
of	O
10	O
different	B-MED
types	O
of	O
biomedical	B-MED
entities	B-MED
including	B-MED
genes	B-MED
,	O
diseases	B-MED
,	O
drugs	B-MED
,	O
targets	B-MED
,	O
transcription	B-MED
factors	I-MED
,	O
miRNAs	B-MED
,	O
and	O
mutations	B-MED
that	O
are	O
relevant	B-MED
to	O
a	O
user	O
's	O
query	B-MED
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	B-MED
,	O
BEST	B-MED
is	O
the	O
only	O
system	B-MED
that	O
processes	B-MED
free	O
text	B-MED
queries	B-MED
and	O
returns	B-MED
up	B-MED
-	I-MED
to	I-MED
-	I-MED
date	I-MED
results	B-MED
in	O
real	B-MED
time	I-MED
including	B-MED
mutation	B-MED
information	B-MED
in	O
the	O
results	B-MED
.	O
BEST	B-MED
is	O
freely	O
accessible	O
at	O
http://best.korea.ac.kr	O
.	O
Radiation	B-MED
-	O
induced	B-MED
Parotid	B-MED
Gland	I-MED
Atrophy	I-MED
in	O
Patients	B-MED
with	O
Head	B-MED
and	I-MED
Neck	I-MED
Cancer	I-MED
After	O
Carbon	B-MED
-	I-MED
ion	I-MED
Radiotherapy	I-MED
This	O
study	B-MED
aimed	O
to	O
clarify	B-MED
the	O
relationship	B-MED
between	O
dosimetric	B-MED
factors	B-MED
and	O
parotid	B-MED
gland	I-MED
(	I-MED
PG	I-MED
)	I-MED
atrophy	I-MED
after	O
carbon	B-MED
ion	I-MED
radiotherapy	I-MED
(	O
C	B-MED
-	I-MED
ion	I-MED
RT	I-MED
)	O
.	O
Fifty	O
-	O
four	O
patients	B-MED
with	O
head	B-MED
and	I-MED
neck	I-MED
tumours	I-MED
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	B-MED
were	O
analyzed	O
.	O
Thirty	O
and	O
24	O
patients	B-MED
were	O
treated	B-MED
with	I-MED
total	B-MED
doses	I-MED
[	O
relative	B-MED
biological	I-MED
effectiveness	I-MED
(	O
RBE	B-MED
)	O
]	O
of	O
57.6	O
Gy	O
and	O
64.0	O
Gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O
PG	B-MED
volumes	B-MED
were	O
measured	B-MED
using	O
computed	B-MED
tomographic	I-MED
images	I-MED
obtained	O
before	O
C	B-MED
-	I-MED
ion	I-MED
RT	I-MED
and	O
every	O
3	O
-	O
6	O
months	B-MED
thereafter	O
.	O
The	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
was	O
46.4	O
months	B-MED
(	O
range	B-MED
=	O
24.0	O
-	O
123.0	O
months	B-MED
)	O
.	O
Univariate	B-MED
analysis	I-MED
showed	O
that	O
PG	B-MED
volumes	B-MED
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
Gy	O
RBE	B-MED
(	O
V5	B-MED
,	O
V10	B-MED
,	O
V15	B-MED
and	O
V20	B-MED
,	O
respectively	O
)	O
,	O
mean	B-MED
dose	B-MED
,	O
and	O
maximum	B-MED
dose	B-MED
were	O
significantly	O
associated	B-MED
with	I-MED
PG	B-MED
atrophy	I-MED
.	O
Multivariate	B-MED
analysis	I-MED
indicated	O
that	O
only	O
V5	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
atrophy	B-MED
.	O
Increasing	B-MED
V5	B-MED
was	O
a	O
significant	O
risk	B-MED
factor	I-MED
for	O
PG	B-MED
atrophy	I-MED
after	O
C	B-MED
-	I-MED
ion	I-MED
RT	I-MED
.	O
The	O
impact	B-MED
of	O
childhood	B-MED
maltreatment	I-MED
on	O
the	O
differential	B-MED
efficacy	B-MED
of	O
CBASP	B-MED
versus	O
escitalopram	B-MED
in	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
:	O
A	O
secondary	B-MED
analysis	I-MED
Childhood	B-MED
maltreatment	I-MED
(	O
CM	B-MED
)	O
has	O
been	O
indicated	B-MED
as	O
a	O
predictor	B-MED
of	O
a	O
differential	B-MED
response	B-MED
to	O
antidepressant	B-MED
treatment	I-MED
with	O
psychotherapy	B-MED
compared	B-MED
to	O
medication	B-MED
.	O
In	O
this	O
secondary	B-MED
analysis	I-MED
,	O
we	O
investigated	B-MED
whether	O
the	O
presence	B-MED
of	O
CM	B-MED
results	B-MED
in	O
a	O
differential	B-MED
indication	B-MED
for	O
the	O
Cognitive	B-MED
Behavioral	I-MED
Analysis	I-MED
System	I-MED
of	I-MED
Psychotherapy	I-MED
(	O
CBASP	B-MED
)	O
or	O
escitalopram	B-MED
plus	O
clinical	B-MED
management	I-MED
(	O
ESC	B-MED
)	O
.	O
Sixty	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
were	O
randomized	B-MED
to	O
either	O
22	O
sessions	B-MED
of	O
CBASP	B-MED
or	O
ESC	B-MED
over	O
the	O
course	B-MED
of	O
8	B-MED
weeks	I-MED
of	O
acute	B-MED
and	O
20	B-MED
weeks	I-MED
of	O
extended	B-MED
treatment	B-MED
at	O
2	O
German	B-MED
treatment	B-MED
sites	I-MED
.	O
CM	B-MED
was	O
assessed	B-MED
using	O
the	O
Childhood	B-MED
Trauma	B-MED
Questionnaire	B-MED
and	O
the	O
clinician	B-MED
rated	B-MED
Early	B-MED
Trauma	I-MED
Inventory	I-MED
.	O
Intention	B-MED
-	I-MED
to	I-MED
-	I-MED
treat	I-MED
analyses	I-MED
were	O
used	O
to	O
examine	O
the	O
impact	B-MED
of	O
CM	B-MED
on	O
depression	B-MED
,	O
global	B-MED
functioning	I-MED
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
.	O
The	O
presence	B-MED
of	O
CM	B-MED
did	O
not	O
result	B-MED
in	O
significant	B-MED
differences	B-MED
in	O
treatment	B-MED
response	I-MED
to	O
CBASP	B-MED
or	O
ESC	B-MED
on	O
any	O
outcome	B-MED
measure	I-MED
after	O
28	B-MED
weeks	I-MED
of	O
treatment	B-MED
independent	B-MED
of	I-MED
the	O
type	O
of	O
CM	B-MED
assessment	B-MED
.	O
After	O
8	B-MED
weeks	I-MED
,	O
a	O
significant	B-MED
CM	B-MED
×	O
treatment	B-MED
interaction	B-MED
was	O
found	B-MED
for	O
scores	B-MED
on	O
the	O
Montgomery	B-MED
-	I-MED
Asberg	I-MED
Depression	I-MED
Rating	I-MED
Scale	I-MED
.	O
Patients	B-MED
with	O
a	O
history	B-MED
of	O
CM	B-MED
receiving	B-MED
CBASP	B-MED
had	O
a	O
significantly	B-MED
lower	I-MED
response	B-MED
rate	I-MED
compared	B-MED
to	O
patients	B-MED
without	O
CM	B-MED
and	O
to	O
those	O
receiving	B-MED
ESC	B-MED
after	O
8	B-MED
weeks	I-MED
.	O
Conclusively	B-MED
,	O
CBASP	B-MED
and	O
ESC	B-MED
are	O
equally	O
effective	B-MED
treatment	B-MED
options	O
for	O
the	O
difficult	B-MED
to	O
treat	B-MED
subgroup	B-MED
of	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
and	O
a	O
history	B-MED
of	O
CM	B-MED
.	O
CM	B-MED
may	O
be	O
a	O
predictor	B-MED
of	O
a	O
longer	B-MED
latency	B-MED
of	O
treatment	B-MED
response	I-MED
in	O
the	O
case	B-MED
of	O
psychotherapy	B-MED
.	O
CBASP	B-MED
and	O
escitalopram	B-MED
are	O
equally	O
effective	B-MED
treatment	B-MED
options	O
for	O
chronic	B-MED
depression	I-MED
.	O
Both	O
treatments	B-MED
are	O
also	O
equally	O
effective	B-MED
for	O
the	O
difficult	B-MED
to	O
treat	B-MED
subgroup	B-MED
of	O
patients	B-MED
with	O
chronic	B-MED
depression	I-MED
and	O
a	O
history	B-MED
of	O
childhood	B-MED
maltreatment	I-MED
.	O
Childhood	B-MED
maltreatment	I-MED
may	O
result	B-MED
in	O
a	O
longer	B-MED
latency	B-MED
of	O
treatment	B-MED
response	I-MED
in	O
the	O
case	B-MED
of	O
psychotherapy	B-MED
.	O
Calibration	B-MED
of	O
Self	B-MED
-	I-MED
Report	I-MED
Measures	B-MED
of	O
Physical	B-MED
Activity	I-MED
and	O
Sedentary	B-MED
Behavior	I-MED
Calibration	B-MED
equations	B-MED
offer	O
potential	B-MED
to	O
improve	B-MED
the	O
accuracy	B-MED
and	O
utility	O
of	O
self	B-MED
-	I-MED
report	I-MED
measures	B-MED
of	O
physical	B-MED
activity	I-MED
(	O
PA	B-MED
)	O
and	O
sedentary	B-MED
behavior	I-MED
(	O
SB	B-MED
)	O
by	O
re	B-MED
-	I-MED
scaling	I-MED
potentially	B-MED
biased	O
estimates	B-MED
.	O
The	O
present	O
study	O
evaluates	O
calibration	B-MED
models	B-MED
designed	O
to	O
estimate	B-MED
PA	B-MED
and	O
SB	B-MED
in	O
a	O
representative	B-MED
sample	O
of	O
adults	B-MED
from	O
the	O
Physical	B-MED
Activity	I-MED
Measurement	B-MED
Survey	I-MED
(	O
PAMS	B-MED
)	O
.	O
Participants	B-MED
in	O
the	O
PAMS	B-MED
project	O
completed	O
replicate	O
single	O
day	O
trials	B-MED
that	O
involved	O
wearing	O
a	O
Sensewear	B-MED
armband	I-MED
(	I-MED
SWA	I-MED
)	I-MED
monitor	B-MED
for	O
24	B-MED
hours	I-MED
followed	O
by	O
a	O
telephone	B-MED
administered	B-MED
24	O
-	O
hour	O
physical	B-MED
activity	I-MED
recall	I-MED
(	O
PAR	B-MED
)	O
.	O
Comprehensive	O
statistical	B-MED
model	I-MED
selection	O
and	O
validation	B-MED
procedures	B-MED
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	B-MED
models	B-MED
designed	O
to	O
predict	B-MED
objectively	B-MED
-	O
measured	B-MED
SB	B-MED
and	O
moderate	B-MED
to	I-MED
vigorous	I-MED
PA	I-MED
(	O
MVPA	B-MED
from	O
self	B-MED
-	I-MED
reported	I-MED
PAR	B-MED
data	O
.	O
Equivalence	B-MED
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	B-MED
of	O
the	O
model-	O
predicted	B-MED
values	O
with	O
the	O
objective	B-MED
measures	B-MED
in	O
a	O
separate	O
holdout	O
sample	O
.	O
The	O
final	O
prediction	O
model	O
for	O
both	O
SB	B-MED
and	O
MVPA	B-MED
included	O
reported	O
time	O
spent	O
in	O
SB	B-MED
and	O
MVPA	B-MED
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	B-MED
,	O
age	B-MED
,	O
education	B-MED
,	O
and	O
BMI	B-MED
.	O
Cross	B-MED
-	I-MED
validation	I-MED
analyses	B-MED
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
SB	B-MED
(	O
r	O
=	O
0.72	O
)	O
and	O
MVPA	B-MED
(	O
r	O
=	O
0.75	O
)	O
.	O
Equivalence	B-MED
testing	O
demonstrated	O
that	O
the	O
model-	O
predicted	B-MED
values	O
were	O
statistically	B-MED
equivalent	O
to	O
the	O
corresponding	O
objective	B-MED
values	O
for	O
both	O
SB	B-MED
and	O
MVPA	B-MED
.	O
The	O
results	O
demonstrate	O
that	O
simple	O
regression	B-MED
models	B-MED
can	O
be	O
used	O
to	O
statistically	B-MED
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self	B-MED
-	I-MED
report	I-MED
measures	B-MED
among	O
different	O
segments	O
of	O
the	O
population	B-MED
.	O
The	O
models	B-MED
produced	O
group	O
estimates	B-MED
from	O
the	O
PAR	B-MED
that	O
were	O
statistically	B-MED
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
SB	B-MED
and	O
MVPA	B-MED
obtained	O
from	O
the	O
objective	O
SWA	B-MED
monitor	B-MED
;	O
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	B-MED
of	O
individual	B-MED
behavior	I-MED
.	O
Assessment	B-MED
of	O
neuroanatomical	B-MED
and	O
behavioural	B-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
methylmercury	B-MED
exposure	B-MED
in	O
zebra	B-MED
finches	I-MED
(	O
Taeniopygia	B-MED
guttata	I-MED
)	O
Methylmercury	B-MED
(	O
MeHg	B-MED
)	O
readily	O
crosses	B-MED
the	O
blood	B-MED
brain	I-MED
barrier	I-MED
and	O
is	O
a	O
known	B-MED
neuro	B-MED
-	O
toxicant	B-MED
.	O
MeHg	B-MED
accumulation	B-MED
in	O
the	O
brain	B-MED
causes	B-MED
histopathological	B-MED
alterations	B-MED
,	O
neurobehavioral	B-MED
changes	B-MED
,	O
and	O
impairments	B-MED
to	O
cognitive	B-MED
motor	B-MED
functions	I-MED
in	O
mammalian	B-MED
models	B-MED
.	O
However	O
,	O
in	O
birds	B-MED
the	O
neurotoxic	B-MED
effects	I-MED
of	O
MeHg	B-MED
on	O
the	O
developing	O
pre	B-MED
-	O
hatching	B-MED
brain	B-MED
and	O
consequent	B-MED
behavioral	B-MED
alterations	I-MED
in	O
adult	B-MED
birds	B-MED
have	O
not	B-MED
received	B-MED
much	O
attention	B-MED
.	O
Moreover	O
,	O
passerine	B-MED
birds	I-MED
are	O
poorly	B-MED
represented	B-MED
in	O
MeHg	B-MED
neurotoxicology	B-MED
studies	B-MED
in	O
comparison	B-MED
to	O
other	O
avian	B-MED
orders	B-MED
.	O
Hence	O
in	O
this	O
study	B-MED
,	O
we	O
used	B-MED
the	O
egg	B-MED
injection	B-MED
method	I-MED
to	O
investigate	B-MED
the	O
long	B-MED
term	I-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
MeHg	B-MED
exposure	B-MED
on	O
brain	B-MED
histopathology	B-MED
and	O
courtship	B-MED
behavior	I-MED
in	O
a	O
model	B-MED
songbird	B-MED
species	B-MED
,	O
the	O
zebra	B-MED
finch	I-MED
(	O
Taeniopygia	B-MED
guttata	I-MED
)	O
.	O
Egg	B-MED
treatment	B-MED
groups	B-MED
included	B-MED
:	O
a	O
low	B-MED
MeHg	B-MED
dose	B-MED
of	O
0.2μg	O
Hg	B-MED
g(-1	O
)	O
egg	B-MED
,	O
a	O
high	B-MED
MeHg	B-MED
dose	B-MED
of	O
3.2μg	O
Hg	B-MED
g(-1	O
)	O
egg	B-MED
,	O
and	O
a	O
vehicle	B-MED
control	I-MED
(	O
water	B-MED
)	O
.	O
No	B-MED
adverse	I-MED
effects	I-MED
of	O
in	B-MED
ovo	I-MED
MeHg	B-MED
treatment	B-MED
were	O
detected	B-MED
on	O
courtship	B-MED
courtship	B-MED
song	I-MED
quality	I-MED
or	O
on	O
mating	B-MED
behavior	I-MED
in	O
experimental	B-MED
males	B-MED
at	O
sexually	B-MED
maturity	I-MED
which	O
would	O
suggest	B-MED
that	O
observable	B-MED
neurobehavioral	B-MED
effects	I-MED
of	O
MeHg	B-MED
exposure	B-MED
may	O
depend	O
on	O
the	O
timing	B-MED
of	O
exposure	B-MED
during	B-MED
offspring	B-MED
development	B-MED
.	O
However	O
,	O
neuroanatomical	B-MED
analysis	B-MED
indicated	B-MED
an	O
increase	B-MED
in	O
telencephalon	B-MED
volume	B-MED
with	O
increased	B-MED
MeHg	B-MED
concentrations	B-MED
which	O
may	O
suggest	B-MED
a	O
prolonged	B-MED
inflammatory	B-MED
response	I-MED
in	O
this	O
region	B-MED
of	I-MED
the	I-MED
brain	I-MED
.	O
Engineering	B-MED
and	O
In	B-MED
Vivo	I-MED
Applications	B-MED
of	O
Riboswitches	B-MED
Riboswitches	B-MED
are	O
common	B-MED
gene	B-MED
regulatory	I-MED
units	I-MED
mostly	O
found	O
in	O
bacteria	B-MED
that	O
are	O
capable	B-MED
of	O
altering	B-MED
gene	B-MED
expression	I-MED
in	O
response	B-MED
to	O
a	O
small	B-MED
molecule	I-MED
.	O
These	O
structured	B-MED
RNA	I-MED
elements	I-MED
consist	O
of	O
two	O
modular	B-MED
subunits	B-MED
:	O
an	O
aptamer	B-MED
domain	I-MED
that	O
binds	B-MED
with	O
high	B-MED
specificity	B-MED
and	O
affinity	B-MED
to	O
a	O
target	B-MED
ligand	B-MED
and	O
an	O
expression	B-MED
platform	O
that	O
transduces	B-MED
ligand	B-MED
binding	I-MED
to	O
a	O
gene	B-MED
expression	I-MED
output	O
.	O
Significant	B-MED
progress	B-MED
has	O
been	O
made	O
in	O
engineering	B-MED
novel	B-MED
aptamer	B-MED
domains	I-MED
for	O
new	B-MED
small	B-MED
molecule	I-MED
inducers	B-MED
of	O
gene	B-MED
expression	I-MED
.	O
Modified	B-MED
expression	B-MED
platforms	O
have	O
also	O
been	O
optimized	B-MED
to	O
function	B-MED
when	O
fused	B-MED
with	O
both	O
natural	B-MED
and	O
synthetic	B-MED
aptamer	B-MED
domains	I-MED
.	O
As	O
this	O
field	B-MED
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	B-MED
scaffolds	B-MED
has	O
permitted	O
the	O
development	B-MED
of	O
tools	B-MED
such	O
as	O
RNA	B-MED
-based	O
fluorescent	B-MED
biosensors	B-MED
.	O
In	O
this	O
review	B-MED
,	O
we	O
summarize	B-MED
the	O
methods	B-MED
that	O
have	O
been	O
developed	O
to	O
engineer	B-MED
new	O
riboswitches	B-MED
and	O
highlight	O
applications	B-MED
of	O
natural	B-MED
and	O
synthetic	B-MED
riboswitches	B-MED
in	O
enzyme	B-MED
and	O
strain	B-MED
engineering	I-MED
,	O
in	O
controlling	O
gene	B-MED
expression	I-MED
and	O
cellular	B-MED
physiology	I-MED
,	O
and	O
in	O
real	B-MED
-	I-MED
time	I-MED
imaging	I-MED
of	O
cellular	B-MED
metabolites	I-MED
and	O
signals	B-MED
.	O
Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20	O
,	O
2017	O
.	O
Please	O
see	O
http://www.annualreviews.org/page/journal/pubdates	O
for	O
revised	O
estimates	O
.	O
Cocaine	B-MED
Use	B-MED
Reverses	B-MED
Striatal	B-MED
Plasticity	I-MED
Produced	B-MED
During	B-MED
Cocaine	B-MED
Seeking	O
Relapse	B-MED
is	O
a	O
two	B-MED
-	O
component	B-MED
process	B-MED
consisting	O
of	O
a	O
highly	B-MED
motivated	B-MED
drug	O
-	O
seeking	O
phase	B-MED
that	O
,	O
if	O
successful	O
,	O
is	O
followed	B-MED
by	I-MED
a	O
drug	B-MED
-	I-MED
using	I-MED
phase	B-MED
resulting	B-MED
in	I-MED
temporary	B-MED
satiation	B-MED
.	O
In	O
rodents	B-MED
,	O
cue	O
-	O
induced	O
drug	O
seeking	O
requires	B-MED
transient	B-MED
synaptic	I-MED
potentiation	I-MED
(	O
t	B-MED
-	I-MED
SP	I-MED
)	O
of	O
cortical	B-MED
glutamatergic	I-MED
synapses	I-MED
on	O
nucleus	B-MED
accumbens	I-MED
core	B-MED
medium	B-MED
spiny	I-MED
neurons	I-MED
,	O
but	O
it	O
is	O
unknown	B-MED
how	O
achieving	O
drug	B-MED
use	I-MED
affects	B-MED
this	O
plasticity	B-MED
.	O
We	O
modeled	B-MED
the	O
two	O
phases	B-MED
of	O
relapse	B-MED
after	O
extinction	B-MED
from	O
cocaine	B-MED
self	B-MED
-	I-MED
administration	I-MED
to	O
assess	B-MED
how	O
cocaine	B-MED
use	O
affects	B-MED
t	B-MED
-	I-MED
SP	I-MED
associated	B-MED
with	I-MED
cue	O
-	O
induced	O
drug	O
seeking	O
.	O
Rats	B-MED
were	O
trained	O
to	O
self	B-MED
-	I-MED
administer	I-MED
cocaine	B-MED
(	O
n	O
=	O
96	O
)	O
or	O
were	O
used	O
as	O
yoked	B-MED
-	O
saline	B-MED
control	B-MED
animals	I-MED
(	O
n	O
=	O
21	O
)	O
.	O
After	O
extinction	B-MED
,	O
reinstatement	B-MED
was	O
initiated	B-MED
by	O
10	O
minutes	B-MED
of	O
cue	O
-	O
induced	O
drug	O
seeking	O
,	O
followed	B-MED
by	I-MED
45	O
minutes	B-MED
with	O
contingent	B-MED
cocaine	B-MED
access	B-MED
,	O
after	O
which	O
cocaine	B-MED
was	O
discontinued	B-MED
and	O
unreinforced	B-MED
lever	I-MED
pressing	I-MED
ensued	I-MED
.	O
Three	B-MED
measures	B-MED
of	O
t	B-MED
-	I-MED
SP	I-MED
were	O
assayed	B-MED
during	B-MED
reinstatement	B-MED
:	O
dendritic	B-MED
spine	I-MED
morphology	B-MED
,	O
alpha	B-MED
-	I-MED
amino-3	I-MED
-	I-MED
hydroxy-5	I-MED
-	I-MED
methyl-4	I-MED
-	I-MED
isoxazole	I-MED
propionic	I-MED
acid	I-MED
(	O
AMPA	B-MED
)	O
to	O
N	B-MED
-	I-MED
methyl	I-MED
-	I-MED
D	I-MED
-	I-MED
aspartate	I-MED
(	O
NMDA	B-MED
)	O
ratios	B-MED
,	O
and	O
matrix	B-MED
metalloproteinase	I-MED
activity	B-MED
.	O
We	O
found	B-MED
that	O
cocaine	B-MED
use	O
for	O
10	O
minutes	B-MED
collapsed	B-MED
all	O
three	B-MED
measures	B-MED
of	O
cue	O
-	O
potentiated	O
t	B-MED
-	I-MED
SP	I-MED
back	O
to	O
baseline	B-MED
.	O
Moreover	O
,	O
when	O
cocaine	B-MED
use	O
was	O
discontinued	B-MED
45	O
minutes	B-MED
later	O
,	O
dendritic	B-MED
spine	I-MED
morphology	B-MED
and	O
AMPA	B-MED
to	O
NMDA	B-MED
ratios	B-MED
were	O
restored	O
as	O
animals	B-MED
became	O
motivated	B-MED
to	O
engage	O
unrewarded	O
lever	B-MED
pressing	I-MED
.	O
Nonreinforced	O
drug	O
seeking	O
was	O
positively	B-MED
correlated	B-MED
with	O
changes	B-MED
in	O
spine	B-MED
morphology	B-MED
,	O
and	O
cocaine	B-MED
access	B-MED
reversed	B-MED
this	O
relationship	B-MED
.	O
Using	O
a	O
novel	B-MED
modification	B-MED
of	O
the	O
reinstatement	B-MED
paradigm	B-MED
,	O
we	O
show	O
that	O
achieving	O
cocaine	B-MED
use	O
reversed	B-MED
the	O
synaptic	B-MED
plasticity	I-MED
underpinning	O
the	O
motivation	B-MED
to	O
seek	O
the	O
drug	B-MED
.	O
Sella	B-MED
turcica	I-MED
bridging	I-MED
and	O
dental	B-MED
anomalies	I-MED
:	O
is	O
there	O
an	O
association	B-MED
?	O
Sella	B-MED
turcica	I-MED
bridging	I-MED
(	O
STB	B-MED
)	O
,	O
or	O
calcification	B-MED
of	O
the	O
interclinoid	B-MED
ligament	I-MED
of	O
sella	B-MED
turcica	I-MED
,	O
has	O
been	O
reported	O
to	O
be	O
associated	B-MED
with	I-MED
some	O
dental	B-MED
anomalies	I-MED
(	O
palatal	B-MED
canine	I-MED
impaction	B-MED
and	O
transposition	B-MED
)	O
.	O
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
find	O
any	O
association	B-MED
between	O
canine	B-MED
impaction	B-MED
,	O
hyperdontia	B-MED
or	O
hypodontia	B-MED
and	O
sellar	B-MED
dimensions	B-MED
or	O
bridging	B-MED
.	O
Lateral	B-MED
cephalometric	B-MED
radiographs	B-MED
from	O
78	O
patients	B-MED
with	O
impacted	B-MED
canines	B-MED
,	O
68	O
with	O
dental	B-MED
agenesis	I-MED
and	O
17	O
with	O
hyperdontia	B-MED
were	O
collected	O
.	O
Linear	B-MED
dimensions	B-MED
of	O
sella	B-MED
turcica	I-MED
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	B-MED
group	I-MED
(	O
47	O
individuals	B-MED
)	O
.	O
A	O
standardize	B-MED
scoring	I-MED
scale	I-MED
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	B-MED
from	O
each	O
radiographs	B-MED
.	O
The	O
frequency	B-MED
of	O
partial	B-MED
and	O
complete	B-MED
calcifications	B-MED
of	O
sella	B-MED
in	O
patients	B-MED
with	O
dental	B-MED
anomalies	I-MED
is	O
increased	B-MED
when	O
compared	O
to	O
controls	B-MED
.	O
STB	B-MED
can	O
influence	O
the	O
interclinoid	B-MED
distance	I-MED
but	O
does	O
not	O
affect	O
other	O
linear	B-MED
dimensions	B-MED
of	O
sella	B-MED
.	O
No	O
statistically	B-MED
significant	I-MED
difference	O
has	O
been	O
found	O
in	O
sellar	B-MED
dimensions	B-MED
and	O
STB	B-MED
expression	O
when	O
evaluating	O
radiographs	B-MED
at	O
different	O
ages	B-MED
.	O
STB	B-MED
is	O
frequently	O
found	O
in	O
patients	B-MED
with	O
dental	B-MED
abnormalities	I-MED
.	O
The	O
transcription	B-MED
factors	I-MED
MS188	B-MED
and	O
AMS	B-MED
form	O
a	O
complex	B-MED
to	O
activate	B-MED
the	O
expression	B-MED
of	O
CYP703A2	B-MED
for	O
sporopollenin	B-MED
biosynthesis	I-MED
in	O
Arabidopsis	B-MED
thaliana	I-MED
The	O
sexine	B-MED
layer	I-MED
of	O
pollen	B-MED
grain	I-MED
is	O
mainly	O
composed	O
of	O
sporopollenins	B-MED
.	O
The	O
sporophytic	B-MED
secretory	I-MED
tapetum	I-MED
is	O
required	B-MED
for	O
the	O
biosynthesis	B-MED
of	I-MED
sporopollenin	I-MED
.	O
Although	O
several	O
enzymes	B-MED
involved	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
have	O
been	O
reported	O
,	O
the	O
regulatory	B-MED
mechanism	I-MED
of	O
these	O
enzymes	B-MED
in	O
tapetal	B-MED
layer	I-MED
remains	O
elusive	O
.	O
ABORTED	B-MED
MICROSPORES	I-MED
(	O
AMS	B-MED
)	O
and	O
MALE	B-MED
STERILE	I-MED
188	I-MED
/	O
MYB103	B-MED
/	O
MYB80	B-MED
(	O
MS188	B-MED
/	O
MYB103	B-MED
/	O
MYB80	B-MED
)	O
are	O
two	O
tapetal	B-MED
cell	I-MED
-specific	O
transcription	B-MED
factors	I-MED
required	B-MED
for	O
pollen	B-MED
wall	I-MED
formation	I-MED
.	O
AMS	B-MED
functions	B-MED
upstream	B-MED
of	O
MS188	B-MED
.	O
Here	O
we	O
report	O
that	O
AMS	B-MED
and	O
MS188	B-MED
target	B-MED
the	O
CYP703A2	B-MED
gene	I-MED
,	O
which	O
is	O
involved	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
.	O
We	O
found	O
that	O
AMS	B-MED
and	O
MS188	B-MED
were	O
localized	B-MED
in	O
tapetum	B-MED
while	O
CYP703A2	B-MED
was	O
localized	B-MED
in	O
both	O
tapetum	B-MED
and	O
locule	B-MED
.	O
Chromatin	B-MED
immunoprecipitation	I-MED
(	O
ChIP	B-MED
)	O
showed	O
that	O
MS188	B-MED
directly	O
bound	B-MED
to	O
the	O
promoter	B-MED
of	O
CYP703A2	B-MED
and	O
luciferase	B-MED
-	I-MED
inducible	I-MED
assay	B-MED
showed	O
that	O
MS188	B-MED
activated	B-MED
the	O
expression	B-MED
of	O
CYP703A2	B-MED
.	O
Yeast	B-MED
two	I-MED
-	I-MED
hybrid	I-MED
and	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
(	O
EMSAs	B-MED
)	O
further	O
demonstrated	O
that	O
MS188	B-MED
complexed	B-MED
with	O
AMS	B-MED
.	O
The	O
expression	B-MED
of	O
CYP703A2	B-MED
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	B-MED
levels	I-MED
of	O
MS188	B-MED
in	O
the	O
ams	B-MED
mutant	B-MED
.	O
Therefore	O
,	O
our	O
data	B-MED
reveal	B-MED
that	O
MS188	B-MED
coordinates	B-MED
with	O
AMS	B-MED
to	O
activate	B-MED
CYP703A2	B-MED
in	O
sporopollenin	B-MED
biosynthesis	I-MED
of	O
plant	B-MED
tapetum	B-MED
.	O
Immune	B-MED
dysregulation	I-MED
in	O
offspring	B-MED
of	O
a	O
bipolar	B-MED
parent	B-MED
.	O
Altered	O
serum	B-MED
levels	B-MED
of	O
immune	B-MED
growth	B-MED
factors	I-MED
at	O
adolescent	B-MED
age	I-MED
Immune	B-MED
dysregulation	I-MED
plays	O
a	O
role	O
in	O
the	O
vulnerability	B-MED
for	O
mood	B-MED
disorders	I-MED
.	O
Immune	B-MED
growth	B-MED
factors	I-MED
,	O
such	O
as	O
Stem	B-MED
Cell	I-MED
Factor	I-MED
(	O
SCF	B-MED
)	O
,	O
Insulin	B-MED
-	I-MED
like	I-MED
Growth	I-MED
Factor	I-MED
-	I-MED
Binding	I-MED
Protein-2	I-MED
(	O
IGF	B-MED
-	I-MED
BP2	I-MED
)	O
,	O
Epidermal	B-MED
Growth	I-MED
Factor	I-MED
(	O
EGF	B-MED
)	O
,	O
IL-7	B-MED
and	O
sCD25	B-MED
have	O
repeatedly	O
been	O
reported	O
altered	B-MED
in	O
patients	B-MED
with	O
mood	B-MED
disorders	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
levels	B-MED
of	O
these	O
factors	B-MED
in	O
serum	B-MED
of	O
adolescent	B-MED
bipolar	B-MED
offspring	B-MED
,	O
who	O
have	O
a	O
heightened	B-MED
risk	B-MED
for	O
mood	B-MED
disorder	I-MED
development	B-MED
and	O
to	O
also	O
analyze	B-MED
the	O
data	B-MED
combined	O
with	O
previously	O
published	B-MED
data	I-MED
.	O
Growth	B-MED
factors	I-MED
were	O
assessed	B-MED
by	O
CBA	B-MED
/	O
ELISA	B-MED
in	O
adolescent	B-MED
bipolar	B-MED
offspring	B-MED
(	O
n=96	O
,	O
mean	B-MED
age	B-MED
=	O
16	O
years	B-MED
)	O
and	O
in	O
age	B-MED
-	O
and	O
gender	B-MED
-	O
matched	B-MED
healthy	B-MED
controls	B-MED
(	O
n=50	O
)	O
.	O
EGF	B-MED
belonged	O
to	O
a	O
mutually	O
correlating	B-MED
cluster	B-MED
of	O
mainly	O
neurotrophic	B-MED
compounds	I-MED
including	O
S100B	B-MED
and	O
BDNF	B-MED
,	O
which	O
were	O
in	O
general	O
decreased	B-MED
in	O
serum	B-MED
.	O
IL-7	B-MED
,	O
SCF	B-MED
,	O
IGF	B-MED
-	I-MED
BP2	I-MED
and	O
sCD25	B-MED
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	B-MED
cluster	B-MED
of	O
immune	B-MED
growth	B-MED
factors	I-MED
,	O
which	O
were	O
in	O
general	O
increased	B-MED
:	O
IGF	B-MED
-	I-MED
BP2	I-MED
significantly	B-MED
in	O
serum	B-MED
of	O
offspring	B-MED
without	O
a	O
mood	B-MED
disorder	I-MED
,	O
IL-7	B-MED
and	O
SCF	B-MED
in	O
serum	B-MED
of	O
offspring	B-MED
who	O
had	O
expirienced	B-MED
a	O
mood	B-MED
episode	I-MED
.	O
This	O
pattern	B-MED
of	O
de	B-MED
-	O
and	O
increases	B-MED
was	O
not	O
different	O
between	O
bipolar	B-MED
offspring	B-MED
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood	B-MED
disorder	I-MED
over	O
time	B-MED
,	O
apart	O
from	O
the	O
IGF	B-MED
-	I-MED
BP2	I-MED
level	B-MED
,	O
which	O
was	O
near	O
significantly	B-MED
higher	O
in	O
offspring	B-MED
later	O
developing	O
a	O
mood	B-MED
disorder	I-MED
.	O
Correlations	B-MED
with	O
the	O
previously	O
published	B-MED
immune	B-MED
-	I-MED
cellular	I-MED
abnormalities	I-MED
were	O
not	O
found	O
.	O
In	O
conclusion	B-MED
non	O
-	O
affected	O
adolescents	B-MED
at	O
familial	B-MED
mood	B-MED
disorder	I-MED
development	B-MED
risk	B-MED
were	O
characterized	B-MED
by	O
a	O
distinct	O
pattern	B-MED
of	O
a	O
series	O
of	O
compounds	B-MED
operating	O
in	O
a	O
network	B-MED
of	O
hematopoiesis	B-MED
,	O
neurogenesis	B-MED
and	O
inflammation	B-MED
.	O
The	O
Role	O
of	O
Metal	B-MED
-	I-MED
on	I-MED
-	I-MED
Metal	I-MED
Bearings	I-MED
in	O
Total	B-MED
Hip	I-MED
Arthroplasty	I-MED
and	O
Hip	B-MED
Resurfacing	I-MED
:	O
Review	B-MED
Article	I-MED
The	O
current	O
role	O
of	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
(	I-MED
MoM	I-MED
)	I-MED
bearings	I-MED
in	O
hip	B-MED
arthroplasty	I-MED
remains	O
controversial	O
.	O
The	O
low	O
wear	O
offered	O
by	O
MoM	B-MED
bearings	I-MED
compared	O
to	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
polyethylene	I-MED
and	O
the	O
possibility	O
of	O
a	O
lower	B-MED
risk	I-MED
of	I-MED
dislocation	B-MED
with	O
larger	B-MED
head	I-MED
sizes	I-MED
,	O
encouraged	O
a	O
trend	B-MED
towards	O
the	O
re	B-MED
-	I-MED
introduction	I-MED
of	O
the	O
MoM	B-MED
bearing	I-MED
couple	O
.	O
However	O
,	O
recent	O
evidence	B-MED
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
MoM	B-MED
bearing	I-MED
have	O
been	O
successful	B-MED
.	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
MoM	B-MED
bearings	I-MED
and	O
address	O
the	O
following	O
issues	O
:	O
(	O
1	O
)	O
the	O
reintroduction	B-MED
of	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
bearings	I-MED
in	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
,	O
(	O
2	O
)	O
the	O
failure	O
of	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
bearings	I-MED
in	O
stemmed	B-MED
total	I-MED
hip	I-MED
arthroplasty	I-MED
,	O
(	O
3	O
)	O
the	O
role	O
of	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
hip	I-MED
resurfacing	I-MED
in	O
modern	O
orthopaedics	B-MED
and	O
(	O
4	O
)	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
hip	I-MED
resurfacing	I-MED
versus	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
.	O
A	O
literature	B-MED
search	O
strategy	B-MED
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
MEDLINE	B-MED
and	O
Embase	B-MED
.	O
The	O
highest	O
quality	B-MED
articles	I-MED
that	O
met	O
the	O
inclusion	B-MED
criteria	I-MED
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	B-MED
were	O
selected	O
.	O
Key	O
search	O
terms	O
included	O
'	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
'	O
,	O
'	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
'	O
and	O
'	O
hip	B-MED
resurfacing	I-MED
'	O
.	O
The	O
initial	O
search	O
retrieved	O
1240	O
articles	B-MED
.	O
Twenty	O
-	O
two	O
articles	B-MED
were	O
selected	O
and	O
used	O
in	O
the	O
review	B-MED
.	O
Metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
hip	I-MED
resurfacing	I-MED
is	O
still	O
a	O
suitable	O
treatment	B-MED
option	O
in	O
specific	B-MED
patient	B-MED
populations	I-MED
with	O
the	O
appropriate	B-MED
implant	B-MED
design	I-MED
and	O
surgical	O
skill	O
,	O
while	O
stemmed	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
total	I-MED
hip	I-MED
arthroplasty	I-MED
should	O
be	O
avoided	O
in	O
all	B-MED
patient	I-MED
populations	I-MED
.	O
Continued	O
follow	B-MED
-	I-MED
up	I-MED
of	O
patients	B-MED
undergoing	O
metal	B-MED
-	I-MED
on	I-MED
-	I-MED
metal	I-MED
hip	I-MED
resurfacing	I-MED
is	O
critical	B-MED
in	O
order	O
to	O
further	O
understand	O
the	O
long	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
of	O
these	O
patients	B-MED
and	O
why	O
certain	O
complications	B-MED
tend	O
to	O
occur	O
with	O
this	O
procedure	O
.	O
Association	B-MED
among	O
prematurity	B-MED
(	O
<	B-MED
30	I-MED
weeks	I-MED
'	I-MED
gestational	I-MED
age	I-MED
)	O
,	O
blood	B-MED
pressure	I-MED
,	O
urinary	B-MED
albumin	B-MED
,	O
calcium	B-MED
,	O
and	O
phosphate	B-MED
in	O
early	B-MED
childhood	I-MED
There	O
is	O
a	O
paucity	O
of	O
data	B-MED
on	O
blood	B-MED
pressures	I-MED
(	O
BP	B-MED
)	O
,	O
urinary	B-MED
albumin	B-MED
,	O
and	O
mineral	B-MED
excretion	B-MED
in	O
early	B-MED
childhood	I-MED
in	O
contemporary	B-MED
cohorts	B-MED
of	O
extremely	B-MED
low	B-MED
gestational	B-MED
age	I-MED
(	O
GA	B-MED
)	O
neonates	B-MED
.	O
Our	O
aim	O
was	O
to	O
compare	B-MED
BPs	B-MED
and	O
the	O
urinary	B-MED
excretion	B-MED
of	O
albumin	B-MED
,	O
calcium	B-MED
,	O
and	O
phosphate	B-MED
in	O
preterm	B-MED
and	O
term	B-MED
-	I-MED
born	I-MED
cohorts	B-MED
in	O
early	B-MED
childhood	I-MED
.	O
This	O
was	O
a	O
prospective	B-MED
observational	I-MED
study	I-MED
conducted	O
at	O
a	O
single	B-MED
center	B-MED
,	O
involving	B-MED
children	B-MED
<	B-MED
5	I-MED
years	I-MED
age	I-MED
,	O
born	B-MED
preterm	I-MED
(	O
GA	B-MED
<	I-MED
30	I-MED
weeks	I-MED
)	O
or	O
at	B-MED
term	I-MED
(	O
≥37	B-MED
weeks	I-MED
'	I-MED
GA	I-MED
)	O
.	O
Urinary	B-MED
albumin	I-MED
(	O
mg	O
/	O
L	O
)	O
,	O
calcium	B-MED
and	O
phosphate	B-MED
levels	I-MED
indexed	B-MED
to	O
creatinine	B-MED
(	O
mg	O
/	O
dL	O
)	O
,	O
and	O
BP	B-MED
were	O
measured	B-MED
.	O
The	O
median	B-MED
(	O
IQR	B-MED
)	O
follow	B-MED
-	I-MED
up	I-MED
age	B-MED
of	O
our	O
cohort	B-MED
(	O
n	O
=	O
106	O
)	O
was	O
30	O
(	O
16	O
-	O
48	O
)	O
months	B-MED
.	O
Preterm	B-MED
-	I-MED
born	I-MED
children	I-MED
(	O
n	O
=	O
55	O
)	O
had	O
a	O
significantly	B-MED
lower	I-MED
mean	B-MED
GA	B-MED
and	O
birth	B-MED
weight	I-MED
and	O
higher	B-MED
mean	B-MED
systolic	B-MED
,	O
diastolic	B-MED
,	O
and	O
mean	B-MED
BPs	I-MED
,	O
compared	B-MED
with	O
term	B-MED
(	O
n	O
=	O
51	O
)	O
controls	B-MED
.	O
A	O
significantly	B-MED
higher	I-MED
proportion	B-MED
of	O
preterm	B-MED
-	I-MED
born	I-MED
children	I-MED
weighed	B-MED
<	B-MED
10th	I-MED
centile	I-MED
and	O
had	O
systolic	B-MED
BP	I-MED
>	B-MED
95th	I-MED
centile	I-MED
at	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Albumin	B-MED
and	O
calcium	B-MED
excretion	B-MED
did	O
not	B-MED
differ	I-MED
between	O
the	O
groups	B-MED
;	O
median	B-MED
urine	B-MED
-	I-MED
phosphate	I-MED
creatinine	I-MED
ratios	I-MED
were	O
higher	B-MED
in	O
the	O
preterm	B-MED
group	I-MED
.	O
On	O
logistic	B-MED
regression	I-MED
,	O
lower	B-MED
GA	B-MED
and	O
younger	B-MED
age	B-MED
at	O
follow	B-MED
-	I-MED
up	I-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
systolic	B-MED
and	O
diastolic	B-MED
BP	I-MED
above	O
the	O
95th	B-MED
centile	I-MED
;	O
male	B-MED
gender	I-MED
was	O
associated	B-MED
with	I-MED
decreased	B-MED
risk	B-MED
of	O
diastolic	B-MED
hypertension	I-MED
.	O
Even	O
in	O
early	B-MED
childhood	I-MED
,	O
children	B-MED
born	I-MED
preterm	I-MED
had	O
significantly	B-MED
elevated	B-MED
BP	B-MED
,	O
compared	B-MED
with	O
their	O
term	B-MED
-	I-MED
born	I-MED
counterparts	B-MED
.	O
Closer	O
monitoring	B-MED
of	O
BPs	B-MED
in	O
this	O
population	B-MED
may	O
be	O
warranted	O
.	O
Prognostic	B-MED
significance	I-MED
of	O
non	B-MED
-	I-MED
HPV16	I-MED
genotypes	I-MED
in	O
oropharyngeal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
OPSCC	B-MED
)	O
positive	B-MED
for	O
HPV16	B-MED
genotype	I-MED
have	O
better	B-MED
overall	B-MED
survival	I-MED
compared	B-MED
with	O
cases	O
positive	O
for	O
other	O
HPV	B-MED
genotypes	I-MED
.	O
We	O
sought	O
to	O
further	O
replicate	B-MED
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	B-MED
by	I-MED
expression	B-MED
of	O
p16	B-MED
tumor	I-MED
suppressor	I-MED
protein	I-MED
.	O
We	O
identified	O
238	O
OPSCC	B-MED
cases	O
from	O
the	O
Carolina	B-MED
Head	I-MED
and	I-MED
Neck	I-MED
Cancer	I-MED
Study	I-MED
(	O
CHANCE	B-MED
)	O
study	O
,	O
a	O
population	B-MED
based	I-MED
case	I-MED
-	I-MED
control	I-MED
study	I-MED
.	O
Tumors	B-MED
that	O
tested	O
positive	B-MED
solely	I-MED
for	O
HPV16	B-MED
genotype	I-MED
and	O
no	O
other	O
genotypes	B-MED
with	O
PCR	B-MED
were	O
classified	B-MED
as	O
HPV16	B-MED
-	I-MED
positive	I-MED
.	O
Tumors	B-MED
positive	B-MED
for	I-MED
any	O
other	O
high	B-MED
-	I-MED
risk	I-MED
HPV	B-MED
genotype	I-MED
were	O
classified	B-MED
as	O
non	B-MED
-	I-MED
HPV16	I-MED
-	I-MED
positive	I-MED
.	O
Expression	B-MED
of	O
p16	B-MED
in	O
the	O
tumor	B-MED
was	O
determined	B-MED
with	O
immunohistochemistry	B-MED
.	O
Follow	O
-	O
up	O
time	O
was	O
calculated	O
from	O
the	O
date	B-MED
of	I-MED
diagnosis	I-MED
to	O
date	B-MED
of	I-MED
death	I-MED
or	O
December	O
31	O
,	O
2013	O
.	O
Overall	B-MED
survival	I-MED
was	O
compared	O
with	O
the	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
curves	I-MED
and	O
log	B-MED
-	I-MED
rank	I-MED
test	I-MED
.	O
Hazard	B-MED
ratios	I-MED
(	O
HR	B-MED
)	O
adjusted	O
for	O
smoking	B-MED
,	O
alcohol	B-MED
use	I-MED
,	O
sex	B-MED
,	O
race	B-MED
,	O
and	O
age	B-MED
was	O
calculated	O
with	O
the	O
Cox	B-MED
proportional	I-MED
hazard	I-MED
regression	I-MED
.	O
Cases	O
with	O
HPV16	B-MED
-	I-MED
positive	I-MED
OPSCC	B-MED
had	O
better	B-MED
overall	B-MED
survival	I-MED
than	O
cases	O
with	O
non	B-MED
-	I-MED
HPV16	I-MED
-	I-MED
positive	I-MED
OPSCC	B-MED
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0.010	O
)	O
.	O
When	O
restricted	O
to	O
OPSCC	B-MED
cases	O
positive	B-MED
for	O
p16	B-MED
expression	I-MED
,	O
the	O
same	O
trend	B-MED
continued	O
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0.002	O
)	O
.	O
In	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non	B-MED
-	I-MED
HPV16	I-MED
-	I-MED
positive	I-MED
OPSCC	B-MED
had	O
greater	B-MED
risk	I-MED
of	I-MED
death	B-MED
compared	O
to	O
cases	O
with	O
HPV16	B-MED
-	I-MED
positive	I-MED
tumors	B-MED
(	O
HR	B-MED
:	O
1.92	O
;	O
95	O
%	O
CI	O
:	O
1.03	O
,	O
3.60	O
)	O
.	O
This	O
finding	B-MED
indicates	B-MED
that	O
HPV	B-MED
genotyping	B-MED
carries	O
valuable	B-MED
prognostic	I-MED
significance	I-MED
in	O
addition	O
to	O
p16	B-MED
status	B-MED
and	O
future	O
survival	O
studies	O
of	O
OPSCC	B-MED
should	O
take	O
into	O
account	O
differing	O
HPV	B-MED
genotypes	I-MED
.	O
Ultrasonography	B-MED
and	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
evaluation	B-MED
of	O
pediatric	B-MED
spinal	B-MED
anomalies	I-MED
Spinal	B-MED
dysraphisms	I-MED
are	O
congenital	B-MED
abnormalities	I-MED
of	O
the	O
spine	B-MED
due	O
to	O
imperfect	O
fusion	B-MED
of	O
midline	B-MED
mesenchymal	B-MED
,	O
bony	B-MED
and	O
neural	B-MED
structures	B-MED
.	O
Imaging	B-MED
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-MED
as	O
significant	O
portion	O
of	O
patients	B-MED
may	O
present	O
with	O
concurrent	B-MED
anomalies	B-MED
that	O
need	O
to	O
be	O
corrected	B-MED
simultaneously	B-MED
to	O
avoid	O
repeat	B-MED
surgeries	I-MED
.	O
The	O
aims	O
of	O
the	O
study	B-MED
were	O
to	O
evaluate	B-MED
Spinal	B-MED
dysraphisms	I-MED
using	O
USG	B-MED
and	O
MRI	B-MED
and	O
to	O
correlate	B-MED
imaging	B-MED
findings	B-MED
with	O
operative	B-MED
findings	B-MED
in	O
patients	B-MED
undergoing	O
surgery	B-MED
.	O
Hospital	B-MED
based	O
observational	B-MED
study	I-MED
conducted	O
over	O
a	O
period	B-MED
of	O
year	B-MED
.	O
38	O
cases	B-MED
of	O
both	O
sexes	B-MED
and	O
below	O
12	O
years	B-MED
of	O
age	B-MED
with	O
spinal	B-MED
dysraphism	I-MED
were	O
studied	O
.	O
USG	B-MED
was	O
performed	O
in	O
29	O
cases	B-MED
where	O
acoustic	B-MED
window	I-MED
was	O
available	O
for	O
proper	O
evaluation	B-MED
.	O
MRI	B-MED
was	O
performed	O
in	O
all	O
cases	B-MED
.	O
USG	B-MED
findings	B-MED
were	O
compared	O
with	O
MRI	B-MED
findings	B-MED
and	O
operative	B-MED
follow	B-MED
up	I-MED
was	O
taken	O
in	O
23	O
cases	B-MED
who	O
underwent	O
operative	B-MED
management	I-MED
.	O
Results	O
were	O
analysed	B-MED
using	O
percentage	B-MED
and	O
arithmetic	B-MED
mean	I-MED
.	O
39.47	O
%	O
cases	B-MED
were	O
male	B-MED
and	O
60.53	O
%	O
cases	B-MED
were	O
female	B-MED
.	O
Neonatal	B-MED
period	I-MED
was	O
the	O
most	O
common	O
presenting	O
age	B-MED
group	I-MED
.	O
Closed	B-MED
spinal	B-MED
dysraphism	I-MED
(	O
63.16	O
%	O
)	O
was	O
more	O
common	O
than	O
open	B-MED
(	O
36.84	O
%	O
)	O
.	O
79.31	O
%	O
cases	B-MED
showed	O
full	O
agreement	O
between	O
spinal	B-MED
USG	B-MED
and	O
MRI	B-MED
examinations	B-MED
and	O
6	O
out	O
of	O
20.69	O
%	O
showed	O
partial	O
agreement	O
.	O
On	O
operative	B-MED
correlation	B-MED
,	O
USG	B-MED
findings	B-MED
were	O
confirmatory	B-MED
in	O
91.30	O
%	O
cases	B-MED
and	O
MRI	B-MED
findings	B-MED
were	O
confirmatory	B-MED
in	O
100	O
%	O
cases	B-MED
.	O
USG	B-MED
can	O
be	O
used	O
as	O
the	O
initial	O
modality	B-MED
for	O
evaluation	B-MED
of	O
spinal	B-MED
dysraphism	I-MED
as	O
well	O
as	O
for	O
screening	B-MED
of	O
suspected	B-MED
cases	B-MED
.	O
MRI	B-MED
is	O
indicated	O
to	O
confirm	O
abnormal	B-MED
USG	B-MED
findings	B-MED
,	O
which	O
shows	O
all	O
concurrent	B-MED
abnormalities	B-MED
and	O
also	O
provides	O
additional	O
anatomical	B-MED
details	B-MED
relevant	O
to	O
surgical	B-MED
planning	I-MED
.	O
MRI	B-MED
-based	O
prostate	B-MED
cancer	I-MED
detection	B-MED
with	O
high	B-MED
-	I-MED
level	I-MED
representation	I-MED
and	O
hierarchical	B-MED
classification	B-MED
Extracting	O
the	O
high	B-MED
-	I-MED
level	I-MED
feature	I-MED
representation	I-MED
by	O
using	O
deep	B-MED
neural	I-MED
networks	I-MED
for	O
detection	B-MED
of	O
prostate	B-MED
cancer	I-MED
,	O
and	O
then	O
based	O
on	O
high	B-MED
-	I-MED
level	I-MED
feature	I-MED
representation	I-MED
constructing	O
hierarchical	B-MED
classification	B-MED
to	O
refine	O
the	O
detection	B-MED
results	B-MED
.	O
High	B-MED
-	I-MED
level	I-MED
feature	I-MED
representation	I-MED
is	O
first	O
learned	O
by	O
a	O
deep	B-MED
learning	I-MED
network	I-MED
,	O
where	O
multiparametric	B-MED
MR	I-MED
images	B-MED
are	O
used	O
as	O
the	O
input	O
data	B-MED
.	O
Then	O
,	O
based	O
on	O
the	O
learned	O
high	B-MED
-	I-MED
level	I-MED
features	I-MED
,	O
a	O
hierarchical	B-MED
classification	B-MED
method	B-MED
is	O
developed	O
,	O
where	O
multiple	B-MED
random	I-MED
forest	I-MED
classifiers	I-MED
are	O
iteratively	B-MED
constructed	I-MED
to	O
refine	O
the	O
detection	B-MED
results	B-MED
of	O
prostate	B-MED
cancer	I-MED
.	O
The	O
experiments	B-MED
were	O
carried	O
on	O
21	O
real	O
patient	B-MED
subjects	O
,	O
and	O
the	O
proposed	O
method	B-MED
achieves	O
an	O
averaged	O
section	B-MED
-	I-MED
based	I-MED
evaluation	I-MED
(	O
SBE	B-MED
)	O
of	O
89.90	O
%	O
,	O
an	O
averaged	O
sensitivity	B-MED
of	O
91.51	O
%	O
,	O
and	O
an	O
averaged	O
specificity	B-MED
of	O
88.47	O
%	O
.	O
The	O
high	B-MED
-	I-MED
level	I-MED
features	I-MED
learned	O
from	O
our	O
proposed	O
method	B-MED
can	O
achieve	O
better	O
performance	B-MED
than	O
the	O
conventional	B-MED
handcrafted	B-MED
features	I-MED
(	O
e.g.	O
,	O
LBP	B-MED
and	O
Haar	B-MED
-	I-MED
like	I-MED
features	I-MED
)	O
in	O
detecting	B-MED
prostate	B-MED
cancer	I-MED
regions	B-MED
,	O
also	O
the	O
context	B-MED
features	B-MED
obtained	O
from	O
the	O
proposed	O
hierarchical	B-MED
classification	B-MED
approach	O
are	O
effective	B-MED
in	O
refining	O
cancer	B-MED
detection	B-MED
result	B-MED
.	O
Association	B-MED
of	O
physical	B-MED
activity	I-MED
on	O
body	B-MED
composition	I-MED
,	O
cardiometabolic	B-MED
risk	I-MED
factors	I-MED
,	O
and	O
prevalence	B-MED
of	O
cardiovascular	B-MED
disease	I-MED
in	O
the	O
Korean	B-MED
population	I-MED
(	O
from	O
the	O
fifth	O
Korea	B-MED
national	B-MED
health	I-MED
and	I-MED
nutrition	I-MED
examination	I-MED
survey	I-MED
,	O
2008	O
-	O
2011	O
)	O
Data	B-MED
regarding	O
associations	B-MED
among	O
physical	B-MED
activity	I-MED
(	O
PA	B-MED
)	O
level	B-MED
,	O
body	B-MED
composition	I-MED
,	O
and	O
prevalence	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
in	O
Asian	B-MED
populations	I-MED
are	O
rare	B-MED
.	O
The	O
International	B-MED
Physical	I-MED
Activity	I-MED
Questionnaire	I-MED
(	O
IPAQ	B-MED
)	O
was	O
utilized	O
to	O
estimate	B-MED
PA	B-MED
levels	B-MED
and	O
analyze	B-MED
the	O
association	B-MED
of	O
PA	B-MED
level	B-MED
with	O
various	O
body	B-MED
composition	I-MED
parameters	B-MED
and	O
the	O
prevalence	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
by	O
using	O
data	B-MED
from	O
the	O
Korean	B-MED
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
from	O
2008	O
to	O
2011	O
.	O
Moderate	B-MED
and	O
high	B-MED
PA	B-MED
levels	B-MED
were	O
associated	B-MED
with	O
lower	B-MED
prevalence	I-MED
of	O
hypertension	B-MED
and	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
lower	B-MED
concentrations	B-MED
of	O
serum	B-MED
ferritin	I-MED
,	O
parathyroid	B-MED
hormone	I-MED
,	O
and	O
alkaline	B-MED
phosphatase	I-MED
.	O
Sarcopenia	B-MED
(	O
low	B-MED
vs.	O
moderate	B-MED
vs.	O
high	B-MED
PA	B-MED
group	B-MED
:	O
14.3	O
%	O
vs.	O
10.5	O
%	O
vs.	O
7.3	O
%	O
,	O
p	B-MED
=	O
0.001	O
)	O
,	O
underweight	B-MED
(	O
5.7	O
%	O
vs.	O
4.9	O
%	O
vs.	O
3.5	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
and	O
central	B-MED
obesity	I-MED
(	O
7.8	O
%	O
vs.	O
6.9	O
%	O
vs.	O
6.3	O
%	O
,	O
p	O
=	O
0.002	O
)	O
were	O
more	O
often	O
observed	B-MED
in	O
the	O
low	B-MED
PA	B-MED
group	B-MED
.	O
The	O
prevalence	B-MED
rates	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
were	O
lower	B-MED
in	O
the	O
moderate	B-MED
(	O
odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
,	O
0.822	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
,	O
0.737	O
-	O
0.916	O
;	O
p	B-MED
=	O
0.001	O
)	O
and	O
high	B-MED
activity	B-MED
groups	B-MED
(	O
OR	B-MED
,	O
0.663	O
;	O
95	O
%	O
CI	B-MED
,	O
0.589	O
-	O
0.748	O
;	O
p	B-MED
=	O
0.001	O
)	O
than	O
in	O
the	O
low	B-MED
activity	B-MED
group	B-MED
,	O
even	O
after	O
adjusting	O
for	O
age	B-MED
,	O
sex	B-MED
,	O
smoking	B-MED
,	O
underlying	B-MED
disease	I-MED
,	O
and	O
general	B-MED
or	O
abdominal	B-MED
obesity	I-MED
and	O
muscle	B-MED
mass	I-MED
.	O
Regular	B-MED
physical	I-MED
activity	I-MED
was	O
associated	B-MED
with	O
a	O
low	B-MED
prevalence	I-MED
of	O
cardiovascular	B-MED
diseases	I-MED
(	O
stroke	B-MED
,	O
myocardial	B-MED
infarction	I-MED
,	O
stable	B-MED
angina	I-MED
,	O
and	O
chronic	B-MED
renal	I-MED
disease	I-MED
)	O
,	O
which	O
was	O
independent	B-MED
of	I-MED
body	B-MED
composition	I-MED
and	O
conventional	O
risk	B-MED
factors	I-MED
in	O
the	O
Korean	B-MED
population	I-MED
,	O
with	O
a	O
positive	B-MED
dose	B-MED
-	I-MED
response	I-MED
relationship	I-MED
.	O
Divided	B-MED
and	O
Sliding	B-MED
Superficial	B-MED
Temporal	I-MED
Artery	I-MED
Flap	B-MED
for	O
Primary	B-MED
Donor	B-MED
-	I-MED
site	I-MED
Closure	B-MED
Superficial	B-MED
temporal	I-MED
artery	I-MED
(	O
STA	B-MED
)	O
flaps	B-MED
are	O
often	O
used	O
for	O
reconstruction	B-MED
of	O
hair	B-MED
-	I-MED
bearing	I-MED
areas	I-MED
.	O
However	O
,	O
primary	B-MED
closure	I-MED
of	O
the	O
donor	B-MED
site	I-MED
is	O
not	O
easy	O
when	O
the	O
size	B-MED
of	O
the	O
necessary	O
skin	B-MED
island	I-MED
is	O
relatively	O
large	B-MED
.	O
In	O
such	O
cases	O
,	O
skin	B-MED
grafts	I-MED
are	O
needed	O
at	O
the	O
donor	B-MED
site	I-MED
,	O
resulting	O
in	O
baldness	B-MED
.	O
We	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	B-MED
and	O
sliding	B-MED
flap	B-MED
technique	B-MED
,	O
which	O
was	O
first	O
reported	O
for	O
primary	B-MED
donor	I-MED
-	I-MED
site	I-MED
closure	I-MED
of	O
a	O
latissimus	B-MED
dorsi	I-MED
musculocutaneous	I-MED
flap	B-MED
.	O
We	O
applied	O
this	O
technique	B-MED
to	O
the	O
hair	B-MED
-	I-MED
bearing	I-MED
STA	I-MED
flap	B-MED
,	O
where	O
primary	B-MED
donor	I-MED
-	I-MED
site	I-MED
closure	I-MED
is	O
extremely	O
beneficial	O
for	O
preventing	B-MED
baldness	B-MED
consequent	O
to	O
skin	B-MED
grafting	I-MED
.	O
The	O
STA	B-MED
flap	B-MED
was	O
divided	B-MED
into	O
3	O
,	O
and	O
creation	B-MED
of	O
large	O
flap	B-MED
was	O
possible	O
.	O
Therefore	O
,	O
we	O
concluded	O
that	O
the	O
divided	B-MED
and	O
sliding	B-MED
STA	B-MED
flap	B-MED
could	O
at	O
least	O
partially	O
solve	O
the	O
donor	B-MED
-	I-MED
site	I-MED
problem	B-MED
.	O
Although	O
further	O
investigation	B-MED
is	O
necessary	O
to	O
validate	B-MED
the	O
maximum	B-MED
possible	B-MED
flap	B-MED
size	B-MED
,	O
this	O
technique	B-MED
may	O
be	O
applicable	O
to	O
at	O
least	O
small	B-MED
defects	B-MED
that	O
are	O
common	O
after	O
skin	B-MED
cancer	I-MED
ablation	B-MED
or	O
trauma	B-MED
.	O
Aryl	B-MED
hydrocarbon	I-MED
receptor	I-MED
(	I-MED
AhR	I-MED
)	I-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
association	O
with	O
infertile	B-MED
oligoasthenoteratozoospermic	B-MED
men	B-MED
and	O
seminal	B-MED
oxidative	B-MED
stress	I-MED
This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	B-MED
hydrocarbon	I-MED
receptor	I-MED
(	I-MED
AhR	I-MED
)	I-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
with	O
infertile	B-MED
oligoasthenoteratozoospermic	B-MED
(	O
OAT	B-MED
)	O
men	B-MED
and	O
seminal	B-MED
oxidative	B-MED
stress	I-MED
(	O
OS	B-MED
)	O
.	O
A	O
total	O
of	O
170	O
Egyptian	B-MED
men	I-MED
were	O
allocated	O
according	O
to	O
their	O
semen	B-MED
analysis	I-MED
into	O
fertile	B-MED
normozoospermic	B-MED
controls	I-MED
(	O
n	O
=	O
50	O
)	O
and	O
infertile	B-MED
OAT	B-MED
men	B-MED
(	O
n	O
=	O
120	O
)	O
.	O
They	O
were	O
subjected	O
to	O
history	B-MED
taking	I-MED
,	O
clinical	B-MED
examination	I-MED
,	O
semen	B-MED
analysis	I-MED
,	O
estimation	B-MED
of	O
seminal	B-MED
glutathione	B-MED
peroxidase	I-MED
(	O
GPx	B-MED
)	O
,	O
and	O
malondialdehyde	B-MED
(	O
MDA	B-MED
)	O
.	O
AhR	B-MED
rs2066853	I-MED
gene	B-MED
polymorphism	I-MED
was	O
identified	O
in	O
the	O
blood	B-MED
by	O
PCR	B-MED
-	O
RFLP	B-MED
.	O
Comparing	O
infertile	B-MED
OAT	B-MED
men	B-MED
with	O
fertile	B-MED
controls	B-MED
,	O
AhR	B-MED
rs2066853	I-MED
genotypes	B-MED
showed	O
decreased	B-MED
prevalence	B-MED
for	O
wild	B-MED
homozygous	B-MED
genotype	I-MED
GG	I-MED
(	O
35.8	O
vs	O
56	O
%	O
)	O
and	O
for	O
heterozygous	B-MED
genotype	I-MED
GA	I-MED
(	O
17.5	O
vs	O
30	O
%	O
)	O
and	O
an	O
increased	B-MED
prevalence	B-MED
for	O
homozygous	B-MED
genotype	I-MED
AA	I-MED
(	O
46.7	O
vs	O
14	O
%	O
)	O
.	O
Distribution	O
of	O
alleles	B-MED
of	O
AhR	B-MED
rs2066853	I-MED
among	O
OAT	B-MED
men	B-MED
compared	O
with	O
fertile	B-MED
men	B-MED
showed	O
decreased	B-MED
prevalence	B-MED
of	O
G	B-MED
allele	I-MED
(	O
44.6	O
vs	O
71	O
%	O
)	O
and	O
an	O
increased	B-MED
prevalence	B-MED
of	O
A	B-MED
allele	I-MED
(	O
55.4	O
vs	O
29	O
%	O
)	O
.	O
Seminal	B-MED
MDA	B-MED
demonstrated	O
significant	O
increase	B-MED
whereas	O
seminal	B-MED
GPx	B-MED
demonstrated	O
significant	O
decrease	B-MED
in	O
cases	O
with	O
AA	B-MED
and	O
GA	B-MED
/	O
AA	B-MED
genotypes	I-MED
compared	O
to	O
cases	O
with	O
GG	B-MED
genotype	I-MED
.	O
It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR	B-MED
rs2066853	I-MED
genotype	B-MED
polymorphism	B-MED
with	O
decreased	B-MED
sperm	B-MED
parameters	O
as	O
well	O
as	O
increased	B-MED
seminal	B-MED
oxidative	B-MED
stress	I-MED
in	O
infertile	B-MED
OAT	B-MED
men	B-MED
.	O
Engaging	B-MED
adolescent	B-MED
girls	I-MED
in	O
transactional	B-MED
sex	I-MED
through	B-MED
compensated	B-MED
dating	B-MED
Transactional	B-MED
sex	I-MED
through	B-MED
so	O
-	O
called	O
compensated	B-MED
dating	B-MED
in	O
adolescent	B-MED
girls	I-MED
is	O
a	O
problem	B-MED
in	O
need	B-MED
of	O
public	B-MED
concern	B-MED
.	O
Compensated	B-MED
dating	B-MED
typically	O
involves	O
the	O
use	B-MED
of	I-MED
information	B-MED
communication	I-MED
technology	I-MED
to	O
advertise	B-MED
,	O
search	B-MED
,	O
bargain	B-MED
,	O
and	O
eventually	O
arrange	O
for	O
transactional	B-MED
sex	I-MED
.	O
The	O
technology	B-MED
enables	B-MED
the	O
sexual	B-MED
partners	I-MED
to	O
maintain	B-MED
privacy	B-MED
and	O
secrecy	B-MED
in	O
transactional	B-MED
sex	I-MED
.	O
Such	O
secrecy	B-MED
necessitates	B-MED
the	O
girls	B-MED
'	O
disclosure	B-MED
about	O
their	O
life	B-MED
experiences	I-MED
in	O
order	B-MED
to	O
address	O
the	O
concern	B-MED
.	O
The	O
disclosure	B-MED
is	O
the	O
focus	B-MED
of	O
the	O
present	O
qualitative	B-MED
study	I-MED
of	O
27	O
girls	B-MED
practicing	B-MED
the	O
dating	B-MED
in	O
Hong	B-MED
Kong	I-MED
,	O
China	B-MED
.	O
Based	B-MED
on	O
the	O
disclosure	B-MED
,	O
the	O
study	B-MED
presents	O
a	O
grounded	B-MED
theory	I-MED
that	O
epitomizes	O
engagement	B-MED
in	O
compensated	B-MED
dating	B-MED
by	O
referential	B-MED
choice	I-MED
.	O
Such	O
a	O
referential	B-MED
choice	I-MED
theory	I-MED
unravels	O
that	O
choice	B-MED
with	O
reference	B-MED
to	O
the	O
family	B-MED
push	B-MED
and	O
social	B-MED
norms	I-MED
sustains	B-MED
the	O
engagement	B-MED
.	O
Meanwhile	O
,	O
the	O
choice	B-MED
rests	O
on	O
expectancy	B-MED
and	O
reinforcement	B-MED
from	O
experiential	B-MED
learning	I-MED
about	O
compensated	B-MED
dating	B-MED
.	O
The	O
theory	B-MED
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-MED
through	B-MED
diverting	B-MED
the	O
referential	B-MED
choice	I-MED
of	O
the	O
dating	B-MED
.	O
Lack	B-MED
of	O
antimicrobial	B-MED
efficacy	B-MED
of	O
mecetronium	B-MED
etilsulfate	I-MED
in	O
propanol	B-MED
-based	O
hand	B-MED
rubs	I-MED
for	O
surgical	B-MED
hand	B-MED
disinfection	I-MED
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
if	O
mecetronium	B-MED
etilsulfate	I-MED
(	O
MES	B-MED
)	O
contributes	O
to	O
overall	O
efficacy	B-MED
in	O
surgical	B-MED
hand	B-MED
disinfection	I-MED
.	O
Three	O
blinded	O
hand	B-MED
rubs	I-MED
(	O
45	O
%	O
iso	B-MED
-	I-MED
propanol	I-MED
,	O
30	O
%	O
n	B-MED
-	I-MED
propanol	I-MED
)	O
were	O
applied	B-MED
for	O
1.5	O
min	O
and	O
compared	B-MED
with	O
the	O
EN	B-MED
12791	I-MED
reference	O
procedure	B-MED
(	O
crossover	B-MED
design	I-MED
)	O
.	O
One	O
commercial	B-MED
hand	B-MED
rub	I-MED
contained	O
0.2	O
%	O
MES	B-MED
,	O
and	O
the	O
two	O
other	O
hand	B-MED
rubs	I-MED
were	O
identical	B-MED
apart	O
from	O
0.2	O
%	O
MES	B-MED
.	O
None	O
of	O
the	O
formulations	B-MED
had	O
a	O
log10	B-MED
reduction	B-MED
after	O
3	O
h	O
that	O
was	O
significantly	O
better	B-MED
compared	B-MED
with	O
the	O
reference	O
procedure	B-MED
[	O
mean	B-MED
1.72	O
(	O
standard	B-MED
deviation	I-MED
1.15	O
)	O
]	O
.	O
The	O
antimicrobial	B-MED
contribution	B-MED
of	O
MES	B-MED
in	O
hand	B-MED
rubs	I-MED
is	O
questionable	O
.	O
The	O
adder	B-MED
(	O
Vipera	B-MED
berus	I-MED
)	O
in	O
Southern	B-MED
Altay	I-MED
Mountains	I-MED
:	O
population	B-MED
characteristics	I-MED
,	O
distribution	B-MED
,	O
morphology	B-MED
and	O
phylogenetic	B-MED
position	I-MED
As	O
the	O
most	O
widely	O
distributed	B-MED
snake	B-MED
in	O
Eurasia	B-MED
,	O
the	O
adder	B-MED
(	O
Vipera	B-MED
berus	I-MED
)	O
has	O
been	O
extensively	B-MED
investigated	B-MED
in	O
Europe	B-MED
but	O
poorly	O
understood	O
in	O
Asia	B-MED
.	O
The	O
Southern	B-MED
Altay	I-MED
Mountains	I-MED
represent	O
the	O
adder	B-MED
's	I-MED
southern	B-MED
distribution	B-MED
limit	B-MED
in	O
Central	B-MED
Asia	I-MED
,	O
whereas	O
its	O
population	B-MED
status	I-MED
has	O
never	O
been	O
assessed	B-MED
.	O
We	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	B-MED
surveys	I-MED
for	O
the	O
adder	B-MED
at	O
two	O
areas	B-MED
of	O
Southern	B-MED
Altay	I-MED
Mountains	I-MED
using	O
a	O
combination	B-MED
of	O
line	B-MED
transects	I-MED
and	O
random	B-MED
searches	B-MED
.	O
We	O
also	O
described	O
the	O
morphological	B-MED
characteristics	I-MED
of	O
the	O
collected	B-MED
specimens	I-MED
and	O
conducted	O
analyses	B-MED
of	O
external	B-MED
morphology	B-MED
and	O
molecular	B-MED
phylogeny	I-MED
.	O
The	O
results	B-MED
showed	O
that	O
the	O
adder	B-MED
distributed	B-MED
in	O
both	O
survey	B-MED
sites	B-MED
and	O
we	O
recorded	B-MED
a	O
total	O
of	O
34	O
sightings	B-MED
.	O
In	O
Kanas	B-MED
river	I-MED
valley	I-MED
,	O
the	O
estimated	B-MED
encounter	B-MED
rate	B-MED
over	O
a	O
total	O
of	O
137	O
km	O
transects	B-MED
was	O
0.15	O
±	O
0.05	O
sightings	B-MED
/km	O
.	O
The	O
occurrence	B-MED
of	O
melanism	B-MED
was	O
only	O
17	O
%	O
.	O
The	O
small	B-MED
size	I-MED
was	O
typical	B-MED
for	O
the	O
adders	B-MED
in	O
Southern	B-MED
Altay	I-MED
Mountains	I-MED
in	O
contrast	O
to	O
other	O
geographic	B-MED
populations	I-MED
of	O
the	O
nominate	B-MED
subspecies	B-MED
.	O
A	O
phylogenetic	B-MED
tree	I-MED
obtained	B-MED
by	O
Bayesian	B-MED
Inference	I-MED
based	O
on	O
DNA	B-MED
sequences	I-MED
of	O
the	O
mitochondrial	B-MED
cytochrome	I-MED
b	I-MED
(	O
1,023	O
bp	O
)	O
grouped	B-MED
them	O
within	O
the	O
Northern	B-MED
clade	I-MED
of	O
the	O
species	B-MED
but	O
failed	O
to	O
separate	B-MED
them	O
from	O
the	O
subspecies	B-MED
V.	B-MED
b.	I-MED
sachalinensis	I-MED
.	O
Our	O
discovery	B-MED
extends	O
the	O
distribution	B-MED
range	B-MED
of	O
V.	B-MED
berus	I-MED
and	O
provides	O
a	O
basis	B-MED
for	O
further	O
researches	B-MED
.	O
We	O
discuss	O
the	O
hypothesis	B-MED
that	O
the	O
adder	B-MED
expands	B-MED
its	O
distribution	B-MED
border	B-MED
to	O
the	O
southwest	B-MED
along	O
the	O
mountains	B-MED
'	O
elevation	B-MED
gradient	B-MED
,	O
but	O
the	O
population	B-MED
abundance	B-MED
declines	B-MED
gradually	B-MED
due	O
to	O
a	O
drying	B-MED
climate	I-MED
.	O
Effect	B-MED
of	O
ultrasonic	B-MED
processing	B-MED
on	O
the	O
changes	O
in	O
activity	B-MED
,	O
aggregation	B-MED
and	O
the	O
secondary	B-MED
and	O
tertiary	B-MED
structure	I-MED
of	O
polyphenol	B-MED
oxidase	I-MED
in	O
oriental	B-MED
sweet	B-MED
melon	I-MED
(	O
Cucumis	B-MED
melo	I-MED
var	I-MED
.	I-MED
makuwa	I-MED
Makino	I-MED
)	O
Polyphenol	B-MED
oxidase	I-MED
(	O
PPO	B-MED
)	O
mainly	O
contributes	B-MED
to	O
the	O
browning	B-MED
reaction	I-MED
of	O
fruits	B-MED
and	O
vegetables	B-MED
and	O
causes	O
serious	B-MED
damage	B-MED
to	O
the	O
quality	B-MED
of	O
sweet	B-MED
melon	I-MED
products	B-MED
.	O
However	O
,	O
traditional	B-MED
methods	B-MED
to	O
inactivate	B-MED
browning	B-MED
may	O
induce	B-MED
more	O
unexpected	B-MED
risks	B-MED
than	O
ultrasonic	B-MED
processing	B-MED
.	O
Meanwhile	O
,	O
there	O
are	O
no	O
reports	B-MED
on	O
the	O
effect	B-MED
of	O
ultrasound	B-MED
on	O
PPO	B-MED
directly	O
purified	B-MED
from	O
sweet	B-MED
melon	I-MED
.	O
The	O
PPO	B-MED
in	O
the	O
original	B-MED
juice	B-MED
was	O
less	O
inactivated	B-MED
than	O
the	O
purified	B-MED
form	O
when	O
treated	B-MED
with	I-MED
ultrasound	B-MED
.	O
As	O
for	O
purified	B-MED
PPO	B-MED
,	O
superior	O
to	O
thermal	B-MED
treatment	I-MED
,	O
less	O
heat	B-MED
was	O
needed	O
to	O
inactivate	B-MED
the	O
PPO	B-MED
with	O
ultrasonic	B-MED
treatment	B-MED
.	O
At	O
intensity	B-MED
lower	I-MED
than	O
200	O
W	O
,	O
ultrasound	B-MED
did	O
not	O
significantly	B-MED
affect	O
the	O
structure	B-MED
and	O
activity	B-MED
of	O
PPO	B-MED
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
latent	B-MED
PPO	B-MED
was	O
activated	B-MED
.	O
At	O
intensity	B-MED
higher	I-MED
than	O
200	O
W	O
,	O
ultrasound	B-MED
inactivated	B-MED
PPO	B-MED
,	O
induced	B-MED
aggregation	B-MED
and	O
dissociation	B-MED
of	O
PPO	B-MED
particles	B-MED
and	O
significantly	B-MED
decreased	I-MED
the	O
α	B-MED
-	I-MED
helix	I-MED
structure	I-MED
content	O
.	O
Low	B-MED
-	I-MED
frequency	I-MED
high	B-MED
-	I-MED
intensity	I-MED
ultrasound	B-MED
caused	O
an	O
inactivation	B-MED
effect	B-MED
and	O
conformational	B-MED
changes	I-MED
of	O
purified	B-MED
PPO	B-MED
from	O
oriental	B-MED
sweet	B-MED
melons	I-MED
.	O
Changes	B-MED
in	O
the	O
PPO	B-MED
structure	B-MED
induced	B-MED
by	O
ultrasound	B-MED
eventually	O
inactivated	B-MED
the	O
enzyme	B-MED
.	O
Ultrasound	B-MED
may	O
be	O
a	O
potential	B-MED
method	B-MED
to	O
inactivate	B-MED
PPO	B-MED
in	O
oriental	B-MED
sweet	B-MED
melons	I-MED
.	O
©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O
Decoding	B-MED
the	O
Interactions	B-MED
Regulating	B-MED
the	O
Active	B-MED
State	I-MED
Mechanics	B-MED
of	O
Eukaryotic	B-MED
Protein	B-MED
Kinases	I-MED
Eukaryotic	B-MED
protein	B-MED
kinases	I-MED
regulate	B-MED
most	O
cellular	B-MED
functions	I-MED
by	O
phosphorylating	B-MED
targeted	B-MED
protein	B-MED
substrates	B-MED
through	B-MED
a	O
highly	B-MED
conserved	B-MED
catalytic	B-MED
core	I-MED
.	O
In	O
the	O
active	B-MED
state	I-MED
,	O
the	O
catalytic	B-MED
core	I-MED
oscillates	B-MED
between	O
open	B-MED
,	O
intermediate	B-MED
,	O
and	O
closed	B-MED
conformations	B-MED
.	O
Currently	B-MED
,	O
the	O
intramolecular	B-MED
interactions	I-MED
that	O
regulate	B-MED
the	O
active	B-MED
state	I-MED
mechanics	B-MED
are	O
not	B-MED
well	I-MED
understood	I-MED
.	O
Here	O
,	O
using	O
cAMP	B-MED
-	I-MED
dependent	I-MED
protein	I-MED
kinase	I-MED
as	O
a	O
representative	B-MED
model	B-MED
coupled	B-MED
with	O
biochemical	B-MED
,	O
biophysical	B-MED
,	O
and	O
computational	B-MED
techniques	I-MED
,	O
we	O
define	O
a	O
set	O
of	O
highly	B-MED
conserved	B-MED
electrostatic	B-MED
and	O
hydrophobic	B-MED
interactions	I-MED
working	O
harmoniously	B-MED
to	O
regulate	B-MED
these	O
mechanics	B-MED
.	O
These	O
include	B-MED
the	O
previously	B-MED
identified	B-MED
salt	B-MED
bridge	I-MED
between	O
a	O
lysine	B-MED
from	O
the	O
β3	B-MED
-	I-MED
strand	I-MED
and	O
a	O
glutamate	B-MED
from	O
the	O
αC	B-MED
-	I-MED
helix	I-MED
as	O
well	O
as	O
an	O
electrostatic	B-MED
interaction	I-MED
between	O
the	O
phosphorylated	B-MED
activation	B-MED
loop	B-MED
and	O
αC	B-MED
-	I-MED
helix	I-MED
and	O
an	O
ensemble	B-MED
of	O
hydrophobic	B-MED
residues	B-MED
of	O
the	O
Regulatory	O
spine	O
and	O
Shell	O
.	O
Moreover	O
,	O
for	O
over	O
three	O
decades	B-MED
it	O
was	O
thought	O
that	O
the	O
highly	B-MED
conserved	B-MED
β3	B-MED
β3	B-MED
-lysine	I-MED
was	O
essential	B-MED
for	O
phosphoryl	B-MED
transfer	I-MED
,	O
but	O
our	O
findings	B-MED
show	O
that	O
the	O
β3	B-MED
β3	B-MED
-lysine	I-MED
is	O
not	O
required	O
for	O
phosphoryl	B-MED
transfer	I-MED
but	O
is	O
essential	B-MED
for	O
the	O
active	B-MED
state	I-MED
mechanics	B-MED
.	O
Changes	B-MED
in	O
risk	B-MED
factors	I-MED
for	O
young	B-MED
male	B-MED
suicide	B-MED
in	O
Newcastle	B-MED
upon	I-MED
Tyne	I-MED
,	O
1961	O
-	O
2009	O
Aims	B-MED
and	O
method	B-MED
To	O
ascertain	O
differences	B-MED
in	O
patterns	B-MED
of	I-MED
suicide	I-MED
in	O
young	B-MED
men	B-MED
over	O
three	O
decades	B-MED
(	O
1960s	O
,	O
1990s	O
and	O
2000s	O
)	O
and	O
discuss	O
implications	B-MED
for	O
suicide	B-MED
prevention	B-MED
.	O
Data	B-MED
on	O
suicides	B-MED
and	O
open	B-MED
verdicts	I-MED
in	O
men	B-MED
aged	O
15	O
-	O
34	O
were	O
obtained	O
from	O
coroner	B-MED
's	I-MED
records	I-MED
in	O
Newcastle	B-MED
upon	I-MED
Tyne	I-MED
and	O
analysed	B-MED
using	O
SPSS	B-MED
software	I-MED
.	O
Results	B-MED
An	O
increase	B-MED
in	O
suicide	B-MED
rates	I-MED
from	O
the	O
first	O
to	O
the	O
second	O
decade	B-MED
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	B-MED
.	O
This	O
was	O
associated	B-MED
with	I-MED
an	O
increasing	B-MED
proportion	B-MED
of	O
single	B-MED
men	B-MED
,	O
those	O
living	B-MED
alone	I-MED
,	O
unemployment	B-MED
,	O
consumption	B-MED
of	I-MED
alcohol	I-MED
,	O
use	O
of	O
hanging	B-MED
,	O
previous	B-MED
suicide	B-MED
attempt	I-MED
and	O
history	B-MED
of	I-MED
treatment	I-MED
for	O
mental	B-MED
illness	I-MED
.	O
Clinical	B-MED
implications	B-MED
This	O
study	B-MED
highlights	O
the	O
need	O
for	O
more	O
interventions	B-MED
and	O
focus	B-MED
to	O
be	O
given	O
to	O
young	B-MED
males	B-MED
in	O
the	O
suicide	B-MED
prevention	B-MED
area	I-MED
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	B-MED
of	I-MED
public	I-MED
health	I-MED
.	O
Areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	B-MED
access	B-MED
to	O
means	B-MED
of	O
suicide	B-MED
,	O
reducing	B-MED
alcohol	B-MED
use	I-MED
,	O
support	B-MED
for	O
relationship	B-MED
difficulties	B-MED
,	O
engagement	B-MED
with	O
mental	B-MED
health	I-MED
services	I-MED
and	O
management	B-MED
of	O
chronic	B-MED
illness	I-MED
.	O
C4b	B-MED
binding	I-MED
protein	I-MED
negatively	B-MED
regulates	I-MED
TLR1	B-MED
/	O
2	B-MED
response	B-MED
TLR2	B-MED
associates	B-MED
with	I-MED
TLR1	B-MED
and	O
recognizes	O
microbial	B-MED
lipoproteins	B-MED
.	O
Pam3CSK4	B-MED
,	O
a	O
triacylated	B-MED
lipoprotein	I-MED
,	O
is	O
anchored	B-MED
to	O
the	O
extracellular	B-MED
domain	I-MED
of	O
TLR1	B-MED
and	O
TLR2	B-MED
and	O
induces	B-MED
pro	B-MED
-	I-MED
inflammatory	I-MED
signals	B-MED
.	O
Here	O
we	O
show	O
that	O
C4b	B-MED
binding	I-MED
protein	I-MED
(	O
C4BP	B-MED
)	O
,	O
which	O
is	O
a	O
complement	B-MED
pathway	I-MED
inhibitor	B-MED
,	O
is	O
a	O
TLR2	B-MED
-associated	O
molecule	O
.	O
Immunoprecipitation	B-MED
assay	I-MED
using	O
anti	B-MED
-	I-MED
TLR2	I-MED
mAb	I-MED
shows	O
that	O
C4BP	B-MED
binds	B-MED
to	I-MED
TLR2	B-MED
.	O
In	O
C4BP	B-MED
-	I-MED
deficient	I-MED
mice	B-MED
,	O
Pam3CSK4	B-MED
-	O
induced	B-MED
IL-6	B-MED
levels	B-MED
were	O
increased	B-MED
compared	B-MED
with	O
wild	B-MED
type	I-MED
mice	I-MED
.	O
In	O
C4BP	B-MED
-	O
expressing	B-MED
cells	B-MED
,	O
Pam3CSK4	B-MED
-	O
induced	B-MED
IL-8	B-MED
production	I-MED
was	O
reduced	B-MED
depending	O
on	O
the	O
C4BP	B-MED
expression	B-MED
levels	I-MED
.	O
These	O
results	O
reveal	B-MED
the	O
important	O
role	O
of	O
C4BP	B-MED
in	O
negative	B-MED
regulation	I-MED
of	O
TLR1	B-MED
/	O
2	B-MED
-	O
dependent	B-MED
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokine	B-MED
production	I-MED
.	O
Furthermore	O
,	O
using	O
a	O
fluorescent	B-MED
conjugated	I-MED
Pam3CSK4	B-MED
,	O
we	O
show	O
that	O
C4BP	B-MED
blocks	B-MED
the	O
binding	B-MED
of	I-MED
Pam3CSK4	B-MED
to	O
TLR1	B-MED
/	O
2	B-MED
.	O
Finally	O
,	O
we	O
show	O
that	O
exogenous	B-MED
C4BP	B-MED
also	O
inhibits	B-MED
Pam3CSK4	B-MED
-	O
induced	B-MED
signaling	I-MED
leading	O
to	O
IL-8	B-MED
production	I-MED
.	O
Our	O
results	O
indicate	O
C4BP	B-MED
binding	B-MED
to	I-MED
TLR2	B-MED
and	O
consequent	B-MED
neutralization	B-MED
of	O
its	O
activity	B-MED
otherwise	O
inducing	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokine	B-MED
production	I-MED
.	O
C4BP	B-MED
is	O
a	O
negative	B-MED
regulator	I-MED
of	O
TLR1	B-MED
/	O
2	B-MED
activity	B-MED
.	O
Recent	B-MED
advances	B-MED
in	O
chitosan	B-MED
-based	O
nanoparticulate	B-MED
pulmonary	B-MED
drug	B-MED
delivery	I-MED
The	O
advent	O
of	O
biodegradable	B-MED
polymer	I-MED
-	O
encapsulated	B-MED
drug	B-MED
nanoparticles	B-MED
has	O
made	O
the	O
pulmonary	B-MED
route	B-MED
of	I-MED
administration	I-MED
an	O
exciting	O
area	O
of	O
drug	B-MED
delivery	I-MED
research	B-MED
.	O
Chitosan	B-MED
,	O
a	O
natural	B-MED
biodegradable	B-MED
and	O
biocompatible	B-MED
polysaccharide	B-MED
has	O
received	B-MED
enormous	O
attention	O
as	O
a	O
carrier	B-MED
for	O
drug	B-MED
delivery	I-MED
.	O
Recently	O
,	O
nanoparticles	B-MED
of	O
chitosan	B-MED
(	O
CS	B-MED
)	O
and	O
its	O
synthetic	B-MED
derivatives	I-MED
have	O
been	O
investigated	B-MED
for	O
the	O
encapsulation	B-MED
and	O
delivery	B-MED
of	O
many	O
drugs	B-MED
with	O
improved	B-MED
targeting	B-MED
and	O
controlled	B-MED
release	I-MED
.	O
Herein	O
,	O
recent	B-MED
advances	B-MED
in	O
the	O
preparation	B-MED
and	O
use	B-MED
of	I-MED
micro-	B-MED
/	O
nanoparticles	B-MED
of	O
chitosan	B-MED
and	O
its	O
derivatives	B-MED
for	O
pulmonary	B-MED
delivery	B-MED
of	O
various	O
therapeutic	B-MED
agents	I-MED
(	O
drugs	B-MED
,	O
genes	B-MED
,	O
vaccines	B-MED
)	O
are	O
reviewed	B-MED
.	O
Although	O
chitosan	B-MED
has	O
wide	O
applications	B-MED
in	O
terms	O
of	O
formulations	B-MED
and	O
routes	B-MED
of	I-MED
drug	I-MED
delivery	I-MED
,	O
this	O
review	B-MED
is	O
focused	O
on	O
pulmonary	B-MED
delivery	B-MED
of	I-MED
drug	I-MED
-	I-MED
encapsulated	I-MED
nanoparticles	I-MED
of	O
chitosan	B-MED
and	O
its	O
derivatives	B-MED
.	O
In	O
addition	O
,	O
the	O
controversial	B-MED
toxicological	B-MED
effects	I-MED
of	O
chitosan	B-MED
nanoparticles	B-MED
for	O
lung	B-MED
delivery	B-MED
will	O
also	O
be	O
discussed	O
.	O
Sulfur	B-MED
and	O
Zinc	B-MED
Availability	B-MED
from	O
Co	B-MED
-	I-MED
granulated	I-MED
Zn	B-MED
-Enriched	O
Elemental	B-MED
Sulfur	I-MED
Fertilizers	B-MED
Acidification	B-MED
by	O
oxidation	B-MED
of	O
elemental	B-MED
sulfur	I-MED
(	O
ES	B-MED
)	O
can	O
solubilize	O
ZnO	B-MED
,	O
providing	O
slow	B-MED
release	B-MED
of	O
both	O
sulfur	B-MED
(	O
S	B-MED
)	O
and	O
zinc	B-MED
(	O
Zn	B-MED
)	O
in	O
soil	O
.	O
For	O
this	O
study	O
,	O
a	O
new	O
granular	B-MED
fertilizer	B-MED
with	O
ES	B-MED
and	O
ZnO	B-MED
was	O
produced	O
and	O
evaluated	B-MED
.	O
The	O
effect	B-MED
of	O
incorporating	O
microorganisms	B-MED
or	O
a	O
carbon	B-MED
source	B-MED
in	O
the	O
granule	B-MED
was	O
also	O
evaluated	B-MED
.	O
Four	O
granulated	B-MED
ES	B-MED
-	I-MED
Zn	I-MED
fertilizers	I-MED
with	O
and	O
without	B-MED
S	B-MED
-	I-MED
oxidizing	I-MED
microorganisms	I-MED
,	O
a	O
commercial	O
ES	O
pastille	O
,	O
ZnSO4	B-MED
,	O
and	O
ZnO	B-MED
were	O
applied	O
to	O
the	O
center	B-MED
of	O
Petri	B-MED
dishes	I-MED
containing	O
two	O
contrasting	B-MED
pH	B-MED
soils	B-MED
.	O
Soil	B-MED
pH	B-MED
,	O
CaCl2	B-MED
-extractable	O
S	B-MED
and	O
Zn	B-MED
,	O
and	O
remaining	O
ES	B-MED
were	O
evaluated	B-MED
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	B-MED
sections	I-MED
(	O
0	O
-	O
5	O
and	O
5	O
-	O
9	O
mm	O
from	O
the	O
fertilizer	B-MED
application	B-MED
site	I-MED
)	O
.	O
A	O
visualization	B-MED
test	I-MED
was	O
performed	O
to	O
evaluate	O
Zn	B-MED
diffusion	B-MED
over	O
time	O
.	O
A	O
significant	B-MED
pH	B-MED
decrease	I-MED
was	O
observed	B-MED
in	O
the	O
acidic	B-MED
soil	B-MED
for	O
all	O
ES	B-MED
-	I-MED
Zn	I-MED
fertilizer	I-MED
treatments	B-MED
and	O
in	O
the	O
alkaline	B-MED
soil	B-MED
for	O
the	O
Acidithiobacillus	B-MED
thiooxidans	I-MED
-	O
inoculated	B-MED
treatment	I-MED
only	O
.	O
In	O
agreement	O
with	O
Zn	B-MED
visualization	B-MED
tests	I-MED
,	O
extractable-	O
Zn	B-MED
concentrations	B-MED
were	O
higher	B-MED
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	B-MED
(	O
62.9	O
mg	O
dm(-3	O
)	O
)	O
compared	O
to	O
the	O
alkaline	B-MED
soil	B-MED
(	O
5.5	O
mg	O
dm(-3	O
)	O
)	O
.	O
Elemental	B-MED
S	I-MED
oxidation	I-MED
was	O
greater	B-MED
in	O
the	O
acidic	B-MED
soil	B-MED
(	O
20.9	O
%	O
)	O
than	O
slightly	O
alkaline	B-MED
soil	B-MED
(	O
12	O
%	O
)	O
.	O
The	O
ES	B-MED
-	I-MED
Zn	I-MED
granular	I-MED
fertilizers	I-MED
increased	B-MED
S	B-MED
and	O
Zn	B-MED
concentrations	B-MED
in	O
soil	B-MED
and	O
can	O
provide	O
a	O
strategically	O
slow	B-MED
release	B-MED
of	O
nutrients	B-MED
to	O
the	O
soil	B-MED
.	O
Genomic	B-MED
characterization	B-MED
of	O
a	O
wild	B-MED
-	I-MED
bird	I-MED
-	O
origin	B-MED
pigeon	B-MED
paramyxovirus	B-MED
type	I-MED
1	I-MED
(	O
PPMV-1	B-MED
)	O
first	O
isolated	B-MED
in	O
the	O
northwest	B-MED
region	I-MED
of	I-MED
China	I-MED
Pigeon	B-MED
paramyxovirus	B-MED
type-1	I-MED
(	O
PPMV-1	B-MED
)	O
is	O
an	O
enzootic	B-MED
in	O
pigeon	B-MED
flocks	B-MED
and	O
causes	O
severe	B-MED
economic	B-MED
losses	I-MED
in	O
the	O
poultry	B-MED
industry	B-MED
in	O
many	O
countries	B-MED
.	O
A	O
PPMV-1	B-MED
isolate	B-MED
,	O
abbreviated	O
as	O
PPMV-1	B-MED
/	I-MED
QL-01	I-MED
/	I-MED
CH/15	I-MED
,	O
was	O
isolated	B-MED
from	O
a	O
great	O
spotted	O
woodpecker	B-MED
in	O
the	O
northwest	B-MED
region	I-MED
of	I-MED
China	I-MED
in	O
2015	O
.	O
The	O
complete	O
genome	B-MED
was	O
sequenced	B-MED
,	O
and	O
the	O
results	B-MED
showed	O
that	O
the	O
virus	B-MED
genome	B-MED
was	O
15,192	O
nt	O
in	O
length	B-MED
,	O
in	O
the	O
gene	B-MED
arrangement	I-MED
3'-NP	I-MED
-	I-MED
P	I-MED
-	I-MED
M	I-MED
-	I-MED
F	I-MED
-	I-MED
HN	I-MED
-	I-MED
L-5	I-MED
'	I-MED
.	O
Several	O
amino	B-MED
acid	I-MED
mutations	B-MED
were	O
identified	B-MED
in	O
the	O
functional	B-MED
domains	I-MED
of	O
the	O
F	B-MED
and	O
HN	B-MED
proteins	I-MED
.	O
The	O
pathogenicity	B-MED
index	I-MED
of	O
the	O
isolate	B-MED
was	O
evaluated	B-MED
,	O
and	O
the	O
mean	B-MED
death	I-MED
time	I-MED
(	O
MDT	B-MED
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral	B-MED
pathogenicity	I-MED
index	I-MED
(	O
ICPI	B-MED
)	O
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	B-MED
was	O
mesogenic	B-MED
.	O
Sequencing	B-MED
results	B-MED
showed	O
that	O
it	O
had	O
a	O
virulent	B-MED
Newcastle	B-MED
disease	I-MED
virus	I-MED
cleavage	B-MED
motif	I-MED
(	I-MED
112)R	I-MED
-	I-MED
R	I-MED
-	I-MED
Q	I-MED
-	I-MED
K	I-MED
-	I-MED
R	I-MED
-	I-MED
F(117	I-MED
)	I-MED
at	O
the	O
fusion	B-MED
protein	I-MED
cleavage	B-MED
site	I-MED
.	O
Morbidity	B-MED
and	O
mortality	B-MED
were	O
70	O
%	O
and	O
50	O
%	O
,	O
after	O
inoculation	B-MED
of	O
pigeons	B-MED
,	O
whereas	O
this	O
virus	B-MED
was	O
nonpathogenic	B-MED
in	O
chickens	B-MED
.	O
Different	O
immune	B-MED
responses	I-MED
of	O
pigeons	B-MED
and	O
chickens	B-MED
were	O
induced	B-MED
in	B-MED
vivo	I-MED
,	O
which	O
led	O
to	O
different	O
HI	B-MED
serum	I-MED
antibody	I-MED
titers	I-MED
.	O
The	O
results	B-MED
of	O
phylogenetic	B-MED
and	O
evolutionary	B-MED
distance	I-MED
analysis	I-MED
showed	O
that	O
this	O
PPMV-1	B-MED
strain	B-MED
belonged	O
to	O
sub	B-MED
-	I-MED
genotype	I-MED
VIa	I-MED
in	O
class	B-MED
II	I-MED
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-MED
and	O
analysis	B-MED
of	O
PPMV-1	B-MED
co	B-MED
-	I-MED
circulation	I-MED
among	O
wild	B-MED
birds	I-MED
and	O
domestic	B-MED
pigeon	I-MED
flocks	B-MED
in	O
China	B-MED
.	O
The	O
data	B-MED
from	O
this	O
study	B-MED
highlight	O
the	O
important	O
role	O
of	O
wild	B-MED
birds	I-MED
in	O
the	O
dissemination	B-MED
of	O
PPMV-1	B-MED
and	O
provide	O
useful	O
references	B-MED
for	O
improving	B-MED
our	O
understanding	O
of	O
the	O
distribution	B-MED
and	O
evolution	B-MED
of	O
PPMV-1	B-MED
in	O
China	B-MED
.	O
Self	B-MED
-	I-MED
reported	I-MED
occupational	B-MED
injuries	I-MED
among	O
industrial	B-MED
beef	B-MED
slaughterhouse	B-MED
workers	B-MED
in	O
the	O
Midwestern	B-MED
United	I-MED
States	I-MED
Although	O
workers	B-MED
in	O
meatpacking	B-MED
facilities	I-MED
in	O
the	O
United	B-MED
States	I-MED
experience	O
high	B-MED
rates	I-MED
of	O
occupational	B-MED
injury	I-MED
,	O
their	O
injury	B-MED
experiences	O
have	O
received	O
limited	O
research	B-MED
attention	O
.	O
Prior	O
research	B-MED
indicates	I-MED
underreporting	B-MED
in	O
injury	B-MED
rates	I-MED
in	O
this	O
industry	B-MED
as	O
well	O
significant	O
variation	O
in	O
injury	B-MED
rates	I-MED
among	O
facilities	O
.	O
To	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational	B-MED
injury	I-MED
among	O
meatpacking	B-MED
workers	B-MED
,	O
we	O
conducted	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
of	O
workers	B-MED
employed	O
at	O
an	O
industrial	B-MED
beefpacking	I-MED
plant	I-MED
in	O
Nebraska	B-MED
,	O
United	B-MED
States	I-MED
(	O
n	O
=	O
137	O
)	O
and	O
interviewed	O
workers	B-MED
about	O
recent	O
injury	B-MED
experiences	O
.	O
We	O
assessed	O
frequency	O
,	O
cause	O
and	O
nature	O
of	O
self	B-MED
-	I-MED
reported	I-MED
injury	B-MED
.	O
We	O
estimated	O
annual	B-MED
incidence	I-MED
rates	I-MED
of	O
self	B-MED
-	I-MED
reported	I-MED
injuries	B-MED
using	O
the	O
OSHA	B-MED
formula	B-MED
and	O
compared	O
these	O
rates	O
to	O
industry	B-MED
-	I-MED
wide	I-MED
data	I-MED
.	O
We	O
also	O
evaluated	O
psychological	B-MED
distress	I-MED
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
Kessler-6	B-MED
scale	I-MED
to	O
assess	O
whether	O
distress	B-MED
was	O
associated	B-MED
with	I-MED
recent	O
occupational	B-MED
injury	I-MED
injury	B-MED
.	O
In	O
this	O
study	O
,	O
15.1	O
%	O
of	O
workers	B-MED
experienced	O
occupational	B-MED
injuries	I-MED
that	O
required	O
time	O
off	O
work	O
,	O
job	B-MED
transfer	I-MED
,	O
or	O
restriction	B-MED
during	I-MED
the	O
past	O
three	O
months	O
.	O
The	O
estimated	O
annual	B-MED
incidence	I-MED
rate	I-MED
was	O
15.2	O
injuries	B-MED
per	O
100	O
full	O
-	O
time	O
workers	B-MED
for	O
these	O
injuries	B-MED
at	O
this	O
plant	B-MED
.	O
Rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50	O
%	O
of	O
injuries	B-MED
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20	O
%	O
of	O
injuries	B-MED
.	O
Use	O
of	O
metal	B-MED
mesh	I-MED
sleeves	B-MED
(	O
POR	O
:	O
0.10	O
(	O
p	O
=	O
0.008	O
)	O
)	O
and	O
metal	B-MED
mesh	I-MED
gloves	B-MED
(	O
POR	O
:	O
0.41	O
(	O
p	O
=	O
0.05	O
)	O
were	O
associated	B-MED
with	I-MED
reduced	O
risk	O
of	O
injury	B-MED
.	O
Use	O
of	O
a	O
carbon	B-MED
steel	B-MED
for	O
knife	B-MED
sharpening	O
(	O
POR	O
:	O
5.2	O
(	O
p	O
=	O
0.02	O
)	O
)	O
was	O
associated	B-MED
with	I-MED
elevated	O
risk	O
of	O
moderate	B-MED
and	I-MED
severe	I-MED
injury	B-MED
.	O
There	O
were	O
no	O
associations	O
between	O
self	B-MED
-	I-MED
reported	I-MED
occupational	B-MED
injury	I-MED
and	O
overall	O
measures	O
of	O
psychological	B-MED
distress	I-MED
.	O
Self	B-MED
-	I-MED
reported	I-MED
incidence	B-MED
rate	I-MED
of	O
severe	B-MED
injury	B-MED
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry	B-MED
estimates	I-MED
.	O
Worker	O
self	B-MED
-	I-MED
reports	I-MED
may	O
illustrate	O
key	O
areas	O
for	O
injury	B-MED
prevention	I-MED
.	O
IL-27	B-MED
Is	O
Essential	O
for	O
Suppression	B-MED
of	O
Experimental	B-MED
Allergic	B-MED
Asthma	I-MED
by	O
the	O
TLR7	B-MED
/	O
8	B-MED
Agonist	B-MED
R848	B-MED
(	O
Resiquimod	B-MED
)	O
Different	O
models	B-MED
of	I-MED
experimental	I-MED
allergic	B-MED
asthma	I-MED
have	O
shown	O
that	O
the	O
TLR7	B-MED
/	O
8	B-MED
agonist	B-MED
resiquimod	B-MED
(	O
R848	B-MED
)	O
is	O
a	O
potential	O
inhibitor	B-MED
of	O
type	B-MED
2	I-MED
helper	I-MED
cell	I-MED
-driven	O
inflammatory	B-MED
responses	I-MED
.	O
However	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	B-MED
effects	I-MED
are	O
not	O
fully	O
understood	O
.	O
Using	O
a	O
model	B-MED
of	I-MED
experimental	I-MED
allergic	B-MED
asthma	I-MED
,	O
we	O
show	O
that	O
induction	B-MED
of	O
IL-27	B-MED
by	O
R848	B-MED
is	O
critical	O
for	O
the	O
observed	O
ameliorative	B-MED
effects	O
.	O
R848	B-MED
significantly	O
inhibited	B-MED
all	O
hallmarks	B-MED
of	O
experimental	B-MED
allergic	B-MED
asthma	I-MED
,	O
including	O
airway	B-MED
hyperreactivity	I-MED
,	O
eosinophilic	B-MED
airway	B-MED
inflammation	B-MED
,	O
mucus	B-MED
hypersecretion	I-MED
,	O
and	O
Ag	B-MED
-	O
specific	B-MED
Ig	I-MED
production	B-MED
.	O
Whereas	O
R848	B-MED
significantly	O
reduced	O
IL-5	B-MED
,	O
IL-13	B-MED
,	O
and	O
IL-17	B-MED
,	O
it	O
induced	O
IFN	B-MED
-	I-MED
γ	I-MED
and	O
IL-27	B-MED
.	O
Neutralization	B-MED
of	O
IL-27	B-MED
completely	O
reversed	O
the	O
therapeutic	B-MED
effect	I-MED
of	O
R848	B-MED
in	O
the	O
experimental	B-MED
asthma	B-MED
model	B-MED
,	O
demonstrating	O
dependence	O
of	O
R848	B-MED
-mediated	O
suppression	B-MED
on	O
IL-27	B-MED
.	O
In	B-MED
vitro	I-MED
,	O
R848	B-MED
induced	B-MED
production	O
of	O
IL-27	B-MED
by	O
murine	B-MED
alveolar	B-MED
macrophages	I-MED
and	O
dendritic	B-MED
cells	I-MED
and	O
enhanced	B-MED
expression	B-MED
of	O
programmed	B-MED
death	I-MED
-	I-MED
ligand	I-MED
1	I-MED
,	O
whose	O
expression	B-MED
on	O
monocytes	B-MED
and	O
dendritic	B-MED
cells	I-MED
has	O
been	O
shown	O
to	O
regulate	B-MED
peripheral	B-MED
tolerance	I-MED
in	O
both	O
murine	B-MED
and	O
human	B-MED
studies	O
.	O
Moreover	O
,	O
in	B-MED
vitro	I-MED
IL-27	B-MED
enhanced	B-MED
secretion	B-MED
of	O
IFN	B-MED
-	I-MED
γ	I-MED
whereas	O
it	O
inhibited	B-MED
IL-5	B-MED
and	O
IL-13	B-MED
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	B-MED
responses	O
.	O
Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	B-MED
-mediated	O
suppression	B-MED
of	O
experimental	B-MED
asthma	B-MED
is	O
dependent	O
on	O
IL-27	B-MED
.	O
These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL-27	B-MED
for	O
the	O
control	O
of	O
Th2	B-MED
-mediated	O
allergic	B-MED
diseases	I-MED
.	O
Prediction	B-MED
of	O
Estrogenic	B-MED
Bioactivity	B-MED
of	O
Environmental	B-MED
Chemical	I-MED
Metabolites	B-MED
The	O
US	B-MED
Environmental	I-MED
Protection	I-MED
Agency	I-MED
's	I-MED
(	O
EPA	B-MED
)	O
Endocrine	B-MED
Disruptor	I-MED
Screening	I-MED
Program	I-MED
(	O
EDSP	B-MED
)	O
is	O
using	O
in	B-MED
vitro	I-MED
data	I-MED
generated	O
from	O
ToxCast	B-MED
/	O
Tox21	B-MED
high	B-MED
-	I-MED
throughput	I-MED
screening	I-MED
assays	I-MED
to	O
assess	O
the	O
endocrine	B-MED
activity	B-MED
of	O
environmental	B-MED
chemicals	I-MED
.	O
Considering	O
that	O
in	B-MED
vitro	I-MED
assays	I-MED
may	O
have	O
limited	O
metabolic	B-MED
capacity	I-MED
,	O
inactive	B-MED
chemicals	I-MED
that	O
are	O
biotransformed	B-MED
into	O
metabolites	B-MED
with	O
endocrine	B-MED
bioactivity	B-MED
may	O
be	O
missed	O
for	O
further	O
screening	B-MED
and	O
testing	B-MED
.	O
Therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	B-MED
and	O
endocrine	B-MED
activity	B-MED
of	O
both	O
parent	B-MED
chemicals	I-MED
and	O
their	O
associated	O
metabolites	B-MED
.	O
We	O
used	O
commercially	O
available	O
software	B-MED
to	O
predict	O
metabolites	B-MED
of	O
50	O
parent	B-MED
compounds	I-MED
,	O
out	O
of	O
which	O
38	O
chemicals	B-MED
are	O
known	O
to	O
have	O
estrogenic	B-MED
metabolites	B-MED
,	O
and	O
12	O
compounds	B-MED
and	O
their	O
metabolites	B-MED
are	O
negative	O
for	O
estrogenic	B-MED
activity	B-MED
.	O
Three	O
ER	B-MED
QSAR	B-MED
models	B-MED
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-MED
bioactivity	B-MED
of	O
the	O
parent	B-MED
compounds	I-MED
and	O
predicted	O
metabolites	B-MED
,	O
the	O
outputs	O
of	O
the	O
models	B-MED
were	O
averaged	O
,	O
and	O
the	O
chemicals	B-MED
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	B-MED
of	O
the	O
parent	B-MED
chemical	I-MED
and	O
metabolites	B-MED
.	O
The	O
metabolite	B-MED
prediction	I-MED
software	I-MED
correctly	O
identified	O
known	O
estrogenic	B-MED
metabolites	B-MED
for	O
26	O
out	O
of	O
27	O
parent	B-MED
chemicals	I-MED
with	O
associated	O
metabolite	B-MED
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-MED
metabolites	B-MED
were	O
predicted	O
as	O
potential	O
biotransformation	B-MED
products	B-MED
derived	O
from	O
the	O
parent	B-MED
chemical	I-MED
.	O
The	O
QSAR	B-MED
models	B-MED
estimated	O
stronger	O
estrogenic	B-MED
activity	B-MED
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-MED
metabolites	B-MED
compared	O
to	O
their	O
parent	B-MED
chemicals	I-MED
.	O
Finally	O
,	O
the	O
three	O
models	B-MED
identified	O
a	O
similar	O
set	O
of	O
parent	B-MED
compounds	I-MED
as	O
top	O
ranked	O
chemicals	B-MED
based	O
on	O
the	O
estrogenicity	B-MED
of	O
putative	O
metabolites	B-MED
.	O
This	O
proposed	O
in	B-MED
silico	I-MED
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-MED
of	O
chemicals	B-MED
with	O
estrogenic	B-MED
metabolites	B-MED
and	O
may	O
reduce	O
potential	O
false	B-MED
negative	I-MED
results	O
from	O
in	B-MED
vitro	I-MED
assays	I-MED
.	O
Heavy	B-MED
Resistance	I-MED
Training	I-MED
in	O
Hypoxia	B-MED
Enhances	B-MED
1RM	B-MED
Squat	B-MED
Performance	B-MED
Purpose	O
:	O
To	O
determine	O
if	O
heavy	B-MED
resistance	I-MED
training	I-MED
in	O
hypoxia	B-MED
(	O
IHRT	B-MED
)	O
is	O
more	O
effective	B-MED
at	O
improving	B-MED
strength	B-MED
,	O
power	B-MED
,	O
and	O
increasing	B-MED
lean	B-MED
mass	I-MED
than	O
the	O
same	O
training	B-MED
in	O
normoxia	O
.	O
Methods	O
:	O
A	O
pair	B-MED
-	I-MED
matched	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
study	I-MED
design	B-MED
included	O
20	O
resistance	B-MED
-	I-MED
trained	I-MED
participants	B-MED
assigned	O
to	O
IHRT	B-MED
(	O
FIO2	B-MED
0.143	O
)	O
or	O
placebo	B-MED
(	O
FIO2	B-MED
0.20	O
)	O
,	O
(	O
n	O
=	O
10	O
per	O
group	B-MED
)	O
.	O
Participants	B-MED
were	O
matched	B-MED
for	O
strength	B-MED
and	O
training	B-MED
.	O
Both	B-MED
groups	B-MED
performed	B-MED
20	O
sessions	B-MED
over	O
7	O
weeks	B-MED
either	O
with	O
IHRT	B-MED
or	O
placebo	B-MED
.	O
All	O
participants	B-MED
were	O
tested	B-MED
for	O
1RM	B-MED
,	O
20	B-MED
-	I-MED
m	I-MED
sprint	B-MED
,	O
body	B-MED
composition	I-MED
,	O
and	O
countermovement	B-MED
jump	I-MED
pre	B-MED
-	O
,	O
mid	B-MED
-	O
,	O
and	O
post	B-MED
-	O
training	B-MED
and	O
compared	B-MED
via	O
magnitude	B-MED
-	O
based	B-MED
inferences	B-MED
.	O
Presentation	O
of	O
Results	O
:	O
Groups	B-MED
were	O
not	B-MED
clearly	I-MED
different	B-MED
for	O
any	O
test	B-MED
at	O
baseline	B-MED
.	O
Training	B-MED
improved	B-MED
both	B-MED
absolute	B-MED
(	O
IHRT	B-MED
:	O
13.1	O
±	O
3.9	O
%	O
,	O
effect	B-MED
size	I-MED
(	O
ES	B-MED
)	O
0.60	O
,	O
placebo	B-MED
9.8	O
±	O
4.7	O
%	O
,	O
ES	B-MED
0.31	O
)	O
and	O
relative	B-MED
1RM	B-MED
(	O
IHRT	B-MED
:	O
13.4	O
±	O
5.1	O
%	O
,	O
ES	B-MED
0.76	O
,	O
placebo	B-MED
9.7	O
±	O
5.3	O
%	O
,	O
ES	B-MED
0.48	O
)	O
at	O
mid	O
.	O
Similarly	O
,	O
at	O
post	B-MED
both	B-MED
groups	B-MED
increased	B-MED
absolute	B-MED
(	O
IHRT	B-MED
:	O
20.7	O
±	O
7.6	O
%	O
,	O
ES	B-MED
0.74	O
,	O
placebo	B-MED
14.1	O
±	O
6.0	O
%	O
,	O
ES	B-MED
0.58	O
)	O
and	O
relative	B-MED
1RM	B-MED
(	O
IHRT	B-MED
:	O
21.6	O
±	O
8.5	O
%	O
,	O
ES	B-MED
1.08	O
,	O
placebo	B-MED
13.2	O
±	O
6.4	O
%	O
,	O
ES	B-MED
0.78	O
)	O
.	O
Importantly	O
,	O
the	O
change	B-MED
in	O
IHRT	B-MED
was	O
greater	B-MED
than	O
placebo	B-MED
at	O
mid	O
for	O
both	B-MED
absolute	B-MED
[	O
4.4	O
%	O
greater	B-MED
change	B-MED
,	O
90	O
%	O
Confidence	B-MED
Interval	I-MED
(	O
CI	B-MED
)	O
1.0:8.0	O
%	O
,	O
ES	B-MED
0.21	O
,	O
and	O
relative	B-MED
strength	B-MED
(	O
5.6	O
%	O
greater	B-MED
change	B-MED
,	O
90	O
%	O
CI	B-MED
1.0:9.4	O
%	O
,	O
ES	B-MED
0.31	O
(	O
relative	B-MED
)	O
]	O
.	O
There	O
was	O
also	O
a	O
greater	B-MED
change	B-MED
for	O
IHRT	B-MED
at	O
post	O
for	O
both	B-MED
absolute	B-MED
(	O
7.0	O
%	O
greater	B-MED
change	B-MED
,	O
90	O
%	O
CI	B-MED
1.3:13	O
%	O
,	O
ES	B-MED
0.33	O
)	O
,	O
and	O
relative	B-MED
1RM	B-MED
(	O
9.2	O
%	O
greater	B-MED
change	B-MED
,	O
90	O
%	O
CI	B-MED
1.6:14.9	O
%	O
,	O
ES	B-MED
0.49	O
)	O
.	O
Only	O
IHRT	B-MED
increased	B-MED
countermovement	B-MED
jump	I-MED
peak	B-MED
power	B-MED
at	O
Post	B-MED
(	O
4.9	O
%	O
,	O
ES	B-MED
0.35	O
)	O
,	O
however	O
the	O
difference	B-MED
between	O
IHRT	B-MED
and	O
placebo	B-MED
was	O
unclear	B-MED
(	O
2.7	O
,	O
90	O
%	O
CI	B-MED
-2.0:7.6	O
%	O
,	O
ES	B-MED
0.20	O
)	O
with	O
no	B-MED
clear	I-MED
differences	B-MED
in	O
speed	B-MED
or	O
body	B-MED
composition	I-MED
throughout	O
.	O
Conclusion	O
:	O
Heavy	B-MED
resistance	I-MED
training	I-MED
in	O
hypoxia	B-MED
is	O
more	O
effective	B-MED
than	O
placebo	B-MED
for	O
improving	B-MED
absolute	B-MED
and	O
relative	B-MED
strength	B-MED
.	O
The	O
Evidence	B-MED
Behind	O
Integrating	B-MED
Palliative	B-MED
Care	I-MED
Into	O
Oncology	B-MED
Practice	B-MED
Palliative	B-MED
care	I-MED
services	I-MED
provided	B-MED
alongside	O
traditional	B-MED
oncology	B-MED
care	I-MED
have	O
been	O
shown	O
to	O
be	O
beneficial	B-MED
to	O
patients	B-MED
and	O
families	B-MED
.	O
This	O
article	B-MED
provides	O
a	O
brief	B-MED
history	B-MED
of	O
palliative	B-MED
care	I-MED
,	O
a	O
pathway	O
to	O
implementing	B-MED
these	O
services	B-MED
into	O
currently	B-MED
established	B-MED
oncology	B-MED
programs	I-MED
,	O
and	O
a	O
brief	O
discussion	B-MED
of	O
common	B-MED
barriers	I-MED
.	O
Insecticidal	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
in	O
laboratory	B-MED
and	O
field	B-MED
populations	B-MED
of	O
Culicoides	B-MED
species	I-MED
:	O
how	O
effective	O
are	O
host	B-MED
-	O
contact	B-MED
reduction	B-MED
methods	B-MED
in	O
India	B-MED
?	O
Bluetongue	B-MED
virus	I-MED
(	O
BTV	B-MED
)	O
is	O
transmitted	B-MED
by	O
Culicoides	B-MED
biting	B-MED
midges	I-MED
and	O
causes	O
bluetongue	B-MED
(	O
BT	B-MED
)	O
,	O
a	O
clinical	B-MED
disease	I-MED
observed	O
primarily	O
in	O
sheep	B-MED
.	O
BT	B-MED
has	O
a	O
detrimental	B-MED
effect	I-MED
on	O
subsistence	O
farmers	B-MED
in	O
India	B-MED
,	O
where	O
hyperendemic	B-MED
outbreaks	I-MED
impact	O
on	O
smallholdings	O
in	O
the	O
southern	B-MED
states	I-MED
of	O
the	O
country	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	B-MED
for	O
testing	O
the	O
toxic	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
on	O
Culicoides	B-MED
and	O
then	O
compare	O
deltamethrin	B-MED
with	O
traditional	B-MED
control	I-MED
methods	I-MED
used	O
by	O
farmers	B-MED
in	O
India	B-MED
.	O
Effects	O
of	O
deltamethrin	B-MED
were	O
initially	O
tested	O
using	O
a	O
colonised	B-MED
strain	I-MED
of	O
Culicoides	B-MED
nubeculosus	I-MED
Meigen	I-MED
and	O
a	O
modified	O
World	B-MED
Health	I-MED
Organisation	I-MED
exposure	B-MED
assay	I-MED
.	O
This	O
method	B-MED
was	O
then	O
applied	O
to	O
field	B-MED
populations	B-MED
of	O
Culicoides	B-MED
spp	I-MED
.	I-MED
in	O
India	B-MED
.	O
The	O
field	B-MED
population	B-MED
of	O
C.	B-MED
oxystoma	I-MED
in	O
India	B-MED
had	O
a	O
greater	O
LC50	O
(	O
0.012	O
±	O
0.009	O
%	O
)	O
for	O
deltamethrin	B-MED
than	O
laboratory	B-MED
-	I-MED
reared	I-MED
C.nubeculosus	B-MED
(	O
0.0013	O
±	O
0.0002	O
%	O
)	O
.	O
Exposure	O
of	O
C.	B-MED
nubeculosus	I-MED
to	O
deltamethrin	B-MED
at	O
higher	O
ambient	B-MED
temperatures	I-MED
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	B-MED
rate	I-MED
at	O
24	O
h	O
post	O
-	O
exposure	O
.	O
Behavioural	B-MED
assays	I-MED
with	O
C.	B-MED
nubeculosus	I-MED
in	O
WHO	B-MED
tubes	B-MED
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-MED
.	O
The	O
field	B-MED
experiments	B-MED
in	O
India	B-MED
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	B-MED
or	O
toxic	B-MED
effects	I-MED
of	O
deltamethrin	B-MED
.	O
Traditional	B-MED
methods	I-MED
such	O
as	O
the	O
application	B-MED
of	O
neem	B-MED
oil	I-MED
and	O
burning	B-MED
of	O
neem	B-MED
leaves	B-MED
also	O
provided	O
no	B-MED
protection	B-MED
.	O
Our	O
study	O
demonstrates	O
that	O
field	B-MED
-collected	O
Culicoides	B-MED
in	O
India	B-MED
are	O
less	O
susceptible	O
to	O
deltamethrin	B-MED
exposure	O
than	O
laboratory	B-MED
-	I-MED
bred	I-MED
C.	B-MED
nubeculosus	I-MED
and	O
traditional	B-MED
methods	I-MED
of	O
insect	B-MED
control	I-MED
do	O
not	O
provide	O
protection	B-MED
to	O
sheep	B-MED
.	O
These	O
low	O
levels	O
of	O
susceptibility	B-MED
to	O
deltamethrin	B-MED
have	O
not	O
been	O
recorded	O
before	O
in	O
field	B-MED
populations	B-MED
of	O
Culicoides	B-MED
and	O
suggest	O
resistance	B-MED
to	O
synthetic	B-MED
pyrethrioids	I-MED
.	O
Alternative	O
insect	B-MED
control	I-MED
methods	B-MED
,	O
in	O
addition	O
to	O
vaccination	B-MED
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	B-MED
livestock	B-MED
from	O
BTV	B-MED
transmission	B-MED
.	O
An	O
approach	O
to	O
functionally	O
relevant	O
clustering	B-MED
of	O
the	O
protein	B-MED
universe	I-MED
:	O
Active	B-MED
site	I-MED
profile	I-MED
-	I-MED
based	I-MED
clustering	I-MED
of	O
protein	B-MED
structures	I-MED
and	O
sequences	B-MED
Protein	B-MED
function	I-MED
identification	O
remains	O
a	O
significant	O
problem	O
.	O
Solving	O
this	O
problem	O
at	O
the	O
molecular	B-MED
functional	I-MED
level	I-MED
would	O
allow	O
mechanistic	O
determinant	O
identification-	O
amino	B-MED
acids	I-MED
that	O
distinguish	O
details	O
between	O
functional	B-MED
families	I-MED
within	O
a	O
superfamily	B-MED
.	O
Active	B-MED
site	I-MED
profiling	I-MED
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants	O
.	O
DASP	B-MED
and	O
DASP2	B-MED
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence	B-MED
databases	I-MED
using	O
active	B-MED
site	I-MED
profiling	I-MED
.	O
Here	O
,	O
TuLIP	B-MED
(	O
Two	B-MED
-	I-MED
Level	I-MED
Iterative	I-MED
clustering	I-MED
Process	I-MED
)	O
is	O
introduced	O
as	O
an	O
iterative	O
,	O
divisive	O
clustering	B-MED
process	I-MED
that	O
utilizes	O
active	B-MED
site	I-MED
profiling	I-MED
to	O
separate	O
structurally	O
characterized	O
superfamily	B-MED
members	O
into	O
functionally	O
relevant	O
clusters	B-MED
.	O
Underlying	O
TuLIP	B-MED
is	O
the	O
observation	O
that	O
functionally	B-MED
relevant	I-MED
families	I-MED
(	O
curated	O
by	O
Structure	B-MED
-	I-MED
Function	I-MED
Linkage	I-MED
Database	I-MED
,	O
SFLD	B-MED
)	O
self	O
-	O
identify	O
in	O
DASP2	B-MED
searches	O
;	O
clusters	B-MED
containing	O
multiple	B-MED
functional	I-MED
families	I-MED
do	O
not	O
.	O
Each	O
TuLIP	B-MED
iteration	O
produces	O
candidate	O
clusters	B-MED
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self	O
-	O
identifies	O
using	O
DASP2	B-MED
.	O
If	O
so	O
,	O
it	O
is	O
deemed	O
a	O
functionally	B-MED
relevant	I-MED
group	I-MED
.	O
Divisive	O
clustering	B-MED
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally	B-MED
relevant	I-MED
group	I-MED
member	O
or	O
a	O
singlet	O
.	O
TuLIP	B-MED
is	O
validated	O
on	O
enolase	B-MED
and	O
glutathione	B-MED
transferase	I-MED
structures	B-MED
,	O
superfamilies	B-MED
well	O
-	O
curated	O
by	O
SFLD	B-MED
.	O
Correlation	B-MED
is	O
strong	O
;	O
small	O
numbers	O
of	O
structures	B-MED
prevent	O
statistically	B-MED
significant	I-MED
analysis	I-MED
.	O
TuLIP	B-MED
-identified	O
enolase	B-MED
clusters	B-MED
are	O
used	O
in	O
DASP2	B-MED
GenBank	I-MED
searches	O
to	O
identify	O
sequences	B-MED
sharing	O
functional	O
site	O
features	O
.	O
Analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96	O
%	O
,	O
false	O
negative	O
rate	O
of	O
4	O
%	O
,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4	O
%	O
.	O
F	B-MED
-	I-MED
measure	I-MED
and	O
performance	B-MED
analysis	I-MED
on	O
the	O
enolase	B-MED
search	O
results	O
and	O
comparison	O
to	O
GEMMA	B-MED
and	O
SCI	B-MED
-	I-MED
PHY	I-MED
demonstrate	O
that	O
TuLIP	B-MED
avoids	O
the	O
over	O
-	O
division	O
problem	O
of	O
these	O
methods	O
.	O
Mechanistic	O
determinants	O
for	O
enolase	B-MED
families	I-MED
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	B-MED
results	O
.	O
Patient	B-MED
Preferences	I-MED
in	O
Treatment	B-MED
Choices	B-MED
for	O
Early	B-MED
-	I-MED
Stage	I-MED
Lung	B-MED
Cancer	I-MED
Decision	B-MED
-	I-MED
making	I-MED
for	O
lung	B-MED
cancer	I-MED
treatment	B-MED
can	O
be	O
complex	B-MED
because	O
it	O
involves	O
both	O
provider	B-MED
recommendations	B-MED
based	O
on	O
the	O
patient	B-MED
's	I-MED
clinical	B-MED
condition	B-MED
and	O
patient	B-MED
preferences	I-MED
.	O
This	O
study	B-MED
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-MED
in	O
lung	B-MED
cancer	I-MED
treatment	B-MED
from	O
the	O
patient	B-MED
's	I-MED
perspective	B-MED
.	O
A	O
conjoint	B-MED
preference	I-MED
experiment	I-MED
began	O
by	O
asking	O
respondents	B-MED
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-MED
with	O
lung	B-MED
cancer	I-MED
.	O
Respondents	B-MED
then	O
chose	B-MED
among	O
procedures	B-MED
that	O
differed	O
regarding	O
treatment	B-MED
modalities	B-MED
,	O
the	O
potential	O
for	O
treatment	B-MED
-related	O
complications	B-MED
,	O
the	O
likelihood	B-MED
of	O
recurrence	B-MED
,	O
provider	B-MED
case	B-MED
volume	B-MED
,	O
and	O
distance	B-MED
needed	B-MED
to	O
travel	B-MED
for	O
treatment	B-MED
.	O
Conjoint	B-MED
analysis	I-MED
derived	O
relative	O
weights	O
for	O
these	O
attributes	B-MED
.	O
A	O
total	O
of	O
225	O
responses	B-MED
were	O
analyzed	B-MED
.	O
Respondents	B-MED
were	O
most	O
willing	O
to	O
accept	O
minimally	B-MED
invasive	B-MED
operations	I-MED
for	O
treatment	B-MED
of	O
their	O
hypothetical	O
lung	B-MED
cancer	I-MED
,	O
followed	O
by	O
stereotactic	B-MED
body	I-MED
radiation	I-MED
therapy	I-MED
(	O
SBRT	B-MED
)	O
;	O
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-MED
.	O
Treatment	B-MED
type	O
and	O
risk	B-MED
of	I-MED
recurrence	I-MED
were	O
the	O
most	O
important	O
attributes	B-MED
from	O
the	O
conjoint	B-MED
experiment	I-MED
(	O
each	O
with	O
a	O
relative	O
weight	O
of	O
0.23	O
)	O
,	O
followed	O
by	O
provider	B-MED
volume	B-MED
(	O
relative	O
weight	O
of	O
0.21	O
)	O
,	O
risk	B-MED
of	O
major	O
complications	B-MED
(	O
relative	O
weight	O
of	O
0.18	O
)	O
,	O
and	O
distance	B-MED
needed	B-MED
to	O
travel	B-MED
for	O
treatment	B-MED
(	O
relative	O
weight	O
of	O
0.15	O
)	O
.	O
Procedural	B-MED
and	O
treatment	B-MED
preferences	B-MED
did	O
not	O
vary	O
with	O
demographics	B-MED
,	O
self	B-MED
-	I-MED
reported	I-MED
health	B-MED
status	I-MED
,	O
or	O
familiarity	B-MED
with	O
the	O
procedures	B-MED
.	O
Survey	B-MED
respondents	B-MED
preferred	O
minimally	B-MED
invasive	B-MED
operations	I-MED
over	O
SBRT	B-MED
or	O
thoracotomy	B-MED
for	O
treatment	B-MED
of	O
early	B-MED
-	I-MED
stage	I-MED
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
Treatment	B-MED
modality	B-MED
and	O
risk	B-MED
of	O
cancer	B-MED
recurrence	I-MED
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-MED
preferences	B-MED
.	O
Provider	B-MED
experience	B-MED
outweighed	O
the	O
potential	O
need	B-MED
to	O
travel	B-MED
for	O
lung	B-MED
cancer	I-MED
treatment	B-MED
.	O
Assessment	B-MED
of	O
Residual	B-MED
Disease	I-MED
With	O
Molecular	B-MED
Breast	I-MED
Imaging	I-MED
in	O
Patients	B-MED
Undergoing	O
Neoadjuvant	B-MED
Therapy	I-MED
:	O
Association	O
With	O
Molecular	B-MED
Subtypes	B-MED
Assessment	B-MED
of	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
therapy	I-MED
for	O
breast	B-MED
cancer	I-MED
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-MED
imaging	B-MED
.	O
This	O
study	B-MED
evaluates	B-MED
the	O
accuracy	B-MED
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-MED
breast	I-MED
imaging	I-MED
(	O
MBI	B-MED
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B-MED
zinc	I-MED
telluride	I-MED
detectors	B-MED
in	O
assessing	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
therapy	I-MED
in	O
patients	B-MED
with	O
breast	B-MED
cancer	I-MED
.	O
Clinical	B-MED
data	I-MED
,	O
imaging	B-MED
,	O
surgical	B-MED
,	O
and	O
pathological	B-MED
findings	B-MED
of	O
51	O
women	B-MED
with	O
breast	B-MED
cancer	I-MED
undergoing	O
neoadjuvant	B-MED
therapy	I-MED
were	O
recorded	O
.	O
MBI	B-MED
findings	B-MED
were	O
correlated	B-MED
with	O
surgical	B-MED
pathology	I-MED
results	I-MED
.	O
Accuracy	B-MED
of	O
MBI	B-MED
in	O
predicting	O
complete	B-MED
pathological	I-MED
response	I-MED
and	O
size	B-MED
of	O
residual	B-MED
disease	I-MED
was	O
assessed	O
according	O
to	O
molecular	B-MED
subtypes	B-MED
.	O
The	O
size	B-MED
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-MED
correlated	B-MED
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	B-MED
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O
This	O
correlation	B-MED
was	O
stronger	O
for	O
triple	B-MED
negative	I-MED
and	O
HER2	B-MED
/	I-MED
neu	I-MED
positive	I-MED
subtypes	B-MED
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O
Sixteen	O
patients	B-MED
(	O
31	O
%	O
)	O
had	O
complete	B-MED
pathological	I-MED
response	I-MED
.	O
The	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
MBI	B-MED
for	O
detecting	O
residual	B-MED
disease	I-MED
were	O
83	O
%	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
,	O
66	O
-	O
93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	B-MED
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O
For	O
triple	B-MED
negative	I-MED
or	O
HER2	B-MED
/	I-MED
neu	I-MED
positive	I-MED
disease	O
the	O
sensitivity	B-MED
and	O
specificity	B-MED
were	O
88	O
%	O
(	O
95	O
%	O
CI	B-MED
,	O
62	O
-	O
98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	B-MED
,	O
43	O
-	O
93	O
)	O
,	O
respectively	O
.	O
The	O
accuracy	B-MED
of	O
MBI	B-MED
in	O
assessing	O
residual	B-MED
disease	I-MED
after	O
neoadjuvant	B-MED
treatment	I-MED
might	O
be	O
related	O
to	O
the	O
molecular	B-MED
subtype	B-MED
.	O
Accuracy	B-MED
is	O
highest	O
in	O
the	O
triple	B-MED
negative	I-MED
and	O
HER2	B-MED
/	I-MED
neu	I-MED
positive	I-MED
subtypes	B-MED
.	O
Mitotic	B-MED
phosphotyrosine	B-MED
network	B-MED
analysis	I-MED
reveals	O
that	O
tyrosine	B-MED
phosphorylation	I-MED
regulates	O
Polo	B-MED
-	I-MED
like	I-MED
kinase	I-MED
1	I-MED
(	O
PLK1	B-MED
)	O
Tyrosine	B-MED
phosphorylation	I-MED
is	O
closely	O
associated	B-MED
with	I-MED
cell	B-MED
proliferation	I-MED
.	O
During	O
the	O
cell	B-MED
cycle	I-MED
,	O
serine	B-MED
and	I-MED
threonine	I-MED
phosphorylation	I-MED
plays	O
the	O
leading	O
role	O
,	O
and	O
such	O
phosphorylation	B-MED
events	O
are	O
most	O
dynamic	B-MED
during	O
the	O
mitotic	B-MED
phase	I-MED
of	O
the	O
cell	B-MED
cycle	I-MED
.	O
However	O
,	O
mitotic	B-MED
phosphotyrosine	B-MED
is	O
not	O
well	O
characterized	O
.	O
Although	O
a	O
few	O
functionally	B-MED
-	O
relevant	B-MED
mitotic	B-MED
phosphotyrosine	B-MED
sites	B-MED
have	O
been	O
characterized	B-MED
,	O
evidence	O
suggests	O
that	O
this	O
modification	B-MED
may	O
be	O
more	O
prevalent	B-MED
than	O
previously	O
appreciated	O
.	O
Here	O
,	O
we	O
examined	B-MED
tyrosine	B-MED
phosphorylation	I-MED
in	O
mitotic	B-MED
human	I-MED
cells	I-MED
including	O
those	O
on	O
spindle	B-MED
-	I-MED
associated	I-MED
proteins	I-MED
.	O
?	O
Database	B-MED
mining	I-MED
confirmed	O
~2000	O
mitotic	B-MED
phosphotyrosine	B-MED
sites	B-MED
,	O
and	O
network	B-MED
analysis	I-MED
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine	B-MED
-	I-MED
phosphorylated	I-MED
proteins	I-MED
,	O
including	O
components	O
of	O
the	O
kinetochore	B-MED
or	O
spindle	B-MED
and	O
SRC	B-MED
family	I-MED
kinases	I-MED
.	O
We	O
identified	O
Polo	B-MED
-	I-MED
like	I-MED
kinase	I-MED
1	I-MED
(	O
PLK1	B-MED
)	O
,	O
a	O
major	O
signaling	B-MED
hub	O
in	O
the	O
spindle	B-MED
subnetwork	B-MED
,	O
as	O
phosphorylated	B-MED
at	O
the	O
conserved	O
Tyr(217	B-MED
)	I-MED
in	O
the	O
kinase	B-MED
domain	I-MED
.	O
Substitution	B-MED
of	O
Tyr(217	B-MED
)	I-MED
with	O
a	O
phosphomimetic	B-MED
residue	I-MED
eliminated	O
PLK1	B-MED
activity	B-MED
in	B-MED
vitro	I-MED
and	O
in	O
cells	B-MED
.	O
Further	O
analysis	B-MED
showed	O
that	O
Tyr(217	B-MED
)	I-MED
phosphorylation	B-MED
reduced	O
the	O
phosphorylation	B-MED
of	I-MED
Thr(210	I-MED
)	I-MED
in	O
the	O
activation	B-MED
loop	I-MED
,	O
a	O
phosphorylation	B-MED
event	O
necessary	O
for	O
PLK1	B-MED
activity	B-MED
.	O
Our	O
data	O
indicate	O
that	O
mitotic	B-MED
tyrosine	B-MED
phosphorylation	I-MED
regulated	O
a	O
key	O
serine	B-MED
/	I-MED
threonine	I-MED
kinase	I-MED
hub	O
in	O
mitotic	B-MED
cells	I-MED
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine	B-MED
phosphorylation	I-MED
events	O
can	O
reveal	O
previously	O
unrecognized	B-MED
regulatory	B-MED
events	I-MED
and	O
complexes	B-MED
associated	O
with	O
specific	O
structures	B-MED
of	O
the	O
cell	B-MED
cycle	I-MED
.	O
Effect	O
of	O
single	B-MED
-	I-MED
dose	I-MED
carbapenem	B-MED
exposure	B-MED
on	O
transcriptional	B-MED
expression	I-MED
of	O
blaNDM-1	B-MED
and	O
mexA	B-MED
in	O
Pseudomonas	B-MED
aeruginosa	I-MED
The	O
therapeutic	B-MED
option	I-MED
of	O
a	O
carbapenem	B-MED
antibiotic	I-MED
is	O
compromised	O
in	O
Pseudomonas	B-MED
aeruginosa	I-MED
owing	O
both	O
to	O
acquired	B-MED
and	O
intrinsic	B-MED
resistance	I-MED
mechanisms	O
.	O
In	O
recent	O
years	O
,	O
New	B-MED
Delhi	I-MED
metallo	I-MED
-	I-MED
β	I-MED
-	I-MED
lactamase	I-MED
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	B-MED
resistance	I-MED
determinant	I-MED
.	O
However	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P.	B-MED
aeruginosa	I-MED
strain	B-MED
possessing	O
both	O
blaNDM-1	B-MED
and	O
an	O
overexpressed	B-MED
MexAB	B-MED
-	I-MED
OprM	I-MED
system	O
during	O
carbapenem	B-MED
therapy	B-MED
.	O
This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	B-MED
isolates	I-MED
of	O
P.	B-MED
aeruginosa	I-MED
when	O
exposed	O
to	O
meropenem	B-MED
.	O
Five	O
strains	B-MED
were	O
used	O
:	O
(	O
i	O
)	O
strain	B-MED
overexpressing	I-MED
MexAB	B-MED
-	I-MED
OprM	I-MED
but	O
with	O
no	B-MED
blaNDM-1	B-MED
;	O
(	O
ii	O
)	O
strain	O
harbouring	O
blaNDM-1	B-MED
but	O
expressing	B-MED
MexAB	B-MED
-	I-MED
OprM	I-MED
at	O
basal	O
level	O
;	O
(	O
iii	O
)	O
strain	B-MED
possessing	O
blaNDM-1	B-MED
and	O
overexpressing	B-MED
MexAB	B-MED
-	I-MED
OprM	I-MED
;	O
(	O
iv	O
)	O
P.	B-MED
aeruginosa	I-MED
PAO1	I-MED
;	O
and	O
(	O
v	O
)	O
P.	B-MED
aeruginosa	I-MED
K2733	I-MED
-	I-MED
PAO1	I-MED
(	O
ΔMexAB	B-MED
-	I-MED
OprM	I-MED
ΔMexCD	B-MED
-	I-MED
OprJ	I-MED
ΔMexEF	B-MED
-	I-MED
OprN	I-MED
ΔMexXY	B-MED
-	I-MED
OprM	I-MED
)	O
into	O
which	O
blaNDM-1	B-MED
was	O
cloned	B-MED
.	O
Strains	B-MED
were	O
incubated	O
in	O
Luria	B-MED
-	I-MED
Bertani	I-MED
broth	I-MED
with	O
and	O
without	O
1μg	O
/	O
mL	O
meropenem	B-MED
.	O
Total	B-MED
RNA	I-MED
was	O
isolated	O
at	O
45	O
-	O
min	O
intervals	O
and	O
was	O
immediately	O
reverse	B-MED
transcribed	I-MED
to	O
cDNA	B-MED
.	O
This	O
was	O
repeated	O
for	O
6h	O
.	O
Quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
PCR	I-MED
was	O
performed	O
for	O
both	O
resistance	B-MED
mechanisms	I-MED
.	O
Meropenem	B-MED
exposure	B-MED
did	O
not	O
significantly	O
elevate	B-MED
transcription	I-MED
of	O
either	O
the	O
blaNDM-1	B-MED
or	O
mexA	B-MED
gene	I-MED
.	O
However	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single	B-MED
-	I-MED
dose	I-MED
exposure	B-MED
to	I-MED
carbapenem	I-MED
,	O
the	O
efflux	B-MED
pump	I-MED
system	I-MED
played	O
a	O
major	O
role	B-MED
in	I-MED
bacterial	I-MED
survival	I-MED
compared	O
with	O
NDM-1	B-MED
.	O
This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	B-MED
response	I-MED
to	I-MED
carbapenem	I-MED
antibiotic	I-MED
when	O
two	O
different	O
resistance	B-MED
mechanisms	I-MED
coexist	O
.	O
This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	B-MED
.	O
Beneficial	B-MED
Effects	I-MED
of	O
Phyllanthus	B-MED
amarus	I-MED
Against	O
High	B-MED
Fructose	I-MED
Diet	I-MED
Induced	O
Insulin	B-MED
Resistance	I-MED
and	O
Hepatic	B-MED
Oxidative	I-MED
Stress	I-MED
in	O
Male	B-MED
Wistar	B-MED
Rats	I-MED
Insulin	B-MED
resistance	I-MED
(	O
IR	B-MED
)	O
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-MED
,	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
,	O
and	O
cardiovascular	B-MED
diseases	I-MED
.	O
Emerging	O
evidence	O
suggests	O
that	O
the	O
high	B-MED
-	I-MED
fructose	I-MED
consumption	B-MED
is	O
a	O
potential	B-MED
and	O
important	O
factor	B-MED
responsible	O
for	O
the	O
rising	B-MED
incidence	I-MED
of	O
IR	B-MED
.	O
The	O
present	O
study	B-MED
investigates	B-MED
the	O
beneficial	B-MED
effects	I-MED
of	O
aqueous	B-MED
extract	I-MED
of	O
Phyllanthus	B-MED
amaru	I-MED
s	O
(	O
PAAE	B-MED
)	O
on	O
IR	B-MED
and	O
oxidative	B-MED
stress	I-MED
in	O
high	B-MED
-	I-MED
fructose	I-MED
(	O
HF	B-MED
)	O
fed	O
male	B-MED
Wistar	B-MED
rats	I-MED
.	O
HF	B-MED
diet	I-MED
(	O
66	O
%	O
of	O
fructose	O
)	O
and	O
PAAE	B-MED
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
were	O
given	O
concurrently	B-MED
to	O
the	O
rats	B-MED
for	O
a	O
period	O
of	O
60	O
days	O
.	O
Fructose	B-MED
-	I-MED
fed	I-MED
rats	B-MED
showed	O
weight	B-MED
gain	I-MED
,	O
hyperglycemia	B-MED
,	O
hyperinsulinemia	B-MED
,	O
impaired	B-MED
glucose	I-MED
tolerance	I-MED
,	O
impaired	B-MED
insulin	I-MED
sensitivity	I-MED
,	O
dyslipidemia	B-MED
,	O
hyperleptinemia	B-MED
,	O
and	O
hypoadiponectinemia	B-MED
(	O
P	O
<	O
0.05	O
)	O
after	O
60	O
days	O
.	O
Co	B-MED
-	I-MED
administration	I-MED
of	O
PAAE	B-MED
along	O
with	O
HF	B-MED
diet	I-MED
significantly	O
ameliorated	O
all	O
these	O
alterations	B-MED
.	O
Regarding	O
hepatic	B-MED
antioxidant	B-MED
status	I-MED
,	O
higher	O
lipid	B-MED
peroxidation	I-MED
and	O
protein	B-MED
oxidation	I-MED
,	O
lower	O
reduced	B-MED
glutathione	I-MED
levels	O
and	O
lower	B-MED
activities	I-MED
of	O
enzymatic	B-MED
antioxidants	I-MED
,	O
and	O
the	O
histopathological	B-MED
changes	I-MED
like	O
mild	O
to	O
severe	O
distortion	B-MED
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver	B-MED
sinusoids	I-MED
observed	O
in	O
the	O
HF	B-MED
diet	I-MED
-fed	O
rats	B-MED
were	O
significantly	O
prevented	O
by	O
PAAE	B-MED
treatment	B-MED
.	O
These	O
findings	O
indicate	O
that	O
PAAE	B-MED
is	O
beneficial	O
in	O
improving	O
insulin	B-MED
sensitivity	I-MED
and	O
attenuating	O
metabolic	B-MED
syndrome	I-MED
and	O
hepatic	B-MED
oxidative	I-MED
stress	I-MED
in	O
fructose	B-MED
-	I-MED
fed	I-MED
rats	B-MED
.	O
Predictive	B-MED
Factors	I-MED
for	O
Long	B-MED
-	I-MED
term	I-MED
Outcome	B-MED
of	O
Subthalamic	B-MED
Nucleus	I-MED
Deep	B-MED
Brain	I-MED
Stimulation	I-MED
for	O
Parkinson	B-MED
's	I-MED
Disease	I-MED
Despite	O
the	O
recognition	O
of	O
the	O
usefulness	B-MED
of	O
subthalamic	B-MED
nucleus	I-MED
deep	B-MED
brain	I-MED
stimulation	I-MED
(	O
STN	B-MED
-	O
DBS	B-MED
)	O
for	O
the	O
treatment	B-MED
of	O
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
,	O
preoperative	B-MED
predictive	B-MED
factors	I-MED
for	O
the	O
long	B-MED
-	I-MED
term	I-MED
outcome	B-MED
of	O
STN	B-MED
-	O
DBS	B-MED
are	O
not	B-MED
sufficiently	B-MED
established	B-MED
.	O
We	O
performed	O
this	O
study	B-MED
to	O
determine	O
such	O
predictive	B-MED
factors	I-MED
.	O
The	O
subjects	B-MED
were	O
66	O
patients	B-MED
who	O
were	O
classified	B-MED
into	O
two	B-MED
groups	B-MED
on	O
the	O
basis	B-MED
of	O
their	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
(	O
ADL	B-MED
)	O
evaluated	O
five	B-MED
years	I-MED
after	B-MED
the	O
STN	B-MED
-	O
DBS	B-MED
surgery	B-MED
:	O
33	O
patients	B-MED
were	O
assigned	B-MED
to	O
the	O
independent	B-MED
ADL	B-MED
group	B-MED
(	O
group	B-MED
I	I-MED
)	O
and	O
the	O
remaining	O
33	O
patients	B-MED
to	O
the	O
dependent	B-MED
ADL	B-MED
group	B-MED
(	O
group	B-MED
D	I-MED
)	O
.	O
Group	B-MED
I	I-MED
patients	B-MED
showed	O
a	O
Schwab	B-MED
and	I-MED
England	I-MED
(	I-MED
S&E	I-MED
)	I-MED
scale	I-MED
S&E	B-MED
score	B-MED
of	O
more	O
than	O
70	O
during	B-MED
the	O
off	B-MED
-	I-MED
period	I-MED
,	O
indicating	O
that	O
these	O
patients	B-MED
can	O
maintain	O
their	O
independent	B-MED
ADL	B-MED
all	B-MED
the	I-MED
time	I-MED
.	O
Group	B-MED
D	I-MED
patients	B-MED
showed	O
a	O
score	B-MED
of	O
70	O
or	O
lower	B-MED
during	B-MED
the	O
off	B-MED
-	I-MED
period	I-MED
,	O
indicating	O
that	O
these	O
patients	B-MED
can	O
not	O
maintain	O
their	O
independent	B-MED
ADL	B-MED
for	O
an	O
entire	B-MED
day	B-MED
.	O
We	O
studied	B-MED
the	O
differences	B-MED
in	O
the	O
preoperative	B-MED
state	I-MED
between	O
these	O
two	B-MED
groups	B-MED
.	O
Statistically	B-MED
significant	I-MED
differences	B-MED
were	O
noted	O
in	O
PD	B-MED
onset	B-MED
age	I-MED
,	O
age	B-MED
at	O
surgery	B-MED
,	O
preoperative	B-MED
unified	B-MED
Parkinson	I-MED
's	I-MED
disease	I-MED
rating	I-MED
scale	I-MED
(	O
UPDRS	B-MED
)	O
part	B-MED
I	I-MED
score	B-MED
,	O
part	B-MED
II	I-MED
score	B-MED
,	O
total	B-MED
subscore	B-MED
for	O
axial	B-MED
symptoms	I-MED
in	O
part	B-MED
III	I-MED
,	O
mini	B-MED
-	I-MED
mental	I-MED
state	I-MED
examination	I-MED
(	I-MED
MMSE	I-MED
)	I-MED
score	I-MED
and	O
S&E	B-MED
score	B-MED
.	O
Multiple	O
logistic	B-MED
regression	I-MED
analysis	I-MED
showed	O
that	O
the	O
significant	B-MED
independent	B-MED
variables	B-MED
related	O
to	O
long	B-MED
-	I-MED
term	I-MED
independent	B-MED
ADL	B-MED
were	O
the	O
age	B-MED
at	O
surgery	B-MED
,	O
MMSE	B-MED
score	I-MED
and	O
preoperative	B-MED
S&E	B-MED
scale	I-MED
score	B-MED
during	B-MED
the	O
off	B-MED
-	I-MED
period	I-MED
.	O
The	O
PD	B-MED
onset	B-MED
age	I-MED
,	O
age	B-MED
at	O
surgery	B-MED
,	O
preoperative	B-MED
high	B-MED
-	O
level	B-MED
ADL	B-MED
,	O
cognitive	B-MED
function	I-MED
,	O
and	O
axial	B-MED
symptoms	I-MED
are	O
important	B-MED
predictive	B-MED
factors	I-MED
for	O
the	O
long	B-MED
-	I-MED
term	I-MED
outcome	B-MED
of	O
STN	B-MED
-	O
DBS	B-MED
.	O
Efficient	O
gene	B-MED
targeting	I-MED
in	O
non	B-MED
-	I-MED
homologous	I-MED
end	I-MED
-	I-MED
joining	I-MED
-deficient	O
Lipomyces	B-MED
starkeyi	I-MED
strains	B-MED
Microbial	B-MED
lipids	B-MED
are	O
sustainable	O
feedstock	O
for	O
the	O
production	B-MED
of	O
oleochemicals	B-MED
and	O
biodiesel	B-MED
.	O
Oleaginous	B-MED
yeasts	I-MED
have	O
recently	O
been	O
proposed	O
as	O
alternative	B-MED
lipid	B-MED
producers	B-MED
to	O
plants	B-MED
and	O
animals	B-MED
to	O
promote	O
sustainability	O
in	O
the	O
chemical	B-MED
and	O
fuel	B-MED
industries	I-MED
.	O
The	O
oleaginous	B-MED
yeast	I-MED
Lipomyces	B-MED
starkeyi	I-MED
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	B-MED
producer	B-MED
.	O
However	O
,	O
improvement	O
of	O
its	O
lipid	B-MED
productivity	B-MED
is	O
essential	O
for	O
the	O
cost	B-MED
-	I-MED
effective	I-MED
production	I-MED
of	O
oleochemicals	B-MED
and	O
fuels	B-MED
.	O
Genetic	B-MED
and	O
metabolic	B-MED
engineering	I-MED
of	O
L.	B-MED
starkeyi	I-MED
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	B-MED
production	B-MED
and	O
our	O
understanding	O
of	O
the	O
mechanisms	B-MED
behind	O
lipid	B-MED
biosynthesis	B-MED
pathways	I-MED
.	O
We	O
previously	O
described	O
an	O
integrative	B-MED
transformation	I-MED
system	I-MED
using	O
a	O
drug	B-MED
-resistant	O
marker	B-MED
for	O
L.	B-MED
starkeyi	I-MED
.	O
However	O
,	O
gene	B-MED
-	I-MED
targeting	I-MED
frequencies	B-MED
were	O
very	O
low	O
because	O
non	B-MED
-	I-MED
homologous	I-MED
recombination	I-MED
is	O
probably	O
predominant	O
in	O
L.	B-MED
starkeyi	I-MED
.	O
Genetic	B-MED
engineering	I-MED
tools	I-MED
for	O
L.	B-MED
starkeyi	I-MED
have	O
not	O
been	O
sufficiently	O
developed	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
genetic	B-MED
tool	I-MED
and	O
its	O
application	B-MED
in	O
L.	B-MED
starkeyi	I-MED
.	O
To	O
develop	O
a	O
highly	O
efficient	O
gene	B-MED
-	I-MED
targeting	I-MED
system	I-MED
for	O
L.	B-MED
starkeyi	I-MED
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	B-MED
by	O
disrupting	B-MED
genes	B-MED
for	O
LsKu70p	B-MED
,	O
LsKu80p	B-MED
,	O
and/or	O
LsLig4p	B-MED
,	O
which	O
share	O
homology	B-MED
with	O
other	O
yeasts	B-MED
Ku70p	B-MED
,	O
Ku80p	B-MED
,	O
and	O
Lig4p	B-MED
,	O
respectively	O
,	O
being	O
involved	O
in	O
non	B-MED
-	I-MED
homologous	I-MED
end	I-MED
-	I-MED
joining	I-MED
pathway	I-MED
.	O
Deletion	B-MED
of	O
the	O
LsLIG4	B-MED
gene	I-MED
dramatically	O
improved	O
the	O
homologous	B-MED
recombination	I-MED
efficiency	B-MED
(	O
80.0	O
%	O
)	O
at	O
the	O
LsURA3	B-MED
locus	B-MED
compared	O
with	O
that	O
in	O
the	O
wild	B-MED
-	I-MED
type	I-MED
strain	B-MED
(	O
1.4	O
%	O
)	O
,	O
when	O
2000	B-MED
-	I-MED
bp	I-MED
homologous	I-MED
flanking	I-MED
regions	I-MED
were	O
used	O
.	O
The	O
homologous	B-MED
recombination	I-MED
efficiencies	B-MED
of	O
the	O
double	O
mutant	B-MED
∆l	B-MED
sku70∆lslig4	I-MED
and	O
the	O
triple	O
mutant	B-MED
∆lsku70∆lsku80∆lslig4	B-MED
were	O
also	O
markedly	O
enhanced	O
.	O
Therefore	O
,	O
the	O
L.	B-MED
starkeyi	I-MED
∆lslig4	B-MED
background	O
strains	B-MED
have	O
promise	O
as	O
efficient	O
recipient	B-MED
strains	I-MED
for	O
genetic	B-MED
and	O
metabolic	B-MED
engineering	I-MED
approaches	B-MED
in	O
this	O
yeast	B-MED
.	O
Predictors	B-MED
of	O
30-	O
day	B-MED
mortality	B-MED
in	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
intracerebral	B-MED
hemorrhage	I-MED
Intracerebral	B-MED
hemorrhage	I-MED
(	O
ICH	B-MED
)	O
is	O
a	O
life	B-MED
threatening	I-MED
entity	O
,	O
and	O
an	O
early	B-MED
outcome	I-MED
assessment	I-MED
is	O
mandatory	O
for	O
optimizing	O
therapeutic	B-MED
efforts	I-MED
.	O
We	O
retrospectively	B-MED
analyzed	B-MED
data	B-MED
from	O
342	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
ICH	B-MED
to	O
evaluate	O
possible	O
predictors	B-MED
of	O
30-	O
day	B-MED
mortality	B-MED
considering	O
clinical	B-MED
,	O
radiological	B-MED
,	O
and	O
therapeutical	B-MED
parameters	B-MED
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-MED
grading	I-MED
scoring	I-MED
systems	I-MED
[	O
(	O
ICH	B-MED
score	I-MED
,	O
FUNC	B-MED
score	I-MED
and	O
intracerebral	B-MED
hemorrhage	I-MED
grading	I-MED
scale	I-MED
(	O
ICH	B-MED
-	I-MED
GS	I-MED
)	O
]	O
on	O
our	O
population	B-MED
to	O
evaluate	O
the	O
correlation	B-MED
of	O
these	O
scores	B-MED
with	O
the	O
30-	O
day	B-MED
mortality	B-MED
in	O
our	O
study	B-MED
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-MED
grading	I-MED
scoring	I-MED
systems	I-MED
[	O
(	O
ICH	B-MED
score	I-MED
,	O
FUNC	B-MED
score	I-MED
and	O
intracerebral	B-MED
hemorrhage	I-MED
grading	I-MED
scale	I-MED
(	O
ICH	B-MED
-	I-MED
GS	I-MED
)	O
]	O
on	O
our	O
population	B-MED
to	O
evaluate	O
the	O
correlation	B-MED
of	O
these	O
scores	B-MED
with	O
the	O
30-	O
day	B-MED
mortality	B-MED
in	O
our	O
study	B-MED
.	O
From	O
342	O
patients	B-MED
(	O
mean	O
age	B-MED
:	O
67	O
years	B-MED
,	O
mean	O
Glasgow	B-MED
Coma	I-MED
Scale	I-MED
[	O
GCS	B-MED
]	O
on	O
admission	B-MED
:	O
9	O
,	O
mean	O
ICH	B-MED
volume	B-MED
:	O
62.19	O
ml	O
,	O
most	O
common	O
hematoma	B-MED
location	B-MED
:	O
basal	B-MED
ganglia	I-MED
[	O
43.9	O
%	O
]	O
)	O
,	O
102	O
received	O
surgical	B-MED
and	O
240	O
conservative	B-MED
treatment	I-MED
.	O
The	O
30-	O
day	B-MED
mortality	B-MED
was	O
25.15	O
%	O
.	O
In	O
a	O
multivariate	B-MED
analysis	I-MED
,	O
GCS	B-MED
(	O
Odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
=	O
0.726	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
=	O
0.661	O
-	O
0.796	O
,	O
P	O
<	O
0.001	O
)	O
,	O
bleeding	B-MED
volume	B-MED
(	O
OR	B-MED
=	O
1.012	O
per	O
ml	O
,	O
95	O
%	O
CI	B-MED
=	O
1.007	O
-	O
1.017	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
infratentorial	B-MED
hematoma	B-MED
location	B-MED
(	O
OR	B-MED
=	O
5.381	O
,	O
95	O
%	O
CI	B-MED
=	O
2.166	O
-	O
13.356	O
,	O
P	O
=	O
0.009	O
)	O
were	O
significant	O
predictors	B-MED
for	O
the	O
30-	O
day	B-MED
mortality	B-MED
.	O
After	O
receiver	B-MED
operating	I-MED
characteristics	I-MED
analysis	B-MED
,	O
we	O
defined	O
a	O
"	O
high	B-MED
-	I-MED
risk	I-MED
group	I-MED
"	O
for	O
an	O
unfavorable	O
short	B-MED
-	I-MED
term	I-MED
outcome	B-MED
with	O
GCS	B-MED
<	O
11	O
and	O
ICH	B-MED
volume	B-MED
>	O
32	O
ml	O
supratentorially	B-MED
or	O
21	O
ml	O
infratentorially	B-MED
.	O
Using	O
Pearson	B-MED
correlation	I-MED
,	O
we	O
found	O
a	O
correlation	B-MED
of	O
0.986	O
between	O
ICH	B-MED
score	I-MED
and	O
30-	O
day	B-MED
mortality	B-MED
(	O
P	O
<	O
0.001	O
)	O
,	O
0.853	O
between	O
FUNC	B-MED
score	I-MED
and	O
30-	O
day	B-MED
mortality	B-MED
(	O
P	O
=	O
0.001	O
)	O
,	O
and	O
0.924	O
between	O
ICH	B-MED
-	I-MED
GS	I-MED
and	O
30-	O
day	B-MED
mortality	B-MED
(	O
P	O
=	O
0.001	O
)	O
.	O
GCS	B-MED
score	B-MED
on	O
admission	B-MED
together	O
with	O
the	O
baseline	B-MED
volume	B-MED
and	O
localization	B-MED
of	O
the	O
hemorrhage	B-MED
are	O
strong	O
predictors	B-MED
for	O
30-	O
day	B-MED
mortality	B-MED
in	O
patients	B-MED
with	O
spontaneous	B-MED
primary	B-MED
intracerebral	B-MED
hemorrhage	I-MED
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high	B-MED
-	I-MED
risk	I-MED
patients	B-MED
with	O
poor	O
short	B-MED
-	I-MED
term	I-MED
outcome	B-MED
.	O
The	O
ICH	B-MED
score	I-MED
and	O
the	O
ICH	B-MED
-	I-MED
GS	I-MED
accurately	B-MED
predict	B-MED
the	O
30-	O
day	B-MED
mortality	B-MED
.	O
A	O
Rasch	B-MED
Rating	I-MED
Scale	I-MED
Analysis	B-MED
of	O
the	O
Presence	B-MED
of	O
Nursing	B-MED
Scale	B-MED
-	O
RN	B-MED
The	O
phenomenon	B-MED
of	O
nursing	B-MED
presence	B-MED
encompasses	O
the	O
emotional	B-MED
connection	B-MED
between	O
nurse	B-MED
and	O
patient	B-MED
,	O
and	O
technical	B-MED
skills	I-MED
performed	B-MED
by	O
the	O
nurse	B-MED
.	O
The	O
Presence	B-MED
of	O
Nursing	B-MED
Scale	B-MED
-	O
RN	B-MED
version	B-MED
(	O
PONS	B-MED
-	O
RN	B-MED
)	O
was	O
developed	B-MED
to	O
measure	B-MED
nurses	B-MED
'	I-MED
perceptions	B-MED
of	O
their	O
ability	B-MED
to	O
be	O
present	B-MED
to	O
their	O
patients	B-MED
.	O
This	O
study	B-MED
summarizes	B-MED
the	O
process	B-MED
of	O
re	B-MED
-	I-MED
evaluation	I-MED
of	O
the	O
psychometric	B-MED
properties	I-MED
of	O
the	O
PONS	B-MED
-	O
RN	B-MED
instrument	O
.	O
A	O
sample	B-MED
of	O
76	O
registered	B-MED
nurses	I-MED
providing	B-MED
direct	B-MED
patient	B-MED
care	I-MED
responded	B-MED
to	O
the	O
31-	O
item	B-MED
questionnaire	B-MED
.	O
The	O
Rasch	B-MED
rating	I-MED
scale	I-MED
model	I-MED
was	O
used	O
for	O
assessing	B-MED
construct	B-MED
validity	I-MED
of	O
PONS	B-MED
-	O
RN	B-MED
data	B-MED
.	O
A	O
principal	B-MED
component	I-MED
analysis	I-MED
(	O
PCA	B-MED
)	O
of	O
residuals	B-MED
supported	B-MED
appropriateness	B-MED
of	O
the	O
subscales	B-MED
defined	O
by	O
a	O
2	B-MED
-	I-MED
dimensional	I-MED
structure	B-MED
.	O
The	O
results	B-MED
of	O
item	B-MED
and	O
person	B-MED
fit	B-MED
analysis	B-MED
,	O
rating	B-MED
scale	I-MED
functioning	B-MED
analysis	B-MED
and	O
reliability	B-MED
analysis	I-MED
have	O
demonstrated	B-MED
that	O
the	O
thirty	O
-	O
one	O
item	B-MED
Presence	B-MED
of	O
Nursing	B-MED
Scale	B-MED
-	O
RN	B-MED
instrument	O
yielded	O
measures	B-MED
with	O
high	B-MED
validity	B-MED
and	I-MED
reliability	I-MED
as	O
two	O
sub	B-MED
-	I-MED
scales	I-MED
.	O
Jou	O
rn	B-MED
Osseointegration	B-MED
behavior	O
of	O
novel	B-MED
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
for	O
dental	B-MED
implants	I-MED
:	O
an	O
in	B-MED
vivo	I-MED
study	B-MED
This	O
study	O
aimed	O
to	O
evaluate	B-MED
the	O
effects	B-MED
of	I-MED
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
on	O
mineral	B-MED
apposition	I-MED
rate	I-MED
and	O
new	O
BIC	B-MED
contact	I-MED
in	O
rabbits	B-MED
.	O
Twelve	O
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
were	O
fabricated	B-MED
and	O
placed	B-MED
into	O
the	O
right	B-MED
femur	B-MED
sites	B-MED
in	O
six	O
rabbits	B-MED
,	O
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
were	O
used	O
as	O
controls	B-MED
in	O
the	O
left	B-MED
femur	B-MED
.	O
Tetracycline	B-MED
and	O
alizarin	B-MED
red	I-MED
were	O
administered	O
3	O
weeks	B-MED
and	O
1	O
week	B-MED
before	O
euthanization	B-MED
,	O
respectively	O
.	O
At	O
4	O
weeks	B-MED
and	O
8	O
weeks	B-MED
after	O
implantation	B-MED
,	O
animals	B-MED
were	O
euthanized	B-MED
,	O
respectively	O
.	O
Surface	B-MED
characterization	B-MED
and	O
implant	B-MED
-	I-MED
bone	I-MED
contact	I-MED
surface	B-MED
analysis	B-MED
were	O
performed	B-MED
by	O
using	O
a	O
scanning	B-MED
electron	I-MED
microscope	I-MED
and	O
an	O
energy	B-MED
dispersive	I-MED
X	I-MED
-	I-MED
ray	I-MED
detector	I-MED
.	O
Mineral	B-MED
apposition	I-MED
rate	I-MED
was	O
evaluated	B-MED
using	O
a	O
confocal	B-MED
laser	I-MED
scanning	I-MED
microscope	I-MED
.	O
Toluidine	B-MED
blue	I-MED
staining	I-MED
was	O
performed	B-MED
on	O
undecalcified	B-MED
sections	B-MED
for	O
histology	B-MED
and	O
histomorphology	B-MED
evaluation	O
.	O
Scanning	B-MED
electron	I-MED
microscope	I-MED
and	O
histomorphology	B-MED
observation	B-MED
revealed	B-MED
a	O
direct	B-MED
contact	I-MED
between	O
implants	B-MED
and	O
bone	B-MED
of	O
all	O
groups	B-MED
.	O
After	O
a	O
healing	B-MED
period	B-MED
of	O
4	O
weeks	B-MED
,	O
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
showed	O
significantly	O
higher	O
mineral	B-MED
apposition	I-MED
rate	I-MED
compared	O
to	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
no	B-MED
significant	I-MED
difference	O
between	O
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
(	O
P	O
>	O
0.05	O
)	O
at	O
8	O
weeks	B-MED
.	O
No	B-MED
significant	I-MED
difference	O
of	O
bone	B-MED
-	I-MED
to	I-MED
-	I-MED
implant	I-MED
contact	I-MED
was	O
observed	B-MED
between	O
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
and	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
implants	B-MED
after	O
a	O
healing	B-MED
period	B-MED
of	O
4	O
weeks	B-MED
and	O
8	O
weeks	B-MED
.	O
This	O
study	O
showed	O
that	O
Ti	B-MED
-	I-MED
Nb	I-MED
-	I-MED
Zr	I-MED
-	I-MED
Ta	I-MED
-	I-MED
Si	I-MED
alloy	I-MED
implants	B-MED
could	O
establish	O
a	O
close	B-MED
direct	I-MED
contact	I-MED
comparedto	O
commercially	O
pure	O
titanium	B-MED
implants	B-MED
implants	B-MED
,	O
improved	B-MED
mineral	B-MED
matrix	I-MED
apposition	I-MED
rate	I-MED
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	B-MED
as	O
a	O
material	B-MED
for	O
dental	B-MED
implants	I-MED
.	O
Microbiological	B-MED
and	O
Clinical	B-MED
Characteristics	I-MED
of	O
Hypermucoviscous	B-MED
Klebsiella	I-MED
pneumoniae	I-MED
Isolates	B-MED
Associated	B-MED
with	I-MED
Invasive	B-MED
Infections	I-MED
in	O
China	B-MED
A	O
distinctive	B-MED
syndrome	I-MED
caused	B-MED
by	I-MED
hypermucoviscous	B-MED
Klebsiella	I-MED
pneumoniae	I-MED
(	O
HMKP	B-MED
)	O
including	O
pyogenic	B-MED
liver	I-MED
abscess	I-MED
(	O
PLA	B-MED
)	O
is	O
now	O
becoming	O
a	O
globally	B-MED
emerging	I-MED
disease	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
22.8	O
%	O
(	O
84/369	O
)	O
of	O
K.	B-MED
pneumoniae	I-MED
clinical	O
isolates	B-MED
associated	B-MED
with	I-MED
various	B-MED
types	I-MED
of	O
invasive	B-MED
infections	I-MED
were	O
identified	O
as	O
HMKP	B-MED
,	O
with	O
45.2	O
%	O
associated	B-MED
with	I-MED
PLA	B-MED
.	O
Multivariate	B-MED
regression	I-MED
analysis	I-MED
showed	O
that	O
male	B-MED
patients	I-MED
with	O
41	O
-	O
50	O
years	B-MED
,	O
PLA	B-MED
,	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
hypertension	B-MED
were	O
independent	B-MED
risk	B-MED
factors	I-MED
for	O
HMKP	B-MED
infections	I-MED
.	O
K2	B-MED
(	O
42.9	O
%	O
,	O
36/84	O
)	O
was	O
the	O
most	O
common	O
capsular	B-MED
serotype	B-MED
among	O
HMKP	B-MED
isolates	B-MED
,	O
followed	O
by	O
K1	B-MED
(	O
23.8	O
%	O
,	O
20/84	O
)	O
.	O
Seventy	B-MED
-	I-MED
five	I-MED
percentage	I-MED
of	O
K1	B-MED
HMKP	B-MED
isolates	B-MED
were	O
associated	B-MED
with	I-MED
PLA	B-MED
,	O
while	O
K2	B-MED
HMKP	B-MED
isolates	B-MED
accounted	B-MED
for	O
more	B-MED
types	I-MED
of	O
invasive	B-MED
infections	I-MED
.	O
The	O
positive	B-MED
rates	B-MED
of	O
iutA	B-MED
,	O
mrkD	B-MED
,	O
aerobactin	B-MED
,	O
iroN	B-MED
,	O
and	O
rmpA	B-MED
among	O
HMKP	B-MED
isolates	B-MED
were	O
significantly	B-MED
higher	I-MED
than	O
those	O
among	O
non	B-MED
-	I-MED
HMKP	I-MED
isolates	B-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
There	O
was	O
a	O
correlation	B-MED
between	O
magA	B-MED
,	O
ybtS	B-MED
,	O
alls	B-MED
,	O
and	O
wcaG	B-MED
and	O
K1	B-MED
isolates	B-MED
.	O
Interestingly	O
,	O
mrkD	B-MED
was	O
exclusively	B-MED
detected	I-MED
among	O
HMKP	B-MED
(	O
32.1	O
%	O
,	O
27/84	O
)	O
and	O
K2	B-MED
isolates	B-MED
(	O
65.9	O
%	O
,	O
27/41	O
)	O
.	O
All	O
K1	B-MED
and	O
K2	B-MED
HMKP	B-MED
and	O
non	B-MED
-	I-MED
HMKP	I-MED
isolates	B-MED
were	O
positive	B-MED
rmpA	B-MED
for	O
rmpA.	O
Aerobactin	B-MED
was	O
found	B-MED
among	O
95.0	O
and	O
97.5	O
%	O
of	O
K1	B-MED
and	O
K2	B-MED
isolates	B-MED
.	O
ST23	B-MED
was	O
found	B-MED
to	O
be	O
the	O
most	B-MED
prevalent	I-MED
ST	B-MED
among	O
69	O
HMKP	B-MED
isolates	B-MED
with	O
K1	B-MED
,	O
K2	B-MED
,	O
K5	B-MED
,	O
K20	B-MED
,	O
and	O
K57	B-MED
(	O
27.5	O
%	O
,	O
19/69	O
)	O
and	O
was	O
only	O
found	B-MED
among	O
K1	B-MED
isolates	B-MED
.	O
ST65	B-MED
was	O
the	O
second	O
most	B-MED
prevalent	I-MED
ST	B-MED
(	O
26.1	O
%	O
,	O
18/69	O
)	O
and	O
was	O
also	O
only	O
found	B-MED
among	O
K2	B-MED
isolates	B-MED
.	O
ST23	B-MED
-	I-MED
K1	I-MED
HMKP	B-MED
isolates	B-MED
(	O
84.2	O
%	O
,	O
16/19	O
)	O
were	O
associated	B-MED
with	I-MED
PLA	B-MED
,	O
while	O
ST65	B-MED
-	I-MED
K2	I-MED
isolates	B-MED
were	O
correlated	B-MED
with	O
more	O
types	B-MED
of	I-MED
infections	I-MED
relative	O
to	O
ST23	B-MED
-	I-MED
K1	I-MED
isolates	B-MED
.	O
PFGE	B-MED
results	B-MED
showed	O
that	O
the	O
homology	B-MED
of	O
84	O
HMKP	B-MED
isolates	B-MED
was	O
diverse	B-MED
.	O
Only	O
five	B-MED
PFGE	B-MED
clusters	B-MED
with	O
more	O
than	O
75	O
%	O
similarity	B-MED
accounted	B-MED
for	O
more	O
than	O
three	B-MED
isolates	B-MED
.	O
These	O
five	B-MED
PFGE	B-MED
clusters	B-MED
only	O
accounted	B-MED
for	O
35	O
(	O
41.7	O
%	O
,	O
35/84	O
)	O
isolates	B-MED
.	O
In	O
conclusion	O
,	O
our	O
study	B-MED
first	O
found	B-MED
that	O
hypertension	B-MED
and	O
male	B-MED
patients	I-MED
with	O
41	O
-	O
50	O
years	B-MED
old	B-MED
were	O
independent	B-MED
risk	B-MED
factors	I-MED
.	O
The	O
composition	B-MED
of	O
ST	B-MED
types	I-MED
and	O
PFGE	B-MED
clusters	B-MED
among	O
K.	B-MED
pneumoniae	I-MED
K2	B-MED
isolates	B-MED
was	O
more	O
diverse	B-MED
than	O
K1	B-MED
isolates	B-MED
.	O
K1	B-MED
and	O
K2	B-MED
HMKP	B-MED
isolates	B-MED
had	O
respective	O
specific	B-MED
profiles	I-MED
of	O
virulence	B-MED
-	O
associated	B-MED
genes	B-MED
.	O
A	O
novel	B-MED
assay	B-MED
to	O
measure	B-MED
tertiary	B-MED
and	O
quaternary	B-MED
amines	I-MED
in	O
wastewater	B-MED
:	O
An	O
indicator	B-MED
for	O
NDMA	B-MED
wastewater	B-MED
precursors	B-MED
This	O
study	B-MED
examined	B-MED
the	O
potential	B-MED
of	O
using	O
a	O
novel	B-MED
bulk	B-MED
amine	I-MED
assay	I-MED
as	O
an	O
approximation	B-MED
for	O
the	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
load	O
in	O
wastewaters	B-MED
and	O
surface	B-MED
water	B-MED
samples	I-MED
,	O
and	O
this	O
approximation	B-MED
was	O
compared	B-MED
to	O
N	B-MED
-	I-MED
nitrosodimethylamine	I-MED
(	O
NDMA	B-MED
)	O
formation	B-MED
potential	B-MED
using	O
chloramines	B-MED
.	O
An	O
existing	O
colorimetric	B-MED
method	I-MED
was	O
examined	B-MED
and	O
optimized	O
for	O
the	O
detection	B-MED
of	O
amines	B-MED
in	O
environmental	B-MED
water	B-MED
samples	I-MED
.	O
The	O
method	B-MED
consists	O
of	O
liquid	B-MED
-	I-MED
liquid	I-MED
extraction	I-MED
followed	O
by	O
a	O
catalyzed	B-MED
reaction	B-MED
to	O
form	O
a	O
yet-	O
undefined	B-MED
product	B-MED
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	B-MED
chromophore	B-MED
and	O
fluorophore	B-MED
.	O
Previous	O
work	O
verified	O
that	O
this	O
reaction	B-MED
was	O
effectively	O
catalyzed	B-MED
by	O
a	O
number	B-MED
of	O
compounds	B-MED
containing	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
moieties	B-MED
.	O
Many	O
tertiary	B-MED
and	O
quaternary	B-MED
compounds	I-MED
are	O
also	O
efficient	B-MED
producers	B-MED
of	O
NDMA	B-MED
under	O
chloramination	B-MED
conditions	B-MED
,	O
and	O
a	O
linear	B-MED
correlation	I-MED
was	O
consequently	B-MED
derived	O
from	O
the	O
bulk	B-MED
amine	I-MED
signals	I-MED
vs.	O
NDMA	B-MED
formation	B-MED
potential	B-MED
in	O
various	O
wastewater	B-MED
samples	B-MED
(	O
R(2	O
)	O
=	O
0.74	O
;	O
n	O
=	O
24	O
;	O
p	O
-	O
value	O
<	O
0.05	O
)	O
.	O
The	O
results	O
provide	O
evidence	B-MED
that	O
approximately	B-MED
2	O
%	O
of	O
the	O
tertiary	B-MED
and	O
quaternary	O
amines	O
measured	B-MED
can	O
form	O
NDMA	B-MED
and	O
an	O
estimated	B-MED
0.01	O
-	O
1.3	O
%	O
of	O
nitrogen	B-MED
in	O
dissolved	B-MED
organic	I-MED
nitrogen	I-MED
originates	I-MED
from	O
these	O
bulk	B-MED
amines	I-MED
.	O
The	O
normalization	B-MED
of	O
NDMA	B-MED
concentration	B-MED
by	O
the	O
amine	B-MED
measurement	B-MED
revealed	O
that	O
ozone	B-MED
effectively	B-MED
destroyed	B-MED
those	O
tertiary	B-MED
and	O
quaternary	B-MED
amine	I-MED
structures	B-MED
more	O
likely	O
to	O
form	O
NDMA	B-MED
in	O
treated	B-MED
wastewater	B-MED
samples	B-MED
.	O
This	O
bulk	B-MED
amine	I-MED
assay	I-MED
illustrates	O
that	O
proxy	O
measurements	B-MED
of	O
tertiary	B-MED
and	O
quaternary	B-MED
amines	I-MED
can	O
be	O
linked	O
to	O
the	O
NDMA	B-MED
formation	B-MED
potential	B-MED
of	O
a	O
given	O
sample	B-MED
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	B-MED
as	O
a	O
characterizing	B-MED
tool	B-MED
for	O
NDMA	B-MED
precursors	B-MED
in	O
wastewater	B-MED
.	O
Development	B-MED
and	O
validation	B-MED
of	O
an	O
easy	O
-	O
to	O
-	O
use	O
risk	B-MED
assessment	I-MED
tool	I-MED
for	O
cumulative	O
low	B-MED
back	I-MED
loading	B-MED
:	O
The	O
Lifting	B-MED
Fatigue	I-MED
Failure	I-MED
Tool	I-MED
(	O
LiFFT	B-MED
)	O
Recent	O
evidence	O
suggests	O
that	O
musculoskeletal	B-MED
disorders	I-MED
(	O
MSDs	B-MED
)	O
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-MED
failure	B-MED
process	I-MED
in	O
affected	B-MED
tissues	B-MED
.	O
This	O
paper	O
describes	O
a	O
new	O
low	B-MED
back	I-MED
exposure	I-MED
assessment	B-MED
tool	I-MED
(	O
the	O
Lifting	B-MED
Fatigue	I-MED
Failure	I-MED
Tool	I-MED
[	O
LiFFT	B-MED
]	O
)	O
,	O
which	O
estimates	O
a	O
"	O
daily	B-MED
dose	I-MED
"	O
of	O
cumulative	B-MED
loading	B-MED
on	O
the	O
low	B-MED
back	I-MED
using	O
fatigue	B-MED
failure	B-MED
principles	B-MED
.	O
Only	O
three	O
variables	B-MED
are	O
necessary	O
to	O
derive	O
the	O
cumulative	B-MED
load	B-MED
associated	B-MED
with	I-MED
a	O
lifting	B-MED
task	B-MED
:	O
the	O
weight	B-MED
of	I-MED
the	I-MED
load	I-MED
,	O
the	O
maximum	O
horizontal	B-MED
distance	I-MED
from	O
the	O
spine	B-MED
to	B-MED
the	I-MED
load	I-MED
,	O
and	O
the	O
number	O
of	O
repetitions	B-MED
for	O
tasks	B-MED
performed	I-MED
during	O
the	O
workday	B-MED
.	O
The	O
new	B-MED
tool	I-MED
was	O
validated	B-MED
using	O
two	O
existing	O
epidemiological	B-MED
databases	B-MED
:	O
the	O
Lumbar	B-MED
Motion	I-MED
Lumbar	B-MED
Motion	I-MED
Monitor	I-MED
(	O
LMM	B-MED
)	O
database	B-MED
,	O
and	O
a	O
database	B-MED
U.S	B-MED
from	O
a	O
U.S.	O
automotive	B-MED
manufacturer	I-MED
.	O
The	O
LiFFT	B-MED
cumulative	B-MED
damage	I-MED
metric	I-MED
explained	O
92	O
%	O
of	O
the	O
deviance	O
in	O
low	B-MED
back	I-MED
disorders	I-MED
(	O
LBDs	B-MED
)	O
in	O
the	O
LMM	B-MED
database	I-MED
and	O
72	O
-	O
95	O
%	O
of	O
the	O
deviance	O
in	O
low	B-MED
back	I-MED
outcomes	I-MED
in	O
the	O
automotive	B-MED
database	I-MED
(	O
depending	O
on	O
the	O
outcome	B-MED
measure	I-MED
)	O
.	O
Thus	O
,	O
LiFFT	B-MED
is	O
practitioner	B-MED
friendly	I-MED
and	O
its	O
cumulative	B-MED
damage	B-MED
metric	I-MED
highly	O
related	O
to	O
low	B-MED
back	I-MED
outcomes	I-MED
.	O
Sustained	B-MED
delivery	I-MED
of	O
vincristine	B-MED
inside	O
an	O
orthotopic	B-MED
mouse	B-MED
sarcoma	I-MED
model	O
decreases	B-MED
tumor	B-MED
growth	I-MED
Sarcoma	B-MED
accounts	O
for	O
20	O
%	O
of	O
solid	B-MED
tumors	I-MED
in	O
children	B-MED
.	O
Surgery	B-MED
has	O
significant	O
morbidity	B-MED
.	O
We	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-MED
directly	O
into	O
tumors	B-MED
through	O
sustained	B-MED
release	I-MED
silk	B-MED
systems	O
could	O
slow	O
tumor	B-MED
growth	I-MED
.	O
Human	B-MED
Ewing	B-MED
sarcoma	I-MED
cells	B-MED
A673	I-MED
were	O
cultured	B-MED
with	O
vincristine	B-MED
and	O
doxorubicin	B-MED
to	O
determine	O
half	B-MED
maximal	I-MED
inhibitory	I-MED
concentration	I-MED
(	O
IC50	B-MED
)	O
.	O
Cells	B-MED
were	O
injected	O
into	O
mouse	B-MED
hind	B-MED
leg	I-MED
to	O
create	O
orthotopic	B-MED
tumors	B-MED
.	O
Tumor	B-MED
volumes	I-MED
were	O
measured	O
using	O
ultrasound	B-MED
.	O
When	O
volume	O
reached	O
>	O
250mm(3	O
,	O
)	O
interventions	B-MED
included	O
:	O
implantation	B-MED
of	O
drug	B-MED
-	I-MED
free	I-MED
silk	B-MED
foam	O
(	O
Control	B-MED
-F	O
)	O
,	O
doxorubicin	B-MED
400μg	O
foam	O
(	B-MED
Dox400	I-MED
-F	O
)	O
,	O
vincristine	B-MED
50μg	O
foam	O
(	O
Vin50	B-MED
-F	O
)	O
,	O
drug	B-MED
-	I-MED
free	I-MED
silk	B-MED
gel	B-MED
(	O
Control	B-MED
-G	O
)	O
,	O
vincristine	B-MED
50μg	O
gel	B-MED
(	O
Vin50	B-MED
-G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	B-MED
vincristine	B-MED
50μg	O
(	O
Vin50	B-MED
-IV	O
)	O
.	O
End	B-MED
-	I-MED
point	I-MED
was	O
volume>1000mm(3	O
)	O
.	O
Kaplan	B-MED
Meier	I-MED
and	O
ANOVA	B-MED
were	O
used	O
.	O
IC50	B-MED
for	O
vincristine	B-MED
and	O
doxorubicin	B-MED
was	O
0.5ng	O
/	O
mL	O
and	O
200ng	O
/	O
mL	O
,	O
respectively	O
.	O
There	O
was	O
no	O
difference	O
between	O
Dox400	B-MED
-F	O
[	O
6±	O
1days	B-MED
to	O
end	B-MED
point	I-MED
(	O
DTEP	B-MED
)	O
]	O
and	O
Control	B-MED
-F	O
(	O
5±1.3	O
DTEP	B-MED
)	O
.	O
Vin50	B-MED
-F	O
(	O
12.4±3.5	O
DTEP	B-MED
)	O
had	O
slower	B-MED
growth	I-MED
compared	O
to	O
Control	B-MED
-F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	B-MED
-F	O
and	O
Vin50	B-MED
-IV	O
(	O
14±0	O
DTEP	B-MED
)	O
.	O
Growth	B-MED
was	I-MED
slowest	I-MED
with	O
Vin50	B-MED
-G	O
,	O
28±10.3	O
DTEP	B-MED
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p<0.05	O
)	O
.	O
Sustained	B-MED
delivery	I-MED
of	O
vincristine	B-MED
inside	O
the	O
sarcoma	B-MED
tumor	B-MED
with	O
silk	B-MED
gel	B-MED
decreased	B-MED
tumor	B-MED
growth	I-MED
.	O
Applying	O
this	O
intratumoral	B-MED
treatment	I-MED
strategy	O
may	O
potentially	O
decrease	B-MED
the	O
extent	O
of	O
surgical	B-MED
excision	I-MED
.	O
Phylogeography	B-MED
of	O
the	O
Spanish	B-MED
Moon	B-MED
Moth	I-MED
Graellsia	B-MED
isabellae	I-MED
(	O
Lepidoptera	B-MED
,	O
Saturniidae	B-MED
)	O
Geographic	B-MED
and	O
demographic	B-MED
factors	I-MED
as	O
well	O
as	O
specialisation	B-MED
to	O
a	O
new	O
host	B-MED
-	I-MED
plant	I-MED
may	O
lead	O
to	O
host	B-MED
-	O
associated	B-MED
differentiation	B-MED
in	O
plant	B-MED
-feeding	O
insects	B-MED
.	O
We	O
explored	O
the	O
phylogeography	B-MED
of	O
a	O
protected	B-MED
moth	B-MED
,	O
Graellsia	B-MED
isabellae	I-MED
,	O
and	O
its	O
two	O
recognised	O
host	B-MED
-	I-MED
plant	I-MED
species	B-MED
(	O
Pinus	B-MED
sylvestris	I-MED
and	O
P.	B-MED
nigra	I-MED
)	O
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	B-MED
history	I-MED
of	O
this	O
iconic	O
lepidopteran	B-MED
.	O
DNA	B-MED
variation	B-MED
in	O
one	O
mitochondrial	B-MED
marker	B-MED
and	O
nine	O
nuclear	B-MED
microsatellite	B-MED
loci	I-MED
revealed	O
a	O
strong	O
phylogeographic	B-MED
pattern	I-MED
across	O
28	O
populations	O
of	O
G.	B-MED
isabellae	I-MED
studied	O
in	O
Spain	B-MED
and	O
France	B-MED
comprising	O
six	O
groups	B-MED
mostly	O
distributed	B-MED
along	O
different	B-MED
mountain	B-MED
ranges	I-MED
.	O
Reanalysis	B-MED
of	O
a	O
previously	O
published	O
chloroplast	B-MED
microsatellite	B-MED
dataset	I-MED
revealed	B-MED
a	O
three	O
and	O
two-	O
group	B-MED
structure	I-MED
for	O
Spanish	B-MED
P.	B-MED
sylvestris	I-MED
and	O
P.	B-MED
nigra	I-MED
,	O
respectively	O
.	O
Overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	B-MED
moth	B-MED
did	O
not	O
match	B-MED
the	O
ones	O
of	O
P.	B-MED
sylvestris	I-MED
and	O
P.	B-MED
nigra	I-MED
.	O
There	O
was	O
no	B-MED
evidence	I-MED
of	I-MED
host	B-MED
-	O
associated	B-MED
differentiation	B-MED
between	O
populations	O
using	O
P.	B-MED
sylvestris	I-MED
and	O
the	O
ones	O
inhabiting	B-MED
P.	B-MED
nigra	I-MED
.	O
The	O
two	O
major	B-MED
mitochondrial	B-MED
clades	B-MED
of	O
G.	B-MED
isabellae	I-MED
likely	O
diverged	O
before	O
the	O
Last	B-MED
Glacial	I-MED
Maximum	I-MED
and	O
geographically	B-MED
separated	B-MED
the	O
species	B-MED
into	O
a	O
"	O
southern	B-MED
"	O
(	O
Central	B-MED
and	I-MED
Southern	I-MED
Iberian	I-MED
clusters	I-MED
)	O
and	O
a	O
"	O
northern	B-MED
"	O
lineage	B-MED
(	O
Eastern	B-MED
Iberian	I-MED
,	O
Pyrenean	B-MED
and	O
French	B-MED
Alpine	I-MED
clusters	I-MED
)	O
.	O
The	O
Eastern	B-MED
Iberian	I-MED
System	I-MED
,	O
where	O
this	O
insect	B-MED
uses	O
both	O
host	B-MED
-	I-MED
plants	I-MED
,	O
harboured	O
the	O
highest	B-MED
level	B-MED
of	O
genetic	B-MED
diversity	B-MED
.	O
Such	O
a	O
group	B-MED
independently	O
colonised	B-MED
the	O
West	B-MED
and	O
East	B-MED
parts	I-MED
of	O
the	O
Pyrenees	B-MED
.	O
Our	O
results	O
point	O
to	O
a	O
native	B-MED
origin	B-MED
for	O
the	O
French	B-MED
populations	I-MED
occurring	B-MED
in	O
the	O
Alps	B-MED
,	O
genetically	B-MED
related	O
to	O
the	O
Eastern	B-MED
Iberian	I-MED
and	O
Pyrenean	B-MED
sites	I-MED
.	O
The	O
Central	B-MED
Iberian	I-MED
group	I-MED
derived	O
from	O
Southern	B-MED
Iberian	I-MED
ancestors	B-MED
.	O
Secondary	B-MED
contacts	B-MED
were	O
inferred	O
between	O
the	O
Southern	B-MED
/	I-MED
Central	I-MED
Iberian	I-MED
populations	I-MED
and	O
Eastern	B-MED
Iberian	I-MED
cluster	I-MED
as	O
well	O
as	O
between	O
the	O
two	O
Pyrenean	B-MED
ones	I-MED
.	O
The	O
mito	B-MED
-	I-MED
nuclear	I-MED
discordance	I-MED
observed	O
with	O
regard	O
to	O
the	O
Eastern	B-MED
Iberian	I-MED
cluster	I-MED
is	O
congruent	B-MED
with	O
a	O
secondary	B-MED
contact	B-MED
after	O
the	O
evolution	B-MED
of	O
mito	B-MED
-	I-MED
nuclear	I-MED
incompatibilities	I-MED
in	O
geographically	B-MED
isolated	I-MED
areas	I-MED
.	O
Gastrointestinal	B-MED
disorders	I-MED
in	O
Curry	B-MED
-	I-MED
Jones	I-MED
syndrome	I-MED
:	O
Clinical	B-MED
and	O
molecular	B-MED
insights	B-MED
from	O
an	O
affected	B-MED
newborn	B-MED
Curry	B-MED
-	I-MED
Jones	I-MED
syndrome	I-MED
(	O
CJS	B-MED
)	O
is	O
a	O
pattern	B-MED
of	O
malformation	B-MED
that	O
includes	O
craniosynostosis	B-MED
,	O
pre	B-MED
-	I-MED
axial	I-MED
polysyndactyly	I-MED
,	O
agenesis	B-MED
of	I-MED
the	I-MED
corpus	I-MED
callosum	I-MED
,	O
cutaneous	B-MED
and	O
gastrointestinal	B-MED
gastrointestinal	B-MED
abnormalities	I-MED
.	O
A	O
recurrent	B-MED
,	O
mosaic	B-MED
mutation	I-MED
of	O
SMO	B-MED
(	I-MED
c.1234	I-MED
C	I-MED
>	I-MED
T	I-MED
;	I-MED
p.	I-MED
Leu412Phe	I-MED
)	I-MED
causes	B-MED
CJS	B-MED
.	O
This	O
report	B-MED
describes	O
the	O
gastrointestinal	B-MED
and	O
surgical	B-MED
findings	I-MED
in	O
a	O
baby	B-MED
with	O
CJS	B-MED
who	O
presented	O
with	O
abdominal	B-MED
obstruction	I-MED
and	O
reviews	B-MED
the	O
spectrum	B-MED
of	I-MED
gastrointestinal	I-MED
malformations	I-MED
gastrointestinal	B-MED
in	O
this	O
rare	B-MED
disorder	I-MED
.	O
A	O
41-	O
week	B-MED
,	O
4,165	O
g	O
,	O
female	B-MED
presented	O
with	O
craniosynostosis	B-MED
,	O
pre	B-MED
-	I-MED
axial	I-MED
polysyndactyly	I-MED
,	O
and	O
cutaneous	B-MED
findings	I-MED
consistent	O
with	O
a	O
clinical	B-MED
diagnosis	I-MED
of	O
CJS	B-MED
.	O
The	O
infant	B-MED
developed	O
abdominal	B-MED
distension	I-MED
beginning	B-MED
on	O
the	O
second	B-MED
day	B-MED
of	O
life	B-MED
.	O
Surgical	B-MED
exploration	I-MED
revealed	B-MED
an	O
intestinal	B-MED
malrotation	I-MED
for	O
which	O
she	O
underwent	O
a	O
Ladd	B-MED
procedure	I-MED
.	O
Multiple	B-MED
small	I-MED
nodules	I-MED
were	O
found	B-MED
on	O
the	O
surface	B-MED
of	I-MED
the	I-MED
small	I-MED
and	I-MED
large	I-MED
bowel	I-MED
in	B-MED
addition	I-MED
to	I-MED
an	O
apparent	B-MED
intestinal	B-MED
duplication	I-MED
that	O
seemed	O
to	O
originate	O
posterior	B-MED
to	O
the	O
pancreas	B-MED
.	O
Histopathology	B-MED
of	O
serosal	B-MED
nodules	B-MED
revealed	B-MED
bundles	B-MED
of	I-MED
smooth	I-MED
muscle	I-MED
with	B-MED
associated	I-MED
ganglion	B-MED
cells	I-MED
.	O
Molecular	B-MED
analysis	I-MED
demonstrated	O
the	O
SMO	B-MED
c.1234	I-MED
C	I-MED
>	I-MED
T	I-MED
mutation	I-MED
in	O
varying	O
amounts	O
in	O
affected	B-MED
skin	B-MED
(	O
up	O
to	O
35	O
%	O
)	O
and	O
intestinal	B-MED
hamartoma	I-MED
(	O
26	O
%	O
)	O
.	O
Gastrointestinal	B-MED
features	B-MED
including	O
structural	B-MED
malformations	I-MED
malformations	B-MED
,	O
motility	B-MED
disorders	I-MED
,	O
and	O
upper	B-MED
GI	I-MED
bleeding	I-MED
are	O
major	O
causes	B-MED
of	O
morbidity	B-MED
in	O
CJS	B-MED
.	O
Smooth	B-MED
muscle	I-MED
Smooth	B-MED
muscle	I-MED
hamartomas	I-MED
are	O
a	O
recognized	B-MED
feature	I-MED
of	O
children	B-MED
with	O
CJS	B-MED
typically	O
presenting	O
with	O
abdominal	B-MED
obstruction	I-MED
requiring	B-MED
surgical	I-MED
intervention	I-MED
.	O
A	O
somatic	B-MED
mutation	I-MED
in	O
SMO	B-MED
likely	O
accounts	O
for	O
the	O
structural	B-MED
malformations	I-MED
malformations	B-MED
and	O
predisposition	B-MED
to	O
form	O
bowel	B-MED
hamartomas	I-MED
and	O
myofibromas	B-MED
.	O
The	O
mutation	B-MED
burden	B-MED
in	O
the	O
involved	B-MED
tissues	B-MED
likely	O
accounts	O
for	O
the	O
variable	B-MED
manifestations	I-MED
.	O
Bioelectrochemical	B-MED
anaerobic	B-MED
sewage	B-MED
treatment	I-MED
technology	B-MED
for	O
Arctic	B-MED
communities	B-MED
This	O
study	B-MED
describes	O
a	O
novel	O
wastewater	B-MED
treatment	B-MED
technology	B-MED
suitable	O
for	O
small	O
remote	B-MED
northern	B-MED
communities	B-MED
.	O
The	O
technology	B-MED
is	O
based	B-MED
on	O
an	O
enhanced	B-MED
biodegradation	B-MED
of	O
organic	B-MED
carbon	I-MED
through	O
a	O
combination	O
of	O
anaerobic	B-MED
methanogenic	B-MED
and	O
microbial	B-MED
electrochemical	B-MED
(	O
bioelectrochemical	B-MED
)	O
degradation	B-MED
processes	I-MED
leading	O
to	O
biomethane	B-MED
production	B-MED
.	O
The	O
microbial	B-MED
electrochemical	B-MED
degradation	B-MED
is	O
achieved	O
in	O
a	O
membraneless	B-MED
flow	I-MED
-through	O
bioanode	B-MED
-	O
biocathode	B-MED
setup	O
operating	B-MED
at	O
an	O
applied	B-MED
voltage	B-MED
below	O
the	O
water	B-MED
electrolysis	B-MED
threshold	B-MED
.	O
Laboratory	B-MED
wastewater	B-MED
treatment	B-MED
tests	B-MED
conducted	O
through	O
a	O
broad	B-MED
range	I-MED
of	O
mesophilic	B-MED
and	O
psychrophilic	B-MED
temperatures	I-MED
(	O
5	O
-	O
23	O
°	O
C	O
)	O
using	O
synthetic	B-MED
wastewater	B-MED
showed	O
a	O
biochemical	B-MED
oxygen	I-MED
demand	I-MED
(	O
BOD5	B-MED
)	O
removal	B-MED
efficiency	B-MED
of	O
90	O
-	O
97	O
%	O
and	O
an	O
effluent	B-MED
BOD5	B-MED
concentration	B-MED
as	O
low	O
as	O
7	O
mg	O
L(-1	O
)	O
.	O
An	O
electricity	B-MED
consumption	B-MED
of	O
0.6	O
kWh	O
kg(-1	O
)	O
of	O
chemical	B-MED
oxygen	I-MED
demand	I-MED
(	O
COD	B-MED
)	O
removed	B-MED
was	O
observed	B-MED
.	O
Low	B-MED
energy	B-MED
consumption	B-MED
coupled	O
with	O
enhanced	B-MED
methane	B-MED
production	B-MED
led	O
to	O
a	O
net	O
positive	B-MED
energy	B-MED
balance	B-MED
in	O
the	O
bioelectrochemical	B-MED
treatment	B-MED
system	B-MED
.	O
Simulating	B-MED
the	O
potential	B-MED
role	B-MED
of	O
media	B-MED
coverage	I-MED
and	O
infected	B-MED
bats	B-MED
in	O
the	O
2014	O
Ebola	B-MED
outbreak	B-MED
Multiple	O
epidemiological	B-MED
models	B-MED
have	O
been	O
developed	B-MED
to	O
model	O
the	O
transmission	B-MED
dynamics	I-MED
of	O
Ebola	B-MED
virus	I-MED
(	I-MED
EBOV	I-MED
)	I-MED
disease	I-MED
in	O
West	B-MED
Africa	I-MED
in	O
2014	O
because	O
the	O
severity	B-MED
of	O
the	O
epidemic	B-MED
is	O
commonly	O
overestimated	O
.	O
A	O
compartmental	B-MED
model	I-MED
that	O
incorporates	O
the	O
media	B-MED
impact	I-MED
and	O
the	O
effect	B-MED
of	O
infected	B-MED
bats	B-MED
was	O
constructed	O
and	O
calibrated	B-MED
using	O
data	B-MED
reported	O
until	O
the	O
end	O
of	O
2014	O
.	O
The	O
final	O
cumulative	B-MED
number	B-MED
of	I-MED
deaths	I-MED
and	O
confirmed	B-MED
cases	B-MED
were	O
estimated	B-MED
to	O
be	O
1.0921×10(4	O
)	O
(	O
95	O
%	O
CI	B-MED
9.7706×10(3)-1.2072×10(4	O
)	O
)	O
and	O
1.5193×10(4	O
)	O
(	O
95	O
%	O
CI	B-MED
1.3593×10(4)-1.6795×10(4	O
)	O
)	O
,	O
respectively	O
.	O
The	O
epidemic	B-MED
was	O
estimated	B-MED
to	O
end	O
on	O
June	O
2015	O
,	O
which	O
was	O
similar	B-MED
to	O
the	O
data	B-MED
reported	B-MED
by	O
the	O
World	B-MED
Health	I-MED
Organization	I-MED
.	O
A	O
sensitivity	B-MED
analysis	I-MED
indicated	B-MED
that	O
an	O
increase	B-MED
of	O
either	O
the	O
media	B-MED
impact	I-MED
or	O
the	O
number	B-MED
of	O
infectious	B-MED
bats	B-MED
that	O
are	O
captured	O
daily	B-MED
can	O
increase	B-MED
the	O
cumulative	B-MED
number	B-MED
of	O
confirmed	B-MED
cases	B-MED
/	O
deaths	B-MED
.	O
Of	O
the	O
considered	O
epidemiological	B-MED
parameters	I-MED
,	O
only	O
the	O
media	B-MED
coverage	I-MED
can	O
significantly	O
reduce	O
both	O
the	O
peak	B-MED
time	I-MED
and	O
the	O
value	B-MED
of	O
the	O
cumulative	B-MED
confirmed	B-MED
cases	B-MED
/	O
deaths	B-MED
.	O
Thus	O
,	O
we	O
propose	O
'	O
the	O
cumulative	B-MED
confirmed	B-MED
cases	B-MED
and	O
deaths	B-MED
'	O
as	O
another	O
media	B-MED
mechanism	B-MED
.	O
In	O
conclusion	O
,	O
the	O
media	B-MED
impact	I-MED
contributed	O
to	O
the	O
control	B-MED
of	O
the	O
2014	O
Ebola	B-MED
outbreak	B-MED
,	O
and	O
infectious	B-MED
bats	B-MED
may	O
be	O
a	O
potential	B-MED
source	B-MED
of	O
the	O
epidemic	B-MED
.	O
The	O
effects	B-MED
of	I-MED
probiotic	B-MED
and	O
synbiotic	B-MED
supplementation	B-MED
on	O
metabolic	B-MED
syndrome	I-MED
indices	B-MED
in	O
adults	B-MED
at	O
risk	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
:	O
study	B-MED
protocol	I-MED
for	O
a	O
randomized	B-MED
controlled	I-MED
trial	I-MED
The	O
incidence	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
,	O
cardiovascular	B-MED
diseases	I-MED
,	O
and	O
obesity	B-MED
has	O
been	O
rising	B-MED
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	B-MED
is	O
particularly	O
intriguing	B-MED
.	O
Recently	O
,	O
dysbiosis	B-MED
of	O
the	O
intestinal	B-MED
microbiota	I-MED
has	O
emerged	O
as	O
a	O
new	B-MED
candidate	B-MED
that	O
may	O
be	O
linked	O
to	O
metabolic	B-MED
diseases	I-MED
.	O
We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	B-MED
microbiota	I-MED
by	O
probiotic	B-MED
or	O
synbiotic	B-MED
supplementation	B-MED
may	B-MED
improve	I-MED
metabolic	B-MED
dysfunction	I-MED
and	O
prevent	B-MED
diabetes	B-MED
in	O
prediabetics	B-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
synthesis	B-MED
and	O
study	B-MED
of	O
synbiotics	B-MED
will	O
be	O
carried	B-MED
out	O
for	O
the	O
first	O
time	O
in	O
Iran	B-MED
.	O
In	O
a	O
randomized	B-MED
triple	I-MED
-	I-MED
blind	I-MED
controlled	I-MED
clinical	I-MED
trial	I-MED
,	O
120	O
adults	B-MED
with	O
impaired	B-MED
glucose	I-MED
tolerance	I-MED
based	O
on	O
the	O
inclusion	B-MED
criteria	I-MED
will	O
be	O
selected	B-MED
by	O
a	O
simple	O
random	B-MED
sampling	B-MED
method	I-MED
and	O
will	O
be	O
randomly	B-MED
allocated	B-MED
to	O
6	O
months	B-MED
of	O
6	O
g	O
/	O
d	O
probiotic	B-MED
,	O
synbiotic	B-MED
or	O
placebo	B-MED
.	O
The	O
fecal	B-MED
abundance	B-MED
of	O
bacteria	B-MED
,	O
blood	B-MED
pressure	I-MED
,	O
height	B-MED
,	O
weight	B-MED
,	O
and	O
waist	B-MED
and	O
hip	B-MED
circumferences	I-MED
will	O
be	O
measured	B-MED
at	O
baseline	B-MED
and	O
following	B-MED
treatment	B-MED
.	O
Also	O
,	O
plasma	B-MED
lipid	I-MED
profiles	I-MED
,	O
HbA1C	B-MED
,	O
fasting	B-MED
plasma	I-MED
glucose	I-MED
,	O
and	O
insulin	B-MED
levels	B-MED
,	O
will	O
be	O
measured	B-MED
and	O
insulin	B-MED
resistance	I-MED
(	O
HOMA	B-MED
-	I-MED
IR	I-MED
)	O
and	O
beta	B-MED
-	I-MED
cell	I-MED
function	I-MED
(	O
HOMA	B-MED
-	I-MED
B	I-MED
)	O
will	O
be	O
calculated	B-MED
at	O
baseline	B-MED
and	O
will	O
be	O
repeated	B-MED
at	O
months	B-MED
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O
The	O
data	B-MED
will	O
be	O
compared	B-MED
within	O
and	O
between	O
groups	B-MED
using	B-MED
statistical	B-MED
methods	I-MED
.	O
The	O
results	B-MED
of	O
this	O
trial	B-MED
could	O
contribute	B-MED
to	O
the	O
evidence	B-MED
-	I-MED
based	I-MED
clinical	I-MED
guidelines	I-MED
that	O
address	O
gut	B-MED
microbiota	I-MED
manipulation	B-MED
to	O
maximize	B-MED
health	B-MED
benefits	I-MED
in	O
prevention	B-MED
and	O
management	B-MED
of	O
metabolic	B-MED
syndrome	I-MED
in	O
prediabetes	B-MED
.	O
Iranian	B-MED
Registry	I-MED
of	O
Clinical	B-MED
Trials	I-MED
:	O
IRCT201511032321N2	B-MED
.	O
Registered	O
on	O
27	O
February	O
2016	O
.	O
Effect	B-MED
of	O
nutritionally	B-MED
induced	I-MED
hyperlipidaemia	B-MED
on	O
in	B-MED
vitro	I-MED
bovine	B-MED
embryo	B-MED
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	B-MED
acid	I-MED
in	O
the	O
diet	B-MED
The	O
present	O
study	B-MED
examined	B-MED
whether	O
the	O
effects	B-MED
of	I-MED
dietary	B-MED
-induced	O
hyperlipidaemia	B-MED
on	O
preimplantation	B-MED
embryo	I-MED
development	I-MED
depend	O
on	O
the	O
predominant	O
fatty	B-MED
acid	I-MED
(	O
FA	B-MED
)	O
type	O
in	O
the	O
diet	B-MED
.	O
In	O
a	O
combined	O
in	B-MED
vivo	I-MED
-	O
in	B-MED
vitro	I-MED
bovine	B-MED
model	B-MED
,	O
two	O
groups	O
of	O
cows	B-MED
(	O
n=3	O
in	O
each	O
group	O
)	O
were	O
fed	B-MED
with	O
three	O
diets	B-MED
consecutively	O
(	O
4	O
weeks	O
feeding	B-MED
for	O
each	O
):	O
(	O
1	O
)	O
a	O
maintenance	B-MED
control	I-MED
diet	I-MED
(	O
CONT	B-MED
)	O
;	O
(	O
2	O
)	O
a	O
high	B-MED
-	O
starch	B-MED
diet	B-MED
rich	O
in	O
saturated	B-MED
fat	I-MED
(	O
SAT	B-MED
)	O
;	O
and	O
(	O
3	O
)	O
a	O
high	B-MED
-	O
starch	B-MED
diet	B-MED
rich	O
in	O
omega-3	B-MED
unsaturated	B-MED
fat	I-MED
(	O
UNSAT	B-MED
)	O
.	O
Two	O
feeding	B-MED
sequences	B-MED
were	O
used	O
to	O
test	O
for	O
carry	O
-	O
over	O
effects	O
:	O
Group	O
A	O
was	O
fed	B-MED
CONT	B-MED
,	O
SAT1	B-MED
and	O
then	O
UNSAT2	B-MED
,	O
whereas	O
Group	O
B	O
was	O
fed	B-MED
CONT	B-MED
,	O
UNSAT1	B-MED
and	O
then	O
SAT2	B-MED
.	O
Serum	B-MED
was	O
collected	O
after	O
each	O
dietary	B-MED
period	B-MED
,	O
analysed	B-MED
and	O
tested	B-MED
in	O
bovine	B-MED
in	B-MED
vitro	I-MED
embryo	B-MED
culture	I-MED
.	O
Introducing	O
SAT	B-MED
and	O
UNSAT	B-MED
diets	B-MED
induced	O
hyperlipidaemia	B-MED
(	O
specifically	O
hypercholesterolaemia	B-MED
and	O
elevated	O
free	B-MED
FAs	I-MED
)	O
and	O
reduced	O
insulin	B-MED
sensitivity	I-MED
.	O
Carry	O
-	O
over	O
effects	O
in	O
serum	B-MED
metabolites	B-MED
and	O
FA	B-MED
profile	I-MED
were	O
dependent	O
on	O
the	O
diet	B-MED
and	O
feeding	B-MED
sequence	B-MED
.	O
SAT1	B-MED
and	O
SAT2	B-MED
serum	B-MED
decreased	O
blastocyst	B-MED
rates	O
and	O
altered	O
blastocyst	B-MED
mRNA	B-MED
expression	I-MED
related	O
to	O
apoptosis	B-MED
and	O
oxidative	B-MED
stress	I-MED
.	O
UNSAT1	B-MED
and	O
UNSAT2	B-MED
serum	B-MED
resulted	O
in	O
normal	O
embryo	B-MED
development	O
and	O
quality	B-MED
.	O
Other	O
in	B-MED
vitro	I-MED
effects	O
depended	O
on	O
the	O
sequence	B-MED
of	O
feeding	B-MED
.	O
In	O
conclusion	O
,	O
substitution	B-MED
of	O
saturated	B-MED
fat	I-MED
with	O
omega-3	B-MED
fat	I-MED
in	O
a	O
high	B-MED
-	I-MED
caloric	I-MED
diet	I-MED
induced	O
hyperlipidaemia	B-MED
with	O
an	O
FA	B-MED
profile	I-MED
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-MED
compared	O
with	O
normolipidaemic	B-MED
controls	I-MED
.	O
Prednisolone	B-MED
is	O
associated	B-MED
with	I-MED
a	O
worse	B-MED
lipid	I-MED
profile	I-MED
than	O
hydrocortisone	B-MED
in	O
patients	B-MED
with	O
adrenal	B-MED
insufficiency	I-MED
Prednisolone	B-MED
is	O
used	O
as	O
glucocorticoid	B-MED
replacement	B-MED
therapy	I-MED
for	O
adrenal	B-MED
insufficiency	I-MED
(	O
AI	B-MED
)	O
.	O
Recent	O
data	B-MED
indicate	O
that	O
its	O
use	O
in	O
AI	B-MED
is	O
associated	B-MED
with	I-MED
low	O
bone	B-MED
mineral	I-MED
density	I-MED
.	O
Data	B-MED
on	O
risk	B-MED
factors	I-MED
for	O
cardiovascular	B-MED
disease	I-MED
in	O
patients	B-MED
with	O
AI	B-MED
treated	B-MED
with	O
prednisolone	B-MED
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-MED
of	O
excess	O
mortality	B-MED
.	O
We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real	O
-	O
world	O
data	B-MED
from	O
the	O
European	B-MED
Adrenal	I-MED
Insufficiency	I-MED
Registry	I-MED
(	O
EU	B-MED
-	I-MED
AIR	I-MED
)	O
.	O
EU	B-MED
-	I-MED
AIR	I-MED
,	O
comprising	O
of	O
19	O
centres	B-MED
across	O
Germany	B-MED
,	O
the	O
Netherlands	B-MED
,	O
Sweden	B-MED
and	O
the	O
UK	B-MED
,	O
commenced	O
enrolling	O
patients	B-MED
with	O
AI	B-MED
in	O
August	O
2012	O
.	O
Patients	B-MED
receiving	O
prednisolone	B-MED
(	O
3	O
-	O
6	O
mg	O
/	O
day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	B-MED
(	O
15	O
-	O
30	O
mg	O
/	O
day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	B-MED
and	O
grouped	B-MED
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	B-MED
:	O
hydrocortisone	B-MED
)	O
by	O
matching	O
for	O
gender	B-MED
,	O
age	B-MED
,	O
duration	B-MED
and	O
type	B-MED
of	I-MED
disease	I-MED
.	O
Data	B-MED
from	O
baseline	B-MED
and	O
follow	B-MED
-	I-MED
up	I-MED
visits	B-MED
were	O
analysed	O
.	O
Data	B-MED
from	O
patients	B-MED
with	O
congenital	B-MED
adrenal	I-MED
hyperplasia	I-MED
were	O
excluded	B-MED
.	O
Significantly	O
higher	O
mean	B-MED
±	I-MED
s.d	I-MED
.	I-MED
total	I-MED
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
(	I-MED
LDL	I-MED
)	I-MED
cholesterol	I-MED
LDL	B-MED
levels	B-MED
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	B-MED
in	O
47	O
patients	B-MED
on	O
prednisolone	B-MED
vs	O
141	O
receiving	O
hydrocortisone	B-MED
at	O
baseline	B-MED
and	O
at	O
follow	B-MED
-	I-MED
up	I-MED
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O
HbA1c	B-MED
,	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
and	O
triglyceride	B-MED
levels	I-MED
,	O
body	B-MED
mass	I-MED
index	I-MED
,	O
systolic	B-MED
and	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
and	O
waist	B-MED
circumference	I-MED
were	O
not	O
significantly	O
different	O
.	O
This	O
is	O
the	O
first	O
matched	B-MED
analysis	B-MED
of	O
its	O
kind	O
.	O
Significantly	O
higher	O
LDL	B-MED
levels	I-MED
in	O
patients	B-MED
receiving	O
prednisolone	B-MED
relative	O
to	O
hydrocortisone	B-MED
could	O
predict	O
a	O
higher	O
relative	O
risk	B-MED
of	O
cardiovascular	B-MED
disease	I-MED
in	O
the	O
former	O
group	B-MED
.	O
Construction	B-MED
of	O
Fused	B-MED
Polyheterocycles	I-MED
through	O
Sequential	B-MED
[	B-MED
4	I-MED
+	I-MED
2	I-MED
]	I-MED
and	I-MED
[	I-MED
3	I-MED
+	I-MED
2	I-MED
]	I-MED
Cycloadditions	I-MED
A	O
method	O
for	O
Pd	B-MED
-	O
catalyzed	B-MED
aerobic	B-MED
oxidative	B-MED
reaction	I-MED
of	O
quinazolinones	B-MED
and	O
alkynes	B-MED
has	O
been	O
developed	O
for	O
sequential	B-MED
[	B-MED
4	I-MED
+	I-MED
2	I-MED
]	I-MED
and	I-MED
[	I-MED
3	I-MED
+	I-MED
2	I-MED
]	I-MED
cycloadditions	I-MED
to	O
assemble	B-MED
a	O
novel	B-MED
fused	B-MED
-	I-MED
polycyclic	I-MED
system	I-MED
containing	O
tetrahydropyridine	B-MED
and	O
dihydrofuran	B-MED
rings	I-MED
.	O
The	O
reaction	B-MED
process	I-MED
involves	O
C	B-MED
-	I-MED
H	I-MED
and	I-MED
N	I-MED
-	I-MED
H	I-MED
bond	I-MED
functionalization	O
for	O
the	O
formation	B-MED
of	O
tetrahydropyridine	B-MED
and	O
an	O
oxygen	B-MED
radical	I-MED
cyclization	B-MED
for	O
the	O
dihydrofuran	B-MED
ring	I-MED
.	O
This	O
atom	B-MED
-	O
and	O
step-	O
economical	B-MED
synthesis	I-MED
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	B-MED
tolerance	B-MED
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	B-MED
of	O
polycyclic	B-MED
molecules	I-MED
with	O
potential	O
pharmaceutical	B-MED
interest	I-MED
.	I-MED
Risk	B-MED
Factors	I-MED
Associated	B-MED
With	I-MED
Repeated	B-MED
HIV	B-MED
Testing	I-MED
Among	O
Internet	B-MED
-Using	O
Men	B-MED
Who	I-MED
Have	I-MED
Sex	I-MED
With	I-MED
Men	I-MED
Men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
(	O
MSM	B-MED
)	O
represent	B-MED
a	O
disproportionately	B-MED
impacted	B-MED
risk	B-MED
group	I-MED
for	O
HIV	B-MED
incidence	B-MED
among	O
at	B-MED
-	I-MED
risk	I-MED
U.S	B-MED
U.S.	O
Few	O
studies	B-MED
have	O
identified	B-MED
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
HIV	B-MED
testing	I-MED
frequency	B-MED
both	O
within	B-MED
and	O
outside	B-MED
of	O
traditional	O
health	B-MED
care	I-MED
settings	I-MED
.	O
MSM	B-MED
enrolled	O
in	O
a	O
prospective	B-MED
cohort	I-MED
were	O
mailed	B-MED
at	B-MED
-	I-MED
home	I-MED
specimen	I-MED
collection	I-MED
kits	I-MED
and	O
followed	B-MED
for	O
a	O
year	B-MED
.	O
Incidence	B-MED
density	I-MED
rate	I-MED
ratios	I-MED
(	O
IDRR	B-MED
)	O
of	O
testing	B-MED
were	O
calculated	B-MED
,	O
and	O
generalized	B-MED
estimating	B-MED
equations	B-MED
were	O
used	O
to	O
analyze	O
the	O
association	B-MED
between	O
HIV	B-MED
testing	I-MED
and	O
behavioral	B-MED
factors	B-MED
.	O
The	O
incidence	B-MED
rate	I-MED
of	O
testing	B-MED
was	O
higher	B-MED
among	O
Black	B-MED
MSM	B-MED
than	O
White	B-MED
MSM	B-MED
(	O
IDRR	B-MED
:	O
1.3	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
CI	B-MED
[	O
1.1	O
,	O
1.5	O
]	O
)	O
and	O
higher	B-MED
among	O
MSM	B-MED
who	O
reported	O
3	O
+	O
condomless	B-MED
condomless	B-MED
anal	I-MED
intercourse	I-MED
partners	I-MED
anal	B-MED
(	O
CAI	B-MED
)	O
than	O
MSM	B-MED
who	O
reported	O
no	B-MED
CAI	B-MED
(	O
IDRR	B-MED
:	O
1.6	O
,	O
95	O
%	O
CI	B-MED
[	O
1.3	O
,	O
2.0	O
]	O
)	O
.	O
Increasing	B-MED
availability	B-MED
of	I-MED
HIV	B-MED
testing	I-MED
outside	B-MED
traditional	O
health	B-MED
care	I-MED
settings	I-MED
,	O
including	O
at	B-MED
-	I-MED
home	I-MED
testing	I-MED
kits	I-MED
,	O
in	O
conjunction	B-MED
with	O
targeted	B-MED
behavioral	B-MED
interventions	B-MED
and	O
biomedical	B-MED
treatment	B-MED
preventions	I-MED
is	O
needed	O
.	O
Establishing	O
in-	O
hospital	B-MED
geriatrics	B-MED
services	I-MED
in	O
Africa	B-MED
:	O
Insights	O
from	O
the	O
University	B-MED
of	I-MED
Benin	I-MED
Teaching	I-MED
Hospital	I-MED
geriatrics	B-MED
project	B-MED
Unawareness	O
of	O
the	O
peculiar	O
healthcare	B-MED
needs	B-MED
of	O
the	O
elderly	B-MED
and	O
resource	B-MED
constraints	B-MED
may	O
be	O
some	O
reasons	O
why	O
until	O
recently	O
,	O
Nigerian	B-MED
hospitals	B-MED
have	O
not	O
been	O
equipped	O
with	O
the	O
human	B-MED
and	O
infrastructural	B-MED
resources	I-MED
required	O
to	O
meet	O
older	B-MED
adults	I-MED
'	O
special	O
healthcare	B-MED
needs	B-MED
.	O
There	O
is	O
paucity	O
of	O
specialized	O
health	B-MED
services	I-MED
for	O
the	O
elderly	B-MED
in	O
Africa	B-MED
.	O
Nigeria	B-MED
,	O
with	O
a	O
population	B-MED
of	O
over	O
170	O
million	O
,	O
did	O
not	O
have	O
any	O
healthcare	B-MED
facility	I-MED
with	O
dedicated	O
services	B-MED
for	O
the	O
elderly	B-MED
until	O
2012	O
.	O
The	O
University	B-MED
of	I-MED
Benin	I-MED
Teaching	I-MED
Hospital	I-MED
(	O
UBTH	B-MED
)	O
in	O
Nigeria	B-MED
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	B-MED
unit	O
in	O
October	O
2013	O
.	O
A	O
prepared	O
environment	O
and	O
trained	B-MED
interdisciplinary	I-MED
teams	I-MED
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare	B-MED
services	I-MED
for	O
the	O
elderly	B-MED
.	O
The	O
ongoing	O
UBTH	B-MED
geriatrics	B-MED
project	B-MED
aims	O
to	O
provide	O
specialized	O
interdisciplinary	B-MED
health	B-MED
services	I-MED
to	O
older	B-MED
adults	I-MED
and	O
to	O
provide	O
training	B-MED
and	O
continuing	O
professional	B-MED
development	I-MED
in	O
geriatrics	B-MED
for	O
healthcare	B-MED
staff	I-MED
.	O
In	O
developing	O
our	O
inpatient	B-MED
services	B-MED
,	O
we	O
adopted	O
the	O
acute	B-MED
care	I-MED
for	I-MED
elders	I-MED
(	O
ACE	B-MED
)	O
model	B-MED
and	O
worked	O
in	O
tandem	O
with	O
the	O
"	O
ABCs	O
"	O
of	O
implementing	O
ACE	B-MED
units	I-MED
.	O
In	O
the	O
face	O
of	O
limited	O
resources	B-MED
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics	B-MED
unit	I-MED
with	O
a	O
trained	O
interdisciplinary	B-MED
team	I-MED
.	O
Family	B-MED
participation	B-MED
is	O
central	O
in	O
our	O
practice	B-MED
.	O
Since	O
October	O
2013	O
,	O
residents	B-MED
and	O
house	B-MED
officers	I-MED
in	O
internal	B-MED
medicine	I-MED
have	O
been	O
undertaking	O
4-	O
and	O
12-	O
weekly	B-MED
rotations	B-MED
,	O
respectively	O
.	O
There	O
is	O
also	O
a	O
robust	O
academic	B-MED
program	I-MED
,	O
which	O
includes	O
once-	O
weekly	B-MED
geriatric	B-MED
pharmacotherapy	B-MED
seminars	B-MED
,	O
once-	O
weekly	B-MED
interdisciplinary	O
seminars	B-MED
,	O
and	O
2-	O
weekly	B-MED
journal	B-MED
club	I-MED
meetings	I-MED
alternating	O
with	O
seminars	B-MED
on	O
geriatric	B-MED
assessment	I-MED
tools	I-MED
.	O
It	O
is	O
possible	O
to	O
establish	O
geriatric	B-MED
services	I-MED
and	O
achieve	O
best	O
practices	B-MED
in	O
resource	O
-	O
limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human	B-MED
resources	I-MED
and	O
infrastructure	B-MED
.	O
We	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	B-MED
in	O
other	O
parts	O
of	O
Africa	B-MED
.	O
Heterogeneity	B-MED
of	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
by	O
tumour	B-MED
characteristics	B-MED
:	O
Large	O
prospective	B-MED
study	I-MED
of	O
UK	B-MED
women	B-MED
Associations	B-MED
between	O
behavioural	B-MED
and	O
other	O
personal	B-MED
factors	B-MED
and	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-MED
characteristics	B-MED
,	O
but	O
evidence	O
is	O
inconsistent	O
.	O
In	O
a	O
large	O
UK	B-MED
-based	O
prospective	B-MED
study	I-MED
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk	B-MED
factors	I-MED
with	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
overall	O
,	O
and	O
across	O
three	O
anatomical	B-MED
sites	I-MED
and	O
four	O
morphological	B-MED
subtypes	B-MED
.	O
Among	O
1.3	O
million	O
women	B-MED
,	O
18,518	O
incident	O
colorectal	B-MED
cancers	I-MED
were	O
identified	O
during	O
13.8	O
(	O
SD	O
3.4	O
)	O
years	O
follow	B-MED
-	I-MED
up	I-MED
via	O
record	O
linkage	O
to	O
national	B-MED
cancer	I-MED
registry	I-MED
data	B-MED
.	O
Cox	B-MED
regression	I-MED
yielded	O
adjusted	O
relative	B-MED
risks	I-MED
.	O
Statistical	B-MED
significance	I-MED
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing	O
.	O
Overall	O
,	O
colorectal	B-MED
cancer	I-MED
risk	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
height	B-MED
,	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
,	O
smoking	B-MED
,	O
alcohol	B-MED
intake	I-MED
,	O
physical	B-MED
activity	I-MED
,	O
parity	B-MED
and	O
menopausal	B-MED
hormone	I-MED
therapy	I-MED
use	O
.	O
For	O
smoking	B-MED
there	O
was	O
substantial	O
heterogeneity	B-MED
across	O
morphological	B-MED
types	B-MED
;	O
relative	B-MED
risks	I-MED
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-MED
both	O
for	O
signet	B-MED
ring	I-MED
cell	I-MED
and	O
for	O
neuroendocrine	B-MED
tumours	I-MED
.	O
Obese	B-MED
women	B-MED
were	O
also	O
at	B-MED
higher	I-MED
risk	I-MED
for	O
signet	B-MED
ring	I-MED
cell	I-MED
tumours	B-MED
.	O
For	O
adenocarcinomas	B-MED
,	O
the	O
large	O
majority	O
of	O
colorectal	B-MED
cancers	I-MED
in	O
the	O
cohort	B-MED
,	O
all	O
risk	B-MED
factor	I-MED
associations	B-MED
were	O
weak	O
.	O
There	O
was	O
little	O
or	O
no	O
heterogeneity	B-MED
in	O
risk	B-MED
between	O
tumours	B-MED
of	O
the	O
right	B-MED
colon	I-MED
,	O
left	B-MED
colon	I-MED
and	O
rectum	B-MED
for	O
any	O
of	O
the	O
14	O
factors	B-MED
examined	O
.	O
These	O
epidemiological	B-MED
findings	B-MED
complement	O
an	O
emerging	O
picture	O
from	O
molecular	B-MED
studies	I-MED
of	O
possible	O
different	O
developmental	B-MED
pathways	B-MED
for	O
different	O
tumour	B-MED
types	B-MED
.	O
Ecotoxicity	B-MED
testing	B-MED
and	O
environmental	B-MED
risk	I-MED
assessment	I-MED
of	O
iron	B-MED
nanomaterials	B-MED
for	O
sub	O
-	O
surface	O
remediation	B-MED
-	O
Recommendations	B-MED
from	O
the	O
FP7	B-MED
project	I-MED
NanoRem	I-MED
Nanoremediation	B-MED
with	O
iron	B-MED
(	O
Fe	B-MED
)	O
nanomaterials	B-MED
opens	O
new	O
doors	O
for	O
treating	B-MED
contaminated	B-MED
soil	B-MED
and	O
groundwater	B-MED
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	B-MED
risks	I-MED
as	O
large	O
quantities	O
of	O
engineered	B-MED
nanomaterials	I-MED
are	O
introduced	O
into	O
the	O
environment	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
have	O
assessed	B-MED
the	O
ecotoxicity	B-MED
of	O
four	O
engineered	O
Fe	B-MED
nanomaterials	B-MED
,	O
specifically	O
,	O
Nano	B-MED
-	I-MED
Goethite	I-MED
,	O
Trap	B-MED
-	I-MED
Ox	I-MED
Fe	I-MED
-	I-MED
zeolites	I-MED
,	O
Carbo	B-MED
-	I-MED
Iron	I-MED
(	O
®	O
)	O
and	O
FerMEG12	B-MED
,	O
developed	O
within	O
the	O
European	B-MED
FP7	I-MED
project	I-MED
NanoRem	I-MED
for	O
sub	O
-	O
surface	O
remediation	B-MED
towards	O
a	O
test	B-MED
battery	I-MED
consisting	O
of	O
eight	O
ecotoxicity	B-MED
tests	B-MED
on	O
bacteria	B-MED
(	O
V.	B-MED
fisheri	I-MED
,	O
E.	B-MED
coli	I-MED
)	O
,	O
algae	B-MED
(	O
P.	B-MED
subcapitata	I-MED
,	O
Chlamydomonas	B-MED
sp	I-MED
.	I-MED
)	O
,	O
crustaceans	B-MED
(	O
D.	B-MED
magna	I-MED
)	O
,	O
worms	B-MED
(	O
E.	B-MED
fetida	I-MED
,	O
L.	B-MED
variegatus	I-MED
)	O
and	O
plants	B-MED
(	O
R.	B-MED
sativus	I-MED
,	O
L.	B-MED
multiflorum	I-MED
)	O
.	O
The	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
Fe	B-MED
oxide	I-MED
and	O
nanoscale	B-MED
zero	I-MED
valent	I-MED
iron	I-MED
(	O
nZVI	B-MED
)	O
,	O
but	O
also	O
hybrid	O
products	O
with	O
Fe	B-MED
loaded	O
into	O
a	O
matrix	B-MED
.	O
All	O
but	O
one	O
material	B-MED
,	O
a	O
ball	B-MED
milled	I-MED
nZVI	I-MED
(	O
FerMEG12	B-MED
)	O
,	O
showed	O
no	B-MED
toxicity	I-MED
in	O
the	O
test	B-MED
battery	I-MED
when	O
tested	O
in	O
concentrations	B-MED
up	O
to	O
100	O
mg	O
/	O
L	O
,	O
which	O
is	O
the	O
cutoff	B-MED
for	O
hazard	B-MED
labeling	B-MED
in	O
chemicals	B-MED
regulation	I-MED
in	O
Europe	B-MED
.	O
However	O
it	O
should	O
be	O
noted	O
that	O
Fe	B-MED
nanomaterials	B-MED
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	B-MED
,	O
aggregation	B-MED
and	O
sedimentation	B-MED
behavior	I-MED
in	O
aqueous	B-MED
media	B-MED
.	O
This	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	B-MED
concerning	O
future	B-MED
testing	I-MED
of	O
Fe	B-MED
nanomaterials	B-MED
and	O
discusses	O
environmental	B-MED
risk	I-MED
assessment	I-MED
considerations	O
related	O
to	O
these	O
.	O
Microbiology	B-MED
of	O
the	O
Upper	B-MED
and	O
Lower	B-MED
Airways	I-MED
in	O
Pediatric	B-MED
Cystic	B-MED
Fibrosis	I-MED
Patients	B-MED
Objective	O
To	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	B-MED
cystic	B-MED
fibrosis	I-MED
(	O
CF	B-MED
)	O
patients	B-MED
who	O
underwent	O
sinus	B-MED
surgery	I-MED
.	O
Study	O
Design	O
Retrospective	B-MED
case	O
series	O
with	O
chart	O
review	O
.	O
Setting	O
Tertiary	B-MED
care	I-MED
children	B-MED
's	I-MED
hospital	I-MED
.	O
Subjects	O
and	O
Methods	O
A	O
total	O
of	O
201	O
paired	O
sinus	B-MED
and	O
pulmonary	B-MED
cultures	I-MED
from	O
105	O
CF	B-MED
patients	B-MED
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O
Demographics	B-MED
and	O
culture	B-MED
results	B-MED
were	O
analyzed	B-MED
.	O
Results	B-MED
The	O
mean	O
age	O
of	O
patients	B-MED
was	O
11.2	O
±	O
5.4	O
years	O
(	O
range	O
,	O
1	O
-	O
27	O
years	O
)	O
,	O
and	O
approximately	O
one	O
-	O
half	O
were	O
female	B-MED
.	O
Methicillin	B-MED
-	O
sensitive	B-MED
Staphylococcus	B-MED
aureus	I-MED
was	O
the	O
most	O
common	O
pathogen	B-MED
overall	O
.	O
A	O
significantly	O
higher	O
prevalence	B-MED
of	O
Pseudomonas	B-MED
aeruginosa	I-MED
(	O
32	O
%	O
for	O
pulmonary	B-MED
and	O
37	O
%	O
for	O
sinus	B-MED
cultures	I-MED
)	O
was	O
observed	O
in	O
older	B-MED
patients	B-MED
versus	O
younger	B-MED
patients	B-MED
(	O
P	B-MED
<	O
.001	O
)	O
.	O
There	O
was	O
low	O
to	O
moderate	B-MED
agreement	B-MED
between	O
sinus	B-MED
and	O
pulmonary	B-MED
cultures	I-MED
(	O
Kappa	B-MED
statistic	B-MED
range	I-MED
,	O
0.03	O
-	O
0.56	O
)	O
.	O
The	O
prevalence	B-MED
of	O
methicillin	B-MED
-	I-MED
resistant	I-MED
S	I-MED
aureus	I-MED
(	O
MRSA	B-MED
)	O
increased	O
significantly	B-MED
for	O
lower	B-MED
respiratory	I-MED
tract	I-MED
culture	I-MED
(	O
from	O
5	O
%	O
to	O
16	O
%	O
)	O
and	O
sinus	B-MED
culture	I-MED
(	O
from	O
5	O
%	O
to	O
27	O
%	O
)	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	B-MED
=	O
.016	O
and	O
P	B-MED
<	O
.001	O
,	O
respectively	O
)	O
.	O
The	O
prevalence	B-MED
of	O
positive	B-MED
sinus	B-MED
cultures	I-MED
increased	O
from	O
40	O
%	O
to	O
85	O
%	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	B-MED
=	O
.018	O
)	O
.	O
Patients	B-MED
with	O
pulmonary	B-MED
MRSA	B-MED
were	O
more	O
likely	O
to	O
be	O
coinfected	B-MED
with	O
pulmonary	B-MED
P	B-MED
aeruginosa	I-MED
(	O
risk	B-MED
ratio	I-MED
,	O
2.4	O
;	O
95	O
%	O
CI	B-MED
,	O
1.2	O
-	O
4.8	O
;	O
P	O
=	O
.015	O
)	O
or	O
Aspergillus	B-MED
fumigatus	I-MED
(	O
risk	B-MED
ratio	I-MED
,	O
2.2	O
;	O
95	O
%	O
CI	B-MED
,	O
1.2	O
-	O
4.8	O
;	O
P	O
=	O
.035	O
)	O
.	O
Conclusions	O
There	O
is	O
low	O
to	O
moderate	B-MED
correlation	B-MED
between	O
pulmonary	B-MED
and	O
sinus	B-MED
pathogens	B-MED
in	O
CF	B-MED
patients	B-MED
.	O
This	O
is	O
important	O
to	O
consider	O
when	O
treating	B-MED
infections	B-MED
.	O
The	O
prevalence	B-MED
of	O
MRSA	B-MED
in	O
sinus	B-MED
cultures	I-MED
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
investigation	B-MED
.	O
Interprofessional	B-MED
primary	B-MED
care	I-MED
team	B-MED
meetings	I-MED
:	O
a	O
qualitative	B-MED
approach	B-MED
comparing	O
observations	B-MED
with	O
personal	B-MED
opinions	B-MED
The	O
number	O
of	O
people	B-MED
with	O
multiple	B-MED
chronic	I-MED
conditions	I-MED
requiring	O
primary	B-MED
care	I-MED
services	I-MED
increases	B-MED
.	O
Professionals	B-MED
from	O
different	O
disciplines	B-MED
collaborate	B-MED
and	O
coordinate	B-MED
care	B-MED
to	O
deal	O
with	O
the	O
complex	O
health	B-MED
care	I-MED
needs	I-MED
.	O
There	O
is	O
lack	B-MED
of	O
information	B-MED
on	O
current	O
practices	O
regarding	O
interprofessional	B-MED
team	B-MED
(	I-MED
IPT	I-MED
)	I-MED
meetings	I-MED
.	O
This	O
study	B-MED
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	B-MED
collaboration	B-MED
in	O
primary	B-MED
care	I-MED
team	B-MED
meetings	I-MED
in	O
the	O
Netherlands	B-MED
by	O
observing	O
the	O
current	B-MED
practice	I-MED
and	O
exploring	O
personal	B-MED
opinions	B-MED
.	O
Qualitative	B-MED
study	I-MED
involving	O
observations	B-MED
of	O
team	B-MED
meeting	I-MED
s	O
and	O
interviews	B-MED
with	O
participants	B-MED
.	O
Eight	O
different	O
IPT	B-MED
meetings	I-MED
(	O
n	O
=	O
8)	O
in	O
different	O
primary	B-MED
care	I-MED
practices	I-MED
were	O
observed	O
by	O
means	O
of	O
video	B-MED
recordings	I-MED
.	O
Experiences	B-MED
were	O
explored	O
by	O
conducting	O
individual	O
semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
(	O
n	O
=	O
60	O
)	O
with	O
participants	B-MED
(	O
i.e.	O
health	B-MED
care	I-MED
professionals	I-MED
from	O
different	O
disciplines	B-MED
)	O
of	O
the	O
observed	O
team	B-MED
meetings	I-MED
.	O
The	O
data	B-MED
were	O
analysed	B-MED
by	O
means	O
of	O
content	B-MED
analysis	I-MED
.	O
Most	O
participants	B-MED
expressed	O
favourable	O
opinions	B-MED
about	O
their	O
team	B-MED
meetings	I-MED
.	O
However	O
,	O
observations	B-MED
showed	O
that	O
team	B-MED
meetings	I-MED
were	O
more	O
or	O
less	O
hectic	O
,	O
and	O
lacked	B-MED
a	O
clear	O
structure	O
and	O
team	B-MED
coordinator	I-MED
or	O
leader	B-MED
.	O
There	O
appears	O
to	O
be	O
a	O
discrepancy	B-MED
between	O
findings	B-MED
from	O
observations	B-MED
and	O
interviews	B-MED
.	O
From	O
the	O
interviews	B-MED
,	O
four	O
main	O
themes	O
were	O
extracted	O
:	O
(	O
1	O
)	O
Team	B-MED
structure	I-MED
and	I-MED
composition	I-MED
,	O
(	O
2	O
)	O
Patient	B-MED
-	I-MED
centredness	I-MED
,	O
(	O
3	O
)	O
Interaction	B-MED
and	O
(	O
4	O
)	O
Attitude	B-MED
and	O
motivation	B-MED
.	O
IPT	B-MED
meetings	I-MED
could	O
benefit	O
from	O
improvements	B-MED
in	O
structure	O
,	O
patient	B-MED
-	I-MED
centredness	I-MED
and	O
leadership	B-MED
by	O
the	O
chairpersons	B-MED
.	O
Given	O
the	O
discrepancy	B-MED
between	O
observations	B-MED
and	O
interviews	B-MED
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	B-MED
team	B-MED
members	I-MED
'	O
awareness	B-MED
of	O
aspects	B-MED
that	O
could	O
be	O
improved	B-MED
before	O
training	B-MED
them	O
in	O
dealing	O
with	O
specific	O
challenges	B-MED
.	O
Experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	B-MED
recovery	B-MED
goals	B-MED
:	O
a	O
collaborative	B-MED
,	O
qualitative	B-MED
study	I-MED
Recovery	B-MED
can	O
be	O
understood	O
as	O
a	O
subjective	B-MED
process	I-MED
guided	O
by	O
personal	B-MED
expectations	B-MED
,	O
goals	B-MED
and	O
hopes	B-MED
.	O
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
explore	O
how	O
persons	B-MED
using	O
a	O
Community	B-MED
Mental	I-MED
Health	I-MED
Centre	I-MED
(	O
CMHC	B-MED
)	O
experienced	O
that	O
their	O
expectations	B-MED
for	O
treatment	B-MED
,	O
and	O
goals	B-MED
and	O
hopes	B-MED
for	O
recovery	B-MED
were	O
supported	O
by	O
the	O
health	B-MED
professionals	I-MED
during	O
treatment	B-MED
.	O
Employing	O
a	O
hermeneutic	B-MED
-phenomenological	O
approach	O
,	O
eight	O
service	B-MED
users	I-MED
were	O
interviewed	O
about	O
their	O
expectations	B-MED
for	O
treatment	B-MED
and	O
their	O
goals	B-MED
and	O
hopes	B-MED
for	O
recovery	B-MED
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health	B-MED
professionals	I-MED
at	O
a	O
CMHC	B-MED
.	O
Two	O
years	B-MED
later	O
,	O
they	O
were	O
re	O
-	O
interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-MED
and	O
support	O
from	O
the	O
health	B-MED
professionals	I-MED
in	O
their	O
work	O
towards	O
these	O
goals	B-MED
and	O
hopes	B-MED
.	O
A	O
collaborative	B-MED
approach	I-MED
was	O
adopted	O
.	O
A	O
co	B-MED
-	I-MED
researcher	I-MED
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	B-MED
.	O
Data	B-MED
were	O
analysed	O
by	O
means	O
of	O
a	O
data	B-MED
-driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic	B-MED
analysis	I-MED
.	O
Five	O
themes	O
reflecting	O
how	O
participants	B-MED
experienced	O
support	O
from	O
health	B-MED
professionals	I-MED
at	O
the	O
CMHC	B-MED
in	O
their	O
work	O
towards	O
their	O
recovery	B-MED
goals	B-MED
were	O
elicited	O
,	O
as	O
follows	O
:	O
developing	B-MED
an	I-MED
understanding	I-MED
of	I-MED
oneself	I-MED
and	O
one	O
's	O
mental	B-MED
health	I-MED
problems	I-MED
;	O
learning	O
how	O
to	O
change	O
feelings	B-MED
and	O
behaviours	B-MED
;	O
being	B-MED
'	I-MED
pushed	I-MED
'	I-MED
into	I-MED
social	I-MED
arenas	I-MED
;	O
finding	B-MED
helpful	I-MED
medication	I-MED
;	O
and	O
counselling	B-MED
in	O
family	B-MED
,	O
practical	B-MED
and	O
financial	B-MED
issues	I-MED
.	O
The	O
participants	B-MED
'	O
expectations	B-MED
about	O
counselling	B-MED
with	O
regard	O
to	O
longer	O
-	O
term	O
family	B-MED
,	O
practical	B-MED
,	O
and	O
financial	B-MED
challenges	I-MED
were	O
insufficiently	O
met	O
by	O
the	O
CMHC	B-MED
.	O
In	O
the	O
experience	O
of	O
the	O
service	B-MED
users	I-MED
,	O
recovery	B-MED
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday	B-MED
life	I-MED
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	B-MED
helpers	B-MED
.	O
To	O
facilitate	O
recovery	B-MED
,	O
health	B-MED
professionals	I-MED
should	O
acknowledge	O
the	O
service	B-MED
user	I-MED
's	I-MED
personal	B-MED
goals	B-MED
and	O
hopes	B-MED
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer	O
-	O
term	O
approach	O
to	O
his	O
or	O
her	O
needs	B-MED
and	O
desires	B-MED
.	O
Acknowledging	O
and	O
facilitating	O
recovery	B-MED
goals	B-MED
by	O
offering	O
counselling	B-MED
with	O
regard	O
to	O
family	B-MED
,	O
practical	B-MED
and	O
financial	B-MED
issues	I-MED
seems	O
particularly	O
important	O
.	O
Back	O
to	O
the	O
Roots	O
:	O
Deep	O
View	O
into	O
the	O
Evolutionary	B-MED
History	B-MED
of	O
ADP	B-MED
-	I-MED
Ribosylation	I-MED
Opened	O
by	O
the	O
DNA	B-MED
-	O
Targeting	B-MED
Toxin	B-MED
-	O
Antitoxin	B-MED
Module	B-MED
DarTG	I-MED
In	O
this	O
issue	O
of	O
Molecular	B-MED
Cell	I-MED
,	O
Jankevicius	O
et	O
al	O
.	O
(	O
2016	O
)	O
characterize	O
the	O
DarTG	B-MED
toxin	B-MED
-	O
antitoxin	B-MED
module	B-MED
in	O
which	O
the	O
DarT	B-MED
toxin	B-MED
ADP	B-MED
-	I-MED
ribosylates	I-MED
single	B-MED
-	I-MED
stranded	I-MED
DNA	I-MED
and	O
the	O
DarG	B-MED
antitoxin	B-MED
counteracts	B-MED
DarT	B-MED
by	O
direct	O
binding	B-MED
and	O
by	O
enzymatic	B-MED
remova	B-MED
l	O
of	O
the	O
ADP	B-MED
-	I-MED
ribosylation	I-MED
.	O
The	O
FLASHE	B-MED
Study	I-MED
:	O
Survey	B-MED
Development	B-MED
,	O
Dyadic	B-MED
Perspectives	O
,	O
and	O
Participant	B-MED
Characteristics	B-MED
The	O
National	B-MED
Cancer	I-MED
Institute	I-MED
developed	O
the	O
Family	B-MED
Life	I-MED
,	O
Activity	B-MED
,	O
Sun	B-MED
,	O
Health	B-MED
,	O
and	O
Eating	B-MED
(	O
FLASHE	B-MED
)	O
Study	B-MED
to	O
examine	O
multiple	O
cancer	B-MED
preventive	I-MED
behaviors	B-MED
within	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
.	O
The	O
purpose	O
of	O
creating	O
FLASHE	B-MED
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	B-MED
activity	I-MED
,	O
diet	B-MED
,	O
and	O
other	O
cancer	B-MED
preventive	I-MED
behaviors	I-MED
and	O
potential	O
correlates	O
among	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
.	O
FLASHE	B-MED
surveys	I-MED
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	B-MED
reviews	I-MED
,	O
scientific	B-MED
input	B-MED
from	O
experts	B-MED
in	O
the	O
field	O
,	O
cognitive	B-MED
testing	I-MED
,	O
and	O
usability	O
testing	O
.	O
This	O
cross	B-MED
-	I-MED
sectional	I-MED
,	O
web	B-MED
-	I-MED
based	I-MED
study	I-MED
of	O
parents	B-MED
and	O
their	O
adolescent	B-MED
children	B-MED
(	O
aged	O
12	O
-	O
17	O
years	O
)	O
was	O
administered	B-MED
between	O
April	B-MED
and	O
October	B-MED
2014	O
.	O
The	O
nationwide	O
sample	O
consisted	O
of	O
1,573	O
parent	B-MED
-	O
adolescent	B-MED
dyads	B-MED
(	O
1,699	O
parents	B-MED
and	O
1,581	O
adolescents	B-MED
)	O
who	O
returned	O
all	O
FLASHE	B-MED
surveys	I-MED
.	O
FLASHE	B-MED
assessed	O
parent	B-MED
and	O
adolescent	B-MED
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	B-MED
domains	O
(	O
including	O
psychosocial	B-MED
variables	I-MED
,	O
parenting	B-MED
,	O
and	O
the	O
community	B-MED
and	O
home	B-MED
environments	I-MED
)	O
.	O
On	O
a	O
subset	O
of	O
example	O
FLASHE	B-MED
items	O
across	O
these	O
domains	O
,	O
responses	B-MED
of	O
parents	B-MED
and	O
adolescents	B-MED
within	O
the	O
same	O
dyads	B-MED
were	O
positively	O
and	O
significantly	O
correlated	B-MED
(	O
r	O
=	O
0.32	O
-	O
0.63	O
)	O
.	O
Analyses	O
were	O
run	O
in	O
2015	O
-	O
2016	O
.	O
FLASHE	B-MED
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	B-MED
questions	I-MED
among	O
individuals	B-MED
or	O
dyads	B-MED
,	O
including	O
the	O
ability	B-MED
to	O
examine	O
similarity	B-MED
between	O
parents	B-MED
and	O
adolescents	B-MED
on	O
many	O
constructs	O
relevant	O
to	O
cancer	B-MED
preventive	I-MED
behaviors	I-MED
.	O
FLASHE	B-MED
data	O
are	O
publicly	O
available	O
for	O
researchers	B-MED
and	O
practitioners	B-MED
to	O
help	O
advance	O
research	B-MED
on	O
cancer	B-MED
preventive	I-MED
health	B-MED
behaviors	I-MED
.	O
The	O
AGES	B-MED
-	I-MED
Reykjavik	I-MED
study	I-MED
atlases	I-MED
:	O
Non	B-MED
-	I-MED
linear	I-MED
multi	B-MED
-	I-MED
spectral	I-MED
template	I-MED
and	O
atlases	B-MED
for	O
studies	B-MED
of	O
the	O
ageing	B-MED
brain	B-MED
Quantitative	B-MED
analyses	I-MED
of	O
brain	B-MED
structures	B-MED
from	O
Magnetic	B-MED
Resonance	I-MED
(	O
MR	B-MED
)	O
image	B-MED
data	B-MED
are	O
often	O
performed	O
using	O
automatic	B-MED
segmentation	B-MED
algorithms	B-MED
.	O
Many	O
of	O
these	O
algorithms	B-MED
rely	O
on	O
templates	B-MED
and	O
atlases	B-MED
in	O
a	O
common	O
coordinate	B-MED
space	I-MED
.	O
Most	O
freely	B-MED
available	B-MED
brain	B-MED
atlases	B-MED
are	O
generated	O
from	O
relatively	O
young	B-MED
individuals	B-MED
and	O
not	O
always	O
derived	O
from	O
well	O
-	O
defined	O
cohort	B-MED
studies	I-MED
.	O
In	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	B-MED
available	B-MED
multi	B-MED
-	I-MED
spectral	I-MED
template	I-MED
with	O
corresponding	O
tissue	B-MED
probability	B-MED
atlases	B-MED
and	O
regional	B-MED
atlases	B-MED
,	O
optimised	B-MED
to	O
use	O
in	O
studies	B-MED
of	O
ageing	B-MED
cohorts	B-MED
(	O
mean	O
age	O
75	O
±	O
5	O
years	O
)	O
.	O
Furthermore	O
,	O
we	O
provide	O
validation	B-MED
data	B-MED
from	O
a	O
regional	B-MED
segmentation	B-MED
pipeline	O
to	O
assure	O
the	O
integrity	B-MED
of	O
the	O
dataset	B-MED
.	O
Dominant	B-MED
and	O
Non-	O
Dominant	B-MED
Frequency	B-MED
Structure	O
of	O
Evoked	B-MED
Ventricular	B-MED
Fibrillation	I-MED
in	O
Dogs	B-MED
with	O
Myocardial	B-MED
Ischemia	I-MED
The	O
first	O
10	O
min	O
of	O
electrically	B-MED
provoked	I-MED
ventricular	B-MED
fibrillation	I-MED
in	O
dogs	B-MED
with	O
ischemic	B-MED
heart	I-MED
disease	I-MED
were	O
characterized	B-MED
by	O
organized	B-MED
myocardial	B-MED
activity	I-MED
evidenced	O
by	O
the	O
dominant	B-MED
ECG	I-MED
frequency	I-MED
structure	O
.	O
During	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-MED
fibrillation	I-MED
,	O
low	B-MED
-	I-MED
frequency	I-MED
oscillations	I-MED
(	O
4	O
-	O
7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-MED
,	O
the	O
dominant	B-MED
frequencies	I-MED
were	O
low	B-MED
and	O
medium	B-MED
(	O
4	O
-	O
12	O
Hz	O
)	O
.	O
After	O
10	O
-	O
min	O
fibrillation	B-MED
,	O
the	O
oscillations	B-MED
became	O
non-	O
dominant	B-MED
.	O
Thus	O
,	O
ischemic	B-MED
myocardium	I-MED
maintains	B-MED
the	O
organized	B-MED
structure	I-MED
of	O
ventricular	B-MED
fibrillation	I-MED
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	B-MED
of	O
automatic	B-MED
diagnostics	I-MED
of	O
abnormal	B-MED
cardiac	I-MED
activity	I-MED
in	O
humans	B-MED
.	O
Evaluation	O
of	O
Three	B-MED
Protein	B-MED
-	I-MED
Extraction	I-MED
Methods	I-MED
for	O
Proteome	B-MED
Analysis	B-MED
of	O
Maize	B-MED
Leaf	B-MED
Midrib	B-MED
,	O
a	O
Compound	B-MED
Tissue	I-MED
Rich	O
in	O
Sclerenchyma	B-MED
Cells	I-MED
Leaf	B-MED
morphology	B-MED
is	O
closely	O
related	O
to	O
the	O
growth	B-MED
and	I-MED
development	I-MED
of	O
maize	B-MED
(	I-MED
Zea	I-MED
mays	I-MED
L.	I-MED
)	I-MED
plants	I-MED
and	O
final	O
kernel	B-MED
production	O
.	O
As	O
an	O
important	O
part	O
of	O
the	O
maize	B-MED
leaf	B-MED
,	O
the	O
midrib	B-MED
holds	O
leaf	B-MED
blades	O
in	O
the	O
aerial	B-MED
position	I-MED
for	O
maximum	O
sunlight	B-MED
capture	O
.	O
Leaf	B-MED
midrib	B-MED
s	O
of	O
adult	B-MED
plants	B-MED
contain	O
substantial	O
sclerenchyma	B-MED
cells	I-MED
with	O
heavily	B-MED
thickened	I-MED
and	O
lignified	B-MED
secondary	B-MED
walls	I-MED
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-MED
,	O
making	O
protein	B-MED
extraction	I-MED
and	O
proteome	B-MED
analysis	B-MED
difficult	O
in	O
leaf	B-MED
midrib	B-MED
tissue	O
.	O
In	O
the	O
present	O
study	O
,	O
three	O
protein	B-MED
-	I-MED
extraction	I-MED
methods	I-MED
that	O
are	O
commonly	O
used	O
in	O
plant	B-MED
proteomics	B-MED
,	O
i.e.	O
,	O
phenol	B-MED
extraction	B-MED
,	O
TCA	B-MED
/	O
acetone	B-MED
extraction	B-MED
,	O
and	O
TCA	B-MED
/	O
acetone	B-MED
/	O
phenol	B-MED
extraction	B-MED
,	O
were	O
qualitatively	B-MED
and	O
quantitatively	B-MED
evaluated	I-MED
based	O
on	O
2DE	O
maps	O
and	O
MS	B-MED
/	I-MED
MS	I-MED
analysis	I-MED
using	O
the	O
midribs	B-MED
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-MED
of	O
maize	B-MED
plants	I-MED
.	O
Microscopy	B-MED
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-MED
underneath	O
maize	B-MED
midrib	B-MED
epidermises	B-MED
(	O
particularly	O
abaxial	B-MED
epidermises	B-MED
)	O
.	O
The	O
spot	O
-	O
number	O
order	O
obtained	O
via	O
2DE	B-MED
mapping	I-MED
was	O
as	O
follows	O
:	O
phenol	B-MED
extraction	B-MED
(	O
655	O
)	O
>	O
TCA	B-MED
/	O
acetone	B-MED
extraction	B-MED
(	O
589	O
)	O
>	O
TCA	B-MED
/	O
acetone	B-MED
/	O
phenol	B-MED
extraction	B-MED
(	O
545	O
)	O
.	O
MS	B-MED
/	I-MED
MS	I-MED
analysis	I-MED
identified	O
a	O
total	O
of	O
17	O
spots	B-MED
that	O
exhibited	O
2	O
-	O
fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	B-MED
methods	O
(	O
using	O
phenol	B-MED
extraction	B-MED
as	O
a	O
control	B-MED
)	O
.	O
Sixteen	O
of	O
the	O
proteins	B-MED
identified	O
were	O
hydrophilic	B-MED
,	O
with	O
GRAVY	B-MED
values	I-MED
ranging	O
from	O
-0.026	O
to	O
-0.487	O
.	O
For	O
all	O
three	B-MED
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high	O
-	O
quality	O
protein	B-MED
samples	O
and	O
good	O
2DE	B-MED
maps	I-MED
for	O
the	O
maize	B-MED
leaf	B-MED
midrib	B-MED
.	O
However	O
,	O
phenol	B-MED
extraction	B-MED
produced	O
a	O
better	O
2DE	B-MED
map	I-MED
with	O
greater	O
resolution	B-MED
between	O
spots	B-MED
,	O
and	O
TCA	B-MED
/	O
acetone	B-MED
extraction	B-MED
produced	O
higher	O
protein	B-MED
yields	B-MED
.	O
Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	B-MED
protein	B-MED
extraction	I-MED
among	O
the	O
three	B-MED
methods	O
.	O
This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-MED
extraction	I-MED
methods	O
for	O
the	O
proteome	B-MED
analysis	B-MED
of	O
recalcitrant	O
plant	B-MED
tissues	I-MED
that	O
are	O
rich	O
in	O
sclerenchyma	B-MED
cells	I-MED
.	O
Genome	B-MED
Sequences	I-MED
of	O
Mycobacteriophages	B-MED
Jane	I-MED
and	I-MED
Sneeze	I-MED
,	O
New	O
Members	O
of	O
Cluster	O
G	O
Jane	O
and	O
Sneeze	O
are	O
newly	O
isolated	B-MED
phages	B-MED
of	O
Mycobacterium	B-MED
smegmatis	I-MED
mc(2)155	I-MED
from	O
Hillsborough	B-MED
,	O
NJ	B-MED
,	O
and	O
Palo	B-MED
Verde	I-MED
,	O
Costa	B-MED
Rica	I-MED
,	O
respectively	O
.	O
Both	O
are	O
cluster	O
G	O
,	O
subcluster	O
G1	O
mycobacteriophages	B-MED
.	O
Notable	O
nucleotide	B-MED
differences	B-MED
exist	O
between	O
genomes	B-MED
in	O
the	O
right	O
half	O
,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-MED
mobile	B-MED
element	I-MED
1	I-MED
(	O
MPME1	O
)	O
in	O
Jane	O
.	O
Thermo	B-MED
-	I-MED
reversible	I-MED
capture	I-MED
and	I-MED
release	I-MED
of	O
DNA	B-MED
by	O
zwitterionic	B-MED
surfactants	I-MED
The	O
thermo	B-MED
-	I-MED
reversible	I-MED
capture	I-MED
and	I-MED
release	I-MED
of	O
DNA	B-MED
were	O
studied	O
by	O
the	O
protonation	B-MED
and	O
deprotonation	B-MED
of	O
alkyldimethylamine	B-MED
oxide	I-MED
(	O
CnDMAO	B-MED
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
)	O
in	O
Tris	B-MED
-	I-MED
HCl	I-MED
buffer	B-MED
solution	I-MED
.	O
DNA	B-MED
/	O
C14DMAO	B-MED
in	O
Tris	B-MED
-	I-MED
HCl	I-MED
buffer	B-MED
solution	I-MED
with	O
pH	B-MED
=	O
7.2	O
is	O
transparent	B-MED
at	O
25	O
°	O
C	O
,	O
indicating	O
that	O
DNA	B-MED
molecules	B-MED
exist	O
mainly	O
in	O
individuals	B-MED
and	O
the	O
binding	B-MED
of	O
C14DMAO	B-MED
is	O
weak	B-MED
.	O
With	O
the	O
increase	B-MED
of	O
temperature	B-MED
,	O
the	O
pH	B-MED
of	O
the	O
buffer	B-MED
solution	I-MED
continuously	O
decreases	B-MED
,	O
which	O
leads	O
to	O
protonation	B-MED
of	O
C14DMAO	B-MED
(	O
C14DMAO	B-MED
+	O
H(+	B-MED
)	I-MED
→	O
C14DMAOH(+	B-MED
)	I-MED
)	O
and	O
an	O
obvious	O
increase	B-MED
of	I-MED
the	I-MED
turbidity	I-MED
of	O
the	O
samples	B-MED
.	O
This	O
indicates	O
a	O
stronger	O
binding	B-MED
of	O
the	O
protonated	B-MED
C14DMAOH(+	B-MED
)	I-MED
to	O
DNA	B-MED
.	O
Further	O
investigations	O
demonstrated	O
the	O
formation	B-MED
of	O
DNA	B-MED
/	O
C14DMAOH(+	B-MED
)	I-MED
complexes	B-MED
,	O
in	O
which	O
the	O
stretched	O
DNA	B-MED
molecules	B-MED
are	O
effectively	O
compacted	B-MED
as	O
evidenced	O
from	O
UV	B-MED
-	I-MED
vis	I-MED
UV	B-MED
-	I-MED
vis	I-MED
absorptions	I-MED
,	O
circular	B-MED
dichroism	I-MED
(	O
CD	B-MED
)	O
measurements	B-MED
,	O
atomic	B-MED
force	I-MED
microscopy	I-MED
(	O
AFM	B-MED
)	O
observations	B-MED
,	O
dynamic	B-MED
light	I-MED
scattering	I-MED
(	O
DLS	B-MED
)	O
measurements	B-MED
and	O
agarose	B-MED
gel	I-MED
electrophoresis	I-MED
(	O
AGE	B-MED
)	O
.	O
Interestingly	O
,	O
when	O
the	O
temperature	B-MED
is	O
turned	O
back	O
to	O
25	O
°	O
C	O
,	O
the	O
compacted	B-MED
DNA	B-MED
molecules	B-MED
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O
This	O
cycle	B-MED
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	B-MED
of	O
efficiency	B-MED
.	O
The	O
effect	B-MED
of	I-MED
the	O
chain	B-MED
length	I-MED
of	O
CnDMAO	B-MED
has	O
also	O
been	O
investigated	O
.	O
When	O
C14DMAO	B-MED
was	O
replaced	O
by	O
C12DMAO	B-MED
,	O
similar	O
phenomena	B-MED
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	B-MED
critical	B-MED
surfactant	B-MED
concentration	B-MED
for	O
DNA	B-MED
compaction	B-MED
and	O
a	O
slightly	O
lower	B-MED
pH	B-MED
of	O
Tris	B-MED
-	I-MED
HCl	I-MED
buffer	B-MED
solution	I-MED
with	O
pH	B-MED
=	O
6.8	O
.	O
For	O
the	O
DNA	B-MED
/	O
C10DMAO	B-MED
system	O
,	O
however	O
,	O
no	O
DNA	B-MED
compaction	B-MED
was	O
observed	O
even	O
in	O
Tris	B-MED
-	I-MED
HCl	I-MED
buffer	B-MED
solution	I-MED
with	O
a	O
much	O
lower	B-MED
pH	B-MED
and	O
a	O
much	O
higher	B-MED
C10DMAO	B-MED
concentration	B-MED
.	O
The	O
negative	B-MED
charges	I-MED
of	O
DNA	B-MED
molecules	B-MED
can	O
easily	O
be	O
neutralized	O
by	O
positive	B-MED
charges	I-MED
of	O
cationic	B-MED
CnDMAOH(+	I-MED
)	I-MED
(	O
n	O
=	O
12	O
and	O
14	O
)	O
micelles	B-MED
.	O
DNA	B-MED
was	O
compacted	B-MED
and	O
then	O
insoluble	O
DNA	B-MED
/	O
CnDMAOH(+	B-MED
)	I-MED
complexes	B-MED
were	O
formed	O
.	O
Because	O
of	O
the	O
much	O
higher	B-MED
critical	B-MED
micelle	B-MED
concentration	B-MED
(	O
cmc	B-MED
)	O
of	O
the	O
shorter	O
chain	B-MED
length	I-MED
C10DMAOH(+	B-MED
)	I-MED
,	O
cationic	B-MED
C10DMAOH(+	I-MED
)	I-MED
micelles	B-MED
can	O
not	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	B-MED
DNA	B-MED
.	O
The	O
strategy	O
may	O
provide	O
an	O
efficient	B-MED
and	O
alternative	B-MED
approach	I-MED
for	O
stimuli	B-MED
-	I-MED
responsive	I-MED
gene	I-MED
therapy	I-MED
and	O
drug	B-MED
release	I-MED
.	O
Extremely	B-MED
Giant	B-MED
Liver	I-MED
Hemangioma	I-MED
(	O
50	O
cm	O
)	O
with	O
Kasabach	B-MED
-	I-MED
Merritt	I-MED
Syndrome	I-MED
A	O
33-	O
year	B-MED
-	O
old	B-MED
male	B-MED
has	O
been	O
found	B-MED
with	O
a	O
giant	B-MED
liver	I-MED
hemangioma	I-MED
of	O
initial	B-MED
size	B-MED
29	O
cm	O
for	O
5	O
years	B-MED
.	O
He	O
received	B-MED
arterial	B-MED
embolization	I-MED
twice	B-MED
in	O
order	O
to	O
shrink	B-MED
the	O
tumor	B-MED
;	O
however	O
,	O
no	B-MED
effect	I-MED
was	O
obtained	B-MED
.	O
The	O
tumor	B-MED
had	O
rapidly	B-MED
grown	B-MED
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-MED
in	O
the	O
hematological	B-MED
and	O
coagulative	B-MED
systems	B-MED
.	O
Preoperative	B-MED
computed	B-MED
tomography	I-MED
revealed	B-MED
that	O
the	O
right	B-MED
hepatic	B-MED
vein	I-MED
,	O
right	B-MED
hepatic	B-MED
artery	I-MED
,	O
and	O
right	B-MED
portal	B-MED
vein	I-MED
were	O
not	B-MED
involved	I-MED
by	O
the	O
hemangioma	B-MED
.	O
Resection	B-MED
of	O
the	O
giant	B-MED
liver	I-MED
hemangioma	I-MED
was	O
successfully	B-MED
performed	B-MED
after	O
intraoperative	B-MED
intentional	B-MED
bloodletting	B-MED
with	O
concurrent	B-MED
blood	B-MED
salvage	I-MED
.	O
All	O
hematological	B-MED
and	O
coagulative	B-MED
abnormalities	B-MED
had	O
returned	B-MED
to	O
normal	B-MED
after	O
the	O
procedure	B-MED
.	O
Recovery	B-MED
of	I-MED
orthographic	B-MED
processing	B-MED
after	O
stroke	B-MED
:	O
A	O
longitudinal	B-MED
fMRI	B-MED
study	O
An	O
intact	O
orthographic	B-MED
processing	B-MED
system	O
is	O
critical	O
for	O
normal	B-MED
reading	I-MED
and	I-MED
spelling	I-MED
.	O
Here	O
we	O
investigate	O
the	O
neural	B-MED
changes	I-MED
associated	O
with	O
impairment	B-MED
and	O
subsequent	O
recovery	B-MED
of	O
the	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	B-MED
left	B-MED
posterior	I-MED
cerebral	I-MED
artery	I-MED
(	I-MED
PCA	I-MED
)	I-MED
stroke	I-MED
.	O
This	O
work	O
describes	O
a	O
longitudinal	B-MED
case	I-MED
study	I-MED
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
MMY	B-MED
,	O
with	O
impairments	B-MED
in	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
for	O
reading	B-MED
and	I-MED
spelling	I-MED
at	O
stroke	B-MED
onset	B-MED
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-MED
.	O
We	O
tested	O
the	O
hypothesis	B-MED
that	O
this	O
acute	B-MED
impairment	B-MED
to	O
reading	B-MED
and	I-MED
spelling	I-MED
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	B-MED
of	I-MED
neural	B-MED
activation	I-MED
in	O
the	O
left	B-MED
fusiform	I-MED
gyrus	I-MED
(	O
FG	B-MED
)	O
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	B-MED
of	I-MED
neural	B-MED
activation	I-MED
in	O
this	O
region	O
.	O
MMY	B-MED
's	I-MED
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	B-MED
changes	I-MED
because	O
she	O
demonstrated	O
a	O
behavioral	B-MED
recovery	B-MED
of	I-MED
naming	I-MED
as	I-MED
well	I-MED
;	O
i.e.	O
,	O
if	O
there	O
is	O
neural	B-MED
recovery	I-MED
for	O
reading	B-MED
and	I-MED
spelling	I-MED
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	B-MED
changes	I-MED
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	B-MED
processing	B-MED
.	O
To	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	B-MED
behavioral	I-MED
and	O
functional	B-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	O
fMRI	B-MED
)	O
data	O
of	O
reading	B-MED
,	O
spelling	B-MED
,	O
and	O
visual	B-MED
object	I-MED
naming	I-MED
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	B-MED
.	O
In	O
confirmation	O
of	O
our	O
hypothesis	B-MED
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
was	O
associated	O
with	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
neural	B-MED
activation	I-MED
in	O
areas	O
previously	O
associated	O
with	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
:	O
i.e.	O
,	O
the	O
left	B-MED
mid	I-MED
-	I-MED
FG	I-MED
and	O
inferior	B-MED
frontal	I-MED
junction	I-MED
(	O
IFJ	B-MED
)	O
.	O
Furthermore	O
,	O
these	O
neural	B-MED
changes	I-MED
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	B-MED
processing	B-MED
,	O
as	O
they	O
were	O
observed	O
for	O
reading	B-MED
and	O
spelling	B-MED
,	O
but	O
not	O
for	O
visual	B-MED
object	I-MED
naming	I-MED
within	O
the	O
left	B-MED
mid	I-MED
-	I-MED
FG	I-MED
.	O
This	O
work	O
shows	O
that	O
left	B-MED
PCA	I-MED
stroke	I-MED
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	B-MED
lexical	B-MED
processing	I-MED
system	O
,	O
not	O
only	O
in	O
the	O
posterior	B-MED
region	I-MED
adjacent	B-MED
to	O
the	O
stroke	B-MED
,	O
but	O
also	O
in	O
relatively	O
distant	B-MED
frontal	I-MED
orthographic	B-MED
processing	B-MED
regions	O
.	O
On	O
the	O
Control	B-MED
of	O
Social	B-MED
Approach	B-MED
-	I-MED
Avoidance	I-MED
Behavior	I-MED
:	O
Neural	B-MED
and	O
Endocrine	B-MED
Mechanisms	B-MED
The	O
ability	B-MED
to	O
control	B-MED
our	O
automatic	B-MED
action	B-MED
tendencies	B-MED
is	O
crucial	B-MED
for	O
adequate	B-MED
social	B-MED
interactions	I-MED
.	O
Emotional	B-MED
events	B-MED
trigger	B-MED
automatic	B-MED
approach	B-MED
and	I-MED
avoidance	I-MED
tendencies	B-MED
.	O
Although	O
these	O
actions	B-MED
may	O
be	O
generally	O
adaptive	B-MED
,	O
the	O
capacity	B-MED
to	O
override	B-MED
these	O
emotional	B-MED
reactions	I-MED
may	O
be	O
key	B-MED
to	O
flexible	B-MED
behavior	B-MED
during	O
social	B-MED
interaction	I-MED
.	O
The	O
present	B-MED
chapter	B-MED
provides	B-MED
a	O
review	B-MED
of	O
the	O
neuroendocrine	B-MED
mechanisms	B-MED
underlying	O
this	O
ability	B-MED
and	O
their	O
relation	B-MED
to	O
social	B-MED
psychopathologies	B-MED
.	O
Aberrant	B-MED
social	B-MED
behavior	I-MED
,	O
such	O
as	O
observed	B-MED
in	O
social	B-MED
anxiety	I-MED
or	O
psychopathy	B-MED
,	O
is	O
marked	B-MED
by	O
abnormalities	B-MED
in	O
approach	B-MED
-	I-MED
avoidance	I-MED
tendencies	B-MED
and	O
the	O
ability	B-MED
to	O
control	B-MED
them	O
.	O
Key	B-MED
neural	B-MED
regions	B-MED
involved	B-MED
in	O
the	O
regulation	B-MED
of	O
approach	B-MED
-	I-MED
avoidance	I-MED
behavior	I-MED
are	O
the	O
amygdala	B-MED
,	O
widely	O
implicated	B-MED
in	O
automatic	B-MED
emotional	B-MED
processing	B-MED
,	O
and	O
the	O
anterior	B-MED
prefrontal	B-MED
cortex	I-MED
,	O
which	O
exerts	B-MED
control	B-MED
over	O
the	O
amygdala	B-MED
.	O
Hormones	B-MED
,	O
especially	O
testosterone	B-MED
and	O
cortisol	B-MED
,	O
have	O
been	O
shown	O
to	O
affect	B-MED
approach	B-MED
-	I-MED
avoidance	I-MED
behavior	I-MED
and	O
the	O
associated	B-MED
neural	B-MED
mechanisms	B-MED
.	O
The	O
present	B-MED
chapter	B-MED
also	O
discusses	O
ways	O
to	O
directly	B-MED
influence	B-MED
social	B-MED
approach	B-MED
and	I-MED
avoidance	I-MED
behavior	I-MED
and	O
will	O
end	O
with	O
a	O
research	B-MED
agenda	B-MED
to	O
further	O
advance	B-MED
this	O
important	B-MED
research	B-MED
field	I-MED
.	O
Control	B-MED
over	O
approach	B-MED
-	I-MED
avoidance	I-MED
tendencies	B-MED
may	O
serve	O
as	O
an	O
exemplar	B-MED
of	O
emotional	B-MED
action	B-MED
regulation	B-MED
and	O
might	O
have	O
a	O
great	B-MED
value	B-MED
in	O
understanding	B-MED
the	O
underlying	O
mechanisms	B-MED
of	O
the	O
development	B-MED
of	O
affective	B-MED
disorders	I-MED
.	O
Stressful	B-MED
life	B-MED
events	I-MED
and	O
leucocyte	B-MED
telomere	I-MED
length	I-MED
:	O
Do	O
lifestyle	B-MED
factors	I-MED
,	O
somatic	B-MED
and	O
mental	B-MED
health	I-MED
,	O
or	O
low	B-MED
grade	I-MED
inflammation	I-MED
mediate	O
this	O
relationship	B-MED
?	O
Results	O
from	O
a	O
cohort	B-MED
of	O
Danish	B-MED
men	I-MED
born	B-MED
in	O
1953	O
Exposure	B-MED
to	I-MED
psychosocial	B-MED
stress	B-MED
is	O
associated	B-MED
with	I-MED
increased	O
risk	B-MED
of	O
a	O
number	O
of	O
somatic	B-MED
and	O
mental	B-MED
disorders	I-MED
with	O
relation	B-MED
relation	B-MED
to	O
immune	B-MED
system	I-MED
functioning	B-MED
.	O
We	O
aimed	O
to	O
explore	O
whether	O
stressful	B-MED
events	I-MED
in	O
early	O
and	O
recent	O
life	B-MED
was	O
associated	B-MED
with	I-MED
leucocyte	B-MED
telomere	I-MED
length	I-MED
(	O
TL	B-MED
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	B-MED
burden	O
of	O
inflammation	B-MED
and	O
oxidative	B-MED
stress	I-MED
occurring	O
during	O
the	O
life	B-MED
course	I-MED
.	O
We	O
specifically	O
aimed	O
to	O
address	B-MED
whether	O
childhood	B-MED
constitutes	O
a	O
sensitive	B-MED
period	I-MED
and	O
how	O
much	O
of	O
the	O
relation	B-MED
between	O
stressful	B-MED
life	O
events	O
and	O
TL	B-MED
is	O
mediated	O
through	O
somatic	B-MED
and	O
mental	B-MED
health	I-MED
,	O
lifestyle	B-MED
,	O
and	O
markers	B-MED
of	O
low	B-MED
-	I-MED
grade	I-MED
inflammation	I-MED
.	O
A	O
cohort	B-MED
of	O
Danish	B-MED
men	I-MED
born	B-MED
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	B-MED
in	O
the	O
Metropolit	B-MED
Cohort	I-MED
.	O
These	O
men	B-MED
underwent	O
a	O
health	B-MED
examination	I-MED
including	O
blood	B-MED
sampling	I-MED
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	B-MED
PCR	I-MED
-	I-MED
based	I-MED
measurement	I-MED
of	O
TL	B-MED
.	O
The	O
relation	B-MED
between	O
stressful	B-MED
life	B-MED
events	I-MED
and	O
TL	B-MED
was	O
analysed	O
using	O
structural	B-MED
equation	I-MED
modelling	I-MED
,	O
which	O
also	O
provided	O
an	O
estimate	B-MED
of	O
the	O
proportion	B-MED
of	O
the	O
total	O
effect	B-MED
mediated	O
by	O
somatic	B-MED
and	O
mental	B-MED
health	I-MED
(	O
cardiovascular	B-MED
disease	I-MED
,	O
body	B-MED
mass	I-MED
and	O
depressive	B-MED
mood	I-MED
)	O
,	O
lifestyle	B-MED
factors	I-MED
,	O
and	O
low	B-MED
grade	I-MED
inflammation	I-MED
(	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
,	O
interleukin	B-MED
(	I-MED
IL)-6	I-MED
and	O
IL-10	B-MED
)	O
.	O
Total	B-MED
number	I-MED
of	O
stressful	B-MED
events	I-MED
experienced	B-MED
during	B-MED
the	O
life	B-MED
course	I-MED
was	O
not	O
associated	B-MED
with	I-MED
TL	B-MED
.	O
In	O
terms	O
of	O
sensitive	B-MED
periods	I-MED
,	O
we	O
found	O
that	O
number	B-MED
of	O
stressful	B-MED
events	I-MED
in	O
childhood	B-MED
was	O
associated	B-MED
with	I-MED
shorter	B-MED
TL	I-MED
(	O
βper	O
number	O
stressful	B-MED
events	I-MED
in	O
childhood	B-MED
=	O
-0.02(SE=-0.02	O
)	O
;	O
P=0.05	O
)	O
.	O
This	O
relation	B-MED
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	B-MED
(	O
β=-0.16	O
;	O
P<0.000	O
)	O
.	O
Thirty	O
percent	O
of	O
the	O
total	O
effect	B-MED
of	O
stressful	B-MED
events	I-MED
in	O
childhood	B-MED
on	O
TL	B-MED
was	O
mediated	O
by	O
the	O
included	O
variables	B-MED
,	O
with	O
the	O
largest	O
proportion	B-MED
being	O
mediated	O
through	O
depressive	B-MED
mood	I-MED
(	O
16	O
%	O
)	O
and	O
CRP	B-MED
(	O
9	O
%	O
)	O
.	O
This	O
study	O
suggests	O
that	O
stressful	B-MED
events	I-MED
in	O
childhood	B-MED
are	O
associated	B-MED
with	I-MED
shorter	B-MED
TL	I-MED
in	O
middle	B-MED
-	I-MED
aged	I-MED
men	I-MED
and	O
that	O
part	O
of	O
this	O
relation	B-MED
is	O
explained	O
by	O
depressive	B-MED
mood	I-MED
and	O
low	B-MED
grade	I-MED
inflammation	I-MED
.	O
Shared	B-MED
Decision	I-MED
Making	I-MED
and	O
the	O
promise	B-MED
of	O
a	O
respectful	O
and	O
equitable	O
healthcare	B-MED
system	I-MED
in	O
Peru	B-MED
Peru	B-MED
has	O
achieved	O
sustained	B-MED
development	I-MED
in	O
the	O
last	O
two	O
decades	B-MED
.	O
However	O
,	O
despite	O
this	O
achievement	O
,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	B-MED
in	O
the	O
quality	B-MED
of	I-MED
education	I-MED
and	O
health	B-MED
;	O
investment	O
in	O
both	O
sectors	B-MED
is	O
among	O
the	O
lowest	O
in	O
the	O
region	B-MED
.	O
This	O
situation	O
perpetuates	O
huge	O
gaps	B-MED
in	O
infrastructure	B-MED
and	O
also	O
conditions	O
a	O
poor	B-MED
literacy	I-MED
level	I-MED
of	O
the	O
population	B-MED
specifically	O
in	O
health	B-MED
.	O
Currently	O
,	O
there	O
is	O
a	O
fragmented	O
model	B-MED
of	O
patient	B-MED
care	I-MED
,	O
in	O
which	O
the	O
systems	B-MED
are	O
exclusive	O
of	O
each	O
other	O
.	O
They	O
do	O
not	O
cooperate	B-MED
or	O
communicate	B-MED
with	O
each	O
other	O
;	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	B-MED
within	O
the	O
system	B-MED
,	O
preventing	O
referral	B-MED
of	I-MED
patients	I-MED
directly	O
from	O
the	O
basic	B-MED
level	I-MED
to	O
the	O
complex	B-MED
level	I-MED
of	O
care	B-MED
when	O
needed	O
.	O
In	O
addition	O
,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	B-MED
of	O
an	O
empathetic	O
,	O
respectful	O
or	O
person	B-MED
-	I-MED
centered	I-MED
clinical	I-MED
practice	I-MED
;	O
instead	O
,	O
economic	B-MED
,	O
social	B-MED
and	O
educational	B-MED
differences	O
perpetuate	O
a	O
paternalistic	O
clinical	B-MED
practice	I-MED
.	O
The	O
task	O
of	O
orienting	O
medical	B-MED
training	I-MED
towards	O
the	O
development	B-MED
of	O
humanism	B-MED
is	O
pending	O
.	O
The	O
patient	B-MED
is	O
the	O
center	O
of	O
the	O
medical	B-MED
act	I-MED
and	O
the	O
main	O
objective	O
of	O
doctors	B-MED
'	I-MED
actions	O
.	O
A	O
humanistic	B-MED
care	I-MED
approach	I-MED
will	O
not	O
only	O
empower	O
the	O
person	B-MED
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his	O
/	O
her	O
health	B-MED
care	I-MED
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic	O
,	O
caring	B-MED
,	O
respectful	B-MED
and	O
kind	O
model	B-MED
of	O
clinical	B-MED
practice	I-MED
.	O
Effects	B-MED
of	I-MED
complex	B-MED
life	B-MED
cycles	I-MED
on	O
genetic	B-MED
diversity	I-MED
:	O
cyclical	B-MED
parthenogenesis	I-MED
Neutral	O
patterns	O
of	O
population	B-MED
genetic	B-MED
diversity	I-MED
in	O
species	B-MED
with	O
complex	B-MED
life	B-MED
cycles	I-MED
are	O
difficult	O
to	O
anticipate	B-MED
.	O
Cyclical	B-MED
parthenogenesis	I-MED
(	O
CP	B-MED
)	O
,	O
in	O
which	O
organisms	B-MED
undergo	O
several	O
rounds	O
of	O
clonal	B-MED
reproduction	B-MED
followed	O
by	O
a	O
sexual	B-MED
event	I-MED
,	O
is	O
one	O
such	O
life	B-MED
cycle	I-MED
.	O
Many	O
species	B-MED
,	O
including	O
crop	B-MED
pests	B-MED
(	O
aphids	B-MED
)	O
,	O
human	B-MED
parasites	I-MED
(	O
trematodes	B-MED
)	O
or	O
models	B-MED
used	O
in	O
evolutionary	B-MED
science	I-MED
(	O
Daphnia	B-MED
)	O
,	O
are	O
cyclical	B-MED
parthenogens	I-MED
.	O
It	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	B-MED
cycle	I-MED
on	O
neutral	O
genetic	B-MED
diversity	I-MED
.	O
In	O
this	O
paper	O
,	O
we	O
describe	O
distributions	B-MED
of	O
genetic	B-MED
diversity	I-MED
under	O
conditions	B-MED
of	O
CP	B-MED
with	O
various	O
clonal	B-MED
phase	B-MED
lengths	B-MED
.	O
Using	O
a	O
Markov	B-MED
chain	I-MED
model	I-MED
of	O
CP	B-MED
for	O
a	O
single	B-MED
locus	B-MED
and	O
individual	O
-	O
based	O
simulations	B-MED
for	O
two	B-MED
loci	B-MED
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	B-MED
from	O
full	O
sexuality	B-MED
are	O
observed	O
after	O
only	O
a	O
few	O
generations	B-MED
of	O
clonality	B-MED
.	O
The	O
convergence	B-MED
towards	O
predictions	B-MED
made	O
under	O
conditions	O
of	O
full	O
clonality	B-MED
during	O
the	O
clonal	B-MED
phase	B-MED
depends	O
on	O
the	O
balance	O
between	O
mutations	B-MED
and	O
genetic	B-MED
drift	I-MED
.	O
Second	O
,	O
the	O
sexual	B-MED
event	I-MED
of	O
CP	B-MED
usually	O
resets	O
the	O
genetic	B-MED
diversity	I-MED
at	O
a	O
single	B-MED
locus	B-MED
towards	O
predictions	B-MED
made	O
under	O
full	O
sexuality	B-MED
.	O
However	O
,	O
this	O
single	O
recombination	B-MED
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	B-MED
phases	I-MED
towards	O
full	B-MED
-	I-MED
sexuality	I-MED
predictions	B-MED
.	O
Finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	B-MED
,	O
CP	B-MED
and	O
acyclic	O
partial	B-MED
clonality	B-MED
(	O
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-MED
are	O
clonally	B-MED
produced	O
within	O
each	O
generation	B-MED
)	O
differentially	O
affect	O
the	O
distribution	B-MED
of	O
genetic	B-MED
diversity	I-MED
.	O
Overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	B-MED
of	O
neutral	O
genetic	B-MED
diversity	I-MED
that	O
may	O
serve	O
as	O
a	O
null	B-MED
model	I-MED
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-MED
or	O
demographic	B-MED
processes	B-MED
in	O
cyclical	B-MED
parthenogens	I-MED
(	O
for	O
example	O
,	O
selection	O
or	O
bottlenecks	O
)	O
.	O
Overnight	B-MED
switching	B-MED
from	O
oxcarbazepine	B-MED
to	O
eslicarbazepine	B-MED
acetate	I-MED
:	O
an	O
observational	B-MED
study	I-MED
There	O
are	O
clinical	B-MED
situations	I-MED
where	O
it	O
might	O
be	O
appropriate	B-MED
to	O
switch	B-MED
patients	B-MED
from	O
immediate	B-MED
-	I-MED
release	I-MED
oxcarbazepine	B-MED
(	O
OXC	B-MED
)	O
to	O
eslicarbazepine	B-MED
acetate	I-MED
(	O
ESL	B-MED
)	O
.	O
We	O
investigated	B-MED
the	O
effects	B-MED
of	I-MED
transitioning	O
patients	B-MED
overnight	B-MED
from	O
OXC	B-MED
to	O
ESL	B-MED
.	O
A	O
retrospective	B-MED
,	O
single	B-MED
-	I-MED
center	I-MED
study	I-MED
was	O
conducted	O
in	O
which	O
patients	B-MED
with	O
drug	B-MED
-	I-MED
resistant	I-MED
focal	B-MED
epilepsy	I-MED
on	O
a	O
stable	O
dose	B-MED
of	O
immediate	B-MED
-	I-MED
release	I-MED
OXC	B-MED
for	O
at	O
least	O
4	B-MED
weeks	I-MED
were	O
switched	B-MED
overnight	B-MED
to	O
ESL	B-MED
.	O
Patients	B-MED
were	O
switched	B-MED
because	O
they	O
experienced	O
persistent	B-MED
seizures	B-MED
with	O
OXC	B-MED
but	O
were	O
unable	B-MED
to	O
tolerate	B-MED
increased	O
OXC	B-MED
dosing	B-MED
due	O
to	O
adverse	B-MED
events	I-MED
.	O
Tolerability	B-MED
was	O
assessed	B-MED
using	O
the	O
Adverse	B-MED
Events	I-MED
Profile	I-MED
(	O
AEP	B-MED
)	O
,	O
quality	B-MED
of	I-MED
life	I-MED
was	O
assessed	B-MED
using	O
the	O
Quality	B-MED
of	I-MED
Life	I-MED
in	I-MED
Epilepsy	I-MED
Inventory	I-MED
10	I-MED
(	O
QOLIE-10	B-MED
)	O
,	O
and	O
alertness	B-MED
was	O
assessed	B-MED
as	O
reaction	B-MED
time	I-MED
using	O
a	O
subtest	O
of	O
the	O
Test	B-MED
Battery	I-MED
for	I-MED
Attention	I-MED
Performance	I-MED
version	I-MED
2.3	I-MED
.	O
Assessments	B-MED
were	O
performed	B-MED
immediately	B-MED
prior	B-MED
to	I-MED
and	O
5	B-MED
days	I-MED
after	O
switching	B-MED
from	O
OXC	B-MED
to	O
ESL	B-MED
(	O
days	B-MED
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O
The	O
analysis	B-MED
included	O
21	O
patients	B-MED
(	O
12	O
women	B-MED
,	O
9	O
men	B-MED
;	O
mean	B-MED
age	I-MED
36	I-MED
years	I-MED
)	O
.	O
After	O
switching	B-MED
from	O
OXC	B-MED
to	O
ESL	B-MED
,	O
there	O
were	O
significant	O
improvements	B-MED
in	O
mean	B-MED
scores	I-MED
for	O
AEP	B-MED
(	O
P<.001	O
)	O
,	O
QOLIE-10	B-MED
(	O
P=.001	O
)	O
,	O
and	O
alertness	B-MED
(	O
P<.05	O
)	O
.	O
Adverse	B-MED
Events	I-MED
Profile	I-MED
total	B-MED
scores	I-MED
improved	B-MED
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	B-MED
,	O
QOLIE-10	B-MED
total	B-MED
scores	I-MED
improved	B-MED
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	B-MED
,	O
and	O
alertness	B-MED
scores	B-MED
improved	B-MED
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	B-MED
.	O
In	O
this	O
short	B-MED
-	I-MED
term	I-MED
,	O
single	B-MED
-	I-MED
center	I-MED
study	I-MED
,	O
an	O
overnight	B-MED
switch	B-MED
from	O
twice	B-MED
-	I-MED
daily	I-MED
OXC	B-MED
to	O
once	B-MED
-	I-MED
daily	I-MED
ESL	B-MED
in	O
patients	B-MED
with	O
drug	B-MED
-	I-MED
resistant	I-MED
focal	B-MED
epilepsies	I-MED
resulted	B-MED
in	O
improvements	B-MED
in	O
side	B-MED
effects	I-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
,	O
and	O
alertness	B-MED
.	O
The	O
application	B-MED
of	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
to	O
reflective	B-MED
writing	I-MED
for	O
medical	B-MED
humanities	I-MED
literature	B-MED
study	I-MED
to	O
enhance	B-MED
students	B-MED
'	I-MED
empathy	B-MED
,	O
critical	B-MED
thinking	I-MED
,	O
and	O
reflective	B-MED
writing	I-MED
To	O
facilitate	O
interdisciplinary	B-MED
collaboration	I-MED
and	O
to	O
make	O
connections	B-MED
between	O
patients	B-MED
'	I-MED
diseases	B-MED
and	O
their	O
social	B-MED
/	O
cultural	B-MED
contexts	I-MED
,	O
the	O
study	B-MED
examined	B-MED
whether	O
the	O
use	O
of	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
in	O
reflective	B-MED
writing	I-MED
for	O
medical	B-MED
humanities	I-MED
literature	O
acquisition	B-MED
could	O
have	O
positive	B-MED
effects	I-MED
on	O
medical	B-MED
university	I-MED
students	B-MED
in	O
terms	O
of	O
empathy	B-MED
,	O
critical	B-MED
thinking	I-MED
,	O
and	O
reflective	B-MED
writing	I-MED
.	O
A	O
15	B-MED
-	I-MED
week	I-MED
quasi	B-MED
-	I-MED
experimental	I-MED
design	I-MED
was	O
conducted	O
to	O
investigate	B-MED
the	O
learning	B-MED
outcomes	I-MED
.	O
After	O
conducting	O
cluster	B-MED
algorithms	I-MED
,	O
heterogeneous	B-MED
learning	I-MED
clusters	I-MED
(	O
experimental	B-MED
group	I-MED
;	O
n	O
=	O
43	O
)	O
and	O
non	B-MED
-	I-MED
heterogeneous	I-MED
learning	I-MED
clusters	I-MED
(	O
control	B-MED
group	I-MED
;	O
n	O
=	O
43	O
)	O
were	O
derived	O
for	O
a	O
medical	B-MED
humanities	I-MED
literature	B-MED
study	I-MED
.	O
Before	O
and	O
after	O
the	O
intervention	B-MED
,	O
an	O
Empathy	B-MED
Scale	I-MED
in	O
Patient	B-MED
Care	I-MED
(	O
ES	B-MED
-	O
PC	B-MED
)	O
,	O
a	O
critical	B-MED
thinking	I-MED
disposition	I-MED
assessment	I-MED
(	O
CTDA	B-MED
-	I-MED
R	I-MED
)	O
,	O
and	O
a	O
reflective	B-MED
writing	I-MED
test	I-MED
were	O
administered	B-MED
to	O
both	O
groups	B-MED
.	O
The	O
findings	O
showed	O
that	O
on	O
the	O
empathy	B-MED
scale	I-MED
,	O
significant	O
differences	O
in	O
the	O
"	O
behavioral	B-MED
empathy	I-MED
,	O
"	O
"	O
affective	B-MED
empathy	I-MED
,	O
"	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post	B-MED
-	I-MED
test	I-MED
mean	I-MED
scores	I-MED
of	O
the	O
experimental	B-MED
group	I-MED
and	O
those	O
of	O
the	O
control	B-MED
group	I-MED
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
"	O
intelligent	B-MED
empathy	I-MED
.	O
"	O
Regarding	O
critical	B-MED
thinking	I-MED
,	O
there	O
were	O
significant	O
differences	O
in	O
"	O
systematicity	B-MED
and	O
analyticity	B-MED
,	O
"	O
"	O
skepticism	B-MED
and	O
well	B-MED
-	I-MED
informed	I-MED
,	O
"	O
"	O
maturity	B-MED
and	O
skepticism	B-MED
,	O
"	O
and	O
overall	O
sections	O
.	O
As	O
for	O
reflective	B-MED
writing	I-MED
,	O
significant	O
differences	O
existed	O
in	O
"	O
ideas	B-MED
,	O
"	O
"	O
voice	B-MED
and	O
point	B-MED
of	I-MED
view	I-MED
,	O
"	O
"	O
critical	B-MED
thinking	I-MED
and	O
representation	B-MED
,	O
"	O
"	O
depth	B-MED
of	I-MED
reflection	I-MED
on	O
personal	B-MED
growth	I-MED
,	O
"	O
and	O
overall	O
sections	O
,	O
but	O
not	O
in	O
"	O
focus	B-MED
and	O
context	B-MED
structure	I-MED
"	O
and	O
"	O
language	B-MED
and	O
conventions	B-MED
.	O
"	O
This	O
study	B-MED
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous	B-MED
cluster	I-MED
grouping	I-MED
in	O
reflective	B-MED
writing	I-MED
about	O
medical	B-MED
humanities	I-MED
literature	O
to	O
facilitate	O
interdisciplinary	B-MED
cooperation	I-MED
to	O
provide	O
more	O
humanizing	O
medical	B-MED
care	I-MED
.	O
Rates	B-MED
and	O
predictors	B-MED
of	O
injury	B-MED
in	O
a	O
population	B-MED
-	O
based	B-MED
cohort	B-MED
of	O
people	B-MED
living	B-MED
with	O
HIV	B-MED
Injuries	B-MED
are	O
responsible	O
for	O
10	O
%	O
of	O
the	O
global	B-MED
burden	B-MED
of	O
disease	B-MED
;	O
however	O
,	O
the	O
epidemiology	B-MED
of	O
injury	B-MED
among	O
people	B-MED
living	I-MED
with	I-MED
HIV	I-MED
(	O
PLHIV	B-MED
)	O
has	O
not	B-MED
been	I-MED
well	I-MED
elucidated	B-MED
.	O
This	O
study	B-MED
seeks	O
to	O
characterize	B-MED
rates	B-MED
and	O
predictors	B-MED
of	O
injury	B-MED
among	O
PLHIV	B-MED
compared	B-MED
to	O
the	O
general	B-MED
population	I-MED
in	O
British	B-MED
Columbia	I-MED
(	O
BC	B-MED
)	O
,	O
Canada	B-MED
.	O
A	O
population	B-MED
-	O
based	B-MED
dataset	B-MED
was	O
created	B-MED
via	O
linkage	B-MED
between	B-MED
the	O
BC	B-MED
Centre	I-MED
for	I-MED
Excellence	I-MED
in	I-MED
HIV	I-MED
/	I-MED
AIDS	I-MED
and	O
PopulationDataBC	B-MED
.	O
PLHIV	B-MED
aged	B-MED
20	B-MED
years	I-MED
and	O
older	B-MED
were	O
compared	B-MED
to	O
a	O
random	B-MED
10	O
%	O
sample	B-MED
of	O
the	O
adult	B-MED
general	B-MED
population	I-MED
.	O
The	O
International	B-MED
Classification	B-MED
of	O
Diseases	B-MED
9	O
and	O
10	O
codes	O
were	O
used	B-MED
to	O
classify	B-MED
unintentional	B-MED
and	O
intentional	B-MED
injuries	I-MED
based	B-MED
on	O
the	O
external	B-MED
cause	I-MED
of	O
the	O
injury	B-MED
from	O
1996	O
to	O
2013	O
.	O
Generalized	B-MED
estimating	I-MED
equation	I-MED
(	O
GEE	B-MED
)	O
Poisson	B-MED
regression	I-MED
models	I-MED
were	O
fit	O
to	O
estimate	B-MED
the	O
effect	B-MED
of	O
HIV	B-MED
status	B-MED
on	O
rates	B-MED
of	O
unintentional	B-MED
and	O
intentional	B-MED
injury	I-MED
,	O
and	O
to	O
identify	B-MED
correlates	B-MED
of	O
injury	B-MED
among	O
PLHIV	B-MED
.	O
The	O
crude	O
incidence	B-MED
rate	I-MED
of	O
unintentional	B-MED
injury	I-MED
was	O
18.56/1000	O
person	B-MED
-	O
years	B-MED
[	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
17.77	O
-	O
19.39	O
]	O
among	O
PLHIV	B-MED
and	O
8.51/1000	O
person	B-MED
-	O
years	B-MED
(	O
95	O
%	O
CI	B-MED
8.42	O
-	O
8.59	O
)	O
in	O
the	O
general	B-MED
population	I-MED
.	O
Among	O
PLHIV	B-MED
,	O
13.45	O
%	O
of	O
deaths	B-MED
were	O
due	B-MED
to	I-MED
injury	B-MED
,	O
compared	B-MED
to	O
5.52	O
%	O
of	O
deaths	B-MED
in	O
the	O
general	B-MED
population	I-MED
.	O
In	O
adjusted	O
models	B-MED
,	O
PLHIV	B-MED
were	O
more	O
likely	O
to	O
report	B-MED
unintentional	B-MED
(	O
incidence	B-MED
rate	I-MED
ratio	B-MED
1.42	O
,	O
95	O
%	O
CI	B-MED
1.32	O
-	O
1.52	O
)	O
and	O
intentional	B-MED
injury	I-MED
(	O
incidence	B-MED
rate	I-MED
ratio	B-MED
1.93	O
,	O
95	O
%	O
CI	B-MED
1.70	O
-	O
2.18	O
)	O
compared	B-MED
to	O
the	O
general	B-MED
population	I-MED
.	O
We	O
identified	B-MED
elevated	B-MED
rates	B-MED
of	O
intentional	B-MED
and	O
unintentional	B-MED
injury	I-MED
among	O
PLHIV	B-MED
.	O
Injuries	B-MED
are	O
largely	B-MED
preventable	B-MED
;	O
as	O
such	O
,	O
targeted	B-MED
efforts	O
are	O
needed	B-MED
to	O
decrease	B-MED
the	O
burden	B-MED
of	O
injury	B-MED
-	O
related	B-MED
disability	B-MED
and	O
death	B-MED
among	O
PLHIV	B-MED
.	O
The	O
Novel	O
miR-9600	B-MED
Suppresses	B-MED
Tumor	B-MED
Progression	I-MED
and	O
Promotes	O
Paclitaxel	B-MED
Sensitivity	B-MED
in	O
Non	B-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
Lung	I-MED
Cancer	I-MED
Through	O
Altering	B-MED
STAT3	B-MED
Expression	B-MED
MicroRNAs	B-MED
have	O
been	O
identified	B-MED
to	O
be	O
involved	O
in	O
center	B-MED
stage	I-MED
of	O
cancer	B-MED
biology	I-MED
.	O
They	O
accommodate	O
cell	B-MED
proliferation	I-MED
and	O
migration	B-MED
by	O
negatively	B-MED
regulate	B-MED
gene	I-MED
expression	I-MED
either	O
by	O
hampering	O
the	O
translation	B-MED
of	O
targeted	B-MED
mRNAs	I-MED
or	O
by	O
promoting	O
their	O
degradation	B-MED
.	O
We	O
characterized	B-MED
and	O
identified	B-MED
the	O
novel	O
miR-9600	B-MED
and	O
its	O
target	B-MED
in	O
human	B-MED
non	B-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
(	O
NSCLC	B-MED
)	O
.	O
Our	O
results	O
demonstrated	O
that	O
the	O
miR-9600	B-MED
were	O
downregulated	B-MED
in	O
NSCLC	B-MED
tissues	B-MED
and	O
cells	B-MED
.	O
It	O
is	O
confirmed	O
that	O
signal	B-MED
transducer	I-MED
and	I-MED
activator	I-MED
of	I-MED
transcription	I-MED
3	I-MED
(	O
STAT3	B-MED
)	O
,	O
a	O
putative	B-MED
target	I-MED
gene	I-MED
,	O
is	O
directly	O
inhibited	B-MED
by	O
miR-9600	B-MED
.	O
The	O
miR-9600	B-MED
markedly	O
suppressed	B-MED
the	O
protein	B-MED
expression	I-MED
of	O
STAT3	B-MED
,	O
but	O
with	O
no	B-MED
significant	I-MED
influence	B-MED
in	O
corresponding	O
mRNA	B-MED
levels	B-MED
,	O
and	O
the	O
direct	O
combination	O
of	O
miR-9600	B-MED
and	O
STAT3	B-MED
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay	O
.	O
miR-9600	B-MED
inhibited	B-MED
cell	B-MED
growth	I-MED
,	O
hampered	O
expression	B-MED
of	O
cell	B-MED
cycle	I-MED
-related	O
proteins	B-MED
and	O
inhibited	B-MED
cell	B-MED
migration	I-MED
and	O
invasion	B-MED
in	O
human	B-MED
NSCLC	B-MED
cell	B-MED
lines	I-MED
.	O
Further	O
,	O
miR-9600	B-MED
significantly	O
suppressed	B-MED
tumor	B-MED
growth	I-MED
in	O
nude	B-MED
mice	I-MED
.	O
Similarly	O
,	O
miR-9600	B-MED
impeded	O
tumorigenesis	B-MED
and	O
metastasis	B-MED
through	O
directly	O
targeting	B-MED
STAT3	B-MED
.	O
Furthermore	O
,	O
we	O
identified	B-MED
that	O
miR-9600	B-MED
augmented	O
paclitaxel	B-MED
and	O
cisplatin	B-MED
sensitivity	B-MED
by	O
downregulating	B-MED
STAT3	B-MED
and	O
promoting	O
chemotherapy	B-MED
-	O
induced	B-MED
apoptosis	B-MED
.	O
These	O
data	O
demonstrate	O
that	O
miR-9600	B-MED
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	B-MED
target	B-MED
for	O
NSCLC	B-MED
.	O
A	O
plea	O
for	O
thoracoscopic	B-MED
resection	B-MED
of	O
solitary	B-MED
pulmonary	I-MED
nodule	I-MED
in	O
cancer	B-MED
patients	B-MED
Solitary	B-MED
pulmonary	I-MED
nodules	I-MED
(	O
SPN	B-MED
)	O
are	O
frequently	O
detected	B-MED
in	O
cancer	B-MED
patients	B-MED
.	O
These	O
lesions	B-MED
are	O
often	O
considered	O
as	O
pulmonary	B-MED
metastases	I-MED
and	O
increasingly	B-MED
treated	B-MED
by	O
non	B-MED
-	I-MED
surgical	I-MED
techniques	I-MED
without	O
histological	B-MED
confirmation	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	B-MED
nature	B-MED
of	O
SPN	B-MED
resected	B-MED
by	O
thoracoscopy	B-MED
and	O
to	O
identify	O
risk	B-MED
factors	I-MED
of	O
malignancy	B-MED
.	O
Single	B-MED
-	I-MED
institution	I-MED
retrospective	I-MED
analysis	I-MED
of	O
all	O
consecutive	B-MED
patients	B-MED
with	O
previously	O
known	O
malignancies	B-MED
who	O
underwent	O
thoracoscopic	B-MED
resection	B-MED
of	O
SPN	B-MED
with	O
unknown	B-MED
diagnosis	B-MED
between	O
2001	O
and	O
2014	O
.	O
One	O
hundred	O
and	O
forty	O
cancer	B-MED
patients	B-MED
underwent	O
thoracoscopic	B-MED
resection	B-MED
of	O
a	O
SPN	B-MED
.	O
The	O
resected	B-MED
SPN	B-MED
was	O
benign	B-MED
in	O
34	O
patients	B-MED
(	O
24.3	O
%	O
)	O
and	O
malignant	B-MED
in	O
106	O
patients	B-MED
.	O
The	O
latter	O
were	O
metastasis	B-MED
in	O
70	O
patients	B-MED
(	O
50	O
%	O
)	O
and	O
a	O
primary	B-MED
lung	B-MED
cancer	I-MED
in	O
36	O
patients	B-MED
(	O
25.7	O
%	O
)	O
.	O
Upon	O
univariate	B-MED
analysis	I-MED
,	O
malignancy	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
age	B-MED
>	O
60	O
years	B-MED
,	O
disease	B-MED
-free	O
interval	B-MED
≥24	O
months	B-MED
,	O
SPN	B-MED
size	B-MED
>	O
8	O
mm	O
,	O
upper	B-MED
lobe	I-MED
localization	B-MED
and	O
SUVmax	B-MED
>	O
2.5	O
on	O
PET	B-MED
-	I-MED
CT	I-MED
.	O
Upon	O
multivariate	B-MED
analysis	I-MED
,	O
upper	B-MED
lobe	I-MED
localization	B-MED
and	O
SUVmax	B-MED
>	O
2.5	O
were	O
associated	B-MED
with	I-MED
malignancy	B-MED
.	O
Smoking	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
SPN	B-MED
containing	O
primary	B-MED
lung	B-MED
cancer	I-MED
.	O
In	O
this	O
series	B-MED
,	O
only	O
50	O
%	O
of	O
SPN	B-MED
in	O
patients	B-MED
with	O
known	O
malignant	B-MED
disease	I-MED
were	O
pulmonary	B-MED
metastases	I-MED
and	O
25	O
%	O
had	O
a	O
newly	B-MED
diagnosed	I-MED
NSCLC	B-MED
.	O
Smoking	B-MED
was	O
associated	B-MED
with	I-MED
primary	B-MED
lung	B-MED
cancer	I-MED
but	O
no	B-MED
other	O
predictor	B-MED
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	B-MED
metastasis	I-MED
and	O
lung	B-MED
cancer	I-MED
.	O
These	O
results	O
endorse	O
the	O
need	O
of	O
histological	B-MED
confirmation	B-MED
of	O
SPN	B-MED
in	O
patients	B-MED
with	O
previous	B-MED
malignancies	B-MED
to	O
avoid	O
diagnostic	B-MED
uncertainty	B-MED
and	O
suboptimal	B-MED
treatments	B-MED
.	O
EZH2	B-MED
and	O
ZFX	B-MED
oncogenes	B-MED
in	O
malignant	B-MED
behaviour	I-MED
of	O
parathyroid	B-MED
neoplasms	I-MED
Several	O
studies	B-MED
reported	O
somatic	B-MED
mutations	I-MED
of	O
many	O
genes	B-MED
(	O
MEN1	B-MED
,	O
CTNNB1	B-MED
,	O
CDKIs	B-MED
and	O
others	O
)	O
in	O
parathyroid	B-MED
adenoma	I-MED
,	O
although	O
with	O
different	B-MED
prevalence	B-MED
.	O
Recently	O
,	O
activating	B-MED
mutations	B-MED
of	O
the	O
EZH2	B-MED
and	O
ZFX	B-MED
oncogenes	B-MED
were	O
identified	O
in	O
benign	B-MED
parathyroid	B-MED
adenoma	I-MED
by	O
whole	B-MED
exome	I-MED
sequencing	I-MED
.	O
The	O
same	O
mutations	B-MED
had	O
been	O
found	O
in	O
blood	B-MED
and	O
ovary	B-MED
malignant	B-MED
tumours	I-MED
.	O
On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	B-MED
that	O
these	O
oncogenes	B-MED
may	O
play	O
a	O
role	O
in	O
the	O
onset	B-MED
of	O
parathyroid	B-MED
tumour	I-MED
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	B-MED
,	O
rather	O
benign	B-MED
,	O
parathyroid	B-MED
neoplasm	I-MED
.	O
Our	O
aim	B-MED
was	O
to	O
verify	O
the	O
occurrence	B-MED
of	O
selected	O
mutations	B-MED
of	O
the	O
EZH2	B-MED
and	O
ZFX	B-MED
genes	I-MED
in	O
an	O
Italian	B-MED
cohort	B-MED
of	O
23	O
sporadic	B-MED
parathyroid	B-MED
carcinomas	I-MED
,	O
12	O
atypical	B-MED
and	O
45	O
typical	B-MED
adenomas	B-MED
.	O
DNA	B-MED
was	O
extracted	B-MED
from	O
paraffin	B-MED
-	I-MED
embedded	I-MED
tissues	I-MED
,	O
PCR	B-MED
amplified	B-MED
and	O
directly	O
sequenced	B-MED
.	O
No	B-MED
mutations	B-MED
were	O
detected	B-MED
in	O
the	O
coding	B-MED
sequence	I-MED
and	O
boundaries	B-MED
of	O
both	O
genes	B-MED
in	O
any	O
of	O
the	O
samples	B-MED
.	O
Two	O
polymorphisms	B-MED
of	O
the	O
EZH2	B-MED
gene	I-MED
were	O
identified	B-MED
with	O
different	B-MED
prevalence	B-MED
:	O
the	O
rs2072407	B-MED
variant	I-MED
was	O
present	B-MED
in	O
the	O
30	O
%	O
of	O
the	O
samples	B-MED
,	O
in	O
keeping	O
with	O
the	O
overall	B-MED
frequency	B-MED
in	O
larger	B-MED
populations	B-MED
,	O
while	O
the	O
rs78589034	B-MED
variant	I-MED
,	O
located	O
close	O
to	O
the	O
5	B-MED
'	I-MED
end	I-MED
of	O
the	O
exon	B-MED
16	I-MED
,	O
was	O
detected	B-MED
in	O
only	O
one	O
proband	B-MED
with	O
familial	B-MED
isolated	B-MED
hyperparathyroidism	B-MED
;	O
we	O
investigated	B-MED
the	O
possible	O
outcome	B-MED
on	O
the	O
splicing	B-MED
process	I-MED
.	O
EZH2	B-MED
and	O
ZFX	B-MED
genes	I-MED
do	O
not	O
seem	O
to	O
have	O
an	O
impact	B-MED
on	O
the	O
onset	B-MED
of	O
most	O
parathyroid	B-MED
tumours	I-MED
,	O
both	O
benign	B-MED
and	O
malignant	B-MED
,	O
though	O
further	O
studies	O
on	O
larger	B-MED
cohorts	B-MED
of	O
different	B-MED
ethnicity	B-MED
are	O
needed	O
.	O
Memory	B-MED
consolidation	I-MED
effects	B-MED
on	O
memory	B-MED
stabilization	I-MED
and	O
item	B-MED
integration	I-MED
in	O
older	B-MED
adults	I-MED
This	O
study	B-MED
examined	O
the	O
differential	B-MED
effects	I-MED
of	O
aging	B-MED
on	O
consolidation	B-MED
processes	I-MED
that	O
strengthen	O
newly	O
acquired	O
memory	B-MED
traces	I-MED
in	O
veridical	O
form	O
(	O
memory	B-MED
stabilization	I-MED
)	O
versus	O
consolidation	B-MED
processes	I-MED
that	O
are	O
responsible	O
for	O
integrating	B-MED
these	O
memory	B-MED
traces	I-MED
into	O
an	O
existing	O
body	O
of	O
knowledge	B-MED
(	O
item	B-MED
integration	I-MED
)	O
.	O
Older	B-MED
adults	I-MED
learned	B-MED
13	O
nonwords	B-MED
and	O
were	O
tested	O
on	O
their	O
memory	B-MED
for	O
the	O
nonwords	B-MED
,	O
and	O
on	O
whether	O
these	O
nonwords	B-MED
impacted	O
upon	O
processing	O
of	O
similar	O
-	O
sounding	O
English	B-MED
words	B-MED
immediately	O
and	O
24	O
hours	B-MED
later	O
.	O
Participants	B-MED
accurately	O
recognized	O
the	O
nonwords	B-MED
immediately	O
,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	B-MED
and	O
recall	B-MED
.	O
In	O
comparison	O
,	O
the	O
nonwords	B-MED
impacted	O
upon	O
processing	B-MED
of	O
similar	B-MED
-	I-MED
sounding	I-MED
words	I-MED
only	O
in	O
the	O
delayed	B-MED
test	I-MED
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
memory	B-MED
consolidation	I-MED
processes	I-MED
may	O
be	O
more	O
evident	O
in	O
item	B-MED
integration	I-MED
than	O
memory	B-MED
stabilization	I-MED
processes	I-MED
for	O
new	O
declarative	O
memories	B-MED
in	O
older	B-MED
adults	I-MED
.	O
Comparative	B-MED
and	O
evolutionary	B-MED
analysis	I-MED
of	O
an	O
adapter	B-MED
molecule	I-MED
MyD88	I-MED
in	O
invertebrate	B-MED
metazoans	B-MED
The	O
myeloid	B-MED
differentiation	I-MED
factor	I-MED
88	I-MED
(	O
MyD88	B-MED
)	O
is	O
an	O
essential	O
adapter	O
in	O
Toll	B-MED
-	I-MED
like	I-MED
receptor	I-MED
(	O
TLR	B-MED
)	O
signalling	B-MED
pathways	I-MED
,	O
with	O
TLR	B-MED
the	O
first	O
pattern	B-MED
-	I-MED
recognition	I-MED
receptor	I-MED
(	O
PRR	B-MED
)	O
that	O
was	O
discovered	O
in	O
Drosophila	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
a	O
MyD88	B-MED
gene	I-MED
was	O
identified	B-MED
and	O
characterized	B-MED
from	O
a	O
commercially	O
important	O
shellfish	B-MED
,	O
Scapharca	B-MED
subcrenata	I-MED
,	O
including	O
a	O
DEATH	B-MED
domain	I-MED
and	O
TIR	B-MED
domain	I-MED
conserved	O
within	O
other	O
molluscs	B-MED
.	O
Furthermore	O
,	O
comparative	B-MED
genomic	I-MED
evidence	I-MED
revealed	O
that	O
MyD88	B-MED
was	O
of	O
different	B-MED
lengths	B-MED
and	O
contained	O
quantitative	B-MED
exon	B-MED
and	O
intron	B-MED
regions	I-MED
,	O
which	O
might	O
be	O
involved	O
in	O
specific	B-MED
mechanisms	I-MED
.	O
To	O
further	O
explore	O
the	O
phylogenetic	B-MED
relationships	I-MED
of	O
invertebrate	B-MED
metazoan	B-MED
MyD88	B-MED
,	O
we	O
applied	O
MrBayes	B-MED
and	I-MED
PhyML	I-MED
software	I-MED
to	O
construct	B-MED
phylogenetic	B-MED
trees	I-MED
using	O
Bayesian	B-MED
and	O
maximum	B-MED
likelihood	I-MED
approaches	I-MED
,	O
respectively	O
,	O
which	O
suggested	O
that	O
the	O
MyD88	B-MED
of	O
Arthropoda	B-MED
was	O
closely	O
related	O
to	O
lower	B-MED
invertebrates	B-MED
,	O
in	O
contrast	B-MED
to	O
morphological	B-MED
taxonomy	B-MED
.	O
Finally	O
,	O
we	O
investigated	B-MED
the	O
evolutionary	B-MED
patterns	I-MED
and	O
location	O
of	O
positive	B-MED
selection	I-MED
sites	I-MED
(	O
PSSs	B-MED
)	O
in	O
the	O
MyD88	B-MED
gene	I-MED
from	O
Arthropoda	B-MED
,	O
Mollusca	B-MED
and	O
Insecta	B-MED
using	O
PAML	B-MED
software	I-MED
with	O
the	O
maximum	B-MED
likelihood	I-MED
method	I-MED
.	O
The	O
data	B-MED
showed	O
that	O
positive	B-MED
selection	I-MED
sites	I-MED
were	O
detected	B-MED
in	O
these	O
groups	B-MED
,	O
and	O
partial	B-MED
sites	I-MED
were	O
located	O
in	O
the	O
TIR	B-MED
domain	I-MED
but	O
were	O
not	B-MED
found	I-MED
in	O
the	O
DEATH	B-MED
domain	I-MED
.	O
To	O
summarize	O
,	O
in	O
this	O
study	B-MED
,	O
we	O
report	O
on	O
the	O
diversification	B-MED
of	O
MyD88	B-MED
in	O
invertebrate	B-MED
metazoans	B-MED
,	O
the	O
specific	B-MED
evolutionary	B-MED
position	I-MED
of	O
Arthropoda	B-MED
MyD88	B-MED
,	O
and	O
the	O
positive	B-MED
selection	B-MED
pressures	I-MED
on	O
MyD88	B-MED
of	O
Arthropoda	B-MED
,	O
Mollusca	B-MED
and	O
Insecta	B-MED
.	O
These	O
results	B-MED
are	O
a	O
valuable	B-MED
contribution	I-MED
to	O
understand	O
and	O
clarify	B-MED
the	O
evolutionary	B-MED
pattern	I-MED
of	O
TLR	B-MED
/	O
MyD88	B-MED
signalling	B-MED
pathways	I-MED
in	O
invertebrate	B-MED
and	O
vertebrate	B-MED
taxa	I-MED
.	O
Variables	B-MED
associated	B-MED
with	I-MED
unplanned	B-MED
general	B-MED
adult	I-MED
ICU	B-MED
admission	I-MED
in	O
hospitalised	B-MED
patients	I-MED
:	O
protocol	B-MED
for	O
a	O
systematic	B-MED
review	B-MED
Failure	B-MED
to	O
promptly	O
identify	B-MED
deterioration	B-MED
in	O
hospitalised	B-MED
patients	I-MED
is	O
associated	B-MED
with	I-MED
delayed	B-MED
admission	B-MED
to	I-MED
intensive	I-MED
care	I-MED
units	I-MED
(	O
ICUs	B-MED
)	O
and	O
poor	B-MED
outcomes	B-MED
.	O
Existing	B-MED
vital	B-MED
sign	I-MED
-based	O
Early	B-MED
Warning	I-MED
Score	I-MED
(	B-MED
EWS	I-MED
)	I-MED
algorithms	B-MED
do	O
not	O
have	O
a	O
sufficiently	B-MED
high	B-MED
positive	B-MED
predictive	B-MED
value	I-MED
to	O
be	O
used	O
for	O
automated	B-MED
activation	B-MED
of	O
an	O
ICU	B-MED
outreach	B-MED
team	I-MED
.	O
Incorporating	B-MED
additional	O
patient	B-MED
data	I-MED
might	O
improve	B-MED
the	O
predictive	B-MED
power	B-MED
of	O
EWS	B-MED
algorithms	B-MED
;	O
however	O
,	O
it	O
is	O
currently	B-MED
not	O
known	O
which	O
patient	B-MED
data	I-MED
(	O
or	O
variables	B-MED
)	O
are	O
most	O
predictive	B-MED
of	O
ICU	B-MED
admission	I-MED
.	O
We	O
describe	O
the	O
protocol	B-MED
for	O
a	O
systematic	B-MED
review	B-MED
of	O
variables	B-MED
associated	B-MED
with	I-MED
ICU	B-MED
admission	I-MED
.	O
MEDLINE	B-MED
,	O
EMBASE	B-MED
,	O
CINAHL	B-MED
and	O
the	O
Cochrane	B-MED
Library	I-MED
,	O
including	B-MED
Cochrane	B-MED
Database	I-MED
of	I-MED
Systematic	I-MED
Reviews	I-MED
and	O
the	O
Cochrane	B-MED
Central	I-MED
Register	I-MED
of	I-MED
Controlled	I-MED
Trials	I-MED
(	B-MED
CENTRAL	I-MED
)	I-MED
will	O
be	O
searched	B-MED
for	O
studies	B-MED
that	O
assess	B-MED
the	O
association	B-MED
of	O
routinely	B-MED
recorded	B-MED
variables	B-MED
associated	B-MED
with	I-MED
subsequent	B-MED
unplanned	B-MED
ICU	B-MED
admission	I-MED
.	O
Only	O
studies	B-MED
involving	B-MED
adult	B-MED
patients	B-MED
admitted	B-MED
to	I-MED
general	B-MED
ICUs	B-MED
will	O
be	O
included	B-MED
.	O
We	O
will	O
extract	B-MED
data	B-MED
relating	B-MED
to	I-MED
the	O
statistical	B-MED
association	I-MED
between	O
ICU	B-MED
admission	I-MED
and	O
predictor	B-MED
variables	B-MED
,	O
the	O
quality	B-MED
of	O
the	O
studies	B-MED
and	O
the	O
generalisability	B-MED
of	O
the	O
findings	B-MED
.	O
The	O
results	B-MED
of	O
this	O
review	B-MED
will	O
aid	B-MED
the	O
development	B-MED
of	O
future	O
models	B-MED
which	O
predict	B-MED
the	O
risk	B-MED
of	O
unplanned	B-MED
ICU	B-MED
admission	I-MED
.	O
PROSPERO	O
:	O
CRD42015029617	O
.	O
The	O
Burden	B-MED
of	O
Mental	B-MED
Disorders	I-MED
in	O
the	O
Eastern	B-MED
Mediterranean	I-MED
Region	I-MED
,	O
1990	O
-	O
2013	O
The	O
Eastern	B-MED
Mediterranean	I-MED
Region	I-MED
(	O
EMR	B-MED
)	O
is	O
witnessing	O
an	O
increase	B-MED
in	O
chronic	B-MED
disorders	I-MED
,	O
including	O
mental	B-MED
illness	I-MED
.	O
With	O
ongoing	O
unrest	O
,	O
this	O
is	O
expected	O
to	O
rise	O
.	O
This	O
is	O
the	O
first	O
study	B-MED
to	O
quantify	O
the	O
burden	B-MED
of	O
mental	B-MED
disorders	I-MED
in	O
the	O
EMR	B-MED
.	O
We	O
used	O
data	B-MED
from	O
the	O
Global	B-MED
Burden	I-MED
of	I-MED
Disease	I-MED
study	I-MED
(	O
GBD	B-MED
)	O
2013	O
.	O
DALYs	B-MED
(	O
disability	B-MED
-	I-MED
adjusted	I-MED
life	I-MED
years	I-MED
)	O
allow	O
assessment	B-MED
of	O
both	O
premature	B-MED
mortality	I-MED
(	O
years	B-MED
of	I-MED
life	I-MED
lost	I-MED
-	O
YLLs	B-MED
)	O
and	O
nonfatal	O
outcomes	O
(	O
years	B-MED
lived	I-MED
with	I-MED
disability	I-MED
-	O
YLDs	B-MED
)	O
.	O
DALYs	B-MED
are	O
computed	O
by	O
adding	O
YLLs	B-MED
and	O
YLDs	B-MED
for	O
each	O
age	O
-	O
sex	O
-	O
country	O
group	O
.	O
In	O
2013	O
,	O
mental	B-MED
disorders	I-MED
contributed	O
to	O
5.6	O
%	O
of	O
the	O
total	B-MED
disease	I-MED
burden	I-MED
in	O
the	O
EMR	B-MED
(	O
1894	O
DALYS	B-MED
/100,000	O
population	B-MED
):	O
2519	O
DALYS	B-MED
/100,000	O
(	O
2590/100,000	O
males	B-MED
,	O
2426/100,000	O
females	B-MED
)	O
in	O
high	B-MED
-	I-MED
income	I-MED
high	B-MED
-	I-MED
income	I-MED
countries	I-MED
,	O
1884	O
DALYS	B-MED
/100,000	O
(	O
1618/100,000	O
males	B-MED
,	O
2157/100,000	O
females	B-MED
)	O
in	O
middle	B-MED
-	I-MED
income	I-MED
countries	B-MED
,	O
1607	O
DALYS	B-MED
/100,000	O
(	O
1500/100,000	O
males	B-MED
,	O
1717/100,000	O
females	B-MED
)	O
in	O
low	B-MED
-	I-MED
income	I-MED
countries	B-MED
.	O
Females	B-MED
had	O
a	O
greater	O
proportion	O
of	O
burden	B-MED
due	O
to	O
mental	B-MED
disorders	I-MED
than	O
did	O
males	B-MED
of	O
equivalent	O
ages	B-MED
,	O
except	O
for	O
those	O
under	O
15	O
years	B-MED
of	I-MED
age	I-MED
.	O
The	O
highest	O
proportion	O
of	O
DALYs	B-MED
occurred	O
in	O
the	O
25	O
-	O
49	O
age	B-MED
group	I-MED
,	O
with	O
a	O
peak	O
in	O
the	O
35	O
-	O
39	O
years	O
age	B-MED
group	I-MED
(	O
5344	O
DALYs	B-MED
/100,000	O
)	O
.	O
The	O
burden	B-MED
of	O
mental	B-MED
disorders	I-MED
in	O
EMR	B-MED
increased	O
from	O
1726	O
DALYs	B-MED
/100,000	O
in	O
1990	O
to	O
1912	O
DALYs	B-MED
/100,000	O
in	O
2013	O
(	O
10.8	O
%	O
increase	O
)	O
.	O
Within	O
the	O
mental	B-MED
disorders	I-MED
group	I-MED
in	O
EMR	B-MED
,	O
depressive	B-MED
disorders	I-MED
accounted	O
for	O
most	O
DALYs	B-MED
,	O
followed	O
by	O
anxiety	B-MED
disorders	I-MED
.	O
Among	O
EMR	B-MED
countries	O
,	O
Palestine	B-MED
had	O
the	O
largest	O
burden	B-MED
of	I-MED
mental	I-MED
disorders	I-MED
mental	B-MED
disorders	I-MED
.	O
Nearly	O
all	O
EMR	B-MED
countries	I-MED
had	O
a	O
higher	O
mental	B-MED
disorder	I-MED
burden	I-MED
compared	O
to	O
the	O
global	O
level	O
.	O
Our	O
findings	O
call	O
for	O
EMR	B-MED
ministries	I-MED
of	O
health	O
to	O
increase	O
provision	B-MED
of	O
mental	B-MED
health	I-MED
services	I-MED
and	O
to	O
address	O
the	O
stigma	B-MED
of	I-MED
mental	I-MED
illness	I-MED
.	O
Moreover	O
,	O
our	O
results	O
showing	O
the	O
accelerating	B-MED
burden	B-MED
of	I-MED
mental	I-MED
health	I-MED
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	B-MED
.	O
Indeed	O
,	O
mental	B-MED
health	I-MED
problems	I-MED
,	O
if	O
not	O
properly	O
addressed	O
,	O
will	O
lead	O
to	O
an	O
increased	B-MED
burden	B-MED
of	I-MED
diseases	I-MED
in	O
the	O
region	B-MED
.	O
Predicting	B-MED
violence	B-MED
and	O
recidivism	B-MED
in	O
a	O
large	O
sample	O
of	O
males	B-MED
on	O
probation	B-MED
or	O
parole	B-MED
This	O
study	B-MED
evaluated	B-MED
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
Iowa	B-MED
Violence	B-MED
and	O
Victimization	B-MED
Instrument	B-MED
in	O
a	O
sample	O
of	O
1961	O
males	B-MED
from	O
the	O
state	O
of	O
Iowa	B-MED
who	O
were	O
on	O
probation	B-MED
or	O
released	B-MED
from	I-MED
prison	I-MED
to	O
parole	B-MED
supervision	B-MED
.	O
This	O
is	O
the	O
first	O
study	B-MED
to	O
examine	O
the	O
potential	B-MED
of	O
the	O
Iowa	B-MED
Violence	B-MED
and	O
Victimization	B-MED
Instrument	B-MED
to	O
predict	B-MED
criminal	B-MED
offenses	I-MED
.	O
The	O
males	B-MED
were	O
followed	O
for	O
30	O
months	B-MED
immediately	O
following	O
their	O
admission	B-MED
to	O
probation	B-MED
or	O
parole	B-MED
.	O
AUC	B-MED
analyses	B-MED
indicated	O
fair	O
to	O
good	O
predictive	B-MED
power	O
for	O
the	O
Iowa	B-MED
Violence	B-MED
and	O
Victimization	B-MED
Instrument	B-MED
for	O
charges	O
of	O
violence	B-MED
and	O
victimization	B-MED
,	O
but	O
chance	O
predictive	B-MED
power	O
for	O
drug	B-MED
offenses	I-MED
.	O
Notably	O
,	O
both	O
scales	O
of	O
the	O
instrument	B-MED
performed	O
equally	O
well	O
at	O
the	O
30-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
Items	O
on	O
the	O
Iowa	B-MED
Violence	B-MED
and	O
Victimization	B-MED
Instrument	B-MED
not	O
only	O
predicted	B-MED
violence	B-MED
,	O
but	O
are	O
straightforward	O
to	O
score	O
.	O
Violence	B-MED
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	B-MED
findings	B-MED
,	O
including	O
the	O
potential	B-MED
to	O
expand	B-MED
the	O
measure	O
to	O
other	O
jurisdictions	B-MED
and	O
populations	B-MED
.	O
Performance	B-MED
and	O
safety	B-MED
of	O
collagenated	B-MED
xenogeneic	I-MED
bone	I-MED
block	I-MED
for	O
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
staged	B-MED
implant	I-MED
placement	I-MED
.	O
A	O
monocenter	B-MED
,	I-MED
prospective	I-MED
single	I-MED
-	I-MED
arm	I-MED
clinical	I-MED
study	I-MED
To	O
assess	B-MED
the	O
clinical	B-MED
safety	I-MED
and	O
performance	B-MED
of	O
collagenated	B-MED
xenogeneic	I-MED
bone	I-MED
block	I-MED
(	O
CXBB	B-MED
)	O
for	O
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
two	B-MED
-	I-MED
stage	I-MED
implant	B-MED
placement	I-MED
.	O
In	O
ten	O
patients	B-MED
exhibiting	B-MED
a	O
single	B-MED
-	O
tooth	B-MED
gap	B-MED
,	O
the	O
surgical	B-MED
procedure	I-MED
included	B-MED
the	O
preparation	B-MED
of	O
mucoperiosteal	B-MED
flaps	I-MED
,	O
a	O
rigid	B-MED
fixation	I-MED
of	O
CXBB	B-MED
(	O
Geistlich	B-MED
Bio	I-MED
-	I-MED
Graft	I-MED
(	I-MED
®	I-MED
)	I-MED
)	O
using	O
an	O
osteosynthesis	B-MED
screw	I-MED
,	O
and	O
contour	B-MED
augmentation	B-MED
.	O
After	O
24	O
weeks	O
of	O
submerged	B-MED
healing	I-MED
,	O
the	O
primary	B-MED
endpoint	I-MED
was	O
defined	O
as	O
the	O
final	B-MED
ridge	B-MED
width	B-MED
sufficient	B-MED
to	O
place	O
an	O
adequately	B-MED
dimensioned	B-MED
titanium	B-MED
implant	I-MED
at	O
the	O
respective	O
sites	B-MED
.	O
Secondary	B-MED
outcomes	I-MED
included	B-MED
,	O
for	O
example	O
,	O
the	O
gain	B-MED
in	O
ridge	B-MED
width	B-MED
(	O
mm	O
)	O
.	O
Clinical	B-MED
parameters	I-MED
(	O
e.g.	O
,	O
bleeding	B-MED
on	I-MED
probing	I-MED
-	O
BOP	B-MED
,	O
probing	B-MED
depth	I-MED
-	O
PD	B-MED
,	O
mucosal	B-MED
recession	I-MED
-	O
MR	B-MED
)	O
were	O
assessed	B-MED
immediately	O
after	O
the	O
cementation	B-MED
of	I-MED
the	I-MED
crown	I-MED
and	O
at	O
the	O
final	B-MED
visit	I-MED
.	O
At	O
24	O
weeks	O
,	O
implant	B-MED
placement	I-MED
could	O
be	O
achieved	B-MED
in	O
8	O
of	O
10	O
patients	B-MED
exhibiting	B-MED
a	O
mean	B-MED
gain	B-MED
in	O
ridge	B-MED
width	B-MED
(	O
mean	B-MED
±	O
SD	B-MED
)	O
of	O
3.88	O
±	O
1.75	O
mm	O
.	O
Histological	B-MED
analysis	B-MED
has	O
pointed	O
to	O
a	O
homogeneous	B-MED
osseous	B-MED
organization	B-MED
of	O
CXBB	B-MED
.	O
The	O
changes	B-MED
of	O
mean	B-MED
BOP	B-MED
,	O
PD	B-MED
,	O
and	O
MR	B-MED
values	B-MED
at	O
the	O
final	B-MED
visit	I-MED
amounted	B-MED
to	O
16.62	O
±	O
32.02	O
%	O
,	O
0.04	O
±	O
0.21	O
mm	O
,	O
and	O
-0.04	O
±	O
0.12	O
mm	O
,	O
respectively	O
.	O
CXBB	B-MED
may	O
be	O
successfully	B-MED
used	O
to	O
support	B-MED
lateral	B-MED
alveolar	I-MED
ridge	I-MED
augmentation	I-MED
and	O
two	B-MED
-	I-MED
stage	I-MED
implant	B-MED
placement	I-MED
.	O
Gut	B-MED
microbiota	I-MED
-mediated	O
protection	B-MED
against	O
diarrheal	B-MED
infections	B-MED
The	O
mammalian	B-MED
gut	B-MED
microbiota	I-MED
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	B-MED
community	B-MED
that	O
resides	B-MED
in	O
the	O
gastrointestinal	B-MED
tract	I-MED
.	O
One	O
major	O
benefit	O
that	O
the	O
gut	B-MED
microbiota	I-MED
provides	O
to	O
its	O
host	B-MED
is	O
colonization	B-MED
resistance	B-MED
-the	O
ability	O
to	O
prevent	B-MED
colonization	B-MED
by	O
foreign	B-MED
microbes	I-MED
,	O
including	O
diarrheal	B-MED
pathogens	B-MED
such	O
as	O
Clostridium	B-MED
difficile	I-MED
,	O
Salmonella	B-MED
enterica	I-MED
serovar	I-MED
Typhimurium	I-MED
and	O
diarrheagenic	B-MED
Escherichia	I-MED
coli	I-MED
.	O
We	O
conducted	O
a	O
literature	B-MED
review	I-MED
of	O
the	O
effects	B-MED
of	I-MED
the	O
gut	B-MED
microbiota	I-MED
on	O
infection	B-MED
by	O
diarrheal	B-MED
pathogens	B-MED
.	O
We	O
used	O
PubMed	B-MED
to	O
search	O
for	O
relevant	O
articles	B-MED
published	O
before	O
July	O
2016	O
,	O
as	O
well	O
as	O
incorporated	O
data	B-MED
from	O
our	O
laboratory	B-MED
.	O
The	O
gut	B-MED
microbiota	I-MED
provides	O
protection	B-MED
from	O
diarrheal	B-MED
infections	B-MED
both	O
by	O
direct	B-MED
inhibition	B-MED
of	O
pathogens	B-MED
and	O
by	O
indirect	B-MED
effects	B-MED
on	O
host	B-MED
functions	B-MED
.	O
Direct	B-MED
effects	B-MED
of	I-MED
the	O
microbiota	B-MED
on	O
diarrheal	B-MED
pathogens	B-MED
include	O
competing	O
for	O
nutrients	B-MED
and	O
producing	O
metabolites	B-MED
that	O
inhibit	B-MED
pathogen	B-MED
growth	B-MED
or	O
virulence	B-MED
.	O
Indirect	B-MED
effects	B-MED
of	I-MED
the	O
gut	B-MED
microbiota	I-MED
include	O
promoting	O
maintenance	B-MED
of	O
the	O
gut	B-MED
mucosal	I-MED
barrier	I-MED
and	O
stimulating	O
innate	B-MED
and	O
adaptive	B-MED
immunity	I-MED
.	O
Human	B-MED
epidemiological	B-MED
studies	I-MED
and	O
experimental	B-MED
infections	B-MED
of	O
laboratory	B-MED
animals	I-MED
both	O
demonstrate	O
that	O
antibiotic	B-MED
treatment	I-MED
can	O
alter	O
the	O
gut	B-MED
microbial	I-MED
community	B-MED
and	O
thereby	O
reduce	O
colonization	B-MED
resistance	B-MED
against	O
diarrheal	B-MED
pathogens	B-MED
.	O
Further	O
research	B-MED
might	O
lead	O
to	O
the	O
development	B-MED
of	O
next	B-MED
-	I-MED
generation	I-MED
probiotics	I-MED
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-MED
resistance	B-MED
and	O
thus	O
prevent	B-MED
travellers	B-MED
'	I-MED
diarrheal	I-MED
.	O
A	O
new	O
angle	B-MED
and	O
its	O
relationship	O
with	O
early	O
fixation	B-MED
failure	I-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	B-MED
is	O
difficult	O
because	O
of	O
deformity	B-MED
of	O
the	O
affected	B-MED
lower	B-MED
extremity	I-MED
.	O
Therefore	O
we	O
designed	O
a	O
new	O
measurement	B-MED
of	O
the	O
orientation	B-MED
of	O
femoral	B-MED
neck	I-MED
fracture	I-MED
and	O
applied	O
this	O
in	O
a	O
retrospective	B-MED
study	I-MED
to	O
assess	O
:	O
(	O
1	O
)	O
its	O
reproducibility	B-MED
,	O
(	O
2	O
)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle	O
,	O
(	O
3	O
)	O
its	O
relationship	O
with	O
the	O
short	B-MED
-	I-MED
term	I-MED
prognosis	I-MED
treated	B-MED
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
.	O
This	O
new	O
measurement	B-MED
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
.	O
Two	O
hundred	O
and	O
twenty	O
-	O
eight	O
patients	B-MED
with	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
three	O
cannulated	B-MED
compression	I-MED
screws	I-MED
were	O
retrospectively	B-MED
analyzed	I-MED
.	O
The	O
VN	O
angle	O
,	O
which	O
was	O
the	O
angle	B-MED
between	O
the	O
fracture	B-MED
line	I-MED
and	O
the	O
vertical	B-MED
of	O
the	O
neck	B-MED
axis	I-MED
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O
The	O
method	O
of	O
ICC	B-MED
was	O
performed	O
to	O
assess	O
the	O
reproducibility	B-MED
of	O
the	O
two	O
angles	B-MED
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre	B-MED
-	I-MED
operative	I-MED
and	O
post	B-MED
-	I-MED
operative	I-MED
radiographs	B-MED
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	B-MED
.	O
These	O
fractures	B-MED
were	O
divided	O
into	O
four	O
groups	B-MED
according	O
to	O
VN	O
angle	O
(	O
VN<0	O
°	O
(	O
n=92	O
)	O
,	O
0	O
°	O
≤VN<10	O
°	O
(	O
n=82	O
)	O
,	O
10	O
°	O
≤VN<15	O
°	O
(	O
n=26	O
)	O
,	O
VN≥15	O
°	O
(	O
n=28	O
)	O
)	O
,	O
and	O
the	O
short	O
-	O
term	O
(	O
within	O
6	O
months	B-MED
)	O
fixation	B-MED
results	O
of	O
radiographs	B-MED
in	O
these	O
fractures	B-MED
were	O
evaluated	O
.	O
The	O
ICC	B-MED
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre	B-MED
-	I-MED
operative	I-MED
radiographs	B-MED
were	O
0.937	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
):	O
0.922	O
-	O
0.950	O
)	O
and	O
0.942	O
respectively	O
(	O
95	O
%	O
CI	B-MED
:	O
0.914	O
-	O
0.970	O
)	O
,	O
indicating	O
both	O
angles	B-MED
had	O
a	O
good	O
inter	B-MED
-	I-MED
rater	I-MED
reproducibility	I-MED
.	O
However	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre	B-MED
-	I-MED
operative	I-MED
and	O
post	B-MED
-	I-MED
operative	I-MED
radiographs	B-MED
(	O
P=0.037	O
)	O
,	O
the	O
absolute	O
difference	O
was	O
10.66±6.47	O
(	O
range	O
:	O
1.72	O
-	O
38.48	O
)	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(	O
P=0.084	O
)	O
and	O
the	O
absolute	O
difference	O
was	O
2.20±1.63	O
(	O
range	O
:	O
0.05	O
-	O
7.56	O
)	O
.	O
The	O
overall	O
fixation	B-MED
failure	I-MED
rate	B-MED
which	O
was	O
defined	O
as	O
screw	B-MED
loosening	I-MED
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	B-MED
displacement	I-MED
or	O
femoral	B-MED
neck	I-MED
shortening	O
was	O
11.84	O
%	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0	O
%	O
,	O
3.24	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
1.64	O
-	O
4.84	O
)	O
,	O
22.69	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
16.43	O
-	O
28.96	O
)	O
,	O
65.45	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
59.36	O
-	O
71.53	O
)	O
.	O
The	O
mean	O
failure	B-MED
rates	I-MED
of	O
fractures	B-MED
according	O
to	O
post	B-MED
-	I-MED
operative	I-MED
Pauwels	O
angle	O
(	O
<	O
30	O
°	O
,	O
30	O
-	O
50	O
°	O
,	O
>	O
50	O
°	O
)	O
were	O
respectively	O
0	O
%	O
,	O
1.46	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
1.42	O
-	O
1.50	O
)	O
and	O
36.24	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
34.93	O
-	O
37.54	O
)	O
.	O
The	O
VN	O
angle	O
has	O
a	O
good	O
inter	B-MED
-	I-MED
rater	I-MED
reproducibility	I-MED
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short	B-MED
-	I-MED
term	I-MED
prognosis	I-MED
of	O
femoral	B-MED
neck	I-MED
fractures	I-MED
treated	O
with	O
cannulated	B-MED
compression	I-MED
screws	I-MED
.	O
Level	O
IV	O
,	O
retrospective	O
diagnostic	O
study	O
.	O
Identification	B-MED
of	O
the	O
anti	B-MED
-	I-MED
mycobacterial	I-MED
functional	B-MED
properties	B-MED
of	O
piperidinol	B-MED
derivatives	I-MED
Tuberculosis	B-MED
(	O
TB	B-MED
)	O
remains	O
a	O
major	O
global	B-MED
health	B-MED
threat	B-MED
and	O
is	O
now	O
the	O
leading	O
cause	B-MED
of	I-MED
death	I-MED
from	O
a	O
single	O
infectious	B-MED
agent	I-MED
worldwide	B-MED
.	O
The	O
current	O
TB	B-MED
drug	B-MED
regimen	B-MED
is	O
inadequate	B-MED
,	O
and	O
new	O
anti	B-MED
-	I-MED
tubercular	I-MED
agents	I-MED
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	B-MED
of	O
drug	B-MED
-	I-MED
resistant	I-MED
TB	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
a	O
piperidinol	B-MED
compound	I-MED
derivative	I-MED
that	O
is	O
highly	O
active	B-MED
against	O
the	O
Mycobacterium	B-MED
tuberculosis	I-MED
bacillus	B-MED
.	O
The	O
antibacterial	B-MED
properties	B-MED
of	O
the	O
piperidinol	B-MED
compound	I-MED
and	O
its	O
corresponding	O
bis	B-MED
-	I-MED
Mannich	I-MED
base	I-MED
analogue	B-MED
were	O
evaluated	B-MED
against	O
M.	B-MED
smegmatis	I-MED
and	O
Gram	B-MED
-	I-MED
negative	I-MED
organisms	I-MED
.	O
Cytotoxicity	B-MED
studies	B-MED
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity	B-MED
index	I-MED
for	O
these	O
compounds	B-MED
.	O
Spontaneous	O
resistant	B-MED
mutants	B-MED
of	O
M.	B-MED
smegmatis	I-MED
were	O
generated	O
against	O
the	O
piperidinol	B-MED
and	O
corresponding	O
bis	B-MED
-	I-MED
Mannich	I-MED
base	I-MED
lead	I-MED
derivatives	I-MED
and	O
whole	O
genome	B-MED
sequencing	I-MED
employed	O
to	O
determine	O
the	O
genetic	B-MED
modifications	I-MED
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-MED
.	O
The	O
piperidinol	B-MED
and	O
the	O
bis	B-MED
-	I-MED
Mannich	I-MED
base	I-MED
analogue	I-MED
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-MED
and	O
rapidly	O
kill	O
this	O
organism	B-MED
with	O
a	O
cytotoxicity	B-MED
selectivity	B-MED
index	I-MED
for	O
mycobacteria	B-MED
of	O
>	O
30	O
-	O
fold	O
.	O
Whole	O
genome	B-MED
sequencing	I-MED
of	O
M.	B-MED
smegmatis	I-MED
strains	B-MED
resistant	B-MED
to	O
the	O
lead	B-MED
compounds	I-MED
led	O
to	O
the	O
identification	B-MED
of	O
a	O
number	O
of	O
single	B-MED
nucleotide	I-MED
polymorphisms	I-MED
indicating	O
multiple	O
targets	O
.	O
Our	O
results	B-MED
indicate	O
that	O
the	O
piperidinol	B-MED
moiety	I-MED
represents	O
an	O
attractive	O
compound	B-MED
class	I-MED
in	O
the	O
pursuit	O
of	O
novel	O
anti	B-MED
-	I-MED
tubercular	I-MED
agents	I-MED
.	O
A	O
role	O
for	O
the	O
locus	B-MED
coeruleus	I-MED
in	O
the	O
analgesic	B-MED
efficacy	I-MED
of	O
N	B-MED
-	I-MED
acetylaspartylglutamate	I-MED
peptidase	I-MED
(	O
GCPII	B-MED
)	O
inhibitors	B-MED
ZJ43	B-MED
and	O
2	B-MED
-	I-MED
PMPA	I-MED
N	B-MED
-	I-MED
acetylaspartylglutamate	I-MED
(	O
NAAG	B-MED
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B-MED
in	O
the	O
mammalian	B-MED
nervous	B-MED
system	I-MED
.	O
NAAG	B-MED
activates	B-MED
a	O
group	B-MED
II	I-MED
metabotropic	I-MED
glutamate	I-MED
receptor	I-MED
(	O
mGluR3	B-MED
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	B-MED
enzyme	I-MED
,	I-MED
glutamate	I-MED
carboxypeptidase	I-MED
II	I-MED
(	O
GCPII	B-MED
)	O
in	B-MED
vivo	I-MED
.	O
Inhibitors	B-MED
of	I-MED
this	I-MED
enzyme	I-MED
are	O
analgesic	B-MED
in	O
animal	B-MED
models	I-MED
of	O
inflammatory	B-MED
,	O
neuropathic	B-MED
and	O
bone	B-MED
cancer	I-MED
pain	B-MED
.	O
NAAG	B-MED
and	O
GCPII	B-MED
are	O
present	O
in	O
the	O
locus	B-MED
coeruleus	I-MED
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	B-MED
inhibitory	B-MED
pain	O
system	O
.	O
In	O
the	O
formalin	B-MED
footpad	B-MED
model	B-MED
,	O
systemic	B-MED
treatment	B-MED
with	O
GCPII	B-MED
inhibitors	I-MED
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-MED
pain	I-MED
response	B-MED
and	O
increases	O
release	O
of	O
spinal	B-MED
noradrenaline	B-MED
.	O
This	O
analgesic	B-MED
efficacy	I-MED
is	O
blocked	B-MED
by	O
systemic	B-MED
injection	B-MED
of	O
a	O
group	B-MED
II	I-MED
mGluR	I-MED
antagonist	B-MED
,	O
by	O
intrathecal	B-MED
(	I-MED
spinal	I-MED
)	I-MED
injection	I-MED
of	O
an	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptor	I-MED
antagonist	I-MED
and	O
by	O
microinjection	B-MED
of	O
an	O
α	B-MED
-	I-MED
amino-3	I-MED
-	I-MED
hydroxy-5	I-MED
-	I-MED
methylisoxazole-4	I-MED
-	I-MED
propionic	I-MED
acid	I-MED
(	I-MED
AMPA	I-MED
)	I-MED
receptor	I-MED
antagonist	I-MED
directly	O
into	O
the	O
contralateral	B-MED
locus	B-MED
coeruleus	I-MED
.	O
Footpad	B-MED
inflammation	B-MED
increases	O
release	O
of	O
glutamate	B-MED
in	O
the	O
contralateral	B-MED
locus	B-MED
coeruleu	I-MED
s	O
and	O
systemic	B-MED
treatment	B-MED
with	O
a	O
GCPII	B-MED
inhibitor	I-MED
blocks	B-MED
this	O
increase	O
.	O
Direct	B-MED
injection	B-MED
of	O
GCPII	B-MED
inhibitors	I-MED
into	O
the	O
contralateral	B-MED
or	O
ipsilatera	B-MED
l	O
locus	B-MED
coeruleus	I-MED
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-MED
pain	I-MED
response	B-MED
in	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
and	O
the	O
contralateral	B-MED
effect	B-MED
also	O
is	O
blocked	B-MED
by	O
intrathecal	B-MED
injection	I-MED
of	O
an	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptor	I-MED
antagonist	I-MED
.	O
These	O
data	O
support	O
the	O
hypothesis	B-MED
that	O
the	O
analgesic	B-MED
efficacy	I-MED
of	O
systemically	O
administered	O
GCPII	B-MED
inhibitors	I-MED
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	B-MED
l	O
locus	B-MED
coeruleus	I-MED
via	O
group	B-MED
II	I-MED
mGluR	I-MED
,	O
AMPA	B-MED
and	O
alpha	B-MED
2	I-MED
adrenergic	I-MED
receptors	I-MED
.	O
Safety	B-MED
of	O
transradial	B-MED
diagnostic	I-MED
cardiac	I-MED
catheterization	I-MED
in	O
patients	B-MED
under	O
oral	B-MED
anticoagulant	B-MED
therapy	I-MED
Cardiac	B-MED
catheterization	I-MED
in	O
anticoagulated	B-MED
patients	B-MED
is	O
usually	O
performed	B-MED
after	O
the	O
anticoagulation	B-MED
has	O
been	O
withdrawn	B-MED
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-MED
therapy	I-MED
with	I-MED
heparin	I-MED
is	O
used	O
.	O
A	O
prospective	O
observational	B-MED
study	I-MED
including	O
489	O
patients	B-MED
undergoing	O
transradial	B-MED
catheterization	I-MED
was	O
conducted	O
.	O
A	O
total	O
of	O
140	O
patients	B-MED
were	O
under	O
acenocoumarol	B-MED
(	O
group	B-MED
A	I-MED
)	O
and	O
they	O
were	O
compared	B-MED
with	O
the	O
remainder	B-MED
(	O
group	B-MED
B	I-MED
)	O
for	O
complications	B-MED
after	O
the	O
procedure	B-MED
(	O
bleeding	B-MED
and	O
vascular	B-MED
access	I-MED
complications	I-MED
)	O
.	O
Patients	B-MED
in	O
group	B-MED
A	I-MED
were	O
older	B-MED
(	O
74±12	O
years	O
vs.	O
68±17	O
years	O
,	O
p<0.01	O
)	O
and	O
the	O
main	O
indication	B-MED
for	O
anticoagulation	B-MED
was	O
atrial	B-MED
fibrillation	I-MED
(	O
58.6	O
%	O
)	O
.	O
No	B-MED
complications	B-MED
occurred	O
during	O
the	O
procedures	B-MED
.	O
There	O
were	O
no	B-MED
acute	B-MED
bleedings	I-MED
just	O
after	B-MED
the	O
bandage	B-MED
removal	B-MED
.	O
During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2.1	O
%	O
)	O
radial	B-MED
occlusions	I-MED
in	O
group	B-MED
A	I-MED
and	O
2	O
(	O
0.6	O
%	O
)	O
in	O
group	B-MED
B	I-MED
(	O
p=0.14	O
)	O
were	O
recorded	B-MED
.	O
Hematomas	B-MED
between	O
5	O
and	O
10	O
cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	B-MED
A	I-MED
vs.	O
4.6	O
%	O
in	O
group	B-MED
B	I-MED
B.	O
During	O
the	O
1	B-MED
-	I-MED
month	I-MED
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
,	O
one	O
more	O
radial	B-MED
occlusion	I-MED
in	O
each	O
group	B-MED
was	O
recorded	B-MED
and	O
there	O
were	O
4	O
(	O
1.1	O
%	O
)	O
additional	O
mild	B-MED
hematomas	B-MED
in	O
group	B-MED
B	I-MED
and	O
none	O
in	O
group	B-MED
A	I-MED
(	O
p=0.48	O
)	O
.	O
Performing	B-MED
a	O
transradial	B-MED
diagnostic	I-MED
cardiac	I-MED
catheterization	I-MED
without	B-MED
removal	B-MED
of	O
the	O
oral	B-MED
chronic	B-MED
anticoagulation	I-MED
appears	O
safe	B-MED
in	O
patients	B-MED
under	O
acenocumarol	B-MED
therapy	B-MED
.	O
Nutritional	B-MED
aspects	I-MED
of	O
night	B-MED
eating	B-MED
and	O
its	O
association	B-MED
with	I-MED
weight	B-MED
status	B-MED
among	O
Korean	B-MED
adolescents	B-MED
A	O
growing	B-MED
body	O
of	O
research	B-MED
has	O
indicated	O
that	O
night	B-MED
eating	B-MED
could	O
be	O
associated	B-MED
with	I-MED
poor	B-MED
diet	I-MED
quality	B-MED
and	O
negative	B-MED
health	B-MED
outcomes	I-MED
.	O
This	O
study	B-MED
examined	O
the	O
nutritional	B-MED
aspects	I-MED
of	O
night	B-MED
eating	B-MED
,	O
its	O
related	O
factors	B-MED
,	O
and	O
the	O
association	B-MED
between	O
night	B-MED
eating	B-MED
and	O
body	B-MED
weight	I-MED
among	O
Korean	B-MED
adolescents	B-MED
.	O
This	O
study	B-MED
analysed	O
the	O
data	B-MED
from	O
a	O
one	O
day	B-MED
24	O
-	O
hour	O
dietary	B-MED
recall	I-MED
as	O
well	O
as	O
a	O
demographic	B-MED
survey	I-MED
of	O
1,738	O
Korean	B-MED
adolescents	B-MED
aged	O
12	O
to	O
18-	O
years	B-MED
-old	O
obtained	O
from	O
the	O
2010	O
-	O
2012	O
Korea	B-MED
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
.	O
'	O
Night	B-MED
eating	B-MED
'	O
was	O
defined	O
as	O
consuming	O
25	O
%	O
or	O
more	O
of	O
one	O
's	O
daily	B-MED
energy	I-MED
intake	I-MED
between	O
21:00	O
and	O
06:00	O
.	O
Subjects	B-MED
complying	O
with	O
the	O
preceding	O
condition	B-MED
were	O
classified	O
as	O
'	O
night	B-MED
eaters	B-MED
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non	B-MED
-	I-MED
night	I-MED
eaters	I-MED
'	O
.	O
Logistic	B-MED
regression	I-MED
analysis	I-MED
examined	O
factors	B-MED
related	O
to	O
night	B-MED
eating	B-MED
.	O
Multiple	B-MED
linear	I-MED
regression	I-MED
analyses	I-MED
were	O
used	O
to	O
examine	O
the	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
BMI	B-MED
z	B-MED
-	I-MED
scores	I-MED
,	O
whereas	O
multinomial	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
examine	O
the	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
weight	B-MED
status	B-MED
.	O
About	O
21	O
%	O
of	O
Korean	B-MED
adolescents	B-MED
appeared	O
to	O
be	O
night	B-MED
eaters	B-MED
.	O
Night	B-MED
eaters	B-MED
showed	O
increased	B-MED
breakfast	B-MED
skipping	B-MED
(	O
P	O
=	O
0.001	O
)	O
,	O
higher	O
energy	B-MED
intake	I-MED
from	O
snacks	B-MED
(	O
P	O
<	O
0.001	O
)	O
,	O
greater	O
proportion	B-MED
of	I-MED
energy	I-MED
intake	I-MED
from	I-MED
fat	I-MED
(	O
P	O
=	O
0.029	O
)	O
,	O
and	O
lower	B-MED
Dietary	I-MED
Diversity	I-MED
Scores	I-MED
(	O
P	O
=	O
0.008	O
)	O
than	O
non	B-MED
-	I-MED
night	I-MED
eaters	I-MED
.	O
Male	B-MED
adolescents	B-MED
presented	O
1.9	O
times	B-MED
higher	O
odds	O
of	O
being	O
night	B-MED
eaters	B-MED
than	O
females	B-MED
.	O
Adolescents	B-MED
whose	O
both	O
parents	B-MED
were	O
night	B-MED
eaters	B-MED
were	O
4.4	O
times	B-MED
as	O
likely	O
to	O
be	O
night	B-MED
eaters	B-MED
as	O
those	O
whose	O
neither	O
parents	B-MED
were	O
.	O
Female	B-MED
adolescents	B-MED
showed	O
a	O
significant	O
relationship	B-MED
between	O
night	B-MED
eating	B-MED
and	O
BMI	B-MED
z	B-MED
-	I-MED
scores	I-MED
(	O
β	O
=	O
0.28	O
,	O
P	O
=	O
0.004	O
)	O
.	O
However	O
,	O
night	B-MED
eating	B-MED
did	O
not	O
increase	B-MED
odds	O
of	O
being	O
overweight	B-MED
or	O
obese	B-MED
in	O
adolescents	B-MED
.	O
Night	B-MED
eating	B-MED
in	O
Korean	B-MED
adolescents	B-MED
was	O
related	O
to	O
undesirable	B-MED
dietary	I-MED
behaviours	I-MED
and	O
low	B-MED
diet	I-MED
quality	I-MED
in	O
general	O
as	O
well	O
as	O
higher	O
BMI	B-MED
z	B-MED
-	I-MED
scores	I-MED
in	O
females	B-MED
.	O
Male	B-MED
gender	B-MED
and	O
parental	B-MED
night	B-MED
eating	B-MED
appeared	O
to	O
be	O
the	O
factors	B-MED
that	O
significantly	O
increased	B-MED
odds	O
of	O
night	B-MED
eating	B-MED
.	O
These	O
results	O
suggest	O
that	O
night	B-MED
eating	B-MED
should	O
be	O
considered	O
when	O
designing	O
nutrition	B-MED
education	I-MED
or	O
intervention	B-MED
programs	I-MED
targeting	O
adolescents	B-MED
.	O
Selective	B-MED
reaching	B-MED
in	O
macaques	B-MED
:	O
evidence	B-MED
for	O
action	B-MED
-centred	O
attention	B-MED
When	O
a	O
monkey	B-MED
selects	B-MED
a	O
piece	O
of	O
food	B-MED
lying	O
on	O
the	O
ground	O
from	O
among	O
other	B-MED
viable	B-MED
objects	B-MED
in	O
the	O
near	B-MED
vicinity	B-MED
,	O
only	O
the	O
desired	B-MED
item	B-MED
governs	B-MED
the	O
particular	O
pattern	B-MED
and	O
direction	B-MED
of	O
the	O
animal	B-MED
's	I-MED
reaching	B-MED
action	B-MED
.	O
It	O
would	O
seem	O
then	O
that	O
selection	B-MED
is	O
an	O
important	B-MED
component	B-MED
controlling	B-MED
the	O
animal	B-MED
's	I-MED
action	B-MED
.	O
But	O
,	O
we	O
may	O
ask	O
,	O
is	O
the	O
selection	B-MED
process	B-MED
in	O
such	O
cases	B-MED
impervious	O
to	O
the	O
presence	B-MED
of	O
other	B-MED
objects	B-MED
that	O
could	O
constitute	B-MED
potential	B-MED
obstacles	B-MED
to	O
or	O
constraints	B-MED
on	O
movement	B-MED
execution	B-MED
?	O
And	O
if	O
it	O
is	O
,	O
in	O
fact	O
,	O
pervious	B-MED
to	O
other	B-MED
objects	B-MED
,	O
do	O
they	O
have	O
a	O
direct	B-MED
influence	B-MED
on	O
the	O
organization	B-MED
of	O
the	O
response	B-MED
?	O
The	O
kinematics	B-MED
of	O
macaques	B-MED
'	O
reaching	B-MED
movements	B-MED
were	O
examined	B-MED
by	O
the	O
current	B-MED
study	B-MED
that	O
analysed	B-MED
some	O
exemplars	O
as	O
they	O
selectively	B-MED
reached	B-MED
to	O
grasp	B-MED
a	O
food	B-MED
item	I-MED
in	O
the	O
absence	B-MED
as	O
well	O
as	O
in	O
the	O
presence	B-MED
of	O
potential	B-MED
obstacles	B-MED
(	O
i.e.	O
,	O
stones	B-MED
)	O
that	O
could	O
affect	B-MED
the	O
arm	B-MED
trajectory	B-MED
.	O
Changes	B-MED
in	O
movement	B-MED
parameterization	B-MED
were	O
noted	B-MED
in	O
temporal	B-MED
measures	B-MED
,	O
such	O
as	O
movement	B-MED
time	B-MED
,	O
as	O
well	O
as	O
in	O
spatial	B-MED
ones	I-MED
,	O
such	O
as	O
paths	O
of	O
trajectory	B-MED
.	O
Generally	O
speaking	O
,	O
the	O
presence	B-MED
of	O
stones	B-MED
in	O
the	O
vicinity	B-MED
of	O
the	O
acting	B-MED
hand	B-MED
stalled	B-MED
the	O
reaching	B-MED
movement	B-MED
and	O
affected	B-MED
the	O
arm	B-MED
trajectory	B-MED
as	O
the	O
hand	B-MED
veered	B-MED
away	I-MED
from	O
the	O
stone	B-MED
even	O
when	O
it	O
was	O
not	B-MED
a	O
physical	B-MED
obstacle	B-MED
.	O
We	O
concluded	O
that	O
nearby	B-MED
objects	B-MED
evoke	O
a	O
motor	B-MED
response	I-MED
in	O
macaques	B-MED
,	O
and	O
the	O
attentional	B-MED
mechanisms	B-MED
that	O
allow	O
for	O
a	O
successful	B-MED
action	B-MED
selection	B-MED
are	O
revealed	B-MED
in	O
the	O
reaching	B-MED
path	B-MED
.	O
The	O
data	B-MED
outlined	O
here	O
concur	O
with	O
human	B-MED
studies	B-MED
indicating	B-MED
that	O
potential	B-MED
obstacles	B-MED
are	O
internally	B-MED
represented	B-MED
,	O
a	O
finding	B-MED
implying	O
basic	B-MED
cognitive	B-MED
operations	B-MED
allowing	O
for	O
action	B-MED
selection	B-MED
in	O
macaques	B-MED
.	O
Delta	B-MED
-	I-MED
frequency	I-MED
stimulation	B-MED
of	O
cerebellar	B-MED
projections	B-MED
can	O
compensate	B-MED
for	O
schizophrenia	B-MED
-related	O
medial	B-MED
frontal	I-MED
dysfunction	I-MED
Schizophrenia	B-MED
involves	O
abnormalities	B-MED
in	O
the	O
medial	B-MED
frontal	I-MED
cortex	I-MED
that	O
lead	O
to	O
cognitive	B-MED
deficits	I-MED
.	O
Here	O
we	O
investigate	B-MED
a	O
novel	B-MED
strategy	B-MED
to	O
normalize	B-MED
medial	B-MED
frontal	I-MED
brain	I-MED
activity	B-MED
by	O
stimulating	B-MED
cerebellar	B-MED
projections	B-MED
.	O
We	O
used	O
an	O
interval	B-MED
timing	I-MED
task	O
to	O
study	B-MED
elementary	O
cognitive	B-MED
processing	I-MED
that	O
requires	O
both	O
frontal	B-MED
and	O
cerebellar	B-MED
networks	I-MED
that	O
are	O
disrupted	B-MED
in	O
patients	B-MED
with	O
schizophrenia	B-MED
.	O
We	O
report	O
three	O
novel	B-MED
findings	B-MED
.	O
First	O
,	O
patients	B-MED
with	O
schizophrenia	B-MED
had	O
dysfunctional	O
delta	B-MED
rhythms	I-MED
between	O
1	O
-	O
4	O
Hz	O
in	O
the	O
medial	B-MED
frontal	I-MED
cortex	I-MED
.	O
We	O
explored	O
cerebellar	B-MED
-	O
frontal	B-MED
interactions	B-MED
in	O
animal	B-MED
models	I-MED
and	O
found	O
that	O
both	O
frontal	B-MED
and	O
cerebellar	B-MED
neurons	I-MED
were	O
modulated	B-MED
during	O
interval	B-MED
timing	I-MED
and	O
had	O
delta	B-MED
-	I-MED
frequency	I-MED
interactions	B-MED
.	O
Finally	O
,	O
delta	B-MED
-	I-MED
frequency	I-MED
optogenetic	B-MED
stimulation	B-MED
of	O
thalamic	B-MED
synaptic	B-MED
terminals	I-MED
of	O
lateral	B-MED
cerebellar	B-MED
projection	B-MED
neurons	B-MED
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial	B-MED
frontal	I-MED
activity	B-MED
in	O
a	O
rodent	B-MED
model	I-MED
of	O
schizophrenia	B-MED
-	I-MED
related	I-MED
frontal	B-MED
dysfunction	I-MED
.	O
These	O
data	B-MED
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-MED
influences	B-MED
medial	B-MED
frontal	I-MED
networks	I-MED
and	O
the	O
role	O
of	O
the	O
cerebellum	B-MED
in	O
cognitive	B-MED
processing	I-MED
.	O
eNOS	B-MED
S	B-MED
-	I-MED
nitrosylates	I-MED
β	B-MED
-	I-MED
actin	I-MED
on	O
Cys374	B-MED
and	O
regulates	B-MED
PKC	B-MED
-	I-MED
θ	I-MED
at	O
the	O
immune	B-MED
synapse	I-MED
by	O
impairing	B-MED
actin	B-MED
binding	I-MED
to	O
profilin-1	B-MED
The	O
actin	B-MED
cytoskeleton	I-MED
coordinates	I-MED
the	I-MED
organization	I-MED
of	O
signaling	B-MED
microclusters	I-MED
at	O
the	O
immune	B-MED
synapse	I-MED
(	O
IS	B-MED
)	O
;	O
however	O
,	O
the	O
mechanisms	B-MED
involved	O
remain	O
poorly	O
understood	O
.	O
We	O
show	O
here	O
that	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
generated	O
by	O
endothelial	B-MED
nitric	I-MED
oxide	I-MED
synthase	I-MED
(	O
eNOS	B-MED
)	O
controls	O
the	O
coalescence	O
of	O
protein	B-MED
kinase	I-MED
C	I-MED
-	I-MED
θ	I-MED
(	O
PKC	B-MED
-	I-MED
θ	I-MED
)	O
at	O
the	O
central	B-MED
supramolecular	I-MED
activation	I-MED
cluster	I-MED
(	O
c	B-MED
-	I-MED
SMAC	I-MED
)	O
of	O
the	O
IS	B-MED
.	O
eNOS	B-MED
translocated	B-MED
with	O
the	O
Golgi	B-MED
to	O
the	O
IS	B-MED
and	O
partially	O
colocalized	B-MED
with	O
F	B-MED
-	I-MED
actin	I-MED
around	O
the	O
c	B-MED
-	I-MED
SMAC	I-MED
.	O
This	O
resulted	O
in	O
reduced	O
actin	B-MED
polymerization	I-MED
and	O
centripetal	O
retrograde	B-MED
flow	I-MED
of	O
β	B-MED
-	I-MED
actin	I-MED
and	O
PKC	B-MED
-	I-MED
θ	I-MED
from	O
the	O
lamellipodium	B-MED
-	I-MED
like	I-MED
distal	B-MED
(	B-MED
d)-SMAC	I-MED
,	O
promoting	B-MED
PKC	B-MED
-	I-MED
θ	I-MED
activation	B-MED
.	O
Furthermore	O
,	O
eNOS	B-MED
-derived	O
NO	B-MED
S	B-MED
-	I-MED
nitrosylated	I-MED
β	B-MED
-	I-MED
actin	I-MED
on	O
Cys374	B-MED
and	O
impaired	B-MED
actin	B-MED
binding	I-MED
to	O
profilin-1	B-MED
(	O
PFN1	B-MED
)	O
,	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	B-MED
agent	O
S	B-MED
-	I-MED
nitroso	I-MED
-	I-MED
L	I-MED
-	I-MED
cysteine	I-MED
(	O
Cys	B-MED
-	I-MED
NO	I-MED
)	O
.	O
The	O
importance	O
of	O
NO	B-MED
and	O
the	O
formation	O
of	O
PFN1	B-MED
-	I-MED
actin	I-MED
complexes	I-MED
on	O
the	O
regulation	B-MED
of	O
PKC	B-MED
-	I-MED
θ	I-MED
was	O
corroborated	O
by	O
overexpression	B-MED
of	O
PFN1	B-MED
-	O
and	O
actin	B-MED
-	I-MED
binding	I-MED
defective	O
mutants	B-MED
of	O
β	B-MED
-	I-MED
actin	I-MED
(	I-MED
C374S	I-MED
)	I-MED
and	O
PFN1	B-MED
(	I-MED
H119E	I-MED
)	I-MED
,	O
respectively	O
,	O
which	O
reduced	O
the	O
coalescence	O
of	O
PKC	B-MED
-	I-MED
θ	I-MED
at	O
the	O
c	B-MED
-	I-MED
SMAC	I-MED
.	O
These	O
findings	O
unveil	O
a	O
novel	O
NO	B-MED
-dependent	O
mechanism	B-MED
by	O
which	O
the	O
actin	B-MED
cytoskeleton	I-MED
controls	I-MED
the	I-MED
organization	I-MED
and	O
activation	B-MED
of	O
signaling	B-MED
microclusters	I-MED
at	O
the	O
IS	B-MED
.	O
Stromal	B-MED
alterations	I-MED
in	O
ovarian	B-MED
cancers	I-MED
via	O
wavelength	B-MED
dependent	B-MED
Second	B-MED
Harmonic	I-MED
Generation	I-MED
microscopy	I-MED
and	O
optical	B-MED
scattering	I-MED
Ovarian	B-MED
cancer	I-MED
remains	O
the	O
most	O
deadly	O
gynecological	B-MED
cancer	B-MED
with	O
a	O
poor	O
aggregate	O
survival	B-MED
rate	I-MED
;	O
however	O
,	O
the	O
specific	B-MED
rates	I-MED
are	O
highly	O
dependent	B-MED
on	O
the	O
stage	O
of	O
the	O
disease	B-MED
upon	O
diagnosis	B-MED
.	O
Current	O
screening	B-MED
and	O
imaging	B-MED
tools	I-MED
are	O
insufficient	O
to	O
detect	O
early	B-MED
lesions	I-MED
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	B-MED
of	O
ovarian	B-MED
cancer	I-MED
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-MED
.	O
As	O
an	O
alternative	O
to	O
current	O
screening	B-MED
and	O
imaging	B-MED
tools	I-MED
,	O
we	O
utilized	O
wavelength	B-MED
dependent	B-MED
collagen	B-MED
-specific	O
Second	B-MED
Harmonic	I-MED
Generation	I-MED
(	I-MED
SHG	I-MED
)	I-MED
imaging	I-MED
microscopy	I-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
to	O
probe	O
the	O
structural	B-MED
differences	B-MED
in	O
the	O
extracellular	B-MED
matrix	I-MED
(	O
ECM	B-MED
)	O
of	O
normal	O
stroma	B-MED
,	O
benign	B-MED
tumors	I-MED
,	O
endometrioid	B-MED
tumors	I-MED
,	O
and	O
low	B-MED
and	O
high	B-MED
-	I-MED
grade	I-MED
serous	I-MED
tumors	I-MED
.	O
The	O
SHG	B-MED
signatures	B-MED
of	O
the	O
emission	O
directionality	O
and	O
conversion	B-MED
efficiency	B-MED
as	O
well	O
as	O
the	O
optical	B-MED
scattering	I-MED
are	O
related	O
to	O
the	O
organization	B-MED
of	O
collagen	B-MED
on	O
the	O
sub	B-MED
-	I-MED
micron	I-MED
size	B-MED
scale	I-MED
and	O
encode	O
structural	B-MED
information	B-MED
.	O
The	O
wavelength	B-MED
dependence	B-MED
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	B-MED
and	O
distribution	B-MED
of	O
collagen	B-MED
fibrils	I-MED
/	O
fibers	B-MED
relative	O
to	O
the	O
interrogating	O
wavelengths	B-MED
.	O
We	O
found	O
a	O
strong	O
wavelength	B-MED
dependence	B-MED
of	O
these	O
metrics	B-MED
that	O
are	O
related	O
to	O
significant	O
structural	B-MED
differences	B-MED
in	O
the	O
collagen	B-MED
organization	B-MED
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	B-MED
of	O
type	B-MED
I	I-MED
and	I-MED
II	I-MED
serous	I-MED
tumors	I-MED
.	O
Moreover	O
,	O
type	B-MED
I	I-MED
endometrioid	I-MED
tumors	I-MED
have	O
strongly	O
differing	O
ECM	B-MED
architecture	O
than	O
the	O
serous	B-MED
malignancies	I-MED
.	O
The	O
SHG	B-MED
metrics	B-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
were	O
used	O
to	O
form	O
a	O
linear	B-MED
discriminant	I-MED
model	I-MED
to	O
classify	O
the	O
tissues	B-MED
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high	B-MED
-	I-MED
grade	I-MED
serous	I-MED
tumors	I-MED
from	O
the	O
other	O
tissue	B-MED
types	I-MED
.	O
High	B-MED
-	I-MED
grade	I-MED
serous	I-MED
tumors	I-MED
account	O
for	O
~70	O
%	O
of	O
ovarian	B-MED
cancers	I-MED
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	B-MED
analysis	I-MED
,	O
understanding	O
the	O
etiology	B-MED
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	B-MED
vivo	I-MED
screening	B-MED
tool	I-MED
.	O
SHG	B-MED
and	O
optical	B-MED
scattering	I-MED
measurements	I-MED
provide	O
sub	O
-	O
resolution	O
information	B-MED
and	O
when	O
combined	O
provide	O
superior	B-MED
diagnostic	I-MED
power	I-MED
over	O
clinical	B-MED
imaging	I-MED
modalities	B-MED
.	O
Additionally	O
the	O
measurements	B-MED
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	B-MED
of	O
ovarian	B-MED
cancer	I-MED
and	O
may	O
potentially	O
assist	O
in	O
treatment	B-MED
protocols	I-MED
.	O
Understanding	O
the	O
altered	B-MED
collagen	B-MED
assembly	O
can	O
supplement	O
histological	B-MED
analysis	I-MED
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	B-MED
.	O
These	O
methods	O
could	O
become	O
an	O
in	B-MED
vivo	I-MED
screening	B-MED
tool	I-MED
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	B-MED
malignancies	I-MED
can	O
metastasize	B-MED
while	O
undetectable	O
by	O
current	O
clinical	B-MED
imaging	I-MED
resolution	O
.	O
Benefit	O
and	O
risk	B-MED
in	O
short	O
term	O
after	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
by	O
direct	B-MED
anterior	I-MED
approach	I-MED
combined	O
with	O
dual	B-MED
mobility	I-MED
cup	I-MED
No	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-MED
associated	O
with	O
the	O
dual	B-MED
mobility	I-MED
cup	I-MED
(	O
DMC	B-MED
)	O
in	O
primary	O
THA	B-MED
via	O
direct	B-MED
anterior	I-MED
approach	I-MED
(	O
DAA	B-MED
)	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
compare	O
the	O
safety	B-MED
and	O
rate	O
of	O
early	O
postoperative	B-MED
complication	I-MED
of	O
the	O
DAA	B-MED
with	O
the	O
DMC	B-MED
for	O
THA	B-MED
with	O
those	O
of	O
the	O
DAA	B-MED
with	O
a	O
single	B-MED
standard	I-MED
cup	I-MED
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
We	O
retrospectively	O
investigated	O
60	O
hips	B-MED
treated	B-MED
in	O
the	O
single-	O
DAA	B-MED
group	B-MED
and	O
60	O
hips	B-MED
treated	B-MED
in	O
the	O
dual-	O
DAA	B-MED
group	B-MED
.	O
A	O
primary	B-MED
/	O
secondary	B-MED
outcome	B-MED
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-MED
-	O
or	O
perioperative	B-MED
complication	B-MED
within	O
the	O
first	O
6	O
months	B-MED
/the	O
operative	B-MED
time	I-MED
and	O
hip	O
function	O
at	O
6	O
months	B-MED
postoperatively	B-MED
.	O
We	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
No	B-MED
intraoperative	B-MED
complications	I-MED
were	O
observed	O
in	O
either	O
group	B-MED
.	O
One	O
anterior	B-MED
dislocation	I-MED
and	O
one	O
periprosthetic	B-MED
hip	I-MED
fracture	I-MED
were	O
occurred	O
in	O
the	O
single-	O
DAA	B-MED
group	B-MED
.	O
The	O
surgical	B-MED
times	I-MED
in	O
the	O
single-	O
DAA	B-MED
and	O
dual-	O
DAA	B-MED
groups	B-MED
were	O
112.0	O
±	O
20.9	O
and	O
121.0	O
±	O
26.9	O
min	O
(	O
p	O
<	O
0.001	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6-	O
month	B-MED
postoperative	B-MED
hip	B-MED
function	I-MED
scores	I-MED
between	O
the	O
two	O
groups	B-MED
.	O
There	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-MED
on	O
intra	B-MED
-	O
and	O
perioperative	B-MED
outcomes	B-MED
.	O
We	O
have	O
demonstrated	O
the	O
short	O
-	O
term	O
safety	B-MED
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
DMC	B-MED
in	O
the	O
DAA	B-MED
compared	O
with	O
the	O
standard	B-MED
single	I-MED
mobility	I-MED
cup	I-MED
.	O
Co	B-MED
-	I-MED
occurrence	I-MED
and	O
clustering	B-MED
of	O
health	B-MED
conditions	B-MED
at	O
age	B-MED
11	O
:	O
cross	B-MED
-	I-MED
sectional	I-MED
findings	B-MED
from	O
the	O
Millennium	B-MED
Cohort	I-MED
Study	I-MED
To	O
identify	O
patterns	O
of	O
co	B-MED
-	I-MED
occurrence	I-MED
and	O
clustering	B-MED
of	O
6	O
common	O
adverse	B-MED
health	B-MED
conditions	B-MED
in	O
11-	O
year	B-MED
-old	O
children	B-MED
and	O
explore	O
differences	B-MED
by	O
sociodemographic	B-MED
factors	I-MED
.	O
Nationally	O
representative	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
Children	B-MED
born	O
in	O
the	O
UK	B-MED
between	O
2000	O
and	O
2002	O
.	O
11	O
399	O
11-	O
year	B-MED
-old	O
singleton	B-MED
children	B-MED
for	O
whom	O
data	B-MED
on	O
all	O
6	O
health	B-MED
conditions	B-MED
and	O
sociodemographic	B-MED
information	I-MED
were	O
available	O
(	O
complete	B-MED
cases	B-MED
)	O
.	O
Prevalence	B-MED
,	O
co	B-MED
-	I-MED
occurrence	I-MED
and	O
clustering	B-MED
of	O
6	O
common	O
health	B-MED
conditions	B-MED
:	O
wheeze	B-MED
;	O
eczema	B-MED
;	O
long	B-MED
-	I-MED
standing	I-MED
illness	I-MED
(	O
excluding	O
wheeze	B-MED
and	O
eczema	B-MED
)	O
;	O
injury	B-MED
;	O
socioemotional	B-MED
difficulties	I-MED
(	O
measured	O
using	O
Strengths	B-MED
and	I-MED
Difficulties	I-MED
Questionnaire	I-MED
)	O
and	O
unfavourable	B-MED
weight	I-MED
(	O
thin	B-MED
/	O
overweight	B-MED
/	O
obese	B-MED
vs	O
normal	B-MED
)	O
.	O
42.4	O
%	O
of	O
children	B-MED
had	O
2	O
or	O
more	O
adverse	B-MED
health	B-MED
conditions	B-MED
(	O
co	B-MED
-	I-MED
occurrence	I-MED
)	O
.	O
Co	B-MED
-	I-MED
occurrence	I-MED
was	O
more	O
common	O
in	O
boys	B-MED
and	O
children	B-MED
from	O
lower	O
income	B-MED
households	B-MED
.	O
Latent	B-MED
class	I-MED
analysis	I-MED
identified	O
6	O
classes	B-MED
:	O
'	O
normative	B-MED
'	O
(	O
57.4	O
%	O
):	O
'	O
atopic	B-MED
burdened	B-MED
'	O
(	O
14.0	O
%	O
)	O
;	O
'	O
socioemotional	B-MED
burdened	I-MED
'	O
(	O
11.0	O
%	O
)	O
;	O
'	O
unfavourable	B-MED
weight	I-MED
/	O
injury	B-MED
'	O
(	O
7.7	O
%	O
)	O
;	O
'	O
eczema	B-MED
/	O
injury	B-MED
'	O
(	O
6.0	O
%	O
)	O
and	O
'	O
eczema	B-MED
/	O
unfavourable	B-MED
weight	I-MED
'	O
(	O
3.9	O
%	O
)	O
.	O
As	O
with	O
co	B-MED
-	I-MED
occurrence	I-MED
,	O
class	B-MED
membership	B-MED
differed	O
by	O
sociodemographic	B-MED
factors	I-MED
:	O
boys	B-MED
,	O
children	B-MED
of	O
mothers	B-MED
with	O
lower	O
educational	B-MED
attainment	I-MED
and	O
children	B-MED
from	O
lower	O
income	B-MED
households	B-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional	B-MED
burdened	I-MED
'	O
class	B-MED
.	O
Children	B-MED
of	O
mothers	B-MED
with	O
higher	O
educational	B-MED
attainment	I-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	B-MED
'	O
and	O
'	O
eczema	B-MED
/	O
unfavourable	B-MED
weight	I-MED
'	O
classes	B-MED
.	O
Co	B-MED
-	I-MED
occurrence	I-MED
of	O
adverse	B-MED
health	B-MED
conditions	B-MED
at	O
age	B-MED
11	O
is	O
common	O
and	O
is	O
associated	B-MED
with	I-MED
adverse	B-MED
socioeconomic	B-MED
circumstances	B-MED
.	O
Holistic	B-MED
,	O
child	B-MED
focused	O
care	B-MED
,	O
particularly	O
in	O
boys	B-MED
and	O
those	O
in	O
lower	O
income	B-MED
groups	B-MED
,	O
may	O
help	O
to	O
prevent	B-MED
and	O
reduce	B-MED
co	B-MED
-	I-MED
occurrence	I-MED
in	O
later	B-MED
childhood	B-MED
and	O
adolescence	B-MED
.	O
Proximal	B-MED
Soil	I-MED
Sensing	I-MED
-	O
A	O
Contribution	B-MED
for	O
Species	B-MED
Habitat	B-MED
Distribution	B-MED
Modelling	B-MED
of	O
Earthworms	B-MED
in	O
Agricultural	B-MED
Soils	B-MED
?	O
Earthworms	B-MED
are	O
important	O
for	O
maintaining	O
soil	B-MED
ecosystem	B-MED
functioning	B-MED
and	O
serve	O
as	O
indicators	B-MED
of	O
soil	B-MED
fertility	B-MED
.	O
However	O
,	O
detection	O
of	O
earthworms	B-MED
is	O
time	B-MED
-	I-MED
consuming	I-MED
,	O
which	O
hinders	O
the	O
assessment	B-MED
of	O
earthworm	B-MED
abundances	B-MED
with	O
high	O
sampling	B-MED
density	B-MED
over	O
entire	O
fields	B-MED
.	O
Recent	O
developments	O
of	O
mobile	B-MED
terrestrial	I-MED
sensor	I-MED
platforms	I-MED
for	O
proximal	B-MED
soil	I-MED
sensing	I-MED
(	O
PSS	B-MED
)	O
provided	O
new	O
tools	B-MED
for	O
collecting	O
dense	O
spatial	O
information	B-MED
of	O
soils	B-MED
using	O
various	O
sensing	B-MED
principles	I-MED
.	O
Yet	O
,	O
the	O
potential	O
of	O
PSS	B-MED
for	O
assessing	B-MED
earthworm	B-MED
habitats	B-MED
is	O
largely	O
unexplored	O
.	O
This	O
study	B-MED
investigates	B-MED
whether	O
PSS	B-MED
data	B-MED
contribute	O
to	O
the	O
spatial	O
prediction	B-MED
of	O
earthworm	B-MED
abundances	B-MED
in	O
species	B-MED
distribution	B-MED
models	B-MED
of	O
agricultural	B-MED
soils	B-MED
.	O
Proximal	B-MED
soil	I-MED
sensing	I-MED
data	B-MED
,	O
e.g.	O
,	O
soil	B-MED
electrical	B-MED
conductivity	I-MED
(	O
EC	B-MED
)	O
,	O
pH	B-MED
,	O
and	O
near	B-MED
infrared	I-MED
absorbance	I-MED
(	O
NIR	B-MED
)	O
,	O
were	O
collected	B-MED
in	O
real	B-MED
-	I-MED
time	I-MED
in	O
a	O
field	B-MED
with	O
two	O
management	B-MED
strategies	I-MED
(	O
reduced	B-MED
tillage	B-MED
/	O
conventional	O
tillage	B-MED
)	O
and	O
sandy	B-MED
to	O
loam	B-MED
soils	I-MED
.	O
PSS	B-MED
was	O
related	O
to	O
observations	B-MED
from	O
a	O
long	B-MED
-	I-MED
term	I-MED
(	O
11	O
years	B-MED
)	O
earthworm	B-MED
observation	B-MED
study	I-MED
conducted	O
at	O
42	O
plots	B-MED
.	O
Earthworms	B-MED
were	O
sampled	B-MED
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	B-MED
blocks	O
and	O
identified	B-MED
to	O
species	B-MED
level	B-MED
.	O
Sensor	B-MED
data	B-MED
were	O
highly	O
correlated	O
with	O
earthworm	B-MED
abundances	B-MED
observed	B-MED
in	O
reduced	B-MED
tillage	B-MED
but	O
less	O
correlated	B-MED
with	O
earthworm	B-MED
abundances	B-MED
observed	B-MED
in	O
conventional	B-MED
tillage	I-MED
.	O
This	O
may	O
indicate	O
that	O
management	B-MED
influences	B-MED
the	O
sensor	B-MED
-	O
earthworm	B-MED
relationship	O
.	O
Generalized	O
additive	O
models	B-MED
and	O
state	B-MED
-	I-MED
space	I-MED
models	I-MED
showed	O
that	O
modelling	B-MED
based	O
on	O
data	B-MED
fusion	O
from	O
EC	B-MED
,	O
pH	B-MED
,	O
and	O
NIR	B-MED
sensors	B-MED
produced	O
better	O
results	B-MED
than	O
modelling	B-MED
without	O
sensor	B-MED
data	B-MED
or	O
data	B-MED
from	O
just	O
a	O
single	O
sensor	B-MED
.	O
Regarding	O
the	O
individual	O
earthworm	B-MED
species	B-MED
,	O
particular	O
sensor	B-MED
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	B-MED
requirements	B-MED
of	O
the	O
earthworms	B-MED
.	O
Earthworm	B-MED
species	B-MED
with	O
soil	B-MED
-specific	O
habitat	B-MED
preferences	B-MED
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	B-MED
by	O
PSS	B-MED
than	O
more	O
ubiquitous	B-MED
species	B-MED
.	O
Our	O
findings	B-MED
suggest	O
that	O
PSS	B-MED
contributes	O
to	O
the	O
spatial	O
modelling	B-MED
of	O
earthworm	B-MED
abundances	B-MED
at	O
field	B-MED
scale	I-MED
and	O
that	O
it	O
will	O
support	O
species	B-MED
distribution	B-MED
modelling	B-MED
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	B-MED
-	O
earthworm	B-MED
relationships	O
in	O
agroecosystems	B-MED
.	O
Management	B-MED
of	O
precipitated	B-MED
opiate	I-MED
withdrawal	I-MED
syndrome	I-MED
induced	B-MED
by	O
nalmefene	B-MED
mistakenly	O
prescribed	B-MED
in	O
opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
:	O
a	O
review	B-MED
for	O
clinicians	B-MED
Nalmefene	B-MED
,	O
a	O
long	B-MED
-	I-MED
acting	I-MED
µ-opioid	I-MED
antagonist	I-MED
approved	B-MED
to	O
treat	B-MED
alcohol	B-MED
use	I-MED
disorder	I-MED
,	O
is	O
occasionally	B-MED
mistakenly	O
prescribed	B-MED
to	O
opiate	B-MED
-	O
dependent	B-MED
or	O
opioid	B-MED
-	O
treated	B-MED
patients	B-MED
.	O
We	O
review	B-MED
recent	O
literature	B-MED
on	O
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
between	O
nalmefene	B-MED
and	O
opioids	B-MED
that	O
lead	O
to	O
precipitated	B-MED
opioid	I-MED
withdrawal	I-MED
,	O
and	O
focus	O
on	O
its	O
management	B-MED
and	O
planning	B-MED
for	O
care	B-MED
at	O
discharge	B-MED
.	O
Areas	O
covered	O
:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	B-MED
review	I-MED
of	O
management	O
of	O
precipitated	B-MED
opioid	I-MED
withdrawal	I-MED
syndrome	I-MED
when	O
nalmefene	B-MED
is	O
associated	B-MED
with	I-MED
an	O
opioid	B-MED
,	O
whether	O
misused	B-MED
or	O
legally	B-MED
prescribed	B-MED
.	O
Expert	B-MED
opinion	I-MED
:	O
When	O
treating	B-MED
an	O
opiate	B-MED
-	O
dependent	B-MED
patient	I-MED
with	O
co	O
-	O
occurring	O
alcohol	B-MED
use	I-MED
disorder	I-MED
,	O
both	O
conditions	B-MED
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	B-MED
attention	I-MED
.	O
New	B-MED
drugs	B-MED
for	O
alcohol	B-MED
use	I-MED
disorder	I-MED
have	O
been	O
approved	B-MED
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	B-MED
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
with	O
opioid	B-MED
medications	B-MED
.	O
Opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
should	O
be	O
intensively	O
monitored	O
for	O
risk	B-MED
factors	I-MED
of	O
alcohol	B-MED
use	I-MED
disorder	I-MED
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	B-MED
maintenance	I-MED
.	O
When	O
nalmefene	B-MED
is	O
administered	B-MED
to	O
opiate	B-MED
-	O
dependent	B-MED
patients	I-MED
,	O
acute	B-MED
opioid	B-MED
withdrawal	I-MED
syndrome	I-MED
may	O
occur	B-MED
.	O
Management	B-MED
of	O
precipitated	O
acute	B-MED
opioid	B-MED
withdrawal	I-MED
may	O
include	B-MED
short	O
or	O
long	B-MED
-	I-MED
acting	I-MED
µ-opioid	I-MED
agonists	I-MED
during	O
hospitalization	B-MED
,	O
in	O
addition	O
to	O
supportive	B-MED
treatment	I-MED
.	O
The	O
best	O
management	B-MED
of	O
polydrug	B-MED
abusers	I-MED
is	O
based	O
on	O
a	O
multidisciplinary	B-MED
approach	I-MED
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-MED
through	B-MED
continuing	B-MED
medical	I-MED
education	I-MED
.	O
Methodological	B-MED
considerations	I-MED
for	O
designing	O
a	O
community	B-MED
water	B-MED
fluoridation	I-MED
cessation	B-MED
study	B-MED
High	B-MED
-	I-MED
quality	I-MED
,	O
up	O
-	O
to	O
-	O
date	O
research	B-MED
on	O
community	B-MED
water	B-MED
fluoridation	I-MED
(	O
CWF	B-MED
)	O
,	O
and	O
especially	O
on	O
the	O
implications	O
of	O
CWF	B-MED
cessation	B-MED
for	O
dental	B-MED
health	I-MED
,	O
is	O
limited	O
.	O
Although	O
CWF	B-MED
cessation	B-MED
studies	B-MED
have	O
been	O
conducted	O
,	O
they	O
are	O
few	O
in	O
number	O
;	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological	B-MED
complexity	I-MED
of	O
conducting	O
such	O
a	O
study	B-MED
.	O
This	O
article	O
draws	O
on	O
a	O
systematic	B-MED
review	I-MED
of	O
existing	O
cessation	B-MED
studies	B-MED
(	O
n=15	O
)	O
to	O
explore	O
methodological	B-MED
considerations	I-MED
of	O
conducting	O
CWF	B-MED
cessation	B-MED
studies	B-MED
in	O
future	B-MED
.	O
We	O
review	O
nine	O
important	O
methodological	B-MED
aspects	I-MED
(	O
study	B-MED
design	I-MED
,	O
comparison	B-MED
community	I-MED
,	O
target	B-MED
population	I-MED
,	O
time	B-MED
frame	I-MED
,	O
sampling	B-MED
strategy	I-MED
,	O
clinical	B-MED
indicators	I-MED
,	O
assessment	B-MED
criteria	I-MED
,	O
covariates	O
and	O
biomarkers	B-MED
)	O
and	O
provide	O
recommendations	B-MED
for	O
planning	B-MED
future	B-MED
CWF	B-MED
cessation	B-MED
studies	B-MED
that	O
examine	O
effects	O
on	O
dental	B-MED
caries	I-MED
.	O
There	O
is	O
no	O
one	O
ideal	O
study	B-MED
design	I-MED
to	O
answer	O
a	O
research	B-MED
question	I-MED
.	O
However	O
,	O
recommendations	B-MED
proposed	O
regarding	O
methodological	B-MED
aspects	I-MED
to	O
conduct	O
an	O
epidemiological	B-MED
study	I-MED
to	O
observe	O
the	O
effects	O
of	O
CWF	B-MED
cessation	B-MED
on	O
dental	B-MED
caries	I-MED
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps	O
,	O
will	O
be	O
useful	O
for	O
researchers	B-MED
who	O
are	O
looking	O
to	O
optimize	B-MED
resources	B-MED
to	O
conduct	O
such	O
a	O
study	B-MED
with	O
standards	O
of	O
rigour	O
.	O
Clinical	B-MED
Pearls	I-MED
in	O
Tremor	B-MED
and	O
Other	O
Hyperkinetic	B-MED
Movement	I-MED
Disorders	B-MED
Hyperkinetic	B-MED
movements	I-MED
,	O
such	O
as	O
tremor	B-MED
,	O
myoclonus	B-MED
,	O
chorea	B-MED
,	O
and	O
dystonia	B-MED
,	O
occur	O
in	O
many	O
neurologic	B-MED
and	O
medical	B-MED
conditions	I-MED
.	O
Accurate	O
clinical	B-MED
evaluation	I-MED
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	B-MED
and	O
treatment	B-MED
of	O
patients	B-MED
with	O
abnormal	B-MED
movements	I-MED
.	O
Cloud	B-MED
-	I-MED
based	I-MED
MOTIFSIM	I-MED
:	O
Detecting	B-MED
Similarity	B-MED
in	O
Large	O
DNA	B-MED
Motif	I-MED
Data	B-MED
Sets	I-MED
We	O
developed	O
the	O
cloud	B-MED
-	I-MED
based	I-MED
MOTIFSIM	I-MED
on	O
Amazon	B-MED
Web	I-MED
Services	I-MED
(	O
AWS	B-MED
)	O
cloud	B-MED
.	O
The	O
tool	B-MED
is	O
an	O
extended	O
version	B-MED
from	O
our	O
web	B-MED
-	I-MED
based	I-MED
tool	I-MED
version	I-MED
2.0	I-MED
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	B-MED
for	O
detecting	B-MED
similarity	B-MED
in	O
multiple	O
DNA	B-MED
motif	I-MED
data	B-MED
sets	I-MED
.	O
This	O
cloud	B-MED
-based	O
version	B-MED
further	O
allows	O
researchers	B-MED
to	O
exploit	O
the	O
computing	B-MED
resources	I-MED
available	O
from	O
AWS	B-MED
to	O
detect	B-MED
similarity	B-MED
in	O
multiple	O
large	O
-	O
scale	O
DNA	B-MED
motif	I-MED
data	B-MED
sets	I-MED
resulting	O
from	O
the	O
next	B-MED
-	I-MED
generation	I-MED
sequencing	I-MED
technology	I-MED
.	O
The	O
tool	B-MED
is	O
highly	O
scalable	O
with	O
expandable	O
AWS	B-MED
.	O
Potential	B-MED
Sunitinib	B-MED
-	O
Induced	B-MED
Coronary	B-MED
Artery	I-MED
and	O
Aortic	B-MED
Dissections	I-MED
Small	B-MED
-	I-MED
molecule	I-MED
multitargeted	I-MED
tyrosine	I-MED
kinase	I-MED
inhibitor	I-MED
(	I-MED
TKI	I-MED
)	I-MED
therapy	I-MED
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-MED
.	O
These	O
drugs	B-MED
have	O
been	O
associated	B-MED
with	I-MED
cardiovascular	B-MED
toxicity	I-MED
,	O
including	O
aortic	B-MED
dissection	I-MED
.	O
To	O
our	O
knowledge	B-MED
,	O
this	O
is	O
the	O
first	B-MED
time	I-MED
that	O
a	O
coronary	B-MED
dissection	I-MED
potentially	B-MED
associated	B-MED
with	I-MED
a	O
TKI	B-MED
treatment	I-MED
has	O
been	O
described	O
.	O
Psychometric	B-MED
analysis	I-MED
of	O
the	O
Patient	B-MED
Health	I-MED
Questionnaire	I-MED
in	O
Danish	B-MED
patients	B-MED
with	O
an	O
implantable	B-MED
cardioverter	I-MED
defibrillator	I-MED
(	O
The	O
DEFIB	B-MED
-	I-MED
WOMEN	I-MED
study	I-MED
)	O
To	O
assess	O
the	O
psychometric	B-MED
properties	I-MED
of	O
the	O
Patient	B-MED
Health	I-MED
Questionnaire	I-MED
(	O
PHQ-9	B-MED
)	O
,	O
a	O
measure	B-MED
of	O
depressive	B-MED
symptoms	I-MED
,	O
in	O
a	O
large	B-MED
Danish	B-MED
national	B-MED
cohort	I-MED
of	O
patients	B-MED
with	O
heart	B-MED
disease	I-MED
,	O
implanted	B-MED
with	O
an	O
implantable	B-MED
cardioverter	I-MED
defibrillator	I-MED
(	O
ICD	B-MED
)	O
,	O
using	O
item	B-MED
response	I-MED
theory	I-MED
.	O
A	O
prospective	B-MED
cohort	I-MED
of	O
patients	B-MED
implanted	B-MED
with	O
an	O
ICD	B-MED
(	O
n=1531	O
;	O
80.4	O
%	O
men	B-MED
)	O
completed	O
the	O
PHQ-9	B-MED
at	O
the	O
time	O
of	O
implant	B-MED
.	O
Data	B-MED
were	O
analyzed	B-MED
using	O
two	O
item	B-MED
response	I-MED
theory	I-MED
models	I-MED
,	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
and	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
.	O
The	O
analysis	B-MED
showed	O
disordered	B-MED
response	I-MED
thresholds	B-MED
in	O
eight	O
of	O
nine	O
items	B-MED
for	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
and	O
five	O
of	O
nine	O
items	B-MED
for	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
,	O
indicating	O
that	O
respondents	B-MED
have	O
difficulty	B-MED
discriminating	B-MED
between	O
response	B-MED
options	O
.	O
When	O
collapsing	O
response	B-MED
options	B-MED
2	O
and	O
3	O
,	O
the	O
rescored	B-MED
PHQ-9	B-MED
had	O
a	O
better	O
fit	O
to	O
both	O
models	B-MED
.	O
The	O
unidimensionality	B-MED
and	O
the	O
precision	B-MED
of	O
the	O
rescored	B-MED
PHQ-9	B-MED
were	O
confirmed	O
.	O
Items	B-MED
did	O
not	O
have	O
any	O
differential	B-MED
functioning	I-MED
(	O
DIF	B-MED
)	O
across	O
educational	B-MED
level	I-MED
,	O
age	B-MED
,	O
indication	B-MED
for	O
ICD	B-MED
implantation	B-MED
,	O
and	O
severity	B-MED
of	O
heart	B-MED
failure	I-MED
that	O
influence	B-MED
depression	B-MED
outcomes	B-MED
in	O
patients	B-MED
with	O
an	O
ICD	B-MED
.	O
One	O
item	O
exhibited	O
DIF	B-MED
by	O
gender	B-MED
.	O
Three	O
items	B-MED
did	O
not	O
fit	O
the	O
partial	B-MED
credit	I-MED
model	I-MED
,	O
but	O
the	O
generalized	B-MED
partial	I-MED
credit	I-MED
model	I-MED
could	O
be	O
fitted	O
to	O
the	O
full	O
item	B-MED
set	I-MED
.	O
The	O
unidimensionality	B-MED
and	O
reliability	B-MED
of	O
the	O
Danish	B-MED
version	I-MED
of	O
the	O
PHQ-9	B-MED
were	O
confirmed	B-MED
.	O
However	O
,	O
the	O
associated	B-MED
consequences	B-MED
of	O
the	O
number	O
of	O
response	B-MED
options	B-MED
(	O
3	O
-	O
point	O
versus	O
4	O
-	O
point	O
Likert	B-MED
scale	I-MED
)	O
need	O
to	O
be	O
further	O
examined	B-MED
for	O
the	O
PHQ-9	B-MED
both	O
as	O
a	O
screening	B-MED
tool	B-MED
and	O
outcome	B-MED
measure	I-MED
.	O
Heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
recombinant	B-MED
human	I-MED
bone	I-MED
morphogenetic	I-MED
protein-7	I-MED
To	O
present	O
the	O
incidence	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
recombinant	B-MED
human	I-MED
bone	I-MED
morphogenetic	I-MED
protein-7	I-MED
(	O
rhBMP-7	B-MED
)	O
for	O
the	O
treatment	B-MED
of	O
nonunions	B-MED
.	O
Bone	B-MED
morphogenetic	I-MED
proteins	I-MED
(	O
BMPs	B-MED
)	O
promote	O
bone	B-MED
formation	I-MED
by	O
auto	B-MED
-	I-MED
induction	I-MED
.	O
Recombinant	B-MED
human	I-MED
BMP-7	I-MED
in	O
combination	O
with	O
bone	B-MED
grafts	I-MED
was	O
used	O
in	O
84	O
patients	B-MED
for	O
the	O
treatment	B-MED
of	O
long	B-MED
bone	I-MED
nonunions	I-MED
.	O
All	O
patients	B-MED
were	O
evaluated	B-MED
radiographicaly	B-MED
for	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
during	O
the	O
standard	B-MED
assessment	B-MED
for	O
the	O
nonunion	B-MED
healing	B-MED
.	O
In	O
all	O
patients	B-MED
(	O
80.9	O
%	O
)	O
with	O
radiographic	B-MED
signs	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
,	O
a	O
CT	B-MED
scan	I-MED
was	O
performed	O
.	O
Nonunion	B-MED
site	B-MED
palpation	B-MED
and	O
ROM	B-MED
evaluation	I-MED
of	O
the	O
adjacent	B-MED
joints	B-MED
were	O
also	O
carried	O
out	O
.	O
Factors	B-MED
related	O
to	O
the	O
patient	B-MED
(	O
age	B-MED
,	O
gender	B-MED
)	O
,	O
the	O
nonunion	B-MED
(	O
location	B-MED
,	O
size	B-MED
,	O
chronicity	B-MED
,	O
number	B-MED
of	I-MED
previous	I-MED
procedures	I-MED
,	O
infection	B-MED
,	O
surrounding	B-MED
tissues	B-MED
condition	B-MED
)	O
and	O
the	O
surgical	B-MED
procedure	I-MED
(	O
graft	B-MED
and	O
fixation	B-MED
type	B-MED
,	O
amount	B-MED
of	O
rhBMP-7	B-MED
)	O
were	O
correlated	B-MED
with	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
and	O
statistical	B-MED
analysis	I-MED
with	O
Pearsons	B-MED
χ	I-MED
(	I-MED
2	I-MED
)	I-MED
test	I-MED
was	O
performed	O
.	O
Eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-MED
treated	B-MED
with	O
rhBMP-7	B-MED
,	O
healed	B-MED
with	O
no	O
need	O
for	O
further	O
procedures	B-MED
.	O
Heterotopic	B-MED
bone	I-MED
formation	I-MED
occurred	O
in	O
15	O
of	O
84	O
patients	B-MED
(	O
17.8	O
%	O
)	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	B-MED
evaluation	I-MED
of	O
the	O
nonunion	B-MED
site	O
,	O
in	O
a	O
mean	B-MED
time	I-MED
of	O
5.5	O
mo	O
after	O
the	O
rhBMP-7	B-MED
application	B-MED
(	O
range	O
3	O
-	O
12	O
)	O
.	O
The	O
heterotopic	B-MED
ossification	I-MED
was	O
located	O
at	O
the	O
femur	B-MED
in	O
8	O
cases	B-MED
,	O
at	O
the	O
tibia	B-MED
in	O
6	O
,	O
and	O
at	O
the	O
humerus	B-MED
in	O
οne	O
patient	B-MED
.	O
In	O
4	O
patients	B-MED
a	O
palpable	B-MED
mass	I-MED
was	O
present	O
and	O
only	O
in	O
one	O
patient	B-MED
,	O
with	O
a	O
para	B-MED
-	I-MED
articular	I-MED
knee	I-MED
nonunion	I-MED
treated	B-MED
with	O
rhBMP-7	B-MED
,	O
the	O
size	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
affected	O
the	O
knee	B-MED
range	I-MED
of	I-MED
motion	I-MED
.	O
All	O
the	O
patients	B-MED
with	O
heterotopic	B-MED
ossification	I-MED
were	O
male	B-MED
.	O
Statistical	B-MED
analysis	I-MED
proved	O
that	O
patient	B-MED
's	I-MED
gender	B-MED
was	O
the	O
only	O
important	O
factor	B-MED
for	O
the	O
development	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
(	O
P	O
=	O
0.007	O
)	O
.	O
Heterotopic	B-MED
ossification	I-MED
after	O
the	O
use	O
of	O
rhBMP-7	B-MED
in	O
nonunions	B-MED
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	B-MED
outcome	I-MED
in	O
most	O
cases	B-MED
,	O
and	O
affected	O
only	O
male	B-MED
patients	B-MED
.	O
Biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
:	O
a	O
review	B-MED
of	I-MED
magnetic	B-MED
signatures	O
from	O
biological	B-MED
sensors	I-MED
Biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	B-MED
magnetism	B-MED
.	O
Particulate	B-MED
matter	I-MED
(	O
PM	B-MED
)	O
in	O
atmospheric	B-MED
pollution	I-MED
contains	O
readily-	O
measurable	B-MED
concentrations	O
of	O
magnetic	B-MED
minerals	I-MED
.	O
Biological	B-MED
surfaces	B-MED
,	O
exposed	O
to	O
atmospheric	B-MED
pollution	I-MED
,	O
accumulate	O
magnetic	B-MED
particles	B-MED
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	B-MED
-	O
specific	B-MED
,	O
time	B-MED
-	I-MED
integrated	I-MED
air	B-MED
quality	I-MED
information	B-MED
.	O
This	O
review	B-MED
summarizes	O
current	O
knowledge	O
of	O
biological	B-MED
material	I-MED
(	O
'	O
sensors	B-MED
'	O
)	O
used	O
for	O
biomagnetic	B-MED
monitoring	I-MED
purposes	O
.	O
Our	O
work	O
addresses	O
:	O
the	O
range	O
of	O
magnetic	B-MED
properties	I-MED
reported	O
for	O
lichens	B-MED
,	O
mosses	B-MED
,	O
leaves	B-MED
,	O
bark	B-MED
,	O
trunk	B-MED
wood	I-MED
,	O
insects	B-MED
,	O
crustaceans	B-MED
,	O
mammal	B-MED
and	O
human	B-MED
tissues	I-MED
;	O
their	O
associations	O
with	O
atmospheric	B-MED
pollutant	I-MED
species	I-MED
(	O
PM	B-MED
,	O
NOx	B-MED
,	O
trace	B-MED
elements	I-MED
,	O
PAHs	B-MED
)	O
;	O
the	O
pros	B-MED
and	I-MED
cons	I-MED
of	O
biomagnetic	B-MED
monitoring	I-MED
of	O
atmospheric	B-MED
pollution	I-MED
;	O
current	O
challenges	O
for	O
large	B-MED
-	I-MED
scale	I-MED
implementation	I-MED
of	O
biomagnetic	B-MED
monitoring	I-MED
;	O
and	O
future	B-MED
perspectives	O
.	O
A	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	B-MED
and	O
policy	B-MED
makers	I-MED
in	O
selecting	O
the	O
most	O
suitable	O
biological	B-MED
sensor	I-MED
for	O
their	O
intended	O
biomagnetic	B-MED
monitoring	I-MED
purpose	O
.	O
Benchmark	O
study	B-MED
on	O
fine	B-MED
-	I-MED
mode	I-MED
aerosol	I-MED
in	O
a	O
big	B-MED
urban	I-MED
area	I-MED
and	O
relevant	B-MED
doses	I-MED
deposited	B-MED
in	O
the	O
human	B-MED
respiratory	B-MED
tract	I-MED
It	O
is	O
well	O
-	O
known	O
that	O
the	O
health	B-MED
effects	B-MED
of	O
PM	B-MED
increase	O
as	O
particle	B-MED
size	I-MED
decreases	O
:	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
UltraFine	B-MED
Particles	I-MED
(	O
UFPs	B-MED
)	O
.	O
Starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	B-MED
of	I-MED
atmospheric	B-MED
aerosol	B-MED
in	O
Rome	B-MED
is	O
characterized	O
by	O
significant	O
levels	B-MED
of	O
PM2.5	B-MED
(	O
almost	O
75	O
%	O
of	O
PM10	B-MED
fraction	O
is	O
PM2.5	B-MED
)	O
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	B-MED
particles	I-MED
in	O
such	O
great	B-MED
urban	I-MED
area	I-MED
.	O
The	O
daytime	B-MED
/	O
nighttime	B-MED
,	O
work-	B-MED
/	O
weekdays	B-MED
and	O
cold	B-MED
/	O
hot	B-MED
seasonal	B-MED
trends	I-MED
of	O
submicron	B-MED
particles	I-MED
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
NOx	B-MED
and	O
total	O
PAH	B-MED
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
UFPs	B-MED
from	O
combustion	B-MED
processes	I-MED
.	O
Furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	B-MED
of	O
submicron	B-MED
particles	I-MED
deposited	B-MED
in	O
the	O
respiratory	B-MED
system	I-MED
(	O
i.e.	O
,	O
head	B-MED
,	O
tracheobronchial	B-MED
and	O
alveolar	B-MED
regions	I-MED
in	O
different	O
lung	B-MED
lobes	I-MED
)	O
has	O
been	O
estimated	O
.	O
Dosimeter	B-MED
estimates	B-MED
were	O
performed	O
with	O
the	O
Multiple	B-MED
-	I-MED
Path	I-MED
Particle	I-MED
Dosimetry	I-MED
model	I-MED
(	O
MPPD	B-MED
v.2.1	I-MED
)	O
.	O
The	O
paper	O
discusses	O
the	O
aerosol	B-MED
doses	B-MED
deposited	B-MED
in	O
the	O
respiratory	B-MED
system	I-MED
of	O
individuals	B-MED
exposed	B-MED
in	O
proximity	O
of	O
traffic	B-MED
.	O
During	O
traffic	B-MED
peak	O
hours	B-MED
,	O
about	O
6.6	O
×	O
10(10	O
)	O
particles	B-MED
are	O
deposited	B-MED
into	O
the	O
respiratory	B-MED
system	I-MED
.	O
Such	O
dose	B-MED
is	O
almost	O
entirely	O
made	O
of	O
UFPs	B-MED
.	O
According	O
to	O
the	O
greater	O
dose	B-MED
estimated	B-MED
,	O
right	B-MED
lung	I-MED
lobes	I-MED
are	O
expected	O
to	O
be	O
more	O
susceptible	B-MED
to	O
respiratory	B-MED
pathologies	B-MED
than	O
left	B-MED
lobes	I-MED
.	O
TRIB3	B-MED
downregulation	B-MED
enhances	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
cytotoxicity	B-MED
in	O
gastric	B-MED
cancer	I-MED
cells	B-MED
TRIB3	B-MED
,	O
which	O
is	O
a	O
pseudokinase	B-MED
known	O
to	O
regulate	B-MED
multiple	I-MED
pro	I-MED
-	I-MED
survival	I-MED
pathways	I-MED
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-MED
target	B-MED
for	O
the	O
treatment	B-MED
of	O
human	B-MED
tumors	B-MED
.	O
However	O
,	O
its	O
precise	O
role	O
in	O
cancer	B-MED
is	O
controversial	O
,	O
as	O
TRIB3	B-MED
protein	B-MED
levels	I-MED
have	O
been	O
associated	O
with	O
both	O
good	B-MED
and	O
poor	B-MED
prognosis	I-MED
in	O
cancer	B-MED
patients	I-MED
.	O
Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	B-MED
expression	B-MED
in	O
the	O
survival	B-MED
of	O
gastric	B-MED
cancer	I-MED
cells	B-MED
exposed	O
to	O
anticancer	B-MED
drugs	I-MED
.	O
We	O
found	O
that	O
the	O
tested	B-MED
anticancer	B-MED
drug	I-MED
,	O
doxorubicin	B-MED
,	O
induced	B-MED
cytotoxicity	B-MED
by	O
decreasing	O
TRIB3	B-MED
transcription	B-MED
,	O
which	O
was	O
followed	O
by	O
apoptotic	B-MED
cell	I-MED
death	I-MED
.	O
Moreover	O
,	O
TRIB3	B-MED
siRNA	I-MED
knockdown	B-MED
appeared	O
to	O
enhance	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
gastric	B-MED
cancer	I-MED
cells	B-MED
,	O
concurrently	O
with	O
altering	O
the	O
expression	B-MED
of	O
downstream	B-MED
apoptotic	B-MED
factors	I-MED
.	O
Conversely	O
,	O
overexpression	B-MED
of	O
TRIB3	B-MED
significantly	O
protected	B-MED
cells	I-MED
against	O
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
.	O
Our	O
results	O
indicate	O
that	O
downregulation	B-MED
of	O
TRIB3	B-MED
appears	O
to	O
promote	B-MED
cell	B-MED
death	I-MED
and	O
enhance	B-MED
doxorubicin	B-MED
-	O
induced	B-MED
apoptosis	B-MED
,	O
supporting	O
the	O
anti	B-MED
-	I-MED
apoptotic	I-MED
role	O
of	O
TRIB3	B-MED
.	O
The	O
inductions	B-MED
of	O
three	O
classes	O
of	O
MAPKs	B-MED
failed	O
to	O
affect	O
doxorubicin	B-MED
-mediated	O
TRIB3	B-MED
downregulation	B-MED
,	O
while	O
TRIB3	B-MED
overexpression	B-MED
did	O
not	O
affect	O
doxorubicin	B-MED
-	O
induced	B-MED
MAPK	B-MED
activation	I-MED
.	O
In	O
sum	O
,	O
our	O
findings	B-MED
indicate	O
that	O
TRIB3	B-MED
plays	O
an	O
anti	B-MED
-	I-MED
apoptotic	I-MED
role	O
in	O
doxorubicin	B-MED
-treated	O
gastric	B-MED
cancer	I-MED
cell	B-MED
lines	I-MED
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	B-MED
expression	B-MED
in	O
response	O
to	O
anticancer	B-MED
drugs	I-MED
,	O
such	O
as	O
doxorubicin	B-MED
,	O
irinotecan	B-MED
or	O
oxaliplatin	B-MED
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B-MED
therapy	I-MED
.	O
Allelic	B-MED
diversity	B-MED
in	O
an	O
NLR	B-MED
gene	I-MED
BPH9	B-MED
enables	O
rice	B-MED
to	O
combat	O
planthopper	B-MED
variation	B-MED
Brown	B-MED
planthopper	I-MED
(	O
BPH	B-MED
)	O
,	O
Nilaparvata	B-MED
lugens	I-MED
Stål	I-MED
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	B-MED
pests	B-MED
of	O
rice	B-MED
(	O
Oryza	B-MED
sativa	I-MED
L.	I-MED
)	O
.	O
Currently	O
,	O
30	O
BPH	B-MED
-	O
resistance	B-MED
genes	I-MED
have	O
been	O
genetically	O
defined	O
,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome	B-MED
regions	I-MED
.	O
Here	O
,	O
we	O
describe	O
molecular	B-MED
cloning	I-MED
and	O
characterization	B-MED
of	O
a	O
BPH	B-MED
-	O
resistance	B-MED
gene	I-MED
,	O
BPH9	B-MED
,	O
mapped	O
on	O
the	O
long	B-MED
arm	I-MED
of	I-MED
rice	I-MED
chromosome	I-MED
12	I-MED
(	O
12L	O
)	O
.	O
BPH9	B-MED
encodes	O
a	O
rare	O
type	O
of	O
nucleotide	B-MED
-	I-MED
binding	I-MED
and	O
leucine	B-MED
-	I-MED
rich	I-MED
repeat	I-MED
NLR	B-MED
(	O
NLR)-containing	O
protein	B-MED
that	O
localizes	O
to	O
the	O
endomembrane	B-MED
system	I-MED
and	O
causes	O
a	O
cell	B-MED
death	I-MED
phenotype	B-MED
.	O
BPH9	B-MED
activates	O
salicylic	B-MED
acid	I-MED
-	O
and	O
jasmonic	B-MED
acid	I-MED
-	O
signaling	B-MED
pathways	I-MED
in	O
rice	B-MED
plants	B-MED
and	O
confers	O
both	O
antixenosis	B-MED
and	O
antibiosis	B-MED
to	O
BPH	B-MED
.	O
We	O
further	O
demonstrated	O
that	O
the	O
eight	O
BPH	B-MED
-	O
resistance	B-MED
genes	I-MED
that	O
are	O
clustered	O
on	O
chromosome	B-MED
12L	I-MED
,	O
including	O
the	O
widely	O
used	O
BPH1	B-MED
,	O
are	O
allelic	O
with	O
each	O
other	O
.	O
To	O
honor	O
the	O
priority	O
in	O
the	O
literature	B-MED
,	O
we	O
thus	O
designated	O
this	O
locus	B-MED
as	O
BPH1/9	B-MED
These	O
eight	O
genes	B-MED
can	O
be	O
classified	O
into	O
four	O
allelotypes	B-MED
,	O
BPH1/9	B-MED
-	I-MED
1	I-MED
,	O
-2	B-MED
,	O
-7	B-MED
,	O
and	O
-9	B-MED
These	O
allelotypes	B-MED
confer	O
varying	O
levels	B-MED
of	O
resistance	B-MED
to	O
different	O
biotypes	B-MED
of	O
BPH	B-MED
.	O
The	O
coding	B-MED
region	I-MED
of	O
BPH1/9	B-MED
shows	O
a	O
high	O
level	O
of	O
diversity	B-MED
in	O
rice	B-MED
germplasm	I-MED
.	O
Homologous	O
fragments	O
of	O
the	O
nucleotide	B-MED
-	I-MED
binding	I-MED
(	O
NB	B-MED
)	O
and	O
leucine	B-MED
-	I-MED
rich	I-MED
repeat	I-MED
(	O
LRR	B-MED
)	O
domains	B-MED
exist	O
,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	B-MED
for	O
generating	O
allele	B-MED
diversity	B-MED
.	O
Our	O
findings	O
reveal	O
a	O
rice	B-MED
plant	B-MED
strategy	O
for	O
modifying	O
the	O
genetic	B-MED
information	I-MED
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	B-MED
herbivores	B-MED
.	O
Further	O
exploration	O
of	O
natural	O
allelic	B-MED
variation	I-MED
and	O
artificial	B-MED
shuffling	I-MED
within	O
this	O
gene	B-MED
may	O
allow	O
breeding	B-MED
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	B-MED
of	O
BPH	B-MED
.	O
Starvation	B-MED
-	O
and	O
antibiotics	B-MED
-induced	O
formation	B-MED
of	O
persister	B-MED
cells	I-MED
in	O
Pseudomonas	B-MED
aeruginosa	I-MED
Planktonic	B-MED
stationary	B-MED
and	I-MED
exponential	I-MED
cultures	I-MED
of	O
Pseudomonas	B-MED
aeruginosa	I-MED
are	O
highly	B-MED
resistant	I-MED
to	O
killing	B-MED
by	O
bactericidal	B-MED
antimicrobials	I-MED
because	O
of	O
the	O
presence	O
of	O
persisters	B-MED
,	O
cells	B-MED
that	O
are	O
multidrug	B-MED
tolerant	I-MED
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	B-MED
of	O
biofilm	B-MED
infections	B-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
formation	B-MED
of	O
persister	B-MED
cells	I-MED
in	O
P.	B-MED
aeruginosa	I-MED
stationary	B-MED
vs.	O
exponential	B-MED
cultures	I-MED
using	O
different	B-MED
class	B-MED
antimicrobials	B-MED
.	O
The	O
susceptibilities	B-MED
of	O
P.	B-MED
aeruginosa	I-MED
PAO1	I-MED
wild	I-MED
-	I-MED
type	I-MED
and	O
mutant	B-MED
strains	I-MED
to	O
antimicrobials	B-MED
were	O
determined	O
by	O
standard	B-MED
microtiter	I-MED
broth	I-MED
dilution	I-MED
method	I-MED
.	O
In	O
order	O
to	O
determine	O
persister	B-MED
formation	B-MED
,	O
dose	B-MED
-	O
and	O
time	B-MED
-dependent	O
killing	B-MED
experiments	I-MED
were	O
performed	B-MED
with	O
antibiotics	B-MED
.	O
Ceftazidime	B-MED
(	O
Cephalosporin	B-MED
)	O
showed	O
little	O
efficacy	B-MED
against	O
either	O
culture	B-MED
.	O
Stationary	B-MED
-	I-MED
phase	I-MED
cells	I-MED
were	O
more	O
tolerant	B-MED
to	O
imipenem	B-MED
(	O
Carbapenem	B-MED
)	O
than	O
exponential	B-MED
cells	I-MED
,	O
leaving	O
a	O
small	O
fraction	B-MED
of	I-MED
persisters	B-MED
at	O
high	B-MED
imipenem	B-MED
concentration	B-MED
in	O
both	O
populations	B-MED
.	O
Polymyxin	B-MED
B	I-MED
(	O
Polymyxin	B-MED
)	O
appeared	O
to	O
be	O
ineffective	O
at	O
low	B-MED
concentrations	I-MED
against	O
both	O
cell	B-MED
populations	I-MED
.	O
Very	O
high	O
polymyxin	B-MED
B	I-MED
concentration	B-MED
completely	O
eradicated	O
exponential	B-MED
cells	I-MED
and	O
regrowth	B-MED
was	O
seen	O
in	O
a	O
stationary	B-MED
population	I-MED
.	O
Stationary	B-MED
cells	I-MED
were	O
more	O
tolerant	B-MED
to	O
tobramycin	B-MED
(	O
Aminoglycoside	B-MED
)	O
than	O
exponential	B-MED
cells	I-MED
but	O
a	O
higher	B-MED
concentration	I-MED
of	O
tobramycin	B-MED
completely	O
eliminated	B-MED
survivors	B-MED
.	O
Ciprofloxacin	B-MED
(	O
Fluoroquinolone	B-MED
)	O
at	O
a	O
low	B-MED
concentration	I-MED
resulted	O
in	O
killing	B-MED
of	O
both	O
cultures	B-MED
of	O
P.	B-MED
aeruginosa	I-MED
,	O
producing	O
persisters	B-MED
that	O
were	O
invulnerable	O
to	O
killing	B-MED
.	O
Stationary	B-MED
cells	I-MED
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-MED
than	O
exponential	B-MED
cells	I-MED
in	O
all	O
of	O
these	O
assays	B-MED
.	O
We	O
also	O
showed	O
that	O
nutrient	B-MED
deprivation	B-MED
(	O
serine	B-MED
starvation	B-MED
)	O
regulated	O
by	O
stringent	B-MED
and	I-MED
general	I-MED
stress	I-MED
response	I-MED
,	O
contribute	O
to	O
the	O
increased	B-MED
tolerance	I-MED
of	O
P.	B-MED
aeruginosa	I-MED
exponential	B-MED
and	I-MED
stationary	I-MED
planktonic	I-MED
cells	I-MED
via	O
production	B-MED
of	O
persisters	B-MED
.	O
Homogeneous	B-MED
synthesis	B-MED
of	O
Ag	B-MED
nanoparticles	I-MED
-doped	O
water	B-MED
-	I-MED
soluble	I-MED
cellulose	I-MED
acetate	I-MED
for	O
versatile	B-MED
applications	B-MED
We	O
report	B-MED
a	O
facile	B-MED
and	O
efficient	B-MED
approach	B-MED
for	O
synthesis	B-MED
of	O
well	B-MED
-	I-MED
dispersed	I-MED
and	O
stable	B-MED
silver	B-MED
nanoparticles	I-MED
(	O
Ag	B-MED
NPs	I-MED
)	O
using	O
water	B-MED
-	I-MED
soluble	I-MED
cellulose	I-MED
acetate	I-MED
(	O
CA	B-MED
)	O
as	O
both	O
reductant	B-MED
and	O
stabilizer	B-MED
.	O
Partially	B-MED
substituted	O
CA	B-MED
with	O
highly	B-MED
active	B-MED
hydroxyl	B-MED
groups	I-MED
and	O
excellent	B-MED
water	B-MED
-	I-MED
solubility	I-MED
is	O
able	B-MED
to	O
reduce	B-MED
silver	B-MED
ions	I-MED
in	O
homogeneous	B-MED
aqueous	B-MED
medium	B-MED
effectively	B-MED
.	O
The	O
synthesized	B-MED
Ag	B-MED
NPs	I-MED
were	O
characterized	B-MED
by	O
UV	B-MED
-	I-MED
vis	I-MED
spectroscopy	I-MED
,	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
,	O
X	B-MED
-	I-MED
ray	I-MED
photoelectron	I-MED
spectroscopy	I-MED
,	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
and	O
energy	B-MED
dispersive	I-MED
X	I-MED
-	I-MED
ray	I-MED
spectroscope	I-MED
analysis	B-MED
.	O
The	O
as-	O
prepared	B-MED
Ag	B-MED
NPs	I-MED
were	O
well	B-MED
-	I-MED
dispersed	I-MED
,	O
showing	O
a	O
surface	B-MED
plasmon	I-MED
resonance	I-MED
peak	B-MED
at	O
426	O
nm	B-MED
.	O
The	O
resulted	O
Ag	B-MED
NPs	I-MED
@	O
CA	B-MED
nanohybrids	B-MED
exhibit	O
high	B-MED
catalytic	B-MED
activity	I-MED
for	O
the	O
reduction	B-MED
of	O
4	B-MED
-	I-MED
nitrophenol	I-MED
to	O
4	B-MED
-	I-MED
aminophenol	I-MED
in	O
the	O
presence	O
of	O
NaBH4	B-MED
.	O
Meanwhile	O
,	O
the	O
nanohybrids	B-MED
are	O
also	O
effective	B-MED
in	O
inhibiting	B-MED
the	O
growth	B-MED
of	O
bacterial	B-MED
.	O
This	O
environmentally	B-MED
friendly	I-MED
method	I-MED
promotes	B-MED
the	O
use	B-MED
of	I-MED
renewable	B-MED
natural	I-MED
resources	I-MED
to	O
prepare	B-MED
a	O
variety	B-MED
of	O
inorganic	B-MED
-	I-MED
organic	I-MED
materials	I-MED
for	O
catalysis	B-MED
,	O
antibacterial	B-MED
,	O
sensors	B-MED
and	O
other	O
applications	B-MED
.	O
Obstacle	B-MED
course	I-MED
runs	I-MED
:	O
review	B-MED
of	O
acquired	O
injuries	B-MED
and	O
illnesses	B-MED
at	O
a	O
series	B-MED
of	O
Canadian	B-MED
events	B-MED
(	O
RACE	B-MED
)	O
The	O
growing	O
popularity	O
of	O
obstacle	B-MED
course	I-MED
runs	I-MED
(	O
OCRs	B-MED
)	O
has	O
led	O
to	O
significant	B-MED
concerns	B-MED
regarding	O
their	O
safety	B-MED
.	O
The	O
influx	O
of	O
injuries	B-MED
and	O
illnesses	B-MED
in	O
rural	B-MED
areas	I-MED
where	O
OCRs	B-MED
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency	B-MED
medical	I-MED
services	I-MED
(	O
EMS	B-MED
)	O
and	O
local	O
EDs	O
.	O
Literature	B-MED
concerning	B-MED
the	O
safety	B-MED
of	O
these	O
events	B-MED
is	O
minimal	B-MED
and	O
mostly	O
consists	O
of	O
media	B-MED
reports	B-MED
.	O
We	O
sought	O
to	O
characterise	B-MED
the	O
injury	B-MED
and	O
illness	B-MED
profile	O
of	O
OCRs	B-MED
and	O
the	O
level	B-MED
of	O
medical	B-MED
care	I-MED
required	O
.	O
This	O
study	B-MED
analysed	B-MED
OCR	B-MED
events	B-MED
occurring	O
in	O
eight	O
locations	O
across	O
Canada	B-MED
from	O
May	O
to	O
August	O
2015	O
(	O
total	O
45	O
285	O
participants	B-MED
)	O
.	O
Data	B-MED
were	O
extracted	B-MED
from	O
event	B-MED
medical	B-MED
charts	I-MED
of	O
patients	B-MED
presenting	O
to	O
the	O
onsite	B-MED
medical	B-MED
team	I-MED
,	O
including	O
injury	B-MED
or	O
illness	B-MED
type	O
,	O
onsite	O
treatment	B-MED
and	O
disposition	B-MED
.	O
There	O
were	O
557	O
race	B-MED
participants	I-MED
treated	B-MED
at	O
eight	O
OCR	B-MED
events	B-MED
(	O
1.2	O
%	O
of	O
all	O
participants	B-MED
)	O
.	O
There	O
were	O
609	O
medical	B-MED
complaints	I-MED
in	O
total	O
.	O
Three	O
quarters	O
of	O
injuries	B-MED
were	O
musculoskeletal	B-MED
in	O
nature	O
.	O
Eighty	O
-	O
nine	O
per	O
cent	O
returned	O
to	O
the	O
event	B-MED
with	O
no	O
need	O
for	O
further	O
medical	B-MED
care	I-MED
.	O
The	O
majority	O
of	O
treatments	B-MED
were	O
completed	O
with	O
first	B-MED
aid	I-MED
and	O
basic	O
medical	B-MED
equipment	I-MED
.	O
Eleven	O
patients	B-MED
(	O
2	O
%	O
of	O
patients	B-MED
)	O
required	O
transfer	O
to	O
hospital	B-MED
by	O
EMS	B-MED
for	O
presentations	O
including	O
fracture	B-MED
,	O
dislocation	B-MED
,	O
head	B-MED
injury	I-MED
,	O
chest	B-MED
pain	I-MED
,	O
fall	B-MED
from	I-MED
height	I-MED
,	O
and	O
abdominal	B-MED
pain	I-MED
.	O
We	O
found	O
that	O
1.2	O
%	O
of	O
race	B-MED
participants	I-MED
presented	O
to	O
onsite	O
medical	B-MED
services	I-MED
.	O
The	O
majority	O
of	O
complaints	O
were	O
minor	B-MED
and	O
musculoskeletal	B-MED
in	O
nature	O
.	O
Only	O
2	O
%	O
of	O
those	O
treated	B-MED
were	O
transferred	O
to	O
hospital	B-MED
through	O
EMS	B-MED
.	O
This	O
is	O
consistent	B-MED
with	I-MED
other	O
types	O
of	O
mass	B-MED
gathering	I-MED
events	B-MED
.	O
Genotyping	B-MED
of	O
Staphylococcus	B-MED
aureus	I-MED
in	O
bovine	B-MED
mastitis	I-MED
and	O
correlation	O
to	O
phenotypic	B-MED
characteristics	B-MED
Reducing	O
the	O
prevalence	O
of	O
mastitis	B-MED
caused	O
by	O
Staphylococcus	B-MED
aureus	I-MED
(	O
S.	B-MED
aureus	I-MED
)	O
is	O
essential	O
to	O
improve	O
animal	B-MED
health	B-MED
and	O
reduce	O
economic	O
losses	O
for	O
farmers	B-MED
.	O
The	O
clinical	O
outcome	O
of	O
acute	B-MED
mastitis	I-MED
and	O
risk	B-MED
of	O
progression	O
to	O
persistent	B-MED
mastitis	B-MED
can	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
be	O
related	O
to	O
genetic	B-MED
variants	I-MED
of	O
the	O
strain	B-MED
causing	O
the	O
infection	B-MED
.	O
In	O
the	O
present	O
study	B-MED
we	O
have	O
used	O
microarrays	B-MED
to	O
investigate	O
the	O
presence	O
of	O
virulence	B-MED
genes	B-MED
in	O
S.	B-MED
aureus	I-MED
isolates	O
from	O
dairy	B-MED
cows	I-MED
with	O
acute	B-MED
clinical	I-MED
mastitis	I-MED
(	O
n=70	O
)	O
and	O
correlated	O
the	O
findings	B-MED
to	O
other	O
genotypic	B-MED
and	O
phenotypic	B-MED
characteristics	B-MED
.	O
Among	O
the	O
most	O
commonly	O
found	O
virulence	B-MED
factors	I-MED
were	O
genes	B-MED
encoding	B-MED
several	O
hemolysin	B-MED
types	B-MED
,	O
leukocidins	B-MED
D	I-MED
and	O
lukM	B-MED
/	O
lukF	B-MED
-	I-MED
P83	I-MED
,	O
clumping	B-MED
factors	I-MED
A	I-MED
and	O
B	B-MED
,	O
fibrinogen	B-MED
binding	I-MED
protein	I-MED
and	O
fibronectin	B-MED
-	I-MED
binding	I-MED
protein	I-MED
A	I-MED
A.	O
Some	O
virulence	B-MED
factors	I-MED
e.g.	O
fibronectin	B-MED
-	I-MED
binding	I-MED
protein	I-MED
B	I-MED
and	O
Staphylococcus	B-MED
aureus	I-MED
surface	B-MED
protein	I-MED
G	I-MED
were	O
less	O
common	O
.	O
Genes	B-MED
coding	O
for	O
several	O
staphylococcal	B-MED
enterotoxins	I-MED
and	O
toxic	B-MED
shock	I-MED
syndrome	I-MED
toxin-1	I-MED
(	O
TSST-1	B-MED
)	O
were	O
commonly	O
found	O
,	O
especially	O
in	O
one	O
major	O
pulsotype	B-MED
.	O
No	B-MED
beta	B-MED
-	I-MED
lactamase	I-MED
genes	I-MED
were	O
found	O
in	O
any	O
common	O
pulsotype	B-MED
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	B-MED
,	O
indicated	O
to	O
be	O
of	O
human	B-MED
origin	I-MED
.	O
Production	O
of	O
TSST-1	B-MED
,	O
enterotoxins	B-MED
,	O
hemolysins	B-MED
and	O
beta	B-MED
-	I-MED
lactamase	I-MED
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	B-MED
.	O
This	O
study	B-MED
reveals	O
a	O
number	O
of	O
genotypic	B-MED
differences	B-MED
and	O
similarities	B-MED
among	O
common	O
and	O
rare	O
pulsotypes	B-MED
of	O
S.	B-MED
aureus	I-MED
from	O
cases	O
of	O
mastitis	B-MED
in	O
Sweden	B-MED
.	O
The	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic	B-MED
tools	I-MED
to	O
guide	O
on	O
-	O
farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-MED
health	B-MED
from	O
a	O
specific	O
S.	B-MED
aureus	I-MED
genotype	B-MED
.	O
Associations	B-MED
of	O
gender	B-MED
and	O
a	O
proxy	B-MED
of	O
female	B-MED
menopausal	B-MED
status	I-MED
with	O
histological	B-MED
features	B-MED
of	O
drug	B-MED
-	I-MED
induced	I-MED
liver	I-MED
injury	I-MED
Gender	B-MED
and	O
menopause	B-MED
may	O
contribute	O
to	O
type	B-MED
and	O
severity	B-MED
of	O
drug	B-MED
-	I-MED
induced	I-MED
liver	I-MED
injury	I-MED
(	O
DILI	B-MED
)	O
by	O
influencing	B-MED
host	B-MED
responses	B-MED
to	O
injury	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
the	O
associations	B-MED
of	O
gender	B-MED
and	O
female	B-MED
age	B-MED
50	O
[	O
a	O
proxy	B-MED
of	O
menopause	B-MED
]	O
with	O
histological	B-MED
features	B-MED
of	O
liver	B-MED
injury	I-MED
in	O
212	O
adults	B-MED
enrolled	O
in	O
the	O
Drug	B-MED
-	I-MED
Induced	I-MED
Liver	I-MED
Injury	I-MED
Network	B-MED
(	O
DILIN	B-MED
)	O
registry	B-MED
.	O
All	O
participants	B-MED
had	O
a	O
causality	B-MED
score	B-MED
of	O
at	O
least	O
'	O
probable	B-MED
'	O
,	O
a	O
liver	B-MED
biopsy	I-MED
within	O
30	O
days	O
of	O
DILI	B-MED
onset	O
,	O
and	O
no	O
prior	O
chronic	B-MED
liver	I-MED
disease	I-MED
.	O
Biochemical	B-MED
and	O
histological	B-MED
injury	B-MED
types	B-MED
were	O
classified	O
as	O
hepatocellular	B-MED
or	O
cholestatic	B-MED
/	I-MED
mixed	I-MED
injury	I-MED
.	O
The	O
cohort	B-MED
was	O
divided	B-MED
into	O
three	O
gender	B-MED
/	O
age	B-MED
categories	B-MED
:	O
men	B-MED
(	O
41.0	O
%	O
)	O
,	O
women	B-MED
<	O
50	O
years	O
(	O
27.4	O
%	O
)	O
and	O
women	B-MED
≥50	O
years	O
of	O
age	B-MED
(	O
31.6	O
%	O
)	O
.	O
Interaction	B-MED
of	O
gender	B-MED
and	O
age	B-MED
category	B-MED
(	O
≥50	O
or	O
not	O
)	O
was	O
assessed	B-MED
.	O
Hepatocellular	B-MED
injury	I-MED
was	O
more	O
prevalent	O
in	O
women	B-MED
<	O
50	O
years	O
vs.	O
others	O
(	O
P=.002	O
)	O
.	O
After	O
adjusting	O
for	O
biochemical	B-MED
injury	B-MED
types	B-MED
,	O
black	B-MED
race	I-MED
and	O
possible	B-MED
ageing	B-MED
effects	B-MED
,	O
more	O
severe	B-MED
interface	O
hepatitis	B-MED
was	O
noted	O
in	O
biopsies	B-MED
of	O
women	B-MED
<	O
50	O
years	O
compared	B-MED
to	O
those	O
of	O
men	B-MED
and	O
women	B-MED
≥50	O
years	O
(	O
P=.009	O
and	O
P=.055	O
respectively	O
)	O
.	O
Compared	B-MED
to	O
those	O
of	O
men	B-MED
,	O
biopsies	B-MED
of	O
women	B-MED
showed	O
greater	B-MED
plasma	B-MED
cell	I-MED
infiltration	I-MED
,	O
hepatocyte	B-MED
apoptosis	I-MED
,	O
hepatocyte	B-MED
rosettes	B-MED
and	O
lobular	B-MED
disarray	O
but	O
less	O
iron	B-MED
-	O
positive	B-MED
hepatocytes	B-MED
and	O
histological	B-MED
cholestasis	B-MED
(	O
P<.05	O
)	O
.	O
These	O
associations	B-MED
persisted	O
after	O
excluding	O
cases	B-MED
of	O
amoxicillin	B-MED
/	I-MED
clavulanic	I-MED
acid	I-MED
,	O
anabolic	B-MED
steroids	I-MED
or	O
nitrofurantoin	B-MED
DILI	B-MED
which	O
showed	O
gender	B-MED
-specific	O
distributions	B-MED
.	O
Gender	B-MED
and	O
a	O
proxy	B-MED
of	O
menopause	B-MED
were	O
associated	B-MED
with	I-MED
various	O
features	B-MED
of	O
inflammation	B-MED
and	O
injury	B-MED
in	O
DILI	B-MED
.	O
Oral	B-MED
health	I-MED
in	O
transition	B-MED
:	O
The	O
Hadza	B-MED
foragers	I-MED
of	O
Tanzania	B-MED
Conventional	B-MED
wisdom	O
holds	O
that	O
a	O
decline	B-MED
in	O
oral	B-MED
health	I-MED
accompanies	O
the	O
transition	B-MED
from	O
hunting	B-MED
and	O
gathering	B-MED
to	O
agriculture	B-MED
,	O
given	O
increased	B-MED
consumption	B-MED
of	O
carbohydrates	B-MED
.	O
This	O
widely	O
touted	O
example	B-MED
of	O
the	O
mismatch	B-MED
between	O
our	O
biology	B-MED
and	O
modern	B-MED
lifestyle	I-MED
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological	B-MED
record	I-MED
of	O
the	O
Neolithic	B-MED
Revolution	I-MED
in	O
the	O
New	B-MED
World	I-MED
.	O
Recent	O
studies	B-MED
of	O
other	O
populations	B-MED
have	O
,	O
however	O
,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	B-MED
.	O
Here	O
,	O
we	O
present	O
the	O
first	O
comprehensive	B-MED
study	B-MED
of	O
oral	B-MED
health	I-MED
among	O
a	O
living	B-MED
population	I-MED
in	O
transition	B-MED
from	O
the	O
bush	B-MED
to	O
village	B-MED
life	I-MED
,	O
the	O
Hadza	B-MED
hunter	B-MED
-	O
gatherers	B-MED
of	O
Tanzania	B-MED
,	O
to	O
test	O
the	O
hypothesis	B-MED
that	O
the	O
shift	B-MED
from	O
foraging	B-MED
to	O
farming	B-MED
,	O
or	O
agricultural	B-MED
intensification	I-MED
,	O
inevitably	O
leads	O
to	O
increased	B-MED
periodontal	B-MED
disease	I-MED
,	O
caries	B-MED
,	O
and	O
orthodontic	B-MED
disorders	B-MED
.	O
Our	O
results	B-MED
showed	O
that	O
women	B-MED
living	B-MED
in	O
villages	B-MED
consuming	B-MED
a	O
mostly	O
agricultural	B-MED
diet	B-MED
exhibited	O
more	O
caries	B-MED
and	O
periodontal	B-MED
disease	I-MED
than	O
those	O
living	B-MED
in	O
the	O
bush	B-MED
consuming	B-MED
a	O
mostly	O
wild	B-MED
-	I-MED
food	I-MED
diet	I-MED
.	O
Furthermore	O
,	O
men	B-MED
living	B-MED
in	O
the	O
bush	B-MED
consuming	B-MED
mostly	O
a	O
wild	B-MED
-	I-MED
food	I-MED
diet	I-MED
had	O
more	O
than	O
those	O
living	B-MED
in	O
the	O
village	B-MED
consuming	B-MED
a	O
mostly	O
agricultural	B-MED
diet	B-MED
.	O
These	O
findings	B-MED
are	O
explained	O
by	O
the	O
high	B-MED
incidence	B-MED
of	O
maize	B-MED
consumption	B-MED
in	O
village	B-MED
settings	O
,	O
along	O
with	O
previously	O
recognized	O
variation	B-MED
in	O
rate	B-MED
of	O
caries	B-MED
between	O
men	B-MED
and	O
women	B-MED
.	O
The	O
unexpected	O
discovery	O
of	O
high	B-MED
caries	B-MED
incidences	B-MED
for	O
men	B-MED
in	O
the	O
bush	B-MED
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	B-MED
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	B-MED
and	O
marijuana	B-MED
.	I-MED
These	O
data	B-MED
support	O
the	O
notions	O
that	O
mechanisms	B-MED
of	O
cariogenesis	B-MED
are	O
multifactorial	B-MED
and	O
that	O
the	O
relationships	B-MED
between	O
oral	B-MED
health	I-MED
and	O
the	O
shift	B-MED
from	O
a	O
predominantly	O
wild	B-MED
-	I-MED
food	I-MED
diet	I-MED
to	O
one	O
dominated	O
by	O
cultigens	B-MED
are	O
nuanced	O
.	O
Coxiella	B-MED
burnetii	I-MED
isolates	B-MED
originating	O
from	O
infected	B-MED
cattle	I-MED
induce	B-MED
a	O
more	O
pronounced	O
proinflammatory	B-MED
cytokine	I-MED
response	I-MED
compared	O
to	O
isolates	B-MED
from	O
infected	B-MED
goats	I-MED
and	O
sheep	B-MED
Coxiella	B-MED
burnetii	I-MED
is	O
the	O
causative	B-MED
agent	I-MED
of	O
Q	B-MED
fever	I-MED
.	O
Although	O
the	O
prevalence	B-MED
of	O
C.	B-MED
burnetii	I-MED
in	O
cattle	B-MED
is	O
much	O
higher	O
than	O
in	O
goats	B-MED
and	O
sheep	B-MED
,	O
infected	B-MED
cattle	I-MED
are	O
rarely	O
associated	B-MED
with	I-MED
human	B-MED
outbreaks	B-MED
.	O
We	O
investigated	B-MED
whether	O
the	O
immune	B-MED
response	I-MED
of	O
humans	B-MED
differs	O
after	O
contact	O
with	O
C.	B-MED
burnetii	I-MED
isolates	B-MED
from	O
different	O
host	B-MED
origins	I-MED
or	O
with	O
different	O
multilocus	B-MED
variable	I-MED
number	I-MED
of	I-MED
tandem	I-MED
repeat	I-MED
analysis	I-MED
(	O
MLVA	B-MED
)	O
genotypes	B-MED
.	O
Cytokine	B-MED
responses	I-MED
were	O
measured	O
in	O
human	B-MED
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
(	O
PBMCs	B-MED
)	O
stimulated	B-MED
with	O
16	O
C.	B-MED
burnetii	I-MED
isolates	B-MED
with	O
known	O
MLVA	B-MED
genotype	B-MED
from	O
goats	B-MED
,	O
sheep	B-MED
,	O
cattle	B-MED
,	O
acute	B-MED
and	O
chronic	B-MED
Q	I-MED
fever	I-MED
patients	B-MED
.	O
Coxiella	B-MED
burnetii	I-MED
isolates	B-MED
originating	O
from	O
cattle	B-MED
induce	B-MED
significantly	O
more	O
IL-1β	B-MED
,	O
TNF	B-MED
-	I-MED
α	I-MED
and	O
IL-22	B-MED
than	O
the	O
isolates	B-MED
from	O
goats	B-MED
,	O
sheep	B-MED
or	O
chronic	B-MED
Q	I-MED
fever	I-MED
patients	B-MED
.	O
Comparing	O
the	O
cytokine	B-MED
induction	B-MED
of	O
the	O
isolates	B-MED
based	O
on	O
their	O
MVLA	B-MED
genotype	B-MED
did	O
not	O
reveal	O
differences	O
in	O
response	B-MED
between	O
the	O
MLVA	B-MED
genotypes	B-MED
.	O
The	O
proinflammatory	B-MED
cytokine	I-MED
response	I-MED
induced	B-MED
in	O
human	B-MED
PBMCs	B-MED
by	O
C.	B-MED
burnetii	I-MED
isolates	B-MED
from	O
cattle	B-MED
may	O
explain	O
the	O
low	O
incidence	B-MED
of	O
human	B-MED
Q	B-MED
fever	I-MED
outbreaks	B-MED
caused	O
by	O
cattle	B-MED
.	O
The	O
cytokine	B-MED
cytokine	B-MED
profile	I-MED
of	O
PBMCs	B-MED
stimulated	B-MED
with	O
C.	B-MED
burnetii	I-MED
isolates	B-MED
from	O
chronic	B-MED
Q	I-MED
fever	I-MED
patients	B-MED
resembles	O
isolates	B-MED
from	O
goats	B-MED
.	O
Furthermore	O
,	O
cytokine	B-MED
responses	I-MED
seem	O
to	O
be	O
depending	O
on	O
host	B-MED
origin	I-MED
than	O
on	O
MLVA	B-MED
genotype	B-MED
.	O
The	O
link	O
between	O
self	B-MED
-	I-MED
perceptions	I-MED
of	O
aging	B-MED
,	O
cancer	B-MED
view	O
and	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
of	O
older	B-MED
people	I-MED
with	O
cancer	B-MED
:	O
A	B-MED
cross	I-MED
-	I-MED
sectional	I-MED
study	I-MED
Older	B-MED
people	I-MED
may	O
suffer	O
from	O
stigmas	B-MED
linked	O
to	O
cancer	B-MED
and	O
aging	B-MED
.	O
Although	O
some	O
studies	B-MED
suggested	O
that	O
a	O
negative	B-MED
view	B-MED
of	O
cancer	B-MED
may	O
increase	O
the	O
level	B-MED
of	I-MED
depression	I-MED
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	B-MED
in	O
the	O
elderly	B-MED
population	I-MED
.	O
Similarly	O
,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-MED
self	B-MED
-	I-MED
perception	I-MED
of	O
aging	B-MED
has	O
deleterious	O
consequences	B-MED
on	O
mental	B-MED
and	O
physical	B-MED
health	I-MED
in	O
normal	O
aging	B-MED
,	O
the	O
influence	O
in	O
pathological	B-MED
contexts	B-MED
,	O
such	O
as	O
oncology	B-MED
,	O
has	O
not	O
been	O
studied	O
.	O
The	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	B-MED
the	O
effect	O
of	O
these	O
two	O
stigmas	B-MED
on	O
the	O
health	B-MED
of	O
elderly	B-MED
oncology	B-MED
patients	B-MED
.	O
101	O
patients	B-MED
suffering	O
from	O
a	O
cancer	B-MED
(	O
breast	B-MED
,	O
gynecological	B-MED
,	O
lung	B-MED
or	O
hematological	B-MED
)	O
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-MED
.	O
Their	O
self	B-MED
-	I-MED
perception	I-MED
of	O
age	B-MED
,	O
cancer	B-MED
view	O
and	O
health	B-MED
(	O
physical	B-MED
and	O
mental	B-MED
)	O
was	O
assessed	O
.	O
Multiple	O
regressions	B-MED
showed	O
that	O
patients	B-MED
with	O
a	O
more	O
negative	B-MED
self	B-MED
-	I-MED
perception	I-MED
of	O
aging	B-MED
and/or	O
more	O
negative	B-MED
cancer	B-MED
view	O
reported	O
poorer	B-MED
global	B-MED
health	I-MED
.	O
We	O
also	O
observed	O
that	O
negative	B-MED
self	B-MED
-	I-MED
perception	I-MED
of	O
aging	B-MED
was	O
associated	B-MED
with	I-MED
worse	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
,	O
whereas	O
negative	B-MED
cancer	B-MED
views	O
were	O
only	O
linked	O
to	O
worse	O
mental	B-MED
health	I-MED
.	O
No	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-MED
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	B-MED
.	O
Older	O
patients	B-MED
with	O
cancer	B-MED
face	O
double	O
stigmatization	B-MED
,	O
due	O
to	O
negative	B-MED
self	B-MED
-	I-MED
perception	I-MED
of	O
aging	B-MED
and	O
cancer	B-MED
,	O
and	O
these	O
stigmas	B-MED
have	O
impacts	O
on	O
global	O
and	O
mental	B-MED
health	I-MED
.	O
Self	B-MED
-	I-MED
perception	I-MED
of	O
aging	B-MED
is	O
also	O
linked	O
to	O
physical	B-MED
health	I-MED
.	O
Longitudinal	B-MED
studies	I-MED
will	O
be	O
necessary	O
to	O
analyze	B-MED
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	B-MED
and	O
health	B-MED
.	O
Pathogenesis	B-MED
of	O
COPD	B-MED
and	O
Asthma	B-MED
Asthma	B-MED
and	O
COPD	B-MED
remain	O
two	O
diseases	B-MED
of	I-MED
the	I-MED
respiratory	I-MED
tract	I-MED
with	O
unmet	B-MED
medical	B-MED
needs	B-MED
.	O
This	O
review	B-MED
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	B-MED
of	O
these	O
two	O
chronic	B-MED
inflammatory	I-MED
diseases	I-MED
of	O
the	O
lung	B-MED
.	O
The	O
review	B-MED
highlights	O
why	O
they	O
are	O
different	O
conditions	B-MED
requiring	O
different	O
approaches	O
to	O
treatment	B-MED
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	B-MED
and	O
treatment	B-MED
of	O
asthma	B-MED
and	O
COPD	B-MED
.	O
Primary	B-MED
pituitary	B-MED
diffuse	B-MED
large	I-MED
B	I-MED
-	I-MED
cell	I-MED
lymphoma	I-MED
with	O
somatotroph	B-MED
hyperplasia	I-MED
and	O
acromegaly	B-MED
:	O
case	B-MED
report	I-MED
Diffuse	B-MED
large	I-MED
B	I-MED
-	I-MED
cell	I-MED
lymphoma	I-MED
(	O
DLBCL	B-MED
)	O
is	O
the	O
most	O
common	B-MED
type	B-MED
of	O
non	B-MED
-	I-MED
Hodgkin	I-MED
lymphoma	I-MED
and	O
comprises	O
approximately	O
30	O
%	O
of	O
all	O
lymphomas	B-MED
.	O
Patients	B-MED
typically	O
present	B-MED
with	O
a	O
nonpainful	B-MED
mass	B-MED
in	O
the	O
neck	B-MED
,	O
groin	B-MED
,	O
or	O
abdomen	B-MED
associated	B-MED
with	I-MED
constitutional	B-MED
symptoms	I-MED
.	O
In	O
this	O
report	B-MED
,	O
however	O
,	O
the	O
authors	B-MED
describe	O
a	O
rare	B-MED
case	B-MED
of	O
a	O
61-	O
year	B-MED
-old	O
woman	B-MED
with	O
hyperprolactinemia	B-MED
,	O
hypothyroidism	B-MED
,	O
and	O
acromegaly	B-MED
(	O
elevation	B-MED
of	O
insulin	B-MED
-	I-MED
like	I-MED
growth	I-MED
factor-1	I-MED
[	O
IGF-1	B-MED
]	O
)	O
with	O
elevated	B-MED
growth	B-MED
hormone	I-MED
-	I-MED
releasing	I-MED
hormone	I-MED
(	O
GHRH	B-MED
)	O
in	O
whom	O
an	O
MRI	B-MED
demonstrated	B-MED
diffuse	B-MED
enlargement	I-MED
of	I-MED
the	I-MED
pituitary	I-MED
gland	I-MED
.	O
Despite	O
medical	B-MED
treatment	I-MED
,	O
the	O
patient	B-MED
had	O
persistent	B-MED
elevation	B-MED
of	O
IGF-1	B-MED
.	O
She	O
underwent	O
a	O
transsphenoidal	B-MED
biopsy	I-MED
,	O
which	O
yielded	B-MED
a	O
diagnosis	B-MED
of	O
DLBCL	B-MED
with	O
an	O
activated	B-MED
B	B-MED
-	I-MED
cell	I-MED
immunophenotype	B-MED
with	O
somatotroph	B-MED
hyperplasia	I-MED
.	O
After	O
stereo	B-MED
-	I-MED
tactic	I-MED
radiation	I-MED
therapy	I-MED
in	O
combination	B-MED
with	O
chemotherapy	B-MED
,	O
she	O
is	O
currently	B-MED
in	O
remission	B-MED
from	O
her	O
lymphoma	B-MED
and	O
has	O
normalized	B-MED
IGF-1	B-MED
levels	B-MED
without	O
medical	B-MED
therapy	I-MED
,	O
8	O
months	B-MED
after	O
her	O
histopathological	B-MED
diagnosis	B-MED
.	O
This	O
is	O
the	O
only	O
reported	B-MED
case	B-MED
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-MED
diagnosis	I-MED
,	O
multidisciplinary	B-MED
evaluation	I-MED
,	O
and	O
critical	B-MED
intraoperative	B-MED
decision	B-MED
-	I-MED
making	I-MED
when	O
treating	B-MED
atypical	O
sellar	B-MED
lesions	B-MED
.	O
Primary	B-MED
neuroendocrine	I-MED
carcinoma	I-MED
of	O
the	O
breast	B-MED
A	O
single	B-MED
Center	I-MED
experience	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
Neuroendocrine	B-MED
carcinoma	I-MED
of	O
the	O
breast	B-MED
is	O
an	O
extremely	B-MED
rare	B-MED
tumor	B-MED
.	O
A	O
standard	B-MED
treatment	B-MED
has	O
yet	O
to	O
be	O
established	B-MED
because	O
only	O
a	O
few	O
cases	B-MED
have	O
been	O
reported	O
in	O
literature	B-MED
.	O
The	O
authors	B-MED
report	O
five	O
cases	B-MED
observed	O
from	O
January	B-MED
2007	O
to	O
December	B-MED
2014	O
and	O
a	O
review	B-MED
of	I-MED
literature	I-MED
.	O
Four	O
patients	B-MED
underwent	O
quadrantectomy	B-MED
and	O
in	O
two	O
cases	B-MED
axillary	B-MED
nodal	I-MED
dissection	I-MED
and	O
only	O
one	O
to	O
mastectomy	B-MED
with	O
axillary	B-MED
nodal	I-MED
dissection	I-MED
.	O
Tumor	B-MED
size	I-MED
was	O
from	O
T1	B-MED
to	O
T2	B-MED
with	O
N0	B-MED
to	O
N1	B-MED
,	O
according	O
TNM	B-MED
classification	I-MED
.	O
Pathological	B-MED
specimens	I-MED
were	O
stained	B-MED
with	O
hematoxylin	B-MED
and	O
eosin	B-MED
and	O
an	O
immunohistochemical	B-MED
panel	B-MED
of	O
antibodies	B-MED
(	O
Neuron	B-MED
-	I-MED
specific	I-MED
enolase	I-MED
,	O
Chromogranin	B-MED
,	O
Synaptophysin	B-MED
,	O
Estrogen	B-MED
and	O
Progesterone	B-MED
receptors	I-MED
,	O
c	B-MED
-	I-MED
erb	I-MED
and	O
Ki-67	B-MED
)	O
.	O
All	O
cases	B-MED
showed	O
markers	B-MED
positivity	O
to	O
Neuron	B-MED
-	I-MED
specific	I-MED
enolase	I-MED
,	O
Chromogranin	B-MED
,	O
Synaptophysin	B-MED
and	O
Estrogen	B-MED
and	O
Progesterone	B-MED
receptors	I-MED
were	O
found	O
.	O
Ki-67	B-MED
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	B-MED
.	O
Adjuvant	B-MED
chemotherapy	I-MED
was	O
administrated	B-MED
in	O
patients	B-MED
with	O
Ki-67	B-MED
>	O
10	O
%	O
;	O
every	O
patients	B-MED
were	O
treated	B-MED
with	O
radiotherapy	B-MED
and	O
with	O
hormonal	B-MED
therapy	I-MED
too	O
.	O
Although	O
Neuroendocrine	B-MED
breast	I-MED
tumor	I-MED
is	O
considered	O
a	O
distinct	O
entity	B-MED
,	O
the	O
best	O
treatment	B-MED
seems	O
to	O
be	O
correlate	B-MED
to	O
the	O
size	B-MED
of	I-MED
tumor	I-MED
and	O
to	O
the	O
lymph	B-MED
node	I-MED
status	B-MED
and	O
to	O
Ki-67	B-MED
index	B-MED
like	O
the	O
common	O
breast	B-MED
cancer	I-MED
.	O
Diagnosis	B-MED
,	O
Neuroendocrine	B-MED
breast	I-MED
carcinoma	I-MED
.	O
Plasma	B-MED
DNA	B-MED
and	O
RNA	B-MED
differentially	B-MED
impact	B-MED
coagulation	B-MED
during	O
abdominal	B-MED
sepsis	I-MED
-an	O
explorative	B-MED
study	I-MED
Cell	B-MED
-	I-MED
free	I-MED
DNA	I-MED
(	O
cfDNA	B-MED
)	O
and	O
extracellular	B-MED
RNA	B-MED
(	O
exRNA	B-MED
)	O
are	O
both	O
suspected	B-MED
to	O
activate	B-MED
coagulation	B-MED
cascades	I-MED
in	O
sepsis	B-MED
.	O
Therefore	O
,	O
our	O
study	B-MED
investigated	B-MED
the	O
influence	B-MED
of	O
plasmatic	B-MED
nucleic	B-MED
acids	I-MED
on	O
coagulation	B-MED
in	O
septic	B-MED
patients	B-MED
in	O
comparison	B-MED
to	O
patients	B-MED
after	O
major	O
abdominal	B-MED
surgery	I-MED
.	O
A	O
total	O
of	O
15	O
patients	B-MED
with	O
sepsis	B-MED
,	O
10	O
postoperative	B-MED
patients	B-MED
,	O
and	O
10	O
healthy	B-MED
volunteers	I-MED
were	O
included	B-MED
in	O
this	O
longitudinal	B-MED
study	I-MED
.	O
Blood	B-MED
was	O
collected	B-MED
at	O
sepsis	B-MED
onset	B-MED
and	O
after	O
surgery	B-MED
respectively	O
,	O
as	O
well	O
as	O
after	O
24	O
,	O
72	O
and	O
168	O
h.	O
Levels	B-MED
of	O
cfDNA	B-MED
and	O
exRNA	B-MED
were	O
measured	B-MED
by	O
quantitative	B-MED
probe	B-MED
-	I-MED
based	I-MED
polymerase	B-MED
chain	I-MED
reaction	I-MED
.	O
In	O
addition	O
,	O
thromboelastography	B-MED
for	O
coagulation	B-MED
as	O
well	O
as	O
thromboaggregometry	B-MED
for	O
platelet	B-MED
function	I-MED
was	O
conducted	O
.	O
Both	O
cfDNA	B-MED
and	O
exRNA	B-MED
were	O
elevated	B-MED
in	O
patients	B-MED
with	O
sepsis	B-MED
compared	B-MED
with	O
postoperative	B-MED
patients	B-MED
and	O
healthy	B-MED
volunteers	I-MED
.	O
While	O
higher	B-MED
exRNA	B-MED
levels	B-MED
correlated	B-MED
with	O
a	O
faster	B-MED
clotting	I-MED
time	I-MED
and	O
more	O
stable	B-MED
clots	I-MED
,	O
cfDNA	B-MED
correlated	B-MED
with	O
a	O
shorter	B-MED
clotting	I-MED
time	I-MED
but	O
also	O
less	O
fibrinolysis	B-MED
.	O
In	O
addition	O
,	O
higher	B-MED
cfDNA	B-MED
seems	O
to	O
be	O
associated	B-MED
with	I-MED
kidney	B-MED
dysfunction	I-MED
as	O
well	O
as	O
with	O
general	O
markers	B-MED
of	O
cell	B-MED
damage	I-MED
(	O
lactate	B-MED
dehydrogenase	I-MED
and	O
lactate	B-MED
)	O
.	O
Both	O
nucleic	B-MED
acid	I-MED
species	O
might	O
be	O
associated	B-MED
with	I-MED
different	B-MED
effects	B-MED
on	O
coagulation	B-MED
during	O
sepsis	B-MED
,	O
with	O
an	O
overall	B-MED
procoagulatory	B-MED
influence	B-MED
.	O
For	O
this	O
reason	O
,	O
individualized	B-MED
therapeutic	B-MED
approaches	I-MED
in	O
patients	B-MED
suffering	B-MED
from	O
coagulation	B-MED
-	O
associated	B-MED
organ	B-MED
dysfunction	I-MED
might	O
be	O
feasible	O
.	O
Ocular	B-MED
toxicity	I-MED
of	O
AUY922	B-MED
in	O
pigmented	B-MED
and	O
albino	B-MED
rats	I-MED
AUY922	B-MED
,	O
a	O
heat	B-MED
shock	I-MED
protein	I-MED
90	I-MED
inhibitor	B-MED
is	O
associated	O
with	O
ocular	B-MED
adverse	B-MED
events	I-MED
(	O
AEs	B-MED
)	O
.	O
To	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-MED
AEs	B-MED
in	O
patients	B-MED
,	O
4	O
investigative	B-MED
studies	I-MED
were	O
performed	O
in	O
a	O
step	B-MED
-	I-MED
wise	I-MED
approach	I-MED
to	O
assess	O
retinal	B-MED
structure	I-MED
and	O
function	O
in	O
pigmented	B-MED
(	O
Brown	B-MED
Norway	I-MED
)	O
and	O
albino	B-MED
(	I-MED
Wistar	I-MED
)	I-MED
rats	I-MED
Wistar	B-MED
.	O
In	O
rats	B-MED
administered	B-MED
30mg	O
/	O
kg	O
of	O
AUY922	B-MED
,	O
the	O
AUC	B-MED
0	O
-	O
24	O
h	B-MED
and	O
Cmax	B-MED
are	O
comparable	O
to	O
that	O
in	O
patients	B-MED
at	O
70mg	O
/	O
m(2	O
)	O
.	O
AUY922	B-MED
at	O
≥30mg	O
/	O
kg	O
was	O
poorly	O
tolerated	O
by	O
rats	B-MED
with	O
morbidity	B-MED
or	O
mortality	B-MED
generally	O
after	O
the	O
third	O
weekly	B-MED
treatment	B-MED
.	O
Electroretinography	B-MED
(	O
ERG	B-MED
)	O
changes	B-MED
were	O
observed	O
at	O
doses	B-MED
≥30mg	O
/	O
kg	O
.	O
The	O
ERG	B-MED
changes	B-MED
were	O
dose	B-MED
dependent	I-MED
,	O
consistent	B-MED
with	O
an	O
effect	O
on	O
the	O
photoreceptors	B-MED
,	O
and	O
fully	O
reversible	B-MED
.	O
The	O
ERG	B-MED
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
Cmax	B-MED
while	O
maintaining	O
AUC	B-MED
.	O
Histopathological	B-MED
changes	B-MED
were	O
seen	O
mainly	O
when	O
rats	B-MED
were	O
administered	B-MED
AUY922	B-MED
at	O
100mg	O
/	O
kg	O
.	O
The	O
2-	O
hour	B-MED
infusion	B-MED
of	O
AUY922	B-MED
at	O
100mg	O
/	O
kg	O
caused	O
disorganization	B-MED
of	O
the	O
outer	B-MED
segment	I-MED
photoreceptor	I-MED
morphology	B-MED
in	O
male	B-MED
Brown	B-MED
Norway	I-MED
rats	I-MED
;	O
the	O
severity	O
of	O
the	O
disorganization	B-MED
increased	O
with	O
the	O
number	O
of	O
administrations	B-MED
,	O
but	O
was	O
reversible	B-MED
during	O
a	O
4-	O
week	B-MED
posttreatment	B-MED
period	I-MED
.	O
There	O
was	O
no	O
major	O
difference	O
in	O
ocular	B-MED
response	B-MED
between	O
Brown	B-MED
Norway	I-MED
and	O
Wistar	B-MED
rats	I-MED
.	O
No	O
changes	O
in	O
serum	B-MED
iron	I-MED
levels	I-MED
,	O
and	O
no	O
changes	O
in	O
rhodopsin	B-MED
,	O
PDE6α	B-MED
,	O
β	B-MED
-	I-MED
transducin	I-MED
concentrations	B-MED
,	O
or	O
retinal	B-MED
pigment	I-MED
epithelium	I-MED
-	I-MED
specific	I-MED
protein	I-MED
RPE65	I-MED
expression	B-MED
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	B-MED
of	O
AUY922	B-MED
at	O
100mg	O
/	O
kg	O
compared	O
to	O
vehicle	B-MED
-	I-MED
treated	I-MED
controls	I-MED
.	O
AUY922	B-MED
retinal	B-MED
toxicity	I-MED
in	O
rats	B-MED
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	B-MED
and	O
is	O
shown	O
to	O
be	O
reversible	B-MED
,	O
while	O
a	O
precise	O
molecular	B-MED
mechanism	I-MED
for	O
the	O
effect	O
was	O
not	O
determined	O
.	O
Young	B-MED
people	B-MED
,	O
mental	B-MED
health	I-MED
practitioners	B-MED
and	O
researchers	B-MED
co	O
-	O
produce	O
a	O
Transition	B-MED
Preparation	I-MED
Programme	I-MED
to	O
improve	O
outcomes	B-MED
and	O
experience	B-MED
for	O
young	B-MED
people	B-MED
leaving	O
Child	B-MED
and	I-MED
Adolescent	I-MED
Mental	I-MED
Health	I-MED
Services	I-MED
(	O
CAMHS	B-MED
)	O
In	O
the	O
UK	B-MED
young	B-MED
people	B-MED
attending	O
child	B-MED
and	I-MED
adolescent	I-MED
mental	I-MED
health	I-MED
services	I-MED
(	O
CAMHS	B-MED
)	O
are	O
required	O
to	O
move	O
on	O
,	O
either	O
through	O
discharge	B-MED
or	O
referral	B-MED
to	I-MED
an	O
adult	B-MED
service	I-MED
,	O
at	O
age	B-MED
17/18	O
,	O
a	O
period	B-MED
of	O
increased	B-MED
risk	B-MED
for	O
onset	B-MED
of	I-MED
mental	B-MED
health	I-MED
problems	I-MED
and	O
other	O
complex	B-MED
psychosocial	B-MED
and	O
physical	B-MED
changes	B-MED
.	O
CAMHS	B-MED
transitions	B-MED
are	O
often	O
poorly	O
managed	O
with	O
negative	B-MED
outcomes	B-MED
for	O
young	B-MED
people	B-MED
.	O
Better	O
preparation	B-MED
may	O
improve	O
outcomes	B-MED
and	O
experience	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
co	O
-	O
produce	O
,	O
with	O
young	B-MED
people	B-MED
who	O
had	O
transitioned	B-MED
or	O
were	O
facing	O
transition	B-MED
from	O
CAMHS	B-MED
,	O
a	O
CAMHS	B-MED
Transition	B-MED
Preparation	I-MED
Programme	I-MED
(	O
TPP	B-MED
)	O
,	O
deliverable	O
in	O
routine	B-MED
NHS	B-MED
settings	O
.	O
Eighteen	O
young	B-MED
people	B-MED
,	O
aged	O
17	O
-	O
22	O
,	O
from	O
three	O
UK	B-MED
National	B-MED
Health	I-MED
Service	I-MED
(	O
NHS	B-MED
)	O
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative	O
,	O
participatory	B-MED
research	I-MED
workshops	I-MED
.	O
Seven	O
parents	B-MED
completed	O
short	O
questionnaires	B-MED
.	O
Thirty	O
clinical	B-MED
staff	I-MED
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	B-MED
to	O
ensure	O
deliverability	O
of	O
young	B-MED
people	B-MED
's	I-MED
ideas	B-MED
.	O
Young	B-MED
people	B-MED
were	O
offered	O
co	B-MED
-	I-MED
research	I-MED
opportunities	I-MED
.	O
Most	O
young	B-MED
people	B-MED
felt	O
anxious	B-MED
,	O
fearful	B-MED
and	O
uncertain	O
on	O
leaving	O
CAMHS	B-MED
and	O
perceived	B-MED
mental	B-MED
health	I-MED
services	I-MED
as	O
uncaring	O
.	O
Participants	B-MED
outlined	O
transition	B-MED
procedures	B-MED
and	O
drafted	O
a	O
range	O
of	O
preparation	B-MED
activities	I-MED
,	O
centred	O
around	O
dedicated	O
Transition	B-MED
Peer	B-MED
Support	I-MED
and	O
a	O
transition	B-MED
booklet	B-MED
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
CAMHS	B-MED
leavers	B-MED
,	O
irrespective	O
of	O
discharge	B-MED
or	O
transfer	B-MED
to	O
an	O
adult	B-MED
service	I-MED
.	O
Preparation	B-MED
should	O
aim	O
to	O
build	O
confidence	B-MED
to	O
help	O
young	B-MED
people	B-MED
take	O
responsibility	B-MED
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	B-MED
world	B-MED
:	O
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough	O
.	O
Some	O
clinicians	B-MED
also	O
felt	O
anxious	B-MED
at	O
transition	B-MED
and	O
recognised	O
the	O
potential	O
impact	B-MED
on	O
young	B-MED
people	B-MED
of	O
poor	O
communication	B-MED
and	O
lack	B-MED
of	O
understanding	O
between	O
services	B-MED
.	O
Parents	B-MED
would	O
appreciate	O
help	O
to	O
support	B-MED
their	O
offspring	B-MED
during	O
the	O
transition	B-MED
period	B-MED
.	O
Clinicians	B-MED
cited	O
lack	B-MED
of	O
funding	O
and	O
inflexible	O
NHS	B-MED
procedures	B-MED
and	O
policies	B-MED
as	O
potential	O
barriers	B-MED
to	O
the	O
implementation	B-MED
of	O
young	B-MED
people	B-MED
's	I-MED
ideas	B-MED
.	O
Nine	O
young	B-MED
people	B-MED
took	O
up	O
co	B-MED
-	I-MED
research	I-MED
opportunities	I-MED
.	O
Mental	B-MED
health	I-MED
services	I-MED
underestimate	O
the	O
anxiety	B-MED
of	O
CAMHS	B-MED
leavers	B-MED
.	O
Young	B-MED
people	B-MED
have	O
clear	O
ideas	B-MED
about	O
the	O
preparation	B-MED
they	O
require	O
to	O
leave	O
CAMHS	B-MED
with	O
the	O
confidence	B-MED
to	O
take	O
responsibility	B-MED
for	O
their	O
own	O
health	B-MED
care	I-MED
.	O
Close	O
collaboration	B-MED
of	O
NHS	B-MED
staff	B-MED
and	O
researchers	B-MED
facilitates	O
the	O
implementation	B-MED
of	O
research	B-MED
findings	B-MED
.	O
A	O
Course	B-MED
-Based	O
Approach	B-MED
to	O
the	O
Doctor	B-MED
of	O
Nursing	B-MED
Practice	I-MED
Project	I-MED
:	O
Supporting	O
Student	B-MED
Growth	O
From	O
Concept	B-MED
to	O
Completion	B-MED
We	O
describe	O
a	O
course	B-MED
-based	O
approach	B-MED
to	O
the	O
doctor	B-MED
of	O
nursing	B-MED
practice	I-MED
project	I-MED
in	O
which	O
students	B-MED
work	B-MED
in	O
groups	B-MED
of	O
8	O
to	O
12	O
with	O
a	O
faculty	B-MED
member	I-MED
to	O
complete	B-MED
individual	O
final	O
projects	B-MED
that	O
require	O
a	O
minimum	B-MED
of	O
360	O
practicum	B-MED
hours	B-MED
in	O
3-	O
semester	B-MED
-long	O
courses	B-MED
.	O
Project	B-MED
teams	I-MED
include	O
agency	B-MED
or	O
community	B-MED
-based	O
mentors	B-MED
.	O
Project	B-MED
findings	I-MED
are	O
disseminated	B-MED
through	O
written	B-MED
and	O
oral	B-MED
reports	I-MED
.	O
This	O
approach	B-MED
preserves	O
faculty	B-MED
resources	B-MED
and	O
provides	O
students	B-MED
with	O
mentoring	B-MED
,	O
opportunities	B-MED
for	O
reflection	B-MED
,	O
and	O
time	B-MED
for	O
project	B-MED
development	I-MED
.	O
The	O
Prevalence	B-MED
of	O
Sleep	B-MED
Apnea	I-MED
in	O
Type	B-MED
B	I-MED
Aortic	I-MED
Dissection	I-MED
:	O
Implications	O
for	O
False	B-MED
Lumen	B-MED
Thrombosis	B-MED
Obstructive	B-MED
sleep	I-MED
apnea	I-MED
(	O
OSA	B-MED
)	O
has	O
been	O
implicated	O
in	O
aortic	B-MED
dissection	I-MED
.	O
Thrombosis	B-MED
of	O
the	O
false	B-MED
lumen	B-MED
is	O
associated	B-MED
with	I-MED
a	O
prognosis	B-MED
of	O
type	B-MED
B	I-MED
aortic	I-MED
dissection	I-MED
(	O
AoD	B-MED
)	O
,	O
and	O
partial	B-MED
thrombosis	I-MED
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	B-MED
of	O
mortality	B-MED
.	O
This	O
study	B-MED
sought	O
to	O
explore	O
whether	O
the	O
severity	B-MED
of	O
OSA	B-MED
is	O
associated	B-MED
with	I-MED
false	B-MED
lumen	B-MED
thrombosis	B-MED
.	O
In	O
this	O
observational	B-MED
study	I-MED
,	O
151	O
type	B-MED
B	I-MED
AoD	I-MED
patients	B-MED
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O
The	O
status	O
of	O
the	O
false	B-MED
lumen	B-MED
was	O
classified	O
as	O
patent	O
,	O
partially	B-MED
thrombosed	B-MED
,	O
or	O
completely	O
thrombosed	B-MED
based	O
on	O
a	O
computer	B-MED
tomography	I-MED
angiography	I-MED
image	B-MED
.	O
Patients	B-MED
were	O
divided	O
into	O
non	B-MED
-	I-MED
OSA	I-MED
group	I-MED
(	O
apnea	B-MED
-	I-MED
hypopnea	I-MED
index	I-MED
[	O
AHI	B-MED
]	O
<	O
5	O
)	O
,	O
and	O
mild	B-MED
(	O
5	O
≤	O
AHI	B-MED
≤	O
15	O
)	O
,	O
moderate	B-MED
(	O
15	O
<	O
AHI	B-MED
≤	O
30	O
)	O
,	O
and	O
severe	B-MED
OSA	I-MED
groups	I-MED
(	O
AHI	B-MED
>	O
30	O
)	O
using	O
the	O
AHI	B-MED
.	O
The	O
prevalence	B-MED
of	O
OSA	B-MED
in	O
type	B-MED
B	I-MED
dissection	I-MED
was	O
66.2	O
%	O
.	O
Among	O
151	O
cases	B-MED
,	O
51	O
patients	B-MED
(	O
33.8	O
%	O
)	O
were	O
in	O
the	O
non	B-MED
-	I-MED
OSA	I-MED
group	I-MED
,	O
56	O
(	O
37.1	O
%	O
)	O
were	O
in	O
the	O
mild	B-MED
group	I-MED
,	O
21	O
(	O
13.9	O
%	O
)	O
were	O
in	O
the	O
moderate	B-MED
group	I-MED
,	O
and	O
23	O
(	O
15.2	O
%	O
)	O
were	O
in	O
the	O
severe	B-MED
group	I-MED
.	O
Additionally	O
,	O
a	O
partially	B-MED
thrombosed	B-MED
false	B-MED
lumen	B-MED
was	O
observed	O
in	O
88	O
patients	B-MED
(	O
58.3	O
%	O
)	O
.	O
Multivariable	B-MED
analysis	I-MED
revealed	O
that	O
OSA	B-MED
severity	B-MED
was	O
positively	B-MED
associated	B-MED
with	I-MED
partial	B-MED
thrombosis	B-MED
(	O
odds	B-MED
ratio	I-MED
,	O
1.784	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
:	O
1.182	O
-	O
2.691	O
,	O
P	O
=	O
.006	O
)	O
after	O
adjusting	O
for	O
other	O
confounding	B-MED
factors	I-MED
.	O
OSA	B-MED
was	O
present	O
in	O
two	O
-	O
thirds	O
of	O
patients	B-MED
with	O
type	B-MED
B	I-MED
AoD	I-MED
AoD.	O
The	O
severity	B-MED
of	O
OSA	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
partial	B-MED
false	B-MED
lumen	B-MED
thrombosis	B-MED
.	O
OSA	B-MED
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	B-MED
and	O
prognosis	B-MED
AoD	B-MED
of	O
AoD.	O
Effectiveness	B-MED
of	O
workers	B-MED
'	O
general	B-MED
health	I-MED
examination	I-MED
in	O
Korea	B-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
:	O
retrospective	B-MED
cohort	I-MED
study	I-MED
using	O
nationwide	O
data	O
Our	O
study	O
evaluated	B-MED
the	O
effectiveness	B-MED
of	O
the	O
Workers	B-MED
'	O
General	B-MED
Health	I-MED
Examination	I-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
.	O
A	O
retrospective	B-MED
cohort	I-MED
of	O
the	O
health	B-MED
examination	I-MED
participants	B-MED
in	O
2006	O
(	O
baseline	O
year	O
:	O
N	O
�	O
€‰=	O
�	O
€‰6,527,045	O
)	O
was	O
used	O
.	O
We	O
identified	O
newly	O
occurring	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
over	O
7	O
years	O
(	O
from	O
2007	O
to	O
2013	O
)	O
.	O
After	O
stratification	B-MED
by	O
age	B-MED
,	O
sex	B-MED
,	O
and	O
national	B-MED
health	I-MED
insurance	I-MED
type	I-MED
,	O
we	O
identified	O
7	O
years	O
'	O
cumulative	B-MED
incidence	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
by	O
health	B-MED
examination	I-MED
compliance	B-MED
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	B-MED
examination	I-MED
period	I-MED
and	O
compliance	B-MED
.	O
The	O
compliant	B-MED
group	I-MED
presented	O
a	O
lower	O
cumulative	B-MED
incidence	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
than	O
the	O
non	B-MED
-	I-MED
compliant	I-MED
group	I-MED
;	O
this	O
result	O
was	O
consistent	O
across	O
sex	B-MED
,	O
working	B-MED
age	B-MED
(	O
40s	O
and	O
50s	O
)	O
,	O
and	O
workplace	B-MED
policyholder	B-MED
.	O
Relative	O
risk	O
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
by	O
health	B-MED
examination	I-MED
period	I-MED
(	O
1	O
and	O
2	O
years	O
)	O
showed	O
statistically	B-MED
significant	I-MED
results	O
in	O
ischemic	B-MED
heart	I-MED
disease	I-MED
for	O
male	O
participants	B-MED
.	O
Of	O
men	B-MED
in	O
their	O
40s	O
,	O
office	B-MED
workers	I-MED
(	O
over	O
a	O
2	O
-	O
year	O
period	O
)	O
presented	O
statistically	O
higher	B-MED
relative	I-MED
risk	I-MED
of	I-MED
ischemic	B-MED
heart	I-MED
disease	I-MED
than	O
non	B-MED
-	I-MED
office	I-MED
workers	I-MED
(	O
over	O
a	O
1	O
-	O
year	O
period	O
:	O
1.03	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
1.02	O
-	O
1.03	O
)	O
.	O
However	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	B-MED
cerebrovascular	B-MED
disease	I-MED
and	O
hemorrhagic	B-MED
cerebrovascular	B-MED
disease	I-MED
for	O
men	B-MED
or	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
for	O
women	B-MED
.	O
A	O
1	O
-	O
year	O
period	O
of	O
Workers	B-MED
'	O
General	B-MED
Health	I-MED
Examinations	I-MED
in	O
non	B-MED
-	I-MED
office	I-MED
workers	I-MED
had	O
a	O
more	O
significant	O
prevention	B-MED
effect	O
on	O
ischemic	B-MED
heart	I-MED
disease	I-MED
than	O
a	O
2	O
-	O
year	O
period	O
in	O
office	B-MED
workers	I-MED
among	O
working	O
age	B-MED
(	O
40s-50s	O
)	O
men	B-MED
.	O
It	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	B-MED
of	O
cardio	B-MED
-	O
cerebrovascular	B-MED
disease	I-MED
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	B-MED
characteristics	I-MED
rather	O
than	O
by	O
health	B-MED
examination	I-MED
period	I-MED
.	O
Does	O
sex	B-MED
really	O
matter	O
?	O
Explaining	O
intraspecies	B-MED
variation	B-MED
in	O
ocean	B-MED
acidification	B-MED
responses	B-MED
Ocean	B-MED
acidification	B-MED
(	O
OA	B-MED
)	O
poses	O
a	O
major	B-MED
threat	I-MED
to	O
marine	O
ecosystems	B-MED
globally	B-MED
,	O
having	O
significant	B-MED
ecological	B-MED
and	O
economic	B-MED
importance	B-MED
.	O
The	O
number	B-MED
and	O
complexity	B-MED
of	O
experiments	B-MED
examining	B-MED
the	O
effects	B-MED
of	I-MED
OA	B-MED
has	O
substantially	B-MED
increased	B-MED
over	O
the	O
past	B-MED
decade	B-MED
,	O
in	O
an	O
attempt	B-MED
to	O
address	B-MED
multi	B-MED
-	I-MED
stressor	I-MED
interactions	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
responses	B-MED
in	O
an	O
increasing	B-MED
range	B-MED
of	O
aquatic	B-MED
organisms	I-MED
.	O
However	O
,	O
differences	B-MED
in	O
the	O
response	B-MED
of	O
males	B-MED
and	O
females	B-MED
to	O
elevated	B-MED
pCO2	I-MED
have	O
been	O
investigated	B-MED
in	O
fewer	B-MED
than	O
4	O
%	O
of	O
studies	O
to	O
date	B-MED
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	B-MED
of	O
determining	O
sex	B-MED
non	B-MED
-	I-MED
destructively	I-MED
,	O
particularly	O
in	O
early	B-MED
life	I-MED
stages	I-MED
.	O
Here	O
we	O
highlight	O
that	O
sex	B-MED
can	O
significantly	B-MED
impact	B-MED
organism	B-MED
responses	B-MED
to	O
OA	B-MED
,	O
differentially	O
affecting	B-MED
physiology	B-MED
,	O
reproduction	B-MED
,	O
biochemistry	B-MED
and	O
ultimately	B-MED
survival	I-MED
.	O
What	O
is	O
more	O
,	O
these	O
impacts	B-MED
do	O
not	O
always	O
conform	O
to	O
ecological	B-MED
theory	I-MED
based	O
on	O
differential	B-MED
resource	B-MED
allocation	I-MED
towards	O
reproduction	B-MED
,	O
which	O
would	O
predict	B-MED
females	B-MED
to	O
be	O
more	O
sensitive	B-MED
to	O
OA	B-MED
owing	O
to	O
the	O
higher	O
production	B-MED
cost	I-MED
of	O
eggs	B-MED
compared	B-MED
with	O
sperm	B-MED
.	O
Therefore	O
,	O
non-	O
sex	B-MED
-	O
specific	B-MED
studies	I-MED
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	B-MED
differences	B-MED
in	O
the	O
responses	B-MED
of	O
males	B-MED
and	O
females	B-MED
to	O
OA	B-MED
,	O
with	O
consequences	B-MED
for	O
forecasting	B-MED
the	O
fate	O
of	O
natural	B-MED
populations	B-MED
in	O
a	O
near	B-MED
-	I-MED
future	I-MED
ocean	B-MED
.	O
Discovering	O
key	O
residues	B-MED
of	O
dengue	B-MED
virus	I-MED
NS2b	B-MED
-	I-MED
NS3	I-MED
-	I-MED
protease	I-MED
:	O
New	O
binding	B-MED
sites	I-MED
for	O
antiviral	B-MED
inhibitors	I-MED
design	O
The	O
NS2B	B-MED
-	I-MED
NS3	I-MED
protease	I-MED
is	O
essential	O
for	O
the	O
Dengue	B-MED
Virus	I-MED
(	O
DENV	B-MED
)	O
replication	B-MED
process	I-MED
.	O
This	O
complex	B-MED
constitutes	O
a	O
target	B-MED
for	O
efficient	O
antiviral	B-MED
discovery	B-MED
because	O
a	O
drug	B-MED
could	O
inhibit	O
the	O
viral	B-MED
polyprotein	I-MED
processing	I-MED
.	O
Furthermore	O
,	O
since	O
the	O
protease	B-MED
is	O
highly	O
conserved	B-MED
between	O
the	O
four	O
Dengue	B-MED
virus	I-MED
serotypes	B-MED
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-MED
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them	O
.	O
In	O
this	O
article	O
,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	B-MED
residues	B-MED
on	O
the	O
function	O
of	O
the	O
Dengue	B-MED
NS2b	B-MED
-	I-MED
NS3	I-MED
Protease	I-MED
.	O
Moreover	O
,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	B-MED
for	O
the	O
search	O
of	O
alternative	O
influential	B-MED
residues	B-MED
,	O
and	O
for	O
non	B-MED
-	I-MED
competitive	I-MED
inhibitor	I-MED
development	B-MED
.	O
First	O
,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	B-MED
alanine	B-MED
scanning	B-MED
mutagenesis	I-MED
,	O
sequence	B-MED
,	O
structure	B-MED
conservation	I-MED
,	O
and	O
other	O
structure	B-MED
-based	O
characteristics	B-MED
.	O
Second	O
,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer	B-MED
perceptron	I-MED
model	I-MED
to	O
identify	O
defined	O
groups	B-MED
(	O
clusters	O
)	O
of	O
key	O
residues	B-MED
as	O
possible	O
candidate	O
pockets	O
for	O
binding	B-MED
sites	I-MED
of	O
new	O
leads	O
on	O
the	O
DENV	B-MED
protease	B-MED
.	O
The	O
identified	O
residues	B-MED
included	O
:	O
i	O
)	O
amino	B-MED
acids	I-MED
close	O
to	O
the	O
beta	B-MED
sheet	I-MED
-loop-	O
beta	B-MED
sheet	I-MED
known	O
to	O
be	O
important	O
in	O
its	O
closed	B-MED
conformation	I-MED
for	O
NS2b	B-MED
ii	O
)	O
residues	B-MED
close	O
to	O
the	O
active	B-MED
site	I-MED
,	O
iii	O
)	O
several	O
residues	B-MED
evenly	O
spread	O
on	O
the	O
NS2b	B-MED
-	I-MED
NS3	I-MED
contact	O
surface	O
,	O
and	O
iv	O
)	O
some	O
inner	O
residues	B-MED
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	B-MED
of	O
the	O
protease	B-MED
.	O
In	O
addition	O
,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	B-MED
with	O
previously	O
identified	O
amino	B-MED
acids	I-MED
part	O
of	O
a	O
highly	O
conserved	O
peptide	B-MED
studied	O
for	O
vaccine	B-MED
development	I-MED
.	O
Effective	B-MED
mercury(II	B-MED
)	I-MED
bioremoval	B-MED
from	O
aqueous	B-MED
solution	I-MED
,	O
and	O
its	O
electrochemical	B-MED
determination	I-MED
This	O
work	O
proposed	O
mercury	B-MED
elimination	B-MED
using	O
agricultural	B-MED
waste	B-MED
(	O
Allium	B-MED
Cepa	I-MED
L	I-MED
.	O
)	O
.	O
The	O
biomass	B-MED
removed	B-MED
99.4	O
%	O
of	O
mercury	B-MED
,	O
following	O
a	O
pseudo	B-MED
-	I-MED
second	I-MED
order	I-MED
kinetics	I-MED
(	O
r(2	O
)	O
=	O
0.9999	O
)	O
.	O
The	O
Langmuir	B-MED
model	I-MED
was	O
adequately	B-MED
fitted	O
to	O
the	O
adsorption	B-MED
isotherm	I-MED
,	O
thereby	O
obtaining	O
the	O
maximum	B-MED
mercury	B-MED
adsorption	B-MED
capacity	B-MED
of	O
111.1	O
±	O
0.3	O
mg	O
g(-1	O
)	O
.	O
The	O
biomass	B-MED
showed	O
high	B-MED
density	B-MED
of	O
strong	B-MED
mercury	B-MED
chelating	B-MED
groups	I-MED
,	O
thus	O
making	O
it	O
economically	B-MED
attractive	B-MED
.	O
Also	O
,	O
the	O
implementation	B-MED
of	O
a	O
mercury	B-MED
-	O
selective	B-MED
electrode	I-MED
for	O
continuous	B-MED
determination	B-MED
in	O
real	B-MED
time	I-MED
is	O
proposed	B-MED
;	O
this	O
electrode	B-MED
replaces	B-MED
techniques	B-MED
like	O
atomic	B-MED
absorption	I-MED
spectroscopy	I-MED
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	B-MED
time	I-MED
studies	B-MED
.	O
This	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	B-MED
for	O
removing	B-MED
mercury(II	B-MED
)	I-MED
from	O
contaminated	B-MED
water	I-MED
for	O
environmental	B-MED
remediation	I-MED
.	O
Epigenome	B-MED
-	I-MED
wide	I-MED
analysis	I-MED
links	O
SMAD3	B-MED
methylation	B-MED
at	O
birth	B-MED
to	O
asthma	B-MED
in	I-MED
children	I-MED
of	O
asthmatic	B-MED
mothers	B-MED
The	O
timing	O
and	O
mechanisms	B-MED
of	O
asthma	B-MED
inception	B-MED
remain	O
imprecisely	O
defined	O
.	O
Although	O
epigenetic	B-MED
mechanisms	B-MED
likely	O
contribute	O
to	O
asthma	B-MED
pathogenesis	B-MED
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-MED
inception	B-MED
.	O
We	O
sought	O
to	O
assess	B-MED
whether	O
the	O
trajectory	O
to	O
asthma	B-MED
begins	O
already	O
at	O
birth	B-MED
and	O
whether	O
epigenetic	B-MED
mechanisms	B-MED
,	O
specifically	O
DNA	B-MED
methylation	I-MED
,	O
contribute	O
to	O
asthma	B-MED
inception	B-MED
.	O
We	O
used	O
the	O
Methylated	B-MED
CpG	I-MED
Island	I-MED
Recovery	I-MED
Assay	I-MED
chip	I-MED
to	O
survey	B-MED
DNA	B-MED
methylation	I-MED
in	O
cord	B-MED
blood	I-MED
mononuclear	B-MED
cells	I-MED
from	O
36	O
children	B-MED
(	O
18	O
nonasthmatic	B-MED
and	O
18	O
asthmatic	B-MED
subjects	B-MED
by	O
age	B-MED
9	O
years	B-MED
)	O
from	O
the	O
Infant	B-MED
Immune	B-MED
Study	B-MED
(	O
IIS	B-MED
)	O
,	O
an	O
unselected	O
birth	B-MED
cohort	B-MED
closely	O
monitored	O
for	O
asthma	B-MED
for	O
a	O
decade	O
.	O
SMAD3	B-MED
methylation	B-MED
in	O
IIS	B-MED
(	O
n	O
=	O
60	O
)	O
and	O
in	O
2	O
replication	B-MED
cohorts	B-MED
(	O
the	O
Manchester	B-MED
Asthma	B-MED
and	O
Allergy	B-MED
Study	I-MED
[	O
n	O
=	O
30	O
]	O
and	O
the	O
Childhood	B-MED
Origins	I-MED
of	I-MED
Asthma	I-MED
Study	B-MED
[	O
n	O
=	O
28	O
]	O
)	O
was	O
analyzed	B-MED
by	O
using	O
bisulfite	B-MED
sequencing	I-MED
or	O
Illumina	B-MED
450	I-MED
K	I-MED
arrays	I-MED
.	O
Cord	B-MED
blood	I-MED
mononuclear	B-MED
cell	I-MED
-derived	O
IL-1β	B-MED
levels	B-MED
were	O
measured	B-MED
by	O
means	O
of	O
ELISA	B-MED
.	O
Neonatal	B-MED
immune	B-MED
cells	B-MED
harbored	O
589	O
differentially	O
methylated	B-MED
regions	I-MED
that	O
distinguished	O
IIS	B-MED
children	B-MED
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-MED
by	O
age	B-MED
9	O
years	B-MED
.	O
In	O
all	O
3	O
cohorts	B-MED
methylation	B-MED
in	O
SMAD3	B-MED
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-MED
-	O
associated	B-MED
,	O
differentially	O
methylated	B-MED
regions	I-MED
,	O
was	O
selectively	O
increased	B-MED
in	O
asthmatic	B-MED
children	B-MED
of	O
asthmatic	B-MED
mothers	B-MED
and	O
was	O
associated	B-MED
with	I-MED
childhood	B-MED
asthma	I-MED
risk	B-MED
.	O
Moreover	O
,	O
SMAD3	B-MED
methylation	B-MED
in	O
IIS	B-MED
neonates	B-MED
with	O
maternal	B-MED
asthma	B-MED
was	O
strongly	O
and	O
positively	O
associated	B-MED
with	I-MED
neonatal	B-MED
production	O
of	O
IL-1β	B-MED
,	O
an	O
innate	B-MED
inflammatory	I-MED
mediator	I-MED
.	O
The	O
trajectory	O
to	O
childhood	B-MED
asthma	I-MED
begins	O
at	O
birth	B-MED
and	O
involves	O
epigenetic	B-MED
modifications	B-MED
in	O
immunoregulatory	B-MED
and	O
proinflammatory	B-MED
pathways	B-MED
.	O
Maternal	B-MED
asthma	B-MED
influences	O
epigenetic	B-MED
mechanisms	B-MED
that	O
contribute	O
to	O
the	O
inception	B-MED
of	O
this	O
trajectory	O
.	O
Individual	B-MED
classification	B-MED
of	O
strong	B-MED
risk	B-MED
attitudes	B-MED
:	O
An	O
application	O
across	O
lottery	B-MED
types	B-MED
and	O
age	B-MED
groups	I-MED
Empirical	B-MED
evaluations	B-MED
of	O
risk	B-MED
attitudes	B-MED
often	O
rely	O
on	O
a	O
weak	B-MED
definition	B-MED
of	O
risk	B-MED
that	O
concerns	O
preferences	O
towards	O
risky	B-MED
and	O
riskless	B-MED
options	I-MED
(	O
e.g.	O
,	O
a	O
lottery	B-MED
vs.	O
a	O
sure	O
outcome	B-MED
)	O
.	O
A	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	B-MED
tend	O
to	O
be	O
weak	B-MED
risk	B-MED
averse	O
in	O
choice	B-MED
contexts	B-MED
involving	O
risky	B-MED
and	O
riskless	B-MED
gains	I-MED
but	O
weak	B-MED
risk	B-MED
seeking	O
in	O
contexts	B-MED
involving	O
losses	B-MED
,	O
a	O
phenomenon	B-MED
known	O
as	O
the	O
reflection	B-MED
effect	I-MED
.	O
Recent	O
attempts	O
to	O
evaluate	O
age	B-MED
differences	I-MED
in	O
risk	B-MED
attitudes	B-MED
have	O
relied	O
on	O
this	O
weak	B-MED
definition	B-MED
,	O
testing	O
whether	O
the	O
reflection	B-MED
effect	I-MED
increases	B-MED
or	O
diminishes	B-MED
as	O
we	O
grow	O
older	B-MED
.	O
The	O
present	O
work	O
argues	O
that	O
weak	B-MED
risk	B-MED
attitudes	B-MED
have	O
limited	O
generalizability	B-MED
and	O
proposes	O
the	O
use	B-MED
of	I-MED
a	O
strong	B-MED
strong	B-MED
definition	B-MED
of	O
risk	B-MED
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	B-MED
with	O
the	O
same	O
expected	O
value	B-MED
but	O
different	B-MED
degrees	B-MED
of	O
risk	B-MED
(	O
i.e.	O
,	O
outcome	B-MED
variance	B-MED
)	O
.	O
A	O
reanalysis	B-MED
of	O
previously	O
-	O
published	O
data	B-MED
and	O
the	O
results	B-MED
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	B-MED
manifests	B-MED
the	O
reflection	B-MED
effect	I-MED
under	O
a	O
strong	B-MED
definition	B-MED
of	O
risk	B-MED
,	O
and	O
that	O
,	O
when	O
facing	O
certain	O
lottery	B-MED
-	O
pair	B-MED
types	I-MED
,	O
older	B-MED
adults	I-MED
appear	O
to	O
be	O
more	O
risk	B-MED
seeking	O
than	O
younger	B-MED
adults	B-MED
.	O
